[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "Specific outcomes upon activation of the c-Jun N-terminal kinase (JNK) pathway critically depend on the intensity and duration of signal transmission. Dual-specificity phosphatases (DUSPs) play a very important role in these events by modulating the extent of JNK phosphorylation and activation and thus regulating cellular responses to stress. M3/6 (DUSP8) is one of the dual-specificity protein phosphatases with distinct specificity towards JNK. It has been shown that M3/6 itself is phosphorylated by JNK upon stimulation with arsenite, but the role of this phosphorylation has not been investigated. In this study, we mapped JNK-induced phosphorylation sites on M3/6 using mass spectrometry. Phosphorylated residues Ser 515, Thr 518 and Ser 520 were identified and site-directed mutagenesis was employed to investigate their role. Upon arsenite stimulation, M3/6 mutated at these sites exhibited decreased phosphorylation compared to the wild-type protein. No difference was observed in terms of the enzyme's in vitro phosphatase activity, its substrate specificity towards JNK isoforms, its interactions with JNK and the scaffold family of JNK-interacting proteins (JIPs), its stability or its subcellular localization. Interestingly, expression of M3/6 phosphorylation mutants delayed the time-course of JNK phosphorylation and activation by arsenite. We propose that phosphorylation of the M3/6 phosphatase by JNK in response to stress stimuli results in attenuation of phosphatase activity and acceleration of JNK activation.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "a351b22b820341a499b92892e91315d8", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[48, 48], [112, 112], [77, 77], [192, 192], [186, 186], [198, 198], [226, 226], [89, 89], [242, 242], [14, 14], [257, 257]], "char_spans": [[260, 262], [630, 632], [444, 446], [1115, 1117], [1079, 1081], [1146, 1148], [1311, 1313], [505, 507], [1418, 1420], [66, 68], [1519, 1521]]}]}], "context_tokens": [["Specific", 0], ["outcomes", 9], ["upon", 18], ["activation", 23], ["of", 34], ["the", 37], ["c", 41], ["-", 42], ["Jun", 43], ["N", 47], ["-", 48], ["terminal", 49], ["kinase", 58], ["(", 65], ["JNK", 66], [")", 69], ["pathway", 71], ["critically", 79], ["depend", 90], ["on", 97], ["the", 100], ["intensity", 104], ["and", 114], ["duration", 118], ["of", 127], ["signal", 130], ["transmission", 137], [".", 149], ["Dual", 151], ["-", 155], ["specificity", 156], ["phosphatases", 168], ["(", 181], ["DUSPs", 182], [")", 187], ["play", 189], ["a", 194], ["very", 196], ["important", 201], ["role", 211], ["in", 216], ["these", 219], ["events", 225], ["by", 232], ["modulating", 235], ["the", 246], ["extent", 250], ["of", 257], ["JNK", 260], ["phosphorylation", 264], ["and", 280], ["activation", 284], ["and", 295], ["thus", 299], ["regulating", 304], ["cellular", 315], ["responses", 324], ["to", 334], ["stress", 337], [".", 343], ["M3/6", 345], ["(", 350], ["DUSP8", 351], [")", 356], ["is", 358], ["one", 361], ["of", 365], ["the", 368], ["dual", 372], ["-", 376], ["specificity", 377], ["protein", 389], ["phosphatases", 397], ["with", 410], ["distinct", 415], ["specificity", 424], ["towards", 436], ["JNK", 444], [".", 447], ["It", 449], ["has", 452], ["been", 456], ["shown", 461], ["that", 467], ["M3/6", 472], ["itself", 477], ["is", 484], ["phosphorylated", 487], ["by", 502], ["JNK", 505], ["upon", 509], ["stimulation", 514], ["with", 526], ["arsenite", 531], [",", 539], ["but", 541], ["the", 545], ["role", 549], ["of", 554], ["this", 557], ["phosphorylation", 562], ["has", 578], ["not", 582], ["been", 586], ["investigated", 591], [".", 603], ["In", 605], ["this", 608], ["study", 613], [",", 618], ["we", 620], ["mapped", 623], ["JNK", 630], ["-", 633], ["induced", 634], ["phosphorylation", 642], ["sites", 658], ["on", 664], ["M3/6", 667], ["using", 672], ["mass", 678], ["spectrometry", 683], [".", 695], ["Phosphorylated", 697], ["residues", 712], ["Ser", 721], ["515", 725], [",", 728], ["Thr", 730], ["518", 734], ["and", 738], ["Ser", 742], ["520", 746], ["were", 750], ["identified", 755], ["and", 766], ["site", 770], ["-", 774], ["directed", 775], ["mutagenesis", 784], ["was", 796], ["employed", 800], ["to", 809], ["investigate", 812], ["their", 824], ["role", 830], [".", 834], ["Upon", 836], ["arsenite", 841], ["stimulation", 850], [",", 861], ["M3/6", 863], ["mutated", 868], ["at", 876], ["these", 879], ["sites", 885], ["exhibited", 891], ["decreased", 901], ["phosphorylation", 911], ["compared", 927], ["to", 936], ["the", 939], ["wild", 943], ["-", 947], ["type", 948], ["protein", 953], [".", 960], ["No", 962], ["difference", 965], ["was", 976], ["observed", 980], ["in", 989], ["terms", 992], ["of", 998], ["the", 1001], ["enzyme", 1005], ["'s", 1011], ["in", 1014], ["vitro", 1017], ["phosphatase", 1023], ["activity", 1035], [",", 1043], ["its", 1045], ["substrate", 1049], ["specificity", 1059], ["towards", 1071], ["JNK", 1079], ["isoforms", 1083], [",", 1091], ["its", 1093], ["interactions", 1097], ["with", 1110], ["JNK", 1115], ["and", 1119], ["the", 1123], ["scaffold", 1127], ["family", 1136], ["of", 1143], ["JNK", 1146], ["-", 1149], ["interacting", 1150], ["proteins", 1162], ["(", 1171], ["JIPs", 1172], [")", 1176], [",", 1177], ["its", 1179], ["stability", 1183], ["or", 1193], ["its", 1196], ["subcellular", 1200], ["localization", 1212], [".", 1224], ["Interestingly", 1226], [",", 1239], ["expression", 1241], ["of", 1252], ["M3/6", 1255], ["phosphorylation", 1260], ["mutants", 1276], ["delayed", 1284], ["the", 1292], ["time", 1296], ["-", 1300], ["course", 1301], ["of", 1308], ["JNK", 1311], ["phosphorylation", 1315], ["and", 1331], ["activation", 1335], ["by", 1346], ["arsenite", 1349], [".", 1357], ["We", 1359], ["propose", 1362], ["that", 1370], ["phosphorylation", 1375], ["of", 1391], ["the", 1394], ["M3/6", 1398], ["phosphatase", 1403], ["by", 1415], ["JNK", 1418], ["in", 1422], ["response", 1425], ["to", 1434], ["stress", 1437], ["stimuli", 1444], ["results", 1452], ["in", 1460], ["attenuation", 1463], ["of", 1475], ["phosphatase", 1478], ["activity", 1490], ["and", 1499], ["acceleration", 1503], ["of", 1516], ["JNK", 1519], ["activation", 1523], [".", 1533]]}
{"context": "Parkinson's disease (PD) is the second most common neurodegenerative disease. A key pathological feature of PD is Lewy bodies, of which the major protein component is \u03b1-synuclein (\u03b1-syn). Human genetic studies have shown that mutations (A53T, A30P, E46K) and multiplication of the \u03b1-syn gene are linked to familial PD. Mice overexpressing the human A53T mutant \u03b1-syn gene develop severe movement disorders. However, the molecular mechanisms of \u03b1-syn toxicity are not well understood. Recently, mitochondrial dysfunction has been linked with multiple neurodegenerative diseases including Parkinson's disease. Here we investigated whether mitochondrial motility, dynamics and respiratory function are affected in primary neurons from a mouse model expressing the human A53T mutation. We found that mitochondrial motility was selectively inhibited in A53T neurons while transport of other organelles was not affected. In addition, A53T expressing neurons showed impairment in mitochondrial membrane potential and mitochondrial respiratory function. Furthermore, we found that rapamycin, an autophagy inducer, rescued the decreased mitochondrial mobility. Taken together, these data demonstrate that A53T \u03b1-syn impairs mitochondrial function and dynamics and the deficit of mitochondrial transport is reversible, providing further understanding of the disease pathogenesis and a potential therapeutic strategy for PD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4687700336544ca7b5e25c199a0d7523", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[31, 33]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["the", 28], ["second", 32], ["most", 39], ["common", 44], ["neurodegenerative", 51], ["disease", 69], [".", 76], ["A", 78], ["key", 80], ["pathological", 84], ["feature", 97], ["of", 105], ["PD", 108], ["is", 111], ["Lewy", 114], ["bodies", 119], [",", 125], ["of", 127], ["which", 130], ["the", 136], ["major", 140], ["protein", 146], ["component", 154], ["is", 164], ["\u03b1", 167], ["-", 168], ["synuclein", 169], ["(", 179], ["\u03b1", 180], ["-", 181], ["syn", 182], [")", 185], [".", 186], ["Human", 188], ["genetic", 194], ["studies", 202], ["have", 210], ["shown", 215], ["that", 221], ["mutations", 226], ["(", 236], ["A53", 237], ["T", 240], [",", 241], ["A30P", 243], [",", 247], ["E46", 249], ["K", 252], [")", 253], ["and", 255], ["multiplication", 259], ["of", 274], ["the", 277], ["\u03b1", 281], ["-", 282], ["syn", 283], ["gene", 287], ["are", 292], ["linked", 296], ["to", 303], ["familial", 306], ["PD", 315], [".", 317], ["Mice", 319], ["overexpressing", 324], ["the", 339], ["human", 343], ["A53", 349], ["T", 352], ["mutant", 354], ["\u03b1", 361], ["-", 362], ["syn", 363], ["gene", 367], ["develop", 372], ["severe", 380], ["movement", 387], ["disorders", 396], [".", 405], ["However", 407], [",", 414], ["the", 416], ["molecular", 420], ["mechanisms", 430], ["of", 441], ["\u03b1", 444], ["-", 445], ["syn", 446], ["toxicity", 450], ["are", 459], ["not", 463], ["well", 467], ["understood", 472], [".", 482], ["Recently", 484], [",", 492], ["mitochondrial", 494], ["dysfunction", 508], ["has", 520], ["been", 524], ["linked", 529], ["with", 536], ["multiple", 541], ["neurodegenerative", 550], ["diseases", 568], ["including", 577], ["Parkinson", 587], ["'s", 596], ["disease", 599], [".", 606], ["Here", 608], ["we", 613], ["investigated", 616], ["whether", 629], ["mitochondrial", 637], ["motility", 651], [",", 659], ["dynamics", 661], ["and", 670], ["respiratory", 674], ["function", 686], ["are", 695], ["affected", 699], ["in", 708], ["primary", 711], ["neurons", 719], ["from", 727], ["a", 732], ["mouse", 734], ["model", 740], ["expressing", 746], ["the", 757], ["human", 761], ["A53", 767], ["T", 770], ["mutation", 772], [".", 780], ["We", 782], ["found", 785], ["that", 791], ["mitochondrial", 796], ["motility", 810], ["was", 819], ["selectively", 823], ["inhibited", 835], ["in", 845], ["A53", 848], ["T", 851], ["neurons", 853], ["while", 861], ["transport", 867], ["of", 877], ["other", 880], ["organelles", 886], ["was", 897], ["not", 901], ["affected", 905], [".", 913], ["In", 915], ["addition", 918], [",", 926], ["A53", 928], ["T", 931], ["expressing", 933], ["neurons", 944], ["showed", 952], ["impairment", 959], ["in", 970], ["mitochondrial", 973], ["membrane", 987], ["potential", 996], ["and", 1006], ["mitochondrial", 1010], ["respiratory", 1024], ["function", 1036], [".", 1044], ["Furthermore", 1046], [",", 1057], ["we", 1059], ["found", 1062], ["that", 1068], ["rapamycin", 1073], [",", 1082], ["an", 1084], ["autophagy", 1087], ["inducer", 1097], [",", 1104], ["rescued", 1106], ["the", 1114], ["decreased", 1118], ["mitochondrial", 1128], ["mobility", 1142], [".", 1150], ["Taken", 1152], ["together", 1158], [",", 1166], ["these", 1168], ["data", 1174], ["demonstrate", 1179], ["that", 1191], ["A53", 1196], ["T", 1199], ["\u03b1", 1201], ["-", 1202], ["syn", 1203], ["impairs", 1207], ["mitochondrial", 1215], ["function", 1229], ["and", 1238], ["dynamics", 1242], ["and", 1251], ["the", 1255], ["deficit", 1259], ["of", 1267], ["mitochondrial", 1270], ["transport", 1284], ["is", 1294], ["reversible", 1297], [",", 1307], ["providing", 1309], ["further", 1319], ["understanding", 1327], ["of", 1341], ["the", 1344], ["disease", 1348], ["pathogenesis", 1356], ["and", 1369], ["a", 1373], ["potential", 1375], ["therapeutic", 1385], ["strategy", 1397], ["for", 1406], ["PD", 1410], [".", 1412]]}
{"context": "Loss-of-function mutations in the gene ced-8 lead to the late appearance of cell corpses during embryonic development in C. elegans. ced-8 functions downstream of or in parallel to-the regulatory cell death gene ced-9 and may function as a cell death effector downstream of the caspase encoded by the programmed cell death killer gene ced-3. In ced-8 mutants, embryonic programmed cell death probably initiates normally but proceeds slowly. ced-8 encodes a transmembrane protein that appears to be localized to the plasma membrane. The CED-8 protein is similar to human XK, a putative membrane transport protein implicated in McLeod Syndrome, a form of hereditary neuroacanthocytosis.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "0574b68d8a1845829336d0bb8c46aef6", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[99, 99]], "char_spans": [[570, 571]]}]}], "context_tokens": [["Loss", 0], ["-", 4], ["of", 5], ["-", 7], ["function", 8], ["mutations", 17], ["in", 27], ["the", 30], ["gene", 34], ["ced-8", 39], ["lead", 45], ["to", 50], ["the", 53], ["late", 57], ["appearance", 62], ["of", 73], ["cell", 76], ["corpses", 81], ["during", 89], ["embryonic", 96], ["development", 106], ["in", 118], ["C.", 121], ["elegans", 124], [".", 131], ["ced-8", 133], ["functions", 139], ["downstream", 149], ["of", 160], ["or", 163], ["in", 166], ["parallel", 169], ["to", 178], ["-", 180], ["the", 181], ["regulatory", 185], ["cell", 196], ["death", 201], ["gene", 207], ["ced-9", 212], ["and", 218], ["may", 222], ["function", 226], ["as", 235], ["a", 238], ["cell", 240], ["death", 245], ["effector", 251], ["downstream", 260], ["of", 271], ["the", 274], ["caspase", 278], ["encoded", 286], ["by", 294], ["the", 297], ["programmed", 301], ["cell", 312], ["death", 317], ["killer", 323], ["gene", 330], ["ced-3", 335], [".", 340], ["In", 342], ["ced-8", 345], ["mutants", 351], [",", 358], ["embryonic", 360], ["programmed", 370], ["cell", 381], ["death", 386], ["probably", 392], ["initiates", 401], ["normally", 411], ["but", 420], ["proceeds", 424], ["slowly", 433], [".", 439], ["ced-8", 441], ["encodes", 447], ["a", 455], ["transmembrane", 457], ["protein", 471], ["that", 479], ["appears", 484], ["to", 492], ["be", 495], ["localized", 498], ["to", 508], ["the", 511], ["plasma", 515], ["membrane", 522], [".", 530], ["The", 532], ["CED-8", 536], ["protein", 542], ["is", 550], ["similar", 553], ["to", 561], ["human", 564], ["XK", 570], [",", 572], ["a", 574], ["putative", 576], ["membrane", 585], ["transport", 594], ["protein", 604], ["implicated", 612], ["in", 623], ["McLeod", 626], ["Syndrome", 633], [",", 641], ["a", 643], ["form", 645], ["of", 650], ["hereditary", 653], ["neuroacanthocytosis", 664], [".", 683]]}
{"context": "Alpha-synuclein forms the major component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies. Here we show that alpha-synuclein is also the major component of the filamentous inclusions of multiple system atrophy which comprises several neurodegenerative diseases with a shared filamentous pathology in nerve cells and glial cells. These findings provide an unexpected link between multiple system atrophy and Lewy body disorders and establish that alpha-synucleinopathies constitute a major class of human neurodegenerative disorder.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a4da3f3b9ad440b69aaf79b7d6f6f893", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2], [32, 34]], "char_spans": [[0, 14], [195, 209]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["forms", 16], ["the", 22], ["major", 26], ["component", 32], ["of", 42], ["Lewy", 45], ["bodies", 50], ["and", 57], ["Lewy", 61], ["neurites", 66], [",", 74], ["the", 76], ["defining", 80], ["neuropathological", 89], ["characteristics", 107], ["of", 123], ["Parkinson", 126], ["'s", 135], ["disease", 138], ["and", 146], ["dementia", 150], ["with", 159], ["Lewy", 164], ["bodies", 169], [".", 175], ["Here", 177], ["we", 182], ["show", 185], ["that", 190], ["alpha", 195], ["-", 200], ["synuclein", 201], ["is", 211], ["also", 214], ["the", 219], ["major", 223], ["component", 229], ["of", 239], ["the", 242], ["filamentous", 246], ["inclusions", 258], ["of", 269], ["multiple", 272], ["system", 281], ["atrophy", 288], ["which", 296], ["comprises", 302], ["several", 312], ["neurodegenerative", 320], ["diseases", 338], ["with", 347], ["a", 352], ["shared", 354], ["filamentous", 361], ["pathology", 373], ["in", 383], ["nerve", 386], ["cells", 392], ["and", 398], ["glial", 402], ["cells", 408], [".", 413], ["These", 415], ["findings", 421], ["provide", 430], ["an", 438], ["unexpected", 441], ["link", 452], ["between", 457], ["multiple", 465], ["system", 474], ["atrophy", 481], ["and", 489], ["Lewy", 493], ["body", 498], ["disorders", 503], ["and", 513], ["establish", 517], ["that", 527], ["alpha", 532], ["-", 537], ["synucleinopathies", 538], ["constitute", 556], ["a", 567], ["major", 569], ["class", 575], ["of", 581], ["human", 584], ["neurodegenerative", 590], ["disorder", 608], [".", 616]]}
{"context": "Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the lysosomal exoglycosidase responsible for the hydrolysis of terminal alpha-galactosyl residues from glycoconjugates and is the defective enzyme causing Fabry disease (McKusick 301500). An unusally elevated level of plasma alpha-Gal A activity (> 2.5 times the normal mean) was detected in two unrelated normal males and the elevated activities were inherited as X-linked traits in their families. Sequencing of the alpha-Gal A coding region, intron/exon boundaries and 5'-flanking region from the proband identified a single mutation, a G-->A transition 30 nt upstream from the initiation of translation codon in exon 1. The -30G-->A mutation occurred in a putative NF kappa B/Ets consensus binding site that was recently shown to inhibit protein binding to the 5'-untranslated region of the gene, providing a possible explanation for its high activity. To further characterize the mutation, the mRNA and protein expressed by this variant allele were studied. Purified plasma and lymphoblast alpha-Gal A activity from individuals with the -30G-->A mutation had normal physical and kinetic properties. In vitro translation of mRNAs from the cloned normal and high plasma activity alleles resulted in similar levels of alpha-Gal A protein, indicating that this mutation did not enhance translation. These findings suggest that the -30G-->A mutation in the 5'-untranslated region of the alpha-Gal A gene enhances transcription, presumably by interfering with the binding of negatively-acting transcription factors which normally decrease alpha-Gal A expression in various cells. Preliminary studies of the frequency of the -30G-->A mutation in 395 unrelated normal males of mixed ancestry revealed two additional unrelated individuals who had high plasma enzymatic activity and the mutation, confirming the effect of this mutation on enzyme expression and suggesting that about 0.5% of normal individuals have high plasma alpha-Gal A activity due to this variant allele.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "cd3dcbcaf34943d0be36358f319a997a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[1, 3]], "char_spans": [[6, 24]]}]}], "context_tokens": [["Human", 0], ["alpha", 6], ["-", 11], ["galactosidase", 12], ["A", 26], ["(", 28], ["EC", 29], ["3.2.1.22", 32], [";", 40], ["alpha", 42], ["-", 47], ["Gal", 48], ["A", 52], [")", 53], ["is", 55], ["the", 58], ["lysosomal", 62], ["exoglycosidase", 72], ["responsible", 87], ["for", 99], ["the", 103], ["hydrolysis", 107], ["of", 118], ["terminal", 121], ["alpha", 130], ["-", 135], ["galactosyl", 136], ["residues", 147], ["from", 156], ["glycoconjugates", 161], ["and", 177], ["is", 181], ["the", 184], ["defective", 188], ["enzyme", 198], ["causing", 205], ["Fabry", 213], ["disease", 219], ["(", 227], ["McKusick", 228], ["301500", 237], [")", 243], [".", 244], ["An", 246], ["unusally", 249], ["elevated", 258], ["level", 267], ["of", 273], ["plasma", 276], ["alpha", 283], ["-", 288], ["Gal", 289], ["A", 293], ["activity", 295], ["(", 304], [">", 305], ["2.5", 307], ["times", 311], ["the", 317], ["normal", 321], ["mean", 328], [")", 332], ["was", 334], ["detected", 338], ["in", 347], ["two", 350], ["unrelated", 354], ["normal", 364], ["males", 371], ["and", 377], ["the", 381], ["elevated", 385], ["activities", 394], ["were", 405], ["inherited", 410], ["as", 420], ["X", 423], ["-", 424], ["linked", 425], ["traits", 432], ["in", 439], ["their", 442], ["families", 448], [".", 456], ["Sequencing", 458], ["of", 469], ["the", 472], ["alpha", 476], ["-", 481], ["Gal", 482], ["A", 486], ["coding", 488], ["region", 495], [",", 501], ["intron", 503], ["/", 509], ["exon", 510], ["boundaries", 515], ["and", 526], ["5'-flanking", 530], ["region", 542], ["from", 549], ["the", 554], ["proband", 558], ["identified", 566], ["a", 577], ["single", 579], ["mutation", 586], [",", 594], ["a", 596], ["G-->A", 598], ["transition", 604], ["30", 615], ["nt", 618], ["upstream", 621], ["from", 630], ["the", 635], ["initiation", 639], ["of", 650], ["translation", 653], ["codon", 665], ["in", 671], ["exon", 674], ["1", 679], [".", 680], ["The", 682], ["-30G-->A", 686], ["mutation", 695], ["occurred", 704], ["in", 713], ["a", 716], ["putative", 718], ["NF", 727], ["kappa", 730], ["B", 736], ["/", 737], ["Ets", 738], ["consensus", 742], ["binding", 752], ["site", 760], ["that", 765], ["was", 770], ["recently", 774], ["shown", 783], ["to", 789], ["inhibit", 792], ["protein", 800], ["binding", 808], ["to", 816], ["the", 819], ["5'-untranslated", 823], ["region", 839], ["of", 846], ["the", 849], ["gene", 853], [",", 857], ["providing", 859], ["a", 869], ["possible", 871], ["explanation", 880], ["for", 892], ["its", 896], ["high", 900], ["activity", 905], [".", 913], ["To", 915], ["further", 918], ["characterize", 926], ["the", 939], ["mutation", 943], [",", 951], ["the", 953], ["mRNA", 957], ["and", 962], ["protein", 966], ["expressed", 974], ["by", 984], ["this", 987], ["variant", 992], ["allele", 1000], ["were", 1007], ["studied", 1012], [".", 1019], ["Purified", 1021], ["plasma", 1030], ["and", 1037], ["lymphoblast", 1041], ["alpha", 1053], ["-", 1058], ["Gal", 1059], ["A", 1063], ["activity", 1065], ["from", 1074], ["individuals", 1079], ["with", 1091], ["the", 1096], ["-30G-->A", 1100], ["mutation", 1109], ["had", 1118], ["normal", 1122], ["physical", 1129], ["and", 1138], ["kinetic", 1142], ["properties", 1150], [".", 1160], ["In", 1162], ["vitro", 1165], ["translation", 1171], ["of", 1183], ["mRNAs", 1186], ["from", 1192], ["the", 1197], ["cloned", 1201], ["normal", 1208], ["and", 1215], ["high", 1219], ["plasma", 1224], ["activity", 1231], ["alleles", 1240], ["resulted", 1248], ["in", 1257], ["similar", 1260], ["levels", 1268], ["of", 1275], ["alpha", 1278], ["-", 1283], ["Gal", 1284], ["A", 1288], ["protein", 1290], [",", 1297], ["indicating", 1299], ["that", 1310], ["this", 1315], ["mutation", 1320], ["did", 1329], ["not", 1333], ["enhance", 1337], ["translation", 1345], [".", 1356], ["These", 1358], ["findings", 1364], ["suggest", 1373], ["that", 1381], ["the", 1386], ["-30G-->A", 1390], ["mutation", 1399], ["in", 1408], ["the", 1411], ["5'-untranslated", 1415], ["region", 1431], ["of", 1438], ["the", 1441], ["alpha", 1445], ["-", 1450], ["Gal", 1451], ["A", 1455], ["gene", 1457], ["enhances", 1462], ["transcription", 1471], [",", 1484], ["presumably", 1486], ["by", 1497], ["interfering", 1500], ["with", 1512], ["the", 1517], ["binding", 1521], ["of", 1529], ["negatively", 1532], ["-", 1542], ["acting", 1543], ["transcription", 1550], ["factors", 1564], ["which", 1572], ["normally", 1578], ["decrease", 1587], ["alpha", 1596], ["-", 1601], ["Gal", 1602], ["A", 1606], ["expression", 1608], ["in", 1619], ["various", 1622], ["cells", 1630], [".", 1635], ["Preliminary", 1637], ["studies", 1649], ["of", 1657], ["the", 1660], ["frequency", 1664], ["of", 1674], ["the", 1677], ["-30G-->A", 1681], ["mutation", 1690], ["in", 1699], ["395", 1702], ["unrelated", 1706], ["normal", 1716], ["males", 1723], ["of", 1729], ["mixed", 1732], ["ancestry", 1738], ["revealed", 1747], ["two", 1756], ["additional", 1760], ["unrelated", 1771], ["individuals", 1781], ["who", 1793], ["had", 1797], ["high", 1801], ["plasma", 1806], ["enzymatic", 1813], ["activity", 1823], ["and", 1832], ["the", 1836], ["mutation", 1840], [",", 1848], ["confirming", 1850], ["the", 1861], ["effect", 1865], ["of", 1872], ["this", 1875], ["mutation", 1880], ["on", 1889], ["enzyme", 1892], ["expression", 1899], ["and", 1910], ["suggesting", 1914], ["that", 1925], ["about", 1930], ["0.5", 1936], ["%", 1939], ["of", 1941], ["normal", 1944], ["individuals", 1951], ["have", 1963], ["high", 1968], ["plasma", 1973], ["alpha", 1980], ["-", 1985], ["Gal", 1986], ["A", 1990], ["activity", 1992], ["due", 2001], ["to", 2005], ["this", 2008], ["variant", 2013], ["allele", 2021], [".", 2027]]}
{"context": "The clinical efficacy of different doses of the specific benzodiazepine antagonist flumazenil was studied in a total of 72 patients with benzodiazepine or ethanol overdose. In a randomized double-blind study, 18 patients (group 1) and eight patients (group 2) with suspected benzodiazepine overdose received 5 mg (group 1) or 1 mg (group 2) flumazenil or placebo, respectively. The stage of coma, heart rate, blood pressure and respiratory rate were monitored within the following 15 min. If no change in the stage of coma was observed, 5 mg (group 1) or 1 mg (group 2) flumazenil were given, and the stage of coma, heart rate and blood pressure were again monitored. In a similar way, the effect of 5 and 1 mg flumazenil was investigated in 13 patients (group 3) and four patients (group 4) with ethanol intoxication. In an open trial, the clinical efficacy of flumazenil for the diagnosis of benzodiazepine or ethanol overdose was studied in 29 patients (group 5). In all patients, a toxicological screening confirmed benzodiazepine or ethanol overdose. None of the patients receiving placebo showed effects on stage of coma, heart rate, blood pressure or respiratory rate. Patients with benzodiazepine overdose who received 5 mg flumazenil regained consciousness about 1-2 min after the end of injection. The effect of 1 mg flumazenil (group 2) on benzodiazepine-induced coma was less pronounced. In patients with ethanol overdose (group 3), ethanol-induced coma was reversed after 5 mg flumazenil more slowly than in patients of group 1. No effect of flumazenil on ethanol-induced coma was observed in group 4. In group 5, flumazenil proved to be useful for diagnosing benzodiazepine or ethanol intoxication. In one patient with coma due to carbamazepine overdose, flumazenil was also found to be effective. Additionally, a possible analytical interference of flumazenil and its metabolites with the identification of other benzodiazepines by a toxicological screening procedure was studied. Even after an oral dose of 200 mg flumazenil, no interference with immunological benzodiazepine assays (EMIT, TDX, and RIA) was found. A metabolite and an artifact of flumazenil could be identified in urine by gas chromatography/mass spectrometry.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "09099c4d930143fdb85f846a03675594", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[304, 304], [320, 320], [147, 147], [11, 11], [177, 177], [291, 291], [342, 342], [357, 357], [116, 116], [383, 383], [408, 408], [258, 258], [239, 239], [65, 65]], "char_spans": [[1555, 1564], [1627, 1636], [711, 720], [83, 92], [862, 871], [1490, 1499], [1769, 1778], [1864, 1873], [570, 579], [2030, 2039], [2163, 2172], [1327, 1336], [1232, 1241], [341, 350]]}]}], "context_tokens": [["The", 0], ["clinical", 4], ["efficacy", 13], ["of", 22], ["different", 25], ["doses", 35], ["of", 41], ["the", 44], ["specific", 48], ["benzodiazepine", 57], ["antagonist", 72], ["flumazenil", 83], ["was", 94], ["studied", 98], ["in", 106], ["a", 109], ["total", 111], ["of", 117], ["72", 120], ["patients", 123], ["with", 132], ["benzodiazepine", 137], ["or", 152], ["ethanol", 155], ["overdose", 163], [".", 171], ["In", 173], ["a", 176], ["randomized", 178], ["double", 189], ["-", 195], ["blind", 196], ["study", 202], [",", 207], ["18", 209], ["patients", 212], ["(", 221], ["group", 222], ["1", 228], [")", 229], ["and", 231], ["eight", 235], ["patients", 241], ["(", 250], ["group", 251], ["2", 257], [")", 258], ["with", 260], ["suspected", 265], ["benzodiazepine", 275], ["overdose", 290], ["received", 299], ["5", 308], ["mg", 310], ["(", 313], ["group", 314], ["1", 320], [")", 321], ["or", 323], ["1", 326], ["mg", 328], ["(", 331], ["group", 332], ["2", 338], [")", 339], ["flumazenil", 341], ["or", 352], ["placebo", 355], [",", 362], ["respectively", 364], [".", 376], ["The", 378], ["stage", 382], ["of", 388], ["coma", 391], [",", 395], ["heart", 397], ["rate", 403], [",", 407], ["blood", 409], ["pressure", 415], ["and", 424], ["respiratory", 428], ["rate", 440], ["were", 445], ["monitored", 450], ["within", 460], ["the", 467], ["following", 471], ["15", 481], ["min", 484], [".", 487], ["If", 489], ["no", 492], ["change", 495], ["in", 502], ["the", 505], ["stage", 509], ["of", 515], ["coma", 518], ["was", 523], ["observed", 527], [",", 535], ["5", 537], ["mg", 539], ["(", 542], ["group", 543], ["1", 549], [")", 550], ["or", 552], ["1", 555], ["mg", 557], ["(", 560], ["group", 561], ["2", 567], [")", 568], ["flumazenil", 570], ["were", 581], ["given", 586], [",", 591], ["and", 593], ["the", 597], ["stage", 601], ["of", 607], ["coma", 610], [",", 614], ["heart", 616], ["rate", 622], ["and", 627], ["blood", 631], ["pressure", 637], ["were", 646], ["again", 651], ["monitored", 657], [".", 666], ["In", 668], ["a", 671], ["similar", 673], ["way", 681], [",", 684], ["the", 686], ["effect", 690], ["of", 697], ["5", 700], ["and", 702], ["1", 706], ["mg", 708], ["flumazenil", 711], ["was", 722], ["investigated", 726], ["in", 739], ["13", 742], ["patients", 745], ["(", 754], ["group", 755], ["3", 761], [")", 762], ["and", 764], ["four", 768], ["patients", 773], ["(", 782], ["group", 783], ["4", 789], [")", 790], ["with", 792], ["ethanol", 797], ["intoxication", 805], [".", 817], ["In", 819], ["an", 822], ["open", 825], ["trial", 830], [",", 835], ["the", 837], ["clinical", 841], ["efficacy", 850], ["of", 859], ["flumazenil", 862], ["for", 873], ["the", 877], ["diagnosis", 881], ["of", 891], ["benzodiazepine", 894], ["or", 909], ["ethanol", 912], ["overdose", 920], ["was", 929], ["studied", 933], ["in", 941], ["29", 944], ["patients", 947], ["(", 956], ["group", 957], ["5", 963], [")", 964], [".", 965], ["In", 967], ["all", 970], ["patients", 974], [",", 982], ["a", 984], ["toxicological", 986], ["screening", 1000], ["confirmed", 1010], ["benzodiazepine", 1020], ["or", 1035], ["ethanol", 1038], ["overdose", 1046], [".", 1054], ["None", 1056], ["of", 1061], ["the", 1064], ["patients", 1068], ["receiving", 1077], ["placebo", 1087], ["showed", 1095], ["effects", 1102], ["on", 1110], ["stage", 1113], ["of", 1119], ["coma", 1122], [",", 1126], ["heart", 1128], ["rate", 1134], [",", 1138], ["blood", 1140], ["pressure", 1146], ["or", 1155], ["respiratory", 1158], ["rate", 1170], [".", 1174], ["Patients", 1176], ["with", 1185], ["benzodiazepine", 1190], ["overdose", 1205], ["who", 1214], ["received", 1218], ["5", 1227], ["mg", 1229], ["flumazenil", 1232], ["regained", 1243], ["consciousness", 1252], ["about", 1266], ["1", 1272], ["-", 1273], ["2", 1274], ["min", 1276], ["after", 1280], ["the", 1286], ["end", 1290], ["of", 1294], ["injection", 1297], [".", 1306], ["The", 1308], ["effect", 1312], ["of", 1319], ["1", 1322], ["mg", 1324], ["flumazenil", 1327], ["(", 1338], ["group", 1339], ["2", 1345], [")", 1346], ["on", 1348], ["benzodiazepine", 1351], ["-", 1365], ["induced", 1366], ["coma", 1374], ["was", 1379], ["less", 1383], ["pronounced", 1388], [".", 1398], ["In", 1400], ["patients", 1403], ["with", 1412], ["ethanol", 1417], ["overdose", 1425], ["(", 1434], ["group", 1435], ["3", 1441], [")", 1442], [",", 1443], ["ethanol", 1445], ["-", 1452], ["induced", 1453], ["coma", 1461], ["was", 1466], ["reversed", 1470], ["after", 1479], ["5", 1485], ["mg", 1487], ["flumazenil", 1490], ["more", 1501], ["slowly", 1506], ["than", 1513], ["in", 1518], ["patients", 1521], ["of", 1530], ["group", 1533], ["1", 1539], [".", 1540], ["No", 1542], ["effect", 1545], ["of", 1552], ["flumazenil", 1555], ["on", 1566], ["ethanol", 1569], ["-", 1576], ["induced", 1577], ["coma", 1585], ["was", 1590], ["observed", 1594], ["in", 1603], ["group", 1606], ["4", 1612], [".", 1613], ["In", 1615], ["group", 1618], ["5", 1624], [",", 1625], ["flumazenil", 1627], ["proved", 1638], ["to", 1645], ["be", 1648], ["useful", 1651], ["for", 1658], ["diagnosing", 1662], ["benzodiazepine", 1673], ["or", 1688], ["ethanol", 1691], ["intoxication", 1699], [".", 1711], ["In", 1713], ["one", 1716], ["patient", 1720], ["with", 1728], ["coma", 1733], ["due", 1738], ["to", 1742], ["carbamazepine", 1745], ["overdose", 1759], [",", 1767], ["flumazenil", 1769], ["was", 1780], ["also", 1784], ["found", 1789], ["to", 1795], ["be", 1798], ["effective", 1801], [".", 1810], ["Additionally", 1812], [",", 1824], ["a", 1826], ["possible", 1828], ["analytical", 1837], ["interference", 1848], ["of", 1861], ["flumazenil", 1864], ["and", 1875], ["its", 1879], ["metabolites", 1883], ["with", 1895], ["the", 1900], ["identification", 1904], ["of", 1919], ["other", 1922], ["benzodiazepines", 1928], ["by", 1944], ["a", 1947], ["toxicological", 1949], ["screening", 1963], ["procedure", 1973], ["was", 1983], ["studied", 1987], [".", 1994], ["Even", 1996], ["after", 2001], ["an", 2007], ["oral", 2010], ["dose", 2015], ["of", 2020], ["200", 2023], ["mg", 2027], ["flumazenil", 2030], [",", 2040], ["no", 2042], ["interference", 2045], ["with", 2058], ["immunological", 2063], ["benzodiazepine", 2077], ["assays", 2092], ["(", 2099], ["EMIT", 2100], [",", 2104], ["TDX", 2106], [",", 2109], ["and", 2111], ["RIA", 2115], [")", 2118], ["was", 2120], ["found", 2124], [".", 2129], ["A", 2131], ["metabolite", 2133], ["and", 2144], ["an", 2148], ["artifact", 2151], ["of", 2160], ["flumazenil", 2163], ["could", 2174], ["be", 2180], ["identified", 2183], ["in", 2194], ["urine", 2197], ["by", 2203], ["gas", 2206], ["chromatography", 2210], ["/", 2224], ["mass", 2225], ["spectrometry", 2230], [".", 2242]]}
{"context": "Parkinson's disease (PD) is a neurodegenerative disease with characteristics and symptoms that are well defined. Nevertheless, its aetiology remains unknown. PD is characterized by the presence of Lewy bodies inside neurons. \u03b1-Synuclein (\u03b1-syn) is a soluble protein present in the pre-synaptic terminal of neurons. Evidence suggests that \u03b1-syn has a fundamental role in PD pathogenesis, given that it is an important component of Lewy bodies localized in the dopaminergic neurons of PD patients. In the present study, we investigated the influence of wild type (WT) and A30P \u03b1-syn overexpression on neuroblastoma SH-SY5Y toxicity induced by the conditioned medium (CM) from primary cultures of glia challenged with lipopolysaccharide (LPS) from Escherichia coli. We observed that SH-SY5Y cells transduced with \u03b1-syn (WT or A30P) and treated with CM from LPS-activated glia cells show evidence of cell death, which is not reverted by NF-\u03baB inhibition by sodium salicylate or by blockage of P50 (NF-\u03baB subunit). Furthermore, the expression of A30P \u03b1-syn in neuroblastoma SH-SY5Y decreases the cell death triggered by the CM of activated glia versus WT \u03b1-syn or control group. This effect of A30P \u03b1-syn may be due to the low MAPK42/44 phosphorylation. This finding is substantiated by MEK1 inhibition by PD98059, decreasing LDH release by CM in SH-SY5Y cells. Our results suggest that SH-SY5Y cells transduced with \u03b1-syn (WT or A30P) and treated with CM from LPS-activated glia cells show cell death, which is not reverted by NF-\u03baB blockage. Additionally, the expression of A30P \u03b1-syn on neuroblastoma SH-SY5Y leads to decreased cell death triggered by the CM of activated glia, when compared to WT \u03b1-syn or control group. The mechanism underlying this process remains to be completely elucidated, but the present data suggest that MAPK42/44 phosphorylation plays an important role in this process. CRD42015020829.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "770cdf4bff11453d9e85c2d6c5857367", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[38, 40]], "char_spans": [[225, 235]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegenerative", 30], ["disease", 48], ["with", 56], ["characteristics", 61], ["and", 77], ["symptoms", 81], ["that", 90], ["are", 95], ["well", 99], ["defined", 104], [".", 111], ["Nevertheless", 113], [",", 125], ["its", 127], ["aetiology", 131], ["remains", 141], ["unknown", 149], [".", 156], ["PD", 158], ["is", 161], ["characterized", 164], ["by", 178], ["the", 181], ["presence", 185], ["of", 194], ["Lewy", 197], ["bodies", 202], ["inside", 209], ["neurons", 216], [".", 223], ["\u03b1", 225], ["-", 226], ["Synuclein", 227], ["(", 237], ["\u03b1", 238], ["-", 239], ["syn", 240], [")", 243], ["is", 245], ["a", 248], ["soluble", 250], ["protein", 258], ["present", 266], ["in", 274], ["the", 277], ["pre", 281], ["-", 284], ["synaptic", 285], ["terminal", 294], ["of", 303], ["neurons", 306], [".", 313], ["Evidence", 315], ["suggests", 324], ["that", 333], ["\u03b1", 338], ["-", 339], ["syn", 340], ["has", 344], ["a", 348], ["fundamental", 350], ["role", 362], ["in", 367], ["PD", 370], ["pathogenesis", 373], [",", 385], ["given", 387], ["that", 393], ["it", 398], ["is", 401], ["an", 404], ["important", 407], ["component", 417], ["of", 427], ["Lewy", 430], ["bodies", 435], ["localized", 442], ["in", 452], ["the", 455], ["dopaminergic", 459], ["neurons", 472], ["of", 480], ["PD", 483], ["patients", 486], [".", 494], ["In", 496], ["the", 499], ["present", 503], ["study", 511], [",", 516], ["we", 518], ["investigated", 521], ["the", 534], ["influence", 538], ["of", 548], ["wild", 551], ["type", 556], ["(", 561], ["WT", 562], [")", 564], ["and", 566], ["A30P", 570], ["\u03b1", 575], ["-", 576], ["syn", 577], ["overexpression", 581], ["on", 596], ["neuroblastoma", 599], ["SH", 613], ["-", 615], ["SY5Y", 616], ["toxicity", 621], ["induced", 630], ["by", 638], ["the", 641], ["conditioned", 645], ["medium", 657], ["(", 664], ["CM", 665], [")", 667], ["from", 669], ["primary", 674], ["cultures", 682], ["of", 691], ["glia", 694], ["challenged", 699], ["with", 710], ["lipopolysaccharide", 715], ["(", 734], ["LPS", 735], [")", 738], ["from", 740], ["Escherichia", 745], ["coli", 757], [".", 761], ["We", 763], ["observed", 766], ["that", 775], ["SH", 780], ["-", 782], ["SY5Y", 783], ["cells", 788], ["transduced", 794], ["with", 805], ["\u03b1", 810], ["-", 811], ["syn", 812], ["(", 816], ["WT", 817], ["or", 820], ["A30P", 823], [")", 827], ["and", 829], ["treated", 833], ["with", 841], ["CM", 846], ["from", 849], ["LPS", 854], ["-", 857], ["activated", 858], ["glia", 868], ["cells", 873], ["show", 879], ["evidence", 884], ["of", 893], ["cell", 896], ["death", 901], [",", 906], ["which", 908], ["is", 914], ["not", 917], ["reverted", 921], ["by", 930], ["NF", 933], ["-", 935], ["\u03baB", 936], ["inhibition", 939], ["by", 950], ["sodium", 953], ["salicylate", 960], ["or", 971], ["by", 974], ["blockage", 977], ["of", 986], ["P50", 989], ["(", 993], ["NF", 994], ["-", 996], ["\u03baB", 997], ["subunit", 1000], [")", 1007], [".", 1008], ["Furthermore", 1010], [",", 1021], ["the", 1023], ["expression", 1027], ["of", 1038], ["A30P", 1041], ["\u03b1", 1046], ["-", 1047], ["syn", 1048], ["in", 1052], ["neuroblastoma", 1055], ["SH", 1069], ["-", 1071], ["SY5Y", 1072], ["decreases", 1077], ["the", 1087], ["cell", 1091], ["death", 1096], ["triggered", 1102], ["by", 1112], ["the", 1115], ["CM", 1119], ["of", 1122], ["activated", 1125], ["glia", 1135], ["versus", 1140], ["WT", 1147], ["\u03b1", 1150], ["-", 1151], ["syn", 1152], ["or", 1156], ["control", 1159], ["group", 1167], [".", 1172], ["This", 1174], ["effect", 1179], ["of", 1186], ["A30P", 1189], ["\u03b1", 1194], ["-", 1195], ["syn", 1196], ["may", 1200], ["be", 1204], ["due", 1207], ["to", 1211], ["the", 1214], ["low", 1218], ["MAPK42/44", 1222], ["phosphorylation", 1232], [".", 1247], ["This", 1249], ["finding", 1254], ["is", 1262], ["substantiated", 1265], ["by", 1279], ["MEK1", 1282], ["inhibition", 1287], ["by", 1298], ["PD98059", 1301], [",", 1308], ["decreasing", 1310], ["LDH", 1321], ["release", 1325], ["by", 1333], ["CM", 1336], ["in", 1339], ["SH", 1342], ["-", 1344], ["SY5Y", 1345], ["cells", 1350], [".", 1355], ["Our", 1357], ["results", 1361], ["suggest", 1369], ["that", 1377], ["SH", 1382], ["-", 1384], ["SY5Y", 1385], ["cells", 1390], ["transduced", 1396], ["with", 1407], ["\u03b1", 1412], ["-", 1413], ["syn", 1414], ["(", 1418], ["WT", 1419], ["or", 1422], ["A30P", 1425], [")", 1429], ["and", 1431], ["treated", 1435], ["with", 1443], ["CM", 1448], ["from", 1451], ["LPS", 1456], ["-", 1459], ["activated", 1460], ["glia", 1470], ["cells", 1475], ["show", 1481], ["cell", 1486], ["death", 1491], [",", 1496], ["which", 1498], ["is", 1504], ["not", 1507], ["reverted", 1511], ["by", 1520], ["NF", 1523], ["-", 1525], ["\u03baB", 1526], ["blockage", 1529], [".", 1537], ["Additionally", 1539], [",", 1551], ["the", 1553], ["expression", 1557], ["of", 1568], ["A30P", 1571], ["\u03b1", 1576], ["-", 1577], ["syn", 1578], ["on", 1582], ["neuroblastoma", 1585], ["SH", 1599], ["-", 1601], ["SY5Y", 1602], ["leads", 1607], ["to", 1613], ["decreased", 1616], ["cell", 1626], ["death", 1631], ["triggered", 1637], ["by", 1647], ["the", 1650], ["CM", 1654], ["of", 1657], ["activated", 1660], ["glia", 1670], [",", 1674], ["when", 1676], ["compared", 1681], ["to", 1690], ["WT", 1693], ["\u03b1", 1696], ["-", 1697], ["syn", 1698], ["or", 1702], ["control", 1705], ["group", 1713], [".", 1718], ["The", 1720], ["mechanism", 1724], ["underlying", 1734], ["this", 1745], ["process", 1750], ["remains", 1758], ["to", 1766], ["be", 1769], ["completely", 1772], ["elucidated", 1783], [",", 1793], ["but", 1795], ["the", 1799], ["present", 1803], ["data", 1811], ["suggest", 1816], ["that", 1824], ["MAPK42/44", 1829], ["phosphorylation", 1839], ["plays", 1855], ["an", 1861], ["important", 1864], ["role", 1874], ["in", 1879], ["this", 1882], ["process", 1887], [".", 1894], ["CRD42015020829", 1896], [".", 1910]]}
{"context": "Although peak finding in next-generation sequencing (NGS) datasets has been addressed extensively, there is no consensus on how to analyze and process biological replicates. Furthermore, most peak finders do not focus on accurate determination of enrichment site widths and are not widely applicable to different types of datasets. We developed JAMM (Joint Analysis of NGS replicates via Mixture Model clustering): a peak finder that can integrate information from biological replicates, determine enrichment site widths accurately and resolve neighboring narrow peaks. JAMM is a universal peak finder that is applicable to different types of datasets. We show that JAMM is among the best performing peak finders in terms of site detection accuracy and in terms of accurate determination of enrichment sites widths. In addition, JAMM's replicate integration improves peak spatial resolution, sorting and peak finding accuracy. JAMM is available for free and can run on Linux machines through the command line: http://code.google.com/p/jamm-peak-finder.", "qas": [{"question": "Which peak calling algorithm employs mixture model clustering under the hood?", "answers": ["JAMM"], "qid": "34f812a7bd0645b481c7269f56ee725d", "question_tokens": [["Which", 0], ["peak", 6], ["calling", 11], ["algorithm", 19], ["employs", 29], ["mixture", 37], ["model", 45], ["clustering", 51], ["under", 62], ["the", 68], ["hood", 72], ["?", 76]], "detected_answers": [{"text": "JAMM", "token_spans": [[139, 139], [93, 93], [154, 154], [58, 58], [111, 111]], "char_spans": [[829, 832], [570, 573], [927, 930], [345, 348], [666, 669]]}]}], "context_tokens": [["Although", 0], ["peak", 9], ["finding", 14], ["in", 22], ["next", 25], ["-", 29], ["generation", 30], ["sequencing", 41], ["(", 52], ["NGS", 53], [")", 56], ["datasets", 58], ["has", 67], ["been", 71], ["addressed", 76], ["extensively", 86], [",", 97], ["there", 99], ["is", 105], ["no", 108], ["consensus", 111], ["on", 121], ["how", 124], ["to", 128], ["analyze", 131], ["and", 139], ["process", 143], ["biological", 151], ["replicates", 162], [".", 172], ["Furthermore", 174], [",", 185], ["most", 187], ["peak", 192], ["finders", 197], ["do", 205], ["not", 208], ["focus", 212], ["on", 218], ["accurate", 221], ["determination", 230], ["of", 244], ["enrichment", 247], ["site", 258], ["widths", 263], ["and", 270], ["are", 274], ["not", 278], ["widely", 282], ["applicable", 289], ["to", 300], ["different", 303], ["types", 313], ["of", 319], ["datasets", 322], [".", 330], ["We", 332], ["developed", 335], ["JAMM", 345], ["(", 350], ["Joint", 351], ["Analysis", 357], ["of", 366], ["NGS", 369], ["replicates", 373], ["via", 384], ["Mixture", 388], ["Model", 396], ["clustering", 402], [")", 412], [":", 413], ["a", 415], ["peak", 417], ["finder", 422], ["that", 429], ["can", 434], ["integrate", 438], ["information", 448], ["from", 460], ["biological", 465], ["replicates", 476], [",", 486], ["determine", 488], ["enrichment", 498], ["site", 509], ["widths", 514], ["accurately", 521], ["and", 532], ["resolve", 536], ["neighboring", 544], ["narrow", 556], ["peaks", 563], [".", 568], ["JAMM", 570], ["is", 575], ["a", 578], ["universal", 580], ["peak", 590], ["finder", 595], ["that", 602], ["is", 607], ["applicable", 610], ["to", 621], ["different", 624], ["types", 634], ["of", 640], ["datasets", 643], [".", 651], ["We", 653], ["show", 656], ["that", 661], ["JAMM", 666], ["is", 671], ["among", 674], ["the", 680], ["best", 684], ["performing", 689], ["peak", 700], ["finders", 705], ["in", 713], ["terms", 716], ["of", 722], ["site", 725], ["detection", 730], ["accuracy", 740], ["and", 749], ["in", 753], ["terms", 756], ["of", 762], ["accurate", 765], ["determination", 774], ["of", 788], ["enrichment", 791], ["sites", 802], ["widths", 808], [".", 814], ["In", 816], ["addition", 819], [",", 827], ["JAMM", 829], ["'s", 833], ["replicate", 836], ["integration", 846], ["improves", 858], ["peak", 867], ["spatial", 872], ["resolution", 880], [",", 890], ["sorting", 892], ["and", 900], ["peak", 904], ["finding", 909], ["accuracy", 917], [".", 925], ["JAMM", 927], ["is", 932], ["available", 935], ["for", 945], ["free", 949], ["and", 954], ["can", 958], ["run", 962], ["on", 966], ["Linux", 969], ["machines", 975], ["through", 984], ["the", 992], ["command", 996], ["line", 1004], [":", 1008], ["http://code.google.com/p/jamm-peak-finder", 1010], [".", 1051]]}
{"context": "Neurological abnormalities associated with spiculated, \"acanthocytic\" red cells in blood have been described as neuroacanthocytosis. This is a heterogeneous group of conditions that can be clearly subdivided on the basis of recent genetic findings. The McLeod Syndrome, one of the core neuroacanthocytosis syndromes, is a rare X-linked disorder caused by mutations of the XK gene, an X-chromosomal gene of unknown function characterized by haemopoietic abnormalities and late-onset neurological and muscular defects. We report two Chilean brothers with the McLeod phenotype who showed important psychiatric features. The diagnosis may be elusive if the presence of acanthocytosis is not properly studied. We describe a method which allowed the diagnosis that unmasked acanthocytosis. Otherwise the condition could have remained undiagnosed as it had been for decades in this family. This syndrome must be considered when assessing a familial movement disorder, specially affecting males with relevant psychiatric features. A reliable test for acanthocytosis assessment is available.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c79bc1f8f85548358708cf9eb729f140", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[62, 62]], "char_spans": [[372, 373]]}]}], "context_tokens": [["Neurological", 0], ["abnormalities", 13], ["associated", 27], ["with", 38], ["spiculated", 43], [",", 53], ["\"", 55], ["acanthocytic", 56], ["\"", 68], ["red", 70], ["cells", 74], ["in", 80], ["blood", 83], ["have", 89], ["been", 94], ["described", 99], ["as", 109], ["neuroacanthocytosis", 112], [".", 131], ["This", 133], ["is", 138], ["a", 141], ["heterogeneous", 143], ["group", 157], ["of", 163], ["conditions", 166], ["that", 177], ["can", 182], ["be", 186], ["clearly", 189], ["subdivided", 197], ["on", 208], ["the", 211], ["basis", 215], ["of", 221], ["recent", 224], ["genetic", 231], ["findings", 239], [".", 247], ["The", 249], ["McLeod", 253], ["Syndrome", 260], [",", 268], ["one", 270], ["of", 274], ["the", 277], ["core", 281], ["neuroacanthocytosis", 286], ["syndromes", 306], [",", 315], ["is", 317], ["a", 320], ["rare", 322], ["X", 327], ["-", 328], ["linked", 329], ["disorder", 336], ["caused", 345], ["by", 352], ["mutations", 355], ["of", 365], ["the", 368], ["XK", 372], ["gene", 375], [",", 379], ["an", 381], ["X", 384], ["-", 385], ["chromosomal", 386], ["gene", 398], ["of", 403], ["unknown", 406], ["function", 414], ["characterized", 423], ["by", 437], ["haemopoietic", 440], ["abnormalities", 453], ["and", 467], ["late", 471], ["-", 475], ["onset", 476], ["neurological", 482], ["and", 495], ["muscular", 499], ["defects", 508], [".", 515], ["We", 517], ["report", 520], ["two", 527], ["Chilean", 531], ["brothers", 539], ["with", 548], ["the", 553], ["McLeod", 557], ["phenotype", 564], ["who", 574], ["showed", 578], ["important", 585], ["psychiatric", 595], ["features", 607], [".", 615], ["The", 617], ["diagnosis", 621], ["may", 631], ["be", 635], ["elusive", 638], ["if", 646], ["the", 649], ["presence", 653], ["of", 662], ["acanthocytosis", 665], ["is", 680], ["not", 683], ["properly", 687], ["studied", 696], [".", 703], ["We", 705], ["describe", 708], ["a", 717], ["method", 719], ["which", 726], ["allowed", 732], ["the", 740], ["diagnosis", 744], ["that", 754], ["unmasked", 759], ["acanthocytosis", 768], [".", 782], ["Otherwise", 784], ["the", 794], ["condition", 798], ["could", 808], ["have", 814], ["remained", 819], ["undiagnosed", 828], ["as", 840], ["it", 843], ["had", 846], ["been", 850], ["for", 855], ["decades", 859], ["in", 867], ["this", 870], ["family", 875], [".", 881], ["This", 883], ["syndrome", 888], ["must", 897], ["be", 902], ["considered", 905], ["when", 916], ["assessing", 921], ["a", 931], ["familial", 933], ["movement", 942], ["disorder", 951], [",", 959], ["specially", 961], ["affecting", 971], ["males", 981], ["with", 987], ["relevant", 992], ["psychiatric", 1001], ["features", 1013], [".", 1021], ["A", 1023], ["reliable", 1025], ["test", 1034], ["for", 1039], ["acanthocytosis", 1043], ["assessment", 1058], ["is", 1069], ["available", 1072], [".", 1081]]}
{"context": "Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor. In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21). We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors (P = 0.004). Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clinically relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors (P = 0.003). Because most mutation-positive tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime (\"never smokers\"), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers. Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers (P = 0.0001). Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concentrations of drug. Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "29f2855a4f1e49cabf0d468c74465cb7", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[12, 19]], "char_spans": [[60, 103]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["the", 21], ["tyrosine", 25], ["kinase", 34], ["(", 41], ["TK", 42], [")", 44], ["domain", 46], ["of", 53], ["the", 56], ["epidermal", 60], ["growth", 70], ["factor", 77], ["receptor", 84], ["(", 93], ["EGFR", 94], [")", 98], ["gene", 100], ["are", 105], ["reportedly", 109], ["associated", 120], ["with", 131], ["sensitivity", 136], ["of", 148], ["lung", 151], ["cancers", 156], ["to", 164], ["gefitinib", 167], ["(", 177], ["Iressa", 178], [")", 184], [",", 185], ["kinase", 187], ["inhibitor", 194], [".", 203], ["In", 205], ["-", 207], ["frame", 208], ["deletions", 214], ["occur", 224], ["in", 230], ["exon", 233], ["19", 238], [",", 240], ["whereas", 242], ["point", 250], ["mutations", 256], ["occur", 266], ["frequently", 272], ["in", 283], ["codon", 286], ["858", 292], ["(", 296], ["exon", 297], ["21", 302], [")", 304], [".", 305], ["We", 307], ["found", 310], ["from", 316], ["sequencing", 321], ["the", 332], ["EGFR", 336], ["TK", 341], ["domain", 344], ["that", 351], ["7", 356], ["of", 358], ["10", 361], ["gefitinib", 364], ["-", 373], ["sensitive", 374], ["tumors", 384], ["had", 391], ["similar", 395], ["types", 403], ["of", 409], ["alterations", 412], [";", 423], ["no", 425], ["mutations", 428], ["were", 438], ["found", 443], ["in", 449], ["eight", 452], ["gefitinib", 458], ["-", 467], ["refractory", 468], ["tumors", 479], ["(", 486], ["P", 487], ["=", 489], ["0.004", 491], [")", 496], [".", 497], ["Five", 499], ["of", 504], ["seven", 507], ["tumors", 513], ["sensitive", 520], ["to", 530], ["erlotinib", 533], ["(", 543], ["Tarceva", 544], [")", 551], [",", 552], ["a", 554], ["related", 556], ["kinase", 564], ["inhibitor", 571], ["for", 581], ["which", 585], ["the", 591], ["clinically", 595], ["relevant", 606], ["target", 615], ["is", 622], ["undocumented", 625], [",", 637], ["had", 639], ["analogous", 643], ["somatic", 653], ["mutations", 661], [",", 670], ["as", 672], ["opposed", 675], ["to", 683], ["none", 686], ["of", 691], ["10", 694], ["erlotinib", 697], ["-", 706], ["refractory", 707], ["tumors", 718], ["(", 725], ["P", 726], ["=", 728], ["0.003", 730], [")", 735], [".", 736], ["Because", 738], ["most", 746], ["mutation", 751], ["-", 759], ["positive", 760], ["tumors", 769], ["were", 776], ["adenocarcinomas", 781], ["from", 797], ["patients", 802], ["who", 811], ["smoked", 815], ["<", 822], ["100", 823], ["cigarettes", 827], ["in", 838], ["a", 841], ["lifetime", 843], ["(", 852], ["\"", 853], ["never", 854], ["smokers", 860], ["\"", 867], [")", 868], [",", 869], ["we", 871], ["screened", 874], ["EGFR", 883], ["exons", 888], ["2", 894], ["-", 895], ["28", 896], ["in", 899], ["15", 902], ["adenocarcinomas", 905], ["resected", 921], ["from", 930], ["untreated", 935], ["never", 945], ["smokers", 951], [".", 958], ["Seven", 960], ["tumors", 966], ["had", 973], ["TK", 977], ["domain", 980], ["mutations", 987], [",", 996], ["in", 998], ["contrast", 1001], ["to", 1010], ["4", 1013], ["of", 1015], ["81", 1018], ["non", 1021], ["-", 1024], ["small", 1025], ["cell", 1031], ["lung", 1036], ["cancers", 1041], ["resected", 1049], ["from", 1058], ["untreated", 1063], ["former", 1073], ["or", 1080], ["current", 1083], ["smokers", 1091], ["(", 1099], ["P", 1100], ["=", 1102], ["0.0001", 1104], [")", 1110], [".", 1111], ["Immunoblotting", 1113], ["of", 1128], ["lysates", 1131], ["from", 1139], ["cells", 1144], ["transiently", 1150], ["transfected", 1162], ["with", 1174], ["various", 1179], ["EGFR", 1187], ["constructs", 1192], ["demonstrated", 1203], ["that", 1216], [",", 1220], ["compared", 1222], ["to", 1231], ["wild", 1234], ["-", 1238], ["type", 1239], ["protein", 1244], [",", 1251], ["an", 1253], ["exon", 1256], ["19", 1261], ["deletion", 1264], ["mutant", 1273], ["induced", 1280], ["diminished", 1288], ["levels", 1299], ["of", 1306], ["phosphotyrosine", 1309], [",", 1324], ["whereas", 1326], ["the", 1334], ["phosphorylation", 1338], ["at", 1354], ["tyrosine", 1357], ["1092", 1366], ["of", 1371], ["an", 1374], ["exon", 1377], ["21", 1382], ["point", 1385], ["mutant", 1391], ["was", 1398], ["inhibited", 1402], ["at", 1412], ["10-fold", 1415], ["lower", 1423], ["concentrations", 1429], ["of", 1444], ["drug", 1447], [".", 1451], ["Collectively", 1453], [",", 1465], ["these", 1467], ["data", 1473], ["show", 1478], ["that", 1483], ["adenocarcinomas", 1488], ["from", 1504], ["never", 1509], ["smokers", 1515], ["comprise", 1523], ["a", 1532], ["distinct", 1534], ["subset", 1543], ["of", 1550], ["lung", 1553], ["cancers", 1558], [",", 1565], ["frequently", 1567], ["containing", 1578], ["mutations", 1589], ["within", 1599], ["the", 1606], ["TK", 1610], ["domain", 1613], ["of", 1620], ["EGFR", 1623], ["that", 1628], ["are", 1633], ["associated", 1637], ["with", 1648], ["gefitinib", 1653], ["and", 1663], ["erlotinib", 1667], ["sensitivity", 1677], [".", 1688]]}
{"context": "CLIP-Seq protocols such as PAR-CLIP, HITS-CLIP or iCLIP allow a genome-wide analysis of protein-RNA interactions. For the processing of the resulting short read data, various tools are utilized. Some of these tools were specifically developed for CLIP-Seq data, whereas others were designed for the analysis of RNA-Seq data. To this date, however, it has not been assessed which of the available tools are most appropriate for the analysis of CLIP-Seq data. This is because an experimental gold standard dataset on which methods can be accessed and compared, is still not available. To address this lack of a gold-standard dataset, we here present Cseq-Simulator, a simulator for PAR-CLIP, HITS-CLIP and iCLIP-data. This simulator can be applied to generate realistic datasets that can serve as surrogates for experimental gold standard dataset. In this work, we also show how Cseq-Simulator can be used to perform a comparison of steps of typical CLIP-Seq analysis pipelines, such as the read alignment or the peak calling. These comparisons show which tools are useful in different settings and also allow identifying pitfalls in the data analysis.", "qas": [{"question": "Which data simulator is available for CLIP-SEQ experiments?", "answers": ["Cseq-Simulator"], "qid": "eb43bbf0c4bb484dba710614100c1204", "question_tokens": [["Which", 0], ["data", 6], ["simulator", 11], ["is", 21], ["available", 24], ["for", 34], ["CLIP", 38], ["-", 42], ["SEQ", 43], ["experiments", 47], ["?", 58]], "detected_answers": [{"text": "Cseq-Simulator", "token_spans": [[132, 134], [179, 181]], "char_spans": [[648, 661], [877, 890]]}]}], "context_tokens": [["CLIP", 0], ["-", 4], ["Seq", 5], ["protocols", 9], ["such", 19], ["as", 24], ["PAR", 27], ["-", 30], ["CLIP", 31], [",", 35], ["HITS", 37], ["-", 41], ["CLIP", 42], ["or", 47], ["iCLIP", 50], ["allow", 56], ["a", 62], ["genome", 64], ["-", 70], ["wide", 71], ["analysis", 76], ["of", 85], ["protein", 88], ["-", 95], ["RNA", 96], ["interactions", 100], [".", 112], ["For", 114], ["the", 118], ["processing", 122], ["of", 133], ["the", 136], ["resulting", 140], ["short", 150], ["read", 156], ["data", 161], [",", 165], ["various", 167], ["tools", 175], ["are", 181], ["utilized", 185], [".", 193], ["Some", 195], ["of", 200], ["these", 203], ["tools", 209], ["were", 215], ["specifically", 220], ["developed", 233], ["for", 243], ["CLIP", 247], ["-", 251], ["Seq", 252], ["data", 256], [",", 260], ["whereas", 262], ["others", 270], ["were", 277], ["designed", 282], ["for", 291], ["the", 295], ["analysis", 299], ["of", 308], ["RNA", 311], ["-", 314], ["Seq", 315], ["data", 319], [".", 323], ["To", 325], ["this", 328], ["date", 333], [",", 337], ["however", 339], [",", 346], ["it", 348], ["has", 351], ["not", 355], ["been", 359], ["assessed", 364], ["which", 373], ["of", 379], ["the", 382], ["available", 386], ["tools", 396], ["are", 402], ["most", 406], ["appropriate", 411], ["for", 423], ["the", 427], ["analysis", 431], ["of", 440], ["CLIP", 443], ["-", 447], ["Seq", 448], ["data", 452], [".", 456], ["This", 458], ["is", 463], ["because", 466], ["an", 474], ["experimental", 477], ["gold", 490], ["standard", 495], ["dataset", 504], ["on", 512], ["which", 515], ["methods", 521], ["can", 529], ["be", 533], ["accessed", 536], ["and", 545], ["compared", 549], [",", 557], ["is", 559], ["still", 562], ["not", 568], ["available", 572], [".", 581], ["To", 583], ["address", 586], ["this", 594], ["lack", 599], ["of", 604], ["a", 607], ["gold", 609], ["-", 613], ["standard", 614], ["dataset", 623], [",", 630], ["we", 632], ["here", 635], ["present", 640], ["Cseq", 648], ["-", 652], ["Simulator", 653], [",", 662], ["a", 664], ["simulator", 666], ["for", 676], ["PAR", 680], ["-", 683], ["CLIP", 684], [",", 688], ["HITS", 690], ["-", 694], ["CLIP", 695], ["and", 700], ["iCLIP", 704], ["-", 709], ["data", 710], [".", 714], ["This", 716], ["simulator", 721], ["can", 731], ["be", 735], ["applied", 738], ["to", 746], ["generate", 749], ["realistic", 758], ["datasets", 768], ["that", 777], ["can", 782], ["serve", 786], ["as", 792], ["surrogates", 795], ["for", 806], ["experimental", 810], ["gold", 823], ["standard", 828], ["dataset", 837], [".", 844], ["In", 846], ["this", 849], ["work", 854], [",", 858], ["we", 860], ["also", 863], ["show", 868], ["how", 873], ["Cseq", 877], ["-", 881], ["Simulator", 882], ["can", 892], ["be", 896], ["used", 899], ["to", 904], ["perform", 907], ["a", 915], ["comparison", 917], ["of", 928], ["steps", 931], ["of", 937], ["typical", 940], ["CLIP", 948], ["-", 952], ["Seq", 953], ["analysis", 957], ["pipelines", 966], [",", 975], ["such", 977], ["as", 982], ["the", 985], ["read", 989], ["alignment", 994], ["or", 1004], ["the", 1007], ["peak", 1011], ["calling", 1016], [".", 1023], ["These", 1025], ["comparisons", 1031], ["show", 1043], ["which", 1048], ["tools", 1054], ["are", 1060], ["useful", 1064], ["in", 1071], ["different", 1074], ["settings", 1084], ["and", 1093], ["also", 1097], ["allow", 1102], ["identifying", 1108], ["pitfalls", 1120], ["in", 1129], ["the", 1132], ["data", 1136], ["analysis", 1141], [".", 1149]]}
{"context": "To investigate whether body mass index (BMI), as a proxy for body fat, influences rheumatoid arthritis (RA) disease activity in a gender-specific manner. Consecutive patients with RA were enrolled from 25 countries into the QUEST-RA program between 2005 and 2008. Clinical and demographic data were collected by treating rheumatologists and by patient self-report. Distributions of Disease Activity Scores (DAS28), BMI, age, and disease duration were assessed for each country and for the entire dataset; mean values between genders were compared using Student's t-tests. An association between BMI and DAS28 was investigated using linear regression, adjusting for age, disease duration and country. A total of 5,161 RA patients (4,082 women and 1,079 men) were included in the analyses. Overall, women were younger, had longer disease duration, and higher DAS28 scores than men, but BMI was similar between genders. The mean DAS28 scores increased with increasing BMI from normal to overweight and obese, among women, whereas the opposite trend was observed among men. Regression results showed BMI (continuous or categorical) to be associated with DAS28. Compared to the normal BMI range, being obese was associated with a larger difference in mean DAS28 (0.23, 95% CI: 0.11, 0.34) than being overweight (0.12, 95% CI: 0.03, 0.21); being underweight was not associated with disease activity. These associations were more pronounced among women, and were not explained by any single component of the DAS28. BMI appears to be associated with RA disease activity in women, but not in men.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "caa2671c22184059b24fc1b2ad609ea4", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[189, 189], [298, 298], [150, 150], [137, 137], [274, 274]], "char_spans": [[1012, 1016], [1565, 1569], [797, 801], [736, 740], [1440, 1444]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["body", 23], ["mass", 28], ["index", 33], ["(", 39], ["BMI", 40], [")", 43], [",", 44], ["as", 46], ["a", 49], ["proxy", 51], ["for", 57], ["body", 61], ["fat", 66], [",", 69], ["influences", 71], ["rheumatoid", 82], ["arthritis", 93], ["(", 103], ["RA", 104], [")", 106], ["disease", 108], ["activity", 116], ["in", 125], ["a", 128], ["gender", 130], ["-", 136], ["specific", 137], ["manner", 146], [".", 152], ["Consecutive", 154], ["patients", 166], ["with", 175], ["RA", 180], ["were", 183], ["enrolled", 188], ["from", 197], ["25", 202], ["countries", 205], ["into", 215], ["the", 220], ["QUEST", 224], ["-", 229], ["RA", 230], ["program", 233], ["between", 241], ["2005", 249], ["and", 254], ["2008", 258], [".", 262], ["Clinical", 264], ["and", 273], ["demographic", 277], ["data", 289], ["were", 294], ["collected", 299], ["by", 309], ["treating", 312], ["rheumatologists", 321], ["and", 337], ["by", 341], ["patient", 344], ["self", 352], ["-", 356], ["report", 357], [".", 363], ["Distributions", 365], ["of", 379], ["Disease", 382], ["Activity", 390], ["Scores", 399], ["(", 406], ["DAS28", 407], [")", 412], [",", 413], ["BMI", 415], [",", 418], ["age", 420], [",", 423], ["and", 425], ["disease", 429], ["duration", 437], ["were", 446], ["assessed", 451], ["for", 460], ["each", 464], ["country", 469], ["and", 477], ["for", 481], ["the", 485], ["entire", 489], ["dataset", 496], [";", 503], ["mean", 505], ["values", 510], ["between", 517], ["genders", 525], ["were", 533], ["compared", 538], ["using", 547], ["Student", 553], ["'s", 560], ["t", 563], ["-", 564], ["tests", 565], [".", 570], ["An", 572], ["association", 575], ["between", 587], ["BMI", 595], ["and", 599], ["DAS28", 603], ["was", 609], ["investigated", 613], ["using", 626], ["linear", 632], ["regression", 639], [",", 649], ["adjusting", 651], ["for", 661], ["age", 665], [",", 668], ["disease", 670], ["duration", 678], ["and", 687], ["country", 691], [".", 698], ["A", 700], ["total", 702], ["of", 708], ["5,161", 711], ["RA", 717], ["patients", 720], ["(", 729], ["4,082", 730], ["women", 736], ["and", 742], ["1,079", 746], ["men", 752], [")", 755], ["were", 757], ["included", 762], ["in", 771], ["the", 774], ["analyses", 778], [".", 786], ["Overall", 788], [",", 795], ["women", 797], ["were", 803], ["younger", 808], [",", 815], ["had", 817], ["longer", 821], ["disease", 828], ["duration", 836], [",", 844], ["and", 846], ["higher", 850], ["DAS28", 857], ["scores", 863], ["than", 870], ["men", 875], [",", 878], ["but", 880], ["BMI", 884], ["was", 888], ["similar", 892], ["between", 900], ["genders", 908], [".", 915], ["The", 917], ["mean", 921], ["DAS28", 926], ["scores", 932], ["increased", 939], ["with", 949], ["increasing", 954], ["BMI", 965], ["from", 969], ["normal", 974], ["to", 981], ["overweight", 984], ["and", 995], ["obese", 999], [",", 1004], ["among", 1006], ["women", 1012], [",", 1017], ["whereas", 1019], ["the", 1027], ["opposite", 1031], ["trend", 1040], ["was", 1046], ["observed", 1050], ["among", 1059], ["men", 1065], [".", 1068], ["Regression", 1070], ["results", 1081], ["showed", 1089], ["BMI", 1096], ["(", 1100], ["continuous", 1101], ["or", 1112], ["categorical", 1115], [")", 1126], ["to", 1128], ["be", 1131], ["associated", 1134], ["with", 1145], ["DAS28", 1150], [".", 1155], ["Compared", 1157], ["to", 1166], ["the", 1169], ["normal", 1173], ["BMI", 1180], ["range", 1184], [",", 1189], ["being", 1191], ["obese", 1197], ["was", 1203], ["associated", 1207], ["with", 1218], ["a", 1223], ["larger", 1225], ["difference", 1232], ["in", 1243], ["mean", 1246], ["DAS28", 1251], ["(", 1257], ["0.23", 1258], [",", 1262], ["95", 1264], ["%", 1266], ["CI", 1268], [":", 1270], ["0.11", 1272], [",", 1276], ["0.34", 1278], [")", 1282], ["than", 1284], ["being", 1289], ["overweight", 1295], ["(", 1306], ["0.12", 1307], [",", 1311], ["95", 1313], ["%", 1315], ["CI", 1317], [":", 1319], ["0.03", 1321], [",", 1325], ["0.21", 1327], [")", 1331], [";", 1332], ["being", 1334], ["underweight", 1340], ["was", 1352], ["not", 1356], ["associated", 1360], ["with", 1371], ["disease", 1376], ["activity", 1384], [".", 1392], ["These", 1394], ["associations", 1400], ["were", 1413], ["more", 1418], ["pronounced", 1423], ["among", 1434], ["women", 1440], [",", 1445], ["and", 1447], ["were", 1451], ["not", 1456], ["explained", 1460], ["by", 1470], ["any", 1473], ["single", 1477], ["component", 1484], ["of", 1494], ["the", 1497], ["DAS28", 1501], [".", 1506], ["BMI", 1508], ["appears", 1512], ["to", 1520], ["be", 1523], ["associated", 1526], ["with", 1537], ["RA", 1542], ["disease", 1545], ["activity", 1553], ["in", 1562], ["women", 1565], [",", 1570], ["but", 1572], ["not", 1576], ["in", 1580], ["men", 1583], [".", 1586]]}
{"context": "Imatinib mesylate (STI 571; Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is an orally available tyrosine kinase inhibitor that targets a constitutively activated BCR-ABL tyrosine kinase with additional inhibitory effects on platelet derived growth factor (PDGF) receptors alpha and beta, and KIT. It has revolutionized the treatment of adult and pediatric patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML) and is also FDA-approved for KIT-positive advanced gastrointestinal tumor (GIST) and dermatofibrosarcoma protuberans. A wide spectrum of dermatologic toxicities has been associated with this agent, among which a maculopapular rash is the most common event. In addition, a variety of pigmentary abnormalities of the skin and mucosal surfaces have been reported. Hypopigmentation is a well-recognized adverse effect. In contrast, paradoxical hyperpigmentation has only rarely been documented. In this case report we describe imatinib-induced cutaneous hyperpigmentation and graying of hair occurring in the same patient with dermatofibrosarcoma protuberans treated with imatinib.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "631900f5ead84eacaf274c45701f595a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[27, 29]], "char_spans": [[172, 178]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["STI", 19], ["571", 23], [";", 26], ["Gleevec", 28], [";", 35], ["Novartis", 37], ["Pharmaceuticals", 46], [",", 61], ["Basel", 63], [",", 68], ["Switzerland", 70], [")", 81], ["is", 83], ["an", 86], ["orally", 89], ["available", 96], ["tyrosine", 106], ["kinase", 115], ["inhibitor", 122], ["that", 132], ["targets", 137], ["a", 145], ["constitutively", 147], ["activated", 162], ["BCR", 172], ["-", 175], ["ABL", 176], ["tyrosine", 180], ["kinase", 189], ["with", 196], ["additional", 201], ["inhibitory", 212], ["effects", 223], ["on", 231], ["platelet", 234], ["derived", 243], ["growth", 251], ["factor", 258], ["(", 265], ["PDGF", 266], [")", 270], ["receptors", 272], ["alpha", 282], ["and", 288], ["beta", 292], [",", 296], ["and", 298], ["KIT", 302], [".", 305], ["It", 307], ["has", 310], ["revolutionized", 314], ["the", 329], ["treatment", 333], ["of", 343], ["adult", 346], ["and", 352], ["pediatric", 356], ["patients", 366], ["with", 375], ["Philadelphia", 380], ["chromosome", 393], ["positive", 404], ["chronic", 413], ["myelogenous", 421], ["leukemia", 433], ["(", 442], ["CML", 443], [")", 446], ["and", 448], ["is", 452], ["also", 455], ["FDA", 460], ["-", 463], ["approved", 464], ["for", 473], ["KIT", 477], ["-", 480], ["positive", 481], ["advanced", 490], ["gastrointestinal", 499], ["tumor", 516], ["(", 522], ["GIST", 523], [")", 527], ["and", 529], ["dermatofibrosarcoma", 533], ["protuberans", 553], [".", 564], ["A", 566], ["wide", 568], ["spectrum", 573], ["of", 582], ["dermatologic", 585], ["toxicities", 598], ["has", 609], ["been", 613], ["associated", 618], ["with", 629], ["this", 634], ["agent", 639], [",", 644], ["among", 646], ["which", 652], ["a", 658], ["maculopapular", 660], ["rash", 674], ["is", 679], ["the", 682], ["most", 686], ["common", 691], ["event", 698], [".", 703], ["In", 705], ["addition", 708], [",", 716], ["a", 718], ["variety", 720], ["of", 728], ["pigmentary", 731], ["abnormalities", 742], ["of", 756], ["the", 759], ["skin", 763], ["and", 768], ["mucosal", 772], ["surfaces", 780], ["have", 789], ["been", 794], ["reported", 799], [".", 807], ["Hypopigmentation", 809], ["is", 826], ["a", 829], ["well", 831], ["-", 835], ["recognized", 836], ["adverse", 847], ["effect", 855], [".", 861], ["In", 863], ["contrast", 866], [",", 874], ["paradoxical", 876], ["hyperpigmentation", 888], ["has", 906], ["only", 910], ["rarely", 915], ["been", 922], ["documented", 927], [".", 937], ["In", 939], ["this", 942], ["case", 947], ["report", 952], ["we", 959], ["describe", 962], ["imatinib", 971], ["-", 979], ["induced", 980], ["cutaneous", 988], ["hyperpigmentation", 998], ["and", 1016], ["graying", 1020], ["of", 1028], ["hair", 1031], ["occurring", 1036], ["in", 1046], ["the", 1049], ["same", 1053], ["patient", 1058], ["with", 1066], ["dermatofibrosarcoma", 1071], ["protuberans", 1091], ["treated", 1103], ["with", 1111], ["imatinib", 1116], [".", 1124]]}
{"context": "Chronic myeloid leukemia (CML) is the first human malignancy for which the promise of targeted therapy has come true. CML is invariably associated with a specific genetic lesion--the t(9;22) chromosomal translocation. As a consequence of this translocation, a BCR-ABL fusion gene is formed on the 22q- derivative (traditionally known as the Philadelphia chromosome) and the deregulated tyrosine kinase activity of the protein encoded by this gene has been shown to be both necessary and sufficient for initiation and maintenance of the disease. Imatinib mesylate, an orally available tyrosine kinase inhibitor that targets Bcr-Abl, entered clinical evaluation in 1998. Its efficacy surpassed almost everyone's predictions, and the observation of high response rates and favorable toxicity profile associated with imatinib therapy led to its approval as first-line treatment for all newly diagnosed CML patients over an exceptionally short period of time. The 6-year results of the Phase III trial have recently been reported and confirm durability of responses and declining incidence of adverse events over time, although, at present, occurrence of unexpected side effects in the long term cannot be excluded. Although imatinib does not 'cure' CML and has to be administered chronically to patients, it has revolutionized both outcome and quality of life of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "b84adc8ad62e42e3b5cd84477d1d0750", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[46, 48], [106, 108]], "char_spans": [[260, 266], [623, 629]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["the", 34], ["first", 38], ["human", 44], ["malignancy", 50], ["for", 61], ["which", 65], ["the", 71], ["promise", 75], ["of", 83], ["targeted", 86], ["therapy", 95], ["has", 103], ["come", 107], ["true", 112], [".", 116], ["CML", 118], ["is", 122], ["invariably", 125], ["associated", 136], ["with", 147], ["a", 152], ["specific", 154], ["genetic", 163], ["lesion", 171], ["--", 177], ["the", 179], ["t(9;22", 183], [")", 189], ["chromosomal", 191], ["translocation", 203], [".", 216], ["As", 218], ["a", 221], ["consequence", 223], ["of", 235], ["this", 238], ["translocation", 243], [",", 256], ["a", 258], ["BCR", 260], ["-", 263], ["ABL", 264], ["fusion", 268], ["gene", 275], ["is", 280], ["formed", 283], ["on", 290], ["the", 293], ["22q-", 297], ["derivative", 302], ["(", 313], ["traditionally", 314], ["known", 328], ["as", 334], ["the", 337], ["Philadelphia", 341], ["chromosome", 354], [")", 364], ["and", 366], ["the", 370], ["deregulated", 374], ["tyrosine", 386], ["kinase", 395], ["activity", 402], ["of", 411], ["the", 414], ["protein", 418], ["encoded", 426], ["by", 434], ["this", 437], ["gene", 442], ["has", 447], ["been", 451], ["shown", 456], ["to", 462], ["be", 465], ["both", 468], ["necessary", 473], ["and", 483], ["sufficient", 487], ["for", 498], ["initiation", 502], ["and", 513], ["maintenance", 517], ["of", 529], ["the", 532], ["disease", 536], [".", 543], ["Imatinib", 545], ["mesylate", 554], [",", 562], ["an", 564], ["orally", 567], ["available", 574], ["tyrosine", 584], ["kinase", 593], ["inhibitor", 600], ["that", 610], ["targets", 615], ["Bcr", 623], ["-", 626], ["Abl", 627], [",", 630], ["entered", 632], ["clinical", 640], ["evaluation", 649], ["in", 660], ["1998", 663], [".", 667], ["Its", 669], ["efficacy", 673], ["surpassed", 682], ["almost", 692], ["everyone", 699], ["'s", 707], ["predictions", 710], [",", 721], ["and", 723], ["the", 727], ["observation", 731], ["of", 743], ["high", 746], ["response", 751], ["rates", 760], ["and", 766], ["favorable", 770], ["toxicity", 780], ["profile", 789], ["associated", 797], ["with", 808], ["imatinib", 813], ["therapy", 822], ["led", 830], ["to", 834], ["its", 837], ["approval", 841], ["as", 850], ["first", 853], ["-", 858], ["line", 859], ["treatment", 864], ["for", 874], ["all", 878], ["newly", 882], ["diagnosed", 888], ["CML", 898], ["patients", 902], ["over", 911], ["an", 916], ["exceptionally", 919], ["short", 933], ["period", 939], ["of", 946], ["time", 949], [".", 953], ["The", 955], ["6-year", 959], ["results", 966], ["of", 974], ["the", 977], ["Phase", 981], ["III", 987], ["trial", 991], ["have", 997], ["recently", 1002], ["been", 1011], ["reported", 1016], ["and", 1025], ["confirm", 1029], ["durability", 1037], ["of", 1048], ["responses", 1051], ["and", 1061], ["declining", 1065], ["incidence", 1075], ["of", 1085], ["adverse", 1088], ["events", 1096], ["over", 1103], ["time", 1108], [",", 1112], ["although", 1114], [",", 1122], ["at", 1124], ["present", 1127], [",", 1134], ["occurrence", 1136], ["of", 1147], ["unexpected", 1150], ["side", 1161], ["effects", 1166], ["in", 1174], ["the", 1177], ["long", 1181], ["term", 1186], ["can", 1191], ["not", 1194], ["be", 1198], ["excluded", 1201], [".", 1209], ["Although", 1211], ["imatinib", 1220], ["does", 1229], ["not", 1234], ["'", 1238], ["cure", 1239], ["'", 1243], ["CML", 1245], ["and", 1249], ["has", 1253], ["to", 1257], ["be", 1260], ["administered", 1263], ["chronically", 1276], ["to", 1288], ["patients", 1291], [",", 1299], ["it", 1301], ["has", 1304], ["revolutionized", 1308], ["both", 1323], ["outcome", 1328], ["and", 1336], ["quality", 1340], ["of", 1348], ["life", 1351], ["of", 1356], ["CML", 1359], ["patients", 1363], [".", 1371]]}
{"context": "Restless legs syndrome/Willis Ekbom disease (RLS/WED) has been recognized as a significant medical disorder since the 17th century. It was studied mostly in the last 50 years in relation to increasing interest in sleep medicine and health-related quality of life. This led to recognition that the disease is not well characterized as restless feelings in the legs. These symptoms are reported in many situations, but the subjective experience of RLS/WED patients differs from that experienced by others. Thus a new name has been introduced that avoids problems of symptom definition of a disease by naming it after those who first characterized it, i.e. 'Willis Ekbom disease'. This article emphasizes the importance of RLS/WED for psychiatry. The disease carries significant increased risk for depression and anxiety disorders. Treatment requires consideration of these co-morbid disorders. RLS/WED can exacerbate or even engender psychiatric disease, so treatment of psychiatric disease should also include consideration of RLS/WED. The need for attention to RLS/WED is particularly significant for depression. Most anti-depressants exacerbate or can even engender RLS/WED. Thus this article seeks to introduce RLS/WED in relation to psychiatric practice. It presents the RLS/WED disease, its overlap with psychiatry and the current treatment options.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "289d6353e4064a62a58db9f9192b3eff", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["/", 22], ["Willis", 23], ["Ekbom", 30], ["disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["has", 54], ["been", 58], ["recognized", 63], ["as", 74], ["a", 77], ["significant", 79], ["medical", 91], ["disorder", 99], ["since", 108], ["the", 114], ["17th", 118], ["century", 123], [".", 130], ["It", 132], ["was", 135], ["studied", 139], ["mostly", 147], ["in", 154], ["the", 157], ["last", 161], ["50", 166], ["years", 169], ["in", 175], ["relation", 178], ["to", 187], ["increasing", 190], ["interest", 201], ["in", 210], ["sleep", 213], ["medicine", 219], ["and", 228], ["health", 232], ["-", 238], ["related", 239], ["quality", 247], ["of", 255], ["life", 258], [".", 262], ["This", 264], ["led", 269], ["to", 273], ["recognition", 276], ["that", 288], ["the", 293], ["disease", 297], ["is", 305], ["not", 308], ["well", 312], ["characterized", 317], ["as", 331], ["restless", 334], ["feelings", 343], ["in", 352], ["the", 355], ["legs", 359], [".", 363], ["These", 365], ["symptoms", 371], ["are", 380], ["reported", 384], ["in", 393], ["many", 396], ["situations", 401], [",", 411], ["but", 413], ["the", 417], ["subjective", 421], ["experience", 432], ["of", 443], ["RLS", 446], ["/", 449], ["WED", 450], ["patients", 454], ["differs", 463], ["from", 471], ["that", 476], ["experienced", 481], ["by", 493], ["others", 496], [".", 502], ["Thus", 504], ["a", 509], ["new", 511], ["name", 515], ["has", 520], ["been", 524], ["introduced", 529], ["that", 540], ["avoids", 545], ["problems", 552], ["of", 561], ["symptom", 564], ["definition", 572], ["of", 583], ["a", 586], ["disease", 588], ["by", 596], ["naming", 599], ["it", 606], ["after", 609], ["those", 615], ["who", 621], ["first", 625], ["characterized", 631], ["it", 645], [",", 647], ["i.e.", 649], ["'", 654], ["Willis", 655], ["Ekbom", 662], ["disease", 668], ["'", 675], [".", 676], ["This", 678], ["article", 683], ["emphasizes", 691], ["the", 702], ["importance", 706], ["of", 717], ["RLS", 720], ["/", 723], ["WED", 724], ["for", 728], ["psychiatry", 732], [".", 742], ["The", 744], ["disease", 748], ["carries", 756], ["significant", 764], ["increased", 776], ["risk", 786], ["for", 791], ["depression", 795], ["and", 806], ["anxiety", 810], ["disorders", 818], [".", 827], ["Treatment", 829], ["requires", 839], ["consideration", 848], ["of", 862], ["these", 865], ["co", 871], ["-", 873], ["morbid", 874], ["disorders", 881], [".", 890], ["RLS", 892], ["/", 895], ["WED", 896], ["can", 900], ["exacerbate", 904], ["or", 915], ["even", 918], ["engender", 923], ["psychiatric", 932], ["disease", 944], [",", 951], ["so", 953], ["treatment", 956], ["of", 966], ["psychiatric", 969], ["disease", 981], ["should", 989], ["also", 996], ["include", 1001], ["consideration", 1009], ["of", 1023], ["RLS", 1026], ["/", 1029], ["WED", 1030], [".", 1033], ["The", 1035], ["need", 1039], ["for", 1044], ["attention", 1048], ["to", 1058], ["RLS", 1061], ["/", 1064], ["WED", 1065], ["is", 1069], ["particularly", 1072], ["significant", 1085], ["for", 1097], ["depression", 1101], [".", 1111], ["Most", 1113], ["anti", 1118], ["-", 1122], ["depressants", 1123], ["exacerbate", 1135], ["or", 1146], ["can", 1149], ["even", 1153], ["engender", 1158], ["RLS", 1167], ["/", 1170], ["WED", 1171], [".", 1174], ["Thus", 1176], ["this", 1181], ["article", 1186], ["seeks", 1194], ["to", 1200], ["introduce", 1203], ["RLS", 1213], ["/", 1216], ["WED", 1217], ["in", 1221], ["relation", 1224], ["to", 1233], ["psychiatric", 1236], ["practice", 1248], [".", 1256], ["It", 1258], ["presents", 1261], ["the", 1270], ["RLS", 1274], ["/", 1277], ["WED", 1278], ["disease", 1282], [",", 1289], ["its", 1291], ["overlap", 1295], ["with", 1303], ["psychiatry", 1308], ["and", 1319], ["the", 1323], ["current", 1327], ["treatment", 1335], ["options", 1345], [".", 1352]]}
{"context": "Mowat-Wilson syndrome is a genetic disease caused by heterozygous mutations or deletions of the zinc finger E-box-binding homeobox 2 (ZEB2) gene. The syndrome is characterized by typical facial features, moderate-to-severe mental retardation, epilepsy and variable congenital malformations, including Hirschsprung disease, genital anomalies, congenital heart disease, agenesis of the corpus callosum, and eye defects. The prevalence of Mowat-Wilson syndrome is currently unknown, but it seems that Mowat-Wilson syndrome is underdiagnosed, particularly in patients without Hirschsprung disease. We report here the first Egyptian case of Mowat-Wilson syndrome who was conceived by intracytoplasmic sperm injection. The patient manifested bilateral sensorineural hearing loss--a new feature not previously reported in cases of Mowat-Wilson syndrome. This report describes the first Egyptian patient of Mowat-Wilson syndrome who was conceived after intracytoplasmic sperm injection, and provides a new evidence for the inclusion of deafness among the congenital defects of the syndrome.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "c3272be6bdea40c9ac22dfe5337dc311", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[26, 26]], "char_spans": [[134, 137]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["genetic", 27], ["disease", 35], ["caused", 43], ["by", 50], ["heterozygous", 53], ["mutations", 66], ["or", 76], ["deletions", 79], ["of", 89], ["the", 92], ["zinc", 96], ["finger", 101], ["E", 108], ["-", 109], ["box", 110], ["-", 113], ["binding", 114], ["homeobox", 122], ["2", 131], ["(", 133], ["ZEB2", 134], [")", 138], ["gene", 140], [".", 144], ["The", 146], ["syndrome", 150], ["is", 159], ["characterized", 162], ["by", 176], ["typical", 179], ["facial", 187], ["features", 194], [",", 202], ["moderate", 204], ["-", 212], ["to", 213], ["-", 215], ["severe", 216], ["mental", 223], ["retardation", 230], [",", 241], ["epilepsy", 243], ["and", 252], ["variable", 256], ["congenital", 265], ["malformations", 276], [",", 289], ["including", 291], ["Hirschsprung", 301], ["disease", 314], [",", 321], ["genital", 323], ["anomalies", 331], [",", 340], ["congenital", 342], ["heart", 353], ["disease", 359], [",", 366], ["agenesis", 368], ["of", 377], ["the", 380], ["corpus", 384], ["callosum", 391], [",", 399], ["and", 401], ["eye", 405], ["defects", 409], [".", 416], ["The", 418], ["prevalence", 422], ["of", 433], ["Mowat", 436], ["-", 441], ["Wilson", 442], ["syndrome", 449], ["is", 458], ["currently", 461], ["unknown", 471], [",", 478], ["but", 480], ["it", 484], ["seems", 487], ["that", 493], ["Mowat", 498], ["-", 503], ["Wilson", 504], ["syndrome", 511], ["is", 520], ["underdiagnosed", 523], [",", 537], ["particularly", 539], ["in", 552], ["patients", 555], ["without", 564], ["Hirschsprung", 572], ["disease", 585], [".", 592], ["We", 594], ["report", 597], ["here", 604], ["the", 609], ["first", 613], ["Egyptian", 619], ["case", 628], ["of", 633], ["Mowat", 636], ["-", 641], ["Wilson", 642], ["syndrome", 649], ["who", 658], ["was", 662], ["conceived", 666], ["by", 676], ["intracytoplasmic", 679], ["sperm", 696], ["injection", 702], [".", 711], ["The", 713], ["patient", 717], ["manifested", 725], ["bilateral", 736], ["sensorineural", 746], ["hearing", 760], ["loss", 768], ["--", 772], ["a", 774], ["new", 776], ["feature", 780], ["not", 788], ["previously", 792], ["reported", 803], ["in", 812], ["cases", 815], ["of", 821], ["Mowat", 824], ["-", 829], ["Wilson", 830], ["syndrome", 837], [".", 845], ["This", 847], ["report", 852], ["describes", 859], ["the", 869], ["first", 873], ["Egyptian", 879], ["patient", 888], ["of", 896], ["Mowat", 899], ["-", 904], ["Wilson", 905], ["syndrome", 912], ["who", 921], ["was", 925], ["conceived", 929], ["after", 939], ["intracytoplasmic", 945], ["sperm", 962], ["injection", 968], [",", 977], ["and", 979], ["provides", 983], ["a", 992], ["new", 994], ["evidence", 998], ["for", 1007], ["the", 1011], ["inclusion", 1015], ["of", 1025], ["deafness", 1028], ["among", 1037], ["the", 1043], ["congenital", 1047], ["defects", 1058], ["of", 1066], ["the", 1069], ["syndrome", 1073], [".", 1081]]}
{"context": "Tropomyosin receptor kinases (Trks) are a family of three similar tyrosine kinases activated by peptide hormones of the neurotrophin family. The nerve growth factor antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA pathway in pain. As an alternative modality, small-molecule inhibitors of the Trks have been pursued in recent years to probe the role of these neurotrophin pathways in pain, cancer and other indications. This paper reviews the patent literature between mid-2009 and 2013, claiming inhibitors of Trk family members as the primary biological targets. Additional patents have been reviewed where Trk is not the main kinase of interest but in which high Trk potency is observed and the chemical matter is particularly noteworthy. Patents pre-dating this period have been reviewed previously. Scifinder and Google were used to find relevant patents and clinical information using Trk or Tropomyosin as the search term. Considerable recent progress has been made in the identification of selective pan Trk inhibitors with pharmacodynamic and pharmacokinetic properties appropriate for clinical evaluation. Inhibitors of both active and inactive conformations of the Trks as well as peripherally restricted molecules have been identified. Furthermore, TrkA-selective allosteric inhibitors have recently been disclosed, which enables the biology of this isoform to be probed. The recent identification of a TrkA gene fusion in a subset of lung cancer patients will increase further the attraction of Trk inhibition to the pharmaceutical industry.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "6f76097048934cc28e54c79c8ca57345", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[24, 26]], "char_spans": [[145, 163]]}]}], "context_tokens": [["Tropomyosin", 0], ["receptor", 12], ["kinases", 21], ["(", 29], ["Trks", 30], [")", 34], ["are", 36], ["a", 40], ["family", 42], ["of", 49], ["three", 52], ["similar", 58], ["tyrosine", 66], ["kinases", 75], ["activated", 83], ["by", 93], ["peptide", 96], ["hormones", 104], ["of", 113], ["the", 116], ["neurotrophin", 120], ["family", 133], [".", 139], ["The", 141], ["nerve", 145], ["growth", 151], ["factor", 158], ["antibody", 165], ["tanezumab", 174], ["has", 184], ["provided", 188], ["clinical", 197], ["proof", 206], ["of", 212], ["concept", 215], ["for", 223], ["inhibition", 227], ["of", 238], ["the", 241], ["TrkA", 245], ["pathway", 250], ["in", 258], ["pain", 261], [".", 265], ["As", 267], ["an", 270], ["alternative", 273], ["modality", 285], [",", 293], ["small", 295], ["-", 300], ["molecule", 301], ["inhibitors", 310], ["of", 321], ["the", 324], ["Trks", 328], ["have", 333], ["been", 338], ["pursued", 343], ["in", 351], ["recent", 354], ["years", 361], ["to", 367], ["probe", 370], ["the", 376], ["role", 380], ["of", 385], ["these", 388], ["neurotrophin", 394], ["pathways", 407], ["in", 416], ["pain", 419], [",", 423], ["cancer", 425], ["and", 432], ["other", 436], ["indications", 442], [".", 453], ["This", 455], ["paper", 460], ["reviews", 466], ["the", 474], ["patent", 478], ["literature", 485], ["between", 496], ["mid-2009", 504], ["and", 513], ["2013", 517], [",", 521], ["claiming", 523], ["inhibitors", 532], ["of", 543], ["Trk", 546], ["family", 550], ["members", 557], ["as", 565], ["the", 568], ["primary", 572], ["biological", 580], ["targets", 591], [".", 598], ["Additional", 600], ["patents", 611], ["have", 619], ["been", 624], ["reviewed", 629], ["where", 638], ["Trk", 644], ["is", 648], ["not", 651], ["the", 655], ["main", 659], ["kinase", 664], ["of", 671], ["interest", 674], ["but", 683], ["in", 687], ["which", 690], ["high", 696], ["Trk", 701], ["potency", 705], ["is", 713], ["observed", 716], ["and", 725], ["the", 729], ["chemical", 733], ["matter", 742], ["is", 749], ["particularly", 752], ["noteworthy", 765], [".", 775], ["Patents", 777], ["pre", 785], ["-", 788], ["dating", 789], ["this", 796], ["period", 801], ["have", 808], ["been", 813], ["reviewed", 818], ["previously", 827], [".", 837], ["Scifinder", 839], ["and", 849], ["Google", 853], ["were", 860], ["used", 865], ["to", 870], ["find", 873], ["relevant", 878], ["patents", 887], ["and", 895], ["clinical", 899], ["information", 908], ["using", 920], ["Trk", 926], ["or", 930], ["Tropomyosin", 933], ["as", 945], ["the", 948], ["search", 952], ["term", 959], [".", 963], ["Considerable", 965], ["recent", 978], ["progress", 985], ["has", 994], ["been", 998], ["made", 1003], ["in", 1008], ["the", 1011], ["identification", 1015], ["of", 1030], ["selective", 1033], ["pan", 1043], ["Trk", 1047], ["inhibitors", 1051], ["with", 1062], ["pharmacodynamic", 1067], ["and", 1083], ["pharmacokinetic", 1087], ["properties", 1103], ["appropriate", 1114], ["for", 1126], ["clinical", 1130], ["evaluation", 1139], [".", 1149], ["Inhibitors", 1151], ["of", 1162], ["both", 1165], ["active", 1170], ["and", 1177], ["inactive", 1181], ["conformations", 1190], ["of", 1204], ["the", 1207], ["Trks", 1211], ["as", 1216], ["well", 1219], ["as", 1224], ["peripherally", 1227], ["restricted", 1240], ["molecules", 1251], ["have", 1261], ["been", 1266], ["identified", 1271], [".", 1281], ["Furthermore", 1283], [",", 1294], ["TrkA", 1296], ["-", 1300], ["selective", 1301], ["allosteric", 1311], ["inhibitors", 1322], ["have", 1333], ["recently", 1338], ["been", 1347], ["disclosed", 1352], [",", 1361], ["which", 1363], ["enables", 1369], ["the", 1377], ["biology", 1381], ["of", 1389], ["this", 1392], ["isoform", 1397], ["to", 1405], ["be", 1408], ["probed", 1411], [".", 1417], ["The", 1419], ["recent", 1423], ["identification", 1430], ["of", 1445], ["a", 1448], ["TrkA", 1450], ["gene", 1455], ["fusion", 1460], ["in", 1467], ["a", 1470], ["subset", 1472], ["of", 1479], ["lung", 1482], ["cancer", 1487], ["patients", 1494], ["will", 1503], ["increase", 1508], ["further", 1517], ["the", 1525], ["attraction", 1529], ["of", 1540], ["Trk", 1543], ["inhibition", 1547], ["to", 1558], ["the", 1561], ["pharmaceutical", 1565], ["industry", 1580], [".", 1588]]}
{"context": "The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells. We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma. A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg. Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematologic toxic effects. The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an additional 20% and 15% of patients in the respective groups had a partial response with lymphocytosis. The response was independent of clinical and genomic risk factors present before treatment, including advanced-stage disease, the number of previous therapies, and the 17p13.1 deletion. At 26 months, the estimated progression-free survival rate was 75% and the rate of overall survival was 83%. Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01105247.).", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "d7642cf38cf1490688ccfa02b942b4ab", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[281, 281], [129, 129], [71, 71]], "char_spans": [[1510, 1518], [702, 710], [416, 424]]}]}], "context_tokens": [["The", 0], ["treatment", 4], ["of", 14], ["relapsed", 17], ["chronic", 26], ["lymphocytic", 34], ["leukemia", 46], ["(", 55], ["CLL", 56], [")", 59], ["has", 61], ["resulted", 65], ["in", 74], ["few", 77], ["durable", 81], ["remissions", 89], [".", 99], ["Bruton", 101], ["'s", 107], ["tyrosine", 110], ["kinase", 119], ["(", 126], ["BTK", 127], [")", 130], [",", 131], ["an", 133], ["essential", 136], ["component", 146], ["of", 156], ["B", 159], ["-", 160], ["cell", 161], ["-", 165], ["receptor", 166], ["signaling", 175], [",", 184], ["mediates", 186], ["interactions", 195], ["with", 208], ["the", 213], ["tumor", 217], ["microenvironment", 223], ["and", 240], ["promotes", 244], ["the", 253], ["survival", 257], ["and", 266], ["proliferation", 270], ["of", 284], ["CLL", 287], ["cells", 291], [".", 296], ["We", 298], ["conducted", 301], ["a", 311], ["phase", 313], ["1b-2", 319], ["multicenter", 324], ["study", 336], ["to", 342], ["assess", 345], ["the", 352], ["safety", 356], [",", 362], ["efficacy", 364], [",", 372], ["pharmacokinetics", 374], [",", 390], ["and", 392], ["pharmacodynamics", 396], ["of", 413], ["ibrutinib", 416], ["(", 426], ["PCI-32765", 427], [")", 436], [",", 437], ["a", 439], ["first", 441], ["-", 446], ["in", 447], ["-", 449], ["class", 450], [",", 455], ["oral", 457], ["covalent", 462], ["inhibitor", 471], ["of", 481], ["BTK", 484], ["designed", 488], ["for", 497], ["treatment", 501], ["of", 511], ["B", 514], ["-", 515], ["cell", 516], ["cancers", 521], [",", 528], ["in", 530], ["patients", 533], ["with", 542], ["relapsed", 547], ["or", 556], ["refractory", 559], ["CLL", 570], ["or", 574], ["small", 577], ["lymphocytic", 583], ["lymphoma", 595], [".", 603], ["A", 605], ["total", 607], ["of", 613], ["85", 616], ["patients", 619], [",", 627], ["the", 629], ["majority", 633], ["of", 642], ["whom", 645], ["were", 650], ["considered", 655], ["to", 666], ["have", 669], ["high", 674], ["-", 678], ["risk", 679], ["disease", 684], [",", 691], ["received", 693], ["ibrutinib", 702], ["orally", 712], ["once", 719], ["daily", 724], [";", 729], ["51", 731], ["received", 734], ["420", 743], ["mg", 747], [",", 749], ["and", 751], ["34", 755], ["received", 758], ["840", 767], ["mg", 771], [".", 773], ["Toxic", 775], ["effects", 781], ["were", 789], ["predominantly", 794], ["grade", 808], ["1", 814], ["or", 816], ["2", 819], ["and", 821], ["included", 825], ["transient", 834], ["diarrhea", 844], [",", 852], ["fatigue", 854], [",", 861], ["and", 863], ["upper", 867], ["respiratory", 873], ["tract", 885], ["infection", 891], [";", 900], ["thus", 902], [",", 906], ["patients", 908], ["could", 917], ["receive", 923], ["extended", 931], ["treatment", 940], ["with", 950], ["minimal", 955], ["hematologic", 963], ["toxic", 975], ["effects", 981], [".", 988], ["The", 990], ["overall", 994], ["response", 1002], ["rate", 1011], ["was", 1016], ["the", 1020], ["same", 1024], ["in", 1029], ["the", 1032], ["group", 1036], ["that", 1042], ["received", 1047], ["420", 1056], ["mg", 1060], ["and", 1063], ["the", 1067], ["group", 1071], ["that", 1077], ["received", 1082], ["840", 1091], ["mg", 1095], ["(", 1098], ["71", 1099], ["%", 1101], [")", 1102], [",", 1103], ["and", 1105], ["an", 1109], ["additional", 1112], ["20", 1123], ["%", 1125], ["and", 1127], ["15", 1131], ["%", 1133], ["of", 1135], ["patients", 1138], ["in", 1147], ["the", 1150], ["respective", 1154], ["groups", 1165], ["had", 1172], ["a", 1176], ["partial", 1178], ["response", 1186], ["with", 1195], ["lymphocytosis", 1200], [".", 1213], ["The", 1215], ["response", 1219], ["was", 1228], ["independent", 1232], ["of", 1244], ["clinical", 1247], ["and", 1256], ["genomic", 1260], ["risk", 1268], ["factors", 1273], ["present", 1281], ["before", 1289], ["treatment", 1296], [",", 1305], ["including", 1307], ["advanced", 1317], ["-", 1325], ["stage", 1326], ["disease", 1332], [",", 1339], ["the", 1341], ["number", 1345], ["of", 1352], ["previous", 1355], ["therapies", 1364], [",", 1373], ["and", 1375], ["the", 1379], ["17p13.1", 1383], ["deletion", 1391], [".", 1399], ["At", 1401], ["26", 1404], ["months", 1407], [",", 1413], ["the", 1415], ["estimated", 1419], ["progression", 1429], ["-", 1440], ["free", 1441], ["survival", 1446], ["rate", 1455], ["was", 1460], ["75", 1464], ["%", 1466], ["and", 1468], ["the", 1472], ["rate", 1476], ["of", 1481], ["overall", 1484], ["survival", 1492], ["was", 1501], ["83", 1505], ["%", 1507], [".", 1508], ["Ibrutinib", 1510], ["was", 1520], ["associated", 1524], ["with", 1535], ["a", 1540], ["high", 1542], ["frequency", 1547], ["of", 1557], ["durable", 1560], ["remissions", 1568], ["in", 1579], ["patients", 1582], ["with", 1591], ["relapsed", 1596], ["or", 1605], ["refractory", 1608], ["CLL", 1619], ["and", 1623], ["small", 1627], ["lymphocytic", 1633], ["lymphoma", 1645], [",", 1653], ["including", 1655], ["patients", 1665], ["with", 1674], ["high", 1679], ["-", 1683], ["risk", 1684], ["genetic", 1689], ["lesions", 1697], [".", 1704], ["(", 1706], ["Funded", 1707], ["by", 1714], ["Pharmacyclics", 1717], ["and", 1731], ["others", 1735], [";", 1741], ["ClinicalTrials.gov", 1743], ["number", 1762], [",", 1768], ["NCT01105247", 1770], [".", 1781], [")", 1782], [".", 1783]]}
{"context": "Gefitinib, the specific inhibitor of the epidermal growth factor receptor (EGFR), may cause growth delay in cancer cell lines. Thorough understanding of the downstream cellular signaling of gefitinib will facilitate the discovery of biomarkers for predicting outcomes and monitoring anti-EGFR therapies, and provide information for key targets for therapeutic intervention. In this study, we investigated the role of transducer of erbB2.1 (TOB1) in gefitinib therapy. Using the lung carcinoma cell lines A549 and NCI-H1975, the results suggested that gefitinib might mediate cell cycle arrest in lung cancer cells at least by targeting TOB1 expression. Gefitinib treatment caused cell cycle arrest predominantly at the G1 phase, which is associated with TOB1 nuclear translocation and its interaction with cyclin D1. We also showed that knockdown of TOB1 expression by RNAi rescued lung cancer cells from gefitinib-induced cell-proliferative arrest. These results suggest that TOB1 interaction with cyclin D1 and nuclear translocation is directly involved in the gefitinib-induced anti-proliferative cell cycle arrest.", "qas": [{"question": "Which is the cellular target of gefitinib?", "answers": ["Epidermal growth factor receptor (EGFR)"], "qid": "69bb73c08e1848e080576cacd9b2c307", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["target", 22], ["of", 29], ["gefitinib", 32], ["?", 41]], "detected_answers": [{"text": "Epidermal growth factor receptor (EGFR)", "token_spans": [[7, 12]], "char_spans": [[41, 78]]}]}], "context_tokens": [["Gefitinib", 0], [",", 9], ["the", 11], ["specific", 15], ["inhibitor", 24], ["of", 34], ["the", 37], ["epidermal", 41], ["growth", 51], ["factor", 58], ["receptor", 65], ["(", 74], ["EGFR", 75], [")", 79], [",", 80], ["may", 82], ["cause", 86], ["growth", 92], ["delay", 99], ["in", 105], ["cancer", 108], ["cell", 115], ["lines", 120], [".", 125], ["Thorough", 127], ["understanding", 136], ["of", 150], ["the", 153], ["downstream", 157], ["cellular", 168], ["signaling", 177], ["of", 187], ["gefitinib", 190], ["will", 200], ["facilitate", 205], ["the", 216], ["discovery", 220], ["of", 230], ["biomarkers", 233], ["for", 244], ["predicting", 248], ["outcomes", 259], ["and", 268], ["monitoring", 272], ["anti", 283], ["-", 287], ["EGFR", 288], ["therapies", 293], [",", 302], ["and", 304], ["provide", 308], ["information", 316], ["for", 328], ["key", 332], ["targets", 336], ["for", 344], ["therapeutic", 348], ["intervention", 360], [".", 372], ["In", 374], ["this", 377], ["study", 382], [",", 387], ["we", 389], ["investigated", 392], ["the", 405], ["role", 409], ["of", 414], ["transducer", 417], ["of", 428], ["erbB2.1", 431], ["(", 439], ["TOB1", 440], [")", 444], ["in", 446], ["gefitinib", 449], ["therapy", 459], [".", 466], ["Using", 468], ["the", 474], ["lung", 478], ["carcinoma", 483], ["cell", 493], ["lines", 498], ["A549", 504], ["and", 509], ["NCI", 513], ["-", 516], ["H1975", 517], [",", 522], ["the", 524], ["results", 528], ["suggested", 536], ["that", 546], ["gefitinib", 551], ["might", 561], ["mediate", 567], ["cell", 575], ["cycle", 580], ["arrest", 586], ["in", 593], ["lung", 596], ["cancer", 601], ["cells", 608], ["at", 614], ["least", 617], ["by", 623], ["targeting", 626], ["TOB1", 636], ["expression", 641], [".", 651], ["Gefitinib", 653], ["treatment", 663], ["caused", 673], ["cell", 680], ["cycle", 685], ["arrest", 691], ["predominantly", 698], ["at", 712], ["the", 715], ["G1", 719], ["phase", 722], [",", 727], ["which", 729], ["is", 735], ["associated", 738], ["with", 749], ["TOB1", 754], ["nuclear", 759], ["translocation", 767], ["and", 781], ["its", 785], ["interaction", 789], ["with", 801], ["cyclin", 806], ["D1", 813], [".", 815], ["We", 817], ["also", 820], ["showed", 825], ["that", 832], ["knockdown", 837], ["of", 847], ["TOB1", 850], ["expression", 855], ["by", 866], ["RNAi", 869], ["rescued", 874], ["lung", 882], ["cancer", 887], ["cells", 894], ["from", 900], ["gefitinib", 905], ["-", 914], ["induced", 915], ["cell", 923], ["-", 927], ["proliferative", 928], ["arrest", 942], [".", 948], ["These", 950], ["results", 956], ["suggest", 964], ["that", 972], ["TOB1", 977], ["interaction", 982], ["with", 994], ["cyclin", 999], ["D1", 1006], ["and", 1009], ["nuclear", 1013], ["translocation", 1021], ["is", 1035], ["directly", 1038], ["involved", 1047], ["in", 1056], ["the", 1059], ["gefitinib", 1063], ["-", 1072], ["induced", 1073], ["anti", 1081], ["-", 1085], ["proliferative", 1086], ["cell", 1100], ["cycle", 1105], ["arrest", 1111], [".", 1117]]}
{"context": "The susceptibility to arbekacin (ABK) of methicillin-resistant Staphylococcus aureus (MRSA) was investigated to find out how it related to aac(6')/aph(2\") gene. In 49 isolates of MRSA for which MIC of ABK ranged from 0.125 to 64 micrograms/ml, the MICs of ABK for 38 strains carrying aac(6')/aph(2\") gene were widely distributed from 0.25 to 64, whereas those for 11 strains without that gene were all < or = 0.5 microgram/ml. Residual rate of ABK activity was higher than that of gentamicin after the reaction with each crude enzyme preparation extracted from 3 isolates of MRSA, carrying aac(6')/aph(2\") and aad(4',4\") genes. Furthermore, 97 strains of MRSA isolated at Kanagawa prefecture in Japan in 1999 were all sensitive to ABK, although 28 strains of them carried aac(6')/aph(2\") gene. These results showed that ABK resistance was not necessarily related to carrying aac(6')/aph(2\") gene in clinical isolates of MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "c28f41488c09478c988e4e82f733d188", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[14, 14], [128, 128], [34, 34], [174, 174], [111, 111]], "char_spans": [[86, 89], [655, 658], [179, 182], [920, 923], [575, 578]]}]}], "context_tokens": [["The", 0], ["susceptibility", 4], ["to", 19], ["arbekacin", 22], ["(", 32], ["ABK", 33], [")", 36], ["of", 38], ["methicillin", 41], ["-", 52], ["resistant", 53], ["Staphylococcus", 63], ["aureus", 78], ["(", 85], ["MRSA", 86], [")", 90], ["was", 92], ["investigated", 96], ["to", 109], ["find", 112], ["out", 117], ["how", 121], ["it", 125], ["related", 128], ["to", 136], ["aac(6')/aph(2", 139], ["\"", 152], [")", 153], ["gene", 155], [".", 159], ["In", 161], ["49", 164], ["isolates", 167], ["of", 176], ["MRSA", 179], ["for", 184], ["which", 188], ["MIC", 194], ["of", 198], ["ABK", 201], ["ranged", 205], ["from", 212], ["0.125", 217], ["to", 223], ["64", 226], ["micrograms", 229], ["/", 239], ["ml", 240], [",", 242], ["the", 244], ["MICs", 248], ["of", 253], ["ABK", 256], ["for", 260], ["38", 264], ["strains", 267], ["carrying", 275], ["aac(6')/aph(2", 284], ["\"", 297], [")", 298], ["gene", 300], ["were", 305], ["widely", 310], ["distributed", 317], ["from", 329], ["0.25", 334], ["to", 339], ["64", 342], [",", 344], ["whereas", 346], ["those", 354], ["for", 360], ["11", 364], ["strains", 367], ["without", 375], ["that", 383], ["gene", 388], ["were", 393], ["all", 398], ["<", 402], ["or", 404], ["=", 407], ["0.5", 409], ["microgram", 413], ["/", 422], ["ml", 423], [".", 425], ["Residual", 427], ["rate", 436], ["of", 441], ["ABK", 444], ["activity", 448], ["was", 457], ["higher", 461], ["than", 468], ["that", 473], ["of", 478], ["gentamicin", 481], ["after", 492], ["the", 498], ["reaction", 502], ["with", 511], ["each", 516], ["crude", 521], ["enzyme", 527], ["preparation", 534], ["extracted", 546], ["from", 556], ["3", 561], ["isolates", 563], ["of", 572], ["MRSA", 575], [",", 579], ["carrying", 581], ["aac(6')/aph(2", 590], ["\"", 603], [")", 604], ["and", 606], ["aad(4',4", 610], ["\"", 618], [")", 619], ["genes", 621], [".", 626], ["Furthermore", 628], [",", 639], ["97", 641], ["strains", 644], ["of", 652], ["MRSA", 655], ["isolated", 660], ["at", 669], ["Kanagawa", 672], ["prefecture", 681], ["in", 692], ["Japan", 695], ["in", 701], ["1999", 704], ["were", 709], ["all", 714], ["sensitive", 718], ["to", 728], ["ABK", 731], [",", 734], ["although", 736], ["28", 745], ["strains", 748], ["of", 756], ["them", 759], ["carried", 764], ["aac(6')/aph(2", 772], ["\"", 785], [")", 786], ["gene", 788], [".", 792], ["These", 794], ["results", 800], ["showed", 808], ["that", 815], ["ABK", 820], ["resistance", 824], ["was", 835], ["not", 839], ["necessarily", 843], ["related", 855], ["to", 863], ["carrying", 866], ["aac(6')/aph(2", 875], ["\"", 888], [")", 889], ["gene", 891], ["in", 896], ["clinical", 899], ["isolates", 908], ["of", 917], ["MRSA", 920], [".", 924]]}
{"context": "Many Prader-Willi syndrome (PWS) and Angelman syndrome (AS) patients have a cytogenetic deletion of 15q11q13. While AS and PWS share a similar cytogenetic anomaly, they have very different clinical phenotypes. DNAs from 4 AS patients were examined using 5 chromosome 15q11q13-specific cloned DNA segments. With the present level of resolution, the molecular deletions between AS and those previously reported for PWS did not appear to differ. However, in contrast to the paternal inheritance of the deleted chromosome 15 observed in the majority of PWS patients, maternal inheritance of the deleted chromosome 15 was demonstrated in the AS patients by restriction fragment length polymorphisms (RFLPs).", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "0886b5bfb37f4842a63d965014d3b9fa", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[1, 4]], "char_spans": [[5, 25]]}]}], "context_tokens": [["Many", 0], ["Prader", 5], ["-", 11], ["Willi", 12], ["syndrome", 18], ["(", 27], ["PWS", 28], [")", 31], ["and", 33], ["Angelman", 37], ["syndrome", 46], ["(", 55], ["AS", 56], [")", 58], ["patients", 60], ["have", 69], ["a", 74], ["cytogenetic", 76], ["deletion", 88], ["of", 97], ["15q11q13", 100], [".", 108], ["While", 110], ["AS", 116], ["and", 119], ["PWS", 123], ["share", 127], ["a", 133], ["similar", 135], ["cytogenetic", 143], ["anomaly", 155], [",", 162], ["they", 164], ["have", 169], ["very", 174], ["different", 179], ["clinical", 189], ["phenotypes", 198], [".", 208], ["DNAs", 210], ["from", 215], ["4", 220], ["AS", 222], ["patients", 225], ["were", 234], ["examined", 239], ["using", 248], ["5", 254], ["chromosome", 256], ["15q11q13-specific", 267], ["cloned", 285], ["DNA", 292], ["segments", 296], [".", 304], ["With", 306], ["the", 311], ["present", 315], ["level", 323], ["of", 329], ["resolution", 332], [",", 342], ["the", 344], ["molecular", 348], ["deletions", 358], ["between", 368], ["AS", 376], ["and", 379], ["those", 383], ["previously", 389], ["reported", 400], ["for", 409], ["PWS", 413], ["did", 417], ["not", 421], ["appear", 425], ["to", 432], ["differ", 435], [".", 441], ["However", 443], [",", 450], ["in", 452], ["contrast", 455], ["to", 464], ["the", 467], ["paternal", 471], ["inheritance", 480], ["of", 492], ["the", 495], ["deleted", 499], ["chromosome", 507], ["15", 518], ["observed", 521], ["in", 530], ["the", 533], ["majority", 537], ["of", 546], ["PWS", 549], ["patients", 553], [",", 561], ["maternal", 563], ["inheritance", 572], ["of", 584], ["the", 587], ["deleted", 591], ["chromosome", 599], ["15", 610], ["was", 613], ["demonstrated", 617], ["in", 630], ["the", 633], ["AS", 637], ["patients", 640], ["by", 649], ["restriction", 652], ["fragment", 664], ["length", 673], ["polymorphisms", 680], ["(", 694], ["RFLPs", 695], [")", 700], [".", 701]]}
{"context": "Idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation. Safety, pharmacokinetics and pharmacodynamics of idarucizumab were investigated in dabigatran-treated, middle-aged, elderly and renally impaired volunteers with characteristics similar to patients receiving anticoagulant therapy. In this randomized, double-blind, crossover study, 46 subjects (12 middle-aged, 45-64\u00a0years; 16 elderly, 65-80\u00a0years; and 18 with mild or moderate renal impairment) received dabigatran etexilate (DE; 220 or 150\u00a0mg twice daily) for 4\u00a0days. Idarucizumab doses of 1, 2.5 and 5\u00a0g or 2\u00a0\u00d7\u00a02.5\u00a0g 1\u00a0h apart, or placebo, were administered as a rapid (5\u00a0min) infusion ~2\u00a0h after DE at steady state. Dabigatran-prolonged diluted thrombin time, ecarin clotting time and activated partial thromboplastin time were reversed to baseline immediately after idarucizumab infusion in all groups. Reversal was sustained with doses \u22652.5\u00a0g. Idarucizumab was well tolerated under all conditions. No impact of age on idarucizumab pharmacokinetics was observed; however, subjects with mild or moderate renal impairment demonstrated increased exposure (up to 84\u00a0%), decreased clearance and prolonged (by up to 49\u00a0%) initial half-life of idarucizumab compared with healthy middle-aged subjects. Impaired renal function was associated with increased exposure and decreased clearance of idarucizumab. Idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers. The results support the clinical use of a 5\u00a0g dose of idarucizumab. http://www.clinicaltrials.gov . Unique identifier: NCT01955720.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "1617e42426ba4b0483170d68366da72d", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[262, 262], [87, 87], [23, 23], [8, 8], [142, 142]], "char_spans": [[1474, 1483], [505, 514], [184, 193], [64, 73], [720, 729]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antibody", 19], ["fragment", 28], ["that", 37], ["specifically", 42], ["reverses", 55], ["dabigatran", 64], ["-", 74], ["mediated", 75], ["anticoagulation", 84], [".", 99], ["Safety", 101], [",", 107], ["pharmacokinetics", 109], ["and", 126], ["pharmacodynamics", 130], ["of", 147], ["idarucizumab", 150], ["were", 163], ["investigated", 168], ["in", 181], ["dabigatran", 184], ["-", 194], ["treated", 195], [",", 202], ["middle", 204], ["-", 210], ["aged", 211], [",", 215], ["elderly", 217], ["and", 225], ["renally", 229], ["impaired", 237], ["volunteers", 246], ["with", 257], ["characteristics", 262], ["similar", 278], ["to", 286], ["patients", 289], ["receiving", 298], ["anticoagulant", 308], ["therapy", 322], [".", 329], ["In", 331], ["this", 334], ["randomized", 339], [",", 349], ["double", 351], ["-", 357], ["blind", 358], [",", 363], ["crossover", 365], ["study", 375], [",", 380], ["46", 382], ["subjects", 385], ["(", 394], ["12", 395], ["middle", 398], ["-", 404], ["aged", 405], [",", 409], ["45", 411], ["-", 413], ["64", 414], ["years", 417], [";", 422], ["16", 424], ["elderly", 427], [",", 434], ["65", 436], ["-", 438], ["80", 439], ["years", 442], [";", 447], ["and", 449], ["18", 453], ["with", 456], ["mild", 461], ["or", 466], ["moderate", 469], ["renal", 478], ["impairment", 484], [")", 494], ["received", 496], ["dabigatran", 505], ["etexilate", 516], ["(", 526], ["DE", 527], [";", 529], ["220", 531], ["or", 535], ["150", 538], ["mg", 542], ["twice", 545], ["daily", 551], [")", 556], ["for", 558], ["4", 562], ["days", 564], [".", 568], ["Idarucizumab", 570], ["doses", 583], ["of", 589], ["1", 592], [",", 593], ["2.5", 595], ["and", 599], ["5", 603], ["g", 605], ["or", 607], ["2", 610], ["\u00d7", 612], ["2.5", 614], ["g", 618], ["1", 620], ["h", 622], ["apart", 624], [",", 629], ["or", 631], ["placebo", 634], [",", 641], ["were", 643], ["administered", 648], ["as", 661], ["a", 664], ["rapid", 666], ["(", 672], ["5", 673], ["min", 675], [")", 678], ["infusion", 680], ["~2", 689], ["h", 692], ["after", 694], ["DE", 700], ["at", 703], ["steady", 706], ["state", 713], [".", 718], ["Dabigatran", 720], ["-", 730], ["prolonged", 731], ["diluted", 741], ["thrombin", 749], ["time", 758], [",", 762], ["ecarin", 764], ["clotting", 771], ["time", 780], ["and", 785], ["activated", 789], ["partial", 799], ["thromboplastin", 807], ["time", 822], ["were", 827], ["reversed", 832], ["to", 841], ["baseline", 844], ["immediately", 853], ["after", 865], ["idarucizumab", 871], ["infusion", 884], ["in", 893], ["all", 896], ["groups", 900], [".", 906], ["Reversal", 908], ["was", 917], ["sustained", 921], ["with", 931], ["doses", 936], ["\u22652.5", 942], ["g.", 947], ["Idarucizumab", 950], ["was", 963], ["well", 967], ["tolerated", 972], ["under", 982], ["all", 988], ["conditions", 992], [".", 1002], ["No", 1004], ["impact", 1007], ["of", 1014], ["age", 1017], ["on", 1021], ["idarucizumab", 1024], ["pharmacokinetics", 1037], ["was", 1054], ["observed", 1058], [";", 1066], ["however", 1068], [",", 1075], ["subjects", 1077], ["with", 1086], ["mild", 1091], ["or", 1096], ["moderate", 1099], ["renal", 1108], ["impairment", 1114], ["demonstrated", 1125], ["increased", 1138], ["exposure", 1148], ["(", 1157], ["up", 1158], ["to", 1161], ["84", 1164], ["%", 1167], [")", 1168], [",", 1169], ["decreased", 1171], ["clearance", 1181], ["and", 1191], ["prolonged", 1195], ["(", 1205], ["by", 1206], ["up", 1209], ["to", 1212], ["49", 1215], ["%", 1218], [")", 1219], ["initial", 1221], ["half", 1229], ["-", 1233], ["life", 1234], ["of", 1239], ["idarucizumab", 1242], ["compared", 1255], ["with", 1264], ["healthy", 1269], ["middle", 1277], ["-", 1283], ["aged", 1284], ["subjects", 1289], [".", 1297], ["Impaired", 1299], ["renal", 1308], ["function", 1314], ["was", 1323], ["associated", 1327], ["with", 1338], ["increased", 1343], ["exposure", 1353], ["and", 1362], ["decreased", 1366], ["clearance", 1376], ["of", 1386], ["idarucizumab", 1389], [".", 1401], ["Idarucizumab", 1403], ["resulted", 1416], ["in", 1425], ["immediate", 1428], [",", 1437], ["complete", 1439], ["and", 1448], ["sustained", 1452], ["reversal", 1462], ["of", 1471], ["dabigatran", 1474], ["anticoagulant", 1485], ["activity", 1499], [",", 1507], ["and", 1509], ["was", 1513], ["safe", 1517], ["and", 1522], ["well", 1526], ["tolerated", 1531], ["in", 1541], ["middle", 1544], ["-", 1550], ["aged", 1551], [",", 1555], ["elderly", 1557], ["and", 1565], ["renally", 1569], ["impaired", 1577], ["volunteers", 1586], [".", 1596], ["The", 1598], ["results", 1602], ["support", 1610], ["the", 1618], ["clinical", 1622], ["use", 1631], ["of", 1635], ["a", 1638], ["5", 1640], ["g", 1642], ["dose", 1644], ["of", 1649], ["idarucizumab", 1652], [".", 1664], ["http://www.clinicaltrials.gov", 1666], [".", 1696], ["Unique", 1698], ["identifier", 1705], [":", 1715], ["NCT01955720", 1717], [".", 1728]]}
{"context": "The Ehlers-Danlos syndrome (EDS), inherited disorder of connective tissue, frequently leads to impairment of various functional areas, including employment. In 35 subjects with classic type EDS, 14 hypermobile, 3 vascular was administered 7 visual analogical scales (pain, stiffness, activities of daily living, instrumental activities of daily living, work, social relations). An impairment of particular significance in total score and in individual areas emerges is in the hypermobile group, followed by classic, less for the vasculature. Overall there is a significant alteration of the quality of life that deserves proper evaluation to facilitate the definition of fitness and the improvement of job insertion in patients with EDS.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "82da9c6e605c480c956b7f95c0e9d90b", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[12, 13]], "char_spans": [[56, 72]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["(", 27], ["EDS", 28], [")", 31], [",", 32], ["inherited", 34], ["disorder", 44], ["of", 53], ["connective", 56], ["tissue", 67], [",", 73], ["frequently", 75], ["leads", 86], ["to", 92], ["impairment", 95], ["of", 106], ["various", 109], ["functional", 117], ["areas", 128], [",", 133], ["including", 135], ["employment", 145], [".", 155], ["In", 157], ["35", 160], ["subjects", 163], ["with", 172], ["classic", 177], ["type", 185], ["EDS", 190], [",", 193], ["14", 195], ["hypermobile", 198], [",", 209], ["3", 211], ["vascular", 213], ["was", 222], ["administered", 226], ["7", 239], ["visual", 241], ["analogical", 248], ["scales", 259], ["(", 266], ["pain", 267], [",", 271], ["stiffness", 273], [",", 282], ["activities", 284], ["of", 295], ["daily", 298], ["living", 304], [",", 310], ["instrumental", 312], ["activities", 325], ["of", 336], ["daily", 339], ["living", 345], [",", 351], ["work", 353], [",", 357], ["social", 359], ["relations", 366], [")", 375], [".", 376], ["An", 378], ["impairment", 381], ["of", 392], ["particular", 395], ["significance", 406], ["in", 419], ["total", 422], ["score", 428], ["and", 434], ["in", 438], ["individual", 441], ["areas", 452], ["emerges", 458], ["is", 466], ["in", 469], ["the", 472], ["hypermobile", 476], ["group", 488], [",", 493], ["followed", 495], ["by", 504], ["classic", 507], [",", 514], ["less", 516], ["for", 521], ["the", 525], ["vasculature", 529], [".", 540], ["Overall", 542], ["there", 550], ["is", 556], ["a", 559], ["significant", 561], ["alteration", 573], ["of", 584], ["the", 587], ["quality", 591], ["of", 599], ["life", 602], ["that", 607], ["deserves", 612], ["proper", 621], ["evaluation", 628], ["to", 639], ["facilitate", 642], ["the", 653], ["definition", 657], ["of", 668], ["fitness", 671], ["and", 679], ["the", 683], ["improvement", 687], ["of", 699], ["job", 702], ["insertion", 706], ["in", 716], ["patients", 719], ["with", 728], ["EDS", 733], [".", 736]]}
{"context": "In 1957, Simpson published a seminal paper defining the risk factors for recurrence following surgical treatment of intracranial meningiomas. Given that Simpson's study was published more than 50 years ago, preceding image guidance technology and MR imaging, the authors reviewed their own experience with surgical treatment of Grade I meningiomas to determine if Simpson's grading scale is still relevant to modern neurosurgical practice. From this cohort, the authors evaluated all patients undergoing craniotomy for resection of a histologically proven WHO Grade I meningioma as their initial therapy. Clinical information was retrospectively reconstructed using patient medical records and radiological data. Recurrence analysis was performed using the Kaplan-Meier method. The 5-year recurrence/progression-free survival for all patients receiving a Simpson Grade I, II, III, or IV resection was 95, 85, 88, and 81%, respectively (p = not significant, log-rank test). Kaplan-Meier analysis revealed no significant difference in recurrence-free survival between patients receiving a Simpson Grade I, II, III, or IV resection. Analysis limited to meningiomas arising from the skull base (excluding the cavernous sinus) similarly found no significant benefit to Simpson Grade I or II resection, and the survival curves were nearly superimposed. In this study of a cohort of patients undergoing surgery for WHO Grade I meningiomas, the authors demonstrate that the benefit of more aggressive attempts to resect the tumor with dura and underlying bone was negligible compared with simply removing the entire tumor, or even leaving small amounts of tumor attached to critical structures. The authors believe that these data reflect an evolution in the nature of meningioma surgery over the past 2 decades, and bring into question the relevance of using Simpson's grading system as the sole predictor of recurrence.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "2ae2864e473745f697faa29712bfb28c", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[303, 303], [90, 90]], "char_spans": [[1761, 1770], [568, 577]]}]}], "context_tokens": [["In", 0], ["1957", 3], [",", 7], ["Simpson", 9], ["published", 17], ["a", 27], ["seminal", 29], ["paper", 37], ["defining", 43], ["the", 52], ["risk", 56], ["factors", 61], ["for", 69], ["recurrence", 73], ["following", 84], ["surgical", 94], ["treatment", 103], ["of", 113], ["intracranial", 116], ["meningiomas", 129], [".", 140], ["Given", 142], ["that", 148], ["Simpson", 153], ["'s", 160], ["study", 163], ["was", 169], ["published", 173], ["more", 183], ["than", 188], ["50", 193], ["years", 196], ["ago", 202], [",", 205], ["preceding", 207], ["image", 217], ["guidance", 223], ["technology", 232], ["and", 243], ["MR", 247], ["imaging", 250], [",", 257], ["the", 259], ["authors", 263], ["reviewed", 271], ["their", 280], ["own", 286], ["experience", 290], ["with", 301], ["surgical", 306], ["treatment", 315], ["of", 325], ["Grade", 328], ["I", 334], ["meningiomas", 336], ["to", 348], ["determine", 351], ["if", 361], ["Simpson", 364], ["'s", 371], ["grading", 374], ["scale", 382], ["is", 388], ["still", 391], ["relevant", 397], ["to", 406], ["modern", 409], ["neurosurgical", 416], ["practice", 430], [".", 438], ["From", 440], ["this", 445], ["cohort", 450], [",", 456], ["the", 458], ["authors", 462], ["evaluated", 470], ["all", 480], ["patients", 484], ["undergoing", 493], ["craniotomy", 504], ["for", 515], ["resection", 519], ["of", 529], ["a", 532], ["histologically", 534], ["proven", 549], ["WHO", 556], ["Grade", 560], ["I", 566], ["meningioma", 568], ["as", 579], ["their", 582], ["initial", 588], ["therapy", 596], [".", 603], ["Clinical", 605], ["information", 614], ["was", 626], ["retrospectively", 630], ["reconstructed", 646], ["using", 660], ["patient", 666], ["medical", 674], ["records", 682], ["and", 690], ["radiological", 694], ["data", 707], [".", 711], ["Recurrence", 713], ["analysis", 724], ["was", 733], ["performed", 737], ["using", 747], ["the", 753], ["Kaplan", 757], ["-", 763], ["Meier", 764], ["method", 770], [".", 776], ["The", 778], ["5-year", 782], ["recurrence", 789], ["/", 799], ["progression", 800], ["-", 811], ["free", 812], ["survival", 817], ["for", 826], ["all", 830], ["patients", 834], ["receiving", 843], ["a", 853], ["Simpson", 855], ["Grade", 863], ["I", 869], [",", 870], ["II", 872], [",", 874], ["III", 876], [",", 879], ["or", 881], ["IV", 884], ["resection", 887], ["was", 897], ["95", 901], [",", 903], ["85", 905], [",", 907], ["88", 909], [",", 911], ["and", 913], ["81", 917], ["%", 919], [",", 920], ["respectively", 922], ["(", 935], ["p", 936], ["=", 938], ["not", 940], ["significant", 944], [",", 955], ["log", 957], ["-", 960], ["rank", 961], ["test", 966], [")", 970], [".", 971], ["Kaplan", 973], ["-", 979], ["Meier", 980], ["analysis", 986], ["revealed", 995], ["no", 1004], ["significant", 1007], ["difference", 1019], ["in", 1030], ["recurrence", 1033], ["-", 1043], ["free", 1044], ["survival", 1049], ["between", 1058], ["patients", 1066], ["receiving", 1075], ["a", 1085], ["Simpson", 1087], ["Grade", 1095], ["I", 1101], [",", 1102], ["II", 1104], [",", 1106], ["III", 1108], [",", 1111], ["or", 1113], ["IV", 1116], ["resection", 1119], [".", 1128], ["Analysis", 1130], ["limited", 1139], ["to", 1147], ["meningiomas", 1150], ["arising", 1162], ["from", 1170], ["the", 1175], ["skull", 1179], ["base", 1185], ["(", 1190], ["excluding", 1191], ["the", 1201], ["cavernous", 1205], ["sinus", 1215], [")", 1220], ["similarly", 1222], ["found", 1232], ["no", 1238], ["significant", 1241], ["benefit", 1253], ["to", 1261], ["Simpson", 1264], ["Grade", 1272], ["I", 1278], ["or", 1280], ["II", 1283], ["resection", 1286], [",", 1295], ["and", 1297], ["the", 1301], ["survival", 1305], ["curves", 1314], ["were", 1321], ["nearly", 1326], ["superimposed", 1333], [".", 1345], ["In", 1347], ["this", 1350], ["study", 1355], ["of", 1361], ["a", 1364], ["cohort", 1366], ["of", 1373], ["patients", 1376], ["undergoing", 1385], ["surgery", 1396], ["for", 1404], ["WHO", 1408], ["Grade", 1412], ["I", 1418], ["meningiomas", 1420], [",", 1431], ["the", 1433], ["authors", 1437], ["demonstrate", 1445], ["that", 1457], ["the", 1462], ["benefit", 1466], ["of", 1474], ["more", 1477], ["aggressive", 1482], ["attempts", 1493], ["to", 1502], ["resect", 1505], ["the", 1512], ["tumor", 1516], ["with", 1522], ["dura", 1527], ["and", 1532], ["underlying", 1536], ["bone", 1547], ["was", 1552], ["negligible", 1556], ["compared", 1567], ["with", 1576], ["simply", 1581], ["removing", 1588], ["the", 1597], ["entire", 1601], ["tumor", 1608], [",", 1613], ["or", 1615], ["even", 1618], ["leaving", 1623], ["small", 1631], ["amounts", 1637], ["of", 1645], ["tumor", 1648], ["attached", 1654], ["to", 1663], ["critical", 1666], ["structures", 1675], [".", 1685], ["The", 1687], ["authors", 1691], ["believe", 1699], ["that", 1707], ["these", 1712], ["data", 1718], ["reflect", 1723], ["an", 1731], ["evolution", 1734], ["in", 1744], ["the", 1747], ["nature", 1751], ["of", 1758], ["meningioma", 1761], ["surgery", 1772], ["over", 1780], ["the", 1785], ["past", 1789], ["2", 1794], ["decades", 1796], [",", 1803], ["and", 1805], ["bring", 1809], ["into", 1815], ["question", 1820], ["the", 1829], ["relevance", 1833], ["of", 1843], ["using", 1846], ["Simpson", 1852], ["'s", 1859], ["grading", 1862], ["system", 1870], ["as", 1877], ["the", 1880], ["sole", 1884], ["predictor", 1889], ["of", 1899], ["recurrence", 1902], [".", 1912]]}
{"context": "The completeness of meningioma resection depends on the resection of dura mater invaded by the tumor. The pathological changes of the dura around the tumor can be interpreted by evaluating the dural tail sign (DTS) on MRI studies. The goal of this study was to clarify the pathological characteristics of the DTSs, propose a classification based on the histopathological and radiological correlation, and identify the invasive range of tumor cells in different types of DTS. The authors retrospectively reviewed 179 patients with convexity meningiomas who underwent Simpson Grade I resection. All patients underwent an enhanced MRI examination preoperatively. The convexity meningiomas were dichotomized into various subtypes in accordance with the 2007 WHO classification of tumors of the CNS, and the DTS was identified based on the Goldsher criteria. The range of resection of the involved dura was 3 cm from the base of the tumor, which corresponded with the length of DTS on MRI studies. Histopathological examination of dura at 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 cm from the base of the tumor was conducted, and the findings were correlated with the preoperative MRI appearance of the DTS. A total of 154 (86%) of 179 convexity meningiomas were classified into WHO Grade I subtype, including transitional (44 [28.6%] of 154), meningothelial (36 [23.4%] of 154), fibrous (23 [14.9%] of 154), psammomatous (22 [14.3%] of 154), secretory (10 [6.5%] of 154), and angiomatous (19 [12.3%] of 154). The other 25 (14%) were non-Grade I (WHO) tumors, including atypical (12 [48%] of 25), anaplastic (5 [20%] of 25), and papillary (8 [32%] of 25). The DTS was classified into 5 types: smooth (16 [8.9%] of 179), nodular (36 [20.1%] of 179), mixed (57 [31.8%] of 179), symmetrical multipolar (15 [8.4%] of 179), and asymmetrical multipolar (55 [30.7%] of 179). There was a significant difference in distribution of DTS type between Grade I and non-Grade I tumors (p = 0.004), whereas the difference was not significant among Grade I tumors (0.841) or among non-Grade I tumors (p = 0.818). All smooth-type DTSs were encountered in Grade I tumors, and the mixed DTS (52 [33.8%] of 154) was the most common type in these tumors. Nodular-type DTS was more commonly seen in non-Grade I tumors (12 [48%] of 25). Tumor invasion was found in 88.3% (158 of 179) of convexity meningiomas, of which the range of invasion in 82.3% (130 of 158) was within 2 cm and that in 94.9% (150 of 158) was within 2.5 cm. The incidence of invasion and the range invaded by tumor cells varied in different types of DTS, and differences were statistically significant (p < 0.001). Nodular-type DTS on MRI studies might be associated with non-Grade I tumors. The range of dural resection for convexity meningiomas should be 2.5 cm from the tumor base, and if this extent of resection is not feasible, the type of DTS should be considered. However, for skull base meningiomas, in which mostly Simpson Grade II resection is achieved, the use of this classification should be further validated. The classification of DTS enables the surgeon to predict preoperatively and then to achieve the optimal range of dural resection that might significantly reduce the recurrence rate of meningiomas.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "dfc371178f7740ec80686c0baf2ecc3a", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[3, 3]], "char_spans": [[20, 29]]}]}], "context_tokens": [["The", 0], ["completeness", 4], ["of", 17], ["meningioma", 20], ["resection", 31], ["depends", 41], ["on", 49], ["the", 52], ["resection", 56], ["of", 66], ["dura", 69], ["mater", 74], ["invaded", 80], ["by", 88], ["the", 91], ["tumor", 95], [".", 100], ["The", 102], ["pathological", 106], ["changes", 119], ["of", 127], ["the", 130], ["dura", 134], ["around", 139], ["the", 146], ["tumor", 150], ["can", 156], ["be", 160], ["interpreted", 163], ["by", 175], ["evaluating", 178], ["the", 189], ["dural", 193], ["tail", 199], ["sign", 204], ["(", 209], ["DTS", 210], [")", 213], ["on", 215], ["MRI", 218], ["studies", 222], [".", 229], ["The", 231], ["goal", 235], ["of", 240], ["this", 243], ["study", 248], ["was", 254], ["to", 258], ["clarify", 261], ["the", 269], ["pathological", 273], ["characteristics", 286], ["of", 302], ["the", 305], ["DTSs", 309], [",", 313], ["propose", 315], ["a", 323], ["classification", 325], ["based", 340], ["on", 346], ["the", 349], ["histopathological", 353], ["and", 371], ["radiological", 375], ["correlation", 388], [",", 399], ["and", 401], ["identify", 405], ["the", 414], ["invasive", 418], ["range", 427], ["of", 433], ["tumor", 436], ["cells", 442], ["in", 448], ["different", 451], ["types", 461], ["of", 467], ["DTS", 470], [".", 473], ["The", 475], ["authors", 479], ["retrospectively", 487], ["reviewed", 503], ["179", 512], ["patients", 516], ["with", 525], ["convexity", 530], ["meningiomas", 540], ["who", 552], ["underwent", 556], ["Simpson", 566], ["Grade", 574], ["I", 580], ["resection", 582], [".", 591], ["All", 593], ["patients", 597], ["underwent", 606], ["an", 616], ["enhanced", 619], ["MRI", 628], ["examination", 632], ["preoperatively", 644], [".", 658], ["The", 660], ["convexity", 664], ["meningiomas", 674], ["were", 686], ["dichotomized", 691], ["into", 704], ["various", 709], ["subtypes", 717], ["in", 726], ["accordance", 729], ["with", 740], ["the", 745], ["2007", 749], ["WHO", 754], ["classification", 758], ["of", 773], ["tumors", 776], ["of", 783], ["the", 786], ["CNS", 790], [",", 793], ["and", 795], ["the", 799], ["DTS", 803], ["was", 807], ["identified", 811], ["based", 822], ["on", 828], ["the", 831], ["Goldsher", 835], ["criteria", 844], [".", 852], ["The", 854], ["range", 858], ["of", 864], ["resection", 867], ["of", 877], ["the", 880], ["involved", 884], ["dura", 893], ["was", 898], ["3", 902], ["cm", 904], ["from", 907], ["the", 912], ["base", 916], ["of", 921], ["the", 924], ["tumor", 928], [",", 933], ["which", 935], ["corresponded", 941], ["with", 954], ["the", 959], ["length", 963], ["of", 970], ["DTS", 973], ["on", 977], ["MRI", 980], ["studies", 984], [".", 991], ["Histopathological", 993], ["examination", 1011], ["of", 1023], ["dura", 1026], ["at", 1031], ["0.5", 1034], [",", 1037], ["1.0", 1039], [",", 1042], ["1.5", 1044], [",", 1047], ["2.0", 1049], [",", 1052], ["2.5", 1054], [",", 1057], ["and", 1059], ["3.0", 1063], ["cm", 1067], ["from", 1070], ["the", 1075], ["base", 1079], ["of", 1084], ["the", 1087], ["tumor", 1091], ["was", 1097], ["conducted", 1101], [",", 1110], ["and", 1112], ["the", 1116], ["findings", 1120], ["were", 1129], ["correlated", 1134], ["with", 1145], ["the", 1150], ["preoperative", 1154], ["MRI", 1167], ["appearance", 1171], ["of", 1182], ["the", 1185], ["DTS", 1189], [".", 1192], ["A", 1194], ["total", 1196], ["of", 1202], ["154", 1205], ["(", 1209], ["86", 1210], ["%", 1212], [")", 1213], ["of", 1215], ["179", 1218], ["convexity", 1222], ["meningiomas", 1232], ["were", 1244], ["classified", 1249], ["into", 1260], ["WHO", 1265], ["Grade", 1269], ["I", 1275], ["subtype", 1277], [",", 1284], ["including", 1286], ["transitional", 1296], ["(", 1309], ["44", 1310], ["[", 1313], ["28.6", 1314], ["%", 1318], ["]", 1319], ["of", 1321], ["154", 1324], [")", 1327], [",", 1328], ["meningothelial", 1330], ["(", 1345], ["36", 1346], ["[", 1349], ["23.4", 1350], ["%", 1354], ["]", 1355], ["of", 1357], ["154", 1360], [")", 1363], [",", 1364], ["fibrous", 1366], ["(", 1374], ["23", 1375], ["[", 1378], ["14.9", 1379], ["%", 1383], ["]", 1384], ["of", 1386], ["154", 1389], [")", 1392], [",", 1393], ["psammomatous", 1395], ["(", 1408], ["22", 1409], ["[", 1412], ["14.3", 1413], ["%", 1417], ["]", 1418], ["of", 1420], ["154", 1423], [")", 1426], [",", 1427], ["secretory", 1429], ["(", 1439], ["10", 1440], ["[", 1443], ["6.5", 1444], ["%", 1447], ["]", 1448], ["of", 1450], ["154", 1453], [")", 1456], [",", 1457], ["and", 1459], ["angiomatous", 1463], ["(", 1475], ["19", 1476], ["[", 1479], ["12.3", 1480], ["%", 1484], ["]", 1485], ["of", 1487], ["154", 1490], [")", 1493], [".", 1494], ["The", 1496], ["other", 1500], ["25", 1506], ["(", 1509], ["14", 1510], ["%", 1512], [")", 1513], ["were", 1515], ["non", 1520], ["-", 1523], ["Grade", 1524], ["I", 1530], ["(", 1532], ["WHO", 1533], [")", 1536], ["tumors", 1538], [",", 1544], ["including", 1546], ["atypical", 1556], ["(", 1565], ["12", 1566], ["[", 1569], ["48", 1570], ["%", 1572], ["]", 1573], ["of", 1575], ["25", 1578], [")", 1580], [",", 1581], ["anaplastic", 1583], ["(", 1594], ["5", 1595], ["[", 1597], ["20", 1598], ["%", 1600], ["]", 1601], ["of", 1603], ["25", 1606], [")", 1608], [",", 1609], ["and", 1611], ["papillary", 1615], ["(", 1625], ["8", 1626], ["[", 1628], ["32", 1629], ["%", 1631], ["]", 1632], ["of", 1634], ["25", 1637], [")", 1639], [".", 1640], ["The", 1642], ["DTS", 1646], ["was", 1650], ["classified", 1654], ["into", 1665], ["5", 1670], ["types", 1672], [":", 1677], ["smooth", 1679], ["(", 1686], ["16", 1687], ["[", 1690], ["8.9", 1691], ["%", 1694], ["]", 1695], ["of", 1697], ["179", 1700], [")", 1703], [",", 1704], ["nodular", 1706], ["(", 1714], ["36", 1715], ["[", 1718], ["20.1", 1719], ["%", 1723], ["]", 1724], ["of", 1726], ["179", 1729], [")", 1732], [",", 1733], ["mixed", 1735], ["(", 1741], ["57", 1742], ["[", 1745], ["31.8", 1746], ["%", 1750], ["]", 1751], ["of", 1753], ["179", 1756], [")", 1759], [",", 1760], ["symmetrical", 1762], ["multipolar", 1774], ["(", 1785], ["15", 1786], ["[", 1789], ["8.4", 1790], ["%", 1793], ["]", 1794], ["of", 1796], ["179", 1799], [")", 1802], [",", 1803], ["and", 1805], ["asymmetrical", 1809], ["multipolar", 1822], ["(", 1833], ["55", 1834], ["[", 1837], ["30.7", 1838], ["%", 1842], ["]", 1843], ["of", 1845], ["179", 1848], [")", 1851], [".", 1852], ["There", 1854], ["was", 1860], ["a", 1864], ["significant", 1866], ["difference", 1878], ["in", 1889], ["distribution", 1892], ["of", 1905], ["DTS", 1908], ["type", 1912], ["between", 1917], ["Grade", 1925], ["I", 1931], ["and", 1933], ["non", 1937], ["-", 1940], ["Grade", 1941], ["I", 1947], ["tumors", 1949], ["(", 1956], ["p", 1957], ["=", 1959], ["0.004", 1961], [")", 1966], [",", 1967], ["whereas", 1969], ["the", 1977], ["difference", 1981], ["was", 1992], ["not", 1996], ["significant", 2000], ["among", 2012], ["Grade", 2018], ["I", 2024], ["tumors", 2026], ["(", 2033], ["0.841", 2034], [")", 2039], ["or", 2041], ["among", 2044], ["non", 2050], ["-", 2053], ["Grade", 2054], ["I", 2060], ["tumors", 2062], ["(", 2069], ["p", 2070], ["=", 2072], ["0.818", 2074], [")", 2079], [".", 2080], ["All", 2082], ["smooth", 2086], ["-", 2092], ["type", 2093], ["DTSs", 2098], ["were", 2103], ["encountered", 2108], ["in", 2120], ["Grade", 2123], ["I", 2129], ["tumors", 2131], [",", 2137], ["and", 2139], ["the", 2143], ["mixed", 2147], ["DTS", 2153], ["(", 2157], ["52", 2158], ["[", 2161], ["33.8", 2162], ["%", 2166], ["]", 2167], ["of", 2169], ["154", 2172], [")", 2175], ["was", 2177], ["the", 2181], ["most", 2185], ["common", 2190], ["type", 2197], ["in", 2202], ["these", 2205], ["tumors", 2211], [".", 2217], ["Nodular", 2219], ["-", 2226], ["type", 2227], ["DTS", 2232], ["was", 2236], ["more", 2240], ["commonly", 2245], ["seen", 2254], ["in", 2259], ["non", 2262], ["-", 2265], ["Grade", 2266], ["I", 2272], ["tumors", 2274], ["(", 2281], ["12", 2282], ["[", 2285], ["48", 2286], ["%", 2288], ["]", 2289], ["of", 2291], ["25", 2294], [")", 2296], [".", 2297], ["Tumor", 2299], ["invasion", 2305], ["was", 2314], ["found", 2318], ["in", 2324], ["88.3", 2327], ["%", 2331], ["(", 2333], ["158", 2334], ["of", 2338], ["179", 2341], [")", 2344], ["of", 2346], ["convexity", 2349], ["meningiomas", 2359], [",", 2370], ["of", 2372], ["which", 2375], ["the", 2381], ["range", 2385], ["of", 2391], ["invasion", 2394], ["in", 2403], ["82.3", 2406], ["%", 2410], ["(", 2412], ["130", 2413], ["of", 2417], ["158", 2420], [")", 2423], ["was", 2425], ["within", 2429], ["2", 2436], ["cm", 2438], ["and", 2441], ["that", 2445], ["in", 2450], ["94.9", 2453], ["%", 2457], ["(", 2459], ["150", 2460], ["of", 2464], ["158", 2467], [")", 2470], ["was", 2472], ["within", 2476], ["2.5", 2483], ["cm", 2487], [".", 2489], ["The", 2491], ["incidence", 2495], ["of", 2505], ["invasion", 2508], ["and", 2517], ["the", 2521], ["range", 2525], ["invaded", 2531], ["by", 2539], ["tumor", 2542], ["cells", 2548], ["varied", 2554], ["in", 2561], ["different", 2564], ["types", 2574], ["of", 2580], ["DTS", 2583], [",", 2586], ["and", 2588], ["differences", 2592], ["were", 2604], ["statistically", 2609], ["significant", 2623], ["(", 2635], ["p", 2636], ["<", 2638], ["0.001", 2640], [")", 2645], [".", 2646], ["Nodular", 2648], ["-", 2655], ["type", 2656], ["DTS", 2661], ["on", 2665], ["MRI", 2668], ["studies", 2672], ["might", 2680], ["be", 2686], ["associated", 2689], ["with", 2700], ["non", 2705], ["-", 2708], ["Grade", 2709], ["I", 2715], ["tumors", 2717], [".", 2723], ["The", 2725], ["range", 2729], ["of", 2735], ["dural", 2738], ["resection", 2744], ["for", 2754], ["convexity", 2758], ["meningiomas", 2768], ["should", 2780], ["be", 2787], ["2.5", 2790], ["cm", 2794], ["from", 2797], ["the", 2802], ["tumor", 2806], ["base", 2812], [",", 2816], ["and", 2818], ["if", 2822], ["this", 2825], ["extent", 2830], ["of", 2837], ["resection", 2840], ["is", 2850], ["not", 2853], ["feasible", 2857], [",", 2865], ["the", 2867], ["type", 2871], ["of", 2876], ["DTS", 2879], ["should", 2883], ["be", 2890], ["considered", 2893], [".", 2903], ["However", 2905], [",", 2912], ["for", 2914], ["skull", 2918], ["base", 2924], ["meningiomas", 2929], [",", 2940], ["in", 2942], ["which", 2945], ["mostly", 2951], ["Simpson", 2958], ["Grade", 2966], ["II", 2972], ["resection", 2975], ["is", 2985], ["achieved", 2988], [",", 2996], ["the", 2998], ["use", 3002], ["of", 3006], ["this", 3009], ["classification", 3014], ["should", 3029], ["be", 3036], ["further", 3039], ["validated", 3047], [".", 3056], ["The", 3058], ["classification", 3062], ["of", 3077], ["DTS", 3080], ["enables", 3084], ["the", 3092], ["surgeon", 3096], ["to", 3104], ["predict", 3107], ["preoperatively", 3115], ["and", 3130], ["then", 3134], ["to", 3139], ["achieve", 3142], ["the", 3150], ["optimal", 3154], ["range", 3162], ["of", 3168], ["dural", 3171], ["resection", 3177], ["that", 3187], ["might", 3192], ["significantly", 3198], ["reduce", 3212], ["the", 3219], ["recurrence", 3223], ["rate", 3234], ["of", 3239], ["meningiomas", 3242], [".", 3253]]}
{"context": "Ehlers-Danlos syndromes (EDSs) constitute a rare group of inherited connective tissue diseases, characterized by multisystemic manifestations and general tissue fragility. Most severe complications include vascular and gastrointestinal (GI) emergencies requiring acute surgery. The purpose of this systematic review was to assess the causes of GI-related surgery and related mortality and morbidity in patients with EDSs. A systematic search was conducted in PubMed, Embase, and Scopus to identify relevant studies. Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines for systematic reviews were followed. According to eligibility criteria, data were extracted and systematically screened by 2 authors. Screening process identified 11 studies with a total of 1,567 patients. Findings indicated that patients with EDSs had a higher occurrence of surgery demanding GI manifestations, including perforation, hemorrhage, rupture of intra-abdominal organs, and rectal prolapse. Most affected was the vascular subtype, of which up to 33% underwent GI surgery and suffered from a lowered average life expectancy of 48 years (range 6-78). Secondary complications of surgery were common in all patients with EDSs. Studies suggested that patients with EDSs present an increased need for GI surgery, but also an increased risk of surgery-related complications, most predominantly seen in the vascular subtype.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "3db08ec88fe14bf684b334546499f137", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14]], "char_spans": [[68, 84]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndromes", 14], ["(", 24], ["EDSs", 25], [")", 29], ["constitute", 31], ["a", 42], ["rare", 44], ["group", 49], ["of", 55], ["inherited", 58], ["connective", 68], ["tissue", 79], ["diseases", 86], [",", 94], ["characterized", 96], ["by", 110], ["multisystemic", 113], ["manifestations", 127], ["and", 142], ["general", 146], ["tissue", 154], ["fragility", 161], [".", 170], ["Most", 172], ["severe", 177], ["complications", 184], ["include", 198], ["vascular", 206], ["and", 215], ["gastrointestinal", 219], ["(", 236], ["GI", 237], [")", 239], ["emergencies", 241], ["requiring", 253], ["acute", 263], ["surgery", 269], [".", 276], ["The", 278], ["purpose", 282], ["of", 290], ["this", 293], ["systematic", 298], ["review", 309], ["was", 316], ["to", 320], ["assess", 323], ["the", 330], ["causes", 334], ["of", 341], ["GI", 344], ["-", 346], ["related", 347], ["surgery", 355], ["and", 363], ["related", 367], ["mortality", 375], ["and", 385], ["morbidity", 389], ["in", 399], ["patients", 402], ["with", 411], ["EDSs", 416], [".", 420], ["A", 422], ["systematic", 424], ["search", 435], ["was", 442], ["conducted", 446], ["in", 456], ["PubMed", 459], [",", 465], ["Embase", 467], [",", 473], ["and", 475], ["Scopus", 479], ["to", 486], ["identify", 489], ["relevant", 498], ["studies", 507], [".", 514], ["Preferred", 516], ["Reporting", 526], ["Items", 536], ["for", 542], ["Systematic", 546], ["Reviews", 557], ["and", 565], ["Meta", 569], ["-", 573], ["Analysis", 574], ["guidelines", 583], ["for", 594], ["systematic", 598], ["reviews", 609], ["were", 617], ["followed", 622], [".", 630], ["According", 632], ["to", 642], ["eligibility", 645], ["criteria", 657], [",", 665], ["data", 667], ["were", 672], ["extracted", 677], ["and", 687], ["systematically", 691], ["screened", 706], ["by", 715], ["2", 718], ["authors", 720], [".", 727], ["Screening", 729], ["process", 739], ["identified", 747], ["11", 758], ["studies", 761], ["with", 769], ["a", 774], ["total", 776], ["of", 782], ["1,567", 785], ["patients", 791], [".", 799], ["Findings", 801], ["indicated", 810], ["that", 820], ["patients", 825], ["with", 834], ["EDSs", 839], ["had", 844], ["a", 848], ["higher", 850], ["occurrence", 857], ["of", 868], ["surgery", 871], ["demanding", 879], ["GI", 889], ["manifestations", 892], [",", 906], ["including", 908], ["perforation", 918], [",", 929], ["hemorrhage", 931], [",", 941], ["rupture", 943], ["of", 951], ["intra", 954], ["-", 959], ["abdominal", 960], ["organs", 970], [",", 976], ["and", 978], ["rectal", 982], ["prolapse", 989], [".", 997], ["Most", 999], ["affected", 1004], ["was", 1013], ["the", 1017], ["vascular", 1021], ["subtype", 1030], [",", 1037], ["of", 1039], ["which", 1042], ["up", 1048], ["to", 1051], ["33", 1054], ["%", 1056], ["underwent", 1058], ["GI", 1068], ["surgery", 1071], ["and", 1079], ["suffered", 1083], ["from", 1092], ["a", 1097], ["lowered", 1099], ["average", 1107], ["life", 1115], ["expectancy", 1120], ["of", 1131], ["48", 1134], ["years", 1137], ["(", 1143], ["range", 1144], ["6", 1150], ["-", 1151], ["78", 1152], [")", 1154], [".", 1155], ["Secondary", 1157], ["complications", 1167], ["of", 1181], ["surgery", 1184], ["were", 1192], ["common", 1197], ["in", 1204], ["all", 1207], ["patients", 1211], ["with", 1220], ["EDSs", 1225], [".", 1229], ["Studies", 1231], ["suggested", 1239], ["that", 1249], ["patients", 1254], ["with", 1263], ["EDSs", 1268], ["present", 1273], ["an", 1281], ["increased", 1284], ["need", 1294], ["for", 1299], ["GI", 1303], ["surgery", 1306], [",", 1313], ["but", 1315], ["also", 1319], ["an", 1324], ["increased", 1327], ["risk", 1337], ["of", 1342], ["surgery", 1345], ["-", 1352], ["related", 1353], ["complications", 1361], [",", 1374], ["most", 1376], ["predominantly", 1381], ["seen", 1395], ["in", 1400], ["the", 1403], ["vascular", 1407], ["subtype", 1416], [".", 1423]]}
{"context": "Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph), which results in the synthesis of the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) fusion oncoprotein, a constitutively active tyrosine kinase. The introduction of imatinib, a tyrosine kinase inhibitor (TKI) that is specific for BCR-ABL, was a major breakthrough in CML therapy. Although most patients respond to first-line imatinib therapy, some experience loss of response (resistance) or require treatment discontinuation because of toxicity (intolerance). For patients with CML, failure on standard-dose imatinib therapy (400 mg daily), imatinib dose escalation (600-800 mg daily) is a second-line option. However, high-dose imatinib is not an appropriate approach for patients who experience drug toxicity, and there remain questions over the durability of responses achieved with this strategy. Alternative second-line options include the TKIs dasatinib and nilotinib. A substantial amount of long-term data for these agents is available. Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacologic profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutation status. To optimize therapeutic benefit, clinicians should select treatment based on each patient's historic response, adverse-event tolerance, and risk factors.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "9f71ac936fe846a99b99d2e030c881b0", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[218, 220], [77, 79], [244, 246], [48, 50]], "char_spans": [[1195, 1201], [441, 447], [1366, 1372], [286, 292]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["progressive", 36], ["and", 48], ["often", 52], ["fatal", 58], ["myeloproliferative", 64], ["neoplasm", 83], [".", 91], ["The", 93], ["hallmark", 97], ["of", 106], ["CML", 109], ["is", 113], ["an", 116], ["acquired", 119], ["chromosomal", 128], ["translocation", 140], ["known", 154], ["as", 160], ["the", 163], ["Philadelphia", 167], ["chromosome", 180], ["(", 191], ["Ph", 192], [")", 194], [",", 195], ["which", 197], ["results", 203], ["in", 211], ["the", 214], ["synthesis", 218], ["of", 228], ["the", 231], ["breakpoint", 235], ["cluster", 246], ["region", 254], ["-", 260], ["Abelson", 261], ["murine", 269], ["leukemia", 276], ["(", 285], ["BCR", 286], ["-", 289], ["ABL", 290], [")", 293], ["fusion", 295], ["oncoprotein", 302], [",", 313], ["a", 315], ["constitutively", 317], ["active", 332], ["tyrosine", 339], ["kinase", 348], [".", 354], ["The", 356], ["introduction", 360], ["of", 373], ["imatinib", 376], [",", 384], ["a", 386], ["tyrosine", 388], ["kinase", 397], ["inhibitor", 404], ["(", 414], ["TKI", 415], [")", 418], ["that", 420], ["is", 425], ["specific", 428], ["for", 437], ["BCR", 441], ["-", 444], ["ABL", 445], [",", 448], ["was", 450], ["a", 454], ["major", 456], ["breakthrough", 462], ["in", 475], ["CML", 478], ["therapy", 482], [".", 489], ["Although", 491], ["most", 500], ["patients", 505], ["respond", 514], ["to", 522], ["first", 525], ["-", 530], ["line", 531], ["imatinib", 536], ["therapy", 545], [",", 552], ["some", 554], ["experience", 559], ["loss", 570], ["of", 575], ["response", 578], ["(", 587], ["resistance", 588], [")", 598], ["or", 600], ["require", 603], ["treatment", 611], ["discontinuation", 621], ["because", 637], ["of", 645], ["toxicity", 648], ["(", 657], ["intolerance", 658], [")", 669], [".", 670], ["For", 672], ["patients", 676], ["with", 685], ["CML", 690], [",", 693], ["failure", 695], ["on", 703], ["standard", 706], ["-", 714], ["dose", 715], ["imatinib", 720], ["therapy", 729], ["(", 737], ["400", 738], ["mg", 742], ["daily", 745], [")", 750], [",", 751], ["imatinib", 753], ["dose", 762], ["escalation", 767], ["(", 778], ["600", 779], ["-", 782], ["800", 783], ["mg", 787], ["daily", 790], [")", 795], ["is", 797], ["a", 800], ["second", 802], ["-", 808], ["line", 809], ["option", 814], [".", 820], ["However", 822], [",", 829], ["high", 831], ["-", 835], ["dose", 836], ["imatinib", 841], ["is", 850], ["not", 853], ["an", 857], ["appropriate", 860], ["approach", 872], ["for", 881], ["patients", 885], ["who", 894], ["experience", 898], ["drug", 909], ["toxicity", 914], [",", 922], ["and", 924], ["there", 928], ["remain", 934], ["questions", 941], ["over", 951], ["the", 956], ["durability", 960], ["of", 971], ["responses", 974], ["achieved", 984], ["with", 993], ["this", 998], ["strategy", 1003], [".", 1011], ["Alternative", 1013], ["second", 1025], ["-", 1031], ["line", 1032], ["options", 1037], ["include", 1045], ["the", 1053], ["TKIs", 1057], ["dasatinib", 1062], ["and", 1072], ["nilotinib", 1076], [".", 1085], ["A", 1087], ["substantial", 1089], ["amount", 1101], ["of", 1108], ["long", 1111], ["-", 1115], ["term", 1116], ["data", 1121], ["for", 1126], ["these", 1130], ["agents", 1136], ["is", 1143], ["available", 1146], [".", 1155], ["Although", 1157], ["both", 1166], ["are", 1171], ["potent", 1175], ["and", 1182], ["specific", 1186], ["BCR", 1195], ["-", 1198], ["ABL", 1199], ["TKIs", 1203], [",", 1207], ["dasatinib", 1209], ["and", 1219], ["nilotinib", 1223], ["exhibit", 1233], ["unique", 1241], ["pharmacologic", 1248], ["profiles", 1262], ["and", 1271], ["response", 1275], ["patterns", 1284], ["relative", 1293], ["to", 1302], ["different", 1305], ["patient", 1315], ["characteristics", 1323], [",", 1338], ["such", 1340], ["as", 1345], ["disease", 1348], ["stage", 1356], ["and", 1362], ["BCR", 1366], ["-", 1369], ["ABL", 1370], ["mutation", 1374], ["status", 1383], [".", 1389], ["To", 1391], ["optimize", 1394], ["therapeutic", 1403], ["benefit", 1415], [",", 1422], ["clinicians", 1424], ["should", 1435], ["select", 1442], ["treatment", 1449], ["based", 1459], ["on", 1465], ["each", 1468], ["patient", 1473], ["'s", 1480], ["historic", 1483], ["response", 1492], [",", 1500], ["adverse", 1502], ["-", 1509], ["event", 1510], ["tolerance", 1516], [",", 1525], ["and", 1527], ["risk", 1531], ["factors", 1536], [".", 1543]]}
{"context": "For dozens of years, a variety of pathological findings have been revealed through previous observations on surgically resected lesions from patients with intractable epilepsy, including excessive number of neurons in the molecular layer of cortices, unexpected existence of white matter neurons, and persistent columnar structure. These findings have sometimes been referred to as microdysgenesis (MD) or mild malformation of cortical development (mMCD), which is defined as microscopic abnormalities of brain formations with no macroscopical and neuroradiological findings. Taylor et al. (1971) described surgical cases with giant neurons and bizarre, grotesque cells as \"focal dysplasia of the cerebral cortices with epilepsy.\" Since 1997, such malformations have subsequently been referred to as focal cortical dysplasia (FCD), in Greenfield's Neuropathology. Since early 2000, the definition of FCD has gradually been given a broader interpretation than the case described by Taylor et al., as shown in Palmini's classification (2004) or the newest classification (2011) proposed by the Neuropathology Task Force of the International League Against Epilepsy (ILAE). The ILAE classification describes 3 types of disease: Type I, Type II, and Type III. Type I is equivalent to some, but not all, pathological phenotypes of MD or mMCD. Type II is Taylor's FCD alone. Type III, which was not included in Palmini's classification, merges brain malformation and other pathological findings. However, the reproducibility of pathological diagnosis by using the ILAE classification was low, except for Type IIb. Hence, future studies are necessary to provide further reliable criteria for the pathological diagnosis of epilepsy patients.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "71df3d8251d84f0f8c452651b470a6ec", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[129, 131]], "char_spans": [[800, 823]]}]}], "context_tokens": [["For", 0], ["dozens", 4], ["of", 11], ["years", 14], [",", 19], ["a", 21], ["variety", 23], ["of", 31], ["pathological", 34], ["findings", 47], ["have", 56], ["been", 61], ["revealed", 66], ["through", 75], ["previous", 83], ["observations", 92], ["on", 105], ["surgically", 108], ["resected", 119], ["lesions", 128], ["from", 136], ["patients", 141], ["with", 150], ["intractable", 155], ["epilepsy", 167], [",", 175], ["including", 177], ["excessive", 187], ["number", 197], ["of", 204], ["neurons", 207], ["in", 215], ["the", 218], ["molecular", 222], ["layer", 232], ["of", 238], ["cortices", 241], [",", 249], ["unexpected", 251], ["existence", 262], ["of", 272], ["white", 275], ["matter", 281], ["neurons", 288], [",", 295], ["and", 297], ["persistent", 301], ["columnar", 312], ["structure", 321], [".", 330], ["These", 332], ["findings", 338], ["have", 347], ["sometimes", 352], ["been", 362], ["referred", 367], ["to", 376], ["as", 379], ["microdysgenesis", 382], ["(", 398], ["MD", 399], [")", 401], ["or", 403], ["mild", 406], ["malformation", 411], ["of", 424], ["cortical", 427], ["development", 436], ["(", 448], ["mMCD", 449], [")", 453], [",", 454], ["which", 456], ["is", 462], ["defined", 465], ["as", 473], ["microscopic", 476], ["abnormalities", 488], ["of", 502], ["brain", 505], ["formations", 511], ["with", 522], ["no", 527], ["macroscopical", 530], ["and", 544], ["neuroradiological", 548], ["findings", 566], [".", 574], ["Taylor", 576], ["et", 583], ["al", 586], [".", 588], ["(", 590], ["1971", 591], [")", 595], ["described", 597], ["surgical", 607], ["cases", 616], ["with", 622], ["giant", 627], ["neurons", 633], ["and", 641], ["bizarre", 645], [",", 652], ["grotesque", 654], ["cells", 664], ["as", 670], ["\"", 673], ["focal", 674], ["dysplasia", 680], ["of", 690], ["the", 693], ["cerebral", 697], ["cortices", 706], ["with", 715], ["epilepsy", 720], [".", 728], ["\"", 729], ["Since", 731], ["1997", 737], [",", 741], ["such", 743], ["malformations", 748], ["have", 762], ["subsequently", 767], ["been", 780], ["referred", 785], ["to", 794], ["as", 797], ["focal", 800], ["cortical", 806], ["dysplasia", 815], ["(", 825], ["FCD", 826], [")", 829], [",", 830], ["in", 832], ["Greenfield", 835], ["'s", 845], ["Neuropathology", 848], [".", 862], ["Since", 864], ["early", 870], ["2000", 876], [",", 880], ["the", 882], ["definition", 886], ["of", 897], ["FCD", 900], ["has", 904], ["gradually", 908], ["been", 918], ["given", 923], ["a", 929], ["broader", 931], ["interpretation", 939], ["than", 954], ["the", 959], ["case", 963], ["described", 968], ["by", 978], ["Taylor", 981], ["et", 988], ["al", 991], [".", 993], [",", 994], ["as", 996], ["shown", 999], ["in", 1005], ["Palmini", 1008], ["'s", 1015], ["classification", 1018], ["(", 1033], ["2004", 1034], [")", 1038], ["or", 1040], ["the", 1043], ["newest", 1047], ["classification", 1054], ["(", 1069], ["2011", 1070], [")", 1074], ["proposed", 1076], ["by", 1085], ["the", 1088], ["Neuropathology", 1092], ["Task", 1107], ["Force", 1112], ["of", 1118], ["the", 1121], ["International", 1125], ["League", 1139], ["Against", 1146], ["Epilepsy", 1154], ["(", 1163], ["ILAE", 1164], [")", 1168], [".", 1169], ["The", 1171], ["ILAE", 1175], ["classification", 1180], ["describes", 1195], ["3", 1205], ["types", 1207], ["of", 1213], ["disease", 1216], [":", 1223], ["Type", 1225], ["I", 1230], [",", 1231], ["Type", 1233], ["II", 1238], [",", 1240], ["and", 1242], ["Type", 1246], ["III", 1251], [".", 1254], ["Type", 1256], ["I", 1261], ["is", 1263], ["equivalent", 1266], ["to", 1277], ["some", 1280], [",", 1284], ["but", 1286], ["not", 1290], ["all", 1294], [",", 1297], ["pathological", 1299], ["phenotypes", 1312], ["of", 1323], ["MD", 1326], ["or", 1329], ["mMCD", 1332], [".", 1336], ["Type", 1338], ["II", 1343], ["is", 1346], ["Taylor", 1349], ["'s", 1355], ["FCD", 1358], ["alone", 1362], [".", 1367], ["Type", 1369], ["III", 1374], [",", 1377], ["which", 1379], ["was", 1385], ["not", 1389], ["included", 1393], ["in", 1402], ["Palmini", 1405], ["'s", 1412], ["classification", 1415], [",", 1429], ["merges", 1431], ["brain", 1438], ["malformation", 1444], ["and", 1457], ["other", 1461], ["pathological", 1467], ["findings", 1480], [".", 1488], ["However", 1490], [",", 1497], ["the", 1499], ["reproducibility", 1503], ["of", 1519], ["pathological", 1522], ["diagnosis", 1535], ["by", 1545], ["using", 1548], ["the", 1554], ["ILAE", 1558], ["classification", 1563], ["was", 1578], ["low", 1582], [",", 1585], ["except", 1587], ["for", 1594], ["Type", 1598], ["IIb", 1603], [".", 1606], ["Hence", 1608], [",", 1613], ["future", 1615], ["studies", 1622], ["are", 1630], ["necessary", 1634], ["to", 1644], ["provide", 1647], ["further", 1655], ["reliable", 1663], ["criteria", 1672], ["for", 1681], ["the", 1685], ["pathological", 1689], ["diagnosis", 1702], ["of", 1712], ["epilepsy", 1715], ["patients", 1724], [".", 1732]]}
{"context": "Diabetic nephropathy is the leading cause of end-stage renal disease in humans in the Western world. The recent development of Na+-glucose cotransporter 2 (SGLT2) inhibitors offers a new antidiabetic therapy via enhanced glucose excretion. Whether this strategy exerts beneficial effects on the development of type 2 diabetic nephropathy is still largely unclear. We investigated the effects of the specific SGLT2 inhibitor empagliflozin in BTBR.Cg-Lep<ob>/WiscJ (BTBR ob/ob) mice, which spontaneously develop type 2 diabetic nephropathy. In the first experiment, BTBR ob/ob mice received either a diet containing 300 ppm empagliflozin or equicaloric placebo chow for 12 wk. In the second experiment, BTBR ob/ob mice received 1 \u03bcg\u00b7kg body wt(-1)\u00b7day(-1) ANG II to induce arterial hypertension and were separated into the same two diet groups for 6 wk. In both experiments, empagliflozin treatment enhanced glucosuria, thereby lowering blood glucose. Independently of hypertension, empagliflozin reduced albuminuria in diabetic mice. However, empagliflozin treatment affected diabetes-related glomerular hypertrophy, markers of renal inflammation, and mesangial matrix expansion only in BTBR ob/ob mice without hypertension. In summary, empagliflozin demonstrated significant antihyperglycemic effects, differentially ameliorating early features of diabetic nephropathy in BTBR ob/ob mice with and without hypertension.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "eee52f339cdf4af89a3273019a0da1ab", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[27, 27], [66, 66]], "char_spans": [[156, 160], [408, 412]]}]}], "context_tokens": [["Diabetic", 0], ["nephropathy", 9], ["is", 21], ["the", 24], ["leading", 28], ["cause", 36], ["of", 42], ["end", 45], ["-", 48], ["stage", 49], ["renal", 55], ["disease", 61], ["in", 69], ["humans", 72], ["in", 79], ["the", 82], ["Western", 86], ["world", 94], [".", 99], ["The", 101], ["recent", 105], ["development", 112], ["of", 124], ["Na+-glucose", 127], ["cotransporter", 139], ["2", 153], ["(", 155], ["SGLT2", 156], [")", 161], ["inhibitors", 163], ["offers", 174], ["a", 181], ["new", 183], ["antidiabetic", 187], ["therapy", 200], ["via", 208], ["enhanced", 212], ["glucose", 221], ["excretion", 229], [".", 238], ["Whether", 240], ["this", 248], ["strategy", 253], ["exerts", 262], ["beneficial", 269], ["effects", 280], ["on", 288], ["the", 291], ["development", 295], ["of", 307], ["type", 310], ["2", 315], ["diabetic", 317], ["nephropathy", 326], ["is", 338], ["still", 341], ["largely", 347], ["unclear", 355], [".", 362], ["We", 364], ["investigated", 367], ["the", 380], ["effects", 384], ["of", 392], ["the", 395], ["specific", 399], ["SGLT2", 408], ["inhibitor", 414], ["empagliflozin", 424], ["in", 438], ["BTBR.Cg", 441], ["-", 448], ["Lep", 449], ["<", 452], ["ob>/WiscJ", 453], ["(", 463], ["BTBR", 464], ["ob", 469], ["/", 471], ["ob", 472], [")", 474], ["mice", 476], [",", 480], ["which", 482], ["spontaneously", 488], ["develop", 502], ["type", 510], ["2", 515], ["diabetic", 517], ["nephropathy", 526], [".", 537], ["In", 539], ["the", 542], ["first", 546], ["experiment", 552], [",", 562], ["BTBR", 564], ["ob", 569], ["/", 571], ["ob", 572], ["mice", 575], ["received", 580], ["either", 589], ["a", 596], ["diet", 598], ["containing", 603], ["300", 614], ["ppm", 618], ["empagliflozin", 622], ["or", 636], ["equicaloric", 639], ["placebo", 651], ["chow", 659], ["for", 664], ["12", 668], ["wk", 671], [".", 673], ["In", 675], ["the", 678], ["second", 682], ["experiment", 689], [",", 699], ["BTBR", 701], ["ob", 706], ["/", 708], ["ob", 709], ["mice", 712], ["received", 717], ["1", 726], ["\u03bcg\u00b7kg", 728], ["body", 734], ["wt(-1)\u00b7day(-1", 739], [")", 752], ["ANG", 754], ["II", 758], ["to", 761], ["induce", 764], ["arterial", 771], ["hypertension", 780], ["and", 793], ["were", 797], ["separated", 802], ["into", 812], ["the", 817], ["same", 821], ["two", 826], ["diet", 830], ["groups", 835], ["for", 842], ["6", 846], ["wk", 848], [".", 850], ["In", 852], ["both", 855], ["experiments", 860], [",", 871], ["empagliflozin", 873], ["treatment", 887], ["enhanced", 897], ["glucosuria", 906], [",", 916], ["thereby", 918], ["lowering", 926], ["blood", 935], ["glucose", 941], [".", 948], ["Independently", 950], ["of", 964], ["hypertension", 967], [",", 979], ["empagliflozin", 981], ["reduced", 995], ["albuminuria", 1003], ["in", 1015], ["diabetic", 1018], ["mice", 1027], [".", 1031], ["However", 1033], [",", 1040], ["empagliflozin", 1042], ["treatment", 1056], ["affected", 1066], ["diabetes", 1075], ["-", 1083], ["related", 1084], ["glomerular", 1092], ["hypertrophy", 1103], [",", 1114], ["markers", 1116], ["of", 1124], ["renal", 1127], ["inflammation", 1133], [",", 1145], ["and", 1147], ["mesangial", 1151], ["matrix", 1161], ["expansion", 1168], ["only", 1178], ["in", 1183], ["BTBR", 1186], ["ob", 1191], ["/", 1193], ["ob", 1194], ["mice", 1197], ["without", 1202], ["hypertension", 1210], [".", 1222], ["In", 1224], ["summary", 1227], [",", 1234], ["empagliflozin", 1236], ["demonstrated", 1250], ["significant", 1263], ["antihyperglycemic", 1275], ["effects", 1293], [",", 1300], ["differentially", 1302], ["ameliorating", 1317], ["early", 1330], ["features", 1336], ["of", 1345], ["diabetic", 1348], ["nephropathy", 1357], ["in", 1369], ["BTBR", 1372], ["ob", 1377], ["/", 1379], ["ob", 1380], ["mice", 1383], ["with", 1388], ["and", 1393], ["without", 1397], ["hypertension", 1405], [".", 1417]]}
{"context": "Postoperative methicillin-resistant Staphylococcus aureus (MRSA) infections are occasionally fatal. We hypothesized that nasal MRSA screening might predict the risk of postoperative MRSA infections. The aim of the current study was to elucidate the relationship between the positivity of nasal MRSA screening and postoperative MRSA infections. Six hundred and fourteen surgical patients who were admitted to the intensive care unit and underwent nasal MRSA screening between April 2006 and March 2011 were divided into MRSA-positive and -negative groups. The incidence of postoperative MRSA infections in the MRSA-positive and MRSA-negative groups were compared, and various risk factors for MRSA infections were evaluated. The incidence of postoperative MRSA infections, such as pneumonia and enteritis, in the MRSA-positive group was significantly higher than that in the MRSA-negative group (41.9 vs. 3.1 %). The significant independent risk factors for postoperative MRSA infections were a positive MRSA screening, an operation lasting more than 300 min and an emergency operation. A positive MRSA screening was the most statistically significant risk factor for postoperative MRSA pneumonia and enteritis, but was not a risk factor for MRSA surgical site infections. Nasal MRSA screening can help to identify patients who have an increased risk of developing postoperative MRSA infections, and would enable physicians to take a prompt action if these complications occur.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "a9817a6931814cc1929eed39d878021d", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[80, 80], [160, 160], [45, 45], [205, 205], [211, 211], [7, 7], [111, 111], [120, 120], [69, 69], [131, 131], [142, 142], [226, 226], [193, 193], [49, 49], [26, 26], [91, 91], [99, 99], [165, 165], [182, 182], [18, 18], [95, 95]], "char_spans": [[519, 522], [971, 974], [294, 297], [1241, 1244], [1278, 1281], [59, 62], [692, 695], [755, 758], [452, 455], [812, 815], [874, 877], [1378, 1381], [1181, 1184], [327, 330], [182, 185], [586, 589], [627, 630], [1003, 1006], [1097, 1100], [127, 130], [609, 612]]}]}], "context_tokens": [["Postoperative", 0], ["methicillin", 14], ["-", 25], ["resistant", 26], ["Staphylococcus", 36], ["aureus", 51], ["(", 58], ["MRSA", 59], [")", 63], ["infections", 65], ["are", 76], ["occasionally", 80], ["fatal", 93], [".", 98], ["We", 100], ["hypothesized", 103], ["that", 116], ["nasal", 121], ["MRSA", 127], ["screening", 132], ["might", 142], ["predict", 148], ["the", 156], ["risk", 160], ["of", 165], ["postoperative", 168], ["MRSA", 182], ["infections", 187], [".", 197], ["The", 199], ["aim", 203], ["of", 207], ["the", 210], ["current", 214], ["study", 222], ["was", 228], ["to", 232], ["elucidate", 235], ["the", 245], ["relationship", 249], ["between", 262], ["the", 270], ["positivity", 274], ["of", 285], ["nasal", 288], ["MRSA", 294], ["screening", 299], ["and", 309], ["postoperative", 313], ["MRSA", 327], ["infections", 332], [".", 342], ["Six", 344], ["hundred", 348], ["and", 356], ["fourteen", 360], ["surgical", 369], ["patients", 378], ["who", 387], ["were", 391], ["admitted", 396], ["to", 405], ["the", 408], ["intensive", 412], ["care", 422], ["unit", 427], ["and", 432], ["underwent", 436], ["nasal", 446], ["MRSA", 452], ["screening", 457], ["between", 467], ["April", 475], ["2006", 481], ["and", 486], ["March", 490], ["2011", 496], ["were", 501], ["divided", 506], ["into", 514], ["MRSA", 519], ["-", 523], ["positive", 524], ["and", 533], ["-negative", 537], ["groups", 547], [".", 553], ["The", 555], ["incidence", 559], ["of", 569], ["postoperative", 572], ["MRSA", 586], ["infections", 591], ["in", 602], ["the", 605], ["MRSA", 609], ["-", 613], ["positive", 614], ["and", 623], ["MRSA", 627], ["-", 631], ["negative", 632], ["groups", 641], ["were", 648], ["compared", 653], [",", 661], ["and", 663], ["various", 667], ["risk", 675], ["factors", 680], ["for", 688], ["MRSA", 692], ["infections", 697], ["were", 708], ["evaluated", 713], [".", 722], ["The", 724], ["incidence", 728], ["of", 738], ["postoperative", 741], ["MRSA", 755], ["infections", 760], [",", 770], ["such", 772], ["as", 777], ["pneumonia", 780], ["and", 790], ["enteritis", 794], [",", 803], ["in", 805], ["the", 808], ["MRSA", 812], ["-", 816], ["positive", 817], ["group", 826], ["was", 832], ["significantly", 836], ["higher", 850], ["than", 857], ["that", 862], ["in", 867], ["the", 870], ["MRSA", 874], ["-", 878], ["negative", 879], ["group", 888], ["(", 894], ["41.9", 895], ["vs.", 900], ["3.1", 904], ["%", 908], [")", 909], [".", 910], ["The", 912], ["significant", 916], ["independent", 928], ["risk", 940], ["factors", 945], ["for", 953], ["postoperative", 957], ["MRSA", 971], ["infections", 976], ["were", 987], ["a", 992], ["positive", 994], ["MRSA", 1003], ["screening", 1008], [",", 1017], ["an", 1019], ["operation", 1022], ["lasting", 1032], ["more", 1040], ["than", 1045], ["300", 1050], ["min", 1054], ["and", 1058], ["an", 1062], ["emergency", 1065], ["operation", 1075], [".", 1084], ["A", 1086], ["positive", 1088], ["MRSA", 1097], ["screening", 1102], ["was", 1112], ["the", 1116], ["most", 1120], ["statistically", 1125], ["significant", 1139], ["risk", 1151], ["factor", 1156], ["for", 1163], ["postoperative", 1167], ["MRSA", 1181], ["pneumonia", 1186], ["and", 1196], ["enteritis", 1200], [",", 1209], ["but", 1211], ["was", 1215], ["not", 1219], ["a", 1223], ["risk", 1225], ["factor", 1230], ["for", 1237], ["MRSA", 1241], ["surgical", 1246], ["site", 1255], ["infections", 1260], [".", 1270], ["Nasal", 1272], ["MRSA", 1278], ["screening", 1283], ["can", 1293], ["help", 1297], ["to", 1302], ["identify", 1305], ["patients", 1314], ["who", 1323], ["have", 1327], ["an", 1332], ["increased", 1335], ["risk", 1345], ["of", 1350], ["developing", 1353], ["postoperative", 1364], ["MRSA", 1378], ["infections", 1383], [",", 1393], ["and", 1395], ["would", 1399], ["enable", 1405], ["physicians", 1412], ["to", 1423], ["take", 1426], ["a", 1431], ["prompt", 1433], ["action", 1440], ["if", 1447], ["these", 1450], ["complications", 1456], ["occur", 1470], [".", 1475]]}
{"context": "The Na(+)/Ca(2+) exchanger (NCX) plays a role in the regulation of intracellular Ca(2+) levels, and nitric oxide (NO) is involved in many pathological conditions including neurodegenerative disorders. We have previously found that sodium nitroprusside (SNP), an NO donor, causes apoptotic-like cell death in cultured glial cells via NCX-mediated pathways and the mechanism for NO-induced cytotoxicity is cell type-dependent. The present study examined using the specific NCX inhibitor 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400) whether NCX is involved in NO-induced injury in cultured neuronal cells. The treatment of neuroblastoma SH-SY5Y cells with SNP resulted in apoptosis and the cytotoxicity was blocked by the mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor U0126 and the p38 MAP kinase (MAPK) inhibitor SB203580, but not by the c-Jun N-terminal kinase (JNK) inhibitor SP60012. SNP increased Ca(2+) influx and intracellular Ca(2+) levels. In addition, SNP increased ERK and p38 MAPK phosphorylation, and production of reactive oxygen species (ROS) in an extracellular Ca(2+)-dependent manner. These effects of SNP were prevented by SEA0400. SNP-induced cytotoxicity was not affected by inhibitors of the Ca(2+), Na(+) and store-operated/capacitative channels. Moreover, SNP-induced increase in intracellular Ca(2+) levels, ROS production and decrease in cell viability were blocked by a cGMP-dependent protein kinase (PKG) inhibitor. These results suggest that Ca(2+) influx via the reverse of NCX is involved in the cascade of NO-induced neuronal apoptosis and NO activates the NCX through guanylate cyclase/PKG pathway.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "78c14f714e4744988b69ad994964895d", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[1, 4]], "char_spans": [[4, 25]]}, {"text": "NCX", "token_spans": [[291, 291], [307, 307], [6, 6], [63, 63], [88, 88], [95, 95]], "char_spans": [[1572, 1574], [1657, 1659], [28, 30], [333, 335], [471, 473], [562, 564]]}]}], "context_tokens": [["The", 0], ["Na(+)/Ca(2", 4], ["+", 14], [")", 15], ["exchanger", 17], ["(", 27], ["NCX", 28], [")", 31], ["plays", 33], ["a", 39], ["role", 41], ["in", 46], ["the", 49], ["regulation", 53], ["of", 64], ["intracellular", 67], ["Ca(2", 81], ["+", 85], [")", 86], ["levels", 88], [",", 94], ["and", 96], ["nitric", 100], ["oxide", 107], ["(", 113], ["NO", 114], [")", 116], ["is", 118], ["involved", 121], ["in", 130], ["many", 133], ["pathological", 138], ["conditions", 151], ["including", 162], ["neurodegenerative", 172], ["disorders", 190], [".", 199], ["We", 201], ["have", 204], ["previously", 209], ["found", 220], ["that", 226], ["sodium", 231], ["nitroprusside", 238], ["(", 252], ["SNP", 253], [")", 256], [",", 257], ["an", 259], ["NO", 262], ["donor", 265], [",", 270], ["causes", 272], ["apoptotic", 279], ["-", 288], ["like", 289], ["cell", 294], ["death", 299], ["in", 305], ["cultured", 308], ["glial", 317], ["cells", 323], ["via", 329], ["NCX", 333], ["-", 336], ["mediated", 337], ["pathways", 346], ["and", 355], ["the", 359], ["mechanism", 363], ["for", 373], ["NO", 377], ["-", 379], ["induced", 380], ["cytotoxicity", 388], ["is", 401], ["cell", 404], ["type", 409], ["-", 413], ["dependent", 414], [".", 423], ["The", 425], ["present", 429], ["study", 437], ["examined", 443], ["using", 452], ["the", 458], ["specific", 462], ["NCX", 471], ["inhibitor", 475], ["2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline", 485], ["(", 544], ["SEA0400", 545], [")", 552], ["whether", 554], ["NCX", 562], ["is", 566], ["involved", 569], ["in", 578], ["NO", 581], ["-", 583], ["induced", 584], ["injury", 592], ["in", 599], ["cultured", 602], ["neuronal", 611], ["cells", 620], [".", 625], ["The", 627], ["treatment", 631], ["of", 641], ["neuroblastoma", 644], ["SH", 658], ["-", 660], ["SY5Y", 661], ["cells", 666], ["with", 672], ["SNP", 677], ["resulted", 681], ["in", 690], ["apoptosis", 693], ["and", 703], ["the", 707], ["cytotoxicity", 711], ["was", 724], ["blocked", 728], ["by", 736], ["the", 739], ["mitogen", 743], ["-", 750], ["activated", 751], ["protein", 761], ["(", 769], ["MAP)/extracellular", 770], ["signal", 789], ["-", 795], ["regulated", 796], ["kinase", 806], ["(", 813], ["ERK", 814], [")", 817], ["kinase", 819], ["inhibitor", 826], ["U0126", 836], ["and", 842], ["the", 846], ["p38", 850], ["MAP", 854], ["kinase", 858], ["(", 865], ["MAPK", 866], [")", 870], ["inhibitor", 872], ["SB203580", 882], [",", 890], ["but", 892], ["not", 896], ["by", 900], ["the", 903], ["c", 907], ["-", 908], ["Jun", 909], ["N", 913], ["-", 914], ["terminal", 915], ["kinase", 924], ["(", 931], ["JNK", 932], [")", 935], ["inhibitor", 937], ["SP60012", 947], [".", 954], ["SNP", 956], ["increased", 960], ["Ca(2", 970], ["+", 974], [")", 975], ["influx", 977], ["and", 984], ["intracellular", 988], ["Ca(2", 1002], ["+", 1006], [")", 1007], ["levels", 1009], [".", 1015], ["In", 1017], ["addition", 1020], [",", 1028], ["SNP", 1030], ["increased", 1034], ["ERK", 1044], ["and", 1048], ["p38", 1052], ["MAPK", 1056], ["phosphorylation", 1061], [",", 1076], ["and", 1078], ["production", 1082], ["of", 1093], ["reactive", 1096], ["oxygen", 1105], ["species", 1112], ["(", 1120], ["ROS", 1121], [")", 1124], ["in", 1126], ["an", 1129], ["extracellular", 1132], ["Ca(2+)-dependent", 1146], ["manner", 1163], [".", 1169], ["These", 1171], ["effects", 1177], ["of", 1185], ["SNP", 1188], ["were", 1192], ["prevented", 1197], ["by", 1207], ["SEA0400", 1210], [".", 1217], ["SNP", 1219], ["-", 1222], ["induced", 1223], ["cytotoxicity", 1231], ["was", 1244], ["not", 1248], ["affected", 1252], ["by", 1261], ["inhibitors", 1264], ["of", 1275], ["the", 1278], ["Ca(2", 1282], ["+", 1286], [")", 1287], [",", 1288], ["Na(+", 1290], [")", 1294], ["and", 1296], ["store", 1300], ["-", 1305], ["operated", 1306], ["/", 1314], ["capacitative", 1315], ["channels", 1328], [".", 1336], ["Moreover", 1338], [",", 1346], ["SNP", 1348], ["-", 1351], ["induced", 1352], ["increase", 1360], ["in", 1369], ["intracellular", 1372], ["Ca(2", 1386], ["+", 1390], [")", 1391], ["levels", 1393], [",", 1399], ["ROS", 1401], ["production", 1405], ["and", 1416], ["decrease", 1420], ["in", 1429], ["cell", 1432], ["viability", 1437], ["were", 1447], ["blocked", 1452], ["by", 1460], ["a", 1463], ["cGMP", 1465], ["-", 1469], ["dependent", 1470], ["protein", 1480], ["kinase", 1488], ["(", 1495], ["PKG", 1496], [")", 1499], ["inhibitor", 1501], [".", 1510], ["These", 1512], ["results", 1518], ["suggest", 1526], ["that", 1534], ["Ca(2", 1539], ["+", 1543], [")", 1544], ["influx", 1546], ["via", 1553], ["the", 1557], ["reverse", 1561], ["of", 1569], ["NCX", 1572], ["is", 1576], ["involved", 1579], ["in", 1588], ["the", 1591], ["cascade", 1595], ["of", 1603], ["NO", 1606], ["-", 1608], ["induced", 1609], ["neuronal", 1617], ["apoptosis", 1626], ["and", 1636], ["NO", 1640], ["activates", 1643], ["the", 1653], ["NCX", 1657], ["through", 1661], ["guanylate", 1669], ["cyclase", 1679], ["/", 1686], ["PKG", 1687], ["pathway", 1691], [".", 1698]]}
{"context": "Lysosomal storage diseases arise from a genetic loss-of-function defect in enzymes mediating key catabolic steps resulting in accumulation of substrate within the lysosome. Treatment of several of these disorders has been achieved by enzyme replacement therapy (ERT), in which a recombinant version of the defective enzyme is expressed in vitro and administered by infusion. However, in many cases the biodistribution of the administered protein does not match that of the accumulated substrate due to the glycosylation-mediated clearance of the enzymes from circulation, resulting in poor or absent substrate clearance from some tissues. To overcome this limitation, we have evaluated several peptide-based targeting motifs to redirect recombinant human alpha-galactosidase (rhalphaGal) to specific receptors. A reversible thiol-based PEGylation chemistry was developed to achieve multivalent peptide display with lysosomal release. In vitro, cell uptake was peptide dependent and independent of the normal mannose-6-phosphate receptor mediated pathway. Surprisingly, despite increased plasma half-life and decreased liver uptake, none of the peptide conjugates showed significantly altered biodistribution in alphaGal-knockout mice. This suggests that these peptide-based targeting motifs are unlikely to provide substantial therapeutic benefit likely due to the complexity of factors affecting PK and biodistribution.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "17805ad0408c48df91cdeb947ccf3371", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[124, 126]], "char_spans": [[755, 773]]}]}], "context_tokens": [["Lysosomal", 0], ["storage", 10], ["diseases", 18], ["arise", 27], ["from", 33], ["a", 38], ["genetic", 40], ["loss", 48], ["-", 52], ["of", 53], ["-", 55], ["function", 56], ["defect", 65], ["in", 72], ["enzymes", 75], ["mediating", 83], ["key", 93], ["catabolic", 97], ["steps", 107], ["resulting", 113], ["in", 123], ["accumulation", 126], ["of", 139], ["substrate", 142], ["within", 152], ["the", 159], ["lysosome", 163], [".", 171], ["Treatment", 173], ["of", 183], ["several", 186], ["of", 194], ["these", 197], ["disorders", 203], ["has", 213], ["been", 217], ["achieved", 222], ["by", 231], ["enzyme", 234], ["replacement", 241], ["therapy", 253], ["(", 261], ["ERT", 262], [")", 265], [",", 266], ["in", 268], ["which", 271], ["a", 277], ["recombinant", 279], ["version", 291], ["of", 299], ["the", 302], ["defective", 306], ["enzyme", 316], ["is", 323], ["expressed", 326], ["in", 336], ["vitro", 339], ["and", 345], ["administered", 349], ["by", 362], ["infusion", 365], [".", 373], ["However", 375], [",", 382], ["in", 384], ["many", 387], ["cases", 392], ["the", 398], ["biodistribution", 402], ["of", 418], ["the", 421], ["administered", 425], ["protein", 438], ["does", 446], ["not", 451], ["match", 455], ["that", 461], ["of", 466], ["the", 469], ["accumulated", 473], ["substrate", 485], ["due", 495], ["to", 499], ["the", 502], ["glycosylation", 506], ["-", 519], ["mediated", 520], ["clearance", 529], ["of", 539], ["the", 542], ["enzymes", 546], ["from", 554], ["circulation", 559], [",", 570], ["resulting", 572], ["in", 582], ["poor", 585], ["or", 590], ["absent", 593], ["substrate", 600], ["clearance", 610], ["from", 620], ["some", 625], ["tissues", 630], [".", 637], ["To", 639], ["overcome", 642], ["this", 651], ["limitation", 656], [",", 666], ["we", 668], ["have", 671], ["evaluated", 676], ["several", 686], ["peptide", 694], ["-", 701], ["based", 702], ["targeting", 708], ["motifs", 718], ["to", 725], ["redirect", 728], ["recombinant", 737], ["human", 749], ["alpha", 755], ["-", 760], ["galactosidase", 761], ["(", 775], ["rhalphaGal", 776], [")", 786], ["to", 788], ["specific", 791], ["receptors", 800], [".", 809], ["A", 811], ["reversible", 813], ["thiol", 824], ["-", 829], ["based", 830], ["PEGylation", 836], ["chemistry", 847], ["was", 857], ["developed", 861], ["to", 871], ["achieve", 874], ["multivalent", 882], ["peptide", 894], ["display", 902], ["with", 910], ["lysosomal", 915], ["release", 925], [".", 932], ["In", 934], ["vitro", 937], [",", 942], ["cell", 944], ["uptake", 949], ["was", 956], ["peptide", 960], ["dependent", 968], ["and", 978], ["independent", 982], ["of", 994], ["the", 997], ["normal", 1001], ["mannose-6-phosphate", 1008], ["receptor", 1028], ["mediated", 1037], ["pathway", 1046], [".", 1053], ["Surprisingly", 1055], [",", 1067], ["despite", 1069], ["increased", 1077], ["plasma", 1087], ["half", 1094], ["-", 1098], ["life", 1099], ["and", 1104], ["decreased", 1108], ["liver", 1118], ["uptake", 1124], [",", 1130], ["none", 1132], ["of", 1137], ["the", 1140], ["peptide", 1144], ["conjugates", 1152], ["showed", 1163], ["significantly", 1170], ["altered", 1184], ["biodistribution", 1192], ["in", 1208], ["alphaGal", 1211], ["-", 1219], ["knockout", 1220], ["mice", 1229], [".", 1233], ["This", 1235], ["suggests", 1240], ["that", 1249], ["these", 1254], ["peptide", 1260], ["-", 1267], ["based", 1268], ["targeting", 1274], ["motifs", 1284], ["are", 1291], ["unlikely", 1295], ["to", 1304], ["provide", 1307], ["substantial", 1315], ["therapeutic", 1327], ["benefit", 1339], ["likely", 1347], ["due", 1354], ["to", 1358], ["the", 1361], ["complexity", 1365], ["of", 1376], ["factors", 1379], ["affecting", 1387], ["PK", 1397], ["and", 1400], ["biodistribution", 1404], [".", 1419]]}
{"context": "Individuals with Mowat-Wilson syndrome (MWS; OMIM#235730) have characteristic facial features, a variety of congenital anomalies such as Hirschsprung disease, and intellectual disabilities caused by mutation or deletion of ZEB2 gene. This deletion or cytogenetic abnormality has been reported primarily from Europe, Australia and the United States, but not in Korea. Here we report a patient with characteristic facial features of MWS, developmental delay and spasticity. High resolution microarray analysis revealed 0.9 Mb deletion of 2q22.3 involving two genes: ZEB2 and GTDC1. This case shows the important role of high resolution microarray in patients with unexplained psychomotor retardation and/or facial dysmorphism. Knowledge about the most striking clinical signs and implementation of effective molecular tests like microarray could significantly increase the detection rate of new cases of MWS in Korea. This is the first reported case of MWS in Korea.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "65d32f6d9c06430c970f8b3020a54497", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[92, 92], [35, 35]], "char_spans": [[564, 567], [223, 226]]}]}], "context_tokens": [["Individuals", 0], ["with", 12], ["Mowat", 17], ["-", 22], ["Wilson", 23], ["syndrome", 30], ["(", 39], ["MWS", 40], [";", 43], ["OMIM#235730", 45], [")", 56], ["have", 58], ["characteristic", 63], ["facial", 78], ["features", 85], [",", 93], ["a", 95], ["variety", 97], ["of", 105], ["congenital", 108], ["anomalies", 119], ["such", 129], ["as", 134], ["Hirschsprung", 137], ["disease", 150], [",", 157], ["and", 159], ["intellectual", 163], ["disabilities", 176], ["caused", 189], ["by", 196], ["mutation", 199], ["or", 208], ["deletion", 211], ["of", 220], ["ZEB2", 223], ["gene", 228], [".", 232], ["This", 234], ["deletion", 239], ["or", 248], ["cytogenetic", 251], ["abnormality", 263], ["has", 275], ["been", 279], ["reported", 284], ["primarily", 293], ["from", 303], ["Europe", 308], [",", 314], ["Australia", 316], ["and", 326], ["the", 330], ["United", 334], ["States", 341], [",", 347], ["but", 349], ["not", 353], ["in", 357], ["Korea", 360], [".", 365], ["Here", 367], ["we", 372], ["report", 375], ["a", 382], ["patient", 384], ["with", 392], ["characteristic", 397], ["facial", 412], ["features", 419], ["of", 428], ["MWS", 431], [",", 434], ["developmental", 436], ["delay", 450], ["and", 456], ["spasticity", 460], [".", 470], ["High", 472], ["resolution", 477], ["microarray", 488], ["analysis", 499], ["revealed", 508], ["0.9", 517], ["Mb", 521], ["deletion", 524], ["of", 533], ["2q22.3", 536], ["involving", 543], ["two", 553], ["genes", 557], [":", 562], ["ZEB2", 564], ["and", 569], ["GTDC1", 573], [".", 578], ["This", 580], ["case", 585], ["shows", 590], ["the", 596], ["important", 600], ["role", 610], ["of", 615], ["high", 618], ["resolution", 623], ["microarray", 634], ["in", 645], ["patients", 648], ["with", 657], ["unexplained", 662], ["psychomotor", 674], ["retardation", 686], ["and/or", 698], ["facial", 705], ["dysmorphism", 712], [".", 723], ["Knowledge", 725], ["about", 735], ["the", 741], ["most", 745], ["striking", 750], ["clinical", 759], ["signs", 768], ["and", 774], ["implementation", 778], ["of", 793], ["effective", 796], ["molecular", 806], ["tests", 816], ["like", 822], ["microarray", 827], ["could", 838], ["significantly", 844], ["increase", 858], ["the", 867], ["detection", 871], ["rate", 881], ["of", 886], ["new", 889], ["cases", 893], ["of", 899], ["MWS", 902], ["in", 906], ["Korea", 909], [".", 914], ["This", 916], ["is", 921], ["the", 924], ["first", 928], ["reported", 934], ["case", 943], ["of", 948], ["MWS", 951], ["in", 955], ["Korea", 958], [".", 963]]}
{"context": "Biallelic mutations of the DNA annealing helicase SMARCAL1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1) cause Schimke immuno-osseous dysplasia (SIOD, MIM 242900), an incompletely penetrant autosomal recessive disorder. Using human, Drosophila and mouse models, we show that the proteins encoded by SMARCAL1 orthologs localize to transcriptionally active chromatin and modulate gene expression. We also show that, as found in SIOD patients, deficiency of the SMARCAL1 orthologs alone is insufficient to cause disease in fruit flies and mice, although such deficiency causes modest diffuse alterations in gene expression. Rather, disease manifests when SMARCAL1 deficiency interacts with genetic and environmental factors that further alter gene expression. We conclude that the SMARCAL1 annealing helicase buffers fluctuations in gene expression and that alterations in gene expression contribute to the penetrance of SIOD.", "qas": [{"question": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "answers": ["HARP", "SMARCAL1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1", "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)"], "qid": "549c82a2fcb04e38a84c3f7661eeeaf0", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["cause", 24], ["Schimke", 30], ["immune", 38], ["-", 44], ["osseous", 45], ["dysplasia", 53], ["?", 62]], "detected_answers": [{"text": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "token_spans": [[7, 30]], "char_spans": [[50, 153]]}]}], "context_tokens": [["Biallelic", 0], ["mutations", 10], ["of", 20], ["the", 23], ["DNA", 27], ["annealing", 31], ["helicase", 41], ["SMARCAL1", 50], ["(", 59], ["SWI", 60], ["/", 63], ["SNF", 64], ["-", 67], ["related", 68], [",", 75], ["matrix", 77], ["-", 83], ["associated", 84], [",", 94], ["actin", 96], ["-", 101], ["dependent", 102], ["regulator", 112], ["of", 122], ["chromatin", 125], [",", 134], ["subfamily", 136], ["a", 146], ["-", 147], ["like", 148], ["1", 153], [")", 154], ["cause", 156], ["Schimke", 162], ["immuno", 170], ["-", 176], ["osseous", 177], ["dysplasia", 185], ["(", 195], ["SIOD", 196], [",", 200], ["MIM", 202], ["242900", 206], [")", 212], [",", 213], ["an", 215], ["incompletely", 218], ["penetrant", 231], ["autosomal", 241], ["recessive", 251], ["disorder", 261], [".", 269], ["Using", 271], ["human", 277], [",", 282], ["Drosophila", 284], ["and", 295], ["mouse", 299], ["models", 305], [",", 311], ["we", 313], ["show", 316], ["that", 321], ["the", 326], ["proteins", 330], ["encoded", 339], ["by", 347], ["SMARCAL1", 350], ["orthologs", 359], ["localize", 369], ["to", 378], ["transcriptionally", 381], ["active", 399], ["chromatin", 406], ["and", 416], ["modulate", 420], ["gene", 429], ["expression", 434], [".", 444], ["We", 446], ["also", 449], ["show", 454], ["that", 459], [",", 463], ["as", 465], ["found", 468], ["in", 474], ["SIOD", 477], ["patients", 482], [",", 490], ["deficiency", 492], ["of", 503], ["the", 506], ["SMARCAL1", 510], ["orthologs", 519], ["alone", 529], ["is", 535], ["insufficient", 538], ["to", 551], ["cause", 554], ["disease", 560], ["in", 568], ["fruit", 571], ["flies", 577], ["and", 583], ["mice", 587], [",", 591], ["although", 593], ["such", 602], ["deficiency", 607], ["causes", 618], ["modest", 625], ["diffuse", 632], ["alterations", 640], ["in", 652], ["gene", 655], ["expression", 660], [".", 670], ["Rather", 672], [",", 678], ["disease", 680], ["manifests", 688], ["when", 698], ["SMARCAL1", 703], ["deficiency", 712], ["interacts", 723], ["with", 733], ["genetic", 738], ["and", 746], ["environmental", 750], ["factors", 764], ["that", 772], ["further", 777], ["alter", 785], ["gene", 791], ["expression", 796], [".", 806], ["We", 808], ["conclude", 811], ["that", 820], ["the", 825], ["SMARCAL1", 829], ["annealing", 838], ["helicase", 848], ["buffers", 857], ["fluctuations", 865], ["in", 878], ["gene", 881], ["expression", 886], ["and", 897], ["that", 901], ["alterations", 906], ["in", 918], ["gene", 921], ["expression", 926], ["contribute", 937], ["to", 948], ["the", 951], ["penetrance", 955], ["of", 966], ["SIOD", 969], [".", 973]]}
{"context": "Ataxin-3 is a ubiquitously expressed deubiqutinating enzyme with important functions in the proteasomal protein degradation pathway and regulation of transcription. The C-terminus of the ataxin-3 protein contains a polyglutamine (PolyQ) region that, when mutationally expanded to over 52 glutamines, causes the neurodegenerative disease spinocerebellar ataxia 3 (SCA3). In spite of extensive research, the molecular mechanisms underlying the cellular toxicity resulting from mutant ataxin-3 remain elusive and no preventive treatment is currently available. It has become clear over the last decade that the hallmark intracellular ataxin-3 aggregates are likely not the main toxic entity in SCA3. Instead, the soluble PolyQ containing fragments arising from proteolytic cleavage of ataxin-3 by caspases and calpains are now regarded to be of greater influence in pathogenesis. In addition, recent evidence suggests potential involvement of a RNA toxicity component in SCA3 and other PolyQ expansion disorders, increasing the pathogenic complexity. Herein, we review the functioning of ataxin-3 and the involvement of known protein and RNA toxicity mechanisms of mutant ataxin-3 that have been discovered, as well as future opportunities for therapeutic intervention.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "5196d6a345bb4a5db1019bc0c286be72", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0], [96, 96], [27, 27], [182, 182], [73, 73], [169, 169], [120, 120]], "char_spans": [[0, 7], [631, 638], [187, 194], [1169, 1176], [482, 489], [1085, 1092], [782, 789]]}]}], "context_tokens": [["Ataxin-3", 0], ["is", 9], ["a", 12], ["ubiquitously", 14], ["expressed", 27], ["deubiqutinating", 37], ["enzyme", 53], ["with", 60], ["important", 65], ["functions", 75], ["in", 85], ["the", 88], ["proteasomal", 92], ["protein", 104], ["degradation", 112], ["pathway", 124], ["and", 132], ["regulation", 136], ["of", 147], ["transcription", 150], [".", 163], ["The", 165], ["C", 169], ["-", 170], ["terminus", 171], ["of", 180], ["the", 183], ["ataxin-3", 187], ["protein", 196], ["contains", 204], ["a", 213], ["polyglutamine", 215], ["(", 229], ["PolyQ", 230], [")", 235], ["region", 237], ["that", 244], [",", 248], ["when", 250], ["mutationally", 255], ["expanded", 268], ["to", 277], ["over", 280], ["52", 285], ["glutamines", 288], [",", 298], ["causes", 300], ["the", 307], ["neurodegenerative", 311], ["disease", 329], ["spinocerebellar", 337], ["ataxia", 353], ["3", 360], ["(", 362], ["SCA3", 363], [")", 367], [".", 368], ["In", 370], ["spite", 373], ["of", 379], ["extensive", 382], ["research", 392], [",", 400], ["the", 402], ["molecular", 406], ["mechanisms", 416], ["underlying", 427], ["the", 438], ["cellular", 442], ["toxicity", 451], ["resulting", 460], ["from", 470], ["mutant", 475], ["ataxin-3", 482], ["remain", 491], ["elusive", 498], ["and", 506], ["no", 510], ["preventive", 513], ["treatment", 524], ["is", 534], ["currently", 537], ["available", 547], [".", 556], ["It", 558], ["has", 561], ["become", 565], ["clear", 572], ["over", 578], ["the", 583], ["last", 587], ["decade", 592], ["that", 599], ["the", 604], ["hallmark", 608], ["intracellular", 617], ["ataxin-3", 631], ["aggregates", 640], ["are", 651], ["likely", 655], ["not", 662], ["the", 666], ["main", 670], ["toxic", 675], ["entity", 681], ["in", 688], ["SCA3", 691], [".", 695], ["Instead", 697], [",", 704], ["the", 706], ["soluble", 710], ["PolyQ", 718], ["containing", 724], ["fragments", 735], ["arising", 745], ["from", 753], ["proteolytic", 758], ["cleavage", 770], ["of", 779], ["ataxin-3", 782], ["by", 791], ["caspases", 794], ["and", 803], ["calpains", 807], ["are", 816], ["now", 820], ["regarded", 824], ["to", 833], ["be", 836], ["of", 839], ["greater", 842], ["influence", 850], ["in", 860], ["pathogenesis", 863], [".", 875], ["In", 877], ["addition", 880], [",", 888], ["recent", 890], ["evidence", 897], ["suggests", 906], ["potential", 915], ["involvement", 925], ["of", 937], ["a", 940], ["RNA", 942], ["toxicity", 946], ["component", 955], ["in", 965], ["SCA3", 968], ["and", 973], ["other", 977], ["PolyQ", 983], ["expansion", 989], ["disorders", 999], [",", 1008], ["increasing", 1010], ["the", 1021], ["pathogenic", 1025], ["complexity", 1036], [".", 1046], ["Herein", 1048], [",", 1054], ["we", 1056], ["review", 1059], ["the", 1066], ["functioning", 1070], ["of", 1082], ["ataxin-3", 1085], ["and", 1094], ["the", 1098], ["involvement", 1102], ["of", 1114], ["known", 1117], ["protein", 1123], ["and", 1131], ["RNA", 1135], ["toxicity", 1139], ["mechanisms", 1148], ["of", 1159], ["mutant", 1162], ["ataxin-3", 1169], ["that", 1178], ["have", 1183], ["been", 1188], ["discovered", 1193], [",", 1203], ["as", 1205], ["well", 1208], ["as", 1213], ["future", 1216], ["opportunities", 1223], ["for", 1237], ["therapeutic", 1241], ["intervention", 1253], [".", 1265]]}
{"context": "Diamond-Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome that is characterized by pure red-cell aplasia and associated physical deformities. It has been proven that defects of ribosomal proteins can lead to this disease and that RPS19 is the most frequently mutated gene in DBA patients. Previous studies suggest that p53-dependent genes and pathways play important roles in RPS19-deficient embryos. However, whether there are other vital factors linked to DBA has not been fully clarified. In this study, we compared the whole genome RNA-Seq data of zebrafish embryos injected with RPS19 morpholino (RPS19 MO), RPS19 and p53 morpholino simultaneously (RPS19+p53 MO) and control morpholino (control). We found that genes enriched in the functions of hematological systems, nervous system development and skeletal and muscular disorders had significant differential expression in RPS19 MO embryos compared with controls. Co-inhibition of p53 partially alleviates the abnormalities for RPS19-deficient embryos. However, the hematopoietic genes, which were down-regulated significantly in RPS19 MO embryos, were not completely recovered by the co-inhibition of p53. Furthermore, we identified the genome-wide p53-dependent and -independent genes and pathways. These results indicate that not only p53 family members but also other factors have important impacts on RPS19-deficient embryos. The detection of potential pathogenic genes and pathways provides us a new paradigm for future research on DBA, which is a systematic and complex hereditary disease.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "2ff9e79323fb48ad9fe911c391aecaa8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[81, 81], [53, 53], [255, 255], [5, 5]], "char_spans": [[479, 481], [296, 298], [1516, 1518], [25, 27]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["rare", 35], ["inherited", 40], ["bone", 50], ["marrow", 55], ["failure", 62], ["syndrome", 70], ["that", 79], ["is", 84], ["characterized", 87], ["by", 101], ["pure", 104], ["red", 109], ["-", 112], ["cell", 113], ["aplasia", 118], ["and", 126], ["associated", 130], ["physical", 141], ["deformities", 150], [".", 161], ["It", 163], ["has", 166], ["been", 170], ["proven", 175], ["that", 182], ["defects", 187], ["of", 195], ["ribosomal", 198], ["proteins", 208], ["can", 217], ["lead", 221], ["to", 226], ["this", 229], ["disease", 234], ["and", 242], ["that", 246], ["RPS19", 251], ["is", 257], ["the", 260], ["most", 264], ["frequently", 269], ["mutated", 280], ["gene", 288], ["in", 293], ["DBA", 296], ["patients", 300], [".", 308], ["Previous", 310], ["studies", 319], ["suggest", 327], ["that", 335], ["p53-dependent", 340], ["genes", 354], ["and", 360], ["pathways", 364], ["play", 373], ["important", 378], ["roles", 388], ["in", 394], ["RPS19-deficient", 397], ["embryos", 413], [".", 420], ["However", 422], [",", 429], ["whether", 431], ["there", 439], ["are", 445], ["other", 449], ["vital", 455], ["factors", 461], ["linked", 469], ["to", 476], ["DBA", 479], ["has", 483], ["not", 487], ["been", 491], ["fully", 496], ["clarified", 502], [".", 511], ["In", 513], ["this", 516], ["study", 521], [",", 526], ["we", 528], ["compared", 531], ["the", 540], ["whole", 544], ["genome", 550], ["RNA", 557], ["-", 560], ["Seq", 561], ["data", 565], ["of", 570], ["zebrafish", 573], ["embryos", 583], ["injected", 591], ["with", 600], ["RPS19", 605], ["morpholino", 611], ["(", 622], ["RPS19", 623], ["MO", 629], [")", 631], [",", 632], ["RPS19", 634], ["and", 640], ["p53", 644], ["morpholino", 648], ["simultaneously", 659], ["(", 674], ["RPS19+p53", 675], ["MO", 685], [")", 687], ["and", 689], ["control", 693], ["morpholino", 701], ["(", 712], ["control", 713], [")", 720], [".", 721], ["We", 723], ["found", 726], ["that", 732], ["genes", 737], ["enriched", 743], ["in", 752], ["the", 755], ["functions", 759], ["of", 769], ["hematological", 772], ["systems", 786], [",", 793], ["nervous", 795], ["system", 803], ["development", 810], ["and", 822], ["skeletal", 826], ["and", 835], ["muscular", 839], ["disorders", 848], ["had", 858], ["significant", 862], ["differential", 874], ["expression", 887], ["in", 898], ["RPS19", 901], ["MO", 907], ["embryos", 910], ["compared", 918], ["with", 927], ["controls", 932], [".", 940], ["Co", 942], ["-", 944], ["inhibition", 945], ["of", 956], ["p53", 959], ["partially", 963], ["alleviates", 973], ["the", 984], ["abnormalities", 988], ["for", 1002], ["RPS19-deficient", 1006], ["embryos", 1022], [".", 1029], ["However", 1031], [",", 1038], ["the", 1040], ["hematopoietic", 1044], ["genes", 1058], [",", 1063], ["which", 1065], ["were", 1071], ["down", 1076], ["-", 1080], ["regulated", 1081], ["significantly", 1091], ["in", 1105], ["RPS19", 1108], ["MO", 1114], ["embryos", 1117], [",", 1124], ["were", 1126], ["not", 1131], ["completely", 1135], ["recovered", 1146], ["by", 1156], ["the", 1159], ["co", 1163], ["-", 1165], ["inhibition", 1166], ["of", 1177], ["p53", 1180], [".", 1183], ["Furthermore", 1185], [",", 1196], ["we", 1198], ["identified", 1201], ["the", 1212], ["genome", 1216], ["-", 1222], ["wide", 1223], ["p53-dependent", 1228], ["and", 1242], ["-independent", 1246], ["genes", 1259], ["and", 1265], ["pathways", 1269], [".", 1277], ["These", 1279], ["results", 1285], ["indicate", 1293], ["that", 1302], ["not", 1307], ["only", 1311], ["p53", 1316], ["family", 1320], ["members", 1327], ["but", 1335], ["also", 1339], ["other", 1344], ["factors", 1350], ["have", 1358], ["important", 1363], ["impacts", 1373], ["on", 1381], ["RPS19-deficient", 1384], ["embryos", 1400], [".", 1407], ["The", 1409], ["detection", 1413], ["of", 1423], ["potential", 1426], ["pathogenic", 1436], ["genes", 1447], ["and", 1453], ["pathways", 1457], ["provides", 1466], ["us", 1475], ["a", 1478], ["new", 1480], ["paradigm", 1484], ["for", 1493], ["future", 1497], ["research", 1504], ["on", 1513], ["DBA", 1516], [",", 1519], ["which", 1521], ["is", 1527], ["a", 1530], ["systematic", 1532], ["and", 1543], ["complex", 1547], ["hereditary", 1555], ["disease", 1566], [".", 1573]]}
{"context": "We investigated the expression of Na(+)/Ca(2+) exchanger (NCX) and the functional role of NCX in retinal damage by using NCX1-heterozygous deficient mice (NCX1(+/-)) and SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy] phenoxy]-5-ethoxyaniline), a selective NCX inhibitor in vivo. We also examined the role of NCX in oxygen-glucose deprivation (OGD) stress with a retinal ganglion cell line (RGC-5) cell culture in vitro. The expression of NCX1 was confirmed and entirely localized in retina by immunoblotting and immunohistochemistry, respectively. NCX1(+/-) mice possessed significant protection against retinal damage induced by intravitreal injection of N-methyl-D-aspartate (NMDA). SEA0400 at 3 and 10 mg/kg significantly reduced NMDA- or high intraocular pressure-induced retinal cell damage in mice. Furthermore, SEA0400 reduced the number of TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling)-positive cells and the expression of phosphorylated mitogen-activated protein kinases (ERK1/2, JNK, p38) induced by NMDA injection. In RGC-5, SEA0400 at 0.3 and 1 microM significantly inhibited OGD-induced cell damage. OGD-induced cell damage was aggravated by ouabain (a Na(+),K(+)-ATPase inhibitor) at 100 microM, and this increased damage was significantly reduced by SEA0400 at 1 microM. In conclusion, these results suggest that NCX1 may play a role in retinal cell death induced by NMDA and ischemia-reperfusion.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "251f6ff810384420b6df79a29f772ff0", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[5, 8]], "char_spans": [[34, 55]]}, {"text": "NCX", "token_spans": [[40, 40], [17, 17], [51, 51], [10, 10]], "char_spans": [[253, 255], [90, 92], [305, 307], [58, 60]]}]}], "context_tokens": [["We", 0], ["investigated", 3], ["the", 16], ["expression", 20], ["of", 31], ["Na(+)/Ca(2", 34], ["+", 44], [")", 45], ["exchanger", 47], ["(", 57], ["NCX", 58], [")", 61], ["and", 63], ["the", 67], ["functional", 71], ["role", 82], ["of", 87], ["NCX", 90], ["in", 94], ["retinal", 97], ["damage", 105], ["by", 112], ["using", 115], ["NCX1-heterozygous", 121], ["deficient", 139], ["mice", 149], ["(", 154], ["NCX1(+/-", 155], [")", 163], [")", 164], ["and", 166], ["SEA0400", 170], ["(", 178], ["2-[4-[(2,5-difluorophenyl)methoxy", 179], ["]", 212], ["phenoxy]-5-ethoxyaniline", 214], [")", 238], [",", 239], ["a", 241], ["selective", 243], ["NCX", 253], ["inhibitor", 257], ["in", 267], ["vivo", 270], [".", 274], ["We", 276], ["also", 279], ["examined", 284], ["the", 293], ["role", 297], ["of", 302], ["NCX", 305], ["in", 309], ["oxygen", 312], ["-", 318], ["glucose", 319], ["deprivation", 327], ["(", 339], ["OGD", 340], [")", 343], ["stress", 345], ["with", 352], ["a", 357], ["retinal", 359], ["ganglion", 367], ["cell", 376], ["line", 381], ["(", 386], ["RGC-5", 387], [")", 392], ["cell", 394], ["culture", 399], ["in", 407], ["vitro", 410], [".", 415], ["The", 417], ["expression", 421], ["of", 432], ["NCX1", 435], ["was", 440], ["confirmed", 444], ["and", 454], ["entirely", 458], ["localized", 467], ["in", 477], ["retina", 480], ["by", 487], ["immunoblotting", 490], ["and", 505], ["immunohistochemistry", 509], [",", 529], ["respectively", 531], [".", 543], ["NCX1(+/-", 545], [")", 553], ["mice", 555], ["possessed", 560], ["significant", 570], ["protection", 582], ["against", 593], ["retinal", 601], ["damage", 609], ["induced", 616], ["by", 624], ["intravitreal", 627], ["injection", 640], ["of", 650], ["N", 653], ["-", 654], ["methyl", 655], ["-", 661], ["D", 662], ["-", 663], ["aspartate", 664], ["(", 674], ["NMDA", 675], [")", 679], [".", 680], ["SEA0400", 682], ["at", 690], ["3", 693], ["and", 695], ["10", 699], ["mg", 702], ["/", 704], ["kg", 705], ["significantly", 708], ["reduced", 722], ["NMDA-", 730], ["or", 736], ["high", 739], ["intraocular", 744], ["pressure", 756], ["-", 764], ["induced", 765], ["retinal", 773], ["cell", 781], ["damage", 786], ["in", 793], ["mice", 796], [".", 800], ["Furthermore", 802], [",", 813], ["SEA0400", 815], ["reduced", 823], ["the", 831], ["number", 835], ["of", 842], ["TUNEL", 845], ["(", 851], ["terminal", 852], ["deoxynucleotidyl", 861], ["transferase", 878], ["dUTP", 890], ["nick", 895], ["-", 899], ["end", 900], ["labeling)-positive", 904], ["cells", 923], ["and", 929], ["the", 933], ["expression", 937], ["of", 948], ["phosphorylated", 951], ["mitogen", 966], ["-", 973], ["activated", 974], ["protein", 984], ["kinases", 992], ["(", 1000], ["ERK1/2", 1001], [",", 1007], ["JNK", 1009], [",", 1012], ["p38", 1014], [")", 1017], ["induced", 1019], ["by", 1027], ["NMDA", 1030], ["injection", 1035], [".", 1044], ["In", 1046], ["RGC-5", 1049], [",", 1054], ["SEA0400", 1056], ["at", 1064], ["0.3", 1067], ["and", 1071], ["1", 1075], ["microM", 1077], ["significantly", 1084], ["inhibited", 1098], ["OGD", 1108], ["-", 1111], ["induced", 1112], ["cell", 1120], ["damage", 1125], [".", 1131], ["OGD", 1133], ["-", 1136], ["induced", 1137], ["cell", 1145], ["damage", 1150], ["was", 1157], ["aggravated", 1161], ["by", 1172], ["ouabain", 1175], ["(", 1183], ["a", 1184], ["Na(+),K(+)-ATPase", 1186], ["inhibitor", 1204], [")", 1213], ["at", 1215], ["100", 1218], ["microM", 1222], [",", 1228], ["and", 1230], ["this", 1234], ["increased", 1239], ["damage", 1249], ["was", 1256], ["significantly", 1260], ["reduced", 1274], ["by", 1282], ["SEA0400", 1285], ["at", 1293], ["1", 1296], ["microM.", 1298], ["In", 1306], ["conclusion", 1309], [",", 1319], ["these", 1321], ["results", 1327], ["suggest", 1335], ["that", 1343], ["NCX1", 1348], ["may", 1353], ["play", 1357], ["a", 1362], ["role", 1364], ["in", 1369], ["retinal", 1372], ["cell", 1380], ["death", 1385], ["induced", 1391], ["by", 1399], ["NMDA", 1402], ["and", 1407], ["ischemia", 1411], ["-", 1419], ["reperfusion", 1420], [".", 1431]]}
{"context": "Antisense therapy with both chemistries of phosphorodiamidate morpholino oligomers (PMOs) and 2'-O-methyl phosphorothioate has demonstrated the capability to induce dystrophin expression in Duchenne muscular dystrophy (DMD) patients in phase II-III clinical trials with benefit in muscle functions. However, potential of the therapy for DMD at different stages of the disease progression is not understood. In this study, we examined the effect of peptide-conjugated PMO (PPMO)-mediated exon skipping on disease progression of utrophin-dystrophin-deficient mice (dko) of four age groups (21-29, 30-39, 40-49 and 50+ days), representing diseases from early stage to advanced stage with severe kyphosis. Biweekly intravenous (i.v.) administration of the PPMO restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. This was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. However, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started. The PPMO treatment alleviated the disease pathology and significantly prolonged the life span of the mice receiving treatment at younger age with mild phenotype. However, restoration of high levels of dystrophin expression failed to prevent disease progression to the mice receiving treatment when disease was already at advanced stage. The results could be critical for design of clinical trials with antisense therapy to DMD.", "qas": [{"question": "In what percentage of skeletal muscle fibers is dystrophin expression restored after PPMO- mediated exon skipping?", "answers": ["100%"], "qid": "d6fb14e3be8245baaf66693d4b546e8f", "question_tokens": [["In", 0], ["what", 3], ["percentage", 8], ["of", 19], ["skeletal", 22], ["muscle", 31], ["fibers", 38], ["is", 45], ["dystrophin", 48], ["expression", 59], ["restored", 70], ["after", 79], ["PPMO-", 85], ["mediated", 91], ["exon", 100], ["skipping", 105], ["?", 113]], "detected_answers": [{"text": "100%", "token_spans": [[145, 145]], "char_spans": [[802, 804]]}]}], "context_tokens": [["Antisense", 0], ["therapy", 10], ["with", 18], ["both", 23], ["chemistries", 28], ["of", 40], ["phosphorodiamidate", 43], ["morpholino", 62], ["oligomers", 73], ["(", 83], ["PMOs", 84], [")", 88], ["and", 90], ["2'-O", 94], ["-", 98], ["methyl", 99], ["phosphorothioate", 106], ["has", 123], ["demonstrated", 127], ["the", 140], ["capability", 144], ["to", 155], ["induce", 158], ["dystrophin", 165], ["expression", 176], ["in", 187], ["Duchenne", 190], ["muscular", 199], ["dystrophy", 208], ["(", 218], ["DMD", 219], [")", 222], ["patients", 224], ["in", 233], ["phase", 236], ["II", 242], ["-", 244], ["III", 245], ["clinical", 249], ["trials", 258], ["with", 265], ["benefit", 270], ["in", 278], ["muscle", 281], ["functions", 288], [".", 297], ["However", 299], [",", 306], ["potential", 308], ["of", 318], ["the", 321], ["therapy", 325], ["for", 333], ["DMD", 337], ["at", 341], ["different", 344], ["stages", 354], ["of", 361], ["the", 364], ["disease", 368], ["progression", 376], ["is", 388], ["not", 391], ["understood", 395], [".", 405], ["In", 407], ["this", 410], ["study", 415], [",", 420], ["we", 422], ["examined", 425], ["the", 434], ["effect", 438], ["of", 445], ["peptide", 448], ["-", 455], ["conjugated", 456], ["PMO", 467], ["(", 471], ["PPMO)-mediated", 472], ["exon", 487], ["skipping", 492], ["on", 501], ["disease", 504], ["progression", 512], ["of", 524], ["utrophin", 527], ["-", 535], ["dystrophin", 536], ["-", 546], ["deficient", 547], ["mice", 557], ["(", 562], ["dko", 563], [")", 566], ["of", 568], ["four", 571], ["age", 576], ["groups", 580], ["(", 587], ["21", 588], ["-", 590], ["29", 591], [",", 593], ["30", 595], ["-", 597], ["39", 598], [",", 600], ["40", 602], ["-", 604], ["49", 605], ["and", 608], ["50", 612], ["+", 614], ["days", 616], [")", 620], [",", 621], ["representing", 623], ["diseases", 636], ["from", 645], ["early", 650], ["stage", 656], ["to", 662], ["advanced", 665], ["stage", 674], ["with", 680], ["severe", 685], ["kyphosis", 692], [".", 700], ["Biweekly", 702], ["intravenous", 711], ["(", 723], ["i.v", 724], [".", 727], [")", 728], ["administration", 730], ["of", 745], ["the", 748], ["PPMO", 752], ["restored", 757], ["the", 766], ["dystrophin", 770], ["expression", 781], ["in", 792], ["nearly", 795], ["100", 802], ["%", 805], ["skeletal", 807], ["muscle", 816], ["fibers", 823], ["in", 830], ["all", 833], ["age", 837], ["groups", 841], [".", 847], ["This", 849], ["was", 854], ["associated", 858], ["with", 869], ["the", 874], ["restoration", 878], ["of", 890], ["dystrophin", 893], ["-", 903], ["associated", 904], ["proteins", 915], ["including", 924], ["functional", 934], ["glycosylated", 945], ["dystroglycan", 958], ["and", 971], ["neuronal", 975], ["nitric", 984], ["synthase", 991], [".", 999], ["However", 1001], [",", 1008], ["therapeutic", 1010], ["outcomes", 1022], ["clearly", 1031], ["depended", 1039], ["on", 1048], ["severity", 1051], ["of", 1060], ["the", 1063], ["disease", 1067], ["at", 1075], ["the", 1078], ["time", 1082], ["the", 1087], ["treatment", 1091], ["started", 1101], [".", 1108], ["The", 1110], ["PPMO", 1114], ["treatment", 1119], ["alleviated", 1129], ["the", 1140], ["disease", 1144], ["pathology", 1152], ["and", 1162], ["significantly", 1166], ["prolonged", 1180], ["the", 1190], ["life", 1194], ["span", 1199], ["of", 1204], ["the", 1207], ["mice", 1211], ["receiving", 1216], ["treatment", 1226], ["at", 1236], ["younger", 1239], ["age", 1247], ["with", 1251], ["mild", 1256], ["phenotype", 1261], [".", 1270], ["However", 1272], [",", 1279], ["restoration", 1281], ["of", 1293], ["high", 1296], ["levels", 1301], ["of", 1308], ["dystrophin", 1311], ["expression", 1322], ["failed", 1333], ["to", 1340], ["prevent", 1343], ["disease", 1351], ["progression", 1359], ["to", 1371], ["the", 1374], ["mice", 1378], ["receiving", 1383], ["treatment", 1393], ["when", 1403], ["disease", 1408], ["was", 1416], ["already", 1420], ["at", 1428], ["advanced", 1431], ["stage", 1440], [".", 1445], ["The", 1447], ["results", 1451], ["could", 1459], ["be", 1465], ["critical", 1468], ["for", 1477], ["design", 1481], ["of", 1488], ["clinical", 1491], ["trials", 1500], ["with", 1507], ["antisense", 1512], ["therapy", 1522], ["to", 1530], ["DMD", 1533], [".", 1536]]}
{"context": "The precursor of the non-Abeta component of Alzheimer's disease amyloid (NACP) (also known as alpha-synuclein) is a presynaptic terminal molecule that abnormally accumulates in the plaques of Alzheimer's disease (AD) and in the Lewy bodies (LBs) of Lewy body variant of AD, diffuse Lewy body disease, and Parkinson's disease. To better understand the distribution of NACP/alpha-synuclein and its fragments in the LB-bearing neurons and neurites, as well as to clarify the patterns of NACP/alpha-synuclein compartmentalization, we studied NACP/alpha-synuclein immunoreactivity using antibodies against the C-terminal, N-terminal, and NAC regions after Proteinase K and formic acid treatment in the cortex of patients with LBs. Furthermore, studies of the subcellular localization of NACP/alpha-synuclein within LB-bearing neurons were performed by immunogold electron microscopy. These studies showed that the N-terminal antibody immunolabeled the LBs and dystrophic neurites with great intensity and, to a lesser extent, the synapses. In contrast, the C-terminal antibody strongly labeled the synapses and, to a lesser extent, the LBs and dystrophic neurites. Whereas Proteinase K treatment enhanced NACP/alpha-synuclein immunoreactivity with the C-terminal antibody, it diminished the N-terminal NACP/alpha-synuclein immunoreactivity. Furthermore, formic acid enhanced LB and dystrophic neurite labeling with both the C- and N-terminal antibodies. In addition, whereas without pretreatment only slight anti-NAC immunoreactivity was found in the LBs, formic acid pretreatment revealed an extensive anti-NAC immunostaining of LBs, plaques, and glial cells. Ultrastructural analysis revealed that NACP/alpha-synuclein immunoreactivity was diffusely distributed within the amorphous electrodense material in the LBs and as small clusters in the filaments of LBs and neurites. These results support the view that aggregated NACP/alpha-synuclein might play an important role in the pathogenesis of disorders associated with LBs.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "d3600ecb55744469b54fde10d8d1c38e", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[247, 249], [100, 102], [20, 22], [228, 230], [109, 111], [153, 155], [351, 353], [315, 317], [75, 77]], "char_spans": [[1302, 1316], [489, 503], [94, 108], [1205, 1219], [543, 557], [787, 801], [1925, 1939], [1700, 1714], [372, 386]]}]}], "context_tokens": [["The", 0], ["precursor", 4], ["of", 14], ["the", 17], ["non", 21], ["-", 24], ["Abeta", 25], ["component", 31], ["of", 41], ["Alzheimer", 44], ["'s", 53], ["disease", 56], ["amyloid", 64], ["(", 72], ["NACP", 73], [")", 77], ["(", 79], ["also", 80], ["known", 85], ["as", 91], ["alpha", 94], ["-", 99], ["synuclein", 100], [")", 109], ["is", 111], ["a", 114], ["presynaptic", 116], ["terminal", 128], ["molecule", 137], ["that", 146], ["abnormally", 151], ["accumulates", 162], ["in", 174], ["the", 177], ["plaques", 181], ["of", 189], ["Alzheimer", 192], ["'s", 201], ["disease", 204], ["(", 212], ["AD", 213], [")", 215], ["and", 217], ["in", 221], ["the", 224], ["Lewy", 228], ["bodies", 233], ["(", 240], ["LBs", 241], [")", 244], ["of", 246], ["Lewy", 249], ["body", 254], ["variant", 259], ["of", 267], ["AD", 270], [",", 272], ["diffuse", 274], ["Lewy", 282], ["body", 287], ["disease", 292], [",", 299], ["and", 301], ["Parkinson", 305], ["'s", 314], ["disease", 317], [".", 324], ["To", 326], ["better", 329], ["understand", 336], ["the", 347], ["distribution", 351], ["of", 364], ["NACP", 367], ["/", 371], ["alpha", 372], ["-", 377], ["synuclein", 378], ["and", 388], ["its", 392], ["fragments", 396], ["in", 406], ["the", 409], ["LB", 413], ["-", 415], ["bearing", 416], ["neurons", 424], ["and", 432], ["neurites", 436], [",", 444], ["as", 446], ["well", 449], ["as", 454], ["to", 457], ["clarify", 460], ["the", 468], ["patterns", 472], ["of", 481], ["NACP", 484], ["/", 488], ["alpha", 489], ["-", 494], ["synuclein", 495], ["compartmentalization", 505], [",", 525], ["we", 527], ["studied", 530], ["NACP", 538], ["/", 542], ["alpha", 543], ["-", 548], ["synuclein", 549], ["immunoreactivity", 559], ["using", 576], ["antibodies", 582], ["against", 593], ["the", 601], ["C", 605], ["-", 606], ["terminal", 607], [",", 615], ["N", 617], ["-", 618], ["terminal", 619], [",", 627], ["and", 629], ["NAC", 633], ["regions", 637], ["after", 645], ["Proteinase", 651], ["K", 662], ["and", 664], ["formic", 668], ["acid", 675], ["treatment", 680], ["in", 690], ["the", 693], ["cortex", 697], ["of", 704], ["patients", 707], ["with", 716], ["LBs", 721], [".", 724], ["Furthermore", 726], [",", 737], ["studies", 739], ["of", 747], ["the", 750], ["subcellular", 754], ["localization", 766], ["of", 779], ["NACP", 782], ["/", 786], ["alpha", 787], ["-", 792], ["synuclein", 793], ["within", 803], ["LB", 810], ["-", 812], ["bearing", 813], ["neurons", 821], ["were", 829], ["performed", 834], ["by", 844], ["immunogold", 847], ["electron", 858], ["microscopy", 867], [".", 877], ["These", 879], ["studies", 885], ["showed", 893], ["that", 900], ["the", 905], ["N", 909], ["-", 910], ["terminal", 911], ["antibody", 920], ["immunolabeled", 929], ["the", 943], ["LBs", 947], ["and", 951], ["dystrophic", 955], ["neurites", 966], ["with", 975], ["great", 980], ["intensity", 986], ["and", 996], [",", 999], ["to", 1001], ["a", 1004], ["lesser", 1006], ["extent", 1013], [",", 1019], ["the", 1021], ["synapses", 1025], [".", 1033], ["In", 1035], ["contrast", 1038], [",", 1046], ["the", 1048], ["C", 1052], ["-", 1053], ["terminal", 1054], ["antibody", 1063], ["strongly", 1072], ["labeled", 1081], ["the", 1089], ["synapses", 1093], ["and", 1102], [",", 1105], ["to", 1107], ["a", 1110], ["lesser", 1112], ["extent", 1119], [",", 1125], ["the", 1127], ["LBs", 1131], ["and", 1135], ["dystrophic", 1139], ["neurites", 1150], [".", 1158], ["Whereas", 1160], ["Proteinase", 1168], ["K", 1179], ["treatment", 1181], ["enhanced", 1191], ["NACP", 1200], ["/", 1204], ["alpha", 1205], ["-", 1210], ["synuclein", 1211], ["immunoreactivity", 1221], ["with", 1238], ["the", 1243], ["C", 1247], ["-", 1248], ["terminal", 1249], ["antibody", 1258], [",", 1266], ["it", 1268], ["diminished", 1271], ["the", 1282], ["N", 1286], ["-", 1287], ["terminal", 1288], ["NACP", 1297], ["/", 1301], ["alpha", 1302], ["-", 1307], ["synuclein", 1308], ["immunoreactivity", 1318], [".", 1334], ["Furthermore", 1336], [",", 1347], ["formic", 1349], ["acid", 1356], ["enhanced", 1361], ["LB", 1370], ["and", 1373], ["dystrophic", 1377], ["neurite", 1388], ["labeling", 1396], ["with", 1405], ["both", 1410], ["the", 1415], ["C-", 1419], ["and", 1422], ["N", 1426], ["-", 1427], ["terminal", 1428], ["antibodies", 1437], [".", 1447], ["In", 1449], ["addition", 1452], [",", 1460], ["whereas", 1462], ["without", 1470], ["pretreatment", 1478], ["only", 1491], ["slight", 1496], ["anti", 1503], ["-", 1507], ["NAC", 1508], ["immunoreactivity", 1512], ["was", 1529], ["found", 1533], ["in", 1539], ["the", 1542], ["LBs", 1546], [",", 1549], ["formic", 1551], ["acid", 1558], ["pretreatment", 1563], ["revealed", 1576], ["an", 1585], ["extensive", 1588], ["anti", 1598], ["-", 1602], ["NAC", 1603], ["immunostaining", 1607], ["of", 1622], ["LBs", 1625], [",", 1628], ["plaques", 1630], [",", 1637], ["and", 1639], ["glial", 1643], ["cells", 1649], [".", 1654], ["Ultrastructural", 1656], ["analysis", 1672], ["revealed", 1681], ["that", 1690], ["NACP", 1695], ["/", 1699], ["alpha", 1700], ["-", 1705], ["synuclein", 1706], ["immunoreactivity", 1716], ["was", 1733], ["diffusely", 1737], ["distributed", 1747], ["within", 1759], ["the", 1766], ["amorphous", 1770], ["electrodense", 1780], ["material", 1793], ["in", 1802], ["the", 1805], ["LBs", 1809], ["and", 1813], ["as", 1817], ["small", 1820], ["clusters", 1826], ["in", 1835], ["the", 1838], ["filaments", 1842], ["of", 1852], ["LBs", 1855], ["and", 1859], ["neurites", 1863], [".", 1871], ["These", 1873], ["results", 1879], ["support", 1887], ["the", 1895], ["view", 1899], ["that", 1904], ["aggregated", 1909], ["NACP", 1920], ["/", 1924], ["alpha", 1925], ["-", 1930], ["synuclein", 1931], ["might", 1941], ["play", 1947], ["an", 1952], ["important", 1955], ["role", 1965], ["in", 1970], ["the", 1973], ["pathogenesis", 1977], ["of", 1990], ["disorders", 1993], ["associated", 2003], ["with", 2014], ["LBs", 2019], [".", 2022]]}
{"context": "Here, we report the biochemical and genetic basis of the Vel blood group antigen, which has been a vexing mystery for decades, especially as anti-Vel regularly causes severe haemolytic transfusion reactions. The protein carrying the Vel blood group antigen was biochemically purified from red blood cell membranes. Mass spectrometry-based de novo peptide sequencing identified this protein to be small integral membrane protein 1 (SMIM1), a previously uncharacterized single-pass membrane protein. Expression of SMIM1 cDNA in Vel- cultured cells generated anti-Vel cell surface reactivity, confirming that SMIM1 encoded the Vel blood group antigen. A cohort of 70 Vel- individuals was found to be uniformly homozygous for a 17 nucleotide deletion in the coding sequence of SMIM1. The genetic homogeneity of the Vel- blood type, likely having a common origin, facilitated the development of two highly specific DNA-based tests for rapid Vel genotyping, which can be easily integrated into blood group genotyping platforms. These results answer a 60-year-old riddle and provide tools of immediate assistance to all clinicians involved in the care of Vel- patients.", "qas": [{"question": "Which gene-defect causes the Vel-blood type?", "answers": ["a 17 nucleotide deletion"], "qid": "1a0f88859ac041309e802081a92d69d7", "question_tokens": [["Which", 0], ["gene", 6], ["-", 10], ["defect", 11], ["causes", 18], ["the", 25], ["Vel", 29], ["-", 32], ["blood", 33], ["type", 39], ["?", 43]], "detected_answers": [{"text": "a 17 nucleotide deletion", "token_spans": [[125, 127]], "char_spans": [[724, 745]]}]}], "context_tokens": [["Here", 0], [",", 4], ["we", 6], ["report", 9], ["the", 16], ["biochemical", 20], ["and", 32], ["genetic", 36], ["basis", 44], ["of", 50], ["the", 53], ["Vel", 57], ["blood", 61], ["group", 67], ["antigen", 73], [",", 80], ["which", 82], ["has", 88], ["been", 92], ["a", 97], ["vexing", 99], ["mystery", 106], ["for", 114], ["decades", 118], [",", 125], ["especially", 127], ["as", 138], ["anti", 141], ["-", 145], ["Vel", 146], ["regularly", 150], ["causes", 160], ["severe", 167], ["haemolytic", 174], ["transfusion", 185], ["reactions", 197], [".", 206], ["The", 208], ["protein", 212], ["carrying", 220], ["the", 229], ["Vel", 233], ["blood", 237], ["group", 243], ["antigen", 249], ["was", 257], ["biochemically", 261], ["purified", 275], ["from", 284], ["red", 289], ["blood", 293], ["cell", 299], ["membranes", 304], [".", 313], ["Mass", 315], ["spectrometry", 320], ["-", 332], ["based", 333], ["de", 339], ["novo", 342], ["peptide", 347], ["sequencing", 355], ["identified", 366], ["this", 377], ["protein", 382], ["to", 390], ["be", 393], ["small", 396], ["integral", 402], ["membrane", 411], ["protein", 420], ["1", 428], ["(", 430], ["SMIM1", 431], [")", 436], [",", 437], ["a", 439], ["previously", 441], ["uncharacterized", 452], ["single", 468], ["-", 474], ["pass", 475], ["membrane", 480], ["protein", 489], [".", 496], ["Expression", 498], ["of", 509], ["SMIM1", 512], ["cDNA", 518], ["in", 523], ["Vel-", 526], ["cultured", 531], ["cells", 540], ["generated", 546], ["anti", 556], ["-", 560], ["Vel", 561], ["cell", 565], ["surface", 570], ["reactivity", 578], [",", 588], ["confirming", 590], ["that", 601], ["SMIM1", 606], ["encoded", 612], ["the", 620], ["Vel", 624], ["blood", 628], ["group", 634], ["antigen", 640], [".", 647], ["A", 649], ["cohort", 651], ["of", 658], ["70", 661], ["Vel-", 664], ["individuals", 669], ["was", 681], ["found", 685], ["to", 691], ["be", 694], ["uniformly", 697], ["homozygous", 707], ["for", 718], ["a", 722], ["17", 724], ["nucleotide", 727], ["deletion", 738], ["in", 747], ["the", 750], ["coding", 754], ["sequence", 761], ["of", 770], ["SMIM1", 773], [".", 778], ["The", 780], ["genetic", 784], ["homogeneity", 792], ["of", 804], ["the", 807], ["Vel-", 811], ["blood", 816], ["type", 822], [",", 826], ["likely", 828], ["having", 835], ["a", 842], ["common", 844], ["origin", 851], [",", 857], ["facilitated", 859], ["the", 871], ["development", 875], ["of", 887], ["two", 890], ["highly", 894], ["specific", 901], ["DNA", 910], ["-", 913], ["based", 914], ["tests", 920], ["for", 926], ["rapid", 930], ["Vel", 936], ["genotyping", 940], [",", 950], ["which", 952], ["can", 958], ["be", 962], ["easily", 965], ["integrated", 972], ["into", 983], ["blood", 988], ["group", 994], ["genotyping", 1000], ["platforms", 1011], [".", 1020], ["These", 1022], ["results", 1028], ["answer", 1036], ["a", 1043], ["60-year", 1045], ["-", 1052], ["old", 1053], ["riddle", 1057], ["and", 1064], ["provide", 1068], ["tools", 1076], ["of", 1082], ["immediate", 1085], ["assistance", 1095], ["to", 1106], ["all", 1109], ["clinicians", 1113], ["involved", 1124], ["in", 1133], ["the", 1136], ["care", 1140], ["of", 1145], ["Vel-", 1148], ["patients", 1153], [".", 1161]]}
{"context": "Two missense mutations (Ala-30 --> Pro and Ala-53 --> Thr) in the gene encoding alpha-synuclein are associated with rare autosomal dominant forms of familial Parkinson's disease. In addition, alpha-synuclein is an abundant component of Lewy bodies in sporadic Parkinson's disease and diffuse Lewy body disease. However, the normal conformation of alpha-synuclein, its cellular localization in neurons, and the effects of the mutations remain to be determined. In the present study, we examine these questions using sensitive fluorescence resonance energy transfer techniques. Transient transfection of alpha-synuclein expression constructs into primary cortical neurons and counterstaining with the lipophilic fluorescent marker, DiI, demonstrates a close association between alpha-synuclein and cellular membranes. Both the N- and C-terminal regions of alpha-synuclein are tightly associated with membranes. A weak interaction also occurs between the N and C termini themselves. The Parkinson's disease-associated mutations have no effect on membrane interaction; however, the Ala-30 --> Pro mutation alters the three-dimensional conformation of alpha-synuclein, as measured by significantly increased fluorescence resonance energy transfer between the N and C termini.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "9cf91c000cf144009e50440635f148d1", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[129, 131], [145, 147], [196, 198], [37, 39], [105, 107], [64, 66], [18, 20]], "char_spans": [[776, 790], [854, 868], [1147, 1161], [192, 206], [602, 616], [347, 361], [80, 94]]}]}], "context_tokens": [["Two", 0], ["missense", 4], ["mutations", 13], ["(", 23], ["Ala-30", 24], ["--", 31], [">", 33], ["Pro", 35], ["and", 39], ["Ala-53", 43], ["--", 50], [">", 52], ["Thr", 54], [")", 57], ["in", 59], ["the", 62], ["gene", 66], ["encoding", 71], ["alpha", 80], ["-", 85], ["synuclein", 86], ["are", 96], ["associated", 100], ["with", 111], ["rare", 116], ["autosomal", 121], ["dominant", 131], ["forms", 140], ["of", 146], ["familial", 149], ["Parkinson", 158], ["'s", 167], ["disease", 170], [".", 177], ["In", 179], ["addition", 182], [",", 190], ["alpha", 192], ["-", 197], ["synuclein", 198], ["is", 208], ["an", 211], ["abundant", 214], ["component", 223], ["of", 233], ["Lewy", 236], ["bodies", 241], ["in", 248], ["sporadic", 251], ["Parkinson", 260], ["'s", 269], ["disease", 272], ["and", 280], ["diffuse", 284], ["Lewy", 292], ["body", 297], ["disease", 302], [".", 309], ["However", 311], [",", 318], ["the", 320], ["normal", 324], ["conformation", 331], ["of", 344], ["alpha", 347], ["-", 352], ["synuclein", 353], [",", 362], ["its", 364], ["cellular", 368], ["localization", 377], ["in", 390], ["neurons", 393], [",", 400], ["and", 402], ["the", 406], ["effects", 410], ["of", 418], ["the", 421], ["mutations", 425], ["remain", 435], ["to", 442], ["be", 445], ["determined", 448], [".", 458], ["In", 460], ["the", 463], ["present", 467], ["study", 475], [",", 480], ["we", 482], ["examine", 485], ["these", 493], ["questions", 499], ["using", 509], ["sensitive", 515], ["fluorescence", 525], ["resonance", 538], ["energy", 548], ["transfer", 555], ["techniques", 564], [".", 574], ["Transient", 576], ["transfection", 586], ["of", 599], ["alpha", 602], ["-", 607], ["synuclein", 608], ["expression", 618], ["constructs", 629], ["into", 640], ["primary", 645], ["cortical", 653], ["neurons", 662], ["and", 670], ["counterstaining", 674], ["with", 690], ["the", 695], ["lipophilic", 699], ["fluorescent", 710], ["marker", 722], [",", 728], ["DiI", 730], [",", 733], ["demonstrates", 735], ["a", 748], ["close", 750], ["association", 756], ["between", 768], ["alpha", 776], ["-", 781], ["synuclein", 782], ["and", 792], ["cellular", 796], ["membranes", 805], [".", 814], ["Both", 816], ["the", 821], ["N-", 825], ["and", 828], ["C", 832], ["-", 833], ["terminal", 834], ["regions", 843], ["of", 851], ["alpha", 854], ["-", 859], ["synuclein", 860], ["are", 870], ["tightly", 874], ["associated", 882], ["with", 893], ["membranes", 898], [".", 907], ["A", 909], ["weak", 911], ["interaction", 916], ["also", 928], ["occurs", 933], ["between", 940], ["the", 948], ["N", 952], ["and", 954], ["C", 958], ["termini", 960], ["themselves", 968], [".", 978], ["The", 980], ["Parkinson", 984], ["'s", 993], ["disease", 996], ["-", 1003], ["associated", 1004], ["mutations", 1015], ["have", 1025], ["no", 1030], ["effect", 1033], ["on", 1040], ["membrane", 1043], ["interaction", 1052], [";", 1063], ["however", 1065], [",", 1072], ["the", 1074], ["Ala-30", 1078], ["--", 1085], [">", 1087], ["Pro", 1089], ["mutation", 1093], ["alters", 1102], ["the", 1109], ["three", 1113], ["-", 1118], ["dimensional", 1119], ["conformation", 1131], ["of", 1144], ["alpha", 1147], ["-", 1152], ["synuclein", 1153], [",", 1162], ["as", 1164], ["measured", 1167], ["by", 1176], ["significantly", 1179], ["increased", 1193], ["fluorescence", 1203], ["resonance", 1216], ["energy", 1226], ["transfer", 1233], ["between", 1242], ["the", 1250], ["N", 1254], ["and", 1256], ["C", 1260], ["termini", 1262], [".", 1269]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is characterized by chromatin relaxation of the D4Z4 macrosatellite array on chromosome 4 and expression of the D4Z4-encoded DUX4 gene in skeletal muscle. The more common form, autosomal dominant FSHD1, is caused by contraction of the D4Z4 array, whereas the genetic determinants and inheritance of D4Z4 array contraction-independent FSHD2 are unclear. Here, we show that mutations in SMCHD1 (encoding structural maintenance of chromosomes flexible hinge domain containing 1) on chromosome 18 reduce SMCHD1 protein levels and segregate with genome-wide D4Z4 CpG hypomethylation in human kindreds. FSHD2 occurs in individuals who inherited both the SMCHD1 mutation and a normal-sized D4Z4 array on a chromosome 4 haplotype permissive for DUX4 expression. Reducing SMCHD1 levels in skeletal muscle results in D4Z4 contraction-independent DUX4 expression. Our study identifies SMCHD1 as an epigenetic modifier of the D4Z4 metastable epiallele and as a causal genetic determinant of FSHD2 and possibly other human diseases subject to epigenetic regulation.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "1e975a42f37e4673a2b441a56ec1c446", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "Facioscapulohumeral dystrophy", "token_spans": [[0, 1]], "char_spans": [[0, 28]]}, {"text": "FSHD", "token_spans": [[3, 3]], "char_spans": [[31, 34]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["characterized", 40], ["by", 54], ["chromatin", 57], ["relaxation", 67], ["of", 78], ["the", 81], ["D4Z4", 85], ["macrosatellite", 90], ["array", 105], ["on", 111], ["chromosome", 114], ["4", 125], ["and", 127], ["expression", 131], ["of", 142], ["the", 145], ["D4Z4-encoded", 149], ["DUX4", 162], ["gene", 167], ["in", 172], ["skeletal", 175], ["muscle", 184], [".", 190], ["The", 192], ["more", 196], ["common", 201], ["form", 208], [",", 212], ["autosomal", 214], ["dominant", 224], ["FSHD1", 233], [",", 238], ["is", 240], ["caused", 243], ["by", 250], ["contraction", 253], ["of", 265], ["the", 268], ["D4Z4", 272], ["array", 277], [",", 282], ["whereas", 284], ["the", 292], ["genetic", 296], ["determinants", 304], ["and", 317], ["inheritance", 321], ["of", 333], ["D4Z4", 336], ["array", 341], ["contraction", 347], ["-", 358], ["independent", 359], ["FSHD2", 371], ["are", 377], ["unclear", 381], [".", 388], ["Here", 390], [",", 394], ["we", 396], ["show", 399], ["that", 404], ["mutations", 409], ["in", 419], ["SMCHD1", 422], ["(", 429], ["encoding", 430], ["structural", 439], ["maintenance", 450], ["of", 462], ["chromosomes", 465], ["flexible", 477], ["hinge", 486], ["domain", 492], ["containing", 499], ["1", 510], [")", 511], ["on", 513], ["chromosome", 516], ["18", 527], ["reduce", 530], ["SMCHD1", 537], ["protein", 544], ["levels", 552], ["and", 559], ["segregate", 563], ["with", 573], ["genome", 578], ["-", 584], ["wide", 585], ["D4Z4", 590], ["CpG", 595], ["hypomethylation", 599], ["in", 615], ["human", 618], ["kindreds", 624], [".", 632], ["FSHD2", 634], ["occurs", 640], ["in", 647], ["individuals", 650], ["who", 662], ["inherited", 666], ["both", 676], ["the", 681], ["SMCHD1", 685], ["mutation", 692], ["and", 701], ["a", 705], ["normal", 707], ["-", 713], ["sized", 714], ["D4Z4", 720], ["array", 725], ["on", 731], ["a", 734], ["chromosome", 736], ["4", 747], ["haplotype", 749], ["permissive", 759], ["for", 770], ["DUX4", 774], ["expression", 779], [".", 789], ["Reducing", 791], ["SMCHD1", 800], ["levels", 807], ["in", 814], ["skeletal", 817], ["muscle", 826], ["results", 833], ["in", 841], ["D4Z4", 844], ["contraction", 849], ["-", 860], ["independent", 861], ["DUX4", 873], ["expression", 878], [".", 888], ["Our", 890], ["study", 894], ["identifies", 900], ["SMCHD1", 911], ["as", 918], ["an", 921], ["epigenetic", 924], ["modifier", 935], ["of", 944], ["the", 947], ["D4Z4", 951], ["metastable", 956], ["epiallele", 967], ["and", 977], ["as", 981], ["a", 984], ["causal", 986], ["genetic", 993], ["determinant", 1001], ["of", 1013], ["FSHD2", 1016], ["and", 1022], ["possibly", 1026], ["other", 1035], ["human", 1041], ["diseases", 1047], ["subject", 1056], ["to", 1064], ["epigenetic", 1067], ["regulation", 1078], [".", 1088]]}
{"context": "The Malaria Policy Advisory Committee to the World Health Organization met in Geneva, Switzerland from 13 to 15 March, 2013. This article provides a summary of the discussions, conclusions and recommendations from that meeting.Meeting sessions included: a review of the efficacy of artemisinin-based combination therapy in Guyana and Suriname; the outcomes from a consultation on non-malaria febrile illness; the outcomes from the second meeting of the Evidence Review Group on malaria burden estimation; an update on the review of the WHO Guidelines for the Treatment of Malaria; an update regarding progress on the constitution of the vector control Technical Expert Group; updates on the RTS, S/AS01 vaccine and the malaria vaccine technology roadmap; financing and resource allocation for malaria control; malaria surveillance and the need for a surveillance, monitoring and evaluation Technical Expert Group; criteria and classification related to malaria elimination; the next meeting of the Evidence Review Group on Intermittent Preventive Treatment in pregnancy; an update on the soon-to-be launched Elimination Scenario Planning Tool; and an update on the process for the Global Technical Strategy for Malaria Control and Elimination (2016-2025).Policy statements, position statements, and guidelines that arise from the MPAC meeting conclusions and recommendations will be formally issued and disseminated to World Health Organization Member States by the World Health Organization Global Malaria Programme.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "08c2300228d848599dbb36a771fdc904", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[128, 128], [83, 83], [67, 67], [138, 138], [141, 141], [100, 100], [249, 249], [162, 162], [1, 1], [207, 207]], "char_spans": [[719, 725], [478, 484], [384, 390], [793, 799], [810, 816], [572, 578], [1499, 1505], [953, 959], [4, 10], [1211, 1217]]}]}], "context_tokens": [["The", 0], ["Malaria", 4], ["Policy", 12], ["Advisory", 19], ["Committee", 28], ["to", 38], ["the", 41], ["World", 45], ["Health", 51], ["Organization", 58], ["met", 71], ["in", 75], ["Geneva", 78], [",", 84], ["Switzerland", 86], ["from", 98], ["13", 103], ["to", 106], ["15", 109], ["March", 112], [",", 117], ["2013", 119], [".", 123], ["This", 125], ["article", 130], ["provides", 138], ["a", 147], ["summary", 149], ["of", 157], ["the", 160], ["discussions", 164], [",", 175], ["conclusions", 177], ["and", 189], ["recommendations", 193], ["from", 209], ["that", 214], ["meeting", 219], [".", 226], ["Meeting", 227], ["sessions", 235], ["included", 244], [":", 252], ["a", 254], ["review", 256], ["of", 263], ["the", 266], ["efficacy", 270], ["of", 279], ["artemisinin", 282], ["-", 293], ["based", 294], ["combination", 300], ["therapy", 312], ["in", 320], ["Guyana", 323], ["and", 330], ["Suriname", 334], [";", 342], ["the", 344], ["outcomes", 348], ["from", 357], ["a", 362], ["consultation", 364], ["on", 377], ["non", 380], ["-", 383], ["malaria", 384], ["febrile", 392], ["illness", 400], [";", 407], ["the", 409], ["outcomes", 413], ["from", 422], ["the", 427], ["second", 431], ["meeting", 438], ["of", 446], ["the", 449], ["Evidence", 453], ["Review", 462], ["Group", 469], ["on", 475], ["malaria", 478], ["burden", 486], ["estimation", 493], [";", 503], ["an", 505], ["update", 508], ["on", 515], ["the", 518], ["review", 522], ["of", 529], ["the", 532], ["WHO", 536], ["Guidelines", 540], ["for", 551], ["the", 555], ["Treatment", 559], ["of", 569], ["Malaria", 572], [";", 579], ["an", 581], ["update", 584], ["regarding", 591], ["progress", 601], ["on", 610], ["the", 613], ["constitution", 617], ["of", 630], ["the", 633], ["vector", 637], ["control", 644], ["Technical", 652], ["Expert", 662], ["Group", 669], [";", 674], ["updates", 676], ["on", 684], ["the", 687], ["RTS", 691], [",", 694], ["S", 696], ["/", 697], ["AS01", 698], ["vaccine", 703], ["and", 711], ["the", 715], ["malaria", 719], ["vaccine", 727], ["technology", 735], ["roadmap", 746], [";", 753], ["financing", 755], ["and", 765], ["resource", 769], ["allocation", 778], ["for", 789], ["malaria", 793], ["control", 801], [";", 808], ["malaria", 810], ["surveillance", 818], ["and", 831], ["the", 835], ["need", 839], ["for", 844], ["a", 848], ["surveillance", 850], [",", 862], ["monitoring", 864], ["and", 875], ["evaluation", 879], ["Technical", 890], ["Expert", 900], ["Group", 907], [";", 912], ["criteria", 914], ["and", 923], ["classification", 927], ["related", 942], ["to", 950], ["malaria", 953], ["elimination", 961], [";", 972], ["the", 974], ["next", 978], ["meeting", 983], ["of", 991], ["the", 994], ["Evidence", 998], ["Review", 1007], ["Group", 1014], ["on", 1020], ["Intermittent", 1023], ["Preventive", 1036], ["Treatment", 1047], ["in", 1057], ["pregnancy", 1060], [";", 1069], ["an", 1071], ["update", 1074], ["on", 1081], ["the", 1084], ["soon", 1088], ["-", 1092], ["to", 1093], ["-", 1095], ["be", 1096], ["launched", 1099], ["Elimination", 1108], ["Scenario", 1120], ["Planning", 1129], ["Tool", 1138], [";", 1142], ["and", 1144], ["an", 1148], ["update", 1151], ["on", 1158], ["the", 1161], ["process", 1165], ["for", 1173], ["the", 1177], ["Global", 1181], ["Technical", 1188], ["Strategy", 1198], ["for", 1207], ["Malaria", 1211], ["Control", 1219], ["and", 1227], ["Elimination", 1231], ["(", 1243], ["2016", 1244], ["-", 1248], ["2025).Policy", 1249], ["statements", 1262], [",", 1272], ["position", 1274], ["statements", 1283], [",", 1293], ["and", 1295], ["guidelines", 1299], ["that", 1310], ["arise", 1315], ["from", 1321], ["the", 1326], ["MPAC", 1330], ["meeting", 1335], ["conclusions", 1343], ["and", 1355], ["recommendations", 1359], ["will", 1375], ["be", 1380], ["formally", 1383], ["issued", 1392], ["and", 1399], ["disseminated", 1403], ["to", 1416], ["World", 1419], ["Health", 1425], ["Organization", 1432], ["Member", 1445], ["States", 1452], ["by", 1459], ["the", 1462], ["World", 1466], ["Health", 1472], ["Organization", 1479], ["Global", 1492], ["Malaria", 1499], ["Programme", 1507], [".", 1516]]}
{"context": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies. These inclusion bodies are the characteristic pathologic lesions of Parkinson disease. Here we define the role of phosphorylation of Ser129 in alpha-synuclein toxicity and inclusion formation using a Drosophila model of Parkinson disease. Mutation of Ser129 to alanine to prevent phosphorylation completely suppresses dopaminergic neuronal loss produced by expression of human alpha-synuclein. In contrast, altering Ser129 to the negatively charged residue aspartate, to mimic phosphorylation, significantly enhances alpha-synuclein toxicity. The G protein-coupled receptor kinase 2 (Gprk2) phosphorylates Ser129 in vivo and enhances alpha-synuclein toxicity. Blocking phosphorylation at Ser129 substantially increases aggregate formation. Thus Ser129 phosphorylation status is crucial in mediating alpha-synuclein neurotoxicity and inclusion formation. Because increased number of inclusion bodies correlates with reduced toxicity, inclusion bodies may protect neurons from alpha-synuclein toxicity.", "qas": [{"question": "Which residue of alpha-synuclein was found to be phosphorylated in Lewy bodies?", "answers": ["Serine 129"], "qid": "7161d325e39f4f4884391fb5e3adb5db", "question_tokens": [["Which", 0], ["residue", 6], ["of", 14], ["alpha", 17], ["-", 22], ["synuclein", 23], ["was", 33], ["found", 37], ["to", 43], ["be", 46], ["phosphorylated", 49], ["in", 64], ["Lewy", 67], ["bodies", 72], ["?", 78]], "detected_answers": [{"text": "Serine 129", "token_spans": [[6, 7]], "char_spans": [[37, 46]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["is", 16], ["phosphorylated", 19], ["at", 34], ["serine", 37], ["129", 44], ["(", 48], ["Ser129", 49], [")", 55], ["in", 57], ["intracellular", 60], ["protein", 74], ["aggregates", 82], ["called", 93], ["Lewy", 100], ["bodies", 105], [".", 111], ["These", 113], ["inclusion", 119], ["bodies", 129], ["are", 136], ["the", 140], ["characteristic", 144], ["pathologic", 159], ["lesions", 170], ["of", 178], ["Parkinson", 181], ["disease", 191], [".", 198], ["Here", 200], ["we", 205], ["define", 208], ["the", 215], ["role", 219], ["of", 224], ["phosphorylation", 227], ["of", 243], ["Ser129", 246], ["in", 253], ["alpha", 256], ["-", 261], ["synuclein", 262], ["toxicity", 272], ["and", 281], ["inclusion", 285], ["formation", 295], ["using", 305], ["a", 311], ["Drosophila", 313], ["model", 324], ["of", 330], ["Parkinson", 333], ["disease", 343], [".", 350], ["Mutation", 352], ["of", 361], ["Ser129", 364], ["to", 371], ["alanine", 374], ["to", 382], ["prevent", 385], ["phosphorylation", 393], ["completely", 409], ["suppresses", 420], ["dopaminergic", 431], ["neuronal", 444], ["loss", 453], ["produced", 458], ["by", 467], ["expression", 470], ["of", 481], ["human", 484], ["alpha", 490], ["-", 495], ["synuclein", 496], [".", 505], ["In", 507], ["contrast", 510], [",", 518], ["altering", 520], ["Ser129", 529], ["to", 536], ["the", 539], ["negatively", 543], ["charged", 554], ["residue", 562], ["aspartate", 570], [",", 579], ["to", 581], ["mimic", 584], ["phosphorylation", 590], [",", 605], ["significantly", 607], ["enhances", 621], ["alpha", 630], ["-", 635], ["synuclein", 636], ["toxicity", 646], [".", 654], ["The", 656], ["G", 660], ["protein", 662], ["-", 669], ["coupled", 670], ["receptor", 678], ["kinase", 687], ["2", 694], ["(", 696], ["Gprk2", 697], [")", 702], ["phosphorylates", 704], ["Ser129", 719], ["in", 726], ["vivo", 729], ["and", 734], ["enhances", 738], ["alpha", 747], ["-", 752], ["synuclein", 753], ["toxicity", 763], [".", 771], ["Blocking", 773], ["phosphorylation", 782], ["at", 798], ["Ser129", 801], ["substantially", 808], ["increases", 822], ["aggregate", 832], ["formation", 842], [".", 851], ["Thus", 853], ["Ser129", 858], ["phosphorylation", 865], ["status", 881], ["is", 888], ["crucial", 891], ["in", 899], ["mediating", 902], ["alpha", 912], ["-", 917], ["synuclein", 918], ["neurotoxicity", 928], ["and", 942], ["inclusion", 946], ["formation", 956], [".", 965], ["Because", 967], ["increased", 975], ["number", 985], ["of", 992], ["inclusion", 995], ["bodies", 1005], ["correlates", 1012], ["with", 1023], ["reduced", 1028], ["toxicity", 1036], [",", 1044], ["inclusion", 1046], ["bodies", 1056], ["may", 1063], ["protect", 1067], ["neurons", 1075], ["from", 1083], ["alpha", 1088], ["-", 1093], ["synuclein", 1094], ["toxicity", 1104], [".", 1112]]}
{"context": "Dabigatran is a direct thrombin inhibitor used to reduce the risk of stroke in patients with nonvalvular atrial fibrillation. For patients who present with an acute stroke despite dabigatran therapy, clinical data on the use of intravenous tissue plasminogen activator (IV-tPA) is limited. There is an anticipated increased risk of symptomatic intracranial hemorrhage (sICH) when using IV-tPA in patients on dabigatran therapy. In 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran. Dabigatran reversal with idarucizumab before administration of IV-tPA might reduce the risk of sICH. We report a case of a 69-year-old stroke patient on dabigatran for paroxysmal atrial fibrillation who presented with an initial National Institutes of Health Stroke Scale (NIHSS) of 12. There was no early evidence of ischemic stroke or hemorrhage on head computed tomography, and coagulation studies implied therapeutic dabigatran levels. After controlling blood pressure, dabigatran was reversed with idarucizumab, and IV-tPA was administrated beginning 197\u2009minutes after he was last seen at his baseline. Subsequent brain magnetic resonance imaging showed 2 punctate infarcts in the left temporal lobe and occipital lobe with no evidence of hemorrhage. The patient was discharged with an NIHSS of 1. Telephone follow-up 2 months later indicated that he was at his prestroke baseline, except for a complaint of worsened short-term memory. Idarucizumab reversal of dabigatran may reduce the risk of sICH and should be considered for acute stroke patients arriving in the IV-tPA time window.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "f9c27593e5f743369c33b2e1ea8791ae", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[0, 0], [176, 176], [97, 97], [29, 29], [71, 71], [263, 263], [168, 168], [126, 126], [95, 95]], "char_spans": [[0, 9], [1049, 1058], [575, 584], [180, 189], [408, 417], [1541, 1550], [996, 1005], [728, 737], [563, 572]]}]}], "context_tokens": [["Dabigatran", 0], ["is", 11], ["a", 14], ["direct", 16], ["thrombin", 23], ["inhibitor", 32], ["used", 42], ["to", 47], ["reduce", 50], ["the", 57], ["risk", 61], ["of", 66], ["stroke", 69], ["in", 76], ["patients", 79], ["with", 88], ["nonvalvular", 93], ["atrial", 105], ["fibrillation", 112], [".", 124], ["For", 126], ["patients", 130], ["who", 139], ["present", 143], ["with", 151], ["an", 156], ["acute", 159], ["stroke", 165], ["despite", 172], ["dabigatran", 180], ["therapy", 191], [",", 198], ["clinical", 200], ["data", 209], ["on", 214], ["the", 217], ["use", 221], ["of", 225], ["intravenous", 228], ["tissue", 240], ["plasminogen", 247], ["activator", 259], ["(", 269], ["IV", 270], ["-", 272], ["tPA", 273], [")", 276], ["is", 278], ["limited", 281], [".", 288], ["There", 290], ["is", 296], ["an", 299], ["anticipated", 302], ["increased", 314], ["risk", 324], ["of", 329], ["symptomatic", 332], ["intracranial", 344], ["hemorrhage", 357], ["(", 368], ["sICH", 369], [")", 373], ["when", 375], ["using", 380], ["IV", 386], ["-", 388], ["tPA", 389], ["in", 393], ["patients", 396], ["on", 405], ["dabigatran", 408], ["therapy", 419], [".", 426], ["In", 428], ["2015", 431], [",", 435], ["the", 437], ["humanized", 441], ["monoclonal", 451], ["antibody", 462], ["fragment", 471], ["idarucizumab", 480], ["was", 493], ["approved", 497], ["for", 506], ["rapid", 510], ["(", 516], ["minutes", 517], [")", 524], ["reversal", 526], ["of", 535], ["anticoagulant", 538], ["effects", 552], ["of", 560], ["dabigatran", 563], [".", 573], ["Dabigatran", 575], ["reversal", 586], ["with", 595], ["idarucizumab", 600], ["before", 613], ["administration", 620], ["of", 635], ["IV", 638], ["-", 640], ["tPA", 641], ["might", 645], ["reduce", 651], ["the", 658], ["risk", 662], ["of", 667], ["sICH", 670], [".", 674], ["We", 676], ["report", 679], ["a", 686], ["case", 688], ["of", 693], ["a", 696], ["69-year", 698], ["-", 705], ["old", 706], ["stroke", 710], ["patient", 717], ["on", 725], ["dabigatran", 728], ["for", 739], ["paroxysmal", 743], ["atrial", 754], ["fibrillation", 761], ["who", 774], ["presented", 778], ["with", 788], ["an", 793], ["initial", 796], ["National", 804], ["Institutes", 813], ["of", 824], ["Health", 827], ["Stroke", 834], ["Scale", 841], ["(", 847], ["NIHSS", 848], [")", 853], ["of", 855], ["12", 858], [".", 860], ["There", 862], ["was", 868], ["no", 872], ["early", 875], ["evidence", 881], ["of", 890], ["ischemic", 893], ["stroke", 902], ["or", 909], ["hemorrhage", 912], ["on", 923], ["head", 926], ["computed", 931], ["tomography", 940], [",", 950], ["and", 952], ["coagulation", 956], ["studies", 968], ["implied", 976], ["therapeutic", 984], ["dabigatran", 996], ["levels", 1007], [".", 1013], ["After", 1015], ["controlling", 1021], ["blood", 1033], ["pressure", 1039], [",", 1047], ["dabigatran", 1049], ["was", 1060], ["reversed", 1064], ["with", 1073], ["idarucizumab", 1078], [",", 1090], ["and", 1092], ["IV", 1096], ["-", 1098], ["tPA", 1099], ["was", 1103], ["administrated", 1107], ["beginning", 1121], ["197", 1131], ["minutes", 1135], ["after", 1143], ["he", 1149], ["was", 1152], ["last", 1156], ["seen", 1161], ["at", 1166], ["his", 1169], ["baseline", 1173], [".", 1181], ["Subsequent", 1183], ["brain", 1194], ["magnetic", 1200], ["resonance", 1209], ["imaging", 1219], ["showed", 1227], ["2", 1234], ["punctate", 1236], ["infarcts", 1245], ["in", 1254], ["the", 1257], ["left", 1261], ["temporal", 1266], ["lobe", 1275], ["and", 1280], ["occipital", 1284], ["lobe", 1294], ["with", 1299], ["no", 1304], ["evidence", 1307], ["of", 1316], ["hemorrhage", 1319], [".", 1329], ["The", 1331], ["patient", 1335], ["was", 1343], ["discharged", 1347], ["with", 1358], ["an", 1363], ["NIHSS", 1366], ["of", 1372], ["1", 1375], [".", 1376], ["Telephone", 1378], ["follow", 1388], ["-", 1394], ["up", 1395], ["2", 1398], ["months", 1400], ["later", 1407], ["indicated", 1413], ["that", 1423], ["he", 1428], ["was", 1431], ["at", 1435], ["his", 1438], ["prestroke", 1442], ["baseline", 1452], [",", 1460], ["except", 1462], ["for", 1469], ["a", 1473], ["complaint", 1475], ["of", 1485], ["worsened", 1488], ["short", 1497], ["-", 1502], ["term", 1503], ["memory", 1508], [".", 1514], ["Idarucizumab", 1516], ["reversal", 1529], ["of", 1538], ["dabigatran", 1541], ["may", 1552], ["reduce", 1556], ["the", 1563], ["risk", 1567], ["of", 1572], ["sICH", 1575], ["and", 1580], ["should", 1584], ["be", 1591], ["considered", 1594], ["for", 1605], ["acute", 1609], ["stroke", 1615], ["patients", 1622], ["arriving", 1631], ["in", 1640], ["the", 1643], ["IV", 1647], ["-", 1649], ["tPA", 1650], ["time", 1654], ["window", 1659], [".", 1665]]}
{"context": "Research during the last 15 years has conclusively shown that viroids are not only fundamentally different from viruses at the molecular level, but that they are most likely not directly related to viruses in an evolutionary sense. Today, viroids are among the most thoroughly studied biological macromolecules. Their molecular structures have been elucidated to a large extent, but much needs to be learned regarding the correlation between molecular structure and biological function. The availability of the tools of recombinant DNA technology in viroid research promises rapid progress in these areas of inquiry.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "e33fefebc3a946c4b17c7aaf7f33de2e", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[41, 41], [10, 10]], "char_spans": [[239, 245], [62, 68]]}]}], "context_tokens": [["Research", 0], ["during", 9], ["the", 16], ["last", 20], ["15", 25], ["years", 28], ["has", 34], ["conclusively", 38], ["shown", 51], ["that", 57], ["viroids", 62], ["are", 70], ["not", 74], ["only", 78], ["fundamentally", 83], ["different", 97], ["from", 107], ["viruses", 112], ["at", 120], ["the", 123], ["molecular", 127], ["level", 137], [",", 142], ["but", 144], ["that", 148], ["they", 153], ["are", 158], ["most", 162], ["likely", 167], ["not", 174], ["directly", 178], ["related", 187], ["to", 195], ["viruses", 198], ["in", 206], ["an", 209], ["evolutionary", 212], ["sense", 225], [".", 230], ["Today", 232], [",", 237], ["viroids", 239], ["are", 247], ["among", 251], ["the", 257], ["most", 261], ["thoroughly", 266], ["studied", 277], ["biological", 285], ["macromolecules", 296], [".", 310], ["Their", 312], ["molecular", 318], ["structures", 328], ["have", 339], ["been", 344], ["elucidated", 349], ["to", 360], ["a", 363], ["large", 365], ["extent", 371], [",", 377], ["but", 379], ["much", 383], ["needs", 388], ["to", 394], ["be", 397], ["learned", 400], ["regarding", 408], ["the", 418], ["correlation", 422], ["between", 434], ["molecular", 442], ["structure", 452], ["and", 462], ["biological", 466], ["function", 477], [".", 485], ["The", 487], ["availability", 491], ["of", 504], ["the", 507], ["tools", 511], ["of", 517], ["recombinant", 520], ["DNA", 532], ["technology", 536], ["in", 547], ["viroid", 550], ["research", 557], ["promises", 566], ["rapid", 575], ["progress", 581], ["in", 590], ["these", 593], ["areas", 599], ["of", 605], ["inquiry", 608], [".", 615]]}
{"context": "Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are present in lung adenocarcinomas that respond to the EGFR inhibitors gefitinib and erlotinib. Two types of mutations account for approximately 90% of mutated cases: short in-frame deletions in exon 19 and a specific point mutation in exon 21 at codon 858 (L858R). Screening for these mutations has been based mainly on direct sequencing. We report here the development and validation of polymerase chain reaction-based assays for these two predominant types of EGFR mutations. The assay for exon 19 mutations is based on length analysis of fluorescently labeled polymerase chain reaction products, and the assay for the exon 21 L858R mutation is based on a new Sau96I restriction site created by this mutation. Using serial dilutions of DNAs from lung cancer cell lines harboring either exon 19 or 21 mutations, we detected these mutations in the presence of up to approximately 90% normal DNA. In a test set of 39 lung cancer samples, direct sequencing detected mutations in 25 cases whereas our assays were positive in 29 cases, including 4 cases in which mutations were not apparent by sequencing. These assays offer higher sensitivity and ease of scoring and eliminate the need for sequencing, providing a robust and accessible approach to the rapid identification of most lung cancer patients likely to respond to EGFR inhibitors.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "a19945a83e2d457caf189e2614c1ac05", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[9, 16]], "char_spans": [[55, 98]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["the", 21], ["tyrosine", 25], ["kinase", 34], ["domain", 41], ["of", 48], ["the", 51], ["epidermal", 55], ["growth", 65], ["factor", 72], ["receptor", 79], ["(", 88], ["EGFR", 89], [")", 93], ["gene", 95], ["are", 100], ["present", 104], ["in", 112], ["lung", 115], ["adenocarcinomas", 120], ["that", 136], ["respond", 141], ["to", 149], ["the", 152], ["EGFR", 156], ["inhibitors", 161], ["gefitinib", 172], ["and", 182], ["erlotinib", 186], [".", 195], ["Two", 197], ["types", 201], ["of", 207], ["mutations", 210], ["account", 220], ["for", 228], ["approximately", 232], ["90", 246], ["%", 248], ["of", 250], ["mutated", 253], ["cases", 261], [":", 266], ["short", 268], ["in", 274], ["-", 276], ["frame", 277], ["deletions", 283], ["in", 293], ["exon", 296], ["19", 301], ["and", 304], ["a", 308], ["specific", 310], ["point", 319], ["mutation", 325], ["in", 334], ["exon", 337], ["21", 342], ["at", 345], ["codon", 348], ["858", 354], ["(", 358], ["L858R", 359], [")", 364], [".", 365], ["Screening", 367], ["for", 377], ["these", 381], ["mutations", 387], ["has", 397], ["been", 401], ["based", 406], ["mainly", 412], ["on", 419], ["direct", 422], ["sequencing", 429], [".", 439], ["We", 441], ["report", 444], ["here", 451], ["the", 456], ["development", 460], ["and", 472], ["validation", 476], ["of", 487], ["polymerase", 490], ["chain", 501], ["reaction", 507], ["-", 515], ["based", 516], ["assays", 522], ["for", 529], ["these", 533], ["two", 539], ["predominant", 543], ["types", 555], ["of", 561], ["EGFR", 564], ["mutations", 569], [".", 578], ["The", 580], ["assay", 584], ["for", 590], ["exon", 594], ["19", 599], ["mutations", 602], ["is", 612], ["based", 615], ["on", 621], ["length", 624], ["analysis", 631], ["of", 640], ["fluorescently", 643], ["labeled", 657], ["polymerase", 665], ["chain", 676], ["reaction", 682], ["products", 691], [",", 699], ["and", 701], ["the", 705], ["assay", 709], ["for", 715], ["the", 719], ["exon", 723], ["21", 728], ["L858R", 731], ["mutation", 737], ["is", 746], ["based", 749], ["on", 755], ["a", 758], ["new", 760], ["Sau96I", 764], ["restriction", 771], ["site", 783], ["created", 788], ["by", 796], ["this", 799], ["mutation", 804], [".", 812], ["Using", 814], ["serial", 820], ["dilutions", 827], ["of", 837], ["DNAs", 840], ["from", 845], ["lung", 850], ["cancer", 855], ["cell", 862], ["lines", 867], ["harboring", 873], ["either", 883], ["exon", 890], ["19", 895], ["or", 898], ["21", 901], ["mutations", 904], [",", 913], ["we", 915], ["detected", 918], ["these", 927], ["mutations", 933], ["in", 943], ["the", 946], ["presence", 950], ["of", 959], ["up", 962], ["to", 965], ["approximately", 968], ["90", 982], ["%", 984], ["normal", 986], ["DNA", 993], [".", 996], ["In", 998], ["a", 1001], ["test", 1003], ["set", 1008], ["of", 1012], ["39", 1015], ["lung", 1018], ["cancer", 1023], ["samples", 1030], [",", 1037], ["direct", 1039], ["sequencing", 1046], ["detected", 1057], ["mutations", 1066], ["in", 1076], ["25", 1079], ["cases", 1082], ["whereas", 1088], ["our", 1096], ["assays", 1100], ["were", 1107], ["positive", 1112], ["in", 1121], ["29", 1124], ["cases", 1127], [",", 1132], ["including", 1134], ["4", 1144], ["cases", 1146], ["in", 1152], ["which", 1155], ["mutations", 1161], ["were", 1171], ["not", 1176], ["apparent", 1180], ["by", 1189], ["sequencing", 1192], [".", 1202], ["These", 1204], ["assays", 1210], ["offer", 1217], ["higher", 1223], ["sensitivity", 1230], ["and", 1242], ["ease", 1246], ["of", 1251], ["scoring", 1254], ["and", 1262], ["eliminate", 1266], ["the", 1276], ["need", 1280], ["for", 1285], ["sequencing", 1289], [",", 1299], ["providing", 1301], ["a", 1311], ["robust", 1313], ["and", 1320], ["accessible", 1324], ["approach", 1335], ["to", 1344], ["the", 1347], ["rapid", 1351], ["identification", 1357], ["of", 1372], ["most", 1375], ["lung", 1380], ["cancer", 1385], ["patients", 1392], ["likely", 1401], ["to", 1408], ["respond", 1411], ["to", 1419], ["EGFR", 1422], ["inhibitors", 1427], [".", 1437]]}
{"context": "In patients with active rheumatoid arthritis despite therapy with DMARDS, treatment with a spleen tyrosine kinase inhibitor has achieved similar response rates to those achieved in clinical trials of other drugs, including biologic agents. Where might these agents fit in the current armamentarium against this disease?", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "6cdfaee03ce4412b9875775aca7ac48e", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[14, 16]], "char_spans": [[91, 112]]}]}], "context_tokens": [["In", 0], ["patients", 3], ["with", 12], ["active", 17], ["rheumatoid", 24], ["arthritis", 35], ["despite", 45], ["therapy", 53], ["with", 61], ["DMARDS", 66], [",", 72], ["treatment", 74], ["with", 84], ["a", 89], ["spleen", 91], ["tyrosine", 98], ["kinase", 107], ["inhibitor", 114], ["has", 124], ["achieved", 128], ["similar", 137], ["response", 145], ["rates", 154], ["to", 160], ["those", 163], ["achieved", 169], ["in", 178], ["clinical", 181], ["trials", 190], ["of", 197], ["other", 200], ["drugs", 206], [",", 211], ["including", 213], ["biologic", 223], ["agents", 232], [".", 238], ["Where", 240], ["might", 246], ["these", 252], ["agents", 258], ["fit", 265], ["in", 269], ["the", 272], ["current", 276], ["armamentarium", 284], ["against", 298], ["this", 306], ["disease", 311], ["?", 318]]}
{"context": "Mutations and deletions of the NSD1 gene, located on chromosome 5q35, are responsible for over 90% of cases of Sotos syndrome. Fluorescent in situ hybridization analysis (FISH), MLPA or multiplex quantitative PCR allow detection of total/partial NSD1 deletions and direct sequencing allows detection of NSD1 mutations. We describe two boys with Sotos syndrome in whom PCR amplification and direct sequencing of the NSD1 gene identified two novel mutations not previously described: c.4736dupG in exon 12 and c.3938_3939insT in exon 7. In addition to the cardinal and major features of the syndrome (abnormal facial appearance, overgrowth, cardiac anomalies, renal anomalies, hypotonia, neonatal jaundice, seizures and brain MRI abnormalities) in both patients, one boy also had cryptorchidism and vertebral anomalies, features considered not common. Despite the wide range of possible combinations of phenotypic features, molecular analysis can correctly identify Sotos syndrome.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "da2112b55fe74ffe80afbc48f42143f7", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[5, 6], [72, 73]], "char_spans": [[31, 39], [415, 423]]}]}], "context_tokens": [["Mutations", 0], ["and", 10], ["deletions", 14], ["of", 24], ["the", 27], ["NSD1", 31], ["gene", 36], [",", 40], ["located", 42], ["on", 50], ["chromosome", 53], ["5q35", 64], [",", 68], ["are", 70], ["responsible", 74], ["for", 86], ["over", 90], ["90", 95], ["%", 97], ["of", 99], ["cases", 102], ["of", 108], ["Sotos", 111], ["syndrome", 117], [".", 125], ["Fluorescent", 127], ["in", 139], ["situ", 142], ["hybridization", 147], ["analysis", 161], ["(", 170], ["FISH", 171], [")", 175], [",", 176], ["MLPA", 178], ["or", 183], ["multiplex", 186], ["quantitative", 196], ["PCR", 209], ["allow", 213], ["detection", 219], ["of", 229], ["total", 232], ["/", 237], ["partial", 238], ["NSD1", 246], ["deletions", 251], ["and", 261], ["direct", 265], ["sequencing", 272], ["allows", 283], ["detection", 290], ["of", 300], ["NSD1", 303], ["mutations", 308], [".", 317], ["We", 319], ["describe", 322], ["two", 331], ["boys", 335], ["with", 340], ["Sotos", 345], ["syndrome", 351], ["in", 360], ["whom", 363], ["PCR", 368], ["amplification", 372], ["and", 386], ["direct", 390], ["sequencing", 397], ["of", 408], ["the", 411], ["NSD1", 415], ["gene", 420], ["identified", 425], ["two", 436], ["novel", 440], ["mutations", 446], ["not", 456], ["previously", 460], ["described", 471], [":", 480], ["c.4736dupG", 482], ["in", 493], ["exon", 496], ["12", 501], ["and", 504], ["c.3938_3939insT", 508], ["in", 524], ["exon", 527], ["7", 532], [".", 533], ["In", 535], ["addition", 538], ["to", 547], ["the", 550], ["cardinal", 554], ["and", 563], ["major", 567], ["features", 573], ["of", 582], ["the", 585], ["syndrome", 589], ["(", 598], ["abnormal", 599], ["facial", 608], ["appearance", 615], [",", 625], ["overgrowth", 627], [",", 637], ["cardiac", 639], ["anomalies", 647], [",", 656], ["renal", 658], ["anomalies", 664], [",", 673], ["hypotonia", 675], [",", 684], ["neonatal", 686], ["jaundice", 695], [",", 703], ["seizures", 705], ["and", 714], ["brain", 718], ["MRI", 724], ["abnormalities", 728], [")", 741], ["in", 743], ["both", 746], ["patients", 751], [",", 759], ["one", 761], ["boy", 765], ["also", 769], ["had", 774], ["cryptorchidism", 778], ["and", 793], ["vertebral", 797], ["anomalies", 807], [",", 816], ["features", 818], ["considered", 827], ["not", 838], ["common", 842], [".", 848], ["Despite", 850], ["the", 858], ["wide", 862], ["range", 867], ["of", 873], ["possible", 876], ["combinations", 885], ["of", 898], ["phenotypic", 901], ["features", 912], [",", 920], ["molecular", 922], ["analysis", 932], ["can", 941], ["correctly", 945], ["identify", 955], ["Sotos", 964], ["syndrome", 970], [".", 978]]}
{"context": "Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region--Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML). Its hematologic and cytogenetic effects have been evaluated in a series of clinical trials. The aim of this study was to report hematologic and cytogenetic response in CML patients during the treatment with imatinib mesylate. A total of 21 patients were treated and observed from July 2006 to December 2008. The median time from CML diagnosis was no more than 12 months, so all the patients received previous treatment with hydroxyurea for which the median time was 3 months. The patients received imatinib mesylate in an effective oral dose of 400 to 800 mg daily, which was followed with peripheral blood counts, bone marrow examination, and cytogenetic studies at 6, 12, 18 and 24 months. Complete hematologic responses were reported for 19 (90.48%) of 21 patients studied. Among 19 patients who had a response, 16 (86%) did so within 3 months. The best cytogenetic response rate at any time during the study treatment with imatinib mesylate, among 14 patients in which cytogenetic response evaluated was: complete cytogenetic response in 7 (50%) patients, partial cytogenetic response in 6 (42.9%) patients and minor cytogenetic response in 1 (7.1%) patient. No patients had progressed to accelerated or blastic phase. The most frequent adverse effects that seemed to be related to treatment with imatinib mesylate were edema and musculoskeletal pain; overall, most were mild. Only one patient discontinued treatment because of hematologic toxic effects. The results obtained in this study confirm that imatinib mesylate induces a complete hematological and cytogenetic response in a high percentage of patients with chronic-phase CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "6a1078ce36c74d609a098b1b566be822", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[20, 22]], "char_spans": [[134, 140]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["a", 19], ["tyrosine", 21], ["kinase", 30], ["inhibitor", 37], ["with", 47], ["specific", 52], ["activity", 61], ["against", 70], ["the", 78], ["breakpoint", 82], ["cluster", 93], ["region", 101], ["--", 107], ["Abelson", 109], ["murine", 117], ["leukemia", 124], ["(", 133], ["BCR", 134], ["-", 137], ["ABL", 138], [")", 141], ["tyrosine", 143], ["kinase", 152], ["has", 159], ["been", 163], ["developed", 168], ["for", 178], ["treatment", 182], ["of", 192], ["chronic", 195], ["myelogenous", 203], ["leukemia", 215], ["(", 224], ["CML", 225], [")", 228], [".", 229], ["Its", 231], ["hematologic", 235], ["and", 247], ["cytogenetic", 251], ["effects", 263], ["have", 271], ["been", 276], ["evaluated", 281], ["in", 291], ["a", 294], ["series", 296], ["of", 303], ["clinical", 306], ["trials", 315], [".", 321], ["The", 323], ["aim", 327], ["of", 331], ["this", 334], ["study", 339], ["was", 345], ["to", 349], ["report", 352], ["hematologic", 359], ["and", 371], ["cytogenetic", 375], ["response", 387], ["in", 396], ["CML", 399], ["patients", 403], ["during", 412], ["the", 419], ["treatment", 423], ["with", 433], ["imatinib", 438], ["mesylate", 447], [".", 455], ["A", 457], ["total", 459], ["of", 465], ["21", 468], ["patients", 471], ["were", 480], ["treated", 485], ["and", 493], ["observed", 497], ["from", 506], ["July", 511], ["2006", 516], ["to", 521], ["December", 524], ["2008", 533], [".", 537], ["The", 539], ["median", 543], ["time", 550], ["from", 555], ["CML", 560], ["diagnosis", 564], ["was", 574], ["no", 578], ["more", 581], ["than", 586], ["12", 591], ["months", 594], [",", 600], ["so", 602], ["all", 605], ["the", 609], ["patients", 613], ["received", 622], ["previous", 631], ["treatment", 640], ["with", 650], ["hydroxyurea", 655], ["for", 667], ["which", 671], ["the", 677], ["median", 681], ["time", 688], ["was", 693], ["3", 697], ["months", 699], [".", 705], ["The", 707], ["patients", 711], ["received", 720], ["imatinib", 729], ["mesylate", 738], ["in", 747], ["an", 750], ["effective", 753], ["oral", 763], ["dose", 768], ["of", 773], ["400", 776], ["to", 780], ["800", 783], ["mg", 787], ["daily", 790], [",", 795], ["which", 797], ["was", 803], ["followed", 807], ["with", 816], ["peripheral", 821], ["blood", 832], ["counts", 838], [",", 844], ["bone", 846], ["marrow", 851], ["examination", 858], [",", 869], ["and", 871], ["cytogenetic", 875], ["studies", 887], ["at", 895], ["6", 898], [",", 899], ["12", 901], [",", 903], ["18", 905], ["and", 908], ["24", 912], ["months", 915], [".", 921], ["Complete", 923], ["hematologic", 932], ["responses", 944], ["were", 954], ["reported", 959], ["for", 968], ["19", 972], ["(", 975], ["90.48", 976], ["%", 981], [")", 982], ["of", 984], ["21", 987], ["patients", 990], ["studied", 999], [".", 1006], ["Among", 1008], ["19", 1014], ["patients", 1017], ["who", 1026], ["had", 1030], ["a", 1034], ["response", 1036], [",", 1044], ["16", 1046], ["(", 1049], ["86", 1050], ["%", 1052], [")", 1053], ["did", 1055], ["so", 1059], ["within", 1062], ["3", 1069], ["months", 1071], [".", 1077], ["The", 1079], ["best", 1083], ["cytogenetic", 1088], ["response", 1100], ["rate", 1109], ["at", 1114], ["any", 1117], ["time", 1121], ["during", 1126], ["the", 1133], ["study", 1137], ["treatment", 1143], ["with", 1153], ["imatinib", 1158], ["mesylate", 1167], [",", 1175], ["among", 1177], ["14", 1183], ["patients", 1186], ["in", 1195], ["which", 1198], ["cytogenetic", 1204], ["response", 1216], ["evaluated", 1225], ["was", 1235], [":", 1238], ["complete", 1240], ["cytogenetic", 1249], ["response", 1261], ["in", 1270], ["7", 1273], ["(", 1275], ["50", 1276], ["%", 1278], [")", 1279], ["patients", 1281], [",", 1289], ["partial", 1291], ["cytogenetic", 1299], ["response", 1311], ["in", 1320], ["6", 1323], ["(", 1325], ["42.9", 1326], ["%", 1330], [")", 1331], ["patients", 1333], ["and", 1342], ["minor", 1346], ["cytogenetic", 1352], ["response", 1364], ["in", 1373], ["1", 1376], ["(", 1378], ["7.1", 1379], ["%", 1382], [")", 1383], ["patient", 1385], [".", 1392], ["No", 1394], ["patients", 1397], ["had", 1406], ["progressed", 1410], ["to", 1421], ["accelerated", 1424], ["or", 1436], ["blastic", 1439], ["phase", 1447], [".", 1452], ["The", 1454], ["most", 1458], ["frequent", 1463], ["adverse", 1472], ["effects", 1480], ["that", 1488], ["seemed", 1493], ["to", 1500], ["be", 1503], ["related", 1506], ["to", 1514], ["treatment", 1517], ["with", 1527], ["imatinib", 1532], ["mesylate", 1541], ["were", 1550], ["edema", 1555], ["and", 1561], ["musculoskeletal", 1565], ["pain", 1581], [";", 1585], ["overall", 1587], [",", 1594], ["most", 1596], ["were", 1601], ["mild", 1606], [".", 1610], ["Only", 1612], ["one", 1617], ["patient", 1621], ["discontinued", 1629], ["treatment", 1642], ["because", 1652], ["of", 1660], ["hematologic", 1663], ["toxic", 1675], ["effects", 1681], [".", 1688], ["The", 1690], ["results", 1694], ["obtained", 1702], ["in", 1711], ["this", 1714], ["study", 1719], ["confirm", 1725], ["that", 1733], ["imatinib", 1738], ["mesylate", 1747], ["induces", 1756], ["a", 1764], ["complete", 1766], ["hematological", 1775], ["and", 1789], ["cytogenetic", 1793], ["response", 1805], ["in", 1814], ["a", 1817], ["high", 1819], ["percentage", 1824], ["of", 1835], ["patients", 1838], ["with", 1847], ["chronic", 1852], ["-", 1859], ["phase", 1860], ["CML", 1866], [".", 1869]]}
{"context": "Shprintzen-Goldberg syndrome (SGS) is characterized by craniosynostosis and marfanoid habitus. The clinical findings of SGS include neurological, cardiovascular, connective tissue, and skeletal abnormalities. Among these skeletal findings, developmental scoliosis is recognized in half of all patients with SGS. However, no earlier reports have described the surgical treatment of scoliosis associated with SGS. Four patients (2 boys and 2 girls; mean age at the time of surgery, 7.3\u00b14.4 y) with SGS who underwent surgical treatment for progressive scoliosis were reviewed. The radiologic findings, operative findings, and perioperative complications were evaluated. The mean preoperative Cobb angle was 102.8\u00b116.9 degrees. The curve patterns were a double curve in 2 cases and a triple curve in 2 cases. Local kyphosis at the thoracolumbar area was recognized in all the cases with a mean kyphosis angle of 49\u00b116 degrees. Growing rod procedures were performed in 2 patients, and posterior correction and fusion were performed in 2 patients. The mean correction rate was 45% in the patients who underwent the growing rod procedures at the time of growing rod placement and 51% in the patients who underwent posterior correction and fusion. Dislodgement of the proximal anchors occurred in 3 of the 4 patients. One patient developed pseudoarthrosis. Two patients developed deep wound infections, and implant removal was necessary in 1 patient. Surgical treatment for scoliosis in patients with SGS was associated with a high incidence of perioperative and postoperative complications including implant dislodgements and deep wound infections attributable to poor bone quality and a thin body habitus, which are characteristic clinical features of this syndrome. Careful preoperative surgical planning and postoperative care are critical for the surgical treatment of scoliosis associated with SGS, especially in infants requiring multiple surgeries. Level IV.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "07d30350f8434b48815eaa39fc6cedd9", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[10, 10]], "char_spans": [[55, 70]]}]}], "context_tokens": [["Shprintzen", 0], ["-", 10], ["Goldberg", 11], ["syndrome", 20], ["(", 29], ["SGS", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["craniosynostosis", 55], ["and", 72], ["marfanoid", 76], ["habitus", 86], [".", 93], ["The", 95], ["clinical", 99], ["findings", 108], ["of", 117], ["SGS", 120], ["include", 124], ["neurological", 132], [",", 144], ["cardiovascular", 146], [",", 160], ["connective", 162], ["tissue", 173], [",", 179], ["and", 181], ["skeletal", 185], ["abnormalities", 194], [".", 207], ["Among", 209], ["these", 215], ["skeletal", 221], ["findings", 230], [",", 238], ["developmental", 240], ["scoliosis", 254], ["is", 264], ["recognized", 267], ["in", 278], ["half", 281], ["of", 286], ["all", 289], ["patients", 293], ["with", 302], ["SGS", 307], [".", 310], ["However", 312], [",", 319], ["no", 321], ["earlier", 324], ["reports", 332], ["have", 340], ["described", 345], ["the", 355], ["surgical", 359], ["treatment", 368], ["of", 378], ["scoliosis", 381], ["associated", 391], ["with", 402], ["SGS", 407], [".", 410], ["Four", 412], ["patients", 417], ["(", 426], ["2", 427], ["boys", 429], ["and", 434], ["2", 438], ["girls", 440], [";", 445], ["mean", 447], ["age", 452], ["at", 456], ["the", 459], ["time", 463], ["of", 468], ["surgery", 471], [",", 478], ["7.3\u00b14.4", 480], ["y", 488], [")", 489], ["with", 491], ["SGS", 496], ["who", 500], ["underwent", 504], ["surgical", 514], ["treatment", 523], ["for", 533], ["progressive", 537], ["scoliosis", 549], ["were", 559], ["reviewed", 564], [".", 572], ["The", 574], ["radiologic", 578], ["findings", 589], [",", 597], ["operative", 599], ["findings", 609], [",", 617], ["and", 619], ["perioperative", 623], ["complications", 637], ["were", 651], ["evaluated", 656], [".", 665], ["The", 667], ["mean", 671], ["preoperative", 676], ["Cobb", 689], ["angle", 694], ["was", 700], ["102.8\u00b116.9", 704], ["degrees", 715], [".", 722], ["The", 724], ["curve", 728], ["patterns", 734], ["were", 743], ["a", 748], ["double", 750], ["curve", 757], ["in", 763], ["2", 766], ["cases", 768], ["and", 774], ["a", 778], ["triple", 780], ["curve", 787], ["in", 793], ["2", 796], ["cases", 798], [".", 803], ["Local", 805], ["kyphosis", 811], ["at", 820], ["the", 823], ["thoracolumbar", 827], ["area", 841], ["was", 846], ["recognized", 850], ["in", 861], ["all", 864], ["the", 868], ["cases", 872], ["with", 878], ["a", 883], ["mean", 885], ["kyphosis", 890], ["angle", 899], ["of", 905], ["49\u00b116", 908], ["degrees", 914], [".", 921], ["Growing", 923], ["rod", 931], ["procedures", 935], ["were", 946], ["performed", 951], ["in", 961], ["2", 964], ["patients", 966], [",", 974], ["and", 976], ["posterior", 980], ["correction", 990], ["and", 1001], ["fusion", 1005], ["were", 1012], ["performed", 1017], ["in", 1027], ["2", 1030], ["patients", 1032], [".", 1040], ["The", 1042], ["mean", 1046], ["correction", 1051], ["rate", 1062], ["was", 1067], ["45", 1071], ["%", 1073], ["in", 1075], ["the", 1078], ["patients", 1082], ["who", 1091], ["underwent", 1095], ["the", 1105], ["growing", 1109], ["rod", 1117], ["procedures", 1121], ["at", 1132], ["the", 1135], ["time", 1139], ["of", 1144], ["growing", 1147], ["rod", 1155], ["placement", 1159], ["and", 1169], ["51", 1173], ["%", 1175], ["in", 1177], ["the", 1180], ["patients", 1184], ["who", 1193], ["underwent", 1197], ["posterior", 1207], ["correction", 1217], ["and", 1228], ["fusion", 1232], [".", 1238], ["Dislodgement", 1240], ["of", 1253], ["the", 1256], ["proximal", 1260], ["anchors", 1269], ["occurred", 1277], ["in", 1286], ["3", 1289], ["of", 1291], ["the", 1294], ["4", 1298], ["patients", 1300], [".", 1308], ["One", 1310], ["patient", 1314], ["developed", 1322], ["pseudoarthrosis", 1332], [".", 1347], ["Two", 1349], ["patients", 1353], ["developed", 1362], ["deep", 1372], ["wound", 1377], ["infections", 1383], [",", 1393], ["and", 1395], ["implant", 1399], ["removal", 1407], ["was", 1415], ["necessary", 1419], ["in", 1429], ["1", 1432], ["patient", 1434], [".", 1441], ["Surgical", 1443], ["treatment", 1452], ["for", 1462], ["scoliosis", 1466], ["in", 1476], ["patients", 1479], ["with", 1488], ["SGS", 1493], ["was", 1497], ["associated", 1501], ["with", 1512], ["a", 1517], ["high", 1519], ["incidence", 1524], ["of", 1534], ["perioperative", 1537], ["and", 1551], ["postoperative", 1555], ["complications", 1569], ["including", 1583], ["implant", 1593], ["dislodgements", 1601], ["and", 1615], ["deep", 1619], ["wound", 1624], ["infections", 1630], ["attributable", 1641], ["to", 1654], ["poor", 1657], ["bone", 1662], ["quality", 1667], ["and", 1675], ["a", 1679], ["thin", 1681], ["body", 1686], ["habitus", 1691], [",", 1698], ["which", 1700], ["are", 1706], ["characteristic", 1710], ["clinical", 1725], ["features", 1734], ["of", 1743], ["this", 1746], ["syndrome", 1751], [".", 1759], ["Careful", 1761], ["preoperative", 1769], ["surgical", 1782], ["planning", 1791], ["and", 1800], ["postoperative", 1804], ["care", 1818], ["are", 1823], ["critical", 1827], ["for", 1836], ["the", 1840], ["surgical", 1844], ["treatment", 1853], ["of", 1863], ["scoliosis", 1866], ["associated", 1876], ["with", 1887], ["SGS", 1892], [",", 1895], ["especially", 1897], ["in", 1908], ["infants", 1911], ["requiring", 1919], ["multiple", 1929], ["surgeries", 1938], [".", 1947], ["Level", 1949], ["IV", 1955], [".", 1957]]}
{"context": "The precise regulation of microRNA (miRNA) transcription and processing is important for eukaryotic development. Plant miRNAs are first transcribed as stem-loop primary miRNAs (pri-miRNAs) by RNA polymerase II,then cleaved in the nucleus into mature miRNAs by Dicer-like 1 (DCL1). We identified a cycling DOF transcription factor, CDF2, which interacts with DCL1 and regulates the accumulation of a population of miRNAs. CDF2 binds directly to the promoters of some miRNAs and works as a transcription activator or repressor for these miRNA genes. CDF2 binds preferentially to the pri-miRNAs regulated by itself and affects DCL1-mediated processing of these pri-miRNAs. Genetically, CDF2 works in the same pathway as miR156 or miR172 to control flowering. We conclude that CDF2 regulates a group of pri-miRNAs at both the transcriptional and posttranscriptional levels to maintain proper levels of their mature miRNAs to control plant development.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "0d62867611e34119b3f038886614e0ab", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[34, 36]], "char_spans": [[192, 208]]}]}], "context_tokens": [["The", 0], ["precise", 4], ["regulation", 12], ["of", 23], ["microRNA", 26], ["(", 35], ["miRNA", 36], [")", 41], ["transcription", 43], ["and", 57], ["processing", 61], ["is", 72], ["important", 75], ["for", 85], ["eukaryotic", 89], ["development", 100], [".", 111], ["Plant", 113], ["miRNAs", 119], ["are", 126], ["first", 130], ["transcribed", 136], ["as", 148], ["stem", 151], ["-", 155], ["loop", 156], ["primary", 161], ["miRNAs", 169], ["(", 176], ["pri", 177], ["-", 180], ["miRNAs", 181], [")", 187], ["by", 189], ["RNA", 192], ["polymerase", 196], ["II", 207], [",", 209], ["then", 210], ["cleaved", 215], ["in", 223], ["the", 226], ["nucleus", 230], ["into", 238], ["mature", 243], ["miRNAs", 250], ["by", 257], ["Dicer", 260], ["-", 265], ["like", 266], ["1", 271], ["(", 273], ["DCL1", 274], [")", 278], [".", 279], ["We", 281], ["identified", 284], ["a", 295], ["cycling", 297], ["DOF", 305], ["transcription", 309], ["factor", 323], [",", 329], ["CDF2", 331], [",", 335], ["which", 337], ["interacts", 343], ["with", 353], ["DCL1", 358], ["and", 363], ["regulates", 367], ["the", 377], ["accumulation", 381], ["of", 394], ["a", 397], ["population", 399], ["of", 410], ["miRNAs", 413], [".", 419], ["CDF2", 421], ["binds", 426], ["directly", 432], ["to", 441], ["the", 444], ["promoters", 448], ["of", 458], ["some", 461], ["miRNAs", 466], ["and", 473], ["works", 477], ["as", 483], ["a", 486], ["transcription", 488], ["activator", 502], ["or", 512], ["repressor", 515], ["for", 525], ["these", 529], ["miRNA", 535], ["genes", 541], [".", 546], ["CDF2", 548], ["binds", 553], ["preferentially", 559], ["to", 574], ["the", 577], ["pri", 581], ["-", 584], ["miRNAs", 585], ["regulated", 592], ["by", 602], ["itself", 605], ["and", 612], ["affects", 616], ["DCL1-mediated", 624], ["processing", 638], ["of", 649], ["these", 652], ["pri", 658], ["-", 661], ["miRNAs", 662], [".", 668], ["Genetically", 670], [",", 681], ["CDF2", 683], ["works", 688], ["in", 694], ["the", 697], ["same", 701], ["pathway", 706], ["as", 714], ["miR156", 717], ["or", 724], ["miR172", 727], ["to", 734], ["control", 737], ["flowering", 745], [".", 754], ["We", 756], ["conclude", 759], ["that", 768], ["CDF2", 773], ["regulates", 778], ["a", 788], ["group", 790], ["of", 796], ["pri", 799], ["-", 802], ["miRNAs", 803], ["at", 810], ["both", 813], ["the", 818], ["transcriptional", 822], ["and", 838], ["posttranscriptional", 842], ["levels", 862], ["to", 869], ["maintain", 872], ["proper", 881], ["levels", 888], ["of", 895], ["their", 898], ["mature", 904], ["miRNAs", 911], ["to", 918], ["control", 921], ["plant", 929], ["development", 935], [".", 946]]}
{"context": "Batten disease [juvenile-onset neuronal ceroid lipofuscinosis (JNCL)], the most common progressive encephalopathy of childhood, is caused by mutations in a novel lysosomal membrane protein (CLN3) with unknown function. In this study, we have confirmed the lysosomal localization of the CLN3 protein by immunoelectron microscopy by co-localizing it with soluble and membrane-associated lysosomal proteins. We have analysed the intracellular processing and localization of two mutants, 461-677del, which is present in 85% of CLN3 alleles and causes the classical JNCL, and E295K [corrected], which is a rare missense mutation associated with an atypical form of JNCL. Pulse-chase labelling and immunoprecipitation of the two mutant proteins in COS-1-cells indicated that 461-677del is synthesized as an approximately 24 kDa truncated polypeptide, whereas the maturation of E295K [corrected] resembles that of the wild-type CLN3 polypeptide. Transient expression of the two mutants in BHK cells showed that 461-677del is retained in the endoplasmic reticulum, whereas E295K [corrected] was capable of reaching the lysosomal compartment. The CLN3 polypeptides were expressed further in mouse primary neurons where the wild-type CLN3 protein was localized both in the cell soma and in neuronal extensions, whereas the 461-677del mutant was arrested in the cell soma. Interestingly, co-localization of the wild-type CLN3 and E295K [corrected] proteins with a synaptic vesicle marker indicates that the CLN3 protein might participate in synaptic vesicle transport/transmission. The data presented here provide clear evidence for a cellular distinction between classical and atypical forms of Batten disease both in neural and non-neural cells.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "6d7b3c37d90b4259923fc6b4defc1056", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[0, 1], [300, 301]], "char_spans": [[0, 13], [1685, 1698]]}, {"text": "juvenile-onset neuronal ceroid lipofuscinosis", "token_spans": [[3, 8]], "char_spans": [[16, 60]]}, {"text": "JNCL", "token_spans": [[120, 120], [99, 99], [10, 10]], "char_spans": [[660, 663], [561, 564], [63, 66]]}]}], "context_tokens": [["Batten", 0], ["disease", 7], ["[", 15], ["juvenile", 16], ["-", 24], ["onset", 25], ["neuronal", 31], ["ceroid", 40], ["lipofuscinosis", 47], ["(", 62], ["JNCL", 63], [")", 67], ["]", 68], [",", 69], ["the", 71], ["most", 75], ["common", 80], ["progressive", 87], ["encephalopathy", 99], ["of", 114], ["childhood", 117], [",", 126], ["is", 128], ["caused", 131], ["by", 138], ["mutations", 141], ["in", 151], ["a", 154], ["novel", 156], ["lysosomal", 162], ["membrane", 172], ["protein", 181], ["(", 189], ["CLN3", 190], [")", 194], ["with", 196], ["unknown", 201], ["function", 209], [".", 217], ["In", 219], ["this", 222], ["study", 227], [",", 232], ["we", 234], ["have", 237], ["confirmed", 242], ["the", 252], ["lysosomal", 256], ["localization", 266], ["of", 279], ["the", 282], ["CLN3", 286], ["protein", 291], ["by", 299], ["immunoelectron", 302], ["microscopy", 317], ["by", 328], ["co", 331], ["-", 333], ["localizing", 334], ["it", 345], ["with", 348], ["soluble", 353], ["and", 361], ["membrane", 365], ["-", 373], ["associated", 374], ["lysosomal", 385], ["proteins", 395], [".", 403], ["We", 405], ["have", 408], ["analysed", 413], ["the", 422], ["intracellular", 426], ["processing", 440], ["and", 451], ["localization", 455], ["of", 468], ["two", 471], ["mutants", 475], [",", 482], ["461", 484], ["-", 487], ["677del", 488], [",", 494], ["which", 496], ["is", 502], ["present", 505], ["in", 513], ["85", 516], ["%", 518], ["of", 520], ["CLN3", 523], ["alleles", 528], ["and", 536], ["causes", 540], ["the", 547], ["classical", 551], ["JNCL", 561], [",", 565], ["and", 567], ["E295", 571], ["K", 575], ["[", 577], ["corrected", 578], ["]", 587], [",", 588], ["which", 590], ["is", 596], ["a", 599], ["rare", 601], ["missense", 606], ["mutation", 615], ["associated", 624], ["with", 635], ["an", 640], ["atypical", 643], ["form", 652], ["of", 657], ["JNCL", 660], [".", 664], ["Pulse", 666], ["-", 671], ["chase", 672], ["labelling", 678], ["and", 688], ["immunoprecipitation", 692], ["of", 712], ["the", 715], ["two", 719], ["mutant", 723], ["proteins", 730], ["in", 739], ["COS-1-cells", 742], ["indicated", 754], ["that", 764], ["461", 769], ["-", 772], ["677del", 773], ["is", 780], ["synthesized", 783], ["as", 795], ["an", 798], ["approximately", 801], ["24", 815], ["kDa", 818], ["truncated", 822], ["polypeptide", 832], [",", 843], ["whereas", 845], ["the", 853], ["maturation", 857], ["of", 868], ["E295", 871], ["K", 875], ["[", 877], ["corrected", 878], ["]", 887], ["resembles", 889], ["that", 899], ["of", 904], ["the", 907], ["wild", 911], ["-", 915], ["type", 916], ["CLN3", 921], ["polypeptide", 926], [".", 937], ["Transient", 939], ["expression", 949], ["of", 960], ["the", 963], ["two", 967], ["mutants", 971], ["in", 979], ["BHK", 982], ["cells", 986], ["showed", 992], ["that", 999], ["461", 1004], ["-", 1007], ["677del", 1008], ["is", 1015], ["retained", 1018], ["in", 1027], ["the", 1030], ["endoplasmic", 1034], ["reticulum", 1046], [",", 1055], ["whereas", 1057], ["E295", 1065], ["K", 1069], ["[", 1071], ["corrected", 1072], ["]", 1081], ["was", 1083], ["capable", 1087], ["of", 1095], ["reaching", 1098], ["the", 1107], ["lysosomal", 1111], ["compartment", 1121], [".", 1132], ["The", 1134], ["CLN3", 1138], ["polypeptides", 1143], ["were", 1156], ["expressed", 1161], ["further", 1171], ["in", 1179], ["mouse", 1182], ["primary", 1188], ["neurons", 1196], ["where", 1204], ["the", 1210], ["wild", 1214], ["-", 1218], ["type", 1219], ["CLN3", 1224], ["protein", 1229], ["was", 1237], ["localized", 1241], ["both", 1251], ["in", 1256], ["the", 1259], ["cell", 1263], ["soma", 1268], ["and", 1273], ["in", 1277], ["neuronal", 1280], ["extensions", 1289], [",", 1299], ["whereas", 1301], ["the", 1309], ["461", 1313], ["-", 1316], ["677del", 1317], ["mutant", 1324], ["was", 1331], ["arrested", 1335], ["in", 1344], ["the", 1347], ["cell", 1351], ["soma", 1356], [".", 1360], ["Interestingly", 1362], [",", 1375], ["co", 1377], ["-", 1379], ["localization", 1380], ["of", 1393], ["the", 1396], ["wild", 1400], ["-", 1404], ["type", 1405], ["CLN3", 1410], ["and", 1415], ["E295", 1419], ["K", 1423], ["[", 1425], ["corrected", 1426], ["]", 1435], ["proteins", 1437], ["with", 1446], ["a", 1451], ["synaptic", 1453], ["vesicle", 1462], ["marker", 1470], ["indicates", 1477], ["that", 1487], ["the", 1492], ["CLN3", 1496], ["protein", 1501], ["might", 1509], ["participate", 1515], ["in", 1527], ["synaptic", 1530], ["vesicle", 1539], ["transport", 1547], ["/", 1556], ["transmission", 1557], [".", 1569], ["The", 1571], ["data", 1575], ["presented", 1580], ["here", 1590], ["provide", 1595], ["clear", 1603], ["evidence", 1609], ["for", 1618], ["a", 1622], ["cellular", 1624], ["distinction", 1633], ["between", 1645], ["classical", 1653], ["and", 1663], ["atypical", 1667], ["forms", 1676], ["of", 1682], ["Batten", 1685], ["disease", 1692], ["both", 1700], ["in", 1705], ["neural", 1708], ["and", 1715], ["non", 1719], ["-", 1722], ["neural", 1723], ["cells", 1730], [".", 1735]]}
{"context": "Mutations of presenilin 1 (PS1) causing Alzheimer's disease selectively increase the secretion of the amyloidogenic betaA4(1-42), whereas knocking out the gene results in decreased production of both betaA4(1-40) and (1-42) amyloid peptides (De Strooper et al. 1998). Therefore, PS1 function is closely linked to the gamma-secretase processing of the amyloid precursor protein (APP). Given the ongoing controversy on the subcellular localization of PS1, it remains unclear at what level of the secretory and endocytic pathways PS1 exerts its activity on APP and on the APP carboxy-terminal fragments that are the direct substrates for gamma-secretase. Therefore, we have reinvestigated the subcellular localization of endogenously expressed PS1 in neurons in vitro and in vivo using confocal microscopy and fine-tuned subcellular fractionation. We show that uncleaved PS1 holoprotein is recovered in the nuclear envelope fraction, whereas the cleaved PS fragments are found mainly in post-ER membranes including the intermediate compartment (IC). PS1 is concentrated in discrete sec23p- and p58/ERGIC-53-positive patches, suggesting its localization in subdomains involved in ER export. PS1 is not found to significant amounts beyond the cis-Golgi. Surprisingly, we found that APP carboxy-terminal fragments also coenrich in the pre-Golgi membrane fractions, consistent with the idea that these fragments are the real substrates for gamma-secretase. Functional evidence that PS1 exerts its effects on gamma-secretase processing of APP in the ER/IC was obtained using a series of APP trafficking mutants. These mutants were investigated in hippocampal neurons derived from transgenic mice expressing PS1wt or PS1 containing clinical mutations (PS1(M146L) and PS1(L286V)) at physiologically relevant levels. We demonstrate that the APP-London and PS1 mutations have additive effects on the increased secretion of betaA4(1-42) relative to betaA4(1-40), indicating that both mutations operate independently. Overall, our data clearly establish that PS1 controls gamma(42)-secretase activity in pre-Golgi compartments. We discuss models that reconcile this conclusion with the effects of PS1 deficiency on the generation of betaA4(1-40) peptide in the late biosynthetic and endocytic pathways.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "c6a3fb62d44040b1a6fe442b2aadc722", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[8, 10]], "char_spans": [[40, 58]]}]}], "context_tokens": [["Mutations", 0], ["of", 10], ["presenilin", 13], ["1", 24], ["(", 26], ["PS1", 27], [")", 30], ["causing", 32], ["Alzheimer", 40], ["'s", 49], ["disease", 52], ["selectively", 60], ["increase", 72], ["the", 81], ["secretion", 85], ["of", 95], ["the", 98], ["amyloidogenic", 102], ["betaA4(1", 116], ["-", 124], ["42", 125], [")", 127], [",", 128], ["whereas", 130], ["knocking", 138], ["out", 147], ["the", 151], ["gene", 155], ["results", 160], ["in", 168], ["decreased", 171], ["production", 181], ["of", 192], ["both", 195], ["betaA4(1", 200], ["-", 208], ["40", 209], [")", 211], ["and", 213], ["(", 217], ["1", 218], ["-", 219], ["42", 220], [")", 222], ["amyloid", 224], ["peptides", 232], ["(", 241], ["De", 242], ["Strooper", 245], ["et", 254], ["al", 257], [".", 259], ["1998", 261], [")", 265], [".", 266], ["Therefore", 268], [",", 277], ["PS1", 279], ["function", 283], ["is", 292], ["closely", 295], ["linked", 303], ["to", 310], ["the", 313], ["gamma", 317], ["-", 322], ["secretase", 323], ["processing", 333], ["of", 344], ["the", 347], ["amyloid", 351], ["precursor", 359], ["protein", 369], ["(", 377], ["APP", 378], [")", 381], [".", 382], ["Given", 384], ["the", 390], ["ongoing", 394], ["controversy", 402], ["on", 414], ["the", 417], ["subcellular", 421], ["localization", 433], ["of", 446], ["PS1", 449], [",", 452], ["it", 454], ["remains", 457], ["unclear", 465], ["at", 473], ["what", 476], ["level", 481], ["of", 487], ["the", 490], ["secretory", 494], ["and", 504], ["endocytic", 508], ["pathways", 518], ["PS1", 527], ["exerts", 531], ["its", 538], ["activity", 542], ["on", 551], ["APP", 554], ["and", 558], ["on", 562], ["the", 565], ["APP", 569], ["carboxy", 573], ["-", 580], ["terminal", 581], ["fragments", 590], ["that", 600], ["are", 605], ["the", 609], ["direct", 613], ["substrates", 620], ["for", 631], ["gamma", 635], ["-", 640], ["secretase", 641], [".", 650], ["Therefore", 652], [",", 661], ["we", 663], ["have", 666], ["reinvestigated", 671], ["the", 686], ["subcellular", 690], ["localization", 702], ["of", 715], ["endogenously", 718], ["expressed", 731], ["PS1", 741], ["in", 745], ["neurons", 748], ["in", 756], ["vitro", 759], ["and", 765], ["in", 769], ["vivo", 772], ["using", 777], ["confocal", 783], ["microscopy", 792], ["and", 803], ["fine", 807], ["-", 811], ["tuned", 812], ["subcellular", 818], ["fractionation", 830], [".", 843], ["We", 845], ["show", 848], ["that", 853], ["uncleaved", 858], ["PS1", 868], ["holoprotein", 872], ["is", 884], ["recovered", 887], ["in", 897], ["the", 900], ["nuclear", 904], ["envelope", 912], ["fraction", 921], [",", 929], ["whereas", 931], ["the", 939], ["cleaved", 943], ["PS", 951], ["fragments", 954], ["are", 964], ["found", 968], ["mainly", 974], ["in", 981], ["post", 984], ["-", 988], ["ER", 989], ["membranes", 992], ["including", 1002], ["the", 1012], ["intermediate", 1016], ["compartment", 1029], ["(", 1041], ["IC", 1042], [")", 1044], [".", 1045], ["PS1", 1047], ["is", 1051], ["concentrated", 1054], ["in", 1067], ["discrete", 1070], ["sec23p-", 1079], ["and", 1087], ["p58/ERGIC-53-positive", 1091], ["patches", 1113], [",", 1120], ["suggesting", 1122], ["its", 1133], ["localization", 1137], ["in", 1150], ["subdomains", 1153], ["involved", 1164], ["in", 1173], ["ER", 1176], ["export", 1179], [".", 1185], ["PS1", 1187], ["is", 1191], ["not", 1194], ["found", 1198], ["to", 1204], ["significant", 1207], ["amounts", 1219], ["beyond", 1227], ["the", 1234], ["cis", 1238], ["-", 1241], ["Golgi", 1242], [".", 1247], ["Surprisingly", 1249], [",", 1261], ["we", 1263], ["found", 1266], ["that", 1272], ["APP", 1277], ["carboxy", 1281], ["-", 1288], ["terminal", 1289], ["fragments", 1298], ["also", 1308], ["coenrich", 1313], ["in", 1322], ["the", 1325], ["pre", 1329], ["-", 1332], ["Golgi", 1333], ["membrane", 1339], ["fractions", 1348], [",", 1357], ["consistent", 1359], ["with", 1370], ["the", 1375], ["idea", 1379], ["that", 1384], ["these", 1389], ["fragments", 1395], ["are", 1405], ["the", 1409], ["real", 1413], ["substrates", 1418], ["for", 1429], ["gamma", 1433], ["-", 1438], ["secretase", 1439], [".", 1448], ["Functional", 1450], ["evidence", 1461], ["that", 1470], ["PS1", 1475], ["exerts", 1479], ["its", 1486], ["effects", 1490], ["on", 1498], ["gamma", 1501], ["-", 1506], ["secretase", 1507], ["processing", 1517], ["of", 1528], ["APP", 1531], ["in", 1535], ["the", 1538], ["ER", 1542], ["/", 1544], ["IC", 1545], ["was", 1548], ["obtained", 1552], ["using", 1561], ["a", 1567], ["series", 1569], ["of", 1576], ["APP", 1579], ["trafficking", 1583], ["mutants", 1595], [".", 1602], ["These", 1604], ["mutants", 1610], ["were", 1618], ["investigated", 1623], ["in", 1636], ["hippocampal", 1639], ["neurons", 1651], ["derived", 1659], ["from", 1667], ["transgenic", 1672], ["mice", 1683], ["expressing", 1688], ["PS1wt", 1699], ["or", 1705], ["PS1", 1708], ["containing", 1712], ["clinical", 1723], ["mutations", 1732], ["(", 1742], ["PS1(M146L", 1743], [")", 1752], ["and", 1754], ["PS1(L286V", 1758], [")", 1767], [")", 1768], ["at", 1770], ["physiologically", 1773], ["relevant", 1789], ["levels", 1798], [".", 1804], ["We", 1806], ["demonstrate", 1809], ["that", 1821], ["the", 1826], ["APP", 1830], ["-", 1833], ["London", 1834], ["and", 1841], ["PS1", 1845], ["mutations", 1849], ["have", 1859], ["additive", 1864], ["effects", 1873], ["on", 1881], ["the", 1884], ["increased", 1888], ["secretion", 1898], ["of", 1908], ["betaA4(1", 1911], ["-", 1919], ["42", 1920], [")", 1922], ["relative", 1924], ["to", 1933], ["betaA4(1", 1936], ["-", 1944], ["40", 1945], [")", 1947], [",", 1948], ["indicating", 1950], ["that", 1961], ["both", 1966], ["mutations", 1971], ["operate", 1981], ["independently", 1989], [".", 2002], ["Overall", 2004], [",", 2011], ["our", 2013], ["data", 2017], ["clearly", 2022], ["establish", 2030], ["that", 2040], ["PS1", 2045], ["controls", 2049], ["gamma(42)-secretase", 2058], ["activity", 2078], ["in", 2087], ["pre", 2090], ["-", 2093], ["Golgi", 2094], ["compartments", 2100], [".", 2112], ["We", 2114], ["discuss", 2117], ["models", 2125], ["that", 2132], ["reconcile", 2137], ["this", 2147], ["conclusion", 2152], ["with", 2163], ["the", 2168], ["effects", 2172], ["of", 2180], ["PS1", 2183], ["deficiency", 2187], ["on", 2198], ["the", 2201], ["generation", 2205], ["of", 2216], ["betaA4(1", 2219], ["-", 2227], ["40", 2228], [")", 2230], ["peptide", 2232], ["in", 2240], ["the", 2243], ["late", 2247], ["biosynthetic", 2252], ["and", 2265], ["endocytic", 2269], ["pathways", 2279], [".", 2287]]}
{"context": "Turner's syndrome (TS) is a chromosomal disorder that results from the loss of the entire or a part of the X-chromosome and occurs in 1/2,500 female births. According to the majority of specific reports, intelligence in TS is generally found to be normal and the prevalence of mental retardation does not seem to be increased in TS except for those patients with a small ring X-chromosome. We evaluated 33 girls with TS with chronological age from 6-18 years. Intellectual assessment included the WISC III and the WAIS-R scales. Our results showed: 1) mean full scale intelligence quotient (FSIQ) was significantly lower than expected based on normative data (p < 0.0005); 2) no correlation was present between height and general intellectual ability; 3) mean performance intelligence quotient (PIQ) was significantly lower than both mean verbal intelligence quotient (VIQ) and FSIQ (p < 0.0025 and p < 0.01, respectively), and most patients had a VIQ-PIQ discrepancy; 4) the frequency of mental retardation in our study group was significantly higher than that observed in the general population (15.1% vs 2.3%, p < 0.025); 5) a significant association was found between karyotype and VIQ, and the best score was achieved in the subgroup of patients with structural abnormalities of the X-chromosome. In the light of these findings we conclude that the clinical picture in TS may encompass a slightly reduced FSIQ, VIQ and especially an inadequate PIQ, but this neurocognitive profile is not significantly affected by statural impairment. Since these neurocognitive defects can be responsible for misdiagnosed school difficulties, we suggest that girls with TS should receive specialized educational support and multidisciplinary care.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "12fa90a3c056479a92f47b23fd5275bf", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[252, 252], [72, 72], [23, 23]], "char_spans": [[1288, 1288], [376, 376], [107, 107]]}]}], "context_tokens": [["Turner", 0], ["'s", 6], ["syndrome", 9], ["(", 18], ["TS", 19], [")", 21], ["is", 23], ["a", 26], ["chromosomal", 28], ["disorder", 40], ["that", 49], ["results", 54], ["from", 62], ["the", 67], ["loss", 71], ["of", 76], ["the", 79], ["entire", 83], ["or", 90], ["a", 93], ["part", 95], ["of", 100], ["the", 103], ["X", 107], ["-", 108], ["chromosome", 109], ["and", 120], ["occurs", 124], ["in", 131], ["1/2,500", 134], ["female", 142], ["births", 149], [".", 155], ["According", 157], ["to", 167], ["the", 170], ["majority", 174], ["of", 183], ["specific", 186], ["reports", 195], [",", 202], ["intelligence", 204], ["in", 217], ["TS", 220], ["is", 223], ["generally", 226], ["found", 236], ["to", 242], ["be", 245], ["normal", 248], ["and", 255], ["the", 259], ["prevalence", 263], ["of", 274], ["mental", 277], ["retardation", 284], ["does", 296], ["not", 301], ["seem", 305], ["to", 310], ["be", 313], ["increased", 316], ["in", 326], ["TS", 329], ["except", 332], ["for", 339], ["those", 343], ["patients", 349], ["with", 358], ["a", 363], ["small", 365], ["ring", 371], ["X", 376], ["-", 377], ["chromosome", 378], [".", 388], ["We", 390], ["evaluated", 393], ["33", 403], ["girls", 406], ["with", 412], ["TS", 417], ["with", 420], ["chronological", 425], ["age", 439], ["from", 443], ["6", 448], ["-", 449], ["18", 450], ["years", 453], [".", 458], ["Intellectual", 460], ["assessment", 473], ["included", 484], ["the", 493], ["WISC", 497], ["III", 502], ["and", 506], ["the", 510], ["WAIS", 514], ["-", 518], ["R", 519], ["scales", 521], [".", 527], ["Our", 529], ["results", 533], ["showed", 541], [":", 547], ["1", 549], [")", 550], ["mean", 552], ["full", 557], ["scale", 562], ["intelligence", 568], ["quotient", 581], ["(", 590], ["FSIQ", 591], [")", 595], ["was", 597], ["significantly", 601], ["lower", 615], ["than", 621], ["expected", 626], ["based", 635], ["on", 641], ["normative", 644], ["data", 654], ["(", 659], ["p", 660], ["<", 662], ["0.0005", 664], [")", 670], [";", 671], ["2", 673], [")", 674], ["no", 676], ["correlation", 679], ["was", 691], ["present", 695], ["between", 703], ["height", 711], ["and", 718], ["general", 722], ["intellectual", 730], ["ability", 743], [";", 750], ["3", 752], [")", 753], ["mean", 755], ["performance", 760], ["intelligence", 772], ["quotient", 785], ["(", 794], ["PIQ", 795], [")", 798], ["was", 800], ["significantly", 804], ["lower", 818], ["than", 824], ["both", 829], ["mean", 834], ["verbal", 839], ["intelligence", 846], ["quotient", 859], ["(", 868], ["VIQ", 869], [")", 872], ["and", 874], ["FSIQ", 878], ["(", 883], ["p", 884], ["<", 886], ["0.0025", 888], ["and", 895], ["p", 899], ["<", 901], ["0.01", 903], [",", 907], ["respectively", 909], [")", 921], [",", 922], ["and", 924], ["most", 928], ["patients", 933], ["had", 942], ["a", 946], ["VIQ", 948], ["-", 951], ["PIQ", 952], ["discrepancy", 956], [";", 967], ["4", 969], [")", 970], ["the", 972], ["frequency", 976], ["of", 986], ["mental", 989], ["retardation", 996], ["in", 1008], ["our", 1011], ["study", 1015], ["group", 1021], ["was", 1027], ["significantly", 1031], ["higher", 1045], ["than", 1052], ["that", 1057], ["observed", 1062], ["in", 1071], ["the", 1074], ["general", 1078], ["population", 1086], ["(", 1097], ["15.1", 1098], ["%", 1102], ["vs", 1104], ["2.3", 1107], ["%", 1110], [",", 1111], ["p", 1113], ["<", 1115], ["0.025", 1117], [")", 1122], [";", 1123], ["5", 1125], [")", 1126], ["a", 1128], ["significant", 1130], ["association", 1142], ["was", 1154], ["found", 1158], ["between", 1164], ["karyotype", 1172], ["and", 1182], ["VIQ", 1186], [",", 1189], ["and", 1191], ["the", 1195], ["best", 1199], ["score", 1204], ["was", 1210], ["achieved", 1214], ["in", 1223], ["the", 1226], ["subgroup", 1230], ["of", 1239], ["patients", 1242], ["with", 1251], ["structural", 1256], ["abnormalities", 1267], ["of", 1281], ["the", 1284], ["X", 1288], ["-", 1289], ["chromosome", 1290], [".", 1300], ["In", 1302], ["the", 1305], ["light", 1309], ["of", 1315], ["these", 1318], ["findings", 1324], ["we", 1333], ["conclude", 1336], ["that", 1345], ["the", 1350], ["clinical", 1354], ["picture", 1363], ["in", 1371], ["TS", 1374], ["may", 1377], ["encompass", 1381], ["a", 1391], ["slightly", 1393], ["reduced", 1402], ["FSIQ", 1410], [",", 1414], ["VIQ", 1416], ["and", 1420], ["especially", 1424], ["an", 1435], ["inadequate", 1438], ["PIQ", 1449], [",", 1452], ["but", 1454], ["this", 1458], ["neurocognitive", 1463], ["profile", 1478], ["is", 1486], ["not", 1489], ["significantly", 1493], ["affected", 1507], ["by", 1516], ["statural", 1519], ["impairment", 1528], [".", 1538], ["Since", 1540], ["these", 1546], ["neurocognitive", 1552], ["defects", 1567], ["can", 1575], ["be", 1579], ["responsible", 1582], ["for", 1594], ["misdiagnosed", 1598], ["school", 1611], ["difficulties", 1618], [",", 1630], ["we", 1632], ["suggest", 1635], ["that", 1643], ["girls", 1648], ["with", 1654], ["TS", 1659], ["should", 1662], ["receive", 1669], ["specialized", 1677], ["educational", 1689], ["support", 1701], ["and", 1709], ["multidisciplinary", 1713], ["care", 1731], [".", 1735]]}
{"context": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis. In the present study, we analyzed the CaSR gene in a Korean family with familial hypocalciuric hypercalcemia (FHH). Genetic studies were performed by direct sequence analysis of the CaSR gene in genomic DNA obtained from peripheral leukocytes. A novel heterozygous G to T substitution at nucleotide position 1711 in exon 6, resulting in the G571W mutation, was identified in the CaSR gene in a 26-year-old female with asymptomatic hypercalcemia, a low calcium/creatinine clearance ratio, and normal intact parathyroid hormone. To study CaSR expression, the mutation was introduced by site-directed mutagenesis into a wild-type (WT) CaSR-expressing pCR3.1 vector, and COS-7 cells were transfected with either the WT or mutant CaSR-containing vector. Transfected cells loaded with Fura-2/AM, a fluorescent indicator of Ca", "qas": [{"question": "What is the function of calcium-sensing receptor (CaSR)?", "answers": ["The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis."], "qid": "1f0adb77304f4c188ae40ccb27db4e56", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["function", 12], ["of", 21], ["calcium", 24], ["-", 31], ["sensing", 32], ["receptor", 40], ["(", 49], ["CaSR", 50], [")", 54], ["?", 55]], "detected_answers": [{"text": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis.", "token_spans": [[1, 24]], "char_spans": [[4, 130]]}]}], "context_tokens": [["The", 0], ["calcium", 4], ["-", 11], ["sensing", 12], ["receptor", 20], ["(", 29], ["CaSR", 30], [")", 34], ["is", 36], ["a", 39], ["G", 41], ["-", 42], ["protein", 43], ["-", 50], ["coupled", 51], ["receptor", 59], ["that", 68], ["plays", 73], ["an", 79], ["essential", 82], ["role", 92], ["in", 97], ["maintaining", 100], ["calcium", 112], ["homeostasis", 120], [".", 131], ["In", 133], ["the", 136], ["present", 140], ["study", 148], [",", 153], ["we", 155], ["analyzed", 158], ["the", 167], ["CaSR", 171], ["gene", 176], ["in", 181], ["a", 184], ["Korean", 186], ["family", 193], ["with", 200], ["familial", 205], ["hypocalciuric", 214], ["hypercalcemia", 228], ["(", 242], ["FHH", 243], [")", 246], [".", 247], ["Genetic", 249], ["studies", 257], ["were", 265], ["performed", 270], ["by", 280], ["direct", 283], ["sequence", 290], ["analysis", 299], ["of", 308], ["the", 311], ["CaSR", 315], ["gene", 320], ["in", 325], ["genomic", 328], ["DNA", 336], ["obtained", 340], ["from", 349], ["peripheral", 354], ["leukocytes", 365], [".", 375], ["A", 377], ["novel", 379], ["heterozygous", 385], ["G", 398], ["to", 400], ["T", 403], ["substitution", 405], ["at", 418], ["nucleotide", 421], ["position", 432], ["1711", 441], ["in", 446], ["exon", 449], ["6", 454], [",", 455], ["resulting", 457], ["in", 467], ["the", 470], ["G571W", 474], ["mutation", 480], [",", 488], ["was", 490], ["identified", 494], ["in", 505], ["the", 508], ["CaSR", 512], ["gene", 517], ["in", 522], ["a", 525], ["26-year", 527], ["-", 534], ["old", 535], ["female", 539], ["with", 546], ["asymptomatic", 551], ["hypercalcemia", 564], [",", 577], ["a", 579], ["low", 581], ["calcium", 585], ["/", 592], ["creatinine", 593], ["clearance", 604], ["ratio", 614], [",", 619], ["and", 621], ["normal", 625], ["intact", 632], ["parathyroid", 639], ["hormone", 651], [".", 658], ["To", 660], ["study", 663], ["CaSR", 669], ["expression", 674], [",", 684], ["the", 686], ["mutation", 690], ["was", 699], ["introduced", 703], ["by", 714], ["site", 717], ["-", 721], ["directed", 722], ["mutagenesis", 731], ["into", 743], ["a", 748], ["wild", 750], ["-", 754], ["type", 755], ["(", 760], ["WT", 761], [")", 763], ["CaSR", 765], ["-", 769], ["expressing", 770], ["pCR3.1", 781], ["vector", 788], [",", 794], ["and", 796], ["COS-7", 800], ["cells", 806], ["were", 812], ["transfected", 817], ["with", 829], ["either", 834], ["the", 841], ["WT", 845], ["or", 848], ["mutant", 851], ["CaSR", 858], ["-", 862], ["containing", 863], ["vector", 874], [".", 880], ["Transfected", 882], ["cells", 894], ["loaded", 900], ["with", 907], ["Fura-2/AM", 912], [",", 921], ["a", 923], ["fluorescent", 925], ["indicator", 937], ["of", 947], ["Ca", 950]]}
{"context": "Three isoforms of human plasma apolipoprotein E (apoE) are ligands to lipoprotein receptors and influence in different manner the synthesis and catabolism of pro-atherogenic triglyceride-rich lipoproteins. Among three isoforms, the apoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD). The conformational transitions of beta-amyloid (Abeta) influenced by apoE and serum amyloid P (SAP) component are key events in AD development, the accumulation of intermediate diffusible and soluble oligomers of Abeta being of particular significance. SAP and apoE, in a different manner for the three isoforms, serve as \"pathological\" chaperones during the aggregation of Abeta considered as a conformation-prone process. In turn, apoE consisting of two domains self-associates in solution and intermediate structures differently populated for the three isoforms exist. The different structures of the three isoforms determine their different distribution among various plasma lipoproteins. The structural and metabolic consideration of the common apoE pathway(s) in two pathologies assumes four molecular targets for AD correction: (i) inhibition of the accumulation of diffusible soluble Abeta oligomers; (ii) inhibition of apoE synthesis and secretion by astrocytes, in particular, under lipid-lowering therapy; (iii) inhibition of the binding of apoE and/or SAP to Abeta; (iv) stimulation of the expression of cholesterol transporter ABCA1.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "d2affbf1297d4be7a210c9cbf1cccbba", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[38, 39]], "char_spans": [[232, 244]]}]}], "context_tokens": [["Three", 0], ["isoforms", 6], ["of", 15], ["human", 18], ["plasma", 24], ["apolipoprotein", 31], ["E", 46], ["(", 48], ["apoE", 49], [")", 53], ["are", 55], ["ligands", 59], ["to", 67], ["lipoprotein", 70], ["receptors", 82], ["and", 92], ["influence", 96], ["in", 106], ["different", 109], ["manner", 119], ["the", 126], ["synthesis", 130], ["and", 140], ["catabolism", 144], ["of", 155], ["pro", 158], ["-", 161], ["atherogenic", 162], ["triglyceride", 174], ["-", 186], ["rich", 187], ["lipoproteins", 192], [".", 204], ["Among", 206], ["three", 212], ["isoforms", 218], [",", 226], ["the", 228], ["apoE4", 232], ["isoform", 238], ["is", 246], ["associated", 249], ["with", 260], ["increased", 265], ["frequency", 275], ["of", 285], ["atherosclerosis", 288], ["and", 304], ["Alzheimer", 308], ["'s", 317], ["disease", 320], ["(", 328], ["AD", 329], [")", 331], [".", 332], ["The", 334], ["conformational", 338], ["transitions", 353], ["of", 365], ["beta", 368], ["-", 372], ["amyloid", 373], ["(", 381], ["Abeta", 382], [")", 387], ["influenced", 389], ["by", 400], ["apoE", 403], ["and", 408], ["serum", 412], ["amyloid", 418], ["P", 426], ["(", 428], ["SAP", 429], [")", 432], ["component", 434], ["are", 444], ["key", 448], ["events", 452], ["in", 459], ["AD", 462], ["development", 465], [",", 476], ["the", 478], ["accumulation", 482], ["of", 495], ["intermediate", 498], ["diffusible", 511], ["and", 522], ["soluble", 526], ["oligomers", 534], ["of", 544], ["Abeta", 547], ["being", 553], ["of", 559], ["particular", 562], ["significance", 573], [".", 585], ["SAP", 587], ["and", 591], ["apoE", 595], [",", 599], ["in", 601], ["a", 604], ["different", 606], ["manner", 616], ["for", 623], ["the", 627], ["three", 631], ["isoforms", 637], [",", 645], ["serve", 647], ["as", 653], ["\"", 656], ["pathological", 657], ["\"", 669], ["chaperones", 671], ["during", 682], ["the", 689], ["aggregation", 693], ["of", 705], ["Abeta", 708], ["considered", 714], ["as", 725], ["a", 728], ["conformation", 730], ["-", 742], ["prone", 743], ["process", 749], [".", 756], ["In", 758], ["turn", 761], [",", 765], ["apoE", 767], ["consisting", 772], ["of", 783], ["two", 786], ["domains", 790], ["self", 798], ["-", 802], ["associates", 803], ["in", 814], ["solution", 817], ["and", 826], ["intermediate", 830], ["structures", 843], ["differently", 854], ["populated", 866], ["for", 876], ["the", 880], ["three", 884], ["isoforms", 890], ["exist", 899], [".", 904], ["The", 906], ["different", 910], ["structures", 920], ["of", 931], ["the", 934], ["three", 938], ["isoforms", 944], ["determine", 953], ["their", 963], ["different", 969], ["distribution", 979], ["among", 992], ["various", 998], ["plasma", 1006], ["lipoproteins", 1013], [".", 1025], ["The", 1027], ["structural", 1031], ["and", 1042], ["metabolic", 1046], ["consideration", 1056], ["of", 1070], ["the", 1073], ["common", 1077], ["apoE", 1084], ["pathway(s", 1089], [")", 1098], ["in", 1100], ["two", 1103], ["pathologies", 1107], ["assumes", 1119], ["four", 1127], ["molecular", 1132], ["targets", 1142], ["for", 1150], ["AD", 1154], ["correction", 1157], [":", 1167], ["(", 1169], ["i", 1170], [")", 1171], ["inhibition", 1173], ["of", 1184], ["the", 1187], ["accumulation", 1191], ["of", 1204], ["diffusible", 1207], ["soluble", 1218], ["Abeta", 1226], ["oligomers", 1232], [";", 1241], ["(", 1243], ["ii", 1244], [")", 1246], ["inhibition", 1248], ["of", 1259], ["apoE", 1262], ["synthesis", 1267], ["and", 1277], ["secretion", 1281], ["by", 1291], ["astrocytes", 1294], [",", 1304], ["in", 1306], ["particular", 1309], [",", 1319], ["under", 1321], ["lipid", 1327], ["-", 1332], ["lowering", 1333], ["therapy", 1342], [";", 1349], ["(", 1351], ["iii", 1352], [")", 1355], ["inhibition", 1357], ["of", 1368], ["the", 1371], ["binding", 1375], ["of", 1383], ["apoE", 1386], ["and/or", 1391], ["SAP", 1398], ["to", 1402], ["Abeta", 1405], [";", 1410], ["(", 1412], ["iv", 1413], [")", 1415], ["stimulation", 1417], ["of", 1429], ["the", 1432], ["expression", 1436], ["of", 1447], ["cholesterol", 1450], ["transporter", 1462], ["ABCA1", 1474], [".", 1479]]}
{"context": "Pannexin2 (Panx2) is the largest of three members of the pannexin proteins. Pannexins are topologically related to connexins and innexins, but serve different functional roles than forming gap junctions. We previously showed that pannexins form oligomeric channels but unlike connexins and innexins, they form only single membrane channels. High levels of Panx2 mRNA and protein in the Central Nervous System (CNS) have been documented. Whereas Pannexin1 (Panx1) is fairly ubiquitous and Pannexin3 (Panx3) is found in skin and connective tissue, both are fully glycosylated, traffic to the plasma membrane and have functions correlated with extracellular ATP release. Here, we describe trafficking and subcellular localizations of exogenous Panx2 and Panx1 protein expression in MDCK, HeLa, and HEK 293T cells as well as endogenous Panx1 and Panx2 patterns in the CNS. Panx2 was found in intracellular localizations, was partially N-glycosylated, and localizations were non-overlapping with Panx1. Confocal images of hippocampal sections immunolabeled for the astrocytic protein GFAP, Panx1 and Panx2 demonstrated that the two isoforms, Panx1 and Panx2, localized at different subcellular compartments in both astrocytes and neurons. Using recombinant fusions of Panx2 with appended genetic tags developed for correlated light and electron microscopy and then expressed in different cell lines, we determined that Panx2 is localized in the membrane of intracellular vesicles and not in the endoplasmic reticulum as initially indicated by calnexin colocalization experiments. Dual immunofluorescence imaging with protein markers for specific vesicle compartments showed that Panx2 vesicles are early endosomal in origin. In electron tomographic volumes, cross-sections of these vesicles displayed fine structural details and close proximity to actin filaments. Thus, pannexins expressed at different subcellular compartments likely exert distinct functional roles, particularly in the nervous system.", "qas": [{"question": "Where is the protein Pannexin1 located?", "answers": ["plasma membrane"], "qid": "08b59657cf0b4a05a3b821cb53bc7eeb", "question_tokens": [["Where", 0], ["is", 6], ["the", 9], ["protein", 13], ["Pannexin1", 21], ["located", 31], ["?", 38]], "detected_answers": [{"text": "plasma membrane", "token_spans": [[103, 104]], "char_spans": [[590, 604]]}]}], "context_tokens": [["Pannexin2", 0], ["(", 10], ["Panx2", 11], [")", 16], ["is", 18], ["the", 21], ["largest", 25], ["of", 33], ["three", 36], ["members", 42], ["of", 50], ["the", 53], ["pannexin", 57], ["proteins", 66], [".", 74], ["Pannexins", 76], ["are", 86], ["topologically", 90], ["related", 104], ["to", 112], ["connexins", 115], ["and", 125], ["innexins", 129], [",", 137], ["but", 139], ["serve", 143], ["different", 149], ["functional", 159], ["roles", 170], ["than", 176], ["forming", 181], ["gap", 189], ["junctions", 193], [".", 202], ["We", 204], ["previously", 207], ["showed", 218], ["that", 225], ["pannexins", 230], ["form", 240], ["oligomeric", 245], ["channels", 256], ["but", 265], ["unlike", 269], ["connexins", 276], ["and", 286], ["innexins", 290], [",", 298], ["they", 300], ["form", 305], ["only", 310], ["single", 315], ["membrane", 322], ["channels", 331], [".", 339], ["High", 341], ["levels", 346], ["of", 353], ["Panx2", 356], ["mRNA", 362], ["and", 367], ["protein", 371], ["in", 379], ["the", 382], ["Central", 386], ["Nervous", 394], ["System", 402], ["(", 409], ["CNS", 410], [")", 413], ["have", 415], ["been", 420], ["documented", 425], [".", 435], ["Whereas", 437], ["Pannexin1", 445], ["(", 455], ["Panx1", 456], [")", 461], ["is", 463], ["fairly", 466], ["ubiquitous", 473], ["and", 484], ["Pannexin3", 488], ["(", 498], ["Panx3", 499], [")", 504], ["is", 506], ["found", 509], ["in", 515], ["skin", 518], ["and", 523], ["connective", 527], ["tissue", 538], [",", 544], ["both", 546], ["are", 551], ["fully", 555], ["glycosylated", 561], [",", 573], ["traffic", 575], ["to", 583], ["the", 586], ["plasma", 590], ["membrane", 597], ["and", 606], ["have", 610], ["functions", 615], ["correlated", 625], ["with", 636], ["extracellular", 641], ["ATP", 655], ["release", 659], [".", 666], ["Here", 668], [",", 672], ["we", 674], ["describe", 677], ["trafficking", 686], ["and", 698], ["subcellular", 702], ["localizations", 714], ["of", 728], ["exogenous", 731], ["Panx2", 741], ["and", 747], ["Panx1", 751], ["protein", 757], ["expression", 765], ["in", 776], ["MDCK", 779], [",", 783], ["HeLa", 785], [",", 789], ["and", 791], ["HEK", 795], ["293", 799], ["T", 802], ["cells", 804], ["as", 810], ["well", 813], ["as", 818], ["endogenous", 821], ["Panx1", 832], ["and", 838], ["Panx2", 842], ["patterns", 848], ["in", 857], ["the", 860], ["CNS", 864], [".", 867], ["Panx2", 869], ["was", 875], ["found", 879], ["in", 885], ["intracellular", 888], ["localizations", 902], [",", 915], ["was", 917], ["partially", 921], ["N", 931], ["-", 932], ["glycosylated", 933], [",", 945], ["and", 947], ["localizations", 951], ["were", 965], ["non", 970], ["-", 973], ["overlapping", 974], ["with", 986], ["Panx1", 991], [".", 996], ["Confocal", 998], ["images", 1007], ["of", 1014], ["hippocampal", 1017], ["sections", 1029], ["immunolabeled", 1038], ["for", 1052], ["the", 1056], ["astrocytic", 1060], ["protein", 1071], ["GFAP", 1079], [",", 1083], ["Panx1", 1085], ["and", 1091], ["Panx2", 1095], ["demonstrated", 1101], ["that", 1114], ["the", 1119], ["two", 1123], ["isoforms", 1127], [",", 1135], ["Panx1", 1137], ["and", 1143], ["Panx2", 1147], [",", 1152], ["localized", 1154], ["at", 1164], ["different", 1167], ["subcellular", 1177], ["compartments", 1189], ["in", 1202], ["both", 1205], ["astrocytes", 1210], ["and", 1221], ["neurons", 1225], [".", 1232], ["Using", 1234], ["recombinant", 1240], ["fusions", 1252], ["of", 1260], ["Panx2", 1263], ["with", 1269], ["appended", 1274], ["genetic", 1283], ["tags", 1291], ["developed", 1296], ["for", 1306], ["correlated", 1310], ["light", 1321], ["and", 1327], ["electron", 1331], ["microscopy", 1340], ["and", 1351], ["then", 1355], ["expressed", 1360], ["in", 1370], ["different", 1373], ["cell", 1383], ["lines", 1388], [",", 1393], ["we", 1395], ["determined", 1398], ["that", 1409], ["Panx2", 1414], ["is", 1420], ["localized", 1423], ["in", 1433], ["the", 1436], ["membrane", 1440], ["of", 1449], ["intracellular", 1452], ["vesicles", 1466], ["and", 1475], ["not", 1479], ["in", 1483], ["the", 1486], ["endoplasmic", 1490], ["reticulum", 1502], ["as", 1512], ["initially", 1515], ["indicated", 1525], ["by", 1535], ["calnexin", 1538], ["colocalization", 1547], ["experiments", 1562], [".", 1573], ["Dual", 1575], ["immunofluorescence", 1580], ["imaging", 1599], ["with", 1607], ["protein", 1612], ["markers", 1620], ["for", 1628], ["specific", 1632], ["vesicle", 1641], ["compartments", 1649], ["showed", 1662], ["that", 1669], ["Panx2", 1674], ["vesicles", 1680], ["are", 1689], ["early", 1693], ["endosomal", 1699], ["in", 1709], ["origin", 1712], [".", 1718], ["In", 1720], ["electron", 1723], ["tomographic", 1732], ["volumes", 1744], [",", 1751], ["cross", 1753], ["-", 1758], ["sections", 1759], ["of", 1768], ["these", 1771], ["vesicles", 1777], ["displayed", 1786], ["fine", 1796], ["structural", 1801], ["details", 1812], ["and", 1820], ["close", 1824], ["proximity", 1830], ["to", 1840], ["actin", 1843], ["filaments", 1849], [".", 1858], ["Thus", 1860], [",", 1864], ["pannexins", 1866], ["expressed", 1876], ["at", 1886], ["different", 1889], ["subcellular", 1899], ["compartments", 1911], ["likely", 1924], ["exert", 1931], ["distinct", 1937], ["functional", 1946], ["roles", 1957], [",", 1962], ["particularly", 1964], ["in", 1977], ["the", 1980], ["nervous", 1984], ["system", 1992], [".", 1998]]}
{"context": "To characterise activation of the type I interferon (IFN) pathway in patients with systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid arthritis (RA) and systemic scleroderma (SSc) and to evaluate the potential to develop a molecular diagnostic tool from the peripheral blood that reflects this activation in disease-affected tissues. Overexpressed transcripts were identified in the whole blood (WB) of 262 patients with SLE, 44 with DM, 33 with PM, 28 with SSc and 89 with RA and compared with 24 healthy subjects using Affymetrix microarrays. A five gene type I IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this pathway in the WB with clinical measurements. A common set of 36 type I IFN inducible transcripts were identified among the most overexpressed in the WB of all subjects. Significant activation of the type I IFN pathway in subgroups of each of the five diseases studied was observed. Baseline disease activity measurements correlated with a type I IFN gene signature in the WB of subjects with SLE, PM and SSc, as did various serum autoantibody levels in subjects with SLE and DM. This signature was also well correlated between disease-affected tissue and WB in subjects with SLE, DM, PM and SSc. The results indicate that the type I IFN pathway is activated in patient subsets of five rheumatic diseases and suggest that these subsets may benefit from anti-IFN therapy.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "3d4407ef652d4c23ba87702480b6b50a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[115, 116]], "char_spans": [[601, 613]]}]}], "context_tokens": [["To", 0], ["characterise", 3], ["activation", 16], ["of", 27], ["the", 30], ["type", 34], ["I", 39], ["interferon", 41], ["(", 52], ["IFN", 53], [")", 56], ["pathway", 58], ["in", 66], ["patients", 69], ["with", 78], ["systemic", 83], ["lupus", 92], ["erythematosus", 98], ["(", 112], ["SLE", 113], [")", 116], [",", 117], ["dermatomyositis", 119], ["(", 135], ["DM", 136], [")", 138], [",", 139], ["polymyositis", 141], ["(", 154], ["PM", 155], [")", 157], [",", 158], ["rheumatoid", 160], ["arthritis", 171], ["(", 181], ["RA", 182], [")", 184], ["and", 186], ["systemic", 190], ["scleroderma", 199], ["(", 211], ["SSc", 212], [")", 215], ["and", 217], ["to", 221], ["evaluate", 224], ["the", 233], ["potential", 237], ["to", 247], ["develop", 250], ["a", 258], ["molecular", 260], ["diagnostic", 270], ["tool", 281], ["from", 286], ["the", 291], ["peripheral", 295], ["blood", 306], ["that", 312], ["reflects", 317], ["this", 326], ["activation", 331], ["in", 342], ["disease", 345], ["-", 352], ["affected", 353], ["tissues", 362], [".", 369], ["Overexpressed", 371], ["transcripts", 385], ["were", 397], ["identified", 402], ["in", 413], ["the", 416], ["whole", 420], ["blood", 426], ["(", 432], ["WB", 433], [")", 435], ["of", 437], ["262", 440], ["patients", 444], ["with", 453], ["SLE", 458], [",", 461], ["44", 463], ["with", 466], ["DM", 471], [",", 473], ["33", 475], ["with", 478], ["PM", 483], [",", 485], ["28", 487], ["with", 490], ["SSc", 495], ["and", 499], ["89", 503], ["with", 506], ["RA", 511], ["and", 514], ["compared", 518], ["with", 527], ["24", 532], ["healthy", 535], ["subjects", 543], ["using", 552], ["Affymetrix", 558], ["microarrays", 569], [".", 580], ["A", 582], ["five", 584], ["gene", 589], ["type", 594], ["I", 599], ["IFN", 601], ["signature", 605], ["was", 615], ["assessed", 619], ["in", 628], ["these", 631], ["subjects", 637], ["to", 646], ["identify", 649], ["subpopulations", 658], ["showing", 673], ["both", 681], ["activation", 686], ["and", 697], ["concordance", 701], ["of", 713], ["the", 716], ["type", 720], ["I", 725], ["IFN", 727], ["pathway", 731], ["in", 739], ["the", 742], ["peripheral", 746], ["blood", 757], ["and", 763], ["disease", 767], ["-", 774], ["affected", 775], ["tissues", 784], ["of", 792], ["each", 795], ["disease", 800], ["and", 808], ["to", 812], ["correlate", 815], ["activation", 825], ["of", 836], ["this", 839], ["pathway", 844], ["in", 852], ["the", 855], ["WB", 859], ["with", 862], ["clinical", 867], ["measurements", 876], [".", 888], ["A", 890], ["common", 892], ["set", 899], ["of", 903], ["36", 906], ["type", 909], ["I", 914], ["IFN", 916], ["inducible", 920], ["transcripts", 930], ["were", 942], ["identified", 947], ["among", 958], ["the", 964], ["most", 968], ["overexpressed", 973], ["in", 987], ["the", 990], ["WB", 994], ["of", 997], ["all", 1000], ["subjects", 1004], [".", 1012], ["Significant", 1014], ["activation", 1026], ["of", 1037], ["the", 1040], ["type", 1044], ["I", 1049], ["IFN", 1051], ["pathway", 1055], ["in", 1063], ["subgroups", 1066], ["of", 1076], ["each", 1079], ["of", 1084], ["the", 1087], ["five", 1091], ["diseases", 1096], ["studied", 1105], ["was", 1113], ["observed", 1117], [".", 1125], ["Baseline", 1127], ["disease", 1136], ["activity", 1144], ["measurements", 1153], ["correlated", 1166], ["with", 1177], ["a", 1182], ["type", 1184], ["I", 1189], ["IFN", 1191], ["gene", 1195], ["signature", 1200], ["in", 1210], ["the", 1213], ["WB", 1217], ["of", 1220], ["subjects", 1223], ["with", 1232], ["SLE", 1237], [",", 1240], ["PM", 1242], ["and", 1245], ["SSc", 1249], [",", 1252], ["as", 1254], ["did", 1257], ["various", 1261], ["serum", 1269], ["autoantibody", 1275], ["levels", 1288], ["in", 1295], ["subjects", 1298], ["with", 1307], ["SLE", 1312], ["and", 1316], ["DM", 1320], [".", 1322], ["This", 1324], ["signature", 1329], ["was", 1339], ["also", 1343], ["well", 1348], ["correlated", 1353], ["between", 1364], ["disease", 1372], ["-", 1379], ["affected", 1380], ["tissue", 1389], ["and", 1396], ["WB", 1400], ["in", 1403], ["subjects", 1406], ["with", 1415], ["SLE", 1420], [",", 1423], ["DM", 1425], [",", 1427], ["PM", 1429], ["and", 1432], ["SSc", 1436], [".", 1439], ["The", 1441], ["results", 1445], ["indicate", 1453], ["that", 1462], ["the", 1467], ["type", 1471], ["I", 1476], ["IFN", 1478], ["pathway", 1482], ["is", 1490], ["activated", 1493], ["in", 1503], ["patient", 1506], ["subsets", 1514], ["of", 1522], ["five", 1525], ["rheumatic", 1530], ["diseases", 1540], ["and", 1549], ["suggest", 1553], ["that", 1561], ["these", 1566], ["subsets", 1572], ["may", 1580], ["benefit", 1584], ["from", 1592], ["anti", 1597], ["-", 1601], ["IFN", 1602], ["therapy", 1606], [".", 1613]]}
{"context": "The reactive oxygen-generating NADPH oxidases (Noxes) function in a variety of biological roles, and can be broadly classified into those that are regulated by subunit interactions and those that are regulated by calcium. The prototypical subunit-regulated Nox, Nox2, is the membrane-associated catalytic subunit of the phagocyte NADPH-oxidase. Nox2 forms a heterodimer with the integral membrane protein, p22phox, and this heterodimer binds to the regulatory subunits p47phox, p67phox, p40phox and the small GTPase Rac, triggering superoxide generation. Nox-organizer protein 1 (NOXO1) and Nox-activator 1 (NOXA1), respective homologs of p47phox and p67phox, together with p22phox and Rac, activate Nox1, a non-phagocytic homolog of Nox2. NOXO1 and p22phox also regulate Nox3, whereas Nox4 requires only p22phox. In this study, we have assembled and analyzed amino acid sequences of Nox regulatory subunit orthologs from vertebrates, a urochordate, an echinoderm, a mollusc, a cnidarian, a choanoflagellate, fungi and a slime mold amoeba to investigate the evolutionary history of these subunits. Ancestral p47phox, p67phox, and p22phox genes are broadly seen in the metazoa, except for the ecdysozoans. The choanoflagellate Monosiga brevicollis, the unicellular organism that is the closest relatives of multicellular animals, encodes early prototypes of p22phox, p47phox as well as the earliest known Nox2-like ancestor of the Nox1-3 subfamily. p67phox- and p47phox-like genes are seen in the sea urchin Strongylocentrotus purpuratus and the limpet Lottia gigantea that also possess Nox2-like co-orthologs of vertebrate Nox1-3. Duplication of primordial p47phox and p67phox genes occurred in vertebrates, with the duplicated branches evolving into NOXO1 and NOXA1. Analysis of characteristic domains of regulatory subunits suggests a novel view of the evolution of Nox: in fish, p40phox participated in regulating both Nox1 and Nox2, but after the appearance of mammals, Nox1 (but not Nox2) became independent of p40phox. In the fish Oryzias latipes, a NOXO1 ortholog retains an autoinhibitory region that is characteristic of mammalian p47phox, and this was subsequently lost from NOXO1 in later vertebrates. Detailed amino acid sequence comparisons identified both putative key residues conserved in characteristic domains and previously unidentified conserved regions. Also, candidate organizer/activator proteins in fungi and amoeba are identified and hypothetical activation models are suggested. This is the first report to provide the comprehensive view of the molecular evolution of regulatory subunits for Nox enzymes. This approach provides clues for understanding the evolution of biochemical and physiological functions for regulatory-subunit-dependent Nox enzymes.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "c9411266b7014dedb3a042e1c5632fa7", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[128, 128], [288, 288], [349, 349], [338, 338], [255, 255]], "char_spans": [[700, 703], [1623, 1626], [1974, 1977], [1922, 1925], [1430, 1433]]}]}], "context_tokens": [["The", 0], ["reactive", 4], ["oxygen", 13], ["-", 19], ["generating", 20], ["NADPH", 31], ["oxidases", 37], ["(", 46], ["Noxes", 47], [")", 52], ["function", 54], ["in", 63], ["a", 66], ["variety", 68], ["of", 76], ["biological", 79], ["roles", 90], [",", 95], ["and", 97], ["can", 101], ["be", 105], ["broadly", 108], ["classified", 116], ["into", 127], ["those", 132], ["that", 138], ["are", 143], ["regulated", 147], ["by", 157], ["subunit", 160], ["interactions", 168], ["and", 181], ["those", 185], ["that", 191], ["are", 196], ["regulated", 200], ["by", 210], ["calcium", 213], [".", 220], ["The", 222], ["prototypical", 226], ["subunit", 239], ["-", 246], ["regulated", 247], ["Nox", 257], [",", 260], ["Nox2", 262], [",", 266], ["is", 268], ["the", 271], ["membrane", 275], ["-", 283], ["associated", 284], ["catalytic", 295], ["subunit", 305], ["of", 313], ["the", 316], ["phagocyte", 320], ["NADPH", 330], ["-", 335], ["oxidase", 336], [".", 343], ["Nox2", 345], ["forms", 350], ["a", 356], ["heterodimer", 358], ["with", 370], ["the", 375], ["integral", 379], ["membrane", 388], ["protein", 397], [",", 404], ["p22phox", 406], [",", 413], ["and", 415], ["this", 419], ["heterodimer", 424], ["binds", 436], ["to", 442], ["the", 445], ["regulatory", 449], ["subunits", 460], ["p47phox", 469], [",", 476], ["p67phox", 478], [",", 485], ["p40phox", 487], ["and", 495], ["the", 499], ["small", 503], ["GTPase", 509], ["Rac", 516], [",", 519], ["triggering", 521], ["superoxide", 532], ["generation", 543], [".", 553], ["Nox", 555], ["-", 558], ["organizer", 559], ["protein", 569], ["1", 577], ["(", 579], ["NOXO1", 580], [")", 585], ["and", 587], ["Nox", 591], ["-", 594], ["activator", 595], ["1", 605], ["(", 607], ["NOXA1", 608], [")", 613], [",", 614], ["respective", 616], ["homologs", 627], ["of", 636], ["p47phox", 639], ["and", 647], ["p67phox", 651], [",", 658], ["together", 660], ["with", 669], ["p22phox", 674], ["and", 682], ["Rac", 686], [",", 689], ["activate", 691], ["Nox1", 700], [",", 704], ["a", 706], ["non", 708], ["-", 711], ["phagocytic", 712], ["homolog", 723], ["of", 731], ["Nox2", 734], [".", 738], ["NOXO1", 740], ["and", 746], ["p22phox", 750], ["also", 758], ["regulate", 763], ["Nox3", 772], [",", 776], ["whereas", 778], ["Nox4", 786], ["requires", 791], ["only", 800], ["p22phox", 805], [".", 812], ["In", 814], ["this", 817], ["study", 822], [",", 827], ["we", 829], ["have", 832], ["assembled", 837], ["and", 847], ["analyzed", 851], ["amino", 860], ["acid", 866], ["sequences", 871], ["of", 881], ["Nox", 884], ["regulatory", 888], ["subunit", 899], ["orthologs", 907], ["from", 917], ["vertebrates", 922], [",", 933], ["a", 935], ["urochordate", 937], [",", 948], ["an", 950], ["echinoderm", 953], [",", 963], ["a", 965], ["mollusc", 967], [",", 974], ["a", 976], ["cnidarian", 978], [",", 987], ["a", 989], ["choanoflagellate", 991], [",", 1007], ["fungi", 1009], ["and", 1015], ["a", 1019], ["slime", 1021], ["mold", 1027], ["amoeba", 1032], ["to", 1039], ["investigate", 1042], ["the", 1054], ["evolutionary", 1058], ["history", 1071], ["of", 1079], ["these", 1082], ["subunits", 1088], [".", 1096], ["Ancestral", 1098], ["p47phox", 1108], [",", 1115], ["p67phox", 1117], [",", 1124], ["and", 1126], ["p22phox", 1130], ["genes", 1138], ["are", 1144], ["broadly", 1148], ["seen", 1156], ["in", 1161], ["the", 1164], ["metazoa", 1168], [",", 1175], ["except", 1177], ["for", 1184], ["the", 1188], ["ecdysozoans", 1192], [".", 1203], ["The", 1205], ["choanoflagellate", 1209], ["Monosiga", 1226], ["brevicollis", 1235], [",", 1246], ["the", 1248], ["unicellular", 1252], ["organism", 1264], ["that", 1273], ["is", 1278], ["the", 1281], ["closest", 1285], ["relatives", 1293], ["of", 1303], ["multicellular", 1306], ["animals", 1320], [",", 1327], ["encodes", 1329], ["early", 1337], ["prototypes", 1343], ["of", 1354], ["p22phox", 1357], [",", 1364], ["p47phox", 1366], ["as", 1374], ["well", 1377], ["as", 1382], ["the", 1385], ["earliest", 1389], ["known", 1398], ["Nox2-like", 1404], ["ancestor", 1414], ["of", 1423], ["the", 1426], ["Nox1", 1430], ["-", 1434], ["3", 1435], ["subfamily", 1437], [".", 1446], ["p67phox-", 1448], ["and", 1457], ["p47phox", 1461], ["-", 1468], ["like", 1469], ["genes", 1474], ["are", 1480], ["seen", 1484], ["in", 1489], ["the", 1492], ["sea", 1496], ["urchin", 1500], ["Strongylocentrotus", 1507], ["purpuratus", 1526], ["and", 1537], ["the", 1541], ["limpet", 1545], ["Lottia", 1552], ["gigantea", 1559], ["that", 1568], ["also", 1573], ["possess", 1578], ["Nox2-like", 1586], ["co", 1596], ["-", 1598], ["orthologs", 1599], ["of", 1609], ["vertebrate", 1612], ["Nox1", 1623], ["-", 1627], ["3", 1628], [".", 1629], ["Duplication", 1631], ["of", 1643], ["primordial", 1646], ["p47phox", 1657], ["and", 1665], ["p67phox", 1669], ["genes", 1677], ["occurred", 1683], ["in", 1692], ["vertebrates", 1695], [",", 1706], ["with", 1708], ["the", 1713], ["duplicated", 1717], ["branches", 1728], ["evolving", 1737], ["into", 1746], ["NOXO1", 1751], ["and", 1757], ["NOXA1", 1761], [".", 1766], ["Analysis", 1768], ["of", 1777], ["characteristic", 1780], ["domains", 1795], ["of", 1803], ["regulatory", 1806], ["subunits", 1817], ["suggests", 1826], ["a", 1835], ["novel", 1837], ["view", 1843], ["of", 1848], ["the", 1851], ["evolution", 1855], ["of", 1865], ["Nox", 1868], [":", 1871], ["in", 1873], ["fish", 1876], [",", 1880], ["p40phox", 1882], ["participated", 1890], ["in", 1903], ["regulating", 1906], ["both", 1917], ["Nox1", 1922], ["and", 1927], ["Nox2", 1931], [",", 1935], ["but", 1937], ["after", 1941], ["the", 1947], ["appearance", 1951], ["of", 1962], ["mammals", 1965], [",", 1972], ["Nox1", 1974], ["(", 1979], ["but", 1980], ["not", 1984], ["Nox2", 1988], [")", 1992], ["became", 1994], ["independent", 2001], ["of", 2013], ["p40phox", 2016], [".", 2023], ["In", 2025], ["the", 2028], ["fish", 2032], ["Oryzias", 2037], ["latipes", 2045], [",", 2052], ["a", 2054], ["NOXO1", 2056], ["ortholog", 2062], ["retains", 2071], ["an", 2079], ["autoinhibitory", 2082], ["region", 2097], ["that", 2104], ["is", 2109], ["characteristic", 2112], ["of", 2127], ["mammalian", 2130], ["p47phox", 2140], [",", 2147], ["and", 2149], ["this", 2153], ["was", 2158], ["subsequently", 2162], ["lost", 2175], ["from", 2180], ["NOXO1", 2185], ["in", 2191], ["later", 2194], ["vertebrates", 2200], [".", 2211], ["Detailed", 2213], ["amino", 2222], ["acid", 2228], ["sequence", 2233], ["comparisons", 2242], ["identified", 2254], ["both", 2265], ["putative", 2270], ["key", 2279], ["residues", 2283], ["conserved", 2292], ["in", 2302], ["characteristic", 2305], ["domains", 2320], ["and", 2328], ["previously", 2332], ["unidentified", 2343], ["conserved", 2356], ["regions", 2366], [".", 2373], ["Also", 2375], [",", 2379], ["candidate", 2381], ["organizer", 2391], ["/", 2400], ["activator", 2401], ["proteins", 2411], ["in", 2420], ["fungi", 2423], ["and", 2429], ["amoeba", 2433], ["are", 2440], ["identified", 2444], ["and", 2455], ["hypothetical", 2459], ["activation", 2472], ["models", 2483], ["are", 2490], ["suggested", 2494], [".", 2503], ["This", 2505], ["is", 2510], ["the", 2513], ["first", 2517], ["report", 2523], ["to", 2530], ["provide", 2533], ["the", 2541], ["comprehensive", 2545], ["view", 2559], ["of", 2564], ["the", 2567], ["molecular", 2571], ["evolution", 2581], ["of", 2591], ["regulatory", 2594], ["subunits", 2605], ["for", 2614], ["Nox", 2618], ["enzymes", 2622], [".", 2629], ["This", 2631], ["approach", 2636], ["provides", 2645], ["clues", 2654], ["for", 2660], ["understanding", 2664], ["the", 2678], ["evolution", 2682], ["of", 2692], ["biochemical", 2695], ["and", 2707], ["physiological", 2711], ["functions", 2725], ["for", 2735], ["regulatory", 2739], ["-", 2749], ["subunit", 2750], ["-", 2757], ["dependent", 2758], ["Nox", 2768], ["enzymes", 2772], [".", 2779]]}
{"context": "Flumazenil, a potent benzodiazepine antagonist, is a newly synthetic imidazo-benzodiazepine, which blocks the neurological effects of benzodiazepines. The purpose of this study was to evaluate the effects of this agent in reversal of benzodiazepine overdose and differentiation of comatous patients with drug overdose. Fifteen comatous patients with suspected sedatives/hypnotics overdose were included in this study and flumazenil 0.25 mg per dose was administrated intravenously. The average score of Glasgow Coma Scale increased from 7.13 +/- 2.92 to 10.93 +/- 3.67 after one dose of flumazenil. Clear consciousness was restored after multiple doses of flumazenil administration. Three cases with different drug history and variant response after flumazenil treatment were also illustrated and discussed. The dosage of flumazenil used in this study ranged from 0.25 mg to 3 mg (average 0.87 +/- 0.74 mg). We concluded that flumazenil is an excellent antidote for benzodiazepine overdose and valuable for differentiating the patients in comatose.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "ebb1ae34a73c4a5d839b1240da0af1a4", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [96, 96], [106, 106], [154, 154], [119, 119], [130, 130], [65, 65]], "char_spans": [[0, 9], [587, 596], [656, 665], [926, 935], [750, 759], [822, 831], [421, 430]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["potent", 14], ["benzodiazepine", 21], ["antagonist", 36], [",", 46], ["is", 48], ["a", 51], ["newly", 53], ["synthetic", 59], ["imidazo", 69], ["-", 76], ["benzodiazepine", 77], [",", 91], ["which", 93], ["blocks", 99], ["the", 106], ["neurological", 110], ["effects", 123], ["of", 131], ["benzodiazepines", 134], [".", 149], ["The", 151], ["purpose", 155], ["of", 163], ["this", 166], ["study", 171], ["was", 177], ["to", 181], ["evaluate", 184], ["the", 193], ["effects", 197], ["of", 205], ["this", 208], ["agent", 213], ["in", 219], ["reversal", 222], ["of", 231], ["benzodiazepine", 234], ["overdose", 249], ["and", 258], ["differentiation", 262], ["of", 278], ["comatous", 281], ["patients", 290], ["with", 299], ["drug", 304], ["overdose", 309], [".", 317], ["Fifteen", 319], ["comatous", 327], ["patients", 336], ["with", 345], ["suspected", 350], ["sedatives", 360], ["/", 369], ["hypnotics", 370], ["overdose", 380], ["were", 389], ["included", 394], ["in", 403], ["this", 406], ["study", 411], ["and", 417], ["flumazenil", 421], ["0.25", 432], ["mg", 437], ["per", 440], ["dose", 444], ["was", 449], ["administrated", 453], ["intravenously", 467], [".", 480], ["The", 482], ["average", 486], ["score", 494], ["of", 500], ["Glasgow", 503], ["Coma", 511], ["Scale", 516], ["increased", 522], ["from", 532], ["7.13", 537], ["+", 542], ["/-", 543], ["2.92", 546], ["to", 551], ["10.93", 554], ["+", 560], ["/-", 561], ["3.67", 564], ["after", 569], ["one", 575], ["dose", 579], ["of", 584], ["flumazenil", 587], [".", 597], ["Clear", 599], ["consciousness", 605], ["was", 619], ["restored", 623], ["after", 632], ["multiple", 638], ["doses", 647], ["of", 653], ["flumazenil", 656], ["administration", 667], [".", 681], ["Three", 683], ["cases", 689], ["with", 695], ["different", 700], ["drug", 710], ["history", 715], ["and", 723], ["variant", 727], ["response", 735], ["after", 744], ["flumazenil", 750], ["treatment", 761], ["were", 771], ["also", 776], ["illustrated", 781], ["and", 793], ["discussed", 797], [".", 806], ["The", 808], ["dosage", 812], ["of", 819], ["flumazenil", 822], ["used", 833], ["in", 838], ["this", 841], ["study", 846], ["ranged", 852], ["from", 859], ["0.25", 864], ["mg", 869], ["to", 872], ["3", 875], ["mg", 877], ["(", 880], ["average", 881], ["0.87", 889], ["+", 894], ["/-", 895], ["0.74", 898], ["mg", 903], [")", 905], [".", 906], ["We", 908], ["concluded", 911], ["that", 921], ["flumazenil", 926], ["is", 937], ["an", 940], ["excellent", 943], ["antidote", 953], ["for", 962], ["benzodiazepine", 966], ["overdose", 981], ["and", 990], ["valuable", 994], ["for", 1003], ["differentiating", 1007], ["the", 1023], ["patients", 1027], ["in", 1036], ["comatose", 1039], [".", 1047]]}
{"context": "Turner's syndrome (TS) is a chromosomal defect with partial or total absence of the X chromosome. Our objective is to report our experience in Greece with patients suffering from TS and trying to conceive; therefore, we present four patients with TS, who underwent In vitro fertilization (ICSI) with donor oocytes in order to get pregnant. Three out of four patients managed to conceive and bring pregnancy to completion. It was shown that patients diagnosed in childhood or adolescence with TS have the possibility to undergo hormone replacement therapy (HRT) and thus, secondary sexual characteristics as well as uterus of almost normal size can develop. Assisted reproduction techniques (ART), predominantly with donated oocytes, could give these patients the possibility to have children.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "80b1b799ab8b4a54ad19e73ff5640506", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[17, 17]], "char_spans": [[84, 84]]}]}], "context_tokens": [["Turner", 0], ["'s", 6], ["syndrome", 9], ["(", 18], ["TS", 19], [")", 21], ["is", 23], ["a", 26], ["chromosomal", 28], ["defect", 40], ["with", 47], ["partial", 52], ["or", 60], ["total", 63], ["absence", 69], ["of", 77], ["the", 80], ["X", 84], ["chromosome", 86], [".", 96], ["Our", 98], ["objective", 102], ["is", 112], ["to", 115], ["report", 118], ["our", 125], ["experience", 129], ["in", 140], ["Greece", 143], ["with", 150], ["patients", 155], ["suffering", 164], ["from", 174], ["TS", 179], ["and", 182], ["trying", 186], ["to", 193], ["conceive", 196], [";", 204], ["therefore", 206], [",", 215], ["we", 217], ["present", 220], ["four", 228], ["patients", 233], ["with", 242], ["TS", 247], [",", 249], ["who", 251], ["underwent", 255], ["In", 265], ["vitro", 268], ["fertilization", 274], ["(", 288], ["ICSI", 289], [")", 293], ["with", 295], ["donor", 300], ["oocytes", 306], ["in", 314], ["order", 317], ["to", 323], ["get", 326], ["pregnant", 330], [".", 338], ["Three", 340], ["out", 346], ["of", 350], ["four", 353], ["patients", 358], ["managed", 367], ["to", 375], ["conceive", 378], ["and", 387], ["bring", 391], ["pregnancy", 397], ["to", 407], ["completion", 410], [".", 420], ["It", 422], ["was", 425], ["shown", 429], ["that", 435], ["patients", 440], ["diagnosed", 449], ["in", 459], ["childhood", 462], ["or", 472], ["adolescence", 475], ["with", 487], ["TS", 492], ["have", 495], ["the", 500], ["possibility", 504], ["to", 516], ["undergo", 519], ["hormone", 527], ["replacement", 535], ["therapy", 547], ["(", 555], ["HRT", 556], [")", 559], ["and", 561], ["thus", 565], [",", 569], ["secondary", 571], ["sexual", 581], ["characteristics", 588], ["as", 604], ["well", 607], ["as", 612], ["uterus", 615], ["of", 622], ["almost", 625], ["normal", 632], ["size", 639], ["can", 644], ["develop", 648], [".", 655], ["Assisted", 657], ["reproduction", 666], ["techniques", 679], ["(", 690], ["ART", 691], [")", 694], [",", 695], ["predominantly", 697], ["with", 711], ["donated", 716], ["oocytes", 724], [",", 731], ["could", 733], ["give", 739], ["these", 744], ["patients", 750], ["the", 759], ["possibility", 763], ["to", 775], ["have", 778], ["children", 783], [".", 791]]}
{"context": "Siltuximab, a chimeric monoclonal antibody with high affinity and specificity for interleukin-6, has been shown to enhance anti-multiple myeloma activity of bortezomib and corticosteroid in vitro. We evaluated the safety, pharmacokinetics, immunogenicity, and antitumor effect of siltuximab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. This open-label, phase 1, dose-escalating study used two doses of siltuximab: 5.5 and 11.0 mg/kg (administered on day 1 of each 21-day cycle). In total, nine patients were treated. The most common grade 3/4 adverse events, lymphopenia (89 %) and thrombocytopenia (44 %), occurred in patients receiving both doses of siltuximab; however, no dose-limiting toxicities (DLTs) were observed. Following intravenous administration of siltuximab at 5.5 and 11.0 mg/kg, the maximum serum concentration and the area under the curve from 0 to 21 days and from 0 to infinity increased in an approximately dose-proportional manner. Mean half-life, total systemic clearance, and volume of distribution were similar at doses of 5.5 and 11.0 mg/kg. Across both doses, six of the nine patients had complete or partial response (22 and 44 %, respectively). In conclusion, as no DLT was observed, the recommended dose for this combination is 11.0 mg/kg once every 3 weeks. The study is registered at http://www.clinicaltrials.gov as NCT01309412.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "5cd7ff3ebd7f4aeea91e08b630ebba14", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[12, 12]], "char_spans": [[82, 94]]}]}], "context_tokens": [["Siltuximab", 0], [",", 10], ["a", 12], ["chimeric", 14], ["monoclonal", 23], ["antibody", 34], ["with", 43], ["high", 48], ["affinity", 53], ["and", 62], ["specificity", 66], ["for", 78], ["interleukin-6", 82], [",", 95], ["has", 97], ["been", 101], ["shown", 106], ["to", 112], ["enhance", 115], ["anti", 123], ["-", 127], ["multiple", 128], ["myeloma", 137], ["activity", 145], ["of", 154], ["bortezomib", 157], ["and", 168], ["corticosteroid", 172], ["in", 187], ["vitro", 190], [".", 195], ["We", 197], ["evaluated", 200], ["the", 210], ["safety", 214], [",", 220], ["pharmacokinetics", 222], [",", 238], ["immunogenicity", 240], [",", 254], ["and", 256], ["antitumor", 260], ["effect", 270], ["of", 277], ["siltuximab", 280], ["in", 291], ["combination", 294], ["with", 306], ["bortezomib", 311], ["and", 322], ["dexamethasone", 326], ["in", 340], ["Japanese", 343], ["patients", 352], ["with", 361], ["relapsed", 366], ["or", 375], ["refractory", 378], ["multiple", 389], ["myeloma", 398], [".", 405], ["This", 407], ["open", 412], ["-", 416], ["label", 417], [",", 422], ["phase", 424], ["1", 430], [",", 431], ["dose", 433], ["-", 437], ["escalating", 438], ["study", 449], ["used", 455], ["two", 460], ["doses", 464], ["of", 470], ["siltuximab", 473], [":", 483], ["5.5", 485], ["and", 489], ["11.0", 493], ["mg", 498], ["/", 500], ["kg", 501], ["(", 504], ["administered", 505], ["on", 518], ["day", 521], ["1", 525], ["of", 527], ["each", 530], ["21-day", 535], ["cycle", 542], [")", 547], [".", 548], ["In", 550], ["total", 553], [",", 558], ["nine", 560], ["patients", 565], ["were", 574], ["treated", 579], [".", 586], ["The", 588], ["most", 592], ["common", 597], ["grade", 604], ["3/4", 610], ["adverse", 614], ["events", 622], [",", 628], ["lymphopenia", 630], ["(", 642], ["89", 643], ["%", 646], [")", 647], ["and", 649], ["thrombocytopenia", 653], ["(", 670], ["44", 671], ["%", 674], [")", 675], [",", 676], ["occurred", 678], ["in", 687], ["patients", 690], ["receiving", 699], ["both", 709], ["doses", 714], ["of", 720], ["siltuximab", 723], [";", 733], ["however", 735], [",", 742], ["no", 744], ["dose", 747], ["-", 751], ["limiting", 752], ["toxicities", 761], ["(", 772], ["DLTs", 773], [")", 777], ["were", 779], ["observed", 784], [".", 792], ["Following", 794], ["intravenous", 804], ["administration", 816], ["of", 831], ["siltuximab", 834], ["at", 845], ["5.5", 848], ["and", 852], ["11.0", 856], ["mg", 861], ["/", 863], ["kg", 864], [",", 866], ["the", 868], ["maximum", 872], ["serum", 880], ["concentration", 886], ["and", 900], ["the", 904], ["area", 908], ["under", 913], ["the", 919], ["curve", 923], ["from", 929], ["0", 934], ["to", 936], ["21", 939], ["days", 942], ["and", 947], ["from", 951], ["0", 956], ["to", 958], ["infinity", 961], ["increased", 970], ["in", 980], ["an", 983], ["approximately", 986], ["dose", 1000], ["-", 1004], ["proportional", 1005], ["manner", 1018], [".", 1024], ["Mean", 1026], ["half", 1031], ["-", 1035], ["life", 1036], [",", 1040], ["total", 1042], ["systemic", 1048], ["clearance", 1057], [",", 1066], ["and", 1068], ["volume", 1072], ["of", 1079], ["distribution", 1082], ["were", 1095], ["similar", 1100], ["at", 1108], ["doses", 1111], ["of", 1117], ["5.5", 1120], ["and", 1124], ["11.0", 1128], ["mg", 1133], ["/", 1135], ["kg", 1136], [".", 1138], ["Across", 1140], ["both", 1147], ["doses", 1152], [",", 1157], ["six", 1159], ["of", 1163], ["the", 1166], ["nine", 1170], ["patients", 1175], ["had", 1184], ["complete", 1188], ["or", 1197], ["partial", 1200], ["response", 1208], ["(", 1217], ["22", 1218], ["and", 1221], ["44", 1225], ["%", 1228], [",", 1229], ["respectively", 1231], [")", 1243], [".", 1244], ["In", 1246], ["conclusion", 1249], [",", 1259], ["as", 1261], ["no", 1264], ["DLT", 1267], ["was", 1271], ["observed", 1275], [",", 1283], ["the", 1285], ["recommended", 1289], ["dose", 1301], ["for", 1306], ["this", 1310], ["combination", 1315], ["is", 1327], ["11.0", 1330], ["mg", 1335], ["/", 1337], ["kg", 1338], ["once", 1341], ["every", 1346], ["3", 1352], ["weeks", 1354], [".", 1359], ["The", 1361], ["study", 1365], ["is", 1371], ["registered", 1374], ["at", 1385], ["http://www.clinicaltrials.gov", 1388], ["as", 1418], ["NCT01309412", 1421], [".", 1432]]}
{"context": "A 60-year-old man diagnosed clinically with Becker's muscular dystrophy 20 years ago by another physician presented with gradually progressive proximal muscle weakness since teenage years. Family history revealed a strong paternal familial inheritance pattern of similar distribution of weakness-face, forearm flexion, knee extension and foot dorsiflexion. Work-ups revealed B12 deficiency and allele 1 deletion in fascioscapulohumeral muscular dystrophy (FSHD) DNA testing. FSHD is the third most common muscular dystrophy. Clinical diagnosis is made from the distinctive pattern of weakness, autosomal-dominant inheritance, and confirmed by genetic testing. This case strongly demonstrates the importance of a thorough and careful clinical evaluation even in a case with a long standing diagnosis.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "ff8ede38609d4622af0f985023a70e89", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[95, 97]], "char_spans": [[594, 611]]}]}], "context_tokens": [["A", 0], ["60-year", 2], ["-", 9], ["old", 10], ["man", 14], ["diagnosed", 18], ["clinically", 28], ["with", 39], ["Becker", 44], ["'s", 50], ["muscular", 53], ["dystrophy", 62], ["20", 72], ["years", 75], ["ago", 81], ["by", 85], ["another", 88], ["physician", 96], ["presented", 106], ["with", 116], ["gradually", 121], ["progressive", 131], ["proximal", 143], ["muscle", 152], ["weakness", 159], ["since", 168], ["teenage", 174], ["years", 182], [".", 187], ["Family", 189], ["history", 196], ["revealed", 204], ["a", 213], ["strong", 215], ["paternal", 222], ["familial", 231], ["inheritance", 240], ["pattern", 252], ["of", 260], ["similar", 263], ["distribution", 271], ["of", 284], ["weakness", 287], ["-", 295], ["face", 296], [",", 300], ["forearm", 302], ["flexion", 310], [",", 317], ["knee", 319], ["extension", 324], ["and", 334], ["foot", 338], ["dorsiflexion", 343], [".", 355], ["Work", 357], ["-", 361], ["ups", 362], ["revealed", 366], ["B12", 375], ["deficiency", 379], ["and", 390], ["allele", 394], ["1", 401], ["deletion", 403], ["in", 412], ["fascioscapulohumeral", 415], ["muscular", 436], ["dystrophy", 445], ["(", 455], ["FSHD", 456], [")", 460], ["DNA", 462], ["testing", 466], [".", 473], ["FSHD", 475], ["is", 480], ["the", 483], ["third", 487], ["most", 493], ["common", 498], ["muscular", 505], ["dystrophy", 514], [".", 523], ["Clinical", 525], ["diagnosis", 534], ["is", 544], ["made", 547], ["from", 552], ["the", 557], ["distinctive", 561], ["pattern", 573], ["of", 581], ["weakness", 584], [",", 592], ["autosomal", 594], ["-", 603], ["dominant", 604], ["inheritance", 613], [",", 624], ["and", 626], ["confirmed", 630], ["by", 640], ["genetic", 643], ["testing", 651], [".", 658], ["This", 660], ["case", 665], ["strongly", 670], ["demonstrates", 679], ["the", 692], ["importance", 696], ["of", 707], ["a", 710], ["thorough", 712], ["and", 721], ["careful", 725], ["clinical", 733], ["evaluation", 742], ["even", 753], ["in", 758], ["a", 761], ["case", 763], ["with", 768], ["a", 773], ["long", 775], ["standing", 780], ["diagnosis", 789], [".", 798]]}
{"context": "The Ehlers-Danlos syndrome is a heritable connective-tissue disorder caused by defects in fibrillar-collagen metabolism. Mutations in the type V collagen genes account for up to 50 percent of cases of classic Ehlers-Danlos syndrome, but many other cases are unexplained. We investigated whether the deficiency of the tenascins, extracellular-matrix proteins that are highly expressed in connective tissues, was associated with the Ehlers-Danlos syndrome. We screened serum samples from 151 patients with the classic, hypermobility, or vascular types of the Ehlers-Danlos syndrome; 75 patients with psoriasis; 93 patients with rheumatoid arthritis; and 21 healthy persons for the presence of tenascin-X and tenascin-C by enzyme-linked immunosorbent assay. We examined the expression of tenascins and type V collagen in skin by immunohistochemical methods and sequenced the tenascin-X gene. Tenascin-X was present in serum from all normal subjects, all patients with psoriasis, all patients with rheumatoid arthritis, and 146 of 151 patients with the Ehlers-Danlos syndrome. Tenascin-X was absent from the serum of the 5 remaining patients with Ehlers-Danlos syndrome, who were unrelated. Tenascin-X deficiency was confirmed in these patients by analysis of skin fibroblasts and by immunostaining of skin. The expression of tenascin-C and type V collagen was normal in these patients. All five of these patients had hypermobile joints, hyperelastic skin, and easy bruising, without atrophic scarring. Tenascin-X mutations were identified in all tenascin-X-deficient patients; one patient had a homozygous tenascin-X gene deletion, one was heterozygous for the deletion, and three others had homozygous truncating point mutations, confirming a causative role for tenascin-X and a recessive pattern of inheritance. Tenascin-X deficiency causes a clinically distinct, recessive form of the Ehlers-Danlos syndrome. This finding indicates that factors other than the collagens or collagen-processing enzymes can cause the syndrome and suggests a central role for tenascin-X in maintaining the integrity of collagenous matrix.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective-tissue", "connective tissue"], "qid": "84ecb54e06cc44c78c9482f8b29d119c", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[8, 10]], "char_spans": [[42, 58]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["is", 27], ["a", 30], ["heritable", 32], ["connective", 42], ["-", 52], ["tissue", 53], ["disorder", 60], ["caused", 69], ["by", 76], ["defects", 79], ["in", 87], ["fibrillar", 90], ["-", 99], ["collagen", 100], ["metabolism", 109], [".", 119], ["Mutations", 121], ["in", 131], ["the", 134], ["type", 138], ["V", 143], ["collagen", 145], ["genes", 154], ["account", 160], ["for", 168], ["up", 172], ["to", 175], ["50", 178], ["percent", 181], ["of", 189], ["cases", 192], ["of", 198], ["classic", 201], ["Ehlers", 209], ["-", 215], ["Danlos", 216], ["syndrome", 223], [",", 231], ["but", 233], ["many", 237], ["other", 242], ["cases", 248], ["are", 254], ["unexplained", 258], [".", 269], ["We", 271], ["investigated", 274], ["whether", 287], ["the", 295], ["deficiency", 299], ["of", 310], ["the", 313], ["tenascins", 317], [",", 326], ["extracellular", 328], ["-", 341], ["matrix", 342], ["proteins", 349], ["that", 358], ["are", 363], ["highly", 367], ["expressed", 374], ["in", 384], ["connective", 387], ["tissues", 398], [",", 405], ["was", 407], ["associated", 411], ["with", 422], ["the", 427], ["Ehlers", 431], ["-", 437], ["Danlos", 438], ["syndrome", 445], [".", 453], ["We", 455], ["screened", 458], ["serum", 467], ["samples", 473], ["from", 481], ["151", 486], ["patients", 490], ["with", 499], ["the", 504], ["classic", 508], [",", 515], ["hypermobility", 517], [",", 530], ["or", 532], ["vascular", 535], ["types", 544], ["of", 550], ["the", 553], ["Ehlers", 557], ["-", 563], ["Danlos", 564], ["syndrome", 571], [";", 579], ["75", 581], ["patients", 584], ["with", 593], ["psoriasis", 598], [";", 607], ["93", 609], ["patients", 612], ["with", 621], ["rheumatoid", 626], ["arthritis", 637], [";", 646], ["and", 648], ["21", 652], ["healthy", 655], ["persons", 663], ["for", 671], ["the", 675], ["presence", 679], ["of", 688], ["tenascin", 691], ["-", 699], ["X", 700], ["and", 702], ["tenascin", 706], ["-", 714], ["C", 715], ["by", 717], ["enzyme", 720], ["-", 726], ["linked", 727], ["immunosorbent", 734], ["assay", 748], [".", 753], ["We", 755], ["examined", 758], ["the", 767], ["expression", 771], ["of", 782], ["tenascins", 785], ["and", 795], ["type", 799], ["V", 804], ["collagen", 806], ["in", 815], ["skin", 818], ["by", 823], ["immunohistochemical", 826], ["methods", 846], ["and", 854], ["sequenced", 858], ["the", 868], ["tenascin", 872], ["-", 880], ["X", 881], ["gene", 883], [".", 887], ["Tenascin", 889], ["-", 897], ["X", 898], ["was", 900], ["present", 904], ["in", 912], ["serum", 915], ["from", 921], ["all", 926], ["normal", 930], ["subjects", 937], [",", 945], ["all", 947], ["patients", 951], ["with", 960], ["psoriasis", 965], [",", 974], ["all", 976], ["patients", 980], ["with", 989], ["rheumatoid", 994], ["arthritis", 1005], [",", 1014], ["and", 1016], ["146", 1020], ["of", 1024], ["151", 1027], ["patients", 1031], ["with", 1040], ["the", 1045], ["Ehlers", 1049], ["-", 1055], ["Danlos", 1056], ["syndrome", 1063], [".", 1071], ["Tenascin", 1073], ["-", 1081], ["X", 1082], ["was", 1084], ["absent", 1088], ["from", 1095], ["the", 1100], ["serum", 1104], ["of", 1110], ["the", 1113], ["5", 1117], ["remaining", 1119], ["patients", 1129], ["with", 1138], ["Ehlers", 1143], ["-", 1149], ["Danlos", 1150], ["syndrome", 1157], [",", 1165], ["who", 1167], ["were", 1171], ["unrelated", 1176], [".", 1185], ["Tenascin", 1187], ["-", 1195], ["X", 1196], ["deficiency", 1198], ["was", 1209], ["confirmed", 1213], ["in", 1223], ["these", 1226], ["patients", 1232], ["by", 1241], ["analysis", 1244], ["of", 1253], ["skin", 1256], ["fibroblasts", 1261], ["and", 1273], ["by", 1277], ["immunostaining", 1280], ["of", 1295], ["skin", 1298], [".", 1302], ["The", 1304], ["expression", 1308], ["of", 1319], ["tenascin", 1322], ["-", 1330], ["C", 1331], ["and", 1333], ["type", 1337], ["V", 1342], ["collagen", 1344], ["was", 1353], ["normal", 1357], ["in", 1364], ["these", 1367], ["patients", 1373], [".", 1381], ["All", 1383], ["five", 1387], ["of", 1392], ["these", 1395], ["patients", 1401], ["had", 1410], ["hypermobile", 1414], ["joints", 1426], [",", 1432], ["hyperelastic", 1434], ["skin", 1447], [",", 1451], ["and", 1453], ["easy", 1457], ["bruising", 1462], [",", 1470], ["without", 1472], ["atrophic", 1480], ["scarring", 1489], [".", 1497], ["Tenascin", 1499], ["-", 1507], ["X", 1508], ["mutations", 1510], ["were", 1520], ["identified", 1525], ["in", 1536], ["all", 1539], ["tenascin", 1543], ["-", 1551], ["X", 1552], ["-", 1553], ["deficient", 1554], ["patients", 1564], [";", 1572], ["one", 1574], ["patient", 1578], ["had", 1586], ["a", 1590], ["homozygous", 1592], ["tenascin", 1603], ["-", 1611], ["X", 1612], ["gene", 1614], ["deletion", 1619], [",", 1627], ["one", 1629], ["was", 1633], ["heterozygous", 1637], ["for", 1650], ["the", 1654], ["deletion", 1658], [",", 1666], ["and", 1668], ["three", 1672], ["others", 1678], ["had", 1685], ["homozygous", 1689], ["truncating", 1700], ["point", 1711], ["mutations", 1717], [",", 1726], ["confirming", 1728], ["a", 1739], ["causative", 1741], ["role", 1751], ["for", 1756], ["tenascin", 1760], ["-", 1768], ["X", 1769], ["and", 1771], ["a", 1775], ["recessive", 1777], ["pattern", 1787], ["of", 1795], ["inheritance", 1798], [".", 1809], ["Tenascin", 1811], ["-", 1819], ["X", 1820], ["deficiency", 1822], ["causes", 1833], ["a", 1840], ["clinically", 1842], ["distinct", 1853], [",", 1861], ["recessive", 1863], ["form", 1873], ["of", 1878], ["the", 1881], ["Ehlers", 1885], ["-", 1891], ["Danlos", 1892], ["syndrome", 1899], [".", 1907], ["This", 1909], ["finding", 1914], ["indicates", 1922], ["that", 1932], ["factors", 1937], ["other", 1945], ["than", 1951], ["the", 1956], ["collagens", 1960], ["or", 1970], ["collagen", 1973], ["-", 1981], ["processing", 1982], ["enzymes", 1993], ["can", 2001], ["cause", 2005], ["the", 2011], ["syndrome", 2015], ["and", 2024], ["suggests", 2028], ["a", 2037], ["central", 2039], ["role", 2047], ["for", 2052], ["tenascin", 2056], ["-", 2064], ["X", 2065], ["in", 2067], ["maintaining", 2070], ["the", 2082], ["integrity", 2086], ["of", 2096], ["collagenous", 2099], ["matrix", 2111], [".", 2117]]}
{"context": "To evaluate short- and mid-term level of imbalance after vestibular schwannoma (VS) microsurgery by the transpetrosal approach, to search for factors predictive of vestibular compensation, and to determine which patient categories need a postoperative vestibular rehabilitation program. Prospective cohort study at a tertiary referral center. Between 2010 and 2011, patients aged 18 to 75 operated on for VS by transpetrosal approaches were included. VS was characterized by its size (Koos classification) and the presence or not of a cystic component. Hearing was classified according to the Gardner Robertson grading. The preoperative workup included an audiogram, computerized video nystagmography (VNG) with caloric testing, gaze study, rotatory tests, click-evoked cervical vestibular evoked myogenic potential measurements (cVEMPs), and subjective visual vertical test. Patients were asked to complete a Dizziness Handicap Inventory (DHI). Postoperatively, patients were reevaluated on D7 (clinical status), D90 (VNG and DHI), and D180 (DHI). Timing and duration of vestibular rehabilitation were also recorded. Forty-eight patients were included. Preoperatively, 77% experienced mild instability problems with a mean DHI score of 14.1 (range 4-32). Postoperatively, 71% reported stable or even improved perceived stability. Mean DHI scores were 28.1 on D90 and 19.8 on D180. Serviceable hearing, cystic transformation, normal cVEMPs, diplopia, and vestibular syndrome on D7 were found to be predictive of worse equilibrium outcome than when absent. A preoperative caloric deficit greater than 75% seemed to be a good prognostic factor. Vestibular rehabilitation was conducted in 56% of patients. Starting it early (<1 mo) seemed to be beneficial for final equilibrium outcome. VS microsurgery provides good stability results. Some preoperative parameters may be predictive of worse or improved balance recovery, as is clinical status on D7.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "44cd890f1a1b4d6a9b055e363d1c3221", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[11, 12]], "char_spans": [[57, 77]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["short-", 12], ["and", 19], ["mid", 23], ["-", 26], ["term", 27], ["level", 32], ["of", 38], ["imbalance", 41], ["after", 51], ["vestibular", 57], ["schwannoma", 68], ["(", 79], ["VS", 80], [")", 82], ["microsurgery", 84], ["by", 97], ["the", 100], ["transpetrosal", 104], ["approach", 118], [",", 126], ["to", 128], ["search", 131], ["for", 138], ["factors", 142], ["predictive", 150], ["of", 161], ["vestibular", 164], ["compensation", 175], [",", 187], ["and", 189], ["to", 193], ["determine", 196], ["which", 206], ["patient", 212], ["categories", 220], ["need", 231], ["a", 236], ["postoperative", 238], ["vestibular", 252], ["rehabilitation", 263], ["program", 278], [".", 285], ["Prospective", 287], ["cohort", 299], ["study", 306], ["at", 312], ["a", 315], ["tertiary", 317], ["referral", 326], ["center", 335], [".", 341], ["Between", 343], ["2010", 351], ["and", 356], ["2011", 360], [",", 364], ["patients", 366], ["aged", 375], ["18", 380], ["to", 383], ["75", 386], ["operated", 389], ["on", 398], ["for", 401], ["VS", 405], ["by", 408], ["transpetrosal", 411], ["approaches", 425], ["were", 436], ["included", 441], [".", 449], ["VS", 451], ["was", 454], ["characterized", 458], ["by", 472], ["its", 475], ["size", 479], ["(", 484], ["Koos", 485], ["classification", 490], [")", 504], ["and", 506], ["the", 510], ["presence", 514], ["or", 523], ["not", 526], ["of", 530], ["a", 533], ["cystic", 535], ["component", 542], [".", 551], ["Hearing", 553], ["was", 561], ["classified", 565], ["according", 576], ["to", 586], ["the", 589], ["Gardner", 593], ["Robertson", 601], ["grading", 611], [".", 618], ["The", 620], ["preoperative", 624], ["workup", 637], ["included", 644], ["an", 653], ["audiogram", 656], [",", 665], ["computerized", 667], ["video", 680], ["nystagmography", 686], ["(", 701], ["VNG", 702], [")", 705], ["with", 707], ["caloric", 712], ["testing", 720], [",", 727], ["gaze", 729], ["study", 734], [",", 739], ["rotatory", 741], ["tests", 750], [",", 755], ["click", 757], ["-", 762], ["evoked", 763], ["cervical", 770], ["vestibular", 779], ["evoked", 790], ["myogenic", 797], ["potential", 806], ["measurements", 816], ["(", 829], ["cVEMPs", 830], [")", 836], [",", 837], ["and", 839], ["subjective", 843], ["visual", 854], ["vertical", 861], ["test", 870], [".", 874], ["Patients", 876], ["were", 885], ["asked", 890], ["to", 896], ["complete", 899], ["a", 908], ["Dizziness", 910], ["Handicap", 920], ["Inventory", 929], ["(", 939], ["DHI", 940], [")", 943], [".", 944], ["Postoperatively", 946], [",", 961], ["patients", 963], ["were", 972], ["reevaluated", 977], ["on", 989], ["D7", 992], ["(", 995], ["clinical", 996], ["status", 1005], [")", 1011], [",", 1012], ["D90", 1014], ["(", 1018], ["VNG", 1019], ["and", 1023], ["DHI", 1027], [")", 1030], [",", 1031], ["and", 1033], ["D180", 1037], ["(", 1042], ["DHI", 1043], [")", 1046], [".", 1047], ["Timing", 1049], ["and", 1056], ["duration", 1060], ["of", 1069], ["vestibular", 1072], ["rehabilitation", 1083], ["were", 1098], ["also", 1103], ["recorded", 1108], [".", 1116], ["Forty", 1118], ["-", 1123], ["eight", 1124], ["patients", 1130], ["were", 1139], ["included", 1144], [".", 1152], ["Preoperatively", 1154], [",", 1168], ["77", 1170], ["%", 1172], ["experienced", 1174], ["mild", 1186], ["instability", 1191], ["problems", 1203], ["with", 1212], ["a", 1217], ["mean", 1219], ["DHI", 1224], ["score", 1228], ["of", 1234], ["14.1", 1237], ["(", 1242], ["range", 1243], ["4", 1249], ["-", 1250], ["32", 1251], [")", 1253], [".", 1254], ["Postoperatively", 1256], [",", 1271], ["71", 1273], ["%", 1275], ["reported", 1277], ["stable", 1286], ["or", 1293], ["even", 1296], ["improved", 1301], ["perceived", 1310], ["stability", 1320], [".", 1329], ["Mean", 1331], ["DHI", 1336], ["scores", 1340], ["were", 1347], ["28.1", 1352], ["on", 1357], ["D90", 1360], ["and", 1364], ["19.8", 1368], ["on", 1373], ["D180", 1376], [".", 1380], ["Serviceable", 1382], ["hearing", 1394], [",", 1401], ["cystic", 1403], ["transformation", 1410], [",", 1424], ["normal", 1426], ["cVEMPs", 1433], [",", 1439], ["diplopia", 1441], [",", 1449], ["and", 1451], ["vestibular", 1455], ["syndrome", 1466], ["on", 1475], ["D7", 1478], ["were", 1481], ["found", 1486], ["to", 1492], ["be", 1495], ["predictive", 1498], ["of", 1509], ["worse", 1512], ["equilibrium", 1518], ["outcome", 1530], ["than", 1538], ["when", 1543], ["absent", 1548], [".", 1554], ["A", 1556], ["preoperative", 1558], ["caloric", 1571], ["deficit", 1579], ["greater", 1587], ["than", 1595], ["75", 1600], ["%", 1602], ["seemed", 1604], ["to", 1611], ["be", 1614], ["a", 1617], ["good", 1619], ["prognostic", 1624], ["factor", 1635], [".", 1641], ["Vestibular", 1643], ["rehabilitation", 1654], ["was", 1669], ["conducted", 1673], ["in", 1683], ["56", 1686], ["%", 1688], ["of", 1690], ["patients", 1693], [".", 1701], ["Starting", 1703], ["it", 1712], ["early", 1715], ["(", 1721], ["<", 1722], ["1", 1723], ["mo", 1725], [")", 1727], ["seemed", 1729], ["to", 1736], ["be", 1739], ["beneficial", 1742], ["for", 1753], ["final", 1757], ["equilibrium", 1763], ["outcome", 1775], [".", 1782], ["VS", 1784], ["microsurgery", 1787], ["provides", 1800], ["good", 1809], ["stability", 1814], ["results", 1824], [".", 1831], ["Some", 1833], ["preoperative", 1838], ["parameters", 1851], ["may", 1862], ["be", 1866], ["predictive", 1869], ["of", 1880], ["worse", 1883], ["or", 1889], ["improved", 1892], ["balance", 1901], ["recovery", 1909], [",", 1917], ["as", 1919], ["is", 1922], ["clinical", 1925], ["status", 1934], ["on", 1941], ["D7", 1944], [".", 1946]]}
{"context": "Willis-Ekbom disease/restless legs syndrome (WED/RLS) is the most common sleep-related movement disorder in pregnancy. We designed a prospective longitudinal study to investigate the correlates of WED/RLS during and after pregnancy. A total of 138 pregnant women with WED/RLS and a control group of 251 age-matched pregnant women were enrolled prospectively. A questionnaire was administered during a face-to-face interview at first evaluation during pregnancy and three months after delivery. Among all women in the first trimester, 15.6% were diagnosed with WED/RLS, whereas 32.8% of those in the second trimester and 38.8% of those in the third trimester were diagnosed with WED/RLS (p\u2009=\u20090.032). In regression analysis, later gestational age [p\u2009<\u20090.001; odds ratio (OR) 1.054] and previous history of WED/RLS (p\u2009=\u20090.001; OR 2.795) were positively correlated with the presence of WED/RLS, while ferritin levels (p\u2009=\u20090.001; OR 0.956) were negatively correlated with the presence of WED/RLS. Ferritin levels were also negatively correlated with the International RLS Study Group severity index (p\u2009=\u20090.041). Forty-eight patients (34.8%) experienced WED/RLS symptomatology after delivery. The ferritin levels were lower, and the mean number of pregnancies was higher, in women with residual WED/RLS (p\u2009=\u20090.008). Our survey showed that WED/RLS was more common in the second and third trimesters. Emergence of WED/RLS during the second trimester was strongly associated with residual WED/RLS. Lower ferritin levels were associated with both WED/RLS in pregnancy and residual WED/RLS after delivery. A higher number of pregnancies were also associated with a greater likelihood of having residual WED/RLS after delivery.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "c13bddb9e37b47c69428caa895cea7ae", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[5, 7]], "char_spans": [[21, 42]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["/", 20], ["restless", 21], ["legs", 30], ["syndrome", 35], ["(", 44], ["WED", 45], ["/", 48], ["RLS", 49], [")", 52], ["is", 54], ["the", 57], ["most", 61], ["common", 66], ["sleep", 73], ["-", 78], ["related", 79], ["movement", 87], ["disorder", 96], ["in", 105], ["pregnancy", 108], [".", 117], ["We", 119], ["designed", 122], ["a", 131], ["prospective", 133], ["longitudinal", 145], ["study", 158], ["to", 164], ["investigate", 167], ["the", 179], ["correlates", 183], ["of", 194], ["WED", 197], ["/", 200], ["RLS", 201], ["during", 205], ["and", 212], ["after", 216], ["pregnancy", 222], [".", 231], ["A", 233], ["total", 235], ["of", 241], ["138", 244], ["pregnant", 248], ["women", 257], ["with", 263], ["WED", 268], ["/", 271], ["RLS", 272], ["and", 276], ["a", 280], ["control", 282], ["group", 290], ["of", 296], ["251", 299], ["age", 303], ["-", 306], ["matched", 307], ["pregnant", 315], ["women", 324], ["were", 330], ["enrolled", 335], ["prospectively", 344], [".", 357], ["A", 359], ["questionnaire", 361], ["was", 375], ["administered", 379], ["during", 392], ["a", 399], ["face", 401], ["-", 405], ["to", 406], ["-", 408], ["face", 409], ["interview", 414], ["at", 424], ["first", 427], ["evaluation", 433], ["during", 444], ["pregnancy", 451], ["and", 461], ["three", 465], ["months", 471], ["after", 478], ["delivery", 484], [".", 492], ["Among", 494], ["all", 500], ["women", 504], ["in", 510], ["the", 513], ["first", 517], ["trimester", 523], [",", 532], ["15.6", 534], ["%", 538], ["were", 540], ["diagnosed", 545], ["with", 555], ["WED", 560], ["/", 563], ["RLS", 564], [",", 567], ["whereas", 569], ["32.8", 577], ["%", 581], ["of", 583], ["those", 586], ["in", 592], ["the", 595], ["second", 599], ["trimester", 606], ["and", 616], ["38.8", 620], ["%", 624], ["of", 626], ["those", 629], ["in", 635], ["the", 638], ["third", 642], ["trimester", 648], ["were", 658], ["diagnosed", 663], ["with", 673], ["WED", 678], ["/", 681], ["RLS", 682], ["(", 686], ["p", 687], ["=", 689], ["0.032", 691], [")", 696], [".", 697], ["In", 699], ["regression", 702], ["analysis", 713], [",", 721], ["later", 723], ["gestational", 729], ["age", 741], ["[", 745], ["p", 746], ["<", 748], ["0.001", 750], [";", 755], ["odds", 757], ["ratio", 762], ["(", 768], ["OR", 769], [")", 771], ["1.054", 773], ["]", 778], ["and", 780], ["previous", 784], ["history", 793], ["of", 801], ["WED", 804], ["/", 807], ["RLS", 808], ["(", 812], ["p", 813], ["=", 815], ["0.001", 817], [";", 822], ["OR", 824], ["2.795", 827], [")", 832], ["were", 834], ["positively", 839], ["correlated", 850], ["with", 861], ["the", 866], ["presence", 870], ["of", 879], ["WED", 882], ["/", 885], ["RLS", 886], [",", 889], ["while", 891], ["ferritin", 897], ["levels", 906], ["(", 913], ["p", 914], ["=", 916], ["0.001", 918], [";", 923], ["OR", 925], ["0.956", 928], [")", 933], ["were", 935], ["negatively", 940], ["correlated", 951], ["with", 962], ["the", 967], ["presence", 971], ["of", 980], ["WED", 983], ["/", 986], ["RLS", 987], [".", 990], ["Ferritin", 992], ["levels", 1001], ["were", 1008], ["also", 1013], ["negatively", 1018], ["correlated", 1029], ["with", 1040], ["the", 1045], ["International", 1049], ["RLS", 1063], ["Study", 1067], ["Group", 1073], ["severity", 1079], ["index", 1088], ["(", 1094], ["p", 1095], ["=", 1097], ["0.041", 1099], [")", 1104], [".", 1105], ["Forty", 1107], ["-", 1112], ["eight", 1113], ["patients", 1119], ["(", 1128], ["34.8", 1129], ["%", 1133], [")", 1134], ["experienced", 1136], ["WED", 1148], ["/", 1151], ["RLS", 1152], ["symptomatology", 1156], ["after", 1171], ["delivery", 1177], [".", 1185], ["The", 1187], ["ferritin", 1191], ["levels", 1200], ["were", 1207], ["lower", 1212], [",", 1217], ["and", 1219], ["the", 1223], ["mean", 1227], ["number", 1232], ["of", 1239], ["pregnancies", 1242], ["was", 1254], ["higher", 1258], [",", 1264], ["in", 1266], ["women", 1269], ["with", 1275], ["residual", 1280], ["WED", 1289], ["/", 1292], ["RLS", 1293], ["(", 1297], ["p", 1298], ["=", 1300], ["0.008", 1302], [")", 1307], [".", 1308], ["Our", 1310], ["survey", 1314], ["showed", 1321], ["that", 1328], ["WED", 1333], ["/", 1336], ["RLS", 1337], ["was", 1341], ["more", 1345], ["common", 1350], ["in", 1357], ["the", 1360], ["second", 1364], ["and", 1371], ["third", 1375], ["trimesters", 1381], [".", 1391], ["Emergence", 1393], ["of", 1403], ["WED", 1406], ["/", 1409], ["RLS", 1410], ["during", 1414], ["the", 1421], ["second", 1425], ["trimester", 1432], ["was", 1442], ["strongly", 1446], ["associated", 1455], ["with", 1466], ["residual", 1471], ["WED", 1480], ["/", 1483], ["RLS", 1484], [".", 1487], ["Lower", 1489], ["ferritin", 1495], ["levels", 1504], ["were", 1511], ["associated", 1516], ["with", 1527], ["both", 1532], ["WED", 1537], ["/", 1540], ["RLS", 1541], ["in", 1545], ["pregnancy", 1548], ["and", 1558], ["residual", 1562], ["WED", 1571], ["/", 1574], ["RLS", 1575], ["after", 1579], ["delivery", 1585], [".", 1593], ["A", 1595], ["higher", 1597], ["number", 1604], ["of", 1611], ["pregnancies", 1614], ["were", 1626], ["also", 1631], ["associated", 1636], ["with", 1647], ["a", 1652], ["greater", 1654], ["likelihood", 1662], ["of", 1673], ["having", 1676], ["residual", 1683], ["WED", 1692], ["/", 1695], ["RLS", 1696], ["after", 1700], ["delivery", 1706], [".", 1714]]}
{"context": "Neuronal loss in specific brain regions and neurons with intracellular inclusions termed Lewy bodies are the pathologic hallmark in both Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Lewy bodies comprise of aggregated intracellular vesicles and proteins and \u03b1-synuclein is reported to be a major protein component. Using human brain tissue from control, PD and DLB and light and confocal immunohistochemistry with antibodies to superoxide dismutase 2 as a marker for mitochondria, \u03b1-synuclein for Lewy bodies and \u03b2III Tubulin for microtubules we have examined the relationship between Lewy bodies and mitochondrial loss. We have shown microtubule regression and mitochondrial and nuclear degradation in neurons with developing Lewy bodies. In PD, multiple Lewy bodies were often observed with \u03b1-synuclein interacting with DNA to cause marked nuclear degradation. In DLB, the mitochondria are drawn into the Lewy body and the mitochondrial integrity is lost. This work suggests that Lewy bodies are cytotoxic. In DLB, we suggest that microtubule regression and mitochondrial loss results in decreased cellular energy and axonal transport that leads to cell death. In PD, \u03b1-synuclein aggregations are associated with intact mitochondria but interacts with and causes nuclear degradation which may be the major cause of cell death.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a26bb24d46114aeaa1d54858c6340119", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[134, 136], [201, 203], [45, 47], [84, 86]], "char_spans": [[809, 819], [1186, 1196], [274, 284], [497, 507]]}]}], "context_tokens": [["Neuronal", 0], ["loss", 9], ["in", 14], ["specific", 17], ["brain", 26], ["regions", 32], ["and", 40], ["neurons", 44], ["with", 52], ["intracellular", 57], ["inclusions", 71], ["termed", 82], ["Lewy", 89], ["bodies", 94], ["are", 101], ["the", 105], ["pathologic", 109], ["hallmark", 120], ["in", 129], ["both", 132], ["Parkinson", 137], ["'s", 146], ["disease", 149], ["(", 157], ["PD", 158], [")", 160], ["and", 162], ["dementia", 166], ["with", 175], ["Lewy", 180], ["bodies", 185], ["(", 192], ["DLB", 193], [")", 196], [".", 197], ["Lewy", 199], ["bodies", 204], ["comprise", 211], ["of", 220], ["aggregated", 223], ["intracellular", 234], ["vesicles", 248], ["and", 257], ["proteins", 261], ["and", 270], ["\u03b1", 274], ["-", 275], ["synuclein", 276], ["is", 286], ["reported", 289], ["to", 298], ["be", 301], ["a", 304], ["major", 306], ["protein", 312], ["component", 320], [".", 329], ["Using", 331], ["human", 337], ["brain", 343], ["tissue", 349], ["from", 356], ["control", 361], [",", 368], ["PD", 370], ["and", 373], ["DLB", 377], ["and", 381], ["light", 385], ["and", 391], ["confocal", 395], ["immunohistochemistry", 404], ["with", 425], ["antibodies", 430], ["to", 441], ["superoxide", 444], ["dismutase", 455], ["2", 465], ["as", 467], ["a", 470], ["marker", 472], ["for", 479], ["mitochondria", 483], [",", 495], ["\u03b1", 497], ["-", 498], ["synuclein", 499], ["for", 509], ["Lewy", 513], ["bodies", 518], ["and", 525], ["\u03b2III", 529], ["Tubulin", 534], ["for", 542], ["microtubules", 546], ["we", 559], ["have", 562], ["examined", 567], ["the", 576], ["relationship", 580], ["between", 593], ["Lewy", 601], ["bodies", 606], ["and", 613], ["mitochondrial", 617], ["loss", 631], [".", 635], ["We", 637], ["have", 640], ["shown", 645], ["microtubule", 651], ["regression", 663], ["and", 674], ["mitochondrial", 678], ["and", 692], ["nuclear", 696], ["degradation", 704], ["in", 716], ["neurons", 719], ["with", 727], ["developing", 732], ["Lewy", 743], ["bodies", 748], [".", 754], ["In", 756], ["PD", 759], [",", 761], ["multiple", 763], ["Lewy", 772], ["bodies", 777], ["were", 784], ["often", 789], ["observed", 795], ["with", 804], ["\u03b1", 809], ["-", 810], ["synuclein", 811], ["interacting", 821], ["with", 833], ["DNA", 838], ["to", 842], ["cause", 845], ["marked", 851], ["nuclear", 858], ["degradation", 866], [".", 877], ["In", 879], ["DLB", 882], [",", 885], ["the", 887], ["mitochondria", 891], ["are", 904], ["drawn", 908], ["into", 914], ["the", 919], ["Lewy", 923], ["body", 928], ["and", 933], ["the", 937], ["mitochondrial", 941], ["integrity", 955], ["is", 965], ["lost", 968], [".", 972], ["This", 974], ["work", 979], ["suggests", 984], ["that", 993], ["Lewy", 998], ["bodies", 1003], ["are", 1010], ["cytotoxic", 1014], [".", 1023], ["In", 1025], ["DLB", 1028], [",", 1031], ["we", 1033], ["suggest", 1036], ["that", 1044], ["microtubule", 1049], ["regression", 1061], ["and", 1072], ["mitochondrial", 1076], ["loss", 1090], ["results", 1095], ["in", 1103], ["decreased", 1106], ["cellular", 1116], ["energy", 1125], ["and", 1132], ["axonal", 1136], ["transport", 1143], ["that", 1153], ["leads", 1158], ["to", 1164], ["cell", 1167], ["death", 1172], [".", 1177], ["In", 1179], ["PD", 1182], [",", 1184], ["\u03b1", 1186], ["-", 1187], ["synuclein", 1188], ["aggregations", 1198], ["are", 1211], ["associated", 1215], ["with", 1226], ["intact", 1231], ["mitochondria", 1238], ["but", 1251], ["interacts", 1255], ["with", 1265], ["and", 1270], ["causes", 1274], ["nuclear", 1281], ["degradation", 1289], ["which", 1301], ["may", 1307], ["be", 1311], ["the", 1314], ["major", 1318], ["cause", 1324], ["of", 1330], ["cell", 1333], ["death", 1338], [".", 1343]]}
{"context": "Bone pain is a common symptom in bone metastases. The therapies that are currently available include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, steroids and gabapentin which have been demonstrated to improve neuropathic pain. In addition, preclinical studies indicate that agents such as transient receptor potential vanilloid 1 antagonists and cannabinoid 2 receptor agonist could be considered as adjuncts in ameliorating opioid side effects. New drugs are in the clinical phase of development, among which the most promising molecules seem to be anti-nerve growth factor (NGF) antibodies. Anti-NGF antibody therapy may be particularly effective in blocking bone cancer pain because NGF appears to be integrally involved in the upregulation, sensitization and disinhibition of multiple neurotransmitters, ion channels and receptors in the primary afferent nerve. The best way to treat bone metastases pain is to improve the control of skeletal disease burden. Recently, denosumab, a noncytotoxic IgG2 monoclonal antibody with high affinity for human RANKL, has been demonstrated to significantly prevent clinically relevant increase in pain compared with zoledronic acid across the tumor types. Based on these data, it has been suggested that denosumab has the potential to become a new standard of treatment in bone metastases management.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "19f21e68fc4946c181d7758601dee5d5", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[175, 175]], "char_spans": [[1065, 1069]]}]}], "context_tokens": [["Bone", 0], ["pain", 5], ["is", 10], ["a", 13], ["common", 15], ["symptom", 22], ["in", 30], ["bone", 33], ["metastases", 38], [".", 48], ["The", 50], ["therapies", 54], ["that", 64], ["are", 69], ["currently", 73], ["available", 83], ["include", 93], ["nonsteroidal", 101], ["anti", 114], ["-", 118], ["inflammatory", 119], ["drugs", 132], ["(", 138], ["NSAIDs", 139], [")", 145], [",", 146], ["opioids", 148], [",", 155], ["steroids", 157], ["and", 166], ["gabapentin", 170], ["which", 181], ["have", 187], ["been", 192], ["demonstrated", 197], ["to", 210], ["improve", 213], ["neuropathic", 221], ["pain", 233], [".", 237], ["In", 239], ["addition", 242], [",", 250], ["preclinical", 252], ["studies", 264], ["indicate", 272], ["that", 281], ["agents", 286], ["such", 293], ["as", 298], ["transient", 301], ["receptor", 311], ["potential", 320], ["vanilloid", 330], ["1", 340], ["antagonists", 342], ["and", 354], ["cannabinoid", 358], ["2", 370], ["receptor", 372], ["agonist", 381], ["could", 389], ["be", 395], ["considered", 398], ["as", 409], ["adjuncts", 412], ["in", 421], ["ameliorating", 424], ["opioid", 437], ["side", 444], ["effects", 449], [".", 456], ["New", 458], ["drugs", 462], ["are", 468], ["in", 472], ["the", 475], ["clinical", 479], ["phase", 488], ["of", 494], ["development", 497], [",", 508], ["among", 510], ["which", 516], ["the", 522], ["most", 526], ["promising", 531], ["molecules", 541], ["seem", 551], ["to", 556], ["be", 559], ["anti", 562], ["-", 566], ["nerve", 567], ["growth", 573], ["factor", 580], ["(", 587], ["NGF", 588], [")", 591], ["antibodies", 593], [".", 603], ["Anti", 605], ["-", 609], ["NGF", 610], ["antibody", 614], ["therapy", 623], ["may", 631], ["be", 635], ["particularly", 638], ["effective", 651], ["in", 661], ["blocking", 664], ["bone", 673], ["cancer", 678], ["pain", 685], ["because", 690], ["NGF", 698], ["appears", 702], ["to", 710], ["be", 713], ["integrally", 716], ["involved", 727], ["in", 736], ["the", 739], ["upregulation", 743], [",", 755], ["sensitization", 757], ["and", 771], ["disinhibition", 775], ["of", 789], ["multiple", 792], ["neurotransmitters", 801], [",", 818], ["ion", 820], ["channels", 824], ["and", 833], ["receptors", 837], ["in", 847], ["the", 850], ["primary", 854], ["afferent", 862], ["nerve", 871], [".", 876], ["The", 878], ["best", 882], ["way", 887], ["to", 891], ["treat", 894], ["bone", 900], ["metastases", 905], ["pain", 916], ["is", 921], ["to", 924], ["improve", 927], ["the", 935], ["control", 939], ["of", 947], ["skeletal", 950], ["disease", 959], ["burden", 967], [".", 973], ["Recently", 975], [",", 983], ["denosumab", 985], [",", 994], ["a", 996], ["noncytotoxic", 998], ["IgG2", 1011], ["monoclonal", 1016], ["antibody", 1027], ["with", 1036], ["high", 1041], ["affinity", 1046], ["for", 1055], ["human", 1059], ["RANKL", 1065], [",", 1070], ["has", 1072], ["been", 1076], ["demonstrated", 1081], ["to", 1094], ["significantly", 1097], ["prevent", 1111], ["clinically", 1119], ["relevant", 1130], ["increase", 1139], ["in", 1148], ["pain", 1151], ["compared", 1156], ["with", 1165], ["zoledronic", 1170], ["acid", 1181], ["across", 1186], ["the", 1193], ["tumor", 1197], ["types", 1203], [".", 1208], ["Based", 1210], ["on", 1216], ["these", 1219], ["data", 1225], [",", 1229], ["it", 1231], ["has", 1234], ["been", 1238], ["suggested", 1243], ["that", 1253], ["denosumab", 1258], ["has", 1268], ["the", 1272], ["potential", 1276], ["to", 1286], ["become", 1289], ["a", 1296], ["new", 1298], ["standard", 1302], ["of", 1311], ["treatment", 1314], ["in", 1324], ["bone", 1327], ["metastases", 1332], ["management", 1343], [".", 1353]]}
{"context": "The mature central nervous system contains precursor cells in the subventricular zone of the lateral ventricle. In this study we examined the possibility to affect fate of precursor cells through exogenous manipulations. The results indicate that administration of thyroid hormone and retinoic acid increases the expression of Ki67, a nuclear antigen associated with cell proliferation, and of nestin, a marker protein for precursor cells in the subventricular zone of adult male rats. Moreover, retinoic acid increases polysialated-neural cell adhesion molecules (PSA-NCAM)-immunoreactivity. These data suggest that nuclear receptor ligands are potential candidates for fate determination of precursor cells in the subventricular zone also in the adult brain.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "2a963d7335cb4cfa9452f4ded58a357f", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[61, 61]], "char_spans": [[394, 399]]}]}], "context_tokens": [["The", 0], ["mature", 4], ["central", 11], ["nervous", 19], ["system", 27], ["contains", 34], ["precursor", 43], ["cells", 53], ["in", 59], ["the", 62], ["subventricular", 66], ["zone", 81], ["of", 86], ["the", 89], ["lateral", 93], ["ventricle", 101], [".", 110], ["In", 112], ["this", 115], ["study", 120], ["we", 126], ["examined", 129], ["the", 138], ["possibility", 142], ["to", 154], ["affect", 157], ["fate", 164], ["of", 169], ["precursor", 172], ["cells", 182], ["through", 188], ["exogenous", 196], ["manipulations", 206], [".", 219], ["The", 221], ["results", 225], ["indicate", 233], ["that", 242], ["administration", 247], ["of", 262], ["thyroid", 265], ["hormone", 273], ["and", 281], ["retinoic", 285], ["acid", 294], ["increases", 299], ["the", 309], ["expression", 313], ["of", 324], ["Ki67", 327], [",", 331], ["a", 333], ["nuclear", 335], ["antigen", 343], ["associated", 351], ["with", 362], ["cell", 367], ["proliferation", 372], [",", 385], ["and", 387], ["of", 391], ["nestin", 394], [",", 400], ["a", 402], ["marker", 404], ["protein", 411], ["for", 419], ["precursor", 423], ["cells", 433], ["in", 439], ["the", 442], ["subventricular", 446], ["zone", 461], ["of", 466], ["adult", 469], ["male", 475], ["rats", 480], [".", 484], ["Moreover", 486], [",", 494], ["retinoic", 496], ["acid", 505], ["increases", 510], ["polysialated", 520], ["-", 532], ["neural", 533], ["cell", 540], ["adhesion", 545], ["molecules", 554], ["(", 564], ["PSA", 565], ["-", 568], ["NCAM)-immunoreactivity", 569], [".", 591], ["These", 593], ["data", 599], ["suggest", 604], ["that", 612], ["nuclear", 617], ["receptor", 625], ["ligands", 634], ["are", 642], ["potential", 646], ["candidates", 656], ["for", 667], ["fate", 671], ["determination", 676], ["of", 690], ["precursor", 693], ["cells", 703], ["in", 709], ["the", 712], ["subventricular", 716], ["zone", 731], ["also", 736], ["in", 741], ["the", 744], ["adult", 748], ["brain", 754], [".", 759]]}
{"context": "Methylation of lysine 9 (K9) in the N-terminus tail of histone H3 (H3) in chromatin is associated with transcriptionally silenced genes and is mediated by histone methyltransferases. Murine G9a is a 1263 amino acid H3-K9 methyltransferase that possesses characteristic SET domain and ANK repeats. In this paper, we have used a series of green fluorescent protein-tagged deletion constructs to identify two nuclear localization signals (NLS), the first NLS embedded between amino acids 24 and 109 and the second between amino acids 394 and 401 of murine G9a. Our data show that both long and short G9a isoforms were capable of entering the nucleus to methylate chromatin. Full-length or N-terminus-deleted G9a isoforms were also catalytically active enzymes that methylated recombinant H3 or synthetic peptides representing the N-terminus tail of H3. In vitro methylation reactions using N-terminus tail peptides resulted in tri-methylation of K9 that remained processive, even in G9a enzymes that lacked an N-terminus region by deletion. Co-expression of G9a and H3 resulted in di- and tri-methylation of H3-K9, while siRNA-mediated knockdown of G9a in HeLa cells resulted in reduction of global H3-K9 di- and tri-methylation. A recombinant deletion mutant enzyme fused with maltose-binding protein (MBP-G9aDelta634) was used for steady-state kinetic analysis with various substrates and was compared with full-length G9a (G9aFL). Turnover numbers of MBP-G9aDelta634 for various substrates was approximately 3-fold less compared with G9aFL, while their Michaelis constants (K(m)) for recombinant H3 were similar. The K(AdoMet)m for MBP-G9aDelta634 was approximately 2.3-2.65 microM with various substrates. Catalytic efficiencies (kcat/K(m)) for both MBP-G9aDelta634 and G9aFL were similar, suggesting that the N-terminus is not essential for catalysis. Furthermore, mutation of conserved amino acids R1097A, W1103A, Y1120A, Y1138A and R1162A, or the metal binding C1168A in the catalytic region, resulted in catalytically impaired enzymes, thereby confirming the involvement of the C-terminus of G9a in catalysis. Thus, distinct domains modulate nuclear targeting and catalytic functions of G9a.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "e57c68a8293d462f9fdab7bb2767c729", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[46, 47]], "char_spans": [[269, 278]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["lysine", 15], ["9", 22], ["(", 24], ["K9", 25], [")", 27], ["in", 29], ["the", 32], ["N", 36], ["-", 37], ["terminus", 38], ["tail", 47], ["of", 52], ["histone", 55], ["H3", 63], ["(", 66], ["H3", 67], [")", 69], ["in", 71], ["chromatin", 74], ["is", 84], ["associated", 87], ["with", 98], ["transcriptionally", 103], ["silenced", 121], ["genes", 130], ["and", 136], ["is", 140], ["mediated", 143], ["by", 152], ["histone", 155], ["methyltransferases", 163], [".", 181], ["Murine", 183], ["G9a", 190], ["is", 194], ["a", 197], ["1263", 199], ["amino", 204], ["acid", 210], ["H3-K9", 215], ["methyltransferase", 221], ["that", 239], ["possesses", 244], ["characteristic", 254], ["SET", 269], ["domain", 273], ["and", 280], ["ANK", 284], ["repeats", 288], [".", 295], ["In", 297], ["this", 300], ["paper", 305], [",", 310], ["we", 312], ["have", 315], ["used", 320], ["a", 325], ["series", 327], ["of", 334], ["green", 337], ["fluorescent", 343], ["protein", 355], ["-", 362], ["tagged", 363], ["deletion", 370], ["constructs", 379], ["to", 390], ["identify", 393], ["two", 402], ["nuclear", 406], ["localization", 414], ["signals", 427], ["(", 435], ["NLS", 436], [")", 439], [",", 440], ["the", 442], ["first", 446], ["NLS", 452], ["embedded", 456], ["between", 465], ["amino", 473], ["acids", 479], ["24", 485], ["and", 488], ["109", 492], ["and", 496], ["the", 500], ["second", 504], ["between", 511], ["amino", 519], ["acids", 525], ["394", 531], ["and", 535], ["401", 539], ["of", 543], ["murine", 546], ["G9a", 553], [".", 556], ["Our", 558], ["data", 562], ["show", 567], ["that", 572], ["both", 577], ["long", 582], ["and", 587], ["short", 591], ["G9a", 597], ["isoforms", 601], ["were", 610], ["capable", 615], ["of", 623], ["entering", 626], ["the", 635], ["nucleus", 639], ["to", 647], ["methylate", 650], ["chromatin", 660], [".", 669], ["Full", 671], ["-", 675], ["length", 676], ["or", 683], ["N", 686], ["-", 687], ["terminus", 688], ["-", 696], ["deleted", 697], ["G9a", 705], ["isoforms", 709], ["were", 718], ["also", 723], ["catalytically", 728], ["active", 742], ["enzymes", 749], ["that", 757], ["methylated", 762], ["recombinant", 773], ["H3", 785], ["or", 788], ["synthetic", 791], ["peptides", 801], ["representing", 810], ["the", 823], ["N", 827], ["-", 828], ["terminus", 829], ["tail", 838], ["of", 843], ["H3", 846], [".", 848], ["In", 850], ["vitro", 853], ["methylation", 859], ["reactions", 871], ["using", 881], ["N", 887], ["-", 888], ["terminus", 889], ["tail", 898], ["peptides", 903], ["resulted", 912], ["in", 921], ["tri", 924], ["-", 927], ["methylation", 928], ["of", 940], ["K9", 943], ["that", 946], ["remained", 951], ["processive", 960], [",", 970], ["even", 972], ["in", 977], ["G9a", 980], ["enzymes", 984], ["that", 992], ["lacked", 997], ["an", 1004], ["N", 1007], ["-", 1008], ["terminus", 1009], ["region", 1018], ["by", 1025], ["deletion", 1028], [".", 1036], ["Co", 1038], ["-", 1040], ["expression", 1041], ["of", 1052], ["G9a", 1055], ["and", 1059], ["H3", 1063], ["resulted", 1066], ["in", 1075], ["di-", 1078], ["and", 1082], ["tri", 1086], ["-", 1089], ["methylation", 1090], ["of", 1102], ["H3-K9", 1105], [",", 1110], ["while", 1112], ["siRNA", 1118], ["-", 1123], ["mediated", 1124], ["knockdown", 1133], ["of", 1143], ["G9a", 1146], ["in", 1150], ["HeLa", 1153], ["cells", 1158], ["resulted", 1164], ["in", 1173], ["reduction", 1176], ["of", 1186], ["global", 1189], ["H3-K9", 1196], ["di-", 1202], ["and", 1206], ["tri", 1210], ["-", 1213], ["methylation", 1214], [".", 1225], ["A", 1227], ["recombinant", 1229], ["deletion", 1241], ["mutant", 1250], ["enzyme", 1257], ["fused", 1264], ["with", 1270], ["maltose", 1275], ["-", 1282], ["binding", 1283], ["protein", 1291], ["(", 1299], ["MBP", 1300], ["-", 1303], ["G9aDelta634", 1304], [")", 1315], ["was", 1317], ["used", 1321], ["for", 1326], ["steady", 1330], ["-", 1336], ["state", 1337], ["kinetic", 1343], ["analysis", 1351], ["with", 1360], ["various", 1365], ["substrates", 1373], ["and", 1384], ["was", 1388], ["compared", 1392], ["with", 1401], ["full", 1406], ["-", 1410], ["length", 1411], ["G9a", 1418], ["(", 1422], ["G9aFL", 1423], [")", 1428], [".", 1429], ["Turnover", 1431], ["numbers", 1440], ["of", 1448], ["MBP", 1451], ["-", 1454], ["G9aDelta634", 1455], ["for", 1467], ["various", 1471], ["substrates", 1479], ["was", 1490], ["approximately", 1494], ["3-fold", 1508], ["less", 1515], ["compared", 1520], ["with", 1529], ["G9aFL", 1534], [",", 1539], ["while", 1541], ["their", 1547], ["Michaelis", 1553], ["constants", 1563], ["(", 1573], ["K(m", 1574], [")", 1577], [")", 1578], ["for", 1580], ["recombinant", 1584], ["H3", 1596], ["were", 1599], ["similar", 1604], [".", 1611], ["The", 1613], ["K(AdoMet)m", 1617], ["for", 1628], ["MBP", 1632], ["-", 1635], ["G9aDelta634", 1636], ["was", 1648], ["approximately", 1652], ["2.3", 1666], ["-", 1669], ["2.65", 1670], ["microM", 1675], ["with", 1682], ["various", 1687], ["substrates", 1695], [".", 1705], ["Catalytic", 1707], ["efficiencies", 1717], ["(", 1730], ["kcat", 1731], ["/", 1735], ["K(m", 1736], [")", 1739], [")", 1740], ["for", 1742], ["both", 1746], ["MBP", 1751], ["-", 1754], ["G9aDelta634", 1755], ["and", 1767], ["G9aFL", 1771], ["were", 1777], ["similar", 1782], [",", 1789], ["suggesting", 1791], ["that", 1802], ["the", 1807], ["N", 1811], ["-", 1812], ["terminus", 1813], ["is", 1822], ["not", 1825], ["essential", 1829], ["for", 1839], ["catalysis", 1843], [".", 1852], ["Furthermore", 1854], [",", 1865], ["mutation", 1867], ["of", 1876], ["conserved", 1879], ["amino", 1889], ["acids", 1895], ["R1097A", 1901], [",", 1907], ["W1103A", 1909], [",", 1915], ["Y1120A", 1917], [",", 1923], ["Y1138A", 1925], ["and", 1932], ["R1162A", 1936], [",", 1942], ["or", 1944], ["the", 1947], ["metal", 1951], ["binding", 1957], ["C1168A", 1965], ["in", 1972], ["the", 1975], ["catalytic", 1979], ["region", 1989], [",", 1995], ["resulted", 1997], ["in", 2006], ["catalytically", 2009], ["impaired", 2023], ["enzymes", 2032], [",", 2039], ["thereby", 2041], ["confirming", 2049], ["the", 2060], ["involvement", 2064], ["of", 2076], ["the", 2079], ["C", 2083], ["-", 2084], ["terminus", 2085], ["of", 2094], ["G9a", 2097], ["in", 2101], ["catalysis", 2104], [".", 2113], ["Thus", 2115], [",", 2119], ["distinct", 2121], ["domains", 2130], ["modulate", 2138], ["nuclear", 2147], ["targeting", 2155], ["and", 2165], ["catalytic", 2169], ["functions", 2179], ["of", 2189], ["G9a", 2192], [".", 2195]]}
{"context": "In yeast, the macromolecular complex Set1/COMPASS is capable of methylating H3K4, a posttranslational modification associated with actively transcribed genes. There is only one Set1 in yeast; yet in mammalian cells there are multiple H3K4 methylases, including Set1A/B, forming human COMPASS complexes, and MLL1-4, forming human COMPASS-like complexes. We have shown that Wdr82, which associates with chromatin in a histone H2B ubiquitination-dependent manner, is a specific component of Set1 complexes but not that of MLL1-4 complexes. RNA interference-mediated knockdown of Wdr82 results in a reduction in the H3K4 trimethylation levels, although these cells still possess active MLL complexes. Comprehensive in vitro enzymatic studies with Set1 and MLL complexes demonstrated that the Set1 complex is a more robust H3K4 trimethylase in vitro than the MLL complexes. Given our in vivo and in vitro observations, it appears that the human Set1 complex plays a more widespread role in H3K4 trimethylation than do the MLL complexes in mammalian cells.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "66e99ba7d17c47c9b3445238952287b4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[37, 37], [173, 173], [11, 11], [142, 142], [110, 110]], "char_spans": [[234, 237], [985, 988], [76, 79], [818, 821], [612, 615]]}]}], "context_tokens": [["In", 0], ["yeast", 3], [",", 8], ["the", 10], ["macromolecular", 14], ["complex", 29], ["Set1/COMPASS", 37], ["is", 50], ["capable", 53], ["of", 61], ["methylating", 64], ["H3K4", 76], [",", 80], ["a", 82], ["posttranslational", 84], ["modification", 102], ["associated", 115], ["with", 126], ["actively", 131], ["transcribed", 140], ["genes", 152], [".", 157], ["There", 159], ["is", 165], ["only", 168], ["one", 173], ["Set1", 177], ["in", 182], ["yeast", 185], [";", 190], ["yet", 192], ["in", 196], ["mammalian", 199], ["cells", 209], ["there", 215], ["are", 221], ["multiple", 225], ["H3K4", 234], ["methylases", 239], [",", 249], ["including", 251], ["Set1A", 261], ["/", 266], ["B", 267], [",", 268], ["forming", 270], ["human", 278], ["COMPASS", 284], ["complexes", 292], [",", 301], ["and", 303], ["MLL1", 307], ["-", 311], ["4", 312], [",", 313], ["forming", 315], ["human", 323], ["COMPASS", 329], ["-", 336], ["like", 337], ["complexes", 342], [".", 351], ["We", 353], ["have", 356], ["shown", 361], ["that", 367], ["Wdr82", 372], [",", 377], ["which", 379], ["associates", 385], ["with", 396], ["chromatin", 401], ["in", 411], ["a", 414], ["histone", 416], ["H2B", 424], ["ubiquitination", 428], ["-", 442], ["dependent", 443], ["manner", 453], [",", 459], ["is", 461], ["a", 464], ["specific", 466], ["component", 475], ["of", 485], ["Set1", 488], ["complexes", 493], ["but", 503], ["not", 507], ["that", 511], ["of", 516], ["MLL1", 519], ["-", 523], ["4", 524], ["complexes", 526], [".", 535], ["RNA", 537], ["interference", 541], ["-", 553], ["mediated", 554], ["knockdown", 563], ["of", 573], ["Wdr82", 576], ["results", 582], ["in", 590], ["a", 593], ["reduction", 595], ["in", 605], ["the", 608], ["H3K4", 612], ["trimethylation", 617], ["levels", 632], [",", 638], ["although", 640], ["these", 649], ["cells", 655], ["still", 661], ["possess", 667], ["active", 675], ["MLL", 682], ["complexes", 686], [".", 695], ["Comprehensive", 697], ["in", 711], ["vitro", 714], ["enzymatic", 720], ["studies", 730], ["with", 738], ["Set1", 743], ["and", 748], ["MLL", 752], ["complexes", 756], ["demonstrated", 766], ["that", 779], ["the", 784], ["Set1", 788], ["complex", 793], ["is", 801], ["a", 804], ["more", 806], ["robust", 811], ["H3K4", 818], ["trimethylase", 823], ["in", 836], ["vitro", 839], ["than", 845], ["the", 850], ["MLL", 854], ["complexes", 858], [".", 867], ["Given", 869], ["our", 875], ["in", 879], ["vivo", 882], ["and", 887], ["in", 891], ["vitro", 894], ["observations", 900], [",", 912], ["it", 914], ["appears", 917], ["that", 925], ["the", 930], ["human", 934], ["Set1", 940], ["complex", 945], ["plays", 953], ["a", 959], ["more", 961], ["widespread", 966], ["role", 977], ["in", 982], ["H3K4", 985], ["trimethylation", 990], ["than", 1005], ["do", 1010], ["the", 1013], ["MLL", 1017], ["complexes", 1021], ["in", 1031], ["mammalian", 1034], ["cells", 1044], [".", 1049]]}
{"context": "The Shprintzen-Goldberg syndrome is an extremely rare syndrome with a characteristic face. This is one of a group of disorders characterized by craniosynostosis and marfanoid features. The aim of this study was to present a new sporadic case of the syndrome and describe in detail the findings at the maxillofacial region.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "0e334455b93e49ba8dc2280657d82443", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[25, 25]], "char_spans": [[144, 159]]}]}], "context_tokens": [["The", 0], ["Shprintzen", 4], ["-", 14], ["Goldberg", 15], ["syndrome", 24], ["is", 33], ["an", 36], ["extremely", 39], ["rare", 49], ["syndrome", 54], ["with", 63], ["a", 68], ["characteristic", 70], ["face", 85], [".", 89], ["This", 91], ["is", 96], ["one", 99], ["of", 103], ["a", 106], ["group", 108], ["of", 114], ["disorders", 117], ["characterized", 127], ["by", 141], ["craniosynostosis", 144], ["and", 161], ["marfanoid", 165], ["features", 175], [".", 183], ["The", 185], ["aim", 189], ["of", 193], ["this", 196], ["study", 201], ["was", 207], ["to", 211], ["present", 214], ["a", 222], ["new", 224], ["sporadic", 228], ["case", 237], ["of", 242], ["the", 245], ["syndrome", 249], ["and", 258], ["describe", 262], ["in", 271], ["detail", 274], ["the", 281], ["findings", 285], ["at", 294], ["the", 297], ["maxillofacial", 301], ["region", 315], [".", 321]]}
{"context": "Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) is a common condition characterized by an irresistible urge to move the legs, concomitant with an unpleasant sensation in the lower limbs, which is typically relieved by movement. Symptoms occur predominantly at rest and prevail in the afternoon or evening. Treatment of patients with RLS/WED is indicated for those patients who suffer from clinically relevant symptoms. The management of mild forms of RLS/WED is mainly based on dopamine agonists (DA) therapy (including pramipexole and ropinirole) and \u03b1-2-\u03b4 calcium-channel ligand. Nevertheless, with passing of time, symptoms tend to become more severe and the patient can eventually develop pharmacoresistance. Furthermore, long-term treatment with dopaminergic agents may be complicated by the development of augmentation, which is defined by an increase in the severity and frequency of RLS/WED symptoms despite adequate treatment. Here, we discuss which are the best therapeutic options when RLS/WED becomes intractable, with a focus on advantages and side effects of the available medications. Prevention strategies include managing lifestyle changes and a good sleep hygiene. Different drug options are available. Switching to longer-acting dopaminergic agents may be a possibility if the patient is well-tolerating DA treatment. An association with \u03b1-2-\u03b4 calcium-channel ligand is another first-line approach. In refractory RLS/WED, opioids such as oxycodone-naloxone have demonstrated good efficacy. Other pharmacological approaches include IV iron, benzodiazepines such as clonazepam, and antiepileptic drugs, with different level of evidence of efficacy. Therefore, the final decision regarding the agent to use in treating severe RLS/WED symptoms should be tailored to the patient, taking into account the symptomatology, comorbidities, the availability of treatment and the history of the disease.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "57c7f4ca7dcc421f8be58691a3878467", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["Legs", 9], ["Syndrome", 14], ["/", 22], ["Willis", 23], ["-", 29], ["Ekbom", 30], ["Disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["is", 54], ["a", 57], ["common", 59], ["condition", 66], ["characterized", 76], ["by", 90], ["an", 93], ["irresistible", 96], ["urge", 109], ["to", 114], ["move", 117], ["the", 122], ["legs", 126], [",", 130], ["concomitant", 132], ["with", 144], ["an", 149], ["unpleasant", 152], ["sensation", 163], ["in", 173], ["the", 176], ["lower", 180], ["limbs", 186], [",", 191], ["which", 193], ["is", 199], ["typically", 202], ["relieved", 212], ["by", 221], ["movement", 224], [".", 232], ["Symptoms", 234], ["occur", 243], ["predominantly", 249], ["at", 263], ["rest", 266], ["and", 271], ["prevail", 275], ["in", 283], ["the", 286], ["afternoon", 290], ["or", 300], ["evening", 303], [".", 310], ["Treatment", 312], ["of", 322], ["patients", 325], ["with", 334], ["RLS", 339], ["/", 342], ["WED", 343], ["is", 347], ["indicated", 350], ["for", 360], ["those", 364], ["patients", 370], ["who", 379], ["suffer", 383], ["from", 390], ["clinically", 395], ["relevant", 406], ["symptoms", 415], [".", 423], ["The", 425], ["management", 429], ["of", 440], ["mild", 443], ["forms", 448], ["of", 454], ["RLS", 457], ["/", 460], ["WED", 461], ["is", 465], ["mainly", 468], ["based", 475], ["on", 481], ["dopamine", 484], ["agonists", 493], ["(", 502], ["DA", 503], [")", 505], ["therapy", 507], ["(", 515], ["including", 516], ["pramipexole", 526], ["and", 538], ["ropinirole", 542], [")", 552], ["and", 554], ["\u03b1-2-\u03b4", 558], ["calcium", 564], ["-", 571], ["channel", 572], ["ligand", 580], [".", 586], ["Nevertheless", 588], [",", 600], ["with", 602], ["passing", 607], ["of", 615], ["time", 618], [",", 622], ["symptoms", 624], ["tend", 633], ["to", 638], ["become", 641], ["more", 648], ["severe", 653], ["and", 660], ["the", 664], ["patient", 668], ["can", 676], ["eventually", 680], ["develop", 691], ["pharmacoresistance", 699], [".", 717], ["Furthermore", 719], [",", 730], ["long", 732], ["-", 736], ["term", 737], ["treatment", 742], ["with", 752], ["dopaminergic", 757], ["agents", 770], ["may", 777], ["be", 781], ["complicated", 784], ["by", 796], ["the", 799], ["development", 803], ["of", 815], ["augmentation", 818], [",", 830], ["which", 832], ["is", 838], ["defined", 841], ["by", 849], ["an", 852], ["increase", 855], ["in", 864], ["the", 867], ["severity", 871], ["and", 880], ["frequency", 884], ["of", 894], ["RLS", 897], ["/", 900], ["WED", 901], ["symptoms", 905], ["despite", 914], ["adequate", 922], ["treatment", 931], [".", 940], ["Here", 942], [",", 946], ["we", 948], ["discuss", 951], ["which", 959], ["are", 965], ["the", 969], ["best", 973], ["therapeutic", 978], ["options", 990], ["when", 998], ["RLS", 1003], ["/", 1006], ["WED", 1007], ["becomes", 1011], ["intractable", 1019], [",", 1030], ["with", 1032], ["a", 1037], ["focus", 1039], ["on", 1045], ["advantages", 1048], ["and", 1059], ["side", 1063], ["effects", 1068], ["of", 1076], ["the", 1079], ["available", 1083], ["medications", 1093], [".", 1104], ["Prevention", 1106], ["strategies", 1117], ["include", 1128], ["managing", 1136], ["lifestyle", 1145], ["changes", 1155], ["and", 1163], ["a", 1167], ["good", 1169], ["sleep", 1174], ["hygiene", 1180], [".", 1187], ["Different", 1189], ["drug", 1199], ["options", 1204], ["are", 1212], ["available", 1216], [".", 1225], ["Switching", 1227], ["to", 1237], ["longer", 1240], ["-", 1246], ["acting", 1247], ["dopaminergic", 1254], ["agents", 1267], ["may", 1274], ["be", 1278], ["a", 1281], ["possibility", 1283], ["if", 1295], ["the", 1298], ["patient", 1302], ["is", 1310], ["well", 1313], ["-", 1317], ["tolerating", 1318], ["DA", 1329], ["treatment", 1332], [".", 1341], ["An", 1343], ["association", 1346], ["with", 1358], ["\u03b1-2-\u03b4", 1363], ["calcium", 1369], ["-", 1376], ["channel", 1377], ["ligand", 1385], ["is", 1392], ["another", 1395], ["first", 1403], ["-", 1408], ["line", 1409], ["approach", 1414], [".", 1422], ["In", 1424], ["refractory", 1427], ["RLS", 1438], ["/", 1441], ["WED", 1442], [",", 1445], ["opioids", 1447], ["such", 1455], ["as", 1460], ["oxycodone", 1463], ["-", 1472], ["naloxone", 1473], ["have", 1482], ["demonstrated", 1487], ["good", 1500], ["efficacy", 1505], [".", 1513], ["Other", 1515], ["pharmacological", 1521], ["approaches", 1537], ["include", 1548], ["IV", 1556], ["iron", 1559], [",", 1563], ["benzodiazepines", 1565], ["such", 1581], ["as", 1586], ["clonazepam", 1589], [",", 1599], ["and", 1601], ["antiepileptic", 1605], ["drugs", 1619], [",", 1624], ["with", 1626], ["different", 1631], ["level", 1641], ["of", 1647], ["evidence", 1650], ["of", 1659], ["efficacy", 1662], [".", 1670], ["Therefore", 1672], [",", 1681], ["the", 1683], ["final", 1687], ["decision", 1693], ["regarding", 1702], ["the", 1712], ["agent", 1716], ["to", 1722], ["use", 1725], ["in", 1729], ["treating", 1732], ["severe", 1741], ["RLS", 1748], ["/", 1751], ["WED", 1752], ["symptoms", 1756], ["should", 1765], ["be", 1772], ["tailored", 1775], ["to", 1784], ["the", 1787], ["patient", 1791], [",", 1798], ["taking", 1800], ["into", 1807], ["account", 1812], ["the", 1820], ["symptomatology", 1824], [",", 1838], ["comorbidities", 1840], [",", 1853], ["the", 1855], ["availability", 1859], ["of", 1872], ["treatment", 1875], ["and", 1885], ["the", 1889], ["history", 1893], ["of", 1901], ["the", 1904], ["disease", 1908], [".", 1915]]}
{"context": "The gene encoding the ribosomal protein S19 (RPS19) is frequently mutated in Diamond-Blackfan anemia (DBA), a congenital erythroblastopenia. The consequence of these mutations on the onset of the disease remains obscure. Here, we show that RPS19 plays an essential role in biogenesis of the 40S small ribosomal subunit in human cells. Knockdown of RPS19 expression by siRNAs impairs 18S rRNA synthesis and formation of 40S subunits and induces apoptosis in HeLa cells. Pre-rRNA processing is altered, which leads to an arrest in the maturation of precursors to the 18S rRNA. Under these conditions, pre-40S particles are not exported to the cytoplasm and accumulate in the nucleoplasm of the cells in perinuclear dots. Consistently, we find that ribosome biogenesis and nucleolar organization is altered in skin fibroblasts from DBA patients bearing mutations in the RPS19 gene. In addition, maturation of the 18S rRNA is also perturbed in cells from a patient bearing no RPS19-related mutation. These results support the hypothesis that DBA is directly related to a defect in ribosome biogenesis and indicate that yet to be discovered DBA-related genes may be involved in the synthesis of the ribosomal subunits.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "85af34b4c81f4eee8ca3336339fad285", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[14, 17]], "char_spans": [[77, 99]]}, {"text": "DBA", "token_spans": [[182, 182], [19, 19], [199, 199], [146, 146]], "char_spans": [[1038, 1040], [102, 104], [1136, 1138], [829, 831]]}]}], "context_tokens": [["The", 0], ["gene", 4], ["encoding", 9], ["the", 18], ["ribosomal", 22], ["protein", 32], ["S19", 40], ["(", 44], ["RPS19", 45], [")", 50], ["is", 52], ["frequently", 55], ["mutated", 66], ["in", 74], ["Diamond", 77], ["-", 84], ["Blackfan", 85], ["anemia", 94], ["(", 101], ["DBA", 102], [")", 105], [",", 106], ["a", 108], ["congenital", 110], ["erythroblastopenia", 121], [".", 139], ["The", 141], ["consequence", 145], ["of", 157], ["these", 160], ["mutations", 166], ["on", 176], ["the", 179], ["onset", 183], ["of", 189], ["the", 192], ["disease", 196], ["remains", 204], ["obscure", 212], [".", 219], ["Here", 221], [",", 225], ["we", 227], ["show", 230], ["that", 235], ["RPS19", 240], ["plays", 246], ["an", 252], ["essential", 255], ["role", 265], ["in", 270], ["biogenesis", 273], ["of", 284], ["the", 287], ["40S", 291], ["small", 295], ["ribosomal", 301], ["subunit", 311], ["in", 319], ["human", 322], ["cells", 328], [".", 333], ["Knockdown", 335], ["of", 345], ["RPS19", 348], ["expression", 354], ["by", 365], ["siRNAs", 368], ["impairs", 375], ["18S", 383], ["rRNA", 387], ["synthesis", 392], ["and", 402], ["formation", 406], ["of", 416], ["40S", 419], ["subunits", 423], ["and", 432], ["induces", 436], ["apoptosis", 444], ["in", 454], ["HeLa", 457], ["cells", 462], [".", 467], ["Pre", 469], ["-", 472], ["rRNA", 473], ["processing", 478], ["is", 489], ["altered", 492], [",", 499], ["which", 501], ["leads", 507], ["to", 513], ["an", 516], ["arrest", 519], ["in", 526], ["the", 529], ["maturation", 533], ["of", 544], ["precursors", 547], ["to", 558], ["the", 561], ["18S", 565], ["rRNA", 569], [".", 573], ["Under", 575], ["these", 581], ["conditions", 587], [",", 597], ["pre-40S", 599], ["particles", 607], ["are", 617], ["not", 621], ["exported", 625], ["to", 634], ["the", 637], ["cytoplasm", 641], ["and", 651], ["accumulate", 655], ["in", 666], ["the", 669], ["nucleoplasm", 673], ["of", 685], ["the", 688], ["cells", 692], ["in", 698], ["perinuclear", 701], ["dots", 713], [".", 717], ["Consistently", 719], [",", 731], ["we", 733], ["find", 736], ["that", 741], ["ribosome", 746], ["biogenesis", 755], ["and", 766], ["nucleolar", 770], ["organization", 780], ["is", 793], ["altered", 796], ["in", 804], ["skin", 807], ["fibroblasts", 812], ["from", 824], ["DBA", 829], ["patients", 833], ["bearing", 842], ["mutations", 850], ["in", 860], ["the", 863], ["RPS19", 867], ["gene", 873], [".", 877], ["In", 879], ["addition", 882], [",", 890], ["maturation", 892], ["of", 903], ["the", 906], ["18S", 910], ["rRNA", 914], ["is", 919], ["also", 922], ["perturbed", 927], ["in", 937], ["cells", 940], ["from", 946], ["a", 951], ["patient", 953], ["bearing", 961], ["no", 969], ["RPS19-related", 972], ["mutation", 986], [".", 994], ["These", 996], ["results", 1002], ["support", 1010], ["the", 1018], ["hypothesis", 1022], ["that", 1033], ["DBA", 1038], ["is", 1042], ["directly", 1045], ["related", 1054], ["to", 1062], ["a", 1065], ["defect", 1067], ["in", 1074], ["ribosome", 1077], ["biogenesis", 1086], ["and", 1097], ["indicate", 1101], ["that", 1110], ["yet", 1115], ["to", 1119], ["be", 1122], ["discovered", 1125], ["DBA", 1136], ["-", 1139], ["related", 1140], ["genes", 1148], ["may", 1154], ["be", 1158], ["involved", 1161], ["in", 1170], ["the", 1173], ["synthesis", 1177], ["of", 1187], ["the", 1190], ["ribosomal", 1194], ["subunits", 1204], [".", 1212]]}
{"context": "Six persons with the classical Angelman syndrome (AS) phenotype and de novo deletions of chromosome 15q11-q13 were studied to determine the parental origin of the chromosome deletion. Four of the 6 patients had informative cytogenetic studies and all demonstrated maternal inheritance of the deletion. These findings, together with other reported cases of the origin of the chromosome 15 deletion in AS, suggest that deletion of the maternally contributed chromosome leads to the AS phenotype. This contrasts with the Prader-Willi syndrome (PWS) in which a similar deletion of the paternally contributed chromosome 15 is observed. In deletion cases, a parental gamete effect such as genomic imprinting may be the best model to explain why apparently identical 15q11-q13 deletions may develop the different phenotypes of AS or PWS.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "03aa34b985ac43f7b28e110d51d52e44", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[85, 88]], "char_spans": [[518, 538]]}]}], "context_tokens": [["Six", 0], ["persons", 4], ["with", 12], ["the", 17], ["classical", 21], ["Angelman", 31], ["syndrome", 40], ["(", 49], ["AS", 50], [")", 52], ["phenotype", 54], ["and", 64], ["de", 68], ["novo", 71], ["deletions", 76], ["of", 86], ["chromosome", 89], ["15q11-q13", 100], ["were", 110], ["studied", 115], ["to", 123], ["determine", 126], ["the", 136], ["parental", 140], ["origin", 149], ["of", 156], ["the", 159], ["chromosome", 163], ["deletion", 174], [".", 182], ["Four", 184], ["of", 189], ["the", 192], ["6", 196], ["patients", 198], ["had", 207], ["informative", 211], ["cytogenetic", 223], ["studies", 235], ["and", 243], ["all", 247], ["demonstrated", 251], ["maternal", 264], ["inheritance", 273], ["of", 285], ["the", 288], ["deletion", 292], [".", 300], ["These", 302], ["findings", 308], [",", 316], ["together", 318], ["with", 327], ["other", 332], ["reported", 338], ["cases", 347], ["of", 353], ["the", 356], ["origin", 360], ["of", 367], ["the", 370], ["chromosome", 374], ["15", 385], ["deletion", 388], ["in", 397], ["AS", 400], [",", 402], ["suggest", 404], ["that", 412], ["deletion", 417], ["of", 426], ["the", 429], ["maternally", 433], ["contributed", 444], ["chromosome", 456], ["leads", 467], ["to", 473], ["the", 476], ["AS", 480], ["phenotype", 483], [".", 492], ["This", 494], ["contrasts", 499], ["with", 509], ["the", 514], ["Prader", 518], ["-", 524], ["Willi", 525], ["syndrome", 531], ["(", 540], ["PWS", 541], [")", 544], ["in", 546], ["which", 549], ["a", 555], ["similar", 557], ["deletion", 565], ["of", 574], ["the", 577], ["paternally", 581], ["contributed", 592], ["chromosome", 604], ["15", 615], ["is", 618], ["observed", 621], [".", 629], ["In", 631], ["deletion", 634], ["cases", 643], [",", 648], ["a", 650], ["parental", 652], ["gamete", 661], ["effect", 668], ["such", 675], ["as", 680], ["genomic", 683], ["imprinting", 691], ["may", 702], ["be", 706], ["the", 709], ["best", 713], ["model", 718], ["to", 724], ["explain", 727], ["why", 735], ["apparently", 739], ["identical", 750], ["15q11-q13", 760], ["deletions", 770], ["may", 780], ["develop", 784], ["the", 792], ["different", 796], ["phenotypes", 806], ["of", 817], ["AS", 820], ["or", 823], ["PWS", 826], [".", 829]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is characterized by chromatin relaxation of the D4Z4 macrosatellite array on chromosome 4 and expression of the D4Z4-encoded DUX4 gene in skeletal muscle. The more common form, autosomal dominant FSHD1, is caused by contraction of the D4Z4 array, whereas the genetic determinants and inheritance of D4Z4 array contraction-independent FSHD2 are unclear. Here, we show that mutations in SMCHD1 (encoding structural maintenance of chromosomes flexible hinge domain containing 1) on chromosome 18 reduce SMCHD1 protein levels and segregate with genome-wide D4Z4 CpG hypomethylation in human kindreds. FSHD2 occurs in individuals who inherited both the SMCHD1 mutation and a normal-sized D4Z4 array on a chromosome 4 haplotype permissive for DUX4 expression. Reducing SMCHD1 levels in skeletal muscle results in D4Z4 contraction-independent DUX4 expression. Our study identifies SMCHD1 as an epigenetic modifier of the D4Z4 metastable epiallele and as a causal genetic determinant of FSHD2 and possibly other human diseases subject to epigenetic regulation.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "a9464ddc76874f33bc3080db5c5c07b9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[34, 35]], "char_spans": [[214, 231]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["characterized", 40], ["by", 54], ["chromatin", 57], ["relaxation", 67], ["of", 78], ["the", 81], ["D4Z4", 85], ["macrosatellite", 90], ["array", 105], ["on", 111], ["chromosome", 114], ["4", 125], ["and", 127], ["expression", 131], ["of", 142], ["the", 145], ["D4Z4-encoded", 149], ["DUX4", 162], ["gene", 167], ["in", 172], ["skeletal", 175], ["muscle", 184], [".", 190], ["The", 192], ["more", 196], ["common", 201], ["form", 208], [",", 212], ["autosomal", 214], ["dominant", 224], ["FSHD1", 233], [",", 238], ["is", 240], ["caused", 243], ["by", 250], ["contraction", 253], ["of", 265], ["the", 268], ["D4Z4", 272], ["array", 277], [",", 282], ["whereas", 284], ["the", 292], ["genetic", 296], ["determinants", 304], ["and", 317], ["inheritance", 321], ["of", 333], ["D4Z4", 336], ["array", 341], ["contraction", 347], ["-", 358], ["independent", 359], ["FSHD2", 371], ["are", 377], ["unclear", 381], [".", 388], ["Here", 390], [",", 394], ["we", 396], ["show", 399], ["that", 404], ["mutations", 409], ["in", 419], ["SMCHD1", 422], ["(", 429], ["encoding", 430], ["structural", 439], ["maintenance", 450], ["of", 462], ["chromosomes", 465], ["flexible", 477], ["hinge", 486], ["domain", 492], ["containing", 499], ["1", 510], [")", 511], ["on", 513], ["chromosome", 516], ["18", 527], ["reduce", 530], ["SMCHD1", 537], ["protein", 544], ["levels", 552], ["and", 559], ["segregate", 563], ["with", 573], ["genome", 578], ["-", 584], ["wide", 585], ["D4Z4", 590], ["CpG", 595], ["hypomethylation", 599], ["in", 615], ["human", 618], ["kindreds", 624], [".", 632], ["FSHD2", 634], ["occurs", 640], ["in", 647], ["individuals", 650], ["who", 662], ["inherited", 666], ["both", 676], ["the", 681], ["SMCHD1", 685], ["mutation", 692], ["and", 701], ["a", 705], ["normal", 707], ["-", 713], ["sized", 714], ["D4Z4", 720], ["array", 725], ["on", 731], ["a", 734], ["chromosome", 736], ["4", 747], ["haplotype", 749], ["permissive", 759], ["for", 770], ["DUX4", 774], ["expression", 779], [".", 789], ["Reducing", 791], ["SMCHD1", 800], ["levels", 807], ["in", 814], ["skeletal", 817], ["muscle", 826], ["results", 833], ["in", 841], ["D4Z4", 844], ["contraction", 849], ["-", 860], ["independent", 861], ["DUX4", 873], ["expression", 878], [".", 888], ["Our", 890], ["study", 894], ["identifies", 900], ["SMCHD1", 911], ["as", 918], ["an", 921], ["epigenetic", 924], ["modifier", 935], ["of", 944], ["the", 947], ["D4Z4", 951], ["metastable", 956], ["epiallele", 967], ["and", 977], ["as", 981], ["a", 984], ["causal", 986], ["genetic", 993], ["determinant", 1001], ["of", 1013], ["FSHD2", 1016], ["and", 1022], ["possibly", 1026], ["other", 1035], ["human", 1041], ["diseases", 1047], ["subject", 1056], ["to", 1064], ["epigenetic", 1067], ["regulation", 1078], [".", 1088]]}
{"context": "With the avalanche of biological sequences generated in the post-genomic age, one of the most challenging problems in computational biology is how to effectively formulate the sequence of a biological sample (such as DNA, RNA or protein) with a discrete model or a vector that can effectively reflect its sequence pattern information or capture its key features concerned. Although several web servers and stand-alone tools were developed to address this problem, all these tools, however, can only handle one type of samples. Furthermore, the number of their built-in properties is limited, and hence it is often difficult for users to formulate the biological sequences according to their desired features or properties. In this article, with a much larger number of built-in properties, we are to propose a much more flexible web server called Pse-in-One (http://bioinformatics.hitsz.edu.cn/Pse-in-One/), which can, through its 28 different modes, generate nearly all the possible feature vectors for DNA, RNA and protein sequences. Particularly, it can also generate those feature vectors with the properties defined by users themselves. These feature vectors can be easily combined with machine-learning algorithms to develop computational predictors and analysis methods for various tasks in bioinformatics and system biology. It is anticipated that the Pse-in-One web server will become a very useful tool in computational proteomics, genomics, as well as biological sequence analysis. Moreover, to maximize users' convenience, its stand-alone version can also be downloaded from http://bioinformatics.hitsz.edu.cn/Pse-in-One/download/, and directly run on Windows, Linux, Unix and Mac OS.", "qas": [{"question": "Which server is used for generating modes of pseudo components of DNA, RNA and protein sequences?", "answers": ["Pse-in-One"], "qid": "6f46d726a7c249e68c5a8726f672c870", "question_tokens": [["Which", 0], ["server", 6], ["is", 13], ["used", 16], ["for", 21], ["generating", 25], ["modes", 36], ["of", 42], ["pseudo", 45], ["components", 52], ["of", 63], ["DNA", 66], [",", 69], ["RNA", 71], ["and", 75], ["protein", 79], ["sequences", 87], ["?", 96]], "detected_answers": [{"text": "Pse-in-One", "token_spans": [[155, 159], [238, 242]], "char_spans": [[847, 856], [1360, 1369]]}]}], "context_tokens": [["With", 0], ["the", 5], ["avalanche", 9], ["of", 19], ["biological", 22], ["sequences", 33], ["generated", 43], ["in", 53], ["the", 56], ["post", 60], ["-", 64], ["genomic", 65], ["age", 73], [",", 76], ["one", 78], ["of", 82], ["the", 85], ["most", 89], ["challenging", 94], ["problems", 106], ["in", 115], ["computational", 118], ["biology", 132], ["is", 140], ["how", 143], ["to", 147], ["effectively", 150], ["formulate", 162], ["the", 172], ["sequence", 176], ["of", 185], ["a", 188], ["biological", 190], ["sample", 201], ["(", 208], ["such", 209], ["as", 214], ["DNA", 217], [",", 220], ["RNA", 222], ["or", 226], ["protein", 229], [")", 236], ["with", 238], ["a", 243], ["discrete", 245], ["model", 254], ["or", 260], ["a", 263], ["vector", 265], ["that", 272], ["can", 277], ["effectively", 281], ["reflect", 293], ["its", 301], ["sequence", 305], ["pattern", 314], ["information", 322], ["or", 334], ["capture", 337], ["its", 345], ["key", 349], ["features", 353], ["concerned", 362], [".", 371], ["Although", 373], ["several", 382], ["web", 390], ["servers", 394], ["and", 402], ["stand", 406], ["-", 411], ["alone", 412], ["tools", 418], ["were", 424], ["developed", 429], ["to", 439], ["address", 442], ["this", 450], ["problem", 455], [",", 462], ["all", 464], ["these", 468], ["tools", 474], [",", 479], ["however", 481], [",", 488], ["can", 490], ["only", 494], ["handle", 499], ["one", 506], ["type", 510], ["of", 515], ["samples", 518], [".", 525], ["Furthermore", 527], [",", 538], ["the", 540], ["number", 544], ["of", 551], ["their", 554], ["built", 560], ["-", 565], ["in", 566], ["properties", 569], ["is", 580], ["limited", 583], [",", 590], ["and", 592], ["hence", 596], ["it", 602], ["is", 605], ["often", 608], ["difficult", 614], ["for", 624], ["users", 628], ["to", 634], ["formulate", 637], ["the", 647], ["biological", 651], ["sequences", 662], ["according", 672], ["to", 682], ["their", 685], ["desired", 691], ["features", 699], ["or", 708], ["properties", 711], [".", 721], ["In", 723], ["this", 726], ["article", 731], [",", 738], ["with", 740], ["a", 745], ["much", 747], ["larger", 752], ["number", 759], ["of", 766], ["built", 769], ["-", 774], ["in", 775], ["properties", 778], [",", 788], ["we", 790], ["are", 793], ["to", 797], ["propose", 800], ["a", 808], ["much", 810], ["more", 815], ["flexible", 820], ["web", 829], ["server", 833], ["called", 840], ["Pse", 847], ["-", 850], ["in", 851], ["-", 853], ["One", 854], ["(", 858], ["http://bioinformatics.hitsz.edu.cn/Pse-in-One/", 859], [")", 905], [",", 906], ["which", 908], ["can", 914], [",", 917], ["through", 919], ["its", 927], ["28", 931], ["different", 934], ["modes", 944], [",", 949], ["generate", 951], ["nearly", 960], ["all", 967], ["the", 971], ["possible", 975], ["feature", 984], ["vectors", 992], ["for", 1000], ["DNA", 1004], [",", 1007], ["RNA", 1009], ["and", 1013], ["protein", 1017], ["sequences", 1025], [".", 1034], ["Particularly", 1036], [",", 1048], ["it", 1050], ["can", 1053], ["also", 1057], ["generate", 1062], ["those", 1071], ["feature", 1077], ["vectors", 1085], ["with", 1093], ["the", 1098], ["properties", 1102], ["defined", 1113], ["by", 1121], ["users", 1124], ["themselves", 1130], [".", 1140], ["These", 1142], ["feature", 1148], ["vectors", 1156], ["can", 1164], ["be", 1168], ["easily", 1171], ["combined", 1178], ["with", 1187], ["machine", 1192], ["-", 1199], ["learning", 1200], ["algorithms", 1209], ["to", 1220], ["develop", 1223], ["computational", 1231], ["predictors", 1245], ["and", 1256], ["analysis", 1260], ["methods", 1269], ["for", 1277], ["various", 1281], ["tasks", 1289], ["in", 1295], ["bioinformatics", 1298], ["and", 1313], ["system", 1317], ["biology", 1324], [".", 1331], ["It", 1333], ["is", 1336], ["anticipated", 1339], ["that", 1351], ["the", 1356], ["Pse", 1360], ["-", 1363], ["in", 1364], ["-", 1366], ["One", 1367], ["web", 1371], ["server", 1375], ["will", 1382], ["become", 1387], ["a", 1394], ["very", 1396], ["useful", 1401], ["tool", 1408], ["in", 1413], ["computational", 1416], ["proteomics", 1430], [",", 1440], ["genomics", 1442], [",", 1450], ["as", 1452], ["well", 1455], ["as", 1460], ["biological", 1463], ["sequence", 1474], ["analysis", 1483], [".", 1491], ["Moreover", 1493], [",", 1501], ["to", 1503], ["maximize", 1506], ["users", 1515], ["'", 1520], ["convenience", 1522], [",", 1533], ["its", 1535], ["stand", 1539], ["-", 1544], ["alone", 1545], ["version", 1551], ["can", 1559], ["also", 1563], ["be", 1568], ["downloaded", 1571], ["from", 1582], ["http://bioinformatics.hitsz.edu.cn/Pse-in-One/download/", 1587], [",", 1642], ["and", 1644], ["directly", 1648], ["run", 1657], ["on", 1661], ["Windows", 1664], [",", 1671], ["Linux", 1673], [",", 1678], ["Unix", 1680], ["and", 1685], ["Mac", 1689], ["OS", 1693], [".", 1695]]}
{"context": "Past studies have documented a crosstalk between H2B ubiquitylation (H2Bub) and H3K4 methylation, but little (if any) direct evidence exists explaining the mechanism underlying H2Bub-dependent H3K4 methylation on chromatin templates. Here, we took advantage of an in vitro histone methyltransferase assay employing a reconstituted yeast Set1 complex (ySet1C) and a recombinant chromatin template containing fully ubiquitylated H2B to gain valuable insights. Combined with genetic analyses, we demonstrate that the n-SET domain within Set1, but not Swd2, is essential for H2Bub-dependent H3K4 methylation. Spp1, a homolog of human CFP1, is conditionally involved in this crosstalk. Our findings extend to the human Set1 complex, underscoring the conserved nature of this disease-relevant crosstalk pathway. As not all members of the H3K4 methyltransferase family contain n-SET domains, our studies draw attention to the n-SET domain as a predictor of an H2B ubiquitylation-sensing mechanism that leads to downstream H3K4 methylation.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "0e9ad5ae9db7422d92338cea8e52e210", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[84, 85], [161, 162]], "char_spans": [[516, 525], [921, 930]]}]}], "context_tokens": [["Past", 0], ["studies", 5], ["have", 13], ["documented", 18], ["a", 29], ["crosstalk", 31], ["between", 41], ["H2B", 49], ["ubiquitylation", 53], ["(", 68], ["H2Bub", 69], [")", 74], ["and", 76], ["H3K4", 80], ["methylation", 85], [",", 96], ["but", 98], ["little", 102], ["(", 109], ["if", 110], ["any", 113], [")", 116], ["direct", 118], ["evidence", 125], ["exists", 134], ["explaining", 141], ["the", 152], ["mechanism", 156], ["underlying", 166], ["H2Bub", 177], ["-", 182], ["dependent", 183], ["H3K4", 193], ["methylation", 198], ["on", 210], ["chromatin", 213], ["templates", 223], [".", 232], ["Here", 234], [",", 238], ["we", 240], ["took", 243], ["advantage", 248], ["of", 258], ["an", 261], ["in", 264], ["vitro", 267], ["histone", 273], ["methyltransferase", 281], ["assay", 299], ["employing", 305], ["a", 315], ["reconstituted", 317], ["yeast", 331], ["Set1", 337], ["complex", 342], ["(", 350], ["ySet1C", 351], [")", 357], ["and", 359], ["a", 363], ["recombinant", 365], ["chromatin", 377], ["template", 387], ["containing", 396], ["fully", 407], ["ubiquitylated", 413], ["H2B", 427], ["to", 431], ["gain", 434], ["valuable", 439], ["insights", 448], [".", 456], ["Combined", 458], ["with", 467], ["genetic", 472], ["analyses", 480], [",", 488], ["we", 490], ["demonstrate", 493], ["that", 505], ["the", 510], ["n", 514], ["-", 515], ["SET", 516], ["domain", 520], ["within", 527], ["Set1", 534], [",", 538], ["but", 540], ["not", 544], ["Swd2", 548], [",", 552], ["is", 554], ["essential", 557], ["for", 567], ["H2Bub", 571], ["-", 576], ["dependent", 577], ["H3K4", 587], ["methylation", 592], [".", 603], ["Spp1", 605], [",", 609], ["a", 611], ["homolog", 613], ["of", 621], ["human", 624], ["CFP1", 630], [",", 634], ["is", 636], ["conditionally", 639], ["involved", 653], ["in", 662], ["this", 665], ["crosstalk", 670], [".", 679], ["Our", 681], ["findings", 685], ["extend", 694], ["to", 701], ["the", 704], ["human", 708], ["Set1", 714], ["complex", 719], [",", 726], ["underscoring", 728], ["the", 741], ["conserved", 745], ["nature", 755], ["of", 762], ["this", 765], ["disease", 770], ["-", 777], ["relevant", 778], ["crosstalk", 787], ["pathway", 797], [".", 804], ["As", 806], ["not", 809], ["all", 813], ["members", 817], ["of", 825], ["the", 828], ["H3K4", 832], ["methyltransferase", 837], ["family", 855], ["contain", 862], ["n", 870], ["-", 871], ["SET", 872], ["domains", 876], [",", 883], ["our", 885], ["studies", 889], ["draw", 897], ["attention", 902], ["to", 912], ["the", 915], ["n", 919], ["-", 920], ["SET", 921], ["domain", 925], ["as", 932], ["a", 935], ["predictor", 937], ["of", 947], ["an", 950], ["H2B", 953], ["ubiquitylation", 957], ["-", 971], ["sensing", 972], ["mechanism", 980], ["that", 990], ["leads", 995], ["to", 1001], ["downstream", 1004], ["H3K4", 1015], ["methylation", 1020], [".", 1031]]}
{"context": "The X-linked McLeod neuroacanthocytosis syndrome is a multisystem disorder with hematologic, neuromuscular, and central nervous system (CNS) manifestations. All carriers of the McLeod blood group phenotype examined so far had at least subclinical signs of systemic involvement. Evaluation of two brothers carrying the McLeod phenotype with neurologic examination, immunohematology, RBC membrane protein Western blotting, analysis of XK DNA sequence and RNA levels, muscle histology including XK/Kell immunohistochemistry, cerebral magnetic resonance imaging (MRI), and quantified positron emission tomography (PET). Immunohematology and Western blotting confirmed presence of the McLeod blood group phenotype. No acanthocytosis or other hematologic anomalies were found. XK gene sequence analysis revealed a missense mutation in exon 3 (E327K). WBC XK RNA levels were not decreased. There were no neuromuscular and CNS signs or symptoms. In addition, no subclinical involvement was discovered on the basis of normal muscle histology with a physiologic pattern of XK and Kell immunohistochemistry, normal cerebral MRI, and quantified PET. Known disease-causing XK gene mutations comprised deletions, nonsense, or splice-site mutations predicting absent or truncated XK protein devoid of the Kell-protein binding site. Although the E327K missense mutation was associated with the immunohematologic characteristics of McLeod syndrome, the mutated XK protein seemed to be largely functional. These findings contribute to the understanding of the physiology of XK and Kell proteins, and the pathogenetic mechanisms of acanthocytosis, myopathy, and striatal neurodegeneration in McLeod syndrome.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "9019bb534c7b4632b5c84114049ce836", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[192, 192], [256, 256], [67, 67], [77, 77], [138, 138], [121, 121], [209, 209], [238, 238], [175, 175]], "char_spans": [[1160, 1161], [1556, 1557], [433, 434], [492, 493], [849, 850], [771, 772], [1265, 1266], [1444, 1445], [1063, 1064]]}]}], "context_tokens": [["The", 0], ["X", 4], ["-", 5], ["linked", 6], ["McLeod", 13], ["neuroacanthocytosis", 20], ["syndrome", 40], ["is", 49], ["a", 52], ["multisystem", 54], ["disorder", 66], ["with", 75], ["hematologic", 80], [",", 91], ["neuromuscular", 93], [",", 106], ["and", 108], ["central", 112], ["nervous", 120], ["system", 128], ["(", 135], ["CNS", 136], [")", 139], ["manifestations", 141], [".", 155], ["All", 157], ["carriers", 161], ["of", 170], ["the", 173], ["McLeod", 177], ["blood", 184], ["group", 190], ["phenotype", 196], ["examined", 206], ["so", 215], ["far", 218], ["had", 222], ["at", 226], ["least", 229], ["subclinical", 235], ["signs", 247], ["of", 253], ["systemic", 256], ["involvement", 265], [".", 276], ["Evaluation", 278], ["of", 289], ["two", 292], ["brothers", 296], ["carrying", 305], ["the", 314], ["McLeod", 318], ["phenotype", 325], ["with", 335], ["neurologic", 340], ["examination", 351], [",", 362], ["immunohematology", 364], [",", 380], ["RBC", 382], ["membrane", 386], ["protein", 395], ["Western", 403], ["blotting", 411], [",", 419], ["analysis", 421], ["of", 430], ["XK", 433], ["DNA", 436], ["sequence", 440], ["and", 449], ["RNA", 453], ["levels", 457], [",", 463], ["muscle", 465], ["histology", 472], ["including", 482], ["XK", 492], ["/", 494], ["Kell", 495], ["immunohistochemistry", 500], [",", 520], ["cerebral", 522], ["magnetic", 531], ["resonance", 540], ["imaging", 550], ["(", 558], ["MRI", 559], [")", 562], [",", 563], ["and", 565], ["quantified", 569], ["positron", 580], ["emission", 589], ["tomography", 598], ["(", 609], ["PET", 610], [")", 613], [".", 614], ["Immunohematology", 616], ["and", 633], ["Western", 637], ["blotting", 645], ["confirmed", 654], ["presence", 664], ["of", 673], ["the", 676], ["McLeod", 680], ["blood", 687], ["group", 693], ["phenotype", 699], [".", 708], ["No", 710], ["acanthocytosis", 713], ["or", 728], ["other", 731], ["hematologic", 737], ["anomalies", 749], ["were", 759], ["found", 764], [".", 769], ["XK", 771], ["gene", 774], ["sequence", 779], ["analysis", 788], ["revealed", 797], ["a", 806], ["missense", 808], ["mutation", 817], ["in", 826], ["exon", 829], ["3", 834], ["(", 836], ["E327", 837], ["K", 841], [")", 842], [".", 843], ["WBC", 845], ["XK", 849], ["RNA", 852], ["levels", 856], ["were", 863], ["not", 868], ["decreased", 872], [".", 881], ["There", 883], ["were", 889], ["no", 894], ["neuromuscular", 897], ["and", 911], ["CNS", 915], ["signs", 919], ["or", 925], ["symptoms", 928], [".", 936], ["In", 938], ["addition", 941], [",", 949], ["no", 951], ["subclinical", 954], ["involvement", 966], ["was", 978], ["discovered", 982], ["on", 993], ["the", 996], ["basis", 1000], ["of", 1006], ["normal", 1009], ["muscle", 1016], ["histology", 1023], ["with", 1033], ["a", 1038], ["physiologic", 1040], ["pattern", 1052], ["of", 1060], ["XK", 1063], ["and", 1066], ["Kell", 1070], ["immunohistochemistry", 1075], [",", 1095], ["normal", 1097], ["cerebral", 1104], ["MRI", 1113], [",", 1116], ["and", 1118], ["quantified", 1122], ["PET", 1133], [".", 1136], ["Known", 1138], ["disease", 1144], ["-", 1151], ["causing", 1152], ["XK", 1160], ["gene", 1163], ["mutations", 1168], ["comprised", 1178], ["deletions", 1188], [",", 1197], ["nonsense", 1199], [",", 1207], ["or", 1209], ["splice", 1212], ["-", 1218], ["site", 1219], ["mutations", 1224], ["predicting", 1234], ["absent", 1245], ["or", 1252], ["truncated", 1255], ["XK", 1265], ["protein", 1268], ["devoid", 1276], ["of", 1283], ["the", 1286], ["Kell", 1290], ["-", 1294], ["protein", 1295], ["binding", 1303], ["site", 1311], [".", 1315], ["Although", 1317], ["the", 1326], ["E327", 1330], ["K", 1334], ["missense", 1336], ["mutation", 1345], ["was", 1354], ["associated", 1358], ["with", 1369], ["the", 1374], ["immunohematologic", 1378], ["characteristics", 1396], ["of", 1412], ["McLeod", 1415], ["syndrome", 1422], [",", 1430], ["the", 1432], ["mutated", 1436], ["XK", 1444], ["protein", 1447], ["seemed", 1455], ["to", 1462], ["be", 1465], ["largely", 1468], ["functional", 1476], [".", 1486], ["These", 1488], ["findings", 1494], ["contribute", 1503], ["to", 1514], ["the", 1517], ["understanding", 1521], ["of", 1535], ["the", 1538], ["physiology", 1542], ["of", 1553], ["XK", 1556], ["and", 1559], ["Kell", 1563], ["proteins", 1568], [",", 1576], ["and", 1578], ["the", 1582], ["pathogenetic", 1586], ["mechanisms", 1599], ["of", 1610], ["acanthocytosis", 1613], [",", 1627], ["myopathy", 1629], [",", 1637], ["and", 1639], ["striatal", 1643], ["neurodegeneration", 1652], ["in", 1670], ["McLeod", 1673], ["syndrome", 1680], [".", 1688]]}
{"context": "Viroids, satellite RNAs, satellites viruses and the human hepatitis delta virus form the 'brotherhood' of the smallest known infectious RNA agents, known as the subviral RNAs. For most of these species, it is generally accepted that characteristics such as cell movement, replication, host specificity and pathogenicity are encoded in their RNA sequences and their resulting RNA structures. Although many sequences are indexed in publicly available databases, these sequence annotation databases do not provide the advanced searches and data manipulation capability for identifying and characterizing subviral RNA motifs. The Subviral RNA database is a web-based environment that facilitates the research and analysis of viroids, satellite RNAs, satellites viruses, the human hepatitis delta virus, and related RNA sequences. It integrates a large number of Subviral RNA sequences, their respective RNA motifs, analysis tools, related publication links and additional pertinent information (ex. links, conferences, announcements), allowing users to efficiently retrieve and analyze relevant information about these small RNA agents. With its design, the Subviral RNA Database could be considered as a fundamental building block for the study of these related RNAs. It is freely available via a web browser at the URL: http://subviral.med.uottawa.ca.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "2617acecfbd24533a69a8513130d6dde", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[116, 116], [0, 0]], "char_spans": [[721, 727], [0, 6]]}]}], "context_tokens": [["Viroids", 0], [",", 7], ["satellite", 9], ["RNAs", 19], [",", 23], ["satellites", 25], ["viruses", 36], ["and", 44], ["the", 48], ["human", 52], ["hepatitis", 58], ["delta", 68], ["virus", 74], ["form", 80], ["the", 85], ["'", 89], ["brotherhood", 90], ["'", 101], ["of", 103], ["the", 106], ["smallest", 110], ["known", 119], ["infectious", 125], ["RNA", 136], ["agents", 140], [",", 146], ["known", 148], ["as", 154], ["the", 157], ["subviral", 161], ["RNAs", 170], [".", 174], ["For", 176], ["most", 180], ["of", 185], ["these", 188], ["species", 194], [",", 201], ["it", 203], ["is", 206], ["generally", 209], ["accepted", 219], ["that", 228], ["characteristics", 233], ["such", 249], ["as", 254], ["cell", 257], ["movement", 262], [",", 270], ["replication", 272], [",", 283], ["host", 285], ["specificity", 290], ["and", 302], ["pathogenicity", 306], ["are", 320], ["encoded", 324], ["in", 332], ["their", 335], ["RNA", 341], ["sequences", 345], ["and", 355], ["their", 359], ["resulting", 365], ["RNA", 375], ["structures", 379], [".", 389], ["Although", 391], ["many", 400], ["sequences", 405], ["are", 415], ["indexed", 419], ["in", 427], ["publicly", 430], ["available", 439], ["databases", 449], [",", 458], ["these", 460], ["sequence", 466], ["annotation", 475], ["databases", 486], ["do", 496], ["not", 499], ["provide", 503], ["the", 511], ["advanced", 515], ["searches", 524], ["and", 533], ["data", 537], ["manipulation", 542], ["capability", 555], ["for", 566], ["identifying", 570], ["and", 582], ["characterizing", 586], ["subviral", 601], ["RNA", 610], ["motifs", 614], [".", 620], ["The", 622], ["Subviral", 626], ["RNA", 635], ["database", 639], ["is", 648], ["a", 651], ["web", 653], ["-", 656], ["based", 657], ["environment", 663], ["that", 675], ["facilitates", 680], ["the", 692], ["research", 696], ["and", 705], ["analysis", 709], ["of", 718], ["viroids", 721], [",", 728], ["satellite", 730], ["RNAs", 740], [",", 744], ["satellites", 746], ["viruses", 757], [",", 764], ["the", 766], ["human", 770], ["hepatitis", 776], ["delta", 786], ["virus", 792], [",", 797], ["and", 799], ["related", 803], ["RNA", 811], ["sequences", 815], [".", 824], ["It", 826], ["integrates", 829], ["a", 840], ["large", 842], ["number", 848], ["of", 855], ["Subviral", 858], ["RNA", 867], ["sequences", 871], [",", 880], ["their", 882], ["respective", 888], ["RNA", 899], ["motifs", 903], [",", 909], ["analysis", 911], ["tools", 920], [",", 925], ["related", 927], ["publication", 935], ["links", 947], ["and", 953], ["additional", 957], ["pertinent", 968], ["information", 978], ["(", 990], ["ex", 991], [".", 993], ["links", 995], [",", 1000], ["conferences", 1002], [",", 1013], ["announcements", 1015], [")", 1028], [",", 1029], ["allowing", 1031], ["users", 1040], ["to", 1046], ["efficiently", 1049], ["retrieve", 1061], ["and", 1070], ["analyze", 1074], ["relevant", 1082], ["information", 1091], ["about", 1103], ["these", 1109], ["small", 1115], ["RNA", 1121], ["agents", 1125], [".", 1131], ["With", 1133], ["its", 1138], ["design", 1142], [",", 1148], ["the", 1150], ["Subviral", 1154], ["RNA", 1163], ["Database", 1167], ["could", 1176], ["be", 1182], ["considered", 1185], ["as", 1196], ["a", 1199], ["fundamental", 1201], ["building", 1213], ["block", 1222], ["for", 1228], ["the", 1232], ["study", 1236], ["of", 1242], ["these", 1245], ["related", 1251], ["RNAs", 1259], [".", 1263], ["It", 1265], ["is", 1268], ["freely", 1271], ["available", 1278], ["via", 1288], ["a", 1292], ["web", 1294], ["browser", 1298], ["at", 1306], ["the", 1309], ["URL", 1313], [":", 1316], ["http://subviral.med.uottawa.ca", 1318], [".", 1348]]}
{"context": "Chediak-Higashi syndrome is a genetic disorder caused by mutations in a gene encoding a protein named LYST in humans (\"lysosomal trafficking regulator\") or Beige in mice. A prominent feature of this disease is the accumulation of enlarged lysosome-related granules in a variety of cells. The genome of Dictyostelium discoideum contains six genes encoding proteins that are related to LYST/Beige in amino acid sequence, and disruption of one of these genes, lvsA (large volume sphere), results in profound defects in cytokinesis. To better understand the function of this family of proteins in membrane trafficking, we have analyzed mutants disrupted in lvsA, lvsB, lvsC, lvsD, lvsE, and lvsF. Of all these, only lvsA and lvsB mutants displayed interesting phenotypes in our assays. lvsA-null cells exhibited defects in phagocytosis and contained abnormal looking contractile vacuole membranes. Loss of LvsB, the Dictyostelium protein most similar to LYST/Beige, resulted in the formation of enlarged vesicles that by multiple criteria appeared to be acidic lysosomes. The rates of endocytosis, phagocytosis, and fluid phase exocytosis were normal in lvsB-null cells. Also, the rates of processing and the efficiency of targeting of lysosomal alpha-mannosidase were normal, although lvsB mutants inefficiently retained alpha-mannosidase, as well as two other lysosomal cysteine proteinases. Finally, results of pulse-chase experiments indicated that an increase in fusion rates accounted for the enlarged lysosomes in lvsB-null cells, suggesting that LvsB acts as a negative regulator of fusion. Our results support the notion that LvsB/LYST/Beige function in a similar manner to regulate lysosome biogenesis.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "40cc928d16714c79baadc63e10e82c30", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["is", 25], ["a", 28], ["genetic", 30], ["disorder", 38], ["caused", 47], ["by", 54], ["mutations", 57], ["in", 67], ["a", 70], ["gene", 72], ["encoding", 77], ["a", 86], ["protein", 88], ["named", 96], ["LYST", 102], ["in", 107], ["humans", 110], ["(", 117], ["\"", 118], ["lysosomal", 119], ["trafficking", 129], ["regulator", 141], ["\"", 150], [")", 151], ["or", 153], ["Beige", 156], ["in", 162], ["mice", 165], [".", 169], ["A", 171], ["prominent", 173], ["feature", 183], ["of", 191], ["this", 194], ["disease", 199], ["is", 207], ["the", 210], ["accumulation", 214], ["of", 227], ["enlarged", 230], ["lysosome", 239], ["-", 247], ["related", 248], ["granules", 256], ["in", 265], ["a", 268], ["variety", 270], ["of", 278], ["cells", 281], [".", 286], ["The", 288], ["genome", 292], ["of", 299], ["Dictyostelium", 302], ["discoideum", 316], ["contains", 327], ["six", 336], ["genes", 340], ["encoding", 346], ["proteins", 355], ["that", 364], ["are", 369], ["related", 373], ["to", 381], ["LYST", 384], ["/", 388], ["Beige", 389], ["in", 395], ["amino", 398], ["acid", 404], ["sequence", 409], [",", 417], ["and", 419], ["disruption", 423], ["of", 434], ["one", 437], ["of", 441], ["these", 444], ["genes", 450], [",", 455], ["lvsA", 457], ["(", 462], ["large", 463], ["volume", 469], ["sphere", 476], [")", 482], [",", 483], ["results", 485], ["in", 493], ["profound", 496], ["defects", 505], ["in", 513], ["cytokinesis", 516], [".", 527], ["To", 529], ["better", 532], ["understand", 539], ["the", 550], ["function", 554], ["of", 563], ["this", 566], ["family", 571], ["of", 578], ["proteins", 581], ["in", 590], ["membrane", 593], ["trafficking", 602], [",", 613], ["we", 615], ["have", 618], ["analyzed", 623], ["mutants", 632], ["disrupted", 640], ["in", 650], ["lvsA", 653], [",", 657], ["lvsB", 659], [",", 663], ["lvsC", 665], [",", 669], ["lvsD", 671], [",", 675], ["lvsE", 677], [",", 681], ["and", 683], ["lvsF.", 687], ["Of", 693], ["all", 696], ["these", 700], [",", 705], ["only", 707], ["lvsA", 712], ["and", 717], ["lvsB", 721], ["mutants", 726], ["displayed", 734], ["interesting", 744], ["phenotypes", 756], ["in", 767], ["our", 770], ["assays", 774], [".", 780], ["lvsA", 782], ["-", 786], ["null", 787], ["cells", 792], ["exhibited", 798], ["defects", 808], ["in", 816], ["phagocytosis", 819], ["and", 832], ["contained", 836], ["abnormal", 846], ["looking", 855], ["contractile", 863], ["vacuole", 875], ["membranes", 883], [".", 892], ["Loss", 894], ["of", 899], ["LvsB", 902], [",", 906], ["the", 908], ["Dictyostelium", 912], ["protein", 926], ["most", 934], ["similar", 939], ["to", 947], ["LYST", 950], ["/", 954], ["Beige", 955], [",", 960], ["resulted", 962], ["in", 971], ["the", 974], ["formation", 978], ["of", 988], ["enlarged", 991], ["vesicles", 1000], ["that", 1009], ["by", 1014], ["multiple", 1017], ["criteria", 1026], ["appeared", 1035], ["to", 1044], ["be", 1047], ["acidic", 1050], ["lysosomes", 1057], [".", 1066], ["The", 1068], ["rates", 1072], ["of", 1078], ["endocytosis", 1081], [",", 1092], ["phagocytosis", 1094], [",", 1106], ["and", 1108], ["fluid", 1112], ["phase", 1118], ["exocytosis", 1124], ["were", 1135], ["normal", 1140], ["in", 1147], ["lvsB", 1150], ["-", 1154], ["null", 1155], ["cells", 1160], [".", 1165], ["Also", 1167], [",", 1171], ["the", 1173], ["rates", 1177], ["of", 1183], ["processing", 1186], ["and", 1197], ["the", 1201], ["efficiency", 1205], ["of", 1216], ["targeting", 1219], ["of", 1229], ["lysosomal", 1232], ["alpha", 1242], ["-", 1247], ["mannosidase", 1248], ["were", 1260], ["normal", 1265], [",", 1271], ["although", 1273], ["lvsB", 1282], ["mutants", 1287], ["inefficiently", 1295], ["retained", 1309], ["alpha", 1318], ["-", 1323], ["mannosidase", 1324], [",", 1335], ["as", 1337], ["well", 1340], ["as", 1345], ["two", 1348], ["other", 1352], ["lysosomal", 1358], ["cysteine", 1368], ["proteinases", 1377], [".", 1388], ["Finally", 1390], [",", 1397], ["results", 1399], ["of", 1407], ["pulse", 1410], ["-", 1415], ["chase", 1416], ["experiments", 1422], ["indicated", 1434], ["that", 1444], ["an", 1449], ["increase", 1452], ["in", 1461], ["fusion", 1464], ["rates", 1471], ["accounted", 1477], ["for", 1487], ["the", 1491], ["enlarged", 1495], ["lysosomes", 1504], ["in", 1514], ["lvsB", 1517], ["-", 1521], ["null", 1522], ["cells", 1527], [",", 1532], ["suggesting", 1534], ["that", 1545], ["LvsB", 1550], ["acts", 1555], ["as", 1560], ["a", 1563], ["negative", 1565], ["regulator", 1574], ["of", 1584], ["fusion", 1587], [".", 1593], ["Our", 1595], ["results", 1599], ["support", 1607], ["the", 1615], ["notion", 1619], ["that", 1626], ["LvsB", 1631], ["/", 1635], ["LYST", 1636], ["/", 1640], ["Beige", 1641], ["function", 1647], ["in", 1656], ["a", 1659], ["similar", 1661], ["manner", 1669], ["to", 1676], ["regulate", 1679], ["lysosome", 1688], ["biogenesis", 1697], [".", 1707]]}
{"context": "Coexpression of PU.1 and GATA-1 is required for proper specification of the mast cell lineage; however, in the myeloid and erythroid lineages, PU.1 and GATA-1 are functionally antagonistic. In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development. We isolated a variant mRNA isoform of GATA-1 in murine mast cells that is significantly upregulated during mast cell differentiation. This isoform contains an alternatively spliced first exon (IB) that is distinct from the first exon (IE) incorporated in the major erythroid mRNA transcript. In contrast to erythroid and megakaryocyte cells, in mast cells we show that PU.1 and GATA-2 predominantly occupy potential cis-regulatory elements in the IB exon region in vivo. Using reporter assays, we identify an enhancer flanking the IB exon that is activated by PU.1. Furthermore, we observe that in PU.1(-/-) fetal liver cells, low levels of the IE GATA-1 isoform is expressed, but the variant IB isoform is absent. Reintroduction of PU.1 restores variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation. Our results are consistent with a transcriptional hierarchy in which PU.1, possibly in concert with GATA-2, activates GATA-1 expression in mast cells in a pathway distinct from that seen in the erythroid and megakaryocytic lineages.", "qas": [{"question": "Which gene controls the expression of GATA-1 isoforms?", "answers": ["PU.1"], "qid": "f6516640f1d44d11963b1679aae29f07", "question_tokens": [["Which", 0], ["gene", 6], ["controls", 11], ["the", 20], ["expression", 24], ["of", 35], ["GATA-1", 38], ["isoforms", 45], ["?", 53]], "detected_answers": [{"text": "PU.1", "token_spans": [[117, 117], [43, 43], [151, 151], [25, 25], [185, 185], [215, 215], [2, 2], [159, 159]], "char_spans": [[689, 692], [250, 253], [880, 883], [143, 146], [1053, 1056], [1256, 1259], [16, 19], [918, 925]]}]}], "context_tokens": [["Coexpression", 0], ["of", 13], ["PU.1", 16], ["and", 21], ["GATA-1", 25], ["is", 32], ["required", 35], ["for", 44], ["proper", 48], ["specification", 55], ["of", 69], ["the", 72], ["mast", 76], ["cell", 81], ["lineage", 86], [";", 93], ["however", 95], [",", 102], ["in", 104], ["the", 107], ["myeloid", 111], ["and", 119], ["erythroid", 123], ["lineages", 133], [",", 141], ["PU.1", 143], ["and", 148], ["GATA-1", 152], ["are", 159], ["functionally", 163], ["antagonistic", 176], [".", 188], ["In", 190], ["this", 193], ["study", 198], [",", 203], ["we", 205], ["report", 208], ["a", 215], ["transcriptional", 217], ["network", 233], ["in", 241], ["which", 244], ["PU.1", 250], ["positively", 255], ["regulates", 266], ["GATA-1", 276], ["expression", 283], ["in", 294], ["mast", 297], ["cell", 302], ["development", 307], [".", 318], ["We", 320], ["isolated", 323], ["a", 332], ["variant", 334], ["mRNA", 342], ["isoform", 347], ["of", 355], ["GATA-1", 358], ["in", 365], ["murine", 368], ["mast", 375], ["cells", 380], ["that", 386], ["is", 391], ["significantly", 394], ["upregulated", 408], ["during", 420], ["mast", 427], ["cell", 432], ["differentiation", 437], [".", 452], ["This", 454], ["isoform", 459], ["contains", 467], ["an", 476], ["alternatively", 479], ["spliced", 493], ["first", 501], ["exon", 507], ["(", 512], ["IB", 513], [")", 515], ["that", 517], ["is", 522], ["distinct", 525], ["from", 534], ["the", 539], ["first", 543], ["exon", 549], ["(", 554], ["IE", 555], [")", 557], ["incorporated", 559], ["in", 572], ["the", 575], ["major", 579], ["erythroid", 585], ["mRNA", 595], ["transcript", 600], [".", 610], ["In", 612], ["contrast", 615], ["to", 624], ["erythroid", 627], ["and", 637], ["megakaryocyte", 641], ["cells", 655], [",", 660], ["in", 662], ["mast", 665], ["cells", 670], ["we", 676], ["show", 679], ["that", 684], ["PU.1", 689], ["and", 694], ["GATA-2", 698], ["predominantly", 705], ["occupy", 719], ["potential", 726], ["cis", 736], ["-", 739], ["regulatory", 740], ["elements", 751], ["in", 760], ["the", 763], ["IB", 767], ["exon", 770], ["region", 775], ["in", 782], ["vivo", 785], [".", 789], ["Using", 791], ["reporter", 797], ["assays", 806], [",", 812], ["we", 814], ["identify", 817], ["an", 826], ["enhancer", 829], ["flanking", 838], ["the", 847], ["IB", 851], ["exon", 854], ["that", 859], ["is", 864], ["activated", 867], ["by", 877], ["PU.1", 880], [".", 884], ["Furthermore", 886], [",", 897], ["we", 899], ["observe", 902], ["that", 910], ["in", 915], ["PU.1(-/-", 918], [")", 926], ["fetal", 928], ["liver", 934], ["cells", 940], [",", 945], ["low", 947], ["levels", 951], ["of", 958], ["the", 961], ["IE", 965], ["GATA-1", 968], ["isoform", 975], ["is", 983], ["expressed", 986], [",", 995], ["but", 997], ["the", 1001], ["variant", 1005], ["IB", 1013], ["isoform", 1016], ["is", 1024], ["absent", 1027], [".", 1033], ["Reintroduction", 1035], ["of", 1050], ["PU.1", 1053], ["restores", 1058], ["variant", 1067], ["IB", 1075], ["isoform", 1078], ["and", 1086], ["upregulates", 1090], ["total", 1102], ["GATA-1", 1108], ["protein", 1115], ["expression", 1123], [",", 1133], ["which", 1135], ["is", 1141], ["concurrent", 1144], ["with", 1155], ["mast", 1160], ["cell", 1165], ["differentiation", 1170], [".", 1185], ["Our", 1187], ["results", 1191], ["are", 1199], ["consistent", 1203], ["with", 1214], ["a", 1219], ["transcriptional", 1221], ["hierarchy", 1237], ["in", 1247], ["which", 1250], ["PU.1", 1256], [",", 1260], ["possibly", 1262], ["in", 1271], ["concert", 1274], ["with", 1282], ["GATA-2", 1287], [",", 1293], ["activates", 1295], ["GATA-1", 1305], ["expression", 1312], ["in", 1323], ["mast", 1326], ["cells", 1331], ["in", 1337], ["a", 1340], ["pathway", 1342], ["distinct", 1350], ["from", 1359], ["that", 1364], ["seen", 1369], ["in", 1374], ["the", 1377], ["erythroid", 1381], ["and", 1391], ["megakaryocytic", 1395], ["lineages", 1410], [".", 1418]]}
{"context": "This study aimed to explore retrospective childhood ADHD symptomatology, psychiatric comorbidity, rates of substance-use disorders (SUD), as well as their association with high-risk health behaviors in prison and adverse health outcomes. A randomly selected representative sample of inmates in the Puerto Rico correctional system (N = 1,179) was assessed with the Spanish-language Wender Utah Rating Scale (WURS); the Composite International Diagnostic Interview (CIDI) modules for lifetime/current major depression disorder (MDD), generalized anxiety disorder (GAD), and SUD; the Davidson Trauma Scale (DTS; posttraumatic stress disorder [PTSD]); and self-reports of in-site high-risk behaviors. Wald \u03c7(2) tests revealed significant associations of ADHD with MDD and PTSD, as well as increased risk for overdosing and intravenous drug use in prison. A logistic regression model adjusted for mood and anxiety comorbidity predicted lifetime SUD diagnosis (odds ratio = 2.38; 95% confidence interval = [1.15, 4.94]). Our results provide further evidence on the association of drug dependence and ADHD symptoms, and their overrepresentation among prison inmates.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "cb4d005ff43d41c896f0469ab1363b38", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[144, 144], [115, 115]], "char_spans": [[768, 771], [640, 643]]}]}], "context_tokens": [["This", 0], ["study", 5], ["aimed", 11], ["to", 17], ["explore", 20], ["retrospective", 28], ["childhood", 42], ["ADHD", 52], ["symptomatology", 57], [",", 71], ["psychiatric", 73], ["comorbidity", 85], [",", 96], ["rates", 98], ["of", 104], ["substance", 107], ["-", 116], ["use", 117], ["disorders", 121], ["(", 131], ["SUD", 132], [")", 135], [",", 136], ["as", 138], ["well", 141], ["as", 146], ["their", 149], ["association", 155], ["with", 167], ["high", 172], ["-", 176], ["risk", 177], ["health", 182], ["behaviors", 189], ["in", 199], ["prison", 202], ["and", 209], ["adverse", 213], ["health", 221], ["outcomes", 228], [".", 236], ["A", 238], ["randomly", 240], ["selected", 249], ["representative", 258], ["sample", 273], ["of", 280], ["inmates", 283], ["in", 291], ["the", 294], ["Puerto", 298], ["Rico", 305], ["correctional", 310], ["system", 323], ["(", 330], ["N", 331], ["=", 333], ["1,179", 335], [")", 340], ["was", 342], ["assessed", 346], ["with", 355], ["the", 360], ["Spanish", 364], ["-", 371], ["language", 372], ["Wender", 381], ["Utah", 388], ["Rating", 393], ["Scale", 400], ["(", 406], ["WURS", 407], [")", 411], [";", 412], ["the", 414], ["Composite", 418], ["International", 428], ["Diagnostic", 442], ["Interview", 453], ["(", 463], ["CIDI", 464], [")", 468], ["modules", 470], ["for", 478], ["lifetime", 482], ["/", 490], ["current", 491], ["major", 499], ["depression", 505], ["disorder", 516], ["(", 525], ["MDD", 526], [")", 529], [",", 530], ["generalized", 532], ["anxiety", 544], ["disorder", 552], ["(", 561], ["GAD", 562], [")", 565], [",", 566], ["and", 568], ["SUD", 572], [";", 575], ["the", 577], ["Davidson", 581], ["Trauma", 590], ["Scale", 597], ["(", 603], ["DTS", 604], [";", 607], ["posttraumatic", 609], ["stress", 623], ["disorder", 630], ["[", 639], ["PTSD", 640], ["]", 644], [")", 645], [";", 646], ["and", 648], ["self", 652], ["-", 656], ["reports", 657], ["of", 665], ["in", 668], ["-", 670], ["site", 671], ["high", 676], ["-", 680], ["risk", 681], ["behaviors", 686], [".", 695], ["Wald", 697], ["\u03c7(2", 702], [")", 705], ["tests", 707], ["revealed", 713], ["significant", 722], ["associations", 734], ["of", 747], ["ADHD", 750], ["with", 755], ["MDD", 760], ["and", 764], ["PTSD", 768], [",", 772], ["as", 774], ["well", 777], ["as", 782], ["increased", 785], ["risk", 795], ["for", 800], ["overdosing", 804], ["and", 815], ["intravenous", 819], ["drug", 831], ["use", 836], ["in", 840], ["prison", 843], [".", 849], ["A", 851], ["logistic", 853], ["regression", 862], ["model", 873], ["adjusted", 879], ["for", 888], ["mood", 892], ["and", 897], ["anxiety", 901], ["comorbidity", 909], ["predicted", 921], ["lifetime", 931], ["SUD", 940], ["diagnosis", 944], ["(", 954], ["odds", 955], ["ratio", 960], ["=", 966], ["2.38", 968], [";", 972], ["95", 974], ["%", 976], ["confidence", 978], ["interval", 989], ["=", 998], ["[", 1000], ["1.15", 1001], [",", 1005], ["4.94", 1007], ["]", 1011], [")", 1012], [".", 1013], ["Our", 1015], ["results", 1019], ["provide", 1027], ["further", 1035], ["evidence", 1043], ["on", 1052], ["the", 1055], ["association", 1059], ["of", 1071], ["drug", 1074], ["dependence", 1079], ["and", 1090], ["ADHD", 1094], ["symptoms", 1099], [",", 1107], ["and", 1109], ["their", 1113], ["overrepresentation", 1119], ["among", 1138], ["prison", 1144], ["inmates", 1151], [".", 1158]]}
{"context": "Little is known about the management of methicillin-resistant Staphylococcus aureus (MRSA) carriers in the German outpatient sector and about the impact of MRSA on their daily life. Reimbursement for MRSA related costs in the German outpatient sector is available since 2012, but its impact has not been studied yet. The aim of the study was to analyze the outpatient management of MRSA carriers from both, physicians' and MRSA carriers' perspective. Paper-based questionnaires were mailed to physicians providing outpatient care and to MRSA carriers in 2013. MRSA carriers were recruited among patients tested positive for MRSA during a hospital stay in 2012. General practitioners, specialists for internal medicine, urologists, and dermatologists working in the outpatient catchment areas of the hospitals were contacted. Out of 910 MRSA carriers 16.5\u00a0% completed the questionnaires; among 851 physicians 9.5\u00a0% participated. 27.3\u00a0% of the responding MRSA carriers stated that no healthcare professional had ever talked to them about MRSA. 17.4\u00a0% reported self-stigmatization in terms of restricting social contacts; 47.3\u00a0% remembered decolonization and 33.3\u00a0% reported that their MRSA status was checked after discharge. Physicians displayed heterogeneous attitude and activity towards MRSA (number of applied decolonization and MRSA screenings). A minority (15.2\u00a0%) were satisfied with the reimbursement of costs, 35.9\u00a0% reported full agreement with the general recommendations for the handling of MRSA carriers. MRSA carriers appear not well informed; (self-) stigmatization is occurring and should be tackled. Greater awareness of MRSA as a problem in the outpatient sector could lead to a better handling of MRSA carriers.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "78d3a470a5fc433fb380a0e051deb39c", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[176, 176], [256, 256], [13, 13], [99, 99], [26, 26], [163, 163], [253, 253], [277, 277], [68, 68], [76, 76], [108, 108], [201, 201], [215, 215], [222, 222], [292, 292], [34, 34], [143, 143], [94, 94]], "char_spans": [[1036, 1039], [1517, 1520], [85, 88], [560, 563], [156, 159], [953, 956], [1502, 1505], [1637, 1640], [382, 385], [423, 426], [624, 627], [1183, 1186], [1289, 1292], [1332, 1335], [1715, 1718], [200, 203], [836, 839], [537, 540]]}]}], "context_tokens": [["Little", 0], ["is", 7], ["known", 10], ["about", 16], ["the", 22], ["management", 26], ["of", 37], ["methicillin", 40], ["-", 51], ["resistant", 52], ["Staphylococcus", 62], ["aureus", 77], ["(", 84], ["MRSA", 85], [")", 89], ["carriers", 91], ["in", 100], ["the", 103], ["German", 107], ["outpatient", 114], ["sector", 125], ["and", 132], ["about", 136], ["the", 142], ["impact", 146], ["of", 153], ["MRSA", 156], ["on", 161], ["their", 164], ["daily", 170], ["life", 176], [".", 180], ["Reimbursement", 182], ["for", 196], ["MRSA", 200], ["related", 205], ["costs", 213], ["in", 219], ["the", 222], ["German", 226], ["outpatient", 233], ["sector", 244], ["is", 251], ["available", 254], ["since", 264], ["2012", 270], [",", 274], ["but", 276], ["its", 280], ["impact", 284], ["has", 291], ["not", 295], ["been", 299], ["studied", 304], ["yet", 312], [".", 315], ["The", 317], ["aim", 321], ["of", 325], ["the", 328], ["study", 332], ["was", 338], ["to", 342], ["analyze", 345], ["the", 353], ["outpatient", 357], ["management", 368], ["of", 379], ["MRSA", 382], ["carriers", 387], ["from", 396], ["both", 401], [",", 405], ["physicians", 407], ["'", 417], ["and", 419], ["MRSA", 423], ["carriers", 428], ["'", 436], ["perspective", 438], [".", 449], ["Paper", 451], ["-", 456], ["based", 457], ["questionnaires", 463], ["were", 478], ["mailed", 483], ["to", 490], ["physicians", 493], ["providing", 504], ["outpatient", 514], ["care", 525], ["and", 530], ["to", 534], ["MRSA", 537], ["carriers", 542], ["in", 551], ["2013", 554], [".", 558], ["MRSA", 560], ["carriers", 565], ["were", 574], ["recruited", 579], ["among", 589], ["patients", 595], ["tested", 604], ["positive", 611], ["for", 620], ["MRSA", 624], ["during", 629], ["a", 636], ["hospital", 638], ["stay", 647], ["in", 652], ["2012", 655], [".", 659], ["General", 661], ["practitioners", 669], [",", 682], ["specialists", 684], ["for", 696], ["internal", 700], ["medicine", 709], [",", 717], ["urologists", 719], [",", 729], ["and", 731], ["dermatologists", 735], ["working", 750], ["in", 758], ["the", 761], ["outpatient", 765], ["catchment", 776], ["areas", 786], ["of", 792], ["the", 795], ["hospitals", 799], ["were", 809], ["contacted", 814], [".", 823], ["Out", 825], ["of", 829], ["910", 832], ["MRSA", 836], ["carriers", 841], ["16.5", 850], ["%", 855], ["completed", 857], ["the", 867], ["questionnaires", 871], [";", 885], ["among", 887], ["851", 893], ["physicians", 897], ["9.5", 908], ["%", 912], ["participated", 914], [".", 926], ["27.3", 928], ["%", 933], ["of", 935], ["the", 938], ["responding", 942], ["MRSA", 953], ["carriers", 958], ["stated", 967], ["that", 974], ["no", 979], ["healthcare", 982], ["professional", 993], ["had", 1006], ["ever", 1010], ["talked", 1015], ["to", 1022], ["them", 1025], ["about", 1030], ["MRSA", 1036], [".", 1040], ["17.4", 1042], ["%", 1047], ["reported", 1049], ["self", 1058], ["-", 1062], ["stigmatization", 1063], ["in", 1078], ["terms", 1081], ["of", 1087], ["restricting", 1090], ["social", 1102], ["contacts", 1109], [";", 1117], ["47.3", 1119], ["%", 1124], ["remembered", 1126], ["decolonization", 1137], ["and", 1152], ["33.3", 1156], ["%", 1161], ["reported", 1163], ["that", 1172], ["their", 1177], ["MRSA", 1183], ["status", 1188], ["was", 1195], ["checked", 1199], ["after", 1207], ["discharge", 1213], [".", 1222], ["Physicians", 1224], ["displayed", 1235], ["heterogeneous", 1245], ["attitude", 1259], ["and", 1268], ["activity", 1272], ["towards", 1281], ["MRSA", 1289], ["(", 1294], ["number", 1295], ["of", 1302], ["applied", 1305], ["decolonization", 1313], ["and", 1328], ["MRSA", 1332], ["screenings", 1337], [")", 1347], [".", 1348], ["A", 1350], ["minority", 1352], ["(", 1361], ["15.2", 1362], ["%", 1367], [")", 1368], ["were", 1370], ["satisfied", 1375], ["with", 1385], ["the", 1390], ["reimbursement", 1394], ["of", 1408], ["costs", 1411], [",", 1416], ["35.9", 1418], ["%", 1423], ["reported", 1425], ["full", 1434], ["agreement", 1439], ["with", 1449], ["the", 1454], ["general", 1458], ["recommendations", 1466], ["for", 1482], ["the", 1486], ["handling", 1490], ["of", 1499], ["MRSA", 1502], ["carriers", 1507], [".", 1515], ["MRSA", 1517], ["carriers", 1522], ["appear", 1531], ["not", 1538], ["well", 1542], ["informed", 1547], [";", 1555], ["(", 1557], ["self-", 1558], [")", 1563], ["stigmatization", 1565], ["is", 1580], ["occurring", 1583], ["and", 1593], ["should", 1597], ["be", 1604], ["tackled", 1607], [".", 1614], ["Greater", 1616], ["awareness", 1624], ["of", 1634], ["MRSA", 1637], ["as", 1642], ["a", 1645], ["problem", 1647], ["in", 1655], ["the", 1658], ["outpatient", 1662], ["sector", 1673], ["could", 1680], ["lead", 1686], ["to", 1691], ["a", 1694], ["better", 1696], ["handling", 1703], ["of", 1712], ["MRSA", 1715], ["carriers", 1720], [".", 1728]]}
{"context": "Nerve growth factor (NGF) antagonism has long been proposed as a chronic pain treatment. In 2010, the FDA suspended clinical trials using tanezumab, a humanized monoclonal anti-NGF antibody, to treat osteoarthritis due to worsening joint damage in 16 patients. Increased physical activity in the absence of acute pain which normally prevents self-harm was purported as a potential cause. Such an adverse effect is consistent with an extension of tanezumab's primary mechanism of action by decreasing pain sensitivity below baseline levels. In animal inflammatory pain models, NGF antagonism decreases intraepidermal nerve fiber (IENF) density and attenuates increases in expression of nociception-related proteins, such as calcitonin gene-related peptide (CGRP) and substance P (SP). Little is known of the effects of NGF antagonism in noninflamed animals and the hypoalgesia that ensues. In the current study, we immunized rats with NGF or cytochrome C (cytC) and examined (1) nocifensive behaviors with thermal latencies, mechanical thresholds, the hot plate test, and the tail flick test, (2) IENF density, and (3) expression of CGRP, SP, voltage-gated sodium channel 1.8 (Nav1.8), and glutaminase in subpopulations of dorsal root ganglion (DRG) neurons separated by size and isolectin B4 (IB4) labeling. Rats with high anti-NGF titers had delayed responses on the hot plate test but no other behavioral abnormalities. Delayed hot plate responses correlated with lower IENF density. CGRP and SP expression was decreased principally in medium (400-800 \u03bcm(2)) and small neurons (<400 \u03bcm(2)), respectively, regardless of IB4 labeling. Expression of Nav1.8 was only decreased in small and medium IB4 negative neurons. NGF immunization appears to result in a more profound antagonism of NGF than tanezumab therapy, but we hypothesize that decreases in IENF density and nociception-related protein expression are potential mechanisms for tanezumab-induced hypoalgesia.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "589de266ea4f4f239030a2ea5f61bf8b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "NGF", "token_spans": [[165, 165], [251, 251], [335, 335], [100, 100], [4, 4], [324, 324], [33, 33], [145, 145]], "char_spans": [[934, 936], [1328, 1330], [1785, 1787], [576, 578], [21, 23], [1717, 1719], [177, 179], [818, 820]]}]}], "context_tokens": [["Nerve", 0], ["growth", 6], ["factor", 13], ["(", 20], ["NGF", 21], [")", 24], ["antagonism", 26], ["has", 37], ["long", 41], ["been", 46], ["proposed", 51], ["as", 60], ["a", 63], ["chronic", 65], ["pain", 73], ["treatment", 78], [".", 87], ["In", 89], ["2010", 92], [",", 96], ["the", 98], ["FDA", 102], ["suspended", 106], ["clinical", 116], ["trials", 125], ["using", 132], ["tanezumab", 138], [",", 147], ["a", 149], ["humanized", 151], ["monoclonal", 161], ["anti", 172], ["-", 176], ["NGF", 177], ["antibody", 181], [",", 189], ["to", 191], ["treat", 194], ["osteoarthritis", 200], ["due", 215], ["to", 219], ["worsening", 222], ["joint", 232], ["damage", 238], ["in", 245], ["16", 248], ["patients", 251], [".", 259], ["Increased", 261], ["physical", 271], ["activity", 280], ["in", 289], ["the", 292], ["absence", 296], ["of", 304], ["acute", 307], ["pain", 313], ["which", 318], ["normally", 324], ["prevents", 333], ["self", 342], ["-", 346], ["harm", 347], ["was", 352], ["purported", 356], ["as", 366], ["a", 369], ["potential", 371], ["cause", 381], [".", 386], ["Such", 388], ["an", 393], ["adverse", 396], ["effect", 404], ["is", 411], ["consistent", 414], ["with", 425], ["an", 430], ["extension", 433], ["of", 443], ["tanezumab", 446], ["'s", 455], ["primary", 458], ["mechanism", 466], ["of", 476], ["action", 479], ["by", 486], ["decreasing", 489], ["pain", 500], ["sensitivity", 505], ["below", 517], ["baseline", 523], ["levels", 532], [".", 538], ["In", 540], ["animal", 543], ["inflammatory", 550], ["pain", 563], ["models", 568], [",", 574], ["NGF", 576], ["antagonism", 580], ["decreases", 591], ["intraepidermal", 601], ["nerve", 616], ["fiber", 622], ["(", 628], ["IENF", 629], [")", 633], ["density", 635], ["and", 643], ["attenuates", 647], ["increases", 658], ["in", 668], ["expression", 671], ["of", 682], ["nociception", 685], ["-", 696], ["related", 697], ["proteins", 705], [",", 713], ["such", 715], ["as", 720], ["calcitonin", 723], ["gene", 734], ["-", 738], ["related", 739], ["peptide", 747], ["(", 755], ["CGRP", 756], [")", 760], ["and", 762], ["substance", 766], ["P", 776], ["(", 778], ["SP", 779], [")", 781], [".", 782], ["Little", 784], ["is", 791], ["known", 794], ["of", 800], ["the", 803], ["effects", 807], ["of", 815], ["NGF", 818], ["antagonism", 822], ["in", 833], ["noninflamed", 836], ["animals", 848], ["and", 856], ["the", 860], ["hypoalgesia", 864], ["that", 876], ["ensues", 881], [".", 887], ["In", 889], ["the", 892], ["current", 896], ["study", 904], [",", 909], ["we", 911], ["immunized", 914], ["rats", 924], ["with", 929], ["NGF", 934], ["or", 938], ["cytochrome", 941], ["C", 952], ["(", 954], ["cytC", 955], [")", 959], ["and", 961], ["examined", 965], ["(", 974], ["1", 975], [")", 976], ["nocifensive", 978], ["behaviors", 990], ["with", 1000], ["thermal", 1005], ["latencies", 1013], [",", 1022], ["mechanical", 1024], ["thresholds", 1035], [",", 1045], ["the", 1047], ["hot", 1051], ["plate", 1055], ["test", 1061], [",", 1065], ["and", 1067], ["the", 1071], ["tail", 1075], ["flick", 1080], ["test", 1086], [",", 1090], ["(", 1092], ["2", 1093], [")", 1094], ["IENF", 1096], ["density", 1101], [",", 1108], ["and", 1110], ["(", 1114], ["3", 1115], [")", 1116], ["expression", 1118], ["of", 1129], ["CGRP", 1132], [",", 1136], ["SP", 1138], [",", 1140], ["voltage", 1142], ["-", 1149], ["gated", 1150], ["sodium", 1156], ["channel", 1163], ["1.8", 1171], ["(", 1175], ["Nav1.8", 1176], [")", 1182], [",", 1183], ["and", 1185], ["glutaminase", 1189], ["in", 1201], ["subpopulations", 1204], ["of", 1219], ["dorsal", 1222], ["root", 1229], ["ganglion", 1234], ["(", 1243], ["DRG", 1244], [")", 1247], ["neurons", 1249], ["separated", 1257], ["by", 1267], ["size", 1270], ["and", 1275], ["isolectin", 1279], ["B4", 1289], ["(", 1292], ["IB4", 1293], [")", 1296], ["labeling", 1298], [".", 1306], ["Rats", 1308], ["with", 1313], ["high", 1318], ["anti", 1323], ["-", 1327], ["NGF", 1328], ["titers", 1332], ["had", 1339], ["delayed", 1343], ["responses", 1351], ["on", 1361], ["the", 1364], ["hot", 1368], ["plate", 1372], ["test", 1378], ["but", 1383], ["no", 1387], ["other", 1390], ["behavioral", 1396], ["abnormalities", 1407], [".", 1420], ["Delayed", 1422], ["hot", 1430], ["plate", 1434], ["responses", 1440], ["correlated", 1450], ["with", 1461], ["lower", 1466], ["IENF", 1472], ["density", 1477], [".", 1484], ["CGRP", 1486], ["and", 1491], ["SP", 1495], ["expression", 1498], ["was", 1509], ["decreased", 1513], ["principally", 1523], ["in", 1535], ["medium", 1538], ["(", 1545], ["400", 1546], ["-", 1549], ["800", 1550], ["\u03bcm(2", 1554], [")", 1558], [")", 1559], ["and", 1561], ["small", 1565], ["neurons", 1571], ["(", 1579], ["<", 1580], ["400", 1581], ["\u03bcm(2", 1585], [")", 1589], [")", 1590], [",", 1591], ["respectively", 1593], [",", 1605], ["regardless", 1607], ["of", 1618], ["IB4", 1621], ["labeling", 1625], [".", 1633], ["Expression", 1635], ["of", 1646], ["Nav1.8", 1649], ["was", 1656], ["only", 1660], ["decreased", 1665], ["in", 1675], ["small", 1678], ["and", 1684], ["medium", 1688], ["IB4", 1695], ["negative", 1699], ["neurons", 1708], [".", 1715], ["NGF", 1717], ["immunization", 1721], ["appears", 1734], ["to", 1742], ["result", 1745], ["in", 1752], ["a", 1755], ["more", 1757], ["profound", 1762], ["antagonism", 1771], ["of", 1782], ["NGF", 1785], ["than", 1789], ["tanezumab", 1794], ["therapy", 1804], [",", 1811], ["but", 1813], ["we", 1817], ["hypothesize", 1820], ["that", 1832], ["decreases", 1837], ["in", 1847], ["IENF", 1850], ["density", 1855], ["and", 1863], ["nociception", 1867], ["-", 1878], ["related", 1879], ["protein", 1887], ["expression", 1895], ["are", 1906], ["potential", 1910], ["mechanisms", 1920], ["for", 1931], ["tanezumab", 1935], ["-", 1944], ["induced", 1945], ["hypoalgesia", 1953], [".", 1964]]}
{"context": "Mutations in the ribosomal protein (RP)S19 gene have been found in about 25% of the cases of Diamond-Blackfan anemia (DBA), a rare congenital hypoplastic anemia that includes variable physical malformations. Various mutations have been identified in the RPS19 gene, but no investigations regarding the effect of these alterations on RPS19 mRNA levels have been performed. It is well established that mutated mRNA containing a premature stop codon (PTC) or lacking a stop codon can be rapidly degraded by specific mechanisms called nonsense mediated decay (NMD) and nonstop decay. To study the involvement of such mechanisms in DBA, we analyzed immortalized lymphoblastoid cells and primary fibroblasts from patients presenting different kinds of mutations in the RPS19 gene, generating allelic deletion, missense, nonsense, and nonstop messengers. We found that RPS19 mRNA levels are decreased in the cells with allelic deletion and, to a variable extent, also in all the cell lines with PTC or nonstop mutations. Further analysis showed that translation inhibition causes a stabilization of the mutated RPS19 mRNA. Our findings indicate that NMD and nonstop decay affect the expression of mutated RPS19 genes; this may help to clarify genotype-phenotype correlations in DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "141cca4558cd4f99b00b0fe5066754ca", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[19, 22]], "char_spans": [[93, 115]]}, {"text": "DBA", "token_spans": [[219, 219], [24, 24], [111, 111]], "char_spans": [[1271, 1273], [118, 120], [627, 629]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["ribosomal", 17], ["protein", 27], ["(", 35], ["RP)S19", 36], ["gene", 43], ["have", 48], ["been", 53], ["found", 58], ["in", 64], ["about", 67], ["25", 73], ["%", 75], ["of", 77], ["the", 80], ["cases", 84], ["of", 90], ["Diamond", 93], ["-", 100], ["Blackfan", 101], ["anemia", 110], ["(", 117], ["DBA", 118], [")", 121], [",", 122], ["a", 124], ["rare", 126], ["congenital", 131], ["hypoplastic", 142], ["anemia", 154], ["that", 161], ["includes", 166], ["variable", 175], ["physical", 184], ["malformations", 193], [".", 206], ["Various", 208], ["mutations", 216], ["have", 226], ["been", 231], ["identified", 236], ["in", 247], ["the", 250], ["RPS19", 254], ["gene", 260], [",", 264], ["but", 266], ["no", 270], ["investigations", 273], ["regarding", 288], ["the", 298], ["effect", 302], ["of", 309], ["these", 312], ["alterations", 318], ["on", 330], ["RPS19", 333], ["mRNA", 339], ["levels", 344], ["have", 351], ["been", 356], ["performed", 361], [".", 370], ["It", 372], ["is", 375], ["well", 378], ["established", 383], ["that", 395], ["mutated", 400], ["mRNA", 408], ["containing", 413], ["a", 424], ["premature", 426], ["stop", 436], ["codon", 441], ["(", 447], ["PTC", 448], [")", 451], ["or", 453], ["lacking", 456], ["a", 464], ["stop", 466], ["codon", 471], ["can", 477], ["be", 481], ["rapidly", 484], ["degraded", 492], ["by", 501], ["specific", 504], ["mechanisms", 513], ["called", 524], ["nonsense", 531], ["mediated", 540], ["decay", 549], ["(", 555], ["NMD", 556], [")", 559], ["and", 561], ["nonstop", 565], ["decay", 573], [".", 578], ["To", 580], ["study", 583], ["the", 589], ["involvement", 593], ["of", 605], ["such", 608], ["mechanisms", 613], ["in", 624], ["DBA", 627], [",", 630], ["we", 632], ["analyzed", 635], ["immortalized", 644], ["lymphoblastoid", 657], ["cells", 672], ["and", 678], ["primary", 682], ["fibroblasts", 690], ["from", 702], ["patients", 707], ["presenting", 716], ["different", 727], ["kinds", 737], ["of", 743], ["mutations", 746], ["in", 756], ["the", 759], ["RPS19", 763], ["gene", 769], [",", 773], ["generating", 775], ["allelic", 786], ["deletion", 794], [",", 802], ["missense", 804], [",", 812], ["nonsense", 814], [",", 822], ["and", 824], ["nonstop", 828], ["messengers", 836], [".", 846], ["We", 848], ["found", 851], ["that", 857], ["RPS19", 862], ["mRNA", 868], ["levels", 873], ["are", 880], ["decreased", 884], ["in", 894], ["the", 897], ["cells", 901], ["with", 907], ["allelic", 912], ["deletion", 920], ["and", 929], [",", 932], ["to", 934], ["a", 937], ["variable", 939], ["extent", 948], [",", 954], ["also", 956], ["in", 961], ["all", 964], ["the", 968], ["cell", 972], ["lines", 977], ["with", 983], ["PTC", 988], ["or", 992], ["nonstop", 995], ["mutations", 1003], [".", 1012], ["Further", 1014], ["analysis", 1022], ["showed", 1031], ["that", 1038], ["translation", 1043], ["inhibition", 1055], ["causes", 1066], ["a", 1073], ["stabilization", 1075], ["of", 1089], ["the", 1092], ["mutated", 1096], ["RPS19", 1104], ["mRNA", 1110], [".", 1114], ["Our", 1116], ["findings", 1120], ["indicate", 1129], ["that", 1138], ["NMD", 1143], ["and", 1147], ["nonstop", 1151], ["decay", 1159], ["affect", 1165], ["the", 1172], ["expression", 1176], ["of", 1187], ["mutated", 1190], ["RPS19", 1198], ["genes", 1204], [";", 1209], ["this", 1211], ["may", 1216], ["help", 1220], ["to", 1225], ["clarify", 1228], ["genotype", 1236], ["-", 1244], ["phenotype", 1245], ["correlations", 1255], ["in", 1268], ["DBA", 1271], [".", 1274]]}
{"context": "Sotos syndrome is a genetic disorder characterized by a typical facial appearance, macrocephaly, accelerated growth, developmental delay, and a variable range of associated abnormalities. The NSD1 gene was recently found to be responsible for Sotos syndrome, and more than 150 patients with NSD1 alterations have been identified. A significant ethnic difference is found in the prevalence of different types of mutation, with a high percentage of microdeletions identified in Japanese Sotos syndrome patients and with intragenic mutations in most non-Japanese patients. NSD1 aberrations are rather specific for Sotos syndrome, but have also been detected in patients lacking one or more major criteria of the disorder, namely overgrowth, macrocephaly, and advanced bone age. Thus, new diagnostic criteria should be considered. Studies have reported different frequencies of mutations versus non-mutations in Sotos syndrome, thus indicating allelic or locus hetereogeneity. Although some authors have suggested genotype/phenotype correlations, further studies are needed.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "e3fcd872a2a34c279d4633b77cd0d266", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[30, 31]], "char_spans": [[192, 200]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["is", 15], ["a", 18], ["genetic", 20], ["disorder", 28], ["characterized", 37], ["by", 51], ["a", 54], ["typical", 56], ["facial", 64], ["appearance", 71], [",", 81], ["macrocephaly", 83], [",", 95], ["accelerated", 97], ["growth", 109], [",", 115], ["developmental", 117], ["delay", 131], [",", 136], ["and", 138], ["a", 142], ["variable", 144], ["range", 153], ["of", 159], ["associated", 162], ["abnormalities", 173], [".", 186], ["The", 188], ["NSD1", 192], ["gene", 197], ["was", 202], ["recently", 206], ["found", 215], ["to", 221], ["be", 224], ["responsible", 227], ["for", 239], ["Sotos", 243], ["syndrome", 249], [",", 257], ["and", 259], ["more", 263], ["than", 268], ["150", 273], ["patients", 277], ["with", 286], ["NSD1", 291], ["alterations", 296], ["have", 308], ["been", 313], ["identified", 318], [".", 328], ["A", 330], ["significant", 332], ["ethnic", 344], ["difference", 351], ["is", 362], ["found", 365], ["in", 371], ["the", 374], ["prevalence", 378], ["of", 389], ["different", 392], ["types", 402], ["of", 408], ["mutation", 411], [",", 419], ["with", 421], ["a", 426], ["high", 428], ["percentage", 433], ["of", 444], ["microdeletions", 447], ["identified", 462], ["in", 473], ["Japanese", 476], ["Sotos", 485], ["syndrome", 491], ["patients", 500], ["and", 509], ["with", 513], ["intragenic", 518], ["mutations", 529], ["in", 539], ["most", 542], ["non", 547], ["-", 550], ["Japanese", 551], ["patients", 560], [".", 568], ["NSD1", 570], ["aberrations", 575], ["are", 587], ["rather", 591], ["specific", 598], ["for", 607], ["Sotos", 611], ["syndrome", 617], [",", 625], ["but", 627], ["have", 631], ["also", 636], ["been", 641], ["detected", 646], ["in", 655], ["patients", 658], ["lacking", 667], ["one", 675], ["or", 679], ["more", 682], ["major", 687], ["criteria", 693], ["of", 702], ["the", 705], ["disorder", 709], [",", 717], ["namely", 719], ["overgrowth", 726], [",", 736], ["macrocephaly", 738], [",", 750], ["and", 752], ["advanced", 756], ["bone", 765], ["age", 770], [".", 773], ["Thus", 775], [",", 779], ["new", 781], ["diagnostic", 785], ["criteria", 796], ["should", 805], ["be", 812], ["considered", 815], [".", 825], ["Studies", 827], ["have", 835], ["reported", 840], ["different", 849], ["frequencies", 859], ["of", 871], ["mutations", 874], ["versus", 884], ["non", 891], ["-", 894], ["mutations", 895], ["in", 905], ["Sotos", 908], ["syndrome", 914], [",", 922], ["thus", 924], ["indicating", 929], ["allelic", 940], ["or", 948], ["locus", 951], ["hetereogeneity", 957], [".", 971], ["Although", 973], ["some", 982], ["authors", 987], ["have", 995], ["suggested", 1000], ["genotype", 1010], ["/", 1018], ["phenotype", 1019], ["correlations", 1029], [",", 1041], ["further", 1043], ["studies", 1051], ["are", 1059], ["needed", 1063], [".", 1069]]}
{"context": "Turner syndrome is a chromosomal disorder in which all or part of one X chromosome is missing. The meiotic or mitotic origin of most cases remains unknown due to the difficulty in detecting hidden mosaicism and to the lack of meiotic segregation studies. We analyzed 15 Turner patients, 10 with a 45,X whereas the rest had a second cell line with abnormal X-chromosomes: a pseudodicentric, an isochromosome, one large and one small ring, and the last with a long arm deletion. Our aims were: to detect X cryptic mosaicism in patients with a 45,X constitution; to determine the parental origin of the abnormality; to infer the zygotic origin of the karyotype and to suggest the timing and mechanism of the error(s) leading to the formation of abnormal X chromosomes from maternal origin. Molecular investigation did not revealed heterozygosity for any microsatellite, excluding X mosaicism in the 45,X cases. Parental origin of the single X chromosome was maternal in 90% of these patients. Three of the structurally abnormal Xs were maternally derived whereas the other two were paternal. These results allowed us to corroborate breakpoints in these abnormal X chromosomes and suggest that the pseudodicentric chromosome originated from post-zygotic sister chromatid exchange, whereas the Xq deleted chromosome probably arose after a recombination event during maternal meiosis.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "fb9765068c0047e8994ba18eabf79e88", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[13, 13], [97, 97], [141, 141], [170, 170], [158, 158], [65, 65], [207, 207]], "char_spans": [[70, 70], [502, 502], [751, 751], [938, 938], [877, 877], [356, 356], [1159, 1159]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["is", 16], ["a", 19], ["chromosomal", 21], ["disorder", 33], ["in", 42], ["which", 45], ["all", 51], ["or", 55], ["part", 58], ["of", 63], ["one", 66], ["X", 70], ["chromosome", 72], ["is", 83], ["missing", 86], [".", 93], ["The", 95], ["meiotic", 99], ["or", 107], ["mitotic", 110], ["origin", 118], ["of", 125], ["most", 128], ["cases", 133], ["remains", 139], ["unknown", 147], ["due", 155], ["to", 159], ["the", 162], ["difficulty", 166], ["in", 177], ["detecting", 180], ["hidden", 190], ["mosaicism", 197], ["and", 207], ["to", 211], ["the", 214], ["lack", 218], ["of", 223], ["meiotic", 226], ["segregation", 234], ["studies", 246], [".", 253], ["We", 255], ["analyzed", 258], ["15", 267], ["Turner", 270], ["patients", 277], [",", 285], ["10", 287], ["with", 290], ["a", 295], ["45,X", 297], ["whereas", 302], ["the", 310], ["rest", 314], ["had", 319], ["a", 323], ["second", 325], ["cell", 332], ["line", 337], ["with", 342], ["abnormal", 347], ["X", 356], ["-", 357], ["chromosomes", 358], [":", 369], ["a", 371], ["pseudodicentric", 373], [",", 388], ["an", 390], ["isochromosome", 393], [",", 406], ["one", 408], ["large", 412], ["and", 418], ["one", 422], ["small", 426], ["ring", 432], [",", 436], ["and", 438], ["the", 442], ["last", 446], ["with", 451], ["a", 456], ["long", 458], ["arm", 463], ["deletion", 467], [".", 475], ["Our", 477], ["aims", 481], ["were", 486], [":", 490], ["to", 492], ["detect", 495], ["X", 502], ["cryptic", 504], ["mosaicism", 512], ["in", 522], ["patients", 525], ["with", 534], ["a", 539], ["45,X", 541], ["constitution", 546], [";", 558], ["to", 560], ["determine", 563], ["the", 573], ["parental", 577], ["origin", 586], ["of", 593], ["the", 596], ["abnormality", 600], [";", 611], ["to", 613], ["infer", 616], ["the", 622], ["zygotic", 626], ["origin", 634], ["of", 641], ["the", 644], ["karyotype", 648], ["and", 658], ["to", 662], ["suggest", 665], ["the", 673], ["timing", 677], ["and", 684], ["mechanism", 688], ["of", 698], ["the", 701], ["error(s", 705], [")", 712], ["leading", 714], ["to", 722], ["the", 725], ["formation", 729], ["of", 739], ["abnormal", 742], ["X", 751], ["chromosomes", 753], ["from", 765], ["maternal", 770], ["origin", 779], [".", 785], ["Molecular", 787], ["investigation", 797], ["did", 811], ["not", 815], ["revealed", 819], ["heterozygosity", 828], ["for", 843], ["any", 847], ["microsatellite", 851], [",", 865], ["excluding", 867], ["X", 877], ["mosaicism", 879], ["in", 889], ["the", 892], ["45,X", 896], ["cases", 901], [".", 906], ["Parental", 908], ["origin", 917], ["of", 924], ["the", 927], ["single", 931], ["X", 938], ["chromosome", 940], ["was", 951], ["maternal", 955], ["in", 964], ["90", 967], ["%", 969], ["of", 971], ["these", 974], ["patients", 980], [".", 988], ["Three", 990], ["of", 996], ["the", 999], ["structurally", 1003], ["abnormal", 1016], ["Xs", 1025], ["were", 1028], ["maternally", 1033], ["derived", 1044], ["whereas", 1052], ["the", 1060], ["other", 1064], ["two", 1070], ["were", 1074], ["paternal", 1079], [".", 1087], ["These", 1089], ["results", 1095], ["allowed", 1103], ["us", 1111], ["to", 1114], ["corroborate", 1117], ["breakpoints", 1129], ["in", 1141], ["these", 1144], ["abnormal", 1150], ["X", 1159], ["chromosomes", 1161], ["and", 1173], ["suggest", 1177], ["that", 1185], ["the", 1190], ["pseudodicentric", 1194], ["chromosome", 1210], ["originated", 1221], ["from", 1232], ["post", 1237], ["-", 1241], ["zygotic", 1242], ["sister", 1250], ["chromatid", 1257], ["exchange", 1267], [",", 1275], ["whereas", 1277], ["the", 1285], ["Xq", 1289], ["deleted", 1292], ["chromosome", 1300], ["probably", 1311], ["arose", 1320], ["after", 1326], ["a", 1332], ["recombination", 1334], ["event", 1348], ["during", 1354], ["maternal", 1361], ["meiosis", 1370], [".", 1377]]}
{"context": "Alpha-synuclein (alphaS) is the primary component of Lewy bodies, the pathological hallmark of Parkinson's Disease. Aggregation of alphaS is thought to proceed from a primarily disordered state with nascent secondary structure through intermediate conformations to oligomeric forms and finally to mature amyloid fibrils. Low pH conditions lead to conformational changes associated with increased alphaS fibril formation. Here we characterize these structural and dynamic changes using solution state NMR measurements of secondary chemical shifts, relaxation parameters, residual dipolar couplings, and paramagnetic relaxation enhancement. We find that the neutralization of negatively charged side-chains eliminates electrostatic repulsion in the C-terminal tail of alphaS and leads to a collapse of this region at low pH. Hydrophobic contacts between the compact C-terminal tail and the NAC (non-amyloid-beta component) region are maintained and may lead to the formation of a globular domain. Transient long-range contacts between the C-terminus of the protein and regions N-terminal to the NAC region are also preserved. Thus, the release of long-range contacts does not play a role in the increased aggregation of alphaS at low pH, which we instead attribute to the increased hydrophobicity of the protein.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "49df234dddfb4af6b70443ee0df3e00d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["(", 16], ["alphaS", 17], [")", 23], ["is", 25], ["the", 28], ["primary", 32], ["component", 40], ["of", 50], ["Lewy", 53], ["bodies", 58], [",", 64], ["the", 66], ["pathological", 70], ["hallmark", 83], ["of", 92], ["Parkinson", 95], ["'s", 104], ["Disease", 107], [".", 114], ["Aggregation", 116], ["of", 128], ["alphaS", 131], ["is", 138], ["thought", 141], ["to", 149], ["proceed", 152], ["from", 160], ["a", 165], ["primarily", 167], ["disordered", 177], ["state", 188], ["with", 194], ["nascent", 199], ["secondary", 207], ["structure", 217], ["through", 227], ["intermediate", 235], ["conformations", 248], ["to", 262], ["oligomeric", 265], ["forms", 276], ["and", 282], ["finally", 286], ["to", 294], ["mature", 297], ["amyloid", 304], ["fibrils", 312], [".", 319], ["Low", 321], ["pH", 325], ["conditions", 328], ["lead", 339], ["to", 344], ["conformational", 347], ["changes", 362], ["associated", 370], ["with", 381], ["increased", 386], ["alphaS", 396], ["fibril", 403], ["formation", 410], [".", 419], ["Here", 421], ["we", 426], ["characterize", 429], ["these", 442], ["structural", 448], ["and", 459], ["dynamic", 463], ["changes", 471], ["using", 479], ["solution", 485], ["state", 494], ["NMR", 500], ["measurements", 504], ["of", 517], ["secondary", 520], ["chemical", 530], ["shifts", 539], [",", 545], ["relaxation", 547], ["parameters", 558], [",", 568], ["residual", 570], ["dipolar", 579], ["couplings", 587], [",", 596], ["and", 598], ["paramagnetic", 602], ["relaxation", 615], ["enhancement", 626], [".", 637], ["We", 639], ["find", 642], ["that", 647], ["the", 652], ["neutralization", 656], ["of", 671], ["negatively", 674], ["charged", 685], ["side", 693], ["-", 697], ["chains", 698], ["eliminates", 705], ["electrostatic", 716], ["repulsion", 730], ["in", 740], ["the", 743], ["C", 747], ["-", 748], ["terminal", 749], ["tail", 758], ["of", 763], ["alphaS", 766], ["and", 773], ["leads", 777], ["to", 783], ["a", 786], ["collapse", 788], ["of", 797], ["this", 800], ["region", 805], ["at", 812], ["low", 815], ["pH.", 819], ["Hydrophobic", 823], ["contacts", 835], ["between", 844], ["the", 852], ["compact", 856], ["C", 864], ["-", 865], ["terminal", 866], ["tail", 875], ["and", 880], ["the", 884], ["NAC", 888], ["(", 892], ["non", 893], ["-", 896], ["amyloid", 897], ["-", 904], ["beta", 905], ["component", 910], [")", 919], ["region", 921], ["are", 928], ["maintained", 932], ["and", 943], ["may", 947], ["lead", 951], ["to", 956], ["the", 959], ["formation", 963], ["of", 973], ["a", 976], ["globular", 978], ["domain", 987], [".", 993], ["Transient", 995], ["long", 1005], ["-", 1009], ["range", 1010], ["contacts", 1016], ["between", 1025], ["the", 1033], ["C", 1037], ["-", 1038], ["terminus", 1039], ["of", 1048], ["the", 1051], ["protein", 1055], ["and", 1063], ["regions", 1067], ["N", 1075], ["-", 1076], ["terminal", 1077], ["to", 1086], ["the", 1089], ["NAC", 1093], ["region", 1097], ["are", 1104], ["also", 1108], ["preserved", 1113], [".", 1122], ["Thus", 1124], [",", 1128], ["the", 1130], ["release", 1134], ["of", 1142], ["long", 1145], ["-", 1149], ["range", 1150], ["contacts", 1156], ["does", 1165], ["not", 1170], ["play", 1174], ["a", 1179], ["role", 1181], ["in", 1186], ["the", 1189], ["increased", 1193], ["aggregation", 1203], ["of", 1215], ["alphaS", 1218], ["at", 1225], ["low", 1228], ["pH", 1232], [",", 1234], ["which", 1236], ["we", 1242], ["instead", 1245], ["attribute", 1253], ["to", 1263], ["the", 1266], ["increased", 1270], ["hydrophobicity", 1280], ["of", 1295], ["the", 1298], ["protein", 1302], [".", 1309]]}
{"context": "Neural stem/progenitor cell (NSP) biology and neurogenesis in adult central nervous system (CNS) are important both towards potential future therapeutic applications for CNS repair, and for the fundamental function of the CNS. In the present study, we report the characterization of NSP population from subventricular zone (SVZ) of neonatal piglet brain using in vivo and in vitro systems. We show that the nestin and vimentin-positive neural progenitor cells are present in the SVZ of the lateral ventricles of neonatal piglet brain. In vitro, piglet NSPs proliferated as neurospheres, expressed the typical protein of neural progenitors, nestin and a range of well-established neurodevelopmental markers. Upon dissociation and subculture, piglet NSPs differentiated into neurons and glial cells. Clonal analysis demonstrates that piglet NSPs are multipotent and retain the capacity to generate both glia and neurons. These cells expressed VEGF, VEGFR1, VEGFR2 and Neuropilin-1 and -2 mRNAs. Real time PCR revealed that SVZ NSPs from newborn piglet expressed total VEGF and all VEGF splice variants. These findings show that piglet NSPs may be helpful to more effectively design growth factor based strategies to enhance endogenous precursor cells for cell transplantation studies potentially leading to the application of this strategy in the nervous system disease and injury.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "93550bd7ff2742e5be0946f9e56d9da7", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[113, 113], [74, 74]], "char_spans": [[640, 645], [407, 412]]}]}], "context_tokens": [["Neural", 0], ["stem", 7], ["/", 11], ["progenitor", 12], ["cell", 23], ["(", 28], ["NSP", 29], [")", 32], ["biology", 34], ["and", 42], ["neurogenesis", 46], ["in", 59], ["adult", 62], ["central", 68], ["nervous", 76], ["system", 84], ["(", 91], ["CNS", 92], [")", 95], ["are", 97], ["important", 101], ["both", 111], ["towards", 116], ["potential", 124], ["future", 134], ["therapeutic", 141], ["applications", 153], ["for", 166], ["CNS", 170], ["repair", 174], [",", 180], ["and", 182], ["for", 186], ["the", 190], ["fundamental", 194], ["function", 206], ["of", 215], ["the", 218], ["CNS", 222], [".", 225], ["In", 227], ["the", 230], ["present", 234], ["study", 242], [",", 247], ["we", 249], ["report", 252], ["the", 259], ["characterization", 263], ["of", 280], ["NSP", 283], ["population", 287], ["from", 298], ["subventricular", 303], ["zone", 318], ["(", 323], ["SVZ", 324], [")", 327], ["of", 329], ["neonatal", 332], ["piglet", 341], ["brain", 348], ["using", 354], ["in", 360], ["vivo", 363], ["and", 368], ["in", 372], ["vitro", 375], ["systems", 381], [".", 388], ["We", 390], ["show", 393], ["that", 398], ["the", 403], ["nestin", 407], ["and", 414], ["vimentin", 418], ["-", 426], ["positive", 427], ["neural", 436], ["progenitor", 443], ["cells", 454], ["are", 460], ["present", 464], ["in", 472], ["the", 475], ["SVZ", 479], ["of", 483], ["the", 486], ["lateral", 490], ["ventricles", 498], ["of", 509], ["neonatal", 512], ["piglet", 521], ["brain", 528], [".", 533], ["In", 535], ["vitro", 538], [",", 543], ["piglet", 545], ["NSPs", 552], ["proliferated", 557], ["as", 570], ["neurospheres", 573], [",", 585], ["expressed", 587], ["the", 597], ["typical", 601], ["protein", 609], ["of", 617], ["neural", 620], ["progenitors", 627], [",", 638], ["nestin", 640], ["and", 647], ["a", 651], ["range", 653], ["of", 659], ["well", 662], ["-", 666], ["established", 667], ["neurodevelopmental", 679], ["markers", 698], [".", 705], ["Upon", 707], ["dissociation", 712], ["and", 725], ["subculture", 729], [",", 739], ["piglet", 741], ["NSPs", 748], ["differentiated", 753], ["into", 768], ["neurons", 773], ["and", 781], ["glial", 785], ["cells", 791], [".", 796], ["Clonal", 798], ["analysis", 805], ["demonstrates", 814], ["that", 827], ["piglet", 832], ["NSPs", 839], ["are", 844], ["multipotent", 848], ["and", 860], ["retain", 864], ["the", 871], ["capacity", 875], ["to", 884], ["generate", 887], ["both", 896], ["glia", 901], ["and", 906], ["neurons", 910], [".", 917], ["These", 919], ["cells", 925], ["expressed", 931], ["VEGF", 941], [",", 945], ["VEGFR1", 947], [",", 953], ["VEGFR2", 955], ["and", 962], ["Neuropilin-1", 966], ["and", 979], ["-2", 983], ["mRNAs", 986], [".", 991], ["Real", 993], ["time", 998], ["PCR", 1003], ["revealed", 1007], ["that", 1016], ["SVZ", 1021], ["NSPs", 1025], ["from", 1030], ["newborn", 1035], ["piglet", 1043], ["expressed", 1050], ["total", 1060], ["VEGF", 1066], ["and", 1071], ["all", 1075], ["VEGF", 1079], ["splice", 1084], ["variants", 1091], [".", 1099], ["These", 1101], ["findings", 1107], ["show", 1116], ["that", 1121], ["piglet", 1126], ["NSPs", 1133], ["may", 1138], ["be", 1142], ["helpful", 1145], ["to", 1153], ["more", 1156], ["effectively", 1161], ["design", 1173], ["growth", 1180], ["factor", 1187], ["based", 1194], ["strategies", 1200], ["to", 1211], ["enhance", 1214], ["endogenous", 1222], ["precursor", 1233], ["cells", 1243], ["for", 1249], ["cell", 1253], ["transplantation", 1258], ["studies", 1274], ["potentially", 1282], ["leading", 1294], ["to", 1302], ["the", 1305], ["application", 1309], ["of", 1321], ["this", 1324], ["strategy", 1329], ["in", 1338], ["the", 1341], ["nervous", 1345], ["system", 1353], ["disease", 1360], ["and", 1368], ["injury", 1372], [".", 1378]]}
{"context": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1), also known as HARP, is an ATP-dependent annealing helicase that stabilizes replication forks during DNA damage. Mutations in this gene are the cause of Schimke immune-osseous dysplasia (SIOD), an autosomal recessive disorder characterized by T-cell immunodeficiency and growth dysfunctions. In this review, we summarize the main roles of SMARCAL1 in DNA repair, telomere maintenance and replication fork stability in response to DNA replication stress.", "qas": [{"question": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "answers": ["SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "HARP"], "qid": "94ca9bf4ee72459085a2b6464d531562", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["cause", 24], ["Schimke", 30], ["immune", 38], ["-", 44], ["osseous", 45], ["dysplasia", 53], ["?", 62]], "detected_answers": [{"text": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "token_spans": [[0, 20]], "char_spans": [[0, 103]]}, {"text": "HARP", "token_spans": [[26, 26]], "char_spans": [[121, 124]]}]}], "context_tokens": [["SMARCAL1", 0], ["(", 9], ["SWI", 10], ["/", 13], ["SNF", 14], ["Related", 18], [",", 25], ["Matrix", 27], ["Associated", 34], [",", 44], ["Actin", 46], ["Dependent", 52], ["Regulator", 62], ["Of", 72], ["Chromatin", 75], [",", 84], ["Subfamily", 86], ["A", 96], ["-", 97], ["Like", 98], ["1", 103], [")", 104], [",", 105], ["also", 107], ["known", 112], ["as", 118], ["HARP", 121], [",", 125], ["is", 127], ["an", 130], ["ATP", 133], ["-", 136], ["dependent", 137], ["annealing", 147], ["helicase", 157], ["that", 166], ["stabilizes", 171], ["replication", 182], ["forks", 194], ["during", 200], ["DNA", 207], ["damage", 211], [".", 217], ["Mutations", 219], ["in", 229], ["this", 232], ["gene", 237], ["are", 242], ["the", 246], ["cause", 250], ["of", 256], ["Schimke", 259], ["immune", 267], ["-", 273], ["osseous", 274], ["dysplasia", 282], ["(", 292], ["SIOD", 293], [")", 297], [",", 298], ["an", 300], ["autosomal", 303], ["recessive", 313], ["disorder", 323], ["characterized", 332], ["by", 346], ["T", 349], ["-", 350], ["cell", 351], ["immunodeficiency", 356], ["and", 373], ["growth", 377], ["dysfunctions", 384], [".", 396], ["In", 398], ["this", 401], ["review", 406], [",", 412], ["we", 414], ["summarize", 417], ["the", 427], ["main", 431], ["roles", 436], ["of", 442], ["SMARCAL1", 445], ["in", 454], ["DNA", 457], ["repair", 461], [",", 467], ["telomere", 469], ["maintenance", 478], ["and", 490], ["replication", 494], ["fork", 506], ["stability", 511], ["in", 521], ["response", 524], ["to", 533], ["DNA", 536], ["replication", 540], ["stress", 552], [".", 558]]}
{"context": "The literature suggests that the d -dimer is useful in patients suspected of having pulmonary embolism and who have a low pretest probability of disease. A previously defined clinical decision rule, the Wells Criteria, may provide a reliable and reproducible means of determining this pretest probability. We evaluate the interrater agreement and external validity of Wells Criteria in determining pretest probability in patients suspected of having pulmonary embolism. This was a prospective observational study. Trained research assistants enrolled patients during 120 random 8-hour shifts. Patients who underwent imaging for pulmonary embolism after a medical history, physical examination, and chest radiograph were enrolled. Treating providers and research assistants determined pretest probability according to Wells Criteria in a blinded fashion. Two d -dimer assays were run. Three-month follow-up for the diagnosis of pulmonary embolism was performed. Interrater agreement tables were created. kappa Values, sensitivities, and specificities were determined. Of the 153 eligible patients, 3 patients were missed, 16 patients declined, and 134 (88%) patients were enrolled. Sixteen (12%) patients were diagnosed with pulmonary embolism. The kappa values for Wells Criteria were 0.54 and 0.72 for the trichotomized and dichotomized scorings, respectively. When Wells Criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively. When Wells Criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively. The immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%). Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.", "qas": [{"question": "What can be predicted with the Wells criteria?", "answers": ["pulmonary embolism"], "qid": "28e8fe6709904ff19ee941b716a6183e", "question_tokens": [["What", 0], ["can", 5], ["be", 9], ["predicted", 12], ["with", 22], ["the", 27], ["Wells", 31], ["criteria", 37], ["?", 45]], "detected_answers": [{"text": "pulmonary embolism", "token_spans": [[96, 97], [70, 71], [294, 295], [261, 262], [364, 365], [201, 202], [14, 15], [146, 147], [283, 284]], "char_spans": [[628, 645], [450, 467], [1682, 1699], [1530, 1547], [2059, 2076], [1224, 1241], [84, 101], [927, 944], [1639, 1656]]}]}], "context_tokens": [["The", 0], ["literature", 4], ["suggests", 15], ["that", 24], ["the", 29], ["d", 33], ["-dimer", 35], ["is", 42], ["useful", 45], ["in", 52], ["patients", 55], ["suspected", 64], ["of", 74], ["having", 77], ["pulmonary", 84], ["embolism", 94], ["and", 103], ["who", 107], ["have", 111], ["a", 116], ["low", 118], ["pretest", 122], ["probability", 130], ["of", 142], ["disease", 145], [".", 152], ["A", 154], ["previously", 156], ["defined", 167], ["clinical", 175], ["decision", 184], ["rule", 193], [",", 197], ["the", 199], ["Wells", 203], ["Criteria", 209], [",", 217], ["may", 219], ["provide", 223], ["a", 231], ["reliable", 233], ["and", 242], ["reproducible", 246], ["means", 259], ["of", 265], ["determining", 268], ["this", 280], ["pretest", 285], ["probability", 293], [".", 304], ["We", 306], ["evaluate", 309], ["the", 318], ["interrater", 322], ["agreement", 333], ["and", 343], ["external", 347], ["validity", 356], ["of", 365], ["Wells", 368], ["Criteria", 374], ["in", 383], ["determining", 386], ["pretest", 398], ["probability", 406], ["in", 418], ["patients", 421], ["suspected", 430], ["of", 440], ["having", 443], ["pulmonary", 450], ["embolism", 460], [".", 468], ["This", 470], ["was", 475], ["a", 479], ["prospective", 481], ["observational", 493], ["study", 507], [".", 512], ["Trained", 514], ["research", 522], ["assistants", 531], ["enrolled", 542], ["patients", 551], ["during", 560], ["120", 567], ["random", 571], ["8-hour", 578], ["shifts", 585], [".", 591], ["Patients", 593], ["who", 602], ["underwent", 606], ["imaging", 616], ["for", 624], ["pulmonary", 628], ["embolism", 638], ["after", 647], ["a", 653], ["medical", 655], ["history", 663], [",", 670], ["physical", 672], ["examination", 681], [",", 692], ["and", 694], ["chest", 698], ["radiograph", 704], ["were", 715], ["enrolled", 720], [".", 728], ["Treating", 730], ["providers", 739], ["and", 749], ["research", 753], ["assistants", 762], ["determined", 773], ["pretest", 784], ["probability", 792], ["according", 804], ["to", 814], ["Wells", 817], ["Criteria", 823], ["in", 832], ["a", 835], ["blinded", 837], ["fashion", 845], [".", 852], ["Two", 854], ["d", 858], ["-dimer", 860], ["assays", 867], ["were", 874], ["run", 879], [".", 882], ["Three", 884], ["-", 889], ["month", 890], ["follow", 896], ["-", 902], ["up", 903], ["for", 906], ["the", 910], ["diagnosis", 914], ["of", 924], ["pulmonary", 927], ["embolism", 937], ["was", 946], ["performed", 950], [".", 959], ["Interrater", 961], ["agreement", 972], ["tables", 982], ["were", 989], ["created", 994], [".", 1001], ["kappa", 1003], ["Values", 1009], [",", 1015], ["sensitivities", 1017], [",", 1030], ["and", 1032], ["specificities", 1036], ["were", 1050], ["determined", 1055], [".", 1065], ["Of", 1067], ["the", 1070], ["153", 1074], ["eligible", 1078], ["patients", 1087], [",", 1095], ["3", 1097], ["patients", 1099], ["were", 1108], ["missed", 1113], [",", 1119], ["16", 1121], ["patients", 1124], ["declined", 1133], [",", 1141], ["and", 1143], ["134", 1147], ["(", 1151], ["88", 1152], ["%", 1154], [")", 1155], ["patients", 1157], ["were", 1166], ["enrolled", 1171], [".", 1179], ["Sixteen", 1181], ["(", 1189], ["12", 1190], ["%", 1192], [")", 1193], ["patients", 1195], ["were", 1204], ["diagnosed", 1209], ["with", 1219], ["pulmonary", 1224], ["embolism", 1234], [".", 1242], ["The", 1244], ["kappa", 1248], ["values", 1254], ["for", 1261], ["Wells", 1265], ["Criteria", 1271], ["were", 1280], ["0.54", 1285], ["and", 1290], ["0.72", 1294], ["for", 1299], ["the", 1303], ["trichotomized", 1307], ["and", 1321], ["dichotomized", 1325], ["scorings", 1338], [",", 1346], ["respectively", 1348], [".", 1360], ["When", 1362], ["Wells", 1367], ["Criteria", 1373], ["were", 1382], ["trichotomized", 1387], ["into", 1401], ["low", 1406], ["pretest", 1410], ["probability", 1418], ["(", 1430], ["n=59", 1431], [",", 1435], ["44", 1437], ["%", 1439], [")", 1440], [",", 1441], ["moderate", 1443], ["pretest", 1452], ["probability", 1460], ["(", 1472], ["n=61", 1473], [",", 1477], ["46", 1479], ["%", 1481], [")", 1482], [",", 1483], ["or", 1485], ["high", 1488], ["pretest", 1493], ["probability", 1501], ["(", 1513], ["n=14", 1514], [",", 1518], ["10", 1520], ["%", 1522], [")", 1523], [",", 1524], ["the", 1526], ["pulmonary", 1530], ["embolism", 1540], ["prevalence", 1549], ["was", 1560], ["2", 1564], ["%", 1565], [",", 1566], ["15", 1568], ["%", 1570], [",", 1571], ["and", 1573], ["43", 1577], ["%", 1579], [",", 1580], ["respectively", 1582], [".", 1594], ["When", 1596], ["Wells", 1601], ["Criteria", 1607], ["were", 1616], ["dichotomized", 1621], ["into", 1634], ["pulmonary", 1639], ["embolism", 1649], ["-", 1657], ["unlikely", 1658], ["(", 1667], ["n=88", 1668], [",", 1672], ["66", 1674], ["%", 1676], [")", 1677], ["or", 1679], ["pulmonary", 1682], ["embolism", 1692], ["-", 1700], ["likely", 1701], ["(", 1708], ["n=46", 1709], [",", 1713], ["34", 1715], ["%", 1717], [")", 1718], [",", 1719], ["the", 1721], ["prevalence", 1725], ["was", 1736], ["3", 1740], ["%", 1741], ["and", 1743], ["28", 1747], ["%", 1749], [",", 1750], ["respectively", 1752], [".", 1764], ["The", 1766], ["immunoturbidimetric", 1770], ["and", 1790], ["rapid", 1794], ["enzyme", 1800], ["-", 1806], ["linked", 1807], ["immunosorbent", 1814], ["assay", 1828], ["d", 1834], ["-dimer", 1836], ["assays", 1843], ["had", 1850], ["similar", 1854], ["sensitivities", 1862], ["(", 1876], ["94", 1877], ["%", 1879], [")", 1880], ["and", 1882], ["specificities", 1886], ["(", 1900], ["45", 1901], ["%", 1903], ["versus", 1905], ["46", 1912], ["%", 1914], [")", 1915], [".", 1916], ["Wells", 1918], ["Criteria", 1924], ["have", 1933], ["a", 1938], ["moderate", 1940], ["to", 1949], ["substantial", 1952], ["interrater", 1964], ["agreement", 1975], ["and", 1985], ["reliably", 1989], ["risk", 1998], ["stratify", 2003], ["pretest", 2012], ["probability", 2020], ["in", 2032], ["patients", 2035], ["with", 2044], ["suspected", 2049], ["pulmonary", 2059], ["embolism", 2069], [".", 2077]]}
{"context": "To investigate the use of tanezumab, a humanized monoclonal antibody that inhibits nerve growth factor, for the treatment of moderate to severe osteoarthritis in Japanese patients. Patients received tanezumab 10, 25, 50, 100, 200\u00a0\u03bcg/kg, or placebo and were followed for 92 or 120 days. Endpoints included the incidence of adverse events (AEs) and the change from baseline to week 8 in pain intensity and the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) subscales. Patients (n\u00a0=\u00a083) were 69% female, age 44-73 years, with a Kellgren-Lawrence X-ray grade of 2-4. At week 8, compared with placebo, tanezumab 25, 100, and 200\u00a0\u03bcg/kg improved index knee pain during walking (-18.5,\u00a0-14.3, and\u00a0-27.6, respectively), index knee pain in the past 24\u00a0h (-19.1,\u00a0-14.6, and\u00a0-24.2, respectively), current index knee pain (-16.5,\u00a0-10.9, and\u00a0-22.8, respectively), and the WOMAC pain (-11.5,\u00a0-9.6, and\u00a0-18.8, respectively), physical function (-8.7,\u00a0-9.5, and\u00a0-17.6, respectively), and stiffness (-20.4,\u00a0-11.2, and\u00a0-10.2, respectively) subscales. Overall, seven patients reported AEs of abnormal peripheral sensation: allodynia (two in the tanezumab 200\u00a0\u03bcg/kg group); paresthesia (two in the tanezumab 200\u00a0\u03bcg/kg group), dysesthesia (one in the tanezumab 200\u00a0\u03bcg/kg group); thermohypoesthesia (one in the tanezumab 100\u00a0\u03bcg/kg group), and decreased vibratory sense (one in the placebo group). All of these AEs were mild to moderate in severity and transient in nature. Tanezumab was safe and generally well tolerated and may improve pain symptoms in Japanese patients with moderate to severe osteoarthritis of the knee. CLINICALTRIALS.GOV IDENTIFIER: NCT00669409.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "6039fcd253ac44cb9e8813354f3d424a", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[13, 15]], "char_spans": [[83, 101]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["use", 19], ["of", 23], ["tanezumab", 26], [",", 35], ["a", 37], ["humanized", 39], ["monoclonal", 49], ["antibody", 60], ["that", 69], ["inhibits", 74], ["nerve", 83], ["growth", 89], ["factor", 96], [",", 102], ["for", 104], ["the", 108], ["treatment", 112], ["of", 122], ["moderate", 125], ["to", 134], ["severe", 137], ["osteoarthritis", 144], ["in", 159], ["Japanese", 162], ["patients", 171], [".", 179], ["Patients", 181], ["received", 190], ["tanezumab", 199], ["10", 209], [",", 211], ["25", 213], [",", 215], ["50", 217], [",", 219], ["100", 221], [",", 224], ["200", 226], ["\u03bcg", 230], ["/", 232], ["kg", 233], [",", 235], ["or", 237], ["placebo", 240], ["and", 248], ["were", 252], ["followed", 257], ["for", 266], ["92", 270], ["or", 273], ["120", 276], ["days", 280], [".", 284], ["Endpoints", 286], ["included", 296], ["the", 305], ["incidence", 309], ["of", 319], ["adverse", 322], ["events", 330], ["(", 337], ["AEs", 338], [")", 341], ["and", 343], ["the", 347], ["change", 351], ["from", 358], ["baseline", 363], ["to", 372], ["week", 375], ["8", 380], ["in", 382], ["pain", 385], ["intensity", 390], ["and", 400], ["the", 404], ["Western", 408], ["Ontario", 416], ["and", 424], ["McMaster", 428], ["Universities", 437], ["Osteoarthritis", 450], ["(", 465], ["WOMAC", 466], [")", 471], ["subscales", 473], [".", 482], ["Patients", 484], ["(", 493], ["n", 494], ["=", 496], ["83", 498], [")", 500], ["were", 502], ["69", 507], ["%", 509], ["female", 511], [",", 517], ["age", 519], ["44", 523], ["-", 525], ["73", 526], ["years", 529], [",", 534], ["with", 536], ["a", 541], ["Kellgren", 543], ["-", 551], ["Lawrence", 552], ["X", 561], ["-", 562], ["ray", 563], ["grade", 567], ["of", 573], ["2", 576], ["-", 577], ["4", 578], [".", 579], ["At", 581], ["week", 584], ["8", 589], [",", 590], ["compared", 592], ["with", 601], ["placebo", 606], [",", 613], ["tanezumab", 615], ["25", 625], [",", 627], ["100", 629], [",", 632], ["and", 634], ["200", 638], ["\u03bcg", 642], ["/", 644], ["kg", 645], ["improved", 648], ["index", 657], ["knee", 663], ["pain", 668], ["during", 673], ["walking", 680], ["(", 688], ["-18.5", 689], [",", 694], ["-14.3", 696], [",", 701], ["and", 703], ["-27.6", 707], [",", 712], ["respectively", 714], [")", 726], [",", 727], ["index", 729], ["knee", 735], ["pain", 740], ["in", 745], ["the", 748], ["past", 752], ["24", 757], ["h", 760], ["(", 762], ["-19.1", 763], [",", 768], ["-14.6", 770], [",", 775], ["and", 777], ["-24.2", 781], [",", 786], ["respectively", 788], [")", 800], [",", 801], ["current", 803], ["index", 811], ["knee", 817], ["pain", 822], ["(", 827], ["-16.5", 828], [",", 833], ["-10.9", 835], [",", 840], ["and", 842], ["-22.8", 846], [",", 851], ["respectively", 853], [")", 865], [",", 866], ["and", 868], ["the", 872], ["WOMAC", 876], ["pain", 882], ["(", 887], ["-11.5", 888], [",", 893], ["-9.6", 895], [",", 899], ["and", 901], ["-18.8", 905], [",", 910], ["respectively", 912], [")", 924], [",", 925], ["physical", 927], ["function", 936], ["(", 945], ["-8.7", 946], [",", 950], ["-9.5", 952], [",", 956], ["and", 958], ["-17.6", 962], [",", 967], ["respectively", 969], [")", 981], [",", 982], ["and", 984], ["stiffness", 988], ["(", 998], ["-20.4", 999], [",", 1004], ["-11.2", 1006], [",", 1011], ["and", 1013], ["-10.2", 1017], [",", 1022], ["respectively", 1024], [")", 1036], ["subscales", 1038], [".", 1047], ["Overall", 1049], [",", 1056], ["seven", 1058], ["patients", 1064], ["reported", 1073], ["AEs", 1082], ["of", 1086], ["abnormal", 1089], ["peripheral", 1098], ["sensation", 1109], [":", 1118], ["allodynia", 1120], ["(", 1130], ["two", 1131], ["in", 1135], ["the", 1138], ["tanezumab", 1142], ["200", 1152], ["\u03bcg", 1156], ["/", 1158], ["kg", 1159], ["group", 1162], [")", 1167], [";", 1168], ["paresthesia", 1170], ["(", 1182], ["two", 1183], ["in", 1187], ["the", 1190], ["tanezumab", 1194], ["200", 1204], ["\u03bcg", 1208], ["/", 1210], ["kg", 1211], ["group", 1214], [")", 1219], [",", 1220], ["dysesthesia", 1222], ["(", 1234], ["one", 1235], ["in", 1239], ["the", 1242], ["tanezumab", 1246], ["200", 1256], ["\u03bcg", 1260], ["/", 1262], ["kg", 1263], ["group", 1266], [")", 1271], [";", 1272], ["thermohypoesthesia", 1274], ["(", 1293], ["one", 1294], ["in", 1298], ["the", 1301], ["tanezumab", 1305], ["100", 1315], ["\u03bcg", 1319], ["/", 1321], ["kg", 1322], ["group", 1325], [")", 1330], [",", 1331], ["and", 1333], ["decreased", 1337], ["vibratory", 1347], ["sense", 1357], ["(", 1363], ["one", 1364], ["in", 1368], ["the", 1371], ["placebo", 1375], ["group", 1383], [")", 1388], [".", 1389], ["All", 1391], ["of", 1395], ["these", 1398], ["AEs", 1404], ["were", 1408], ["mild", 1413], ["to", 1418], ["moderate", 1421], ["in", 1430], ["severity", 1433], ["and", 1442], ["transient", 1446], ["in", 1456], ["nature", 1459], [".", 1465], ["Tanezumab", 1467], ["was", 1477], ["safe", 1481], ["and", 1486], ["generally", 1490], ["well", 1500], ["tolerated", 1505], ["and", 1515], ["may", 1519], ["improve", 1523], ["pain", 1531], ["symptoms", 1536], ["in", 1545], ["Japanese", 1548], ["patients", 1557], ["with", 1566], ["moderate", 1571], ["to", 1580], ["severe", 1583], ["osteoarthritis", 1590], ["of", 1605], ["the", 1608], ["knee", 1612], [".", 1616], ["CLINICALTRIALS.GOV", 1618], ["IDENTIFIER", 1637], [":", 1647], ["NCT00669409", 1649], [".", 1660]]}
{"context": "Eighty-eight Staphylococcus aureus clinical isolates meeting criteria for borderline oxacillin resistance (intermediate susceptibility or resistance to oxacillin but susceptibility to amoxicillin/clavulanic acid upon disk diffusion testing) were studied to determine optimal test techniques and conditions for differentiating borderline oxacillin-resistant Staphylococcus aureus (BORSA) from methicillin-resistant Staphylococcus aureus (MRSA). Further testing revealed three distinct resistance patterns: 61 strains (69%) consistently met BORSA criteria and had average beta-lactamase levels five- to six-fold higher than oxacillin-susceptible controls; 11 strains (13%) were markedly heteroresistant MRSA with delayed appearance of resistant colonies leading to spurious susceptibility to amoxicillin/clavulanic acid; 16 strains (18%) appeared to be oxacillin-susceptible on repetitive testing. Under conditions used to elicit intrinsic methicillin resistance in Staphylococcus aureus, a large percentage of BORSA appeared resistant to amoxicillin/clavulanic acid. This clearly shows that BORSA may be misidentified as MRSA while heteroresistant MRSA may appear to be BORSA. It is concluded that amoxicillin/clavulanic acid zone sizes should be measured after a full 24 hours of incubation, that susceptibility testing of Staphylococcus aureus under certain environmental conditions should be interpreted with caution, and that MIC testing is the most reliable technique for differentiating these two resistance patterns in Staphylococcus aureus.", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "3d2f68914f0e4658990df1920e00cd94", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[43, 48]], "char_spans": [[326, 377]]}]}], "context_tokens": [["Eighty", 0], ["-", 6], ["eight", 7], ["Staphylococcus", 13], ["aureus", 28], ["clinical", 35], ["isolates", 44], ["meeting", 53], ["criteria", 61], ["for", 70], ["borderline", 74], ["oxacillin", 85], ["resistance", 95], ["(", 106], ["intermediate", 107], ["susceptibility", 120], ["or", 135], ["resistance", 138], ["to", 149], ["oxacillin", 152], ["but", 162], ["susceptibility", 166], ["to", 181], ["amoxicillin", 184], ["/", 195], ["clavulanic", 196], ["acid", 207], ["upon", 212], ["disk", 217], ["diffusion", 222], ["testing", 232], [")", 239], ["were", 241], ["studied", 246], ["to", 254], ["determine", 257], ["optimal", 267], ["test", 275], ["techniques", 280], ["and", 291], ["conditions", 295], ["for", 306], ["differentiating", 310], ["borderline", 326], ["oxacillin", 337], ["-", 346], ["resistant", 347], ["Staphylococcus", 357], ["aureus", 372], ["(", 379], ["BORSA", 380], [")", 385], ["from", 387], ["methicillin", 392], ["-", 403], ["resistant", 404], ["Staphylococcus", 414], ["aureus", 429], ["(", 436], ["MRSA", 437], [")", 441], [".", 442], ["Further", 444], ["testing", 452], ["revealed", 460], ["three", 469], ["distinct", 475], ["resistance", 484], ["patterns", 495], [":", 503], ["61", 505], ["strains", 508], ["(", 516], ["69", 517], ["%", 519], [")", 520], ["consistently", 522], ["met", 535], ["BORSA", 539], ["criteria", 545], ["and", 554], ["had", 558], ["average", 562], ["beta", 570], ["-", 574], ["lactamase", 575], ["levels", 585], ["five-", 592], ["to", 598], ["six", 601], ["-", 604], ["fold", 605], ["higher", 610], ["than", 617], ["oxacillin", 622], ["-", 631], ["susceptible", 632], ["controls", 644], [";", 652], ["11", 654], ["strains", 657], ["(", 665], ["13", 666], ["%", 668], [")", 669], ["were", 671], ["markedly", 676], ["heteroresistant", 685], ["MRSA", 701], ["with", 706], ["delayed", 711], ["appearance", 719], ["of", 730], ["resistant", 733], ["colonies", 743], ["leading", 752], ["to", 760], ["spurious", 763], ["susceptibility", 772], ["to", 787], ["amoxicillin", 790], ["/", 801], ["clavulanic", 802], ["acid", 813], [";", 817], ["16", 819], ["strains", 822], ["(", 830], ["18", 831], ["%", 833], [")", 834], ["appeared", 836], ["to", 845], ["be", 848], ["oxacillin", 851], ["-", 860], ["susceptible", 861], ["on", 873], ["repetitive", 876], ["testing", 887], [".", 894], ["Under", 896], ["conditions", 902], ["used", 913], ["to", 918], ["elicit", 921], ["intrinsic", 928], ["methicillin", 938], ["resistance", 950], ["in", 961], ["Staphylococcus", 964], ["aureus", 979], [",", 985], ["a", 987], ["large", 989], ["percentage", 995], ["of", 1006], ["BORSA", 1009], ["appeared", 1015], ["resistant", 1024], ["to", 1034], ["amoxicillin", 1037], ["/", 1048], ["clavulanic", 1049], ["acid", 1060], [".", 1064], ["This", 1066], ["clearly", 1071], ["shows", 1079], ["that", 1085], ["BORSA", 1090], ["may", 1096], ["be", 1100], ["misidentified", 1103], ["as", 1117], ["MRSA", 1120], ["while", 1125], ["heteroresistant", 1131], ["MRSA", 1147], ["may", 1152], ["appear", 1156], ["to", 1163], ["be", 1166], ["BORSA", 1169], [".", 1174], ["It", 1176], ["is", 1179], ["concluded", 1182], ["that", 1192], ["amoxicillin", 1197], ["/", 1208], ["clavulanic", 1209], ["acid", 1220], ["zone", 1225], ["sizes", 1230], ["should", 1236], ["be", 1243], ["measured", 1246], ["after", 1255], ["a", 1261], ["full", 1263], ["24", 1268], ["hours", 1271], ["of", 1277], ["incubation", 1280], [",", 1290], ["that", 1292], ["susceptibility", 1297], ["testing", 1312], ["of", 1320], ["Staphylococcus", 1323], ["aureus", 1338], ["under", 1345], ["certain", 1351], ["environmental", 1359], ["conditions", 1373], ["should", 1384], ["be", 1391], ["interpreted", 1394], ["with", 1406], ["caution", 1411], [",", 1418], ["and", 1420], ["that", 1424], ["MIC", 1429], ["testing", 1433], ["is", 1441], ["the", 1444], ["most", 1448], ["reliable", 1453], ["technique", 1462], ["for", 1472], ["differentiating", 1476], ["these", 1492], ["two", 1498], ["resistance", 1502], ["patterns", 1513], ["in", 1522], ["Staphylococcus", 1525], ["aureus", 1540], [".", 1546]]}
{"context": "Diamond-Blackfan anemia (DBA) is a congenital bone marrow failure syndrome characterized by hypoproliferative anemia, associated physical malformations and a predisposition to cancer. DBA has been associated with mutations and deletions in the large and small ribosomal protein genes, and genetic aberrations have been detected in \u223c50-60% of patients. In this study, nine Korean DBA patients were screened for mutations in eight known DBA genes (RPS19, RPS24, RPS17, RPS10, RPS26, RPL35A, RPL5 and RPL11) using the direct sequencing method. Mutations in RPS19, RPS26 and RPS17 were detected in four, two and one patient, respectively. Among the mutations detected in RPS19, two mutations were novel (c.26T>A, c.357-2A>G). For the mutation-negative cases, array-CGH analysis was performed to identify copy-number variations, and no deletions involving the known DBA gene regions were identified. The relative mRNA expression of RPS19 estimated using real-time quantitative PCR analysis revealed two- to fourfold reductions in RPS19 mRNA expression in three patients with RPS19 mutations, and p53 protein expression analysis by immunohistochemistry showed variable but significant nuclear staining in the DBA patients. In conclusion, heterozygous mutations in the known DBA genes RPS19, RPS26 and RPS17 were detected in seven out of nine Korean DBA patients. Among these patients, RPS19 was the most frequently mutated gene. In addition, decreased RPS19 mRNA expression and p53 overexpression were observed in the Korean DBA patients, which supports the hypothesis that haploinsufficiency and p53 hyperactivation represent a central pathway underlying the pathogenesis of DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "7b98e597897f4b24bd7030143bae73d8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[5, 5], [229, 229], [74, 74], [218, 218], [294, 294], [28, 28], [244, 244], [167, 167], [274, 274], [65, 65]], "char_spans": [[25, 27], [1268, 1270], [435, 437], [1203, 1205], [1670, 1672], [184, 186], [1343, 1345], [861, 863], [1519, 1521], [379, 381]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["congenital", 35], ["bone", 46], ["marrow", 51], ["failure", 58], ["syndrome", 66], ["characterized", 75], ["by", 89], ["hypoproliferative", 92], ["anemia", 110], [",", 116], ["associated", 118], ["physical", 129], ["malformations", 138], ["and", 152], ["a", 156], ["predisposition", 158], ["to", 173], ["cancer", 176], [".", 182], ["DBA", 184], ["has", 188], ["been", 192], ["associated", 197], ["with", 208], ["mutations", 213], ["and", 223], ["deletions", 227], ["in", 237], ["the", 240], ["large", 244], ["and", 250], ["small", 254], ["ribosomal", 260], ["protein", 270], ["genes", 278], [",", 283], ["and", 285], ["genetic", 289], ["aberrations", 297], ["have", 309], ["been", 314], ["detected", 319], ["in", 328], ["\u223c50", 331], ["-", 334], ["60", 335], ["%", 337], ["of", 339], ["patients", 342], [".", 350], ["In", 352], ["this", 355], ["study", 360], [",", 365], ["nine", 367], ["Korean", 372], ["DBA", 379], ["patients", 383], ["were", 392], ["screened", 397], ["for", 406], ["mutations", 410], ["in", 420], ["eight", 423], ["known", 429], ["DBA", 435], ["genes", 439], ["(", 445], ["RPS19", 446], [",", 451], ["RPS24", 453], [",", 458], ["RPS17", 460], [",", 465], ["RPS10", 467], [",", 472], ["RPS26", 474], [",", 479], ["RPL35A", 481], [",", 487], ["RPL5", 489], ["and", 494], ["RPL11", 498], [")", 503], ["using", 505], ["the", 511], ["direct", 515], ["sequencing", 522], ["method", 533], [".", 539], ["Mutations", 541], ["in", 551], ["RPS19", 554], [",", 559], ["RPS26", 561], ["and", 567], ["RPS17", 571], ["were", 577], ["detected", 582], ["in", 591], ["four", 594], [",", 598], ["two", 600], ["and", 604], ["one", 608], ["patient", 612], [",", 619], ["respectively", 621], [".", 633], ["Among", 635], ["the", 641], ["mutations", 645], ["detected", 655], ["in", 664], ["RPS19", 667], [",", 672], ["two", 674], ["mutations", 678], ["were", 688], ["novel", 693], ["(", 699], ["c.26T", 700], [">", 705], ["A", 706], [",", 707], ["c.357", 709], ["-", 714], ["2A", 715], [">", 717], ["G", 718], [")", 719], [".", 720], ["For", 722], ["the", 726], ["mutation", 730], ["-", 738], ["negative", 739], ["cases", 748], [",", 753], ["array", 755], ["-", 760], ["CGH", 761], ["analysis", 765], ["was", 774], ["performed", 778], ["to", 788], ["identify", 791], ["copy", 800], ["-", 804], ["number", 805], ["variations", 812], [",", 822], ["and", 824], ["no", 828], ["deletions", 831], ["involving", 841], ["the", 851], ["known", 855], ["DBA", 861], ["gene", 865], ["regions", 870], ["were", 878], ["identified", 883], [".", 893], ["The", 895], ["relative", 899], ["mRNA", 908], ["expression", 913], ["of", 924], ["RPS19", 927], ["estimated", 933], ["using", 943], ["real", 949], ["-", 953], ["time", 954], ["quantitative", 959], ["PCR", 972], ["analysis", 976], ["revealed", 985], ["two-", 994], ["to", 999], ["fourfold", 1002], ["reductions", 1011], ["in", 1022], ["RPS19", 1025], ["mRNA", 1031], ["expression", 1036], ["in", 1047], ["three", 1050], ["patients", 1056], ["with", 1065], ["RPS19", 1070], ["mutations", 1076], [",", 1085], ["and", 1087], ["p53", 1091], ["protein", 1095], ["expression", 1103], ["analysis", 1114], ["by", 1123], ["immunohistochemistry", 1126], ["showed", 1147], ["variable", 1154], ["but", 1163], ["significant", 1167], ["nuclear", 1179], ["staining", 1187], ["in", 1196], ["the", 1199], ["DBA", 1203], ["patients", 1207], [".", 1215], ["In", 1217], ["conclusion", 1220], [",", 1230], ["heterozygous", 1232], ["mutations", 1245], ["in", 1255], ["the", 1258], ["known", 1262], ["DBA", 1268], ["genes", 1272], ["RPS19", 1278], [",", 1283], ["RPS26", 1285], ["and", 1291], ["RPS17", 1295], ["were", 1301], ["detected", 1306], ["in", 1315], ["seven", 1318], ["out", 1324], ["of", 1328], ["nine", 1331], ["Korean", 1336], ["DBA", 1343], ["patients", 1347], [".", 1355], ["Among", 1357], ["these", 1363], ["patients", 1369], [",", 1377], ["RPS19", 1379], ["was", 1385], ["the", 1389], ["most", 1393], ["frequently", 1398], ["mutated", 1409], ["gene", 1417], [".", 1421], ["In", 1423], ["addition", 1426], [",", 1434], ["decreased", 1436], ["RPS19", 1446], ["mRNA", 1452], ["expression", 1457], ["and", 1468], ["p53", 1472], ["overexpression", 1476], ["were", 1491], ["observed", 1496], ["in", 1505], ["the", 1508], ["Korean", 1512], ["DBA", 1519], ["patients", 1523], [",", 1531], ["which", 1533], ["supports", 1539], ["the", 1548], ["hypothesis", 1552], ["that", 1563], ["haploinsufficiency", 1568], ["and", 1587], ["p53", 1591], ["hyperactivation", 1595], ["represent", 1611], ["a", 1621], ["central", 1623], ["pathway", 1631], ["underlying", 1639], ["the", 1650], ["pathogenesis", 1654], ["of", 1667], ["DBA", 1670], [".", 1673]]}
{"context": "Selenium, an essential trace element, is incorporated into selenoproteins as selenocysteine (Sec), the 21st amino acid. In order to synthesize selenoproteins, a translational reprogramming event must occur since Sec is encoded by the UGA stop codon. In mammals, the recoding of UGA as Sec depends on the selenocysteine insertion sequence (SECIS) element, a stem-loop structure in the 3' untranslated region of the transcript. The SECIS acts as a platform for RNA-binding proteins, which mediate or regulate the recoding mechanism. Using UV crosslinking, we identified a 110 kDa protein, which binds with high affinity to SECIS elements from a subset of selenoprotein mRNAs. The crosslinking activity was purified by RNA affinity chromatography and identified as nucleolin by mass spectrometry analysis. In vitro binding assays showed that purified nucleolin discriminates among SECIS elements in the absence of other factors. Based on siRNA experiments, nucleolin is required for the optimal expression of certain selenoproteins. There was a good correlation between the affinity of nucleolin for a SECIS and its effect on selenoprotein expression. As selenoprotein transcript levels and localization did not change in siRNA-treated cells, our results suggest that nucleolin selectively enhances the expression of a subset of selenoproteins at the translational level.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0a4156b343cd4fec9fc3e8a4b0331052", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[80, 80], [116, 116], [60, 60], [153, 153], [190, 190]], "char_spans": [[430, 434], [621, 625], [339, 343], [878, 882], [1099, 1103]]}]}], "context_tokens": [["Selenium", 0], [",", 8], ["an", 10], ["essential", 13], ["trace", 23], ["element", 29], [",", 36], ["is", 38], ["incorporated", 41], ["into", 54], ["selenoproteins", 59], ["as", 74], ["selenocysteine", 77], ["(", 92], ["Sec", 93], [")", 96], [",", 97], ["the", 99], ["21st", 103], ["amino", 108], ["acid", 114], [".", 118], ["In", 120], ["order", 123], ["to", 129], ["synthesize", 132], ["selenoproteins", 143], [",", 157], ["a", 159], ["translational", 161], ["reprogramming", 175], ["event", 189], ["must", 195], ["occur", 200], ["since", 206], ["Sec", 212], ["is", 216], ["encoded", 219], ["by", 227], ["the", 230], ["UGA", 234], ["stop", 238], ["codon", 243], [".", 248], ["In", 250], ["mammals", 253], [",", 260], ["the", 262], ["recoding", 266], ["of", 275], ["UGA", 278], ["as", 282], ["Sec", 285], ["depends", 289], ["on", 297], ["the", 300], ["selenocysteine", 304], ["insertion", 319], ["sequence", 329], ["(", 338], ["SECIS", 339], [")", 344], ["element", 346], [",", 353], ["a", 355], ["stem", 357], ["-", 361], ["loop", 362], ["structure", 367], ["in", 377], ["the", 380], ["3", 384], ["'", 385], ["untranslated", 387], ["region", 400], ["of", 407], ["the", 410], ["transcript", 414], [".", 424], ["The", 426], ["SECIS", 430], ["acts", 436], ["as", 441], ["a", 444], ["platform", 446], ["for", 455], ["RNA", 459], ["-", 462], ["binding", 463], ["proteins", 471], [",", 479], ["which", 481], ["mediate", 487], ["or", 495], ["regulate", 498], ["the", 507], ["recoding", 511], ["mechanism", 520], [".", 529], ["Using", 531], ["UV", 537], ["crosslinking", 540], [",", 552], ["we", 554], ["identified", 557], ["a", 568], ["110", 570], ["kDa", 574], ["protein", 578], [",", 585], ["which", 587], ["binds", 593], ["with", 599], ["high", 604], ["affinity", 609], ["to", 618], ["SECIS", 621], ["elements", 627], ["from", 636], ["a", 641], ["subset", 643], ["of", 650], ["selenoprotein", 653], ["mRNAs", 667], [".", 672], ["The", 674], ["crosslinking", 678], ["activity", 691], ["was", 700], ["purified", 704], ["by", 713], ["RNA", 716], ["affinity", 720], ["chromatography", 729], ["and", 744], ["identified", 748], ["as", 759], ["nucleolin", 762], ["by", 772], ["mass", 775], ["spectrometry", 780], ["analysis", 793], [".", 801], ["In", 803], ["vitro", 806], ["binding", 812], ["assays", 820], ["showed", 827], ["that", 834], ["purified", 839], ["nucleolin", 848], ["discriminates", 858], ["among", 872], ["SECIS", 878], ["elements", 884], ["in", 893], ["the", 896], ["absence", 900], ["of", 908], ["other", 911], ["factors", 917], [".", 924], ["Based", 926], ["on", 932], ["siRNA", 935], ["experiments", 941], [",", 952], ["nucleolin", 954], ["is", 964], ["required", 967], ["for", 976], ["the", 980], ["optimal", 984], ["expression", 992], ["of", 1003], ["certain", 1006], ["selenoproteins", 1014], [".", 1028], ["There", 1030], ["was", 1036], ["a", 1040], ["good", 1042], ["correlation", 1047], ["between", 1059], ["the", 1067], ["affinity", 1071], ["of", 1080], ["nucleolin", 1083], ["for", 1093], ["a", 1097], ["SECIS", 1099], ["and", 1105], ["its", 1109], ["effect", 1113], ["on", 1120], ["selenoprotein", 1123], ["expression", 1137], [".", 1147], ["As", 1149], ["selenoprotein", 1152], ["transcript", 1166], ["levels", 1177], ["and", 1184], ["localization", 1188], ["did", 1201], ["not", 1205], ["change", 1209], ["in", 1216], ["siRNA", 1219], ["-", 1224], ["treated", 1225], ["cells", 1233], [",", 1238], ["our", 1240], ["results", 1244], ["suggest", 1252], ["that", 1260], ["nucleolin", 1265], ["selectively", 1275], ["enhances", 1287], ["the", 1296], ["expression", 1300], ["of", 1311], ["a", 1314], ["subset", 1316], ["of", 1323], ["selenoproteins", 1326], ["at", 1341], ["the", 1344], ["translational", 1348], ["level", 1362], [".", 1367]]}
{"context": "The incorporation of histone variant H2A.Z into nucleosomes plays essential roles in regulating chromatin structure and gene expression. A multisubunit complex containing chromatin remodeling protein Swr1 is responsible for the deposition of H2A.Z in budding yeast and mammals. Here, we show that the JmjC domain protein Msc1 is a novel component of the fission yeast Swr1 complex and is required for Swr1-mediated incorporation of H2A.Z into nucleosomes at gene promoters. Loss of Msc1, Swr1, or H2A.Z results in loss of silencing at centromeres and defective chromosome segregation, although centromeric levels of CENP-A, a centromere-specific histone H3 variant that is required for setting up the chromatin structure at centromeres, remain unchanged. Intriguingly, H2A.Z is required for the expression of another centromere protein, CENP-C, and overexpression of CENP-C rescues centromere silencing defects associated with H2A.Z loss. These results demonstrate the importance of H2A.Z and CENP-C in maintaining a silenced chromatin state at centromeres.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "aca0c2813cab4d7ca0129b61b2f3dc20", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[58, 58], [78, 78], [26, 26]], "char_spans": [[368, 371], [488, 491], [200, 203]]}]}], "context_tokens": [["The", 0], ["incorporation", 4], ["of", 18], ["histone", 21], ["variant", 29], ["H2A.Z", 37], ["into", 43], ["nucleosomes", 48], ["plays", 60], ["essential", 66], ["roles", 76], ["in", 82], ["regulating", 85], ["chromatin", 96], ["structure", 106], ["and", 116], ["gene", 120], ["expression", 125], [".", 135], ["A", 137], ["multisubunit", 139], ["complex", 152], ["containing", 160], ["chromatin", 171], ["remodeling", 181], ["protein", 192], ["Swr1", 200], ["is", 205], ["responsible", 208], ["for", 220], ["the", 224], ["deposition", 228], ["of", 239], ["H2A.Z", 242], ["in", 248], ["budding", 251], ["yeast", 259], ["and", 265], ["mammals", 269], [".", 276], ["Here", 278], [",", 282], ["we", 284], ["show", 287], ["that", 292], ["the", 297], ["JmjC", 301], ["domain", 306], ["protein", 313], ["Msc1", 321], ["is", 326], ["a", 329], ["novel", 331], ["component", 337], ["of", 347], ["the", 350], ["fission", 354], ["yeast", 362], ["Swr1", 368], ["complex", 373], ["and", 381], ["is", 385], ["required", 388], ["for", 397], ["Swr1-mediated", 401], ["incorporation", 415], ["of", 429], ["H2A.Z", 432], ["into", 438], ["nucleosomes", 443], ["at", 455], ["gene", 458], ["promoters", 463], [".", 472], ["Loss", 474], ["of", 479], ["Msc1", 482], [",", 486], ["Swr1", 488], [",", 492], ["or", 494], ["H2A.Z", 497], ["results", 503], ["in", 511], ["loss", 514], ["of", 519], ["silencing", 522], ["at", 532], ["centromeres", 535], ["and", 547], ["defective", 551], ["chromosome", 561], ["segregation", 572], [",", 583], ["although", 585], ["centromeric", 594], ["levels", 606], ["of", 613], ["CENP", 616], ["-", 620], ["A", 621], [",", 622], ["a", 624], ["centromere", 626], ["-", 636], ["specific", 637], ["histone", 646], ["H3", 654], ["variant", 657], ["that", 665], ["is", 670], ["required", 673], ["for", 682], ["setting", 686], ["up", 694], ["the", 697], ["chromatin", 701], ["structure", 711], ["at", 721], ["centromeres", 724], [",", 735], ["remain", 737], ["unchanged", 744], [".", 753], ["Intriguingly", 755], [",", 767], ["H2A.Z", 769], ["is", 775], ["required", 778], ["for", 787], ["the", 791], ["expression", 795], ["of", 806], ["another", 809], ["centromere", 817], ["protein", 828], [",", 835], ["CENP", 837], ["-", 841], ["C", 842], [",", 843], ["and", 845], ["overexpression", 849], ["of", 864], ["CENP", 867], ["-", 871], ["C", 872], ["rescues", 874], ["centromere", 882], ["silencing", 893], ["defects", 903], ["associated", 911], ["with", 922], ["H2A.Z", 927], ["loss", 933], [".", 937], ["These", 939], ["results", 945], ["demonstrate", 953], ["the", 965], ["importance", 969], ["of", 980], ["H2A.Z", 983], ["and", 989], ["CENP", 993], ["-", 997], ["C", 998], ["in", 1000], ["maintaining", 1003], ["a", 1015], ["silenced", 1017], ["chromatin", 1026], ["state", 1036], ["at", 1042], ["centromeres", 1045], [".", 1056]]}
{"context": "CML (chronic myeloid leukaemia) is a myeloproliferative disease that originates in an HSC (haemopoietic stem cell) as a result of the t(9;22) translocation, giving rise to the Ph (Philadelphia chromosome) and bcr-abl oncoprotein. The disease starts in CP (chronic phase), but as a result of genomic instability, it progresses over time to accelerated phase and then to BC (blast crisis), becoming increasingly resistant to therapy. bcr-abl is a constitutively active tyrosine kinase that has been targeted by TKIs (tyrosine kinase inhibitors), including IM (imatinib mesylate), nilotinib and dasatinib. We have developed various flow cytometry techniques to enable us to isolate candidate CML stem cells from CP patients at diagnosis that efflux Hoechst dye, express CD34, lack CD38 and are cytokine-non-responsive in culture over periods of up to 12 days in growth factors. These stem cells have been shown to regenerate bcr-abl-positive haemopoiesis in immunocompromised mice upon transplantation. We previously demonstrated that IM was antiproliferative for CML stem cells but did not induce apoptosis. Clinical experience now confirms that IM may not target CML stem cells in vivo with few patients achieving complete molecular remission and relapse occurring rapidly upon drug withdrawal. Our recent efforts have focused on understanding why CML stem cells are resistant to IM and on trying to find novel ways to induce apoptosis of this population. We have shown that CML stem cells express very high levels of functional wild-type bcr-abl; no kinase domain mutations have been detected in the stem cell population. Dasatinib, a more potent multitargeted TKI than IM, inhibits bcr-abl activity more efficiently than IM but still does not induce apoptosis of the stem cell population. Most recently, we have tested a number of novel drug combinations and found that FTIs (farnesyl transferase inhibitors) have activity against CML. BMS-214662 is the most effective of these and induces apoptosis of phenotypically and functionally defined CML stem cells in vitro, as a single agent and in combination with IM or dasatinib. The effect against CML stem cells is selective with little effect on normal stem cells. The drug is also effective against BC CML stem cells and equally effective against wild-type and mutant bcr-abl, including the most resistant mutant T315I. In association with apoptosis, there is activation of caspase 8 and caspase 3, inhibition of the MAPK pathway, IAP-1 (inhibitor of apoptosis protein-1), NF-kappaB (nuclear factor kappaB) and iNOS (inducible nitric oxide synthase). Furthermore, BMS-214662 synergizes with MEK1/2 [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase 1/2] inhibitors, suggesting a second mechanism other that RAS inhibition for induction of apoptosis. Our intentions are now to explore the activity of BMS-214662 in other cancer stem cell disorders and to move this preclinical work to a clinical trial combining dasatinib with BMS-214662 in CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "88390fb06cb44b229884042b868e9663", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[84, 86], [278, 280], [420, 422], [39, 41], [306, 308], [175, 177]], "char_spans": [[432, 438], [1538, 1544], [2320, 2326], [209, 215], [1683, 1689], [922, 928]]}]}], "context_tokens": [["CML", 0], ["(", 4], ["chronic", 5], ["myeloid", 13], ["leukaemia", 21], [")", 30], ["is", 32], ["a", 35], ["myeloproliferative", 37], ["disease", 56], ["that", 64], ["originates", 69], ["in", 80], ["an", 83], ["HSC", 86], ["(", 90], ["haemopoietic", 91], ["stem", 104], ["cell", 109], [")", 113], ["as", 115], ["a", 118], ["result", 120], ["of", 127], ["the", 130], ["t(9;22", 134], [")", 140], ["translocation", 142], [",", 155], ["giving", 157], ["rise", 164], ["to", 169], ["the", 172], ["Ph", 176], ["(", 179], ["Philadelphia", 180], ["chromosome", 193], [")", 203], ["and", 205], ["bcr", 209], ["-", 212], ["abl", 213], ["oncoprotein", 217], [".", 228], ["The", 230], ["disease", 234], ["starts", 242], ["in", 249], ["CP", 252], ["(", 255], ["chronic", 256], ["phase", 264], [")", 269], [",", 270], ["but", 272], ["as", 276], ["a", 279], ["result", 281], ["of", 288], ["genomic", 291], ["instability", 299], [",", 310], ["it", 312], ["progresses", 315], ["over", 326], ["time", 331], ["to", 336], ["accelerated", 339], ["phase", 351], ["and", 357], ["then", 361], ["to", 366], ["BC", 369], ["(", 372], ["blast", 373], ["crisis", 379], [")", 385], [",", 386], ["becoming", 388], ["increasingly", 397], ["resistant", 410], ["to", 420], ["therapy", 423], [".", 430], ["bcr", 432], ["-", 435], ["abl", 436], ["is", 440], ["a", 443], ["constitutively", 445], ["active", 460], ["tyrosine", 467], ["kinase", 476], ["that", 483], ["has", 488], ["been", 492], ["targeted", 497], ["by", 506], ["TKIs", 509], ["(", 514], ["tyrosine", 515], ["kinase", 524], ["inhibitors", 531], [")", 541], [",", 542], ["including", 544], ["IM", 554], ["(", 557], ["imatinib", 558], ["mesylate", 567], [")", 575], [",", 576], ["nilotinib", 578], ["and", 588], ["dasatinib", 592], [".", 601], ["We", 603], ["have", 606], ["developed", 611], ["various", 621], ["flow", 629], ["cytometry", 634], ["techniques", 644], ["to", 655], ["enable", 658], ["us", 665], ["to", 668], ["isolate", 671], ["candidate", 679], ["CML", 689], ["stem", 693], ["cells", 698], ["from", 704], ["CP", 709], ["patients", 712], ["at", 721], ["diagnosis", 724], ["that", 734], ["efflux", 739], ["Hoechst", 746], ["dye", 754], [",", 757], ["express", 759], ["CD34", 767], [",", 771], ["lack", 773], ["CD38", 778], ["and", 783], ["are", 787], ["cytokine", 791], ["-", 799], ["non", 800], ["-", 803], ["responsive", 804], ["in", 815], ["culture", 818], ["over", 826], ["periods", 831], ["of", 839], ["up", 842], ["to", 845], ["12", 848], ["days", 851], ["in", 856], ["growth", 859], ["factors", 866], [".", 873], ["These", 875], ["stem", 881], ["cells", 886], ["have", 892], ["been", 897], ["shown", 902], ["to", 908], ["regenerate", 911], ["bcr", 922], ["-", 925], ["abl", 926], ["-", 929], ["positive", 930], ["haemopoiesis", 939], ["in", 952], ["immunocompromised", 955], ["mice", 973], ["upon", 978], ["transplantation", 983], [".", 998], ["We", 1000], ["previously", 1003], ["demonstrated", 1014], ["that", 1027], ["IM", 1032], ["was", 1035], ["antiproliferative", 1039], ["for", 1057], ["CML", 1061], ["stem", 1065], ["cells", 1070], ["but", 1076], ["did", 1080], ["not", 1084], ["induce", 1088], ["apoptosis", 1095], [".", 1104], ["Clinical", 1106], ["experience", 1115], ["now", 1126], ["confirms", 1130], ["that", 1139], ["IM", 1144], ["may", 1147], ["not", 1151], ["target", 1155], ["CML", 1162], ["stem", 1166], ["cells", 1171], ["in", 1177], ["vivo", 1180], ["with", 1185], ["few", 1190], ["patients", 1194], ["achieving", 1203], ["complete", 1213], ["molecular", 1222], ["remission", 1232], ["and", 1242], ["relapse", 1246], ["occurring", 1254], ["rapidly", 1264], ["upon", 1272], ["drug", 1277], ["withdrawal", 1282], [".", 1292], ["Our", 1294], ["recent", 1298], ["efforts", 1305], ["have", 1313], ["focused", 1318], ["on", 1326], ["understanding", 1329], ["why", 1343], ["CML", 1347], ["stem", 1351], ["cells", 1356], ["are", 1362], ["resistant", 1366], ["to", 1376], ["IM", 1379], ["and", 1382], ["on", 1386], ["trying", 1389], ["to", 1396], ["find", 1399], ["novel", 1404], ["ways", 1410], ["to", 1415], ["induce", 1418], ["apoptosis", 1425], ["of", 1435], ["this", 1438], ["population", 1443], [".", 1453], ["We", 1455], ["have", 1458], ["shown", 1463], ["that", 1469], ["CML", 1474], ["stem", 1478], ["cells", 1483], ["express", 1489], ["very", 1497], ["high", 1502], ["levels", 1507], ["of", 1514], ["functional", 1517], ["wild", 1528], ["-", 1532], ["type", 1533], ["bcr", 1538], ["-", 1541], ["abl", 1542], [";", 1545], ["no", 1547], ["kinase", 1550], ["domain", 1557], ["mutations", 1564], ["have", 1574], ["been", 1579], ["detected", 1584], ["in", 1593], ["the", 1596], ["stem", 1600], ["cell", 1605], ["population", 1610], [".", 1620], ["Dasatinib", 1622], [",", 1631], ["a", 1633], ["more", 1635], ["potent", 1640], ["multitargeted", 1647], ["TKI", 1661], ["than", 1665], ["IM", 1670], [",", 1672], ["inhibits", 1674], ["bcr", 1683], ["-", 1686], ["abl", 1687], ["activity", 1691], ["more", 1700], ["efficiently", 1705], ["than", 1717], ["IM", 1722], ["but", 1725], ["still", 1729], ["does", 1735], ["not", 1740], ["induce", 1744], ["apoptosis", 1751], ["of", 1761], ["the", 1764], ["stem", 1768], ["cell", 1773], ["population", 1778], [".", 1788], ["Most", 1790], ["recently", 1795], [",", 1803], ["we", 1805], ["have", 1808], ["tested", 1813], ["a", 1820], ["number", 1822], ["of", 1829], ["novel", 1832], ["drug", 1838], ["combinations", 1843], ["and", 1856], ["found", 1860], ["that", 1866], ["FTIs", 1871], ["(", 1876], ["farnesyl", 1877], ["transferase", 1886], ["inhibitors", 1898], [")", 1908], ["have", 1910], ["activity", 1915], ["against", 1924], ["CML", 1932], [".", 1935], ["BMS-214662", 1937], ["is", 1948], ["the", 1951], ["most", 1955], ["effective", 1960], ["of", 1970], ["these", 1973], ["and", 1979], ["induces", 1983], ["apoptosis", 1991], ["of", 2001], ["phenotypically", 2004], ["and", 2019], ["functionally", 2023], ["defined", 2036], ["CML", 2044], ["stem", 2048], ["cells", 2053], ["in", 2059], ["vitro", 2062], [",", 2067], ["as", 2069], ["a", 2072], ["single", 2074], ["agent", 2081], ["and", 2087], ["in", 2091], ["combination", 2094], ["with", 2106], ["IM", 2111], ["or", 2114], ["dasatinib", 2117], [".", 2126], ["The", 2128], ["effect", 2132], ["against", 2139], ["CML", 2147], ["stem", 2151], ["cells", 2156], ["is", 2162], ["selective", 2165], ["with", 2175], ["little", 2180], ["effect", 2187], ["on", 2194], ["normal", 2197], ["stem", 2204], ["cells", 2209], [".", 2214], ["The", 2216], ["drug", 2220], ["is", 2225], ["also", 2228], ["effective", 2233], ["against", 2243], ["BC", 2251], ["CML", 2254], ["stem", 2258], ["cells", 2263], ["and", 2269], ["equally", 2273], ["effective", 2281], ["against", 2291], ["wild", 2299], ["-", 2303], ["type", 2304], ["and", 2309], ["mutant", 2313], ["bcr", 2320], ["-", 2323], ["abl", 2324], [",", 2327], ["including", 2329], ["the", 2339], ["most", 2343], ["resistant", 2348], ["mutant", 2358], ["T315I.", 2365], ["In", 2372], ["association", 2375], ["with", 2387], ["apoptosis", 2392], [",", 2401], ["there", 2403], ["is", 2409], ["activation", 2412], ["of", 2423], ["caspase", 2426], ["8", 2434], ["and", 2436], ["caspase", 2440], ["3", 2448], [",", 2449], ["inhibition", 2451], ["of", 2462], ["the", 2465], ["MAPK", 2469], ["pathway", 2474], [",", 2481], ["IAP-1", 2483], ["(", 2489], ["inhibitor", 2490], ["of", 2500], ["apoptosis", 2503], ["protein-1", 2513], [")", 2522], [",", 2523], ["NF", 2525], ["-", 2527], ["kappaB", 2528], ["(", 2535], ["nuclear", 2536], ["factor", 2544], ["kappaB", 2551], [")", 2557], ["and", 2559], ["iNOS", 2563], ["(", 2568], ["inducible", 2569], ["nitric", 2579], ["oxide", 2586], ["synthase", 2592], [")", 2600], [".", 2601], ["Furthermore", 2603], [",", 2614], ["BMS-214662", 2616], ["synergizes", 2627], ["with", 2638], ["MEK1/2", 2643], ["[", 2650], ["MAPK", 2651], ["(", 2656], ["mitogen", 2657], ["-", 2664], ["activated", 2665], ["protein", 2675], ["kinase)/ERK", 2683], ["(", 2695], ["extracellular", 2696], ["-", 2709], ["signal", 2710], ["-", 2716], ["regulated", 2717], ["kinase", 2727], [")", 2733], ["kinase", 2735], ["1/2", 2742], ["]", 2745], ["inhibitors", 2747], [",", 2757], ["suggesting", 2759], ["a", 2770], ["second", 2772], ["mechanism", 2779], ["other", 2789], ["that", 2795], ["RAS", 2800], ["inhibition", 2804], ["for", 2815], ["induction", 2819], ["of", 2829], ["apoptosis", 2832], [".", 2841], ["Our", 2843], ["intentions", 2847], ["are", 2858], ["now", 2862], ["to", 2866], ["explore", 2869], ["the", 2877], ["activity", 2881], ["of", 2890], ["BMS-214662", 2893], ["in", 2904], ["other", 2907], ["cancer", 2913], ["stem", 2920], ["cell", 2925], ["disorders", 2930], ["and", 2940], ["to", 2944], ["move", 2947], ["this", 2952], ["preclinical", 2957], ["work", 2969], ["to", 2974], ["a", 2977], ["clinical", 2979], ["trial", 2988], ["combining", 2994], ["dasatinib", 3004], ["with", 3014], ["BMS-214662", 3019], ["in", 3030], ["CML", 3033], [".", 3036]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent adult muscular dystrophies. The common clinical signs usually appear during the second decade of life but when the first molecular dysregulations occur is still unknown. Our aim was to determine whether molecular dysregulations can be identified during FSHD fetal muscle development. We compared muscle biopsies derived from FSHD1 fetuses and the cells derived from some of these biopsies with biopsies and cells derived from control fetuses. We mainly focus on DUX4 isoform expression because the expression of DUX4 has been confirmed in both FSHD cells and biopsies by several laboratories. We measured DUX4 isoform expression by using qRT-PCR in fetal FSHD1 myotubes treated or not with an shRNA directed against DUX4 mRNA. We also analyzed DUX4 downstream target gene expression in myotubes and fetal or adult FSHD1 and control quadriceps biopsies. We show that both DUX4-FL isoforms are already expressed in FSHD1 myotubes. Interestingly, DUX4-FL expression level is much lower in trapezius than in quadriceps myotubes, which is confirmed by the level of expression of DUX4 downstream genes. We observed that TRIM43 and MBD3L2 are already overexpressed in FSHD1 fetal quadriceps biopsies, at similar levels to those observed in adult FSHD1 quadriceps biopsies. These results indicate that molecular markers of the disease are already expressed during fetal life, thus opening a new field of investigation for mechanisms leading to FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "ecab61b49d944c2daff330eafcf4f174", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[99, 99], [4, 4], [51, 51], [247, 247]], "char_spans": [[619, 622], [40, 43], [328, 331], [1511, 1514]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["one", 49], ["of", 53], ["the", 56], ["most", 60], ["prevalent", 65], ["adult", 75], ["muscular", 81], ["dystrophies", 90], [".", 101], ["The", 103], ["common", 107], ["clinical", 114], ["signs", 123], ["usually", 129], ["appear", 137], ["during", 144], ["the", 151], ["second", 155], ["decade", 162], ["of", 169], ["life", 172], ["but", 177], ["when", 181], ["the", 186], ["first", 190], ["molecular", 196], ["dysregulations", 206], ["occur", 221], ["is", 227], ["still", 230], ["unknown", 236], [".", 243], ["Our", 245], ["aim", 249], ["was", 253], ["to", 257], ["determine", 260], ["whether", 270], ["molecular", 278], ["dysregulations", 288], ["can", 303], ["be", 307], ["identified", 310], ["during", 321], ["FSHD", 328], ["fetal", 333], ["muscle", 339], ["development", 346], [".", 357], ["We", 359], ["compared", 362], ["muscle", 371], ["biopsies", 378], ["derived", 387], ["from", 395], ["FSHD1", 400], ["fetuses", 406], ["and", 414], ["the", 418], ["cells", 422], ["derived", 428], ["from", 436], ["some", 441], ["of", 446], ["these", 449], ["biopsies", 455], ["with", 464], ["biopsies", 469], ["and", 478], ["cells", 482], ["derived", 488], ["from", 496], ["control", 501], ["fetuses", 509], [".", 516], ["We", 518], ["mainly", 521], ["focus", 528], ["on", 534], ["DUX4", 537], ["isoform", 542], ["expression", 550], ["because", 561], ["the", 569], ["expression", 573], ["of", 584], ["DUX4", 587], ["has", 592], ["been", 596], ["confirmed", 601], ["in", 611], ["both", 614], ["FSHD", 619], ["cells", 624], ["and", 630], ["biopsies", 634], ["by", 643], ["several", 646], ["laboratories", 654], [".", 666], ["We", 668], ["measured", 671], ["DUX4", 680], ["isoform", 685], ["expression", 693], ["by", 704], ["using", 707], ["qRT", 713], ["-", 716], ["PCR", 717], ["in", 721], ["fetal", 724], ["FSHD1", 730], ["myotubes", 736], ["treated", 745], ["or", 753], ["not", 756], ["with", 760], ["an", 765], ["shRNA", 768], ["directed", 774], ["against", 783], ["DUX4", 791], ["mRNA", 796], [".", 800], ["We", 802], ["also", 805], ["analyzed", 810], ["DUX4", 819], ["downstream", 824], ["target", 835], ["gene", 842], ["expression", 847], ["in", 858], ["myotubes", 861], ["and", 870], ["fetal", 874], ["or", 880], ["adult", 883], ["FSHD1", 889], ["and", 895], ["control", 899], ["quadriceps", 907], ["biopsies", 918], [".", 926], ["We", 928], ["show", 931], ["that", 936], ["both", 941], ["DUX4-FL", 946], ["isoforms", 954], ["are", 963], ["already", 967], ["expressed", 975], ["in", 985], ["FSHD1", 988], ["myotubes", 994], [".", 1002], ["Interestingly", 1004], [",", 1017], ["DUX4-FL", 1019], ["expression", 1027], ["level", 1038], ["is", 1044], ["much", 1047], ["lower", 1052], ["in", 1058], ["trapezius", 1061], ["than", 1071], ["in", 1076], ["quadriceps", 1079], ["myotubes", 1090], [",", 1098], ["which", 1100], ["is", 1106], ["confirmed", 1109], ["by", 1119], ["the", 1122], ["level", 1126], ["of", 1132], ["expression", 1135], ["of", 1146], ["DUX4", 1149], ["downstream", 1154], ["genes", 1165], [".", 1170], ["We", 1172], ["observed", 1175], ["that", 1184], ["TRIM43", 1189], ["and", 1196], ["MBD3L2", 1200], ["are", 1207], ["already", 1211], ["overexpressed", 1219], ["in", 1233], ["FSHD1", 1236], ["fetal", 1242], ["quadriceps", 1248], ["biopsies", 1259], [",", 1267], ["at", 1269], ["similar", 1272], ["levels", 1280], ["to", 1287], ["those", 1290], ["observed", 1296], ["in", 1305], ["adult", 1308], ["FSHD1", 1314], ["quadriceps", 1320], ["biopsies", 1331], [".", 1339], ["These", 1341], ["results", 1347], ["indicate", 1355], ["that", 1364], ["molecular", 1369], ["markers", 1379], ["of", 1387], ["the", 1390], ["disease", 1394], ["are", 1402], ["already", 1406], ["expressed", 1414], ["during", 1424], ["fetal", 1431], ["life", 1437], [",", 1441], ["thus", 1443], ["opening", 1448], ["a", 1456], ["new", 1458], ["field", 1462], ["of", 1468], ["investigation", 1471], ["for", 1485], ["mechanisms", 1489], ["leading", 1500], ["to", 1508], ["FSHD", 1511], [".", 1515]]}
{"context": "The objective was to determine the composition of the Cystic Fibrosis (CF) Population attending specialist UK CF centres in terms of age, gender, age at diagnosis, genotype and ethnicity. With the planned introduction of the national CF screening programme in the UK, cystic fibrosis transmembrane regulator (CFTR) mutations were compared between different ethnic groups enabling a UK-specific frequency of mutations to be defined. Data were analysed from the patient biographies held in the UK CF Database (see www.cystic-fibrosis.org.uk). The currently registered population of 5,274 CF patients is 96.3% Caucasian with a male preponderance that significantly increases with age. The majority of the 196 non-Caucasian CF patients are from the Indian Subcontinent (ISC), of which one in 84 UK CF patients are of Pakistani origin. The commonest CFTR mutation, deltaF508, is found in 74.1% of all CF chromosomes. In the Caucasian CF population, 57.5% are deltaF508 homozygotes but the UK ISC CF population with only 24.7%, has significantly fewer deltaF508 homozygotes patients (95% confidence interval (CI) 0.2-0.4). The distribution of Caucasian patients with deltaF508/deltaF508, deltaF508/Other and Other/Other does not fit the expected distribution with a Hardy-Weinberg model unless those patients without a detected mutation are excluded (P<0.001). The UK CF Database has shown the UK CF population to have distinct characteristics separate from the North American and European CF Registries. The ISC group contains many mutations not recognised by current genetic analysis, and one in four ISC patients have no CFTR mutations identified. The CFTR analysis proposed for the screening programme would detect 96% of patients registered in the database, but is unlikely to achieve the desired >80% detection rates in the ethnic minority groups. Screen-positive, non-Caucasian infants without an identifiable CFTR mutation should be referred for a sweat test and genetic counselling when serum trypsinogen concentrations remain elevated after birth.", "qas": [{"question": "Which is the most common CFTR mutation in Caucasians?", "answers": ["deltaF508"], "qid": "7d3f2b1fca4442a8ae60dafaeaa4cb04", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["CFTR", 25], ["mutation", 30], ["in", 39], ["Caucasians", 42], ["?", 52]], "detected_answers": [{"text": "deltaF508", "token_spans": [[152, 152], [173, 173], [189, 189]], "char_spans": [[860, 868], [954, 962], [1046, 1054]]}]}], "context_tokens": [["The", 0], ["objective", 4], ["was", 14], ["to", 18], ["determine", 21], ["the", 31], ["composition", 35], ["of", 47], ["the", 50], ["Cystic", 54], ["Fibrosis", 61], ["(", 70], ["CF", 71], [")", 73], ["Population", 75], ["attending", 86], ["specialist", 96], ["UK", 107], ["CF", 110], ["centres", 113], ["in", 121], ["terms", 124], ["of", 130], ["age", 133], [",", 136], ["gender", 138], [",", 144], ["age", 146], ["at", 150], ["diagnosis", 153], [",", 162], ["genotype", 164], ["and", 173], ["ethnicity", 177], [".", 186], ["With", 188], ["the", 193], ["planned", 197], ["introduction", 205], ["of", 218], ["the", 221], ["national", 225], ["CF", 234], ["screening", 237], ["programme", 247], ["in", 257], ["the", 260], ["UK", 264], [",", 266], ["cystic", 268], ["fibrosis", 275], ["transmembrane", 284], ["regulator", 298], ["(", 308], ["CFTR", 309], [")", 313], ["mutations", 315], ["were", 325], ["compared", 330], ["between", 339], ["different", 347], ["ethnic", 357], ["groups", 364], ["enabling", 371], ["a", 380], ["UK", 382], ["-", 384], ["specific", 385], ["frequency", 394], ["of", 404], ["mutations", 407], ["to", 417], ["be", 420], ["defined", 423], [".", 430], ["Data", 432], ["were", 437], ["analysed", 442], ["from", 451], ["the", 456], ["patient", 460], ["biographies", 468], ["held", 480], ["in", 485], ["the", 488], ["UK", 492], ["CF", 495], ["Database", 498], ["(", 507], ["see", 508], ["www.cystic-fibrosis.org.uk", 512], [")", 538], [".", 539], ["The", 541], ["currently", 545], ["registered", 555], ["population", 566], ["of", 577], ["5,274", 580], ["CF", 586], ["patients", 589], ["is", 598], ["96.3", 601], ["%", 605], ["Caucasian", 607], ["with", 617], ["a", 622], ["male", 624], ["preponderance", 629], ["that", 643], ["significantly", 648], ["increases", 662], ["with", 672], ["age", 677], [".", 680], ["The", 682], ["majority", 686], ["of", 695], ["the", 698], ["196", 702], ["non", 706], ["-", 709], ["Caucasian", 710], ["CF", 720], ["patients", 723], ["are", 732], ["from", 736], ["the", 741], ["Indian", 745], ["Subcontinent", 752], ["(", 765], ["ISC", 766], [")", 769], [",", 770], ["of", 772], ["which", 775], ["one", 781], ["in", 785], ["84", 788], ["UK", 791], ["CF", 794], ["patients", 797], ["are", 806], ["of", 810], ["Pakistani", 813], ["origin", 823], [".", 829], ["The", 831], ["commonest", 835], ["CFTR", 845], ["mutation", 850], [",", 858], ["deltaF508", 860], [",", 869], ["is", 871], ["found", 874], ["in", 880], ["74.1", 883], ["%", 887], ["of", 889], ["all", 892], ["CF", 896], ["chromosomes", 899], [".", 910], ["In", 912], ["the", 915], ["Caucasian", 919], ["CF", 929], ["population", 932], [",", 942], ["57.5", 944], ["%", 948], ["are", 950], ["deltaF508", 954], ["homozygotes", 964], ["but", 976], ["the", 980], ["UK", 984], ["ISC", 987], ["CF", 991], ["population", 994], ["with", 1005], ["only", 1010], ["24.7", 1015], ["%", 1019], [",", 1020], ["has", 1022], ["significantly", 1026], ["fewer", 1040], ["deltaF508", 1046], ["homozygotes", 1056], ["patients", 1068], ["(", 1077], ["95", 1078], ["%", 1080], ["confidence", 1082], ["interval", 1093], ["(", 1102], ["CI", 1103], [")", 1105], ["0.2", 1107], ["-", 1110], ["0.4", 1111], [")", 1114], [".", 1115], ["The", 1117], ["distribution", 1121], ["of", 1134], ["Caucasian", 1137], ["patients", 1147], ["with", 1156], ["deltaF508/deltaF508", 1161], [",", 1180], ["deltaF508/Other", 1182], ["and", 1198], ["Other", 1202], ["/", 1207], ["Other", 1208], ["does", 1214], ["not", 1219], ["fit", 1223], ["the", 1227], ["expected", 1231], ["distribution", 1240], ["with", 1253], ["a", 1258], ["Hardy", 1260], ["-", 1265], ["Weinberg", 1266], ["model", 1275], ["unless", 1281], ["those", 1288], ["patients", 1294], ["without", 1303], ["a", 1311], ["detected", 1313], ["mutation", 1322], ["are", 1331], ["excluded", 1335], ["(", 1344], ["P<0.001", 1345], [")", 1352], [".", 1353], ["The", 1355], ["UK", 1359], ["CF", 1362], ["Database", 1365], ["has", 1374], ["shown", 1378], ["the", 1384], ["UK", 1388], ["CF", 1391], ["population", 1394], ["to", 1405], ["have", 1408], ["distinct", 1413], ["characteristics", 1422], ["separate", 1438], ["from", 1447], ["the", 1452], ["North", 1456], ["American", 1462], ["and", 1471], ["European", 1475], ["CF", 1484], ["Registries", 1487], [".", 1497], ["The", 1499], ["ISC", 1503], ["group", 1507], ["contains", 1513], ["many", 1522], ["mutations", 1527], ["not", 1537], ["recognised", 1541], ["by", 1552], ["current", 1555], ["genetic", 1563], ["analysis", 1571], [",", 1579], ["and", 1581], ["one", 1585], ["in", 1589], ["four", 1592], ["ISC", 1597], ["patients", 1601], ["have", 1610], ["no", 1615], ["CFTR", 1618], ["mutations", 1623], ["identified", 1633], [".", 1643], ["The", 1645], ["CFTR", 1649], ["analysis", 1654], ["proposed", 1663], ["for", 1672], ["the", 1676], ["screening", 1680], ["programme", 1690], ["would", 1700], ["detect", 1706], ["96", 1713], ["%", 1715], ["of", 1717], ["patients", 1720], ["registered", 1729], ["in", 1740], ["the", 1743], ["database", 1747], [",", 1755], ["but", 1757], ["is", 1761], ["unlikely", 1764], ["to", 1773], ["achieve", 1776], ["the", 1784], ["desired", 1788], [">", 1796], ["80", 1797], ["%", 1799], ["detection", 1801], ["rates", 1811], ["in", 1817], ["the", 1820], ["ethnic", 1824], ["minority", 1831], ["groups", 1840], [".", 1846], ["Screen", 1848], ["-", 1854], ["positive", 1855], [",", 1863], ["non", 1865], ["-", 1868], ["Caucasian", 1869], ["infants", 1879], ["without", 1887], ["an", 1895], ["identifiable", 1898], ["CFTR", 1911], ["mutation", 1916], ["should", 1925], ["be", 1932], ["referred", 1935], ["for", 1944], ["a", 1948], ["sweat", 1950], ["test", 1956], ["and", 1961], ["genetic", 1965], ["counselling", 1973], ["when", 1985], ["serum", 1990], ["trypsinogen", 1996], ["concentrations", 2008], ["remain", 2023], ["elevated", 2030], ["after", 2039], ["birth", 2045], [".", 2050]]}
{"context": "Flumazenil, a specific benzodiazepine antagonist, is useful in reversing the sedation and respiratory depression that often occur when benzodiazepines are administered to patients undergoing anesthesia or when patients have taken an intentional benzodiazepine overdose. Judicious use of flumazenil may provide useful diagnostic information and may obviate the need for mechanical ventilation and other invasive supportive measures. Although some controversy exists regarding the possible precipitation of seizure activity in the setting of mixed tricyclic antidepressant-benzodiazepine overdose, worldwide experience with flumazenil has validated its safety and efficacy.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "b4b16d825b304cf98373a45e742826da", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [85, 85], [40, 40]], "char_spans": [[0, 9], [622, 631], [287, 296]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["specific", 14], ["benzodiazepine", 23], ["antagonist", 38], [",", 48], ["is", 50], ["useful", 53], ["in", 60], ["reversing", 63], ["the", 73], ["sedation", 77], ["and", 86], ["respiratory", 90], ["depression", 102], ["that", 113], ["often", 118], ["occur", 124], ["when", 130], ["benzodiazepines", 135], ["are", 151], ["administered", 155], ["to", 168], ["patients", 171], ["undergoing", 180], ["anesthesia", 191], ["or", 202], ["when", 205], ["patients", 210], ["have", 219], ["taken", 224], ["an", 230], ["intentional", 233], ["benzodiazepine", 245], ["overdose", 260], [".", 268], ["Judicious", 270], ["use", 280], ["of", 284], ["flumazenil", 287], ["may", 298], ["provide", 302], ["useful", 310], ["diagnostic", 317], ["information", 328], ["and", 340], ["may", 344], ["obviate", 348], ["the", 356], ["need", 360], ["for", 365], ["mechanical", 369], ["ventilation", 380], ["and", 392], ["other", 396], ["invasive", 402], ["supportive", 411], ["measures", 422], [".", 430], ["Although", 432], ["some", 441], ["controversy", 446], ["exists", 458], ["regarding", 465], ["the", 475], ["possible", 479], ["precipitation", 488], ["of", 502], ["seizure", 505], ["activity", 513], ["in", 522], ["the", 525], ["setting", 529], ["of", 537], ["mixed", 540], ["tricyclic", 546], ["antidepressant", 556], ["-", 570], ["benzodiazepine", 571], ["overdose", 586], [",", 594], ["worldwide", 596], ["experience", 606], ["with", 617], ["flumazenil", 622], ["has", 633], ["validated", 637], ["its", 647], ["safety", 651], ["and", 658], ["efficacy", 662], [".", 670]]}
{"context": "Selenoprotein P (SeP) is an extracellular glycoprotein with 8-10 selenocysteines per molecule, containing approximately 50% of total selenium in human serum. An antioxidant function of SeP has been postulated. In the present study, we show that SeP protects low-density lipoproteins (LDL) against oxidation in a cell-free in-vitro system. LDL were isolated from human blood plasma and oxidized with CuCl2, 2,2'-azobis(2-amidinopropane) (AAPH) or peroxynitrite in the presence or absence of SeP, using the formation of conjugated dienes as parameter for lipid peroxidation. SeP delayed the CuCl2- and AAPH-induced LDL oxidation significantly and more efficiently than bovine serum albumin used as control. In contrast, SeP was not capable of inhibiting peroxynitrite-induced LDL oxidation. The protection of LDL against CuCl2- and AAPH-induced oxidation provides evidence for the antioxidant capacity of SeP. Because SeP associates with endothelial membranes, it may act in vivo as a protective factor inhibiting the oxidation of LDL by reactive oxygen species.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "bc72c59b993848e78839cf94591aaa7c", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[0, 1]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Selenoprotein", 0], ["P", 14], ["(", 16], ["SeP", 17], [")", 20], ["is", 22], ["an", 25], ["extracellular", 28], ["glycoprotein", 42], ["with", 55], ["8", 60], ["-", 61], ["10", 62], ["selenocysteines", 65], ["per", 81], ["molecule", 85], [",", 93], ["containing", 95], ["approximately", 106], ["50", 120], ["%", 122], ["of", 124], ["total", 127], ["selenium", 133], ["in", 142], ["human", 145], ["serum", 151], [".", 156], ["An", 158], ["antioxidant", 161], ["function", 173], ["of", 182], ["SeP", 185], ["has", 189], ["been", 193], ["postulated", 198], [".", 208], ["In", 210], ["the", 213], ["present", 217], ["study", 225], [",", 230], ["we", 232], ["show", 235], ["that", 240], ["SeP", 245], ["protects", 249], ["low", 258], ["-", 261], ["density", 262], ["lipoproteins", 270], ["(", 283], ["LDL", 284], [")", 287], ["against", 289], ["oxidation", 297], ["in", 307], ["a", 310], ["cell", 312], ["-", 316], ["free", 317], ["in", 322], ["-", 324], ["vitro", 325], ["system", 331], [".", 337], ["LDL", 339], ["were", 343], ["isolated", 348], ["from", 357], ["human", 362], ["blood", 368], ["plasma", 374], ["and", 381], ["oxidized", 385], ["with", 394], ["CuCl2", 399], [",", 404], ["2,2'-azobis(2-amidinopropane", 406], [")", 434], ["(", 436], ["AAPH", 437], [")", 441], ["or", 443], ["peroxynitrite", 446], ["in", 460], ["the", 463], ["presence", 467], ["or", 476], ["absence", 479], ["of", 487], ["SeP", 490], [",", 493], ["using", 495], ["the", 501], ["formation", 505], ["of", 515], ["conjugated", 518], ["dienes", 529], ["as", 536], ["parameter", 539], ["for", 549], ["lipid", 553], ["peroxidation", 559], [".", 571], ["SeP", 573], ["delayed", 577], ["the", 585], ["CuCl2-", 589], ["and", 596], ["AAPH", 600], ["-", 604], ["induced", 605], ["LDL", 613], ["oxidation", 617], ["significantly", 627], ["and", 641], ["more", 645], ["efficiently", 650], ["than", 662], ["bovine", 667], ["serum", 674], ["albumin", 680], ["used", 688], ["as", 693], ["control", 696], [".", 703], ["In", 705], ["contrast", 708], [",", 716], ["SeP", 718], ["was", 722], ["not", 726], ["capable", 730], ["of", 738], ["inhibiting", 741], ["peroxynitrite", 752], ["-", 765], ["induced", 766], ["LDL", 774], ["oxidation", 778], [".", 787], ["The", 789], ["protection", 793], ["of", 804], ["LDL", 807], ["against", 811], ["CuCl2-", 819], ["and", 826], ["AAPH", 830], ["-", 834], ["induced", 835], ["oxidation", 843], ["provides", 853], ["evidence", 862], ["for", 871], ["the", 875], ["antioxidant", 879], ["capacity", 891], ["of", 900], ["SeP.", 903], ["Because", 908], ["SeP", 916], ["associates", 920], ["with", 931], ["endothelial", 936], ["membranes", 948], [",", 957], ["it", 959], ["may", 962], ["act", 966], ["in", 970], ["vivo", 973], ["as", 978], ["a", 981], ["protective", 983], ["factor", 994], ["inhibiting", 1001], ["the", 1012], ["oxidation", 1016], ["of", 1026], ["LDL", 1029], ["by", 1033], ["reactive", 1036], ["oxygen", 1045], ["species", 1052], [".", 1059]]}
{"context": "Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacked efficacy. Although a potent blocker of hERG, it produced no serious adverse events. We attributed the unexpected result to offsetting Multiple Ion Channel Effects (MICE). Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter. Vanoxerine terminated AF/AFL in an animal model and a dose-ranging clinical trial. Reversion to normal rhythm was associated with QT prolongation yet absent proarrhythmia markers for Torsade de Pointes (TdP). To understand the QT/TdP discordance, we used quantitative profiling and compared vanoxerine with dofetilide, a selective hERG-blocking torsadogen used for intractable AF, verapamil, a non-torsadogenic MICE comparator and bepridil, a torsadogenic MICE comparator. At clinically relevant concentrations, verapamil blocked hCav1.2 and hERG, as did vanoxerine and bepridil both of which also blocked hNav1.5. In acute experiments and simulations, dofetilide produced early after depolarizations (EADs) and arrhythmias, whereas verapamil, vanoxerine and bepridil produced no proarrhythmia markers. Of the MICE drugs only bepridil inhibited hERG trafficking following overnight exposure. The results are consistent with the emphasis on MICE of the CiPA assay. Additionally we propose that trafficking inhibition of hERG be added to CiPA.", "qas": [{"question": "What alternate indication has Vanoxerine been repositioned for?", "answers": ["atrial fibrillation and flutter"], "qid": "1a4946e6636c4ab3a37f421bb4397409", "question_tokens": [["What", 0], ["alternate", 5], ["indication", 15], ["has", 26], ["Vanoxerine", 30], ["been", 41], ["repositioned", 46], ["for", 59], ["?", 62]], "detected_answers": [{"text": "atrial fibrillation and flutter", "token_spans": [[61, 64]], "char_spans": [[367, 397]]}]}], "context_tokens": [["Vanoxerine", 0], ["has", 11], ["been", 15], ["in", 20], ["clinical", 23], ["trials", 32], ["for", 39], ["Parkinsonism", 43], [",", 55], ["depression", 57], ["and", 68], ["cocaine", 72], ["addiction", 80], ["but", 90], ["lacked", 94], ["efficacy", 101], [".", 109], ["Although", 111], ["a", 120], ["potent", 122], ["blocker", 129], ["of", 137], ["hERG", 140], [",", 144], ["it", 146], ["produced", 149], ["no", 158], ["serious", 161], ["adverse", 169], ["events", 177], [".", 183], ["We", 185], ["attributed", 188], ["the", 199], ["unexpected", 203], ["result", 214], ["to", 221], ["offsetting", 224], ["Multiple", 235], ["Ion", 244], ["Channel", 248], ["Effects", 256], ["(", 264], ["MICE", 265], [")", 269], [".", 270], ["Vanoxerine", 272], ["'s", 282], ["effects", 285], ["were", 293], ["strongly", 298], ["frequency", 307], ["-", 316], ["dependent", 317], ["and", 327], ["we", 331], ["repositioned", 334], ["it", 347], ["for", 350], ["treatment", 354], ["of", 364], ["atrial", 367], ["fibrillation", 374], ["and", 387], ["flutter", 391], [".", 398], ["Vanoxerine", 400], ["terminated", 411], ["AF", 422], ["/", 424], ["AFL", 425], ["in", 429], ["an", 432], ["animal", 435], ["model", 442], ["and", 448], ["a", 452], ["dose", 454], ["-", 458], ["ranging", 459], ["clinical", 467], ["trial", 476], [".", 481], ["Reversion", 483], ["to", 493], ["normal", 496], ["rhythm", 503], ["was", 510], ["associated", 514], ["with", 525], ["QT", 530], ["prolongation", 533], ["yet", 546], ["absent", 550], ["proarrhythmia", 557], ["markers", 571], ["for", 579], ["Torsade", 583], ["de", 591], ["Pointes", 594], ["(", 602], ["TdP", 603], [")", 606], [".", 607], ["To", 609], ["understand", 612], ["the", 623], ["QT", 627], ["/", 629], ["TdP", 630], ["discordance", 634], [",", 645], ["we", 647], ["used", 650], ["quantitative", 655], ["profiling", 668], ["and", 678], ["compared", 682], ["vanoxerine", 691], ["with", 702], ["dofetilide", 707], [",", 717], ["a", 719], ["selective", 721], ["hERG", 731], ["-", 735], ["blocking", 736], ["torsadogen", 745], ["used", 756], ["for", 761], ["intractable", 765], ["AF", 777], [",", 779], ["verapamil", 781], [",", 790], ["a", 792], ["non", 794], ["-", 797], ["torsadogenic", 798], ["MICE", 811], ["comparator", 816], ["and", 827], ["bepridil", 831], [",", 839], ["a", 841], ["torsadogenic", 843], ["MICE", 856], ["comparator", 861], [".", 871], ["At", 873], ["clinically", 876], ["relevant", 887], ["concentrations", 896], [",", 910], ["verapamil", 912], ["blocked", 922], ["hCav1.2", 930], ["and", 938], ["hERG", 942], [",", 946], ["as", 948], ["did", 951], ["vanoxerine", 955], ["and", 966], ["bepridil", 970], ["both", 979], ["of", 984], ["which", 987], ["also", 993], ["blocked", 998], ["hNav1.5", 1006], [".", 1013], ["In", 1015], ["acute", 1018], ["experiments", 1024], ["and", 1036], ["simulations", 1040], [",", 1051], ["dofetilide", 1053], ["produced", 1064], ["early", 1073], ["after", 1079], ["depolarizations", 1085], ["(", 1101], ["EADs", 1102], [")", 1106], ["and", 1108], ["arrhythmias", 1112], [",", 1123], ["whereas", 1125], ["verapamil", 1133], [",", 1142], ["vanoxerine", 1144], ["and", 1155], ["bepridil", 1159], ["produced", 1168], ["no", 1177], ["proarrhythmia", 1180], ["markers", 1194], [".", 1201], ["Of", 1203], ["the", 1206], ["MICE", 1210], ["drugs", 1215], ["only", 1221], ["bepridil", 1226], ["inhibited", 1235], ["hERG", 1245], ["trafficking", 1250], ["following", 1262], ["overnight", 1272], ["exposure", 1282], [".", 1290], ["The", 1292], ["results", 1296], ["are", 1304], ["consistent", 1308], ["with", 1319], ["the", 1324], ["emphasis", 1328], ["on", 1337], ["MICE", 1340], ["of", 1345], ["the", 1348], ["CiPA", 1352], ["assay", 1357], [".", 1362], ["Additionally", 1364], ["we", 1377], ["propose", 1380], ["that", 1388], ["trafficking", 1393], ["inhibition", 1405], ["of", 1416], ["hERG", 1419], ["be", 1424], ["added", 1427], ["to", 1433], ["CiPA", 1436], [".", 1440]]}
{"context": "Hereditary long QT syndrome (LQTS) is a genetically heterogeneous disease characterized by prolonged QT intervals and an increased risk for ventricular arrhythmias and sudden cardiac death. Mutations in the voltage-gated potassium channel subunit KCNQ1 induce the most common form of LQTS. KCNQ1 is associated with two different entities of LQTS, the autosomal-dominant Romano-Ward syndrome (RWS), and the autosomal-recessive Jervell and Lange-Nielsen syndrome (JLNS) characterized by bilateral deafness in addition to cardiac arrhythmias. In this study, we investigate and discuss dominant-negative I(Ks) current reduction by a KCNQ1 deletion mutation identified in a RWS family. Single-strand conformation polymorphism analysis and direct sequencing were used to screen LQTS genes for mutations. Mutant KCNQ1 channels were heterologously expressed in Xenopus oocytes, and potassium currents were recorded using the two-microelectrode voltage clamp technique. A heterozygous deletion of three nucleotides (CTT) identified in the KCNQ1 gene caused the loss of a single phenylalanine residue at position 339 (KCNQ1-deltaF339). Electrophysiological measurements in the presence and absence of the regulatory beta-subunit KCNE1 revealed that mutant and wild type forms of an N-terminal truncated KCNQ1 subunit (isoform 2) caused much stronger dominant-negative current reduction than the mutant form of the full-length KCNQ1 subunit (isoform 1). This study highlights the functional relevance of the truncated KCNQ1 splice variant (isoform 2) in establishment and mode of inheritance in long QT syndrome. In the RWS family presented here, the autosomal-dominant trait is caused by multiple dominant-negative effects provoked by heteromultimeric channels formed by wild type and mutant KCNQ1-isoforms in combination with KCNE1.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "3c809ea1a7604eca9f5319c8cf28554b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[282, 284], [58, 60]], "char_spans": [[1640, 1657], [351, 368]]}]}], "context_tokens": [["Hereditary", 0], ["long", 11], ["QT", 16], ["syndrome", 19], ["(", 28], ["LQTS", 29], [")", 33], ["is", 35], ["a", 38], ["genetically", 40], ["heterogeneous", 52], ["disease", 66], ["characterized", 74], ["by", 88], ["prolonged", 91], ["QT", 101], ["intervals", 104], ["and", 114], ["an", 118], ["increased", 121], ["risk", 131], ["for", 136], ["ventricular", 140], ["arrhythmias", 152], ["and", 164], ["sudden", 168], ["cardiac", 175], ["death", 183], [".", 188], ["Mutations", 190], ["in", 200], ["the", 203], ["voltage", 207], ["-", 214], ["gated", 215], ["potassium", 221], ["channel", 231], ["subunit", 239], ["KCNQ1", 247], ["induce", 253], ["the", 260], ["most", 264], ["common", 269], ["form", 276], ["of", 281], ["LQTS", 284], [".", 288], ["KCNQ1", 290], ["is", 296], ["associated", 299], ["with", 310], ["two", 315], ["different", 319], ["entities", 329], ["of", 338], ["LQTS", 341], [",", 345], ["the", 347], ["autosomal", 351], ["-", 360], ["dominant", 361], ["Romano", 370], ["-", 376], ["Ward", 377], ["syndrome", 382], ["(", 391], ["RWS", 392], [")", 395], [",", 396], ["and", 398], ["the", 402], ["autosomal", 406], ["-", 415], ["recessive", 416], ["Jervell", 426], ["and", 434], ["Lange", 438], ["-", 443], ["Nielsen", 444], ["syndrome", 452], ["(", 461], ["JLNS", 462], [")", 466], ["characterized", 468], ["by", 482], ["bilateral", 485], ["deafness", 495], ["in", 504], ["addition", 507], ["to", 516], ["cardiac", 519], ["arrhythmias", 527], [".", 538], ["In", 540], ["this", 543], ["study", 548], [",", 553], ["we", 555], ["investigate", 558], ["and", 570], ["discuss", 574], ["dominant", 582], ["-", 590], ["negative", 591], ["I(Ks", 600], [")", 604], ["current", 606], ["reduction", 614], ["by", 624], ["a", 627], ["KCNQ1", 629], ["deletion", 635], ["mutation", 644], ["identified", 653], ["in", 664], ["a", 667], ["RWS", 669], ["family", 673], [".", 679], ["Single", 681], ["-", 687], ["strand", 688], ["conformation", 695], ["polymorphism", 708], ["analysis", 721], ["and", 730], ["direct", 734], ["sequencing", 741], ["were", 752], ["used", 757], ["to", 762], ["screen", 765], ["LQTS", 772], ["genes", 777], ["for", 783], ["mutations", 787], [".", 796], ["Mutant", 798], ["KCNQ1", 805], ["channels", 811], ["were", 820], ["heterologously", 825], ["expressed", 840], ["in", 850], ["Xenopus", 853], ["oocytes", 861], [",", 868], ["and", 870], ["potassium", 874], ["currents", 884], ["were", 893], ["recorded", 898], ["using", 907], ["the", 913], ["two", 917], ["-", 920], ["microelectrode", 921], ["voltage", 936], ["clamp", 944], ["technique", 950], [".", 959], ["A", 961], ["heterozygous", 963], ["deletion", 976], ["of", 985], ["three", 988], ["nucleotides", 994], ["(", 1006], ["CTT", 1007], [")", 1010], ["identified", 1012], ["in", 1023], ["the", 1026], ["KCNQ1", 1030], ["gene", 1036], ["caused", 1041], ["the", 1048], ["loss", 1052], ["of", 1057], ["a", 1060], ["single", 1062], ["phenylalanine", 1069], ["residue", 1083], ["at", 1091], ["position", 1094], ["339", 1103], ["(", 1107], ["KCNQ1-deltaF339", 1108], [")", 1123], [".", 1124], ["Electrophysiological", 1126], ["measurements", 1147], ["in", 1160], ["the", 1163], ["presence", 1167], ["and", 1176], ["absence", 1180], ["of", 1188], ["the", 1191], ["regulatory", 1195], ["beta", 1206], ["-", 1210], ["subunit", 1211], ["KCNE1", 1219], ["revealed", 1225], ["that", 1234], ["mutant", 1239], ["and", 1246], ["wild", 1250], ["type", 1255], ["forms", 1260], ["of", 1266], ["an", 1269], ["N", 1272], ["-", 1273], ["terminal", 1274], ["truncated", 1283], ["KCNQ1", 1293], ["subunit", 1299], ["(", 1307], ["isoform", 1308], ["2", 1316], [")", 1317], ["caused", 1319], ["much", 1326], ["stronger", 1331], ["dominant", 1340], ["-", 1348], ["negative", 1349], ["current", 1358], ["reduction", 1366], ["than", 1376], ["the", 1381], ["mutant", 1385], ["form", 1392], ["of", 1397], ["the", 1400], ["full", 1404], ["-", 1408], ["length", 1409], ["KCNQ1", 1416], ["subunit", 1422], ["(", 1430], ["isoform", 1431], ["1", 1439], [")", 1440], [".", 1441], ["This", 1443], ["study", 1448], ["highlights", 1454], ["the", 1465], ["functional", 1469], ["relevance", 1480], ["of", 1490], ["the", 1493], ["truncated", 1497], ["KCNQ1", 1507], ["splice", 1513], ["variant", 1520], ["(", 1528], ["isoform", 1529], ["2", 1537], [")", 1538], ["in", 1540], ["establishment", 1543], ["and", 1557], ["mode", 1561], ["of", 1566], ["inheritance", 1569], ["in", 1581], ["long", 1584], ["QT", 1589], ["syndrome", 1592], [".", 1600], ["In", 1602], ["the", 1605], ["RWS", 1609], ["family", 1613], ["presented", 1620], ["here", 1630], [",", 1634], ["the", 1636], ["autosomal", 1640], ["-", 1649], ["dominant", 1650], ["trait", 1659], ["is", 1665], ["caused", 1668], ["by", 1675], ["multiple", 1678], ["dominant", 1687], ["-", 1695], ["negative", 1696], ["effects", 1705], ["provoked", 1713], ["by", 1722], ["heteromultimeric", 1725], ["channels", 1742], ["formed", 1751], ["by", 1758], ["wild", 1761], ["type", 1766], ["and", 1771], ["mutant", 1775], ["KCNQ1-isoforms", 1782], ["in", 1797], ["combination", 1800], ["with", 1812], ["KCNE1", 1817], [".", 1822]]}
{"context": "The Ehlers-Danlos syndromes (EDS) comprise a heterogenous group of heritable disorders of connective tissue, characterized by joint hypermobility, skin hyperextensibility and tissue fragility. Most EDS types are caused by mutations in genes encoding different types of collagen or enzymes, essential for normal processing of collagen. Oral health was assessed in 31 subjects with EDS (16 with hypermobility EDS, nine with classical EDS and six with vascular EDS), including signs and symptoms of temporomandibular disorders (TMD), alterations of dental hard tissues, oral mucosa and periodontium, and was compared with matched controls. All EDS subjects were symptomatic for TMD and reported recurrent temporomandibular joint (TMJ) dislocations. Abnormal pulp shape (13%) and pulp calcification (78%) were observed in subjects affected with classical EDS. Caries experience was higher in EDS compared with controls and was related to poor oral hygiene, influenced by increased mucosal fragility and restraint of (wrist) joint mobility. The overall periodontal status in EDS was poor, with 62% of EDS subjects presenting high periodontal treatment needs (community periodontal index for treatment need, CPITN = II). Oral health may be severely compromised in EDS as a result of specific alterations of collagen in orofacial structures. When considering dental treatment in EDS, a number of tissue responses (mucosa, periodontium, pulp) and precautions (TMJ dislocation) should be anticipated.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "e43d93e0fc3b425690165278b7db59e3", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[16, 17]], "char_spans": [[90, 106]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndromes", 18], ["(", 28], ["EDS", 29], [")", 32], ["comprise", 34], ["a", 43], ["heterogenous", 45], ["group", 58], ["of", 64], ["heritable", 67], ["disorders", 77], ["of", 87], ["connective", 90], ["tissue", 101], [",", 107], ["characterized", 109], ["by", 123], ["joint", 126], ["hypermobility", 132], [",", 145], ["skin", 147], ["hyperextensibility", 152], ["and", 171], ["tissue", 175], ["fragility", 182], [".", 191], ["Most", 193], ["EDS", 198], ["types", 202], ["are", 208], ["caused", 212], ["by", 219], ["mutations", 222], ["in", 232], ["genes", 235], ["encoding", 241], ["different", 250], ["types", 260], ["of", 266], ["collagen", 269], ["or", 278], ["enzymes", 281], [",", 288], ["essential", 290], ["for", 300], ["normal", 304], ["processing", 311], ["of", 322], ["collagen", 325], [".", 333], ["Oral", 335], ["health", 340], ["was", 347], ["assessed", 351], ["in", 360], ["31", 363], ["subjects", 366], ["with", 375], ["EDS", 380], ["(", 384], ["16", 385], ["with", 388], ["hypermobility", 393], ["EDS", 407], [",", 410], ["nine", 412], ["with", 417], ["classical", 422], ["EDS", 432], ["and", 436], ["six", 440], ["with", 444], ["vascular", 449], ["EDS", 458], [")", 461], [",", 462], ["including", 464], ["signs", 474], ["and", 480], ["symptoms", 484], ["of", 493], ["temporomandibular", 496], ["disorders", 514], ["(", 524], ["TMD", 525], [")", 528], [",", 529], ["alterations", 531], ["of", 543], ["dental", 546], ["hard", 553], ["tissues", 558], [",", 565], ["oral", 567], ["mucosa", 572], ["and", 579], ["periodontium", 583], [",", 595], ["and", 597], ["was", 601], ["compared", 605], ["with", 614], ["matched", 619], ["controls", 627], [".", 635], ["All", 637], ["EDS", 641], ["subjects", 645], ["were", 654], ["symptomatic", 659], ["for", 671], ["TMD", 675], ["and", 679], ["reported", 683], ["recurrent", 692], ["temporomandibular", 702], ["joint", 720], ["(", 726], ["TMJ", 727], [")", 730], ["dislocations", 732], [".", 744], ["Abnormal", 746], ["pulp", 755], ["shape", 760], ["(", 766], ["13", 767], ["%", 769], [")", 770], ["and", 772], ["pulp", 776], ["calcification", 781], ["(", 795], ["78", 796], ["%", 798], [")", 799], ["were", 801], ["observed", 806], ["in", 815], ["subjects", 818], ["affected", 827], ["with", 836], ["classical", 841], ["EDS", 851], [".", 854], ["Caries", 856], ["experience", 863], ["was", 874], ["higher", 878], ["in", 885], ["EDS", 888], ["compared", 892], ["with", 901], ["controls", 906], ["and", 915], ["was", 919], ["related", 923], ["to", 931], ["poor", 934], ["oral", 939], ["hygiene", 944], [",", 951], ["influenced", 953], ["by", 964], ["increased", 967], ["mucosal", 977], ["fragility", 985], ["and", 995], ["restraint", 999], ["of", 1009], ["(", 1012], ["wrist", 1013], [")", 1018], ["joint", 1020], ["mobility", 1026], [".", 1034], ["The", 1036], ["overall", 1040], ["periodontal", 1048], ["status", 1060], ["in", 1067], ["EDS", 1070], ["was", 1074], ["poor", 1078], [",", 1082], ["with", 1084], ["62", 1089], ["%", 1091], ["of", 1093], ["EDS", 1096], ["subjects", 1100], ["presenting", 1109], ["high", 1120], ["periodontal", 1125], ["treatment", 1137], ["needs", 1147], ["(", 1153], ["community", 1154], ["periodontal", 1164], ["index", 1176], ["for", 1182], ["treatment", 1186], ["need", 1196], [",", 1200], ["CPITN", 1202], ["=", 1208], ["II", 1210], [")", 1212], [".", 1213], ["Oral", 1215], ["health", 1220], ["may", 1227], ["be", 1231], ["severely", 1234], ["compromised", 1243], ["in", 1255], ["EDS", 1258], ["as", 1262], ["a", 1265], ["result", 1267], ["of", 1274], ["specific", 1277], ["alterations", 1286], ["of", 1298], ["collagen", 1301], ["in", 1310], ["orofacial", 1313], ["structures", 1323], [".", 1333], ["When", 1335], ["considering", 1340], ["dental", 1352], ["treatment", 1359], ["in", 1369], ["EDS", 1372], [",", 1375], ["a", 1377], ["number", 1379], ["of", 1386], ["tissue", 1389], ["responses", 1396], ["(", 1406], ["mucosa", 1407], [",", 1413], ["periodontium", 1415], [",", 1427], ["pulp", 1429], [")", 1433], ["and", 1435], ["precautions", 1439], ["(", 1451], ["TMJ", 1452], ["dislocation", 1456], [")", 1467], ["should", 1469], ["be", 1476], ["anticipated", 1479], [".", 1490]]}
{"context": "We have used a non-replicating recombinant adenovirus, Ad5MCMVlacZ, which expresses the beta-galactosidase reporter gene, to examine both constitutive and inducible repair of UV-damaged DNA in repair proficient CHO-AA8 Chinese hamster ovary cells and in mutant CHO-UV61 cells which are deficient in the transcription-coupled repair (TCR) pathway of nucleotide excision repair. Host cell reactivation (HCR) of beta-galactosidase activity for UV-irradiated Ad5MCMVlacZ was significantly reduced in non-irradiated CHO-UV61 cells compared to that in non-irradiated CHO-AA8 cells suggesting that repair in the transcribed strand of the UV-damaged reporter gene in untreated cells utilizes TCR. Prior UV-irradiation of cells with low UV fluences resulted in a transient enhancement of HCR for expression of the UV-damaged reporter gene in CHO-AA8 cells but not in TCR deficient CHO-UV61 cells. These results suggest the presence of an inducible DNA pathway in CHO cells that results from an enhancement of TCR or a mechanism that involves the TCR pathway.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "eda2a1c711434788b5b1baf539f5db9a", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[111, 112]], "char_spans": [[605, 622]]}]}], "context_tokens": [["We", 0], ["have", 3], ["used", 8], ["a", 13], ["non", 15], ["-", 18], ["replicating", 19], ["recombinant", 31], ["adenovirus", 43], [",", 53], ["Ad5MCMVlacZ", 55], [",", 66], ["which", 68], ["expresses", 74], ["the", 84], ["beta", 88], ["-", 92], ["galactosidase", 93], ["reporter", 107], ["gene", 116], [",", 120], ["to", 122], ["examine", 125], ["both", 133], ["constitutive", 138], ["and", 151], ["inducible", 155], ["repair", 165], ["of", 172], ["UV", 175], ["-", 177], ["damaged", 178], ["DNA", 186], ["in", 190], ["repair", 193], ["proficient", 200], ["CHO", 211], ["-", 214], ["AA8", 215], ["Chinese", 219], ["hamster", 227], ["ovary", 235], ["cells", 241], ["and", 247], ["in", 251], ["mutant", 254], ["CHO", 261], ["-", 264], ["UV61", 265], ["cells", 270], ["which", 276], ["are", 282], ["deficient", 286], ["in", 296], ["the", 299], ["transcription", 303], ["-", 316], ["coupled", 317], ["repair", 325], ["(", 332], ["TCR", 333], [")", 336], ["pathway", 338], ["of", 346], ["nucleotide", 349], ["excision", 360], ["repair", 369], [".", 375], ["Host", 377], ["cell", 382], ["reactivation", 387], ["(", 400], ["HCR", 401], [")", 404], ["of", 406], ["beta", 409], ["-", 413], ["galactosidase", 414], ["activity", 428], ["for", 437], ["UV", 441], ["-", 443], ["irradiated", 444], ["Ad5MCMVlacZ", 455], ["was", 467], ["significantly", 471], ["reduced", 485], ["in", 493], ["non", 496], ["-", 499], ["irradiated", 500], ["CHO", 511], ["-", 514], ["UV61", 515], ["cells", 520], ["compared", 526], ["to", 535], ["that", 538], ["in", 543], ["non", 546], ["-", 549], ["irradiated", 550], ["CHO", 561], ["-", 564], ["AA8", 565], ["cells", 569], ["suggesting", 575], ["that", 586], ["repair", 591], ["in", 598], ["the", 601], ["transcribed", 605], ["strand", 617], ["of", 624], ["the", 627], ["UV", 631], ["-", 633], ["damaged", 634], ["reporter", 642], ["gene", 651], ["in", 656], ["untreated", 659], ["cells", 669], ["utilizes", 675], ["TCR", 684], [".", 687], ["Prior", 689], ["UV", 695], ["-", 697], ["irradiation", 698], ["of", 710], ["cells", 713], ["with", 719], ["low", 724], ["UV", 728], ["fluences", 731], ["resulted", 740], ["in", 749], ["a", 752], ["transient", 754], ["enhancement", 764], ["of", 776], ["HCR", 779], ["for", 783], ["expression", 787], ["of", 798], ["the", 801], ["UV", 805], ["-", 807], ["damaged", 808], ["reporter", 816], ["gene", 825], ["in", 830], ["CHO", 833], ["-", 836], ["AA8", 837], ["cells", 841], ["but", 847], ["not", 851], ["in", 855], ["TCR", 858], ["deficient", 862], ["CHO", 872], ["-", 875], ["UV61", 876], ["cells", 881], [".", 886], ["These", 888], ["results", 894], ["suggest", 902], ["the", 910], ["presence", 914], ["of", 923], ["an", 926], ["inducible", 929], ["DNA", 939], ["pathway", 943], ["in", 951], ["CHO", 954], ["cells", 958], ["that", 964], ["results", 969], ["from", 977], ["an", 982], ["enhancement", 985], ["of", 997], ["TCR", 1000], ["or", 1004], ["a", 1007], ["mechanism", 1009], ["that", 1019], ["involves", 1024], ["the", 1033], ["TCR", 1037], ["pathway", 1041], [".", 1048]]}
{"context": "Many neurodegenerative diseases are associated with the aggregation of misfolded proteins into amyloid oligomers or fibrils that are deposited as pathological lesions within areas of the brain. An attractive therapeutic strategy for preventing or ameliorating amyloid formation is to identify agents that inhibit the onset or propagation of protein aggregation. Here we demonstrate how solid-state nuclear magnetic resonance (ssNMR) may be used to identify key residues within amyloidogenic protein sequences that may be targeted to inhibit the aggregation of the host protein. For alpha-synuclein, the major protein component of Lewy bodies associated with Parkinson's disease, we have used a combination of ssNMR and biochemical data to identify the key region for self-aggregation of the protein as residues 77-82 (VAQKTV). We used our new structural information to design a peptide derived from residues 77 to 82 of alpha-synuclein with an N-methyl group at the C-terminal residue, which was able to disrupt the aggregation of alpha-synuclein. Thus, we have shown how structural data obtained from ssNMR can guide the design of modified peptides for use as amyloid inhibitors, as a primary step toward developing therapeutic compounds for prevention and/or treatment of amyloid diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "ec3fbfeea1b541fd86801d3f230fe7ac", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[179, 181], [90, 92], [155, 157]], "char_spans": [[1031, 1045], [582, 596], [920, 934]]}]}], "context_tokens": [["Many", 0], ["neurodegenerative", 5], ["diseases", 23], ["are", 32], ["associated", 36], ["with", 47], ["the", 52], ["aggregation", 56], ["of", 68], ["misfolded", 71], ["proteins", 81], ["into", 90], ["amyloid", 95], ["oligomers", 103], ["or", 113], ["fibrils", 116], ["that", 124], ["are", 129], ["deposited", 133], ["as", 143], ["pathological", 146], ["lesions", 159], ["within", 167], ["areas", 174], ["of", 180], ["the", 183], ["brain", 187], [".", 192], ["An", 194], ["attractive", 197], ["therapeutic", 208], ["strategy", 220], ["for", 229], ["preventing", 233], ["or", 244], ["ameliorating", 247], ["amyloid", 260], ["formation", 268], ["is", 278], ["to", 281], ["identify", 284], ["agents", 293], ["that", 300], ["inhibit", 305], ["the", 313], ["onset", 317], ["or", 323], ["propagation", 326], ["of", 338], ["protein", 341], ["aggregation", 349], [".", 360], ["Here", 362], ["we", 367], ["demonstrate", 370], ["how", 382], ["solid", 386], ["-", 391], ["state", 392], ["nuclear", 398], ["magnetic", 406], ["resonance", 415], ["(", 425], ["ssNMR", 426], [")", 431], ["may", 433], ["be", 437], ["used", 440], ["to", 445], ["identify", 448], ["key", 457], ["residues", 461], ["within", 470], ["amyloidogenic", 477], ["protein", 491], ["sequences", 499], ["that", 509], ["may", 514], ["be", 518], ["targeted", 521], ["to", 530], ["inhibit", 533], ["the", 541], ["aggregation", 545], ["of", 557], ["the", 560], ["host", 564], ["protein", 569], [".", 576], ["For", 578], ["alpha", 582], ["-", 587], ["synuclein", 588], [",", 597], ["the", 599], ["major", 603], ["protein", 609], ["component", 617], ["of", 627], ["Lewy", 630], ["bodies", 635], ["associated", 642], ["with", 653], ["Parkinson", 658], ["'s", 667], ["disease", 670], [",", 677], ["we", 679], ["have", 682], ["used", 687], ["a", 692], ["combination", 694], ["of", 706], ["ssNMR", 709], ["and", 715], ["biochemical", 719], ["data", 731], ["to", 736], ["identify", 739], ["the", 748], ["key", 752], ["region", 756], ["for", 763], ["self", 767], ["-", 771], ["aggregation", 772], ["of", 784], ["the", 787], ["protein", 791], ["as", 799], ["residues", 802], ["77", 811], ["-", 813], ["82", 814], ["(", 817], ["VAQKTV", 818], [")", 824], [".", 825], ["We", 827], ["used", 830], ["our", 835], ["new", 839], ["structural", 843], ["information", 854], ["to", 866], ["design", 869], ["a", 876], ["peptide", 878], ["derived", 886], ["from", 894], ["residues", 899], ["77", 908], ["to", 911], ["82", 914], ["of", 917], ["alpha", 920], ["-", 925], ["synuclein", 926], ["with", 936], ["an", 941], ["N", 944], ["-", 945], ["methyl", 946], ["group", 953], ["at", 959], ["the", 962], ["C", 966], ["-", 967], ["terminal", 968], ["residue", 977], [",", 984], ["which", 986], ["was", 992], ["able", 996], ["to", 1001], ["disrupt", 1004], ["the", 1012], ["aggregation", 1016], ["of", 1028], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], [".", 1046], ["Thus", 1048], [",", 1052], ["we", 1054], ["have", 1057], ["shown", 1062], ["how", 1068], ["structural", 1072], ["data", 1083], ["obtained", 1088], ["from", 1097], ["ssNMR", 1102], ["can", 1108], ["guide", 1112], ["the", 1118], ["design", 1122], ["of", 1129], ["modified", 1132], ["peptides", 1141], ["for", 1150], ["use", 1154], ["as", 1158], ["amyloid", 1161], ["inhibitors", 1169], [",", 1179], ["as", 1181], ["a", 1184], ["primary", 1186], ["step", 1194], ["toward", 1199], ["developing", 1206], ["therapeutic", 1217], ["compounds", 1229], ["for", 1239], ["prevention", 1243], ["and/or", 1254], ["treatment", 1261], ["of", 1271], ["amyloid", 1274], ["diseases", 1282], [".", 1290]]}
{"context": "Christianson syndrome (CS) is an X-linked neurodevelopmental and neurological disorder characterized in males by core symptoms that include non-verbal status, intellectual disability, epilepsy, truncal ataxia, postnatal microcephaly and hyperkinesis. CS is caused by mutations in the SLC9A6 gene, which encodes a multipass transmembrane sodium (potassium)-hydrogen exchanger 6 (NHE6) protein, functional in early recycling endosomes. The extent and variability of the CS phenotype in female heterozygotes, who presumably express the wild-type and mutant SLC9A6 alleles mosaically as a result of X-chromosome inactivation (XCI), have not yet been systematically characterized. Slc9a6 knockout mice (Slc9a6 KO) were generated by insertion of the bacterial lacZ/\u03b2-galactosidase (\u03b2-Gal) reporter into exon 6 of the X-linked gene. Mutant Slc9a6 KO male mice have been shown to develop late endosomal/lysosomal dysfunction associated with glycolipid accumulation in selected neuronal populations and patterned degeneration of Purkinje cells (PCs). In heterozygous female Slc9a6 KO mice, \u03b2-Gal serves as a transcriptional/XCI reporter and thus facilitates testing of effects of mosaic expression of the mutant allele on penetrance of the abnormal phenotype. Using \u03b2-Gal, we demonstrated mosaic expression of the mutant Slc9a6 allele and mosaically distributed lysosomal glycolipid accumulation and PC pathology in the brains of heterozygous Slc9a6 KO female mice. At the behavioral level, we showed that heterozygous female mice suffer from visuospatial memory and motor coordination deficits similar to but less severe than those observed in X-chromosome hemizygous mutant males. Our studies in heterozygous Slc9a6 KO female mice provide important clues for understanding the likely phenotypic range of Christianson syndrome among females heterozygous for SLC9A6 mutations and might improve diagnostic practice and genetic counseling by helping to characterize this presumably underappreciated patient/carrier group.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "d941cbf53efb4218a8348c71b146a2d2", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[291, 291], [150, 150], [118, 118], [92, 92], [185, 185], [231, 231], [247, 247], [311, 311], [114, 114], [47, 47]], "char_spans": [[1702, 1707], [833, 838], [698, 703], [554, 559], [1065, 1070], [1312, 1317], [1434, 1439], [1850, 1855], [676, 681], [284, 289]]}]}], "context_tokens": [["Christianson", 0], ["syndrome", 13], ["(", 22], ["CS", 23], [")", 25], ["is", 27], ["an", 30], ["X", 33], ["-", 34], ["linked", 35], ["neurodevelopmental", 42], ["and", 61], ["neurological", 65], ["disorder", 78], ["characterized", 87], ["in", 101], ["males", 104], ["by", 110], ["core", 113], ["symptoms", 118], ["that", 127], ["include", 132], ["non", 140], ["-", 143], ["verbal", 144], ["status", 151], [",", 157], ["intellectual", 159], ["disability", 172], [",", 182], ["epilepsy", 184], [",", 192], ["truncal", 194], ["ataxia", 202], [",", 208], ["postnatal", 210], ["microcephaly", 220], ["and", 233], ["hyperkinesis", 237], [".", 249], ["CS", 251], ["is", 254], ["caused", 257], ["by", 264], ["mutations", 267], ["in", 277], ["the", 280], ["SLC9A6", 284], ["gene", 291], [",", 295], ["which", 297], ["encodes", 303], ["a", 311], ["multipass", 313], ["transmembrane", 323], ["sodium", 337], ["(", 344], ["potassium)-hydrogen", 345], ["exchanger", 365], ["6", 375], ["(", 377], ["NHE6", 378], [")", 382], ["protein", 384], [",", 391], ["functional", 393], ["in", 404], ["early", 407], ["recycling", 413], ["endosomes", 423], [".", 432], ["The", 434], ["extent", 438], ["and", 445], ["variability", 449], ["of", 461], ["the", 464], ["CS", 468], ["phenotype", 471], ["in", 481], ["female", 484], ["heterozygotes", 491], [",", 504], ["who", 506], ["presumably", 510], ["express", 521], ["the", 529], ["wild", 533], ["-", 537], ["type", 538], ["and", 543], ["mutant", 547], ["SLC9A6", 554], ["alleles", 561], ["mosaically", 569], ["as", 580], ["a", 583], ["result", 585], ["of", 592], ["X", 595], ["-", 596], ["chromosome", 597], ["inactivation", 608], ["(", 621], ["XCI", 622], [")", 625], [",", 626], ["have", 628], ["not", 633], ["yet", 637], ["been", 641], ["systematically", 646], ["characterized", 661], [".", 674], ["Slc9a6", 676], ["knockout", 683], ["mice", 692], ["(", 697], ["Slc9a6", 698], ["KO", 705], [")", 707], ["were", 709], ["generated", 714], ["by", 724], ["insertion", 727], ["of", 737], ["the", 740], ["bacterial", 744], ["lacZ", 754], ["/", 758], ["\u03b2", 759], ["-", 760], ["galactosidase", 761], ["(", 775], ["\u03b2", 776], ["-", 777], ["Gal", 778], [")", 781], ["reporter", 783], ["into", 792], ["exon", 797], ["6", 802], ["of", 804], ["the", 807], ["X", 811], ["-", 812], ["linked", 813], ["gene", 820], [".", 824], ["Mutant", 826], ["Slc9a6", 833], ["KO", 840], ["male", 843], ["mice", 848], ["have", 853], ["been", 858], ["shown", 863], ["to", 869], ["develop", 872], ["late", 880], ["endosomal", 885], ["/", 894], ["lysosomal", 895], ["dysfunction", 905], ["associated", 917], ["with", 928], ["glycolipid", 933], ["accumulation", 944], ["in", 957], ["selected", 960], ["neuronal", 969], ["populations", 978], ["and", 990], ["patterned", 994], ["degeneration", 1004], ["of", 1017], ["Purkinje", 1020], ["cells", 1029], ["(", 1035], ["PCs", 1036], [")", 1039], [".", 1040], ["In", 1042], ["heterozygous", 1045], ["female", 1058], ["Slc9a6", 1065], ["KO", 1072], ["mice", 1075], [",", 1079], ["\u03b2", 1081], ["-", 1082], ["Gal", 1083], ["serves", 1087], ["as", 1094], ["a", 1097], ["transcriptional", 1099], ["/", 1114], ["XCI", 1115], ["reporter", 1119], ["and", 1128], ["thus", 1132], ["facilitates", 1137], ["testing", 1149], ["of", 1157], ["effects", 1160], ["of", 1168], ["mosaic", 1171], ["expression", 1178], ["of", 1189], ["the", 1192], ["mutant", 1196], ["allele", 1203], ["on", 1210], ["penetrance", 1213], ["of", 1224], ["the", 1227], ["abnormal", 1231], ["phenotype", 1240], [".", 1249], ["Using", 1251], ["\u03b2", 1257], ["-", 1258], ["Gal", 1259], [",", 1262], ["we", 1264], ["demonstrated", 1267], ["mosaic", 1280], ["expression", 1287], ["of", 1298], ["the", 1301], ["mutant", 1305], ["Slc9a6", 1312], ["allele", 1319], ["and", 1326], ["mosaically", 1330], ["distributed", 1341], ["lysosomal", 1353], ["glycolipid", 1363], ["accumulation", 1374], ["and", 1387], ["PC", 1391], ["pathology", 1394], ["in", 1404], ["the", 1407], ["brains", 1411], ["of", 1418], ["heterozygous", 1421], ["Slc9a6", 1434], ["KO", 1441], ["female", 1444], ["mice", 1451], [".", 1455], ["At", 1457], ["the", 1460], ["behavioral", 1464], ["level", 1475], [",", 1480], ["we", 1482], ["showed", 1485], ["that", 1492], ["heterozygous", 1497], ["female", 1510], ["mice", 1517], ["suffer", 1522], ["from", 1529], ["visuospatial", 1534], ["memory", 1547], ["and", 1554], ["motor", 1558], ["coordination", 1564], ["deficits", 1577], ["similar", 1586], ["to", 1594], ["but", 1597], ["less", 1601], ["severe", 1606], ["than", 1613], ["those", 1618], ["observed", 1624], ["in", 1633], ["X", 1636], ["-", 1637], ["chromosome", 1638], ["hemizygous", 1649], ["mutant", 1660], ["males", 1667], [".", 1672], ["Our", 1674], ["studies", 1678], ["in", 1686], ["heterozygous", 1689], ["Slc9a6", 1702], ["KO", 1709], ["female", 1712], ["mice", 1719], ["provide", 1724], ["important", 1732], ["clues", 1742], ["for", 1748], ["understanding", 1752], ["the", 1766], ["likely", 1770], ["phenotypic", 1777], ["range", 1788], ["of", 1794], ["Christianson", 1797], ["syndrome", 1810], ["among", 1819], ["females", 1825], ["heterozygous", 1833], ["for", 1846], ["SLC9A6", 1850], ["mutations", 1857], ["and", 1867], ["might", 1871], ["improve", 1877], ["diagnostic", 1885], ["practice", 1896], ["and", 1905], ["genetic", 1909], ["counseling", 1917], ["by", 1928], ["helping", 1931], ["to", 1939], ["characterize", 1942], ["this", 1955], ["presumably", 1960], ["underappreciated", 1971], ["patient", 1988], ["/", 1995], ["carrier", 1996], ["group", 2004], [".", 2009]]}
{"context": "Hepcidin, a 25-amino-acid peptide secreted by the liver, distributed in the plasma and excreted in urine, is a key central regulator of body iron homeostasis. This hormone decreases export of cellular iron by binding to ferroportin, an iron exporter present at the basolateral surface of enterocytes and macrophages (the sites of dietary iron absorption and iron recycling, respectively), inducing its internalization and degradation. Hepcidin contains eight cysteine residues that form four disulfide bridges, which stabilize a hairpin-shaped structure with two beta sheets. We noticed in the sequence of hepcidin a Cys*-X-Cys* motif which can act as a metal binding site able to trap iron and/or copper. We have tested this hypothesis using a pseudopeptidic synthetic bis-disulfide analogue and we have shown that direct metalation of such ligand leads to the formation of a copper(III) complex with the typical N(2)S(2)\u00a0donor set. This compound crystallizes in the orthorhombic system, space group Imma. The Cu(III) configuration is square planar, built up from two carboximado-N and two thiolato-S donors. This complex is converted back to the bis-disulfide, with release of the copper salt, upon oxidation with iodine.", "qas": [{"question": "How many disulfide bridges has the protein hepcidin got?", "answers": ["Hepcidin contains eight cysteine residues that form four disulfide bridges"], "qid": "1f9ba193c3004e76bc6c7b235f7af430", "question_tokens": [["How", 0], ["many", 4], ["disulfide", 9], ["bridges", 19], ["has", 27], ["the", 31], ["protein", 35], ["hepcidin", 43], ["got", 52], ["?", 55]], "detected_answers": [{"text": "Hepcidin contains eight cysteine residues that form four disulfide bridges", "token_spans": [[75, 84]], "char_spans": [[435, 508]]}]}], "context_tokens": [["Hepcidin", 0], [",", 8], ["a", 10], ["25-amino", 12], ["-", 20], ["acid", 21], ["peptide", 26], ["secreted", 34], ["by", 43], ["the", 46], ["liver", 50], [",", 55], ["distributed", 57], ["in", 69], ["the", 72], ["plasma", 76], ["and", 83], ["excreted", 87], ["in", 96], ["urine", 99], [",", 104], ["is", 106], ["a", 109], ["key", 111], ["central", 115], ["regulator", 123], ["of", 133], ["body", 136], ["iron", 141], ["homeostasis", 146], [".", 157], ["This", 159], ["hormone", 164], ["decreases", 172], ["export", 182], ["of", 189], ["cellular", 192], ["iron", 201], ["by", 206], ["binding", 209], ["to", 217], ["ferroportin", 220], [",", 231], ["an", 233], ["iron", 236], ["exporter", 241], ["present", 250], ["at", 258], ["the", 261], ["basolateral", 265], ["surface", 277], ["of", 285], ["enterocytes", 288], ["and", 300], ["macrophages", 304], ["(", 316], ["the", 317], ["sites", 321], ["of", 327], ["dietary", 330], ["iron", 338], ["absorption", 343], ["and", 354], ["iron", 358], ["recycling", 363], [",", 372], ["respectively", 374], [")", 386], [",", 387], ["inducing", 389], ["its", 398], ["internalization", 402], ["and", 418], ["degradation", 422], [".", 433], ["Hepcidin", 435], ["contains", 444], ["eight", 453], ["cysteine", 459], ["residues", 468], ["that", 477], ["form", 482], ["four", 487], ["disulfide", 492], ["bridges", 502], [",", 509], ["which", 511], ["stabilize", 517], ["a", 527], ["hairpin", 529], ["-", 536], ["shaped", 537], ["structure", 544], ["with", 554], ["two", 559], ["beta", 563], ["sheets", 568], [".", 574], ["We", 576], ["noticed", 579], ["in", 587], ["the", 590], ["sequence", 594], ["of", 603], ["hepcidin", 606], ["a", 615], ["Cys*-X", 617], ["-", 623], ["Cys", 624], ["*", 627], ["motif", 629], ["which", 635], ["can", 641], ["act", 645], ["as", 649], ["a", 652], ["metal", 654], ["binding", 660], ["site", 668], ["able", 673], ["to", 678], ["trap", 681], ["iron", 686], ["and/or", 691], ["copper", 698], [".", 704], ["We", 706], ["have", 709], ["tested", 714], ["this", 721], ["hypothesis", 726], ["using", 737], ["a", 743], ["pseudopeptidic", 745], ["synthetic", 760], ["bis", 770], ["-", 773], ["disulfide", 774], ["analogue", 784], ["and", 793], ["we", 797], ["have", 800], ["shown", 805], ["that", 811], ["direct", 816], ["metalation", 823], ["of", 834], ["such", 837], ["ligand", 842], ["leads", 849], ["to", 855], ["the", 858], ["formation", 862], ["of", 872], ["a", 875], ["copper(III", 877], [")", 887], ["complex", 889], ["with", 897], ["the", 902], ["typical", 906], ["N(2)S(2", 914], [")", 921], ["donor", 923], ["set", 929], [".", 932], ["This", 934], ["compound", 939], ["crystallizes", 948], ["in", 961], ["the", 964], ["orthorhombic", 968], ["system", 981], [",", 987], ["space", 989], ["group", 995], ["Imma", 1001], [".", 1005], ["The", 1007], ["Cu(III", 1011], [")", 1017], ["configuration", 1019], ["is", 1033], ["square", 1036], ["planar", 1043], [",", 1049], ["built", 1051], ["up", 1057], ["from", 1060], ["two", 1065], ["carboximado", 1069], ["-", 1080], ["N", 1081], ["and", 1083], ["two", 1087], ["thiolato", 1091], ["-", 1099], ["S", 1100], ["donors", 1102], [".", 1108], ["This", 1110], ["complex", 1115], ["is", 1123], ["converted", 1126], ["back", 1136], ["to", 1141], ["the", 1144], ["bis", 1148], ["-", 1151], ["disulfide", 1152], [",", 1161], ["with", 1163], ["release", 1168], ["of", 1176], ["the", 1179], ["copper", 1183], ["salt", 1190], [",", 1194], ["upon", 1196], ["oxidation", 1201], ["with", 1211], ["iodine", 1216], [".", 1222]]}
{"context": "Calcium activated gene transcription through Nuclear Factor of Activated T-cells, (NFAT) proteins, is emerging as a ubiquitous mechanism for the control of important physiological processes. Of the five mammalian NFAT isoforms, transcriptional activities of NFATs 1-4 are stimulated by a calcium driven association between the ubiquitous phosphatase calcineurin and the calcium-sensing protein calmodulin. Published in vitro evidence has suggested that other members of the calmodulin super-family, in particular the neuronal calcium sensor (NCS) proteins, can similarly modulate calcineurin activity. In this study we have assessed the ability of NCS proteins to interact directly with calcineurin in vitro and report a specific if weak association between various NCS proteins and the phosphatase. In an extension to these analyses we have also examined the effects of over-expression of NCS-1 or NCS-1 mutants on calcineurin signalling in HeLa cells in experiments examining the dephosphorylation of an NFAT-GFP reporter construct as a readout of calcineurin activity. Results from these experiments indicate that NCS-1 was not able to detectably modulate calcineurin/NFAT signalling in a live mammalian cell system, findings that are consistent with the idea that calmodulin and not NCS-1 or other NCS family proteins is the physiologically relevant modulator of calcineurin activity.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "8c7b90d3f4324749a409830dd407b9ea", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[96, 96], [154, 154], [57, 57], [225, 225], [114, 114], [191, 191], [175, 175]], "char_spans": [[580, 590], [916, 926], [350, 360], [1367, 1377], [687, 697], [1159, 1169], [1050, 1060]]}, {"text": "CaN", "token_spans": [[93, 93]], "char_spans": [[557, 559]]}]}], "context_tokens": [["Calcium", 0], ["activated", 8], ["gene", 18], ["transcription", 23], ["through", 37], ["Nuclear", 45], ["Factor", 53], ["of", 60], ["Activated", 63], ["T", 73], ["-", 74], ["cells", 75], [",", 80], ["(", 82], ["NFAT", 83], [")", 87], ["proteins", 89], [",", 97], ["is", 99], ["emerging", 102], ["as", 111], ["a", 114], ["ubiquitous", 116], ["mechanism", 127], ["for", 137], ["the", 141], ["control", 145], ["of", 153], ["important", 156], ["physiological", 166], ["processes", 180], [".", 189], ["Of", 191], ["the", 194], ["five", 198], ["mammalian", 203], ["NFAT", 213], ["isoforms", 218], [",", 226], ["transcriptional", 228], ["activities", 244], ["of", 255], ["NFATs", 258], ["1", 264], ["-", 265], ["4", 266], ["are", 268], ["stimulated", 272], ["by", 283], ["a", 286], ["calcium", 288], ["driven", 296], ["association", 303], ["between", 315], ["the", 323], ["ubiquitous", 327], ["phosphatase", 338], ["calcineurin", 350], ["and", 362], ["the", 366], ["calcium", 370], ["-", 377], ["sensing", 378], ["protein", 386], ["calmodulin", 394], [".", 404], ["Published", 406], ["in", 416], ["vitro", 419], ["evidence", 425], ["has", 434], ["suggested", 438], ["that", 448], ["other", 453], ["members", 459], ["of", 467], ["the", 470], ["calmodulin", 474], ["super", 485], ["-", 490], ["family", 491], [",", 497], ["in", 499], ["particular", 502], ["the", 513], ["neuronal", 517], ["calcium", 526], ["sensor", 534], ["(", 541], ["NCS", 542], [")", 545], ["proteins", 547], [",", 555], ["can", 557], ["similarly", 561], ["modulate", 571], ["calcineurin", 580], ["activity", 592], [".", 600], ["In", 602], ["this", 605], ["study", 610], ["we", 616], ["have", 619], ["assessed", 624], ["the", 633], ["ability", 637], ["of", 645], ["NCS", 648], ["proteins", 652], ["to", 661], ["interact", 664], ["directly", 673], ["with", 682], ["calcineurin", 687], ["in", 699], ["vitro", 702], ["and", 708], ["report", 712], ["a", 719], ["specific", 721], ["if", 730], ["weak", 733], ["association", 738], ["between", 750], ["various", 758], ["NCS", 766], ["proteins", 770], ["and", 779], ["the", 783], ["phosphatase", 787], [".", 798], ["In", 800], ["an", 803], ["extension", 806], ["to", 816], ["these", 819], ["analyses", 825], ["we", 834], ["have", 837], ["also", 842], ["examined", 847], ["the", 856], ["effects", 860], ["of", 868], ["over", 871], ["-", 875], ["expression", 876], ["of", 887], ["NCS-1", 890], ["or", 896], ["NCS-1", 899], ["mutants", 905], ["on", 913], ["calcineurin", 916], ["signalling", 928], ["in", 939], ["HeLa", 942], ["cells", 947], ["in", 953], ["experiments", 956], ["examining", 968], ["the", 978], ["dephosphorylation", 982], ["of", 1000], ["an", 1003], ["NFAT", 1006], ["-", 1010], ["GFP", 1011], ["reporter", 1015], ["construct", 1024], ["as", 1034], ["a", 1037], ["readout", 1039], ["of", 1047], ["calcineurin", 1050], ["activity", 1062], [".", 1070], ["Results", 1072], ["from", 1080], ["these", 1085], ["experiments", 1091], ["indicate", 1103], ["that", 1112], ["NCS-1", 1117], ["was", 1123], ["not", 1127], ["able", 1131], ["to", 1136], ["detectably", 1139], ["modulate", 1150], ["calcineurin", 1159], ["/", 1170], ["NFAT", 1171], ["signalling", 1176], ["in", 1187], ["a", 1190], ["live", 1192], ["mammalian", 1197], ["cell", 1207], ["system", 1212], [",", 1218], ["findings", 1220], ["that", 1229], ["are", 1234], ["consistent", 1238], ["with", 1249], ["the", 1254], ["idea", 1258], ["that", 1263], ["calmodulin", 1268], ["and", 1279], ["not", 1283], ["NCS-1", 1287], ["or", 1293], ["other", 1296], ["NCS", 1302], ["family", 1306], ["proteins", 1313], ["is", 1322], ["the", 1325], ["physiologically", 1329], ["relevant", 1345], ["modulator", 1354], ["of", 1364], ["calcineurin", 1367], ["activity", 1379], [".", 1387]]}
{"context": "The centriole and basal body (CBB) structure nucleates cilia and flagella, and is an essential component of the centrosome, underlying eukaryotic microtubule-based motility, cell division and polarity. In recent years, components of the CBB-assembly machinery have been identified, but little is known about their regulation and evolution. Given the diversity of cellular contexts encountered in eukaryotes, but the remarkable conservation of CBB morphology, we asked whether general mechanistic principles could explain CBB assembly. We analysed the distribution of each component of the human CBB-assembly machinery across eukaryotes as a strategy to generate testable hypotheses. We found an evolutionarily cohesive and ancestral module, which we term UNIMOD and is defined by three components (SAS6, SAS4/CPAP and BLD10/CEP135), that correlates with the occurrence of CBBs. Unexpectedly, other players (SAK/PLK4, SPD2/CEP192 and CP110) emerged in a taxon-specific manner. We report that gene duplication plays an important role in the evolution of CBB components and show that, in the case of BLD10/CEP135, this is a source of tissue specificity in CBB and flagella biogenesis. Moreover, we observe extreme protein divergence amongst CBB components and show experimentally that there is loss of cross-species complementation among SAK/PLK4 family members, suggesting species-specific adaptations in CBB assembly. We propose that the UNIMOD theory explains the conservation of CBB architecture and that taxon- and tissue-specific molecular innovations, gained through emergence, duplication and divergence, play important roles in coordinating CBB biogenesis and function in different cellular contexts.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "57611d6d9eaa48c5981f8236cc47fd2e", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[21, 21]], "char_spans": [[112, 121]]}]}], "context_tokens": [["The", 0], ["centriole", 4], ["and", 14], ["basal", 18], ["body", 24], ["(", 29], ["CBB", 30], [")", 33], ["structure", 35], ["nucleates", 45], ["cilia", 55], ["and", 61], ["flagella", 65], [",", 73], ["and", 75], ["is", 79], ["an", 82], ["essential", 85], ["component", 95], ["of", 105], ["the", 108], ["centrosome", 112], [",", 122], ["underlying", 124], ["eukaryotic", 135], ["microtubule", 146], ["-", 157], ["based", 158], ["motility", 164], [",", 172], ["cell", 174], ["division", 179], ["and", 188], ["polarity", 192], [".", 200], ["In", 202], ["recent", 205], ["years", 212], [",", 217], ["components", 219], ["of", 230], ["the", 233], ["CBB", 237], ["-", 240], ["assembly", 241], ["machinery", 250], ["have", 260], ["been", 265], ["identified", 270], [",", 280], ["but", 282], ["little", 286], ["is", 293], ["known", 296], ["about", 302], ["their", 308], ["regulation", 314], ["and", 325], ["evolution", 329], [".", 338], ["Given", 340], ["the", 346], ["diversity", 350], ["of", 360], ["cellular", 363], ["contexts", 372], ["encountered", 381], ["in", 393], ["eukaryotes", 396], [",", 406], ["but", 408], ["the", 412], ["remarkable", 416], ["conservation", 427], ["of", 440], ["CBB", 443], ["morphology", 447], [",", 457], ["we", 459], ["asked", 462], ["whether", 468], ["general", 476], ["mechanistic", 484], ["principles", 496], ["could", 507], ["explain", 513], ["CBB", 521], ["assembly", 525], [".", 533], ["We", 535], ["analysed", 538], ["the", 547], ["distribution", 551], ["of", 564], ["each", 567], ["component", 572], ["of", 582], ["the", 585], ["human", 589], ["CBB", 595], ["-", 598], ["assembly", 599], ["machinery", 608], ["across", 618], ["eukaryotes", 625], ["as", 636], ["a", 639], ["strategy", 641], ["to", 650], ["generate", 653], ["testable", 662], ["hypotheses", 671], [".", 681], ["We", 683], ["found", 686], ["an", 692], ["evolutionarily", 695], ["cohesive", 710], ["and", 719], ["ancestral", 723], ["module", 733], [",", 739], ["which", 741], ["we", 747], ["term", 750], ["UNIMOD", 755], ["and", 762], ["is", 766], ["defined", 769], ["by", 777], ["three", 780], ["components", 786], ["(", 797], ["SAS6", 798], [",", 802], ["SAS4/CPAP", 804], ["and", 814], ["BLD10/CEP135", 818], [")", 830], [",", 831], ["that", 833], ["correlates", 838], ["with", 849], ["the", 854], ["occurrence", 858], ["of", 869], ["CBBs", 872], [".", 876], ["Unexpectedly", 878], [",", 890], ["other", 892], ["players", 898], ["(", 906], ["SAK", 907], ["/", 910], ["PLK4", 911], [",", 915], ["SPD2/CEP192", 917], ["and", 929], ["CP110", 933], [")", 938], ["emerged", 940], ["in", 948], ["a", 951], ["taxon", 953], ["-", 958], ["specific", 959], ["manner", 968], [".", 974], ["We", 976], ["report", 979], ["that", 986], ["gene", 991], ["duplication", 996], ["plays", 1008], ["an", 1014], ["important", 1017], ["role", 1027], ["in", 1032], ["the", 1035], ["evolution", 1039], ["of", 1049], ["CBB", 1052], ["components", 1056], ["and", 1067], ["show", 1071], ["that", 1076], [",", 1080], ["in", 1082], ["the", 1085], ["case", 1089], ["of", 1094], ["BLD10/CEP135", 1097], [",", 1109], ["this", 1111], ["is", 1116], ["a", 1119], ["source", 1121], ["of", 1128], ["tissue", 1131], ["specificity", 1138], ["in", 1150], ["CBB", 1153], ["and", 1157], ["flagella", 1161], ["biogenesis", 1170], [".", 1180], ["Moreover", 1182], [",", 1190], ["we", 1192], ["observe", 1195], ["extreme", 1203], ["protein", 1211], ["divergence", 1219], ["amongst", 1230], ["CBB", 1238], ["components", 1242], ["and", 1253], ["show", 1257], ["experimentally", 1262], ["that", 1277], ["there", 1282], ["is", 1288], ["loss", 1291], ["of", 1296], ["cross", 1299], ["-", 1304], ["species", 1305], ["complementation", 1313], ["among", 1329], ["SAK", 1335], ["/", 1338], ["PLK4", 1339], ["family", 1344], ["members", 1351], [",", 1358], ["suggesting", 1360], ["species", 1371], ["-", 1378], ["specific", 1379], ["adaptations", 1388], ["in", 1400], ["CBB", 1403], ["assembly", 1407], [".", 1415], ["We", 1417], ["propose", 1420], ["that", 1428], ["the", 1433], ["UNIMOD", 1437], ["theory", 1444], ["explains", 1451], ["the", 1460], ["conservation", 1464], ["of", 1477], ["CBB", 1480], ["architecture", 1484], ["and", 1497], ["that", 1501], ["taxon-", 1506], ["and", 1513], ["tissue", 1517], ["-", 1523], ["specific", 1524], ["molecular", 1533], ["innovations", 1543], [",", 1554], ["gained", 1556], ["through", 1563], ["emergence", 1571], [",", 1580], ["duplication", 1582], ["and", 1594], ["divergence", 1598], [",", 1608], ["play", 1610], ["important", 1615], ["roles", 1625], ["in", 1631], ["coordinating", 1634], ["CBB", 1647], ["biogenesis", 1651], ["and", 1662], ["function", 1666], ["in", 1675], ["different", 1678], ["cellular", 1688], ["contexts", 1697], [".", 1705]]}
{"context": "To determine whether voxel-based morphometry (VBM) might contribute to the detection of cortical dysplasia within the temporal pole in patients with mesial temporal lobe epilepsy and hippocampal sclerosis (MTLE/HS). Eighteen patients with intractable MTLE/HS and 30 sex- and age-matched healthy controls were included in the study. All of the patients fulfilled the diagnostic criteria for MTLE/HS and underwent anteromedial temporal resection. VBM without a modulation step was applied to the magnetic resonance (MR) images of the brain. Statistical parametric maps were used to compare structural characteristics such as gray matter concentration (GMC) within the temporal pole among patients and controls separately. The acquired data were then statistically analyzed to determine the congruency between visually inspected MR imaging (MRI) scans and VBM results in the detection of morphologic abnormalities in the temporal pole compared to postoperative histopathologic findings of cortical dysplasia. Histopathologic examination revealed cortical dysplasia within the temporal pole in 11 patients. In detail, according to Palmini's classification, mild malformations of cortical development (mMCDs) were disclosed in three patients, focal cortical dysplasia (FCD) type Ia in three patients, and FCD type Ib in five patients. Some type of structural temporal pole abnormality was suggested by VBM in 14 patients and by visually inspected MRI scans in 11 patients. The results of VBM were in agreement with the presence/absence of cortical dysplasia in 13 patients (72.2%); this correspondence was significant (p = 0.047). In one case, VBM was false negative and in four cases it was false positive. There was congruence between the results of visual analysis and histologic proof in 55.6% of examined patients, which was not significant. We found that VBM made a superior contribution to the detection of temporopolar structural malformations (cortical dysplasia) compared to visual inspection. The agreement with postoperative histopathologic proof was clearly significant for VBM results and nonsignificant for visual inspection.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "83d14fe95f5740f0a8febe5c79a52938", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[202, 204]], "char_spans": [[1238, 1261]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["whether", 13], ["voxel", 21], ["-", 26], ["based", 27], ["morphometry", 33], ["(", 45], ["VBM", 46], [")", 49], ["might", 51], ["contribute", 57], ["to", 68], ["the", 71], ["detection", 75], ["of", 85], ["cortical", 88], ["dysplasia", 97], ["within", 107], ["the", 114], ["temporal", 118], ["pole", 127], ["in", 132], ["patients", 135], ["with", 144], ["mesial", 149], ["temporal", 156], ["lobe", 165], ["epilepsy", 170], ["and", 179], ["hippocampal", 183], ["sclerosis", 195], ["(", 205], ["MTLE", 206], ["/", 210], ["HS", 211], [")", 213], [".", 214], ["Eighteen", 216], ["patients", 225], ["with", 234], ["intractable", 239], ["MTLE", 251], ["/", 255], ["HS", 256], ["and", 259], ["30", 263], ["sex-", 266], ["and", 271], ["age", 275], ["-", 278], ["matched", 279], ["healthy", 287], ["controls", 295], ["were", 304], ["included", 309], ["in", 318], ["the", 321], ["study", 325], [".", 330], ["All", 332], ["of", 336], ["the", 339], ["patients", 343], ["fulfilled", 352], ["the", 362], ["diagnostic", 366], ["criteria", 377], ["for", 386], ["MTLE", 390], ["/", 394], ["HS", 395], ["and", 398], ["underwent", 402], ["anteromedial", 412], ["temporal", 425], ["resection", 434], [".", 443], ["VBM", 445], ["without", 449], ["a", 457], ["modulation", 459], ["step", 470], ["was", 475], ["applied", 479], ["to", 487], ["the", 490], ["magnetic", 494], ["resonance", 503], ["(", 513], ["MR", 514], [")", 516], ["images", 518], ["of", 525], ["the", 528], ["brain", 532], [".", 537], ["Statistical", 539], ["parametric", 551], ["maps", 562], ["were", 567], ["used", 572], ["to", 577], ["compare", 580], ["structural", 588], ["characteristics", 599], ["such", 615], ["as", 620], ["gray", 623], ["matter", 628], ["concentration", 635], ["(", 649], ["GMC", 650], [")", 653], ["within", 655], ["the", 662], ["temporal", 666], ["pole", 675], ["among", 680], ["patients", 686], ["and", 695], ["controls", 699], ["separately", 708], [".", 718], ["The", 720], ["acquired", 724], ["data", 733], ["were", 738], ["then", 743], ["statistically", 748], ["analyzed", 762], ["to", 771], ["determine", 774], ["the", 784], ["congruency", 788], ["between", 799], ["visually", 807], ["inspected", 816], ["MR", 826], ["imaging", 829], ["(", 837], ["MRI", 838], [")", 841], ["scans", 843], ["and", 849], ["VBM", 853], ["results", 857], ["in", 865], ["the", 868], ["detection", 872], ["of", 882], ["morphologic", 885], ["abnormalities", 897], ["in", 911], ["the", 914], ["temporal", 918], ["pole", 927], ["compared", 932], ["to", 941], ["postoperative", 944], ["histopathologic", 958], ["findings", 974], ["of", 983], ["cortical", 986], ["dysplasia", 995], [".", 1004], ["Histopathologic", 1006], ["examination", 1022], ["revealed", 1034], ["cortical", 1043], ["dysplasia", 1052], ["within", 1062], ["the", 1069], ["temporal", 1073], ["pole", 1082], ["in", 1087], ["11", 1090], ["patients", 1093], [".", 1101], ["In", 1103], ["detail", 1106], [",", 1112], ["according", 1114], ["to", 1124], ["Palmini", 1127], ["'s", 1134], ["classification", 1137], [",", 1151], ["mild", 1153], ["malformations", 1158], ["of", 1172], ["cortical", 1175], ["development", 1184], ["(", 1196], ["mMCDs", 1197], [")", 1202], ["were", 1204], ["disclosed", 1209], ["in", 1219], ["three", 1222], ["patients", 1228], [",", 1236], ["focal", 1238], ["cortical", 1244], ["dysplasia", 1253], ["(", 1263], ["FCD", 1264], [")", 1267], ["type", 1269], ["Ia", 1274], ["in", 1277], ["three", 1280], ["patients", 1286], [",", 1294], ["and", 1296], ["FCD", 1300], ["type", 1304], ["Ib", 1309], ["in", 1312], ["five", 1315], ["patients", 1320], [".", 1328], ["Some", 1330], ["type", 1335], ["of", 1340], ["structural", 1343], ["temporal", 1354], ["pole", 1363], ["abnormality", 1368], ["was", 1380], ["suggested", 1384], ["by", 1394], ["VBM", 1397], ["in", 1401], ["14", 1404], ["patients", 1407], ["and", 1416], ["by", 1420], ["visually", 1423], ["inspected", 1432], ["MRI", 1442], ["scans", 1446], ["in", 1452], ["11", 1455], ["patients", 1458], [".", 1466], ["The", 1468], ["results", 1472], ["of", 1480], ["VBM", 1483], ["were", 1487], ["in", 1492], ["agreement", 1495], ["with", 1505], ["the", 1510], ["presence", 1514], ["/", 1522], ["absence", 1523], ["of", 1531], ["cortical", 1534], ["dysplasia", 1543], ["in", 1553], ["13", 1556], ["patients", 1559], ["(", 1568], ["72.2", 1569], ["%", 1573], [")", 1574], [";", 1575], ["this", 1577], ["correspondence", 1582], ["was", 1597], ["significant", 1601], ["(", 1613], ["p", 1614], ["=", 1616], ["0.047", 1618], [")", 1623], [".", 1624], ["In", 1626], ["one", 1629], ["case", 1633], [",", 1637], ["VBM", 1639], ["was", 1643], ["false", 1647], ["negative", 1653], ["and", 1662], ["in", 1666], ["four", 1669], ["cases", 1674], ["it", 1680], ["was", 1683], ["false", 1687], ["positive", 1693], [".", 1701], ["There", 1703], ["was", 1709], ["congruence", 1713], ["between", 1724], ["the", 1732], ["results", 1736], ["of", 1744], ["visual", 1747], ["analysis", 1754], ["and", 1763], ["histologic", 1767], ["proof", 1778], ["in", 1784], ["55.6", 1787], ["%", 1791], ["of", 1793], ["examined", 1796], ["patients", 1805], [",", 1813], ["which", 1815], ["was", 1821], ["not", 1825], ["significant", 1829], [".", 1840], ["We", 1842], ["found", 1845], ["that", 1851], ["VBM", 1856], ["made", 1860], ["a", 1865], ["superior", 1867], ["contribution", 1876], ["to", 1889], ["the", 1892], ["detection", 1896], ["of", 1906], ["temporopolar", 1909], ["structural", 1922], ["malformations", 1933], ["(", 1947], ["cortical", 1948], ["dysplasia", 1957], [")", 1966], ["compared", 1968], ["to", 1977], ["visual", 1980], ["inspection", 1987], [".", 1997], ["The", 1999], ["agreement", 2003], ["with", 2013], ["postoperative", 2018], ["histopathologic", 2032], ["proof", 2048], ["was", 2054], ["clearly", 2058], ["significant", 2066], ["for", 2078], ["VBM", 2082], ["results", 2086], ["and", 2094], ["nonsignificant", 2098], ["for", 2113], ["visual", 2117], ["inspection", 2124], [".", 2134]]}
{"context": "Parkinson's disease (PD) is characterized by the progressive loss of substantia nigra dopaminergic neurons and the presence of cytoplasmic inclusions named Lewy bodies. Two missense mutations of the alpha-synuclein (alpha-syn; A30P and A53T) have been described in several families with an autosomal dominant form of PD. alpha-Syn also constitutes one of the main components of Lewy bodies in sporadic cases of PD. To develop an animal model of PD, lentiviral vectors expressing different human or rat forms of alpha-syn were injected into the substantia nigra of rats. In contrast to transgenic mice models, a selective loss of nigral dopaminergic neurons associated with a dopaminergic denervation of the striatum was observed in animals expressing either wild-type or mutant forms of human alpha-syn. This neuronal degeneration correlates with the appearance of abundant alpha-syn-positive inclusions and extensive neuritic pathology detected with both alpha-syn and silver staining. Lentiviral-mediated expression of wild-type or mutated forms of human alpha-syn recapitulates the essential neuropathological features of PD. Rat alpha-syn similarly leads to protein aggregation but without cell loss, suggesting that inclusions are not the primary cause of cell degeneration in PD. Viral-mediated genetic models may contribute to elucidate the mechanism of alpha-syn-induced cell death and allow the screening of candidate therapeutic molecules.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "d8e3b9a07469427db951cf2a0ae90c0f", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[32, 34]], "char_spans": [[199, 213]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["characterized", 28], ["by", 42], ["the", 45], ["progressive", 49], ["loss", 61], ["of", 66], ["substantia", 69], ["nigra", 80], ["dopaminergic", 86], ["neurons", 99], ["and", 107], ["the", 111], ["presence", 115], ["of", 124], ["cytoplasmic", 127], ["inclusions", 139], ["named", 150], ["Lewy", 156], ["bodies", 161], [".", 167], ["Two", 169], ["missense", 173], ["mutations", 182], ["of", 192], ["the", 195], ["alpha", 199], ["-", 204], ["synuclein", 205], ["(", 215], ["alpha", 216], ["-", 221], ["syn", 222], [";", 225], ["A30P", 227], ["and", 232], ["A53", 236], ["T", 239], [")", 240], ["have", 242], ["been", 247], ["described", 252], ["in", 262], ["several", 265], ["families", 273], ["with", 282], ["an", 287], ["autosomal", 290], ["dominant", 300], ["form", 309], ["of", 314], ["PD", 317], [".", 319], ["alpha", 321], ["-", 326], ["Syn", 327], ["also", 331], ["constitutes", 336], ["one", 348], ["of", 352], ["the", 355], ["main", 359], ["components", 364], ["of", 375], ["Lewy", 378], ["bodies", 383], ["in", 390], ["sporadic", 393], ["cases", 402], ["of", 408], ["PD", 411], [".", 413], ["To", 415], ["develop", 418], ["an", 426], ["animal", 429], ["model", 436], ["of", 442], ["PD", 445], [",", 447], ["lentiviral", 449], ["vectors", 460], ["expressing", 468], ["different", 479], ["human", 489], ["or", 495], ["rat", 498], ["forms", 502], ["of", 508], ["alpha", 511], ["-", 516], ["syn", 517], ["were", 521], ["injected", 526], ["into", 535], ["the", 540], ["substantia", 544], ["nigra", 555], ["of", 561], ["rats", 564], [".", 568], ["In", 570], ["contrast", 573], ["to", 582], ["transgenic", 585], ["mice", 596], ["models", 601], [",", 607], ["a", 609], ["selective", 611], ["loss", 621], ["of", 626], ["nigral", 629], ["dopaminergic", 636], ["neurons", 649], ["associated", 657], ["with", 668], ["a", 673], ["dopaminergic", 675], ["denervation", 688], ["of", 700], ["the", 703], ["striatum", 707], ["was", 716], ["observed", 720], ["in", 729], ["animals", 732], ["expressing", 740], ["either", 751], ["wild", 758], ["-", 762], ["type", 763], ["or", 768], ["mutant", 771], ["forms", 778], ["of", 784], ["human", 787], ["alpha", 793], ["-", 798], ["syn", 799], [".", 802], ["This", 804], ["neuronal", 809], ["degeneration", 818], ["correlates", 831], ["with", 842], ["the", 847], ["appearance", 851], ["of", 862], ["abundant", 865], ["alpha", 874], ["-", 879], ["syn", 880], ["-", 883], ["positive", 884], ["inclusions", 893], ["and", 904], ["extensive", 908], ["neuritic", 918], ["pathology", 927], ["detected", 937], ["with", 946], ["both", 951], ["alpha", 956], ["-", 961], ["syn", 962], ["and", 966], ["silver", 970], ["staining", 977], [".", 985], ["Lentiviral", 987], ["-", 997], ["mediated", 998], ["expression", 1007], ["of", 1018], ["wild", 1021], ["-", 1025], ["type", 1026], ["or", 1031], ["mutated", 1034], ["forms", 1042], ["of", 1048], ["human", 1051], ["alpha", 1057], ["-", 1062], ["syn", 1063], ["recapitulates", 1067], ["the", 1081], ["essential", 1085], ["neuropathological", 1095], ["features", 1113], ["of", 1122], ["PD", 1125], [".", 1127], ["Rat", 1129], ["alpha", 1133], ["-", 1138], ["syn", 1139], ["similarly", 1143], ["leads", 1153], ["to", 1159], ["protein", 1162], ["aggregation", 1170], ["but", 1182], ["without", 1186], ["cell", 1194], ["loss", 1199], [",", 1203], ["suggesting", 1205], ["that", 1216], ["inclusions", 1221], ["are", 1232], ["not", 1236], ["the", 1240], ["primary", 1244], ["cause", 1252], ["of", 1258], ["cell", 1261], ["degeneration", 1266], ["in", 1279], ["PD", 1282], [".", 1284], ["Viral", 1286], ["-", 1291], ["mediated", 1292], ["genetic", 1301], ["models", 1309], ["may", 1316], ["contribute", 1320], ["to", 1331], ["elucidate", 1334], ["the", 1344], ["mechanism", 1348], ["of", 1358], ["alpha", 1361], ["-", 1366], ["syn", 1367], ["-", 1370], ["induced", 1371], ["cell", 1379], ["death", 1384], ["and", 1390], ["allow", 1394], ["the", 1400], ["screening", 1404], ["of", 1414], ["candidate", 1417], ["therapeutic", 1427], ["molecules", 1439], [".", 1448]]}
{"context": "Mutations in the K-ras oncogene and in the p53 tumor suppressor gene are commonly identified in sporadic cases of pancreatic adenocarcinoma. Although these genes might serve as useful markers for early diagnosis of pancreatic carcinoma in patients at risk for the development of this disease, familial pancreatic carcinomas have not been studied for these mutations. We recently had the opportunity to examine a pancreas prophylactically removed from a patient with a strong family history of pancreatic carcinoma. This gave us the unique opportunity to study the early events in the development of familial adenocarcinoma of the pancreas. Histopathological examination of the pancreas revealed multifocal papillary and nonpapillary mucinous duct hyperplasia. Seven of these foci were microdissected and analyzed for K-ras and p53 mutations. The K-ras mutations were detected by combined mutant-enriched polymerase chain reaction-restriction fragment length polymorphism analysis and characterized further by allele-specific oligonucleotide hybridization. Five of the seven duct lesions harbored activating point mutations in codon 12 of K-ras; a G to A transition was found in four and a G to C transversion in one. In contrast, these lesions did not harbor detectable p53 mutations as determined by denaturing gradient gel electrophoresis of exons 5 to 8, nor was there overexpression of the p53 protein as determined by immunohistochemistry. These findings suggest that mutations in K-ras represent an early event in the pathogenesis of pancreatic carcinoma. In addition, monitoring of patients with a strong family history of pancreatic carcinoma for K-ras mutations may identify patients at risk for the development of invasive carcinoma.", "qas": [{"question": "Which is the molecular mechanism underlying K-ras alterations in carcinomas?", "answers": ["Point mutations"], "qid": "1a7c755b01c04164ba29934405c67228", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["molecular", 13], ["mechanism", 23], ["underlying", 33], ["K", 44], ["-", 45], ["ras", 46], ["alterations", 50], ["in", 62], ["carcinomas", 65], ["?", 75]], "detected_answers": [{"text": "Point mutations", "token_spans": [[173, 174]], "char_spans": [[1107, 1121]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["K", 17], ["-", 18], ["ras", 19], ["oncogene", 23], ["and", 32], ["in", 36], ["the", 39], ["p53", 43], ["tumor", 47], ["suppressor", 53], ["gene", 64], ["are", 69], ["commonly", 73], ["identified", 82], ["in", 93], ["sporadic", 96], ["cases", 105], ["of", 111], ["pancreatic", 114], ["adenocarcinoma", 125], [".", 139], ["Although", 141], ["these", 150], ["genes", 156], ["might", 162], ["serve", 168], ["as", 174], ["useful", 177], ["markers", 184], ["for", 192], ["early", 196], ["diagnosis", 202], ["of", 212], ["pancreatic", 215], ["carcinoma", 226], ["in", 236], ["patients", 239], ["at", 248], ["risk", 251], ["for", 256], ["the", 260], ["development", 264], ["of", 276], ["this", 279], ["disease", 284], [",", 291], ["familial", 293], ["pancreatic", 302], ["carcinomas", 313], ["have", 324], ["not", 329], ["been", 333], ["studied", 338], ["for", 346], ["these", 350], ["mutations", 356], [".", 365], ["We", 367], ["recently", 370], ["had", 379], ["the", 383], ["opportunity", 387], ["to", 399], ["examine", 402], ["a", 410], ["pancreas", 412], ["prophylactically", 421], ["removed", 438], ["from", 446], ["a", 451], ["patient", 453], ["with", 461], ["a", 466], ["strong", 468], ["family", 475], ["history", 482], ["of", 490], ["pancreatic", 493], ["carcinoma", 504], [".", 513], ["This", 515], ["gave", 520], ["us", 525], ["the", 528], ["unique", 532], ["opportunity", 539], ["to", 551], ["study", 554], ["the", 560], ["early", 564], ["events", 570], ["in", 577], ["the", 580], ["development", 584], ["of", 596], ["familial", 599], ["adenocarcinoma", 608], ["of", 623], ["the", 626], ["pancreas", 630], [".", 638], ["Histopathological", 640], ["examination", 658], ["of", 670], ["the", 673], ["pancreas", 677], ["revealed", 686], ["multifocal", 695], ["papillary", 706], ["and", 716], ["nonpapillary", 720], ["mucinous", 733], ["duct", 742], ["hyperplasia", 747], [".", 758], ["Seven", 760], ["of", 766], ["these", 769], ["foci", 775], ["were", 780], ["microdissected", 785], ["and", 800], ["analyzed", 804], ["for", 813], ["K", 817], ["-", 818], ["ras", 819], ["and", 823], ["p53", 827], ["mutations", 831], [".", 840], ["The", 842], ["K", 846], ["-", 847], ["ras", 848], ["mutations", 852], ["were", 862], ["detected", 867], ["by", 876], ["combined", 879], ["mutant", 888], ["-", 894], ["enriched", 895], ["polymerase", 904], ["chain", 915], ["reaction", 921], ["-", 929], ["restriction", 930], ["fragment", 942], ["length", 951], ["polymorphism", 958], ["analysis", 971], ["and", 980], ["characterized", 984], ["further", 998], ["by", 1006], ["allele", 1009], ["-", 1015], ["specific", 1016], ["oligonucleotide", 1025], ["hybridization", 1041], [".", 1054], ["Five", 1056], ["of", 1061], ["the", 1064], ["seven", 1068], ["duct", 1074], ["lesions", 1079], ["harbored", 1087], ["activating", 1096], ["point", 1107], ["mutations", 1113], ["in", 1123], ["codon", 1126], ["12", 1132], ["of", 1135], ["K", 1138], ["-", 1139], ["ras", 1140], [";", 1143], ["a", 1145], ["G", 1147], ["to", 1149], ["A", 1152], ["transition", 1154], ["was", 1165], ["found", 1169], ["in", 1175], ["four", 1178], ["and", 1183], ["a", 1187], ["G", 1189], ["to", 1191], ["C", 1194], ["transversion", 1196], ["in", 1209], ["one", 1212], [".", 1215], ["In", 1217], ["contrast", 1220], [",", 1228], ["these", 1230], ["lesions", 1236], ["did", 1244], ["not", 1248], ["harbor", 1252], ["detectable", 1259], ["p53", 1270], ["mutations", 1274], ["as", 1284], ["determined", 1287], ["by", 1298], ["denaturing", 1301], ["gradient", 1312], ["gel", 1321], ["electrophoresis", 1325], ["of", 1341], ["exons", 1344], ["5", 1350], ["to", 1352], ["8", 1355], [",", 1356], ["nor", 1358], ["was", 1362], ["there", 1366], ["overexpression", 1372], ["of", 1387], ["the", 1390], ["p53", 1394], ["protein", 1398], ["as", 1406], ["determined", 1409], ["by", 1420], ["immunohistochemistry", 1423], [".", 1443], ["These", 1445], ["findings", 1451], ["suggest", 1460], ["that", 1468], ["mutations", 1473], ["in", 1483], ["K", 1486], ["-", 1487], ["ras", 1488], ["represent", 1492], ["an", 1502], ["early", 1505], ["event", 1511], ["in", 1517], ["the", 1520], ["pathogenesis", 1524], ["of", 1537], ["pancreatic", 1540], ["carcinoma", 1551], [".", 1560], ["In", 1562], ["addition", 1565], [",", 1573], ["monitoring", 1575], ["of", 1586], ["patients", 1589], ["with", 1598], ["a", 1603], ["strong", 1605], ["family", 1612], ["history", 1619], ["of", 1627], ["pancreatic", 1630], ["carcinoma", 1641], ["for", 1651], ["K", 1655], ["-", 1656], ["ras", 1657], ["mutations", 1661], ["may", 1671], ["identify", 1675], ["patients", 1684], ["at", 1693], ["risk", 1696], ["for", 1701], ["the", 1705], ["development", 1709], ["of", 1721], ["invasive", 1724], ["carcinoma", 1733], [".", 1742]]}
{"context": "Neural stem/progenitor cells (NSCs) reside in the subventricular zone (SVZ) and subgranular zone of the hippocampal dentate gyrus in adult mammals. The ubiquitin ligase HRD1 is associated with degradation of amyloid precursor protein and believed to be specifically expressed in neurons and not in astrocytes. We investigated expression of HRD1 using immunohistochemistry and found colocalization of HRD1 with the NSC marker protein nestin and glial fibrillary acidic protein in the NSCs of the SVZ (the SVZ astrocytes) but not in the hippocampus. In the hippocampal dentate gyrus, HRD1 is localized in the nucleus of nestin-positive cells.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "2955684affa14660b9c3b54689b9b2d2", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[106, 106], [70, 70]], "char_spans": [[618, 623], [433, 438]]}]}], "context_tokens": [["Neural", 0], ["stem", 7], ["/", 11], ["progenitor", 12], ["cells", 23], ["(", 29], ["NSCs", 30], [")", 34], ["reside", 36], ["in", 43], ["the", 46], ["subventricular", 50], ["zone", 65], ["(", 70], ["SVZ", 71], [")", 74], ["and", 76], ["subgranular", 80], ["zone", 92], ["of", 97], ["the", 100], ["hippocampal", 104], ["dentate", 116], ["gyrus", 124], ["in", 130], ["adult", 133], ["mammals", 139], [".", 146], ["The", 148], ["ubiquitin", 152], ["ligase", 162], ["HRD1", 169], ["is", 174], ["associated", 177], ["with", 188], ["degradation", 193], ["of", 205], ["amyloid", 208], ["precursor", 216], ["protein", 226], ["and", 234], ["believed", 238], ["to", 247], ["be", 250], ["specifically", 253], ["expressed", 266], ["in", 276], ["neurons", 279], ["and", 287], ["not", 291], ["in", 295], ["astrocytes", 298], [".", 308], ["We", 310], ["investigated", 313], ["expression", 326], ["of", 337], ["HRD1", 340], ["using", 345], ["immunohistochemistry", 351], ["and", 372], ["found", 376], ["colocalization", 382], ["of", 397], ["HRD1", 400], ["with", 405], ["the", 410], ["NSC", 414], ["marker", 418], ["protein", 425], ["nestin", 433], ["and", 440], ["glial", 444], ["fibrillary", 450], ["acidic", 461], ["protein", 468], ["in", 476], ["the", 479], ["NSCs", 483], ["of", 488], ["the", 491], ["SVZ", 495], ["(", 499], ["the", 500], ["SVZ", 504], ["astrocytes", 508], [")", 518], ["but", 520], ["not", 524], ["in", 528], ["the", 531], ["hippocampus", 535], [".", 546], ["In", 548], ["the", 551], ["hippocampal", 555], ["dentate", 567], ["gyrus", 575], [",", 580], ["HRD1", 582], ["is", 587], ["localized", 590], ["in", 600], ["the", 603], ["nucleus", 607], ["of", 615], ["nestin", 618], ["-", 624], ["positive", 625], ["cells", 634], [".", 639]]}
{"context": "Opioid overdose is rarely the primary cause of altered mental status in cancer patients receiving opioid therapy. The inappropriate administration of naloxone to reverse an abnormal mental status can cause severe withdrawal symptoms and pain. To illustrate this problem, we report the case of a patient inappropriately treated with naloxone and the results of a retrospective review of the medical records of 15 consecutive patients with cancer treated with naloxone in the emergency department over a 5-month period. We offer guidelines for a more thoughtful approach to the management of patients with cancer who present with encephalopathy.", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "bbac40c6eb3c41cd806dbc42ad8f54dc", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[52, 52], [72, 72], [22, 22]], "char_spans": [[332, 339], [458, 465], [150, 157]]}]}], "context_tokens": [["Opioid", 0], ["overdose", 7], ["is", 16], ["rarely", 19], ["the", 26], ["primary", 30], ["cause", 38], ["of", 44], ["altered", 47], ["mental", 55], ["status", 62], ["in", 69], ["cancer", 72], ["patients", 79], ["receiving", 88], ["opioid", 98], ["therapy", 105], [".", 112], ["The", 114], ["inappropriate", 118], ["administration", 132], ["of", 147], ["naloxone", 150], ["to", 159], ["reverse", 162], ["an", 170], ["abnormal", 173], ["mental", 182], ["status", 189], ["can", 196], ["cause", 200], ["severe", 206], ["withdrawal", 213], ["symptoms", 224], ["and", 233], ["pain", 237], [".", 241], ["To", 243], ["illustrate", 246], ["this", 257], ["problem", 262], [",", 269], ["we", 271], ["report", 274], ["the", 281], ["case", 285], ["of", 290], ["a", 293], ["patient", 295], ["inappropriately", 303], ["treated", 319], ["with", 327], ["naloxone", 332], ["and", 341], ["the", 345], ["results", 349], ["of", 357], ["a", 360], ["retrospective", 362], ["review", 376], ["of", 383], ["the", 386], ["medical", 390], ["records", 398], ["of", 406], ["15", 409], ["consecutive", 412], ["patients", 424], ["with", 433], ["cancer", 438], ["treated", 445], ["with", 453], ["naloxone", 458], ["in", 467], ["the", 470], ["emergency", 474], ["department", 484], ["over", 495], ["a", 500], ["5-month", 502], ["period", 510], [".", 516], ["We", 518], ["offer", 521], ["guidelines", 527], ["for", 538], ["a", 542], ["more", 544], ["thoughtful", 549], ["approach", 560], ["to", 569], ["the", 572], ["management", 576], ["of", 587], ["patients", 590], ["with", 599], ["cancer", 604], ["who", 611], ["present", 615], ["with", 623], ["encephalopathy", 628], [".", 642]]}
{"context": "The article briefly summarizes the milestones leading to current knowledge and the possibility of treating one of the most widespread and perhaps least known diseases, restless legs syndrome (RLS). Until the mid-twentieth century, the syndrome first described by Willis (1685), was sporadically reported in medical literature and in most cases deemed a bizzare condition. It was only with Ekbom's detailed clinical description of the syndrome (1944) and the polygraphic recordings of Coccagna et al. (1962) that RLS became well-recognised clinical entity. Since then, almost all sleep laboratories have devoted much of their research to discovering the pathogenetic mechanisms underlying the disease and devise increasingly specific treatment. Major advances have been made in recent years, but a full understanding of RLS is still a long way off.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "4f93de9591b34369ba45f43f3f6efb52", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[26, 28]], "char_spans": [[168, 189]]}]}], "context_tokens": [["The", 0], ["article", 4], ["briefly", 12], ["summarizes", 20], ["the", 31], ["milestones", 35], ["leading", 46], ["to", 54], ["current", 57], ["knowledge", 65], ["and", 75], ["the", 79], ["possibility", 83], ["of", 95], ["treating", 98], ["one", 107], ["of", 111], ["the", 114], ["most", 118], ["widespread", 123], ["and", 134], ["perhaps", 138], ["least", 146], ["known", 152], ["diseases", 158], [",", 166], ["restless", 168], ["legs", 177], ["syndrome", 182], ["(", 191], ["RLS", 192], [")", 195], [".", 196], ["Until", 198], ["the", 204], ["mid", 208], ["-", 211], ["twentieth", 212], ["century", 222], [",", 229], ["the", 231], ["syndrome", 235], ["first", 244], ["described", 250], ["by", 260], ["Willis", 263], ["(", 270], ["1685", 271], [")", 275], [",", 276], ["was", 278], ["sporadically", 282], ["reported", 295], ["in", 304], ["medical", 307], ["literature", 315], ["and", 326], ["in", 330], ["most", 333], ["cases", 338], ["deemed", 344], ["a", 351], ["bizzare", 353], ["condition", 361], [".", 370], ["It", 372], ["was", 375], ["only", 379], ["with", 384], ["Ekbom", 389], ["'s", 394], ["detailed", 397], ["clinical", 406], ["description", 415], ["of", 427], ["the", 430], ["syndrome", 434], ["(", 443], ["1944", 444], [")", 448], ["and", 450], ["the", 454], ["polygraphic", 458], ["recordings", 470], ["of", 481], ["Coccagna", 484], ["et", 493], ["al", 496], [".", 498], ["(", 500], ["1962", 501], [")", 505], ["that", 507], ["RLS", 512], ["became", 516], ["well", 523], ["-", 527], ["recognised", 528], ["clinical", 539], ["entity", 548], [".", 554], ["Since", 556], ["then", 562], [",", 566], ["almost", 568], ["all", 575], ["sleep", 579], ["laboratories", 585], ["have", 598], ["devoted", 603], ["much", 611], ["of", 616], ["their", 619], ["research", 625], ["to", 634], ["discovering", 637], ["the", 649], ["pathogenetic", 653], ["mechanisms", 666], ["underlying", 677], ["the", 688], ["disease", 692], ["and", 700], ["devise", 704], ["increasingly", 711], ["specific", 724], ["treatment", 733], [".", 742], ["Major", 744], ["advances", 750], ["have", 759], ["been", 764], ["made", 769], ["in", 774], ["recent", 777], ["years", 784], [",", 789], ["but", 791], ["a", 795], ["full", 797], ["understanding", 802], ["of", 816], ["RLS", 819], ["is", 823], ["still", 826], ["a", 832], ["long", 834], ["way", 839], ["off", 843], [".", 846]]}
{"context": "Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran. We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of dabigatran in patients who had serious bleeding (group A) or required an urgent procedure (group B). The primary end point was the maximum percentage reversal of the anticoagulant effect of dabigatran within 4 hours after the administration of idarucizumab, on the basis of the determination at a central laboratory of the dilute thrombin time or ecarin clotting time. A key secondary end point was the restoration of hemostasis. This interim analysis included 90 patients who received idarucizumab (51 patients in group A and 39 in group B). Among 68 patients with an elevated dilute thrombin time and 81 with an elevated ecarin clotting time at baseline, the median maximum percentage reversal was 100% (95% confidence interval, 100 to 100). Idarucizumab normalized the test results in 88 to 98% of the patients, an effect that was evident within minutes. Concentrations of unbound dabigatran remained below 20 ng per milliliter at 24 hours in 79% of the patients. Among 35 patients in group A who could be assessed, hemostasis, as determined by local investigators, was restored at a median of 11.4 hours. Among 36 patients in group B who underwent a procedure, normal intraoperative hemostasis was reported in 33, and mildly or moderately abnormal hemostasis was reported in 2 patients and 1 patient, respectively. One thrombotic event occurred within 72 hours after idarucizumab administration in a patient in whom anticoagulants had not been reinitiated. Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes. (Funded by Boehringer Ingelheim; RE-VERSE AD ClinicalTrials.gov number, NCT02104947.).", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "ed0c4a0629ff46d1b8993188f8a0e5c4", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[326, 326], [90, 90], [28, 28], [217, 217], [55, 55]], "char_spans": [[1870, 1879], [538, 547], [177, 186], [1232, 1241], [348, 357]]}]}], "context_tokens": [["Specific", 0], ["reversal", 9], ["agents", 18], ["for", 25], ["non", 29], ["-", 32], ["vitamin", 33], ["K", 41], ["antagonist", 43], ["oral", 54], ["anticoagulants", 59], ["are", 74], ["lacking", 78], [".", 85], ["Idarucizumab", 87], [",", 99], ["an", 101], ["antibody", 104], ["fragment", 113], [",", 121], ["was", 123], ["developed", 127], ["to", 137], ["reverse", 140], ["the", 148], ["anticoagulant", 152], ["effects", 166], ["of", 174], ["dabigatran", 177], [".", 187], ["We", 189], ["undertook", 192], ["this", 202], ["prospective", 207], ["cohort", 219], ["study", 226], ["to", 232], ["determine", 235], ["the", 245], ["safety", 249], ["of", 256], ["5", 259], ["g", 261], ["of", 263], ["intravenous", 266], ["idarucizumab", 278], ["and", 291], ["its", 295], ["capacity", 299], ["to", 308], ["reverse", 311], ["the", 319], ["anticoagulant", 323], ["effects", 337], ["of", 345], ["dabigatran", 348], ["in", 359], ["patients", 362], ["who", 371], ["had", 375], ["serious", 379], ["bleeding", 387], ["(", 396], ["group", 397], ["A", 403], [")", 404], ["or", 406], ["required", 409], ["an", 418], ["urgent", 421], ["procedure", 428], ["(", 438], ["group", 439], ["B", 445], [")", 446], [".", 447], ["The", 449], ["primary", 453], ["end", 461], ["point", 465], ["was", 471], ["the", 475], ["maximum", 479], ["percentage", 487], ["reversal", 498], ["of", 507], ["the", 510], ["anticoagulant", 514], ["effect", 528], ["of", 535], ["dabigatran", 538], ["within", 549], ["4", 556], ["hours", 558], ["after", 564], ["the", 570], ["administration", 574], ["of", 589], ["idarucizumab", 592], [",", 604], ["on", 606], ["the", 609], ["basis", 613], ["of", 619], ["the", 622], ["determination", 626], ["at", 640], ["a", 643], ["central", 645], ["laboratory", 653], ["of", 664], ["the", 667], ["dilute", 671], ["thrombin", 678], ["time", 687], ["or", 692], ["ecarin", 695], ["clotting", 702], ["time", 711], [".", 715], ["A", 717], ["key", 719], ["secondary", 723], ["end", 733], ["point", 737], ["was", 743], ["the", 747], ["restoration", 751], ["of", 763], ["hemostasis", 766], [".", 776], ["This", 778], ["interim", 783], ["analysis", 791], ["included", 800], ["90", 809], ["patients", 812], ["who", 821], ["received", 825], ["idarucizumab", 834], ["(", 847], ["51", 848], ["patients", 851], ["in", 860], ["group", 863], ["A", 869], ["and", 871], ["39", 875], ["in", 878], ["group", 881], ["B", 887], [")", 888], [".", 889], ["Among", 891], ["68", 897], ["patients", 900], ["with", 909], ["an", 914], ["elevated", 917], ["dilute", 926], ["thrombin", 933], ["time", 942], ["and", 947], ["81", 951], ["with", 954], ["an", 959], ["elevated", 962], ["ecarin", 971], ["clotting", 978], ["time", 987], ["at", 992], ["baseline", 995], [",", 1003], ["the", 1005], ["median", 1009], ["maximum", 1016], ["percentage", 1024], ["reversal", 1035], ["was", 1044], ["100", 1048], ["%", 1051], ["(", 1053], ["95", 1054], ["%", 1056], ["confidence", 1058], ["interval", 1069], [",", 1077], ["100", 1079], ["to", 1083], ["100", 1086], [")", 1089], [".", 1090], ["Idarucizumab", 1092], ["normalized", 1105], ["the", 1116], ["test", 1120], ["results", 1125], ["in", 1133], ["88", 1136], ["to", 1139], ["98", 1142], ["%", 1144], ["of", 1146], ["the", 1149], ["patients", 1153], [",", 1161], ["an", 1163], ["effect", 1166], ["that", 1173], ["was", 1178], ["evident", 1182], ["within", 1190], ["minutes", 1197], [".", 1204], ["Concentrations", 1206], ["of", 1221], ["unbound", 1224], ["dabigatran", 1232], ["remained", 1243], ["below", 1252], ["20", 1258], ["ng", 1261], ["per", 1264], ["milliliter", 1268], ["at", 1279], ["24", 1282], ["hours", 1285], ["in", 1291], ["79", 1294], ["%", 1296], ["of", 1298], ["the", 1301], ["patients", 1305], [".", 1313], ["Among", 1315], ["35", 1321], ["patients", 1324], ["in", 1333], ["group", 1336], ["A", 1342], ["who", 1344], ["could", 1348], ["be", 1354], ["assessed", 1357], [",", 1365], ["hemostasis", 1367], [",", 1377], ["as", 1379], ["determined", 1382], ["by", 1393], ["local", 1396], ["investigators", 1402], [",", 1415], ["was", 1417], ["restored", 1421], ["at", 1430], ["a", 1433], ["median", 1435], ["of", 1442], ["11.4", 1445], ["hours", 1450], [".", 1455], ["Among", 1457], ["36", 1463], ["patients", 1466], ["in", 1475], ["group", 1478], ["B", 1484], ["who", 1486], ["underwent", 1490], ["a", 1500], ["procedure", 1502], [",", 1511], ["normal", 1513], ["intraoperative", 1520], ["hemostasis", 1535], ["was", 1546], ["reported", 1550], ["in", 1559], ["33", 1562], [",", 1564], ["and", 1566], ["mildly", 1570], ["or", 1577], ["moderately", 1580], ["abnormal", 1591], ["hemostasis", 1600], ["was", 1611], ["reported", 1615], ["in", 1624], ["2", 1627], ["patients", 1629], ["and", 1638], ["1", 1642], ["patient", 1644], [",", 1651], ["respectively", 1653], [".", 1665], ["One", 1667], ["thrombotic", 1671], ["event", 1682], ["occurred", 1688], ["within", 1697], ["72", 1704], ["hours", 1707], ["after", 1713], ["idarucizumab", 1719], ["administration", 1732], ["in", 1747], ["a", 1750], ["patient", 1752], ["in", 1760], ["whom", 1763], ["anticoagulants", 1768], ["had", 1783], ["not", 1787], ["been", 1791], ["reinitiated", 1796], [".", 1807], ["Idarucizumab", 1809], ["completely", 1822], ["reversed", 1833], ["the", 1842], ["anticoagulant", 1846], ["effect", 1860], ["of", 1867], ["dabigatran", 1870], ["within", 1881], ["minutes", 1888], [".", 1895], ["(", 1897], ["Funded", 1898], ["by", 1905], ["Boehringer", 1908], ["Ingelheim", 1919], [";", 1928], ["RE", 1930], ["-", 1932], ["VERSE", 1933], ["AD", 1939], ["ClinicalTrials.gov", 1942], ["number", 1961], [",", 1967], ["NCT02104947", 1969], [".", 1980], [")", 1981], [".", 1982]]}
{"context": "Interleukin-1\u03b2 (IL-1\u03b2) is a proinflammatory cytokine that is implicated in many autoinflammatory disorders, but is also important in defense against pathogens. Thus, there is a need to safely and effectively modulate IL-1\u03b2 activity to reduce pathology while maintaining function. Gevokizumab is a potent anti-IL-1\u03b2 antibody being developed as a treatment for diseases in which IL-1\u03b2 has been associated with pathogenesis. Previous data indicated that gevokizumab negatively modulates IL-1\u03b2 signaling through an allosteric mechanism. Because IL-1\u03b2 signaling is a complex, dynamic process involving multiple components, it is important to understand the kinetics of IL-1\u03b2 signaling and the impact of gevokizumab on this process. In the present study, we measured the impact of gevokizumab on the IL-1\u03b2 system using Schild analysis and surface plasmon resonance studies, both of which demonstrated that gevokizumab decreases the binding affinity of IL-1\u03b2 for the IL-1 receptor type I (IL-1RI) signaling receptor, but not the IL-1 counter-regulatory decoy receptor (IL-1 receptor type II). Gevokizumab inhibits both the binding of IL-1\u03b2 to IL-1RI and the subsequent recruitment of IL-1 accessory protein primarily by reducing the association rates of these interactions. Based on this information and recently published structural data, we propose that gevokizumab decreases the association rate for binding of IL-1\u03b2 to its receptor by altering the electrostatic surface potential of IL-1\u03b2, thus reducing the contribution of electrostatic steering to the rapid association rate. These data indicate, therefore, that gevokizumab is a unique inhibitor of IL-1\u03b2 signaling that may offer an alternative to current therapies for IL-1\u03b2-associated autoinflammatory diseases.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "5389373ddbe048119c1dbeb0494dd528", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[128, 128], [51, 51], [227, 227], [150, 150], [266, 266], [2, 2], [277, 277], [36, 36], [76, 76], [84, 84], [185, 185], [238, 238], [104, 104], [62, 62]], "char_spans": [[794, 798], [309, 313], [1407, 1411], [946, 950], [1649, 1653], [16, 20], [1720, 1724], [217, 221], [484, 488], [541, 545], [1127, 1131], [1480, 1484], [664, 668], [377, 381]]}]}], "context_tokens": [["Interleukin-1\u03b2", 0], ["(", 15], ["IL-1\u03b2", 16], [")", 21], ["is", 23], ["a", 26], ["proinflammatory", 28], ["cytokine", 44], ["that", 53], ["is", 58], ["implicated", 61], ["in", 72], ["many", 75], ["autoinflammatory", 80], ["disorders", 97], [",", 106], ["but", 108], ["is", 112], ["also", 115], ["important", 120], ["in", 130], ["defense", 133], ["against", 141], ["pathogens", 149], [".", 158], ["Thus", 160], [",", 164], ["there", 166], ["is", 172], ["a", 175], ["need", 177], ["to", 182], ["safely", 185], ["and", 192], ["effectively", 196], ["modulate", 208], ["IL-1\u03b2", 217], ["activity", 223], ["to", 232], ["reduce", 235], ["pathology", 242], ["while", 252], ["maintaining", 258], ["function", 270], [".", 278], ["Gevokizumab", 280], ["is", 292], ["a", 295], ["potent", 297], ["anti", 304], ["-", 308], ["IL-1\u03b2", 309], ["antibody", 315], ["being", 324], ["developed", 330], ["as", 340], ["a", 343], ["treatment", 345], ["for", 355], ["diseases", 359], ["in", 368], ["which", 371], ["IL-1\u03b2", 377], ["has", 383], ["been", 387], ["associated", 392], ["with", 403], ["pathogenesis", 408], [".", 420], ["Previous", 422], ["data", 431], ["indicated", 436], ["that", 446], ["gevokizumab", 451], ["negatively", 463], ["modulates", 474], ["IL-1\u03b2", 484], ["signaling", 490], ["through", 500], ["an", 508], ["allosteric", 511], ["mechanism", 522], [".", 531], ["Because", 533], ["IL-1\u03b2", 541], ["signaling", 547], ["is", 557], ["a", 560], ["complex", 562], [",", 569], ["dynamic", 571], ["process", 579], ["involving", 587], ["multiple", 597], ["components", 606], [",", 616], ["it", 618], ["is", 621], ["important", 624], ["to", 634], ["understand", 637], ["the", 648], ["kinetics", 652], ["of", 661], ["IL-1\u03b2", 664], ["signaling", 670], ["and", 680], ["the", 684], ["impact", 688], ["of", 695], ["gevokizumab", 698], ["on", 710], ["this", 713], ["process", 718], [".", 725], ["In", 727], ["the", 730], ["present", 734], ["study", 742], [",", 747], ["we", 749], ["measured", 752], ["the", 761], ["impact", 765], ["of", 772], ["gevokizumab", 775], ["on", 787], ["the", 790], ["IL-1\u03b2", 794], ["system", 800], ["using", 807], ["Schild", 813], ["analysis", 820], ["and", 829], ["surface", 833], ["plasmon", 841], ["resonance", 849], ["studies", 859], [",", 866], ["both", 868], ["of", 873], ["which", 876], ["demonstrated", 882], ["that", 895], ["gevokizumab", 900], ["decreases", 912], ["the", 922], ["binding", 926], ["affinity", 934], ["of", 943], ["IL-1\u03b2", 946], ["for", 952], ["the", 956], ["IL-1", 960], ["receptor", 965], ["type", 974], ["I", 979], ["(", 981], ["IL-1RI", 982], [")", 988], ["signaling", 990], ["receptor", 1000], [",", 1008], ["but", 1010], ["not", 1014], ["the", 1018], ["IL-1", 1022], ["counter", 1027], ["-", 1034], ["regulatory", 1035], ["decoy", 1046], ["receptor", 1052], ["(", 1061], ["IL-1", 1062], ["receptor", 1067], ["type", 1076], ["II", 1081], [")", 1083], [".", 1084], ["Gevokizumab", 1086], ["inhibits", 1098], ["both", 1107], ["the", 1112], ["binding", 1116], ["of", 1124], ["IL-1\u03b2", 1127], ["to", 1133], ["IL-1RI", 1136], ["and", 1143], ["the", 1147], ["subsequent", 1151], ["recruitment", 1162], ["of", 1174], ["IL-1", 1177], ["accessory", 1182], ["protein", 1192], ["primarily", 1200], ["by", 1210], ["reducing", 1213], ["the", 1222], ["association", 1226], ["rates", 1238], ["of", 1244], ["these", 1247], ["interactions", 1253], [".", 1265], ["Based", 1267], ["on", 1273], ["this", 1276], ["information", 1281], ["and", 1293], ["recently", 1297], ["published", 1306], ["structural", 1316], ["data", 1327], [",", 1331], ["we", 1333], ["propose", 1336], ["that", 1344], ["gevokizumab", 1349], ["decreases", 1361], ["the", 1371], ["association", 1375], ["rate", 1387], ["for", 1392], ["binding", 1396], ["of", 1404], ["IL-1\u03b2", 1407], ["to", 1413], ["its", 1416], ["receptor", 1420], ["by", 1429], ["altering", 1432], ["the", 1441], ["electrostatic", 1445], ["surface", 1459], ["potential", 1467], ["of", 1477], ["IL-1\u03b2", 1480], [",", 1485], ["thus", 1487], ["reducing", 1492], ["the", 1501], ["contribution", 1505], ["of", 1518], ["electrostatic", 1521], ["steering", 1535], ["to", 1544], ["the", 1547], ["rapid", 1551], ["association", 1557], ["rate", 1569], [".", 1573], ["These", 1575], ["data", 1581], ["indicate", 1586], [",", 1594], ["therefore", 1596], [",", 1605], ["that", 1607], ["gevokizumab", 1612], ["is", 1624], ["a", 1627], ["unique", 1629], ["inhibitor", 1636], ["of", 1646], ["IL-1\u03b2", 1649], ["signaling", 1655], ["that", 1665], ["may", 1670], ["offer", 1674], ["an", 1680], ["alternative", 1683], ["to", 1695], ["current", 1698], ["therapies", 1706], ["for", 1716], ["IL-1\u03b2", 1720], ["-", 1725], ["associated", 1726], ["autoinflammatory", 1737], ["diseases", 1754], [".", 1762]]}
{"context": "Dasatinib is an oral small molecule inhibitor of Abl and Src family tyrosine kinases (SFK), including p56(Lck) (Lck). Given the central importance of Lck in transmitting signals from the T-cell receptor (TCR) signaling complex and the potent ability of dasatinib to inhibit Lck activity, we hypothesized this agent could provide a novel route of immunomodulation via targeted inhibition of antigen-induced signaling. Herein, we show that dasatinib inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-cell responses. However, dasatinib-mediated inhibition does not induce apoptosis because the effect is reversible or may be overcome by signals bypassing the TCR, such as phorbol ester. Signal transduction and proliferative responses via IL-2 remain essentially unperturbed, suggesting that dasatinib displays specificity for TCR signaling. In addition, dasatinib combined with cyclosporine A or rapamycin led to a much more potent inhibition of T-cell activation, suggesting that targeted inhibition of Lck could be a useful adjunct for enhanced immunomodulation. In combination with currently available immunomodulatory agents, SFK inhibition could potentially increase immunomodulatory efficacy while minimizing toxicity of individual agents.", "qas": [{"question": "Does dasatinib promote or inhibit T-cell proliferation?", "answers": ["inhibits"], "qid": "61ec5684d44c4296809c466509051021", "question_tokens": [["Does", 0], ["dasatinib", 5], ["promote", 15], ["or", 23], ["inhibit", 26], ["T", 34], ["-", 35], ["cell", 36], ["proliferation", 41], ["?", 54]], "detected_answers": [{"text": "inhibits", "token_spans": [[82, 82]], "char_spans": [[448, 455]]}]}], "context_tokens": [["Dasatinib", 0], ["is", 10], ["an", 13], ["oral", 16], ["small", 21], ["molecule", 27], ["inhibitor", 36], ["of", 46], ["Abl", 49], ["and", 53], ["Src", 57], ["family", 61], ["tyrosine", 68], ["kinases", 77], ["(", 85], ["SFK", 86], [")", 89], [",", 90], ["including", 92], ["p56(Lck", 102], [")", 109], ["(", 111], ["Lck", 112], [")", 115], [".", 116], ["Given", 118], ["the", 124], ["central", 128], ["importance", 136], ["of", 147], ["Lck", 150], ["in", 154], ["transmitting", 157], ["signals", 170], ["from", 178], ["the", 183], ["T", 187], ["-", 188], ["cell", 189], ["receptor", 194], ["(", 203], ["TCR", 204], [")", 207], ["signaling", 209], ["complex", 219], ["and", 227], ["the", 231], ["potent", 235], ["ability", 242], ["of", 250], ["dasatinib", 253], ["to", 263], ["inhibit", 266], ["Lck", 274], ["activity", 278], [",", 286], ["we", 288], ["hypothesized", 291], ["this", 304], ["agent", 309], ["could", 315], ["provide", 321], ["a", 329], ["novel", 331], ["route", 337], ["of", 343], ["immunomodulation", 346], ["via", 363], ["targeted", 367], ["inhibition", 376], ["of", 387], ["antigen", 390], ["-", 397], ["induced", 398], ["signaling", 406], [".", 415], ["Herein", 417], [",", 423], ["we", 425], ["show", 428], ["that", 433], ["dasatinib", 438], ["inhibits", 448], ["TCR", 457], ["-", 460], ["mediated", 461], ["signal", 470], ["transduction", 477], [",", 489], ["cellular", 491], ["proliferation", 500], [",", 513], ["cytokine", 515], ["production", 524], [",", 534], ["and", 536], ["in", 540], ["vivo", 543], ["T", 548], ["-", 549], ["cell", 550], ["responses", 555], [".", 564], ["However", 566], [",", 573], ["dasatinib", 575], ["-", 584], ["mediated", 585], ["inhibition", 594], ["does", 605], ["not", 610], ["induce", 614], ["apoptosis", 621], ["because", 631], ["the", 639], ["effect", 643], ["is", 650], ["reversible", 653], ["or", 664], ["may", 667], ["be", 671], ["overcome", 674], ["by", 683], ["signals", 686], ["bypassing", 694], ["the", 704], ["TCR", 708], [",", 711], ["such", 713], ["as", 718], ["phorbol", 721], ["ester", 729], [".", 734], ["Signal", 736], ["transduction", 743], ["and", 756], ["proliferative", 760], ["responses", 774], ["via", 784], ["IL-2", 788], ["remain", 793], ["essentially", 800], ["unperturbed", 812], [",", 823], ["suggesting", 825], ["that", 836], ["dasatinib", 841], ["displays", 851], ["specificity", 860], ["for", 872], ["TCR", 876], ["signaling", 880], [".", 889], ["In", 891], ["addition", 894], [",", 902], ["dasatinib", 904], ["combined", 914], ["with", 923], ["cyclosporine", 928], ["A", 941], ["or", 943], ["rapamycin", 946], ["led", 956], ["to", 960], ["a", 963], ["much", 965], ["more", 970], ["potent", 975], ["inhibition", 982], ["of", 993], ["T", 996], ["-", 997], ["cell", 998], ["activation", 1003], [",", 1013], ["suggesting", 1015], ["that", 1026], ["targeted", 1031], ["inhibition", 1040], ["of", 1051], ["Lck", 1054], ["could", 1058], ["be", 1064], ["a", 1067], ["useful", 1069], ["adjunct", 1076], ["for", 1084], ["enhanced", 1088], ["immunomodulation", 1097], [".", 1113], ["In", 1115], ["combination", 1118], ["with", 1130], ["currently", 1135], ["available", 1145], ["immunomodulatory", 1155], ["agents", 1172], [",", 1178], ["SFK", 1180], ["inhibition", 1184], ["could", 1195], ["potentially", 1201], ["increase", 1213], ["immunomodulatory", 1222], ["efficacy", 1239], ["while", 1248], ["minimizing", 1254], ["toxicity", 1265], ["of", 1274], ["individual", 1277], ["agents", 1288], [".", 1294]]}
{"context": "Neurobiology of speech and language has previously been studied in the KE family, in which half of the members have severe impairment in both speech and language. The gene responsible for the phenotype was mapped to chromosome 7q31 and identified as the FOXP2 gene, coding for a transcription factor containing a polyglutamine tract and a forkhead DNA-binding domain. Because of linkage studies implicating 7q31 in autism, where language impairment is a component of the disorder, and in specific language impairment, FOXP2 has also been considered as a potential susceptibility locus for the language deficits in autism and/or specific language impairment. In this study, we characterized mice with a disruption in the murine Foxp2 gene. Disruption of both copies of the Foxp2 gene caused severe motor impairment, premature death, and an absence of ultrasonic vocalizations that are elicited when pups are removed from their mothers. Disruption of a single copy of the gene led to modest developmental delay but a significant alteration in ultrasonic vocalization in response to such separation. Learning and memory appear normal in the heterozygous animals. Cerebellar abnormalities were observed in mice with disruptions in Foxp2, with Purkinje cells particularly affected. Our findings support a role for Foxp2 in cerebellar development and in a developmental process that subsumes social communication functions in diverse organisms.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "7dd09d57cc444e8eb573053076049159", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[123, 123], [218, 218], [132, 132], [44, 44], [204, 204], [89, 89]], "char_spans": [[727, 731], [1309, 1313], [772, 776], [254, 258], [1227, 1231], [518, 522]]}]}], "context_tokens": [["Neurobiology", 0], ["of", 13], ["speech", 16], ["and", 23], ["language", 27], ["has", 36], ["previously", 40], ["been", 51], ["studied", 56], ["in", 64], ["the", 67], ["KE", 71], ["family", 74], [",", 80], ["in", 82], ["which", 85], ["half", 91], ["of", 96], ["the", 99], ["members", 103], ["have", 111], ["severe", 116], ["impairment", 123], ["in", 134], ["both", 137], ["speech", 142], ["and", 149], ["language", 153], [".", 161], ["The", 163], ["gene", 167], ["responsible", 172], ["for", 184], ["the", 188], ["phenotype", 192], ["was", 202], ["mapped", 206], ["to", 213], ["chromosome", 216], ["7q31", 227], ["and", 232], ["identified", 236], ["as", 247], ["the", 250], ["FOXP2", 254], ["gene", 260], [",", 264], ["coding", 266], ["for", 273], ["a", 277], ["transcription", 279], ["factor", 293], ["containing", 300], ["a", 311], ["polyglutamine", 313], ["tract", 327], ["and", 333], ["a", 337], ["forkhead", 339], ["DNA", 348], ["-", 351], ["binding", 352], ["domain", 360], [".", 366], ["Because", 368], ["of", 376], ["linkage", 379], ["studies", 387], ["implicating", 395], ["7q31", 407], ["in", 412], ["autism", 415], [",", 421], ["where", 423], ["language", 429], ["impairment", 438], ["is", 449], ["a", 452], ["component", 454], ["of", 464], ["the", 467], ["disorder", 471], [",", 479], ["and", 481], ["in", 485], ["specific", 488], ["language", 497], ["impairment", 506], [",", 516], ["FOXP2", 518], ["has", 524], ["also", 528], ["been", 533], ["considered", 538], ["as", 549], ["a", 552], ["potential", 554], ["susceptibility", 564], ["locus", 579], ["for", 585], ["the", 589], ["language", 593], ["deficits", 602], ["in", 611], ["autism", 614], ["and/or", 621], ["specific", 628], ["language", 637], ["impairment", 646], [".", 656], ["In", 658], ["this", 661], ["study", 666], [",", 671], ["we", 673], ["characterized", 676], ["mice", 690], ["with", 695], ["a", 700], ["disruption", 702], ["in", 713], ["the", 716], ["murine", 720], ["Foxp2", 727], ["gene", 733], [".", 737], ["Disruption", 739], ["of", 750], ["both", 753], ["copies", 758], ["of", 765], ["the", 768], ["Foxp2", 772], ["gene", 778], ["caused", 783], ["severe", 790], ["motor", 797], ["impairment", 803], [",", 813], ["premature", 815], ["death", 825], [",", 830], ["and", 832], ["an", 836], ["absence", 839], ["of", 847], ["ultrasonic", 850], ["vocalizations", 861], ["that", 875], ["are", 880], ["elicited", 884], ["when", 893], ["pups", 898], ["are", 903], ["removed", 907], ["from", 915], ["their", 920], ["mothers", 926], [".", 933], ["Disruption", 935], ["of", 946], ["a", 949], ["single", 951], ["copy", 958], ["of", 963], ["the", 966], ["gene", 970], ["led", 975], ["to", 979], ["modest", 982], ["developmental", 989], ["delay", 1003], ["but", 1009], ["a", 1013], ["significant", 1015], ["alteration", 1027], ["in", 1038], ["ultrasonic", 1041], ["vocalization", 1052], ["in", 1065], ["response", 1068], ["to", 1077], ["such", 1080], ["separation", 1085], [".", 1095], ["Learning", 1097], ["and", 1106], ["memory", 1110], ["appear", 1117], ["normal", 1124], ["in", 1131], ["the", 1134], ["heterozygous", 1138], ["animals", 1151], [".", 1158], ["Cerebellar", 1160], ["abnormalities", 1171], ["were", 1185], ["observed", 1190], ["in", 1199], ["mice", 1202], ["with", 1207], ["disruptions", 1212], ["in", 1224], ["Foxp2", 1227], [",", 1232], ["with", 1234], ["Purkinje", 1239], ["cells", 1248], ["particularly", 1254], ["affected", 1267], [".", 1275], ["Our", 1277], ["findings", 1281], ["support", 1290], ["a", 1298], ["role", 1300], ["for", 1305], ["Foxp2", 1309], ["in", 1315], ["cerebellar", 1318], ["development", 1329], ["and", 1341], ["in", 1345], ["a", 1348], ["developmental", 1350], ["process", 1364], ["that", 1372], ["subsumes", 1377], ["social", 1386], ["communication", 1393], ["functions", 1407], ["in", 1417], ["diverse", 1420], ["organisms", 1428], [".", 1437]]}
{"context": "The subventricular zone (SVZ) is an embryonic remnant that persists and remains mitotically active throughout adulthood. The rodent SVZ harbors neuronal precursors, principally in its anterior part, and generates neuroblasts that migrate tangentially into the olfactory bulb, thus forming the so-called rostral migratory stream. This study aimed at characterizing the SVZ in the human brain. Antibodies raised against the widely used SVZ molecular markers nestin, glial fibrillary acidic protein, beta-tubulin-III and polysialylated neural cell adhesion molecule, have allowed us to characterize in detail a zone similar to the rodent SVZ in humans. Virtually all portions of the lateral ventricle, as well as the ventral (hypothalamic) sector of the third ventricle, displayed immunoreactivity for most of the molecular markers. The midline region of the septum (septal recess) and the ventral portion of the SVZ displayed a particularly intense immunostaining for all SVZ markers. These two regions may represent zones of adult neurogenesis that are unique to primates. Furthermore, the anti-apoptotic protein Bcl-2 was found to be actively synthesized and co-expressed with all the other markers throughout the entire SVZ. This study reveals that a well-developed SVZ exists in the adult human brain and suggests that Bcl-2 might play an important role in the functional organization of such a system.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "2c9f3d096d9b474e81e534d2b2027f2b", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[74, 74]], "char_spans": [[456, 461]]}]}], "context_tokens": [["The", 0], ["subventricular", 4], ["zone", 19], ["(", 24], ["SVZ", 25], [")", 28], ["is", 30], ["an", 33], ["embryonic", 36], ["remnant", 46], ["that", 54], ["persists", 59], ["and", 68], ["remains", 72], ["mitotically", 80], ["active", 92], ["throughout", 99], ["adulthood", 110], [".", 119], ["The", 121], ["rodent", 125], ["SVZ", 132], ["harbors", 136], ["neuronal", 144], ["precursors", 153], [",", 163], ["principally", 165], ["in", 177], ["its", 180], ["anterior", 184], ["part", 193], [",", 197], ["and", 199], ["generates", 203], ["neuroblasts", 213], ["that", 225], ["migrate", 230], ["tangentially", 238], ["into", 251], ["the", 256], ["olfactory", 260], ["bulb", 270], [",", 274], ["thus", 276], ["forming", 281], ["the", 289], ["so", 293], ["-", 295], ["called", 296], ["rostral", 303], ["migratory", 311], ["stream", 321], [".", 327], ["This", 329], ["study", 334], ["aimed", 340], ["at", 346], ["characterizing", 349], ["the", 364], ["SVZ", 368], ["in", 372], ["the", 375], ["human", 379], ["brain", 385], [".", 390], ["Antibodies", 392], ["raised", 403], ["against", 410], ["the", 418], ["widely", 422], ["used", 429], ["SVZ", 434], ["molecular", 438], ["markers", 448], ["nestin", 456], [",", 462], ["glial", 464], ["fibrillary", 470], ["acidic", 481], ["protein", 488], [",", 495], ["beta", 497], ["-", 501], ["tubulin", 502], ["-", 509], ["III", 510], ["and", 514], ["polysialylated", 518], ["neural", 533], ["cell", 540], ["adhesion", 545], ["molecule", 554], [",", 562], ["have", 564], ["allowed", 569], ["us", 577], ["to", 580], ["characterize", 583], ["in", 596], ["detail", 599], ["a", 606], ["zone", 608], ["similar", 613], ["to", 621], ["the", 624], ["rodent", 628], ["SVZ", 635], ["in", 639], ["humans", 642], [".", 648], ["Virtually", 650], ["all", 660], ["portions", 664], ["of", 673], ["the", 676], ["lateral", 680], ["ventricle", 688], [",", 697], ["as", 699], ["well", 702], ["as", 707], ["the", 710], ["ventral", 714], ["(", 722], ["hypothalamic", 723], [")", 735], ["sector", 737], ["of", 744], ["the", 747], ["third", 751], ["ventricle", 757], [",", 766], ["displayed", 768], ["immunoreactivity", 778], ["for", 795], ["most", 799], ["of", 804], ["the", 807], ["molecular", 811], ["markers", 821], [".", 828], ["The", 830], ["midline", 834], ["region", 842], ["of", 849], ["the", 852], ["septum", 856], ["(", 863], ["septal", 864], ["recess", 871], [")", 877], ["and", 879], ["the", 883], ["ventral", 887], ["portion", 895], ["of", 903], ["the", 906], ["SVZ", 910], ["displayed", 914], ["a", 924], ["particularly", 926], ["intense", 939], ["immunostaining", 947], ["for", 962], ["all", 966], ["SVZ", 970], ["markers", 974], [".", 981], ["These", 983], ["two", 989], ["regions", 993], ["may", 1001], ["represent", 1005], ["zones", 1015], ["of", 1021], ["adult", 1024], ["neurogenesis", 1030], ["that", 1043], ["are", 1048], ["unique", 1052], ["to", 1059], ["primates", 1062], [".", 1070], ["Furthermore", 1072], [",", 1083], ["the", 1085], ["anti", 1089], ["-", 1093], ["apoptotic", 1094], ["protein", 1104], ["Bcl-2", 1112], ["was", 1118], ["found", 1122], ["to", 1128], ["be", 1131], ["actively", 1134], ["synthesized", 1143], ["and", 1155], ["co", 1159], ["-", 1161], ["expressed", 1162], ["with", 1172], ["all", 1177], ["the", 1181], ["other", 1185], ["markers", 1191], ["throughout", 1199], ["the", 1210], ["entire", 1214], ["SVZ", 1221], [".", 1224], ["This", 1226], ["study", 1231], ["reveals", 1237], ["that", 1245], ["a", 1250], ["well", 1252], ["-", 1256], ["developed", 1257], ["SVZ", 1267], ["exists", 1271], ["in", 1278], ["the", 1281], ["adult", 1285], ["human", 1291], ["brain", 1297], ["and", 1303], ["suggests", 1307], ["that", 1316], ["Bcl-2", 1321], ["might", 1327], ["play", 1333], ["an", 1338], ["important", 1341], ["role", 1351], ["in", 1356], ["the", 1359], ["functional", 1363], ["organization", 1374], ["of", 1387], ["such", 1390], ["a", 1395], ["system", 1397], [".", 1403]]}
{"context": "Common cellular and molecular mechanisms including protein aggregation and inclusion body formation are involved in many neurodegenerative diseases. \u03b1-Synuclein is a major component of Lewy bodies in Parkinson's disease (PD) as well as in glial cytoplasmic inclusions in multiple system atrophy (MSA). Tau is a principal component of neurofibrillary and glial tangles in tauopathies. Recently, TDP-43 was identified as a component of ubiquitinated inclusions in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PD is traditionally considered a movement disorder with hallmark lesions in the brainstem pigmented nuclei. However, pathological changes occur in widespread regions of the central and peripheral nervous systems in this disease. Furthermore, primary glial involvement (\"gliodegeneration\") can be observed in PD and MSA as well as in tauopathy. The present article reviews abnormal protein accumulation and inclusion body formation inside and outside the central nervous system.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "1943cdaa336f472f827be07ba6e57bb5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[19, 21]], "char_spans": [[149, 159]]}]}], "context_tokens": [["Common", 0], ["cellular", 7], ["and", 16], ["molecular", 20], ["mechanisms", 30], ["including", 41], ["protein", 51], ["aggregation", 59], ["and", 71], ["inclusion", 75], ["body", 85], ["formation", 90], ["are", 100], ["involved", 104], ["in", 113], ["many", 116], ["neurodegenerative", 121], ["diseases", 139], [".", 147], ["\u03b1", 149], ["-", 150], ["Synuclein", 151], ["is", 161], ["a", 164], ["major", 166], ["component", 172], ["of", 182], ["Lewy", 185], ["bodies", 190], ["in", 197], ["Parkinson", 200], ["'s", 209], ["disease", 212], ["(", 220], ["PD", 221], [")", 223], ["as", 225], ["well", 228], ["as", 233], ["in", 236], ["glial", 239], ["cytoplasmic", 245], ["inclusions", 257], ["in", 268], ["multiple", 271], ["system", 280], ["atrophy", 287], ["(", 295], ["MSA", 296], [")", 299], [".", 300], ["Tau", 302], ["is", 306], ["a", 309], ["principal", 311], ["component", 321], ["of", 331], ["neurofibrillary", 334], ["and", 350], ["glial", 354], ["tangles", 360], ["in", 368], ["tauopathies", 371], [".", 382], ["Recently", 384], [",", 392], ["TDP-43", 394], ["was", 401], ["identified", 405], ["as", 416], ["a", 419], ["component", 421], ["of", 431], ["ubiquitinated", 434], ["inclusions", 448], ["in", 459], ["amyotrophic", 462], ["lateral", 474], ["sclerosis", 482], ["and", 492], ["frontotemporal", 496], ["lobar", 511], ["degeneration", 517], [".", 529], ["PD", 531], ["is", 534], ["traditionally", 537], ["considered", 551], ["a", 562], ["movement", 564], ["disorder", 573], ["with", 582], ["hallmark", 587], ["lesions", 596], ["in", 604], ["the", 607], ["brainstem", 611], ["pigmented", 621], ["nuclei", 631], [".", 637], ["However", 639], [",", 646], ["pathological", 648], ["changes", 661], ["occur", 669], ["in", 675], ["widespread", 678], ["regions", 689], ["of", 697], ["the", 700], ["central", 704], ["and", 712], ["peripheral", 716], ["nervous", 727], ["systems", 735], ["in", 743], ["this", 746], ["disease", 751], [".", 758], ["Furthermore", 760], [",", 771], ["primary", 773], ["glial", 781], ["involvement", 787], ["(", 799], ["\"", 800], ["gliodegeneration", 801], ["\"", 817], [")", 818], ["can", 820], ["be", 824], ["observed", 827], ["in", 836], ["PD", 839], ["and", 842], ["MSA", 846], ["as", 850], ["well", 853], ["as", 858], ["in", 861], ["tauopathy", 864], [".", 873], ["The", 875], ["present", 879], ["article", 887], ["reviews", 895], ["abnormal", 903], ["protein", 912], ["accumulation", 920], ["and", 933], ["inclusion", 937], ["body", 947], ["formation", 952], ["inside", 962], ["and", 969], ["outside", 973], ["the", 981], ["central", 985], ["nervous", 993], ["system", 1001], [".", 1007]]}
{"context": "To assess gender differences in disease characteristics and treatment responses over time in a disease-modifying antirheumatic drug (DMARD)-naive seropositive early rheumatoid arthritis (RA) cohort. Patients with polyarticular disease who were DMARD-naive and had seropositive early RA (< 14 months) were recruited by the Western Consortium of Practicing Rheumatologists. Each patient was examined at study entry, after 6 and 12 months, and yearly thereafter. Clinical and demographic data were collected. We investigated gender differences in baseline disease characteristics and treatment using chi-squared, Mann-Whitney U, and t tests. We used generalized estimating equations (GEE) models for repeated measures to examine whether the rate of change of specific disease outcomes during the first 2 years after DMARD initiation was significantly influenced by gender. At baseline, men (n = 67) and women (n = 225) had similar disease activity and radiographic damage; men, however, had significantly worse erosion, while women had worse joint space narrowing. Despite similar treatment, women had worse disease progression over the 2-year followup, as assessed by trends in Disease Activity Score 28/erythrocyte sedimentation rate (DAS28-ESR4), physician global scores, and tender joint counts. In the GEE model, gender was significantly associated with the rate of change of DAS28-ESR4 scores (p = 0.009), although not independently associated with disease activity. Self-reported measures (Health Assessment Questionnaire-Disability Index, patient global scores, fatigue, pain) were worse among women at baseline and throughout the study period. Men were more likely to achieve remission. At baseline, men and women had similar disease activity and joint damage. Responses to treatment over time were better among men in this prebiologic era; women had worse progression despite similar treatment.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "4dea6626ae0746408e89bcdce7226c6f", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[155, 155], [179, 179], [278, 278], [323, 323], [300, 300], [190, 190]], "char_spans": [[900, 904], [1023, 1027], [1599, 1603], [1847, 1851], [1714, 1718], [1089, 1093]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["gender", 10], ["differences", 17], ["in", 29], ["disease", 32], ["characteristics", 40], ["and", 56], ["treatment", 60], ["responses", 70], ["over", 80], ["time", 85], ["in", 90], ["a", 93], ["disease", 95], ["-", 102], ["modifying", 103], ["antirheumatic", 113], ["drug", 127], ["(", 132], ["DMARD)-naive", 133], ["seropositive", 146], ["early", 159], ["rheumatoid", 165], ["arthritis", 176], ["(", 186], ["RA", 187], [")", 189], ["cohort", 191], [".", 197], ["Patients", 199], ["with", 208], ["polyarticular", 213], ["disease", 227], ["who", 235], ["were", 239], ["DMARD", 244], ["-", 249], ["naive", 250], ["and", 256], ["had", 260], ["seropositive", 264], ["early", 277], ["RA", 283], ["(", 286], ["<", 287], ["14", 289], ["months", 292], [")", 298], ["were", 300], ["recruited", 305], ["by", 315], ["the", 318], ["Western", 322], ["Consortium", 330], ["of", 341], ["Practicing", 344], ["Rheumatologists", 355], [".", 370], ["Each", 372], ["patient", 377], ["was", 385], ["examined", 389], ["at", 398], ["study", 401], ["entry", 407], [",", 412], ["after", 414], ["6", 420], ["and", 422], ["12", 426], ["months", 429], [",", 435], ["and", 437], ["yearly", 441], ["thereafter", 448], [".", 458], ["Clinical", 460], ["and", 469], ["demographic", 473], ["data", 485], ["were", 490], ["collected", 495], [".", 504], ["We", 506], ["investigated", 509], ["gender", 522], ["differences", 529], ["in", 541], ["baseline", 544], ["disease", 553], ["characteristics", 561], ["and", 577], ["treatment", 581], ["using", 591], ["chi", 597], ["-", 600], ["squared", 601], [",", 608], ["Mann", 610], ["-", 614], ["Whitney", 615], ["U", 623], [",", 624], ["and", 626], ["t", 630], ["tests", 632], [".", 637], ["We", 639], ["used", 642], ["generalized", 647], ["estimating", 659], ["equations", 670], ["(", 680], ["GEE", 681], [")", 684], ["models", 686], ["for", 693], ["repeated", 697], ["measures", 706], ["to", 715], ["examine", 718], ["whether", 726], ["the", 734], ["rate", 738], ["of", 743], ["change", 746], ["of", 753], ["specific", 756], ["disease", 765], ["outcomes", 773], ["during", 782], ["the", 789], ["first", 793], ["2", 799], ["years", 801], ["after", 807], ["DMARD", 813], ["initiation", 819], ["was", 830], ["significantly", 834], ["influenced", 848], ["by", 859], ["gender", 862], [".", 868], ["At", 870], ["baseline", 873], [",", 881], ["men", 883], ["(", 887], ["n", 888], ["=", 890], ["67", 892], [")", 894], ["and", 896], ["women", 900], ["(", 906], ["n", 907], ["=", 909], ["225", 911], [")", 914], ["had", 916], ["similar", 920], ["disease", 928], ["activity", 936], ["and", 945], ["radiographic", 949], ["damage", 962], [";", 968], ["men", 970], [",", 973], ["however", 975], [",", 982], ["had", 984], ["significantly", 988], ["worse", 1002], ["erosion", 1008], [",", 1015], ["while", 1017], ["women", 1023], ["had", 1029], ["worse", 1033], ["joint", 1039], ["space", 1045], ["narrowing", 1051], [".", 1060], ["Despite", 1062], ["similar", 1070], ["treatment", 1078], [",", 1087], ["women", 1089], ["had", 1095], ["worse", 1099], ["disease", 1105], ["progression", 1113], ["over", 1125], ["the", 1130], ["2-year", 1134], ["followup", 1141], [",", 1149], ["as", 1151], ["assessed", 1154], ["by", 1163], ["trends", 1166], ["in", 1173], ["Disease", 1176], ["Activity", 1184], ["Score", 1193], ["28/erythrocyte", 1199], ["sedimentation", 1214], ["rate", 1228], ["(", 1233], ["DAS28-ESR4", 1234], [")", 1244], [",", 1245], ["physician", 1247], ["global", 1257], ["scores", 1264], [",", 1270], ["and", 1272], ["tender", 1276], ["joint", 1283], ["counts", 1289], [".", 1295], ["In", 1297], ["the", 1300], ["GEE", 1304], ["model", 1308], [",", 1313], ["gender", 1315], ["was", 1322], ["significantly", 1326], ["associated", 1340], ["with", 1351], ["the", 1356], ["rate", 1360], ["of", 1365], ["change", 1368], ["of", 1375], ["DAS28-ESR4", 1378], ["scores", 1389], ["(", 1396], ["p", 1397], ["=", 1399], ["0.009", 1401], [")", 1406], [",", 1407], ["although", 1409], ["not", 1418], ["independently", 1422], ["associated", 1436], ["with", 1447], ["disease", 1452], ["activity", 1460], [".", 1468], ["Self", 1470], ["-", 1474], ["reported", 1475], ["measures", 1484], ["(", 1493], ["Health", 1494], ["Assessment", 1501], ["Questionnaire", 1512], ["-", 1525], ["Disability", 1526], ["Index", 1537], [",", 1542], ["patient", 1544], ["global", 1552], ["scores", 1559], [",", 1565], ["fatigue", 1567], [",", 1574], ["pain", 1576], [")", 1580], ["were", 1582], ["worse", 1587], ["among", 1593], ["women", 1599], ["at", 1605], ["baseline", 1608], ["and", 1617], ["throughout", 1621], ["the", 1632], ["study", 1636], ["period", 1642], [".", 1648], ["Men", 1650], ["were", 1654], ["more", 1659], ["likely", 1664], ["to", 1671], ["achieve", 1674], ["remission", 1682], [".", 1691], ["At", 1693], ["baseline", 1696], [",", 1704], ["men", 1706], ["and", 1710], ["women", 1714], ["had", 1720], ["similar", 1724], ["disease", 1732], ["activity", 1740], ["and", 1749], ["joint", 1753], ["damage", 1759], [".", 1765], ["Responses", 1767], ["to", 1777], ["treatment", 1780], ["over", 1790], ["time", 1795], ["were", 1800], ["better", 1805], ["among", 1812], ["men", 1818], ["in", 1822], ["this", 1825], ["prebiologic", 1830], ["era", 1842], [";", 1845], ["women", 1847], ["had", 1853], ["worse", 1857], ["progression", 1863], ["despite", 1875], ["similar", 1883], ["treatment", 1891], [".", 1900]]}
{"context": "Low back pain with or without radiculopathy is an important cause of disability and economic expenditure. However, many patients are not meeting optimal pain control through existing treatments. Recent studies have linked nerve growth factor (NGF) and the pathophysiology of persistent pain. Anti-NGF could be an alternative drug treatment for low back pain. Systematically review the efficacy and safety of anti-NGF in the treatment of low back pain. A systematic review of the literature with no language, date or publication status restriction, using Medline, EMBASE, Cochrane Library, and the clinicaltrials.gov database. Additional literature was retrieved by conferring with experts in the field or reviewing bibliographies and annals of meetings and congresses. Search terms included \"monoclonal antibodies,\" \"nerve growth factor,\" \"anti-ngf,\" \"fulranumab,\" \"tanezumab,\" \"sciatica,\" \"back pain,\" and \"spine.\" Inclusion criteria were observational studies with safety as an outcome and randomized or nonrandomized controlled trials studying the efficacy and/or the safety of anti-NGF drugs on low back pain. Exclusion criteria included patients with autoimmune conditions or osteoporosis. Studies were assessed independently by 2 authors regarding inclusion/exclusion criteria, risk of bias, clinical relevance, and quality of evidence (GRADE approach). 1,168 studies were retrieved. After excluding duplicates and applying the inclusion/exclusion criteria, 4 RCTs remained (n = 2,109): 2 for tanezumab, one for REGN475, and one for fulranumab. Only the tanezumab studies showed any significant difference over placebo (n = 1,563) for both pain relief and functional improvement. There is very low evidence that systemically administered anti-NGF therapy has a small positive effect compared to placebo for both pain relief (standarized mean difference [SMD] = -0.29, 95% confidence interval [CI] -0.58 to 0.00) and functional improvement (SMD = -0.21, 95%CI -0.37 to -0.05 ) of low back pain. There was low evidence of adverse effects (AEs) compared to placebo and low evidence of neurological AEs than placebo (relative risk = 1.93, 95%CI 1.41 to 2.64).Tanezumab, as a specific anti-NGF treatment, showed low evidence of a small to moderate effect for pain relief of low back pain (SMD = -0.44, 95%CI -0.81 to -0.07); and low evidence of a small effect for functional improvement (SMD = -0.26, 95%CI -0.40 to -0.12) with systemic administration, although not clinically significant. Tanezumab and anti-NGFs overall had, respectively, moderate and low evidence of overall AEs and serious AEs and a higher risk of developing neurological AEs when compared with placebo. Although anti-NGF, specifically tanezumab, showed a low-to-moderate effect on pain relief and functional improvement, it cannot be recommended for low back pain treatment. Without more research on the pathophysiology of anti-NGFs and adverse effects, its use is not safe in the overall population. However, as corroborated by the US Food and Drug Administration, this meta-analysis underscores a role for greater insight into anti-NGF therapy for painful conditions that are refractory to current drugs, such as oncologic pain, chronic pancreatitis, and phantom-limb pain. Given the pathophysiology of axial pain involving inflammatory mediators and the adverse effects of systemic anti-NGF use, consideration of local therapies may warrant further exploration.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "2ab00371c0644e0ca45158c35d6dbf8e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[139, 141], [35, 37]], "char_spans": [[817, 835], [222, 240]]}, {"text": "NGF", "token_spans": [[147, 147], [197, 197], [314, 314], [499, 499], [579, 579], [404, 404], [39, 39], [71, 71], [50, 50], [622, 622]], "char_spans": [[845, 847], [1086, 1088], [1749, 1751], [2690, 2692], [3107, 3109], [2191, 2193], [243, 245], [413, 415], [297, 299], [3363, 3365]]}]}], "context_tokens": [["Low", 0], ["back", 4], ["pain", 9], ["with", 14], ["or", 19], ["without", 22], ["radiculopathy", 30], ["is", 44], ["an", 47], ["important", 50], ["cause", 60], ["of", 66], ["disability", 69], ["and", 80], ["economic", 84], ["expenditure", 93], [".", 104], ["However", 106], [",", 113], ["many", 115], ["patients", 120], ["are", 129], ["not", 133], ["meeting", 137], ["optimal", 145], ["pain", 153], ["control", 158], ["through", 166], ["existing", 174], ["treatments", 183], [".", 193], ["Recent", 195], ["studies", 202], ["have", 210], ["linked", 215], ["nerve", 222], ["growth", 228], ["factor", 235], ["(", 242], ["NGF", 243], [")", 246], ["and", 248], ["the", 252], ["pathophysiology", 256], ["of", 272], ["persistent", 275], ["pain", 286], [".", 290], ["Anti", 292], ["-", 296], ["NGF", 297], ["could", 301], ["be", 307], ["an", 310], ["alternative", 313], ["drug", 325], ["treatment", 330], ["for", 340], ["low", 344], ["back", 348], ["pain", 353], [".", 357], ["Systematically", 359], ["review", 374], ["the", 381], ["efficacy", 385], ["and", 394], ["safety", 398], ["of", 405], ["anti", 408], ["-", 412], ["NGF", 413], ["in", 417], ["the", 420], ["treatment", 424], ["of", 434], ["low", 437], ["back", 441], ["pain", 446], [".", 450], ["A", 452], ["systematic", 454], ["review", 465], ["of", 472], ["the", 475], ["literature", 479], ["with", 490], ["no", 495], ["language", 498], [",", 506], ["date", 508], ["or", 513], ["publication", 516], ["status", 528], ["restriction", 535], [",", 546], ["using", 548], ["Medline", 554], [",", 561], ["EMBASE", 563], [",", 569], ["Cochrane", 571], ["Library", 580], [",", 587], ["and", 589], ["the", 593], ["clinicaltrials.gov", 597], ["database", 616], [".", 624], ["Additional", 626], ["literature", 637], ["was", 648], ["retrieved", 652], ["by", 662], ["conferring", 665], ["with", 676], ["experts", 681], ["in", 689], ["the", 692], ["field", 696], ["or", 702], ["reviewing", 705], ["bibliographies", 715], ["and", 730], ["annals", 734], ["of", 741], ["meetings", 744], ["and", 753], ["congresses", 757], [".", 767], ["Search", 769], ["terms", 776], ["included", 782], ["\"", 791], ["monoclonal", 792], ["antibodies", 803], [",", 813], ["\"", 814], ["\"", 816], ["nerve", 817], ["growth", 823], ["factor", 830], [",", 836], ["\"", 837], ["\"", 839], ["anti", 840], ["-", 844], ["ngf", 845], [",", 848], ["\"", 849], ["\"", 851], ["fulranumab", 852], [",", 862], ["\"", 863], ["\"", 865], ["tanezumab", 866], [",", 875], ["\"", 876], ["\"", 878], ["sciatica", 879], [",", 887], ["\"", 888], ["\"", 890], ["back", 891], ["pain", 896], [",", 900], ["\"", 901], ["and", 903], ["\"", 907], ["spine", 908], [".", 913], ["\"", 914], ["Inclusion", 916], ["criteria", 926], ["were", 935], ["observational", 940], ["studies", 954], ["with", 962], ["safety", 967], ["as", 974], ["an", 977], ["outcome", 980], ["and", 988], ["randomized", 992], ["or", 1003], ["nonrandomized", 1006], ["controlled", 1020], ["trials", 1031], ["studying", 1038], ["the", 1047], ["efficacy", 1051], ["and/or", 1060], ["the", 1067], ["safety", 1071], ["of", 1078], ["anti", 1081], ["-", 1085], ["NGF", 1086], ["drugs", 1090], ["on", 1096], ["low", 1099], ["back", 1103], ["pain", 1108], [".", 1112], ["Exclusion", 1114], ["criteria", 1124], ["included", 1133], ["patients", 1142], ["with", 1151], ["autoimmune", 1156], ["conditions", 1167], ["or", 1178], ["osteoporosis", 1181], [".", 1193], ["Studies", 1195], ["were", 1203], ["assessed", 1208], ["independently", 1217], ["by", 1231], ["2", 1234], ["authors", 1236], ["regarding", 1244], ["inclusion", 1254], ["/", 1263], ["exclusion", 1264], ["criteria", 1274], [",", 1282], ["risk", 1284], ["of", 1289], ["bias", 1292], [",", 1296], ["clinical", 1298], ["relevance", 1307], [",", 1316], ["and", 1318], ["quality", 1322], ["of", 1330], ["evidence", 1333], ["(", 1342], ["GRADE", 1343], ["approach", 1349], [")", 1357], [".", 1358], ["1,168", 1360], ["studies", 1366], ["were", 1374], ["retrieved", 1379], [".", 1388], ["After", 1390], ["excluding", 1396], ["duplicates", 1406], ["and", 1417], ["applying", 1421], ["the", 1430], ["inclusion", 1434], ["/", 1443], ["exclusion", 1444], ["criteria", 1454], [",", 1462], ["4", 1464], ["RCTs", 1466], ["remained", 1471], ["(", 1480], ["n", 1481], ["=", 1483], ["2,109", 1485], [")", 1490], [":", 1491], ["2", 1493], ["for", 1495], ["tanezumab", 1499], [",", 1508], ["one", 1510], ["for", 1514], ["REGN475", 1518], [",", 1525], ["and", 1527], ["one", 1531], ["for", 1535], ["fulranumab", 1539], [".", 1549], ["Only", 1551], ["the", 1556], ["tanezumab", 1560], ["studies", 1570], ["showed", 1578], ["any", 1585], ["significant", 1589], ["difference", 1601], ["over", 1612], ["placebo", 1617], ["(", 1625], ["n", 1626], ["=", 1628], ["1,563", 1630], [")", 1635], ["for", 1637], ["both", 1641], ["pain", 1646], ["relief", 1651], ["and", 1658], ["functional", 1662], ["improvement", 1673], [".", 1684], ["There", 1686], ["is", 1692], ["very", 1695], ["low", 1700], ["evidence", 1704], ["that", 1713], ["systemically", 1718], ["administered", 1731], ["anti", 1744], ["-", 1748], ["NGF", 1749], ["therapy", 1753], ["has", 1761], ["a", 1765], ["small", 1767], ["positive", 1773], ["effect", 1782], ["compared", 1789], ["to", 1798], ["placebo", 1801], ["for", 1809], ["both", 1813], ["pain", 1818], ["relief", 1823], ["(", 1830], ["standarized", 1831], ["mean", 1843], ["difference", 1848], ["[", 1859], ["SMD", 1860], ["]", 1863], ["=", 1865], ["-0.29", 1867], [",", 1872], ["95", 1874], ["%", 1876], ["confidence", 1878], ["interval", 1889], ["[", 1898], ["CI", 1899], ["]", 1901], ["-0.58", 1903], ["to", 1909], ["0.00", 1912], [")", 1916], ["and", 1918], ["functional", 1922], ["improvement", 1933], ["(", 1945], ["SMD", 1946], ["=", 1950], ["-0.21", 1952], [",", 1957], ["95%CI", 1959], ["-0.37", 1965], ["to", 1971], ["-0.05", 1974], [")", 1980], ["of", 1982], ["low", 1985], ["back", 1989], ["pain", 1994], [".", 1998], ["There", 2000], ["was", 2006], ["low", 2010], ["evidence", 2014], ["of", 2023], ["adverse", 2026], ["effects", 2034], ["(", 2042], ["AEs", 2043], [")", 2046], ["compared", 2048], ["to", 2057], ["placebo", 2060], ["and", 2068], ["low", 2072], ["evidence", 2076], ["of", 2085], ["neurological", 2088], ["AEs", 2101], ["than", 2105], ["placebo", 2110], ["(", 2118], ["relative", 2119], ["risk", 2128], ["=", 2133], ["1.93", 2135], [",", 2139], ["95%CI", 2141], ["1.41", 2147], ["to", 2152], ["2.64).Tanezumab", 2155], [",", 2170], ["as", 2172], ["a", 2175], ["specific", 2177], ["anti", 2186], ["-", 2190], ["NGF", 2191], ["treatment", 2195], [",", 2204], ["showed", 2206], ["low", 2213], ["evidence", 2217], ["of", 2226], ["a", 2229], ["small", 2231], ["to", 2237], ["moderate", 2240], ["effect", 2249], ["for", 2256], ["pain", 2260], ["relief", 2265], ["of", 2272], ["low", 2275], ["back", 2279], ["pain", 2284], ["(", 2289], ["SMD", 2290], ["=", 2294], ["-0.44", 2296], [",", 2301], ["95%CI", 2303], ["-0.81", 2309], ["to", 2315], ["-0.07", 2318], [")", 2323], [";", 2324], ["and", 2326], ["low", 2330], ["evidence", 2334], ["of", 2343], ["a", 2346], ["small", 2348], ["effect", 2354], ["for", 2361], ["functional", 2365], ["improvement", 2376], ["(", 2388], ["SMD", 2389], ["=", 2393], ["-0.26", 2395], [",", 2400], ["95%CI", 2402], ["-0.40", 2408], ["to", 2414], ["-0.12", 2417], [")", 2422], ["with", 2424], ["systemic", 2429], ["administration", 2438], [",", 2452], ["although", 2454], ["not", 2463], ["clinically", 2467], ["significant", 2478], [".", 2489], ["Tanezumab", 2491], ["and", 2501], ["anti", 2505], ["-", 2509], ["NGFs", 2510], ["overall", 2515], ["had", 2523], [",", 2526], ["respectively", 2528], [",", 2540], ["moderate", 2542], ["and", 2551], ["low", 2555], ["evidence", 2559], ["of", 2568], ["overall", 2571], ["AEs", 2579], ["and", 2583], ["serious", 2587], ["AEs", 2595], ["and", 2599], ["a", 2603], ["higher", 2605], ["risk", 2612], ["of", 2617], ["developing", 2620], ["neurological", 2631], ["AEs", 2644], ["when", 2648], ["compared", 2653], ["with", 2662], ["placebo", 2667], [".", 2674], ["Although", 2676], ["anti", 2685], ["-", 2689], ["NGF", 2690], [",", 2693], ["specifically", 2695], ["tanezumab", 2708], [",", 2717], ["showed", 2719], ["a", 2726], ["low", 2728], ["-", 2731], ["to", 2732], ["-", 2734], ["moderate", 2735], ["effect", 2744], ["on", 2751], ["pain", 2754], ["relief", 2759], ["and", 2766], ["functional", 2770], ["improvement", 2781], [",", 2792], ["it", 2794], ["can", 2797], ["not", 2800], ["be", 2804], ["recommended", 2807], ["for", 2819], ["low", 2823], ["back", 2827], ["pain", 2832], ["treatment", 2837], [".", 2846], ["Without", 2848], ["more", 2856], ["research", 2861], ["on", 2870], ["the", 2873], ["pathophysiology", 2877], ["of", 2893], ["anti", 2896], ["-", 2900], ["NGFs", 2901], ["and", 2906], ["adverse", 2910], ["effects", 2918], [",", 2925], ["its", 2927], ["use", 2931], ["is", 2935], ["not", 2938], ["safe", 2942], ["in", 2947], ["the", 2950], ["overall", 2954], ["population", 2962], [".", 2972], ["However", 2974], [",", 2981], ["as", 2983], ["corroborated", 2986], ["by", 2999], ["the", 3002], ["US", 3006], ["Food", 3009], ["and", 3014], ["Drug", 3018], ["Administration", 3023], [",", 3037], ["this", 3039], ["meta", 3044], ["-", 3048], ["analysis", 3049], ["underscores", 3058], ["a", 3070], ["role", 3072], ["for", 3077], ["greater", 3081], ["insight", 3089], ["into", 3097], ["anti", 3102], ["-", 3106], ["NGF", 3107], ["therapy", 3111], ["for", 3119], ["painful", 3123], ["conditions", 3131], ["that", 3142], ["are", 3147], ["refractory", 3151], ["to", 3162], ["current", 3165], ["drugs", 3173], [",", 3178], ["such", 3180], ["as", 3185], ["oncologic", 3188], ["pain", 3198], [",", 3202], ["chronic", 3204], ["pancreatitis", 3212], [",", 3224], ["and", 3226], ["phantom", 3230], ["-", 3237], ["limb", 3238], ["pain", 3243], [".", 3247], ["Given", 3249], ["the", 3255], ["pathophysiology", 3259], ["of", 3275], ["axial", 3278], ["pain", 3284], ["involving", 3289], ["inflammatory", 3299], ["mediators", 3312], ["and", 3322], ["the", 3326], ["adverse", 3330], ["effects", 3338], ["of", 3346], ["systemic", 3349], ["anti", 3358], ["-", 3362], ["NGF", 3363], ["use", 3367], [",", 3370], ["consideration", 3372], ["of", 3386], ["local", 3389], ["therapies", 3395], ["may", 3405], ["warrant", 3409], ["further", 3417], ["exploration", 3425], [".", 3436]]}
{"context": "Transcription-coupled repair (TCR) is the major pathway involved in the removal of UV-induced photolesions from the transcribed strand of active genes. Two Cockayne syndrome (CS) complementation group proteins, CSA and CSB, are important for TCR repair. The molecular mechanisms by which CS proteins regulate TCR remain elusive. Here, we report the characterization of KIAA1530, an evolutionarily conserved protein that participates in this pathway through its interaction with CSA and the TFIIH complex. We found that UV irradiation led to the recruitment of KIAA1530 onto chromatin in a CSA-dependent manner. Cells lacking KIAA1530 were highly sensitive to UV irradiation and displayed deficiency in TCR. In addition, KIAA1530 depletion abrogated stability of the CSB protein following UV irradiation. More excitingly, we found that a unique CSA mutant (W361C), which was previously identified in a patient with UV(s)S syndrome, showed defective KIAA1530 binding and resulted in a failure of recruiting KIAA1530 and stabilizing CSB after UV treatment. Together, our data not only reveal that KIAA1530 is an important player in TCR but also lead to a better understanding of the molecular mechanism underlying UV(s)S syndrome.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "0ee48960a85e4cb08d71437204c23131", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[22, 23]], "char_spans": [[116, 133]]}]}], "context_tokens": [["Transcription", 0], ["-", 13], ["coupled", 14], ["repair", 22], ["(", 29], ["TCR", 30], [")", 33], ["is", 35], ["the", 38], ["major", 42], ["pathway", 48], ["involved", 56], ["in", 65], ["the", 68], ["removal", 72], ["of", 80], ["UV", 83], ["-", 85], ["induced", 86], ["photolesions", 94], ["from", 107], ["the", 112], ["transcribed", 116], ["strand", 128], ["of", 135], ["active", 138], ["genes", 145], [".", 150], ["Two", 152], ["Cockayne", 156], ["syndrome", 165], ["(", 174], ["CS", 175], [")", 177], ["complementation", 179], ["group", 195], ["proteins", 201], [",", 209], ["CSA", 211], ["and", 215], ["CSB", 219], [",", 222], ["are", 224], ["important", 228], ["for", 238], ["TCR", 242], ["repair", 246], [".", 252], ["The", 254], ["molecular", 258], ["mechanisms", 268], ["by", 279], ["which", 282], ["CS", 288], ["proteins", 291], ["regulate", 300], ["TCR", 309], ["remain", 313], ["elusive", 320], [".", 327], ["Here", 329], [",", 333], ["we", 335], ["report", 338], ["the", 345], ["characterization", 349], ["of", 366], ["KIAA1530", 369], [",", 377], ["an", 379], ["evolutionarily", 382], ["conserved", 397], ["protein", 407], ["that", 415], ["participates", 420], ["in", 433], ["this", 436], ["pathway", 441], ["through", 449], ["its", 457], ["interaction", 461], ["with", 473], ["CSA", 478], ["and", 482], ["the", 486], ["TFIIH", 490], ["complex", 496], [".", 503], ["We", 505], ["found", 508], ["that", 514], ["UV", 519], ["irradiation", 522], ["led", 534], ["to", 538], ["the", 541], ["recruitment", 545], ["of", 557], ["KIAA1530", 560], ["onto", 569], ["chromatin", 574], ["in", 584], ["a", 587], ["CSA", 589], ["-", 592], ["dependent", 593], ["manner", 603], [".", 609], ["Cells", 611], ["lacking", 617], ["KIAA1530", 625], ["were", 634], ["highly", 639], ["sensitive", 646], ["to", 656], ["UV", 659], ["irradiation", 662], ["and", 674], ["displayed", 678], ["deficiency", 688], ["in", 699], ["TCR", 702], [".", 705], ["In", 707], ["addition", 710], [",", 718], ["KIAA1530", 720], ["depletion", 729], ["abrogated", 739], ["stability", 749], ["of", 759], ["the", 762], ["CSB", 766], ["protein", 770], ["following", 778], ["UV", 788], ["irradiation", 791], [".", 802], ["More", 804], ["excitingly", 809], [",", 819], ["we", 821], ["found", 824], ["that", 830], ["a", 835], ["unique", 837], ["CSA", 844], ["mutant", 848], ["(", 855], ["W361C", 856], [")", 861], [",", 862], ["which", 864], ["was", 870], ["previously", 874], ["identified", 885], ["in", 896], ["a", 899], ["patient", 901], ["with", 909], ["UV(s)S", 914], ["syndrome", 921], [",", 929], ["showed", 931], ["defective", 938], ["KIAA1530", 948], ["binding", 957], ["and", 965], ["resulted", 969], ["in", 978], ["a", 981], ["failure", 983], ["of", 991], ["recruiting", 994], ["KIAA1530", 1005], ["and", 1014], ["stabilizing", 1018], ["CSB", 1030], ["after", 1034], ["UV", 1040], ["treatment", 1043], [".", 1052], ["Together", 1054], [",", 1062], ["our", 1064], ["data", 1068], ["not", 1073], ["only", 1077], ["reveal", 1082], ["that", 1089], ["KIAA1530", 1094], ["is", 1103], ["an", 1106], ["important", 1109], ["player", 1119], ["in", 1126], ["TCR", 1129], ["but", 1133], ["also", 1137], ["lead", 1142], ["to", 1147], ["a", 1150], ["better", 1152], ["understanding", 1159], ["of", 1173], ["the", 1176], ["molecular", 1180], ["mechanism", 1190], ["underlying", 1200], ["UV(s)S", 1211], ["syndrome", 1218], [".", 1226]]}
{"context": "In this randomized, double-blind, placebo controlled phase 2 study we investigated tanezumab, a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for interstitial cystitis pain. Patients with interstitial cystitis received a single intravenous dose of 200 \u03bcg/kg tanezumab or placebo. Patients recorded daily pain scores (on an 11-point numerical rating scale) 7 days before attending study visits and completed a urinary symptom diary for 3 of those days. Patients also completed the Interstitial Cystitis Symptom Index questionnaire and a global response assessment. The primary end point was change in average daily numerical rating scale pain score from baseline to week 6. Secondary end points included global response assessment, Interstitial Cystitis Symptom Index score, micturition and urgency episode frequency per 24 hours, and mean voided volume per micturition. The incidence of adverse events was also assessed. A total of 34 patients received tanezumab and 30 received placebo. At week 6 tanezumab produced a significant reduction from baseline in average daily pain score vs placebo (treatment difference [LS mean, 90% CI] was -1.4 [-2.2, -0.5]). A significantly higher proportion of patients on tanezumab responded as improved in the global response assessment and tanezumab also significantly reduced urgency episode frequency vs placebo. Tanezumab had no significant effect on Interstitial Cystitis Symptom Index score, micturition frequency or mean voided volume per micturition. The most common adverse events were headache (tanezumab 20.6%, placebo 16.7%) and paresthesia (tanezumab 17.6%, placebo 3.3%). Tanezumab has shown preliminary efficacy in the treatment of pain associated with interstitial cystitis.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "e516230f0c0040adab7360b90e76c7e0", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[24, 26]], "char_spans": [[153, 171]]}]}], "context_tokens": [["In", 0], ["this", 3], ["randomized", 8], [",", 18], ["double", 20], ["-", 26], ["blind", 27], [",", 32], ["placebo", 34], ["controlled", 42], ["phase", 53], ["2", 59], ["study", 61], ["we", 67], ["investigated", 70], ["tanezumab", 83], [",", 92], ["a", 94], ["humanized", 96], ["monoclonal", 106], ["antibody", 117], ["that", 126], ["specifically", 131], ["inhibits", 144], ["nerve", 153], ["growth", 159], ["factor", 166], ["as", 173], ["a", 176], ["treatment", 178], ["for", 188], ["interstitial", 192], ["cystitis", 205], ["pain", 214], [".", 218], ["Patients", 220], ["with", 229], ["interstitial", 234], ["cystitis", 247], ["received", 256], ["a", 265], ["single", 267], ["intravenous", 274], ["dose", 286], ["of", 291], ["200", 294], ["\u03bcg", 298], ["/", 300], ["kg", 301], ["tanezumab", 304], ["or", 314], ["placebo", 317], [".", 324], ["Patients", 326], ["recorded", 335], ["daily", 344], ["pain", 350], ["scores", 355], ["(", 362], ["on", 363], ["an", 366], ["11-point", 369], ["numerical", 378], ["rating", 388], ["scale", 395], [")", 400], ["7", 402], ["days", 404], ["before", 409], ["attending", 416], ["study", 426], ["visits", 432], ["and", 439], ["completed", 443], ["a", 453], ["urinary", 455], ["symptom", 463], ["diary", 471], ["for", 477], ["3", 481], ["of", 483], ["those", 486], ["days", 492], [".", 496], ["Patients", 498], ["also", 507], ["completed", 512], ["the", 522], ["Interstitial", 526], ["Cystitis", 539], ["Symptom", 548], ["Index", 556], ["questionnaire", 562], ["and", 576], ["a", 580], ["global", 582], ["response", 589], ["assessment", 598], [".", 608], ["The", 610], ["primary", 614], ["end", 622], ["point", 626], ["was", 632], ["change", 636], ["in", 643], ["average", 646], ["daily", 654], ["numerical", 660], ["rating", 670], ["scale", 677], ["pain", 683], ["score", 688], ["from", 694], ["baseline", 699], ["to", 708], ["week", 711], ["6", 716], [".", 717], ["Secondary", 719], ["end", 729], ["points", 733], ["included", 740], ["global", 749], ["response", 756], ["assessment", 765], [",", 775], ["Interstitial", 777], ["Cystitis", 790], ["Symptom", 799], ["Index", 807], ["score", 813], [",", 818], ["micturition", 820], ["and", 832], ["urgency", 836], ["episode", 844], ["frequency", 852], ["per", 862], ["24", 866], ["hours", 869], [",", 874], ["and", 876], ["mean", 880], ["voided", 885], ["volume", 892], ["per", 899], ["micturition", 903], [".", 914], ["The", 916], ["incidence", 920], ["of", 930], ["adverse", 933], ["events", 941], ["was", 948], ["also", 952], ["assessed", 957], [".", 965], ["A", 967], ["total", 969], ["of", 975], ["34", 978], ["patients", 981], ["received", 990], ["tanezumab", 999], ["and", 1009], ["30", 1013], ["received", 1016], ["placebo", 1025], [".", 1032], ["At", 1034], ["week", 1037], ["6", 1042], ["tanezumab", 1044], ["produced", 1054], ["a", 1063], ["significant", 1065], ["reduction", 1077], ["from", 1087], ["baseline", 1092], ["in", 1101], ["average", 1104], ["daily", 1112], ["pain", 1118], ["score", 1123], ["vs", 1129], ["placebo", 1132], ["(", 1140], ["treatment", 1141], ["difference", 1151], ["[", 1162], ["LS", 1163], ["mean", 1166], [",", 1170], ["90", 1172], ["%", 1174], ["CI", 1176], ["]", 1178], ["was", 1180], ["-1.4", 1184], ["[", 1189], ["-2.2", 1190], [",", 1194], ["-0.5", 1196], ["]", 1200], [")", 1201], [".", 1202], ["A", 1204], ["significantly", 1206], ["higher", 1220], ["proportion", 1227], ["of", 1238], ["patients", 1241], ["on", 1250], ["tanezumab", 1253], ["responded", 1263], ["as", 1273], ["improved", 1276], ["in", 1285], ["the", 1288], ["global", 1292], ["response", 1299], ["assessment", 1308], ["and", 1319], ["tanezumab", 1323], ["also", 1333], ["significantly", 1338], ["reduced", 1352], ["urgency", 1360], ["episode", 1368], ["frequency", 1376], ["vs", 1386], ["placebo", 1389], [".", 1396], ["Tanezumab", 1398], ["had", 1408], ["no", 1412], ["significant", 1415], ["effect", 1427], ["on", 1434], ["Interstitial", 1437], ["Cystitis", 1450], ["Symptom", 1459], ["Index", 1467], ["score", 1473], [",", 1478], ["micturition", 1480], ["frequency", 1492], ["or", 1502], ["mean", 1505], ["voided", 1510], ["volume", 1517], ["per", 1524], ["micturition", 1528], [".", 1539], ["The", 1541], ["most", 1545], ["common", 1550], ["adverse", 1557], ["events", 1565], ["were", 1572], ["headache", 1577], ["(", 1586], ["tanezumab", 1587], ["20.6", 1597], ["%", 1601], [",", 1602], ["placebo", 1604], ["16.7", 1612], ["%", 1616], [")", 1617], ["and", 1619], ["paresthesia", 1623], ["(", 1635], ["tanezumab", 1636], ["17.6", 1646], ["%", 1650], [",", 1651], ["placebo", 1653], ["3.3", 1661], ["%", 1664], [")", 1665], [".", 1666], ["Tanezumab", 1668], ["has", 1678], ["shown", 1682], ["preliminary", 1688], ["efficacy", 1700], ["in", 1709], ["the", 1712], ["treatment", 1716], ["of", 1726], ["pain", 1729], ["associated", 1734], ["with", 1745], ["interstitial", 1750], ["cystitis", 1763], [".", 1771]]}
{"context": "To validate the presence and demonstrate the clinical value of the type I interferon (IFN)-signature during arthritis development. In 115 seropositive arthralgia patients who were followed for the development of arthritis (Amsterdam Reade cohort), and 25 presymptomatic individuals who developed rheumatoid arthritis (RA) later, and 45 population-based controls (Northern Sweden cohort), the expression levels of 7 type I IFN response genes were determined with multiplex qPCR and an IFN-score was calculated. The diagnostic performance of the IFN-score was evaluated using Cox regression and Receiver Operating Characteristics (ROC)-curve analysis. In 44 of the 115 at-risk individuals (38%) from the Amsterdam Reade cohort, arthritis developed after a median period of 8 months (IQR 5-13). Stratification of these individuals based on the IFN-score revealed that 15 out of 25 IFN(high) individuals converted to arthritis, compared with 29 out of 90 IFN(low) individuals (p=0.011). In the Northern Sweden cohort, the level of the IFN-score was also significantly increased in presymptomatic individuals who developed RA compared with population-based controls (p=0.002). Cox regression analysis of the Amsterdam Reade cohort showed that the hazard ratio (HR) for development of arthritis was 2.38 (p=0.008) for IFN(high) at-risk individuals after correction for anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF). The ROC-curve area under the curve (AUC) for the IFN-score combined with ACPA and RF in the prediction of arthritis was 78.5% (p=0.0001, 95% CI 0.70 to 0.87). The results demonstrated clinical utility for the IFN-signature as a biomarker in the prediction of arthritis development.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["IFN-signature", "Interferon signature", "IFN signature"], "qid": "78f9bca0ee664b74b0be699e63138b9b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[307, 309]], "char_spans": [[1644, 1656]]}]}], "context_tokens": [["To", 0], ["validate", 3], ["the", 12], ["presence", 16], ["and", 25], ["demonstrate", 29], ["the", 41], ["clinical", 45], ["value", 54], ["of", 60], ["the", 63], ["type", 67], ["I", 72], ["interferon", 74], ["(", 85], ["IFN)-signature", 86], ["during", 101], ["arthritis", 108], ["development", 118], [".", 129], ["In", 131], ["115", 134], ["seropositive", 138], ["arthralgia", 151], ["patients", 162], ["who", 171], ["were", 175], ["followed", 180], ["for", 189], ["the", 193], ["development", 197], ["of", 209], ["arthritis", 212], ["(", 222], ["Amsterdam", 223], ["Reade", 233], ["cohort", 239], [")", 245], [",", 246], ["and", 248], ["25", 252], ["presymptomatic", 255], ["individuals", 270], ["who", 282], ["developed", 286], ["rheumatoid", 296], ["arthritis", 307], ["(", 317], ["RA", 318], [")", 320], ["later", 322], [",", 327], ["and", 329], ["45", 333], ["population", 336], ["-", 346], ["based", 347], ["controls", 353], ["(", 362], ["Northern", 363], ["Sweden", 372], ["cohort", 379], [")", 385], [",", 386], ["the", 388], ["expression", 392], ["levels", 403], ["of", 410], ["7", 413], ["type", 415], ["I", 420], ["IFN", 422], ["response", 426], ["genes", 435], ["were", 441], ["determined", 446], ["with", 457], ["multiplex", 462], ["qPCR", 472], ["and", 477], ["an", 481], ["IFN", 484], ["-", 487], ["score", 488], ["was", 494], ["calculated", 498], [".", 508], ["The", 510], ["diagnostic", 514], ["performance", 525], ["of", 537], ["the", 540], ["IFN", 544], ["-", 547], ["score", 548], ["was", 554], ["evaluated", 558], ["using", 568], ["Cox", 574], ["regression", 578], ["and", 589], ["Receiver", 593], ["Operating", 602], ["Characteristics", 612], ["(", 628], ["ROC)-curve", 629], ["analysis", 640], [".", 648], ["In", 650], ["44", 653], ["of", 656], ["the", 659], ["115", 663], ["at", 667], ["-", 669], ["risk", 670], ["individuals", 675], ["(", 687], ["38", 688], ["%", 690], [")", 691], ["from", 693], ["the", 698], ["Amsterdam", 702], ["Reade", 712], ["cohort", 718], [",", 724], ["arthritis", 726], ["developed", 736], ["after", 746], ["a", 752], ["median", 754], ["period", 761], ["of", 768], ["8", 771], ["months", 773], ["(", 780], ["IQR", 781], ["5", 785], ["-", 786], ["13", 787], [")", 789], [".", 790], ["Stratification", 792], ["of", 807], ["these", 810], ["individuals", 816], ["based", 828], ["on", 834], ["the", 837], ["IFN", 841], ["-", 844], ["score", 845], ["revealed", 851], ["that", 860], ["15", 865], ["out", 868], ["of", 872], ["25", 875], ["IFN(high", 878], [")", 886], ["individuals", 888], ["converted", 900], ["to", 910], ["arthritis", 913], [",", 922], ["compared", 924], ["with", 933], ["29", 938], ["out", 941], ["of", 945], ["90", 948], ["IFN(low", 951], [")", 958], ["individuals", 960], ["(", 972], ["p=0.011", 973], [")", 980], [".", 981], ["In", 983], ["the", 986], ["Northern", 990], ["Sweden", 999], ["cohort", 1006], [",", 1012], ["the", 1014], ["level", 1018], ["of", 1024], ["the", 1027], ["IFN", 1031], ["-", 1034], ["score", 1035], ["was", 1041], ["also", 1045], ["significantly", 1050], ["increased", 1064], ["in", 1074], ["presymptomatic", 1077], ["individuals", 1092], ["who", 1104], ["developed", 1108], ["RA", 1118], ["compared", 1121], ["with", 1130], ["population", 1135], ["-", 1145], ["based", 1146], ["controls", 1152], ["(", 1161], ["p=0.002", 1162], [")", 1169], [".", 1170], ["Cox", 1172], ["regression", 1176], ["analysis", 1187], ["of", 1196], ["the", 1199], ["Amsterdam", 1203], ["Reade", 1213], ["cohort", 1219], ["showed", 1226], ["that", 1233], ["the", 1238], ["hazard", 1242], ["ratio", 1249], ["(", 1255], ["HR", 1256], [")", 1258], ["for", 1260], ["development", 1264], ["of", 1276], ["arthritis", 1279], ["was", 1289], ["2.38", 1293], ["(", 1298], ["p=0.008", 1299], [")", 1306], ["for", 1308], ["IFN(high", 1312], [")", 1320], ["at", 1322], ["-", 1324], ["risk", 1325], ["individuals", 1330], ["after", 1342], ["correction", 1348], ["for", 1359], ["anticitrullinated", 1363], ["protein", 1381], ["antibodies", 1389], ["(", 1400], ["ACPA", 1401], [")", 1405], ["and", 1407], ["rheumatoid", 1411], ["factor", 1422], ["(", 1429], ["RF", 1430], [")", 1432], [".", 1433], ["The", 1435], ["ROC", 1439], ["-", 1442], ["curve", 1443], ["area", 1449], ["under", 1454], ["the", 1460], ["curve", 1464], ["(", 1470], ["AUC", 1471], [")", 1474], ["for", 1476], ["the", 1480], ["IFN", 1484], ["-", 1487], ["score", 1488], ["combined", 1494], ["with", 1503], ["ACPA", 1508], ["and", 1513], ["RF", 1517], ["in", 1520], ["the", 1523], ["prediction", 1527], ["of", 1538], ["arthritis", 1541], ["was", 1551], ["78.5", 1555], ["%", 1559], ["(", 1561], ["p=0.0001", 1562], [",", 1570], ["95", 1572], ["%", 1574], ["CI", 1576], ["0.70", 1579], ["to", 1584], ["0.87", 1587], [")", 1591], [".", 1592], ["The", 1594], ["results", 1598], ["demonstrated", 1606], ["clinical", 1619], ["utility", 1628], ["for", 1636], ["the", 1640], ["IFN", 1644], ["-", 1647], ["signature", 1648], ["as", 1658], ["a", 1661], ["biomarker", 1663], ["in", 1673], ["the", 1676], ["prediction", 1680], ["of", 1691], ["arthritis", 1694], ["development", 1704], [".", 1715]]}
{"context": "Aging research in vertebrates is hampered by the lack of short-lived models. Annual fishes of the genus Nothobranchius live in East African seasonal ponds. Their life expectancy in the wild is limited by the duration of the wet season and their lifespan in captivity is also short. Nothobranchius are popular aquarium fishes and many different species are kept as captive strains, providing rich material for comparative studies. The present paper aims at reviving the interest in these fishes by reporting that: (1) Nothobranchius can be cultured, and their eggs stored dry at room temperature for months or years, offering inexpensive methods of embryo storage; (2) Nothobranchius show accelerated growth and expression of aging biomarkers at the level of histology and behaviour; (3) the species Nothobranchius furzeri has a maximum lifespan of only 3 months and offers the possibility to perform investigations thus far unthinkable in a vertebrate, such as drug screening with life-long pharmacological treatments and experimental evolution; (4) when the lifespan of different species is compared, a general correlation is found between wet season duration in their natural habitat and longevity in captivity; and (5) vertebrate aging-related genes, such as p66Shc and MTP, can be easily isolated in Nothobranchius by homology cloning. These fishes can become excellent models for aging studies. They can be employed to test the effects of experimental manipulation on aging at a pace comparable with that of Drosophila and to probe the effects of natural selection on the evolution of aging-related genes.", "qas": [{"question": "What can Nothobranchius furzeri be used as a model system for?", "answers": ["aging research"], "qid": "ea59c7ee76424a47bdecc74c9987666f", "question_tokens": [["What", 0], ["can", 5], ["Nothobranchius", 9], ["furzeri", 24], ["be", 32], ["used", 35], ["as", 40], ["a", 43], ["model", 45], ["system", 51], ["for", 58], ["?", 61]], "detected_answers": [{"text": "aging research", "token_spans": [[0, 1]], "char_spans": [[0, 13]]}]}], "context_tokens": [["Aging", 0], ["research", 6], ["in", 15], ["vertebrates", 18], ["is", 30], ["hampered", 33], ["by", 42], ["the", 45], ["lack", 49], ["of", 54], ["short", 57], ["-", 62], ["lived", 63], ["models", 69], [".", 75], ["Annual", 77], ["fishes", 84], ["of", 91], ["the", 94], ["genus", 98], ["Nothobranchius", 104], ["live", 119], ["in", 124], ["East", 127], ["African", 132], ["seasonal", 140], ["ponds", 149], [".", 154], ["Their", 156], ["life", 162], ["expectancy", 167], ["in", 178], ["the", 181], ["wild", 185], ["is", 190], ["limited", 193], ["by", 201], ["the", 204], ["duration", 208], ["of", 217], ["the", 220], ["wet", 224], ["season", 228], ["and", 235], ["their", 239], ["lifespan", 245], ["in", 254], ["captivity", 257], ["is", 267], ["also", 270], ["short", 275], [".", 280], ["Nothobranchius", 282], ["are", 297], ["popular", 301], ["aquarium", 309], ["fishes", 318], ["and", 325], ["many", 329], ["different", 334], ["species", 344], ["are", 352], ["kept", 356], ["as", 361], ["captive", 364], ["strains", 372], [",", 379], ["providing", 381], ["rich", 391], ["material", 396], ["for", 405], ["comparative", 409], ["studies", 421], [".", 428], ["The", 430], ["present", 434], ["paper", 442], ["aims", 448], ["at", 453], ["reviving", 456], ["the", 465], ["interest", 469], ["in", 478], ["these", 481], ["fishes", 487], ["by", 494], ["reporting", 497], ["that", 507], [":", 511], ["(", 513], ["1", 514], [")", 515], ["Nothobranchius", 517], ["can", 532], ["be", 536], ["cultured", 539], [",", 547], ["and", 549], ["their", 553], ["eggs", 559], ["stored", 564], ["dry", 571], ["at", 575], ["room", 578], ["temperature", 583], ["for", 595], ["months", 599], ["or", 606], ["years", 609], [",", 614], ["offering", 616], ["inexpensive", 625], ["methods", 637], ["of", 645], ["embryo", 648], ["storage", 655], [";", 662], ["(", 664], ["2", 665], [")", 666], ["Nothobranchius", 668], ["show", 683], ["accelerated", 688], ["growth", 700], ["and", 707], ["expression", 711], ["of", 722], ["aging", 725], ["biomarkers", 731], ["at", 742], ["the", 745], ["level", 749], ["of", 755], ["histology", 758], ["and", 768], ["behaviour", 772], [";", 781], ["(", 783], ["3", 784], [")", 785], ["the", 787], ["species", 791], ["Nothobranchius", 799], ["furzeri", 814], ["has", 822], ["a", 826], ["maximum", 828], ["lifespan", 836], ["of", 845], ["only", 848], ["3", 853], ["months", 855], ["and", 862], ["offers", 866], ["the", 873], ["possibility", 877], ["to", 889], ["perform", 892], ["investigations", 900], ["thus", 915], ["far", 920], ["unthinkable", 924], ["in", 936], ["a", 939], ["vertebrate", 941], [",", 951], ["such", 953], ["as", 958], ["drug", 961], ["screening", 966], ["with", 976], ["life", 981], ["-", 985], ["long", 986], ["pharmacological", 991], ["treatments", 1007], ["and", 1018], ["experimental", 1022], ["evolution", 1035], [";", 1044], ["(", 1046], ["4", 1047], [")", 1048], ["when", 1050], ["the", 1055], ["lifespan", 1059], ["of", 1068], ["different", 1071], ["species", 1081], ["is", 1089], ["compared", 1092], [",", 1100], ["a", 1102], ["general", 1104], ["correlation", 1112], ["is", 1124], ["found", 1127], ["between", 1133], ["wet", 1141], ["season", 1145], ["duration", 1152], ["in", 1161], ["their", 1164], ["natural", 1170], ["habitat", 1178], ["and", 1186], ["longevity", 1190], ["in", 1200], ["captivity", 1203], [";", 1212], ["and", 1214], ["(", 1218], ["5", 1219], [")", 1220], ["vertebrate", 1222], ["aging", 1233], ["-", 1238], ["related", 1239], ["genes", 1247], [",", 1252], ["such", 1254], ["as", 1259], ["p66Shc", 1262], ["and", 1269], ["MTP", 1273], [",", 1276], ["can", 1278], ["be", 1282], ["easily", 1285], ["isolated", 1292], ["in", 1301], ["Nothobranchius", 1304], ["by", 1319], ["homology", 1322], ["cloning", 1331], [".", 1338], ["These", 1340], ["fishes", 1346], ["can", 1353], ["become", 1357], ["excellent", 1364], ["models", 1374], ["for", 1381], ["aging", 1385], ["studies", 1391], [".", 1398], ["They", 1400], ["can", 1405], ["be", 1409], ["employed", 1412], ["to", 1421], ["test", 1424], ["the", 1429], ["effects", 1433], ["of", 1441], ["experimental", 1444], ["manipulation", 1457], ["on", 1470], ["aging", 1473], ["at", 1479], ["a", 1482], ["pace", 1484], ["comparable", 1489], ["with", 1500], ["that", 1505], ["of", 1510], ["Drosophila", 1513], ["and", 1524], ["to", 1528], ["probe", 1531], ["the", 1537], ["effects", 1541], ["of", 1549], ["natural", 1552], ["selection", 1560], ["on", 1570], ["the", 1573], ["evolution", 1577], ["of", 1587], ["aging", 1590], ["-", 1595], ["related", 1596], ["genes", 1604], [".", 1609]]}
{"context": "Selenoprotein P is a protein of considerable intrigue, due to its unusual composition and requirements for its biosynthesis. Whereas most selenoproteins contain a single selenocysteine residue, the human, bovine and rodent selenoprotein P genes encode proteins containing 10-12 selenocysteines. Selenoprotein P genes have, to date, only been reported in mammals, and the function of the protein remains elusive. Herein, we report the identification and characterization of nonmammalian selenoprotein P in the zebrafish Danio rerio. Sequencing of the cDNA revealed the presence of 17 selenocysteine codons, the highest number reported in any protein. Two histidine-rich regions present in the mammalian selenoprotein P sequences are conserved in the zebrafish protein, and two SECIS elements are present in the 3' untranslated region. Whole-mount in situ hybridization of zebrafish embryos revealed high levels of expression of selenoprotein P mRNA in fertilized eggs and in the yolk sac of developing embryos. Transient transfection of the cDNA in mammalian cells resulted in efficient expression of the full-length secreted selenoprotein. A single N-glycosylation site is predicted, and shown to be utilized. Discovery of selenoprotein P in the zebrafish opens a previously unavailable avenue for genetic investigation of the functions of this unusual protein.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "b54a930870644fa1b3afc3f2c6bb1029", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[0, 1], [154, 155], [116, 117], [79, 80], [46, 47], [206, 207], [35, 36]], "char_spans": [[0, 14], [927, 941], [702, 716], [486, 500], [295, 309], [1223, 1237], [223, 237]]}]}], "context_tokens": [["Selenoprotein", 0], ["P", 14], ["is", 16], ["a", 19], ["protein", 21], ["of", 29], ["considerable", 32], ["intrigue", 45], [",", 53], ["due", 55], ["to", 59], ["its", 62], ["unusual", 66], ["composition", 74], ["and", 86], ["requirements", 90], ["for", 103], ["its", 107], ["biosynthesis", 111], [".", 123], ["Whereas", 125], ["most", 133], ["selenoproteins", 138], ["contain", 153], ["a", 161], ["single", 163], ["selenocysteine", 170], ["residue", 185], [",", 192], ["the", 194], ["human", 198], [",", 203], ["bovine", 205], ["and", 212], ["rodent", 216], ["selenoprotein", 223], ["P", 237], ["genes", 239], ["encode", 245], ["proteins", 252], ["containing", 261], ["10", 272], ["-", 274], ["12", 275], ["selenocysteines", 278], [".", 293], ["Selenoprotein", 295], ["P", 309], ["genes", 311], ["have", 317], [",", 321], ["to", 323], ["date", 326], [",", 330], ["only", 332], ["been", 337], ["reported", 342], ["in", 351], ["mammals", 354], [",", 361], ["and", 363], ["the", 367], ["function", 371], ["of", 380], ["the", 383], ["protein", 387], ["remains", 395], ["elusive", 403], [".", 410], ["Herein", 412], [",", 418], ["we", 420], ["report", 423], ["the", 430], ["identification", 434], ["and", 449], ["characterization", 453], ["of", 470], ["nonmammalian", 473], ["selenoprotein", 486], ["P", 500], ["in", 502], ["the", 505], ["zebrafish", 509], ["Danio", 519], ["rerio", 525], [".", 530], ["Sequencing", 532], ["of", 543], ["the", 546], ["cDNA", 550], ["revealed", 555], ["the", 564], ["presence", 568], ["of", 577], ["17", 580], ["selenocysteine", 583], ["codons", 598], [",", 604], ["the", 606], ["highest", 610], ["number", 618], ["reported", 625], ["in", 634], ["any", 637], ["protein", 641], [".", 648], ["Two", 650], ["histidine", 654], ["-", 663], ["rich", 664], ["regions", 669], ["present", 677], ["in", 685], ["the", 688], ["mammalian", 692], ["selenoprotein", 702], ["P", 716], ["sequences", 718], ["are", 728], ["conserved", 732], ["in", 742], ["the", 745], ["zebrafish", 749], ["protein", 759], [",", 766], ["and", 768], ["two", 772], ["SECIS", 776], ["elements", 782], ["are", 791], ["present", 795], ["in", 803], ["the", 806], ["3", 810], ["'", 811], ["untranslated", 813], ["region", 826], [".", 832], ["Whole", 834], ["-", 839], ["mount", 840], ["in", 846], ["situ", 849], ["hybridization", 854], ["of", 868], ["zebrafish", 871], ["embryos", 881], ["revealed", 889], ["high", 898], ["levels", 903], ["of", 910], ["expression", 913], ["of", 924], ["selenoprotein", 927], ["P", 941], ["mRNA", 943], ["in", 948], ["fertilized", 951], ["eggs", 962], ["and", 967], ["in", 971], ["the", 974], ["yolk", 978], ["sac", 983], ["of", 987], ["developing", 990], ["embryos", 1001], [".", 1008], ["Transient", 1010], ["transfection", 1020], ["of", 1033], ["the", 1036], ["cDNA", 1040], ["in", 1045], ["mammalian", 1048], ["cells", 1058], ["resulted", 1064], ["in", 1073], ["efficient", 1076], ["expression", 1086], ["of", 1097], ["the", 1100], ["full", 1104], ["-", 1108], ["length", 1109], ["secreted", 1116], ["selenoprotein", 1125], [".", 1138], ["A", 1140], ["single", 1142], ["N", 1149], ["-", 1150], ["glycosylation", 1151], ["site", 1165], ["is", 1170], ["predicted", 1173], [",", 1182], ["and", 1184], ["shown", 1188], ["to", 1194], ["be", 1197], ["utilized", 1200], [".", 1208], ["Discovery", 1210], ["of", 1220], ["selenoprotein", 1223], ["P", 1237], ["in", 1239], ["the", 1242], ["zebrafish", 1246], ["opens", 1256], ["a", 1262], ["previously", 1264], ["unavailable", 1275], ["avenue", 1287], ["for", 1294], ["genetic", 1298], ["investigation", 1306], ["of", 1320], ["the", 1323], ["functions", 1327], ["of", 1337], ["this", 1340], ["unusual", 1345], ["protein", 1353], [".", 1360]]}
{"context": "Lack of specific antidotes is a major concern in intracerebral hemorrhage (ICH) related to direct anticoagulants including dabigatran (OAC-ICH). We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab. Pretreatment with DE increased intracerebral hematoma volume and cerebral hemoglobin content. Idarucizumab in equimolar dose prevented excess hematoma expansion for both DE doses. In more extensive ICH, idarucizumab significantly reduced mortality. Thus, idarucizumab prevents excess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.", "qas": [{"question": "Idarucizumab is an antidote of which drug?", "answers": ["dabigatran"], "qid": "37ea67d513cc47e680a8cad150662beb", "question_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antidote", 19], ["of", 28], ["which", 31], ["drug", 37], ["?", 41]], "detected_answers": [{"text": "dabigatran", "token_spans": [[121, 121], [19, 19], [49, 49], [38, 38]], "char_spans": [[746, 755], [123, 132], [260, 269], [219, 228]]}]}], "context_tokens": [["Lack", 0], ["of", 5], ["specific", 8], ["antidotes", 17], ["is", 27], ["a", 30], ["major", 32], ["concern", 38], ["in", 46], ["intracerebral", 49], ["hemorrhage", 63], ["(", 74], ["ICH", 75], [")", 78], ["related", 80], ["to", 88], ["direct", 91], ["anticoagulants", 98], ["including", 113], ["dabigatran", 123], ["(", 134], ["OAC", 135], ["-", 138], ["ICH", 139], [")", 142], [".", 143], ["We", 145], ["examined", 148], ["the", 157], ["efficacy", 161], ["of", 170], ["idarucizumab", 173], [",", 185], ["an", 187], ["antibody", 190], ["fragment", 199], ["binding", 208], ["to", 216], ["dabigatran", 219], [",", 229], ["in", 231], ["a", 234], ["mouse", 236], ["model", 242], ["of", 248], ["OAC", 251], ["-", 254], ["ICH", 255], [".", 258], ["Dabigatran", 260], ["etexilate", 271], ["(", 281], ["DE", 282], [")", 284], ["dose", 286], ["-", 290], ["dependently", 291], ["prolonged", 303], ["diluted", 313], ["thrombin", 321], ["time", 330], ["and", 335], ["tail", 339], ["-", 343], ["vein", 344], ["bleeding", 349], ["time", 358], [",", 362], ["which", 364], ["were", 370], ["reversed", 375], ["by", 384], ["idarucizumab", 387], [".", 399], ["Pretreatment", 401], ["with", 414], ["DE", 419], ["increased", 422], ["intracerebral", 432], ["hematoma", 446], ["volume", 455], ["and", 462], ["cerebral", 466], ["hemoglobin", 475], ["content", 486], [".", 493], ["Idarucizumab", 495], ["in", 508], ["equimolar", 511], ["dose", 521], ["prevented", 526], ["excess", 536], ["hematoma", 543], ["expansion", 552], ["for", 562], ["both", 566], ["DE", 571], ["doses", 574], [".", 579], ["In", 581], ["more", 584], ["extensive", 589], ["ICH", 599], [",", 602], ["idarucizumab", 604], ["significantly", 617], ["reduced", 631], ["mortality", 639], [".", 648], ["Thus", 650], [",", 654], ["idarucizumab", 656], ["prevents", 669], ["excess", 678], ["intracerebral", 685], ["hematoma", 699], ["formation", 708], ["in", 718], ["mice", 721], ["anticoagulated", 726], ["with", 741], ["dabigatran", 746], ["and", 757], ["reduces", 761], ["mortality", 769], [".", 778]]}
{"context": "Lewy bodies, neuropathological hallmarks of Parkinson's disease and dementia with Lewy bodies, comprise alpha-synuclein filaments and other less defined proteins. Characterization of Lewy body proteins that interact with alpha-synuclein may provide insight into the mechanism of Lewy body formation. Double immunofluorescence labeling and confocal microscopy revealed approximately 80% of cortical Lewy bodies contained microtubule-associated protein 1B (MAP-1B) that overlapped with alpha-synuclein. Lewy bodies were isolated using an immunomagnetic technique from brain tissue of patients dying with dementia with Lewy bodies. Lewy body proteins were resolved by polyacrylamide gel electrophoresis. Immunoblotting confirmed the presence of MAP-1B and alpha-synuclein in purified Lewy bodies. Direct binding studies revealed a high affinity interaction (IC(50) approximately 20 nm) between MAP-1B and alpha-synuclein. The MAP-1B-binding sites were mapped to the last 45 amino acids of the alpha-synuclein C terminus. MAP-1B also bound in vitro assembled alpha-synuclein fibrils. Thus, MAP-1B may be involved in the pathogenesis of Lewy bodies via its interaction with monomeric and fibrillar alpha-synuclein.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "61399ac72d9a4c4397aa7b80ee902d25", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[172, 174], [196, 198], [141, 143], [74, 76], [16, 18], [160, 162], [34, 36], [115, 117]], "char_spans": [[1055, 1069], [1193, 1207], [902, 916], [484, 498], [104, 118], [990, 1004], [221, 235], [753, 767]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], [",", 11], ["neuropathological", 13], ["hallmarks", 31], ["of", 41], ["Parkinson", 44], ["'s", 53], ["disease", 56], ["and", 64], ["dementia", 68], ["with", 77], ["Lewy", 82], ["bodies", 87], [",", 93], ["comprise", 95], ["alpha", 104], ["-", 109], ["synuclein", 110], ["filaments", 120], ["and", 130], ["other", 134], ["less", 140], ["defined", 145], ["proteins", 153], [".", 161], ["Characterization", 163], ["of", 180], ["Lewy", 183], ["body", 188], ["proteins", 193], ["that", 202], ["interact", 207], ["with", 216], ["alpha", 221], ["-", 226], ["synuclein", 227], ["may", 237], ["provide", 241], ["insight", 249], ["into", 257], ["the", 262], ["mechanism", 266], ["of", 276], ["Lewy", 279], ["body", 284], ["formation", 289], [".", 298], ["Double", 300], ["immunofluorescence", 307], ["labeling", 326], ["and", 335], ["confocal", 339], ["microscopy", 348], ["revealed", 359], ["approximately", 368], ["80", 382], ["%", 384], ["of", 386], ["cortical", 389], ["Lewy", 398], ["bodies", 403], ["contained", 410], ["microtubule", 420], ["-", 431], ["associated", 432], ["protein", 443], ["1B", 451], ["(", 454], ["MAP-1B", 455], [")", 461], ["that", 463], ["overlapped", 468], ["with", 479], ["alpha", 484], ["-", 489], ["synuclein", 490], [".", 499], ["Lewy", 501], ["bodies", 506], ["were", 513], ["isolated", 518], ["using", 527], ["an", 533], ["immunomagnetic", 536], ["technique", 551], ["from", 561], ["brain", 566], ["tissue", 572], ["of", 579], ["patients", 582], ["dying", 591], ["with", 597], ["dementia", 602], ["with", 611], ["Lewy", 616], ["bodies", 621], [".", 627], ["Lewy", 629], ["body", 634], ["proteins", 639], ["were", 648], ["resolved", 653], ["by", 662], ["polyacrylamide", 665], ["gel", 680], ["electrophoresis", 684], [".", 699], ["Immunoblotting", 701], ["confirmed", 716], ["the", 726], ["presence", 730], ["of", 739], ["MAP-1B", 742], ["and", 749], ["alpha", 753], ["-", 758], ["synuclein", 759], ["in", 769], ["purified", 772], ["Lewy", 781], ["bodies", 786], [".", 792], ["Direct", 794], ["binding", 801], ["studies", 809], ["revealed", 817], ["a", 826], ["high", 828], ["affinity", 833], ["interaction", 842], ["(", 854], ["IC(50", 855], [")", 860], ["approximately", 862], ["20", 876], ["nm", 879], [")", 881], ["between", 883], ["MAP-1B", 891], ["and", 898], ["alpha", 902], ["-", 907], ["synuclein", 908], [".", 917], ["The", 919], ["MAP-1B", 923], ["-", 929], ["binding", 930], ["sites", 938], ["were", 944], ["mapped", 949], ["to", 956], ["the", 959], ["last", 963], ["45", 968], ["amino", 971], ["acids", 977], ["of", 983], ["the", 986], ["alpha", 990], ["-", 995], ["synuclein", 996], ["C", 1006], ["terminus", 1008], [".", 1016], ["MAP-1B", 1018], ["also", 1025], ["bound", 1030], ["in", 1036], ["vitro", 1039], ["assembled", 1045], ["alpha", 1055], ["-", 1060], ["synuclein", 1061], ["fibrils", 1071], [".", 1078], ["Thus", 1080], [",", 1084], ["MAP-1B", 1086], ["may", 1093], ["be", 1097], ["involved", 1100], ["in", 1109], ["the", 1112], ["pathogenesis", 1116], ["of", 1129], ["Lewy", 1132], ["bodies", 1137], ["via", 1144], ["its", 1148], ["interaction", 1152], ["with", 1164], ["monomeric", 1169], ["and", 1179], ["fibrillar", 1183], ["alpha", 1193], ["-", 1198], ["synuclein", 1199], [".", 1208]]}
{"context": "Focusing on three Anglo-American outbreaks of industrial anthrax, this essay engages the question of how local circumstances influenced the transmission of scientific knowledge in the late nineteenth century. Walpole (Massachusetts), Glasgow, and Bradford (Yorkshire) served as important nodes of transnational investigation into anthrax. Knowledge about the morphology and behavior of Bacillus anthracis changed little while in transit between these nodes, even during complex debates about the nature of bacterial morphology, disease causation, and spontaneous generation. Working independently of their more famous counterparts (Robert Koch and Louis Pasteur), Anglo-American anthrax investigators used visual representations of anthrax bacilli to persuade their peers that a specific, identifiable cause produced all forms of anthrax-malignant pustule (cutaneous anthrax), intestinal anthrax, and woolsorter's disease (pneumonic anthrax). By the late 1870s, this point of view also supported what we would today call an ecological notion of the disease's origins in the interactions of people, animals, and microorganisms in the context of global commerce.", "qas": [{"question": "What organism causes woolsorter's disease", "answers": ["Bacillus Anthracis"], "qid": "7cb5e988b4514ab3944739cfd8b67239", "question_tokens": [["What", 0], ["organism", 5], ["causes", 14], ["woolsorter", 21], ["'s", 31], ["disease", 34]], "detected_answers": [{"text": "Bacillus Anthracis", "token_spans": [[61, 62]], "char_spans": [[386, 403]]}]}], "context_tokens": [["Focusing", 0], ["on", 9], ["three", 12], ["Anglo", 18], ["-", 23], ["American", 24], ["outbreaks", 33], ["of", 43], ["industrial", 46], ["anthrax", 57], [",", 64], ["this", 66], ["essay", 71], ["engages", 77], ["the", 85], ["question", 89], ["of", 98], ["how", 101], ["local", 105], ["circumstances", 111], ["influenced", 125], ["the", 136], ["transmission", 140], ["of", 153], ["scientific", 156], ["knowledge", 167], ["in", 177], ["the", 180], ["late", 184], ["nineteenth", 189], ["century", 200], [".", 207], ["Walpole", 209], ["(", 217], ["Massachusetts", 218], [")", 231], [",", 232], ["Glasgow", 234], [",", 241], ["and", 243], ["Bradford", 247], ["(", 256], ["Yorkshire", 257], [")", 266], ["served", 268], ["as", 275], ["important", 278], ["nodes", 288], ["of", 294], ["transnational", 297], ["investigation", 311], ["into", 325], ["anthrax", 330], [".", 337], ["Knowledge", 339], ["about", 349], ["the", 355], ["morphology", 359], ["and", 370], ["behavior", 374], ["of", 383], ["Bacillus", 386], ["anthracis", 395], ["changed", 405], ["little", 413], ["while", 420], ["in", 426], ["transit", 429], ["between", 437], ["these", 445], ["nodes", 451], [",", 456], ["even", 458], ["during", 463], ["complex", 470], ["debates", 478], ["about", 486], ["the", 492], ["nature", 496], ["of", 503], ["bacterial", 506], ["morphology", 516], [",", 526], ["disease", 528], ["causation", 536], [",", 545], ["and", 547], ["spontaneous", 551], ["generation", 563], [".", 573], ["Working", 575], ["independently", 583], ["of", 597], ["their", 600], ["more", 606], ["famous", 611], ["counterparts", 618], ["(", 631], ["Robert", 632], ["Koch", 639], ["and", 644], ["Louis", 648], ["Pasteur", 654], [")", 661], [",", 662], ["Anglo", 664], ["-", 669], ["American", 670], ["anthrax", 679], ["investigators", 687], ["used", 701], ["visual", 706], ["representations", 713], ["of", 729], ["anthrax", 732], ["bacilli", 740], ["to", 748], ["persuade", 751], ["their", 760], ["peers", 766], ["that", 772], ["a", 777], ["specific", 779], [",", 787], ["identifiable", 789], ["cause", 802], ["produced", 808], ["all", 817], ["forms", 821], ["of", 827], ["anthrax", 830], ["-", 837], ["malignant", 838], ["pustule", 848], ["(", 856], ["cutaneous", 857], ["anthrax", 867], [")", 874], [",", 875], ["intestinal", 877], ["anthrax", 888], [",", 895], ["and", 897], ["woolsorter", 901], ["'s", 911], ["disease", 914], ["(", 922], ["pneumonic", 923], ["anthrax", 933], [")", 940], [".", 941], ["By", 943], ["the", 946], ["late", 950], ["1870s", 955], [",", 960], ["this", 962], ["point", 967], ["of", 973], ["view", 976], ["also", 981], ["supported", 986], ["what", 996], ["we", 1001], ["would", 1004], ["today", 1010], ["call", 1016], ["an", 1021], ["ecological", 1024], ["notion", 1035], ["of", 1042], ["the", 1045], ["disease", 1049], ["'s", 1056], ["origins", 1059], ["in", 1067], ["the", 1070], ["interactions", 1074], ["of", 1087], ["people", 1090], [",", 1096], ["animals", 1098], [",", 1105], ["and", 1107], ["microorganisms", 1111], ["in", 1126], ["the", 1129], ["context", 1133], ["of", 1141], ["global", 1144], ["commerce", 1151], [".", 1159]]}
{"context": "The superoxide-producing phagocyte NADPH oxidase gp91(phox)/Nox2 and the non-phagocytic oxidases Nox1 and Nox3 each form a complex in the membrane with p22(phox), which provides both stabilization and a docking site for organizer proteins. The p22(phox)-complexed Nox2 and Nox1 are dormant on their own, and their activation requires soluble supportive proteins such as a Nox organizer (p47(phox) or Noxo1) and a Nox activator (p67(phox) or Noxa1). The small GTPase Rac directly binds to the activators, and thus plays an essential role in the Nox2-based oxidase containing p47(phox) and p67(phox) or a positive role in Nox1 activity supported by Noxo1 and Noxa1. Although Nox3 complexed with p22(phox) constitutively produce superoxide, the production can be enhanced by supportive proteins. Here we compare the roles of Rac in these p22(phox)-dependent oxidases using the organizer and activator in different combinations. Expression of constitutively active Rac1(Q61L) is essential for activation of the Nox2- or Nox1-based oxidase containing the organizer p47(phox) and either p67(phox) or Noxa1. When these oxidases use Noxo1 as an organizer instead of p47(phox), they produce a small but significant amount of superoxide without expression of Rac1(Q61L), although the production is enhanced by Rac1(Q61L). Thus p47(phox) is likely related to strict dependence on Rac. The Nox3-based oxidase has a similar tendency in the change of the dependence: Rac plays a positive role in Nox3 activation in the presence of p47(phox) and either p67(phox) or Noxa1, whereas Rac fails to upregulate Nox3 activity when p47(phox) is replaced with Noxo1. We also demonstrate that, in the Nox3-based oxidase containing solely p67(phox) as supportive protein, expression of Rac1(Q61L) enhances not only superoxide production but also membrane translocation of p67(phox). Since the enhancements are not observed with a mutant p67(phox) defective in binding to Rac, this GTPase appear to directly recruit p67(phox) to the membrane.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "3e6978c75bef49edbd8b728bbe7b06de", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[44, 44], [111, 111], [14, 14]], "char_spans": [[273, 276], [620, 623], [97, 100]]}]}], "context_tokens": [["The", 0], ["superoxide", 4], ["-", 14], ["producing", 15], ["phagocyte", 25], ["NADPH", 35], ["oxidase", 41], ["gp91(phox)/Nox2", 49], ["and", 65], ["the", 69], ["non", 73], ["-", 76], ["phagocytic", 77], ["oxidases", 88], ["Nox1", 97], ["and", 102], ["Nox3", 106], ["each", 111], ["form", 116], ["a", 121], ["complex", 123], ["in", 131], ["the", 134], ["membrane", 138], ["with", 147], ["p22(phox", 152], [")", 160], [",", 161], ["which", 163], ["provides", 169], ["both", 178], ["stabilization", 183], ["and", 197], ["a", 201], ["docking", 203], ["site", 211], ["for", 216], ["organizer", 220], ["proteins", 230], [".", 238], ["The", 240], ["p22(phox)-complexed", 244], ["Nox2", 264], ["and", 269], ["Nox1", 273], ["are", 278], ["dormant", 282], ["on", 290], ["their", 293], ["own", 299], [",", 302], ["and", 304], ["their", 308], ["activation", 314], ["requires", 325], ["soluble", 334], ["supportive", 342], ["proteins", 353], ["such", 362], ["as", 367], ["a", 370], ["Nox", 372], ["organizer", 376], ["(", 386], ["p47(phox", 387], [")", 395], ["or", 397], ["Noxo1", 400], [")", 405], ["and", 407], ["a", 411], ["Nox", 413], ["activator", 417], ["(", 427], ["p67(phox", 428], [")", 436], ["or", 438], ["Noxa1", 441], [")", 446], [".", 447], ["The", 449], ["small", 453], ["GTPase", 459], ["Rac", 466], ["directly", 470], ["binds", 479], ["to", 485], ["the", 488], ["activators", 492], [",", 502], ["and", 504], ["thus", 508], ["plays", 513], ["an", 519], ["essential", 522], ["role", 532], ["in", 537], ["the", 540], ["Nox2-based", 544], ["oxidase", 555], ["containing", 563], ["p47(phox", 574], [")", 582], ["and", 584], ["p67(phox", 588], [")", 596], ["or", 598], ["a", 601], ["positive", 603], ["role", 612], ["in", 617], ["Nox1", 620], ["activity", 625], ["supported", 634], ["by", 644], ["Noxo1", 647], ["and", 653], ["Noxa1", 657], [".", 662], ["Although", 664], ["Nox3", 673], ["complexed", 678], ["with", 688], ["p22(phox", 693], [")", 701], ["constitutively", 703], ["produce", 718], ["superoxide", 726], [",", 736], ["the", 738], ["production", 742], ["can", 753], ["be", 757], ["enhanced", 760], ["by", 769], ["supportive", 772], ["proteins", 783], [".", 791], ["Here", 793], ["we", 798], ["compare", 801], ["the", 809], ["roles", 813], ["of", 819], ["Rac", 822], ["in", 826], ["these", 829], ["p22(phox)-dependent", 835], ["oxidases", 855], ["using", 864], ["the", 870], ["organizer", 874], ["and", 884], ["activator", 888], ["in", 898], ["different", 901], ["combinations", 911], [".", 923], ["Expression", 925], ["of", 936], ["constitutively", 939], ["active", 954], ["Rac1(Q61L", 961], [")", 970], ["is", 972], ["essential", 975], ["for", 985], ["activation", 989], ["of", 1000], ["the", 1003], ["Nox2-", 1007], ["or", 1013], ["Nox1-based", 1016], ["oxidase", 1027], ["containing", 1035], ["the", 1046], ["organizer", 1050], ["p47(phox", 1060], [")", 1068], ["and", 1070], ["either", 1074], ["p67(phox", 1081], [")", 1089], ["or", 1091], ["Noxa1", 1094], [".", 1099], ["When", 1101], ["these", 1106], ["oxidases", 1112], ["use", 1121], ["Noxo1", 1125], ["as", 1131], ["an", 1134], ["organizer", 1137], ["instead", 1147], ["of", 1155], ["p47(phox", 1158], [")", 1166], [",", 1167], ["they", 1169], ["produce", 1174], ["a", 1182], ["small", 1184], ["but", 1190], ["significant", 1194], ["amount", 1206], ["of", 1213], ["superoxide", 1216], ["without", 1227], ["expression", 1235], ["of", 1246], ["Rac1(Q61L", 1249], [")", 1258], [",", 1259], ["although", 1261], ["the", 1270], ["production", 1274], ["is", 1285], ["enhanced", 1288], ["by", 1297], ["Rac1(Q61L", 1300], [")", 1309], [".", 1310], ["Thus", 1312], ["p47(phox", 1317], [")", 1325], ["is", 1327], ["likely", 1330], ["related", 1337], ["to", 1345], ["strict", 1348], ["dependence", 1355], ["on", 1366], ["Rac", 1369], [".", 1372], ["The", 1374], ["Nox3-based", 1378], ["oxidase", 1389], ["has", 1397], ["a", 1401], ["similar", 1403], ["tendency", 1411], ["in", 1420], ["the", 1423], ["change", 1427], ["of", 1434], ["the", 1437], ["dependence", 1441], [":", 1451], ["Rac", 1453], ["plays", 1457], ["a", 1463], ["positive", 1465], ["role", 1474], ["in", 1479], ["Nox3", 1482], ["activation", 1487], ["in", 1498], ["the", 1501], ["presence", 1505], ["of", 1514], ["p47(phox", 1517], [")", 1525], ["and", 1527], ["either", 1531], ["p67(phox", 1538], [")", 1546], ["or", 1548], ["Noxa1", 1551], [",", 1556], ["whereas", 1558], ["Rac", 1566], ["fails", 1570], ["to", 1576], ["upregulate", 1579], ["Nox3", 1590], ["activity", 1595], ["when", 1604], ["p47(phox", 1609], [")", 1617], ["is", 1619], ["replaced", 1622], ["with", 1631], ["Noxo1", 1636], [".", 1641], ["We", 1643], ["also", 1646], ["demonstrate", 1651], ["that", 1663], [",", 1667], ["in", 1669], ["the", 1672], ["Nox3-based", 1676], ["oxidase", 1687], ["containing", 1695], ["solely", 1706], ["p67(phox", 1713], [")", 1721], ["as", 1723], ["supportive", 1726], ["protein", 1737], [",", 1744], ["expression", 1746], ["of", 1757], ["Rac1(Q61L", 1760], [")", 1769], ["enhances", 1771], ["not", 1780], ["only", 1784], ["superoxide", 1789], ["production", 1800], ["but", 1811], ["also", 1815], ["membrane", 1820], ["translocation", 1829], ["of", 1843], ["p67(phox", 1846], [")", 1854], [".", 1855], ["Since", 1857], ["the", 1863], ["enhancements", 1867], ["are", 1880], ["not", 1884], ["observed", 1888], ["with", 1897], ["a", 1902], ["mutant", 1904], ["p67(phox", 1911], [")", 1919], ["defective", 1921], ["in", 1931], ["binding", 1934], ["to", 1942], ["Rac", 1945], [",", 1948], ["this", 1950], ["GTPase", 1955], ["appear", 1962], ["to", 1969], ["directly", 1972], ["recruit", 1981], ["p67(phox", 1989], [")", 1997], ["to", 1999], ["the", 2002], ["membrane", 2006], [".", 2014]]}
{"context": "Normal B lymphocytes receive signals from B-cell antigen receptor (BCR) that are triggered by binding of the BCR to an external antigen. Tonic signaling through the BCR provides growth and signals to chronic lymphocytic leukemia (CLL) cells, and plays an important role in the pathogenesis and progression of the disease. Antigen engagement of BCR is followed by intracellular recruitment and activation of BCR-associated kinases including spleen tyrosine kinase (Syk), Bruton's tyrosine kinase (Btk) and phosphatidylinositol 3-kinases (PI3K). Inhibition of signaling pathways downstream of the BCR induces disruption of chemokine-mediated CLL cell migration and cell killing. BCR signal transduction inhibitors represent a promising new strategy for targeted CLL treatment. A number of therapeutic agents have recently been developed with significant activity in CLL. The compounds that are currently investigated in patients with CLL include ibrutinib -inhibitor of Btk, fostamatinib-inhibitor of Syk and idelalisib (GS-1101) -a specific isoform of the PI3K (PI3K) inhibitor. The clinical activity of ibrutinib, GS-1101 and fostamatinib in patients with CLL is associated with marked lymphocytosis due to release of tumor cells from the lymph nodes into the peripheral blood. Further studies are ongoing with single agents and their combinations with other targeted and conventional therapies. This article will review the preclinical rationale of BCR signaling inhibitors in the treatment of CLL, and the clinical evidence supporting the use of these agents in CLL patients.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "15acdfafb8db4713a4ed63acfd61cd30", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[76, 78]], "char_spans": [[440, 461]]}]}], "context_tokens": [["Normal", 0], ["B", 7], ["lymphocytes", 9], ["receive", 21], ["signals", 29], ["from", 37], ["B", 42], ["-", 43], ["cell", 44], ["antigen", 49], ["receptor", 57], ["(", 66], ["BCR", 67], [")", 70], ["that", 72], ["are", 77], ["triggered", 81], ["by", 91], ["binding", 94], ["of", 102], ["the", 105], ["BCR", 109], ["to", 113], ["an", 116], ["external", 119], ["antigen", 128], [".", 135], ["Tonic", 137], ["signaling", 143], ["through", 153], ["the", 161], ["BCR", 165], ["provides", 169], ["growth", 178], ["and", 185], ["signals", 189], ["to", 197], ["chronic", 200], ["lymphocytic", 208], ["leukemia", 220], ["(", 229], ["CLL", 230], [")", 233], ["cells", 235], [",", 240], ["and", 242], ["plays", 246], ["an", 252], ["important", 255], ["role", 265], ["in", 270], ["the", 273], ["pathogenesis", 277], ["and", 290], ["progression", 294], ["of", 306], ["the", 309], ["disease", 313], [".", 320], ["Antigen", 322], ["engagement", 330], ["of", 341], ["BCR", 344], ["is", 348], ["followed", 351], ["by", 360], ["intracellular", 363], ["recruitment", 377], ["and", 389], ["activation", 393], ["of", 404], ["BCR", 407], ["-", 410], ["associated", 411], ["kinases", 422], ["including", 430], ["spleen", 440], ["tyrosine", 447], ["kinase", 456], ["(", 463], ["Syk", 464], [")", 467], [",", 468], ["Bruton", 470], ["'s", 476], ["tyrosine", 479], ["kinase", 488], ["(", 495], ["Btk", 496], [")", 499], ["and", 501], ["phosphatidylinositol", 505], ["3-kinases", 526], ["(", 536], ["PI3", 537], ["K", 540], [")", 541], [".", 542], ["Inhibition", 544], ["of", 555], ["signaling", 558], ["pathways", 568], ["downstream", 577], ["of", 588], ["the", 591], ["BCR", 595], ["induces", 599], ["disruption", 607], ["of", 618], ["chemokine", 621], ["-", 630], ["mediated", 631], ["CLL", 640], ["cell", 644], ["migration", 649], ["and", 659], ["cell", 663], ["killing", 668], [".", 675], ["BCR", 677], ["signal", 681], ["transduction", 688], ["inhibitors", 701], ["represent", 712], ["a", 722], ["promising", 724], ["new", 734], ["strategy", 738], ["for", 747], ["targeted", 751], ["CLL", 760], ["treatment", 764], [".", 773], ["A", 775], ["number", 777], ["of", 784], ["therapeutic", 787], ["agents", 799], ["have", 806], ["recently", 811], ["been", 820], ["developed", 825], ["with", 835], ["significant", 840], ["activity", 852], ["in", 861], ["CLL", 864], [".", 867], ["The", 869], ["compounds", 873], ["that", 883], ["are", 888], ["currently", 892], ["investigated", 902], ["in", 915], ["patients", 918], ["with", 927], ["CLL", 932], ["include", 936], ["ibrutinib", 944], ["-inhibitor", 954], ["of", 965], ["Btk", 968], [",", 971], ["fostamatinib", 973], ["-", 985], ["inhibitor", 986], ["of", 996], ["Syk", 999], ["and", 1003], ["idelalisib", 1007], ["(", 1018], ["GS-1101", 1019], [")", 1026], ["-a", 1028], ["specific", 1031], ["isoform", 1040], ["of", 1048], ["the", 1051], ["PI3", 1055], ["K", 1058], ["(", 1060], ["PI3", 1061], ["K", 1064], [")", 1065], ["inhibitor", 1067], [".", 1076], ["The", 1078], ["clinical", 1082], ["activity", 1091], ["of", 1100], ["ibrutinib", 1103], [",", 1112], ["GS-1101", 1114], ["and", 1122], ["fostamatinib", 1126], ["in", 1139], ["patients", 1142], ["with", 1151], ["CLL", 1156], ["is", 1160], ["associated", 1163], ["with", 1174], ["marked", 1179], ["lymphocytosis", 1186], ["due", 1200], ["to", 1204], ["release", 1207], ["of", 1215], ["tumor", 1218], ["cells", 1224], ["from", 1230], ["the", 1235], ["lymph", 1239], ["nodes", 1245], ["into", 1251], ["the", 1256], ["peripheral", 1260], ["blood", 1271], [".", 1276], ["Further", 1278], ["studies", 1286], ["are", 1294], ["ongoing", 1298], ["with", 1306], ["single", 1311], ["agents", 1318], ["and", 1325], ["their", 1329], ["combinations", 1335], ["with", 1348], ["other", 1353], ["targeted", 1359], ["and", 1368], ["conventional", 1372], ["therapies", 1385], [".", 1394], ["This", 1396], ["article", 1401], ["will", 1409], ["review", 1414], ["the", 1421], ["preclinical", 1425], ["rationale", 1437], ["of", 1447], ["BCR", 1450], ["signaling", 1454], ["inhibitors", 1464], ["in", 1475], ["the", 1478], ["treatment", 1482], ["of", 1492], ["CLL", 1495], [",", 1498], ["and", 1500], ["the", 1504], ["clinical", 1508], ["evidence", 1517], ["supporting", 1526], ["the", 1537], ["use", 1541], ["of", 1545], ["these", 1548], ["agents", 1554], ["in", 1561], ["CLL", 1564], ["patients", 1568], [".", 1576]]}
{"context": "A study was performed to determine the utility of the 8-point recognition of stroke in the emergency room (ROSIER) instrument as a diagnostic tool in a large Irish emergency department. Fifty patients had ROSIER scores completed by doctors. Diagnoses achieved using the score were compared with discharge diagnoses. Relations between ROSIER score, impairment and length of stay were assessed. Forty-seven patients (94%) had a ROSIER Score > or =1 indicating a stroke, 44 (94%) of these had stroke confirmed on investigation. Two patients with stroke were missed and three were wrongly identified. Positive predictive value for the ROSIER was 94%. ROSIER correlated with Scandinavian neurological stroke score. (r = -0.414, p = 0.003) and was associated with increasing length of stay in survivors (p = 0.16, one-way ANOVA. F = 3.116, df = 6). The ROSIER is a suitable and useful adjunct in the assessment of stroke patients in Ireland.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "84e440c52ada4da9ab59b02ebf6421e1", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[13, 13], [179, 179], [102, 102], [84, 84], [126, 126], [94, 94]], "char_spans": [[77, 82], [908, 913], [543, 548], [460, 465], [696, 701], [490, 495]]}]}], "context_tokens": [["A", 0], ["study", 2], ["was", 8], ["performed", 12], ["to", 22], ["determine", 25], ["the", 35], ["utility", 39], ["of", 47], ["the", 50], ["8-point", 54], ["recognition", 62], ["of", 74], ["stroke", 77], ["in", 84], ["the", 87], ["emergency", 91], ["room", 101], ["(", 106], ["ROSIER", 107], [")", 113], ["instrument", 115], ["as", 126], ["a", 129], ["diagnostic", 131], ["tool", 142], ["in", 147], ["a", 150], ["large", 152], ["Irish", 158], ["emergency", 164], ["department", 174], [".", 184], ["Fifty", 186], ["patients", 192], ["had", 201], ["ROSIER", 205], ["scores", 212], ["completed", 219], ["by", 229], ["doctors", 232], [".", 239], ["Diagnoses", 241], ["achieved", 251], ["using", 260], ["the", 266], ["score", 270], ["were", 276], ["compared", 281], ["with", 290], ["discharge", 295], ["diagnoses", 305], [".", 314], ["Relations", 316], ["between", 326], ["ROSIER", 334], ["score", 341], [",", 346], ["impairment", 348], ["and", 359], ["length", 363], ["of", 370], ["stay", 373], ["were", 378], ["assessed", 383], [".", 391], ["Forty", 393], ["-", 398], ["seven", 399], ["patients", 405], ["(", 414], ["94", 415], ["%", 417], [")", 418], ["had", 420], ["a", 424], ["ROSIER", 426], ["Score", 433], [">", 439], ["or", 441], ["=", 444], ["1", 445], ["indicating", 447], ["a", 458], ["stroke", 460], [",", 466], ["44", 468], ["(", 471], ["94", 472], ["%", 474], [")", 475], ["of", 477], ["these", 480], ["had", 486], ["stroke", 490], ["confirmed", 497], ["on", 507], ["investigation", 510], [".", 523], ["Two", 525], ["patients", 529], ["with", 538], ["stroke", 543], ["were", 550], ["missed", 555], ["and", 562], ["three", 566], ["were", 572], ["wrongly", 577], ["identified", 585], [".", 595], ["Positive", 597], ["predictive", 606], ["value", 617], ["for", 623], ["the", 627], ["ROSIER", 631], ["was", 638], ["94", 642], ["%", 644], [".", 645], ["ROSIER", 647], ["correlated", 654], ["with", 665], ["Scandinavian", 670], ["neurological", 683], ["stroke", 696], ["score", 703], [".", 708], ["(", 710], ["r", 711], ["=", 713], ["-0.414", 715], [",", 721], ["p", 723], ["=", 725], ["0.003", 727], [")", 732], ["and", 734], ["was", 738], ["associated", 742], ["with", 753], ["increasing", 758], ["length", 769], ["of", 776], ["stay", 779], ["in", 784], ["survivors", 787], ["(", 797], ["p", 798], ["=", 800], ["0.16", 802], [",", 806], ["one", 808], ["-", 811], ["way", 812], ["ANOVA", 816], [".", 821], ["F", 823], ["=", 825], ["3.116", 827], [",", 832], ["df", 834], ["=", 837], ["6", 839], [")", 840], [".", 841], ["The", 843], ["ROSIER", 847], ["is", 854], ["a", 857], ["suitable", 859], ["and", 868], ["useful", 872], ["adjunct", 879], ["in", 887], ["the", 890], ["assessment", 894], ["of", 905], ["stroke", 908], ["patients", 915], ["in", 924], ["Ireland", 927], [".", 934]]}
{"context": "Periodic limb movement disorder (PLMD) is one of the commonest neurological disorders and causes significant disability, if left untreated. However, it is rarely diagnosed in clinical practice, probably due to lack of awareness and/or lack of necessary diagnostic facilities. Restless leg syndrome (RLS), aging, pregnancy, uraemia, iron deficiency, polyneuropathy are some of the common causes of secondary PLMD. Clinical presentation, polysomnographic findings and management of six patients of PLMD have been discussed in this report.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "f17066e29bca4700bcdd4b135925f533", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[59, 59]], "char_spans": [[332, 335]]}]}], "context_tokens": [["Periodic", 0], ["limb", 9], ["movement", 14], ["disorder", 23], ["(", 32], ["PLMD", 33], [")", 37], ["is", 39], ["one", 42], ["of", 46], ["the", 49], ["commonest", 53], ["neurological", 63], ["disorders", 76], ["and", 86], ["causes", 90], ["significant", 97], ["disability", 109], [",", 119], ["if", 121], ["left", 124], ["untreated", 129], [".", 138], ["However", 140], [",", 147], ["it", 149], ["is", 152], ["rarely", 155], ["diagnosed", 162], ["in", 172], ["clinical", 175], ["practice", 184], [",", 192], ["probably", 194], ["due", 203], ["to", 207], ["lack", 210], ["of", 215], ["awareness", 218], ["and/or", 228], ["lack", 235], ["of", 240], ["necessary", 243], ["diagnostic", 253], ["facilities", 264], [".", 274], ["Restless", 276], ["leg", 285], ["syndrome", 289], ["(", 298], ["RLS", 299], [")", 302], [",", 303], ["aging", 305], [",", 310], ["pregnancy", 312], [",", 321], ["uraemia", 323], [",", 330], ["iron", 332], ["deficiency", 337], [",", 347], ["polyneuropathy", 349], ["are", 364], ["some", 368], ["of", 373], ["the", 376], ["common", 380], ["causes", 387], ["of", 394], ["secondary", 397], ["PLMD", 407], [".", 411], ["Clinical", 413], ["presentation", 422], [",", 434], ["polysomnographic", 436], ["findings", 453], ["and", 462], ["management", 466], ["of", 477], ["six", 480], ["patients", 484], ["of", 493], ["PLMD", 496], ["have", 501], ["been", 506], ["discussed", 511], ["in", 521], ["this", 524], ["report", 529], [".", 535]]}
{"context": "Selenium (Se) is an essential trace element primarily found in selenoproteins as the 21st amino acid (selenocysteine, Sec, or U). Selenoproteins play an important role in growth and proliferation and are typically involved in cellular redox balance. Selenocysteine is encoded by an in-frame UGA codon specified by a stem-loop structure, the Sec insertion sequence element (SECIS), which, in eukaryotes, is located in the 3'-untranslated region (UTR). The availability of the Naegleria gruberi (ATCC 30224) genome sequence and the use of this organism as a model system for the pathogenic amoeba N. fowleri allowed us to investigate the Sec incorporation pathway in this primitive eukaryote. Using bioinformatics tools, we identified gene sequences encoding PSTK (O-phosphoseryl-tRNA(Sec) kinase), SepSecS (O-phosphoseryl-tRNA:selenocysteinyl-tRNA synthase), SelD/SPS2 (selenophosphate synthetase), EFSec (selenocysteine-specific elongation factor) and SBP (SECIS binding protein). These findings were confirmed by RT-PCR and by sequencing. A potential tRNA(Ser)Sec (SelC) gene and a putative selenoprotein with sequence similarity to a mitochondrial thioredoxin reductase (TR3) were also identified. Our results show that the selenocysteine incorporation machinery is indeed present in N. gruberi. Interestingly, the SelD/SPS2 gene is 2214 bp in length and contains two distinct domains. The N-terminal region shows sequence similarity to predicted methyltransferase proteins, and the C-terminal region is homologous to prokaryotic SelD/SPS2. Our results suggest the possibility of novel selenoproteins.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0c52975c66384d66a1af964bd53fdfc5", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[181, 181], [69, 69]], "char_spans": [[957, 961], [373, 377]]}]}], "context_tokens": [["Selenium", 0], ["(", 9], ["Se", 10], [")", 12], ["is", 14], ["an", 17], ["essential", 20], ["trace", 30], ["element", 36], ["primarily", 44], ["found", 54], ["in", 60], ["selenoproteins", 63], ["as", 78], ["the", 81], ["21st", 85], ["amino", 90], ["acid", 96], ["(", 101], ["selenocysteine", 102], [",", 116], ["Sec", 118], [",", 121], ["or", 123], ["U", 126], [")", 127], [".", 128], ["Selenoproteins", 130], ["play", 145], ["an", 150], ["important", 153], ["role", 163], ["in", 168], ["growth", 171], ["and", 178], ["proliferation", 182], ["and", 196], ["are", 200], ["typically", 204], ["involved", 214], ["in", 223], ["cellular", 226], ["redox", 235], ["balance", 241], [".", 248], ["Selenocysteine", 250], ["is", 265], ["encoded", 268], ["by", 276], ["an", 279], ["in", 282], ["-", 284], ["frame", 285], ["UGA", 291], ["codon", 295], ["specified", 301], ["by", 311], ["a", 314], ["stem", 316], ["-", 320], ["loop", 321], ["structure", 326], [",", 335], ["the", 337], ["Sec", 341], ["insertion", 345], ["sequence", 355], ["element", 364], ["(", 372], ["SECIS", 373], [")", 378], [",", 379], ["which", 381], [",", 386], ["in", 388], ["eukaryotes", 391], [",", 401], ["is", 403], ["located", 406], ["in", 414], ["the", 417], ["3'-untranslated", 421], ["region", 437], ["(", 444], ["UTR", 445], [")", 448], [".", 449], ["The", 451], ["availability", 455], ["of", 468], ["the", 471], ["Naegleria", 475], ["gruberi", 485], ["(", 493], ["ATCC", 494], ["30224", 499], [")", 504], ["genome", 506], ["sequence", 513], ["and", 522], ["the", 526], ["use", 530], ["of", 534], ["this", 537], ["organism", 542], ["as", 551], ["a", 554], ["model", 556], ["system", 562], ["for", 569], ["the", 573], ["pathogenic", 577], ["amoeba", 588], ["N.", 595], ["fowleri", 598], ["allowed", 606], ["us", 614], ["to", 617], ["investigate", 620], ["the", 632], ["Sec", 636], ["incorporation", 640], ["pathway", 654], ["in", 662], ["this", 665], ["primitive", 670], ["eukaryote", 680], [".", 689], ["Using", 691], ["bioinformatics", 697], ["tools", 712], [",", 717], ["we", 719], ["identified", 722], ["gene", 733], ["sequences", 738], ["encoding", 748], ["PSTK", 757], ["(", 762], ["O", 763], ["-", 764], ["phosphoseryl", 765], ["-", 777], ["tRNA(Sec", 778], [")", 786], ["kinase", 788], [")", 794], [",", 795], ["SepSecS", 797], ["(", 805], ["O", 806], ["-", 807], ["phosphoseryl", 808], ["-", 820], ["tRNA", 821], [":", 825], ["selenocysteinyl", 826], ["-", 841], ["tRNA", 842], ["synthase", 847], [")", 855], [",", 856], ["SelD", 858], ["/", 862], ["SPS2", 863], ["(", 868], ["selenophosphate", 869], ["synthetase", 885], [")", 895], [",", 896], ["EFSec", 898], ["(", 904], ["selenocysteine", 905], ["-", 919], ["specific", 920], ["elongation", 929], ["factor", 940], [")", 946], ["and", 948], ["SBP", 952], ["(", 956], ["SECIS", 957], ["binding", 963], ["protein", 971], [")", 978], [".", 979], ["These", 981], ["findings", 987], ["were", 996], ["confirmed", 1001], ["by", 1011], ["RT", 1014], ["-", 1016], ["PCR", 1017], ["and", 1021], ["by", 1025], ["sequencing", 1028], [".", 1038], ["A", 1040], ["potential", 1042], ["tRNA(Ser)Sec", 1052], ["(", 1065], ["SelC", 1066], [")", 1070], ["gene", 1072], ["and", 1077], ["a", 1081], ["putative", 1083], ["selenoprotein", 1092], ["with", 1106], ["sequence", 1111], ["similarity", 1120], ["to", 1131], ["a", 1134], ["mitochondrial", 1136], ["thioredoxin", 1150], ["reductase", 1162], ["(", 1172], ["TR3", 1173], [")", 1176], ["were", 1178], ["also", 1183], ["identified", 1188], [".", 1198], ["Our", 1200], ["results", 1204], ["show", 1212], ["that", 1217], ["the", 1222], ["selenocysteine", 1226], ["incorporation", 1241], ["machinery", 1255], ["is", 1265], ["indeed", 1268], ["present", 1275], ["in", 1283], ["N.", 1286], ["gruberi", 1289], [".", 1296], ["Interestingly", 1298], [",", 1311], ["the", 1313], ["SelD", 1317], ["/", 1321], ["SPS2", 1322], ["gene", 1327], ["is", 1332], ["2214", 1335], ["bp", 1340], ["in", 1343], ["length", 1346], ["and", 1353], ["contains", 1357], ["two", 1366], ["distinct", 1370], ["domains", 1379], [".", 1386], ["The", 1388], ["N", 1392], ["-", 1393], ["terminal", 1394], ["region", 1403], ["shows", 1410], ["sequence", 1416], ["similarity", 1425], ["to", 1436], ["predicted", 1439], ["methyltransferase", 1449], ["proteins", 1467], [",", 1475], ["and", 1477], ["the", 1481], ["C", 1485], ["-", 1486], ["terminal", 1487], ["region", 1496], ["is", 1503], ["homologous", 1506], ["to", 1517], ["prokaryotic", 1520], ["SelD", 1532], ["/", 1536], ["SPS2", 1537], [".", 1541], ["Our", 1543], ["results", 1547], ["suggest", 1555], ["the", 1563], ["possibility", 1567], ["of", 1579], ["novel", 1582], ["selenoproteins", 1588], [".", 1602]]}
{"context": "Human \u03b1-synuclein is a small-sized, natively unfolded protein that in fibrillar form is the primary component of Lewy bodies, the pathological hallmark of Parkinson's disease. Experimental evidence suggests that \u03b1-synuclein aggregation is the key event that triggers neurotoxicity although additional findings have proposed a protective role of \u03b1-synuclein against oxidative stress. One way to address the mechanism of this protective action is to evaluate \u03b1-synuclein-mediated protection by delivering this protein inside cells using a chimeric protein fused with the Tat-transduction domain of HIV Tat, named TAT-\u03b1-synuclein. A reliable protocol was designed to efficiently express and purify two different forms of human \u03b1-synuclein. The synthetic cDNAs encoding for the native \u03b1-synuclein and the fusion protein with the transduction domain of Tat protein from HIV were overexpressed in a BL21(DE3) E. coli strain as His-tagged proteins. The recombinant proteins largely localized (\u2265 85%) to the periplasmic space. By using a quick purification protocol, based on recovery of periplasmic space content and metal-chelating chromatography, the recombinant \u03b1-synuclein protein forms could be purified in a single step to \u2265 95% purity. Both \u03b1-synuclein recombinant proteins form fibrils and the TAT-\u03b1-synuclein is also cytotoxic in the micromolar concentration range. To further characterize the molecular mechanisms of \u03b1-synuclein neurotoxicity both in vitro and in vivo and to evaluate the relevance of extracellular \u03b1-synuclein for the pathogenesis and progression of Parkinson's disease, a suitable method to produce different high-quality forms of this pathological protein is required. Our optimized expression and purification procedure offers an easier and faster means of producing different forms (i.e., both the native and the TAT-fusion form) of soluble recombinant \u03b1-synuclein than previously described procedures.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "2270a17d1c8b4ecba24ad304bcb2f5ad", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[1, 3], [126, 128], [254, 256], [235, 237], [37, 39], [77, 79], [205, 207], [333, 335], [57, 59], [137, 139], [271, 273], [224, 226], [107, 109]], "char_spans": [[6, 16], [724, 734], [1420, 1430], [1299, 1309], [212, 222], [457, 467], [1158, 1168], [1878, 1888], [345, 355], [781, 791], [1519, 1529], [1241, 1251], [615, 625]]}]}], "context_tokens": [["Human", 0], ["\u03b1", 6], ["-", 7], ["synuclein", 8], ["is", 18], ["a", 21], ["small", 23], ["-", 28], ["sized", 29], [",", 34], ["natively", 36], ["unfolded", 45], ["protein", 54], ["that", 62], ["in", 67], ["fibrillar", 70], ["form", 80], ["is", 85], ["the", 88], ["primary", 92], ["component", 100], ["of", 110], ["Lewy", 113], ["bodies", 118], [",", 124], ["the", 126], ["pathological", 130], ["hallmark", 143], ["of", 152], ["Parkinson", 155], ["'s", 164], ["disease", 167], [".", 174], ["Experimental", 176], ["evidence", 189], ["suggests", 198], ["that", 207], ["\u03b1", 212], ["-", 213], ["synuclein", 214], ["aggregation", 224], ["is", 236], ["the", 239], ["key", 243], ["event", 247], ["that", 253], ["triggers", 258], ["neurotoxicity", 267], ["although", 281], ["additional", 290], ["findings", 301], ["have", 310], ["proposed", 315], ["a", 324], ["protective", 326], ["role", 337], ["of", 342], ["\u03b1", 345], ["-", 346], ["synuclein", 347], ["against", 357], ["oxidative", 365], ["stress", 375], [".", 381], ["One", 383], ["way", 387], ["to", 391], ["address", 394], ["the", 402], ["mechanism", 406], ["of", 416], ["this", 419], ["protective", 424], ["action", 435], ["is", 442], ["to", 445], ["evaluate", 448], ["\u03b1", 457], ["-", 458], ["synuclein", 459], ["-", 468], ["mediated", 469], ["protection", 478], ["by", 489], ["delivering", 492], ["this", 503], ["protein", 508], ["inside", 516], ["cells", 523], ["using", 529], ["a", 535], ["chimeric", 537], ["protein", 546], ["fused", 554], ["with", 560], ["the", 565], ["Tat", 569], ["-", 572], ["transduction", 573], ["domain", 586], ["of", 593], ["HIV", 596], ["Tat", 600], [",", 603], ["named", 605], ["TAT", 611], ["-", 614], ["\u03b1", 615], ["-", 616], ["synuclein", 617], [".", 626], ["A", 628], ["reliable", 630], ["protocol", 639], ["was", 648], ["designed", 652], ["to", 661], ["efficiently", 664], ["express", 676], ["and", 684], ["purify", 688], ["two", 695], ["different", 699], ["forms", 709], ["of", 715], ["human", 718], ["\u03b1", 724], ["-", 725], ["synuclein", 726], [".", 735], ["The", 737], ["synthetic", 741], ["cDNAs", 751], ["encoding", 757], ["for", 766], ["the", 770], ["native", 774], ["\u03b1", 781], ["-", 782], ["synuclein", 783], ["and", 793], ["the", 797], ["fusion", 801], ["protein", 808], ["with", 816], ["the", 821], ["transduction", 825], ["domain", 838], ["of", 845], ["Tat", 848], ["protein", 852], ["from", 860], ["HIV", 865], ["were", 869], ["overexpressed", 874], ["in", 888], ["a", 891], ["BL21(DE3", 893], [")", 901], ["E.", 903], ["coli", 906], ["strain", 911], ["as", 918], ["His", 921], ["-", 924], ["tagged", 925], ["proteins", 932], [".", 940], ["The", 942], ["recombinant", 946], ["proteins", 958], ["largely", 967], ["localized", 975], ["(", 985], ["\u2265", 986], ["85", 988], ["%", 990], [")", 991], ["to", 993], ["the", 996], ["periplasmic", 1000], ["space", 1012], [".", 1017], ["By", 1019], ["using", 1022], ["a", 1028], ["quick", 1030], ["purification", 1036], ["protocol", 1049], [",", 1057], ["based", 1059], ["on", 1065], ["recovery", 1068], ["of", 1077], ["periplasmic", 1080], ["space", 1092], ["content", 1098], ["and", 1106], ["metal", 1110], ["-", 1115], ["chelating", 1116], ["chromatography", 1126], [",", 1140], ["the", 1142], ["recombinant", 1146], ["\u03b1", 1158], ["-", 1159], ["synuclein", 1160], ["protein", 1170], ["forms", 1178], ["could", 1184], ["be", 1190], ["purified", 1193], ["in", 1202], ["a", 1205], ["single", 1207], ["step", 1214], ["to", 1219], ["\u2265", 1222], ["95", 1224], ["%", 1226], ["purity", 1228], [".", 1234], ["Both", 1236], ["\u03b1", 1241], ["-", 1242], ["synuclein", 1243], ["recombinant", 1253], ["proteins", 1265], ["form", 1274], ["fibrils", 1279], ["and", 1287], ["the", 1291], ["TAT", 1295], ["-", 1298], ["\u03b1", 1299], ["-", 1300], ["synuclein", 1301], ["is", 1311], ["also", 1314], ["cytotoxic", 1319], ["in", 1329], ["the", 1332], ["micromolar", 1336], ["concentration", 1347], ["range", 1361], [".", 1366], ["To", 1368], ["further", 1371], ["characterize", 1379], ["the", 1392], ["molecular", 1396], ["mechanisms", 1406], ["of", 1417], ["\u03b1", 1420], ["-", 1421], ["synuclein", 1422], ["neurotoxicity", 1432], ["both", 1446], ["in", 1451], ["vitro", 1454], ["and", 1460], ["in", 1464], ["vivo", 1467], ["and", 1472], ["to", 1476], ["evaluate", 1479], ["the", 1488], ["relevance", 1492], ["of", 1502], ["extracellular", 1505], ["\u03b1", 1519], ["-", 1520], ["synuclein", 1521], ["for", 1531], ["the", 1535], ["pathogenesis", 1539], ["and", 1552], ["progression", 1556], ["of", 1568], ["Parkinson", 1571], ["'s", 1580], ["disease", 1583], [",", 1590], ["a", 1592], ["suitable", 1594], ["method", 1603], ["to", 1610], ["produce", 1613], ["different", 1621], ["high", 1631], ["-", 1635], ["quality", 1636], ["forms", 1644], ["of", 1650], ["this", 1653], ["pathological", 1658], ["protein", 1671], ["is", 1679], ["required", 1682], [".", 1690], ["Our", 1692], ["optimized", 1696], ["expression", 1706], ["and", 1717], ["purification", 1721], ["procedure", 1734], ["offers", 1744], ["an", 1751], ["easier", 1754], ["and", 1761], ["faster", 1765], ["means", 1772], ["of", 1778], ["producing", 1781], ["different", 1791], ["forms", 1801], ["(", 1807], ["i.e.", 1808], [",", 1812], ["both", 1814], ["the", 1819], ["native", 1823], ["and", 1830], ["the", 1834], ["TAT", 1838], ["-", 1841], ["fusion", 1842], ["form", 1849], [")", 1853], ["of", 1855], ["soluble", 1858], ["recombinant", 1866], ["\u03b1", 1878], ["-", 1879], ["synuclein", 1880], ["than", 1890], ["previously", 1895], ["described", 1906], ["procedures", 1916], [".", 1926]]}
{"context": "Attempts to prevent HIV infection through pre-exposure prophylaxis (PrEP) include topical application of anti-HIV drugs to the mucosal sites of infection; however, a potential role for local drug metabolizing enzymes in modulating the exposure of the mucosal tissues to these drugs has yet to be explored. Here we present the first report that enzymes belonging to the cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) families of drug metabolizing enzymes are expressed and active in vaginal and colorectal tissue using biopsies collected from healthy volunteers. In doing so, we discovered that dapivirine and maraviroc, a non-nucleoside reverse transcriptase inhibitor and an entry inhibitor currently in development as microbicides for HIV PrEP, are differentially metabolized in colorectal tissue and vaginal tissue. Taken together, these data should help to guide the optimization of small molecules being developed for HIV PrEP.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "a245513a68e54764b2b701bf8135c90a", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[157, 157], [19, 19], [127, 127], [3, 3]], "char_spans": [[936, 938], [110, 112], [750, 752], [20, 22]]}]}], "context_tokens": [["Attempts", 0], ["to", 9], ["prevent", 12], ["HIV", 20], ["infection", 24], ["through", 34], ["pre", 42], ["-", 45], ["exposure", 46], ["prophylaxis", 55], ["(", 67], ["PrEP", 68], [")", 72], ["include", 74], ["topical", 82], ["application", 90], ["of", 102], ["anti", 105], ["-", 109], ["HIV", 110], ["drugs", 114], ["to", 120], ["the", 123], ["mucosal", 127], ["sites", 135], ["of", 141], ["infection", 144], [";", 153], ["however", 155], [",", 162], ["a", 164], ["potential", 166], ["role", 176], ["for", 181], ["local", 185], ["drug", 191], ["metabolizing", 196], ["enzymes", 209], ["in", 217], ["modulating", 220], ["the", 231], ["exposure", 235], ["of", 244], ["the", 247], ["mucosal", 251], ["tissues", 259], ["to", 267], ["these", 270], ["drugs", 276], ["has", 282], ["yet", 286], ["to", 290], ["be", 293], ["explored", 296], [".", 304], ["Here", 306], ["we", 311], ["present", 314], ["the", 322], ["first", 326], ["report", 332], ["that", 339], ["enzymes", 344], ["belonging", 352], ["to", 362], ["the", 365], ["cytochrome", 369], ["P450", 380], ["(", 385], ["CYP", 386], [")", 389], ["and", 391], ["UDP", 395], ["-", 398], ["glucuronosyltransferase", 399], ["(", 423], ["UGT", 424], [")", 427], ["families", 429], ["of", 438], ["drug", 441], ["metabolizing", 446], ["enzymes", 459], ["are", 467], ["expressed", 471], ["and", 481], ["active", 485], ["in", 492], ["vaginal", 495], ["and", 503], ["colorectal", 507], ["tissue", 518], ["using", 525], ["biopsies", 531], ["collected", 540], ["from", 550], ["healthy", 555], ["volunteers", 563], [".", 573], ["In", 575], ["doing", 578], ["so", 584], [",", 586], ["we", 588], ["discovered", 591], ["that", 602], ["dapivirine", 607], ["and", 618], ["maraviroc", 622], [",", 631], ["a", 633], ["non", 635], ["-", 638], ["nucleoside", 639], ["reverse", 650], ["transcriptase", 658], ["inhibitor", 672], ["and", 682], ["an", 686], ["entry", 689], ["inhibitor", 695], ["currently", 705], ["in", 715], ["development", 718], ["as", 730], ["microbicides", 733], ["for", 746], ["HIV", 750], ["PrEP", 754], [",", 758], ["are", 760], ["differentially", 764], ["metabolized", 779], ["in", 791], ["colorectal", 794], ["tissue", 805], ["and", 812], ["vaginal", 816], ["tissue", 824], [".", 830], ["Taken", 832], ["together", 838], [",", 846], ["these", 848], ["data", 854], ["should", 859], ["help", 866], ["to", 871], ["guide", 874], ["the", 880], ["optimization", 884], ["of", 897], ["small", 900], ["molecules", 906], ["being", 916], ["developed", 922], ["for", 932], ["HIV", 936], ["PrEP", 940], [".", 944]]}
{"context": "There has been no previous side-by-side comparison of the diagnostic criteria for restless legs syndrome (RLS) (Willis-Ekbom disease) and growing pains. In our review, we explore this comparison emphasizing overlaps and disconnects, summarize recent literature exploring the relationship between the 2 entities, and make suggestions for future research. There is considerable overlap in the diagnostic criteria for childhood RLS and growing pains. The literature also indicates that RLS and growing pains more commonly occur together than one would expect based on chance alone, and the family histories of RLS and growing pains often are overlapping. Leg rubbing to obtain relief from leg discomfort is common to both disorders, though walking to obtain relief seems unique to RLS. Childhood RLS also has been reported to be painful in up to 45% of cases. The development of standard diagnostic criteria is necessary to move forward in the field of growing pains research. A quantitative and validated rating scale for growing pains severity already exists. Because of the clinical and genetic similarity between RLS and growing pains, studies that parallel those previously performed in RLS patients are recommended for growing pains patients. For example, a genome wide association study in growing pains patients of all possible genes with particular attention to those identified as related to RLS and a therapeutic trial of medications known to be effective in RLS would be welcome. Abnormalities in vitamin D metabolism also may be common to both disorders.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "3dc26f38ab6044c4a7bf30e5bd9852c6", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[16, 18]], "char_spans": [[82, 103]]}]}], "context_tokens": [["There", 0], ["has", 6], ["been", 10], ["no", 15], ["previous", 18], ["side", 27], ["-", 31], ["by", 32], ["-", 34], ["side", 35], ["comparison", 40], ["of", 51], ["the", 54], ["diagnostic", 58], ["criteria", 69], ["for", 78], ["restless", 82], ["legs", 91], ["syndrome", 96], ["(", 105], ["RLS", 106], [")", 109], ["(", 111], ["Willis", 112], ["-", 118], ["Ekbom", 119], ["disease", 125], [")", 132], ["and", 134], ["growing", 138], ["pains", 146], [".", 151], ["In", 153], ["our", 156], ["review", 160], [",", 166], ["we", 168], ["explore", 171], ["this", 179], ["comparison", 184], ["emphasizing", 195], ["overlaps", 207], ["and", 216], ["disconnects", 220], [",", 231], ["summarize", 233], ["recent", 243], ["literature", 250], ["exploring", 261], ["the", 271], ["relationship", 275], ["between", 288], ["the", 296], ["2", 300], ["entities", 302], [",", 310], ["and", 312], ["make", 316], ["suggestions", 321], ["for", 333], ["future", 337], ["research", 344], [".", 352], ["There", 354], ["is", 360], ["considerable", 363], ["overlap", 376], ["in", 384], ["the", 387], ["diagnostic", 391], ["criteria", 402], ["for", 411], ["childhood", 415], ["RLS", 425], ["and", 429], ["growing", 433], ["pains", 441], [".", 446], ["The", 448], ["literature", 452], ["also", 463], ["indicates", 468], ["that", 478], ["RLS", 483], ["and", 487], ["growing", 491], ["pains", 499], ["more", 505], ["commonly", 510], ["occur", 519], ["together", 525], ["than", 534], ["one", 539], ["would", 543], ["expect", 549], ["based", 556], ["on", 562], ["chance", 565], ["alone", 572], [",", 577], ["and", 579], ["the", 583], ["family", 587], ["histories", 594], ["of", 604], ["RLS", 607], ["and", 611], ["growing", 615], ["pains", 623], ["often", 629], ["are", 635], ["overlapping", 639], [".", 650], ["Leg", 652], ["rubbing", 656], ["to", 664], ["obtain", 667], ["relief", 674], ["from", 681], ["leg", 686], ["discomfort", 690], ["is", 701], ["common", 704], ["to", 711], ["both", 714], ["disorders", 719], [",", 728], ["though", 730], ["walking", 737], ["to", 745], ["obtain", 748], ["relief", 755], ["seems", 762], ["unique", 768], ["to", 775], ["RLS", 778], [".", 781], ["Childhood", 783], ["RLS", 793], ["also", 797], ["has", 802], ["been", 806], ["reported", 811], ["to", 820], ["be", 823], ["painful", 826], ["in", 834], ["up", 837], ["to", 840], ["45", 843], ["%", 845], ["of", 847], ["cases", 850], [".", 855], ["The", 857], ["development", 861], ["of", 873], ["standard", 876], ["diagnostic", 885], ["criteria", 896], ["is", 905], ["necessary", 908], ["to", 918], ["move", 921], ["forward", 926], ["in", 934], ["the", 937], ["field", 941], ["of", 947], ["growing", 950], ["pains", 958], ["research", 964], [".", 972], ["A", 974], ["quantitative", 976], ["and", 989], ["validated", 993], ["rating", 1003], ["scale", 1010], ["for", 1016], ["growing", 1020], ["pains", 1028], ["severity", 1034], ["already", 1043], ["exists", 1051], [".", 1057], ["Because", 1059], ["of", 1067], ["the", 1070], ["clinical", 1074], ["and", 1083], ["genetic", 1087], ["similarity", 1095], ["between", 1106], ["RLS", 1114], ["and", 1118], ["growing", 1122], ["pains", 1130], [",", 1135], ["studies", 1137], ["that", 1145], ["parallel", 1150], ["those", 1159], ["previously", 1165], ["performed", 1176], ["in", 1186], ["RLS", 1189], ["patients", 1193], ["are", 1202], ["recommended", 1206], ["for", 1218], ["growing", 1222], ["pains", 1230], ["patients", 1236], [".", 1244], ["For", 1246], ["example", 1250], [",", 1257], ["a", 1259], ["genome", 1261], ["wide", 1268], ["association", 1273], ["study", 1285], ["in", 1291], ["growing", 1294], ["pains", 1302], ["patients", 1308], ["of", 1317], ["all", 1320], ["possible", 1324], ["genes", 1333], ["with", 1339], ["particular", 1344], ["attention", 1355], ["to", 1365], ["those", 1368], ["identified", 1374], ["as", 1385], ["related", 1388], ["to", 1396], ["RLS", 1399], ["and", 1403], ["a", 1407], ["therapeutic", 1409], ["trial", 1421], ["of", 1427], ["medications", 1430], ["known", 1442], ["to", 1448], ["be", 1451], ["effective", 1454], ["in", 1464], ["RLS", 1467], ["would", 1471], ["be", 1477], ["welcome", 1480], [".", 1487], ["Abnormalities", 1489], ["in", 1503], ["vitamin", 1506], ["D", 1514], ["metabolism", 1516], ["also", 1527], ["may", 1532], ["be", 1536], ["common", 1539], ["to", 1546], ["both", 1549], ["disorders", 1554], [".", 1563]]}
{"context": "We have previously shown that NADPH oxidase (NOX) lies upstream of uncoupled endothelial nitric oxide synthase (eNOS), which is known to occur in diabetic endothelium. However, it remains unclear which specific NOX isoform(s) is responsible for eNOS uncoupling and endothelial dysfunction in diabetic mouse models. The aim of the present study was to test the hypothesis that one or more NOX isoform(s) mediate(s) diabetic uncoupling of eNOS, which has been shown to occur in patients with diabetes to contribute to endothelial dysfunction. Diabetes was induced by streptozotocin administration. The N (\u03c9)-nitro-L-arginine methyl ester (L-NAME)-sensitive superoxide production of aortic segments, reflective of eNOS uncoupling activity, was determined by electron spin resonance. The L-NAME-sensitive superoxide production was more than doubled in wild-type diabetic mice, implicating uncoupling of eNOS. This was abolished in diabetic p47 ( phox-/-) (also known as Ncf1 (-/-)) mice, but preserved in Nox2 (-/y) (also known as Cybb (-/-)) mice made diabetic. The eNOS uncoupling activity was markedly attenuated in diabetic mice transfected with Nox1 or Nox1 organiser 1 (Noxo1) short interfering RNA (siRNA), and abolished in Nox1 (-/y) diabetic mice. Diabetes-induced impairment in endothelium-dependent vasorelaxation was also significantly attenuated in the Nox1 (-/y) mice made diabetic. By contrast, Nox4 siRNA, or inhibition of mitochondrial complex I or III with rotenone or siRNA, respectively, had no effect on diabetic uncoupling of eNOS. Overexpression of Dhfr, or oral administration of folic acid to improve dihydrofolate reductase (DHFR) function, recoupled eNOS in diabetes to improve endothelial function. Our data demonstrate for the first time that the p47(phox) and NOXO1-dependent activation of NOX1, but not that of NOX2, NOX4 or mitochondrion, mediates diabetic uncoupling of eNOS. NOX1-null mice are protected from diabetic endothelial dysfunction. Novel approaches to inhibit NOX1 and/or improve DHFR function, may prove to have therapeutic potential for diabetic endothelial dysfunction.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "33aa8ce035c44ae2b854b9bd20914504", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[251, 251], [229, 229], [211, 211], [213, 213], [363, 363], [332, 332]], "char_spans": [[1362, 1365], [1227, 1230], [1146, 1149], [1154, 1157], [2001, 2004], [1816, 1819]]}]}], "context_tokens": [["We", 0], ["have", 3], ["previously", 8], ["shown", 19], ["that", 25], ["NADPH", 30], ["oxidase", 36], ["(", 44], ["NOX", 45], [")", 48], ["lies", 50], ["upstream", 55], ["of", 64], ["uncoupled", 67], ["endothelial", 77], ["nitric", 89], ["oxide", 96], ["synthase", 102], ["(", 111], ["eNOS", 112], [")", 116], [",", 117], ["which", 119], ["is", 125], ["known", 128], ["to", 134], ["occur", 137], ["in", 143], ["diabetic", 146], ["endothelium", 155], [".", 166], ["However", 168], [",", 175], ["it", 177], ["remains", 180], ["unclear", 188], ["which", 196], ["specific", 202], ["NOX", 211], ["isoform(s", 215], [")", 224], ["is", 226], ["responsible", 229], ["for", 241], ["eNOS", 245], ["uncoupling", 250], ["and", 261], ["endothelial", 265], ["dysfunction", 277], ["in", 289], ["diabetic", 292], ["mouse", 301], ["models", 307], [".", 313], ["The", 315], ["aim", 319], ["of", 323], ["the", 326], ["present", 330], ["study", 338], ["was", 344], ["to", 348], ["test", 351], ["the", 356], ["hypothesis", 360], ["that", 371], ["one", 376], ["or", 380], ["more", 383], ["NOX", 388], ["isoform(s", 392], [")", 401], ["mediate(s", 403], [")", 412], ["diabetic", 414], ["uncoupling", 423], ["of", 434], ["eNOS", 437], [",", 441], ["which", 443], ["has", 449], ["been", 453], ["shown", 458], ["to", 464], ["occur", 467], ["in", 473], ["patients", 476], ["with", 485], ["diabetes", 490], ["to", 499], ["contribute", 502], ["to", 513], ["endothelial", 516], ["dysfunction", 528], [".", 539], ["Diabetes", 541], ["was", 550], ["induced", 554], ["by", 562], ["streptozotocin", 565], ["administration", 580], [".", 594], ["The", 596], ["N", 600], ["(", 602], ["\u03c9)-nitro", 603], ["-", 611], ["L", 612], ["-", 613], ["arginine", 614], ["methyl", 623], ["ester", 630], ["(", 636], ["L", 637], ["-", 638], ["NAME)-sensitive", 639], ["superoxide", 655], ["production", 666], ["of", 677], ["aortic", 680], ["segments", 687], [",", 695], ["reflective", 697], ["of", 708], ["eNOS", 711], ["uncoupling", 716], ["activity", 727], [",", 735], ["was", 737], ["determined", 741], ["by", 752], ["electron", 755], ["spin", 764], ["resonance", 769], [".", 778], ["The", 780], ["L", 784], ["-", 785], ["NAME", 786], ["-", 790], ["sensitive", 791], ["superoxide", 801], ["production", 812], ["was", 823], ["more", 827], ["than", 832], ["doubled", 837], ["in", 845], ["wild", 848], ["-", 852], ["type", 853], ["diabetic", 858], ["mice", 867], [",", 871], ["implicating", 873], ["uncoupling", 885], ["of", 896], ["eNOS", 899], [".", 903], ["This", 905], ["was", 910], ["abolished", 914], ["in", 924], ["diabetic", 927], ["p47", 936], ["(", 940], ["phox-/-", 942], [")", 949], ["(", 951], ["also", 952], ["known", 957], ["as", 963], ["Ncf1", 966], ["(", 971], ["-/-", 972], [")", 975], [")", 976], ["mice", 978], [",", 982], ["but", 984], ["preserved", 988], ["in", 998], ["Nox2", 1001], ["(", 1006], ["-/y", 1007], [")", 1010], ["(", 1012], ["also", 1013], ["known", 1018], ["as", 1024], ["Cybb", 1027], ["(", 1032], ["-/-", 1033], [")", 1036], [")", 1037], ["mice", 1039], ["made", 1044], ["diabetic", 1049], [".", 1057], ["The", 1059], ["eNOS", 1063], ["uncoupling", 1068], ["activity", 1079], ["was", 1088], ["markedly", 1092], ["attenuated", 1101], ["in", 1112], ["diabetic", 1115], ["mice", 1124], ["transfected", 1129], ["with", 1141], ["Nox1", 1146], ["or", 1151], ["Nox1", 1154], ["organiser", 1159], ["1", 1169], ["(", 1171], ["Noxo1", 1172], [")", 1177], ["short", 1179], ["interfering", 1185], ["RNA", 1197], ["(", 1201], ["siRNA", 1202], [")", 1207], [",", 1208], ["and", 1210], ["abolished", 1214], ["in", 1224], ["Nox1", 1227], ["(", 1232], ["-/y", 1233], [")", 1236], ["diabetic", 1238], ["mice", 1247], [".", 1251], ["Diabetes", 1253], ["-", 1261], ["induced", 1262], ["impairment", 1270], ["in", 1281], ["endothelium", 1284], ["-", 1295], ["dependent", 1296], ["vasorelaxation", 1306], ["was", 1321], ["also", 1325], ["significantly", 1330], ["attenuated", 1344], ["in", 1355], ["the", 1358], ["Nox1", 1362], ["(", 1367], ["-/y", 1368], [")", 1371], ["mice", 1373], ["made", 1378], ["diabetic", 1383], [".", 1391], ["By", 1393], ["contrast", 1396], [",", 1404], ["Nox4", 1406], ["siRNA", 1411], [",", 1416], ["or", 1418], ["inhibition", 1421], ["of", 1432], ["mitochondrial", 1435], ["complex", 1449], ["I", 1457], ["or", 1459], ["III", 1462], ["with", 1466], ["rotenone", 1471], ["or", 1480], ["siRNA", 1483], [",", 1488], ["respectively", 1490], [",", 1502], ["had", 1504], ["no", 1508], ["effect", 1511], ["on", 1518], ["diabetic", 1521], ["uncoupling", 1530], ["of", 1541], ["eNOS", 1544], [".", 1548], ["Overexpression", 1550], ["of", 1565], ["Dhfr", 1568], [",", 1572], ["or", 1574], ["oral", 1577], ["administration", 1582], ["of", 1597], ["folic", 1600], ["acid", 1606], ["to", 1611], ["improve", 1614], ["dihydrofolate", 1622], ["reductase", 1636], ["(", 1646], ["DHFR", 1647], [")", 1651], ["function", 1653], [",", 1661], ["recoupled", 1663], ["eNOS", 1673], ["in", 1678], ["diabetes", 1681], ["to", 1690], ["improve", 1693], ["endothelial", 1701], ["function", 1713], [".", 1721], ["Our", 1723], ["data", 1727], ["demonstrate", 1732], ["for", 1744], ["the", 1748], ["first", 1752], ["time", 1758], ["that", 1763], ["the", 1768], ["p47(phox", 1772], [")", 1780], ["and", 1782], ["NOXO1-dependent", 1786], ["activation", 1802], ["of", 1813], ["NOX1", 1816], [",", 1820], ["but", 1822], ["not", 1826], ["that", 1830], ["of", 1835], ["NOX2", 1838], [",", 1842], ["NOX4", 1844], ["or", 1849], ["mitochondrion", 1852], [",", 1865], ["mediates", 1867], ["diabetic", 1876], ["uncoupling", 1885], ["of", 1896], ["eNOS", 1899], [".", 1903], ["NOX1-null", 1905], ["mice", 1915], ["are", 1920], ["protected", 1924], ["from", 1934], ["diabetic", 1939], ["endothelial", 1948], ["dysfunction", 1960], [".", 1971], ["Novel", 1973], ["approaches", 1979], ["to", 1990], ["inhibit", 1993], ["NOX1", 2001], ["and/or", 2006], ["improve", 2013], ["DHFR", 2021], ["function", 2026], [",", 2034], ["may", 2036], ["prove", 2040], ["to", 2046], ["have", 2049], ["therapeutic", 2054], ["potential", 2066], ["for", 2076], ["diabetic", 2080], ["endothelial", 2089], ["dysfunction", 2101], [".", 2112]]}
{"context": "Schimke immuno-osseous dysplasia (OMIM 242900) is an uncommon autosomal-recessive multisystem disease caused by mutations in SMARCAL1 (swi/snf-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1), a gene encoding a putative chromatin remodeling protein. Neurologic manifestations identified to date relate to enhanced atherosclerosis and cerebrovascular disease. Based on a clinical survey, we determined that half of Schimke immuno-osseous dysplasia patients have a small head circumference, and 15% have social, language, motor, or cognitive abnormalities. Postmortem examination of 2 Schimke immuno-osseous dysplasia patients showed low brain weights and subtle brain histologic abnormalities suggestive of perturbed neuron-glial migration such as heterotopia, irregular cortical thickness, incomplete gyral formation, and poor definition of cortical layers. We found that SMARCAL1 is highly expressed in the developing and adult mouse and human brain, including neural precursors and neuronal lineage cells. These observations suggest that SMARCAL1 deficiency may influence brain development and function in addition to its previously recognized effect on cerebral circulation.", "qas": [{"question": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "answers": ["HARP", "SMARCAL1 (swi/snf-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1", "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)"], "qid": "86b60944892d4aba80de48bd155dcdcb", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["cause", 24], ["Schimke", 30], ["immune", 38], ["-", 44], ["osseous", 45], ["dysplasia", 53], ["?", 62]], "detected_answers": [{"text": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "token_spans": [[21, 44]], "char_spans": [[125, 228]]}]}], "context_tokens": [["Schimke", 0], ["immuno", 8], ["-", 14], ["osseous", 15], ["dysplasia", 23], ["(", 33], ["OMIM", 34], ["242900", 39], [")", 45], ["is", 47], ["an", 50], ["uncommon", 53], ["autosomal", 62], ["-", 71], ["recessive", 72], ["multisystem", 82], ["disease", 94], ["caused", 102], ["by", 109], ["mutations", 112], ["in", 122], ["SMARCAL1", 125], ["(", 134], ["swi", 135], ["/", 138], ["snf", 139], ["-", 142], ["related", 143], [",", 150], ["matrix", 152], ["-", 158], ["associated", 159], [",", 169], ["actin", 171], ["-", 176], ["dependent", 177], ["regulator", 187], ["of", 197], ["chromatin", 200], [",", 209], ["subfamily", 211], ["a", 221], ["-", 222], ["like", 223], ["1", 228], [")", 229], [",", 230], ["a", 232], ["gene", 234], ["encoding", 239], ["a", 248], ["putative", 250], ["chromatin", 259], ["remodeling", 269], ["protein", 280], [".", 287], ["Neurologic", 289], ["manifestations", 300], ["identified", 315], ["to", 326], ["date", 329], ["relate", 334], ["to", 341], ["enhanced", 344], ["atherosclerosis", 353], ["and", 369], ["cerebrovascular", 373], ["disease", 389], [".", 396], ["Based", 398], ["on", 404], ["a", 407], ["clinical", 409], ["survey", 418], [",", 424], ["we", 426], ["determined", 429], ["that", 440], ["half", 445], ["of", 450], ["Schimke", 453], ["immuno", 461], ["-", 467], ["osseous", 468], ["dysplasia", 476], ["patients", 486], ["have", 495], ["a", 500], ["small", 502], ["head", 508], ["circumference", 513], [",", 526], ["and", 528], ["15", 532], ["%", 534], ["have", 536], ["social", 541], [",", 547], ["language", 549], [",", 557], ["motor", 559], [",", 564], ["or", 566], ["cognitive", 569], ["abnormalities", 579], [".", 592], ["Postmortem", 594], ["examination", 605], ["of", 617], ["2", 620], ["Schimke", 622], ["immuno", 630], ["-", 636], ["osseous", 637], ["dysplasia", 645], ["patients", 655], ["showed", 664], ["low", 671], ["brain", 675], ["weights", 681], ["and", 689], ["subtle", 693], ["brain", 700], ["histologic", 706], ["abnormalities", 717], ["suggestive", 731], ["of", 742], ["perturbed", 745], ["neuron", 755], ["-", 761], ["glial", 762], ["migration", 768], ["such", 778], ["as", 783], ["heterotopia", 786], [",", 797], ["irregular", 799], ["cortical", 809], ["thickness", 818], [",", 827], ["incomplete", 829], ["gyral", 840], ["formation", 846], [",", 855], ["and", 857], ["poor", 861], ["definition", 866], ["of", 877], ["cortical", 880], ["layers", 889], [".", 895], ["We", 897], ["found", 900], ["that", 906], ["SMARCAL1", 911], ["is", 920], ["highly", 923], ["expressed", 930], ["in", 940], ["the", 943], ["developing", 947], ["and", 958], ["adult", 962], ["mouse", 968], ["and", 974], ["human", 978], ["brain", 984], [",", 989], ["including", 991], ["neural", 1001], ["precursors", 1008], ["and", 1019], ["neuronal", 1023], ["lineage", 1032], ["cells", 1040], [".", 1045], ["These", 1047], ["observations", 1053], ["suggest", 1066], ["that", 1074], ["SMARCAL1", 1079], ["deficiency", 1088], ["may", 1099], ["influence", 1103], ["brain", 1113], ["development", 1119], ["and", 1131], ["function", 1135], ["in", 1144], ["addition", 1147], ["to", 1156], ["its", 1159], ["previously", 1163], ["recognized", 1174], ["effect", 1185], ["on", 1192], ["cerebral", 1195], ["circulation", 1204], [".", 1215]]}
{"context": "Chronic myelogenous leukemia (CML) accounts for 15-20% of adult leukemias but is very rare in children (2%). Fewer than 10% of CML patients are younger than 20 years. CML is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome or the BCR-ABL fusion oncogene. The objective of this paper is to present the monitoring of imatinib therapy in two children with CML by the BCR-ABL fusion gene expression assessment from peripheral blood with quantitative real-time polymerase chain reaction (PCR) method. The 18 and six months follow-up of the patients included clinical examination, routine laboratory tests, bone marrow aspirate investigation including cytogenetic tests and the major BCR-ABL fusion gene expression measurement with qRT-PCR method from the peripheral blood. Patient No. 1 diagnosed with chronic phase CML showed excellent adherence to daily 400 mg imatinib treatment and achieved complete hematologic (CHR) and cytogenetic response (CCR) by three months and major molecular response (MMR) by 12 months, with lack of side effects due to imatinib. Patient No. 2 experienced severe hematologic toxicity, which necessitated temporary withdrawal of the drug. Transient non-compliance together with imatinib dose reduction has driven to treatment failure. In this case, mutational analysis is warranted. BCR-ABL fusion gene expression level measurement from peripheral blood with qRT-PCR method is an excellent tool in the follow-up of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee2bb6f12fef47d0a3ddeb7d9f328f4d", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[132, 134], [244, 246], [54, 56], [80, 82]], "char_spans": [[720, 726], [1350, 1356], [272, 278], [406, 412]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["accounts", 35], ["for", 44], ["15", 48], ["-", 50], ["20", 51], ["%", 53], ["of", 55], ["adult", 58], ["leukemias", 64], ["but", 74], ["is", 78], ["very", 81], ["rare", 86], ["in", 91], ["children", 94], ["(", 103], ["2", 104], ["%", 105], [")", 106], [".", 107], ["Fewer", 109], ["than", 115], ["10", 120], ["%", 122], ["of", 124], ["CML", 127], ["patients", 131], ["are", 140], ["younger", 144], ["than", 152], ["20", 157], ["years", 160], [".", 165], ["CML", 167], ["is", 171], ["a", 174], ["myeloproliferative", 176], ["disorder", 195], ["characterized", 204], ["by", 218], ["the", 221], ["presence", 225], ["of", 234], ["the", 237], ["Philadelphia", 241], ["chromosome", 254], ["or", 265], ["the", 268], ["BCR", 272], ["-", 275], ["ABL", 276], ["fusion", 280], ["oncogene", 287], [".", 295], ["The", 297], ["objective", 301], ["of", 311], ["this", 314], ["paper", 319], ["is", 325], ["to", 328], ["present", 331], ["the", 339], ["monitoring", 343], ["of", 354], ["imatinib", 357], ["therapy", 366], ["in", 374], ["two", 377], ["children", 381], ["with", 390], ["CML", 395], ["by", 399], ["the", 402], ["BCR", 406], ["-", 409], ["ABL", 410], ["fusion", 414], ["gene", 421], ["expression", 426], ["assessment", 437], ["from", 448], ["peripheral", 453], ["blood", 464], ["with", 470], ["quantitative", 475], ["real", 488], ["-", 492], ["time", 493], ["polymerase", 498], ["chain", 509], ["reaction", 515], ["(", 524], ["PCR", 525], [")", 528], ["method", 530], [".", 536], ["The", 538], ["18", 542], ["and", 545], ["six", 549], ["months", 553], ["follow", 560], ["-", 566], ["up", 567], ["of", 570], ["the", 573], ["patients", 577], ["included", 586], ["clinical", 595], ["examination", 604], [",", 615], ["routine", 617], ["laboratory", 625], ["tests", 636], [",", 641], ["bone", 643], ["marrow", 648], ["aspirate", 655], ["investigation", 664], ["including", 678], ["cytogenetic", 688], ["tests", 700], ["and", 706], ["the", 710], ["major", 714], ["BCR", 720], ["-", 723], ["ABL", 724], ["fusion", 728], ["gene", 735], ["expression", 740], ["measurement", 751], ["with", 763], ["qRT", 768], ["-", 771], ["PCR", 772], ["method", 776], ["from", 783], ["the", 788], ["peripheral", 792], ["blood", 803], [".", 808], ["Patient", 810], ["No", 818], [".", 820], ["1", 822], ["diagnosed", 824], ["with", 834], ["chronic", 839], ["phase", 847], ["CML", 853], ["showed", 857], ["excellent", 864], ["adherence", 874], ["to", 884], ["daily", 887], ["400", 893], ["mg", 897], ["imatinib", 900], ["treatment", 909], ["and", 919], ["achieved", 923], ["complete", 932], ["hematologic", 941], ["(", 953], ["CHR", 954], [")", 957], ["and", 959], ["cytogenetic", 963], ["response", 975], ["(", 984], ["CCR", 985], [")", 988], ["by", 990], ["three", 993], ["months", 999], ["and", 1006], ["major", 1010], ["molecular", 1016], ["response", 1026], ["(", 1035], ["MMR", 1036], [")", 1039], ["by", 1041], ["12", 1044], ["months", 1047], [",", 1053], ["with", 1055], ["lack", 1060], ["of", 1065], ["side", 1068], ["effects", 1073], ["due", 1081], ["to", 1085], ["imatinib", 1088], [".", 1096], ["Patient", 1098], ["No", 1106], [".", 1108], ["2", 1110], ["experienced", 1112], ["severe", 1124], ["hematologic", 1131], ["toxicity", 1143], [",", 1151], ["which", 1153], ["necessitated", 1159], ["temporary", 1172], ["withdrawal", 1182], ["of", 1193], ["the", 1196], ["drug", 1200], [".", 1204], ["Transient", 1206], ["non", 1216], ["-", 1219], ["compliance", 1220], ["together", 1231], ["with", 1240], ["imatinib", 1245], ["dose", 1254], ["reduction", 1259], ["has", 1269], ["driven", 1273], ["to", 1280], ["treatment", 1283], ["failure", 1293], [".", 1300], ["In", 1302], ["this", 1305], ["case", 1310], [",", 1314], ["mutational", 1316], ["analysis", 1327], ["is", 1336], ["warranted", 1339], [".", 1348], ["BCR", 1350], ["-", 1353], ["ABL", 1354], ["fusion", 1358], ["gene", 1365], ["expression", 1370], ["level", 1381], ["measurement", 1387], ["from", 1399], ["peripheral", 1404], ["blood", 1415], ["with", 1421], ["qRT", 1426], ["-", 1429], ["PCR", 1430], ["method", 1434], ["is", 1441], ["an", 1444], ["excellent", 1447], ["tool", 1457], ["in", 1462], ["the", 1465], ["follow", 1469], ["-", 1475], ["up", 1476], ["of", 1479], ["CML", 1482], ["patients", 1486], [".", 1494]]}
{"context": "In melanoma, transition to the vertical growth phase is the critical step in conversion to a deadly malignant disease. Here, we offer the first evidence that an antioxidant enzyme has a key role in this transition. We found that the antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells. Silencing Prx2 expression stimulated proliferation and migration, whereas ectopic expression of Prx2 produced the opposite effect. Mechanistic investigations indicated that Prx2 negatively regulated Src/ERK activation status, which in turn fortified adherens junctions function by increasing E-cadherin expression and phospho-Y654-dependent retention of \u03b2-catenin in the plasma membrane. In murine melanoma cells, Prx2 silencing enhanced lung metastasis in vivo. Interestingly, the natural compound gliotoxin, which is known to exert a Prx-like activity, inhibited proliferation and migration as well as lung metastasis of Prx2-deficient melanoma cells. Overall, our findings reveal that Prx2 is a key regulator of invasion and metastasis in melanoma, and also suggest a pharmacologic strategy to effectively decrease deadly malignant forms of this disease.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "4725ab4959074b2b82db8e9b8383de5d", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[44, 44], [30, 30]], "char_spans": [[233, 243], [161, 171]]}]}], "context_tokens": [["In", 0], ["melanoma", 3], [",", 11], ["transition", 13], ["to", 24], ["the", 27], ["vertical", 31], ["growth", 40], ["phase", 47], ["is", 53], ["the", 56], ["critical", 60], ["step", 69], ["in", 74], ["conversion", 77], ["to", 88], ["a", 91], ["deadly", 93], ["malignant", 100], ["disease", 110], [".", 117], ["Here", 119], [",", 123], ["we", 125], ["offer", 128], ["the", 134], ["first", 138], ["evidence", 144], ["that", 153], ["an", 158], ["antioxidant", 161], ["enzyme", 173], ["has", 180], ["a", 184], ["key", 186], ["role", 190], ["in", 195], ["this", 198], ["transition", 203], [".", 213], ["We", 215], ["found", 218], ["that", 224], ["the", 229], ["antioxidant", 233], ["enzyme", 245], ["peroxiredoxin-2", 252], ["(", 268], ["Prx2", 269], [")", 273], ["inversely", 275], ["correlated", 285], ["with", 296], ["the", 301], ["metastatic", 305], ["capacity", 316], ["of", 325], ["human", 328], ["melanoma", 334], ["cells", 343], [".", 348], ["Silencing", 350], ["Prx2", 360], ["expression", 365], ["stimulated", 376], ["proliferation", 387], ["and", 401], ["migration", 405], [",", 414], ["whereas", 416], ["ectopic", 424], ["expression", 432], ["of", 443], ["Prx2", 446], ["produced", 451], ["the", 460], ["opposite", 464], ["effect", 473], [".", 479], ["Mechanistic", 481], ["investigations", 493], ["indicated", 508], ["that", 518], ["Prx2", 523], ["negatively", 528], ["regulated", 539], ["Src", 549], ["/", 552], ["ERK", 553], ["activation", 557], ["status", 568], [",", 574], ["which", 576], ["in", 582], ["turn", 585], ["fortified", 590], ["adherens", 600], ["junctions", 609], ["function", 619], ["by", 628], ["increasing", 631], ["E", 642], ["-", 643], ["cadherin", 644], ["expression", 653], ["and", 664], ["phospho", 668], ["-", 675], ["Y654-dependent", 676], ["retention", 691], ["of", 701], ["\u03b2", 704], ["-", 705], ["catenin", 706], ["in", 714], ["the", 717], ["plasma", 721], ["membrane", 728], [".", 736], ["In", 738], ["murine", 741], ["melanoma", 748], ["cells", 757], [",", 762], ["Prx2", 764], ["silencing", 769], ["enhanced", 779], ["lung", 788], ["metastasis", 793], ["in", 804], ["vivo", 807], [".", 811], ["Interestingly", 813], [",", 826], ["the", 828], ["natural", 832], ["compound", 840], ["gliotoxin", 849], [",", 858], ["which", 860], ["is", 866], ["known", 869], ["to", 875], ["exert", 878], ["a", 884], ["Prx", 886], ["-", 889], ["like", 890], ["activity", 895], [",", 903], ["inhibited", 905], ["proliferation", 915], ["and", 929], ["migration", 933], ["as", 943], ["well", 946], ["as", 951], ["lung", 954], ["metastasis", 959], ["of", 970], ["Prx2-deficient", 973], ["melanoma", 988], ["cells", 997], [".", 1002], ["Overall", 1004], [",", 1011], ["our", 1013], ["findings", 1017], ["reveal", 1026], ["that", 1033], ["Prx2", 1038], ["is", 1043], ["a", 1046], ["key", 1048], ["regulator", 1052], ["of", 1062], ["invasion", 1065], ["and", 1074], ["metastasis", 1078], ["in", 1089], ["melanoma", 1092], [",", 1100], ["and", 1102], ["also", 1106], ["suggest", 1111], ["a", 1119], ["pharmacologic", 1121], ["strategy", 1135], ["to", 1144], ["effectively", 1147], ["decrease", 1159], ["deadly", 1168], ["malignant", 1175], ["forms", 1185], ["of", 1191], ["this", 1194], ["disease", 1199], [".", 1206]]}
{"context": "Restless legs syndrome (RLS), recently renamed Willis-Ekbom disease (WED), is a common movement disorder. It is characterised by the need to move mainly the legs due to uncomfortable, sometimes painful sensations in the legs, which have a diurnal variation and a release with movement. Management is complex. First, centres should establish the severity of RLS using a simple 10-item RLS severity rating scale (IRLS). They should also exclude secondary causes, in particular ensuring normal iron levels. Mild cases can be managed by lifestyle changes, but patients with a IRLS score above 15 usually require pharmacological treatment. Dopaminergic therapies remain the mainstay of medical therapies, with recent evidence suggesting opioids may be particularly effective. This article focuses on the different treatment strategies in RLS, their associated complications and ways to manage them.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "9cce10bf0b6546509cf2de1aba61138e", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["recently", 30], ["renamed", 39], ["Willis", 47], ["-", 53], ["Ekbom", 54], ["disease", 60], ["(", 68], ["WED", 69], [")", 72], [",", 73], ["is", 75], ["a", 78], ["common", 80], ["movement", 87], ["disorder", 96], [".", 104], ["It", 106], ["is", 109], ["characterised", 112], ["by", 126], ["the", 129], ["need", 133], ["to", 138], ["move", 141], ["mainly", 146], ["the", 153], ["legs", 157], ["due", 162], ["to", 166], ["uncomfortable", 169], [",", 182], ["sometimes", 184], ["painful", 194], ["sensations", 202], ["in", 213], ["the", 216], ["legs", 220], [",", 224], ["which", 226], ["have", 232], ["a", 237], ["diurnal", 239], ["variation", 247], ["and", 257], ["a", 261], ["release", 263], ["with", 271], ["movement", 276], [".", 284], ["Management", 286], ["is", 297], ["complex", 300], [".", 307], ["First", 309], [",", 314], ["centres", 316], ["should", 324], ["establish", 331], ["the", 341], ["severity", 345], ["of", 354], ["RLS", 357], ["using", 361], ["a", 367], ["simple", 369], ["10-item", 376], ["RLS", 384], ["severity", 388], ["rating", 397], ["scale", 404], ["(", 410], ["IRLS", 411], [")", 415], [".", 416], ["They", 418], ["should", 423], ["also", 430], ["exclude", 435], ["secondary", 443], ["causes", 453], [",", 459], ["in", 461], ["particular", 464], ["ensuring", 475], ["normal", 484], ["iron", 491], ["levels", 496], [".", 502], ["Mild", 504], ["cases", 509], ["can", 515], ["be", 519], ["managed", 522], ["by", 530], ["lifestyle", 533], ["changes", 543], [",", 550], ["but", 552], ["patients", 556], ["with", 565], ["a", 570], ["IRLS", 572], ["score", 577], ["above", 583], ["15", 589], ["usually", 592], ["require", 600], ["pharmacological", 608], ["treatment", 624], [".", 633], ["Dopaminergic", 635], ["therapies", 648], ["remain", 658], ["the", 665], ["mainstay", 669], ["of", 678], ["medical", 681], ["therapies", 689], [",", 698], ["with", 700], ["recent", 705], ["evidence", 712], ["suggesting", 721], ["opioids", 732], ["may", 740], ["be", 744], ["particularly", 747], ["effective", 760], [".", 769], ["This", 771], ["article", 776], ["focuses", 784], ["on", 792], ["the", 795], ["different", 799], ["treatment", 809], ["strategies", 819], ["in", 830], ["RLS", 833], [",", 836], ["their", 838], ["associated", 844], ["complications", 855], ["and", 869], ["ways", 873], ["to", 878], ["manage", 881], ["them", 888], [".", 892]]}
{"context": "To assess the efficacy and safety of R788 (fostamatinib disodium), an inhibitor of spleen tyrosine kinase (Syk), in patients with active rheumatoid arthritis (RA) that did not respond to biologic therapies. A total of 219 patients with active RA in whom treatment with biologic agents had failed were enrolled in a 3-month multicenter, randomized, double-blind, placebo-controlled trial of R788. The primary end point was the percentage of patients who met the American College of Rheumatology 20% improvement criteria (achieved an ACR20 response) at month 3. Secondary end points included changes in inflammation and damage, as assessed by magnetic resonance imaging (MRI), and changes in the Disease Activity Score. The ACR20 response in the R788 100 mg twice daily group was 38%, versus 37% in the placebo group, at month 3. No significant differences were achieved in the ACR20, ACR50, or ACR70 response levels at 3 months. There were differences between the groups from baseline to month 3 in the secondary end points C-reactive protein (CRP) level and synovitis score on MRI. There were baseline differences in steroid use, prior biologic use, and synovitis score on MRI between the R788 group and the placebo group that may have affected the outcomes. A high placebo response rate was seen in this trial, and exploratory analysis suggested that this may in part have been driven by patients who entered the trial with an elevated erythrocyte sedimentation rate but normal CRP level. Our findings indicate that there were no differences in the primary end point between the R788 and placebo groups. Differences were observed between the R788 and placebo groups in secondary end points, particularly in those patients who entered the study with an elevated CRP level.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "da2a8dc6772a49fb956f810030d12b53", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[16, 18]], "char_spans": [[83, 104]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["efficacy", 14], ["and", 23], ["safety", 27], ["of", 34], ["R788", 37], ["(", 42], ["fostamatinib", 43], ["disodium", 56], [")", 64], [",", 65], ["an", 67], ["inhibitor", 70], ["of", 80], ["spleen", 83], ["tyrosine", 90], ["kinase", 99], ["(", 106], ["Syk", 107], [")", 110], [",", 111], ["in", 113], ["patients", 116], ["with", 125], ["active", 130], ["rheumatoid", 137], ["arthritis", 148], ["(", 158], ["RA", 159], [")", 161], ["that", 163], ["did", 168], ["not", 172], ["respond", 176], ["to", 184], ["biologic", 187], ["therapies", 196], [".", 205], ["A", 207], ["total", 209], ["of", 215], ["219", 218], ["patients", 222], ["with", 231], ["active", 236], ["RA", 243], ["in", 246], ["whom", 249], ["treatment", 254], ["with", 264], ["biologic", 269], ["agents", 278], ["had", 285], ["failed", 289], ["were", 296], ["enrolled", 301], ["in", 310], ["a", 313], ["3-month", 315], ["multicenter", 323], [",", 334], ["randomized", 336], [",", 346], ["double", 348], ["-", 354], ["blind", 355], [",", 360], ["placebo", 362], ["-", 369], ["controlled", 370], ["trial", 381], ["of", 387], ["R788", 390], [".", 394], ["The", 396], ["primary", 400], ["end", 408], ["point", 412], ["was", 418], ["the", 422], ["percentage", 426], ["of", 437], ["patients", 440], ["who", 449], ["met", 453], ["the", 457], ["American", 461], ["College", 470], ["of", 478], ["Rheumatology", 481], ["20", 494], ["%", 496], ["improvement", 498], ["criteria", 510], ["(", 519], ["achieved", 520], ["an", 529], ["ACR20", 532], ["response", 538], [")", 546], ["at", 548], ["month", 551], ["3", 557], [".", 558], ["Secondary", 560], ["end", 570], ["points", 574], ["included", 581], ["changes", 590], ["in", 598], ["inflammation", 601], ["and", 614], ["damage", 618], [",", 624], ["as", 626], ["assessed", 629], ["by", 638], ["magnetic", 641], ["resonance", 650], ["imaging", 660], ["(", 668], ["MRI", 669], [")", 672], [",", 673], ["and", 675], ["changes", 679], ["in", 687], ["the", 690], ["Disease", 694], ["Activity", 702], ["Score", 711], [".", 716], ["The", 718], ["ACR20", 722], ["response", 728], ["in", 737], ["the", 740], ["R788", 744], ["100", 749], ["mg", 753], ["twice", 756], ["daily", 762], ["group", 768], ["was", 774], ["38", 778], ["%", 780], [",", 781], ["versus", 783], ["37", 790], ["%", 792], ["in", 794], ["the", 797], ["placebo", 801], ["group", 809], [",", 814], ["at", 816], ["month", 819], ["3", 825], [".", 826], ["No", 828], ["significant", 831], ["differences", 843], ["were", 855], ["achieved", 860], ["in", 869], ["the", 872], ["ACR20", 876], [",", 881], ["ACR50", 883], [",", 888], ["or", 890], ["ACR70", 893], ["response", 899], ["levels", 908], ["at", 915], ["3", 918], ["months", 920], [".", 926], ["There", 928], ["were", 934], ["differences", 939], ["between", 951], ["the", 959], ["groups", 963], ["from", 970], ["baseline", 975], ["to", 984], ["month", 987], ["3", 993], ["in", 995], ["the", 998], ["secondary", 1002], ["end", 1012], ["points", 1016], ["C", 1023], ["-", 1024], ["reactive", 1025], ["protein", 1034], ["(", 1042], ["CRP", 1043], [")", 1046], ["level", 1048], ["and", 1054], ["synovitis", 1058], ["score", 1068], ["on", 1074], ["MRI", 1077], [".", 1080], ["There", 1082], ["were", 1088], ["baseline", 1093], ["differences", 1102], ["in", 1114], ["steroid", 1117], ["use", 1125], [",", 1128], ["prior", 1130], ["biologic", 1136], ["use", 1145], [",", 1148], ["and", 1150], ["synovitis", 1154], ["score", 1164], ["on", 1170], ["MRI", 1173], ["between", 1177], ["the", 1185], ["R788", 1189], ["group", 1194], ["and", 1200], ["the", 1204], ["placebo", 1208], ["group", 1216], ["that", 1222], ["may", 1227], ["have", 1231], ["affected", 1236], ["the", 1245], ["outcomes", 1249], [".", 1257], ["A", 1259], ["high", 1261], ["placebo", 1266], ["response", 1274], ["rate", 1283], ["was", 1288], ["seen", 1292], ["in", 1297], ["this", 1300], ["trial", 1305], [",", 1310], ["and", 1312], ["exploratory", 1316], ["analysis", 1328], ["suggested", 1337], ["that", 1347], ["this", 1352], ["may", 1357], ["in", 1361], ["part", 1364], ["have", 1369], ["been", 1374], ["driven", 1379], ["by", 1386], ["patients", 1389], ["who", 1398], ["entered", 1402], ["the", 1410], ["trial", 1414], ["with", 1420], ["an", 1425], ["elevated", 1428], ["erythrocyte", 1437], ["sedimentation", 1449], ["rate", 1463], ["but", 1468], ["normal", 1472], ["CRP", 1479], ["level", 1483], [".", 1488], ["Our", 1490], ["findings", 1494], ["indicate", 1503], ["that", 1512], ["there", 1517], ["were", 1523], ["no", 1528], ["differences", 1531], ["in", 1543], ["the", 1546], ["primary", 1550], ["end", 1558], ["point", 1562], ["between", 1568], ["the", 1576], ["R788", 1580], ["and", 1585], ["placebo", 1589], ["groups", 1597], [".", 1603], ["Differences", 1605], ["were", 1617], ["observed", 1622], ["between", 1631], ["the", 1639], ["R788", 1643], ["and", 1648], ["placebo", 1652], ["groups", 1660], ["in", 1667], ["secondary", 1670], ["end", 1680], ["points", 1684], [",", 1690], ["particularly", 1692], ["in", 1705], ["those", 1708], ["patients", 1714], ["who", 1723], ["entered", 1727], ["the", 1735], ["study", 1739], ["with", 1745], ["an", 1750], ["elevated", 1753], ["CRP", 1762], ["level", 1766], [".", 1771]]}
{"context": "NADPH oxidase (Nox) family enzymes are one of the main sources of cellular reactive oxygen species (ROS), which have been shown to function as second messenger molecules. To date, seven members of this family have been reported, including Nox1-5 and Duox1 and -2. With the exception of Nox2, the regulation of the Nox enzymes is still poorly understood. Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase, for its activity. In this study, we investigate the role of the tyrosine kinase c-Src in the regulation of ROS formation by Nox1. We show that c-Src induces Nox1-mediated ROS generation in the HT29 human colon carcinoma cell line through a Rac-dependent mechanism. Treatment of HT29 cells with the Src inhibitor PP2, expression of a kinase-inactive form of c-Src, and c-Src depletion by small interfering RNA (siRNA) reduce both ROS generation and the levels of active Rac1. This is associated with decreased Src-mediated phosphorylation and activation of the Rac1-guanine nucleotide exchange factor Vav2. Consistent with this, Vav2 siRNA that specifically reduces endogenous Vav2 protein is able to dramatically decrease Nox1-dependent ROS generation and abolish c-Src-induced Nox1 activity. Together, these results establish c-Src as an important regulator of Nox1 activity, and they may provide insight into the mechanisms of tumor formation in colon cancers.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "fdc8771a13204b6eb28d48a0e3f1d6c5", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[259, 259], [125, 125], [243, 243], [71, 71], [46, 46]], "char_spans": [[1353, 1356], [615, 618], [1269, 1272], [354, 357], [239, 242]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["(", 14], ["Nox", 15], [")", 18], ["family", 20], ["enzymes", 27], ["are", 35], ["one", 39], ["of", 43], ["the", 46], ["main", 50], ["sources", 55], ["of", 63], ["cellular", 66], ["reactive", 75], ["oxygen", 84], ["species", 91], ["(", 99], ["ROS", 100], [")", 103], [",", 104], ["which", 106], ["have", 112], ["been", 117], ["shown", 122], ["to", 128], ["function", 131], ["as", 140], ["second", 143], ["messenger", 150], ["molecules", 160], [".", 169], ["To", 171], ["date", 174], [",", 178], ["seven", 180], ["members", 186], ["of", 194], ["this", 197], ["family", 202], ["have", 209], ["been", 214], ["reported", 219], [",", 227], ["including", 229], ["Nox1", 239], ["-", 243], ["5", 244], ["and", 246], ["Duox1", 250], ["and", 256], ["-2", 260], [".", 262], ["With", 264], ["the", 269], ["exception", 273], ["of", 283], ["Nox2", 286], [",", 290], ["the", 292], ["regulation", 296], ["of", 307], ["the", 310], ["Nox", 314], ["enzymes", 318], ["is", 326], ["still", 329], ["poorly", 335], ["understood", 342], [".", 352], ["Nox1", 354], ["is", 359], ["highly", 362], ["expressed", 369], ["in", 379], ["the", 382], ["colon", 386], [",", 391], ["and", 393], ["it", 397], ["requires", 400], ["two", 409], ["cytosolic", 413], ["regulators", 423], [",", 433], ["NoxO1", 435], ["and", 441], ["NoxA1", 445], [",", 450], ["as", 452], ["well", 455], ["as", 460], ["the", 463], ["binding", 467], ["of", 475], ["Rac1", 478], ["GTPase", 483], [",", 489], ["for", 491], ["its", 495], ["activity", 499], [".", 507], ["In", 509], ["this", 512], ["study", 517], [",", 522], ["we", 524], ["investigate", 527], ["the", 539], ["role", 543], ["of", 548], ["the", 551], ["tyrosine", 555], ["kinase", 564], ["c", 571], ["-", 572], ["Src", 573], ["in", 577], ["the", 580], ["regulation", 584], ["of", 595], ["ROS", 598], ["formation", 602], ["by", 612], ["Nox1", 615], [".", 619], ["We", 621], ["show", 624], ["that", 629], ["c", 634], ["-", 635], ["Src", 636], ["induces", 640], ["Nox1-mediated", 648], ["ROS", 662], ["generation", 666], ["in", 677], ["the", 680], ["HT29", 684], ["human", 689], ["colon", 695], ["carcinoma", 701], ["cell", 711], ["line", 716], ["through", 721], ["a", 729], ["Rac", 731], ["-", 734], ["dependent", 735], ["mechanism", 745], [".", 754], ["Treatment", 756], ["of", 766], ["HT29", 769], ["cells", 774], ["with", 780], ["the", 785], ["Src", 789], ["inhibitor", 793], ["PP2", 803], [",", 806], ["expression", 808], ["of", 819], ["a", 822], ["kinase", 824], ["-", 830], ["inactive", 831], ["form", 840], ["of", 845], ["c", 848], ["-", 849], ["Src", 850], [",", 853], ["and", 855], ["c", 859], ["-", 860], ["Src", 861], ["depletion", 865], ["by", 875], ["small", 878], ["interfering", 884], ["RNA", 896], ["(", 900], ["siRNA", 901], [")", 906], ["reduce", 908], ["both", 915], ["ROS", 920], ["generation", 924], ["and", 935], ["the", 939], ["levels", 943], ["of", 950], ["active", 953], ["Rac1", 960], [".", 964], ["This", 966], ["is", 971], ["associated", 974], ["with", 985], ["decreased", 990], ["Src", 1000], ["-", 1003], ["mediated", 1004], ["phosphorylation", 1013], ["and", 1029], ["activation", 1033], ["of", 1044], ["the", 1047], ["Rac1-guanine", 1051], ["nucleotide", 1064], ["exchange", 1075], ["factor", 1084], ["Vav2", 1091], [".", 1095], ["Consistent", 1097], ["with", 1108], ["this", 1113], [",", 1117], ["Vav2", 1119], ["siRNA", 1124], ["that", 1130], ["specifically", 1135], ["reduces", 1148], ["endogenous", 1156], ["Vav2", 1167], ["protein", 1172], ["is", 1180], ["able", 1183], ["to", 1188], ["dramatically", 1191], ["decrease", 1204], ["Nox1-dependent", 1213], ["ROS", 1228], ["generation", 1232], ["and", 1243], ["abolish", 1247], ["c", 1255], ["-", 1256], ["Src", 1257], ["-", 1260], ["induced", 1261], ["Nox1", 1269], ["activity", 1274], [".", 1282], ["Together", 1284], [",", 1292], ["these", 1294], ["results", 1300], ["establish", 1308], ["c", 1318], ["-", 1319], ["Src", 1320], ["as", 1324], ["an", 1327], ["important", 1330], ["regulator", 1340], ["of", 1350], ["Nox1", 1353], ["activity", 1358], [",", 1366], ["and", 1368], ["they", 1372], ["may", 1377], ["provide", 1381], ["insight", 1389], ["into", 1397], ["the", 1402], ["mechanisms", 1406], ["of", 1417], ["tumor", 1420], ["formation", 1426], ["in", 1436], ["colon", 1439], ["cancers", 1445], [".", 1452]]}
{"context": "The CRISPR/Cas system in prokaryotes provides resistance against invading viruses and plasmids. Three distinct stages in the mechanism can be recognized. Initially, fragments of invader DNA are integrated as new spacers into the repetitive CRISPR locus. Subsequently, the CRISPR is transcribed and the transcript is cleaved by a Cas protein within the repeats, generating short RNAs (crRNAs) that contain the spacer sequence. Finally, crRNAs guide the Cas protein machinery to a complementary invader target, either DNA or RNA, resulting in inhibition of virus or plasmid proliferation. In this article, we discuss our current understanding of this fascinating adaptive and heritable defense system, and describe functional similarities and differences with RNAi in eukaryotes.", "qas": [{"question": "Gene silencing can be achieved by RNA interference (RNAi) in eukaryotic organisms. What is the name of the analogous process in prokaryotic organisms?", "answers": ["CRISPR-Cas"], "qid": "3b60bd7ce68145749fb65cfe5ee7d2cf", "question_tokens": [["Gene", 0], ["silencing", 5], ["can", 15], ["be", 19], ["achieved", 22], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["in", 58], ["eukaryotic", 61], ["organisms", 72], [".", 81], ["What", 83], ["is", 88], ["the", 91], ["name", 95], ["of", 100], ["the", 103], ["analogous", 107], ["process", 117], ["in", 125], ["prokaryotic", 128], ["organisms", 140], ["?", 149]], "detected_answers": [{"text": "CRISPR-Cas", "token_spans": [[1, 3]], "char_spans": [[4, 13]]}]}], "context_tokens": [["The", 0], ["CRISPR", 4], ["/", 10], ["Cas", 11], ["system", 15], ["in", 22], ["prokaryotes", 25], ["provides", 37], ["resistance", 46], ["against", 57], ["invading", 65], ["viruses", 74], ["and", 82], ["plasmids", 86], [".", 94], ["Three", 96], ["distinct", 102], ["stages", 111], ["in", 118], ["the", 121], ["mechanism", 125], ["can", 135], ["be", 139], ["recognized", 142], [".", 152], ["Initially", 154], [",", 163], ["fragments", 165], ["of", 175], ["invader", 178], ["DNA", 186], ["are", 190], ["integrated", 194], ["as", 205], ["new", 208], ["spacers", 212], ["into", 220], ["the", 225], ["repetitive", 229], ["CRISPR", 240], ["locus", 247], [".", 252], ["Subsequently", 254], [",", 266], ["the", 268], ["CRISPR", 272], ["is", 279], ["transcribed", 282], ["and", 294], ["the", 298], ["transcript", 302], ["is", 313], ["cleaved", 316], ["by", 324], ["a", 327], ["Cas", 329], ["protein", 333], ["within", 341], ["the", 348], ["repeats", 352], [",", 359], ["generating", 361], ["short", 372], ["RNAs", 378], ["(", 383], ["crRNAs", 384], [")", 390], ["that", 392], ["contain", 397], ["the", 405], ["spacer", 409], ["sequence", 416], [".", 424], ["Finally", 426], [",", 433], ["crRNAs", 435], ["guide", 442], ["the", 448], ["Cas", 452], ["protein", 456], ["machinery", 464], ["to", 474], ["a", 477], ["complementary", 479], ["invader", 493], ["target", 501], [",", 507], ["either", 509], ["DNA", 516], ["or", 520], ["RNA", 523], [",", 526], ["resulting", 528], ["in", 538], ["inhibition", 541], ["of", 552], ["virus", 555], ["or", 561], ["plasmid", 564], ["proliferation", 572], [".", 585], ["In", 587], ["this", 590], ["article", 595], [",", 602], ["we", 604], ["discuss", 607], ["our", 615], ["current", 619], ["understanding", 627], ["of", 641], ["this", 644], ["fascinating", 649], ["adaptive", 661], ["and", 670], ["heritable", 674], ["defense", 684], ["system", 692], [",", 698], ["and", 700], ["describe", 704], ["functional", 713], ["similarities", 724], ["and", 737], ["differences", 741], ["with", 753], ["RNAi", 758], ["in", 763], ["eukaryotes", 766], [".", 776]]}
{"context": "In the previous study, we generated a rat model of dilated cardiomyopathy (DCM) induced by adriamycin and found that the expression of lncRNA H19 was significantly upregulated in myocardial tissue. The present study was aimed to investigate the potential role of H19 in the pathogenesis of adriamycin-induced DCM. H19 knockdown in the myocardium of DCM rats attenuated cardiomyocyte apoptosis and improved left ventricular structure and function. Adriamycin treatment was associated with elevated H19 and miR-675 expression and increased apoptosis in neonatal cardiomyocytes. Enforced expression of miR-675 was found to induce apoptosis in cardiomyocytes with adriamycin treatment and H19-siRNA transfection. The 3'-untranslated region of PA2G4 was cloned downstream of a luciferase reporter construct and cotransfected into HEK293 cells with miR-675 mimic. The results of luciferase assay showed that PA2G4 was a direct target of miR-675. The expression of PA2G4 was reduced in cardiomyocytes transfected with miR-675 mimic. Moreover, H19 knockdown was found to increase PA2G4 expression and suppress apoptosis in cardiomyocytes exposed to adriamycin. In conclusion, our study suggests that H19/miR-675 axis is involved in the promotion of cardiomyocyte apoptosis by targeting PA2G4, which may provide a new therapeutic strategy for the treatment of adriamycin-induced DCM.", "qas": [{"question": "Name an lncRNA associated with dilated cardiomyopathy.", "answers": ["lncRNA H19"], "qid": "3c81cb4513234032a3bb15f1165ca927", "question_tokens": [["Name", 0], ["an", 5], ["lncRNA", 8], ["associated", 15], ["with", 26], ["dilated", 31], ["cardiomyopathy", 39], [".", 53]], "detected_answers": [{"text": "lncRNA H19", "token_spans": [[25, 26]], "char_spans": [[135, 144]]}]}], "context_tokens": [["In", 0], ["the", 3], ["previous", 7], ["study", 16], [",", 21], ["we", 23], ["generated", 26], ["a", 36], ["rat", 38], ["model", 42], ["of", 48], ["dilated", 51], ["cardiomyopathy", 59], ["(", 74], ["DCM", 75], [")", 78], ["induced", 80], ["by", 88], ["adriamycin", 91], ["and", 102], ["found", 106], ["that", 112], ["the", 117], ["expression", 121], ["of", 132], ["lncRNA", 135], ["H19", 142], ["was", 146], ["significantly", 150], ["upregulated", 164], ["in", 176], ["myocardial", 179], ["tissue", 190], [".", 196], ["The", 198], ["present", 202], ["study", 210], ["was", 216], ["aimed", 220], ["to", 226], ["investigate", 229], ["the", 241], ["potential", 245], ["role", 255], ["of", 260], ["H19", 263], ["in", 267], ["the", 270], ["pathogenesis", 274], ["of", 287], ["adriamycin", 290], ["-", 300], ["induced", 301], ["DCM", 309], [".", 312], ["H19", 314], ["knockdown", 318], ["in", 328], ["the", 331], ["myocardium", 335], ["of", 346], ["DCM", 349], ["rats", 353], ["attenuated", 358], ["cardiomyocyte", 369], ["apoptosis", 383], ["and", 393], ["improved", 397], ["left", 406], ["ventricular", 411], ["structure", 423], ["and", 433], ["function", 437], [".", 445], ["Adriamycin", 447], ["treatment", 458], ["was", 468], ["associated", 472], ["with", 483], ["elevated", 488], ["H19", 497], ["and", 501], ["miR-675", 505], ["expression", 513], ["and", 524], ["increased", 528], ["apoptosis", 538], ["in", 548], ["neonatal", 551], ["cardiomyocytes", 560], [".", 574], ["Enforced", 576], ["expression", 585], ["of", 596], ["miR-675", 599], ["was", 607], ["found", 611], ["to", 617], ["induce", 620], ["apoptosis", 627], ["in", 637], ["cardiomyocytes", 640], ["with", 655], ["adriamycin", 660], ["treatment", 671], ["and", 681], ["H19-siRNA", 685], ["transfection", 695], [".", 707], ["The", 709], ["3'-untranslated", 713], ["region", 729], ["of", 736], ["PA2G4", 739], ["was", 745], ["cloned", 749], ["downstream", 756], ["of", 767], ["a", 770], ["luciferase", 772], ["reporter", 783], ["construct", 792], ["and", 802], ["cotransfected", 806], ["into", 820], ["HEK293", 825], ["cells", 832], ["with", 838], ["miR-675", 843], ["mimic", 851], [".", 856], ["The", 858], ["results", 862], ["of", 870], ["luciferase", 873], ["assay", 884], ["showed", 890], ["that", 897], ["PA2G4", 902], ["was", 908], ["a", 912], ["direct", 914], ["target", 921], ["of", 928], ["miR-675", 931], [".", 938], ["The", 940], ["expression", 944], ["of", 955], ["PA2G4", 958], ["was", 964], ["reduced", 968], ["in", 976], ["cardiomyocytes", 979], ["transfected", 994], ["with", 1006], ["miR-675", 1011], ["mimic", 1019], [".", 1024], ["Moreover", 1026], [",", 1034], ["H19", 1036], ["knockdown", 1040], ["was", 1050], ["found", 1054], ["to", 1060], ["increase", 1063], ["PA2G4", 1072], ["expression", 1078], ["and", 1089], ["suppress", 1093], ["apoptosis", 1102], ["in", 1112], ["cardiomyocytes", 1115], ["exposed", 1130], ["to", 1138], ["adriamycin", 1141], [".", 1151], ["In", 1153], ["conclusion", 1156], [",", 1166], ["our", 1168], ["study", 1172], ["suggests", 1178], ["that", 1187], ["H19/miR-675", 1192], ["axis", 1204], ["is", 1209], ["involved", 1212], ["in", 1221], ["the", 1224], ["promotion", 1228], ["of", 1238], ["cardiomyocyte", 1241], ["apoptosis", 1255], ["by", 1265], ["targeting", 1268], ["PA2G4", 1278], [",", 1283], ["which", 1285], ["may", 1291], ["provide", 1295], ["a", 1303], ["new", 1305], ["therapeutic", 1309], ["strategy", 1321], ["for", 1330], ["the", 1334], ["treatment", 1338], ["of", 1348], ["adriamycin", 1351], ["-", 1361], ["induced", 1362], ["DCM", 1370], [".", 1373]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem. Rapid detection of MRSA-colonized patients has the potential to limit spread of the organism. We evaluated the sensitivities and specificities of MRSA detection by two molecular methods (IDI-MRSA PCR assay and GenoType MRSA Direct PCR assay) and three selective MRSA agars (MRSA ID, MRSASelect, and CHROMagar MRSA), using 205 (101 nasal, 52 groin, and 52 axillary samples) samples from consecutive known MRSA-infected and/or -colonized patients. All detection methods had higher MRSA detection rates for nasal swabs than for axillary and groin swabs. Detection of MRSA by IDI-MRSA was the most sensitive method, independent of the site (94% for nasal samples, 80% for nonnasal samples, and 90% overall). The sensitivities of the GenoType MRSA Direct assay and the MRSA ID, MRSASelect, and CHROMagar MRSA agars with nasal swabs were 70%, 72%, 68%, and 75%, respectively. All detection methods had high specificities (95 to 99%), independent of the swab site. Extended incubation for a further 24 h with selective MRSA agars increased the detection of MRSA, with a corresponding decline in specificity secondary to a significant increase in false-positive results. There was a noticeable difference in test performance of the GenoType MRSA Direct assay in detection of MRSA (28/38 samples [74%]) compared with detection of nonmultiresistant MRSA (17/31 samples [55%]) (susceptible to two or more non-beta-lactam antibiotics). This was not observed with selective MRSA agar plates or IDI-MRSA. Although it is more expensive, in addition to rapid turnaround times of 2 to 4 h, IDI-MRSA offers greater detection of MRSA colonization, independent of the swab site, than do conventional selective agars and GenoType MRSA Direct.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "b942fc23c0bf4ebe9bf8e76ac4b3a998", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[161, 161], [351, 351], [16, 16], [51, 51], [117, 117], [6, 6], [308, 308], [121, 121], [259, 259], [59, 59], [69, 69], [253, 253], [302, 302], [62, 62], [335, 335], [90, 90], [102, 102], [217, 217], [273, 273], [37, 37], [330, 330], [156, 156], [168, 168], [46, 46], [223, 223]], "char_spans": [[841, 844], [1786, 1789], [96, 99], [296, 299], [641, 644], [45, 48], [1562, 1565], [653, 656], [1344, 1347], [339, 342], [386, 389], [1310, 1313], [1538, 1541], [351, 354], [1687, 1690], [481, 484], [556, 559], [1089, 1092], [1416, 1419], [223, 226], [1654, 1657], [815, 818], [876, 879], [268, 271], [1127, 1130]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["is", 51], ["an", 54], ["increasing", 57], ["problem", 68], [".", 75], ["Rapid", 77], ["detection", 83], ["of", 93], ["MRSA", 96], ["-", 100], ["colonized", 101], ["patients", 111], ["has", 120], ["the", 124], ["potential", 128], ["to", 138], ["limit", 141], ["spread", 147], ["of", 154], ["the", 157], ["organism", 161], [".", 169], ["We", 171], ["evaluated", 174], ["the", 184], ["sensitivities", 188], ["and", 202], ["specificities", 206], ["of", 220], ["MRSA", 223], ["detection", 228], ["by", 238], ["two", 241], ["molecular", 245], ["methods", 255], ["(", 263], ["IDI", 264], ["-", 267], ["MRSA", 268], ["PCR", 273], ["assay", 277], ["and", 283], ["GenoType", 287], ["MRSA", 296], ["Direct", 301], ["PCR", 308], ["assay", 312], [")", 317], ["and", 319], ["three", 323], ["selective", 329], ["MRSA", 339], ["agars", 344], ["(", 350], ["MRSA", 351], ["ID", 356], [",", 358], ["MRSASelect", 360], [",", 370], ["and", 372], ["CHROMagar", 376], ["MRSA", 386], [")", 390], [",", 391], ["using", 393], ["205", 399], ["(", 403], ["101", 404], ["nasal", 408], [",", 413], ["52", 415], ["groin", 418], [",", 423], ["and", 425], ["52", 429], ["axillary", 432], ["samples", 441], [")", 448], ["samples", 450], ["from", 458], ["consecutive", 463], ["known", 475], ["MRSA", 481], ["-", 485], ["infected", 486], ["and/or", 495], ["-colonized", 502], ["patients", 513], [".", 521], ["All", 523], ["detection", 527], ["methods", 537], ["had", 545], ["higher", 549], ["MRSA", 556], ["detection", 561], ["rates", 571], ["for", 577], ["nasal", 581], ["swabs", 587], ["than", 593], ["for", 598], ["axillary", 602], ["and", 611], ["groin", 615], ["swabs", 621], [".", 626], ["Detection", 628], ["of", 638], ["MRSA", 641], ["by", 646], ["IDI", 649], ["-", 652], ["MRSA", 653], ["was", 658], ["the", 662], ["most", 666], ["sensitive", 671], ["method", 681], [",", 687], ["independent", 689], ["of", 701], ["the", 704], ["site", 708], ["(", 713], ["94", 714], ["%", 716], ["for", 718], ["nasal", 722], ["samples", 728], [",", 735], ["80", 737], ["%", 739], ["for", 741], ["nonnasal", 745], ["samples", 754], [",", 761], ["and", 763], ["90", 767], ["%", 769], ["overall", 771], [")", 778], [".", 779], ["The", 781], ["sensitivities", 785], ["of", 799], ["the", 802], ["GenoType", 806], ["MRSA", 815], ["Direct", 820], ["assay", 827], ["and", 833], ["the", 837], ["MRSA", 841], ["ID", 846], [",", 848], ["MRSASelect", 850], [",", 860], ["and", 862], ["CHROMagar", 866], ["MRSA", 876], ["agars", 881], ["with", 887], ["nasal", 892], ["swabs", 898], ["were", 904], ["70", 909], ["%", 911], [",", 912], ["72", 914], ["%", 916], [",", 917], ["68", 919], ["%", 921], [",", 922], ["and", 924], ["75", 928], ["%", 930], [",", 931], ["respectively", 933], [".", 945], ["All", 947], ["detection", 951], ["methods", 961], ["had", 969], ["high", 973], ["specificities", 978], ["(", 992], ["95", 993], ["to", 996], ["99", 999], ["%", 1001], [")", 1002], [",", 1003], ["independent", 1005], ["of", 1017], ["the", 1020], ["swab", 1024], ["site", 1029], [".", 1033], ["Extended", 1035], ["incubation", 1044], ["for", 1055], ["a", 1059], ["further", 1061], ["24", 1069], ["h", 1072], ["with", 1074], ["selective", 1079], ["MRSA", 1089], ["agars", 1094], ["increased", 1100], ["the", 1110], ["detection", 1114], ["of", 1124], ["MRSA", 1127], [",", 1131], ["with", 1133], ["a", 1138], ["corresponding", 1140], ["decline", 1154], ["in", 1162], ["specificity", 1165], ["secondary", 1177], ["to", 1187], ["a", 1190], ["significant", 1192], ["increase", 1204], ["in", 1213], ["false", 1216], ["-", 1221], ["positive", 1222], ["results", 1231], [".", 1238], ["There", 1240], ["was", 1246], ["a", 1250], ["noticeable", 1252], ["difference", 1263], ["in", 1274], ["test", 1277], ["performance", 1282], ["of", 1294], ["the", 1297], ["GenoType", 1301], ["MRSA", 1310], ["Direct", 1315], ["assay", 1322], ["in", 1328], ["detection", 1331], ["of", 1341], ["MRSA", 1344], ["(", 1349], ["28/38", 1350], ["samples", 1356], ["[", 1364], ["74", 1365], ["%", 1367], ["]", 1368], [")", 1369], ["compared", 1371], ["with", 1380], ["detection", 1385], ["of", 1395], ["nonmultiresistant", 1398], ["MRSA", 1416], ["(", 1421], ["17/31", 1422], ["samples", 1428], ["[", 1436], ["55", 1437], ["%", 1439], ["]", 1440], [")", 1441], ["(", 1443], ["susceptible", 1444], ["to", 1456], ["two", 1459], ["or", 1463], ["more", 1466], ["non", 1471], ["-", 1474], ["beta", 1475], ["-", 1479], ["lactam", 1480], ["antibiotics", 1487], [")", 1498], [".", 1499], ["This", 1501], ["was", 1506], ["not", 1510], ["observed", 1514], ["with", 1523], ["selective", 1528], ["MRSA", 1538], ["agar", 1543], ["plates", 1548], ["or", 1555], ["IDI", 1558], ["-", 1561], ["MRSA", 1562], [".", 1566], ["Although", 1568], ["it", 1577], ["is", 1580], ["more", 1583], ["expensive", 1588], [",", 1597], ["in", 1599], ["addition", 1602], ["to", 1611], ["rapid", 1614], ["turnaround", 1620], ["times", 1631], ["of", 1637], ["2", 1640], ["to", 1642], ["4", 1645], ["h", 1647], [",", 1648], ["IDI", 1650], ["-", 1653], ["MRSA", 1654], ["offers", 1659], ["greater", 1666], ["detection", 1674], ["of", 1684], ["MRSA", 1687], ["colonization", 1692], [",", 1704], ["independent", 1706], ["of", 1718], ["the", 1721], ["swab", 1725], ["site", 1730], [",", 1734], ["than", 1736], ["do", 1741], ["conventional", 1744], ["selective", 1757], ["agars", 1767], ["and", 1773], ["GenoType", 1777], ["MRSA", 1786], ["Direct", 1791], [".", 1797]]}
{"context": "Deletions of the proximal long arm of chromosome 15 (bands 15q11q13) are found in the majority of patients with two distinct genetic disorders, Angelman syndrome (AS) and Prader-Willi syndrome (PWS). The deleted regions in the two syndromes, defined cytogenetically and by using cloned DNA probes, are similar. However, deletions in AS occur on the maternally inherited chromosome 15, and deletions in PWS occur on the paternally derived chromosome 15. This observation has led to the suggestion that one or more genes in this region show differential expression dependent on parental origin (genetic imprinting). No genes of known function have previously been mapped to this region. We show here that the gene encoding the GABAA (gamma-aminobutyric acid) receptor beta 3 subunit maps to the AS/PWS region. Deletion of this gene (GABRB3) was found in AS and PWS patients with interstitial cytogenetic deletions. Evidence of beta 3 gene deletion was also found in an AS patient with an unbalanced 13;15 translocation but not in a PWS patient with an unbalanced 9;15 translocation. The localization of this receptor gene to the AS/PWS region suggests a possible role of the inhibitory neurotransmitter GABA in the pathogenesis of one or both of these syndromes.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "b2abafc04b054092acd209ab0f099725", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[32, 35]], "char_spans": [[171, 191]]}]}], "context_tokens": [["Deletions", 0], ["of", 10], ["the", 13], ["proximal", 17], ["long", 26], ["arm", 31], ["of", 35], ["chromosome", 38], ["15", 49], ["(", 52], ["bands", 53], ["15q11q13", 59], [")", 67], ["are", 69], ["found", 73], ["in", 79], ["the", 82], ["majority", 86], ["of", 95], ["patients", 98], ["with", 107], ["two", 112], ["distinct", 116], ["genetic", 125], ["disorders", 133], [",", 142], ["Angelman", 144], ["syndrome", 153], ["(", 162], ["AS", 163], [")", 165], ["and", 167], ["Prader", 171], ["-", 177], ["Willi", 178], ["syndrome", 184], ["(", 193], ["PWS", 194], [")", 197], [".", 198], ["The", 200], ["deleted", 204], ["regions", 212], ["in", 220], ["the", 223], ["two", 227], ["syndromes", 231], [",", 240], ["defined", 242], ["cytogenetically", 250], ["and", 266], ["by", 270], ["using", 273], ["cloned", 279], ["DNA", 286], ["probes", 290], [",", 296], ["are", 298], ["similar", 302], [".", 309], ["However", 311], [",", 318], ["deletions", 320], ["in", 330], ["AS", 333], ["occur", 336], ["on", 342], ["the", 345], ["maternally", 349], ["inherited", 360], ["chromosome", 370], ["15", 381], [",", 383], ["and", 385], ["deletions", 389], ["in", 399], ["PWS", 402], ["occur", 406], ["on", 412], ["the", 415], ["paternally", 419], ["derived", 430], ["chromosome", 438], ["15", 449], [".", 451], ["This", 453], ["observation", 458], ["has", 470], ["led", 474], ["to", 478], ["the", 481], ["suggestion", 485], ["that", 496], ["one", 501], ["or", 505], ["more", 508], ["genes", 513], ["in", 519], ["this", 522], ["region", 527], ["show", 534], ["differential", 539], ["expression", 552], ["dependent", 563], ["on", 573], ["parental", 576], ["origin", 585], ["(", 592], ["genetic", 593], ["imprinting", 601], [")", 611], [".", 612], ["No", 614], ["genes", 617], ["of", 623], ["known", 626], ["function", 632], ["have", 641], ["previously", 646], ["been", 657], ["mapped", 662], ["to", 669], ["this", 672], ["region", 677], [".", 683], ["We", 685], ["show", 688], ["here", 693], ["that", 698], ["the", 703], ["gene", 707], ["encoding", 712], ["the", 721], ["GABAA", 725], ["(", 731], ["gamma", 732], ["-", 737], ["aminobutyric", 738], ["acid", 751], [")", 755], ["receptor", 757], ["beta", 766], ["3", 771], ["subunit", 773], ["maps", 781], ["to", 786], ["the", 789], ["AS", 793], ["/", 795], ["PWS", 796], ["region", 800], [".", 806], ["Deletion", 808], ["of", 817], ["this", 820], ["gene", 825], ["(", 830], ["GABRB3", 831], [")", 837], ["was", 839], ["found", 843], ["in", 849], ["AS", 852], ["and", 855], ["PWS", 859], ["patients", 863], ["with", 872], ["interstitial", 877], ["cytogenetic", 890], ["deletions", 902], [".", 911], ["Evidence", 913], ["of", 922], ["beta", 925], ["3", 930], ["gene", 932], ["deletion", 937], ["was", 946], ["also", 950], ["found", 955], ["in", 961], ["an", 964], ["AS", 967], ["patient", 970], ["with", 978], ["an", 983], ["unbalanced", 986], ["13;15", 997], ["translocation", 1003], ["but", 1017], ["not", 1021], ["in", 1025], ["a", 1028], ["PWS", 1030], ["patient", 1034], ["with", 1042], ["an", 1047], ["unbalanced", 1050], ["9;15", 1061], ["translocation", 1066], [".", 1079], ["The", 1081], ["localization", 1085], ["of", 1098], ["this", 1101], ["receptor", 1106], ["gene", 1115], ["to", 1120], ["the", 1123], ["AS", 1127], ["/", 1129], ["PWS", 1130], ["region", 1134], ["suggests", 1141], ["a", 1150], ["possible", 1152], ["role", 1161], ["of", 1166], ["the", 1169], ["inhibitory", 1173], ["neurotransmitter", 1184], ["GABA", 1201], ["in", 1206], ["the", 1209], ["pathogenesis", 1213], ["of", 1226], ["one", 1229], ["or", 1233], ["both", 1236], ["of", 1241], ["these", 1244], ["syndromes", 1250], [".", 1259]]}
{"context": "Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis. In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (nearly all of whom were negative for the human immunodeficiency virus) with pulmonary multidrug-resistant tuberculosis to receive delamanid, at a dose of 100 mg twice daily (161 patients) or 200 mg twice daily (160 patients), or placebo (160 patients) for 2 months in combination with a background drug regimen developed according to World Health Organization guidelines. Sputum cultures were assessed weekly with the use of both liquid broth and solid medium; sputum-culture conversion was defined as a series of five or more consecutive cultures that were negative for growth of M. tuberculosis. The primary efficacy end point was the proportion of patients with sputum-culture conversion in liquid broth medium at 2 months. Among patients who received a background drug regimen plus 100 mg of delamanid twice daily, 45.4% had sputum-culture conversion in liquid broth at 2 months, as compared with 29.6% of patients who received a background drug regimen plus placebo (P=0.008). Likewise, as compared with the placebo group, the group that received the background drug regimen plus 200 mg of delamanid twice daily had a higher proportion of patients with sputum-culture conversion (41.9%, P=0.04). The findings were similar with assessment of sputum-culture conversion in solid medium. Most adverse events were mild to moderate in severity and were evenly distributed across groups. Although no clinical events due to QT prolongation on electrocardiography were observed, QT prolongation was reported significantly more frequently in the groups that received delamanid. Delamanid was associated with an increase in sputum-culture conversion at 2 months among patients with multidrug-resistant tuberculosis. This finding suggests that delamanid could enhance treatment options for multidrug-resistant tuberculosis. (Funded by Otsuka Pharmaceutical Development and Commercialization; ClinicalTrials.gov number, NCT00685360.).", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "9dd06b2102304cdc8188c97c503ffb35", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[165, 165], [374, 374], [76, 76], [359, 359], [40, 40]], "char_spans": [[933, 944], [2152, 2163], [455, 466], [2045, 2056], [239, 250]]}]}], "context_tokens": [["Delamanid", 0], ["(", 10], ["OPC-67683", 11], [")", 20], [",", 21], ["a", 23], ["nitro", 25], ["-", 30], ["dihydro", 31], ["-", 38], ["imidazooxazole", 39], ["derivative", 54], [",", 64], ["is", 66], ["a", 69], ["new", 71], ["antituberculosis", 75], ["medication", 92], ["that", 103], ["inhibits", 108], ["mycolic", 117], ["acid", 125], ["synthesis", 130], ["and", 140], ["has", 144], ["shown", 148], ["potent", 154], ["in", 161], ["vitro", 164], ["and", 170], ["in", 174], ["vivo", 177], ["activity", 182], ["against", 191], ["drug", 199], ["-", 203], ["resistant", 204], ["strains", 214], ["of", 222], ["Mycobacterium", 225], ["tuberculosis", 239], [".", 251], ["In", 253], ["this", 256], ["randomized", 261], [",", 271], ["placebo", 273], ["-", 280], ["controlled", 281], [",", 291], ["multinational", 293], ["clinical", 307], ["trial", 316], [",", 321], ["we", 323], ["assigned", 326], ["481", 335], ["patients", 339], ["(", 348], ["nearly", 349], ["all", 356], ["of", 360], ["whom", 363], ["were", 368], ["negative", 373], ["for", 382], ["the", 386], ["human", 390], ["immunodeficiency", 396], ["virus", 413], [")", 418], ["with", 420], ["pulmonary", 425], ["multidrug", 435], ["-", 444], ["resistant", 445], ["tuberculosis", 455], ["to", 468], ["receive", 471], ["delamanid", 479], [",", 488], ["at", 490], ["a", 493], ["dose", 495], ["of", 500], ["100", 503], ["mg", 507], ["twice", 510], ["daily", 516], ["(", 522], ["161", 523], ["patients", 527], [")", 535], ["or", 537], ["200", 540], ["mg", 544], ["twice", 547], ["daily", 553], ["(", 559], ["160", 560], ["patients", 564], [")", 572], [",", 573], ["or", 575], ["placebo", 578], ["(", 586], ["160", 587], ["patients", 591], [")", 599], ["for", 601], ["2", 605], ["months", 607], ["in", 614], ["combination", 617], ["with", 629], ["a", 634], ["background", 636], ["drug", 647], ["regimen", 652], ["developed", 660], ["according", 670], ["to", 680], ["World", 683], ["Health", 689], ["Organization", 696], ["guidelines", 709], [".", 719], ["Sputum", 721], ["cultures", 728], ["were", 737], ["assessed", 742], ["weekly", 751], ["with", 758], ["the", 763], ["use", 767], ["of", 771], ["both", 774], ["liquid", 779], ["broth", 786], ["and", 792], ["solid", 796], ["medium", 802], [";", 808], ["sputum", 810], ["-", 816], ["culture", 817], ["conversion", 825], ["was", 836], ["defined", 840], ["as", 848], ["a", 851], ["series", 853], ["of", 860], ["five", 863], ["or", 868], ["more", 871], ["consecutive", 876], ["cultures", 888], ["that", 897], ["were", 902], ["negative", 907], ["for", 916], ["growth", 920], ["of", 927], ["M.", 930], ["tuberculosis", 933], [".", 945], ["The", 947], ["primary", 951], ["efficacy", 959], ["end", 968], ["point", 972], ["was", 978], ["the", 982], ["proportion", 986], ["of", 997], ["patients", 1000], ["with", 1009], ["sputum", 1014], ["-", 1020], ["culture", 1021], ["conversion", 1029], ["in", 1040], ["liquid", 1043], ["broth", 1050], ["medium", 1056], ["at", 1063], ["2", 1066], ["months", 1068], [".", 1074], ["Among", 1076], ["patients", 1082], ["who", 1091], ["received", 1095], ["a", 1104], ["background", 1106], ["drug", 1117], ["regimen", 1122], ["plus", 1130], ["100", 1135], ["mg", 1139], ["of", 1142], ["delamanid", 1145], ["twice", 1155], ["daily", 1161], [",", 1166], ["45.4", 1168], ["%", 1172], ["had", 1174], ["sputum", 1178], ["-", 1184], ["culture", 1185], ["conversion", 1193], ["in", 1204], ["liquid", 1207], ["broth", 1214], ["at", 1220], ["2", 1223], ["months", 1225], [",", 1231], ["as", 1233], ["compared", 1236], ["with", 1245], ["29.6", 1250], ["%", 1254], ["of", 1256], ["patients", 1259], ["who", 1268], ["received", 1272], ["a", 1281], ["background", 1283], ["drug", 1294], ["regimen", 1299], ["plus", 1307], ["placebo", 1312], ["(", 1320], ["P=0.008", 1321], [")", 1328], [".", 1329], ["Likewise", 1331], [",", 1339], ["as", 1341], ["compared", 1344], ["with", 1353], ["the", 1358], ["placebo", 1362], ["group", 1370], [",", 1375], ["the", 1377], ["group", 1381], ["that", 1387], ["received", 1392], ["the", 1401], ["background", 1405], ["drug", 1416], ["regimen", 1421], ["plus", 1429], ["200", 1434], ["mg", 1438], ["of", 1441], ["delamanid", 1444], ["twice", 1454], ["daily", 1460], ["had", 1466], ["a", 1470], ["higher", 1472], ["proportion", 1479], ["of", 1490], ["patients", 1493], ["with", 1502], ["sputum", 1507], ["-", 1513], ["culture", 1514], ["conversion", 1522], ["(", 1533], ["41.9", 1534], ["%", 1538], [",", 1539], ["P=0.04", 1541], [")", 1547], [".", 1548], ["The", 1550], ["findings", 1554], ["were", 1563], ["similar", 1568], ["with", 1576], ["assessment", 1581], ["of", 1592], ["sputum", 1595], ["-", 1601], ["culture", 1602], ["conversion", 1610], ["in", 1621], ["solid", 1624], ["medium", 1630], [".", 1636], ["Most", 1638], ["adverse", 1643], ["events", 1651], ["were", 1658], ["mild", 1663], ["to", 1668], ["moderate", 1671], ["in", 1680], ["severity", 1683], ["and", 1692], ["were", 1696], ["evenly", 1701], ["distributed", 1708], ["across", 1720], ["groups", 1727], [".", 1733], ["Although", 1735], ["no", 1744], ["clinical", 1747], ["events", 1756], ["due", 1763], ["to", 1767], ["QT", 1770], ["prolongation", 1773], ["on", 1786], ["electrocardiography", 1789], ["were", 1809], ["observed", 1814], [",", 1822], ["QT", 1824], ["prolongation", 1827], ["was", 1840], ["reported", 1844], ["significantly", 1853], ["more", 1867], ["frequently", 1872], ["in", 1883], ["the", 1886], ["groups", 1890], ["that", 1897], ["received", 1902], ["delamanid", 1911], [".", 1920], ["Delamanid", 1922], ["was", 1932], ["associated", 1936], ["with", 1947], ["an", 1952], ["increase", 1955], ["in", 1964], ["sputum", 1967], ["-", 1973], ["culture", 1974], ["conversion", 1982], ["at", 1993], ["2", 1996], ["months", 1998], ["among", 2005], ["patients", 2011], ["with", 2020], ["multidrug", 2025], ["-", 2034], ["resistant", 2035], ["tuberculosis", 2045], [".", 2057], ["This", 2059], ["finding", 2064], ["suggests", 2072], ["that", 2081], ["delamanid", 2086], ["could", 2096], ["enhance", 2102], ["treatment", 2110], ["options", 2120], ["for", 2128], ["multidrug", 2132], ["-", 2141], ["resistant", 2142], ["tuberculosis", 2152], [".", 2164], ["(", 2166], ["Funded", 2167], ["by", 2174], ["Otsuka", 2177], ["Pharmaceutical", 2184], ["Development", 2199], ["and", 2211], ["Commercialization", 2215], [";", 2232], ["ClinicalTrials.gov", 2234], ["number", 2253], [",", 2259], ["NCT00685360", 2261], [".", 2272], [")", 2273], [".", 2274]]}
{"context": "The Muenke syndrome (MS) is characterized by unicoronal or bicoronal craniosynostosis, midfacial hypoplasia, ocular hypertelorism, and a variety of minor abnormalities associated with a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. The birth prevalence is approximately one in 10,000 live births, accounting for 8-10% of patients with coronal synostosis. Although MS is a relatively common diagnosis in patients with craniosynostosis syndromes, with autosomal dominant inheritance, there has been no report of MS, in an affected Korean family with typical cephalo-facial morphology that has been confirmed by molecular studies. Here, we report a familial case of MS in a female patient with a Pro250Arg mutation in exon 7 (IgII-IGIII linker domain) of the FGFR3 gene. This patient had mild midfacial hypoplasia, hypertelorism, downslanting palpebral fissures, a beak shaped nose, plagio-brachycephaly, and mild neurodevelopmental delay. The same mutation was confirmed in the patient's mother, two of the mother's sisters and the maternal grandfather. The severity of the cephalo-facial anomalies was variable among these family members.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "d053f9773d0649b8b2acea49e06af19f", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[32, 38]], "char_spans": [[202, 243]]}]}], "context_tokens": [["The", 0], ["Muenke", 4], ["syndrome", 11], ["(", 20], ["MS", 21], [")", 23], ["is", 25], ["characterized", 28], ["by", 42], ["unicoronal", 45], ["or", 56], ["bicoronal", 59], ["craniosynostosis", 69], [",", 85], ["midfacial", 87], ["hypoplasia", 97], [",", 107], ["ocular", 109], ["hypertelorism", 116], [",", 129], ["and", 131], ["a", 135], ["variety", 137], ["of", 145], ["minor", 148], ["abnormalities", 154], ["associated", 168], ["with", 179], ["a", 184], ["mutation", 186], ["in", 195], ["the", 198], ["fibroblast", 202], ["growth", 213], ["factor", 220], ["receptor", 227], ["3", 236], ["(", 238], ["FGFR3", 239], [")", 244], ["gene", 246], [".", 250], ["The", 252], ["birth", 256], ["prevalence", 262], ["is", 273], ["approximately", 276], ["one", 290], ["in", 294], ["10,000", 297], ["live", 304], ["births", 309], [",", 315], ["accounting", 317], ["for", 328], ["8", 332], ["-", 333], ["10", 334], ["%", 336], ["of", 338], ["patients", 341], ["with", 350], ["coronal", 355], ["synostosis", 363], [".", 373], ["Although", 375], ["MS", 384], ["is", 387], ["a", 390], ["relatively", 392], ["common", 403], ["diagnosis", 410], ["in", 420], ["patients", 423], ["with", 432], ["craniosynostosis", 437], ["syndromes", 454], [",", 463], ["with", 465], ["autosomal", 470], ["dominant", 480], ["inheritance", 489], [",", 500], ["there", 502], ["has", 508], ["been", 512], ["no", 517], ["report", 520], ["of", 527], ["MS", 530], [",", 532], ["in", 534], ["an", 537], ["affected", 540], ["Korean", 549], ["family", 556], ["with", 563], ["typical", 568], ["cephalo", 576], ["-", 583], ["facial", 584], ["morphology", 591], ["that", 602], ["has", 607], ["been", 611], ["confirmed", 616], ["by", 626], ["molecular", 629], ["studies", 639], [".", 646], ["Here", 648], [",", 652], ["we", 654], ["report", 657], ["a", 664], ["familial", 666], ["case", 675], ["of", 680], ["MS", 683], ["in", 686], ["a", 689], ["female", 691], ["patient", 698], ["with", 706], ["a", 711], ["Pro250Arg", 713], ["mutation", 723], ["in", 732], ["exon", 735], ["7", 740], ["(", 742], ["IgII", 743], ["-", 747], ["IGIII", 748], ["linker", 754], ["domain", 761], [")", 767], ["of", 769], ["the", 772], ["FGFR3", 776], ["gene", 782], [".", 786], ["This", 788], ["patient", 793], ["had", 801], ["mild", 805], ["midfacial", 810], ["hypoplasia", 820], [",", 830], ["hypertelorism", 832], [",", 845], ["downslanting", 847], ["palpebral", 860], ["fissures", 870], [",", 878], ["a", 880], ["beak", 882], ["shaped", 887], ["nose", 894], [",", 898], ["plagio", 900], ["-", 906], ["brachycephaly", 907], [",", 920], ["and", 922], ["mild", 926], ["neurodevelopmental", 931], ["delay", 950], [".", 955], ["The", 957], ["same", 961], ["mutation", 966], ["was", 975], ["confirmed", 979], ["in", 989], ["the", 992], ["patient", 996], ["'s", 1003], ["mother", 1006], [",", 1012], ["two", 1014], ["of", 1018], ["the", 1021], ["mother", 1025], ["'s", 1031], ["sisters", 1034], ["and", 1042], ["the", 1046], ["maternal", 1050], ["grandfather", 1059], [".", 1070], ["The", 1072], ["severity", 1076], ["of", 1085], ["the", 1088], ["cephalo", 1092], ["-", 1099], ["facial", 1100], ["anomalies", 1107], ["was", 1117], ["variable", 1121], ["among", 1130], ["these", 1136], ["family", 1142], ["members", 1149], [".", 1156]]}
{"context": "Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. We investigated this novel combination regimen in patients with Bcr-Abl(+) malignancies. In a phase I dose-escalation study, imatinib was administered orally daily, and flavopiridol by 1\u00a0h intravenous infusion weekly for 3\u00a0weeks every 4\u00a0weeks. Adults with chronic myelogenous leukemia or Philadelphia chromosome-positive acute leukemia were eligible. Patients were divided into two strata based on peripheral blood and bone marrow blast counts. The primary objective was to identify the recommended phase II doses for the combination. Correlative pharmacokinetic and pharmacodynamic studies were also performed. A total of 21 patients received study treatment. Four dose levels were evaluated before the study was closed following the approval of the second-generation Bcr-Abl tyrosine kinase inhibitors (TKIs). Five patients responded, including four sustained responses. Four patients had stable disease. All but one responder, and all patients with stable disease had previously been treated with imatinib. One patient had a complete response sustained for 30\u00a0months. Changes in expression of phospho-Bcr/Abl, -Stat5, and Mcl-1 were monitored. No major pharmacokinetic interaction was observed. This is the first study to evaluate the combination of a CDK inhibitor and a TKI in humans. The combination of flavopiridol and imatinib is tolerable and produces encouraging responses, including in some patients with imatinib-resistant disease.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee5c985a3d3b4cd89647bbe76b8def7b", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[66, 68], [244, 246], [184, 186], [6, 8]], "char_spans": [[376, 384], [1416, 1422], [1081, 1087], [32, 38]]}]}], "context_tokens": [["Imatinib", 0], ["is", 9], ["an", 12], ["inhibitor", 15], ["of", 25], ["the", 28], ["Bcr", 32], ["-", 35], ["Abl", 36], ["tyrosine", 40], ["kinase", 49], [";", 55], ["however", 57], [",", 64], ["resistance", 66], ["is", 77], ["common", 80], [".", 86], ["Flavopiridol", 88], [",", 100], ["a", 102], ["cyclin", 104], ["-", 110], ["dependent", 111], ["kinase", 121], ["(", 128], ["CDK", 129], [")", 132], ["inhibitor", 134], [",", 143], ["down", 145], ["-", 149], ["regulates", 150], ["short", 160], ["-", 165], ["lived", 166], ["anti", 172], ["-", 176], ["apoptotic", 177], ["proteins", 187], ["via", 196], ["inhibition", 200], ["of", 211], ["transcription", 214], [".", 227], ["In", 229], ["preclinical", 232], ["studies", 244], [",", 251], ["flavopiridol", 253], ["synergizes", 266], ["with", 277], ["imatinib", 282], ["to", 291], ["induce", 294], ["apoptosis", 301], [".", 310], ["We", 312], ["investigated", 315], ["this", 328], ["novel", 333], ["combination", 339], ["regimen", 351], ["in", 359], ["patients", 362], ["with", 371], ["Bcr", 376], ["-", 379], ["Abl(+", 380], [")", 385], ["malignancies", 387], [".", 399], ["In", 401], ["a", 404], ["phase", 406], ["I", 412], ["dose", 414], ["-", 418], ["escalation", 419], ["study", 430], [",", 435], ["imatinib", 437], ["was", 446], ["administered", 450], ["orally", 463], ["daily", 470], [",", 475], ["and", 477], ["flavopiridol", 481], ["by", 494], ["1", 497], ["h", 499], ["intravenous", 501], ["infusion", 513], ["weekly", 522], ["for", 529], ["3", 533], ["weeks", 535], ["every", 541], ["4", 547], ["weeks", 549], [".", 554], ["Adults", 556], ["with", 563], ["chronic", 568], ["myelogenous", 576], ["leukemia", 588], ["or", 597], ["Philadelphia", 600], ["chromosome", 613], ["-", 623], ["positive", 624], ["acute", 633], ["leukemia", 639], ["were", 648], ["eligible", 653], [".", 661], ["Patients", 663], ["were", 672], ["divided", 677], ["into", 685], ["two", 690], ["strata", 694], ["based", 701], ["on", 707], ["peripheral", 710], ["blood", 721], ["and", 727], ["bone", 731], ["marrow", 736], ["blast", 743], ["counts", 749], [".", 755], ["The", 757], ["primary", 761], ["objective", 769], ["was", 779], ["to", 783], ["identify", 786], ["the", 795], ["recommended", 799], ["phase", 811], ["II", 817], ["doses", 820], ["for", 826], ["the", 830], ["combination", 834], [".", 845], ["Correlative", 847], ["pharmacokinetic", 859], ["and", 875], ["pharmacodynamic", 879], ["studies", 895], ["were", 903], ["also", 908], ["performed", 913], [".", 922], ["A", 924], ["total", 926], ["of", 932], ["21", 935], ["patients", 938], ["received", 947], ["study", 956], ["treatment", 962], [".", 971], ["Four", 973], ["dose", 978], ["levels", 983], ["were", 990], ["evaluated", 995], ["before", 1005], ["the", 1012], ["study", 1016], ["was", 1022], ["closed", 1026], ["following", 1033], ["the", 1043], ["approval", 1047], ["of", 1056], ["the", 1059], ["second", 1063], ["-", 1069], ["generation", 1070], ["Bcr", 1081], ["-", 1084], ["Abl", 1085], ["tyrosine", 1089], ["kinase", 1098], ["inhibitors", 1105], ["(", 1116], ["TKIs", 1117], [")", 1121], [".", 1122], ["Five", 1124], ["patients", 1129], ["responded", 1138], [",", 1147], ["including", 1149], ["four", 1159], ["sustained", 1164], ["responses", 1174], [".", 1183], ["Four", 1185], ["patients", 1190], ["had", 1199], ["stable", 1203], ["disease", 1210], [".", 1217], ["All", 1219], ["but", 1223], ["one", 1227], ["responder", 1231], [",", 1240], ["and", 1242], ["all", 1246], ["patients", 1250], ["with", 1259], ["stable", 1264], ["disease", 1271], ["had", 1279], ["previously", 1283], ["been", 1294], ["treated", 1299], ["with", 1307], ["imatinib", 1312], [".", 1320], ["One", 1322], ["patient", 1326], ["had", 1334], ["a", 1338], ["complete", 1340], ["response", 1349], ["sustained", 1358], ["for", 1368], ["30", 1372], ["months", 1375], [".", 1381], ["Changes", 1383], ["in", 1391], ["expression", 1394], ["of", 1405], ["phospho", 1408], ["-", 1415], ["Bcr", 1416], ["/", 1419], ["Abl", 1420], [",", 1423], ["-Stat5", 1425], [",", 1431], ["and", 1433], ["Mcl-1", 1437], ["were", 1443], ["monitored", 1448], [".", 1457], ["No", 1459], ["major", 1462], ["pharmacokinetic", 1468], ["interaction", 1484], ["was", 1496], ["observed", 1500], [".", 1508], ["This", 1510], ["is", 1515], ["the", 1518], ["first", 1522], ["study", 1528], ["to", 1534], ["evaluate", 1537], ["the", 1546], ["combination", 1550], ["of", 1562], ["a", 1565], ["CDK", 1567], ["inhibitor", 1571], ["and", 1581], ["a", 1585], ["TKI", 1587], ["in", 1591], ["humans", 1594], [".", 1600], ["The", 1602], ["combination", 1606], ["of", 1618], ["flavopiridol", 1621], ["and", 1634], ["imatinib", 1638], ["is", 1647], ["tolerable", 1650], ["and", 1660], ["produces", 1664], ["encouraging", 1673], ["responses", 1685], [",", 1694], ["including", 1696], ["in", 1706], ["some", 1709], ["patients", 1714], ["with", 1723], ["imatinib", 1728], ["-", 1736], ["resistant", 1737], ["disease", 1747], [".", 1754]]}
{"context": "To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis. Three multicenter, randomized, double-masked, placebo-controlled, dose-ranging phase III studies: SHIELD, INSURE, and ENDURE. A total of 118 patients with Beh\u00e7et's uveitis (SHIELD study); 31 patients with active, noninfectious, non-Beh\u00e7et's uveitis (INSURE study); and 125 patients with quiescent, noninfectious, non-Beh\u00e7et's uveitis (ENDURE study) were enrolled. After an initial subcutaneous (s.c.) loading phase in each treatment arm, patients received s.c. maintenance therapy with secukinumab 300 mg every 2 weeks (q2w), secukinumab 300 mg monthly (q4w), or placebo in the SHIELD study; secukinumab 300 mg q2w, secukinumab 300 mg q4w, secukinumab 150 mg q4w, or placebo in the INSURE study; or secukinumab 300 mg q2w, secukinumab 300 mg q4w, secukinumab 150 mg q4w, or placebo in the ENDURE study. Reduction of uveitis recurrence or vitreous haze score during withdrawal of concomitant immunosuppressive medication (ISM). Other end points included best-corrected visual acuity, ISM use (expressed as a standardized ISM score), and safety outcomes. After completion or early termination of each trial, there were no statistically significant differences in uveitis recurrence between the secukinumab treatment groups and placebo groups in any study. Secukinumab was associated with a significant reduction in mean total post-baseline ISM score (P = 0.019; 300 mg q4w vs. placebo) in the SHIELD study. Likewise, secukinumab was associated with a greater median reduction in ISM score versus placebo in the INSURE study, although no statistical analysis of the difference was conducted because of the small sample size. Overall, there was no loss in visual acuity reported in any treatment group during follow-up in all 3 studies. According to descriptive safety statistics, the frequencies of ocular and nonocular adverse events seemed to be slightly higher among secukinumab groups versus placebo across the 3 studies. The primary efficacy end points of the 3 studies were not met. The secondary efficacy data from these studies suggest a beneficial effect of secukinumab in reducing the use of concomitant ISM.", "qas": [{"question": "Which molecule is targeted by a monoclonal antibody Secukinumab?", "answers": ["interleukin-17A"], "qid": "a40b195dc80a430a92a47b3b524bd7c3", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["a", 30], ["monoclonal", 32], ["antibody", 43], ["Secukinumab", 52], ["?", 63]], "detected_answers": [{"text": "interleukin-17A", "token_spans": [[19, 19]], "char_spans": [[119, 133]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["efficacy", 17], ["and", 26], ["safety", 30], ["of", 37], ["different", 40], ["doses", 50], ["of", 56], ["secukinumab", 59], [",", 70], ["a", 72], ["fully", 74], ["human", 80], ["monoclonal", 86], ["antibody", 97], ["for", 106], ["targeted", 110], ["interleukin-17A", 119], ["blockade", 135], [",", 143], ["in", 145], ["patients", 148], ["with", 157], ["noninfectious", 162], ["uveitis", 176], [".", 183], ["Three", 185], ["multicenter", 191], [",", 202], ["randomized", 204], [",", 214], ["double", 216], ["-", 222], ["masked", 223], [",", 229], ["placebo", 231], ["-", 238], ["controlled", 239], [",", 249], ["dose", 251], ["-", 255], ["ranging", 256], ["phase", 264], ["III", 270], ["studies", 274], [":", 281], ["SHIELD", 283], [",", 289], ["INSURE", 291], [",", 297], ["and", 299], ["ENDURE", 303], [".", 309], ["A", 311], ["total", 313], ["of", 319], ["118", 322], ["patients", 326], ["with", 335], ["Beh\u00e7et", 340], ["'s", 346], ["uveitis", 349], ["(", 357], ["SHIELD", 358], ["study", 365], [")", 370], [";", 371], ["31", 373], ["patients", 376], ["with", 385], ["active", 390], [",", 396], ["noninfectious", 398], [",", 411], ["non", 413], ["-", 416], ["Beh\u00e7et", 417], ["'s", 423], ["uveitis", 426], ["(", 434], ["INSURE", 435], ["study", 442], [")", 447], [";", 448], ["and", 450], ["125", 454], ["patients", 458], ["with", 467], ["quiescent", 472], [",", 481], ["noninfectious", 483], [",", 496], ["non", 498], ["-", 501], ["Beh\u00e7et", 502], ["'s", 508], ["uveitis", 511], ["(", 519], ["ENDURE", 520], ["study", 527], [")", 532], ["were", 534], ["enrolled", 539], [".", 547], ["After", 549], ["an", 555], ["initial", 558], ["subcutaneous", 566], ["(", 579], ["s.c", 580], [".", 583], [")", 584], ["loading", 586], ["phase", 594], ["in", 600], ["each", 603], ["treatment", 608], ["arm", 618], [",", 621], ["patients", 623], ["received", 632], ["s.c", 641], [".", 644], ["maintenance", 646], ["therapy", 658], ["with", 666], ["secukinumab", 671], ["300", 683], ["mg", 687], ["every", 690], ["2", 696], ["weeks", 698], ["(", 704], ["q2w", 705], [")", 708], [",", 709], ["secukinumab", 711], ["300", 723], ["mg", 727], ["monthly", 730], ["(", 738], ["q4w", 739], [")", 742], [",", 743], ["or", 745], ["placebo", 748], ["in", 756], ["the", 759], ["SHIELD", 763], ["study", 770], [";", 775], ["secukinumab", 777], ["300", 789], ["mg", 793], ["q2w", 796], [",", 799], ["secukinumab", 801], ["300", 813], ["mg", 817], ["q4w", 820], [",", 823], ["secukinumab", 825], ["150", 837], ["mg", 841], ["q4w", 844], [",", 847], ["or", 849], ["placebo", 852], ["in", 860], ["the", 863], ["INSURE", 867], ["study", 874], [";", 879], ["or", 881], ["secukinumab", 884], ["300", 896], ["mg", 900], ["q2w", 903], [",", 906], ["secukinumab", 908], ["300", 920], ["mg", 924], ["q4w", 927], [",", 930], ["secukinumab", 932], ["150", 944], ["mg", 948], ["q4w", 951], [",", 954], ["or", 956], ["placebo", 959], ["in", 967], ["the", 970], ["ENDURE", 974], ["study", 981], [".", 986], ["Reduction", 988], ["of", 998], ["uveitis", 1001], ["recurrence", 1009], ["or", 1020], ["vitreous", 1023], ["haze", 1032], ["score", 1037], ["during", 1043], ["withdrawal", 1050], ["of", 1061], ["concomitant", 1064], ["immunosuppressive", 1076], ["medication", 1094], ["(", 1105], ["ISM", 1106], [")", 1109], [".", 1110], ["Other", 1112], ["end", 1118], ["points", 1122], ["included", 1129], ["best", 1138], ["-", 1142], ["corrected", 1143], ["visual", 1153], ["acuity", 1160], [",", 1166], ["ISM", 1168], ["use", 1172], ["(", 1176], ["expressed", 1177], ["as", 1187], ["a", 1190], ["standardized", 1192], ["ISM", 1205], ["score", 1209], [")", 1214], [",", 1215], ["and", 1217], ["safety", 1221], ["outcomes", 1228], [".", 1236], ["After", 1238], ["completion", 1244], ["or", 1255], ["early", 1258], ["termination", 1264], ["of", 1276], ["each", 1279], ["trial", 1284], [",", 1289], ["there", 1291], ["were", 1297], ["no", 1302], ["statistically", 1305], ["significant", 1319], ["differences", 1331], ["in", 1343], ["uveitis", 1346], ["recurrence", 1354], ["between", 1365], ["the", 1373], ["secukinumab", 1377], ["treatment", 1389], ["groups", 1399], ["and", 1406], ["placebo", 1410], ["groups", 1418], ["in", 1425], ["any", 1428], ["study", 1432], [".", 1437], ["Secukinumab", 1439], ["was", 1451], ["associated", 1455], ["with", 1466], ["a", 1471], ["significant", 1473], ["reduction", 1485], ["in", 1495], ["mean", 1498], ["total", 1503], ["post", 1509], ["-", 1513], ["baseline", 1514], ["ISM", 1523], ["score", 1527], ["(", 1533], ["P", 1534], ["=", 1536], ["0.019", 1538], [";", 1543], ["300", 1545], ["mg", 1549], ["q4w", 1552], ["vs.", 1556], ["placebo", 1560], [")", 1567], ["in", 1569], ["the", 1572], ["SHIELD", 1576], ["study", 1583], [".", 1588], ["Likewise", 1590], [",", 1598], ["secukinumab", 1600], ["was", 1612], ["associated", 1616], ["with", 1627], ["a", 1632], ["greater", 1634], ["median", 1642], ["reduction", 1649], ["in", 1659], ["ISM", 1662], ["score", 1666], ["versus", 1672], ["placebo", 1679], ["in", 1687], ["the", 1690], ["INSURE", 1694], ["study", 1701], [",", 1706], ["although", 1708], ["no", 1717], ["statistical", 1720], ["analysis", 1732], ["of", 1741], ["the", 1744], ["difference", 1748], ["was", 1759], ["conducted", 1763], ["because", 1773], ["of", 1781], ["the", 1784], ["small", 1788], ["sample", 1794], ["size", 1801], [".", 1805], ["Overall", 1807], [",", 1814], ["there", 1816], ["was", 1822], ["no", 1826], ["loss", 1829], ["in", 1834], ["visual", 1837], ["acuity", 1844], ["reported", 1851], ["in", 1860], ["any", 1863], ["treatment", 1867], ["group", 1877], ["during", 1883], ["follow", 1890], ["-", 1896], ["up", 1897], ["in", 1900], ["all", 1903], ["3", 1907], ["studies", 1909], [".", 1916], ["According", 1918], ["to", 1928], ["descriptive", 1931], ["safety", 1943], ["statistics", 1950], [",", 1960], ["the", 1962], ["frequencies", 1966], ["of", 1978], ["ocular", 1981], ["and", 1988], ["nonocular", 1992], ["adverse", 2002], ["events", 2010], ["seemed", 2017], ["to", 2024], ["be", 2027], ["slightly", 2030], ["higher", 2039], ["among", 2046], ["secukinumab", 2052], ["groups", 2064], ["versus", 2071], ["placebo", 2078], ["across", 2086], ["the", 2093], ["3", 2097], ["studies", 2099], [".", 2106], ["The", 2108], ["primary", 2112], ["efficacy", 2120], ["end", 2129], ["points", 2133], ["of", 2140], ["the", 2143], ["3", 2147], ["studies", 2149], ["were", 2157], ["not", 2162], ["met", 2166], [".", 2169], ["The", 2171], ["secondary", 2175], ["efficacy", 2185], ["data", 2194], ["from", 2199], ["these", 2204], ["studies", 2210], ["suggest", 2218], ["a", 2226], ["beneficial", 2228], ["effect", 2239], ["of", 2246], ["secukinumab", 2249], ["in", 2261], ["reducing", 2264], ["the", 2273], ["use", 2277], ["of", 2281], ["concomitant", 2284], ["ISM", 2296], [".", 2299]]}
{"context": "X monosomic mice (39,XO) have a remarkably mild phenotype when compared to women with Turner syndrome (45,XO). The generally accepted hypothesis to explain this discrepancy is that the number of genes on the mouse X chromosome which escape X inactivation, and thus are expressed at higher levels in females, is very small. However this hypothesis has never been tested and only a small number of genes have been assayed for their X-inactivation status in the mouse. We performed a global expression analysis in four somatic tissues (brain, liver, kidney and muscle) of adult 40,XX and 39,XO mice using the Illumina Mouse WG-6 v1_1 Expression BeadChip and an extensive validation by quantitative real time PCR, in order to identify which genes are expressed from both X chromosomes. We identified several genes on the X chromosome which are overexpressed in XX females, including those previously reported as escaping X inactivation, as well as new candidates. However, the results obtained by microarray and qPCR were not fully concordant, illustrating the difficulty in ascertaining modest fold changes, such as those expected for genes escaping X inactivation. Remarkably, considerable variation was observed between tissues, suggesting that inactivation patterns may be tissue-dependent. Our analysis also exposed several autosomal genes involved in mitochondrial metabolism and in protein translation which are differentially expressed between XX and XO mice, revealing secondary transcriptional changes to the alteration in X chromosome dosage. Our results support the prediction that the mouse inactive X chromosome is largely silent, while providing a list of the genes potentially escaping X inactivation in rodents. Although the lower expression of X-linked genes in XO mice may not be relevant in the particular tissues/systems which are affected in human X chromosome monosomy, genes deregulated in XO mice are good candidates for further study in an involvement in Turner Syndrome phenotype.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "f60eb4dfa5774b8c8a56567d0989deff", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[0, 0], [43, 43], [149, 149], [203, 203], [286, 286], [140, 140], [164, 164], [39, 39], [296, 296], [318, 318], [258, 258], [79, 79], [271, 271]], "char_spans": [[0, 0], [240, 240], [817, 817], [1147, 1147], [1698, 1698], [767, 767], [917, 917], [214, 214], [1758, 1758], [1866, 1866], [1529, 1529], [430, 430], [1609, 1609]]}]}], "context_tokens": [["X", 0], ["monosomic", 2], ["mice", 12], ["(", 17], ["39,XO", 18], [")", 23], ["have", 25], ["a", 30], ["remarkably", 32], ["mild", 43], ["phenotype", 48], ["when", 58], ["compared", 63], ["to", 72], ["women", 75], ["with", 81], ["Turner", 86], ["syndrome", 93], ["(", 102], ["45,XO", 103], [")", 108], [".", 109], ["The", 111], ["generally", 115], ["accepted", 125], ["hypothesis", 134], ["to", 145], ["explain", 148], ["this", 156], ["discrepancy", 161], ["is", 173], ["that", 176], ["the", 181], ["number", 185], ["of", 192], ["genes", 195], ["on", 201], ["the", 204], ["mouse", 208], ["X", 214], ["chromosome", 216], ["which", 227], ["escape", 233], ["X", 240], ["inactivation", 242], [",", 254], ["and", 256], ["thus", 260], ["are", 265], ["expressed", 269], ["at", 279], ["higher", 282], ["levels", 289], ["in", 296], ["females", 299], [",", 306], ["is", 308], ["very", 311], ["small", 316], [".", 321], ["However", 323], ["this", 331], ["hypothesis", 336], ["has", 347], ["never", 351], ["been", 357], ["tested", 362], ["and", 369], ["only", 373], ["a", 378], ["small", 380], ["number", 386], ["of", 393], ["genes", 396], ["have", 402], ["been", 407], ["assayed", 412], ["for", 420], ["their", 424], ["X", 430], ["-", 431], ["inactivation", 432], ["status", 445], ["in", 452], ["the", 455], ["mouse", 459], [".", 464], ["We", 466], ["performed", 469], ["a", 479], ["global", 481], ["expression", 488], ["analysis", 499], ["in", 508], ["four", 511], ["somatic", 516], ["tissues", 524], ["(", 532], ["brain", 533], [",", 538], ["liver", 540], [",", 545], ["kidney", 547], ["and", 554], ["muscle", 558], [")", 564], ["of", 566], ["adult", 569], ["40,XX", 575], ["and", 581], ["39,XO", 585], ["mice", 591], ["using", 596], ["the", 602], ["Illumina", 606], ["Mouse", 615], ["WG-6", 621], ["v1_1", 626], ["Expression", 631], ["BeadChip", 642], ["and", 651], ["an", 655], ["extensive", 658], ["validation", 668], ["by", 679], ["quantitative", 682], ["real", 695], ["time", 700], ["PCR", 705], [",", 708], ["in", 710], ["order", 713], ["to", 719], ["identify", 722], ["which", 731], ["genes", 737], ["are", 743], ["expressed", 747], ["from", 757], ["both", 762], ["X", 767], ["chromosomes", 769], [".", 780], ["We", 782], ["identified", 785], ["several", 796], ["genes", 804], ["on", 810], ["the", 813], ["X", 817], ["chromosome", 819], ["which", 830], ["are", 836], ["overexpressed", 840], ["in", 854], ["XX", 857], ["females", 860], [",", 867], ["including", 869], ["those", 879], ["previously", 885], ["reported", 896], ["as", 905], ["escaping", 908], ["X", 917], ["inactivation", 919], [",", 931], ["as", 933], ["well", 936], ["as", 941], ["new", 944], ["candidates", 948], [".", 958], ["However", 960], [",", 967], ["the", 969], ["results", 973], ["obtained", 981], ["by", 990], ["microarray", 993], ["and", 1004], ["qPCR", 1008], ["were", 1013], ["not", 1018], ["fully", 1022], ["concordant", 1028], [",", 1038], ["illustrating", 1040], ["the", 1053], ["difficulty", 1057], ["in", 1068], ["ascertaining", 1071], ["modest", 1084], ["fold", 1091], ["changes", 1096], [",", 1103], ["such", 1105], ["as", 1110], ["those", 1113], ["expected", 1119], ["for", 1128], ["genes", 1132], ["escaping", 1138], ["X", 1147], ["inactivation", 1149], [".", 1161], ["Remarkably", 1163], [",", 1173], ["considerable", 1175], ["variation", 1188], ["was", 1198], ["observed", 1202], ["between", 1211], ["tissues", 1219], [",", 1226], ["suggesting", 1228], ["that", 1239], ["inactivation", 1244], ["patterns", 1257], ["may", 1266], ["be", 1270], ["tissue", 1273], ["-", 1279], ["dependent", 1280], [".", 1289], ["Our", 1291], ["analysis", 1295], ["also", 1304], ["exposed", 1309], ["several", 1317], ["autosomal", 1325], ["genes", 1335], ["involved", 1341], ["in", 1350], ["mitochondrial", 1353], ["metabolism", 1367], ["and", 1378], ["in", 1382], ["protein", 1385], ["translation", 1393], ["which", 1405], ["are", 1411], ["differentially", 1415], ["expressed", 1430], ["between", 1440], ["XX", 1448], ["and", 1451], ["XO", 1455], ["mice", 1458], [",", 1462], ["revealing", 1464], ["secondary", 1474], ["transcriptional", 1484], ["changes", 1500], ["to", 1508], ["the", 1511], ["alteration", 1515], ["in", 1526], ["X", 1529], ["chromosome", 1531], ["dosage", 1542], [".", 1548], ["Our", 1550], ["results", 1554], ["support", 1562], ["the", 1570], ["prediction", 1574], ["that", 1585], ["the", 1590], ["mouse", 1594], ["inactive", 1600], ["X", 1609], ["chromosome", 1611], ["is", 1622], ["largely", 1625], ["silent", 1633], [",", 1639], ["while", 1641], ["providing", 1647], ["a", 1657], ["list", 1659], ["of", 1664], ["the", 1667], ["genes", 1671], ["potentially", 1677], ["escaping", 1689], ["X", 1698], ["inactivation", 1700], ["in", 1713], ["rodents", 1716], [".", 1723], ["Although", 1725], ["the", 1734], ["lower", 1738], ["expression", 1744], ["of", 1755], ["X", 1758], ["-", 1759], ["linked", 1760], ["genes", 1767], ["in", 1773], ["XO", 1776], ["mice", 1779], ["may", 1784], ["not", 1788], ["be", 1792], ["relevant", 1795], ["in", 1804], ["the", 1807], ["particular", 1811], ["tissues", 1822], ["/", 1829], ["systems", 1830], ["which", 1838], ["are", 1844], ["affected", 1848], ["in", 1857], ["human", 1860], ["X", 1866], ["chromosome", 1868], ["monosomy", 1879], [",", 1887], ["genes", 1889], ["deregulated", 1895], ["in", 1907], ["XO", 1910], ["mice", 1913], ["are", 1918], ["good", 1922], ["candidates", 1927], ["for", 1938], ["further", 1942], ["study", 1950], ["in", 1956], ["an", 1959], ["involvement", 1962], ["in", 1974], ["Turner", 1977], ["Syndrome", 1984], ["phenotype", 1993], [".", 2002]]}
{"context": "Groucho (Gro) is a Drosophila melanogaster transcriptional corepressor that directly interacts with the histone deacetylase Rpd3. Although previous studies suggest that this interaction is required for repression of Gro-responsive reporters in cultured cells, the in vivo significance of this interaction and the mechanism by which it leads to repression remain largely unexplored. In this study, we show that Gro is partially dependent on Rpd3 for repression, supporting the idea that Rpd3-mediated repression is one mode of Gro-mediated repression. We demonstrate that Gro colocalizes with Rpd3 to the chromatin of a target gene and that this is accompanied by the deacetylation of specific lysines within the N-terminal tails of histones H3 and H4. Gro overexpression leads to wing patterning defects and ectopic repression in the wing disc of transcription directed by the vestigial quadrant enhancer. These effects are reversed by the histone deacetylase inhibitors TSA and HC-Toxin and by the reduction of Rpd3 gene dosage. Furthermore, repression of the vestigial quadrant enhancer is accompanied by a Gro-mediated increase in nucleosome density, an effect that is reversed by histone deacetylase inhibitors. We propose a model in which Gro-mediated histone deacetylation results in increased nucleosome density leading to transcriptional repression.", "qas": [{"question": "What is the Drosophila melanogaster Groucho protein?", "answers": ["Groucho (Gro) is a Drosophila melanogaster transcriptional corepressor"], "qid": "cb1860ac490e4c2cb4db0aaf636faa83", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["Drosophila", 12], ["melanogaster", 23], ["Groucho", 36], ["protein", 44], ["?", 51]], "detected_answers": [{"text": "Groucho (Gro) is a Drosophila melanogaster transcriptional corepressor", "token_spans": [[0, 9]], "char_spans": [[0, 69]]}]}], "context_tokens": [["Groucho", 0], ["(", 8], ["Gro", 9], [")", 12], ["is", 14], ["a", 17], ["Drosophila", 19], ["melanogaster", 30], ["transcriptional", 43], ["corepressor", 59], ["that", 71], ["directly", 76], ["interacts", 85], ["with", 95], ["the", 100], ["histone", 104], ["deacetylase", 112], ["Rpd3", 124], [".", 128], ["Although", 130], ["previous", 139], ["studies", 148], ["suggest", 156], ["that", 164], ["this", 169], ["interaction", 174], ["is", 186], ["required", 189], ["for", 198], ["repression", 202], ["of", 213], ["Gro", 216], ["-", 219], ["responsive", 220], ["reporters", 231], ["in", 241], ["cultured", 244], ["cells", 253], [",", 258], ["the", 260], ["in", 264], ["vivo", 267], ["significance", 272], ["of", 285], ["this", 288], ["interaction", 293], ["and", 305], ["the", 309], ["mechanism", 313], ["by", 323], ["which", 326], ["it", 332], ["leads", 335], ["to", 341], ["repression", 344], ["remain", 355], ["largely", 362], ["unexplored", 370], [".", 380], ["In", 382], ["this", 385], ["study", 390], [",", 395], ["we", 397], ["show", 400], ["that", 405], ["Gro", 410], ["is", 414], ["partially", 417], ["dependent", 427], ["on", 437], ["Rpd3", 440], ["for", 445], ["repression", 449], [",", 459], ["supporting", 461], ["the", 472], ["idea", 476], ["that", 481], ["Rpd3-mediated", 486], ["repression", 500], ["is", 511], ["one", 514], ["mode", 518], ["of", 523], ["Gro", 526], ["-", 529], ["mediated", 530], ["repression", 539], [".", 549], ["We", 551], ["demonstrate", 554], ["that", 566], ["Gro", 571], ["colocalizes", 575], ["with", 587], ["Rpd3", 592], ["to", 597], ["the", 600], ["chromatin", 604], ["of", 614], ["a", 617], ["target", 619], ["gene", 626], ["and", 631], ["that", 635], ["this", 640], ["is", 645], ["accompanied", 648], ["by", 660], ["the", 663], ["deacetylation", 667], ["of", 681], ["specific", 684], ["lysines", 693], ["within", 701], ["the", 708], ["N", 712], ["-", 713], ["terminal", 714], ["tails", 723], ["of", 729], ["histones", 732], ["H3", 741], ["and", 744], ["H4", 748], [".", 750], ["Gro", 752], ["overexpression", 756], ["leads", 771], ["to", 777], ["wing", 780], ["patterning", 785], ["defects", 796], ["and", 804], ["ectopic", 808], ["repression", 816], ["in", 827], ["the", 830], ["wing", 834], ["disc", 839], ["of", 844], ["transcription", 847], ["directed", 861], ["by", 870], ["the", 873], ["vestigial", 877], ["quadrant", 887], ["enhancer", 896], [".", 904], ["These", 906], ["effects", 912], ["are", 920], ["reversed", 924], ["by", 933], ["the", 936], ["histone", 940], ["deacetylase", 948], ["inhibitors", 960], ["TSA", 971], ["and", 975], ["HC", 979], ["-", 981], ["Toxin", 982], ["and", 988], ["by", 992], ["the", 995], ["reduction", 999], ["of", 1009], ["Rpd3", 1012], ["gene", 1017], ["dosage", 1022], [".", 1028], ["Furthermore", 1030], [",", 1041], ["repression", 1043], ["of", 1054], ["the", 1057], ["vestigial", 1061], ["quadrant", 1071], ["enhancer", 1080], ["is", 1089], ["accompanied", 1092], ["by", 1104], ["a", 1107], ["Gro", 1109], ["-", 1112], ["mediated", 1113], ["increase", 1122], ["in", 1131], ["nucleosome", 1134], ["density", 1145], [",", 1152], ["an", 1154], ["effect", 1157], ["that", 1164], ["is", 1169], ["reversed", 1172], ["by", 1181], ["histone", 1184], ["deacetylase", 1192], ["inhibitors", 1204], [".", 1214], ["We", 1216], ["propose", 1219], ["a", 1227], ["model", 1229], ["in", 1235], ["which", 1238], ["Gro", 1244], ["-", 1247], ["mediated", 1248], ["histone", 1257], ["deacetylation", 1265], ["results", 1279], ["in", 1287], ["increased", 1290], ["nucleosome", 1300], ["density", 1311], ["leading", 1319], ["to", 1327], ["transcriptional", 1330], ["repression", 1346], [".", 1356]]}
{"context": "Secretory phospholipase A2 (sPLA2), which links surfactant catabolism and lung inflammation, is associated with lung stiffness, surfactant dysfunction, and degree of respiratory support in acute respiratory distress syndrome and in some forms of neonatal lung injury. Varespladib potently inhibits sPLA2 in animal models. The authors investigate varespladib ex vivo efficacy in different forms of neonatal lung injury. Bronchoalveolar lavage fluid was obtained from 40 neonates affected by hyaline membrane disease, infections, or meconium aspiration and divided in 4 aliquots added with increasing varespladib or saline. sPLA2 activity, proteins, and albumin were measured. Dilution was corrected with the urea ratio. Varespladib was also tested in vitro against pancreatic sPLA2 mixed with different albumin concentration. Varespladib was able to inhibit sPLA2 in the types of neonatal lung injury investigated. sPLA2 activity was reduced in hyaline membrane disease (P < .0001), infections (P = .003), and meconium aspiration (P = .04) using 40 \u00b5M varespladib; 10 \u00b5M was able to lower enzyme activity (P = .001), with an IC(50) of 87 \u00b5M. An inverse relationship existed between protein level and activity reduction (r = 0.5; P = .029). The activity reduction/protein ratio tended to be higher in hyaline membrane disease. Varespladib efficacy was higher in vitro than in lavage fluids obtained from neonates (P < .001).", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "1aedf35d15b449439a4efb13c4c5ebd0", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[0, 2]], "char_spans": [[0, 25]]}]}], "context_tokens": [["Secretory", 0], ["phospholipase", 10], ["A2", 24], ["(", 27], ["sPLA2", 28], [")", 33], [",", 34], ["which", 36], ["links", 42], ["surfactant", 48], ["catabolism", 59], ["and", 70], ["lung", 74], ["inflammation", 79], [",", 91], ["is", 93], ["associated", 96], ["with", 107], ["lung", 112], ["stiffness", 117], [",", 126], ["surfactant", 128], ["dysfunction", 139], [",", 150], ["and", 152], ["degree", 156], ["of", 163], ["respiratory", 166], ["support", 178], ["in", 186], ["acute", 189], ["respiratory", 195], ["distress", 207], ["syndrome", 216], ["and", 225], ["in", 229], ["some", 232], ["forms", 237], ["of", 243], ["neonatal", 246], ["lung", 255], ["injury", 260], [".", 266], ["Varespladib", 268], ["potently", 280], ["inhibits", 289], ["sPLA2", 298], ["in", 304], ["animal", 307], ["models", 314], [".", 320], ["The", 322], ["authors", 326], ["investigate", 334], ["varespladib", 346], ["ex", 358], ["vivo", 361], ["efficacy", 366], ["in", 375], ["different", 378], ["forms", 388], ["of", 394], ["neonatal", 397], ["lung", 406], ["injury", 411], [".", 417], ["Bronchoalveolar", 419], ["lavage", 435], ["fluid", 442], ["was", 448], ["obtained", 452], ["from", 461], ["40", 466], ["neonates", 469], ["affected", 478], ["by", 487], ["hyaline", 490], ["membrane", 498], ["disease", 507], [",", 514], ["infections", 516], [",", 526], ["or", 528], ["meconium", 531], ["aspiration", 540], ["and", 551], ["divided", 555], ["in", 563], ["4", 566], ["aliquots", 568], ["added", 577], ["with", 583], ["increasing", 588], ["varespladib", 599], ["or", 611], ["saline", 614], [".", 620], ["sPLA2", 622], ["activity", 628], [",", 636], ["proteins", 638], [",", 646], ["and", 648], ["albumin", 652], ["were", 660], ["measured", 665], [".", 673], ["Dilution", 675], ["was", 684], ["corrected", 688], ["with", 698], ["the", 703], ["urea", 707], ["ratio", 712], [".", 717], ["Varespladib", 719], ["was", 731], ["also", 735], ["tested", 740], ["in", 747], ["vitro", 750], ["against", 756], ["pancreatic", 764], ["sPLA2", 775], ["mixed", 781], ["with", 787], ["different", 792], ["albumin", 802], ["concentration", 810], [".", 823], ["Varespladib", 825], ["was", 837], ["able", 841], ["to", 846], ["inhibit", 849], ["sPLA2", 857], ["in", 863], ["the", 866], ["types", 870], ["of", 876], ["neonatal", 879], ["lung", 888], ["injury", 893], ["investigated", 900], [".", 912], ["sPLA2", 914], ["activity", 920], ["was", 929], ["reduced", 933], ["in", 941], ["hyaline", 944], ["membrane", 952], ["disease", 961], ["(", 969], ["P", 970], ["<", 972], [".0001", 974], [")", 979], [",", 980], ["infections", 982], ["(", 993], ["P", 994], ["=", 996], [".003", 998], [")", 1002], [",", 1003], ["and", 1005], ["meconium", 1009], ["aspiration", 1018], ["(", 1029], ["P", 1030], ["=", 1032], [".04", 1034], [")", 1037], ["using", 1039], ["40", 1045], ["\u00b5M", 1048], ["varespladib", 1051], [";", 1062], ["10", 1064], ["\u00b5M", 1067], ["was", 1070], ["able", 1074], ["to", 1079], ["lower", 1082], ["enzyme", 1088], ["activity", 1095], ["(", 1104], ["P", 1105], ["=", 1107], [".001", 1109], [")", 1113], [",", 1114], ["with", 1116], ["an", 1121], ["IC(50", 1124], [")", 1129], ["of", 1131], ["87", 1134], ["\u00b5M.", 1137], ["An", 1141], ["inverse", 1144], ["relationship", 1152], ["existed", 1165], ["between", 1173], ["protein", 1181], ["level", 1189], ["and", 1195], ["activity", 1199], ["reduction", 1208], ["(", 1218], ["r", 1219], ["=", 1221], ["0.5", 1223], [";", 1226], ["P", 1228], ["=", 1230], [".029", 1232], [")", 1236], [".", 1237], ["The", 1239], ["activity", 1243], ["reduction", 1252], ["/", 1261], ["protein", 1262], ["ratio", 1270], ["tended", 1276], ["to", 1283], ["be", 1286], ["higher", 1289], ["in", 1296], ["hyaline", 1299], ["membrane", 1307], ["disease", 1316], [".", 1323], ["Varespladib", 1325], ["efficacy", 1337], ["was", 1346], ["higher", 1350], ["in", 1357], ["vitro", 1360], ["than", 1366], ["in", 1371], ["lavage", 1374], ["fluids", 1381], ["obtained", 1388], ["from", 1397], ["neonates", 1402], ["(", 1411], ["P", 1412], ["<", 1414], [".001", 1416], [")", 1420], [".", 1421]]}
{"context": "Change in gene expression associated with pancreatic cancer could be attributed to the variation in histone posttranslational modifications leading to subsequent remodeling of the chromatin template during transcription. However, the interconnected network of molecules involved in regulating such processes remains elusive. hPaf1/PD2, a subunit of the human PAF-complex, involved in the regulation of transcriptional elongation has oncogenic potential. Our study explores the possibility that regulation of histone methylation by hPaf1 can contribute towards alteration in gene expression by nucleosomal rearrangement. Here, we show that knockdown of hPaf1/PD2 leads to decreased di- and tri-methylation at histone H3 lysine 4 residues in pancreatic cancer cells. Interestingly, hPaf1/PD2 colocalizes with MLL1 (Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K4 residues. Also, a reduction in hPaf1 level resulted in reduced MLL1 expression and a corresponding decrease in the level of CHD1 (Chromohelicase DNA-binding protein 1), an ATPase dependent chromatin remodeling enzyme that specifically binds to H3K4 di and trimethyl marks. hPaf1/PD2 was also found to interact and colocalize with CHD1 in both cytoplasmic and nuclear extracts of pancreatic cancer cells. Further, reduced level of CHD1 localization in the nucleus in hPaf1/PD2 Knockdown cells could be rescued by ectopic expression of hPaf1/PD2. Micrococcal nuclease digestion showed an altered chromatin structure in hPaf1/PD2-KD cells. Overall, our results suggest that hPaf1/PD2 in association with MLL1 regulates methylation of H3K4 residues, as well as interacts and regulates nuclear shuttling of chromatin remodeling protein CHD1, facilitating its function in pancreatic cancer cells.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "98cb43e4ec95414598cd781412a5d3b8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[253, 253], [177, 177], [134, 134]], "char_spans": [[1620, 1623], [1133, 1136], [884, 887]]}]}], "context_tokens": [["Change", 0], ["in", 7], ["gene", 10], ["expression", 15], ["associated", 26], ["with", 37], ["pancreatic", 42], ["cancer", 53], ["could", 60], ["be", 66], ["attributed", 69], ["to", 80], ["the", 83], ["variation", 87], ["in", 97], ["histone", 100], ["posttranslational", 108], ["modifications", 126], ["leading", 140], ["to", 148], ["subsequent", 151], ["remodeling", 162], ["of", 173], ["the", 176], ["chromatin", 180], ["template", 190], ["during", 199], ["transcription", 206], [".", 219], ["However", 221], [",", 228], ["the", 230], ["interconnected", 234], ["network", 249], ["of", 257], ["molecules", 260], ["involved", 270], ["in", 279], ["regulating", 282], ["such", 293], ["processes", 298], ["remains", 308], ["elusive", 316], [".", 323], ["hPaf1/PD2", 325], [",", 334], ["a", 336], ["subunit", 338], ["of", 346], ["the", 349], ["human", 353], ["PAF", 359], ["-", 362], ["complex", 363], [",", 370], ["involved", 372], ["in", 381], ["the", 384], ["regulation", 388], ["of", 399], ["transcriptional", 402], ["elongation", 418], ["has", 429], ["oncogenic", 433], ["potential", 443], [".", 452], ["Our", 454], ["study", 458], ["explores", 464], ["the", 473], ["possibility", 477], ["that", 489], ["regulation", 494], ["of", 505], ["histone", 508], ["methylation", 516], ["by", 528], ["hPaf1", 531], ["can", 537], ["contribute", 541], ["towards", 552], ["alteration", 560], ["in", 571], ["gene", 574], ["expression", 579], ["by", 590], ["nucleosomal", 593], ["rearrangement", 605], [".", 618], ["Here", 620], [",", 624], ["we", 626], ["show", 629], ["that", 634], ["knockdown", 639], ["of", 649], ["hPaf1/PD2", 652], ["leads", 662], ["to", 668], ["decreased", 671], ["di-", 681], ["and", 685], ["tri", 689], ["-", 692], ["methylation", 693], ["at", 705], ["histone", 708], ["H3", 716], ["lysine", 719], ["4", 726], ["residues", 728], ["in", 737], ["pancreatic", 740], ["cancer", 751], ["cells", 758], [".", 763], ["Interestingly", 765], [",", 778], ["hPaf1/PD2", 780], ["colocalizes", 790], ["with", 802], ["MLL1", 807], ["(", 812], ["Mixed", 813], ["Lineage", 819], ["Leukemia", 827], ["1", 836], [")", 837], [",", 838], ["a", 840], ["histone", 842], ["methyltransferase", 850], ["that", 868], ["methylates", 873], ["H3K4", 884], ["residues", 889], [".", 897], ["Also", 899], [",", 903], ["a", 905], ["reduction", 907], ["in", 917], ["hPaf1", 920], ["level", 926], ["resulted", 932], ["in", 941], ["reduced", 944], ["MLL1", 952], ["expression", 957], ["and", 968], ["a", 972], ["corresponding", 974], ["decrease", 988], ["in", 997], ["the", 1000], ["level", 1004], ["of", 1010], ["CHD1", 1013], ["(", 1018], ["Chromohelicase", 1019], ["DNA", 1034], ["-", 1037], ["binding", 1038], ["protein", 1046], ["1", 1054], [")", 1055], [",", 1056], ["an", 1058], ["ATPase", 1061], ["dependent", 1068], ["chromatin", 1078], ["remodeling", 1088], ["enzyme", 1099], ["that", 1106], ["specifically", 1111], ["binds", 1124], ["to", 1130], ["H3K4", 1133], ["di", 1138], ["and", 1141], ["trimethyl", 1145], ["marks", 1155], [".", 1160], ["hPaf1/PD2", 1162], ["was", 1172], ["also", 1176], ["found", 1181], ["to", 1187], ["interact", 1190], ["and", 1199], ["colocalize", 1203], ["with", 1214], ["CHD1", 1219], ["in", 1224], ["both", 1227], ["cytoplasmic", 1232], ["and", 1244], ["nuclear", 1248], ["extracts", 1256], ["of", 1265], ["pancreatic", 1268], ["cancer", 1279], ["cells", 1286], [".", 1291], ["Further", 1293], [",", 1300], ["reduced", 1302], ["level", 1310], ["of", 1316], ["CHD1", 1319], ["localization", 1324], ["in", 1337], ["the", 1340], ["nucleus", 1344], ["in", 1352], ["hPaf1/PD2", 1355], ["Knockdown", 1365], ["cells", 1375], ["could", 1381], ["be", 1387], ["rescued", 1390], ["by", 1398], ["ectopic", 1401], ["expression", 1409], ["of", 1420], ["hPaf1/PD2", 1423], [".", 1432], ["Micrococcal", 1434], ["nuclease", 1446], ["digestion", 1455], ["showed", 1465], ["an", 1472], ["altered", 1475], ["chromatin", 1483], ["structure", 1493], ["in", 1503], ["hPaf1/PD2-KD", 1506], ["cells", 1519], [".", 1524], ["Overall", 1526], [",", 1533], ["our", 1535], ["results", 1539], ["suggest", 1547], ["that", 1555], ["hPaf1/PD2", 1560], ["in", 1570], ["association", 1573], ["with", 1585], ["MLL1", 1590], ["regulates", 1595], ["methylation", 1605], ["of", 1617], ["H3K4", 1620], ["residues", 1625], [",", 1633], ["as", 1635], ["well", 1638], ["as", 1643], ["interacts", 1646], ["and", 1656], ["regulates", 1660], ["nuclear", 1670], ["shuttling", 1678], ["of", 1688], ["chromatin", 1691], ["remodeling", 1701], ["protein", 1712], ["CHD1", 1720], [",", 1724], ["facilitating", 1726], ["its", 1739], ["function", 1743], ["in", 1752], ["pancreatic", 1755], ["cancer", 1766], ["cells", 1773], [".", 1778]]}
{"context": "Chronic myelogenous leukemia (CML) is a clonal hematopoietic disorder caused by the reciprocal translocation between chromosome 9 and 22. As a result of this translocation, a novel fusion gene, BCR-ABL, is created on Philadelphia (Ph) chromosome, and the constitutive activity of the BCR-ABL protein tyrosine kinase plays a critical role in the disease pathogenesis. Imatinib mesylate, a selective BCR-ABL tyrosine kinase inhibitor, was first given to a patient with CML in June 1998. Since then, it has continued to demonstrate remarkable efficacy in treating patients with CML. Based upon the results of early phase I and II studies, a phase III study (IRIS Study) that was randomized to first-line imatinib (400 mg/day) or to standard treatment with interferon+low-dose Ara-C, was conducted on 1,106 patients newly diagnosed (within 6 months) with chronic-phase CML. After median follow-up of 30 months, imatinib showed significantly superior tolerability, hematologic and cytogenetic responses (major cytogenetic response, 90%; complete cytogenetic response, 82%), and overall survival (95% without censoring allo-HSCT). Although imatinib is the first-line therapy and has changed the paradigm of CML treatment strategy, questions remain as to the meaning of cytogenetic and molecular response, curability, optimal dose, and relation with allo-HSCT.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "90bd5d6d1bbd4a51af5bf2328d5aebb7", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[73, 75], [53, 55], [34, 36]], "char_spans": [[398, 404], [284, 290], [194, 200]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["a", 38], ["clonal", 40], ["hematopoietic", 47], ["disorder", 61], ["caused", 70], ["by", 77], ["the", 80], ["reciprocal", 84], ["translocation", 95], ["between", 109], ["chromosome", 117], ["9", 128], ["and", 130], ["22", 134], [".", 136], ["As", 138], ["a", 141], ["result", 143], ["of", 150], ["this", 153], ["translocation", 158], [",", 171], ["a", 173], ["novel", 175], ["fusion", 181], ["gene", 188], [",", 192], ["BCR", 194], ["-", 197], ["ABL", 198], [",", 201], ["is", 203], ["created", 206], ["on", 214], ["Philadelphia", 217], ["(", 230], ["Ph", 231], [")", 233], ["chromosome", 235], [",", 245], ["and", 247], ["the", 251], ["constitutive", 255], ["activity", 268], ["of", 277], ["the", 280], ["BCR", 284], ["-", 287], ["ABL", 288], ["protein", 292], ["tyrosine", 300], ["kinase", 309], ["plays", 316], ["a", 322], ["critical", 324], ["role", 333], ["in", 338], ["the", 341], ["disease", 345], ["pathogenesis", 353], [".", 365], ["Imatinib", 367], ["mesylate", 376], [",", 384], ["a", 386], ["selective", 388], ["BCR", 398], ["-", 401], ["ABL", 402], ["tyrosine", 406], ["kinase", 415], ["inhibitor", 422], [",", 431], ["was", 433], ["first", 437], ["given", 443], ["to", 449], ["a", 452], ["patient", 454], ["with", 462], ["CML", 467], ["in", 471], ["June", 474], ["1998", 479], [".", 483], ["Since", 485], ["then", 491], [",", 495], ["it", 497], ["has", 500], ["continued", 504], ["to", 514], ["demonstrate", 517], ["remarkable", 529], ["efficacy", 540], ["in", 549], ["treating", 552], ["patients", 561], ["with", 570], ["CML", 575], [".", 578], ["Based", 580], ["upon", 586], ["the", 591], ["results", 595], ["of", 603], ["early", 606], ["phase", 612], ["I", 618], ["and", 620], ["II", 624], ["studies", 627], [",", 634], ["a", 636], ["phase", 638], ["III", 644], ["study", 648], ["(", 654], ["IRIS", 655], ["Study", 660], [")", 665], ["that", 667], ["was", 672], ["randomized", 676], ["to", 687], ["first", 690], ["-", 695], ["line", 696], ["imatinib", 701], ["(", 710], ["400", 711], ["mg", 715], ["/", 717], ["day", 718], [")", 721], ["or", 723], ["to", 726], ["standard", 729], ["treatment", 738], ["with", 748], ["interferon+low", 753], ["-", 767], ["dose", 768], ["Ara", 773], ["-", 776], ["C", 777], [",", 778], ["was", 780], ["conducted", 784], ["on", 794], ["1,106", 797], ["patients", 803], ["newly", 812], ["diagnosed", 818], ["(", 828], ["within", 829], ["6", 836], ["months", 838], [")", 844], ["with", 846], ["chronic", 851], ["-", 858], ["phase", 859], ["CML", 865], [".", 868], ["After", 870], ["median", 876], ["follow", 883], ["-", 889], ["up", 890], ["of", 893], ["30", 896], ["months", 899], [",", 905], ["imatinib", 907], ["showed", 916], ["significantly", 923], ["superior", 937], ["tolerability", 946], [",", 958], ["hematologic", 960], ["and", 972], ["cytogenetic", 976], ["responses", 988], ["(", 998], ["major", 999], ["cytogenetic", 1005], ["response", 1017], [",", 1025], ["90", 1027], ["%", 1029], [";", 1030], ["complete", 1032], ["cytogenetic", 1041], ["response", 1053], [",", 1061], ["82", 1063], ["%", 1065], [")", 1066], [",", 1067], ["and", 1069], ["overall", 1073], ["survival", 1081], ["(", 1090], ["95", 1091], ["%", 1093], ["without", 1095], ["censoring", 1103], ["allo", 1113], ["-", 1117], ["HSCT", 1118], [")", 1122], [".", 1123], ["Although", 1125], ["imatinib", 1134], ["is", 1143], ["the", 1146], ["first", 1150], ["-", 1155], ["line", 1156], ["therapy", 1161], ["and", 1169], ["has", 1173], ["changed", 1177], ["the", 1185], ["paradigm", 1189], ["of", 1198], ["CML", 1201], ["treatment", 1205], ["strategy", 1215], [",", 1223], ["questions", 1225], ["remain", 1235], ["as", 1242], ["to", 1245], ["the", 1248], ["meaning", 1252], ["of", 1260], ["cytogenetic", 1263], ["and", 1275], ["molecular", 1279], ["response", 1289], [",", 1297], ["curability", 1299], [",", 1309], ["optimal", 1311], ["dose", 1319], [",", 1323], ["and", 1325], ["relation", 1329], ["with", 1338], ["allo", 1343], ["-", 1347], ["HSCT", 1348], [".", 1352]]}
{"context": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic. In search for the pathophysiology and causative agent of VE, we performed a cross-sectional study on clinical, serological and neuroimaging data on chronic VE patients during two medical expeditions to three villages within the Viliuiski river basin in the Republic of Sakha in 2000 and to the capital Yakutsk in 2006. The severity of the core clinical picture with predominant sensory ataxia, gait apraxia, lower limb spasticity, cognitive impairment and bladder dysfunction correlated with the degree of MRI findings showing enlargement of inner ventricular spaces as in communicating hydrocephalus. Laboratory studies revealed transient eosinophilia during the preceding acute meningitis-like phase, but no ongoing inflammatory process in the CSF. We found immune reactions against Toxocara canis in the majority of chronic VE patients but rarely in controls (P = 0.025; Fisher's exact test). Histological analysis of subacute to subchronic VE brain samples showed eosinophilic infiltrations with no signs of persistent Toxocara canis infection. Our data showed that pressure by the communicating hydrocephalus as a mechanical factor is the major pathogenic mechanism in chronic VE, most likely triggered by eosinophilic meningitis. There are no signs for an ongoing inflammatory process in chronic VE. The past eosinophilic reaction in VE might be caused by Toxocara ssp. infection and might therefore represent the first hint for an initial cause leading to the development of chronic VE. Our data provide a framework for future studies and potential therapeutic interventions for this enigmatic epidemic neurological disease potentially spreading in Sakha Republic.", "qas": [{"question": "Viliuisk encephalomyelitis is diagnosed in which geographical area?", "answers": ["Northeast Siberia"], "qid": "15bd193287ec4c43b761c54699d4ca55", "question_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["is", 27], ["diagnosed", 30], ["in", 40], ["which", 43], ["geographical", 49], ["area", 62], ["?", 66]], "detected_answers": [{"text": "Northeast Siberia", "token_spans": [[11, 12]], "char_spans": [[70, 86]]}]}], "context_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["(", 27], ["VE", 28], [")", 30], ["is", 32], ["an", 35], ["endemic", 38], ["neurological", 46], ["disease", 59], ["in", 67], ["Northeast", 70], ["Siberia", 80], ["and", 88], ["generally", 92], ["considered", 102], ["to", 113], ["be", 116], ["a", 119], ["chronic", 121], ["encephalomyelitis", 129], ["of", 147], ["unknown", 150], ["origin", 158], ["actually", 165], ["spreading", 174], ["in", 184], ["the", 187], ["Sakha", 191], ["(", 197], ["Yakutian", 198], [")", 206], ["Republic", 208], [".", 216], ["In", 218], ["search", 221], ["for", 228], ["the", 232], ["pathophysiology", 236], ["and", 252], ["causative", 256], ["agent", 266], ["of", 272], ["VE", 275], [",", 277], ["we", 279], ["performed", 282], ["a", 292], ["cross", 294], ["-", 299], ["sectional", 300], ["study", 310], ["on", 316], ["clinical", 319], [",", 327], ["serological", 329], ["and", 341], ["neuroimaging", 345], ["data", 358], ["on", 363], ["chronic", 366], ["VE", 374], ["patients", 377], ["during", 386], ["two", 393], ["medical", 397], ["expeditions", 405], ["to", 417], ["three", 420], ["villages", 426], ["within", 435], ["the", 442], ["Viliuiski", 446], ["river", 456], ["basin", 462], ["in", 468], ["the", 471], ["Republic", 475], ["of", 484], ["Sakha", 487], ["in", 493], ["2000", 496], ["and", 501], ["to", 505], ["the", 508], ["capital", 512], ["Yakutsk", 520], ["in", 528], ["2006", 531], [".", 535], ["The", 537], ["severity", 541], ["of", 550], ["the", 553], ["core", 557], ["clinical", 562], ["picture", 571], ["with", 579], ["predominant", 584], ["sensory", 596], ["ataxia", 604], [",", 610], ["gait", 612], ["apraxia", 617], [",", 624], ["lower", 626], ["limb", 632], ["spasticity", 637], [",", 647], ["cognitive", 649], ["impairment", 659], ["and", 670], ["bladder", 674], ["dysfunction", 682], ["correlated", 694], ["with", 705], ["the", 710], ["degree", 714], ["of", 721], ["MRI", 724], ["findings", 728], ["showing", 737], ["enlargement", 745], ["of", 757], ["inner", 760], ["ventricular", 766], ["spaces", 778], ["as", 785], ["in", 788], ["communicating", 791], ["hydrocephalus", 805], [".", 818], ["Laboratory", 820], ["studies", 831], ["revealed", 839], ["transient", 848], ["eosinophilia", 858], ["during", 871], ["the", 878], ["preceding", 882], ["acute", 892], ["meningitis", 898], ["-", 908], ["like", 909], ["phase", 914], [",", 919], ["but", 921], ["no", 925], ["ongoing", 928], ["inflammatory", 936], ["process", 949], ["in", 957], ["the", 960], ["CSF", 964], [".", 967], ["We", 969], ["found", 972], ["immune", 978], ["reactions", 985], ["against", 995], ["Toxocara", 1003], ["canis", 1012], ["in", 1018], ["the", 1021], ["majority", 1025], ["of", 1034], ["chronic", 1037], ["VE", 1045], ["patients", 1048], ["but", 1057], ["rarely", 1061], ["in", 1068], ["controls", 1071], ["(", 1080], ["P", 1081], ["=", 1083], ["0.025", 1085], [";", 1090], ["Fisher", 1092], ["'s", 1098], ["exact", 1101], ["test", 1107], [")", 1111], [".", 1112], ["Histological", 1114], ["analysis", 1127], ["of", 1136], ["subacute", 1139], ["to", 1148], ["subchronic", 1151], ["VE", 1162], ["brain", 1165], ["samples", 1171], ["showed", 1179], ["eosinophilic", 1186], ["infiltrations", 1199], ["with", 1213], ["no", 1218], ["signs", 1221], ["of", 1227], ["persistent", 1230], ["Toxocara", 1241], ["canis", 1250], ["infection", 1256], [".", 1265], ["Our", 1267], ["data", 1271], ["showed", 1276], ["that", 1283], ["pressure", 1288], ["by", 1297], ["the", 1300], ["communicating", 1304], ["hydrocephalus", 1318], ["as", 1332], ["a", 1335], ["mechanical", 1337], ["factor", 1348], ["is", 1355], ["the", 1358], ["major", 1362], ["pathogenic", 1368], ["mechanism", 1379], ["in", 1389], ["chronic", 1392], ["VE", 1400], [",", 1402], ["most", 1404], ["likely", 1409], ["triggered", 1416], ["by", 1426], ["eosinophilic", 1429], ["meningitis", 1442], [".", 1452], ["There", 1454], ["are", 1460], ["no", 1464], ["signs", 1467], ["for", 1473], ["an", 1477], ["ongoing", 1480], ["inflammatory", 1488], ["process", 1501], ["in", 1509], ["chronic", 1512], ["VE", 1520], [".", 1522], ["The", 1524], ["past", 1528], ["eosinophilic", 1533], ["reaction", 1546], ["in", 1555], ["VE", 1558], ["might", 1561], ["be", 1567], ["caused", 1570], ["by", 1577], ["Toxocara", 1580], ["ssp", 1589], [".", 1592], ["infection", 1594], ["and", 1604], ["might", 1608], ["therefore", 1614], ["represent", 1624], ["the", 1634], ["first", 1638], ["hint", 1644], ["for", 1649], ["an", 1653], ["initial", 1656], ["cause", 1664], ["leading", 1670], ["to", 1678], ["the", 1681], ["development", 1685], ["of", 1697], ["chronic", 1700], ["VE", 1708], [".", 1710], ["Our", 1712], ["data", 1716], ["provide", 1721], ["a", 1729], ["framework", 1731], ["for", 1741], ["future", 1745], ["studies", 1752], ["and", 1760], ["potential", 1764], ["therapeutic", 1774], ["interventions", 1786], ["for", 1800], ["this", 1804], ["enigmatic", 1809], ["epidemic", 1819], ["neurological", 1828], ["disease", 1841], ["potentially", 1849], ["spreading", 1861], ["in", 1871], ["Sakha", 1874], ["Republic", 1880], [".", 1888]]}
{"context": "Two forms of neurofibromatosis, type 1 (NF1) and type 2 (NF2) are connected with genes localized on chromosomes 17 and 22, respectively. The genes that are inactivated in neurofibromatosis code for the proteins neurofibromine and merline, respectively. Since inactivation leads to neoplasia, they are called tumour suppressor genes. Neurofibromine shows resemblances to proteins that serve to inactivate oncogenes. Merline has a relationship with proteins that connect the cytoskeleton and the cell membrane. The precise function of the proteins is still unknown. The NF1 gene is characterized by extraordinarily high sensitivity to mutation; half the NF1 patients have not inherited the disease. In the familial form of neurofibromatosis, a mutated gene is inherited and the normal allele in the tumour is inactivated, making tumour growth possible. In the sporadic form of neurofibromatosis, both normal alleles are inactivated locally in the tissue so that a tumour develops in that place.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "02a0b88b776d4b2d90874b4cebd2bc40", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[8, 8], [96, 96], [109, 109]], "char_spans": [[40, 42], [568, 570], [652, 654]]}]}], "context_tokens": [["Two", 0], ["forms", 4], ["of", 10], ["neurofibromatosis", 13], [",", 30], ["type", 32], ["1", 37], ["(", 39], ["NF1", 40], [")", 43], ["and", 45], ["type", 49], ["2", 54], ["(", 56], ["NF2", 57], [")", 60], ["are", 62], ["connected", 66], ["with", 76], ["genes", 81], ["localized", 87], ["on", 97], ["chromosomes", 100], ["17", 112], ["and", 115], ["22", 119], [",", 121], ["respectively", 123], [".", 135], ["The", 137], ["genes", 141], ["that", 147], ["are", 152], ["inactivated", 156], ["in", 168], ["neurofibromatosis", 171], ["code", 189], ["for", 194], ["the", 198], ["proteins", 202], ["neurofibromine", 211], ["and", 226], ["merline", 230], [",", 237], ["respectively", 239], [".", 251], ["Since", 253], ["inactivation", 259], ["leads", 272], ["to", 278], ["neoplasia", 281], [",", 290], ["they", 292], ["are", 297], ["called", 301], ["tumour", 308], ["suppressor", 315], ["genes", 326], [".", 331], ["Neurofibromine", 333], ["shows", 348], ["resemblances", 354], ["to", 367], ["proteins", 370], ["that", 379], ["serve", 384], ["to", 390], ["inactivate", 393], ["oncogenes", 404], [".", 413], ["Merline", 415], ["has", 423], ["a", 427], ["relationship", 429], ["with", 442], ["proteins", 447], ["that", 456], ["connect", 461], ["the", 469], ["cytoskeleton", 473], ["and", 486], ["the", 490], ["cell", 494], ["membrane", 499], [".", 507], ["The", 509], ["precise", 513], ["function", 521], ["of", 530], ["the", 533], ["proteins", 537], ["is", 546], ["still", 549], ["unknown", 555], [".", 562], ["The", 564], ["NF1", 568], ["gene", 572], ["is", 577], ["characterized", 580], ["by", 594], ["extraordinarily", 597], ["high", 613], ["sensitivity", 618], ["to", 630], ["mutation", 633], [";", 641], ["half", 643], ["the", 648], ["NF1", 652], ["patients", 656], ["have", 665], ["not", 670], ["inherited", 674], ["the", 684], ["disease", 688], [".", 695], ["In", 697], ["the", 700], ["familial", 704], ["form", 713], ["of", 718], ["neurofibromatosis", 721], [",", 738], ["a", 740], ["mutated", 742], ["gene", 750], ["is", 755], ["inherited", 758], ["and", 768], ["the", 772], ["normal", 776], ["allele", 783], ["in", 790], ["the", 793], ["tumour", 797], ["is", 804], ["inactivated", 807], [",", 818], ["making", 820], ["tumour", 827], ["growth", 834], ["possible", 841], [".", 849], ["In", 851], ["the", 854], ["sporadic", 858], ["form", 867], ["of", 872], ["neurofibromatosis", 875], [",", 892], ["both", 894], ["normal", 899], ["alleles", 906], ["are", 914], ["inactivated", 918], ["locally", 930], ["in", 938], ["the", 941], ["tissue", 945], ["so", 952], ["that", 955], ["a", 960], ["tumour", 962], ["develops", 969], ["in", 978], ["that", 981], ["place", 986], [".", 991]]}
{"context": "Infectious mononucleosis is a common, usually self-limited disease. However, infectious mononucleosis may present with severe manifestations. Complications may also occur. Consequently, diagnostic and treatment issues regarding infectious mononucleosis are of major importance. In this review, we focus on the evaluation of articles providing diagnosis and treatment data for infectious mononucleosis, published during the past 2 years. Twelve studies, deriving from extended search in PubMed, were included. Nine studies provided diagnosis data. The evaluated diagnostic methods were real-time PCR (RT-PCR), IgM/IgG antibodies measured with different assays [measurement of Epstein-Barr virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/monocyte counts, C-reactive protein values, and monospot test]. The sensitivities reported for RT-PCR were high. The available treatment data were scarce (three studies). Two of them suggested that antivirals (mainly acyclovir and valacyclovir) may have a role in the treatment of infectious mononucleosis with complications, whereas the remaining study presented novel potential therapeutic patents including 5-substituted uracyle, azacytosine derivatives, and peptides inhibiting EBV-mediated membrane fusion. RT-PCR and measurement of EBV-VL may provide useful tools for the early diagnosis of infectious mononucleosis in cases with inconclusive serological results. Antiviral agents may provide a useful treatment option in patients with severe infectious mononucleosis.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "fba1c150697a4864bbf8aedacd2d8a94", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[113, 116]], "char_spans": [[675, 692]]}]}], "context_tokens": [["Infectious", 0], ["mononucleosis", 11], ["is", 25], ["a", 28], ["common", 30], [",", 36], ["usually", 38], ["self", 46], ["-", 50], ["limited", 51], ["disease", 59], [".", 66], ["However", 68], [",", 75], ["infectious", 77], ["mononucleosis", 88], ["may", 102], ["present", 106], ["with", 114], ["severe", 119], ["manifestations", 126], [".", 140], ["Complications", 142], ["may", 156], ["also", 160], ["occur", 165], [".", 170], ["Consequently", 172], [",", 184], ["diagnostic", 186], ["and", 197], ["treatment", 201], ["issues", 211], ["regarding", 218], ["infectious", 228], ["mononucleosis", 239], ["are", 253], ["of", 257], ["major", 260], ["importance", 266], [".", 276], ["In", 278], ["this", 281], ["review", 286], [",", 292], ["we", 294], ["focus", 297], ["on", 303], ["the", 306], ["evaluation", 310], ["of", 321], ["articles", 324], ["providing", 333], ["diagnosis", 343], ["and", 353], ["treatment", 357], ["data", 367], ["for", 372], ["infectious", 376], ["mononucleosis", 387], [",", 400], ["published", 402], ["during", 412], ["the", 419], ["past", 423], ["2", 428], ["years", 430], [".", 435], ["Twelve", 437], ["studies", 444], [",", 451], ["deriving", 453], ["from", 462], ["extended", 467], ["search", 476], ["in", 483], ["PubMed", 486], [",", 492], ["were", 494], ["included", 499], [".", 507], ["Nine", 509], ["studies", 514], ["provided", 522], ["diagnosis", 531], ["data", 541], [".", 545], ["The", 547], ["evaluated", 551], ["diagnostic", 561], ["methods", 572], ["were", 580], ["real", 585], ["-", 589], ["time", 590], ["PCR", 595], ["(", 599], ["RT", 600], ["-", 602], ["PCR", 603], [")", 606], [",", 607], ["IgM", 609], ["/", 612], ["IgG", 613], ["antibodies", 617], ["measured", 628], ["with", 637], ["different", 642], ["assays", 652], ["[", 659], ["measurement", 660], ["of", 672], ["Epstein", 675], ["-", 682], ["Barr", 683], ["virus", 688], ["viral", 694], ["load", 700], ["(", 705], ["EBV", 706], ["-", 709], ["VL", 710], [")", 712], ["in", 714], ["peripheral", 717], ["blood", 728], [",", 733], ["neutrophil", 735], ["/", 745], ["lymphocyte", 746], ["/", 756], ["monocyte", 757], ["counts", 766], [",", 772], ["C", 774], ["-", 775], ["reactive", 776], ["protein", 785], ["values", 793], [",", 799], ["and", 801], ["monospot", 805], ["test].", 814], ["The", 821], ["sensitivities", 825], ["reported", 839], ["for", 848], ["RT", 852], ["-", 854], ["PCR", 855], ["were", 859], ["high", 864], [".", 868], ["The", 870], ["available", 874], ["treatment", 884], ["data", 894], ["were", 899], ["scarce", 904], ["(", 911], ["three", 912], ["studies", 918], [")", 925], [".", 926], ["Two", 928], ["of", 932], ["them", 935], ["suggested", 940], ["that", 950], ["antivirals", 955], ["(", 966], ["mainly", 967], ["acyclovir", 974], ["and", 984], ["valacyclovir", 988], [")", 1000], ["may", 1002], ["have", 1006], ["a", 1011], ["role", 1013], ["in", 1018], ["the", 1021], ["treatment", 1025], ["of", 1035], ["infectious", 1038], ["mononucleosis", 1049], ["with", 1063], ["complications", 1068], [",", 1081], ["whereas", 1083], ["the", 1091], ["remaining", 1095], ["study", 1105], ["presented", 1111], ["novel", 1121], ["potential", 1127], ["therapeutic", 1137], ["patents", 1149], ["including", 1157], ["5-substituted", 1167], ["uracyle", 1181], [",", 1188], ["azacytosine", 1190], ["derivatives", 1202], [",", 1213], ["and", 1215], ["peptides", 1219], ["inhibiting", 1228], ["EBV", 1239], ["-", 1242], ["mediated", 1243], ["membrane", 1252], ["fusion", 1261], [".", 1267], ["RT", 1269], ["-", 1271], ["PCR", 1272], ["and", 1276], ["measurement", 1280], ["of", 1292], ["EBV", 1295], ["-", 1298], ["VL", 1299], ["may", 1302], ["provide", 1306], ["useful", 1314], ["tools", 1321], ["for", 1327], ["the", 1331], ["early", 1335], ["diagnosis", 1341], ["of", 1351], ["infectious", 1354], ["mononucleosis", 1365], ["in", 1379], ["cases", 1382], ["with", 1388], ["inconclusive", 1393], ["serological", 1406], ["results", 1418], [".", 1425], ["Antiviral", 1427], ["agents", 1437], ["may", 1444], ["provide", 1448], ["a", 1456], ["useful", 1458], ["treatment", 1465], ["option", 1475], ["in", 1482], ["patients", 1485], ["with", 1494], ["severe", 1499], ["infectious", 1506], ["mononucleosis", 1517], [".", 1530]]}
{"context": "To clarify the association between clinically defined simple stress urinary incontinence (SUI) symptoms and urodynamic SUI, we examined the relationship between Valsalva leak point pressure (VLPP) as measured by the Q-tip test and Stamey grade in simple female SUI. Two hundred grade I or II female SUI patients with SUI symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by Q-tip test; stress test; and cystometry, including VLPP measurement. On the basis of the VLPP, patients were classified into urethral hypermobility [UH, subdivided into anatomical incontinence (AI) and equivocal incontinence (EI)] or intrinsic sphincter deficiency groups for analysis of the relationship between VLPP and Stamey grade and Q-tip angle. Seventy-eight patients were included, and the mean patient age was 54 \u00b1 7.5 years, mean SUI symptom duration 2.8 years (range 0.5-6 years), mean VLPP 103.6 \u00b1 18.4 cm H2O, and mean Q-tip angle 28.6\u00b0 \u00b1 7.2\u00b0. Fifty-three patients were categorized as Stamey grade I, 25 as Stamey grade II, 51 as AI, and 27 as EI. VLPP was found to be negatively correlated with Q-tip angle (Rs = -0.798, Y = -0.313X + 60.95, P < 0.001), and classifications of VLPP and Stamey grade have positive correlation (\u03c7 (2) = 4.9130, P = 0.0267). In simple female SUI, VLPP is associated with the Q-tip angle and Stamey grade, which may help to reduce some of urodynamic items.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "804f275edde947989343c29d6110428e", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[8, 10]], "char_spans": [[61, 87]]}]}], "context_tokens": [["To", 0], ["clarify", 3], ["the", 11], ["association", 15], ["between", 27], ["clinically", 35], ["defined", 46], ["simple", 54], ["stress", 61], ["urinary", 68], ["incontinence", 76], ["(", 89], ["SUI", 90], [")", 93], ["symptoms", 95], ["and", 104], ["urodynamic", 108], ["SUI", 119], [",", 122], ["we", 124], ["examined", 127], ["the", 136], ["relationship", 140], ["between", 153], ["Valsalva", 161], ["leak", 170], ["point", 175], ["pressure", 181], ["(", 190], ["VLPP", 191], [")", 195], ["as", 197], ["measured", 200], ["by", 209], ["the", 212], ["Q", 216], ["-", 217], ["tip", 218], ["test", 222], ["and", 227], ["Stamey", 231], ["grade", 238], ["in", 244], ["simple", 247], ["female", 254], ["SUI", 261], [".", 264], ["Two", 266], ["hundred", 270], ["grade", 278], ["I", 284], ["or", 286], ["II", 289], ["female", 292], ["SUI", 299], ["patients", 303], ["with", 312], ["SUI", 317], ["symptom", 321], ["were", 329], ["examined", 334], ["by", 343], ["reviewing", 346], ["medical", 356], ["history", 364], [";", 371], ["physical", 373], ["examination", 382], [";", 393], ["urethral", 395], ["mobility", 404], ["as", 413], ["assessed", 416], ["by", 425], ["Q", 428], ["-", 429], ["tip", 430], ["test", 434], [";", 438], ["stress", 440], ["test", 447], [";", 451], ["and", 453], ["cystometry", 457], [",", 467], ["including", 469], ["VLPP", 479], ["measurement", 484], [".", 495], ["On", 497], ["the", 500], ["basis", 504], ["of", 510], ["the", 513], ["VLPP", 517], [",", 521], ["patients", 523], ["were", 532], ["classified", 537], ["into", 548], ["urethral", 553], ["hypermobility", 562], ["[", 576], ["UH", 577], [",", 579], ["subdivided", 581], ["into", 592], ["anatomical", 597], ["incontinence", 608], ["(", 621], ["AI", 622], [")", 624], ["and", 626], ["equivocal", 630], ["incontinence", 640], ["(", 653], ["EI", 654], [")", 656], ["]", 657], ["or", 659], ["intrinsic", 662], ["sphincter", 672], ["deficiency", 682], ["groups", 693], ["for", 700], ["analysis", 704], ["of", 713], ["the", 716], ["relationship", 720], ["between", 733], ["VLPP", 741], ["and", 746], ["Stamey", 750], ["grade", 757], ["and", 763], ["Q", 767], ["-", 768], ["tip", 769], ["angle", 773], [".", 778], ["Seventy", 780], ["-", 787], ["eight", 788], ["patients", 794], ["were", 803], ["included", 808], [",", 816], ["and", 818], ["the", 822], ["mean", 826], ["patient", 831], ["age", 839], ["was", 843], ["54", 847], ["\u00b1", 850], ["7.5", 852], ["years", 856], [",", 861], ["mean", 863], ["SUI", 868], ["symptom", 872], ["duration", 880], ["2.8", 889], ["years", 893], ["(", 899], ["range", 900], ["0.5", 906], ["-", 909], ["6", 910], ["years", 912], [")", 917], [",", 918], ["mean", 920], ["VLPP", 925], ["103.6", 930], ["\u00b1", 936], ["18.4", 938], ["cm", 943], ["H2O", 946], [",", 949], ["and", 951], ["mean", 955], ["Q", 960], ["-", 961], ["tip", 962], ["angle", 966], ["28.6", 972], ["\u00b0", 976], ["\u00b1", 978], ["7.2", 980], ["\u00b0", 983], [".", 984], ["Fifty", 986], ["-", 991], ["three", 992], ["patients", 998], ["were", 1007], ["categorized", 1012], ["as", 1024], ["Stamey", 1027], ["grade", 1034], ["I", 1040], [",", 1041], ["25", 1043], ["as", 1046], ["Stamey", 1049], ["grade", 1056], ["II", 1062], [",", 1064], ["51", 1066], ["as", 1069], ["AI", 1072], [",", 1074], ["and", 1076], ["27", 1080], ["as", 1083], ["EI", 1086], [".", 1088], ["VLPP", 1090], ["was", 1095], ["found", 1099], ["to", 1105], ["be", 1108], ["negatively", 1111], ["correlated", 1122], ["with", 1133], ["Q", 1138], ["-", 1139], ["tip", 1140], ["angle", 1144], ["(", 1150], ["Rs", 1151], ["=", 1154], ["-0.798", 1156], [",", 1162], ["Y", 1164], ["=", 1166], ["-0.313X", 1168], ["+", 1176], ["60.95", 1178], [",", 1183], ["P", 1185], ["<", 1187], ["0.001", 1189], [")", 1194], [",", 1195], ["and", 1197], ["classifications", 1201], ["of", 1217], ["VLPP", 1220], ["and", 1225], ["Stamey", 1229], ["grade", 1236], ["have", 1242], ["positive", 1247], ["correlation", 1256], ["(", 1268], ["\u03c7", 1269], ["(", 1271], ["2", 1272], [")", 1273], ["=", 1275], ["4.9130", 1277], [",", 1283], ["P", 1285], ["=", 1287], ["0.0267", 1289], [")", 1295], [".", 1296], ["In", 1298], ["simple", 1301], ["female", 1308], ["SUI", 1315], [",", 1318], ["VLPP", 1320], ["is", 1325], ["associated", 1328], ["with", 1339], ["the", 1344], ["Q", 1348], ["-", 1349], ["tip", 1350], ["angle", 1354], ["and", 1360], ["Stamey", 1364], ["grade", 1371], [",", 1376], ["which", 1378], ["may", 1384], ["help", 1388], ["to", 1393], ["reduce", 1396], ["some", 1403], ["of", 1408], ["urodynamic", 1411], ["items", 1422], [".", 1427]]}
{"context": "Dasatinib (BMS-354825) is a Src/ABL tyrosine kinase inhibitor currently approved for the treatment of chronic myeloid leukemia. Dasatinib has increased potency against ABL compared to the current therapy imatinib, and is effective in many cases where disease is resistant to imatinib. Dasatinib also inhibits many Src-family tyrosine kinases. We have demonstrated in this study that dasatinib is able to block the function of normal human T-lymphocytes in vitro at clinically relevant concentrations. T-cell functions including proliferation, activation and cytokine production were all uniformly inhibited in the presence of dasatinib. We also demonstrated inhibition of TCR signalling through Src-family kinase LCK, and predicted that inhibition of LCK and other kinases involved in T-cell signalling by dasatinib is responsible for the suppression of T-cell function. These findings raise the concern about potential T-cell inhibition in patients taking dasatinib, and suggest a possible application for the treatment of T-cell mediated immune disorders.", "qas": [{"question": "Does dasatinib promote or inhibit T-cell proliferation?", "answers": ["inhibits"], "qid": "5b937d99df5342ca8ffb9a12ec8714ce", "question_tokens": [["Does", 0], ["dasatinib", 5], ["promote", 15], ["or", 23], ["inhibit", 26], ["T", 34], ["-", 35], ["cell", 36], ["proliferation", 41], ["?", 54]], "detected_answers": [{"text": "inhibits", "token_spans": [[50, 50]], "char_spans": [[300, 307]]}]}], "context_tokens": [["Dasatinib", 0], ["(", 10], ["BMS-354825", 11], [")", 21], ["is", 23], ["a", 26], ["Src", 28], ["/", 31], ["ABL", 32], ["tyrosine", 36], ["kinase", 45], ["inhibitor", 52], ["currently", 62], ["approved", 72], ["for", 81], ["the", 85], ["treatment", 89], ["of", 99], ["chronic", 102], ["myeloid", 110], ["leukemia", 118], [".", 126], ["Dasatinib", 128], ["has", 138], ["increased", 142], ["potency", 152], ["against", 160], ["ABL", 168], ["compared", 172], ["to", 181], ["the", 184], ["current", 188], ["therapy", 196], ["imatinib", 204], [",", 212], ["and", 214], ["is", 218], ["effective", 221], ["in", 231], ["many", 234], ["cases", 239], ["where", 245], ["disease", 251], ["is", 259], ["resistant", 262], ["to", 272], ["imatinib", 275], [".", 283], ["Dasatinib", 285], ["also", 295], ["inhibits", 300], ["many", 309], ["Src", 314], ["-", 317], ["family", 318], ["tyrosine", 325], ["kinases", 334], [".", 341], ["We", 343], ["have", 346], ["demonstrated", 351], ["in", 364], ["this", 367], ["study", 372], ["that", 378], ["dasatinib", 383], ["is", 393], ["able", 396], ["to", 401], ["block", 404], ["the", 410], ["function", 414], ["of", 423], ["normal", 426], ["human", 433], ["T", 439], ["-", 440], ["lymphocytes", 441], ["in", 453], ["vitro", 456], ["at", 462], ["clinically", 465], ["relevant", 476], ["concentrations", 485], [".", 499], ["T", 501], ["-", 502], ["cell", 503], ["functions", 508], ["including", 518], ["proliferation", 528], [",", 541], ["activation", 543], ["and", 554], ["cytokine", 558], ["production", 567], ["were", 578], ["all", 583], ["uniformly", 587], ["inhibited", 597], ["in", 607], ["the", 610], ["presence", 614], ["of", 623], ["dasatinib", 626], [".", 635], ["We", 637], ["also", 640], ["demonstrated", 645], ["inhibition", 658], ["of", 669], ["TCR", 672], ["signalling", 676], ["through", 687], ["Src", 695], ["-", 698], ["family", 699], ["kinase", 706], ["LCK", 713], [",", 716], ["and", 718], ["predicted", 722], ["that", 732], ["inhibition", 737], ["of", 748], ["LCK", 751], ["and", 755], ["other", 759], ["kinases", 765], ["involved", 773], ["in", 782], ["T", 785], ["-", 786], ["cell", 787], ["signalling", 792], ["by", 803], ["dasatinib", 806], ["is", 816], ["responsible", 819], ["for", 831], ["the", 835], ["suppression", 839], ["of", 851], ["T", 854], ["-", 855], ["cell", 856], ["function", 861], [".", 869], ["These", 871], ["findings", 877], ["raise", 886], ["the", 892], ["concern", 896], ["about", 904], ["potential", 910], ["T", 920], ["-", 921], ["cell", 922], ["inhibition", 927], ["in", 938], ["patients", 941], ["taking", 950], ["dasatinib", 957], [",", 966], ["and", 968], ["suggest", 972], ["a", 980], ["possible", 982], ["application", 991], ["for", 1003], ["the", 1007], ["treatment", 1011], ["of", 1021], ["T", 1024], ["-", 1025], ["cell", 1026], ["mediated", 1031], ["immune", 1040], ["disorders", 1047], [".", 1056]]}
{"context": "Given the potential clinical benefit of inhibiting Na+/Ca2+ exchanger (NCX) activity during myocardial ischemia reperfusion (I/R), pharmacological approaches have been pursued to both inhibit and clarify the importance of this exchanger. SEA0400 was reported to have a potent NCX selectivity. Thus, we examined the effect of SEA0400 on NCX currents and I/R induced intracellular Ca2+ overload in mouse ventricular myocytes using patch clamp techniques and fluorescence measurements. Ischemia significantly inhibited inward and outward NCX current (from -0.04+/-0.01 nA to 0 nA at -100 mV; from 0.23+/-0.08 nA to 0.11+/-0.03 nA at +50 mV, n=7), Subsequent reperfusion not only restored the current rapidly but enhanced the current amplitude obviously, especially the outward currents (from 0.23+/-0.08 nA to 0.49+/-0.12 nA at +50 mV, n=7). [Ca2+]i, expressed as the ratio of Fura-2 fluorescence intensity, increased to 138+/-7% (P<0.01) during ischemia and to 210+/-11% (P<0.01) after reperfusion. The change of NCX current and the increase of [Ca2+]i during I/R can be blocked by SEA0400 in a dose-dependent manner with an EC50 value of 31 nM and 28 nM for the inward and outward NCX current, respectively. The results suggested that SEA0400 is a potent NCX inhibitor, which can protect mouse cardiac myocytes from Ca2+ overload during I/R injuries.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "adf00e4aac1141ad956eda51c049bd02", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[59, 59], [11, 11], [181, 181], [219, 219], [88, 88], [232, 232], [47, 47]], "char_spans": [[336, 338], [71, 73], [1011, 1013], [1180, 1182], [535, 537], [1254, 1256], [276, 278]]}]}], "context_tokens": [["Given", 0], ["the", 6], ["potential", 10], ["clinical", 20], ["benefit", 29], ["of", 37], ["inhibiting", 40], ["Na+/Ca2", 51], ["+", 58], ["exchanger", 60], ["(", 70], ["NCX", 71], [")", 74], ["activity", 76], ["during", 85], ["myocardial", 92], ["ischemia", 103], ["reperfusion", 112], ["(", 124], ["I", 125], ["/", 126], ["R", 127], [")", 128], [",", 129], ["pharmacological", 131], ["approaches", 147], ["have", 158], ["been", 163], ["pursued", 168], ["to", 176], ["both", 179], ["inhibit", 184], ["and", 192], ["clarify", 196], ["the", 204], ["importance", 208], ["of", 219], ["this", 222], ["exchanger", 227], [".", 236], ["SEA0400", 238], ["was", 246], ["reported", 250], ["to", 259], ["have", 262], ["a", 267], ["potent", 269], ["NCX", 276], ["selectivity", 280], [".", 291], ["Thus", 293], [",", 297], ["we", 299], ["examined", 302], ["the", 311], ["effect", 315], ["of", 322], ["SEA0400", 325], ["on", 333], ["NCX", 336], ["currents", 340], ["and", 349], ["I", 353], ["/", 354], ["R", 355], ["induced", 357], ["intracellular", 365], ["Ca2", 379], ["+", 382], ["overload", 384], ["in", 393], ["mouse", 396], ["ventricular", 402], ["myocytes", 414], ["using", 423], ["patch", 429], ["clamp", 435], ["techniques", 441], ["and", 452], ["fluorescence", 456], ["measurements", 469], [".", 481], ["Ischemia", 483], ["significantly", 492], ["inhibited", 506], ["inward", 516], ["and", 523], ["outward", 527], ["NCX", 535], ["current", 539], ["(", 547], ["from", 548], ["-0.04+/-0.01", 553], ["nA", 566], ["to", 569], ["0", 572], ["nA", 574], ["at", 577], ["-100", 580], ["mV", 585], [";", 587], ["from", 589], ["0.23+/-0.08", 594], ["nA", 606], ["to", 609], ["0.11+/-0.03", 612], ["nA", 624], ["at", 627], ["+50", 630], ["mV", 634], [",", 636], ["n=7", 638], [")", 641], [",", 642], ["Subsequent", 644], ["reperfusion", 655], ["not", 667], ["only", 671], ["restored", 676], ["the", 685], ["current", 689], ["rapidly", 697], ["but", 705], ["enhanced", 709], ["the", 718], ["current", 722], ["amplitude", 730], ["obviously", 740], [",", 749], ["especially", 751], ["the", 762], ["outward", 766], ["currents", 774], ["(", 783], ["from", 784], ["0.23+/-0.08", 789], ["nA", 801], ["to", 804], ["0.49+/-0.12", 807], ["nA", 819], ["at", 822], ["+50", 825], ["mV", 829], [",", 831], ["n=7", 833], [")", 836], [".", 837], ["[", 839], ["Ca2+]i", 840], [",", 846], ["expressed", 848], ["as", 858], ["the", 861], ["ratio", 865], ["of", 871], ["Fura-2", 874], ["fluorescence", 881], ["intensity", 894], [",", 903], ["increased", 905], ["to", 915], ["138+/-7", 918], ["%", 925], ["(", 927], ["P<0.01", 928], [")", 934], ["during", 936], ["ischemia", 943], ["and", 952], ["to", 956], ["210+/-11", 959], ["%", 967], ["(", 969], ["P<0.01", 970], [")", 976], ["after", 978], ["reperfusion", 984], [".", 995], ["The", 997], ["change", 1001], ["of", 1008], ["NCX", 1011], ["current", 1015], ["and", 1023], ["the", 1027], ["increase", 1031], ["of", 1040], ["[", 1043], ["Ca2+]i", 1044], ["during", 1051], ["I", 1058], ["/", 1059], ["R", 1060], ["can", 1062], ["be", 1066], ["blocked", 1069], ["by", 1077], ["SEA0400", 1080], ["in", 1088], ["a", 1091], ["dose", 1093], ["-", 1097], ["dependent", 1098], ["manner", 1108], ["with", 1115], ["an", 1120], ["EC50", 1123], ["value", 1128], ["of", 1134], ["31", 1137], ["nM", 1140], ["and", 1143], ["28", 1147], ["nM", 1150], ["for", 1153], ["the", 1157], ["inward", 1161], ["and", 1168], ["outward", 1172], ["NCX", 1180], ["current", 1184], [",", 1191], ["respectively", 1193], [".", 1205], ["The", 1207], ["results", 1211], ["suggested", 1219], ["that", 1229], ["SEA0400", 1234], ["is", 1242], ["a", 1245], ["potent", 1247], ["NCX", 1254], ["inhibitor", 1258], [",", 1267], ["which", 1269], ["can", 1275], ["protect", 1279], ["mouse", 1287], ["cardiac", 1293], ["myocytes", 1301], ["from", 1310], ["Ca2", 1315], ["+", 1318], ["overload", 1320], ["during", 1329], ["I", 1336], ["/", 1337], ["R", 1338], ["injuries", 1340], [".", 1348]]}
{"context": "The two major virulence factors of Bacillus anthracis are the tripartite toxin and the polyglutamate capsule, which are encoded by genes on the large plasmids, pXO1 and pXO2, respectively. The genes atxA, located on pXO1, and acpA, located on pXO2, encode positive trans-acting proteins that are involved in bicarbonate-mediated regulation of toxin and capsule production, respectively. A derivative strain cured of pXO1 produced less capsular substance than the parent strain harbouring both pXO1 and pXO2, and electroporation of the strain cured of pXO1 with a plasmid containing the cloned atxA gene resulted in an increased level of capsule production. An acpA-null mutant was complemented by not only acpA but also the atxA gene. The cap region, which is essential for encapsulation, contains three genes capB, capC, and capA, arranged in that order. The atxA gene stimulated capsule synthesis from the cloned cap region. Transcriptional analysis of cap by RNA slot-blot hybridization and primer-extension analysis revealed that atxA activated expression of cap in trans at the transcriptional level. These results indicate that cross-talk occurs, in which the pXO1-located gene, atxA, activates transcription of the cap region genes located on pXO2. We identified two major apparent transcriptional start sites, designated P1 and P2, located at positions 731 bp and 625 bp, respectively, upstream of the translation-initiation codon of capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment of 70 bp extending upstream of the P1 site. These results suggest that cross-talk by atxA to the genes encoding capsule synthesis is caused by the interaction of the atxA gene product with a regulatory sequence upstream of cap.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "cf65aa1d62524b4690d8d12f1565be18", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "bicarbonate", "token_spans": [[281, 281], [58, 58]], "char_spans": [[1568, 1578], [308, 318]]}]}], "context_tokens": [["The", 0], ["two", 4], ["major", 8], ["virulence", 14], ["factors", 24], ["of", 32], ["Bacillus", 35], ["anthracis", 44], ["are", 54], ["the", 58], ["tripartite", 62], ["toxin", 73], ["and", 79], ["the", 83], ["polyglutamate", 87], ["capsule", 101], [",", 108], ["which", 110], ["are", 116], ["encoded", 120], ["by", 128], ["genes", 131], ["on", 137], ["the", 140], ["large", 144], ["plasmids", 150], [",", 158], ["pXO1", 160], ["and", 165], ["pXO2", 169], [",", 173], ["respectively", 175], [".", 187], ["The", 189], ["genes", 193], ["atxA", 199], [",", 203], ["located", 205], ["on", 213], ["pXO1", 216], [",", 220], ["and", 222], ["acpA", 226], [",", 230], ["located", 232], ["on", 240], ["pXO2", 243], [",", 247], ["encode", 249], ["positive", 256], ["trans", 265], ["-", 270], ["acting", 271], ["proteins", 278], ["that", 287], ["are", 292], ["involved", 296], ["in", 305], ["bicarbonate", 308], ["-", 319], ["mediated", 320], ["regulation", 329], ["of", 340], ["toxin", 343], ["and", 349], ["capsule", 353], ["production", 361], [",", 371], ["respectively", 373], [".", 385], ["A", 387], ["derivative", 389], ["strain", 400], ["cured", 407], ["of", 413], ["pXO1", 416], ["produced", 421], ["less", 430], ["capsular", 435], ["substance", 444], ["than", 454], ["the", 459], ["parent", 463], ["strain", 470], ["harbouring", 477], ["both", 488], ["pXO1", 493], ["and", 498], ["pXO2", 502], [",", 506], ["and", 508], ["electroporation", 512], ["of", 528], ["the", 531], ["strain", 535], ["cured", 542], ["of", 548], ["pXO1", 551], ["with", 556], ["a", 561], ["plasmid", 563], ["containing", 571], ["the", 582], ["cloned", 586], ["atxA", 593], ["gene", 598], ["resulted", 603], ["in", 612], ["an", 615], ["increased", 618], ["level", 628], ["of", 634], ["capsule", 637], ["production", 645], [".", 655], ["An", 657], ["acpA", 660], ["-", 664], ["null", 665], ["mutant", 670], ["was", 677], ["complemented", 681], ["by", 694], ["not", 697], ["only", 701], ["acpA", 706], ["but", 711], ["also", 715], ["the", 720], ["atxA", 724], ["gene", 729], [".", 733], ["The", 735], ["cap", 739], ["region", 743], [",", 749], ["which", 751], ["is", 757], ["essential", 760], ["for", 770], ["encapsulation", 774], [",", 787], ["contains", 789], ["three", 798], ["genes", 804], ["capB", 810], [",", 814], ["capC", 816], [",", 820], ["and", 822], ["capA", 826], [",", 830], ["arranged", 832], ["in", 841], ["that", 844], ["order", 849], [".", 854], ["The", 856], ["atxA", 860], ["gene", 865], ["stimulated", 870], ["capsule", 881], ["synthesis", 889], ["from", 899], ["the", 904], ["cloned", 908], ["cap", 915], ["region", 919], [".", 925], ["Transcriptional", 927], ["analysis", 943], ["of", 952], ["cap", 955], ["by", 959], ["RNA", 962], ["slot", 966], ["-", 970], ["blot", 971], ["hybridization", 976], ["and", 990], ["primer", 994], ["-", 1000], ["extension", 1001], ["analysis", 1011], ["revealed", 1020], ["that", 1029], ["atxA", 1034], ["activated", 1039], ["expression", 1049], ["of", 1060], ["cap", 1063], ["in", 1067], ["trans", 1070], ["at", 1076], ["the", 1079], ["transcriptional", 1083], ["level", 1099], [".", 1104], ["These", 1106], ["results", 1112], ["indicate", 1120], ["that", 1129], ["cross", 1134], ["-", 1139], ["talk", 1140], ["occurs", 1145], [",", 1151], ["in", 1153], ["which", 1156], ["the", 1162], ["pXO1-located", 1166], ["gene", 1179], [",", 1183], ["atxA", 1185], [",", 1189], ["activates", 1191], ["transcription", 1201], ["of", 1215], ["the", 1218], ["cap", 1222], ["region", 1226], ["genes", 1233], ["located", 1239], ["on", 1247], ["pXO2", 1250], [".", 1254], ["We", 1256], ["identified", 1259], ["two", 1270], ["major", 1274], ["apparent", 1280], ["transcriptional", 1289], ["start", 1305], ["sites", 1311], [",", 1316], ["designated", 1318], ["P1", 1329], ["and", 1332], ["P2", 1336], [",", 1338], ["located", 1340], ["at", 1348], ["positions", 1351], ["731", 1361], ["bp", 1365], ["and", 1368], ["625", 1372], ["bp", 1376], [",", 1378], ["respectively", 1380], [",", 1392], ["upstream", 1394], ["of", 1403], ["the", 1406], ["translation", 1410], ["-", 1421], ["initiation", 1422], ["codon", 1433], ["of", 1439], ["capB.", 1442], ["Transcription", 1448], ["initiated", 1462], ["from", 1472], ["P1", 1477], ["and", 1480], ["P2", 1484], ["was", 1487], ["activated", 1491], ["by", 1501], ["both", 1504], ["atxA", 1509], ["and", 1514], ["acpA", 1518], [",", 1522], ["and", 1524], ["activation", 1528], ["appeared", 1539], ["to", 1548], ["be", 1551], ["stimulated", 1554], ["by", 1565], ["bicarbonate", 1568], [".", 1579], ["Deletion", 1581], ["analysis", 1590], ["of", 1599], ["the", 1602], ["upstream", 1606], ["region", 1615], ["of", 1622], ["the", 1625], ["cap", 1629], ["promoter", 1633], ["revealed", 1642], ["that", 1651], ["activation", 1656], ["by", 1667], ["both", 1670], ["atxA", 1675], ["and", 1680], ["acpA", 1684], ["required", 1689], ["a", 1698], ["DNA", 1700], ["segment", 1704], ["of", 1712], ["70", 1715], ["bp", 1718], ["extending", 1721], ["upstream", 1731], ["of", 1740], ["the", 1743], ["P1", 1747], ["site", 1750], [".", 1754], ["These", 1756], ["results", 1762], ["suggest", 1770], ["that", 1778], ["cross", 1783], ["-", 1788], ["talk", 1789], ["by", 1794], ["atxA", 1797], ["to", 1802], ["the", 1805], ["genes", 1809], ["encoding", 1815], ["capsule", 1824], ["synthesis", 1832], ["is", 1842], ["caused", 1845], ["by", 1852], ["the", 1855], ["interaction", 1859], ["of", 1871], ["the", 1874], ["atxA", 1878], ["gene", 1883], ["product", 1888], ["with", 1896], ["a", 1901], ["regulatory", 1903], ["sequence", 1914], ["upstream", 1923], ["of", 1932], ["cap", 1935], [".", 1938]]}
{"context": "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. A special feature of the Sry gene is its ability to generate linear and circular transcripts, both transcribed in the sense orientation. Here we remark that both sense (e.g. Sry RNA) and antisense (e.g. CDR1as) transcripts could circularize and behave as miRNAs sponges, and importantly, that also protein-coding segments of mRNAs could also assume this role. Thus, it is reasonable to think that the linear Sry sense transcript could additionally act as a miRNA sponge, or as an endogenous competing RNA for miR-138.", "qas": [{"question": "Which miRNA is targeted by SRY/Sox9?", "answers": ["mir-138"], "qid": "71b0e329f10047c39ece3b5149f7ae9c", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["targeted", 15], ["by", 24], ["SRY", 27], ["/", 30], ["Sox9", 31], ["?", 35]], "detected_answers": [{"text": "mir-138", "token_spans": [[52, 52], [153, 153]], "char_spans": [[284, 290], [826, 832]]}]}], "context_tokens": [["Recently", 0], [",", 8], ["the", 10], ["sex", 14], ["determining", 18], ["region", 30], ["Y", 37], ["(", 39], ["Sry", 41], [")", 44], ["and", 46], ["the", 50], ["cerebellar", 54], ["degeneration", 65], ["-", 77], ["related", 78], ["protein", 86], ["1", 94], ["(", 96], ["CDR1as", 98], [")", 104], ["RNA", 106], ["transcripts", 110], ["have", 122], ["been", 127], ["described", 132], ["to", 142], ["function", 145], ["as", 154], ["a", 157], ["new", 159], ["class", 163], ["of", 169], ["post", 172], ["-", 176], ["transcriptional", 177], ["regulatory", 193], ["RNAs", 204], ["that", 209], ["behave", 214], ["as", 221], ["circular", 224], ["endogenous", 233], ["RNA", 244], ["sponges", 248], ["for", 256], ["the", 260], ["micro", 264], ["RNAs", 270], ["(", 275], ["miRNAs", 276], [")", 282], ["miR-138", 284], ["and", 292], ["miR-7", 296], [",", 301], ["respectively", 303], [".", 315], ["A", 317], ["special", 319], ["feature", 327], ["of", 335], ["the", 338], ["Sry", 342], ["gene", 346], ["is", 351], ["its", 354], ["ability", 358], ["to", 366], ["generate", 369], ["linear", 378], ["and", 385], ["circular", 389], ["transcripts", 398], [",", 409], ["both", 411], ["transcribed", 416], ["in", 428], ["the", 431], ["sense", 435], ["orientation", 441], [".", 452], ["Here", 454], ["we", 459], ["remark", 462], ["that", 469], ["both", 474], ["sense", 479], ["(", 485], ["e.g.", 486], ["Sry", 491], ["RNA", 495], [")", 498], ["and", 500], ["antisense", 504], ["(", 514], ["e.g.", 515], ["CDR1as", 520], [")", 526], ["transcripts", 528], ["could", 540], ["circularize", 546], ["and", 558], ["behave", 562], ["as", 569], ["miRNAs", 572], ["sponges", 579], [",", 586], ["and", 588], ["importantly", 592], [",", 603], ["that", 605], ["also", 610], ["protein", 615], ["-", 622], ["coding", 623], ["segments", 630], ["of", 639], ["mRNAs", 642], ["could", 648], ["also", 654], ["assume", 659], ["this", 666], ["role", 671], [".", 675], ["Thus", 677], [",", 681], ["it", 683], ["is", 686], ["reasonable", 689], ["to", 700], ["think", 703], ["that", 709], ["the", 714], ["linear", 718], ["Sry", 725], ["sense", 729], ["transcript", 735], ["could", 746], ["additionally", 752], ["act", 765], ["as", 769], ["a", 772], ["miRNA", 774], ["sponge", 780], [",", 786], ["or", 788], ["as", 791], ["an", 794], ["endogenous", 797], ["competing", 808], ["RNA", 818], ["for", 822], ["miR-138", 826], [".", 833]]}
{"context": "We transplanted adult whole bone marrow prelabeled with bromodeoxyuridine (BrdU) into the ischemic boundary zone of the adult rat brain at 1 day after 2 h of middle cerebral artery occlusion (MCAo). Approximately 3.3% of 10(6) transplanted bone marrow cells were BrdU reactive at 14 days after MCAo. BrdU-reactive cells expressed neuronal and astrocytic proteins, neuronal nuclei protein (NeuN, 1%), and glial fibrillary acidic protein (GFAP, 5%) immunoreactivities, respectively. In addition, bone marrow transplantation promoted proliferation of ependymal and subependymal cells, identified by nestin (a neuroepithelial stem cell marker), within the ventricular zone and subventricular zone (VZ/SVZ). These data suggest that intracerebral transplantation of bone marrow could potentially be used to induce plasticity in ischemic brain.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "69369bb8e0cf4025bff67e3552f85dad", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[107, 107]], "char_spans": [[596, 601]]}]}], "context_tokens": [["We", 0], ["transplanted", 3], ["adult", 16], ["whole", 22], ["bone", 28], ["marrow", 33], ["prelabeled", 40], ["with", 51], ["bromodeoxyuridine", 56], ["(", 74], ["BrdU", 75], [")", 79], ["into", 81], ["the", 86], ["ischemic", 90], ["boundary", 99], ["zone", 108], ["of", 113], ["the", 116], ["adult", 120], ["rat", 126], ["brain", 130], ["at", 136], ["1", 139], ["day", 141], ["after", 145], ["2", 151], ["h", 153], ["of", 155], ["middle", 158], ["cerebral", 165], ["artery", 174], ["occlusion", 181], ["(", 191], ["MCAo", 192], [")", 196], [".", 197], ["Approximately", 199], ["3.3", 213], ["%", 216], ["of", 218], ["10(6", 221], [")", 225], ["transplanted", 227], ["bone", 240], ["marrow", 245], ["cells", 252], ["were", 258], ["BrdU", 263], ["reactive", 268], ["at", 277], ["14", 280], ["days", 283], ["after", 288], ["MCAo", 294], [".", 298], ["BrdU", 300], ["-", 304], ["reactive", 305], ["cells", 314], ["expressed", 320], ["neuronal", 330], ["and", 339], ["astrocytic", 343], ["proteins", 354], [",", 362], ["neuronal", 364], ["nuclei", 373], ["protein", 380], ["(", 388], ["NeuN", 389], [",", 393], ["1", 395], ["%", 396], [")", 397], [",", 398], ["and", 400], ["glial", 404], ["fibrillary", 410], ["acidic", 421], ["protein", 428], ["(", 436], ["GFAP", 437], [",", 441], ["5", 443], ["%", 444], [")", 445], ["immunoreactivities", 447], [",", 465], ["respectively", 467], [".", 479], ["In", 481], ["addition", 484], [",", 492], ["bone", 494], ["marrow", 499], ["transplantation", 506], ["promoted", 522], ["proliferation", 531], ["of", 545], ["ependymal", 548], ["and", 558], ["subependymal", 562], ["cells", 575], [",", 580], ["identified", 582], ["by", 593], ["nestin", 596], ["(", 603], ["a", 604], ["neuroepithelial", 606], ["stem", 622], ["cell", 627], ["marker", 632], [")", 638], [",", 639], ["within", 641], ["the", 648], ["ventricular", 652], ["zone", 664], ["and", 669], ["subventricular", 673], ["zone", 688], ["(", 693], ["VZ", 694], ["/", 696], ["SVZ", 697], [")", 700], [".", 701], ["These", 703], ["data", 709], ["suggest", 714], ["that", 722], ["intracerebral", 727], ["transplantation", 741], ["of", 757], ["bone", 760], ["marrow", 765], ["could", 772], ["potentially", 778], ["be", 790], ["used", 793], ["to", 798], ["induce", 801], ["plasticity", 808], ["in", 819], ["ischemic", 822], ["brain", 831], [".", 836]]}
{"context": "Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3), may be the most common dominantly inherited ataxia in the world. Here I will review historical, clinical, neuropathological, genetic, and pathogenic features of MJD, and finish with a brief discussion of present, and possible future, treatment for this currently incurable disorder. Like many other dominantly inherited ataxias, MJD/SCA3 shows remarkable clinical heterogeneity, reflecting the underlying genetic defect: an unstable CAG trinucleotide repeat that varies in size among affected persons. This pathogenic repeat in MJD/SCA3 encodes an expanded tract of the amino acid glutamine in the disease protein, which is known as ataxin-3. MJD/SCA3 is one of nine identified polyglutamine neurodegenerative diseases which share features of pathogenesis centered on protein misfolding and accumulation. The specific properties of MJD/SCA3 and its disease protein are discussed in light of what is known about the entire class of polyglutamine diseases.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "789a207c9dc24db295601719ba0be075", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[128, 128]], "char_spans": [[715, 722]]}]}], "context_tokens": [["Machado", 0], ["-", 7], ["Joseph", 8], ["disease", 15], ["(", 23], ["MJD", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["spinocerebellar", 44], ["ataxia", 60], ["type", 67], ["3", 72], ["(", 74], ["SCA3", 75], [")", 79], [",", 80], ["may", 82], ["be", 86], ["the", 89], ["most", 93], ["common", 98], ["dominantly", 105], ["inherited", 116], ["ataxia", 126], ["in", 133], ["the", 136], ["world", 140], [".", 145], ["Here", 147], ["I", 152], ["will", 154], ["review", 159], ["historical", 166], [",", 176], ["clinical", 178], [",", 186], ["neuropathological", 188], [",", 205], ["genetic", 207], [",", 214], ["and", 216], ["pathogenic", 220], ["features", 231], ["of", 240], ["MJD", 243], [",", 246], ["and", 248], ["finish", 252], ["with", 259], ["a", 264], ["brief", 266], ["discussion", 272], ["of", 283], ["present", 286], [",", 293], ["and", 295], ["possible", 299], ["future", 308], [",", 314], ["treatment", 316], ["for", 326], ["this", 330], ["currently", 335], ["incurable", 345], ["disorder", 355], [".", 363], ["Like", 365], ["many", 370], ["other", 375], ["dominantly", 381], ["inherited", 392], ["ataxias", 402], [",", 409], ["MJD", 411], ["/", 414], ["SCA3", 415], ["shows", 420], ["remarkable", 426], ["clinical", 437], ["heterogeneity", 446], [",", 459], ["reflecting", 461], ["the", 472], ["underlying", 476], ["genetic", 487], ["defect", 495], [":", 501], ["an", 503], ["unstable", 506], ["CAG", 515], ["trinucleotide", 519], ["repeat", 533], ["that", 540], ["varies", 545], ["in", 552], ["size", 555], ["among", 560], ["affected", 566], ["persons", 575], [".", 582], ["This", 584], ["pathogenic", 589], ["repeat", 600], ["in", 607], ["MJD", 610], ["/", 613], ["SCA3", 614], ["encodes", 619], ["an", 627], ["expanded", 630], ["tract", 639], ["of", 645], ["the", 648], ["amino", 652], ["acid", 658], ["glutamine", 663], ["in", 673], ["the", 676], ["disease", 680], ["protein", 688], [",", 695], ["which", 697], ["is", 703], ["known", 706], ["as", 712], ["ataxin-3", 715], [".", 723], ["MJD", 725], ["/", 728], ["SCA3", 729], ["is", 734], ["one", 737], ["of", 741], ["nine", 744], ["identified", 749], ["polyglutamine", 760], ["neurodegenerative", 774], ["diseases", 792], ["which", 801], ["share", 807], ["features", 813], ["of", 822], ["pathogenesis", 825], ["centered", 838], ["on", 847], ["protein", 850], ["misfolding", 858], ["and", 869], ["accumulation", 873], [".", 885], ["The", 887], ["specific", 891], ["properties", 900], ["of", 911], ["MJD", 914], ["/", 917], ["SCA3", 918], ["and", 923], ["its", 927], ["disease", 931], ["protein", 939], ["are", 947], ["discussed", 951], ["in", 961], ["light", 964], ["of", 970], ["what", 973], ["is", 978], ["known", 981], ["about", 987], ["the", 993], ["entire", 997], ["class", 1004], ["of", 1010], ["polyglutamine", 1013], ["diseases", 1027], [".", 1035]]}
{"context": "In recent years, we have seen remarkable progress in our understanding of the disease mechanism underlying facioscapulohumeral muscular dystrophy (FSHD). The purpose of this review is to provide a comprehensive overview of our current understanding of the disease mechanism and to discuss the observations supporting the possibility of a developmental defect in this disorder. In the majority of cases, FSHD is caused by contraction of the D4Z4 repeat array (FSHD1). This results in local chromatin relaxation and stable expression of the DUX4 retrogene in skeletal muscle, but only when a polymorphic DUX4 polyadenylation signal is present. In some cases (FSHD2), D4Z4 chromatin relaxation and stable DUX4 expression occur in the absence of D4Z4 array contraction. DUX4 is a germline transcription factor and its expression in skeletal muscle leads to activation of early stem cell and germline programs and transcriptional activation of retroelements. Recent studies have provided a plausible disease mechanism for FSHD in which FSHD results from inappropriate expression of the germline transcription factor DUX4. The genes regulated by DUX4 suggest several mechanisms of muscle damage, and provide potential biomarkers and therapeutic targets that should be investigated in future studies.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "942b79bc7d384edd901fe2769f46512d", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[65, 65], [167, 167], [21, 21], [170, 170]], "char_spans": [[403, 406], [1017, 1020], [147, 150], [1031, 1034]]}]}], "context_tokens": [["In", 0], ["recent", 3], ["years", 10], [",", 15], ["we", 17], ["have", 20], ["seen", 25], ["remarkable", 30], ["progress", 41], ["in", 50], ["our", 53], ["understanding", 57], ["of", 71], ["the", 74], ["disease", 78], ["mechanism", 86], ["underlying", 96], ["facioscapulohumeral", 107], ["muscular", 127], ["dystrophy", 136], ["(", 146], ["FSHD", 147], [")", 151], [".", 152], ["The", 154], ["purpose", 158], ["of", 166], ["this", 169], ["review", 174], ["is", 181], ["to", 184], ["provide", 187], ["a", 195], ["comprehensive", 197], ["overview", 211], ["of", 220], ["our", 223], ["current", 227], ["understanding", 235], ["of", 249], ["the", 252], ["disease", 256], ["mechanism", 264], ["and", 274], ["to", 278], ["discuss", 281], ["the", 289], ["observations", 293], ["supporting", 306], ["the", 317], ["possibility", 321], ["of", 333], ["a", 336], ["developmental", 338], ["defect", 352], ["in", 359], ["this", 362], ["disorder", 367], [".", 375], ["In", 377], ["the", 380], ["majority", 384], ["of", 393], ["cases", 396], [",", 401], ["FSHD", 403], ["is", 408], ["caused", 411], ["by", 418], ["contraction", 421], ["of", 433], ["the", 436], ["D4Z4", 440], ["repeat", 445], ["array", 452], ["(", 458], ["FSHD1", 459], [")", 464], [".", 465], ["This", 467], ["results", 472], ["in", 480], ["local", 483], ["chromatin", 489], ["relaxation", 499], ["and", 510], ["stable", 514], ["expression", 521], ["of", 532], ["the", 535], ["DUX4", 539], ["retrogene", 544], ["in", 554], ["skeletal", 557], ["muscle", 566], [",", 572], ["but", 574], ["only", 578], ["when", 583], ["a", 588], ["polymorphic", 590], ["DUX4", 602], ["polyadenylation", 607], ["signal", 623], ["is", 630], ["present", 633], [".", 640], ["In", 642], ["some", 645], ["cases", 650], ["(", 656], ["FSHD2", 657], [")", 662], [",", 663], ["D4Z4", 665], ["chromatin", 670], ["relaxation", 680], ["and", 691], ["stable", 695], ["DUX4", 702], ["expression", 707], ["occur", 718], ["in", 724], ["the", 727], ["absence", 731], ["of", 739], ["D4Z4", 742], ["array", 747], ["contraction", 753], [".", 764], ["DUX4", 766], ["is", 771], ["a", 774], ["germline", 776], ["transcription", 785], ["factor", 799], ["and", 806], ["its", 810], ["expression", 814], ["in", 825], ["skeletal", 828], ["muscle", 837], ["leads", 844], ["to", 850], ["activation", 853], ["of", 864], ["early", 867], ["stem", 873], ["cell", 878], ["and", 883], ["germline", 887], ["programs", 896], ["and", 905], ["transcriptional", 909], ["activation", 925], ["of", 936], ["retroelements", 939], [".", 952], ["Recent", 954], ["studies", 961], ["have", 969], ["provided", 974], ["a", 983], ["plausible", 985], ["disease", 995], ["mechanism", 1003], ["for", 1013], ["FSHD", 1017], ["in", 1022], ["which", 1025], ["FSHD", 1031], ["results", 1036], ["from", 1044], ["inappropriate", 1049], ["expression", 1063], ["of", 1074], ["the", 1077], ["germline", 1081], ["transcription", 1090], ["factor", 1104], ["DUX4", 1111], [".", 1115], ["The", 1117], ["genes", 1121], ["regulated", 1127], ["by", 1137], ["DUX4", 1140], ["suggest", 1145], ["several", 1153], ["mechanisms", 1161], ["of", 1172], ["muscle", 1175], ["damage", 1182], [",", 1188], ["and", 1190], ["provide", 1194], ["potential", 1202], ["biomarkers", 1212], ["and", 1223], ["therapeutic", 1227], ["targets", 1239], ["that", 1247], ["should", 1252], ["be", 1259], ["investigated", 1262], ["in", 1275], ["future", 1278], ["studies", 1285], [".", 1292]]}
{"context": "Parkinson's disease (PD) is a neurodegenerative disorder characterized by the appearance of intracytoplasmic inclusions called Lewy bodies (LB) in dopamine neurons in the substantia nigra and the progressive loss of these neurons. Recently, mutations in the alpha-synuclein gene have been identified in early-onset familial PD, and alpha-synuclein has been shown to be a major component of LB in all patients. Yet, the pathophysiological function of alpha-synuclein remains unknown. In this report, we have investigated the toxic effects of adenovirus-mediated alpha-synuclein overexpression on dopamine neurons in rat primary mesencephalic cultures and in a rat dopaminergic cell line - the large T-antigen immortalized, mesencephalon-derived 1RB3AN27 (N27). Adenovirus-transduced cultures showed high-level expression of alpha-synuclein within the cells. Overexpression of human mutant alpha-synuclein (Ala(53)Thr) selectively induced apoptotic programmed cell death of primary dopamine neurons as well as N27 cells. The mutant protein also potentiated the neurotoxicity of 6-hydroxydopamine (6-OHDA). By contrast, overexpression of wild-type human alpha-synuclein was not directly neurotoxic but did increase cell death after 6-OHDA. Overexpression of wild-type rat alpha-synuclein had no effect on dopamine cell survival or 6-OHDA neurotoxicity. These results indicate that overexpression of human mutant alpha-synuclein directly leads to dopamine neuron death, and overexpression of either human mutant or human wild-type alpha-synuclein renders dopamine neurons more vulnerable to neurotoxic insults.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "d46479c4ece34bc181a6026e994a86e9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[81, 83], [222, 224], [244, 246], [101, 103], [157, 159], [58, 60], [201, 203], [265, 267], [146, 148], [43, 45]], "char_spans": [[450, 464], [1269, 1283], [1409, 1423], [561, 575], [888, 902], [332, 346], [1151, 1165], [1527, 1541], [823, 837], [258, 272]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegenerative", 30], ["disorder", 48], ["characterized", 57], ["by", 71], ["the", 74], ["appearance", 78], ["of", 89], ["intracytoplasmic", 92], ["inclusions", 109], ["called", 120], ["Lewy", 127], ["bodies", 132], ["(", 139], ["LB", 140], [")", 142], ["in", 144], ["dopamine", 147], ["neurons", 156], ["in", 164], ["the", 167], ["substantia", 171], ["nigra", 182], ["and", 188], ["the", 192], ["progressive", 196], ["loss", 208], ["of", 213], ["these", 216], ["neurons", 222], [".", 229], ["Recently", 231], [",", 239], ["mutations", 241], ["in", 251], ["the", 254], ["alpha", 258], ["-", 263], ["synuclein", 264], ["gene", 274], ["have", 279], ["been", 284], ["identified", 289], ["in", 300], ["early", 303], ["-", 308], ["onset", 309], ["familial", 315], ["PD", 324], [",", 326], ["and", 328], ["alpha", 332], ["-", 337], ["synuclein", 338], ["has", 348], ["been", 352], ["shown", 357], ["to", 363], ["be", 366], ["a", 369], ["major", 371], ["component", 377], ["of", 387], ["LB", 390], ["in", 393], ["all", 396], ["patients", 400], [".", 408], ["Yet", 410], [",", 413], ["the", 415], ["pathophysiological", 419], ["function", 438], ["of", 447], ["alpha", 450], ["-", 455], ["synuclein", 456], ["remains", 466], ["unknown", 474], [".", 481], ["In", 483], ["this", 486], ["report", 491], [",", 497], ["we", 499], ["have", 502], ["investigated", 507], ["the", 520], ["toxic", 524], ["effects", 530], ["of", 538], ["adenovirus", 541], ["-", 551], ["mediated", 552], ["alpha", 561], ["-", 566], ["synuclein", 567], ["overexpression", 577], ["on", 592], ["dopamine", 595], ["neurons", 604], ["in", 612], ["rat", 615], ["primary", 619], ["mesencephalic", 627], ["cultures", 641], ["and", 650], ["in", 654], ["a", 657], ["rat", 659], ["dopaminergic", 663], ["cell", 676], ["line", 681], ["-", 686], ["the", 688], ["large", 692], ["T", 698], ["-", 699], ["antigen", 700], ["immortalized", 708], [",", 720], ["mesencephalon", 722], ["-", 735], ["derived", 736], ["1RB3AN27", 744], ["(", 753], ["N27", 754], [")", 757], [".", 758], ["Adenovirus", 760], ["-", 770], ["transduced", 771], ["cultures", 782], ["showed", 791], ["high", 798], ["-", 802], ["level", 803], ["expression", 809], ["of", 820], ["alpha", 823], ["-", 828], ["synuclein", 829], ["within", 839], ["the", 846], ["cells", 850], [".", 855], ["Overexpression", 857], ["of", 872], ["human", 875], ["mutant", 881], ["alpha", 888], ["-", 893], ["synuclein", 894], ["(", 904], ["Ala(53)Thr", 905], [")", 915], ["selectively", 917], ["induced", 929], ["apoptotic", 937], ["programmed", 947], ["cell", 958], ["death", 963], ["of", 969], ["primary", 972], ["dopamine", 980], ["neurons", 989], ["as", 997], ["well", 1000], ["as", 1005], ["N27", 1008], ["cells", 1012], [".", 1017], ["The", 1019], ["mutant", 1023], ["protein", 1030], ["also", 1038], ["potentiated", 1043], ["the", 1055], ["neurotoxicity", 1059], ["of", 1073], ["6-hydroxydopamine", 1076], ["(", 1094], ["6-OHDA", 1095], [")", 1101], [".", 1102], ["By", 1104], ["contrast", 1107], [",", 1115], ["overexpression", 1117], ["of", 1132], ["wild", 1135], ["-", 1139], ["type", 1140], ["human", 1145], ["alpha", 1151], ["-", 1156], ["synuclein", 1157], ["was", 1167], ["not", 1171], ["directly", 1175], ["neurotoxic", 1184], ["but", 1195], ["did", 1199], ["increase", 1203], ["cell", 1212], ["death", 1217], ["after", 1223], ["6-OHDA", 1229], [".", 1235], ["Overexpression", 1237], ["of", 1252], ["wild", 1255], ["-", 1259], ["type", 1260], ["rat", 1265], ["alpha", 1269], ["-", 1274], ["synuclein", 1275], ["had", 1285], ["no", 1289], ["effect", 1292], ["on", 1299], ["dopamine", 1302], ["cell", 1311], ["survival", 1316], ["or", 1325], ["6-OHDA", 1328], ["neurotoxicity", 1335], [".", 1348], ["These", 1350], ["results", 1356], ["indicate", 1364], ["that", 1373], ["overexpression", 1378], ["of", 1393], ["human", 1396], ["mutant", 1402], ["alpha", 1409], ["-", 1414], ["synuclein", 1415], ["directly", 1425], ["leads", 1434], ["to", 1440], ["dopamine", 1443], ["neuron", 1452], ["death", 1459], [",", 1464], ["and", 1466], ["overexpression", 1470], ["of", 1485], ["either", 1488], ["human", 1495], ["mutant", 1501], ["or", 1508], ["human", 1511], ["wild", 1517], ["-", 1521], ["type", 1522], ["alpha", 1527], ["-", 1532], ["synuclein", 1533], ["renders", 1543], ["dopamine", 1551], ["neurons", 1560], ["more", 1568], ["vulnerable", 1573], ["to", 1584], ["neurotoxic", 1587], ["insults", 1598], [".", 1605]]}
{"context": "The discovery of the Hippo pathway can be traced back to two areas of research. Genetic screens in fruit flies led to the identification of the Hippo pathway kinases and scaffolding proteins that function together to suppress cell proliferation and tumor growth. Independent research, often in the context of muscle biology, described Tead (TEA domain) transcription factors, which bind CATTCC DNA motifs to regulate gene expression. These two research areas were joined by the finding that the Hippo pathway regulates the activity of Tead transcription factors mainly through phosphorylation of the transcriptional coactivators Yap and Taz, which bind to and activate Teads. Additionally, many other signal transduction proteins crosstalk to members of the Hippo pathway forming a Hippo signal transduction network. We discuss evidence that the Hippo signal transduction network plays important roles in myogenesis, regeneration, muscular dystrophy, and rhabdomyosarcoma in skeletal muscle, as well as in myogenesis, organ size control, and regeneration of the heart. Understanding the role of Hippo kinases in skeletal and heart muscle physiology could have important implications for translational research.", "qas": [{"question": "Which are the coactivators of the Yes-associated protein (yap)?", "answers": ["Tead (TEA domain) transcription factors."], "qid": "42652e9339554e27af6c273cfd698386", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["coactivators", 14], ["of", 27], ["the", 30], ["Yes", 34], ["-", 37], ["associated", 38], ["protein", 49], ["(", 57], ["yap", 58], [")", 61], ["?", 62]], "detected_answers": [{"text": "Tead (TEA domain) transcription factors.", "token_spans": [[56, 62]], "char_spans": [[335, 373]]}]}], "context_tokens": [["The", 0], ["discovery", 4], ["of", 14], ["the", 17], ["Hippo", 21], ["pathway", 27], ["can", 35], ["be", 39], ["traced", 42], ["back", 49], ["to", 54], ["two", 57], ["areas", 61], ["of", 67], ["research", 70], [".", 78], ["Genetic", 80], ["screens", 88], ["in", 96], ["fruit", 99], ["flies", 105], ["led", 111], ["to", 115], ["the", 118], ["identification", 122], ["of", 137], ["the", 140], ["Hippo", 144], ["pathway", 150], ["kinases", 158], ["and", 166], ["scaffolding", 170], ["proteins", 182], ["that", 191], ["function", 196], ["together", 205], ["to", 214], ["suppress", 217], ["cell", 226], ["proliferation", 231], ["and", 245], ["tumor", 249], ["growth", 255], [".", 261], ["Independent", 263], ["research", 275], [",", 283], ["often", 285], ["in", 291], ["the", 294], ["context", 298], ["of", 306], ["muscle", 309], ["biology", 316], [",", 323], ["described", 325], ["Tead", 335], ["(", 340], ["TEA", 341], ["domain", 345], [")", 351], ["transcription", 353], ["factors", 367], [",", 374], ["which", 376], ["bind", 382], ["CATTCC", 387], ["DNA", 394], ["motifs", 398], ["to", 405], ["regulate", 408], ["gene", 417], ["expression", 422], [".", 432], ["These", 434], ["two", 440], ["research", 444], ["areas", 453], ["were", 459], ["joined", 464], ["by", 471], ["the", 474], ["finding", 478], ["that", 486], ["the", 491], ["Hippo", 495], ["pathway", 501], ["regulates", 509], ["the", 519], ["activity", 523], ["of", 532], ["Tead", 535], ["transcription", 540], ["factors", 554], ["mainly", 562], ["through", 569], ["phosphorylation", 577], ["of", 593], ["the", 596], ["transcriptional", 600], ["coactivators", 616], ["Yap", 629], ["and", 633], ["Taz", 637], [",", 640], ["which", 642], ["bind", 648], ["to", 653], ["and", 656], ["activate", 660], ["Teads", 669], [".", 674], ["Additionally", 676], [",", 688], ["many", 690], ["other", 695], ["signal", 701], ["transduction", 708], ["proteins", 721], ["crosstalk", 730], ["to", 740], ["members", 743], ["of", 751], ["the", 754], ["Hippo", 758], ["pathway", 764], ["forming", 772], ["a", 780], ["Hippo", 782], ["signal", 788], ["transduction", 795], ["network", 808], [".", 815], ["We", 817], ["discuss", 820], ["evidence", 828], ["that", 837], ["the", 842], ["Hippo", 846], ["signal", 852], ["transduction", 859], ["network", 872], ["plays", 880], ["important", 886], ["roles", 896], ["in", 902], ["myogenesis", 905], [",", 915], ["regeneration", 917], [",", 929], ["muscular", 931], ["dystrophy", 940], [",", 949], ["and", 951], ["rhabdomyosarcoma", 955], ["in", 972], ["skeletal", 975], ["muscle", 984], [",", 990], ["as", 992], ["well", 995], ["as", 1000], ["in", 1003], ["myogenesis", 1006], [",", 1016], ["organ", 1018], ["size", 1024], ["control", 1029], [",", 1036], ["and", 1038], ["regeneration", 1042], ["of", 1055], ["the", 1058], ["heart", 1062], [".", 1067], ["Understanding", 1069], ["the", 1083], ["role", 1087], ["of", 1092], ["Hippo", 1095], ["kinases", 1101], ["in", 1109], ["skeletal", 1112], ["and", 1121], ["heart", 1125], ["muscle", 1131], ["physiology", 1138], ["could", 1149], ["have", 1155], ["important", 1160], ["implications", 1170], ["for", 1183], ["translational", 1187], ["research", 1201], [".", 1209]]}
{"context": "The CRISPR-Cas (clustered regularly interspaced short palindromic repeats, CRISPR-associated genes) is an adaptive immunity system in bacteria and archaea that functions via a distinct self-non-self recognition mechanism that is partially analogous to the mechanism of eukaryotic RNA interference (RNAi). The CRISPR-Cas system incorporates fragments of virus or plasmid DNA into the CRISPR repeat cassettes and employs the processed transcripts of these spacers as guide RNAs to cleave the cognate foreign DNA or RNA. The Cas proteins, however, are not homologous to the proteins involved in RNAi and comprise numerous, highly diverged families. The majority of the Cas proteins contain diverse variants of the RNA recognition motif (RRM), a widespread RNA-binding domain. Despite the fast evolution that is typical of the cas genes, the presence of diverse versions of the RRM in most Cas proteins provides for a simple scenario for the evolution of the three distinct types of CRISPR-cas systems. In addition to several proteins that are directly implicated in the immune response, the cas genes encode a variety of proteins that are homologous to prokaryotic toxins that typically possess nuclease activity. The predicted toxins associated with CRISPR-Cas systems include the essential Cas2 protein, proteins of COG1517 that, in addition to a ligand-binding domain and a helix-turn-helix domain, typically contain different nuclease domains and several other predicted nucleases. The tight association of the CRISPR-Cas immunity systems with predicted toxins that, upon activation, would induce dormancy or cell death suggests that adaptive immunity and dormancy/suicide response are functionally coupled. Such coupling could manifest in the persistence state being induced and potentially providing conditions for more effective action of the immune system or in cell death being triggered when immunity fails.", "qas": [{"question": "Gene silencing can be achieved by RNA interference (RNAi) in eukaryotic organisms. What is the name of the analogous process in prokaryotic organisms?", "answers": ["CRISPR-Cas"], "qid": "c40581ee9c7a4286b6e7d0e14ece96df", "question_tokens": [["Gene", 0], ["silencing", 5], ["can", 15], ["be", 19], ["achieved", 22], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["in", 58], ["eukaryotic", 61], ["organisms", 72], [".", 81], ["What", 83], ["is", 88], ["the", 91], ["name", 95], ["of", 100], ["the", 103], ["analogous", 107], ["process", 117], ["in", 125], ["prokaryotic", 128], ["organisms", 140], ["?", 149]], "detected_answers": [{"text": "CRISPR-Cas", "token_spans": [[1, 3], [268, 270], [54, 56], [220, 222], [176, 178]], "char_spans": [[4, 13], [1512, 1521], [309, 318], [1248, 1257], [979, 988]]}]}], "context_tokens": [["The", 0], ["CRISPR", 4], ["-", 10], ["Cas", 11], ["(", 15], ["clustered", 16], ["regularly", 26], ["interspaced", 36], ["short", 48], ["palindromic", 54], ["repeats", 66], [",", 73], ["CRISPR", 75], ["-", 81], ["associated", 82], ["genes", 93], [")", 98], ["is", 100], ["an", 103], ["adaptive", 106], ["immunity", 115], ["system", 124], ["in", 131], ["bacteria", 134], ["and", 143], ["archaea", 147], ["that", 155], ["functions", 160], ["via", 170], ["a", 174], ["distinct", 176], ["self", 185], ["-", 189], ["non", 190], ["-", 193], ["self", 194], ["recognition", 199], ["mechanism", 211], ["that", 221], ["is", 226], ["partially", 229], ["analogous", 239], ["to", 249], ["the", 252], ["mechanism", 256], ["of", 266], ["eukaryotic", 269], ["RNA", 280], ["interference", 284], ["(", 297], ["RNAi", 298], [")", 302], [".", 303], ["The", 305], ["CRISPR", 309], ["-", 315], ["Cas", 316], ["system", 320], ["incorporates", 327], ["fragments", 340], ["of", 350], ["virus", 353], ["or", 359], ["plasmid", 362], ["DNA", 370], ["into", 374], ["the", 379], ["CRISPR", 383], ["repeat", 390], ["cassettes", 397], ["and", 407], ["employs", 411], ["the", 419], ["processed", 423], ["transcripts", 433], ["of", 445], ["these", 448], ["spacers", 454], ["as", 462], ["guide", 465], ["RNAs", 471], ["to", 476], ["cleave", 479], ["the", 486], ["cognate", 490], ["foreign", 498], ["DNA", 506], ["or", 510], ["RNA", 513], [".", 516], ["The", 518], ["Cas", 522], ["proteins", 526], [",", 534], ["however", 536], [",", 543], ["are", 545], ["not", 549], ["homologous", 553], ["to", 564], ["the", 567], ["proteins", 571], ["involved", 580], ["in", 589], ["RNAi", 592], ["and", 597], ["comprise", 601], ["numerous", 610], [",", 618], ["highly", 620], ["diverged", 627], ["families", 636], [".", 644], ["The", 646], ["majority", 650], ["of", 659], ["the", 662], ["Cas", 666], ["proteins", 670], ["contain", 679], ["diverse", 687], ["variants", 695], ["of", 704], ["the", 707], ["RNA", 711], ["recognition", 715], ["motif", 727], ["(", 733], ["RRM", 734], [")", 737], [",", 738], ["a", 740], ["widespread", 742], ["RNA", 753], ["-", 756], ["binding", 757], ["domain", 765], [".", 771], ["Despite", 773], ["the", 781], ["fast", 785], ["evolution", 790], ["that", 800], ["is", 805], ["typical", 808], ["of", 816], ["the", 819], ["cas", 823], ["genes", 827], [",", 832], ["the", 834], ["presence", 838], ["of", 847], ["diverse", 850], ["versions", 858], ["of", 867], ["the", 870], ["RRM", 874], ["in", 878], ["most", 881], ["Cas", 886], ["proteins", 890], ["provides", 899], ["for", 908], ["a", 912], ["simple", 914], ["scenario", 921], ["for", 930], ["the", 934], ["evolution", 938], ["of", 948], ["the", 951], ["three", 955], ["distinct", 961], ["types", 970], ["of", 976], ["CRISPR", 979], ["-", 985], ["cas", 986], ["systems", 990], [".", 997], ["In", 999], ["addition", 1002], ["to", 1011], ["several", 1014], ["proteins", 1022], ["that", 1031], ["are", 1036], ["directly", 1040], ["implicated", 1049], ["in", 1060], ["the", 1063], ["immune", 1067], ["response", 1074], [",", 1082], ["the", 1084], ["cas", 1088], ["genes", 1092], ["encode", 1098], ["a", 1105], ["variety", 1107], ["of", 1115], ["proteins", 1118], ["that", 1127], ["are", 1132], ["homologous", 1136], ["to", 1147], ["prokaryotic", 1150], ["toxins", 1162], ["that", 1169], ["typically", 1174], ["possess", 1184], ["nuclease", 1192], ["activity", 1201], [".", 1209], ["The", 1211], ["predicted", 1215], ["toxins", 1225], ["associated", 1232], ["with", 1243], ["CRISPR", 1248], ["-", 1254], ["Cas", 1255], ["systems", 1259], ["include", 1267], ["the", 1275], ["essential", 1279], ["Cas2", 1289], ["protein", 1294], [",", 1301], ["proteins", 1303], ["of", 1312], ["COG1517", 1315], ["that", 1323], [",", 1327], ["in", 1329], ["addition", 1332], ["to", 1341], ["a", 1344], ["ligand", 1346], ["-", 1352], ["binding", 1353], ["domain", 1361], ["and", 1368], ["a", 1372], ["helix", 1374], ["-", 1379], ["turn", 1380], ["-", 1384], ["helix", 1385], ["domain", 1391], [",", 1397], ["typically", 1399], ["contain", 1409], ["different", 1417], ["nuclease", 1427], ["domains", 1436], ["and", 1444], ["several", 1448], ["other", 1456], ["predicted", 1462], ["nucleases", 1472], [".", 1481], ["The", 1483], ["tight", 1487], ["association", 1493], ["of", 1505], ["the", 1508], ["CRISPR", 1512], ["-", 1518], ["Cas", 1519], ["immunity", 1523], ["systems", 1532], ["with", 1540], ["predicted", 1545], ["toxins", 1555], ["that", 1562], [",", 1566], ["upon", 1568], ["activation", 1573], [",", 1583], ["would", 1585], ["induce", 1591], ["dormancy", 1598], ["or", 1607], ["cell", 1610], ["death", 1615], ["suggests", 1621], ["that", 1630], ["adaptive", 1635], ["immunity", 1644], ["and", 1653], ["dormancy", 1657], ["/", 1665], ["suicide", 1666], ["response", 1674], ["are", 1683], ["functionally", 1687], ["coupled", 1700], [".", 1707], ["Such", 1709], ["coupling", 1714], ["could", 1723], ["manifest", 1729], ["in", 1738], ["the", 1741], ["persistence", 1745], ["state", 1757], ["being", 1763], ["induced", 1769], ["and", 1777], ["potentially", 1781], ["providing", 1793], ["conditions", 1803], ["for", 1814], ["more", 1818], ["effective", 1823], ["action", 1833], ["of", 1840], ["the", 1843], ["immune", 1847], ["system", 1854], ["or", 1861], ["in", 1864], ["cell", 1867], ["death", 1872], ["being", 1878], ["triggered", 1884], ["when", 1894], ["immunity", 1899], ["fails", 1908], [".", 1913]]}
{"context": "Mutations in the amyloid precursor protein gene were the first to be recognized as a cause of Alzheimer's disease (AD). We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile), known as London mutation. In 1 family, this mutation was responsible for AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far. Two subjects of the other family with AD diagnosis were carriers of the same mutation. All AD subjects showed a cognitive profile characterized by early impairment in long-term memory, shifting abilities and affective symptoms beginning in the fifth decade of life.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "f9dd23b8836640968364324126b3087b", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[17, 19]], "char_spans": [[94, 112]]}, {"text": "AD", "token_spans": [[107, 107], [63, 63], [21, 21], [97, 97]], "char_spans": [[551, 552], [333, 334], [115, 116], [498, 499]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["amyloid", 17], ["precursor", 25], ["protein", 35], ["gene", 43], ["were", 48], ["the", 53], ["first", 57], ["to", 63], ["be", 66], ["recognized", 69], ["as", 80], ["a", 83], ["cause", 85], ["of", 91], ["Alzheimer", 94], ["'s", 103], ["disease", 106], ["(", 114], ["AD", 115], [")", 117], [".", 118], ["We", 120], ["describe", 123], ["2", 132], ["Italian", 134], ["families", 142], ["showing", 151], ["the", 159], ["missense", 163], ["mutation", 172], ["in", 181], ["exon", 184], ["17", 189], ["of", 192], ["the", 195], ["amyloid", 199], ["precursor", 207], ["protein", 217], ["gene", 225], ["on", 230], ["chromosome", 233], ["21", 244], ["(", 247], ["Val717Ile", 248], [")", 257], [",", 258], ["known", 260], ["as", 266], ["London", 269], ["mutation", 276], [".", 284], ["In", 286], ["1", 289], ["family", 291], [",", 297], ["this", 299], ["mutation", 304], ["was", 313], ["responsible", 317], ["for", 329], ["AD", 333], ["in", 336], ["3", 339], ["out", 341], ["of", 345], ["7", 348], ["siblings", 350], ["and", 359], ["it", 363], ["is", 366], ["also", 369], ["present", 374], ["in", 382], ["a", 385], ["fourth", 387], ["sibling", 394], ["who", 402], ["has", 406], ["only", 410], ["shown", 415], ["signs", 421], ["of", 427], ["executive", 430], ["dysfunction", 440], ["so", 452], ["far", 455], [".", 458], ["Two", 460], ["subjects", 464], ["of", 473], ["the", 476], ["other", 480], ["family", 486], ["with", 493], ["AD", 498], ["diagnosis", 501], ["were", 511], ["carriers", 516], ["of", 525], ["the", 528], ["same", 532], ["mutation", 537], [".", 545], ["All", 547], ["AD", 551], ["subjects", 554], ["showed", 563], ["a", 570], ["cognitive", 572], ["profile", 582], ["characterized", 590], ["by", 604], ["early", 607], ["impairment", 613], ["in", 624], ["long", 627], ["-", 631], ["term", 632], ["memory", 637], [",", 643], ["shifting", 645], ["abilities", 654], ["and", 664], ["affective", 668], ["symptoms", 678], ["beginning", 687], ["in", 697], ["the", 700], ["fifth", 704], ["decade", 710], ["of", 717], ["life", 720], [".", 724]]}
{"context": "Although chronic stress is known to be linked with memory and other neurological disorders, little is known about the relationship between chronic stress and the onset or development of Alzheimer's disease (AD). In this study, we investigated the effects of long-term stress on the onset and severity of cognitive deficits and pathological changes in APPV717I-CT100 mice overexpressing human APP-CT100 containing the London mutation (V717I) after exposure to immobilization stress. We found that chronic immobilization stress accelerated cognitive impairments, as accessed by the Passive avoidance and the Social Transfer of Food Preference (STFP) tests. Moreover, the numbers and densities of vascular and extracellular deposits containing amyloid beta peptide (Abeta) and carboxyl-terminal fragments of amyloid precursor protein (APP-CTFs), which are pathologic markers of AD, were significantly elevated in stressed animals, especially in the hippocampus. Moreover, stressed animals, also showed highly elevated levels of neurodegeneration and tau phosphorylation and increased intraneuronal Abeta and APP-CTFs immunoreactivities in the hippocampus and in the entorhinal and piriform cortex. This study provides the first evidence that chronic stress accelerates the onset and severity of cognitive deficits and that these are highly correlated with pathological changes, which thus indicates that chronic stress may be an important contributor to the onset and development of AD.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "b1ad29199ed6423184843a3ceb0c058c", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[30, 32]], "char_spans": [[186, 204]]}, {"text": "AD", "token_spans": [[150, 150], [243, 243], [34, 34]], "char_spans": [[875, 876], [1480, 1481], [207, 208]]}]}], "context_tokens": [["Although", 0], ["chronic", 9], ["stress", 17], ["is", 24], ["known", 27], ["to", 33], ["be", 36], ["linked", 39], ["with", 46], ["memory", 51], ["and", 58], ["other", 62], ["neurological", 68], ["disorders", 81], [",", 90], ["little", 92], ["is", 99], ["known", 102], ["about", 108], ["the", 114], ["relationship", 118], ["between", 131], ["chronic", 139], ["stress", 147], ["and", 154], ["the", 158], ["onset", 162], ["or", 168], ["development", 171], ["of", 183], ["Alzheimer", 186], ["'s", 195], ["disease", 198], ["(", 206], ["AD", 207], [")", 209], [".", 210], ["In", 212], ["this", 215], ["study", 220], [",", 225], ["we", 227], ["investigated", 230], ["the", 243], ["effects", 247], ["of", 255], ["long", 258], ["-", 262], ["term", 263], ["stress", 268], ["on", 275], ["the", 278], ["onset", 282], ["and", 288], ["severity", 292], ["of", 301], ["cognitive", 304], ["deficits", 314], ["and", 323], ["pathological", 327], ["changes", 340], ["in", 348], ["APPV717I", 351], ["-", 359], ["CT100", 360], ["mice", 366], ["overexpressing", 371], ["human", 386], ["APP", 392], ["-", 395], ["CT100", 396], ["containing", 402], ["the", 413], ["London", 417], ["mutation", 424], ["(", 433], ["V717I", 434], [")", 439], ["after", 441], ["exposure", 447], ["to", 456], ["immobilization", 459], ["stress", 474], [".", 480], ["We", 482], ["found", 485], ["that", 491], ["chronic", 496], ["immobilization", 504], ["stress", 519], ["accelerated", 526], ["cognitive", 538], ["impairments", 548], [",", 559], ["as", 561], ["accessed", 564], ["by", 573], ["the", 576], ["Passive", 580], ["avoidance", 588], ["and", 598], ["the", 602], ["Social", 606], ["Transfer", 613], ["of", 622], ["Food", 625], ["Preference", 630], ["(", 641], ["STFP", 642], [")", 646], ["tests", 648], [".", 653], ["Moreover", 655], [",", 663], ["the", 665], ["numbers", 669], ["and", 677], ["densities", 681], ["of", 691], ["vascular", 694], ["and", 703], ["extracellular", 707], ["deposits", 721], ["containing", 730], ["amyloid", 741], ["beta", 749], ["peptide", 754], ["(", 762], ["Abeta", 763], [")", 768], ["and", 770], ["carboxyl", 774], ["-", 782], ["terminal", 783], ["fragments", 792], ["of", 802], ["amyloid", 805], ["precursor", 813], ["protein", 823], ["(", 831], ["APP", 832], ["-", 835], ["CTFs", 836], [")", 840], [",", 841], ["which", 843], ["are", 849], ["pathologic", 853], ["markers", 864], ["of", 872], ["AD", 875], [",", 877], ["were", 879], ["significantly", 884], ["elevated", 898], ["in", 907], ["stressed", 910], ["animals", 919], [",", 926], ["especially", 928], ["in", 939], ["the", 942], ["hippocampus", 946], [".", 957], ["Moreover", 959], [",", 967], ["stressed", 969], ["animals", 978], [",", 985], ["also", 987], ["showed", 992], ["highly", 999], ["elevated", 1006], ["levels", 1015], ["of", 1022], ["neurodegeneration", 1025], ["and", 1043], ["tau", 1047], ["phosphorylation", 1051], ["and", 1067], ["increased", 1071], ["intraneuronal", 1081], ["Abeta", 1095], ["and", 1101], ["APP", 1105], ["-", 1108], ["CTFs", 1109], ["immunoreactivities", 1114], ["in", 1133], ["the", 1136], ["hippocampus", 1140], ["and", 1152], ["in", 1156], ["the", 1159], ["entorhinal", 1163], ["and", 1174], ["piriform", 1178], ["cortex", 1187], [".", 1193], ["This", 1195], ["study", 1200], ["provides", 1206], ["the", 1215], ["first", 1219], ["evidence", 1225], ["that", 1234], ["chronic", 1239], ["stress", 1247], ["accelerates", 1254], ["the", 1266], ["onset", 1270], ["and", 1276], ["severity", 1280], ["of", 1289], ["cognitive", 1292], ["deficits", 1302], ["and", 1311], ["that", 1315], ["these", 1320], ["are", 1326], ["highly", 1330], ["correlated", 1337], ["with", 1348], ["pathological", 1353], ["changes", 1366], [",", 1373], ["which", 1375], ["thus", 1381], ["indicates", 1386], ["that", 1396], ["chronic", 1401], ["stress", 1409], ["may", 1416], ["be", 1420], ["an", 1423], ["important", 1426], ["contributor", 1436], ["to", 1448], ["the", 1451], ["onset", 1455], ["and", 1461], ["development", 1465], ["of", 1477], ["AD", 1480], [".", 1482]]}
{"context": "Katayama fever is an acute clinical condition characterised by high fever, dry cough and general malaise occurring during early Schistosoma spp. infection. It is predominantly reported in travellers from non-endemic regions. Whereas the immunological response to Schistosoma infection is well characterised, alterations in inflammatory markers and coagulation in response to acute infection are poorly understood. Here we report the clinical, laboratory and radiological characteristics of three returning travellers with Katayama fever. Inflammatory markers and coagulation status were assessed repeatedly during follow-up to characterise the host response to infection. Radiographic findings were correlated with clinical and laboratory markers. Clinical symptoms were suggestive of a significant inflammatory response in all patients including high fever (>39\u00b0C), cough, and general malaise. Classical inflammatory markers including blood sedimentation rate, C-reactive protein, and serum amyloid A were only moderately elevated. Marked eosinophilia (33-42% of white blood cells) was observed and persisted despite anti-inflammatory and anthelminthic treatment for up to 32 weeks. Analysis of blood coagulation markers indicated increased coagulability reflected by elevated D-dimer values (0.57-1.17 \u03bcg/ml) and high thrombin generating potentials (peak thrombin activity: 311-384 nM). One patient showed particularly high levels of microparticle-associated tissue factor activity at initial presentation (1.64 pg/ml). Multiple pulmonary and hepatic opacities demonstrated by computed tomography (CT) scanning were associated with raised inflammatory markers in one patient. The characterisation of the inflammatory response, blood coagulation parameters and radiological findings in three patients adds to our current understanding of Katayama fever and serves as a starting point for further systematic investigations of the pathophysiology of this acute helminthic infection.", "qas": [{"question": "What causes Katayama Fever?", "answers": ["Schistosoma spp"], "qid": "89d498b4ba614556a6e601b0a267b76b", "question_tokens": [["What", 0], ["causes", 5], ["Katayama", 12], ["Fever", 21], ["?", 26]], "detected_answers": [{"text": "Schistosoma spp", "token_spans": [[20, 21]], "char_spans": [[128, 142]]}]}], "context_tokens": [["Katayama", 0], ["fever", 9], ["is", 15], ["an", 18], ["acute", 21], ["clinical", 27], ["condition", 36], ["characterised", 46], ["by", 60], ["high", 63], ["fever", 68], [",", 73], ["dry", 75], ["cough", 79], ["and", 85], ["general", 89], ["malaise", 97], ["occurring", 105], ["during", 115], ["early", 122], ["Schistosoma", 128], ["spp", 140], [".", 143], ["infection", 145], [".", 154], ["It", 156], ["is", 159], ["predominantly", 162], ["reported", 176], ["in", 185], ["travellers", 188], ["from", 199], ["non", 204], ["-", 207], ["endemic", 208], ["regions", 216], [".", 223], ["Whereas", 225], ["the", 233], ["immunological", 237], ["response", 251], ["to", 260], ["Schistosoma", 263], ["infection", 275], ["is", 285], ["well", 288], ["characterised", 293], [",", 306], ["alterations", 308], ["in", 320], ["inflammatory", 323], ["markers", 336], ["and", 344], ["coagulation", 348], ["in", 360], ["response", 363], ["to", 372], ["acute", 375], ["infection", 381], ["are", 391], ["poorly", 395], ["understood", 402], [".", 412], ["Here", 414], ["we", 419], ["report", 422], ["the", 429], ["clinical", 433], [",", 441], ["laboratory", 443], ["and", 454], ["radiological", 458], ["characteristics", 471], ["of", 487], ["three", 490], ["returning", 496], ["travellers", 506], ["with", 517], ["Katayama", 522], ["fever", 531], [".", 536], ["Inflammatory", 538], ["markers", 551], ["and", 559], ["coagulation", 563], ["status", 575], ["were", 582], ["assessed", 587], ["repeatedly", 596], ["during", 607], ["follow", 614], ["-", 620], ["up", 621], ["to", 624], ["characterise", 627], ["the", 640], ["host", 644], ["response", 649], ["to", 658], ["infection", 661], [".", 670], ["Radiographic", 672], ["findings", 685], ["were", 694], ["correlated", 699], ["with", 710], ["clinical", 715], ["and", 724], ["laboratory", 728], ["markers", 739], [".", 746], ["Clinical", 748], ["symptoms", 757], ["were", 766], ["suggestive", 771], ["of", 782], ["a", 785], ["significant", 787], ["inflammatory", 799], ["response", 812], ["in", 821], ["all", 824], ["patients", 828], ["including", 837], ["high", 847], ["fever", 852], ["(", 858], [">", 859], ["39", 860], ["\u00b0", 862], ["C", 863], [")", 864], [",", 865], ["cough", 867], [",", 872], ["and", 874], ["general", 878], ["malaise", 886], [".", 893], ["Classical", 895], ["inflammatory", 905], ["markers", 918], ["including", 926], ["blood", 936], ["sedimentation", 942], ["rate", 956], [",", 960], ["C", 962], ["-", 963], ["reactive", 964], ["protein", 973], [",", 980], ["and", 982], ["serum", 986], ["amyloid", 992], ["A", 1000], ["were", 1002], ["only", 1007], ["moderately", 1012], ["elevated", 1023], [".", 1031], ["Marked", 1033], ["eosinophilia", 1040], ["(", 1053], ["33", 1054], ["-", 1056], ["42", 1057], ["%", 1059], ["of", 1061], ["white", 1064], ["blood", 1070], ["cells", 1076], [")", 1081], ["was", 1083], ["observed", 1087], ["and", 1096], ["persisted", 1100], ["despite", 1110], ["anti", 1118], ["-", 1122], ["inflammatory", 1123], ["and", 1136], ["anthelminthic", 1140], ["treatment", 1154], ["for", 1164], ["up", 1168], ["to", 1171], ["32", 1174], ["weeks", 1177], [".", 1182], ["Analysis", 1184], ["of", 1193], ["blood", 1196], ["coagulation", 1202], ["markers", 1214], ["indicated", 1222], ["increased", 1232], ["coagulability", 1242], ["reflected", 1256], ["by", 1266], ["elevated", 1269], ["D", 1278], ["-", 1279], ["dimer", 1280], ["values", 1286], ["(", 1293], ["0.57", 1294], ["-", 1298], ["1.17", 1299], ["\u03bcg", 1304], ["/", 1306], ["ml", 1307], [")", 1309], ["and", 1311], ["high", 1315], ["thrombin", 1320], ["generating", 1329], ["potentials", 1340], ["(", 1351], ["peak", 1352], ["thrombin", 1357], ["activity", 1366], [":", 1374], ["311", 1376], ["-", 1379], ["384", 1380], ["nM", 1384], [")", 1386], [".", 1387], ["One", 1389], ["patient", 1393], ["showed", 1401], ["particularly", 1408], ["high", 1421], ["levels", 1426], ["of", 1433], ["microparticle", 1436], ["-", 1449], ["associated", 1450], ["tissue", 1461], ["factor", 1468], ["activity", 1475], ["at", 1484], ["initial", 1487], ["presentation", 1495], ["(", 1508], ["1.64", 1509], ["pg", 1514], ["/", 1516], ["ml", 1517], [")", 1519], [".", 1520], ["Multiple", 1522], ["pulmonary", 1531], ["and", 1541], ["hepatic", 1545], ["opacities", 1553], ["demonstrated", 1563], ["by", 1576], ["computed", 1579], ["tomography", 1588], ["(", 1599], ["CT", 1600], [")", 1602], ["scanning", 1604], ["were", 1613], ["associated", 1618], ["with", 1629], ["raised", 1634], ["inflammatory", 1641], ["markers", 1654], ["in", 1662], ["one", 1665], ["patient", 1669], [".", 1676], ["The", 1678], ["characterisation", 1682], ["of", 1699], ["the", 1702], ["inflammatory", 1706], ["response", 1719], [",", 1727], ["blood", 1729], ["coagulation", 1735], ["parameters", 1747], ["and", 1758], ["radiological", 1762], ["findings", 1775], ["in", 1784], ["three", 1787], ["patients", 1793], ["adds", 1802], ["to", 1807], ["our", 1810], ["current", 1814], ["understanding", 1822], ["of", 1836], ["Katayama", 1839], ["fever", 1848], ["and", 1854], ["serves", 1858], ["as", 1865], ["a", 1868], ["starting", 1870], ["point", 1879], ["for", 1885], ["further", 1889], ["systematic", 1897], ["investigations", 1908], ["of", 1923], ["the", 1926], ["pathophysiology", 1930], ["of", 1946], ["this", 1949], ["acute", 1954], ["helminthic", 1960], ["infection", 1971], [".", 1980]]}
{"context": "Patients with splenomegaly and abnormally high leukocyte counts were first recognized in France, Germany, and Scotland in the 1840s. The only well-documented therapy in the 19th century was use of arsenic in one or other form, which did undoubtedly reduce the leukocyte count but probably did little or nothing to prolong life. These early cases were probably examples of chronic myeloid leukemia (CML) (then called chronic granulocytic leukemia). In the 20th century important steps in unraveling the pathogenesis of CML were the discovery of the Philadelphia chromosome in 1960, and of the (9;22) translocation in 1973. There followed definition of the breakpoint cluster region on chromosome 22 in 1984 and the demonstration of the BCR-ABL transcript in CML in 1985. In the first half of the 20th century patients were treated predominantly with radiotherapy, and later on with busulfan, hydroxycarbamide, or interferon-alfa (IFN-\u03b1). From 1980 onwards allogeneic stem cell transplantation (SCT) became the treatment of choice for eligible patients. The era of tyrosine kinase inhibitors (TKI) began in 1998 and today the use of the original TKI, imatinib, has replaced SCT as initial therapy for patients who present with CML in chronic phase.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7a34cd7025714d5fa78883088d8a1b82", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[130, 132]], "char_spans": [[735, 741]]}]}], "context_tokens": [["Patients", 0], ["with", 9], ["splenomegaly", 14], ["and", 27], ["abnormally", 31], ["high", 42], ["leukocyte", 47], ["counts", 57], ["were", 64], ["first", 69], ["recognized", 75], ["in", 86], ["France", 89], [",", 95], ["Germany", 97], [",", 104], ["and", 106], ["Scotland", 110], ["in", 119], ["the", 122], ["1840s", 126], [".", 131], ["The", 133], ["only", 137], ["well", 142], ["-", 146], ["documented", 147], ["therapy", 158], ["in", 166], ["the", 169], ["19th", 173], ["century", 178], ["was", 186], ["use", 190], ["of", 194], ["arsenic", 197], ["in", 205], ["one", 208], ["or", 212], ["other", 215], ["form", 221], [",", 225], ["which", 227], ["did", 233], ["undoubtedly", 237], ["reduce", 249], ["the", 256], ["leukocyte", 260], ["count", 270], ["but", 276], ["probably", 280], ["did", 289], ["little", 293], ["or", 300], ["nothing", 303], ["to", 311], ["prolong", 314], ["life", 322], [".", 326], ["These", 328], ["early", 334], ["cases", 340], ["were", 346], ["probably", 351], ["examples", 360], ["of", 369], ["chronic", 372], ["myeloid", 380], ["leukemia", 388], ["(", 397], ["CML", 398], [")", 401], ["(", 403], ["then", 404], ["called", 409], ["chronic", 416], ["granulocytic", 424], ["leukemia", 437], [")", 445], [".", 446], ["In", 448], ["the", 451], ["20th", 455], ["century", 460], ["important", 468], ["steps", 478], ["in", 484], ["unraveling", 487], ["the", 498], ["pathogenesis", 502], ["of", 515], ["CML", 518], ["were", 522], ["the", 527], ["discovery", 531], ["of", 541], ["the", 544], ["Philadelphia", 548], ["chromosome", 561], ["in", 572], ["1960", 575], [",", 579], ["and", 581], ["of", 585], ["the", 588], ["(", 592], ["9;22", 593], [")", 597], ["translocation", 599], ["in", 613], ["1973", 616], [".", 620], ["There", 622], ["followed", 628], ["definition", 637], ["of", 648], ["the", 651], ["breakpoint", 655], ["cluster", 666], ["region", 674], ["on", 681], ["chromosome", 684], ["22", 695], ["in", 698], ["1984", 701], ["and", 706], ["the", 710], ["demonstration", 714], ["of", 728], ["the", 731], ["BCR", 735], ["-", 738], ["ABL", 739], ["transcript", 743], ["in", 754], ["CML", 757], ["in", 761], ["1985", 764], [".", 768], ["In", 770], ["the", 773], ["first", 777], ["half", 783], ["of", 788], ["the", 791], ["20th", 795], ["century", 800], ["patients", 808], ["were", 817], ["treated", 822], ["predominantly", 830], ["with", 844], ["radiotherapy", 849], [",", 861], ["and", 863], ["later", 867], ["on", 873], ["with", 876], ["busulfan", 881], [",", 889], ["hydroxycarbamide", 891], [",", 907], ["or", 909], ["interferon", 912], ["-", 922], ["alfa", 923], ["(", 928], ["IFN", 929], ["-", 932], ["\u03b1", 933], [")", 934], [".", 935], ["From", 937], ["1980", 942], ["onwards", 947], ["allogeneic", 955], ["stem", 966], ["cell", 971], ["transplantation", 976], ["(", 992], ["SCT", 993], [")", 996], ["became", 998], ["the", 1005], ["treatment", 1009], ["of", 1019], ["choice", 1022], ["for", 1029], ["eligible", 1033], ["patients", 1042], [".", 1050], ["The", 1052], ["era", 1056], ["of", 1060], ["tyrosine", 1063], ["kinase", 1072], ["inhibitors", 1079], ["(", 1090], ["TKI", 1091], [")", 1094], ["began", 1096], ["in", 1102], ["1998", 1105], ["and", 1110], ["today", 1114], ["the", 1120], ["use", 1124], ["of", 1128], ["the", 1131], ["original", 1135], ["TKI", 1144], [",", 1147], ["imatinib", 1149], [",", 1157], ["has", 1159], ["replaced", 1163], ["SCT", 1172], ["as", 1176], ["initial", 1179], ["therapy", 1187], ["for", 1195], ["patients", 1199], ["who", 1208], ["present", 1212], ["with", 1220], ["CML", 1225], ["in", 1229], ["chronic", 1232], ["phase", 1240], [".", 1245]]}
{"context": "Both restless legs syndrome ([RLS], also known as Willis-Ekbom Disease [WED]) and depression are common during pregnancy. However, no prior studies have assessed if pregnant women with RLS have an elevated risk of depression during and/or after pregnancy. 1,428 women who were pregnant in gestational week 16-17 were asked to participate in a longitudinal survey. They were followed by web-based questionnaires in gestational week 17 and 32, and 6 weeks after delivery. Data were also retrieved from prenatal and birth records. Two different sets of criteria were used to examine the prevalence of RLS in the cohort (International Restless Legs Syndrome Society Group standard criteria and the later developed CH-RLSQ11 questionnaire). The latter questionnaire attempts to exclude those with common \"mimics\" of RLS. Adjusted odds ratio for depression in gestational week 17, 32, and postpartum week 6 in relation to pre-pregnancy RLS onset and moderate to severe symptom severity were 4.74 (2.30 - 9.76), 3.67 (1.85 - 7.28), and 2.58 (1.28 - 5.21), respectively. No significant associations were seen in pregnant women with de novo RLS during pregnancy. When using the standard diagnostic RLS criteria and frequency of symptoms more than 2-3 days per week, the prevalence of RLS was 12.3%. With the CH-RLSQ11 questionnaire and the same threshold for frequency of symptoms the prevalence was 6.5%. Women with RLS onset before pregnancy with moderate or severe symptoms had an increased risk of both antenatal and postnatal depression. The self-reported prevalence of RLS during pregnancy is lower when a questionnaire dealing with \"mimics\" is used.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "c1bbf8276dad42dc8e9a68753159154e", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[1, 3], [119, 121]], "char_spans": [[5, 26], [631, 652]]}]}], "context_tokens": [["Both", 0], ["restless", 5], ["legs", 14], ["syndrome", 19], ["(", 28], ["[", 29], ["RLS", 30], ["]", 33], [",", 34], ["also", 36], ["known", 41], ["as", 47], ["Willis", 50], ["-", 56], ["Ekbom", 57], ["Disease", 63], ["[", 71], ["WED", 72], ["]", 75], [")", 76], ["and", 78], ["depression", 82], ["are", 93], ["common", 97], ["during", 104], ["pregnancy", 111], [".", 120], ["However", 122], [",", 129], ["no", 131], ["prior", 134], ["studies", 140], ["have", 148], ["assessed", 153], ["if", 162], ["pregnant", 165], ["women", 174], ["with", 180], ["RLS", 185], ["have", 189], ["an", 194], ["elevated", 197], ["risk", 206], ["of", 211], ["depression", 214], ["during", 225], ["and/or", 232], ["after", 239], ["pregnancy", 245], [".", 254], ["1,428", 256], ["women", 262], ["who", 268], ["were", 272], ["pregnant", 277], ["in", 286], ["gestational", 289], ["week", 301], ["16", 306], ["-", 308], ["17", 309], ["were", 312], ["asked", 317], ["to", 323], ["participate", 326], ["in", 338], ["a", 341], ["longitudinal", 343], ["survey", 356], [".", 362], ["They", 364], ["were", 369], ["followed", 374], ["by", 383], ["web", 386], ["-", 389], ["based", 390], ["questionnaires", 396], ["in", 411], ["gestational", 414], ["week", 426], ["17", 431], ["and", 434], ["32", 438], [",", 440], ["and", 442], ["6", 446], ["weeks", 448], ["after", 454], ["delivery", 460], [".", 468], ["Data", 470], ["were", 475], ["also", 480], ["retrieved", 485], ["from", 495], ["prenatal", 500], ["and", 509], ["birth", 513], ["records", 519], [".", 526], ["Two", 528], ["different", 532], ["sets", 542], ["of", 547], ["criteria", 550], ["were", 559], ["used", 564], ["to", 569], ["examine", 572], ["the", 580], ["prevalence", 584], ["of", 595], ["RLS", 598], ["in", 602], ["the", 605], ["cohort", 609], ["(", 616], ["International", 617], ["Restless", 631], ["Legs", 640], ["Syndrome", 645], ["Society", 654], ["Group", 662], ["standard", 668], ["criteria", 677], ["and", 686], ["the", 690], ["later", 694], ["developed", 700], ["CH", 710], ["-", 712], ["RLSQ11", 713], ["questionnaire", 720], [")", 733], [".", 734], ["The", 736], ["latter", 740], ["questionnaire", 747], ["attempts", 761], ["to", 770], ["exclude", 773], ["those", 781], ["with", 787], ["common", 792], ["\"", 799], ["mimics", 800], ["\"", 806], ["of", 808], ["RLS", 811], [".", 814], ["Adjusted", 816], ["odds", 825], ["ratio", 830], ["for", 836], ["depression", 840], ["in", 851], ["gestational", 854], ["week", 866], ["17", 871], [",", 873], ["32", 875], [",", 877], ["and", 879], ["postpartum", 883], ["week", 894], ["6", 899], ["in", 901], ["relation", 904], ["to", 913], ["pre", 916], ["-", 919], ["pregnancy", 920], ["RLS", 930], ["onset", 934], ["and", 940], ["moderate", 944], ["to", 953], ["severe", 956], ["symptom", 963], ["severity", 971], ["were", 980], ["4.74", 985], ["(", 990], ["2.30", 991], ["-", 996], ["9.76", 998], [")", 1002], [",", 1003], ["3.67", 1005], ["(", 1010], ["1.85", 1011], ["-", 1016], ["7.28", 1018], [")", 1022], [",", 1023], ["and", 1025], ["2.58", 1029], ["(", 1034], ["1.28", 1035], ["-", 1040], ["5.21", 1042], [")", 1046], [",", 1047], ["respectively", 1049], [".", 1061], ["No", 1063], ["significant", 1066], ["associations", 1078], ["were", 1091], ["seen", 1096], ["in", 1101], ["pregnant", 1104], ["women", 1113], ["with", 1119], ["de", 1124], ["novo", 1127], ["RLS", 1132], ["during", 1136], ["pregnancy", 1143], [".", 1152], ["When", 1154], ["using", 1159], ["the", 1165], ["standard", 1169], ["diagnostic", 1178], ["RLS", 1189], ["criteria", 1193], ["and", 1202], ["frequency", 1206], ["of", 1216], ["symptoms", 1219], ["more", 1228], ["than", 1233], ["2", 1238], ["-", 1239], ["3", 1240], ["days", 1242], ["per", 1247], ["week", 1251], [",", 1255], ["the", 1257], ["prevalence", 1261], ["of", 1272], ["RLS", 1275], ["was", 1279], ["12.3", 1283], ["%", 1287], [".", 1288], ["With", 1290], ["the", 1295], ["CH", 1299], ["-", 1301], ["RLSQ11", 1302], ["questionnaire", 1309], ["and", 1323], ["the", 1327], ["same", 1331], ["threshold", 1336], ["for", 1346], ["frequency", 1350], ["of", 1360], ["symptoms", 1363], ["the", 1372], ["prevalence", 1376], ["was", 1387], ["6.5", 1391], ["%", 1394], [".", 1395], ["Women", 1397], ["with", 1403], ["RLS", 1408], ["onset", 1412], ["before", 1418], ["pregnancy", 1425], ["with", 1435], ["moderate", 1440], ["or", 1449], ["severe", 1452], ["symptoms", 1459], ["had", 1468], ["an", 1472], ["increased", 1475], ["risk", 1485], ["of", 1490], ["both", 1493], ["antenatal", 1498], ["and", 1508], ["postnatal", 1512], ["depression", 1522], [".", 1532], ["The", 1534], ["self", 1538], ["-", 1542], ["reported", 1543], ["prevalence", 1552], ["of", 1563], ["RLS", 1566], ["during", 1570], ["pregnancy", 1577], ["is", 1587], ["lower", 1590], ["when", 1596], ["a", 1601], ["questionnaire", 1603], ["dealing", 1617], ["with", 1625], ["\"", 1630], ["mimics", 1631], ["\"", 1637], ["is", 1639], ["used", 1642], [".", 1646]]}
{"context": "Acrokeratosis paraneoplastic (Bazex syndrome) is a rare, but distinctive paraneoplastic dermatosis characterized by erythematosquamous lesions located at the acral sites and is most commonly associated with carcinomas of the upper aerodigestive tract. We report a 58-year-old female with a history of a pigmented rash on her extremities, thick keratotic plaques on her hands, and brittle nails. Chest imaging revealed a right upper lobe mass that was proven to be small cell lung carcinoma. While Bazex syndrome has been described in the dermatology literature, it is also important for the radiologist to be aware of this entity and its common presentations.", "qas": [{"question": "Name synonym of Acrokeratosis paraneoplastica.", "answers": ["Bazex syndrome"], "qid": "17fe85e739194ecda4e790b9d6224dc0", "question_tokens": [["Name", 0], ["synonym", 5], ["of", 13], ["Acrokeratosis", 16], ["paraneoplastica", 30], [".", 45]], "detected_answers": [{"text": "Bazex syndrome", "token_spans": [[84, 85], [3, 4]], "char_spans": [[497, 510], [30, 43]]}]}], "context_tokens": [["Acrokeratosis", 0], ["paraneoplastic", 14], ["(", 29], ["Bazex", 30], ["syndrome", 36], [")", 44], ["is", 46], ["a", 49], ["rare", 51], [",", 55], ["but", 57], ["distinctive", 61], ["paraneoplastic", 73], ["dermatosis", 88], ["characterized", 99], ["by", 113], ["erythematosquamous", 116], ["lesions", 135], ["located", 143], ["at", 151], ["the", 154], ["acral", 158], ["sites", 164], ["and", 170], ["is", 174], ["most", 177], ["commonly", 182], ["associated", 191], ["with", 202], ["carcinomas", 207], ["of", 218], ["the", 221], ["upper", 225], ["aerodigestive", 231], ["tract", 245], [".", 250], ["We", 252], ["report", 255], ["a", 262], ["58-year", 264], ["-", 271], ["old", 272], ["female", 276], ["with", 283], ["a", 288], ["history", 290], ["of", 298], ["a", 301], ["pigmented", 303], ["rash", 313], ["on", 318], ["her", 321], ["extremities", 325], [",", 336], ["thick", 338], ["keratotic", 344], ["plaques", 354], ["on", 362], ["her", 365], ["hands", 369], [",", 374], ["and", 376], ["brittle", 380], ["nails", 388], [".", 393], ["Chest", 395], ["imaging", 401], ["revealed", 409], ["a", 418], ["right", 420], ["upper", 426], ["lobe", 432], ["mass", 437], ["that", 442], ["was", 447], ["proven", 451], ["to", 458], ["be", 461], ["small", 464], ["cell", 470], ["lung", 475], ["carcinoma", 480], [".", 489], ["While", 491], ["Bazex", 497], ["syndrome", 503], ["has", 512], ["been", 516], ["described", 521], ["in", 531], ["the", 534], ["dermatology", 538], ["literature", 550], [",", 560], ["it", 562], ["is", 565], ["also", 568], ["important", 573], ["for", 583], ["the", 587], ["radiologist", 591], ["to", 603], ["be", 606], ["aware", 609], ["of", 615], ["this", 618], ["entity", 623], ["and", 630], ["its", 634], ["common", 638], ["presentations", 645], [".", 658]]}
{"context": "McLeod syndrome and chorea-acanthocytosis are classified with the so-called neuroacanthocytosis group of syndromes. Both lead to progressive basal ganglia degeneration and were not easily distinguished in the past. With the discovery of their molecular bases, mutations of the X-linked gene XK and autosomal recessive mutations of the gene coding for chorein, respectively, the two phenotypes can now be differentiated and extend the diagnostic spectrum in patients presenting with chorea. The present review compares the two conditions and proposes a practical approach to diagnosis and treatment. Better-defined disease concepts should eventually replace the umbrella term of \"neuroacanthocytosis.\" Animal models are needed to understand the underlying mechanisms. A final common pathway is likely for the pathogenesis of these conditions and is most probably shared with Huntington's disease.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "4678fd2baf4f4fc2a3d6a5f6d70178ed", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[49, 49]], "char_spans": [[291, 292]]}]}], "context_tokens": [["McLeod", 0], ["syndrome", 7], ["and", 16], ["chorea", 20], ["-", 26], ["acanthocytosis", 27], ["are", 42], ["classified", 46], ["with", 57], ["the", 62], ["so", 66], ["-", 68], ["called", 69], ["neuroacanthocytosis", 76], ["group", 96], ["of", 102], ["syndromes", 105], [".", 114], ["Both", 116], ["lead", 121], ["to", 126], ["progressive", 129], ["basal", 141], ["ganglia", 147], ["degeneration", 155], ["and", 168], ["were", 172], ["not", 177], ["easily", 181], ["distinguished", 188], ["in", 202], ["the", 205], ["past", 209], [".", 213], ["With", 215], ["the", 220], ["discovery", 224], ["of", 234], ["their", 237], ["molecular", 243], ["bases", 253], [",", 258], ["mutations", 260], ["of", 270], ["the", 273], ["X", 277], ["-", 278], ["linked", 279], ["gene", 286], ["XK", 291], ["and", 294], ["autosomal", 298], ["recessive", 308], ["mutations", 318], ["of", 328], ["the", 331], ["gene", 335], ["coding", 340], ["for", 347], ["chorein", 351], [",", 358], ["respectively", 360], [",", 372], ["the", 374], ["two", 378], ["phenotypes", 382], ["can", 393], ["now", 397], ["be", 401], ["differentiated", 404], ["and", 419], ["extend", 423], ["the", 430], ["diagnostic", 434], ["spectrum", 445], ["in", 454], ["patients", 457], ["presenting", 466], ["with", 477], ["chorea", 482], [".", 488], ["The", 490], ["present", 494], ["review", 502], ["compares", 509], ["the", 518], ["two", 522], ["conditions", 526], ["and", 537], ["proposes", 541], ["a", 550], ["practical", 552], ["approach", 562], ["to", 571], ["diagnosis", 574], ["and", 584], ["treatment", 588], [".", 597], ["Better", 599], ["-", 605], ["defined", 606], ["disease", 614], ["concepts", 622], ["should", 631], ["eventually", 638], ["replace", 649], ["the", 657], ["umbrella", 661], ["term", 670], ["of", 675], ["\"", 678], ["neuroacanthocytosis", 679], [".", 698], ["\"", 699], ["Animal", 701], ["models", 708], ["are", 715], ["needed", 719], ["to", 726], ["understand", 729], ["the", 740], ["underlying", 744], ["mechanisms", 755], [".", 765], ["A", 767], ["final", 769], ["common", 775], ["pathway", 782], ["is", 790], ["likely", 793], ["for", 800], ["the", 804], ["pathogenesis", 808], ["of", 821], ["these", 824], ["conditions", 830], ["and", 841], ["is", 845], ["most", 848], ["probably", 853], ["shared", 862], ["with", 869], ["Huntington", 874], ["'s", 884], ["disease", 887], [".", 894]]}
{"context": "It is unanimously accepted that there is an unmet need for pain medications that are both effective and safe. Unfortunately, no really novel analgesics have been approved over the past three decades. In view of both experimental and clinical evidence of a major role for nerve growth factor (NGF) in the generation and maintenance of a wide range of pain states, drug discovery efforts focusing on the development of anti-NGF agents have aroused particular interest. Several humanized anti-NGF monoclonal antibodies (mAbs) have entered clinical trials as potential analgesics. In this respect, tanezumab is at an advanced stage of clinical development while fulranumab, fasinumab and ABT-110, previously known as PG110, are in early phases of clinical development. This Current Opinion article aims at describing the rationale for targeting NGF for pain, reviewing the analgesic efficacy and safety of anti-NGF agents based on data from fully published studies, conference abstracts, and the US Food and Drug Administration (FDA) website, and discussing the possible future of these agents in managing chronic pain. Anti-NGF mAbs produced significant pain relief and functional improvement in patients with osteoarthritis of the knee and/or hip. Conversely, studies in non-specific lower back pain generated mixed results; overall, this condition appeared to be less responsive to anti-NGF agents than osteoarthritis. Finally, there was no conclusive evidence of the effectiveness of anti-NGF mAbs in some types of chronic visceral or neuropathic pain. Furthermore, these studies raised safety concerns about anti-NGF mAbs. As a class, these drugs may cause or worsen peripheral neuropathies. But the most problematic issue-which prompted the FDA to place studies of these compounds on clinical hold in 2010-was rapid joint destruction leading to joint replacement surgery. The aetiologies of these side effects have been much debated and their pathophysiology is poorly understood. After an Arthritis Advisory Committee meeting held in March 2012, pharmaceutical companies negotiated with the FDA on the conditions for restarting clinical studies. Although the FDA lifted its clinical hold, there remain many unresolved issues about the long-term efficacy and safety of anti-NGF mAbs. While acknowledging that the future of these drugs is unforeseeable, it appears that they may not be the safe and effective painkillers that have been awaited for decades.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "9345b19e2b08406092884e3a093f3bd3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[48, 50]], "char_spans": [[271, 289]]}, {"text": "NGF", "token_spans": [[77, 77], [262, 262], [52, 52], [244, 244], [199, 199], [284, 284], [396, 396], [88, 88], [146, 146], [159, 159]], "char_spans": [[422, 424], [1489, 1491], [292, 294], [1386, 1388], [1121, 1123], [1614, 1616], [2276, 2278], [490, 492], [841, 843], [907, 909]]}]}], "context_tokens": [["It", 0], ["is", 3], ["unanimously", 6], ["accepted", 18], ["that", 27], ["there", 32], ["is", 38], ["an", 41], ["unmet", 44], ["need", 50], ["for", 55], ["pain", 59], ["medications", 64], ["that", 76], ["are", 81], ["both", 85], ["effective", 90], ["and", 100], ["safe", 104], [".", 108], ["Unfortunately", 110], [",", 123], ["no", 125], ["really", 128], ["novel", 135], ["analgesics", 141], ["have", 152], ["been", 157], ["approved", 162], ["over", 171], ["the", 176], ["past", 180], ["three", 185], ["decades", 191], [".", 198], ["In", 200], ["view", 203], ["of", 208], ["both", 211], ["experimental", 216], ["and", 229], ["clinical", 233], ["evidence", 242], ["of", 251], ["a", 254], ["major", 256], ["role", 262], ["for", 267], ["nerve", 271], ["growth", 277], ["factor", 284], ["(", 291], ["NGF", 292], [")", 295], ["in", 297], ["the", 300], ["generation", 304], ["and", 315], ["maintenance", 319], ["of", 331], ["a", 334], ["wide", 336], ["range", 341], ["of", 347], ["pain", 350], ["states", 355], [",", 361], ["drug", 363], ["discovery", 368], ["efforts", 378], ["focusing", 386], ["on", 395], ["the", 398], ["development", 402], ["of", 414], ["anti", 417], ["-", 421], ["NGF", 422], ["agents", 426], ["have", 433], ["aroused", 438], ["particular", 446], ["interest", 457], [".", 465], ["Several", 467], ["humanized", 475], ["anti", 485], ["-", 489], ["NGF", 490], ["monoclonal", 494], ["antibodies", 505], ["(", 516], ["mAbs", 517], [")", 521], ["have", 523], ["entered", 528], ["clinical", 536], ["trials", 545], ["as", 552], ["potential", 555], ["analgesics", 565], [".", 575], ["In", 577], ["this", 580], ["respect", 585], [",", 592], ["tanezumab", 594], ["is", 604], ["at", 607], ["an", 610], ["advanced", 613], ["stage", 622], ["of", 628], ["clinical", 631], ["development", 640], ["while", 652], ["fulranumab", 658], [",", 668], ["fasinumab", 670], ["and", 680], ["ABT-110", 684], [",", 691], ["previously", 693], ["known", 704], ["as", 710], ["PG110", 713], [",", 718], ["are", 720], ["in", 724], ["early", 727], ["phases", 733], ["of", 740], ["clinical", 743], ["development", 752], [".", 763], ["This", 765], ["Current", 770], ["Opinion", 778], ["article", 786], ["aims", 794], ["at", 799], ["describing", 802], ["the", 813], ["rationale", 817], ["for", 827], ["targeting", 831], ["NGF", 841], ["for", 845], ["pain", 849], [",", 853], ["reviewing", 855], ["the", 865], ["analgesic", 869], ["efficacy", 879], ["and", 888], ["safety", 892], ["of", 899], ["anti", 902], ["-", 906], ["NGF", 907], ["agents", 911], ["based", 918], ["on", 924], ["data", 927], ["from", 932], ["fully", 937], ["published", 943], ["studies", 953], [",", 960], ["conference", 962], ["abstracts", 973], [",", 982], ["and", 984], ["the", 988], ["US", 992], ["Food", 995], ["and", 1000], ["Drug", 1004], ["Administration", 1009], ["(", 1024], ["FDA", 1025], [")", 1028], ["website", 1030], [",", 1037], ["and", 1039], ["discussing", 1043], ["the", 1054], ["possible", 1058], ["future", 1067], ["of", 1074], ["these", 1077], ["agents", 1083], ["in", 1090], ["managing", 1093], ["chronic", 1102], ["pain", 1110], [".", 1114], ["Anti", 1116], ["-", 1120], ["NGF", 1121], ["mAbs", 1125], ["produced", 1130], ["significant", 1139], ["pain", 1151], ["relief", 1156], ["and", 1163], ["functional", 1167], ["improvement", 1178], ["in", 1190], ["patients", 1193], ["with", 1202], ["osteoarthritis", 1207], ["of", 1222], ["the", 1225], ["knee", 1229], ["and/or", 1234], ["hip", 1241], [".", 1244], ["Conversely", 1246], [",", 1256], ["studies", 1258], ["in", 1266], ["non", 1269], ["-", 1272], ["specific", 1273], ["lower", 1282], ["back", 1288], ["pain", 1293], ["generated", 1298], ["mixed", 1308], ["results", 1314], [";", 1321], ["overall", 1323], [",", 1330], ["this", 1332], ["condition", 1337], ["appeared", 1347], ["to", 1356], ["be", 1359], ["less", 1362], ["responsive", 1367], ["to", 1378], ["anti", 1381], ["-", 1385], ["NGF", 1386], ["agents", 1390], ["than", 1397], ["osteoarthritis", 1402], [".", 1416], ["Finally", 1418], [",", 1425], ["there", 1427], ["was", 1433], ["no", 1437], ["conclusive", 1440], ["evidence", 1451], ["of", 1460], ["the", 1463], ["effectiveness", 1467], ["of", 1481], ["anti", 1484], ["-", 1488], ["NGF", 1489], ["mAbs", 1493], ["in", 1498], ["some", 1501], ["types", 1506], ["of", 1512], ["chronic", 1515], ["visceral", 1523], ["or", 1532], ["neuropathic", 1535], ["pain", 1547], [".", 1551], ["Furthermore", 1553], [",", 1564], ["these", 1566], ["studies", 1572], ["raised", 1580], ["safety", 1587], ["concerns", 1594], ["about", 1603], ["anti", 1609], ["-", 1613], ["NGF", 1614], ["mAbs", 1618], [".", 1622], ["As", 1624], ["a", 1627], ["class", 1629], [",", 1634], ["these", 1636], ["drugs", 1642], ["may", 1648], ["cause", 1652], ["or", 1658], ["worsen", 1661], ["peripheral", 1668], ["neuropathies", 1679], [".", 1691], ["But", 1693], ["the", 1697], ["most", 1701], ["problematic", 1706], ["issue", 1718], ["-", 1723], ["which", 1724], ["prompted", 1730], ["the", 1739], ["FDA", 1743], ["to", 1747], ["place", 1750], ["studies", 1756], ["of", 1764], ["these", 1767], ["compounds", 1773], ["on", 1783], ["clinical", 1786], ["hold", 1795], ["in", 1800], ["2010-was", 1803], ["rapid", 1812], ["joint", 1818], ["destruction", 1824], ["leading", 1836], ["to", 1844], ["joint", 1847], ["replacement", 1853], ["surgery", 1865], [".", 1872], ["The", 1874], ["aetiologies", 1878], ["of", 1890], ["these", 1893], ["side", 1899], ["effects", 1904], ["have", 1912], ["been", 1917], ["much", 1922], ["debated", 1927], ["and", 1935], ["their", 1939], ["pathophysiology", 1945], ["is", 1961], ["poorly", 1964], ["understood", 1971], [".", 1981], ["After", 1983], ["an", 1989], ["Arthritis", 1992], ["Advisory", 2002], ["Committee", 2011], ["meeting", 2021], ["held", 2029], ["in", 2034], ["March", 2037], ["2012", 2043], [",", 2047], ["pharmaceutical", 2049], ["companies", 2064], ["negotiated", 2074], ["with", 2085], ["the", 2090], ["FDA", 2094], ["on", 2098], ["the", 2101], ["conditions", 2105], ["for", 2116], ["restarting", 2120], ["clinical", 2131], ["studies", 2140], [".", 2147], ["Although", 2149], ["the", 2158], ["FDA", 2162], ["lifted", 2166], ["its", 2173], ["clinical", 2177], ["hold", 2186], [",", 2190], ["there", 2192], ["remain", 2198], ["many", 2205], ["unresolved", 2210], ["issues", 2221], ["about", 2228], ["the", 2234], ["long", 2238], ["-", 2242], ["term", 2243], ["efficacy", 2248], ["and", 2257], ["safety", 2261], ["of", 2268], ["anti", 2271], ["-", 2275], ["NGF", 2276], ["mAbs", 2280], [".", 2284], ["While", 2286], ["acknowledging", 2292], ["that", 2306], ["the", 2311], ["future", 2315], ["of", 2322], ["these", 2325], ["drugs", 2331], ["is", 2337], ["unforeseeable", 2340], [",", 2353], ["it", 2355], ["appears", 2358], ["that", 2366], ["they", 2371], ["may", 2376], ["not", 2380], ["be", 2384], ["the", 2387], ["safe", 2391], ["and", 2396], ["effective", 2400], ["painkillers", 2410], ["that", 2422], ["have", 2427], ["been", 2432], ["awaited", 2437], ["for", 2445], ["decades", 2449], [".", 2456]]}
{"context": "Susceptibility to autoimmune disorders results from the interaction of multiple genetic factors that regulate the threshold of autoreactivity. Genome-wide microsatellite screens and large-scale single nucleotide polymorphism (SNP) association studies have identified chromosomal loci that are associated with specific disorders including systemic lupus erythematosus, rheumatoid arthritis, juvenile arthritis, multiple sclerosis, and diabetes. Numerous candidate gene association studies have in turn investigated the association of specific genes within these chromosomal regions, with susceptibility to autoimmune diseases (e.g. FcgammaReceptors, TYK2 and systemic lupus). More recently, large-scale differential gene expression studies performed on selected tissues from patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature in lupus). In the future, integrated analyses of gene (and protein) expression together with SNP data will allow us to sketch an intelligible picture of the genesis of autoimmunity in humans. This review sets out to illustrate how the most recent advances in the field of systemic lupus erythematosus, rheumatoid arthritis and juvenile arthritis have led to a better understanding of these disorders.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "b57e6d932c6f403896f80cdbf5c54bf9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "Interferon signature", "token_spans": [[137, 138]], "char_spans": [[936, 955]]}]}], "context_tokens": [["Susceptibility", 0], ["to", 15], ["autoimmune", 18], ["disorders", 29], ["results", 39], ["from", 47], ["the", 52], ["interaction", 56], ["of", 68], ["multiple", 71], ["genetic", 80], ["factors", 88], ["that", 96], ["regulate", 101], ["the", 110], ["threshold", 114], ["of", 124], ["autoreactivity", 127], [".", 141], ["Genome", 143], ["-", 149], ["wide", 150], ["microsatellite", 155], ["screens", 170], ["and", 178], ["large", 182], ["-", 187], ["scale", 188], ["single", 194], ["nucleotide", 201], ["polymorphism", 212], ["(", 225], ["SNP", 226], [")", 229], ["association", 231], ["studies", 243], ["have", 251], ["identified", 256], ["chromosomal", 267], ["loci", 279], ["that", 284], ["are", 289], ["associated", 293], ["with", 304], ["specific", 309], ["disorders", 318], ["including", 328], ["systemic", 338], ["lupus", 347], ["erythematosus", 353], [",", 366], ["rheumatoid", 368], ["arthritis", 379], [",", 388], ["juvenile", 390], ["arthritis", 399], [",", 408], ["multiple", 410], ["sclerosis", 419], [",", 428], ["and", 430], ["diabetes", 434], [".", 442], ["Numerous", 444], ["candidate", 453], ["gene", 463], ["association", 468], ["studies", 480], ["have", 488], ["in", 493], ["turn", 496], ["investigated", 501], ["the", 514], ["association", 518], ["of", 530], ["specific", 533], ["genes", 542], ["within", 548], ["these", 555], ["chromosomal", 561], ["regions", 573], [",", 580], ["with", 582], ["susceptibility", 587], ["to", 602], ["autoimmune", 605], ["diseases", 616], ["(", 625], ["e.g.", 626], ["FcgammaReceptors", 631], [",", 647], ["TYK2", 649], ["and", 654], ["systemic", 658], ["lupus", 667], [")", 672], [".", 673], ["More", 675], ["recently", 680], [",", 688], ["large", 690], ["-", 695], ["scale", 696], ["differential", 702], ["gene", 715], ["expression", 720], ["studies", 731], ["performed", 739], ["on", 749], ["selected", 752], ["tissues", 761], ["from", 769], ["patients", 774], ["with", 783], ["autoimmune", 788], ["disorders", 799], [",", 808], ["have", 810], ["led", 815], ["to", 819], ["the", 822], ["identification", 826], ["of", 841], ["gene", 844], ["signatures", 849], ["associated", 860], ["with", 871], ["the", 876], ["activation", 880], ["of", 891], ["specific", 894], ["pathways", 903], ["in", 912], ["these", 915], ["diseases", 921], ["(", 930], ["e.g.", 931], ["interferon", 936], ["signature", 947], ["in", 957], ["lupus", 960], [")", 965], [".", 966], ["In", 968], ["the", 971], ["future", 975], [",", 981], ["integrated", 983], ["analyses", 994], ["of", 1003], ["gene", 1006], ["(", 1011], ["and", 1012], ["protein", 1016], [")", 1023], ["expression", 1025], ["together", 1036], ["with", 1045], ["SNP", 1050], ["data", 1054], ["will", 1059], ["allow", 1064], ["us", 1070], ["to", 1073], ["sketch", 1076], ["an", 1083], ["intelligible", 1086], ["picture", 1099], ["of", 1107], ["the", 1110], ["genesis", 1114], ["of", 1122], ["autoimmunity", 1125], ["in", 1138], ["humans", 1141], [".", 1147], ["This", 1149], ["review", 1154], ["sets", 1161], ["out", 1166], ["to", 1170], ["illustrate", 1173], ["how", 1184], ["the", 1188], ["most", 1192], ["recent", 1197], ["advances", 1204], ["in", 1213], ["the", 1216], ["field", 1220], ["of", 1226], ["systemic", 1229], ["lupus", 1238], ["erythematosus", 1244], [",", 1257], ["rheumatoid", 1259], ["arthritis", 1270], ["and", 1280], ["juvenile", 1284], ["arthritis", 1293], ["have", 1303], ["led", 1308], ["to", 1312], ["a", 1315], ["better", 1317], ["understanding", 1324], ["of", 1338], ["these", 1341], ["disorders", 1347], [".", 1356]]}
{"context": "To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent. A literature search was conducted consisting of a PubMed database using the MeSH term idarucizumab and the key word dabigatran antidote. Studies evaluating the pharmacology, pharmacokinetics, safety, and efficacy of idarucizumab for the reversal of the anticoagulant activity of dabigatran were included. Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran. Studies evaluating reversal of dabigatran-induced anticoagulation have demonstrated immediate, complete, and sustained effects with idarucizumab. Idarucizumab did not overcorrect thrombin generation. Additionally, evaluations have shown that dabigatran can be safely reinitiated 24 hours after the administration of idarucizumab. The United States Food and Drug Administration granted priority review for the biologic license application and accelerated approval for idarucizumab. Idarucizumab represents an encouraging development in the reversal of dabigatran. Its novel mechanism of action, pharmacokinetics, tolerability, and lack of thrombotic events contribute positively to its use in patients who experience bleeding or for those who require emergent surgery or procedures.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "ef28a6cc8b5d472b98e489b35d514e0b", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[186, 186], [108, 108], [60, 60], [84, 84], [23, 23], [114, 114], [143, 143]], "char_spans": [[1252, 1261], [689, 698], [366, 375], [529, 538], [143, 152], [732, 741], [943, 952]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["role", 16], ["of", 21], ["idarucizumab", 24], [",", 36], ["a", 38], ["humanized", 40], ["monoclonal", 50], ["antibody", 61], ["fragment", 70], [",", 78], ["as", 80], ["a", 83], ["specific", 85], ["reversal", 94], ["agent", 103], ["for", 109], ["the", 113], ["anticoagulant", 117], ["activity", 131], ["of", 140], ["dabigatran", 143], ["and", 154], ["to", 158], ["review", 161], ["the", 168], ["pharmacology", 172], [",", 184], ["pharmacokinetic", 186], ["properties", 202], [",", 212], ["efficacy", 214], [",", 222], ["and", 224], ["safety", 228], ["of", 235], ["this", 238], ["agent", 243], [".", 248], ["A", 250], ["literature", 252], ["search", 263], ["was", 270], ["conducted", 274], ["consisting", 284], ["of", 295], ["a", 298], ["PubMed", 300], ["database", 307], ["using", 316], ["the", 322], ["MeSH", 326], ["term", 331], ["idarucizumab", 336], ["and", 349], ["the", 353], ["key", 357], ["word", 361], ["dabigatran", 366], ["antidote", 377], [".", 385], ["Studies", 387], ["evaluating", 395], ["the", 406], ["pharmacology", 410], [",", 422], ["pharmacokinetics", 424], [",", 440], ["safety", 442], [",", 448], ["and", 450], ["efficacy", 454], ["of", 463], ["idarucizumab", 466], ["for", 479], ["the", 483], ["reversal", 487], ["of", 496], ["the", 499], ["anticoagulant", 503], ["activity", 517], ["of", 526], ["dabigatran", 529], ["were", 540], ["included", 545], [".", 553], ["Idarucizumab", 555], ["represents", 568], ["a", 579], ["novel", 581], ["treatment", 587], ["option", 597], ["as", 604], ["it", 607], ["is", 610], ["the", 613], ["only", 617], ["humanized", 622], [",", 631], ["monoclonal", 633], ["antibody", 644], ["fragment", 653], ["that", 662], ["specifically", 667], ["binds", 680], ["to", 686], ["dabigatran", 689], [".", 699], ["Studies", 701], ["evaluating", 709], ["reversal", 720], ["of", 729], ["dabigatran", 732], ["-", 742], ["induced", 743], ["anticoagulation", 751], ["have", 767], ["demonstrated", 772], ["immediate", 785], [",", 794], ["complete", 796], [",", 804], ["and", 806], ["sustained", 810], ["effects", 820], ["with", 828], ["idarucizumab", 833], [".", 845], ["Idarucizumab", 847], ["did", 860], ["not", 864], ["overcorrect", 868], ["thrombin", 880], ["generation", 889], [".", 899], ["Additionally", 901], [",", 913], ["evaluations", 915], ["have", 927], ["shown", 932], ["that", 938], ["dabigatran", 943], ["can", 954], ["be", 958], ["safely", 961], ["reinitiated", 968], ["24", 980], ["hours", 983], ["after", 989], ["the", 995], ["administration", 999], ["of", 1014], ["idarucizumab", 1017], [".", 1029], ["The", 1031], ["United", 1035], ["States", 1042], ["Food", 1049], ["and", 1054], ["Drug", 1058], ["Administration", 1063], ["granted", 1078], ["priority", 1086], ["review", 1095], ["for", 1102], ["the", 1106], ["biologic", 1110], ["license", 1119], ["application", 1127], ["and", 1139], ["accelerated", 1143], ["approval", 1155], ["for", 1164], ["idarucizumab", 1168], [".", 1180], ["Idarucizumab", 1182], ["represents", 1195], ["an", 1206], ["encouraging", 1209], ["development", 1221], ["in", 1233], ["the", 1236], ["reversal", 1240], ["of", 1249], ["dabigatran", 1252], [".", 1262], ["Its", 1264], ["novel", 1268], ["mechanism", 1274], ["of", 1284], ["action", 1287], [",", 1293], ["pharmacokinetics", 1295], [",", 1311], ["tolerability", 1313], [",", 1325], ["and", 1327], ["lack", 1331], ["of", 1336], ["thrombotic", 1339], ["events", 1350], ["contribute", 1357], ["positively", 1368], ["to", 1379], ["its", 1382], ["use", 1386], ["in", 1390], ["patients", 1393], ["who", 1402], ["experience", 1406], ["bleeding", 1417], ["or", 1426], ["for", 1429], ["those", 1433], ["who", 1439], ["require", 1443], ["emergent", 1451], ["surgery", 1460], ["or", 1468], ["procedures", 1471], [".", 1481]]}
{"context": "Erythrasma is a skin infection which is caused by Corynebacterium minutissimum. Interdigital erythrasma is the most common form. The aim of this study was to detect the frequency and risk factors of interdigital erythrasma in patients with clinically suspected tinea pedis. This study was conducted between June and December 2010 and included 122 patients who had interdigital foot lesions. All patients were examined using a Wood's lamp. The smears were stained using Gram's method. Direct examination was performed using 20% potassium hydroxide. Sabouraud dextrose agar and brain heart infusion agar were used for cultures. Moreover, the demographical characteristics of patients, concomitant diseases and clinical findings were also recorded. Cases that were found to be positive on Wood's lamp examination and/or Gram staining/culture were considered as erythrasma. The rate of erythrasma was found to be 46.7%. The mean age was 43.6 years, and the disease was more prevalent in men. The most common clinical finding was desquamation. Mycological examination was found as positive in 40.35% of the patients. No growth was observed in bacteriological cultures. It was found that using only Wood's lamp examination or Gram staining resulted in 11 (9%) and 19 positive patients (15.6%), respectively, whereas using both Wood's lamp examination and Gram staining concurrently resulted in 27 positive patients (22.1%). Interdigital erythrasma is a commonly seen condition and can clinically mimic tinea pedis. A Wood's lamp is a good diagnostic tool, but Gram staining, particularly in those with a negative Wood's lamp result, may be a useful method.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "f259dac2d37f4a20997aff4a16f394eb", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[9, 10]], "char_spans": [[50, 77]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["skin", 16], ["infection", 21], ["which", 31], ["is", 37], ["caused", 40], ["by", 47], ["Corynebacterium", 50], ["minutissimum", 66], [".", 78], ["Interdigital", 80], ["erythrasma", 93], ["is", 104], ["the", 107], ["most", 111], ["common", 116], ["form", 123], [".", 127], ["The", 129], ["aim", 133], ["of", 137], ["this", 140], ["study", 145], ["was", 151], ["to", 155], ["detect", 158], ["the", 165], ["frequency", 169], ["and", 179], ["risk", 183], ["factors", 188], ["of", 196], ["interdigital", 199], ["erythrasma", 212], ["in", 223], ["patients", 226], ["with", 235], ["clinically", 240], ["suspected", 251], ["tinea", 261], ["pedis", 267], [".", 272], ["This", 274], ["study", 279], ["was", 285], ["conducted", 289], ["between", 299], ["June", 307], ["and", 312], ["December", 316], ["2010", 325], ["and", 330], ["included", 334], ["122", 343], ["patients", 347], ["who", 356], ["had", 360], ["interdigital", 364], ["foot", 377], ["lesions", 382], [".", 389], ["All", 391], ["patients", 395], ["were", 404], ["examined", 409], ["using", 418], ["a", 424], ["Wood", 426], ["'s", 430], ["lamp", 433], [".", 437], ["The", 439], ["smears", 443], ["were", 450], ["stained", 455], ["using", 463], ["Gram", 469], ["'s", 473], ["method", 476], [".", 482], ["Direct", 484], ["examination", 491], ["was", 503], ["performed", 507], ["using", 517], ["20", 523], ["%", 525], ["potassium", 527], ["hydroxide", 537], [".", 546], ["Sabouraud", 548], ["dextrose", 558], ["agar", 567], ["and", 572], ["brain", 576], ["heart", 582], ["infusion", 588], ["agar", 597], ["were", 602], ["used", 607], ["for", 612], ["cultures", 616], [".", 624], ["Moreover", 626], [",", 634], ["the", 636], ["demographical", 640], ["characteristics", 654], ["of", 670], ["patients", 673], [",", 681], ["concomitant", 683], ["diseases", 695], ["and", 704], ["clinical", 708], ["findings", 717], ["were", 726], ["also", 731], ["recorded", 736], [".", 744], ["Cases", 746], ["that", 752], ["were", 757], ["found", 762], ["to", 768], ["be", 771], ["positive", 774], ["on", 783], ["Wood", 786], ["'s", 790], ["lamp", 793], ["examination", 798], ["and/or", 810], ["Gram", 817], ["staining", 822], ["/", 830], ["culture", 831], ["were", 839], ["considered", 844], ["as", 855], ["erythrasma", 858], [".", 868], ["The", 870], ["rate", 874], ["of", 879], ["erythrasma", 882], ["was", 893], ["found", 897], ["to", 903], ["be", 906], ["46.7", 909], ["%", 913], [".", 914], ["The", 916], ["mean", 920], ["age", 925], ["was", 929], ["43.6", 933], ["years", 938], [",", 943], ["and", 945], ["the", 949], ["disease", 953], ["was", 961], ["more", 965], ["prevalent", 970], ["in", 980], ["men", 983], [".", 986], ["The", 988], ["most", 992], ["common", 997], ["clinical", 1004], ["finding", 1013], ["was", 1021], ["desquamation", 1025], [".", 1037], ["Mycological", 1039], ["examination", 1051], ["was", 1063], ["found", 1067], ["as", 1073], ["positive", 1076], ["in", 1085], ["40.35", 1088], ["%", 1093], ["of", 1095], ["the", 1098], ["patients", 1102], [".", 1110], ["No", 1112], ["growth", 1115], ["was", 1122], ["observed", 1126], ["in", 1135], ["bacteriological", 1138], ["cultures", 1154], [".", 1162], ["It", 1164], ["was", 1167], ["found", 1171], ["that", 1177], ["using", 1182], ["only", 1188], ["Wood", 1193], ["'s", 1197], ["lamp", 1200], ["examination", 1205], ["or", 1217], ["Gram", 1220], ["staining", 1225], ["resulted", 1234], ["in", 1243], ["11", 1246], ["(", 1249], ["9", 1250], ["%", 1251], [")", 1252], ["and", 1254], ["19", 1258], ["positive", 1261], ["patients", 1270], ["(", 1279], ["15.6", 1280], ["%", 1284], [")", 1285], [",", 1286], ["respectively", 1288], [",", 1300], ["whereas", 1302], ["using", 1310], ["both", 1316], ["Wood", 1321], ["'s", 1325], ["lamp", 1328], ["examination", 1333], ["and", 1345], ["Gram", 1349], ["staining", 1354], ["concurrently", 1363], ["resulted", 1376], ["in", 1385], ["27", 1388], ["positive", 1391], ["patients", 1400], ["(", 1409], ["22.1", 1410], ["%", 1414], [")", 1415], [".", 1416], ["Interdigital", 1418], ["erythrasma", 1431], ["is", 1442], ["a", 1445], ["commonly", 1447], ["seen", 1456], ["condition", 1461], ["and", 1471], ["can", 1475], ["clinically", 1479], ["mimic", 1490], ["tinea", 1496], ["pedis", 1502], [".", 1507], ["A", 1509], ["Wood", 1511], ["'s", 1515], ["lamp", 1518], ["is", 1523], ["a", 1526], ["good", 1528], ["diagnostic", 1533], ["tool", 1544], [",", 1548], ["but", 1550], ["Gram", 1554], ["staining", 1559], [",", 1567], ["particularly", 1569], ["in", 1582], ["those", 1585], ["with", 1591], ["a", 1596], ["negative", 1598], ["Wood", 1607], ["'s", 1611], ["lamp", 1614], ["result", 1619], [",", 1625], ["may", 1627], ["be", 1631], ["a", 1634], ["useful", 1636], ["method", 1643], [".", 1649]]}
{"context": "Defects in DNA mismatch repair have been associated with both hereditary and sporadic forms of cancer. Recently, it has been shown that human cell lines deficient in mismatch repair were also defective in the transcription-coupled repair (TCR) of UV-induced DNA damage. We examined whether TCR of ionizing radiation-induced DNA damage also requires the genes involved in DNA mismatch repair. Cells defective in the hMSH2 gene were deficient in the removal of oxidative damage, including thymine glycols, from the transcribed strand of an active gene. However, an hMLH1 mutant showed normal levels of TCR. By comparison, defects in either hMSH2 or hMLH1 resulted in reduced TCR of UV damage. Introducing chromosomes carrying either hMSH2 or hMLH1 into these cell lines restored their ability to carry out TCR. Deficiencies in either hMSH2 or hMLH1 did not result in decreased overall genomic levels of repair or lead to an increased sensitivity to either UV or ionizing radiation. Our results provide the first evidence for a protein that is absolutely required for the preferential removal of UV-induced DNA damage but not oxidative DNA damage from the transcribed strand of an active human gene.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "10f594ced5e64fcfaf6ab93cda76d0f5", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[92, 93], [205, 206]], "char_spans": [[513, 530], [1153, 1170]]}]}], "context_tokens": [["Defects", 0], ["in", 8], ["DNA", 11], ["mismatch", 15], ["repair", 24], ["have", 31], ["been", 36], ["associated", 41], ["with", 52], ["both", 57], ["hereditary", 62], ["and", 73], ["sporadic", 77], ["forms", 86], ["of", 92], ["cancer", 95], [".", 101], ["Recently", 103], [",", 111], ["it", 113], ["has", 116], ["been", 120], ["shown", 125], ["that", 131], ["human", 136], ["cell", 142], ["lines", 147], ["deficient", 153], ["in", 163], ["mismatch", 166], ["repair", 175], ["were", 182], ["also", 187], ["defective", 192], ["in", 202], ["the", 205], ["transcription", 209], ["-", 222], ["coupled", 223], ["repair", 231], ["(", 238], ["TCR", 239], [")", 242], ["of", 244], ["UV", 247], ["-", 249], ["induced", 250], ["DNA", 258], ["damage", 262], [".", 268], ["We", 270], ["examined", 273], ["whether", 282], ["TCR", 290], ["of", 294], ["ionizing", 297], ["radiation", 306], ["-", 315], ["induced", 316], ["DNA", 324], ["damage", 328], ["also", 335], ["requires", 340], ["the", 349], ["genes", 353], ["involved", 359], ["in", 368], ["DNA", 371], ["mismatch", 375], ["repair", 384], [".", 390], ["Cells", 392], ["defective", 398], ["in", 408], ["the", 411], ["hMSH2", 415], ["gene", 421], ["were", 426], ["deficient", 431], ["in", 441], ["the", 444], ["removal", 448], ["of", 456], ["oxidative", 459], ["damage", 469], [",", 475], ["including", 477], ["thymine", 487], ["glycols", 495], [",", 502], ["from", 504], ["the", 509], ["transcribed", 513], ["strand", 525], ["of", 532], ["an", 535], ["active", 538], ["gene", 545], [".", 549], ["However", 551], [",", 558], ["an", 560], ["hMLH1", 563], ["mutant", 569], ["showed", 576], ["normal", 583], ["levels", 590], ["of", 597], ["TCR", 600], [".", 603], ["By", 605], ["comparison", 608], [",", 618], ["defects", 620], ["in", 628], ["either", 631], ["hMSH2", 638], ["or", 644], ["hMLH1", 647], ["resulted", 653], ["in", 662], ["reduced", 665], ["TCR", 673], ["of", 677], ["UV", 680], ["damage", 683], [".", 689], ["Introducing", 691], ["chromosomes", 703], ["carrying", 715], ["either", 724], ["hMSH2", 731], ["or", 737], ["hMLH1", 740], ["into", 746], ["these", 751], ["cell", 757], ["lines", 762], ["restored", 768], ["their", 777], ["ability", 783], ["to", 791], ["carry", 794], ["out", 800], ["TCR", 804], [".", 807], ["Deficiencies", 809], ["in", 822], ["either", 825], ["hMSH2", 832], ["or", 838], ["hMLH1", 841], ["did", 847], ["not", 851], ["result", 855], ["in", 862], ["decreased", 865], ["overall", 875], ["genomic", 883], ["levels", 891], ["of", 898], ["repair", 901], ["or", 908], ["lead", 911], ["to", 916], ["an", 919], ["increased", 922], ["sensitivity", 932], ["to", 944], ["either", 947], ["UV", 954], ["or", 957], ["ionizing", 960], ["radiation", 969], [".", 978], ["Our", 980], ["results", 984], ["provide", 992], ["the", 1000], ["first", 1004], ["evidence", 1010], ["for", 1019], ["a", 1023], ["protein", 1025], ["that", 1033], ["is", 1038], ["absolutely", 1041], ["required", 1052], ["for", 1061], ["the", 1065], ["preferential", 1069], ["removal", 1082], ["of", 1090], ["UV", 1093], ["-", 1095], ["induced", 1096], ["DNA", 1104], ["damage", 1108], ["but", 1115], ["not", 1119], ["oxidative", 1123], ["DNA", 1133], ["damage", 1137], ["from", 1144], ["the", 1149], ["transcribed", 1153], ["strand", 1165], ["of", 1172], ["an", 1175], ["active", 1178], ["human", 1185], ["gene", 1191], [".", 1195]]}
{"context": "Posterior cruciate ligament (PCL) injuries have a reported incidence of between 3 and 37%, depending on the clinical setting. The most common mechanism of injury in motor vehicle accidents is a dashboard injury or direct force to the proximal anterior tibia. Sports related injuries result from hyperflexion of the knee with the foot typically plantarflexed. The latter mechanism is the most common cause of isolated PCL injuries, while in the trauma population as many as 95% of patients with knee injuries have combined ligamentous damage. Improved knowledge at an anatomical, biomechanical and clinical level has provided the orthopaedist with a more defined treatment algorithm. Isolated, partial PCL injuries (grades I and II) can best be treated nonoperatively while complete injuries (grade III) may require operative treatment based on clinical symptoms. All combined ligamentous injuries usually respond best with surgical management.", "qas": [{"question": "Which ligament is most commonly injured in dashboard injury?", "answers": ["Posterior cruciate ligament"], "qid": "39e074f0b0694efe8d9c2907bb62096b", "question_tokens": [["Which", 0], ["ligament", 6], ["is", 15], ["most", 18], ["commonly", 23], ["injured", 32], ["in", 40], ["dashboard", 43], ["injury", 53], ["?", 59]], "detected_answers": [{"text": "Posterior cruciate ligament", "token_spans": [[0, 2]], "char_spans": [[0, 26]]}]}], "context_tokens": [["Posterior", 0], ["cruciate", 10], ["ligament", 19], ["(", 28], ["PCL", 29], [")", 32], ["injuries", 34], ["have", 43], ["a", 48], ["reported", 50], ["incidence", 59], ["of", 69], ["between", 72], ["3", 80], ["and", 82], ["37", 86], ["%", 88], [",", 89], ["depending", 91], ["on", 101], ["the", 104], ["clinical", 108], ["setting", 117], [".", 124], ["The", 126], ["most", 130], ["common", 135], ["mechanism", 142], ["of", 152], ["injury", 155], ["in", 162], ["motor", 165], ["vehicle", 171], ["accidents", 179], ["is", 189], ["a", 192], ["dashboard", 194], ["injury", 204], ["or", 211], ["direct", 214], ["force", 221], ["to", 227], ["the", 230], ["proximal", 234], ["anterior", 243], ["tibia", 252], [".", 257], ["Sports", 259], ["related", 266], ["injuries", 274], ["result", 283], ["from", 290], ["hyperflexion", 295], ["of", 308], ["the", 311], ["knee", 315], ["with", 320], ["the", 325], ["foot", 329], ["typically", 334], ["plantarflexed", 344], [".", 357], ["The", 359], ["latter", 363], ["mechanism", 370], ["is", 380], ["the", 383], ["most", 387], ["common", 392], ["cause", 399], ["of", 405], ["isolated", 408], ["PCL", 417], ["injuries", 421], [",", 429], ["while", 431], ["in", 437], ["the", 440], ["trauma", 444], ["population", 451], ["as", 462], ["many", 465], ["as", 470], ["95", 473], ["%", 475], ["of", 477], ["patients", 480], ["with", 489], ["knee", 494], ["injuries", 499], ["have", 508], ["combined", 513], ["ligamentous", 522], ["damage", 534], [".", 540], ["Improved", 542], ["knowledge", 551], ["at", 561], ["an", 564], ["anatomical", 567], [",", 577], ["biomechanical", 579], ["and", 593], ["clinical", 597], ["level", 606], ["has", 612], ["provided", 616], ["the", 625], ["orthopaedist", 629], ["with", 642], ["a", 647], ["more", 649], ["defined", 654], ["treatment", 662], ["algorithm", 672], [".", 681], ["Isolated", 683], [",", 691], ["partial", 693], ["PCL", 701], ["injuries", 705], ["(", 714], ["grades", 715], ["I", 722], ["and", 724], ["II", 728], [")", 730], ["can", 732], ["best", 736], ["be", 741], ["treated", 744], ["nonoperatively", 752], ["while", 767], ["complete", 773], ["injuries", 782], ["(", 791], ["grade", 792], ["III", 798], [")", 801], ["may", 803], ["require", 807], ["operative", 815], ["treatment", 825], ["based", 835], ["on", 841], ["clinical", 844], ["symptoms", 853], [".", 861], ["All", 863], ["combined", 867], ["ligamentous", 876], ["injuries", 888], ["usually", 897], ["respond", 905], ["best", 913], ["with", 918], ["surgical", 923], ["management", 932], [".", 942]]}
{"context": "We generated a genome-wide replication profile in the genome of Lachancea kluyveri and assessed the relationship between replication and base composition. This species diverged from Saccharomyces cerevisiae before the ancestral whole genome duplication. The genome comprises eight chromosomes among which a chromosomal arm of 1 Mb has a G + C-content much higher than the rest of the genome. We identified 252 active replication origins in L. kluyveri and found considerable divergence in origin location with S. cerevisiae and with Lachancea waltii. Although some global features of S. cerevisiae replication are conserved: Centromeres replicate early, whereas telomeres replicate late, we found that replication origins both in L. kluyveri and L. waltii do not behave as evolutionary fragile sites. In L. kluyveri, replication timing along chromosomes alternates between regions of early and late activating origins, except for the 1 Mb GC-rich chromosomal arm. This chromosomal arm contains an origin consensus motif different from other chromosomes and is replicated early during S-phase. We showed that precocious replication results from the specific absence of late firing origins in this chromosomal arm. In addition, we found a correlation between GC-content and distance from replication origins as well as a lack of replication-associated compositional skew between leading and lagging strands specifically in this GC-rich chromosomal arm. These findings suggest that the unusual base composition in the genome of L. kluyveri could be linked to replication.", "qas": [{"question": "Do origins of replication close to yeast centromeres fire early or late?", "answers": ["Early"], "qid": "d8b6714eca6845d68ff4a83b405e4a77", "question_tokens": [["Do", 0], ["origins", 3], ["of", 11], ["replication", 14], ["close", 26], ["to", 32], ["yeast", 35], ["centromeres", 41], ["fire", 53], ["early", 58], ["or", 64], ["late", 67], ["?", 71]], "detected_answers": [{"text": "Early", "token_spans": [[174, 174], [103, 103], [142, 142]], "char_spans": [[1071, 1075], [647, 651], [884, 888]]}]}], "context_tokens": [["We", 0], ["generated", 3], ["a", 13], ["genome", 15], ["-", 21], ["wide", 22], ["replication", 27], ["profile", 39], ["in", 47], ["the", 50], ["genome", 54], ["of", 61], ["Lachancea", 64], ["kluyveri", 74], ["and", 83], ["assessed", 87], ["the", 96], ["relationship", 100], ["between", 113], ["replication", 121], ["and", 133], ["base", 137], ["composition", 142], [".", 153], ["This", 155], ["species", 160], ["diverged", 168], ["from", 177], ["Saccharomyces", 182], ["cerevisiae", 196], ["before", 207], ["the", 214], ["ancestral", 218], ["whole", 228], ["genome", 234], ["duplication", 241], [".", 252], ["The", 254], ["genome", 258], ["comprises", 265], ["eight", 275], ["chromosomes", 281], ["among", 293], ["which", 299], ["a", 305], ["chromosomal", 307], ["arm", 319], ["of", 323], ["1", 326], ["Mb", 328], ["has", 331], ["a", 335], ["G", 337], ["+", 339], ["C", 341], ["-", 342], ["content", 343], ["much", 351], ["higher", 356], ["than", 363], ["the", 368], ["rest", 372], ["of", 377], ["the", 380], ["genome", 384], [".", 390], ["We", 392], ["identified", 395], ["252", 406], ["active", 410], ["replication", 417], ["origins", 429], ["in", 437], ["L.", 440], ["kluyveri", 443], ["and", 452], ["found", 456], ["considerable", 462], ["divergence", 475], ["in", 486], ["origin", 489], ["location", 496], ["with", 505], ["S.", 510], ["cerevisiae", 513], ["and", 524], ["with", 528], ["Lachancea", 533], ["waltii", 543], [".", 549], ["Although", 551], ["some", 560], ["global", 565], ["features", 572], ["of", 581], ["S.", 584], ["cerevisiae", 587], ["replication", 598], ["are", 610], ["conserved", 614], [":", 623], ["Centromeres", 625], ["replicate", 637], ["early", 647], [",", 652], ["whereas", 654], ["telomeres", 662], ["replicate", 672], ["late", 682], [",", 686], ["we", 688], ["found", 691], ["that", 697], ["replication", 702], ["origins", 714], ["both", 722], ["in", 727], ["L.", 730], ["kluyveri", 733], ["and", 742], ["L.", 746], ["waltii", 749], ["do", 756], ["not", 759], ["behave", 763], ["as", 770], ["evolutionary", 773], ["fragile", 786], ["sites", 794], [".", 799], ["In", 801], ["L.", 804], ["kluyveri", 807], [",", 815], ["replication", 817], ["timing", 829], ["along", 836], ["chromosomes", 842], ["alternates", 854], ["between", 865], ["regions", 873], ["of", 881], ["early", 884], ["and", 890], ["late", 894], ["activating", 899], ["origins", 910], [",", 917], ["except", 919], ["for", 926], ["the", 930], ["1", 934], ["Mb", 936], ["GC", 939], ["-", 941], ["rich", 942], ["chromosomal", 947], ["arm", 959], [".", 962], ["This", 964], ["chromosomal", 969], ["arm", 981], ["contains", 985], ["an", 994], ["origin", 997], ["consensus", 1004], ["motif", 1014], ["different", 1020], ["from", 1030], ["other", 1035], ["chromosomes", 1041], ["and", 1053], ["is", 1057], ["replicated", 1060], ["early", 1071], ["during", 1077], ["S", 1084], ["-", 1085], ["phase", 1086], [".", 1091], ["We", 1093], ["showed", 1096], ["that", 1103], ["precocious", 1108], ["replication", 1119], ["results", 1131], ["from", 1139], ["the", 1144], ["specific", 1148], ["absence", 1157], ["of", 1165], ["late", 1168], ["firing", 1173], ["origins", 1180], ["in", 1188], ["this", 1191], ["chromosomal", 1196], ["arm", 1208], [".", 1211], ["In", 1213], ["addition", 1216], [",", 1224], ["we", 1226], ["found", 1229], ["a", 1235], ["correlation", 1237], ["between", 1249], ["GC", 1257], ["-", 1259], ["content", 1260], ["and", 1268], ["distance", 1272], ["from", 1281], ["replication", 1286], ["origins", 1298], ["as", 1306], ["well", 1309], ["as", 1314], ["a", 1317], ["lack", 1319], ["of", 1324], ["replication", 1327], ["-", 1338], ["associated", 1339], ["compositional", 1350], ["skew", 1364], ["between", 1369], ["leading", 1377], ["and", 1385], ["lagging", 1389], ["strands", 1397], ["specifically", 1405], ["in", 1418], ["this", 1421], ["GC", 1426], ["-", 1428], ["rich", 1429], ["chromosomal", 1434], ["arm", 1446], [".", 1449], ["These", 1451], ["findings", 1457], ["suggest", 1466], ["that", 1474], ["the", 1479], ["unusual", 1483], ["base", 1491], ["composition", 1496], ["in", 1508], ["the", 1511], ["genome", 1515], ["of", 1522], ["L.", 1525], ["kluyveri", 1528], ["could", 1537], ["be", 1543], ["linked", 1546], ["to", 1553], ["replication", 1556], [".", 1567]]}
{"context": "\u03b1-Synuclein is the major pathological component of synucleinopathies including Parkinson's disease and dementia with Lewy bodies. Recent studies have demonstrated that \u03b1-synuclein also plays important roles in the release of synaptic vesicles and synaptic membrane recycling in healthy neurons. However, the precise relationship between the pathogenicity and physiological functions of \u03b1-synuclein remains to be elucidated. To address this issue, we investigated the subcellular localization of \u03b1-synuclein in normal and pathological conditions using primary mouse hippocampal neuronal cultures. While some neurons expressed high levels of \u03b1-synuclein in presynaptic boutons and cell bodies, other neurons either did not or only very weakly expressed the protein. These \u03b1-synuclein-negative cells were identified as inhibitory neurons by immunostaining with specific antibodies against glutamic acid decarboxylase (GAD), parvalbumin, and somatostatin. In contrast, \u03b1-synuclein-positive synapses were colocalized with the excitatory synapse marker vesicular glutamate transporter-1. This expression profile of \u03b1-synuclein was conserved in the hippocampus in vivo. In addition, we found that while presynaptic \u03b1-synuclein colocalizes with synapsin, a marker of presynaptic vesicles, it is not essential for activity-dependent membrane recycling induced by high potassium treatment. Exogenous supply of preformed fibrils generated by recombinant \u03b1-synuclein was shown to promote the formation of Lewy body (LB) -like intracellular aggregates involving endogenous \u03b1-synuclein. GAD-positive neurons did not form LB-like aggregates following treatment with preformed fibrils, however, exogenous expression of human \u03b1-synuclein allowed intracellular aggregate formation in these cells. These results suggest the presence of a different mechanism for regulation of the expression of \u03b1-synuclein between excitatory and inhibitory neurons. Furthermore, \u03b1-synuclein expression levels may determine the efficiency of intracellular aggregate formation in different neuronal subtypes.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "02aedd384e0844e18fd9364151f02926", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[195, 197], [305, 307], [176, 178], [252, 254], [316, 318], [155, 157], [77, 79], [58, 60], [232, 234], [279, 281], [25, 27], [123, 125], [0, 2], [99, 101]], "char_spans": [[1208, 1218], [1875, 1885], [1109, 1119], [1560, 1570], [1943, 1953], [965, 975], [495, 505], [386, 396], [1443, 1453], [1709, 1719], [168, 178], [770, 780], [0, 10], [640, 650]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["is", 12], ["the", 15], ["major", 19], ["pathological", 25], ["component", 38], ["of", 48], ["synucleinopathies", 51], ["including", 69], ["Parkinson", 79], ["'s", 88], ["disease", 91], ["and", 99], ["dementia", 103], ["with", 112], ["Lewy", 117], ["bodies", 122], [".", 128], ["Recent", 130], ["studies", 137], ["have", 145], ["demonstrated", 150], ["that", 163], ["\u03b1", 168], ["-", 169], ["synuclein", 170], ["also", 180], ["plays", 185], ["important", 191], ["roles", 201], ["in", 207], ["the", 210], ["release", 214], ["of", 222], ["synaptic", 225], ["vesicles", 234], ["and", 243], ["synaptic", 247], ["membrane", 256], ["recycling", 265], ["in", 275], ["healthy", 278], ["neurons", 286], [".", 293], ["However", 295], [",", 302], ["the", 304], ["precise", 308], ["relationship", 316], ["between", 329], ["the", 337], ["pathogenicity", 341], ["and", 355], ["physiological", 359], ["functions", 373], ["of", 383], ["\u03b1", 386], ["-", 387], ["synuclein", 388], ["remains", 398], ["to", 406], ["be", 409], ["elucidated", 412], [".", 422], ["To", 424], ["address", 427], ["this", 435], ["issue", 440], [",", 445], ["we", 447], ["investigated", 450], ["the", 463], ["subcellular", 467], ["localization", 479], ["of", 492], ["\u03b1", 495], ["-", 496], ["synuclein", 497], ["in", 507], ["normal", 510], ["and", 517], ["pathological", 521], ["conditions", 534], ["using", 545], ["primary", 551], ["mouse", 559], ["hippocampal", 565], ["neuronal", 577], ["cultures", 586], [".", 594], ["While", 596], ["some", 602], ["neurons", 607], ["expressed", 615], ["high", 625], ["levels", 630], ["of", 637], ["\u03b1", 640], ["-", 641], ["synuclein", 642], ["in", 652], ["presynaptic", 655], ["boutons", 667], ["and", 675], ["cell", 679], ["bodies", 684], [",", 690], ["other", 692], ["neurons", 698], ["either", 706], ["did", 713], ["not", 717], ["or", 721], ["only", 724], ["very", 729], ["weakly", 734], ["expressed", 741], ["the", 751], ["protein", 755], [".", 762], ["These", 764], ["\u03b1", 770], ["-", 771], ["synuclein", 772], ["-", 781], ["negative", 782], ["cells", 791], ["were", 797], ["identified", 802], ["as", 813], ["inhibitory", 816], ["neurons", 827], ["by", 835], ["immunostaining", 838], ["with", 853], ["specific", 858], ["antibodies", 867], ["against", 878], ["glutamic", 886], ["acid", 895], ["decarboxylase", 900], ["(", 914], ["GAD", 915], [")", 918], [",", 919], ["parvalbumin", 921], [",", 932], ["and", 934], ["somatostatin", 938], [".", 950], ["In", 952], ["contrast", 955], [",", 963], ["\u03b1", 965], ["-", 966], ["synuclein", 967], ["-", 976], ["positive", 977], ["synapses", 986], ["were", 995], ["colocalized", 1000], ["with", 1012], ["the", 1017], ["excitatory", 1021], ["synapse", 1032], ["marker", 1040], ["vesicular", 1047], ["glutamate", 1057], ["transporter-1", 1067], [".", 1080], ["This", 1082], ["expression", 1087], ["profile", 1098], ["of", 1106], ["\u03b1", 1109], ["-", 1110], ["synuclein", 1111], ["was", 1121], ["conserved", 1125], ["in", 1135], ["the", 1138], ["hippocampus", 1142], ["in", 1154], ["vivo", 1157], [".", 1161], ["In", 1163], ["addition", 1166], [",", 1174], ["we", 1176], ["found", 1179], ["that", 1185], ["while", 1190], ["presynaptic", 1196], ["\u03b1", 1208], ["-", 1209], ["synuclein", 1210], ["colocalizes", 1220], ["with", 1232], ["synapsin", 1237], [",", 1245], ["a", 1247], ["marker", 1249], ["of", 1256], ["presynaptic", 1259], ["vesicles", 1271], [",", 1279], ["it", 1281], ["is", 1284], ["not", 1287], ["essential", 1291], ["for", 1301], ["activity", 1305], ["-", 1313], ["dependent", 1314], ["membrane", 1324], ["recycling", 1333], ["induced", 1343], ["by", 1351], ["high", 1354], ["potassium", 1359], ["treatment", 1369], [".", 1378], ["Exogenous", 1380], ["supply", 1390], ["of", 1397], ["preformed", 1400], ["fibrils", 1410], ["generated", 1418], ["by", 1428], ["recombinant", 1431], ["\u03b1", 1443], ["-", 1444], ["synuclein", 1445], ["was", 1455], ["shown", 1459], ["to", 1465], ["promote", 1468], ["the", 1476], ["formation", 1480], ["of", 1490], ["Lewy", 1493], ["body", 1498], ["(", 1503], ["LB", 1504], [")", 1506], ["-like", 1508], ["intracellular", 1514], ["aggregates", 1528], ["involving", 1539], ["endogenous", 1549], ["\u03b1", 1560], ["-", 1561], ["synuclein", 1562], [".", 1571], ["GAD", 1573], ["-", 1576], ["positive", 1577], ["neurons", 1586], ["did", 1594], ["not", 1598], ["form", 1602], ["LB", 1607], ["-", 1609], ["like", 1610], ["aggregates", 1615], ["following", 1626], ["treatment", 1636], ["with", 1646], ["preformed", 1651], ["fibrils", 1661], [",", 1668], ["however", 1670], [",", 1677], ["exogenous", 1679], ["expression", 1689], ["of", 1700], ["human", 1703], ["\u03b1", 1709], ["-", 1710], ["synuclein", 1711], ["allowed", 1721], ["intracellular", 1729], ["aggregate", 1743], ["formation", 1753], ["in", 1763], ["these", 1766], ["cells", 1772], [".", 1777], ["These", 1779], ["results", 1785], ["suggest", 1793], ["the", 1801], ["presence", 1805], ["of", 1814], ["a", 1817], ["different", 1819], ["mechanism", 1829], ["for", 1839], ["regulation", 1843], ["of", 1854], ["the", 1857], ["expression", 1861], ["of", 1872], ["\u03b1", 1875], ["-", 1876], ["synuclein", 1877], ["between", 1887], ["excitatory", 1895], ["and", 1906], ["inhibitory", 1910], ["neurons", 1921], [".", 1928], ["Furthermore", 1930], [",", 1941], ["\u03b1", 1943], ["-", 1944], ["synuclein", 1945], ["expression", 1955], ["levels", 1966], ["may", 1973], ["determine", 1977], ["the", 1987], ["efficiency", 1991], ["of", 2002], ["intracellular", 2005], ["aggregate", 2019], ["formation", 2029], ["in", 2039], ["different", 2042], ["neuronal", 2052], ["subtypes", 2061], [".", 2069]]}
{"context": "Parkinson's disease (PD) is a neurodegnerative disorder that is pathologically characterized by the presence of Lewy bodies in the brain. We show that Lewy bodies in PD are strongly immunoreactive for torsinA, the protein product of the DYT1 gene, which is associated with primary generalized dystonia. In the substantia nigra, torsinA immunoreactivity is localized to the periphery of Lewy bodies, whereas, in cortical Lewy bodies it is uniformly distributed. The significance of this finding is unknown, but may implicate torsinA in neuronal dysfunction that occurs in PD as well as in primary dystonia.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "630e6932bb704bc7a85107087e4dd2ea", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegnerative", 30], ["disorder", 47], ["that", 56], ["is", 61], ["pathologically", 64], ["characterized", 79], ["by", 93], ["the", 96], ["presence", 100], ["of", 109], ["Lewy", 112], ["bodies", 117], ["in", 124], ["the", 127], ["brain", 131], [".", 136], ["We", 138], ["show", 141], ["that", 146], ["Lewy", 151], ["bodies", 156], ["in", 163], ["PD", 166], ["are", 169], ["strongly", 173], ["immunoreactive", 182], ["for", 197], ["torsinA", 201], [",", 208], ["the", 210], ["protein", 214], ["product", 222], ["of", 230], ["the", 233], ["DYT1", 237], ["gene", 242], [",", 246], ["which", 248], ["is", 254], ["associated", 257], ["with", 268], ["primary", 273], ["generalized", 281], ["dystonia", 293], [".", 301], ["In", 303], ["the", 306], ["substantia", 310], ["nigra", 321], [",", 326], ["torsinA", 328], ["immunoreactivity", 336], ["is", 353], ["localized", 356], ["to", 366], ["the", 369], ["periphery", 373], ["of", 383], ["Lewy", 386], ["bodies", 391], [",", 397], ["whereas", 399], [",", 406], ["in", 408], ["cortical", 411], ["Lewy", 420], ["bodies", 425], ["it", 432], ["is", 435], ["uniformly", 438], ["distributed", 448], [".", 459], ["The", 461], ["significance", 465], ["of", 478], ["this", 481], ["finding", 486], ["is", 494], ["unknown", 497], [",", 504], ["but", 506], ["may", 510], ["implicate", 514], ["torsinA", 524], ["in", 532], ["neuronal", 535], ["dysfunction", 544], ["that", 556], ["occurs", 561], ["in", 568], ["PD", 571], ["as", 574], ["well", 577], ["as", 582], ["in", 585], ["primary", 588], ["dystonia", 596], [".", 604]]}
{"context": "Epidermal growth factor receptor (EGFR) gene mutations have been found in a subset of non-small cell lung cancer (NSCLC) with good clinical response to gefitinib therapy. A quick and sensitive method with large throughput is required to utilize the information to determine whether the molecular targeted therapy should be applied for the particular NSCLC patients. Using probes for the 13 different mutations including 11 that have already been reported, we have genotyped the EGFR mutation status in 94 NSCLC patients using the TaqMan PCR assay. We have also genotyped the EGFR mutations status in additional 182 NSCLC patients, as well as 63 gastric, 95 esophagus and 70 colon carcinoma patients. In 94 NSCLC samples, the result of the TaqMan PCR assay perfectly matched with that of the sequencing excluding one patient. In one sample in which no EGFR mutation was detected by direct sequencing, the TaqMan PCR assay detected a mutation. This patient was a gefitinib responder. In a serial dilution study, the assay could detect a mutant sample diluted in 1/10 with a wild-type sample. Of 182 NSCLC samples, 46 mutations were detected. EGFR mutation was significantly correlated with gender, smoking status, pathological subtypes, and differentiation of lung cancers. There was no mutation detected by the TaqMan PCR assay in gastric, esophagus and colon carcinomas. TaqMan PCR assay is a rapid and sensitive method of detection of EGFR mutations with high throughput, and may be useful to determine whether gefitinib should be offered for the treatment of NSCLC patients. The TaqMan PCR assay can offer us a complementary and confirmative test.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "db82e6a831de4a5e9ce53368a088128a", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[0, 7]], "char_spans": [[0, 43]]}]}], "context_tokens": [["Epidermal", 0], ["growth", 10], ["factor", 17], ["receptor", 24], ["(", 33], ["EGFR", 34], [")", 38], ["gene", 40], ["mutations", 45], ["have", 55], ["been", 60], ["found", 65], ["in", 71], ["a", 74], ["subset", 76], ["of", 83], ["non", 86], ["-", 89], ["small", 90], ["cell", 96], ["lung", 101], ["cancer", 106], ["(", 113], ["NSCLC", 114], [")", 119], ["with", 121], ["good", 126], ["clinical", 131], ["response", 140], ["to", 149], ["gefitinib", 152], ["therapy", 162], [".", 169], ["A", 171], ["quick", 173], ["and", 179], ["sensitive", 183], ["method", 193], ["with", 200], ["large", 205], ["throughput", 211], ["is", 222], ["required", 225], ["to", 234], ["utilize", 237], ["the", 245], ["information", 249], ["to", 261], ["determine", 264], ["whether", 274], ["the", 282], ["molecular", 286], ["targeted", 296], ["therapy", 305], ["should", 313], ["be", 320], ["applied", 323], ["for", 331], ["the", 335], ["particular", 339], ["NSCLC", 350], ["patients", 356], [".", 364], ["Using", 366], ["probes", 372], ["for", 379], ["the", 383], ["13", 387], ["different", 390], ["mutations", 400], ["including", 410], ["11", 420], ["that", 423], ["have", 428], ["already", 433], ["been", 441], ["reported", 446], [",", 454], ["we", 456], ["have", 459], ["genotyped", 464], ["the", 474], ["EGFR", 478], ["mutation", 483], ["status", 492], ["in", 499], ["94", 502], ["NSCLC", 505], ["patients", 511], ["using", 520], ["the", 526], ["TaqMan", 530], ["PCR", 537], ["assay", 541], [".", 546], ["We", 548], ["have", 551], ["also", 556], ["genotyped", 561], ["the", 571], ["EGFR", 575], ["mutations", 580], ["status", 590], ["in", 597], ["additional", 600], ["182", 611], ["NSCLC", 615], ["patients", 621], [",", 629], ["as", 631], ["well", 634], ["as", 639], ["63", 642], ["gastric", 645], [",", 652], ["95", 654], ["esophagus", 657], ["and", 667], ["70", 671], ["colon", 674], ["carcinoma", 680], ["patients", 690], [".", 698], ["In", 700], ["94", 703], ["NSCLC", 706], ["samples", 712], [",", 719], ["the", 721], ["result", 725], ["of", 732], ["the", 735], ["TaqMan", 739], ["PCR", 746], ["assay", 750], ["perfectly", 756], ["matched", 766], ["with", 774], ["that", 779], ["of", 784], ["the", 787], ["sequencing", 791], ["excluding", 802], ["one", 812], ["patient", 816], [".", 823], ["In", 825], ["one", 828], ["sample", 832], ["in", 839], ["which", 842], ["no", 848], ["EGFR", 851], ["mutation", 856], ["was", 865], ["detected", 869], ["by", 878], ["direct", 881], ["sequencing", 888], [",", 898], ["the", 900], ["TaqMan", 904], ["PCR", 911], ["assay", 915], ["detected", 921], ["a", 930], ["mutation", 932], [".", 940], ["This", 942], ["patient", 947], ["was", 955], ["a", 959], ["gefitinib", 961], ["responder", 971], [".", 980], ["In", 982], ["a", 985], ["serial", 987], ["dilution", 994], ["study", 1003], [",", 1008], ["the", 1010], ["assay", 1014], ["could", 1020], ["detect", 1026], ["a", 1033], ["mutant", 1035], ["sample", 1042], ["diluted", 1049], ["in", 1057], ["1/10", 1060], ["with", 1065], ["a", 1070], ["wild", 1072], ["-", 1076], ["type", 1077], ["sample", 1082], [".", 1088], ["Of", 1090], ["182", 1093], ["NSCLC", 1097], ["samples", 1103], [",", 1110], ["46", 1112], ["mutations", 1115], ["were", 1125], ["detected", 1130], [".", 1138], ["EGFR", 1140], ["mutation", 1145], ["was", 1154], ["significantly", 1158], ["correlated", 1172], ["with", 1183], ["gender", 1188], [",", 1194], ["smoking", 1196], ["status", 1204], [",", 1210], ["pathological", 1212], ["subtypes", 1225], [",", 1233], ["and", 1235], ["differentiation", 1239], ["of", 1255], ["lung", 1258], ["cancers", 1263], [".", 1270], ["There", 1272], ["was", 1278], ["no", 1282], ["mutation", 1285], ["detected", 1294], ["by", 1303], ["the", 1306], ["TaqMan", 1310], ["PCR", 1317], ["assay", 1321], ["in", 1327], ["gastric", 1330], [",", 1337], ["esophagus", 1339], ["and", 1349], ["colon", 1353], ["carcinomas", 1359], [".", 1369], ["TaqMan", 1371], ["PCR", 1378], ["assay", 1382], ["is", 1388], ["a", 1391], ["rapid", 1393], ["and", 1399], ["sensitive", 1403], ["method", 1413], ["of", 1420], ["detection", 1423], ["of", 1433], ["EGFR", 1436], ["mutations", 1441], ["with", 1451], ["high", 1456], ["throughput", 1461], [",", 1471], ["and", 1473], ["may", 1477], ["be", 1481], ["useful", 1484], ["to", 1491], ["determine", 1494], ["whether", 1504], ["gefitinib", 1512], ["should", 1522], ["be", 1529], ["offered", 1532], ["for", 1540], ["the", 1544], ["treatment", 1548], ["of", 1558], ["NSCLC", 1561], ["patients", 1567], [".", 1575], ["The", 1577], ["TaqMan", 1581], ["PCR", 1588], ["assay", 1592], ["can", 1598], ["offer", 1602], ["us", 1608], ["a", 1611], ["complementary", 1613], ["and", 1627], ["confirmative", 1631], ["test", 1644], [".", 1648]]}
{"context": "Cytoskeletal proteins belonging to the spectrin family have an elongated structure composed of repetitive units. The three-dimensional solution structure of the 16th repeat from chicken brain alpha-spectrin (R16) has been determined by NMR spectroscopy and distance geometry-simulated annealing calculations. We used a total of 1035 distance restraints, which included 719 NOE-based values obtained by applying the ambiguous restraints for iterative assignment (ARIA) method. In addition, we performed a direct refinement against 1H-chemical shifts. The final ensemble of 20 structures shows an average RMSD of 1.52 A from the mean for the backbone atoms, excluding loops and N and C termini. R16 is made up of three antiparallel alpha-helices separated by two loops, and folds into a left-handed coiled-coil. The basic unit of spectrin is an antiparallel heterodimer composed of two homologous chains, beta and alpha. These assemble a tetramer via a mechanism that relies on the completion of a single repeat by association of the partial repeats located at the C terminus of the beta-chain (two helices) and at the N terminus of the alpha-chain (one helix). This tetramer is the assemblage able to cross-link actin filaments. Model building by homology of the \"tetramerization\" repeat from human erythrocyte spectrin illuminates the possible role of point mutations which cause hemolytic anemias.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "792b104e025543b5b32f47d3bb1b5c44", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[128, 128], [155, 155]], "char_spans": [[717, 728], [843, 854]]}]}], "context_tokens": [["Cytoskeletal", 0], ["proteins", 13], ["belonging", 22], ["to", 32], ["the", 35], ["spectrin", 39], ["family", 48], ["have", 55], ["an", 60], ["elongated", 63], ["structure", 73], ["composed", 83], ["of", 92], ["repetitive", 95], ["units", 106], [".", 111], ["The", 113], ["three", 117], ["-", 122], ["dimensional", 123], ["solution", 135], ["structure", 144], ["of", 154], ["the", 157], ["16th", 161], ["repeat", 166], ["from", 173], ["chicken", 178], ["brain", 186], ["alpha", 192], ["-", 197], ["spectrin", 198], ["(", 207], ["R16", 208], [")", 211], ["has", 213], ["been", 217], ["determined", 222], ["by", 233], ["NMR", 236], ["spectroscopy", 240], ["and", 253], ["distance", 257], ["geometry", 266], ["-", 274], ["simulated", 275], ["annealing", 285], ["calculations", 295], [".", 307], ["We", 309], ["used", 312], ["a", 317], ["total", 319], ["of", 325], ["1035", 328], ["distance", 333], ["restraints", 342], [",", 352], ["which", 354], ["included", 360], ["719", 369], ["NOE", 373], ["-", 376], ["based", 377], ["values", 383], ["obtained", 390], ["by", 399], ["applying", 402], ["the", 411], ["ambiguous", 415], ["restraints", 425], ["for", 436], ["iterative", 440], ["assignment", 450], ["(", 461], ["ARIA", 462], [")", 466], ["method", 468], [".", 474], ["In", 476], ["addition", 479], [",", 487], ["we", 489], ["performed", 492], ["a", 502], ["direct", 504], ["refinement", 511], ["against", 522], ["1H", 530], ["-", 532], ["chemical", 533], ["shifts", 542], [".", 548], ["The", 550], ["final", 554], ["ensemble", 560], ["of", 569], ["20", 572], ["structures", 575], ["shows", 586], ["an", 592], ["average", 595], ["RMSD", 603], ["of", 608], ["1.52", 611], ["A", 616], ["from", 618], ["the", 623], ["mean", 627], ["for", 632], ["the", 636], ["backbone", 640], ["atoms", 649], [",", 654], ["excluding", 656], ["loops", 666], ["and", 672], ["N", 676], ["and", 678], ["C", 682], ["termini", 684], [".", 691], ["R16", 693], ["is", 697], ["made", 700], ["up", 705], ["of", 708], ["three", 711], ["antiparallel", 717], ["alpha", 730], ["-", 735], ["helices", 736], ["separated", 744], ["by", 754], ["two", 757], ["loops", 761], [",", 766], ["and", 768], ["folds", 772], ["into", 778], ["a", 783], ["left", 785], ["-", 789], ["handed", 790], ["coiled", 797], ["-", 803], ["coil", 804], [".", 808], ["The", 810], ["basic", 814], ["unit", 820], ["of", 825], ["spectrin", 828], ["is", 837], ["an", 840], ["antiparallel", 843], ["heterodimer", 856], ["composed", 868], ["of", 877], ["two", 880], ["homologous", 884], ["chains", 895], [",", 901], ["beta", 903], ["and", 908], ["alpha", 912], [".", 917], ["These", 919], ["assemble", 925], ["a", 934], ["tetramer", 936], ["via", 945], ["a", 949], ["mechanism", 951], ["that", 961], ["relies", 966], ["on", 973], ["the", 976], ["completion", 980], ["of", 991], ["a", 994], ["single", 996], ["repeat", 1003], ["by", 1010], ["association", 1013], ["of", 1025], ["the", 1028], ["partial", 1032], ["repeats", 1040], ["located", 1048], ["at", 1056], ["the", 1059], ["C", 1063], ["terminus", 1065], ["of", 1074], ["the", 1077], ["beta", 1081], ["-", 1085], ["chain", 1086], ["(", 1092], ["two", 1093], ["helices", 1097], [")", 1104], ["and", 1106], ["at", 1110], ["the", 1113], ["N", 1117], ["terminus", 1119], ["of", 1128], ["the", 1131], ["alpha", 1135], ["-", 1140], ["chain", 1141], ["(", 1147], ["one", 1148], ["helix", 1152], [")", 1157], [".", 1158], ["This", 1160], ["tetramer", 1165], ["is", 1174], ["the", 1177], ["assemblage", 1181], ["able", 1192], ["to", 1197], ["cross", 1200], ["-", 1205], ["link", 1206], ["actin", 1211], ["filaments", 1217], [".", 1226], ["Model", 1228], ["building", 1234], ["by", 1243], ["homology", 1246], ["of", 1255], ["the", 1258], ["\"", 1262], ["tetramerization", 1263], ["\"", 1278], ["repeat", 1280], ["from", 1287], ["human", 1292], ["erythrocyte", 1298], ["spectrin", 1310], ["illuminates", 1319], ["the", 1331], ["possible", 1335], ["role", 1344], ["of", 1349], ["point", 1352], ["mutations", 1358], ["which", 1368], ["cause", 1374], ["hemolytic", 1380], ["anemias", 1390], [".", 1397]]}
{"context": "The BCR-ABL fusion gene represents the hallmark of chronic myelogenous leukemia (CML) and is derived from a translocation between chromosome 9 and 22. The majority of CML patients have a breakpoint in the major BCR region of the BCR gene giving rise to e13a2 or e14a2 BCR-ABL transcripts. Occasionally, other BCR breakpoints occur. The current report describes two e6a2 CML patients with imatinib treatment failure and unusual disease progression. One patient was Philadelphia chromosome positive and one was Philadelphia chromosome negative with an atypical BCR-ABL rearrangement, ins (22;9).", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "da064d93bc6d4d6fa5b680d9a08d7890", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[95, 97], [1, 3], [51, 53]], "char_spans": [[559, 565], [4, 10], [268, 274]]}]}], "context_tokens": [["The", 0], ["BCR", 4], ["-", 7], ["ABL", 8], ["fusion", 12], ["gene", 19], ["represents", 24], ["the", 35], ["hallmark", 39], ["of", 48], ["chronic", 51], ["myelogenous", 59], ["leukemia", 71], ["(", 80], ["CML", 81], [")", 84], ["and", 86], ["is", 90], ["derived", 93], ["from", 101], ["a", 106], ["translocation", 108], ["between", 122], ["chromosome", 130], ["9", 141], ["and", 143], ["22", 147], [".", 149], ["The", 151], ["majority", 155], ["of", 164], ["CML", 167], ["patients", 171], ["have", 180], ["a", 185], ["breakpoint", 187], ["in", 198], ["the", 201], ["major", 205], ["BCR", 211], ["region", 215], ["of", 222], ["the", 225], ["BCR", 229], ["gene", 233], ["giving", 238], ["rise", 245], ["to", 250], ["e13a2", 253], ["or", 259], ["e14a2", 262], ["BCR", 268], ["-", 271], ["ABL", 272], ["transcripts", 276], [".", 287], ["Occasionally", 289], [",", 301], ["other", 303], ["BCR", 309], ["breakpoints", 313], ["occur", 325], [".", 330], ["The", 332], ["current", 336], ["report", 344], ["describes", 351], ["two", 361], ["e6a2", 365], ["CML", 370], ["patients", 374], ["with", 383], ["imatinib", 388], ["treatment", 397], ["failure", 407], ["and", 415], ["unusual", 419], ["disease", 427], ["progression", 435], [".", 446], ["One", 448], ["patient", 452], ["was", 460], ["Philadelphia", 464], ["chromosome", 477], ["positive", 488], ["and", 497], ["one", 501], ["was", 505], ["Philadelphia", 509], ["chromosome", 522], ["negative", 533], ["with", 542], ["an", 547], ["atypical", 550], ["BCR", 559], ["-", 562], ["ABL", 563], ["rearrangement", 567], [",", 580], ["ins", 582], ["(", 586], ["22;9", 587], [")", 591], [".", 592]]}
{"context": "Oral empagliflozin (Jardiance(\u00ae)), a sodium glucose cotransporter-2 (SGLT2) inhibitor, is a convenient once-daily treatment for adult patients with type 2 diabetes mellitus. By inhibiting reabsorption of glucose from the proximal tubules in the kidney via inhibition of SGLT2, empagliflozin provides a novel insulin-independent mechanism of lowering blood glucose. In several phase III trials (\u2264104\u00a0weeks' duration; typically 24\u00a0weeks' duration) and extension studies (typically\u00a0\u226576\u00a0weeks' treatment), empagliflozin monotherapy or add-on therapy to other antihyperglycaemics, including insulin, improved glycaemic control and reduced bodyweight and systolic blood pressure in adult patients with type 2 diabetes. In a large phase III trial, as add-on therapy to metformin, empagliflozin was shown to be noninferior to glimepiride at 52 and 104\u00a0weeks and superior to glimepiride at 104\u00a0weeks, in terms of reductions in glycated haemoglobin level (primary endpoint). Empagliflozin was well tolerated by participants in these clinical trials, with most adverse events being mild or moderate in intensity. Empagliflozin treatment appeared to have no intrinsic risk of hypoglycaemia, although hypoglycaemia occurred more frequently when empagliflozin was coadministered with insulin and/or a sulfonylurea. With its insulin-independent mechanism of action, empagliflozin monotherapy or combination therapy with other antidiabetic drugs, including insulin, provides a useful addition to the therapeutic options for the management of type 2 diabetes. This article reviews the pharmacological properties and clinical use of empagliflozin in patients with type 2 diabetes.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "95f5fe67a6334781a72627254072209a", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[49, 49], [14, 14]], "char_spans": [[270, 274], [69, 73]]}]}], "context_tokens": [["Oral", 0], ["empagliflozin", 5], ["(", 19], ["Jardiance", 20], ["(", 29], ["\u00ae", 30], [")", 31], [")", 32], [",", 33], ["a", 35], ["sodium", 37], ["glucose", 44], ["cotransporter-2", 52], ["(", 68], ["SGLT2", 69], [")", 74], ["inhibitor", 76], [",", 85], ["is", 87], ["a", 90], ["convenient", 92], ["once", 103], ["-", 107], ["daily", 108], ["treatment", 114], ["for", 124], ["adult", 128], ["patients", 134], ["with", 143], ["type", 148], ["2", 153], ["diabetes", 155], ["mellitus", 164], [".", 172], ["By", 174], ["inhibiting", 177], ["reabsorption", 188], ["of", 201], ["glucose", 204], ["from", 212], ["the", 217], ["proximal", 221], ["tubules", 230], ["in", 238], ["the", 241], ["kidney", 245], ["via", 252], ["inhibition", 256], ["of", 267], ["SGLT2", 270], [",", 275], ["empagliflozin", 277], ["provides", 291], ["a", 300], ["novel", 302], ["insulin", 308], ["-", 315], ["independent", 316], ["mechanism", 328], ["of", 338], ["lowering", 341], ["blood", 350], ["glucose", 356], [".", 363], ["In", 365], ["several", 368], ["phase", 376], ["III", 382], ["trials", 386], ["(", 393], ["\u2264104", 394], ["weeks", 399], ["'", 404], ["duration", 406], [";", 414], ["typically", 416], ["24", 426], ["weeks", 429], ["'", 434], ["duration", 436], [")", 444], ["and", 446], ["extension", 450], ["studies", 460], ["(", 468], ["typically", 469], ["\u226576", 479], ["weeks", 483], ["'", 488], ["treatment", 490], [")", 499], [",", 500], ["empagliflozin", 502], ["monotherapy", 516], ["or", 528], ["add", 531], ["-", 534], ["on", 535], ["therapy", 538], ["to", 546], ["other", 549], ["antihyperglycaemics", 555], [",", 574], ["including", 576], ["insulin", 586], [",", 593], ["improved", 595], ["glycaemic", 604], ["control", 614], ["and", 622], ["reduced", 626], ["bodyweight", 634], ["and", 645], ["systolic", 649], ["blood", 658], ["pressure", 664], ["in", 673], ["adult", 676], ["patients", 682], ["with", 691], ["type", 696], ["2", 701], ["diabetes", 703], [".", 711], ["In", 713], ["a", 716], ["large", 718], ["phase", 724], ["III", 730], ["trial", 734], [",", 739], ["as", 741], ["add", 744], ["-", 747], ["on", 748], ["therapy", 751], ["to", 759], ["metformin", 762], [",", 771], ["empagliflozin", 773], ["was", 787], ["shown", 791], ["to", 797], ["be", 800], ["noninferior", 803], ["to", 815], ["glimepiride", 818], ["at", 830], ["52", 833], ["and", 836], ["104", 840], ["weeks", 844], ["and", 850], ["superior", 854], ["to", 863], ["glimepiride", 866], ["at", 878], ["104", 881], ["weeks", 885], [",", 890], ["in", 892], ["terms", 895], ["of", 901], ["reductions", 904], ["in", 915], ["glycated", 918], ["haemoglobin", 927], ["level", 939], ["(", 945], ["primary", 946], ["endpoint", 954], [")", 962], [".", 963], ["Empagliflozin", 965], ["was", 979], ["well", 983], ["tolerated", 988], ["by", 998], ["participants", 1001], ["in", 1014], ["these", 1017], ["clinical", 1023], ["trials", 1032], [",", 1038], ["with", 1040], ["most", 1045], ["adverse", 1050], ["events", 1058], ["being", 1065], ["mild", 1071], ["or", 1076], ["moderate", 1079], ["in", 1088], ["intensity", 1091], [".", 1100], ["Empagliflozin", 1102], ["treatment", 1116], ["appeared", 1126], ["to", 1135], ["have", 1138], ["no", 1143], ["intrinsic", 1146], ["risk", 1156], ["of", 1161], ["hypoglycaemia", 1164], [",", 1177], ["although", 1179], ["hypoglycaemia", 1188], ["occurred", 1202], ["more", 1211], ["frequently", 1216], ["when", 1227], ["empagliflozin", 1232], ["was", 1246], ["coadministered", 1250], ["with", 1265], ["insulin", 1270], ["and/or", 1278], ["a", 1285], ["sulfonylurea", 1287], [".", 1299], ["With", 1301], ["its", 1306], ["insulin", 1310], ["-", 1317], ["independent", 1318], ["mechanism", 1330], ["of", 1340], ["action", 1343], [",", 1349], ["empagliflozin", 1351], ["monotherapy", 1365], ["or", 1377], ["combination", 1380], ["therapy", 1392], ["with", 1400], ["other", 1405], ["antidiabetic", 1411], ["drugs", 1424], [",", 1429], ["including", 1431], ["insulin", 1441], [",", 1448], ["provides", 1450], ["a", 1459], ["useful", 1461], ["addition", 1468], ["to", 1477], ["the", 1480], ["therapeutic", 1484], ["options", 1496], ["for", 1504], ["the", 1508], ["management", 1512], ["of", 1523], ["type", 1526], ["2", 1531], ["diabetes", 1533], [".", 1541], ["This", 1543], ["article", 1548], ["reviews", 1556], ["the", 1564], ["pharmacological", 1568], ["properties", 1584], ["and", 1595], ["clinical", 1599], ["use", 1608], ["of", 1612], ["empagliflozin", 1615], ["in", 1629], ["patients", 1632], ["with", 1641], ["type", 1646], ["2", 1651], ["diabetes", 1653], [".", 1661]]}
{"context": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1 activator 1, and Rac1. Interleukin-1beta, flagellin, interferon-gamma, and tumor necrosis factor alpha (TNF-alpha) similarly induced Nox1 in a colon cancer cell line (T84), whereas only TNF-alpha fully induced NOXO1 and upregulated superoxide-producing activity by ninefold. This upregulation was canceled by knockdown of NOXO1 with small interfering RNAs. TNF-alpha rapidly phosphorylated p38 mitogen-activated protein kinase and c-Jun N-terminal kinase 1/2, followed by phosphorylation of c-Jun and c-Fos and appearance of an AP-1 binding activity within 30 min. We cloned the 5' flank of the human NOXO1 gene (-3888 to +263 bp), and found that the region between -585 and -452 bp, which contains consensus elements of YY-1, AP-1, and Ets, and the GC-rich region encoding three putative binding sites for SP-1, was crucial for TNF-alpha-dependent promoter activity. Serial mutation analysis of the elements identified an AP-1 binding site (from -561 to -551 bp, agtAAGtcatg) as a crucial element for TNF-alpha-stimulated transcription of the human NOXO1 gene, which was also confirmed by the AP-1 decoy experiments. Thus, TNF-alpha acts as a potent activator of Nox1-based oxidase in colon epithelial cells, suggesting a potential role of this oxidase in inflammation of the colon.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "6779bef390824d269a423840772240f6", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}, {"text": "NOX1", "token_spans": [[4, 4], [49, 49], [22, 22]], "char_spans": [[17, 20], [238, 241], [100, 103]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["1", 14], ["(", 16], ["Nox1", 17], [")", 21], ["is", 23], ["a", 26], ["multicomponent", 28], ["enzyme", 43], ["consisting", 50], ["of", 61], ["p22(phox", 64], [")", 72], [",", 73], ["Nox", 75], ["organizer", 79], ["1", 89], ["(", 91], ["NOXO1", 92], [")", 97], [",", 98], ["Nox1", 100], ["activator", 105], ["1", 115], [",", 116], ["and", 118], ["Rac1", 122], [".", 126], ["Interleukin-1beta", 128], [",", 145], ["flagellin", 147], [",", 156], ["interferon", 158], ["-", 168], ["gamma", 169], [",", 174], ["and", 176], ["tumor", 180], ["necrosis", 186], ["factor", 195], ["alpha", 202], ["(", 208], ["TNF", 209], ["-", 212], ["alpha", 213], [")", 218], ["similarly", 220], ["induced", 230], ["Nox1", 238], ["in", 243], ["a", 246], ["colon", 248], ["cancer", 254], ["cell", 261], ["line", 266], ["(", 271], ["T84", 272], [")", 275], [",", 276], ["whereas", 278], ["only", 286], ["TNF", 291], ["-", 294], ["alpha", 295], ["fully", 301], ["induced", 307], ["NOXO1", 315], ["and", 321], ["upregulated", 325], ["superoxide", 337], ["-", 347], ["producing", 348], ["activity", 358], ["by", 367], ["ninefold", 370], [".", 378], ["This", 380], ["upregulation", 385], ["was", 398], ["canceled", 402], ["by", 411], ["knockdown", 414], ["of", 424], ["NOXO1", 427], ["with", 433], ["small", 438], ["interfering", 444], ["RNAs", 456], [".", 460], ["TNF", 462], ["-", 465], ["alpha", 466], ["rapidly", 472], ["phosphorylated", 480], ["p38", 495], ["mitogen", 499], ["-", 506], ["activated", 507], ["protein", 517], ["kinase", 525], ["and", 532], ["c", 536], ["-", 537], ["Jun", 538], ["N", 542], ["-", 543], ["terminal", 544], ["kinase", 553], ["1/2", 560], [",", 563], ["followed", 565], ["by", 574], ["phosphorylation", 577], ["of", 593], ["c", 596], ["-", 597], ["Jun", 598], ["and", 602], ["c", 606], ["-", 607], ["Fos", 608], ["and", 612], ["appearance", 616], ["of", 627], ["an", 630], ["AP-1", 633], ["binding", 638], ["activity", 646], ["within", 655], ["30", 662], ["min", 665], [".", 668], ["We", 670], ["cloned", 673], ["the", 680], ["5", 684], ["'", 685], ["flank", 687], ["of", 693], ["the", 696], ["human", 700], ["NOXO1", 706], ["gene", 712], ["(", 717], ["-3888", 718], ["to", 724], ["+263", 727], ["bp", 732], [")", 734], [",", 735], ["and", 737], ["found", 741], ["that", 747], ["the", 752], ["region", 756], ["between", 763], ["-585", 771], ["and", 776], ["-452", 780], ["bp", 785], [",", 787], ["which", 789], ["contains", 795], ["consensus", 804], ["elements", 814], ["of", 823], ["YY-1", 826], [",", 830], ["AP-1", 832], [",", 836], ["and", 838], ["Ets", 842], [",", 845], ["and", 847], ["the", 851], ["GC", 855], ["-", 857], ["rich", 858], ["region", 863], ["encoding", 870], ["three", 879], ["putative", 885], ["binding", 894], ["sites", 902], ["for", 908], ["SP-1", 912], [",", 916], ["was", 918], ["crucial", 922], ["for", 930], ["TNF", 934], ["-", 937], ["alpha", 938], ["-", 943], ["dependent", 944], ["promoter", 954], ["activity", 963], [".", 971], ["Serial", 973], ["mutation", 980], ["analysis", 989], ["of", 998], ["the", 1001], ["elements", 1005], ["identified", 1014], ["an", 1025], ["AP-1", 1028], ["binding", 1033], ["site", 1041], ["(", 1046], ["from", 1047], ["-561", 1052], ["to", 1057], ["-551", 1060], ["bp", 1065], [",", 1067], ["agtAAGtcatg", 1069], [")", 1080], ["as", 1082], ["a", 1085], ["crucial", 1087], ["element", 1095], ["for", 1103], ["TNF", 1107], ["-", 1110], ["alpha", 1111], ["-", 1116], ["stimulated", 1117], ["transcription", 1128], ["of", 1142], ["the", 1145], ["human", 1149], ["NOXO1", 1155], ["gene", 1161], [",", 1165], ["which", 1167], ["was", 1173], ["also", 1177], ["confirmed", 1182], ["by", 1192], ["the", 1195], ["AP-1", 1199], ["decoy", 1204], ["experiments", 1210], [".", 1221], ["Thus", 1223], [",", 1227], ["TNF", 1229], ["-", 1232], ["alpha", 1233], ["acts", 1239], ["as", 1244], ["a", 1247], ["potent", 1249], ["activator", 1256], ["of", 1266], ["Nox1-based", 1269], ["oxidase", 1280], ["in", 1288], ["colon", 1291], ["epithelial", 1297], ["cells", 1308], [",", 1313], ["suggesting", 1315], ["a", 1326], ["potential", 1328], ["role", 1338], ["of", 1343], ["this", 1346], ["oxidase", 1351], ["in", 1359], ["inflammation", 1362], ["of", 1375], ["the", 1378], ["colon", 1382], [".", 1387]]}
{"context": "The Ca2+ overload by Ca2+ influx via Na+/Ca2+ exchanger (NCX) is a critical mechanism in myocardial ischemia/reperfusion injury. We investigated protective effects of a novel selective inhibitor of NCX, SEA0400, on cardiac function and energy metabolism during ischemia and reperfusion. Langendorff-perfused rat hearts were exposed to 35 minutes global ischemia and 40 minutes reperfusion. Using 31P nuclear magnetic resonance spectroscopy, cardiac phosphocreatine (PCr), ATP, and pHi were monitored. SEA0400 did not change the basic cardiac function, but improved the recovery of left ventricular developed pressure (LVDP) after reperfusion (27.6 +/- 4.9 mm Hg in control, 101.2 +/- 19.3 mm Hg in 0.1 microM, and 115.5 +/- 13.3 mm Hg in 1 microM SEA0400, means +/- SE, n = 6, P < 0.05). SEA0400 reduced left ventricular end-diastolic pressure and increased coronary flow after reperfusion. SEA0400 improved the recoveries of cardiac phosphocreatine and ATP after reperfusion, but did not affect pHi. There were significant linear correlations between left ventricular developed pressure and cardiac phosphocreatine (r = 0.79, P < 0.05), and left ventricular developed pressure and ATP (r = 0.80, P < 0.05). However, SEA0400 increased the incidence and duration of reperfusion ventricular arrhythmias. SEA0400 added only after reperfusion also improved both the contractile function and energy metabolism. It is concluded that the selective inhibition of NCX may be effective to preserve high-energy phosphates and to improve cardiac function after reperfusion, but may not be able to prevent fatal arrhythmias.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "e732552a8ada436c980aa2d6f437c42b", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[36, 36], [13, 13], [266, 266]], "char_spans": [[198, 200], [57, 59], [1455, 1457]]}]}], "context_tokens": [["The", 0], ["Ca2", 4], ["+", 7], ["overload", 9], ["by", 18], ["Ca2", 21], ["+", 24], ["influx", 26], ["via", 33], ["Na+/Ca2", 37], ["+", 44], ["exchanger", 46], ["(", 56], ["NCX", 57], [")", 60], ["is", 62], ["a", 65], ["critical", 67], ["mechanism", 76], ["in", 86], ["myocardial", 89], ["ischemia", 100], ["/", 108], ["reperfusion", 109], ["injury", 121], [".", 127], ["We", 129], ["investigated", 132], ["protective", 145], ["effects", 156], ["of", 164], ["a", 167], ["novel", 169], ["selective", 175], ["inhibitor", 185], ["of", 195], ["NCX", 198], [",", 201], ["SEA0400", 203], [",", 210], ["on", 212], ["cardiac", 215], ["function", 223], ["and", 232], ["energy", 236], ["metabolism", 243], ["during", 254], ["ischemia", 261], ["and", 270], ["reperfusion", 274], [".", 285], ["Langendorff", 287], ["-", 298], ["perfused", 299], ["rat", 308], ["hearts", 312], ["were", 319], ["exposed", 324], ["to", 332], ["35", 335], ["minutes", 338], ["global", 346], ["ischemia", 353], ["and", 362], ["40", 366], ["minutes", 369], ["reperfusion", 377], [".", 388], ["Using", 390], ["31P", 396], ["nuclear", 400], ["magnetic", 408], ["resonance", 417], ["spectroscopy", 427], [",", 439], ["cardiac", 441], ["phosphocreatine", 449], ["(", 465], ["PCr", 466], [")", 469], [",", 470], ["ATP", 472], [",", 475], ["and", 477], ["pHi", 481], ["were", 485], ["monitored", 490], [".", 499], ["SEA0400", 501], ["did", 509], ["not", 513], ["change", 517], ["the", 524], ["basic", 528], ["cardiac", 534], ["function", 542], [",", 550], ["but", 552], ["improved", 556], ["the", 565], ["recovery", 569], ["of", 578], ["left", 581], ["ventricular", 586], ["developed", 598], ["pressure", 608], ["(", 617], ["LVDP", 618], [")", 622], ["after", 624], ["reperfusion", 630], ["(", 642], ["27.6", 643], ["+", 648], ["/-", 649], ["4.9", 652], ["mm", 656], ["Hg", 659], ["in", 662], ["control", 665], [",", 672], ["101.2", 674], ["+", 680], ["/-", 681], ["19.3", 684], ["mm", 689], ["Hg", 692], ["in", 695], ["0.1", 698], ["microM", 702], [",", 708], ["and", 710], ["115.5", 714], ["+", 720], ["/-", 721], ["13.3", 724], ["mm", 729], ["Hg", 732], ["in", 735], ["1", 738], ["microM", 740], ["SEA0400", 747], [",", 754], ["means", 756], ["+", 762], ["/-", 763], ["SE", 766], [",", 768], ["n", 770], ["=", 772], ["6", 774], [",", 775], ["P", 777], ["<", 779], ["0.05", 781], [")", 785], [".", 786], ["SEA0400", 788], ["reduced", 796], ["left", 804], ["ventricular", 809], ["end", 821], ["-", 824], ["diastolic", 825], ["pressure", 835], ["and", 844], ["increased", 848], ["coronary", 858], ["flow", 867], ["after", 872], ["reperfusion", 878], [".", 889], ["SEA0400", 891], ["improved", 899], ["the", 908], ["recoveries", 912], ["of", 923], ["cardiac", 926], ["phosphocreatine", 934], ["and", 950], ["ATP", 954], ["after", 958], ["reperfusion", 964], [",", 975], ["but", 977], ["did", 981], ["not", 985], ["affect", 989], ["pHi", 996], [".", 999], ["There", 1001], ["were", 1007], ["significant", 1012], ["linear", 1024], ["correlations", 1031], ["between", 1044], ["left", 1052], ["ventricular", 1057], ["developed", 1069], ["pressure", 1079], ["and", 1088], ["cardiac", 1092], ["phosphocreatine", 1100], ["(", 1116], ["r", 1117], ["=", 1119], ["0.79", 1121], [",", 1125], ["P", 1127], ["<", 1129], ["0.05", 1131], [")", 1135], [",", 1136], ["and", 1138], ["left", 1142], ["ventricular", 1147], ["developed", 1159], ["pressure", 1169], ["and", 1178], ["ATP", 1182], ["(", 1186], ["r", 1187], ["=", 1189], ["0.80", 1191], [",", 1195], ["P", 1197], ["<", 1199], ["0.05", 1201], [")", 1205], [".", 1206], ["However", 1208], [",", 1215], ["SEA0400", 1217], ["increased", 1225], ["the", 1235], ["incidence", 1239], ["and", 1249], ["duration", 1253], ["of", 1262], ["reperfusion", 1265], ["ventricular", 1277], ["arrhythmias", 1289], [".", 1300], ["SEA0400", 1302], ["added", 1310], ["only", 1316], ["after", 1321], ["reperfusion", 1327], ["also", 1339], ["improved", 1344], ["both", 1353], ["the", 1358], ["contractile", 1362], ["function", 1374], ["and", 1383], ["energy", 1387], ["metabolism", 1394], [".", 1404], ["It", 1406], ["is", 1409], ["concluded", 1412], ["that", 1422], ["the", 1427], ["selective", 1431], ["inhibition", 1441], ["of", 1452], ["NCX", 1455], ["may", 1459], ["be", 1463], ["effective", 1466], ["to", 1476], ["preserve", 1479], ["high", 1488], ["-", 1492], ["energy", 1493], ["phosphates", 1500], ["and", 1511], ["to", 1515], ["improve", 1518], ["cardiac", 1526], ["function", 1534], ["after", 1543], ["reperfusion", 1549], [",", 1560], ["but", 1562], ["may", 1566], ["not", 1570], ["be", 1574], ["able", 1577], ["to", 1582], ["prevent", 1585], ["fatal", 1593], ["arrhythmias", 1599], [".", 1610]]}
{"context": "\u03b1-Synuclein (\u03b1Syn), which forms amyloid fibrils, is linked to the neuronal pathology of Parkinson's disease, as it is the major fibrillar component of Lewy bodies, the inclusions that are characteristic of the disease. Oligomeric structures, common to many neurodegenerative disease-related proteins, may in fact be the primary toxic species, while the amyloid fibrils exist either as a less toxic dead-end species or even as a beneficial mechanism for clearing damaged proteins. To alter the progression of the aggregation and gain insights into the prefibrillar structures, we determined the effect of heme on \u03b1Syn oligomerization by several different techniques, including native (nondenaturing) polyacrylamide gel electrophoresis, thioflavin T fluorescence, transmission electron microscopy, atomic force microscopy, circular dichroism, and membrane permeation using a calcein release assay. During aggregation, heme is able to bind the \u03b1Syn in a specific fashion, stabilizing distinct oligomeric conformations and promoting the formation of \u03b1Syn into annular structures, thereby delaying and/or inhibiting the fibrillation process. These results indicate that heme may play a regulatory role in the progression of Parkinson's disease; in addition, they provide insights into how the aggregation process may be altered, which may be applicable to the understanding of many neurodegenerative diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "bbcdadd974b7443eae14570e28207e80", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 10]]}, {"text": "\u03b1Syn", "token_spans": [[175, 175], [4, 4], [160, 160], [111, 111]], "char_spans": [[1046, 1049], [13, 16], [941, 944], [612, 615]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["(", 12], ["\u03b1Syn", 13], [")", 17], [",", 18], ["which", 20], ["forms", 26], ["amyloid", 32], ["fibrils", 40], [",", 47], ["is", 49], ["linked", 52], ["to", 59], ["the", 62], ["neuronal", 66], ["pathology", 75], ["of", 85], ["Parkinson", 88], ["'s", 97], ["disease", 100], [",", 107], ["as", 109], ["it", 112], ["is", 115], ["the", 118], ["major", 122], ["fibrillar", 128], ["component", 138], ["of", 148], ["Lewy", 151], ["bodies", 156], [",", 162], ["the", 164], ["inclusions", 168], ["that", 179], ["are", 184], ["characteristic", 188], ["of", 203], ["the", 206], ["disease", 210], [".", 217], ["Oligomeric", 219], ["structures", 230], [",", 240], ["common", 242], ["to", 249], ["many", 252], ["neurodegenerative", 257], ["disease", 275], ["-", 282], ["related", 283], ["proteins", 291], [",", 299], ["may", 301], ["in", 305], ["fact", 308], ["be", 313], ["the", 316], ["primary", 320], ["toxic", 328], ["species", 334], [",", 341], ["while", 343], ["the", 349], ["amyloid", 353], ["fibrils", 361], ["exist", 369], ["either", 375], ["as", 382], ["a", 385], ["less", 387], ["toxic", 392], ["dead", 398], ["-", 402], ["end", 403], ["species", 407], ["or", 415], ["even", 418], ["as", 423], ["a", 426], ["beneficial", 428], ["mechanism", 439], ["for", 449], ["clearing", 453], ["damaged", 462], ["proteins", 470], [".", 478], ["To", 480], ["alter", 483], ["the", 489], ["progression", 493], ["of", 505], ["the", 508], ["aggregation", 512], ["and", 524], ["gain", 528], ["insights", 533], ["into", 542], ["the", 547], ["prefibrillar", 551], ["structures", 564], [",", 574], ["we", 576], ["determined", 579], ["the", 590], ["effect", 594], ["of", 601], ["heme", 604], ["on", 609], ["\u03b1Syn", 612], ["oligomerization", 617], ["by", 633], ["several", 636], ["different", 644], ["techniques", 654], [",", 664], ["including", 666], ["native", 676], ["(", 683], ["nondenaturing", 684], [")", 697], ["polyacrylamide", 699], ["gel", 714], ["electrophoresis", 718], [",", 733], ["thioflavin", 735], ["T", 746], ["fluorescence", 748], [",", 760], ["transmission", 762], ["electron", 775], ["microscopy", 784], [",", 794], ["atomic", 796], ["force", 803], ["microscopy", 809], [",", 819], ["circular", 821], ["dichroism", 830], [",", 839], ["and", 841], ["membrane", 845], ["permeation", 854], ["using", 865], ["a", 871], ["calcein", 873], ["release", 881], ["assay", 889], [".", 894], ["During", 896], ["aggregation", 903], [",", 914], ["heme", 916], ["is", 921], ["able", 924], ["to", 929], ["bind", 932], ["the", 937], ["\u03b1Syn", 941], ["in", 946], ["a", 949], ["specific", 951], ["fashion", 960], [",", 967], ["stabilizing", 969], ["distinct", 981], ["oligomeric", 990], ["conformations", 1001], ["and", 1015], ["promoting", 1019], ["the", 1029], ["formation", 1033], ["of", 1043], ["\u03b1Syn", 1046], ["into", 1051], ["annular", 1056], ["structures", 1064], [",", 1074], ["thereby", 1076], ["delaying", 1084], ["and/or", 1093], ["inhibiting", 1100], ["the", 1111], ["fibrillation", 1115], ["process", 1128], [".", 1135], ["These", 1137], ["results", 1143], ["indicate", 1151], ["that", 1160], ["heme", 1165], ["may", 1170], ["play", 1174], ["a", 1179], ["regulatory", 1181], ["role", 1192], ["in", 1197], ["the", 1200], ["progression", 1204], ["of", 1216], ["Parkinson", 1219], ["'s", 1228], ["disease", 1231], [";", 1238], ["in", 1240], ["addition", 1243], [",", 1251], ["they", 1253], ["provide", 1258], ["insights", 1266], ["into", 1275], ["how", 1280], ["the", 1284], ["aggregation", 1288], ["process", 1300], ["may", 1308], ["be", 1312], ["altered", 1315], [",", 1322], ["which", 1324], ["may", 1330], ["be", 1334], ["applicable", 1337], ["to", 1348], ["the", 1351], ["understanding", 1355], ["of", 1369], ["many", 1372], ["neurodegenerative", 1377], ["diseases", 1395], [".", 1403]]}
{"context": "Cep135 is a 135-kDa, coiled-coil centrosome protein important for microtubule organization in mammalian cells [Ohta et al., 2002: J. Cell Biol. 156:87-99]. To identify Cep135-interacting molecules, we screened yeast two-hybrid libraries. One clone encoded dynamitin, a p50 dynactin subunit, which localized at the centrosome and has been shown to be involved in anchoring microtubules to centrosomes. The central domain of p50 binds to the C-terminal sequence of Cep135; this was further confirmed by immunoprecipitation and immunostaining of CHO cells co-expressing the binding domains for Cep135 and p50. Exogenous p50 lacking the Cep 135-binding domain failed to locate at the centrosome, suggesting that Cep135 is required for initial targeting of the centrosome. Altered levels of Cep135 and p50 by RNAi and protein overexpression caused the release of endogenous partner molecules from centrosomes. This also resulted in dislocation of other centrosomal molecules, such as gamma-tubulin and pericentrin, ultimately leading to disorganization of microtubule patterns. These results suggest that Cep135 and p50 play an important role in assembly and maintenance of functional microtubule-organizing centers.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "08c3aa54125445ca90f9fe4a6632bcf7", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[134, 134], [8, 8], [59, 59], [122, 122]], "char_spans": [[756, 765], [33, 42], [314, 323], [680, 689]]}]}], "context_tokens": [["Cep135", 0], ["is", 7], ["a", 10], ["135-kDa", 12], [",", 19], ["coiled", 21], ["-", 27], ["coil", 28], ["centrosome", 33], ["protein", 44], ["important", 52], ["for", 62], ["microtubule", 66], ["organization", 78], ["in", 91], ["mammalian", 94], ["cells", 104], ["[", 110], ["Ohta", 111], ["et", 116], ["al", 119], [".", 121], [",", 122], ["2002", 124], [":", 128], ["J.", 130], ["Cell", 133], ["Biol", 138], [".", 142], ["156:87", 144], ["-", 150], ["99].", 151], ["To", 156], ["identify", 159], ["Cep135-interacting", 168], ["molecules", 187], [",", 196], ["we", 198], ["screened", 201], ["yeast", 210], ["two", 216], ["-", 219], ["hybrid", 220], ["libraries", 227], [".", 236], ["One", 238], ["clone", 242], ["encoded", 248], ["dynamitin", 256], [",", 265], ["a", 267], ["p50", 269], ["dynactin", 273], ["subunit", 282], [",", 289], ["which", 291], ["localized", 297], ["at", 307], ["the", 310], ["centrosome", 314], ["and", 325], ["has", 329], ["been", 333], ["shown", 338], ["to", 344], ["be", 347], ["involved", 350], ["in", 359], ["anchoring", 362], ["microtubules", 372], ["to", 385], ["centrosomes", 388], [".", 399], ["The", 401], ["central", 405], ["domain", 413], ["of", 420], ["p50", 423], ["binds", 427], ["to", 433], ["the", 436], ["C", 440], ["-", 441], ["terminal", 442], ["sequence", 451], ["of", 460], ["Cep135", 463], [";", 469], ["this", 471], ["was", 476], ["further", 480], ["confirmed", 488], ["by", 498], ["immunoprecipitation", 501], ["and", 521], ["immunostaining", 525], ["of", 540], ["CHO", 543], ["cells", 547], ["co", 553], ["-", 555], ["expressing", 556], ["the", 567], ["binding", 571], ["domains", 579], ["for", 587], ["Cep135", 591], ["and", 598], ["p50", 602], [".", 605], ["Exogenous", 607], ["p50", 617], ["lacking", 621], ["the", 629], ["Cep", 633], ["135-binding", 637], ["domain", 649], ["failed", 656], ["to", 663], ["locate", 666], ["at", 673], ["the", 676], ["centrosome", 680], [",", 690], ["suggesting", 692], ["that", 703], ["Cep135", 708], ["is", 715], ["required", 718], ["for", 727], ["initial", 731], ["targeting", 739], ["of", 749], ["the", 752], ["centrosome", 756], [".", 766], ["Altered", 768], ["levels", 776], ["of", 783], ["Cep135", 786], ["and", 793], ["p50", 797], ["by", 801], ["RNAi", 804], ["and", 809], ["protein", 813], ["overexpression", 821], ["caused", 836], ["the", 843], ["release", 847], ["of", 855], ["endogenous", 858], ["partner", 869], ["molecules", 877], ["from", 887], ["centrosomes", 892], [".", 903], ["This", 905], ["also", 910], ["resulted", 915], ["in", 924], ["dislocation", 927], ["of", 939], ["other", 942], ["centrosomal", 948], ["molecules", 960], [",", 969], ["such", 971], ["as", 976], ["gamma", 979], ["-", 984], ["tubulin", 985], ["and", 993], ["pericentrin", 997], [",", 1008], ["ultimately", 1010], ["leading", 1021], ["to", 1029], ["disorganization", 1032], ["of", 1048], ["microtubule", 1051], ["patterns", 1063], [".", 1071], ["These", 1073], ["results", 1079], ["suggest", 1087], ["that", 1095], ["Cep135", 1100], ["and", 1107], ["p50", 1111], ["play", 1115], ["an", 1120], ["important", 1123], ["role", 1133], ["in", 1138], ["assembly", 1141], ["and", 1150], ["maintenance", 1154], ["of", 1166], ["functional", 1169], ["microtubule", 1180], ["-", 1191], ["organizing", 1192], ["centers", 1203], [".", 1210]]}
{"context": "The methylation of lysine residues of histones plays a pivotal role in the regulation of chromatin structure and gene expression. Here, we report two crystal structures of SET7/9, a histone methyltransferase (HMTase) that transfers methyl groups to Lys4 of histone H3, in complex with S-adenosyl-L-methionine (AdoMet) determined at 1.7 and 2.3 A resolution. The structures reveal an active site consisting of: (i) a binding pocket between the SET domain and a c-SET helix where an AdoMet molecule in an unusual conformation binds; (ii) a narrow substrate-specific channel that only unmethylated lysine residues can access; and (iii) a catalytic tyrosine residue. The methyl group of AdoMet is directed to the narrow channel where a substrate lysine enters from the opposite side. We demonstrate that SET7/9 can transfer two but not three methyl groups to unmodified Lys4 of H3 without substrate dissociation. The unusual features of the SET domain-containing HMTase discriminate between the un- and methylated lysine substrate, and the methylation sites for the histone H3 tail.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "56ed50d7657b481ea0e2512c19bb0438", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[85, 86], [176, 177]], "char_spans": [[443, 452], [937, 946]]}]}], "context_tokens": [["The", 0], ["methylation", 4], ["of", 16], ["lysine", 19], ["residues", 26], ["of", 35], ["histones", 38], ["plays", 47], ["a", 53], ["pivotal", 55], ["role", 63], ["in", 68], ["the", 71], ["regulation", 75], ["of", 86], ["chromatin", 89], ["structure", 99], ["and", 109], ["gene", 113], ["expression", 118], [".", 128], ["Here", 130], [",", 134], ["we", 136], ["report", 139], ["two", 146], ["crystal", 150], ["structures", 158], ["of", 169], ["SET7/9", 172], [",", 178], ["a", 180], ["histone", 182], ["methyltransferase", 190], ["(", 208], ["HMTase", 209], [")", 215], ["that", 217], ["transfers", 222], ["methyl", 232], ["groups", 239], ["to", 246], ["Lys4", 249], ["of", 254], ["histone", 257], ["H3", 265], [",", 267], ["in", 269], ["complex", 272], ["with", 280], ["S", 285], ["-", 286], ["adenosyl", 287], ["-", 295], ["L", 296], ["-", 297], ["methionine", 298], ["(", 309], ["AdoMet", 310], [")", 316], ["determined", 318], ["at", 329], ["1.7", 332], ["and", 336], ["2.3", 340], ["A", 344], ["resolution", 346], [".", 356], ["The", 358], ["structures", 362], ["reveal", 373], ["an", 380], ["active", 383], ["site", 390], ["consisting", 395], ["of", 406], [":", 408], ["(", 410], ["i", 411], [")", 412], ["a", 414], ["binding", 416], ["pocket", 424], ["between", 431], ["the", 439], ["SET", 443], ["domain", 447], ["and", 454], ["a", 458], ["c", 460], ["-", 461], ["SET", 462], ["helix", 466], ["where", 472], ["an", 478], ["AdoMet", 481], ["molecule", 488], ["in", 497], ["an", 500], ["unusual", 503], ["conformation", 511], ["binds", 524], [";", 529], ["(", 531], ["ii", 532], [")", 534], ["a", 536], ["narrow", 538], ["substrate", 545], ["-", 554], ["specific", 555], ["channel", 564], ["that", 572], ["only", 577], ["unmethylated", 582], ["lysine", 595], ["residues", 602], ["can", 611], ["access", 615], [";", 621], ["and", 623], ["(", 627], ["iii", 628], [")", 631], ["a", 633], ["catalytic", 635], ["tyrosine", 645], ["residue", 654], [".", 661], ["The", 663], ["methyl", 667], ["group", 674], ["of", 680], ["AdoMet", 683], ["is", 690], ["directed", 693], ["to", 702], ["the", 705], ["narrow", 709], ["channel", 716], ["where", 724], ["a", 730], ["substrate", 732], ["lysine", 742], ["enters", 749], ["from", 756], ["the", 761], ["opposite", 765], ["side", 774], [".", 778], ["We", 780], ["demonstrate", 783], ["that", 795], ["SET7/9", 800], ["can", 807], ["transfer", 811], ["two", 820], ["but", 824], ["not", 828], ["three", 832], ["methyl", 838], ["groups", 845], ["to", 852], ["unmodified", 855], ["Lys4", 866], ["of", 871], ["H3", 874], ["without", 877], ["substrate", 885], ["dissociation", 895], [".", 907], ["The", 909], ["unusual", 913], ["features", 921], ["of", 930], ["the", 933], ["SET", 937], ["domain", 941], ["-", 947], ["containing", 948], ["HMTase", 959], ["discriminate", 966], ["between", 979], ["the", 987], ["un-", 991], ["and", 995], ["methylated", 999], ["lysine", 1010], ["substrate", 1017], [",", 1026], ["and", 1028], ["the", 1032], ["methylation", 1036], ["sites", 1048], ["for", 1054], ["the", 1058], ["histone", 1062], ["H3", 1070], ["tail", 1073], [".", 1077]]}
{"context": "We previously identified a mammalian Set1A complex analogous to the yeast Set1/COMPASS histone H3-Lys4 methyltransferase complex (Lee, J.-H., and Skalnik, D. G. (2005) J. Biol. Chem. 280, 41725-41731). Data base analysis indicates that human Set1A protein shares 39% identity with an uncharacterized SET domain protein, KIAA1076, hereafter denoted Set1B. Immunoprecipitation and mass spectrometry reveal that Set1B associates with a approximately 450 kDa complex that contains all five non-catalytic components of the Set1A complex, including CFP1, Rbbp5, Ash2, Wdr5, and Wdr82. These data reveal two human protein complexes that differ only in the identity of the catalytic histone methyltransferase. In vitro assays demonstrate that the Set1B complex is a histone methyltransferase that produces trimethylated histone H3 at Lys(4). Both Set1A and Set1B are widely expressed. Inducible expression of the carboxyl terminus of either Set1A or Set1B decreases steady-state levels of both endogenous Set1A and Set1B protein, but does not alter the expression of the non-catalytic components of the Set1 complexes. A 123-amino acid fragment upstream of the Set1A SET domain is necessary for interaction with CFP1, Ash2, Rbbp5, and Wdr5. This protein domain is also required to mediate feedback inhibition of Set1A and Set1B expression, which is a consequence of reduced Set1A and Set1B stability when not associated with the methyltransferase complex. Confocal microscopy reveals that Set1A and Set1B each localize to a largely non-overlapping set of euchromatic nuclear speckles, suggesting that Set1A and Set1B each bind to a unique set of target genes and thus make non-redundant contributions to the epigenetic control of chromatin structure and gene expression.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "7b483c4cbcd8422c8a975ae0c76fa06c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[56, 57], [201, 202]], "char_spans": [[300, 309], [1159, 1168]]}]}], "context_tokens": [["We", 0], ["previously", 3], ["identified", 14], ["a", 25], ["mammalian", 27], ["Set1A", 37], ["complex", 43], ["analogous", 51], ["to", 61], ["the", 64], ["yeast", 68], ["Set1/COMPASS", 74], ["histone", 87], ["H3-Lys4", 95], ["methyltransferase", 103], ["complex", 121], ["(", 129], ["Lee", 130], [",", 133], ["J.-H.", 135], [",", 140], ["and", 142], ["Skalnik", 146], [",", 153], ["D.", 155], ["G.", 158], ["(", 161], ["2005", 162], [")", 166], ["J.", 168], ["Biol", 171], [".", 175], ["Chem", 177], [".", 181], ["280", 183], [",", 186], ["41725", 188], ["-", 193], ["41731", 194], [")", 199], [".", 200], ["Data", 202], ["base", 207], ["analysis", 212], ["indicates", 221], ["that", 231], ["human", 236], ["Set1A", 242], ["protein", 248], ["shares", 256], ["39", 263], ["%", 265], ["identity", 267], ["with", 276], ["an", 281], ["uncharacterized", 284], ["SET", 300], ["domain", 304], ["protein", 311], [",", 318], ["KIAA1076", 320], [",", 328], ["hereafter", 330], ["denoted", 340], ["Set1B.", 348], ["Immunoprecipitation", 355], ["and", 375], ["mass", 379], ["spectrometry", 384], ["reveal", 397], ["that", 404], ["Set1B", 409], ["associates", 415], ["with", 426], ["a", 431], ["approximately", 433], ["450", 447], ["kDa", 451], ["complex", 455], ["that", 463], ["contains", 468], ["all", 477], ["five", 481], ["non", 486], ["-", 489], ["catalytic", 490], ["components", 500], ["of", 511], ["the", 514], ["Set1A", 518], ["complex", 524], [",", 531], ["including", 533], ["CFP1", 543], [",", 547], ["Rbbp5", 549], [",", 554], ["Ash2", 556], [",", 560], ["Wdr5", 562], [",", 566], ["and", 568], ["Wdr82", 572], [".", 577], ["These", 579], ["data", 585], ["reveal", 590], ["two", 597], ["human", 601], ["protein", 607], ["complexes", 615], ["that", 625], ["differ", 630], ["only", 637], ["in", 642], ["the", 645], ["identity", 649], ["of", 658], ["the", 661], ["catalytic", 665], ["histone", 675], ["methyltransferase", 683], [".", 700], ["In", 702], ["vitro", 705], ["assays", 711], ["demonstrate", 718], ["that", 730], ["the", 735], ["Set1B", 739], ["complex", 745], ["is", 753], ["a", 756], ["histone", 758], ["methyltransferase", 766], ["that", 784], ["produces", 789], ["trimethylated", 798], ["histone", 812], ["H3", 820], ["at", 823], ["Lys(4", 826], [")", 831], [".", 832], ["Both", 834], ["Set1A", 839], ["and", 845], ["Set1B", 849], ["are", 855], ["widely", 859], ["expressed", 866], [".", 875], ["Inducible", 877], ["expression", 887], ["of", 898], ["the", 901], ["carboxyl", 905], ["terminus", 914], ["of", 923], ["either", 926], ["Set1A", 933], ["or", 939], ["Set1B", 942], ["decreases", 948], ["steady", 958], ["-", 964], ["state", 965], ["levels", 971], ["of", 978], ["both", 981], ["endogenous", 986], ["Set1A", 997], ["and", 1003], ["Set1B", 1007], ["protein", 1013], [",", 1020], ["but", 1022], ["does", 1026], ["not", 1031], ["alter", 1035], ["the", 1041], ["expression", 1045], ["of", 1056], ["the", 1059], ["non", 1063], ["-", 1066], ["catalytic", 1067], ["components", 1077], ["of", 1088], ["the", 1091], ["Set1", 1095], ["complexes", 1100], [".", 1109], ["A", 1111], ["123-amino", 1113], ["acid", 1123], ["fragment", 1128], ["upstream", 1137], ["of", 1146], ["the", 1149], ["Set1A", 1153], ["SET", 1159], ["domain", 1163], ["is", 1170], ["necessary", 1173], ["for", 1183], ["interaction", 1187], ["with", 1199], ["CFP1", 1204], [",", 1208], ["Ash2", 1210], [",", 1214], ["Rbbp5", 1216], [",", 1221], ["and", 1223], ["Wdr5", 1227], [".", 1231], ["This", 1233], ["protein", 1238], ["domain", 1246], ["is", 1253], ["also", 1256], ["required", 1261], ["to", 1270], ["mediate", 1273], ["feedback", 1281], ["inhibition", 1290], ["of", 1301], ["Set1A", 1304], ["and", 1310], ["Set1B", 1314], ["expression", 1320], [",", 1330], ["which", 1332], ["is", 1338], ["a", 1341], ["consequence", 1343], ["of", 1355], ["reduced", 1358], ["Set1A", 1366], ["and", 1372], ["Set1B", 1376], ["stability", 1382], ["when", 1392], ["not", 1397], ["associated", 1401], ["with", 1412], ["the", 1417], ["methyltransferase", 1421], ["complex", 1439], [".", 1446], ["Confocal", 1448], ["microscopy", 1457], ["reveals", 1468], ["that", 1476], ["Set1A", 1481], ["and", 1487], ["Set1B", 1491], ["each", 1497], ["localize", 1502], ["to", 1511], ["a", 1514], ["largely", 1516], ["non", 1524], ["-", 1527], ["overlapping", 1528], ["set", 1540], ["of", 1544], ["euchromatic", 1547], ["nuclear", 1559], ["speckles", 1567], [",", 1575], ["suggesting", 1577], ["that", 1588], ["Set1A", 1593], ["and", 1599], ["Set1B", 1603], ["each", 1609], ["bind", 1614], ["to", 1619], ["a", 1622], ["unique", 1624], ["set", 1631], ["of", 1635], ["target", 1638], ["genes", 1645], ["and", 1651], ["thus", 1655], ["make", 1660], ["non", 1665], ["-", 1668], ["redundant", 1669], ["contributions", 1679], ["to", 1693], ["the", 1696], ["epigenetic", 1700], ["control", 1711], ["of", 1719], ["chromatin", 1722], ["structure", 1732], ["and", 1742], ["gene", 1746], ["expression", 1751], [".", 1761]]}
{"context": "TIA-1 is an RNA binding protein that promotes the assembly of stress granules (SGs), discrete cytoplasmic inclusions into which stalled translation initiation complexes are dynamically recruited in cells subjected to environmental stress. The RNA recognition motifs of TIA-1 are linked to a glutamine-rich prion-related domain (PRD). Truncation mutants lacking the PRD domain do not induce spontaneous SGs and are not recruited to arsenite-induced SGs, whereas the PRD forms aggregates that are recruited to SGs in low-level-expressing cells but prevent SG assembly in high-level-expressing cells. The PRD of TIA-1 exhibits many characteristics of prions: concentration-dependent aggregation that is inhibited by the molecular chaperone heat shock protein (HSP)70; resistance to protease digestion; sequestration of HSP27, HSP40, and HSP70; and induction of HSP70, a feedback regulator of PRD disaggregation. Substitution of the PRD with the aggregation domain of a yeast prion, SUP35-NM, reconstitutes SG assembly, confirming that a prion domain can mediate the assembly of SGs. Mouse embryomic fibroblasts (MEFs) lacking TIA-1 exhibit impaired ability to form SGs, although they exhibit normal phosphorylation of eukaryotic initiation factor (eIF)2alpha in response to arsenite. Our results reveal that prion-like aggregation of TIA-1 regulates SG formation downstream of eIF2alpha phosphorylation in response to stress.", "qas": [{"question": "Which domain of TIA-1 is necessary for stress granule assembly?", "answers": ["The glutamine-rich prion-related domain (PRD)"], "qid": "b0c5cb7e458c48f9a369b023a6f154ef", "question_tokens": [["Which", 0], ["domain", 6], ["of", 13], ["TIA-1", 16], ["is", 22], ["necessary", 25], ["for", 35], ["stress", 39], ["granule", 46], ["assembly", 54], ["?", 62]], "detected_answers": [{"text": "The glutamine-rich prion-related domain (PRD)", "token_spans": [[46, 54]], "char_spans": [[291, 330]]}]}], "context_tokens": [["TIA-1", 0], ["is", 6], ["an", 9], ["RNA", 12], ["binding", 16], ["protein", 24], ["that", 32], ["promotes", 37], ["the", 46], ["assembly", 50], ["of", 59], ["stress", 62], ["granules", 69], ["(", 78], ["SGs", 79], [")", 82], [",", 83], ["discrete", 85], ["cytoplasmic", 94], ["inclusions", 106], ["into", 117], ["which", 122], ["stalled", 128], ["translation", 136], ["initiation", 148], ["complexes", 159], ["are", 169], ["dynamically", 173], ["recruited", 185], ["in", 195], ["cells", 198], ["subjected", 204], ["to", 214], ["environmental", 217], ["stress", 231], [".", 237], ["The", 239], ["RNA", 243], ["recognition", 247], ["motifs", 259], ["of", 266], ["TIA-1", 269], ["are", 275], ["linked", 279], ["to", 286], ["a", 289], ["glutamine", 291], ["-", 300], ["rich", 301], ["prion", 306], ["-", 311], ["related", 312], ["domain", 320], ["(", 327], ["PRD", 328], [")", 331], [".", 332], ["Truncation", 334], ["mutants", 345], ["lacking", 353], ["the", 361], ["PRD", 365], ["domain", 369], ["do", 376], ["not", 379], ["induce", 383], ["spontaneous", 390], ["SGs", 402], ["and", 406], ["are", 410], ["not", 414], ["recruited", 418], ["to", 428], ["arsenite", 431], ["-", 439], ["induced", 440], ["SGs", 448], [",", 451], ["whereas", 453], ["the", 461], ["PRD", 465], ["forms", 469], ["aggregates", 475], ["that", 486], ["are", 491], ["recruited", 495], ["to", 505], ["SGs", 508], ["in", 512], ["low", 515], ["-", 518], ["level", 519], ["-", 524], ["expressing", 525], ["cells", 536], ["but", 542], ["prevent", 546], ["SG", 554], ["assembly", 557], ["in", 566], ["high", 569], ["-", 573], ["level", 574], ["-", 579], ["expressing", 580], ["cells", 591], [".", 596], ["The", 598], ["PRD", 602], ["of", 606], ["TIA-1", 609], ["exhibits", 615], ["many", 624], ["characteristics", 629], ["of", 645], ["prions", 648], [":", 654], ["concentration", 656], ["-", 669], ["dependent", 670], ["aggregation", 680], ["that", 692], ["is", 697], ["inhibited", 700], ["by", 710], ["the", 713], ["molecular", 717], ["chaperone", 727], ["heat", 737], ["shock", 742], ["protein", 748], ["(", 756], ["HSP)70", 757], [";", 763], ["resistance", 765], ["to", 776], ["protease", 779], ["digestion", 788], [";", 797], ["sequestration", 799], ["of", 813], ["HSP27", 816], [",", 821], ["HSP40", 823], [",", 828], ["and", 830], ["HSP70", 834], [";", 839], ["and", 841], ["induction", 845], ["of", 855], ["HSP70", 858], [",", 863], ["a", 865], ["feedback", 867], ["regulator", 876], ["of", 886], ["PRD", 889], ["disaggregation", 893], [".", 907], ["Substitution", 909], ["of", 922], ["the", 925], ["PRD", 929], ["with", 933], ["the", 938], ["aggregation", 942], ["domain", 954], ["of", 961], ["a", 964], ["yeast", 966], ["prion", 972], [",", 977], ["SUP35-NM", 979], [",", 987], ["reconstitutes", 989], ["SG", 1003], ["assembly", 1006], [",", 1014], ["confirming", 1016], ["that", 1027], ["a", 1032], ["prion", 1034], ["domain", 1040], ["can", 1047], ["mediate", 1051], ["the", 1059], ["assembly", 1063], ["of", 1072], ["SGs", 1075], [".", 1078], ["Mouse", 1080], ["embryomic", 1086], ["fibroblasts", 1096], ["(", 1108], ["MEFs", 1109], [")", 1113], ["lacking", 1115], ["TIA-1", 1123], ["exhibit", 1129], ["impaired", 1137], ["ability", 1146], ["to", 1154], ["form", 1157], ["SGs", 1162], [",", 1165], ["although", 1167], ["they", 1176], ["exhibit", 1181], ["normal", 1189], ["phosphorylation", 1196], ["of", 1212], ["eukaryotic", 1215], ["initiation", 1226], ["factor", 1237], ["(", 1244], ["eIF)2alpha", 1245], ["in", 1256], ["response", 1259], ["to", 1268], ["arsenite", 1271], [".", 1279], ["Our", 1281], ["results", 1285], ["reveal", 1293], ["that", 1300], ["prion", 1305], ["-", 1310], ["like", 1311], ["aggregation", 1316], ["of", 1328], ["TIA-1", 1331], ["regulates", 1337], ["SG", 1347], ["formation", 1350], ["downstream", 1360], ["of", 1371], ["eIF2alpha", 1374], ["phosphorylation", 1384], ["in", 1400], ["response", 1403], ["to", 1412], ["stress", 1415], [".", 1421]]}
{"context": "SEA0400 is a selective inhibitor of the Na(+)/Ca(2+) exchanger having equal potencies to suppress both the forward and reverse mode operation of the Na(+)/Ca(2+) exchanger. Present experiments were designed to study the effect of partial blockade of Na(+)/Ca(2+) exchanger on Ca(2+) handling in isolated rat ventricular myocytes. Intracellular Ca(2+) transient and cell shortening were measured in ventricular myocytes loaded with Fura-2-AM fluorescent dye. Partial blockade of Na(+)/Ca(2+) exchanger was induced by superfusion of the cells with SEA0400 at a concentration of 0.3 microM. Amplitude of the intracellular Ca(2+) transient and cell shortening was significantly increased by SEA0400 in both field stimulated and voltage clamped myocytes, without significant elevation of diastolic Ca(2+) level and the decay time constant of the Ca(2+) transient. In patch clamped myocytes the SEA0400 induced increase in the Ca(2+) transient and cell shortening was accompanied by significant reduction of peak L-type Ca(2+) current. These effects can be explained by the autoregulative nature of cardiac Ca(2+) handling, as the reduced Ca(2+) efflux from the cell results in an increased Ca(2+) load to the sarcoplasmic reticulum leading to increased Ca(2+) release, which in turn may decrease the L-type Ca(2+) current by accelaration of Ca(2+) dependent inactivation of L-type Ca(2+) current. Our results suggest that complex changes in the Ca(2+) cycling can occur after selective pharmacological inhibition of the Na(+)/Ca(2+) exchanger.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "4fe2e279a8224262a6918b198e8b0ed1", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[42, 45], [79, 82], [7, 10], [272, 275], [25, 28]], "char_spans": [[250, 271], [478, 499], [40, 61], [1515, 1536], [149, 170]]}]}], "context_tokens": [["SEA0400", 0], ["is", 8], ["a", 11], ["selective", 13], ["inhibitor", 23], ["of", 33], ["the", 36], ["Na(+)/Ca(2", 40], ["+", 50], [")", 51], ["exchanger", 53], ["having", 63], ["equal", 70], ["potencies", 76], ["to", 86], ["suppress", 89], ["both", 98], ["the", 103], ["forward", 107], ["and", 115], ["reverse", 119], ["mode", 127], ["operation", 132], ["of", 142], ["the", 145], ["Na(+)/Ca(2", 149], ["+", 159], [")", 160], ["exchanger", 162], [".", 171], ["Present", 173], ["experiments", 181], ["were", 193], ["designed", 198], ["to", 207], ["study", 210], ["the", 216], ["effect", 220], ["of", 227], ["partial", 230], ["blockade", 238], ["of", 247], ["Na(+)/Ca(2", 250], ["+", 260], [")", 261], ["exchanger", 263], ["on", 273], ["Ca(2", 276], ["+", 280], [")", 281], ["handling", 283], ["in", 292], ["isolated", 295], ["rat", 304], ["ventricular", 308], ["myocytes", 320], [".", 328], ["Intracellular", 330], ["Ca(2", 344], ["+", 348], [")", 349], ["transient", 351], ["and", 361], ["cell", 365], ["shortening", 370], ["were", 381], ["measured", 386], ["in", 395], ["ventricular", 398], ["myocytes", 410], ["loaded", 419], ["with", 426], ["Fura-2-AM", 431], ["fluorescent", 441], ["dye", 453], [".", 456], ["Partial", 458], ["blockade", 466], ["of", 475], ["Na(+)/Ca(2", 478], ["+", 488], [")", 489], ["exchanger", 491], ["was", 501], ["induced", 505], ["by", 513], ["superfusion", 516], ["of", 528], ["the", 531], ["cells", 535], ["with", 541], ["SEA0400", 546], ["at", 554], ["a", 557], ["concentration", 559], ["of", 573], ["0.3", 576], ["microM.", 580], ["Amplitude", 588], ["of", 598], ["the", 601], ["intracellular", 605], ["Ca(2", 619], ["+", 623], [")", 624], ["transient", 626], ["and", 636], ["cell", 640], ["shortening", 645], ["was", 656], ["significantly", 660], ["increased", 674], ["by", 684], ["SEA0400", 687], ["in", 695], ["both", 698], ["field", 703], ["stimulated", 709], ["and", 720], ["voltage", 724], ["clamped", 732], ["myocytes", 740], [",", 748], ["without", 750], ["significant", 758], ["elevation", 770], ["of", 780], ["diastolic", 783], ["Ca(2", 793], ["+", 797], [")", 798], ["level", 800], ["and", 806], ["the", 810], ["decay", 814], ["time", 820], ["constant", 825], ["of", 834], ["the", 837], ["Ca(2", 841], ["+", 845], [")", 846], ["transient", 848], [".", 857], ["In", 859], ["patch", 862], ["clamped", 868], ["myocytes", 876], ["the", 885], ["SEA0400", 889], ["induced", 897], ["increase", 905], ["in", 914], ["the", 917], ["Ca(2", 921], ["+", 925], [")", 926], ["transient", 928], ["and", 938], ["cell", 942], ["shortening", 947], ["was", 958], ["accompanied", 962], ["by", 974], ["significant", 977], ["reduction", 989], ["of", 999], ["peak", 1002], ["L", 1007], ["-", 1008], ["type", 1009], ["Ca(2", 1014], ["+", 1018], [")", 1019], ["current", 1021], [".", 1028], ["These", 1030], ["effects", 1036], ["can", 1044], ["be", 1048], ["explained", 1051], ["by", 1061], ["the", 1064], ["autoregulative", 1068], ["nature", 1083], ["of", 1090], ["cardiac", 1093], ["Ca(2", 1101], ["+", 1105], [")", 1106], ["handling", 1108], [",", 1116], ["as", 1118], ["the", 1121], ["reduced", 1125], ["Ca(2", 1133], ["+", 1137], [")", 1138], ["efflux", 1140], ["from", 1147], ["the", 1152], ["cell", 1156], ["results", 1161], ["in", 1169], ["an", 1172], ["increased", 1175], ["Ca(2", 1185], ["+", 1189], [")", 1190], ["load", 1192], ["to", 1197], ["the", 1200], ["sarcoplasmic", 1204], ["reticulum", 1217], ["leading", 1227], ["to", 1235], ["increased", 1238], ["Ca(2", 1248], ["+", 1252], [")", 1253], ["release", 1255], [",", 1262], ["which", 1264], ["in", 1270], ["turn", 1273], ["may", 1278], ["decrease", 1282], ["the", 1291], ["L", 1295], ["-", 1296], ["type", 1297], ["Ca(2", 1302], ["+", 1306], [")", 1307], ["current", 1309], ["by", 1317], ["accelaration", 1320], ["of", 1333], ["Ca(2", 1336], ["+", 1340], [")", 1341], ["dependent", 1343], ["inactivation", 1353], ["of", 1366], ["L", 1369], ["-", 1370], ["type", 1371], ["Ca(2", 1376], ["+", 1380], [")", 1381], ["current", 1383], [".", 1390], ["Our", 1392], ["results", 1396], ["suggest", 1404], ["that", 1412], ["complex", 1417], ["changes", 1425], ["in", 1433], ["the", 1436], ["Ca(2", 1440], ["+", 1444], [")", 1445], ["cycling", 1447], ["can", 1455], ["occur", 1459], ["after", 1465], ["selective", 1471], ["pharmacological", 1481], ["inhibition", 1497], ["of", 1508], ["the", 1511], ["Na(+)/Ca(2", 1515], ["+", 1525], [")", 1526], ["exchanger", 1528], [".", 1537]]}
{"context": "Patients with multiple myeloma (MM) experience pathologic fractures, bone pain, hypercalcemia, neurologic symptoms, and renal insufficiency with substantial morbidity and mortality. Bisphosphonates have been used successfully for the management of MM-related bone disease. Increased incidence of osteonecrosis of the jaw has been observed in patients with cancer receiving bisphosphonate therapy. Recent advances in the pathobiology of MM-related bone disease and other cancer-related bone metastases have led to the identification of novel therapeutic targets, such as receptor activator of nuclear factor-kappaB (RANK); its ligand (RANKL); and a decoy receptor, osteoprotegerin, for the development of potential targeted agents. Initials studies have demonstrated that targeting RANK/ RANKL signaling with the fully human monoclonal antibody denosumab prevented skeletal complications in patients with MM and other cancers with bone metastases. Ongoing studies evaluating the clinical utility of denosumab in cancer- related bone destruction have been discussed. In addition, several potential targets, such as macrophage inflammatory protein-1alpha, chemokine receptors 1 and 5, interleukin-3, and Wnt signaling, are b riefly described.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "3e9485482dda405c9488b643f9e2b125", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[105, 105], [130, 130]], "char_spans": [[634, 638], [787, 791]]}]}], "context_tokens": [["Patients", 0], ["with", 9], ["multiple", 14], ["myeloma", 23], ["(", 31], ["MM", 32], [")", 34], ["experience", 36], ["pathologic", 47], ["fractures", 58], [",", 67], ["bone", 69], ["pain", 74], [",", 78], ["hypercalcemia", 80], [",", 93], ["neurologic", 95], ["symptoms", 106], [",", 114], ["and", 116], ["renal", 120], ["insufficiency", 126], ["with", 140], ["substantial", 145], ["morbidity", 157], ["and", 167], ["mortality", 171], [".", 180], ["Bisphosphonates", 182], ["have", 198], ["been", 203], ["used", 208], ["successfully", 213], ["for", 226], ["the", 230], ["management", 234], ["of", 245], ["MM", 248], ["-", 250], ["related", 251], ["bone", 259], ["disease", 264], [".", 271], ["Increased", 273], ["incidence", 283], ["of", 293], ["osteonecrosis", 296], ["of", 310], ["the", 313], ["jaw", 317], ["has", 321], ["been", 325], ["observed", 330], ["in", 339], ["patients", 342], ["with", 351], ["cancer", 356], ["receiving", 363], ["bisphosphonate", 373], ["therapy", 388], [".", 395], ["Recent", 397], ["advances", 404], ["in", 413], ["the", 416], ["pathobiology", 420], ["of", 433], ["MM", 436], ["-", 438], ["related", 439], ["bone", 447], ["disease", 452], ["and", 460], ["other", 464], ["cancer", 470], ["-", 476], ["related", 477], ["bone", 485], ["metastases", 490], ["have", 501], ["led", 506], ["to", 510], ["the", 513], ["identification", 517], ["of", 532], ["novel", 535], ["therapeutic", 541], ["targets", 553], [",", 560], ["such", 562], ["as", 567], ["receptor", 570], ["activator", 579], ["of", 589], ["nuclear", 592], ["factor", 600], ["-", 606], ["kappaB", 607], ["(", 614], ["RANK", 615], [")", 619], [";", 620], ["its", 622], ["ligand", 626], ["(", 633], ["RANKL", 634], [")", 639], [";", 640], ["and", 642], ["a", 646], ["decoy", 648], ["receptor", 654], [",", 662], ["osteoprotegerin", 664], [",", 679], ["for", 681], ["the", 685], ["development", 689], ["of", 701], ["potential", 704], ["targeted", 714], ["agents", 723], [".", 729], ["Initials", 731], ["studies", 740], ["have", 748], ["demonstrated", 753], ["that", 766], ["targeting", 771], ["RANK/", 781], ["RANKL", 787], ["signaling", 793], ["with", 803], ["the", 808], ["fully", 812], ["human", 818], ["monoclonal", 824], ["antibody", 835], ["denosumab", 844], ["prevented", 854], ["skeletal", 864], ["complications", 873], ["in", 887], ["patients", 890], ["with", 899], ["MM", 904], ["and", 907], ["other", 911], ["cancers", 917], ["with", 925], ["bone", 930], ["metastases", 935], [".", 945], ["Ongoing", 947], ["studies", 955], ["evaluating", 963], ["the", 974], ["clinical", 978], ["utility", 987], ["of", 995], ["denosumab", 998], ["in", 1008], ["cancer-", 1011], ["related", 1019], ["bone", 1027], ["destruction", 1032], ["have", 1044], ["been", 1049], ["discussed", 1054], [".", 1063], ["In", 1065], ["addition", 1068], [",", 1076], ["several", 1078], ["potential", 1086], ["targets", 1096], [",", 1103], ["such", 1105], ["as", 1110], ["macrophage", 1113], ["inflammatory", 1124], ["protein-1alpha", 1137], [",", 1151], ["chemokine", 1153], ["receptors", 1163], ["1", 1173], ["and", 1175], ["5", 1179], [",", 1180], ["interleukin-3", 1182], [",", 1195], ["and", 1197], ["Wnt", 1201], ["signaling", 1205], [",", 1214], ["are", 1216], ["b", 1220], ["riefly", 1222], ["described", 1229], [".", 1238]]}
{"context": "Idarucizumab is a monoclonal antibody fragment that binds dabigatran with high affinity in a 1:1 molar ratio. We investigated the safety, tolerability, and efficacy of increasing doses of idarucizumab for the reversal of anticoagulant effects of dabigatran in a two-part phase 1 study (rising-dose assessment and dose-finding, proof-of-concept investigation). Here we present the results of the proof-of-concept part of the study. In this randomised, placebo-controlled, double-blind, proof-of-concept phase 1 study, we enrolled healthy volunteers (aged 18-45 years) with a body-mass index of 18\u00b75-29\u00b79 kg/m(2) into one of four dose groups at SGS Life Sciences Clinical Research Services, Belgium. Participants were randomly assigned within groups in a 3:1 ratio to idarucizumab or placebo using a pseudorandom number generator and a supplied seed number. Participants and care providers were masked to treatment assignment. All participants received oral dabigatran etexilate 220 mg twice daily for 3 days and a final dose on day 4. Idarucizumab (1 g, 2 g, or 4 g 5-min infusion, or 5 g plus 2\u00b75 g in two 5-min infusions given 1 h apart) was administered about 2 h after the final dabigatran etexilate dose. The primary endpoint was incidence of drug-related adverse events, analysed in all randomly assigned participants who received at least one dose of dabigatran etexilate. Reversal of diluted thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and thrombin time (TT) were secondary endpoints assessed by measuring the area under the effect curve from 2 h to 12 h (AUEC2-12) after dabigatran etexilate ingestion on days 3 and 4. This trial is registered with ClinicalTrials.gov, number NCT01688830. Between Feb 23, and Nov 29, 2013, 47 men completed this part of the study. 12 were enrolled into each of the 1 g, 2 g, or 5 g plus 2\u00b75 g idarucizumab groups (nine to idarucizumab and three to placebo in each group), and 11 were enrolled into the 4 g idarucizumab group (eight to idarucizumab and three to placebo). Drug-related adverse events were all of mild intensity and reported in seven participants: one in the 1 g idarucizumab group (infusion site erythema and hot flushes), one in the 5 g plus 2\u00b75 g idarucizumab group (epistaxis); one receiving placebo (infusion site haematoma), and four during dabigatran etexilate pretreatment (three haematuria and one epistaxis). Idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 AUEC2-12 to day 3 AUEC2-12 for dTT was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction). No serious or severe adverse events were reported, no adverse event led to discontinuation of treatment, and no clinically relevant difference in incidence of adverse events was noted between treatment groups. These phase 1 results show that idarucizumab was associated with immediate, complete, and sustained reversal of dabigatran-induced anticoagulation in healthy men, and was well tolerated with no unexpected or clinically relevant safety concerns, supporting further testing. Further clinical studies are in progress. Boehringer Ingelheim Pharma GmbH & Co KG.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "2997ce0116fe4da1afc9fa4cdf7e48d6", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[267, 267], [474, 474], [490, 490], [324, 324], [39, 39], [184, 184], [8, 8], [238, 238], [623, 623]], "char_spans": [[1357, 1366], [2353, 2362], [2474, 2483], [1630, 1639], [246, 255], [956, 965], [58, 67], [1182, 1191], [3132, 3141]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["monoclonal", 18], ["antibody", 29], ["fragment", 38], ["that", 47], ["binds", 52], ["dabigatran", 58], ["with", 69], ["high", 74], ["affinity", 79], ["in", 88], ["a", 91], ["1:1", 93], ["molar", 97], ["ratio", 103], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["safety", 130], [",", 136], ["tolerability", 138], [",", 150], ["and", 152], ["efficacy", 156], ["of", 165], ["increasing", 168], ["doses", 179], ["of", 185], ["idarucizumab", 188], ["for", 201], ["the", 205], ["reversal", 209], ["of", 218], ["anticoagulant", 221], ["effects", 235], ["of", 243], ["dabigatran", 246], ["in", 257], ["a", 260], ["two", 262], ["-", 265], ["part", 266], ["phase", 271], ["1", 277], ["study", 279], ["(", 285], ["rising", 286], ["-", 292], ["dose", 293], ["assessment", 298], ["and", 309], ["dose", 313], ["-", 317], ["finding", 318], [",", 325], ["proof", 327], ["-", 332], ["of", 333], ["-", 335], ["concept", 336], ["investigation", 344], [")", 357], [".", 358], ["Here", 360], ["we", 365], ["present", 368], ["the", 376], ["results", 380], ["of", 388], ["the", 391], ["proof", 395], ["-", 400], ["of", 401], ["-", 403], ["concept", 404], ["part", 412], ["of", 417], ["the", 420], ["study", 424], [".", 429], ["In", 431], ["this", 434], ["randomised", 439], [",", 449], ["placebo", 451], ["-", 458], ["controlled", 459], [",", 469], ["double", 471], ["-", 477], ["blind", 478], [",", 483], ["proof", 485], ["-", 490], ["of", 491], ["-", 493], ["concept", 494], ["phase", 502], ["1", 508], ["study", 510], [",", 515], ["we", 517], ["enrolled", 520], ["healthy", 529], ["volunteers", 537], ["(", 548], ["aged", 549], ["18", 554], ["-", 556], ["45", 557], ["years", 560], [")", 565], ["with", 567], ["a", 572], ["body", 574], ["-", 578], ["mass", 579], ["index", 584], ["of", 590], ["18\u00b75", 593], ["-", 597], ["29\u00b79", 598], ["kg", 603], ["/", 605], ["m(2", 606], [")", 609], ["into", 611], ["one", 616], ["of", 620], ["four", 623], ["dose", 628], ["groups", 633], ["at", 640], ["SGS", 643], ["Life", 647], ["Sciences", 652], ["Clinical", 661], ["Research", 670], ["Services", 679], [",", 687], ["Belgium", 689], [".", 696], ["Participants", 698], ["were", 711], ["randomly", 716], ["assigned", 725], ["within", 734], ["groups", 741], ["in", 748], ["a", 751], ["3:1", 753], ["ratio", 757], ["to", 763], ["idarucizumab", 766], ["or", 779], ["placebo", 782], ["using", 790], ["a", 796], ["pseudorandom", 798], ["number", 811], ["generator", 818], ["and", 828], ["a", 832], ["supplied", 834], ["seed", 843], ["number", 848], [".", 854], ["Participants", 856], ["and", 869], ["care", 873], ["providers", 878], ["were", 888], ["masked", 893], ["to", 900], ["treatment", 903], ["assignment", 913], [".", 923], ["All", 925], ["participants", 929], ["received", 942], ["oral", 951], ["dabigatran", 956], ["etexilate", 967], ["220", 977], ["mg", 981], ["twice", 984], ["daily", 990], ["for", 996], ["3", 1000], ["days", 1002], ["and", 1007], ["a", 1011], ["final", 1013], ["dose", 1019], ["on", 1024], ["day", 1027], ["4", 1031], [".", 1032], ["Idarucizumab", 1034], ["(", 1047], ["1", 1048], ["g", 1050], [",", 1051], ["2", 1053], ["g", 1055], [",", 1056], ["or", 1058], ["4", 1061], ["g", 1063], ["5-min", 1065], ["infusion", 1071], [",", 1079], ["or", 1081], ["5", 1084], ["g", 1086], ["plus", 1088], ["2\u00b75", 1093], ["g", 1097], ["in", 1099], ["two", 1102], ["5-min", 1106], ["infusions", 1112], ["given", 1122], ["1", 1128], ["h", 1130], ["apart", 1132], [")", 1137], ["was", 1139], ["administered", 1143], ["about", 1156], ["2", 1162], ["h", 1164], ["after", 1166], ["the", 1172], ["final", 1176], ["dabigatran", 1182], ["etexilate", 1193], ["dose", 1203], [".", 1207], ["The", 1209], ["primary", 1213], ["endpoint", 1221], ["was", 1230], ["incidence", 1234], ["of", 1244], ["drug", 1247], ["-", 1251], ["related", 1252], ["adverse", 1260], ["events", 1268], [",", 1274], ["analysed", 1276], ["in", 1285], ["all", 1288], ["randomly", 1292], ["assigned", 1301], ["participants", 1310], ["who", 1323], ["received", 1327], ["at", 1336], ["least", 1339], ["one", 1345], ["dose", 1349], ["of", 1354], ["dabigatran", 1357], ["etexilate", 1368], [".", 1377], ["Reversal", 1379], ["of", 1388], ["diluted", 1391], ["thrombin", 1399], ["time", 1408], ["(", 1413], ["dTT", 1414], [")", 1417], [",", 1418], ["ecarin", 1420], ["clotting", 1427], ["time", 1436], ["(", 1441], ["ECT", 1442], [")", 1445], [",", 1446], ["activated", 1448], ["partial", 1458], ["thromboplastin", 1466], ["time", 1481], ["(", 1486], ["aPTT", 1487], [")", 1491], [",", 1492], ["and", 1494], ["thrombin", 1498], ["time", 1507], ["(", 1512], ["TT", 1513], [")", 1515], ["were", 1517], ["secondary", 1522], ["endpoints", 1532], ["assessed", 1542], ["by", 1551], ["measuring", 1554], ["the", 1564], ["area", 1568], ["under", 1573], ["the", 1579], ["effect", 1583], ["curve", 1590], ["from", 1596], ["2", 1601], ["h", 1603], ["to", 1605], ["12", 1608], ["h", 1611], ["(", 1613], ["AUEC2", 1614], ["-", 1619], ["12", 1620], [")", 1622], ["after", 1624], ["dabigatran", 1630], ["etexilate", 1641], ["ingestion", 1651], ["on", 1661], ["days", 1664], ["3", 1669], ["and", 1671], ["4", 1675], [".", 1676], ["This", 1678], ["trial", 1683], ["is", 1689], ["registered", 1692], ["with", 1703], ["ClinicalTrials.gov", 1708], [",", 1726], ["number", 1728], ["NCT01688830", 1735], [".", 1746], ["Between", 1748], ["Feb", 1756], ["23", 1760], [",", 1762], ["and", 1764], ["Nov", 1768], ["29", 1772], [",", 1774], ["2013", 1776], [",", 1780], ["47", 1782], ["men", 1785], ["completed", 1789], ["this", 1799], ["part", 1804], ["of", 1809], ["the", 1812], ["study", 1816], [".", 1821], ["12", 1823], ["were", 1826], ["enrolled", 1831], ["into", 1840], ["each", 1845], ["of", 1850], ["the", 1853], ["1", 1857], ["g", 1859], [",", 1860], ["2", 1862], ["g", 1864], [",", 1865], ["or", 1867], ["5", 1870], ["g", 1872], ["plus", 1874], ["2\u00b75", 1879], ["g", 1883], ["idarucizumab", 1885], ["groups", 1898], ["(", 1905], ["nine", 1906], ["to", 1911], ["idarucizumab", 1914], ["and", 1927], ["three", 1931], ["to", 1937], ["placebo", 1940], ["in", 1948], ["each", 1951], ["group", 1956], [")", 1961], [",", 1962], ["and", 1964], ["11", 1968], ["were", 1971], ["enrolled", 1976], ["into", 1985], ["the", 1990], ["4", 1994], ["g", 1996], ["idarucizumab", 1998], ["group", 2011], ["(", 2017], ["eight", 2018], ["to", 2024], ["idarucizumab", 2027], ["and", 2040], ["three", 2044], ["to", 2050], ["placebo", 2053], [")", 2060], [".", 2061], ["Drug", 2063], ["-", 2067], ["related", 2068], ["adverse", 2076], ["events", 2084], ["were", 2091], ["all", 2096], ["of", 2100], ["mild", 2103], ["intensity", 2108], ["and", 2118], ["reported", 2122], ["in", 2131], ["seven", 2134], ["participants", 2140], [":", 2152], ["one", 2154], ["in", 2158], ["the", 2161], ["1", 2165], ["g", 2167], ["idarucizumab", 2169], ["group", 2182], ["(", 2188], ["infusion", 2189], ["site", 2198], ["erythema", 2203], ["and", 2212], ["hot", 2216], ["flushes", 2220], [")", 2227], [",", 2228], ["one", 2230], ["in", 2234], ["the", 2237], ["5", 2241], ["g", 2243], ["plus", 2245], ["2\u00b75", 2250], ["g", 2254], ["idarucizumab", 2256], ["group", 2269], ["(", 2275], ["epistaxis", 2276], [")", 2285], [";", 2286], ["one", 2288], ["receiving", 2292], ["placebo", 2302], ["(", 2310], ["infusion", 2311], ["site", 2320], ["haematoma", 2325], [")", 2334], [",", 2335], ["and", 2337], ["four", 2341], ["during", 2346], ["dabigatran", 2353], ["etexilate", 2364], ["pretreatment", 2374], ["(", 2387], ["three", 2388], ["haematuria", 2394], ["and", 2405], ["one", 2409], ["epistaxis", 2413], [")", 2422], [".", 2423], ["Idarucizumab", 2425], ["immediately", 2438], ["and", 2450], ["completely", 2454], ["reversed", 2465], ["dabigatran", 2474], ["-", 2484], ["induced", 2485], ["anticoagulation", 2493], ["in", 2509], ["a", 2512], ["dose", 2514], ["-", 2518], ["dependent", 2519], ["manner", 2529], [";", 2535], ["the", 2537], ["mean", 2541], ["ratio", 2546], ["of", 2552], ["day", 2555], ["4", 2559], ["AUEC2", 2561], ["-", 2566], ["12", 2567], ["to", 2570], ["day", 2573], ["3", 2577], ["AUEC2", 2579], ["-", 2584], ["12", 2585], ["for", 2588], ["dTT", 2592], ["was", 2596], ["1\u00b701", 2600], ["with", 2605], ["placebo", 2610], [",", 2617], ["0\u00b726", 2619], ["with", 2624], ["1", 2629], ["g", 2631], ["idarucizumab", 2633], ["(", 2646], ["74", 2647], ["%", 2649], ["reduction", 2651], [")", 2660], [",", 2661], ["0\u00b706", 2663], ["with", 2668], ["2", 2673], ["g", 2675], ["idarucizumab", 2677], ["(", 2690], ["94", 2691], ["%", 2693], ["reduction", 2695], [")", 2704], [",", 2705], ["0\u00b702", 2707], ["with", 2712], ["4", 2717], ["g", 2719], ["idarucizumab", 2721], ["(", 2734], ["98", 2735], ["%", 2737], ["reduction", 2739], [")", 2748], [",", 2749], ["and", 2751], ["0\u00b701", 2755], ["with", 2760], ["5", 2765], ["g", 2767], ["plus", 2769], ["2\u00b75", 2774], ["g", 2778], ["idarucizumab", 2780], ["(", 2793], ["99", 2794], ["%", 2796], ["reduction", 2798], [")", 2807], [".", 2808], ["No", 2810], ["serious", 2813], ["or", 2821], ["severe", 2824], ["adverse", 2831], ["events", 2839], ["were", 2846], ["reported", 2851], [",", 2859], ["no", 2861], ["adverse", 2864], ["event", 2872], ["led", 2878], ["to", 2882], ["discontinuation", 2885], ["of", 2901], ["treatment", 2904], [",", 2913], ["and", 2915], ["no", 2919], ["clinically", 2922], ["relevant", 2933], ["difference", 2942], ["in", 2953], ["incidence", 2956], ["of", 2966], ["adverse", 2969], ["events", 2977], ["was", 2984], ["noted", 2988], ["between", 2994], ["treatment", 3002], ["groups", 3012], [".", 3018], ["These", 3020], ["phase", 3026], ["1", 3032], ["results", 3034], ["show", 3042], ["that", 3047], ["idarucizumab", 3052], ["was", 3065], ["associated", 3069], ["with", 3080], ["immediate", 3085], [",", 3094], ["complete", 3096], [",", 3104], ["and", 3106], ["sustained", 3110], ["reversal", 3120], ["of", 3129], ["dabigatran", 3132], ["-", 3142], ["induced", 3143], ["anticoagulation", 3151], ["in", 3167], ["healthy", 3170], ["men", 3178], [",", 3181], ["and", 3183], ["was", 3187], ["well", 3191], ["tolerated", 3196], ["with", 3206], ["no", 3211], ["unexpected", 3214], ["or", 3225], ["clinically", 3228], ["relevant", 3239], ["safety", 3248], ["concerns", 3255], [",", 3263], ["supporting", 3265], ["further", 3276], ["testing", 3284], [".", 3291], ["Further", 3293], ["clinical", 3301], ["studies", 3310], ["are", 3318], ["in", 3322], ["progress", 3325], [".", 3333], ["Boehringer", 3335], ["Ingelheim", 3346], ["Pharma", 3356], ["GmbH", 3363], ["&", 3368], ["Co", 3370], ["KG", 3373], [".", 3375]]}
{"context": "We investigated high- or low-dose irradiation-responsive proteins using proteomics on two-dimensional (2D) PAGE, and the effects of ageing on cell responses to radiation in variously aged rat astrocytes. After 5 Gy irradiation, the relative abundance of peroxiredoxin 2, an antioxidant enzyme, and latexin, an inhibitor of carboxypeptidase, increased. The induction of these proteins was suppressed by ageing, suggesting that the response to high-dose radiation decreased with ageing. The relative abundance of elongation factor 2 (EF-2) fragment increased 3 h and reduced 24 h after 0.1 Gy irradiation. Temporal enhancement of the EF-2 fragment due to low-dose irradiation was suppressed by ageing. Since radiation adaptive response in cultured astrocytes was observed 3 h but not 24 h after 0.1 Gy irradiation and suppressed by ageing as previously reported, alteration of the EF-2 fragment corresponded to the radiation adaptive response. We also examined phospho-protein profiles, resulting in the relative abundance of phospho-EF-1beta and phospho-beta-actin being altered by 0.1 Gy irradiation; however, ageing did not affect the alteration of phospho-EF-1beta and phospho-beta-actin, unlike the EF-2 fragment. The results suggested that the EF-2 fragment was a possible candidate for the protein responsible for the radiation adaptive response in cultured astrocytes.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "b7cd2f0a380d4d14b488e20ddf88b204", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[51, 51]], "char_spans": [[274, 284]]}]}], "context_tokens": [["We", 0], ["investigated", 3], ["high-", 16], ["or", 22], ["low", 25], ["-", 28], ["dose", 29], ["irradiation", 34], ["-", 45], ["responsive", 46], ["proteins", 57], ["using", 66], ["proteomics", 72], ["on", 83], ["two", 86], ["-", 89], ["dimensional", 90], ["(", 102], ["2D", 103], [")", 105], ["PAGE", 107], [",", 111], ["and", 113], ["the", 117], ["effects", 121], ["of", 129], ["ageing", 132], ["on", 139], ["cell", 142], ["responses", 147], ["to", 157], ["radiation", 160], ["in", 170], ["variously", 173], ["aged", 183], ["rat", 188], ["astrocytes", 192], [".", 202], ["After", 204], ["5", 210], ["Gy", 212], ["irradiation", 215], [",", 226], ["the", 228], ["relative", 232], ["abundance", 241], ["of", 251], ["peroxiredoxin", 254], ["2", 268], [",", 269], ["an", 271], ["antioxidant", 274], ["enzyme", 286], [",", 292], ["and", 294], ["latexin", 298], [",", 305], ["an", 307], ["inhibitor", 310], ["of", 320], ["carboxypeptidase", 323], [",", 339], ["increased", 341], [".", 350], ["The", 352], ["induction", 356], ["of", 366], ["these", 369], ["proteins", 375], ["was", 384], ["suppressed", 388], ["by", 399], ["ageing", 402], [",", 408], ["suggesting", 410], ["that", 421], ["the", 426], ["response", 430], ["to", 439], ["high", 442], ["-", 446], ["dose", 447], ["radiation", 452], ["decreased", 462], ["with", 472], ["ageing", 477], [".", 483], ["The", 485], ["relative", 489], ["abundance", 498], ["of", 508], ["elongation", 511], ["factor", 522], ["2", 529], ["(", 531], ["EF-2", 532], [")", 536], ["fragment", 538], ["increased", 547], ["3", 557], ["h", 559], ["and", 561], ["reduced", 565], ["24", 573], ["h", 576], ["after", 578], ["0.1", 584], ["Gy", 588], ["irradiation", 591], [".", 602], ["Temporal", 604], ["enhancement", 613], ["of", 625], ["the", 628], ["EF-2", 632], ["fragment", 637], ["due", 646], ["to", 650], ["low", 653], ["-", 656], ["dose", 657], ["irradiation", 662], ["was", 674], ["suppressed", 678], ["by", 689], ["ageing", 692], [".", 698], ["Since", 700], ["radiation", 706], ["adaptive", 716], ["response", 725], ["in", 734], ["cultured", 737], ["astrocytes", 746], ["was", 757], ["observed", 761], ["3", 770], ["h", 772], ["but", 774], ["not", 778], ["24", 782], ["h", 785], ["after", 787], ["0.1", 793], ["Gy", 797], ["irradiation", 800], ["and", 812], ["suppressed", 816], ["by", 827], ["ageing", 830], ["as", 837], ["previously", 840], ["reported", 851], [",", 859], ["alteration", 861], ["of", 872], ["the", 875], ["EF-2", 879], ["fragment", 884], ["corresponded", 893], ["to", 906], ["the", 909], ["radiation", 913], ["adaptive", 923], ["response", 932], [".", 940], ["We", 942], ["also", 945], ["examined", 950], ["phospho", 959], ["-", 966], ["protein", 967], ["profiles", 975], [",", 983], ["resulting", 985], ["in", 995], ["the", 998], ["relative", 1002], ["abundance", 1011], ["of", 1021], ["phospho", 1024], ["-", 1031], ["EF-1beta", 1032], ["and", 1041], ["phospho", 1045], ["-", 1052], ["beta", 1053], ["-", 1057], ["actin", 1058], ["being", 1064], ["altered", 1070], ["by", 1078], ["0.1", 1081], ["Gy", 1085], ["irradiation", 1088], [";", 1099], ["however", 1101], [",", 1108], ["ageing", 1110], ["did", 1117], ["not", 1121], ["affect", 1125], ["the", 1132], ["alteration", 1136], ["of", 1147], ["phospho", 1150], ["-", 1157], ["EF-1beta", 1158], ["and", 1167], ["phospho", 1171], ["-", 1178], ["beta", 1179], ["-", 1183], ["actin", 1184], [",", 1189], ["unlike", 1191], ["the", 1198], ["EF-2", 1202], ["fragment", 1207], [".", 1215], ["The", 1217], ["results", 1221], ["suggested", 1229], ["that", 1239], ["the", 1244], ["EF-2", 1248], ["fragment", 1253], ["was", 1262], ["a", 1266], ["possible", 1268], ["candidate", 1277], ["for", 1287], ["the", 1291], ["protein", 1295], ["responsible", 1303], ["for", 1315], ["the", 1319], ["radiation", 1323], ["adaptive", 1333], ["response", 1342], ["in", 1351], ["cultured", 1354], ["astrocytes", 1363], [".", 1373]]}
{"context": "The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Data were obtained from the Psocare Registry on those patients (n\u00a0=\u00a04946) with age >\u00a018\u00a0years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Latent tuberculosis infection was diagnosed in 8\u00b73% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4\u00b73% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen-ultraviolet A (P\u00a0<\u00a00\u00b705). Independent factors associated with LTBI were male sex [odds ratio (OR) 1\u00b730, 95% confidence interval (CI) 1\u00b704-1\u00b762; P\u00a0=\u00a00\u00b702], age over 55\u00a0years (OR 2\u00b793, 95% CI 2\u00b718-3\u00b793; P\u00a0<\u00a00\u00b7001) and being entered into a conventional treatment (OR 3\u00b783, 95% CI 3\u00b710-4\u00b774; P\u00a0<\u00a00\u00b7001). Positive history of tuberculosis was seen in 1% of patients (n\u00a0=\u00a049). The nationwide prevalence of LTBI in Italian patients with psoriasis candidate to systemic treatment is high, and screening is recommended prior to biological treatment.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "4edb95a363144efdb21977cc7f1912a8", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[104, 104], [5, 5], [101, 101], [250, 250]], "char_spans": [[615, 626], [36, 47], [594, 605], [1229, 1240]]}]}], "context_tokens": [["The", 0], ["nationwide", 4], ["prevalence", 15], ["of", 26], ["latent", 29], ["tuberculosis", 36], ["infection", 49], ["(", 59], ["LTBI", 60], [")", 64], ["in", 66], ["Italian", 69], ["patients", 77], ["with", 86], ["psoriasis", 91], ["has", 101], ["never", 105], ["been", 111], ["investigated", 116], [".", 128], ["To", 130], ["estimate", 133], ["the", 142], ["nationwide", 146], ["prevalence", 157], ["of", 168], ["LTBI", 171], ["in", 176], ["Italian", 179], ["patients", 187], ["with", 196], ["psoriasis", 201], ["who", 211], ["are", 215], ["candidates", 219], ["for", 230], ["systemic", 234], ["treatment", 243], [".", 252], ["Data", 254], ["were", 259], ["obtained", 264], ["from", 273], ["the", 278], ["Psocare", 282], ["Registry", 290], ["on", 299], ["those", 302], ["patients", 308], ["(", 317], ["n", 318], ["=", 320], ["4946", 322], [")", 326], ["with", 328], ["age", 333], [">", 337], ["18", 339], ["years", 342], [",", 347], ["systemic", 349], ["treatment", 358], ["at", 368], ["entry", 371], ["specified", 377], ["and", 387], ["tuberculin", 391], ["skin", 402], ["test", 407], ["(", 412], ["TST", 413], [")", 416], ["performed", 418], ["according", 428], ["to", 438], ["the", 441], ["Mantoux", 445], ["method", 453], [".", 459], ["LTBI", 461], ["diagnosis", 466], ["was", 476], ["based", 480], ["on", 486], ["a", 489], ["positive", 491], ["TST", 500], ["result", 504], ["in", 511], ["the", 514], ["absence", 518], ["of", 526], ["any", 529], ["clinical", 533], [",", 541], ["radiological", 543], ["or", 556], ["microbiological", 559], ["evidence", 575], ["of", 584], ["active", 587], ["tuberculosis", 594], [".", 606], ["Latent", 608], ["tuberculosis", 615], ["infection", 628], ["was", 638], ["diagnosed", 642], ["in", 652], ["8\u00b73", 655], ["%", 658], ["of", 660], ["patients", 663], ["with", 672], ["psoriasis", 677], ["(", 687], ["409", 688], ["of", 692], ["4946", 695], [")", 699], [".", 700], ["The", 702], ["prevalence", 706], ["of", 717], ["LTBI", 720], ["was", 725], ["lower", 729], ["in", 735], ["patients", 738], ["on", 747], ["biologics", 750], ["than", 760], ["in", 765], ["those", 768], ["on", 774], ["conventional", 777], ["systemic", 790], ["treatments", 799], [",", 809], ["ranging", 811], ["from", 819], ["4\u00b73", 824], ["%", 827], ["(", 829], ["19", 830], ["of", 833], ["444", 836], [")", 839], ["of", 841], ["patients", 844], ["on", 853], ["adalimumab", 856], ["to", 867], ["31", 870], ["%", 872], ["(", 874], ["eight", 875], ["of", 881], ["26", 884], [")", 886], ["of", 888], ["those", 891], ["on", 897], ["psoralen", 900], ["-", 908], ["ultraviolet", 909], ["A", 921], ["(", 923], ["P", 924], ["<", 926], ["0\u00b705", 928], [")", 932], [".", 933], ["Independent", 935], ["factors", 947], ["associated", 955], ["with", 966], ["LTBI", 971], ["were", 976], ["male", 981], ["sex", 986], ["[", 990], ["odds", 991], ["ratio", 996], ["(", 1002], ["OR", 1003], [")", 1005], ["1\u00b730", 1007], [",", 1011], ["95", 1013], ["%", 1015], ["confidence", 1017], ["interval", 1028], ["(", 1037], ["CI", 1038], [")", 1040], ["1\u00b704", 1042], ["-", 1046], ["1\u00b762", 1047], [";", 1051], ["P", 1053], ["=", 1055], ["0\u00b702", 1057], ["]", 1061], [",", 1062], ["age", 1064], ["over", 1068], ["55", 1073], ["years", 1076], ["(", 1082], ["OR", 1083], ["2\u00b793", 1086], [",", 1090], ["95", 1092], ["%", 1094], ["CI", 1096], ["2\u00b718", 1099], ["-", 1103], ["3\u00b793", 1104], [";", 1108], ["P", 1110], ["<", 1112], ["0\u00b7001", 1114], [")", 1119], ["and", 1121], ["being", 1125], ["entered", 1131], ["into", 1139], ["a", 1144], ["conventional", 1146], ["treatment", 1159], ["(", 1169], ["OR", 1170], ["3\u00b783", 1173], [",", 1177], ["95", 1179], ["%", 1181], ["CI", 1183], ["3\u00b710", 1186], ["-", 1190], ["4\u00b774", 1191], [";", 1195], ["P", 1197], ["<", 1199], ["0\u00b7001", 1201], [")", 1206], [".", 1207], ["Positive", 1209], ["history", 1218], ["of", 1226], ["tuberculosis", 1229], ["was", 1242], ["seen", 1246], ["in", 1251], ["1", 1254], ["%", 1255], ["of", 1257], ["patients", 1260], ["(", 1269], ["n", 1270], ["=", 1272], ["49", 1274], [")", 1276], [".", 1277], ["The", 1279], ["nationwide", 1283], ["prevalence", 1294], ["of", 1305], ["LTBI", 1308], ["in", 1313], ["Italian", 1316], ["patients", 1324], ["with", 1333], ["psoriasis", 1338], ["candidate", 1348], ["to", 1358], ["systemic", 1361], ["treatment", 1370], ["is", 1380], ["high", 1383], [",", 1387], ["and", 1389], ["screening", 1393], ["is", 1403], ["recommended", 1406], ["prior", 1418], ["to", 1424], ["biological", 1427], ["treatment", 1438], [".", 1447]]}
{"context": "The generation of reactive oxygen species (ROS) is required for proper cell signaling, but must be tightly regulated to minimize deleterious oxidizing effects. Activation of the NADPH oxidases (Nox) triggers ROS production and, thus, regulatory mechanisms exist to properly control Nox activity. In this study, we report a novel mechanism in which Nox1 activity is regulated through the proteasomal degradation of Nox organizer 1 (NoxO1). We found that through the interaction between NoxO1 and growth receptor-bound protein 2 (Grb2), the Casitas B-lineage lymphoma (Cbl) E3 ligase was recruited, leading to decreased NoxO1 stability and a subsequent reduction in ROS generation upon epidermal growth factor (EGF) stimulation. Additionally, we show that EGF-mediated phosphorylation of NoxO1 induced its release from Grb2 and facilitated its association with Nox activator 1 (NoxA1) to stimulate ROS production. Consistently, overexpression of Grb2 resulted in decreased Nox1 activity, whereas knockdown of Grb2 led to increased Nox1 activity in response to EGF. CRISPR/Cas9-mediated NoxO1 knockout in human colon cancer cells abrogated anchorage-independent growth on soft agar and tumor-forming ability in athymic nude mice. Moreover, the expression and stability of NoxO1 were significantly increased in human colon cancer tissues compared with normal colon. Taken together, these results support a model whereby Nox1 activity and ROS generation are regulated by Grb2/Cbl-mediated proteolysis of NoxO1 in response to EGF, providing new insight into the processes by which excessive ROS production may promote oncogenic signaling to drive colorectal tumorigenesis.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "9017897d71c2434d90f474f17544eebd", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[172, 172], [247, 247], [182, 182], [62, 62]], "char_spans": [[971, 974], [1416, 1419], [1029, 1032], [348, 351]]}]}], "context_tokens": [["The", 0], ["generation", 4], ["of", 15], ["reactive", 18], ["oxygen", 27], ["species", 34], ["(", 42], ["ROS", 43], [")", 46], ["is", 48], ["required", 51], ["for", 60], ["proper", 64], ["cell", 71], ["signaling", 76], [",", 85], ["but", 87], ["must", 91], ["be", 96], ["tightly", 99], ["regulated", 107], ["to", 117], ["minimize", 120], ["deleterious", 129], ["oxidizing", 141], ["effects", 151], [".", 158], ["Activation", 160], ["of", 171], ["the", 174], ["NADPH", 178], ["oxidases", 184], ["(", 193], ["Nox", 194], [")", 197], ["triggers", 199], ["ROS", 208], ["production", 212], ["and", 223], [",", 226], ["thus", 228], [",", 232], ["regulatory", 234], ["mechanisms", 245], ["exist", 256], ["to", 262], ["properly", 265], ["control", 274], ["Nox", 282], ["activity", 286], [".", 294], ["In", 296], ["this", 299], ["study", 304], [",", 309], ["we", 311], ["report", 314], ["a", 321], ["novel", 323], ["mechanism", 329], ["in", 339], ["which", 342], ["Nox1", 348], ["activity", 353], ["is", 362], ["regulated", 365], ["through", 375], ["the", 383], ["proteasomal", 387], ["degradation", 399], ["of", 411], ["Nox", 414], ["organizer", 418], ["1", 428], ["(", 430], ["NoxO1", 431], [")", 436], [".", 437], ["We", 439], ["found", 442], ["that", 448], ["through", 453], ["the", 461], ["interaction", 465], ["between", 477], ["NoxO1", 485], ["and", 491], ["growth", 495], ["receptor", 502], ["-", 510], ["bound", 511], ["protein", 517], ["2", 525], ["(", 527], ["Grb2", 528], [")", 532], [",", 533], ["the", 535], ["Casitas", 539], ["B", 547], ["-", 548], ["lineage", 549], ["lymphoma", 557], ["(", 566], ["Cbl", 567], [")", 570], ["E3", 572], ["ligase", 575], ["was", 582], ["recruited", 586], [",", 595], ["leading", 597], ["to", 605], ["decreased", 608], ["NoxO1", 618], ["stability", 624], ["and", 634], ["a", 638], ["subsequent", 640], ["reduction", 651], ["in", 661], ["ROS", 664], ["generation", 668], ["upon", 679], ["epidermal", 684], ["growth", 694], ["factor", 701], ["(", 708], ["EGF", 709], [")", 712], ["stimulation", 714], [".", 725], ["Additionally", 727], [",", 739], ["we", 741], ["show", 744], ["that", 749], ["EGF", 754], ["-", 757], ["mediated", 758], ["phosphorylation", 767], ["of", 783], ["NoxO1", 786], ["induced", 792], ["its", 800], ["release", 804], ["from", 812], ["Grb2", 817], ["and", 822], ["facilitated", 826], ["its", 838], ["association", 842], ["with", 854], ["Nox", 859], ["activator", 863], ["1", 873], ["(", 875], ["NoxA1", 876], [")", 881], ["to", 883], ["stimulate", 886], ["ROS", 896], ["production", 900], [".", 910], ["Consistently", 912], [",", 924], ["overexpression", 926], ["of", 941], ["Grb2", 944], ["resulted", 949], ["in", 958], ["decreased", 961], ["Nox1", 971], ["activity", 976], [",", 984], ["whereas", 986], ["knockdown", 994], ["of", 1004], ["Grb2", 1007], ["led", 1012], ["to", 1016], ["increased", 1019], ["Nox1", 1029], ["activity", 1034], ["in", 1043], ["response", 1046], ["to", 1055], ["EGF", 1058], [".", 1061], ["CRISPR", 1063], ["/", 1069], ["Cas9-mediated", 1070], ["NoxO1", 1084], ["knockout", 1090], ["in", 1099], ["human", 1102], ["colon", 1108], ["cancer", 1114], ["cells", 1121], ["abrogated", 1127], ["anchorage", 1137], ["-", 1146], ["independent", 1147], ["growth", 1159], ["on", 1166], ["soft", 1169], ["agar", 1174], ["and", 1179], ["tumor", 1183], ["-", 1188], ["forming", 1189], ["ability", 1197], ["in", 1205], ["athymic", 1208], ["nude", 1216], ["mice", 1221], [".", 1225], ["Moreover", 1227], [",", 1235], ["the", 1237], ["expression", 1241], ["and", 1252], ["stability", 1256], ["of", 1266], ["NoxO1", 1269], ["were", 1275], ["significantly", 1280], ["increased", 1294], ["in", 1304], ["human", 1307], ["colon", 1313], ["cancer", 1319], ["tissues", 1326], ["compared", 1334], ["with", 1343], ["normal", 1348], ["colon", 1355], [".", 1360], ["Taken", 1362], ["together", 1368], [",", 1376], ["these", 1378], ["results", 1384], ["support", 1392], ["a", 1400], ["model", 1402], ["whereby", 1408], ["Nox1", 1416], ["activity", 1421], ["and", 1430], ["ROS", 1434], ["generation", 1438], ["are", 1449], ["regulated", 1453], ["by", 1463], ["Grb2/Cbl", 1466], ["-", 1474], ["mediated", 1475], ["proteolysis", 1484], ["of", 1496], ["NoxO1", 1499], ["in", 1505], ["response", 1508], ["to", 1517], ["EGF", 1520], [",", 1523], ["providing", 1525], ["new", 1535], ["insight", 1539], ["into", 1547], ["the", 1552], ["processes", 1556], ["by", 1566], ["which", 1569], ["excessive", 1575], ["ROS", 1585], ["production", 1589], ["may", 1600], ["promote", 1604], ["oncogenic", 1612], ["signaling", 1622], ["to", 1632], ["drive", 1635], ["colorectal", 1641], ["tumorigenesis", 1652], [".", 1665]]}
{"context": "To investigate the influence of age and gender on the components of the 28-joint Disease Activity Score (DAS28) in patients with rheumatoid arthritis (RA), and to clarify whether a high DAS28 can be equally interpreted in all age groups, independent of gender. A prospective cohort of 553 patients with RA was studied for approximately 20 years after diagnosis. The single measures of disease activity and the share of different components of the DAS28 (eg, erythrocyte sedimentation rate; ESR) were analysed and compared between three age groups (<45, 45-65 and >65 years) and per gender, using analysis of variance (ANOVA). The performance of the DAS28 and its components was explored in moderate to high and low DAS28 categories. Linear mixed model analysis was used to design the models best predicting ESR and the share of ESR. ESR significantly increased with age, independent of other variables of disease activity. This increase was more pronounced in male than in female patients. Nevertheless, the share of ESR increased with age only in male patients with a low DAS28 (<3.2). If the DAS28 score was >3.2, age and gender did not have a significant effect on any components of the DAS28. C-reactive protein (CRP) and DAS28(CRP) were not influenced by age. A high DAS28 was found to perform equally in all age groups, in men and women, despite the elevating effect of age on ESR. In elderly men with low disease activity, remission rate could be underestimated by an elevated ESR.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "a41b67e4e4004aa6a155ea9bb5d45fc4", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[264, 264]], "char_spans": [[1337, 1341]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["influence", 19], ["of", 29], ["age", 32], ["and", 36], ["gender", 40], ["on", 47], ["the", 50], ["components", 54], ["of", 65], ["the", 68], ["28-joint", 72], ["Disease", 81], ["Activity", 89], ["Score", 98], ["(", 104], ["DAS28", 105], [")", 110], ["in", 112], ["patients", 115], ["with", 124], ["rheumatoid", 129], ["arthritis", 140], ["(", 150], ["RA", 151], [")", 153], [",", 154], ["and", 156], ["to", 160], ["clarify", 163], ["whether", 171], ["a", 179], ["high", 181], ["DAS28", 186], ["can", 192], ["be", 196], ["equally", 199], ["interpreted", 207], ["in", 219], ["all", 222], ["age", 226], ["groups", 230], [",", 236], ["independent", 238], ["of", 250], ["gender", 253], [".", 259], ["A", 261], ["prospective", 263], ["cohort", 275], ["of", 282], ["553", 285], ["patients", 289], ["with", 298], ["RA", 303], ["was", 306], ["studied", 310], ["for", 318], ["approximately", 322], ["20", 336], ["years", 339], ["after", 345], ["diagnosis", 351], [".", 360], ["The", 362], ["single", 366], ["measures", 373], ["of", 382], ["disease", 385], ["activity", 393], ["and", 402], ["the", 406], ["share", 410], ["of", 416], ["different", 419], ["components", 429], ["of", 440], ["the", 443], ["DAS28", 447], ["(", 453], ["eg", 454], [",", 456], ["erythrocyte", 458], ["sedimentation", 470], ["rate", 484], [";", 488], ["ESR", 490], [")", 493], ["were", 495], ["analysed", 500], ["and", 509], ["compared", 513], ["between", 522], ["three", 530], ["age", 536], ["groups", 540], ["(", 547], ["<", 548], ["45", 549], [",", 551], ["45", 553], ["-", 555], ["65", 556], ["and", 559], [">", 563], ["65", 564], ["years", 567], [")", 572], ["and", 574], ["per", 578], ["gender", 582], [",", 588], ["using", 590], ["analysis", 596], ["of", 605], ["variance", 608], ["(", 617], ["ANOVA", 618], [")", 623], [".", 624], ["The", 626], ["performance", 630], ["of", 642], ["the", 645], ["DAS28", 649], ["and", 655], ["its", 659], ["components", 663], ["was", 674], ["explored", 678], ["in", 687], ["moderate", 690], ["to", 699], ["high", 702], ["and", 707], ["low", 711], ["DAS28", 715], ["categories", 721], [".", 731], ["Linear", 733], ["mixed", 740], ["model", 746], ["analysis", 752], ["was", 761], ["used", 765], ["to", 770], ["design", 773], ["the", 780], ["models", 784], ["best", 791], ["predicting", 796], ["ESR", 807], ["and", 811], ["the", 815], ["share", 819], ["of", 825], ["ESR", 828], [".", 831], ["ESR", 833], ["significantly", 837], ["increased", 851], ["with", 861], ["age", 866], [",", 869], ["independent", 871], ["of", 883], ["other", 886], ["variables", 892], ["of", 902], ["disease", 905], ["activity", 913], [".", 921], ["This", 923], ["increase", 928], ["was", 937], ["more", 941], ["pronounced", 946], ["in", 957], ["male", 960], ["than", 965], ["in", 970], ["female", 973], ["patients", 980], [".", 988], ["Nevertheless", 990], [",", 1002], ["the", 1004], ["share", 1008], ["of", 1014], ["ESR", 1017], ["increased", 1021], ["with", 1031], ["age", 1036], ["only", 1040], ["in", 1045], ["male", 1048], ["patients", 1053], ["with", 1062], ["a", 1067], ["low", 1069], ["DAS28", 1073], ["(", 1079], ["<", 1080], ["3.2", 1081], [")", 1084], [".", 1085], ["If", 1087], ["the", 1090], ["DAS28", 1094], ["score", 1100], ["was", 1106], [">", 1110], ["3.2", 1111], [",", 1114], ["age", 1116], ["and", 1120], ["gender", 1124], ["did", 1131], ["not", 1135], ["have", 1139], ["a", 1144], ["significant", 1146], ["effect", 1158], ["on", 1165], ["any", 1168], ["components", 1172], ["of", 1183], ["the", 1186], ["DAS28", 1190], [".", 1195], ["C", 1197], ["-", 1198], ["reactive", 1199], ["protein", 1208], ["(", 1216], ["CRP", 1217], [")", 1220], ["and", 1222], ["DAS28(CRP", 1226], [")", 1235], ["were", 1237], ["not", 1242], ["influenced", 1246], ["by", 1257], ["age", 1260], [".", 1263], ["A", 1265], ["high", 1267], ["DAS28", 1272], ["was", 1278], ["found", 1282], ["to", 1288], ["perform", 1291], ["equally", 1299], ["in", 1307], ["all", 1310], ["age", 1314], ["groups", 1318], [",", 1324], ["in", 1326], ["men", 1329], ["and", 1333], ["women", 1337], [",", 1342], ["despite", 1344], ["the", 1352], ["elevating", 1356], ["effect", 1366], ["of", 1373], ["age", 1376], ["on", 1380], ["ESR", 1383], [".", 1386], ["In", 1388], ["elderly", 1391], ["men", 1399], ["with", 1403], ["low", 1408], ["disease", 1412], ["activity", 1420], [",", 1428], ["remission", 1430], ["rate", 1440], ["could", 1445], ["be", 1451], ["underestimated", 1454], ["by", 1469], ["an", 1472], ["elevated", 1475], ["ESR", 1484], [".", 1487]]}
{"context": "During 1970 and 1971, I discovered that a devastating disease of potato plants is not caused by a virus, as had been assumed, but by a new type of subviral pathogen, the viroid. Viroids are so small--one fiftieth of the size of the smallest viruses--that many scientists initially doubted their existence. We now know that viroids cause many damaging diseases of crop plants. Fortunately, new methods that are based on the unique properties of viroids now promise effective control.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "bb93a89c6e904635a4afe3015d50c0e3", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[65, 65], [86, 86], [38, 38]], "char_spans": [[323, 329], [444, 450], [178, 184]]}]}], "context_tokens": [["During", 0], ["1970", 7], ["and", 12], ["1971", 16], [",", 20], ["I", 22], ["discovered", 24], ["that", 35], ["a", 40], ["devastating", 42], ["disease", 54], ["of", 62], ["potato", 65], ["plants", 72], ["is", 79], ["not", 82], ["caused", 86], ["by", 93], ["a", 96], ["virus", 98], [",", 103], ["as", 105], ["had", 108], ["been", 112], ["assumed", 117], [",", 124], ["but", 126], ["by", 130], ["a", 133], ["new", 135], ["type", 139], ["of", 144], ["subviral", 147], ["pathogen", 156], [",", 164], ["the", 166], ["viroid", 170], [".", 176], ["Viroids", 178], ["are", 186], ["so", 190], ["small", 193], ["--", 198], ["one", 200], ["fiftieth", 204], ["of", 213], ["the", 216], ["size", 220], ["of", 225], ["the", 228], ["smallest", 232], ["viruses", 241], ["--", 248], ["that", 250], ["many", 255], ["scientists", 260], ["initially", 271], ["doubted", 281], ["their", 289], ["existence", 295], [".", 304], ["We", 306], ["now", 309], ["know", 313], ["that", 318], ["viroids", 323], ["cause", 331], ["many", 337], ["damaging", 342], ["diseases", 351], ["of", 360], ["crop", 363], ["plants", 368], [".", 374], ["Fortunately", 376], [",", 387], ["new", 389], ["methods", 393], ["that", 401], ["are", 406], ["based", 410], ["on", 416], ["the", 419], ["unique", 423], ["properties", 430], ["of", 441], ["viroids", 444], ["now", 452], ["promise", 456], ["effective", 464], ["control", 474], [".", 481]]}
{"context": "Transcription of the major Bacillus anthracis virulence genes is triggered by CO2, a signal mimicking the host environment. A 182-kb plasmid, pXO1, carries the anthrax toxin genes and the genes responsible for their regulation of transcription, namely atxA and, pagR, the second gene of the pag operon. AtxA has major effects on the physiology of B. anthracis. It coordinates the transcription activation of the toxin genes with that of the capsule biosynthetic enzyme operon, located on the second virulence plasmid, pXO2. In rich medium, B. anthracis synthesises alternatively two S-layer proteins (Sap and EA1). An exponential phase \"Sap-layer\" is subsequently replaced by a stationary phase \"EA1-layer\". S-layer gene transcription is controlled by alternative sigma factors and by Sap acting as a transcriptional repressor of eag. Furthermore, in vitro in presence of CO2 and in vivo, AtxA is part of the sap and eag regulatory network. Only eag is significantly expressed in these conditions and this is due to AtxA activating eag and repressing sap transcription. PagR, and not AtxA itself, is the direct effector of this regulation by binding to sap and eag promoter regions. Therefore, PagR mediates the effect of AtxA on eag and sap and is the most downstream element of a signalling cascade initiated by AtxA. Taken together, these results indicate that the B. anthracis transcriptional regulator AtxA is controlling the synthesis of the three toxin components and of the surface elements (capsule and S-layer). Thus, AtxA is a master regulator that coordinates the response to host signals by orchestrating positive and negative controls over genes located on all genetic elements.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "877eabc12fb54287bc30ec4db7f37e8a", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "CO2", "token_spans": [[160, 160], [11, 11]], "char_spans": [[872, 874], [78, 80]]}]}], "context_tokens": [["Transcription", 0], ["of", 14], ["the", 17], ["major", 21], ["Bacillus", 27], ["anthracis", 36], ["virulence", 46], ["genes", 56], ["is", 62], ["triggered", 65], ["by", 75], ["CO2", 78], [",", 81], ["a", 83], ["signal", 85], ["mimicking", 92], ["the", 102], ["host", 106], ["environment", 111], [".", 122], ["A", 124], ["182-kb", 126], ["plasmid", 133], [",", 140], ["pXO1", 142], [",", 146], ["carries", 148], ["the", 156], ["anthrax", 160], ["toxin", 168], ["genes", 174], ["and", 180], ["the", 184], ["genes", 188], ["responsible", 194], ["for", 206], ["their", 210], ["regulation", 216], ["of", 227], ["transcription", 230], [",", 243], ["namely", 245], ["atxA", 252], ["and", 257], [",", 260], ["pagR", 262], [",", 266], ["the", 268], ["second", 272], ["gene", 279], ["of", 284], ["the", 287], ["pag", 291], ["operon", 295], [".", 301], ["AtxA", 303], ["has", 308], ["major", 312], ["effects", 318], ["on", 326], ["the", 329], ["physiology", 333], ["of", 344], ["B.", 347], ["anthracis", 350], [".", 359], ["It", 361], ["coordinates", 364], ["the", 376], ["transcription", 380], ["activation", 394], ["of", 405], ["the", 408], ["toxin", 412], ["genes", 418], ["with", 424], ["that", 429], ["of", 434], ["the", 437], ["capsule", 441], ["biosynthetic", 449], ["enzyme", 462], ["operon", 469], [",", 475], ["located", 477], ["on", 485], ["the", 488], ["second", 492], ["virulence", 499], ["plasmid", 509], [",", 516], ["pXO2", 518], [".", 522], ["In", 524], ["rich", 527], ["medium", 532], [",", 538], ["B.", 540], ["anthracis", 543], ["synthesises", 553], ["alternatively", 565], ["two", 579], ["S", 583], ["-", 584], ["layer", 585], ["proteins", 591], ["(", 600], ["Sap", 601], ["and", 605], ["EA1", 609], [")", 612], [".", 613], ["An", 615], ["exponential", 618], ["phase", 630], ["\"", 636], ["Sap", 637], ["-", 640], ["layer", 641], ["\"", 646], ["is", 648], ["subsequently", 651], ["replaced", 664], ["by", 673], ["a", 676], ["stationary", 678], ["phase", 689], ["\"", 695], ["EA1-layer", 696], ["\"", 705], [".", 706], ["S", 708], ["-", 709], ["layer", 710], ["gene", 716], ["transcription", 721], ["is", 735], ["controlled", 738], ["by", 749], ["alternative", 752], ["sigma", 764], ["factors", 770], ["and", 778], ["by", 782], ["Sap", 785], ["acting", 789], ["as", 796], ["a", 799], ["transcriptional", 801], ["repressor", 817], ["of", 827], ["eag", 830], [".", 833], ["Furthermore", 835], [",", 846], ["in", 848], ["vitro", 851], ["in", 857], ["presence", 860], ["of", 869], ["CO2", 872], ["and", 876], ["in", 880], ["vivo", 883], [",", 887], ["AtxA", 889], ["is", 894], ["part", 897], ["of", 902], ["the", 905], ["sap", 909], ["and", 913], ["eag", 917], ["regulatory", 921], ["network", 932], [".", 939], ["Only", 941], ["eag", 946], ["is", 950], ["significantly", 953], ["expressed", 967], ["in", 977], ["these", 980], ["conditions", 986], ["and", 997], ["this", 1001], ["is", 1006], ["due", 1009], ["to", 1013], ["AtxA", 1016], ["activating", 1021], ["eag", 1032], ["and", 1036], ["repressing", 1040], ["sap", 1051], ["transcription", 1055], [".", 1068], ["PagR", 1070], [",", 1074], ["and", 1076], ["not", 1080], ["AtxA", 1084], ["itself", 1089], [",", 1095], ["is", 1097], ["the", 1100], ["direct", 1104], ["effector", 1111], ["of", 1120], ["this", 1123], ["regulation", 1128], ["by", 1139], ["binding", 1142], ["to", 1150], ["sap", 1153], ["and", 1157], ["eag", 1161], ["promoter", 1165], ["regions", 1174], [".", 1181], ["Therefore", 1183], [",", 1192], ["PagR", 1194], ["mediates", 1199], ["the", 1208], ["effect", 1212], ["of", 1219], ["AtxA", 1222], ["on", 1227], ["eag", 1230], ["and", 1234], ["sap", 1238], ["and", 1242], ["is", 1246], ["the", 1249], ["most", 1253], ["downstream", 1258], ["element", 1269], ["of", 1277], ["a", 1280], ["signalling", 1282], ["cascade", 1293], ["initiated", 1301], ["by", 1311], ["AtxA.", 1314], ["Taken", 1320], ["together", 1326], [",", 1334], ["these", 1336], ["results", 1342], ["indicate", 1350], ["that", 1359], ["the", 1364], ["B.", 1368], ["anthracis", 1371], ["transcriptional", 1381], ["regulator", 1397], ["AtxA", 1407], ["is", 1412], ["controlling", 1415], ["the", 1427], ["synthesis", 1431], ["of", 1441], ["the", 1444], ["three", 1448], ["toxin", 1454], ["components", 1460], ["and", 1471], ["of", 1475], ["the", 1478], ["surface", 1482], ["elements", 1490], ["(", 1499], ["capsule", 1500], ["and", 1508], ["S", 1512], ["-", 1513], ["layer", 1514], [")", 1519], [".", 1520], ["Thus", 1522], [",", 1526], ["AtxA", 1528], ["is", 1533], ["a", 1536], ["master", 1538], ["regulator", 1545], ["that", 1555], ["coordinates", 1560], ["the", 1572], ["response", 1576], ["to", 1585], ["host", 1588], ["signals", 1593], ["by", 1601], ["orchestrating", 1604], ["positive", 1618], ["and", 1627], ["negative", 1631], ["controls", 1640], ["over", 1649], ["genes", 1654], ["located", 1660], ["on", 1668], ["all", 1671], ["genetic", 1675], ["elements", 1683], [".", 1691]]}
{"context": "It has been reported that the R497K polymorphism of the epidermal growth factor receptor (EGFR) gene has attenuated functions in ligand binding, tyrosine kinase activation, and growth stimulation. On other hand, EGFR gene mutations at kinase domain in non-small cell lung cancer (NSCLC) have been examined for their ability to predict sensitivity to gefitinib or erlotinib. We investigated the EGFR mutations and/or R497K polymorphism statuses in 225 surgically treated NSCLC cases. 192 adenocarcinoma cases were included. The presence or absence of EGFR polymorphism of exon 13 was analyzed by PCR-RFLP method. EGFR mutations at kinase domain were found from 95 of 225 lung cancer patients. In 86.2% of patients, homo- or heterozygous Lys497 allele was present. No correlation existed between R497K EGFR genotype and clinico-pathological features, such as gender, smoking status, and pathological subtypes. EGFR mutation status was not correlated with R497KEGFR genotype of lung cancers. In node-negative patients, R497KEGFR genotype was not correlated with disease outcome. In node-positive patients, however, R497K EGFR was significantly associated with better overall survival. This association was attributable to neo-adjuvant or adjuvant chemotherapy. In 46 total gefitinib treated NSCLC patients, the prognosis was not different between the EGFR wild type (GG) patients and AG+AA patients. R497KEGFR polymorphism might be associated with favorable prognosis of advanced lung cancers and correlated with chemosensitivity.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "98bf14cf3f54411fb46b808b1029b76d", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[11, 18]], "char_spans": [[56, 99]]}]}], "context_tokens": [["It", 0], ["has", 3], ["been", 7], ["reported", 12], ["that", 21], ["the", 26], ["R497", 30], ["K", 34], ["polymorphism", 36], ["of", 49], ["the", 52], ["epidermal", 56], ["growth", 66], ["factor", 73], ["receptor", 80], ["(", 89], ["EGFR", 90], [")", 94], ["gene", 96], ["has", 101], ["attenuated", 105], ["functions", 116], ["in", 126], ["ligand", 129], ["binding", 136], [",", 143], ["tyrosine", 145], ["kinase", 154], ["activation", 161], [",", 171], ["and", 173], ["growth", 177], ["stimulation", 184], [".", 195], ["On", 197], ["other", 200], ["hand", 206], [",", 210], ["EGFR", 212], ["gene", 217], ["mutations", 222], ["at", 232], ["kinase", 235], ["domain", 242], ["in", 249], ["non", 252], ["-", 255], ["small", 256], ["cell", 262], ["lung", 267], ["cancer", 272], ["(", 279], ["NSCLC", 280], [")", 285], ["have", 287], ["been", 292], ["examined", 297], ["for", 306], ["their", 310], ["ability", 316], ["to", 324], ["predict", 327], ["sensitivity", 335], ["to", 347], ["gefitinib", 350], ["or", 360], ["erlotinib", 363], [".", 372], ["We", 374], ["investigated", 377], ["the", 390], ["EGFR", 394], ["mutations", 399], ["and/or", 409], ["R497", 416], ["K", 420], ["polymorphism", 422], ["statuses", 435], ["in", 444], ["225", 447], ["surgically", 451], ["treated", 462], ["NSCLC", 470], ["cases", 476], [".", 481], ["192", 483], ["adenocarcinoma", 487], ["cases", 502], ["were", 508], ["included", 513], [".", 521], ["The", 523], ["presence", 527], ["or", 536], ["absence", 539], ["of", 547], ["EGFR", 550], ["polymorphism", 555], ["of", 568], ["exon", 571], ["13", 576], ["was", 579], ["analyzed", 583], ["by", 592], ["PCR", 595], ["-", 598], ["RFLP", 599], ["method", 604], [".", 610], ["EGFR", 612], ["mutations", 617], ["at", 627], ["kinase", 630], ["domain", 637], ["were", 644], ["found", 649], ["from", 655], ["95", 660], ["of", 663], ["225", 666], ["lung", 670], ["cancer", 675], ["patients", 682], [".", 690], ["In", 692], ["86.2", 695], ["%", 699], ["of", 701], ["patients", 704], [",", 712], ["homo-", 714], ["or", 720], ["heterozygous", 723], ["Lys497", 736], ["allele", 743], ["was", 750], ["present", 754], [".", 761], ["No", 763], ["correlation", 766], ["existed", 778], ["between", 786], ["R497", 794], ["K", 798], ["EGFR", 800], ["genotype", 805], ["and", 814], ["clinico", 818], ["-", 825], ["pathological", 826], ["features", 839], [",", 847], ["such", 849], ["as", 854], ["gender", 857], [",", 863], ["smoking", 865], ["status", 873], [",", 879], ["and", 881], ["pathological", 885], ["subtypes", 898], [".", 906], ["EGFR", 908], ["mutation", 913], ["status", 922], ["was", 929], ["not", 933], ["correlated", 937], ["with", 948], ["R497KEGFR", 953], ["genotype", 963], ["of", 972], ["lung", 975], ["cancers", 980], [".", 987], ["In", 989], ["node", 992], ["-", 996], ["negative", 997], ["patients", 1006], [",", 1014], ["R497KEGFR", 1016], ["genotype", 1026], ["was", 1035], ["not", 1039], ["correlated", 1043], ["with", 1054], ["disease", 1059], ["outcome", 1067], [".", 1074], ["In", 1076], ["node", 1079], ["-", 1083], ["positive", 1084], ["patients", 1093], [",", 1101], ["however", 1103], [",", 1110], ["R497", 1112], ["K", 1116], ["EGFR", 1118], ["was", 1123], ["significantly", 1127], ["associated", 1141], ["with", 1152], ["better", 1157], ["overall", 1164], ["survival", 1172], [".", 1180], ["This", 1182], ["association", 1187], ["was", 1199], ["attributable", 1203], ["to", 1216], ["neo", 1219], ["-", 1222], ["adjuvant", 1223], ["or", 1232], ["adjuvant", 1235], ["chemotherapy", 1244], [".", 1256], ["In", 1258], ["46", 1261], ["total", 1264], ["gefitinib", 1270], ["treated", 1280], ["NSCLC", 1288], ["patients", 1294], [",", 1302], ["the", 1304], ["prognosis", 1308], ["was", 1318], ["not", 1322], ["different", 1326], ["between", 1336], ["the", 1344], ["EGFR", 1348], ["wild", 1353], ["type", 1358], ["(", 1363], ["GG", 1364], [")", 1366], ["patients", 1368], ["and", 1377], ["AG+AA", 1381], ["patients", 1387], [".", 1395], ["R497KEGFR", 1397], ["polymorphism", 1407], ["might", 1420], ["be", 1426], ["associated", 1429], ["with", 1440], ["favorable", 1445], ["prognosis", 1455], ["of", 1465], ["advanced", 1468], ["lung", 1477], ["cancers", 1482], ["and", 1490], ["correlated", 1494], ["with", 1505], ["chemosensitivity", 1510], [".", 1526]]}
{"context": "Asymptomatic colonization with methicillin-resistant Staphylococcus aureus (MRSA) has been described as a risk factor for subsequent MRSA infection. MRSA is an important nosocomial pathogen but has currently been reported in patients without typical risk factors for nosocomial acquisition. This study was designed to evaluate the impact of asymptomatic nares MRSA colonization on the development of subsequent MRSA infection. The incidence of MRSA infection was examined in patients with and patients without MRSA or methicillin-susceptible S. aureus (MSSA) colonization at admission to the hospital and in those who developed colonization during hospitalization. Patients admitted to 5 representative hospital units were prospectively evaluated. Nares samples were obtained for culture at admission and during hospitalization. Laboratory culture results were monitored to identify all MRSA infections that occurred during the study period and 1 year thereafter. Of the 758 patients who had cultures of nares samples performed at admission, 3.4% were colonized with MRSA, and 21% were colonized with MSSA. A total of 19% of patients with MRSA colonization at admission and 25% who acquired MRSA colonization during hospitalization developed infection with MRSA, compared with 1.5% and 2.0% of patients colonized with MSSA (P<.01) and uncolonized (P<.01), respectively, at admission. MRSA colonization at admission increased the risk of subsequent MRSA infection, compared with MSSA colonization (relative risk [RR], 13; 95% confidence interval [CI], 2.7-64) or no staphylococcal colonization (RR, 9.5; 95% CI, 3.6-25) at admission. Acquisition of MRSA colonization also increased the risk for subsequent MRSA infection, compared with no acquisition (RR, 12; 95% CI, 4.0-38). MRSA colonization of nares, either present at admission to the hospital or acquired during hospitalization, increases the risk for MRSA infection. Identifying MRSA colonization at admission could target a high-risk population that may benefit from interventions to decrease the risk for subsequent MRSA infection.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "eb949241f90c4716aa3b61abe11efb88", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[237, 237], [341, 341], [134, 134], [363, 363], [20, 20], [184, 184], [337, 337], [68, 68], [316, 316], [78, 78], [62, 62], [193, 193], [166, 166], [295, 295], [228, 228], [23, 23], [9, 9], [55, 55], [200, 200], [287, 287]], "char_spans": [[1448, 1451], [1935, 1938], [887, 890], [2074, 2077], [133, 136], [1139, 1142], [1907, 1910], [444, 447], [1776, 1779], [510, 513], [411, 414], [1191, 1194], [1067, 1070], [1705, 1708], [1384, 1387], [149, 152], [76, 79], [360, 363], [1257, 1260], [1648, 1651]]}]}], "context_tokens": [["Asymptomatic", 0], ["colonization", 13], ["with", 26], ["methicillin", 31], ["-", 42], ["resistant", 43], ["Staphylococcus", 53], ["aureus", 68], ["(", 75], ["MRSA", 76], [")", 80], ["has", 82], ["been", 86], ["described", 91], ["as", 101], ["a", 104], ["risk", 106], ["factor", 111], ["for", 118], ["subsequent", 122], ["MRSA", 133], ["infection", 138], [".", 147], ["MRSA", 149], ["is", 154], ["an", 157], ["important", 160], ["nosocomial", 170], ["pathogen", 181], ["but", 190], ["has", 194], ["currently", 198], ["been", 208], ["reported", 213], ["in", 222], ["patients", 225], ["without", 234], ["typical", 242], ["risk", 250], ["factors", 255], ["for", 263], ["nosocomial", 267], ["acquisition", 278], [".", 289], ["This", 291], ["study", 296], ["was", 302], ["designed", 306], ["to", 315], ["evaluate", 318], ["the", 327], ["impact", 331], ["of", 338], ["asymptomatic", 341], ["nares", 354], ["MRSA", 360], ["colonization", 365], ["on", 378], ["the", 381], ["development", 385], ["of", 397], ["subsequent", 400], ["MRSA", 411], ["infection", 416], [".", 425], ["The", 427], ["incidence", 431], ["of", 441], ["MRSA", 444], ["infection", 449], ["was", 459], ["examined", 463], ["in", 472], ["patients", 475], ["with", 484], ["and", 489], ["patients", 493], ["without", 502], ["MRSA", 510], ["or", 515], ["methicillin", 518], ["-", 529], ["susceptible", 530], ["S.", 542], ["aureus", 545], ["(", 552], ["MSSA", 553], [")", 557], ["colonization", 559], ["at", 572], ["admission", 575], ["to", 585], ["the", 588], ["hospital", 592], ["and", 601], ["in", 605], ["those", 608], ["who", 614], ["developed", 618], ["colonization", 628], ["during", 641], ["hospitalization", 648], [".", 663], ["Patients", 665], ["admitted", 674], ["to", 683], ["5", 686], ["representative", 688], ["hospital", 703], ["units", 712], ["were", 718], ["prospectively", 723], ["evaluated", 737], [".", 746], ["Nares", 748], ["samples", 754], ["were", 762], ["obtained", 767], ["for", 776], ["culture", 780], ["at", 788], ["admission", 791], ["and", 801], ["during", 805], ["hospitalization", 812], [".", 827], ["Laboratory", 829], ["culture", 840], ["results", 848], ["were", 856], ["monitored", 861], ["to", 871], ["identify", 874], ["all", 883], ["MRSA", 887], ["infections", 892], ["that", 903], ["occurred", 908], ["during", 917], ["the", 924], ["study", 928], ["period", 934], ["and", 941], ["1", 945], ["year", 947], ["thereafter", 952], [".", 962], ["Of", 964], ["the", 967], ["758", 971], ["patients", 975], ["who", 984], ["had", 988], ["cultures", 992], ["of", 1001], ["nares", 1004], ["samples", 1010], ["performed", 1018], ["at", 1028], ["admission", 1031], [",", 1040], ["3.4", 1042], ["%", 1045], ["were", 1047], ["colonized", 1052], ["with", 1062], ["MRSA", 1067], [",", 1071], ["and", 1073], ["21", 1077], ["%", 1079], ["were", 1081], ["colonized", 1086], ["with", 1096], ["MSSA", 1101], [".", 1105], ["A", 1107], ["total", 1109], ["of", 1115], ["19", 1118], ["%", 1120], ["of", 1122], ["patients", 1125], ["with", 1134], ["MRSA", 1139], ["colonization", 1144], ["at", 1157], ["admission", 1160], ["and", 1170], ["25", 1174], ["%", 1176], ["who", 1178], ["acquired", 1182], ["MRSA", 1191], ["colonization", 1196], ["during", 1209], ["hospitalization", 1216], ["developed", 1232], ["infection", 1242], ["with", 1252], ["MRSA", 1257], [",", 1261], ["compared", 1263], ["with", 1272], ["1.5", 1277], ["%", 1280], ["and", 1282], ["2.0", 1286], ["%", 1289], ["of", 1291], ["patients", 1294], ["colonized", 1303], ["with", 1313], ["MSSA", 1318], ["(", 1323], ["P<.01", 1324], [")", 1329], ["and", 1331], ["uncolonized", 1335], ["(", 1347], ["P<.01", 1348], [")", 1353], [",", 1354], ["respectively", 1356], [",", 1368], ["at", 1370], ["admission", 1373], [".", 1382], ["MRSA", 1384], ["colonization", 1389], ["at", 1402], ["admission", 1405], ["increased", 1415], ["the", 1425], ["risk", 1429], ["of", 1434], ["subsequent", 1437], ["MRSA", 1448], ["infection", 1453], [",", 1462], ["compared", 1464], ["with", 1473], ["MSSA", 1478], ["colonization", 1483], ["(", 1496], ["relative", 1497], ["risk", 1506], ["[", 1511], ["RR", 1512], ["]", 1514], [",", 1515], ["13", 1517], [";", 1519], ["95", 1521], ["%", 1523], ["confidence", 1525], ["interval", 1536], ["[", 1545], ["CI", 1546], ["]", 1548], [",", 1549], ["2.7", 1551], ["-", 1554], ["64", 1555], [")", 1557], ["or", 1559], ["no", 1562], ["staphylococcal", 1565], ["colonization", 1580], ["(", 1593], ["RR", 1594], [",", 1596], ["9.5", 1598], [";", 1601], ["95", 1603], ["%", 1605], ["CI", 1607], [",", 1609], ["3.6", 1611], ["-", 1614], ["25", 1615], [")", 1617], ["at", 1619], ["admission", 1622], [".", 1631], ["Acquisition", 1633], ["of", 1645], ["MRSA", 1648], ["colonization", 1653], ["also", 1666], ["increased", 1671], ["the", 1681], ["risk", 1685], ["for", 1690], ["subsequent", 1694], ["MRSA", 1705], ["infection", 1710], [",", 1719], ["compared", 1721], ["with", 1730], ["no", 1735], ["acquisition", 1738], ["(", 1750], ["RR", 1751], [",", 1753], ["12", 1755], [";", 1757], ["95", 1759], ["%", 1761], ["CI", 1763], [",", 1765], ["4.0", 1767], ["-", 1770], ["38", 1771], [")", 1773], [".", 1774], ["MRSA", 1776], ["colonization", 1781], ["of", 1794], ["nares", 1797], [",", 1802], ["either", 1804], ["present", 1811], ["at", 1819], ["admission", 1822], ["to", 1832], ["the", 1835], ["hospital", 1839], ["or", 1848], ["acquired", 1851], ["during", 1860], ["hospitalization", 1867], [",", 1882], ["increases", 1884], ["the", 1894], ["risk", 1898], ["for", 1903], ["MRSA", 1907], ["infection", 1912], [".", 1921], ["Identifying", 1923], ["MRSA", 1935], ["colonization", 1940], ["at", 1953], ["admission", 1956], ["could", 1966], ["target", 1972], ["a", 1979], ["high", 1981], ["-", 1985], ["risk", 1986], ["population", 1991], ["that", 2002], ["may", 2007], ["benefit", 2011], ["from", 2019], ["interventions", 2024], ["to", 2038], ["decrease", 2041], ["the", 2050], ["risk", 2054], ["for", 2059], ["subsequent", 2063], ["MRSA", 2074], ["infection", 2079], [".", 2088]]}
{"context": "In vivo brain microdialysis was used to assess the effects of tolcapone, a novel central and peripheral inhibitor of catechol-O-methyltransferase on striatal 3,4-dihydroxyphenyl-L-alanine (L-dopa) and dopamine metabolism. The oral administration of 30 mg/kg of tolcapone failed to change dopamine output but elicited a marked and long-lasting decrease of the extracellular levels of homovanillic acid (HVA) and 3-methoxytyramine with a concomitant increase of 3,4-dihydroxyphenylacetic acid (DOPAC). The administration of L-dopa (20 and 60 mg/kg p.o.) + benserazide (15 mg/kg p.o.) resulted in dose-dependent increase of dialysate levels of L-dopa and 3-O-methyl-DOPA. Tolcapone (30 mg/kg p.o.), given as adjunct to both doses of L-dopa, markedly enhanced the elevation or extracellular L-dopa, while it completely prevented the formation of 3-O-methyl-DOPA. In another experiment, the administration of L-dopa + benserazide (30 + 15 mg/kg p.o.) resulted in increased extracellular levels of dopamine, DOPAC, HVA and 3-methoxytyramine. The co-administration of tolcapone (30 mg/kg p.o.) further increased dopamine and DOPAC levels, whereas HVA and 3-methoxytyramine effluxes were reduced. These findings support the notion that tolcapone has the ability to enhance striatal dopamine neurotransmission by increasing L-dopa bioavailability through peripheral and central inhibition of L-dopa O-methylation, as well as by blocking the central conversion of dopamine into 3-methoxytyramine.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "08994280294d46b78596738f2a8bd39a", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[33, 35], [161, 163], [124, 126], [91, 93], [260, 262], [270, 272], [185, 187], [151, 153]], "char_spans": [[189, 194], [787, 792], [641, 646], [522, 527], [1315, 1320], [1383, 1388], [904, 909], [730, 735]]}]}], "context_tokens": [["In", 0], ["vivo", 3], ["brain", 8], ["microdialysis", 14], ["was", 28], ["used", 32], ["to", 37], ["assess", 40], ["the", 47], ["effects", 51], ["of", 59], ["tolcapone", 62], [",", 71], ["a", 73], ["novel", 75], ["central", 81], ["and", 89], ["peripheral", 93], ["inhibitor", 104], ["of", 114], ["catechol", 117], ["-", 125], ["O", 126], ["-", 127], ["methyltransferase", 128], ["on", 146], ["striatal", 149], ["3,4-dihydroxyphenyl", 158], ["-", 177], ["L", 178], ["-", 179], ["alanine", 180], ["(", 188], ["L", 189], ["-", 190], ["dopa", 191], [")", 195], ["and", 197], ["dopamine", 201], ["metabolism", 210], [".", 220], ["The", 222], ["oral", 226], ["administration", 231], ["of", 246], ["30", 249], ["mg", 252], ["/", 254], ["kg", 255], ["of", 258], ["tolcapone", 261], ["failed", 271], ["to", 278], ["change", 281], ["dopamine", 288], ["output", 297], ["but", 304], ["elicited", 308], ["a", 317], ["marked", 319], ["and", 326], ["long", 330], ["-", 334], ["lasting", 335], ["decrease", 343], ["of", 352], ["the", 355], ["extracellular", 359], ["levels", 373], ["of", 380], ["homovanillic", 383], ["acid", 396], ["(", 401], ["HVA", 402], [")", 405], ["and", 407], ["3-methoxytyramine", 411], ["with", 429], ["a", 434], ["concomitant", 436], ["increase", 448], ["of", 457], ["3,4-dihydroxyphenylacetic", 460], ["acid", 486], ["(", 491], ["DOPAC", 492], [")", 497], [".", 498], ["The", 500], ["administration", 504], ["of", 519], ["L", 522], ["-", 523], ["dopa", 524], ["(", 529], ["20", 530], ["and", 533], ["60", 537], ["mg", 540], ["/", 542], ["kg", 543], ["p.o", 546], [".", 549], [")", 550], ["+", 552], ["benserazide", 554], ["(", 566], ["15", 567], ["mg", 570], ["/", 572], ["kg", 573], ["p.o", 576], [".", 579], [")", 580], ["resulted", 582], ["in", 591], ["dose", 594], ["-", 598], ["dependent", 599], ["increase", 609], ["of", 618], ["dialysate", 621], ["levels", 631], ["of", 638], ["L", 641], ["-", 642], ["dopa", 643], ["and", 648], ["3-O", 652], ["-", 655], ["methyl", 656], ["-", 662], ["DOPA", 663], [".", 667], ["Tolcapone", 669], ["(", 679], ["30", 680], ["mg", 683], ["/", 685], ["kg", 686], ["p.o", 689], [".", 692], [")", 693], [",", 694], ["given", 696], ["as", 702], ["adjunct", 705], ["to", 713], ["both", 716], ["doses", 721], ["of", 727], ["L", 730], ["-", 731], ["dopa", 732], [",", 736], ["markedly", 738], ["enhanced", 747], ["the", 756], ["elevation", 760], ["or", 770], ["extracellular", 773], ["L", 787], ["-", 788], ["dopa", 789], [",", 793], ["while", 795], ["it", 801], ["completely", 804], ["prevented", 815], ["the", 825], ["formation", 829], ["of", 839], ["3-O", 842], ["-", 845], ["methyl", 846], ["-", 852], ["DOPA", 853], [".", 857], ["In", 859], ["another", 862], ["experiment", 870], [",", 880], ["the", 882], ["administration", 886], ["of", 901], ["L", 904], ["-", 905], ["dopa", 906], ["+", 911], ["benserazide", 913], ["(", 925], ["30", 926], ["+", 929], ["15", 931], ["mg", 934], ["/", 936], ["kg", 937], ["p.o", 940], [".", 943], [")", 944], ["resulted", 946], ["in", 955], ["increased", 958], ["extracellular", 968], ["levels", 982], ["of", 989], ["dopamine", 992], [",", 1000], ["DOPAC", 1002], [",", 1007], ["HVA", 1009], ["and", 1013], ["3-methoxytyramine", 1017], [".", 1034], ["The", 1036], ["co", 1040], ["-", 1042], ["administration", 1043], ["of", 1058], ["tolcapone", 1061], ["(", 1071], ["30", 1072], ["mg", 1075], ["/", 1077], ["kg", 1078], ["p.o", 1081], [".", 1084], [")", 1085], ["further", 1087], ["increased", 1095], ["dopamine", 1105], ["and", 1114], ["DOPAC", 1118], ["levels", 1124], [",", 1130], ["whereas", 1132], ["HVA", 1140], ["and", 1144], ["3-methoxytyramine", 1148], ["effluxes", 1166], ["were", 1175], ["reduced", 1180], [".", 1187], ["These", 1189], ["findings", 1195], ["support", 1204], ["the", 1212], ["notion", 1216], ["that", 1223], ["tolcapone", 1228], ["has", 1238], ["the", 1242], ["ability", 1246], ["to", 1254], ["enhance", 1257], ["striatal", 1265], ["dopamine", 1274], ["neurotransmission", 1283], ["by", 1301], ["increasing", 1304], ["L", 1315], ["-", 1316], ["dopa", 1317], ["bioavailability", 1322], ["through", 1338], ["peripheral", 1346], ["and", 1357], ["central", 1361], ["inhibition", 1369], ["of", 1380], ["L", 1383], ["-", 1384], ["dopa", 1385], ["O", 1390], ["-", 1391], ["methylation", 1392], [",", 1403], ["as", 1405], ["well", 1408], ["as", 1413], ["by", 1416], ["blocking", 1419], ["the", 1428], ["central", 1432], ["conversion", 1440], ["of", 1451], ["dopamine", 1454], ["into", 1463], ["3-methoxytyramine", 1468], [".", 1485]]}
{"context": "Heme is critical for a variety of cellular processes, but excess intracellular heme may result in oxidative stress and membrane injury. Feline leukemia virus subgroup C receptor (FLVCR1), a member of the SLC49 family of four paralogous genes, is a cell surface heme exporter, essential for erythropoiesis and systemic iron homeostasis. Disruption of FLVCR1 function blocks development of erythroid progenitors, likely due to heme toxicity. Mutations of SLC49A1 encoding FLVCR1 are noted in patients with a rare neurodegenerative disorder: posterior column ataxia with retinitis pigmentosa. FLVCR2 is highly homologous to FLVCR1 and may function as a cellular heme importer. Mutations of SLC49A2 encoding FLVCR2 are observed in Fowler syndrome, a rare proliferative vascular disorder of the brain. The functions of the remaining members of the SLC49 family, MFSD7 and DIRC2 (encoded by the SLC49A3 and SLC49A4 genes), are unknown, although the latter is implicated in hereditary renal carcinomas. SLC48A1 (heme responsive gene-1, HRG-1), the sole member of the SLC48 family, is associated with the endosome and appears to transport heme from the endosome into the cytosol.", "qas": [{"question": "Which SLC family is FLVCR1 a member of?", "answers": ["SLC49"], "qid": "a338247c1f654179887259220bfbd8d6", "question_tokens": [["Which", 0], ["SLC", 6], ["family", 10], ["is", 17], ["FLVCR1", 20], ["a", 27], ["member", 29], ["of", 36], ["?", 38]], "detected_answers": [{"text": "SLC49", "token_spans": [[140, 140], [37, 37]], "char_spans": [[843, 847], [204, 208]]}]}], "context_tokens": [["Heme", 0], ["is", 5], ["critical", 8], ["for", 17], ["a", 21], ["variety", 23], ["of", 31], ["cellular", 34], ["processes", 43], [",", 52], ["but", 54], ["excess", 58], ["intracellular", 65], ["heme", 79], ["may", 84], ["result", 88], ["in", 95], ["oxidative", 98], ["stress", 108], ["and", 115], ["membrane", 119], ["injury", 128], [".", 134], ["Feline", 136], ["leukemia", 143], ["virus", 152], ["subgroup", 158], ["C", 167], ["receptor", 169], ["(", 178], ["FLVCR1", 179], [")", 185], [",", 186], ["a", 188], ["member", 190], ["of", 197], ["the", 200], ["SLC49", 204], ["family", 210], ["of", 217], ["four", 220], ["paralogous", 225], ["genes", 236], [",", 241], ["is", 243], ["a", 246], ["cell", 248], ["surface", 253], ["heme", 261], ["exporter", 266], [",", 274], ["essential", 276], ["for", 286], ["erythropoiesis", 290], ["and", 305], ["systemic", 309], ["iron", 318], ["homeostasis", 323], [".", 334], ["Disruption", 336], ["of", 347], ["FLVCR1", 350], ["function", 357], ["blocks", 366], ["development", 373], ["of", 385], ["erythroid", 388], ["progenitors", 398], [",", 409], ["likely", 411], ["due", 418], ["to", 422], ["heme", 425], ["toxicity", 430], [".", 438], ["Mutations", 440], ["of", 450], ["SLC49A1", 453], ["encoding", 461], ["FLVCR1", 470], ["are", 477], ["noted", 481], ["in", 487], ["patients", 490], ["with", 499], ["a", 504], ["rare", 506], ["neurodegenerative", 511], ["disorder", 529], [":", 537], ["posterior", 539], ["column", 549], ["ataxia", 556], ["with", 563], ["retinitis", 568], ["pigmentosa", 578], [".", 588], ["FLVCR2", 590], ["is", 597], ["highly", 600], ["homologous", 607], ["to", 618], ["FLVCR1", 621], ["and", 628], ["may", 632], ["function", 636], ["as", 645], ["a", 648], ["cellular", 650], ["heme", 659], ["importer", 664], [".", 672], ["Mutations", 674], ["of", 684], ["SLC49A2", 687], ["encoding", 695], ["FLVCR2", 704], ["are", 711], ["observed", 715], ["in", 724], ["Fowler", 727], ["syndrome", 734], [",", 742], ["a", 744], ["rare", 746], ["proliferative", 751], ["vascular", 765], ["disorder", 774], ["of", 783], ["the", 786], ["brain", 790], [".", 795], ["The", 797], ["functions", 801], ["of", 811], ["the", 814], ["remaining", 818], ["members", 828], ["of", 836], ["the", 839], ["SLC49", 843], ["family", 849], [",", 855], ["MFSD7", 857], ["and", 863], ["DIRC2", 867], ["(", 873], ["encoded", 874], ["by", 882], ["the", 885], ["SLC49A3", 889], ["and", 897], ["SLC49A4", 901], ["genes", 909], [")", 914], [",", 915], ["are", 917], ["unknown", 921], [",", 928], ["although", 930], ["the", 939], ["latter", 943], ["is", 950], ["implicated", 953], ["in", 964], ["hereditary", 967], ["renal", 978], ["carcinomas", 984], [".", 994], ["SLC48A1", 996], ["(", 1004], ["heme", 1005], ["responsive", 1010], ["gene-1", 1021], [",", 1027], ["HRG-1", 1029], [")", 1034], [",", 1035], ["the", 1037], ["sole", 1041], ["member", 1046], ["of", 1053], ["the", 1056], ["SLC48", 1060], ["family", 1066], [",", 1072], ["is", 1074], ["associated", 1077], ["with", 1088], ["the", 1093], ["endosome", 1097], ["and", 1106], ["appears", 1110], ["to", 1118], ["transport", 1121], ["heme", 1131], ["from", 1136], ["the", 1141], ["endosome", 1145], ["into", 1154], ["the", 1159], ["cytosol", 1163], [".", 1170]]}
{"context": "Ataxin-3, the disease protein in the neurodegenerative disorder Spinocerebellar Ataxia Type 3 or Machado Joseph disease, is a cysteine protease implicated in the ubiquitin proteasome pathway. It contains multiple ubiquitin binding sites through which it anchors polyubiquitin chains of different linkages that are then cleaved by the N-terminal catalytic (Josephin) domain. The properties of the ubiquitin interacting motifs (UIMs) in the C-terminus of ataxin-3 are well established. Very little is known, however, about how two recently identified ubiquitin-binding sites in the Josephin domain contribute to ubiquitin chain binding and cleavage. In the current study, we sought to define the specific contribution of the Josephin domain to the catalytic properties of ataxin-3 and assess how the topology and affinity of these binding sites modulate ataxin-3 activity. Using NMR we modeled the structure of diUb/Josephin complexes and showed that linkage preferences are imposed by the topology of the two binding sites. Enzymatic studies further helped us to determine a precise hierarchy between the sites. We establish that the structure of Josephin dictates specificity for K48-linked chains. Site 1, which is close to the active site, is indispensable for cleavage. Our studies open the way to understand better the cellular function of ataxin-3 and its link to pathology.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "5e25c3d45f5646e79edcd84d6308a178", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0], [227, 227], [75, 75], [142, 142], [129, 129]], "char_spans": [[0, 7], [1344, 1351], [453, 460], [852, 859], [770, 777]]}]}], "context_tokens": [["Ataxin-3", 0], [",", 8], ["the", 10], ["disease", 14], ["protein", 22], ["in", 30], ["the", 33], ["neurodegenerative", 37], ["disorder", 55], ["Spinocerebellar", 64], ["Ataxia", 80], ["Type", 87], ["3", 92], ["or", 94], ["Machado", 97], ["Joseph", 105], ["disease", 112], [",", 119], ["is", 121], ["a", 124], ["cysteine", 126], ["protease", 135], ["implicated", 144], ["in", 155], ["the", 158], ["ubiquitin", 162], ["proteasome", 172], ["pathway", 183], [".", 190], ["It", 192], ["contains", 195], ["multiple", 204], ["ubiquitin", 213], ["binding", 223], ["sites", 231], ["through", 237], ["which", 245], ["it", 251], ["anchors", 254], ["polyubiquitin", 262], ["chains", 276], ["of", 283], ["different", 286], ["linkages", 296], ["that", 305], ["are", 310], ["then", 314], ["cleaved", 319], ["by", 327], ["the", 330], ["N", 334], ["-", 335], ["terminal", 336], ["catalytic", 345], ["(", 355], ["Josephin", 356], [")", 364], ["domain", 366], [".", 372], ["The", 374], ["properties", 378], ["of", 389], ["the", 392], ["ubiquitin", 396], ["interacting", 406], ["motifs", 418], ["(", 425], ["UIMs", 426], [")", 430], ["in", 432], ["the", 435], ["C", 439], ["-", 440], ["terminus", 441], ["of", 450], ["ataxin-3", 453], ["are", 462], ["well", 466], ["established", 471], [".", 482], ["Very", 484], ["little", 489], ["is", 496], ["known", 499], [",", 504], ["however", 506], [",", 513], ["about", 515], ["how", 521], ["two", 525], ["recently", 529], ["identified", 538], ["ubiquitin", 549], ["-", 558], ["binding", 559], ["sites", 567], ["in", 573], ["the", 576], ["Josephin", 580], ["domain", 589], ["contribute", 596], ["to", 607], ["ubiquitin", 610], ["chain", 620], ["binding", 626], ["and", 634], ["cleavage", 638], [".", 646], ["In", 648], ["the", 651], ["current", 655], ["study", 663], [",", 668], ["we", 670], ["sought", 673], ["to", 680], ["define", 683], ["the", 690], ["specific", 694], ["contribution", 703], ["of", 716], ["the", 719], ["Josephin", 723], ["domain", 732], ["to", 739], ["the", 742], ["catalytic", 746], ["properties", 756], ["of", 767], ["ataxin-3", 770], ["and", 779], ["assess", 783], ["how", 790], ["the", 794], ["topology", 798], ["and", 807], ["affinity", 811], ["of", 820], ["these", 823], ["binding", 829], ["sites", 837], ["modulate", 843], ["ataxin-3", 852], ["activity", 861], [".", 869], ["Using", 871], ["NMR", 877], ["we", 881], ["modeled", 884], ["the", 892], ["structure", 896], ["of", 906], ["diUb", 909], ["/", 913], ["Josephin", 914], ["complexes", 923], ["and", 933], ["showed", 937], ["that", 944], ["linkage", 949], ["preferences", 957], ["are", 969], ["imposed", 973], ["by", 981], ["the", 984], ["topology", 988], ["of", 997], ["the", 1000], ["two", 1004], ["binding", 1008], ["sites", 1016], [".", 1021], ["Enzymatic", 1023], ["studies", 1033], ["further", 1041], ["helped", 1049], ["us", 1056], ["to", 1059], ["determine", 1062], ["a", 1072], ["precise", 1074], ["hierarchy", 1082], ["between", 1092], ["the", 1100], ["sites", 1104], [".", 1109], ["We", 1111], ["establish", 1114], ["that", 1124], ["the", 1129], ["structure", 1133], ["of", 1143], ["Josephin", 1146], ["dictates", 1155], ["specificity", 1164], ["for", 1176], ["K48-linked", 1180], ["chains", 1191], [".", 1197], ["Site", 1199], ["1", 1204], [",", 1205], ["which", 1207], ["is", 1213], ["close", 1216], ["to", 1222], ["the", 1225], ["active", 1229], ["site", 1236], [",", 1240], ["is", 1242], ["indispensable", 1245], ["for", 1259], ["cleavage", 1263], [".", 1271], ["Our", 1273], ["studies", 1277], ["open", 1285], ["the", 1290], ["way", 1294], ["to", 1298], ["understand", 1301], ["better", 1312], ["the", 1319], ["cellular", 1323], ["function", 1332], ["of", 1341], ["ataxin-3", 1344], ["and", 1353], ["its", 1357], ["link", 1361], ["to", 1366], ["pathology", 1369], [".", 1378]]}
{"context": "The classical view of the molecular clock is based on interlocked transcriptional-translational feedback loops. Because a substantial fraction of the mammalian genome is expressed in a circadian manner, chromatin remodeling has been proposed to be crucial in clock function. Here we show that Lys4 (K4) trimethylation of histone H3 is rhythmic and follows the same profile as previously described H3 acetylation on circadian promoters. MLL1, a mammalian homolog of Drosophila trithorax, is an H3K4-specific methyltransferase implicated in transcriptional control. We demonstrate that MLL1 is essential for circadian transcription and cyclic H3K4 trimethylation. MLL1 is in a complex with CLOCK-BMAL1 and contributes to its rhythmic recruitment to circadian promoters and to H3 acetylation. Yet MLL1 fails to interact with CLOCK\u039419, providing an explanation for this mutation's dominant negative phenotype. Our results favor a scenario in which H3K4 trimethylation by MLL1 is required to establish a permissive chromatin state for circadian transcription.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "795cf9fac2ef407ba53defde51145ed3", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[153, 153], [101, 101]], "char_spans": [[944, 947], [641, 644]]}]}], "context_tokens": [["The", 0], ["classical", 4], ["view", 14], ["of", 19], ["the", 22], ["molecular", 26], ["clock", 36], ["is", 42], ["based", 45], ["on", 51], ["interlocked", 54], ["transcriptional", 66], ["-", 81], ["translational", 82], ["feedback", 96], ["loops", 105], [".", 110], ["Because", 112], ["a", 120], ["substantial", 122], ["fraction", 134], ["of", 143], ["the", 146], ["mammalian", 150], ["genome", 160], ["is", 167], ["expressed", 170], ["in", 180], ["a", 183], ["circadian", 185], ["manner", 195], [",", 201], ["chromatin", 203], ["remodeling", 213], ["has", 224], ["been", 228], ["proposed", 233], ["to", 242], ["be", 245], ["crucial", 248], ["in", 256], ["clock", 259], ["function", 265], [".", 273], ["Here", 275], ["we", 280], ["show", 283], ["that", 288], ["Lys4", 293], ["(", 298], ["K4", 299], [")", 301], ["trimethylation", 303], ["of", 318], ["histone", 321], ["H3", 329], ["is", 332], ["rhythmic", 335], ["and", 344], ["follows", 348], ["the", 356], ["same", 360], ["profile", 365], ["as", 373], ["previously", 376], ["described", 387], ["H3", 397], ["acetylation", 400], ["on", 412], ["circadian", 415], ["promoters", 425], [".", 434], ["MLL1", 436], [",", 440], ["a", 442], ["mammalian", 444], ["homolog", 454], ["of", 462], ["Drosophila", 465], ["trithorax", 476], [",", 485], ["is", 487], ["an", 490], ["H3K4-specific", 493], ["methyltransferase", 507], ["implicated", 525], ["in", 536], ["transcriptional", 539], ["control", 555], [".", 562], ["We", 564], ["demonstrate", 567], ["that", 579], ["MLL1", 584], ["is", 589], ["essential", 592], ["for", 602], ["circadian", 606], ["transcription", 616], ["and", 630], ["cyclic", 634], ["H3K4", 641], ["trimethylation", 646], [".", 660], ["MLL1", 662], ["is", 667], ["in", 670], ["a", 673], ["complex", 675], ["with", 683], ["CLOCK", 688], ["-", 693], ["BMAL1", 694], ["and", 700], ["contributes", 704], ["to", 716], ["its", 719], ["rhythmic", 723], ["recruitment", 732], ["to", 744], ["circadian", 747], ["promoters", 757], ["and", 767], ["to", 771], ["H3", 774], ["acetylation", 777], [".", 788], ["Yet", 790], ["MLL1", 794], ["fails", 799], ["to", 805], ["interact", 808], ["with", 817], ["CLOCK\u039419", 822], [",", 830], ["providing", 832], ["an", 842], ["explanation", 845], ["for", 857], ["this", 861], ["mutation", 866], ["'s", 874], ["dominant", 877], ["negative", 886], ["phenotype", 895], [".", 904], ["Our", 906], ["results", 910], ["favor", 918], ["a", 924], ["scenario", 926], ["in", 935], ["which", 938], ["H3K4", 944], ["trimethylation", 949], ["by", 964], ["MLL1", 967], ["is", 972], ["required", 975], ["to", 984], ["establish", 987], ["a", 997], ["permissive", 999], ["chromatin", 1010], ["state", 1020], ["for", 1026], ["circadian", 1030], ["transcription", 1040], [".", 1053]]}
{"context": "Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Despite significant progresses in the last decades, the origin of this cancer remains unclear and no efficient therapy exists. PDAC does not arise de novo: three remarkable different types of pancreatic lesions can evolve towards pancreatic cancer. These precursor lesions include: Pancreatic intraepithelial neoplasia (PanIN) that are microscopic lesions of the pancreas, Intraductal Papillary Mucinous Neoplasms (IPMN) and Mucinous Cystic Neoplasms (MCN) that are both macroscopic lesions. However, the cellular origin of these lesions is still a matter of debate. Classically, neoplasm initiation or progression is driven by several genetic and epigenetic alterations. The aim of this review is to assemble the current information on genetic mutations and epigenetic disorders that affect genes during pancreatic carcinogenesis. We will further discuss the interest of the genetic and epigenetic alterations for the diagnosis and prognosis of PDAC. Large genetic alterations (chromosomal deletion/amplification) and single point mutations are well described for carcinogenesis inducers. Mutations classically occur within key regions of the genome. Consequences are various and include activation of mitogenic pathways or silencing of apoptotic processes. Alterations of K-RAS, P16 and DPC4 genes are frequently observed in PDAC samples and have been described to arise gradually during carcinogenesis. DNA methylation is an epigenetic process involved in imprinting and X chromosome inactivation. Alteration of DNA methylation patterns leads to deregulation of gene expression, in the absence of mutation. Both genetic and epigenetic events influence genes and non-coding RNA expression, with dramatic effects on proliferation, survival and invasion. Besides improvement in our fundamental understanding of PDAC development, highlighting the molecular alterations that occur in pancreatic carcinogenesis could provide new clinical tools for early diagnosis of PDAC and the molecular basis for the development of new effective therapies.", "qas": [{"question": "Which is the molecular mechanism underlying K-ras alterations in carcinomas?", "answers": ["Point mutations"], "qid": "2729af5d87194532a74ffb452dcb9886", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["molecular", 13], ["mechanism", 23], ["underlying", 33], ["K", 44], ["-", 45], ["ras", 46], ["alterations", 50], ["in", 62], ["carcinomas", 65], ["?", 75]], "detected_answers": [{"text": "Point mutations", "token_spans": [[180, 181]], "char_spans": [[1111, 1125]]}]}], "context_tokens": [["Pancreatic", 0], ["ductal", 11], ["adenocarcinoma", 18], ["(", 33], ["PDAC", 34], [")", 38], ["is", 40], ["one", 43], ["of", 47], ["the", 50], ["most", 54], ["lethal", 59], ["cancers", 66], ["worldwide", 74], [".", 83], ["Despite", 85], ["significant", 93], ["progresses", 105], ["in", 116], ["the", 119], ["last", 123], ["decades", 128], [",", 135], ["the", 137], ["origin", 141], ["of", 148], ["this", 151], ["cancer", 156], ["remains", 163], ["unclear", 171], ["and", 179], ["no", 183], ["efficient", 186], ["therapy", 196], ["exists", 204], [".", 210], ["PDAC", 212], ["does", 217], ["not", 222], ["arise", 226], ["de", 232], ["novo", 235], [":", 239], ["three", 241], ["remarkable", 247], ["different", 258], ["types", 268], ["of", 274], ["pancreatic", 277], ["lesions", 288], ["can", 296], ["evolve", 300], ["towards", 307], ["pancreatic", 315], ["cancer", 326], [".", 332], ["These", 334], ["precursor", 340], ["lesions", 350], ["include", 358], [":", 365], ["Pancreatic", 367], ["intraepithelial", 378], ["neoplasia", 394], ["(", 404], ["PanIN", 405], [")", 410], ["that", 412], ["are", 417], ["microscopic", 421], ["lesions", 433], ["of", 441], ["the", 444], ["pancreas", 448], [",", 456], ["Intraductal", 458], ["Papillary", 470], ["Mucinous", 480], ["Neoplasms", 489], ["(", 499], ["IPMN", 500], [")", 504], ["and", 506], ["Mucinous", 510], ["Cystic", 519], ["Neoplasms", 526], ["(", 536], ["MCN", 537], [")", 540], ["that", 542], ["are", 547], ["both", 551], ["macroscopic", 556], ["lesions", 568], [".", 575], ["However", 577], [",", 584], ["the", 586], ["cellular", 590], ["origin", 599], ["of", 606], ["these", 609], ["lesions", 615], ["is", 623], ["still", 626], ["a", 632], ["matter", 634], ["of", 641], ["debate", 644], [".", 650], ["Classically", 652], [",", 663], ["neoplasm", 665], ["initiation", 674], ["or", 685], ["progression", 688], ["is", 700], ["driven", 703], ["by", 710], ["several", 713], ["genetic", 721], ["and", 729], ["epigenetic", 733], ["alterations", 744], [".", 755], ["The", 757], ["aim", 761], ["of", 765], ["this", 768], ["review", 773], ["is", 780], ["to", 783], ["assemble", 786], ["the", 795], ["current", 799], ["information", 807], ["on", 819], ["genetic", 822], ["mutations", 830], ["and", 840], ["epigenetic", 844], ["disorders", 855], ["that", 865], ["affect", 870], ["genes", 877], ["during", 883], ["pancreatic", 890], ["carcinogenesis", 901], [".", 915], ["We", 917], ["will", 920], ["further", 925], ["discuss", 933], ["the", 941], ["interest", 945], ["of", 954], ["the", 957], ["genetic", 961], ["and", 969], ["epigenetic", 973], ["alterations", 984], ["for", 996], ["the", 1000], ["diagnosis", 1004], ["and", 1014], ["prognosis", 1018], ["of", 1028], ["PDAC", 1031], [".", 1035], ["Large", 1037], ["genetic", 1043], ["alterations", 1051], ["(", 1063], ["chromosomal", 1064], ["deletion", 1076], ["/", 1084], ["amplification", 1085], [")", 1098], ["and", 1100], ["single", 1104], ["point", 1111], ["mutations", 1117], ["are", 1127], ["well", 1131], ["described", 1136], ["for", 1146], ["carcinogenesis", 1150], ["inducers", 1165], [".", 1173], ["Mutations", 1175], ["classically", 1185], ["occur", 1197], ["within", 1203], ["key", 1210], ["regions", 1214], ["of", 1222], ["the", 1225], ["genome", 1229], [".", 1235], ["Consequences", 1237], ["are", 1250], ["various", 1254], ["and", 1262], ["include", 1266], ["activation", 1274], ["of", 1285], ["mitogenic", 1288], ["pathways", 1298], ["or", 1307], ["silencing", 1310], ["of", 1320], ["apoptotic", 1323], ["processes", 1333], [".", 1342], ["Alterations", 1344], ["of", 1356], ["K", 1359], ["-", 1360], ["RAS", 1361], [",", 1364], ["P16", 1366], ["and", 1370], ["DPC4", 1374], ["genes", 1379], ["are", 1385], ["frequently", 1389], ["observed", 1400], ["in", 1409], ["PDAC", 1412], ["samples", 1417], ["and", 1425], ["have", 1429], ["been", 1434], ["described", 1439], ["to", 1449], ["arise", 1452], ["gradually", 1458], ["during", 1468], ["carcinogenesis", 1475], [".", 1489], ["DNA", 1491], ["methylation", 1495], ["is", 1507], ["an", 1510], ["epigenetic", 1513], ["process", 1524], ["involved", 1532], ["in", 1541], ["imprinting", 1544], ["and", 1555], ["X", 1559], ["chromosome", 1561], ["inactivation", 1572], [".", 1584], ["Alteration", 1586], ["of", 1597], ["DNA", 1600], ["methylation", 1604], ["patterns", 1616], ["leads", 1625], ["to", 1631], ["deregulation", 1634], ["of", 1647], ["gene", 1650], ["expression", 1655], [",", 1665], ["in", 1667], ["the", 1670], ["absence", 1674], ["of", 1682], ["mutation", 1685], [".", 1693], ["Both", 1695], ["genetic", 1700], ["and", 1708], ["epigenetic", 1712], ["events", 1723], ["influence", 1730], ["genes", 1740], ["and", 1746], ["non", 1750], ["-", 1753], ["coding", 1754], ["RNA", 1761], ["expression", 1765], [",", 1775], ["with", 1777], ["dramatic", 1782], ["effects", 1791], ["on", 1799], ["proliferation", 1802], [",", 1815], ["survival", 1817], ["and", 1826], ["invasion", 1830], [".", 1838], ["Besides", 1840], ["improvement", 1848], ["in", 1860], ["our", 1863], ["fundamental", 1867], ["understanding", 1879], ["of", 1893], ["PDAC", 1896], ["development", 1901], [",", 1912], ["highlighting", 1914], ["the", 1927], ["molecular", 1931], ["alterations", 1941], ["that", 1953], ["occur", 1958], ["in", 1964], ["pancreatic", 1967], ["carcinogenesis", 1978], ["could", 1993], ["provide", 1999], ["new", 2007], ["clinical", 2011], ["tools", 2020], ["for", 2026], ["early", 2030], ["diagnosis", 2036], ["of", 2046], ["PDAC", 2049], ["and", 2054], ["the", 2058], ["molecular", 2062], ["basis", 2072], ["for", 2078], ["the", 2082], ["development", 2086], ["of", 2098], ["new", 2101], ["effective", 2105], ["therapies", 2115], [".", 2124]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disease, characterized by an autosomal dominant mode of inheritance, facial involvement, and selectivity and asymmetry of muscle involvement. In general, FSHD typically presents before age 20 years. Usually, FSHD muscle involvement starts in the face and then progresses to the shoulder girdle, the humeral muscles and the abdominal muscles, and then the anterolateral compartment of the leg. Disease severity is highly variable and progression is very slow. About 20% of FSHD patients become wheelchair-bound. Lifespan is not shortened. The diagnosis of FSHD is based on a genetic test by which a deletion of 3.3kb DNA repeats (named D4Z4 and mapping to the subtelomeric region of chromosome 4q35) is identified. The progressive pattern of FSHD requires that the severity of symptoms as well as their physical, social and psychological impact be evaluated on a regular basis. A yearly assessment is recommended. Multidisciplinary management of FSHD--consisting of a combination of genetic counselling, functional assessment, an assessment by a physical therapist, prescription of symptomatic therapies and prevention of known complications of this disease--is required. Prescription of physical therapy sessions and orthopedic appliances are to be adapted to the patient's deficiencies and contractures.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular\ndystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "938e72116a3b4c978813f177d96b52ba", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["\n", 63], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[14, 15]], "char_spans": [[94, 111]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["neuromuscular", 51], ["disease", 65], [",", 72], ["characterized", 74], ["by", 88], ["an", 91], ["autosomal", 94], ["dominant", 104], ["mode", 113], ["of", 118], ["inheritance", 121], [",", 132], ["facial", 134], ["involvement", 141], [",", 152], ["and", 154], ["selectivity", 158], ["and", 170], ["asymmetry", 174], ["of", 184], ["muscle", 187], ["involvement", 194], [".", 205], ["In", 207], ["general", 210], [",", 217], ["FSHD", 219], ["typically", 224], ["presents", 234], ["before", 243], ["age", 250], ["20", 254], ["years", 257], [".", 262], ["Usually", 264], [",", 271], ["FSHD", 273], ["muscle", 278], ["involvement", 285], ["starts", 297], ["in", 304], ["the", 307], ["face", 311], ["and", 316], ["then", 320], ["progresses", 325], ["to", 336], ["the", 339], ["shoulder", 343], ["girdle", 352], [",", 358], ["the", 360], ["humeral", 364], ["muscles", 372], ["and", 380], ["the", 384], ["abdominal", 388], ["muscles", 398], [",", 405], ["and", 407], ["then", 411], ["the", 416], ["anterolateral", 420], ["compartment", 434], ["of", 446], ["the", 449], ["leg", 453], [".", 456], ["Disease", 458], ["severity", 466], ["is", 475], ["highly", 478], ["variable", 485], ["and", 494], ["progression", 498], ["is", 510], ["very", 513], ["slow", 518], [".", 522], ["About", 524], ["20", 530], ["%", 532], ["of", 534], ["FSHD", 537], ["patients", 542], ["become", 551], ["wheelchair", 558], ["-", 568], ["bound", 569], [".", 574], ["Lifespan", 576], ["is", 585], ["not", 588], ["shortened", 592], [".", 601], ["The", 603], ["diagnosis", 607], ["of", 617], ["FSHD", 620], ["is", 625], ["based", 628], ["on", 634], ["a", 637], ["genetic", 639], ["test", 647], ["by", 652], ["which", 655], ["a", 661], ["deletion", 663], ["of", 672], ["3.3", 675], ["kb", 678], ["DNA", 681], ["repeats", 685], ["(", 693], ["named", 694], ["D4Z4", 700], ["and", 705], ["mapping", 709], ["to", 717], ["the", 720], ["subtelomeric", 724], ["region", 737], ["of", 744], ["chromosome", 747], ["4q35", 758], [")", 762], ["is", 764], ["identified", 767], [".", 777], ["The", 779], ["progressive", 783], ["pattern", 795], ["of", 803], ["FSHD", 806], ["requires", 811], ["that", 820], ["the", 825], ["severity", 829], ["of", 838], ["symptoms", 841], ["as", 850], ["well", 853], ["as", 858], ["their", 861], ["physical", 867], [",", 875], ["social", 877], ["and", 884], ["psychological", 888], ["impact", 902], ["be", 909], ["evaluated", 912], ["on", 922], ["a", 925], ["regular", 927], ["basis", 935], [".", 940], ["A", 942], ["yearly", 944], ["assessment", 951], ["is", 962], ["recommended", 965], [".", 976], ["Multidisciplinary", 978], ["management", 996], ["of", 1007], ["FSHD", 1010], ["--", 1014], ["consisting", 1016], ["of", 1027], ["a", 1030], ["combination", 1032], ["of", 1044], ["genetic", 1047], ["counselling", 1055], [",", 1066], ["functional", 1068], ["assessment", 1079], [",", 1089], ["an", 1091], ["assessment", 1094], ["by", 1105], ["a", 1108], ["physical", 1110], ["therapist", 1119], [",", 1128], ["prescription", 1130], ["of", 1143], ["symptomatic", 1146], ["therapies", 1158], ["and", 1168], ["prevention", 1172], ["of", 1183], ["known", 1186], ["complications", 1192], ["of", 1206], ["this", 1209], ["disease", 1214], ["--", 1221], ["is", 1223], ["required", 1226], [".", 1234], ["Prescription", 1236], ["of", 1249], ["physical", 1252], ["therapy", 1261], ["sessions", 1269], ["and", 1278], ["orthopedic", 1282], ["appliances", 1293], ["are", 1304], ["to", 1308], ["be", 1311], ["adapted", 1314], ["to", 1322], ["the", 1325], ["patient", 1329], ["'s", 1336], ["deficiencies", 1339], ["and", 1352], ["contractures", 1356], [".", 1368]]}
{"context": "Reactive oxygen species (ROS) production by NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOXA1), and Rac1. Contrary to that of its phagocyte counterpart NOX2, the molecular basis of NOX1 regulation is not clear. Because NOXO1 lacks the phosphorylated region found in its homolog p47(PHOX), the current view is that NOX1 activation occurs without NOXO1 phosphorylation. Here, however, we demonstrate that phorbol myristate acetate (PMA) stimulates NOXO1 phosphorylation in a transfected human embryonic kidney (HEK) 293 epithelial cell model via protein kinase C and identify Ser-154 as the major phosphorylated site. Endogenous NOXO1 from T84 colon epithelial cells was also phosphorylated, suggesting that NOXO1 phosphorylation is physiologically relevant. In transfected HEK-293 cells, PMA-induced phosphorylation on Ser-154 enhanced NOXO1 binding to NOXA1 (+97%) and to the p22(PHOX) C-terminal region (+384%), increased NOXO1 colocalization with p22(PHOX), and allowed optimal ROS production by NOX1 as demonstrated by the use of S154A and S154D mutants compared with that by wild-type NOXO1 (P<0.05). Pulldown experiments revealed that phos-phorylation on Ser-154 was sufficient to markedly enhance NOXO1 binding to NOXA1, which in turn acts as a molecular switch, allowing optimal interaction of NOXO1 with p22(PHOX). This study unexpectedly revealed that full assembly and activation of NOX1 is a tightly regulated process in which NOXO1 phosphorylation on Ser-154 is the initial trigger.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "ce8e78ef06ed459386b6f776879b5c3c", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[8, 10]], "char_spans": [[44, 58]]}, {"text": "NOX1", "token_spans": [[275, 275], [205, 205], [90, 90], [12, 12], [66, 66]], "char_spans": [[1543, 1546], [1148, 1151], [464, 467], [61, 64], [331, 334]]}]}], "context_tokens": [["Reactive", 0], ["oxygen", 9], ["species", 16], ["(", 24], ["ROS", 25], [")", 28], ["production", 30], ["by", 41], ["NADPH", 44], ["oxidase", 50], ["1", 58], ["(", 60], ["NOX1", 61], [")", 65], [",", 66], ["which", 68], ["is", 74], ["mainly", 77], ["expressed", 84], ["in", 94], ["colon", 97], ["epithelial", 103], ["cells", 114], [",", 119], ["requires", 121], ["the", 130], ["membrane", 134], ["-", 142], ["bound", 143], ["component", 149], ["p22(PHOX", 159], [")", 167], ["and", 169], ["the", 173], ["cytosolic", 177], ["partners", 187], ["NOX", 196], ["organizer", 200], ["1", 210], ["(", 212], ["NOXO1", 213], [")", 218], [",", 219], ["NOX", 221], ["activator", 225], ["1", 235], ["(", 237], ["NOXA1", 238], [")", 243], [",", 244], ["and", 246], ["Rac1", 250], [".", 254], ["Contrary", 256], ["to", 265], ["that", 268], ["of", 273], ["its", 276], ["phagocyte", 280], ["counterpart", 290], ["NOX2", 302], [",", 306], ["the", 308], ["molecular", 312], ["basis", 322], ["of", 328], ["NOX1", 331], ["regulation", 336], ["is", 347], ["not", 350], ["clear", 354], [".", 359], ["Because", 361], ["NOXO1", 369], ["lacks", 375], ["the", 381], ["phosphorylated", 385], ["region", 400], ["found", 407], ["in", 413], ["its", 416], ["homolog", 420], ["p47(PHOX", 428], [")", 436], [",", 437], ["the", 439], ["current", 443], ["view", 451], ["is", 456], ["that", 459], ["NOX1", 464], ["activation", 469], ["occurs", 480], ["without", 487], ["NOXO1", 495], ["phosphorylation", 501], [".", 516], ["Here", 518], [",", 522], ["however", 524], [",", 531], ["we", 533], ["demonstrate", 536], ["that", 548], ["phorbol", 553], ["myristate", 561], ["acetate", 571], ["(", 579], ["PMA", 580], [")", 583], ["stimulates", 585], ["NOXO1", 596], ["phosphorylation", 602], ["in", 618], ["a", 621], ["transfected", 623], ["human", 635], ["embryonic", 641], ["kidney", 651], ["(", 658], ["HEK", 659], [")", 662], ["293", 664], ["epithelial", 668], ["cell", 679], ["model", 684], ["via", 690], ["protein", 694], ["kinase", 702], ["C", 709], ["and", 711], ["identify", 715], ["Ser-154", 724], ["as", 732], ["the", 735], ["major", 739], ["phosphorylated", 745], ["site", 760], [".", 764], ["Endogenous", 766], ["NOXO1", 777], ["from", 783], ["T84", 788], ["colon", 792], ["epithelial", 798], ["cells", 809], ["was", 815], ["also", 819], ["phosphorylated", 824], [",", 838], ["suggesting", 840], ["that", 851], ["NOXO1", 856], ["phosphorylation", 862], ["is", 878], ["physiologically", 881], ["relevant", 897], [".", 905], ["In", 907], ["transfected", 910], ["HEK-293", 922], ["cells", 930], [",", 935], ["PMA", 937], ["-", 940], ["induced", 941], ["phosphorylation", 949], ["on", 965], ["Ser-154", 968], ["enhanced", 976], ["NOXO1", 985], ["binding", 991], ["to", 999], ["NOXA1", 1002], ["(", 1008], ["+97", 1009], ["%", 1012], [")", 1013], ["and", 1015], ["to", 1019], ["the", 1022], ["p22(PHOX", 1026], [")", 1034], ["C", 1036], ["-", 1037], ["terminal", 1038], ["region", 1047], ["(", 1054], ["+384", 1055], ["%", 1059], [")", 1060], [",", 1061], ["increased", 1063], ["NOXO1", 1073], ["colocalization", 1079], ["with", 1094], ["p22(PHOX", 1099], [")", 1107], [",", 1108], ["and", 1110], ["allowed", 1114], ["optimal", 1122], ["ROS", 1130], ["production", 1134], ["by", 1145], ["NOX1", 1148], ["as", 1153], ["demonstrated", 1156], ["by", 1169], ["the", 1172], ["use", 1176], ["of", 1180], ["S154A", 1183], ["and", 1189], ["S154D", 1193], ["mutants", 1199], ["compared", 1207], ["with", 1216], ["that", 1221], ["by", 1226], ["wild", 1229], ["-", 1233], ["type", 1234], ["NOXO1", 1239], ["(", 1245], ["P<0.05", 1246], [")", 1252], [".", 1253], ["Pulldown", 1255], ["experiments", 1264], ["revealed", 1276], ["that", 1285], ["phos", 1290], ["-", 1294], ["phorylation", 1295], ["on", 1307], ["Ser-154", 1310], ["was", 1318], ["sufficient", 1322], ["to", 1333], ["markedly", 1336], ["enhance", 1345], ["NOXO1", 1353], ["binding", 1359], ["to", 1367], ["NOXA1", 1370], [",", 1375], ["which", 1377], ["in", 1383], ["turn", 1386], ["acts", 1391], ["as", 1396], ["a", 1399], ["molecular", 1401], ["switch", 1411], [",", 1417], ["allowing", 1419], ["optimal", 1428], ["interaction", 1436], ["of", 1448], ["NOXO1", 1451], ["with", 1457], ["p22(PHOX", 1462], [")", 1470], [".", 1471], ["This", 1473], ["study", 1478], ["unexpectedly", 1484], ["revealed", 1497], ["that", 1506], ["full", 1511], ["assembly", 1516], ["and", 1525], ["activation", 1529], ["of", 1540], ["NOX1", 1543], ["is", 1548], ["a", 1551], ["tightly", 1553], ["regulated", 1561], ["process", 1571], ["in", 1579], ["which", 1582], ["NOXO1", 1588], ["phosphorylation", 1594], ["on", 1610], ["Ser-154", 1613], ["is", 1621], ["the", 1624], ["initial", 1628], ["trigger", 1636], [".", 1643]]}
{"context": "A novel 135 kDa centrosomal component (Cep135) was identified by immunoscreening of a mammalian expression library with monoclonal antibodies raised against clam centrosomes. It is predicted to be a highly coiled-coil protein with an extensive alpha-helix, suggesting that Cep135 is a structural component of the centrosome. To evaluate how the protein is arranged in the centrosomal structure, we overexpressed Cep135 polypeptides in CHO cells by transient transfection. HA- or GFP-tagged full (amino acids 1-1144) as well as truncated (#10, 29-1144; Delta3, 29-812) polypeptides become localized at the centrosome and induce cytoplasmic dots of various size and number in CHO cells. Centrosomes are associated with massive approximately 7 nm filaments and dense particles organized in a whorl-like arrangement in which parallel-oriented dense lines appear with a regular approximately 7 nm periodicity. The same filamentous aggregates are also detected in cytoplasmic dots, indicating that overexpressed Cep135 can assemble into elaborate higher-ordered structures in and outside the centrosome. Sf9 cells infected with baculovirus containing Cep135 sequences induce filamentous polymers which are distinctive from the whorl seen in CHO cells; #10 forms highly packed spheroids, but the Delta3-containing structure looks loose. Both structures show an internal repeating unit of dense and less dense stripes. Although the distance between the outer end of two adjacent dense lines is similar between two types of polymers ( approximately 120 nm), the dense stripe of Delta3 polymers ( approximately 40 nm) is wider than #10 ( approximately 30 nm). The light band of Delta3 ( approximately 40 nm) is thus narrower than #10 ( approximately 60 nm). Since thin fibers are frequently seen to extend from one dense line to the next, the coiled-coil rod of Cep135 may span the light band. These results suggest that overexpressed Cep135 assemble into distinctive polymers in a domain-specific manner.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "62f547c5c52345068b263ed7bbd85032", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[190, 190], [53, 53], [114, 114]], "char_spans": [[1086, 1095], [313, 322], [605, 614]]}]}], "context_tokens": [["A", 0], ["novel", 2], ["135", 8], ["kDa", 12], ["centrosomal", 16], ["component", 28], ["(", 38], ["Cep135", 39], [")", 45], ["was", 47], ["identified", 51], ["by", 62], ["immunoscreening", 65], ["of", 81], ["a", 84], ["mammalian", 86], ["expression", 96], ["library", 107], ["with", 115], ["monoclonal", 120], ["antibodies", 131], ["raised", 142], ["against", 149], ["clam", 157], ["centrosomes", 162], [".", 173], ["It", 175], ["is", 178], ["predicted", 181], ["to", 191], ["be", 194], ["a", 197], ["highly", 199], ["coiled", 206], ["-", 212], ["coil", 213], ["protein", 218], ["with", 226], ["an", 231], ["extensive", 234], ["alpha", 244], ["-", 249], ["helix", 250], [",", 255], ["suggesting", 257], ["that", 268], ["Cep135", 273], ["is", 280], ["a", 283], ["structural", 285], ["component", 296], ["of", 306], ["the", 309], ["centrosome", 313], [".", 323], ["To", 325], ["evaluate", 328], ["how", 337], ["the", 341], ["protein", 345], ["is", 353], ["arranged", 356], ["in", 365], ["the", 368], ["centrosomal", 372], ["structure", 384], [",", 393], ["we", 395], ["overexpressed", 398], ["Cep135", 412], ["polypeptides", 419], ["in", 432], ["CHO", 435], ["cells", 439], ["by", 445], ["transient", 448], ["transfection", 458], [".", 470], ["HA-", 472], ["or", 476], ["GFP", 479], ["-", 482], ["tagged", 483], ["full", 490], ["(", 495], ["amino", 496], ["acids", 502], ["1", 508], ["-", 509], ["1144", 510], [")", 514], ["as", 516], ["well", 519], ["as", 524], ["truncated", 527], ["(", 537], ["#", 538], ["10", 539], [",", 541], ["29", 543], ["-", 545], ["1144", 546], [";", 550], ["Delta3", 552], [",", 558], ["29", 560], ["-", 562], ["812", 563], [")", 566], ["polypeptides", 568], ["become", 581], ["localized", 588], ["at", 598], ["the", 601], ["centrosome", 605], ["and", 616], ["induce", 620], ["cytoplasmic", 627], ["dots", 639], ["of", 644], ["various", 647], ["size", 655], ["and", 660], ["number", 664], ["in", 671], ["CHO", 674], ["cells", 678], [".", 683], ["Centrosomes", 685], ["are", 697], ["associated", 701], ["with", 712], ["massive", 717], ["approximately", 725], ["7", 739], ["nm", 741], ["filaments", 744], ["and", 754], ["dense", 758], ["particles", 764], ["organized", 774], ["in", 784], ["a", 787], ["whorl", 789], ["-", 794], ["like", 795], ["arrangement", 800], ["in", 812], ["which", 815], ["parallel", 821], ["-", 829], ["oriented", 830], ["dense", 839], ["lines", 845], ["appear", 851], ["with", 858], ["a", 863], ["regular", 865], ["approximately", 873], ["7", 887], ["nm", 889], ["periodicity", 892], [".", 903], ["The", 905], ["same", 909], ["filamentous", 914], ["aggregates", 926], ["are", 937], ["also", 941], ["detected", 946], ["in", 955], ["cytoplasmic", 958], ["dots", 970], [",", 974], ["indicating", 976], ["that", 987], ["overexpressed", 992], ["Cep135", 1006], ["can", 1013], ["assemble", 1017], ["into", 1026], ["elaborate", 1031], ["higher", 1041], ["-", 1047], ["ordered", 1048], ["structures", 1056], ["in", 1067], ["and", 1070], ["outside", 1074], ["the", 1082], ["centrosome", 1086], [".", 1096], ["Sf9", 1098], ["cells", 1102], ["infected", 1108], ["with", 1117], ["baculovirus", 1122], ["containing", 1134], ["Cep135", 1145], ["sequences", 1152], ["induce", 1162], ["filamentous", 1169], ["polymers", 1181], ["which", 1190], ["are", 1196], ["distinctive", 1200], ["from", 1212], ["the", 1217], ["whorl", 1221], ["seen", 1227], ["in", 1232], ["CHO", 1235], ["cells", 1239], [";", 1244], ["#", 1246], ["10", 1247], ["forms", 1250], ["highly", 1256], ["packed", 1263], ["spheroids", 1270], [",", 1279], ["but", 1281], ["the", 1285], ["Delta3-containing", 1289], ["structure", 1307], ["looks", 1317], ["loose", 1323], [".", 1328], ["Both", 1330], ["structures", 1335], ["show", 1346], ["an", 1351], ["internal", 1354], ["repeating", 1363], ["unit", 1373], ["of", 1378], ["dense", 1381], ["and", 1387], ["less", 1391], ["dense", 1396], ["stripes", 1402], [".", 1409], ["Although", 1411], ["the", 1420], ["distance", 1424], ["between", 1433], ["the", 1441], ["outer", 1445], ["end", 1451], ["of", 1455], ["two", 1458], ["adjacent", 1462], ["dense", 1471], ["lines", 1477], ["is", 1483], ["similar", 1486], ["between", 1494], ["two", 1502], ["types", 1506], ["of", 1512], ["polymers", 1515], ["(", 1524], ["approximately", 1526], ["120", 1540], ["nm", 1544], [")", 1546], [",", 1547], ["the", 1549], ["dense", 1553], ["stripe", 1559], ["of", 1566], ["Delta3", 1569], ["polymers", 1576], ["(", 1585], ["approximately", 1587], ["40", 1601], ["nm", 1604], [")", 1606], ["is", 1608], ["wider", 1611], ["than", 1617], ["#", 1622], ["10", 1623], ["(", 1626], ["approximately", 1628], ["30", 1642], ["nm", 1645], [")", 1647], [".", 1648], ["The", 1650], ["light", 1654], ["band", 1660], ["of", 1665], ["Delta3", 1668], ["(", 1675], ["approximately", 1677], ["40", 1691], ["nm", 1694], [")", 1696], ["is", 1698], ["thus", 1701], ["narrower", 1706], ["than", 1715], ["#", 1720], ["10", 1721], ["(", 1724], ["approximately", 1726], ["60", 1740], ["nm", 1743], [")", 1745], [".", 1746], ["Since", 1748], ["thin", 1754], ["fibers", 1759], ["are", 1766], ["frequently", 1770], ["seen", 1781], ["to", 1786], ["extend", 1789], ["from", 1796], ["one", 1801], ["dense", 1805], ["line", 1811], ["to", 1816], ["the", 1819], ["next", 1823], [",", 1827], ["the", 1829], ["coiled", 1833], ["-", 1839], ["coil", 1840], ["rod", 1845], ["of", 1849], ["Cep135", 1852], ["may", 1859], ["span", 1863], ["the", 1868], ["light", 1872], ["band", 1878], [".", 1882], ["These", 1884], ["results", 1890], ["suggest", 1898], ["that", 1906], ["overexpressed", 1911], ["Cep135", 1925], ["assemble", 1932], ["into", 1941], ["distinctive", 1946], ["polymers", 1958], ["in", 1967], ["a", 1970], ["domain", 1972], ["-", 1978], ["specific", 1979], ["manner", 1988], [".", 1994]]}
{"context": "Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an autosomal dominant heart muscle disorder that causes arrhythmia, heart failure, and sudden death. Previously we mapped the genetic locus for the triad of autosomal recessive ARVC, palmoplantar keratoderma, and woolly hair (Naxos disease) to chromosome 17q21, in which the gene for plakoglobin is encoded. This protein is a key component of desmosomes and adherens junctions, and is important for the tight adhesion of many cell types, including those in the heart and skin. We studied 19 individuals with Naxos disease, as well as unaffected family members and unrelated individuals from the neighbouring Greek islands of Naxos and Milos. Gene sequence was determined by reverse transcriptase PCR from RNA isolated from the skin of an affected individual and mutations in other cases were confirmed by restriction-enzyme analysis. A homozygous 2 base pair deletion in the plakoglobin gene was identified only in the 19 affected individuals. This deletion caused a frameshift and premature termination of the protein, which was shown by western blot analysis. 29 clinically unaffected family members were heterozygous for the mutation; 20 unrelated individuals from Naxos and 43 autosomal dominant ARVC probands were homozygous for the normal allele. The finding of a deletion in plakoglobin in ARVC suggests that the proteins involved in cell-cell adhesion play an important part in maintaining myocyte integrity, and when junctions are disrupted, cell death, and fibrofatty replacement occur. Therefore, the discovery of a mutation in a protein with functions in maintaining cell junction integrity has important implications for other dominant forms of ARVC, related cardiomyopathies, and other cutaneous diseases.", "qas": [{"question": "Which gene is mutated in a subtype of arrhythmogenic right ventricular cardiomyopathy known as Naxos disease?", "answers": ["The Plakoglobin gene", "plakoglobin[jup]"], "qid": "204004adaf394da29332aa0a6d83a243", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["mutated", 14], ["in", 22], ["a", 25], ["subtype", 27], ["of", 35], ["arrhythmogenic", 38], ["right", 53], ["ventricular", 59], ["cardiomyopathy", 71], ["known", 86], ["as", 92], ["Naxos", 95], ["disease", 101], ["?", 108]], "detected_answers": [{"text": "The Plakoglobin gene", "token_spans": [[160, 161]], "char_spans": [[933, 948]]}]}], "context_tokens": [["Arrhythmogenic", 0], ["right", 15], ["ventricular", 21], ["cardiomyopathy", 33], ["(", 48], ["ARVC", 49], [")", 53], ["is", 55], ["an", 58], ["autosomal", 61], ["dominant", 71], ["heart", 80], ["muscle", 86], ["disorder", 93], ["that", 102], ["causes", 107], ["arrhythmia", 114], [",", 124], ["heart", 126], ["failure", 132], [",", 139], ["and", 141], ["sudden", 145], ["death", 152], [".", 157], ["Previously", 159], ["we", 170], ["mapped", 173], ["the", 180], ["genetic", 184], ["locus", 192], ["for", 198], ["the", 202], ["triad", 206], ["of", 212], ["autosomal", 215], ["recessive", 225], ["ARVC", 235], [",", 239], ["palmoplantar", 241], ["keratoderma", 254], [",", 265], ["and", 267], ["woolly", 271], ["hair", 278], ["(", 283], ["Naxos", 284], ["disease", 290], [")", 297], ["to", 299], ["chromosome", 302], ["17q21", 313], [",", 318], ["in", 320], ["which", 323], ["the", 329], ["gene", 333], ["for", 338], ["plakoglobin", 342], ["is", 354], ["encoded", 357], [".", 364], ["This", 366], ["protein", 371], ["is", 379], ["a", 382], ["key", 384], ["component", 388], ["of", 398], ["desmosomes", 401], ["and", 412], ["adherens", 416], ["junctions", 425], [",", 434], ["and", 436], ["is", 440], ["important", 443], ["for", 453], ["the", 457], ["tight", 461], ["adhesion", 467], ["of", 476], ["many", 479], ["cell", 484], ["types", 489], [",", 494], ["including", 496], ["those", 506], ["in", 512], ["the", 515], ["heart", 519], ["and", 525], ["skin", 529], [".", 533], ["We", 535], ["studied", 538], ["19", 546], ["individuals", 549], ["with", 561], ["Naxos", 566], ["disease", 572], [",", 579], ["as", 581], ["well", 584], ["as", 589], ["unaffected", 592], ["family", 603], ["members", 610], ["and", 618], ["unrelated", 622], ["individuals", 632], ["from", 644], ["the", 649], ["neighbouring", 653], ["Greek", 666], ["islands", 672], ["of", 680], ["Naxos", 683], ["and", 689], ["Milos", 693], [".", 698], ["Gene", 700], ["sequence", 705], ["was", 714], ["determined", 718], ["by", 729], ["reverse", 732], ["transcriptase", 740], ["PCR", 754], ["from", 758], ["RNA", 763], ["isolated", 767], ["from", 776], ["the", 781], ["skin", 785], ["of", 790], ["an", 793], ["affected", 796], ["individual", 805], ["and", 816], ["mutations", 820], ["in", 830], ["other", 833], ["cases", 839], ["were", 845], ["confirmed", 850], ["by", 860], ["restriction", 863], ["-", 874], ["enzyme", 875], ["analysis", 882], [".", 890], ["A", 892], ["homozygous", 894], ["2", 905], ["base", 907], ["pair", 912], ["deletion", 917], ["in", 926], ["the", 929], ["plakoglobin", 933], ["gene", 945], ["was", 950], ["identified", 954], ["only", 965], ["in", 970], ["the", 973], ["19", 977], ["affected", 980], ["individuals", 989], [".", 1000], ["This", 1002], ["deletion", 1007], ["caused", 1016], ["a", 1023], ["frameshift", 1025], ["and", 1036], ["premature", 1040], ["termination", 1050], ["of", 1062], ["the", 1065], ["protein", 1069], [",", 1076], ["which", 1078], ["was", 1084], ["shown", 1088], ["by", 1094], ["western", 1097], ["blot", 1105], ["analysis", 1110], [".", 1118], ["29", 1120], ["clinically", 1123], ["unaffected", 1134], ["family", 1145], ["members", 1152], ["were", 1160], ["heterozygous", 1165], ["for", 1178], ["the", 1182], ["mutation", 1186], [";", 1194], ["20", 1196], ["unrelated", 1199], ["individuals", 1209], ["from", 1221], ["Naxos", 1226], ["and", 1232], ["43", 1236], ["autosomal", 1239], ["dominant", 1249], ["ARVC", 1258], ["probands", 1263], ["were", 1272], ["homozygous", 1277], ["for", 1288], ["the", 1292], ["normal", 1296], ["allele", 1303], [".", 1309], ["The", 1311], ["finding", 1315], ["of", 1323], ["a", 1326], ["deletion", 1328], ["in", 1337], ["plakoglobin", 1340], ["in", 1352], ["ARVC", 1355], ["suggests", 1360], ["that", 1369], ["the", 1374], ["proteins", 1378], ["involved", 1387], ["in", 1396], ["cell", 1399], ["-", 1403], ["cell", 1404], ["adhesion", 1409], ["play", 1418], ["an", 1423], ["important", 1426], ["part", 1436], ["in", 1441], ["maintaining", 1444], ["myocyte", 1456], ["integrity", 1464], [",", 1473], ["and", 1475], ["when", 1479], ["junctions", 1484], ["are", 1494], ["disrupted", 1498], [",", 1507], ["cell", 1509], ["death", 1514], [",", 1519], ["and", 1521], ["fibrofatty", 1525], ["replacement", 1536], ["occur", 1548], [".", 1553], ["Therefore", 1555], [",", 1564], ["the", 1566], ["discovery", 1570], ["of", 1580], ["a", 1583], ["mutation", 1585], ["in", 1594], ["a", 1597], ["protein", 1599], ["with", 1607], ["functions", 1612], ["in", 1622], ["maintaining", 1625], ["cell", 1637], ["junction", 1642], ["integrity", 1651], ["has", 1661], ["important", 1665], ["implications", 1675], ["for", 1688], ["other", 1692], ["dominant", 1698], ["forms", 1707], ["of", 1713], ["ARVC", 1716], [",", 1720], ["related", 1722], ["cardiomyopathies", 1730], [",", 1746], ["and", 1748], ["other", 1752], ["cutaneous", 1758], ["diseases", 1768], [".", 1776]]}
{"context": "The subventricular zone of the rodent brain retains the capacity of generating new neurons in adulthood. The newly formed neuroblasts migrate rostrally toward the olfactory bulb, where they differentiate as granular and periglomerular interneurons. The reported presence of differentiated neurons expressing the neuronal isoform of nitric oxide synthase (NOS) in the periphery of the neurogenic region and the organization of their varicose axons as a network in which the precursors are immersed raised the hypothesis that endogenous nitric oxide (NO) may participate in the control of neurogenesis in the subventricular zone. Systemic administration of the NOS inhibitors N(omega)-nitro-L-arginine methyl ester or 7-nitroindazole to adult mice produced a dose- and time-dependent increase in the number of mitotic cells in the subventricular zone, rostral migratory stream, and olfactory bulb, but not in the dentate gyrus of the hippocampus, without affecting apoptosis. In the subventricular zone, this effect was exerted selectively on a precursor subpopulation expressing nestin but not neuronal or glial cell-specific proteins. In addition, in the olfactory bulb, analysis of maturation markers in the newly generated neurons indicated that chronic NOS inhibition caused a delay in neuronal differentiation. Postmitotic cell survival and migration were not affected when NO production was impaired. Our results suggest that NO, produced by nitrergic neurons in the adult mouse subventricular zone and olfactory bulb, exerts a negative control on the size of the undifferentiated precursor pool and promotes neuronal differentiation.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "ab3ff6a5a146419f8fd61b433587067c", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[173, 173]], "char_spans": [[1078, 1083]]}]}], "context_tokens": [["The", 0], ["subventricular", 4], ["zone", 19], ["of", 24], ["the", 27], ["rodent", 31], ["brain", 38], ["retains", 44], ["the", 52], ["capacity", 56], ["of", 65], ["generating", 68], ["new", 79], ["neurons", 83], ["in", 91], ["adulthood", 94], [".", 103], ["The", 105], ["newly", 109], ["formed", 115], ["neuroblasts", 122], ["migrate", 134], ["rostrally", 142], ["toward", 152], ["the", 159], ["olfactory", 163], ["bulb", 173], [",", 177], ["where", 179], ["they", 185], ["differentiate", 190], ["as", 204], ["granular", 207], ["and", 216], ["periglomerular", 220], ["interneurons", 235], [".", 247], ["The", 249], ["reported", 253], ["presence", 262], ["of", 271], ["differentiated", 274], ["neurons", 289], ["expressing", 297], ["the", 308], ["neuronal", 312], ["isoform", 321], ["of", 329], ["nitric", 332], ["oxide", 339], ["synthase", 345], ["(", 354], ["NOS", 355], [")", 358], ["in", 360], ["the", 363], ["periphery", 367], ["of", 377], ["the", 380], ["neurogenic", 384], ["region", 395], ["and", 402], ["the", 406], ["organization", 410], ["of", 423], ["their", 426], ["varicose", 432], ["axons", 441], ["as", 447], ["a", 450], ["network", 452], ["in", 460], ["which", 463], ["the", 469], ["precursors", 473], ["are", 484], ["immersed", 488], ["raised", 497], ["the", 504], ["hypothesis", 508], ["that", 519], ["endogenous", 524], ["nitric", 535], ["oxide", 542], ["(", 548], ["NO", 549], [")", 551], ["may", 553], ["participate", 557], ["in", 569], ["the", 572], ["control", 576], ["of", 584], ["neurogenesis", 587], ["in", 600], ["the", 603], ["subventricular", 607], ["zone", 622], [".", 626], ["Systemic", 628], ["administration", 637], ["of", 652], ["the", 655], ["NOS", 659], ["inhibitors", 663], ["N(omega)-nitro", 674], ["-", 688], ["L", 689], ["-", 690], ["arginine", 691], ["methyl", 700], ["ester", 707], ["or", 713], ["7-nitroindazole", 716], ["to", 732], ["adult", 735], ["mice", 741], ["produced", 746], ["a", 755], ["dose-", 757], ["and", 763], ["time", 767], ["-", 771], ["dependent", 772], ["increase", 782], ["in", 791], ["the", 794], ["number", 798], ["of", 805], ["mitotic", 808], ["cells", 816], ["in", 822], ["the", 825], ["subventricular", 829], ["zone", 844], [",", 848], ["rostral", 850], ["migratory", 858], ["stream", 868], [",", 874], ["and", 876], ["olfactory", 880], ["bulb", 890], [",", 894], ["but", 896], ["not", 900], ["in", 904], ["the", 907], ["dentate", 911], ["gyrus", 919], ["of", 925], ["the", 928], ["hippocampus", 932], [",", 943], ["without", 945], ["affecting", 953], ["apoptosis", 963], [".", 972], ["In", 974], ["the", 977], ["subventricular", 981], ["zone", 996], [",", 1000], ["this", 1002], ["effect", 1007], ["was", 1014], ["exerted", 1018], ["selectively", 1026], ["on", 1038], ["a", 1041], ["precursor", 1043], ["subpopulation", 1053], ["expressing", 1067], ["nestin", 1078], ["but", 1085], ["not", 1089], ["neuronal", 1093], ["or", 1102], ["glial", 1105], ["cell", 1111], ["-", 1115], ["specific", 1116], ["proteins", 1125], [".", 1133], ["In", 1135], ["addition", 1138], [",", 1146], ["in", 1148], ["the", 1151], ["olfactory", 1155], ["bulb", 1165], [",", 1169], ["analysis", 1171], ["of", 1180], ["maturation", 1183], ["markers", 1194], ["in", 1202], ["the", 1205], ["newly", 1209], ["generated", 1215], ["neurons", 1225], ["indicated", 1233], ["that", 1243], ["chronic", 1248], ["NOS", 1256], ["inhibition", 1260], ["caused", 1271], ["a", 1278], ["delay", 1280], ["in", 1286], ["neuronal", 1289], ["differentiation", 1298], [".", 1313], ["Postmitotic", 1315], ["cell", 1327], ["survival", 1332], ["and", 1341], ["migration", 1345], ["were", 1355], ["not", 1360], ["affected", 1364], ["when", 1373], ["NO", 1378], ["production", 1381], ["was", 1392], ["impaired", 1396], [".", 1404], ["Our", 1406], ["results", 1410], ["suggest", 1418], ["that", 1426], ["NO", 1431], [",", 1433], ["produced", 1435], ["by", 1444], ["nitrergic", 1447], ["neurons", 1457], ["in", 1465], ["the", 1468], ["adult", 1472], ["mouse", 1478], ["subventricular", 1484], ["zone", 1499], ["and", 1504], ["olfactory", 1508], ["bulb", 1518], [",", 1522], ["exerts", 1524], ["a", 1531], ["negative", 1533], ["control", 1542], ["on", 1550], ["the", 1553], ["size", 1557], ["of", 1562], ["the", 1565], ["undifferentiated", 1569], ["precursor", 1586], ["pool", 1596], ["and", 1601], ["promotes", 1605], ["neuronal", 1614], ["differentiation", 1623], [".", 1638]]}
{"context": "To evaluate the role of apoptosis in the pathogenesis of brain lesions in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a hereditary microangiopathy leading to cognitive decline and dementia, caused by mutations in the NOTCH3 gene. Detection of apoptotic nuclei in temporal lobe, brain stem, medulla oblongata, hippocampus and basal ganglia from one young CADASIL patient was performed by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL). Our results showed a great involvement of glial cells in apoptotic cell death in the majority of the brain regions examined; neuronal apoptosis was significantly present only in the brain stem region. We hypothesized that in the early stages of the disease neuronal involvement of apoptosis is limited to the cells of the brain stem, sparing the cortical area which is involved in neuronal apoptosis and cognitive decline later.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "63bd935131b94b97a6120e16b7ff3249", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[41, 42]], "char_spans": [[275, 285]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["role", 16], ["of", 21], ["apoptosis", 24], ["in", 34], ["the", 37], ["pathogenesis", 41], ["of", 54], ["brain", 57], ["lesions", 63], ["in", 71], ["cerebral", 74], ["autosomal", 83], ["dominant", 93], ["arteriopathy", 102], ["with", 115], ["subcortical", 120], ["infarcts", 132], ["and", 141], ["leukoencephalopathy", 145], ["(", 165], ["CADASIL", 166], [")", 173], [",", 174], ["a", 176], ["hereditary", 178], ["microangiopathy", 189], ["leading", 205], ["to", 213], ["cognitive", 216], ["decline", 226], ["and", 234], ["dementia", 238], [",", 246], ["caused", 248], ["by", 255], ["mutations", 258], ["in", 268], ["the", 271], ["NOTCH3", 275], ["gene", 282], [".", 286], ["Detection", 288], ["of", 298], ["apoptotic", 301], ["nuclei", 311], ["in", 318], ["temporal", 321], ["lobe", 330], [",", 334], ["brain", 336], ["stem", 342], [",", 346], ["medulla", 348], ["oblongata", 356], [",", 365], ["hippocampus", 367], ["and", 379], ["basal", 383], ["ganglia", 389], ["from", 397], ["one", 402], ["young", 406], ["CADASIL", 412], ["patient", 420], ["was", 428], ["performed", 432], ["by", 442], ["terminal", 445], ["deoxynucleotidyl", 454], ["transferase", 471], ["(", 483], ["TdT)-mediated", 484], ["dUTP", 498], ["nick", 503], ["end", 508], ["-", 511], ["labeling", 512], ["(", 521], ["TUNEL", 522], [")", 527], [".", 528], ["Our", 530], ["results", 534], ["showed", 542], ["a", 549], ["great", 551], ["involvement", 557], ["of", 569], ["glial", 572], ["cells", 578], ["in", 584], ["apoptotic", 587], ["cell", 597], ["death", 602], ["in", 608], ["the", 611], ["majority", 615], ["of", 624], ["the", 627], ["brain", 631], ["regions", 637], ["examined", 645], [";", 653], ["neuronal", 655], ["apoptosis", 664], ["was", 674], ["significantly", 678], ["present", 692], ["only", 700], ["in", 705], ["the", 708], ["brain", 712], ["stem", 718], ["region", 723], [".", 729], ["We", 731], ["hypothesized", 734], ["that", 747], ["in", 752], ["the", 755], ["early", 759], ["stages", 765], ["of", 772], ["the", 775], ["disease", 779], ["neuronal", 787], ["involvement", 796], ["of", 808], ["apoptosis", 811], ["is", 821], ["limited", 824], ["to", 832], ["the", 835], ["cells", 839], ["of", 845], ["the", 848], ["brain", 852], ["stem", 858], [",", 862], ["sparing", 864], ["the", 872], ["cortical", 876], ["area", 885], ["which", 890], ["is", 896], ["involved", 899], ["in", 908], ["neuronal", 911], ["apoptosis", 920], ["and", 930], ["cognitive", 934], ["decline", 944], ["later", 952], [".", 957]]}
{"context": "Apical membrane antigen 1 (AMA1) is an asexual blood-stage protein expressed in the invasive merozoite form of Plasmodia species, which are the causative agent of malaria. We have complemented the function of Plasmodium falciparum AMA1 (PfAMA1) with a divergent AMA1 transgene from Plasmodium chabaudi (PcAMA1). It was not possible to disrupt the PfAMA1 gene using 'knock-out' plasmids, although we demonstrate that the PfAMA1 gene can be targeted by homologous recombination. These experiments suggest that PfAMA1 is critical, perhaps essential, for blood-stage growth. Importantly, we showed that PcAMA1 expression in P. falciparum provides trans-species complementation to at least 35% of the function of endogenous PfAMA1 in human red cells. Furthermore, expression of this transgene in P. falciparum leads to more efficient invasion of murine erythrocytes. These results indicate an important role for AMA1 in the invasion of red blood cells (RBCs) across divergent Plasmodium species.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "e3479299b8474eb5a5963d6564d7faa9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium species", "token_spans": [[173, 174]], "char_spans": [[971, 988]]}]}], "context_tokens": [["Apical", 0], ["membrane", 7], ["antigen", 16], ["1", 24], ["(", 26], ["AMA1", 27], [")", 31], ["is", 33], ["an", 36], ["asexual", 39], ["blood", 47], ["-", 52], ["stage", 53], ["protein", 59], ["expressed", 67], ["in", 77], ["the", 80], ["invasive", 84], ["merozoite", 93], ["form", 103], ["of", 108], ["Plasmodia", 111], ["species", 121], [",", 128], ["which", 130], ["are", 136], ["the", 140], ["causative", 144], ["agent", 154], ["of", 160], ["malaria", 163], [".", 170], ["We", 172], ["have", 175], ["complemented", 180], ["the", 193], ["function", 197], ["of", 206], ["Plasmodium", 209], ["falciparum", 220], ["AMA1", 231], ["(", 236], ["PfAMA1", 237], [")", 243], ["with", 245], ["a", 250], ["divergent", 252], ["AMA1", 262], ["transgene", 267], ["from", 277], ["Plasmodium", 282], ["chabaudi", 293], ["(", 302], ["PcAMA1", 303], [")", 309], [".", 310], ["It", 312], ["was", 315], ["not", 319], ["possible", 323], ["to", 332], ["disrupt", 335], ["the", 343], ["PfAMA1", 347], ["gene", 354], ["using", 359], ["'", 365], ["knock", 366], ["-", 371], ["out", 372], ["'", 375], ["plasmids", 377], [",", 385], ["although", 387], ["we", 396], ["demonstrate", 399], ["that", 411], ["the", 416], ["PfAMA1", 420], ["gene", 427], ["can", 432], ["be", 436], ["targeted", 439], ["by", 448], ["homologous", 451], ["recombination", 462], [".", 475], ["These", 477], ["experiments", 483], ["suggest", 495], ["that", 503], ["PfAMA1", 508], ["is", 515], ["critical", 518], [",", 526], ["perhaps", 528], ["essential", 536], [",", 545], ["for", 547], ["blood", 551], ["-", 556], ["stage", 557], ["growth", 563], [".", 569], ["Importantly", 571], [",", 582], ["we", 584], ["showed", 587], ["that", 594], ["PcAMA1", 599], ["expression", 606], ["in", 617], ["P.", 620], ["falciparum", 623], ["provides", 634], ["trans", 643], ["-", 648], ["species", 649], ["complementation", 657], ["to", 673], ["at", 676], ["least", 679], ["35", 685], ["%", 687], ["of", 689], ["the", 692], ["function", 696], ["of", 705], ["endogenous", 708], ["PfAMA1", 719], ["in", 726], ["human", 729], ["red", 735], ["cells", 739], [".", 744], ["Furthermore", 746], [",", 757], ["expression", 759], ["of", 770], ["this", 773], ["transgene", 778], ["in", 788], ["P.", 791], ["falciparum", 794], ["leads", 805], ["to", 811], ["more", 814], ["efficient", 819], ["invasion", 829], ["of", 838], ["murine", 841], ["erythrocytes", 848], [".", 860], ["These", 862], ["results", 868], ["indicate", 876], ["an", 885], ["important", 888], ["role", 898], ["for", 903], ["AMA1", 907], ["in", 912], ["the", 915], ["invasion", 919], ["of", 928], ["red", 931], ["blood", 935], ["cells", 941], ["(", 947], ["RBCs", 948], [")", 952], ["across", 954], ["divergent", 961], ["Plasmodium", 971], ["species", 982], [".", 989]]}
{"context": "Cystic fibrosis (CF) is the most common inherited disorder in Caucasian populations, with over 1400 mutations identified in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene. Mutations in the CFTR gene may be also causative for CBAVD (Congenital Bilateral Absence of the Vas Deferens). The type and distribution of mutations varies widely between different countries and/or ethnic groups, and is relatively unknown in Iran. We therefore performed a comprehensive analysis of the CFTR gene in Iranian CF patients. 69 Iranian CF patients, and 1 CBAVD patient, were analysed for mutations in the complete coding region, and its exon/intron junctions, of their CFTR genes, using different methods, such as ARMS (amplification refractory mutation system)-PCR, SSCP (single stranded conformation polymorphism) analysis, restriction enzyme digestion analysis, direct sequencing, and MLPA (Multiplex Ligation-mediated Probe Amplification). CFTR mutation analysis revealed the identification of 37 mutations in 69 Iranian CF patients. Overall, 81.9% (113/138) CFTR genes derived from Iranian CF patients could be characterized for a disease-causing mutation. The CBAVD patient was found to be homozygous for the p.W1145R mutation. The most common mutations were p.F508del (DeltaF508) (18.1%), c.2183_2184delAAinsG (2183AA>G) (6.5%), p.S466X (5.8%), p.N1303K (4.3%), c.2789+5G>A (4.3%), p.G542X (3.6%), c.3120+1G>A (3.6%), p.R334W (2.9%) and c.3130delA (2.9%). These 9 types of mutant CFTR genes totaled for 52% of all CFTR genes derived from the 69 Iranian CF patients. Eight mutations, c.406-8T>C, p.A566D, c.2576delA, c.2752-1_2756delGGTGGCinsTTG, p.T1036I, p.W1145R, c.3850-24G>A, c.1342-?_1524+?del, were found for the first time in this study. We identified 37 CFTR mutations in 69 well characterized Iranian CF patients, obtaining a CFTR mutation detection rate of 81.9%, the highest detection rate obtained in the Iranian population so far. These findings will assist in genetic counseling, prenatal diagnosis and future screening of CF in Iran.", "qas": [{"question": "Which is the most common CFTR mutation in Caucasians?", "answers": ["deltaF508"], "qid": "721f570c564a469791dc784b8d46492b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["CFTR", 25], ["mutation", 30], ["in", 39], ["Caucasians", 42], ["?", 52]], "detected_answers": [{"text": "deltaF508", "token_spans": [[226, 226]], "char_spans": [[1282, 1290]]}]}], "context_tokens": [["Cystic", 0], ["fibrosis", 7], ["(", 16], ["CF", 17], [")", 19], ["is", 21], ["the", 24], ["most", 28], ["common", 33], ["inherited", 40], ["disorder", 50], ["in", 59], ["Caucasian", 62], ["populations", 72], [",", 83], ["with", 85], ["over", 90], ["1400", 95], ["mutations", 100], ["identified", 110], ["in", 121], ["the", 124], ["Cystic", 128], ["Fibrosis", 135], ["Transmembrane", 144], ["conductance", 158], ["Regulator", 170], ["(", 180], ["CFTR", 181], [")", 185], ["gene", 187], [".", 191], ["Mutations", 193], ["in", 203], ["the", 206], ["CFTR", 210], ["gene", 215], ["may", 220], ["be", 224], ["also", 227], ["causative", 232], ["for", 242], ["CBAVD", 246], ["(", 252], ["Congenital", 253], ["Bilateral", 264], ["Absence", 274], ["of", 282], ["the", 285], ["Vas", 289], ["Deferens", 293], [")", 301], [".", 302], ["The", 304], ["type", 308], ["and", 313], ["distribution", 317], ["of", 330], ["mutations", 333], ["varies", 343], ["widely", 350], ["between", 357], ["different", 365], ["countries", 375], ["and/or", 385], ["ethnic", 392], ["groups", 399], [",", 405], ["and", 407], ["is", 411], ["relatively", 414], ["unknown", 425], ["in", 433], ["Iran", 436], [".", 440], ["We", 442], ["therefore", 445], ["performed", 455], ["a", 465], ["comprehensive", 467], ["analysis", 481], ["of", 490], ["the", 493], ["CFTR", 497], ["gene", 502], ["in", 507], ["Iranian", 510], ["CF", 518], ["patients", 521], [".", 529], ["69", 531], ["Iranian", 534], ["CF", 542], ["patients", 545], [",", 553], ["and", 555], ["1", 559], ["CBAVD", 561], ["patient", 567], [",", 574], ["were", 576], ["analysed", 581], ["for", 590], ["mutations", 594], ["in", 604], ["the", 607], ["complete", 611], ["coding", 620], ["region", 627], [",", 633], ["and", 635], ["its", 639], ["exon", 643], ["/", 647], ["intron", 648], ["junctions", 655], [",", 664], ["of", 666], ["their", 669], ["CFTR", 675], ["genes", 680], [",", 685], ["using", 687], ["different", 693], ["methods", 703], [",", 710], ["such", 712], ["as", 717], ["ARMS", 720], ["(", 725], ["amplification", 726], ["refractory", 740], ["mutation", 751], ["system)-PCR", 760], [",", 771], ["SSCP", 773], ["(", 778], ["single", 779], ["stranded", 786], ["conformation", 795], ["polymorphism", 808], [")", 820], ["analysis", 822], [",", 830], ["restriction", 832], ["enzyme", 844], ["digestion", 851], ["analysis", 861], [",", 869], ["direct", 871], ["sequencing", 878], [",", 888], ["and", 890], ["MLPA", 894], ["(", 899], ["Multiplex", 900], ["Ligation", 910], ["-", 918], ["mediated", 919], ["Probe", 928], ["Amplification", 934], [")", 947], [".", 948], ["CFTR", 950], ["mutation", 955], ["analysis", 964], ["revealed", 973], ["the", 982], ["identification", 986], ["of", 1001], ["37", 1004], ["mutations", 1007], ["in", 1017], ["69", 1020], ["Iranian", 1023], ["CF", 1031], ["patients", 1034], [".", 1042], ["Overall", 1044], [",", 1051], ["81.9", 1053], ["%", 1057], ["(", 1059], ["113/138", 1060], [")", 1067], ["CFTR", 1069], ["genes", 1074], ["derived", 1080], ["from", 1088], ["Iranian", 1093], ["CF", 1101], ["patients", 1104], ["could", 1113], ["be", 1119], ["characterized", 1122], ["for", 1136], ["a", 1140], ["disease", 1142], ["-", 1149], ["causing", 1150], ["mutation", 1158], [".", 1166], ["The", 1168], ["CBAVD", 1172], ["patient", 1178], ["was", 1186], ["found", 1190], ["to", 1196], ["be", 1199], ["homozygous", 1202], ["for", 1213], ["the", 1217], ["p", 1221], [".", 1222], ["W1145R", 1223], ["mutation", 1230], [".", 1238], ["The", 1240], ["most", 1244], ["common", 1249], ["mutations", 1256], ["were", 1266], ["p", 1271], [".", 1272], ["F508del", 1273], ["(", 1281], ["DeltaF508", 1282], [")", 1291], ["(", 1293], ["18.1", 1294], ["%", 1298], [")", 1299], [",", 1300], ["c.2183_2184delAAinsG", 1302], ["(", 1323], ["2183AA", 1324], [">", 1330], ["G", 1331], [")", 1332], ["(", 1334], ["6.5", 1335], ["%", 1338], [")", 1339], [",", 1340], ["p", 1342], [".", 1343], ["S466X", 1344], ["(", 1350], ["5.8", 1351], ["%", 1354], [")", 1355], [",", 1356], ["p", 1358], [".", 1359], ["N1303", 1360], ["K", 1365], ["(", 1367], ["4.3", 1368], ["%", 1371], [")", 1372], [",", 1373], ["c.2789", 1375], ["+", 1381], ["5G", 1382], [">", 1384], ["A", 1385], ["(", 1387], ["4.3", 1388], ["%", 1391], [")", 1392], [",", 1393], ["p", 1395], [".", 1396], ["G542X", 1397], ["(", 1403], ["3.6", 1404], ["%", 1407], [")", 1408], [",", 1409], ["c.3120", 1411], ["+", 1417], ["1G", 1418], [">", 1420], ["A", 1421], ["(", 1423], ["3.6", 1424], ["%", 1427], [")", 1428], [",", 1429], ["p", 1431], [".", 1432], ["R334W", 1433], ["(", 1439], ["2.9", 1440], ["%", 1443], [")", 1444], ["and", 1446], ["c.3130delA", 1450], ["(", 1461], ["2.9", 1462], ["%", 1465], [")", 1466], [".", 1467], ["These", 1469], ["9", 1475], ["types", 1477], ["of", 1483], ["mutant", 1486], ["CFTR", 1493], ["genes", 1498], ["totaled", 1504], ["for", 1512], ["52", 1516], ["%", 1518], ["of", 1520], ["all", 1523], ["CFTR", 1527], ["genes", 1532], ["derived", 1538], ["from", 1546], ["the", 1551], ["69", 1555], ["Iranian", 1558], ["CF", 1566], ["patients", 1569], [".", 1577], ["Eight", 1579], ["mutations", 1585], [",", 1594], ["c.406", 1596], ["-", 1601], ["8T", 1602], [">", 1604], ["C", 1605], [",", 1606], ["p", 1608], [".", 1609], ["A566D", 1610], [",", 1615], ["c.2576delA", 1617], [",", 1627], ["c.2752", 1629], ["-", 1635], ["1_2756delGGTGGCinsTTG", 1636], [",", 1657], ["p", 1659], [".", 1660], ["T1036I", 1661], [",", 1667], ["p", 1669], [".", 1670], ["W1145R", 1671], [",", 1677], ["c.3850", 1679], ["-", 1685], ["24G", 1686], [">", 1689], ["A", 1690], [",", 1691], ["c.1342-?_1524+?del", 1693], [",", 1711], ["were", 1713], ["found", 1718], ["for", 1724], ["the", 1728], ["first", 1732], ["time", 1738], ["in", 1743], ["this", 1746], ["study", 1751], [".", 1756], ["We", 1758], ["identified", 1761], ["37", 1772], ["CFTR", 1775], ["mutations", 1780], ["in", 1790], ["69", 1793], ["well", 1796], ["characterized", 1801], ["Iranian", 1815], ["CF", 1823], ["patients", 1826], [",", 1834], ["obtaining", 1836], ["a", 1846], ["CFTR", 1848], ["mutation", 1853], ["detection", 1862], ["rate", 1872], ["of", 1877], ["81.9", 1880], ["%", 1884], [",", 1885], ["the", 1887], ["highest", 1891], ["detection", 1899], ["rate", 1909], ["obtained", 1914], ["in", 1923], ["the", 1926], ["Iranian", 1930], ["population", 1938], ["so", 1949], ["far", 1952], [".", 1955], ["These", 1957], ["findings", 1963], ["will", 1972], ["assist", 1977], ["in", 1984], ["genetic", 1987], ["counseling", 1995], [",", 2005], ["prenatal", 2007], ["diagnosis", 2016], ["and", 2026], ["future", 2030], ["screening", 2037], ["of", 2047], ["CF", 2050], ["in", 2053], ["Iran", 2056], [".", 2060]]}
{"context": "Dendritic cells (DCs), professional antigen-presenting cells with the unique ability to initiate primary T-cell responses, are present in atherosclerotic lesions where they are exposed to oxidative stress that generates cytotoxic reactive oxygen species (ROS). A large body of evidence indicates that cell death is a major modulating factor of atherogenesis. We examined antioxidant defence systems of human monocyte-derived (mo)DCs and monocytes in response to oxidative stress. Oxidative stress was induced by addition of tertiary-butylhydroperoxide (tert-BHP, 30 min). Cellular responses were evaluated using flow cytometry and confocal live cell imaging (both using 5-(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein diacetate, CM-H(2)DCFDA). Viability was assessed by the neutral red assay. Total RNA was extracted for a PCR profiler array. Five genes were selected for confirmation by Taqman gene expression assays, and by immunoblotting or immunohistochemistry for protein levels. Tert-BHP increased CM-H(2)DCFDA fluorescence and caused cell death. Interestingly, all processes occurred more slowly in moDCs than in monocytes. The mRNA profiler array showed more than 2-fold differential expression of 32 oxidative stress-related genes in unstimulated moDCs, including peroxiredoxin-2 (PRDX2), an enzyme reducing hydrogen peroxide and lipid peroxides. PRDX2 upregulation was confirmed by Taqman assays, immunoblotting and immunohistochemistry. Silencing PRDX2 in moDCs by means of siRNA significantly increased CM-DCF fluorescence and cell death upon tert-BHP-stimulation. Our results indicate that moDCs exhibit higher intracellular antioxidant capacities, making them better equipped to resist oxidative stress than monocytes. Upregulation of PRDX2 is involved in the neutralization of ROS in moDCs. Taken together, this points to better survival skills of DCs in oxidative stress environments, such as atherosclerotic plaques.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "e0afb40c95bf43ecb23eaab63790e3b4", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[64, 64], [270, 270]], "char_spans": [[371, 381], [1644, 1654]]}]}], "context_tokens": [["Dendritic", 0], ["cells", 10], ["(", 16], ["DCs", 17], [")", 20], [",", 21], ["professional", 23], ["antigen", 36], ["-", 43], ["presenting", 44], ["cells", 55], ["with", 61], ["the", 66], ["unique", 70], ["ability", 77], ["to", 85], ["initiate", 88], ["primary", 97], ["T", 105], ["-", 106], ["cell", 107], ["responses", 112], [",", 121], ["are", 123], ["present", 127], ["in", 135], ["atherosclerotic", 138], ["lesions", 154], ["where", 162], ["they", 168], ["are", 173], ["exposed", 177], ["to", 185], ["oxidative", 188], ["stress", 198], ["that", 205], ["generates", 210], ["cytotoxic", 220], ["reactive", 230], ["oxygen", 239], ["species", 246], ["(", 254], ["ROS", 255], [")", 258], [".", 259], ["A", 261], ["large", 263], ["body", 269], ["of", 274], ["evidence", 277], ["indicates", 286], ["that", 296], ["cell", 301], ["death", 306], ["is", 312], ["a", 315], ["major", 317], ["modulating", 323], ["factor", 334], ["of", 341], ["atherogenesis", 344], [".", 357], ["We", 359], ["examined", 362], ["antioxidant", 371], ["defence", 383], ["systems", 391], ["of", 399], ["human", 402], ["monocyte", 408], ["-", 416], ["derived", 417], ["(", 425], ["mo)DCs", 426], ["and", 433], ["monocytes", 437], ["in", 447], ["response", 450], ["to", 459], ["oxidative", 462], ["stress", 472], [".", 478], ["Oxidative", 480], ["stress", 490], ["was", 497], ["induced", 501], ["by", 509], ["addition", 512], ["of", 521], ["tertiary", 524], ["-", 532], ["butylhydroperoxide", 533], ["(", 552], ["tert", 553], ["-", 557], ["BHP", 558], [",", 561], ["30", 563], ["min", 566], [")", 569], [".", 570], ["Cellular", 572], ["responses", 581], ["were", 591], ["evaluated", 596], ["using", 606], ["flow", 612], ["cytometry", 617], ["and", 627], ["confocal", 631], ["live", 640], ["cell", 645], ["imaging", 650], ["(", 658], ["both", 659], ["using", 664], ["5-(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein", 670], ["diacetate", 724], [",", 733], ["CM", 735], ["-", 737], ["H(2)DCFDA", 738], [")", 747], [".", 748], ["Viability", 750], ["was", 760], ["assessed", 764], ["by", 773], ["the", 776], ["neutral", 780], ["red", 788], ["assay", 792], [".", 797], ["Total", 799], ["RNA", 805], ["was", 809], ["extracted", 813], ["for", 823], ["a", 827], ["PCR", 829], ["profiler", 833], ["array", 842], [".", 847], ["Five", 849], ["genes", 854], ["were", 860], ["selected", 865], ["for", 874], ["confirmation", 878], ["by", 891], ["Taqman", 894], ["gene", 901], ["expression", 906], ["assays", 917], [",", 923], ["and", 925], ["by", 929], ["immunoblotting", 932], ["or", 947], ["immunohistochemistry", 950], ["for", 971], ["protein", 975], ["levels", 983], [".", 989], ["Tert", 991], ["-", 995], ["BHP", 996], ["increased", 1000], ["CM", 1010], ["-", 1012], ["H(2)DCFDA", 1013], ["fluorescence", 1023], ["and", 1036], ["caused", 1040], ["cell", 1047], ["death", 1052], [".", 1057], ["Interestingly", 1059], [",", 1072], ["all", 1074], ["processes", 1078], ["occurred", 1088], ["more", 1097], ["slowly", 1102], ["in", 1109], ["moDCs", 1112], ["than", 1118], ["in", 1123], ["monocytes", 1126], [".", 1135], ["The", 1137], ["mRNA", 1141], ["profiler", 1146], ["array", 1155], ["showed", 1161], ["more", 1168], ["than", 1173], ["2-fold", 1178], ["differential", 1185], ["expression", 1198], ["of", 1209], ["32", 1212], ["oxidative", 1215], ["stress", 1225], ["-", 1231], ["related", 1232], ["genes", 1240], ["in", 1246], ["unstimulated", 1249], ["moDCs", 1262], [",", 1267], ["including", 1269], ["peroxiredoxin-2", 1279], ["(", 1295], ["PRDX2", 1296], [")", 1301], [",", 1302], ["an", 1304], ["enzyme", 1307], ["reducing", 1314], ["hydrogen", 1323], ["peroxide", 1332], ["and", 1341], ["lipid", 1345], ["peroxides", 1351], [".", 1360], ["PRDX2", 1362], ["upregulation", 1368], ["was", 1381], ["confirmed", 1385], ["by", 1395], ["Taqman", 1398], ["assays", 1405], [",", 1411], ["immunoblotting", 1413], ["and", 1428], ["immunohistochemistry", 1432], [".", 1452], ["Silencing", 1454], ["PRDX2", 1464], ["in", 1470], ["moDCs", 1473], ["by", 1479], ["means", 1482], ["of", 1488], ["siRNA", 1491], ["significantly", 1497], ["increased", 1511], ["CM", 1521], ["-", 1523], ["DCF", 1524], ["fluorescence", 1528], ["and", 1541], ["cell", 1545], ["death", 1550], ["upon", 1556], ["tert", 1561], ["-", 1565], ["BHP", 1566], ["-", 1569], ["stimulation", 1570], [".", 1581], ["Our", 1583], ["results", 1587], ["indicate", 1595], ["that", 1604], ["moDCs", 1609], ["exhibit", 1615], ["higher", 1623], ["intracellular", 1630], ["antioxidant", 1644], ["capacities", 1656], [",", 1666], ["making", 1668], ["them", 1675], ["better", 1680], ["equipped", 1687], ["to", 1696], ["resist", 1699], ["oxidative", 1706], ["stress", 1716], ["than", 1723], ["monocytes", 1728], [".", 1737], ["Upregulation", 1739], ["of", 1752], ["PRDX2", 1755], ["is", 1761], ["involved", 1764], ["in", 1773], ["the", 1776], ["neutralization", 1780], ["of", 1795], ["ROS", 1798], ["in", 1802], ["moDCs", 1805], [".", 1810], ["Taken", 1812], ["together", 1818], [",", 1826], ["this", 1828], ["points", 1833], ["to", 1840], ["better", 1843], ["survival", 1850], ["skills", 1859], ["of", 1866], ["DCs", 1869], ["in", 1873], ["oxidative", 1876], ["stress", 1886], ["environments", 1893], [",", 1905], ["such", 1907], ["as", 1912], ["atherosclerotic", 1915], ["plaques", 1931], [".", 1938]]}
{"context": "Plasmids are ubiquitous mobile elements that serve as a pool of many host beneficial traits such as antibiotic resistance in bacterial communities. To understand the importance of plasmids in horizontal gene transfer, we need to gain insight into the 'evolutionary history' of these plasmids, i.e. the range of hosts in which they have evolved. Since extensive data support the proposal that foreign DNA acquires the host's nucleotide composition during long-term residence, comparison of nucleotide composition of plasmids and chromosomes could shed light on a plasmid's evolutionary history. The average absolute dinucleotide relative abundance difference, termed delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and plasmids. Here, we introduce the Mahalanobis distance, which takes into account the variance-covariance structure of the chromosome signatures. We demonstrate that the Mahalanobis distance is better than the delta-distance at measuring genomic signature differences between plasmids and chromosomes of potential hosts. We illustrate the usefulness of this metric for proposing candidate long-term hosts for plasmids, focusing on the virulence plasmids pXO1 from Bacillus anthracis, and pO157 from Escherichia coli O157:H7, as well as the broad host range multi-drug resistance plasmid pB10 from an unknown host.", "qas": [{"question": "Which is the most common measure of differences between dinucleotide relative abundance \"genomic signatures\"", "answers": ["delta-distance"], "qid": "082b7ea2976047d8b572fd00bfddec04", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["measure", 25], ["of", 33], ["differences", 36], ["between", 48], ["dinucleotide", 56], ["relative", 69], ["abundance", 78], ["\"", 88], ["genomic", 89], ["signatures", 97], ["\"", 107]], "detected_answers": [{"text": "delta-distance", "token_spans": [[108, 110], [167, 169]], "char_spans": [[666, 679], [1023, 1036]]}]}], "context_tokens": [["Plasmids", 0], ["are", 9], ["ubiquitous", 13], ["mobile", 24], ["elements", 31], ["that", 40], ["serve", 45], ["as", 51], ["a", 54], ["pool", 56], ["of", 61], ["many", 64], ["host", 69], ["beneficial", 74], ["traits", 85], ["such", 92], ["as", 97], ["antibiotic", 100], ["resistance", 111], ["in", 122], ["bacterial", 125], ["communities", 135], [".", 146], ["To", 148], ["understand", 151], ["the", 162], ["importance", 166], ["of", 177], ["plasmids", 180], ["in", 189], ["horizontal", 192], ["gene", 203], ["transfer", 208], [",", 216], ["we", 218], ["need", 221], ["to", 226], ["gain", 229], ["insight", 234], ["into", 242], ["the", 247], ["'", 251], ["evolutionary", 252], ["history", 265], ["'", 272], ["of", 274], ["these", 277], ["plasmids", 283], [",", 291], ["i.e.", 293], ["the", 298], ["range", 302], ["of", 308], ["hosts", 311], ["in", 317], ["which", 320], ["they", 326], ["have", 331], ["evolved", 336], [".", 343], ["Since", 345], ["extensive", 351], ["data", 361], ["support", 366], ["the", 374], ["proposal", 378], ["that", 387], ["foreign", 392], ["DNA", 400], ["acquires", 404], ["the", 413], ["host", 417], ["'s", 421], ["nucleotide", 424], ["composition", 435], ["during", 447], ["long", 454], ["-", 458], ["term", 459], ["residence", 464], [",", 473], ["comparison", 475], ["of", 486], ["nucleotide", 489], ["composition", 500], ["of", 512], ["plasmids", 515], ["and", 524], ["chromosomes", 528], ["could", 540], ["shed", 546], ["light", 551], ["on", 557], ["a", 560], ["plasmid", 562], ["'s", 569], ["evolutionary", 572], ["history", 585], [".", 592], ["The", 594], ["average", 598], ["absolute", 606], ["dinucleotide", 615], ["relative", 628], ["abundance", 637], ["difference", 647], [",", 657], ["termed", 659], ["delta", 666], ["-", 671], ["distance", 672], [",", 680], ["has", 682], ["been", 686], ["commonly", 691], ["used", 700], ["to", 705], ["measure", 708], ["differences", 716], ["in", 728], ["dinucleotide", 731], ["composition", 744], [",", 755], ["or", 757], ["'", 760], ["genomic", 761], ["signature", 769], ["'", 778], [",", 779], ["between", 781], ["bacterial", 789], ["chromosomes", 799], ["and", 811], ["plasmids", 815], [".", 823], ["Here", 825], [",", 829], ["we", 831], ["introduce", 834], ["the", 844], ["Mahalanobis", 848], ["distance", 860], [",", 868], ["which", 870], ["takes", 876], ["into", 882], ["account", 887], ["the", 895], ["variance", 899], ["-", 907], ["covariance", 908], ["structure", 919], ["of", 929], ["the", 932], ["chromosome", 936], ["signatures", 947], [".", 957], ["We", 959], ["demonstrate", 962], ["that", 974], ["the", 979], ["Mahalanobis", 983], ["distance", 995], ["is", 1004], ["better", 1007], ["than", 1014], ["the", 1019], ["delta", 1023], ["-", 1028], ["distance", 1029], ["at", 1038], ["measuring", 1041], ["genomic", 1051], ["signature", 1059], ["differences", 1069], ["between", 1081], ["plasmids", 1089], ["and", 1098], ["chromosomes", 1102], ["of", 1114], ["potential", 1117], ["hosts", 1127], [".", 1132], ["We", 1134], ["illustrate", 1137], ["the", 1148], ["usefulness", 1152], ["of", 1163], ["this", 1166], ["metric", 1171], ["for", 1178], ["proposing", 1182], ["candidate", 1192], ["long", 1202], ["-", 1206], ["term", 1207], ["hosts", 1212], ["for", 1218], ["plasmids", 1222], [",", 1230], ["focusing", 1232], ["on", 1241], ["the", 1244], ["virulence", 1248], ["plasmids", 1258], ["pXO1", 1267], ["from", 1272], ["Bacillus", 1277], ["anthracis", 1286], [",", 1295], ["and", 1297], ["pO157", 1301], ["from", 1307], ["Escherichia", 1312], ["coli", 1324], ["O157:H7", 1329], [",", 1336], ["as", 1338], ["well", 1341], ["as", 1346], ["the", 1349], ["broad", 1353], ["host", 1359], ["range", 1364], ["multi", 1370], ["-", 1375], ["drug", 1376], ["resistance", 1381], ["plasmid", 1392], ["pB10", 1400], ["from", 1405], ["an", 1410], ["unknown", 1413], ["host", 1421], [".", 1425]]}
{"context": "The purpose of this study is to determine the sensibility of each imaging tool in identifying focal cortical dysplasia (FCD) in children and adolescents with epilepsy and to define the prognostic factors of pediatric and adolescent epilepsy surgery. We identified 48 children with FCD who underwent resective surgery and analyzed their preoperative data. The results of various anatomic and functional neuroimaging studies were compared for accuracy in locating the lesion. We also investigated clinical factors that affected the outcome of surgical treatment. Brain magnetic resonance imaging (MRI) was able to localize FCD in 30 patients and fluorodeoxyglucose positron emission tomography (FDG-PET) and/or subtraction ictal single photon emission computed tomography (SPECT) coregistered with MRI provided additional information that helped to define the lesion in 13 patients. When comparing the pathologic results between a mild malformation of cortical development (MCD) and FCD type I and II, we noted a strong tendency for patients with FCD to have MRI abnormalities (p = 0.005). In addition, severe pathologic features (Palmini's classification, FCD type II) (p = 0.025) showed significant correlation with a better surgical outcome. To define the primary epileptogenic area, various interictal epileptiform discharges and the results of multimodal neuroimaging studies were helpful, and younger age at the time of operation could aid in more favorable surgical outcomes (p = 0.048). Our study showed a significant relationship between pathologic grade and the detectability of FCD by brain MRI. In addition, early surgery can be justified by showing that advanced neuroimaging studies in children with FCD and even with extensive epileptiform discharges have a higher rate of success.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "4e97ba94bae54666969f2d440b9221ff", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[16, 18]], "char_spans": [[94, 117]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["study", 20], ["is", 26], ["to", 29], ["determine", 32], ["the", 42], ["sensibility", 46], ["of", 58], ["each", 61], ["imaging", 66], ["tool", 74], ["in", 79], ["identifying", 82], ["focal", 94], ["cortical", 100], ["dysplasia", 109], ["(", 119], ["FCD", 120], [")", 123], ["in", 125], ["children", 128], ["and", 137], ["adolescents", 141], ["with", 153], ["epilepsy", 158], ["and", 167], ["to", 171], ["define", 174], ["the", 181], ["prognostic", 185], ["factors", 196], ["of", 204], ["pediatric", 207], ["and", 217], ["adolescent", 221], ["epilepsy", 232], ["surgery", 241], [".", 248], ["We", 250], ["identified", 253], ["48", 264], ["children", 267], ["with", 276], ["FCD", 281], ["who", 285], ["underwent", 289], ["resective", 299], ["surgery", 309], ["and", 317], ["analyzed", 321], ["their", 330], ["preoperative", 336], ["data", 349], [".", 353], ["The", 355], ["results", 359], ["of", 367], ["various", 370], ["anatomic", 378], ["and", 387], ["functional", 391], ["neuroimaging", 402], ["studies", 415], ["were", 423], ["compared", 428], ["for", 437], ["accuracy", 441], ["in", 450], ["locating", 453], ["the", 462], ["lesion", 466], [".", 472], ["We", 474], ["also", 477], ["investigated", 482], ["clinical", 495], ["factors", 504], ["that", 512], ["affected", 517], ["the", 526], ["outcome", 530], ["of", 538], ["surgical", 541], ["treatment", 550], [".", 559], ["Brain", 561], ["magnetic", 567], ["resonance", 576], ["imaging", 586], ["(", 594], ["MRI", 595], [")", 598], ["was", 600], ["able", 604], ["to", 609], ["localize", 612], ["FCD", 621], ["in", 625], ["30", 628], ["patients", 631], ["and", 640], ["fluorodeoxyglucose", 644], ["positron", 663], ["emission", 672], ["tomography", 681], ["(", 692], ["FDG", 693], ["-", 696], ["PET", 697], [")", 700], ["and/or", 702], ["subtraction", 709], ["ictal", 721], ["single", 727], ["photon", 734], ["emission", 741], ["computed", 750], ["tomography", 759], ["(", 770], ["SPECT", 771], [")", 776], ["coregistered", 778], ["with", 791], ["MRI", 796], ["provided", 800], ["additional", 809], ["information", 820], ["that", 832], ["helped", 837], ["to", 844], ["define", 847], ["the", 854], ["lesion", 858], ["in", 865], ["13", 868], ["patients", 871], [".", 879], ["When", 881], ["comparing", 886], ["the", 896], ["pathologic", 900], ["results", 911], ["between", 919], ["a", 927], ["mild", 929], ["malformation", 934], ["of", 947], ["cortical", 950], ["development", 959], ["(", 971], ["MCD", 972], [")", 975], ["and", 977], ["FCD", 981], ["type", 985], ["I", 990], ["and", 992], ["II", 996], [",", 998], ["we", 1000], ["noted", 1003], ["a", 1009], ["strong", 1011], ["tendency", 1018], ["for", 1027], ["patients", 1031], ["with", 1040], ["FCD", 1045], ["to", 1049], ["have", 1052], ["MRI", 1057], ["abnormalities", 1061], ["(", 1075], ["p", 1076], ["=", 1078], ["0.005", 1080], [")", 1085], [".", 1086], ["In", 1088], ["addition", 1091], [",", 1099], ["severe", 1101], ["pathologic", 1108], ["features", 1119], ["(", 1128], ["Palmini", 1129], ["'s", 1136], ["classification", 1139], [",", 1153], ["FCD", 1155], ["type", 1159], ["II", 1164], [")", 1166], ["(", 1168], ["p", 1169], ["=", 1171], ["0.025", 1173], [")", 1178], ["showed", 1180], ["significant", 1187], ["correlation", 1199], ["with", 1211], ["a", 1216], ["better", 1218], ["surgical", 1225], ["outcome", 1234], [".", 1241], ["To", 1243], ["define", 1246], ["the", 1253], ["primary", 1257], ["epileptogenic", 1265], ["area", 1279], [",", 1283], ["various", 1285], ["interictal", 1293], ["epileptiform", 1304], ["discharges", 1317], ["and", 1328], ["the", 1332], ["results", 1336], ["of", 1344], ["multimodal", 1347], ["neuroimaging", 1358], ["studies", 1371], ["were", 1379], ["helpful", 1384], [",", 1391], ["and", 1393], ["younger", 1397], ["age", 1405], ["at", 1409], ["the", 1412], ["time", 1416], ["of", 1421], ["operation", 1424], ["could", 1434], ["aid", 1440], ["in", 1444], ["more", 1447], ["favorable", 1452], ["surgical", 1462], ["outcomes", 1471], ["(", 1480], ["p", 1481], ["=", 1483], ["0.048", 1485], [")", 1490], [".", 1491], ["Our", 1493], ["study", 1497], ["showed", 1503], ["a", 1510], ["significant", 1512], ["relationship", 1524], ["between", 1537], ["pathologic", 1545], ["grade", 1556], ["and", 1562], ["the", 1566], ["detectability", 1570], ["of", 1584], ["FCD", 1587], ["by", 1591], ["brain", 1594], ["MRI", 1600], [".", 1603], ["In", 1605], ["addition", 1608], [",", 1616], ["early", 1618], ["surgery", 1624], ["can", 1632], ["be", 1636], ["justified", 1639], ["by", 1649], ["showing", 1652], ["that", 1660], ["advanced", 1665], ["neuroimaging", 1674], ["studies", 1687], ["in", 1695], ["children", 1698], ["with", 1707], ["FCD", 1712], ["and", 1716], ["even", 1720], ["with", 1725], ["extensive", 1730], ["epileptiform", 1740], ["discharges", 1753], ["have", 1764], ["a", 1769], ["higher", 1771], ["rate", 1778], ["of", 1783], ["success", 1786], [".", 1793]]}
{"context": "Chronic myeloid leukemia (CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by imatinib is effective to control the tyrosyl phosphorylation of the protein related to the cell signaling. BCR-ABL mRNA is overexpressed in the minimal residual disease (MRD), known as an early sign of relapse. Between December 2005 and June 2008, we measured BCR-ABL mRNA levels in the bone marrow (BM) from patients by quantitative real-time polymerase chain reaction (RQ-PCR) in Aomori Prefectural Central Hospital. Eighty-six samples from 26 patients were collected. Among the 26 CML patients, 11 patients (42%) were in the pretreatment group. Seven (64%) of the 11 patients achieved complete molecular response (CMR). In the post-treatment group consisting of the remaining 15 patients, 9 (60%) patients achieved CMR. The patients receiving imatinib at a dose over 300 mg per day required 13 (6-77) months [median (range)] to achieve CMR. On the other hand, the patients receiving a dose below 300 mg per day required 29.5 (11-84) months [median (range)]. When BCR-ABL mRNA was detected during the treatment course of patients with CMR, careful observation of BCR-ABL mRNA was useful for tracking the clinical course of patients. In conclusion, the BCR-ABL mRNA level was useful for monitoring the clinical course in 26 patients with CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "412a49803a00424099cd84a75d92bd63", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[295, 297], [36, 38], [101, 103], [69, 71], [10, 12], [277, 279], [259, 261]], "char_spans": [[1409, 1415], [172, 178], [515, 521], [362, 368], [48, 54], [1320, 1326], [1221, 1227]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["caused", 34], ["by", 41], ["the", 44], ["BCR", 48], ["-", 51], ["ABL", 52], ["oncogene", 56], [".", 64], ["The", 66], ["Philadelphia", 70], ["chromosome", 83], ["(", 94], ["Ph", 95], [")", 97], ["from", 99], ["a", 104], ["reciprocal", 106], ["translocation", 117], [",", 130], ["t(9;22", 132], [")", 138], ["(", 140], ["q34;q11", 141], [")", 148], ["causes", 150], ["a", 157], ["fusion", 159], ["gene", 166], [",", 170], ["BCR", 172], ["-", 175], ["ABL", 176], [",", 179], ["that", 181], ["encodes", 186], ["a", 194], ["constitutively", 196], ["active", 211], ["tyrosine", 218], ["kinase", 227], [".", 233], ["Treatment", 235], ["of", 245], ["CML", 248], ["by", 252], ["imatinib", 255], ["is", 264], ["effective", 267], ["to", 277], ["control", 280], ["the", 288], ["tyrosyl", 292], ["phosphorylation", 300], ["of", 316], ["the", 319], ["protein", 323], ["related", 331], ["to", 339], ["the", 342], ["cell", 346], ["signaling", 351], [".", 360], ["BCR", 362], ["-", 365], ["ABL", 366], ["mRNA", 370], ["is", 375], ["overexpressed", 378], ["in", 392], ["the", 395], ["minimal", 399], ["residual", 407], ["disease", 416], ["(", 424], ["MRD", 425], [")", 428], [",", 429], ["known", 431], ["as", 437], ["an", 440], ["early", 443], ["sign", 449], ["of", 454], ["relapse", 457], [".", 464], ["Between", 466], ["December", 474], ["2005", 483], ["and", 488], ["June", 492], ["2008", 497], [",", 501], ["we", 503], ["measured", 506], ["BCR", 515], ["-", 518], ["ABL", 519], ["mRNA", 523], ["levels", 528], ["in", 535], ["the", 538], ["bone", 542], ["marrow", 547], ["(", 554], ["BM", 555], [")", 557], ["from", 559], ["patients", 564], ["by", 573], ["quantitative", 576], ["real", 589], ["-", 593], ["time", 594], ["polymerase", 599], ["chain", 610], ["reaction", 616], ["(", 625], ["RQ", 626], ["-", 628], ["PCR", 629], [")", 632], ["in", 634], ["Aomori", 637], ["Prefectural", 644], ["Central", 656], ["Hospital", 664], [".", 672], ["Eighty", 674], ["-", 680], ["six", 681], ["samples", 685], ["from", 693], ["26", 698], ["patients", 701], ["were", 710], ["collected", 715], [".", 724], ["Among", 726], ["the", 732], ["26", 736], ["CML", 739], ["patients", 743], [",", 751], ["11", 753], ["patients", 756], ["(", 765], ["42", 766], ["%", 768], [")", 769], ["were", 771], ["in", 776], ["the", 779], ["pretreatment", 783], ["group", 796], [".", 801], ["Seven", 803], ["(", 809], ["64", 810], ["%", 812], [")", 813], ["of", 815], ["the", 818], ["11", 822], ["patients", 825], ["achieved", 834], ["complete", 843], ["molecular", 852], ["response", 862], ["(", 871], ["CMR", 872], [")", 875], [".", 876], ["In", 878], ["the", 881], ["post", 885], ["-", 889], ["treatment", 890], ["group", 900], ["consisting", 906], ["of", 917], ["the", 920], ["remaining", 924], ["15", 934], ["patients", 937], [",", 945], ["9", 947], ["(", 949], ["60", 950], ["%", 952], [")", 953], ["patients", 955], ["achieved", 964], ["CMR", 973], [".", 976], ["The", 978], ["patients", 982], ["receiving", 991], ["imatinib", 1001], ["at", 1010], ["a", 1013], ["dose", 1015], ["over", 1020], ["300", 1025], ["mg", 1029], ["per", 1032], ["day", 1036], ["required", 1040], ["13", 1049], ["(", 1052], ["6", 1053], ["-", 1054], ["77", 1055], [")", 1057], ["months", 1059], ["[", 1066], ["median", 1067], ["(", 1074], ["range", 1075], [")", 1080], ["]", 1081], ["to", 1083], ["achieve", 1086], ["CMR", 1094], [".", 1097], ["On", 1099], ["the", 1102], ["other", 1106], ["hand", 1112], [",", 1116], ["the", 1118], ["patients", 1122], ["receiving", 1131], ["a", 1141], ["dose", 1143], ["below", 1148], ["300", 1154], ["mg", 1158], ["per", 1161], ["day", 1165], ["required", 1169], ["29.5", 1178], ["(", 1183], ["11", 1184], ["-", 1186], ["84", 1187], [")", 1189], ["months", 1191], ["[", 1198], ["median", 1199], ["(", 1206], ["range)].", 1207], ["When", 1216], ["BCR", 1221], ["-", 1224], ["ABL", 1225], ["mRNA", 1229], ["was", 1234], ["detected", 1238], ["during", 1247], ["the", 1254], ["treatment", 1258], ["course", 1268], ["of", 1275], ["patients", 1278], ["with", 1287], ["CMR", 1292], [",", 1295], ["careful", 1297], ["observation", 1305], ["of", 1317], ["BCR", 1320], ["-", 1323], ["ABL", 1324], ["mRNA", 1328], ["was", 1333], ["useful", 1337], ["for", 1344], ["tracking", 1348], ["the", 1357], ["clinical", 1361], ["course", 1370], ["of", 1377], ["patients", 1380], [".", 1388], ["In", 1390], ["conclusion", 1393], [",", 1403], ["the", 1405], ["BCR", 1409], ["-", 1412], ["ABL", 1413], ["mRNA", 1417], ["level", 1422], ["was", 1428], ["useful", 1432], ["for", 1439], ["monitoring", 1443], ["the", 1454], ["clinical", 1458], ["course", 1467], ["in", 1474], ["26", 1477], ["patients", 1480], ["with", 1489], ["CML", 1494], [".", 1497]]}
{"context": "Chronic myeloid leukemia (CML) originates from the hematopoietic stem cell and is characterized by the reciprocal translocation t(9;22)(q34;q11), which results in the BCR-ABL fusion gene on chromosome 22q-, also known as the Philadelphia chromosome. This chimeric gene codes for a cytoplasmic protein with constitutive tyrosine-kinase activity, responsible for cellular transformation and leukemogenesis in CML. The aim of this observational cohort study was to discriminate and quantify BCR-ABL transcripts in the peripheral blood of patients with CML who were treated with imatinib mesylate (Glivec, Novartis). Twenty-two patients were followed for six months during treatment. Quantitative real time polymerase chain reaction was performed before treatment and after 3 and 6 months from treatment initiation. As compared with the third month, there was a significant decrease in BCR-ABL expression in the sixth month of treatment (P = 0.0002). At the sixth month, there was a significant difference in the levels of the two major transcripts of BCR-ABL, B2A2 and B3A2 (P = 0.0347), indicating that B2A2 may be more sensitive to imatinib. The results of our study indicate that imatinib is able to modify the natural history of CML, and raise the hypothesis that patients who express the B2A2 transcript may have a better prognosis.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "e19160c7bb354a72b145aeab75882fde", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[78, 80], [182, 184], [26, 28], [147, 149]], "char_spans": [[488, 494], [1048, 1054], [167, 173], [882, 888]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["originates", 31], ["from", 42], ["the", 47], ["hematopoietic", 51], ["stem", 65], ["cell", 70], ["and", 75], ["is", 79], ["characterized", 82], ["by", 96], ["the", 99], ["reciprocal", 103], ["translocation", 114], ["t(9;22)(q34;q11", 128], [")", 143], [",", 144], ["which", 146], ["results", 152], ["in", 160], ["the", 163], ["BCR", 167], ["-", 170], ["ABL", 171], ["fusion", 175], ["gene", 182], ["on", 187], ["chromosome", 190], ["22q-", 201], [",", 205], ["also", 207], ["known", 212], ["as", 218], ["the", 221], ["Philadelphia", 225], ["chromosome", 238], [".", 248], ["This", 250], ["chimeric", 255], ["gene", 264], ["codes", 269], ["for", 275], ["a", 279], ["cytoplasmic", 281], ["protein", 293], ["with", 301], ["constitutive", 306], ["tyrosine", 319], ["-", 327], ["kinase", 328], ["activity", 335], [",", 343], ["responsible", 345], ["for", 357], ["cellular", 361], ["transformation", 370], ["and", 385], ["leukemogenesis", 389], ["in", 404], ["CML", 407], [".", 410], ["The", 412], ["aim", 416], ["of", 420], ["this", 423], ["observational", 428], ["cohort", 442], ["study", 449], ["was", 455], ["to", 459], ["discriminate", 462], ["and", 475], ["quantify", 479], ["BCR", 488], ["-", 491], ["ABL", 492], ["transcripts", 496], ["in", 508], ["the", 511], ["peripheral", 515], ["blood", 526], ["of", 532], ["patients", 535], ["with", 544], ["CML", 549], ["who", 553], ["were", 557], ["treated", 562], ["with", 570], ["imatinib", 575], ["mesylate", 584], ["(", 593], ["Glivec", 594], [",", 600], ["Novartis", 602], [")", 610], [".", 611], ["Twenty", 613], ["-", 619], ["two", 620], ["patients", 624], ["were", 633], ["followed", 638], ["for", 647], ["six", 651], ["months", 655], ["during", 662], ["treatment", 669], [".", 678], ["Quantitative", 680], ["real", 693], ["time", 698], ["polymerase", 703], ["chain", 714], ["reaction", 720], ["was", 729], ["performed", 733], ["before", 743], ["treatment", 750], ["and", 760], ["after", 764], ["3", 770], ["and", 772], ["6", 776], ["months", 778], ["from", 785], ["treatment", 790], ["initiation", 800], [".", 810], ["As", 812], ["compared", 815], ["with", 824], ["the", 829], ["third", 833], ["month", 839], [",", 844], ["there", 846], ["was", 852], ["a", 856], ["significant", 858], ["decrease", 870], ["in", 879], ["BCR", 882], ["-", 885], ["ABL", 886], ["expression", 890], ["in", 901], ["the", 904], ["sixth", 908], ["month", 914], ["of", 920], ["treatment", 923], ["(", 933], ["P", 934], ["=", 936], ["0.0002", 938], [")", 944], [".", 945], ["At", 947], ["the", 950], ["sixth", 954], ["month", 960], [",", 965], ["there", 967], ["was", 973], ["a", 977], ["significant", 979], ["difference", 991], ["in", 1002], ["the", 1005], ["levels", 1009], ["of", 1016], ["the", 1019], ["two", 1023], ["major", 1027], ["transcripts", 1033], ["of", 1045], ["BCR", 1048], ["-", 1051], ["ABL", 1052], [",", 1055], ["B2A2", 1057], ["and", 1062], ["B3A2", 1066], ["(", 1071], ["P", 1072], ["=", 1074], ["0.0347", 1076], [")", 1082], [",", 1083], ["indicating", 1085], ["that", 1096], ["B2A2", 1101], ["may", 1106], ["be", 1110], ["more", 1113], ["sensitive", 1118], ["to", 1128], ["imatinib", 1131], [".", 1139], ["The", 1141], ["results", 1145], ["of", 1153], ["our", 1156], ["study", 1160], ["indicate", 1166], ["that", 1175], ["imatinib", 1180], ["is", 1189], ["able", 1192], ["to", 1197], ["modify", 1200], ["the", 1207], ["natural", 1211], ["history", 1219], ["of", 1227], ["CML", 1230], [",", 1233], ["and", 1235], ["raise", 1239], ["the", 1245], ["hypothesis", 1249], ["that", 1260], ["patients", 1265], ["who", 1274], ["express", 1278], ["the", 1286], ["B2A2", 1290], ["transcript", 1295], ["may", 1306], ["have", 1310], ["a", 1315], ["better", 1317], ["prognosis", 1324], [".", 1333]]}
{"context": "Natively disordered proteins are a growing class of anomalies to the structure-function paradigm. The natively disordered protein alpha-synuclein is the primary component of Lewy bodies, the cellular hallmark of Parkinson's disease. We noticed a dramatic difference in dilute solution 1H-15N Heteronuclear Single Quantum Coherence (HSQC) spectra of wild-type alpha-synuclein and two disease-related mutants (A30P and A53T), with spectra collected at 35 degrees C showing fewer cross-peaks than spectra acquired at 10 degrees C. Here, we show the change to be the result of a reversible conformational exchange linked to an increase in hydrodynamic radius and secondary structure as the temperature is raised. Combined with analytical ultracentrifugation data showing alpha-synuclein to be monomeric at both temperatures, we conclude that the poor quality of the 1H-15N HSQC spectra obtained at 35 degrees C is due to conformational fluctuations that occur on the proton chemical shift time scale. Using a truncated variant of alpha-synuclein, we show the conformational exchange occurs in the first 100 amino acids of the protein. Our data illustrate a key difference between globular and natively disordered proteins. The properties of globular proteins change little with solution conditions until they denature cooperatively, but the properties of natively disordered proteins can vary dramatically with solution conditions.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "8af93cd51edd4155854b8bc805023cf9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[132, 134], [60, 62], [20, 22], [178, 180]], "char_spans": [[767, 781], [359, 373], [130, 144], [1026, 1040]]}]}], "context_tokens": [["Natively", 0], ["disordered", 9], ["proteins", 20], ["are", 29], ["a", 33], ["growing", 35], ["class", 43], ["of", 49], ["anomalies", 52], ["to", 62], ["the", 65], ["structure", 69], ["-", 78], ["function", 79], ["paradigm", 88], [".", 96], ["The", 98], ["natively", 102], ["disordered", 111], ["protein", 122], ["alpha", 130], ["-", 135], ["synuclein", 136], ["is", 146], ["the", 149], ["primary", 153], ["component", 161], ["of", 171], ["Lewy", 174], ["bodies", 179], [",", 185], ["the", 187], ["cellular", 191], ["hallmark", 200], ["of", 209], ["Parkinson", 212], ["'s", 221], ["disease", 224], [".", 231], ["We", 233], ["noticed", 236], ["a", 244], ["dramatic", 246], ["difference", 255], ["in", 266], ["dilute", 269], ["solution", 276], ["1H-15N", 285], ["Heteronuclear", 292], ["Single", 306], ["Quantum", 313], ["Coherence", 321], ["(", 331], ["HSQC", 332], [")", 336], ["spectra", 338], ["of", 346], ["wild", 349], ["-", 353], ["type", 354], ["alpha", 359], ["-", 364], ["synuclein", 365], ["and", 375], ["two", 379], ["disease", 383], ["-", 390], ["related", 391], ["mutants", 399], ["(", 407], ["A30P", 408], ["and", 413], ["A53", 417], ["T", 420], [")", 421], [",", 422], ["with", 424], ["spectra", 429], ["collected", 437], ["at", 447], ["35", 450], ["degrees", 453], ["C", 461], ["showing", 463], ["fewer", 471], ["cross", 477], ["-", 482], ["peaks", 483], ["than", 489], ["spectra", 494], ["acquired", 502], ["at", 511], ["10", 514], ["degrees", 517], ["C.", 525], ["Here", 528], [",", 532], ["we", 534], ["show", 537], ["the", 542], ["change", 546], ["to", 553], ["be", 556], ["the", 559], ["result", 563], ["of", 570], ["a", 573], ["reversible", 575], ["conformational", 586], ["exchange", 601], ["linked", 610], ["to", 617], ["an", 620], ["increase", 623], ["in", 632], ["hydrodynamic", 635], ["radius", 648], ["and", 655], ["secondary", 659], ["structure", 669], ["as", 679], ["the", 682], ["temperature", 686], ["is", 698], ["raised", 701], [".", 707], ["Combined", 709], ["with", 718], ["analytical", 723], ["ultracentrifugation", 734], ["data", 754], ["showing", 759], ["alpha", 767], ["-", 772], ["synuclein", 773], ["to", 783], ["be", 786], ["monomeric", 789], ["at", 799], ["both", 802], ["temperatures", 807], [",", 819], ["we", 821], ["conclude", 824], ["that", 833], ["the", 838], ["poor", 842], ["quality", 847], ["of", 855], ["the", 858], ["1H-15N", 862], ["HSQC", 869], ["spectra", 874], ["obtained", 882], ["at", 891], ["35", 894], ["degrees", 897], ["C", 905], ["is", 907], ["due", 910], ["to", 914], ["conformational", 917], ["fluctuations", 932], ["that", 945], ["occur", 950], ["on", 956], ["the", 959], ["proton", 963], ["chemical", 970], ["shift", 979], ["time", 985], ["scale", 990], [".", 995], ["Using", 997], ["a", 1003], ["truncated", 1005], ["variant", 1015], ["of", 1023], ["alpha", 1026], ["-", 1031], ["synuclein", 1032], [",", 1041], ["we", 1043], ["show", 1046], ["the", 1051], ["conformational", 1055], ["exchange", 1070], ["occurs", 1079], ["in", 1086], ["the", 1089], ["first", 1093], ["100", 1099], ["amino", 1103], ["acids", 1109], ["of", 1115], ["the", 1118], ["protein", 1122], [".", 1129], ["Our", 1131], ["data", 1135], ["illustrate", 1140], ["a", 1151], ["key", 1153], ["difference", 1157], ["between", 1168], ["globular", 1176], ["and", 1185], ["natively", 1189], ["disordered", 1198], ["proteins", 1209], [".", 1217], ["The", 1219], ["properties", 1223], ["of", 1234], ["globular", 1237], ["proteins", 1246], ["change", 1255], ["little", 1262], ["with", 1269], ["solution", 1274], ["conditions", 1283], ["until", 1294], ["they", 1300], ["denature", 1305], ["cooperatively", 1314], [",", 1327], ["but", 1329], ["the", 1333], ["properties", 1337], ["of", 1348], ["natively", 1351], ["disordered", 1360], ["proteins", 1371], ["can", 1380], ["vary", 1384], ["dramatically", 1389], ["with", 1402], ["solution", 1407], ["conditions", 1416], [".", 1426]]}
{"context": "The BCR/ABL gene fusion, the hallmark of chronic myelogenous leukemia (CML) is generated in 2-10% of patients by a variant Ph translocation involving 9q34, 22q11.2, and one or more additional genomic regions. The objective of this study was the characterization by conventional and molecular cytogenetics of complex variant Ph translocations present at diagnosis. FISH studies were performed in 7 cases using the LSI BCR/ABL ES probe allowing the detection of the fusion BCR/ABL gene on the Ph chromosome in all of them and 9q34 deletions in 2 cases. Three cryptic complex rearrangements were detected by FISH studies. The third and the fourth chromosome regions involved in the 8 complex variant translocations were: 1q21, 1p36, 5q31, 11q13, 12q13, 12p13, and 20q12. In conclusion, FISH studies have been useful in the detection of the BCR/ABL rearrangements and 9q34 deletions, and to identify complex rearrangements that differ from the ones previously established by conventional cytogenetics.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "85a18e64fb2d47b0afeee4832c599891", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[1, 5]], "char_spans": [[4, 22]]}]}], "context_tokens": [["The", 0], ["BCR", 4], ["/", 7], ["ABL", 8], ["gene", 12], ["fusion", 17], [",", 23], ["the", 25], ["hallmark", 29], ["of", 38], ["chronic", 41], ["myelogenous", 49], ["leukemia", 61], ["(", 70], ["CML", 71], [")", 74], ["is", 76], ["generated", 79], ["in", 89], ["2", 92], ["-", 93], ["10", 94], ["%", 96], ["of", 98], ["patients", 101], ["by", 110], ["a", 113], ["variant", 115], ["Ph", 123], ["translocation", 126], ["involving", 140], ["9q34", 150], [",", 154], ["22q11.2", 156], [",", 163], ["and", 165], ["one", 169], ["or", 173], ["more", 176], ["additional", 181], ["genomic", 192], ["regions", 200], [".", 207], ["The", 209], ["objective", 213], ["of", 223], ["this", 226], ["study", 231], ["was", 237], ["the", 241], ["characterization", 245], ["by", 262], ["conventional", 265], ["and", 278], ["molecular", 282], ["cytogenetics", 292], ["of", 305], ["complex", 308], ["variant", 316], ["Ph", 324], ["translocations", 327], ["present", 342], ["at", 350], ["diagnosis", 353], [".", 362], ["FISH", 364], ["studies", 369], ["were", 377], ["performed", 382], ["in", 392], ["7", 395], ["cases", 397], ["using", 403], ["the", 409], ["LSI", 413], ["BCR", 417], ["/", 420], ["ABL", 421], ["ES", 425], ["probe", 428], ["allowing", 434], ["the", 443], ["detection", 447], ["of", 457], ["the", 460], ["fusion", 464], ["BCR", 471], ["/", 474], ["ABL", 475], ["gene", 479], ["on", 484], ["the", 487], ["Ph", 491], ["chromosome", 494], ["in", 505], ["all", 508], ["of", 512], ["them", 515], ["and", 520], ["9q34", 524], ["deletions", 529], ["in", 539], ["2", 542], ["cases", 544], [".", 549], ["Three", 551], ["cryptic", 557], ["complex", 565], ["rearrangements", 573], ["were", 588], ["detected", 593], ["by", 602], ["FISH", 605], ["studies", 610], [".", 617], ["The", 619], ["third", 623], ["and", 629], ["the", 633], ["fourth", 637], ["chromosome", 644], ["regions", 655], ["involved", 663], ["in", 672], ["the", 675], ["8", 679], ["complex", 681], ["variant", 689], ["translocations", 697], ["were", 712], [":", 716], ["1q21", 718], [",", 722], ["1p36", 724], [",", 728], ["5q31", 730], [",", 734], ["11q13", 736], [",", 741], ["12q13", 743], [",", 748], ["12p13", 750], [",", 755], ["and", 757], ["20q12", 761], [".", 766], ["In", 768], ["conclusion", 771], [",", 781], ["FISH", 783], ["studies", 788], ["have", 796], ["been", 801], ["useful", 806], ["in", 813], ["the", 816], ["detection", 820], ["of", 830], ["the", 833], ["BCR", 837], ["/", 840], ["ABL", 841], ["rearrangements", 845], ["and", 860], ["9q34", 864], ["deletions", 869], [",", 878], ["and", 880], ["to", 884], ["identify", 887], ["complex", 896], ["rearrangements", 904], ["that", 919], ["differ", 924], ["from", 931], ["the", 936], ["ones", 940], ["previously", 945], ["established", 956], ["by", 968], ["conventional", 971], ["cytogenetics", 984], [".", 996]]}
{"context": "Neurofibromatosis type 1 is one of the most common autosomal dominant disorders, affecting about 1:3,500 individuals. NF1 exon 7 displays weakly defined exon-intron boundaries, and is particularly prone to missplicing. In this study we investigated the expression of exon 7 transcripts using bioinformatic identification of splicing regulatory sequences, and functional minigene analysis of four sequence changes [c.910C>T (R304X), c.945G>A/c.946C>A (Q315Q/L316M), c.1005T>C (N335N)] identified in exon 7 of three different NF1 patients. Our results detected the presence of three exonic splicing enhancers (ESEs) and one putative exonic splicing silencer (ESS) element. The wild type minigene assay resulted in three alternative isoforms, including a transcript lacking NF1 exon 7 (NF1DeltaE7). Both the wild type and the mutated constructs shared NF1DeltaE7 in addition to the complete messenger, but displayed a different ratio between the two transcripts. In the presence of R304X and Q315Q/L316M mutations, the relative proportion between the different isoforms is shifted toward the expression of NF1DeltaE7, while in the presence of N335N variant, the NF1DeltaE7 expression is abolished. In conclusion, it appears mandatory to investigate the role of each nucleotide change within the NF1 coding sequence, since a significant proportion of NF1 exon 7 mutations affects pre-mRNA splicing, by disrupting exonic splicing motifs and modifying the delicate balance between aberrantly and correctly spliced transcripts.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "8264477aefe0438e81189bea1f1be19d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[99, 99], [141, 141], [232, 232], [18, 18], [241, 241]], "char_spans": [[524, 526], [771, 773], [1292, 1294], [118, 120], [1347, 1349]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["is", 25], ["one", 28], ["of", 32], ["the", 35], ["most", 39], ["common", 44], ["autosomal", 51], ["dominant", 61], ["disorders", 70], [",", 79], ["affecting", 81], ["about", 91], ["1:3,500", 97], ["individuals", 105], [".", 116], ["NF1", 118], ["exon", 122], ["7", 127], ["displays", 129], ["weakly", 138], ["defined", 145], ["exon", 153], ["-", 157], ["intron", 158], ["boundaries", 165], [",", 175], ["and", 177], ["is", 181], ["particularly", 184], ["prone", 197], ["to", 203], ["missplicing", 206], [".", 217], ["In", 219], ["this", 222], ["study", 227], ["we", 233], ["investigated", 236], ["the", 249], ["expression", 253], ["of", 264], ["exon", 267], ["7", 272], ["transcripts", 274], ["using", 286], ["bioinformatic", 292], ["identification", 306], ["of", 321], ["splicing", 324], ["regulatory", 333], ["sequences", 344], [",", 353], ["and", 355], ["functional", 359], ["minigene", 370], ["analysis", 379], ["of", 388], ["four", 391], ["sequence", 396], ["changes", 405], ["[", 413], ["c.910C", 414], [">", 420], ["T", 421], ["(", 423], ["R304X", 424], [")", 429], [",", 430], ["c.945G", 432], [">", 438], ["A", 439], ["/", 440], ["c.946C", 441], [">", 447], ["A", 448], ["(", 450], ["Q315Q", 451], ["/", 456], ["L316", 457], ["M", 461], [")", 462], [",", 463], ["c.1005T", 465], [">", 472], ["C", 473], ["(", 475], ["N335N", 476], [")", 481], ["]", 482], ["identified", 484], ["in", 495], ["exon", 498], ["7", 503], ["of", 505], ["three", 508], ["different", 514], ["NF1", 524], ["patients", 528], [".", 536], ["Our", 538], ["results", 542], ["detected", 550], ["the", 559], ["presence", 563], ["of", 572], ["three", 575], ["exonic", 581], ["splicing", 588], ["enhancers", 597], ["(", 607], ["ESEs", 608], [")", 612], ["and", 614], ["one", 618], ["putative", 622], ["exonic", 631], ["splicing", 638], ["silencer", 647], ["(", 656], ["ESS", 657], [")", 660], ["element", 662], [".", 669], ["The", 671], ["wild", 675], ["type", 680], ["minigene", 685], ["assay", 694], ["resulted", 700], ["in", 709], ["three", 712], ["alternative", 718], ["isoforms", 730], [",", 738], ["including", 740], ["a", 750], ["transcript", 752], ["lacking", 763], ["NF1", 771], ["exon", 775], ["7", 780], ["(", 782], ["NF1DeltaE7", 783], [")", 793], [".", 794], ["Both", 796], ["the", 801], ["wild", 805], ["type", 810], ["and", 815], ["the", 819], ["mutated", 823], ["constructs", 831], ["shared", 842], ["NF1DeltaE7", 849], ["in", 860], ["addition", 863], ["to", 872], ["the", 875], ["complete", 879], ["messenger", 888], [",", 897], ["but", 899], ["displayed", 903], ["a", 913], ["different", 915], ["ratio", 925], ["between", 931], ["the", 939], ["two", 943], ["transcripts", 947], [".", 958], ["In", 960], ["the", 963], ["presence", 967], ["of", 976], ["R304X", 979], ["and", 985], ["Q315Q", 989], ["/", 994], ["L316", 995], ["M", 999], ["mutations", 1001], [",", 1010], ["the", 1012], ["relative", 1016], ["proportion", 1025], ["between", 1036], ["the", 1044], ["different", 1048], ["isoforms", 1058], ["is", 1067], ["shifted", 1070], ["toward", 1078], ["the", 1085], ["expression", 1089], ["of", 1100], ["NF1DeltaE7", 1103], [",", 1113], ["while", 1115], ["in", 1121], ["the", 1124], ["presence", 1128], ["of", 1137], ["N335N", 1140], ["variant", 1146], [",", 1153], ["the", 1155], ["NF1DeltaE7", 1159], ["expression", 1170], ["is", 1181], ["abolished", 1184], [".", 1193], ["In", 1195], ["conclusion", 1198], [",", 1208], ["it", 1210], ["appears", 1213], ["mandatory", 1221], ["to", 1231], ["investigate", 1234], ["the", 1246], ["role", 1250], ["of", 1255], ["each", 1258], ["nucleotide", 1263], ["change", 1274], ["within", 1281], ["the", 1288], ["NF1", 1292], ["coding", 1296], ["sequence", 1303], [",", 1311], ["since", 1313], ["a", 1319], ["significant", 1321], ["proportion", 1333], ["of", 1344], ["NF1", 1347], ["exon", 1351], ["7", 1356], ["mutations", 1358], ["affects", 1368], ["pre", 1376], ["-", 1379], ["mRNA", 1380], ["splicing", 1385], [",", 1393], ["by", 1395], ["disrupting", 1398], ["exonic", 1409], ["splicing", 1416], ["motifs", 1425], ["and", 1432], ["modifying", 1436], ["the", 1446], ["delicate", 1450], ["balance", 1459], ["between", 1467], ["aberrantly", 1475], ["and", 1486], ["correctly", 1490], ["spliced", 1500], ["transcripts", 1508], [".", 1519]]}
{"context": "RNA editing is proposed as a modulator of transcriptomes, but its biological impact has not been fully elucidated. In particular, its importance for transposable elements is controversial. We found RNA editing on antisense read-through transcripts of KP elements, one of the deletion derivatives of P transposable elements in Drosophila melanogaster. Three kinds of RNA editing were detected at 20 sites around the terminal inverted repeats (TIR); 15 A-to-G, four U-to-C, and one C-to-U conversions. A-to-G conversions are suggested to be attributed to A-to-I RNA editing on KP element RNAs, because inosine (I) in RNA is recognized as G by reverse transcriptase. TIRs were deduced to form dsRNAs as a putative target of ADAR. This is the first report of RNA editing on mobile elements of Drosophila.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "ed3c30f4b2954727ac67c7b6e40750c9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[150, 150]], "char_spans": [[721, 724]]}]}], "context_tokens": [["RNA", 0], ["editing", 4], ["is", 12], ["proposed", 15], ["as", 24], ["a", 27], ["modulator", 29], ["of", 39], ["transcriptomes", 42], [",", 56], ["but", 58], ["its", 62], ["biological", 66], ["impact", 77], ["has", 84], ["not", 88], ["been", 92], ["fully", 97], ["elucidated", 103], [".", 113], ["In", 115], ["particular", 118], [",", 128], ["its", 130], ["importance", 134], ["for", 145], ["transposable", 149], ["elements", 162], ["is", 171], ["controversial", 174], [".", 187], ["We", 189], ["found", 192], ["RNA", 198], ["editing", 202], ["on", 210], ["antisense", 213], ["read", 223], ["-", 227], ["through", 228], ["transcripts", 236], ["of", 248], ["KP", 251], ["elements", 254], [",", 262], ["one", 264], ["of", 268], ["the", 271], ["deletion", 275], ["derivatives", 284], ["of", 296], ["P", 299], ["transposable", 301], ["elements", 314], ["in", 323], ["Drosophila", 326], ["melanogaster", 337], [".", 349], ["Three", 351], ["kinds", 357], ["of", 363], ["RNA", 366], ["editing", 370], ["were", 378], ["detected", 383], ["at", 392], ["20", 395], ["sites", 398], ["around", 404], ["the", 411], ["terminal", 415], ["inverted", 424], ["repeats", 433], ["(", 441], ["TIR", 442], [")", 445], [";", 446], ["15", 448], ["A", 451], ["-", 452], ["to", 453], ["-", 455], ["G", 456], [",", 457], ["four", 459], ["U", 464], ["-", 465], ["to", 466], ["-", 468], ["C", 469], [",", 470], ["and", 472], ["one", 476], ["C", 480], ["-", 481], ["to", 482], ["-", 484], ["U", 485], ["conversions", 487], [".", 498], ["A", 500], ["-", 501], ["to", 502], ["-", 504], ["G", 505], ["conversions", 507], ["are", 519], ["suggested", 523], ["to", 533], ["be", 536], ["attributed", 539], ["to", 550], ["A", 553], ["-", 554], ["to", 555], ["-", 557], ["I", 558], ["RNA", 560], ["editing", 564], ["on", 572], ["KP", 575], ["element", 578], ["RNAs", 586], [",", 590], ["because", 592], ["inosine", 600], ["(", 608], ["I", 609], [")", 610], ["in", 612], ["RNA", 615], ["is", 619], ["recognized", 622], ["as", 633], ["G", 636], ["by", 638], ["reverse", 641], ["transcriptase", 649], [".", 662], ["TIRs", 664], ["were", 669], ["deduced", 674], ["to", 682], ["form", 685], ["dsRNAs", 690], ["as", 697], ["a", 700], ["putative", 702], ["target", 711], ["of", 718], ["ADAR", 721], [".", 725], ["This", 727], ["is", 732], ["the", 735], ["first", 739], ["report", 745], ["of", 752], ["RNA", 755], ["editing", 759], ["on", 767], ["mobile", 770], ["elements", 777], ["of", 786], ["Drosophila", 789], [".", 799]]}
{"context": "The management of pain associated with chronic musculoskeletal conditions represents a significant challenge for the clinician. There remains a need for novel medications that have a significant analgesic benefit and are also safe and well tolerated. Both pre-clinical and clinical data have provided evidence of the role of nerve growth factor (NGF) in a multitude of pain eliciting conditions. Therefore, the development of monoclonal antibodies to NGF for chronic painful musculoskeletal conditions has generated interest. Areas covered: This manuscript is a review that examines both the pharmacological properties and clinical studies of tanezumab, the most widely studied antibody to NGF, for management of osteoarthritis (OA) and low back pain. In addition, the safety and tolerability profile and development history of tanezumab are also discussed. Expert opinion: Most studies provide strong support for the ability of tanezumab to provide clinically meaningful pain relief in individuals with these conditions, with longer-term studies suggesting durability of effect. The adverse event profile appears favorable, assuming the risk mitigation strategies are effective at reducing the incidence of joint-related side effects. Further data are being collected to define the optimal dose and dosing strategy in both OA and chronic low back pain.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "a1677a4677f04576b7808123469477f1", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[52, 54]], "char_spans": [[325, 343]]}, {"text": "NGF", "token_spans": [[56, 56], [110, 110], [74, 74]], "char_spans": [[346, 348], [690, 692], [451, 453]]}]}], "context_tokens": [["The", 0], ["management", 4], ["of", 15], ["pain", 18], ["associated", 23], ["with", 34], ["chronic", 39], ["musculoskeletal", 47], ["conditions", 63], ["represents", 74], ["a", 85], ["significant", 87], ["challenge", 99], ["for", 109], ["the", 113], ["clinician", 117], [".", 126], ["There", 128], ["remains", 134], ["a", 142], ["need", 144], ["for", 149], ["novel", 153], ["medications", 159], ["that", 171], ["have", 176], ["a", 181], ["significant", 183], ["analgesic", 195], ["benefit", 205], ["and", 213], ["are", 217], ["also", 221], ["safe", 226], ["and", 231], ["well", 235], ["tolerated", 240], [".", 249], ["Both", 251], ["pre", 256], ["-", 259], ["clinical", 260], ["and", 269], ["clinical", 273], ["data", 282], ["have", 287], ["provided", 292], ["evidence", 301], ["of", 310], ["the", 313], ["role", 317], ["of", 322], ["nerve", 325], ["growth", 331], ["factor", 338], ["(", 345], ["NGF", 346], [")", 349], ["in", 351], ["a", 354], ["multitude", 356], ["of", 366], ["pain", 369], ["eliciting", 374], ["conditions", 384], [".", 394], ["Therefore", 396], [",", 405], ["the", 407], ["development", 411], ["of", 423], ["monoclonal", 426], ["antibodies", 437], ["to", 448], ["NGF", 451], ["for", 455], ["chronic", 459], ["painful", 467], ["musculoskeletal", 475], ["conditions", 491], ["has", 502], ["generated", 506], ["interest", 516], [".", 524], ["Areas", 526], ["covered", 532], [":", 539], ["This", 541], ["manuscript", 546], ["is", 557], ["a", 560], ["review", 562], ["that", 569], ["examines", 574], ["both", 583], ["the", 588], ["pharmacological", 592], ["properties", 608], ["and", 619], ["clinical", 623], ["studies", 632], ["of", 640], ["tanezumab", 643], [",", 652], ["the", 654], ["most", 658], ["widely", 663], ["studied", 670], ["antibody", 678], ["to", 687], ["NGF", 690], [",", 693], ["for", 695], ["management", 699], ["of", 710], ["osteoarthritis", 713], ["(", 728], ["OA", 729], [")", 731], ["and", 733], ["low", 737], ["back", 741], ["pain", 746], [".", 750], ["In", 752], ["addition", 755], [",", 763], ["the", 765], ["safety", 769], ["and", 776], ["tolerability", 780], ["profile", 793], ["and", 801], ["development", 805], ["history", 817], ["of", 825], ["tanezumab", 828], ["are", 838], ["also", 842], ["discussed", 847], [".", 856], ["Expert", 858], ["opinion", 865], [":", 872], ["Most", 874], ["studies", 879], ["provide", 887], ["strong", 895], ["support", 902], ["for", 910], ["the", 914], ["ability", 918], ["of", 926], ["tanezumab", 929], ["to", 939], ["provide", 942], ["clinically", 950], ["meaningful", 961], ["pain", 972], ["relief", 977], ["in", 984], ["individuals", 987], ["with", 999], ["these", 1004], ["conditions", 1010], [",", 1020], ["with", 1022], ["longer", 1027], ["-", 1033], ["term", 1034], ["studies", 1039], ["suggesting", 1047], ["durability", 1058], ["of", 1069], ["effect", 1072], [".", 1078], ["The", 1080], ["adverse", 1084], ["event", 1092], ["profile", 1098], ["appears", 1106], ["favorable", 1114], [",", 1123], ["assuming", 1125], ["the", 1134], ["risk", 1138], ["mitigation", 1143], ["strategies", 1154], ["are", 1165], ["effective", 1169], ["at", 1179], ["reducing", 1182], ["the", 1191], ["incidence", 1195], ["of", 1205], ["joint", 1208], ["-", 1213], ["related", 1214], ["side", 1222], ["effects", 1227], [".", 1234], ["Further", 1236], ["data", 1244], ["are", 1249], ["being", 1253], ["collected", 1259], ["to", 1269], ["define", 1272], ["the", 1279], ["optimal", 1283], ["dose", 1291], ["and", 1296], ["dosing", 1300], ["strategy", 1307], ["in", 1316], ["both", 1319], ["OA", 1324], ["and", 1327], ["chronic", 1331], ["low", 1339], ["back", 1343], ["pain", 1348], [".", 1352]]}
{"context": "The health benefits of leisure-time physical activity are well known, however the effects of engaging in competitive sports on health are uncertain. This literature review examines mortality and longevity of elite athletes and attempts to understand the association between long-term vigorous exercise training and survival rates. Fourteen articles of epidemiological studies were identified and classified by type of sport. Life expectancy, standardised mortality ratio, standardised proportionate mortality ratio, mortality rate, and mortality odds ratio for all causes of death were used to analyse mortality and longevity of elite athletes. It appears that elite endurance (aerobic) athletes and mixed-sports (aerobic and anaerobic) athletes survive longer than the general population, as indicated by lower mortality and higher longevity. Lower cardiovascular disease mortality is likely the primary reason for their better survival rates. On the other hand, there are inconsistent results among studies of power (anaerobic) athletes. When elite athletes engaging in various sports are analysed together, their mortality is lower than that of the general population. In conclusion, long-term vigorous exercise training is associated with increased survival rates of specific groups of athletes.", "qas": [{"question": "What is the life expectancy of professional athletes in respect to the general population?", "answers": ["longer than the general population", "No clear results indicating improved life expectancy in professional athletes"], "qid": "5a537555a5e843839c53a7739cd95f64", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["life", 12], ["expectancy", 17], ["of", 28], ["professional", 31], ["athletes", 44], ["in", 53], ["respect", 56], ["to", 64], ["the", 67], ["general", 71], ["population", 79], ["?", 89]], "detected_answers": [{"text": "longer than the general population", "token_spans": [[122, 126]], "char_spans": [[754, 787]]}]}], "context_tokens": [["The", 0], ["health", 4], ["benefits", 11], ["of", 20], ["leisure", 23], ["-", 30], ["time", 31], ["physical", 36], ["activity", 45], ["are", 54], ["well", 58], ["known", 63], [",", 68], ["however", 70], ["the", 78], ["effects", 82], ["of", 90], ["engaging", 93], ["in", 102], ["competitive", 105], ["sports", 117], ["on", 124], ["health", 127], ["are", 134], ["uncertain", 138], [".", 147], ["This", 149], ["literature", 154], ["review", 165], ["examines", 172], ["mortality", 181], ["and", 191], ["longevity", 195], ["of", 205], ["elite", 208], ["athletes", 214], ["and", 223], ["attempts", 227], ["to", 236], ["understand", 239], ["the", 250], ["association", 254], ["between", 266], ["long", 274], ["-", 278], ["term", 279], ["vigorous", 284], ["exercise", 293], ["training", 302], ["and", 311], ["survival", 315], ["rates", 324], [".", 329], ["Fourteen", 331], ["articles", 340], ["of", 349], ["epidemiological", 352], ["studies", 368], ["were", 376], ["identified", 381], ["and", 392], ["classified", 396], ["by", 407], ["type", 410], ["of", 415], ["sport", 418], [".", 423], ["Life", 425], ["expectancy", 430], [",", 440], ["standardised", 442], ["mortality", 455], ["ratio", 465], [",", 470], ["standardised", 472], ["proportionate", 485], ["mortality", 499], ["ratio", 509], [",", 514], ["mortality", 516], ["rate", 526], [",", 530], ["and", 532], ["mortality", 536], ["odds", 546], ["ratio", 551], ["for", 557], ["all", 561], ["causes", 565], ["of", 572], ["death", 575], ["were", 581], ["used", 586], ["to", 591], ["analyse", 594], ["mortality", 602], ["and", 612], ["longevity", 616], ["of", 626], ["elite", 629], ["athletes", 635], [".", 643], ["It", 645], ["appears", 648], ["that", 656], ["elite", 661], ["endurance", 667], ["(", 677], ["aerobic", 678], [")", 685], ["athletes", 687], ["and", 696], ["mixed", 700], ["-", 705], ["sports", 706], ["(", 713], ["aerobic", 714], ["and", 722], ["anaerobic", 726], [")", 735], ["athletes", 737], ["survive", 746], ["longer", 754], ["than", 761], ["the", 766], ["general", 770], ["population", 778], [",", 788], ["as", 790], ["indicated", 793], ["by", 803], ["lower", 806], ["mortality", 812], ["and", 822], ["higher", 826], ["longevity", 833], [".", 842], ["Lower", 844], ["cardiovascular", 850], ["disease", 865], ["mortality", 873], ["is", 883], ["likely", 886], ["the", 893], ["primary", 897], ["reason", 905], ["for", 912], ["their", 916], ["better", 922], ["survival", 929], ["rates", 938], [".", 943], ["On", 945], ["the", 948], ["other", 952], ["hand", 958], [",", 962], ["there", 964], ["are", 970], ["inconsistent", 974], ["results", 987], ["among", 995], ["studies", 1001], ["of", 1009], ["power", 1012], ["(", 1018], ["anaerobic", 1019], [")", 1028], ["athletes", 1030], [".", 1038], ["When", 1040], ["elite", 1045], ["athletes", 1051], ["engaging", 1060], ["in", 1069], ["various", 1072], ["sports", 1080], ["are", 1087], ["analysed", 1091], ["together", 1100], [",", 1108], ["their", 1110], ["mortality", 1116], ["is", 1126], ["lower", 1129], ["than", 1135], ["that", 1140], ["of", 1145], ["the", 1148], ["general", 1152], ["population", 1160], [".", 1170], ["In", 1172], ["conclusion", 1175], [",", 1185], ["long", 1187], ["-", 1191], ["term", 1192], ["vigorous", 1197], ["exercise", 1206], ["training", 1215], ["is", 1224], ["associated", 1227], ["with", 1238], ["increased", 1243], ["survival", 1253], ["rates", 1262], ["of", 1268], ["specific", 1271], ["groups", 1280], ["of", 1287], ["athletes", 1290], [".", 1298]]}
{"context": "Parkinson's disease and dementia with Lewy bodies are very frequent neurological disorders of the elderly. Mutations in the alpha-synuclein (alphaSYN) gene cause Parkinson's disease, often associated with dementia. Neuropathologically these diseases are characterized by the presence of Lewy bodies and Lewy neurites, intraneuronal inclusions mostly composed of alphaSYN protein fibrils. Moreover, alphaSYN is phosphorylated at S129 (phospho-serine-129 [PSer129]) in neuropathological lesions. Using our (Thy1)-[A30P]alphaSYN transgenic mouse model that develops age-dependent impairment in fear conditioning behavior, we investigated PSer129 immunostaining in the brain. We found distinct staining patterns using new, sensitive monoclonal antibodies. Somal and nuclear PSer129 immunoreactivity increased with age in hippocampal and cortical areas as well as the lateral/basolateral amygdalar nuclei and was present also in young, pre-symptomatic mice, but not wild-type controls. The tendency of PSer129 immunostaining to accumulate in the nucleus was confirmed in cell culture. (Thy1)-[A30P]alphaSYN transgenic mice further developed age-dependent, specific neuritic/terminal alphaSYN pathology in the medial parts of the central amygdalar nucleus and one of its projection areas, the lateral hypothalamus. Interestingly, this type of PSer129 neuropathology was thioflavine S negative, unlike the Lewy-like neuropathology present in the brain stem of (Thy1)-[A30P]alphaSYN mice. Thus, alphaSYN becomes phosphorylated in distinct parts of the brain in this alpha-synucleinopathy mouse model, showing age-dependent increases of nuclear PSer129 in cortical brain areas and the formation of neuritic/terminal PSer129 neuropathology with variable amyloid quality within the fear conditioning circuitry and the brain stem.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "3005311091144dfdb1464aeae598c703", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[20, 22]], "char_spans": [[124, 138]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["and", 20], ["dementia", 24], ["with", 33], ["Lewy", 38], ["bodies", 43], ["are", 50], ["very", 54], ["frequent", 59], ["neurological", 68], ["disorders", 81], ["of", 91], ["the", 94], ["elderly", 98], [".", 105], ["Mutations", 107], ["in", 117], ["the", 120], ["alpha", 124], ["-", 129], ["synuclein", 130], ["(", 140], ["alphaSYN", 141], [")", 149], ["gene", 151], ["cause", 156], ["Parkinson", 162], ["'s", 171], ["disease", 174], [",", 181], ["often", 183], ["associated", 189], ["with", 200], ["dementia", 205], [".", 213], ["Neuropathologically", 215], ["these", 235], ["diseases", 241], ["are", 250], ["characterized", 254], ["by", 268], ["the", 271], ["presence", 275], ["of", 284], ["Lewy", 287], ["bodies", 292], ["and", 299], ["Lewy", 303], ["neurites", 308], [",", 316], ["intraneuronal", 318], ["inclusions", 332], ["mostly", 343], ["composed", 350], ["of", 359], ["alphaSYN", 362], ["protein", 371], ["fibrils", 379], [".", 386], ["Moreover", 388], [",", 396], ["alphaSYN", 398], ["is", 407], ["phosphorylated", 410], ["at", 425], ["S129", 428], ["(", 433], ["phospho", 434], ["-", 441], ["serine-129", 442], ["[", 453], ["PSer129", 454], ["]", 461], [")", 462], ["in", 464], ["neuropathological", 467], ["lesions", 485], [".", 492], ["Using", 494], ["our", 500], ["(", 504], ["Thy1)-[A30P]alphaSYN", 505], ["transgenic", 526], ["mouse", 537], ["model", 543], ["that", 549], ["develops", 554], ["age", 563], ["-", 566], ["dependent", 567], ["impairment", 577], ["in", 588], ["fear", 591], ["conditioning", 596], ["behavior", 609], [",", 617], ["we", 619], ["investigated", 622], ["PSer129", 635], ["immunostaining", 643], ["in", 658], ["the", 661], ["brain", 665], [".", 670], ["We", 672], ["found", 675], ["distinct", 681], ["staining", 690], ["patterns", 699], ["using", 708], ["new", 714], [",", 717], ["sensitive", 719], ["monoclonal", 729], ["antibodies", 740], [".", 750], ["Somal", 752], ["and", 758], ["nuclear", 762], ["PSer129", 770], ["immunoreactivity", 778], ["increased", 795], ["with", 805], ["age", 810], ["in", 814], ["hippocampal", 817], ["and", 829], ["cortical", 833], ["areas", 842], ["as", 848], ["well", 851], ["as", 856], ["the", 859], ["lateral", 863], ["/", 870], ["basolateral", 871], ["amygdalar", 883], ["nuclei", 893], ["and", 900], ["was", 904], ["present", 908], ["also", 916], ["in", 921], ["young", 924], [",", 929], ["pre", 931], ["-", 934], ["symptomatic", 935], ["mice", 947], [",", 951], ["but", 953], ["not", 957], ["wild", 961], ["-", 965], ["type", 966], ["controls", 971], [".", 979], ["The", 981], ["tendency", 985], ["of", 994], ["PSer129", 997], ["immunostaining", 1005], ["to", 1020], ["accumulate", 1023], ["in", 1034], ["the", 1037], ["nucleus", 1041], ["was", 1049], ["confirmed", 1053], ["in", 1063], ["cell", 1066], ["culture", 1071], [".", 1078], ["(", 1080], ["Thy1)-[A30P]alphaSYN", 1081], ["transgenic", 1102], ["mice", 1113], ["further", 1118], ["developed", 1126], ["age", 1136], ["-", 1139], ["dependent", 1140], [",", 1149], ["specific", 1151], ["neuritic", 1160], ["/", 1168], ["terminal", 1169], ["alphaSYN", 1178], ["pathology", 1187], ["in", 1197], ["the", 1200], ["medial", 1204], ["parts", 1211], ["of", 1217], ["the", 1220], ["central", 1224], ["amygdalar", 1232], ["nucleus", 1242], ["and", 1250], ["one", 1254], ["of", 1258], ["its", 1261], ["projection", 1265], ["areas", 1276], [",", 1281], ["the", 1283], ["lateral", 1287], ["hypothalamus", 1295], [".", 1307], ["Interestingly", 1309], [",", 1322], ["this", 1324], ["type", 1329], ["of", 1334], ["PSer129", 1337], ["neuropathology", 1345], ["was", 1360], ["thioflavine", 1364], ["S", 1376], ["negative", 1378], [",", 1386], ["unlike", 1388], ["the", 1395], ["Lewy", 1399], ["-", 1403], ["like", 1404], ["neuropathology", 1409], ["present", 1424], ["in", 1432], ["the", 1435], ["brain", 1439], ["stem", 1445], ["of", 1450], ["(", 1453], ["Thy1)-[A30P]alphaSYN", 1454], ["mice", 1475], [".", 1479], ["Thus", 1481], [",", 1485], ["alphaSYN", 1487], ["becomes", 1496], ["phosphorylated", 1504], ["in", 1519], ["distinct", 1522], ["parts", 1531], ["of", 1537], ["the", 1540], ["brain", 1544], ["in", 1550], ["this", 1553], ["alpha", 1558], ["-", 1563], ["synucleinopathy", 1564], ["mouse", 1580], ["model", 1586], [",", 1591], ["showing", 1593], ["age", 1601], ["-", 1604], ["dependent", 1605], ["increases", 1615], ["of", 1625], ["nuclear", 1628], ["PSer129", 1636], ["in", 1644], ["cortical", 1647], ["brain", 1656], ["areas", 1662], ["and", 1668], ["the", 1672], ["formation", 1676], ["of", 1686], ["neuritic", 1689], ["/", 1697], ["terminal", 1698], ["PSer129", 1707], ["neuropathology", 1715], ["with", 1730], ["variable", 1735], ["amyloid", 1744], ["quality", 1752], ["within", 1760], ["the", 1767], ["fear", 1771], ["conditioning", 1776], ["circuitry", 1789], ["and", 1799], ["the", 1803], ["brain", 1807], ["stem", 1813], [".", 1817]]}
{"context": "Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, which causes progressive and eventually fatal loss of motor function. Here, we describe genetic and pathologic characterization of brain tissue banked from 19 ALS patients over nearly 20\u00a0years at the Department of Anatomy and the Centre for Brain Research, University of Auckland, New Zealand. We screened for mutations in SOD1, TARDBP, FUS, and C9ORF72 genes and for neuropathology caused by phosphorylated TDP-43, dipeptide repeats (DPRs), and ubiquilin. We identified 2 cases with C9ORF72 repeat expansions. Both harbored phosphorylated TDP-43 and DPR inclusions. We show that DPR inclusions can incorporate or occur independently of ubiquilin. We also identified 1 case with a UBQLN2 mutation, which showed phosphorylated TDP-43 and characteristic ubiquilin protein inclusions. This is the first study of ALS genetics in New Zealand, adding New Zealand to the growing list of countries in which C9ORF72 repeat expansion and UBQLN2 mutations are detected in ALS cases.", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "56561ee2c5e6437da905d1d0cb1db046", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[175, 175], [4, 4], [37, 37], [149, 149]], "char_spans": [[1041, 1043], [31, 33], [239, 241], [889, 891]]}, {"text": "amyotrophic lateral sclerosis", "token_spans": [[0, 2]], "char_spans": [[0, 28]]}]}], "context_tokens": [["Amyotrophic", 0], ["lateral", 12], ["sclerosis", 20], ["(", 30], ["ALS", 31], [")", 34], ["is", 36], ["a", 39], ["devastating", 41], ["neurodegenerative", 53], ["disease", 71], [",", 78], ["which", 80], ["causes", 86], ["progressive", 93], ["and", 105], ["eventually", 109], ["fatal", 120], ["loss", 126], ["of", 131], ["motor", 134], ["function", 140], [".", 148], ["Here", 150], [",", 154], ["we", 156], ["describe", 159], ["genetic", 168], ["and", 176], ["pathologic", 180], ["characterization", 191], ["of", 208], ["brain", 211], ["tissue", 217], ["banked", 224], ["from", 231], ["19", 236], ["ALS", 239], ["patients", 243], ["over", 252], ["nearly", 257], ["20", 264], ["years", 267], ["at", 273], ["the", 276], ["Department", 280], ["of", 291], ["Anatomy", 294], ["and", 302], ["the", 306], ["Centre", 310], ["for", 317], ["Brain", 321], ["Research", 327], [",", 335], ["University", 337], ["of", 348], ["Auckland", 351], [",", 359], ["New", 361], ["Zealand", 365], [".", 372], ["We", 374], ["screened", 377], ["for", 386], ["mutations", 390], ["in", 400], ["SOD1", 403], [",", 407], ["TARDBP", 409], [",", 415], ["FUS", 417], [",", 420], ["and", 422], ["C9ORF72", 426], ["genes", 434], ["and", 440], ["for", 444], ["neuropathology", 448], ["caused", 463], ["by", 470], ["phosphorylated", 473], ["TDP-43", 488], [",", 494], ["dipeptide", 496], ["repeats", 506], ["(", 514], ["DPRs", 515], [")", 519], [",", 520], ["and", 522], ["ubiquilin", 526], [".", 535], ["We", 537], ["identified", 540], ["2", 551], ["cases", 553], ["with", 559], ["C9ORF72", 564], ["repeat", 572], ["expansions", 579], [".", 589], ["Both", 591], ["harbored", 596], ["phosphorylated", 605], ["TDP-43", 620], ["and", 627], ["DPR", 631], ["inclusions", 635], [".", 645], ["We", 647], ["show", 650], ["that", 655], ["DPR", 660], ["inclusions", 664], ["can", 675], ["incorporate", 679], ["or", 691], ["occur", 694], ["independently", 700], ["of", 714], ["ubiquilin", 717], [".", 726], ["We", 728], ["also", 731], ["identified", 736], ["1", 747], ["case", 749], ["with", 754], ["a", 759], ["UBQLN2", 761], ["mutation", 768], [",", 776], ["which", 778], ["showed", 784], ["phosphorylated", 791], ["TDP-43", 806], ["and", 813], ["characteristic", 817], ["ubiquilin", 832], ["protein", 842], ["inclusions", 850], [".", 860], ["This", 862], ["is", 867], ["the", 870], ["first", 874], ["study", 880], ["of", 886], ["ALS", 889], ["genetics", 893], ["in", 902], ["New", 905], ["Zealand", 909], [",", 916], ["adding", 918], ["New", 925], ["Zealand", 929], ["to", 937], ["the", 940], ["growing", 944], ["list", 952], ["of", 957], ["countries", 960], ["in", 970], ["which", 973], ["C9ORF72", 979], ["repeat", 987], ["expansion", 994], ["and", 1004], ["UBQLN2", 1008], ["mutations", 1015], ["are", 1025], ["detected", 1029], ["in", 1038], ["ALS", 1041], ["cases", 1045], [".", 1050]]}
{"context": "The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations. The usual clinical dose of gefitinib (250 mg/d) is only one third of its maximum tolerated dose, whereas the dose of erlotinib (150 mg/d) is at its maximum tolerated dose. In NSCLC cell lines, both TKIs have similar micromolar inhibitory concentrations. We explored whether erlotinib at 25 mg/d (trough serum concentration similar to gefitinib 250 mg/d) would be efficacious in EGFR-mutated NSCLC. To study the inhibitory concentrations of gefitinib and erlotinib, we exposed EGFR-mutated cell lines (HCC827, H3255, PC-9, and H1975) to increasing concentrations of these TKIs. Further on, we performed a retrospective evaluation of seven patients with advanced EGFR-mutated (exon 19 deletions and L858R) NSCLC that were given erlotinib at 25 mg/d as their first EGFR TKI. Gefitinib and erlotinib generated similar inhibitory curves across our panel of EGFR-mutated NSCLC cell lines with overlapping mean 50% inhibitory concentration 95% confidence intervals for HCC827, PC-9, and H1975. Both drugs also displayed a high degree of correlation in mean 50% inhibitory concentration (Pearson's r = 0.99, p = 0.0417). Of the seven patients, five patients (71.5%) had partial responses to erlotinib 25 mg/d. Median progression-free survival was 17 months (95% confidence interval, 6-35 months). Toxicities were minimal, with only two (28.5%) patients having a rash and none experiencing (0%) diarrhea. In NSCLC cell lines, gefitinib and erlotinib have similar inhibitory profiles. In patients with NSCLC and EGFR-activating mutations, a dose of erlotinib 25 mg/d (equivalent to gefitinib 250 mg/d) leads to impressive response rates and progression-free survival similar to the growing experience with the approved doses of gefitinib (250 mg/d) and erlotinib (150 mg/d). Identifying prospectively the lowest and clinically active dose ranges of erlotinib and gefitinib will help further to personalize care for patients with tumors harboring EGFR mutations.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "2e559521de4543c0bcd36ddc1c47fc44", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[23, 30]], "char_spans": [[121, 164]]}]}], "context_tokens": [["The", 0], ["tyrosine", 4], ["kinase", 13], ["inhibitors", 20], ["(", 31], ["TKIs", 32], [")", 36], ["gefitinib", 38], ["and", 48], ["erlotinib", 52], ["are", 62], ["effective", 66], ["in", 76], ["non", 79], ["-", 82], ["small", 83], ["cell", 89], ["lung", 94], ["cancers", 99], ["(", 107], ["NSCLCs", 108], [")", 114], ["with", 116], ["epidermal", 121], ["growth", 131], ["factor", 138], ["receptor", 145], ["(", 154], ["EGFR", 155], [")", 159], ["gene", 161], ["mutations", 166], [".", 175], ["The", 177], ["usual", 181], ["clinical", 187], ["dose", 196], ["of", 201], ["gefitinib", 204], ["(", 214], ["250", 215], ["mg", 219], ["/", 221], ["d", 222], [")", 223], ["is", 225], ["only", 228], ["one", 233], ["third", 237], ["of", 243], ["its", 246], ["maximum", 250], ["tolerated", 258], ["dose", 268], [",", 272], ["whereas", 274], ["the", 282], ["dose", 286], ["of", 291], ["erlotinib", 294], ["(", 304], ["150", 305], ["mg", 309], ["/", 311], ["d", 312], [")", 313], ["is", 315], ["at", 318], ["its", 321], ["maximum", 325], ["tolerated", 333], ["dose", 343], [".", 347], ["In", 349], ["NSCLC", 352], ["cell", 358], ["lines", 363], [",", 368], ["both", 370], ["TKIs", 375], ["have", 380], ["similar", 385], ["micromolar", 393], ["inhibitory", 404], ["concentrations", 415], [".", 429], ["We", 431], ["explored", 434], ["whether", 443], ["erlotinib", 451], ["at", 461], ["25", 464], ["mg", 467], ["/", 469], ["d", 470], ["(", 472], ["trough", 473], ["serum", 480], ["concentration", 486], ["similar", 500], ["to", 508], ["gefitinib", 511], ["250", 521], ["mg", 525], ["/", 527], ["d", 528], [")", 529], ["would", 531], ["be", 537], ["efficacious", 540], ["in", 552], ["EGFR", 555], ["-", 559], ["mutated", 560], ["NSCLC", 568], [".", 573], ["To", 575], ["study", 578], ["the", 584], ["inhibitory", 588], ["concentrations", 599], ["of", 614], ["gefitinib", 617], ["and", 627], ["erlotinib", 631], [",", 640], ["we", 642], ["exposed", 645], ["EGFR", 653], ["-", 657], ["mutated", 658], ["cell", 666], ["lines", 671], ["(", 677], ["HCC827", 678], [",", 684], ["H3255", 686], [",", 691], ["PC-9", 693], [",", 697], ["and", 699], ["H1975", 703], [")", 708], ["to", 710], ["increasing", 713], ["concentrations", 724], ["of", 739], ["these", 742], ["TKIs", 748], [".", 752], ["Further", 754], ["on", 762], [",", 764], ["we", 766], ["performed", 769], ["a", 779], ["retrospective", 781], ["evaluation", 795], ["of", 806], ["seven", 809], ["patients", 815], ["with", 824], ["advanced", 829], ["EGFR", 838], ["-", 842], ["mutated", 843], ["(", 851], ["exon", 852], ["19", 857], ["deletions", 860], ["and", 870], ["L858R", 874], [")", 879], ["NSCLC", 881], ["that", 887], ["were", 892], ["given", 897], ["erlotinib", 903], ["at", 913], ["25", 916], ["mg", 919], ["/", 921], ["d", 922], ["as", 924], ["their", 927], ["first", 933], ["EGFR", 939], ["TKI", 944], [".", 947], ["Gefitinib", 949], ["and", 959], ["erlotinib", 963], ["generated", 973], ["similar", 983], ["inhibitory", 991], ["curves", 1002], ["across", 1009], ["our", 1016], ["panel", 1020], ["of", 1026], ["EGFR", 1029], ["-", 1033], ["mutated", 1034], ["NSCLC", 1042], ["cell", 1048], ["lines", 1053], ["with", 1059], ["overlapping", 1064], ["mean", 1076], ["50", 1081], ["%", 1083], ["inhibitory", 1085], ["concentration", 1096], ["95", 1110], ["%", 1112], ["confidence", 1114], ["intervals", 1125], ["for", 1135], ["HCC827", 1139], [",", 1145], ["PC-9", 1147], [",", 1151], ["and", 1153], ["H1975", 1157], [".", 1162], ["Both", 1164], ["drugs", 1169], ["also", 1175], ["displayed", 1180], ["a", 1190], ["high", 1192], ["degree", 1197], ["of", 1204], ["correlation", 1207], ["in", 1219], ["mean", 1222], ["50", 1227], ["%", 1229], ["inhibitory", 1231], ["concentration", 1242], ["(", 1256], ["Pearson", 1257], ["'s", 1264], ["r", 1267], ["=", 1269], ["0.99", 1271], [",", 1275], ["p", 1277], ["=", 1279], ["0.0417", 1281], [")", 1287], [".", 1288], ["Of", 1290], ["the", 1293], ["seven", 1297], ["patients", 1303], [",", 1311], ["five", 1313], ["patients", 1318], ["(", 1327], ["71.5", 1328], ["%", 1332], [")", 1333], ["had", 1335], ["partial", 1339], ["responses", 1347], ["to", 1357], ["erlotinib", 1360], ["25", 1370], ["mg", 1373], ["/", 1375], ["d", 1376], [".", 1377], ["Median", 1379], ["progression", 1386], ["-", 1397], ["free", 1398], ["survival", 1403], ["was", 1412], ["17", 1416], ["months", 1419], ["(", 1426], ["95", 1427], ["%", 1429], ["confidence", 1431], ["interval", 1442], [",", 1450], ["6", 1452], ["-", 1453], ["35", 1454], ["months", 1457], [")", 1463], [".", 1464], ["Toxicities", 1466], ["were", 1477], ["minimal", 1482], [",", 1489], ["with", 1491], ["only", 1496], ["two", 1501], ["(", 1505], ["28.5", 1506], ["%", 1510], [")", 1511], ["patients", 1513], ["having", 1522], ["a", 1529], ["rash", 1531], ["and", 1536], ["none", 1540], ["experiencing", 1545], ["(", 1558], ["0", 1559], ["%", 1560], [")", 1561], ["diarrhea", 1563], [".", 1571], ["In", 1573], ["NSCLC", 1576], ["cell", 1582], ["lines", 1587], [",", 1592], ["gefitinib", 1594], ["and", 1604], ["erlotinib", 1608], ["have", 1618], ["similar", 1623], ["inhibitory", 1631], ["profiles", 1642], [".", 1650], ["In", 1652], ["patients", 1655], ["with", 1664], ["NSCLC", 1669], ["and", 1675], ["EGFR", 1679], ["-", 1683], ["activating", 1684], ["mutations", 1695], [",", 1704], ["a", 1706], ["dose", 1708], ["of", 1713], ["erlotinib", 1716], ["25", 1726], ["mg", 1729], ["/", 1731], ["d", 1732], ["(", 1734], ["equivalent", 1735], ["to", 1746], ["gefitinib", 1749], ["250", 1759], ["mg", 1763], ["/", 1765], ["d", 1766], [")", 1767], ["leads", 1769], ["to", 1775], ["impressive", 1778], ["response", 1789], ["rates", 1798], ["and", 1804], ["progression", 1808], ["-", 1819], ["free", 1820], ["survival", 1825], ["similar", 1834], ["to", 1842], ["the", 1845], ["growing", 1849], ["experience", 1857], ["with", 1868], ["the", 1873], ["approved", 1877], ["doses", 1886], ["of", 1892], ["gefitinib", 1895], ["(", 1905], ["250", 1906], ["mg", 1910], ["/", 1912], ["d", 1913], [")", 1914], ["and", 1916], ["erlotinib", 1920], ["(", 1930], ["150", 1931], ["mg", 1935], ["/", 1937], ["d", 1938], [")", 1939], [".", 1940], ["Identifying", 1942], ["prospectively", 1954], ["the", 1968], ["lowest", 1972], ["and", 1979], ["clinically", 1983], ["active", 1994], ["dose", 2001], ["ranges", 2006], ["of", 2013], ["erlotinib", 2016], ["and", 2026], ["gefitinib", 2030], ["will", 2040], ["help", 2045], ["further", 2050], ["to", 2058], ["personalize", 2061], ["care", 2073], ["for", 2078], ["patients", 2082], ["with", 2091], ["tumors", 2096], ["harboring", 2103], ["EGFR", 2113], ["mutations", 2118], [".", 2127]]}
{"context": "Neurofibromatosis type 1 (NF1) is the most common genetic disease affecting the nervous system. Patients typically develop many tumors over their lifetime, leading to increased morbidity and mortality. The NF1 gene, mutated in NF1, is also commonly mutated in sporadic glioblastoma multiforme (GBM). Because both NF1 and GBM are currently incurable, new therapeutic approaches are clearly needed. Natural products represent an opportunity to develop new therapies, as they have been evolutionarily selected to play targeted roles in organisms. Schweinfurthin A is a prenylated stilbene natural product that has previously shown specific inhibitory activity against brain and hematopoietic tumor lines. We show that patient-derived GBM and NF1 malignant peripheral nerve sheath tumor (MPNST) lines, as well as tumor lines derived from the Nf1-/+;Trp53-/+ (NPcis) mouse model of astrocytoma and MPNST are highly sensitive to inhibition by schweinfurthin A and its synthetic analogs. In contrast, primary mouse astrocytes are resistant to the growth inhibitory effects of schweinfurthin A, suggesting that schweinfurthin A may act specifically on tumor cells. Stable transfection of the GTPase-activating protein related domain of Nf1 into Nf1-/-;Trp53-/- astrocytoma cells confers resistance to schweinfurthin A. In addition, the profound effect of schweinfurthin A on dynamic reorganization of the actin cytoskeleton led us to discover that schweinfurthin A inhibits growth factor-stimulated Rho signaling. In summary, we have identified a class of small molecules that specifically inhibit growth of cells from both central and peripheral nervous system tumors and seem to act on NF1-deficient cells through cytoskeletal reorganization correlating to changes in Rho signaling.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "0d78800e67c54fad88dcb0110c4ca8f4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[203, 203], [122, 122], [4, 4], [55, 55], [39, 39], [34, 34]], "char_spans": [[1228, 1230], [739, 741], [26, 28], [313, 315], [227, 229], [206, 208]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["the", 34], ["most", 38], ["common", 43], ["genetic", 50], ["disease", 58], ["affecting", 66], ["the", 76], ["nervous", 80], ["system", 88], [".", 94], ["Patients", 96], ["typically", 105], ["develop", 115], ["many", 123], ["tumors", 128], ["over", 135], ["their", 140], ["lifetime", 146], [",", 154], ["leading", 156], ["to", 164], ["increased", 167], ["morbidity", 177], ["and", 187], ["mortality", 191], [".", 200], ["The", 202], ["NF1", 206], ["gene", 210], [",", 214], ["mutated", 216], ["in", 224], ["NF1", 227], [",", 230], ["is", 232], ["also", 235], ["commonly", 240], ["mutated", 249], ["in", 257], ["sporadic", 260], ["glioblastoma", 269], ["multiforme", 282], ["(", 293], ["GBM", 294], [")", 297], [".", 298], ["Because", 300], ["both", 308], ["NF1", 313], ["and", 317], ["GBM", 321], ["are", 325], ["currently", 329], ["incurable", 339], [",", 348], ["new", 350], ["therapeutic", 354], ["approaches", 366], ["are", 377], ["clearly", 381], ["needed", 389], [".", 395], ["Natural", 397], ["products", 405], ["represent", 414], ["an", 424], ["opportunity", 427], ["to", 439], ["develop", 442], ["new", 450], ["therapies", 454], [",", 463], ["as", 465], ["they", 468], ["have", 473], ["been", 478], ["evolutionarily", 483], ["selected", 498], ["to", 507], ["play", 510], ["targeted", 515], ["roles", 524], ["in", 530], ["organisms", 533], [".", 542], ["Schweinfurthin", 544], ["A", 559], ["is", 561], ["a", 564], ["prenylated", 566], ["stilbene", 577], ["natural", 586], ["product", 594], ["that", 602], ["has", 607], ["previously", 611], ["shown", 622], ["specific", 628], ["inhibitory", 637], ["activity", 648], ["against", 657], ["brain", 665], ["and", 671], ["hematopoietic", 675], ["tumor", 689], ["lines", 695], [".", 700], ["We", 702], ["show", 705], ["that", 710], ["patient", 715], ["-", 722], ["derived", 723], ["GBM", 731], ["and", 735], ["NF1", 739], ["malignant", 743], ["peripheral", 753], ["nerve", 764], ["sheath", 770], ["tumor", 777], ["(", 783], ["MPNST", 784], [")", 789], ["lines", 791], [",", 796], ["as", 798], ["well", 801], ["as", 806], ["tumor", 809], ["lines", 815], ["derived", 821], ["from", 829], ["the", 834], ["Nf1-/+;Trp53-/+", 838], ["(", 854], ["NPcis", 855], [")", 860], ["mouse", 862], ["model", 868], ["of", 874], ["astrocytoma", 877], ["and", 889], ["MPNST", 893], ["are", 899], ["highly", 903], ["sensitive", 910], ["to", 920], ["inhibition", 923], ["by", 934], ["schweinfurthin", 937], ["A", 952], ["and", 954], ["its", 958], ["synthetic", 962], ["analogs", 972], [".", 979], ["In", 981], ["contrast", 984], [",", 992], ["primary", 994], ["mouse", 1002], ["astrocytes", 1008], ["are", 1019], ["resistant", 1023], ["to", 1033], ["the", 1036], ["growth", 1040], ["inhibitory", 1047], ["effects", 1058], ["of", 1066], ["schweinfurthin", 1069], ["A", 1084], [",", 1085], ["suggesting", 1087], ["that", 1098], ["schweinfurthin", 1103], ["A", 1118], ["may", 1120], ["act", 1124], ["specifically", 1128], ["on", 1141], ["tumor", 1144], ["cells", 1150], [".", 1155], ["Stable", 1157], ["transfection", 1164], ["of", 1177], ["the", 1180], ["GTPase", 1184], ["-", 1190], ["activating", 1191], ["protein", 1202], ["related", 1210], ["domain", 1218], ["of", 1225], ["Nf1", 1228], ["into", 1232], ["Nf1-/-;Trp53-/-", 1237], ["astrocytoma", 1253], ["cells", 1265], ["confers", 1271], ["resistance", 1279], ["to", 1290], ["schweinfurthin", 1293], ["A.", 1308], ["In", 1311], ["addition", 1314], [",", 1322], ["the", 1324], ["profound", 1328], ["effect", 1337], ["of", 1344], ["schweinfurthin", 1347], ["A", 1362], ["on", 1364], ["dynamic", 1367], ["reorganization", 1375], ["of", 1390], ["the", 1393], ["actin", 1397], ["cytoskeleton", 1403], ["led", 1416], ["us", 1420], ["to", 1423], ["discover", 1426], ["that", 1435], ["schweinfurthin", 1440], ["A", 1455], ["inhibits", 1457], ["growth", 1466], ["factor", 1473], ["-", 1479], ["stimulated", 1480], ["Rho", 1491], ["signaling", 1495], [".", 1504], ["In", 1506], ["summary", 1509], [",", 1516], ["we", 1518], ["have", 1521], ["identified", 1526], ["a", 1537], ["class", 1539], ["of", 1545], ["small", 1548], ["molecules", 1554], ["that", 1564], ["specifically", 1569], ["inhibit", 1582], ["growth", 1590], ["of", 1597], ["cells", 1600], ["from", 1606], ["both", 1611], ["central", 1616], ["and", 1624], ["peripheral", 1628], ["nervous", 1639], ["system", 1647], ["tumors", 1654], ["and", 1661], ["seem", 1665], ["to", 1670], ["act", 1673], ["on", 1677], ["NF1-deficient", 1680], ["cells", 1694], ["through", 1700], ["cytoskeletal", 1708], ["reorganization", 1721], ["correlating", 1736], ["to", 1748], ["changes", 1751], ["in", 1759], ["Rho", 1762], ["signaling", 1766], [".", 1775]]}
{"context": "Stress signals elicit a wide variety of cellular responses, many of which converge on the phosphorylation of JNK and p38 kinases, the activation of which has been well-characterized. How these kinases are switched off by dephosphorylation is not well understood. Here we describe how diverse cellular stresses affect differently the stability and activity of a JNK-inactivating dual-specificity threonine-tyrosine phosphatase M3/6. Both anisomycin and arsenite activate the JNK pathway and, in addition, inactivate the M3/6 phosphatase. However, while anisomycin treatment of cells leads to M3/6 protein degradation, arsenite appears to inactivate M3/6 directly. These results might have implications for the mechanism of tumour promotion by arsenic.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "b7441dc6481f4a8c8ea767fe70d618bb", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[79, 79], [61, 61], [18, 18]], "char_spans": [[474, 476], [361, 363], [109, 111]]}]}], "context_tokens": [["Stress", 0], ["signals", 7], ["elicit", 15], ["a", 22], ["wide", 24], ["variety", 29], ["of", 37], ["cellular", 40], ["responses", 49], [",", 58], ["many", 60], ["of", 65], ["which", 68], ["converge", 74], ["on", 83], ["the", 86], ["phosphorylation", 90], ["of", 106], ["JNK", 109], ["and", 113], ["p38", 117], ["kinases", 121], [",", 128], ["the", 130], ["activation", 134], ["of", 145], ["which", 148], ["has", 154], ["been", 158], ["well", 163], ["-", 167], ["characterized", 168], [".", 181], ["How", 183], ["these", 187], ["kinases", 193], ["are", 201], ["switched", 205], ["off", 214], ["by", 218], ["dephosphorylation", 221], ["is", 239], ["not", 242], ["well", 246], ["understood", 251], [".", 261], ["Here", 263], ["we", 268], ["describe", 271], ["how", 280], ["diverse", 284], ["cellular", 292], ["stresses", 301], ["affect", 310], ["differently", 317], ["the", 329], ["stability", 333], ["and", 343], ["activity", 347], ["of", 356], ["a", 359], ["JNK", 361], ["-", 364], ["inactivating", 365], ["dual", 378], ["-", 382], ["specificity", 383], ["threonine", 395], ["-", 404], ["tyrosine", 405], ["phosphatase", 414], ["M3/6", 426], [".", 430], ["Both", 432], ["anisomycin", 437], ["and", 448], ["arsenite", 452], ["activate", 461], ["the", 470], ["JNK", 474], ["pathway", 478], ["and", 486], [",", 489], ["in", 491], ["addition", 494], [",", 502], ["inactivate", 504], ["the", 515], ["M3/6", 519], ["phosphatase", 524], [".", 535], ["However", 537], [",", 544], ["while", 546], ["anisomycin", 552], ["treatment", 563], ["of", 573], ["cells", 576], ["leads", 582], ["to", 588], ["M3/6", 591], ["protein", 596], ["degradation", 604], [",", 615], ["arsenite", 617], ["appears", 626], ["to", 634], ["inactivate", 637], ["M3/6", 648], ["directly", 653], [".", 661], ["These", 663], ["results", 669], ["might", 677], ["have", 683], ["implications", 688], ["for", 701], ["the", 705], ["mechanism", 709], ["of", 719], ["tumour", 722], ["promotion", 729], ["by", 739], ["arsenic", 742], [".", 749]]}
{"context": "Flumazenil, a specific benzodiazepine antagonist, was evaluated as adjunctive therapy in the management of benzodiazepine overdose. Thirteen emergency departments enrolled 326 patients in this double-blind, placebo-controlled trial; 162 patients were randomly allocated to receive flumazenil (maximum dose, 30 ml, providing 3 mg of flumazenil), and 164 were allocated to receive placebo (maximum dose, 30 ml). A successful response was the attainment of a score of 1 or 2 on the Clinical Global Impression Scale (CGIS), denoting a very much improved or much improved status, 10 minutes after the start of intravenous administration of the test drug. Among those patients whose drug screen revealed the presence of benzodiazepines, 75 (77%) of 97 patients given flumazenil and 13 (16%) of 83 given placebo attained such a response. The mean CGIS score at 10 minutes for benzodiazepine-positive patients treated with flumazenil was 1.95 versus 3.58 for those given placebo. As determined by the Neurobehavioral Assessment Scale, 61% of patients who initially responded became resedated; in these patients, the effect of flumazenil lasted a median of 90 minutes. At the investigator's discretion, patients who did not achieve a criterion response in the double-blind trial could receive open-label flumazenil, titrated as in the double-blind phase. Among the benzodiazepine-positive patients, 9 (53%) of 17 patients from the flumazenil group responded to the additional flumazenil, and 58 (81%) of patients previously given placebo responded. Safety was assessed in all 326 patients given the test drug. The most frequent adverse experiences after the administration of flumazenil were agitation (7%), vomiting (7%), abnormal crying (4%), and nausea (4%); these effects were observed with a lower frequency in the placebo group. Serious adverse experiences were reported in 4 patients; these included seizures and cardiac arrhythmias. Of the 3 patients with seizures, 2 had ingested large doses of cyclic antidepressants in addition to the benzodiazepine. The toxicology screen for 1 of the 2 showed 1900 ng/ml of amoxapine and 900 ng/ml of nortriptyline; the toxicology screen for the other, who also had ventricular tachycardia, showed 1928 ng/ml of loxapine and 301 ng/ml of amoxapine. The results of this study confirm published reports of the efficacy of flumazenil in reversing benzodiazepine-induced sedation in patients with benzodiazepine overdose. This was accomplished irrespective of the presence of coingested drugs. Flumazenil is not recommended for patients with serious cyclic antidepressant poisoning or those who use benzodiazepines therapeutically to control seizure disorders. When used as recommended, however, flumazenil has been shown to have an acceptable safety level.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "c0676b791a034e7e90ddf7a04c68ddd2", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [272, 272], [43, 43], [205, 205], [170, 170], [266, 266], [502, 502], [140, 140], [308, 308], [55, 55], [473, 473], [238, 238], [449, 449]], "char_spans": [[0, 9], [1467, 1476], [281, 290], [1118, 1127], [915, 924], [1422, 1431], [2729, 2738], [761, 770], [1667, 1676], [332, 341], [2527, 2536], [1295, 1304], [2357, 2366]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["specific", 14], ["benzodiazepine", 23], ["antagonist", 38], [",", 48], ["was", 50], ["evaluated", 54], ["as", 64], ["adjunctive", 67], ["therapy", 78], ["in", 86], ["the", 89], ["management", 93], ["of", 104], ["benzodiazepine", 107], ["overdose", 122], [".", 130], ["Thirteen", 132], ["emergency", 141], ["departments", 151], ["enrolled", 163], ["326", 172], ["patients", 176], ["in", 185], ["this", 188], ["double", 193], ["-", 199], ["blind", 200], [",", 205], ["placebo", 207], ["-", 214], ["controlled", 215], ["trial", 226], [";", 231], ["162", 233], ["patients", 237], ["were", 246], ["randomly", 251], ["allocated", 260], ["to", 270], ["receive", 273], ["flumazenil", 281], ["(", 292], ["maximum", 293], ["dose", 301], [",", 305], ["30", 307], ["ml", 310], [",", 312], ["providing", 314], ["3", 324], ["mg", 326], ["of", 329], ["flumazenil", 332], [")", 342], [",", 343], ["and", 345], ["164", 349], ["were", 353], ["allocated", 358], ["to", 368], ["receive", 371], ["placebo", 379], ["(", 387], ["maximum", 388], ["dose", 396], [",", 400], ["30", 402], ["ml", 405], [")", 407], [".", 408], ["A", 410], ["successful", 412], ["response", 423], ["was", 432], ["the", 436], ["attainment", 440], ["of", 451], ["a", 454], ["score", 456], ["of", 462], ["1", 465], ["or", 467], ["2", 470], ["on", 472], ["the", 475], ["Clinical", 479], ["Global", 488], ["Impression", 495], ["Scale", 506], ["(", 512], ["CGIS", 513], [")", 517], [",", 518], ["denoting", 520], ["a", 529], ["very", 531], ["much", 536], ["improved", 541], ["or", 550], ["much", 553], ["improved", 558], ["status", 567], [",", 573], ["10", 575], ["minutes", 578], ["after", 586], ["the", 592], ["start", 596], ["of", 602], ["intravenous", 605], ["administration", 617], ["of", 632], ["the", 635], ["test", 639], ["drug", 644], [".", 648], ["Among", 650], ["those", 656], ["patients", 662], ["whose", 671], ["drug", 677], ["screen", 682], ["revealed", 689], ["the", 698], ["presence", 702], ["of", 711], ["benzodiazepines", 714], [",", 729], ["75", 731], ["(", 734], ["77", 735], ["%", 737], [")", 738], ["of", 740], ["97", 743], ["patients", 746], ["given", 755], ["flumazenil", 761], ["and", 772], ["13", 776], ["(", 779], ["16", 780], ["%", 782], [")", 783], ["of", 785], ["83", 788], ["given", 791], ["placebo", 797], ["attained", 805], ["such", 814], ["a", 819], ["response", 821], [".", 829], ["The", 831], ["mean", 835], ["CGIS", 840], ["score", 845], ["at", 851], ["10", 854], ["minutes", 857], ["for", 865], ["benzodiazepine", 869], ["-", 883], ["positive", 884], ["patients", 893], ["treated", 902], ["with", 910], ["flumazenil", 915], ["was", 926], ["1.95", 930], ["versus", 935], ["3.58", 942], ["for", 947], ["those", 951], ["given", 957], ["placebo", 963], [".", 970], ["As", 972], ["determined", 975], ["by", 986], ["the", 989], ["Neurobehavioral", 993], ["Assessment", 1009], ["Scale", 1020], [",", 1025], ["61", 1027], ["%", 1029], ["of", 1031], ["patients", 1034], ["who", 1043], ["initially", 1047], ["responded", 1057], ["became", 1067], ["resedated", 1074], [";", 1083], ["in", 1085], ["these", 1088], ["patients", 1094], [",", 1102], ["the", 1104], ["effect", 1108], ["of", 1115], ["flumazenil", 1118], ["lasted", 1129], ["a", 1136], ["median", 1138], ["of", 1145], ["90", 1148], ["minutes", 1151], [".", 1158], ["At", 1160], ["the", 1163], ["investigator", 1167], ["'s", 1179], ["discretion", 1182], [",", 1192], ["patients", 1194], ["who", 1203], ["did", 1207], ["not", 1211], ["achieve", 1215], ["a", 1223], ["criterion", 1225], ["response", 1235], ["in", 1244], ["the", 1247], ["double", 1251], ["-", 1257], ["blind", 1258], ["trial", 1264], ["could", 1270], ["receive", 1276], ["open", 1284], ["-", 1288], ["label", 1289], ["flumazenil", 1295], [",", 1305], ["titrated", 1307], ["as", 1316], ["in", 1319], ["the", 1322], ["double", 1326], ["-", 1332], ["blind", 1333], ["phase", 1339], [".", 1344], ["Among", 1346], ["the", 1352], ["benzodiazepine", 1356], ["-", 1370], ["positive", 1371], ["patients", 1380], [",", 1388], ["9", 1390], ["(", 1392], ["53", 1393], ["%", 1395], [")", 1396], ["of", 1398], ["17", 1401], ["patients", 1404], ["from", 1413], ["the", 1418], ["flumazenil", 1422], ["group", 1433], ["responded", 1439], ["to", 1449], ["the", 1452], ["additional", 1456], ["flumazenil", 1467], [",", 1477], ["and", 1479], ["58", 1483], ["(", 1486], ["81", 1487], ["%", 1489], [")", 1490], ["of", 1492], ["patients", 1495], ["previously", 1504], ["given", 1515], ["placebo", 1521], ["responded", 1529], [".", 1538], ["Safety", 1540], ["was", 1547], ["assessed", 1551], ["in", 1560], ["all", 1563], ["326", 1567], ["patients", 1571], ["given", 1580], ["the", 1586], ["test", 1590], ["drug", 1595], [".", 1599], ["The", 1601], ["most", 1605], ["frequent", 1610], ["adverse", 1619], ["experiences", 1627], ["after", 1639], ["the", 1645], ["administration", 1649], ["of", 1664], ["flumazenil", 1667], ["were", 1678], ["agitation", 1683], ["(", 1693], ["7", 1694], ["%", 1695], [")", 1696], [",", 1697], ["vomiting", 1699], ["(", 1708], ["7", 1709], ["%", 1710], [")", 1711], [",", 1712], ["abnormal", 1714], ["crying", 1723], ["(", 1730], ["4", 1731], ["%", 1732], [")", 1733], [",", 1734], ["and", 1736], ["nausea", 1740], ["(", 1747], ["4", 1748], ["%", 1749], [")", 1750], [";", 1751], ["these", 1753], ["effects", 1759], ["were", 1767], ["observed", 1772], ["with", 1781], ["a", 1786], ["lower", 1788], ["frequency", 1794], ["in", 1804], ["the", 1807], ["placebo", 1811], ["group", 1819], [".", 1824], ["Serious", 1826], ["adverse", 1834], ["experiences", 1842], ["were", 1854], ["reported", 1859], ["in", 1868], ["4", 1871], ["patients", 1873], [";", 1881], ["these", 1883], ["included", 1889], ["seizures", 1898], ["and", 1907], ["cardiac", 1911], ["arrhythmias", 1919], [".", 1930], ["Of", 1932], ["the", 1935], ["3", 1939], ["patients", 1941], ["with", 1950], ["seizures", 1955], [",", 1963], ["2", 1965], ["had", 1967], ["ingested", 1971], ["large", 1980], ["doses", 1986], ["of", 1992], ["cyclic", 1995], ["antidepressants", 2002], ["in", 2018], ["addition", 2021], ["to", 2030], ["the", 2033], ["benzodiazepine", 2037], [".", 2051], ["The", 2053], ["toxicology", 2057], ["screen", 2068], ["for", 2075], ["1", 2079], ["of", 2081], ["the", 2084], ["2", 2088], ["showed", 2090], ["1900", 2097], ["ng", 2102], ["/", 2104], ["ml", 2105], ["of", 2108], ["amoxapine", 2111], ["and", 2121], ["900", 2125], ["ng", 2129], ["/", 2131], ["ml", 2132], ["of", 2135], ["nortriptyline", 2138], [";", 2151], ["the", 2153], ["toxicology", 2157], ["screen", 2168], ["for", 2175], ["the", 2179], ["other", 2183], [",", 2188], ["who", 2190], ["also", 2194], ["had", 2199], ["ventricular", 2203], ["tachycardia", 2215], [",", 2226], ["showed", 2228], ["1928", 2235], ["ng", 2240], ["/", 2242], ["ml", 2243], ["of", 2246], ["loxapine", 2249], ["and", 2258], ["301", 2262], ["ng", 2266], ["/", 2268], ["ml", 2269], ["of", 2272], ["amoxapine", 2275], [".", 2284], ["The", 2286], ["results", 2290], ["of", 2298], ["this", 2301], ["study", 2306], ["confirm", 2312], ["published", 2320], ["reports", 2330], ["of", 2338], ["the", 2341], ["efficacy", 2345], ["of", 2354], ["flumazenil", 2357], ["in", 2368], ["reversing", 2371], ["benzodiazepine", 2381], ["-", 2395], ["induced", 2396], ["sedation", 2404], ["in", 2413], ["patients", 2416], ["with", 2425], ["benzodiazepine", 2430], ["overdose", 2445], [".", 2453], ["This", 2455], ["was", 2460], ["accomplished", 2464], ["irrespective", 2477], ["of", 2490], ["the", 2493], ["presence", 2497], ["of", 2506], ["coingested", 2509], ["drugs", 2520], [".", 2525], ["Flumazenil", 2527], ["is", 2538], ["not", 2541], ["recommended", 2545], ["for", 2557], ["patients", 2561], ["with", 2570], ["serious", 2575], ["cyclic", 2583], ["antidepressant", 2590], ["poisoning", 2605], ["or", 2615], ["those", 2618], ["who", 2624], ["use", 2628], ["benzodiazepines", 2632], ["therapeutically", 2648], ["to", 2664], ["control", 2667], ["seizure", 2675], ["disorders", 2683], [".", 2692], ["When", 2694], ["used", 2699], ["as", 2704], ["recommended", 2707], [",", 2718], ["however", 2720], [",", 2727], ["flumazenil", 2729], ["has", 2740], ["been", 2744], ["shown", 2749], ["to", 2755], ["have", 2758], ["an", 2763], ["acceptable", 2766], ["safety", 2777], ["level", 2784], [".", 2789]]}
{"context": "The worldwide expansion in the use of benzodiazepines has led to their frequent, and often inappropriate, use and to increase in their involvement in self-induced poisoning and iatrogenic overdosing. Flumazenil is a specific and competitive antagonist at the central benzodiazepine receptor, reversing all effects of benzodiazepine agonists without tranquillising or anticonvulsant actions. Incremental intravenous bolus injections of flumazenil 0.1 to 0.3 mg are the most effective and well tolerated in the diagnosis and treatment of pure benzodiazepine overdose; additional boluses or an infusion (0.3 to 0.5 mg/h) can be given to prevent patients from relapsing into coma. Intravenous flumazenil 10 to 20 micrograms/kg is effective in neonates and small children. Intramuscular, oral (20 to 25 mg 3 times daily or as required) and rectal administration may be used as alternatives in long term regimens. Patients with mixed-drug overdose require higher doses (up to 2 mg bolus, approximately equal to 1 mg/h infusion) to regain consciousness. Children and the elderly, chronically ill patients, and pregnant women and their fetuses all respond satisfactorily to flumazenil, but the usefulness of the drug in patients with hepatic encephalopathy and alcohol overdose is debatable. The use of flumazenil results in complete awakening with restoration of upper airway protective reflexes, thus enabling gastric lavage to be performed and transfer of the patient from the emergency room to another hospital department. Resumption of effective spontaneous respiration allows for expeditious extubation, weaning off mechanical ventilation or the avoidance of endotracheal intubation. While flumazenil is not associated with haemodynamic adverse effects, caution should be exercised when using this agent in patients who have co-ingested chloral hydrate to carbamazepine or whose ECG shows abnormalities typical to those seen after overdose with tricyclic antidepressants (TCAs); the use of flumazenil in the presence of these drugs can sometimes induce treatable cardiac dysrrhythmia. Flumazenil per se does not induce adverse effects. Coma reversal by flumazenil may cause mild, short-lived reactions caused by sudden awakening. Withdrawal symptoms in long term benzodiazepine users and seizures in patients who have taken an overdose of TCA or carbamazepine and a benzodiazepine can occur with flumazenil; these symptoms are avoidable by utilising slow flumazenil dose titration.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "369cc5a5643045aebe426287af31c52b", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[64, 64], [224, 224], [355, 355], [395, 395], [202, 202], [404, 404], [329, 329], [343, 343], [280, 280], [34, 34], [111, 111]], "char_spans": [[435, 444], [1295, 1304], [2151, 2160], [2394, 2403], [1166, 1175], [2453, 2462], [1988, 1997], [2083, 2092], [1688, 1697], [200, 209], [689, 698]]}]}], "context_tokens": [["The", 0], ["worldwide", 4], ["expansion", 14], ["in", 24], ["the", 27], ["use", 31], ["of", 35], ["benzodiazepines", 38], ["has", 54], ["led", 58], ["to", 62], ["their", 65], ["frequent", 71], [",", 79], ["and", 81], ["often", 85], ["inappropriate", 91], [",", 104], ["use", 106], ["and", 110], ["to", 114], ["increase", 117], ["in", 126], ["their", 129], ["involvement", 135], ["in", 147], ["self", 150], ["-", 154], ["induced", 155], ["poisoning", 163], ["and", 173], ["iatrogenic", 177], ["overdosing", 188], [".", 198], ["Flumazenil", 200], ["is", 211], ["a", 214], ["specific", 216], ["and", 225], ["competitive", 229], ["antagonist", 241], ["at", 252], ["the", 255], ["central", 259], ["benzodiazepine", 267], ["receptor", 282], [",", 290], ["reversing", 292], ["all", 302], ["effects", 306], ["of", 314], ["benzodiazepine", 317], ["agonists", 332], ["without", 341], ["tranquillising", 349], ["or", 364], ["anticonvulsant", 367], ["actions", 382], [".", 389], ["Incremental", 391], ["intravenous", 403], ["bolus", 415], ["injections", 421], ["of", 432], ["flumazenil", 435], ["0.1", 446], ["to", 450], ["0.3", 453], ["mg", 457], ["are", 460], ["the", 464], ["most", 468], ["effective", 473], ["and", 483], ["well", 487], ["tolerated", 492], ["in", 502], ["the", 505], ["diagnosis", 509], ["and", 519], ["treatment", 523], ["of", 533], ["pure", 536], ["benzodiazepine", 541], ["overdose", 556], [";", 564], ["additional", 566], ["boluses", 577], ["or", 585], ["an", 588], ["infusion", 591], ["(", 600], ["0.3", 601], ["to", 605], ["0.5", 608], ["mg", 612], ["/", 614], ["h", 615], [")", 616], ["can", 618], ["be", 622], ["given", 625], ["to", 631], ["prevent", 634], ["patients", 642], ["from", 651], ["relapsing", 656], ["into", 666], ["coma", 671], [".", 675], ["Intravenous", 677], ["flumazenil", 689], ["10", 700], ["to", 703], ["20", 706], ["micrograms", 709], ["/", 719], ["kg", 720], ["is", 723], ["effective", 726], ["in", 736], ["neonates", 739], ["and", 748], ["small", 752], ["children", 758], [".", 766], ["Intramuscular", 768], [",", 781], ["oral", 783], ["(", 788], ["20", 789], ["to", 792], ["25", 795], ["mg", 798], ["3", 801], ["times", 803], ["daily", 809], ["or", 815], ["as", 818], ["required", 821], [")", 829], ["and", 831], ["rectal", 835], ["administration", 842], ["may", 857], ["be", 861], ["used", 864], ["as", 869], ["alternatives", 872], ["in", 885], ["long", 888], ["term", 893], ["regimens", 898], [".", 906], ["Patients", 908], ["with", 917], ["mixed", 922], ["-", 927], ["drug", 928], ["overdose", 933], ["require", 942], ["higher", 950], ["doses", 957], ["(", 963], ["up", 964], ["to", 967], ["2", 970], ["mg", 972], ["bolus", 975], [",", 980], ["approximately", 982], ["equal", 996], ["to", 1002], ["1", 1005], ["mg", 1007], ["/", 1009], ["h", 1010], ["infusion", 1012], [")", 1020], ["to", 1022], ["regain", 1025], ["consciousness", 1032], [".", 1045], ["Children", 1047], ["and", 1056], ["the", 1060], ["elderly", 1064], [",", 1071], ["chronically", 1073], ["ill", 1085], ["patients", 1089], [",", 1097], ["and", 1099], ["pregnant", 1103], ["women", 1112], ["and", 1118], ["their", 1122], ["fetuses", 1128], ["all", 1136], ["respond", 1140], ["satisfactorily", 1148], ["to", 1163], ["flumazenil", 1166], [",", 1176], ["but", 1178], ["the", 1182], ["usefulness", 1186], ["of", 1197], ["the", 1200], ["drug", 1204], ["in", 1209], ["patients", 1212], ["with", 1221], ["hepatic", 1226], ["encephalopathy", 1234], ["and", 1249], ["alcohol", 1253], ["overdose", 1261], ["is", 1270], ["debatable", 1273], [".", 1282], ["The", 1284], ["use", 1288], ["of", 1292], ["flumazenil", 1295], ["results", 1306], ["in", 1314], ["complete", 1317], ["awakening", 1326], ["with", 1336], ["restoration", 1341], ["of", 1353], ["upper", 1356], ["airway", 1362], ["protective", 1369], ["reflexes", 1380], [",", 1388], ["thus", 1390], ["enabling", 1395], ["gastric", 1404], ["lavage", 1412], ["to", 1419], ["be", 1422], ["performed", 1425], ["and", 1435], ["transfer", 1439], ["of", 1448], ["the", 1451], ["patient", 1455], ["from", 1463], ["the", 1468], ["emergency", 1472], ["room", 1482], ["to", 1487], ["another", 1490], ["hospital", 1498], ["department", 1507], [".", 1517], ["Resumption", 1519], ["of", 1530], ["effective", 1533], ["spontaneous", 1543], ["respiration", 1555], ["allows", 1567], ["for", 1574], ["expeditious", 1578], ["extubation", 1590], [",", 1600], ["weaning", 1602], ["off", 1610], ["mechanical", 1614], ["ventilation", 1625], ["or", 1637], ["the", 1640], ["avoidance", 1644], ["of", 1654], ["endotracheal", 1657], ["intubation", 1670], [".", 1680], ["While", 1682], ["flumazenil", 1688], ["is", 1699], ["not", 1702], ["associated", 1706], ["with", 1717], ["haemodynamic", 1722], ["adverse", 1735], ["effects", 1743], [",", 1750], ["caution", 1752], ["should", 1760], ["be", 1767], ["exercised", 1770], ["when", 1780], ["using", 1785], ["this", 1791], ["agent", 1796], ["in", 1802], ["patients", 1805], ["who", 1814], ["have", 1818], ["co", 1823], ["-", 1825], ["ingested", 1826], ["chloral", 1835], ["hydrate", 1843], ["to", 1851], ["carbamazepine", 1854], ["or", 1868], ["whose", 1871], ["ECG", 1877], ["shows", 1881], ["abnormalities", 1887], ["typical", 1901], ["to", 1909], ["those", 1912], ["seen", 1918], ["after", 1923], ["overdose", 1929], ["with", 1938], ["tricyclic", 1943], ["antidepressants", 1953], ["(", 1969], ["TCAs", 1970], [")", 1974], [";", 1975], ["the", 1977], ["use", 1981], ["of", 1985], ["flumazenil", 1988], ["in", 1999], ["the", 2002], ["presence", 2006], ["of", 2015], ["these", 2018], ["drugs", 2024], ["can", 2030], ["sometimes", 2034], ["induce", 2044], ["treatable", 2051], ["cardiac", 2061], ["dysrrhythmia", 2069], [".", 2081], ["Flumazenil", 2083], ["per", 2094], ["se", 2098], ["does", 2101], ["not", 2106], ["induce", 2110], ["adverse", 2117], ["effects", 2125], [".", 2132], ["Coma", 2134], ["reversal", 2139], ["by", 2148], ["flumazenil", 2151], ["may", 2162], ["cause", 2166], ["mild", 2172], [",", 2176], ["short", 2178], ["-", 2183], ["lived", 2184], ["reactions", 2190], ["caused", 2200], ["by", 2207], ["sudden", 2210], ["awakening", 2217], [".", 2226], ["Withdrawal", 2228], ["symptoms", 2239], ["in", 2248], ["long", 2251], ["term", 2256], ["benzodiazepine", 2261], ["users", 2276], ["and", 2282], ["seizures", 2286], ["in", 2295], ["patients", 2298], ["who", 2307], ["have", 2311], ["taken", 2316], ["an", 2322], ["overdose", 2325], ["of", 2334], ["TCA", 2337], ["or", 2341], ["carbamazepine", 2344], ["and", 2358], ["a", 2362], ["benzodiazepine", 2364], ["can", 2379], ["occur", 2383], ["with", 2389], ["flumazenil", 2394], [";", 2404], ["these", 2406], ["symptoms", 2412], ["are", 2421], ["avoidable", 2425], ["by", 2435], ["utilising", 2438], ["slow", 2448], ["flumazenil", 2453], ["dose", 2464], ["titration", 2469], [".", 2478]]}
{"context": "Selective degradation of proteins by the ubiquitin-proteasome pathway is a critical determinant for maintaining cellular homeostasis. Most intracellular proteins are degraded by the proteasome, a multicatalytic enzyme complex containing a 20S catalytic core and two 19S regulatory complexes. Many proteasome target proteins are involved in the regulation of important processes of carcinogenesis and cancer cell survival, such as cell cycle progression, cell proliferation, differentiation and apoptosis. Indeed, the ubiquitin-proteasome-dependent degradation pathway plays an essential role in both the up-regulation of cell proliferation and down-regulation of cell death in human cancer cells. Both in vitro and in vivo experimental and clinical results have demonstrated the potential use of proteasome inhibitors as novel anticancer drugs. Proteasome inhibition in cancer cells leads to accumulation of pro-apoptotic target proteins followed by induction of cell death. The clinical efficacy of the proteasome inhibitor bortezomib toward multiple myeloma and other hematologic malignancies provides the \"proof of concept\" that targeting the proteasome is a promising strategy for cancer treatment. Several other proteasome inhibitors have also been identified from natural resources, such as marine microbial metabolites, green tea polyphenols, flavonoids, and medicinal compounds. Additionally, the use of metal complexes as proteasome inhibitors has also been investigated as a potential anticancer strategy. The clinical significance of targeting the tumor survival-associated proteasome pathway for cancer treatment, intervention and prevention will be discussed.", "qas": [{"question": "Which is the target of bortezomib used in cancer therapy?", "answers": ["The ubiquitin/proteasome pathway"], "qid": "db311c7e2115419da83e01e6c5610862", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["bortezomib", 23], ["used", 34], ["in", 39], ["cancer", 42], ["therapy", 49], ["?", 56]], "detected_answers": [{"text": "The ubiquitin/proteasome pathway", "token_spans": [[6, 9]], "char_spans": [[41, 68]]}]}], "context_tokens": [["Selective", 0], ["degradation", 10], ["of", 22], ["proteins", 25], ["by", 34], ["the", 37], ["ubiquitin", 41], ["-", 50], ["proteasome", 51], ["pathway", 62], ["is", 70], ["a", 73], ["critical", 75], ["determinant", 84], ["for", 96], ["maintaining", 100], ["cellular", 112], ["homeostasis", 121], [".", 132], ["Most", 134], ["intracellular", 139], ["proteins", 153], ["are", 162], ["degraded", 166], ["by", 175], ["the", 178], ["proteasome", 182], [",", 192], ["a", 194], ["multicatalytic", 196], ["enzyme", 211], ["complex", 218], ["containing", 226], ["a", 237], ["20S", 239], ["catalytic", 243], ["core", 253], ["and", 258], ["two", 262], ["19S", 266], ["regulatory", 270], ["complexes", 281], [".", 290], ["Many", 292], ["proteasome", 297], ["target", 308], ["proteins", 315], ["are", 324], ["involved", 328], ["in", 337], ["the", 340], ["regulation", 344], ["of", 355], ["important", 358], ["processes", 368], ["of", 378], ["carcinogenesis", 381], ["and", 396], ["cancer", 400], ["cell", 407], ["survival", 412], [",", 420], ["such", 422], ["as", 427], ["cell", 430], ["cycle", 435], ["progression", 441], [",", 452], ["cell", 454], ["proliferation", 459], [",", 472], ["differentiation", 474], ["and", 490], ["apoptosis", 494], [".", 503], ["Indeed", 505], [",", 511], ["the", 513], ["ubiquitin", 517], ["-", 526], ["proteasome", 527], ["-", 537], ["dependent", 538], ["degradation", 548], ["pathway", 560], ["plays", 568], ["an", 574], ["essential", 577], ["role", 587], ["in", 592], ["both", 595], ["the", 600], ["up", 604], ["-", 606], ["regulation", 607], ["of", 618], ["cell", 621], ["proliferation", 626], ["and", 640], ["down", 644], ["-", 648], ["regulation", 649], ["of", 660], ["cell", 663], ["death", 668], ["in", 674], ["human", 677], ["cancer", 683], ["cells", 690], [".", 695], ["Both", 697], ["in", 702], ["vitro", 705], ["and", 711], ["in", 715], ["vivo", 718], ["experimental", 723], ["and", 736], ["clinical", 740], ["results", 749], ["have", 757], ["demonstrated", 762], ["the", 775], ["potential", 779], ["use", 789], ["of", 793], ["proteasome", 796], ["inhibitors", 807], ["as", 818], ["novel", 821], ["anticancer", 827], ["drugs", 838], [".", 843], ["Proteasome", 845], ["inhibition", 856], ["in", 867], ["cancer", 870], ["cells", 877], ["leads", 883], ["to", 889], ["accumulation", 892], ["of", 905], ["pro", 908], ["-", 911], ["apoptotic", 912], ["target", 922], ["proteins", 929], ["followed", 938], ["by", 947], ["induction", 950], ["of", 960], ["cell", 963], ["death", 968], [".", 973], ["The", 975], ["clinical", 979], ["efficacy", 988], ["of", 997], ["the", 1000], ["proteasome", 1004], ["inhibitor", 1015], ["bortezomib", 1025], ["toward", 1036], ["multiple", 1043], ["myeloma", 1052], ["and", 1060], ["other", 1064], ["hematologic", 1070], ["malignancies", 1082], ["provides", 1095], ["the", 1104], ["\"", 1108], ["proof", 1109], ["of", 1115], ["concept", 1118], ["\"", 1125], ["that", 1127], ["targeting", 1132], ["the", 1142], ["proteasome", 1146], ["is", 1157], ["a", 1160], ["promising", 1162], ["strategy", 1172], ["for", 1181], ["cancer", 1185], ["treatment", 1192], [".", 1201], ["Several", 1203], ["other", 1211], ["proteasome", 1217], ["inhibitors", 1228], ["have", 1239], ["also", 1244], ["been", 1249], ["identified", 1254], ["from", 1265], ["natural", 1270], ["resources", 1278], [",", 1287], ["such", 1289], ["as", 1294], ["marine", 1297], ["microbial", 1304], ["metabolites", 1314], [",", 1325], ["green", 1327], ["tea", 1333], ["polyphenols", 1337], [",", 1348], ["flavonoids", 1350], [",", 1360], ["and", 1362], ["medicinal", 1366], ["compounds", 1376], [".", 1385], ["Additionally", 1387], [",", 1399], ["the", 1401], ["use", 1405], ["of", 1409], ["metal", 1412], ["complexes", 1418], ["as", 1428], ["proteasome", 1431], ["inhibitors", 1442], ["has", 1453], ["also", 1457], ["been", 1462], ["investigated", 1467], ["as", 1480], ["a", 1483], ["potential", 1485], ["anticancer", 1495], ["strategy", 1506], [".", 1514], ["The", 1516], ["clinical", 1520], ["significance", 1529], ["of", 1542], ["targeting", 1545], ["the", 1555], ["tumor", 1559], ["survival", 1565], ["-", 1573], ["associated", 1574], ["proteasome", 1585], ["pathway", 1596], ["for", 1604], ["cancer", 1608], ["treatment", 1615], [",", 1624], ["intervention", 1626], ["and", 1639], ["prevention", 1643], ["will", 1654], ["be", 1659], ["discussed", 1662], [".", 1671]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited cerebrovascular disease due to mutations involving loss or gain of a cysteine residue in the NOTCH3 gene. A cluster of mutations around exons 3 and 4 was originally reported. Identification of pathogenic mutation is important for diagnostic confirmation of the disease, however genetic counselling and testing of relatives at risk is critical in mutation carriers. Mutation analysis of the NOTCH3 gene was performed through direct sequencing in 140 patients with clinical suspicion of CADASIL. Patients underwent genetic counselling pre and post testing. The 2-23 exons containing all EGF-like domains were screened. 14 familial forms of the disease have been identified with 14 different causative mutations in exons 2, 3, 4, 5, 7, 10, 14, 19, 20 and 22 of the NOTCH3 gene; no pathogenetic mutations have been identified in exons 6 and 8; several genetic variations both in coding as well as in intronic regions were identified too. Our data confirm the importance of screening the whole EGF-like domains region of NOTCH3 gene for the molecular diagnosis of CADASIL among the Italian population too. Moreover genetic variants different from loss or gain of a cysteine residue are identified and presented.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "18b6217da1e544f0816a04e6db73ff7d", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[224, 224], [26, 26]], "char_spans": [[1277, 1284], [186, 193]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["an", 104], ["inherited", 107], ["cerebrovascular", 117], ["disease", 133], ["due", 141], ["to", 145], ["mutations", 148], ["involving", 158], ["loss", 168], ["or", 173], ["gain", 176], ["of", 181], ["a", 184], ["cysteine", 186], ["residue", 195], ["in", 203], ["the", 206], ["NOTCH3", 210], ["gene", 217], [".", 221], ["A", 223], ["cluster", 225], ["of", 233], ["mutations", 236], ["around", 246], ["exons", 253], ["3", 259], ["and", 261], ["4", 265], ["was", 267], ["originally", 271], ["reported", 282], [".", 290], ["Identification", 292], ["of", 307], ["pathogenic", 310], ["mutation", 321], ["is", 330], ["important", 333], ["for", 343], ["diagnostic", 347], ["confirmation", 358], ["of", 371], ["the", 374], ["disease", 378], [",", 385], ["however", 387], ["genetic", 395], ["counselling", 403], ["and", 415], ["testing", 419], ["of", 427], ["relatives", 430], ["at", 440], ["risk", 443], ["is", 448], ["critical", 451], ["in", 460], ["mutation", 463], ["carriers", 472], [".", 480], ["Mutation", 482], ["analysis", 491], ["of", 500], ["the", 503], ["NOTCH3", 507], ["gene", 514], ["was", 519], ["performed", 523], ["through", 533], ["direct", 541], ["sequencing", 548], ["in", 559], ["140", 562], ["patients", 566], ["with", 575], ["clinical", 580], ["suspicion", 589], ["of", 599], ["CADASIL", 602], [".", 609], ["Patients", 611], ["underwent", 620], ["genetic", 630], ["counselling", 638], ["pre", 650], ["and", 654], ["post", 658], ["testing", 663], [".", 670], ["The", 672], ["2", 676], ["-", 677], ["23", 678], ["exons", 681], ["containing", 687], ["all", 698], ["EGF", 702], ["-", 705], ["like", 706], ["domains", 711], ["were", 719], ["screened", 724], [".", 732], ["14", 734], ["familial", 737], ["forms", 746], ["of", 752], ["the", 755], ["disease", 759], ["have", 767], ["been", 772], ["identified", 777], ["with", 788], ["14", 793], ["different", 796], ["causative", 806], ["mutations", 816], ["in", 826], ["exons", 829], ["2", 835], [",", 836], ["3", 838], [",", 839], ["4", 841], [",", 842], ["5", 844], [",", 845], ["7", 847], [",", 848], ["10", 850], [",", 852], ["14", 854], [",", 856], ["19", 858], [",", 860], ["20", 862], ["and", 865], ["22", 869], ["of", 872], ["the", 875], ["NOTCH3", 879], ["gene", 886], [";", 890], ["no", 892], ["pathogenetic", 895], ["mutations", 908], ["have", 918], ["been", 923], ["identified", 928], ["in", 939], ["exons", 942], ["6", 948], ["and", 950], ["8", 954], [";", 955], ["several", 957], ["genetic", 965], ["variations", 973], ["both", 984], ["in", 989], ["coding", 992], ["as", 999], ["well", 1002], ["as", 1007], ["in", 1010], ["intronic", 1013], ["regions", 1022], ["were", 1030], ["identified", 1035], ["too", 1046], [".", 1049], ["Our", 1051], ["data", 1055], ["confirm", 1060], ["the", 1068], ["importance", 1072], ["of", 1083], ["screening", 1086], ["the", 1096], ["whole", 1100], ["EGF", 1106], ["-", 1109], ["like", 1110], ["domains", 1115], ["region", 1123], ["of", 1130], ["NOTCH3", 1133], ["gene", 1140], ["for", 1145], ["the", 1149], ["molecular", 1153], ["diagnosis", 1163], ["of", 1173], ["CADASIL", 1176], ["among", 1184], ["the", 1190], ["Italian", 1194], ["population", 1202], ["too", 1213], [".", 1216], ["Moreover", 1218], ["genetic", 1227], ["variants", 1235], ["different", 1244], ["from", 1254], ["loss", 1259], ["or", 1264], ["gain", 1267], ["of", 1272], ["a", 1275], ["cysteine", 1277], ["residue", 1286], ["are", 1294], ["identified", 1298], ["and", 1309], ["presented", 1313], [".", 1322]]}
{"context": "Theories for restless legs syndrome (RLS) pathogenesis include iron deficiency, dopamine dysregulation and peripheral neuropathy. Increased prevalence of small intestinal bacterial overgrowth (SIBO) in controlled studies in RLS and case reports of post-infectious RLS suggest potential roles for inflammation and immunological alterations. A literature search for all conditions associated with RLS was performed. These included secondary RLS disorders and factors that may exacerbate RLS. All of these conditions were reviewed with respect to potential pathogenesis including reports of iron deficiency, neuropathy, SIBO, inflammation and immune changes. A condition was defined as highly-associated if there was a prevalence study that utilized an appropriate control group. Small case reports were recorded but not included as definite RLS-associated conditions. Fifty four diseases, syndromes and conditions have been reported to cause and/or exacerbate RLS. Of these, 38 have been reported to have a higher prevalence than age-matched controls, 9 have adequate sized reports and have general acceptance as RLS-associated conditions and 7 have been reported in case report form. Overall, 42 of the 47 RLS-associated conditions (89%) have also been associated with inflammatory and/or immune changes. In addition, 43% have been associated with peripheral iron deficiency, 40% with peripheral neuropathy and 32% with SIBO. Most of the remaining conditions have yet to be studied for these factors. The fact that 95% of the 38 highly-associated RLS conditions are also associated with inflammatory/immune changes suggests the possibility that RLS may be mediated or affected through these mechanisms. Inflammation can be responsible for iron deficiency and hypothetically could cause central nervous system iron deficiency-induced RLS. Alternatively, an immune reaction to gastrointestinal bacteria or other antigens may hypothetically cause RLS by a direct immunological attack on the central or peripheral nervous system.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "cf13cc1b9e0a4705a20d0630e0acbe2a", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[229, 229], [10, 10], [297, 297], [89, 89], [306, 306]], "char_spans": [[1358, 1361], [63, 66], [1738, 1741], [588, 591], [1808, 1811]]}]}], "context_tokens": [["Theories", 0], ["for", 9], ["restless", 13], ["legs", 22], ["syndrome", 27], ["(", 36], ["RLS", 37], [")", 40], ["pathogenesis", 42], ["include", 55], ["iron", 63], ["deficiency", 68], [",", 78], ["dopamine", 80], ["dysregulation", 89], ["and", 103], ["peripheral", 107], ["neuropathy", 118], [".", 128], ["Increased", 130], ["prevalence", 140], ["of", 151], ["small", 154], ["intestinal", 160], ["bacterial", 171], ["overgrowth", 181], ["(", 192], ["SIBO", 193], [")", 197], ["in", 199], ["controlled", 202], ["studies", 213], ["in", 221], ["RLS", 224], ["and", 228], ["case", 232], ["reports", 237], ["of", 245], ["post", 248], ["-", 252], ["infectious", 253], ["RLS", 264], ["suggest", 268], ["potential", 276], ["roles", 286], ["for", 292], ["inflammation", 296], ["and", 309], ["immunological", 313], ["alterations", 327], [".", 338], ["A", 340], ["literature", 342], ["search", 353], ["for", 360], ["all", 364], ["conditions", 368], ["associated", 379], ["with", 390], ["RLS", 395], ["was", 399], ["performed", 403], [".", 412], ["These", 414], ["included", 420], ["secondary", 429], ["RLS", 439], ["disorders", 443], ["and", 453], ["factors", 457], ["that", 465], ["may", 470], ["exacerbate", 474], ["RLS", 485], [".", 488], ["All", 490], ["of", 494], ["these", 497], ["conditions", 503], ["were", 514], ["reviewed", 519], ["with", 528], ["respect", 533], ["to", 541], ["potential", 544], ["pathogenesis", 554], ["including", 567], ["reports", 577], ["of", 585], ["iron", 588], ["deficiency", 593], [",", 603], ["neuropathy", 605], [",", 615], ["SIBO", 617], [",", 621], ["inflammation", 623], ["and", 636], ["immune", 640], ["changes", 647], [".", 654], ["A", 656], ["condition", 658], ["was", 668], ["defined", 672], ["as", 680], ["highly", 683], ["-", 689], ["associated", 690], ["if", 701], ["there", 704], ["was", 710], ["a", 714], ["prevalence", 716], ["study", 727], ["that", 733], ["utilized", 738], ["an", 747], ["appropriate", 750], ["control", 762], ["group", 770], [".", 775], ["Small", 777], ["case", 783], ["reports", 788], ["were", 796], ["recorded", 801], ["but", 810], ["not", 814], ["included", 818], ["as", 827], ["definite", 830], ["RLS", 839], ["-", 842], ["associated", 843], ["conditions", 854], [".", 864], ["Fifty", 866], ["four", 872], ["diseases", 877], [",", 885], ["syndromes", 887], ["and", 897], ["conditions", 901], ["have", 912], ["been", 917], ["reported", 922], ["to", 931], ["cause", 934], ["and/or", 940], ["exacerbate", 947], ["RLS", 958], [".", 961], ["Of", 963], ["these", 966], [",", 971], ["38", 973], ["have", 976], ["been", 981], ["reported", 986], ["to", 995], ["have", 998], ["a", 1003], ["higher", 1005], ["prevalence", 1012], ["than", 1023], ["age", 1028], ["-", 1031], ["matched", 1032], ["controls", 1040], [",", 1048], ["9", 1050], ["have", 1052], ["adequate", 1057], ["sized", 1066], ["reports", 1072], ["and", 1080], ["have", 1084], ["general", 1089], ["acceptance", 1097], ["as", 1108], ["RLS", 1111], ["-", 1114], ["associated", 1115], ["conditions", 1126], ["and", 1137], ["7", 1141], ["have", 1143], ["been", 1148], ["reported", 1153], ["in", 1162], ["case", 1165], ["report", 1170], ["form", 1177], [".", 1181], ["Overall", 1183], [",", 1190], ["42", 1192], ["of", 1195], ["the", 1198], ["47", 1202], ["RLS", 1205], ["-", 1208], ["associated", 1209], ["conditions", 1220], ["(", 1231], ["89", 1232], ["%", 1234], [")", 1235], ["have", 1237], ["also", 1242], ["been", 1247], ["associated", 1252], ["with", 1263], ["inflammatory", 1268], ["and/or", 1281], ["immune", 1288], ["changes", 1295], [".", 1302], ["In", 1304], ["addition", 1307], [",", 1315], ["43", 1317], ["%", 1319], ["have", 1321], ["been", 1326], ["associated", 1331], ["with", 1342], ["peripheral", 1347], ["iron", 1358], ["deficiency", 1363], [",", 1373], ["40", 1375], ["%", 1377], ["with", 1379], ["peripheral", 1384], ["neuropathy", 1395], ["and", 1406], ["32", 1410], ["%", 1412], ["with", 1414], ["SIBO", 1419], [".", 1423], ["Most", 1425], ["of", 1430], ["the", 1433], ["remaining", 1437], ["conditions", 1447], ["have", 1458], ["yet", 1463], ["to", 1467], ["be", 1470], ["studied", 1473], ["for", 1481], ["these", 1485], ["factors", 1491], [".", 1498], ["The", 1500], ["fact", 1504], ["that", 1509], ["95", 1514], ["%", 1516], ["of", 1518], ["the", 1521], ["38", 1525], ["highly", 1528], ["-", 1534], ["associated", 1535], ["RLS", 1546], ["conditions", 1550], ["are", 1561], ["also", 1565], ["associated", 1570], ["with", 1581], ["inflammatory", 1586], ["/", 1598], ["immune", 1599], ["changes", 1606], ["suggests", 1614], ["the", 1623], ["possibility", 1627], ["that", 1639], ["RLS", 1644], ["may", 1648], ["be", 1652], ["mediated", 1655], ["or", 1664], ["affected", 1667], ["through", 1676], ["these", 1684], ["mechanisms", 1690], [".", 1700], ["Inflammation", 1702], ["can", 1715], ["be", 1719], ["responsible", 1722], ["for", 1734], ["iron", 1738], ["deficiency", 1743], ["and", 1754], ["hypothetically", 1758], ["could", 1773], ["cause", 1779], ["central", 1785], ["nervous", 1793], ["system", 1801], ["iron", 1808], ["deficiency", 1813], ["-", 1823], ["induced", 1824], ["RLS", 1832], [".", 1835], ["Alternatively", 1837], [",", 1850], ["an", 1852], ["immune", 1855], ["reaction", 1862], ["to", 1871], ["gastrointestinal", 1874], ["bacteria", 1891], ["or", 1900], ["other", 1903], ["antigens", 1909], ["may", 1918], ["hypothetically", 1922], ["cause", 1937], ["RLS", 1943], ["by", 1947], ["a", 1950], ["direct", 1952], ["immunological", 1959], ["attack", 1973], ["on", 1980], ["the", 1983], ["central", 1987], ["or", 1995], ["peripheral", 1998], ["nervous", 2009], ["system", 2017], [".", 2023]]}
{"context": "The aim of this study was to evaluate the efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder (PTSD). This 12-week, multicenter, double-blind study randomized patients to receive either tiagabine or placebo. Tiagabine (administered in divided doses) was initiated at 4 mg/d (2 mg BID) and individually titrated of up to 4 mg/d weekly to a maximum dose of 16 mg/d. Assessments included the Clinician-Administered PTSD Scale, Clinical Global Impressions of Change, Treatment Outcome PTSD Scale, Davidson Trauma Scale, Connor-Davidson Resilience Scale, Sheehan Disability Scale, Massachusetts General Hospital Sexual Functioning Questionnaire, and Montgomery-Asberg Depression Rating Scale. A total of 232 patients (tiagabine, n = 116; placebo, n = 116) were randomized. There were no significant differences in change from baseline in the Clinician-Administered PTSD Scale total score at final visit for tiagabine compared with placebo (P = 0.85). Similarly, no significant differences were observed with tiagabine on the other efficacy outcome measures (described above) compared with placebo. Tiagabine was generally well tolerated and not associated with weight gain, changes in sexual function, or worsening of depressive symptoms. Tiagabine was not significantly different from placebo in the treatment of symptoms of PTSD. Additional studies are needed to assess the role of drugs that target the gamma-aminobutyric acid system in the treatment of PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b5c03080f08845128cbb48af0b93fc6d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[18, 22]], "char_spans": [[104, 133]]}, {"text": "PTSD", "token_spans": [[91, 91], [246, 246], [102, 102], [169, 169], [24, 24], [270, 270]], "char_spans": [[453, 456], [1362, 1365], [522, 525], [901, 904], [136, 139], [1493, 1496]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["evaluate", 29], ["the", 38], ["efficacy", 42], ["and", 51], ["tolerability", 55], ["of", 68], ["tiagabine", 71], ["in", 81], ["adult", 84], ["patients", 90], ["with", 99], ["post", 104], ["-", 108], ["traumatic", 109], ["stress", 119], ["disorder", 126], ["(", 135], ["PTSD", 136], [")", 140], [".", 141], ["This", 143], ["12-week", 148], [",", 155], ["multicenter", 157], [",", 168], ["double", 170], ["-", 176], ["blind", 177], ["study", 183], ["randomized", 189], ["patients", 200], ["to", 209], ["receive", 212], ["either", 220], ["tiagabine", 227], ["or", 237], ["placebo", 240], [".", 247], ["Tiagabine", 249], ["(", 259], ["administered", 260], ["in", 273], ["divided", 276], ["doses", 284], [")", 289], ["was", 291], ["initiated", 295], ["at", 305], ["4", 308], ["mg", 310], ["/", 312], ["d", 313], ["(", 315], ["2", 316], ["mg", 318], ["BID", 321], [")", 324], ["and", 326], ["individually", 330], ["titrated", 343], ["of", 352], ["up", 355], ["to", 358], ["4", 361], ["mg", 363], ["/", 365], ["d", 366], ["weekly", 368], ["to", 375], ["a", 378], ["maximum", 380], ["dose", 388], ["of", 393], ["16", 396], ["mg", 399], ["/", 401], ["d", 402], [".", 403], ["Assessments", 405], ["included", 417], ["the", 426], ["Clinician", 430], ["-", 439], ["Administered", 440], ["PTSD", 453], ["Scale", 458], [",", 463], ["Clinical", 465], ["Global", 474], ["Impressions", 481], ["of", 493], ["Change", 496], [",", 502], ["Treatment", 504], ["Outcome", 514], ["PTSD", 522], ["Scale", 527], [",", 532], ["Davidson", 534], ["Trauma", 543], ["Scale", 550], [",", 555], ["Connor", 557], ["-", 563], ["Davidson", 564], ["Resilience", 573], ["Scale", 584], [",", 589], ["Sheehan", 591], ["Disability", 599], ["Scale", 610], [",", 615], ["Massachusetts", 617], ["General", 631], ["Hospital", 639], ["Sexual", 648], ["Functioning", 655], ["Questionnaire", 667], [",", 680], ["and", 682], ["Montgomery", 686], ["-", 696], ["Asberg", 697], ["Depression", 704], ["Rating", 715], ["Scale", 722], [".", 727], ["A", 729], ["total", 731], ["of", 737], ["232", 740], ["patients", 744], ["(", 753], ["tiagabine", 754], [",", 763], ["n", 765], ["=", 767], ["116", 769], [";", 772], ["placebo", 774], [",", 781], ["n", 783], ["=", 785], ["116", 787], [")", 790], ["were", 792], ["randomized", 797], [".", 807], ["There", 809], ["were", 815], ["no", 820], ["significant", 823], ["differences", 835], ["in", 847], ["change", 850], ["from", 857], ["baseline", 862], ["in", 871], ["the", 874], ["Clinician", 878], ["-", 887], ["Administered", 888], ["PTSD", 901], ["Scale", 906], ["total", 912], ["score", 918], ["at", 924], ["final", 927], ["visit", 933], ["for", 939], ["tiagabine", 943], ["compared", 953], ["with", 962], ["placebo", 967], ["(", 975], ["P", 976], ["=", 978], ["0.85", 980], [")", 984], [".", 985], ["Similarly", 987], [",", 996], ["no", 998], ["significant", 1001], ["differences", 1013], ["were", 1025], ["observed", 1030], ["with", 1039], ["tiagabine", 1044], ["on", 1054], ["the", 1057], ["other", 1061], ["efficacy", 1067], ["outcome", 1076], ["measures", 1084], ["(", 1093], ["described", 1094], ["above", 1104], [")", 1109], ["compared", 1111], ["with", 1120], ["placebo", 1125], [".", 1132], ["Tiagabine", 1134], ["was", 1144], ["generally", 1148], ["well", 1158], ["tolerated", 1163], ["and", 1173], ["not", 1177], ["associated", 1181], ["with", 1192], ["weight", 1197], ["gain", 1204], [",", 1208], ["changes", 1210], ["in", 1218], ["sexual", 1221], ["function", 1228], [",", 1236], ["or", 1238], ["worsening", 1241], ["of", 1251], ["depressive", 1254], ["symptoms", 1265], [".", 1273], ["Tiagabine", 1275], ["was", 1285], ["not", 1289], ["significantly", 1293], ["different", 1307], ["from", 1317], ["placebo", 1322], ["in", 1330], ["the", 1333], ["treatment", 1337], ["of", 1347], ["symptoms", 1350], ["of", 1359], ["PTSD", 1362], [".", 1366], ["Additional", 1368], ["studies", 1379], ["are", 1387], ["needed", 1391], ["to", 1398], ["assess", 1401], ["the", 1408], ["role", 1412], ["of", 1417], ["drugs", 1420], ["that", 1426], ["target", 1431], ["the", 1438], ["gamma", 1442], ["-", 1447], ["aminobutyric", 1448], ["acid", 1461], ["system", 1466], ["in", 1473], ["the", 1476], ["treatment", 1480], ["of", 1490], ["PTSD", 1493], [".", 1497]]}
{"context": "Treslin/TICRR (TopBP1-interacting, replication stimulating protein/TopBP1-interacting, checkpoint, and replication regulator), the human ortholog of the yeast Sld3 protein, is an essential DNA replication factor that is regulated by cyclin-dependent kinases and the DNA damage checkpoint. We identified MDM two binding protein (MTBP) as a factor that interacts with Treslin/TICRR throughout the cell cycle. We show that MTBP depletion by means of small interfering RNA inhibits DNA replication by preventing assembly of the CMG (Cdc45-MCM-GINS) holohelicase during origin firing. Although MTBP has been implicated in the function of the p53 tumor suppressor, we found MTBP is required for DNA replication irrespective of a cell's p53 status. We propose that MTBP acts with Treslin/TICRR to integrate signals from cell cycle and DNA damage response pathways to control the initiation of DNA replication in human cells.", "qas": [{"question": "Which factor interacts with Treslin/TICRR throughout the cell cycle of human cells?", "answers": ["MDM two binding protein (MTBP)"], "qid": "470f42e7c572482a84dd8e9d4a279059", "question_tokens": [["Which", 0], ["factor", 6], ["interacts", 13], ["with", 23], ["Treslin", 28], ["/", 35], ["TICRR", 36], ["throughout", 42], ["the", 53], ["cell", 57], ["cycle", 62], ["of", 68], ["human", 71], ["cells", 77], ["?", 82]], "detected_answers": [{"text": "MDM two binding protein (MTBP)", "token_spans": [[50, 55]], "char_spans": [[303, 331]]}]}], "context_tokens": [["Treslin", 0], ["/", 7], ["TICRR", 8], ["(", 14], ["TopBP1-interacting", 15], [",", 33], ["replication", 35], ["stimulating", 47], ["protein", 59], ["/", 66], ["TopBP1-interacting", 67], [",", 85], ["checkpoint", 87], [",", 97], ["and", 99], ["replication", 103], ["regulator", 115], [")", 124], [",", 125], ["the", 127], ["human", 131], ["ortholog", 137], ["of", 146], ["the", 149], ["yeast", 153], ["Sld3", 159], ["protein", 164], [",", 171], ["is", 173], ["an", 176], ["essential", 179], ["DNA", 189], ["replication", 193], ["factor", 205], ["that", 212], ["is", 217], ["regulated", 220], ["by", 230], ["cyclin", 233], ["-", 239], ["dependent", 240], ["kinases", 250], ["and", 258], ["the", 262], ["DNA", 266], ["damage", 270], ["checkpoint", 277], [".", 287], ["We", 289], ["identified", 292], ["MDM", 303], ["two", 307], ["binding", 311], ["protein", 319], ["(", 327], ["MTBP", 328], [")", 332], ["as", 334], ["a", 337], ["factor", 339], ["that", 346], ["interacts", 351], ["with", 361], ["Treslin", 366], ["/", 373], ["TICRR", 374], ["throughout", 380], ["the", 391], ["cell", 395], ["cycle", 400], [".", 405], ["We", 407], ["show", 410], ["that", 415], ["MTBP", 420], ["depletion", 425], ["by", 435], ["means", 438], ["of", 444], ["small", 447], ["interfering", 453], ["RNA", 465], ["inhibits", 469], ["DNA", 478], ["replication", 482], ["by", 494], ["preventing", 497], ["assembly", 508], ["of", 517], ["the", 520], ["CMG", 524], ["(", 528], ["Cdc45-MCM", 529], ["-", 538], ["GINS", 539], [")", 543], ["holohelicase", 545], ["during", 558], ["origin", 565], ["firing", 572], [".", 578], ["Although", 580], ["MTBP", 589], ["has", 594], ["been", 598], ["implicated", 603], ["in", 614], ["the", 617], ["function", 621], ["of", 630], ["the", 633], ["p53", 637], ["tumor", 641], ["suppressor", 647], [",", 657], ["we", 659], ["found", 662], ["MTBP", 668], ["is", 673], ["required", 676], ["for", 685], ["DNA", 689], ["replication", 693], ["irrespective", 705], ["of", 718], ["a", 721], ["cell", 723], ["'s", 727], ["p53", 730], ["status", 734], [".", 740], ["We", 742], ["propose", 745], ["that", 753], ["MTBP", 758], ["acts", 763], ["with", 768], ["Treslin", 773], ["/", 780], ["TICRR", 781], ["to", 787], ["integrate", 790], ["signals", 800], ["from", 808], ["cell", 813], ["cycle", 818], ["and", 824], ["DNA", 828], ["damage", 832], ["response", 839], ["pathways", 848], ["to", 857], ["control", 860], ["the", 868], ["initiation", 872], ["of", 883], ["DNA", 886], ["replication", 890], ["in", 902], ["human", 905], ["cells", 911], [".", 916]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a dominant disease linked to contraction of an array of tandem 3.3-kb repeats (D4Z4) at 4q35. Within each repeat unit is a gene, DUX4, that can encode a protein containing two homeodomains. A DUX4 transcript derived from the last repeat unit in a contracted array is associated with pathogenesis but it is unclear how. Using exon-based microarrays, the expression profiles of myogenic precursor cells were determined. Both undifferentiated myoblasts and myoblasts differentiated to myotubes derived from FSHD patients and controls were studied after immunocytochemical verification of the quality of the cultures. To further our understanding of FSHD and normal myogenesis, the expression profiles obtained were compared to those of 19 non-muscle cell types analyzed by identical methods. Many of the ~17,000 examined genes were differentially expressed (>2-fold, p<0.01) in control myoblasts or myotubes vs. non-muscle cells (2185 and 3006, respectively) or in FSHD vs. control myoblasts or myotubes (295 and 797, respectively). Surprisingly, despite the morphologically normal differentiation of FSHD myoblasts to myotubes, most of the disease-related dysregulation was seen as dampening of normal myogenesis-specific expression changes, including in genes for muscle structure, mitochondrial function, stress responses, and signal transduction. Other classes of genes, including those encoding extracellular matrix or pro-inflammatory proteins, were upregulated in FSHD myogenic cells independent of an inverse myogenesis association. Importantly, the disease-linked DUX4 RNA isoform was detected by RT-PCR in FSHD myoblast and myotube preparations only at extremely low levels. Unique insights into myogenesis-specific gene expression were also obtained. For example, all four Argonaute genes involved in RNA-silencing were significantly upregulated during normal (but not FSHD) myogenesis relative to non-muscle cell types. DUX4's pathogenic effect in FSHD may occur transiently at or before the stage of myoblast formation to establish a cascade of gene dysregulation. This contrasts with the current emphasis on toxic effects of experimentally upregulated DUX4 expression at the myoblast or myotube stages. Our model could explain why DUX4's inappropriate expression was barely detectable in myoblasts and myotubes but nonetheless linked to FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "7d7dfb5ece1846bc8fab1c8af7bcce92", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[256, 256], [115, 115], [325, 325], [282, 282], [341, 341], [196, 196], [4, 4], [174, 174], [402, 402], [94, 94]], "char_spans": [[1517, 1520], [695, 698], [1926, 1929], [1662, 1665], [2006, 2009], [1147, 1150], [40, 43], [1011, 1014], [2397, 2400], [553, 556]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["dominant", 51], ["disease", 60], ["linked", 68], ["to", 75], ["contraction", 78], ["of", 90], ["an", 93], ["array", 96], ["of", 102], ["tandem", 105], ["3.3-kb", 112], ["repeats", 119], ["(", 127], ["D4Z4", 128], [")", 132], ["at", 134], ["4q35", 137], [".", 141], ["Within", 143], ["each", 150], ["repeat", 155], ["unit", 162], ["is", 167], ["a", 170], ["gene", 172], [",", 176], ["DUX4", 178], [",", 182], ["that", 184], ["can", 189], ["encode", 193], ["a", 200], ["protein", 202], ["containing", 210], ["two", 221], ["homeodomains", 225], [".", 237], ["A", 239], ["DUX4", 241], ["transcript", 246], ["derived", 257], ["from", 265], ["the", 270], ["last", 274], ["repeat", 279], ["unit", 286], ["in", 291], ["a", 294], ["contracted", 296], ["array", 307], ["is", 313], ["associated", 316], ["with", 327], ["pathogenesis", 332], ["but", 345], ["it", 349], ["is", 352], ["unclear", 355], ["how", 363], [".", 366], ["Using", 368], ["exon", 374], ["-", 378], ["based", 379], ["microarrays", 385], [",", 396], ["the", 398], ["expression", 402], ["profiles", 413], ["of", 422], ["myogenic", 425], ["precursor", 434], ["cells", 444], ["were", 450], ["determined", 455], [".", 465], ["Both", 467], ["undifferentiated", 472], ["myoblasts", 489], ["and", 499], ["myoblasts", 503], ["differentiated", 513], ["to", 528], ["myotubes", 531], ["derived", 540], ["from", 548], ["FSHD", 553], ["patients", 558], ["and", 567], ["controls", 571], ["were", 580], ["studied", 585], ["after", 593], ["immunocytochemical", 599], ["verification", 618], ["of", 631], ["the", 634], ["quality", 638], ["of", 646], ["the", 649], ["cultures", 653], [".", 661], ["To", 663], ["further", 666], ["our", 674], ["understanding", 678], ["of", 692], ["FSHD", 695], ["and", 700], ["normal", 704], ["myogenesis", 711], [",", 721], ["the", 723], ["expression", 727], ["profiles", 738], ["obtained", 747], ["were", 756], ["compared", 761], ["to", 770], ["those", 773], ["of", 779], ["19", 782], ["non", 785], ["-", 788], ["muscle", 789], ["cell", 796], ["types", 801], ["analyzed", 807], ["by", 816], ["identical", 819], ["methods", 829], [".", 836], ["Many", 838], ["of", 843], ["the", 846], ["~17,000", 850], ["examined", 858], ["genes", 867], ["were", 873], ["differentially", 878], ["expressed", 893], ["(", 903], [">", 904], ["2-fold", 905], [",", 911], ["p<0.01", 913], [")", 919], ["in", 921], ["control", 924], ["myoblasts", 932], ["or", 942], ["myotubes", 945], ["vs.", 954], ["non", 958], ["-", 961], ["muscle", 962], ["cells", 969], ["(", 975], ["2185", 976], ["and", 981], ["3006", 985], [",", 989], ["respectively", 991], [")", 1003], ["or", 1005], ["in", 1008], ["FSHD", 1011], ["vs.", 1016], ["control", 1020], ["myoblasts", 1028], ["or", 1038], ["myotubes", 1041], ["(", 1050], ["295", 1051], ["and", 1055], ["797", 1059], [",", 1062], ["respectively", 1064], [")", 1076], [".", 1077], ["Surprisingly", 1079], [",", 1091], ["despite", 1093], ["the", 1101], ["morphologically", 1105], ["normal", 1121], ["differentiation", 1128], ["of", 1144], ["FSHD", 1147], ["myoblasts", 1152], ["to", 1162], ["myotubes", 1165], [",", 1173], ["most", 1175], ["of", 1180], ["the", 1183], ["disease", 1187], ["-", 1194], ["related", 1195], ["dysregulation", 1203], ["was", 1217], ["seen", 1221], ["as", 1226], ["dampening", 1229], ["of", 1239], ["normal", 1242], ["myogenesis", 1249], ["-", 1259], ["specific", 1260], ["expression", 1269], ["changes", 1280], [",", 1287], ["including", 1289], ["in", 1299], ["genes", 1302], ["for", 1308], ["muscle", 1312], ["structure", 1319], [",", 1328], ["mitochondrial", 1330], ["function", 1344], [",", 1352], ["stress", 1354], ["responses", 1361], [",", 1370], ["and", 1372], ["signal", 1376], ["transduction", 1383], [".", 1395], ["Other", 1397], ["classes", 1403], ["of", 1411], ["genes", 1414], [",", 1419], ["including", 1421], ["those", 1431], ["encoding", 1437], ["extracellular", 1446], ["matrix", 1460], ["or", 1467], ["pro", 1470], ["-", 1473], ["inflammatory", 1474], ["proteins", 1487], [",", 1495], ["were", 1497], ["upregulated", 1502], ["in", 1514], ["FSHD", 1517], ["myogenic", 1522], ["cells", 1531], ["independent", 1537], ["of", 1549], ["an", 1552], ["inverse", 1555], ["myogenesis", 1563], ["association", 1574], [".", 1585], ["Importantly", 1587], [",", 1598], ["the", 1600], ["disease", 1604], ["-", 1611], ["linked", 1612], ["DUX4", 1619], ["RNA", 1624], ["isoform", 1628], ["was", 1636], ["detected", 1640], ["by", 1649], ["RT", 1652], ["-", 1654], ["PCR", 1655], ["in", 1659], ["FSHD", 1662], ["myoblast", 1667], ["and", 1676], ["myotube", 1680], ["preparations", 1688], ["only", 1701], ["at", 1706], ["extremely", 1709], ["low", 1719], ["levels", 1723], [".", 1729], ["Unique", 1731], ["insights", 1738], ["into", 1747], ["myogenesis", 1752], ["-", 1762], ["specific", 1763], ["gene", 1772], ["expression", 1777], ["were", 1788], ["also", 1793], ["obtained", 1798], [".", 1806], ["For", 1808], ["example", 1812], [",", 1819], ["all", 1821], ["four", 1825], ["Argonaute", 1830], ["genes", 1840], ["involved", 1846], ["in", 1855], ["RNA", 1858], ["-", 1861], ["silencing", 1862], ["were", 1872], ["significantly", 1877], ["upregulated", 1891], ["during", 1903], ["normal", 1910], ["(", 1917], ["but", 1918], ["not", 1922], ["FSHD", 1926], [")", 1930], ["myogenesis", 1932], ["relative", 1943], ["to", 1952], ["non", 1955], ["-", 1958], ["muscle", 1959], ["cell", 1966], ["types", 1971], [".", 1976], ["DUX4", 1978], ["'s", 1982], ["pathogenic", 1985], ["effect", 1996], ["in", 2003], ["FSHD", 2006], ["may", 2011], ["occur", 2015], ["transiently", 2021], ["at", 2033], ["or", 2036], ["before", 2039], ["the", 2046], ["stage", 2050], ["of", 2056], ["myoblast", 2059], ["formation", 2068], ["to", 2078], ["establish", 2081], ["a", 2091], ["cascade", 2093], ["of", 2101], ["gene", 2104], ["dysregulation", 2109], [".", 2122], ["This", 2124], ["contrasts", 2129], ["with", 2139], ["the", 2144], ["current", 2148], ["emphasis", 2156], ["on", 2165], ["toxic", 2168], ["effects", 2174], ["of", 2182], ["experimentally", 2185], ["upregulated", 2200], ["DUX4", 2212], ["expression", 2217], ["at", 2228], ["the", 2231], ["myoblast", 2235], ["or", 2244], ["myotube", 2247], ["stages", 2255], [".", 2261], ["Our", 2263], ["model", 2267], ["could", 2273], ["explain", 2279], ["why", 2287], ["DUX4", 2291], ["'s", 2295], ["inappropriate", 2298], ["expression", 2312], ["was", 2323], ["barely", 2327], ["detectable", 2334], ["in", 2345], ["myoblasts", 2348], ["and", 2358], ["myotubes", 2362], ["but", 2371], ["nonetheless", 2375], ["linked", 2387], ["to", 2394], ["FSHD", 2397], [".", 2401]]}
{"context": "The natively disordered protein alpha-synuclein is the primary component of Lewy bodies, the cellular hallmark of Parkinson's disease. Most studies of this protein are performed in dilute solution, but its biologically relevant role is performed in the crowded environment inside cells. We addressed the effects of macromolecular crowding on alpha-synuclein by combining NMR data acquired in living Escherichia coli with in vitro NMR data. The crowded environment in the E.coli periplasm prevents a conformational change that is detected at 35 degrees C in dilute solution. This change is associated with an increase in hydrodynamic radius and the formation of secondary structure in the N-terminal 100 amino acid residues. By preventing this temperature-induced conformational change, crowding in the E.coli periplasm stabilizes the disordered monomer. We obtain the same stabilization in vitro upon crowding alpha-synuclein with 300 g/l of bovine serum albumin, indicating that crowding alone is sufficient to stabilize the disordered, monomeric protein. Two disease-associated variants (A30P and A53T) behave in the same way in both dilute solution and in the E.coli periplasm. These data reveal the importance of approaching the effects of macromolecular crowding on a case-by-case basis. Additionally, our work shows that discrete structured protein conformations may not be achieved by alpha-synuclein inside cells, implicating the commonly overlooked aspect of macromolecular crowding as a possible factor in the etiology of Parkinson's disease.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "ef3220cd0654492584edc7a94fda2c33", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[150, 152], [56, 58], [4, 6], [239, 241]], "char_spans": [[910, 924], [342, 356], [32, 46], [1392, 1406]]}]}], "context_tokens": [["The", 0], ["natively", 4], ["disordered", 13], ["protein", 24], ["alpha", 32], ["-", 37], ["synuclein", 38], ["is", 48], ["the", 51], ["primary", 55], ["component", 63], ["of", 73], ["Lewy", 76], ["bodies", 81], [",", 87], ["the", 89], ["cellular", 93], ["hallmark", 102], ["of", 111], ["Parkinson", 114], ["'s", 123], ["disease", 126], [".", 133], ["Most", 135], ["studies", 140], ["of", 148], ["this", 151], ["protein", 156], ["are", 164], ["performed", 168], ["in", 178], ["dilute", 181], ["solution", 188], [",", 196], ["but", 198], ["its", 202], ["biologically", 206], ["relevant", 219], ["role", 228], ["is", 233], ["performed", 236], ["in", 246], ["the", 249], ["crowded", 253], ["environment", 261], ["inside", 273], ["cells", 280], [".", 285], ["We", 287], ["addressed", 290], ["the", 300], ["effects", 304], ["of", 312], ["macromolecular", 315], ["crowding", 330], ["on", 339], ["alpha", 342], ["-", 347], ["synuclein", 348], ["by", 358], ["combining", 361], ["NMR", 371], ["data", 375], ["acquired", 380], ["in", 389], ["living", 392], ["Escherichia", 399], ["coli", 411], ["with", 416], ["in", 421], ["vitro", 424], ["NMR", 430], ["data", 434], [".", 438], ["The", 440], ["crowded", 444], ["environment", 452], ["in", 464], ["the", 467], ["E.coli", 471], ["periplasm", 478], ["prevents", 488], ["a", 497], ["conformational", 499], ["change", 514], ["that", 521], ["is", 526], ["detected", 529], ["at", 538], ["35", 541], ["degrees", 544], ["C", 552], ["in", 554], ["dilute", 557], ["solution", 564], [".", 572], ["This", 574], ["change", 579], ["is", 586], ["associated", 589], ["with", 600], ["an", 605], ["increase", 608], ["in", 617], ["hydrodynamic", 620], ["radius", 633], ["and", 640], ["the", 644], ["formation", 648], ["of", 658], ["secondary", 661], ["structure", 671], ["in", 681], ["the", 684], ["N", 688], ["-", 689], ["terminal", 690], ["100", 699], ["amino", 703], ["acid", 709], ["residues", 714], [".", 722], ["By", 724], ["preventing", 727], ["this", 738], ["temperature", 743], ["-", 754], ["induced", 755], ["conformational", 763], ["change", 778], [",", 784], ["crowding", 786], ["in", 795], ["the", 798], ["E.coli", 802], ["periplasm", 809], ["stabilizes", 819], ["the", 830], ["disordered", 834], ["monomer", 845], [".", 852], ["We", 854], ["obtain", 857], ["the", 864], ["same", 868], ["stabilization", 873], ["in", 887], ["vitro", 890], ["upon", 896], ["crowding", 901], ["alpha", 910], ["-", 915], ["synuclein", 916], ["with", 926], ["300", 931], ["g", 935], ["/", 936], ["l", 937], ["of", 939], ["bovine", 942], ["serum", 949], ["albumin", 955], [",", 962], ["indicating", 964], ["that", 975], ["crowding", 980], ["alone", 989], ["is", 995], ["sufficient", 998], ["to", 1009], ["stabilize", 1012], ["the", 1022], ["disordered", 1026], [",", 1036], ["monomeric", 1038], ["protein", 1048], [".", 1055], ["Two", 1057], ["disease", 1061], ["-", 1068], ["associated", 1069], ["variants", 1080], ["(", 1089], ["A30P", 1090], ["and", 1095], ["A53", 1099], ["T", 1102], [")", 1103], ["behave", 1105], ["in", 1112], ["the", 1115], ["same", 1119], ["way", 1124], ["in", 1128], ["both", 1131], ["dilute", 1136], ["solution", 1143], ["and", 1152], ["in", 1156], ["the", 1159], ["E.coli", 1163], ["periplasm", 1170], [".", 1179], ["These", 1181], ["data", 1187], ["reveal", 1192], ["the", 1199], ["importance", 1203], ["of", 1214], ["approaching", 1217], ["the", 1229], ["effects", 1233], ["of", 1241], ["macromolecular", 1244], ["crowding", 1259], ["on", 1268], ["a", 1271], ["case", 1273], ["-", 1277], ["by", 1278], ["-", 1280], ["case", 1281], ["basis", 1286], [".", 1291], ["Additionally", 1293], [",", 1305], ["our", 1307], ["work", 1311], ["shows", 1316], ["that", 1322], ["discrete", 1327], ["structured", 1336], ["protein", 1347], ["conformations", 1355], ["may", 1369], ["not", 1373], ["be", 1377], ["achieved", 1380], ["by", 1389], ["alpha", 1392], ["-", 1397], ["synuclein", 1398], ["inside", 1408], ["cells", 1415], [",", 1420], ["implicating", 1422], ["the", 1434], ["commonly", 1438], ["overlooked", 1447], ["aspect", 1458], ["of", 1465], ["macromolecular", 1468], ["crowding", 1483], ["as", 1492], ["a", 1495], ["possible", 1497], ["factor", 1506], ["in", 1513], ["the", 1516], ["etiology", 1520], ["of", 1529], ["Parkinson", 1532], ["'s", 1541], ["disease", 1544], [".", 1551]]}
{"context": "A novel Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II) inhibitor, KN-93 potently inhibits gastric acid secretion from parietal cells. As previously reported (1), treatment of parietal cells with a selective inhibitor of CaM kinase II, KN-62 resulted in the inhibition of cholinergic-stimulated rabbit parietal cell secretion, whereas it failed to inhibit the histamine and forskolin response. In contrast effects of carbachol, histamine and forskolin were significantly inhibited by KN-93 with an IC50 of 0.15, 0.3 and 1 microM, respectively; these effects occurred without any changes in intracellular cyclic AMP and Ca2+ levels. In the present study we investigated the mechanism by which KN-93 acts upon the acid-secreting machinery of gastric parietal cells. Neither redistribution of the proton pump activity nor the morphological transformation were affected by KN-93. The drug only weakly inhibited the H+, K(+)-ATPase activity but strongly dissipated the proton gradient formed in the gastric membrane vesicles and reduced the volume of luminal space. Thus KN-93 acts at pH gradient formation whereas KN-62 acts only at CaM Kinase II.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II", "CAMK2"], "qid": "b747f9b082a644009fdd2023df633b19", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "CaM kinase II", "token_spans": [[193, 195], [9, 11], [41, 43]], "char_spans": [[1141, 1153], [53, 65], [233, 245]]}]}], "context_tokens": [["A", 0], ["novel", 2], ["Ca2+/calmodulin", 8], ["-", 23], ["dependent", 24], ["protein", 34], ["kinase", 42], ["II", 49], ["(", 52], ["CaM", 53], ["Kinase", 57], ["II", 64], [")", 66], ["inhibitor", 68], [",", 77], ["KN-93", 79], ["potently", 85], ["inhibits", 94], ["gastric", 103], ["acid", 111], ["secretion", 116], ["from", 126], ["parietal", 131], ["cells", 140], [".", 145], ["As", 147], ["previously", 150], ["reported", 161], ["(", 170], ["1", 171], [")", 172], [",", 173], ["treatment", 175], ["of", 185], ["parietal", 188], ["cells", 197], ["with", 203], ["a", 208], ["selective", 210], ["inhibitor", 220], ["of", 230], ["CaM", 233], ["kinase", 237], ["II", 244], [",", 246], ["KN-62", 248], ["resulted", 254], ["in", 263], ["the", 266], ["inhibition", 270], ["of", 281], ["cholinergic", 284], ["-", 295], ["stimulated", 296], ["rabbit", 307], ["parietal", 314], ["cell", 323], ["secretion", 328], [",", 337], ["whereas", 339], ["it", 347], ["failed", 350], ["to", 357], ["inhibit", 360], ["the", 368], ["histamine", 372], ["and", 382], ["forskolin", 386], ["response", 396], [".", 404], ["In", 406], ["contrast", 409], ["effects", 418], ["of", 426], ["carbachol", 429], [",", 438], ["histamine", 440], ["and", 450], ["forskolin", 454], ["were", 464], ["significantly", 469], ["inhibited", 483], ["by", 493], ["KN-93", 496], ["with", 502], ["an", 507], ["IC50", 510], ["of", 515], ["0.15", 518], [",", 522], ["0.3", 524], ["and", 528], ["1", 532], ["microM", 534], [",", 540], ["respectively", 542], [";", 554], ["these", 556], ["effects", 562], ["occurred", 570], ["without", 579], ["any", 587], ["changes", 591], ["in", 599], ["intracellular", 602], ["cyclic", 616], ["AMP", 623], ["and", 627], ["Ca2", 631], ["+", 634], ["levels", 636], [".", 642], ["In", 644], ["the", 647], ["present", 651], ["study", 659], ["we", 665], ["investigated", 668], ["the", 681], ["mechanism", 685], ["by", 695], ["which", 698], ["KN-93", 704], ["acts", 710], ["upon", 715], ["the", 720], ["acid", 724], ["-", 728], ["secreting", 729], ["machinery", 739], ["of", 749], ["gastric", 752], ["parietal", 760], ["cells", 769], [".", 774], ["Neither", 776], ["redistribution", 784], ["of", 799], ["the", 802], ["proton", 806], ["pump", 813], ["activity", 818], ["nor", 827], ["the", 831], ["morphological", 835], ["transformation", 849], ["were", 864], ["affected", 869], ["by", 878], ["KN-93", 881], [".", 886], ["The", 888], ["drug", 892], ["only", 897], ["weakly", 902], ["inhibited", 909], ["the", 919], ["H+", 923], [",", 925], ["K(+)-ATPase", 927], ["activity", 939], ["but", 948], ["strongly", 952], ["dissipated", 961], ["the", 972], ["proton", 976], ["gradient", 983], ["formed", 992], ["in", 999], ["the", 1002], ["gastric", 1006], ["membrane", 1014], ["vesicles", 1023], ["and", 1032], ["reduced", 1036], ["the", 1044], ["volume", 1048], ["of", 1055], ["luminal", 1058], ["space", 1066], [".", 1071], ["Thus", 1073], ["KN-93", 1078], ["acts", 1084], ["at", 1089], ["pH", 1092], ["gradient", 1095], ["formation", 1104], ["whereas", 1114], ["KN-62", 1122], ["acts", 1128], ["only", 1133], ["at", 1138], ["CaM", 1141], ["Kinase", 1145], ["II", 1152], [".", 1154]]}
{"context": "Screening specimens were homogenised in saline 0.9% w/v before either direct inoculation or following enrichment in broth on three chromogenic media (MRSA-ID, CHROMagar MRSA and MRSA Select) and ORSAB medium for the detection of methicillin-resistant Staphylococcus aureus (MRSA). In total, 102 of 466 specimens yielded MRSA on at least one medium. After incubation for 16-18 h, the sensitivity was 51%, 59%, 47% and 65% on MRSA-ID, CHROMagar MRSA, ORSAB and MRSA Select, respectively, compared with 82%, 75%, 67% and 80%, respectively, after 42 h, and 93%, 95%, 79% and not tested, respectively, following broth enrichment. There were significantly more MRSA colonies on MRSA-Select after 16-18 h than on ORSAB or MRSA ID (p 0.001 and 0.0022, respectively), whereas there were more MRSA colonies after 42 h on MRSA-ID and MRSA-Select than on ORSAB (p 0.0004 and 0.012, respectively). The specificity of the media for identifying MRSA based on the colour of colonies after incubation for 16-18 h was 100%, 99%, 99% and 100%, respectively, compared with 98%, 97%, 98% and 98%, respectively, after 42 h, and 100%, 99%, 100% and not tested, respectively, following broth enrichment. The speed of detection (mean time to report a positive result) was 1.65, 1.72, 2.31 and 1.35 days, respectively. For each of the three media tested following enrichment, the use of an enrichment broth increased the detection rate of MRSA by 16-24%.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "026a270369604faaa147cd6e84abe86b", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[48, 48], [32, 32], [59, 59], [149, 149], [98, 98], [176, 176], [182, 182], [186, 186], [146, 146], [208, 208], [25, 25], [89, 89], [322, 322], [30, 30], [161, 161], [94, 94]], "char_spans": [[274, 277], [178, 181], [320, 323], [672, 675], [459, 462], [783, 786], [811, 814], [823, 826], [655, 658], [930, 933], [150, 153], [424, 427], [1413, 1416], [169, 172], [715, 718], [443, 446]]}]}], "context_tokens": [["Screening", 0], ["specimens", 10], ["were", 20], ["homogenised", 25], ["in", 37], ["saline", 40], ["0.9", 47], ["%", 50], ["w", 52], ["/", 53], ["v", 54], ["before", 56], ["either", 63], ["direct", 70], ["inoculation", 77], ["or", 89], ["following", 92], ["enrichment", 102], ["in", 113], ["broth", 116], ["on", 122], ["three", 125], ["chromogenic", 131], ["media", 143], ["(", 149], ["MRSA", 150], ["-", 154], ["ID", 155], [",", 157], ["CHROMagar", 159], ["MRSA", 169], ["and", 174], ["MRSA", 178], ["Select", 183], [")", 189], ["and", 191], ["ORSAB", 195], ["medium", 201], ["for", 208], ["the", 212], ["detection", 216], ["of", 226], ["methicillin", 229], ["-", 240], ["resistant", 241], ["Staphylococcus", 251], ["aureus", 266], ["(", 273], ["MRSA", 274], [")", 278], [".", 279], ["In", 281], ["total", 284], [",", 289], ["102", 291], ["of", 295], ["466", 298], ["specimens", 302], ["yielded", 312], ["MRSA", 320], ["on", 325], ["at", 328], ["least", 331], ["one", 337], ["medium", 341], [".", 347], ["After", 349], ["incubation", 355], ["for", 366], ["16", 370], ["-", 372], ["18", 373], ["h", 376], [",", 377], ["the", 379], ["sensitivity", 383], ["was", 395], ["51", 399], ["%", 401], [",", 402], ["59", 404], ["%", 406], [",", 407], ["47", 409], ["%", 411], ["and", 413], ["65", 417], ["%", 419], ["on", 421], ["MRSA", 424], ["-", 428], ["ID", 429], [",", 431], ["CHROMagar", 433], ["MRSA", 443], [",", 447], ["ORSAB", 449], ["and", 455], ["MRSA", 459], ["Select", 464], [",", 470], ["respectively", 472], [",", 484], ["compared", 486], ["with", 495], ["82", 500], ["%", 502], [",", 503], ["75", 505], ["%", 507], [",", 508], ["67", 510], ["%", 512], ["and", 514], ["80", 518], ["%", 520], [",", 521], ["respectively", 523], [",", 535], ["after", 537], ["42", 543], ["h", 546], [",", 547], ["and", 549], ["93", 553], ["%", 555], [",", 556], ["95", 558], ["%", 560], [",", 561], ["79", 563], ["%", 565], ["and", 567], ["not", 571], ["tested", 575], [",", 581], ["respectively", 583], [",", 595], ["following", 597], ["broth", 607], ["enrichment", 613], [".", 623], ["There", 625], ["were", 631], ["significantly", 636], ["more", 650], ["MRSA", 655], ["colonies", 660], ["on", 669], ["MRSA", 672], ["-", 676], ["Select", 677], ["after", 684], ["16", 690], ["-", 692], ["18", 693], ["h", 696], ["than", 698], ["on", 703], ["ORSAB", 706], ["or", 712], ["MRSA", 715], ["ID", 720], ["(", 723], ["p", 724], ["0.001", 726], ["and", 732], ["0.0022", 736], [",", 742], ["respectively", 744], [")", 756], [",", 757], ["whereas", 759], ["there", 767], ["were", 773], ["more", 778], ["MRSA", 783], ["colonies", 788], ["after", 797], ["42", 803], ["h", 806], ["on", 808], ["MRSA", 811], ["-", 815], ["ID", 816], ["and", 819], ["MRSA", 823], ["-", 827], ["Select", 828], ["than", 835], ["on", 840], ["ORSAB", 843], ["(", 849], ["p", 850], ["0.0004", 852], ["and", 859], ["0.012", 863], [",", 868], ["respectively", 870], [")", 882], [".", 883], ["The", 885], ["specificity", 889], ["of", 901], ["the", 904], ["media", 908], ["for", 914], ["identifying", 918], ["MRSA", 930], ["based", 935], ["on", 941], ["the", 944], ["colour", 948], ["of", 955], ["colonies", 958], ["after", 967], ["incubation", 973], ["for", 984], ["16", 988], ["-", 990], ["18", 991], ["h", 994], ["was", 996], ["100", 1000], ["%", 1003], [",", 1004], ["99", 1006], ["%", 1008], [",", 1009], ["99", 1011], ["%", 1013], ["and", 1015], ["100", 1019], ["%", 1022], [",", 1023], ["respectively", 1025], [",", 1037], ["compared", 1039], ["with", 1048], ["98", 1053], ["%", 1055], [",", 1056], ["97", 1058], ["%", 1060], [",", 1061], ["98", 1063], ["%", 1065], ["and", 1067], ["98", 1071], ["%", 1073], [",", 1074], ["respectively", 1076], [",", 1088], ["after", 1090], ["42", 1096], ["h", 1099], [",", 1100], ["and", 1102], ["100", 1106], ["%", 1109], [",", 1110], ["99", 1112], ["%", 1114], [",", 1115], ["100", 1117], ["%", 1120], ["and", 1122], ["not", 1126], ["tested", 1130], [",", 1136], ["respectively", 1138], [",", 1150], ["following", 1152], ["broth", 1162], ["enrichment", 1168], [".", 1178], ["The", 1180], ["speed", 1184], ["of", 1190], ["detection", 1193], ["(", 1203], ["mean", 1204], ["time", 1209], ["to", 1214], ["report", 1217], ["a", 1224], ["positive", 1226], ["result", 1235], [")", 1241], ["was", 1243], ["1.65", 1247], [",", 1251], ["1.72", 1253], [",", 1257], ["2.31", 1259], ["and", 1264], ["1.35", 1268], ["days", 1273], [",", 1277], ["respectively", 1279], [".", 1291], ["For", 1293], ["each", 1297], ["of", 1302], ["the", 1305], ["three", 1309], ["media", 1315], ["tested", 1321], ["following", 1328], ["enrichment", 1338], [",", 1348], ["the", 1350], ["use", 1354], ["of", 1358], ["an", 1361], ["enrichment", 1364], ["broth", 1375], ["increased", 1381], ["the", 1391], ["detection", 1395], ["rate", 1405], ["of", 1410], ["MRSA", 1413], ["by", 1418], ["16", 1421], ["-", 1423], ["24", 1424], ["%", 1426], [".", 1427]]}
{"context": "Untreated sleep disorders may contribute to secondary causes of uncontrolled hypertension, cardiovascular disease (CVD), and stroke. Restless legs syndrome, or Willis-Ekbom Disease (RLS/WED), is a common sensorimotor disorder with a circadian rhythmicity defined by an uncontrollable urge to move the legs that worsens during periods of inactivity or at rest in the evening, often resulting in sleep disruptions. Sleep disorders such as insomnia and obstructive sleep apnea (OSA) are established risk factors for increased risk of hypertension and vascular diseases. This literature review outlines the lessons learned from studies demonstrating insomnia and OSA as risk factors for hypertension and vascular diseases to support the epidemiologic and physiologic evidence suggesting a similar increase in hypertension and vascular disease risk due to RLS. Understanding the relationships between RLS and hypertension, CVD, and stroke has important implications for reducing the risks associated with these diseases.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "3117044f9a5c499699d0b54e0b238a5a", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[21, 23]], "char_spans": [[133, 154]]}]}], "context_tokens": [["Untreated", 0], ["sleep", 10], ["disorders", 16], ["may", 26], ["contribute", 30], ["to", 41], ["secondary", 44], ["causes", 54], ["of", 61], ["uncontrolled", 64], ["hypertension", 77], [",", 89], ["cardiovascular", 91], ["disease", 106], ["(", 114], ["CVD", 115], [")", 118], [",", 119], ["and", 121], ["stroke", 125], [".", 131], ["Restless", 133], ["legs", 142], ["syndrome", 147], [",", 155], ["or", 157], ["Willis", 160], ["-", 166], ["Ekbom", 167], ["Disease", 173], ["(", 181], ["RLS", 182], ["/", 185], ["WED", 186], [")", 189], [",", 190], ["is", 192], ["a", 195], ["common", 197], ["sensorimotor", 204], ["disorder", 217], ["with", 226], ["a", 231], ["circadian", 233], ["rhythmicity", 243], ["defined", 255], ["by", 263], ["an", 266], ["uncontrollable", 269], ["urge", 284], ["to", 289], ["move", 292], ["the", 297], ["legs", 301], ["that", 306], ["worsens", 311], ["during", 319], ["periods", 326], ["of", 334], ["inactivity", 337], ["or", 348], ["at", 351], ["rest", 354], ["in", 359], ["the", 362], ["evening", 366], [",", 373], ["often", 375], ["resulting", 381], ["in", 391], ["sleep", 394], ["disruptions", 400], [".", 411], ["Sleep", 413], ["disorders", 419], ["such", 429], ["as", 434], ["insomnia", 437], ["and", 446], ["obstructive", 450], ["sleep", 462], ["apnea", 468], ["(", 474], ["OSA", 475], [")", 478], ["are", 480], ["established", 484], ["risk", 496], ["factors", 501], ["for", 509], ["increased", 513], ["risk", 523], ["of", 528], ["hypertension", 531], ["and", 544], ["vascular", 548], ["diseases", 557], [".", 565], ["This", 567], ["literature", 572], ["review", 583], ["outlines", 590], ["the", 599], ["lessons", 603], ["learned", 611], ["from", 619], ["studies", 624], ["demonstrating", 632], ["insomnia", 646], ["and", 655], ["OSA", 659], ["as", 663], ["risk", 666], ["factors", 671], ["for", 679], ["hypertension", 683], ["and", 696], ["vascular", 700], ["diseases", 709], ["to", 718], ["support", 721], ["the", 729], ["epidemiologic", 733], ["and", 747], ["physiologic", 751], ["evidence", 763], ["suggesting", 772], ["a", 783], ["similar", 785], ["increase", 793], ["in", 802], ["hypertension", 805], ["and", 818], ["vascular", 822], ["disease", 831], ["risk", 839], ["due", 844], ["to", 848], ["RLS", 851], [".", 854], ["Understanding", 856], ["the", 870], ["relationships", 874], ["between", 888], ["RLS", 896], ["and", 900], ["hypertension", 904], [",", 916], ["CVD", 918], [",", 921], ["and", 923], ["stroke", 927], ["has", 934], ["important", 938], ["implications", 948], ["for", 961], ["reducing", 965], ["the", 974], ["risks", 978], ["associated", 984], ["with", 995], ["these", 1000], ["diseases", 1006], [".", 1014]]}
{"context": "Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal immune disorder characterized by uncontrolled lymphocyte- and macrophage-activation. The resulting hypercytokinemia and cell infiltration of organs lead to the clinical and laboratory features of HLH. Viral infections and other triggers can induce both, inherited and acquired forms of HLH. Disease-causing mutations in the genes encoding perforin (PRF1, FHL2), munc13-4 (UNC13D, FHL3), syntaxin 11 (STX11, FHL4), and munc18-2 (UNC18-2/STXBP2, FHL5) have been previously identified in Familial Hemophagocyic Lymphohistiocytosis (FHL), whereas mutation in RAB27A and LYST account for Griscelli syndome type 2 and Chediak-Higashi syndrome, respectively. These genes all encode proteins which are involved in the cytotoxic activity of lymphocytes. The inability of activated cytotoxic cells to clear antigen-presenting targets results in sustained immune stimulation, likely accounting for the unremitting polyclonal CD8 T-cell activation and hyperimmune reaction which characterizes FHL. Treatment of HLH consists of elimination of the trigger and immunosuppressive treatment in order to induce remission from the uncontrolled inflammation. Allogeneic hematopoietic stem cell transplantation can be indicated in the inherited forms of HLH.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "ec77a7e4587a4882bcd45d55cf28a629", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[122, 125]], "char_spans": [[676, 699]]}]}], "context_tokens": [["Hemophagocytic", 0], ["lymphohistiocytosis", 15], ["(", 35], ["HLH", 36], [")", 39], ["is", 41], ["a", 44], ["potentially", 46], ["fatal", 58], ["immune", 64], ["disorder", 71], ["characterized", 80], ["by", 94], ["uncontrolled", 97], ["lymphocyte-", 110], ["and", 122], ["macrophage", 126], ["-", 136], ["activation", 137], [".", 147], ["The", 149], ["resulting", 153], ["hypercytokinemia", 163], ["and", 180], ["cell", 184], ["infiltration", 189], ["of", 202], ["organs", 205], ["lead", 212], ["to", 217], ["the", 220], ["clinical", 224], ["and", 233], ["laboratory", 237], ["features", 248], ["of", 257], ["HLH", 260], [".", 263], ["Viral", 265], ["infections", 271], ["and", 282], ["other", 286], ["triggers", 292], ["can", 301], ["induce", 305], ["both", 312], [",", 316], ["inherited", 318], ["and", 328], ["acquired", 332], ["forms", 341], ["of", 347], ["HLH", 350], [".", 353], ["Disease", 355], ["-", 362], ["causing", 363], ["mutations", 371], ["in", 381], ["the", 384], ["genes", 388], ["encoding", 394], ["perforin", 403], ["(", 412], ["PRF1", 413], [",", 417], ["FHL2", 419], [")", 423], [",", 424], ["munc13", 426], ["-", 432], ["4", 433], ["(", 435], ["UNC13D", 436], [",", 442], ["FHL3", 444], [")", 448], [",", 449], ["syntaxin", 451], ["11", 460], ["(", 463], ["STX11", 464], [",", 469], ["FHL4", 471], [")", 475], [",", 476], ["and", 478], ["munc18", 482], ["-", 488], ["2", 489], ["(", 491], ["UNC18", 492], ["-", 497], ["2/STXBP2", 498], [",", 506], ["FHL5", 508], [")", 512], ["have", 514], ["been", 519], ["previously", 524], ["identified", 535], ["in", 546], ["Familial", 549], ["Hemophagocyic", 558], ["Lymphohistiocytosis", 572], ["(", 592], ["FHL", 593], [")", 596], [",", 597], ["whereas", 599], ["mutation", 607], ["in", 616], ["RAB27A", 619], ["and", 626], ["LYST", 630], ["account", 635], ["for", 643], ["Griscelli", 647], ["syndome", 657], ["type", 665], ["2", 670], ["and", 672], ["Chediak", 676], ["-", 683], ["Higashi", 684], ["syndrome", 692], [",", 700], ["respectively", 702], [".", 714], ["These", 716], ["genes", 722], ["all", 728], ["encode", 732], ["proteins", 739], ["which", 748], ["are", 754], ["involved", 758], ["in", 767], ["the", 770], ["cytotoxic", 774], ["activity", 784], ["of", 793], ["lymphocytes", 796], [".", 807], ["The", 809], ["inability", 813], ["of", 823], ["activated", 826], ["cytotoxic", 836], ["cells", 846], ["to", 852], ["clear", 855], ["antigen", 861], ["-", 868], ["presenting", 869], ["targets", 880], ["results", 888], ["in", 896], ["sustained", 899], ["immune", 909], ["stimulation", 916], [",", 927], ["likely", 929], ["accounting", 936], ["for", 947], ["the", 951], ["unremitting", 955], ["polyclonal", 967], ["CD8", 978], ["T", 982], ["-", 983], ["cell", 984], ["activation", 989], ["and", 1000], ["hyperimmune", 1004], ["reaction", 1016], ["which", 1025], ["characterizes", 1031], ["FHL", 1045], [".", 1048], ["Treatment", 1050], ["of", 1060], ["HLH", 1063], ["consists", 1067], ["of", 1076], ["elimination", 1079], ["of", 1091], ["the", 1094], ["trigger", 1098], ["and", 1106], ["immunosuppressive", 1110], ["treatment", 1128], ["in", 1138], ["order", 1141], ["to", 1147], ["induce", 1150], ["remission", 1157], ["from", 1167], ["the", 1172], ["uncontrolled", 1176], ["inflammation", 1189], [".", 1201], ["Allogeneic", 1203], ["hematopoietic", 1214], ["stem", 1228], ["cell", 1233], ["transplantation", 1238], ["can", 1254], ["be", 1258], ["indicated", 1261], ["in", 1271], ["the", 1274], ["inherited", 1278], ["forms", 1288], ["of", 1294], ["HLH", 1297], [".", 1300]]}
{"context": "The malaria vaccine candidate antigen RTS,S includes parts of the pre-erythrocytic stage circumsporozoite protein fused to the Hepatitis B surface antigen. Two Adjuvant Systems are in development for this vaccine, an oil-in water emulsion--based formulation (AS02) and a formulation based on liposomes (AS01). In this Phase II, double-blind study (NCT00307021), 180 healthy Gabonese children aged 18 months to 4 years were randomized to receive either RTS,S/AS01(E) or RTS,S/AS02(D), on a 0-1-2 month vaccination schedule. The children were followed-up daily for six days after each vaccination and monthly for 14 months. Blood samples were collected at 4 time-points. Both vaccines were well tolerated. Safety parameters were distributed similarly between the two groups. Both vaccines elicited a strong specific immune response after Doses 2 and 3 with a ratio of anti-CS GMT titers (AS02(D)/AS01(E)) of 0.88 (95% CI: 0.68-1.15) post-Dose 3. After Doses 2 and 3 of experimental vaccines, anti-CS and anti-HBs antibody GMTs were higher in children who had been previously vaccinated with at least one dose of hepatitis B vaccine compared to those not previously vaccinated. RTS,S/AS01(E) proved similarly as well tolerated and immunogenic as RTS,S/AS02(D), completing an essential step in the age de-escalation process within the RTS,S clinical development plan. ClinicalTrials.gov. NCT00307021.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "b3cdf347d3884750ab5f93ca7c8f1257", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[1, 1]], "char_spans": [[4, 10]]}]}], "context_tokens": [["The", 0], ["malaria", 4], ["vaccine", 12], ["candidate", 20], ["antigen", 30], ["RTS", 38], [",", 41], ["S", 42], ["includes", 44], ["parts", 53], ["of", 59], ["the", 62], ["pre", 66], ["-", 69], ["erythrocytic", 70], ["stage", 83], ["circumsporozoite", 89], ["protein", 106], ["fused", 114], ["to", 120], ["the", 123], ["Hepatitis", 127], ["B", 137], ["surface", 139], ["antigen", 147], [".", 154], ["Two", 156], ["Adjuvant", 160], ["Systems", 169], ["are", 177], ["in", 181], ["development", 184], ["for", 196], ["this", 200], ["vaccine", 205], [",", 212], ["an", 214], ["oil", 217], ["-", 220], ["in", 221], ["water", 224], ["emulsion", 230], ["--", 238], ["based", 240], ["formulation", 246], ["(", 258], ["AS02", 259], [")", 263], ["and", 265], ["a", 269], ["formulation", 271], ["based", 283], ["on", 289], ["liposomes", 292], ["(", 302], ["AS01", 303], [")", 307], [".", 308], ["In", 310], ["this", 313], ["Phase", 318], ["II", 324], [",", 326], ["double", 328], ["-", 334], ["blind", 335], ["study", 341], ["(", 347], ["NCT00307021", 348], [")", 359], [",", 360], ["180", 362], ["healthy", 366], ["Gabonese", 374], ["children", 383], ["aged", 392], ["18", 397], ["months", 400], ["to", 407], ["4", 410], ["years", 412], ["were", 418], ["randomized", 423], ["to", 434], ["receive", 437], ["either", 445], ["RTS", 452], [",", 455], ["S", 456], ["/", 457], ["AS01(E", 458], [")", 464], ["or", 466], ["RTS", 469], [",", 472], ["S", 473], ["/", 474], ["AS02(D", 475], [")", 481], [",", 482], ["on", 484], ["a", 487], ["0", 489], ["-", 490], ["1", 491], ["-", 492], ["2", 493], ["month", 495], ["vaccination", 501], ["schedule", 513], [".", 521], ["The", 523], ["children", 527], ["were", 536], ["followed", 541], ["-", 549], ["up", 550], ["daily", 553], ["for", 559], ["six", 563], ["days", 567], ["after", 572], ["each", 578], ["vaccination", 583], ["and", 595], ["monthly", 599], ["for", 607], ["14", 611], ["months", 614], [".", 620], ["Blood", 622], ["samples", 628], ["were", 636], ["collected", 641], ["at", 651], ["4", 654], ["time", 656], ["-", 660], ["points", 661], [".", 667], ["Both", 669], ["vaccines", 674], ["were", 683], ["well", 688], ["tolerated", 693], [".", 702], ["Safety", 704], ["parameters", 711], ["were", 722], ["distributed", 727], ["similarly", 739], ["between", 749], ["the", 757], ["two", 761], ["groups", 765], [".", 771], ["Both", 773], ["vaccines", 778], ["elicited", 787], ["a", 796], ["strong", 798], ["specific", 805], ["immune", 814], ["response", 821], ["after", 830], ["Doses", 836], ["2", 842], ["and", 844], ["3", 848], ["with", 850], ["a", 855], ["ratio", 857], ["of", 863], ["anti", 866], ["-", 870], ["CS", 871], ["GMT", 874], ["titers", 878], ["(", 885], ["AS02(D)/AS01(E", 886], [")", 900], [")", 901], ["of", 903], ["0.88", 906], ["(", 911], ["95", 912], ["%", 914], ["CI", 916], [":", 918], ["0.68", 920], ["-", 924], ["1.15", 925], [")", 929], ["post", 931], ["-", 935], ["Dose", 936], ["3", 941], [".", 942], ["After", 944], ["Doses", 950], ["2", 956], ["and", 958], ["3", 962], ["of", 964], ["experimental", 967], ["vaccines", 980], [",", 988], ["anti", 990], ["-", 994], ["CS", 995], ["and", 998], ["anti", 1002], ["-", 1006], ["HBs", 1007], ["antibody", 1011], ["GMTs", 1020], ["were", 1025], ["higher", 1030], ["in", 1037], ["children", 1040], ["who", 1049], ["had", 1053], ["been", 1057], ["previously", 1062], ["vaccinated", 1073], ["with", 1084], ["at", 1089], ["least", 1092], ["one", 1098], ["dose", 1102], ["of", 1107], ["hepatitis", 1110], ["B", 1120], ["vaccine", 1122], ["compared", 1130], ["to", 1139], ["those", 1142], ["not", 1148], ["previously", 1152], ["vaccinated", 1163], [".", 1173], ["RTS", 1175], [",", 1178], ["S", 1179], ["/", 1180], ["AS01(E", 1181], [")", 1187], ["proved", 1189], ["similarly", 1196], ["as", 1206], ["well", 1209], ["tolerated", 1214], ["and", 1224], ["immunogenic", 1228], ["as", 1240], ["RTS", 1243], [",", 1246], ["S", 1247], ["/", 1248], ["AS02(D", 1249], [")", 1255], [",", 1256], ["completing", 1258], ["an", 1269], ["essential", 1272], ["step", 1282], ["in", 1287], ["the", 1290], ["age", 1294], ["de", 1298], ["-", 1300], ["escalation", 1301], ["process", 1312], ["within", 1320], ["the", 1327], ["RTS", 1331], [",", 1334], ["S", 1335], ["clinical", 1337], ["development", 1346], ["plan", 1358], [".", 1362], ["ClinicalTrials.gov", 1364], [".", 1382], ["NCT00307021", 1384], [".", 1395]]}
{"context": "Centrioles are essential for the formation of cilia and flagella. They also form the core of the centrosome, which organizes microtubule arrays important for cell shape, polarity, motility and division. Here, we have used super-resolution 3D-structured illumination microscopy to analyse the spatial relationship of 18 centriole and pericentriolar matrix (PCM) components of human centrosomes at different cell cycle stages. During mitosis, PCM proteins formed extended networks with interspersed \u03b3-Tubulin. During interphase, most proteins were arranged at specific distances from the walls of centrioles, resulting in ring staining, often with discernible density masses. Through use of site-specific antibodies, we found the C-terminus of Cep152 to be closer to centrioles than the N-terminus, illustrating the power of 3D-SIM to study protein disposition. Appendage proteins showed rings with multiple density masses, and the number of these masses was strongly reduced during mitosis. At the proximal end of centrioles, Sas-6 formed a dot at the site of daughter centriole assembly, consistent with its role in cartwheel formation. Plk4 and STIL co-localized with Sas-6, but Cep135 was associated mostly with mother centrioles. Remarkably, Plk4 formed a dot on the surface of the mother centriole before Sas-6 staining became detectable, indicating that Plk4 constitutes an early marker for the site of nascent centriole formation. Our study provides novel insights into the architecture of human centrosomes and illustrates the power of super-resolution microscopy in revealing the relative localization of centriole and PCM proteins in unprecedented detail.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "9ac493dfeaa446d1b53b353bcedbf4eb", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[18, 18]], "char_spans": [[97, 106]]}]}], "context_tokens": [["Centrioles", 0], ["are", 11], ["essential", 15], ["for", 25], ["the", 29], ["formation", 33], ["of", 43], ["cilia", 46], ["and", 52], ["flagella", 56], [".", 64], ["They", 66], ["also", 71], ["form", 76], ["the", 81], ["core", 85], ["of", 90], ["the", 93], ["centrosome", 97], [",", 107], ["which", 109], ["organizes", 115], ["microtubule", 125], ["arrays", 137], ["important", 144], ["for", 154], ["cell", 158], ["shape", 163], [",", 168], ["polarity", 170], [",", 178], ["motility", 180], ["and", 189], ["division", 193], [".", 201], ["Here", 203], [",", 207], ["we", 209], ["have", 212], ["used", 217], ["super", 222], ["-", 227], ["resolution", 228], ["3D", 239], ["-", 241], ["structured", 242], ["illumination", 253], ["microscopy", 266], ["to", 277], ["analyse", 280], ["the", 288], ["spatial", 292], ["relationship", 300], ["of", 313], ["18", 316], ["centriole", 319], ["and", 329], ["pericentriolar", 333], ["matrix", 348], ["(", 355], ["PCM", 356], [")", 359], ["components", 361], ["of", 372], ["human", 375], ["centrosomes", 381], ["at", 393], ["different", 396], ["cell", 406], ["cycle", 411], ["stages", 417], [".", 423], ["During", 425], ["mitosis", 432], [",", 439], ["PCM", 441], ["proteins", 445], ["formed", 454], ["extended", 461], ["networks", 470], ["with", 479], ["interspersed", 484], ["\u03b3", 497], ["-", 498], ["Tubulin", 499], [".", 506], ["During", 508], ["interphase", 515], [",", 525], ["most", 527], ["proteins", 532], ["were", 541], ["arranged", 546], ["at", 555], ["specific", 558], ["distances", 567], ["from", 577], ["the", 582], ["walls", 586], ["of", 592], ["centrioles", 595], [",", 605], ["resulting", 607], ["in", 617], ["ring", 620], ["staining", 625], [",", 633], ["often", 635], ["with", 641], ["discernible", 646], ["density", 658], ["masses", 666], [".", 672], ["Through", 674], ["use", 682], ["of", 686], ["site", 689], ["-", 693], ["specific", 694], ["antibodies", 703], [",", 713], ["we", 715], ["found", 718], ["the", 724], ["C", 728], ["-", 729], ["terminus", 730], ["of", 739], ["Cep152", 742], ["to", 749], ["be", 752], ["closer", 755], ["to", 762], ["centrioles", 765], ["than", 776], ["the", 781], ["N", 785], ["-", 786], ["terminus", 787], [",", 795], ["illustrating", 797], ["the", 810], ["power", 814], ["of", 820], ["3D", 823], ["-", 825], ["SIM", 826], ["to", 830], ["study", 833], ["protein", 839], ["disposition", 847], [".", 858], ["Appendage", 860], ["proteins", 870], ["showed", 879], ["rings", 886], ["with", 892], ["multiple", 897], ["density", 906], ["masses", 914], [",", 920], ["and", 922], ["the", 926], ["number", 930], ["of", 937], ["these", 940], ["masses", 946], ["was", 953], ["strongly", 957], ["reduced", 966], ["during", 974], ["mitosis", 981], [".", 988], ["At", 990], ["the", 993], ["proximal", 997], ["end", 1006], ["of", 1010], ["centrioles", 1013], [",", 1023], ["Sas-6", 1025], ["formed", 1031], ["a", 1038], ["dot", 1040], ["at", 1044], ["the", 1047], ["site", 1051], ["of", 1056], ["daughter", 1059], ["centriole", 1068], ["assembly", 1078], [",", 1086], ["consistent", 1088], ["with", 1099], ["its", 1104], ["role", 1108], ["in", 1113], ["cartwheel", 1116], ["formation", 1126], [".", 1135], ["Plk4", 1137], ["and", 1142], ["STIL", 1146], ["co", 1151], ["-", 1153], ["localized", 1154], ["with", 1164], ["Sas-6", 1169], [",", 1174], ["but", 1176], ["Cep135", 1180], ["was", 1187], ["associated", 1191], ["mostly", 1202], ["with", 1209], ["mother", 1214], ["centrioles", 1221], [".", 1231], ["Remarkably", 1233], [",", 1243], ["Plk4", 1245], ["formed", 1250], ["a", 1257], ["dot", 1259], ["on", 1263], ["the", 1266], ["surface", 1270], ["of", 1278], ["the", 1281], ["mother", 1285], ["centriole", 1292], ["before", 1302], ["Sas-6", 1309], ["staining", 1315], ["became", 1324], ["detectable", 1331], [",", 1341], ["indicating", 1343], ["that", 1354], ["Plk4", 1359], ["constitutes", 1364], ["an", 1376], ["early", 1379], ["marker", 1385], ["for", 1392], ["the", 1396], ["site", 1400], ["of", 1405], ["nascent", 1408], ["centriole", 1416], ["formation", 1426], [".", 1435], ["Our", 1437], ["study", 1441], ["provides", 1447], ["novel", 1456], ["insights", 1462], ["into", 1471], ["the", 1476], ["architecture", 1480], ["of", 1493], ["human", 1496], ["centrosomes", 1502], ["and", 1514], ["illustrates", 1518], ["the", 1530], ["power", 1534], ["of", 1540], ["super", 1543], ["-", 1548], ["resolution", 1549], ["microscopy", 1560], ["in", 1571], ["revealing", 1574], ["the", 1584], ["relative", 1588], ["localization", 1597], ["of", 1610], ["centriole", 1613], ["and", 1623], ["PCM", 1627], ["proteins", 1631], ["in", 1640], ["unprecedented", 1643], ["detail", 1657], [".", 1663]]}
{"context": "Bazex syndrome (acrokeratosis paraneoplastica) is a rare paraneoplastic syndrome that usually occurs in males over 40 years old and is particularly associated with squamous cell carcinoma of the upper aerodigestive tract and adenopathy above the diaphragm. The objectives of our article are (1) to describe a unique case of acrokeratosis paraneoplastica and (2) to review the current literature regarding skin findings, commonly associated neoplasms, and treatment options relative to this condition. We describe a 68-year-old female with lobular breast carcinoma, complicated by local and distant recurrences, who presented with a 1-year history of prominent acral skin and nail changes. Our patient's clinical skin findings improved significantly following treatment and partial remission of her underlying malignancy. Our patient represents one of few females described with this syndrome, which is especially rare in association with lobular breast carcinoma. Further, the patient's presentation is unique as she was discovered to demonstrate laboratory findings consistent with coexistent porphyria cutanea tarda and relative zinc deficiency.", "qas": [{"question": "Name synonym of Acrokeratosis paraneoplastica.", "answers": ["Bazex syndrome"], "qid": "b5173fd9f31f44a4b8a0a7793cff9f0f", "question_tokens": [["Name", 0], ["synonym", 5], ["of", 13], ["Acrokeratosis", 16], ["paraneoplastica", 30], [".", 45]], "detected_answers": [{"text": "Bazex syndrome", "token_spans": [[0, 1]], "char_spans": [[0, 13]]}]}], "context_tokens": [["Bazex", 0], ["syndrome", 6], ["(", 15], ["acrokeratosis", 16], ["paraneoplastica", 30], [")", 45], ["is", 47], ["a", 50], ["rare", 52], ["paraneoplastic", 57], ["syndrome", 72], ["that", 81], ["usually", 86], ["occurs", 94], ["in", 101], ["males", 104], ["over", 110], ["40", 115], ["years", 118], ["old", 124], ["and", 128], ["is", 132], ["particularly", 135], ["associated", 148], ["with", 159], ["squamous", 164], ["cell", 173], ["carcinoma", 178], ["of", 188], ["the", 191], ["upper", 195], ["aerodigestive", 201], ["tract", 215], ["and", 221], ["adenopathy", 225], ["above", 236], ["the", 242], ["diaphragm", 246], [".", 255], ["The", 257], ["objectives", 261], ["of", 272], ["our", 275], ["article", 279], ["are", 287], ["(", 291], ["1", 292], [")", 293], ["to", 295], ["describe", 298], ["a", 307], ["unique", 309], ["case", 316], ["of", 321], ["acrokeratosis", 324], ["paraneoplastica", 338], ["and", 354], ["(", 358], ["2", 359], [")", 360], ["to", 362], ["review", 365], ["the", 372], ["current", 376], ["literature", 384], ["regarding", 395], ["skin", 405], ["findings", 410], [",", 418], ["commonly", 420], ["associated", 429], ["neoplasms", 440], [",", 449], ["and", 451], ["treatment", 455], ["options", 465], ["relative", 473], ["to", 482], ["this", 485], ["condition", 490], [".", 499], ["We", 501], ["describe", 504], ["a", 513], ["68-year", 515], ["-", 522], ["old", 523], ["female", 527], ["with", 534], ["lobular", 539], ["breast", 547], ["carcinoma", 554], [",", 563], ["complicated", 565], ["by", 577], ["local", 580], ["and", 586], ["distant", 590], ["recurrences", 598], [",", 609], ["who", 611], ["presented", 615], ["with", 625], ["a", 630], ["1-year", 632], ["history", 639], ["of", 647], ["prominent", 650], ["acral", 660], ["skin", 666], ["and", 671], ["nail", 675], ["changes", 680], [".", 687], ["Our", 689], ["patient", 693], ["'s", 700], ["clinical", 703], ["skin", 712], ["findings", 717], ["improved", 726], ["significantly", 735], ["following", 749], ["treatment", 759], ["and", 769], ["partial", 773], ["remission", 781], ["of", 791], ["her", 794], ["underlying", 798], ["malignancy", 809], [".", 819], ["Our", 821], ["patient", 825], ["represents", 833], ["one", 844], ["of", 848], ["few", 851], ["females", 855], ["described", 863], ["with", 873], ["this", 878], ["syndrome", 883], [",", 891], ["which", 893], ["is", 899], ["especially", 902], ["rare", 913], ["in", 918], ["association", 921], ["with", 933], ["lobular", 938], ["breast", 946], ["carcinoma", 953], [".", 962], ["Further", 964], [",", 971], ["the", 973], ["patient", 977], ["'s", 984], ["presentation", 987], ["is", 1000], ["unique", 1003], ["as", 1010], ["she", 1013], ["was", 1017], ["discovered", 1021], ["to", 1032], ["demonstrate", 1035], ["laboratory", 1047], ["findings", 1058], ["consistent", 1067], ["with", 1078], ["coexistent", 1083], ["porphyria", 1094], ["cutanea", 1104], ["tarda", 1112], ["and", 1118], ["relative", 1122], ["zinc", 1131], ["deficiency", 1136], [".", 1146]]}
{"context": "Upon oxygen shift-down, Mycobacterium tuberculosis complex bacteria can induce a genetic program characterized by halted duplication, which is called Non-replicating persistence (NRP). During this phase, at least 48 genes, collectively named Dormancy survival regulator (DosR) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions. It remains unclear whether expression of NRP genes occurs within the tissue of Mycobacterium bovis naturally infected cattle. In order to start dissecting this question, total RNA from bovine lymph node tissues of sacrificed tuberculin reacting animals was isolated and transcription of genes required for in\u00a0vivo duplication (esxB and fbpB) and in\u00a0vitro NRP (hspX, pfkB, and mb2660c) were analyzed by RT-PCR approaches. Detection of transcripts was positive in bovine tissue samples for genes hspX, pfkB, and mb2660c in 84, 32, and 21%, respectively. NRP genes were upregulated even in animals with a negative IFN-\u03b3 in\u00a0vitro test, and the expression of NRP genes occurred more often than expression of the esxB gene.", "qas": [{"question": "How many genes constitute the DosR regulon, controlled by the dormancy survival regulator (DosR) in Mycobacterium tuberculosis?", "answers": ["48 genes"], "qid": "34689931e2824bf58d7aa234d7a4eed3", "question_tokens": [["How", 0], ["many", 4], ["genes", 9], ["constitute", 15], ["the", 26], ["DosR", 30], ["regulon", 35], [",", 42], ["controlled", 44], ["by", 55], ["the", 58], ["dormancy", 62], ["survival", 71], ["regulator", 80], ["(", 90], ["DosR", 91], [")", 95], ["in", 97], ["Mycobacterium", 100], ["tuberculosis", 114], ["?", 126]], "detected_answers": [{"text": "48 genes", "token_spans": [[37, 38]], "char_spans": [[213, 220]]}]}], "context_tokens": [["Upon", 0], ["oxygen", 5], ["shift", 12], ["-", 17], ["down", 18], [",", 22], ["Mycobacterium", 24], ["tuberculosis", 38], ["complex", 51], ["bacteria", 59], ["can", 68], ["induce", 72], ["a", 79], ["genetic", 81], ["program", 89], ["characterized", 97], ["by", 111], ["halted", 114], ["duplication", 121], [",", 132], ["which", 134], ["is", 140], ["called", 143], ["Non", 150], ["-", 153], ["replicating", 154], ["persistence", 166], ["(", 178], ["NRP", 179], [")", 182], [".", 183], ["During", 185], ["this", 192], ["phase", 197], [",", 202], ["at", 204], ["least", 207], ["48", 213], ["genes", 216], [",", 221], ["collectively", 223], ["named", 236], ["Dormancy", 242], ["survival", 251], ["regulator", 260], ["(", 270], ["DosR", 271], [")", 275], ["regulon", 277], [",", 284], ["are", 286], ["important", 290], ["for", 300], ["the", 304], ["long", 308], ["-", 312], ["term", 313], ["survival", 318], ["of", 327], ["bacilli", 330], ["under", 338], ["a", 344], ["non", 346], ["-", 349], ["respiring", 350], ["state", 360], [",", 365], ["a", 367], ["condition", 369], ["that", 379], ["bacilli", 384], ["encounter", 392], ["inside", 402], ["granulomatous", 409], ["lesions", 423], [".", 430], ["It", 432], ["remains", 435], ["unclear", 443], ["whether", 451], ["expression", 459], ["of", 470], ["NRP", 473], ["genes", 477], ["occurs", 483], ["within", 490], ["the", 497], ["tissue", 501], ["of", 508], ["Mycobacterium", 511], ["bovis", 525], ["naturally", 531], ["infected", 541], ["cattle", 550], [".", 556], ["In", 558], ["order", 561], ["to", 567], ["start", 570], ["dissecting", 576], ["this", 587], ["question", 592], [",", 600], ["total", 602], ["RNA", 608], ["from", 612], ["bovine", 617], ["lymph", 624], ["node", 630], ["tissues", 635], ["of", 643], ["sacrificed", 646], ["tuberculin", 657], ["reacting", 668], ["animals", 677], ["was", 685], ["isolated", 689], ["and", 698], ["transcription", 702], ["of", 716], ["genes", 719], ["required", 725], ["for", 734], ["in", 738], ["vivo", 741], ["duplication", 746], ["(", 758], ["esxB", 759], ["and", 764], ["fbpB", 768], [")", 772], ["and", 774], ["in", 778], ["vitro", 781], ["NRP", 787], ["(", 791], ["hspX", 792], [",", 796], ["pfkB", 798], [",", 802], ["and", 804], ["mb2660c", 808], [")", 815], ["were", 817], ["analyzed", 822], ["by", 831], ["RT", 834], ["-", 836], ["PCR", 837], ["approaches", 841], [".", 851], ["Detection", 853], ["of", 863], ["transcripts", 866], ["was", 878], ["positive", 882], ["in", 891], ["bovine", 894], ["tissue", 901], ["samples", 908], ["for", 916], ["genes", 920], ["hspX", 926], [",", 930], ["pfkB", 932], [",", 936], ["and", 938], ["mb2660c", 942], ["in", 950], ["84", 953], [",", 955], ["32", 957], [",", 959], ["and", 961], ["21", 965], ["%", 967], [",", 968], ["respectively", 970], [".", 982], ["NRP", 984], ["genes", 988], ["were", 994], ["upregulated", 999], ["even", 1011], ["in", 1016], ["animals", 1019], ["with", 1027], ["a", 1032], ["negative", 1034], ["IFN", 1043], ["-", 1046], ["\u03b3", 1047], ["in", 1049], ["vitro", 1052], ["test", 1058], [",", 1062], ["and", 1064], ["the", 1068], ["expression", 1072], ["of", 1083], ["NRP", 1086], ["genes", 1090], ["occurred", 1096], ["more", 1105], ["often", 1110], ["than", 1116], ["expression", 1121], ["of", 1132], ["the", 1135], ["esxB", 1139], ["gene", 1144], [".", 1148]]}
{"context": "Centrosomes are composed of a centriole pair surrounded by an intricate proteinaceous matrix referred to as pericentriolar material. Although the mechanisms underpinning the control of centriole duplication are now well understood, we know relatively little about the control of centrosome size and shape. Here we used interaction proteomics to identify the E3 ligase HERC2 and the neuralized homologue NEURL4 as novel interaction partners of the centrosomal protein CP110. Using high resolution imaging, we find that HERC2 and NEURL4 localize to the centrosome and that interfering with their function alters centrosome morphology through the appearance of aberrant filamentous structures that stain for a subset of pericentriolar material proteins including pericentrin and CEP135. Using an RNA interference-resistant transgene approach in combination with structure-function analyses, we show that the association between CP110 and HERC2 depends on nonoverlapping regions of NEURL4. Whereas CP110 binding to NEURL4 is dispensable for the regulation of pericentriolar material architecture, its association with HERC2 is required to maintain normal centrosome integrity. NEURL4 is a substrate of HERC2, and together these results indicate that the NEURL4-HERC2 complex participates in the ubiquitin-dependent regulation of centrosome architecture.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "edb15e5cd3594668933fa0a9f6c83206", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[173, 173], [86, 86], [41, 41], [200, 200], [94, 94]], "char_spans": [[1151, 1160], [551, 560], [279, 288], [1325, 1334], [610, 619]]}]}], "context_tokens": [["Centrosomes", 0], ["are", 12], ["composed", 16], ["of", 25], ["a", 28], ["centriole", 30], ["pair", 40], ["surrounded", 45], ["by", 56], ["an", 59], ["intricate", 62], ["proteinaceous", 72], ["matrix", 86], ["referred", 93], ["to", 102], ["as", 105], ["pericentriolar", 108], ["material", 123], [".", 131], ["Although", 133], ["the", 142], ["mechanisms", 146], ["underpinning", 157], ["the", 170], ["control", 174], ["of", 182], ["centriole", 185], ["duplication", 195], ["are", 207], ["now", 211], ["well", 215], ["understood", 220], [",", 230], ["we", 232], ["know", 235], ["relatively", 240], ["little", 251], ["about", 258], ["the", 264], ["control", 268], ["of", 276], ["centrosome", 279], ["size", 290], ["and", 295], ["shape", 299], [".", 304], ["Here", 306], ["we", 311], ["used", 314], ["interaction", 319], ["proteomics", 331], ["to", 342], ["identify", 345], ["the", 354], ["E3", 358], ["ligase", 361], ["HERC2", 368], ["and", 374], ["the", 378], ["neuralized", 382], ["homologue", 393], ["NEURL4", 403], ["as", 410], ["novel", 413], ["interaction", 419], ["partners", 431], ["of", 440], ["the", 443], ["centrosomal", 447], ["protein", 459], ["CP110", 467], [".", 472], ["Using", 474], ["high", 480], ["resolution", 485], ["imaging", 496], [",", 503], ["we", 505], ["find", 508], ["that", 513], ["HERC2", 518], ["and", 524], ["NEURL4", 528], ["localize", 535], ["to", 544], ["the", 547], ["centrosome", 551], ["and", 562], ["that", 566], ["interfering", 571], ["with", 583], ["their", 588], ["function", 594], ["alters", 603], ["centrosome", 610], ["morphology", 621], ["through", 632], ["the", 640], ["appearance", 644], ["of", 655], ["aberrant", 658], ["filamentous", 667], ["structures", 679], ["that", 690], ["stain", 695], ["for", 701], ["a", 705], ["subset", 707], ["of", 714], ["pericentriolar", 717], ["material", 732], ["proteins", 741], ["including", 750], ["pericentrin", 760], ["and", 772], ["CEP135", 776], [".", 782], ["Using", 784], ["an", 790], ["RNA", 793], ["interference", 797], ["-", 809], ["resistant", 810], ["transgene", 820], ["approach", 830], ["in", 839], ["combination", 842], ["with", 854], ["structure", 859], ["-", 868], ["function", 869], ["analyses", 878], [",", 886], ["we", 888], ["show", 891], ["that", 896], ["the", 901], ["association", 905], ["between", 917], ["CP110", 925], ["and", 931], ["HERC2", 935], ["depends", 941], ["on", 949], ["nonoverlapping", 952], ["regions", 967], ["of", 975], ["NEURL4", 978], [".", 984], ["Whereas", 986], ["CP110", 994], ["binding", 1000], ["to", 1008], ["NEURL4", 1011], ["is", 1018], ["dispensable", 1021], ["for", 1033], ["the", 1037], ["regulation", 1041], ["of", 1052], ["pericentriolar", 1055], ["material", 1070], ["architecture", 1079], [",", 1091], ["its", 1093], ["association", 1097], ["with", 1109], ["HERC2", 1114], ["is", 1120], ["required", 1123], ["to", 1132], ["maintain", 1135], ["normal", 1144], ["centrosome", 1151], ["integrity", 1162], [".", 1171], ["NEURL4", 1173], ["is", 1180], ["a", 1183], ["substrate", 1185], ["of", 1195], ["HERC2", 1198], [",", 1203], ["and", 1205], ["together", 1209], ["these", 1218], ["results", 1224], ["indicate", 1232], ["that", 1241], ["the", 1246], ["NEURL4-HERC2", 1250], ["complex", 1263], ["participates", 1271], ["in", 1284], ["the", 1287], ["ubiquitin", 1291], ["-", 1300], ["dependent", 1301], ["regulation", 1311], ["of", 1322], ["centrosome", 1325], ["architecture", 1336], [".", 1348]]}
{"context": "The Ehlers-Danlos syndrome (EDS) comprises a group of hereditary connective tissue disorders. Periventricular nodular heterotopia (PNH) is a human neuronal migration disorder characterised by seizures and conglomerates of neural cells around the lateral ventricles of the brain, caused by FLNA mutations. FLNA encodes filamin A, an actin binding protein involved in cytoskeletal organisation. The amino-terminal actin binding domain (ABD) of filamins contains two tandem calponin homology domains, CHD1 and CHD2. To report clinical and genetic analyses in a Spanish family affected by a connective tissue disorder suggestive of EDS type III and PNH. A clinical and molecular study was undertaken in the three affected women. Clinical histories, physical and neurological examinations, brain magnetic resonance imaging studies, and skin biopsies were done. Genetic analysis of the FLNA gene was undertaken by direct sequencing and restriction fragment length polymorphism analysis. Mutation analysis of the FLNA gene resulted in the identification of a novel mutation in exon 3 (c.383C-->T) segregating with the combination of both syndromes. This mutation results in a substitution of an alanine residue (A128V) in CHD1. The findings suggest that the Ala128Val mutation causes the dual EDS-PNH phenotype. This association constitutes a new variant within the EDS spectrum. This is the first description of a familial EDS-PNH association with a mutation in FLNA.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "684689885e4249239d6a8040baf14481", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14], [100, 101]], "char_spans": [[65, 81], [587, 603]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["(", 27], ["EDS", 28], [")", 31], ["comprises", 33], ["a", 43], ["group", 45], ["of", 51], ["hereditary", 54], ["connective", 65], ["tissue", 76], ["disorders", 83], [".", 92], ["Periventricular", 94], ["nodular", 110], ["heterotopia", 118], ["(", 130], ["PNH", 131], [")", 134], ["is", 136], ["a", 139], ["human", 141], ["neuronal", 147], ["migration", 156], ["disorder", 166], ["characterised", 175], ["by", 189], ["seizures", 192], ["and", 201], ["conglomerates", 205], ["of", 219], ["neural", 222], ["cells", 229], ["around", 235], ["the", 242], ["lateral", 246], ["ventricles", 254], ["of", 265], ["the", 268], ["brain", 272], [",", 277], ["caused", 279], ["by", 286], ["FLNA", 289], ["mutations", 294], [".", 303], ["FLNA", 305], ["encodes", 310], ["filamin", 318], ["A", 326], [",", 327], ["an", 329], ["actin", 332], ["binding", 338], ["protein", 346], ["involved", 354], ["in", 363], ["cytoskeletal", 366], ["organisation", 379], [".", 391], ["The", 393], ["amino", 397], ["-", 402], ["terminal", 403], ["actin", 412], ["binding", 418], ["domain", 426], ["(", 433], ["ABD", 434], [")", 437], ["of", 439], ["filamins", 442], ["contains", 451], ["two", 460], ["tandem", 464], ["calponin", 471], ["homology", 480], ["domains", 489], [",", 496], ["CHD1", 498], ["and", 503], ["CHD2", 507], [".", 511], ["To", 513], ["report", 516], ["clinical", 523], ["and", 532], ["genetic", 536], ["analyses", 544], ["in", 553], ["a", 556], ["Spanish", 558], ["family", 566], ["affected", 573], ["by", 582], ["a", 585], ["connective", 587], ["tissue", 598], ["disorder", 605], ["suggestive", 614], ["of", 625], ["EDS", 628], ["type", 632], ["III", 637], ["and", 641], ["PNH", 645], [".", 648], ["A", 650], ["clinical", 652], ["and", 661], ["molecular", 665], ["study", 675], ["was", 681], ["undertaken", 685], ["in", 696], ["the", 699], ["three", 703], ["affected", 709], ["women", 718], [".", 723], ["Clinical", 725], ["histories", 734], [",", 743], ["physical", 745], ["and", 754], ["neurological", 758], ["examinations", 771], [",", 783], ["brain", 785], ["magnetic", 791], ["resonance", 800], ["imaging", 810], ["studies", 818], [",", 825], ["and", 827], ["skin", 831], ["biopsies", 836], ["were", 845], ["done", 850], [".", 854], ["Genetic", 856], ["analysis", 864], ["of", 873], ["the", 876], ["FLNA", 880], ["gene", 885], ["was", 890], ["undertaken", 894], ["by", 905], ["direct", 908], ["sequencing", 915], ["and", 926], ["restriction", 930], ["fragment", 942], ["length", 951], ["polymorphism", 958], ["analysis", 971], [".", 979], ["Mutation", 981], ["analysis", 990], ["of", 999], ["the", 1002], ["FLNA", 1006], ["gene", 1011], ["resulted", 1016], ["in", 1025], ["the", 1028], ["identification", 1032], ["of", 1047], ["a", 1050], ["novel", 1052], ["mutation", 1058], ["in", 1067], ["exon", 1070], ["3", 1075], ["(", 1077], ["c.383C-->T", 1078], [")", 1088], ["segregating", 1090], ["with", 1102], ["the", 1107], ["combination", 1111], ["of", 1123], ["both", 1126], ["syndromes", 1131], [".", 1140], ["This", 1142], ["mutation", 1147], ["results", 1156], ["in", 1164], ["a", 1167], ["substitution", 1169], ["of", 1182], ["an", 1185], ["alanine", 1188], ["residue", 1196], ["(", 1204], ["A128V", 1205], [")", 1210], ["in", 1212], ["CHD1", 1215], [".", 1219], ["The", 1221], ["findings", 1225], ["suggest", 1234], ["that", 1242], ["the", 1247], ["Ala128Val", 1251], ["mutation", 1261], ["causes", 1270], ["the", 1277], ["dual", 1281], ["EDS", 1286], ["-", 1289], ["PNH", 1290], ["phenotype", 1294], [".", 1303], ["This", 1305], ["association", 1310], ["constitutes", 1322], ["a", 1334], ["new", 1336], ["variant", 1340], ["within", 1348], ["the", 1355], ["EDS", 1359], ["spectrum", 1363], [".", 1371], ["This", 1373], ["is", 1378], ["the", 1381], ["first", 1385], ["description", 1391], ["of", 1403], ["a", 1406], ["familial", 1408], ["EDS", 1417], ["-", 1420], ["PNH", 1421], ["association", 1425], ["with", 1437], ["a", 1442], ["mutation", 1444], ["in", 1453], ["FLNA", 1456], [".", 1460]]}
{"context": "The SP790 study (ClinicalTrials.gov, NCT00136045) showed benefits of rotigotine over placebo in improving symptom severity of restless legs syndrome (RLS), also known as Willis-Ekbom disease, on the International Restless Legs Syndrome Study Group rating scale (IRLS), Clinical Global Impression item 1 (CGI-1), RLS 6-item questionnaire (RLS-6), and the RLS-quality of life questionnaire (RLS-QoL) in patients with moderate to severe idiopathic RLS. To provide clinical context for the IRLS and to guide the choice of assessment scales for RLS studies, our post hoc analysis of SP790 data evaluated associations between the IRLS and the CGI-1, IRLS and RLS-6, and the IRLS and RLS-QoL. Scale associations were analyzed at baseline and at the end of maintenance (EoM) using data from the safety set (rotigotine and placebo groups combined [n=458]). Changes from baseline to EoM in IRLS score vs comparator scale scores also were analyzed. There was a trend towards increasing IRLS severity category with increasing CGI-1, RLS-6, and RLS-QoL score. Pearson product moment correlation coefficients showed correlations between IRLS and comparator scale scores at baseline and EoM as well as correlations for change from baseline to EoM. Correlations between the IRLS and comparator scales were substantial. These data indicate that the IRLS is clinically meaningful. The IRLS and CGI-1 are generally sufficient to evaluate the overall severity and impact of RLS symptoms in clinical trials.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "ad2342b8121d4fafa653d33df74f5afc", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[37, 39], [19, 21]], "char_spans": [[213, 234], [126, 147]]}]}], "context_tokens": [["The", 0], ["SP790", 4], ["study", 10], ["(", 16], ["ClinicalTrials.gov", 17], [",", 35], ["NCT00136045", 37], [")", 48], ["showed", 50], ["benefits", 57], ["of", 66], ["rotigotine", 69], ["over", 80], ["placebo", 85], ["in", 93], ["improving", 96], ["symptom", 106], ["severity", 114], ["of", 123], ["restless", 126], ["legs", 135], ["syndrome", 140], ["(", 149], ["RLS", 150], [")", 153], [",", 154], ["also", 156], ["known", 161], ["as", 167], ["Willis", 170], ["-", 176], ["Ekbom", 177], ["disease", 183], [",", 190], ["on", 192], ["the", 195], ["International", 199], ["Restless", 213], ["Legs", 222], ["Syndrome", 227], ["Study", 236], ["Group", 242], ["rating", 248], ["scale", 255], ["(", 261], ["IRLS", 262], [")", 266], [",", 267], ["Clinical", 269], ["Global", 278], ["Impression", 285], ["item", 296], ["1", 301], ["(", 303], ["CGI-1", 304], [")", 309], [",", 310], ["RLS", 312], ["6-item", 316], ["questionnaire", 323], ["(", 337], ["RLS-6", 338], [")", 343], [",", 344], ["and", 346], ["the", 350], ["RLS", 354], ["-", 357], ["quality", 358], ["of", 366], ["life", 369], ["questionnaire", 374], ["(", 388], ["RLS", 389], ["-", 392], ["QoL", 393], [")", 396], ["in", 398], ["patients", 401], ["with", 410], ["moderate", 415], ["to", 424], ["severe", 427], ["idiopathic", 434], ["RLS", 445], [".", 448], ["To", 450], ["provide", 453], ["clinical", 461], ["context", 470], ["for", 478], ["the", 482], ["IRLS", 486], ["and", 491], ["to", 495], ["guide", 498], ["the", 504], ["choice", 508], ["of", 515], ["assessment", 518], ["scales", 529], ["for", 536], ["RLS", 540], ["studies", 544], [",", 551], ["our", 553], ["post", 557], ["hoc", 562], ["analysis", 566], ["of", 575], ["SP790", 578], ["data", 584], ["evaluated", 589], ["associations", 599], ["between", 612], ["the", 620], ["IRLS", 624], ["and", 629], ["the", 633], ["CGI-1", 637], [",", 642], ["IRLS", 644], ["and", 649], ["RLS-6", 653], [",", 658], ["and", 660], ["the", 664], ["IRLS", 668], ["and", 673], ["RLS", 677], ["-", 680], ["QoL.", 681], ["Scale", 686], ["associations", 692], ["were", 705], ["analyzed", 710], ["at", 719], ["baseline", 722], ["and", 731], ["at", 735], ["the", 738], ["end", 742], ["of", 746], ["maintenance", 749], ["(", 761], ["EoM", 762], [")", 765], ["using", 767], ["data", 773], ["from", 778], ["the", 783], ["safety", 787], ["set", 794], ["(", 798], ["rotigotine", 799], ["and", 810], ["placebo", 814], ["groups", 822], ["combined", 829], ["[", 838], ["n=458", 839], ["]", 844], [")", 845], [".", 846], ["Changes", 848], ["from", 856], ["baseline", 861], ["to", 870], ["EoM", 873], ["in", 877], ["IRLS", 880], ["score", 885], ["vs", 891], ["comparator", 894], ["scale", 905], ["scores", 911], ["also", 918], ["were", 923], ["analyzed", 928], [".", 936], ["There", 938], ["was", 944], ["a", 948], ["trend", 950], ["towards", 956], ["increasing", 964], ["IRLS", 975], ["severity", 980], ["category", 989], ["with", 998], ["increasing", 1003], ["CGI-1", 1014], [",", 1019], ["RLS-6", 1021], [",", 1026], ["and", 1028], ["RLS", 1032], ["-", 1035], ["QoL", 1036], ["score", 1040], [".", 1045], ["Pearson", 1047], ["product", 1055], ["moment", 1063], ["correlation", 1070], ["coefficients", 1082], ["showed", 1095], ["correlations", 1102], ["between", 1115], ["IRLS", 1123], ["and", 1128], ["comparator", 1132], ["scale", 1143], ["scores", 1149], ["at", 1156], ["baseline", 1159], ["and", 1168], ["EoM", 1172], ["as", 1176], ["well", 1179], ["as", 1184], ["correlations", 1187], ["for", 1200], ["change", 1204], ["from", 1211], ["baseline", 1216], ["to", 1225], ["EoM.", 1228], ["Correlations", 1233], ["between", 1246], ["the", 1254], ["IRLS", 1258], ["and", 1263], ["comparator", 1267], ["scales", 1278], ["were", 1285], ["substantial", 1290], [".", 1301], ["These", 1303], ["data", 1309], ["indicate", 1314], ["that", 1323], ["the", 1328], ["IRLS", 1332], ["is", 1337], ["clinically", 1340], ["meaningful", 1351], [".", 1361], ["The", 1363], ["IRLS", 1367], ["and", 1372], ["CGI-1", 1376], ["are", 1382], ["generally", 1386], ["sufficient", 1396], ["to", 1407], ["evaluate", 1410], ["the", 1419], ["overall", 1423], ["severity", 1431], ["and", 1440], ["impact", 1444], ["of", 1451], ["RLS", 1454], ["symptoms", 1458], ["in", 1467], ["clinical", 1470], ["trials", 1479], [".", 1485]]}
{"context": "Interstitial deletions of chromosome band Xq26.3 are rare. We report on a 2-year-old boy in whom array comparative genomic hybridization analysis revealed an interstitial 314 kb deletion in Xq26.3 affecting SLC9A6 and FHL1. Mutations in SLC9A6 are associated with Christianson syndrome (OMIM 300243), a syndromic form of X-linked mental retardation (XLMR) characterized by microcephaly, severe global developmental delay, ataxia and seizures. FHL1 mutations cause Emery-Dreifuss muscular dystrophy (OMIM 310300), X-linked myopathy with postural muscle atrophy (XMPMA, OMIM 300696), scapuloperoneal myopathy (OMIM 300695), or reducing body myopathy (OMIM 300717, 300718). The clinical problems of the patient reported here comprised severe intellectual disability, absent speech, ataxia, epilepsy, and gastroesophageal reflux, and could mostly be attributed to SLC9A6 insufficiency. In contrast to the majority of reported Christianson syndrome patients who were microcephalic, this patient was normocephalic, but his head circumference had decelerated from the 50th centile at birth to the 25th centile at the age of 2 \u00b2/\u00b9\u00b2 years. Muscle problems due to the FHL1 deletion are not to be expected before late childhood, which is the earliest age of onset for FHL1 associated Emery-Dreifuss muscular dystrophy. This patient broadens the spectrum of SLC9A6 mutations and contributes to the clinical delineation of Christianson syndrome. This is also the first patient with a deletion affecting both SLC9A6 and the complete FHL1 gene.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "66ed19703ab9429588260046aacc2ac1", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[235, 235], [151, 151], [39, 39], [258, 258], [33, 33]], "char_spans": [[1346, 1351], [860, 865], [237, 242], [1495, 1500], [207, 212]]}]}], "context_tokens": [["Interstitial", 0], ["deletions", 13], ["of", 23], ["chromosome", 26], ["band", 37], ["Xq26.3", 42], ["are", 49], ["rare", 53], [".", 57], ["We", 59], ["report", 62], ["on", 69], ["a", 72], ["2-year", 74], ["-", 80], ["old", 81], ["boy", 85], ["in", 89], ["whom", 92], ["array", 97], ["comparative", 103], ["genomic", 115], ["hybridization", 123], ["analysis", 137], ["revealed", 146], ["an", 155], ["interstitial", 158], ["314", 171], ["kb", 175], ["deletion", 178], ["in", 187], ["Xq26.3", 190], ["affecting", 197], ["SLC9A6", 207], ["and", 214], ["FHL1", 218], [".", 222], ["Mutations", 224], ["in", 234], ["SLC9A6", 237], ["are", 244], ["associated", 248], ["with", 259], ["Christianson", 264], ["syndrome", 277], ["(", 286], ["OMIM", 287], ["300243", 292], [")", 298], [",", 299], ["a", 301], ["syndromic", 303], ["form", 313], ["of", 318], ["X", 321], ["-", 322], ["linked", 323], ["mental", 330], ["retardation", 337], ["(", 349], ["XLMR", 350], [")", 354], ["characterized", 356], ["by", 370], ["microcephaly", 373], [",", 385], ["severe", 387], ["global", 394], ["developmental", 401], ["delay", 415], [",", 420], ["ataxia", 422], ["and", 429], ["seizures", 433], [".", 441], ["FHL1", 443], ["mutations", 448], ["cause", 458], ["Emery", 464], ["-", 469], ["Dreifuss", 470], ["muscular", 479], ["dystrophy", 488], ["(", 498], ["OMIM", 499], ["310300", 504], [")", 510], [",", 511], ["X", 513], ["-", 514], ["linked", 515], ["myopathy", 522], ["with", 531], ["postural", 536], ["muscle", 545], ["atrophy", 552], ["(", 560], ["XMPMA", 561], [",", 566], ["OMIM", 568], ["300696", 573], [")", 579], [",", 580], ["scapuloperoneal", 582], ["myopathy", 598], ["(", 607], ["OMIM", 608], ["300695", 613], [")", 619], [",", 620], ["or", 622], ["reducing", 625], ["body", 634], ["myopathy", 639], ["(", 648], ["OMIM", 649], ["300717", 654], [",", 660], ["300718", 662], [")", 668], [".", 669], ["The", 671], ["clinical", 675], ["problems", 684], ["of", 693], ["the", 696], ["patient", 700], ["reported", 708], ["here", 717], ["comprised", 722], ["severe", 732], ["intellectual", 739], ["disability", 752], [",", 762], ["absent", 764], ["speech", 771], [",", 777], ["ataxia", 779], [",", 785], ["epilepsy", 787], [",", 795], ["and", 797], ["gastroesophageal", 801], ["reflux", 818], [",", 824], ["and", 826], ["could", 830], ["mostly", 836], ["be", 843], ["attributed", 846], ["to", 857], ["SLC9A6", 860], ["insufficiency", 867], [".", 880], ["In", 882], ["contrast", 885], ["to", 894], ["the", 897], ["majority", 901], ["of", 910], ["reported", 913], ["Christianson", 922], ["syndrome", 935], ["patients", 944], ["who", 953], ["were", 957], ["microcephalic", 962], [",", 975], ["this", 977], ["patient", 982], ["was", 990], ["normocephalic", 994], [",", 1007], ["but", 1009], ["his", 1013], ["head", 1017], ["circumference", 1022], ["had", 1036], ["decelerated", 1040], ["from", 1052], ["the", 1057], ["50th", 1061], ["centile", 1066], ["at", 1074], ["birth", 1077], ["to", 1083], ["the", 1086], ["25th", 1090], ["centile", 1095], ["at", 1103], ["the", 1106], ["age", 1110], ["of", 1114], ["2", 1117], ["\u00b2/\u00b9\u00b2", 1119], ["years", 1124], [".", 1129], ["Muscle", 1131], ["problems", 1138], ["due", 1147], ["to", 1151], ["the", 1154], ["FHL1", 1158], ["deletion", 1163], ["are", 1172], ["not", 1176], ["to", 1180], ["be", 1183], ["expected", 1186], ["before", 1195], ["late", 1202], ["childhood", 1207], [",", 1216], ["which", 1218], ["is", 1224], ["the", 1227], ["earliest", 1231], ["age", 1240], ["of", 1244], ["onset", 1247], ["for", 1253], ["FHL1", 1257], ["associated", 1262], ["Emery", 1273], ["-", 1278], ["Dreifuss", 1279], ["muscular", 1288], ["dystrophy", 1297], [".", 1306], ["This", 1308], ["patient", 1313], ["broadens", 1321], ["the", 1330], ["spectrum", 1334], ["of", 1343], ["SLC9A6", 1346], ["mutations", 1353], ["and", 1363], ["contributes", 1367], ["to", 1379], ["the", 1382], ["clinical", 1386], ["delineation", 1395], ["of", 1407], ["Christianson", 1410], ["syndrome", 1423], [".", 1431], ["This", 1433], ["is", 1438], ["also", 1441], ["the", 1446], ["first", 1450], ["patient", 1456], ["with", 1464], ["a", 1469], ["deletion", 1471], ["affecting", 1480], ["both", 1490], ["SLC9A6", 1495], ["and", 1502], ["the", 1506], ["complete", 1510], ["FHL1", 1519], ["gene", 1524], [".", 1528]]}
{"context": "To investigate whether the effects of nerve growth factor (NGF) inhibition with tanezumab on rats with medial meniscal tear (MMT) effectively model rapidly progressive osteoarthritis (RPOA) observed in clinical trials. Male Lewis rats underwent MMT surgery and were treated weekly with tanezumab (0.1, 1 or 10\u2005mg/kg), isotype control or vehicle for 7, 14 or 28\u2005days. Gait deficiency was measured to assess weight-bearing on the operated limb. Joint damage was assessed via histopathology. A second arm, delayed onset of treatment (starting 3-8\u2005weeks after MMT surgery) was used to control for analgesia early in the disease process. A third arm, mid-tibial amputation, evaluated the dependency of the model on weight-bearing. Gait deficiency in untreated rats was present 3-7\u2005days after MMT surgery, with a return to normal weight-bearing by days 14-28. Prophylactic treatment with tanezumab prevented gait deficiency and resulted in more severe cartilage damage. When onset of treatment with tanezumab was delayed to 3-8\u2005weeks after MMT surgery, there was no increase in cartilage damage. Mid-tibial amputation completely prevented cartilage damage in untreated MMT rats. These data suggest that analgesia due to NGF inhibition during the acute injury phase is responsible for increased voluntary weight-bearing and subsequent cartilage damage in the rat MMT model. This model failed to replicate the hypotrophic bone response observed in tanezumab-treated patients with RPOA.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "50ae8202b2234d05a6012bace0a32fa7", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[6, 8]], "char_spans": [[38, 56]]}, {"text": "NGF", "token_spans": [[232, 232], [10, 10]], "char_spans": [[1214, 1216], [59, 61]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["the", 23], ["effects", 27], ["of", 35], ["nerve", 38], ["growth", 44], ["factor", 51], ["(", 58], ["NGF", 59], [")", 62], ["inhibition", 64], ["with", 75], ["tanezumab", 80], ["on", 90], ["rats", 93], ["with", 98], ["medial", 103], ["meniscal", 110], ["tear", 119], ["(", 124], ["MMT", 125], [")", 128], ["effectively", 130], ["model", 142], ["rapidly", 148], ["progressive", 156], ["osteoarthritis", 168], ["(", 183], ["RPOA", 184], [")", 188], ["observed", 190], ["in", 199], ["clinical", 202], ["trials", 211], [".", 217], ["Male", 219], ["Lewis", 224], ["rats", 230], ["underwent", 235], ["MMT", 245], ["surgery", 249], ["and", 257], ["were", 261], ["treated", 266], ["weekly", 274], ["with", 281], ["tanezumab", 286], ["(", 296], ["0.1", 297], [",", 300], ["1", 302], ["or", 304], ["10", 307], ["mg", 310], ["/", 312], ["kg", 313], [")", 315], [",", 316], ["isotype", 318], ["control", 326], ["or", 334], ["vehicle", 337], ["for", 345], ["7", 349], [",", 350], ["14", 352], ["or", 355], ["28", 358], ["days", 361], [".", 365], ["Gait", 367], ["deficiency", 372], ["was", 383], ["measured", 387], ["to", 396], ["assess", 399], ["weight", 406], ["-", 412], ["bearing", 413], ["on", 421], ["the", 424], ["operated", 428], ["limb", 437], [".", 441], ["Joint", 443], ["damage", 449], ["was", 456], ["assessed", 460], ["via", 469], ["histopathology", 473], [".", 487], ["A", 489], ["second", 491], ["arm", 498], [",", 501], ["delayed", 503], ["onset", 511], ["of", 517], ["treatment", 520], ["(", 530], ["starting", 531], ["3", 540], ["-", 541], ["8", 542], ["weeks", 544], ["after", 550], ["MMT", 556], ["surgery", 560], [")", 567], ["was", 569], ["used", 573], ["to", 578], ["control", 581], ["for", 589], ["analgesia", 593], ["early", 603], ["in", 609], ["the", 612], ["disease", 616], ["process", 624], [".", 631], ["A", 633], ["third", 635], ["arm", 641], [",", 644], ["mid", 646], ["-", 649], ["tibial", 650], ["amputation", 657], [",", 667], ["evaluated", 669], ["the", 679], ["dependency", 683], ["of", 694], ["the", 697], ["model", 701], ["on", 707], ["weight", 710], ["-", 716], ["bearing", 717], [".", 724], ["Gait", 726], ["deficiency", 731], ["in", 742], ["untreated", 745], ["rats", 755], ["was", 760], ["present", 764], ["3", 772], ["-", 773], ["7", 774], ["days", 776], ["after", 781], ["MMT", 787], ["surgery", 791], [",", 798], ["with", 800], ["a", 805], ["return", 807], ["to", 814], ["normal", 817], ["weight", 824], ["-", 830], ["bearing", 831], ["by", 839], ["days", 842], ["14", 847], ["-", 849], ["28", 850], [".", 852], ["Prophylactic", 854], ["treatment", 867], ["with", 877], ["tanezumab", 882], ["prevented", 892], ["gait", 902], ["deficiency", 907], ["and", 918], ["resulted", 922], ["in", 931], ["more", 934], ["severe", 939], ["cartilage", 946], ["damage", 956], [".", 962], ["When", 964], ["onset", 969], ["of", 975], ["treatment", 978], ["with", 988], ["tanezumab", 993], ["was", 1003], ["delayed", 1007], ["to", 1015], ["3", 1018], ["-", 1019], ["8", 1020], ["weeks", 1022], ["after", 1028], ["MMT", 1034], ["surgery", 1038], [",", 1045], ["there", 1047], ["was", 1053], ["no", 1057], ["increase", 1060], ["in", 1069], ["cartilage", 1072], ["damage", 1082], [".", 1088], ["Mid", 1090], ["-", 1093], ["tibial", 1094], ["amputation", 1101], ["completely", 1112], ["prevented", 1123], ["cartilage", 1133], ["damage", 1143], ["in", 1150], ["untreated", 1153], ["MMT", 1163], ["rats", 1167], [".", 1171], ["These", 1173], ["data", 1179], ["suggest", 1184], ["that", 1192], ["analgesia", 1197], ["due", 1207], ["to", 1211], ["NGF", 1214], ["inhibition", 1218], ["during", 1229], ["the", 1236], ["acute", 1240], ["injury", 1246], ["phase", 1253], ["is", 1259], ["responsible", 1262], ["for", 1274], ["increased", 1278], ["voluntary", 1288], ["weight", 1298], ["-", 1304], ["bearing", 1305], ["and", 1313], ["subsequent", 1317], ["cartilage", 1328], ["damage", 1338], ["in", 1345], ["the", 1348], ["rat", 1352], ["MMT", 1356], ["model", 1360], [".", 1365], ["This", 1367], ["model", 1372], ["failed", 1378], ["to", 1385], ["replicate", 1388], ["the", 1398], ["hypotrophic", 1402], ["bone", 1414], ["response", 1419], ["observed", 1428], ["in", 1437], ["tanezumab", 1440], ["-", 1449], ["treated", 1450], ["patients", 1458], ["with", 1467], ["RPOA", 1472], [".", 1476]]}
{"context": "An overdose of oral anticoagulants represents a challenging scenario for emergency physicians. Dabigatran, an oral direct thrombin inhibitor, is increasingly used in place of warfarin. The lack of an antidote is a concern in patients who overdose on dabigatran, even though the drug can be eliminated with hemodialysis. Idarucizumab is an antibody fragment that binds dabigatran with high affinity. It reverses the anticoagulant effect of dabigatran within minutes and is approved for the reversal of dabigatran during emergency situations. We describe the use of idarucizumab in the management of a 68-year-old woman who was taking dabigatran 150\u2009mg twice daily and ingested 125 capsules. Despite gastric lavage and administration of activated charcoal within two hours of drug intake, the activated partial thromboplastin time (aPTT) and prothrombin time (PT) remained prolonged. The administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26\u2009s, PT from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s). The initially planned emergency hemodialysis was canceled. This case highlights the potential use of idarucizumab for the management of massive dabigatran overdoses.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "2b3f550f6fc74ff89e6391af6883b958", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[13, 13], [61, 61], [42, 42], [163, 163], [219, 219], [105, 105], [72, 72], [82, 82]], "char_spans": [[95, 104], [368, 377], [250, 259], [999, 1008], [1298, 1307], [633, 642], [439, 448], [501, 510]]}]}], "context_tokens": [["An", 0], ["overdose", 3], ["of", 12], ["oral", 15], ["anticoagulants", 20], ["represents", 35], ["a", 46], ["challenging", 48], ["scenario", 60], ["for", 69], ["emergency", 73], ["physicians", 83], [".", 93], ["Dabigatran", 95], [",", 105], ["an", 107], ["oral", 110], ["direct", 115], ["thrombin", 122], ["inhibitor", 131], [",", 140], ["is", 142], ["increasingly", 145], ["used", 158], ["in", 163], ["place", 166], ["of", 172], ["warfarin", 175], [".", 183], ["The", 185], ["lack", 189], ["of", 194], ["an", 197], ["antidote", 200], ["is", 209], ["a", 212], ["concern", 214], ["in", 222], ["patients", 225], ["who", 234], ["overdose", 238], ["on", 247], ["dabigatran", 250], [",", 260], ["even", 262], ["though", 267], ["the", 274], ["drug", 278], ["can", 283], ["be", 287], ["eliminated", 290], ["with", 301], ["hemodialysis", 306], [".", 318], ["Idarucizumab", 320], ["is", 333], ["an", 336], ["antibody", 339], ["fragment", 348], ["that", 357], ["binds", 362], ["dabigatran", 368], ["with", 379], ["high", 384], ["affinity", 389], [".", 397], ["It", 399], ["reverses", 402], ["the", 411], ["anticoagulant", 415], ["effect", 429], ["of", 436], ["dabigatran", 439], ["within", 450], ["minutes", 457], ["and", 465], ["is", 469], ["approved", 472], ["for", 481], ["the", 485], ["reversal", 489], ["of", 498], ["dabigatran", 501], ["during", 512], ["emergency", 519], ["situations", 529], [".", 539], ["We", 541], ["describe", 544], ["the", 553], ["use", 557], ["of", 561], ["idarucizumab", 564], ["in", 577], ["the", 580], ["management", 584], ["of", 595], ["a", 598], ["68-year", 600], ["-", 607], ["old", 608], ["woman", 612], ["who", 618], ["was", 622], ["taking", 626], ["dabigatran", 633], ["150", 644], ["mg", 648], ["twice", 651], ["daily", 657], ["and", 663], ["ingested", 667], ["125", 676], ["capsules", 680], [".", 688], ["Despite", 690], ["gastric", 698], ["lavage", 706], ["and", 713], ["administration", 717], ["of", 732], ["activated", 735], ["charcoal", 745], ["within", 754], ["two", 761], ["hours", 765], ["of", 771], ["drug", 774], ["intake", 779], [",", 785], ["the", 787], ["activated", 791], ["partial", 801], ["thromboplastin", 809], ["time", 824], ["(", 829], ["aPTT", 830], [")", 834], ["and", 836], ["prothrombin", 840], ["time", 852], ["(", 857], ["PT", 858], [")", 860], ["remained", 862], ["prolonged", 871], [".", 880], ["The", 882], ["administration", 886], ["of", 901], ["5", 904], ["g", 906], ["of", 908], ["intravenous", 911], ["idarucizumab", 923], ["promptly", 936], ["and", 945], ["completely", 949], ["reversed", 960], ["the", 969], ["anticoagulant", 973], ["activity", 987], ["of", 996], ["dabigatran", 999], ["as", 1010], ["assessed", 1013], ["by", 1022], ["routine", 1025], ["and", 1033], ["specific", 1037], ["coagulation", 1046], ["assays", 1058], ["(", 1065], ["aPTT", 1066], ["from", 1071], ["to", 1076], ["75", 1079], ["to", 1082], ["26", 1085], ["s", 1088], [",", 1089], ["PT", 1091], ["from", 1094], ["26", 1099], ["to", 1102], ["11", 1105], ["s", 1108], ["and", 1110], ["diluted", 1114], ["thrombin", 1122], ["time", 1131], ["from", 1136], ["92", 1141], ["to", 1144], ["27", 1147], ["s", 1150], [")", 1151], [".", 1152], ["The", 1154], ["initially", 1158], ["planned", 1168], ["emergency", 1176], ["hemodialysis", 1186], ["was", 1199], ["canceled", 1203], [".", 1211], ["This", 1213], ["case", 1218], ["highlights", 1223], ["the", 1234], ["potential", 1238], ["use", 1248], ["of", 1252], ["idarucizumab", 1255], ["for", 1268], ["the", 1272], ["management", 1276], ["of", 1287], ["massive", 1290], ["dabigatran", 1298], ["overdoses", 1309], [".", 1318]]}
{"context": "The McLeod phenotype is derived from various forms of XK gene defects that result in the absence of XK protein, and is defined hematologically by the absence of Kx antigen, weakening of Kell system antigens, and red cell acanthocytosis. Individuals with the McLeod phenotype usually develop late-onset neuromuscular abnormalities known as the McLeod syndrome (MLS). MLS is an X-linked multi-system disorder caused by absence of XK alone, or when the disorder is caused by large deletions, it may be accompanied with Duchenne muscular dystrophy (DMD), chronic granulomatous disease (CYBB), retinitis pigmentosa (RPGR), and ornithine transcarbamylase deficiency (OTC). XK defects derived from a large deletion at the XK locus (Xp21.1) have not been characterized at the molecular level. In this study, the deletion breakpoints of two novel cases of McLeod phenotype with extensive deletions are reported. Case 1 has greater than 1.12 million base-pairs (mb) deletion around the XK locus with 7 genes affected. Case 2 has greater than 5.65 mb deletion from TCTE1L to DMD encompassing 20 genes. Phylogenetic analyses demonstrated that DMD, XK and CYBB have close paralogs, some of which may partially substitute for the functions of their counterparts. The loci around XK are highly conserved from fish to human; however, the disorders are probably specific to mammals, and may coincide with the translocation of the loci to the X chromosome after the speciation in birds. The non-synonymous to synonymous nucleotide substitution rate ratio (omega=dN/dS) in these genes was examined. CYBB and RPGR show evidence of positive selection, whereas DMD, XK and OTC are subject to selective constraint.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "22c0308943bd43cc8df2cab2658af54e", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[133, 133], [235, 235], [124, 124], [212, 212], [9, 9], [183, 183], [18, 18], [308, 308], [78, 78]], "char_spans": [[715, 716], [1265, 1266], [667, 668], [1136, 1137], [54, 55], [976, 977], [100, 101], [1644, 1645], [428, 429]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["phenotype", 11], ["is", 21], ["derived", 24], ["from", 32], ["various", 37], ["forms", 45], ["of", 51], ["XK", 54], ["gene", 57], ["defects", 62], ["that", 70], ["result", 75], ["in", 82], ["the", 85], ["absence", 89], ["of", 97], ["XK", 100], ["protein", 103], [",", 110], ["and", 112], ["is", 116], ["defined", 119], ["hematologically", 127], ["by", 143], ["the", 146], ["absence", 150], ["of", 158], ["Kx", 161], ["antigen", 164], [",", 171], ["weakening", 173], ["of", 183], ["Kell", 186], ["system", 191], ["antigens", 198], [",", 206], ["and", 208], ["red", 212], ["cell", 216], ["acanthocytosis", 221], [".", 235], ["Individuals", 237], ["with", 249], ["the", 254], ["McLeod", 258], ["phenotype", 265], ["usually", 275], ["develop", 283], ["late", 291], ["-", 295], ["onset", 296], ["neuromuscular", 302], ["abnormalities", 316], ["known", 330], ["as", 336], ["the", 339], ["McLeod", 343], ["syndrome", 350], ["(", 359], ["MLS", 360], [")", 363], [".", 364], ["MLS", 366], ["is", 370], ["an", 373], ["X", 376], ["-", 377], ["linked", 378], ["multi", 385], ["-", 390], ["system", 391], ["disorder", 398], ["caused", 407], ["by", 414], ["absence", 417], ["of", 425], ["XK", 428], ["alone", 431], [",", 436], ["or", 438], ["when", 441], ["the", 446], ["disorder", 450], ["is", 459], ["caused", 462], ["by", 469], ["large", 472], ["deletions", 478], [",", 487], ["it", 489], ["may", 492], ["be", 496], ["accompanied", 499], ["with", 511], ["Duchenne", 516], ["muscular", 525], ["dystrophy", 534], ["(", 544], ["DMD", 545], [")", 548], [",", 549], ["chronic", 551], ["granulomatous", 559], ["disease", 573], ["(", 581], ["CYBB", 582], [")", 586], [",", 587], ["retinitis", 589], ["pigmentosa", 599], ["(", 610], ["RPGR", 611], [")", 615], [",", 616], ["and", 618], ["ornithine", 622], ["transcarbamylase", 632], ["deficiency", 649], ["(", 660], ["OTC", 661], [")", 664], [".", 665], ["XK", 667], ["defects", 670], ["derived", 678], ["from", 686], ["a", 691], ["large", 693], ["deletion", 699], ["at", 708], ["the", 711], ["XK", 715], ["locus", 718], ["(", 724], ["Xp21.1", 725], [")", 731], ["have", 733], ["not", 738], ["been", 742], ["characterized", 747], ["at", 761], ["the", 764], ["molecular", 768], ["level", 778], [".", 783], ["In", 785], ["this", 788], ["study", 793], [",", 798], ["the", 800], ["deletion", 804], ["breakpoints", 813], ["of", 825], ["two", 828], ["novel", 832], ["cases", 838], ["of", 844], ["McLeod", 847], ["phenotype", 854], ["with", 864], ["extensive", 869], ["deletions", 879], ["are", 889], ["reported", 893], [".", 901], ["Case", 903], ["1", 908], ["has", 910], ["greater", 914], ["than", 922], ["1.12", 927], ["million", 932], ["base", 940], ["-", 944], ["pairs", 945], ["(", 951], ["mb", 952], [")", 954], ["deletion", 956], ["around", 965], ["the", 972], ["XK", 976], ["locus", 979], ["with", 985], ["7", 990], ["genes", 992], ["affected", 998], [".", 1006], ["Case", 1008], ["2", 1013], ["has", 1015], ["greater", 1019], ["than", 1027], ["5.65", 1032], ["mb", 1037], ["deletion", 1040], ["from", 1049], ["TCTE1L", 1054], ["to", 1061], ["DMD", 1064], ["encompassing", 1068], ["20", 1081], ["genes", 1084], [".", 1089], ["Phylogenetic", 1091], ["analyses", 1104], ["demonstrated", 1113], ["that", 1126], ["DMD", 1131], [",", 1134], ["XK", 1136], ["and", 1139], ["CYBB", 1143], ["have", 1148], ["close", 1153], ["paralogs", 1159], [",", 1167], ["some", 1169], ["of", 1174], ["which", 1177], ["may", 1183], ["partially", 1187], ["substitute", 1197], ["for", 1208], ["the", 1212], ["functions", 1216], ["of", 1226], ["their", 1229], ["counterparts", 1235], [".", 1247], ["The", 1249], ["loci", 1253], ["around", 1258], ["XK", 1265], ["are", 1268], ["highly", 1272], ["conserved", 1279], ["from", 1289], ["fish", 1294], ["to", 1299], ["human", 1302], [";", 1307], ["however", 1309], [",", 1316], ["the", 1318], ["disorders", 1322], ["are", 1332], ["probably", 1336], ["specific", 1345], ["to", 1354], ["mammals", 1357], [",", 1364], ["and", 1366], ["may", 1370], ["coincide", 1374], ["with", 1383], ["the", 1388], ["translocation", 1392], ["of", 1406], ["the", 1409], ["loci", 1413], ["to", 1418], ["the", 1421], ["X", 1425], ["chromosome", 1427], ["after", 1438], ["the", 1444], ["speciation", 1448], ["in", 1459], ["birds", 1462], [".", 1467], ["The", 1469], ["non", 1473], ["-", 1476], ["synonymous", 1477], ["to", 1488], ["synonymous", 1491], ["nucleotide", 1502], ["substitution", 1513], ["rate", 1526], ["ratio", 1531], ["(", 1537], ["omega", 1538], ["=", 1543], ["dN", 1544], ["/", 1546], ["dS", 1547], [")", 1549], ["in", 1551], ["these", 1554], ["genes", 1560], ["was", 1566], ["examined", 1570], [".", 1578], ["CYBB", 1580], ["and", 1585], ["RPGR", 1589], ["show", 1594], ["evidence", 1599], ["of", 1608], ["positive", 1611], ["selection", 1620], [",", 1629], ["whereas", 1631], ["DMD", 1639], [",", 1642], ["XK", 1644], ["and", 1647], ["OTC", 1651], ["are", 1655], ["subject", 1659], ["to", 1667], ["selective", 1670], ["constraint", 1680], [".", 1690]]}
{"context": "CADASIL is a cerebrovascular disease caused by mutations in the NOTCH3 gene. Most mutations result in a gain or loss of cysteine residue in one of the 34 epidermal growth factor-like repeats in the extracellular domain of the Notch3 protein, thus sparing the number of cysteine residues. To date, more than 130 different mutations in the NOTCH3 gene have been reported in CADASIL patients, of which 95% are missense point mutations. Many polymorphisms have also been identified in the NOTCH3 coding sequence, some of them leading to amino acid substitutions. The aim of the present study was to analyze the NOTCH3 gene in a large group of patients affected by leukoencephalopathy and to investigate the presence of genetic variants. The molecular analysis revealed several nucleotide alterations. In particular, we identified 20 different mutations, 22 polymorphisms, and 8 genetic variants of unknown pathological significance never reported previously. We hope that this NOTCH3 gene mutational analysis, performed in such a significant number of unrelated and related patients affected by leukoencephalopathy, will help in molecular screening for the NOTCH3 gene, thus contributing to enlargement of the NOTCH3 gene variation database.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "3aa0a515baa742df87b15ccd76e1ea2d", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[49, 49], [22, 22]], "char_spans": [[269, 276], [120, 127]]}]}], "context_tokens": [["CADASIL", 0], ["is", 8], ["a", 11], ["cerebrovascular", 13], ["disease", 29], ["caused", 37], ["by", 44], ["mutations", 47], ["in", 57], ["the", 60], ["NOTCH3", 64], ["gene", 71], [".", 75], ["Most", 77], ["mutations", 82], ["result", 92], ["in", 99], ["a", 102], ["gain", 104], ["or", 109], ["loss", 112], ["of", 117], ["cysteine", 120], ["residue", 129], ["in", 137], ["one", 140], ["of", 144], ["the", 147], ["34", 151], ["epidermal", 154], ["growth", 164], ["factor", 171], ["-", 177], ["like", 178], ["repeats", 183], ["in", 191], ["the", 194], ["extracellular", 198], ["domain", 212], ["of", 219], ["the", 222], ["Notch3", 226], ["protein", 233], [",", 240], ["thus", 242], ["sparing", 247], ["the", 255], ["number", 259], ["of", 266], ["cysteine", 269], ["residues", 278], [".", 286], ["To", 288], ["date", 291], [",", 295], ["more", 297], ["than", 302], ["130", 307], ["different", 311], ["mutations", 321], ["in", 331], ["the", 334], ["NOTCH3", 338], ["gene", 345], ["have", 350], ["been", 355], ["reported", 360], ["in", 369], ["CADASIL", 372], ["patients", 380], [",", 388], ["of", 390], ["which", 393], ["95", 399], ["%", 401], ["are", 403], ["missense", 407], ["point", 416], ["mutations", 422], [".", 431], ["Many", 433], ["polymorphisms", 438], ["have", 452], ["also", 457], ["been", 462], ["identified", 467], ["in", 478], ["the", 481], ["NOTCH3", 485], ["coding", 492], ["sequence", 499], [",", 507], ["some", 509], ["of", 514], ["them", 517], ["leading", 522], ["to", 530], ["amino", 533], ["acid", 539], ["substitutions", 544], [".", 557], ["The", 559], ["aim", 563], ["of", 567], ["the", 570], ["present", 574], ["study", 582], ["was", 588], ["to", 592], ["analyze", 595], ["the", 603], ["NOTCH3", 607], ["gene", 614], ["in", 619], ["a", 622], ["large", 624], ["group", 630], ["of", 636], ["patients", 639], ["affected", 648], ["by", 657], ["leukoencephalopathy", 660], ["and", 680], ["to", 684], ["investigate", 687], ["the", 699], ["presence", 703], ["of", 712], ["genetic", 715], ["variants", 723], [".", 731], ["The", 733], ["molecular", 737], ["analysis", 747], ["revealed", 756], ["several", 765], ["nucleotide", 773], ["alterations", 784], [".", 795], ["In", 797], ["particular", 800], [",", 810], ["we", 812], ["identified", 815], ["20", 826], ["different", 829], ["mutations", 839], [",", 848], ["22", 850], ["polymorphisms", 853], [",", 866], ["and", 868], ["8", 872], ["genetic", 874], ["variants", 882], ["of", 891], ["unknown", 894], ["pathological", 902], ["significance", 915], ["never", 928], ["reported", 934], ["previously", 943], [".", 953], ["We", 955], ["hope", 958], ["that", 963], ["this", 968], ["NOTCH3", 973], ["gene", 980], ["mutational", 985], ["analysis", 996], [",", 1004], ["performed", 1006], ["in", 1016], ["such", 1019], ["a", 1024], ["significant", 1026], ["number", 1038], ["of", 1045], ["unrelated", 1048], ["and", 1058], ["related", 1062], ["patients", 1070], ["affected", 1079], ["by", 1088], ["leukoencephalopathy", 1091], [",", 1110], ["will", 1112], ["help", 1117], ["in", 1122], ["molecular", 1125], ["screening", 1135], ["for", 1145], ["the", 1149], ["NOTCH3", 1153], ["gene", 1160], [",", 1164], ["thus", 1166], ["contributing", 1171], ["to", 1184], ["enlargement", 1187], ["of", 1199], ["the", 1202], ["NOTCH3", 1206], ["gene", 1213], ["variation", 1218], ["database", 1228], [".", 1236]]}
{"context": "Mammalian selenium-containing proteins identified thus far contain selenium in the form of a selenocysteine residue encoded by UGA. These proteins lack common amino acid sequence motifs, but 3'-untranslated regions of selenoprotein genes contain a common stem-loop structure, selenocysteine insertion sequence (SECIS) element, that is necessary for decoding UGA as selenocysteine rather than a stop signal. We describe here a computer program, SECISearch, that identifies mammalian selenoprotein genes by recognizing SECIS elements on the basis of their primary and secondary structures and free energy requirements. When SECISearch was applied to search human dbEST, two new mammalian selenoproteins, designated SelT and SelR, were identified. We determined their cDNA sequences and expressed them in a monkey cell line as fusion proteins with a green fluorescent protein. Incorporation of selenium into new proteins was confirmed by metabolic labeling with (75)Se, and expression of SelT was additionally documented in immunoblot assays. SelT and SelR did not have homology to previously characterized proteins, but their putative homologs were detected in various organisms. SelR homologs were present in every organism characterized by complete genome sequencing. The data suggest applicability of SECISearch for identification of new selenoprotein genes in nucleotide data bases.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0d1597667c614526ba0ceede9a3ecc54", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[48, 48], [82, 82]], "char_spans": [[311, 315], [517, 521]]}]}], "context_tokens": [["Mammalian", 0], ["selenium", 10], ["-", 18], ["containing", 19], ["proteins", 30], ["identified", 39], ["thus", 50], ["far", 55], ["contain", 59], ["selenium", 67], ["in", 76], ["the", 79], ["form", 83], ["of", 88], ["a", 91], ["selenocysteine", 93], ["residue", 108], ["encoded", 116], ["by", 124], ["UGA", 127], [".", 130], ["These", 132], ["proteins", 138], ["lack", 147], ["common", 152], ["amino", 159], ["acid", 165], ["sequence", 170], ["motifs", 179], [",", 185], ["but", 187], ["3'-untranslated", 191], ["regions", 207], ["of", 215], ["selenoprotein", 218], ["genes", 232], ["contain", 238], ["a", 246], ["common", 248], ["stem", 255], ["-", 259], ["loop", 260], ["structure", 265], [",", 274], ["selenocysteine", 276], ["insertion", 291], ["sequence", 301], ["(", 310], ["SECIS", 311], [")", 316], ["element", 318], [",", 325], ["that", 327], ["is", 332], ["necessary", 335], ["for", 345], ["decoding", 349], ["UGA", 358], ["as", 362], ["selenocysteine", 365], ["rather", 380], ["than", 387], ["a", 392], ["stop", 394], ["signal", 399], [".", 405], ["We", 407], ["describe", 410], ["here", 419], ["a", 424], ["computer", 426], ["program", 435], [",", 442], ["SECISearch", 444], [",", 454], ["that", 456], ["identifies", 461], ["mammalian", 472], ["selenoprotein", 482], ["genes", 496], ["by", 502], ["recognizing", 505], ["SECIS", 517], ["elements", 523], ["on", 532], ["the", 535], ["basis", 539], ["of", 545], ["their", 548], ["primary", 554], ["and", 562], ["secondary", 566], ["structures", 576], ["and", 587], ["free", 591], ["energy", 596], ["requirements", 603], [".", 615], ["When", 617], ["SECISearch", 622], ["was", 633], ["applied", 637], ["to", 645], ["search", 648], ["human", 655], ["dbEST", 661], [",", 666], ["two", 668], ["new", 672], ["mammalian", 676], ["selenoproteins", 686], [",", 700], ["designated", 702], ["SelT", 713], ["and", 718], ["SelR", 722], [",", 726], ["were", 728], ["identified", 733], [".", 743], ["We", 745], ["determined", 748], ["their", 759], ["cDNA", 765], ["sequences", 770], ["and", 780], ["expressed", 784], ["them", 794], ["in", 799], ["a", 802], ["monkey", 804], ["cell", 811], ["line", 816], ["as", 821], ["fusion", 824], ["proteins", 831], ["with", 840], ["a", 845], ["green", 847], ["fluorescent", 853], ["protein", 865], [".", 872], ["Incorporation", 874], ["of", 888], ["selenium", 891], ["into", 900], ["new", 905], ["proteins", 909], ["was", 918], ["confirmed", 922], ["by", 932], ["metabolic", 935], ["labeling", 945], ["with", 954], ["(", 959], ["75)Se", 960], [",", 965], ["and", 967], ["expression", 971], ["of", 982], ["SelT", 985], ["was", 990], ["additionally", 994], ["documented", 1007], ["in", 1018], ["immunoblot", 1021], ["assays", 1032], [".", 1038], ["SelT", 1040], ["and", 1045], ["SelR", 1049], ["did", 1054], ["not", 1058], ["have", 1062], ["homology", 1067], ["to", 1076], ["previously", 1079], ["characterized", 1090], ["proteins", 1104], [",", 1112], ["but", 1114], ["their", 1118], ["putative", 1124], ["homologs", 1133], ["were", 1142], ["detected", 1147], ["in", 1156], ["various", 1159], ["organisms", 1167], [".", 1176], ["SelR", 1178], ["homologs", 1183], ["were", 1192], ["present", 1197], ["in", 1205], ["every", 1208], ["organism", 1214], ["characterized", 1223], ["by", 1237], ["complete", 1240], ["genome", 1249], ["sequencing", 1256], [".", 1266], ["The", 1268], ["data", 1272], ["suggest", 1277], ["applicability", 1285], ["of", 1299], ["SECISearch", 1302], ["for", 1313], ["identification", 1317], ["of", 1332], ["new", 1335], ["selenoprotein", 1339], ["genes", 1353], ["in", 1359], ["nucleotide", 1362], ["data", 1373], ["bases", 1378], [".", 1383]]}
{"context": "Primary sinonasal intestinal-type adenocarcinomas (ITAC) are defined on the basis of their morphological similarities to colorectal adenocarcinomas (CRA). Thus, differential diagnosis with sinonasal metastasis of CRA could be a real challenge. Neuroendocrine differentiation has been variably described in several types of adenocarcinomas and notably in ITACs and CRAs. In a series of 25 ITACs and 25 lymph node metastasis of CRAs (nmCRA), we analysed neuroendocrine differentiation by immunohistochemistry with anti-chromogranin A and synaptophysin antibodies. Neuroendocrine differentiation (chromogranin A and/or synaptophysin positivity) was significantly different (p=0.0002) in ITACs (72%) and in nmCRAs (20%). In conclusion, presence of neuroendocrine cells seems more in favour of a sinonasal intestinal-type adenocarcinoma, than metastatic CRA. This immunohistochemical study could be useful in difficult cases and should be an interesting complement in a clinical discussion.", "qas": [{"question": "Which cell type has the protein Chromogranin A as marker?", "answers": ["neuroendocrine cells"], "qid": "ec272621cd3149a5b39e759406ab8844", "question_tokens": [["Which", 0], ["cell", 6], ["type", 11], ["has", 16], ["the", 20], ["protein", 24], ["Chromogranin", 32], ["A", 45], ["as", 47], ["marker", 50], ["?", 56]], "detected_answers": [{"text": "neuroendocrine cells", "token_spans": [[124, 125]], "char_spans": [[744, 763]]}]}], "context_tokens": [["Primary", 0], ["sinonasal", 8], ["intestinal", 18], ["-", 28], ["type", 29], ["adenocarcinomas", 34], ["(", 50], ["ITAC", 51], [")", 55], ["are", 57], ["defined", 61], ["on", 69], ["the", 72], ["basis", 76], ["of", 82], ["their", 85], ["morphological", 91], ["similarities", 105], ["to", 118], ["colorectal", 121], ["adenocarcinomas", 132], ["(", 148], ["CRA", 149], [")", 152], [".", 153], ["Thus", 155], [",", 159], ["differential", 161], ["diagnosis", 174], ["with", 184], ["sinonasal", 189], ["metastasis", 199], ["of", 210], ["CRA", 213], ["could", 217], ["be", 223], ["a", 226], ["real", 228], ["challenge", 233], [".", 242], ["Neuroendocrine", 244], ["differentiation", 259], ["has", 275], ["been", 279], ["variably", 284], ["described", 293], ["in", 303], ["several", 306], ["types", 314], ["of", 320], ["adenocarcinomas", 323], ["and", 339], ["notably", 343], ["in", 351], ["ITACs", 354], ["and", 360], ["CRAs", 364], [".", 368], ["In", 370], ["a", 373], ["series", 375], ["of", 382], ["25", 385], ["ITACs", 388], ["and", 394], ["25", 398], ["lymph", 401], ["node", 407], ["metastasis", 412], ["of", 423], ["CRAs", 426], ["(", 431], ["nmCRA", 432], [")", 437], [",", 438], ["we", 440], ["analysed", 443], ["neuroendocrine", 452], ["differentiation", 467], ["by", 483], ["immunohistochemistry", 486], ["with", 507], ["anti", 512], ["-", 516], ["chromogranin", 517], ["A", 530], ["and", 532], ["synaptophysin", 536], ["antibodies", 550], [".", 560], ["Neuroendocrine", 562], ["differentiation", 577], ["(", 593], ["chromogranin", 594], ["A", 607], ["and/or", 609], ["synaptophysin", 616], ["positivity", 630], [")", 640], ["was", 642], ["significantly", 646], ["different", 660], ["(", 670], ["p=0.0002", 671], [")", 679], ["in", 681], ["ITACs", 684], ["(", 690], ["72", 691], ["%", 693], [")", 694], ["and", 696], ["in", 700], ["nmCRAs", 703], ["(", 710], ["20", 711], ["%", 713], [")", 714], [".", 715], ["In", 717], ["conclusion", 720], [",", 730], ["presence", 732], ["of", 741], ["neuroendocrine", 744], ["cells", 759], ["seems", 765], ["more", 771], ["in", 776], ["favour", 779], ["of", 786], ["a", 789], ["sinonasal", 791], ["intestinal", 801], ["-", 811], ["type", 812], ["adenocarcinoma", 817], [",", 831], ["than", 833], ["metastatic", 838], ["CRA", 849], [".", 852], ["This", 854], ["immunohistochemical", 859], ["study", 879], ["could", 885], ["be", 891], ["useful", 894], ["in", 901], ["difficult", 904], ["cases", 914], ["and", 920], ["should", 924], ["be", 931], ["an", 934], ["interesting", 937], ["complement", 949], ["in", 960], ["a", 963], ["clinical", 965], ["discussion", 974], [".", 984]]}
{"context": "Abnormal accumulation of Abeta and tau in senile plaques (SP) and neurofibrillary tangles (NFTs) is a key event in Alzheimer's disease (AD). Here, we show that T668-phosphorylated cytoplasmic domain of APP (pT668-ACD) accumulates Abeta and tau in AD and its transgenic models. Anti-pT668 immunostaining of AD brain sections with hydrated autoclave enhancement identified SP neurites and NFTs in which pT668-ACD colocalizes with tau. We produced and examined transgenic (Tg) mice that overexpress human APP695, harboring the double Swedish/London mutation, and develop age-dependently Abeta plaques in the brain. All Abeta plaques contain co-accumulations of pT668-ACD, but co-accumulation of tau appears in only a fraction of Abeta plaques in older animals. We also examined the established tau Tg mice that overexpress the smallest human brain tau isoform and develop neuronal accumulations of tau in older animals. Examination of the old tau Tg mice showed that neuronal cells affected by tau accumulation induce co-accumulation of pT668-ACD. We speculate that in AD brains, extracellular Abeta deposition is accompanied by intracellular accumulation of pT668-ACD, followed by tau accumulation in the SP with dystrophic neurites and that neuronal cells affected by tau accumulation induce co-accumulation of pT668-ACD in NFTs. Thus, pT668-ACD is likely to mediate pathological interaction between Abeta and tau.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "359b351dab714a9eb679ec9eef3d8227", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[23, 25]], "char_spans": [[115, 133]]}, {"text": "AD", "token_spans": [[191, 191], [59, 59], [48, 48], [27, 27]], "char_spans": [[1066, 1067], [306, 307], [247, 248], [136, 137]]}]}], "context_tokens": [["Abnormal", 0], ["accumulation", 9], ["of", 22], ["Abeta", 25], ["and", 31], ["tau", 35], ["in", 39], ["senile", 42], ["plaques", 49], ["(", 57], ["SP", 58], [")", 60], ["and", 62], ["neurofibrillary", 66], ["tangles", 82], ["(", 90], ["NFTs", 91], [")", 95], ["is", 97], ["a", 100], ["key", 102], ["event", 106], ["in", 112], ["Alzheimer", 115], ["'s", 124], ["disease", 127], ["(", 135], ["AD", 136], [")", 138], [".", 139], ["Here", 141], [",", 145], ["we", 147], ["show", 150], ["that", 155], ["T668-phosphorylated", 160], ["cytoplasmic", 180], ["domain", 192], ["of", 199], ["APP", 202], ["(", 206], ["pT668-ACD", 207], [")", 216], ["accumulates", 218], ["Abeta", 230], ["and", 236], ["tau", 240], ["in", 244], ["AD", 247], ["and", 250], ["its", 254], ["transgenic", 258], ["models", 269], [".", 275], ["Anti", 277], ["-", 281], ["pT668", 282], ["immunostaining", 288], ["of", 303], ["AD", 306], ["brain", 309], ["sections", 315], ["with", 324], ["hydrated", 329], ["autoclave", 338], ["enhancement", 348], ["identified", 360], ["SP", 371], ["neurites", 374], ["and", 383], ["NFTs", 387], ["in", 392], ["which", 395], ["pT668-ACD", 401], ["colocalizes", 411], ["with", 423], ["tau", 428], [".", 431], ["We", 433], ["produced", 436], ["and", 445], ["examined", 449], ["transgenic", 458], ["(", 469], ["Tg", 470], [")", 472], ["mice", 474], ["that", 479], ["overexpress", 484], ["human", 496], ["APP695", 502], [",", 508], ["harboring", 510], ["the", 520], ["double", 524], ["Swedish", 531], ["/", 538], ["London", 539], ["mutation", 546], [",", 554], ["and", 556], ["develop", 560], ["age", 568], ["-", 571], ["dependently", 572], ["Abeta", 584], ["plaques", 590], ["in", 598], ["the", 601], ["brain", 605], [".", 610], ["All", 612], ["Abeta", 616], ["plaques", 622], ["contain", 630], ["co", 638], ["-", 640], ["accumulations", 641], ["of", 655], ["pT668-ACD", 658], [",", 667], ["but", 669], ["co", 673], ["-", 675], ["accumulation", 676], ["of", 689], ["tau", 692], ["appears", 696], ["in", 704], ["only", 707], ["a", 712], ["fraction", 714], ["of", 723], ["Abeta", 726], ["plaques", 732], ["in", 740], ["older", 743], ["animals", 749], [".", 756], ["We", 758], ["also", 761], ["examined", 766], ["the", 775], ["established", 779], ["tau", 791], ["Tg", 795], ["mice", 798], ["that", 803], ["overexpress", 808], ["the", 820], ["smallest", 824], ["human", 833], ["brain", 839], ["tau", 845], ["isoform", 849], ["and", 857], ["develop", 861], ["neuronal", 869], ["accumulations", 878], ["of", 892], ["tau", 895], ["in", 899], ["older", 902], ["animals", 908], [".", 915], ["Examination", 917], ["of", 929], ["the", 932], ["old", 936], ["tau", 940], ["Tg", 944], ["mice", 947], ["showed", 952], ["that", 959], ["neuronal", 964], ["cells", 973], ["affected", 979], ["by", 988], ["tau", 991], ["accumulation", 995], ["induce", 1008], ["co", 1015], ["-", 1017], ["accumulation", 1018], ["of", 1031], ["pT668-ACD", 1034], [".", 1043], ["We", 1045], ["speculate", 1048], ["that", 1058], ["in", 1063], ["AD", 1066], ["brains", 1069], [",", 1075], ["extracellular", 1077], ["Abeta", 1091], ["deposition", 1097], ["is", 1108], ["accompanied", 1111], ["by", 1123], ["intracellular", 1126], ["accumulation", 1140], ["of", 1153], ["pT668-ACD", 1156], [",", 1165], ["followed", 1167], ["by", 1176], ["tau", 1179], ["accumulation", 1183], ["in", 1196], ["the", 1199], ["SP", 1203], ["with", 1206], ["dystrophic", 1211], ["neurites", 1222], ["and", 1231], ["that", 1235], ["neuronal", 1240], ["cells", 1249], ["affected", 1255], ["by", 1264], ["tau", 1267], ["accumulation", 1271], ["induce", 1284], ["co", 1291], ["-", 1293], ["accumulation", 1294], ["of", 1307], ["pT668-ACD", 1310], ["in", 1320], ["NFTs", 1323], [".", 1327], ["Thus", 1329], [",", 1333], ["pT668-ACD", 1335], ["is", 1345], ["likely", 1348], ["to", 1355], ["mediate", 1358], ["pathological", 1366], ["interaction", 1379], ["between", 1391], ["Abeta", 1399], ["and", 1405], ["tau", 1409], [".", 1412]]}
{"context": "Protein kinases (PKs) and lipid kinases (LKs) are good choices for targets of signal transduction therapy as these enzymes are involved in signaling pathways, and are often related to the pathogenesis of lymphoid malignancies. The attractiveness of PKs and LKs as drug able targets is enhanced by the fact that they are enzymes whose biological activity can be turned off by drugs that block their catalytic site. In the last few years small molecular kinase inhibitors (KIs) have been synthesized and become available for preclinical studies and clinical trials. The first KI, introduced into clinical practice in 1998, was imatinib mesylate, which became the first choice drug in chronic myeloid leukemia. More recently, several KIs have been developed to target the proximal B-cell receptor (BCR) signaling pathway including spleen tyrosine kinase inhibitor (Fostamatinib) and Bruton's tyrosine kinase inhibitors (Ibrutinib, AVL-263). These agents are currently evaluated in early clinical trials in chronic lymphocytic leukemia (CLL) and other diseases. Cyclin-dependent kinase (Cdk) inhibitors, flavopiridol (alvocidib), BMS-387032 (SNS-032), sunitinib and sorafenib are currently under evaluation in clinical trials for relapsed/refractory CLL. Multi-tyrosine kinase inhibitors including vandetanib (ZD6474) bosutinib (SKI-606), TKI258 (CHIR-258), pazopanib (GW786034) and axitinib (AG013736) have been also developed for the treatment of lymphoid malignancies. Phosphatidylinositol 3-kinases (PI3K ) are a family of lipid kinases that mediate signals from cell surface receptors. CAL-101 (GS-1101) is an oral PI3K\u03b4-specific inhibitor which has shown preclinical and clinical activity against CLL. This article summarizes recent achievements in the mechanism of action, pharmacological properties and clinical activity and toxicity of PK and LK inhibitors in CLL.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "1eb2d0fe88414c37812859c1e4d6e1b5", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[161, 161]], "char_spans": [[917, 925]]}]}], "context_tokens": [["Protein", 0], ["kinases", 8], ["(", 16], ["PKs", 17], [")", 20], ["and", 22], ["lipid", 26], ["kinases", 32], ["(", 40], ["LKs", 41], [")", 44], ["are", 46], ["good", 50], ["choices", 55], ["for", 63], ["targets", 67], ["of", 75], ["signal", 78], ["transduction", 85], ["therapy", 98], ["as", 106], ["these", 109], ["enzymes", 115], ["are", 123], ["involved", 127], ["in", 136], ["signaling", 139], ["pathways", 149], [",", 157], ["and", 159], ["are", 163], ["often", 167], ["related", 173], ["to", 181], ["the", 184], ["pathogenesis", 188], ["of", 201], ["lymphoid", 204], ["malignancies", 213], [".", 225], ["The", 227], ["attractiveness", 231], ["of", 246], ["PKs", 249], ["and", 253], ["LKs", 257], ["as", 261], ["drug", 264], ["able", 269], ["targets", 274], ["is", 282], ["enhanced", 285], ["by", 294], ["the", 297], ["fact", 301], ["that", 306], ["they", 311], ["are", 316], ["enzymes", 320], ["whose", 328], ["biological", 334], ["activity", 345], ["can", 354], ["be", 358], ["turned", 361], ["off", 368], ["by", 372], ["drugs", 375], ["that", 381], ["block", 386], ["their", 392], ["catalytic", 398], ["site", 408], [".", 412], ["In", 414], ["the", 417], ["last", 421], ["few", 426], ["years", 430], ["small", 436], ["molecular", 442], ["kinase", 452], ["inhibitors", 459], ["(", 470], ["KIs", 471], [")", 474], ["have", 476], ["been", 481], ["synthesized", 486], ["and", 498], ["become", 502], ["available", 509], ["for", 519], ["preclinical", 523], ["studies", 535], ["and", 543], ["clinical", 547], ["trials", 556], [".", 562], ["The", 564], ["first", 568], ["KI", 574], [",", 576], ["introduced", 578], ["into", 589], ["clinical", 594], ["practice", 603], ["in", 612], ["1998", 615], [",", 619], ["was", 621], ["imatinib", 625], ["mesylate", 634], [",", 642], ["which", 644], ["became", 650], ["the", 657], ["first", 661], ["choice", 667], ["drug", 674], ["in", 679], ["chronic", 682], ["myeloid", 690], ["leukemia", 698], [".", 706], ["More", 708], ["recently", 713], [",", 721], ["several", 723], ["KIs", 731], ["have", 735], ["been", 740], ["developed", 745], ["to", 755], ["target", 758], ["the", 765], ["proximal", 769], ["B", 778], ["-", 779], ["cell", 780], ["receptor", 785], ["(", 794], ["BCR", 795], [")", 798], ["signaling", 800], ["pathway", 810], ["including", 818], ["spleen", 828], ["tyrosine", 835], ["kinase", 844], ["inhibitor", 851], ["(", 861], ["Fostamatinib", 862], [")", 874], ["and", 876], ["Bruton", 880], ["'s", 886], ["tyrosine", 889], ["kinase", 898], ["inhibitors", 905], ["(", 916], ["Ibrutinib", 917], [",", 926], ["AVL-263", 928], [")", 935], [".", 936], ["These", 938], ["agents", 944], ["are", 951], ["currently", 955], ["evaluated", 965], ["in", 975], ["early", 978], ["clinical", 984], ["trials", 993], ["in", 1000], ["chronic", 1003], ["lymphocytic", 1011], ["leukemia", 1023], ["(", 1032], ["CLL", 1033], [")", 1036], ["and", 1038], ["other", 1042], ["diseases", 1048], [".", 1056], ["Cyclin", 1058], ["-", 1064], ["dependent", 1065], ["kinase", 1075], ["(", 1082], ["Cdk", 1083], [")", 1086], ["inhibitors", 1088], [",", 1098], ["flavopiridol", 1100], ["(", 1113], ["alvocidib", 1114], [")", 1123], [",", 1124], ["BMS-387032", 1126], ["(", 1137], ["SNS-032", 1138], [")", 1145], [",", 1146], ["sunitinib", 1148], ["and", 1158], ["sorafenib", 1162], ["are", 1172], ["currently", 1176], ["under", 1186], ["evaluation", 1192], ["in", 1203], ["clinical", 1206], ["trials", 1215], ["for", 1222], ["relapsed", 1226], ["/", 1234], ["refractory", 1235], ["CLL", 1246], [".", 1249], ["Multi", 1251], ["-", 1256], ["tyrosine", 1257], ["kinase", 1266], ["inhibitors", 1273], ["including", 1284], ["vandetanib", 1294], ["(", 1305], ["ZD6474", 1306], [")", 1312], ["bosutinib", 1314], ["(", 1324], ["SKI-606", 1325], [")", 1332], [",", 1333], ["TKI258", 1335], ["(", 1342], ["CHIR-258", 1343], [")", 1351], [",", 1352], ["pazopanib", 1354], ["(", 1364], ["GW786034", 1365], [")", 1373], ["and", 1375], ["axitinib", 1379], ["(", 1388], ["AG013736", 1389], [")", 1397], ["have", 1399], ["been", 1404], ["also", 1409], ["developed", 1414], ["for", 1424], ["the", 1428], ["treatment", 1432], ["of", 1442], ["lymphoid", 1445], ["malignancies", 1454], [".", 1466], ["Phosphatidylinositol", 1468], ["3-kinases", 1489], ["(", 1499], ["PI3", 1500], ["K", 1503], [")", 1505], ["are", 1507], ["a", 1511], ["family", 1513], ["of", 1520], ["lipid", 1523], ["kinases", 1529], ["that", 1537], ["mediate", 1542], ["signals", 1550], ["from", 1558], ["cell", 1563], ["surface", 1568], ["receptors", 1576], [".", 1585], ["CAL-101", 1587], ["(", 1595], ["GS-1101", 1596], [")", 1603], ["is", 1605], ["an", 1608], ["oral", 1611], ["PI3K\u03b4", 1616], ["-", 1621], ["specific", 1622], ["inhibitor", 1631], ["which", 1641], ["has", 1647], ["shown", 1651], ["preclinical", 1657], ["and", 1669], ["clinical", 1673], ["activity", 1682], ["against", 1691], ["CLL", 1699], [".", 1702], ["This", 1704], ["article", 1709], ["summarizes", 1717], ["recent", 1728], ["achievements", 1735], ["in", 1748], ["the", 1751], ["mechanism", 1755], ["of", 1765], ["action", 1768], [",", 1774], ["pharmacological", 1776], ["properties", 1792], ["and", 1803], ["clinical", 1807], ["activity", 1816], ["and", 1825], ["toxicity", 1829], ["of", 1838], ["PK", 1841], ["and", 1844], ["LK", 1848], ["inhibitors", 1851], ["in", 1862], ["CLL", 1865], [".", 1868]]}
{"context": "A blinded, retrospective study was performed to determine the value of supine abdominal radiographs in diagnosing pneumoperitoneum. Supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including Rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-V sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant). One or more of these signs were present in 26 cases (59%) of pneumoperitoneum, including the right-upper-quadrant gas sign in 18 cases (41%), Rigler's sign in 14 cases (32%), and the falciform ligament and football signs in one case each (2%). Unfortunately, there were frequent errors in the interpretation of the right-upper-quadrant gas sign and Rigler's sign, with a total of 11 false-positive cases (13%). Further analysis of the true-positive right-upper-quadrant gas signs showed that these gas collections were always triangular or linear with an inferolateral to superomedial orientation and, if triangular, a concave superolateral border. In the true-positive Rigler's signs, the bowel wall thickness ranged from 1 to 8 mm, whereas the false positives all had a bowel wall thickness of 1 mm or less. Proper interpretation of the various signs of pneumoperitoneum on supine films should lead to more accurate diagnosis of this condition.", "qas": [{"question": "Falciform ligament sign is characteristic to which disease?", "answers": ["pneumoperitoneum"], "qid": "9305f4338a854725ab83e9b81c3c35b4", "question_tokens": [["Falciform", 0], ["ligament", 10], ["sign", 19], ["is", 24], ["characteristic", 27], ["to", 42], ["which", 45], ["disease", 51], ["?", 58]], "detected_answers": [{"text": "pneumoperitoneum", "token_spans": [[309, 309], [54, 54], [25, 25], [17, 17], [143, 143]], "char_spans": [[1553, 1568], [344, 359], [162, 177], [114, 129], [758, 773]]}]}], "context_tokens": [["A", 0], ["blinded", 2], [",", 9], ["retrospective", 11], ["study", 25], ["was", 31], ["performed", 35], ["to", 45], ["determine", 48], ["the", 58], ["value", 62], ["of", 68], ["supine", 71], ["abdominal", 78], ["radiographs", 88], ["in", 100], ["diagnosing", 103], ["pneumoperitoneum", 114], [".", 130], ["Supine", 132], ["films", 139], ["from", 145], ["44", 150], ["cases", 153], ["of", 159], ["pneumoperitoneum", 162], ["were", 179], ["randomly", 184], ["interspersed", 193], ["among", 206], ["supine", 212], ["films", 219], ["from", 225], ["87", 230], ["control", 233], ["subjects", 241], ["without", 250], ["free", 258], ["air", 263], [",", 266], ["and", 268], ["the", 272], ["films", 276], ["were", 282], ["reviewed", 287], ["for", 296], ["the", 300], ["presence", 304], ["or", 313], ["absence", 316], ["of", 324], ["various", 327], ["signs", 335], ["of", 341], ["pneumoperitoneum", 344], [",", 360], ["including", 362], ["Rigler", 372], ["'s", 378], ["sign", 381], ["(", 386], ["gas", 387], ["on", 391], ["both", 394], ["sides", 399], ["of", 405], ["the", 408], ["bowel", 412], ["wall", 418], [")", 422], [",", 423], ["the", 425], ["falciform", 429], ["ligament", 439], ["sign", 448], ["(", 453], ["gas", 454], ["outlining", 458], ["the", 468], ["falciform", 472], ["ligament", 482], [")", 490], [",", 491], ["the", 493], ["football", 497], ["sign", 506], ["(", 511], ["gas", 512], ["outlining", 516], ["the", 526], ["peritoneal", 530], ["cavity", 541], [")", 547], [",", 548], ["the", 550], ["inverted", 554], ["-", 562], ["V", 563], ["sign", 565], ["(", 570], ["gas", 571], ["outlining", 575], ["the", 585], ["medial", 589], ["umbilical", 596], ["folds", 606], [")", 611], [",", 612], ["and", 614], ["the", 618], ["right", 622], ["-", 627], ["upper", 628], ["-", 633], ["quadrant", 634], ["gas", 643], ["sign", 647], ["(", 652], ["localized", 653], ["gas", 663], ["in", 667], ["the", 670], ["right", 674], ["upper", 680], ["quadrant", 686], [")", 694], [".", 695], ["One", 697], ["or", 701], ["more", 704], ["of", 709], ["these", 712], ["signs", 718], ["were", 724], ["present", 729], ["in", 737], ["26", 740], ["cases", 743], ["(", 749], ["59", 750], ["%", 752], [")", 753], ["of", 755], ["pneumoperitoneum", 758], [",", 774], ["including", 776], ["the", 786], ["right", 790], ["-", 795], ["upper", 796], ["-", 801], ["quadrant", 802], ["gas", 811], ["sign", 815], ["in", 820], ["18", 823], ["cases", 826], ["(", 832], ["41", 833], ["%", 835], [")", 836], [",", 837], ["Rigler", 839], ["'s", 845], ["sign", 848], ["in", 853], ["14", 856], ["cases", 859], ["(", 865], ["32", 866], ["%", 868], [")", 869], [",", 870], ["and", 872], ["the", 876], ["falciform", 880], ["ligament", 890], ["and", 899], ["football", 903], ["signs", 912], ["in", 918], ["one", 921], ["case", 925], ["each", 930], ["(", 935], ["2", 936], ["%", 937], [")", 938], [".", 939], ["Unfortunately", 941], [",", 954], ["there", 956], ["were", 962], ["frequent", 967], ["errors", 976], ["in", 983], ["the", 986], ["interpretation", 990], ["of", 1005], ["the", 1008], ["right", 1012], ["-", 1017], ["upper", 1018], ["-", 1023], ["quadrant", 1024], ["gas", 1033], ["sign", 1037], ["and", 1042], ["Rigler", 1046], ["'s", 1052], ["sign", 1055], [",", 1059], ["with", 1061], ["a", 1066], ["total", 1068], ["of", 1074], ["11", 1077], ["false", 1080], ["-", 1085], ["positive", 1086], ["cases", 1095], ["(", 1101], ["13", 1102], ["%", 1104], [")", 1105], [".", 1106], ["Further", 1108], ["analysis", 1116], ["of", 1125], ["the", 1128], ["true", 1132], ["-", 1136], ["positive", 1137], ["right", 1146], ["-", 1151], ["upper", 1152], ["-", 1157], ["quadrant", 1158], ["gas", 1167], ["signs", 1171], ["showed", 1177], ["that", 1184], ["these", 1189], ["gas", 1195], ["collections", 1199], ["were", 1211], ["always", 1216], ["triangular", 1223], ["or", 1234], ["linear", 1237], ["with", 1244], ["an", 1249], ["inferolateral", 1252], ["to", 1266], ["superomedial", 1269], ["orientation", 1282], ["and", 1294], [",", 1297], ["if", 1299], ["triangular", 1302], [",", 1312], ["a", 1314], ["concave", 1316], ["superolateral", 1324], ["border", 1338], [".", 1344], ["In", 1346], ["the", 1349], ["true", 1353], ["-", 1357], ["positive", 1358], ["Rigler", 1367], ["'s", 1373], ["signs", 1376], [",", 1381], ["the", 1383], ["bowel", 1387], ["wall", 1393], ["thickness", 1398], ["ranged", 1408], ["from", 1415], ["1", 1420], ["to", 1422], ["8", 1425], ["mm", 1427], [",", 1429], ["whereas", 1431], ["the", 1439], ["false", 1443], ["positives", 1449], ["all", 1459], ["had", 1463], ["a", 1467], ["bowel", 1469], ["wall", 1475], ["thickness", 1480], ["of", 1490], ["1", 1493], ["mm", 1495], ["or", 1498], ["less", 1501], [".", 1505], ["Proper", 1507], ["interpretation", 1514], ["of", 1529], ["the", 1532], ["various", 1536], ["signs", 1544], ["of", 1550], ["pneumoperitoneum", 1553], ["on", 1570], ["supine", 1573], ["films", 1580], ["should", 1586], ["lead", 1593], ["to", 1598], ["more", 1601], ["accurate", 1606], ["diagnosis", 1615], ["of", 1625], ["this", 1628], ["condition", 1633], [".", 1642]]}
{"context": "A dedicated excision repair pathway, termed transcription-coupled repair (TCR), targets the removal of DNA lesions from transcribed strands of expressed genes. Transcription arrest at the site of the lesion has been proposed as the first step for initiation of TCR. In support of this model, a strong correlation between arrest of transcription by a lesion in vitro and TCR of that lesion in vivo has been found in most cases analyzed. TCR has been reported for oxidative DNA damage; however, very little is known about how frequently occurring and spontaneous DNA damage, such as depurination and base deamination, affects progression of the transcription complex. We have previously determined that the oxidative lesion, thymine glycol, is a significant block to transcription by T7 RNA polymerase (T7 RNAP) but has no detectable effect on transcription by RNA polymerase II (RNAP II) in a reconstituted system with all of the required factors. Another oxidative lesion, 8-oxoguanine, only slightly blocked T7 RNAP and caused RNAP II to briefly pause at the lesion before bypassing it. Because an abasic site is an intermediate in the repair of oxidative damage, it was of interest to learn whether it arrested transcription. Using in vitro transcription assays and substrates containing a specifically positioned lesion, we found that an abasic site in the transcribed strand is a 60% block to transcription by T7 RNAP but nearly a complete block to transcription by mammalian RNAP II. An abasic site in the nontranscribed strand did not block either polymerase. Our results clearly indicate that an abasic site is a much stronger block to transcription than either a thymine glycol or an 8-oxoguanine. Because the predominant model for TCR postulates that only lesions that block RNAP will be subject to TCR, our findings suggest that the abasic site may be sufficient to initiate TCR in vivo.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "6960bdbb74c3432a83bd3a3c0a6c30f1", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[242, 243]], "char_spans": [[1360, 1377]]}]}], "context_tokens": [["A", 0], ["dedicated", 2], ["excision", 12], ["repair", 21], ["pathway", 28], [",", 35], ["termed", 37], ["transcription", 44], ["-", 57], ["coupled", 58], ["repair", 66], ["(", 73], ["TCR", 74], [")", 77], [",", 78], ["targets", 80], ["the", 88], ["removal", 92], ["of", 100], ["DNA", 103], ["lesions", 107], ["from", 115], ["transcribed", 120], ["strands", 132], ["of", 140], ["expressed", 143], ["genes", 153], [".", 158], ["Transcription", 160], ["arrest", 174], ["at", 181], ["the", 184], ["site", 188], ["of", 193], ["the", 196], ["lesion", 200], ["has", 207], ["been", 211], ["proposed", 216], ["as", 225], ["the", 228], ["first", 232], ["step", 238], ["for", 243], ["initiation", 247], ["of", 258], ["TCR", 261], [".", 264], ["In", 266], ["support", 269], ["of", 277], ["this", 280], ["model", 285], [",", 290], ["a", 292], ["strong", 294], ["correlation", 301], ["between", 313], ["arrest", 321], ["of", 328], ["transcription", 331], ["by", 345], ["a", 348], ["lesion", 350], ["in", 357], ["vitro", 360], ["and", 366], ["TCR", 370], ["of", 374], ["that", 377], ["lesion", 382], ["in", 389], ["vivo", 392], ["has", 397], ["been", 401], ["found", 406], ["in", 412], ["most", 415], ["cases", 420], ["analyzed", 426], [".", 434], ["TCR", 436], ["has", 440], ["been", 444], ["reported", 449], ["for", 458], ["oxidative", 462], ["DNA", 472], ["damage", 476], [";", 482], ["however", 484], [",", 491], ["very", 493], ["little", 498], ["is", 505], ["known", 508], ["about", 514], ["how", 520], ["frequently", 524], ["occurring", 535], ["and", 545], ["spontaneous", 549], ["DNA", 561], ["damage", 565], [",", 571], ["such", 573], ["as", 578], ["depurination", 581], ["and", 594], ["base", 598], ["deamination", 603], [",", 614], ["affects", 616], ["progression", 624], ["of", 636], ["the", 639], ["transcription", 643], ["complex", 657], [".", 664], ["We", 666], ["have", 669], ["previously", 674], ["determined", 685], ["that", 696], ["the", 701], ["oxidative", 705], ["lesion", 715], [",", 721], ["thymine", 723], ["glycol", 731], [",", 737], ["is", 739], ["a", 742], ["significant", 744], ["block", 756], ["to", 762], ["transcription", 765], ["by", 779], ["T7", 782], ["RNA", 785], ["polymerase", 789], ["(", 800], ["T7", 801], ["RNAP", 804], [")", 808], ["but", 810], ["has", 814], ["no", 818], ["detectable", 821], ["effect", 832], ["on", 839], ["transcription", 842], ["by", 856], ["RNA", 859], ["polymerase", 863], ["II", 874], ["(", 877], ["RNAP", 878], ["II", 883], [")", 885], ["in", 887], ["a", 890], ["reconstituted", 892], ["system", 906], ["with", 913], ["all", 918], ["of", 922], ["the", 925], ["required", 929], ["factors", 938], [".", 945], ["Another", 947], ["oxidative", 955], ["lesion", 965], [",", 971], ["8-oxoguanine", 973], [",", 985], ["only", 987], ["slightly", 992], ["blocked", 1001], ["T7", 1009], ["RNAP", 1012], ["and", 1017], ["caused", 1021], ["RNAP", 1028], ["II", 1033], ["to", 1036], ["briefly", 1039], ["pause", 1047], ["at", 1053], ["the", 1056], ["lesion", 1060], ["before", 1067], ["bypassing", 1074], ["it", 1084], [".", 1086], ["Because", 1088], ["an", 1096], ["abasic", 1099], ["site", 1106], ["is", 1111], ["an", 1114], ["intermediate", 1117], ["in", 1130], ["the", 1133], ["repair", 1137], ["of", 1144], ["oxidative", 1147], ["damage", 1157], [",", 1163], ["it", 1165], ["was", 1168], ["of", 1172], ["interest", 1175], ["to", 1184], ["learn", 1187], ["whether", 1193], ["it", 1201], ["arrested", 1204], ["transcription", 1213], [".", 1226], ["Using", 1228], ["in", 1234], ["vitro", 1237], ["transcription", 1243], ["assays", 1257], ["and", 1264], ["substrates", 1268], ["containing", 1279], ["a", 1290], ["specifically", 1292], ["positioned", 1305], ["lesion", 1316], [",", 1322], ["we", 1324], ["found", 1327], ["that", 1333], ["an", 1338], ["abasic", 1341], ["site", 1348], ["in", 1353], ["the", 1356], ["transcribed", 1360], ["strand", 1372], ["is", 1379], ["a", 1382], ["60", 1384], ["%", 1386], ["block", 1388], ["to", 1394], ["transcription", 1397], ["by", 1411], ["T7", 1414], ["RNAP", 1417], ["but", 1422], ["nearly", 1426], ["a", 1433], ["complete", 1435], ["block", 1444], ["to", 1450], ["transcription", 1453], ["by", 1467], ["mammalian", 1470], ["RNAP", 1480], ["II", 1485], [".", 1487], ["An", 1489], ["abasic", 1492], ["site", 1499], ["in", 1504], ["the", 1507], ["nontranscribed", 1511], ["strand", 1526], ["did", 1533], ["not", 1537], ["block", 1541], ["either", 1547], ["polymerase", 1554], [".", 1564], ["Our", 1566], ["results", 1570], ["clearly", 1578], ["indicate", 1586], ["that", 1595], ["an", 1600], ["abasic", 1603], ["site", 1610], ["is", 1615], ["a", 1618], ["much", 1620], ["stronger", 1625], ["block", 1634], ["to", 1640], ["transcription", 1643], ["than", 1657], ["either", 1662], ["a", 1669], ["thymine", 1671], ["glycol", 1679], ["or", 1686], ["an", 1689], ["8-oxoguanine", 1692], [".", 1704], ["Because", 1706], ["the", 1714], ["predominant", 1718], ["model", 1730], ["for", 1736], ["TCR", 1740], ["postulates", 1744], ["that", 1755], ["only", 1760], ["lesions", 1765], ["that", 1773], ["block", 1778], ["RNAP", 1784], ["will", 1789], ["be", 1794], ["subject", 1797], ["to", 1805], ["TCR", 1808], [",", 1811], ["our", 1813], ["findings", 1817], ["suggest", 1826], ["that", 1834], ["the", 1839], ["abasic", 1843], ["site", 1850], ["may", 1855], ["be", 1859], ["sufficient", 1862], ["to", 1873], ["initiate", 1876], ["TCR", 1885], ["in", 1889], ["vivo", 1892], [".", 1896]]}
{"context": "Carpal tunnel syndrome (CTS) is the most common median nerve neuropathy, accounting for 90% of all neuropathies. Carpal tunnel syndrome presents in 3.8% of the general population, with a higher prevalence among women. There are several risk factors associated with CTS, including both medical and non medical factors. The pathophysiologic mechanisms involved in the median nerve compression and traction are thought to be complex, and as yet are not fully understood. The present review aimed to provide an overview of the pathophysiology of median nerve neuropathy in the carpal tunnel, and subsequent development of CTS.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "7d31ab9e001e4207a7f6499a2b13dd0e", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[64, 64], [95, 95], [10, 10]], "char_spans": [[366, 371], [542, 547], [48, 53]]}]}], "context_tokens": [["Carpal", 0], ["tunnel", 7], ["syndrome", 14], ["(", 23], ["CTS", 24], [")", 27], ["is", 29], ["the", 32], ["most", 36], ["common", 41], ["median", 48], ["nerve", 55], ["neuropathy", 61], [",", 71], ["accounting", 73], ["for", 84], ["90", 88], ["%", 90], ["of", 92], ["all", 95], ["neuropathies", 99], [".", 111], ["Carpal", 113], ["tunnel", 120], ["syndrome", 127], ["presents", 136], ["in", 145], ["3.8", 148], ["%", 151], ["of", 153], ["the", 156], ["general", 160], ["population", 168], [",", 178], ["with", 180], ["a", 185], ["higher", 187], ["prevalence", 194], ["among", 205], ["women", 211], [".", 216], ["There", 218], ["are", 224], ["several", 228], ["risk", 236], ["factors", 241], ["associated", 249], ["with", 260], ["CTS", 265], [",", 268], ["including", 270], ["both", 280], ["medical", 285], ["and", 293], ["non", 297], ["medical", 301], ["factors", 309], [".", 316], ["The", 318], ["pathophysiologic", 322], ["mechanisms", 339], ["involved", 350], ["in", 359], ["the", 362], ["median", 366], ["nerve", 373], ["compression", 379], ["and", 391], ["traction", 395], ["are", 404], ["thought", 408], ["to", 416], ["be", 419], ["complex", 422], [",", 429], ["and", 431], ["as", 435], ["yet", 438], ["are", 442], ["not", 446], ["fully", 450], ["understood", 456], [".", 466], ["The", 468], ["present", 472], ["review", 480], ["aimed", 487], ["to", 493], ["provide", 496], ["an", 504], ["overview", 507], ["of", 516], ["the", 519], ["pathophysiology", 523], ["of", 539], ["median", 542], ["nerve", 549], ["neuropathy", 555], ["in", 566], ["the", 569], ["carpal", 573], ["tunnel", 580], [",", 586], ["and", 588], ["subsequent", 592], ["development", 603], ["of", 615], ["CTS", 618], [".", 621]]}
{"context": "Mitogen-activated protein kinase (MAPK) cascades are involved in the regulation of cellular proliferation, differentiation, survival, apoptosis, as well as in inflammatory responses. Signal intensity and duration have been recognized as crucial parameters determining MAPK signaling output. Phosphatases play a particularly important role in this respect, by tightly controlling MAPK phosphorylation and activation. M3/6 (DUSP8) is a dual-specificity phosphatase implicated in the dephosphorylation and inactivation of JNK and, to a lesser extent, p38 MAPKs and is found in a complex with these kinases, along with other pathway components, held together by scaffold proteins. The JNK family consists of three genes, giving rise to at least ten different splice variants. Some functional differences between these gene products have been demonstrated, but the underlying molecular mechanisms and the roles of individual splice variants are still incompletely understood. We have investigated the interaction of M3/6 with JNK isoforms, as well as scaffold proteins of the JNK interacting protein (JIP) family, in order to elucidate the contribution of M3/6 to the regulation of distinct JNK signaling modules. M3/6 exhibited stronger binding towards JNK1\u03b2 and JNK2\u03b1 isoforms and this was reflected in higher enzymatic activity towards JNK2\u03b12 when compared to JNK1\u03b11 in vitro. After activation of the pathway by exposure of cells to arsenite, the interaction of M3/6 with JNK1\u03b1 and JNK3 was enhanced, whereas that with JNK1\u03b2 or JNK2\u03b1 decreased. The modulation of binding affinities was found to be independent of JNK-mediated M3/6 phosphorylation. Furthermore, arsenite treatment resulted in an inducible recruitment of M3/6 to JNK-interacting protein 3 (JIP3) scaffold complexes, while its interaction with JIP1 or JIP2 was constitutive. The presented data suggest an isoform-specific role for the M3/6 phosphatase and the dynamic targeting of M3/6 towards distinct JNK-containing signaling complexes.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "0e17fa4dc2be4a299e36c5cf49b2fbee", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[288, 288], [81, 81], [198, 198], [330, 330], [167, 167], [270, 270], [114, 114], [177, 177]], "char_spans": [[1726, 1728], [519, 521], [1186, 1188], [1965, 1967], [1021, 1023], [1611, 1613], [681, 683], [1071, 1073]]}]}], "context_tokens": [["Mitogen", 0], ["-", 7], ["activated", 8], ["protein", 18], ["kinase", 26], ["(", 33], ["MAPK", 34], [")", 38], ["cascades", 40], ["are", 49], ["involved", 53], ["in", 62], ["the", 65], ["regulation", 69], ["of", 80], ["cellular", 83], ["proliferation", 92], [",", 105], ["differentiation", 107], [",", 122], ["survival", 124], [",", 132], ["apoptosis", 134], [",", 143], ["as", 145], ["well", 148], ["as", 153], ["in", 156], ["inflammatory", 159], ["responses", 172], [".", 181], ["Signal", 183], ["intensity", 190], ["and", 200], ["duration", 204], ["have", 213], ["been", 218], ["recognized", 223], ["as", 234], ["crucial", 237], ["parameters", 245], ["determining", 256], ["MAPK", 268], ["signaling", 273], ["output", 283], [".", 289], ["Phosphatases", 291], ["play", 304], ["a", 309], ["particularly", 311], ["important", 324], ["role", 334], ["in", 339], ["this", 342], ["respect", 347], [",", 354], ["by", 356], ["tightly", 359], ["controlling", 367], ["MAPK", 379], ["phosphorylation", 384], ["and", 400], ["activation", 404], [".", 414], ["M3/6", 416], ["(", 421], ["DUSP8", 422], [")", 427], ["is", 429], ["a", 432], ["dual", 434], ["-", 438], ["specificity", 439], ["phosphatase", 451], ["implicated", 463], ["in", 474], ["the", 477], ["dephosphorylation", 481], ["and", 499], ["inactivation", 503], ["of", 516], ["JNK", 519], ["and", 523], [",", 526], ["to", 528], ["a", 531], ["lesser", 533], ["extent", 540], [",", 546], ["p38", 548], ["MAPKs", 552], ["and", 558], ["is", 562], ["found", 565], ["in", 571], ["a", 574], ["complex", 576], ["with", 584], ["these", 589], ["kinases", 595], [",", 602], ["along", 604], ["with", 610], ["other", 615], ["pathway", 621], ["components", 629], [",", 639], ["held", 641], ["together", 646], ["by", 655], ["scaffold", 658], ["proteins", 667], [".", 675], ["The", 677], ["JNK", 681], ["family", 685], ["consists", 692], ["of", 701], ["three", 704], ["genes", 710], [",", 715], ["giving", 717], ["rise", 724], ["to", 729], ["at", 732], ["least", 735], ["ten", 741], ["different", 745], ["splice", 755], ["variants", 762], [".", 770], ["Some", 772], ["functional", 777], ["differences", 788], ["between", 800], ["these", 808], ["gene", 814], ["products", 819], ["have", 828], ["been", 833], ["demonstrated", 838], [",", 850], ["but", 852], ["the", 856], ["underlying", 860], ["molecular", 871], ["mechanisms", 881], ["and", 892], ["the", 896], ["roles", 900], ["of", 906], ["individual", 909], ["splice", 920], ["variants", 927], ["are", 936], ["still", 940], ["incompletely", 946], ["understood", 959], [".", 969], ["We", 971], ["have", 974], ["investigated", 979], ["the", 992], ["interaction", 996], ["of", 1008], ["M3/6", 1011], ["with", 1016], ["JNK", 1021], ["isoforms", 1025], [",", 1033], ["as", 1035], ["well", 1038], ["as", 1043], ["scaffold", 1046], ["proteins", 1055], ["of", 1064], ["the", 1067], ["JNK", 1071], ["interacting", 1075], ["protein", 1087], ["(", 1095], ["JIP", 1096], [")", 1099], ["family", 1101], [",", 1107], ["in", 1109], ["order", 1112], ["to", 1118], ["elucidate", 1121], ["the", 1131], ["contribution", 1135], ["of", 1148], ["M3/6", 1151], ["to", 1156], ["the", 1159], ["regulation", 1163], ["of", 1174], ["distinct", 1177], ["JNK", 1186], ["signaling", 1190], ["modules", 1200], [".", 1207], ["M3/6", 1209], ["exhibited", 1214], ["stronger", 1224], ["binding", 1233], ["towards", 1241], ["JNK1\u03b2", 1249], ["and", 1255], ["JNK2\u03b1", 1259], ["isoforms", 1265], ["and", 1274], ["this", 1278], ["was", 1283], ["reflected", 1287], ["in", 1297], ["higher", 1300], ["enzymatic", 1307], ["activity", 1317], ["towards", 1326], ["JNK2\u03b12", 1334], ["when", 1341], ["compared", 1346], ["to", 1355], ["JNK1\u03b11", 1358], ["in", 1365], ["vitro", 1368], [".", 1373], ["After", 1375], ["activation", 1381], ["of", 1392], ["the", 1395], ["pathway", 1399], ["by", 1407], ["exposure", 1410], ["of", 1419], ["cells", 1422], ["to", 1428], ["arsenite", 1431], [",", 1439], ["the", 1441], ["interaction", 1445], ["of", 1457], ["M3/6", 1460], ["with", 1465], ["JNK1\u03b1", 1470], ["and", 1476], ["JNK3", 1480], ["was", 1485], ["enhanced", 1489], [",", 1497], ["whereas", 1499], ["that", 1507], ["with", 1512], ["JNK1\u03b2", 1517], ["or", 1523], ["JNK2\u03b1", 1526], ["decreased", 1532], [".", 1541], ["The", 1543], ["modulation", 1547], ["of", 1558], ["binding", 1561], ["affinities", 1569], ["was", 1580], ["found", 1584], ["to", 1590], ["be", 1593], ["independent", 1596], ["of", 1608], ["JNK", 1611], ["-", 1614], ["mediated", 1615], ["M3/6", 1624], ["phosphorylation", 1629], [".", 1644], ["Furthermore", 1646], [",", 1657], ["arsenite", 1659], ["treatment", 1668], ["resulted", 1678], ["in", 1687], ["an", 1690], ["inducible", 1693], ["recruitment", 1703], ["of", 1715], ["M3/6", 1718], ["to", 1723], ["JNK", 1726], ["-", 1729], ["interacting", 1730], ["protein", 1742], ["3", 1750], ["(", 1752], ["JIP3", 1753], [")", 1757], ["scaffold", 1759], ["complexes", 1768], [",", 1777], ["while", 1779], ["its", 1785], ["interaction", 1789], ["with", 1801], ["JIP1", 1806], ["or", 1811], ["JIP2", 1814], ["was", 1819], ["constitutive", 1823], [".", 1835], ["The", 1837], ["presented", 1841], ["data", 1851], ["suggest", 1856], ["an", 1864], ["isoform", 1867], ["-", 1874], ["specific", 1875], ["role", 1884], ["for", 1889], ["the", 1893], ["M3/6", 1897], ["phosphatase", 1902], ["and", 1914], ["the", 1918], ["dynamic", 1922], ["targeting", 1930], ["of", 1940], ["M3/6", 1943], ["towards", 1948], ["distinct", 1956], ["JNK", 1965], ["-", 1968], ["containing", 1969], ["signaling", 1980], ["complexes", 1990], [".", 1999]]}
{"context": "Molecular remodeling in heart failure includes slowing of repolarization, leading to proarrhythmia. To evaluate the effects of Na(+)/Ca(2+) exchanger (NCX) inhibition on repolarization as a novel antiarrhythmic concept in chronic heart failure (CHF). CHF was induced by rapid ventricular pacing in rabbits. Left ventricular function was assessed by echocardiography. Monophasic action potentials (MAPs) showed a prolongation of repolarization in CHF after atrioventricular block and stimulation at different cycle lengths. Sotalol (100 \u03bcM, n = 13) or veratridine (0.5 \u03bcM; n = 15) resulted in a further significant increase in the MAP duration. CHF was associated with an increased dispersion of repolarization, as compared with sotalol-treated (+22 \u00b1 7 ms; P < .05) and veratridine-treated (+20 \u00b1 6 ms; P < .05) sham hearts. In the presence of a low potassium concentration, sotalol and veratridine reproducibly induced early afterdepolarizations (EADs) and polymorphic ventricular tachyarrhythmias (VTs). SEA0400 (1 \u03bcM), a pharmacological inhibitor of NCX, significantly shortened the MAP duration (P < .01) and reduced dispersion (P < .05). It suppressed EAD in 6 of 13 sotalol-treated failing hearts and in 9 of 10 veratridine-treated failing hearts, leading to a reduction in VT (60% in sotalol-treated failing hearts and 83% in veratridine-treated failing hearts). Simulations using a mathematical model showed a reduction in the action potential duration and the number of EADs by the NCX block in all subgroups. In an experimental model of CHF, the acute inhibition of NCX (1) reduces the MAP duration, (2) decreases dispersion of repolarization, and (3) suppresses EAD and VT. Our observations indicate for the first time that pharmacological NCX inhibition increases repolarization reserve and protects against VTs in heart failure.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "71fee14086b941aea68a85c15ba9b987", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[19, 22]], "char_spans": [[127, 148]]}, {"text": "NCX", "token_spans": [[283, 283], [335, 335], [300, 300], [24, 24], [193, 193]], "char_spans": [[1491, 1493], [1751, 1753], [1576, 1578], [151, 153], [1053, 1055]]}]}], "context_tokens": [["Molecular", 0], ["remodeling", 10], ["in", 21], ["heart", 24], ["failure", 30], ["includes", 38], ["slowing", 47], ["of", 55], ["repolarization", 58], [",", 72], ["leading", 74], ["to", 82], ["proarrhythmia", 85], [".", 98], ["To", 100], ["evaluate", 103], ["the", 112], ["effects", 116], ["of", 124], ["Na(+)/Ca(2", 127], ["+", 137], [")", 138], ["exchanger", 140], ["(", 150], ["NCX", 151], [")", 154], ["inhibition", 156], ["on", 167], ["repolarization", 170], ["as", 185], ["a", 188], ["novel", 190], ["antiarrhythmic", 196], ["concept", 211], ["in", 219], ["chronic", 222], ["heart", 230], ["failure", 236], ["(", 244], ["CHF", 245], [")", 248], [".", 249], ["CHF", 251], ["was", 255], ["induced", 259], ["by", 267], ["rapid", 270], ["ventricular", 276], ["pacing", 288], ["in", 295], ["rabbits", 298], [".", 305], ["Left", 307], ["ventricular", 312], ["function", 324], ["was", 333], ["assessed", 337], ["by", 346], ["echocardiography", 349], [".", 365], ["Monophasic", 367], ["action", 378], ["potentials", 385], ["(", 396], ["MAPs", 397], [")", 401], ["showed", 403], ["a", 410], ["prolongation", 412], ["of", 425], ["repolarization", 428], ["in", 443], ["CHF", 446], ["after", 450], ["atrioventricular", 456], ["block", 473], ["and", 479], ["stimulation", 483], ["at", 495], ["different", 498], ["cycle", 508], ["lengths", 514], [".", 521], ["Sotalol", 523], ["(", 531], ["100", 532], ["\u03bcM", 536], [",", 538], ["n", 540], ["=", 542], ["13", 544], [")", 546], ["or", 548], ["veratridine", 551], ["(", 563], ["0.5", 564], ["\u03bcM", 568], [";", 570], ["n", 572], ["=", 574], ["15", 576], [")", 578], ["resulted", 580], ["in", 589], ["a", 592], ["further", 594], ["significant", 602], ["increase", 614], ["in", 623], ["the", 626], ["MAP", 630], ["duration", 634], [".", 642], ["CHF", 644], ["was", 648], ["associated", 652], ["with", 663], ["an", 668], ["increased", 671], ["dispersion", 681], ["of", 692], ["repolarization", 695], [",", 709], ["as", 711], ["compared", 714], ["with", 723], ["sotalol", 728], ["-", 735], ["treated", 736], ["(", 744], ["+22", 745], ["\u00b1", 749], ["7", 751], ["ms", 753], [";", 755], ["P", 757], ["<", 759], [".05", 761], [")", 764], ["and", 766], ["veratridine", 770], ["-", 781], ["treated", 782], ["(", 790], ["+20", 791], ["\u00b1", 795], ["6", 797], ["ms", 799], [";", 801], ["P", 803], ["<", 805], [".05", 807], [")", 810], ["sham", 812], ["hearts", 817], [".", 823], ["In", 825], ["the", 828], ["presence", 832], ["of", 841], ["a", 844], ["low", 846], ["potassium", 850], ["concentration", 860], [",", 873], ["sotalol", 875], ["and", 883], ["veratridine", 887], ["reproducibly", 899], ["induced", 912], ["early", 920], ["afterdepolarizations", 926], ["(", 947], ["EADs", 948], [")", 952], ["and", 954], ["polymorphic", 958], ["ventricular", 970], ["tachyarrhythmias", 982], ["(", 999], ["VTs", 1000], [")", 1003], [".", 1004], ["SEA0400", 1006], ["(", 1014], ["1", 1015], ["\u03bcM", 1017], [")", 1019], [",", 1020], ["a", 1022], ["pharmacological", 1024], ["inhibitor", 1040], ["of", 1050], ["NCX", 1053], [",", 1056], ["significantly", 1058], ["shortened", 1072], ["the", 1082], ["MAP", 1086], ["duration", 1090], ["(", 1099], ["P", 1100], ["<", 1102], [".01", 1104], [")", 1107], ["and", 1109], ["reduced", 1113], ["dispersion", 1121], ["(", 1132], ["P", 1133], ["<", 1135], [".05", 1137], [")", 1140], [".", 1141], ["It", 1143], ["suppressed", 1146], ["EAD", 1157], ["in", 1161], ["6", 1164], ["of", 1166], ["13", 1169], ["sotalol", 1172], ["-", 1179], ["treated", 1180], ["failing", 1188], ["hearts", 1196], ["and", 1203], ["in", 1207], ["9", 1210], ["of", 1212], ["10", 1215], ["veratridine", 1218], ["-", 1229], ["treated", 1230], ["failing", 1238], ["hearts", 1246], [",", 1252], ["leading", 1254], ["to", 1262], ["a", 1265], ["reduction", 1267], ["in", 1277], ["VT", 1280], ["(", 1283], ["60", 1284], ["%", 1286], ["in", 1288], ["sotalol", 1291], ["-", 1298], ["treated", 1299], ["failing", 1307], ["hearts", 1315], ["and", 1322], ["83", 1326], ["%", 1328], ["in", 1330], ["veratridine", 1333], ["-", 1344], ["treated", 1345], ["failing", 1353], ["hearts", 1361], [")", 1367], [".", 1368], ["Simulations", 1370], ["using", 1382], ["a", 1388], ["mathematical", 1390], ["model", 1403], ["showed", 1409], ["a", 1416], ["reduction", 1418], ["in", 1428], ["the", 1431], ["action", 1435], ["potential", 1442], ["duration", 1452], ["and", 1461], ["the", 1465], ["number", 1469], ["of", 1476], ["EADs", 1479], ["by", 1484], ["the", 1487], ["NCX", 1491], ["block", 1495], ["in", 1501], ["all", 1504], ["subgroups", 1508], [".", 1517], ["In", 1519], ["an", 1522], ["experimental", 1525], ["model", 1538], ["of", 1544], ["CHF", 1547], [",", 1550], ["the", 1552], ["acute", 1556], ["inhibition", 1562], ["of", 1573], ["NCX", 1576], ["(", 1580], ["1", 1581], [")", 1582], ["reduces", 1584], ["the", 1592], ["MAP", 1596], ["duration", 1600], [",", 1608], ["(", 1610], ["2", 1611], [")", 1612], ["decreases", 1614], ["dispersion", 1624], ["of", 1635], ["repolarization", 1638], [",", 1652], ["and", 1654], ["(", 1658], ["3", 1659], [")", 1660], ["suppresses", 1662], ["EAD", 1673], ["and", 1677], ["VT", 1681], [".", 1683], ["Our", 1685], ["observations", 1689], ["indicate", 1702], ["for", 1711], ["the", 1715], ["first", 1719], ["time", 1725], ["that", 1730], ["pharmacological", 1735], ["NCX", 1751], ["inhibition", 1755], ["increases", 1766], ["repolarization", 1776], ["reserve", 1791], ["and", 1799], ["protects", 1803], ["against", 1812], ["VTs", 1820], ["in", 1824], ["heart", 1827], ["failure", 1833], [".", 1840]]}
{"context": "Detection of latent tuberculosis infection is an important step in the control of tuberculosis. The tuberculin skin test is the only proven method for identifying tuberculosis infection in patients who do not have tuberculosis disease. The prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (Mantoux technique). Interpretation of the Mantoux test was based on the size of induration in millimeters and the individual risk profile of the patients, according to the guidelines of the American Thoracic Society and the Centers for Disease Control, revised in 1989. Of 697 tested patients, 252 showed test results consistent with tuberculosis infection (36.2%). 55 of these 697 patients had active tuberculosis disease or a prior history of tuberculosis (7.9%). A positive tuberculin skin test was found in 197 of 642 patients (30.7%) with a diagnosis different from tuberculosis (COPD, pneumonia, cancer and others). In our study, the sensitivity of the tuberculin skin test for active tuberculosis infection was 95%. The present study revealed a high prevalence of tuberculosis infection among hospitalized patients in a pneumological department. Further studies are needed to assess the usefulness of routine tuberculin skin testing in hospitalized populations.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "a2d8fa1d4aec4b51af662fbe80cc7535", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[144, 144], [3, 3], [13, 13], [26, 26], [123, 123], [171, 171], [195, 195], [137, 137], [40, 40], [34, 34], [209, 209]], "char_spans": [[865, 876], [20, 31], [82, 93], [163, 174], [754, 765], [991, 1002], [1111, 1122], [822, 833], [254, 265], [214, 225], [1191, 1202]]}]}], "context_tokens": [["Detection", 0], ["of", 10], ["latent", 13], ["tuberculosis", 20], ["infection", 33], ["is", 43], ["an", 46], ["important", 49], ["step", 59], ["in", 64], ["the", 67], ["control", 71], ["of", 79], ["tuberculosis", 82], [".", 94], ["The", 96], ["tuberculin", 100], ["skin", 111], ["test", 116], ["is", 121], ["the", 124], ["only", 128], ["proven", 133], ["method", 140], ["for", 147], ["identifying", 151], ["tuberculosis", 163], ["infection", 176], ["in", 186], ["patients", 189], ["who", 198], ["do", 202], ["not", 205], ["have", 209], ["tuberculosis", 214], ["disease", 227], [".", 234], ["The", 236], ["prevalence", 240], ["of", 251], ["tuberculosis", 254], ["infection", 267], ["among", 277], ["hospitalized", 283], ["patients", 296], ["in", 305], ["a", 308], ["pneumological", 310], ["department", 324], ["of", 335], ["an", 338], ["inner", 341], ["-", 346], ["city", 347], ["hospital", 352], ["was", 361], ["evaluated", 365], [",", 374], ["using", 376], ["the", 382], ["intradermal", 386], ["tuberculin", 398], ["skin", 409], ["test", 414], ["(", 419], ["Mantoux", 420], ["technique", 428], [")", 437], [".", 438], ["Interpretation", 440], ["of", 455], ["the", 458], ["Mantoux", 462], ["test", 470], ["was", 475], ["based", 479], ["on", 485], ["the", 488], ["size", 492], ["of", 497], ["induration", 500], ["in", 511], ["millimeters", 514], ["and", 526], ["the", 530], ["individual", 534], ["risk", 545], ["profile", 550], ["of", 558], ["the", 561], ["patients", 565], [",", 573], ["according", 575], ["to", 585], ["the", 588], ["guidelines", 592], ["of", 603], ["the", 606], ["American", 610], ["Thoracic", 619], ["Society", 628], ["and", 636], ["the", 640], ["Centers", 644], ["for", 652], ["Disease", 656], ["Control", 664], [",", 671], ["revised", 673], ["in", 681], ["1989", 684], [".", 688], ["Of", 690], ["697", 693], ["tested", 697], ["patients", 704], [",", 712], ["252", 714], ["showed", 718], ["test", 725], ["results", 730], ["consistent", 738], ["with", 749], ["tuberculosis", 754], ["infection", 767], ["(", 777], ["36.2", 778], ["%", 782], [")", 783], [".", 784], ["55", 786], ["of", 789], ["these", 792], ["697", 798], ["patients", 802], ["had", 811], ["active", 815], ["tuberculosis", 822], ["disease", 835], ["or", 843], ["a", 846], ["prior", 848], ["history", 854], ["of", 862], ["tuberculosis", 865], ["(", 878], ["7.9", 879], ["%", 882], [")", 883], [".", 884], ["A", 886], ["positive", 888], ["tuberculin", 897], ["skin", 908], ["test", 913], ["was", 918], ["found", 922], ["in", 928], ["197", 931], ["of", 935], ["642", 938], ["patients", 942], ["(", 951], ["30.7", 952], ["%", 956], [")", 957], ["with", 959], ["a", 964], ["diagnosis", 966], ["different", 976], ["from", 986], ["tuberculosis", 991], ["(", 1004], ["COPD", 1005], [",", 1009], ["pneumonia", 1011], [",", 1020], ["cancer", 1022], ["and", 1029], ["others", 1033], [")", 1039], [".", 1040], ["In", 1042], ["our", 1045], ["study", 1049], [",", 1054], ["the", 1056], ["sensitivity", 1060], ["of", 1072], ["the", 1075], ["tuberculin", 1079], ["skin", 1090], ["test", 1095], ["for", 1100], ["active", 1104], ["tuberculosis", 1111], ["infection", 1124], ["was", 1134], ["95", 1138], ["%", 1140], [".", 1141], ["The", 1143], ["present", 1147], ["study", 1155], ["revealed", 1161], ["a", 1170], ["high", 1172], ["prevalence", 1177], ["of", 1188], ["tuberculosis", 1191], ["infection", 1204], ["among", 1214], ["hospitalized", 1220], ["patients", 1233], ["in", 1242], ["a", 1245], ["pneumological", 1247], ["department", 1261], [".", 1271], ["Further", 1273], ["studies", 1281], ["are", 1289], ["needed", 1293], ["to", 1300], ["assess", 1303], ["the", 1310], ["usefulness", 1314], ["of", 1325], ["routine", 1328], ["tuberculin", 1336], ["skin", 1347], ["testing", 1352], ["in", 1360], ["hospitalized", 1363], ["populations", 1376], [".", 1387]]}
{"context": "Recurrent syncope, malignant ventricular arrhythmias, and sudden death are complications of the long QT syndrome (LQTS). Two well-known syndromes with long QT intervals are known. The Jervell and Lange-Nielsen syndrome (JLNS) is characterized by prolongation of the QT interval, deafness, and autosomal-recessive inheritance, and the Romano-Ward syndrome is characterized by a prolonged QT interval, autosomal-dominant inheritance, and no deafness. In the present study assessment was performed of the diagnostic importance of the ventricular derepolarization parameters, clinical features, and prevalence of JLNS among 132 children with congenital hearing loss (CHL). In the CHL group the mean QT, QTc, JT, and JTc intervals and the dispersion values (QT-d, JT-d, QTc-d, and JTc-d) were significantly longer than those of control subjects (n = 96) (P < 0.05). Patients with CHL and JLNS (n = 5) had significantly longer mean values of QT, QTc, JT, and JTc intervals and dispersion values than those of CHL without JLNS (n = 127) and control subjects (P < 0.05). The results suggest that assessment of ventricular derepolarization parameters in children with CHL will be helpful in the early detection of JLNS because infants with CHL cannot accurately describe the symptoms of syncope.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "e5d58ee5c70045e09f9863cc375814b3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[74, 76]], "char_spans": [[400, 417]]}]}], "context_tokens": [["Recurrent", 0], ["syncope", 10], [",", 17], ["malignant", 19], ["ventricular", 29], ["arrhythmias", 41], [",", 52], ["and", 54], ["sudden", 58], ["death", 65], ["are", 71], ["complications", 75], ["of", 89], ["the", 92], ["long", 96], ["QT", 101], ["syndrome", 104], ["(", 113], ["LQTS", 114], [")", 118], [".", 119], ["Two", 121], ["well", 125], ["-", 129], ["known", 130], ["syndromes", 136], ["with", 146], ["long", 151], ["QT", 156], ["intervals", 159], ["are", 169], ["known", 173], [".", 178], ["The", 180], ["Jervell", 184], ["and", 192], ["Lange", 196], ["-", 201], ["Nielsen", 202], ["syndrome", 210], ["(", 219], ["JLNS", 220], [")", 224], ["is", 226], ["characterized", 229], ["by", 243], ["prolongation", 246], ["of", 259], ["the", 262], ["QT", 266], ["interval", 269], [",", 277], ["deafness", 279], [",", 287], ["and", 289], ["autosomal", 293], ["-", 302], ["recessive", 303], ["inheritance", 313], [",", 324], ["and", 326], ["the", 330], ["Romano", 334], ["-", 340], ["Ward", 341], ["syndrome", 346], ["is", 355], ["characterized", 358], ["by", 372], ["a", 375], ["prolonged", 377], ["QT", 387], ["interval", 390], [",", 398], ["autosomal", 400], ["-", 409], ["dominant", 410], ["inheritance", 419], [",", 430], ["and", 432], ["no", 436], ["deafness", 439], [".", 447], ["In", 449], ["the", 452], ["present", 456], ["study", 464], ["assessment", 470], ["was", 481], ["performed", 485], ["of", 495], ["the", 498], ["diagnostic", 502], ["importance", 513], ["of", 524], ["the", 527], ["ventricular", 531], ["derepolarization", 543], ["parameters", 560], [",", 570], ["clinical", 572], ["features", 581], [",", 589], ["and", 591], ["prevalence", 595], ["of", 606], ["JLNS", 609], ["among", 614], ["132", 620], ["children", 624], ["with", 633], ["congenital", 638], ["hearing", 649], ["loss", 657], ["(", 662], ["CHL", 663], [")", 666], [".", 667], ["In", 669], ["the", 672], ["CHL", 676], ["group", 680], ["the", 686], ["mean", 690], ["QT", 695], [",", 697], ["QTc", 699], [",", 702], ["JT", 704], [",", 706], ["and", 708], ["JTc", 712], ["intervals", 716], ["and", 726], ["the", 730], ["dispersion", 734], ["values", 745], ["(", 752], ["QT", 753], ["-", 755], ["d", 756], [",", 757], ["JT", 759], ["-", 761], ["d", 762], [",", 763], ["QTc", 765], ["-", 768], ["d", 769], [",", 770], ["and", 772], ["JTc", 776], ["-", 779], ["d", 780], [")", 781], ["were", 783], ["significantly", 788], ["longer", 802], ["than", 809], ["those", 814], ["of", 820], ["control", 823], ["subjects", 831], ["(", 840], ["n", 841], ["=", 843], ["96", 845], [")", 847], ["(", 849], ["P", 850], ["<", 852], ["0.05", 854], [")", 858], [".", 859], ["Patients", 861], ["with", 870], ["CHL", 875], ["and", 879], ["JLNS", 883], ["(", 888], ["n", 889], ["=", 891], ["5", 893], [")", 894], ["had", 896], ["significantly", 900], ["longer", 914], ["mean", 921], ["values", 926], ["of", 933], ["QT", 936], [",", 938], ["QTc", 940], [",", 943], ["JT", 945], [",", 947], ["and", 949], ["JTc", 953], ["intervals", 957], ["and", 967], ["dispersion", 971], ["values", 982], ["than", 989], ["those", 994], ["of", 1000], ["CHL", 1003], ["without", 1007], ["JLNS", 1015], ["(", 1020], ["n", 1021], ["=", 1023], ["127", 1025], [")", 1028], ["and", 1030], ["control", 1034], ["subjects", 1042], ["(", 1051], ["P", 1052], ["<", 1054], ["0.05", 1056], [")", 1060], [".", 1061], ["The", 1063], ["results", 1067], ["suggest", 1075], ["that", 1083], ["assessment", 1088], ["of", 1099], ["ventricular", 1102], ["derepolarization", 1114], ["parameters", 1131], ["in", 1142], ["children", 1145], ["with", 1154], ["CHL", 1159], ["will", 1163], ["be", 1168], ["helpful", 1171], ["in", 1179], ["the", 1182], ["early", 1186], ["detection", 1192], ["of", 1202], ["JLNS", 1205], ["because", 1210], ["infants", 1218], ["with", 1226], ["CHL", 1231], ["can", 1235], ["not", 1238], ["accurately", 1242], ["describe", 1253], ["the", 1262], ["symptoms", 1266], ["of", 1275], ["syncope", 1278], [".", 1285]]}
{"context": "Selexipag is a first-in-class orally available selective non-prostanoid IP receptor agonist. This review was based on a PubMed search and focuses on the potential role of selexipag in the treatment of pulmonary arterial hypertension (PAH). Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679. Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors. This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized. In addition, the selexipag metabolite has a half-life of 7.9 h, thus permitting oral dosing twice daily. Selexipag showed effects on pharmacodynamic end points obtained with right heart catheterization in a Phase II trial in patients with PAH, and is being evaluated in the ongoing Phase III trial (GRIPHON trial, Clinicaltrials.gov NCT01106014). The signal of a beneficial effect of selexipag on disease progression may become more robust for long term under prolonged exposure. Pending the GRIPHON trial results, selexipag could provide a convenient first-line prostacyclin treatment option for patients with PAH.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "d69c9463ec08444a919447d7f33855f7", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[38, 40]], "char_spans": [[201, 231]]}]}], "context_tokens": [["Selexipag", 0], ["is", 10], ["a", 13], ["first", 15], ["-", 20], ["in", 21], ["-", 23], ["class", 24], ["orally", 30], ["available", 37], ["selective", 47], ["non", 57], ["-", 60], ["prostanoid", 61], ["IP", 72], ["receptor", 75], ["agonist", 84], [".", 91], ["This", 93], ["review", 98], ["was", 105], ["based", 109], ["on", 115], ["a", 118], ["PubMed", 120], ["search", 127], ["and", 134], ["focuses", 138], ["on", 146], ["the", 149], ["potential", 153], ["role", 163], ["of", 168], ["selexipag", 171], ["in", 181], ["the", 184], ["treatment", 188], ["of", 198], ["pulmonary", 201], ["arterial", 211], ["hypertension", 220], ["(", 233], ["PAH", 234], [")", 237], [".", 238], ["Selexipag", 240], ["is", 250], ["rapidly", 253], ["hydrolyzed", 261], ["to", 272], ["an", 275], ["active", 278], ["metabolite", 285], [",", 295], ["ACT-333679", 297], [".", 307], ["Both", 309], ["selexipag", 314], ["and", 324], ["its", 328], ["metabolite", 332], ["are", 343], ["highly", 347], ["selective", 354], ["for", 364], ["the", 368], ["IP", 372], ["receptor", 375], ["compared", 384], ["with", 393], ["other", 398], ["prostanoid", 404], ["receptors", 415], [".", 424], ["This", 426], ["selectivity", 431], ["for", 443], ["the", 447], ["IP", 451], ["receptor", 454], ["offers", 463], ["the", 470], ["potential", 474], ["for", 484], ["improved", 488], ["tolerability", 497], ["with", 510], ["selexipag", 515], [",", 524], ["as", 526], ["side", 529], ["effects", 534], ["(", 542], ["e.g.", 543], [",", 547], ["nausea", 549], ["and", 556], ["vomiting", 560], [")", 568], ["that", 570], ["might", 575], ["result", 581], ["from", 588], ["activation", 593], ["of", 604], ["the", 607], ["other", 611], ["prostanoid", 617], ["receptors", 628], ["may", 638], ["be", 642], ["minimized", 645], [".", 654], ["In", 656], ["addition", 659], [",", 667], ["the", 669], ["selexipag", 673], ["metabolite", 683], ["has", 694], ["a", 698], ["half", 700], ["-", 704], ["life", 705], ["of", 710], ["7.9", 713], ["h", 717], [",", 718], ["thus", 720], ["permitting", 725], ["oral", 736], ["dosing", 741], ["twice", 748], ["daily", 754], [".", 759], ["Selexipag", 761], ["showed", 771], ["effects", 778], ["on", 786], ["pharmacodynamic", 789], ["end", 805], ["points", 809], ["obtained", 816], ["with", 825], ["right", 830], ["heart", 836], ["catheterization", 842], ["in", 858], ["a", 861], ["Phase", 863], ["II", 869], ["trial", 872], ["in", 878], ["patients", 881], ["with", 890], ["PAH", 895], [",", 898], ["and", 900], ["is", 904], ["being", 907], ["evaluated", 913], ["in", 923], ["the", 926], ["ongoing", 930], ["Phase", 938], ["III", 944], ["trial", 948], ["(", 954], ["GRIPHON", 955], ["trial", 963], [",", 968], ["Clinicaltrials.gov", 970], ["NCT01106014", 989], [")", 1000], [".", 1001], ["The", 1003], ["signal", 1007], ["of", 1014], ["a", 1017], ["beneficial", 1019], ["effect", 1030], ["of", 1037], ["selexipag", 1040], ["on", 1050], ["disease", 1053], ["progression", 1061], ["may", 1073], ["become", 1077], ["more", 1084], ["robust", 1089], ["for", 1096], ["long", 1100], ["term", 1105], ["under", 1110], ["prolonged", 1116], ["exposure", 1126], [".", 1134], ["Pending", 1136], ["the", 1144], ["GRIPHON", 1148], ["trial", 1156], ["results", 1162], [",", 1169], ["selexipag", 1171], ["could", 1181], ["provide", 1187], ["a", 1195], ["convenient", 1197], ["first", 1208], ["-", 1213], ["line", 1214], ["prostacyclin", 1219], ["treatment", 1232], ["option", 1242], ["for", 1249], ["patients", 1253], ["with", 1262], ["PAH", 1267], [".", 1270]]}
{"context": "Forces deployed to the first Gulf War report more ill health than veterans who did not serve there. Many studies of post-Gulf morbidity are based on relatively small sample sizes and selection bias is often a concern. In a setting where selection bias relating to the ill health of veterans may be reduced, we: i) examined self-reported adult ill health in a large sample of male UK Gulf War veterans and a demographically similar non-deployed comparison group; and ii) explored self-reported ill health among veterans who believed that they had Gulf War syndrome. This study uses data from a retrospective cohort study of reproduction and child health in which a validated postal questionnaire was sent to all UK Gulf War veterans (GWV) and a comparison cohort of Armed Service personnel who were not deployed to the Gulf (NGWV). The cohort for analysis comprises 42,818 males who responded to the questionnaire. We confirmed that GWV report higher rates of general ill health. GWV were significantly more likely to have reported at least one new medical symptom or disease since 1990 than NGWV (61% versus 37%, OR 2.7, 95% CI 2.5-2.8). They were also more likely to report higher numbers of symptoms. The strongest associations were for mood swings (OR 20.9, 95%CI 16.2-27.0), memory loss/lack of concentration (OR 19.6, 95% CI 15.5-24.8), night sweats (OR 9.9, 95% CI 6.5-15.2), general fatigue (OR 9.6, 95% CI 8.3-11.1) and sexual dysfunction (OR 4.6, 95%CI 3.2-6.6). 6% of GWV believed they had Gulf War syndrome (GWS), and this was associated with the highest symptom reporting. Increased levels of reported ill health among GWV were confirmed. This study was the first to use a questionnaire which did not focus specifically on the veterans' symptoms themselves. Nevertheless, the results are consistent with those of other studies of post-Gulf war illness and thus strengthen overall findings in this area of research. Further examination of the mechanisms underlying the reporting of ill health is required.", "qas": [{"question": "What memory problems are reported in the \" Gulf war syndrome\"", "answers": ["memory loss"], "qid": "b59f8200d7c241df95bf00fcbea3ba21", "question_tokens": [["What", 0], ["memory", 5], ["problems", 12], ["are", 21], ["reported", 25], ["in", 34], ["the", 37], ["\"", 41], ["Gulf", 43], ["war", 48], ["syndrome", 52], ["\"", 60]], "detected_answers": [{"text": "memory loss", "token_spans": [[251, 252]], "char_spans": [[1279, 1289]]}]}], "context_tokens": [["Forces", 0], ["deployed", 7], ["to", 16], ["the", 19], ["first", 23], ["Gulf", 29], ["War", 34], ["report", 38], ["more", 45], ["ill", 50], ["health", 54], ["than", 61], ["veterans", 66], ["who", 75], ["did", 79], ["not", 83], ["serve", 87], ["there", 93], [".", 98], ["Many", 100], ["studies", 105], ["of", 113], ["post", 116], ["-", 120], ["Gulf", 121], ["morbidity", 126], ["are", 136], ["based", 140], ["on", 146], ["relatively", 149], ["small", 160], ["sample", 166], ["sizes", 173], ["and", 179], ["selection", 183], ["bias", 193], ["is", 198], ["often", 201], ["a", 207], ["concern", 209], [".", 216], ["In", 218], ["a", 221], ["setting", 223], ["where", 231], ["selection", 237], ["bias", 247], ["relating", 252], ["to", 261], ["the", 264], ["ill", 268], ["health", 272], ["of", 279], ["veterans", 282], ["may", 291], ["be", 295], ["reduced", 298], [",", 305], ["we", 307], [":", 309], ["i", 311], [")", 312], ["examined", 314], ["self", 323], ["-", 327], ["reported", 328], ["adult", 337], ["ill", 343], ["health", 347], ["in", 354], ["a", 357], ["large", 359], ["sample", 365], ["of", 372], ["male", 375], ["UK", 380], ["Gulf", 383], ["War", 388], ["veterans", 392], ["and", 401], ["a", 405], ["demographically", 407], ["similar", 423], ["non", 431], ["-", 434], ["deployed", 435], ["comparison", 444], ["group", 455], [";", 460], ["and", 462], ["ii", 466], [")", 468], ["explored", 470], ["self", 479], ["-", 483], ["reported", 484], ["ill", 493], ["health", 497], ["among", 504], ["veterans", 510], ["who", 519], ["believed", 523], ["that", 532], ["they", 537], ["had", 542], ["Gulf", 546], ["War", 551], ["syndrome", 555], [".", 563], ["This", 565], ["study", 570], ["uses", 576], ["data", 581], ["from", 586], ["a", 591], ["retrospective", 593], ["cohort", 607], ["study", 614], ["of", 620], ["reproduction", 623], ["and", 636], ["child", 640], ["health", 646], ["in", 653], ["which", 656], ["a", 662], ["validated", 664], ["postal", 674], ["questionnaire", 681], ["was", 695], ["sent", 699], ["to", 704], ["all", 707], ["UK", 711], ["Gulf", 714], ["War", 719], ["veterans", 723], ["(", 732], ["GWV", 733], [")", 736], ["and", 738], ["a", 742], ["comparison", 744], ["cohort", 755], ["of", 762], ["Armed", 765], ["Service", 771], ["personnel", 779], ["who", 789], ["were", 793], ["not", 798], ["deployed", 802], ["to", 811], ["the", 814], ["Gulf", 818], ["(", 823], ["NGWV", 824], [")", 828], [".", 829], ["The", 831], ["cohort", 835], ["for", 842], ["analysis", 846], ["comprises", 855], ["42,818", 865], ["males", 872], ["who", 878], ["responded", 882], ["to", 892], ["the", 895], ["questionnaire", 899], [".", 912], ["We", 914], ["confirmed", 917], ["that", 927], ["GWV", 932], ["report", 936], ["higher", 943], ["rates", 950], ["of", 956], ["general", 959], ["ill", 967], ["health", 971], [".", 977], ["GWV", 979], ["were", 983], ["significantly", 988], ["more", 1002], ["likely", 1007], ["to", 1014], ["have", 1017], ["reported", 1022], ["at", 1031], ["least", 1034], ["one", 1040], ["new", 1044], ["medical", 1048], ["symptom", 1056], ["or", 1064], ["disease", 1067], ["since", 1075], ["1990", 1081], ["than", 1086], ["NGWV", 1091], ["(", 1096], ["61", 1097], ["%", 1099], ["versus", 1101], ["37", 1108], ["%", 1110], [",", 1111], ["OR", 1113], ["2.7", 1116], [",", 1119], ["95", 1121], ["%", 1123], ["CI", 1125], ["2.5", 1128], ["-", 1131], ["2.8", 1132], [")", 1135], [".", 1136], ["They", 1138], ["were", 1143], ["also", 1148], ["more", 1153], ["likely", 1158], ["to", 1165], ["report", 1168], ["higher", 1175], ["numbers", 1182], ["of", 1190], ["symptoms", 1193], [".", 1201], ["The", 1203], ["strongest", 1207], ["associations", 1217], ["were", 1230], ["for", 1235], ["mood", 1239], ["swings", 1244], ["(", 1251], ["OR", 1252], ["20.9", 1255], [",", 1259], ["95%CI", 1261], ["16.2", 1267], ["-", 1271], ["27.0", 1272], [")", 1276], [",", 1277], ["memory", 1279], ["loss", 1286], ["/", 1290], ["lack", 1291], ["of", 1296], ["concentration", 1299], ["(", 1313], ["OR", 1314], ["19.6", 1317], [",", 1321], ["95", 1323], ["%", 1325], ["CI", 1327], ["15.5", 1330], ["-", 1334], ["24.8", 1335], [")", 1339], [",", 1340], ["night", 1342], ["sweats", 1348], ["(", 1355], ["OR", 1356], ["9.9", 1359], [",", 1362], ["95", 1364], ["%", 1366], ["CI", 1368], ["6.5", 1371], ["-", 1374], ["15.2", 1375], [")", 1379], [",", 1380], ["general", 1382], ["fatigue", 1390], ["(", 1398], ["OR", 1399], ["9.6", 1402], [",", 1405], ["95", 1407], ["%", 1409], ["CI", 1411], ["8.3", 1414], ["-", 1417], ["11.1", 1418], [")", 1422], ["and", 1424], ["sexual", 1428], ["dysfunction", 1435], ["(", 1447], ["OR", 1448], ["4.6", 1451], [",", 1454], ["95%CI", 1456], ["3.2", 1462], ["-", 1465], ["6.6", 1466], [")", 1469], [".", 1470], ["6", 1472], ["%", 1473], ["of", 1475], ["GWV", 1478], ["believed", 1482], ["they", 1491], ["had", 1496], ["Gulf", 1500], ["War", 1505], ["syndrome", 1509], ["(", 1518], ["GWS", 1519], [")", 1522], [",", 1523], ["and", 1525], ["this", 1529], ["was", 1534], ["associated", 1538], ["with", 1549], ["the", 1554], ["highest", 1558], ["symptom", 1566], ["reporting", 1574], [".", 1583], ["Increased", 1585], ["levels", 1595], ["of", 1602], ["reported", 1605], ["ill", 1614], ["health", 1618], ["among", 1625], ["GWV", 1631], ["were", 1635], ["confirmed", 1640], [".", 1649], ["This", 1651], ["study", 1656], ["was", 1662], ["the", 1666], ["first", 1670], ["to", 1676], ["use", 1679], ["a", 1683], ["questionnaire", 1685], ["which", 1699], ["did", 1705], ["not", 1709], ["focus", 1713], ["specifically", 1719], ["on", 1732], ["the", 1735], ["veterans", 1739], ["'", 1747], ["symptoms", 1749], ["themselves", 1758], [".", 1768], ["Nevertheless", 1770], [",", 1782], ["the", 1784], ["results", 1788], ["are", 1796], ["consistent", 1800], ["with", 1811], ["those", 1816], ["of", 1822], ["other", 1825], ["studies", 1831], ["of", 1839], ["post", 1842], ["-", 1846], ["Gulf", 1847], ["war", 1852], ["illness", 1856], ["and", 1864], ["thus", 1868], ["strengthen", 1873], ["overall", 1884], ["findings", 1892], ["in", 1901], ["this", 1904], ["area", 1909], ["of", 1914], ["research", 1917], [".", 1925], ["Further", 1927], ["examination", 1935], ["of", 1947], ["the", 1950], ["mechanisms", 1954], ["underlying", 1965], ["the", 1976], ["reporting", 1980], ["of", 1990], ["ill", 1993], ["health", 1997], ["is", 2004], ["required", 2007], [".", 2015]]}
{"context": "The aim of this study was to elucidate the role of lysyl oxidase (LOX) and lysyl oxidase like (LOXL) 2 in pathologic wound healing after glaucoma surgery. We therefore investigated the expression of LOX and LOXL2 and evaluated the therapeutic potential of anti-LOX (GS-639556, formerly M64) and anti-LOXL2 (GS-607601, formerly AB0023) antibodies in a rabbit model of glaucoma trabeculectomy. Ocular expression of LOX and LOXL2 was investigated by immunohistologic staining at different time points after trabeculectomy. Treatment with GS-639556 or GS-607601 was initiated in rabbits immediately after trabeculectomy by giving both intracameral and subconjunctival injections. Thereafter, the antibodies were given twice a week subconjunctivally until day 30 after surgery (day of euthanization). Treatment outcome was studied by clinical investigation of the bleb and by immunohistochemical analysis of angiogenesis, inflammation, and collagen deposition. LOX and LOXL2 were both upregulated in Tenon's capsule and the conjunctiva after glaucoma surgery. Repeated administration of LOX- or LOXL2-targeting monoclonal antibodies increased bleb area and bleb survival. Analyses of immunohistologic stainings showed that both antibodies significantly decreased fibrosis, whereas the anti-LOXL2 antibody also significantly reduced blood vessel density and inflammation. Targeting LOXL2 with an inhibitory monoclonal antibody (GS-607601) reduced pathologic angiogenesis, inflammation, and fibrosis. These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.", "qas": [{"question": "What is the drug target for Simtuzumab?", "answers": ["LOXL2"], "qid": "09d197c3c5924d1ca53e19a939eede2e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["drug", 12], ["target", 17], ["for", 24], ["Simtuzumab", 28], ["?", 38]], "detected_answers": [{"text": "LOXL2", "token_spans": [[80, 80], [205, 205], [59, 59], [217, 217], [40, 40], [239, 239], [159, 159]], "char_spans": [[421, 425], [1285, 1289], [300, 304], [1376, 1380], [207, 211], [1521, 1525], [964, 968]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["elucidate", 29], ["the", 39], ["role", 43], ["of", 48], ["lysyl", 51], ["oxidase", 57], ["(", 65], ["LOX", 66], [")", 69], ["and", 71], ["lysyl", 75], ["oxidase", 81], ["like", 89], ["(", 94], ["LOXL", 95], [")", 99], ["2", 101], ["in", 103], ["pathologic", 106], ["wound", 117], ["healing", 123], ["after", 131], ["glaucoma", 137], ["surgery", 146], [".", 153], ["We", 155], ["therefore", 158], ["investigated", 168], ["the", 181], ["expression", 185], ["of", 196], ["LOX", 199], ["and", 203], ["LOXL2", 207], ["and", 213], ["evaluated", 217], ["the", 227], ["therapeutic", 231], ["potential", 243], ["of", 253], ["anti", 256], ["-", 260], ["LOX", 261], ["(", 265], ["GS-639556", 266], [",", 275], ["formerly", 277], ["M64", 286], [")", 289], ["and", 291], ["anti", 295], ["-", 299], ["LOXL2", 300], ["(", 306], ["GS-607601", 307], [",", 316], ["formerly", 318], ["AB0023", 327], [")", 333], ["antibodies", 335], ["in", 346], ["a", 349], ["rabbit", 351], ["model", 358], ["of", 364], ["glaucoma", 367], ["trabeculectomy", 376], [".", 390], ["Ocular", 392], ["expression", 399], ["of", 410], ["LOX", 413], ["and", 417], ["LOXL2", 421], ["was", 427], ["investigated", 431], ["by", 444], ["immunohistologic", 447], ["staining", 464], ["at", 473], ["different", 476], ["time", 486], ["points", 491], ["after", 498], ["trabeculectomy", 504], [".", 518], ["Treatment", 520], ["with", 530], ["GS-639556", 535], ["or", 545], ["GS-607601", 548], ["was", 558], ["initiated", 562], ["in", 572], ["rabbits", 575], ["immediately", 583], ["after", 595], ["trabeculectomy", 601], ["by", 616], ["giving", 619], ["both", 626], ["intracameral", 631], ["and", 644], ["subconjunctival", 648], ["injections", 664], [".", 674], ["Thereafter", 676], [",", 686], ["the", 688], ["antibodies", 692], ["were", 703], ["given", 708], ["twice", 714], ["a", 720], ["week", 722], ["subconjunctivally", 727], ["until", 745], ["day", 751], ["30", 755], ["after", 758], ["surgery", 764], ["(", 772], ["day", 773], ["of", 777], ["euthanization", 780], [")", 793], [".", 794], ["Treatment", 796], ["outcome", 806], ["was", 814], ["studied", 818], ["by", 826], ["clinical", 829], ["investigation", 838], ["of", 852], ["the", 855], ["bleb", 859], ["and", 864], ["by", 868], ["immunohistochemical", 871], ["analysis", 891], ["of", 900], ["angiogenesis", 903], [",", 915], ["inflammation", 917], [",", 929], ["and", 931], ["collagen", 935], ["deposition", 944], [".", 954], ["LOX", 956], ["and", 960], ["LOXL2", 964], ["were", 970], ["both", 975], ["upregulated", 980], ["in", 992], ["Tenon", 995], ["'s", 1000], ["capsule", 1003], ["and", 1011], ["the", 1015], ["conjunctiva", 1019], ["after", 1031], ["glaucoma", 1037], ["surgery", 1046], [".", 1053], ["Repeated", 1055], ["administration", 1064], ["of", 1079], ["LOX-", 1082], ["or", 1087], ["LOXL2-targeting", 1090], ["monoclonal", 1106], ["antibodies", 1117], ["increased", 1128], ["bleb", 1138], ["area", 1143], ["and", 1148], ["bleb", 1152], ["survival", 1157], [".", 1165], ["Analyses", 1167], ["of", 1176], ["immunohistologic", 1179], ["stainings", 1196], ["showed", 1206], ["that", 1213], ["both", 1218], ["antibodies", 1223], ["significantly", 1234], ["decreased", 1248], ["fibrosis", 1258], [",", 1266], ["whereas", 1268], ["the", 1276], ["anti", 1280], ["-", 1284], ["LOXL2", 1285], ["antibody", 1291], ["also", 1300], ["significantly", 1305], ["reduced", 1319], ["blood", 1327], ["vessel", 1333], ["density", 1340], ["and", 1348], ["inflammation", 1352], [".", 1364], ["Targeting", 1366], ["LOXL2", 1376], ["with", 1382], ["an", 1387], ["inhibitory", 1390], ["monoclonal", 1401], ["antibody", 1412], ["(", 1421], ["GS-607601", 1422], [")", 1431], ["reduced", 1433], ["pathologic", 1441], ["angiogenesis", 1452], [",", 1464], ["inflammation", 1466], [",", 1478], ["and", 1480], ["fibrosis", 1484], [".", 1492], ["These", 1494], ["results", 1500], ["suggest", 1508], ["that", 1516], ["LOXL2", 1521], ["could", 1527], ["be", 1533], ["an", 1536], ["appealing", 1539], ["target", 1549], ["for", 1556], ["treatment", 1560], ["of", 1570], ["scar", 1573], ["formation", 1578], ["after", 1588], ["glaucoma", 1594], ["surgery", 1603], [",", 1610], ["and", 1612], ["point", 1616], ["to", 1622], ["the", 1625], ["potential", 1629], ["therapeutic", 1639], ["benefits", 1651], ["of", 1660], ["simtuzumab", 1663], [",", 1673], ["a", 1675], ["humanized", 1677], ["monoclonal", 1687], ["antibody", 1698], ["derived", 1707], ["from", 1715], ["GS-607601", 1720], [".", 1729]]}
{"context": "Despite that deep brain stimulation (DBS) of the globus pallidus internus (GPi) is emerging as the favored intervention for patients with medically intractable dystonia, the pathophysiological mechanisms of dystonia are largely unclear. In eight patients with primary dystonia who were treated with bilateral chronic pallidal stimulation, we correlated symptom-related electromyogram (EMG) activity of the most affected muscles with the local field potentials (LFPs) recorded from the globus pallidus electrodes. In 5 dystonic patients with mobile involuntary movements, rhythmic EMG bursts in the contralateral muscles were coherent with the oscillations in the pallidal LFPs at the burst frequency. In contrast, no significant coherence was seen between EMG and LFPs either for the sustained activity separated out from the compound EMGs in those 5 cases, or in the EMGs in 3 other cases without mobile involuntary movements and rhythmic EMG bursts. In comparison with the resting condition, in both active and passive movements, significant modulation in the GPi LFPs was seen in the range of 8-16 Hz. The finding of significant coherence between GPi oscillations and rhythmic EMG bursts but not sustained tonic EMG activity suggests that the synchronized pallidal activity may be directly related to the rhythmic involuntary movements. In contrast, the sustained hypertonic muscle activity may be represented by less synchronized activity in the pallidum. Thus, the pallidum may play different roles in generating different components of the dystonic symptom complex.", "qas": [{"question": "Neurostimulation of which nucleus is used for treatment of dystonia?", "answers": ["globus pallidus internus"], "qid": "f2a831f2a3fc46d1a5b456712da85b80", "question_tokens": [["Neurostimulation", 0], ["of", 17], ["which", 20], ["nucleus", 26], ["is", 34], ["used", 37], ["for", 42], ["treatment", 46], ["of", 56], ["dystonia", 59], ["?", 67]], "detected_answers": [{"text": "globus pallidus internus", "token_spans": [[10, 12]], "char_spans": [[49, 72]]}]}], "context_tokens": [["Despite", 0], ["that", 8], ["deep", 13], ["brain", 18], ["stimulation", 24], ["(", 36], ["DBS", 37], [")", 40], ["of", 42], ["the", 45], ["globus", 49], ["pallidus", 56], ["internus", 65], ["(", 74], ["GPi", 75], [")", 78], ["is", 80], ["emerging", 83], ["as", 92], ["the", 95], ["favored", 99], ["intervention", 107], ["for", 120], ["patients", 124], ["with", 133], ["medically", 138], ["intractable", 148], ["dystonia", 160], [",", 168], ["the", 170], ["pathophysiological", 174], ["mechanisms", 193], ["of", 204], ["dystonia", 207], ["are", 216], ["largely", 220], ["unclear", 228], [".", 235], ["In", 237], ["eight", 240], ["patients", 246], ["with", 255], ["primary", 260], ["dystonia", 268], ["who", 277], ["were", 281], ["treated", 286], ["with", 294], ["bilateral", 299], ["chronic", 309], ["pallidal", 317], ["stimulation", 326], [",", 337], ["we", 339], ["correlated", 342], ["symptom", 353], ["-", 360], ["related", 361], ["electromyogram", 369], ["(", 384], ["EMG", 385], [")", 388], ["activity", 390], ["of", 399], ["the", 402], ["most", 406], ["affected", 411], ["muscles", 420], ["with", 428], ["the", 433], ["local", 437], ["field", 443], ["potentials", 449], ["(", 460], ["LFPs", 461], [")", 465], ["recorded", 467], ["from", 476], ["the", 481], ["globus", 485], ["pallidus", 492], ["electrodes", 501], [".", 511], ["In", 513], ["5", 516], ["dystonic", 518], ["patients", 527], ["with", 536], ["mobile", 541], ["involuntary", 548], ["movements", 560], [",", 569], ["rhythmic", 571], ["EMG", 580], ["bursts", 584], ["in", 591], ["the", 594], ["contralateral", 598], ["muscles", 612], ["were", 620], ["coherent", 625], ["with", 634], ["the", 639], ["oscillations", 643], ["in", 656], ["the", 659], ["pallidal", 663], ["LFPs", 672], ["at", 677], ["the", 680], ["burst", 684], ["frequency", 690], [".", 699], ["In", 701], ["contrast", 704], [",", 712], ["no", 714], ["significant", 717], ["coherence", 729], ["was", 739], ["seen", 743], ["between", 748], ["EMG", 756], ["and", 760], ["LFPs", 764], ["either", 769], ["for", 776], ["the", 780], ["sustained", 784], ["activity", 794], ["separated", 803], ["out", 813], ["from", 817], ["the", 822], ["compound", 826], ["EMGs", 835], ["in", 840], ["those", 843], ["5", 849], ["cases", 851], [",", 856], ["or", 858], ["in", 861], ["the", 864], ["EMGs", 868], ["in", 873], ["3", 876], ["other", 878], ["cases", 884], ["without", 890], ["mobile", 898], ["involuntary", 905], ["movements", 917], ["and", 927], ["rhythmic", 931], ["EMG", 940], ["bursts", 944], [".", 950], ["In", 952], ["comparison", 955], ["with", 966], ["the", 971], ["resting", 975], ["condition", 983], [",", 992], ["in", 994], ["both", 997], ["active", 1002], ["and", 1009], ["passive", 1013], ["movements", 1021], [",", 1030], ["significant", 1032], ["modulation", 1044], ["in", 1055], ["the", 1058], ["GPi", 1062], ["LFPs", 1066], ["was", 1071], ["seen", 1075], ["in", 1080], ["the", 1083], ["range", 1087], ["of", 1093], ["8", 1096], ["-", 1097], ["16", 1098], ["Hz", 1101], [".", 1103], ["The", 1105], ["finding", 1109], ["of", 1117], ["significant", 1120], ["coherence", 1132], ["between", 1142], ["GPi", 1150], ["oscillations", 1154], ["and", 1167], ["rhythmic", 1171], ["EMG", 1180], ["bursts", 1184], ["but", 1191], ["not", 1195], ["sustained", 1199], ["tonic", 1209], ["EMG", 1215], ["activity", 1219], ["suggests", 1228], ["that", 1237], ["the", 1242], ["synchronized", 1246], ["pallidal", 1259], ["activity", 1268], ["may", 1277], ["be", 1281], ["directly", 1284], ["related", 1293], ["to", 1301], ["the", 1304], ["rhythmic", 1308], ["involuntary", 1317], ["movements", 1329], [".", 1338], ["In", 1340], ["contrast", 1343], [",", 1351], ["the", 1353], ["sustained", 1357], ["hypertonic", 1367], ["muscle", 1378], ["activity", 1385], ["may", 1394], ["be", 1398], ["represented", 1401], ["by", 1413], ["less", 1416], ["synchronized", 1421], ["activity", 1434], ["in", 1443], ["the", 1446], ["pallidum", 1450], [".", 1458], ["Thus", 1460], [",", 1464], ["the", 1466], ["pallidum", 1470], ["may", 1479], ["play", 1483], ["different", 1488], ["roles", 1498], ["in", 1504], ["generating", 1507], ["different", 1518], ["components", 1528], ["of", 1539], ["the", 1542], ["dystonic", 1546], ["symptom", 1555], ["complex", 1563], [".", 1570]]}
{"context": "Selenoprotein P (Sepp1) is a secreted protein that is made up of 2 domains. The larger N-terminal domain contains 1 selenocysteine residue in a redox motif and the smaller C-terminal domain contains the other 9 selenocysteines. Sepp1 isoforms of varying lengths occur but quantitation of them has not been achieved. Hepatic synthesis of Sepp1 affects whole-body selenium content and the liver is the source of most plasma Sepp1. ApoER2, a member of the lipoprotein receptor family, binds Sepp1 and facilitates its uptake into the testis and retention of its selenium by the brain. Megalin, another lipoprotein receptor, facilitates uptake of filtered Sepp1 into proximal tubule cells of the kidney. Thus, Sepp1 serves in homeostasis and distribution of selenium. Mice with deletion of Sepp1 suffer greater morbidity and mortality from infection with Trypanosoma congolense than do wild-type mice. Mice that express only the N-terminal domain of Sepp1 have the same severity of illness as wild-type mice, indicating that the protective function of Sepp1 against the infection resides in the N-terminal (redox) domain. Thus, Sepp1 has several functions. In addition, plasma Sepp1 concentration falls in selenium deficiency and, therefore, it can be used as an index of selenium nutritional status.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "109aecf700c048eb8d16d5d20b654c22", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[0, 1]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Selenoprotein", 0], ["P", 14], ["(", 16], ["Sepp1", 17], [")", 22], ["is", 24], ["a", 27], ["secreted", 29], ["protein", 38], ["that", 46], ["is", 51], ["made", 54], ["up", 59], ["of", 62], ["2", 65], ["domains", 67], [".", 74], ["The", 76], ["larger", 80], ["N", 87], ["-", 88], ["terminal", 89], ["domain", 98], ["contains", 105], ["1", 114], ["selenocysteine", 116], ["residue", 131], ["in", 139], ["a", 142], ["redox", 144], ["motif", 150], ["and", 156], ["the", 160], ["smaller", 164], ["C", 172], ["-", 173], ["terminal", 174], ["domain", 183], ["contains", 190], ["the", 199], ["other", 203], ["9", 209], ["selenocysteines", 211], [".", 226], ["Sepp1", 228], ["isoforms", 234], ["of", 243], ["varying", 246], ["lengths", 254], ["occur", 262], ["but", 268], ["quantitation", 272], ["of", 285], ["them", 288], ["has", 293], ["not", 297], ["been", 301], ["achieved", 306], [".", 314], ["Hepatic", 316], ["synthesis", 324], ["of", 334], ["Sepp1", 337], ["affects", 343], ["whole", 351], ["-", 356], ["body", 357], ["selenium", 362], ["content", 371], ["and", 379], ["the", 383], ["liver", 387], ["is", 393], ["the", 396], ["source", 400], ["of", 407], ["most", 410], ["plasma", 415], ["Sepp1", 422], [".", 427], ["ApoER2", 429], [",", 435], ["a", 437], ["member", 439], ["of", 446], ["the", 449], ["lipoprotein", 453], ["receptor", 465], ["family", 474], [",", 480], ["binds", 482], ["Sepp1", 488], ["and", 494], ["facilitates", 498], ["its", 510], ["uptake", 514], ["into", 521], ["the", 526], ["testis", 530], ["and", 537], ["retention", 541], ["of", 551], ["its", 554], ["selenium", 558], ["by", 567], ["the", 570], ["brain", 574], [".", 579], ["Megalin", 581], [",", 588], ["another", 590], ["lipoprotein", 598], ["receptor", 610], [",", 618], ["facilitates", 620], ["uptake", 632], ["of", 639], ["filtered", 642], ["Sepp1", 651], ["into", 657], ["proximal", 662], ["tubule", 671], ["cells", 678], ["of", 684], ["the", 687], ["kidney", 691], [".", 697], ["Thus", 699], [",", 703], ["Sepp1", 705], ["serves", 711], ["in", 718], ["homeostasis", 721], ["and", 733], ["distribution", 737], ["of", 750], ["selenium", 753], [".", 761], ["Mice", 763], ["with", 768], ["deletion", 773], ["of", 782], ["Sepp1", 785], ["suffer", 791], ["greater", 798], ["morbidity", 806], ["and", 816], ["mortality", 820], ["from", 830], ["infection", 835], ["with", 845], ["Trypanosoma", 850], ["congolense", 862], ["than", 873], ["do", 878], ["wild", 881], ["-", 885], ["type", 886], ["mice", 891], [".", 895], ["Mice", 897], ["that", 902], ["express", 907], ["only", 915], ["the", 920], ["N", 924], ["-", 925], ["terminal", 926], ["domain", 935], ["of", 942], ["Sepp1", 945], ["have", 951], ["the", 956], ["same", 960], ["severity", 965], ["of", 974], ["illness", 977], ["as", 985], ["wild", 988], ["-", 992], ["type", 993], ["mice", 998], [",", 1002], ["indicating", 1004], ["that", 1015], ["the", 1020], ["protective", 1024], ["function", 1035], ["of", 1044], ["Sepp1", 1047], ["against", 1053], ["the", 1061], ["infection", 1065], ["resides", 1075], ["in", 1083], ["the", 1086], ["N", 1090], ["-", 1091], ["terminal", 1092], ["(", 1101], ["redox", 1102], [")", 1107], ["domain", 1109], [".", 1115], ["Thus", 1117], [",", 1121], ["Sepp1", 1123], ["has", 1129], ["several", 1133], ["functions", 1141], [".", 1150], ["In", 1152], ["addition", 1155], [",", 1163], ["plasma", 1165], ["Sepp1", 1172], ["concentration", 1178], ["falls", 1192], ["in", 1198], ["selenium", 1201], ["deficiency", 1210], ["and", 1221], [",", 1224], ["therefore", 1226], [",", 1235], ["it", 1237], ["can", 1240], ["be", 1244], ["used", 1247], ["as", 1252], ["an", 1255], ["index", 1258], ["of", 1264], ["selenium", 1267], ["nutritional", 1276], ["status", 1288], [".", 1294]]}
{"context": "The SWR1 complex (SWR1C) in yeast catalyzes the replacement of nucleosomal H2A with the H2AZ variant, which ensures full activation of underlying genes. We compared the phenotype of mutants in the homologs of SWR1C components in Arabidopsis thaliana. Mutations in Arabidopsis SWC6 (AtSWC6), SUPPRESSOR OF FRIGIDA 3 (SUF3) and PHOTOPERIOD-INDEPENDENT EARLY FLOWERING 1 (PIE1), homologs of SWC6, ARP6 and SWR1, respectively, caused similar developmental defects, including leaf serration, weak apical dominance, flowers with extra petals and early flowering by reduction in expression of FLOWERING LOCUS C (FLC), a strong floral repressor. Chromatin immunoprecipitation assays showed that AtSWC6 and SUF3 bind to the proximal region of the FLC promoter, and protoplast transfection assays showed that AtSWC6 colocalizes with SUF3. Protein interaction analyses suggested the formation of a complex between PIE1, SUF3, AtSWC6 and AtSWC2. In addition, H2AZ, a substrate of SWR1C, interacts with both PIE1 and AtSWC2. Finally, knockdown of the H2AZ genes by RNA interference or artificial microRNA caused a phenotype similar to that of atswc6 or suf3. Our results strongly support the presence of an SWR1C-like complex in Arabidopsis that ensures proper development, including floral repression through full activation of FLC.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "40d8ce56de49432180bd5735b35937f1", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[75, 75], [1, 1]], "char_spans": [[403, 406], [4, 7]]}]}], "context_tokens": [["The", 0], ["SWR1", 4], ["complex", 9], ["(", 17], ["SWR1C", 18], [")", 23], ["in", 25], ["yeast", 28], ["catalyzes", 34], ["the", 44], ["replacement", 48], ["of", 60], ["nucleosomal", 63], ["H2A", 75], ["with", 79], ["the", 84], ["H2AZ", 88], ["variant", 93], [",", 100], ["which", 102], ["ensures", 108], ["full", 116], ["activation", 121], ["of", 132], ["underlying", 135], ["genes", 146], [".", 151], ["We", 153], ["compared", 156], ["the", 165], ["phenotype", 169], ["of", 179], ["mutants", 182], ["in", 190], ["the", 193], ["homologs", 197], ["of", 206], ["SWR1C", 209], ["components", 215], ["in", 226], ["Arabidopsis", 229], ["thaliana", 241], [".", 249], ["Mutations", 251], ["in", 261], ["Arabidopsis", 264], ["SWC6", 276], ["(", 281], ["AtSWC6", 282], [")", 288], [",", 289], ["SUPPRESSOR", 291], ["OF", 302], ["FRIGIDA", 305], ["3", 313], ["(", 315], ["SUF3", 316], [")", 320], ["and", 322], ["PHOTOPERIOD", 326], ["-", 337], ["INDEPENDENT", 338], ["EARLY", 350], ["FLOWERING", 356], ["1", 366], ["(", 368], ["PIE1", 369], [")", 373], [",", 374], ["homologs", 376], ["of", 385], ["SWC6", 388], [",", 392], ["ARP6", 394], ["and", 399], ["SWR1", 403], [",", 407], ["respectively", 409], [",", 421], ["caused", 423], ["similar", 430], ["developmental", 438], ["defects", 452], [",", 459], ["including", 461], ["leaf", 471], ["serration", 476], [",", 485], ["weak", 487], ["apical", 492], ["dominance", 499], [",", 508], ["flowers", 510], ["with", 518], ["extra", 523], ["petals", 529], ["and", 536], ["early", 540], ["flowering", 546], ["by", 556], ["reduction", 559], ["in", 569], ["expression", 572], ["of", 583], ["FLOWERING", 586], ["LOCUS", 596], ["C", 602], ["(", 604], ["FLC", 605], [")", 608], [",", 609], ["a", 611], ["strong", 613], ["floral", 620], ["repressor", 627], [".", 636], ["Chromatin", 638], ["immunoprecipitation", 648], ["assays", 668], ["showed", 675], ["that", 682], ["AtSWC6", 687], ["and", 694], ["SUF3", 698], ["bind", 703], ["to", 708], ["the", 711], ["proximal", 715], ["region", 724], ["of", 731], ["the", 734], ["FLC", 738], ["promoter", 742], [",", 750], ["and", 752], ["protoplast", 756], ["transfection", 767], ["assays", 780], ["showed", 787], ["that", 794], ["AtSWC6", 799], ["colocalizes", 806], ["with", 818], ["SUF3", 823], [".", 827], ["Protein", 829], ["interaction", 837], ["analyses", 849], ["suggested", 858], ["the", 868], ["formation", 872], ["of", 882], ["a", 885], ["complex", 887], ["between", 895], ["PIE1", 903], [",", 907], ["SUF3", 909], [",", 913], ["AtSWC6", 915], ["and", 922], ["AtSWC2", 926], [".", 932], ["In", 934], ["addition", 937], [",", 945], ["H2AZ", 947], [",", 951], ["a", 953], ["substrate", 955], ["of", 965], ["SWR1C", 968], [",", 973], ["interacts", 975], ["with", 985], ["both", 990], ["PIE1", 995], ["and", 1000], ["AtSWC2", 1004], [".", 1010], ["Finally", 1012], [",", 1019], ["knockdown", 1021], ["of", 1031], ["the", 1034], ["H2AZ", 1038], ["genes", 1043], ["by", 1049], ["RNA", 1052], ["interference", 1056], ["or", 1069], ["artificial", 1072], ["microRNA", 1083], ["caused", 1092], ["a", 1099], ["phenotype", 1101], ["similar", 1111], ["to", 1119], ["that", 1122], ["of", 1127], ["atswc6", 1130], ["or", 1137], ["suf3", 1140], [".", 1144], ["Our", 1146], ["results", 1150], ["strongly", 1158], ["support", 1167], ["the", 1175], ["presence", 1179], ["of", 1188], ["an", 1191], ["SWR1C", 1194], ["-", 1199], ["like", 1200], ["complex", 1205], ["in", 1213], ["Arabidopsis", 1216], ["that", 1228], ["ensures", 1233], ["proper", 1241], ["development", 1248], [",", 1259], ["including", 1261], ["floral", 1271], ["repression", 1278], ["through", 1289], ["full", 1297], ["activation", 1302], ["of", 1313], ["FLC", 1316], [".", 1319]]}
{"context": "The purpose of this paper is to assess the reliability and validity of the Spanish version of the Davidson trauma scale (DTS-S) and to determine the prevalence and correlates of post-traumatic stress disorder (PTSD) symptoms in a non-clinical random sample of prison inmates. Probabilistic samples of 1,179 inmates from 26 penal institutions in Puerto Rico were selected using a multistage sampling design. Population estimates and correlations were obtained for PTSD, generalized anxiety and depression. The reliability, factor structure, and convergent validity of the DTS-S were assessed. Cross-validation was employed to confirm the results of the factor analyses. Using the cut-offs adopted by the scale's author, 136 (13.4 percent) of the inmates are likely to have current PTSD and 117 (11.6 percent) reach the cut-off for sub-threshold PTSD. Confirmatory factor analysis generated two factors explaining 53 percent of the variance. High reliabilities were obtained for the total scale (\u03b1=0.95) and for the frequency and severity scales (\u03b1=0.90 and 0.91). Significantly higher DTS-S scores were found for females (t=2.26, p<0.025), for inmates diagnosed with depression or anxiety (t=2.02, p<0.05), and those reporting suicide attempts (t=4.47, p<0.0001). Findings support that the DTS-S is a reliable and valid measure to assess PTSD symptoms in Latino inmate populations and to identify individuals at risk for the disorder that require confirmatory diagnosis and clinical interventions.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b6a2b5c8312645a99ca848d823503319", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[34, 38]], "char_spans": [[178, 207]]}, {"text": "PTSD", "token_spans": [[160, 160], [144, 144], [40, 40], [254, 254], [81, 81]], "char_spans": [[844, 847], [780, 783], [210, 213], [1337, 1340], [463, 466]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["paper", 20], ["is", 26], ["to", 29], ["assess", 32], ["the", 39], ["reliability", 43], ["and", 55], ["validity", 59], ["of", 68], ["the", 71], ["Spanish", 75], ["version", 83], ["of", 91], ["the", 94], ["Davidson", 98], ["trauma", 107], ["scale", 114], ["(", 120], ["DTS", 121], ["-", 124], ["S", 125], [")", 126], ["and", 128], ["to", 132], ["determine", 135], ["the", 145], ["prevalence", 149], ["and", 160], ["correlates", 164], ["of", 175], ["post", 178], ["-", 182], ["traumatic", 183], ["stress", 193], ["disorder", 200], ["(", 209], ["PTSD", 210], [")", 214], ["symptoms", 216], ["in", 225], ["a", 228], ["non", 230], ["-", 233], ["clinical", 234], ["random", 243], ["sample", 250], ["of", 257], ["prison", 260], ["inmates", 267], [".", 274], ["Probabilistic", 276], ["samples", 290], ["of", 298], ["1,179", 301], ["inmates", 307], ["from", 315], ["26", 320], ["penal", 323], ["institutions", 329], ["in", 342], ["Puerto", 345], ["Rico", 352], ["were", 357], ["selected", 362], ["using", 371], ["a", 377], ["multistage", 379], ["sampling", 390], ["design", 399], [".", 405], ["Population", 407], ["estimates", 418], ["and", 428], ["correlations", 432], ["were", 445], ["obtained", 450], ["for", 459], ["PTSD", 463], [",", 467], ["generalized", 469], ["anxiety", 481], ["and", 489], ["depression", 493], [".", 503], ["The", 505], ["reliability", 509], [",", 520], ["factor", 522], ["structure", 529], [",", 538], ["and", 540], ["convergent", 544], ["validity", 555], ["of", 564], ["the", 567], ["DTS", 571], ["-", 574], ["S", 575], ["were", 577], ["assessed", 582], [".", 590], ["Cross", 592], ["-", 597], ["validation", 598], ["was", 609], ["employed", 613], ["to", 622], ["confirm", 625], ["the", 633], ["results", 637], ["of", 645], ["the", 648], ["factor", 652], ["analyses", 659], [".", 667], ["Using", 669], ["the", 675], ["cut", 679], ["-", 682], ["offs", 683], ["adopted", 688], ["by", 696], ["the", 699], ["scale", 703], ["'s", 708], ["author", 711], [",", 717], ["136", 719], ["(", 723], ["13.4", 724], ["percent", 729], [")", 736], ["of", 738], ["the", 741], ["inmates", 745], ["are", 753], ["likely", 757], ["to", 764], ["have", 767], ["current", 772], ["PTSD", 780], ["and", 785], ["117", 789], ["(", 793], ["11.6", 794], ["percent", 799], [")", 806], ["reach", 808], ["the", 814], ["cut", 818], ["-", 821], ["off", 822], ["for", 826], ["sub", 830], ["-", 833], ["threshold", 834], ["PTSD", 844], [".", 848], ["Confirmatory", 850], ["factor", 863], ["analysis", 870], ["generated", 879], ["two", 889], ["factors", 893], ["explaining", 901], ["53", 912], ["percent", 915], ["of", 923], ["the", 926], ["variance", 930], [".", 938], ["High", 940], ["reliabilities", 945], ["were", 959], ["obtained", 964], ["for", 973], ["the", 977], ["total", 981], ["scale", 987], ["(", 993], ["\u03b1=0.95", 994], [")", 1000], ["and", 1002], ["for", 1006], ["the", 1010], ["frequency", 1014], ["and", 1024], ["severity", 1028], ["scales", 1037], ["(", 1044], ["\u03b1=0.90", 1045], ["and", 1052], ["0.91", 1056], [")", 1060], [".", 1061], ["Significantly", 1063], ["higher", 1077], ["DTS", 1084], ["-", 1087], ["S", 1088], ["scores", 1090], ["were", 1097], ["found", 1102], ["for", 1108], ["females", 1112], ["(", 1120], ["t=2.26", 1121], [",", 1127], ["p<0.025", 1129], [")", 1136], [",", 1137], ["for", 1139], ["inmates", 1143], ["diagnosed", 1151], ["with", 1161], ["depression", 1166], ["or", 1177], ["anxiety", 1180], ["(", 1188], ["t=2.02", 1189], [",", 1195], ["p<0.05", 1197], [")", 1203], [",", 1204], ["and", 1206], ["those", 1210], ["reporting", 1216], ["suicide", 1226], ["attempts", 1234], ["(", 1243], ["t=4.47", 1244], [",", 1250], ["p<0.0001", 1252], [")", 1260], [".", 1261], ["Findings", 1263], ["support", 1272], ["that", 1280], ["the", 1285], ["DTS", 1289], ["-", 1292], ["S", 1293], ["is", 1295], ["a", 1298], ["reliable", 1300], ["and", 1309], ["valid", 1313], ["measure", 1319], ["to", 1327], ["assess", 1330], ["PTSD", 1337], ["symptoms", 1342], ["in", 1351], ["Latino", 1354], ["inmate", 1361], ["populations", 1368], ["and", 1380], ["to", 1384], ["identify", 1387], ["individuals", 1396], ["at", 1408], ["risk", 1411], ["for", 1416], ["the", 1420], ["disorder", 1424], ["that", 1433], ["require", 1438], ["confirmatory", 1446], ["diagnosis", 1459], ["and", 1469], ["clinical", 1473], ["interventions", 1482], [".", 1495]]}
{"context": "Alpha-synuclein (\u03b1-Syn) is the principal protein component of Lewy bodies, a pathological hallmark of Parkinson's disease (PD). This protein may regulate protein phosphatase 2A (PP2A) activity, although the molecular mechanisms for \u03b1-Syn-mediated regulation of PP2A and the potential neuroprotective actions of PP2A against PD-associated pathology remain largely unexplored. We found that \u03b1-Syn gene overexpression in SK-N-SH cells and primary neurons led to PP2A/C phosphorylation at Y307, a known target of Src kinase, and consequent phosphatase inhibition. In addition, phospho-activated Src (p-Y416 Src, pSrc) was higher in SK-N-SH cells and primary neurons overexpressing \u03b1-Syn. Thus, \u03b1-Syn may promote Src activation and PP2A inactivation, leading to hyperphosphorylation of proteins. Immunoprecipitation revealed higher calmodulin/Src complex formation in \u03b1-Syn-overexpressing cells and \u03b1-Syn transgenic mice. A TUNEL apoptosis assay and an MTT cell viability assay demonstrated that the PP2A activator C2-ceramide protected neurons against \u03b1-Syn-induced cell injury. Buffering the Ca(2+) elevations induced by \u03b1-Syn overexpression ameliorated the cytotoxicity of \u03b1-Syn. Our findings define a potential molecular mechanism for \u03b1-Syn-mediated regulation of PP2A through formation of the calmodulin/Src complex, activation of Src, and Src-mediated phospho-inhibition of PP2A. Overexpression of \u03b1-Syn may lead to neurodegeneration in PD in part by suppressing the endogenous neuroprotective activity of PP2A.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "cf97c5fcf3d94305a47f705ecb7271f5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["(", 16], ["\u03b1", 17], ["-", 18], ["Syn", 19], [")", 22], ["is", 24], ["the", 27], ["principal", 31], ["protein", 41], ["component", 49], ["of", 59], ["Lewy", 62], ["bodies", 67], [",", 73], ["a", 75], ["pathological", 77], ["hallmark", 90], ["of", 99], ["Parkinson", 102], ["'s", 111], ["disease", 114], ["(", 122], ["PD", 123], [")", 125], [".", 126], ["This", 128], ["protein", 133], ["may", 141], ["regulate", 145], ["protein", 154], ["phosphatase", 162], ["2A", 174], ["(", 177], ["PP2A", 178], [")", 182], ["activity", 184], [",", 192], ["although", 194], ["the", 203], ["molecular", 207], ["mechanisms", 217], ["for", 228], ["\u03b1", 232], ["-", 233], ["Syn", 234], ["-", 237], ["mediated", 238], ["regulation", 247], ["of", 258], ["PP2A", 261], ["and", 266], ["the", 270], ["potential", 274], ["neuroprotective", 284], ["actions", 300], ["of", 308], ["PP2A", 311], ["against", 316], ["PD", 324], ["-", 326], ["associated", 327], ["pathology", 338], ["remain", 348], ["largely", 355], ["unexplored", 363], [".", 373], ["We", 375], ["found", 378], ["that", 384], ["\u03b1", 389], ["-", 390], ["Syn", 391], ["gene", 395], ["overexpression", 400], ["in", 415], ["SK", 418], ["-", 420], ["N", 421], ["-", 422], ["SH", 423], ["cells", 426], ["and", 432], ["primary", 436], ["neurons", 444], ["led", 452], ["to", 456], ["PP2A", 459], ["/", 463], ["C", 464], ["phosphorylation", 466], ["at", 482], ["Y307", 485], [",", 489], ["a", 491], ["known", 493], ["target", 499], ["of", 506], ["Src", 509], ["kinase", 513], [",", 519], ["and", 521], ["consequent", 525], ["phosphatase", 536], ["inhibition", 548], [".", 558], ["In", 560], ["addition", 563], [",", 571], ["phospho", 573], ["-", 580], ["activated", 581], ["Src", 591], ["(", 595], ["p", 596], ["-", 597], ["Y416", 598], ["Src", 603], [",", 606], ["pSrc", 608], [")", 612], ["was", 614], ["higher", 618], ["in", 625], ["SK", 628], ["-", 630], ["N", 631], ["-", 632], ["SH", 633], ["cells", 636], ["and", 642], ["primary", 646], ["neurons", 654], ["overexpressing", 662], ["\u03b1", 677], ["-", 678], ["Syn", 679], [".", 682], ["Thus", 684], [",", 688], ["\u03b1", 690], ["-", 691], ["Syn", 692], ["may", 696], ["promote", 700], ["Src", 708], ["activation", 712], ["and", 723], ["PP2A", 727], ["inactivation", 732], [",", 744], ["leading", 746], ["to", 754], ["hyperphosphorylation", 757], ["of", 778], ["proteins", 781], [".", 789], ["Immunoprecipitation", 791], ["revealed", 811], ["higher", 820], ["calmodulin", 827], ["/", 837], ["Src", 838], ["complex", 842], ["formation", 850], ["in", 860], ["\u03b1", 863], ["-", 864], ["Syn", 865], ["-", 868], ["overexpressing", 869], ["cells", 884], ["and", 890], ["\u03b1", 894], ["-", 895], ["Syn", 896], ["transgenic", 900], ["mice", 911], [".", 915], ["A", 917], ["TUNEL", 919], ["apoptosis", 925], ["assay", 935], ["and", 941], ["an", 945], ["MTT", 948], ["cell", 952], ["viability", 957], ["assay", 967], ["demonstrated", 973], ["that", 986], ["the", 991], ["PP2A", 995], ["activator", 1000], ["C2-ceramide", 1010], ["protected", 1022], ["neurons", 1032], ["against", 1040], ["\u03b1", 1048], ["-", 1049], ["Syn", 1050], ["-", 1053], ["induced", 1054], ["cell", 1062], ["injury", 1067], [".", 1073], ["Buffering", 1075], ["the", 1085], ["Ca(2", 1089], ["+", 1093], [")", 1094], ["elevations", 1096], ["induced", 1107], ["by", 1115], ["\u03b1", 1118], ["-", 1119], ["Syn", 1120], ["overexpression", 1124], ["ameliorated", 1139], ["the", 1151], ["cytotoxicity", 1155], ["of", 1168], ["\u03b1", 1171], ["-", 1172], ["Syn", 1173], [".", 1176], ["Our", 1178], ["findings", 1182], ["define", 1191], ["a", 1198], ["potential", 1200], ["molecular", 1210], ["mechanism", 1220], ["for", 1230], ["\u03b1", 1234], ["-", 1235], ["Syn", 1236], ["-", 1239], ["mediated", 1240], ["regulation", 1249], ["of", 1260], ["PP2A", 1263], ["through", 1268], ["formation", 1276], ["of", 1286], ["the", 1289], ["calmodulin", 1293], ["/", 1303], ["Src", 1304], ["complex", 1308], [",", 1315], ["activation", 1317], ["of", 1328], ["Src", 1331], [",", 1334], ["and", 1336], ["Src", 1340], ["-", 1343], ["mediated", 1344], ["phospho", 1353], ["-", 1360], ["inhibition", 1361], ["of", 1372], ["PP2A.", 1375], ["Overexpression", 1381], ["of", 1396], ["\u03b1", 1399], ["-", 1400], ["Syn", 1401], ["may", 1405], ["lead", 1409], ["to", 1414], ["neurodegeneration", 1417], ["in", 1435], ["PD", 1438], ["in", 1441], ["part", 1444], ["by", 1449], ["suppressing", 1452], ["the", 1464], ["endogenous", 1468], ["neuroprotective", 1479], ["activity", 1495], ["of", 1504], ["PP2A.", 1507]]}
{"context": "Diamond-Blackfan anemia (DBA) is a rare congenital red-cell aplasia characterized by anemia, bone-marrow erythroblastopenia, and congenital anomalies and is associated with heterozygous mutations in the ribosomal protein (RP) S19 gene (RPS19) in approximately 25% of probands. We report identification of de novo nonsense and splice-site mutations in another RP, RPS24 (encoded by RPS24 [10q22-q23]) in approximately 2% of RPS19 mutation-negative probands. This finding strongly suggests that DBA is a disorder of ribosome synthesis and that mutations in other RP or associated genes that lead to disrupted ribosomal biogenesis and/or function may also cause DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "f987a6c739454ffa9a27e24c4e5235c2", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[93, 93], [120, 120], [5, 5]], "char_spans": [[493, 495], [659, 661], [25, 27]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["rare", 35], ["congenital", 40], ["red", 51], ["-", 54], ["cell", 55], ["aplasia", 60], ["characterized", 68], ["by", 82], ["anemia", 85], [",", 91], ["bone", 93], ["-", 97], ["marrow", 98], ["erythroblastopenia", 105], [",", 123], ["and", 125], ["congenital", 129], ["anomalies", 140], ["and", 150], ["is", 154], ["associated", 157], ["with", 168], ["heterozygous", 173], ["mutations", 186], ["in", 196], ["the", 199], ["ribosomal", 203], ["protein", 213], ["(", 221], ["RP", 222], [")", 224], ["S19", 226], ["gene", 230], ["(", 235], ["RPS19", 236], [")", 241], ["in", 243], ["approximately", 246], ["25", 260], ["%", 262], ["of", 264], ["probands", 267], [".", 275], ["We", 277], ["report", 280], ["identification", 287], ["of", 302], ["de", 305], ["novo", 308], ["nonsense", 313], ["and", 322], ["splice", 326], ["-", 332], ["site", 333], ["mutations", 338], ["in", 348], ["another", 351], ["RP", 359], [",", 361], ["RPS24", 363], ["(", 369], ["encoded", 370], ["by", 378], ["RPS24", 381], ["[", 387], ["10q22-q23", 388], ["]", 397], [")", 398], ["in", 400], ["approximately", 403], ["2", 417], ["%", 418], ["of", 420], ["RPS19", 423], ["mutation", 429], ["-", 437], ["negative", 438], ["probands", 447], [".", 455], ["This", 457], ["finding", 462], ["strongly", 470], ["suggests", 479], ["that", 488], ["DBA", 493], ["is", 497], ["a", 500], ["disorder", 502], ["of", 511], ["ribosome", 514], ["synthesis", 523], ["and", 533], ["that", 537], ["mutations", 542], ["in", 552], ["other", 555], ["RP", 561], ["or", 564], ["associated", 567], ["genes", 578], ["that", 584], ["lead", 589], ["to", 594], ["disrupted", 597], ["ribosomal", 607], ["biogenesis", 617], ["and/or", 628], ["function", 635], ["may", 644], ["also", 648], ["cause", 653], ["DBA", 659], [".", 662]]}
{"context": "RNA editing by deamination of specific adenosine bases to inosines during pre-mRNA processing generates edited isoforms of proteins. Recoding RNA editing is more widespread in Drosophila than in vertebrates. Editing levels rise strongly at metamorphosis, and Adar(5G1) null mutant flies lack editing events in hundreds of CNS transcripts; mutant flies have reduced viability, severely defective locomotion and age-dependent neurodegeneration. On the other hand, overexpressing an adult dADAR isoform with high enzymatic activity ubiquitously during larval and pupal stages is lethal. Advantage was taken of this to screen for genetic modifiers; Adar overexpression lethality is rescued by reduced dosage of the Rdl (Resistant to dieldrin), gene encoding a subunit of inhibitory GABA receptors. Reduced dosage of the Gad1 gene encoding the GABA synthetase also rescues Adar overexpression lethality. Drosophila Adar(5G1) mutant phenotypes are ameliorated by feeding GABA modulators. We demonstrate that neuronal excitability is linked to dADAR expression levels in individual neurons; Adar-overexpressing larval motor neurons show reduced excitability whereas Adar(5G1) null mutant or targeted Adar knockdown motor neurons exhibit increased excitability. GABA inhibitory signalling is impaired in human epileptic and autistic conditions, and vertebrate ADARs may have a relevant evolutionarily conserved control over neuronal excitability.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "8c9513c5db4344709452efcb0a8fca01", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[104, 104], [189, 189], [173, 173], [142, 142]], "char_spans": [[645, 648], [1193, 1196], [1084, 1087], [868, 871]]}]}], "context_tokens": [["RNA", 0], ["editing", 4], ["by", 12], ["deamination", 15], ["of", 27], ["specific", 30], ["adenosine", 39], ["bases", 49], ["to", 55], ["inosines", 58], ["during", 67], ["pre", 74], ["-", 77], ["mRNA", 78], ["processing", 83], ["generates", 94], ["edited", 104], ["isoforms", 111], ["of", 120], ["proteins", 123], [".", 131], ["Recoding", 133], ["RNA", 142], ["editing", 146], ["is", 154], ["more", 157], ["widespread", 162], ["in", 173], ["Drosophila", 176], ["than", 187], ["in", 192], ["vertebrates", 195], [".", 206], ["Editing", 208], ["levels", 216], ["rise", 223], ["strongly", 228], ["at", 237], ["metamorphosis", 240], [",", 253], ["and", 255], ["Adar(5G1", 259], [")", 267], ["null", 269], ["mutant", 274], ["flies", 281], ["lack", 287], ["editing", 292], ["events", 300], ["in", 307], ["hundreds", 310], ["of", 319], ["CNS", 322], ["transcripts", 326], [";", 337], ["mutant", 339], ["flies", 346], ["have", 352], ["reduced", 357], ["viability", 365], [",", 374], ["severely", 376], ["defective", 385], ["locomotion", 395], ["and", 406], ["age", 410], ["-", 413], ["dependent", 414], ["neurodegeneration", 424], [".", 441], ["On", 443], ["the", 446], ["other", 450], ["hand", 456], [",", 460], ["overexpressing", 462], ["an", 477], ["adult", 480], ["dADAR", 486], ["isoform", 492], ["with", 500], ["high", 505], ["enzymatic", 510], ["activity", 520], ["ubiquitously", 529], ["during", 542], ["larval", 549], ["and", 556], ["pupal", 560], ["stages", 566], ["is", 573], ["lethal", 576], [".", 582], ["Advantage", 584], ["was", 594], ["taken", 598], ["of", 604], ["this", 607], ["to", 612], ["screen", 615], ["for", 622], ["genetic", 626], ["modifiers", 634], [";", 643], ["Adar", 645], ["overexpression", 650], ["lethality", 665], ["is", 675], ["rescued", 678], ["by", 686], ["reduced", 689], ["dosage", 697], ["of", 704], ["the", 707], ["Rdl", 711], ["(", 715], ["Resistant", 716], ["to", 726], ["dieldrin", 729], [")", 737], [",", 738], ["gene", 740], ["encoding", 745], ["a", 754], ["subunit", 756], ["of", 764], ["inhibitory", 767], ["GABA", 778], ["receptors", 783], [".", 792], ["Reduced", 794], ["dosage", 802], ["of", 809], ["the", 812], ["Gad1", 816], ["gene", 821], ["encoding", 826], ["the", 835], ["GABA", 839], ["synthetase", 844], ["also", 855], ["rescues", 860], ["Adar", 868], ["overexpression", 873], ["lethality", 888], [".", 897], ["Drosophila", 899], ["Adar(5G1", 910], [")", 918], ["mutant", 920], ["phenotypes", 927], ["are", 938], ["ameliorated", 942], ["by", 954], ["feeding", 957], ["GABA", 965], ["modulators", 970], [".", 980], ["We", 982], ["demonstrate", 985], ["that", 997], ["neuronal", 1002], ["excitability", 1011], ["is", 1024], ["linked", 1027], ["to", 1034], ["dADAR", 1037], ["expression", 1043], ["levels", 1054], ["in", 1061], ["individual", 1064], ["neurons", 1075], [";", 1082], ["Adar", 1084], ["-", 1088], ["overexpressing", 1089], ["larval", 1104], ["motor", 1111], ["neurons", 1117], ["show", 1125], ["reduced", 1130], ["excitability", 1138], ["whereas", 1151], ["Adar(5G1", 1159], [")", 1167], ["null", 1169], ["mutant", 1174], ["or", 1181], ["targeted", 1184], ["Adar", 1193], ["knockdown", 1198], ["motor", 1208], ["neurons", 1214], ["exhibit", 1222], ["increased", 1230], ["excitability", 1240], [".", 1252], ["GABA", 1254], ["inhibitory", 1259], ["signalling", 1270], ["is", 1281], ["impaired", 1284], ["in", 1293], ["human", 1296], ["epileptic", 1302], ["and", 1312], ["autistic", 1316], ["conditions", 1325], [",", 1335], ["and", 1337], ["vertebrate", 1341], ["ADARs", 1352], ["may", 1358], ["have", 1362], ["a", 1367], ["relevant", 1369], ["evolutionarily", 1378], ["conserved", 1393], ["control", 1403], ["over", 1411], ["neuronal", 1416], ["excitability", 1425], [".", 1437]]}
{"context": "Riociguat (Adempas(\u00ae)), a soluble guanylate cyclase stimulator, is a new, first-in-class drug approved for the treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) [inoperable or persistent/recurrent following surgery] or pulmonary arterial hypertension (PAH). It has been designated an orphan medicine by the European Medicines Agency and the US FDA. This article reviews the available pharmacological properties of oral riociguat and its clinical efficacy and tolerability in adults with CTEPH or PAH. Riociguat is effective and well tolerated in patients with inoperable CTEPH or persistent/recurrent CTEPH following pulmonary endarterectomy, and in patients with PAH. It has a positive result on exercise capacity and pulmonary haemodynamics, and improves WHO functional class. Most adverse events can be attributed to the vasodilatory mechanism of riociguat; however, there is a potential for serious bleeding and fetal harm, and riociguat use is contraindicated in pregnant patients. Pulmonary endarterectomy remains the first treatment of choice for CTEPH, as it is potentially curative. Head-to-head trials comparing riociguat with the approved phosphodiesterase type 5 inhibitors in patients with PAH would be of value for the placement of riociguat in the management of this disease. Riociguat is a promising addition to the treatment options for patients with CTEPH or PAH.", "qas": [{"question": "What is generic name of drug Adempas?", "answers": ["riociguat"], "qid": "1c213ca20e164591b8e737b5184e9108", "question_tokens": [["What", 0], ["is", 5], ["generic", 8], ["name", 16], ["of", 21], ["drug", 24], ["Adempas", 29], ["?", 36]], "detected_answers": [{"text": "riociguat", "token_spans": [[0, 0], [81, 81], [166, 166], [150, 150], [198, 198], [218, 218], [226, 226], [95, 95]], "char_spans": [[0, 8], [450, 458], [963, 971], [881, 889], [1153, 1161], [1277, 1285], [1322, 1330], [532, 540]]}]}], "context_tokens": [["Riociguat", 0], ["(", 10], ["Adempas", 11], ["(", 18], ["\u00ae", 19], [")", 20], [")", 21], [",", 22], ["a", 24], ["soluble", 26], ["guanylate", 34], ["cyclase", 44], ["stimulator", 52], [",", 62], ["is", 64], ["a", 67], ["new", 69], [",", 72], ["first", 74], ["-", 79], ["in", 80], ["-", 82], ["class", 83], ["drug", 89], ["approved", 94], ["for", 103], ["the", 107], ["treatment", 111], ["of", 121], ["patients", 124], ["with", 133], ["chronic", 138], ["thromboembolic", 146], ["pulmonary", 161], ["hypertension", 171], ["(", 184], ["CTEPH", 185], [")", 190], ["[", 192], ["inoperable", 193], ["or", 204], ["persistent", 207], ["/", 217], ["recurrent", 218], ["following", 228], ["surgery", 238], ["]", 245], ["or", 247], ["pulmonary", 250], ["arterial", 260], ["hypertension", 269], ["(", 282], ["PAH", 283], [")", 286], [".", 287], ["It", 289], ["has", 292], ["been", 296], ["designated", 301], ["an", 312], ["orphan", 315], ["medicine", 322], ["by", 331], ["the", 334], ["European", 338], ["Medicines", 347], ["Agency", 357], ["and", 364], ["the", 368], ["US", 372], ["FDA", 375], [".", 378], ["This", 380], ["article", 385], ["reviews", 393], ["the", 401], ["available", 405], ["pharmacological", 415], ["properties", 431], ["of", 442], ["oral", 445], ["riociguat", 450], ["and", 460], ["its", 464], ["clinical", 468], ["efficacy", 477], ["and", 486], ["tolerability", 490], ["in", 503], ["adults", 506], ["with", 513], ["CTEPH", 518], ["or", 524], ["PAH", 527], [".", 530], ["Riociguat", 532], ["is", 542], ["effective", 545], ["and", 555], ["well", 559], ["tolerated", 564], ["in", 574], ["patients", 577], ["with", 586], ["inoperable", 591], ["CTEPH", 602], ["or", 608], ["persistent", 611], ["/", 621], ["recurrent", 622], ["CTEPH", 632], ["following", 638], ["pulmonary", 648], ["endarterectomy", 658], [",", 672], ["and", 674], ["in", 678], ["patients", 681], ["with", 690], ["PAH", 695], [".", 698], ["It", 700], ["has", 703], ["a", 707], ["positive", 709], ["result", 718], ["on", 725], ["exercise", 728], ["capacity", 737], ["and", 746], ["pulmonary", 750], ["haemodynamics", 760], [",", 773], ["and", 775], ["improves", 779], ["WHO", 788], ["functional", 792], ["class", 803], [".", 808], ["Most", 810], ["adverse", 815], ["events", 823], ["can", 830], ["be", 834], ["attributed", 837], ["to", 848], ["the", 851], ["vasodilatory", 855], ["mechanism", 868], ["of", 878], ["riociguat", 881], [";", 890], ["however", 892], [",", 899], ["there", 901], ["is", 907], ["a", 910], ["potential", 912], ["for", 922], ["serious", 926], ["bleeding", 934], ["and", 943], ["fetal", 947], ["harm", 953], [",", 957], ["and", 959], ["riociguat", 963], ["use", 973], ["is", 977], ["contraindicated", 980], ["in", 996], ["pregnant", 999], ["patients", 1008], [".", 1016], ["Pulmonary", 1018], ["endarterectomy", 1028], ["remains", 1043], ["the", 1051], ["first", 1055], ["treatment", 1061], ["of", 1071], ["choice", 1074], ["for", 1081], ["CTEPH", 1085], [",", 1090], ["as", 1092], ["it", 1095], ["is", 1098], ["potentially", 1101], ["curative", 1113], [".", 1121], ["Head", 1123], ["-", 1127], ["to", 1128], ["-", 1130], ["head", 1131], ["trials", 1136], ["comparing", 1143], ["riociguat", 1153], ["with", 1163], ["the", 1168], ["approved", 1172], ["phosphodiesterase", 1181], ["type", 1199], ["5", 1204], ["inhibitors", 1206], ["in", 1217], ["patients", 1220], ["with", 1229], ["PAH", 1234], ["would", 1238], ["be", 1244], ["of", 1247], ["value", 1250], ["for", 1256], ["the", 1260], ["placement", 1264], ["of", 1274], ["riociguat", 1277], ["in", 1287], ["the", 1290], ["management", 1294], ["of", 1305], ["this", 1308], ["disease", 1313], [".", 1320], ["Riociguat", 1322], ["is", 1332], ["a", 1335], ["promising", 1337], ["addition", 1347], ["to", 1356], ["the", 1359], ["treatment", 1363], ["options", 1373], ["for", 1381], ["patients", 1385], ["with", 1394], ["CTEPH", 1399], ["or", 1405], ["PAH", 1408], [".", 1411]]}
{"context": "Empirical data have challenged chronic posttraumatic stress disorder (PTSD) consisting of three dimensions. In the present study we aimed to determine the factor structure of acute posttraumatic symptoms in two recently traumatized samples. In sample 1, 203 civilian trauma survivors were administered the Davidson Trauma Scale (DTS) approximately 1 week posttrauma. In sample 2, 182 civilian treatment seeking trauma survivors completed the DTS at an average of 41.4 days posttrauma. Our confirmatory factor analyses indicated that a 4-factor intercorrelated model provided the best representation of the data in both samples. The four factors are best described as reexperiencing, active avoidance, dysphoria, and hyperarousal. For acute posttraumatic symptoms, the empirical data suggest to split the avoidance cluster into 'Active avoidance' and 'Dysphoria'-confirming findings in studies on chronic PTSD. In future revisions of the DSM, the diagnostic criteria for PTSD may need to be adapted to fit the research findings.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "154d75312f834698b4172f50c831682d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[145, 145], [9, 9], [158, 158]], "char_spans": [[904, 907], [70, 73], [970, 973]]}]}], "context_tokens": [["Empirical", 0], ["data", 10], ["have", 15], ["challenged", 20], ["chronic", 31], ["posttraumatic", 39], ["stress", 53], ["disorder", 60], ["(", 69], ["PTSD", 70], [")", 74], ["consisting", 76], ["of", 87], ["three", 90], ["dimensions", 96], [".", 106], ["In", 108], ["the", 111], ["present", 115], ["study", 123], ["we", 129], ["aimed", 132], ["to", 138], ["determine", 141], ["the", 151], ["factor", 155], ["structure", 162], ["of", 172], ["acute", 175], ["posttraumatic", 181], ["symptoms", 195], ["in", 204], ["two", 207], ["recently", 211], ["traumatized", 220], ["samples", 232], [".", 239], ["In", 241], ["sample", 244], ["1", 251], [",", 252], ["203", 254], ["civilian", 258], ["trauma", 267], ["survivors", 274], ["were", 284], ["administered", 289], ["the", 302], ["Davidson", 306], ["Trauma", 315], ["Scale", 322], ["(", 328], ["DTS", 329], [")", 332], ["approximately", 334], ["1", 348], ["week", 350], ["posttrauma", 355], [".", 365], ["In", 367], ["sample", 370], ["2", 377], [",", 378], ["182", 380], ["civilian", 384], ["treatment", 393], ["seeking", 403], ["trauma", 411], ["survivors", 418], ["completed", 428], ["the", 438], ["DTS", 442], ["at", 446], ["an", 449], ["average", 452], ["of", 460], ["41.4", 463], ["days", 468], ["posttrauma", 473], [".", 483], ["Our", 485], ["confirmatory", 489], ["factor", 502], ["analyses", 509], ["indicated", 518], ["that", 528], ["a", 533], ["4-factor", 535], ["intercorrelated", 544], ["model", 560], ["provided", 566], ["the", 575], ["best", 579], ["representation", 584], ["of", 599], ["the", 602], ["data", 606], ["in", 611], ["both", 614], ["samples", 619], [".", 626], ["The", 628], ["four", 632], ["factors", 637], ["are", 645], ["best", 649], ["described", 654], ["as", 664], ["reexperiencing", 667], [",", 681], ["active", 683], ["avoidance", 690], [",", 699], ["dysphoria", 701], [",", 710], ["and", 712], ["hyperarousal", 716], [".", 728], ["For", 730], ["acute", 734], ["posttraumatic", 740], ["symptoms", 754], [",", 762], ["the", 764], ["empirical", 768], ["data", 778], ["suggest", 783], ["to", 791], ["split", 794], ["the", 800], ["avoidance", 804], ["cluster", 814], ["into", 822], ["'", 827], ["Active", 828], ["avoidance", 835], ["'", 844], ["and", 846], ["'", 850], ["Dysphoria'-confirming", 851], ["findings", 873], ["in", 882], ["studies", 885], ["on", 893], ["chronic", 896], ["PTSD", 904], [".", 908], ["In", 910], ["future", 913], ["revisions", 920], ["of", 930], ["the", 933], ["DSM", 937], [",", 940], ["the", 942], ["diagnostic", 946], ["criteria", 957], ["for", 966], ["PTSD", 970], ["may", 975], ["need", 979], ["to", 984], ["be", 987], ["adapted", 990], ["to", 998], ["fit", 1001], ["the", 1005], ["research", 1009], ["findings", 1018], [".", 1026]]}
{"context": "Previously, using a chromosomal reversion assay system, we established that an adaptive mutagenic process occurs in nongrowing Bacillus subtilis cells under stress, and we demonstrated that multiple mechanisms are involved in generating these mutations (41, 43). In an attempt to delineate how these mutations are generated, we began an investigation into whether or not transcription and transcription-associated proteins influence adaptive mutagenesis. In B. subtilis, the Mfd protein (transcription repair coupling factor) facilitates removal of RNA polymerase stalled at transcriptional blockages and recruitment of repair proteins to DNA lesions on the transcribed strand. Here we demonstrate that the loss of Mfd has a depressive effect on stationary-phase mutagenesis. An association between Mfd mutagenesis and aspects of transcription is discussed.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase", "stationary-phase"], "qid": "91db4f5a6e754a4889b60c8eb22bc009", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[120, 122]], "char_spans": [[746, 761]]}]}], "context_tokens": [["Previously", 0], [",", 10], ["using", 12], ["a", 18], ["chromosomal", 20], ["reversion", 32], ["assay", 42], ["system", 48], [",", 54], ["we", 56], ["established", 59], ["that", 71], ["an", 76], ["adaptive", 79], ["mutagenic", 88], ["process", 98], ["occurs", 106], ["in", 113], ["nongrowing", 116], ["Bacillus", 127], ["subtilis", 136], ["cells", 145], ["under", 151], ["stress", 157], [",", 163], ["and", 165], ["we", 169], ["demonstrated", 172], ["that", 185], ["multiple", 190], ["mechanisms", 199], ["are", 210], ["involved", 214], ["in", 223], ["generating", 226], ["these", 237], ["mutations", 243], ["(", 253], ["41", 254], [",", 256], ["43", 258], [")", 260], [".", 261], ["In", 263], ["an", 266], ["attempt", 269], ["to", 277], ["delineate", 280], ["how", 290], ["these", 294], ["mutations", 300], ["are", 310], ["generated", 314], [",", 323], ["we", 325], ["began", 328], ["an", 334], ["investigation", 337], ["into", 351], ["whether", 356], ["or", 364], ["not", 367], ["transcription", 371], ["and", 385], ["transcription", 389], ["-", 402], ["associated", 403], ["proteins", 414], ["influence", 423], ["adaptive", 433], ["mutagenesis", 442], [".", 453], ["In", 455], ["B.", 458], ["subtilis", 461], [",", 469], ["the", 471], ["Mfd", 475], ["protein", 479], ["(", 487], ["transcription", 488], ["repair", 502], ["coupling", 509], ["factor", 518], [")", 524], ["facilitates", 526], ["removal", 538], ["of", 546], ["RNA", 549], ["polymerase", 553], ["stalled", 564], ["at", 572], ["transcriptional", 575], ["blockages", 591], ["and", 601], ["recruitment", 605], ["of", 617], ["repair", 620], ["proteins", 627], ["to", 636], ["DNA", 639], ["lesions", 643], ["on", 651], ["the", 654], ["transcribed", 658], ["strand", 670], [".", 676], ["Here", 678], ["we", 683], ["demonstrate", 686], ["that", 698], ["the", 703], ["loss", 707], ["of", 712], ["Mfd", 715], ["has", 719], ["a", 723], ["depressive", 725], ["effect", 736], ["on", 743], ["stationary", 746], ["-", 756], ["phase", 757], ["mutagenesis", 763], [".", 774], ["An", 776], ["association", 779], ["between", 791], ["Mfd", 799], ["mutagenesis", 803], ["and", 815], ["aspects", 819], ["of", 827], ["transcription", 830], ["is", 844], ["discussed", 847], [".", 856]]}
{"context": "Nerve growth factor (NGF) is indispensable during normal embryonic development and critical for the amplification of pain signals in adults. Intervention in NGF signaling holds promise for the alleviation of pain resulting from human diseases such as osteoarthritis, cancer and chronic lower back disorders. We developed a fast, high-fidelity method to convert a hybridoma-derived NGF-targeted mouse antibody into a clinical candidate. This method, termed Library Scanning Mutagenesis (LSM), resulted in the ultra-high affinity antibody tanezumab, a first-in-class anti-hyperalgesic specific for an NGF epitope. Functional and structural comparisons between tanezumab and the mouse 911 precursor antibody using neurotrophin-specific cell survival assays and X-ray crystal structures of both Fab-antigen complexes illustrated high fidelity retention of the NGF epitope. These results suggest the potential for wide applicability of the LSM method for optimization of well-characterized antibodies during humanization.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "702ca078e3664e4f8f2e876395b0f7d4", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "NGF", "token_spans": [[64, 64], [107, 107], [147, 147], [4, 4], [25, 25]], "char_spans": [[381, 383], [599, 601], [856, 858], [21, 23], [157, 159]]}]}], "context_tokens": [["Nerve", 0], ["growth", 6], ["factor", 13], ["(", 20], ["NGF", 21], [")", 24], ["is", 26], ["indispensable", 29], ["during", 43], ["normal", 50], ["embryonic", 57], ["development", 67], ["and", 79], ["critical", 83], ["for", 92], ["the", 96], ["amplification", 100], ["of", 114], ["pain", 117], ["signals", 122], ["in", 130], ["adults", 133], [".", 139], ["Intervention", 141], ["in", 154], ["NGF", 157], ["signaling", 161], ["holds", 171], ["promise", 177], ["for", 185], ["the", 189], ["alleviation", 193], ["of", 205], ["pain", 208], ["resulting", 213], ["from", 223], ["human", 228], ["diseases", 234], ["such", 243], ["as", 248], ["osteoarthritis", 251], [",", 265], ["cancer", 267], ["and", 274], ["chronic", 278], ["lower", 286], ["back", 292], ["disorders", 297], [".", 306], ["We", 308], ["developed", 311], ["a", 321], ["fast", 323], [",", 327], ["high", 329], ["-", 333], ["fidelity", 334], ["method", 343], ["to", 350], ["convert", 353], ["a", 361], ["hybridoma", 363], ["-", 372], ["derived", 373], ["NGF", 381], ["-", 384], ["targeted", 385], ["mouse", 394], ["antibody", 400], ["into", 409], ["a", 414], ["clinical", 416], ["candidate", 425], [".", 434], ["This", 436], ["method", 441], [",", 447], ["termed", 449], ["Library", 456], ["Scanning", 464], ["Mutagenesis", 473], ["(", 485], ["LSM", 486], [")", 489], [",", 490], ["resulted", 492], ["in", 501], ["the", 504], ["ultra", 508], ["-", 513], ["high", 514], ["affinity", 519], ["antibody", 528], ["tanezumab", 537], [",", 546], ["a", 548], ["first", 550], ["-", 555], ["in", 556], ["-", 558], ["class", 559], ["anti", 565], ["-", 569], ["hyperalgesic", 570], ["specific", 583], ["for", 592], ["an", 596], ["NGF", 599], ["epitope", 603], [".", 610], ["Functional", 612], ["and", 623], ["structural", 627], ["comparisons", 638], ["between", 650], ["tanezumab", 658], ["and", 668], ["the", 672], ["mouse", 676], ["911", 682], ["precursor", 686], ["antibody", 696], ["using", 705], ["neurotrophin", 711], ["-", 723], ["specific", 724], ["cell", 733], ["survival", 738], ["assays", 747], ["and", 754], ["X", 758], ["-", 759], ["ray", 760], ["crystal", 764], ["structures", 772], ["of", 783], ["both", 786], ["Fab", 791], ["-", 794], ["antigen", 795], ["complexes", 803], ["illustrated", 813], ["high", 825], ["fidelity", 830], ["retention", 839], ["of", 849], ["the", 852], ["NGF", 856], ["epitope", 860], [".", 867], ["These", 869], ["results", 875], ["suggest", 883], ["the", 891], ["potential", 895], ["for", 905], ["wide", 909], ["applicability", 914], ["of", 928], ["the", 931], ["LSM", 935], ["method", 939], ["for", 946], ["optimization", 950], ["of", 963], ["well", 966], ["-", 970], ["characterized", 971], ["antibodies", 985], ["during", 996], ["humanization", 1003], [".", 1015]]}
{"context": "We previously conducted a proof of principle; dose escalation study in Duchenne muscular dystrophy (DMD) patients using the morpholino splice-switching oligonucleotide AVI-4658 (eteplirsen) that induces skipping of dystrophin exon 51 in patients with relevant deletions, restores the open reading frame and induces dystrophin protein expression after intramuscular (i.m.) injection. We now show that this dystrophin expression was accompanied by an elevated expression of \u03b1-sarcoglycan, \u03b2-dystroglycan (BDG) and--in relevant cases--neuronal nitric oxide synthase (nNOS) at the sarcolemma, each of which is a component of a different subcomplex of the dystrophin-associated glycoprotein complex (DAPC). As expected, nNOS expression was relocalized to the sarcolemma in Duchenne patients in whom the dystrophin deletion left the nNOS-binding domain (exons 42-45) intact, whereas this did not occur in patients with deletions that involved this domain. Our results indicate that the novel internally deleted and shorter dystrophin induced by skipping exon 51 in patients with amenable deletions, can also restore the dystrophin-associated complex, further suggesting preserved functionality of the newly translated dystrophin.", "qas": [{"question": "What is the role of eteplirsen in DMD patients?", "answers": ["skipping of dystrophin exon 51"], "qid": "3d5eec0702a04e5a95da8cdd5d1454d8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["role", 12], ["of", 17], ["eteplirsen", 20], ["in", 31], ["DMD", 34], ["patients", 38], ["?", 46]], "detected_answers": [{"text": "skipping of dystrophin exon 51", "token_spans": [[32, 36]], "char_spans": [[203, 232]]}]}], "context_tokens": [["We", 0], ["previously", 3], ["conducted", 14], ["a", 24], ["proof", 26], ["of", 32], ["principle", 35], [";", 44], ["dose", 46], ["escalation", 51], ["study", 62], ["in", 68], ["Duchenne", 71], ["muscular", 80], ["dystrophy", 89], ["(", 99], ["DMD", 100], [")", 103], ["patients", 105], ["using", 114], ["the", 120], ["morpholino", 124], ["splice", 135], ["-", 141], ["switching", 142], ["oligonucleotide", 152], ["AVI-4658", 168], ["(", 177], ["eteplirsen", 178], [")", 188], ["that", 190], ["induces", 195], ["skipping", 203], ["of", 212], ["dystrophin", 215], ["exon", 226], ["51", 231], ["in", 234], ["patients", 237], ["with", 246], ["relevant", 251], ["deletions", 260], [",", 269], ["restores", 271], ["the", 280], ["open", 284], ["reading", 289], ["frame", 297], ["and", 303], ["induces", 307], ["dystrophin", 315], ["protein", 326], ["expression", 334], ["after", 345], ["intramuscular", 351], ["(", 365], ["i.m", 366], [".", 369], [")", 370], ["injection", 372], [".", 381], ["We", 383], ["now", 386], ["show", 390], ["that", 395], ["this", 400], ["dystrophin", 405], ["expression", 416], ["was", 427], ["accompanied", 431], ["by", 443], ["an", 446], ["elevated", 449], ["expression", 458], ["of", 469], ["\u03b1", 472], ["-", 473], ["sarcoglycan", 474], [",", 485], ["\u03b2", 487], ["-", 488], ["dystroglycan", 489], ["(", 502], ["BDG", 503], [")", 506], ["and", 508], ["--", 511], ["in", 513], ["relevant", 516], ["cases", 525], ["--", 530], ["neuronal", 532], ["nitric", 541], ["oxide", 548], ["synthase", 554], ["(", 563], ["nNOS", 564], [")", 568], ["at", 570], ["the", 573], ["sarcolemma", 577], [",", 587], ["each", 589], ["of", 594], ["which", 597], ["is", 603], ["a", 606], ["component", 608], ["of", 618], ["a", 621], ["different", 623], ["subcomplex", 633], ["of", 644], ["the", 647], ["dystrophin", 651], ["-", 661], ["associated", 662], ["glycoprotein", 673], ["complex", 686], ["(", 694], ["DAPC", 695], [")", 699], [".", 700], ["As", 702], ["expected", 705], [",", 713], ["nNOS", 715], ["expression", 720], ["was", 731], ["relocalized", 735], ["to", 747], ["the", 750], ["sarcolemma", 754], ["in", 765], ["Duchenne", 768], ["patients", 777], ["in", 786], ["whom", 789], ["the", 794], ["dystrophin", 798], ["deletion", 809], ["left", 818], ["the", 823], ["nNOS", 827], ["-", 831], ["binding", 832], ["domain", 840], ["(", 847], ["exons", 848], ["42", 854], ["-", 856], ["45", 857], [")", 859], ["intact", 861], [",", 867], ["whereas", 869], ["this", 877], ["did", 882], ["not", 886], ["occur", 890], ["in", 896], ["patients", 899], ["with", 908], ["deletions", 913], ["that", 923], ["involved", 928], ["this", 937], ["domain", 942], [".", 948], ["Our", 950], ["results", 954], ["indicate", 962], ["that", 971], ["the", 976], ["novel", 980], ["internally", 986], ["deleted", 997], ["and", 1005], ["shorter", 1009], ["dystrophin", 1017], ["induced", 1028], ["by", 1036], ["skipping", 1039], ["exon", 1048], ["51", 1053], ["in", 1056], ["patients", 1059], ["with", 1068], ["amenable", 1073], ["deletions", 1082], [",", 1091], ["can", 1093], ["also", 1097], ["restore", 1102], ["the", 1110], ["dystrophin", 1114], ["-", 1124], ["associated", 1125], ["complex", 1136], [",", 1143], ["further", 1145], ["suggesting", 1153], ["preserved", 1164], ["functionality", 1174], ["of", 1188], ["the", 1191], ["newly", 1195], ["translated", 1201], ["dystrophin", 1212], [".", 1222]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensorimotor disorder that can result in considerable sleep disruption. This narrative review provides an overview of RLS diagnosis and reports epidemiologic evidence for an association between RLS and mood disorders. Possible links between RLS, sleep disturbances, and mood disorders are considered, and theoretical pathophysiologic pathways are discussed. Finally, pharmacologic therapies for RLS are summarized. A PubMed search was performed using the search term restless legs syndrome in combination with affective/anxiety, antidepressants, anxiety/anxiety disorder, attention deficit hyperactivity disorder, depression/depressive disorder, mood/mood disorder, neuropsychiatric, panic/panic disorder, psychiatric disorder, and psychosis. English-language articles published between January 1993 and May 2013 were retrieved. Additional studies were identified from the reference lists of relevant publications. 173 publications were retrieved. Articles related to the association between idiopathic RLS and depression, anxiety, and mood disorders were reviewed. In total, 32 epidemiologic studies were identified. These studies were reviewed in detail and ranked according to quality. Data were extracted on the basis of relevance to the topic. Epidemiologic studies were assessed using 3 parameters: methodology, data quality, and generalizability of the results. Each factor was scored from 1 (high quality) to 4 (low quality), giving a total score of between 3 and 12 for each study. RLS and mood disorders are frequently comorbid. Recognition and appropriate treatment of comorbid RLS are particularly important in patients with psychiatric disorders, as RLS is a common medical reason for insomnia, and antidepressant use may exacerbate sensory symptoms.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "f69aed865e4f4461b59e86ff393595b6", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2], [88, 90]], "char_spans": [[0, 21], [538, 559]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], [",", 64], ["is", 66], ["a", 69], ["sensorimotor", 71], ["disorder", 84], ["that", 93], ["can", 98], ["result", 102], ["in", 109], ["considerable", 112], ["sleep", 125], ["disruption", 131], [".", 141], ["This", 143], ["narrative", 148], ["review", 158], ["provides", 165], ["an", 174], ["overview", 177], ["of", 186], ["RLS", 189], ["diagnosis", 193], ["and", 203], ["reports", 207], ["epidemiologic", 215], ["evidence", 229], ["for", 238], ["an", 242], ["association", 245], ["between", 257], ["RLS", 265], ["and", 269], ["mood", 273], ["disorders", 278], [".", 287], ["Possible", 289], ["links", 298], ["between", 304], ["RLS", 312], [",", 315], ["sleep", 317], ["disturbances", 323], [",", 335], ["and", 337], ["mood", 341], ["disorders", 346], ["are", 356], ["considered", 360], [",", 370], ["and", 372], ["theoretical", 376], ["pathophysiologic", 388], ["pathways", 405], ["are", 414], ["discussed", 418], [".", 427], ["Finally", 429], [",", 436], ["pharmacologic", 438], ["therapies", 452], ["for", 462], ["RLS", 466], ["are", 470], ["summarized", 474], [".", 484], ["A", 486], ["PubMed", 488], ["search", 495], ["was", 502], ["performed", 506], ["using", 516], ["the", 522], ["search", 526], ["term", 533], ["restless", 538], ["legs", 547], ["syndrome", 552], ["in", 561], ["combination", 564], ["with", 576], ["affective", 581], ["/", 590], ["anxiety", 591], [",", 598], ["antidepressants", 600], [",", 615], ["anxiety", 617], ["/", 624], ["anxiety", 625], ["disorder", 633], [",", 641], ["attention", 643], ["deficit", 653], ["hyperactivity", 661], ["disorder", 675], [",", 683], ["depression", 685], ["/", 695], ["depressive", 696], ["disorder", 707], [",", 715], ["mood", 717], ["/", 721], ["mood", 722], ["disorder", 727], [",", 735], ["neuropsychiatric", 737], [",", 753], ["panic", 755], ["/", 760], ["panic", 761], ["disorder", 767], [",", 775], ["psychiatric", 777], ["disorder", 789], [",", 797], ["and", 799], ["psychosis", 803], [".", 812], ["English", 814], ["-", 821], ["language", 822], ["articles", 831], ["published", 840], ["between", 850], ["January", 858], ["1993", 866], ["and", 871], ["May", 875], ["2013", 879], ["were", 884], ["retrieved", 889], [".", 898], ["Additional", 900], ["studies", 911], ["were", 919], ["identified", 924], ["from", 935], ["the", 940], ["reference", 944], ["lists", 954], ["of", 960], ["relevant", 963], ["publications", 972], [".", 984], ["173", 986], ["publications", 990], ["were", 1003], ["retrieved", 1008], [".", 1017], ["Articles", 1019], ["related", 1028], ["to", 1036], ["the", 1039], ["association", 1043], ["between", 1055], ["idiopathic", 1063], ["RLS", 1074], ["and", 1078], ["depression", 1082], [",", 1092], ["anxiety", 1094], [",", 1101], ["and", 1103], ["mood", 1107], ["disorders", 1112], ["were", 1122], ["reviewed", 1127], [".", 1135], ["In", 1137], ["total", 1140], [",", 1145], ["32", 1147], ["epidemiologic", 1150], ["studies", 1164], ["were", 1172], ["identified", 1177], [".", 1187], ["These", 1189], ["studies", 1195], ["were", 1203], ["reviewed", 1208], ["in", 1217], ["detail", 1220], ["and", 1227], ["ranked", 1231], ["according", 1238], ["to", 1248], ["quality", 1251], [".", 1258], ["Data", 1260], ["were", 1265], ["extracted", 1270], ["on", 1280], ["the", 1283], ["basis", 1287], ["of", 1293], ["relevance", 1296], ["to", 1306], ["the", 1309], ["topic", 1313], [".", 1318], ["Epidemiologic", 1320], ["studies", 1334], ["were", 1342], ["assessed", 1347], ["using", 1356], ["3", 1362], ["parameters", 1364], [":", 1374], ["methodology", 1376], [",", 1387], ["data", 1389], ["quality", 1394], [",", 1401], ["and", 1403], ["generalizability", 1407], ["of", 1424], ["the", 1427], ["results", 1431], [".", 1438], ["Each", 1440], ["factor", 1445], ["was", 1452], ["scored", 1456], ["from", 1463], ["1", 1468], ["(", 1470], ["high", 1471], ["quality", 1476], [")", 1483], ["to", 1485], ["4", 1488], ["(", 1490], ["low", 1491], ["quality", 1495], [")", 1502], [",", 1503], ["giving", 1505], ["a", 1512], ["total", 1514], ["score", 1520], ["of", 1526], ["between", 1529], ["3", 1537], ["and", 1539], ["12", 1543], ["for", 1546], ["each", 1550], ["study", 1555], [".", 1560], ["RLS", 1562], ["and", 1566], ["mood", 1570], ["disorders", 1575], ["are", 1585], ["frequently", 1589], ["comorbid", 1600], [".", 1608], ["Recognition", 1610], ["and", 1622], ["appropriate", 1626], ["treatment", 1638], ["of", 1648], ["comorbid", 1651], ["RLS", 1660], ["are", 1664], ["particularly", 1668], ["important", 1681], ["in", 1691], ["patients", 1694], ["with", 1703], ["psychiatric", 1708], ["disorders", 1720], [",", 1729], ["as", 1731], ["RLS", 1734], ["is", 1738], ["a", 1741], ["common", 1743], ["medical", 1750], ["reason", 1758], ["for", 1765], ["insomnia", 1769], [",", 1777], ["and", 1779], ["antidepressant", 1783], ["use", 1798], ["may", 1802], ["exacerbate", 1806], ["sensory", 1817], ["symptoms", 1825], [".", 1833]]}
{"context": "Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by Philadelphia chromosome and resultant production of the constitutively activated BCR-ABL tyrosine kinase. Imatinib (STI571), selective inhibitor of the ABL-tyrosine kinase, inhibits the activity of BCR-ABL tyrosine kinase. A phase I and II study of STI571 showed remarkable cytogenetic effect in patients with interferon-refractory CML, offering new hope for therapy for CML. It will, however, require long-term follow-up data from phase II and III clinical studies to validate the effect of STI571 on survival. As therapy for CML improves, monitoring minimal residual disease will be important.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "0bb3119e6d6d48ffa24785cf272e280e", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[48, 50], [24, 26]], "char_spans": [[291, 297], [174, 180]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["clonal", 36], ["hematopoietic", 43], ["stem", 57], ["cell", 62], ["disorder", 67], ["characterized", 76], ["by", 90], ["Philadelphia", 93], ["chromosome", 106], ["and", 117], ["resultant", 121], ["production", 131], ["of", 142], ["the", 145], ["constitutively", 149], ["activated", 164], ["BCR", 174], ["-", 177], ["ABL", 178], ["tyrosine", 182], ["kinase", 191], [".", 197], ["Imatinib", 199], ["(", 208], ["STI571", 209], [")", 215], [",", 216], ["selective", 218], ["inhibitor", 228], ["of", 238], ["the", 241], ["ABL", 245], ["-", 248], ["tyrosine", 249], ["kinase", 258], [",", 264], ["inhibits", 266], ["the", 275], ["activity", 279], ["of", 288], ["BCR", 291], ["-", 294], ["ABL", 295], ["tyrosine", 299], ["kinase", 308], [".", 314], ["A", 316], ["phase", 318], ["I", 324], ["and", 326], ["II", 330], ["study", 333], ["of", 339], ["STI571", 342], ["showed", 349], ["remarkable", 356], ["cytogenetic", 367], ["effect", 379], ["in", 386], ["patients", 389], ["with", 398], ["interferon", 403], ["-", 413], ["refractory", 414], ["CML", 425], [",", 428], ["offering", 430], ["new", 439], ["hope", 443], ["for", 448], ["therapy", 452], ["for", 460], ["CML", 464], [".", 467], ["It", 469], ["will", 472], [",", 476], ["however", 478], [",", 485], ["require", 487], ["long", 495], ["-", 499], ["term", 500], ["follow", 505], ["-", 511], ["up", 512], ["data", 515], ["from", 520], ["phase", 525], ["II", 531], ["and", 534], ["III", 538], ["clinical", 542], ["studies", 551], ["to", 559], ["validate", 562], ["the", 571], ["effect", 575], ["of", 582], ["STI571", 585], ["on", 592], ["survival", 595], [".", 603], ["As", 605], ["therapy", 608], ["for", 616], ["CML", 620], ["improves", 624], [",", 632], ["monitoring", 634], ["minimal", 645], ["residual", 653], ["disease", 662], ["will", 670], ["be", 675], ["important", 678], [".", 687]]}
{"context": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM). PubMed was searched using the search terms empagliflozin, BI 10773, and BI10773, for entries between January 1, 2000, and December 1, 2014. Reference lists from retrieved articles were searched manually for additional peer-reviewed publications. All publications reporting clinical trials of empagliflozin were eligible for inclusion. Empagliflozin is a new once-daily oral SGLT2 inhibitor with a mechanism of action that is independent of \u03b2-cell function and the insulin pathway. Data from a comprehensive phase III clinical trial program have demonstrated its efficacy as monotherapy, as add-on to other glucose-lowering agents, and in different patient populations. In these studies, empagliflozin resulted in improvements in blood glucose levels as well as reductions in body weight and blood pressure. Empagliflozin was well tolerated and was not associated with an increased risk of hypoglycemia versus placebo. The oral antidiabetes agent, empagliflozin, can be used as monotherapy or alongside other glucose-lowering treatments, including insulin, to treat T2DM.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "8e4362d962304849af0e9a9cf344f780", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[108, 108], [14, 14]], "char_spans": [[621, 625], [81, 85]]}]}], "context_tokens": [["To", 0], ["review", 3], ["available", 10], ["studies", 20], ["of", 28], ["empagliflozin", 31], [",", 44], ["a", 46], ["sodium", 48], ["glucose", 55], ["co", 63], ["-", 65], ["transporter-2", 66], ["(", 80], ["SGLT2", 81], [")", 86], ["inhibitor", 88], ["approved", 98], ["in", 107], ["2014", 110], ["by", 115], ["the", 118], ["European", 122], ["Commission", 131], ["and", 142], ["the", 146], ["United", 150], ["States", 157], ["Food", 164], ["and", 169], ["Drug", 173], ["Administration", 178], ["for", 193], ["the", 197], ["treatment", 201], ["of", 211], ["type", 214], ["2", 219], ["diabetes", 221], ["mellitus", 230], ["(", 239], ["T2DM", 240], [")", 244], [".", 245], ["PubMed", 247], ["was", 254], ["searched", 258], ["using", 267], ["the", 273], ["search", 277], ["terms", 284], ["empagliflozin", 290], [",", 303], ["BI", 305], ["10773", 308], [",", 313], ["and", 315], ["BI10773", 319], [",", 326], ["for", 328], ["entries", 332], ["between", 340], ["January", 348], ["1", 356], [",", 357], ["2000", 359], [",", 363], ["and", 365], ["December", 369], ["1", 378], [",", 379], ["2014", 381], [".", 385], ["Reference", 387], ["lists", 397], ["from", 403], ["retrieved", 408], ["articles", 418], ["were", 427], ["searched", 432], ["manually", 441], ["for", 450], ["additional", 454], ["peer", 465], ["-", 469], ["reviewed", 470], ["publications", 479], [".", 491], ["All", 493], ["publications", 497], ["reporting", 510], ["clinical", 520], ["trials", 529], ["of", 536], ["empagliflozin", 539], ["were", 553], ["eligible", 558], ["for", 567], ["inclusion", 571], [".", 580], ["Empagliflozin", 582], ["is", 596], ["a", 599], ["new", 601], ["once", 605], ["-", 609], ["daily", 610], ["oral", 616], ["SGLT2", 621], ["inhibitor", 627], ["with", 637], ["a", 642], ["mechanism", 644], ["of", 654], ["action", 657], ["that", 664], ["is", 669], ["independent", 672], ["of", 684], ["\u03b2", 687], ["-", 688], ["cell", 689], ["function", 694], ["and", 703], ["the", 707], ["insulin", 711], ["pathway", 719], [".", 726], ["Data", 728], ["from", 733], ["a", 738], ["comprehensive", 740], ["phase", 754], ["III", 760], ["clinical", 764], ["trial", 773], ["program", 779], ["have", 787], ["demonstrated", 792], ["its", 805], ["efficacy", 809], ["as", 818], ["monotherapy", 821], [",", 832], ["as", 834], ["add", 837], ["-", 840], ["on", 841], ["to", 844], ["other", 847], ["glucose", 853], ["-", 860], ["lowering", 861], ["agents", 870], [",", 876], ["and", 878], ["in", 882], ["different", 885], ["patient", 895], ["populations", 903], [".", 914], ["In", 916], ["these", 919], ["studies", 925], [",", 932], ["empagliflozin", 934], ["resulted", 948], ["in", 957], ["improvements", 960], ["in", 973], ["blood", 976], ["glucose", 982], ["levels", 990], ["as", 997], ["well", 1000], ["as", 1005], ["reductions", 1008], ["in", 1019], ["body", 1022], ["weight", 1027], ["and", 1034], ["blood", 1038], ["pressure", 1044], [".", 1052], ["Empagliflozin", 1054], ["was", 1068], ["well", 1072], ["tolerated", 1077], ["and", 1087], ["was", 1091], ["not", 1095], ["associated", 1099], ["with", 1110], ["an", 1115], ["increased", 1118], ["risk", 1128], ["of", 1133], ["hypoglycemia", 1136], ["versus", 1149], ["placebo", 1156], [".", 1163], ["The", 1165], ["oral", 1169], ["antidiabetes", 1174], ["agent", 1187], [",", 1192], ["empagliflozin", 1194], [",", 1207], ["can", 1209], ["be", 1213], ["used", 1216], ["as", 1221], ["monotherapy", 1224], ["or", 1236], ["alongside", 1239], ["other", 1249], ["glucose", 1255], ["-", 1262], ["lowering", 1263], ["treatments", 1272], [",", 1282], ["including", 1284], ["insulin", 1294], [",", 1301], ["to", 1303], ["treat", 1306], ["T2DM", 1312], [".", 1316]]}
{"context": "Fibrillar \u03b1-synuclein (\u03b1-Syn) is the principal component of Lewy bodies, which are evident in individuals affected by Parkinson disease (PD). This neuropathologic form of \u03b1-Syn plays a central role in PD progression as it has been shown to propagate between neurons. Tools that interfere with \u03b1-Syn assembly or change the physicochemical properties of the fibrils have potential therapeutic properties as they may be sufficient to interfere with and/or halt cell-to-cell transmission and the systematic spread of \u03b1-Syn assemblies within the central nervous system. Vertebrate molecular chaperones from the constitutive/heat-inducible heat shock protein 70 (Hsc/p70) family have been shown to hinder the assembly of soluble \u03b1-Syn into fibrils and to bind to the fibrils and very significantly reduce their toxicity. To understand how Hsc70 family members sequester soluble \u03b1-Syn, we set up experiments to identify the molecular chaperone-\u03b1-Syn surface interfaces. We cross-linked human Hsc70 and its yeast homologue Ssa1p and \u03b1-Syn using a chemical cross-linker and mapped the Hsc70- and Ssa1p-\u03b1-Syn interface. We show that the client binding domain of Hsc70 and Ssa1p binds two regions within \u03b1-Syn similar to a tweezer, with the first spanning residues 10-45 and the second spanning residues 97-102. Our findings define what is necessary and sufficient for engineering Hsc70- and Ssa1p-derived polypeptide with minichaperone properties with a potential as therapeutic agents in Parkinson disease through their ability to affect \u03b1-Syn assembly and/or toxicity.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "344f79431db040ea8cbbb6cb3a1b171a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[1, 3]], "char_spans": [[10, 20]]}]}], "context_tokens": [["Fibrillar", 0], ["\u03b1", 10], ["-", 11], ["synuclein", 12], ["(", 22], ["\u03b1", 23], ["-", 24], ["Syn", 25], [")", 28], ["is", 30], ["the", 33], ["principal", 37], ["component", 47], ["of", 57], ["Lewy", 60], ["bodies", 65], [",", 71], ["which", 73], ["are", 79], ["evident", 83], ["in", 91], ["individuals", 94], ["affected", 106], ["by", 115], ["Parkinson", 118], ["disease", 128], ["(", 136], ["PD", 137], [")", 139], [".", 140], ["This", 142], ["neuropathologic", 147], ["form", 163], ["of", 168], ["\u03b1", 171], ["-", 172], ["Syn", 173], ["plays", 177], ["a", 183], ["central", 185], ["role", 193], ["in", 198], ["PD", 201], ["progression", 204], ["as", 216], ["it", 219], ["has", 222], ["been", 226], ["shown", 231], ["to", 237], ["propagate", 240], ["between", 250], ["neurons", 258], [".", 265], ["Tools", 267], ["that", 273], ["interfere", 278], ["with", 288], ["\u03b1", 293], ["-", 294], ["Syn", 295], ["assembly", 299], ["or", 308], ["change", 311], ["the", 318], ["physicochemical", 322], ["properties", 338], ["of", 349], ["the", 352], ["fibrils", 356], ["have", 364], ["potential", 369], ["therapeutic", 379], ["properties", 391], ["as", 402], ["they", 405], ["may", 410], ["be", 414], ["sufficient", 417], ["to", 428], ["interfere", 431], ["with", 441], ["and/or", 446], ["halt", 453], ["cell", 458], ["-", 462], ["to", 463], ["-", 465], ["cell", 466], ["transmission", 471], ["and", 484], ["the", 488], ["systematic", 492], ["spread", 503], ["of", 510], ["\u03b1", 513], ["-", 514], ["Syn", 515], ["assemblies", 519], ["within", 530], ["the", 537], ["central", 541], ["nervous", 549], ["system", 557], [".", 563], ["Vertebrate", 565], ["molecular", 576], ["chaperones", 586], ["from", 597], ["the", 602], ["constitutive", 606], ["/", 618], ["heat", 619], ["-", 623], ["inducible", 624], ["heat", 634], ["shock", 639], ["protein", 645], ["70", 653], ["(", 656], ["Hsc", 657], ["/", 660], ["p70", 661], [")", 664], ["family", 666], ["have", 673], ["been", 678], ["shown", 683], ["to", 689], ["hinder", 692], ["the", 699], ["assembly", 703], ["of", 712], ["soluble", 715], ["\u03b1", 723], ["-", 724], ["Syn", 725], ["into", 729], ["fibrils", 734], ["and", 742], ["to", 746], ["bind", 749], ["to", 754], ["the", 757], ["fibrils", 761], ["and", 769], ["very", 773], ["significantly", 778], ["reduce", 792], ["their", 799], ["toxicity", 805], [".", 813], ["To", 815], ["understand", 818], ["how", 829], ["Hsc70", 833], ["family", 839], ["members", 846], ["sequester", 854], ["soluble", 864], ["\u03b1", 872], ["-", 873], ["Syn", 874], [",", 877], ["we", 879], ["set", 882], ["up", 886], ["experiments", 889], ["to", 901], ["identify", 904], ["the", 913], ["molecular", 917], ["chaperone", 927], ["-", 936], ["\u03b1", 937], ["-", 938], ["Syn", 939], ["surface", 943], ["interfaces", 951], [".", 961], ["We", 963], ["cross", 966], ["-", 971], ["linked", 972], ["human", 979], ["Hsc70", 985], ["and", 991], ["its", 995], ["yeast", 999], ["homologue", 1005], ["Ssa1p", 1015], ["and", 1021], ["\u03b1", 1025], ["-", 1026], ["Syn", 1027], ["using", 1031], ["a", 1037], ["chemical", 1039], ["cross", 1048], ["-", 1053], ["linker", 1054], ["and", 1061], ["mapped", 1065], ["the", 1072], ["Hsc70-", 1076], ["and", 1083], ["Ssa1p", 1087], ["-", 1092], ["\u03b1", 1093], ["-", 1094], ["Syn", 1095], ["interface", 1099], [".", 1108], ["We", 1110], ["show", 1113], ["that", 1118], ["the", 1123], ["client", 1127], ["binding", 1134], ["domain", 1142], ["of", 1149], ["Hsc70", 1152], ["and", 1158], ["Ssa1p", 1162], ["binds", 1168], ["two", 1174], ["regions", 1178], ["within", 1186], ["\u03b1", 1193], ["-", 1194], ["Syn", 1195], ["similar", 1199], ["to", 1207], ["a", 1210], ["tweezer", 1212], [",", 1219], ["with", 1221], ["the", 1226], ["first", 1230], ["spanning", 1236], ["residues", 1245], ["10", 1254], ["-", 1256], ["45", 1257], ["and", 1260], ["the", 1264], ["second", 1268], ["spanning", 1275], ["residues", 1284], ["97", 1293], ["-", 1295], ["102", 1296], [".", 1299], ["Our", 1301], ["findings", 1305], ["define", 1314], ["what", 1321], ["is", 1326], ["necessary", 1329], ["and", 1339], ["sufficient", 1343], ["for", 1354], ["engineering", 1358], ["Hsc70-", 1370], ["and", 1377], ["Ssa1p", 1381], ["-", 1386], ["derived", 1387], ["polypeptide", 1395], ["with", 1407], ["minichaperone", 1412], ["properties", 1426], ["with", 1437], ["a", 1442], ["potential", 1444], ["as", 1454], ["therapeutic", 1457], ["agents", 1469], ["in", 1476], ["Parkinson", 1479], ["disease", 1489], ["through", 1497], ["their", 1505], ["ability", 1511], ["to", 1519], ["affect", 1522], ["\u03b1", 1529], ["-", 1530], ["Syn", 1531], ["assembly", 1535], ["and/or", 1544], ["toxicity", 1551], [".", 1559]]}
{"context": "Parkinson's disease (PD) is characterized as a neurodegenerative movement disorder presenting with rigidity, resting tremor, disturbances in balance and slowness in movement. An important pathologic feature of PD is the presence of Lewy bodies. The primary structural component of Lewy bodies are fibrils composed primarily of alpha-synuclein, a highly conserved 140 amino acid protein that is predominantly expressed in neurons and which may play a role in synaptic plasticity and neurotransmission. Numerous studies suggest the aggregation and modification of alpha-synuclein as a key step leading to Lewy body formation and neuronal cell loss associated with PD. Because of the central role of alpha-synuclein in PD, it represents a novel drug target for the possible treatment of this disease. In this review, an overview of the role of alpha-synuclein in PD will be discussed with an emphasis on recent studies utilizing an immunization approach against alpha-synuclein as a possible treatment option for this debilitating disease.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "8cb2d5ed371845bdbc1aef1bc23e2418", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[116, 118], [165, 167], [53, 55], [90, 92], [146, 148]], "char_spans": [[697, 711], [959, 973], [327, 341], [562, 576], [841, 855]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["characterized", 28], ["as", 42], ["a", 45], ["neurodegenerative", 47], ["movement", 65], ["disorder", 74], ["presenting", 83], ["with", 94], ["rigidity", 99], [",", 107], ["resting", 109], ["tremor", 117], [",", 123], ["disturbances", 125], ["in", 138], ["balance", 141], ["and", 149], ["slowness", 153], ["in", 162], ["movement", 165], [".", 173], ["An", 175], ["important", 178], ["pathologic", 188], ["feature", 199], ["of", 207], ["PD", 210], ["is", 213], ["the", 216], ["presence", 220], ["of", 229], ["Lewy", 232], ["bodies", 237], [".", 243], ["The", 245], ["primary", 249], ["structural", 257], ["component", 268], ["of", 278], ["Lewy", 281], ["bodies", 286], ["are", 293], ["fibrils", 297], ["composed", 305], ["primarily", 314], ["of", 324], ["alpha", 327], ["-", 332], ["synuclein", 333], [",", 342], ["a", 344], ["highly", 346], ["conserved", 353], ["140", 363], ["amino", 367], ["acid", 373], ["protein", 378], ["that", 386], ["is", 391], ["predominantly", 394], ["expressed", 408], ["in", 418], ["neurons", 421], ["and", 429], ["which", 433], ["may", 439], ["play", 443], ["a", 448], ["role", 450], ["in", 455], ["synaptic", 458], ["plasticity", 467], ["and", 478], ["neurotransmission", 482], [".", 499], ["Numerous", 501], ["studies", 510], ["suggest", 518], ["the", 526], ["aggregation", 530], ["and", 542], ["modification", 546], ["of", 559], ["alpha", 562], ["-", 567], ["synuclein", 568], ["as", 578], ["a", 581], ["key", 583], ["step", 587], ["leading", 592], ["to", 600], ["Lewy", 603], ["body", 608], ["formation", 613], ["and", 623], ["neuronal", 627], ["cell", 636], ["loss", 641], ["associated", 646], ["with", 657], ["PD", 662], [".", 664], ["Because", 666], ["of", 674], ["the", 677], ["central", 681], ["role", 689], ["of", 694], ["alpha", 697], ["-", 702], ["synuclein", 703], ["in", 713], ["PD", 716], [",", 718], ["it", 720], ["represents", 723], ["a", 734], ["novel", 736], ["drug", 742], ["target", 747], ["for", 754], ["the", 758], ["possible", 762], ["treatment", 771], ["of", 781], ["this", 784], ["disease", 789], [".", 796], ["In", 798], ["this", 801], ["review", 806], [",", 812], ["an", 814], ["overview", 817], ["of", 826], ["the", 829], ["role", 833], ["of", 838], ["alpha", 841], ["-", 846], ["synuclein", 847], ["in", 857], ["PD", 860], ["will", 863], ["be", 868], ["discussed", 871], ["with", 881], ["an", 886], ["emphasis", 889], ["on", 898], ["recent", 901], ["studies", 908], ["utilizing", 916], ["an", 926], ["immunization", 929], ["approach", 942], ["against", 951], ["alpha", 959], ["-", 964], ["synuclein", 965], ["as", 975], ["a", 978], ["possible", 980], ["treatment", 989], ["option", 999], ["for", 1006], ["this", 1010], ["debilitating", 1015], ["disease", 1028], [".", 1035]]}
{"context": "Methylation of lysine residues in the N-terminal tails of histones is thought to represent an important component of the mechanism that regulates chromatin structure. The evolutionarily conserved SET domain occurs in most proteins known to possess histone lysine methyltransferase activity. We present here the crystal structure of a large fragment of human SET7/9 that contains a N-terminal beta-sheet domain as well as the conserved SET domain. Mutagenesis identifies two residues in the C terminus of the protein that appear essential for catalytic activity toward lysine-4 of histone H3. Furthermore, we show how the cofactor AdoMet binds to this domain and present biochemical data supporting the role of invariant residues in catalysis, binding of AdoMet, and interactions with the peptide substrate.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "3f7b340bb0f840e98a015f2346104288", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[72, 73], [30, 31]], "char_spans": [[435, 444], [196, 205]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["lysine", 15], ["residues", 22], ["in", 31], ["the", 34], ["N", 38], ["-", 39], ["terminal", 40], ["tails", 49], ["of", 55], ["histones", 58], ["is", 67], ["thought", 70], ["to", 78], ["represent", 81], ["an", 91], ["important", 94], ["component", 104], ["of", 114], ["the", 117], ["mechanism", 121], ["that", 131], ["regulates", 136], ["chromatin", 146], ["structure", 156], [".", 165], ["The", 167], ["evolutionarily", 171], ["conserved", 186], ["SET", 196], ["domain", 200], ["occurs", 207], ["in", 214], ["most", 217], ["proteins", 222], ["known", 231], ["to", 237], ["possess", 240], ["histone", 248], ["lysine", 256], ["methyltransferase", 263], ["activity", 281], [".", 289], ["We", 291], ["present", 294], ["here", 302], ["the", 307], ["crystal", 311], ["structure", 319], ["of", 329], ["a", 332], ["large", 334], ["fragment", 340], ["of", 349], ["human", 352], ["SET7/9", 358], ["that", 365], ["contains", 370], ["a", 379], ["N", 381], ["-", 382], ["terminal", 383], ["beta", 392], ["-", 396], ["sheet", 397], ["domain", 403], ["as", 410], ["well", 413], ["as", 418], ["the", 421], ["conserved", 425], ["SET", 435], ["domain", 439], [".", 445], ["Mutagenesis", 447], ["identifies", 459], ["two", 470], ["residues", 474], ["in", 483], ["the", 486], ["C", 490], ["terminus", 492], ["of", 501], ["the", 504], ["protein", 508], ["that", 516], ["appear", 521], ["essential", 528], ["for", 538], ["catalytic", 542], ["activity", 552], ["toward", 561], ["lysine-4", 568], ["of", 577], ["histone", 580], ["H3", 588], [".", 590], ["Furthermore", 592], [",", 603], ["we", 605], ["show", 608], ["how", 613], ["the", 617], ["cofactor", 621], ["AdoMet", 630], ["binds", 637], ["to", 643], ["this", 646], ["domain", 651], ["and", 658], ["present", 662], ["biochemical", 670], ["data", 682], ["supporting", 687], ["the", 698], ["role", 702], ["of", 707], ["invariant", 710], ["residues", 720], ["in", 729], ["catalysis", 732], [",", 741], ["binding", 743], ["of", 751], ["AdoMet", 754], [",", 760], ["and", 762], ["interactions", 766], ["with", 779], ["the", 784], ["peptide", 788], ["substrate", 796], [".", 805]]}
{"context": "Hospitalization for exacerbation of COPD is associated with a high risk of mortality. A risk-prediction model using information easily obtained on admission could help to identify high-risk individuals. The CURB65 score was developed to predict mortality risk in community acquired pneumonia. A retrospective study found that this score was also associated with mortality in COPD exacerbations. We conducted a prospective study to assess the utility of the CURB65 score in acute COPD exacerbations. Consecutive patients with physician diagnosed COPD exacerbations admitted to a public hospital during a 1-year period were studied prospectively. The CURB65 scores were calculated from information obtained at initial hospital presentation. CURB65\u2003=\u2003one point each for Confusion, Urea\u2003>\u20037 mmol/L, Respiratory rate\u2003\u2265\u200330/min, low Blood pressure, age\u2003\u2265\u200365 years. 30-day mortality data were available for 249 of 252 patients. CURB65 scores on admission significantly predicted risk of death during the hospital admission and at 30\u2003days. The 30-day mortality by score groups were: low risk (scores 0-1) 2.0% (2/98), moderate risk (score 2) 6.7% (6/90) and high risk (scores 3-5) 21.3% (13/61). CURB65 scores were not predictive of 1-year mortality. A simple 6-point score based on confusion, blood urea, respiratory rate, blood pressure and age can be used to stratify patients with COPD exacerbation into different management groups. The CURB65 score was as effective in predicting early mortality in our cohort of acute COPD exacerbations as it was in previous cohorts with community acquired pneumonia. Our findings suggest that CURB65 scores can help clinicians to assess patients with exacerbation of COPD.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "930ebd41e49942059fff966207ce5c03", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[288, 288], [46, 46]], "char_spans": [[1588, 1596], [282, 290]]}]}], "context_tokens": [["Hospitalization", 0], ["for", 16], ["exacerbation", 20], ["of", 33], ["COPD", 36], ["is", 41], ["associated", 44], ["with", 55], ["a", 60], ["high", 62], ["risk", 67], ["of", 72], ["mortality", 75], [".", 84], ["A", 86], ["risk", 88], ["-", 92], ["prediction", 93], ["model", 104], ["using", 110], ["information", 116], ["easily", 128], ["obtained", 135], ["on", 144], ["admission", 147], ["could", 157], ["help", 163], ["to", 168], ["identify", 171], ["high", 180], ["-", 184], ["risk", 185], ["individuals", 190], [".", 201], ["The", 203], ["CURB65", 207], ["score", 214], ["was", 220], ["developed", 224], ["to", 234], ["predict", 237], ["mortality", 245], ["risk", 255], ["in", 260], ["community", 263], ["acquired", 273], ["pneumonia", 282], [".", 291], ["A", 293], ["retrospective", 295], ["study", 309], ["found", 315], ["that", 321], ["this", 326], ["score", 331], ["was", 337], ["also", 341], ["associated", 346], ["with", 357], ["mortality", 362], ["in", 372], ["COPD", 375], ["exacerbations", 380], [".", 393], ["We", 395], ["conducted", 398], ["a", 408], ["prospective", 410], ["study", 422], ["to", 428], ["assess", 431], ["the", 438], ["utility", 442], ["of", 450], ["the", 453], ["CURB65", 457], ["score", 464], ["in", 470], ["acute", 473], ["COPD", 479], ["exacerbations", 484], [".", 497], ["Consecutive", 499], ["patients", 511], ["with", 520], ["physician", 525], ["diagnosed", 535], ["COPD", 545], ["exacerbations", 550], ["admitted", 564], ["to", 573], ["a", 576], ["public", 578], ["hospital", 585], ["during", 594], ["a", 601], ["1-year", 603], ["period", 610], ["were", 617], ["studied", 622], ["prospectively", 630], [".", 643], ["The", 645], ["CURB65", 649], ["scores", 656], ["were", 663], ["calculated", 668], ["from", 679], ["information", 684], ["obtained", 696], ["at", 705], ["initial", 708], ["hospital", 716], ["presentation", 725], [".", 737], ["CURB65", 739], ["=", 746], ["one", 748], ["point", 752], ["each", 758], ["for", 763], ["Confusion", 767], [",", 776], ["Urea", 778], [">", 783], ["7", 785], ["mmol", 787], ["/", 791], ["L", 792], [",", 793], ["Respiratory", 795], ["rate", 807], ["\u2265", 812], ["30/min", 814], [",", 820], ["low", 822], ["Blood", 826], ["pressure", 832], [",", 840], ["age", 842], ["\u2265", 846], ["65", 848], ["years", 851], [".", 856], ["30-day", 858], ["mortality", 865], ["data", 875], ["were", 880], ["available", 885], ["for", 895], ["249", 899], ["of", 903], ["252", 906], ["patients", 910], [".", 918], ["CURB65", 920], ["scores", 927], ["on", 934], ["admission", 937], ["significantly", 947], ["predicted", 961], ["risk", 971], ["of", 976], ["death", 979], ["during", 985], ["the", 992], ["hospital", 996], ["admission", 1005], ["and", 1015], ["at", 1019], ["30", 1022], ["days", 1025], [".", 1029], ["The", 1031], ["30-day", 1035], ["mortality", 1042], ["by", 1052], ["score", 1055], ["groups", 1061], ["were", 1068], [":", 1072], ["low", 1074], ["risk", 1078], ["(", 1083], ["scores", 1084], ["0", 1091], ["-", 1092], ["1", 1093], [")", 1094], ["2.0", 1096], ["%", 1099], ["(", 1101], ["2/98", 1102], [")", 1106], [",", 1107], ["moderate", 1109], ["risk", 1118], ["(", 1123], ["score", 1124], ["2", 1130], [")", 1131], ["6.7", 1133], ["%", 1136], ["(", 1138], ["6/90", 1139], [")", 1143], ["and", 1145], ["high", 1149], ["risk", 1154], ["(", 1159], ["scores", 1160], ["3", 1167], ["-", 1168], ["5", 1169], [")", 1170], ["21.3", 1172], ["%", 1176], ["(", 1178], ["13/61", 1179], [")", 1184], [".", 1185], ["CURB65", 1187], ["scores", 1194], ["were", 1201], ["not", 1206], ["predictive", 1210], ["of", 1221], ["1-year", 1224], ["mortality", 1231], [".", 1240], ["A", 1242], ["simple", 1244], ["6-point", 1251], ["score", 1259], ["based", 1265], ["on", 1271], ["confusion", 1274], [",", 1283], ["blood", 1285], ["urea", 1291], [",", 1295], ["respiratory", 1297], ["rate", 1309], [",", 1313], ["blood", 1315], ["pressure", 1321], ["and", 1330], ["age", 1334], ["can", 1338], ["be", 1342], ["used", 1345], ["to", 1350], ["stratify", 1353], ["patients", 1362], ["with", 1371], ["COPD", 1376], ["exacerbation", 1381], ["into", 1394], ["different", 1399], ["management", 1409], ["groups", 1420], [".", 1426], ["The", 1428], ["CURB65", 1432], ["score", 1439], ["was", 1445], ["as", 1449], ["effective", 1452], ["in", 1462], ["predicting", 1465], ["early", 1476], ["mortality", 1482], ["in", 1492], ["our", 1495], ["cohort", 1499], ["of", 1506], ["acute", 1509], ["COPD", 1515], ["exacerbations", 1520], ["as", 1534], ["it", 1537], ["was", 1540], ["in", 1544], ["previous", 1547], ["cohorts", 1556], ["with", 1564], ["community", 1569], ["acquired", 1579], ["pneumonia", 1588], [".", 1597], ["Our", 1599], ["findings", 1603], ["suggest", 1612], ["that", 1620], ["CURB65", 1625], ["scores", 1632], ["can", 1639], ["help", 1643], ["clinicians", 1648], ["to", 1659], ["assess", 1662], ["patients", 1669], ["with", 1678], ["exacerbation", 1683], ["of", 1696], ["COPD", 1699], [".", 1703]]}
{"context": "A central feature of Alzheimer's disease is the cleavage of the amyloid precursor protein (APP) to form beta-amyloid peptide (Abeta) by the beta-secretase and gamma-secretase enzymes. Although this has been shown to occur after endocytosis of APP from the cell surface, the exact compartments of APP processing are not well defined. We have previously demonstrated that APP and gamma-secretase proteins and activity are highly enriched in purified rat liver lysosomes. In order to examine the lysosomal distribution and trafficking of APP in cultured cells, we generated constructs containing APP fused to a C-terminal fluorescent protein tag and N-terminal HA-epitope tag. These were co-transfected with a panel of fluorescent-protein tagged compartment markers. Here we demonstrate using laser-scanning confocal microscopy that although APP is present throughout the endosomal/lysosomal system in transfected Cos7 and neuronal SN56 cell lines as well as in immunostained cultured mouse neurons, it is enriched in the lysosome. We also show that the Swedish and London mutations reduce the amount of APP in the lysosome. Surprisingly, in addition to its expected trafficking from the cell surface to the early and then late endosomes, we find that cell-surface labelled APP is transported rapidly and directly from the cell surface to lysosomes in both Cos7 and SN56 cells. This rapid transit to the lysosome is blocked by the presence of either the London or Swedish mutations. These results demonstrate the presence of a novel, rapid and specific transport pathway from the cell surface to the lysosomes. This suggests that regulation of lysosomal traffic could regulate APP processing and that the lysosome could play a central role in the pathophysiology of Alzheimer's disease.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "09c00290afa34b8c9b894ac93f398090", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[314, 316], [4, 6]], "char_spans": [[1763, 1781], [21, 39]]}]}], "context_tokens": [["A", 0], ["central", 2], ["feature", 10], ["of", 18], ["Alzheimer", 21], ["'s", 30], ["disease", 33], ["is", 41], ["the", 44], ["cleavage", 48], ["of", 57], ["the", 60], ["amyloid", 64], ["precursor", 72], ["protein", 82], ["(", 90], ["APP", 91], [")", 94], ["to", 96], ["form", 99], ["beta", 104], ["-", 108], ["amyloid", 109], ["peptide", 117], ["(", 125], ["Abeta", 126], [")", 131], ["by", 133], ["the", 136], ["beta", 140], ["-", 144], ["secretase", 145], ["and", 155], ["gamma", 159], ["-", 164], ["secretase", 165], ["enzymes", 175], [".", 182], ["Although", 184], ["this", 193], ["has", 198], ["been", 202], ["shown", 207], ["to", 213], ["occur", 216], ["after", 222], ["endocytosis", 228], ["of", 240], ["APP", 243], ["from", 247], ["the", 252], ["cell", 256], ["surface", 261], [",", 268], ["the", 270], ["exact", 274], ["compartments", 280], ["of", 293], ["APP", 296], ["processing", 300], ["are", 311], ["not", 315], ["well", 319], ["defined", 324], [".", 331], ["We", 333], ["have", 336], ["previously", 341], ["demonstrated", 352], ["that", 365], ["APP", 370], ["and", 374], ["gamma", 378], ["-", 383], ["secretase", 384], ["proteins", 394], ["and", 403], ["activity", 407], ["are", 416], ["highly", 420], ["enriched", 427], ["in", 436], ["purified", 439], ["rat", 448], ["liver", 452], ["lysosomes", 458], [".", 467], ["In", 469], ["order", 472], ["to", 478], ["examine", 481], ["the", 489], ["lysosomal", 493], ["distribution", 503], ["and", 516], ["trafficking", 520], ["of", 532], ["APP", 535], ["in", 539], ["cultured", 542], ["cells", 551], [",", 556], ["we", 558], ["generated", 561], ["constructs", 571], ["containing", 582], ["APP", 593], ["fused", 597], ["to", 603], ["a", 606], ["C", 608], ["-", 609], ["terminal", 610], ["fluorescent", 619], ["protein", 631], ["tag", 639], ["and", 643], ["N", 647], ["-", 648], ["terminal", 649], ["HA", 658], ["-", 660], ["epitope", 661], ["tag", 669], [".", 672], ["These", 674], ["were", 680], ["co", 685], ["-", 687], ["transfected", 688], ["with", 700], ["a", 705], ["panel", 707], ["of", 713], ["fluorescent", 716], ["-", 727], ["protein", 728], ["tagged", 736], ["compartment", 743], ["markers", 755], [".", 762], ["Here", 764], ["we", 769], ["demonstrate", 772], ["using", 784], ["laser", 790], ["-", 795], ["scanning", 796], ["confocal", 805], ["microscopy", 814], ["that", 825], ["although", 830], ["APP", 839], ["is", 843], ["present", 846], ["throughout", 854], ["the", 865], ["endosomal", 869], ["/", 878], ["lysosomal", 879], ["system", 889], ["in", 896], ["transfected", 899], ["Cos7", 911], ["and", 916], ["neuronal", 920], ["SN56", 929], ["cell", 934], ["lines", 939], ["as", 945], ["well", 948], ["as", 953], ["in", 956], ["immunostained", 959], ["cultured", 973], ["mouse", 982], ["neurons", 988], [",", 995], ["it", 997], ["is", 1000], ["enriched", 1003], ["in", 1012], ["the", 1015], ["lysosome", 1019], [".", 1027], ["We", 1029], ["also", 1032], ["show", 1037], ["that", 1042], ["the", 1047], ["Swedish", 1051], ["and", 1059], ["London", 1063], ["mutations", 1070], ["reduce", 1080], ["the", 1087], ["amount", 1091], ["of", 1098], ["APP", 1101], ["in", 1105], ["the", 1108], ["lysosome", 1112], [".", 1120], ["Surprisingly", 1122], [",", 1134], ["in", 1136], ["addition", 1139], ["to", 1148], ["its", 1151], ["expected", 1155], ["trafficking", 1164], ["from", 1176], ["the", 1181], ["cell", 1185], ["surface", 1190], ["to", 1198], ["the", 1201], ["early", 1205], ["and", 1211], ["then", 1215], ["late", 1220], ["endosomes", 1225], [",", 1234], ["we", 1236], ["find", 1239], ["that", 1244], ["cell", 1249], ["-", 1253], ["surface", 1254], ["labelled", 1262], ["APP", 1271], ["is", 1275], ["transported", 1278], ["rapidly", 1290], ["and", 1298], ["directly", 1302], ["from", 1311], ["the", 1316], ["cell", 1320], ["surface", 1325], ["to", 1333], ["lysosomes", 1336], ["in", 1346], ["both", 1349], ["Cos7", 1354], ["and", 1359], ["SN56", 1363], ["cells", 1368], [".", 1373], ["This", 1375], ["rapid", 1380], ["transit", 1386], ["to", 1394], ["the", 1397], ["lysosome", 1401], ["is", 1410], ["blocked", 1413], ["by", 1421], ["the", 1424], ["presence", 1428], ["of", 1437], ["either", 1440], ["the", 1447], ["London", 1451], ["or", 1458], ["Swedish", 1461], ["mutations", 1469], [".", 1478], ["These", 1480], ["results", 1486], ["demonstrate", 1494], ["the", 1506], ["presence", 1510], ["of", 1519], ["a", 1522], ["novel", 1524], [",", 1529], ["rapid", 1531], ["and", 1537], ["specific", 1541], ["transport", 1550], ["pathway", 1560], ["from", 1568], ["the", 1573], ["cell", 1577], ["surface", 1582], ["to", 1590], ["the", 1593], ["lysosomes", 1597], [".", 1606], ["This", 1608], ["suggests", 1613], ["that", 1622], ["regulation", 1627], ["of", 1638], ["lysosomal", 1641], ["traffic", 1651], ["could", 1659], ["regulate", 1665], ["APP", 1674], ["processing", 1678], ["and", 1689], ["that", 1693], ["the", 1698], ["lysosome", 1702], ["could", 1711], ["play", 1717], ["a", 1722], ["central", 1724], ["role", 1732], ["in", 1737], ["the", 1740], ["pathophysiology", 1744], ["of", 1760], ["Alzheimer", 1763], ["'s", 1772], ["disease", 1775], [".", 1782]]}
{"context": "Restless legs syndrome (RLS)/Willis-Ekbom disease (WED) has a significant negative effect on quality of life. The decreased quality of life is similar to that of other chronic diseases, such as diabetes type 2, depression, and osteoarthritis. RLS/WED disrupts sleep length, sleep quality, and daytime alertness. Sleep disruption can contribute to depression. RLS/WED has been associated with cardiovascular disease and high blood pressure, possibly because of increased sympathetic tone caused by periodic limb movements of sleep. RLS/WED is underdiagnosed, leading to chronic sleep disruption and daytime consequences. Patients with RLS/WED have decreased productivity at work, which potentially has far-reaching economic consequences.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "f67084a71c774272be8ec7fc8baa5f52", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS)/Willis", 24], ["-", 35], ["Ekbom", 36], ["disease", 42], ["(", 50], ["WED", 51], [")", 54], ["has", 56], ["a", 60], ["significant", 62], ["negative", 74], ["effect", 83], ["on", 90], ["quality", 93], ["of", 101], ["life", 104], [".", 108], ["The", 110], ["decreased", 114], ["quality", 124], ["of", 132], ["life", 135], ["is", 140], ["similar", 143], ["to", 151], ["that", 154], ["of", 159], ["other", 162], ["chronic", 168], ["diseases", 176], [",", 184], ["such", 186], ["as", 191], ["diabetes", 194], ["type", 203], ["2", 208], [",", 209], ["depression", 211], [",", 221], ["and", 223], ["osteoarthritis", 227], [".", 241], ["RLS", 243], ["/", 246], ["WED", 247], ["disrupts", 251], ["sleep", 260], ["length", 266], [",", 272], ["sleep", 274], ["quality", 280], [",", 287], ["and", 289], ["daytime", 293], ["alertness", 301], [".", 310], ["Sleep", 312], ["disruption", 318], ["can", 329], ["contribute", 333], ["to", 344], ["depression", 347], [".", 357], ["RLS", 359], ["/", 362], ["WED", 363], ["has", 367], ["been", 371], ["associated", 376], ["with", 387], ["cardiovascular", 392], ["disease", 407], ["and", 415], ["high", 419], ["blood", 424], ["pressure", 430], [",", 438], ["possibly", 440], ["because", 449], ["of", 457], ["increased", 460], ["sympathetic", 470], ["tone", 482], ["caused", 487], ["by", 494], ["periodic", 497], ["limb", 506], ["movements", 511], ["of", 521], ["sleep", 524], [".", 529], ["RLS", 531], ["/", 534], ["WED", 535], ["is", 539], ["underdiagnosed", 542], [",", 556], ["leading", 558], ["to", 566], ["chronic", 569], ["sleep", 577], ["disruption", 583], ["and", 594], ["daytime", 598], ["consequences", 606], [".", 618], ["Patients", 620], ["with", 629], ["RLS", 634], ["/", 637], ["WED", 638], ["have", 642], ["decreased", 647], ["productivity", 657], ["at", 670], ["work", 673], [",", 677], ["which", 679], ["potentially", 685], ["has", 697], ["far", 701], ["-", 704], ["reaching", 705], ["economic", 714], ["consequences", 723], [".", 735]]}
{"context": "Chronic myelogenous leukemia (CML) is characterized by a molecular aberration, a fusion BCR-ABL gene encoding for aberrant tyrosine kinase activity, which is crucial in the pathogenesis of CML. In vitro, inhibition of BCR-ABL protein tyrosine kinase activity by a tyrosine kinase inhibitor, Imatinib mesylate (STI571; formerly CGP57148B), successfully suppressed proliferation/survival of the BCR-ABL positive clones. In clinical studies, hematologic and cytogenetic remissions have been achieved in most patients with chronic phase CML; in accelerated and blastic phases of CML, STI571 appeared less effective. In the current study, the authors tested combinations of STI571 and cytarabine and homoharringtonine (HHT), drugs with documented activity in CML. The single agents and their combinations were studied for in vitro effect on proliferation of BCR-ABL positive cell lines KBM5 and KBM7 by 3(4,5-dimethylthiazol-2yl)-2,5 diphenyl-tetrazolium bromide assay and on primary patient-derived BCR-ABL cells by clonogenic assays. The in vitro additive, synergistic, or antagonistic effects of cytarabine and HHT with STI571 were then investigated by computer-assisted analysis using the CalcuSyn software. STI571 consistently suppressed BCR-ABL positive cell proliferation with a dose-effect correlation. In the model system used, STI571/cytarabine and STI571/HHT combinations were more effective in inhibiting KBM5 and KBM7 cell growth than each drug as single agent. These results were also verified in primary CML-derived clonogenic cells in semisolid cultures. In this experimental system, our studies documented additive or synergistic effects with STI571 plus cytarabine or HHT, supporting the future use of STI571 combinations in clinical trials in patients with Philadelphia chromosome-positive leukemias.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee0fc9bc759e4496ab701a203ebb0a81", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[148, 150], [69, 71], [170, 172], [40, 42], [210, 212], [15, 17]], "char_spans": [[853, 859], [393, 399], [995, 1001], [218, 224], [1238, 1244], [88, 94]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["a", 55], ["molecular", 57], ["aberration", 67], [",", 77], ["a", 79], ["fusion", 81], ["BCR", 88], ["-", 91], ["ABL", 92], ["gene", 96], ["encoding", 101], ["for", 110], ["aberrant", 114], ["tyrosine", 123], ["kinase", 132], ["activity", 139], [",", 147], ["which", 149], ["is", 155], ["crucial", 158], ["in", 166], ["the", 169], ["pathogenesis", 173], ["of", 186], ["CML", 189], [".", 192], ["In", 194], ["vitro", 197], [",", 202], ["inhibition", 204], ["of", 215], ["BCR", 218], ["-", 221], ["ABL", 222], ["protein", 226], ["tyrosine", 234], ["kinase", 243], ["activity", 250], ["by", 259], ["a", 262], ["tyrosine", 264], ["kinase", 273], ["inhibitor", 280], [",", 289], ["Imatinib", 291], ["mesylate", 300], ["(", 309], ["STI571", 310], [";", 316], ["formerly", 318], ["CGP57148B", 327], [")", 336], [",", 337], ["successfully", 339], ["suppressed", 352], ["proliferation", 363], ["/", 376], ["survival", 377], ["of", 386], ["the", 389], ["BCR", 393], ["-", 396], ["ABL", 397], ["positive", 401], ["clones", 410], [".", 416], ["In", 418], ["clinical", 421], ["studies", 430], [",", 437], ["hematologic", 439], ["and", 451], ["cytogenetic", 455], ["remissions", 467], ["have", 478], ["been", 483], ["achieved", 488], ["in", 497], ["most", 500], ["patients", 505], ["with", 514], ["chronic", 519], ["phase", 527], ["CML", 533], [";", 536], ["in", 538], ["accelerated", 541], ["and", 553], ["blastic", 557], ["phases", 565], ["of", 572], ["CML", 575], [",", 578], ["STI571", 580], ["appeared", 587], ["less", 596], ["effective", 601], [".", 610], ["In", 612], ["the", 615], ["current", 619], ["study", 627], [",", 632], ["the", 634], ["authors", 638], ["tested", 646], ["combinations", 653], ["of", 666], ["STI571", 669], ["and", 676], ["cytarabine", 680], ["and", 691], ["homoharringtonine", 695], ["(", 713], ["HHT", 714], [")", 717], [",", 718], ["drugs", 720], ["with", 726], ["documented", 731], ["activity", 742], ["in", 751], ["CML", 754], [".", 757], ["The", 759], ["single", 763], ["agents", 770], ["and", 777], ["their", 781], ["combinations", 787], ["were", 800], ["studied", 805], ["for", 813], ["in", 817], ["vitro", 820], ["effect", 826], ["on", 833], ["proliferation", 836], ["of", 850], ["BCR", 853], ["-", 856], ["ABL", 857], ["positive", 861], ["cell", 870], ["lines", 875], ["KBM5", 881], ["and", 886], ["KBM7", 890], ["by", 895], ["3(4,5-dimethylthiazol-2yl)-2,5", 898], ["diphenyl", 929], ["-", 937], ["tetrazolium", 938], ["bromide", 950], ["assay", 958], ["and", 964], ["on", 968], ["primary", 971], ["patient", 979], ["-", 986], ["derived", 987], ["BCR", 995], ["-", 998], ["ABL", 999], ["cells", 1003], ["by", 1009], ["clonogenic", 1012], ["assays", 1023], [".", 1029], ["The", 1031], ["in", 1035], ["vitro", 1038], ["additive", 1044], [",", 1052], ["synergistic", 1054], [",", 1065], ["or", 1067], ["antagonistic", 1070], ["effects", 1083], ["of", 1091], ["cytarabine", 1094], ["and", 1105], ["HHT", 1109], ["with", 1113], ["STI571", 1118], ["were", 1125], ["then", 1130], ["investigated", 1135], ["by", 1148], ["computer", 1151], ["-", 1159], ["assisted", 1160], ["analysis", 1169], ["using", 1178], ["the", 1184], ["CalcuSyn", 1188], ["software", 1197], [".", 1205], ["STI571", 1207], ["consistently", 1214], ["suppressed", 1227], ["BCR", 1238], ["-", 1241], ["ABL", 1242], ["positive", 1246], ["cell", 1255], ["proliferation", 1260], ["with", 1274], ["a", 1279], ["dose", 1281], ["-", 1285], ["effect", 1286], ["correlation", 1293], [".", 1304], ["In", 1306], ["the", 1309], ["model", 1313], ["system", 1319], ["used", 1326], [",", 1330], ["STI571/cytarabine", 1332], ["and", 1350], ["STI571/HHT", 1354], ["combinations", 1365], ["were", 1378], ["more", 1383], ["effective", 1388], ["in", 1398], ["inhibiting", 1401], ["KBM5", 1412], ["and", 1417], ["KBM7", 1421], ["cell", 1426], ["growth", 1431], ["than", 1438], ["each", 1443], ["drug", 1448], ["as", 1453], ["single", 1456], ["agent", 1463], [".", 1468], ["These", 1470], ["results", 1476], ["were", 1484], ["also", 1489], ["verified", 1494], ["in", 1503], ["primary", 1506], ["CML", 1514], ["-", 1517], ["derived", 1518], ["clonogenic", 1526], ["cells", 1537], ["in", 1543], ["semisolid", 1546], ["cultures", 1556], [".", 1564], ["In", 1566], ["this", 1569], ["experimental", 1574], ["system", 1587], [",", 1593], ["our", 1595], ["studies", 1599], ["documented", 1607], ["additive", 1618], ["or", 1627], ["synergistic", 1630], ["effects", 1642], ["with", 1650], ["STI571", 1655], ["plus", 1662], ["cytarabine", 1667], ["or", 1678], ["HHT", 1681], [",", 1684], ["supporting", 1686], ["the", 1697], ["future", 1701], ["use", 1708], ["of", 1712], ["STI571", 1715], ["combinations", 1722], ["in", 1735], ["clinical", 1738], ["trials", 1747], ["in", 1754], ["patients", 1757], ["with", 1766], ["Philadelphia", 1771], ["chromosome", 1784], ["-", 1794], ["positive", 1795], ["leukemias", 1804], [".", 1813]]}
{"context": "Treatment of CLL patients with conventional cytotoxic agents is often combined with significant toxicity that prevents broad application especially in elderly patients. In addition, relapse frequently occurs after application of conventional chemotherapy in CLL. Recently several new chemo-free treatment options have been introduced within clinical trials. Among them are monoclonal antibodies, most of them targeting the CD20 molecule: besides the licensed drugs rituximab and ofatumumab obinutuzumab, although in combination with chemotherapy, has recently shown high clinical efficacy in front-line treatment of elderly patients with CLL. Lenalidomide as monotherapy has demonstrated clinical efficacy in patients with relapsed disease and first data within clinical trials have been generated in the front-line setting. A promising class of novel agents has been designed to block aberrant signaling from the B-cell receptor. Ibrutinib acts by inhibiting the Bruton's tyrosine kinase (BTK) while idelalisib represents a first-in-class specific inhibitor of the phosphoinositol-3 kinase (PI3K) delta isoform. Another class of drugs with potential impact for chemo-free treatment strategies in CLL are the BH3-mimetic inhibitors of the Bcl-2 family of pro-survival proteins. Other interesting candidate drugs that are currently explored for CLL patients include small modular immunopharmaceutical (SMIP) proteins (e. g. TRU-016), CDK inhibitors (e. g. dinaciclib), HDAC inhibitors and others. Given all these novel agents and targets, chemo-free or at least chemo-reduced concepts may become reality in the near future for our patients suffering from CLL.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "f2a99dbd8b2344b8b93f9e08e0029f24", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[146, 146]], "char_spans": [[931, 939]]}]}], "context_tokens": [["Treatment", 0], ["of", 10], ["CLL", 13], ["patients", 17], ["with", 26], ["conventional", 31], ["cytotoxic", 44], ["agents", 54], ["is", 61], ["often", 64], ["combined", 70], ["with", 79], ["significant", 84], ["toxicity", 96], ["that", 105], ["prevents", 110], ["broad", 119], ["application", 125], ["especially", 137], ["in", 148], ["elderly", 151], ["patients", 159], [".", 167], ["In", 169], ["addition", 172], [",", 180], ["relapse", 182], ["frequently", 190], ["occurs", 201], ["after", 208], ["application", 214], ["of", 226], ["conventional", 229], ["chemotherapy", 242], ["in", 255], ["CLL", 258], [".", 261], ["Recently", 263], ["several", 272], ["new", 280], ["chemo", 284], ["-", 289], ["free", 290], ["treatment", 295], ["options", 305], ["have", 313], ["been", 318], ["introduced", 323], ["within", 334], ["clinical", 341], ["trials", 350], [".", 356], ["Among", 358], ["them", 364], ["are", 369], ["monoclonal", 373], ["antibodies", 384], [",", 394], ["most", 396], ["of", 401], ["them", 404], ["targeting", 409], ["the", 419], ["CD20", 423], ["molecule", 428], [":", 436], ["besides", 438], ["the", 446], ["licensed", 450], ["drugs", 459], ["rituximab", 465], ["and", 475], ["ofatumumab", 479], ["obinutuzumab", 490], [",", 502], ["although", 504], ["in", 513], ["combination", 516], ["with", 528], ["chemotherapy", 533], [",", 545], ["has", 547], ["recently", 551], ["shown", 560], ["high", 566], ["clinical", 571], ["efficacy", 580], ["in", 589], ["front", 592], ["-", 597], ["line", 598], ["treatment", 603], ["of", 613], ["elderly", 616], ["patients", 624], ["with", 633], ["CLL", 638], [".", 641], ["Lenalidomide", 643], ["as", 656], ["monotherapy", 659], ["has", 671], ["demonstrated", 675], ["clinical", 688], ["efficacy", 697], ["in", 706], ["patients", 709], ["with", 718], ["relapsed", 723], ["disease", 732], ["and", 740], ["first", 744], ["data", 750], ["within", 755], ["clinical", 762], ["trials", 771], ["have", 778], ["been", 783], ["generated", 788], ["in", 798], ["the", 801], ["front", 805], ["-", 810], ["line", 811], ["setting", 816], [".", 823], ["A", 825], ["promising", 827], ["class", 837], ["of", 843], ["novel", 846], ["agents", 852], ["has", 859], ["been", 863], ["designed", 868], ["to", 877], ["block", 880], ["aberrant", 886], ["signaling", 895], ["from", 905], ["the", 910], ["B", 914], ["-", 915], ["cell", 916], ["receptor", 921], [".", 929], ["Ibrutinib", 931], ["acts", 941], ["by", 946], ["inhibiting", 949], ["the", 960], ["Bruton", 964], ["'s", 970], ["tyrosine", 973], ["kinase", 982], ["(", 989], ["BTK", 990], [")", 993], ["while", 995], ["idelalisib", 1001], ["represents", 1012], ["a", 1023], ["first", 1025], ["-", 1030], ["in", 1031], ["-", 1033], ["class", 1034], ["specific", 1040], ["inhibitor", 1049], ["of", 1059], ["the", 1062], ["phosphoinositol-3", 1066], ["kinase", 1084], ["(", 1091], ["PI3", 1092], ["K", 1095], [")", 1096], ["delta", 1098], ["isoform", 1104], [".", 1111], ["Another", 1113], ["class", 1121], ["of", 1127], ["drugs", 1130], ["with", 1136], ["potential", 1141], ["impact", 1151], ["for", 1158], ["chemo", 1162], ["-", 1167], ["free", 1168], ["treatment", 1173], ["strategies", 1183], ["in", 1194], ["CLL", 1197], ["are", 1201], ["the", 1205], ["BH3-mimetic", 1209], ["inhibitors", 1221], ["of", 1232], ["the", 1235], ["Bcl-2", 1239], ["family", 1245], ["of", 1252], ["pro", 1255], ["-", 1258], ["survival", 1259], ["proteins", 1268], [".", 1276], ["Other", 1278], ["interesting", 1284], ["candidate", 1296], ["drugs", 1306], ["that", 1312], ["are", 1317], ["currently", 1321], ["explored", 1331], ["for", 1340], ["CLL", 1344], ["patients", 1348], ["include", 1357], ["small", 1365], ["modular", 1371], ["immunopharmaceutical", 1379], ["(", 1400], ["SMIP", 1401], [")", 1405], ["proteins", 1407], ["(", 1416], ["e.", 1417], ["g.", 1420], ["TRU-016", 1423], [")", 1430], [",", 1431], ["CDK", 1433], ["inhibitors", 1437], ["(", 1448], ["e.", 1449], ["g.", 1452], ["dinaciclib", 1455], [")", 1465], [",", 1466], ["HDAC", 1468], ["inhibitors", 1473], ["and", 1484], ["others", 1488], [".", 1494], ["Given", 1496], ["all", 1502], ["these", 1506], ["novel", 1512], ["agents", 1518], ["and", 1525], ["targets", 1529], [",", 1536], ["chemo", 1538], ["-", 1543], ["free", 1544], ["or", 1549], ["at", 1552], ["least", 1555], ["chemo", 1561], ["-", 1566], ["reduced", 1567], ["concepts", 1575], ["may", 1584], ["become", 1588], ["reality", 1595], ["in", 1603], ["the", 1606], ["near", 1610], ["future", 1615], ["for", 1622], ["our", 1626], ["patients", 1630], ["suffering", 1639], ["from", 1649], ["CLL", 1654], [".", 1657]]}
{"context": "MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression that act by direct base pairing to target sites within untranslated regions of messenger RNAs. Recently, miRNA activity has been shown to be affected by the presence of miRNA sponge transcripts, the so-called competing endogenous RNA in humans and target mimicry in plants. We previously identified a highly expressed circular RNA (circRNA) in human and mouse brain. Here we show that this circRNA acts as a miR-7 sponge; we term this circular transcript ciRS-7 (circular RNA sponge for miR-7). ciRS-7 contains more than 70 selectively conserved miRNA target sites, and it is highly and widely associated with Argonaute (AGO) proteins in a miR-7-dependent manner. Although the circRNA is completely resistant to miRNA-mediated target destabilization, it strongly suppresses miR-7 activity, resulting in increased levels of miR-7 targets. In the mouse brain, we observe overlapping co-expression of ciRS-7 and miR-7, particularly in neocortical and hippocampal neurons, suggesting a high degree of endogenous interaction. We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon. This study serves as the first, to our knowledge, functional analysis of a naturally expressed circRNA.", "qas": [{"question": "Which miRNA is targeted by SRY/Sox9?", "answers": ["mir-138"], "qid": "aac69dde3c754b6ab56366207d37f1f7", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["targeted", 15], ["by", 24], ["SRY", 27], ["/", 30], ["Sox9", 31], ["?", 35]], "detected_answers": [{"text": "mir-138", "token_spans": [[214, 214]], "char_spans": [[1199, 1205]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["important", 23], ["post", 33], ["-", 37], ["transcriptional", 38], ["regulators", 54], ["of", 65], ["gene", 68], ["expression", 73], ["that", 84], ["act", 89], ["by", 93], ["direct", 96], ["base", 103], ["pairing", 108], ["to", 116], ["target", 119], ["sites", 126], ["within", 132], ["untranslated", 139], ["regions", 152], ["of", 160], ["messenger", 163], ["RNAs", 173], [".", 177], ["Recently", 179], [",", 187], ["miRNA", 189], ["activity", 195], ["has", 204], ["been", 208], ["shown", 213], ["to", 219], ["be", 222], ["affected", 225], ["by", 234], ["the", 237], ["presence", 241], ["of", 250], ["miRNA", 253], ["sponge", 259], ["transcripts", 266], [",", 277], ["the", 279], ["so", 283], ["-", 285], ["called", 286], ["competing", 293], ["endogenous", 303], ["RNA", 314], ["in", 318], ["humans", 321], ["and", 328], ["target", 332], ["mimicry", 339], ["in", 347], ["plants", 350], [".", 356], ["We", 358], ["previously", 361], ["identified", 372], ["a", 383], ["highly", 385], ["expressed", 392], ["circular", 402], ["RNA", 411], ["(", 415], ["circRNA", 416], [")", 423], ["in", 425], ["human", 428], ["and", 434], ["mouse", 438], ["brain", 444], [".", 449], ["Here", 451], ["we", 456], ["show", 459], ["that", 464], ["this", 469], ["circRNA", 474], ["acts", 482], ["as", 487], ["a", 490], ["miR-7", 492], ["sponge", 498], [";", 504], ["we", 506], ["term", 509], ["this", 514], ["circular", 519], ["transcript", 528], ["ciRS-7", 539], ["(", 546], ["circular", 547], ["RNA", 556], ["sponge", 560], ["for", 567], ["miR-7", 571], [")", 576], [".", 577], ["ciRS-7", 579], ["contains", 586], ["more", 595], ["than", 600], ["70", 605], ["selectively", 608], ["conserved", 620], ["miRNA", 630], ["target", 636], ["sites", 643], [",", 648], ["and", 650], ["it", 654], ["is", 657], ["highly", 660], ["and", 667], ["widely", 671], ["associated", 678], ["with", 689], ["Argonaute", 694], ["(", 704], ["AGO", 705], [")", 708], ["proteins", 710], ["in", 719], ["a", 722], ["miR-7-dependent", 724], ["manner", 740], [".", 746], ["Although", 748], ["the", 757], ["circRNA", 761], ["is", 769], ["completely", 772], ["resistant", 783], ["to", 793], ["miRNA", 796], ["-", 801], ["mediated", 802], ["target", 811], ["destabilization", 818], [",", 833], ["it", 835], ["strongly", 838], ["suppresses", 847], ["miR-7", 858], ["activity", 864], [",", 872], ["resulting", 874], ["in", 884], ["increased", 887], ["levels", 897], ["of", 904], ["miR-7", 907], ["targets", 913], [".", 920], ["In", 922], ["the", 925], ["mouse", 929], ["brain", 935], [",", 940], ["we", 942], ["observe", 945], ["overlapping", 953], ["co", 965], ["-", 967], ["expression", 968], ["of", 979], ["ciRS-7", 982], ["and", 989], ["miR-7", 993], [",", 998], ["particularly", 1000], ["in", 1013], ["neocortical", 1016], ["and", 1028], ["hippocampal", 1032], ["neurons", 1044], [",", 1051], ["suggesting", 1053], ["a", 1064], ["high", 1066], ["degree", 1071], ["of", 1078], ["endogenous", 1081], ["interaction", 1092], [".", 1103], ["We", 1105], ["further", 1108], ["show", 1116], ["that", 1121], ["the", 1126], ["testis", 1130], ["-", 1136], ["specific", 1137], ["circRNA", 1146], [",", 1153], ["sex", 1155], ["-", 1158], ["determining", 1159], ["region", 1171], ["Y", 1178], ["(", 1180], ["Sry", 1181], [")", 1184], [",", 1185], ["serves", 1187], ["as", 1194], ["a", 1197], ["miR-138", 1199], ["sponge", 1207], [",", 1213], ["suggesting", 1215], ["that", 1226], ["miRNA", 1231], ["sponge", 1237], ["effects", 1244], ["achieved", 1252], ["by", 1261], ["circRNA", 1264], ["formation", 1272], ["are", 1282], ["a", 1286], ["general", 1288], ["phenomenon", 1296], [".", 1306], ["This", 1308], ["study", 1313], ["serves", 1319], ["as", 1326], ["the", 1329], ["first", 1333], [",", 1338], ["to", 1340], ["our", 1343], ["knowledge", 1347], [",", 1356], ["functional", 1358], ["analysis", 1369], ["of", 1378], ["a", 1381], ["naturally", 1383], ["expressed", 1393], ["circRNA", 1403], [".", 1410]]}
{"context": "Restless legs syndrome is a neurological disorder characterized by an urgency to move the legs during periods of rest. Data from a variety of sources provide a compelling argument that the amount of iron in the brain is lower in individuals with restless legs syndrome compared with neurologically normal individuals. Moreover, a significant percentage of patients with restless legs syndrome are responsive to intravenous iron therapy. The mechanism underlying the decreased iron concentrations in restless legs syndrome brains is unknown. We hypothesize that the source of the brain iron deficit is at the blood-brain interface. Thus we analysed the expression of iron management proteins in the epithelial cells of the choroid plexus and the brain microvasculature in post-mortem tissues. The choroid plexus, obtained at autopsy, from 18 neurologically normal controls and 14 individuals who had primary restless legs syndrome was subjected to histochemical staining for iron and immunostaining for iron management proteins. Iron and heavy chain ferritin staining was reduced in the epithelial cells of choroid plexus in restless legs syndrome. Divalent metal transporter, ferroportin, transferrin and its receptor were upregulated in the choroid plexus in restless legs syndrome. Microvessels were isolated from the motor cortex of 11 restless legs syndrome and 14 control brains obtained at autopsy and quantitative immunoblot analyses was performed. Expression of heavy chain ferritin, transferrin and its receptor in the microvessels from restless legs syndrome was significantly decreased compared with the controls but divalent metal protein 1, ferroportin, prohepcidin, mitochondrial ferritin and light-chain ferritin remained unchanged. The presence of an iron regulatory protein was demonstrated in the brain microvasculature and the activity of this protein is decreased in restless legs syndrome; a finding similar to our earlier report in neuromelanin cells from the substantia nigra of restless legs syndrome brains. This study reveals that there are alterations in the iron management protein profile in restless legs syndrome compared with controls at the site of blood-brain interface suggesting fundamental differences in brain iron acquisition in individuals with restless legs syndrome. Furthermore, the decrease in transferrin receptor expression in the microvasculature in the presence of relative brain iron deficiency reported in restless legs syndrome brains may underlie the problems associated with brain iron acquisition in restless legs syndrome. The consistent finding of loss of iron regulatory protein activity in restless legs syndrome brain tissue further implicates this protein as a factor in the underlying cause of the iron deficiency in the restless legs syndrome brain. The data herein provide evidence for regulation of iron uptake and storage within brain microvessels that challenge the existing paradigm that the blood-brain barrier is merely a transport system.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "240a062b131041ab863a237c0c0a8a73", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[158, 158], [93, 93], [75, 75], [109, 109], [67, 67], [166, 166], [397, 397], [332, 332], [356, 356], [281, 281], [410, 410], [450, 450], [34, 34], [382, 382], [433, 433], [162, 162]], "char_spans": [[974, 977], [585, 588], [476, 479], [666, 669], [423, 426], [1028, 1031], [2534, 2537], [2086, 2089], [2248, 2251], [1767, 1770], [2612, 2615], [2863, 2866], [199, 202], [2428, 2431], [2759, 2762], [1002, 1005]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["is", 23], ["a", 26], ["neurological", 28], ["disorder", 41], ["characterized", 50], ["by", 64], ["an", 67], ["urgency", 70], ["to", 78], ["move", 81], ["the", 86], ["legs", 90], ["during", 95], ["periods", 102], ["of", 110], ["rest", 113], [".", 117], ["Data", 119], ["from", 124], ["a", 129], ["variety", 131], ["of", 139], ["sources", 142], ["provide", 150], ["a", 158], ["compelling", 160], ["argument", 171], ["that", 180], ["the", 185], ["amount", 189], ["of", 196], ["iron", 199], ["in", 204], ["the", 207], ["brain", 211], ["is", 217], ["lower", 220], ["in", 226], ["individuals", 229], ["with", 241], ["restless", 246], ["legs", 255], ["syndrome", 260], ["compared", 269], ["with", 278], ["neurologically", 283], ["normal", 298], ["individuals", 305], [".", 316], ["Moreover", 318], [",", 326], ["a", 328], ["significant", 330], ["percentage", 342], ["of", 353], ["patients", 356], ["with", 365], ["restless", 370], ["legs", 379], ["syndrome", 384], ["are", 393], ["responsive", 397], ["to", 408], ["intravenous", 411], ["iron", 423], ["therapy", 428], [".", 435], ["The", 437], ["mechanism", 441], ["underlying", 451], ["the", 462], ["decreased", 466], ["iron", 476], ["concentrations", 481], ["in", 496], ["restless", 499], ["legs", 508], ["syndrome", 513], ["brains", 522], ["is", 529], ["unknown", 532], [".", 539], ["We", 541], ["hypothesize", 544], ["that", 556], ["the", 561], ["source", 565], ["of", 572], ["the", 575], ["brain", 579], ["iron", 585], ["deficit", 590], ["is", 598], ["at", 601], ["the", 604], ["blood", 608], ["-", 613], ["brain", 614], ["interface", 620], [".", 629], ["Thus", 631], ["we", 636], ["analysed", 639], ["the", 648], ["expression", 652], ["of", 663], ["iron", 666], ["management", 671], ["proteins", 682], ["in", 691], ["the", 694], ["epithelial", 698], ["cells", 709], ["of", 715], ["the", 718], ["choroid", 722], ["plexus", 730], ["and", 737], ["the", 741], ["brain", 745], ["microvasculature", 751], ["in", 768], ["post", 771], ["-", 775], ["mortem", 776], ["tissues", 783], [".", 790], ["The", 792], ["choroid", 796], ["plexus", 804], [",", 810], ["obtained", 812], ["at", 821], ["autopsy", 824], [",", 831], ["from", 833], ["18", 838], ["neurologically", 841], ["normal", 856], ["controls", 863], ["and", 872], ["14", 876], ["individuals", 879], ["who", 891], ["had", 895], ["primary", 899], ["restless", 907], ["legs", 916], ["syndrome", 921], ["was", 930], ["subjected", 934], ["to", 944], ["histochemical", 947], ["staining", 961], ["for", 970], ["iron", 974], ["and", 979], ["immunostaining", 983], ["for", 998], ["iron", 1002], ["management", 1007], ["proteins", 1018], [".", 1026], ["Iron", 1028], ["and", 1033], ["heavy", 1037], ["chain", 1043], ["ferritin", 1049], ["staining", 1058], ["was", 1067], ["reduced", 1071], ["in", 1079], ["the", 1082], ["epithelial", 1086], ["cells", 1097], ["of", 1103], ["choroid", 1106], ["plexus", 1114], ["in", 1121], ["restless", 1124], ["legs", 1133], ["syndrome", 1138], [".", 1146], ["Divalent", 1148], ["metal", 1157], ["transporter", 1163], [",", 1174], ["ferroportin", 1176], [",", 1187], ["transferrin", 1189], ["and", 1201], ["its", 1205], ["receptor", 1209], ["were", 1218], ["upregulated", 1223], ["in", 1235], ["the", 1238], ["choroid", 1242], ["plexus", 1250], ["in", 1257], ["restless", 1260], ["legs", 1269], ["syndrome", 1274], [".", 1282], ["Microvessels", 1284], ["were", 1297], ["isolated", 1302], ["from", 1311], ["the", 1316], ["motor", 1320], ["cortex", 1326], ["of", 1333], ["11", 1336], ["restless", 1339], ["legs", 1348], ["syndrome", 1353], ["and", 1362], ["14", 1366], ["control", 1369], ["brains", 1377], ["obtained", 1384], ["at", 1393], ["autopsy", 1396], ["and", 1404], ["quantitative", 1408], ["immunoblot", 1421], ["analyses", 1432], ["was", 1441], ["performed", 1445], [".", 1454], ["Expression", 1456], ["of", 1467], ["heavy", 1470], ["chain", 1476], ["ferritin", 1482], [",", 1490], ["transferrin", 1492], ["and", 1504], ["its", 1508], ["receptor", 1512], ["in", 1521], ["the", 1524], ["microvessels", 1528], ["from", 1541], ["restless", 1546], ["legs", 1555], ["syndrome", 1560], ["was", 1569], ["significantly", 1573], ["decreased", 1587], ["compared", 1597], ["with", 1606], ["the", 1611], ["controls", 1615], ["but", 1624], ["divalent", 1628], ["metal", 1637], ["protein", 1643], ["1", 1651], [",", 1652], ["ferroportin", 1654], [",", 1665], ["prohepcidin", 1667], [",", 1678], ["mitochondrial", 1680], ["ferritin", 1694], ["and", 1703], ["light", 1707], ["-", 1712], ["chain", 1713], ["ferritin", 1719], ["remained", 1728], ["unchanged", 1737], [".", 1746], ["The", 1748], ["presence", 1752], ["of", 1761], ["an", 1764], ["iron", 1767], ["regulatory", 1772], ["protein", 1783], ["was", 1791], ["demonstrated", 1795], ["in", 1808], ["the", 1811], ["brain", 1815], ["microvasculature", 1821], ["and", 1838], ["the", 1842], ["activity", 1846], ["of", 1855], ["this", 1858], ["protein", 1863], ["is", 1871], ["decreased", 1874], ["in", 1884], ["restless", 1887], ["legs", 1896], ["syndrome", 1901], [";", 1909], ["a", 1911], ["finding", 1913], ["similar", 1921], ["to", 1929], ["our", 1932], ["earlier", 1936], ["report", 1944], ["in", 1951], ["neuromelanin", 1954], ["cells", 1967], ["from", 1973], ["the", 1978], ["substantia", 1982], ["nigra", 1993], ["of", 1999], ["restless", 2002], ["legs", 2011], ["syndrome", 2016], ["brains", 2025], [".", 2031], ["This", 2033], ["study", 2038], ["reveals", 2044], ["that", 2052], ["there", 2057], ["are", 2063], ["alterations", 2067], ["in", 2079], ["the", 2082], ["iron", 2086], ["management", 2091], ["protein", 2102], ["profile", 2110], ["in", 2118], ["restless", 2121], ["legs", 2130], ["syndrome", 2135], ["compared", 2144], ["with", 2153], ["controls", 2158], ["at", 2167], ["the", 2170], ["site", 2174], ["of", 2179], ["blood", 2182], ["-", 2187], ["brain", 2188], ["interface", 2194], ["suggesting", 2204], ["fundamental", 2215], ["differences", 2227], ["in", 2239], ["brain", 2242], ["iron", 2248], ["acquisition", 2253], ["in", 2265], ["individuals", 2268], ["with", 2280], ["restless", 2285], ["legs", 2294], ["syndrome", 2299], [".", 2307], ["Furthermore", 2309], [",", 2320], ["the", 2322], ["decrease", 2326], ["in", 2335], ["transferrin", 2338], ["receptor", 2350], ["expression", 2359], ["in", 2370], ["the", 2373], ["microvasculature", 2377], ["in", 2394], ["the", 2397], ["presence", 2401], ["of", 2410], ["relative", 2413], ["brain", 2422], ["iron", 2428], ["deficiency", 2433], ["reported", 2444], ["in", 2453], ["restless", 2456], ["legs", 2465], ["syndrome", 2470], ["brains", 2479], ["may", 2486], ["underlie", 2490], ["the", 2499], ["problems", 2503], ["associated", 2512], ["with", 2523], ["brain", 2528], ["iron", 2534], ["acquisition", 2539], ["in", 2551], ["restless", 2554], ["legs", 2563], ["syndrome", 2568], [".", 2576], ["The", 2578], ["consistent", 2582], ["finding", 2593], ["of", 2601], ["loss", 2604], ["of", 2609], ["iron", 2612], ["regulatory", 2617], ["protein", 2628], ["activity", 2636], ["in", 2645], ["restless", 2648], ["legs", 2657], ["syndrome", 2662], ["brain", 2671], ["tissue", 2677], ["further", 2684], ["implicates", 2692], ["this", 2703], ["protein", 2708], ["as", 2716], ["a", 2719], ["factor", 2721], ["in", 2728], ["the", 2731], ["underlying", 2735], ["cause", 2746], ["of", 2752], ["the", 2755], ["iron", 2759], ["deficiency", 2764], ["in", 2775], ["the", 2778], ["restless", 2782], ["legs", 2791], ["syndrome", 2796], ["brain", 2805], [".", 2810], ["The", 2812], ["data", 2816], ["herein", 2821], ["provide", 2828], ["evidence", 2836], ["for", 2845], ["regulation", 2849], ["of", 2860], ["iron", 2863], ["uptake", 2868], ["and", 2875], ["storage", 2879], ["within", 2887], ["brain", 2894], ["microvessels", 2900], ["that", 2913], ["challenge", 2918], ["the", 2928], ["existing", 2932], ["paradigm", 2941], ["that", 2950], ["the", 2955], ["blood", 2959], ["-", 2964], ["brain", 2965], ["barrier", 2971], ["is", 2979], ["merely", 2982], ["a", 2989], ["transport", 2991], ["system", 3001], [".", 3007]]}
{"context": "Bladder pain syndrome (BPS)/interstitial cystitis (IC) is associated with sensory lower urinary tract symptoms. Unfortunately, many of the existing oral treatments are ineffective in most patients of BPS/IC, which is the motivation for developing new drugs and therapeutic approaches. This review covers the latest drugs that have been investigated in BPS/IC patients. Intravesical treatments offer the opportunity to directly target the painful bladder with less systemic side effects. In this review, the authors analyze the existing literature supporting the treatment of BPS/IC with conventional drugs including heparin, hyaluronic acid, chondroitin sulfate, and dimethylsulfoxide (DMSO). Furthermore, investigational drugs such as tanezumab and adalimumab, capable of sequestering nerve growth factor (NGF), and Tumor necrosis factor-\u03b1 (TNF- \u03b1) are discussed. Investigational treatments such as liposomes, botulinum toxin (BTX), liposomal BTX, PD-0299685 (a Ca(2+) channel \u02512\u03b4 ligand), continuous intravesical lidocaine, and AQX-1125 (a novel SHIP1 activating compound) are also covered. New investigational drugs offer promising improvements in clinical outcomes for BPS/IC patients; however, BPS/IC is a chronic pain disorder that is very vulnerable to a strong placebo effect. In addition, BPS/IC is a heterogeneous disorder that can be classified into several phenotypes. Since different phenotypes of BPS/IC respond differently to systemic and intravesical treatments, the authors believe that new drugs developed for BPS/IC are more likely to meet their predetermined clinical endpoints if the inclusion/exclusion criterion is tailored to specific phenotype of BPS/IC patients.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "8d8314284e3742b58233aac35847fb78", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[129, 131]], "char_spans": [[786, 804]]}, {"text": "NGF", "token_spans": [[133, 133]], "char_spans": [[807, 809]]}]}], "context_tokens": [["Bladder", 0], ["pain", 8], ["syndrome", 13], ["(", 22], ["BPS)/interstitial", 23], ["cystitis", 41], ["(", 50], ["IC", 51], [")", 53], ["is", 55], ["associated", 58], ["with", 69], ["sensory", 74], ["lower", 82], ["urinary", 88], ["tract", 96], ["symptoms", 102], [".", 110], ["Unfortunately", 112], [",", 125], ["many", 127], ["of", 132], ["the", 135], ["existing", 139], ["oral", 148], ["treatments", 153], ["are", 164], ["ineffective", 168], ["in", 180], ["most", 183], ["patients", 188], ["of", 197], ["BPS", 200], ["/", 203], ["IC", 204], [",", 206], ["which", 208], ["is", 214], ["the", 217], ["motivation", 221], ["for", 232], ["developing", 236], ["new", 247], ["drugs", 251], ["and", 257], ["therapeutic", 261], ["approaches", 273], [".", 283], ["This", 285], ["review", 290], ["covers", 297], ["the", 304], ["latest", 308], ["drugs", 315], ["that", 321], ["have", 326], ["been", 331], ["investigated", 336], ["in", 349], ["BPS", 352], ["/", 355], ["IC", 356], ["patients", 359], [".", 367], ["Intravesical", 369], ["treatments", 382], ["offer", 393], ["the", 399], ["opportunity", 403], ["to", 415], ["directly", 418], ["target", 427], ["the", 434], ["painful", 438], ["bladder", 446], ["with", 454], ["less", 459], ["systemic", 464], ["side", 473], ["effects", 478], [".", 485], ["In", 487], ["this", 490], ["review", 495], [",", 501], ["the", 503], ["authors", 507], ["analyze", 515], ["the", 523], ["existing", 527], ["literature", 536], ["supporting", 547], ["the", 558], ["treatment", 562], ["of", 572], ["BPS", 575], ["/", 578], ["IC", 579], ["with", 582], ["conventional", 587], ["drugs", 600], ["including", 606], ["heparin", 616], [",", 623], ["hyaluronic", 625], ["acid", 636], [",", 640], ["chondroitin", 642], ["sulfate", 654], [",", 661], ["and", 663], ["dimethylsulfoxide", 667], ["(", 685], ["DMSO", 686], [")", 690], [".", 691], ["Furthermore", 693], [",", 704], ["investigational", 706], ["drugs", 722], ["such", 728], ["as", 733], ["tanezumab", 736], ["and", 746], ["adalimumab", 750], [",", 760], ["capable", 762], ["of", 770], ["sequestering", 773], ["nerve", 786], ["growth", 792], ["factor", 799], ["(", 806], ["NGF", 807], [")", 810], [",", 811], ["and", 813], ["Tumor", 817], ["necrosis", 823], ["factor", 832], ["-", 838], ["\u03b1", 839], ["(", 841], ["TNF-", 842], ["\u03b1", 847], [")", 848], ["are", 850], ["discussed", 854], [".", 863], ["Investigational", 865], ["treatments", 881], ["such", 892], ["as", 897], ["liposomes", 900], [",", 909], ["botulinum", 911], ["toxin", 921], ["(", 927], ["BTX", 928], [")", 931], [",", 932], ["liposomal", 934], ["BTX", 944], [",", 947], ["PD-0299685", 949], ["(", 960], ["a", 961], ["Ca(2", 963], ["+", 967], [")", 968], ["channel", 970], ["\u02512\u03b4", 978], ["ligand", 982], [")", 988], [",", 989], ["continuous", 991], ["intravesical", 1002], ["lidocaine", 1015], [",", 1024], ["and", 1026], ["AQX-1125", 1030], ["(", 1039], ["a", 1040], ["novel", 1042], ["SHIP1", 1048], ["activating", 1054], ["compound", 1065], [")", 1073], ["are", 1075], ["also", 1079], ["covered", 1084], [".", 1091], ["New", 1093], ["investigational", 1097], ["drugs", 1113], ["offer", 1119], ["promising", 1125], ["improvements", 1135], ["in", 1148], ["clinical", 1151], ["outcomes", 1160], ["for", 1169], ["BPS", 1173], ["/", 1176], ["IC", 1177], ["patients", 1180], [";", 1188], ["however", 1190], [",", 1197], ["BPS", 1199], ["/", 1202], ["IC", 1203], ["is", 1206], ["a", 1209], ["chronic", 1211], ["pain", 1219], ["disorder", 1224], ["that", 1233], ["is", 1238], ["very", 1241], ["vulnerable", 1246], ["to", 1257], ["a", 1260], ["strong", 1262], ["placebo", 1269], ["effect", 1277], [".", 1283], ["In", 1285], ["addition", 1288], [",", 1296], ["BPS", 1298], ["/", 1301], ["IC", 1302], ["is", 1305], ["a", 1308], ["heterogeneous", 1310], ["disorder", 1324], ["that", 1333], ["can", 1338], ["be", 1342], ["classified", 1345], ["into", 1356], ["several", 1361], ["phenotypes", 1369], [".", 1379], ["Since", 1381], ["different", 1387], ["phenotypes", 1397], ["of", 1408], ["BPS", 1411], ["/", 1414], ["IC", 1415], ["respond", 1418], ["differently", 1426], ["to", 1438], ["systemic", 1441], ["and", 1450], ["intravesical", 1454], ["treatments", 1467], [",", 1477], ["the", 1479], ["authors", 1483], ["believe", 1491], ["that", 1499], ["new", 1504], ["drugs", 1508], ["developed", 1514], ["for", 1524], ["BPS", 1528], ["/", 1531], ["IC", 1532], ["are", 1535], ["more", 1539], ["likely", 1544], ["to", 1551], ["meet", 1554], ["their", 1559], ["predetermined", 1565], ["clinical", 1579], ["endpoints", 1588], ["if", 1598], ["the", 1601], ["inclusion", 1605], ["/", 1614], ["exclusion", 1615], ["criterion", 1625], ["is", 1635], ["tailored", 1638], ["to", 1647], ["specific", 1650], ["phenotype", 1659], ["of", 1669], ["BPS", 1672], ["/", 1675], ["IC", 1676], ["patients", 1679], [".", 1687]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is characterised by abnormal sensations in the legs as well as dysaesthesia. Although the aetiology of RLS has not yet been determined, it may be associated with systemic inflammation. The neutrophil-to-lymphocyte ratio (NLR) is a new and simple marker indicating systemic inflammation. The present study aimed to investigate the relationship between systemic inflammation and RLS through the use of the NLR. A total of 75 newly diagnosed patients with RLS and 56 healthy control subjects were included in the study. Baseline NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. The NLRs of the two groups were compared. There were no significant differences in gender and age between the two groups. The NLR was 1.96 \u00b1 0.66 in the patient group and 1.67 \u00b1 0.68 in the control group (p = 0.005). Receiver operating characteristic analysis was performed to determine the cut-off value of NLR to predict RLS. The NLR was predictive at 1.58 with a 64% sensitivity and 50% specificity (95% confidence interval 0.55-0.74, area under curve 0.648 \u00b1 0.05). The NLR was found to be statistically higher in patients with RLS and may be used to predict RLS. The aetiology of RLS remains undetermined. The present study showed that systemic inflammation may play a role in RLS. However, RLS could also be associated with systemic inflammatory diseases. This relationship is supported by high NLR values, which are related to chronic systemic inflammation.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "10121cea2cf84ddb98d1d1e853f2f446", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], [",", 64], ["is", 66], ["characterised", 69], ["by", 83], ["abnormal", 86], ["sensations", 95], ["in", 106], ["the", 109], ["legs", 113], ["as", 118], ["well", 121], ["as", 126], ["dysaesthesia", 129], [".", 141], ["Although", 143], ["the", 152], ["aetiology", 156], ["of", 166], ["RLS", 169], ["has", 173], ["not", 177], ["yet", 181], ["been", 185], ["determined", 190], [",", 200], ["it", 202], ["may", 205], ["be", 209], ["associated", 212], ["with", 223], ["systemic", 228], ["inflammation", 237], [".", 249], ["The", 251], ["neutrophil", 255], ["-", 265], ["to", 266], ["-", 268], ["lymphocyte", 269], ["ratio", 280], ["(", 286], ["NLR", 287], [")", 290], ["is", 292], ["a", 295], ["new", 297], ["and", 301], ["simple", 305], ["marker", 312], ["indicating", 319], ["systemic", 330], ["inflammation", 339], [".", 351], ["The", 353], ["present", 357], ["study", 365], ["aimed", 371], ["to", 377], ["investigate", 380], ["the", 392], ["relationship", 396], ["between", 409], ["systemic", 417], ["inflammation", 426], ["and", 439], ["RLS", 443], ["through", 447], ["the", 455], ["use", 459], ["of", 463], ["the", 466], ["NLR", 470], [".", 473], ["A", 475], ["total", 477], ["of", 483], ["75", 486], ["newly", 489], ["diagnosed", 495], ["patients", 505], ["with", 514], ["RLS", 519], ["and", 523], ["56", 527], ["healthy", 530], ["control", 538], ["subjects", 546], ["were", 555], ["included", 560], ["in", 569], ["the", 572], ["study", 576], [".", 581], ["Baseline", 583], ["NLR", 592], ["was", 596], ["calculated", 600], ["by", 611], ["dividing", 614], ["the", 623], ["absolute", 627], ["neutrophil", 636], ["count", 647], ["by", 653], ["the", 656], ["absolute", 660], ["lymphocyte", 669], ["count", 680], [".", 685], ["The", 687], ["NLRs", 691], ["of", 696], ["the", 699], ["two", 703], ["groups", 707], ["were", 714], ["compared", 719], [".", 727], ["There", 729], ["were", 735], ["no", 740], ["significant", 743], ["differences", 755], ["in", 767], ["gender", 770], ["and", 777], ["age", 781], ["between", 785], ["the", 793], ["two", 797], ["groups", 801], [".", 807], ["The", 809], ["NLR", 813], ["was", 817], ["1.96", 821], ["\u00b1", 826], ["0.66", 828], ["in", 833], ["the", 836], ["patient", 840], ["group", 848], ["and", 854], ["1.67", 858], ["\u00b1", 863], ["0.68", 865], ["in", 870], ["the", 873], ["control", 877], ["group", 885], ["(", 891], ["p", 892], ["=", 894], ["0.005", 896], [")", 901], [".", 902], ["Receiver", 904], ["operating", 913], ["characteristic", 923], ["analysis", 938], ["was", 947], ["performed", 951], ["to", 961], ["determine", 964], ["the", 974], ["cut", 978], ["-", 981], ["off", 982], ["value", 986], ["of", 992], ["NLR", 995], ["to", 999], ["predict", 1002], ["RLS", 1010], [".", 1013], ["The", 1015], ["NLR", 1019], ["was", 1023], ["predictive", 1027], ["at", 1038], ["1.58", 1041], ["with", 1046], ["a", 1051], ["64", 1053], ["%", 1055], ["sensitivity", 1057], ["and", 1069], ["50", 1073], ["%", 1075], ["specificity", 1077], ["(", 1089], ["95", 1090], ["%", 1092], ["confidence", 1094], ["interval", 1105], ["0.55", 1114], ["-", 1118], ["0.74", 1119], [",", 1123], ["area", 1125], ["under", 1130], ["curve", 1136], ["0.648", 1142], ["\u00b1", 1148], ["0.05", 1150], [")", 1154], [".", 1155], ["The", 1157], ["NLR", 1161], ["was", 1165], ["found", 1169], ["to", 1175], ["be", 1178], ["statistically", 1181], ["higher", 1195], ["in", 1202], ["patients", 1205], ["with", 1214], ["RLS", 1219], ["and", 1223], ["may", 1227], ["be", 1231], ["used", 1234], ["to", 1239], ["predict", 1242], ["RLS", 1250], [".", 1253], ["The", 1255], ["aetiology", 1259], ["of", 1269], ["RLS", 1272], ["remains", 1276], ["undetermined", 1284], [".", 1296], ["The", 1298], ["present", 1302], ["study", 1310], ["showed", 1316], ["that", 1323], ["systemic", 1328], ["inflammation", 1337], ["may", 1350], ["play", 1354], ["a", 1359], ["role", 1361], ["in", 1366], ["RLS", 1369], [".", 1372], ["However", 1374], [",", 1381], ["RLS", 1383], ["could", 1387], ["also", 1393], ["be", 1398], ["associated", 1401], ["with", 1412], ["systemic", 1417], ["inflammatory", 1426], ["diseases", 1439], [".", 1447], ["This", 1449], ["relationship", 1454], ["is", 1467], ["supported", 1470], ["by", 1480], ["high", 1483], ["NLR", 1488], ["values", 1492], [",", 1498], ["which", 1500], ["are", 1506], ["related", 1510], ["to", 1518], ["chronic", 1521], ["systemic", 1529], ["inflammation", 1538], [".", 1550]]}
{"context": "Clozapine reduces L-3,4-dihydroxyphenylalanine (L-Dopa)-induced dyskinesias in parkinsonian patients. To test if the antidyskinetic effect of clozapine is related to antagonism at the dopamine D(4) receptor, we investigated the effect of 8-methyl-6-(4-methyl-1-piperazinyl)-11H-pyrido[2,3-b][1, 4]benzodiazepine (JL-18), a structural analog of clozapine which is more selective for this receptor. Four 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-treated cynomolgus monkeys with a stable parkinsonian syndrome and reproducible dyskinesias to L-Dopa were used in this study. They were injected subcutaneously (s.c.) with L-Dopa methyl ester (125 mg per animal) plus benserazide (50 mg per animal; L-Dopa/benserazide) alone or in combination with JL-18 (at the doses of 0.1, 0.3, or 0.9 mg/kg, s.c.). Subcutaneous injection of sterile saline was used as control. L-Dopa/benserazide increased locomotion and improved parkinsonism but also induced dyskinesias. Co-administration of JL-18, at low doses (0.1, 0.3 mg/kg) with L-Dopa/benserazide, produced a dose-dependent reduction in L-Dopa-induced dyskinesias without a parallel return to parkinsonism. The present results suggest that novel selective dopamine D(4) receptor antagonists may represent a useful tool to reduce L-Dopa-induced dyskinesias.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "7084fb7065f745f3870b1046a517cc3a", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[231, 233], [199, 201], [93, 95], [186, 188], [153, 155], [112, 114], [75, 77]], "char_spans": [[1279, 1284], [1087, 1092], [628, 633], [1028, 1033], [869, 874], [704, 709], [550, 555]]}]}], "context_tokens": [["Clozapine", 0], ["reduces", 10], ["L-3,4-dihydroxyphenylalanine", 18], ["(", 47], ["L", 48], ["-", 49], ["Dopa)-induced", 50], ["dyskinesias", 64], ["in", 76], ["parkinsonian", 79], ["patients", 92], [".", 100], ["To", 102], ["test", 105], ["if", 110], ["the", 113], ["antidyskinetic", 117], ["effect", 132], ["of", 139], ["clozapine", 142], ["is", 152], ["related", 155], ["to", 163], ["antagonism", 166], ["at", 177], ["the", 180], ["dopamine", 184], ["D(4", 193], [")", 196], ["receptor", 198], [",", 206], ["we", 208], ["investigated", 211], ["the", 224], ["effect", 228], ["of", 235], ["8-methyl-6-(4-methyl-1-piperazinyl)-11H", 238], ["-", 277], ["pyrido[2,3-b][1", 278], [",", 293], ["4]benzodiazepine", 295], ["(", 312], ["JL-18", 313], [")", 318], [",", 319], ["a", 321], ["structural", 323], ["analog", 334], ["of", 341], ["clozapine", 344], ["which", 354], ["is", 360], ["more", 363], ["selective", 368], ["for", 378], ["this", 382], ["receptor", 387], [".", 395], ["Four", 397], ["1-methyl-4-phenyl-1,2,3", 402], [",", 425], ["6-tetrahydropyridine", 427], ["(", 448], ["MPTP)-treated", 449], ["cynomolgus", 463], ["monkeys", 474], ["with", 482], ["a", 487], ["stable", 489], ["parkinsonian", 496], ["syndrome", 509], ["and", 518], ["reproducible", 522], ["dyskinesias", 535], ["to", 547], ["L", 550], ["-", 551], ["Dopa", 552], ["were", 557], ["used", 562], ["in", 567], ["this", 570], ["study", 575], [".", 580], ["They", 582], ["were", 587], ["injected", 592], ["subcutaneously", 601], ["(", 616], ["s.c", 617], [".", 620], [")", 621], ["with", 623], ["L", 628], ["-", 629], ["Dopa", 630], ["methyl", 635], ["ester", 642], ["(", 648], ["125", 649], ["mg", 653], ["per", 656], ["animal", 660], [")", 666], ["plus", 668], ["benserazide", 673], ["(", 685], ["50", 686], ["mg", 689], ["per", 692], ["animal", 696], [";", 702], ["L", 704], ["-", 705], ["Dopa", 706], ["/", 710], ["benserazide", 711], [")", 722], ["alone", 724], ["or", 730], ["in", 733], ["combination", 736], ["with", 748], ["JL-18", 753], ["(", 759], ["at", 760], ["the", 763], ["doses", 767], ["of", 773], ["0.1", 776], [",", 779], ["0.3", 781], [",", 784], ["or", 786], ["0.9", 789], ["mg", 793], ["/", 795], ["kg", 796], [",", 798], ["s.c", 800], [".", 803], [")", 804], [".", 805], ["Subcutaneous", 807], ["injection", 820], ["of", 830], ["sterile", 833], ["saline", 841], ["was", 848], ["used", 852], ["as", 857], ["control", 860], [".", 867], ["L", 869], ["-", 870], ["Dopa", 871], ["/", 875], ["benserazide", 876], ["increased", 888], ["locomotion", 898], ["and", 909], ["improved", 913], ["parkinsonism", 922], ["but", 935], ["also", 939], ["induced", 944], ["dyskinesias", 952], [".", 963], ["Co", 965], ["-", 967], ["administration", 968], ["of", 983], ["JL-18", 986], [",", 991], ["at", 993], ["low", 996], ["doses", 1000], ["(", 1006], ["0.1", 1007], [",", 1010], ["0.3", 1012], ["mg", 1016], ["/", 1018], ["kg", 1019], [")", 1021], ["with", 1023], ["L", 1028], ["-", 1029], ["Dopa", 1030], ["/", 1034], ["benserazide", 1035], [",", 1046], ["produced", 1048], ["a", 1057], ["dose", 1059], ["-", 1063], ["dependent", 1064], ["reduction", 1074], ["in", 1084], ["L", 1087], ["-", 1088], ["Dopa", 1089], ["-", 1093], ["induced", 1094], ["dyskinesias", 1102], ["without", 1114], ["a", 1122], ["parallel", 1124], ["return", 1133], ["to", 1140], ["parkinsonism", 1143], [".", 1155], ["The", 1157], ["present", 1161], ["results", 1169], ["suggest", 1177], ["that", 1185], ["novel", 1190], ["selective", 1196], ["dopamine", 1206], ["D(4", 1215], [")", 1218], ["receptor", 1220], ["antagonists", 1229], ["may", 1241], ["represent", 1245], ["a", 1255], ["useful", 1257], ["tool", 1264], ["to", 1269], ["reduce", 1272], ["L", 1279], ["-", 1280], ["Dopa", 1281], ["-", 1285], ["induced", 1286], ["dyskinesias", 1294], [".", 1305]]}
{"context": "Infections generally occur in intravenous drug abuse (IVDA) patients, most commonly affecting the spine and proximal joints. Numerous serious musculoskeletal complications of IVDA may involve the upper extremity, however. Soft-tissue complications in the upper extremity of IVDA patients include cellulitis, ulceration, abscess, pyomyositis, septic bursitis, tenosynovitis, and necrotizing fasciitis. Foreign bodies in soft tissue due to needle fragments are common findings. Primary bone and joint IVDA complications include osteomyelitis (acute and chronic) and septic arthritis. Other IVDA complications in the upper extremity affecting blood vessels and lymphatics include hematoma, arterial aneurysm and pseudoaneurysm, thrombosis, thrombophlebitis, \"puffy hand\" syndrome, and lymphadenopathy. These complications usually present as urgent issues requiring prompt and accurate evaluation in the acute setting. Diagnostic imaging not only aids in making the correct diagnosis but also permits precise definition of the location and extent of these abnormalities. We review the imaging findings and illustrate a wide range of disabling and even life-threatening complications affecting the upper extremity of IVDA patients that require early diagnosis for optimal outcome.", "qas": [{"question": "What causes \"Puffy hand syndrome\"?", "answers": ["intravenous drug abuse"], "qid": "b303b77c66f64d6c905ec9262e272043", "question_tokens": [["What", 0], ["causes", 5], ["\"", 12], ["Puffy", 13], ["hand", 19], ["syndrome", 24], ["\"", 32], ["?", 33]], "detected_answers": [{"text": "intravenous drug abuse", "token_spans": [[4, 6]], "char_spans": [[30, 51]]}]}], "context_tokens": [["Infections", 0], ["generally", 11], ["occur", 21], ["in", 27], ["intravenous", 30], ["drug", 42], ["abuse", 47], ["(", 53], ["IVDA", 54], [")", 58], ["patients", 60], [",", 68], ["most", 70], ["commonly", 75], ["affecting", 84], ["the", 94], ["spine", 98], ["and", 104], ["proximal", 108], ["joints", 117], [".", 123], ["Numerous", 125], ["serious", 134], ["musculoskeletal", 142], ["complications", 158], ["of", 172], ["IVDA", 175], ["may", 180], ["involve", 184], ["the", 192], ["upper", 196], ["extremity", 202], [",", 211], ["however", 213], [".", 220], ["Soft", 222], ["-", 226], ["tissue", 227], ["complications", 234], ["in", 248], ["the", 251], ["upper", 255], ["extremity", 261], ["of", 271], ["IVDA", 274], ["patients", 279], ["include", 288], ["cellulitis", 296], [",", 306], ["ulceration", 308], [",", 318], ["abscess", 320], [",", 327], ["pyomyositis", 329], [",", 340], ["septic", 342], ["bursitis", 349], [",", 357], ["tenosynovitis", 359], [",", 372], ["and", 374], ["necrotizing", 378], ["fasciitis", 390], [".", 399], ["Foreign", 401], ["bodies", 409], ["in", 416], ["soft", 419], ["tissue", 424], ["due", 431], ["to", 435], ["needle", 438], ["fragments", 445], ["are", 455], ["common", 459], ["findings", 466], [".", 474], ["Primary", 476], ["bone", 484], ["and", 489], ["joint", 493], ["IVDA", 499], ["complications", 504], ["include", 518], ["osteomyelitis", 526], ["(", 540], ["acute", 541], ["and", 547], ["chronic", 551], [")", 558], ["and", 560], ["septic", 564], ["arthritis", 571], [".", 580], ["Other", 582], ["IVDA", 588], ["complications", 593], ["in", 607], ["the", 610], ["upper", 614], ["extremity", 620], ["affecting", 630], ["blood", 640], ["vessels", 646], ["and", 654], ["lymphatics", 658], ["include", 669], ["hematoma", 677], [",", 685], ["arterial", 687], ["aneurysm", 696], ["and", 705], ["pseudoaneurysm", 709], [",", 723], ["thrombosis", 725], [",", 735], ["thrombophlebitis", 737], [",", 753], ["\"", 755], ["puffy", 756], ["hand", 762], ["\"", 766], ["syndrome", 768], [",", 776], ["and", 778], ["lymphadenopathy", 782], [".", 797], ["These", 799], ["complications", 805], ["usually", 819], ["present", 827], ["as", 835], ["urgent", 838], ["issues", 845], ["requiring", 852], ["prompt", 862], ["and", 869], ["accurate", 873], ["evaluation", 882], ["in", 893], ["the", 896], ["acute", 900], ["setting", 906], [".", 913], ["Diagnostic", 915], ["imaging", 926], ["not", 934], ["only", 938], ["aids", 943], ["in", 948], ["making", 951], ["the", 958], ["correct", 962], ["diagnosis", 970], ["but", 980], ["also", 984], ["permits", 989], ["precise", 997], ["definition", 1005], ["of", 1016], ["the", 1019], ["location", 1023], ["and", 1032], ["extent", 1036], ["of", 1043], ["these", 1046], ["abnormalities", 1052], [".", 1065], ["We", 1067], ["review", 1070], ["the", 1077], ["imaging", 1081], ["findings", 1089], ["and", 1098], ["illustrate", 1102], ["a", 1113], ["wide", 1115], ["range", 1120], ["of", 1126], ["disabling", 1129], ["and", 1139], ["even", 1143], ["life", 1148], ["-", 1152], ["threatening", 1153], ["complications", 1165], ["affecting", 1179], ["the", 1189], ["upper", 1193], ["extremity", 1199], ["of", 1209], ["IVDA", 1212], ["patients", 1217], ["that", 1226], ["require", 1231], ["early", 1239], ["diagnosis", 1245], ["for", 1255], ["optimal", 1259], ["outcome", 1267], [".", 1274]]}
{"context": "Growth differentiation factor 15 (GDF15), a distant member of the transforming growth factor (TGF)-\u03b2 family, is a secreted protein that circulates as a 25-kDa dimer. In humans, elevated GDF15 correlates with weight loss, and the administration of GDF15 to mice with obesity reduces body weight, at least in part, by decreasing food intake. The mechanisms through which GDF15 reduces body weight remain poorly understood, because the cognate receptor for GDF15 is unknown. Here we show that recombinant GDF15 induces weight loss in mice fed a high-fat diet and in nonhuman primates with spontaneous obesity. Furthermore, we find that GDF15 binds with high affinity to GDNF family receptor \u03b1-like (GFRAL), a distant relative of receptors for a distinct class of the TGF-\u03b2 superfamily ligands. Gfral is expressed in neurons of the area postrema and nucleus of the solitary tract in mice and humans, and genetic deletion of the receptor abrogates the ability of GDF15 to decrease food intake and body weight in mice. In addition, diet-induced obesity and insulin resistance are exacerbated in GFRAL-deficient mice, suggesting a homeostatic role for this receptor in metabolism. Finally, we demonstrate that GDF15-induced cell signaling requires the interaction of GFRAL with the coreceptor RET. Our data identify GFRAL as a new regulator of body weight and as the bona fide receptor mediating the metabolic effects of GDF15, enabling a more comprehensive assessment of GDF15 as a potential pharmacotherapy for the treatment of obesity.", "qas": [{"question": "How does increased GDF15 affect body weight?", "answers": ["Reduces body weight"], "qid": "de1a17e690e849e3a857822511b54678", "question_tokens": [["How", 0], ["does", 4], ["increased", 9], ["GDF15", 19], ["affect", 25], ["body", 32], ["weight", 37], ["?", 43]], "detected_answers": [{"text": "Reduces body weight", "token_spans": [[69, 71], [50, 52]], "char_spans": [[375, 393], [274, 292]]}]}], "context_tokens": [["Growth", 0], ["differentiation", 7], ["factor", 23], ["15", 30], ["(", 33], ["GDF15", 34], [")", 39], [",", 40], ["a", 42], ["distant", 44], ["member", 52], ["of", 59], ["the", 62], ["transforming", 66], ["growth", 79], ["factor", 86], ["(", 93], ["TGF)-\u03b2", 94], ["family", 101], [",", 107], ["is", 109], ["a", 112], ["secreted", 114], ["protein", 123], ["that", 131], ["circulates", 136], ["as", 147], ["a", 150], ["25-kDa", 152], ["dimer", 159], [".", 164], ["In", 166], ["humans", 169], [",", 175], ["elevated", 177], ["GDF15", 186], ["correlates", 192], ["with", 203], ["weight", 208], ["loss", 215], [",", 219], ["and", 221], ["the", 225], ["administration", 229], ["of", 244], ["GDF15", 247], ["to", 253], ["mice", 256], ["with", 261], ["obesity", 266], ["reduces", 274], ["body", 282], ["weight", 287], [",", 293], ["at", 295], ["least", 298], ["in", 304], ["part", 307], [",", 311], ["by", 313], ["decreasing", 316], ["food", 327], ["intake", 332], [".", 338], ["The", 340], ["mechanisms", 344], ["through", 355], ["which", 363], ["GDF15", 369], ["reduces", 375], ["body", 383], ["weight", 388], ["remain", 395], ["poorly", 402], ["understood", 409], [",", 419], ["because", 421], ["the", 429], ["cognate", 433], ["receptor", 441], ["for", 450], ["GDF15", 454], ["is", 460], ["unknown", 463], [".", 470], ["Here", 472], ["we", 477], ["show", 480], ["that", 485], ["recombinant", 490], ["GDF15", 502], ["induces", 508], ["weight", 516], ["loss", 523], ["in", 528], ["mice", 531], ["fed", 536], ["a", 540], ["high", 542], ["-", 546], ["fat", 547], ["diet", 551], ["and", 556], ["in", 560], ["nonhuman", 563], ["primates", 572], ["with", 581], ["spontaneous", 586], ["obesity", 598], [".", 605], ["Furthermore", 607], [",", 618], ["we", 620], ["find", 623], ["that", 628], ["GDF15", 633], ["binds", 639], ["with", 645], ["high", 650], ["affinity", 655], ["to", 664], ["GDNF", 667], ["family", 672], ["receptor", 679], ["\u03b1", 688], ["-", 689], ["like", 690], ["(", 695], ["GFRAL", 696], [")", 701], [",", 702], ["a", 704], ["distant", 706], ["relative", 714], ["of", 723], ["receptors", 726], ["for", 736], ["a", 740], ["distinct", 742], ["class", 751], ["of", 757], ["the", 760], ["TGF", 764], ["-", 767], ["\u03b2", 768], ["superfamily", 770], ["ligands", 782], [".", 789], ["Gfral", 791], ["is", 797], ["expressed", 800], ["in", 810], ["neurons", 813], ["of", 821], ["the", 824], ["area", 828], ["postrema", 833], ["and", 842], ["nucleus", 846], ["of", 854], ["the", 857], ["solitary", 861], ["tract", 870], ["in", 876], ["mice", 879], ["and", 884], ["humans", 888], [",", 894], ["and", 896], ["genetic", 900], ["deletion", 908], ["of", 917], ["the", 920], ["receptor", 924], ["abrogates", 933], ["the", 943], ["ability", 947], ["of", 955], ["GDF15", 958], ["to", 964], ["decrease", 967], ["food", 976], ["intake", 981], ["and", 988], ["body", 992], ["weight", 997], ["in", 1004], ["mice", 1007], [".", 1011], ["In", 1013], ["addition", 1016], [",", 1024], ["diet", 1026], ["-", 1030], ["induced", 1031], ["obesity", 1039], ["and", 1047], ["insulin", 1051], ["resistance", 1059], ["are", 1070], ["exacerbated", 1074], ["in", 1086], ["GFRAL", 1089], ["-", 1094], ["deficient", 1095], ["mice", 1105], [",", 1109], ["suggesting", 1111], ["a", 1122], ["homeostatic", 1124], ["role", 1136], ["for", 1141], ["this", 1145], ["receptor", 1150], ["in", 1159], ["metabolism", 1162], [".", 1172], ["Finally", 1174], [",", 1181], ["we", 1183], ["demonstrate", 1186], ["that", 1198], ["GDF15-induced", 1203], ["cell", 1217], ["signaling", 1222], ["requires", 1232], ["the", 1241], ["interaction", 1245], ["of", 1257], ["GFRAL", 1260], ["with", 1266], ["the", 1271], ["coreceptor", 1275], ["RET", 1286], [".", 1289], ["Our", 1291], ["data", 1295], ["identify", 1300], ["GFRAL", 1309], ["as", 1315], ["a", 1318], ["new", 1320], ["regulator", 1324], ["of", 1334], ["body", 1337], ["weight", 1342], ["and", 1349], ["as", 1353], ["the", 1356], ["bona", 1360], ["fide", 1365], ["receptor", 1370], ["mediating", 1379], ["the", 1389], ["metabolic", 1393], ["effects", 1403], ["of", 1411], ["GDF15", 1414], [",", 1419], ["enabling", 1421], ["a", 1430], ["more", 1432], ["comprehensive", 1437], ["assessment", 1451], ["of", 1462], ["GDF15", 1465], ["as", 1471], ["a", 1474], ["potential", 1476], ["pharmacotherapy", 1486], ["for", 1502], ["the", 1506], ["treatment", 1510], ["of", 1520], ["obesity", 1523], [".", 1530]]}
{"context": "The origin of brain tumors has attracted much controversy. Recent advances in neural stem cell biology coupled with the new concepts of central nervous system development have raised interesting possibilities regarding the oncogenic properties of neural stem/progenitor cells. To elucidate these putative properties further, the clinical materials from an infant brain tumor were analyzed, focusing on the relation with the neural stem/progenitor cells. The expression of neural stem/progenitor cell markers in the tumor cells and the cellular components of the infant brain tumor were examined using immunohistochemistry. The tumor cell biology was analyzed both in culture and in the grafted brain environment. Three main bodies of evidence were demonstrated indicating that the tumor was of possible subventricular zone postnatal or adult normal neural stem cell origin. First, in the tumor specimen we demonstrated the strong positive expression of the neural stem/progenitor cell markers, nestin and Musashi-1. Second, immunohistochemistry revealed the presence of neuronal, astrocytic, and immature precursor cells in the tumor tissue, similar to the cellular components of the subventricular zone, thereby pointing to the subventricular zone as the possible origin of the tumor. The subventricular zone also is one of the strong candidates for the location of postnatal/adult neural stem cells. This cellular evidence was strengthened further by the clinicoradiological findings that demonstrated the involvement of the subventricular zone of the lateral ventricle by the tumor. Third, in the in vitro and in vivo experiments, a dynamic shift in expression patterns between neural stem cells (nestin, Musashi-1) and differentiated cells (glial fibrillary acidic protein, neuron-specific Class III beta-tubulin) markers was seen, similar to the proposed behavior of postnatal/adult neural stem cells in situ. These findings suggest that this brain tumor originated from neural stem cells located in the subventricular zone, and the further possibility of the general oncogenic potential of neural stem cells.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "71a8f4bdfee54f928c7a8b69ef3ca448", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[161, 161], [278, 278]], "char_spans": [[994, 999], [1700, 1705]]}]}], "context_tokens": [["The", 0], ["origin", 4], ["of", 11], ["brain", 14], ["tumors", 20], ["has", 27], ["attracted", 31], ["much", 41], ["controversy", 46], [".", 57], ["Recent", 59], ["advances", 66], ["in", 75], ["neural", 78], ["stem", 85], ["cell", 90], ["biology", 95], ["coupled", 103], ["with", 111], ["the", 116], ["new", 120], ["concepts", 124], ["of", 133], ["central", 136], ["nervous", 144], ["system", 152], ["development", 159], ["have", 171], ["raised", 176], ["interesting", 183], ["possibilities", 195], ["regarding", 209], ["the", 219], ["oncogenic", 223], ["properties", 233], ["of", 244], ["neural", 247], ["stem", 254], ["/", 258], ["progenitor", 259], ["cells", 270], [".", 275], ["To", 277], ["elucidate", 280], ["these", 290], ["putative", 296], ["properties", 305], ["further", 316], [",", 323], ["the", 325], ["clinical", 329], ["materials", 338], ["from", 348], ["an", 353], ["infant", 356], ["brain", 363], ["tumor", 369], ["were", 375], ["analyzed", 380], [",", 388], ["focusing", 390], ["on", 399], ["the", 402], ["relation", 406], ["with", 415], ["the", 420], ["neural", 424], ["stem", 431], ["/", 435], ["progenitor", 436], ["cells", 447], [".", 452], ["The", 454], ["expression", 458], ["of", 469], ["neural", 472], ["stem", 479], ["/", 483], ["progenitor", 484], ["cell", 495], ["markers", 500], ["in", 508], ["the", 511], ["tumor", 515], ["cells", 521], ["and", 527], ["the", 531], ["cellular", 535], ["components", 544], ["of", 555], ["the", 558], ["infant", 562], ["brain", 569], ["tumor", 575], ["were", 581], ["examined", 586], ["using", 595], ["immunohistochemistry", 601], [".", 621], ["The", 623], ["tumor", 627], ["cell", 633], ["biology", 638], ["was", 646], ["analyzed", 650], ["both", 659], ["in", 664], ["culture", 667], ["and", 675], ["in", 679], ["the", 682], ["grafted", 686], ["brain", 694], ["environment", 700], [".", 711], ["Three", 713], ["main", 719], ["bodies", 724], ["of", 731], ["evidence", 734], ["were", 743], ["demonstrated", 748], ["indicating", 761], ["that", 772], ["the", 777], ["tumor", 781], ["was", 787], ["of", 791], ["possible", 794], ["subventricular", 803], ["zone", 818], ["postnatal", 823], ["or", 833], ["adult", 836], ["normal", 842], ["neural", 849], ["stem", 856], ["cell", 861], ["origin", 866], [".", 872], ["First", 874], [",", 879], ["in", 881], ["the", 884], ["tumor", 888], ["specimen", 894], ["we", 903], ["demonstrated", 906], ["the", 919], ["strong", 923], ["positive", 930], ["expression", 939], ["of", 950], ["the", 953], ["neural", 957], ["stem", 964], ["/", 968], ["progenitor", 969], ["cell", 980], ["markers", 985], [",", 992], ["nestin", 994], ["and", 1001], ["Musashi-1", 1005], [".", 1014], ["Second", 1016], [",", 1022], ["immunohistochemistry", 1024], ["revealed", 1045], ["the", 1054], ["presence", 1058], ["of", 1067], ["neuronal", 1070], [",", 1078], ["astrocytic", 1080], [",", 1090], ["and", 1092], ["immature", 1096], ["precursor", 1105], ["cells", 1115], ["in", 1121], ["the", 1124], ["tumor", 1128], ["tissue", 1134], [",", 1140], ["similar", 1142], ["to", 1150], ["the", 1153], ["cellular", 1157], ["components", 1166], ["of", 1177], ["the", 1180], ["subventricular", 1184], ["zone", 1199], [",", 1203], ["thereby", 1205], ["pointing", 1213], ["to", 1222], ["the", 1225], ["subventricular", 1229], ["zone", 1244], ["as", 1249], ["the", 1252], ["possible", 1256], ["origin", 1265], ["of", 1272], ["the", 1275], ["tumor", 1279], [".", 1284], ["The", 1286], ["subventricular", 1290], ["zone", 1305], ["also", 1310], ["is", 1315], ["one", 1318], ["of", 1322], ["the", 1325], ["strong", 1329], ["candidates", 1336], ["for", 1347], ["the", 1351], ["location", 1355], ["of", 1364], ["postnatal", 1367], ["/", 1376], ["adult", 1377], ["neural", 1383], ["stem", 1390], ["cells", 1395], [".", 1400], ["This", 1402], ["cellular", 1407], ["evidence", 1416], ["was", 1425], ["strengthened", 1429], ["further", 1442], ["by", 1450], ["the", 1453], ["clinicoradiological", 1457], ["findings", 1477], ["that", 1486], ["demonstrated", 1491], ["the", 1504], ["involvement", 1508], ["of", 1520], ["the", 1523], ["subventricular", 1527], ["zone", 1542], ["of", 1547], ["the", 1550], ["lateral", 1554], ["ventricle", 1562], ["by", 1572], ["the", 1575], ["tumor", 1579], [".", 1584], ["Third", 1586], [",", 1591], ["in", 1593], ["the", 1596], ["in", 1600], ["vitro", 1603], ["and", 1609], ["in", 1613], ["vivo", 1616], ["experiments", 1621], [",", 1632], ["a", 1634], ["dynamic", 1636], ["shift", 1644], ["in", 1650], ["expression", 1653], ["patterns", 1664], ["between", 1673], ["neural", 1681], ["stem", 1688], ["cells", 1693], ["(", 1699], ["nestin", 1700], [",", 1706], ["Musashi-1", 1708], [")", 1717], ["and", 1719], ["differentiated", 1723], ["cells", 1738], ["(", 1744], ["glial", 1745], ["fibrillary", 1751], ["acidic", 1762], ["protein", 1769], [",", 1776], ["neuron", 1778], ["-", 1784], ["specific", 1785], ["Class", 1794], ["III", 1800], ["beta", 1804], ["-", 1808], ["tubulin", 1809], [")", 1816], ["markers", 1818], ["was", 1826], ["seen", 1830], [",", 1834], ["similar", 1836], ["to", 1844], ["the", 1847], ["proposed", 1851], ["behavior", 1860], ["of", 1869], ["postnatal", 1872], ["/", 1881], ["adult", 1882], ["neural", 1888], ["stem", 1895], ["cells", 1900], ["in", 1906], ["situ", 1909], [".", 1913], ["These", 1915], ["findings", 1921], ["suggest", 1930], ["that", 1938], ["this", 1943], ["brain", 1948], ["tumor", 1954], ["originated", 1960], ["from", 1971], ["neural", 1976], ["stem", 1983], ["cells", 1988], ["located", 1994], ["in", 2002], ["the", 2005], ["subventricular", 2009], ["zone", 2024], [",", 2028], ["and", 2030], ["the", 2034], ["further", 2038], ["possibility", 2046], ["of", 2058], ["the", 2061], ["general", 2065], ["oncogenic", 2073], ["potential", 2083], ["of", 2093], ["neural", 2096], ["stem", 2103], ["cells", 2108], [".", 2113]]}
{"context": "The overlap between symptoms of PTSD and MDD is substantial. PTSD symptoms arise after a traumatic experience and the trauma is present in all of the diagnostic clusters. In individuals who have experienced a trauma a long time before, it is difficult to establish the exact moment of onset of their symptoms in relation to the trauma suffered. We proposed to raise awareness among operators who may encounter this problem, with the aim of providing them with valuable help in order to achieve a correct differential diagnosis. A sample of subjects suffering from PTSD without comorbidity was assessed to confirm the diagnosis and the severity of post-traumatic symptoms. The Kruskal-Wallis test was used to compare any modifications in the parameters analyzed through the Davidson Trauma Scale with the presence and severity of depressive symptoms as evaluated by the Hamilton-D scale. Half of the PSTD patients recruited showed values of HAM-D > 18, although an active Major Depressive Episode was clinically excluded. Symptom of \"numbing\", despite being different from the apathy experienced in depression, is identified as a depressive symptom by the HAM-D. Giving prevalence to depressive symptoms may be misleading for diagnosis and may ultimately result in inappropriate treatment.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "dbf89c9e9b394c7eae08a4dc8b5b7ce5", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[99, 99], [11, 11], [5, 5]], "char_spans": [[564, 567], [61, 64], [32, 35]]}]}], "context_tokens": [["The", 0], ["overlap", 4], ["between", 12], ["symptoms", 20], ["of", 29], ["PTSD", 32], ["and", 37], ["MDD", 41], ["is", 45], ["substantial", 48], [".", 59], ["PTSD", 61], ["symptoms", 66], ["arise", 75], ["after", 81], ["a", 87], ["traumatic", 89], ["experience", 99], ["and", 110], ["the", 114], ["trauma", 118], ["is", 125], ["present", 128], ["in", 136], ["all", 139], ["of", 143], ["the", 146], ["diagnostic", 150], ["clusters", 161], [".", 169], ["In", 171], ["individuals", 174], ["who", 186], ["have", 190], ["experienced", 195], ["a", 207], ["trauma", 209], ["a", 216], ["long", 218], ["time", 223], ["before", 228], [",", 234], ["it", 236], ["is", 239], ["difficult", 242], ["to", 252], ["establish", 255], ["the", 265], ["exact", 269], ["moment", 275], ["of", 282], ["onset", 285], ["of", 291], ["their", 294], ["symptoms", 300], ["in", 309], ["relation", 312], ["to", 321], ["the", 324], ["trauma", 328], ["suffered", 335], [".", 343], ["We", 345], ["proposed", 348], ["to", 357], ["raise", 360], ["awareness", 366], ["among", 376], ["operators", 382], ["who", 392], ["may", 396], ["encounter", 400], ["this", 410], ["problem", 415], [",", 422], ["with", 424], ["the", 429], ["aim", 433], ["of", 437], ["providing", 440], ["them", 450], ["with", 455], ["valuable", 460], ["help", 469], ["in", 474], ["order", 477], ["to", 483], ["achieve", 486], ["a", 494], ["correct", 496], ["differential", 504], ["diagnosis", 517], [".", 526], ["A", 528], ["sample", 530], ["of", 537], ["subjects", 540], ["suffering", 549], ["from", 559], ["PTSD", 564], ["without", 569], ["comorbidity", 577], ["was", 589], ["assessed", 593], ["to", 602], ["confirm", 605], ["the", 613], ["diagnosis", 617], ["and", 627], ["the", 631], ["severity", 635], ["of", 644], ["post", 647], ["-", 651], ["traumatic", 652], ["symptoms", 662], [".", 670], ["The", 672], ["Kruskal", 676], ["-", 683], ["Wallis", 684], ["test", 691], ["was", 696], ["used", 700], ["to", 705], ["compare", 708], ["any", 716], ["modifications", 720], ["in", 734], ["the", 737], ["parameters", 741], ["analyzed", 752], ["through", 761], ["the", 769], ["Davidson", 773], ["Trauma", 782], ["Scale", 789], ["with", 795], ["the", 800], ["presence", 804], ["and", 813], ["severity", 817], ["of", 826], ["depressive", 829], ["symptoms", 840], ["as", 849], ["evaluated", 852], ["by", 862], ["the", 865], ["Hamilton", 869], ["-", 877], ["D", 878], ["scale", 880], [".", 885], ["Half", 887], ["of", 892], ["the", 895], ["PSTD", 899], ["patients", 904], ["recruited", 913], ["showed", 923], ["values", 930], ["of", 937], ["HAM", 940], ["-", 943], ["D", 944], [">", 946], ["18", 948], [",", 950], ["although", 952], ["an", 961], ["active", 964], ["Major", 971], ["Depressive", 977], ["Episode", 988], ["was", 996], ["clinically", 1000], ["excluded", 1011], [".", 1019], ["Symptom", 1021], ["of", 1029], ["\"", 1032], ["numbing", 1033], ["\"", 1040], [",", 1041], ["despite", 1043], ["being", 1051], ["different", 1057], ["from", 1067], ["the", 1072], ["apathy", 1076], ["experienced", 1083], ["in", 1095], ["depression", 1098], [",", 1108], ["is", 1110], ["identified", 1113], ["as", 1124], ["a", 1127], ["depressive", 1129], ["symptom", 1140], ["by", 1148], ["the", 1151], ["HAM", 1155], ["-", 1158], ["D.", 1159], ["Giving", 1162], ["prevalence", 1169], ["to", 1180], ["depressive", 1183], ["symptoms", 1194], ["may", 1203], ["be", 1207], ["misleading", 1210], ["for", 1221], ["diagnosis", 1225], ["and", 1235], ["may", 1239], ["ultimately", 1243], ["result", 1254], ["in", 1261], ["inappropriate", 1264], ["treatment", 1278], [".", 1287]]}
{"context": "Type 2 diabetes mellitus (T2DM) is increasing worldwide. Treatment of T2DM continues to present challenges, with a significant proportion of patients failing to achieve and maintain glycemic targets. Despite the availability of many oral antidiabetic agents, therapeutic efficacy is also offset by side effects such as weight gain and hypoglycemia. Therefore, the search for novel therapeutic agents with an improved benefit-risk profile continues. In the following review we focus on a novel class of oral antidiabetic drugs, the sodium glucose transporter protein 2 (SGLT2) inhibitors, which have unique characteristics. SGLT2 inhibitors focus on the kidney as a therapeutic target, where they inhibit the reabsorption of glucose in the proximal tubule, causing an increase in urinary glucose excretion. Doing this, they reduce plasma glucose independently of the \u03b2-cell function of the pancreas. SGLT2 inhibitors are effective at lowering hemoglobin A1c, but also induce weight loss and reduce blood pressure, with a low risk of hypoglycemia. In general, the SGLT2 inhibitors are well tolerated, with the most frequent adverse events being mild urinal and genital infections. Since their primary site of effect is the kidney, these drugs are less effective in patients with impaired kidney function but evidence is emerging that these drugs may also have a protective effect against diabetic nephropathy. This review focuses on the most extensively studied SGLT2 inhibitors dapagliflozin, canagliflozin and empagliflozin. Dapagliflozin and canagliflozin have already been approved for marketing by the US Food and Drug Administration. The European Medicines Agency has accepted all three drugs for marketing.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "4978663209ad4e3098899ad04290262e", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[96, 96], [154, 154], [105, 105], [249, 249], [184, 184]], "char_spans": [[569, 573], [899, 903], [623, 627], [1460, 1464], [1062, 1066]]}]}], "context_tokens": [["Type", 0], ["2", 5], ["diabetes", 7], ["mellitus", 16], ["(", 25], ["T2DM", 26], [")", 30], ["is", 32], ["increasing", 35], ["worldwide", 46], [".", 55], ["Treatment", 57], ["of", 67], ["T2DM", 70], ["continues", 75], ["to", 85], ["present", 88], ["challenges", 96], [",", 106], ["with", 108], ["a", 113], ["significant", 115], ["proportion", 127], ["of", 138], ["patients", 141], ["failing", 150], ["to", 158], ["achieve", 161], ["and", 169], ["maintain", 173], ["glycemic", 182], ["targets", 191], [".", 198], ["Despite", 200], ["the", 208], ["availability", 212], ["of", 225], ["many", 228], ["oral", 233], ["antidiabetic", 238], ["agents", 251], [",", 257], ["therapeutic", 259], ["efficacy", 271], ["is", 280], ["also", 283], ["offset", 288], ["by", 295], ["side", 298], ["effects", 303], ["such", 311], ["as", 316], ["weight", 319], ["gain", 326], ["and", 331], ["hypoglycemia", 335], [".", 347], ["Therefore", 349], [",", 358], ["the", 360], ["search", 364], ["for", 371], ["novel", 375], ["therapeutic", 381], ["agents", 393], ["with", 400], ["an", 405], ["improved", 408], ["benefit", 417], ["-", 424], ["risk", 425], ["profile", 430], ["continues", 438], [".", 447], ["In", 449], ["the", 452], ["following", 456], ["review", 466], ["we", 473], ["focus", 476], ["on", 482], ["a", 485], ["novel", 487], ["class", 493], ["of", 499], ["oral", 502], ["antidiabetic", 507], ["drugs", 520], [",", 525], ["the", 527], ["sodium", 531], ["glucose", 538], ["transporter", 546], ["protein", 558], ["2", 566], ["(", 568], ["SGLT2", 569], [")", 574], ["inhibitors", 576], [",", 586], ["which", 588], ["have", 594], ["unique", 599], ["characteristics", 606], [".", 621], ["SGLT2", 623], ["inhibitors", 629], ["focus", 640], ["on", 646], ["the", 649], ["kidney", 653], ["as", 660], ["a", 663], ["therapeutic", 665], ["target", 677], [",", 683], ["where", 685], ["they", 691], ["inhibit", 696], ["the", 704], ["reabsorption", 708], ["of", 721], ["glucose", 724], ["in", 732], ["the", 735], ["proximal", 739], ["tubule", 748], [",", 754], ["causing", 756], ["an", 764], ["increase", 767], ["in", 776], ["urinary", 779], ["glucose", 787], ["excretion", 795], [".", 804], ["Doing", 806], ["this", 812], [",", 816], ["they", 818], ["reduce", 823], ["plasma", 830], ["glucose", 837], ["independently", 845], ["of", 859], ["the", 862], ["\u03b2", 866], ["-", 867], ["cell", 868], ["function", 873], ["of", 882], ["the", 885], ["pancreas", 889], [".", 897], ["SGLT2", 899], ["inhibitors", 905], ["are", 916], ["effective", 920], ["at", 930], ["lowering", 933], ["hemoglobin", 942], ["A1c", 953], [",", 956], ["but", 958], ["also", 962], ["induce", 967], ["weight", 974], ["loss", 981], ["and", 986], ["reduce", 990], ["blood", 997], ["pressure", 1003], [",", 1011], ["with", 1013], ["a", 1018], ["low", 1020], ["risk", 1024], ["of", 1029], ["hypoglycemia", 1032], [".", 1044], ["In", 1046], ["general", 1049], [",", 1056], ["the", 1058], ["SGLT2", 1062], ["inhibitors", 1068], ["are", 1079], ["well", 1083], ["tolerated", 1088], [",", 1097], ["with", 1099], ["the", 1104], ["most", 1108], ["frequent", 1113], ["adverse", 1122], ["events", 1130], ["being", 1137], ["mild", 1143], ["urinal", 1148], ["and", 1155], ["genital", 1159], ["infections", 1167], [".", 1177], ["Since", 1179], ["their", 1185], ["primary", 1191], ["site", 1199], ["of", 1204], ["effect", 1207], ["is", 1214], ["the", 1217], ["kidney", 1221], [",", 1227], ["these", 1229], ["drugs", 1235], ["are", 1241], ["less", 1245], ["effective", 1250], ["in", 1260], ["patients", 1263], ["with", 1272], ["impaired", 1277], ["kidney", 1286], ["function", 1293], ["but", 1302], ["evidence", 1306], ["is", 1315], ["emerging", 1318], ["that", 1327], ["these", 1332], ["drugs", 1338], ["may", 1344], ["also", 1348], ["have", 1353], ["a", 1358], ["protective", 1360], ["effect", 1371], ["against", 1378], ["diabetic", 1386], ["nephropathy", 1395], [".", 1406], ["This", 1408], ["review", 1413], ["focuses", 1420], ["on", 1428], ["the", 1431], ["most", 1435], ["extensively", 1440], ["studied", 1452], ["SGLT2", 1460], ["inhibitors", 1466], ["dapagliflozin", 1477], [",", 1490], ["canagliflozin", 1492], ["and", 1506], ["empagliflozin", 1510], [".", 1523], ["Dapagliflozin", 1525], ["and", 1539], ["canagliflozin", 1543], ["have", 1557], ["already", 1562], ["been", 1570], ["approved", 1575], ["for", 1584], ["marketing", 1588], ["by", 1598], ["the", 1601], ["US", 1605], ["Food", 1608], ["and", 1613], ["Drug", 1617], ["Administration", 1622], [".", 1636], ["The", 1638], ["European", 1642], ["Medicines", 1651], ["Agency", 1661], ["has", 1668], ["accepted", 1672], ["all", 1681], ["three", 1685], ["drugs", 1691], ["for", 1697], ["marketing", 1701], [".", 1710]]}
{"context": "The aim of this study was to assess to what extent patients with meticillin-resistant Staphylococcus aureus (MRSA) at respiratory sites shed viable MRSA into the air of hospital rooms. We also evaluated whether the distance from the patient could influence the level of contamination. Air sampling was performed directly onto MRSA-selective agar in 24 hospital rooms containing patients with MRSA colonization or infection of the respiratory tract. Samplings were performed in duplicate at 0.5, 1 and 2-3 m from the patients' heads. Clinical and environmental isolates were compared using antimicrobial resistance patterns and pulsed-field gel electrophoresis. MRSA strains were isolated from 21 out of 24 rooms, in quantities varying from between 1 and 78 cfu/m3. In each of the 21 rooms, at least one of the environmental isolates was identical to a clinical isolate from the patient in that room. There was no significant difference in MRSA counts between the distance from the patient's head and the sampler. This study demonstrates that most patients with MRSA infection or colonisation of the respiratory tract shed viable MRSA into the air of their room. The results emphasise the need to study MRSA in air in more detail in order to improve infection control recommendations.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "1a6e6e4476ac4f3694bbf44eba26b5a9", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[67, 67], [19, 19], [26, 26], [169, 169], [215, 215], [56, 56], [200, 200], [190, 190], [113, 113]], "char_spans": [[392, 395], [109, 112], [148, 151], [939, 942], [1202, 1205], [326, 329], [1129, 1132], [1061, 1064], [661, 664]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["assess", 29], ["to", 36], ["what", 39], ["extent", 44], ["patients", 51], ["with", 60], ["meticillin", 65], ["-", 75], ["resistant", 76], ["Staphylococcus", 86], ["aureus", 101], ["(", 108], ["MRSA", 109], [")", 113], ["at", 115], ["respiratory", 118], ["sites", 130], ["shed", 136], ["viable", 141], ["MRSA", 148], ["into", 153], ["the", 158], ["air", 162], ["of", 166], ["hospital", 169], ["rooms", 178], [".", 183], ["We", 185], ["also", 188], ["evaluated", 193], ["whether", 203], ["the", 211], ["distance", 215], ["from", 224], ["the", 229], ["patient", 233], ["could", 241], ["influence", 247], ["the", 257], ["level", 261], ["of", 267], ["contamination", 270], [".", 283], ["Air", 285], ["sampling", 289], ["was", 298], ["performed", 302], ["directly", 312], ["onto", 321], ["MRSA", 326], ["-", 330], ["selective", 331], ["agar", 341], ["in", 346], ["24", 349], ["hospital", 352], ["rooms", 361], ["containing", 367], ["patients", 378], ["with", 387], ["MRSA", 392], ["colonization", 397], ["or", 410], ["infection", 413], ["of", 423], ["the", 426], ["respiratory", 430], ["tract", 442], [".", 447], ["Samplings", 449], ["were", 459], ["performed", 464], ["in", 474], ["duplicate", 477], ["at", 487], ["0.5", 490], [",", 493], ["1", 495], ["and", 497], ["2", 501], ["-", 502], ["3", 503], ["m", 505], ["from", 507], ["the", 512], ["patients", 516], ["'", 524], ["heads", 526], [".", 531], ["Clinical", 533], ["and", 542], ["environmental", 546], ["isolates", 560], ["were", 569], ["compared", 574], ["using", 583], ["antimicrobial", 589], ["resistance", 603], ["patterns", 614], ["and", 623], ["pulsed", 627], ["-", 633], ["field", 634], ["gel", 640], ["electrophoresis", 644], [".", 659], ["MRSA", 661], ["strains", 666], ["were", 674], ["isolated", 679], ["from", 688], ["21", 693], ["out", 696], ["of", 700], ["24", 703], ["rooms", 706], [",", 711], ["in", 713], ["quantities", 716], ["varying", 727], ["from", 735], ["between", 740], ["1", 748], ["and", 750], ["78", 754], ["cfu", 757], ["/", 760], ["m3", 761], [".", 763], ["In", 765], ["each", 768], ["of", 773], ["the", 776], ["21", 780], ["rooms", 783], [",", 788], ["at", 790], ["least", 793], ["one", 799], ["of", 803], ["the", 806], ["environmental", 810], ["isolates", 824], ["was", 833], ["identical", 837], ["to", 847], ["a", 850], ["clinical", 852], ["isolate", 861], ["from", 869], ["the", 874], ["patient", 878], ["in", 886], ["that", 889], ["room", 894], [".", 898], ["There", 900], ["was", 906], ["no", 910], ["significant", 913], ["difference", 925], ["in", 936], ["MRSA", 939], ["counts", 944], ["between", 951], ["the", 959], ["distance", 963], ["from", 972], ["the", 977], ["patient", 981], ["'s", 988], ["head", 991], ["and", 996], ["the", 1000], ["sampler", 1004], [".", 1011], ["This", 1013], ["study", 1018], ["demonstrates", 1024], ["that", 1037], ["most", 1042], ["patients", 1047], ["with", 1056], ["MRSA", 1061], ["infection", 1066], ["or", 1076], ["colonisation", 1079], ["of", 1092], ["the", 1095], ["respiratory", 1099], ["tract", 1111], ["shed", 1117], ["viable", 1122], ["MRSA", 1129], ["into", 1134], ["the", 1139], ["air", 1143], ["of", 1147], ["their", 1150], ["room", 1156], [".", 1160], ["The", 1162], ["results", 1166], ["emphasise", 1174], ["the", 1184], ["need", 1188], ["to", 1193], ["study", 1196], ["MRSA", 1202], ["in", 1207], ["air", 1210], ["in", 1214], ["more", 1217], ["detail", 1222], ["in", 1229], ["order", 1232], ["to", 1238], ["improve", 1241], ["infection", 1249], ["control", 1259], ["recommendations", 1267], [".", 1282]]}
{"context": "To study the clinical and molecular characteristics of methicillin-resistant Staphylococcus aureus (MRSA) infection in children. A total of 37 MRSA strains were isolated from hospitalized patients in Children's Hospital of Fudan University from March 2009 to November 2011. The clinical characteristics were investigated by a cohort study. Furthermore, the mecA, Panton-Valentine leucocidin (PVL) genes were detected by polymerase chain reaction (PCR), and the genotypes of SCCmec were determined by multiplex PCR. (1) Among the 37 MRSA isolates, infections with 21 were acquired from hospital (HA-MRSA), and 16 isolates were acquired from community (CA-MRSA). (2) In the study, MRSA frequently caused respiratory tract infection, and most of the strains were isolated from intensive care unit (ICU). (3) CA-MRSA was most frequently associated with skin and soft tissue infections (SSTI), suppurative tonsillitis, even pneumonia and septicemia. HA-MRSA infection was more aggressive, most frequently associated with pneumonia, septicemia, and central nervous system (CNS) infections, such as meningitis. In children with fever caused by HA-MRSA or CA-MRSA infection, HA-MRSA showed a longer duration of fever, for 10.5 days. C-reactive protein (CRP) level caused by HA-MRSA (63.00 mg/L) was higher than CA-MRSA (9.50 mg/L) , and there were statistically significant differences between the groups (t = 2.5670, P < 0.05). However, there were no statistically significant differences between the groups in white blood cell count (WBC) or procalcitonin (PCT) level. (4) Among 37 MRSA isolates, the whole isolates were mecA gene positive (100%). SCCmec genotyping results showed that the most frequent SCCmec types were type III, 17 isolates, the others including type IV 8 isolates, type II1 isolates, nontypable 11 isolates, type I and type V were not found in this group. Therein, among 21 HA-MRSA isolates, SCCmec III was the most common, 15 isolates, type IV 1 isolates, nontypable 5 isolates; among 16 CA-MRSA isolates, SCCmec type IV was the most common, 7 isolates, type III 2 isolates, type II 1 isolate, nontypable 6 isolates. (5) Among the 37 MRSA isolates, 28 were PVL gene positive; and among 21 HA-MRSA isolates, 17 were PVL gene positive; Among 16 CA-MRSA isolates, 11 were PVL gene positive; There were no statistically significant differences between the groups (\u03c7(2) = 0.735, P > 0.05) . Compared with CA-MRSA, HA-MRSA infection was more aggressive, and induced higher C reactive protein; the dominant epidemic strains of CA-MRSA was SCCmec type IV, and HA-MRSA was SCCmec type III; the positive rate of PVL gene was high.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "b4d2ae32fe78473ead5fbb79a9000745", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[461, 461], [531, 531], [108, 108], [121, 121], [263, 263], [131, 131], [251, 251], [387, 387], [507, 507], [222, 222], [14, 14], [447, 447], [321, 321], [511, 511], [218, 218], [474, 474], [24, 24], [227, 227], [413, 413], [540, 540], [183, 183], [158, 158], [95, 95]], "char_spans": [[2208, 2211], [2539, 2542], [598, 601], [654, 657], [1306, 1309], [679, 682], [1269, 1272], [1892, 1895], [2419, 2422], [1151, 1154], [100, 103], [2150, 2153], [1576, 1579], [2428, 2431], [1140, 1143], [2262, 2265], [143, 146], [1170, 1173], [2007, 2010], [2571, 2574], [948, 951], [808, 811], [532, 535]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["clinical", 13], ["and", 22], ["molecular", 26], ["characteristics", 36], ["of", 52], ["methicillin", 55], ["-", 66], ["resistant", 67], ["Staphylococcus", 77], ["aureus", 92], ["(", 99], ["MRSA", 100], [")", 104], ["infection", 106], ["in", 116], ["children", 119], [".", 127], ["A", 129], ["total", 131], ["of", 137], ["37", 140], ["MRSA", 143], ["strains", 148], ["were", 156], ["isolated", 161], ["from", 170], ["hospitalized", 175], ["patients", 188], ["in", 197], ["Children", 200], ["'s", 208], ["Hospital", 211], ["of", 220], ["Fudan", 223], ["University", 229], ["from", 240], ["March", 245], ["2009", 251], ["to", 256], ["November", 259], ["2011", 268], [".", 272], ["The", 274], ["clinical", 278], ["characteristics", 287], ["were", 303], ["investigated", 308], ["by", 321], ["a", 324], ["cohort", 326], ["study", 333], [".", 338], ["Furthermore", 340], [",", 351], ["the", 353], ["mecA", 357], [",", 361], ["Panton", 363], ["-", 369], ["Valentine", 370], ["leucocidin", 380], ["(", 391], ["PVL", 392], [")", 395], ["genes", 397], ["were", 403], ["detected", 408], ["by", 417], ["polymerase", 420], ["chain", 431], ["reaction", 437], ["(", 446], ["PCR", 447], [")", 450], [",", 451], ["and", 453], ["the", 457], ["genotypes", 461], ["of", 471], ["SCCmec", 474], ["were", 481], ["determined", 486], ["by", 497], ["multiplex", 500], ["PCR", 510], [".", 513], ["(", 515], ["1", 516], [")", 517], ["Among", 519], ["the", 525], ["37", 529], ["MRSA", 532], ["isolates", 537], [",", 545], ["infections", 547], ["with", 558], ["21", 563], ["were", 566], ["acquired", 571], ["from", 580], ["hospital", 585], ["(", 594], ["HA", 595], ["-", 597], ["MRSA", 598], [")", 602], [",", 603], ["and", 605], ["16", 609], ["isolates", 612], ["were", 621], ["acquired", 626], ["from", 635], ["community", 640], ["(", 650], ["CA", 651], ["-", 653], ["MRSA", 654], [")", 658], [".", 659], ["(", 661], ["2", 662], [")", 663], ["In", 665], ["the", 668], ["study", 672], [",", 677], ["MRSA", 679], ["frequently", 684], ["caused", 695], ["respiratory", 702], ["tract", 714], ["infection", 720], [",", 729], ["and", 731], ["most", 735], ["of", 740], ["the", 743], ["strains", 747], ["were", 755], ["isolated", 760], ["from", 769], ["intensive", 774], ["care", 784], ["unit", 789], ["(", 794], ["ICU", 795], [")", 798], [".", 799], ["(", 801], ["3", 802], [")", 803], ["CA", 805], ["-", 807], ["MRSA", 808], ["was", 813], ["most", 817], ["frequently", 822], ["associated", 833], ["with", 844], ["skin", 849], ["and", 854], ["soft", 858], ["tissue", 863], ["infections", 870], ["(", 881], ["SSTI", 882], [")", 886], [",", 887], ["suppurative", 889], ["tonsillitis", 901], [",", 912], ["even", 914], ["pneumonia", 919], ["and", 929], ["septicemia", 933], [".", 943], ["HA", 945], ["-", 947], ["MRSA", 948], ["infection", 953], ["was", 963], ["more", 967], ["aggressive", 972], [",", 982], ["most", 984], ["frequently", 989], ["associated", 1000], ["with", 1011], ["pneumonia", 1016], [",", 1025], ["septicemia", 1027], [",", 1037], ["and", 1039], ["central", 1043], ["nervous", 1051], ["system", 1059], ["(", 1066], ["CNS", 1067], [")", 1070], ["infections", 1072], [",", 1082], ["such", 1084], ["as", 1089], ["meningitis", 1092], [".", 1102], ["In", 1104], ["children", 1107], ["with", 1116], ["fever", 1121], ["caused", 1127], ["by", 1134], ["HA", 1137], ["-", 1139], ["MRSA", 1140], ["or", 1145], ["CA", 1148], ["-", 1150], ["MRSA", 1151], ["infection", 1156], [",", 1165], ["HA", 1167], ["-", 1169], ["MRSA", 1170], ["showed", 1175], ["a", 1182], ["longer", 1184], ["duration", 1191], ["of", 1200], ["fever", 1203], [",", 1208], ["for", 1210], ["10.5", 1214], ["days", 1219], [".", 1223], ["C", 1225], ["-", 1226], ["reactive", 1227], ["protein", 1236], ["(", 1244], ["CRP", 1245], [")", 1248], ["level", 1250], ["caused", 1256], ["by", 1263], ["HA", 1266], ["-", 1268], ["MRSA", 1269], ["(", 1274], ["63.00", 1275], ["mg", 1281], ["/", 1283], ["L", 1284], [")", 1285], ["was", 1287], ["higher", 1291], ["than", 1298], ["CA", 1303], ["-", 1305], ["MRSA", 1306], ["(", 1311], ["9.50", 1312], ["mg", 1317], ["/", 1319], ["L", 1320], [")", 1321], [",", 1323], ["and", 1325], ["there", 1329], ["were", 1335], ["statistically", 1340], ["significant", 1354], ["differences", 1366], ["between", 1378], ["the", 1386], ["groups", 1390], ["(", 1397], ["t", 1398], ["=", 1400], ["2.5670", 1402], [",", 1408], ["P", 1410], ["<", 1412], ["0.05", 1414], [")", 1418], [".", 1419], ["However", 1421], [",", 1428], ["there", 1430], ["were", 1436], ["no", 1441], ["statistically", 1444], ["significant", 1458], ["differences", 1470], ["between", 1482], ["the", 1490], ["groups", 1494], ["in", 1501], ["white", 1504], ["blood", 1510], ["cell", 1516], ["count", 1521], ["(", 1527], ["WBC", 1528], [")", 1531], ["or", 1533], ["procalcitonin", 1536], ["(", 1550], ["PCT", 1551], [")", 1554], ["level", 1556], [".", 1561], ["(", 1563], ["4", 1564], [")", 1565], ["Among", 1567], ["37", 1573], ["MRSA", 1576], ["isolates", 1581], [",", 1589], ["the", 1591], ["whole", 1595], ["isolates", 1601], ["were", 1610], ["mecA", 1615], ["gene", 1620], ["positive", 1625], ["(", 1634], ["100", 1635], ["%", 1638], [")", 1639], [".", 1640], ["SCCmec", 1642], ["genotyping", 1649], ["results", 1660], ["showed", 1668], ["that", 1675], ["the", 1680], ["most", 1684], ["frequent", 1689], ["SCCmec", 1698], ["types", 1705], ["were", 1711], ["type", 1716], ["III", 1721], [",", 1724], ["17", 1726], ["isolates", 1729], [",", 1737], ["the", 1739], ["others", 1743], ["including", 1750], ["type", 1760], ["IV", 1765], ["8", 1768], ["isolates", 1770], [",", 1778], ["type", 1780], ["II1", 1785], ["isolates", 1789], [",", 1797], ["nontypable", 1799], ["11", 1810], ["isolates", 1813], [",", 1821], ["type", 1823], ["I", 1828], ["and", 1830], ["type", 1834], ["V", 1839], ["were", 1841], ["not", 1846], ["found", 1850], ["in", 1856], ["this", 1859], ["group", 1864], [".", 1869], ["Therein", 1871], [",", 1878], ["among", 1880], ["21", 1886], ["HA", 1889], ["-", 1891], ["MRSA", 1892], ["isolates", 1897], [",", 1905], ["SCCmec", 1907], ["III", 1914], ["was", 1918], ["the", 1922], ["most", 1926], ["common", 1931], [",", 1937], ["15", 1939], ["isolates", 1942], [",", 1950], ["type", 1952], ["IV", 1957], ["1", 1960], ["isolates", 1962], [",", 1970], ["nontypable", 1972], ["5", 1983], ["isolates", 1985], [";", 1993], ["among", 1995], ["16", 2001], ["CA", 2004], ["-", 2006], ["MRSA", 2007], ["isolates", 2012], [",", 2020], ["SCCmec", 2022], ["type", 2029], ["IV", 2034], ["was", 2037], ["the", 2041], ["most", 2045], ["common", 2050], [",", 2056], ["7", 2058], ["isolates", 2060], [",", 2068], ["type", 2070], ["III", 2075], ["2", 2079], ["isolates", 2081], [",", 2089], ["type", 2091], ["II", 2096], ["1", 2099], ["isolate", 2101], [",", 2108], ["nontypable", 2110], ["6", 2121], ["isolates", 2123], [".", 2131], ["(", 2133], ["5", 2134], [")", 2135], ["Among", 2137], ["the", 2143], ["37", 2147], ["MRSA", 2150], ["isolates", 2155], [",", 2163], ["28", 2165], ["were", 2168], ["PVL", 2173], ["gene", 2177], ["positive", 2182], [";", 2190], ["and", 2192], ["among", 2196], ["21", 2202], ["HA", 2205], ["-", 2207], ["MRSA", 2208], ["isolates", 2213], [",", 2221], ["17", 2223], ["were", 2226], ["PVL", 2231], ["gene", 2235], ["positive", 2240], [";", 2248], ["Among", 2250], ["16", 2256], ["CA", 2259], ["-", 2261], ["MRSA", 2262], ["isolates", 2267], [",", 2275], ["11", 2277], ["were", 2280], ["PVL", 2285], ["gene", 2289], ["positive", 2294], [";", 2302], ["There", 2304], ["were", 2310], ["no", 2315], ["statistically", 2318], ["significant", 2332], ["differences", 2344], ["between", 2356], ["the", 2364], ["groups", 2368], ["(", 2375], ["\u03c7(2", 2376], [")", 2379], ["=", 2381], ["0.735", 2383], [",", 2388], ["P", 2390], [">", 2392], ["0.05", 2394], [")", 2398], [".", 2400], ["Compared", 2402], ["with", 2411], ["CA", 2416], ["-", 2418], ["MRSA", 2419], [",", 2423], ["HA", 2425], ["-", 2427], ["MRSA", 2428], ["infection", 2433], ["was", 2443], ["more", 2447], ["aggressive", 2452], [",", 2462], ["and", 2464], ["induced", 2468], ["higher", 2476], ["C", 2483], ["reactive", 2485], ["protein", 2494], [";", 2501], ["the", 2503], ["dominant", 2507], ["epidemic", 2516], ["strains", 2525], ["of", 2533], ["CA", 2536], ["-", 2538], ["MRSA", 2539], ["was", 2544], ["SCCmec", 2548], ["type", 2555], ["IV", 2560], [",", 2562], ["and", 2564], ["HA", 2568], ["-", 2570], ["MRSA", 2571], ["was", 2576], ["SCCmec", 2580], ["type", 2587], ["III", 2592], [";", 2595], ["the", 2597], ["positive", 2601], ["rate", 2610], ["of", 2615], ["PVL", 2618], ["gene", 2622], ["was", 2627], ["high", 2631], [".", 2635]]}
{"context": "Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars, easy bruising, and generalized joint hypermobility. It comprises Ehlers-Danlos syndrome type I and Ehlers-Danlos syndrome type II, but it is now apparent that these form a continuum of clinical findings and differ only in phenotypic severity. It is currently estimated that approximately 50% of patients with a clinical diagnosis of classic Ehlers-Danlos syndrome harbor mutations in the COL5A1 and the COL5A2 gene, encoding the \u03b11 and the \u03b12-chain of type V collagen, respectively. However, because no prospective molecular studies of COL5A1 and COL5A2 have been performed in a clinically well-defined patient group, this number may underestimate the real proportion of patients with classic Ehlers-Danlos syndrome harboring a mutation in one of these genes. In the majority of patients with molecularly characterized classic Ehlers-Danlos syndrome, the disease is caused by a mutation leading to a nonfunctional COL5A1 allele and resulting in haploinsufficiency of type V collagen. A smaller proportion of patients harbor a structural mutation in COL5A1 or COL5A2, causing the production of a functionally defective type V collagen protein. Most mutations identified so far result in a reduced amount of type V collagen in the connective tissues available for collagen fibrillogenesis. Inter- and intrafamilial phenotypic variability is observed, but no genotype-phenotype correlations have been observed. No treatment for the underlying defect is presently available for Ehlers-Danlos syndrome. However, a series of preventive guidelines are applicable.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "90435bdf04fb46fd88c52fcb14d2c478", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[8, 9]], "char_spans": [[46, 62]]}]}], "context_tokens": [["Classic", 0], ["Ehlers", 8], ["-", 14], ["Danlos", 15], ["syndrome", 22], ["is", 31], ["a", 34], ["heritable", 36], ["connective", 46], ["tissue", 57], ["disorder", 64], ["characterized", 73], ["by", 87], ["skin", 90], ["hyperextensibility", 95], [",", 113], ["fragile", 115], ["and", 123], ["soft", 127], ["skin", 132], [",", 136], ["delayed", 138], ["wound", 146], ["healing", 152], ["with", 160], ["formation", 165], ["of", 175], ["atrophic", 178], ["scars", 187], [",", 192], ["easy", 194], ["bruising", 199], [",", 207], ["and", 209], ["generalized", 213], ["joint", 225], ["hypermobility", 231], [".", 244], ["It", 246], ["comprises", 249], ["Ehlers", 259], ["-", 265], ["Danlos", 266], ["syndrome", 273], ["type", 282], ["I", 287], ["and", 289], ["Ehlers", 293], ["-", 299], ["Danlos", 300], ["syndrome", 307], ["type", 316], ["II", 321], [",", 323], ["but", 325], ["it", 329], ["is", 332], ["now", 335], ["apparent", 339], ["that", 348], ["these", 353], ["form", 359], ["a", 364], ["continuum", 366], ["of", 376], ["clinical", 379], ["findings", 388], ["and", 397], ["differ", 401], ["only", 408], ["in", 413], ["phenotypic", 416], ["severity", 427], [".", 435], ["It", 437], ["is", 440], ["currently", 443], ["estimated", 453], ["that", 463], ["approximately", 468], ["50", 482], ["%", 484], ["of", 486], ["patients", 489], ["with", 498], ["a", 503], ["clinical", 505], ["diagnosis", 514], ["of", 524], ["classic", 527], ["Ehlers", 535], ["-", 541], ["Danlos", 542], ["syndrome", 549], ["harbor", 558], ["mutations", 565], ["in", 575], ["the", 578], ["COL5A1", 582], ["and", 589], ["the", 593], ["COL5A2", 597], ["gene", 604], [",", 608], ["encoding", 610], ["the", 619], ["\u03b11", 623], ["and", 626], ["the", 630], ["\u03b12-chain", 634], ["of", 643], ["type", 646], ["V", 651], ["collagen", 653], [",", 661], ["respectively", 663], [".", 675], ["However", 677], [",", 684], ["because", 686], ["no", 694], ["prospective", 697], ["molecular", 709], ["studies", 719], ["of", 727], ["COL5A1", 730], ["and", 737], ["COL5A2", 741], ["have", 748], ["been", 753], ["performed", 758], ["in", 768], ["a", 771], ["clinically", 773], ["well", 784], ["-", 788], ["defined", 789], ["patient", 797], ["group", 805], [",", 810], ["this", 812], ["number", 817], ["may", 824], ["underestimate", 828], ["the", 842], ["real", 846], ["proportion", 851], ["of", 862], ["patients", 865], ["with", 874], ["classic", 879], ["Ehlers", 887], ["-", 893], ["Danlos", 894], ["syndrome", 901], ["harboring", 910], ["a", 920], ["mutation", 922], ["in", 931], ["one", 934], ["of", 938], ["these", 941], ["genes", 947], [".", 952], ["In", 954], ["the", 957], ["majority", 961], ["of", 970], ["patients", 973], ["with", 982], ["molecularly", 987], ["characterized", 999], ["classic", 1013], ["Ehlers", 1021], ["-", 1027], ["Danlos", 1028], ["syndrome", 1035], [",", 1043], ["the", 1045], ["disease", 1049], ["is", 1057], ["caused", 1060], ["by", 1067], ["a", 1070], ["mutation", 1072], ["leading", 1081], ["to", 1089], ["a", 1092], ["nonfunctional", 1094], ["COL5A1", 1108], ["allele", 1115], ["and", 1122], ["resulting", 1126], ["in", 1136], ["haploinsufficiency", 1139], ["of", 1158], ["type", 1161], ["V", 1166], ["collagen", 1168], [".", 1176], ["A", 1178], ["smaller", 1180], ["proportion", 1188], ["of", 1199], ["patients", 1202], ["harbor", 1211], ["a", 1218], ["structural", 1220], ["mutation", 1231], ["in", 1240], ["COL5A1", 1243], ["or", 1250], ["COL5A2", 1253], [",", 1259], ["causing", 1261], ["the", 1269], ["production", 1273], ["of", 1284], ["a", 1287], ["functionally", 1289], ["defective", 1302], ["type", 1312], ["V", 1317], ["collagen", 1319], ["protein", 1328], [".", 1335], ["Most", 1337], ["mutations", 1342], ["identified", 1352], ["so", 1363], ["far", 1366], ["result", 1370], ["in", 1377], ["a", 1380], ["reduced", 1382], ["amount", 1390], ["of", 1397], ["type", 1400], ["V", 1405], ["collagen", 1407], ["in", 1416], ["the", 1419], ["connective", 1423], ["tissues", 1434], ["available", 1442], ["for", 1452], ["collagen", 1456], ["fibrillogenesis", 1465], [".", 1480], ["Inter-", 1482], ["and", 1489], ["intrafamilial", 1493], ["phenotypic", 1507], ["variability", 1518], ["is", 1530], ["observed", 1533], [",", 1541], ["but", 1543], ["no", 1547], ["genotype", 1550], ["-", 1558], ["phenotype", 1559], ["correlations", 1569], ["have", 1582], ["been", 1587], ["observed", 1592], [".", 1600], ["No", 1602], ["treatment", 1605], ["for", 1615], ["the", 1619], ["underlying", 1623], ["defect", 1634], ["is", 1641], ["presently", 1644], ["available", 1654], ["for", 1664], ["Ehlers", 1668], ["-", 1674], ["Danlos", 1675], ["syndrome", 1682], [".", 1690], ["However", 1692], [",", 1699], ["a", 1701], ["series", 1703], ["of", 1710], ["preventive", 1713], ["guidelines", 1724], ["are", 1735], ["applicable", 1739], [".", 1749]]}
{"context": "Nucleotide excision repair (NER) mechanism is the major pathway responsible for the removal of a large variety of bulky lesions from the genome. Two different NER subpathways have been identified, i.e. the transcription-coupled and the global genome repair pathways. For DNA-damage induced by ultraviolet light both transcription-coupled repair and global genome repair are essential to confer resistance to cytotoxic effects. To gain further insight into the contribution of NER subpathways in the repair of bulky lesions and in their prevention of biological effects we measured the rate of repair of dG-C8-AF in active and inactive genes in normal human cells, XP-C cells (only transcription-coupled repair) and XP-A cells (completely NER-deficient) exposed to NA-AAF. XP-C cells are only slightly more sensitive to NA-AAF than normal cells and, like normal cells, they are able to recover RNA synthesis repressed by the treatment. In contrast, XP-A cells are sensitive to NA-AAF and unable to recover from RNA synthesis inhibition. Repair of dG-C8-AF in the active ADA gene proceeds in a biphasic way and without strand specificity, with a subclass of lesions quickly repaired during the first 8 h after treatment. Repair in the inactive 754 gene occurs more slowly than in the ADA gene. In XP-C cells, repair of dG-C8-AF in the ADA gene is confined to the transcribed strand and occurs at about half the rate of repair seen in normal cells. Repair in the inactive 754 gene in XP-C cells is virtually absent. Consistent with these results we found that repair replication in XP-C is drastically reduced when compared with normal cells and abolished by alpha-amanitin indicating that the repair in XP-C cells is mediated by transcription-coupled repair only. Our data suggest that dG-C8-AF is a target for transcription-coupled repair and that this repair pathway is the main pathway or recovery of RNA synthesis inhibition conferring resistance to cytotoxic effects of NA-AAF. In spite of this, repair of dG-C8-AF in active genes in normal cells by transcription-coupled repair and global genome repair is not additive, but dominated by global genome repair. This indicates that the subset of lesions which are capable of stalling RNA polymerase II, and are, therefore, a substrate for TCR, are also the lesions which are very efficiently recognized by the global genome repair system.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "bcb2d242686c440fb698f05cac959004", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[268, 269]], "char_spans": [[1361, 1378]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], ["mechanism", 33], ["is", 43], ["the", 46], ["major", 50], ["pathway", 56], ["responsible", 64], ["for", 76], ["the", 80], ["removal", 84], ["of", 92], ["a", 95], ["large", 97], ["variety", 103], ["of", 111], ["bulky", 114], ["lesions", 120], ["from", 128], ["the", 133], ["genome", 137], [".", 143], ["Two", 145], ["different", 149], ["NER", 159], ["subpathways", 163], ["have", 175], ["been", 180], ["identified", 185], [",", 195], ["i.e.", 197], ["the", 202], ["transcription", 206], ["-", 219], ["coupled", 220], ["and", 228], ["the", 232], ["global", 236], ["genome", 243], ["repair", 250], ["pathways", 257], [".", 265], ["For", 267], ["DNA", 271], ["-", 274], ["damage", 275], ["induced", 282], ["by", 290], ["ultraviolet", 293], ["light", 305], ["both", 311], ["transcription", 316], ["-", 329], ["coupled", 330], ["repair", 338], ["and", 345], ["global", 349], ["genome", 356], ["repair", 363], ["are", 370], ["essential", 374], ["to", 384], ["confer", 387], ["resistance", 394], ["to", 405], ["cytotoxic", 408], ["effects", 418], [".", 425], ["To", 427], ["gain", 430], ["further", 435], ["insight", 443], ["into", 451], ["the", 456], ["contribution", 460], ["of", 473], ["NER", 476], ["subpathways", 480], ["in", 492], ["the", 495], ["repair", 499], ["of", 506], ["bulky", 509], ["lesions", 515], ["and", 523], ["in", 527], ["their", 530], ["prevention", 536], ["of", 547], ["biological", 550], ["effects", 561], ["we", 569], ["measured", 572], ["the", 581], ["rate", 585], ["of", 590], ["repair", 593], ["of", 600], ["dG", 603], ["-", 605], ["C8-AF", 606], ["in", 612], ["active", 615], ["and", 622], ["inactive", 626], ["genes", 635], ["in", 641], ["normal", 644], ["human", 651], ["cells", 657], [",", 662], ["XP", 664], ["-", 666], ["C", 667], ["cells", 669], ["(", 675], ["only", 676], ["transcription", 681], ["-", 694], ["coupled", 695], ["repair", 703], [")", 709], ["and", 711], ["XP", 715], ["-", 717], ["A", 718], ["cells", 720], ["(", 726], ["completely", 727], ["NER", 738], ["-", 741], ["deficient", 742], [")", 751], ["exposed", 753], ["to", 761], ["NA", 764], ["-", 766], ["AAF", 767], [".", 770], ["XP", 772], ["-", 774], ["C", 775], ["cells", 777], ["are", 783], ["only", 787], ["slightly", 792], ["more", 801], ["sensitive", 806], ["to", 816], ["NA", 819], ["-", 821], ["AAF", 822], ["than", 826], ["normal", 831], ["cells", 838], ["and", 844], [",", 847], ["like", 849], ["normal", 854], ["cells", 861], [",", 866], ["they", 868], ["are", 873], ["able", 877], ["to", 882], ["recover", 885], ["RNA", 893], ["synthesis", 897], ["repressed", 907], ["by", 917], ["the", 920], ["treatment", 924], [".", 933], ["In", 935], ["contrast", 938], [",", 946], ["XP", 948], ["-", 950], ["A", 951], ["cells", 953], ["are", 959], ["sensitive", 963], ["to", 973], ["NA", 976], ["-", 978], ["AAF", 979], ["and", 983], ["unable", 987], ["to", 994], ["recover", 997], ["from", 1005], ["RNA", 1010], ["synthesis", 1014], ["inhibition", 1024], [".", 1034], ["Repair", 1036], ["of", 1043], ["dG", 1046], ["-", 1048], ["C8-AF", 1049], ["in", 1055], ["the", 1058], ["active", 1062], ["ADA", 1069], ["gene", 1073], ["proceeds", 1078], ["in", 1087], ["a", 1090], ["biphasic", 1092], ["way", 1101], ["and", 1105], ["without", 1109], ["strand", 1117], ["specificity", 1124], [",", 1135], ["with", 1137], ["a", 1142], ["subclass", 1144], ["of", 1153], ["lesions", 1156], ["quickly", 1164], ["repaired", 1172], ["during", 1181], ["the", 1188], ["first", 1192], ["8", 1198], ["h", 1200], ["after", 1202], ["treatment", 1208], [".", 1217], ["Repair", 1219], ["in", 1226], ["the", 1229], ["inactive", 1233], ["754", 1242], ["gene", 1246], ["occurs", 1251], ["more", 1258], ["slowly", 1263], ["than", 1270], ["in", 1275], ["the", 1278], ["ADA", 1282], ["gene", 1286], [".", 1290], ["In", 1292], ["XP", 1295], ["-", 1297], ["C", 1298], ["cells", 1300], [",", 1305], ["repair", 1307], ["of", 1314], ["dG", 1317], ["-", 1319], ["C8-AF", 1320], ["in", 1326], ["the", 1329], ["ADA", 1333], ["gene", 1337], ["is", 1342], ["confined", 1345], ["to", 1354], ["the", 1357], ["transcribed", 1361], ["strand", 1373], ["and", 1380], ["occurs", 1384], ["at", 1391], ["about", 1394], ["half", 1400], ["the", 1405], ["rate", 1409], ["of", 1414], ["repair", 1417], ["seen", 1424], ["in", 1429], ["normal", 1432], ["cells", 1439], [".", 1444], ["Repair", 1446], ["in", 1453], ["the", 1456], ["inactive", 1460], ["754", 1469], ["gene", 1473], ["in", 1478], ["XP", 1481], ["-", 1483], ["C", 1484], ["cells", 1486], ["is", 1492], ["virtually", 1495], ["absent", 1505], [".", 1511], ["Consistent", 1513], ["with", 1524], ["these", 1529], ["results", 1535], ["we", 1543], ["found", 1546], ["that", 1552], ["repair", 1557], ["replication", 1564], ["in", 1576], ["XP", 1579], ["-", 1581], ["C", 1582], ["is", 1584], ["drastically", 1587], ["reduced", 1599], ["when", 1607], ["compared", 1612], ["with", 1621], ["normal", 1626], ["cells", 1633], ["and", 1639], ["abolished", 1643], ["by", 1653], ["alpha", 1656], ["-", 1661], ["amanitin", 1662], ["indicating", 1671], ["that", 1682], ["the", 1687], ["repair", 1691], ["in", 1698], ["XP", 1701], ["-", 1703], ["C", 1704], ["cells", 1706], ["is", 1712], ["mediated", 1715], ["by", 1724], ["transcription", 1727], ["-", 1740], ["coupled", 1741], ["repair", 1749], ["only", 1756], [".", 1760], ["Our", 1762], ["data", 1766], ["suggest", 1771], ["that", 1779], ["dG", 1784], ["-", 1786], ["C8-AF", 1787], ["is", 1793], ["a", 1796], ["target", 1798], ["for", 1805], ["transcription", 1809], ["-", 1822], ["coupled", 1823], ["repair", 1831], ["and", 1838], ["that", 1842], ["this", 1847], ["repair", 1852], ["pathway", 1859], ["is", 1867], ["the", 1870], ["main", 1874], ["pathway", 1879], ["or", 1887], ["recovery", 1890], ["of", 1899], ["RNA", 1902], ["synthesis", 1906], ["inhibition", 1916], ["conferring", 1927], ["resistance", 1938], ["to", 1949], ["cytotoxic", 1952], ["effects", 1962], ["of", 1970], ["NA", 1973], ["-", 1975], ["AAF", 1976], [".", 1979], ["In", 1981], ["spite", 1984], ["of", 1990], ["this", 1993], [",", 1997], ["repair", 1999], ["of", 2006], ["dG", 2009], ["-", 2011], ["C8-AF", 2012], ["in", 2018], ["active", 2021], ["genes", 2028], ["in", 2034], ["normal", 2037], ["cells", 2044], ["by", 2050], ["transcription", 2053], ["-", 2066], ["coupled", 2067], ["repair", 2075], ["and", 2082], ["global", 2086], ["genome", 2093], ["repair", 2100], ["is", 2107], ["not", 2110], ["additive", 2114], [",", 2122], ["but", 2124], ["dominated", 2128], ["by", 2138], ["global", 2141], ["genome", 2148], ["repair", 2155], [".", 2161], ["This", 2163], ["indicates", 2168], ["that", 2178], ["the", 2183], ["subset", 2187], ["of", 2194], ["lesions", 2197], ["which", 2205], ["are", 2211], ["capable", 2215], ["of", 2223], ["stalling", 2226], ["RNA", 2235], ["polymerase", 2239], ["II", 2250], [",", 2252], ["and", 2254], ["are", 2258], [",", 2261], ["therefore", 2263], [",", 2272], ["a", 2274], ["substrate", 2276], ["for", 2286], ["TCR", 2290], [",", 2293], ["are", 2295], ["also", 2299], ["the", 2304], ["lesions", 2308], ["which", 2316], ["are", 2322], ["very", 2326], ["efficiently", 2331], ["recognized", 2343], ["by", 2354], ["the", 2357], ["global", 2361], ["genome", 2368], ["repair", 2375], ["system", 2382], [".", 2388]]}
{"context": "The yeast Spt-Ada-Gcn5-acetyltransferase (SAGA) complex is a transcription coactivator that contains a histone H2B deubiquitination activity mediated by its Ubp8 subunit. Full enzymatic activity requires the formation of a quaternary complex, the deubiquitination module (DUBm) of SAGA, which is composed of Ubp8, Sus1, Sgf11, and Sgf73. The crystal structures of the DUBm have shed light on the structure/function relationship of this complex. Specifically, both Sgf11 and Sgf73 contain zinc finger domains (ZnF) that appear essential for the DUBm activity. Whereas Sgf73 N-terminal ZnF is important for DUBm stability, Sgf11 C-terminal ZnF appears to be involved in DUBm function. To further characterize the role of these two zinc fingers, we have solved their structure by NMR. We show that, contrary to the previously reported structures, Sgf73 ZnF adopts a C2H2 coordination with unusual tautomeric forms for the coordinating histidines. We further report that the Sgf11 ZnF, but not the Sgf73 ZnF, binds to nucleosomal DNA with a binding interface composed of arginine residues located within the ZnF \u03b1-helix. Mutational analyses both in vitro and in vivo provide evidence for the functional relevance of our structural observations. The combined interpretation of our results leads to an uncommon ZnF-DNA interaction between the SAGA DUBm and nucleosomes, thus providing further functional insights into SAGA's epigenetic modulation of the chromatin structure.", "qas": [{"question": "What does the SAGA complex acronym stands for?", "answers": ["Spt-Ada-Gcn5-acetyltransferase"], "qid": "c407bea87e58496cb312d3fd2e5eedc2", "question_tokens": [["What", 0], ["does", 5], ["the", 10], ["SAGA", 14], ["complex", 19], ["acronym", 27], ["stands", 35], ["for", 42], ["?", 45]], "detected_answers": [{"text": "Spt-Ada-Gcn5-acetyltransferase", "token_spans": [[2, 6]], "char_spans": [[10, 39]]}]}], "context_tokens": [["The", 0], ["yeast", 4], ["Spt", 10], ["-", 13], ["Ada", 14], ["-", 17], ["Gcn5-acetyltransferase", 18], ["(", 41], ["SAGA", 42], [")", 46], ["complex", 48], ["is", 56], ["a", 59], ["transcription", 61], ["coactivator", 75], ["that", 87], ["contains", 92], ["a", 101], ["histone", 103], ["H2B", 111], ["deubiquitination", 115], ["activity", 132], ["mediated", 141], ["by", 150], ["its", 153], ["Ubp8", 157], ["subunit", 162], [".", 169], ["Full", 171], ["enzymatic", 176], ["activity", 186], ["requires", 195], ["the", 204], ["formation", 208], ["of", 218], ["a", 221], ["quaternary", 223], ["complex", 234], [",", 241], ["the", 243], ["deubiquitination", 247], ["module", 264], ["(", 271], ["DUBm", 272], [")", 276], ["of", 278], ["SAGA", 281], [",", 285], ["which", 287], ["is", 293], ["composed", 296], ["of", 305], ["Ubp8", 308], [",", 312], ["Sus1", 314], [",", 318], ["Sgf11", 320], [",", 325], ["and", 327], ["Sgf73", 331], [".", 336], ["The", 338], ["crystal", 342], ["structures", 350], ["of", 361], ["the", 364], ["DUBm", 368], ["have", 373], ["shed", 378], ["light", 383], ["on", 389], ["the", 392], ["structure", 396], ["/", 405], ["function", 406], ["relationship", 415], ["of", 428], ["this", 431], ["complex", 436], [".", 443], ["Specifically", 445], [",", 457], ["both", 459], ["Sgf11", 464], ["and", 470], ["Sgf73", 474], ["contain", 480], ["zinc", 488], ["finger", 493], ["domains", 500], ["(", 508], ["ZnF", 509], [")", 512], ["that", 514], ["appear", 519], ["essential", 526], ["for", 536], ["the", 540], ["DUBm", 544], ["activity", 549], [".", 557], ["Whereas", 559], ["Sgf73", 567], ["N", 573], ["-", 574], ["terminal", 575], ["ZnF", 584], ["is", 588], ["important", 591], ["for", 601], ["DUBm", 605], ["stability", 610], [",", 619], ["Sgf11", 621], ["C", 627], ["-", 628], ["terminal", 629], ["ZnF", 638], ["appears", 642], ["to", 650], ["be", 653], ["involved", 656], ["in", 665], ["DUBm", 668], ["function", 673], [".", 681], ["To", 683], ["further", 686], ["characterize", 694], ["the", 707], ["role", 711], ["of", 716], ["these", 719], ["two", 725], ["zinc", 729], ["fingers", 734], [",", 741], ["we", 743], ["have", 746], ["solved", 751], ["their", 758], ["structure", 764], ["by", 774], ["NMR", 777], [".", 780], ["We", 782], ["show", 785], ["that", 790], [",", 794], ["contrary", 796], ["to", 805], ["the", 808], ["previously", 812], ["reported", 823], ["structures", 832], [",", 842], ["Sgf73", 844], ["ZnF", 850], ["adopts", 854], ["a", 861], ["C2H2", 863], ["coordination", 868], ["with", 881], ["unusual", 886], ["tautomeric", 894], ["forms", 905], ["for", 911], ["the", 915], ["coordinating", 919], ["histidines", 932], [".", 942], ["We", 944], ["further", 947], ["report", 955], ["that", 962], ["the", 967], ["Sgf11", 971], ["ZnF", 977], [",", 980], ["but", 982], ["not", 986], ["the", 990], ["Sgf73", 994], ["ZnF", 1000], [",", 1003], ["binds", 1005], ["to", 1011], ["nucleosomal", 1014], ["DNA", 1026], ["with", 1030], ["a", 1035], ["binding", 1037], ["interface", 1045], ["composed", 1055], ["of", 1064], ["arginine", 1067], ["residues", 1076], ["located", 1085], ["within", 1093], ["the", 1100], ["ZnF", 1104], ["\u03b1", 1108], ["-", 1109], ["helix", 1110], [".", 1115], ["Mutational", 1117], ["analyses", 1128], ["both", 1137], ["in", 1142], ["vitro", 1145], ["and", 1151], ["in", 1155], ["vivo", 1158], ["provide", 1163], ["evidence", 1171], ["for", 1180], ["the", 1184], ["functional", 1188], ["relevance", 1199], ["of", 1209], ["our", 1212], ["structural", 1216], ["observations", 1227], [".", 1239], ["The", 1241], ["combined", 1245], ["interpretation", 1254], ["of", 1269], ["our", 1272], ["results", 1276], ["leads", 1284], ["to", 1290], ["an", 1293], ["uncommon", 1296], ["ZnF", 1305], ["-", 1308], ["DNA", 1309], ["interaction", 1313], ["between", 1325], ["the", 1333], ["SAGA", 1337], ["DUBm", 1342], ["and", 1347], ["nucleosomes", 1351], [",", 1362], ["thus", 1364], ["providing", 1369], ["further", 1379], ["functional", 1387], ["insights", 1398], ["into", 1407], ["SAGA", 1412], ["'s", 1416], ["epigenetic", 1419], ["modulation", 1430], ["of", 1441], ["the", 1444], ["chromatin", 1448], ["structure", 1458], [".", 1467]]}
{"context": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and chaperone-like protein critical for cell function. This study examined whether the levels of lymphocyte PRDX-2 are altered over 1 month following ultra-endurance exercise. Nine middle-aged men undertook a single-stage, multi-day 233 km (145 mile) ultra-endurance running race. Blood was collected immediately before (Pre), upon completion/retirement (Post), and following the race at Day 1, Day 7 and Day 28. Lymphocyte lysates were examined for PRDX-2 by reducing and non-reducing SDS-PAGE with western blotting. In a sub-group of men who completed the race (n = 4), PRDX-2 oligomeric state (indicative of redox status) was investigated. Ultra-endurance exercise caused significant changes in lymphocyte PRDX-2 (F(4,32) 3.409, p = 0.020, \u03b7(2) = 0.299): 7 days after the race, PRDX-2 levels in lymphocytes had fallen to 30% of pre-race values (p = 0.013) and returned to near-normal levels at Day 28. Non-reducing gels demonstrated that dimeric PRDX-2 (intracellular reduced PRDX-2 monomers) was increased in three of four race completers immediately post-race, indicative of an 'antioxidant response'. Moreover, monomeric PRDX-2 was also increased immediately post-race in two of four race-completing subjects, indicative of oxidative damage, which was not detectable by Day 7. Lymphocyte PRDX-2 was decreased below normal levels 7 days after ultra-endurance exercise. Excessive accumulation of reactive oxygen species induced by ultra-endurance exercise may underlie depletion of lymphocyte PRDX-2 by triggering its turnover after oxidation. Low levels of lymphocyte PRDX-2 could influence cell function and might, in part, explain reports of dysregulated immunity following ultra-endurance exercise.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "5972815d8210470eb84c3da30f0aa090", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[234, 234], [6, 6]], "char_spans": [[1127, 1137], [31, 41]]}]}], "context_tokens": [["Peroxiredoxin-2", 0], ["(", 16], ["PRDX-2", 17], [")", 23], ["is", 25], ["an", 28], ["antioxidant", 31], ["and", 43], ["chaperone", 47], ["-", 56], ["like", 57], ["protein", 62], ["critical", 70], ["for", 79], ["cell", 83], ["function", 88], [".", 96], ["This", 98], ["study", 103], ["examined", 109], ["whether", 118], ["the", 126], ["levels", 130], ["of", 137], ["lymphocyte", 140], ["PRDX-2", 151], ["are", 158], ["altered", 162], ["over", 170], ["1", 175], ["month", 177], ["following", 183], ["ultra", 193], ["-", 198], ["endurance", 199], ["exercise", 209], [".", 217], ["Nine", 219], ["middle", 224], ["-", 230], ["aged", 231], ["men", 236], ["undertook", 240], ["a", 250], ["single", 252], ["-", 258], ["stage", 259], [",", 264], ["multi", 266], ["-", 271], ["day", 272], ["233", 276], ["km", 280], ["(", 283], ["145", 284], ["mile", 288], [")", 292], ["ultra", 294], ["-", 299], ["endurance", 300], ["running", 310], ["race", 318], [".", 322], ["Blood", 324], ["was", 330], ["collected", 334], ["immediately", 344], ["before", 356], ["(", 363], ["Pre", 364], [")", 367], [",", 368], ["upon", 370], ["completion", 375], ["/", 385], ["retirement", 386], ["(", 397], ["Post", 398], [")", 402], [",", 403], ["and", 405], ["following", 409], ["the", 419], ["race", 423], ["at", 428], ["Day", 431], ["1", 435], [",", 436], ["Day", 438], ["7", 442], ["and", 444], ["Day", 448], ["28", 452], [".", 454], ["Lymphocyte", 456], ["lysates", 467], ["were", 475], ["examined", 480], ["for", 489], ["PRDX-2", 493], ["by", 500], ["reducing", 503], ["and", 512], ["non", 516], ["-", 519], ["reducing", 520], ["SDS", 529], ["-", 532], ["PAGE", 533], ["with", 538], ["western", 543], ["blotting", 551], [".", 559], ["In", 561], ["a", 564], ["sub", 566], ["-", 569], ["group", 570], ["of", 576], ["men", 579], ["who", 583], ["completed", 587], ["the", 597], ["race", 601], ["(", 606], ["n", 607], ["=", 609], ["4", 611], [")", 612], [",", 613], ["PRDX-2", 615], ["oligomeric", 622], ["state", 633], ["(", 639], ["indicative", 640], ["of", 651], ["redox", 654], ["status", 660], [")", 666], ["was", 668], ["investigated", 672], [".", 684], ["Ultra", 686], ["-", 691], ["endurance", 692], ["exercise", 702], ["caused", 711], ["significant", 718], ["changes", 730], ["in", 738], ["lymphocyte", 741], ["PRDX-2", 752], ["(", 759], ["F(4,32", 760], [")", 766], ["3.409", 768], [",", 773], ["p", 775], ["=", 777], ["0.020", 779], [",", 784], ["\u03b7(2", 786], [")", 789], ["=", 791], ["0.299", 793], [")", 798], [":", 799], ["7", 801], ["days", 803], ["after", 808], ["the", 814], ["race", 818], [",", 822], ["PRDX-2", 824], ["levels", 831], ["in", 838], ["lymphocytes", 841], ["had", 853], ["fallen", 857], ["to", 864], ["30", 867], ["%", 869], ["of", 871], ["pre", 874], ["-", 877], ["race", 878], ["values", 883], ["(", 890], ["p", 891], ["=", 893], ["0.013", 895], [")", 900], ["and", 902], ["returned", 906], ["to", 915], ["near", 918], ["-", 922], ["normal", 923], ["levels", 930], ["at", 937], ["Day", 940], ["28", 944], [".", 946], ["Non", 948], ["-", 951], ["reducing", 952], ["gels", 961], ["demonstrated", 966], ["that", 979], ["dimeric", 984], ["PRDX-2", 992], ["(", 999], ["intracellular", 1000], ["reduced", 1014], ["PRDX-2", 1022], ["monomers", 1029], [")", 1037], ["was", 1039], ["increased", 1043], ["in", 1053], ["three", 1056], ["of", 1062], ["four", 1065], ["race", 1070], ["completers", 1075], ["immediately", 1086], ["post", 1098], ["-", 1102], ["race", 1103], [",", 1107], ["indicative", 1109], ["of", 1120], ["an", 1123], ["'", 1126], ["antioxidant", 1127], ["response", 1139], ["'", 1147], [".", 1148], ["Moreover", 1150], [",", 1158], ["monomeric", 1160], ["PRDX-2", 1170], ["was", 1177], ["also", 1181], ["increased", 1186], ["immediately", 1196], ["post", 1208], ["-", 1212], ["race", 1213], ["in", 1218], ["two", 1221], ["of", 1225], ["four", 1228], ["race", 1233], ["-", 1237], ["completing", 1238], ["subjects", 1249], [",", 1257], ["indicative", 1259], ["of", 1270], ["oxidative", 1273], ["damage", 1283], [",", 1289], ["which", 1291], ["was", 1297], ["not", 1301], ["detectable", 1305], ["by", 1316], ["Day", 1319], ["7", 1323], [".", 1324], ["Lymphocyte", 1326], ["PRDX-2", 1337], ["was", 1344], ["decreased", 1348], ["below", 1358], ["normal", 1364], ["levels", 1371], ["7", 1378], ["days", 1380], ["after", 1385], ["ultra", 1391], ["-", 1396], ["endurance", 1397], ["exercise", 1407], [".", 1415], ["Excessive", 1417], ["accumulation", 1427], ["of", 1440], ["reactive", 1443], ["oxygen", 1452], ["species", 1459], ["induced", 1467], ["by", 1475], ["ultra", 1478], ["-", 1483], ["endurance", 1484], ["exercise", 1494], ["may", 1503], ["underlie", 1507], ["depletion", 1516], ["of", 1526], ["lymphocyte", 1529], ["PRDX-2", 1540], ["by", 1547], ["triggering", 1550], ["its", 1561], ["turnover", 1565], ["after", 1574], ["oxidation", 1580], [".", 1589], ["Low", 1591], ["levels", 1595], ["of", 1602], ["lymphocyte", 1605], ["PRDX-2", 1616], ["could", 1623], ["influence", 1629], ["cell", 1639], ["function", 1644], ["and", 1653], ["might", 1657], [",", 1662], ["in", 1664], ["part", 1667], [",", 1671], ["explain", 1673], ["reports", 1681], ["of", 1689], ["dysregulated", 1692], ["immunity", 1705], ["following", 1714], ["ultra", 1724], ["-", 1729], ["endurance", 1730], ["exercise", 1740], [".", 1748]]}
{"context": "Nucleotide excision repair (NER) is a multistep process capable to remove a variety of DNA distorting lesions from prokaryotic and eukaryotic genomes. In eukaryotic cells, the process requires more than 30 proteins to perform the different steps, i.e. recognition of DNA damage, single strand incisions and excision of the lesion-containing DNA fragment and DNA repair synthesis/ligation. NER can operate via two subpathways: global genome repair (GGR) and a specialized pathway coupled to active transcription (transcription-coupled repair, TCR) and directed to DNA lesions in the transcribed strand of active genes. Both in vivo as well as in cultured cells the fast removal of transcription blocking lesions by TCR is crucial to escape from lethal effects of inhibited transcription inhibition The most delicate step in NER is the recognition of the DNA lesions in their different chromatin context and the mechanism of damage recognition in GGR and TCR is principally different and requires specific proteins. In GGR, the XPC-HR23B is essential for the formation of the incision complex. In TCR the Cockayne syndrome (CS) gene products are key players in the recognition of a stalled RNA polymerase the presumed signaling structure for repair of transcribed strands. In this study, we show that the extent of recovery of UV-inhibited transcription and TCR strictly depends on the amount of CSB protein as well as the amount of DNA damage present in the cell. This indicates that the ratio between DNA damage frequency and CSB protein concentration in the cell is rather critical for acute cellular response, i.e. recovery of inhibited transcription upon DNA damage infliction, and hence cellular survival.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "dfc374abfd1246c8bd30686662c51d05", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[103, 104]], "char_spans": [[582, 599]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], ["is", 33], ["a", 36], ["multistep", 38], ["process", 48], ["capable", 56], ["to", 64], ["remove", 67], ["a", 74], ["variety", 76], ["of", 84], ["DNA", 87], ["distorting", 91], ["lesions", 102], ["from", 110], ["prokaryotic", 115], ["and", 127], ["eukaryotic", 131], ["genomes", 142], [".", 149], ["In", 151], ["eukaryotic", 154], ["cells", 165], [",", 170], ["the", 172], ["process", 176], ["requires", 184], ["more", 193], ["than", 198], ["30", 203], ["proteins", 206], ["to", 215], ["perform", 218], ["the", 226], ["different", 230], ["steps", 240], [",", 245], ["i.e.", 247], ["recognition", 252], ["of", 264], ["DNA", 267], ["damage", 271], [",", 277], ["single", 279], ["strand", 286], ["incisions", 293], ["and", 303], ["excision", 307], ["of", 316], ["the", 319], ["lesion", 323], ["-", 329], ["containing", 330], ["DNA", 341], ["fragment", 345], ["and", 354], ["DNA", 358], ["repair", 362], ["synthesis", 369], ["/", 378], ["ligation", 379], [".", 387], ["NER", 389], ["can", 393], ["operate", 397], ["via", 405], ["two", 409], ["subpathways", 413], [":", 424], ["global", 426], ["genome", 433], ["repair", 440], ["(", 447], ["GGR", 448], [")", 451], ["and", 453], ["a", 457], ["specialized", 459], ["pathway", 471], ["coupled", 479], ["to", 487], ["active", 490], ["transcription", 497], ["(", 511], ["transcription", 512], ["-", 525], ["coupled", 526], ["repair", 534], [",", 540], ["TCR", 542], [")", 545], ["and", 547], ["directed", 551], ["to", 560], ["DNA", 563], ["lesions", 567], ["in", 575], ["the", 578], ["transcribed", 582], ["strand", 594], ["of", 601], ["active", 604], ["genes", 611], [".", 616], ["Both", 618], ["in", 623], ["vivo", 626], ["as", 631], ["well", 634], ["as", 639], ["in", 642], ["cultured", 645], ["cells", 654], ["the", 660], ["fast", 664], ["removal", 669], ["of", 677], ["transcription", 680], ["blocking", 694], ["lesions", 703], ["by", 711], ["TCR", 714], ["is", 718], ["crucial", 721], ["to", 729], ["escape", 732], ["from", 739], ["lethal", 744], ["effects", 751], ["of", 759], ["inhibited", 762], ["transcription", 772], ["inhibition", 786], ["The", 797], ["most", 801], ["delicate", 806], ["step", 815], ["in", 820], ["NER", 823], ["is", 827], ["the", 830], ["recognition", 834], ["of", 846], ["the", 849], ["DNA", 853], ["lesions", 857], ["in", 865], ["their", 868], ["different", 874], ["chromatin", 884], ["context", 894], ["and", 902], ["the", 906], ["mechanism", 910], ["of", 920], ["damage", 923], ["recognition", 930], ["in", 942], ["GGR", 945], ["and", 949], ["TCR", 953], ["is", 957], ["principally", 960], ["different", 972], ["and", 982], ["requires", 986], ["specific", 995], ["proteins", 1004], [".", 1012], ["In", 1014], ["GGR", 1017], [",", 1020], ["the", 1022], ["XPC", 1026], ["-", 1029], ["HR23B", 1030], ["is", 1036], ["essential", 1039], ["for", 1049], ["the", 1053], ["formation", 1057], ["of", 1067], ["the", 1070], ["incision", 1074], ["complex", 1083], [".", 1090], ["In", 1092], ["TCR", 1095], ["the", 1099], ["Cockayne", 1103], ["syndrome", 1112], ["(", 1121], ["CS", 1122], [")", 1124], ["gene", 1126], ["products", 1131], ["are", 1140], ["key", 1144], ["players", 1148], ["in", 1156], ["the", 1159], ["recognition", 1163], ["of", 1175], ["a", 1178], ["stalled", 1180], ["RNA", 1188], ["polymerase", 1192], ["the", 1203], ["presumed", 1207], ["signaling", 1216], ["structure", 1226], ["for", 1236], ["repair", 1240], ["of", 1247], ["transcribed", 1250], ["strands", 1262], [".", 1269], ["In", 1271], ["this", 1274], ["study", 1279], [",", 1284], ["we", 1286], ["show", 1289], ["that", 1294], ["the", 1299], ["extent", 1303], ["of", 1310], ["recovery", 1313], ["of", 1322], ["UV", 1325], ["-", 1327], ["inhibited", 1328], ["transcription", 1338], ["and", 1352], ["TCR", 1356], ["strictly", 1360], ["depends", 1369], ["on", 1377], ["the", 1380], ["amount", 1384], ["of", 1391], ["CSB", 1394], ["protein", 1398], ["as", 1406], ["well", 1409], ["as", 1414], ["the", 1417], ["amount", 1421], ["of", 1428], ["DNA", 1431], ["damage", 1435], ["present", 1442], ["in", 1450], ["the", 1453], ["cell", 1457], [".", 1461], ["This", 1463], ["indicates", 1468], ["that", 1478], ["the", 1483], ["ratio", 1487], ["between", 1493], ["DNA", 1501], ["damage", 1505], ["frequency", 1512], ["and", 1522], ["CSB", 1526], ["protein", 1530], ["concentration", 1538], ["in", 1552], ["the", 1555], ["cell", 1559], ["is", 1564], ["rather", 1567], ["critical", 1574], ["for", 1583], ["acute", 1587], ["cellular", 1593], ["response", 1602], [",", 1610], ["i.e.", 1612], ["recovery", 1617], ["of", 1626], ["inhibited", 1629], ["transcription", 1639], ["upon", 1653], ["DNA", 1658], ["damage", 1662], ["infliction", 1669], [",", 1679], ["and", 1681], ["hence", 1685], ["cellular", 1691], ["survival", 1700], [".", 1708]]}
{"context": "Inherited ventricular arrhythmias such as the long QT syndrome (LQTS), Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), idiopathic ventricular fibrillation (VF), and arrhythmogenic right ventricular cardiomyopathy (ARVC) account for a relevant proportion of sudden cardiac death cases in young patients cohorts. The detailed pathogenetic mechanisms of inherited ventricular arrhythmias are still poorly understood because systematic investigations are difficult to perform due to low patient numbers and the lack of appropriate experimental models. However, recent advances in research and science have identified a genetic background for many of these diseases. In LQTS, various mutations in different genes encoding for cardiac potassium and sodium channel proteins have been identified (\"channelopathy\"), and initial progress in genotype-phenotype correlation is made. Mutations in the cardiac sodium channel gene have also been identified in a subset of patients with Brugada syndrome, whereas a genetic background has not yet been demonstrated in idiopathic VF and right ventricular outflow-tract tachycardia (RVO-VT). Very recently, mutations in the cardiac ryanodine receptor gene have been identified in CPVT and in a subgroup of patients with ARVC. Although several chromosomal loci were suggested, no other responsible genes or mutations have been found in autosomal dominant forms of ARVC. However, in Naxos disease, a recessive form of ARVC with coexpression of palmoplantar keratoderma and woolly hair, a mutation in the plakoglobin gene has recently been discovered, thus underscoring the potential role of genetic alterations in cytoskeletal proteins in ARVC. In the next years, significant progress in the genetic diagnosis pathophysiologic understanding of disease mechanisms, genotype-phenotype correlation, and the development of gene- or target-directed treatment strategies can be expected in the field of inherited ventricular arrhythmias. This review summarizes the current knowledge of the molecular mechanisms, including aspects of pathoanatomy, autonomic innervation, genetics, and genotype-phenotype correlations with their potential implications for diagnosis and treatment of inherited ventricular arrhythmias.", "qas": [{"question": "Which gene is mutated in a subtype of arrhythmogenic right ventricular cardiomyopathy known as Naxos disease?", "answers": ["The Plakoglobin gene", "plakoglobin[jup]"], "qid": "82cb45ef0dce4731bfd7549461b332ab", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["mutated", 14], ["in", 22], ["a", 25], ["subtype", 27], ["of", 35], ["arrhythmogenic", 38], ["right", 53], ["ventricular", 59], ["cardiomyopathy", 71], ["known", 86], ["as", 92], ["Naxos", 95], ["disease", 101], ["?", 108]], "detected_answers": [{"text": "The Plakoglobin gene", "token_spans": [[257, 258]], "char_spans": [[1565, 1580]]}]}], "context_tokens": [["Inherited", 0], ["ventricular", 10], ["arrhythmias", 22], ["such", 34], ["as", 39], ["the", 42], ["long", 46], ["QT", 51], ["syndrome", 54], ["(", 63], ["LQTS", 64], [")", 68], [",", 69], ["Brugada", 71], ["syndrome", 79], [",", 87], ["catecholaminergic", 89], ["polymorphic", 107], ["ventricular", 119], ["tachycardia", 131], ["(", 143], ["CPVT", 144], [")", 148], [",", 149], ["idiopathic", 151], ["ventricular", 162], ["fibrillation", 174], ["(", 187], ["VF", 188], [")", 190], [",", 191], ["and", 193], ["arrhythmogenic", 197], ["right", 212], ["ventricular", 218], ["cardiomyopathy", 230], ["(", 245], ["ARVC", 246], [")", 250], ["account", 252], ["for", 260], ["a", 264], ["relevant", 266], ["proportion", 275], ["of", 286], ["sudden", 289], ["cardiac", 296], ["death", 304], ["cases", 310], ["in", 316], ["young", 319], ["patients", 325], ["cohorts", 334], [".", 341], ["The", 343], ["detailed", 347], ["pathogenetic", 356], ["mechanisms", 369], ["of", 380], ["inherited", 383], ["ventricular", 393], ["arrhythmias", 405], ["are", 417], ["still", 421], ["poorly", 427], ["understood", 434], ["because", 445], ["systematic", 453], ["investigations", 464], ["are", 479], ["difficult", 483], ["to", 493], ["perform", 496], ["due", 504], ["to", 508], ["low", 511], ["patient", 515], ["numbers", 523], ["and", 531], ["the", 535], ["lack", 539], ["of", 544], ["appropriate", 547], ["experimental", 559], ["models", 572], [".", 578], ["However", 580], [",", 587], ["recent", 589], ["advances", 596], ["in", 605], ["research", 608], ["and", 617], ["science", 621], ["have", 629], ["identified", 634], ["a", 645], ["genetic", 647], ["background", 655], ["for", 666], ["many", 670], ["of", 675], ["these", 678], ["diseases", 684], [".", 692], ["In", 694], ["LQTS", 697], [",", 701], ["various", 703], ["mutations", 711], ["in", 721], ["different", 724], ["genes", 734], ["encoding", 740], ["for", 749], ["cardiac", 753], ["potassium", 761], ["and", 771], ["sodium", 775], ["channel", 782], ["proteins", 790], ["have", 799], ["been", 804], ["identified", 809], ["(", 820], ["\"", 821], ["channelopathy", 822], ["\"", 835], [")", 836], [",", 837], ["and", 839], ["initial", 843], ["progress", 851], ["in", 860], ["genotype", 863], ["-", 871], ["phenotype", 872], ["correlation", 882], ["is", 894], ["made", 897], [".", 901], ["Mutations", 903], ["in", 913], ["the", 916], ["cardiac", 920], ["sodium", 928], ["channel", 935], ["gene", 943], ["have", 948], ["also", 953], ["been", 958], ["identified", 963], ["in", 974], ["a", 977], ["subset", 979], ["of", 986], ["patients", 989], ["with", 998], ["Brugada", 1003], ["syndrome", 1011], [",", 1019], ["whereas", 1021], ["a", 1029], ["genetic", 1031], ["background", 1039], ["has", 1050], ["not", 1054], ["yet", 1058], ["been", 1062], ["demonstrated", 1067], ["in", 1080], ["idiopathic", 1083], ["VF", 1094], ["and", 1097], ["right", 1101], ["ventricular", 1107], ["outflow", 1119], ["-", 1126], ["tract", 1127], ["tachycardia", 1133], ["(", 1145], ["RVO", 1146], ["-", 1149], ["VT", 1150], [")", 1152], [".", 1153], ["Very", 1155], ["recently", 1160], [",", 1168], ["mutations", 1170], ["in", 1180], ["the", 1183], ["cardiac", 1187], ["ryanodine", 1195], ["receptor", 1205], ["gene", 1214], ["have", 1219], ["been", 1224], ["identified", 1229], ["in", 1240], ["CPVT", 1243], ["and", 1248], ["in", 1252], ["a", 1255], ["subgroup", 1257], ["of", 1266], ["patients", 1269], ["with", 1278], ["ARVC", 1283], [".", 1287], ["Although", 1289], ["several", 1298], ["chromosomal", 1306], ["loci", 1318], ["were", 1323], ["suggested", 1328], [",", 1337], ["no", 1339], ["other", 1342], ["responsible", 1348], ["genes", 1360], ["or", 1366], ["mutations", 1369], ["have", 1379], ["been", 1384], ["found", 1389], ["in", 1395], ["autosomal", 1398], ["dominant", 1408], ["forms", 1417], ["of", 1423], ["ARVC", 1426], [".", 1430], ["However", 1432], [",", 1439], ["in", 1441], ["Naxos", 1444], ["disease", 1450], [",", 1457], ["a", 1459], ["recessive", 1461], ["form", 1471], ["of", 1476], ["ARVC", 1479], ["with", 1484], ["coexpression", 1489], ["of", 1502], ["palmoplantar", 1505], ["keratoderma", 1518], ["and", 1530], ["woolly", 1534], ["hair", 1541], [",", 1545], ["a", 1547], ["mutation", 1549], ["in", 1558], ["the", 1561], ["plakoglobin", 1565], ["gene", 1577], ["has", 1582], ["recently", 1586], ["been", 1595], ["discovered", 1600], [",", 1610], ["thus", 1612], ["underscoring", 1617], ["the", 1630], ["potential", 1634], ["role", 1644], ["of", 1649], ["genetic", 1652], ["alterations", 1660], ["in", 1672], ["cytoskeletal", 1675], ["proteins", 1688], ["in", 1697], ["ARVC", 1700], [".", 1704], ["In", 1706], ["the", 1709], ["next", 1713], ["years", 1718], [",", 1723], ["significant", 1725], ["progress", 1737], ["in", 1746], ["the", 1749], ["genetic", 1753], ["diagnosis", 1761], ["pathophysiologic", 1771], ["understanding", 1788], ["of", 1802], ["disease", 1805], ["mechanisms", 1813], [",", 1823], ["genotype", 1825], ["-", 1833], ["phenotype", 1834], ["correlation", 1844], [",", 1855], ["and", 1857], ["the", 1861], ["development", 1865], ["of", 1877], ["gene-", 1880], ["or", 1886], ["target", 1889], ["-", 1895], ["directed", 1896], ["treatment", 1905], ["strategies", 1915], ["can", 1926], ["be", 1930], ["expected", 1933], ["in", 1942], ["the", 1945], ["field", 1949], ["of", 1955], ["inherited", 1958], ["ventricular", 1968], ["arrhythmias", 1980], [".", 1991], ["This", 1993], ["review", 1998], ["summarizes", 2005], ["the", 2016], ["current", 2020], ["knowledge", 2028], ["of", 2038], ["the", 2041], ["molecular", 2045], ["mechanisms", 2055], [",", 2065], ["including", 2067], ["aspects", 2077], ["of", 2085], ["pathoanatomy", 2088], [",", 2100], ["autonomic", 2102], ["innervation", 2112], [",", 2123], ["genetics", 2125], [",", 2133], ["and", 2135], ["genotype", 2139], ["-", 2147], ["phenotype", 2148], ["correlations", 2158], ["with", 2171], ["their", 2176], ["potential", 2182], ["implications", 2192], ["for", 2205], ["diagnosis", 2209], ["and", 2219], ["treatment", 2223], ["of", 2233], ["inherited", 2236], ["ventricular", 2246], ["arrhythmias", 2258], [".", 2269]]}
{"context": "Imatinib mesylate (Glivec) is a selective inhibitor of bcr-abl tyrosine kinase, the product of the Philadelphia chromosome, which is the hallmark of chronic myeloid leukaemia (CML). With imatinib, complete cytogenetic response (CCR) can be achieved in over 70% of newly diagnosed patients with CML. However, the optimal long-term management of patients who achieve CCR after imatinib is unknown. With longer follow-up, it is anticipated that some patients are likely to progress and become candidates for autologous transplantation. We studied filgrastim (r-metHuG-CSF) mobilisation of peripheral blood stem cells (PBSC) in 32 patients who have achieved CCR with imatinib. Our data demonstrate that (1) the target CD34(+) cell yields of >/=2.0 x 10(6)/kg were attained with filgrastim 10 microg/kg/day, in 9/18 (50%) of patients during uninterrupted imatinib therapy, and in 10/14 (70%) when imatinib was temporarily withheld. The median CD34(+) cell yield per aphaeresis was 0.70 x 10(6)/kg (range 0.14-2.18) and 2.90 x 10(6)/kg (range 0.15-8.71) in the two groups, respectively (P&<0.005). (2) The cell yields did not correlate with the duration of imatinib administration. (3) There was no impact of the mobilisation procedure on the level of leukaemia as measured by serial blood bcr-abl levels using real-time quantitative PCR with either protocol. (4) bcr-abl remained detectable at low levels in the harvests in most but not all patients. In conclusion, filgrastim can safely be used to mobilise PBSC in patients who have achieved CCR with imatinib, but CD34(+) cell yields are significantly improved when imatinib is temporarily withheld.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "5900db93e2d94cedaf489326063c2ede", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[258, 260], [10, 12], [275, 277]], "char_spans": [[1284, 1290], [55, 61], [1358, 1364]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["Glivec", 19], [")", 25], ["is", 27], ["a", 30], ["selective", 32], ["inhibitor", 42], ["of", 52], ["bcr", 55], ["-", 58], ["abl", 59], ["tyrosine", 63], ["kinase", 72], [",", 78], ["the", 80], ["product", 84], ["of", 92], ["the", 95], ["Philadelphia", 99], ["chromosome", 112], [",", 122], ["which", 124], ["is", 130], ["the", 133], ["hallmark", 137], ["of", 146], ["chronic", 149], ["myeloid", 157], ["leukaemia", 165], ["(", 175], ["CML", 176], [")", 179], [".", 180], ["With", 182], ["imatinib", 187], [",", 195], ["complete", 197], ["cytogenetic", 206], ["response", 218], ["(", 227], ["CCR", 228], [")", 231], ["can", 233], ["be", 237], ["achieved", 240], ["in", 249], ["over", 252], ["70", 257], ["%", 259], ["of", 261], ["newly", 264], ["diagnosed", 270], ["patients", 280], ["with", 289], ["CML", 294], [".", 297], ["However", 299], [",", 306], ["the", 308], ["optimal", 312], ["long", 320], ["-", 324], ["term", 325], ["management", 330], ["of", 341], ["patients", 344], ["who", 353], ["achieve", 357], ["CCR", 365], ["after", 369], ["imatinib", 375], ["is", 384], ["unknown", 387], [".", 394], ["With", 396], ["longer", 401], ["follow", 408], ["-", 414], ["up", 415], [",", 417], ["it", 419], ["is", 422], ["anticipated", 425], ["that", 437], ["some", 442], ["patients", 447], ["are", 456], ["likely", 460], ["to", 467], ["progress", 470], ["and", 479], ["become", 483], ["candidates", 490], ["for", 501], ["autologous", 505], ["transplantation", 516], [".", 531], ["We", 533], ["studied", 536], ["filgrastim", 544], ["(", 555], ["r", 556], ["-", 557], ["metHuG", 558], ["-", 564], ["CSF", 565], [")", 568], ["mobilisation", 570], ["of", 583], ["peripheral", 586], ["blood", 597], ["stem", 603], ["cells", 608], ["(", 614], ["PBSC", 615], [")", 619], ["in", 621], ["32", 624], ["patients", 627], ["who", 636], ["have", 640], ["achieved", 645], ["CCR", 654], ["with", 658], ["imatinib", 663], [".", 671], ["Our", 673], ["data", 677], ["demonstrate", 682], ["that", 694], ["(", 699], ["1", 700], [")", 701], ["the", 703], ["target", 707], ["CD34(+", 714], [")", 720], ["cell", 722], ["yields", 727], ["of", 734], [">", 737], ["/=2.0", 738], ["x", 744], ["10(6)/kg", 746], ["were", 755], ["attained", 760], ["with", 769], ["filgrastim", 774], ["10", 785], ["microg", 788], ["/", 794], ["kg", 795], ["/", 797], ["day", 798], [",", 801], ["in", 803], ["9/18", 806], ["(", 811], ["50", 812], ["%", 814], [")", 815], ["of", 817], ["patients", 820], ["during", 829], ["uninterrupted", 836], ["imatinib", 850], ["therapy", 859], [",", 866], ["and", 868], ["in", 872], ["10/14", 875], ["(", 881], ["70", 882], ["%", 884], [")", 885], ["when", 887], ["imatinib", 892], ["was", 901], ["temporarily", 905], ["withheld", 917], [".", 925], ["The", 927], ["median", 931], ["CD34(+", 938], [")", 944], ["cell", 946], ["yield", 951], ["per", 957], ["aphaeresis", 961], ["was", 972], ["0.70", 976], ["x", 981], ["10(6)/kg", 983], ["(", 992], ["range", 993], ["0.14", 999], ["-", 1003], ["2.18", 1004], [")", 1008], ["and", 1010], ["2.90", 1014], ["x", 1019], ["10(6)/kg", 1021], ["(", 1030], ["range", 1031], ["0.15", 1037], ["-", 1041], ["8.71", 1042], [")", 1046], ["in", 1048], ["the", 1051], ["two", 1055], ["groups", 1059], [",", 1065], ["respectively", 1067], ["(", 1080], ["P&<0.005", 1081], [")", 1089], [".", 1090], ["(", 1092], ["2", 1093], [")", 1094], ["The", 1096], ["cell", 1100], ["yields", 1105], ["did", 1112], ["not", 1116], ["correlate", 1120], ["with", 1130], ["the", 1135], ["duration", 1139], ["of", 1148], ["imatinib", 1151], ["administration", 1160], [".", 1174], ["(", 1176], ["3", 1177], [")", 1178], ["There", 1180], ["was", 1186], ["no", 1190], ["impact", 1193], ["of", 1200], ["the", 1203], ["mobilisation", 1207], ["procedure", 1220], ["on", 1230], ["the", 1233], ["level", 1237], ["of", 1243], ["leukaemia", 1246], ["as", 1256], ["measured", 1259], ["by", 1268], ["serial", 1271], ["blood", 1278], ["bcr", 1284], ["-", 1287], ["abl", 1288], ["levels", 1292], ["using", 1299], ["real", 1305], ["-", 1309], ["time", 1310], ["quantitative", 1315], ["PCR", 1328], ["with", 1332], ["either", 1337], ["protocol", 1344], [".", 1352], ["(", 1354], ["4", 1355], [")", 1356], ["bcr", 1358], ["-", 1361], ["abl", 1362], ["remained", 1366], ["detectable", 1375], ["at", 1386], ["low", 1389], ["levels", 1393], ["in", 1400], ["the", 1403], ["harvests", 1407], ["in", 1416], ["most", 1419], ["but", 1424], ["not", 1428], ["all", 1432], ["patients", 1436], [".", 1444], ["In", 1446], ["conclusion", 1449], [",", 1459], ["filgrastim", 1461], ["can", 1472], ["safely", 1476], ["be", 1483], ["used", 1486], ["to", 1491], ["mobilise", 1494], ["PBSC", 1503], ["in", 1508], ["patients", 1511], ["who", 1520], ["have", 1524], ["achieved", 1529], ["CCR", 1538], ["with", 1542], ["imatinib", 1547], [",", 1555], ["but", 1557], ["CD34(+", 1561], [")", 1567], ["cell", 1569], ["yields", 1574], ["are", 1581], ["significantly", 1585], ["improved", 1599], ["when", 1608], ["imatinib", 1613], ["is", 1622], ["temporarily", 1625], ["withheld", 1637], [".", 1645]]}
{"context": "Prostate cancer is the most common cancer in men in Europe and the United             States, and the third leading cause of death from cancer in Europe. Survival of             prostate cancer cells is dependent on the activation of androgen receptors (AR),             that are overexpressed in this tumor. Furthermore, ~90% of prostate cancer patients             that respond to first-line androgen deprivation therapy (ADT) undergo rapid progression.             This condition is defined as castration-resistant prostate cancer (CRPC). Docetaxel-based             regimens significantly improve overall survival (OS) in patients with CRPC and             represent the only treatment strategy approved by the Food and Drug Administration             (FDA). Recently, abiraterone (second hormonal therapy) and cabazitaxel (new taxane)             have been shown to improve survival in patients with CRPC who progressed following             docetaxel-based chemotherapy. Vaccine therapy has also been demonstrated to improve             OS in patients with asymptomatic or minimally symptomatic metastatic CRPC. Additional             therapeutic targets have been analyzed in prostate cancer, including apoptosis,             angiogenic receptors, vitamin D and Src pathways. Several phase II studies are             ongoing. The high frequency of prostate cancer-related metastatic bone disease             has led to consider this pathway as a therapeutic target. To this end, several             bone-targeted agents have been investigated, most notably zoledronic acid, which             is highly effective at stabilizing the bone and preventing skeletal complications.             More recently, a nuclear factor-\u03b2 ligand (RANKL) inhibitor, denosumab, has been             developed for the treatment of bone metastases.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "db3d5700fb404c9d9b22de58652e441b", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[265, 265]], "char_spans": [[1736, 1740]]}]}], "context_tokens": [["Prostate", 0], ["cancer", 9], ["is", 16], ["the", 19], ["most", 23], ["common", 28], ["cancer", 35], ["in", 42], ["men", 45], ["in", 49], ["Europe", 52], ["and", 59], ["the", 63], ["United", 67], ["States", 86], [",", 92], ["and", 94], ["the", 98], ["third", 102], ["leading", 108], ["cause", 116], ["of", 122], ["death", 125], ["from", 131], ["cancer", 136], ["in", 143], ["Europe", 146], [".", 152], ["Survival", 154], ["of", 163], ["prostate", 178], ["cancer", 187], ["cells", 194], ["is", 200], ["dependent", 203], ["on", 213], ["the", 216], ["activation", 220], ["of", 231], ["androgen", 234], ["receptors", 243], ["(", 253], ["AR", 254], [")", 256], [",", 257], ["that", 271], ["are", 276], ["overexpressed", 280], ["in", 294], ["this", 297], ["tumor", 302], [".", 307], ["Furthermore", 309], [",", 320], ["~90", 322], ["%", 325], ["of", 327], ["prostate", 330], ["cancer", 339], ["patients", 346], ["that", 367], ["respond", 372], ["to", 380], ["first", 383], ["-", 388], ["line", 389], ["androgen", 394], ["deprivation", 403], ["therapy", 415], ["(", 423], ["ADT", 424], [")", 427], ["undergo", 429], ["rapid", 437], ["progression", 443], [".", 454], ["This", 468], ["condition", 473], ["is", 483], ["defined", 486], ["as", 494], ["castration", 497], ["-", 507], ["resistant", 508], ["prostate", 518], ["cancer", 527], ["(", 534], ["CRPC", 535], [")", 539], [".", 540], ["Docetaxel", 542], ["-", 551], ["based", 552], ["regimens", 570], ["significantly", 579], ["improve", 593], ["overall", 601], ["survival", 609], ["(", 618], ["OS", 619], [")", 621], ["in", 623], ["patients", 626], ["with", 635], ["CRPC", 640], ["and", 645], ["represent", 661], ["the", 671], ["only", 675], ["treatment", 680], ["strategy", 690], ["approved", 699], ["by", 708], ["the", 711], ["Food", 715], ["and", 720], ["Drug", 724], ["Administration", 729], ["(", 756], ["FDA", 757], [")", 760], [".", 761], ["Recently", 763], [",", 771], ["abiraterone", 773], ["(", 785], ["second", 786], ["hormonal", 793], ["therapy", 802], [")", 809], ["and", 811], ["cabazitaxel", 815], ["(", 827], ["new", 828], ["taxane", 832], [")", 838], ["have", 852], ["been", 857], ["shown", 862], ["to", 868], ["improve", 871], ["survival", 879], ["in", 888], ["patients", 891], ["with", 900], ["CRPC", 905], ["who", 910], ["progressed", 914], ["following", 925], ["docetaxel", 947], ["-", 956], ["based", 957], ["chemotherapy", 963], [".", 975], ["Vaccine", 977], ["therapy", 985], ["has", 993], ["also", 997], ["been", 1002], ["demonstrated", 1007], ["to", 1020], ["improve", 1023], ["OS", 1043], ["in", 1046], ["patients", 1049], ["with", 1058], ["asymptomatic", 1063], ["or", 1076], ["minimally", 1079], ["symptomatic", 1089], ["metastatic", 1101], ["CRPC", 1112], [".", 1116], ["Additional", 1118], ["therapeutic", 1141], ["targets", 1153], ["have", 1161], ["been", 1166], ["analyzed", 1171], ["in", 1180], ["prostate", 1183], ["cancer", 1192], [",", 1198], ["including", 1200], ["apoptosis", 1210], [",", 1219], ["angiogenic", 1233], ["receptors", 1244], [",", 1253], ["vitamin", 1255], ["D", 1263], ["and", 1265], ["Src", 1269], ["pathways", 1273], [".", 1281], ["Several", 1283], ["phase", 1291], ["II", 1297], ["studies", 1300], ["are", 1308], ["ongoing", 1324], [".", 1331], ["The", 1333], ["high", 1337], ["frequency", 1342], ["of", 1352], ["prostate", 1355], ["cancer", 1364], ["-", 1370], ["related", 1371], ["metastatic", 1379], ["bone", 1390], ["disease", 1395], ["has", 1415], ["led", 1419], ["to", 1423], ["consider", 1426], ["this", 1435], ["pathway", 1440], ["as", 1448], ["a", 1451], ["therapeutic", 1453], ["target", 1465], [".", 1471], ["To", 1473], ["this", 1476], ["end", 1481], [",", 1484], ["several", 1486], ["bone", 1506], ["-", 1510], ["targeted", 1511], ["agents", 1520], ["have", 1527], ["been", 1532], ["investigated", 1537], [",", 1549], ["most", 1551], ["notably", 1556], ["zoledronic", 1564], ["acid", 1575], [",", 1579], ["which", 1581], ["is", 1599], ["highly", 1602], ["effective", 1609], ["at", 1619], ["stabilizing", 1622], ["the", 1634], ["bone", 1638], ["and", 1643], ["preventing", 1647], ["skeletal", 1658], ["complications", 1667], [".", 1680], ["More", 1694], ["recently", 1699], [",", 1707], ["a", 1709], ["nuclear", 1711], ["factor", 1719], ["-", 1725], ["\u03b2", 1726], ["ligand", 1728], ["(", 1735], ["RANKL", 1736], [")", 1741], ["inhibitor", 1743], [",", 1752], ["denosumab", 1754], [",", 1763], ["has", 1765], ["been", 1769], ["developed", 1786], ["for", 1796], ["the", 1800], ["treatment", 1804], ["of", 1814], ["bone", 1817], ["metastases", 1822], [".", 1832]]}
{"context": "Mutations in the gene that encodes Fibroblast Growth Factor Receptor 3 (FGFR3) are associated with Achondroplasia (MIM 100800), Hypochondroplasia (MIM 146000), Muenke Syndrome (MIM 602849), Thanatophoric Dysplasia (MIM 187600, MIM 187601) and Lacrimo-Auriculo-Dento-Digital Syndrome (MIM 149730).Here we report a clinical and molecular study in a large cohort of 125 Portuguese patients with these skeletal disorders. The identification of the P250R mutation allowed the confirmation of the Muenke Syndrome in 9 out of the 52 cases referred. Two known mutations were found in the Thanatophoric Dysplasia referred cases. No mutations were identified in the LADD syndrome patient. In Achondroplasia and Hypochondroplasia, genetic heterogeneity was present amongst the 70 clinically diagnosed patients with 5 different mutations identified. As in other studies, complex phenotypic heterogeneity amongst patients carrying the same gene defect was observed. In several cases, the new amino acids encoded, as a consequence of mutations, were related to the severity of patients' phenotype. The presence of 10 misdiagnosed cases emphasizes the importance of performing mutation analysis of the hotspot regions responsible for both dysplasias (Ach and Hch). For patients with an unquestionable clinical diagnosis, lacking the most common mutations, a complete screening of FGFR3 is necessary.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "761f9e814759455eb96445c42ae4b986", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[6, 12]], "char_spans": [[35, 76]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["gene", 17], ["that", 22], ["encodes", 27], ["Fibroblast", 35], ["Growth", 46], ["Factor", 53], ["Receptor", 60], ["3", 69], ["(", 71], ["FGFR3", 72], [")", 77], ["are", 79], ["associated", 83], ["with", 94], ["Achondroplasia", 99], ["(", 114], ["MIM", 115], ["100800", 119], [")", 125], [",", 126], ["Hypochondroplasia", 128], ["(", 146], ["MIM", 147], ["146000", 151], [")", 157], [",", 158], ["Muenke", 160], ["Syndrome", 167], ["(", 176], ["MIM", 177], ["602849", 181], [")", 187], [",", 188], ["Thanatophoric", 190], ["Dysplasia", 204], ["(", 214], ["MIM", 215], ["187600", 219], [",", 225], ["MIM", 227], ["187601", 231], [")", 237], ["and", 239], ["Lacrimo", 243], ["-", 250], ["Auriculo", 251], ["-", 259], ["Dento", 260], ["-", 265], ["Digital", 266], ["Syndrome", 274], ["(", 283], ["MIM", 284], ["149730).Here", 288], ["we", 301], ["report", 304], ["a", 311], ["clinical", 313], ["and", 322], ["molecular", 326], ["study", 336], ["in", 342], ["a", 345], ["large", 347], ["cohort", 353], ["of", 360], ["125", 363], ["Portuguese", 367], ["patients", 378], ["with", 387], ["these", 392], ["skeletal", 398], ["disorders", 407], [".", 416], ["The", 418], ["identification", 422], ["of", 437], ["the", 440], ["P250R", 444], ["mutation", 450], ["allowed", 459], ["the", 467], ["confirmation", 471], ["of", 484], ["the", 487], ["Muenke", 491], ["Syndrome", 498], ["in", 507], ["9", 510], ["out", 512], ["of", 516], ["the", 519], ["52", 523], ["cases", 526], ["referred", 532], [".", 540], ["Two", 542], ["known", 546], ["mutations", 552], ["were", 562], ["found", 567], ["in", 573], ["the", 576], ["Thanatophoric", 580], ["Dysplasia", 594], ["referred", 604], ["cases", 613], [".", 618], ["No", 620], ["mutations", 623], ["were", 633], ["identified", 638], ["in", 649], ["the", 652], ["LADD", 656], ["syndrome", 661], ["patient", 670], [".", 677], ["In", 679], ["Achondroplasia", 682], ["and", 697], ["Hypochondroplasia", 701], [",", 718], ["genetic", 720], ["heterogeneity", 728], ["was", 742], ["present", 746], ["amongst", 754], ["the", 762], ["70", 766], ["clinically", 769], ["diagnosed", 780], ["patients", 790], ["with", 799], ["5", 804], ["different", 806], ["mutations", 816], ["identified", 826], [".", 836], ["As", 838], ["in", 841], ["other", 844], ["studies", 850], [",", 857], ["complex", 859], ["phenotypic", 867], ["heterogeneity", 878], ["amongst", 892], ["patients", 900], ["carrying", 909], ["the", 918], ["same", 922], ["gene", 927], ["defect", 932], ["was", 939], ["observed", 943], [".", 951], ["In", 953], ["several", 956], ["cases", 964], [",", 969], ["the", 971], ["new", 975], ["amino", 979], ["acids", 985], ["encoded", 991], [",", 998], ["as", 1000], ["a", 1003], ["consequence", 1005], ["of", 1017], ["mutations", 1020], [",", 1029], ["were", 1031], ["related", 1036], ["to", 1044], ["the", 1047], ["severity", 1051], ["of", 1060], ["patients", 1063], ["'", 1071], ["phenotype", 1073], [".", 1082], ["The", 1084], ["presence", 1088], ["of", 1097], ["10", 1100], ["misdiagnosed", 1103], ["cases", 1116], ["emphasizes", 1122], ["the", 1133], ["importance", 1137], ["of", 1148], ["performing", 1151], ["mutation", 1162], ["analysis", 1171], ["of", 1180], ["the", 1183], ["hotspot", 1187], ["regions", 1195], ["responsible", 1203], ["for", 1215], ["both", 1219], ["dysplasias", 1224], ["(", 1235], ["Ach", 1236], ["and", 1240], ["Hch", 1244], [")", 1247], [".", 1248], ["For", 1250], ["patients", 1254], ["with", 1263], ["an", 1268], ["unquestionable", 1271], ["clinical", 1286], ["diagnosis", 1295], [",", 1304], ["lacking", 1306], ["the", 1314], ["most", 1318], ["common", 1323], ["mutations", 1330], [",", 1339], ["a", 1341], ["complete", 1343], ["screening", 1352], ["of", 1362], ["FGFR3", 1365], ["is", 1371], ["necessary", 1374], [".", 1383]]}
{"context": "Lack of specific antidotes is a major concern in intracerebral hemorrhage (ICH) related to direct anticoagulants including dabigatran (OAC-ICH). We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab. Pretreatment with DE increased intracerebral hematoma volume and cerebral hemoglobin content. Idarucizumab in equimolar dose prevented excess hematoma expansion for both DE doses. In more extensive ICH, idarucizumab significantly reduced mortality. Thus, idarucizumab prevents excess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "6aac3d7c2f5e40e09f41b4cb9a267ef5", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[121, 121], [19, 19], [49, 49], [38, 38]], "char_spans": [[746, 755], [123, 132], [260, 269], [219, 228]]}]}], "context_tokens": [["Lack", 0], ["of", 5], ["specific", 8], ["antidotes", 17], ["is", 27], ["a", 30], ["major", 32], ["concern", 38], ["in", 46], ["intracerebral", 49], ["hemorrhage", 63], ["(", 74], ["ICH", 75], [")", 78], ["related", 80], ["to", 88], ["direct", 91], ["anticoagulants", 98], ["including", 113], ["dabigatran", 123], ["(", 134], ["OAC", 135], ["-", 138], ["ICH", 139], [")", 142], [".", 143], ["We", 145], ["examined", 148], ["the", 157], ["efficacy", 161], ["of", 170], ["idarucizumab", 173], [",", 185], ["an", 187], ["antibody", 190], ["fragment", 199], ["binding", 208], ["to", 216], ["dabigatran", 219], [",", 229], ["in", 231], ["a", 234], ["mouse", 236], ["model", 242], ["of", 248], ["OAC", 251], ["-", 254], ["ICH", 255], [".", 258], ["Dabigatran", 260], ["etexilate", 271], ["(", 281], ["DE", 282], [")", 284], ["dose", 286], ["-", 290], ["dependently", 291], ["prolonged", 303], ["diluted", 313], ["thrombin", 321], ["time", 330], ["and", 335], ["tail", 339], ["-", 343], ["vein", 344], ["bleeding", 349], ["time", 358], [",", 362], ["which", 364], ["were", 370], ["reversed", 375], ["by", 384], ["idarucizumab", 387], [".", 399], ["Pretreatment", 401], ["with", 414], ["DE", 419], ["increased", 422], ["intracerebral", 432], ["hematoma", 446], ["volume", 455], ["and", 462], ["cerebral", 466], ["hemoglobin", 475], ["content", 486], [".", 493], ["Idarucizumab", 495], ["in", 508], ["equimolar", 511], ["dose", 521], ["prevented", 526], ["excess", 536], ["hematoma", 543], ["expansion", 552], ["for", 562], ["both", 566], ["DE", 571], ["doses", 574], [".", 579], ["In", 581], ["more", 584], ["extensive", 589], ["ICH", 599], [",", 602], ["idarucizumab", 604], ["significantly", 617], ["reduced", 631], ["mortality", 639], [".", 648], ["Thus", 650], [",", 654], ["idarucizumab", 656], ["prevents", 669], ["excess", 678], ["intracerebral", 685], ["hematoma", 699], ["formation", 708], ["in", 718], ["mice", 721], ["anticoagulated", 726], ["with", 741], ["dabigatran", 746], ["and", 757], ["reduces", 761], ["mortality", 769], [".", 778]]}
{"context": "Since reports that precursor cells in the adult subventricular zone (SVZ) contribute to regenerative neuro- and gliogenesis in CA1, we wondered whether a similar route of migration might also exist under physiological conditions. Permanent labeling of SVZ precursor cells with a lentiviral vector for green fluorescent protein did not reveal any migration from the SVZ into CA1 in the intact murine brain. However, in a nestin-GFP reporter mouse we found proliferating cells within the corpus callosum/alveus region expressing nestin and glial fibrillary acidic protein similar to precursor cells in the neighboring neurogenic region of the adult dentate gyrus. Within 3 weeks of BrdU administration, BrdU-positive nestin-GFP-expressing protoplasmic astrocytes emerged in CA1. Similar to precursor cells isolated from the dentate gyrus and the SVZ, nestin-GFP-expressing cells from corpus callosum/alveus were self-renewing and multipotent in vitro, whereas cells isolated from CA1 were not. Nestin-GFP-expressing cells in CA1 differentiated into postmitotic astrocytes characterized by S100beta expression. No new neurons were found in CA1. The number of nestin-GFP-expressing astrocytes in CA1 was increased by environmental enrichment. We conclude that astrogenesis in CA1 is influenced by environmental conditions. However, SVZ precursor cells do not contribute to physiological cellular plasticity in CA1.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "030fff89fcaf4f7a8d31056a6f48f949", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[171, 171], [119, 119], [71, 71], [199, 199], [88, 88], [143, 143]], "char_spans": [[992, 997], [715, 720], [420, 425], [1156, 1161], [527, 532], [849, 854]]}]}], "context_tokens": [["Since", 0], ["reports", 6], ["that", 14], ["precursor", 19], ["cells", 29], ["in", 35], ["the", 38], ["adult", 42], ["subventricular", 48], ["zone", 63], ["(", 68], ["SVZ", 69], [")", 72], ["contribute", 74], ["to", 85], ["regenerative", 88], ["neuro-", 101], ["and", 108], ["gliogenesis", 112], ["in", 124], ["CA1", 127], [",", 130], ["we", 132], ["wondered", 135], ["whether", 144], ["a", 152], ["similar", 154], ["route", 162], ["of", 168], ["migration", 171], ["might", 181], ["also", 187], ["exist", 192], ["under", 198], ["physiological", 204], ["conditions", 218], [".", 228], ["Permanent", 230], ["labeling", 240], ["of", 249], ["SVZ", 252], ["precursor", 256], ["cells", 266], ["with", 272], ["a", 277], ["lentiviral", 279], ["vector", 290], ["for", 297], ["green", 301], ["fluorescent", 307], ["protein", 319], ["did", 327], ["not", 331], ["reveal", 335], ["any", 342], ["migration", 346], ["from", 356], ["the", 361], ["SVZ", 365], ["into", 369], ["CA1", 374], ["in", 378], ["the", 381], ["intact", 385], ["murine", 392], ["brain", 399], [".", 404], ["However", 406], [",", 413], ["in", 415], ["a", 418], ["nestin", 420], ["-", 426], ["GFP", 427], ["reporter", 431], ["mouse", 440], ["we", 446], ["found", 449], ["proliferating", 455], ["cells", 469], ["within", 475], ["the", 482], ["corpus", 486], ["callosum", 493], ["/", 501], ["alveus", 502], ["region", 509], ["expressing", 516], ["nestin", 527], ["and", 534], ["glial", 538], ["fibrillary", 544], ["acidic", 555], ["protein", 562], ["similar", 570], ["to", 578], ["precursor", 581], ["cells", 591], ["in", 597], ["the", 600], ["neighboring", 604], ["neurogenic", 616], ["region", 627], ["of", 634], ["the", 637], ["adult", 641], ["dentate", 647], ["gyrus", 655], [".", 660], ["Within", 662], ["3", 669], ["weeks", 671], ["of", 677], ["BrdU", 680], ["administration", 685], [",", 699], ["BrdU", 701], ["-", 705], ["positive", 706], ["nestin", 715], ["-", 721], ["GFP", 722], ["-", 725], ["expressing", 726], ["protoplasmic", 737], ["astrocytes", 750], ["emerged", 761], ["in", 769], ["CA1", 772], [".", 775], ["Similar", 777], ["to", 785], ["precursor", 788], ["cells", 798], ["isolated", 804], ["from", 813], ["the", 818], ["dentate", 822], ["gyrus", 830], ["and", 836], ["the", 840], ["SVZ", 844], [",", 847], ["nestin", 849], ["-", 855], ["GFP", 856], ["-", 859], ["expressing", 860], ["cells", 871], ["from", 877], ["corpus", 882], ["callosum", 889], ["/", 897], ["alveus", 898], ["were", 905], ["self", 910], ["-", 914], ["renewing", 915], ["and", 924], ["multipotent", 928], ["in", 940], ["vitro", 943], [",", 948], ["whereas", 950], ["cells", 958], ["isolated", 964], ["from", 973], ["CA1", 978], ["were", 982], ["not", 987], [".", 990], ["Nestin", 992], ["-", 998], ["GFP", 999], ["-", 1002], ["expressing", 1003], ["cells", 1014], ["in", 1020], ["CA1", 1023], ["differentiated", 1027], ["into", 1042], ["postmitotic", 1047], ["astrocytes", 1059], ["characterized", 1070], ["by", 1084], ["S100beta", 1087], ["expression", 1096], [".", 1106], ["No", 1108], ["new", 1111], ["neurons", 1115], ["were", 1123], ["found", 1128], ["in", 1134], ["CA1", 1137], [".", 1140], ["The", 1142], ["number", 1146], ["of", 1153], ["nestin", 1156], ["-", 1162], ["GFP", 1163], ["-", 1166], ["expressing", 1167], ["astrocytes", 1178], ["in", 1189], ["CA1", 1192], ["was", 1196], ["increased", 1200], ["by", 1210], ["environmental", 1213], ["enrichment", 1227], [".", 1237], ["We", 1239], ["conclude", 1242], ["that", 1251], ["astrogenesis", 1256], ["in", 1269], ["CA1", 1272], ["is", 1276], ["influenced", 1279], ["by", 1290], ["environmental", 1293], ["conditions", 1307], [".", 1317], ["However", 1319], [",", 1326], ["SVZ", 1328], ["precursor", 1332], ["cells", 1342], ["do", 1348], ["not", 1351], ["contribute", 1355], ["to", 1366], ["physiological", 1369], ["cellular", 1383], ["plasticity", 1392], ["in", 1403], ["CA1", 1406], [".", 1409]]}
{"context": "The structurally novel macrolide FK506 (refs 1,2) has recently been demonstrated to have potent immunosuppressive activity at concentrations several hundredfold lower than cyclosporin A (CsA). Cyclosporin A, a cyclic peptide, has found widespread clinical use in the prevention of graft rejection following bone marrow and organ transplantation. The mechanisms of immunosuppression mediated by FK506 and CsA appear to be remarkably similar, suggesting that these unrelated structures act on a common receptor or on similar molecular targets, perhaps the CsA receptor, cyclophilin, which has recently been shown by Fischer et al. and Takahashi et al. to have cis-trans peptidyl-prolyl isomerase activity. We have prepared an FK506 affinity matrix and purified a binding protein for FK506 from bovine thymus and from human spleen. This FK506-binding protein (FKBP) has a relative molecular mass (Mr) of approximately 14,000(14K), a pI of 8.8-8.9, and does not cross-react with antisera against cyclophilin. The first 40 N-terminal residues of the bovine and 16 residues of the human FKBP were determined; the 16-residue fragments are identical to each other and unrelated to any known sequences. This protein catalyses the cis-trans isomerization of the proline amide in a tetrapeptide substrate and FK506 inhibits the action of this new isomerase. The FKBP and cyclophilin appear to be members of an emerging class of novel proteins that regulate T cell activation and other metabolic processes, perhaps by the recognition (and possibly the isomerization) of proline-containing epitopes in target proteins.", "qas": [{"question": "Which is the receptor for the immunosuppressive drug cyclosporin A (CsA)?", "answers": ["cyclophilin"], "qid": "90bdfabdb48f4ced82219e53d43212a0", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["the", 26], ["immunosuppressive", 30], ["drug", 48], ["cyclosporin", 53], ["A", 65], ["(", 67], ["CsA", 68], [")", 71], ["?", 72]], "detected_answers": [{"text": "cyclophilin", "token_spans": [[91, 91], [243, 243], [177, 177]], "char_spans": [[568, 578], [1360, 1370], [992, 1002]]}]}], "context_tokens": [["The", 0], ["structurally", 4], ["novel", 17], ["macrolide", 23], ["FK506", 33], ["(", 39], ["refs", 40], ["1,2", 45], [")", 48], ["has", 50], ["recently", 54], ["been", 63], ["demonstrated", 68], ["to", 81], ["have", 84], ["potent", 89], ["immunosuppressive", 96], ["activity", 114], ["at", 123], ["concentrations", 126], ["several", 141], ["hundredfold", 149], ["lower", 161], ["than", 167], ["cyclosporin", 172], ["A", 184], ["(", 186], ["CsA", 187], [")", 190], [".", 191], ["Cyclosporin", 193], ["A", 205], [",", 206], ["a", 208], ["cyclic", 210], ["peptide", 217], [",", 224], ["has", 226], ["found", 230], ["widespread", 236], ["clinical", 247], ["use", 256], ["in", 260], ["the", 263], ["prevention", 267], ["of", 278], ["graft", 281], ["rejection", 287], ["following", 297], ["bone", 307], ["marrow", 312], ["and", 319], ["organ", 323], ["transplantation", 329], [".", 344], ["The", 346], ["mechanisms", 350], ["of", 361], ["immunosuppression", 364], ["mediated", 382], ["by", 391], ["FK506", 394], ["and", 400], ["CsA", 404], ["appear", 408], ["to", 415], ["be", 418], ["remarkably", 421], ["similar", 432], [",", 439], ["suggesting", 441], ["that", 452], ["these", 457], ["unrelated", 463], ["structures", 473], ["act", 484], ["on", 488], ["a", 491], ["common", 493], ["receptor", 500], ["or", 509], ["on", 512], ["similar", 515], ["molecular", 523], ["targets", 533], [",", 540], ["perhaps", 542], ["the", 550], ["CsA", 554], ["receptor", 558], [",", 566], ["cyclophilin", 568], [",", 579], ["which", 581], ["has", 587], ["recently", 591], ["been", 600], ["shown", 605], ["by", 611], ["Fischer", 614], ["et", 622], ["al", 625], [".", 627], ["and", 629], ["Takahashi", 633], ["et", 643], ["al", 646], [".", 648], ["to", 650], ["have", 653], ["cis", 658], ["-", 661], ["trans", 662], ["peptidyl", 668], ["-", 676], ["prolyl", 677], ["isomerase", 684], ["activity", 694], [".", 702], ["We", 704], ["have", 707], ["prepared", 712], ["an", 721], ["FK506", 724], ["affinity", 730], ["matrix", 739], ["and", 746], ["purified", 750], ["a", 759], ["binding", 761], ["protein", 769], ["for", 777], ["FK506", 781], ["from", 787], ["bovine", 792], ["thymus", 799], ["and", 806], ["from", 810], ["human", 815], ["spleen", 821], [".", 827], ["This", 829], ["FK506-binding", 834], ["protein", 848], ["(", 856], ["FKBP", 857], [")", 861], ["has", 863], ["a", 867], ["relative", 869], ["molecular", 878], ["mass", 888], ["(", 893], ["Mr", 894], [")", 896], ["of", 898], ["approximately", 901], ["14,000(14", 915], ["K", 924], [")", 925], [",", 926], ["a", 928], ["pI", 930], ["of", 933], ["8.8", 936], ["-", 939], ["8.9", 940], [",", 943], ["and", 945], ["does", 949], ["not", 954], ["cross", 958], ["-", 963], ["react", 964], ["with", 970], ["antisera", 975], ["against", 984], ["cyclophilin", 992], [".", 1003], ["The", 1005], ["first", 1009], ["40", 1015], ["N", 1018], ["-", 1019], ["terminal", 1020], ["residues", 1029], ["of", 1038], ["the", 1041], ["bovine", 1045], ["and", 1052], ["16", 1056], ["residues", 1059], ["of", 1068], ["the", 1071], ["human", 1075], ["FKBP", 1081], ["were", 1086], ["determined", 1091], [";", 1101], ["the", 1103], ["16-residue", 1107], ["fragments", 1118], ["are", 1128], ["identical", 1132], ["to", 1142], ["each", 1145], ["other", 1150], ["and", 1156], ["unrelated", 1160], ["to", 1170], ["any", 1173], ["known", 1177], ["sequences", 1183], [".", 1192], ["This", 1194], ["protein", 1199], ["catalyses", 1207], ["the", 1217], ["cis", 1221], ["-", 1224], ["trans", 1225], ["isomerization", 1231], ["of", 1245], ["the", 1248], ["proline", 1252], ["amide", 1260], ["in", 1266], ["a", 1269], ["tetrapeptide", 1271], ["substrate", 1284], ["and", 1294], ["FK506", 1298], ["inhibits", 1304], ["the", 1313], ["action", 1317], ["of", 1324], ["this", 1327], ["new", 1332], ["isomerase", 1336], [".", 1345], ["The", 1347], ["FKBP", 1351], ["and", 1356], ["cyclophilin", 1360], ["appear", 1372], ["to", 1379], ["be", 1382], ["members", 1385], ["of", 1393], ["an", 1396], ["emerging", 1399], ["class", 1408], ["of", 1414], ["novel", 1417], ["proteins", 1423], ["that", 1432], ["regulate", 1437], ["T", 1446], ["cell", 1448], ["activation", 1453], ["and", 1464], ["other", 1468], ["metabolic", 1474], ["processes", 1484], [",", 1493], ["perhaps", 1495], ["by", 1503], ["the", 1506], ["recognition", 1510], ["(", 1522], ["and", 1523], ["possibly", 1527], ["the", 1536], ["isomerization", 1540], [")", 1553], ["of", 1555], ["proline", 1558], ["-", 1565], ["containing", 1566], ["epitopes", 1577], ["in", 1586], ["target", 1589], ["proteins", 1596], [".", 1604]]}
{"context": "Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium. But there is no consensus as to what constitutes an alpha-proteobacterial gene. Is it a gene found in all or several alpha-proteobacteria, or in only one? Here, we examine the proportion of alpha-proteobacterial genes in alpha-proteobacterial genomes by means of sequence comparisons. We find that each alpha-proteobacterium harbours a particular collection of genes and that, depending upon the lineage examined, between 97 and 33% are alpha-proteobacterial by the nearest-neighbour criterion. Our findings bear upon attempts to reconstruct the mitochondrial ancestor and upon inferences concerning the collection of genes that the mitochondrial ancestor possessed at the time that it became an endosymbiont.", "qas": [{"question": "Which species of bacteria did the mitochondria originate from?", "answers": ["Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium."], "qid": "1bcd341d9896445e8554027ad01ed066", "question_tokens": [["Which", 0], ["species", 6], ["of", 14], ["bacteria", 17], ["did", 26], ["the", 30], ["mitochondria", 34], ["originate", 47], ["from", 57], ["?", 61]], "detected_answers": [{"text": "Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium.", "token_spans": [[0, 11]], "char_spans": [[0, 78]]}]}], "context_tokens": [["Biologists", 0], ["agree", 11], ["that", 17], ["the", 22], ["ancestor", 26], ["of", 35], ["mitochondria", 38], ["was", 51], ["an", 55], ["alpha", 58], ["-", 63], ["proteobacterium", 64], [".", 79], ["But", 81], ["there", 85], ["is", 91], ["no", 94], ["consensus", 97], ["as", 107], ["to", 110], ["what", 113], ["constitutes", 118], ["an", 130], ["alpha", 133], ["-", 138], ["proteobacterial", 139], ["gene", 155], [".", 159], ["Is", 161], ["it", 164], ["a", 167], ["gene", 169], ["found", 174], ["in", 180], ["all", 183], ["or", 187], ["several", 190], ["alpha", 198], ["-", 203], ["proteobacteria", 204], [",", 218], ["or", 220], ["in", 223], ["only", 226], ["one", 231], ["?", 234], ["Here", 236], [",", 240], ["we", 242], ["examine", 245], ["the", 253], ["proportion", 257], ["of", 268], ["alpha", 271], ["-", 276], ["proteobacterial", 277], ["genes", 293], ["in", 299], ["alpha", 302], ["-", 307], ["proteobacterial", 308], ["genomes", 324], ["by", 332], ["means", 335], ["of", 341], ["sequence", 344], ["comparisons", 353], [".", 364], ["We", 366], ["find", 369], ["that", 374], ["each", 379], ["alpha", 384], ["-", 389], ["proteobacterium", 390], ["harbours", 406], ["a", 415], ["particular", 417], ["collection", 428], ["of", 439], ["genes", 442], ["and", 448], ["that", 452], [",", 456], ["depending", 458], ["upon", 468], ["the", 473], ["lineage", 477], ["examined", 485], [",", 493], ["between", 495], ["97", 503], ["and", 506], ["33", 510], ["%", 512], ["are", 514], ["alpha", 518], ["-", 523], ["proteobacterial", 524], ["by", 540], ["the", 543], ["nearest", 547], ["-", 554], ["neighbour", 555], ["criterion", 565], [".", 574], ["Our", 576], ["findings", 580], ["bear", 589], ["upon", 594], ["attempts", 599], ["to", 608], ["reconstruct", 611], ["the", 623], ["mitochondrial", 627], ["ancestor", 641], ["and", 650], ["upon", 654], ["inferences", 659], ["concerning", 670], ["the", 681], ["collection", 685], ["of", 696], ["genes", 699], ["that", 705], ["the", 710], ["mitochondrial", 714], ["ancestor", 728], ["possessed", 737], ["at", 747], ["the", 750], ["time", 754], ["that", 759], ["it", 764], ["became", 767], ["an", 774], ["endosymbiont", 777], [".", 789]]}
{"context": "Histone variant H2A.Z-containing nucleosomes exist at most eukaryotic promoters and play important roles in gene transcription and genome stability. The multisubunit nucleosome-remodeling enzyme complex SWR1, conserved from yeast to mammals, catalyzes the ATP-dependent replacement of histone H2A in canonical nucleosomes with H2A.Z. How SWR1 catalyzes the replacement reaction is largely unknown. Here, we determined the crystal structure of the N-terminal region (599-627) of the catalytic subunit Swr1, termed Swr1-Z domain, in complex with the H2A.Z-H2B dimer at 1.78 \u00c5 resolution. The Swr1-Z domain forms a 310 helix and an irregular chain. A conserved LxxLF motif in the Swr1-Z 310 helix specifically recognizes the \u03b1C helix of H2A.Z. Our results show that the Swr1-Z domain can deliver the H2A.Z-H2B dimer to the DNA-(H3-H4)2 tetrasome to form the nucleosome by a histone chaperone mechanism.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "fd3253087bbd4003b295d765450a9097", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[83, 83], [52, 52], [29, 29]], "char_spans": [[500, 503], [338, 341], [203, 206]]}]}], "context_tokens": [["Histone", 0], ["variant", 8], ["H2A.Z", 16], ["-", 21], ["containing", 22], ["nucleosomes", 33], ["exist", 45], ["at", 51], ["most", 54], ["eukaryotic", 59], ["promoters", 70], ["and", 80], ["play", 84], ["important", 89], ["roles", 99], ["in", 105], ["gene", 108], ["transcription", 113], ["and", 127], ["genome", 131], ["stability", 138], [".", 147], ["The", 149], ["multisubunit", 153], ["nucleosome", 166], ["-", 176], ["remodeling", 177], ["enzyme", 188], ["complex", 195], ["SWR1", 203], [",", 207], ["conserved", 209], ["from", 219], ["yeast", 224], ["to", 230], ["mammals", 233], [",", 240], ["catalyzes", 242], ["the", 252], ["ATP", 256], ["-", 259], ["dependent", 260], ["replacement", 270], ["of", 282], ["histone", 285], ["H2A", 293], ["in", 297], ["canonical", 300], ["nucleosomes", 310], ["with", 322], ["H2A.Z.", 327], ["How", 334], ["SWR1", 338], ["catalyzes", 343], ["the", 353], ["replacement", 357], ["reaction", 369], ["is", 378], ["largely", 381], ["unknown", 389], [".", 396], ["Here", 398], [",", 402], ["we", 404], ["determined", 407], ["the", 418], ["crystal", 422], ["structure", 430], ["of", 440], ["the", 443], ["N", 447], ["-", 448], ["terminal", 449], ["region", 458], ["(", 465], ["599", 466], ["-", 469], ["627", 470], [")", 473], ["of", 475], ["the", 478], ["catalytic", 482], ["subunit", 492], ["Swr1", 500], [",", 504], ["termed", 506], ["Swr1-Z", 513], ["domain", 520], [",", 526], ["in", 528], ["complex", 531], ["with", 539], ["the", 544], ["H2A.Z", 548], ["-", 553], ["H2B", 554], ["dimer", 558], ["at", 564], ["1.78", 567], ["\u00c5", 572], ["resolution", 574], [".", 584], ["The", 586], ["Swr1-Z", 590], ["domain", 597], ["forms", 604], ["a", 610], ["310", 612], ["helix", 616], ["and", 622], ["an", 626], ["irregular", 629], ["chain", 639], [".", 644], ["A", 646], ["conserved", 648], ["LxxLF", 658], ["motif", 664], ["in", 670], ["the", 673], ["Swr1-Z", 677], ["310", 684], ["helix", 688], ["specifically", 694], ["recognizes", 707], ["the", 718], ["\u03b1C", 722], ["helix", 725], ["of", 731], ["H2A.Z.", 734], ["Our", 741], ["results", 745], ["show", 753], ["that", 758], ["the", 763], ["Swr1-Z", 767], ["domain", 774], ["can", 781], ["deliver", 785], ["the", 793], ["H2A.Z", 797], ["-", 802], ["H2B", 803], ["dimer", 807], ["to", 813], ["the", 816], ["DNA-(H3-H4)2", 820], ["tetrasome", 833], ["to", 843], ["form", 846], ["the", 851], ["nucleosome", 855], ["by", 866], ["a", 869], ["histone", 871], ["chaperone", 879], ["mechanism", 889], [".", 898]]}
{"context": "Nusinersen (ISIS-SMNRx or ISIS 396443) is an antisense oligonucleotide drug administered intrathecally to treat spinal muscular atrophy. We summarize lumbar puncture experience in children with spinal muscular atrophy during a phase 1 open-label study of nusinersen and its extension. During the studies, 73 lumbar punctures were performed in 28 patients 2 to 14 years of age with type 2/3 spinal muscular atrophy. No complications occurred in 50 (68%) lumbar punctures; in 23 (32%) procedures, adverse events were attributed to lumbar puncture. Most common adverse events were headache (n = 9), back pain (n = 9), and post-lumbar puncture syndrome (n = 8). In a subgroup analysis, adverse events were more frequent in older children, children with type 3 spinal muscular atrophy, and with a 21- or 22-gauge needle compared to a 24-gauge needle or smaller. Lumbar punctures were successfully performed in children with spinal muscular atrophy; lumbar puncture-related adverse event frequency was similar to that previously reported in children.", "qas": [{"question": "Which disease is treated with Nusinersen?", "answers": ["Spinal Muscular Atrophy", "SMA"], "qid": "01296d63b9d147bc84e380acbd71b4cb", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["treated", 17], ["with", 25], ["Nusinersen", 30], ["?", 40]], "detected_answers": [{"text": "Spinal Muscular Atrophy", "token_spans": [[18, 20], [68, 70], [30, 32], [149, 151], [176, 178]], "char_spans": [[112, 134], [390, 412], [194, 216], [756, 778], [919, 941]]}]}], "context_tokens": [["Nusinersen", 0], ["(", 11], ["ISIS", 12], ["-", 16], ["SMNRx", 17], ["or", 23], ["ISIS", 26], ["396443", 31], [")", 37], ["is", 39], ["an", 42], ["antisense", 45], ["oligonucleotide", 55], ["drug", 71], ["administered", 76], ["intrathecally", 89], ["to", 103], ["treat", 106], ["spinal", 112], ["muscular", 119], ["atrophy", 128], [".", 135], ["We", 137], ["summarize", 140], ["lumbar", 150], ["puncture", 157], ["experience", 166], ["in", 177], ["children", 180], ["with", 189], ["spinal", 194], ["muscular", 201], ["atrophy", 210], ["during", 218], ["a", 225], ["phase", 227], ["1", 233], ["open", 235], ["-", 239], ["label", 240], ["study", 246], ["of", 252], ["nusinersen", 255], ["and", 266], ["its", 270], ["extension", 274], [".", 283], ["During", 285], ["the", 292], ["studies", 296], [",", 303], ["73", 305], ["lumbar", 308], ["punctures", 315], ["were", 325], ["performed", 330], ["in", 340], ["28", 343], ["patients", 346], ["2", 355], ["to", 357], ["14", 360], ["years", 363], ["of", 369], ["age", 372], ["with", 376], ["type", 381], ["2/3", 386], ["spinal", 390], ["muscular", 397], ["atrophy", 406], [".", 413], ["No", 415], ["complications", 418], ["occurred", 432], ["in", 441], ["50", 444], ["(", 447], ["68", 448], ["%", 450], [")", 451], ["lumbar", 453], ["punctures", 460], [";", 469], ["in", 471], ["23", 474], ["(", 477], ["32", 478], ["%", 480], [")", 481], ["procedures", 483], [",", 493], ["adverse", 495], ["events", 503], ["were", 510], ["attributed", 515], ["to", 526], ["lumbar", 529], ["puncture", 536], [".", 544], ["Most", 546], ["common", 551], ["adverse", 558], ["events", 566], ["were", 573], ["headache", 578], ["(", 587], ["n", 588], ["=", 590], ["9", 592], [")", 593], [",", 594], ["back", 596], ["pain", 601], ["(", 606], ["n", 607], ["=", 609], ["9", 611], [")", 612], [",", 613], ["and", 615], ["post", 619], ["-", 623], ["lumbar", 624], ["puncture", 631], ["syndrome", 640], ["(", 649], ["n", 650], ["=", 652], ["8)", 654], [".", 656], ["In", 658], ["a", 661], ["subgroup", 663], ["analysis", 672], [",", 680], ["adverse", 682], ["events", 690], ["were", 697], ["more", 702], ["frequent", 707], ["in", 716], ["older", 719], ["children", 725], [",", 733], ["children", 735], ["with", 744], ["type", 749], ["3", 754], ["spinal", 756], ["muscular", 763], ["atrophy", 772], [",", 779], ["and", 781], ["with", 785], ["a", 790], ["21-", 792], ["or", 796], ["22-gauge", 799], ["needle", 808], ["compared", 815], ["to", 824], ["a", 827], ["24-gauge", 829], ["needle", 838], ["or", 845], ["smaller", 848], [".", 855], ["Lumbar", 857], ["punctures", 864], ["were", 874], ["successfully", 879], ["performed", 892], ["in", 902], ["children", 905], ["with", 914], ["spinal", 919], ["muscular", 926], ["atrophy", 935], [";", 942], ["lumbar", 944], ["puncture", 951], ["-", 959], ["related", 960], ["adverse", 968], ["event", 976], ["frequency", 982], ["was", 992], ["similar", 996], ["to", 1004], ["that", 1007], ["previously", 1012], ["reported", 1023], ["in", 1032], ["children", 1035], [".", 1043]]}
{"context": "Magnetic resonance imaging (MRI) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. MRI performs somewhat better than any of several common tests--probe to bone (PTB), erythrocyte sedimentation rate (ESR) >70 mm/hr, C-reactive protein (CRP) >14 mg/L, procalcitonin >0.3 ng/mL, and ulcer size >2 cm\u00b2--although PTB has the highest specificity of any test and is commonly used together with MRI. No studies have directly compared MRI with a combination of these tests, which may assist in diagnosis.", "qas": [{"question": "Which disease can be diagnosed with the \"probe to bone\" test?", "answers": ["diabetic foot osteomyelitis"], "qid": "63e453c58aac4f2abda1af843d1f2c50", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["diagnosed", 21], ["with", 31], ["the", 36], ["\"", 40], ["probe", 41], ["to", 47], ["bone", 50], ["\"", 54], ["test", 56], ["?", 60]], "detected_answers": [{"text": "diabetic foot osteomyelitis", "token_spans": [[31, 33]], "char_spans": [[140, 166]]}]}], "context_tokens": [["Magnetic", 0], ["resonance", 9], ["imaging", 19], ["(", 27], ["MRI", 28], [")", 31], ["has", 33], ["a", 37], ["higher", 39], ["sensitivity", 46], ["and", 58], ["specificity", 62], ["(", 74], ["90", 75], ["%", 77], ["and", 79], ["79", 83], ["%", 85], [")", 86], ["than", 88], ["plain", 93], ["radiography", 99], ["(", 111], ["54", 112], ["%", 114], ["and", 116], ["68", 120], ["%", 122], [")", 123], ["for", 125], ["diagnosing", 129], ["diabetic", 140], ["foot", 149], ["osteomyelitis", 154], [".", 167], ["MRI", 169], ["performs", 173], ["somewhat", 182], ["better", 191], ["than", 198], ["any", 203], ["of", 207], ["several", 210], ["common", 218], ["tests", 225], ["--", 230], ["probe", 232], ["to", 238], ["bone", 241], ["(", 246], ["PTB", 247], [")", 250], [",", 251], ["erythrocyte", 253], ["sedimentation", 265], ["rate", 279], ["(", 284], ["ESR", 285], [")", 288], [">", 290], ["70", 291], ["mm", 294], ["/", 296], ["hr", 297], [",", 299], ["C", 301], ["-", 302], ["reactive", 303], ["protein", 312], ["(", 320], ["CRP", 321], [")", 324], [">", 326], ["14", 327], ["mg", 330], ["/", 332], ["L", 333], [",", 334], ["procalcitonin", 336], [">", 350], ["0.3", 351], ["ng", 355], ["/", 357], ["mL", 358], [",", 360], ["and", 362], ["ulcer", 366], ["size", 372], [">", 377], ["2", 378], ["cm\u00b2--although", 380], ["PTB", 394], ["has", 398], ["the", 402], ["highest", 406], ["specificity", 414], ["of", 426], ["any", 429], ["test", 433], ["and", 438], ["is", 442], ["commonly", 445], ["used", 454], ["together", 459], ["with", 468], ["MRI", 473], [".", 476], ["No", 478], ["studies", 481], ["have", 489], ["directly", 494], ["compared", 503], ["MRI", 512], ["with", 516], ["a", 521], ["combination", 523], ["of", 535], ["these", 538], ["tests", 544], [",", 549], ["which", 551], ["may", 557], ["assist", 561], ["in", 568], ["diagnosis", 571], [".", 580]]}
{"context": "Defects in DNA mismatch repair have been shown to lead to increased genomic instability and mutability. We recently found that human cells defective in the DNA mismatch repair gene, hMSH2, were deficient in the transcription-coupled repair (TCR) of both oxidative DNA damage, including thymine glycols, and UV-induced DNA damage. However, in a hMLH1 mutant, only a reduction in the TCR of UV damage was observed. In this study, we examined whether TCR of thymine glycols in Saccharomyces cerecisiae also requires the genes involved in DNA mismatch repair. We found that yeast cells containing mutations in MSH2 were deficient in the removal of thymine glycols from the transcribed strand of the RPB2 gene, while cells with mutations in either MLH1 or PMS1 alone showed near normal levels of TCR of thymine glycols. Interestingly, double mutants in the MLH1 and PMS1 genes were deficient in TCR of thymine glycols. Taken together, these results suggest that these two MutL homologues can act independently of each other, but that they have overlapping roles in TCR. Overall levels of thymine glycol removal were not reduced in the mismatch repair mutants. In contrast to the results with thymine glycols, no defects in TCR of pyrimidine dimers were found in cells with mutations in MSH2, MLH1, PMS1, and MLH1/PMS1.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "e3dbeab284f84daeb820a11a28cd701d", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[123, 124]], "char_spans": [[669, 686]]}]}], "context_tokens": [["Defects", 0], ["in", 8], ["DNA", 11], ["mismatch", 15], ["repair", 24], ["have", 31], ["been", 36], ["shown", 41], ["to", 47], ["lead", 50], ["to", 55], ["increased", 58], ["genomic", 68], ["instability", 76], ["and", 88], ["mutability", 92], [".", 102], ["We", 104], ["recently", 107], ["found", 116], ["that", 122], ["human", 127], ["cells", 133], ["defective", 139], ["in", 149], ["the", 152], ["DNA", 156], ["mismatch", 160], ["repair", 169], ["gene", 176], [",", 180], ["hMSH2", 182], [",", 187], ["were", 189], ["deficient", 194], ["in", 204], ["the", 207], ["transcription", 211], ["-", 224], ["coupled", 225], ["repair", 233], ["(", 240], ["TCR", 241], [")", 244], ["of", 246], ["both", 249], ["oxidative", 254], ["DNA", 264], ["damage", 268], [",", 274], ["including", 276], ["thymine", 286], ["glycols", 294], [",", 301], ["and", 303], ["UV", 307], ["-", 309], ["induced", 310], ["DNA", 318], ["damage", 322], [".", 328], ["However", 330], [",", 337], ["in", 339], ["a", 342], ["hMLH1", 344], ["mutant", 350], [",", 356], ["only", 358], ["a", 363], ["reduction", 365], ["in", 375], ["the", 378], ["TCR", 382], ["of", 386], ["UV", 389], ["damage", 392], ["was", 399], ["observed", 403], [".", 411], ["In", 413], ["this", 416], ["study", 421], [",", 426], ["we", 428], ["examined", 431], ["whether", 440], ["TCR", 448], ["of", 452], ["thymine", 455], ["glycols", 463], ["in", 471], ["Saccharomyces", 474], ["cerecisiae", 488], ["also", 499], ["requires", 504], ["the", 513], ["genes", 517], ["involved", 523], ["in", 532], ["DNA", 535], ["mismatch", 539], ["repair", 548], [".", 554], ["We", 556], ["found", 559], ["that", 565], ["yeast", 570], ["cells", 576], ["containing", 582], ["mutations", 593], ["in", 603], ["MSH2", 606], ["were", 611], ["deficient", 616], ["in", 626], ["the", 629], ["removal", 633], ["of", 641], ["thymine", 644], ["glycols", 652], ["from", 660], ["the", 665], ["transcribed", 669], ["strand", 681], ["of", 688], ["the", 691], ["RPB2", 695], ["gene", 700], [",", 704], ["while", 706], ["cells", 712], ["with", 718], ["mutations", 723], ["in", 733], ["either", 736], ["MLH1", 743], ["or", 748], ["PMS1", 751], ["alone", 756], ["showed", 762], ["near", 769], ["normal", 774], ["levels", 781], ["of", 788], ["TCR", 791], ["of", 795], ["thymine", 798], ["glycols", 806], [".", 813], ["Interestingly", 815], [",", 828], ["double", 830], ["mutants", 837], ["in", 845], ["the", 848], ["MLH1", 852], ["and", 857], ["PMS1", 861], ["genes", 866], ["were", 872], ["deficient", 877], ["in", 887], ["TCR", 890], ["of", 894], ["thymine", 897], ["glycols", 905], [".", 912], ["Taken", 914], ["together", 920], [",", 928], ["these", 930], ["results", 936], ["suggest", 944], ["that", 952], ["these", 957], ["two", 963], ["MutL", 967], ["homologues", 972], ["can", 983], ["act", 987], ["independently", 991], ["of", 1005], ["each", 1008], ["other", 1013], [",", 1018], ["but", 1020], ["that", 1024], ["they", 1029], ["have", 1034], ["overlapping", 1039], ["roles", 1051], ["in", 1057], ["TCR", 1060], [".", 1063], ["Overall", 1065], ["levels", 1073], ["of", 1080], ["thymine", 1083], ["glycol", 1091], ["removal", 1098], ["were", 1106], ["not", 1111], ["reduced", 1115], ["in", 1123], ["the", 1126], ["mismatch", 1130], ["repair", 1139], ["mutants", 1146], [".", 1153], ["In", 1155], ["contrast", 1158], ["to", 1167], ["the", 1170], ["results", 1174], ["with", 1182], ["thymine", 1187], ["glycols", 1195], [",", 1202], ["no", 1204], ["defects", 1207], ["in", 1215], ["TCR", 1218], ["of", 1222], ["pyrimidine", 1225], ["dimers", 1236], ["were", 1243], ["found", 1248], ["in", 1254], ["cells", 1257], ["with", 1263], ["mutations", 1268], ["in", 1278], ["MSH2", 1281], [",", 1285], ["MLH1", 1287], [",", 1291], ["PMS1", 1293], [",", 1297], ["and", 1299], ["MLH1/PMS1", 1303], [".", 1312]]}
{"context": "The first step in the management of restless legs syndrome (RLS) is to identify, and if possible to treat any condition which might cause or worsen RLS, such as iron deficiency or some drug treatments. The patients suffering from RLS should be prompted to keep a healthy sleep schedule. Drug treatment should be restricted to patients with a clear clinical diagnosis, decided on an individual basis, when the clinical impact is serious. Four drug classes are central to the treatment of RLS: dopaminergic agents, some antiepileptics, opioids, and benzodiazepines. Dopaminergic agonists are the treatment of choice, especially when daily treatment is indicated, or if the symptoms are severe. Two dopaminergic agonists are licensed in France for the treatment of RLS: ropinirole (Adartrel) and pramipexole (Sifrol). After initiation of treatment, the patients should benefit from a regular follow-up in order to evaluate the efficacy of treatment and to identify possible side-effects. Special care should be given to the detection of augmentation, a phenomenon characterized by a paradoxical worsening of the symptoms with treatment. Some particular conditions, such as RLS comorbid with renal insufficiency, during pregnancy, and in the child are discussed.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "aea77da44e294600b63d4260d7490d59", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[33, 33]], "char_spans": [[161, 164]]}]}], "context_tokens": [["The", 0], ["first", 4], ["step", 10], ["in", 15], ["the", 18], ["management", 22], ["of", 33], ["restless", 36], ["legs", 45], ["syndrome", 50], ["(", 59], ["RLS", 60], [")", 63], ["is", 65], ["to", 68], ["identify", 71], [",", 79], ["and", 81], ["if", 85], ["possible", 88], ["to", 97], ["treat", 100], ["any", 106], ["condition", 110], ["which", 120], ["might", 126], ["cause", 132], ["or", 138], ["worsen", 141], ["RLS", 148], [",", 151], ["such", 153], ["as", 158], ["iron", 161], ["deficiency", 166], ["or", 177], ["some", 180], ["drug", 185], ["treatments", 190], [".", 200], ["The", 202], ["patients", 206], ["suffering", 215], ["from", 225], ["RLS", 230], ["should", 234], ["be", 241], ["prompted", 244], ["to", 253], ["keep", 256], ["a", 261], ["healthy", 263], ["sleep", 271], ["schedule", 277], [".", 285], ["Drug", 287], ["treatment", 292], ["should", 302], ["be", 309], ["restricted", 312], ["to", 323], ["patients", 326], ["with", 335], ["a", 340], ["clear", 342], ["clinical", 348], ["diagnosis", 357], [",", 366], ["decided", 368], ["on", 376], ["an", 379], ["individual", 382], ["basis", 393], [",", 398], ["when", 400], ["the", 405], ["clinical", 409], ["impact", 418], ["is", 425], ["serious", 428], [".", 435], ["Four", 437], ["drug", 442], ["classes", 447], ["are", 455], ["central", 459], ["to", 467], ["the", 470], ["treatment", 474], ["of", 484], ["RLS", 487], [":", 490], ["dopaminergic", 492], ["agents", 505], [",", 511], ["some", 513], ["antiepileptics", 518], [",", 532], ["opioids", 534], [",", 541], ["and", 543], ["benzodiazepines", 547], [".", 562], ["Dopaminergic", 564], ["agonists", 577], ["are", 586], ["the", 590], ["treatment", 594], ["of", 604], ["choice", 607], [",", 613], ["especially", 615], ["when", 626], ["daily", 631], ["treatment", 637], ["is", 647], ["indicated", 650], [",", 659], ["or", 661], ["if", 664], ["the", 667], ["symptoms", 671], ["are", 680], ["severe", 684], [".", 690], ["Two", 692], ["dopaminergic", 696], ["agonists", 709], ["are", 718], ["licensed", 722], ["in", 731], ["France", 734], ["for", 741], ["the", 745], ["treatment", 749], ["of", 759], ["RLS", 762], [":", 765], ["ropinirole", 767], ["(", 778], ["Adartrel", 779], [")", 787], ["and", 789], ["pramipexole", 793], ["(", 805], ["Sifrol", 806], [")", 812], [".", 813], ["After", 815], ["initiation", 821], ["of", 832], ["treatment", 835], [",", 844], ["the", 846], ["patients", 850], ["should", 859], ["benefit", 866], ["from", 874], ["a", 879], ["regular", 881], ["follow", 889], ["-", 895], ["up", 896], ["in", 899], ["order", 902], ["to", 908], ["evaluate", 911], ["the", 920], ["efficacy", 924], ["of", 933], ["treatment", 936], ["and", 946], ["to", 950], ["identify", 953], ["possible", 962], ["side", 971], ["-", 975], ["effects", 976], [".", 983], ["Special", 985], ["care", 993], ["should", 998], ["be", 1005], ["given", 1008], ["to", 1014], ["the", 1017], ["detection", 1021], ["of", 1031], ["augmentation", 1034], [",", 1046], ["a", 1048], ["phenomenon", 1050], ["characterized", 1061], ["by", 1075], ["a", 1078], ["paradoxical", 1080], ["worsening", 1092], ["of", 1102], ["the", 1105], ["symptoms", 1109], ["with", 1118], ["treatment", 1123], [".", 1132], ["Some", 1134], ["particular", 1139], ["conditions", 1150], [",", 1160], ["such", 1162], ["as", 1167], ["RLS", 1170], ["comorbid", 1174], ["with", 1183], ["renal", 1188], ["insufficiency", 1194], [",", 1207], ["during", 1209], ["pregnancy", 1216], [",", 1225], ["and", 1227], ["in", 1231], ["the", 1234], ["child", 1238], ["are", 1244], ["discussed", 1248], [".", 1257]]}
{"context": "The mammalian radiation has corresponded with rapid changes in noncoding regions of the genome, but we lack a comprehensive understanding of regulatory evolution in mammals. Here, we track the evolution of promoters and enhancers active in liver across 20 mammalian species from six diverse orders by profiling genomic enrichment of H3K27 acetylation and H3K4 trimethylation. We report that rapid evolution of enhancers is a universal feature of mammalian genomes. Most of the recently evolved enhancers arise from ancestral DNA exaptation, rather than lineage-specific expansions of repeat elements. In contrast, almost all liver promoters are partially or fully conserved across these species. Our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences. These results provide important insight into the functional genetics underpinning mammalian regulatory evolution.", "qas": [{"question": "Are human enhancers or promoters evolving faster?", "answers": ["enhancers"], "qid": "ce06b70fdbb149389828f705b0d6faaf", "question_tokens": [["Are", 0], ["human", 4], ["enhancers", 10], ["or", 20], ["promoters", 23], ["evolving", 33], ["faster", 42], ["?", 48]], "detected_answers": [{"text": "enhancers", "token_spans": [[119, 119], [36, 36], [65, 65], [79, 79]], "char_spans": [[742, 750], [220, 228], [410, 418], [494, 502]]}]}], "context_tokens": [["The", 0], ["mammalian", 4], ["radiation", 14], ["has", 24], ["corresponded", 28], ["with", 41], ["rapid", 46], ["changes", 52], ["in", 60], ["noncoding", 63], ["regions", 73], ["of", 81], ["the", 84], ["genome", 88], [",", 94], ["but", 96], ["we", 100], ["lack", 103], ["a", 108], ["comprehensive", 110], ["understanding", 124], ["of", 138], ["regulatory", 141], ["evolution", 152], ["in", 162], ["mammals", 165], [".", 172], ["Here", 174], [",", 178], ["we", 180], ["track", 183], ["the", 189], ["evolution", 193], ["of", 203], ["promoters", 206], ["and", 216], ["enhancers", 220], ["active", 230], ["in", 237], ["liver", 240], ["across", 246], ["20", 253], ["mammalian", 256], ["species", 266], ["from", 274], ["six", 279], ["diverse", 283], ["orders", 291], ["by", 298], ["profiling", 301], ["genomic", 311], ["enrichment", 319], ["of", 330], ["H3K27", 333], ["acetylation", 339], ["and", 351], ["H3K4", 355], ["trimethylation", 360], [".", 374], ["We", 376], ["report", 379], ["that", 386], ["rapid", 391], ["evolution", 397], ["of", 407], ["enhancers", 410], ["is", 420], ["a", 423], ["universal", 425], ["feature", 435], ["of", 443], ["mammalian", 446], ["genomes", 456], [".", 463], ["Most", 465], ["of", 470], ["the", 473], ["recently", 477], ["evolved", 486], ["enhancers", 494], ["arise", 504], ["from", 510], ["ancestral", 515], ["DNA", 525], ["exaptation", 529], [",", 539], ["rather", 541], ["than", 548], ["lineage", 553], ["-", 560], ["specific", 561], ["expansions", 570], ["of", 581], ["repeat", 584], ["elements", 591], [".", 599], ["In", 601], ["contrast", 604], [",", 612], ["almost", 614], ["all", 621], ["liver", 625], ["promoters", 631], ["are", 641], ["partially", 645], ["or", 655], ["fully", 658], ["conserved", 664], ["across", 674], ["these", 681], ["species", 687], [".", 694], ["Our", 696], ["data", 700], ["further", 705], ["reveal", 713], ["that", 720], ["recently", 725], ["evolved", 734], ["enhancers", 742], ["can", 752], ["be", 756], ["associated", 759], ["with", 770], ["genes", 775], ["under", 781], ["positive", 787], ["selection", 796], [",", 805], ["demonstrating", 807], ["the", 821], ["power", 825], ["of", 831], ["this", 834], ["approach", 839], ["for", 848], ["annotating", 852], ["regulatory", 863], ["adaptations", 874], ["in", 886], ["genomic", 889], ["sequences", 897], [".", 906], ["These", 908], ["results", 914], ["provide", 922], ["important", 930], ["insight", 940], ["into", 948], ["the", 953], ["functional", 957], ["genetics", 968], ["underpinning", 977], ["mammalian", 990], ["regulatory", 1000], ["evolution", 1011], [".", 1020]]}
{"context": "Heat shock proteins (Hsp) are known to enhance cell survival under various stress conditions. In the heart, the small Hsp20 has emerged as a key mediator of protection against apoptosis, remodeling, and ischemia/reperfusion injury. Moreover, Hsp20 has been implicated in modulation of cardiac contractility ex vivo. The objective of this study was to determine the in vivo role of Hsp20 in the heart and the mechanisms underlying its regulatory effects in calcium (Ca) cycling. Hsp20 overexpression in intact animals resulted in significant enhancement of cardiac function, coupled with augmented Ca cycling and sarcoplasmic reticulum Ca load in isolated cardiomyocytes. This was associated with specific increases in phosphorylation of phospholamban (PLN) at both Ser16 and Thr17, relieving its inhibition of the apparent Ca affinity of SERCA2a. Accordingly, the inotropic effects of Hsp20 were abrogated in cardiomyocytes expressing nonphosphorylatable PLN (S16A/T17A). Interestingly, the activity of type 1 protein phosphatase (PP1), a known regulator of PLN signaling, was significantly reduced by Hsp20 overexpression, suggesting that the Hsp20 stimulatory effects are partially mediated through the PP1-PLN axis. This hypothesis was supported by cell fractionation, coimmunoprecipitation, and coimmunolocalization studies, which revealed an association between Hsp20, PP1, and PLN. Furthermore, recombinant protein studies confirmed a physical interaction between AA 73 to 160 in Hsp20 and AA 163 to 330 in PP1. Hsp20 is a novel regulator of sarcoplasmic reticulum Ca cycling by targeting the PP1-PLN axis. These findings, coupled with the well-recognized cardioprotective role of Hsp20, suggest a dual benefit of targeting Hsp20 in heart disease.", "qas": [{"question": "Which protein phosphatase has been found to interact with the heat shock protein, HSP20?", "answers": ["Protein phosphatase 1", "PP1"], "qid": "04c9df99ae544e2a96f40f77fd2378b2", "question_tokens": [["Which", 0], ["protein", 6], ["phosphatase", 14], ["has", 26], ["been", 30], ["found", 35], ["to", 41], ["interact", 44], ["with", 53], ["the", 58], ["heat", 62], ["shock", 67], ["protein", 73], [",", 80], ["HSP20", 82], ["?", 87]], "detected_answers": [{"text": "PP1", "token_spans": [[227, 227], [175, 175], [254, 254]], "char_spans": [[1374, 1376], [1031, 1033], [1513, 1515]]}]}], "context_tokens": [["Heat", 0], ["shock", 5], ["proteins", 11], ["(", 20], ["Hsp", 21], [")", 24], ["are", 26], ["known", 30], ["to", 36], ["enhance", 39], ["cell", 47], ["survival", 52], ["under", 61], ["various", 67], ["stress", 75], ["conditions", 82], [".", 92], ["In", 94], ["the", 97], ["heart", 101], [",", 106], ["the", 108], ["small", 112], ["Hsp20", 118], ["has", 124], ["emerged", 128], ["as", 136], ["a", 139], ["key", 141], ["mediator", 145], ["of", 154], ["protection", 157], ["against", 168], ["apoptosis", 176], [",", 185], ["remodeling", 187], [",", 197], ["and", 199], ["ischemia", 203], ["/", 211], ["reperfusion", 212], ["injury", 224], [".", 230], ["Moreover", 232], [",", 240], ["Hsp20", 242], ["has", 248], ["been", 252], ["implicated", 257], ["in", 268], ["modulation", 271], ["of", 282], ["cardiac", 285], ["contractility", 293], ["ex", 307], ["vivo", 310], [".", 314], ["The", 316], ["objective", 320], ["of", 330], ["this", 333], ["study", 338], ["was", 344], ["to", 348], ["determine", 351], ["the", 361], ["in", 365], ["vivo", 368], ["role", 373], ["of", 378], ["Hsp20", 381], ["in", 387], ["the", 390], ["heart", 394], ["and", 400], ["the", 404], ["mechanisms", 408], ["underlying", 419], ["its", 430], ["regulatory", 434], ["effects", 445], ["in", 453], ["calcium", 456], ["(", 464], ["Ca", 465], [")", 467], ["cycling", 469], [".", 476], ["Hsp20", 478], ["overexpression", 484], ["in", 499], ["intact", 502], ["animals", 509], ["resulted", 517], ["in", 526], ["significant", 529], ["enhancement", 541], ["of", 553], ["cardiac", 556], ["function", 564], [",", 572], ["coupled", 574], ["with", 582], ["augmented", 587], ["Ca", 597], ["cycling", 600], ["and", 608], ["sarcoplasmic", 612], ["reticulum", 625], ["Ca", 635], ["load", 638], ["in", 643], ["isolated", 646], ["cardiomyocytes", 655], [".", 669], ["This", 671], ["was", 676], ["associated", 680], ["with", 691], ["specific", 696], ["increases", 705], ["in", 715], ["phosphorylation", 718], ["of", 734], ["phospholamban", 737], ["(", 751], ["PLN", 752], [")", 755], ["at", 757], ["both", 760], ["Ser16", 765], ["and", 771], ["Thr17", 775], [",", 780], ["relieving", 782], ["its", 792], ["inhibition", 796], ["of", 807], ["the", 810], ["apparent", 814], ["Ca", 823], ["affinity", 826], ["of", 835], ["SERCA2a", 838], [".", 845], ["Accordingly", 847], [",", 858], ["the", 860], ["inotropic", 864], ["effects", 874], ["of", 882], ["Hsp20", 885], ["were", 891], ["abrogated", 896], ["in", 906], ["cardiomyocytes", 909], ["expressing", 924], ["nonphosphorylatable", 935], ["PLN", 955], ["(", 959], ["S16A", 960], ["/", 964], ["T17A", 965], [")", 969], [".", 970], ["Interestingly", 972], [",", 985], ["the", 987], ["activity", 991], ["of", 1000], ["type", 1003], ["1", 1008], ["protein", 1010], ["phosphatase", 1018], ["(", 1030], ["PP1", 1031], [")", 1034], [",", 1035], ["a", 1037], ["known", 1039], ["regulator", 1045], ["of", 1055], ["PLN", 1058], ["signaling", 1062], [",", 1071], ["was", 1073], ["significantly", 1077], ["reduced", 1091], ["by", 1099], ["Hsp20", 1102], ["overexpression", 1108], [",", 1122], ["suggesting", 1124], ["that", 1135], ["the", 1140], ["Hsp20", 1144], ["stimulatory", 1150], ["effects", 1162], ["are", 1170], ["partially", 1174], ["mediated", 1184], ["through", 1193], ["the", 1201], ["PP1-PLN", 1205], ["axis", 1213], [".", 1217], ["This", 1219], ["hypothesis", 1224], ["was", 1235], ["supported", 1239], ["by", 1249], ["cell", 1252], ["fractionation", 1257], [",", 1270], ["coimmunoprecipitation", 1272], [",", 1293], ["and", 1295], ["coimmunolocalization", 1299], ["studies", 1320], [",", 1327], ["which", 1329], ["revealed", 1335], ["an", 1344], ["association", 1347], ["between", 1359], ["Hsp20", 1367], [",", 1372], ["PP1", 1374], [",", 1377], ["and", 1379], ["PLN", 1383], [".", 1386], ["Furthermore", 1388], [",", 1399], ["recombinant", 1401], ["protein", 1413], ["studies", 1421], ["confirmed", 1429], ["a", 1439], ["physical", 1441], ["interaction", 1450], ["between", 1462], ["AA", 1470], ["73", 1473], ["to", 1476], ["160", 1479], ["in", 1483], ["Hsp20", 1486], ["and", 1492], ["AA", 1496], ["163", 1499], ["to", 1503], ["330", 1506], ["in", 1510], ["PP1", 1513], [".", 1516], ["Hsp20", 1518], ["is", 1524], ["a", 1527], ["novel", 1529], ["regulator", 1535], ["of", 1545], ["sarcoplasmic", 1548], ["reticulum", 1561], ["Ca", 1571], ["cycling", 1574], ["by", 1582], ["targeting", 1585], ["the", 1595], ["PP1-PLN", 1599], ["axis", 1607], [".", 1611], ["These", 1613], ["findings", 1619], [",", 1627], ["coupled", 1629], ["with", 1637], ["the", 1642], ["well", 1646], ["-", 1650], ["recognized", 1651], ["cardioprotective", 1662], ["role", 1679], ["of", 1684], ["Hsp20", 1687], [",", 1692], ["suggest", 1694], ["a", 1702], ["dual", 1704], ["benefit", 1709], ["of", 1717], ["targeting", 1720], ["Hsp20", 1730], ["in", 1736], ["heart", 1739], ["disease", 1745], [".", 1752]]}
{"context": "Prior studies, all using SPECT techniques, failed to find any differences for dopamine transporter (DAT) in restless legs syndrome (RLS) subjects. The distinct pharmacokinetic properties associated with SPECT-determined DAT along with rapid biodynamic changes in DAT may, however, have missed membrane-bound DAT differences. The current studies assessed real-time DAT binding potentials (BP) in striatum of RLS patients using (11)C-methylphenidate and PET techniques. RLS medications were stopped at least 11 days prior to the PET study. Clinical severity of RLS was also assessed. PET scans were performed at 2 different times of day (starting at 08:30 and 19:30) in separate groups of subjects. The primary outcome measure was total striatal DAT BP. Thirty-six patients with primary RLS and 34 age- and gender-matched controls. RLS subjects had significantly lower DAT binding in the striatum compared to controls on both the Day and the Night scans. DAT was decreased in putamen and caudate but not the ventral striatum of RLS subjects. There were no diurnal differences in DAT for the total group or for control and RLS separately. DAT BP did not correlate with any clinical measures of RLS. The current study found a significant decrease in DAT BP in two independent studies. These results when viewed along with prior RLS SPECT and autopsy studies of DAT, and cell culture studies with iron deficiency and DAT, suggest that membrane-bound striatal DAT, but not total cellular DAT, may be decreased in RLS.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "b2a12b8918344a65a2cc5f9b028e8d2b", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[258, 258]], "char_spans": [[1392, 1395]]}]}], "context_tokens": [["Prior", 0], ["studies", 6], [",", 13], ["all", 15], ["using", 19], ["SPECT", 25], ["techniques", 31], [",", 41], ["failed", 43], ["to", 50], ["find", 53], ["any", 58], ["differences", 62], ["for", 74], ["dopamine", 78], ["transporter", 87], ["(", 99], ["DAT", 100], [")", 103], ["in", 105], ["restless", 108], ["legs", 117], ["syndrome", 122], ["(", 131], ["RLS", 132], [")", 135], ["subjects", 137], [".", 145], ["The", 147], ["distinct", 151], ["pharmacokinetic", 160], ["properties", 176], ["associated", 187], ["with", 198], ["SPECT", 203], ["-", 208], ["determined", 209], ["DAT", 220], ["along", 224], ["with", 230], ["rapid", 235], ["biodynamic", 241], ["changes", 252], ["in", 260], ["DAT", 263], ["may", 267], [",", 270], ["however", 272], [",", 279], ["have", 281], ["missed", 286], ["membrane", 293], ["-", 301], ["bound", 302], ["DAT", 308], ["differences", 312], [".", 323], ["The", 325], ["current", 329], ["studies", 337], ["assessed", 345], ["real", 354], ["-", 358], ["time", 359], ["DAT", 364], ["binding", 368], ["potentials", 376], ["(", 387], ["BP", 388], [")", 390], ["in", 392], ["striatum", 395], ["of", 404], ["RLS", 407], ["patients", 411], ["using", 420], ["(", 426], ["11)C", 427], ["-", 431], ["methylphenidate", 432], ["and", 448], ["PET", 452], ["techniques", 456], [".", 466], ["RLS", 468], ["medications", 472], ["were", 484], ["stopped", 489], ["at", 497], ["least", 500], ["11", 506], ["days", 509], ["prior", 514], ["to", 520], ["the", 523], ["PET", 527], ["study", 531], [".", 536], ["Clinical", 538], ["severity", 547], ["of", 556], ["RLS", 559], ["was", 563], ["also", 567], ["assessed", 572], [".", 580], ["PET", 582], ["scans", 586], ["were", 592], ["performed", 597], ["at", 607], ["2", 610], ["different", 612], ["times", 622], ["of", 628], ["day", 631], ["(", 635], ["starting", 636], ["at", 645], ["08:30", 648], ["and", 654], ["19:30", 658], [")", 663], ["in", 665], ["separate", 668], ["groups", 677], ["of", 684], ["subjects", 687], [".", 695], ["The", 697], ["primary", 701], ["outcome", 709], ["measure", 717], ["was", 725], ["total", 729], ["striatal", 735], ["DAT", 744], ["BP", 748], [".", 750], ["Thirty", 752], ["-", 758], ["six", 759], ["patients", 763], ["with", 772], ["primary", 777], ["RLS", 785], ["and", 789], ["34", 793], ["age-", 796], ["and", 801], ["gender", 805], ["-", 811], ["matched", 812], ["controls", 820], [".", 828], ["RLS", 830], ["subjects", 834], ["had", 843], ["significantly", 847], ["lower", 861], ["DAT", 867], ["binding", 871], ["in", 879], ["the", 882], ["striatum", 886], ["compared", 895], ["to", 904], ["controls", 907], ["on", 916], ["both", 919], ["the", 924], ["Day", 928], ["and", 932], ["the", 936], ["Night", 940], ["scans", 946], [".", 951], ["DAT", 953], ["was", 957], ["decreased", 961], ["in", 971], ["putamen", 974], ["and", 982], ["caudate", 986], ["but", 994], ["not", 998], ["the", 1002], ["ventral", 1006], ["striatum", 1014], ["of", 1023], ["RLS", 1026], ["subjects", 1030], [".", 1038], ["There", 1040], ["were", 1046], ["no", 1051], ["diurnal", 1054], ["differences", 1062], ["in", 1074], ["DAT", 1077], ["for", 1081], ["the", 1085], ["total", 1089], ["group", 1095], ["or", 1101], ["for", 1104], ["control", 1108], ["and", 1116], ["RLS", 1120], ["separately", 1124], [".", 1134], ["DAT", 1136], ["BP", 1140], ["did", 1143], ["not", 1147], ["correlate", 1151], ["with", 1161], ["any", 1166], ["clinical", 1170], ["measures", 1179], ["of", 1188], ["RLS", 1191], [".", 1194], ["The", 1196], ["current", 1200], ["study", 1208], ["found", 1214], ["a", 1220], ["significant", 1222], ["decrease", 1234], ["in", 1243], ["DAT", 1246], ["BP", 1250], ["in", 1253], ["two", 1256], ["independent", 1260], ["studies", 1272], [".", 1279], ["These", 1281], ["results", 1287], ["when", 1295], ["viewed", 1300], ["along", 1307], ["with", 1313], ["prior", 1318], ["RLS", 1324], ["SPECT", 1328], ["and", 1334], ["autopsy", 1338], ["studies", 1346], ["of", 1354], ["DAT", 1357], [",", 1360], ["and", 1362], ["cell", 1366], ["culture", 1371], ["studies", 1379], ["with", 1387], ["iron", 1392], ["deficiency", 1397], ["and", 1408], ["DAT", 1412], [",", 1415], ["suggest", 1417], ["that", 1425], ["membrane", 1430], ["-", 1438], ["bound", 1439], ["striatal", 1445], ["DAT", 1454], [",", 1457], ["but", 1459], ["not", 1463], ["total", 1467], ["cellular", 1473], ["DAT", 1482], [",", 1485], ["may", 1487], ["be", 1491], ["decreased", 1494], ["in", 1504], ["RLS", 1507], [".", 1510]]}
{"context": "Chaperone-mediated autophagy (CMA) is a selective form of autophagy whose distinctive feature is the fact that substrate proteins are translocated directly from the cytosol across the lysosomal membrane for degradation inside lysosomes. CMA substrates are cytosolic proteins bearing a pentapeptide motif in their sequence that, when recognized by the cytosolic chaperone HSPA8/HSC70, targets them to the surface of the lysosomes. Once there, substrate proteins bind to the lysosome-associated membrane protein type 2 isoform A (LAMP2A), inducing assembly of this receptor protein into a higher molecular weight protein complex that is used by the substrate proteins to reach the lysosomal lumen. CMA is constitutively active in most cells but it is maximally activated under conditions of stress.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "00514408a6c643d68ffbd2cf86d20e0e", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[86, 86]], "char_spans": [[528, 533]]}]}], "context_tokens": [["Chaperone", 0], ["-", 9], ["mediated", 10], ["autophagy", 19], ["(", 29], ["CMA", 30], [")", 33], ["is", 35], ["a", 38], ["selective", 40], ["form", 50], ["of", 55], ["autophagy", 58], ["whose", 68], ["distinctive", 74], ["feature", 86], ["is", 94], ["the", 97], ["fact", 101], ["that", 106], ["substrate", 111], ["proteins", 121], ["are", 130], ["translocated", 134], ["directly", 147], ["from", 156], ["the", 161], ["cytosol", 165], ["across", 173], ["the", 180], ["lysosomal", 184], ["membrane", 194], ["for", 203], ["degradation", 207], ["inside", 219], ["lysosomes", 226], [".", 235], ["CMA", 237], ["substrates", 241], ["are", 252], ["cytosolic", 256], ["proteins", 266], ["bearing", 275], ["a", 283], ["pentapeptide", 285], ["motif", 298], ["in", 304], ["their", 307], ["sequence", 313], ["that", 322], [",", 326], ["when", 328], ["recognized", 333], ["by", 344], ["the", 347], ["cytosolic", 351], ["chaperone", 361], ["HSPA8/HSC70", 371], [",", 382], ["targets", 384], ["them", 392], ["to", 397], ["the", 400], ["surface", 404], ["of", 412], ["the", 415], ["lysosomes", 419], [".", 428], ["Once", 430], ["there", 435], [",", 440], ["substrate", 442], ["proteins", 452], ["bind", 461], ["to", 466], ["the", 469], ["lysosome", 473], ["-", 481], ["associated", 482], ["membrane", 493], ["protein", 502], ["type", 510], ["2", 515], ["isoform", 517], ["A", 525], ["(", 527], ["LAMP2A", 528], [")", 534], [",", 535], ["inducing", 537], ["assembly", 546], ["of", 555], ["this", 558], ["receptor", 563], ["protein", 572], ["into", 580], ["a", 585], ["higher", 587], ["molecular", 594], ["weight", 604], ["protein", 611], ["complex", 619], ["that", 627], ["is", 632], ["used", 635], ["by", 640], ["the", 643], ["substrate", 647], ["proteins", 657], ["to", 666], ["reach", 669], ["the", 675], ["lysosomal", 679], ["lumen", 689], [".", 694], ["CMA", 696], ["is", 700], ["constitutively", 703], ["active", 718], ["in", 725], ["most", 728], ["cells", 733], ["but", 739], ["it", 743], ["is", 746], ["maximally", 749], ["activated", 759], ["under", 769], ["conditions", 775], ["of", 786], ["stress", 789], [".", 795]]}
{"context": "Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm characterized by the presence of the Philadelphia chromosome. This arises from a balanced translocation between chromosomes 9 and 22, creating the bcr-abl fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation, which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy. After imatinib treatment, > 90% of patients had a complete hematologic response, and 70%-80% had a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging and exhibit a major change in the natural history of the disease. The understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance. The outlook today for patients with CML is much brighter than that of a few years ago.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "daeaeaba2d634317b4b23a5d6051f0e1", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[37, 39], [71, 73]], "char_spans": [[238, 244], [418, 424]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["a", 38], ["progressive", 40], ["and", 52], ["often", 56], ["fatal", 62], ["hematopoietic", 68], ["neoplasm", 82], ["characterized", 91], ["by", 105], ["the", 108], ["presence", 112], ["of", 121], ["the", 124], ["Philadelphia", 128], ["chromosome", 141], [".", 151], ["This", 153], ["arises", 158], ["from", 165], ["a", 170], ["balanced", 172], ["translocation", 181], ["between", 195], ["chromosomes", 203], ["9", 215], ["and", 217], ["22", 221], [",", 223], ["creating", 225], ["the", 234], ["bcr", 238], ["-", 241], ["abl", 242], ["fusion", 246], ["gene", 253], [".", 257], ["It", 259], ["is", 262], ["often", 265], ["stated", 271], ["that", 278], ["the", 283], ["only", 287], ["proven", 292], ["curative", 299], ["option", 308], ["is", 315], ["allogeneic", 318], ["stem", 329], ["cell", 334], ["transplantation", 339], [",", 354], ["which", 356], ["is", 362], ["indicated", 365], ["for", 375], ["only", 379], ["a", 384], ["limited", 386], ["subset", 394], ["of", 401], ["patients", 404], [".", 412], ["The", 414], ["Bcr", 418], ["-", 421], ["Abl", 422], ["tyrosine", 426], ["kinase", 435], ["inhibitor", 442], ["imatinib", 452], ["represented", 461], ["a", 473], ["major", 475], ["advance", 481], ["over", 489], ["conventional", 494], ["CML", 507], ["therapy", 511], [".", 518], ["After", 520], ["imatinib", 526], ["treatment", 535], [",", 544], [">", 546], ["90", 548], ["%", 550], ["of", 552], ["patients", 555], ["had", 564], ["a", 568], ["complete", 570], ["hematologic", 579], ["response", 591], [",", 599], ["and", 601], ["70%-80", 605], ["%", 611], ["had", 613], ["a", 617], ["complete", 619], ["cytogenetic", 628], ["response", 640], [".", 648], ["With", 650], ["5", 655], ["years", 657], ["of", 663], ["follow", 666], ["-", 672], ["up", 673], [",", 675], ["the", 677], ["data", 681], ["are", 686], ["very", 690], ["encouraging", 695], ["and", 707], ["exhibit", 711], ["a", 719], ["major", 721], ["change", 727], ["in", 734], ["the", 737], ["natural", 741], ["history", 749], ["of", 757], ["the", 760], ["disease", 764], [".", 771], ["The", 773], ["understanding", 777], ["of", 791], ["some", 794], ["of", 799], ["the", 802], ["mechanisms", 806], ["of", 817], ["resistance", 820], ["to", 831], ["imatinib", 834], ["has", 843], ["led", 847], ["to", 851], ["a", 854], ["rapid", 856], ["development", 862], ["of", 874], ["new", 877], ["agents", 881], ["that", 888], ["might", 893], ["overcome", 899], ["this", 908], ["resistance", 913], [".", 923], ["The", 925], ["outlook", 929], ["today", 937], ["for", 943], ["patients", 947], ["with", 956], ["CML", 961], ["is", 965], ["much", 968], ["brighter", 973], ["than", 982], ["that", 987], ["of", 992], ["a", 995], ["few", 997], ["years", 1001], ["ago", 1007], [".", 1010]]}
{"context": "Acute lung injury is a life-threatening condition characterized by surfactant dysfunction and raised secretory phospholipase A2 (sPLA2) activity. Varespladib is a sPLA2 inhibitor shown to be effective in animal models of acute lung injury. We aimed at investigating the effect of co-administration of surfactant and varespladib on sPLA2 activity. Alveolar macrophages were cultured and stimulated with lipopolysaccharide and then treated with either varespladib, surfactant, varespladib followed by surfactant or nothing. sPLA2 activity, free fatty acids, tumour necrosis factor-\u03b1 (TNF-\u03b1) and protein concentrations were measured in culture supernatants. Treatment with varespladib (p=0.019) and varespladib + surfactant (p=0.013), reduced the enzyme activity by approximately 15% from the basal level measured in the untreated cultures. Surfactant, varespladib and varespladib + surfactant, respectively decreased free fatty acids by -45% (p=0.045), - 62% (p=0.009) and -48% (p=0.015), from the baseline concentration of the untreated cultures. Varespladib and poractant- \u03b1 co-administration reduces sPLA2 activity and free fatty acids release in cultured rat alveolar macrophages, although a clear drug synergy was not evident. Since co-administration may be useful to reduce inflammation and surfactant inactivation in acute lung injury, further in vivo studies are warranted to verify its clinical usefulness.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "5b8df96552584828a665c27a635ad167", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[15, 17]], "char_spans": [[101, 126]]}]}], "context_tokens": [["Acute", 0], ["lung", 6], ["injury", 11], ["is", 18], ["a", 21], ["life", 23], ["-", 27], ["threatening", 28], ["condition", 40], ["characterized", 50], ["by", 64], ["surfactant", 67], ["dysfunction", 78], ["and", 90], ["raised", 94], ["secretory", 101], ["phospholipase", 111], ["A2", 125], ["(", 128], ["sPLA2", 129], [")", 134], ["activity", 136], [".", 144], ["Varespladib", 146], ["is", 158], ["a", 161], ["sPLA2", 163], ["inhibitor", 169], ["shown", 179], ["to", 185], ["be", 188], ["effective", 191], ["in", 201], ["animal", 204], ["models", 211], ["of", 218], ["acute", 221], ["lung", 227], ["injury", 232], [".", 238], ["We", 240], ["aimed", 243], ["at", 249], ["investigating", 252], ["the", 266], ["effect", 270], ["of", 277], ["co", 280], ["-", 282], ["administration", 283], ["of", 298], ["surfactant", 301], ["and", 312], ["varespladib", 316], ["on", 328], ["sPLA2", 331], ["activity", 337], [".", 345], ["Alveolar", 347], ["macrophages", 356], ["were", 368], ["cultured", 373], ["and", 382], ["stimulated", 386], ["with", 397], ["lipopolysaccharide", 402], ["and", 421], ["then", 425], ["treated", 430], ["with", 438], ["either", 443], ["varespladib", 450], [",", 461], ["surfactant", 463], [",", 473], ["varespladib", 475], ["followed", 487], ["by", 496], ["surfactant", 499], ["or", 510], ["nothing", 513], [".", 520], ["sPLA2", 522], ["activity", 528], [",", 536], ["free", 538], ["fatty", 543], ["acids", 549], [",", 554], ["tumour", 556], ["necrosis", 563], ["factor", 572], ["-", 578], ["\u03b1", 579], ["(", 581], ["TNF", 582], ["-", 585], ["\u03b1", 586], [")", 587], ["and", 589], ["protein", 593], ["concentrations", 601], ["were", 616], ["measured", 621], ["in", 630], ["culture", 633], ["supernatants", 641], [".", 653], ["Treatment", 655], ["with", 665], ["varespladib", 670], ["(", 682], ["p=0.019", 683], [")", 690], ["and", 692], ["varespladib", 696], ["+", 708], ["surfactant", 710], ["(", 721], ["p=0.013", 722], [")", 729], [",", 730], ["reduced", 732], ["the", 740], ["enzyme", 744], ["activity", 751], ["by", 760], ["approximately", 763], ["15", 777], ["%", 779], ["from", 781], ["the", 786], ["basal", 790], ["level", 796], ["measured", 802], ["in", 811], ["the", 814], ["untreated", 818], ["cultures", 828], [".", 836], ["Surfactant", 838], [",", 848], ["varespladib", 850], ["and", 862], ["varespladib", 866], ["+", 878], ["surfactant", 880], [",", 890], ["respectively", 892], ["decreased", 905], ["free", 915], ["fatty", 920], ["acids", 926], ["by", 932], ["-45", 935], ["%", 938], ["(", 940], ["p=0.045", 941], [")", 948], [",", 949], ["-", 951], ["62", 953], ["%", 955], ["(", 957], ["p=0.009", 958], [")", 965], ["and", 967], ["-48", 971], ["%", 974], ["(", 976], ["p=0.015", 977], [")", 984], [",", 985], ["from", 987], ["the", 992], ["baseline", 996], ["concentration", 1005], ["of", 1019], ["the", 1022], ["untreated", 1026], ["cultures", 1036], [".", 1044], ["Varespladib", 1046], ["and", 1058], ["poractant-", 1062], ["\u03b1", 1073], ["co", 1075], ["-", 1077], ["administration", 1078], ["reduces", 1093], ["sPLA2", 1101], ["activity", 1107], ["and", 1116], ["free", 1120], ["fatty", 1125], ["acids", 1131], ["release", 1137], ["in", 1145], ["cultured", 1148], ["rat", 1157], ["alveolar", 1161], ["macrophages", 1170], [",", 1181], ["although", 1183], ["a", 1192], ["clear", 1194], ["drug", 1200], ["synergy", 1205], ["was", 1213], ["not", 1217], ["evident", 1221], [".", 1228], ["Since", 1230], ["co", 1236], ["-", 1238], ["administration", 1239], ["may", 1254], ["be", 1258], ["useful", 1261], ["to", 1268], ["reduce", 1271], ["inflammation", 1278], ["and", 1291], ["surfactant", 1295], ["inactivation", 1306], ["in", 1319], ["acute", 1322], ["lung", 1328], ["injury", 1333], [",", 1339], ["further", 1341], ["in", 1349], ["vivo", 1352], ["studies", 1357], ["are", 1365], ["warranted", 1369], ["to", 1379], ["verify", 1382], ["its", 1389], ["clinical", 1393], ["usefulness", 1402], [".", 1412]]}
{"context": "Highly conserved sequences at the 5' splice site and branch site of U12-dependent introns are important determinants for splicing by U12-dependent spliceosomes. This study investigates the in vivo splicing phenotypes of mutations in the branch site consensus sequence of the U12-dependent intron F from a human NOL1 (P120) minigene. Intron F contains a fully consensus branch site sequence (UUCCUUAAC). Mutations at each position were analyzed for their effects on U12-dependent splicing in vivo. Mutations at most positions resulted in a significant reduction of correct U12-dependent splicing. Defects observed included increased unspliced RNA levels, the activation of cryptic U2-dependent 5' and 3' splice sites, and the activation of cryptic U12-dependent branch/3' splice sites. A strong correlation was observed between the predicted thermodynamic stability of the branch site: U12 snRNA interaction and correct U12-dependent splicing. The lack of a polypyrimidine tract between the branch site and 3' splice site of U12-dependent introns and the observed reliance on base-pairing interactions for correct U12-dependent splicing emphasize the importance of RNA/RNA interactions during U12-dependent intron recognition and proper splice site selection.", "qas": [{"question": "Which is the branch site consensus sequence in U12-dependent introns?", "answers": ["UUCCUUAAC"], "qid": "b43e2230834144e38cbeb13c23ffd134", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["branch", 13], ["site", 20], ["consensus", 25], ["sequence", 35], ["in", 44], ["U12-dependent", 47], ["introns", 61], ["?", 68]], "detected_answers": [{"text": "UUCCUUAAC", "token_spans": [[64, 64]], "char_spans": [[391, 399]]}]}], "context_tokens": [["Highly", 0], ["conserved", 7], ["sequences", 17], ["at", 27], ["the", 30], ["5", 34], ["'", 35], ["splice", 37], ["site", 44], ["and", 49], ["branch", 53], ["site", 60], ["of", 65], ["U12-dependent", 68], ["introns", 82], ["are", 90], ["important", 94], ["determinants", 104], ["for", 117], ["splicing", 121], ["by", 130], ["U12-dependent", 133], ["spliceosomes", 147], [".", 159], ["This", 161], ["study", 166], ["investigates", 172], ["the", 185], ["in", 189], ["vivo", 192], ["splicing", 197], ["phenotypes", 206], ["of", 217], ["mutations", 220], ["in", 230], ["the", 233], ["branch", 237], ["site", 244], ["consensus", 249], ["sequence", 259], ["of", 268], ["the", 271], ["U12-dependent", 275], ["intron", 289], ["F", 296], ["from", 298], ["a", 303], ["human", 305], ["NOL1", 311], ["(", 316], ["P120", 317], [")", 321], ["minigene", 323], [".", 331], ["Intron", 333], ["F", 340], ["contains", 342], ["a", 351], ["fully", 353], ["consensus", 359], ["branch", 369], ["site", 376], ["sequence", 381], ["(", 390], ["UUCCUUAAC", 391], [")", 400], [".", 401], ["Mutations", 403], ["at", 413], ["each", 416], ["position", 421], ["were", 430], ["analyzed", 435], ["for", 444], ["their", 448], ["effects", 454], ["on", 462], ["U12-dependent", 465], ["splicing", 479], ["in", 488], ["vivo", 491], [".", 495], ["Mutations", 497], ["at", 507], ["most", 510], ["positions", 515], ["resulted", 525], ["in", 534], ["a", 537], ["significant", 539], ["reduction", 551], ["of", 561], ["correct", 564], ["U12-dependent", 572], ["splicing", 586], [".", 594], ["Defects", 596], ["observed", 604], ["included", 613], ["increased", 622], ["unspliced", 632], ["RNA", 642], ["levels", 646], [",", 652], ["the", 654], ["activation", 658], ["of", 669], ["cryptic", 672], ["U2-dependent", 680], ["5", 693], ["'", 694], ["and", 696], ["3", 700], ["'", 701], ["splice", 703], ["sites", 710], [",", 715], ["and", 717], ["the", 721], ["activation", 725], ["of", 736], ["cryptic", 739], ["U12-dependent", 747], ["branch/3", 761], ["'", 769], ["splice", 771], ["sites", 778], [".", 783], ["A", 785], ["strong", 787], ["correlation", 794], ["was", 806], ["observed", 810], ["between", 819], ["the", 827], ["predicted", 831], ["thermodynamic", 841], ["stability", 855], ["of", 865], ["the", 868], ["branch", 872], ["site", 879], [":", 883], ["U12", 885], ["snRNA", 889], ["interaction", 895], ["and", 907], ["correct", 911], ["U12-dependent", 919], ["splicing", 933], [".", 941], ["The", 943], ["lack", 947], ["of", 952], ["a", 955], ["polypyrimidine", 957], ["tract", 972], ["between", 978], ["the", 986], ["branch", 990], ["site", 997], ["and", 1002], ["3", 1006], ["'", 1007], ["splice", 1009], ["site", 1016], ["of", 1021], ["U12-dependent", 1024], ["introns", 1038], ["and", 1046], ["the", 1050], ["observed", 1054], ["reliance", 1063], ["on", 1072], ["base", 1075], ["-", 1079], ["pairing", 1080], ["interactions", 1088], ["for", 1101], ["correct", 1105], ["U12-dependent", 1113], ["splicing", 1127], ["emphasize", 1136], ["the", 1146], ["importance", 1150], ["of", 1161], ["RNA", 1164], ["/", 1167], ["RNA", 1168], ["interactions", 1172], ["during", 1185], ["U12-dependent", 1192], ["intron", 1206], ["recognition", 1213], ["and", 1225], ["proper", 1229], ["splice", 1236], ["site", 1243], ["selection", 1248], [".", 1257]]}
{"context": "The McLeod syndrome is an X-linked disorder caused by mutations of the XK gene encoding the XK protein. The syndrome is characterized by absent Kx erythrocyte antigen, weak expression of Kell blood group system antigens, and acanthocytosis. In some allelic variants, elevated creatine kinase, myopathy, neurogenic muscle atrophy, and progressive chorea are found. We describe a family with a novel point mutation in the XK gene consisting of a C to T base transition at nucleotide position 977, introducing a stop codon. Among seven affected males, five manifested with psychiatric disorders such as depression, bipolar disorder, or personality disorder, but only two presented with chorea Positron emission tomography and magnetic resonance volumetry revealed reduced striatal 2-fluoro-2-deoxy-glucose (FDG) uptake and diminished volumes of the caudate nucleus and putamen that correlated with disease duration. In contrast, none of 12 female mutation carriers showed psychiatric or movement disorders. However, a semidominant effect of the mutation was suggested by erythrocyte and blood group mosaicism and reduced striatal FDG uptake without structural abnormalities. Therefore, patients with psychiatric signs or symptoms segregating in an X-linked trait should be examined for acanthocytosis and Kell/Kx blood group serology.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "2f7b7e71153e42089cfb1ba8aff9bd9e", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[18, 18], [75, 75], [14, 14]], "char_spans": [[92, 93], [420, 421], [71, 72]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["an", 23], ["X", 26], ["-", 27], ["linked", 28], ["disorder", 35], ["caused", 44], ["by", 51], ["mutations", 54], ["of", 64], ["the", 67], ["XK", 71], ["gene", 74], ["encoding", 79], ["the", 88], ["XK", 92], ["protein", 95], [".", 102], ["The", 104], ["syndrome", 108], ["is", 117], ["characterized", 120], ["by", 134], ["absent", 137], ["Kx", 144], ["erythrocyte", 147], ["antigen", 159], [",", 166], ["weak", 168], ["expression", 173], ["of", 184], ["Kell", 187], ["blood", 192], ["group", 198], ["system", 204], ["antigens", 211], [",", 219], ["and", 221], ["acanthocytosis", 225], [".", 239], ["In", 241], ["some", 244], ["allelic", 249], ["variants", 257], [",", 265], ["elevated", 267], ["creatine", 276], ["kinase", 285], [",", 291], ["myopathy", 293], [",", 301], ["neurogenic", 303], ["muscle", 314], ["atrophy", 321], [",", 328], ["and", 330], ["progressive", 334], ["chorea", 346], ["are", 353], ["found", 357], [".", 362], ["We", 364], ["describe", 367], ["a", 376], ["family", 378], ["with", 385], ["a", 390], ["novel", 392], ["point", 398], ["mutation", 404], ["in", 413], ["the", 416], ["XK", 420], ["gene", 423], ["consisting", 428], ["of", 439], ["a", 442], ["C", 444], ["to", 446], ["T", 449], ["base", 451], ["transition", 456], ["at", 467], ["nucleotide", 470], ["position", 481], ["977", 490], [",", 493], ["introducing", 495], ["a", 507], ["stop", 509], ["codon", 514], [".", 519], ["Among", 521], ["seven", 527], ["affected", 533], ["males", 542], [",", 547], ["five", 549], ["manifested", 554], ["with", 565], ["psychiatric", 570], ["disorders", 582], ["such", 592], ["as", 597], ["depression", 600], [",", 610], ["bipolar", 612], ["disorder", 620], [",", 628], ["or", 630], ["personality", 633], ["disorder", 645], [",", 653], ["but", 655], ["only", 659], ["two", 664], ["presented", 668], ["with", 678], ["chorea", 683], ["Positron", 690], ["emission", 699], ["tomography", 708], ["and", 719], ["magnetic", 723], ["resonance", 732], ["volumetry", 742], ["revealed", 752], ["reduced", 761], ["striatal", 769], ["2-fluoro-2-deoxy", 778], ["-", 794], ["glucose", 795], ["(", 803], ["FDG", 804], [")", 807], ["uptake", 809], ["and", 816], ["diminished", 820], ["volumes", 831], ["of", 839], ["the", 842], ["caudate", 846], ["nucleus", 854], ["and", 862], ["putamen", 866], ["that", 874], ["correlated", 879], ["with", 890], ["disease", 895], ["duration", 903], [".", 911], ["In", 913], ["contrast", 916], [",", 924], ["none", 926], ["of", 931], ["12", 934], ["female", 937], ["mutation", 944], ["carriers", 953], ["showed", 962], ["psychiatric", 969], ["or", 981], ["movement", 984], ["disorders", 993], [".", 1002], ["However", 1004], [",", 1011], ["a", 1013], ["semidominant", 1015], ["effect", 1028], ["of", 1035], ["the", 1038], ["mutation", 1042], ["was", 1051], ["suggested", 1055], ["by", 1065], ["erythrocyte", 1068], ["and", 1080], ["blood", 1084], ["group", 1090], ["mosaicism", 1096], ["and", 1106], ["reduced", 1110], ["striatal", 1118], ["FDG", 1127], ["uptake", 1131], ["without", 1138], ["structural", 1146], ["abnormalities", 1157], [".", 1170], ["Therefore", 1172], [",", 1181], ["patients", 1183], ["with", 1192], ["psychiatric", 1197], ["signs", 1209], ["or", 1215], ["symptoms", 1218], ["segregating", 1227], ["in", 1239], ["an", 1242], ["X", 1245], ["-", 1246], ["linked", 1247], ["trait", 1254], ["should", 1260], ["be", 1267], ["examined", 1270], ["for", 1279], ["acanthocytosis", 1283], ["and", 1298], ["Kell", 1302], ["/", 1306], ["Kx", 1307], ["blood", 1310], ["group", 1316], ["serology", 1322], [".", 1330]]}
{"context": "Mutations in the CLN3 gene, which encodes a lysosomal membrane protein, are responsible for the neurodegenerative disorder juvenile Batten disease. A previous study on the yeast homolog to CLN3, designated Btn1p, revealed a potential role for CLN3 in the transport of arginine into the yeast vacuole, the equivalent organelle to the mammalian lysosome. Lysosomes isolated from lymphoblast cell lines, established from individuals with juvenile Batten disease-bearing mutations in CLN3, but not age-matched controls, demonstrate defective transport of arginine. Furthermore, we show that there is a depletion of arginine in cells derived from individuals with juvenile Batten disease. We have, therefore, characterized lysosomal arginine transport in normal lysosomes and show that it is ATP-, v-ATPase- and cationic-dependent. This and previous studies have shown that both arginine and lysine are transported by the same transport system, designated system c. However, we report that lysosomes isolated from juvenile Batten disease lymphoblasts are only defective for arginine transport. These results suggest that the CLN3 defect in juvenile Batten disease may affect how intracellular levels of arginine are regulated or distributed throughout the cell. This assertion is supported by two other experimental approaches. First, an antibody to CLN3 can block lysosomal arginine transport and second, expression of CLN3 in JNCL cells using a lentiviral vector can restore lysosomal arginine transport. CLN3 may have a role in regulating intracellular levels of arginine possibly through control of the transport of this amino acid into lysosomes.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "3dc4e3f9a1154fac800afd66066ee701", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[20, 21], [172, 173], [191, 192], [72, 73], [111, 112]], "char_spans": [[132, 145], [1018, 1031], [1144, 1157], [444, 457], [668, 681]]}, {"text": "JNCL", "token_spans": [[236, 236]], "char_spans": [[1423, 1426]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["CLN3", 17], ["gene", 22], [",", 26], ["which", 28], ["encodes", 34], ["a", 42], ["lysosomal", 44], ["membrane", 54], ["protein", 63], [",", 70], ["are", 72], ["responsible", 76], ["for", 88], ["the", 92], ["neurodegenerative", 96], ["disorder", 114], ["juvenile", 123], ["Batten", 132], ["disease", 139], [".", 146], ["A", 148], ["previous", 150], ["study", 159], ["on", 165], ["the", 168], ["yeast", 172], ["homolog", 178], ["to", 186], ["CLN3", 189], [",", 193], ["designated", 195], ["Btn1p", 206], [",", 211], ["revealed", 213], ["a", 222], ["potential", 224], ["role", 234], ["for", 239], ["CLN3", 243], ["in", 248], ["the", 251], ["transport", 255], ["of", 265], ["arginine", 268], ["into", 277], ["the", 282], ["yeast", 286], ["vacuole", 292], [",", 299], ["the", 301], ["equivalent", 305], ["organelle", 316], ["to", 326], ["the", 329], ["mammalian", 333], ["lysosome", 343], [".", 351], ["Lysosomes", 353], ["isolated", 363], ["from", 372], ["lymphoblast", 377], ["cell", 389], ["lines", 394], [",", 399], ["established", 401], ["from", 413], ["individuals", 418], ["with", 430], ["juvenile", 435], ["Batten", 444], ["disease", 451], ["-", 458], ["bearing", 459], ["mutations", 467], ["in", 477], ["CLN3", 480], [",", 484], ["but", 486], ["not", 490], ["age", 494], ["-", 497], ["matched", 498], ["controls", 506], [",", 514], ["demonstrate", 516], ["defective", 528], ["transport", 538], ["of", 548], ["arginine", 551], [".", 559], ["Furthermore", 561], [",", 572], ["we", 574], ["show", 577], ["that", 582], ["there", 587], ["is", 593], ["a", 596], ["depletion", 598], ["of", 608], ["arginine", 611], ["in", 620], ["cells", 623], ["derived", 629], ["from", 637], ["individuals", 642], ["with", 654], ["juvenile", 659], ["Batten", 668], ["disease", 675], [".", 682], ["We", 684], ["have", 687], [",", 691], ["therefore", 693], [",", 702], ["characterized", 704], ["lysosomal", 718], ["arginine", 728], ["transport", 737], ["in", 747], ["normal", 750], ["lysosomes", 757], ["and", 767], ["show", 771], ["that", 776], ["it", 781], ["is", 784], ["ATP-", 787], [",", 791], ["v", 793], ["-", 794], ["ATPase-", 795], ["and", 803], ["cationic", 807], ["-", 815], ["dependent", 816], [".", 825], ["This", 827], ["and", 832], ["previous", 836], ["studies", 845], ["have", 853], ["shown", 858], ["that", 864], ["both", 869], ["arginine", 874], ["and", 883], ["lysine", 887], ["are", 894], ["transported", 898], ["by", 910], ["the", 913], ["same", 917], ["transport", 922], ["system", 932], [",", 938], ["designated", 940], ["system", 951], ["c.", 958], ["However", 961], [",", 968], ["we", 970], ["report", 973], ["that", 980], ["lysosomes", 985], ["isolated", 995], ["from", 1004], ["juvenile", 1009], ["Batten", 1018], ["disease", 1025], ["lymphoblasts", 1033], ["are", 1046], ["only", 1050], ["defective", 1055], ["for", 1065], ["arginine", 1069], ["transport", 1078], [".", 1087], ["These", 1089], ["results", 1095], ["suggest", 1103], ["that", 1111], ["the", 1116], ["CLN3", 1120], ["defect", 1125], ["in", 1132], ["juvenile", 1135], ["Batten", 1144], ["disease", 1151], ["may", 1159], ["affect", 1163], ["how", 1170], ["intracellular", 1174], ["levels", 1188], ["of", 1195], ["arginine", 1198], ["are", 1207], ["regulated", 1211], ["or", 1221], ["distributed", 1224], ["throughout", 1236], ["the", 1247], ["cell", 1251], [".", 1255], ["This", 1257], ["assertion", 1262], ["is", 1272], ["supported", 1275], ["by", 1285], ["two", 1288], ["other", 1292], ["experimental", 1298], ["approaches", 1311], [".", 1321], ["First", 1323], [",", 1328], ["an", 1330], ["antibody", 1333], ["to", 1342], ["CLN3", 1345], ["can", 1350], ["block", 1354], ["lysosomal", 1360], ["arginine", 1370], ["transport", 1379], ["and", 1389], ["second", 1393], [",", 1399], ["expression", 1401], ["of", 1412], ["CLN3", 1415], ["in", 1420], ["JNCL", 1423], ["cells", 1428], ["using", 1434], ["a", 1440], ["lentiviral", 1442], ["vector", 1453], ["can", 1460], ["restore", 1464], ["lysosomal", 1472], ["arginine", 1482], ["transport", 1491], [".", 1500], ["CLN3", 1502], ["may", 1507], ["have", 1511], ["a", 1516], ["role", 1518], ["in", 1523], ["regulating", 1526], ["intracellular", 1537], ["levels", 1551], ["of", 1558], ["arginine", 1561], ["possibly", 1570], ["through", 1579], ["control", 1587], ["of", 1595], ["the", 1598], ["transport", 1602], ["of", 1612], ["this", 1615], ["amino", 1620], ["acid", 1626], ["into", 1631], ["lysosomes", 1636], [".", 1645]]}
{"context": "Clinical features variability between familial and sporadic restless legs syndrome/Willis-Ekbom disease (RLS/WED) has been previously reported. With this retrospective cohort study, we aimed to determine the clinical and polysomnographic characteristics of 400 RLS/WED patients. Patients with familial RLS/WED were significantly younger than sporadic RLS/WED, while clinical and polysomnographic characteristics were similar in both groups. No difference was found for the age-at-onset between idiopathic and secondary RLS/WED. Periodic limb movements (PLM) index and REM sleep time were higher in idiopathic RLS/WED. Time of onset of symptoms was in the evening or at bedtime in 28.04 and 37.80% of patients, respectively, while in 21.34% of patients onset was more than 1 h after sleep onset. Impulse control and compulsive behaviours (ICBs) were found in 13.29% patients on dopamine agonist therapy. Our analyses support the hypothesis that patients with a familial history of RLS/WED may have a genetic component. Nevertheless, the dichotomy between early and late onset disease seems to be less sharp than previously reported. A large proportion of RLS/WED patients can have atypical features, therefore making the diagnosis challenging. Some cases can be missed even when the patient refers to a sleep specialist, as revealed by the partial absence of daytime symptoms, the high comorbidity with insomnia and other sleep complaints and the high percentage of symptoms beginning after sleep onset. This draws attention on the importance of a careful evaluation of the patient, to recognize potentially treatable secondary forms of RLS/WED.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "c287836b570a4d18b1c683334df92f91", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[7, 9]], "char_spans": [[60, 81]]}]}], "context_tokens": [["Clinical", 0], ["features", 9], ["variability", 18], ["between", 30], ["familial", 38], ["and", 47], ["sporadic", 51], ["restless", 60], ["legs", 69], ["syndrome", 74], ["/", 82], ["Willis", 83], ["-", 89], ["Ekbom", 90], ["disease", 96], ["(", 104], ["RLS", 105], ["/", 108], ["WED", 109], [")", 112], ["has", 114], ["been", 118], ["previously", 123], ["reported", 134], [".", 142], ["With", 144], ["this", 149], ["retrospective", 154], ["cohort", 168], ["study", 175], [",", 180], ["we", 182], ["aimed", 185], ["to", 191], ["determine", 194], ["the", 204], ["clinical", 208], ["and", 217], ["polysomnographic", 221], ["characteristics", 238], ["of", 254], ["400", 257], ["RLS", 261], ["/", 264], ["WED", 265], ["patients", 269], [".", 277], ["Patients", 279], ["with", 288], ["familial", 293], ["RLS", 302], ["/", 305], ["WED", 306], ["were", 310], ["significantly", 315], ["younger", 329], ["than", 337], ["sporadic", 342], ["RLS", 351], ["/", 354], ["WED", 355], [",", 358], ["while", 360], ["clinical", 366], ["and", 375], ["polysomnographic", 379], ["characteristics", 396], ["were", 412], ["similar", 417], ["in", 425], ["both", 428], ["groups", 433], [".", 439], ["No", 441], ["difference", 444], ["was", 455], ["found", 459], ["for", 465], ["the", 469], ["age", 473], ["-", 476], ["at", 477], ["-", 479], ["onset", 480], ["between", 486], ["idiopathic", 494], ["and", 505], ["secondary", 509], ["RLS", 519], ["/", 522], ["WED", 523], [".", 526], ["Periodic", 528], ["limb", 537], ["movements", 542], ["(", 552], ["PLM", 553], [")", 556], ["index", 558], ["and", 564], ["REM", 568], ["sleep", 572], ["time", 578], ["were", 583], ["higher", 588], ["in", 595], ["idiopathic", 598], ["RLS", 609], ["/", 612], ["WED", 613], [".", 616], ["Time", 618], ["of", 623], ["onset", 626], ["of", 632], ["symptoms", 635], ["was", 644], ["in", 648], ["the", 651], ["evening", 655], ["or", 663], ["at", 666], ["bedtime", 669], ["in", 677], ["28.04", 680], ["and", 686], ["37.80", 690], ["%", 695], ["of", 697], ["patients", 700], [",", 708], ["respectively", 710], [",", 722], ["while", 724], ["in", 730], ["21.34", 733], ["%", 738], ["of", 740], ["patients", 743], ["onset", 752], ["was", 758], ["more", 762], ["than", 767], ["1", 772], ["h", 774], ["after", 776], ["sleep", 782], ["onset", 788], [".", 793], ["Impulse", 795], ["control", 803], ["and", 811], ["compulsive", 815], ["behaviours", 826], ["(", 837], ["ICBs", 838], [")", 842], ["were", 844], ["found", 849], ["in", 855], ["13.29", 858], ["%", 863], ["patients", 865], ["on", 874], ["dopamine", 877], ["agonist", 886], ["therapy", 894], [".", 901], ["Our", 903], ["analyses", 907], ["support", 916], ["the", 924], ["hypothesis", 928], ["that", 939], ["patients", 944], ["with", 953], ["a", 958], ["familial", 960], ["history", 969], ["of", 977], ["RLS", 980], ["/", 983], ["WED", 984], ["may", 988], ["have", 992], ["a", 997], ["genetic", 999], ["component", 1007], [".", 1016], ["Nevertheless", 1018], [",", 1030], ["the", 1032], ["dichotomy", 1036], ["between", 1046], ["early", 1054], ["and", 1060], ["late", 1064], ["onset", 1069], ["disease", 1075], ["seems", 1083], ["to", 1089], ["be", 1092], ["less", 1095], ["sharp", 1100], ["than", 1106], ["previously", 1111], ["reported", 1122], [".", 1130], ["A", 1132], ["large", 1134], ["proportion", 1140], ["of", 1151], ["RLS", 1154], ["/", 1157], ["WED", 1158], ["patients", 1162], ["can", 1171], ["have", 1175], ["atypical", 1180], ["features", 1189], [",", 1197], ["therefore", 1199], ["making", 1209], ["the", 1216], ["diagnosis", 1220], ["challenging", 1230], [".", 1241], ["Some", 1243], ["cases", 1248], ["can", 1254], ["be", 1258], ["missed", 1261], ["even", 1268], ["when", 1273], ["the", 1278], ["patient", 1282], ["refers", 1290], ["to", 1297], ["a", 1300], ["sleep", 1302], ["specialist", 1308], [",", 1318], ["as", 1320], ["revealed", 1323], ["by", 1332], ["the", 1335], ["partial", 1339], ["absence", 1347], ["of", 1355], ["daytime", 1358], ["symptoms", 1366], [",", 1374], ["the", 1376], ["high", 1380], ["comorbidity", 1385], ["with", 1397], ["insomnia", 1402], ["and", 1411], ["other", 1415], ["sleep", 1421], ["complaints", 1427], ["and", 1438], ["the", 1442], ["high", 1446], ["percentage", 1451], ["of", 1462], ["symptoms", 1465], ["beginning", 1474], ["after", 1484], ["sleep", 1490], ["onset", 1496], [".", 1501], ["This", 1503], ["draws", 1508], ["attention", 1514], ["on", 1524], ["the", 1527], ["importance", 1531], ["of", 1542], ["a", 1545], ["careful", 1547], ["evaluation", 1555], ["of", 1566], ["the", 1569], ["patient", 1573], [",", 1580], ["to", 1582], ["recognize", 1585], ["potentially", 1595], ["treatable", 1607], ["secondary", 1617], ["forms", 1627], ["of", 1633], ["RLS", 1636], ["/", 1639], ["WED", 1640], [".", 1643]]}
{"context": "The TNF family member receptor activator for NF-\u03baB ligand (RANKL) and its receptors RANK and osteoprotegerin are key regulators of bone remodeling but also influence cellular functions of tumor and immune effector cells. In this work, we studied the involvement of RANK-RANKL interaction in NK cell-mediated immunosurveillance of acute myeloid leukemia (AML). Substantial levels of RANKL were found to be expressed on leukemia cells in 53 of 78 (68%) investigated patients. Signaling via RANKL into the leukemia cells stimulated their metabolic activity and induced the release of cytokines involved in AML pathophysiology. In addition, the immunomodulatory factors released by AML cells upon RANKL signaling impaired the anti-leukemia reactivity of NK cells and induced RANK expression, and NK cells of AML patients displayed significantly upregulated RANK expression compared with healthy controls. Treatment of AML cells with the clinically available RANKL Ab Denosumab resulted in enhanced NK cell anti-leukemia reactivity. This was due to both blockade of the release of NK-inhibitory factors by AML cells and prevention of RANK signaling into NK cells. The latter was found to directly impair NK anti-leukemia reactivity with a more pronounced effect on IFN-\u03b3 production compared with cytotoxicity. Together, our data unravel a previously unknown function of the RANK-RANKL molecule system in AML pathophysiology as well as NK cell function and suggest that neutralization of RANKL with therapeutic Abs may serve to reinforce NK cell reactivity in leukemia patients.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "d8c9be80bd4a48e8898ad993a1531d7f", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[161, 161], [256, 256], [90, 90], [68, 68], [12, 12], [121, 121], [239, 239], [49, 49]], "char_spans": [[954, 958], [1482, 1486], [488, 492], [382, 386], [59, 63], [693, 697], [1374, 1378], [270, 274]]}]}], "context_tokens": [["The", 0], ["TNF", 4], ["family", 8], ["member", 15], ["receptor", 22], ["activator", 31], ["for", 41], ["NF", 45], ["-", 47], ["\u03baB", 48], ["ligand", 51], ["(", 58], ["RANKL", 59], [")", 64], ["and", 66], ["its", 70], ["receptors", 74], ["RANK", 84], ["and", 89], ["osteoprotegerin", 93], ["are", 109], ["key", 113], ["regulators", 117], ["of", 128], ["bone", 131], ["remodeling", 136], ["but", 147], ["also", 151], ["influence", 156], ["cellular", 166], ["functions", 175], ["of", 185], ["tumor", 188], ["and", 194], ["immune", 198], ["effector", 205], ["cells", 214], [".", 219], ["In", 221], ["this", 224], ["work", 229], [",", 233], ["we", 235], ["studied", 238], ["the", 246], ["involvement", 250], ["of", 262], ["RANK", 265], ["-", 269], ["RANKL", 270], ["interaction", 276], ["in", 288], ["NK", 291], ["cell", 294], ["-", 298], ["mediated", 299], ["immunosurveillance", 308], ["of", 327], ["acute", 330], ["myeloid", 336], ["leukemia", 344], ["(", 353], ["AML", 354], [")", 357], [".", 358], ["Substantial", 360], ["levels", 372], ["of", 379], ["RANKL", 382], ["were", 388], ["found", 393], ["to", 399], ["be", 402], ["expressed", 405], ["on", 415], ["leukemia", 418], ["cells", 427], ["in", 433], ["53", 436], ["of", 439], ["78", 442], ["(", 445], ["68", 446], ["%", 448], [")", 449], ["investigated", 451], ["patients", 464], [".", 472], ["Signaling", 474], ["via", 484], ["RANKL", 488], ["into", 494], ["the", 499], ["leukemia", 503], ["cells", 512], ["stimulated", 518], ["their", 529], ["metabolic", 535], ["activity", 545], ["and", 554], ["induced", 558], ["the", 566], ["release", 570], ["of", 578], ["cytokines", 581], ["involved", 591], ["in", 600], ["AML", 603], ["pathophysiology", 607], [".", 622], ["In", 624], ["addition", 627], [",", 635], ["the", 637], ["immunomodulatory", 641], ["factors", 658], ["released", 666], ["by", 675], ["AML", 678], ["cells", 682], ["upon", 688], ["RANKL", 693], ["signaling", 699], ["impaired", 709], ["the", 718], ["anti", 722], ["-", 726], ["leukemia", 727], ["reactivity", 736], ["of", 747], ["NK", 750], ["cells", 753], ["and", 759], ["induced", 763], ["RANK", 771], ["expression", 776], [",", 786], ["and", 788], ["NK", 792], ["cells", 795], ["of", 801], ["AML", 804], ["patients", 808], ["displayed", 817], ["significantly", 827], ["upregulated", 841], ["RANK", 853], ["expression", 858], ["compared", 869], ["with", 878], ["healthy", 883], ["controls", 891], [".", 899], ["Treatment", 901], ["of", 911], ["AML", 914], ["cells", 918], ["with", 924], ["the", 929], ["clinically", 933], ["available", 944], ["RANKL", 954], ["Ab", 960], ["Denosumab", 963], ["resulted", 973], ["in", 982], ["enhanced", 985], ["NK", 994], ["cell", 997], ["anti", 1002], ["-", 1006], ["leukemia", 1007], ["reactivity", 1016], [".", 1026], ["This", 1028], ["was", 1033], ["due", 1037], ["to", 1041], ["both", 1044], ["blockade", 1049], ["of", 1058], ["the", 1061], ["release", 1065], ["of", 1073], ["NK", 1076], ["-", 1078], ["inhibitory", 1079], ["factors", 1090], ["by", 1098], ["AML", 1101], ["cells", 1105], ["and", 1111], ["prevention", 1115], ["of", 1126], ["RANK", 1129], ["signaling", 1134], ["into", 1144], ["NK", 1149], ["cells", 1152], [".", 1157], ["The", 1159], ["latter", 1163], ["was", 1170], ["found", 1174], ["to", 1180], ["directly", 1183], ["impair", 1192], ["NK", 1199], ["anti", 1202], ["-", 1206], ["leukemia", 1207], ["reactivity", 1216], ["with", 1227], ["a", 1232], ["more", 1234], ["pronounced", 1239], ["effect", 1250], ["on", 1257], ["IFN", 1260], ["-", 1263], ["\u03b3", 1264], ["production", 1266], ["compared", 1277], ["with", 1286], ["cytotoxicity", 1291], [".", 1303], ["Together", 1305], [",", 1313], ["our", 1315], ["data", 1319], ["unravel", 1324], ["a", 1332], ["previously", 1334], ["unknown", 1345], ["function", 1353], ["of", 1362], ["the", 1365], ["RANK", 1369], ["-", 1373], ["RANKL", 1374], ["molecule", 1380], ["system", 1389], ["in", 1396], ["AML", 1399], ["pathophysiology", 1403], ["as", 1419], ["well", 1422], ["as", 1427], ["NK", 1430], ["cell", 1433], ["function", 1438], ["and", 1447], ["suggest", 1451], ["that", 1459], ["neutralization", 1464], ["of", 1479], ["RANKL", 1482], ["with", 1488], ["therapeutic", 1493], ["Abs", 1505], ["may", 1509], ["serve", 1513], ["to", 1519], ["reinforce", 1522], ["NK", 1532], ["cell", 1535], ["reactivity", 1540], ["in", 1551], ["leukemia", 1554], ["patients", 1563], [".", 1571]]}
{"context": "Long QT and short QT syndromes (LQTS and SQTS) are cardiac repolarization abnormalities that are characterized by length perturbations of the QT interval as measured on electrocardiogram (ECG). Prolonged QT interval and a propensity for ventricular tachycardia of the torsades de pointes (TdP) type are characteristic of LQTS, while SQTS is characterized by shortened QT interval with tall peaked T-waves and a propensity for atrial fibrillation. Both syndromes represent a high risk for syncope and sudden death. LQTS exists as a congenital genetic disease (cLQTS) with more than 700 mutations described in 12 genes (LQT1-12), but can also be acquired (aLQTS). The genetic forms of LQTS include Romano-Ward syndrome (RWS), which is characterized by isolated LQTS and an autosomal dominant pattern of inheritance, and syndromes with LQTS in association with other conditions. The latter includes Jervell and Lange-Nielsen syndrome (JLNS), Andersen syndrome (AS), and Timothy syndrome (TS). The genetics are further complicated by the occurrence of double and triple heterozygotes in LQTS and a considerable number of nonpathogenic rare polymorphisms in the involved genes. SQTS is a very rare condition, caused by mutations in five genes (SQTS1-5). The present mutation update is a comprehensive description of all known LQTS- and SQTS-associated mutations.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "857f5bd2ba3140ffa45bbf468805dfa3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[145, 146]], "char_spans": [[771, 788]]}]}], "context_tokens": [["Long", 0], ["QT", 5], ["and", 8], ["short", 12], ["QT", 18], ["syndromes", 21], ["(", 31], ["LQTS", 32], ["and", 37], ["SQTS", 41], [")", 45], ["are", 47], ["cardiac", 51], ["repolarization", 59], ["abnormalities", 74], ["that", 88], ["are", 93], ["characterized", 97], ["by", 111], ["length", 114], ["perturbations", 121], ["of", 135], ["the", 138], ["QT", 142], ["interval", 145], ["as", 154], ["measured", 157], ["on", 166], ["electrocardiogram", 169], ["(", 187], ["ECG", 188], [")", 191], [".", 192], ["Prolonged", 194], ["QT", 204], ["interval", 207], ["and", 216], ["a", 220], ["propensity", 222], ["for", 233], ["ventricular", 237], ["tachycardia", 249], ["of", 261], ["the", 264], ["torsades", 268], ["de", 277], ["pointes", 280], ["(", 288], ["TdP", 289], [")", 292], ["type", 294], ["are", 299], ["characteristic", 303], ["of", 318], ["LQTS", 321], [",", 325], ["while", 327], ["SQTS", 333], ["is", 338], ["characterized", 341], ["by", 355], ["shortened", 358], ["QT", 368], ["interval", 371], ["with", 380], ["tall", 385], ["peaked", 390], ["T", 397], ["-", 398], ["waves", 399], ["and", 405], ["a", 409], ["propensity", 411], ["for", 422], ["atrial", 426], ["fibrillation", 433], [".", 445], ["Both", 447], ["syndromes", 452], ["represent", 462], ["a", 472], ["high", 474], ["risk", 479], ["for", 484], ["syncope", 488], ["and", 496], ["sudden", 500], ["death", 507], [".", 512], ["LQTS", 514], ["exists", 519], ["as", 526], ["a", 529], ["congenital", 531], ["genetic", 542], ["disease", 550], ["(", 558], ["cLQTS", 559], [")", 564], ["with", 566], ["more", 571], ["than", 576], ["700", 581], ["mutations", 585], ["described", 595], ["in", 605], ["12", 608], ["genes", 611], ["(", 617], ["LQT1", 618], ["-", 622], ["12", 623], [")", 625], [",", 626], ["but", 628], ["can", 632], ["also", 636], ["be", 641], ["acquired", 644], ["(", 653], ["aLQTS", 654], [")", 659], [".", 660], ["The", 662], ["genetic", 666], ["forms", 674], ["of", 680], ["LQTS", 683], ["include", 688], ["Romano", 696], ["-", 702], ["Ward", 703], ["syndrome", 708], ["(", 717], ["RWS", 718], [")", 721], [",", 722], ["which", 724], ["is", 730], ["characterized", 733], ["by", 747], ["isolated", 750], ["LQTS", 759], ["and", 764], ["an", 768], ["autosomal", 771], ["dominant", 781], ["pattern", 790], ["of", 798], ["inheritance", 801], [",", 812], ["and", 814], ["syndromes", 818], ["with", 828], ["LQTS", 833], ["in", 838], ["association", 841], ["with", 853], ["other", 858], ["conditions", 864], [".", 874], ["The", 876], ["latter", 880], ["includes", 887], ["Jervell", 896], ["and", 904], ["Lange", 908], ["-", 913], ["Nielsen", 914], ["syndrome", 922], ["(", 931], ["JLNS", 932], [")", 936], [",", 937], ["Andersen", 939], ["syndrome", 948], ["(", 957], ["AS", 958], [")", 960], [",", 961], ["and", 963], ["Timothy", 967], ["syndrome", 975], ["(", 984], ["TS", 985], [")", 987], [".", 988], ["The", 990], ["genetics", 994], ["are", 1003], ["further", 1007], ["complicated", 1015], ["by", 1027], ["the", 1030], ["occurrence", 1034], ["of", 1045], ["double", 1048], ["and", 1055], ["triple", 1059], ["heterozygotes", 1066], ["in", 1080], ["LQTS", 1083], ["and", 1088], ["a", 1092], ["considerable", 1094], ["number", 1107], ["of", 1114], ["nonpathogenic", 1117], ["rare", 1131], ["polymorphisms", 1136], ["in", 1150], ["the", 1153], ["involved", 1157], ["genes", 1166], [".", 1171], ["SQTS", 1173], ["is", 1178], ["a", 1181], ["very", 1183], ["rare", 1188], ["condition", 1193], [",", 1202], ["caused", 1204], ["by", 1211], ["mutations", 1214], ["in", 1224], ["five", 1227], ["genes", 1232], ["(", 1238], ["SQTS1", 1239], ["-", 1244], ["5", 1245], [")", 1246], [".", 1247], ["The", 1249], ["present", 1253], ["mutation", 1261], ["update", 1270], ["is", 1277], ["a", 1280], ["comprehensive", 1282], ["description", 1296], ["of", 1308], ["all", 1311], ["known", 1315], ["LQTS-", 1321], ["and", 1327], ["SQTS", 1331], ["-", 1335], ["associated", 1336], ["mutations", 1347], [".", 1356]]}
{"context": "Hypospadias, when the urethra opens on the ventral side of the penis, is a common malformation seen in about 3 per 1,000 male births. It is a complex disorder associated with genetic and environmental factors and can be part of genetic syndromes. Mowat-Wilson syndrome (MWS) is a multiple congenital anomaly syndrome characterized by a distinct facial phenotype, Hirschsprung disease, microcephaly and mental retardation. It is caused by mutations in the zinc finger homeo box 1B gene, ZFHX1B (SIP1). To date, 68 deletion/mutation-positive cases have been reported. Genitourinary anomalies are common in MWS. Here we report that hypospadias is common in males with this syndrome. In 39 patients where this information was available, hypospadias was present in 46% of patients (18/39). In the 3 Italian male cases reported here, hypospadias was always present. MWS should be considered by endocrinologists in patients with hypospadias associated with developmental delays/mental retardation, in particular in the presence of a distinct facial phenotype.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "ace3060b5e2147889d7d4709d6cd1e57", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[88, 88]], "char_spans": [[486, 491]]}]}], "context_tokens": [["Hypospadias", 0], [",", 11], ["when", 13], ["the", 18], ["urethra", 22], ["opens", 30], ["on", 36], ["the", 39], ["ventral", 43], ["side", 51], ["of", 56], ["the", 59], ["penis", 63], [",", 68], ["is", 70], ["a", 73], ["common", 75], ["malformation", 82], ["seen", 95], ["in", 100], ["about", 103], ["3", 109], ["per", 111], ["1,000", 115], ["male", 121], ["births", 126], [".", 132], ["It", 134], ["is", 137], ["a", 140], ["complex", 142], ["disorder", 150], ["associated", 159], ["with", 170], ["genetic", 175], ["and", 183], ["environmental", 187], ["factors", 201], ["and", 209], ["can", 213], ["be", 217], ["part", 220], ["of", 225], ["genetic", 228], ["syndromes", 236], [".", 245], ["Mowat", 247], ["-", 252], ["Wilson", 253], ["syndrome", 260], ["(", 269], ["MWS", 270], [")", 273], ["is", 275], ["a", 278], ["multiple", 280], ["congenital", 289], ["anomaly", 300], ["syndrome", 308], ["characterized", 317], ["by", 331], ["a", 334], ["distinct", 336], ["facial", 345], ["phenotype", 352], [",", 361], ["Hirschsprung", 363], ["disease", 376], [",", 383], ["microcephaly", 385], ["and", 398], ["mental", 402], ["retardation", 409], [".", 420], ["It", 422], ["is", 425], ["caused", 428], ["by", 435], ["mutations", 438], ["in", 448], ["the", 451], ["zinc", 455], ["finger", 460], ["homeo", 467], ["box", 473], ["1B", 477], ["gene", 480], [",", 484], ["ZFHX1B", 486], ["(", 493], ["SIP1", 494], [")", 498], [".", 499], ["To", 501], ["date", 504], [",", 508], ["68", 510], ["deletion", 513], ["/", 521], ["mutation", 522], ["-", 530], ["positive", 531], ["cases", 540], ["have", 546], ["been", 551], ["reported", 556], [".", 564], ["Genitourinary", 566], ["anomalies", 580], ["are", 590], ["common", 594], ["in", 601], ["MWS", 604], [".", 607], ["Here", 609], ["we", 614], ["report", 617], ["that", 624], ["hypospadias", 629], ["is", 641], ["common", 644], ["in", 651], ["males", 654], ["with", 660], ["this", 665], ["syndrome", 670], [".", 678], ["In", 680], ["39", 683], ["patients", 686], ["where", 695], ["this", 701], ["information", 706], ["was", 718], ["available", 722], [",", 731], ["hypospadias", 733], ["was", 745], ["present", 749], ["in", 757], ["46", 760], ["%", 762], ["of", 764], ["patients", 767], ["(", 776], ["18/39", 777], [")", 782], [".", 783], ["In", 785], ["the", 788], ["3", 792], ["Italian", 794], ["male", 802], ["cases", 807], ["reported", 813], ["here", 822], [",", 826], ["hypospadias", 828], ["was", 840], ["always", 844], ["present", 851], [".", 858], ["MWS", 860], ["should", 864], ["be", 871], ["considered", 874], ["by", 885], ["endocrinologists", 888], ["in", 905], ["patients", 908], ["with", 917], ["hypospadias", 922], ["associated", 934], ["with", 945], ["developmental", 950], ["delays", 964], ["/", 970], ["mental", 971], ["retardation", 978], [",", 989], ["in", 991], ["particular", 994], ["in", 1005], ["the", 1008], ["presence", 1012], ["of", 1021], ["a", 1024], ["distinct", 1026], ["facial", 1035], ["phenotype", 1042], [".", 1051]]}
{"context": "Interleukin-1\u03b2 (IL-1\u03b2) is a potent mediator of inflammatory responses and plays a role in the differentiation of a number of lymphoid cells. In several inflammatory and autoimmune diseases, serum levels of IL-1\u03b2 are elevated and correlate with disease development and severity. The central role of the IL-1 pathway in several diseases has been validated by inhibitors currently in clinical development or approved by the FDA. However, the need to effectively modulate IL-1\u03b2-mediated local inflammation with the systemic delivery of an efficacious, safe and convenient drug still exists. To meet these challenges, we developed XOMA 052 (gevokizumab), a potent anti-IL-1\u03b2 neutralizing antibody that was designed in silico and humanized using Human Engineering\u2122 technology. XOMA 052 has a 300 femtomolar binding affinity for human IL-1\u03b2 and an in vitro potency in the low picomolar range. XOMA 052 binds to a unique IL-1\u03b2 epitope where residues critical for binding have been identified. We have previously reported that XOMA 052 is efficacious in vivo in a diet-induced obesity mouse model thought to be driven by low levels of chronic inflammation. We report here that XOMA 052 also reduces acute inflammation in vivo, neutralizing the effect of exogenously administered human IL-1\u03b2 and blocking peritonitis in a mouse model of acute gout. Based on its high potency, novel mechanism of action, long half-life, and high affinity, XOMA 052 provides a new strategy for the treatment of a number of inflammatory, autoimmune and metabolic diseases in which the role of IL-1\u03b2 is central to pathogenesis.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "f129d78a420746cd9b0364aa8ac1fa28", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[141, 141], [35, 35], [115, 115], [2, 2], [220, 220], [276, 276], [78, 78], [159, 159]], "char_spans": [[828, 832], [206, 210], [664, 668], [16, 20], [1276, 1280], [1563, 1567], [468, 472], [913, 917]]}]}], "context_tokens": [["Interleukin-1\u03b2", 0], ["(", 15], ["IL-1\u03b2", 16], [")", 21], ["is", 23], ["a", 26], ["potent", 28], ["mediator", 35], ["of", 44], ["inflammatory", 47], ["responses", 60], ["and", 70], ["plays", 74], ["a", 80], ["role", 82], ["in", 87], ["the", 90], ["differentiation", 94], ["of", 110], ["a", 113], ["number", 115], ["of", 122], ["lymphoid", 125], ["cells", 134], [".", 139], ["In", 141], ["several", 144], ["inflammatory", 152], ["and", 165], ["autoimmune", 169], ["diseases", 180], [",", 188], ["serum", 190], ["levels", 196], ["of", 203], ["IL-1\u03b2", 206], ["are", 212], ["elevated", 216], ["and", 225], ["correlate", 229], ["with", 239], ["disease", 244], ["development", 252], ["and", 264], ["severity", 268], [".", 276], ["The", 278], ["central", 282], ["role", 290], ["of", 295], ["the", 298], ["IL-1", 302], ["pathway", 307], ["in", 315], ["several", 318], ["diseases", 326], ["has", 335], ["been", 339], ["validated", 344], ["by", 354], ["inhibitors", 357], ["currently", 368], ["in", 378], ["clinical", 381], ["development", 390], ["or", 402], ["approved", 405], ["by", 414], ["the", 417], ["FDA", 421], [".", 424], ["However", 426], [",", 433], ["the", 435], ["need", 439], ["to", 444], ["effectively", 447], ["modulate", 459], ["IL-1\u03b2", 468], ["-", 473], ["mediated", 474], ["local", 483], ["inflammation", 489], ["with", 502], ["the", 507], ["systemic", 511], ["delivery", 520], ["of", 529], ["an", 532], ["efficacious", 535], [",", 546], ["safe", 548], ["and", 553], ["convenient", 557], ["drug", 568], ["still", 573], ["exists", 579], [".", 585], ["To", 587], ["meet", 590], ["these", 595], ["challenges", 601], [",", 611], ["we", 613], ["developed", 616], ["XOMA", 626], ["052", 631], ["(", 635], ["gevokizumab", 636], [")", 647], [",", 648], ["a", 650], ["potent", 652], ["anti", 659], ["-", 663], ["IL-1\u03b2", 664], ["neutralizing", 670], ["antibody", 683], ["that", 692], ["was", 697], ["designed", 701], ["in", 710], ["silico", 713], ["and", 720], ["humanized", 724], ["using", 734], ["Human", 740], ["Engineering", 746], ["\u2122", 757], ["technology", 759], [".", 769], ["XOMA", 771], ["052", 776], ["has", 780], ["a", 784], ["300", 786], ["femtomolar", 790], ["binding", 801], ["affinity", 809], ["for", 818], ["human", 822], ["IL-1\u03b2", 828], ["and", 834], ["an", 838], ["in", 841], ["vitro", 844], ["potency", 850], ["in", 858], ["the", 861], ["low", 865], ["picomolar", 869], ["range", 879], [".", 884], ["XOMA", 886], ["052", 891], ["binds", 895], ["to", 901], ["a", 904], ["unique", 906], ["IL-1\u03b2", 913], ["epitope", 919], ["where", 927], ["residues", 933], ["critical", 942], ["for", 951], ["binding", 955], ["have", 963], ["been", 968], ["identified", 973], [".", 983], ["We", 985], ["have", 988], ["previously", 993], ["reported", 1004], ["that", 1013], ["XOMA", 1018], ["052", 1023], ["is", 1027], ["efficacious", 1030], ["in", 1042], ["vivo", 1045], ["in", 1050], ["a", 1053], ["diet", 1055], ["-", 1059], ["induced", 1060], ["obesity", 1068], ["mouse", 1076], ["model", 1082], ["thought", 1088], ["to", 1096], ["be", 1099], ["driven", 1102], ["by", 1109], ["low", 1112], ["levels", 1116], ["of", 1123], ["chronic", 1126], ["inflammation", 1134], [".", 1146], ["We", 1148], ["report", 1151], ["here", 1158], ["that", 1163], ["XOMA", 1168], ["052", 1173], ["also", 1177], ["reduces", 1182], ["acute", 1190], ["inflammation", 1196], ["in", 1209], ["vivo", 1212], [",", 1216], ["neutralizing", 1218], ["the", 1231], ["effect", 1235], ["of", 1242], ["exogenously", 1245], ["administered", 1257], ["human", 1270], ["IL-1\u03b2", 1276], ["and", 1282], ["blocking", 1286], ["peritonitis", 1295], ["in", 1307], ["a", 1310], ["mouse", 1312], ["model", 1318], ["of", 1324], ["acute", 1327], ["gout", 1333], [".", 1337], ["Based", 1339], ["on", 1345], ["its", 1348], ["high", 1352], ["potency", 1357], [",", 1364], ["novel", 1366], ["mechanism", 1372], ["of", 1382], ["action", 1385], [",", 1391], ["long", 1393], ["half", 1398], ["-", 1402], ["life", 1403], [",", 1407], ["and", 1409], ["high", 1413], ["affinity", 1418], [",", 1426], ["XOMA", 1428], ["052", 1433], ["provides", 1437], ["a", 1446], ["new", 1448], ["strategy", 1452], ["for", 1461], ["the", 1465], ["treatment", 1469], ["of", 1479], ["a", 1482], ["number", 1484], ["of", 1491], ["inflammatory", 1494], [",", 1506], ["autoimmune", 1508], ["and", 1519], ["metabolic", 1523], ["diseases", 1533], ["in", 1542], ["which", 1545], ["the", 1551], ["role", 1555], ["of", 1560], ["IL-1\u03b2", 1563], ["is", 1569], ["central", 1572], ["to", 1580], ["pathogenesis", 1583], [".", 1595]]}
{"context": "ADARs are RNA editing enzymes that target double stranded RNA and convert adenosine to inosine, which is read by translation machinery as if it were guanosine. Aside from their role in generating protein diversity in the central nervous system, ADARs have been implicated in the hypermutation of some RNA viruses, although why this hypermutation occurs is not well understood. Here we describe the hypermutation of adenosines to guanosines in the genome of the sigma virus--a negative sense RNA virus that infects Drosophila melanogaster. The clustering of these mutations and the context in which they occur indicates that they have been caused by ADARs. However, ADAR-editing of viral RNA is either rare or edited viral RNA are rapidly degraded, as we only detected evidence for editing in two of the 104 viral isolates we studied. This is the first evidence for ADARs targeting viruses outside of mammals, and it raises the possibility that ADARs could play a role in the antiviral defences of insects.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "67f5860ba0e248caa2b54394c294ce80", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[114, 114]], "char_spans": [[665, 668]]}]}], "context_tokens": [["ADARs", 0], ["are", 6], ["RNA", 10], ["editing", 14], ["enzymes", 22], ["that", 30], ["target", 35], ["double", 42], ["stranded", 49], ["RNA", 58], ["and", 62], ["convert", 66], ["adenosine", 74], ["to", 84], ["inosine", 87], [",", 94], ["which", 96], ["is", 102], ["read", 105], ["by", 110], ["translation", 113], ["machinery", 125], ["as", 135], ["if", 138], ["it", 141], ["were", 144], ["guanosine", 149], [".", 158], ["Aside", 160], ["from", 166], ["their", 171], ["role", 177], ["in", 182], ["generating", 185], ["protein", 196], ["diversity", 204], ["in", 214], ["the", 217], ["central", 221], ["nervous", 229], ["system", 237], [",", 243], ["ADARs", 245], ["have", 251], ["been", 256], ["implicated", 261], ["in", 272], ["the", 275], ["hypermutation", 279], ["of", 293], ["some", 296], ["RNA", 301], ["viruses", 305], [",", 312], ["although", 314], ["why", 323], ["this", 327], ["hypermutation", 332], ["occurs", 346], ["is", 353], ["not", 356], ["well", 360], ["understood", 365], [".", 375], ["Here", 377], ["we", 382], ["describe", 385], ["the", 394], ["hypermutation", 398], ["of", 412], ["adenosines", 415], ["to", 426], ["guanosines", 429], ["in", 440], ["the", 443], ["genome", 447], ["of", 454], ["the", 457], ["sigma", 461], ["virus", 467], ["--", 472], ["a", 474], ["negative", 476], ["sense", 485], ["RNA", 491], ["virus", 495], ["that", 501], ["infects", 506], ["Drosophila", 514], ["melanogaster", 525], [".", 537], ["The", 539], ["clustering", 543], ["of", 554], ["these", 557], ["mutations", 563], ["and", 573], ["the", 577], ["context", 581], ["in", 589], ["which", 592], ["they", 598], ["occur", 603], ["indicates", 609], ["that", 619], ["they", 624], ["have", 629], ["been", 634], ["caused", 639], ["by", 646], ["ADARs", 649], [".", 654], ["However", 656], [",", 663], ["ADAR", 665], ["-", 669], ["editing", 670], ["of", 678], ["viral", 681], ["RNA", 687], ["is", 691], ["either", 694], ["rare", 701], ["or", 706], ["edited", 709], ["viral", 716], ["RNA", 722], ["are", 726], ["rapidly", 730], ["degraded", 738], [",", 746], ["as", 748], ["we", 751], ["only", 754], ["detected", 759], ["evidence", 768], ["for", 777], ["editing", 781], ["in", 789], ["two", 792], ["of", 796], ["the", 799], ["104", 803], ["viral", 807], ["isolates", 813], ["we", 822], ["studied", 825], [".", 832], ["This", 834], ["is", 839], ["the", 842], ["first", 846], ["evidence", 852], ["for", 861], ["ADARs", 865], ["targeting", 871], ["viruses", 881], ["outside", 889], ["of", 897], ["mammals", 900], [",", 907], ["and", 909], ["it", 913], ["raises", 916], ["the", 923], ["possibility", 927], ["that", 939], ["ADARs", 944], ["could", 950], ["play", 956], ["a", 961], ["role", 963], ["in", 968], ["the", 971], ["antiviral", 975], ["defences", 985], ["of", 994], ["insects", 997], [".", 1004]]}
{"context": "1. Using SEA0400, a potent and selective inhibitor of the Na+-Ca2+ exchanger (NCX), we examined whether NCX is involved in nitric oxide (NO)-induced disturbance of endoplasmic reticulum (ER) Ca2+ homeostasis followed by apoptosis in cultured rat microglia. 2. Sodium nitroprusside (SNP), an NO donor, decreased cell viability in a dose- and time-dependent manner with apoptotic cell death in cultured microglia. 3. Treatment with SNP decreased the ER Ca2+ levels as evaluated by measuring the increase in cytosolic Ca2+ level induced by exposing cells to thapsigargin, an irreversible inhibitor of ER Ca2+-ATPase. 4. The treatment with SNP also increased mRNA expression of CHOP and GPR78, makers of ER stress. 5. SEA0400 at 0.3-1.0 microM protected microglia against SNP-induced apoptosis. 6. SEA0400 blocked not only the SNP-induced decrease in ER Ca2+ levels but also SNP-induced increase in CHOP and GRP78 mRNAs. 7. SEA0400 did not affect capacitative Ca2+ entry in the presence and absence of SNP. 8. SNP increased Na+-dependent 45Ca2+ uptake and this increase was blocked by SEA0400. 9. These results suggest that SNP induces apoptosis via the ER stress pathway and SEA0400 attenuates SNP-induced apoptosis via suppression of the ER stress in cultured microglia. Our findings imply that NCX plays a role in ER Ca2+ depletion under pathological conditions.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "0e4286e02a654fdcade9b809d5a16301", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[250, 250], [16, 16], [22, 22]], "char_spans": [[1293, 1295], [78, 80], [104, 106]]}]}], "context_tokens": [["1", 0], [".", 1], ["Using", 3], ["SEA0400", 9], [",", 16], ["a", 18], ["potent", 20], ["and", 27], ["selective", 31], ["inhibitor", 41], ["of", 51], ["the", 54], ["Na+-Ca2", 58], ["+", 65], ["exchanger", 67], ["(", 77], ["NCX", 78], [")", 81], [",", 82], ["we", 84], ["examined", 87], ["whether", 96], ["NCX", 104], ["is", 108], ["involved", 111], ["in", 120], ["nitric", 123], ["oxide", 130], ["(", 136], ["NO)-induced", 137], ["disturbance", 149], ["of", 161], ["endoplasmic", 164], ["reticulum", 176], ["(", 186], ["ER", 187], [")", 189], ["Ca2", 191], ["+", 194], ["homeostasis", 196], ["followed", 208], ["by", 217], ["apoptosis", 220], ["in", 230], ["cultured", 233], ["rat", 242], ["microglia", 246], [".", 255], ["2", 257], [".", 258], ["Sodium", 260], ["nitroprusside", 267], ["(", 281], ["SNP", 282], [")", 285], [",", 286], ["an", 288], ["NO", 291], ["donor", 294], [",", 299], ["decreased", 301], ["cell", 311], ["viability", 316], ["in", 326], ["a", 329], ["dose-", 331], ["and", 337], ["time", 341], ["-", 345], ["dependent", 346], ["manner", 356], ["with", 363], ["apoptotic", 368], ["cell", 378], ["death", 383], ["in", 389], ["cultured", 392], ["microglia", 401], [".", 410], ["3", 412], [".", 413], ["Treatment", 415], ["with", 425], ["SNP", 430], ["decreased", 434], ["the", 444], ["ER", 448], ["Ca2", 451], ["+", 454], ["levels", 456], ["as", 463], ["evaluated", 466], ["by", 476], ["measuring", 479], ["the", 489], ["increase", 493], ["in", 502], ["cytosolic", 505], ["Ca2", 515], ["+", 518], ["level", 520], ["induced", 526], ["by", 534], ["exposing", 537], ["cells", 546], ["to", 552], ["thapsigargin", 555], [",", 567], ["an", 569], ["irreversible", 572], ["inhibitor", 585], ["of", 595], ["ER", 598], ["Ca2", 601], ["+", 604], ["-ATPase", 605], [".", 612], ["4", 614], [".", 615], ["The", 617], ["treatment", 621], ["with", 631], ["SNP", 636], ["also", 640], ["increased", 645], ["mRNA", 655], ["expression", 660], ["of", 671], ["CHOP", 674], ["and", 679], ["GPR78", 683], [",", 688], ["makers", 690], ["of", 697], ["ER", 700], ["stress", 703], [".", 709], ["5", 711], [".", 712], ["SEA0400", 714], ["at", 722], ["0.3", 725], ["-", 728], ["1.0", 729], ["microM", 733], ["protected", 740], ["microglia", 750], ["against", 760], ["SNP", 768], ["-", 771], ["induced", 772], ["apoptosis", 780], [".", 789], ["6", 791], [".", 792], ["SEA0400", 794], ["blocked", 802], ["not", 810], ["only", 814], ["the", 819], ["SNP", 823], ["-", 826], ["induced", 827], ["decrease", 835], ["in", 844], ["ER", 847], ["Ca2", 850], ["+", 853], ["levels", 855], ["but", 862], ["also", 866], ["SNP", 871], ["-", 874], ["induced", 875], ["increase", 883], ["in", 892], ["CHOP", 895], ["and", 900], ["GRP78", 904], ["mRNAs", 910], [".", 915], ["7", 917], [".", 918], ["SEA0400", 920], ["did", 928], ["not", 932], ["affect", 936], ["capacitative", 943], ["Ca2", 956], ["+", 959], ["entry", 961], ["in", 967], ["the", 970], ["presence", 974], ["and", 983], ["absence", 987], ["of", 995], ["SNP", 998], [".", 1001], ["8", 1003], [".", 1004], ["SNP", 1006], ["increased", 1010], ["Na+-dependent", 1020], ["45Ca2", 1034], ["+", 1039], ["uptake", 1041], ["and", 1048], ["this", 1052], ["increase", 1057], ["was", 1066], ["blocked", 1070], ["by", 1078], ["SEA0400", 1081], [".", 1088], ["9", 1090], [".", 1091], ["These", 1093], ["results", 1099], ["suggest", 1107], ["that", 1115], ["SNP", 1120], ["induces", 1124], ["apoptosis", 1132], ["via", 1142], ["the", 1146], ["ER", 1150], ["stress", 1153], ["pathway", 1160], ["and", 1168], ["SEA0400", 1172], ["attenuates", 1180], ["SNP", 1191], ["-", 1194], ["induced", 1195], ["apoptosis", 1203], ["via", 1213], ["suppression", 1217], ["of", 1229], ["the", 1232], ["ER", 1236], ["stress", 1239], ["in", 1246], ["cultured", 1249], ["microglia", 1258], [".", 1267], ["Our", 1269], ["findings", 1273], ["imply", 1282], ["that", 1288], ["NCX", 1293], ["plays", 1297], ["a", 1303], ["role", 1305], ["in", 1310], ["ER", 1313], ["Ca2", 1316], ["+", 1319], ["depletion", 1321], ["under", 1331], ["pathological", 1337], ["conditions", 1350], [".", 1360]]}
{"context": "Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality. Here we describe the rationale and design of the Phase 3 APOLLO study, a randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of patisiran in patients with hATTR amyloidosis with polyneuropathy. Eligible patients are 18-85\u00a0years old with hATTR amyloidosis, investigator-estimated survival of \u22652\u00a0years, Neuropathy Impairment Score (NIS) of 5-130, and polyneuropathy disability score\u00a0\u2264IIIb. Patients are randomized 2:1 to receive either intravenous patisiran 0.3\u00a0mg/kg or placebo once every 3\u00a0weeks. The primary objective is to determine the efficacy of patisiran at 18\u00a0months based on the difference in the change in modified NIS+7 (a composite measure of motor strength, sensation, reflexes, nerve conduction, and autonomic function) between the patisiran and placebo groups. Secondary objectives are to evaluate the effect of patisiran on Norfolk-Diabetic Neuropathy quality of life questionnaire score, nutritional status (as evaluated by modified body mass index), motor function (as measured by NIS-weakness and timed 10-m walk test), and autonomic symptoms (as measured by the Composite Autonomic Symptom Score-31 questionnaire). Exploratory objectives include assessment of cardiac function and pathologic evaluation to assess nerve fiber innervation and amyloid burden. Safety of patisiran will be assessed throughout the study. APOLLO represents the largest randomized, Phase 3 study to date in patients with hATTR amyloidosis, with endpoints that capture the multisystemic nature of this disease. This trial is registered at clinicaltrials.gov ( NCT01960348 ); October 9, 2013.", "qas": [{"question": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?", "answers": ["Patisiran"], "qid": "f6d7e1841db1466093bc4a2667512ecc", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["RNAi", 24], ["investigational", 29], ["drug", 45], ["being", 50], ["developed", 56], ["against", 66], ["hereditary", 74], ["amyloidosis", 85], ["?", 96]], "detected_answers": [{"text": "Patisiran", "token_spans": [[0, 0], [269, 269], [70, 70], [180, 180], [124, 124], [193, 193], [145, 145]], "char_spans": [[0, 8], [1558, 1566], [400, 408], [1017, 1025], [718, 726], [1098, 1106], [823, 831]]}]}], "context_tokens": [["Patisiran", 0], ["is", 10], ["an", 13], ["investigational", 16], ["RNA", 32], ["interference", 36], ["(", 49], ["RNAi", 50], [")", 54], ["therapeutic", 56], ["in", 68], ["development", 71], ["for", 83], ["the", 87], ["treatment", 91], ["of", 101], ["hereditary", 104], ["ATTR", 115], ["(", 120], ["hATTR", 121], [")", 126], ["amyloidosis", 128], [",", 139], ["a", 141], ["progressive", 143], ["disease", 155], ["associated", 163], ["with", 174], ["significant", 179], ["disability", 191], [",", 201], ["morbidity", 203], [",", 212], ["and", 214], ["mortality", 218], [".", 227], ["Here", 229], ["we", 234], ["describe", 237], ["the", 246], ["rationale", 250], ["and", 260], ["design", 264], ["of", 271], ["the", 274], ["Phase", 278], ["3", 284], ["APOLLO", 286], ["study", 293], [",", 298], ["a", 300], ["randomized", 302], [",", 312], ["double", 314], ["-", 320], ["blind", 321], [",", 326], ["placebo", 328], ["-", 335], ["controlled", 336], [",", 346], ["global", 348], ["study", 355], ["to", 361], ["evaluate", 364], ["the", 373], ["efficacy", 377], ["and", 386], ["safety", 390], ["of", 397], ["patisiran", 400], ["in", 410], ["patients", 413], ["with", 422], ["hATTR", 427], ["amyloidosis", 433], ["with", 445], ["polyneuropathy", 450], [".", 464], ["Eligible", 466], ["patients", 475], ["are", 484], ["18", 488], ["-", 490], ["85", 491], ["years", 494], ["old", 500], ["with", 504], ["hATTR", 509], ["amyloidosis", 515], [",", 526], ["investigator", 528], ["-", 540], ["estimated", 541], ["survival", 551], ["of", 560], ["\u22652", 563], ["years", 566], [",", 571], ["Neuropathy", 573], ["Impairment", 584], ["Score", 595], ["(", 601], ["NIS", 602], [")", 605], ["of", 607], ["5", 610], ["-", 611], ["130", 612], [",", 615], ["and", 617], ["polyneuropathy", 621], ["disability", 636], ["score", 647], ["\u2264IIIb", 653], [".", 658], ["Patients", 660], ["are", 669], ["randomized", 673], ["2:1", 684], ["to", 688], ["receive", 691], ["either", 699], ["intravenous", 706], ["patisiran", 718], ["0.3", 728], ["mg", 732], ["/", 734], ["kg", 735], ["or", 738], ["placebo", 741], ["once", 749], ["every", 754], ["3", 760], ["weeks", 762], [".", 767], ["The", 769], ["primary", 773], ["objective", 781], ["is", 791], ["to", 794], ["determine", 797], ["the", 807], ["efficacy", 811], ["of", 820], ["patisiran", 823], ["at", 833], ["18", 836], ["months", 839], ["based", 846], ["on", 852], ["the", 855], ["difference", 859], ["in", 870], ["the", 873], ["change", 877], ["in", 884], ["modified", 887], ["NIS+7", 896], ["(", 902], ["a", 903], ["composite", 905], ["measure", 915], ["of", 923], ["motor", 926], ["strength", 932], [",", 940], ["sensation", 942], [",", 951], ["reflexes", 953], [",", 961], ["nerve", 963], ["conduction", 969], [",", 979], ["and", 981], ["autonomic", 985], ["function", 995], [")", 1003], ["between", 1005], ["the", 1013], ["patisiran", 1017], ["and", 1027], ["placebo", 1031], ["groups", 1039], [".", 1045], ["Secondary", 1047], ["objectives", 1057], ["are", 1068], ["to", 1072], ["evaluate", 1075], ["the", 1084], ["effect", 1088], ["of", 1095], ["patisiran", 1098], ["on", 1108], ["Norfolk", 1111], ["-", 1118], ["Diabetic", 1119], ["Neuropathy", 1128], ["quality", 1139], ["of", 1147], ["life", 1150], ["questionnaire", 1155], ["score", 1169], [",", 1174], ["nutritional", 1176], ["status", 1188], ["(", 1195], ["as", 1196], ["evaluated", 1199], ["by", 1209], ["modified", 1212], ["body", 1221], ["mass", 1226], ["index", 1231], [")", 1236], [",", 1237], ["motor", 1239], ["function", 1245], ["(", 1254], ["as", 1255], ["measured", 1258], ["by", 1267], ["NIS", 1270], ["-", 1273], ["weakness", 1274], ["and", 1283], ["timed", 1287], ["10-m", 1293], ["walk", 1298], ["test", 1303], [")", 1307], [",", 1308], ["and", 1310], ["autonomic", 1314], ["symptoms", 1324], ["(", 1333], ["as", 1334], ["measured", 1337], ["by", 1346], ["the", 1349], ["Composite", 1353], ["Autonomic", 1363], ["Symptom", 1373], ["Score-31", 1381], ["questionnaire", 1390], [")", 1403], [".", 1404], ["Exploratory", 1406], ["objectives", 1418], ["include", 1429], ["assessment", 1437], ["of", 1448], ["cardiac", 1451], ["function", 1459], ["and", 1468], ["pathologic", 1472], ["evaluation", 1483], ["to", 1494], ["assess", 1497], ["nerve", 1504], ["fiber", 1510], ["innervation", 1516], ["and", 1528], ["amyloid", 1532], ["burden", 1540], [".", 1546], ["Safety", 1548], ["of", 1555], ["patisiran", 1558], ["will", 1568], ["be", 1573], ["assessed", 1576], ["throughout", 1585], ["the", 1596], ["study", 1600], [".", 1605], ["APOLLO", 1607], ["represents", 1614], ["the", 1625], ["largest", 1629], ["randomized", 1637], [",", 1647], ["Phase", 1649], ["3", 1655], ["study", 1657], ["to", 1663], ["date", 1666], ["in", 1671], ["patients", 1674], ["with", 1683], ["hATTR", 1688], ["amyloidosis", 1694], [",", 1705], ["with", 1707], ["endpoints", 1712], ["that", 1722], ["capture", 1727], ["the", 1735], ["multisystemic", 1739], ["nature", 1753], ["of", 1760], ["this", 1763], ["disease", 1768], [".", 1775], ["This", 1777], ["trial", 1782], ["is", 1788], ["registered", 1791], ["at", 1802], ["clinicaltrials.gov", 1805], ["(", 1824], ["NCT01960348", 1826], [")", 1838], [";", 1839], ["October", 1841], ["9", 1849], [",", 1850], ["2013", 1852], [".", 1856]]}
{"context": "In many genomic studies, one works with genome-position-dependent data, e.g. ChIP-chip or ChIP-Seq scores. Using conventional tools, it can be difficult to get a good feel for the data, especially the distribution of features. This article argues that the so-called Hilbert curve visualization can complement genome browsers and help to get further insights into the structure of one's data. This is demonstrated with examples from different use cases. An open-source application, called HilbertVis, is presented that allows the user to produce and interactively explore such plots. http://www.ebi.ac.uk/huber-srv/hilbert/.", "qas": [{"question": "Which R/bioconductor package utilizes the Hilbert curve in order to visualize genomic data?", "answers": ["HilbertVis"], "qid": "0d068226dea64534a6062b1fe2b2d4a6", "question_tokens": [["Which", 0], ["R", 6], ["/", 7], ["bioconductor", 8], ["package", 21], ["utilizes", 29], ["the", 38], ["Hilbert", 42], ["curve", 50], ["in", 56], ["order", 59], ["to", 65], ["visualize", 68], ["genomic", 78], ["data", 86], ["?", 90]], "detected_answers": [{"text": "HilbertVis", "token_spans": [[94, 94]], "char_spans": [[488, 497]]}]}], "context_tokens": [["In", 0], ["many", 3], ["genomic", 8], ["studies", 16], [",", 23], ["one", 25], ["works", 29], ["with", 35], ["genome", 40], ["-", 46], ["position", 47], ["-", 55], ["dependent", 56], ["data", 66], [",", 70], ["e.g.", 72], ["ChIP", 77], ["-", 81], ["chip", 82], ["or", 87], ["ChIP", 90], ["-", 94], ["Seq", 95], ["scores", 99], [".", 105], ["Using", 107], ["conventional", 113], ["tools", 126], [",", 131], ["it", 133], ["can", 136], ["be", 140], ["difficult", 143], ["to", 153], ["get", 156], ["a", 160], ["good", 162], ["feel", 167], ["for", 172], ["the", 176], ["data", 180], [",", 184], ["especially", 186], ["the", 197], ["distribution", 201], ["of", 214], ["features", 217], [".", 225], ["This", 227], ["article", 232], ["argues", 240], ["that", 247], ["the", 252], ["so", 256], ["-", 258], ["called", 259], ["Hilbert", 266], ["curve", 274], ["visualization", 280], ["can", 294], ["complement", 298], ["genome", 309], ["browsers", 316], ["and", 325], ["help", 329], ["to", 334], ["get", 337], ["further", 341], ["insights", 349], ["into", 358], ["the", 363], ["structure", 367], ["of", 377], ["one", 380], ["'s", 383], ["data", 386], [".", 390], ["This", 392], ["is", 397], ["demonstrated", 400], ["with", 413], ["examples", 418], ["from", 427], ["different", 432], ["use", 442], ["cases", 446], [".", 451], ["An", 453], ["open", 456], ["-", 460], ["source", 461], ["application", 468], [",", 479], ["called", 481], ["HilbertVis", 488], [",", 498], ["is", 500], ["presented", 503], ["that", 513], ["allows", 518], ["the", 525], ["user", 529], ["to", 534], ["produce", 537], ["and", 545], ["interactively", 549], ["explore", 563], ["such", 571], ["plots", 576], [".", 581], ["http://www.ebi.ac.uk", 583], ["/", 603], ["huber", 604], ["-", 609], ["srv", 610], ["/", 613], ["hilbert/.", 614]]}
{"context": "The major protein constituent of Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein, but other proteins, in particular the microtubule-associated protein tau, have been implicated in the pathogenesis of LBs. Tau is the major structural component of neurofibrillary tangles (NFTs). Both direct immunochemical studies of partially purified LBs and indirect immunohistochemical studies have suggested that LBs may contain tau, but most of these studies were based upon a single tau antibody, and immunologic cross-reactivity was not completely excluded. To gain insight into the relation between tau and alpha-synuclein in LBs, double immunostaining was performed in Lewy body cases with a rabbit polyclonal antibody to alpha-synuclein and a panel of monoclonal antibodies to phospho- and nonphospho-tau epitopes (Alz50, CP9, CP13, PG5, TG3, PHFI) that spanned the length of the tau molecule. Tau-immunoreactive LBs were present in the medulla in 80% of the cases, irrespective of Braak stage. All tau antibodies recognized at least some LBs, arguing against nonspecific antibody cross-reactivity. In most lesions the tau immunostaining was present at the periphery of the LB. The phospho-tau antibody, TG3, detected more LBs than any of the other tau antibodies. The proportion of LBs with tau immunoreactivity was greatest in neurons vulnerable to NETs, such as those in the locus ceruleus and basal nucleus of Meynert, and least in neurons resistant to NFTs, such as the dorsal motor nucleus of the vagus in the medulla. The present results suggest that tau may coaggregate with alpha-synuclein in LBs, especially in neuronal populations vulnerable to both NFTs and LBs.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "dd51992abbdc4acdbe0da902d5a6786a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[306, 308], [138, 140], [118, 120], [27, 29]], "char_spans": [[1661, 1675], [799, 813], [683, 697], [150, 164]]}]}], "context_tokens": [["The", 0], ["major", 4], ["protein", 10], ["constituent", 18], ["of", 30], ["Lewy", 33], ["bodies", 38], ["(", 45], ["LBs", 46], [")", 49], [",", 50], ["the", 52], ["pathological", 56], ["hallmark", 69], ["of", 78], ["Parkinson", 81], ["disease", 91], ["and", 99], ["dementia", 103], ["with", 112], ["Lewy", 117], ["bodies", 122], [",", 128], ["is", 130], ["considered", 133], ["to", 144], ["be", 147], ["alpha", 150], ["-", 155], ["synuclein", 156], [",", 165], ["but", 167], ["other", 171], ["proteins", 177], [",", 185], ["in", 187], ["particular", 190], ["the", 201], ["microtubule", 205], ["-", 216], ["associated", 217], ["protein", 228], ["tau", 236], [",", 239], ["have", 241], ["been", 246], ["implicated", 251], ["in", 262], ["the", 265], ["pathogenesis", 269], ["of", 282], ["LBs", 285], [".", 288], ["Tau", 290], ["is", 294], ["the", 297], ["major", 301], ["structural", 307], ["component", 318], ["of", 328], ["neurofibrillary", 331], ["tangles", 347], ["(", 355], ["NFTs", 356], [")", 360], [".", 361], ["Both", 363], ["direct", 368], ["immunochemical", 375], ["studies", 390], ["of", 398], ["partially", 401], ["purified", 411], ["LBs", 420], ["and", 424], ["indirect", 428], ["immunohistochemical", 437], ["studies", 457], ["have", 465], ["suggested", 470], ["that", 480], ["LBs", 485], ["may", 489], ["contain", 493], ["tau", 501], [",", 504], ["but", 506], ["most", 510], ["of", 515], ["these", 518], ["studies", 524], ["were", 532], ["based", 537], ["upon", 543], ["a", 548], ["single", 550], ["tau", 557], ["antibody", 561], [",", 569], ["and", 571], ["immunologic", 575], ["cross", 587], ["-", 592], ["reactivity", 593], ["was", 604], ["not", 608], ["completely", 612], ["excluded", 623], [".", 631], ["To", 633], ["gain", 636], ["insight", 641], ["into", 649], ["the", 654], ["relation", 658], ["between", 667], ["tau", 675], ["and", 679], ["alpha", 683], ["-", 688], ["synuclein", 689], ["in", 699], ["LBs", 702], [",", 705], ["double", 707], ["immunostaining", 714], ["was", 729], ["performed", 733], ["in", 743], ["Lewy", 746], ["body", 751], ["cases", 756], ["with", 762], ["a", 767], ["rabbit", 769], ["polyclonal", 776], ["antibody", 787], ["to", 796], ["alpha", 799], ["-", 804], ["synuclein", 805], ["and", 815], ["a", 819], ["panel", 821], ["of", 827], ["monoclonal", 830], ["antibodies", 841], ["to", 852], ["phospho-", 855], ["and", 864], ["nonphospho", 868], ["-", 878], ["tau", 879], ["epitopes", 883], ["(", 892], ["Alz50", 893], [",", 898], ["CP9", 900], [",", 903], ["CP13", 905], [",", 909], ["PG5", 911], [",", 914], ["TG3", 916], [",", 919], ["PHFI", 921], [")", 925], ["that", 927], ["spanned", 932], ["the", 940], ["length", 944], ["of", 951], ["the", 954], ["tau", 958], ["molecule", 962], [".", 970], ["Tau", 972], ["-", 975], ["immunoreactive", 976], ["LBs", 991], ["were", 995], ["present", 1000], ["in", 1008], ["the", 1011], ["medulla", 1015], ["in", 1023], ["80", 1026], ["%", 1028], ["of", 1030], ["the", 1033], ["cases", 1037], [",", 1042], ["irrespective", 1044], ["of", 1057], ["Braak", 1060], ["stage", 1066], [".", 1071], ["All", 1073], ["tau", 1077], ["antibodies", 1081], ["recognized", 1092], ["at", 1103], ["least", 1106], ["some", 1112], ["LBs", 1117], [",", 1120], ["arguing", 1122], ["against", 1130], ["nonspecific", 1138], ["antibody", 1150], ["cross", 1159], ["-", 1164], ["reactivity", 1165], [".", 1175], ["In", 1177], ["most", 1180], ["lesions", 1185], ["the", 1193], ["tau", 1197], ["immunostaining", 1201], ["was", 1216], ["present", 1220], ["at", 1228], ["the", 1231], ["periphery", 1235], ["of", 1245], ["the", 1248], ["LB", 1252], [".", 1254], ["The", 1256], ["phospho", 1260], ["-", 1267], ["tau", 1268], ["antibody", 1272], [",", 1280], ["TG3", 1282], [",", 1285], ["detected", 1287], ["more", 1296], ["LBs", 1301], ["than", 1305], ["any", 1310], ["of", 1314], ["the", 1317], ["other", 1321], ["tau", 1327], ["antibodies", 1331], [".", 1341], ["The", 1343], ["proportion", 1347], ["of", 1358], ["LBs", 1361], ["with", 1365], ["tau", 1370], ["immunoreactivity", 1374], ["was", 1391], ["greatest", 1395], ["in", 1404], ["neurons", 1407], ["vulnerable", 1415], ["to", 1426], ["NETs", 1429], [",", 1433], ["such", 1435], ["as", 1440], ["those", 1443], ["in", 1449], ["the", 1452], ["locus", 1456], ["ceruleus", 1462], ["and", 1471], ["basal", 1475], ["nucleus", 1481], ["of", 1489], ["Meynert", 1492], [",", 1499], ["and", 1501], ["least", 1505], ["in", 1511], ["neurons", 1514], ["resistant", 1522], ["to", 1532], ["NFTs", 1535], [",", 1539], ["such", 1541], ["as", 1546], ["the", 1549], ["dorsal", 1553], ["motor", 1560], ["nucleus", 1566], ["of", 1574], ["the", 1577], ["vagus", 1581], ["in", 1587], ["the", 1590], ["medulla", 1594], [".", 1601], ["The", 1603], ["present", 1607], ["results", 1615], ["suggest", 1623], ["that", 1631], ["tau", 1636], ["may", 1640], ["coaggregate", 1644], ["with", 1656], ["alpha", 1661], ["-", 1666], ["synuclein", 1667], ["in", 1677], ["LBs", 1680], [",", 1683], ["especially", 1685], ["in", 1696], ["neuronal", 1699], ["populations", 1708], ["vulnerable", 1720], ["to", 1731], ["both", 1734], ["NFTs", 1739], ["and", 1744], ["LBs", 1748], [".", 1751]]}
{"context": "The product of the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor gene, menin, is an integral component of MLL1/MLL2 histone methyltransferase complexes specific for Lys4 of histone H3 (H3K4). We show that menin is a transcriptional coactivator of the nuclear receptors for estrogen and vitamin D. Activation of the endogenous estrogen-responsive TFF1 (pS2) gene results in promoter recruitment of menin and in elevated trimethylation of H3K4. Knockdown of menin reduces both activated TFF1 (pS2) transcription and H3K4 trimethylation. In addition, menin can directly interact with the estrogen receptor-alpha (ERalpha) in a hormone-dependent manner. The majority of disease-related MEN1 mutations prevent menin-ERalpha interaction. Importantly, ERalpha-interacting mutants are also defective in coactivator function. Our results indicate that menin is a critical link between recruitment of histone methyltransferase complexes and nuclear receptor-mediated transcription.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "70cf419b833d4e9abc7eac1c6be3673c", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[91, 91], [77, 77], [34, 34]], "char_spans": [[528, 531], [451, 454], [199, 202]]}]}], "context_tokens": [["The", 0], ["product", 4], ["of", 12], ["the", 15], ["multiple", 19], ["endocrine", 28], ["neoplasia", 38], ["type", 48], ["1", 53], ["(", 55], ["MEN1", 56], [")", 60], ["tumor", 62], ["suppressor", 68], ["gene", 79], [",", 83], ["menin", 85], [",", 90], ["is", 92], ["an", 95], ["integral", 98], ["component", 107], ["of", 117], ["MLL1/MLL2", 120], ["histone", 130], ["methyltransferase", 138], ["complexes", 156], ["specific", 166], ["for", 175], ["Lys4", 179], ["of", 184], ["histone", 187], ["H3", 195], ["(", 198], ["H3K4", 199], [")", 203], [".", 204], ["We", 206], ["show", 209], ["that", 214], ["menin", 219], ["is", 225], ["a", 228], ["transcriptional", 230], ["coactivator", 246], ["of", 258], ["the", 261], ["nuclear", 265], ["receptors", 273], ["for", 283], ["estrogen", 287], ["and", 296], ["vitamin", 300], ["D.", 308], ["Activation", 311], ["of", 322], ["the", 325], ["endogenous", 329], ["estrogen", 340], ["-", 348], ["responsive", 349], ["TFF1", 360], ["(", 365], ["pS2", 366], [")", 369], ["gene", 371], ["results", 376], ["in", 384], ["promoter", 387], ["recruitment", 396], ["of", 408], ["menin", 411], ["and", 417], ["in", 421], ["elevated", 424], ["trimethylation", 433], ["of", 448], ["H3K4", 451], [".", 455], ["Knockdown", 457], ["of", 467], ["menin", 470], ["reduces", 476], ["both", 484], ["activated", 489], ["TFF1", 499], ["(", 504], ["pS2", 505], [")", 508], ["transcription", 510], ["and", 524], ["H3K4", 528], ["trimethylation", 533], [".", 547], ["In", 549], ["addition", 552], [",", 560], ["menin", 562], ["can", 568], ["directly", 572], ["interact", 581], ["with", 590], ["the", 595], ["estrogen", 599], ["receptor", 608], ["-", 616], ["alpha", 617], ["(", 623], ["ERalpha", 624], [")", 631], ["in", 633], ["a", 636], ["hormone", 638], ["-", 645], ["dependent", 646], ["manner", 656], [".", 662], ["The", 664], ["majority", 668], ["of", 677], ["disease", 680], ["-", 687], ["related", 688], ["MEN1", 696], ["mutations", 701], ["prevent", 711], ["menin", 719], ["-", 724], ["ERalpha", 725], ["interaction", 733], [".", 744], ["Importantly", 746], [",", 757], ["ERalpha", 759], ["-", 766], ["interacting", 767], ["mutants", 779], ["are", 787], ["also", 791], ["defective", 796], ["in", 806], ["coactivator", 809], ["function", 821], [".", 829], ["Our", 831], ["results", 835], ["indicate", 843], ["that", 852], ["menin", 857], ["is", 863], ["a", 866], ["critical", 868], ["link", 877], ["between", 882], ["recruitment", 890], ["of", 902], ["histone", 905], ["methyltransferase", 913], ["complexes", 931], ["and", 941], ["nuclear", 945], ["receptor", 953], ["-", 961], ["mediated", 962], ["transcription", 971], [".", 984]]}
{"context": "Increased expression of nerve growth factor in injured or inflamed tissue is associated with increased pain. This proof-of-concept study was designed to investigate the safety and analgesic efficacy of tanezumab, a humanized monoclonal antibody that binds and inhibits nerve growth factor. We randomly assigned 450 patients with osteoarthritis of the knee to receive tanezumab (administered at a dose of 10, 25, 50, 100, or 200 \u03bcg per kilogram of body weight) or placebo on days 1 and 56. The primary efficacy measures were knee pain while walking and the patient's global assessment of response to therapy. We also assessed pain, stiffness, and physical function using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); the rate of response using the criteria of the Outcome Measures for Rheumatology Committee and Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative (OMERACT-OARSI); and safety. When averaged over weeks 1 through 16, the mean reductions from baseline in knee pain while walking ranged from 45 to 62% with various doses of tanezumab, as compared with 22% with placebo (P<0.001). Tanezumab, as compared with placebo, was also associated with significantly greater improvements in the response to therapy as assessed with the use of the patients' global assessment measure (mean increases in score of 29 to 47% with various doses of tanezumab, as compared with 19% with placebo; P\u22640.001). The rate of response according to the OMERACT-OARSI criteria ranged from 74 to 93% with tanezumab treatment, as compared with 44% with placebo (P<0.001). The rates of adverse events were 68% and 55% in the tanezumab and placebo groups, respectively. The most common adverse events among tanezumab-treated patients were headache (9% of the patients), upper respiratory tract infection (7%), and paresthesia (7%). In this proof-of-concept study, treatment with tanezumab was associated with a reduction in joint pain and improvement in function, with mild and moderate adverse events, among patients with moderate-to-severe osteoarthritis of the knee. (Funded by Rinat Neuroscience; ClinicalTrials.gov number, NCT00394563.).", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "cf8660626db24842b789111d454df139", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[44, 46], [3, 5]], "char_spans": [[269, 287], [24, 42]]}]}], "context_tokens": [["Increased", 0], ["expression", 10], ["of", 21], ["nerve", 24], ["growth", 30], ["factor", 37], ["in", 44], ["injured", 47], ["or", 55], ["inflamed", 58], ["tissue", 67], ["is", 74], ["associated", 77], ["with", 88], ["increased", 93], ["pain", 103], [".", 107], ["This", 109], ["proof", 114], ["-", 119], ["of", 120], ["-", 122], ["concept", 123], ["study", 131], ["was", 137], ["designed", 141], ["to", 150], ["investigate", 153], ["the", 165], ["safety", 169], ["and", 176], ["analgesic", 180], ["efficacy", 190], ["of", 199], ["tanezumab", 202], [",", 211], ["a", 213], ["humanized", 215], ["monoclonal", 225], ["antibody", 236], ["that", 245], ["binds", 250], ["and", 256], ["inhibits", 260], ["nerve", 269], ["growth", 275], ["factor", 282], [".", 288], ["We", 290], ["randomly", 293], ["assigned", 302], ["450", 311], ["patients", 315], ["with", 324], ["osteoarthritis", 329], ["of", 344], ["the", 347], ["knee", 351], ["to", 356], ["receive", 359], ["tanezumab", 367], ["(", 377], ["administered", 378], ["at", 391], ["a", 394], ["dose", 396], ["of", 401], ["10", 404], [",", 406], ["25", 408], [",", 410], ["50", 412], [",", 414], ["100", 416], [",", 419], ["or", 421], ["200", 424], ["\u03bcg", 428], ["per", 431], ["kilogram", 435], ["of", 444], ["body", 447], ["weight", 452], [")", 458], ["or", 460], ["placebo", 463], ["on", 471], ["days", 474], ["1", 479], ["and", 481], ["56", 485], [".", 487], ["The", 489], ["primary", 493], ["efficacy", 501], ["measures", 510], ["were", 519], ["knee", 524], ["pain", 529], ["while", 534], ["walking", 540], ["and", 548], ["the", 552], ["patient", 556], ["'s", 563], ["global", 566], ["assessment", 573], ["of", 584], ["response", 587], ["to", 596], ["therapy", 599], [".", 606], ["We", 608], ["also", 611], ["assessed", 616], ["pain", 625], [",", 629], ["stiffness", 631], [",", 640], ["and", 642], ["physical", 646], ["function", 655], ["using", 664], ["the", 670], ["Western", 674], ["Ontario", 682], ["and", 690], ["McMaster", 694], ["Universities", 703], ["Osteoarthritis", 716], ["Index", 731], ["(", 737], ["WOMAC", 738], [")", 743], [";", 744], ["the", 746], ["rate", 750], ["of", 755], ["response", 758], ["using", 767], ["the", 773], ["criteria", 777], ["of", 786], ["the", 789], ["Outcome", 793], ["Measures", 801], ["for", 810], ["Rheumatology", 814], ["Committee", 827], ["and", 837], ["Osteoarthritis", 841], ["Research", 856], ["Society", 865], ["International", 873], ["Standing", 887], ["Committee", 896], ["for", 906], ["Clinical", 910], ["Trials", 919], ["Response", 926], ["Criteria", 935], ["Initiative", 944], ["(", 955], ["OMERACT", 956], ["-", 963], ["OARSI", 964], [")", 969], [";", 970], ["and", 972], ["safety", 976], [".", 982], ["When", 984], ["averaged", 989], ["over", 998], ["weeks", 1003], ["1", 1009], ["through", 1011], ["16", 1019], [",", 1021], ["the", 1023], ["mean", 1027], ["reductions", 1032], ["from", 1043], ["baseline", 1048], ["in", 1057], ["knee", 1060], ["pain", 1065], ["while", 1070], ["walking", 1076], ["ranged", 1084], ["from", 1091], ["45", 1096], ["to", 1099], ["62", 1102], ["%", 1104], ["with", 1106], ["various", 1111], ["doses", 1119], ["of", 1125], ["tanezumab", 1128], [",", 1137], ["as", 1139], ["compared", 1142], ["with", 1151], ["22", 1156], ["%", 1158], ["with", 1160], ["placebo", 1165], ["(", 1173], ["P<0.001", 1174], [")", 1181], [".", 1182], ["Tanezumab", 1184], [",", 1193], ["as", 1195], ["compared", 1198], ["with", 1207], ["placebo", 1212], [",", 1219], ["was", 1221], ["also", 1225], ["associated", 1230], ["with", 1241], ["significantly", 1246], ["greater", 1260], ["improvements", 1268], ["in", 1281], ["the", 1284], ["response", 1288], ["to", 1297], ["therapy", 1300], ["as", 1308], ["assessed", 1311], ["with", 1320], ["the", 1325], ["use", 1329], ["of", 1333], ["the", 1336], ["patients", 1340], ["'", 1348], ["global", 1350], ["assessment", 1357], ["measure", 1368], ["(", 1376], ["mean", 1377], ["increases", 1382], ["in", 1392], ["score", 1395], ["of", 1401], ["29", 1404], ["to", 1407], ["47", 1410], ["%", 1412], ["with", 1414], ["various", 1419], ["doses", 1427], ["of", 1433], ["tanezumab", 1436], [",", 1445], ["as", 1447], ["compared", 1450], ["with", 1459], ["19", 1464], ["%", 1466], ["with", 1468], ["placebo", 1473], [";", 1480], ["P\u22640.001", 1482], [")", 1489], [".", 1490], ["The", 1492], ["rate", 1496], ["of", 1501], ["response", 1504], ["according", 1513], ["to", 1523], ["the", 1526], ["OMERACT", 1530], ["-", 1537], ["OARSI", 1538], ["criteria", 1544], ["ranged", 1553], ["from", 1560], ["74", 1565], ["to", 1568], ["93", 1571], ["%", 1573], ["with", 1575], ["tanezumab", 1580], ["treatment", 1590], [",", 1599], ["as", 1601], ["compared", 1604], ["with", 1613], ["44", 1618], ["%", 1620], ["with", 1622], ["placebo", 1627], ["(", 1635], ["P<0.001", 1636], [")", 1643], [".", 1644], ["The", 1646], ["rates", 1650], ["of", 1656], ["adverse", 1659], ["events", 1667], ["were", 1674], ["68", 1679], ["%", 1681], ["and", 1683], ["55", 1687], ["%", 1689], ["in", 1691], ["the", 1694], ["tanezumab", 1698], ["and", 1708], ["placebo", 1712], ["groups", 1720], [",", 1726], ["respectively", 1728], [".", 1740], ["The", 1742], ["most", 1746], ["common", 1751], ["adverse", 1758], ["events", 1766], ["among", 1773], ["tanezumab", 1779], ["-", 1788], ["treated", 1789], ["patients", 1797], ["were", 1806], ["headache", 1811], ["(", 1820], ["9", 1821], ["%", 1822], ["of", 1824], ["the", 1827], ["patients", 1831], [")", 1839], [",", 1840], ["upper", 1842], ["respiratory", 1848], ["tract", 1860], ["infection", 1866], ["(", 1876], ["7", 1877], ["%", 1878], [")", 1879], [",", 1880], ["and", 1882], ["paresthesia", 1886], ["(", 1898], ["7", 1899], ["%", 1900], [")", 1901], [".", 1902], ["In", 1904], ["this", 1907], ["proof", 1912], ["-", 1917], ["of", 1918], ["-", 1920], ["concept", 1921], ["study", 1929], [",", 1934], ["treatment", 1936], ["with", 1946], ["tanezumab", 1951], ["was", 1961], ["associated", 1965], ["with", 1976], ["a", 1981], ["reduction", 1983], ["in", 1993], ["joint", 1996], ["pain", 2002], ["and", 2007], ["improvement", 2011], ["in", 2023], ["function", 2026], [",", 2034], ["with", 2036], ["mild", 2041], ["and", 2046], ["moderate", 2050], ["adverse", 2059], ["events", 2067], [",", 2073], ["among", 2075], ["patients", 2081], ["with", 2090], ["moderate", 2095], ["-", 2103], ["to", 2104], ["-", 2106], ["severe", 2107], ["osteoarthritis", 2114], ["of", 2129], ["the", 2132], ["knee", 2136], [".", 2140], ["(", 2142], ["Funded", 2143], ["by", 2150], ["Rinat", 2153], ["Neuroscience", 2159], [";", 2171], ["ClinicalTrials.gov", 2173], ["number", 2192], [",", 2198], ["NCT00394563", 2200], [".", 2211], [")", 2212], [".", 2213]]}
{"context": "The 2016 Conference on Retroviruses and Opportunistic Infections (CROI) highlighted hot spots in HIV infection. Men who have sex with men (MSM), transgender populations, people who inject drugs, fisherfolk, migrants, adolescents, and older adults are heavily impacted in a number of regions. Stigma contributes to risk behaviors and HIV acquisition across populations. HIV testing is a crucial first step in the HIV care continuum, and several large community-based surveys are underway in Africa to increase HIV testing, linkage to care, and uptake of antiretroviral treatment. Advances in preexposure prophylaxis (PrEP) featured prominently at CROI 2016. Two large efficacy trials of a vaginal ring containing the investigational drug dapivirine demonstrated efficacy and safety in preventing HIV infections in women in Africa. Data on the safety of long-acting injectable PrEP and several investigational PrEP drugs and formulations were also presented. Knowledge and use of PrEP among MSM in the United States appears to be increasing, and high uptake was seen among black MSM when provided as part of a culturally tailored support program. The use of broadly neutralizing antibodies for HIV prevention is a novel and promising approach to be evaluated in efficacy trials.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "b6d97f2cc9864e81ae3ccfefeac8cedd", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[91, 91], [74, 74], [60, 60], [136, 136], [206, 206], [65, 65], [15, 15]], "char_spans": [[509, 511], [412, 414], [333, 335], [795, 797], [1192, 1194], [369, 371], [97, 99]]}]}], "context_tokens": [["The", 0], ["2016", 4], ["Conference", 9], ["on", 20], ["Retroviruses", 23], ["and", 36], ["Opportunistic", 40], ["Infections", 54], ["(", 65], ["CROI", 66], [")", 70], ["highlighted", 72], ["hot", 84], ["spots", 88], ["in", 94], ["HIV", 97], ["infection", 101], [".", 110], ["Men", 112], ["who", 116], ["have", 120], ["sex", 125], ["with", 129], ["men", 134], ["(", 138], ["MSM", 139], [")", 142], [",", 143], ["transgender", 145], ["populations", 157], [",", 168], ["people", 170], ["who", 177], ["inject", 181], ["drugs", 188], [",", 193], ["fisherfolk", 195], [",", 205], ["migrants", 207], [",", 215], ["adolescents", 217], [",", 228], ["and", 230], ["older", 234], ["adults", 240], ["are", 247], ["heavily", 251], ["impacted", 259], ["in", 268], ["a", 271], ["number", 273], ["of", 280], ["regions", 283], [".", 290], ["Stigma", 292], ["contributes", 299], ["to", 311], ["risk", 314], ["behaviors", 319], ["and", 329], ["HIV", 333], ["acquisition", 337], ["across", 349], ["populations", 356], [".", 367], ["HIV", 369], ["testing", 373], ["is", 381], ["a", 384], ["crucial", 386], ["first", 394], ["step", 400], ["in", 405], ["the", 408], ["HIV", 412], ["care", 416], ["continuum", 421], [",", 430], ["and", 432], ["several", 436], ["large", 444], ["community", 450], ["-", 459], ["based", 460], ["surveys", 466], ["are", 474], ["underway", 478], ["in", 487], ["Africa", 490], ["to", 497], ["increase", 500], ["HIV", 509], ["testing", 513], [",", 520], ["linkage", 522], ["to", 530], ["care", 533], [",", 537], ["and", 539], ["uptake", 543], ["of", 550], ["antiretroviral", 553], ["treatment", 568], [".", 577], ["Advances", 579], ["in", 588], ["preexposure", 591], ["prophylaxis", 603], ["(", 615], ["PrEP", 616], [")", 620], ["featured", 622], ["prominently", 631], ["at", 643], ["CROI", 646], ["2016", 651], [".", 655], ["Two", 657], ["large", 661], ["efficacy", 667], ["trials", 676], ["of", 683], ["a", 686], ["vaginal", 688], ["ring", 696], ["containing", 701], ["the", 712], ["investigational", 716], ["drug", 732], ["dapivirine", 737], ["demonstrated", 748], ["efficacy", 761], ["and", 770], ["safety", 774], ["in", 781], ["preventing", 784], ["HIV", 795], ["infections", 799], ["in", 810], ["women", 813], ["in", 819], ["Africa", 822], [".", 828], ["Data", 830], ["on", 835], ["the", 838], ["safety", 842], ["of", 849], ["long", 852], ["-", 856], ["acting", 857], ["injectable", 864], ["PrEP", 875], ["and", 880], ["several", 884], ["investigational", 892], ["PrEP", 908], ["drugs", 913], ["and", 919], ["formulations", 923], ["were", 936], ["also", 941], ["presented", 946], [".", 955], ["Knowledge", 957], ["and", 967], ["use", 971], ["of", 975], ["PrEP", 978], ["among", 983], ["MSM", 989], ["in", 993], ["the", 996], ["United", 1000], ["States", 1007], ["appears", 1014], ["to", 1022], ["be", 1025], ["increasing", 1028], [",", 1038], ["and", 1040], ["high", 1044], ["uptake", 1049], ["was", 1056], ["seen", 1060], ["among", 1065], ["black", 1071], ["MSM", 1077], ["when", 1081], ["provided", 1086], ["as", 1095], ["part", 1098], ["of", 1103], ["a", 1106], ["culturally", 1108], ["tailored", 1119], ["support", 1128], ["program", 1136], [".", 1143], ["The", 1145], ["use", 1149], ["of", 1153], ["broadly", 1156], ["neutralizing", 1164], ["antibodies", 1177], ["for", 1188], ["HIV", 1192], ["prevention", 1196], ["is", 1207], ["a", 1210], ["novel", 1212], ["and", 1218], ["promising", 1222], ["approach", 1232], ["to", 1241], ["be", 1244], ["evaluated", 1247], ["in", 1257], ["efficacy", 1260], ["trials", 1269], [".", 1275]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by formation of a BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22. Recently the development of new fluorescence in-situ hybridization (FISH) techniques has allowed identification of unexpected deletions of the reciprocal translocation product, the derivative chromosome 9, in 10% to 15% of patients with CML. These deletions are large, span the translocation breakpoint, and occur at the same time as the Ph translocation. Such deletions therefore give rise to previously unsuspected molecular heterogeneity from the very beginning of this disease, and there is mounting evidence for similar deletions associated with other translocations. Several studies have demonstrated that CML patients who carry derivative chromosome 9 deletions exhibit a more rapid progression to blast crisis and a shorter survival. Deletion status is independent of, and more powerful than, the Sokal and Hasford/European prognostic scoring systems. The poor prognosis associated with deletions is seen in patients treated with hydroxyurea or interferon, and preliminary evidence suggests that patients with deletions may also have a worse outcome than nondeleted patients following stem cell transplantation or treatment with imatinib. Poor outcome cannot be attributed to loss of the reciprocal ABL-BCR fusion gene expression alone, and is likely to reflect loss of one or more critical genes within the deleted region. The molecular heterogeneity associated with the Philadelphia translocation provides a new paradigm with potential relevance to all malignancies associated with reciprocal chromosomal translocations and/or fusion gene formation.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "1d0edfd264d5465fadb7c6268c608128", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "ABL/BCR fusion", "token_spans": [[229, 232]], "char_spans": [[1388, 1401]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["formation", 51], ["of", 61], ["a", 64], ["BCR", 66], ["-", 69], ["ABL", 70], ["fusion", 74], ["gene", 81], [",", 85], ["usually", 87], ["as", 95], ["a", 98], ["consequence", 100], ["of", 112], ["the", 115], ["Philadelphia", 119], ["(", 132], ["Ph", 133], [")", 135], ["translocation", 137], ["between", 151], ["chromosomes", 159], ["9", 171], ["and", 173], ["22", 177], [".", 179], ["Recently", 181], ["the", 190], ["development", 194], ["of", 206], ["new", 209], ["fluorescence", 213], ["in", 226], ["-", 228], ["situ", 229], ["hybridization", 234], ["(", 248], ["FISH", 249], [")", 253], ["techniques", 255], ["has", 266], ["allowed", 270], ["identification", 278], ["of", 293], ["unexpected", 296], ["deletions", 307], ["of", 317], ["the", 320], ["reciprocal", 324], ["translocation", 335], ["product", 349], [",", 356], ["the", 358], ["derivative", 362], ["chromosome", 373], ["9", 384], [",", 385], ["in", 387], ["10", 390], ["%", 392], ["to", 394], ["15", 397], ["%", 399], ["of", 401], ["patients", 404], ["with", 413], ["CML", 418], [".", 421], ["These", 423], ["deletions", 429], ["are", 439], ["large", 443], [",", 448], ["span", 450], ["the", 455], ["translocation", 459], ["breakpoint", 473], [",", 483], ["and", 485], ["occur", 489], ["at", 495], ["the", 498], ["same", 502], ["time", 507], ["as", 512], ["the", 515], ["Ph", 519], ["translocation", 522], [".", 535], ["Such", 537], ["deletions", 542], ["therefore", 552], ["give", 562], ["rise", 567], ["to", 572], ["previously", 575], ["unsuspected", 586], ["molecular", 598], ["heterogeneity", 608], ["from", 622], ["the", 627], ["very", 631], ["beginning", 636], ["of", 646], ["this", 649], ["disease", 654], [",", 661], ["and", 663], ["there", 667], ["is", 673], ["mounting", 676], ["evidence", 685], ["for", 694], ["similar", 698], ["deletions", 706], ["associated", 716], ["with", 727], ["other", 732], ["translocations", 738], [".", 752], ["Several", 754], ["studies", 762], ["have", 770], ["demonstrated", 775], ["that", 788], ["CML", 793], ["patients", 797], ["who", 806], ["carry", 810], ["derivative", 816], ["chromosome", 827], ["9", 838], ["deletions", 840], ["exhibit", 850], ["a", 858], ["more", 860], ["rapid", 865], ["progression", 871], ["to", 883], ["blast", 886], ["crisis", 892], ["and", 899], ["a", 903], ["shorter", 905], ["survival", 913], [".", 921], ["Deletion", 923], ["status", 932], ["is", 939], ["independent", 942], ["of", 954], [",", 956], ["and", 958], ["more", 962], ["powerful", 967], ["than", 976], [",", 980], ["the", 982], ["Sokal", 986], ["and", 992], ["Hasford", 996], ["/", 1003], ["European", 1004], ["prognostic", 1013], ["scoring", 1024], ["systems", 1032], [".", 1039], ["The", 1041], ["poor", 1045], ["prognosis", 1050], ["associated", 1060], ["with", 1071], ["deletions", 1076], ["is", 1086], ["seen", 1089], ["in", 1094], ["patients", 1097], ["treated", 1106], ["with", 1114], ["hydroxyurea", 1119], ["or", 1131], ["interferon", 1134], [",", 1144], ["and", 1146], ["preliminary", 1150], ["evidence", 1162], ["suggests", 1171], ["that", 1180], ["patients", 1185], ["with", 1194], ["deletions", 1199], ["may", 1209], ["also", 1213], ["have", 1218], ["a", 1223], ["worse", 1225], ["outcome", 1231], ["than", 1239], ["nondeleted", 1244], ["patients", 1255], ["following", 1264], ["stem", 1274], ["cell", 1279], ["transplantation", 1284], ["or", 1300], ["treatment", 1303], ["with", 1313], ["imatinib", 1318], [".", 1326], ["Poor", 1328], ["outcome", 1333], ["can", 1341], ["not", 1344], ["be", 1348], ["attributed", 1351], ["to", 1362], ["loss", 1365], ["of", 1370], ["the", 1373], ["reciprocal", 1377], ["ABL", 1388], ["-", 1391], ["BCR", 1392], ["fusion", 1396], ["gene", 1403], ["expression", 1408], ["alone", 1419], [",", 1424], ["and", 1426], ["is", 1430], ["likely", 1433], ["to", 1440], ["reflect", 1443], ["loss", 1451], ["of", 1456], ["one", 1459], ["or", 1463], ["more", 1466], ["critical", 1471], ["genes", 1480], ["within", 1486], ["the", 1493], ["deleted", 1497], ["region", 1505], [".", 1511], ["The", 1513], ["molecular", 1517], ["heterogeneity", 1527], ["associated", 1541], ["with", 1552], ["the", 1557], ["Philadelphia", 1561], ["translocation", 1574], ["provides", 1588], ["a", 1597], ["new", 1599], ["paradigm", 1603], ["with", 1612], ["potential", 1617], ["relevance", 1627], ["to", 1637], ["all", 1640], ["malignancies", 1644], ["associated", 1657], ["with", 1668], ["reciprocal", 1673], ["chromosomal", 1684], ["translocations", 1696], ["and/or", 1711], ["fusion", 1718], ["gene", 1725], ["formation", 1730], [".", 1739]]}
{"context": "Giant-cell tumor of bone is a rare, locally aggressive tumor that typically occurs in the bones of skeletally mature young adults in their second to fourth decades. Traditionally, surgery has been the mainstay of therapy for this disease, but the disease can recur even with optimal procedures. Furthermore, it may occur in locations where a surgical approach would be morbid. The maturation of the understanding of the role of the receptor activator of nuclear factor-\u03baB ligand (RANKL) in the pathophysiology of giant-cell tumor of bone has led to the use of denosumab, a monoclonal antibody against RANKL, in this disease. In 2013, the US Food and Drug Administration approved denosumab for use in patients with recurrent/unresectable/metastatic giant-cell tumor of bone or for patients in whom surgery would be morbid.", "qas": [{"question": "Which is the target of the drug Denosumab?", "answers": ["receptor activator of nuclear factor-\u03baB ligand", "RANKL"], "qid": "ce4f694e2894496cb11f3d96bd206a41", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["the", 23], ["drug", 27], ["Denosumab", 32], ["?", 41]], "detected_answers": [{"text": "receptor activator of nuclear factor-\u03baB ligand", "token_spans": [[79, 86]], "char_spans": [[432, 477]]}, {"text": "RANKL", "token_spans": [[88, 88], [112, 112]], "char_spans": [[480, 484], [601, 605]]}]}], "context_tokens": [["Giant", 0], ["-", 5], ["cell", 6], ["tumor", 11], ["of", 17], ["bone", 20], ["is", 25], ["a", 28], ["rare", 30], [",", 34], ["locally", 36], ["aggressive", 44], ["tumor", 55], ["that", 61], ["typically", 66], ["occurs", 76], ["in", 83], ["the", 86], ["bones", 90], ["of", 96], ["skeletally", 99], ["mature", 110], ["young", 117], ["adults", 123], ["in", 130], ["their", 133], ["second", 139], ["to", 146], ["fourth", 149], ["decades", 156], [".", 163], ["Traditionally", 165], [",", 178], ["surgery", 180], ["has", 188], ["been", 192], ["the", 197], ["mainstay", 201], ["of", 210], ["therapy", 213], ["for", 221], ["this", 225], ["disease", 230], [",", 237], ["but", 239], ["the", 243], ["disease", 247], ["can", 255], ["recur", 259], ["even", 265], ["with", 270], ["optimal", 275], ["procedures", 283], [".", 293], ["Furthermore", 295], [",", 306], ["it", 308], ["may", 311], ["occur", 315], ["in", 321], ["locations", 324], ["where", 334], ["a", 340], ["surgical", 342], ["approach", 351], ["would", 360], ["be", 366], ["morbid", 369], [".", 375], ["The", 377], ["maturation", 381], ["of", 392], ["the", 395], ["understanding", 399], ["of", 413], ["the", 416], ["role", 420], ["of", 425], ["the", 428], ["receptor", 432], ["activator", 441], ["of", 451], ["nuclear", 454], ["factor", 462], ["-", 468], ["\u03baB", 469], ["ligand", 472], ["(", 479], ["RANKL", 480], [")", 485], ["in", 487], ["the", 490], ["pathophysiology", 494], ["of", 510], ["giant", 513], ["-", 518], ["cell", 519], ["tumor", 524], ["of", 530], ["bone", 533], ["has", 538], ["led", 542], ["to", 546], ["the", 549], ["use", 553], ["of", 557], ["denosumab", 560], [",", 569], ["a", 571], ["monoclonal", 573], ["antibody", 584], ["against", 593], ["RANKL", 601], [",", 606], ["in", 608], ["this", 611], ["disease", 616], [".", 623], ["In", 625], ["2013", 628], [",", 632], ["the", 634], ["US", 638], ["Food", 641], ["and", 646], ["Drug", 650], ["Administration", 655], ["approved", 670], ["denosumab", 679], ["for", 689], ["use", 693], ["in", 697], ["patients", 700], ["with", 709], ["recurrent", 714], ["/", 723], ["unresectable", 724], ["/", 736], ["metastatic", 737], ["giant", 748], ["-", 753], ["cell", 754], ["tumor", 759], ["of", 765], ["bone", 768], ["or", 773], ["for", 776], ["patients", 780], ["in", 789], ["whom", 792], ["surgery", 797], ["would", 805], ["be", 811], ["morbid", 814], [".", 820]]}
{"context": "The similarities of the larval and nymph stages of the tick and louse (Pthirus pubis) may lead to misdiagnosis in rare cases of infestation of the eyelashes. The most frequent manifestations of tick in the eye are conjunctivitis, uveitis, keratitis, and vasculitis. Tick inoculation of the skin can locally lead to formation of granuloma and abscess. More concerning is the potential systemic sequelae that can result from transmission of zoonoses such as Lyme disease. P. pubis can cause pruritic eyelid margins or unusual blepharoconjunctivitis. We present a case of phthiriasis palpebrarum in a 4-year-old boy.", "qas": [{"question": "What is the cause of Phthiriasis Palpebrarum?", "answers": ["Pthirus pubis"], "qid": "d99ab786d2ec4d17b1540cf721370ef0", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["cause", 12], ["of", 18], ["Phthiriasis", 21], ["Palpebrarum", 33], ["?", 44]], "detected_answers": [{"text": "Pthirus pubis", "token_spans": [[14, 15]], "char_spans": [[71, 83]]}]}], "context_tokens": [["The", 0], ["similarities", 4], ["of", 17], ["the", 20], ["larval", 24], ["and", 31], ["nymph", 35], ["stages", 41], ["of", 48], ["the", 51], ["tick", 55], ["and", 60], ["louse", 64], ["(", 70], ["Pthirus", 71], ["pubis", 79], [")", 84], ["may", 86], ["lead", 90], ["to", 95], ["misdiagnosis", 98], ["in", 111], ["rare", 114], ["cases", 119], ["of", 125], ["infestation", 128], ["of", 140], ["the", 143], ["eyelashes", 147], [".", 156], ["The", 158], ["most", 162], ["frequent", 167], ["manifestations", 176], ["of", 191], ["tick", 194], ["in", 199], ["the", 202], ["eye", 206], ["are", 210], ["conjunctivitis", 214], [",", 228], ["uveitis", 230], [",", 237], ["keratitis", 239], [",", 248], ["and", 250], ["vasculitis", 254], [".", 264], ["Tick", 266], ["inoculation", 271], ["of", 283], ["the", 286], ["skin", 290], ["can", 295], ["locally", 299], ["lead", 307], ["to", 312], ["formation", 315], ["of", 325], ["granuloma", 328], ["and", 338], ["abscess", 342], [".", 349], ["More", 351], ["concerning", 356], ["is", 367], ["the", 370], ["potential", 374], ["systemic", 384], ["sequelae", 393], ["that", 402], ["can", 407], ["result", 411], ["from", 418], ["transmission", 423], ["of", 436], ["zoonoses", 439], ["such", 448], ["as", 453], ["Lyme", 456], ["disease", 461], [".", 468], ["P.", 470], ["pubis", 473], ["can", 479], ["cause", 483], ["pruritic", 489], ["eyelid", 498], ["margins", 505], ["or", 513], ["unusual", 516], ["blepharoconjunctivitis", 524], [".", 546], ["We", 548], ["present", 551], ["a", 559], ["case", 561], ["of", 566], ["phthiriasis", 569], ["palpebrarum", 581], ["in", 593], ["a", 596], ["4-year", 598], ["-", 604], ["old", 605], ["boy", 609], [".", 612]]}
{"context": "p73 is a p53 family transcription factor. Due to the presence in the 5' flanking region of two promoters, there are two N-terminal variants, TAp73, which retains a fully active transactivation domain (TA), and \u0394Np73, in which the N terminus is truncated. In addition, extensive 3' splicing gives rise to at least seven distinctive isoforms; TAp73-selective knockout highlights its role as a regulator of cell death, senescence and tumor suppressor. \u0394Np73-selective knockout, on the other hand, highlights anti-apoptotic function of \u0394Np73 and its involvement in DNA damage response. In this work, we investigated the expression pattern of murine p73 C-terminal isoforms. By using a RT-PCR approach, we were able to detect mRNAs of all the C-terminal isoforms described in humans. We characterized their in vivo expression profile in mouse organs and in different mouse developmental stages. Finally, we investigated p73 C-terminal expression profile following DNA damage, ex vivo after primary cultures treatment and in vivo after systemic administration of cytotoxic compounds. Overall, our study first elucidates spatio-temporal expression of mouse p73 isoforms and provides novel insights on their expression-switch under triggered conditions.", "qas": [{"question": "How many TAp73 isoforms have been identified in humans?", "answers": ["seven", "7"], "qid": "4d0d8f548cf94dc489db689b3aa53512", "question_tokens": [["How", 0], ["many", 4], ["TAp73", 9], ["isoforms", 15], ["have", 24], ["been", 29], ["identified", 34], ["in", 45], ["humans", 48], ["?", 54]], "detected_answers": [{"text": "seven", "token_spans": [[66, 66]], "char_spans": [[313, 317]]}]}], "context_tokens": [["p73", 0], ["is", 4], ["a", 7], ["p53", 9], ["family", 13], ["transcription", 20], ["factor", 34], [".", 40], ["Due", 42], ["to", 46], ["the", 49], ["presence", 53], ["in", 62], ["the", 65], ["5", 69], ["'", 70], ["flanking", 72], ["region", 81], ["of", 88], ["two", 91], ["promoters", 95], [",", 104], ["there", 106], ["are", 112], ["two", 116], ["N", 120], ["-", 121], ["terminal", 122], ["variants", 131], [",", 139], ["TAp73", 141], [",", 146], ["which", 148], ["retains", 154], ["a", 162], ["fully", 164], ["active", 170], ["transactivation", 177], ["domain", 193], ["(", 200], ["TA", 201], [")", 203], [",", 204], ["and", 206], ["\u0394Np73", 210], [",", 215], ["in", 217], ["which", 220], ["the", 226], ["N", 230], ["terminus", 232], ["is", 241], ["truncated", 244], [".", 253], ["In", 255], ["addition", 258], [",", 266], ["extensive", 268], ["3", 278], ["'", 279], ["splicing", 281], ["gives", 290], ["rise", 296], ["to", 301], ["at", 304], ["least", 307], ["seven", 313], ["distinctive", 319], ["isoforms", 331], [";", 339], ["TAp73-selective", 341], ["knockout", 357], ["highlights", 366], ["its", 377], ["role", 381], ["as", 386], ["a", 389], ["regulator", 391], ["of", 401], ["cell", 404], ["death", 409], [",", 414], ["senescence", 416], ["and", 427], ["tumor", 431], ["suppressor", 437], [".", 447], ["\u0394Np73-selective", 449], ["knockout", 465], [",", 473], ["on", 475], ["the", 478], ["other", 482], ["hand", 488], [",", 492], ["highlights", 494], ["anti", 505], ["-", 509], ["apoptotic", 510], ["function", 520], ["of", 529], ["\u0394Np73", 532], ["and", 538], ["its", 542], ["involvement", 546], ["in", 558], ["DNA", 561], ["damage", 565], ["response", 572], [".", 580], ["In", 582], ["this", 585], ["work", 590], [",", 594], ["we", 596], ["investigated", 599], ["the", 612], ["expression", 616], ["pattern", 627], ["of", 635], ["murine", 638], ["p73", 645], ["C", 649], ["-", 650], ["terminal", 651], ["isoforms", 660], [".", 668], ["By", 670], ["using", 673], ["a", 679], ["RT", 681], ["-", 683], ["PCR", 684], ["approach", 688], [",", 696], ["we", 698], ["were", 701], ["able", 706], ["to", 711], ["detect", 714], ["mRNAs", 721], ["of", 727], ["all", 730], ["the", 734], ["C", 738], ["-", 739], ["terminal", 740], ["isoforms", 749], ["described", 758], ["in", 768], ["humans", 771], [".", 777], ["We", 779], ["characterized", 782], ["their", 796], ["in", 802], ["vivo", 805], ["expression", 810], ["profile", 821], ["in", 829], ["mouse", 832], ["organs", 838], ["and", 845], ["in", 849], ["different", 852], ["mouse", 862], ["developmental", 868], ["stages", 882], [".", 888], ["Finally", 890], [",", 897], ["we", 899], ["investigated", 902], ["p73", 915], ["C", 919], ["-", 920], ["terminal", 921], ["expression", 930], ["profile", 941], ["following", 949], ["DNA", 959], ["damage", 963], [",", 969], ["ex", 971], ["vivo", 974], ["after", 979], ["primary", 985], ["cultures", 993], ["treatment", 1002], ["and", 1012], ["in", 1016], ["vivo", 1019], ["after", 1024], ["systemic", 1030], ["administration", 1039], ["of", 1054], ["cytotoxic", 1057], ["compounds", 1067], [".", 1076], ["Overall", 1078], [",", 1085], ["our", 1087], ["study", 1091], ["first", 1097], ["elucidates", 1103], ["spatio", 1114], ["-", 1120], ["temporal", 1121], ["expression", 1130], ["of", 1141], ["mouse", 1144], ["p73", 1150], ["isoforms", 1154], ["and", 1163], ["provides", 1167], ["novel", 1176], ["insights", 1182], ["on", 1191], ["their", 1194], ["expression", 1200], ["-", 1210], ["switch", 1211], ["under", 1218], ["triggered", 1224], ["conditions", 1234], [".", 1244]]}
{"context": "The Sotos syndrome gene product, NSD1, is a SET domain histone methyltransferase that primarily dimethylates nucleosomal histone H3 lysine 36 (H3K36). To date, the intrinsic properties of NSD1 that determine its nucleosomal substrate selectivity and dimethyl H3K36 product specificity remain unknown. The 1.7 \u00c5 structure of the catalytic domain of NSD1 presented here shows that a regulatory loop adopts a conformation that prevents free access of H3K36 to the bound S-adenosyl-L-methionine. Molecular dynamics simulation and computational docking revealed that this normally inhibitory loop can adopt an active conformation, allowing H3K36 access to the active site, and that the nucleosome may stabilize the active conformation of the regulatory loop. Hence, our study reveals an autoregulatory mechanism of NSD1 and provides insight into the molecular mechanism of the nucleosomal substrate selectivity of this disease-related H3K36 methyltransferase.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "d8dc6dcb02604df98e1a216e74a229fa", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[10, 11]], "char_spans": [[44, 53]]}]}], "context_tokens": [["The", 0], ["Sotos", 4], ["syndrome", 10], ["gene", 19], ["product", 24], [",", 31], ["NSD1", 33], [",", 37], ["is", 39], ["a", 42], ["SET", 44], ["domain", 48], ["histone", 55], ["methyltransferase", 63], ["that", 81], ["primarily", 86], ["dimethylates", 96], ["nucleosomal", 109], ["histone", 121], ["H3", 129], ["lysine", 132], ["36", 139], ["(", 142], ["H3K36", 143], [")", 148], [".", 149], ["To", 151], ["date", 154], [",", 158], ["the", 160], ["intrinsic", 164], ["properties", 174], ["of", 185], ["NSD1", 188], ["that", 193], ["determine", 198], ["its", 208], ["nucleosomal", 212], ["substrate", 224], ["selectivity", 234], ["and", 246], ["dimethyl", 250], ["H3K36", 259], ["product", 265], ["specificity", 273], ["remain", 285], ["unknown", 292], [".", 299], ["The", 301], ["1.7", 305], ["\u00c5", 309], ["structure", 311], ["of", 321], ["the", 324], ["catalytic", 328], ["domain", 338], ["of", 345], ["NSD1", 348], ["presented", 353], ["here", 363], ["shows", 368], ["that", 374], ["a", 379], ["regulatory", 381], ["loop", 392], ["adopts", 397], ["a", 404], ["conformation", 406], ["that", 419], ["prevents", 424], ["free", 433], ["access", 438], ["of", 445], ["H3K36", 448], ["to", 454], ["the", 457], ["bound", 461], ["S", 467], ["-", 468], ["adenosyl", 469], ["-", 477], ["L", 478], ["-", 479], ["methionine", 480], [".", 490], ["Molecular", 492], ["dynamics", 502], ["simulation", 511], ["and", 522], ["computational", 526], ["docking", 540], ["revealed", 548], ["that", 557], ["this", 562], ["normally", 567], ["inhibitory", 576], ["loop", 587], ["can", 592], ["adopt", 596], ["an", 602], ["active", 605], ["conformation", 612], [",", 624], ["allowing", 626], ["H3K36", 635], ["access", 641], ["to", 648], ["the", 651], ["active", 655], ["site", 662], [",", 666], ["and", 668], ["that", 672], ["the", 677], ["nucleosome", 681], ["may", 692], ["stabilize", 696], ["the", 706], ["active", 710], ["conformation", 717], ["of", 730], ["the", 733], ["regulatory", 737], ["loop", 748], [".", 752], ["Hence", 754], [",", 759], ["our", 761], ["study", 765], ["reveals", 771], ["an", 779], ["autoregulatory", 782], ["mechanism", 797], ["of", 807], ["NSD1", 810], ["and", 815], ["provides", 819], ["insight", 828], ["into", 836], ["the", 841], ["molecular", 845], ["mechanism", 855], ["of", 865], ["the", 868], ["nucleosomal", 872], ["substrate", 884], ["selectivity", 894], ["of", 906], ["this", 909], ["disease", 914], ["-", 921], ["related", 922], ["H3K36", 930], ["methyltransferase", 936], [".", 953]]}
{"context": "Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder that is characterized by splenomegaly and marked elevation of the blood leukocyte count with granulocyte in maturity. Ph chromosome was identified in CML in 1960 and was found to clearly result from reciprocal translocation between chromosome 9 and chromosome 22 (t(q;22)) (q34;q11). CML arises from a single pluripotent hematopoietic stem cell with the Ph chromosome and demonstration of the Ph chromosome in blood or marrow cells establishes and unequivocal diagnosis of CML. The Ph chromosome is recognized as the cytogenetic result of a rearrangement of the ABL gene on chromosome 9 and the BCL gene on chromosome 22, which leads to the creation of a BCR/ABL fusion gene on chromosome 22. Abnormal ABL-related protein with increased tyrosine kinase activity suggested a molecular mechanism of CML. The BCR/ABL fusion gene can be found not only in the chromosome but in interphase nuclei by fluorescence in situ hybridization (FISH). We employed both fluorescence activated cell sorter (FACS) and FISH to study the lineage involvement of individual stem cells and progenitor cells in patients with CML. Evidence of BCR/ABL fusion was found in pluripotent stem cells (CD34+, Thy1+), myeloid cells, B progenitor cells (CD34+, CD19+) and T/NK progenitor cells (CD34+, CD7+, CD5+) but not mature T cells (CD3+) or natural killer cells (CD3-, CD56+). These data suggested that BCR/ABL gene fusion occurs in pluripotent stem cells and that Ph+ T cells and natural killer cells are eliminated during differentiation.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "6d9bef92c6174aa29bde5d03ae2f5809", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[281, 285]], "char_spans": [[1444, 1462]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["hematopoietic", 36], ["stem", 50], ["cell", 55], ["disorder", 60], ["that", 69], ["is", 74], ["characterized", 77], ["by", 91], ["splenomegaly", 94], ["and", 107], ["marked", 111], ["elevation", 118], ["of", 128], ["the", 131], ["blood", 135], ["leukocyte", 141], ["count", 151], ["with", 157], ["granulocyte", 162], ["in", 174], ["maturity", 177], [".", 185], ["Ph", 187], ["chromosome", 190], ["was", 201], ["identified", 205], ["in", 216], ["CML", 219], ["in", 223], ["1960", 226], ["and", 231], ["was", 235], ["found", 239], ["to", 245], ["clearly", 248], ["result", 256], ["from", 263], ["reciprocal", 268], ["translocation", 279], ["between", 293], ["chromosome", 301], ["9", 312], ["and", 314], ["chromosome", 318], ["22", 329], ["(", 332], ["t(q;22", 333], [")", 339], [")", 340], ["(", 342], ["q34;q11", 343], [")", 350], [".", 351], ["CML", 353], ["arises", 357], ["from", 364], ["a", 369], ["single", 371], ["pluripotent", 378], ["hematopoietic", 390], ["stem", 404], ["cell", 409], ["with", 414], ["the", 419], ["Ph", 423], ["chromosome", 426], ["and", 437], ["demonstration", 441], ["of", 455], ["the", 458], ["Ph", 462], ["chromosome", 465], ["in", 476], ["blood", 479], ["or", 485], ["marrow", 488], ["cells", 495], ["establishes", 501], ["and", 513], ["unequivocal", 517], ["diagnosis", 529], ["of", 539], ["CML", 542], [".", 545], ["The", 547], ["Ph", 551], ["chromosome", 554], ["is", 565], ["recognized", 568], ["as", 579], ["the", 582], ["cytogenetic", 586], ["result", 598], ["of", 605], ["a", 608], ["rearrangement", 610], ["of", 624], ["the", 627], ["ABL", 631], ["gene", 635], ["on", 640], ["chromosome", 643], ["9", 654], ["and", 656], ["the", 660], ["BCL", 664], ["gene", 668], ["on", 673], ["chromosome", 676], ["22", 687], [",", 689], ["which", 691], ["leads", 697], ["to", 703], ["the", 706], ["creation", 710], ["of", 719], ["a", 722], ["BCR", 724], ["/", 727], ["ABL", 728], ["fusion", 732], ["gene", 739], ["on", 744], ["chromosome", 747], ["22", 758], [".", 760], ["Abnormal", 762], ["ABL", 771], ["-", 774], ["related", 775], ["protein", 783], ["with", 791], ["increased", 796], ["tyrosine", 806], ["kinase", 815], ["activity", 822], ["suggested", 831], ["a", 841], ["molecular", 843], ["mechanism", 853], ["of", 863], ["CML", 866], [".", 869], ["The", 871], ["BCR", 875], ["/", 878], ["ABL", 879], ["fusion", 883], ["gene", 890], ["can", 895], ["be", 899], ["found", 902], ["not", 908], ["only", 912], ["in", 917], ["the", 920], ["chromosome", 924], ["but", 935], ["in", 939], ["interphase", 942], ["nuclei", 953], ["by", 960], ["fluorescence", 963], ["in", 976], ["situ", 979], ["hybridization", 984], ["(", 998], ["FISH", 999], [")", 1003], [".", 1004], ["We", 1006], ["employed", 1009], ["both", 1018], ["fluorescence", 1023], ["activated", 1036], ["cell", 1046], ["sorter", 1051], ["(", 1058], ["FACS", 1059], [")", 1063], ["and", 1065], ["FISH", 1069], ["to", 1074], ["study", 1077], ["the", 1083], ["lineage", 1087], ["involvement", 1095], ["of", 1107], ["individual", 1110], ["stem", 1121], ["cells", 1126], ["and", 1132], ["progenitor", 1136], ["cells", 1147], ["in", 1153], ["patients", 1156], ["with", 1165], ["CML", 1170], [".", 1173], ["Evidence", 1175], ["of", 1184], ["BCR", 1187], ["/", 1190], ["ABL", 1191], ["fusion", 1195], ["was", 1202], ["found", 1206], ["in", 1212], ["pluripotent", 1215], ["stem", 1227], ["cells", 1232], ["(", 1238], ["CD34", 1239], ["+", 1243], [",", 1244], ["Thy1", 1246], ["+", 1250], [")", 1251], [",", 1252], ["myeloid", 1254], ["cells", 1262], [",", 1267], ["B", 1269], ["progenitor", 1271], ["cells", 1282], ["(", 1288], ["CD34", 1289], ["+", 1293], [",", 1294], ["CD19", 1296], ["+", 1300], [")", 1301], ["and", 1303], ["T", 1307], ["/", 1308], ["NK", 1309], ["progenitor", 1312], ["cells", 1323], ["(", 1329], ["CD34", 1330], ["+", 1334], [",", 1335], ["CD7", 1337], ["+", 1340], [",", 1341], ["CD5", 1343], ["+", 1346], [")", 1347], ["but", 1349], ["not", 1353], ["mature", 1357], ["T", 1364], ["cells", 1366], ["(", 1372], ["CD3", 1373], ["+", 1376], [")", 1377], ["or", 1379], ["natural", 1382], ["killer", 1390], ["cells", 1397], ["(", 1403], ["CD3-", 1404], [",", 1408], ["CD56", 1410], ["+", 1414], [")", 1415], [".", 1416], ["These", 1418], ["data", 1424], ["suggested", 1429], ["that", 1439], ["BCR", 1444], ["/", 1447], ["ABL", 1448], ["gene", 1452], ["fusion", 1457], ["occurs", 1464], ["in", 1471], ["pluripotent", 1474], ["stem", 1486], ["cells", 1491], ["and", 1497], ["that", 1501], ["Ph+", 1506], ["T", 1510], ["cells", 1512], ["and", 1518], ["natural", 1522], ["killer", 1530], ["cells", 1537], ["are", 1543], ["eliminated", 1547], ["during", 1558], ["differentiation", 1565], [".", 1580]]}
{"context": "The selective degradation of cytosolic proteins in lysosomes by chaperone-mediated autophagy depends, at least in part, on the levels of a substrate receptor at the lysosomal membrane. We have previously identified this receptor as the lysosome-associated membrane protein type 2a (lamp2a) and showed that levels of lamp2a at the lysosomal membrane directly correlate with the activity of the proteolytic pathway. Here we show that levels of lamp2a at the lysosomal membrane are mainly controlled by changes in its half-life and its distribution between the lysosomal membrane and the matrix. The lysosomal degradation of lamp2a requires the combined action of at least two different proteolytic activities at the lysosomal membrane. Lamp2a is released from the membrane by the action of these proteases, and then the truncated lamp2a is rapidly degraded within the lysosomal matrix. Membrane degradation of lamp2a is a regulated process that is inhibited in the presence of substrates for chaperone-mediated autophagy and under conditions that activate that type of autophagy. Uptake of substrate proteins also results in transport of some intact lamp2a from the lysosomal membrane into the matrix. This fraction of lamp2a can be reinserted back into the lysosomal membrane. The traffic of lamp2a through the lysosomal matrix is not mediated by vesicles, and lamp2a reinsertion requires the lysosomal membrane potential and protein components of the lysosomal membrane. The distribution of lamp2a between the lysosomal membrane and matrix is a dynamic process that contributes to the regulation of lysosomal membrane levels of lamp2a and consequently to the activity of the chaperone-mediated autophagic pathway.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "f33d6fecbf754206bd68d7fc7adad530", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[48, 48], [123, 123], [203, 203], [106, 106], [246, 246], [267, 267], [76, 76], [140, 140], [55, 55], [228, 228], [152, 152], [216, 216], [191, 191]], "char_spans": [[282, 287], [734, 739], [1217, 1222], [622, 627], [1491, 1496], [1628, 1633], [442, 447], [828, 833], [316, 321], [1360, 1365], [908, 913], [1291, 1296], [1148, 1153]]}]}], "context_tokens": [["The", 0], ["selective", 4], ["degradation", 14], ["of", 26], ["cytosolic", 29], ["proteins", 39], ["in", 48], ["lysosomes", 51], ["by", 61], ["chaperone", 64], ["-", 73], ["mediated", 74], ["autophagy", 83], ["depends", 93], [",", 100], ["at", 102], ["least", 105], ["in", 111], ["part", 114], [",", 118], ["on", 120], ["the", 123], ["levels", 127], ["of", 134], ["a", 137], ["substrate", 139], ["receptor", 149], ["at", 158], ["the", 161], ["lysosomal", 165], ["membrane", 175], [".", 183], ["We", 185], ["have", 188], ["previously", 193], ["identified", 204], ["this", 215], ["receptor", 220], ["as", 229], ["the", 232], ["lysosome", 236], ["-", 244], ["associated", 245], ["membrane", 256], ["protein", 265], ["type", 273], ["2a", 278], ["(", 281], ["lamp2a", 282], [")", 288], ["and", 290], ["showed", 294], ["that", 301], ["levels", 306], ["of", 313], ["lamp2a", 316], ["at", 323], ["the", 326], ["lysosomal", 330], ["membrane", 340], ["directly", 349], ["correlate", 358], ["with", 368], ["the", 373], ["activity", 377], ["of", 386], ["the", 389], ["proteolytic", 393], ["pathway", 405], [".", 412], ["Here", 414], ["we", 419], ["show", 422], ["that", 427], ["levels", 432], ["of", 439], ["lamp2a", 442], ["at", 449], ["the", 452], ["lysosomal", 456], ["membrane", 466], ["are", 475], ["mainly", 479], ["controlled", 486], ["by", 497], ["changes", 500], ["in", 508], ["its", 511], ["half", 515], ["-", 519], ["life", 520], ["and", 525], ["its", 529], ["distribution", 533], ["between", 546], ["the", 554], ["lysosomal", 558], ["membrane", 568], ["and", 577], ["the", 581], ["matrix", 585], [".", 591], ["The", 593], ["lysosomal", 597], ["degradation", 607], ["of", 619], ["lamp2a", 622], ["requires", 629], ["the", 638], ["combined", 642], ["action", 651], ["of", 658], ["at", 661], ["least", 664], ["two", 670], ["different", 674], ["proteolytic", 684], ["activities", 696], ["at", 707], ["the", 710], ["lysosomal", 714], ["membrane", 724], [".", 732], ["Lamp2a", 734], ["is", 741], ["released", 744], ["from", 753], ["the", 758], ["membrane", 762], ["by", 771], ["the", 774], ["action", 778], ["of", 785], ["these", 788], ["proteases", 794], [",", 803], ["and", 805], ["then", 809], ["the", 814], ["truncated", 818], ["lamp2a", 828], ["is", 835], ["rapidly", 838], ["degraded", 846], ["within", 855], ["the", 862], ["lysosomal", 866], ["matrix", 876], [".", 882], ["Membrane", 884], ["degradation", 893], ["of", 905], ["lamp2a", 908], ["is", 915], ["a", 918], ["regulated", 920], ["process", 930], ["that", 938], ["is", 943], ["inhibited", 946], ["in", 956], ["the", 959], ["presence", 963], ["of", 972], ["substrates", 975], ["for", 986], ["chaperone", 990], ["-", 999], ["mediated", 1000], ["autophagy", 1009], ["and", 1019], ["under", 1023], ["conditions", 1029], ["that", 1040], ["activate", 1045], ["that", 1054], ["type", 1059], ["of", 1064], ["autophagy", 1067], [".", 1076], ["Uptake", 1078], ["of", 1085], ["substrate", 1088], ["proteins", 1098], ["also", 1107], ["results", 1112], ["in", 1120], ["transport", 1123], ["of", 1133], ["some", 1136], ["intact", 1141], ["lamp2a", 1148], ["from", 1155], ["the", 1160], ["lysosomal", 1164], ["membrane", 1174], ["into", 1183], ["the", 1188], ["matrix", 1192], [".", 1198], ["This", 1200], ["fraction", 1205], ["of", 1214], ["lamp2a", 1217], ["can", 1224], ["be", 1228], ["reinserted", 1231], ["back", 1242], ["into", 1247], ["the", 1252], ["lysosomal", 1256], ["membrane", 1266], [".", 1274], ["The", 1276], ["traffic", 1280], ["of", 1288], ["lamp2a", 1291], ["through", 1298], ["the", 1306], ["lysosomal", 1310], ["matrix", 1320], ["is", 1327], ["not", 1330], ["mediated", 1334], ["by", 1343], ["vesicles", 1346], [",", 1354], ["and", 1356], ["lamp2a", 1360], ["reinsertion", 1367], ["requires", 1379], ["the", 1388], ["lysosomal", 1392], ["membrane", 1402], ["potential", 1411], ["and", 1421], ["protein", 1425], ["components", 1433], ["of", 1444], ["the", 1447], ["lysosomal", 1451], ["membrane", 1461], [".", 1469], ["The", 1471], ["distribution", 1475], ["of", 1488], ["lamp2a", 1491], ["between", 1498], ["the", 1506], ["lysosomal", 1510], ["membrane", 1520], ["and", 1529], ["matrix", 1533], ["is", 1540], ["a", 1543], ["dynamic", 1545], ["process", 1553], ["that", 1561], ["contributes", 1566], ["to", 1578], ["the", 1581], ["regulation", 1585], ["of", 1596], ["lysosomal", 1599], ["membrane", 1609], ["levels", 1618], ["of", 1625], ["lamp2a", 1628], ["and", 1635], ["consequently", 1639], ["to", 1652], ["the", 1655], ["activity", 1659], ["of", 1668], ["the", 1671], ["chaperone", 1675], ["-", 1684], ["mediated", 1685], ["autophagic", 1694], ["pathway", 1705], [".", 1712]]}
{"context": "Although malaria has become a serious public health problem in Mauritania since the late 1990s, few documented data on its epidemiology exist. The objective of this study was to assess the morbidity of clinical malaria among children in Nouakchott. Three hundred and one febrile children, consulting at three health facilities of Nouakchott, were screened for malaria in 2009 (n=216) and 2010 (n=85). Plasmodium species identification and parasite density were determined by microscopic examination of Giemsa-stained thin and thick films and confirmed by rapid diagnostic test and nested PCR. Of 301 febrile children, 105 (34.9%) were malaria-positive by nested PCR and 87 (28.9%) by microscopy. Plasmodium vivax represented 97.1% (102/105) and P. falciparum accounted for 2.9% (3/105) of positive cases. All positive children under five years old were infected with P. vivax. The highest numbers of malaria positives were found during or shortly after the rainy season and the lowest during the dry season. Fifty-four of 105 (51.4%) malaria cases, all with P. vivax, had never travelled outside Nouakchott. Individuals belonging to the Moors ethnic group represented 97.0% of P. vivax cases. Results of the present study indicate that malaria is endemic in Nouakchott and that P. vivax is the principal causative agent. Regular surveillance is required to monitor malaria prevalence and incidence, and further measures are needed to counter the possible spread of malaria in the country.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "03a16d0eb3134070ad262ad943d2c738", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium species", "token_spans": [[72, 73]], "char_spans": [[401, 418]]}]}], "context_tokens": [["Although", 0], ["malaria", 9], ["has", 17], ["become", 21], ["a", 28], ["serious", 30], ["public", 38], ["health", 45], ["problem", 52], ["in", 60], ["Mauritania", 63], ["since", 74], ["the", 80], ["late", 84], ["1990s", 89], [",", 94], ["few", 96], ["documented", 100], ["data", 111], ["on", 116], ["its", 119], ["epidemiology", 123], ["exist", 136], [".", 141], ["The", 143], ["objective", 147], ["of", 157], ["this", 160], ["study", 165], ["was", 171], ["to", 175], ["assess", 178], ["the", 185], ["morbidity", 189], ["of", 199], ["clinical", 202], ["malaria", 211], ["among", 219], ["children", 225], ["in", 234], ["Nouakchott", 237], [".", 247], ["Three", 249], ["hundred", 255], ["and", 263], ["one", 267], ["febrile", 271], ["children", 279], [",", 287], ["consulting", 289], ["at", 300], ["three", 303], ["health", 309], ["facilities", 316], ["of", 327], ["Nouakchott", 330], [",", 340], ["were", 342], ["screened", 347], ["for", 356], ["malaria", 360], ["in", 368], ["2009", 371], ["(", 376], ["n=216", 377], [")", 382], ["and", 384], ["2010", 388], ["(", 393], ["n=85", 394], [")", 398], [".", 399], ["Plasmodium", 401], ["species", 412], ["identification", 420], ["and", 435], ["parasite", 439], ["density", 448], ["were", 456], ["determined", 461], ["by", 472], ["microscopic", 475], ["examination", 487], ["of", 499], ["Giemsa", 502], ["-", 508], ["stained", 509], ["thin", 517], ["and", 522], ["thick", 526], ["films", 532], ["and", 538], ["confirmed", 542], ["by", 552], ["rapid", 555], ["diagnostic", 561], ["test", 572], ["and", 577], ["nested", 581], ["PCR", 588], [".", 591], ["Of", 593], ["301", 596], ["febrile", 600], ["children", 608], [",", 616], ["105", 618], ["(", 622], ["34.9", 623], ["%", 627], [")", 628], ["were", 630], ["malaria", 635], ["-", 642], ["positive", 643], ["by", 652], ["nested", 655], ["PCR", 662], ["and", 666], ["87", 670], ["(", 673], ["28.9", 674], ["%", 678], [")", 679], ["by", 681], ["microscopy", 684], [".", 694], ["Plasmodium", 696], ["vivax", 707], ["represented", 713], ["97.1", 725], ["%", 729], ["(", 731], ["102/105", 732], [")", 739], ["and", 741], ["P.", 745], ["falciparum", 748], ["accounted", 759], ["for", 769], ["2.9", 773], ["%", 776], ["(", 778], ["3/105", 779], [")", 784], ["of", 786], ["positive", 789], ["cases", 798], [".", 803], ["All", 805], ["positive", 809], ["children", 818], ["under", 827], ["five", 833], ["years", 838], ["old", 844], ["were", 848], ["infected", 853], ["with", 862], ["P.", 867], ["vivax", 870], [".", 875], ["The", 877], ["highest", 881], ["numbers", 889], ["of", 897], ["malaria", 900], ["positives", 908], ["were", 918], ["found", 923], ["during", 929], ["or", 936], ["shortly", 939], ["after", 947], ["the", 953], ["rainy", 957], ["season", 963], ["and", 970], ["the", 974], ["lowest", 978], ["during", 985], ["the", 992], ["dry", 996], ["season", 1000], [".", 1006], ["Fifty", 1008], ["-", 1013], ["four", 1014], ["of", 1019], ["105", 1022], ["(", 1026], ["51.4", 1027], ["%", 1031], [")", 1032], ["malaria", 1034], ["cases", 1042], [",", 1047], ["all", 1049], ["with", 1053], ["P.", 1058], ["vivax", 1061], [",", 1066], ["had", 1068], ["never", 1072], ["travelled", 1078], ["outside", 1088], ["Nouakchott", 1096], [".", 1106], ["Individuals", 1108], ["belonging", 1120], ["to", 1130], ["the", 1133], ["Moors", 1137], ["ethnic", 1143], ["group", 1150], ["represented", 1156], ["97.0", 1168], ["%", 1172], ["of", 1174], ["P.", 1177], ["vivax", 1180], ["cases", 1186], [".", 1191], ["Results", 1193], ["of", 1201], ["the", 1204], ["present", 1208], ["study", 1216], ["indicate", 1222], ["that", 1231], ["malaria", 1236], ["is", 1244], ["endemic", 1247], ["in", 1255], ["Nouakchott", 1258], ["and", 1269], ["that", 1273], ["P.", 1278], ["vivax", 1281], ["is", 1287], ["the", 1290], ["principal", 1294], ["causative", 1304], ["agent", 1314], [".", 1319], ["Regular", 1321], ["surveillance", 1329], ["is", 1342], ["required", 1345], ["to", 1354], ["monitor", 1357], ["malaria", 1365], ["prevalence", 1373], ["and", 1384], ["incidence", 1388], [",", 1397], ["and", 1399], ["further", 1403], ["measures", 1411], ["are", 1420], ["needed", 1424], ["to", 1431], ["counter", 1434], ["the", 1442], ["possible", 1446], ["spread", 1455], ["of", 1462], ["malaria", 1465], ["in", 1473], ["the", 1476], ["country", 1480], [".", 1487]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by the Philadelphia translocation that fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9. The chimerical Bcr-Abl protein expressed by CML cells has constitutive tyrosine kinase activity, which is essential for the pathogenesis of the disease. Imatinib, an ATP-competitive selective inhibitor of Bcr-Abl, has unprecedented efficacy for the treatment of CML. Most patients with early stage disease achieve durable complete hematological and complete cytogenetic remissions, with minimal toxicity. In contrast, responses are less stable in patients with advanced CML. This review highlights the pathogenesis of CML, its clinical features, and the development of imatinib as a specific molecularly targeted therapy. Aspects of disease monitoring and side effects are covered as well as resistance to imatinib and strategies to overcome resistance, such as alternative signal transduction inhibitors and drug combinations. Perspectives for further development are also discussed.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "d31cc811c4ed4d9a840643c3c97ec8b6", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[30, 32], [63, 65]], "char_spans": [[183, 189], [373, 379]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["the", 51], ["Philadelphia", 55], ["translocation", 68], ["that", 82], ["fuses", 87], ["BCR", 93], ["sequences", 97], ["from", 107], ["chromosome", 112], ["22", 123], ["upstream", 126], ["of", 135], ["the", 138], ["ABL", 142], ["gene", 146], ["on", 151], ["chromosome", 154], ["9", 165], [".", 166], ["The", 168], ["chimerical", 172], ["Bcr", 183], ["-", 186], ["Abl", 187], ["protein", 191], ["expressed", 199], ["by", 209], ["CML", 212], ["cells", 216], ["has", 222], ["constitutive", 226], ["tyrosine", 239], ["kinase", 248], ["activity", 255], [",", 263], ["which", 265], ["is", 271], ["essential", 274], ["for", 284], ["the", 288], ["pathogenesis", 292], ["of", 305], ["the", 308], ["disease", 312], [".", 319], ["Imatinib", 321], [",", 329], ["an", 331], ["ATP", 334], ["-", 337], ["competitive", 338], ["selective", 350], ["inhibitor", 360], ["of", 370], ["Bcr", 373], ["-", 376], ["Abl", 377], [",", 380], ["has", 382], ["unprecedented", 386], ["efficacy", 400], ["for", 409], ["the", 413], ["treatment", 417], ["of", 427], ["CML", 430], [".", 433], ["Most", 435], ["patients", 440], ["with", 449], ["early", 454], ["stage", 460], ["disease", 466], ["achieve", 474], ["durable", 482], ["complete", 490], ["hematological", 499], ["and", 513], ["complete", 517], ["cytogenetic", 526], ["remissions", 538], [",", 548], ["with", 550], ["minimal", 555], ["toxicity", 563], [".", 571], ["In", 573], ["contrast", 576], [",", 584], ["responses", 586], ["are", 596], ["less", 600], ["stable", 605], ["in", 612], ["patients", 615], ["with", 624], ["advanced", 629], ["CML", 638], [".", 641], ["This", 643], ["review", 648], ["highlights", 655], ["the", 666], ["pathogenesis", 670], ["of", 683], ["CML", 686], [",", 689], ["its", 691], ["clinical", 695], ["features", 704], [",", 712], ["and", 714], ["the", 718], ["development", 722], ["of", 734], ["imatinib", 737], ["as", 746], ["a", 749], ["specific", 751], ["molecularly", 760], ["targeted", 772], ["therapy", 781], [".", 788], ["Aspects", 790], ["of", 798], ["disease", 801], ["monitoring", 809], ["and", 820], ["side", 824], ["effects", 829], ["are", 837], ["covered", 841], ["as", 849], ["well", 852], ["as", 857], ["resistance", 860], ["to", 871], ["imatinib", 874], ["and", 883], ["strategies", 887], ["to", 898], ["overcome", 901], ["resistance", 910], [",", 920], ["such", 922], ["as", 927], ["alternative", 930], ["signal", 942], ["transduction", 949], ["inhibitors", 962], ["and", 973], ["drug", 977], ["combinations", 982], [".", 994], ["Perspectives", 996], ["for", 1009], ["further", 1013], ["development", 1021], ["are", 1033], ["also", 1037], ["discussed", 1042], [".", 1051]]}
{"context": "Interleukin-1\u03b2 (IL-1\u03b2) is a key orchestrator in inflammatory and several immune responses. IL-1\u03b2 exerts its effects through interleukin-1 receptor type I (IL-1RI) and interleukin-1 receptor accessory protein (IL-1RAcP), which together form a heterotrimeric signaling-competent complex. Canakinumab and gevokizumab are highly specific IL-1\u03b2 monoclonal antibodies. Canakinumab is known to neutralize IL-1\u03b2 by competing for binding to IL-1R and therefore blocking signaling by the antigen:antibody complex. Gevokizumab is claimed to be a regulatory therapeutic antibody that modulates IL-1\u03b2 bioactivity by reducing the affinity for its IL-1RI:IL-1RAcP signaling complex. How IL-1\u03b2 signaling is affected by both canakinumab and gevokizumab was not yet experimentally determined. We have analyzed the crystal structures of canakinumab and gevokizumab antibody binding fragment (Fab) as well as of their binary complexes with IL-1\u03b2. Furthermore, we characterized the epitopes on IL-1\u03b2 employed by the antibodies by NMR epitope mapping studies. The direct comparison of NMR and X-ray data shows that the epitope defined by the crystal structure encompasses predominantly those residues whose NMR resonances are severely perturbed upon complex formation. The antigen:Fab co-structures confirm the previously identified key contact residues on IL-1\u03b2 and provide insight into the mechanisms leading to their distinct modulation of IL-1\u03b2 signaling. A significant steric overlap of the binding interfaces of IL-1R and canakinumab on IL-1\u03b2 causes competitive inhibition of the association of IL-1\u03b2 and its receptor. In contrast, gevokizumab occupies an allosteric site on IL-1\u03b2 and complex formation results in a minor reduction of binding affinity to IL-1RI. This suggests two different mechanisms of IL-1\u03b2 pathway attenuation.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "2f0cee196ddb4065924495ca24e444df", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[144, 144], [61, 61], [90, 90], [52, 52], [212, 212], [105, 105], [153, 153], [249, 249], [263, 263], [284, 284], [225, 225], [2, 2], [15, 15], [241, 241]], "char_spans": [[920, 924], [398, 402], [582, 586], [334, 338], [1335, 1339], [672, 676], [973, 977], [1579, 1583], [1659, 1663], [1789, 1793], [1421, 1425], [16, 20], [91, 95], [1521, 1525]]}]}], "context_tokens": [["Interleukin-1\u03b2", 0], ["(", 15], ["IL-1\u03b2", 16], [")", 21], ["is", 23], ["a", 26], ["key", 28], ["orchestrator", 32], ["in", 45], ["inflammatory", 48], ["and", 61], ["several", 65], ["immune", 73], ["responses", 80], [".", 89], ["IL-1\u03b2", 91], ["exerts", 97], ["its", 104], ["effects", 108], ["through", 116], ["interleukin-1", 124], ["receptor", 138], ["type", 147], ["I", 152], ["(", 154], ["IL-1RI", 155], [")", 161], ["and", 163], ["interleukin-1", 167], ["receptor", 181], ["accessory", 190], ["protein", 200], ["(", 208], ["IL-1RAcP", 209], [")", 217], [",", 218], ["which", 220], ["together", 226], ["form", 235], ["a", 240], ["heterotrimeric", 242], ["signaling", 257], ["-", 266], ["competent", 267], ["complex", 277], [".", 284], ["Canakinumab", 286], ["and", 298], ["gevokizumab", 302], ["are", 314], ["highly", 318], ["specific", 325], ["IL-1\u03b2", 334], ["monoclonal", 340], ["antibodies", 351], [".", 361], ["Canakinumab", 363], ["is", 375], ["known", 378], ["to", 384], ["neutralize", 387], ["IL-1\u03b2", 398], ["by", 404], ["competing", 407], ["for", 417], ["binding", 421], ["to", 429], ["IL-1R", 432], ["and", 438], ["therefore", 442], ["blocking", 452], ["signaling", 461], ["by", 471], ["the", 474], ["antigen", 478], [":", 485], ["antibody", 486], ["complex", 495], [".", 502], ["Gevokizumab", 504], ["is", 516], ["claimed", 519], ["to", 527], ["be", 530], ["a", 533], ["regulatory", 535], ["therapeutic", 546], ["antibody", 558], ["that", 567], ["modulates", 572], ["IL-1\u03b2", 582], ["bioactivity", 588], ["by", 600], ["reducing", 603], ["the", 612], ["affinity", 616], ["for", 625], ["its", 629], ["IL-1RI", 633], [":", 639], ["IL-1RAcP", 640], ["signaling", 649], ["complex", 659], [".", 666], ["How", 668], ["IL-1\u03b2", 672], ["signaling", 678], ["is", 688], ["affected", 691], ["by", 700], ["both", 703], ["canakinumab", 708], ["and", 720], ["gevokizumab", 724], ["was", 736], ["not", 740], ["yet", 744], ["experimentally", 748], ["determined", 763], [".", 773], ["We", 775], ["have", 778], ["analyzed", 783], ["the", 792], ["crystal", 796], ["structures", 804], ["of", 815], ["canakinumab", 818], ["and", 830], ["gevokizumab", 834], ["antibody", 846], ["binding", 855], ["fragment", 863], ["(", 872], ["Fab", 873], [")", 876], ["as", 878], ["well", 881], ["as", 886], ["of", 889], ["their", 892], ["binary", 898], ["complexes", 905], ["with", 915], ["IL-1\u03b2", 920], [".", 925], ["Furthermore", 927], [",", 938], ["we", 940], ["characterized", 943], ["the", 957], ["epitopes", 961], ["on", 970], ["IL-1\u03b2", 973], ["employed", 979], ["by", 988], ["the", 991], ["antibodies", 995], ["by", 1006], ["NMR", 1009], ["epitope", 1013], ["mapping", 1021], ["studies", 1029], [".", 1036], ["The", 1038], ["direct", 1042], ["comparison", 1049], ["of", 1060], ["NMR", 1063], ["and", 1067], ["X", 1071], ["-", 1072], ["ray", 1073], ["data", 1077], ["shows", 1082], ["that", 1088], ["the", 1093], ["epitope", 1097], ["defined", 1105], ["by", 1113], ["the", 1116], ["crystal", 1120], ["structure", 1128], ["encompasses", 1138], ["predominantly", 1150], ["those", 1164], ["residues", 1170], ["whose", 1179], ["NMR", 1185], ["resonances", 1189], ["are", 1200], ["severely", 1204], ["perturbed", 1213], ["upon", 1223], ["complex", 1228], ["formation", 1236], [".", 1245], ["The", 1247], ["antigen", 1251], [":", 1258], ["Fab", 1259], ["co", 1263], ["-", 1265], ["structures", 1266], ["confirm", 1277], ["the", 1285], ["previously", 1289], ["identified", 1300], ["key", 1311], ["contact", 1315], ["residues", 1323], ["on", 1332], ["IL-1\u03b2", 1335], ["and", 1341], ["provide", 1345], ["insight", 1353], ["into", 1361], ["the", 1366], ["mechanisms", 1370], ["leading", 1381], ["to", 1389], ["their", 1392], ["distinct", 1398], ["modulation", 1407], ["of", 1418], ["IL-1\u03b2", 1421], ["signaling", 1427], [".", 1436], ["A", 1438], ["significant", 1440], ["steric", 1452], ["overlap", 1459], ["of", 1467], ["the", 1470], ["binding", 1474], ["interfaces", 1482], ["of", 1493], ["IL-1R", 1496], ["and", 1502], ["canakinumab", 1506], ["on", 1518], ["IL-1\u03b2", 1521], ["causes", 1527], ["competitive", 1534], ["inhibition", 1546], ["of", 1557], ["the", 1560], ["association", 1564], ["of", 1576], ["IL-1\u03b2", 1579], ["and", 1585], ["its", 1589], ["receptor", 1593], [".", 1601], ["In", 1603], ["contrast", 1606], [",", 1614], ["gevokizumab", 1616], ["occupies", 1628], ["an", 1637], ["allosteric", 1640], ["site", 1651], ["on", 1656], ["IL-1\u03b2", 1659], ["and", 1665], ["complex", 1669], ["formation", 1677], ["results", 1687], ["in", 1695], ["a", 1698], ["minor", 1700], ["reduction", 1706], ["of", 1716], ["binding", 1719], ["affinity", 1727], ["to", 1736], ["IL-1RI", 1739], [".", 1745], ["This", 1747], ["suggests", 1752], ["two", 1761], ["different", 1765], ["mechanisms", 1775], ["of", 1786], ["IL-1\u03b2", 1789], ["pathway", 1795], ["attenuation", 1803], [".", 1814]]}
{"context": "Mowat-Wilson syndrome (MWS) is a rare genetic condition where variable and multiple congenital anomalies including Hirschsprung's disease, intellectual disability, and prominent facial features are present. At molecular level, MWS is characterized by many different described mutations in the zinc finger E-box protein 2 (ZEB2) gene, ultimately leading to loss of gene function. This report is the first to describe the association of MWS with two different asynchronous malignant brain tumors (medulloblastoma and glioblastoma) occurring in a child.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "1d067f852f5b46409f02c83de355022e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[55, 55]], "char_spans": [[322, 325]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["rare", 33], ["genetic", 38], ["condition", 46], ["where", 56], ["variable", 62], ["and", 71], ["multiple", 75], ["congenital", 84], ["anomalies", 95], ["including", 105], ["Hirschsprung", 115], ["'s", 127], ["disease", 130], [",", 137], ["intellectual", 139], ["disability", 152], [",", 162], ["and", 164], ["prominent", 168], ["facial", 178], ["features", 185], ["are", 194], ["present", 198], [".", 205], ["At", 207], ["molecular", 210], ["level", 220], [",", 225], ["MWS", 227], ["is", 231], ["characterized", 234], ["by", 248], ["many", 251], ["different", 256], ["described", 266], ["mutations", 276], ["in", 286], ["the", 289], ["zinc", 293], ["finger", 298], ["E", 305], ["-", 306], ["box", 307], ["protein", 311], ["2", 319], ["(", 321], ["ZEB2", 322], [")", 326], ["gene", 328], [",", 332], ["ultimately", 334], ["leading", 345], ["to", 353], ["loss", 356], ["of", 361], ["gene", 364], ["function", 369], [".", 377], ["This", 379], ["report", 384], ["is", 391], ["the", 394], ["first", 398], ["to", 404], ["describe", 407], ["the", 416], ["association", 420], ["of", 432], ["MWS", 435], ["with", 439], ["two", 444], ["different", 448], ["asynchronous", 458], ["malignant", 471], ["brain", 481], ["tumors", 487], ["(", 494], ["medulloblastoma", 495], ["and", 511], ["glioblastoma", 515], [")", 527], ["occurring", 529], ["in", 539], ["a", 542], ["child", 544], [".", 549]]}
{"context": "Mutations in NOTCH3 are the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a hereditary angiopathy causing stroke and vascular dementia. All CADASIL mutations identified so far result in the loss or gain of one cysteine residue within epidermal growth factor (EGF)-like repeat domains. Here an in-frame deletion causing a loss of three cysteine residues within EGF repeat 6 is reported. These data are consistent with the hypothesis that the change toward an odd number of cysteine residues within a given EGF repeat and therefore an unpaired, reactive cysteine residue is the common and critical molecular event in CADASIL.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "04da2c70e07e4c2581afe158af0e1759", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[65, 65], [89, 89], [43, 43], [102, 102]], "char_spans": [[400, 407], [537, 544], [275, 282], [617, 624]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["NOTCH3", 13], ["are", 20], ["the", 24], ["cause", 28], ["of", 34], ["cerebral", 37], ["autosomal", 46], ["dominant", 56], ["arteriopathy", 65], ["with", 78], ["subcortical", 83], ["infarcts", 95], ["and", 104], ["leukoencephalopathy", 108], ["(", 128], ["CADASIL", 129], [")", 136], [",", 137], ["a", 139], ["hereditary", 141], ["angiopathy", 152], ["causing", 163], ["stroke", 171], ["and", 178], ["vascular", 182], ["dementia", 191], [".", 199], ["All", 201], ["CADASIL", 205], ["mutations", 213], ["identified", 223], ["so", 234], ["far", 237], ["result", 241], ["in", 248], ["the", 251], ["loss", 255], ["or", 260], ["gain", 263], ["of", 268], ["one", 271], ["cysteine", 275], ["residue", 284], ["within", 292], ["epidermal", 299], ["growth", 309], ["factor", 316], ["(", 323], ["EGF)-like", 324], ["repeat", 334], ["domains", 341], [".", 348], ["Here", 350], ["an", 355], ["in", 358], ["-", 360], ["frame", 361], ["deletion", 367], ["causing", 376], ["a", 384], ["loss", 386], ["of", 391], ["three", 394], ["cysteine", 400], ["residues", 409], ["within", 418], ["EGF", 425], ["repeat", 429], ["6", 436], ["is", 438], ["reported", 441], [".", 449], ["These", 451], ["data", 457], ["are", 462], ["consistent", 466], ["with", 477], ["the", 482], ["hypothesis", 486], ["that", 497], ["the", 502], ["change", 506], ["toward", 513], ["an", 520], ["odd", 523], ["number", 527], ["of", 534], ["cysteine", 537], ["residues", 546], ["within", 555], ["a", 562], ["given", 564], ["EGF", 570], ["repeat", 574], ["and", 581], ["therefore", 585], ["an", 595], ["unpaired", 598], [",", 606], ["reactive", 608], ["cysteine", 617], ["residue", 626], ["is", 634], ["the", 637], ["common", 641], ["and", 648], ["critical", 652], ["molecular", 661], ["event", 671], ["in", 677], ["CADASIL", 680], [".", 687]]}
{"context": "Recently, bi-allelic mutations in the transcription factor RFX6 were described as the cause of a rare condition characterized by neonatal diabetes with pancreatic and biliary hypoplasia and duodenal/jejunal atresia. A male infant developed severe hyperglycemia (446\u2009mg/dL) within 24\u2009h of birth. Acute abdominal concerns by day five necessitated exploratory surgery that revealed duodenal atresia, gallbladder agenesis, annular pancreas and intestinal malrotation. He also exhibited chronic diarrhea and feeding intolerance, cholestatic jaundice, and subsequent liver failure. He died of sepsis at four months old while awaiting liver transplantation. The phenotype of neonatal diabetes with intestinal atresia and biliary agenesis clearly pointed to RFX6 as the causative gene; indeed, whole exome sequencing revealed a novel homozygous RFX6 mutation c.779A>C; p.Lys260Thr (K260T). This missense mutation also changes the consensus 5' splice donor site before intron 7 and is thus predicted to cause disruption in splicing. Both parents, who were not known to be related, were heterozygous carriers. Targeted genetic testing based on consideration of phenotypic features may reveal a cause among the many genes now associated with heterogeneous forms of monogenic neonatal diabetes. Our study demonstrates the feasibility of using modern sequencing technology to identify one such rare cause. Continued research is needed to determine the possible cost-effectiveness of this approach, especially when clear phenotypic clues are absent. Further study of patients with RFX6 mutations should clarify its role in pancreatic, intestinal and enteroendocrine cellular development and explain features such as the diarrhea exhibited in our case.", "qas": [{"question": "Which gene is associated with the Mitchell-Riley syndrome?", "answers": ["RFX6"], "qid": "2e07fab624c345f486c1445ba1811034", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["the", 30], ["Mitchell", 34], ["-", 42], ["Riley", 43], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "RFX6", "token_spans": [[120, 120], [135, 135], [261, 261], [10, 10]], "char_spans": [[750, 753], [837, 840], [1567, 1570], [59, 62]]}]}], "context_tokens": [["Recently", 0], [",", 8], ["bi", 10], ["-", 12], ["allelic", 13], ["mutations", 21], ["in", 31], ["the", 34], ["transcription", 38], ["factor", 52], ["RFX6", 59], ["were", 64], ["described", 69], ["as", 79], ["the", 82], ["cause", 86], ["of", 92], ["a", 95], ["rare", 97], ["condition", 102], ["characterized", 112], ["by", 126], ["neonatal", 129], ["diabetes", 138], ["with", 147], ["pancreatic", 152], ["and", 163], ["biliary", 167], ["hypoplasia", 175], ["and", 186], ["duodenal", 190], ["/", 198], ["jejunal", 199], ["atresia", 207], [".", 214], ["A", 216], ["male", 218], ["infant", 223], ["developed", 230], ["severe", 240], ["hyperglycemia", 247], ["(", 261], ["446", 262], ["mg", 266], ["/", 268], ["dL", 269], [")", 271], ["within", 273], ["24", 280], ["h", 283], ["of", 285], ["birth", 288], [".", 293], ["Acute", 295], ["abdominal", 301], ["concerns", 311], ["by", 320], ["day", 323], ["five", 327], ["necessitated", 332], ["exploratory", 345], ["surgery", 357], ["that", 365], ["revealed", 370], ["duodenal", 379], ["atresia", 388], [",", 395], ["gallbladder", 397], ["agenesis", 409], [",", 417], ["annular", 419], ["pancreas", 427], ["and", 436], ["intestinal", 440], ["malrotation", 451], [".", 462], ["He", 464], ["also", 467], ["exhibited", 472], ["chronic", 482], ["diarrhea", 490], ["and", 499], ["feeding", 503], ["intolerance", 511], [",", 522], ["cholestatic", 524], ["jaundice", 536], [",", 544], ["and", 546], ["subsequent", 550], ["liver", 561], ["failure", 567], [".", 574], ["He", 576], ["died", 579], ["of", 584], ["sepsis", 587], ["at", 594], ["four", 597], ["months", 602], ["old", 609], ["while", 613], ["awaiting", 619], ["liver", 628], ["transplantation", 634], [".", 649], ["The", 651], ["phenotype", 655], ["of", 665], ["neonatal", 668], ["diabetes", 677], ["with", 686], ["intestinal", 691], ["atresia", 702], ["and", 710], ["biliary", 714], ["agenesis", 722], ["clearly", 731], ["pointed", 739], ["to", 747], ["RFX6", 750], ["as", 755], ["the", 758], ["causative", 762], ["gene", 772], [";", 776], ["indeed", 778], [",", 784], ["whole", 786], ["exome", 792], ["sequencing", 798], ["revealed", 809], ["a", 818], ["novel", 820], ["homozygous", 826], ["RFX6", 837], ["mutation", 842], ["c.779A", 851], [">", 857], ["C", 858], [";", 859], ["p", 861], [".", 862], ["Lys260Thr", 863], ["(", 873], ["K260", 874], ["T", 878], [")", 879], [".", 880], ["This", 882], ["missense", 887], ["mutation", 896], ["also", 905], ["changes", 910], ["the", 918], ["consensus", 922], ["5", 932], ["'", 933], ["splice", 935], ["donor", 942], ["site", 948], ["before", 953], ["intron", 960], ["7", 967], ["and", 969], ["is", 973], ["thus", 976], ["predicted", 981], ["to", 991], ["cause", 994], ["disruption", 1000], ["in", 1011], ["splicing", 1014], [".", 1022], ["Both", 1024], ["parents", 1029], [",", 1036], ["who", 1038], ["were", 1042], ["not", 1047], ["known", 1051], ["to", 1057], ["be", 1060], ["related", 1063], [",", 1070], ["were", 1072], ["heterozygous", 1077], ["carriers", 1090], [".", 1098], ["Targeted", 1100], ["genetic", 1109], ["testing", 1117], ["based", 1125], ["on", 1131], ["consideration", 1134], ["of", 1148], ["phenotypic", 1151], ["features", 1162], ["may", 1171], ["reveal", 1175], ["a", 1182], ["cause", 1184], ["among", 1190], ["the", 1196], ["many", 1200], ["genes", 1205], ["now", 1211], ["associated", 1215], ["with", 1226], ["heterogeneous", 1231], ["forms", 1245], ["of", 1251], ["monogenic", 1254], ["neonatal", 1264], ["diabetes", 1273], [".", 1281], ["Our", 1283], ["study", 1287], ["demonstrates", 1293], ["the", 1306], ["feasibility", 1310], ["of", 1322], ["using", 1325], ["modern", 1331], ["sequencing", 1338], ["technology", 1349], ["to", 1360], ["identify", 1363], ["one", 1372], ["such", 1376], ["rare", 1381], ["cause", 1386], [".", 1391], ["Continued", 1393], ["research", 1403], ["is", 1412], ["needed", 1415], ["to", 1422], ["determine", 1425], ["the", 1435], ["possible", 1439], ["cost", 1448], ["-", 1452], ["effectiveness", 1453], ["of", 1467], ["this", 1470], ["approach", 1475], [",", 1483], ["especially", 1485], ["when", 1496], ["clear", 1501], ["phenotypic", 1507], ["clues", 1518], ["are", 1524], ["absent", 1528], [".", 1534], ["Further", 1536], ["study", 1544], ["of", 1550], ["patients", 1553], ["with", 1562], ["RFX6", 1567], ["mutations", 1572], ["should", 1582], ["clarify", 1589], ["its", 1597], ["role", 1601], ["in", 1606], ["pancreatic", 1609], [",", 1619], ["intestinal", 1621], ["and", 1632], ["enteroendocrine", 1636], ["cellular", 1652], ["development", 1661], ["and", 1673], ["explain", 1677], ["features", 1685], ["such", 1694], ["as", 1699], ["the", 1702], ["diarrhea", 1706], ["exhibited", 1715], ["in", 1725], ["our", 1728], ["case", 1732], [".", 1736]]}
{"context": "Romano-Ward syndrome is an autosomal dominant long-QT syndrome (LQTS) that predisposes affected individuals to sudden death from tachyarrhythmias. We investigated the molecular basis of LQTS in a Taiwanese kindred. Clinical and genetic analyses revealed that a mutation was linked to the human ether-a-go-go-related gene (HERG). The coding sequences and exon-intron borders of HERG were amplified by means of polymerase chain reaction and subjected to single-strand conformation polymorphism (SSCP) analysis. An exon with an aberrant SSCP pattern was cloned and sequenced to study the molecular lesion. A C-->T transition in codon 614, leading to substitution of a valine for an alanine residue in the pore region of the HERG protein, was identified. Analysis with Bsp12861 endonuclease digestion showed the mutation to be present in all affected family members. Given that an unaffected paternal uncle had inherited the same allele from the grandfather as the proband's father, a de novo mutation had apparently occurred in the father and was transmitted to his offspring. In addition to offering presymptomatic genetic diagnosis, identification of the disease-causing mutation may suggest new therapeutic approaches for treatment and prevention of this cardiovascular disease.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "d838cda896684309ac3a07c8d28d403e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[6, 7]], "char_spans": [[27, 44]]}]}], "context_tokens": [["Romano", 0], ["-", 6], ["Ward", 7], ["syndrome", 12], ["is", 21], ["an", 24], ["autosomal", 27], ["dominant", 37], ["long", 46], ["-", 50], ["QT", 51], ["syndrome", 54], ["(", 63], ["LQTS", 64], [")", 68], ["that", 70], ["predisposes", 75], ["affected", 87], ["individuals", 96], ["to", 108], ["sudden", 111], ["death", 118], ["from", 124], ["tachyarrhythmias", 129], [".", 145], ["We", 147], ["investigated", 150], ["the", 163], ["molecular", 167], ["basis", 177], ["of", 183], ["LQTS", 186], ["in", 191], ["a", 194], ["Taiwanese", 196], ["kindred", 206], [".", 213], ["Clinical", 215], ["and", 224], ["genetic", 228], ["analyses", 236], ["revealed", 245], ["that", 254], ["a", 259], ["mutation", 261], ["was", 270], ["linked", 274], ["to", 281], ["the", 284], ["human", 288], ["ether", 294], ["-", 299], ["a", 300], ["-", 301], ["go", 302], ["-", 304], ["go", 305], ["-", 307], ["related", 308], ["gene", 316], ["(", 321], ["HERG", 322], [")", 326], [".", 327], ["The", 329], ["coding", 333], ["sequences", 340], ["and", 350], ["exon", 354], ["-", 358], ["intron", 359], ["borders", 366], ["of", 374], ["HERG", 377], ["were", 382], ["amplified", 387], ["by", 397], ["means", 400], ["of", 406], ["polymerase", 409], ["chain", 420], ["reaction", 426], ["and", 435], ["subjected", 439], ["to", 449], ["single", 452], ["-", 458], ["strand", 459], ["conformation", 466], ["polymorphism", 479], ["(", 492], ["SSCP", 493], [")", 497], ["analysis", 499], [".", 507], ["An", 509], ["exon", 512], ["with", 517], ["an", 522], ["aberrant", 525], ["SSCP", 534], ["pattern", 539], ["was", 547], ["cloned", 551], ["and", 558], ["sequenced", 562], ["to", 572], ["study", 575], ["the", 581], ["molecular", 585], ["lesion", 595], [".", 601], ["A", 603], ["C-->T", 605], ["transition", 611], ["in", 622], ["codon", 625], ["614", 631], [",", 634], ["leading", 636], ["to", 644], ["substitution", 647], ["of", 660], ["a", 663], ["valine", 665], ["for", 672], ["an", 676], ["alanine", 679], ["residue", 687], ["in", 695], ["the", 698], ["pore", 702], ["region", 707], ["of", 714], ["the", 717], ["HERG", 721], ["protein", 726], [",", 733], ["was", 735], ["identified", 739], [".", 749], ["Analysis", 751], ["with", 760], ["Bsp12861", 765], ["endonuclease", 774], ["digestion", 787], ["showed", 797], ["the", 804], ["mutation", 808], ["to", 817], ["be", 820], ["present", 823], ["in", 831], ["all", 834], ["affected", 838], ["family", 847], ["members", 854], [".", 861], ["Given", 863], ["that", 869], ["an", 874], ["unaffected", 877], ["paternal", 888], ["uncle", 897], ["had", 903], ["inherited", 907], ["the", 917], ["same", 921], ["allele", 926], ["from", 933], ["the", 938], ["grandfather", 942], ["as", 954], ["the", 957], ["proband", 961], ["'s", 968], ["father", 971], [",", 977], ["a", 979], ["de", 981], ["novo", 984], ["mutation", 989], ["had", 998], ["apparently", 1002], ["occurred", 1013], ["in", 1022], ["the", 1025], ["father", 1029], ["and", 1036], ["was", 1040], ["transmitted", 1044], ["to", 1056], ["his", 1059], ["offspring", 1063], [".", 1072], ["In", 1074], ["addition", 1077], ["to", 1086], ["offering", 1089], ["presymptomatic", 1098], ["genetic", 1113], ["diagnosis", 1121], [",", 1130], ["identification", 1132], ["of", 1147], ["the", 1150], ["disease", 1154], ["-", 1161], ["causing", 1162], ["mutation", 1170], ["may", 1179], ["suggest", 1183], ["new", 1191], ["therapeutic", 1195], ["approaches", 1207], ["for", 1218], ["treatment", 1222], ["and", 1232], ["prevention", 1236], ["of", 1247], ["this", 1250], ["cardiovascular", 1255], ["disease", 1270], [".", 1277]]}
{"context": "Lamp2a acts as a receptor in the lysosomal membrane for substrate proteins of chaperone-mediated autophagy. Using antibodies specific for the cytosolic tail of lamp2a and others recognizing all lamp2 isoforms, we found that in rat liver lamp2a represents 25% of lamp2s in the lysosome. We show that lamp2a levels in the lysosomal membrane in rat liver and fibroblasts in culture directly correlate with rates of chaperone-mediated autophagy in a variety of physiological and pathological conditions. The concentration of other lamp2s in the lysosomal membrane show no correlation under the same conditions. Furthermore, substrate proteins bind to lamp2a but not to other lamp2s. Four positively-charged amino acids uniquely present in the cytosolic tail of lamp2a are required for the binding of substrate proteins. Lamp2a also distributes to an unique subpopulation of perinuclear lysosomes in cultured fibroblasts in response to serum withdrawal, and lamp2a, more than other lamp2s, tends to multimerize. These characteristics may be important for lamp2a to act as a receptor for chaperone-mediated autophagy.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "4688b81a249a4edd87b46d5ce300cfcf", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[0, 0], [107, 107], [53, 53], [26, 26], [157, 157], [137, 137], [40, 40], [174, 174], [127, 127]], "char_spans": [[0, 5], [647, 652], [299, 304], [160, 165], [953, 958], [816, 821], [237, 242], [1050, 1055], [757, 762]]}]}], "context_tokens": [["Lamp2a", 0], ["acts", 7], ["as", 12], ["a", 15], ["receptor", 17], ["in", 26], ["the", 29], ["lysosomal", 33], ["membrane", 43], ["for", 52], ["substrate", 56], ["proteins", 66], ["of", 75], ["chaperone", 78], ["-", 87], ["mediated", 88], ["autophagy", 97], [".", 106], ["Using", 108], ["antibodies", 114], ["specific", 125], ["for", 134], ["the", 138], ["cytosolic", 142], ["tail", 152], ["of", 157], ["lamp2a", 160], ["and", 167], ["others", 171], ["recognizing", 178], ["all", 190], ["lamp2", 194], ["isoforms", 200], [",", 208], ["we", 210], ["found", 213], ["that", 219], ["in", 224], ["rat", 227], ["liver", 231], ["lamp2a", 237], ["represents", 244], ["25", 255], ["%", 257], ["of", 259], ["lamp2s", 262], ["in", 269], ["the", 272], ["lysosome", 276], [".", 284], ["We", 286], ["show", 289], ["that", 294], ["lamp2a", 299], ["levels", 306], ["in", 313], ["the", 316], ["lysosomal", 320], ["membrane", 330], ["in", 339], ["rat", 342], ["liver", 346], ["and", 352], ["fibroblasts", 356], ["in", 368], ["culture", 371], ["directly", 379], ["correlate", 388], ["with", 398], ["rates", 403], ["of", 409], ["chaperone", 412], ["-", 421], ["mediated", 422], ["autophagy", 431], ["in", 441], ["a", 444], ["variety", 446], ["of", 454], ["physiological", 457], ["and", 471], ["pathological", 475], ["conditions", 488], [".", 498], ["The", 500], ["concentration", 504], ["of", 518], ["other", 521], ["lamp2s", 527], ["in", 534], ["the", 537], ["lysosomal", 541], ["membrane", 551], ["show", 560], ["no", 565], ["correlation", 568], ["under", 580], ["the", 586], ["same", 590], ["conditions", 595], [".", 605], ["Furthermore", 607], [",", 618], ["substrate", 620], ["proteins", 630], ["bind", 639], ["to", 644], ["lamp2a", 647], ["but", 654], ["not", 658], ["to", 662], ["other", 665], ["lamp2s", 671], [".", 677], ["Four", 679], ["positively", 684], ["-", 694], ["charged", 695], ["amino", 703], ["acids", 709], ["uniquely", 715], ["present", 724], ["in", 732], ["the", 735], ["cytosolic", 739], ["tail", 749], ["of", 754], ["lamp2a", 757], ["are", 764], ["required", 768], ["for", 777], ["the", 781], ["binding", 785], ["of", 793], ["substrate", 796], ["proteins", 806], [".", 814], ["Lamp2a", 816], ["also", 823], ["distributes", 828], ["to", 840], ["an", 843], ["unique", 846], ["subpopulation", 853], ["of", 867], ["perinuclear", 870], ["lysosomes", 882], ["in", 892], ["cultured", 895], ["fibroblasts", 904], ["in", 916], ["response", 919], ["to", 928], ["serum", 931], ["withdrawal", 937], [",", 947], ["and", 949], ["lamp2a", 953], [",", 959], ["more", 961], ["than", 966], ["other", 971], ["lamp2s", 977], [",", 983], ["tends", 985], ["to", 991], ["multimerize", 994], [".", 1005], ["These", 1007], ["characteristics", 1013], ["may", 1029], ["be", 1033], ["important", 1036], ["for", 1046], ["lamp2a", 1050], ["to", 1057], ["act", 1060], ["as", 1064], ["a", 1067], ["receptor", 1069], ["for", 1078], ["chaperone", 1082], ["-", 1091], ["mediated", 1092], ["autophagy", 1101], [".", 1110]]}
{"context": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. Imatinib induces complete haematological and cytogenetic response in high percentage of patients. The aim of this study was to identify potential prognostic factors before beginning treatment with imatinib associated with complete cytogenetic response. We analyzed 20 patients with newly diagnosed Philadelphia positive chronic myelogenous leukemia treated at our institution from June 2006 until May 2009. These patients were treated with imatinib mesylate in oral dose of 400 to 800 mg daily. Complete blood counts were performed every month, while serum chemistry evaluations and bone marrow evaluations including morphology and cytogenetics were performed every 6 months. Of the 20 patients analyzed in this study, 19 (95%) achieved complete haematologic response within three months. In all patients cytogenetic analyses were done and all have achieved absolute cytogenetic response. The best cytogenetic response rate at any time during study treatment among 20 patients was: complete cytogenetic response in 15, partial cytogenetic response in three and minor cytogenetic response in two patients. Among 11 observed base-line patients' characteristics five were independent predictors of a high rate of complete cytogenetic response; the absence of blasts and basophils in peripheral blood, the presence of less than 5 percent of bone marrow blasts, white blood cell count less than 10 x 10(9)/L and the absence of splenomegaly (p < 0.01). Our results showed that some pre-treatment characteristics of patients might be the cause of differences in treatment outcome. On the basis of this analysis, we identified several pre-treatment patients' characteristics to be independent prognostic factors for achievement of complete cytogenetic response.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "6a2e5c9b921c417c892010de2379c6d7", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[5, 7]], "char_spans": [[31, 37]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["a", 19], ["selective", 21], ["Bcr", 31], ["-", 34], ["Abl", 35], ["tyrosine", 39], ["kinase", 48], ["inhibitor", 55], [",", 64], ["has", 66], ["proved", 70], ["to", 77], ["be", 80], ["most", 83], ["effective", 88], ["therapy", 98], ["of", 106], ["Philadelphia", 109], ["chromosome", 122], ["-", 132], ["positive", 133], ["chronic", 142], ["myelogenous", 150], ["leukemia", 162], [".", 170], ["Imatinib", 172], ["induces", 181], ["complete", 189], ["haematological", 198], ["and", 213], ["cytogenetic", 217], ["response", 229], ["in", 238], ["high", 241], ["percentage", 246], ["of", 257], ["patients", 260], [".", 268], ["The", 270], ["aim", 274], ["of", 278], ["this", 281], ["study", 286], ["was", 292], ["to", 296], ["identify", 299], ["potential", 308], ["prognostic", 318], ["factors", 329], ["before", 337], ["beginning", 344], ["treatment", 354], ["with", 364], ["imatinib", 369], ["associated", 378], ["with", 389], ["complete", 394], ["cytogenetic", 403], ["response", 415], [".", 423], ["We", 425], ["analyzed", 428], ["20", 437], ["patients", 440], ["with", 449], ["newly", 454], ["diagnosed", 460], ["Philadelphia", 470], ["positive", 483], ["chronic", 492], ["myelogenous", 500], ["leukemia", 512], ["treated", 521], ["at", 529], ["our", 532], ["institution", 536], ["from", 548], ["June", 553], ["2006", 558], ["until", 563], ["May", 569], ["2009", 573], [".", 577], ["These", 579], ["patients", 585], ["were", 594], ["treated", 599], ["with", 607], ["imatinib", 612], ["mesylate", 621], ["in", 630], ["oral", 633], ["dose", 638], ["of", 643], ["400", 646], ["to", 650], ["800", 653], ["mg", 657], ["daily", 660], [".", 665], ["Complete", 667], ["blood", 676], ["counts", 682], ["were", 689], ["performed", 694], ["every", 704], ["month", 710], [",", 715], ["while", 717], ["serum", 723], ["chemistry", 729], ["evaluations", 739], ["and", 751], ["bone", 755], ["marrow", 760], ["evaluations", 767], ["including", 779], ["morphology", 789], ["and", 800], ["cytogenetics", 804], ["were", 817], ["performed", 822], ["every", 832], ["6", 838], ["months", 840], [".", 846], ["Of", 848], ["the", 851], ["20", 855], ["patients", 858], ["analyzed", 867], ["in", 876], ["this", 879], ["study", 884], [",", 889], ["19", 891], ["(", 894], ["95", 895], ["%", 897], [")", 898], ["achieved", 900], ["complete", 909], ["haematologic", 918], ["response", 931], ["within", 940], ["three", 947], ["months", 953], [".", 959], ["In", 961], ["all", 964], ["patients", 968], ["cytogenetic", 977], ["analyses", 989], ["were", 998], ["done", 1003], ["and", 1008], ["all", 1012], ["have", 1016], ["achieved", 1021], ["absolute", 1030], ["cytogenetic", 1039], ["response", 1051], [".", 1059], ["The", 1061], ["best", 1065], ["cytogenetic", 1070], ["response", 1082], ["rate", 1091], ["at", 1096], ["any", 1099], ["time", 1103], ["during", 1108], ["study", 1115], ["treatment", 1121], ["among", 1131], ["20", 1137], ["patients", 1140], ["was", 1149], [":", 1152], ["complete", 1154], ["cytogenetic", 1163], ["response", 1175], ["in", 1184], ["15", 1187], [",", 1189], ["partial", 1191], ["cytogenetic", 1199], ["response", 1211], ["in", 1220], ["three", 1223], ["and", 1229], ["minor", 1233], ["cytogenetic", 1239], ["response", 1251], ["in", 1260], ["two", 1263], ["patients", 1267], [".", 1275], ["Among", 1277], ["11", 1283], ["observed", 1286], ["base", 1295], ["-", 1299], ["line", 1300], ["patients", 1305], ["'", 1313], ["characteristics", 1315], ["five", 1331], ["were", 1336], ["independent", 1341], ["predictors", 1353], ["of", 1364], ["a", 1367], ["high", 1369], ["rate", 1374], ["of", 1379], ["complete", 1382], ["cytogenetic", 1391], ["response", 1403], [";", 1411], ["the", 1413], ["absence", 1417], ["of", 1425], ["blasts", 1428], ["and", 1435], ["basophils", 1439], ["in", 1449], ["peripheral", 1452], ["blood", 1463], [",", 1468], ["the", 1470], ["presence", 1474], ["of", 1483], ["less", 1486], ["than", 1491], ["5", 1496], ["percent", 1498], ["of", 1506], ["bone", 1509], ["marrow", 1514], ["blasts", 1521], [",", 1527], ["white", 1529], ["blood", 1535], ["cell", 1541], ["count", 1546], ["less", 1552], ["than", 1557], ["10", 1562], ["x", 1565], ["10(9)/L", 1567], ["and", 1575], ["the", 1579], ["absence", 1583], ["of", 1591], ["splenomegaly", 1594], ["(", 1607], ["p", 1608], ["<", 1610], ["0.01", 1612], [")", 1616], [".", 1617], ["Our", 1619], ["results", 1623], ["showed", 1631], ["that", 1638], ["some", 1643], ["pre", 1648], ["-", 1651], ["treatment", 1652], ["characteristics", 1662], ["of", 1678], ["patients", 1681], ["might", 1690], ["be", 1696], ["the", 1699], ["cause", 1703], ["of", 1709], ["differences", 1712], ["in", 1724], ["treatment", 1727], ["outcome", 1737], [".", 1744], ["On", 1746], ["the", 1749], ["basis", 1753], ["of", 1759], ["this", 1762], ["analysis", 1767], [",", 1775], ["we", 1777], ["identified", 1780], ["several", 1791], ["pre", 1799], ["-", 1802], ["treatment", 1803], ["patients", 1813], ["'", 1821], ["characteristics", 1823], ["to", 1839], ["be", 1842], ["independent", 1845], ["prognostic", 1857], ["factors", 1868], ["for", 1876], ["achievement", 1880], ["of", 1892], ["complete", 1895], ["cytogenetic", 1904], ["response", 1916], [".", 1924]]}
{"context": "Genomic context analysis, also known as phylogenetic profiling, is widely used to infer functional interactions between proteins but rarely applied to non-coding cis-regulatory DNA elements. We were wondering whether this approach could provide insights about utlraconserved non-coding elements (UCNEs). These elements are organized as large clusters, so-called gene regulatory blocks (GRBs) around key developmental genes. Their molecular functions and the reasons for their high degree of conservation remain enigmatic. In a special setting of genomic context analysis, we analyzed the fate of GRBs after a whole-genome duplication event in five fish genomes. We found that in most cases all UCNEs were retained together as a single block, whereas the corresponding target genes were often retained in two copies, one completely devoid of UCNEs. This 'winner-takes-all' pattern suggests that UCNEs of a GRB function in a highly cooperative manner. We propose that the multitude of interactions between UCNEs is the reason for their extreme sequence conservation. Supplementary data are available at Bioinformatics online and at http://ccg.vital-it.ch/ucne/", "qas": [{"question": "How are ultraconserved elements called when they form clusters?", "answers": ["gene regulatory blocks (GRBs)"], "qid": "f7321b2110b94a3bba595a160b668297", "question_tokens": [["How", 0], ["are", 4], ["ultraconserved", 8], ["elements", 23], ["called", 32], ["when", 39], ["they", 44], ["form", 49], ["clusters", 54], ["?", 62]], "detected_answers": [{"text": "gene regulatory blocks (GRBs)", "token_spans": [[62, 66]], "char_spans": [[362, 389]]}]}], "context_tokens": [["Genomic", 0], ["context", 8], ["analysis", 16], [",", 24], ["also", 26], ["known", 31], ["as", 37], ["phylogenetic", 40], ["profiling", 53], [",", 62], ["is", 64], ["widely", 67], ["used", 74], ["to", 79], ["infer", 82], ["functional", 88], ["interactions", 99], ["between", 112], ["proteins", 120], ["but", 129], ["rarely", 133], ["applied", 140], ["to", 148], ["non", 151], ["-", 154], ["coding", 155], ["cis", 162], ["-", 165], ["regulatory", 166], ["DNA", 177], ["elements", 181], [".", 189], ["We", 191], ["were", 194], ["wondering", 199], ["whether", 209], ["this", 217], ["approach", 222], ["could", 231], ["provide", 237], ["insights", 245], ["about", 254], ["utlraconserved", 260], ["non", 275], ["-", 278], ["coding", 279], ["elements", 286], ["(", 295], ["UCNEs", 296], [")", 301], [".", 302], ["These", 304], ["elements", 310], ["are", 319], ["organized", 323], ["as", 333], ["large", 336], ["clusters", 342], [",", 350], ["so", 352], ["-", 354], ["called", 355], ["gene", 362], ["regulatory", 367], ["blocks", 378], ["(", 385], ["GRBs", 386], [")", 390], ["around", 392], ["key", 399], ["developmental", 403], ["genes", 417], [".", 422], ["Their", 424], ["molecular", 430], ["functions", 440], ["and", 450], ["the", 454], ["reasons", 458], ["for", 466], ["their", 470], ["high", 476], ["degree", 481], ["of", 488], ["conservation", 491], ["remain", 504], ["enigmatic", 511], [".", 520], ["In", 522], ["a", 525], ["special", 527], ["setting", 535], ["of", 543], ["genomic", 546], ["context", 554], ["analysis", 562], [",", 570], ["we", 572], ["analyzed", 575], ["the", 584], ["fate", 588], ["of", 593], ["GRBs", 596], ["after", 601], ["a", 607], ["whole", 609], ["-", 614], ["genome", 615], ["duplication", 622], ["event", 634], ["in", 640], ["five", 643], ["fish", 648], ["genomes", 653], [".", 660], ["We", 662], ["found", 665], ["that", 671], ["in", 676], ["most", 679], ["cases", 684], ["all", 690], ["UCNEs", 694], ["were", 700], ["retained", 705], ["together", 714], ["as", 723], ["a", 726], ["single", 728], ["block", 735], [",", 740], ["whereas", 742], ["the", 750], ["corresponding", 754], ["target", 768], ["genes", 775], ["were", 781], ["often", 786], ["retained", 792], ["in", 801], ["two", 804], ["copies", 808], [",", 814], ["one", 816], ["completely", 820], ["devoid", 831], ["of", 838], ["UCNEs", 841], [".", 846], ["This", 848], ["'", 853], ["winner", 854], ["-", 860], ["takes", 861], ["-", 866], ["all", 867], ["'", 870], ["pattern", 872], ["suggests", 880], ["that", 889], ["UCNEs", 894], ["of", 900], ["a", 903], ["GRB", 905], ["function", 909], ["in", 918], ["a", 921], ["highly", 923], ["cooperative", 930], ["manner", 942], [".", 948], ["We", 950], ["propose", 953], ["that", 961], ["the", 966], ["multitude", 970], ["of", 980], ["interactions", 983], ["between", 996], ["UCNEs", 1004], ["is", 1010], ["the", 1013], ["reason", 1017], ["for", 1024], ["their", 1028], ["extreme", 1034], ["sequence", 1042], ["conservation", 1051], [".", 1063], ["Supplementary", 1065], ["data", 1079], ["are", 1084], ["available", 1088], ["at", 1098], ["Bioinformatics", 1101], ["online", 1116], ["and", 1123], ["at", 1127], ["http://ccg.vital-it.ch/ucne/", 1130]]}
{"context": "mDia proteins are members of the formin family of actin nucleating proteins that polymerize linear actin filaments. Such filaments form the core of thin, tubular, membrane-bound cell surface protrusions known as filopodia, which are a major feature of mammalian cell morphology. Filopodia are dynamic structures that help cells sense environmental cues, and play a role in cell migration, axon guidance, angiogenesis and other processes. RhoGTPases bind to and control the activity of mDia proteins, and several other binding partners of the three mDia1 isoforms-mDia1, mDia2 and mDia3-have been documented. Two independent pathways controlling mammalian filopodium formation have emerged, with one driven by the RhoGTPase Cdc42, and the other by Rif. While mDia2 has been the main formin implicated in forming filopodia, mDia1 has recently surfaced as the key formin utilized by both the Cdc42 and Rif pathways to drive filopodial protrusion.", "qas": [{"question": "What family do mDia proteins belong in?", "answers": ["mDia proteins are members of the formin family"], "qid": "df45d243d5b846c9b8dd26f62bbe479e", "question_tokens": [["What", 0], ["family", 5], ["do", 12], ["mDia", 15], ["proteins", 20], ["belong", 29], ["in", 36], ["?", 38]], "detected_answers": [{"text": "mDia proteins are members of the formin family", "token_spans": [[0, 7]], "char_spans": [[0, 45]]}]}], "context_tokens": [["mDia", 0], ["proteins", 5], ["are", 14], ["members", 18], ["of", 26], ["the", 29], ["formin", 33], ["family", 40], ["of", 47], ["actin", 50], ["nucleating", 56], ["proteins", 67], ["that", 76], ["polymerize", 81], ["linear", 92], ["actin", 99], ["filaments", 105], [".", 114], ["Such", 116], ["filaments", 121], ["form", 131], ["the", 136], ["core", 140], ["of", 145], ["thin", 148], [",", 152], ["tubular", 154], [",", 161], ["membrane", 163], ["-", 171], ["bound", 172], ["cell", 178], ["surface", 183], ["protrusions", 191], ["known", 203], ["as", 209], ["filopodia", 212], [",", 221], ["which", 223], ["are", 229], ["a", 233], ["major", 235], ["feature", 241], ["of", 249], ["mammalian", 252], ["cell", 262], ["morphology", 267], [".", 277], ["Filopodia", 279], ["are", 289], ["dynamic", 293], ["structures", 301], ["that", 312], ["help", 317], ["cells", 322], ["sense", 328], ["environmental", 334], ["cues", 348], [",", 352], ["and", 354], ["play", 358], ["a", 363], ["role", 365], ["in", 370], ["cell", 373], ["migration", 378], [",", 387], ["axon", 389], ["guidance", 394], [",", 402], ["angiogenesis", 404], ["and", 417], ["other", 421], ["processes", 427], [".", 436], ["RhoGTPases", 438], ["bind", 449], ["to", 454], ["and", 457], ["control", 461], ["the", 469], ["activity", 473], ["of", 482], ["mDia", 485], ["proteins", 490], [",", 498], ["and", 500], ["several", 504], ["other", 512], ["binding", 518], ["partners", 526], ["of", 535], ["the", 538], ["three", 542], ["mDia1", 548], ["isoforms", 554], ["-", 562], ["mDia1", 563], [",", 568], ["mDia2", 570], ["and", 576], ["mDia3-have", 580], ["been", 591], ["documented", 596], [".", 606], ["Two", 608], ["independent", 612], ["pathways", 624], ["controlling", 633], ["mammalian", 645], ["filopodium", 655], ["formation", 666], ["have", 676], ["emerged", 681], [",", 688], ["with", 690], ["one", 695], ["driven", 699], ["by", 706], ["the", 709], ["RhoGTPase", 713], ["Cdc42", 723], [",", 728], ["and", 730], ["the", 734], ["other", 738], ["by", 744], ["Rif", 747], [".", 750], ["While", 752], ["mDia2", 758], ["has", 764], ["been", 768], ["the", 773], ["main", 777], ["formin", 782], ["implicated", 789], ["in", 800], ["forming", 803], ["filopodia", 811], [",", 820], ["mDia1", 822], ["has", 828], ["recently", 832], ["surfaced", 841], ["as", 850], ["the", 853], ["key", 857], ["formin", 861], ["utilized", 868], ["by", 877], ["both", 880], ["the", 885], ["Cdc42", 889], ["and", 895], ["Rif", 899], ["pathways", 903], ["to", 912], ["drive", 915], ["filopodial", 921], ["protrusion", 932], [".", 942]]}
{"context": "Nucleotide excision repair (NER) is a remarkably versatile DNA repair system, essential for maintenance of genomic stability. Hereditary alterations in NER enzymes can result in increased cancer propensity, but also in developmental, neurodegenerative, and progeroid syndromes. NER can be operationally divided in three subtypes, which share many common steps: global genomic repair (GGR) operates on the whole genome level, transcription domain-associated repair (DAR) is a concentration of NER activity within transcription factories, and transcription-coupled repair (TCR) provides faster repair of the transcribed strand of active genes. Interestingly, ubiquitination plays an important role in all three classes of NER, as well as in associated phenomena, such as damage signalling by histone ubiquitination, and degradation of stalled RNA polymerase II when repair does not occur in a timely manner.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "eac37c9c5ffd4618bcc7270e473097f6", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[103, 104]], "char_spans": [[606, 623]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], ["is", 33], ["a", 36], ["remarkably", 38], ["versatile", 49], ["DNA", 59], ["repair", 63], ["system", 70], [",", 76], ["essential", 78], ["for", 88], ["maintenance", 92], ["of", 104], ["genomic", 107], ["stability", 115], [".", 124], ["Hereditary", 126], ["alterations", 137], ["in", 149], ["NER", 152], ["enzymes", 156], ["can", 164], ["result", 168], ["in", 175], ["increased", 178], ["cancer", 188], ["propensity", 195], [",", 205], ["but", 207], ["also", 211], ["in", 216], ["developmental", 219], [",", 232], ["neurodegenerative", 234], [",", 251], ["and", 253], ["progeroid", 257], ["syndromes", 267], [".", 276], ["NER", 278], ["can", 282], ["be", 286], ["operationally", 289], ["divided", 303], ["in", 311], ["three", 314], ["subtypes", 320], [",", 328], ["which", 330], ["share", 336], ["many", 342], ["common", 347], ["steps", 354], [":", 359], ["global", 361], ["genomic", 368], ["repair", 376], ["(", 383], ["GGR", 384], [")", 387], ["operates", 389], ["on", 398], ["the", 401], ["whole", 405], ["genome", 411], ["level", 418], [",", 423], ["transcription", 425], ["domain", 439], ["-", 445], ["associated", 446], ["repair", 457], ["(", 464], ["DAR", 465], [")", 468], ["is", 470], ["a", 473], ["concentration", 475], ["of", 489], ["NER", 492], ["activity", 496], ["within", 505], ["transcription", 512], ["factories", 526], [",", 535], ["and", 537], ["transcription", 541], ["-", 554], ["coupled", 555], ["repair", 563], ["(", 570], ["TCR", 571], [")", 574], ["provides", 576], ["faster", 585], ["repair", 592], ["of", 599], ["the", 602], ["transcribed", 606], ["strand", 618], ["of", 625], ["active", 628], ["genes", 635], [".", 640], ["Interestingly", 642], [",", 655], ["ubiquitination", 657], ["plays", 672], ["an", 678], ["important", 681], ["role", 691], ["in", 696], ["all", 699], ["three", 703], ["classes", 709], ["of", 717], ["NER", 720], [",", 723], ["as", 725], ["well", 728], ["as", 733], ["in", 736], ["associated", 739], ["phenomena", 750], [",", 759], ["such", 761], ["as", 766], ["damage", 769], ["signalling", 776], ["by", 787], ["histone", 790], ["ubiquitination", 798], [",", 812], ["and", 814], ["degradation", 818], ["of", 830], ["stalled", 833], ["RNA", 841], ["polymerase", 845], ["II", 856], ["when", 859], ["repair", 864], ["does", 871], ["not", 876], ["occur", 880], ["in", 886], ["a", 889], ["timely", 891], ["manner", 898], [".", 904]]}
{"context": "The development of novel oral anticoagulants (NOACs) has revolutionized oral anticoagulation. Rapid incorporation of NOACs into general practice has heightened the demand for directed reversal agents. Idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran. While it is a welcome addition to reversal strategies of dabigatran, a number of clinical questions exist regarding its place in therapy. We describe controversies regarding the use of idarucizumab therapy in patients with dabigatran-associated bleeding. Although existing clinical studies show a rapid reversal of coagulation assays, these studies did not describe a corresponding improvement in mortality or rapid cessation of hemorrhage. It is questionable how heavily clinicians can rely upon the use of the surrogate endpoints in clinical studies, such as ecarin clotting time and dilute thrombin time. Another issue is whether patients exhibiting re-elevation of coagulation assays would benefit from an additional dose of idarucizumab, because this has not been studied. It is currently unclear if blood products must be given in addition to idarucizumab can be used as monotherapy. The initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran. As more clinical practice experience is gained with the agent and the remaining data on its use are released, clinicians can better guide the clinical use of idarucizumab. At present, there is currently not enough evidence for idarucizumab to be used as monotherapy.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "dc40f38b59fd40f9bfc5fdd3040d8e0c", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[60, 60], [48, 48], [211, 211], [86, 86]], "char_spans": [[385, 394], [316, 325], [1317, 1326], [551, 560]]}]}], "context_tokens": [["The", 0], ["development", 4], ["of", 16], ["novel", 19], ["oral", 25], ["anticoagulants", 30], ["(", 45], ["NOACs", 46], [")", 51], ["has", 53], ["revolutionized", 57], ["oral", 72], ["anticoagulation", 77], [".", 92], ["Rapid", 94], ["incorporation", 100], ["of", 114], ["NOACs", 117], ["into", 123], ["general", 128], ["practice", 136], ["has", 145], ["heightened", 149], ["the", 160], ["demand", 164], ["for", 171], ["directed", 175], ["reversal", 184], ["agents", 193], [".", 199], ["Idarucizumab", 201], ["is", 214], ["a", 217], ["targeted", 219], ["reversal", 228], ["agent", 237], ["that", 243], ["is", 248], ["approved", 251], ["for", 260], ["the", 264], ["urgent", 268], ["reversal", 275], ["of", 284], ["the", 287], ["anticoagulant", 291], ["effects", 305], ["of", 313], ["dabigatran", 316], [".", 326], ["While", 328], ["it", 334], ["is", 337], ["a", 340], ["welcome", 342], ["addition", 350], ["to", 359], ["reversal", 362], ["strategies", 371], ["of", 382], ["dabigatran", 385], [",", 395], ["a", 397], ["number", 399], ["of", 406], ["clinical", 409], ["questions", 418], ["exist", 428], ["regarding", 434], ["its", 444], ["place", 448], ["in", 454], ["therapy", 457], [".", 464], ["We", 466], ["describe", 469], ["controversies", 478], ["regarding", 492], ["the", 502], ["use", 506], ["of", 510], ["idarucizumab", 513], ["therapy", 526], ["in", 534], ["patients", 537], ["with", 546], ["dabigatran", 551], ["-", 561], ["associated", 562], ["bleeding", 573], [".", 581], ["Although", 583], ["existing", 592], ["clinical", 601], ["studies", 610], ["show", 618], ["a", 623], ["rapid", 625], ["reversal", 631], ["of", 640], ["coagulation", 643], ["assays", 655], [",", 661], ["these", 663], ["studies", 669], ["did", 677], ["not", 681], ["describe", 685], ["a", 694], ["corresponding", 696], ["improvement", 710], ["in", 722], ["mortality", 725], ["or", 735], ["rapid", 738], ["cessation", 744], ["of", 754], ["hemorrhage", 757], [".", 767], ["It", 769], ["is", 772], ["questionable", 775], ["how", 788], ["heavily", 792], ["clinicians", 800], ["can", 811], ["rely", 815], ["upon", 820], ["the", 825], ["use", 829], ["of", 833], ["the", 836], ["surrogate", 840], ["endpoints", 850], ["in", 860], ["clinical", 863], ["studies", 872], [",", 879], ["such", 881], ["as", 886], ["ecarin", 889], ["clotting", 896], ["time", 905], ["and", 910], ["dilute", 914], ["thrombin", 921], ["time", 930], [".", 934], ["Another", 936], ["issue", 944], ["is", 950], ["whether", 953], ["patients", 961], ["exhibiting", 970], ["re", 981], ["-", 983], ["elevation", 984], ["of", 994], ["coagulation", 997], ["assays", 1009], ["would", 1016], ["benefit", 1022], ["from", 1030], ["an", 1035], ["additional", 1038], ["dose", 1049], ["of", 1054], ["idarucizumab", 1057], [",", 1069], ["because", 1071], ["this", 1079], ["has", 1084], ["not", 1088], ["been", 1092], ["studied", 1097], [".", 1104], ["It", 1106], ["is", 1109], ["currently", 1112], ["unclear", 1122], ["if", 1130], ["blood", 1133], ["products", 1139], ["must", 1148], ["be", 1153], ["given", 1156], ["in", 1162], ["addition", 1165], ["to", 1174], ["idarucizumab", 1177], ["can", 1190], ["be", 1194], ["used", 1197], ["as", 1202], ["monotherapy", 1205], [".", 1216], ["The", 1218], ["initial", 1222], ["data", 1230], ["suggest", 1235], ["a", 1243], ["definite", 1245], ["role", 1254], ["for", 1259], ["idarucizumab", 1263], ["in", 1276], ["treatment", 1279], ["of", 1289], ["bleeding", 1292], ["associated", 1301], ["with", 1312], ["dabigatran", 1317], [".", 1327], ["As", 1329], ["more", 1332], ["clinical", 1337], ["practice", 1346], ["experience", 1355], ["is", 1366], ["gained", 1369], ["with", 1376], ["the", 1381], ["agent", 1385], ["and", 1391], ["the", 1395], ["remaining", 1399], ["data", 1409], ["on", 1414], ["its", 1417], ["use", 1421], ["are", 1425], ["released", 1429], [",", 1437], ["clinicians", 1439], ["can", 1450], ["better", 1454], ["guide", 1461], ["the", 1467], ["clinical", 1471], ["use", 1480], ["of", 1484], ["idarucizumab", 1487], [".", 1499], ["At", 1501], ["present", 1504], [",", 1511], ["there", 1513], ["is", 1519], ["currently", 1522], ["not", 1532], ["enough", 1536], ["evidence", 1543], ["for", 1552], ["idarucizumab", 1556], ["to", 1569], ["be", 1572], ["used", 1575], ["as", 1580], ["monotherapy", 1583], [".", 1594]]}
{"context": "Parkinson's disease (PD) is the second most common neurodegenerative disorder that is characterized by two major neuropathological hallmarks: the degeneration of dopaminergic neurons in the substantia nigra (SN) and the presence of Lewy bodies in the surviving SN neurons, as well as other regions of the central and peripheral nervous system. Animal models have been invaluable tools for investigating the underlying mechanisms of the pathogenesis of PD and testing new potential symptomatic, neuroprotective and neurorestorative therapies. However, the usefulness of these models is dependent on how precisely they replicate the features of clinical PD with some studies now employing combined gene-environment models to replicate more of the affected pathways. The rotenone model of PD has become of great interest following the seminal paper by the Greenamyre group in 2000 (Betarbet et al., 2000). This paper reported for the first time that systemic rotenone was able to reproduce the two pathological hallmarks of PD as well as certain parkinsonian motor deficits. Since 2000, many research groups have actively used the rotenone model worldwide. This paper will review rotenone models, focusing upon their ability to reproduce the two pathological hallmarks of PD, motor deficits, extranigral pathology and non-motor symptoms. We will also summarize the recent advances in neuroprotective therapies, focusing on those that investigated non-motor symptoms and review rotenone models used in combination with PD genetic models to investigate gene-environment interactions.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "93e3e9fa03db483194b1dc67af0aa5af", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["the", 28], ["second", 32], ["most", 39], ["common", 44], ["neurodegenerative", 51], ["disorder", 69], ["that", 78], ["is", 83], ["characterized", 86], ["by", 100], ["two", 103], ["major", 107], ["neuropathological", 113], ["hallmarks", 131], [":", 140], ["the", 142], ["degeneration", 146], ["of", 159], ["dopaminergic", 162], ["neurons", 175], ["in", 183], ["the", 186], ["substantia", 190], ["nigra", 201], ["(", 207], ["SN", 208], [")", 210], ["and", 212], ["the", 216], ["presence", 220], ["of", 229], ["Lewy", 232], ["bodies", 237], ["in", 244], ["the", 247], ["surviving", 251], ["SN", 261], ["neurons", 264], [",", 271], ["as", 273], ["well", 276], ["as", 281], ["other", 284], ["regions", 290], ["of", 298], ["the", 301], ["central", 305], ["and", 313], ["peripheral", 317], ["nervous", 328], ["system", 336], [".", 342], ["Animal", 344], ["models", 351], ["have", 358], ["been", 363], ["invaluable", 368], ["tools", 379], ["for", 385], ["investigating", 389], ["the", 403], ["underlying", 407], ["mechanisms", 418], ["of", 429], ["the", 432], ["pathogenesis", 436], ["of", 449], ["PD", 452], ["and", 455], ["testing", 459], ["new", 467], ["potential", 471], ["symptomatic", 481], [",", 492], ["neuroprotective", 494], ["and", 510], ["neurorestorative", 514], ["therapies", 531], [".", 540], ["However", 542], [",", 549], ["the", 551], ["usefulness", 555], ["of", 566], ["these", 569], ["models", 575], ["is", 582], ["dependent", 585], ["on", 595], ["how", 598], ["precisely", 602], ["they", 612], ["replicate", 617], ["the", 627], ["features", 631], ["of", 640], ["clinical", 643], ["PD", 652], ["with", 655], ["some", 660], ["studies", 665], ["now", 673], ["employing", 677], ["combined", 687], ["gene", 696], ["-", 700], ["environment", 701], ["models", 713], ["to", 720], ["replicate", 723], ["more", 733], ["of", 738], ["the", 741], ["affected", 745], ["pathways", 754], [".", 762], ["The", 764], ["rotenone", 768], ["model", 777], ["of", 783], ["PD", 786], ["has", 789], ["become", 793], ["of", 800], ["great", 803], ["interest", 809], ["following", 818], ["the", 828], ["seminal", 832], ["paper", 840], ["by", 846], ["the", 849], ["Greenamyre", 853], ["group", 864], ["in", 870], ["2000", 873], ["(", 878], ["Betarbet", 879], ["et", 888], ["al", 891], [".", 893], [",", 894], ["2000", 896], [")", 900], [".", 901], ["This", 903], ["paper", 908], ["reported", 914], ["for", 923], ["the", 927], ["first", 931], ["time", 937], ["that", 942], ["systemic", 947], ["rotenone", 956], ["was", 965], ["able", 969], ["to", 974], ["reproduce", 977], ["the", 987], ["two", 991], ["pathological", 995], ["hallmarks", 1008], ["of", 1018], ["PD", 1021], ["as", 1024], ["well", 1027], ["as", 1032], ["certain", 1035], ["parkinsonian", 1043], ["motor", 1056], ["deficits", 1062], [".", 1070], ["Since", 1072], ["2000", 1078], [",", 1082], ["many", 1084], ["research", 1089], ["groups", 1098], ["have", 1105], ["actively", 1110], ["used", 1119], ["the", 1124], ["rotenone", 1128], ["model", 1137], ["worldwide", 1143], [".", 1152], ["This", 1154], ["paper", 1159], ["will", 1165], ["review", 1170], ["rotenone", 1177], ["models", 1186], [",", 1192], ["focusing", 1194], ["upon", 1203], ["their", 1208], ["ability", 1214], ["to", 1222], ["reproduce", 1225], ["the", 1235], ["two", 1239], ["pathological", 1243], ["hallmarks", 1256], ["of", 1266], ["PD", 1269], [",", 1271], ["motor", 1273], ["deficits", 1279], [",", 1287], ["extranigral", 1289], ["pathology", 1301], ["and", 1311], ["non", 1315], ["-", 1318], ["motor", 1319], ["symptoms", 1325], [".", 1333], ["We", 1335], ["will", 1338], ["also", 1343], ["summarize", 1348], ["the", 1358], ["recent", 1362], ["advances", 1369], ["in", 1378], ["neuroprotective", 1381], ["therapies", 1397], [",", 1406], ["focusing", 1408], ["on", 1417], ["those", 1420], ["that", 1426], ["investigated", 1431], ["non", 1444], ["-", 1447], ["motor", 1448], ["symptoms", 1454], ["and", 1463], ["review", 1467], ["rotenone", 1474], ["models", 1483], ["used", 1490], ["in", 1495], ["combination", 1498], ["with", 1510], ["PD", 1515], ["genetic", 1518], ["models", 1526], ["to", 1533], ["investigate", 1536], ["gene", 1548], ["-", 1552], ["environment", 1553], ["interactions", 1565], [".", 1577]]}
{"context": "The advent of antibiotics for the treatment of tuberculosis (TB) represented a major breakthrough in the fight against the disease. However, since its first use, antibiotic therapy has been associated with the emergence of resistance to drugs. The incorrect use of anti-TB drugs, either due to prescription errors, low patient compliance, or poor quality of drugs, led to the widespread emergence of Mycobacterium tuberculosis strains with an expanding spectrum of resistance. The spread of multidrug-resistant (MDR) strains (ie, strains resistant to both isoniazid and rifampicin) has represented a major threat to TB control since the 1990s. In 2006, the first cases of MDR strains with further resistance to fluoroquinolone and injectable drugs were described and named extensively drug-resistant TB (XDR-TB). The emergence of XDR-TB strains is a result of mismanagement of MDR cases, and treatment relies on drugs that are less potent and more toxic than those used to treat drug-susceptible or MDR strains. Furthermore, treatment success is lower and mortality higher than achieved in MDR-TB cases, and the number of drugs necessary in the intensive phase of treatment may be higher than the four drugs recommended for MDR-TB. Linezolid may represent a valuable drug to treat cases of XDR-TB. Delamanid, bedaquiline, and PA-824 are new anti-TB agents in the development pipeline that have the potential to enhance the cure rate of XDR-TB. The best measures to prevent new cases of XDR-TB are the correct management of MDR-TB patients, early detection, and proper treatment of existing patients with XDR-TB.", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "e7dd43f614bd4a44808e13eb2dbde1f6", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[8, 8], [75, 75]], "char_spans": [[47, 58], [414, 425]]}]}], "context_tokens": [["The", 0], ["advent", 4], ["of", 11], ["antibiotics", 14], ["for", 26], ["the", 30], ["treatment", 34], ["of", 44], ["tuberculosis", 47], ["(", 60], ["TB", 61], [")", 63], ["represented", 65], ["a", 77], ["major", 79], ["breakthrough", 85], ["in", 98], ["the", 101], ["fight", 105], ["against", 111], ["the", 119], ["disease", 123], [".", 130], ["However", 132], [",", 139], ["since", 141], ["its", 147], ["first", 151], ["use", 157], [",", 160], ["antibiotic", 162], ["therapy", 173], ["has", 181], ["been", 185], ["associated", 190], ["with", 201], ["the", 206], ["emergence", 210], ["of", 220], ["resistance", 223], ["to", 234], ["drugs", 237], [".", 242], ["The", 244], ["incorrect", 248], ["use", 258], ["of", 262], ["anti", 265], ["-", 269], ["TB", 270], ["drugs", 273], [",", 278], ["either", 280], ["due", 287], ["to", 291], ["prescription", 294], ["errors", 307], [",", 313], ["low", 315], ["patient", 319], ["compliance", 327], [",", 337], ["or", 339], ["poor", 342], ["quality", 347], ["of", 355], ["drugs", 358], [",", 363], ["led", 365], ["to", 369], ["the", 372], ["widespread", 376], ["emergence", 387], ["of", 397], ["Mycobacterium", 400], ["tuberculosis", 414], ["strains", 427], ["with", 435], ["an", 440], ["expanding", 443], ["spectrum", 453], ["of", 462], ["resistance", 465], [".", 475], ["The", 477], ["spread", 481], ["of", 488], ["multidrug", 491], ["-", 500], ["resistant", 501], ["(", 511], ["MDR", 512], [")", 515], ["strains", 517], ["(", 525], ["ie", 526], [",", 528], ["strains", 530], ["resistant", 538], ["to", 548], ["both", 551], ["isoniazid", 556], ["and", 566], ["rifampicin", 570], [")", 580], ["has", 582], ["represented", 586], ["a", 598], ["major", 600], ["threat", 606], ["to", 613], ["TB", 616], ["control", 619], ["since", 627], ["the", 633], ["1990s", 637], [".", 642], ["In", 644], ["2006", 647], [",", 651], ["the", 653], ["first", 657], ["cases", 663], ["of", 669], ["MDR", 672], ["strains", 676], ["with", 684], ["further", 689], ["resistance", 697], ["to", 708], ["fluoroquinolone", 711], ["and", 727], ["injectable", 731], ["drugs", 742], ["were", 748], ["described", 753], ["and", 763], ["named", 767], ["extensively", 773], ["drug", 785], ["-", 789], ["resistant", 790], ["TB", 800], ["(", 803], ["XDR", 804], ["-", 807], ["TB", 808], [")", 810], [".", 811], ["The", 813], ["emergence", 817], ["of", 827], ["XDR", 830], ["-", 833], ["TB", 834], ["strains", 837], ["is", 845], ["a", 848], ["result", 850], ["of", 857], ["mismanagement", 860], ["of", 874], ["MDR", 877], ["cases", 881], [",", 886], ["and", 888], ["treatment", 892], ["relies", 902], ["on", 909], ["drugs", 912], ["that", 918], ["are", 923], ["less", 927], ["potent", 932], ["and", 939], ["more", 943], ["toxic", 948], ["than", 954], ["those", 959], ["used", 965], ["to", 970], ["treat", 973], ["drug", 979], ["-", 983], ["susceptible", 984], ["or", 996], ["MDR", 999], ["strains", 1003], [".", 1010], ["Furthermore", 1012], [",", 1023], ["treatment", 1025], ["success", 1035], ["is", 1043], ["lower", 1046], ["and", 1052], ["mortality", 1056], ["higher", 1066], ["than", 1073], ["achieved", 1078], ["in", 1087], ["MDR", 1090], ["-", 1093], ["TB", 1094], ["cases", 1097], [",", 1102], ["and", 1104], ["the", 1108], ["number", 1112], ["of", 1119], ["drugs", 1122], ["necessary", 1128], ["in", 1138], ["the", 1141], ["intensive", 1145], ["phase", 1155], ["of", 1161], ["treatment", 1164], ["may", 1174], ["be", 1178], ["higher", 1181], ["than", 1188], ["the", 1193], ["four", 1197], ["drugs", 1202], ["recommended", 1208], ["for", 1220], ["MDR", 1224], ["-", 1227], ["TB", 1228], [".", 1230], ["Linezolid", 1232], ["may", 1242], ["represent", 1246], ["a", 1256], ["valuable", 1258], ["drug", 1267], ["to", 1272], ["treat", 1275], ["cases", 1281], ["of", 1287], ["XDR", 1290], ["-", 1293], ["TB", 1294], [".", 1296], ["Delamanid", 1298], [",", 1307], ["bedaquiline", 1309], [",", 1320], ["and", 1322], ["PA-824", 1326], ["are", 1333], ["new", 1337], ["anti", 1341], ["-", 1345], ["TB", 1346], ["agents", 1349], ["in", 1356], ["the", 1359], ["development", 1363], ["pipeline", 1375], ["that", 1384], ["have", 1389], ["the", 1394], ["potential", 1398], ["to", 1408], ["enhance", 1411], ["the", 1419], ["cure", 1423], ["rate", 1428], ["of", 1433], ["XDR", 1436], ["-", 1439], ["TB", 1440], [".", 1442], ["The", 1444], ["best", 1448], ["measures", 1453], ["to", 1462], ["prevent", 1465], ["new", 1473], ["cases", 1477], ["of", 1483], ["XDR", 1486], ["-", 1489], ["TB", 1490], ["are", 1493], ["the", 1497], ["correct", 1501], ["management", 1509], ["of", 1520], ["MDR", 1523], ["-", 1526], ["TB", 1527], ["patients", 1530], [",", 1538], ["early", 1540], ["detection", 1546], [",", 1555], ["and", 1557], ["proper", 1561], ["treatment", 1568], ["of", 1578], ["existing", 1581], ["patients", 1590], ["with", 1599], ["XDR", 1604], ["-", 1607], ["TB", 1608], [".", 1610]]}
{"context": "Sotos syndrome is an overgrowth syndrome with characteristic facial gestalt and mental retardation of variable severity. Haploinsufficiency of the NSD1 gene has been implicated as the major cause of Sotos syndrome, with a predominance of microdeletions reported in Japanese patients. This study was conducted to investigate into the spectrum of NSD1 gene mutations in southern Chinese patients with Sotos syndrome. Thirty-six Chinese patients with Sotos syndrome and two patients with Weaver syndrome were subject to molecular testing. NSD1 gene mutations were detected in 26 (72%) Sotos patients. Microdeletion was found in only 3 patients, while the other 23 had point mutations (6 frameshift, 8 nonsense, 2 spice site, and 7 missense). Of these, 19 mutations were never reported. NSD1 gene mutations were not found in the two patients with Weaver syndrome. Most cases of Sotos syndrome are caused by NSD1 gene defects, but the spectrum of mutations is different from that of Japanese patients. Genotype-phenotype correlation showed that patients with microdeletions might be more prone to congenital heart disease but less likely to have somatic overgrowth. The two patients with Weaver syndrome were not found to have NSD1 gene mutations, but the number was too small for any conclusion to be drawn.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "2cf9e36ee549421b84170a93d439b69d", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[160, 161], [138, 139], [20, 21], [84, 85], [53, 54], [213, 214]], "char_spans": [[903, 911], [783, 791], [147, 155], [536, 544], [345, 353], [1222, 1230]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["is", 15], ["an", 18], ["overgrowth", 21], ["syndrome", 32], ["with", 41], ["characteristic", 46], ["facial", 61], ["gestalt", 68], ["and", 76], ["mental", 80], ["retardation", 87], ["of", 99], ["variable", 102], ["severity", 111], [".", 119], ["Haploinsufficiency", 121], ["of", 140], ["the", 143], ["NSD1", 147], ["gene", 152], ["has", 157], ["been", 161], ["implicated", 166], ["as", 177], ["the", 180], ["major", 184], ["cause", 190], ["of", 196], ["Sotos", 199], ["syndrome", 205], [",", 213], ["with", 215], ["a", 220], ["predominance", 222], ["of", 235], ["microdeletions", 238], ["reported", 253], ["in", 262], ["Japanese", 265], ["patients", 274], [".", 282], ["This", 284], ["study", 289], ["was", 295], ["conducted", 299], ["to", 309], ["investigate", 312], ["into", 324], ["the", 329], ["spectrum", 333], ["of", 342], ["NSD1", 345], ["gene", 350], ["mutations", 355], ["in", 365], ["southern", 368], ["Chinese", 377], ["patients", 385], ["with", 394], ["Sotos", 399], ["syndrome", 405], [".", 413], ["Thirty", 415], ["-", 421], ["six", 422], ["Chinese", 426], ["patients", 434], ["with", 443], ["Sotos", 448], ["syndrome", 454], ["and", 463], ["two", 467], ["patients", 471], ["with", 480], ["Weaver", 485], ["syndrome", 492], ["were", 501], ["subject", 506], ["to", 514], ["molecular", 517], ["testing", 527], [".", 534], ["NSD1", 536], ["gene", 541], ["mutations", 546], ["were", 556], ["detected", 561], ["in", 570], ["26", 573], ["(", 576], ["72", 577], ["%", 579], [")", 580], ["Sotos", 582], ["patients", 588], [".", 596], ["Microdeletion", 598], ["was", 612], ["found", 616], ["in", 622], ["only", 625], ["3", 630], ["patients", 632], [",", 640], ["while", 642], ["the", 648], ["other", 652], ["23", 658], ["had", 661], ["point", 665], ["mutations", 671], ["(", 681], ["6", 682], ["frameshift", 684], [",", 694], ["8", 696], ["nonsense", 698], [",", 706], ["2", 708], ["spice", 710], ["site", 716], [",", 720], ["and", 722], ["7", 726], ["missense", 728], [")", 736], [".", 737], ["Of", 739], ["these", 742], [",", 747], ["19", 749], ["mutations", 752], ["were", 762], ["never", 767], ["reported", 773], [".", 781], ["NSD1", 783], ["gene", 788], ["mutations", 793], ["were", 803], ["not", 808], ["found", 812], ["in", 818], ["the", 821], ["two", 825], ["patients", 829], ["with", 838], ["Weaver", 843], ["syndrome", 850], [".", 858], ["Most", 860], ["cases", 865], ["of", 871], ["Sotos", 874], ["syndrome", 880], ["are", 889], ["caused", 893], ["by", 900], ["NSD1", 903], ["gene", 908], ["defects", 913], [",", 920], ["but", 922], ["the", 926], ["spectrum", 930], ["of", 939], ["mutations", 942], ["is", 952], ["different", 955], ["from", 965], ["that", 970], ["of", 975], ["Japanese", 978], ["patients", 987], [".", 995], ["Genotype", 997], ["-", 1005], ["phenotype", 1006], ["correlation", 1016], ["showed", 1028], ["that", 1035], ["patients", 1040], ["with", 1049], ["microdeletions", 1054], ["might", 1069], ["be", 1075], ["more", 1078], ["prone", 1083], ["to", 1089], ["congenital", 1092], ["heart", 1103], ["disease", 1109], ["but", 1117], ["less", 1121], ["likely", 1126], ["to", 1133], ["have", 1136], ["somatic", 1141], ["overgrowth", 1149], [".", 1159], ["The", 1161], ["two", 1165], ["patients", 1169], ["with", 1178], ["Weaver", 1183], ["syndrome", 1190], ["were", 1199], ["not", 1204], ["found", 1208], ["to", 1214], ["have", 1217], ["NSD1", 1222], ["gene", 1227], ["mutations", 1232], [",", 1241], ["but", 1243], ["the", 1247], ["number", 1251], ["was", 1258], ["too", 1262], ["small", 1266], ["for", 1272], ["any", 1276], ["conclusion", 1280], ["to", 1291], ["be", 1294], ["drawn", 1297], [".", 1302]]}
{"context": "Respirasomes are macromolecular assemblies of the respiratory chain complexes I, III and IV in the inner mitochondrial membrane. We determined the structure of supercomplex I", "qas": [{"question": "Where is the respirasome located?", "answers": ["In the inner mitochondrial membrane"], "qid": "33ef66d3e9fc40e58b68c9f3044a109b", "question_tokens": [["Where", 0], ["is", 6], ["the", 9], ["respirasome", 13], ["located", 25], ["?", 32]], "detected_answers": [{"text": "In the inner mitochondrial membrane", "token_spans": [[14, 18]], "char_spans": [[92, 126]]}]}], "context_tokens": [["Respirasomes", 0], ["are", 13], ["macromolecular", 17], ["assemblies", 32], ["of", 43], ["the", 46], ["respiratory", 50], ["chain", 62], ["complexes", 68], ["I", 78], [",", 79], ["III", 81], ["and", 85], ["IV", 89], ["in", 92], ["the", 95], ["inner", 99], ["mitochondrial", 105], ["membrane", 119], [".", 127], ["We", 129], ["determined", 132], ["the", 143], ["structure", 147], ["of", 157], ["supercomplex", 160], ["I", 173]]}
{"context": "Allelic polymorphism of the apolipoprotein E (ApoE) gene (ApoE \u03b52, ApoE \u03b53 and ApoE \u03b54 alleles) gives rise to three protein isoforms (ApoE2, ApoE3 and ApoE4) that differ by 1 or 2 amino acids. Inheritance of the ApoE \u03b54 allele is a risk factor for developing Alzheimer's disease (AD). The potential diagnostic value of ApoE protein levels in biological fluids (i.e. cerebrospinal fluid, plasma and serum) for distinguishing between AD patients and healthy elderly subjects is subject to great controversy. Although a recent study reported subnormal total ApoE and ApoE4 levels in the plasma of AD patients, other studies have found normal or even elevated protein levels (versus controls). Because all previously reported assays were based on immunoenzymatic techniques, we decided to develop an orthogonal assay based on targeted mass spectrometry by tracking (i) a proteotypic peptide common to all ApoE isoforms and (ii) a peptide that is specific for the \u03b54 allele. After trypsin digestion, the ApoE4-specific peptide contains an oxidation-prone methionine residue. The endogenous methionine oxidation level was evaluated in a small cohort (n=68) of heterozygous \u03b53\u03b54 carriers containing both healthy controls and AD patients. As expected, the proportion of oxidized residues varied from 0 to 10%, with an average of 5%. We therefore developed a standardized strategy for the unbiased, absolute quantification of ApoE4, based on performic acid oxidization of methionine. Once the sample workflow had been thoroughly validated, it was applied to the concomitant quantification of total ApoE and ApoE4 isoform in a large case-control study (n=669). The final measurements were consistent with most previously reported ApoE concentration values and confirm the influence of the different alleles on the protein expression level. Our results illustrate (i) the reliability of selected reaction monitoring-based assays and (ii) the value of the oxidization step for unbiased monitoring of methionine-containing proteotypic peptides. Furthermore, a statistical analysis indicated that neither total ApoE and ApoE4 levels nor the ApoE/ApoE4 ratio correlated with the diagnosis of AD. These findings reinforce the conclusions of previous studies in which plasma ApoE levels had no obvious clinical significance.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "2594b3b5c34d4b7f830baf5eb3094b4c", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[286, 287]], "char_spans": [[1598, 1610]]}]}], "context_tokens": [["Allelic", 0], ["polymorphism", 8], ["of", 21], ["the", 24], ["apolipoprotein", 28], ["E", 43], ["(", 45], ["ApoE", 46], [")", 50], ["gene", 52], ["(", 57], ["ApoE", 58], ["\u03b52", 63], [",", 65], ["ApoE", 67], ["\u03b53", 72], ["and", 75], ["ApoE", 79], ["\u03b54", 84], ["alleles", 87], [")", 94], ["gives", 96], ["rise", 102], ["to", 107], ["three", 110], ["protein", 116], ["isoforms", 124], ["(", 133], ["ApoE2", 134], [",", 139], ["ApoE3", 141], ["and", 147], ["ApoE4", 151], [")", 156], ["that", 158], ["differ", 163], ["by", 170], ["1", 173], ["or", 175], ["2", 178], ["amino", 180], ["acids", 186], [".", 191], ["Inheritance", 193], ["of", 205], ["the", 208], ["ApoE", 212], ["\u03b54", 217], ["allele", 220], ["is", 227], ["a", 230], ["risk", 232], ["factor", 237], ["for", 244], ["developing", 248], ["Alzheimer", 259], ["'s", 268], ["disease", 271], ["(", 279], ["AD", 280], [")", 282], [".", 283], ["The", 285], ["potential", 289], ["diagnostic", 299], ["value", 310], ["of", 316], ["ApoE", 319], ["protein", 324], ["levels", 332], ["in", 339], ["biological", 342], ["fluids", 353], ["(", 360], ["i.e.", 361], ["cerebrospinal", 366], ["fluid", 380], [",", 385], ["plasma", 387], ["and", 394], ["serum", 398], [")", 403], ["for", 405], ["distinguishing", 409], ["between", 424], ["AD", 432], ["patients", 435], ["and", 444], ["healthy", 448], ["elderly", 456], ["subjects", 464], ["is", 473], ["subject", 476], ["to", 484], ["great", 487], ["controversy", 493], [".", 504], ["Although", 506], ["a", 515], ["recent", 517], ["study", 524], ["reported", 530], ["subnormal", 539], ["total", 549], ["ApoE", 555], ["and", 560], ["ApoE4", 564], ["levels", 570], ["in", 577], ["the", 580], ["plasma", 584], ["of", 591], ["AD", 594], ["patients", 597], [",", 605], ["other", 607], ["studies", 613], ["have", 621], ["found", 626], ["normal", 632], ["or", 639], ["even", 642], ["elevated", 647], ["protein", 656], ["levels", 664], ["(", 671], ["versus", 672], ["controls", 679], [")", 687], [".", 688], ["Because", 690], ["all", 698], ["previously", 702], ["reported", 713], ["assays", 722], ["were", 729], ["based", 734], ["on", 740], ["immunoenzymatic", 743], ["techniques", 759], [",", 769], ["we", 771], ["decided", 774], ["to", 782], ["develop", 785], ["an", 793], ["orthogonal", 796], ["assay", 807], ["based", 813], ["on", 819], ["targeted", 822], ["mass", 831], ["spectrometry", 836], ["by", 849], ["tracking", 852], ["(", 861], ["i", 862], [")", 863], ["a", 865], ["proteotypic", 867], ["peptide", 879], ["common", 887], ["to", 894], ["all", 897], ["ApoE", 901], ["isoforms", 906], ["and", 915], ["(", 919], ["ii", 920], [")", 922], ["a", 924], ["peptide", 926], ["that", 934], ["is", 939], ["specific", 942], ["for", 951], ["the", 955], ["\u03b54", 959], ["allele", 962], [".", 968], ["After", 970], ["trypsin", 976], ["digestion", 984], [",", 993], ["the", 995], ["ApoE4-specific", 999], ["peptide", 1014], ["contains", 1022], ["an", 1031], ["oxidation", 1034], ["-", 1043], ["prone", 1044], ["methionine", 1050], ["residue", 1061], [".", 1068], ["The", 1070], ["endogenous", 1074], ["methionine", 1085], ["oxidation", 1096], ["level", 1106], ["was", 1112], ["evaluated", 1116], ["in", 1126], ["a", 1129], ["small", 1131], ["cohort", 1137], ["(", 1144], ["n=68", 1145], [")", 1149], ["of", 1151], ["heterozygous", 1154], ["\u03b53\u03b54", 1167], ["carriers", 1172], ["containing", 1181], ["both", 1192], ["healthy", 1197], ["controls", 1205], ["and", 1214], ["AD", 1218], ["patients", 1221], [".", 1229], ["As", 1231], ["expected", 1234], [",", 1242], ["the", 1244], ["proportion", 1248], ["of", 1259], ["oxidized", 1262], ["residues", 1271], ["varied", 1280], ["from", 1287], ["0", 1292], ["to", 1294], ["10", 1297], ["%", 1299], [",", 1300], ["with", 1302], ["an", 1307], ["average", 1310], ["of", 1318], ["5", 1321], ["%", 1322], [".", 1323], ["We", 1325], ["therefore", 1328], ["developed", 1338], ["a", 1348], ["standardized", 1350], ["strategy", 1363], ["for", 1372], ["the", 1376], ["unbiased", 1380], [",", 1388], ["absolute", 1390], ["quantification", 1399], ["of", 1414], ["ApoE4", 1417], [",", 1422], ["based", 1424], ["on", 1430], ["performic", 1433], ["acid", 1443], ["oxidization", 1448], ["of", 1460], ["methionine", 1463], [".", 1473], ["Once", 1475], ["the", 1480], ["sample", 1484], ["workflow", 1491], ["had", 1500], ["been", 1504], ["thoroughly", 1509], ["validated", 1520], [",", 1529], ["it", 1531], ["was", 1534], ["applied", 1538], ["to", 1546], ["the", 1549], ["concomitant", 1553], ["quantification", 1565], ["of", 1580], ["total", 1583], ["ApoE", 1589], ["and", 1594], ["ApoE4", 1598], ["isoform", 1604], ["in", 1612], ["a", 1615], ["large", 1617], ["case", 1623], ["-", 1627], ["control", 1628], ["study", 1636], ["(", 1642], ["n=669", 1643], [")", 1648], [".", 1649], ["The", 1651], ["final", 1655], ["measurements", 1661], ["were", 1674], ["consistent", 1679], ["with", 1690], ["most", 1695], ["previously", 1700], ["reported", 1711], ["ApoE", 1720], ["concentration", 1725], ["values", 1739], ["and", 1746], ["confirm", 1750], ["the", 1758], ["influence", 1762], ["of", 1772], ["the", 1775], ["different", 1779], ["alleles", 1789], ["on", 1797], ["the", 1800], ["protein", 1804], ["expression", 1812], ["level", 1823], [".", 1828], ["Our", 1830], ["results", 1834], ["illustrate", 1842], ["(", 1853], ["i", 1854], [")", 1855], ["the", 1857], ["reliability", 1861], ["of", 1873], ["selected", 1876], ["reaction", 1885], ["monitoring", 1894], ["-", 1904], ["based", 1905], ["assays", 1911], ["and", 1918], ["(", 1922], ["ii", 1923], [")", 1925], ["the", 1927], ["value", 1931], ["of", 1937], ["the", 1940], ["oxidization", 1944], ["step", 1956], ["for", 1961], ["unbiased", 1965], ["monitoring", 1974], ["of", 1985], ["methionine", 1988], ["-", 1998], ["containing", 1999], ["proteotypic", 2010], ["peptides", 2022], [".", 2030], ["Furthermore", 2032], [",", 2043], ["a", 2045], ["statistical", 2047], ["analysis", 2059], ["indicated", 2068], ["that", 2078], ["neither", 2083], ["total", 2091], ["ApoE", 2097], ["and", 2102], ["ApoE4", 2106], ["levels", 2112], ["nor", 2119], ["the", 2123], ["ApoE", 2127], ["/", 2131], ["ApoE4", 2132], ["ratio", 2138], ["correlated", 2144], ["with", 2155], ["the", 2160], ["diagnosis", 2164], ["of", 2174], ["AD", 2177], [".", 2179], ["These", 2181], ["findings", 2187], ["reinforce", 2196], ["the", 2206], ["conclusions", 2210], ["of", 2222], ["previous", 2225], ["studies", 2234], ["in", 2242], ["which", 2245], ["plasma", 2251], ["ApoE", 2258], ["levels", 2263], ["had", 2270], ["no", 2274], ["obvious", 2277], ["clinical", 2285], ["significance", 2294], [".", 2306]]}
{"context": "To study the impact of genetic and lifestyle factors on protein biomarkers and develop personally normalized plasma protein profiles (PNPPP) controlling for non-disease-related variance. Proximity extension assays were used to measure 145 proteins in 632 controls and 344 cases with non-communicable diseases. Genetic and lifestyle factors explained 20-88% of the variation in healthy controls. Adjusting for these factors reduced the number of candidate biomarkers by 63%. PNPPP efficiently controls for non-disease-related variance, allowing both for efficient discovery of novel biomarkers and for covariate-independent linear cut-offs suitable for clinical use.", "qas": [{"question": "What is PNPPP?", "answers": ["personally normalized plasma protein profiles"], "qid": "fd51aa90ceb147e78cd27c4328ac7962", "question_tokens": [["What", 0], ["is", 5], ["PNPPP", 8], ["?", 13]], "detected_answers": [{"text": "personally normalized plasma protein profiles", "token_spans": [[14, 18]], "char_spans": [[87, 131]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["impact", 13], ["of", 20], ["genetic", 23], ["and", 31], ["lifestyle", 35], ["factors", 45], ["on", 53], ["protein", 56], ["biomarkers", 64], ["and", 75], ["develop", 79], ["personally", 87], ["normalized", 98], ["plasma", 109], ["protein", 116], ["profiles", 124], ["(", 133], ["PNPPP", 134], [")", 139], ["controlling", 141], ["for", 153], ["non", 157], ["-", 160], ["disease", 161], ["-", 168], ["related", 169], ["variance", 177], [".", 185], ["Proximity", 187], ["extension", 197], ["assays", 207], ["were", 214], ["used", 219], ["to", 224], ["measure", 227], ["145", 235], ["proteins", 239], ["in", 248], ["632", 251], ["controls", 255], ["and", 264], ["344", 268], ["cases", 272], ["with", 278], ["non", 283], ["-", 286], ["communicable", 287], ["diseases", 300], [".", 308], ["Genetic", 310], ["and", 318], ["lifestyle", 322], ["factors", 332], ["explained", 340], ["20", 350], ["-", 352], ["88", 353], ["%", 355], ["of", 357], ["the", 360], ["variation", 364], ["in", 374], ["healthy", 377], ["controls", 385], [".", 393], ["Adjusting", 395], ["for", 405], ["these", 409], ["factors", 415], ["reduced", 423], ["the", 431], ["number", 435], ["of", 442], ["candidate", 445], ["biomarkers", 455], ["by", 466], ["63", 469], ["%", 471], [".", 472], ["PNPPP", 474], ["efficiently", 480], ["controls", 492], ["for", 501], ["non", 505], ["-", 508], ["disease", 509], ["-", 516], ["related", 517], ["variance", 525], [",", 533], ["allowing", 535], ["both", 544], ["for", 549], ["efficient", 553], ["discovery", 563], ["of", 573], ["novel", 576], ["biomarkers", 582], ["and", 593], ["for", 597], ["covariate", 601], ["-", 610], ["independent", 611], ["linear", 623], ["cut", 630], ["-", 633], ["offs", 634], ["suitable", 639], ["for", 648], ["clinical", 652], ["use", 661], [".", 664]]}
{"context": "Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI) designed as a prototypic short-acting BCR-ABL-targeted TKI that inhibits BCR-ABL with greater potency compared with imatinib, nilotinib, bosutinib, and ponatinib and has been shown to have potential immunomodulatory effects. Dasatinib is approved for the treatment of all phases of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to prior imatinib treatment and first-line treatment for CML in chronic phase. In this article, the development of dasatinib as a treatment for patients with CML is reviewed. This is a review of the relevant literature regarding dasatinib development in CML (2003-2013). Dasatinib demonstrates efficacy against most BCR-ABL mutations arising during imatinib therapy and is effective in treating patients with imatinib resistance due to other mechanisms. Randomized trial data show that first-line dasatinib provides superior responses compared with imatinib and enables patients to achieve early, deep responses correlated with improved longer-term outcomes. Dasatinib has a generally acceptable safety profile, with most adverse events (AEs) proving manageable and reversible. Cytopenias are commonly observed with dasatinib, and some nonhematologic AEs including pleural effusion have been consistently reported. Dasatinib is an effective treatment option for patients with CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "5c2cbb8eaf4742919bc8a56682ea0e5a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[138, 140], [20, 22], [28, 30]], "char_spans": [[779, 785], [98, 104], [133, 139]]}]}], "context_tokens": [["Dasatinib", 0], ["is", 10], ["a", 13], ["dual", 15], ["Abl", 20], ["/", 23], ["Src", 24], ["tyrosine", 28], ["kinase", 37], ["inhibitor", 44], ["(", 54], ["TKI", 55], [")", 58], ["designed", 60], ["as", 69], ["a", 72], ["prototypic", 74], ["short", 85], ["-", 90], ["acting", 91], ["BCR", 98], ["-", 101], ["ABL", 102], ["-", 105], ["targeted", 106], ["TKI", 115], ["that", 119], ["inhibits", 124], ["BCR", 133], ["-", 136], ["ABL", 137], ["with", 141], ["greater", 146], ["potency", 154], ["compared", 162], ["with", 171], ["imatinib", 176], [",", 184], ["nilotinib", 186], [",", 195], ["bosutinib", 197], [",", 206], ["and", 208], ["ponatinib", 212], ["and", 222], ["has", 226], ["been", 230], ["shown", 235], ["to", 241], ["have", 244], ["potential", 249], ["immunomodulatory", 259], ["effects", 276], [".", 283], ["Dasatinib", 285], ["is", 295], ["approved", 298], ["for", 307], ["the", 311], ["treatment", 315], ["of", 325], ["all", 328], ["phases", 332], ["of", 339], ["chronic", 342], ["myeloid", 350], ["leukemia", 358], ["(", 367], ["CML", 368], [")", 371], ["and", 373], ["Philadelphia", 377], ["chromosome", 390], ["-", 400], ["positive", 401], ["acute", 410], ["lymphoblastic", 416], ["leukemia", 430], ["resistant", 439], ["or", 449], ["intolerant", 452], ["to", 463], ["prior", 466], ["imatinib", 472], ["treatment", 481], ["and", 491], ["first", 495], ["-", 500], ["line", 501], ["treatment", 506], ["for", 516], ["CML", 520], ["in", 524], ["chronic", 527], ["phase", 535], [".", 540], ["In", 542], ["this", 545], ["article", 550], [",", 557], ["the", 559], ["development", 563], ["of", 575], ["dasatinib", 578], ["as", 588], ["a", 591], ["treatment", 593], ["for", 603], ["patients", 607], ["with", 616], ["CML", 621], ["is", 625], ["reviewed", 628], [".", 636], ["This", 638], ["is", 643], ["a", 646], ["review", 648], ["of", 655], ["the", 658], ["relevant", 662], ["literature", 671], ["regarding", 682], ["dasatinib", 692], ["development", 702], ["in", 714], ["CML", 717], ["(", 721], ["2003", 722], ["-", 726], ["2013", 727], [")", 731], [".", 732], ["Dasatinib", 734], ["demonstrates", 744], ["efficacy", 757], ["against", 766], ["most", 774], ["BCR", 779], ["-", 782], ["ABL", 783], ["mutations", 787], ["arising", 797], ["during", 805], ["imatinib", 812], ["therapy", 821], ["and", 829], ["is", 833], ["effective", 836], ["in", 846], ["treating", 849], ["patients", 858], ["with", 867], ["imatinib", 872], ["resistance", 881], ["due", 892], ["to", 896], ["other", 899], ["mechanisms", 905], [".", 915], ["Randomized", 917], ["trial", 928], ["data", 934], ["show", 939], ["that", 944], ["first", 949], ["-", 954], ["line", 955], ["dasatinib", 960], ["provides", 970], ["superior", 979], ["responses", 988], ["compared", 998], ["with", 1007], ["imatinib", 1012], ["and", 1021], ["enables", 1025], ["patients", 1033], ["to", 1042], ["achieve", 1045], ["early", 1053], [",", 1058], ["deep", 1060], ["responses", 1065], ["correlated", 1075], ["with", 1086], ["improved", 1091], ["longer", 1100], ["-", 1106], ["term", 1107], ["outcomes", 1112], [".", 1120], ["Dasatinib", 1122], ["has", 1132], ["a", 1136], ["generally", 1138], ["acceptable", 1148], ["safety", 1159], ["profile", 1166], [",", 1173], ["with", 1175], ["most", 1180], ["adverse", 1185], ["events", 1193], ["(", 1200], ["AEs", 1201], [")", 1204], ["proving", 1206], ["manageable", 1214], ["and", 1225], ["reversible", 1229], [".", 1239], ["Cytopenias", 1241], ["are", 1252], ["commonly", 1256], ["observed", 1265], ["with", 1274], ["dasatinib", 1279], [",", 1288], ["and", 1290], ["some", 1294], ["nonhematologic", 1299], ["AEs", 1314], ["including", 1318], ["pleural", 1328], ["effusion", 1336], ["have", 1345], ["been", 1350], ["consistently", 1355], ["reported", 1368], [".", 1376], ["Dasatinib", 1378], ["is", 1388], ["an", 1391], ["effective", 1394], ["treatment", 1404], ["option", 1414], ["for", 1421], ["patients", 1425], ["with", 1434], ["CML", 1439], [".", 1442]]}
{"context": "Nox activator 1 (NoxA1) is a homologue of p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1. The phosphorylation of cytosolic regulatory components by multiple kinases plays important roles in assembly and activity of the phagocyte NADPH oxidase (Nox2) system, but little is known about regulation by phosphorylation in the Nox1 system. Here we identify Ser(172) and Ser(461) of NoxA1 as phosphorylation sites for protein kinase A (PKA). A consequence of this phosphorylation was the enhancement of NoxA1 complex formation with 14-3-3 proteins. Using both a transfected human embryonic kidney 293 cell Nox1 model system and endogenous Nox1 in colon cell lines, we showed that the elevation of cAMP inhibits, whereas the inhibition of PKA enhances, Nox1-dependent ROS production through effects on NoxA1. Inhibition of Nox1 activity was intensified by the availability of 14-3-3zeta protein, and this regulatory interaction was dependent on PKA-phosphorylatable sites at Ser(172) and Ser(461) in NoxA1. We showed that phosphorylation and 14-3-3 binding induce the dissociation of NoxA1 from the Nox1 complex at the plasma membrane, suggesting a mechanism for the inhibitory effect on Nox1 activity. Our data establish that PKA-phosphorylated NoxA1 is a new binding partner of 14-3-3 protein(s) and that this forms the basis of a novel mechanism regulating the formation of ROS by Nox1 and, potentially, other NoxA1-regulated Nox family members.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "1d136608f31e4ac89782b0aa4082ddf6", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[272, 272], [74, 74], [164, 164], [36, 36], [132, 132], [217, 217], [232, 232], [127, 127]], "char_spans": [[1472, 1475], [417, 420], [911, 914], [180, 183], [728, 731], [1187, 1190], [1276, 1279], [695, 698]]}]}], "context_tokens": [["Nox", 0], ["activator", 4], ["1", 14], ["(", 16], ["NoxA1", 17], [")", 22], ["is", 24], ["a", 27], ["homologue", 29], ["of", 39], ["p67(phox", 42], [")", 50], ["that", 52], ["acts", 57], ["in", 62], ["conjunction", 65], ["with", 77], ["Nox", 82], ["organizer", 86], ["1", 96], ["(", 98], ["NoxO1", 99], [")", 104], ["to", 106], ["regulate", 109], ["reactive", 118], ["oxygen", 127], ["species", 134], ["(", 142], ["ROS", 143], [")", 146], ["production", 148], ["by", 159], ["the", 162], ["NADPH", 166], ["oxidase", 172], ["Nox1", 180], [".", 184], ["The", 186], ["phosphorylation", 190], ["of", 206], ["cytosolic", 209], ["regulatory", 219], ["components", 230], ["by", 241], ["multiple", 244], ["kinases", 253], ["plays", 261], ["important", 267], ["roles", 277], ["in", 283], ["assembly", 286], ["and", 295], ["activity", 299], ["of", 308], ["the", 311], ["phagocyte", 315], ["NADPH", 325], ["oxidase", 331], ["(", 339], ["Nox2", 340], [")", 344], ["system", 346], [",", 352], ["but", 354], ["little", 358], ["is", 365], ["known", 368], ["about", 374], ["regulation", 380], ["by", 391], ["phosphorylation", 394], ["in", 410], ["the", 413], ["Nox1", 417], ["system", 422], [".", 428], ["Here", 430], ["we", 435], ["identify", 438], ["Ser(172", 447], [")", 454], ["and", 456], ["Ser(461", 460], [")", 467], ["of", 469], ["NoxA1", 472], ["as", 478], ["phosphorylation", 481], ["sites", 497], ["for", 503], ["protein", 507], ["kinase", 515], ["A", 522], ["(", 524], ["PKA", 525], [")", 528], [".", 529], ["A", 531], ["consequence", 533], ["of", 545], ["this", 548], ["phosphorylation", 553], ["was", 569], ["the", 573], ["enhancement", 577], ["of", 589], ["NoxA1", 592], ["complex", 598], ["formation", 606], ["with", 616], ["14", 621], ["-", 623], ["3", 624], ["-", 625], ["3", 626], ["proteins", 628], [".", 636], ["Using", 638], ["both", 644], ["a", 649], ["transfected", 651], ["human", 663], ["embryonic", 669], ["kidney", 679], ["293", 686], ["cell", 690], ["Nox1", 695], ["model", 700], ["system", 706], ["and", 713], ["endogenous", 717], ["Nox1", 728], ["in", 733], ["colon", 736], ["cell", 742], ["lines", 747], [",", 752], ["we", 754], ["showed", 757], ["that", 764], ["the", 769], ["elevation", 773], ["of", 783], ["cAMP", 786], ["inhibits", 791], [",", 799], ["whereas", 801], ["the", 809], ["inhibition", 813], ["of", 824], ["PKA", 827], ["enhances", 831], [",", 839], ["Nox1-dependent", 841], ["ROS", 856], ["production", 860], ["through", 871], ["effects", 879], ["on", 887], ["NoxA1", 890], [".", 895], ["Inhibition", 897], ["of", 908], ["Nox1", 911], ["activity", 916], ["was", 925], ["intensified", 929], ["by", 941], ["the", 944], ["availability", 948], ["of", 961], ["14", 964], ["-", 966], ["3", 967], ["-", 968], ["3zeta", 969], ["protein", 975], [",", 982], ["and", 984], ["this", 988], ["regulatory", 993], ["interaction", 1004], ["was", 1016], ["dependent", 1020], ["on", 1030], ["PKA", 1033], ["-", 1036], ["phosphorylatable", 1037], ["sites", 1054], ["at", 1060], ["Ser(172", 1063], [")", 1070], ["and", 1072], ["Ser(461", 1076], [")", 1083], ["in", 1085], ["NoxA1", 1088], [".", 1093], ["We", 1095], ["showed", 1098], ["that", 1105], ["phosphorylation", 1110], ["and", 1126], ["14", 1130], ["-", 1132], ["3", 1133], ["-", 1134], ["3", 1135], ["binding", 1137], ["induce", 1145], ["the", 1152], ["dissociation", 1156], ["of", 1169], ["NoxA1", 1172], ["from", 1178], ["the", 1183], ["Nox1", 1187], ["complex", 1192], ["at", 1200], ["the", 1203], ["plasma", 1207], ["membrane", 1214], [",", 1222], ["suggesting", 1224], ["a", 1235], ["mechanism", 1237], ["for", 1247], ["the", 1251], ["inhibitory", 1255], ["effect", 1266], ["on", 1273], ["Nox1", 1276], ["activity", 1281], [".", 1289], ["Our", 1291], ["data", 1295], ["establish", 1300], ["that", 1310], ["PKA", 1315], ["-", 1318], ["phosphorylated", 1319], ["NoxA1", 1334], ["is", 1340], ["a", 1343], ["new", 1345], ["binding", 1349], ["partner", 1357], ["of", 1365], ["14", 1368], ["-", 1370], ["3", 1371], ["-", 1372], ["3", 1373], ["protein(s", 1375], [")", 1384], ["and", 1386], ["that", 1390], ["this", 1395], ["forms", 1400], ["the", 1406], ["basis", 1410], ["of", 1416], ["a", 1419], ["novel", 1421], ["mechanism", 1427], ["regulating", 1437], ["the", 1448], ["formation", 1452], ["of", 1462], ["ROS", 1465], ["by", 1469], ["Nox1", 1472], ["and", 1477], [",", 1480], ["potentially", 1482], [",", 1493], ["other", 1495], ["NoxA1-regulated", 1501], ["Nox", 1517], ["family", 1521], ["members", 1528], [".", 1535]]}
{"context": "Most previously reported mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) result in an odd number of cysteine residues within the epidermal growth factor (EGF)-like repeats in Notch3. We report here R75P mutation in two Japanese CADASIL families not directly involving cysteine residues located within the first EGF-like repeats. Probands in both families had repeated episodes of stroke, depression, dementia as well as T2 high-intensity lesions in the basal ganglia and periventricular white matter, but fewer white matter lesions in the temporal pole on MRI. These families provide new insights into the diagnosis and pathomechanisms of CADASIL.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "bcde6357432f432684078b4f2374b9d8", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[23, 23], [49, 49]], "char_spans": [[166, 173], [334, 341]]}]}], "context_tokens": [["Most", 0], ["previously", 5], ["reported", 16], ["mutations", 25], ["in", 35], ["cerebral", 38], ["autosomal", 47], ["dominant", 57], ["arteriopathy", 66], ["with", 79], ["subcortical", 84], ["infarcts", 96], ["and", 105], ["leukoencephalopathy", 109], ["(", 129], ["CADASIL", 130], [")", 137], ["result", 139], ["in", 146], ["an", 149], ["odd", 152], ["number", 156], ["of", 163], ["cysteine", 166], ["residues", 175], ["within", 184], ["the", 191], ["epidermal", 195], ["growth", 205], ["factor", 212], ["(", 219], ["EGF)-like", 220], ["repeats", 230], ["in", 238], ["Notch3", 241], [".", 247], ["We", 249], ["report", 252], ["here", 259], ["R75P", 264], ["mutation", 269], ["in", 278], ["two", 281], ["Japanese", 285], ["CADASIL", 294], ["families", 302], ["not", 311], ["directly", 315], ["involving", 324], ["cysteine", 334], ["residues", 343], ["located", 352], ["within", 360], ["the", 367], ["first", 371], ["EGF", 377], ["-", 380], ["like", 381], ["repeats", 386], [".", 393], ["Probands", 395], ["in", 404], ["both", 407], ["families", 412], ["had", 421], ["repeated", 425], ["episodes", 434], ["of", 443], ["stroke", 446], [",", 452], ["depression", 454], [",", 464], ["dementia", 466], ["as", 475], ["well", 478], ["as", 483], ["T2", 486], ["high", 489], ["-", 493], ["intensity", 494], ["lesions", 504], ["in", 512], ["the", 515], ["basal", 519], ["ganglia", 525], ["and", 533], ["periventricular", 537], ["white", 553], ["matter", 559], [",", 565], ["but", 567], ["fewer", 571], ["white", 577], ["matter", 583], ["lesions", 590], ["in", 598], ["the", 601], ["temporal", 605], ["pole", 614], ["on", 619], ["MRI", 622], [".", 625], ["These", 627], ["families", 633], ["provide", 642], ["new", 650], ["insights", 654], ["into", 663], ["the", 668], ["diagnosis", 672], ["and", 682], ["pathomechanisms", 686], ["of", 702], ["CADASIL", 705], [".", 712]]}
{"context": "Since the initial approval of imatinib much has been learned about its resistance mechanisms, and efforts have continued to improve upon BCR-ABL tyrosine kinase inhibitor therapy. Targeted therapy with TKIs has continued to be an area of active research and development in the care of acute and chronic leukemia patients. This article reviews current approved and investigational TKI treatments for chronic myelogenous leukemia (CML), Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph + ALL) and acute myelogenous leukemia (AML). There are now more potent BCR-ABL TKIs approved, which allow for additional options when determining front-line and second-line CML and Ph + ALL treatments. The T315I mutation is an ever-present challenge. Ponatinib, a pan BCR-ABL TKI, while still under investigation, is very hopeful with its ability to overcome T315I mutations in resistant CML and Ph + ALL patients. Because nilotinib and dasatinib have not been directly compared, at present we recommend selecting one or the other based on the side-effect profile, drug interactions, patient comorbidities, and mutational status. FLT-3 inhibition is of particular interest in AML patients with FLT-3 internal tandem duplication mutations; this type of targeted therapy continues to be studied.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "20881870f0d2416882fd571c09f5bccb", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[97, 99], [22, 24], [138, 140]], "char_spans": [[572, 578], [137, 143], [769, 775]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["initial", 10], ["approval", 18], ["of", 27], ["imatinib", 30], ["much", 39], ["has", 44], ["been", 48], ["learned", 53], ["about", 61], ["its", 67], ["resistance", 71], ["mechanisms", 82], [",", 92], ["and", 94], ["efforts", 98], ["have", 106], ["continued", 111], ["to", 121], ["improve", 124], ["upon", 132], ["BCR", 137], ["-", 140], ["ABL", 141], ["tyrosine", 145], ["kinase", 154], ["inhibitor", 161], ["therapy", 171], [".", 178], ["Targeted", 180], ["therapy", 189], ["with", 197], ["TKIs", 202], ["has", 207], ["continued", 211], ["to", 221], ["be", 224], ["an", 227], ["area", 230], ["of", 235], ["active", 238], ["research", 245], ["and", 254], ["development", 258], ["in", 270], ["the", 273], ["care", 277], ["of", 282], ["acute", 285], ["and", 291], ["chronic", 295], ["leukemia", 303], ["patients", 312], [".", 320], ["This", 322], ["article", 327], ["reviews", 335], ["current", 343], ["approved", 351], ["and", 360], ["investigational", 364], ["TKI", 380], ["treatments", 384], ["for", 395], ["chronic", 399], ["myelogenous", 407], ["leukemia", 419], ["(", 428], ["CML", 429], [")", 432], [",", 433], ["Philadelphia", 435], ["-", 447], ["chromosome", 448], ["positive", 459], ["acute", 468], ["lymphoblastic", 474], ["leukemia", 488], ["(", 497], ["Ph", 498], ["+", 501], ["ALL", 503], [")", 506], ["and", 508], ["acute", 512], ["myelogenous", 518], ["leukemia", 530], ["(", 539], ["AML", 540], [")", 543], [".", 544], ["There", 546], ["are", 552], ["now", 556], ["more", 560], ["potent", 565], ["BCR", 572], ["-", 575], ["ABL", 576], ["TKIs", 580], ["approved", 585], [",", 593], ["which", 595], ["allow", 601], ["for", 607], ["additional", 611], ["options", 622], ["when", 630], ["determining", 635], ["front", 647], ["-", 652], ["line", 653], ["and", 658], ["second", 662], ["-", 668], ["line", 669], ["CML", 674], ["and", 678], ["Ph", 682], ["+", 685], ["ALL", 687], ["treatments", 691], [".", 701], ["The", 703], ["T315I", 707], ["mutation", 713], ["is", 722], ["an", 725], ["ever", 728], ["-", 732], ["present", 733], ["challenge", 741], [".", 750], ["Ponatinib", 752], [",", 761], ["a", 763], ["pan", 765], ["BCR", 769], ["-", 772], ["ABL", 773], ["TKI", 777], [",", 780], ["while", 782], ["still", 788], ["under", 794], ["investigation", 800], [",", 813], ["is", 815], ["very", 818], ["hopeful", 823], ["with", 831], ["its", 836], ["ability", 840], ["to", 848], ["overcome", 851], ["T315I", 860], ["mutations", 866], ["in", 876], ["resistant", 879], ["CML", 889], ["and", 893], ["Ph", 897], ["+", 900], ["ALL", 902], ["patients", 906], [".", 914], ["Because", 916], ["nilotinib", 924], ["and", 934], ["dasatinib", 938], ["have", 948], ["not", 953], ["been", 957], ["directly", 962], ["compared", 971], [",", 979], ["at", 981], ["present", 984], ["we", 992], ["recommend", 995], ["selecting", 1005], ["one", 1015], ["or", 1019], ["the", 1022], ["other", 1026], ["based", 1032], ["on", 1038], ["the", 1041], ["side", 1045], ["-", 1049], ["effect", 1050], ["profile", 1057], [",", 1064], ["drug", 1066], ["interactions", 1071], [",", 1083], ["patient", 1085], ["comorbidities", 1093], [",", 1106], ["and", 1108], ["mutational", 1112], ["status", 1123], [".", 1129], ["FLT-3", 1131], ["inhibition", 1137], ["is", 1148], ["of", 1151], ["particular", 1154], ["interest", 1165], ["in", 1174], ["AML", 1177], ["patients", 1181], ["with", 1190], ["FLT-3", 1195], ["internal", 1201], ["tandem", 1210], ["duplication", 1217], ["mutations", 1229], [";", 1238], ["this", 1240], ["type", 1245], ["of", 1250], ["targeted", 1253], ["therapy", 1262], ["continues", 1270], ["to", 1280], ["be", 1283], ["studied", 1286], [".", 1293]]}
{"context": "We describe the clinical characteristics and epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in children with cystic fibrosis (CF) from the U.S. CF center with the highest MRSA prevalence. Medical records of children with CF were retrospectively reviewed from 1997-2009. MRSA clinical isolates from 2007-2009 were analyzed by polymerase chain reaction and pulsed field gel electrophoresis. The prevalence of MRSA was 1% in 1997 and 49% in 2009. Fifty-five children (26%) had persistent MRSA infection. Sixty-eight percent of MRSA isolates were hospital-associated (HA) MRSA, of which 52% were pulsed-field type USA 100. Ninety-three percent of HA MRSA isolates were clindamycin resistant. Twelve children acquired MRSA before 1 year of age, 83% of whom were hospitalized prior to acquisition of MRSA. Ten of 11 sibling pairs carried indistinguishable MRSA strains. Children with persistent MRSA were hospitalized more often (P\u2009=\u2009.01), required inhaled medications more frequently (P\u2009=\u2009.01), and had higher rates of Pseudomonas aeruginosa coinfection (P\u2009<\u2009.001). MRSA prevalence in children with CF is increasing, and most children are infected with HA MRSA. Exposure to health care facilities and gastrointestinal surgeries may facilitate early acquisition of MRSA. Siblings carry indistinguishable MRSA strains, indicating household transmission of MRSA. Children with persistent MRSA had worse pulmonary morbidity. Coinfection with MRSA and P aeruginosa is likely associated with further increased pulmonary morbidity.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "4e1c49bbf28c4f2e9198848bf13a61dc", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[32, 32], [139, 139], [171, 171], [243, 243], [250, 250], [71, 71], [263, 263], [14, 14], [130, 130], [255, 255], [207, 207], [49, 49], [110, 110], [93, 93], [101, 101], [165, 165], [156, 156], [238, 238], [223, 223]], "char_spans": [[191, 194], [733, 736], [909, 912], [1318, 1321], [1369, 1372], [427, 430], [1453, 1456], [106, 109], [666, 669], [1400, 1403], [1081, 1084], [290, 293], [588, 591], [505, 508], [544, 547], [870, 873], [814, 817], [1279, 1282], [1171, 1174]]}]}], "context_tokens": [["We", 0], ["describe", 3], ["the", 12], ["clinical", 16], ["characteristics", 25], ["and", 41], ["epidemiology", 45], ["of", 58], ["methicillin", 61], ["-", 72], ["resistant", 73], ["Staphylococcus", 83], ["aureus", 98], ["(", 105], ["MRSA", 106], [")", 110], ["in", 112], ["children", 115], ["with", 124], ["cystic", 129], ["fibrosis", 136], ["(", 145], ["CF", 146], [")", 148], ["from", 150], ["the", 155], ["U.S.", 159], ["CF", 164], ["center", 167], ["with", 174], ["the", 179], ["highest", 183], ["MRSA", 191], ["prevalence", 196], [".", 206], ["Medical", 208], ["records", 216], ["of", 224], ["children", 227], ["with", 236], ["CF", 241], ["were", 244], ["retrospectively", 249], ["reviewed", 265], ["from", 274], ["1997", 279], ["-", 283], ["2009", 284], [".", 288], ["MRSA", 290], ["clinical", 295], ["isolates", 304], ["from", 313], ["2007", 318], ["-", 322], ["2009", 323], ["were", 328], ["analyzed", 333], ["by", 342], ["polymerase", 345], ["chain", 356], ["reaction", 362], ["and", 371], ["pulsed", 375], ["field", 382], ["gel", 388], ["electrophoresis", 392], [".", 407], ["The", 409], ["prevalence", 413], ["of", 424], ["MRSA", 427], ["was", 432], ["1", 436], ["%", 437], ["in", 439], ["1997", 442], ["and", 447], ["49", 451], ["%", 453], ["in", 455], ["2009", 458], [".", 462], ["Fifty", 464], ["-", 469], ["five", 470], ["children", 475], ["(", 484], ["26", 485], ["%", 487], [")", 488], ["had", 490], ["persistent", 494], ["MRSA", 505], ["infection", 510], [".", 519], ["Sixty", 521], ["-", 526], ["eight", 527], ["percent", 533], ["of", 541], ["MRSA", 544], ["isolates", 549], ["were", 558], ["hospital", 563], ["-", 571], ["associated", 572], ["(", 583], ["HA", 584], [")", 586], ["MRSA", 588], [",", 592], ["of", 594], ["which", 597], ["52", 603], ["%", 605], ["were", 607], ["pulsed", 612], ["-", 618], ["field", 619], ["type", 625], ["USA", 630], ["100", 634], [".", 637], ["Ninety", 639], ["-", 645], ["three", 646], ["percent", 652], ["of", 660], ["HA", 663], ["MRSA", 666], ["isolates", 671], ["were", 680], ["clindamycin", 685], ["resistant", 697], [".", 706], ["Twelve", 708], ["children", 715], ["acquired", 724], ["MRSA", 733], ["before", 738], ["1", 745], ["year", 747], ["of", 752], ["age", 755], [",", 758], ["83", 760], ["%", 762], ["of", 764], ["whom", 767], ["were", 772], ["hospitalized", 777], ["prior", 790], ["to", 796], ["acquisition", 799], ["of", 811], ["MRSA", 814], [".", 818], ["Ten", 820], ["of", 824], ["11", 827], ["sibling", 830], ["pairs", 838], ["carried", 844], ["indistinguishable", 852], ["MRSA", 870], ["strains", 875], [".", 882], ["Children", 884], ["with", 893], ["persistent", 898], ["MRSA", 909], ["were", 914], ["hospitalized", 919], ["more", 932], ["often", 937], ["(", 943], ["P", 944], ["=", 946], [".01", 948], [")", 951], [",", 952], ["required", 954], ["inhaled", 963], ["medications", 971], ["more", 983], ["frequently", 988], ["(", 999], ["P", 1000], ["=", 1002], [".01", 1004], [")", 1007], [",", 1008], ["and", 1010], ["had", 1014], ["higher", 1018], ["rates", 1025], ["of", 1031], ["Pseudomonas", 1034], ["aeruginosa", 1046], ["coinfection", 1057], ["(", 1069], ["P", 1070], ["<", 1072], [".001", 1074], [")", 1078], [".", 1079], ["MRSA", 1081], ["prevalence", 1086], ["in", 1097], ["children", 1100], ["with", 1109], ["CF", 1114], ["is", 1117], ["increasing", 1120], [",", 1130], ["and", 1132], ["most", 1136], ["children", 1141], ["are", 1150], ["infected", 1154], ["with", 1163], ["HA", 1168], ["MRSA", 1171], [".", 1175], ["Exposure", 1177], ["to", 1186], ["health", 1189], ["care", 1196], ["facilities", 1201], ["and", 1212], ["gastrointestinal", 1216], ["surgeries", 1233], ["may", 1243], ["facilitate", 1247], ["early", 1258], ["acquisition", 1264], ["of", 1276], ["MRSA", 1279], [".", 1283], ["Siblings", 1285], ["carry", 1294], ["indistinguishable", 1300], ["MRSA", 1318], ["strains", 1323], [",", 1330], ["indicating", 1332], ["household", 1343], ["transmission", 1353], ["of", 1366], ["MRSA", 1369], [".", 1373], ["Children", 1375], ["with", 1384], ["persistent", 1389], ["MRSA", 1400], ["had", 1405], ["worse", 1409], ["pulmonary", 1415], ["morbidity", 1425], [".", 1434], ["Coinfection", 1436], ["with", 1448], ["MRSA", 1453], ["and", 1458], ["P", 1462], ["aeruginosa", 1464], ["is", 1475], ["likely", 1478], ["associated", 1485], ["with", 1496], ["further", 1501], ["increased", 1509], ["pulmonary", 1519], ["morbidity", 1529], [".", 1538]]}
{"context": "Neutrophil elastase gene (ELANE) mutations are responsible for the majority of cases of severe congenital neutropenia (CN) and cyclic neutropenia (CyN). We screened CN (n\u00a0=\u00a0395) or CyN (n\u00a0=\u00a092) patients for ELANE mutations and investigated the impact of mutations on mRNA expression, protein expression, and activity. We found 116 different mutations in 162 (41%) CN patients and 26 in 51 (55%) CyN patients, 69 of them were novel. CyN-associated mutations were predicted to be more benign than CN-associated mutations, but the mutation severity largely overlapped. The frequency of acquired CSF3R mutations, malignant transformation, and the need for hematopoietic stem cell transplantation was significantly higher in CN patients with ELANE mutation than in ELANE mutation negative patients. Cellular elastase activity was reduced in neutrophils from CN/CyN patients, irrespective of the mutation status. In CN, enzymatic activity was significantly lower in patients with ELANE mutations compared with those with wild-type ELANE. Despite differences in the spectrum of mutations in CN or CyN, type or localization of mutation only partially determine the clinical phenotype. Specific ELANE mutations have limited predictive value for leukemogenesis; the risk for leukemia was correlated with disease severity rather than with occurrence of an ELANE mutation.", "qas": [{"question": "Which gene is most commonly associated with severe congenital and cyclic neutropenia?", "answers": ["The neutrophil elastase gene (ELANE)"], "qid": "2cf03749226444fea30c672c678b3d63", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["most", 14], ["commonly", 19], ["associated", 28], ["with", 39], ["severe", 44], ["congenital", 51], ["and", 62], ["cyclic", 66], ["neutropenia", 73], ["?", 84]], "detected_answers": [{"text": "The neutrophil elastase gene (ELANE)", "token_spans": [[0, 4]], "char_spans": [[0, 30]]}]}], "context_tokens": [["Neutrophil", 0], ["elastase", 11], ["gene", 20], ["(", 25], ["ELANE", 26], [")", 31], ["mutations", 33], ["are", 43], ["responsible", 47], ["for", 59], ["the", 63], ["majority", 67], ["of", 76], ["cases", 79], ["of", 85], ["severe", 88], ["congenital", 95], ["neutropenia", 106], ["(", 118], ["CN", 119], [")", 121], ["and", 123], ["cyclic", 127], ["neutropenia", 134], ["(", 146], ["CyN", 147], [")", 150], [".", 151], ["We", 153], ["screened", 156], ["CN", 165], ["(", 168], ["n", 169], ["=", 171], ["395", 173], [")", 176], ["or", 178], ["CyN", 181], ["(", 185], ["n", 186], ["=", 188], ["92", 190], [")", 192], ["patients", 194], ["for", 203], ["ELANE", 207], ["mutations", 213], ["and", 223], ["investigated", 227], ["the", 240], ["impact", 244], ["of", 251], ["mutations", 254], ["on", 264], ["mRNA", 267], ["expression", 272], [",", 282], ["protein", 284], ["expression", 292], [",", 302], ["and", 304], ["activity", 308], [".", 316], ["We", 318], ["found", 321], ["116", 327], ["different", 331], ["mutations", 341], ["in", 351], ["162", 354], ["(", 358], ["41", 359], ["%", 361], [")", 362], ["CN", 364], ["patients", 367], ["and", 376], ["26", 380], ["in", 383], ["51", 386], ["(", 389], ["55", 390], ["%", 392], [")", 393], ["CyN", 395], ["patients", 399], [",", 407], ["69", 409], ["of", 412], ["them", 415], ["were", 420], ["novel", 425], [".", 430], ["CyN", 432], ["-", 435], ["associated", 436], ["mutations", 447], ["were", 457], ["predicted", 462], ["to", 472], ["be", 475], ["more", 478], ["benign", 483], ["than", 490], ["CN", 495], ["-", 497], ["associated", 498], ["mutations", 509], [",", 518], ["but", 520], ["the", 524], ["mutation", 528], ["severity", 537], ["largely", 546], ["overlapped", 554], [".", 564], ["The", 566], ["frequency", 570], ["of", 580], ["acquired", 583], ["CSF3R", 592], ["mutations", 598], [",", 607], ["malignant", 609], ["transformation", 619], [",", 633], ["and", 635], ["the", 639], ["need", 643], ["for", 648], ["hematopoietic", 652], ["stem", 666], ["cell", 671], ["transplantation", 676], ["was", 692], ["significantly", 696], ["higher", 710], ["in", 717], ["CN", 720], ["patients", 723], ["with", 732], ["ELANE", 737], ["mutation", 743], ["than", 752], ["in", 757], ["ELANE", 760], ["mutation", 766], ["negative", 775], ["patients", 784], [".", 792], ["Cellular", 794], ["elastase", 803], ["activity", 812], ["was", 821], ["reduced", 825], ["in", 833], ["neutrophils", 836], ["from", 848], ["CN", 853], ["/", 855], ["CyN", 856], ["patients", 860], [",", 868], ["irrespective", 870], ["of", 883], ["the", 886], ["mutation", 890], ["status", 899], [".", 905], ["In", 907], ["CN", 910], [",", 912], ["enzymatic", 914], ["activity", 924], ["was", 933], ["significantly", 937], ["lower", 951], ["in", 957], ["patients", 960], ["with", 969], ["ELANE", 974], ["mutations", 980], ["compared", 990], ["with", 999], ["those", 1004], ["with", 1010], ["wild", 1015], ["-", 1019], ["type", 1020], ["ELANE", 1025], [".", 1030], ["Despite", 1032], ["differences", 1040], ["in", 1052], ["the", 1055], ["spectrum", 1059], ["of", 1068], ["mutations", 1071], ["in", 1081], ["CN", 1084], ["or", 1087], ["CyN", 1090], [",", 1093], ["type", 1095], ["or", 1100], ["localization", 1103], ["of", 1116], ["mutation", 1119], ["only", 1128], ["partially", 1133], ["determine", 1143], ["the", 1153], ["clinical", 1157], ["phenotype", 1166], [".", 1175], ["Specific", 1177], ["ELANE", 1186], ["mutations", 1192], ["have", 1202], ["limited", 1207], ["predictive", 1215], ["value", 1226], ["for", 1232], ["leukemogenesis", 1236], [";", 1250], ["the", 1252], ["risk", 1256], ["for", 1261], ["leukemia", 1265], ["was", 1274], ["correlated", 1278], ["with", 1289], ["disease", 1294], ["severity", 1302], ["rather", 1311], ["than", 1318], ["with", 1323], ["occurrence", 1328], ["of", 1339], ["an", 1342], ["ELANE", 1345], ["mutation", 1351], [".", 1359]]}
{"context": "The eukaryotic cell encounters more than one million various kinds of DNA lesions per day. The nucleotide excision repair (NER) pathway is one of the most important repair mechanisms that removes a wide spectrum of different DNA lesions. NER operates through two sub pathways: global genome repair (GGR) and transcription-coupled repair (TCR). GGR repairs the DNA damage throughout the entire genome and is initiated by the HR23B/XPC complex, while the CSB protein-governed TCR process removes DNA lesions from the actively transcribed strand. The sequence of events and the role of particular NER proteins are currently being extensively discussed. NER proteins also participate in other cellular processes like replication, transcription, chromatin maintenance and protein turnover. Defects in NER underlay severe genetic disorders: xeroderma pigmentosum (XP), Cockayne syndrome (CS) and trichothiodystrophy (TTD).", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "ffeaee2811f94587ba59b0c3f1305a3a", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[97, 98]], "char_spans": [[524, 541]]}]}], "context_tokens": [["The", 0], ["eukaryotic", 4], ["cell", 15], ["encounters", 20], ["more", 31], ["than", 36], ["one", 41], ["million", 45], ["various", 53], ["kinds", 61], ["of", 67], ["DNA", 70], ["lesions", 74], ["per", 82], ["day", 86], [".", 89], ["The", 91], ["nucleotide", 95], ["excision", 106], ["repair", 115], ["(", 122], ["NER", 123], [")", 126], ["pathway", 128], ["is", 136], ["one", 139], ["of", 143], ["the", 146], ["most", 150], ["important", 155], ["repair", 165], ["mechanisms", 172], ["that", 183], ["removes", 188], ["a", 196], ["wide", 198], ["spectrum", 203], ["of", 212], ["different", 215], ["DNA", 225], ["lesions", 229], [".", 236], ["NER", 238], ["operates", 242], ["through", 251], ["two", 259], ["sub", 263], ["pathways", 267], [":", 275], ["global", 277], ["genome", 284], ["repair", 291], ["(", 298], ["GGR", 299], [")", 302], ["and", 304], ["transcription", 308], ["-", 321], ["coupled", 322], ["repair", 330], ["(", 337], ["TCR", 338], [")", 341], [".", 342], ["GGR", 344], ["repairs", 348], ["the", 356], ["DNA", 360], ["damage", 364], ["throughout", 371], ["the", 382], ["entire", 386], ["genome", 393], ["and", 400], ["is", 404], ["initiated", 407], ["by", 417], ["the", 420], ["HR23B", 424], ["/", 429], ["XPC", 430], ["complex", 434], [",", 441], ["while", 443], ["the", 449], ["CSB", 453], ["protein", 457], ["-", 464], ["governed", 465], ["TCR", 474], ["process", 478], ["removes", 486], ["DNA", 494], ["lesions", 498], ["from", 506], ["the", 511], ["actively", 515], ["transcribed", 524], ["strand", 536], [".", 542], ["The", 544], ["sequence", 548], ["of", 557], ["events", 560], ["and", 567], ["the", 571], ["role", 575], ["of", 580], ["particular", 583], ["NER", 594], ["proteins", 598], ["are", 607], ["currently", 611], ["being", 621], ["extensively", 627], ["discussed", 639], [".", 648], ["NER", 650], ["proteins", 654], ["also", 663], ["participate", 668], ["in", 680], ["other", 683], ["cellular", 689], ["processes", 698], ["like", 708], ["replication", 713], [",", 724], ["transcription", 726], [",", 739], ["chromatin", 741], ["maintenance", 751], ["and", 763], ["protein", 767], ["turnover", 775], [".", 783], ["Defects", 785], ["in", 793], ["NER", 796], ["underlay", 800], ["severe", 809], ["genetic", 816], ["disorders", 824], [":", 833], ["xeroderma", 835], ["pigmentosum", 845], ["(", 857], ["XP", 858], [")", 860], [",", 861], ["Cockayne", 863], ["syndrome", 872], ["(", 881], ["CS", 882], [")", 884], ["and", 886], ["trichothiodystrophy", 890], ["(", 910], ["TTD", 911], [")", 914], [".", 915]]}
{"context": "The RNA editing enzyme ADAR chemically modifies adenosine (A) to inosine (I), which is interpreted by the ribosome as a guanosine. Here we assess cotranscriptional A-to-I editing in Drosophila by isolating nascent RNA from adult fly heads and subjecting samples to high throughput sequencing. There are a large number of edited sites within nascent exons. Nascent RNA from an ADAR-null strain was also sequenced, indicating that almost all A-to-I events require ADAR. Moreover, mRNA editing levels correlate with editing levels within the cognate nascent RNA sequence, indicating that the extent of editing is set cotranscriptionally. Surprisingly, the nascent data also identify an excess of intronic over exonic editing sites. These intronic sites occur preferentially within introns that are poorly spliced cotranscriptionally, suggesting a link between editing and splicing. We conclude that ADAR-mediated editing is more widespread than previously indicated and largely occurs cotranscriptionally.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "3b3c2659bbbc4cff90c610175d5dae05", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[158, 158], [4, 4], [71, 71], [90, 90]], "char_spans": [[896, 899], [23, 26], [376, 379], [462, 465]]}]}], "context_tokens": [["The", 0], ["RNA", 4], ["editing", 8], ["enzyme", 16], ["ADAR", 23], ["chemically", 28], ["modifies", 39], ["adenosine", 48], ["(", 58], ["A", 59], [")", 60], ["to", 62], ["inosine", 65], ["(", 73], ["I", 74], [")", 75], [",", 76], ["which", 78], ["is", 84], ["interpreted", 87], ["by", 99], ["the", 102], ["ribosome", 106], ["as", 115], ["a", 118], ["guanosine", 120], [".", 129], ["Here", 131], ["we", 136], ["assess", 139], ["cotranscriptional", 146], ["A", 164], ["-", 165], ["to", 166], ["-", 168], ["I", 169], ["editing", 171], ["in", 179], ["Drosophila", 182], ["by", 193], ["isolating", 196], ["nascent", 206], ["RNA", 214], ["from", 218], ["adult", 223], ["fly", 229], ["heads", 233], ["and", 239], ["subjecting", 243], ["samples", 254], ["to", 262], ["high", 265], ["throughput", 270], ["sequencing", 281], [".", 291], ["There", 293], ["are", 299], ["a", 303], ["large", 305], ["number", 311], ["of", 318], ["edited", 321], ["sites", 328], ["within", 334], ["nascent", 341], ["exons", 349], [".", 354], ["Nascent", 356], ["RNA", 364], ["from", 368], ["an", 373], ["ADAR", 376], ["-", 380], ["null", 381], ["strain", 386], ["was", 393], ["also", 397], ["sequenced", 402], [",", 411], ["indicating", 413], ["that", 424], ["almost", 429], ["all", 436], ["A", 440], ["-", 441], ["to", 442], ["-", 444], ["I", 445], ["events", 447], ["require", 454], ["ADAR", 462], [".", 466], ["Moreover", 468], [",", 476], ["mRNA", 478], ["editing", 483], ["levels", 491], ["correlate", 498], ["with", 508], ["editing", 513], ["levels", 521], ["within", 528], ["the", 535], ["cognate", 539], ["nascent", 547], ["RNA", 555], ["sequence", 559], [",", 567], ["indicating", 569], ["that", 580], ["the", 585], ["extent", 589], ["of", 596], ["editing", 599], ["is", 607], ["set", 610], ["cotranscriptionally", 614], [".", 633], ["Surprisingly", 635], [",", 647], ["the", 649], ["nascent", 653], ["data", 661], ["also", 666], ["identify", 671], ["an", 680], ["excess", 683], ["of", 690], ["intronic", 693], ["over", 702], ["exonic", 707], ["editing", 714], ["sites", 722], [".", 727], ["These", 729], ["intronic", 735], ["sites", 744], ["occur", 750], ["preferentially", 756], ["within", 771], ["introns", 778], ["that", 786], ["are", 791], ["poorly", 795], ["spliced", 802], ["cotranscriptionally", 810], [",", 829], ["suggesting", 831], ["a", 842], ["link", 844], ["between", 849], ["editing", 857], ["and", 865], ["splicing", 869], [".", 877], ["We", 879], ["conclude", 882], ["that", 891], ["ADAR", 896], ["-", 900], ["mediated", 901], ["editing", 910], ["is", 918], ["more", 921], ["widespread", 926], ["than", 937], ["previously", 942], ["indicated", 953], ["and", 963], ["largely", 967], ["occurs", 975], ["cotranscriptionally", 982], [".", 1001]]}
{"context": "Cancer cells frequently induce aberrant centrosomes, which have been implicated in cancer initiation and progression. Human colorectal cancer cells, HCT116, contain aberrant centrioles composed of disorganized cylindrical microtubules and displaced appendages. These cells also express unique centrosome-related structures associated with a subset of centrosomal components, including gamma-tubulin, centrin and PCM1. During hydroxyurea treatment, these abnormal structures become more abundant and undergo a change in shape from small dots to elongated fibers. Although gamma-tubulin seems to exist as a ring complex, the abnormal structures do not support microtubule nucleation. Several lines of evidence suggest that the fibers correspond to a disorganized form of centriolar microtubules. Plk4, a mammalian homolog of ZYG-1 essential for initiation of centriole biogenesis, is not associated with the gamma-tubulin-specific abnormal centrosomes. The amount of Plk4 at each centrosome was less in cells with abnormal centrosomes than cells without gamma-tubulin-specific abnormal centrosomes. In addition, the formation of abnormal structures was abolished by expression of exogenous Plk4, but not SAS6 and Cep135/Bld10p, which are downstream regulators required for the organization of nine-triplet microtubules. These results suggest that HCT116 cells fail to organize the ninefold symmetry of centrioles due to insufficient Plk4.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "edef18590b2a40aea0dfe32bad4780ea", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[156, 156], [41, 41]], "char_spans": [[978, 987], [293, 302]]}]}], "context_tokens": [["Cancer", 0], ["cells", 7], ["frequently", 13], ["induce", 24], ["aberrant", 31], ["centrosomes", 40], [",", 51], ["which", 53], ["have", 59], ["been", 64], ["implicated", 69], ["in", 80], ["cancer", 83], ["initiation", 90], ["and", 101], ["progression", 105], [".", 116], ["Human", 118], ["colorectal", 124], ["cancer", 135], ["cells", 142], [",", 147], ["HCT116", 149], [",", 155], ["contain", 157], ["aberrant", 165], ["centrioles", 174], ["composed", 185], ["of", 194], ["disorganized", 197], ["cylindrical", 210], ["microtubules", 222], ["and", 235], ["displaced", 239], ["appendages", 249], [".", 259], ["These", 261], ["cells", 267], ["also", 273], ["express", 278], ["unique", 286], ["centrosome", 293], ["-", 303], ["related", 304], ["structures", 312], ["associated", 323], ["with", 334], ["a", 339], ["subset", 341], ["of", 348], ["centrosomal", 351], ["components", 363], [",", 373], ["including", 375], ["gamma", 385], ["-", 390], ["tubulin", 391], [",", 398], ["centrin", 400], ["and", 408], ["PCM1", 412], [".", 416], ["During", 418], ["hydroxyurea", 425], ["treatment", 437], [",", 446], ["these", 448], ["abnormal", 454], ["structures", 463], ["become", 474], ["more", 481], ["abundant", 486], ["and", 495], ["undergo", 499], ["a", 507], ["change", 509], ["in", 516], ["shape", 519], ["from", 525], ["small", 530], ["dots", 536], ["to", 541], ["elongated", 544], ["fibers", 554], [".", 560], ["Although", 562], ["gamma", 571], ["-", 576], ["tubulin", 577], ["seems", 585], ["to", 591], ["exist", 594], ["as", 600], ["a", 603], ["ring", 605], ["complex", 610], [",", 617], ["the", 619], ["abnormal", 623], ["structures", 632], ["do", 643], ["not", 646], ["support", 650], ["microtubule", 658], ["nucleation", 670], [".", 680], ["Several", 682], ["lines", 690], ["of", 696], ["evidence", 699], ["suggest", 708], ["that", 716], ["the", 721], ["fibers", 725], ["correspond", 732], ["to", 743], ["a", 746], ["disorganized", 748], ["form", 761], ["of", 766], ["centriolar", 769], ["microtubules", 780], [".", 792], ["Plk4", 794], [",", 798], ["a", 800], ["mammalian", 802], ["homolog", 812], ["of", 820], ["ZYG-1", 823], ["essential", 829], ["for", 839], ["initiation", 843], ["of", 854], ["centriole", 857], ["biogenesis", 867], [",", 877], ["is", 879], ["not", 882], ["associated", 886], ["with", 897], ["the", 902], ["gamma", 906], ["-", 911], ["tubulin", 912], ["-", 919], ["specific", 920], ["abnormal", 929], ["centrosomes", 938], [".", 949], ["The", 951], ["amount", 955], ["of", 962], ["Plk4", 965], ["at", 970], ["each", 973], ["centrosome", 978], ["was", 989], ["less", 993], ["in", 998], ["cells", 1001], ["with", 1007], ["abnormal", 1012], ["centrosomes", 1021], ["than", 1033], ["cells", 1038], ["without", 1044], ["gamma", 1052], ["-", 1057], ["tubulin", 1058], ["-", 1065], ["specific", 1066], ["abnormal", 1075], ["centrosomes", 1084], [".", 1095], ["In", 1097], ["addition", 1100], [",", 1108], ["the", 1110], ["formation", 1114], ["of", 1124], ["abnormal", 1127], ["structures", 1136], ["was", 1147], ["abolished", 1151], ["by", 1161], ["expression", 1164], ["of", 1175], ["exogenous", 1178], ["Plk4", 1188], [",", 1192], ["but", 1194], ["not", 1198], ["SAS6", 1202], ["and", 1207], ["Cep135/Bld10p", 1211], [",", 1224], ["which", 1226], ["are", 1232], ["downstream", 1236], ["regulators", 1247], ["required", 1258], ["for", 1267], ["the", 1271], ["organization", 1275], ["of", 1288], ["nine", 1291], ["-", 1295], ["triplet", 1296], ["microtubules", 1304], [".", 1316], ["These", 1318], ["results", 1324], ["suggest", 1332], ["that", 1340], ["HCT116", 1345], ["cells", 1352], ["fail", 1358], ["to", 1363], ["organize", 1366], ["the", 1375], ["ninefold", 1379], ["symmetry", 1388], ["of", 1397], ["centrioles", 1400], ["due", 1411], ["to", 1415], ["insufficient", 1418], ["Plk4", 1431], [".", 1435]]}
{"context": "Recent evidence suggests that abnormal activation of cyclin-dependent kinase 5 (cdk5) is a critical prodeath signal in stroke. However, the mechanism(s) by which cdk5 promotes death is unclear. Complicating the role of cdk5 are the observations that cdk5 can exist in multiple cellular regions and possess both prosurvival and prodeath characteristics. In particular, the critical role of cytoplasmic or nuclear cdk5 in neuronal jury, in vivo, is unclear. Therefore, we determined where cdk5 was activated in models of ischemia and how manipulation of cdk5 in differing compartments may affect neuronal death. Here, we show a critical function for cytoplasmic cdk5 in both focal and global models of stroke, in vivo. Cdk5 is activated in the cytoplasm and expression of DNcdk5 localized to the cytoplasm is protective. Importantly, we also demonstrate the antioxidant enzyme Prx2 (peroxiredoxin 2) as a critical cytoplasmic target of cdk5. In contrast, the role of cdk5 in the nucleus is context-dependent. Following focal ischemia, nuclear cdk5 is activated and functionally relevant while there is no evidence for such activation following global ischemia. Importantly, myocyte enhancer factor 2D (MEF2D), a previously described nuclear target of cdk5 in vitro, is also phosphorylated by cdk5 following focal ischemia. In addition, MEF2D expression in this paradigm ameliorates death. Together, our results address the critical issue of cdk5 activity compartmentalization, as well as define critical substrates for both cytoplasmic and nuclear cdk5 activity in adult models of stroke.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "1907600356cb4afeb53267a9f83291d7", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[151, 151]], "char_spans": [[856, 866]]}]}], "context_tokens": [["Recent", 0], ["evidence", 7], ["suggests", 16], ["that", 25], ["abnormal", 30], ["activation", 39], ["of", 50], ["cyclin", 53], ["-", 59], ["dependent", 60], ["kinase", 70], ["5", 77], ["(", 79], ["cdk5", 80], [")", 84], ["is", 86], ["a", 89], ["critical", 91], ["prodeath", 100], ["signal", 109], ["in", 116], ["stroke", 119], [".", 125], ["However", 127], [",", 134], ["the", 136], ["mechanism(s", 140], [")", 151], ["by", 153], ["which", 156], ["cdk5", 162], ["promotes", 167], ["death", 176], ["is", 182], ["unclear", 185], [".", 192], ["Complicating", 194], ["the", 207], ["role", 211], ["of", 216], ["cdk5", 219], ["are", 224], ["the", 228], ["observations", 232], ["that", 245], ["cdk5", 250], ["can", 255], ["exist", 259], ["in", 265], ["multiple", 268], ["cellular", 277], ["regions", 286], ["and", 294], ["possess", 298], ["both", 306], ["prosurvival", 311], ["and", 323], ["prodeath", 327], ["characteristics", 336], [".", 351], ["In", 353], ["particular", 356], [",", 366], ["the", 368], ["critical", 372], ["role", 381], ["of", 386], ["cytoplasmic", 389], ["or", 401], ["nuclear", 404], ["cdk5", 412], ["in", 417], ["neuronal", 420], ["jury", 429], [",", 433], ["in", 435], ["vivo", 438], [",", 442], ["is", 444], ["unclear", 447], [".", 454], ["Therefore", 456], [",", 465], ["we", 467], ["determined", 470], ["where", 481], ["cdk5", 487], ["was", 492], ["activated", 496], ["in", 506], ["models", 509], ["of", 516], ["ischemia", 519], ["and", 528], ["how", 532], ["manipulation", 536], ["of", 549], ["cdk5", 552], ["in", 557], ["differing", 560], ["compartments", 570], ["may", 583], ["affect", 587], ["neuronal", 594], ["death", 603], [".", 608], ["Here", 610], [",", 614], ["we", 616], ["show", 619], ["a", 624], ["critical", 626], ["function", 635], ["for", 644], ["cytoplasmic", 648], ["cdk5", 660], ["in", 665], ["both", 668], ["focal", 673], ["and", 679], ["global", 683], ["models", 690], ["of", 697], ["stroke", 700], [",", 706], ["in", 708], ["vivo", 711], [".", 715], ["Cdk5", 717], ["is", 722], ["activated", 725], ["in", 735], ["the", 738], ["cytoplasm", 742], ["and", 752], ["expression", 756], ["of", 767], ["DNcdk5", 770], ["localized", 777], ["to", 787], ["the", 790], ["cytoplasm", 794], ["is", 804], ["protective", 807], [".", 817], ["Importantly", 819], [",", 830], ["we", 832], ["also", 835], ["demonstrate", 840], ["the", 852], ["antioxidant", 856], ["enzyme", 868], ["Prx2", 875], ["(", 880], ["peroxiredoxin", 881], ["2", 895], [")", 896], ["as", 898], ["a", 901], ["critical", 903], ["cytoplasmic", 912], ["target", 924], ["of", 931], ["cdk5", 934], [".", 938], ["In", 940], ["contrast", 943], [",", 951], ["the", 953], ["role", 957], ["of", 962], ["cdk5", 965], ["in", 970], ["the", 973], ["nucleus", 977], ["is", 985], ["context", 988], ["-", 995], ["dependent", 996], [".", 1005], ["Following", 1007], ["focal", 1017], ["ischemia", 1023], [",", 1031], ["nuclear", 1033], ["cdk5", 1041], ["is", 1046], ["activated", 1049], ["and", 1059], ["functionally", 1063], ["relevant", 1076], ["while", 1085], ["there", 1091], ["is", 1097], ["no", 1100], ["evidence", 1103], ["for", 1112], ["such", 1116], ["activation", 1121], ["following", 1132], ["global", 1142], ["ischemia", 1149], [".", 1157], ["Importantly", 1159], [",", 1170], ["myocyte", 1172], ["enhancer", 1180], ["factor", 1189], ["2D", 1196], ["(", 1199], ["MEF2D", 1200], [")", 1205], [",", 1206], ["a", 1208], ["previously", 1210], ["described", 1221], ["nuclear", 1231], ["target", 1239], ["of", 1246], ["cdk5", 1249], ["in", 1254], ["vitro", 1257], [",", 1262], ["is", 1264], ["also", 1267], ["phosphorylated", 1272], ["by", 1287], ["cdk5", 1290], ["following", 1295], ["focal", 1305], ["ischemia", 1311], [".", 1319], ["In", 1321], ["addition", 1324], [",", 1332], ["MEF2D", 1334], ["expression", 1340], ["in", 1351], ["this", 1354], ["paradigm", 1359], ["ameliorates", 1368], ["death", 1380], [".", 1385], ["Together", 1387], [",", 1395], ["our", 1397], ["results", 1401], ["address", 1409], ["the", 1417], ["critical", 1421], ["issue", 1430], ["of", 1436], ["cdk5", 1439], ["activity", 1444], ["compartmentalization", 1453], [",", 1473], ["as", 1475], ["well", 1478], ["as", 1483], ["define", 1486], ["critical", 1493], ["substrates", 1502], ["for", 1513], ["both", 1517], ["cytoplasmic", 1522], ["and", 1534], ["nuclear", 1538], ["cdk5", 1546], ["activity", 1551], ["in", 1560], ["adult", 1563], ["models", 1569], ["of", 1576], ["stroke", 1579], [".", 1585]]}
{"context": "Flumazenil is a competitive benzodiazepine antagonist that acts to reverse their sedative and hypnotic effects. It is indicated in the management of benzodiazepine overdose, but its role in the routine reversal of endoscopic conscious sedation has not been defined. Patients undergoing diagnostic upper endoscopy who received sedation with either diazepam or midazolam alone were given flumazenil 0.2 mg incrementally immediately following the procedure until awake. They were then asked to repeat three psychomotor tests measuring cognitive and motor skills, with their baseline scores compared with postprocedure scores over a 3-hour period. Full psychomotor function was restored to baseline values within 30 minutes after flumazenil in 79% of patients, with no differences in the reversal of psychomotor skill impairment observed between diazepam and midazolam sedation. There was no evidence of rebound sedation seen for up to 3 hours. No significant anterograde amnesia was evident in 78% of individuals. These results demonstrate that flumazenil's effects on reversing psychomotor impairment are similar when midazolam or diazepam are used for conscious sedation. However, the potential usefulness of routine flumazenil reversal of conscious sedation will require further evaluation of specific psychomotor performance skills (such as driving a car) before we lift the admonition against leaving the endoscopic suite unattended, driving a vehicle, or operating complicated machinery for several hours.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "8c08be9367e44a248f7e98941e6d911d", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [163, 163], [189, 189], [109, 109], [58, 58]], "char_spans": [[0, 9], [1042, 1051], [1216, 1225], [726, 735], [386, 395]]}]}], "context_tokens": [["Flumazenil", 0], ["is", 11], ["a", 14], ["competitive", 16], ["benzodiazepine", 28], ["antagonist", 43], ["that", 54], ["acts", 59], ["to", 64], ["reverse", 67], ["their", 75], ["sedative", 81], ["and", 90], ["hypnotic", 94], ["effects", 103], [".", 110], ["It", 112], ["is", 115], ["indicated", 118], ["in", 128], ["the", 131], ["management", 135], ["of", 146], ["benzodiazepine", 149], ["overdose", 164], [",", 172], ["but", 174], ["its", 178], ["role", 182], ["in", 187], ["the", 190], ["routine", 194], ["reversal", 202], ["of", 211], ["endoscopic", 214], ["conscious", 225], ["sedation", 235], ["has", 244], ["not", 248], ["been", 252], ["defined", 257], [".", 264], ["Patients", 266], ["undergoing", 275], ["diagnostic", 286], ["upper", 297], ["endoscopy", 303], ["who", 313], ["received", 317], ["sedation", 326], ["with", 335], ["either", 340], ["diazepam", 347], ["or", 356], ["midazolam", 359], ["alone", 369], ["were", 375], ["given", 380], ["flumazenil", 386], ["0.2", 397], ["mg", 401], ["incrementally", 404], ["immediately", 418], ["following", 430], ["the", 440], ["procedure", 444], ["until", 454], ["awake", 460], [".", 465], ["They", 467], ["were", 472], ["then", 477], ["asked", 482], ["to", 488], ["repeat", 491], ["three", 498], ["psychomotor", 504], ["tests", 516], ["measuring", 522], ["cognitive", 532], ["and", 542], ["motor", 546], ["skills", 552], [",", 558], ["with", 560], ["their", 565], ["baseline", 571], ["scores", 580], ["compared", 587], ["with", 596], ["postprocedure", 601], ["scores", 615], ["over", 622], ["a", 627], ["3-hour", 629], ["period", 636], [".", 642], ["Full", 644], ["psychomotor", 649], ["function", 661], ["was", 670], ["restored", 674], ["to", 683], ["baseline", 686], ["values", 695], ["within", 702], ["30", 709], ["minutes", 712], ["after", 720], ["flumazenil", 726], ["in", 737], ["79", 740], ["%", 742], ["of", 744], ["patients", 747], [",", 755], ["with", 757], ["no", 762], ["differences", 765], ["in", 777], ["the", 780], ["reversal", 784], ["of", 793], ["psychomotor", 796], ["skill", 808], ["impairment", 814], ["observed", 825], ["between", 834], ["diazepam", 842], ["and", 851], ["midazolam", 855], ["sedation", 865], [".", 873], ["There", 875], ["was", 881], ["no", 885], ["evidence", 888], ["of", 897], ["rebound", 900], ["sedation", 908], ["seen", 917], ["for", 922], ["up", 926], ["to", 929], ["3", 932], ["hours", 934], [".", 939], ["No", 941], ["significant", 944], ["anterograde", 956], ["amnesia", 968], ["was", 976], ["evident", 980], ["in", 988], ["78", 991], ["%", 993], ["of", 995], ["individuals", 998], [".", 1009], ["These", 1011], ["results", 1017], ["demonstrate", 1025], ["that", 1037], ["flumazenil", 1042], ["'s", 1052], ["effects", 1055], ["on", 1063], ["reversing", 1066], ["psychomotor", 1076], ["impairment", 1088], ["are", 1099], ["similar", 1103], ["when", 1111], ["midazolam", 1116], ["or", 1126], ["diazepam", 1129], ["are", 1138], ["used", 1142], ["for", 1147], ["conscious", 1151], ["sedation", 1161], [".", 1169], ["However", 1171], [",", 1178], ["the", 1180], ["potential", 1184], ["usefulness", 1194], ["of", 1205], ["routine", 1208], ["flumazenil", 1216], ["reversal", 1227], ["of", 1236], ["conscious", 1239], ["sedation", 1249], ["will", 1258], ["require", 1263], ["further", 1271], ["evaluation", 1279], ["of", 1290], ["specific", 1293], ["psychomotor", 1302], ["performance", 1314], ["skills", 1326], ["(", 1333], ["such", 1334], ["as", 1339], ["driving", 1342], ["a", 1350], ["car", 1352], [")", 1355], ["before", 1357], ["we", 1364], ["lift", 1367], ["the", 1372], ["admonition", 1376], ["against", 1387], ["leaving", 1395], ["the", 1403], ["endoscopic", 1407], ["suite", 1418], ["unattended", 1424], [",", 1434], ["driving", 1436], ["a", 1444], ["vehicle", 1446], [",", 1453], ["or", 1455], ["operating", 1458], ["complicated", 1468], ["machinery", 1480], ["for", 1490], ["several", 1494], ["hours", 1502], [".", 1507]]}
{"context": "Stress-induced mutagenesis describes the accumulation of mutations that occur in nongrowing cells, in contrast to mutagenesis that occurs in actively dividing populations, and has been referred to as stationary-phase or adaptive mutagenesis. The most widely studied system for stress-induced mutagenesis involves monitoring the appearance of Lac(+) revertants of the strain FC40 under starvation conditions in Escherichia coli. The SOS-inducible translesion DNA polymerase DinB plays an important role in this phenomenon. Loss of DinB (DNA pol IV) function results in a severe reduction of Lac(+) revertants. We previously reported that NusA, an essential component of elongating RNA polymerases, interacts with DinB. Here we report our unexpected observation that wild-type NusA function is required for stress-induced mutagenesis. We present evidence that this effect is unlikely to be due to defects in transcription of lac genes but rather is due to an inability to adapt and mutate in response to environmental stress. Furthermore, we extended our analysis to the formation of stress-induced mutants in response to antibiotic treatment, observing the same striking abolition of mutagenesis under entirely different conditions. Our results are the first to implicate NusA as a crucial participant in the phenomenon of stress-induced mutagenesis.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase", "stationary-phase"], "qid": "1daf44d1e59d499da16d3746bd6277c2", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[32, 34]], "char_spans": [[200, 215]]}]}], "context_tokens": [["Stress", 0], ["-", 6], ["induced", 7], ["mutagenesis", 15], ["describes", 27], ["the", 37], ["accumulation", 41], ["of", 54], ["mutations", 57], ["that", 67], ["occur", 72], ["in", 78], ["nongrowing", 81], ["cells", 92], [",", 97], ["in", 99], ["contrast", 102], ["to", 111], ["mutagenesis", 114], ["that", 126], ["occurs", 131], ["in", 138], ["actively", 141], ["dividing", 150], ["populations", 159], [",", 170], ["and", 172], ["has", 176], ["been", 180], ["referred", 185], ["to", 194], ["as", 197], ["stationary", 200], ["-", 210], ["phase", 211], ["or", 217], ["adaptive", 220], ["mutagenesis", 229], [".", 240], ["The", 242], ["most", 246], ["widely", 251], ["studied", 258], ["system", 266], ["for", 273], ["stress", 277], ["-", 283], ["induced", 284], ["mutagenesis", 292], ["involves", 304], ["monitoring", 313], ["the", 324], ["appearance", 328], ["of", 339], ["Lac(+", 342], [")", 347], ["revertants", 349], ["of", 360], ["the", 363], ["strain", 367], ["FC40", 374], ["under", 379], ["starvation", 385], ["conditions", 396], ["in", 407], ["Escherichia", 410], ["coli", 422], [".", 426], ["The", 428], ["SOS", 432], ["-", 435], ["inducible", 436], ["translesion", 446], ["DNA", 458], ["polymerase", 462], ["DinB", 473], ["plays", 478], ["an", 484], ["important", 487], ["role", 497], ["in", 502], ["this", 505], ["phenomenon", 510], [".", 520], ["Loss", 522], ["of", 527], ["DinB", 530], ["(", 535], ["DNA", 536], ["pol", 540], ["IV", 544], [")", 546], ["function", 548], ["results", 557], ["in", 565], ["a", 568], ["severe", 570], ["reduction", 577], ["of", 587], ["Lac(+", 590], [")", 595], ["revertants", 597], [".", 607], ["We", 609], ["previously", 612], ["reported", 623], ["that", 632], ["NusA", 637], [",", 641], ["an", 643], ["essential", 646], ["component", 656], ["of", 666], ["elongating", 669], ["RNA", 680], ["polymerases", 684], [",", 695], ["interacts", 697], ["with", 707], ["DinB.", 712], ["Here", 718], ["we", 723], ["report", 726], ["our", 733], ["unexpected", 737], ["observation", 748], ["that", 760], ["wild", 765], ["-", 769], ["type", 770], ["NusA", 775], ["function", 780], ["is", 789], ["required", 792], ["for", 801], ["stress", 805], ["-", 811], ["induced", 812], ["mutagenesis", 820], [".", 831], ["We", 833], ["present", 836], ["evidence", 844], ["that", 853], ["this", 858], ["effect", 863], ["is", 870], ["unlikely", 873], ["to", 882], ["be", 885], ["due", 888], ["to", 892], ["defects", 895], ["in", 903], ["transcription", 906], ["of", 920], ["lac", 923], ["genes", 927], ["but", 933], ["rather", 937], ["is", 944], ["due", 947], ["to", 951], ["an", 954], ["inability", 957], ["to", 967], ["adapt", 970], ["and", 976], ["mutate", 980], ["in", 987], ["response", 990], ["to", 999], ["environmental", 1002], ["stress", 1016], [".", 1022], ["Furthermore", 1024], [",", 1035], ["we", 1037], ["extended", 1040], ["our", 1049], ["analysis", 1053], ["to", 1062], ["the", 1065], ["formation", 1069], ["of", 1079], ["stress", 1082], ["-", 1088], ["induced", 1089], ["mutants", 1097], ["in", 1105], ["response", 1108], ["to", 1117], ["antibiotic", 1120], ["treatment", 1131], [",", 1140], ["observing", 1142], ["the", 1152], ["same", 1156], ["striking", 1161], ["abolition", 1170], ["of", 1180], ["mutagenesis", 1183], ["under", 1195], ["entirely", 1201], ["different", 1210], ["conditions", 1220], [".", 1230], ["Our", 1232], ["results", 1236], ["are", 1244], ["the", 1248], ["first", 1252], ["to", 1258], ["implicate", 1261], ["NusA", 1271], ["as", 1276], ["a", 1279], ["crucial", 1281], ["participant", 1289], ["in", 1301], ["the", 1304], ["phenomenon", 1308], ["of", 1319], ["stress", 1322], ["-", 1328], ["induced", 1329], ["mutagenesis", 1337], [".", 1348]]}
{"context": "Heroin overdose is a major cause of death among heroin users, and often occurs in the company of other users. However, sudden death after injection is rare, giving ample opportunity for intervention. Naloxone hydrochloride, an injectable opioid antagonist which reverses the respiratory depression, sedation and hypotension associated with opioids, has long been used to treat opioid overdose. Experts have suggested that, as part of a comprehensive overdose prevention strategy, naloxone should be provided to heroin users for peer administration after an overdose. A trial could be conducted to determine whether this intervention improves the management of overdose or results in a net increase in harm (by undermining existing prevention strategies, precipitating naloxone-related complications, or resulting in riskier heroin use).", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "6e72346d9baf4bee8b690349f4e87241", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[80, 80], [37, 37], [125, 125]], "char_spans": [[480, 487], [200, 207], [768, 775]]}]}], "context_tokens": [["Heroin", 0], ["overdose", 7], ["is", 16], ["a", 19], ["major", 21], ["cause", 27], ["of", 33], ["death", 36], ["among", 42], ["heroin", 48], ["users", 55], [",", 60], ["and", 62], ["often", 66], ["occurs", 72], ["in", 79], ["the", 82], ["company", 86], ["of", 94], ["other", 97], ["users", 103], [".", 108], ["However", 110], [",", 117], ["sudden", 119], ["death", 126], ["after", 132], ["injection", 138], ["is", 148], ["rare", 151], [",", 155], ["giving", 157], ["ample", 164], ["opportunity", 170], ["for", 182], ["intervention", 186], [".", 198], ["Naloxone", 200], ["hydrochloride", 209], [",", 222], ["an", 224], ["injectable", 227], ["opioid", 238], ["antagonist", 245], ["which", 256], ["reverses", 262], ["the", 271], ["respiratory", 275], ["depression", 287], [",", 297], ["sedation", 299], ["and", 308], ["hypotension", 312], ["associated", 324], ["with", 335], ["opioids", 340], [",", 347], ["has", 349], ["long", 353], ["been", 358], ["used", 363], ["to", 368], ["treat", 371], ["opioid", 377], ["overdose", 384], [".", 392], ["Experts", 394], ["have", 402], ["suggested", 407], ["that", 417], [",", 421], ["as", 423], ["part", 426], ["of", 431], ["a", 434], ["comprehensive", 436], ["overdose", 450], ["prevention", 459], ["strategy", 470], [",", 478], ["naloxone", 480], ["should", 489], ["be", 496], ["provided", 499], ["to", 508], ["heroin", 511], ["users", 518], ["for", 524], ["peer", 528], ["administration", 533], ["after", 548], ["an", 554], ["overdose", 557], [".", 565], ["A", 567], ["trial", 569], ["could", 575], ["be", 581], ["conducted", 584], ["to", 594], ["determine", 597], ["whether", 607], ["this", 615], ["intervention", 620], ["improves", 633], ["the", 642], ["management", 646], ["of", 657], ["overdose", 660], ["or", 669], ["results", 672], ["in", 680], ["a", 683], ["net", 685], ["increase", 689], ["in", 698], ["harm", 701], ["(", 706], ["by", 707], ["undermining", 710], ["existing", 722], ["prevention", 731], ["strategies", 742], [",", 752], ["precipitating", 754], ["naloxone", 768], ["-", 776], ["related", 777], ["complications", 785], [",", 798], ["or", 800], ["resulting", 803], ["in", 813], ["riskier", 816], ["heroin", 824], ["use", 831], [")", 834], [".", 835]]}
{"context": "Idarucizumab is a monoclonal antibody fragment that binds dabigatran with high affinity in a 1:1 molar ratio. We investigated the safety, tolerability, and efficacy of increasing doses of idarucizumab for the reversal of anticoagulant effects of dabigatran in a two-part phase 1 study (rising-dose assessment and dose-finding, proof-of-concept investigation). Here we present the results of the proof-of-concept part of the study. In this randomised, placebo-controlled, double-blind, proof-of-concept phase 1 study, we enrolled healthy volunteers (aged 18-45 years) with a body-mass index of 18\u00b75-29\u00b79 kg/m(2) into one of four dose groups at SGS Life Sciences Clinical Research Services, Belgium. Participants were randomly assigned within groups in a 3:1 ratio to idarucizumab or placebo using a pseudorandom number generator and a supplied seed number. Participants and care providers were masked to treatment assignment. All participants received oral dabigatran etexilate 220 mg twice daily for 3 days and a final dose on day 4. Idarucizumab (1 g, 2 g, or 4 g 5-min infusion, or 5 g plus 2\u00b75 g in two 5-min infusions given 1 h apart) was administered about 2 h after the final dabigatran etexilate dose. The primary endpoint was incidence of drug-related adverse events, analysed in all randomly assigned participants who received at least one dose of dabigatran etexilate. Reversal of diluted thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and thrombin time (TT) were secondary endpoints assessed by measuring the area under the effect curve from 2 h to 12 h (AUEC2-12) after dabigatran etexilate ingestion on days 3 and 4. This trial is registered with ClinicalTrials.gov, number NCT01688830. Between Feb 23, and Nov 29, 2013, 47 men completed this part of the study. 12 were enrolled into each of the 1 g, 2 g, or 5 g plus 2\u00b75 g idarucizumab groups (nine to idarucizumab and three to placebo in each group), and 11 were enrolled into the 4 g idarucizumab group (eight to idarucizumab and three to placebo). Drug-related adverse events were all of mild intensity and reported in seven participants: one in the 1 g idarucizumab group (infusion site erythema and hot flushes), one in the 5 g plus 2\u00b75 g idarucizumab group (epistaxis); one receiving placebo (infusion site haematoma), and four during dabigatran etexilate pretreatment (three haematuria and one epistaxis). Idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 AUEC2-12 to day 3 AUEC2-12 for dTT was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction). No serious or severe adverse events were reported, no adverse event led to discontinuation of treatment, and no clinically relevant difference in incidence of adverse events was noted between treatment groups. These phase 1 results show that idarucizumab was associated with immediate, complete, and sustained reversal of dabigatran-induced anticoagulation in healthy men, and was well tolerated with no unexpected or clinically relevant safety concerns, supporting further testing. Further clinical studies are in progress. Boehringer Ingelheim Pharma GmbH & Co KG.", "qas": [{"question": "Idarucizumab is an antidote of which drug?", "answers": ["dabigatran"], "qid": "88499aa29e45416bba7bf6cc24031571", "question_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antidote", 19], ["of", 28], ["which", 31], ["drug", 37], ["?", 41]], "detected_answers": [{"text": "dabigatran", "token_spans": [[267, 267], [474, 474], [490, 490], [324, 324], [39, 39], [184, 184], [8, 8], [238, 238], [623, 623]], "char_spans": [[1357, 1366], [2353, 2362], [2474, 2483], [1630, 1639], [246, 255], [956, 965], [58, 67], [1182, 1191], [3132, 3141]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["monoclonal", 18], ["antibody", 29], ["fragment", 38], ["that", 47], ["binds", 52], ["dabigatran", 58], ["with", 69], ["high", 74], ["affinity", 79], ["in", 88], ["a", 91], ["1:1", 93], ["molar", 97], ["ratio", 103], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["safety", 130], [",", 136], ["tolerability", 138], [",", 150], ["and", 152], ["efficacy", 156], ["of", 165], ["increasing", 168], ["doses", 179], ["of", 185], ["idarucizumab", 188], ["for", 201], ["the", 205], ["reversal", 209], ["of", 218], ["anticoagulant", 221], ["effects", 235], ["of", 243], ["dabigatran", 246], ["in", 257], ["a", 260], ["two", 262], ["-", 265], ["part", 266], ["phase", 271], ["1", 277], ["study", 279], ["(", 285], ["rising", 286], ["-", 292], ["dose", 293], ["assessment", 298], ["and", 309], ["dose", 313], ["-", 317], ["finding", 318], [",", 325], ["proof", 327], ["-", 332], ["of", 333], ["-", 335], ["concept", 336], ["investigation", 344], [")", 357], [".", 358], ["Here", 360], ["we", 365], ["present", 368], ["the", 376], ["results", 380], ["of", 388], ["the", 391], ["proof", 395], ["-", 400], ["of", 401], ["-", 403], ["concept", 404], ["part", 412], ["of", 417], ["the", 420], ["study", 424], [".", 429], ["In", 431], ["this", 434], ["randomised", 439], [",", 449], ["placebo", 451], ["-", 458], ["controlled", 459], [",", 469], ["double", 471], ["-", 477], ["blind", 478], [",", 483], ["proof", 485], ["-", 490], ["of", 491], ["-", 493], ["concept", 494], ["phase", 502], ["1", 508], ["study", 510], [",", 515], ["we", 517], ["enrolled", 520], ["healthy", 529], ["volunteers", 537], ["(", 548], ["aged", 549], ["18", 554], ["-", 556], ["45", 557], ["years", 560], [")", 565], ["with", 567], ["a", 572], ["body", 574], ["-", 578], ["mass", 579], ["index", 584], ["of", 590], ["18\u00b75", 593], ["-", 597], ["29\u00b79", 598], ["kg", 603], ["/", 605], ["m(2", 606], [")", 609], ["into", 611], ["one", 616], ["of", 620], ["four", 623], ["dose", 628], ["groups", 633], ["at", 640], ["SGS", 643], ["Life", 647], ["Sciences", 652], ["Clinical", 661], ["Research", 670], ["Services", 679], [",", 687], ["Belgium", 689], [".", 696], ["Participants", 698], ["were", 711], ["randomly", 716], ["assigned", 725], ["within", 734], ["groups", 741], ["in", 748], ["a", 751], ["3:1", 753], ["ratio", 757], ["to", 763], ["idarucizumab", 766], ["or", 779], ["placebo", 782], ["using", 790], ["a", 796], ["pseudorandom", 798], ["number", 811], ["generator", 818], ["and", 828], ["a", 832], ["supplied", 834], ["seed", 843], ["number", 848], [".", 854], ["Participants", 856], ["and", 869], ["care", 873], ["providers", 878], ["were", 888], ["masked", 893], ["to", 900], ["treatment", 903], ["assignment", 913], [".", 923], ["All", 925], ["participants", 929], ["received", 942], ["oral", 951], ["dabigatran", 956], ["etexilate", 967], ["220", 977], ["mg", 981], ["twice", 984], ["daily", 990], ["for", 996], ["3", 1000], ["days", 1002], ["and", 1007], ["a", 1011], ["final", 1013], ["dose", 1019], ["on", 1024], ["day", 1027], ["4", 1031], [".", 1032], ["Idarucizumab", 1034], ["(", 1047], ["1", 1048], ["g", 1050], [",", 1051], ["2", 1053], ["g", 1055], [",", 1056], ["or", 1058], ["4", 1061], ["g", 1063], ["5-min", 1065], ["infusion", 1071], [",", 1079], ["or", 1081], ["5", 1084], ["g", 1086], ["plus", 1088], ["2\u00b75", 1093], ["g", 1097], ["in", 1099], ["two", 1102], ["5-min", 1106], ["infusions", 1112], ["given", 1122], ["1", 1128], ["h", 1130], ["apart", 1132], [")", 1137], ["was", 1139], ["administered", 1143], ["about", 1156], ["2", 1162], ["h", 1164], ["after", 1166], ["the", 1172], ["final", 1176], ["dabigatran", 1182], ["etexilate", 1193], ["dose", 1203], [".", 1207], ["The", 1209], ["primary", 1213], ["endpoint", 1221], ["was", 1230], ["incidence", 1234], ["of", 1244], ["drug", 1247], ["-", 1251], ["related", 1252], ["adverse", 1260], ["events", 1268], [",", 1274], ["analysed", 1276], ["in", 1285], ["all", 1288], ["randomly", 1292], ["assigned", 1301], ["participants", 1310], ["who", 1323], ["received", 1327], ["at", 1336], ["least", 1339], ["one", 1345], ["dose", 1349], ["of", 1354], ["dabigatran", 1357], ["etexilate", 1368], [".", 1377], ["Reversal", 1379], ["of", 1388], ["diluted", 1391], ["thrombin", 1399], ["time", 1408], ["(", 1413], ["dTT", 1414], [")", 1417], [",", 1418], ["ecarin", 1420], ["clotting", 1427], ["time", 1436], ["(", 1441], ["ECT", 1442], [")", 1445], [",", 1446], ["activated", 1448], ["partial", 1458], ["thromboplastin", 1466], ["time", 1481], ["(", 1486], ["aPTT", 1487], [")", 1491], [",", 1492], ["and", 1494], ["thrombin", 1498], ["time", 1507], ["(", 1512], ["TT", 1513], [")", 1515], ["were", 1517], ["secondary", 1522], ["endpoints", 1532], ["assessed", 1542], ["by", 1551], ["measuring", 1554], ["the", 1564], ["area", 1568], ["under", 1573], ["the", 1579], ["effect", 1583], ["curve", 1590], ["from", 1596], ["2", 1601], ["h", 1603], ["to", 1605], ["12", 1608], ["h", 1611], ["(", 1613], ["AUEC2", 1614], ["-", 1619], ["12", 1620], [")", 1622], ["after", 1624], ["dabigatran", 1630], ["etexilate", 1641], ["ingestion", 1651], ["on", 1661], ["days", 1664], ["3", 1669], ["and", 1671], ["4", 1675], [".", 1676], ["This", 1678], ["trial", 1683], ["is", 1689], ["registered", 1692], ["with", 1703], ["ClinicalTrials.gov", 1708], [",", 1726], ["number", 1728], ["NCT01688830", 1735], [".", 1746], ["Between", 1748], ["Feb", 1756], ["23", 1760], [",", 1762], ["and", 1764], ["Nov", 1768], ["29", 1772], [",", 1774], ["2013", 1776], [",", 1780], ["47", 1782], ["men", 1785], ["completed", 1789], ["this", 1799], ["part", 1804], ["of", 1809], ["the", 1812], ["study", 1816], [".", 1821], ["12", 1823], ["were", 1826], ["enrolled", 1831], ["into", 1840], ["each", 1845], ["of", 1850], ["the", 1853], ["1", 1857], ["g", 1859], [",", 1860], ["2", 1862], ["g", 1864], [",", 1865], ["or", 1867], ["5", 1870], ["g", 1872], ["plus", 1874], ["2\u00b75", 1879], ["g", 1883], ["idarucizumab", 1885], ["groups", 1898], ["(", 1905], ["nine", 1906], ["to", 1911], ["idarucizumab", 1914], ["and", 1927], ["three", 1931], ["to", 1937], ["placebo", 1940], ["in", 1948], ["each", 1951], ["group", 1956], [")", 1961], [",", 1962], ["and", 1964], ["11", 1968], ["were", 1971], ["enrolled", 1976], ["into", 1985], ["the", 1990], ["4", 1994], ["g", 1996], ["idarucizumab", 1998], ["group", 2011], ["(", 2017], ["eight", 2018], ["to", 2024], ["idarucizumab", 2027], ["and", 2040], ["three", 2044], ["to", 2050], ["placebo", 2053], [")", 2060], [".", 2061], ["Drug", 2063], ["-", 2067], ["related", 2068], ["adverse", 2076], ["events", 2084], ["were", 2091], ["all", 2096], ["of", 2100], ["mild", 2103], ["intensity", 2108], ["and", 2118], ["reported", 2122], ["in", 2131], ["seven", 2134], ["participants", 2140], [":", 2152], ["one", 2154], ["in", 2158], ["the", 2161], ["1", 2165], ["g", 2167], ["idarucizumab", 2169], ["group", 2182], ["(", 2188], ["infusion", 2189], ["site", 2198], ["erythema", 2203], ["and", 2212], ["hot", 2216], ["flushes", 2220], [")", 2227], [",", 2228], ["one", 2230], ["in", 2234], ["the", 2237], ["5", 2241], ["g", 2243], ["plus", 2245], ["2\u00b75", 2250], ["g", 2254], ["idarucizumab", 2256], ["group", 2269], ["(", 2275], ["epistaxis", 2276], [")", 2285], [";", 2286], ["one", 2288], ["receiving", 2292], ["placebo", 2302], ["(", 2310], ["infusion", 2311], ["site", 2320], ["haematoma", 2325], [")", 2334], [",", 2335], ["and", 2337], ["four", 2341], ["during", 2346], ["dabigatran", 2353], ["etexilate", 2364], ["pretreatment", 2374], ["(", 2387], ["three", 2388], ["haematuria", 2394], ["and", 2405], ["one", 2409], ["epistaxis", 2413], [")", 2422], [".", 2423], ["Idarucizumab", 2425], ["immediately", 2438], ["and", 2450], ["completely", 2454], ["reversed", 2465], ["dabigatran", 2474], ["-", 2484], ["induced", 2485], ["anticoagulation", 2493], ["in", 2509], ["a", 2512], ["dose", 2514], ["-", 2518], ["dependent", 2519], ["manner", 2529], [";", 2535], ["the", 2537], ["mean", 2541], ["ratio", 2546], ["of", 2552], ["day", 2555], ["4", 2559], ["AUEC2", 2561], ["-", 2566], ["12", 2567], ["to", 2570], ["day", 2573], ["3", 2577], ["AUEC2", 2579], ["-", 2584], ["12", 2585], ["for", 2588], ["dTT", 2592], ["was", 2596], ["1\u00b701", 2600], ["with", 2605], ["placebo", 2610], [",", 2617], ["0\u00b726", 2619], ["with", 2624], ["1", 2629], ["g", 2631], ["idarucizumab", 2633], ["(", 2646], ["74", 2647], ["%", 2649], ["reduction", 2651], [")", 2660], [",", 2661], ["0\u00b706", 2663], ["with", 2668], ["2", 2673], ["g", 2675], ["idarucizumab", 2677], ["(", 2690], ["94", 2691], ["%", 2693], ["reduction", 2695], [")", 2704], [",", 2705], ["0\u00b702", 2707], ["with", 2712], ["4", 2717], ["g", 2719], ["idarucizumab", 2721], ["(", 2734], ["98", 2735], ["%", 2737], ["reduction", 2739], [")", 2748], [",", 2749], ["and", 2751], ["0\u00b701", 2755], ["with", 2760], ["5", 2765], ["g", 2767], ["plus", 2769], ["2\u00b75", 2774], ["g", 2778], ["idarucizumab", 2780], ["(", 2793], ["99", 2794], ["%", 2796], ["reduction", 2798], [")", 2807], [".", 2808], ["No", 2810], ["serious", 2813], ["or", 2821], ["severe", 2824], ["adverse", 2831], ["events", 2839], ["were", 2846], ["reported", 2851], [",", 2859], ["no", 2861], ["adverse", 2864], ["event", 2872], ["led", 2878], ["to", 2882], ["discontinuation", 2885], ["of", 2901], ["treatment", 2904], [",", 2913], ["and", 2915], ["no", 2919], ["clinically", 2922], ["relevant", 2933], ["difference", 2942], ["in", 2953], ["incidence", 2956], ["of", 2966], ["adverse", 2969], ["events", 2977], ["was", 2984], ["noted", 2988], ["between", 2994], ["treatment", 3002], ["groups", 3012], [".", 3018], ["These", 3020], ["phase", 3026], ["1", 3032], ["results", 3034], ["show", 3042], ["that", 3047], ["idarucizumab", 3052], ["was", 3065], ["associated", 3069], ["with", 3080], ["immediate", 3085], [",", 3094], ["complete", 3096], [",", 3104], ["and", 3106], ["sustained", 3110], ["reversal", 3120], ["of", 3129], ["dabigatran", 3132], ["-", 3142], ["induced", 3143], ["anticoagulation", 3151], ["in", 3167], ["healthy", 3170], ["men", 3178], [",", 3181], ["and", 3183], ["was", 3187], ["well", 3191], ["tolerated", 3196], ["with", 3206], ["no", 3211], ["unexpected", 3214], ["or", 3225], ["clinically", 3228], ["relevant", 3239], ["safety", 3248], ["concerns", 3255], [",", 3263], ["supporting", 3265], ["further", 3276], ["testing", 3284], [".", 3291], ["Further", 3293], ["clinical", 3301], ["studies", 3310], ["are", 3318], ["in", 3322], ["progress", 3325], [".", 3333], ["Boehringer", 3335], ["Ingelheim", 3346], ["Pharma", 3356], ["GmbH", 3363], ["&", 3368], ["Co", 3370], ["KG", 3373], [".", 3375]]}
{"context": "H2A.Z is a highly conserved variant of histone H2A with well-characterized roles in transcriptional regulation. We previously reported that H2A.Z and Mcd1, a subunit of the cohesin complex, regulate the establishment of transcriptional silencing at telomeres in Saccharomyces cerevisiae and that H2A.Z broadly dissociated from chromatin during the anaphase-to-telophase transition, coincident with the dissociation of Mcd1 from chromosomes and dissolution of cohesion. In this study, we show that depletion of H2A.Z causes precocious loss of sister chromatid cohesion in yeast without loss of Mcd1 from chromosomes. H2A.Z is deposited into chromatin by the SWR1 complex and is subject to acetylation of its four N-terminal tail lysine residues by the NuA4 and SAGA histone acetyltransferase complexes. We found that cells compromised for function of the SWR1 complex were defective in cohesion, as were cells expressing a form of H2A.Z not subject to acetylation. Finally, inactivation of H2A.Z in metaphase-blocked cells led immediately to cohesion defects, suggesting a direct role for H2A.Z in the maintenance of sister chromatid cohesion.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "4ef05543761e4948b74e9fa078a5e4bc", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[140, 140], [106, 106]], "char_spans": [[854, 857], [657, 660]]}]}], "context_tokens": [["H2A.Z", 0], ["is", 6], ["a", 9], ["highly", 11], ["conserved", 18], ["variant", 28], ["of", 36], ["histone", 39], ["H2A", 47], ["with", 51], ["well", 56], ["-", 60], ["characterized", 61], ["roles", 75], ["in", 81], ["transcriptional", 84], ["regulation", 100], [".", 110], ["We", 112], ["previously", 115], ["reported", 126], ["that", 135], ["H2A.Z", 140], ["and", 146], ["Mcd1", 150], [",", 154], ["a", 156], ["subunit", 158], ["of", 166], ["the", 169], ["cohesin", 173], ["complex", 181], [",", 188], ["regulate", 190], ["the", 199], ["establishment", 203], ["of", 217], ["transcriptional", 220], ["silencing", 236], ["at", 246], ["telomeres", 249], ["in", 259], ["Saccharomyces", 262], ["cerevisiae", 276], ["and", 287], ["that", 291], ["H2A.Z", 296], ["broadly", 302], ["dissociated", 310], ["from", 322], ["chromatin", 327], ["during", 337], ["the", 344], ["anaphase", 348], ["-", 356], ["to", 357], ["-", 359], ["telophase", 360], ["transition", 370], [",", 380], ["coincident", 382], ["with", 393], ["the", 398], ["dissociation", 402], ["of", 415], ["Mcd1", 418], ["from", 423], ["chromosomes", 428], ["and", 440], ["dissolution", 444], ["of", 456], ["cohesion", 459], [".", 467], ["In", 469], ["this", 472], ["study", 477], [",", 482], ["we", 484], ["show", 487], ["that", 492], ["depletion", 497], ["of", 507], ["H2A.Z", 510], ["causes", 516], ["precocious", 523], ["loss", 534], ["of", 539], ["sister", 542], ["chromatid", 549], ["cohesion", 559], ["in", 568], ["yeast", 571], ["without", 577], ["loss", 585], ["of", 590], ["Mcd1", 593], ["from", 598], ["chromosomes", 603], [".", 614], ["H2A.Z", 616], ["is", 622], ["deposited", 625], ["into", 635], ["chromatin", 640], ["by", 650], ["the", 653], ["SWR1", 657], ["complex", 662], ["and", 670], ["is", 674], ["subject", 677], ["to", 685], ["acetylation", 688], ["of", 700], ["its", 703], ["four", 707], ["N", 712], ["-", 713], ["terminal", 714], ["tail", 723], ["lysine", 728], ["residues", 735], ["by", 744], ["the", 747], ["NuA4", 751], ["and", 756], ["SAGA", 760], ["histone", 765], ["acetyltransferase", 773], ["complexes", 791], [".", 800], ["We", 802], ["found", 805], ["that", 811], ["cells", 816], ["compromised", 822], ["for", 834], ["function", 838], ["of", 847], ["the", 850], ["SWR1", 854], ["complex", 859], ["were", 867], ["defective", 872], ["in", 882], ["cohesion", 885], [",", 893], ["as", 895], ["were", 898], ["cells", 903], ["expressing", 909], ["a", 920], ["form", 922], ["of", 927], ["H2A.Z", 930], ["not", 936], ["subject", 940], ["to", 948], ["acetylation", 951], [".", 962], ["Finally", 964], [",", 971], ["inactivation", 973], ["of", 986], ["H2A.Z", 989], ["in", 995], ["metaphase", 998], ["-", 1007], ["blocked", 1008], ["cells", 1016], ["led", 1022], ["immediately", 1026], ["to", 1038], ["cohesion", 1041], ["defects", 1050], [",", 1057], ["suggesting", 1059], ["a", 1070], ["direct", 1072], ["role", 1079], ["for", 1084], ["H2A.Z", 1088], ["in", 1094], ["the", 1097], ["maintenance", 1101], ["of", 1113], ["sister", 1116], ["chromatid", 1123], ["cohesion", 1133], [".", 1141]]}
{"context": "The aim of the present study was to investigate the antibiotic susceptibility patterns and molecular epidemiology of clinical methicillin-resistant Staphylococcus aureus (MRSA) isolates recovered in 24 hospitals in 20 cities in Croatia from October to December 2004. A total of 1815 consecutive S. aureus isolates were recovered, 248 of which were MRSA. The MRSA isolates were analysed using spa typing, multilocus sequence typing and SCCmec typing. Furthermore, the presence of Panton-Valentine leukocidin (PVL) genes was determined as a genetic marker for community-associated MRSA. The MRSA prevalence was 14%. Ninety-six per cent of the MRSA isolates were resistant to ciprofloxacin, 95% to clindamycin and azithromycin, 94% to gentamicin, and 93% to erythromycin. The majority of the MRSA isolates (78%) was associated with the ST111-MRSA-I clone. In addition, various other endemic MRSA clones were observed, such as the ST247-MRSA-I (4%), the ST45-MRSA-IV (2%), the ST5-MRSA-I (2%), the ST239-MRSA-III (2%), the ST5-MRSA-II (1%), the ST8-MRSA-IV (1%) and the ST5-MRSA-IV (<1%) clones. Furthermore, we observed one PVL-negative ST80-MRSA-IV isolate. Four PVL-positive MRSA isolates were found, associated with ST8-MRSA-IV, ST80-MRSA-IV and ST80-MRSA-I. The ST111-MRSA-I clone was predominant in Croatia. Future surveillance studies of MRSA are important to elucidate whether changes in the clonal distribution of MRSA will occur, and if the minor endemic MRSA clones observed in the present study will replace the ST111-MRSA-I clone on a large scale.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "d763f93b6e6f410da3bf3ba40aa856aa", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[114, 114], [101, 101], [253, 253], [285, 285], [60, 60], [164, 164], [57, 57], [297, 297], [24, 24], [306, 306], [98, 98], [143, 143]], "char_spans": [[641, 644], [589, 592], [1174, 1177], [1341, 1344], [358, 361], [888, 891], [348, 351], [1419, 1422], [171, 174], [1461, 1464], [579, 582], [789, 792]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["the", 11], ["present", 15], ["study", 23], ["was", 29], ["to", 33], ["investigate", 36], ["the", 48], ["antibiotic", 52], ["susceptibility", 63], ["patterns", 78], ["and", 87], ["molecular", 91], ["epidemiology", 101], ["of", 114], ["clinical", 117], ["methicillin", 126], ["-", 137], ["resistant", 138], ["Staphylococcus", 148], ["aureus", 163], ["(", 170], ["MRSA", 171], [")", 175], ["isolates", 177], ["recovered", 186], ["in", 196], ["24", 199], ["hospitals", 202], ["in", 212], ["20", 215], ["cities", 218], ["in", 225], ["Croatia", 228], ["from", 236], ["October", 241], ["to", 249], ["December", 252], ["2004", 261], [".", 265], ["A", 267], ["total", 269], ["of", 275], ["1815", 278], ["consecutive", 283], ["S.", 295], ["aureus", 298], ["isolates", 305], ["were", 314], ["recovered", 319], [",", 328], ["248", 330], ["of", 334], ["which", 337], ["were", 343], ["MRSA", 348], [".", 352], ["The", 354], ["MRSA", 358], ["isolates", 363], ["were", 372], ["analysed", 377], ["using", 386], ["spa", 392], ["typing", 396], [",", 402], ["multilocus", 404], ["sequence", 415], ["typing", 424], ["and", 431], ["SCCmec", 435], ["typing", 442], [".", 448], ["Furthermore", 450], [",", 461], ["the", 463], ["presence", 467], ["of", 476], ["Panton", 479], ["-", 485], ["Valentine", 486], ["leukocidin", 496], ["(", 507], ["PVL", 508], [")", 511], ["genes", 513], ["was", 519], ["determined", 523], ["as", 534], ["a", 537], ["genetic", 539], ["marker", 547], ["for", 554], ["community", 558], ["-", 567], ["associated", 568], ["MRSA", 579], [".", 583], ["The", 585], ["MRSA", 589], ["prevalence", 594], ["was", 605], ["14", 609], ["%", 611], [".", 612], ["Ninety", 614], ["-", 620], ["six", 621], ["per", 625], ["cent", 629], ["of", 634], ["the", 637], ["MRSA", 641], ["isolates", 646], ["were", 655], ["resistant", 660], ["to", 670], ["ciprofloxacin", 673], [",", 686], ["95", 688], ["%", 690], ["to", 692], ["clindamycin", 695], ["and", 707], ["azithromycin", 711], [",", 723], ["94", 725], ["%", 727], ["to", 729], ["gentamicin", 732], [",", 742], ["and", 744], ["93", 748], ["%", 750], ["to", 752], ["erythromycin", 755], [".", 767], ["The", 769], ["majority", 773], ["of", 782], ["the", 785], ["MRSA", 789], ["isolates", 794], ["(", 803], ["78", 804], ["%", 806], [")", 807], ["was", 809], ["associated", 813], ["with", 824], ["the", 829], ["ST111-MRSA", 833], ["-", 843], ["I", 844], ["clone", 846], [".", 851], ["In", 853], ["addition", 856], [",", 864], ["various", 866], ["other", 874], ["endemic", 880], ["MRSA", 888], ["clones", 893], ["were", 900], ["observed", 905], [",", 913], ["such", 915], ["as", 920], ["the", 923], ["ST247-MRSA", 927], ["-", 937], ["I", 938], ["(", 940], ["4", 941], ["%", 942], [")", 943], [",", 944], ["the", 946], ["ST45-MRSA", 950], ["-", 959], ["IV", 960], ["(", 963], ["2", 964], ["%", 965], [")", 966], [",", 967], ["the", 969], ["ST5-MRSA", 973], ["-", 981], ["I", 982], ["(", 984], ["2", 985], ["%", 986], [")", 987], [",", 988], ["the", 990], ["ST239-MRSA", 994], ["-", 1004], ["III", 1005], ["(", 1009], ["2", 1010], ["%", 1011], [")", 1012], [",", 1013], ["the", 1015], ["ST5-MRSA", 1019], ["-", 1027], ["II", 1028], ["(", 1031], ["1", 1032], ["%", 1033], [")", 1034], [",", 1035], ["the", 1037], ["ST8-MRSA", 1041], ["-", 1049], ["IV", 1050], ["(", 1053], ["1", 1054], ["%", 1055], [")", 1056], ["and", 1058], ["the", 1062], ["ST5-MRSA", 1066], ["-", 1074], ["IV", 1075], ["(", 1078], ["<", 1079], ["1", 1080], ["%", 1081], [")", 1082], ["clones", 1084], [".", 1090], ["Furthermore", 1092], [",", 1103], ["we", 1105], ["observed", 1108], ["one", 1117], ["PVL", 1121], ["-", 1124], ["negative", 1125], ["ST80-MRSA", 1134], ["-", 1143], ["IV", 1144], ["isolate", 1147], [".", 1154], ["Four", 1156], ["PVL", 1161], ["-", 1164], ["positive", 1165], ["MRSA", 1174], ["isolates", 1179], ["were", 1188], ["found", 1193], [",", 1198], ["associated", 1200], ["with", 1211], ["ST8-MRSA", 1216], ["-", 1224], ["IV", 1225], [",", 1227], ["ST80-MRSA", 1229], ["-", 1238], ["IV", 1239], ["and", 1242], ["ST80-MRSA", 1246], ["-", 1255], ["I.", 1256], ["The", 1259], ["ST111-MRSA", 1263], ["-", 1273], ["I", 1274], ["clone", 1276], ["was", 1282], ["predominant", 1286], ["in", 1298], ["Croatia", 1301], [".", 1308], ["Future", 1310], ["surveillance", 1317], ["studies", 1330], ["of", 1338], ["MRSA", 1341], ["are", 1346], ["important", 1350], ["to", 1360], ["elucidate", 1363], ["whether", 1373], ["changes", 1381], ["in", 1389], ["the", 1392], ["clonal", 1396], ["distribution", 1403], ["of", 1416], ["MRSA", 1419], ["will", 1424], ["occur", 1429], [",", 1434], ["and", 1436], ["if", 1440], ["the", 1443], ["minor", 1447], ["endemic", 1453], ["MRSA", 1461], ["clones", 1466], ["observed", 1473], ["in", 1482], ["the", 1485], ["present", 1489], ["study", 1497], ["will", 1503], ["replace", 1508], ["the", 1516], ["ST111-MRSA", 1520], ["-", 1530], ["I", 1531], ["clone", 1533], ["on", 1539], ["a", 1542], ["large", 1544], ["scale", 1550], [".", 1555]]}
{"context": "Deubiquitinating enzymes (DUbs) play important roles in many ubiquitin-dependent pathways, yet how DUbs themselves are regulated is not well understood. Here, we provide insight into the mechanism by which ubiquitination directly enhances the activity of ataxin-3, a DUb implicated in protein quality control and the disease protein in the polyglutamine neurodegenerative disorder, Spinocerebellar Ataxia Type 3. We identify Lys-117, which resides near the catalytic triad, as the primary site of ubiquitination in wild type and pathogenic ataxin-3. Further studies indicate that ubiquitin-dependent activation of ataxin-3 at Lys-117 is important for its ability to reduce high molecular weight ubiquitinated species in cells. Ubiquitination at Lys-117 also facilitates the ability of ataxin-3 to induce aggresome formation in cells. Finally, structure-function studies support a model of activation whereby ubiquitination at Lys-117 enhances ataxin-3 activity independent of the known ubiquitin-binding sites in ataxin-3, most likely through a direct conformational change in or near the catalytic domain.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "76df6ea078eb43ef838474f8a30b5d15", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[160, 160], [149, 149], [99, 99], [125, 125], [42, 42], [88, 88]], "char_spans": [[1013, 1020], [943, 950], [614, 621], [785, 792], [255, 262], [540, 547]]}]}], "context_tokens": [["Deubiquitinating", 0], ["enzymes", 17], ["(", 25], ["DUbs", 26], [")", 30], ["play", 32], ["important", 37], ["roles", 47], ["in", 53], ["many", 56], ["ubiquitin", 61], ["-", 70], ["dependent", 71], ["pathways", 81], [",", 89], ["yet", 91], ["how", 95], ["DUbs", 99], ["themselves", 104], ["are", 115], ["regulated", 119], ["is", 129], ["not", 132], ["well", 136], ["understood", 141], [".", 151], ["Here", 153], [",", 157], ["we", 159], ["provide", 162], ["insight", 170], ["into", 178], ["the", 183], ["mechanism", 187], ["by", 197], ["which", 200], ["ubiquitination", 206], ["directly", 221], ["enhances", 230], ["the", 239], ["activity", 243], ["of", 252], ["ataxin-3", 255], [",", 263], ["a", 265], ["DUb", 267], ["implicated", 271], ["in", 282], ["protein", 285], ["quality", 293], ["control", 301], ["and", 309], ["the", 313], ["disease", 317], ["protein", 325], ["in", 333], ["the", 336], ["polyglutamine", 340], ["neurodegenerative", 354], ["disorder", 372], [",", 380], ["Spinocerebellar", 382], ["Ataxia", 398], ["Type", 405], ["3", 410], [".", 411], ["We", 413], ["identify", 416], ["Lys-117", 425], [",", 432], ["which", 434], ["resides", 440], ["near", 448], ["the", 453], ["catalytic", 457], ["triad", 467], [",", 472], ["as", 474], ["the", 477], ["primary", 481], ["site", 489], ["of", 494], ["ubiquitination", 497], ["in", 512], ["wild", 515], ["type", 520], ["and", 525], ["pathogenic", 529], ["ataxin-3", 540], [".", 548], ["Further", 550], ["studies", 558], ["indicate", 566], ["that", 575], ["ubiquitin", 580], ["-", 589], ["dependent", 590], ["activation", 600], ["of", 611], ["ataxin-3", 614], ["at", 623], ["Lys-117", 626], ["is", 634], ["important", 637], ["for", 647], ["its", 651], ["ability", 655], ["to", 663], ["reduce", 666], ["high", 673], ["molecular", 678], ["weight", 688], ["ubiquitinated", 695], ["species", 709], ["in", 717], ["cells", 720], [".", 725], ["Ubiquitination", 727], ["at", 742], ["Lys-117", 745], ["also", 753], ["facilitates", 758], ["the", 770], ["ability", 774], ["of", 782], ["ataxin-3", 785], ["to", 794], ["induce", 797], ["aggresome", 804], ["formation", 814], ["in", 824], ["cells", 827], [".", 832], ["Finally", 834], [",", 841], ["structure", 843], ["-", 852], ["function", 853], ["studies", 862], ["support", 870], ["a", 878], ["model", 880], ["of", 886], ["activation", 889], ["whereby", 900], ["ubiquitination", 908], ["at", 923], ["Lys-117", 926], ["enhances", 934], ["ataxin-3", 943], ["activity", 952], ["independent", 961], ["of", 973], ["the", 976], ["known", 980], ["ubiquitin", 986], ["-", 995], ["binding", 996], ["sites", 1004], ["in", 1010], ["ataxin-3", 1013], [",", 1021], ["most", 1023], ["likely", 1028], ["through", 1035], ["a", 1043], ["direct", 1045], ["conformational", 1052], ["change", 1067], ["in", 1074], ["or", 1077], ["near", 1080], ["the", 1085], ["catalytic", 1089], ["domain", 1099], [".", 1105]]}
{"context": "During mitosis, Promyelocytic leukemia nuclear bodies (PML NBs) change dramatically in morphology and composition, but little is known about function of PML in mitosis. Here, we show that PML is phosphorylated at T409 (PML p409) in a mitosis-specific manner. More importantly, PML p409 contributes to maintain the duration of pro-metaphase and regulates spindle checkpoint. Deficient PML p409 caused a shortening of pro-metaphase and challenged the nocodazole-triggered mitotic arrest. T409A mutation led to a higher frequency of misaligned chromosomes on metaphase plate, and subsequently death in late mitosis. In addition, inhibition of PML p409 repressed growth of tumor cells, suggesting that PML p409 is a potential target for cancer therapy. Collectively, our study demonstrated an important phosphorylated site of PML, which contributed to explore the role of PML in mitosis.", "qas": [{"question": "What is the effect of nocodazole cell treatment?", "answers": ["Mitotic arrest"], "qid": "fb1932c2568743f8a7e02da6141a50f9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["nocodazole", 22], ["cell", 33], ["treatment", 38], ["?", 47]], "detected_answers": [{"text": "Mitotic arrest", "token_spans": [[85, 86]], "char_spans": [[470, 483]]}]}], "context_tokens": [["During", 0], ["mitosis", 7], [",", 14], ["Promyelocytic", 16], ["leukemia", 30], ["nuclear", 39], ["bodies", 47], ["(", 54], ["PML", 55], ["NBs", 59], [")", 62], ["change", 64], ["dramatically", 71], ["in", 84], ["morphology", 87], ["and", 98], ["composition", 102], [",", 113], ["but", 115], ["little", 119], ["is", 126], ["known", 129], ["about", 135], ["function", 141], ["of", 150], ["PML", 153], ["in", 157], ["mitosis", 160], [".", 167], ["Here", 169], [",", 173], ["we", 175], ["show", 178], ["that", 183], ["PML", 188], ["is", 192], ["phosphorylated", 195], ["at", 210], ["T409", 213], ["(", 218], ["PML", 219], ["p409", 223], [")", 227], ["in", 229], ["a", 232], ["mitosis", 234], ["-", 241], ["specific", 242], ["manner", 251], [".", 257], ["More", 259], ["importantly", 264], [",", 275], ["PML", 277], ["p409", 281], ["contributes", 286], ["to", 298], ["maintain", 301], ["the", 310], ["duration", 314], ["of", 323], ["pro", 326], ["-", 329], ["metaphase", 330], ["and", 340], ["regulates", 344], ["spindle", 354], ["checkpoint", 362], [".", 372], ["Deficient", 374], ["PML", 384], ["p409", 388], ["caused", 393], ["a", 400], ["shortening", 402], ["of", 413], ["pro", 416], ["-", 419], ["metaphase", 420], ["and", 430], ["challenged", 434], ["the", 445], ["nocodazole", 449], ["-", 459], ["triggered", 460], ["mitotic", 470], ["arrest", 478], [".", 484], ["T409A", 486], ["mutation", 492], ["led", 501], ["to", 505], ["a", 508], ["higher", 510], ["frequency", 517], ["of", 527], ["misaligned", 530], ["chromosomes", 541], ["on", 553], ["metaphase", 556], ["plate", 566], [",", 571], ["and", 573], ["subsequently", 577], ["death", 590], ["in", 596], ["late", 599], ["mitosis", 604], [".", 611], ["In", 613], ["addition", 616], [",", 624], ["inhibition", 626], ["of", 637], ["PML", 640], ["p409", 644], ["repressed", 649], ["growth", 659], ["of", 666], ["tumor", 669], ["cells", 675], [",", 680], ["suggesting", 682], ["that", 693], ["PML", 698], ["p409", 702], ["is", 707], ["a", 710], ["potential", 712], ["target", 722], ["for", 729], ["cancer", 733], ["therapy", 740], [".", 747], ["Collectively", 749], [",", 761], ["our", 763], ["study", 767], ["demonstrated", 773], ["an", 786], ["important", 789], ["phosphorylated", 799], ["site", 814], ["of", 819], ["PML", 822], [",", 825], ["which", 827], ["contributed", 833], ["to", 845], ["explore", 848], ["the", 856], ["role", 860], ["of", 865], ["PML", 868], ["in", 872], ["mitosis", 875], [".", 882]]}
{"context": "The Philadelphia chromosome translocation (t(9;22)) results in the molecular juxtaposition of two genes, BCR and ABL, to form an aberrant BCR-ABL gene on chromosome 22. BCR-ABL is critical to the pathogenesis of chronic myelogenous leukemia and a subset of acute leukemias. The chimeric Bcr-Abl protein has constitutively elevated tyrosine phosphokinase activity. This abnormal enzymatic activation is critical to the oncogenic potential of Bcr-Abl. Initially, protein kinases were thought to be poor therapeutic targets because of their ubiquitous nature and crucial role in many normal physiologic processes. However, the advent of imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland), formerly known as STI571 and CGP57148B, demonstrated that designer kinase inhibitors could be specific. This agent has shown striking activity in chronic myelogenous leukemia. It also inhibits phosphorylation of Kit (stem-cell factor receptor) and platelet-derived growth factor receptor. In addition, it has shown similar impressive responses, with little host toxicity, in gastrointestinal stromal tumors, which harbor activating Kit mutations, and in tumors with activated platelet-derived growth factor receptor. The studies of imatinib mesylate provide proof-of-principle for using aberrant kinases as a therapeutic target and are a model for the promise of molecular therapeutics. This paper reviews the current knowledge on the function of Bcr-Abl and its normal counterparts (Bcr and Abl), as well as the impact of this knowledge on the development of a remarkably successful targeted therapy approach.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ec447381a9274cb2925d3a6a913cd81a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[33, 35], [76, 78], [54, 56], [249, 251], [25, 27]], "char_spans": [[169, 175], [441, 447], [287, 293], [1456, 1462], [138, 144]]}]}], "context_tokens": [["The", 0], ["Philadelphia", 4], ["chromosome", 17], ["translocation", 28], ["(", 42], ["t(9;22", 43], [")", 49], [")", 50], ["results", 52], ["in", 60], ["the", 63], ["molecular", 67], ["juxtaposition", 77], ["of", 91], ["two", 94], ["genes", 98], [",", 103], ["BCR", 105], ["and", 109], ["ABL", 113], [",", 116], ["to", 118], ["form", 121], ["an", 126], ["aberrant", 129], ["BCR", 138], ["-", 141], ["ABL", 142], ["gene", 146], ["on", 151], ["chromosome", 154], ["22", 165], [".", 167], ["BCR", 169], ["-", 172], ["ABL", 173], ["is", 177], ["critical", 180], ["to", 189], ["the", 192], ["pathogenesis", 196], ["of", 209], ["chronic", 212], ["myelogenous", 220], ["leukemia", 232], ["and", 241], ["a", 245], ["subset", 247], ["of", 254], ["acute", 257], ["leukemias", 263], [".", 272], ["The", 274], ["chimeric", 278], ["Bcr", 287], ["-", 290], ["Abl", 291], ["protein", 295], ["has", 303], ["constitutively", 307], ["elevated", 322], ["tyrosine", 331], ["phosphokinase", 340], ["activity", 354], [".", 362], ["This", 364], ["abnormal", 369], ["enzymatic", 378], ["activation", 388], ["is", 399], ["critical", 402], ["to", 411], ["the", 414], ["oncogenic", 418], ["potential", 428], ["of", 438], ["Bcr", 441], ["-", 444], ["Abl", 445], [".", 448], ["Initially", 450], [",", 459], ["protein", 461], ["kinases", 469], ["were", 477], ["thought", 482], ["to", 490], ["be", 493], ["poor", 496], ["therapeutic", 501], ["targets", 513], ["because", 521], ["of", 529], ["their", 532], ["ubiquitous", 538], ["nature", 549], ["and", 556], ["crucial", 560], ["role", 568], ["in", 573], ["many", 576], ["normal", 581], ["physiologic", 588], ["processes", 600], [".", 609], ["However", 611], [",", 618], ["the", 620], ["advent", 624], ["of", 631], ["imatinib", 634], ["mesylate", 643], ["(", 652], ["Gleevec", 653], [",", 660], ["Novartis", 662], ["Pharmaceuticals", 671], [",", 686], ["Basel", 688], [",", 693], ["Switzerland", 695], [")", 706], [",", 707], ["formerly", 709], ["known", 718], ["as", 724], ["STI571", 727], ["and", 734], ["CGP57148B", 738], [",", 747], ["demonstrated", 749], ["that", 762], ["designer", 767], ["kinase", 776], ["inhibitors", 783], ["could", 794], ["be", 800], ["specific", 803], [".", 811], ["This", 813], ["agent", 818], ["has", 824], ["shown", 828], ["striking", 834], ["activity", 843], ["in", 852], ["chronic", 855], ["myelogenous", 863], ["leukemia", 875], [".", 883], ["It", 885], ["also", 888], ["inhibits", 893], ["phosphorylation", 902], ["of", 918], ["Kit", 921], ["(", 925], ["stem", 926], ["-", 930], ["cell", 931], ["factor", 936], ["receptor", 943], [")", 951], ["and", 953], ["platelet", 957], ["-", 965], ["derived", 966], ["growth", 974], ["factor", 981], ["receptor", 988], [".", 996], ["In", 998], ["addition", 1001], [",", 1009], ["it", 1011], ["has", 1014], ["shown", 1018], ["similar", 1024], ["impressive", 1032], ["responses", 1043], [",", 1052], ["with", 1054], ["little", 1059], ["host", 1066], ["toxicity", 1071], [",", 1079], ["in", 1081], ["gastrointestinal", 1084], ["stromal", 1101], ["tumors", 1109], [",", 1115], ["which", 1117], ["harbor", 1123], ["activating", 1130], ["Kit", 1141], ["mutations", 1145], [",", 1154], ["and", 1156], ["in", 1160], ["tumors", 1163], ["with", 1170], ["activated", 1175], ["platelet", 1185], ["-", 1193], ["derived", 1194], ["growth", 1202], ["factor", 1209], ["receptor", 1216], [".", 1224], ["The", 1226], ["studies", 1230], ["of", 1238], ["imatinib", 1241], ["mesylate", 1250], ["provide", 1259], ["proof", 1267], ["-", 1272], ["of", 1273], ["-", 1275], ["principle", 1276], ["for", 1286], ["using", 1290], ["aberrant", 1296], ["kinases", 1305], ["as", 1313], ["a", 1316], ["therapeutic", 1318], ["target", 1330], ["and", 1337], ["are", 1341], ["a", 1345], ["model", 1347], ["for", 1353], ["the", 1357], ["promise", 1361], ["of", 1369], ["molecular", 1372], ["therapeutics", 1382], [".", 1394], ["This", 1396], ["paper", 1401], ["reviews", 1407], ["the", 1415], ["current", 1419], ["knowledge", 1427], ["on", 1437], ["the", 1440], ["function", 1444], ["of", 1453], ["Bcr", 1456], ["-", 1459], ["Abl", 1460], ["and", 1464], ["its", 1468], ["normal", 1472], ["counterparts", 1479], ["(", 1492], ["Bcr", 1493], ["and", 1497], ["Abl", 1501], [")", 1504], [",", 1505], ["as", 1507], ["well", 1510], ["as", 1515], ["the", 1518], ["impact", 1522], ["of", 1529], ["this", 1532], ["knowledge", 1537], ["on", 1547], ["the", 1550], ["development", 1554], ["of", 1566], ["a", 1569], ["remarkably", 1571], ["successful", 1582], ["targeted", 1593], ["therapy", 1602], ["approach", 1610], [".", 1618]]}
{"context": "Transgenic mice expressing a human mutant alpha-galactosidase with an R301Q substitution, which was found in a patient with a variant form of Fabry disease, were established. The mice transcribed a sufficient amount of alpha-galactosidase mRNA, but the steady-state levels of the enzyme protein were decreased in liver, kidney and heart, only residual activity being detected in these tissues. The mice will be useful for the clarification of the defective regulation of the structurally altered enzyme protein expressed by the mutant gene at the organ or individual level as well as for the evaluation of drugs that stabilize and/or activate the mutant alpha-galactosidase.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "0b96af4f05454584acfec3b094cb01bf", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[114, 116], [38, 40], [6, 8]], "char_spans": [[654, 672], [219, 237], [42, 60]]}]}], "context_tokens": [["Transgenic", 0], ["mice", 11], ["expressing", 16], ["a", 27], ["human", 29], ["mutant", 35], ["alpha", 42], ["-", 47], ["galactosidase", 48], ["with", 62], ["an", 67], ["R301Q", 70], ["substitution", 76], [",", 88], ["which", 90], ["was", 96], ["found", 100], ["in", 106], ["a", 109], ["patient", 111], ["with", 119], ["a", 124], ["variant", 126], ["form", 134], ["of", 139], ["Fabry", 142], ["disease", 148], [",", 155], ["were", 157], ["established", 162], [".", 173], ["The", 175], ["mice", 179], ["transcribed", 184], ["a", 196], ["sufficient", 198], ["amount", 209], ["of", 216], ["alpha", 219], ["-", 224], ["galactosidase", 225], ["mRNA", 239], [",", 243], ["but", 245], ["the", 249], ["steady", 253], ["-", 259], ["state", 260], ["levels", 266], ["of", 273], ["the", 276], ["enzyme", 280], ["protein", 287], ["were", 295], ["decreased", 300], ["in", 310], ["liver", 313], [",", 318], ["kidney", 320], ["and", 327], ["heart", 331], [",", 336], ["only", 338], ["residual", 343], ["activity", 352], ["being", 361], ["detected", 367], ["in", 376], ["these", 379], ["tissues", 385], [".", 392], ["The", 394], ["mice", 398], ["will", 403], ["be", 408], ["useful", 411], ["for", 418], ["the", 422], ["clarification", 426], ["of", 440], ["the", 443], ["defective", 447], ["regulation", 457], ["of", 468], ["the", 471], ["structurally", 475], ["altered", 488], ["enzyme", 496], ["protein", 503], ["expressed", 511], ["by", 521], ["the", 524], ["mutant", 528], ["gene", 535], ["at", 540], ["the", 543], ["organ", 547], ["or", 553], ["individual", 556], ["level", 567], ["as", 573], ["well", 576], ["as", 581], ["for", 584], ["the", 588], ["evaluation", 592], ["of", 603], ["drugs", 606], ["that", 612], ["stabilize", 617], ["and/or", 627], ["activate", 634], ["the", 643], ["mutant", 647], ["alpha", 654], ["-", 659], ["galactosidase", 660], [".", 673]]}
{"context": "Since the discovery of non-coding, small, highly structured, satellite RNAs (satRNAs) and viroids as subviral pathogens of plants , have been of great interest to molecular biologists as possible living fossils of pre-cellular evolution in an RNA world. Despite extensive studies performed in the last four decades, there is still mystery surrounding the origin and evolutionary relationship between these subviral pathogens. Recent technical advances revealed some commonly shared replication features between these two subviral pathogens. In this review, we discuss our current perception of replication and evolutionary origin of these petite RNA pathogens.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "0133a9c3b1f74db79d96f61d59105870", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[19, 19]], "char_spans": [[90, 96]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["discovery", 10], ["of", 20], ["non", 23], ["-", 26], ["coding", 27], [",", 33], ["small", 35], [",", 40], ["highly", 42], ["structured", 49], [",", 59], ["satellite", 61], ["RNAs", 71], ["(", 76], ["satRNAs", 77], [")", 84], ["and", 86], ["viroids", 90], ["as", 98], ["subviral", 101], ["pathogens", 110], ["of", 120], ["plants", 123], [",", 130], ["have", 132], ["been", 137], ["of", 142], ["great", 145], ["interest", 151], ["to", 160], ["molecular", 163], ["biologists", 173], ["as", 184], ["possible", 187], ["living", 196], ["fossils", 203], ["of", 211], ["pre", 214], ["-", 217], ["cellular", 218], ["evolution", 227], ["in", 237], ["an", 240], ["RNA", 243], ["world", 247], [".", 252], ["Despite", 254], ["extensive", 262], ["studies", 272], ["performed", 280], ["in", 290], ["the", 293], ["last", 297], ["four", 302], ["decades", 307], [",", 314], ["there", 316], ["is", 322], ["still", 325], ["mystery", 331], ["surrounding", 339], ["the", 351], ["origin", 355], ["and", 362], ["evolutionary", 366], ["relationship", 379], ["between", 392], ["these", 400], ["subviral", 406], ["pathogens", 415], [".", 424], ["Recent", 426], ["technical", 433], ["advances", 443], ["revealed", 452], ["some", 461], ["commonly", 466], ["shared", 475], ["replication", 482], ["features", 494], ["between", 503], ["these", 511], ["two", 517], ["subviral", 521], ["pathogens", 530], [".", 539], ["In", 541], ["this", 544], ["review", 549], [",", 555], ["we", 557], ["discuss", 560], ["our", 568], ["current", 572], ["perception", 580], ["of", 591], ["replication", 594], ["and", 606], ["evolutionary", 610], ["origin", 623], ["of", 630], ["these", 633], ["petite", 639], ["RNA", 646], ["pathogens", 650], [".", 659]]}
{"context": "Muenke syndrome, defined by heterozygosity for a Pro250Arg substitution in fibroblast growth factor receptor 3 (FGFR3), is the most common genetic cause of craniosynostosis in humans. We have used gene targeting to introduce the Muenke syndrome mutation (equivalent to P244R) into the murine Fgfr3 gene. A rounded skull and shortened snout (often skewed) with dental malocclusion was observed in a minority of heterozygotes and many homozygotes. Development of this incompletely penetrant skull phenotype was dependent on genetic background and sex, with males more often affected. However, these cranial abnormalities were rarely attributable to craniosynostosis, which was only present in 2/364 mutants; more commonly, we found fusion of the premaxillary and/or zygomatic sutures. We also found decreased cortical thickness and bone mineral densities in long bones. We conclude that although both cranial and long bone development is variably affected by the murine Fgfr3(P244R) mutation, coronal craniosynostosis is not reliably reproduced.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "0e24607baaa74369a7171110551ca197", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[11, 17]], "char_spans": [[75, 116]]}]}], "context_tokens": [["Muenke", 0], ["syndrome", 7], [",", 15], ["defined", 17], ["by", 25], ["heterozygosity", 28], ["for", 43], ["a", 47], ["Pro250Arg", 49], ["substitution", 59], ["in", 72], ["fibroblast", 75], ["growth", 86], ["factor", 93], ["receptor", 100], ["3", 109], ["(", 111], ["FGFR3", 112], [")", 117], [",", 118], ["is", 120], ["the", 123], ["most", 127], ["common", 132], ["genetic", 139], ["cause", 147], ["of", 153], ["craniosynostosis", 156], ["in", 173], ["humans", 176], [".", 182], ["We", 184], ["have", 187], ["used", 192], ["gene", 197], ["targeting", 202], ["to", 212], ["introduce", 215], ["the", 225], ["Muenke", 229], ["syndrome", 236], ["mutation", 245], ["(", 254], ["equivalent", 255], ["to", 266], ["P244R", 269], [")", 274], ["into", 276], ["the", 281], ["murine", 285], ["Fgfr3", 292], ["gene", 298], [".", 302], ["A", 304], ["rounded", 306], ["skull", 314], ["and", 320], ["shortened", 324], ["snout", 334], ["(", 340], ["often", 341], ["skewed", 347], [")", 353], ["with", 355], ["dental", 360], ["malocclusion", 367], ["was", 380], ["observed", 384], ["in", 393], ["a", 396], ["minority", 398], ["of", 407], ["heterozygotes", 410], ["and", 424], ["many", 428], ["homozygotes", 433], [".", 444], ["Development", 446], ["of", 458], ["this", 461], ["incompletely", 466], ["penetrant", 479], ["skull", 489], ["phenotype", 495], ["was", 505], ["dependent", 509], ["on", 519], ["genetic", 522], ["background", 530], ["and", 541], ["sex", 545], [",", 548], ["with", 550], ["males", 555], ["more", 561], ["often", 566], ["affected", 572], [".", 580], ["However", 582], [",", 589], ["these", 591], ["cranial", 597], ["abnormalities", 605], ["were", 619], ["rarely", 624], ["attributable", 631], ["to", 644], ["craniosynostosis", 647], [",", 663], ["which", 665], ["was", 671], ["only", 675], ["present", 680], ["in", 688], ["2/364", 691], ["mutants", 697], [";", 704], ["more", 706], ["commonly", 711], [",", 719], ["we", 721], ["found", 724], ["fusion", 730], ["of", 737], ["the", 740], ["premaxillary", 744], ["and/or", 757], ["zygomatic", 764], ["sutures", 774], [".", 781], ["We", 783], ["also", 786], ["found", 791], ["decreased", 797], ["cortical", 807], ["thickness", 816], ["and", 826], ["bone", 830], ["mineral", 835], ["densities", 843], ["in", 853], ["long", 856], ["bones", 861], [".", 866], ["We", 868], ["conclude", 871], ["that", 880], ["although", 885], ["both", 894], ["cranial", 899], ["and", 907], ["long", 911], ["bone", 916], ["development", 921], ["is", 933], ["variably", 936], ["affected", 945], ["by", 954], ["the", 957], ["murine", 961], ["Fgfr3(P244R", 968], [")", 979], ["mutation", 981], [",", 989], ["coronal", 991], ["craniosynostosis", 999], ["is", 1016], ["not", 1019], ["reliably", 1023], ["reproduced", 1032], [".", 1042]]}
{"context": "It is well known that autonomic failure is severer in patients with dementia with Lewy bodies (DLB) compared with patients with Parkinson's disease (PD). According to the Braak's hypothesis, Lewy bodies first appear in the olfactory bulb or peripheral autonomic nervous system. Lewy bodies in the peripheral autonomic nervous system ascend to dorsal motor nuclei of vagus nerve, while those in the olfactory bulb expand to the limbic system. Lewy bodies later attain the substantia nigra. However, it seems that Braak staging can not explain difference in severity of autonomic failure between DLB and PD. As a possibility, in DLB patients with significant autonomic failure, Lewy bodies may have been localized to the peripheral autonomic nervous system in a long time before onset of dementia or parkinsonism, and propagation of Lewy bodies into the central nervous system may be initiated by apparition of certain promotion factor, such as ageing and amyloid-\u03b2.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "db39b179aff4498e87b78355b6034f5b", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[23, 27]], "char_spans": [[128, 150]]}]}], "context_tokens": [["It", 0], ["is", 3], ["well", 6], ["known", 11], ["that", 17], ["autonomic", 22], ["failure", 32], ["is", 40], ["severer", 43], ["in", 51], ["patients", 54], ["with", 63], ["dementia", 68], ["with", 77], ["Lewy", 82], ["bodies", 87], ["(", 94], ["DLB", 95], [")", 98], ["compared", 100], ["with", 109], ["patients", 114], ["with", 123], ["Parkinson", 128], ["'s", 137], ["disease", 140], ["(", 148], ["PD", 149], [")", 151], [".", 152], ["According", 154], ["to", 164], ["the", 167], ["Braak", 171], ["'s", 176], ["hypothesis", 179], [",", 189], ["Lewy", 191], ["bodies", 196], ["first", 203], ["appear", 209], ["in", 216], ["the", 219], ["olfactory", 223], ["bulb", 233], ["or", 238], ["peripheral", 241], ["autonomic", 252], ["nervous", 262], ["system", 270], [".", 276], ["Lewy", 278], ["bodies", 283], ["in", 290], ["the", 293], ["peripheral", 297], ["autonomic", 308], ["nervous", 318], ["system", 326], ["ascend", 333], ["to", 340], ["dorsal", 343], ["motor", 350], ["nuclei", 356], ["of", 363], ["vagus", 366], ["nerve", 372], [",", 377], ["while", 379], ["those", 385], ["in", 391], ["the", 394], ["olfactory", 398], ["bulb", 408], ["expand", 413], ["to", 420], ["the", 423], ["limbic", 427], ["system", 434], [".", 440], ["Lewy", 442], ["bodies", 447], ["later", 454], ["attain", 460], ["the", 467], ["substantia", 471], ["nigra", 482], [".", 487], ["However", 489], [",", 496], ["it", 498], ["seems", 501], ["that", 507], ["Braak", 512], ["staging", 518], ["can", 526], ["not", 530], ["explain", 534], ["difference", 542], ["in", 553], ["severity", 556], ["of", 565], ["autonomic", 568], ["failure", 578], ["between", 586], ["DLB", 594], ["and", 598], ["PD", 602], [".", 604], ["As", 606], ["a", 609], ["possibility", 611], [",", 622], ["in", 624], ["DLB", 627], ["patients", 631], ["with", 640], ["significant", 645], ["autonomic", 657], ["failure", 667], [",", 674], ["Lewy", 676], ["bodies", 681], ["may", 688], ["have", 692], ["been", 697], ["localized", 702], ["to", 712], ["the", 715], ["peripheral", 719], ["autonomic", 730], ["nervous", 740], ["system", 748], ["in", 755], ["a", 758], ["long", 760], ["time", 765], ["before", 770], ["onset", 777], ["of", 783], ["dementia", 786], ["or", 795], ["parkinsonism", 798], [",", 810], ["and", 812], ["propagation", 816], ["of", 828], ["Lewy", 831], ["bodies", 836], ["into", 843], ["the", 848], ["central", 852], ["nervous", 860], ["system", 868], ["may", 875], ["be", 879], ["initiated", 882], ["by", 892], ["apparition", 895], ["of", 906], ["certain", 909], ["promotion", 917], ["factor", 927], [",", 933], ["such", 935], ["as", 940], ["ageing", 943], ["and", 950], ["amyloid", 954], ["-", 961], ["\u03b2", 962], [".", 963]]}
{"context": "Ehlers-Danlos syndrome type 4, the vascular type, is a rare, life-threatening inherited disorder of the connective tissue. Affected patients are at risk of arterial, bowel and uterine rupture during pregnancy. Generally, this syndrome remains undiagnosed until a sudden, acute presentation with organ rupture, and results in premature death, even if the patients survive the first and second major complications. An early diagnosis with genetic assays can help to plan the best treatment, which is often challenging due to the frailty of the arterial tissue. We report on a 28-year-old lady who presented with spontaneous rupture of a pseudoaneurysm of the posterior tibial artery.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "1a2e7aaf9e9148c98bfc8b68db1ea274", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[22, 23]], "char_spans": [[104, 120]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["type", 23], ["4", 28], [",", 29], ["the", 31], ["vascular", 35], ["type", 44], [",", 48], ["is", 50], ["a", 53], ["rare", 55], [",", 59], ["life", 61], ["-", 65], ["threatening", 66], ["inherited", 78], ["disorder", 88], ["of", 97], ["the", 100], ["connective", 104], ["tissue", 115], [".", 121], ["Affected", 123], ["patients", 132], ["are", 141], ["at", 145], ["risk", 148], ["of", 153], ["arterial", 156], [",", 164], ["bowel", 166], ["and", 172], ["uterine", 176], ["rupture", 184], ["during", 192], ["pregnancy", 199], [".", 208], ["Generally", 210], [",", 219], ["this", 221], ["syndrome", 226], ["remains", 235], ["undiagnosed", 243], ["until", 255], ["a", 261], ["sudden", 263], [",", 269], ["acute", 271], ["presentation", 277], ["with", 290], ["organ", 295], ["rupture", 301], [",", 308], ["and", 310], ["results", 314], ["in", 322], ["premature", 325], ["death", 335], [",", 340], ["even", 342], ["if", 347], ["the", 350], ["patients", 354], ["survive", 363], ["the", 371], ["first", 375], ["and", 381], ["second", 385], ["major", 392], ["complications", 398], [".", 411], ["An", 413], ["early", 416], ["diagnosis", 422], ["with", 432], ["genetic", 437], ["assays", 445], ["can", 452], ["help", 456], ["to", 461], ["plan", 464], ["the", 469], ["best", 473], ["treatment", 478], [",", 487], ["which", 489], ["is", 495], ["often", 498], ["challenging", 504], ["due", 516], ["to", 520], ["the", 523], ["frailty", 527], ["of", 535], ["the", 538], ["arterial", 542], ["tissue", 551], [".", 557], ["We", 559], ["report", 562], ["on", 569], ["a", 572], ["28-year", 574], ["-", 581], ["old", 582], ["lady", 586], ["who", 591], ["presented", 595], ["with", 605], ["spontaneous", 610], ["rupture", 622], ["of", 630], ["a", 633], ["pseudoaneurysm", 635], ["of", 650], ["the", 653], ["posterior", 657], ["tibial", 667], ["artery", 674], [".", 680]]}
{"context": "Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose <300\u00a0mg per day) due to intolerance, in comparison to optimal-dose imatinib (\u2265300\u00a0mg per day) in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The Kaplan-Meier estimates of the median time to complete cytogenetic response, major molecular response, and complete molecular response were longer for 31 patients receiving low-dose imatinib (360, 1360, and 1420\u00a0days, respectively) than 74 patients receiving optimal-dose imatinib (170, 420, and 720\u00a0days, respectively). However, the differences in response shrank over time and progression-free survival were comparable between the two groups. These findings suggest that long-term treatment with low-dose imatinib is an acceptable alternative for patients with intolerance to the optimal dose.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "169d1ca25e78425dbd60b6192286d3dd", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[4, 6]], "char_spans": [[23, 29]]}]}], "context_tokens": [["Imatinib", 0], ["was", 9], ["the", 13], ["first", 17], ["BCR", 23], ["-", 26], ["ABL", 27], ["tyrosine", 31], ["kinase", 40], ["inhibitor", 47], ["to", 57], ["become", 60], ["clinically", 67], ["available", 78], [".", 87], ["In", 89], ["this", 92], ["study", 97], [",", 102], ["we", 104], ["retrospectively", 107], ["evaluated", 123], ["the", 133], ["long", 137], ["-", 141], ["term", 142], ["efficacy", 147], ["of", 156], ["low", 159], ["-", 162], ["dose", 163], ["imatinib", 168], ["(", 177], ["final", 178], ["maintenance", 184], ["dose", 196], ["<", 201], ["300", 202], ["mg", 206], ["per", 209], ["day", 213], [")", 216], ["due", 218], ["to", 222], ["intolerance", 225], [",", 236], ["in", 238], ["comparison", 241], ["to", 252], ["optimal", 255], ["-", 262], ["dose", 263], ["imatinib", 268], ["(", 277], ["\u2265300", 278], ["mg", 283], ["per", 286], ["day", 290], [")", 293], ["in", 295], ["patients", 298], ["with", 307], ["Philadelphia", 312], ["chromosome", 325], ["-", 335], ["positive", 336], ["chronic", 345], ["myeloid", 353], ["leukemia", 361], ["in", 370], ["the", 373], ["chronic", 377], ["phase", 385], [".", 390], ["The", 392], ["Kaplan", 396], ["-", 402], ["Meier", 403], ["estimates", 409], ["of", 419], ["the", 422], ["median", 426], ["time", 433], ["to", 438], ["complete", 441], ["cytogenetic", 450], ["response", 462], [",", 470], ["major", 472], ["molecular", 478], ["response", 488], [",", 496], ["and", 498], ["complete", 502], ["molecular", 511], ["response", 521], ["were", 530], ["longer", 535], ["for", 542], ["31", 546], ["patients", 549], ["receiving", 558], ["low", 568], ["-", 571], ["dose", 572], ["imatinib", 577], ["(", 586], ["360", 587], [",", 590], ["1360", 592], [",", 596], ["and", 598], ["1420", 602], ["days", 607], [",", 611], ["respectively", 613], [")", 625], ["than", 627], ["74", 632], ["patients", 635], ["receiving", 644], ["optimal", 654], ["-", 661], ["dose", 662], ["imatinib", 667], ["(", 676], ["170", 677], [",", 680], ["420", 682], [",", 685], ["and", 687], ["720", 691], ["days", 695], [",", 699], ["respectively", 701], [")", 713], [".", 714], ["However", 716], [",", 723], ["the", 725], ["differences", 729], ["in", 741], ["response", 744], ["shrank", 753], ["over", 760], ["time", 765], ["and", 770], ["progression", 774], ["-", 785], ["free", 786], ["survival", 791], ["were", 800], ["comparable", 805], ["between", 816], ["the", 824], ["two", 828], ["groups", 832], [".", 838], ["These", 840], ["findings", 846], ["suggest", 855], ["that", 863], ["long", 868], ["-", 872], ["term", 873], ["treatment", 878], ["with", 888], ["low", 893], ["-", 896], ["dose", 897], ["imatinib", 902], ["is", 911], ["an", 914], ["acceptable", 917], ["alternative", 928], ["for", 940], ["patients", 944], ["with", 953], ["intolerance", 958], ["to", 970], ["the", 973], ["optimal", 977], ["dose", 985], [".", 989]]}
{"context": "Ataxin-3 (AT3) is the protein that triggers the inherited neurodegenerative disorder spinocerebellar ataxia type 3 when its polyglutamine (polyQ) stretch close to the C-terminus exceeds a critical length. AT3 consists of the N-terminal globular Josephin domain (JD) and the C-terminal disordered one. It cleaves isopeptide bonds between ubiquitin monomers, an event involved in protein quality control mechanisms. AT3 has been implicated in the pathway that sorts aggregated protein to aggresomes via microtubules, in which dynein and histone deacetylase 6 (HDAC6) also seem to be involved. By taking advantage of small angle X-ray scattering (SAXS) and surface plasmon resonance (SPR), we have investigated the interaction of AT3 with tubulin and HDAC6. Based on SAXS results, the AT3 oligomer, consisting of 6-7 subunits, tightly binds to the tubulin hexameric oligomer in a \"parallel\" fashion. By SPR analysis we have demonstrated that AT3 binds to tubulin dimer with a 50nM affinity. Binding fits with a Langmuir 1:1 model and involves a single binding interface. Nevertheless, the interaction surface consists of three distinct, discontinuous tubulin-binding regions (TBR), one located in the JD, and the two others in the disordered domain, upstream and downstream of the polyQ stretch. In the absence of any of the three TBRs, the affinity is drastically reduced. By SPR we have also provided the first evidence of direct binding of AT3 to HDAC6, with affinity in the range 0.1-1\u03bcM. These results shed light on the interactions among the components of the transport machinery that sorts aggregate protein to the aggresome, and pave the way to in vivo studies aimed at further clarifying their roles.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "ff352f0d6455402e93166f8e35e032b3", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0]], "char_spans": [[0, 7]]}]}], "context_tokens": [["Ataxin-3", 0], ["(", 9], ["AT3", 10], [")", 13], ["is", 15], ["the", 18], ["protein", 22], ["that", 30], ["triggers", 35], ["the", 44], ["inherited", 48], ["neurodegenerative", 58], ["disorder", 76], ["spinocerebellar", 85], ["ataxia", 101], ["type", 108], ["3", 113], ["when", 115], ["its", 120], ["polyglutamine", 124], ["(", 138], ["polyQ", 139], [")", 144], ["stretch", 146], ["close", 154], ["to", 160], ["the", 163], ["C", 167], ["-", 168], ["terminus", 169], ["exceeds", 178], ["a", 186], ["critical", 188], ["length", 197], [".", 203], ["AT3", 205], ["consists", 209], ["of", 218], ["the", 221], ["N", 225], ["-", 226], ["terminal", 227], ["globular", 236], ["Josephin", 245], ["domain", 254], ["(", 261], ["JD", 262], [")", 264], ["and", 266], ["the", 270], ["C", 274], ["-", 275], ["terminal", 276], ["disordered", 285], ["one", 296], [".", 299], ["It", 301], ["cleaves", 304], ["isopeptide", 312], ["bonds", 323], ["between", 329], ["ubiquitin", 337], ["monomers", 347], [",", 355], ["an", 357], ["event", 360], ["involved", 366], ["in", 375], ["protein", 378], ["quality", 386], ["control", 394], ["mechanisms", 402], [".", 412], ["AT3", 414], ["has", 418], ["been", 422], ["implicated", 427], ["in", 438], ["the", 441], ["pathway", 445], ["that", 453], ["sorts", 458], ["aggregated", 464], ["protein", 475], ["to", 483], ["aggresomes", 486], ["via", 497], ["microtubules", 501], [",", 513], ["in", 515], ["which", 518], ["dynein", 524], ["and", 531], ["histone", 535], ["deacetylase", 543], ["6", 555], ["(", 557], ["HDAC6", 558], [")", 563], ["also", 565], ["seem", 570], ["to", 575], ["be", 578], ["involved", 581], [".", 589], ["By", 591], ["taking", 594], ["advantage", 601], ["of", 611], ["small", 614], ["angle", 620], ["X", 626], ["-", 627], ["ray", 628], ["scattering", 632], ["(", 643], ["SAXS", 644], [")", 648], ["and", 650], ["surface", 654], ["plasmon", 662], ["resonance", 670], ["(", 680], ["SPR", 681], [")", 684], [",", 685], ["we", 687], ["have", 690], ["investigated", 695], ["the", 708], ["interaction", 712], ["of", 724], ["AT3", 727], ["with", 731], ["tubulin", 736], ["and", 744], ["HDAC6", 748], [".", 753], ["Based", 755], ["on", 761], ["SAXS", 764], ["results", 769], [",", 776], ["the", 778], ["AT3", 782], ["oligomer", 786], [",", 794], ["consisting", 796], ["of", 807], ["6", 810], ["-", 811], ["7", 812], ["subunits", 814], [",", 822], ["tightly", 824], ["binds", 832], ["to", 838], ["the", 841], ["tubulin", 845], ["hexameric", 853], ["oligomer", 863], ["in", 872], ["a", 875], ["\"", 877], ["parallel", 878], ["\"", 886], ["fashion", 888], [".", 895], ["By", 897], ["SPR", 900], ["analysis", 904], ["we", 913], ["have", 916], ["demonstrated", 921], ["that", 934], ["AT3", 939], ["binds", 943], ["to", 949], ["tubulin", 952], ["dimer", 960], ["with", 966], ["a", 971], ["50nM", 973], ["affinity", 978], [".", 986], ["Binding", 988], ["fits", 996], ["with", 1001], ["a", 1006], ["Langmuir", 1008], ["1:1", 1017], ["model", 1021], ["and", 1027], ["involves", 1031], ["a", 1040], ["single", 1042], ["binding", 1049], ["interface", 1057], [".", 1066], ["Nevertheless", 1068], [",", 1080], ["the", 1082], ["interaction", 1086], ["surface", 1098], ["consists", 1106], ["of", 1115], ["three", 1118], ["distinct", 1124], [",", 1132], ["discontinuous", 1134], ["tubulin", 1148], ["-", 1155], ["binding", 1156], ["regions", 1164], ["(", 1172], ["TBR", 1173], [")", 1176], [",", 1177], ["one", 1179], ["located", 1183], ["in", 1191], ["the", 1194], ["JD", 1198], [",", 1200], ["and", 1202], ["the", 1206], ["two", 1210], ["others", 1214], ["in", 1221], ["the", 1224], ["disordered", 1228], ["domain", 1239], [",", 1245], ["upstream", 1247], ["and", 1256], ["downstream", 1260], ["of", 1271], ["the", 1274], ["polyQ", 1278], ["stretch", 1284], [".", 1291], ["In", 1293], ["the", 1296], ["absence", 1300], ["of", 1308], ["any", 1311], ["of", 1315], ["the", 1318], ["three", 1322], ["TBRs", 1328], [",", 1332], ["the", 1334], ["affinity", 1338], ["is", 1347], ["drastically", 1350], ["reduced", 1362], [".", 1369], ["By", 1371], ["SPR", 1374], ["we", 1378], ["have", 1381], ["also", 1386], ["provided", 1391], ["the", 1400], ["first", 1404], ["evidence", 1410], ["of", 1419], ["direct", 1422], ["binding", 1429], ["of", 1437], ["AT3", 1440], ["to", 1444], ["HDAC6", 1447], [",", 1452], ["with", 1454], ["affinity", 1459], ["in", 1468], ["the", 1471], ["range", 1475], ["0.1", 1481], ["-", 1484], ["1\u03bcM.", 1485], ["These", 1490], ["results", 1496], ["shed", 1504], ["light", 1509], ["on", 1515], ["the", 1518], ["interactions", 1522], ["among", 1535], ["the", 1541], ["components", 1545], ["of", 1556], ["the", 1559], ["transport", 1563], ["machinery", 1573], ["that", 1583], ["sorts", 1588], ["aggregate", 1594], ["protein", 1604], ["to", 1612], ["the", 1615], ["aggresome", 1619], [",", 1628], ["and", 1630], ["pave", 1634], ["the", 1639], ["way", 1643], ["to", 1647], ["in", 1650], ["vivo", 1653], ["studies", 1658], ["aimed", 1666], ["at", 1672], ["further", 1675], ["clarifying", 1683], ["their", 1694], ["roles", 1700], [".", 1705]]}
{"context": "In eukaryotic cells, there are two sub-pathways of nucleotide excision repair (NER), the global genome (gg) NER and the transcription-coupled repair (TCR). TCR can preferentially remove the bulky DNA lesions located at the transcribed strand of a transcriptional active gene more rapidly than those at the untranscribed strand or overall genomic DNA. This strand-specific repair in a suitable restriction fragment is usually determined by alkaline gel electrophoresis followed by Southern blotting transfer and hybridization with an indirect end-labeled single-stranded probe. Here we describe a new method of TCR assay based on strand-specific-PCR (SS-PCR). Using this method, we have investigated the role of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a member of the phosphatidylinositol 3-kinase-related protein kinases (PIKK) family, in the TCR pathway of UV-induced DNA damage. Although depletion of DNA-PKcs sensitized HeLa cells to UV radiation, it did not affect the ggNER efficiency of UV-induced cyclobutane pyrimidine dimers (CPD) damage. We postulated that DNA-PKcs may involve in the TCR process. To test this hypothesis, we have firstly developed a novel method of TCR assay based on the strand-specific PCR technology with a set of smart primers, which allows the strand-specific amplification of a restricted gene fragment of UV radiation-damaged genomic DNA in mammalian cells. Using this new method, we confirmed that siRNA-mediated downregulation of Cockayne syndrome B resulted in a deficiency of TCR of the UV-damaged dihydrofolate reductase (DHFR) gene. In addition, DMSO-induced silencing of the c-myc gene led to a decreased TCR efficiency of UV radiation-damaged c-myc gene in HL60 cells. On the basis of the above methodology verification, we found that the depletion of DNA-PKcs mediated by siRNA significantly decreased the TCR capacity of repairing the UV-induced CPDs damage in DHFR gene in HeLa cells, indicating that DNA-PKcs may also be involved in the TCR pathway of DNA damage repair. By means of immunoprecipitation and MALDI-TOF-Mass spectrometric analysis, we have revealed the interaction of DNA-PKcs and cyclin T2, which is a subunit of the human transcription elongation factor (P-TEFb). While the P-TEFb complex can phosphorylate the serine 2 of the carboxyl-terminal domain (CTD) of RNA polymerase II and promote transcription elongation. A new method of TCR assay was developed based the strand-specific-PCR (SS-PCR). Our data suggest that DNA-PKcs plays a role in the TCR pathway of UV-damaged DNA. One possible mechanistic hypothesis is that DNA-PKcs may function through associating with CyclinT2/CDK9 (P-TEFb) to modulate the activity of RNA Pol II, which has already been identified as a key molecule recognizing and initializing TCR.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "bdc9cd8b282d4eb29e42242885c5b466", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[46, 47]], "char_spans": [[223, 240]]}]}], "context_tokens": [["In", 0], ["eukaryotic", 3], ["cells", 14], [",", 19], ["there", 21], ["are", 27], ["two", 31], ["sub", 35], ["-", 38], ["pathways", 39], ["of", 48], ["nucleotide", 51], ["excision", 62], ["repair", 71], ["(", 78], ["NER", 79], [")", 82], [",", 83], ["the", 85], ["global", 89], ["genome", 96], ["(", 103], ["gg", 104], [")", 106], ["NER", 108], ["and", 112], ["the", 116], ["transcription", 120], ["-", 133], ["coupled", 134], ["repair", 142], ["(", 149], ["TCR", 150], [")", 153], [".", 154], ["TCR", 156], ["can", 160], ["preferentially", 164], ["remove", 179], ["the", 186], ["bulky", 190], ["DNA", 196], ["lesions", 200], ["located", 208], ["at", 216], ["the", 219], ["transcribed", 223], ["strand", 235], ["of", 242], ["a", 245], ["transcriptional", 247], ["active", 263], ["gene", 270], ["more", 275], ["rapidly", 280], ["than", 288], ["those", 293], ["at", 299], ["the", 302], ["untranscribed", 306], ["strand", 320], ["or", 327], ["overall", 330], ["genomic", 338], ["DNA", 346], [".", 349], ["This", 351], ["strand", 356], ["-", 362], ["specific", 363], ["repair", 372], ["in", 379], ["a", 382], ["suitable", 384], ["restriction", 393], ["fragment", 405], ["is", 414], ["usually", 417], ["determined", 425], ["by", 436], ["alkaline", 439], ["gel", 448], ["electrophoresis", 452], ["followed", 468], ["by", 477], ["Southern", 480], ["blotting", 489], ["transfer", 498], ["and", 507], ["hybridization", 511], ["with", 525], ["an", 530], ["indirect", 533], ["end", 542], ["-", 545], ["labeled", 546], ["single", 554], ["-", 560], ["stranded", 561], ["probe", 570], [".", 575], ["Here", 577], ["we", 582], ["describe", 585], ["a", 594], ["new", 596], ["method", 600], ["of", 607], ["TCR", 610], ["assay", 614], ["based", 620], ["on", 626], ["strand", 629], ["-", 635], ["specific", 636], ["-", 644], ["PCR", 645], ["(", 649], ["SS", 650], ["-", 652], ["PCR", 653], [")", 656], [".", 657], ["Using", 659], ["this", 665], ["method", 670], [",", 676], ["we", 678], ["have", 681], ["investigated", 686], ["the", 699], ["role", 703], ["of", 708], ["DNA", 711], ["-", 714], ["dependent", 715], ["protein", 725], ["kinase", 733], ["catalytic", 740], ["subunit", 750], ["(", 758], ["DNA", 759], ["-", 762], ["PKcs", 763], [")", 767], [",", 768], ["a", 770], ["member", 772], ["of", 779], ["the", 782], ["phosphatidylinositol", 786], ["3-kinase", 807], ["-", 815], ["related", 816], ["protein", 824], ["kinases", 832], ["(", 840], ["PIKK", 841], [")", 845], ["family", 847], [",", 853], ["in", 855], ["the", 858], ["TCR", 862], ["pathway", 866], ["of", 874], ["UV", 877], ["-", 879], ["induced", 880], ["DNA", 888], ["damage", 892], [".", 898], ["Although", 900], ["depletion", 909], ["of", 919], ["DNA", 922], ["-", 925], ["PKcs", 926], ["sensitized", 931], ["HeLa", 942], ["cells", 947], ["to", 953], ["UV", 956], ["radiation", 959], [",", 968], ["it", 970], ["did", 973], ["not", 977], ["affect", 981], ["the", 988], ["ggNER", 992], ["efficiency", 998], ["of", 1009], ["UV", 1012], ["-", 1014], ["induced", 1015], ["cyclobutane", 1023], ["pyrimidine", 1035], ["dimers", 1046], ["(", 1053], ["CPD", 1054], [")", 1057], ["damage", 1059], [".", 1065], ["We", 1067], ["postulated", 1070], ["that", 1081], ["DNA", 1086], ["-", 1089], ["PKcs", 1090], ["may", 1095], ["involve", 1099], ["in", 1107], ["the", 1110], ["TCR", 1114], ["process", 1118], [".", 1125], ["To", 1127], ["test", 1130], ["this", 1135], ["hypothesis", 1140], [",", 1150], ["we", 1152], ["have", 1155], ["firstly", 1160], ["developed", 1168], ["a", 1178], ["novel", 1180], ["method", 1186], ["of", 1193], ["TCR", 1196], ["assay", 1200], ["based", 1206], ["on", 1212], ["the", 1215], ["strand", 1219], ["-", 1225], ["specific", 1226], ["PCR", 1235], ["technology", 1239], ["with", 1250], ["a", 1255], ["set", 1257], ["of", 1261], ["smart", 1264], ["primers", 1270], [",", 1277], ["which", 1279], ["allows", 1285], ["the", 1292], ["strand", 1296], ["-", 1302], ["specific", 1303], ["amplification", 1312], ["of", 1326], ["a", 1329], ["restricted", 1331], ["gene", 1342], ["fragment", 1347], ["of", 1356], ["UV", 1359], ["radiation", 1362], ["-", 1371], ["damaged", 1372], ["genomic", 1380], ["DNA", 1388], ["in", 1392], ["mammalian", 1395], ["cells", 1405], [".", 1410], ["Using", 1412], ["this", 1418], ["new", 1423], ["method", 1427], [",", 1433], ["we", 1435], ["confirmed", 1438], ["that", 1448], ["siRNA", 1453], ["-", 1458], ["mediated", 1459], ["downregulation", 1468], ["of", 1483], ["Cockayne", 1486], ["syndrome", 1495], ["B", 1504], ["resulted", 1506], ["in", 1515], ["a", 1518], ["deficiency", 1520], ["of", 1531], ["TCR", 1534], ["of", 1538], ["the", 1541], ["UV", 1545], ["-", 1547], ["damaged", 1548], ["dihydrofolate", 1556], ["reductase", 1570], ["(", 1580], ["DHFR", 1581], [")", 1585], ["gene", 1587], [".", 1591], ["In", 1593], ["addition", 1596], [",", 1604], ["DMSO", 1606], ["-", 1610], ["induced", 1611], ["silencing", 1619], ["of", 1629], ["the", 1632], ["c", 1636], ["-", 1637], ["myc", 1638], ["gene", 1642], ["led", 1647], ["to", 1651], ["a", 1654], ["decreased", 1656], ["TCR", 1666], ["efficiency", 1670], ["of", 1681], ["UV", 1684], ["radiation", 1687], ["-", 1696], ["damaged", 1697], ["c", 1705], ["-", 1706], ["myc", 1707], ["gene", 1711], ["in", 1716], ["HL60", 1719], ["cells", 1724], [".", 1729], ["On", 1731], ["the", 1734], ["basis", 1738], ["of", 1744], ["the", 1747], ["above", 1751], ["methodology", 1757], ["verification", 1769], [",", 1781], ["we", 1783], ["found", 1786], ["that", 1792], ["the", 1797], ["depletion", 1801], ["of", 1811], ["DNA", 1814], ["-", 1817], ["PKcs", 1818], ["mediated", 1823], ["by", 1832], ["siRNA", 1835], ["significantly", 1841], ["decreased", 1855], ["the", 1865], ["TCR", 1869], ["capacity", 1873], ["of", 1882], ["repairing", 1885], ["the", 1895], ["UV", 1899], ["-", 1901], ["induced", 1902], ["CPDs", 1910], ["damage", 1915], ["in", 1922], ["DHFR", 1925], ["gene", 1930], ["in", 1935], ["HeLa", 1938], ["cells", 1943], [",", 1948], ["indicating", 1950], ["that", 1961], ["DNA", 1966], ["-", 1969], ["PKcs", 1970], ["may", 1975], ["also", 1979], ["be", 1984], ["involved", 1987], ["in", 1996], ["the", 1999], ["TCR", 2003], ["pathway", 2007], ["of", 2015], ["DNA", 2018], ["damage", 2022], ["repair", 2029], [".", 2035], ["By", 2037], ["means", 2040], ["of", 2046], ["immunoprecipitation", 2049], ["and", 2069], ["MALDI", 2073], ["-", 2078], ["TOF", 2079], ["-", 2082], ["Mass", 2083], ["spectrometric", 2088], ["analysis", 2102], [",", 2110], ["we", 2112], ["have", 2115], ["revealed", 2120], ["the", 2129], ["interaction", 2133], ["of", 2145], ["DNA", 2148], ["-", 2151], ["PKcs", 2152], ["and", 2157], ["cyclin", 2161], ["T2", 2168], [",", 2170], ["which", 2172], ["is", 2178], ["a", 2181], ["subunit", 2183], ["of", 2191], ["the", 2194], ["human", 2198], ["transcription", 2204], ["elongation", 2218], ["factor", 2229], ["(", 2236], ["P", 2237], ["-", 2238], ["TEFb", 2239], [")", 2243], [".", 2244], ["While", 2246], ["the", 2252], ["P", 2256], ["-", 2257], ["TEFb", 2258], ["complex", 2263], ["can", 2271], ["phosphorylate", 2275], ["the", 2289], ["serine", 2293], ["2", 2300], ["of", 2302], ["the", 2305], ["carboxyl", 2309], ["-", 2317], ["terminal", 2318], ["domain", 2327], ["(", 2334], ["CTD", 2335], [")", 2338], ["of", 2340], ["RNA", 2343], ["polymerase", 2347], ["II", 2358], ["and", 2361], ["promote", 2365], ["transcription", 2373], ["elongation", 2387], [".", 2397], ["A", 2399], ["new", 2401], ["method", 2405], ["of", 2412], ["TCR", 2415], ["assay", 2419], ["was", 2425], ["developed", 2429], ["based", 2439], ["the", 2445], ["strand", 2449], ["-", 2455], ["specific", 2456], ["-", 2464], ["PCR", 2465], ["(", 2469], ["SS", 2470], ["-", 2472], ["PCR", 2473], [")", 2476], [".", 2477], ["Our", 2479], ["data", 2483], ["suggest", 2488], ["that", 2496], ["DNA", 2501], ["-", 2504], ["PKcs", 2505], ["plays", 2510], ["a", 2516], ["role", 2518], ["in", 2523], ["the", 2526], ["TCR", 2530], ["pathway", 2534], ["of", 2542], ["UV", 2545], ["-", 2547], ["damaged", 2548], ["DNA", 2556], [".", 2559], ["One", 2561], ["possible", 2565], ["mechanistic", 2574], ["hypothesis", 2586], ["is", 2597], ["that", 2600], ["DNA", 2605], ["-", 2608], ["PKcs", 2609], ["may", 2614], ["function", 2618], ["through", 2627], ["associating", 2635], ["with", 2647], ["CyclinT2/CDK9", 2652], ["(", 2666], ["P", 2667], ["-", 2668], ["TEFb", 2669], [")", 2673], ["to", 2675], ["modulate", 2678], ["the", 2687], ["activity", 2691], ["of", 2700], ["RNA", 2703], ["Pol", 2707], ["II", 2711], [",", 2713], ["which", 2715], ["has", 2721], ["already", 2725], ["been", 2733], ["identified", 2738], ["as", 2749], ["a", 2752], ["key", 2754], ["molecule", 2758], ["recognizing", 2767], ["and", 2779], ["initializing", 2783], ["TCR", 2796], [".", 2799]]}
{"context": "The Long QT syndrome (LQTS) is a relatively rare disorder. It has a major clinical impact as affected individuals are prone to syncope and sudden arrhythmogenic cardiac death. The LQTS comprises three groups of patients. The Jervell-Lange-Nielsen syndrome is characterized by an autosomal recessive pattern of inheritance and congenital neural deafness. The Romano-Ward syndrome shows an autosomal dominant pattern of inheritance and normal hearing. Patients with the sporadic form of LQTS have no evidence of familial transmission and have normal hearing. Imbalance of sympathetic cardiac innervation with predominance of the left stellate ganglion and an intrinsic myocardial defect leading to early afterdepolarization are the two pathogenetic mechanisms of LQTS discussed today. More recently a genetic basis for the Romano-Ward LQTS has been reported. The genetic linkage to the Harvey ras-1 gene provides the basis for a new hypothesis that an impairment of guanine nucleotide binding proteins is responsible for symptoms observed in LQTS. This paper discusses the genetic basis, pathology and pathophysiology of LQTS and tries to unify the different theories.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "26694e93ebbc4962895a9d5377a2e4e8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[68, 69]], "char_spans": [[388, 405]]}]}], "context_tokens": [["The", 0], ["Long", 4], ["QT", 9], ["syndrome", 12], ["(", 21], ["LQTS", 22], [")", 26], ["is", 28], ["a", 31], ["relatively", 33], ["rare", 44], ["disorder", 49], [".", 57], ["It", 59], ["has", 62], ["a", 66], ["major", 68], ["clinical", 74], ["impact", 83], ["as", 90], ["affected", 93], ["individuals", 102], ["are", 114], ["prone", 118], ["to", 124], ["syncope", 127], ["and", 135], ["sudden", 139], ["arrhythmogenic", 146], ["cardiac", 161], ["death", 169], [".", 174], ["The", 176], ["LQTS", 180], ["comprises", 185], ["three", 195], ["groups", 201], ["of", 208], ["patients", 211], [".", 219], ["The", 221], ["Jervell", 225], ["-", 232], ["Lange", 233], ["-", 238], ["Nielsen", 239], ["syndrome", 247], ["is", 256], ["characterized", 259], ["by", 273], ["an", 276], ["autosomal", 279], ["recessive", 289], ["pattern", 299], ["of", 307], ["inheritance", 310], ["and", 322], ["congenital", 326], ["neural", 337], ["deafness", 344], [".", 352], ["The", 354], ["Romano", 358], ["-", 364], ["Ward", 365], ["syndrome", 370], ["shows", 379], ["an", 385], ["autosomal", 388], ["dominant", 398], ["pattern", 407], ["of", 415], ["inheritance", 418], ["and", 430], ["normal", 434], ["hearing", 441], [".", 448], ["Patients", 450], ["with", 459], ["the", 464], ["sporadic", 468], ["form", 477], ["of", 482], ["LQTS", 485], ["have", 490], ["no", 495], ["evidence", 498], ["of", 507], ["familial", 510], ["transmission", 519], ["and", 532], ["have", 536], ["normal", 541], ["hearing", 548], [".", 555], ["Imbalance", 557], ["of", 567], ["sympathetic", 570], ["cardiac", 582], ["innervation", 590], ["with", 602], ["predominance", 607], ["of", 620], ["the", 623], ["left", 627], ["stellate", 632], ["ganglion", 641], ["and", 650], ["an", 654], ["intrinsic", 657], ["myocardial", 667], ["defect", 678], ["leading", 685], ["to", 693], ["early", 696], ["afterdepolarization", 702], ["are", 722], ["the", 726], ["two", 730], ["pathogenetic", 734], ["mechanisms", 747], ["of", 758], ["LQTS", 761], ["discussed", 766], ["today", 776], [".", 781], ["More", 783], ["recently", 788], ["a", 797], ["genetic", 799], ["basis", 807], ["for", 813], ["the", 817], ["Romano", 821], ["-", 827], ["Ward", 828], ["LQTS", 833], ["has", 838], ["been", 842], ["reported", 847], [".", 855], ["The", 857], ["genetic", 861], ["linkage", 869], ["to", 877], ["the", 880], ["Harvey", 884], ["ras-1", 891], ["gene", 897], ["provides", 902], ["the", 911], ["basis", 915], ["for", 921], ["a", 925], ["new", 927], ["hypothesis", 931], ["that", 942], ["an", 947], ["impairment", 950], ["of", 961], ["guanine", 964], ["nucleotide", 972], ["binding", 983], ["proteins", 991], ["is", 1000], ["responsible", 1003], ["for", 1015], ["symptoms", 1019], ["observed", 1028], ["in", 1037], ["LQTS", 1040], [".", 1044], ["This", 1046], ["paper", 1051], ["discusses", 1057], ["the", 1067], ["genetic", 1071], ["basis", 1079], [",", 1084], ["pathology", 1086], ["and", 1096], ["pathophysiology", 1100], ["of", 1116], ["LQTS", 1119], ["and", 1124], ["tries", 1128], ["to", 1134], ["unify", 1137], ["the", 1143], ["different", 1147], ["theories", 1157], [".", 1165]]}
{"context": "Shprintzen-Goldberg syndrome is one of a group of disorders characterized by craniosynostosis and marfanoid habitus. Eleven cases were reported previously. We present 4 new patients and review one of the patients of the original report of Shprintzen and Goldberg [1982: J Craniofac Genet Dev Biol 2:65-74], 15 years later. The clinical and radiologic findings on our patients are compared with those of the previously reported patients and also with those of Furlong et al. [1987: Am J Med Genet 26:599-604] and Lacombe and Battin [1993: Clin Dysmorphol 2: 220-224], who share many of the characteristics of Shprintzen-Goldberg syndrome. Some of the clinical data are helpful in determining if the patients of Furlong et al. [1987: Am J Med Genet 26:599-604] and Lacombe and Battin [1993: Clin Dysmorphol 2: 220-224] have a separate syndrome or represent a variant of Shprintzen-Goldberg syndrome. However, radiologic investigations appear to be more specific, since an abnormality of the first and second cervical vertebrae, hydrocephalus, dilatation of the lateral ventricles, and a Chiari-I malformation of the brain were found only in the patients with Shprintzen-Goldberg syndrome. The apparently diagnostic findings of the 15 patients with this syndrome may be helpful in differentiating between Shprintzen-Goldberg syndrome and other syndromes with craniosynostosis and marfanoid habitus.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "3dfda990261e42298551bc5ea767d706", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[257, 257], [13, 13]], "char_spans": [[1356, 1371], [77, 92]]}]}], "context_tokens": [["Shprintzen", 0], ["-", 10], ["Goldberg", 11], ["syndrome", 20], ["is", 29], ["one", 32], ["of", 36], ["a", 39], ["group", 41], ["of", 47], ["disorders", 50], ["characterized", 60], ["by", 74], ["craniosynostosis", 77], ["and", 94], ["marfanoid", 98], ["habitus", 108], [".", 115], ["Eleven", 117], ["cases", 124], ["were", 130], ["reported", 135], ["previously", 144], [".", 154], ["We", 156], ["present", 159], ["4", 167], ["new", 169], ["patients", 173], ["and", 182], ["review", 186], ["one", 193], ["of", 197], ["the", 200], ["patients", 204], ["of", 213], ["the", 216], ["original", 220], ["report", 229], ["of", 236], ["Shprintzen", 239], ["and", 250], ["Goldberg", 254], ["[", 263], ["1982", 264], [":", 268], ["J", 270], ["Craniofac", 272], ["Genet", 282], ["Dev", 288], ["Biol", 292], ["2:65", 297], ["-", 301], ["74", 302], ["]", 304], [",", 305], ["15", 307], ["years", 310], ["later", 316], [".", 321], ["The", 323], ["clinical", 327], ["and", 336], ["radiologic", 340], ["findings", 351], ["on", 360], ["our", 363], ["patients", 367], ["are", 376], ["compared", 380], ["with", 389], ["those", 394], ["of", 400], ["the", 403], ["previously", 407], ["reported", 418], ["patients", 427], ["and", 436], ["also", 440], ["with", 445], ["those", 450], ["of", 456], ["Furlong", 459], ["et", 467], ["al", 470], [".", 472], ["[", 474], ["1987", 475], [":", 479], ["Am", 481], ["J", 484], ["Med", 486], ["Genet", 490], ["26:599", 496], ["-", 502], ["604", 503], ["]", 506], ["and", 508], ["Lacombe", 512], ["and", 520], ["Battin", 524], ["[", 531], ["1993", 532], [":", 536], ["Clin", 538], ["Dysmorphol", 543], ["2", 554], [":", 555], ["220", 557], ["-", 560], ["224", 561], ["]", 564], [",", 565], ["who", 567], ["share", 571], ["many", 577], ["of", 582], ["the", 585], ["characteristics", 589], ["of", 605], ["Shprintzen", 608], ["-", 618], ["Goldberg", 619], ["syndrome", 628], [".", 636], ["Some", 638], ["of", 643], ["the", 646], ["clinical", 650], ["data", 659], ["are", 664], ["helpful", 668], ["in", 676], ["determining", 679], ["if", 691], ["the", 694], ["patients", 698], ["of", 707], ["Furlong", 710], ["et", 718], ["al", 721], [".", 723], ["[", 725], ["1987", 726], [":", 730], ["Am", 732], ["J", 735], ["Med", 737], ["Genet", 741], ["26:599", 747], ["-", 753], ["604", 754], ["]", 757], ["and", 759], ["Lacombe", 763], ["and", 771], ["Battin", 775], ["[", 782], ["1993", 783], [":", 787], ["Clin", 789], ["Dysmorphol", 794], ["2", 805], [":", 806], ["220", 808], ["-", 811], ["224", 812], ["]", 815], ["have", 817], ["a", 822], ["separate", 824], ["syndrome", 833], ["or", 842], ["represent", 845], ["a", 855], ["variant", 857], ["of", 865], ["Shprintzen", 868], ["-", 878], ["Goldberg", 879], ["syndrome", 888], [".", 896], ["However", 898], [",", 905], ["radiologic", 907], ["investigations", 918], ["appear", 933], ["to", 940], ["be", 943], ["more", 946], ["specific", 951], [",", 959], ["since", 961], ["an", 967], ["abnormality", 970], ["of", 982], ["the", 985], ["first", 989], ["and", 995], ["second", 999], ["cervical", 1006], ["vertebrae", 1015], [",", 1024], ["hydrocephalus", 1026], [",", 1039], ["dilatation", 1041], ["of", 1052], ["the", 1055], ["lateral", 1059], ["ventricles", 1067], [",", 1077], ["and", 1079], ["a", 1083], ["Chiari", 1085], ["-", 1091], ["I", 1092], ["malformation", 1094], ["of", 1107], ["the", 1110], ["brain", 1114], ["were", 1120], ["found", 1125], ["only", 1131], ["in", 1136], ["the", 1139], ["patients", 1143], ["with", 1152], ["Shprintzen", 1157], ["-", 1167], ["Goldberg", 1168], ["syndrome", 1177], [".", 1185], ["The", 1187], ["apparently", 1191], ["diagnostic", 1202], ["findings", 1213], ["of", 1222], ["the", 1225], ["15", 1229], ["patients", 1232], ["with", 1241], ["this", 1246], ["syndrome", 1251], ["may", 1260], ["be", 1264], ["helpful", 1267], ["in", 1275], ["differentiating", 1278], ["between", 1294], ["Shprintzen", 1302], ["-", 1312], ["Goldberg", 1313], ["syndrome", 1322], ["and", 1331], ["other", 1335], ["syndromes", 1341], ["with", 1351], ["craniosynostosis", 1356], ["and", 1373], ["marfanoid", 1377], ["habitus", 1387], [".", 1394]]}
{"context": "The Romano-Ward long-QT Syndrome (LQTS) is an autosomal dominant inherited trait characterized by prolonged QT interval on ECG, life-threatening arrhythmias, syncope, and sudden death in affected individuals. A gene responsible for this disorder has been shown to be linked to the Harvey ras-1 locus (H-ras-1) DNA marker on the short arm of chromosome 11 (11p) in 7 families. The purpose of this study was to determine, by analyzing 23 families with LQTS for linkage to chromosome 11p, whether evidence exists for more than one gene causing LQTS (ie, locus heterogeneity). Twenty-three families (262 family members) were clinically evaluated using medical histories, ECGs, and Holter recordings. Each corrected QT interval (QTc) were determined using Bazett's formula. Blood for DNA extraction and cell line immortalization was obtained after informed consent. Southern blotting and polymerase chain reaction were performed, and linkage analysis carried out using the LINKAGE computer program (v 5.03). Genetic heterogeneity was determined using the HOMOG 2 (v 2.51) computer program. Twenty-three families were studied for evidence of linkage to chromosome 11p using the H-ras-1 locus probe pTBB-2 and multiple flanking markers, including tyrosine hydroxylase (TH). Two-point linkage analysis using pTBB-2 and TH markers was consistent with linkage in 15 of 23 families, with the maximum single-family LOD score of +3.038 occurring at theta = 0. However, 8 of 23 families had negative LOD scores, with the values in 4 families being less than -2 at theta = 0, consistent with exclusion of linkage. Analysis with the HOMOG program was consistent with genetic heterogeneity (P < .0001). Multipoint linkage data using pTBB-2 and TH were also examined for evidence of heterogeneity. HOMOG analysis of multipoint LOD scores from 100 cM surrounding the H-ras-1 locus also supported heterogeneity (P < .001). In the 23 families with LQTS analyzed for linkage to the H-ras-1 locus on chromosome 11p15.5, 15 of 23 families had LOD scores consistent with linkage. The remaining 8 of 23 families had negative LOD scores, 4 of which were definitively excluded from linkage. Thus, genetic heterogeneity is definitively (P < .001) demonstrated for this disorder.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "16cda57d6f444810a77096b293729095", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[13, 14]], "char_spans": [[46, 63]]}]}], "context_tokens": [["The", 0], ["Romano", 4], ["-", 10], ["Ward", 11], ["long", 16], ["-", 20], ["QT", 21], ["Syndrome", 24], ["(", 33], ["LQTS", 34], [")", 38], ["is", 40], ["an", 43], ["autosomal", 46], ["dominant", 56], ["inherited", 65], ["trait", 75], ["characterized", 81], ["by", 95], ["prolonged", 98], ["QT", 108], ["interval", 111], ["on", 120], ["ECG", 123], [",", 126], ["life", 128], ["-", 132], ["threatening", 133], ["arrhythmias", 145], [",", 156], ["syncope", 158], [",", 165], ["and", 167], ["sudden", 171], ["death", 178], ["in", 184], ["affected", 187], ["individuals", 196], [".", 207], ["A", 209], ["gene", 211], ["responsible", 216], ["for", 228], ["this", 232], ["disorder", 237], ["has", 246], ["been", 250], ["shown", 255], ["to", 261], ["be", 264], ["linked", 267], ["to", 274], ["the", 277], ["Harvey", 281], ["ras-1", 288], ["locus", 294], ["(", 300], ["H", 301], ["-", 302], ["ras-1", 303], [")", 308], ["DNA", 310], ["marker", 314], ["on", 321], ["the", 324], ["short", 328], ["arm", 334], ["of", 338], ["chromosome", 341], ["11", 352], ["(", 355], ["11p", 356], [")", 359], ["in", 361], ["7", 364], ["families", 366], [".", 374], ["The", 376], ["purpose", 380], ["of", 388], ["this", 391], ["study", 396], ["was", 402], ["to", 406], ["determine", 409], [",", 418], ["by", 420], ["analyzing", 423], ["23", 433], ["families", 436], ["with", 445], ["LQTS", 450], ["for", 455], ["linkage", 459], ["to", 467], ["chromosome", 470], ["11p", 481], [",", 484], ["whether", 486], ["evidence", 494], ["exists", 503], ["for", 510], ["more", 514], ["than", 519], ["one", 524], ["gene", 528], ["causing", 533], ["LQTS", 541], ["(", 546], ["ie", 547], [",", 549], ["locus", 551], ["heterogeneity", 557], [")", 570], [".", 571], ["Twenty", 573], ["-", 579], ["three", 580], ["families", 586], ["(", 595], ["262", 596], ["family", 600], ["members", 607], [")", 614], ["were", 616], ["clinically", 621], ["evaluated", 632], ["using", 642], ["medical", 648], ["histories", 656], [",", 665], ["ECGs", 667], [",", 671], ["and", 673], ["Holter", 677], ["recordings", 684], [".", 694], ["Each", 696], ["corrected", 701], ["QT", 711], ["interval", 714], ["(", 723], ["QTc", 724], [")", 727], ["were", 729], ["determined", 734], ["using", 745], ["Bazett", 751], ["'s", 757], ["formula", 760], [".", 767], ["Blood", 769], ["for", 775], ["DNA", 779], ["extraction", 783], ["and", 794], ["cell", 798], ["line", 803], ["immortalization", 808], ["was", 824], ["obtained", 828], ["after", 837], ["informed", 843], ["consent", 852], [".", 859], ["Southern", 861], ["blotting", 870], ["and", 879], ["polymerase", 883], ["chain", 894], ["reaction", 900], ["were", 909], ["performed", 914], [",", 923], ["and", 925], ["linkage", 929], ["analysis", 937], ["carried", 946], ["out", 954], ["using", 958], ["the", 964], ["LINKAGE", 968], ["computer", 976], ["program", 985], ["(", 993], ["v", 994], ["5.03", 996], [")", 1000], [".", 1001], ["Genetic", 1003], ["heterogeneity", 1011], ["was", 1025], ["determined", 1029], ["using", 1040], ["the", 1046], ["HOMOG", 1050], ["2", 1056], ["(", 1058], ["v", 1059], ["2.51", 1061], [")", 1065], ["computer", 1067], ["program", 1076], [".", 1083], ["Twenty", 1085], ["-", 1091], ["three", 1092], ["families", 1098], ["were", 1107], ["studied", 1112], ["for", 1120], ["evidence", 1124], ["of", 1133], ["linkage", 1136], ["to", 1144], ["chromosome", 1147], ["11p", 1158], ["using", 1162], ["the", 1168], ["H", 1172], ["-", 1173], ["ras-1", 1174], ["locus", 1180], ["probe", 1186], ["pTBB-2", 1192], ["and", 1199], ["multiple", 1203], ["flanking", 1212], ["markers", 1221], [",", 1228], ["including", 1230], ["tyrosine", 1240], ["hydroxylase", 1249], ["(", 1261], ["TH", 1262], [")", 1264], [".", 1265], ["Two", 1267], ["-", 1270], ["point", 1271], ["linkage", 1277], ["analysis", 1285], ["using", 1294], ["pTBB-2", 1300], ["and", 1307], ["TH", 1311], ["markers", 1314], ["was", 1322], ["consistent", 1326], ["with", 1337], ["linkage", 1342], ["in", 1350], ["15", 1353], ["of", 1356], ["23", 1359], ["families", 1362], [",", 1370], ["with", 1372], ["the", 1377], ["maximum", 1381], ["single", 1389], ["-", 1395], ["family", 1396], ["LOD", 1403], ["score", 1407], ["of", 1413], ["+3.038", 1416], ["occurring", 1423], ["at", 1433], ["theta", 1436], ["=", 1442], ["0", 1444], [".", 1445], ["However", 1447], [",", 1454], ["8", 1456], ["of", 1458], ["23", 1461], ["families", 1464], ["had", 1473], ["negative", 1477], ["LOD", 1486], ["scores", 1490], [",", 1496], ["with", 1498], ["the", 1503], ["values", 1507], ["in", 1514], ["4", 1517], ["families", 1519], ["being", 1528], ["less", 1534], ["than", 1539], ["-2", 1544], ["at", 1547], ["theta", 1550], ["=", 1556], ["0", 1558], [",", 1559], ["consistent", 1561], ["with", 1572], ["exclusion", 1577], ["of", 1587], ["linkage", 1590], [".", 1597], ["Analysis", 1599], ["with", 1608], ["the", 1613], ["HOMOG", 1617], ["program", 1623], ["was", 1631], ["consistent", 1635], ["with", 1646], ["genetic", 1651], ["heterogeneity", 1659], ["(", 1673], ["P", 1674], ["<", 1676], [".0001", 1678], [")", 1683], [".", 1684], ["Multipoint", 1686], ["linkage", 1697], ["data", 1705], ["using", 1710], ["pTBB-2", 1716], ["and", 1723], ["TH", 1727], ["were", 1730], ["also", 1735], ["examined", 1740], ["for", 1749], ["evidence", 1753], ["of", 1762], ["heterogeneity", 1765], [".", 1778], ["HOMOG", 1780], ["analysis", 1786], ["of", 1795], ["multipoint", 1798], ["LOD", 1809], ["scores", 1813], ["from", 1820], ["100", 1825], ["cM", 1829], ["surrounding", 1832], ["the", 1844], ["H", 1848], ["-", 1849], ["ras-1", 1850], ["locus", 1856], ["also", 1862], ["supported", 1867], ["heterogeneity", 1877], ["(", 1891], ["P", 1892], ["<", 1894], [".001", 1896], [")", 1900], [".", 1901], ["In", 1903], ["the", 1906], ["23", 1910], ["families", 1913], ["with", 1922], ["LQTS", 1927], ["analyzed", 1932], ["for", 1941], ["linkage", 1945], ["to", 1953], ["the", 1956], ["H", 1960], ["-", 1961], ["ras-1", 1962], ["locus", 1968], ["on", 1974], ["chromosome", 1977], ["11p15.5", 1988], [",", 1995], ["15", 1997], ["of", 2000], ["23", 2003], ["families", 2006], ["had", 2015], ["LOD", 2019], ["scores", 2023], ["consistent", 2030], ["with", 2041], ["linkage", 2046], [".", 2053], ["The", 2055], ["remaining", 2059], ["8", 2069], ["of", 2071], ["23", 2074], ["families", 2077], ["had", 2086], ["negative", 2090], ["LOD", 2099], ["scores", 2103], [",", 2109], ["4", 2111], ["of", 2113], ["which", 2116], ["were", 2122], ["definitively", 2127], ["excluded", 2140], ["from", 2149], ["linkage", 2154], [".", 2161], ["Thus", 2163], [",", 2167], ["genetic", 2169], ["heterogeneity", 2177], ["is", 2191], ["definitively", 2194], ["(", 2207], ["P", 2208], ["<", 2210], [".001", 2212], [")", 2216], ["demonstrated", 2218], ["for", 2231], ["this", 2235], ["disorder", 2240], [".", 2248]]}
{"context": "The McLeod syndrome is a rare X-linked recessive disorder characterized by blood group, neuromuscular and haematopoietic abnormalities. It is caused by XK gene defects and may include large deletions in the Xp21 region. Analysis of three unrelated McLeod patients for the presence of the XK, DMD, CYBB, ETX1, RPGR and OTC loci, as well as for the DXS709 marker, revealed deletions from the 39th exon of DMD to the ETX1 locus (patient Be), from the XK to RPGR loci (patient Bi) and from the XK to CYBB loci (patient Lh). All three patients normally expressed the Lutheran (Lu) red cell antigens, thus excluding the interval between the RPGR and DMD genes as site of the XS locus, previously mapped to the Xp21.2-Xq21.1 region and thought to regulate the expression of the LU blood group gene on chromosome 19.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "e6169de72a8e46a8bfd4b79a1daa5dc7", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[100, 100], [89, 89], [25, 25], [49, 49]], "char_spans": [[490, 491], [448, 449], [152, 153], [288, 289]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["a", 23], ["rare", 25], ["X", 30], ["-", 31], ["linked", 32], ["recessive", 39], ["disorder", 49], ["characterized", 58], ["by", 72], ["blood", 75], ["group", 81], [",", 86], ["neuromuscular", 88], ["and", 102], ["haematopoietic", 106], ["abnormalities", 121], [".", 134], ["It", 136], ["is", 139], ["caused", 142], ["by", 149], ["XK", 152], ["gene", 155], ["defects", 160], ["and", 168], ["may", 172], ["include", 176], ["large", 184], ["deletions", 190], ["in", 200], ["the", 203], ["Xp21", 207], ["region", 212], [".", 218], ["Analysis", 220], ["of", 229], ["three", 232], ["unrelated", 238], ["McLeod", 248], ["patients", 255], ["for", 264], ["the", 268], ["presence", 272], ["of", 281], ["the", 284], ["XK", 288], [",", 290], ["DMD", 292], [",", 295], ["CYBB", 297], [",", 301], ["ETX1", 303], [",", 307], ["RPGR", 309], ["and", 314], ["OTC", 318], ["loci", 322], [",", 326], ["as", 328], ["well", 331], ["as", 336], ["for", 339], ["the", 343], ["DXS709", 347], ["marker", 354], [",", 360], ["revealed", 362], ["deletions", 371], ["from", 381], ["the", 386], ["39th", 390], ["exon", 395], ["of", 400], ["DMD", 403], ["to", 407], ["the", 410], ["ETX1", 414], ["locus", 419], ["(", 425], ["patient", 426], ["Be", 434], [")", 436], [",", 437], ["from", 439], ["the", 444], ["XK", 448], ["to", 451], ["RPGR", 454], ["loci", 459], ["(", 464], ["patient", 465], ["Bi", 473], [")", 475], ["and", 477], ["from", 481], ["the", 486], ["XK", 490], ["to", 493], ["CYBB", 496], ["loci", 501], ["(", 506], ["patient", 507], ["Lh", 515], [")", 517], [".", 518], ["All", 520], ["three", 524], ["patients", 530], ["normally", 539], ["expressed", 548], ["the", 558], ["Lutheran", 562], ["(", 571], ["Lu", 572], [")", 574], ["red", 576], ["cell", 580], ["antigens", 585], [",", 593], ["thus", 595], ["excluding", 600], ["the", 610], ["interval", 614], ["between", 623], ["the", 631], ["RPGR", 635], ["and", 640], ["DMD", 644], ["genes", 648], ["as", 654], ["site", 657], ["of", 662], ["the", 665], ["XS", 669], ["locus", 672], [",", 677], ["previously", 679], ["mapped", 690], ["to", 697], ["the", 700], ["Xp21.2-Xq21.1", 704], ["region", 718], ["and", 725], ["thought", 729], ["to", 737], ["regulate", 740], ["the", 749], ["expression", 753], ["of", 764], ["the", 767], ["LU", 771], ["blood", 774], ["group", 780], ["gene", 786], ["on", 791], ["chromosome", 794], ["19", 805], [".", 807]]}
{"context": "Tuberculosis is responsible for more then 2 million deaths worldwide each year and vies with HIV as the world's most fatal infectious disease. In many developing countries, attempts to control the spread of infection rely solely on identification and treatment of those with active disease, ignoring subclinical infection. However, in developed countries, large efforts are also expended to identify and give prophylactic drugs to people with latent tuberculosis infection. Until recently, the 100-year-old tuberculin skin test (Mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations. Advances in scientific knowledge have led to the development of tests for tuberculosis that measure the production of interferon-gamma by T-cells stimulated in vitro with Mycobacterium tuberculosis-specific antigens. These interferon-gamma tests are highly specific and unaffected by prior Bacille Calmette-Gu\u00e9rin vaccination or immune reactivity to most atypical mycobacteria. They are more sensitive than the tuberculin skin test in detecting people with active tuberculosis, and their results correlate more closely with M. tuberculosis exposure risk factors than the tuberculin skin test in people likely to have latent tuberculosis infection. Science has caught up with one of the oldest diagnostic tests still in use worldwide, and the adoption of new, tuberculosis-specific interferon-gamma-based tests should move us one step closer to better control of this insidious pathogen.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "fc2548420f034a03b63b99f76249f358", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[0, 0], [99, 99], [122, 122], [74, 74], [234, 234], [140, 140], [184, 184], [194, 194], [209, 209]], "char_spans": [[0, 11], [593, 604], [732, 743], [450, 461], [1417, 1428], [843, 854], [1122, 1133], [1185, 1196], [1282, 1293]]}]}], "context_tokens": [["Tuberculosis", 0], ["is", 13], ["responsible", 16], ["for", 28], ["more", 32], ["then", 37], ["2", 42], ["million", 44], ["deaths", 52], ["worldwide", 59], ["each", 69], ["year", 74], ["and", 79], ["vies", 83], ["with", 88], ["HIV", 93], ["as", 97], ["the", 100], ["world", 104], ["'s", 109], ["most", 112], ["fatal", 117], ["infectious", 123], ["disease", 134], [".", 141], ["In", 143], ["many", 146], ["developing", 151], ["countries", 162], [",", 171], ["attempts", 173], ["to", 182], ["control", 185], ["the", 193], ["spread", 197], ["of", 204], ["infection", 207], ["rely", 217], ["solely", 222], ["on", 229], ["identification", 232], ["and", 247], ["treatment", 251], ["of", 261], ["those", 264], ["with", 270], ["active", 275], ["disease", 282], [",", 289], ["ignoring", 291], ["subclinical", 300], ["infection", 312], [".", 321], ["However", 323], [",", 330], ["in", 332], ["developed", 335], ["countries", 345], [",", 354], ["large", 356], ["efforts", 362], ["are", 370], ["also", 374], ["expended", 379], ["to", 388], ["identify", 391], ["and", 400], ["give", 404], ["prophylactic", 409], ["drugs", 422], ["to", 428], ["people", 431], ["with", 438], ["latent", 443], ["tuberculosis", 450], ["infection", 463], [".", 472], ["Until", 474], ["recently", 480], [",", 488], ["the", 490], ["100-year", 494], ["-", 502], ["old", 503], ["tuberculin", 507], ["skin", 518], ["test", 523], ["(", 528], ["Mantoux", 529], [")", 536], ["has", 538], ["been", 542], ["the", 547], ["only", 551], ["available", 556], ["diagnostic", 566], ["test", 577], ["for", 582], ["latent", 586], ["tuberculosis", 593], ["infection", 606], [",", 615], ["despite", 617], ["its", 625], ["many", 629], ["well", 634], ["-", 638], ["known", 639], ["limitations", 645], [".", 656], ["Advances", 658], ["in", 667], ["scientific", 670], ["knowledge", 681], ["have", 691], ["led", 696], ["to", 700], ["the", 703], ["development", 707], ["of", 719], ["tests", 722], ["for", 728], ["tuberculosis", 732], ["that", 745], ["measure", 750], ["the", 758], ["production", 762], ["of", 773], ["interferon", 776], ["-", 786], ["gamma", 787], ["by", 793], ["T", 796], ["-", 797], ["cells", 798], ["stimulated", 804], ["in", 815], ["vitro", 818], ["with", 824], ["Mycobacterium", 829], ["tuberculosis", 843], ["-", 855], ["specific", 856], ["antigens", 865], [".", 873], ["These", 875], ["interferon", 881], ["-", 891], ["gamma", 892], ["tests", 898], ["are", 904], ["highly", 908], ["specific", 915], ["and", 924], ["unaffected", 928], ["by", 939], ["prior", 942], ["Bacille", 948], ["Calmette", 956], ["-", 964], ["Gu\u00e9rin", 965], ["vaccination", 972], ["or", 984], ["immune", 987], ["reactivity", 994], ["to", 1005], ["most", 1008], ["atypical", 1013], ["mycobacteria", 1022], [".", 1034], ["They", 1036], ["are", 1041], ["more", 1045], ["sensitive", 1050], ["than", 1060], ["the", 1065], ["tuberculin", 1069], ["skin", 1080], ["test", 1085], ["in", 1090], ["detecting", 1093], ["people", 1103], ["with", 1110], ["active", 1115], ["tuberculosis", 1122], [",", 1134], ["and", 1136], ["their", 1140], ["results", 1146], ["correlate", 1154], ["more", 1164], ["closely", 1169], ["with", 1177], ["M.", 1182], ["tuberculosis", 1185], ["exposure", 1198], ["risk", 1207], ["factors", 1212], ["than", 1220], ["the", 1225], ["tuberculin", 1229], ["skin", 1240], ["test", 1245], ["in", 1250], ["people", 1253], ["likely", 1260], ["to", 1267], ["have", 1270], ["latent", 1275], ["tuberculosis", 1282], ["infection", 1295], [".", 1304], ["Science", 1306], ["has", 1314], ["caught", 1318], ["up", 1325], ["with", 1328], ["one", 1333], ["of", 1337], ["the", 1340], ["oldest", 1344], ["diagnostic", 1351], ["tests", 1362], ["still", 1368], ["in", 1374], ["use", 1377], ["worldwide", 1381], [",", 1390], ["and", 1392], ["the", 1396], ["adoption", 1400], ["of", 1409], ["new", 1412], [",", 1415], ["tuberculosis", 1417], ["-", 1429], ["specific", 1430], ["interferon", 1439], ["-", 1449], ["gamma", 1450], ["-", 1455], ["based", 1456], ["tests", 1462], ["should", 1468], ["move", 1475], ["us", 1480], ["one", 1483], ["step", 1487], ["closer", 1492], ["to", 1499], ["better", 1502], ["control", 1509], ["of", 1517], ["this", 1520], ["insidious", 1525], ["pathogen", 1535], [".", 1543]]}
{"context": "Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML). Because of the excellent hematologic and cytogenetic responses, imatinib has moved toward first-line treatment for newly diagnosed CML. However, the emergence of resistance to imatinib remains a major problem in the treatment of Ph-positive leukemia. Several mechanisms of imatinib resistance have been identified, including BCR-ABL gene amplification that leads to overexpression of the BCR-ABL protein, point mutations in the BCR-ABL kinase domain that interfere with imatinib binding, and point mutations outside of the kinase domain that allosterically inhibit imatinib binding to BCR-ABL. The need for alternative or additional treatment for imatinib-resistant BCR-ABL-positive leukemia has guided the way to the design of a second generation of targeted therapies, which has resulted mainly in the development of novel small-molecule inhibitors such as AMN107, dasatinib, NS-187, and ON012380. The major goal of these efforts is to create new compounds that are more potent than imatinib and/or more effective against imatinib-resistant BCR-ABL clones. In this review, we discuss the next generation of BCR-ABL kinase inhibitors for overcoming imatinib resistance.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "f60b00cd2c9944dc95889093639a4381", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[102, 104], [142, 144], [211, 213], [93, 95], [13, 15], [226, 228], [82, 84], [127, 129]], "char_spans": [[609, 615], [847, 853], [1224, 1230], [569, 575], [93, 99], [1290, 1296], [506, 512], [766, 772]]}]}], "context_tokens": [["Imatinib", 0], ["was", 9], ["developed", 13], ["as", 23], ["the", 26], ["first", 30], ["molecularly", 36], ["targeted", 48], ["therapy", 57], ["to", 65], ["specifically", 68], ["inhibit", 81], ["the", 89], ["BCR", 93], ["-", 96], ["ABL", 97], ["kinase", 101], ["in", 108], ["Philadelphia", 111], ["chromosome", 124], ["(", 135], ["Ph)-positive", 136], ["chronic", 149], ["myeloid", 157], ["leukemia", 165], ["(", 174], ["CML", 175], [")", 178], [".", 179], ["Because", 181], ["of", 189], ["the", 192], ["excellent", 196], ["hematologic", 206], ["and", 218], ["cytogenetic", 222], ["responses", 234], [",", 243], ["imatinib", 245], ["has", 254], ["moved", 258], ["toward", 264], ["first", 271], ["-", 276], ["line", 277], ["treatment", 282], ["for", 292], ["newly", 296], ["diagnosed", 302], ["CML", 312], [".", 315], ["However", 317], [",", 324], ["the", 326], ["emergence", 330], ["of", 340], ["resistance", 343], ["to", 354], ["imatinib", 357], ["remains", 366], ["a", 374], ["major", 376], ["problem", 382], ["in", 390], ["the", 393], ["treatment", 397], ["of", 407], ["Ph", 410], ["-", 412], ["positive", 413], ["leukemia", 422], [".", 430], ["Several", 432], ["mechanisms", 440], ["of", 451], ["imatinib", 454], ["resistance", 463], ["have", 474], ["been", 479], ["identified", 484], [",", 494], ["including", 496], ["BCR", 506], ["-", 509], ["ABL", 510], ["gene", 514], ["amplification", 519], ["that", 533], ["leads", 538], ["to", 544], ["overexpression", 547], ["of", 562], ["the", 565], ["BCR", 569], ["-", 572], ["ABL", 573], ["protein", 577], [",", 584], ["point", 586], ["mutations", 592], ["in", 602], ["the", 605], ["BCR", 609], ["-", 612], ["ABL", 613], ["kinase", 617], ["domain", 624], ["that", 631], ["interfere", 636], ["with", 646], ["imatinib", 651], ["binding", 660], [",", 667], ["and", 669], ["point", 673], ["mutations", 679], ["outside", 689], ["of", 697], ["the", 700], ["kinase", 704], ["domain", 711], ["that", 718], ["allosterically", 723], ["inhibit", 738], ["imatinib", 746], ["binding", 755], ["to", 763], ["BCR", 766], ["-", 769], ["ABL", 770], [".", 773], ["The", 775], ["need", 779], ["for", 784], ["alternative", 788], ["or", 800], ["additional", 803], ["treatment", 814], ["for", 824], ["imatinib", 828], ["-", 836], ["resistant", 837], ["BCR", 847], ["-", 850], ["ABL", 851], ["-", 854], ["positive", 855], ["leukemia", 864], ["has", 873], ["guided", 877], ["the", 884], ["way", 888], ["to", 892], ["the", 895], ["design", 899], ["of", 906], ["a", 909], ["second", 911], ["generation", 918], ["of", 929], ["targeted", 932], ["therapies", 941], [",", 950], ["which", 952], ["has", 958], ["resulted", 962], ["mainly", 971], ["in", 978], ["the", 981], ["development", 985], ["of", 997], ["novel", 1000], ["small", 1006], ["-", 1011], ["molecule", 1012], ["inhibitors", 1021], ["such", 1032], ["as", 1037], ["AMN107", 1040], [",", 1046], ["dasatinib", 1048], [",", 1057], ["NS-187", 1059], [",", 1065], ["and", 1067], ["ON012380", 1071], [".", 1079], ["The", 1081], ["major", 1085], ["goal", 1091], ["of", 1096], ["these", 1099], ["efforts", 1105], ["is", 1113], ["to", 1116], ["create", 1119], ["new", 1126], ["compounds", 1130], ["that", 1140], ["are", 1145], ["more", 1149], ["potent", 1154], ["than", 1161], ["imatinib", 1166], ["and/or", 1175], ["more", 1182], ["effective", 1187], ["against", 1197], ["imatinib", 1205], ["-", 1213], ["resistant", 1214], ["BCR", 1224], ["-", 1227], ["ABL", 1228], ["clones", 1232], [".", 1238], ["In", 1240], ["this", 1243], ["review", 1248], [",", 1254], ["we", 1256], ["discuss", 1259], ["the", 1267], ["next", 1271], ["generation", 1276], ["of", 1287], ["BCR", 1290], ["-", 1293], ["ABL", 1294], ["kinase", 1298], ["inhibitors", 1305], ["for", 1316], ["overcoming", 1320], ["imatinib", 1331], ["resistance", 1340], [".", 1350]]}
{"context": "Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), we randomly assigned 738 patients (in the ERASURE study) and 1306 patients (in the FIXTURE study) to subcutaneous secukinumab at a dose of 300 mg or 150 mg (administered once weekly for 5 weeks, then every 4 weeks), placebo, or (in the FIXTURE study only) etanercept at a dose of 50 mg (administered twice weekly for 12 weeks, then once weekly). The objective of each study was to show the superiority of secukinumab over placebo at week 12 with respect to the proportion of patients who had a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) and a score of 0 (clear) or 1 (almost clear) on a 5-point modified investigator's global assessment (coprimary end points). The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 81.6% with 300 mg of secukinumab, 71.6% with 150 mg of secukinumab, and 4.5% with placebo; in the FIXTURE study, the rates were 77.1% with 300 mg of secukinumab, 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo (P<0.001 for each secukinumab dose vs. comparators). The proportion of patients with a response of 0 or 1 on the modified investigator's global assessment at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 65.3% with 300 mg of secukinumab, 51.2% with 150 mg of secukinumab, and 2.4% with placebo; in the FIXTURE study, the rates were 62.5% with 300 mg of secukinumab, 51.1% with 150 mg of secukinumab, 27.2% with etanercept, and 2.8% with placebo (P<0.001 for each secukinumab dose vs. comparators). The rates of infection were higher with secukinumab than with placebo in both studies and were similar to those with etanercept. Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov numbers, NCT01365455 and NCT01358578, respectively.).", "qas": [{"question": "Which molecule is targeted by a monoclonal antibody Secukinumab?", "answers": ["interleukin-17A"], "qid": "d6448dc3be2e45b2be46a0805cc13200", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["a", 30], ["monoclonal", 32], ["antibody", 43], ["Secukinumab", 52], ["?", 63]], "detected_answers": [{"text": "interleukin-17A", "token_spans": [[0, 0], [21, 21], [478, 478]], "char_spans": [[0, 14], [123, 137], [2400, 2414]]}]}], "context_tokens": [["Interleukin-17A", 0], ["is", 16], ["considered", 19], ["to", 30], ["be", 33], ["central", 36], ["to", 44], ["the", 47], ["pathogenesis", 51], ["of", 64], ["psoriasis", 67], [".", 76], ["We", 78], ["evaluated", 81], ["secukinumab", 91], [",", 102], ["a", 104], ["fully", 106], ["human", 112], ["anti", 118], ["-", 122], ["interleukin-17A", 123], ["monoclonal", 139], ["antibody", 150], [",", 158], ["in", 160], ["patients", 163], ["with", 172], ["moderate", 177], ["-", 185], ["to", 186], ["-", 188], ["severe", 189], ["plaque", 196], ["psoriasis", 203], [".", 212], ["In", 214], ["two", 217], ["phase", 221], ["3", 227], [",", 228], ["double", 230], ["-", 236], ["blind", 237], [",", 242], ["52-week", 244], ["trials", 252], [",", 258], ["ERASURE", 260], ["(", 268], ["Efficacy", 269], ["of", 278], ["Response", 281], ["and", 290], ["Safety", 294], ["of", 301], ["Two", 304], ["Fixed", 308], ["Secukinumab", 314], ["Regimens", 326], ["in", 335], ["Psoriasis", 338], [")", 347], ["and", 349], ["FIXTURE", 353], ["(", 361], ["Full", 362], ["Year", 367], ["Investigative", 372], ["Examination", 386], ["of", 398], ["Secukinumab", 401], ["vs.", 413], ["Etanercept", 417], ["Using", 428], ["Two", 434], ["Dosing", 438], ["Regimens", 445], ["to", 454], ["Determine", 457], ["Efficacy", 467], ["in", 476], ["Psoriasis", 479], [")", 488], [",", 489], ["we", 491], ["randomly", 494], ["assigned", 503], ["738", 512], ["patients", 516], ["(", 525], ["in", 526], ["the", 529], ["ERASURE", 533], ["study", 541], [")", 546], ["and", 548], ["1306", 552], ["patients", 557], ["(", 566], ["in", 567], ["the", 570], ["FIXTURE", 574], ["study", 582], [")", 587], ["to", 589], ["subcutaneous", 592], ["secukinumab", 605], ["at", 617], ["a", 620], ["dose", 622], ["of", 627], ["300", 630], ["mg", 634], ["or", 637], ["150", 640], ["mg", 644], ["(", 647], ["administered", 648], ["once", 661], ["weekly", 666], ["for", 673], ["5", 677], ["weeks", 679], [",", 684], ["then", 686], ["every", 691], ["4", 697], ["weeks", 699], [")", 704], [",", 705], ["placebo", 707], [",", 714], ["or", 716], ["(", 719], ["in", 720], ["the", 723], ["FIXTURE", 727], ["study", 735], ["only", 741], [")", 745], ["etanercept", 747], ["at", 758], ["a", 761], ["dose", 763], ["of", 768], ["50", 771], ["mg", 774], ["(", 777], ["administered", 778], ["twice", 791], ["weekly", 797], ["for", 804], ["12", 808], ["weeks", 811], [",", 816], ["then", 818], ["once", 823], ["weekly", 828], [")", 834], [".", 835], ["The", 837], ["objective", 841], ["of", 851], ["each", 854], ["study", 859], ["was", 865], ["to", 869], ["show", 872], ["the", 877], ["superiority", 881], ["of", 893], ["secukinumab", 896], ["over", 908], ["placebo", 913], ["at", 921], ["week", 924], ["12", 929], ["with", 932], ["respect", 937], ["to", 945], ["the", 948], ["proportion", 952], ["of", 963], ["patients", 966], ["who", 975], ["had", 979], ["a", 983], ["reduction", 985], ["of", 995], ["75", 998], ["%", 1000], ["or", 1002], ["more", 1005], ["from", 1010], ["baseline", 1015], ["in", 1024], ["the", 1027], ["psoriasis", 1031], ["area", 1041], ["-", 1045], ["and", 1046], ["-", 1049], ["severity", 1050], ["index", 1059], ["score", 1065], ["(", 1071], ["PASI", 1072], ["75", 1077], [")", 1079], ["and", 1081], ["a", 1085], ["score", 1087], ["of", 1093], ["0", 1096], ["(", 1098], ["clear", 1099], [")", 1104], ["or", 1106], ["1", 1109], ["(", 1111], ["almost", 1112], ["clear", 1119], [")", 1124], ["on", 1126], ["a", 1129], ["5-point", 1131], ["modified", 1139], ["investigator", 1148], ["'s", 1160], ["global", 1163], ["assessment", 1170], ["(", 1181], ["coprimary", 1182], ["end", 1192], ["points", 1196], [")", 1202], [".", 1203], ["The", 1205], ["proportion", 1209], ["of", 1220], ["patients", 1223], ["who", 1232], ["met", 1236], ["the", 1240], ["criterion", 1244], ["for", 1254], ["PASI", 1258], ["75", 1263], ["at", 1266], ["week", 1269], ["12", 1274], ["was", 1277], ["higher", 1281], ["with", 1288], ["each", 1293], ["secukinumab", 1298], ["dose", 1310], ["than", 1315], ["with", 1320], ["placebo", 1325], ["or", 1333], ["etanercept", 1336], [":", 1346], ["in", 1348], ["the", 1351], ["ERASURE", 1355], ["study", 1363], [",", 1368], ["the", 1370], ["rates", 1374], ["were", 1380], ["81.6", 1385], ["%", 1389], ["with", 1391], ["300", 1396], ["mg", 1400], ["of", 1403], ["secukinumab", 1406], [",", 1417], ["71.6", 1419], ["%", 1423], ["with", 1425], ["150", 1430], ["mg", 1434], ["of", 1437], ["secukinumab", 1440], [",", 1451], ["and", 1453], ["4.5", 1457], ["%", 1460], ["with", 1462], ["placebo", 1467], [";", 1474], ["in", 1476], ["the", 1479], ["FIXTURE", 1483], ["study", 1491], [",", 1496], ["the", 1498], ["rates", 1502], ["were", 1508], ["77.1", 1513], ["%", 1517], ["with", 1519], ["300", 1524], ["mg", 1528], ["of", 1531], ["secukinumab", 1534], [",", 1545], ["67.0", 1547], ["%", 1551], ["with", 1553], ["150", 1558], ["mg", 1562], ["of", 1565], ["secukinumab", 1568], [",", 1579], ["44.0", 1581], ["%", 1585], ["with", 1587], ["etanercept", 1592], [",", 1602], ["and", 1604], ["4.9", 1608], ["%", 1611], ["with", 1613], ["placebo", 1618], ["(", 1626], ["P<0.001", 1627], ["for", 1635], ["each", 1639], ["secukinumab", 1644], ["dose", 1656], ["vs.", 1661], ["comparators", 1665], [")", 1676], [".", 1677], ["The", 1679], ["proportion", 1683], ["of", 1694], ["patients", 1697], ["with", 1706], ["a", 1711], ["response", 1713], ["of", 1722], ["0", 1725], ["or", 1727], ["1", 1730], ["on", 1732], ["the", 1735], ["modified", 1739], ["investigator", 1748], ["'s", 1760], ["global", 1763], ["assessment", 1770], ["at", 1781], ["week", 1784], ["12", 1789], ["was", 1792], ["higher", 1796], ["with", 1803], ["each", 1808], ["secukinumab", 1813], ["dose", 1825], ["than", 1830], ["with", 1835], ["placebo", 1840], ["or", 1848], ["etanercept", 1851], [":", 1861], ["in", 1863], ["the", 1866], ["ERASURE", 1870], ["study", 1878], [",", 1883], ["the", 1885], ["rates", 1889], ["were", 1895], ["65.3", 1900], ["%", 1904], ["with", 1906], ["300", 1911], ["mg", 1915], ["of", 1918], ["secukinumab", 1921], [",", 1932], ["51.2", 1934], ["%", 1938], ["with", 1940], ["150", 1945], ["mg", 1949], ["of", 1952], ["secukinumab", 1955], [",", 1966], ["and", 1968], ["2.4", 1972], ["%", 1975], ["with", 1977], ["placebo", 1982], [";", 1989], ["in", 1991], ["the", 1994], ["FIXTURE", 1998], ["study", 2006], [",", 2011], ["the", 2013], ["rates", 2017], ["were", 2023], ["62.5", 2028], ["%", 2032], ["with", 2034], ["300", 2039], ["mg", 2043], ["of", 2046], ["secukinumab", 2049], [",", 2060], ["51.1", 2062], ["%", 2066], ["with", 2068], ["150", 2073], ["mg", 2077], ["of", 2080], ["secukinumab", 2083], [",", 2094], ["27.2", 2096], ["%", 2100], ["with", 2102], ["etanercept", 2107], [",", 2117], ["and", 2119], ["2.8", 2123], ["%", 2126], ["with", 2128], ["placebo", 2133], ["(", 2141], ["P<0.001", 2142], ["for", 2150], ["each", 2154], ["secukinumab", 2159], ["dose", 2171], ["vs.", 2176], ["comparators", 2180], [")", 2191], [".", 2192], ["The", 2194], ["rates", 2198], ["of", 2204], ["infection", 2207], ["were", 2217], ["higher", 2222], ["with", 2229], ["secukinumab", 2234], ["than", 2246], ["with", 2251], ["placebo", 2256], ["in", 2264], ["both", 2267], ["studies", 2272], ["and", 2280], ["were", 2284], ["similar", 2289], ["to", 2297], ["those", 2300], ["with", 2306], ["etanercept", 2311], [".", 2321], ["Secukinumab", 2323], ["was", 2335], ["effective", 2339], ["for", 2349], ["psoriasis", 2353], ["in", 2363], ["two", 2366], ["randomized", 2370], ["trials", 2381], [",", 2387], ["validating", 2389], ["interleukin-17A", 2400], ["as", 2416], ["a", 2419], ["therapeutic", 2421], ["target", 2433], [".", 2439], ["(", 2441], ["Funded", 2442], ["by", 2449], ["Novartis", 2452], ["Pharmaceuticals", 2461], [";", 2476], ["ERASURE", 2478], ["and", 2486], ["FIXTURE", 2490], ["ClinicalTrials.gov", 2498], ["numbers", 2517], [",", 2524], ["NCT01365455", 2526], ["and", 2538], ["NCT01358578", 2542], [",", 2553], ["respectively", 2555], [".", 2567], [")", 2568], [".", 2569]]}
{"context": "Excessive neointima formation often occurs after arterial injury. Interleukin-1\u03b2 (IL-1\u03b2) is a potent pleiotropic cytokine that has been shown to regulate neointimal proliferation. We investigated the effects of the IL-1\u03b2 modulator gevokizumab in a rat carotid denudation model. Sprague-Dawley rats were subjected to balloon denudation of the right carotid artery and were then randomized to receive a single subcutaneous infusion immediately after balloon injury of saline (control group, n\u00a0=\u00a013) or gevokizumab (gevokizumab groups, n\u00a0=\u00a015 in each group: 1, 10 and 50\u00a0mg/kg). We evaluated the treatment effects on carotid intima-media thickness (IMT) using ultrasonography, on endothelial regrowth using Evans Blue staining and on inflammatory response using histology. We also assessed the effects of IL-1\u03b2 and gevokizumab on human umbilical vein endothelial cells (HUVEC) and rat smooth muscle cells. We found that carotid IMT, in the proximal part of the denuded artery at day 28, was decreased by gevokizumab 1\u00a0mg/kg compared with controls. Neointima area and the intima/media area ratio were both reduced in the gevokizumab 1 mg/kg-treated group. Gevokizumab at the 1\u00a0mg/kg dose also improved endothelial regrowth. No effect was observed with gevokizumab 10 or 50\u00a0mg/kg. Gevokizumab also decreased the inflammatory effect of IL-1\u03b2 in in\u00a0vitro cell experiments and protected HUVECs from IL-1\u03b2's deleterious effects on cell migration, apoptosis and proliferation. A single administration of gevokizumab 1\u00a0mg/kg improves endothelial regrowth and reduces neointima formation in rats following carotid denudation, at least in part through its beneficial effects on endothelial cells.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "8ed1ba42499c4aceadfd18b13356a2ba", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[245, 245], [11, 11], [141, 141], [255, 255], [33, 33]], "char_spans": [[1330, 1334], [82, 86], [802, 806], [1391, 1395], [215, 219]]}]}], "context_tokens": [["Excessive", 0], ["neointima", 10], ["formation", 20], ["often", 30], ["occurs", 36], ["after", 43], ["arterial", 49], ["injury", 58], [".", 64], ["Interleukin-1\u03b2", 66], ["(", 81], ["IL-1\u03b2", 82], [")", 87], ["is", 89], ["a", 92], ["potent", 94], ["pleiotropic", 101], ["cytokine", 113], ["that", 122], ["has", 127], ["been", 131], ["shown", 136], ["to", 142], ["regulate", 145], ["neointimal", 154], ["proliferation", 165], [".", 178], ["We", 180], ["investigated", 183], ["the", 196], ["effects", 200], ["of", 208], ["the", 211], ["IL-1\u03b2", 215], ["modulator", 221], ["gevokizumab", 231], ["in", 243], ["a", 246], ["rat", 248], ["carotid", 252], ["denudation", 260], ["model", 271], [".", 276], ["Sprague", 278], ["-", 285], ["Dawley", 286], ["rats", 293], ["were", 298], ["subjected", 303], ["to", 313], ["balloon", 316], ["denudation", 324], ["of", 335], ["the", 338], ["right", 342], ["carotid", 348], ["artery", 356], ["and", 363], ["were", 367], ["then", 372], ["randomized", 377], ["to", 388], ["receive", 391], ["a", 399], ["single", 401], ["subcutaneous", 408], ["infusion", 421], ["immediately", 430], ["after", 442], ["balloon", 448], ["injury", 456], ["of", 463], ["saline", 466], ["(", 473], ["control", 474], ["group", 482], [",", 487], ["n", 489], ["=", 491], ["13", 493], [")", 495], ["or", 497], ["gevokizumab", 500], ["(", 512], ["gevokizumab", 513], ["groups", 525], [",", 531], ["n", 533], ["=", 535], ["15", 537], ["in", 540], ["each", 543], ["group", 548], [":", 553], ["1", 555], [",", 556], ["10", 558], ["and", 561], ["50", 565], ["mg", 568], ["/", 570], ["kg", 571], [")", 573], [".", 574], ["We", 576], ["evaluated", 579], ["the", 589], ["treatment", 593], ["effects", 603], ["on", 611], ["carotid", 614], ["intima", 622], ["-", 628], ["media", 629], ["thickness", 635], ["(", 645], ["IMT", 646], [")", 649], ["using", 651], ["ultrasonography", 657], [",", 672], ["on", 674], ["endothelial", 677], ["regrowth", 689], ["using", 698], ["Evans", 704], ["Blue", 710], ["staining", 715], ["and", 724], ["on", 728], ["inflammatory", 731], ["response", 744], ["using", 753], ["histology", 759], [".", 768], ["We", 770], ["also", 773], ["assessed", 778], ["the", 787], ["effects", 791], ["of", 799], ["IL-1\u03b2", 802], ["and", 808], ["gevokizumab", 812], ["on", 824], ["human", 827], ["umbilical", 833], ["vein", 843], ["endothelial", 848], ["cells", 860], ["(", 866], ["HUVEC", 867], [")", 872], ["and", 874], ["rat", 878], ["smooth", 882], ["muscle", 889], ["cells", 896], [".", 901], ["We", 903], ["found", 906], ["that", 912], ["carotid", 917], ["IMT", 925], [",", 928], ["in", 930], ["the", 933], ["proximal", 937], ["part", 946], ["of", 951], ["the", 954], ["denuded", 958], ["artery", 966], ["at", 973], ["day", 976], ["28", 980], [",", 982], ["was", 984], ["decreased", 988], ["by", 998], ["gevokizumab", 1001], ["1", 1013], ["mg", 1015], ["/", 1017], ["kg", 1018], ["compared", 1021], ["with", 1030], ["controls", 1035], [".", 1043], ["Neointima", 1045], ["area", 1055], ["and", 1060], ["the", 1064], ["intima", 1068], ["/", 1074], ["media", 1075], ["area", 1081], ["ratio", 1086], ["were", 1092], ["both", 1097], ["reduced", 1102], ["in", 1110], ["the", 1113], ["gevokizumab", 1117], ["1", 1129], ["mg", 1131], ["/", 1133], ["kg", 1134], ["-", 1136], ["treated", 1137], ["group", 1145], [".", 1150], ["Gevokizumab", 1152], ["at", 1164], ["the", 1167], ["1", 1171], ["mg", 1173], ["/", 1175], ["kg", 1176], ["dose", 1179], ["also", 1184], ["improved", 1189], ["endothelial", 1198], ["regrowth", 1210], [".", 1218], ["No", 1220], ["effect", 1223], ["was", 1230], ["observed", 1234], ["with", 1243], ["gevokizumab", 1248], ["10", 1260], ["or", 1263], ["50", 1266], ["mg", 1269], ["/", 1271], ["kg", 1272], [".", 1274], ["Gevokizumab", 1276], ["also", 1288], ["decreased", 1293], ["the", 1303], ["inflammatory", 1307], ["effect", 1320], ["of", 1327], ["IL-1\u03b2", 1330], ["in", 1336], ["in", 1339], ["vitro", 1342], ["cell", 1348], ["experiments", 1353], ["and", 1365], ["protected", 1369], ["HUVECs", 1379], ["from", 1386], ["IL-1\u03b2", 1391], ["'s", 1396], ["deleterious", 1399], ["effects", 1411], ["on", 1419], ["cell", 1422], ["migration", 1427], [",", 1436], ["apoptosis", 1438], ["and", 1448], ["proliferation", 1452], [".", 1465], ["A", 1467], ["single", 1469], ["administration", 1476], ["of", 1491], ["gevokizumab", 1494], ["1", 1506], ["mg", 1508], ["/", 1510], ["kg", 1511], ["improves", 1514], ["endothelial", 1523], ["regrowth", 1535], ["and", 1544], ["reduces", 1548], ["neointima", 1556], ["formation", 1566], ["in", 1576], ["rats", 1579], ["following", 1584], ["carotid", 1594], ["denudation", 1602], [",", 1612], ["at", 1614], ["least", 1617], ["in", 1623], ["part", 1626], ["through", 1631], ["its", 1639], ["beneficial", 1643], ["effects", 1654], ["on", 1662], ["endothelial", 1665], ["cells", 1677], [".", 1682]]}
{"context": "Ribosomal protein S19 (RPS19) is frequently mutated in Diamond-Blackfan anemia (DBA), a rare congenital hypoplastic anemia. Recent studies have shown that RPS19 expression decreases during terminal erythroid differentiation. Currently no information is available on the subcellular localization of normal RPS19 and the potential effects of various RPS19 mutations on cellular localization. In the present study, using wild-type and mutant RPS19 cDNA, we explored the subcellular distribution of normal and mutant proteins in a fibroblast cell line (Cos-7 cells). RPS19 was detected primarily in the nucleus, and more specifically in the nucleoli, where RPS19 colocalized with the nucleolar protein nucleolin. Using various N-terminal and C-terminal deletion constructs, we identified 2 nucleolar localization signals (NoSs) in RPS19: the first comprising amino acids Met1 to Arg16 in the NH2-terminus and the second comprising Gly120 to Asn142 in the COOH-terminus. Importantly, 2 mutations identified in DBA patients, Val15Phe and Gly127Gln, each of which localized to 1 of the 2 NoS, failed to localize RPS19 to the nucleolus. In addition to their mislocalization, there was a dramatic decrease in the expression of the 2 mutant proteins compared to the wild type. This decrease in protein expression was specific for the mutant RPS19, since expression of other proteins was normal. The present findings enable us to document the nucleolar localization signals in RPS19 and help define the phenotypic consequences of some mutations in RPS19 in DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "457215d830bf41e89e644ec8a579e6a3", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[10, 13]], "char_spans": [[55, 77]]}, {"text": "DBA", "token_spans": [[173, 173], [15, 15], [269, 269]], "char_spans": [[1005, 1007], [80, 82], [1546, 1548]]}]}], "context_tokens": [["Ribosomal", 0], ["protein", 10], ["S19", 18], ["(", 22], ["RPS19", 23], [")", 28], ["is", 30], ["frequently", 33], ["mutated", 44], ["in", 52], ["Diamond", 55], ["-", 62], ["Blackfan", 63], ["anemia", 72], ["(", 79], ["DBA", 80], [")", 83], [",", 84], ["a", 86], ["rare", 88], ["congenital", 93], ["hypoplastic", 104], ["anemia", 116], [".", 122], ["Recent", 124], ["studies", 131], ["have", 139], ["shown", 144], ["that", 150], ["RPS19", 155], ["expression", 161], ["decreases", 172], ["during", 182], ["terminal", 189], ["erythroid", 198], ["differentiation", 208], [".", 223], ["Currently", 225], ["no", 235], ["information", 238], ["is", 250], ["available", 253], ["on", 263], ["the", 266], ["subcellular", 270], ["localization", 282], ["of", 295], ["normal", 298], ["RPS19", 305], ["and", 311], ["the", 315], ["potential", 319], ["effects", 329], ["of", 337], ["various", 340], ["RPS19", 348], ["mutations", 354], ["on", 364], ["cellular", 367], ["localization", 376], [".", 388], ["In", 390], ["the", 393], ["present", 397], ["study", 405], [",", 410], ["using", 412], ["wild", 418], ["-", 422], ["type", 423], ["and", 428], ["mutant", 432], ["RPS19", 439], ["cDNA", 445], [",", 449], ["we", 451], ["explored", 454], ["the", 463], ["subcellular", 467], ["distribution", 479], ["of", 492], ["normal", 495], ["and", 502], ["mutant", 506], ["proteins", 513], ["in", 522], ["a", 525], ["fibroblast", 527], ["cell", 538], ["line", 543], ["(", 548], ["Cos-7", 549], ["cells", 555], [")", 560], [".", 561], ["RPS19", 563], ["was", 569], ["detected", 573], ["primarily", 582], ["in", 592], ["the", 595], ["nucleus", 599], [",", 606], ["and", 608], ["more", 612], ["specifically", 617], ["in", 630], ["the", 633], ["nucleoli", 637], [",", 645], ["where", 647], ["RPS19", 653], ["colocalized", 659], ["with", 671], ["the", 676], ["nucleolar", 680], ["protein", 690], ["nucleolin", 698], [".", 707], ["Using", 709], ["various", 715], ["N", 723], ["-", 724], ["terminal", 725], ["and", 734], ["C", 738], ["-", 739], ["terminal", 740], ["deletion", 749], ["constructs", 758], [",", 768], ["we", 770], ["identified", 773], ["2", 784], ["nucleolar", 786], ["localization", 796], ["signals", 809], ["(", 817], ["NoSs", 818], [")", 822], ["in", 824], ["RPS19", 827], [":", 832], ["the", 834], ["first", 838], ["comprising", 844], ["amino", 855], ["acids", 861], ["Met1", 867], ["to", 872], ["Arg16", 875], ["in", 881], ["the", 884], ["NH2-terminus", 888], ["and", 901], ["the", 905], ["second", 909], ["comprising", 916], ["Gly120", 927], ["to", 934], ["Asn142", 937], ["in", 944], ["the", 947], ["COOH", 951], ["-", 955], ["terminus", 956], [".", 964], ["Importantly", 966], [",", 977], ["2", 979], ["mutations", 981], ["identified", 991], ["in", 1002], ["DBA", 1005], ["patients", 1009], [",", 1017], ["Val15Phe", 1019], ["and", 1028], ["Gly127Gln", 1032], [",", 1041], ["each", 1043], ["of", 1048], ["which", 1051], ["localized", 1057], ["to", 1067], ["1", 1070], ["of", 1072], ["the", 1075], ["2", 1079], ["NoS", 1081], [",", 1084], ["failed", 1086], ["to", 1093], ["localize", 1096], ["RPS19", 1105], ["to", 1111], ["the", 1114], ["nucleolus", 1118], [".", 1127], ["In", 1129], ["addition", 1132], ["to", 1141], ["their", 1144], ["mislocalization", 1150], [",", 1165], ["there", 1167], ["was", 1173], ["a", 1177], ["dramatic", 1179], ["decrease", 1188], ["in", 1197], ["the", 1200], ["expression", 1204], ["of", 1215], ["the", 1218], ["2", 1222], ["mutant", 1224], ["proteins", 1231], ["compared", 1240], ["to", 1249], ["the", 1252], ["wild", 1256], ["type", 1261], [".", 1265], ["This", 1267], ["decrease", 1272], ["in", 1281], ["protein", 1284], ["expression", 1292], ["was", 1303], ["specific", 1307], ["for", 1316], ["the", 1320], ["mutant", 1324], ["RPS19", 1331], [",", 1336], ["since", 1338], ["expression", 1344], ["of", 1355], ["other", 1358], ["proteins", 1364], ["was", 1373], ["normal", 1377], [".", 1383], ["The", 1385], ["present", 1389], ["findings", 1397], ["enable", 1406], ["us", 1413], ["to", 1416], ["document", 1419], ["the", 1428], ["nucleolar", 1432], ["localization", 1442], ["signals", 1455], ["in", 1463], ["RPS19", 1466], ["and", 1472], ["help", 1476], ["define", 1481], ["the", 1488], ["phenotypic", 1492], ["consequences", 1503], ["of", 1516], ["some", 1519], ["mutations", 1524], ["in", 1534], ["RPS19", 1537], ["in", 1543], ["DBA", 1546], [".", 1549]]}
{"context": "To compare the outcome of outside-in biological and synthetic transobturator tape (TOT) operation, including subjective and objective success rates, urodynamics, and quality of life. One hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (SUI) were randomized into biological material TOT (PELVILACE\u00ae TO) or synthetic material TOT (ALIGN\u00aeTO Urethral Support System) groups. Preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, Q-tip test, and urodynamics were performed. For the evaluation of quality of life, the King's Health Questionnaire, Urogenital Distress Inventory-6, Incontinence Impact Questionnaire-7, and Prolapse Quality of Life were used. There was no significant difference between the two groups regarding objective and subjective cure rates and quality of life. At 1-year follow-up, the subjective cure rate was 68 % in the biological material TOT and 70 % in the synthetic material TOT group. No perioperative complications developed. Groin pain developed in 2 patients in the biological TOT group and 1 patient had dehiscence in the periurethral incision, which healed with local estrogen. Two patients had transient urinary retention in the synthetic TOT group, 1 patient developed groin pain, and 1 patient had mesh erosion observed at the 1-year follow-up. Transobturator tape with biological material in the management of SUI has a rate of success and patient satisfaction similar to those of synthetic material at 1-year follow-up. Studies with longer follow-up and larger cohorts are necessary to evaluate possible autolysis and degradation of biological slings and a possible reduction in efficacy over time.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "bc7735fd4a4446a7a5c1378082daf71f", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[40, 42]], "char_spans": [[246, 272]]}]}], "context_tokens": [["To", 0], ["compare", 3], ["the", 11], ["outcome", 15], ["of", 23], ["outside", 26], ["-", 33], ["in", 34], ["biological", 37], ["and", 48], ["synthetic", 52], ["transobturator", 62], ["tape", 77], ["(", 82], ["TOT", 83], [")", 86], ["operation", 88], [",", 97], ["including", 99], ["subjective", 109], ["and", 120], ["objective", 124], ["success", 134], ["rates", 142], [",", 147], ["urodynamics", 149], [",", 160], ["and", 162], ["quality", 166], ["of", 174], ["life", 177], [".", 181], ["One", 183], ["hundred", 187], ["patients", 195], ["suffering", 204], ["from", 214], ["clinical", 219], ["and/or", 228], ["urodynamic", 235], ["stress", 246], ["urinary", 253], ["incontinence", 261], ["(", 274], ["SUI", 275], [")", 278], ["were", 280], ["randomized", 285], ["into", 296], ["biological", 301], ["material", 312], ["TOT", 321], ["(", 325], ["PELVILACE", 326], ["\u00ae", 335], ["TO", 337], [")", 339], ["or", 341], ["synthetic", 344], ["material", 354], ["TOT", 363], ["(", 367], ["ALIGN", 368], ["\u00ae", 373], ["TO", 374], ["Urethral", 377], ["Support", 386], ["System", 394], [")", 400], ["groups", 402], [".", 408], ["Preoperative", 410], ["and", 423], ["at", 427], ["1", 430], ["year", 432], ["postoperative", 437], ["urogynecological", 451], ["symptom", 468], ["assessment", 476], [",", 486], ["1-h", 488], ["pad", 492], ["test", 496], [",", 500], ["4-day", 502], ["bladder", 508], ["diary", 516], [",", 521], ["stress", 523], ["test", 530], [",", 534], ["Q", 536], ["-", 537], ["tip", 538], ["test", 542], [",", 546], ["and", 548], ["urodynamics", 552], ["were", 564], ["performed", 569], [".", 578], ["For", 580], ["the", 584], ["evaluation", 588], ["of", 599], ["quality", 602], ["of", 610], ["life", 613], [",", 617], ["the", 619], ["King", 623], ["'s", 627], ["Health", 630], ["Questionnaire", 637], [",", 650], ["Urogenital", 652], ["Distress", 663], ["Inventory-6", 672], [",", 683], ["Incontinence", 685], ["Impact", 698], ["Questionnaire-7", 705], [",", 720], ["and", 722], ["Prolapse", 726], ["Quality", 735], ["of", 743], ["Life", 746], ["were", 751], ["used", 756], [".", 760], ["There", 762], ["was", 768], ["no", 772], ["significant", 775], ["difference", 787], ["between", 798], ["the", 806], ["two", 810], ["groups", 814], ["regarding", 821], ["objective", 831], ["and", 841], ["subjective", 845], ["cure", 856], ["rates", 861], ["and", 867], ["quality", 871], ["of", 879], ["life", 882], [".", 886], ["At", 888], ["1-year", 891], ["follow", 898], ["-", 904], ["up", 905], [",", 907], ["the", 909], ["subjective", 913], ["cure", 924], ["rate", 929], ["was", 934], ["68", 938], ["%", 941], ["in", 943], ["the", 946], ["biological", 950], ["material", 961], ["TOT", 970], ["and", 974], ["70", 978], ["%", 981], ["in", 983], ["the", 986], ["synthetic", 990], ["material", 1000], ["TOT", 1009], ["group", 1013], [".", 1018], ["No", 1020], ["perioperative", 1023], ["complications", 1037], ["developed", 1051], [".", 1060], ["Groin", 1062], ["pain", 1068], ["developed", 1073], ["in", 1083], ["2", 1086], ["patients", 1088], ["in", 1097], ["the", 1100], ["biological", 1104], ["TOT", 1115], ["group", 1119], ["and", 1125], ["1", 1129], ["patient", 1131], ["had", 1139], ["dehiscence", 1143], ["in", 1154], ["the", 1157], ["periurethral", 1161], ["incision", 1174], [",", 1182], ["which", 1184], ["healed", 1190], ["with", 1197], ["local", 1202], ["estrogen", 1208], [".", 1216], ["Two", 1218], ["patients", 1222], ["had", 1231], ["transient", 1235], ["urinary", 1245], ["retention", 1253], ["in", 1263], ["the", 1266], ["synthetic", 1270], ["TOT", 1280], ["group", 1284], [",", 1289], ["1", 1291], ["patient", 1293], ["developed", 1301], ["groin", 1311], ["pain", 1317], [",", 1321], ["and", 1323], ["1", 1327], ["patient", 1329], ["had", 1337], ["mesh", 1341], ["erosion", 1346], ["observed", 1354], ["at", 1363], ["the", 1366], ["1-year", 1370], ["follow", 1377], ["-", 1383], ["up", 1384], [".", 1386], ["Transobturator", 1388], ["tape", 1403], ["with", 1408], ["biological", 1413], ["material", 1424], ["in", 1433], ["the", 1436], ["management", 1440], ["of", 1451], ["SUI", 1454], ["has", 1458], ["a", 1462], ["rate", 1464], ["of", 1469], ["success", 1472], ["and", 1480], ["patient", 1484], ["satisfaction", 1492], ["similar", 1505], ["to", 1513], ["those", 1516], ["of", 1522], ["synthetic", 1525], ["material", 1535], ["at", 1544], ["1-year", 1547], ["follow", 1554], ["-", 1560], ["up", 1561], [".", 1563], ["Studies", 1565], ["with", 1573], ["longer", 1578], ["follow", 1585], ["-", 1591], ["up", 1592], ["and", 1595], ["larger", 1599], ["cohorts", 1606], ["are", 1614], ["necessary", 1618], ["to", 1628], ["evaluate", 1631], ["possible", 1640], ["autolysis", 1649], ["and", 1659], ["degradation", 1663], ["of", 1675], ["biological", 1678], ["slings", 1689], ["and", 1696], ["a", 1700], ["possible", 1702], ["reduction", 1711], ["in", 1721], ["efficacy", 1724], ["over", 1733], ["time", 1738], [".", 1742]]}
{"context": "Polyglutamine diseases, including Huntington's disease, designate a group of nine neurodegenerative disorders characterized by the presence of a toxic polyglutamine expansion in specific target proteins. Using cell and mouse models, we have shown that expanded polyglutamine led to activation of the stress kinase JNK and the transcription factor AP-1, which are implicated in neuronal death. Polyglutamine expansion-induced stress shared common features with protein-damaging stress such as heat shock, because activation of JNK involved inhibition of JNK phosphatase activities. Indeed, expanded polyglutamine impaired the solubility of the dual-specificity JNK phosphatase M3/6. Aggregation of M3/6 by polyglutamine expansion appeared to be indirect, because M3/6 was not recruited into polyglutamine inclusions. The heat shock protein HSP70, which is known to inhibit JNK during the heat shock response, suppressed polyglutamine-mediated aggregation of M3/6 and activation of JNK. Interestingly, levels of HSP70 were down-regulated by polyglutamine expansion. We suggest that reduction of HSP70 by expanded polyglutamine is implicated in aggregation and inhibition of M3/6 and in activation of JNK and AP-1.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "db7adf06a3c547ec93d26a22ee2e1de9", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[48, 48], [83, 83], [155, 155], [138, 138], [103, 103], [87, 87], [191, 191]], "char_spans": [[314, 316], [526, 528], [980, 982], [872, 874], [660, 662], [553, 555], [1198, 1200]]}]}], "context_tokens": [["Polyglutamine", 0], ["diseases", 14], [",", 22], ["including", 24], ["Huntington", 34], ["'s", 44], ["disease", 47], [",", 54], ["designate", 56], ["a", 66], ["group", 68], ["of", 74], ["nine", 77], ["neurodegenerative", 82], ["disorders", 100], ["characterized", 110], ["by", 124], ["the", 127], ["presence", 131], ["of", 140], ["a", 143], ["toxic", 145], ["polyglutamine", 151], ["expansion", 165], ["in", 175], ["specific", 178], ["target", 187], ["proteins", 194], [".", 202], ["Using", 204], ["cell", 210], ["and", 215], ["mouse", 219], ["models", 225], [",", 231], ["we", 233], ["have", 236], ["shown", 241], ["that", 247], ["expanded", 252], ["polyglutamine", 261], ["led", 275], ["to", 279], ["activation", 282], ["of", 293], ["the", 296], ["stress", 300], ["kinase", 307], ["JNK", 314], ["and", 318], ["the", 322], ["transcription", 326], ["factor", 340], ["AP-1", 347], [",", 351], ["which", 353], ["are", 359], ["implicated", 363], ["in", 374], ["neuronal", 377], ["death", 386], [".", 391], ["Polyglutamine", 393], ["expansion", 407], ["-", 416], ["induced", 417], ["stress", 425], ["shared", 432], ["common", 439], ["features", 446], ["with", 455], ["protein", 460], ["-", 467], ["damaging", 468], ["stress", 477], ["such", 484], ["as", 489], ["heat", 492], ["shock", 497], [",", 502], ["because", 504], ["activation", 512], ["of", 523], ["JNK", 526], ["involved", 530], ["inhibition", 539], ["of", 550], ["JNK", 553], ["phosphatase", 557], ["activities", 569], [".", 579], ["Indeed", 581], [",", 587], ["expanded", 589], ["polyglutamine", 598], ["impaired", 612], ["the", 621], ["solubility", 625], ["of", 636], ["the", 639], ["dual", 643], ["-", 647], ["specificity", 648], ["JNK", 660], ["phosphatase", 664], ["M3/6", 676], [".", 680], ["Aggregation", 682], ["of", 694], ["M3/6", 697], ["by", 702], ["polyglutamine", 705], ["expansion", 719], ["appeared", 729], ["to", 738], ["be", 741], ["indirect", 744], [",", 752], ["because", 754], ["M3/6", 762], ["was", 767], ["not", 771], ["recruited", 775], ["into", 785], ["polyglutamine", 790], ["inclusions", 804], [".", 814], ["The", 816], ["heat", 820], ["shock", 825], ["protein", 831], ["HSP70", 839], [",", 844], ["which", 846], ["is", 852], ["known", 855], ["to", 861], ["inhibit", 864], ["JNK", 872], ["during", 876], ["the", 883], ["heat", 887], ["shock", 892], ["response", 898], [",", 906], ["suppressed", 908], ["polyglutamine", 919], ["-", 932], ["mediated", 933], ["aggregation", 942], ["of", 954], ["M3/6", 957], ["and", 962], ["activation", 966], ["of", 977], ["JNK", 980], [".", 983], ["Interestingly", 985], [",", 998], ["levels", 1000], ["of", 1007], ["HSP70", 1010], ["were", 1016], ["down", 1021], ["-", 1025], ["regulated", 1026], ["by", 1036], ["polyglutamine", 1039], ["expansion", 1053], [".", 1062], ["We", 1064], ["suggest", 1067], ["that", 1075], ["reduction", 1080], ["of", 1090], ["HSP70", 1093], ["by", 1099], ["expanded", 1102], ["polyglutamine", 1111], ["is", 1125], ["implicated", 1128], ["in", 1139], ["aggregation", 1142], ["and", 1154], ["inhibition", 1158], ["of", 1169], ["M3/6", 1172], ["and", 1177], ["in", 1181], ["activation", 1184], ["of", 1195], ["JNK", 1198], ["and", 1202], ["AP-1", 1206], [".", 1210]]}
{"context": "Kx is lacking in the RBCs of patients with the McLeod syndrome. This condition is sometimes associated with chronic granulomatous disease (CGD). If given allogeneic RBCs, CGD patients with the McLeod phenotype may produce anti-Kx and anti-Km, and only phenotypically matched McLeod blood would be compatible. McLeod phenotype persons without CGD have made anti-Km but not anti-Kx (2 examples), and thus both McLeod and K(O) blood would be compatible. RBCs from a transfused patient with the McLeod phenotype but not with CGD (non-CGD McLeod) were typed for the Kell blood group antigens, and the plasma was analyzed for the presence of antibody by agglutination. The molecular basis was determined by analyzing for XK protein on RBC membranes by Western immunoblotting, by sequencing the XK gene, and by RFLP. The RBCs did not react with anti-Kx + anti-Km and showed weakening of Kell system antigens. The patient's plasma reacted moderately (2+) with RBCs of common Kell type and strongly (4+) with K(O) RBCs and RBCs of common Kell type treated with dithiothreitol, and did not react with McLeod RBCs. XK protein was absent from the RBC membranes. The XK gene had a point mutation in the donor splice site of intron 1 (G>C). This is the first report describing the molecular alteration in a non-CGD McLeod patient who has made anti-Kx. The immune response of people with the McLeod phenotype can vary, and K(O) blood may not always be compatible.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "ae5bb34ab378486298ab61b3973ece7b", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[232, 232], [150, 150], [222, 222], [138, 138]], "char_spans": [[1154, 1155], [788, 789], [1104, 1105], [715, 716]]}]}], "context_tokens": [["Kx", 0], ["is", 3], ["lacking", 6], ["in", 14], ["the", 17], ["RBCs", 21], ["of", 26], ["patients", 29], ["with", 38], ["the", 43], ["McLeod", 47], ["syndrome", 54], [".", 62], ["This", 64], ["condition", 69], ["is", 79], ["sometimes", 82], ["associated", 92], ["with", 103], ["chronic", 108], ["granulomatous", 116], ["disease", 130], ["(", 138], ["CGD", 139], [")", 142], [".", 143], ["If", 145], ["given", 148], ["allogeneic", 154], ["RBCs", 165], [",", 169], ["CGD", 171], ["patients", 175], ["with", 184], ["the", 189], ["McLeod", 193], ["phenotype", 200], ["may", 210], ["produce", 214], ["anti", 222], ["-", 226], ["Kx", 227], ["and", 230], ["anti", 234], ["-", 238], ["Km", 239], [",", 241], ["and", 243], ["only", 247], ["phenotypically", 252], ["matched", 267], ["McLeod", 275], ["blood", 282], ["would", 288], ["be", 294], ["compatible", 297], [".", 307], ["McLeod", 309], ["phenotype", 316], ["persons", 326], ["without", 334], ["CGD", 342], ["have", 346], ["made", 351], ["anti", 356], ["-", 360], ["Km", 361], ["but", 364], ["not", 368], ["anti", 372], ["-", 376], ["Kx", 377], ["(", 380], ["2", 381], ["examples", 383], [")", 391], [",", 392], ["and", 394], ["thus", 398], ["both", 403], ["McLeod", 408], ["and", 415], ["K(O", 419], [")", 422], ["blood", 424], ["would", 430], ["be", 436], ["compatible", 439], [".", 449], ["RBCs", 451], ["from", 456], ["a", 461], ["transfused", 463], ["patient", 474], ["with", 482], ["the", 487], ["McLeod", 491], ["phenotype", 498], ["but", 508], ["not", 512], ["with", 516], ["CGD", 521], ["(", 525], ["non", 526], ["-", 529], ["CGD", 530], ["McLeod", 534], [")", 540], ["were", 542], ["typed", 547], ["for", 553], ["the", 557], ["Kell", 561], ["blood", 566], ["group", 572], ["antigens", 578], [",", 586], ["and", 588], ["the", 592], ["plasma", 596], ["was", 603], ["analyzed", 607], ["for", 616], ["the", 620], ["presence", 624], ["of", 633], ["antibody", 636], ["by", 645], ["agglutination", 648], [".", 661], ["The", 663], ["molecular", 667], ["basis", 677], ["was", 683], ["determined", 687], ["by", 698], ["analyzing", 701], ["for", 711], ["XK", 715], ["protein", 718], ["on", 726], ["RBC", 729], ["membranes", 733], ["by", 743], ["Western", 746], ["immunoblotting", 754], [",", 768], ["by", 770], ["sequencing", 773], ["the", 784], ["XK", 788], ["gene", 791], [",", 795], ["and", 797], ["by", 801], ["RFLP", 804], [".", 808], ["The", 810], ["RBCs", 814], ["did", 819], ["not", 823], ["react", 827], ["with", 833], ["anti", 838], ["-", 842], ["Kx", 843], ["+", 846], ["anti", 848], ["-", 852], ["Km", 853], ["and", 856], ["showed", 860], ["weakening", 867], ["of", 877], ["Kell", 880], ["system", 885], ["antigens", 892], [".", 900], ["The", 902], ["patient", 906], ["'s", 913], ["plasma", 916], ["reacted", 923], ["moderately", 931], ["(", 942], ["2", 943], ["+", 944], [")", 945], ["with", 947], ["RBCs", 952], ["of", 957], ["common", 960], ["Kell", 967], ["type", 972], ["and", 977], ["strongly", 981], ["(", 990], ["4", 991], ["+", 992], [")", 993], ["with", 995], ["K(O", 1000], [")", 1003], ["RBCs", 1005], ["and", 1010], ["RBCs", 1014], ["of", 1019], ["common", 1022], ["Kell", 1029], ["type", 1034], ["treated", 1039], ["with", 1047], ["dithiothreitol", 1052], [",", 1066], ["and", 1068], ["did", 1072], ["not", 1076], ["react", 1080], ["with", 1086], ["McLeod", 1091], ["RBCs", 1098], [".", 1102], ["XK", 1104], ["protein", 1107], ["was", 1115], ["absent", 1119], ["from", 1126], ["the", 1131], ["RBC", 1135], ["membranes", 1139], [".", 1148], ["The", 1150], ["XK", 1154], ["gene", 1157], ["had", 1162], ["a", 1166], ["point", 1168], ["mutation", 1174], ["in", 1183], ["the", 1186], ["donor", 1190], ["splice", 1196], ["site", 1203], ["of", 1208], ["intron", 1211], ["1", 1218], ["(", 1220], ["G", 1221], [">", 1222], ["C", 1223], [")", 1224], [".", 1225], ["This", 1227], ["is", 1232], ["the", 1235], ["first", 1239], ["report", 1245], ["describing", 1252], ["the", 1263], ["molecular", 1267], ["alteration", 1277], ["in", 1288], ["a", 1291], ["non", 1293], ["-", 1296], ["CGD", 1297], ["McLeod", 1301], ["patient", 1308], ["who", 1316], ["has", 1320], ["made", 1324], ["anti", 1329], ["-", 1333], ["Kx", 1334], [".", 1336], ["The", 1338], ["immune", 1342], ["response", 1349], ["of", 1358], ["people", 1361], ["with", 1368], ["the", 1373], ["McLeod", 1377], ["phenotype", 1384], ["can", 1394], ["vary", 1398], [",", 1402], ["and", 1404], ["K(O", 1408], [")", 1411], ["blood", 1413], ["may", 1419], ["not", 1423], ["always", 1427], ["be", 1434], ["compatible", 1437], [".", 1447]]}
{"context": "Calcineurin signaling has been implicated in a broad spectrum of developmental processes in a variety of organ systems. Calcineurin is a calmodulin-dependent, calcium-activated protein phosphatase composed of catalytic and regulatory subunits. The serine/threonine-specific phosphatase functions within a signal transduction pathway that regulates gene expression and biological responses in many developmentally important cell types. Calcineurin signaling was first defined in T lymphocytes as a regulator of nuclear factor of activated T cells (NFAT) transcription factor nuclear translocation and activation. Recent studies have demonstrated the vital nature of calcium/calcineurin/NFAT signaling in cardiovascular and skeletal muscle development in vertebrates. Inhibition, mutation, or forced expression of calcineurin pathway genes result in defects or alterations in cardiomyocyte maturation, heart valve formation, vascular development, skeletal muscle differentiation and fiber-type switching, and cardiac and skeletal muscle hypertrophy. Conserved calcineurin genes are found in invertebrates such as Drosophila and Caenorhabditis elegans, and genetic studies have demonstrated specific myogenic functions for the phosphatase in their development. The ability to investigate calcineurin signaling pathways in vertebrates and model genetic organisms provides a great potential to more fully comprehend the functions of calcineurin and its interacting genes in heart, blood vessel, and muscle development.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "f5da104a83c341a2b668ac142d827213", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[0, 0], [160, 160], [19, 19], [192, 192], [124, 124], [212, 212], [103, 103], [65, 65]], "char_spans": [[0, 10], [1058, 1068], [120, 130], [1285, 1295], [812, 822], [1428, 1438], [673, 683], [435, 445]]}]}], "context_tokens": [["Calcineurin", 0], ["signaling", 12], ["has", 22], ["been", 26], ["implicated", 31], ["in", 42], ["a", 45], ["broad", 47], ["spectrum", 53], ["of", 62], ["developmental", 65], ["processes", 79], ["in", 89], ["a", 92], ["variety", 94], ["of", 102], ["organ", 105], ["systems", 111], [".", 118], ["Calcineurin", 120], ["is", 132], ["a", 135], ["calmodulin", 137], ["-", 147], ["dependent", 148], [",", 157], ["calcium", 159], ["-", 166], ["activated", 167], ["protein", 177], ["phosphatase", 185], ["composed", 197], ["of", 206], ["catalytic", 209], ["and", 219], ["regulatory", 223], ["subunits", 234], [".", 242], ["The", 244], ["serine", 248], ["/", 254], ["threonine", 255], ["-", 264], ["specific", 265], ["phosphatase", 274], ["functions", 286], ["within", 296], ["a", 303], ["signal", 305], ["transduction", 312], ["pathway", 325], ["that", 333], ["regulates", 338], ["gene", 348], ["expression", 353], ["and", 364], ["biological", 368], ["responses", 379], ["in", 389], ["many", 392], ["developmentally", 397], ["important", 413], ["cell", 423], ["types", 428], [".", 433], ["Calcineurin", 435], ["signaling", 447], ["was", 457], ["first", 461], ["defined", 467], ["in", 475], ["T", 478], ["lymphocytes", 480], ["as", 492], ["a", 495], ["regulator", 497], ["of", 507], ["nuclear", 510], ["factor", 518], ["of", 525], ["activated", 528], ["T", 538], ["cells", 540], ["(", 546], ["NFAT", 547], [")", 551], ["transcription", 553], ["factor", 567], ["nuclear", 574], ["translocation", 582], ["and", 596], ["activation", 600], [".", 610], ["Recent", 612], ["studies", 619], ["have", 627], ["demonstrated", 632], ["the", 645], ["vital", 649], ["nature", 655], ["of", 662], ["calcium", 665], ["/", 672], ["calcineurin", 673], ["/", 684], ["NFAT", 685], ["signaling", 690], ["in", 700], ["cardiovascular", 703], ["and", 718], ["skeletal", 722], ["muscle", 731], ["development", 738], ["in", 750], ["vertebrates", 753], [".", 764], ["Inhibition", 766], [",", 776], ["mutation", 778], [",", 786], ["or", 788], ["forced", 791], ["expression", 798], ["of", 809], ["calcineurin", 812], ["pathway", 824], ["genes", 832], ["result", 838], ["in", 845], ["defects", 848], ["or", 856], ["alterations", 859], ["in", 871], ["cardiomyocyte", 874], ["maturation", 888], [",", 898], ["heart", 900], ["valve", 906], ["formation", 912], [",", 921], ["vascular", 923], ["development", 932], [",", 943], ["skeletal", 945], ["muscle", 954], ["differentiation", 961], ["and", 977], ["fiber", 981], ["-", 986], ["type", 987], ["switching", 992], [",", 1001], ["and", 1003], ["cardiac", 1007], ["and", 1015], ["skeletal", 1019], ["muscle", 1028], ["hypertrophy", 1035], [".", 1046], ["Conserved", 1048], ["calcineurin", 1058], ["genes", 1070], ["are", 1076], ["found", 1080], ["in", 1086], ["invertebrates", 1089], ["such", 1103], ["as", 1108], ["Drosophila", 1111], ["and", 1122], ["Caenorhabditis", 1126], ["elegans", 1141], [",", 1148], ["and", 1150], ["genetic", 1154], ["studies", 1162], ["have", 1170], ["demonstrated", 1175], ["specific", 1188], ["myogenic", 1197], ["functions", 1206], ["for", 1216], ["the", 1220], ["phosphatase", 1224], ["in", 1236], ["their", 1239], ["development", 1245], [".", 1256], ["The", 1258], ["ability", 1262], ["to", 1270], ["investigate", 1273], ["calcineurin", 1285], ["signaling", 1297], ["pathways", 1307], ["in", 1316], ["vertebrates", 1319], ["and", 1331], ["model", 1335], ["genetic", 1341], ["organisms", 1349], ["provides", 1359], ["a", 1368], ["great", 1370], ["potential", 1376], ["to", 1386], ["more", 1389], ["fully", 1394], ["comprehend", 1400], ["the", 1411], ["functions", 1415], ["of", 1425], ["calcineurin", 1428], ["and", 1440], ["its", 1444], ["interacting", 1448], ["genes", 1460], ["in", 1466], ["heart", 1469], [",", 1474], ["blood", 1476], ["vessel", 1482], [",", 1488], ["and", 1490], ["muscle", 1494], ["development", 1501], [".", 1512]]}
{"context": "Oxidative stress activates the c-Jun N-terminal kinase (JNK) pathway. However, the exact mechanisms by which reactive oxygen species (ROS) activate JNK are unclear. We found that the ability of hydrogen peroxide (H(2)O(2)) to induce JNK activation varied in different cell types. Pyrrolidine dithiocarbamate (PDTC), a presumed antioxidant, induced JNK activation on its own and enhanced JNK activation by H(2)O(2) in many cell types, including Jurkat, HEK293, and LNCaP and Tsu-Pr1 prostate cancer cells. The activation of JNK by PDTC, in the presence or absence of exogenous H(2)O(2), was dependent on its chelating ability to metal ions, most likely copper ions. Despite the strong JNK-activating ability, H(2)O(2) plus PDTC did not induce significant activation of the upstream kinases, SEK1/MKK4 and MKK7. However, the JNK inactivation rate was slower in cells treated with H(2)O(2) plus PDTC compared with the rate in cells treated with ultraviolet C (UV-C). Treatment of H(2)O(2) plus PDTC significantly decreased the expression levels of a JNK phosphatase, M3/6 (also named hVH-5), but not the levels of other phosphatases (PP2A and PP4). In contrast, UV-C irradiation did not cause the down-regulation of M3/6. These results suggest that JNK activation by H(2)O(2) plus PDTC resulted from the down-regulation of JNK phosphatases. Our data also reveal a necessity to carefully evaluate the pharmacological and biochemical properties of PDTC.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "c5027f2833494601b4a79b125f0210f2", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[48, 48], [160, 160], [67, 67], [74, 74], [102, 102], [134, 134], [202, 202], [12, 12], [246, 246], [260, 260], [30, 30]], "char_spans": [[233, 235], [823, 825], [348, 350], [387, 389], [523, 525], [684, 686], [1047, 1049], [56, 58], [1246, 1248], [1320, 1322], [148, 150]]}]}], "context_tokens": [["Oxidative", 0], ["stress", 10], ["activates", 17], ["the", 27], ["c", 31], ["-", 32], ["Jun", 33], ["N", 37], ["-", 38], ["terminal", 39], ["kinase", 48], ["(", 55], ["JNK", 56], [")", 59], ["pathway", 61], [".", 68], ["However", 70], [",", 77], ["the", 79], ["exact", 83], ["mechanisms", 89], ["by", 100], ["which", 103], ["reactive", 109], ["oxygen", 118], ["species", 125], ["(", 133], ["ROS", 134], [")", 137], ["activate", 139], ["JNK", 148], ["are", 152], ["unclear", 156], [".", 163], ["We", 165], ["found", 168], ["that", 174], ["the", 179], ["ability", 183], ["of", 191], ["hydrogen", 194], ["peroxide", 203], ["(", 212], ["H(2)O(2", 213], [")", 220], [")", 221], ["to", 223], ["induce", 226], ["JNK", 233], ["activation", 237], ["varied", 248], ["in", 255], ["different", 258], ["cell", 268], ["types", 273], [".", 278], ["Pyrrolidine", 280], ["dithiocarbamate", 292], ["(", 308], ["PDTC", 309], [")", 313], [",", 314], ["a", 316], ["presumed", 318], ["antioxidant", 327], [",", 338], ["induced", 340], ["JNK", 348], ["activation", 352], ["on", 363], ["its", 366], ["own", 370], ["and", 374], ["enhanced", 378], ["JNK", 387], ["activation", 391], ["by", 402], ["H(2)O(2", 405], [")", 412], ["in", 414], ["many", 417], ["cell", 422], ["types", 427], [",", 432], ["including", 434], ["Jurkat", 444], [",", 450], ["HEK293", 452], [",", 458], ["and", 460], ["LNCaP", 464], ["and", 470], ["Tsu", 474], ["-", 477], ["Pr1", 478], ["prostate", 482], ["cancer", 491], ["cells", 498], [".", 503], ["The", 505], ["activation", 509], ["of", 520], ["JNK", 523], ["by", 527], ["PDTC", 530], [",", 534], ["in", 536], ["the", 539], ["presence", 543], ["or", 552], ["absence", 555], ["of", 563], ["exogenous", 566], ["H(2)O(2", 576], [")", 583], [",", 584], ["was", 586], ["dependent", 590], ["on", 600], ["its", 603], ["chelating", 607], ["ability", 617], ["to", 625], ["metal", 628], ["ions", 634], [",", 638], ["most", 640], ["likely", 645], ["copper", 652], ["ions", 659], [".", 663], ["Despite", 665], ["the", 673], ["strong", 677], ["JNK", 684], ["-", 687], ["activating", 688], ["ability", 699], [",", 706], ["H(2)O(2", 708], [")", 715], ["plus", 717], ["PDTC", 722], ["did", 727], ["not", 731], ["induce", 735], ["significant", 742], ["activation", 754], ["of", 765], ["the", 768], ["upstream", 772], ["kinases", 781], [",", 788], ["SEK1/MKK4", 790], ["and", 800], ["MKK7", 804], [".", 808], ["However", 810], [",", 817], ["the", 819], ["JNK", 823], ["inactivation", 827], ["rate", 840], ["was", 845], ["slower", 849], ["in", 856], ["cells", 859], ["treated", 865], ["with", 873], ["H(2)O(2", 878], [")", 885], ["plus", 887], ["PDTC", 892], ["compared", 897], ["with", 906], ["the", 911], ["rate", 915], ["in", 920], ["cells", 923], ["treated", 929], ["with", 937], ["ultraviolet", 942], ["C", 954], ["(", 956], ["UV", 957], ["-", 959], ["C", 960], [")", 961], [".", 962], ["Treatment", 964], ["of", 974], ["H(2)O(2", 977], [")", 984], ["plus", 986], ["PDTC", 991], ["significantly", 996], ["decreased", 1010], ["the", 1020], ["expression", 1024], ["levels", 1035], ["of", 1042], ["a", 1045], ["JNK", 1047], ["phosphatase", 1051], [",", 1062], ["M3/6", 1064], ["(", 1069], ["also", 1070], ["named", 1075], ["hVH-5", 1081], [")", 1086], [",", 1087], ["but", 1089], ["not", 1093], ["the", 1097], ["levels", 1101], ["of", 1108], ["other", 1111], ["phosphatases", 1117], ["(", 1130], ["PP2A", 1131], ["and", 1136], ["PP4", 1140], [")", 1143], [".", 1144], ["In", 1146], ["contrast", 1149], [",", 1157], ["UV", 1159], ["-", 1161], ["C", 1162], ["irradiation", 1164], ["did", 1176], ["not", 1180], ["cause", 1184], ["the", 1190], ["down", 1194], ["-", 1198], ["regulation", 1199], ["of", 1210], ["M3/6", 1213], [".", 1217], ["These", 1219], ["results", 1225], ["suggest", 1233], ["that", 1241], ["JNK", 1246], ["activation", 1250], ["by", 1261], ["H(2)O(2", 1264], [")", 1271], ["plus", 1273], ["PDTC", 1278], ["resulted", 1283], ["from", 1292], ["the", 1297], ["down", 1301], ["-", 1305], ["regulation", 1306], ["of", 1317], ["JNK", 1320], ["phosphatases", 1324], [".", 1336], ["Our", 1338], ["data", 1342], ["also", 1347], ["reveal", 1352], ["a", 1359], ["necessity", 1361], ["to", 1371], ["carefully", 1374], ["evaluate", 1384], ["the", 1393], ["pharmacological", 1397], ["and", 1413], ["biochemical", 1417], ["properties", 1429], ["of", 1440], ["PDTC", 1443], [".", 1447]]}
{"context": "One of the major histopathological hallmarks of Alzheimer's disease (AD) is cerebral deposits of extracellular \u03b2-amyloid peptides. Preclinical studies have pointed to glucagon-like peptide 1 (GLP-1) receptors as a potential novel target in the treatment of AD. GLP-1 receptor agonists, including exendin-4 and liraglutide, have been shown to promote plaque-lowering and mnemonic effects of in a number of experimental models of AD. Transgenic mouse models carrying genetic mutations of amyloid protein precursor (APP) and presenilin-1 (PS1) are commonly used to assess the pharmacodynamics of potential amyloidosis-lowering and pro-cognitive compounds. In this study, effects of long-term liraglutide treatment were therefore determined in two double APP/PS1 transgenic mouse models of Alzheimer's disease carrying different clinical APP/PS1 mutations, i.e. the 'London' (hAPPLon/PS1A246E) and 'Swedish' mutation variant (hAPPSwe/PS1\u0394E9) of APP, with co-expression of distinct PS1 variants. Liraglutide was administered in 5 month-old hAPPLon/PS1A246E mice for 3 months (100 or 500 ng/kg/day, s.c.), or 7 month-old hAPPSwe/PS1\u0394E9 mice for 5 months (500 ng/kg/day, s.c.). In both models, regional plaque load was quantified throughout the brain using stereological methods. Vehicle-dosed hAPPSwe/PS1\u0394E9 mice exhibited considerably higher cerebral plaque load than hAPPLon/PS1A246E control mice. Compared to vehicle-dosed transgenic controls, liraglutide treatment had no effect on the plaque levels in hAPPLon/PS1A246E and hAPPSwe/PS1\u0394E9 mice. In conclusion, long-term liraglutide treatment exhibited no effect on cerebral plaque load in two transgenic mouse models of low- and high-grade amyloidosis, which suggests differential sensitivity to long-term liraglutide treatment in various transgenic mouse models mimicking distinct pathological hallmarks of AD.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "9e28aa040a2f43c3ab63eeba84b5f4de", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[138, 140], [7, 9]], "char_spans": [[786, 804], [48, 66]]}, {"text": "AD", "token_spans": [[76, 76], [11, 11], [346, 346], [46, 46]], "char_spans": [[428, 429], [69, 70], [1856, 1857], [257, 258]]}]}], "context_tokens": [["One", 0], ["of", 4], ["the", 7], ["major", 11], ["histopathological", 17], ["hallmarks", 35], ["of", 45], ["Alzheimer", 48], ["'s", 57], ["disease", 60], ["(", 68], ["AD", 69], [")", 71], ["is", 73], ["cerebral", 76], ["deposits", 85], ["of", 94], ["extracellular", 97], ["\u03b2", 111], ["-", 112], ["amyloid", 113], ["peptides", 121], [".", 129], ["Preclinical", 131], ["studies", 143], ["have", 151], ["pointed", 156], ["to", 164], ["glucagon", 167], ["-", 175], ["like", 176], ["peptide", 181], ["1", 189], ["(", 191], ["GLP-1", 192], [")", 197], ["receptors", 199], ["as", 209], ["a", 212], ["potential", 214], ["novel", 224], ["target", 230], ["in", 237], ["the", 240], ["treatment", 244], ["of", 254], ["AD", 257], [".", 259], ["GLP-1", 261], ["receptor", 267], ["agonists", 276], [",", 284], ["including", 286], ["exendin-4", 296], ["and", 306], ["liraglutide", 310], [",", 321], ["have", 323], ["been", 328], ["shown", 333], ["to", 339], ["promote", 342], ["plaque", 350], ["-", 356], ["lowering", 357], ["and", 366], ["mnemonic", 370], ["effects", 379], ["of", 387], ["in", 390], ["a", 393], ["number", 395], ["of", 402], ["experimental", 405], ["models", 418], ["of", 425], ["AD", 428], [".", 430], ["Transgenic", 432], ["mouse", 443], ["models", 449], ["carrying", 456], ["genetic", 465], ["mutations", 473], ["of", 483], ["amyloid", 486], ["protein", 494], ["precursor", 502], ["(", 512], ["APP", 513], [")", 516], ["and", 518], ["presenilin-1", 522], ["(", 535], ["PS1", 536], [")", 539], ["are", 541], ["commonly", 545], ["used", 554], ["to", 559], ["assess", 562], ["the", 569], ["pharmacodynamics", 573], ["of", 590], ["potential", 593], ["amyloidosis", 603], ["-", 614], ["lowering", 615], ["and", 624], ["pro", 628], ["-", 631], ["cognitive", 632], ["compounds", 642], [".", 651], ["In", 653], ["this", 656], ["study", 661], [",", 666], ["effects", 668], ["of", 676], ["long", 679], ["-", 683], ["term", 684], ["liraglutide", 689], ["treatment", 701], ["were", 711], ["therefore", 716], ["determined", 726], ["in", 737], ["two", 740], ["double", 744], ["APP", 751], ["/", 754], ["PS1", 755], ["transgenic", 759], ["mouse", 770], ["models", 776], ["of", 783], ["Alzheimer", 786], ["'s", 795], ["disease", 798], ["carrying", 806], ["different", 815], ["clinical", 825], ["APP", 834], ["/", 837], ["PS1", 838], ["mutations", 842], [",", 851], ["i.e.", 853], ["the", 858], ["'", 862], ["London", 863], ["'", 869], ["(", 871], ["hAPPLon", 872], ["/", 879], ["PS1A246E", 880], [")", 888], ["and", 890], ["'", 894], ["Swedish", 895], ["'", 902], ["mutation", 904], ["variant", 913], ["(", 921], ["hAPPSwe", 922], ["/", 929], ["PS1\u0394E9", 930], [")", 936], ["of", 938], ["APP", 941], [",", 944], ["with", 946], ["co", 951], ["-", 953], ["expression", 954], ["of", 965], ["distinct", 968], ["PS1", 977], ["variants", 981], [".", 989], ["Liraglutide", 991], ["was", 1003], ["administered", 1007], ["in", 1020], ["5", 1023], ["month", 1025], ["-", 1030], ["old", 1031], ["hAPPLon", 1035], ["/", 1042], ["PS1A246E", 1043], ["mice", 1052], ["for", 1057], ["3", 1061], ["months", 1063], ["(", 1070], ["100", 1071], ["or", 1075], ["500", 1078], ["ng", 1082], ["/", 1084], ["kg", 1085], ["/", 1087], ["day", 1088], [",", 1091], ["s.c", 1093], [".", 1096], [")", 1097], [",", 1098], ["or", 1100], ["7", 1103], ["month", 1105], ["-", 1110], ["old", 1111], ["hAPPSwe", 1115], ["/", 1122], ["PS1\u0394E9", 1123], ["mice", 1130], ["for", 1135], ["5", 1139], ["months", 1141], ["(", 1148], ["500", 1149], ["ng", 1153], ["/", 1155], ["kg", 1156], ["/", 1158], ["day", 1159], [",", 1162], ["s.c", 1164], [".", 1167], [")", 1168], [".", 1169], ["In", 1171], ["both", 1174], ["models", 1179], [",", 1185], ["regional", 1187], ["plaque", 1196], ["load", 1203], ["was", 1208], ["quantified", 1212], ["throughout", 1223], ["the", 1234], ["brain", 1238], ["using", 1244], ["stereological", 1250], ["methods", 1264], [".", 1271], ["Vehicle", 1273], ["-", 1280], ["dosed", 1281], ["hAPPSwe", 1287], ["/", 1294], ["PS1\u0394E9", 1295], ["mice", 1302], ["exhibited", 1307], ["considerably", 1317], ["higher", 1330], ["cerebral", 1337], ["plaque", 1346], ["load", 1353], ["than", 1358], ["hAPPLon", 1363], ["/", 1370], ["PS1A246E", 1371], ["control", 1380], ["mice", 1388], [".", 1392], ["Compared", 1394], ["to", 1403], ["vehicle", 1406], ["-", 1413], ["dosed", 1414], ["transgenic", 1420], ["controls", 1431], [",", 1439], ["liraglutide", 1441], ["treatment", 1453], ["had", 1463], ["no", 1467], ["effect", 1470], ["on", 1477], ["the", 1480], ["plaque", 1484], ["levels", 1491], ["in", 1498], ["hAPPLon", 1501], ["/", 1508], ["PS1A246E", 1509], ["and", 1518], ["hAPPSwe", 1522], ["/", 1529], ["PS1\u0394E9", 1530], ["mice", 1537], [".", 1541], ["In", 1543], ["conclusion", 1546], [",", 1556], ["long", 1558], ["-", 1562], ["term", 1563], ["liraglutide", 1568], ["treatment", 1580], ["exhibited", 1590], ["no", 1600], ["effect", 1603], ["on", 1610], ["cerebral", 1613], ["plaque", 1622], ["load", 1629], ["in", 1634], ["two", 1637], ["transgenic", 1641], ["mouse", 1652], ["models", 1658], ["of", 1665], ["low-", 1668], ["and", 1673], ["high", 1677], ["-", 1681], ["grade", 1682], ["amyloidosis", 1688], [",", 1699], ["which", 1701], ["suggests", 1707], ["differential", 1716], ["sensitivity", 1729], ["to", 1741], ["long", 1744], ["-", 1748], ["term", 1749], ["liraglutide", 1754], ["treatment", 1766], ["in", 1776], ["various", 1779], ["transgenic", 1787], ["mouse", 1798], ["models", 1804], ["mimicking", 1811], ["distinct", 1821], ["pathological", 1830], ["hallmarks", 1843], ["of", 1853], ["AD", 1856], [".", 1858]]}
{"context": "Na\u00efve and primed pluripotent states retain distinct molecular properties, yet limited knowledge exists on how their state transitions are regulated. Here, we identify Mettl3, an N(6)-methyladenosine (m(6)A) transferase, as a regulator for terminating murine na\u00efve pluripotency. Mettl3 knockout preimplantation epiblasts and na\u00efve embryonic stem cells are depleted for m(6)A in mRNAs, yet are viable. However, they fail to adequately terminate their na\u00efve state and, subsequently, undergo aberrant and restricted lineage priming at the postimplantation stage, which leads to early embryonic lethality. m(6)A predominantly and directly reduces mRNA stability, including that of key na\u00efve pluripotency-promoting transcripts. This study highlights a critical role for an mRNA epigenetic modification in vivo and identifies regulatory modules that functionally influence na\u00efve and primed pluripotency in an opposing manner.", "qas": [{"question": "Which properties of the mRNA does N6-methyladenosine (m6A) affect?", "answers": ["mRNA stability"], "qid": "e2dccc6fa3a84b67a72cd87b03a0db2e", "question_tokens": [["Which", 0], ["properties", 6], ["of", 17], ["the", 20], ["mRNA", 24], ["does", 29], ["N6-methyladenosine", 34], ["(", 53], ["m6A", 54], [")", 57], ["affect", 59], ["?", 65]], "detected_answers": [{"text": "mRNA stability", "token_spans": [[101, 102]], "char_spans": [[642, 655]]}]}], "context_tokens": [["Na\u00efve", 0], ["and", 6], ["primed", 10], ["pluripotent", 17], ["states", 29], ["retain", 36], ["distinct", 43], ["molecular", 52], ["properties", 62], [",", 72], ["yet", 74], ["limited", 78], ["knowledge", 86], ["exists", 96], ["on", 103], ["how", 106], ["their", 110], ["state", 116], ["transitions", 122], ["are", 134], ["regulated", 138], [".", 147], ["Here", 149], [",", 153], ["we", 155], ["identify", 158], ["Mettl3", 167], [",", 173], ["an", 175], ["N(6)-methyladenosine", 178], ["(", 199], ["m(6)A", 200], [")", 205], ["transferase", 207], [",", 218], ["as", 220], ["a", 223], ["regulator", 225], ["for", 235], ["terminating", 239], ["murine", 251], ["na\u00efve", 258], ["pluripotency", 264], [".", 276], ["Mettl3", 278], ["knockout", 285], ["preimplantation", 294], ["epiblasts", 310], ["and", 320], ["na\u00efve", 324], ["embryonic", 330], ["stem", 340], ["cells", 345], ["are", 351], ["depleted", 355], ["for", 364], ["m(6)A", 368], ["in", 374], ["mRNAs", 377], [",", 382], ["yet", 384], ["are", 388], ["viable", 392], [".", 398], ["However", 400], [",", 407], ["they", 409], ["fail", 414], ["to", 419], ["adequately", 422], ["terminate", 433], ["their", 443], ["na\u00efve", 449], ["state", 455], ["and", 461], [",", 464], ["subsequently", 466], [",", 478], ["undergo", 480], ["aberrant", 488], ["and", 497], ["restricted", 501], ["lineage", 512], ["priming", 520], ["at", 528], ["the", 531], ["postimplantation", 535], ["stage", 552], [",", 557], ["which", 559], ["leads", 565], ["to", 571], ["early", 574], ["embryonic", 580], ["lethality", 590], [".", 599], ["m(6)A", 601], ["predominantly", 607], ["and", 621], ["directly", 625], ["reduces", 634], ["mRNA", 642], ["stability", 647], [",", 656], ["including", 658], ["that", 668], ["of", 673], ["key", 676], ["na\u00efve", 680], ["pluripotency", 686], ["-", 698], ["promoting", 699], ["transcripts", 709], [".", 720], ["This", 722], ["study", 727], ["highlights", 733], ["a", 744], ["critical", 746], ["role", 755], ["for", 760], ["an", 764], ["mRNA", 767], ["epigenetic", 772], ["modification", 783], ["in", 796], ["vivo", 799], ["and", 804], ["identifies", 808], ["regulatory", 819], ["modules", 830], ["that", 838], ["functionally", 843], ["influence", 856], ["na\u00efve", 866], ["and", 872], ["primed", 876], ["pluripotency", 883], ["in", 896], ["an", 899], ["opposing", 902], ["manner", 911], [".", 917]]}
{"context": "Dystrophic myotonia is a sufficiently rare disease inherited mainly by the autosomal dominant type. Clinical picture is characterized by the myotonic, myopathic, and endocrine-autonomic syndrome. A clinical, genetic, and electromyographic study was carried out to elucidate the problem of this condition inheritance, its intra- and interfamilial clinical polymorphism, and effects of environmental factors on its course and outcomes.", "qas": [{"question": "How is myotonic dystrophy inherited?", "answers": ["autosomal dominant"], "qid": "52cd8f90006a41c999627c367f252ff3", "question_tokens": [["How", 0], ["is", 4], ["myotonic", 7], ["dystrophy", 16], ["inherited", 26], ["?", 35]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[11, 12]], "char_spans": [[75, 92]]}]}], "context_tokens": [["Dystrophic", 0], ["myotonia", 11], ["is", 20], ["a", 23], ["sufficiently", 25], ["rare", 38], ["disease", 43], ["inherited", 51], ["mainly", 61], ["by", 68], ["the", 71], ["autosomal", 75], ["dominant", 85], ["type", 94], [".", 98], ["Clinical", 100], ["picture", 109], ["is", 117], ["characterized", 120], ["by", 134], ["the", 137], ["myotonic", 141], [",", 149], ["myopathic", 151], [",", 160], ["and", 162], ["endocrine", 166], ["-", 175], ["autonomic", 176], ["syndrome", 186], [".", 194], ["A", 196], ["clinical", 198], [",", 206], ["genetic", 208], [",", 215], ["and", 217], ["electromyographic", 221], ["study", 239], ["was", 245], ["carried", 249], ["out", 257], ["to", 261], ["elucidate", 264], ["the", 274], ["problem", 278], ["of", 286], ["this", 289], ["condition", 294], ["inheritance", 304], [",", 315], ["its", 317], ["intra-", 321], ["and", 328], ["interfamilial", 332], ["clinical", 346], ["polymorphism", 355], [",", 367], ["and", 369], ["effects", 373], ["of", 381], ["environmental", 384], ["factors", 398], ["on", 406], ["its", 409], ["course", 413], ["and", 420], ["outcomes", 424], [".", 432]]}
{"context": "\u03b1-Synuclein is the major protein component of Lewy bodies--the pathological hallmark of Parkinson's disease (PD) and Dementia with Lewy bodies (DLB). Its accumulation into intracellular aggregates is implicated in the process of Lewy body formation. However, its roles in both normal function, and disease, remain controversial. Using a novel model of chronic oxidative stress in cultured dopaminergic and cortical neurons, we report that endogenous \u03b1-synuclein is upregulated in response to low dose toxicity. This response is conserved between subpopulations of cortical and dopaminergic neurons, and confers relative resistance to apoptosis following secondary insult. Additional acute oxidative stress leads to intracellular accumulation of \u03b1-synuclein. These punctate deposits colocalize with ubiquitin, which is central to proteosome-mediated protein degeneration, and is the second major component of Lewy bodies. The current results imply that differential levels of \u03b1-synuclein expression may influence neuronal vulnerability in chronic neurodegenerative diseases. They further support a 'two hit' hypothesis for Lewy body formation, whereby mild stress causes a protective upregulation of \u03b1-synuclein. However, such increased levels of \u03b1-synuclein may drive its accumulation, following additional toxic insult. Finally, these results support a common mechanism for degeneration of dopaminergic and cortical neurons, affected in PD, and DLB, respectively.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4504ae5e0d41435984b259c276b8cf7f", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[80, 82], [0, 2], [197, 199], [207, 209], [162, 164], [123, 125]], "char_spans": [[450, 460], [0, 10], [1199, 1209], [1246, 1256], [975, 985], [745, 755]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["is", 12], ["the", 15], ["major", 19], ["protein", 25], ["component", 33], ["of", 43], ["Lewy", 46], ["bodies", 51], ["--", 57], ["the", 59], ["pathological", 63], ["hallmark", 76], ["of", 85], ["Parkinson", 88], ["'s", 97], ["disease", 100], ["(", 108], ["PD", 109], [")", 111], ["and", 113], ["Dementia", 117], ["with", 126], ["Lewy", 131], ["bodies", 136], ["(", 143], ["DLB", 144], [")", 147], [".", 148], ["Its", 150], ["accumulation", 154], ["into", 167], ["intracellular", 172], ["aggregates", 186], ["is", 197], ["implicated", 200], ["in", 211], ["the", 214], ["process", 218], ["of", 226], ["Lewy", 229], ["body", 234], ["formation", 239], [".", 248], ["However", 250], [",", 257], ["its", 259], ["roles", 263], ["in", 269], ["both", 272], ["normal", 277], ["function", 284], [",", 292], ["and", 294], ["disease", 298], [",", 305], ["remain", 307], ["controversial", 314], [".", 327], ["Using", 329], ["a", 335], ["novel", 337], ["model", 343], ["of", 349], ["chronic", 352], ["oxidative", 360], ["stress", 370], ["in", 377], ["cultured", 380], ["dopaminergic", 389], ["and", 402], ["cortical", 406], ["neurons", 415], [",", 422], ["we", 424], ["report", 427], ["that", 434], ["endogenous", 439], ["\u03b1", 450], ["-", 451], ["synuclein", 452], ["is", 462], ["upregulated", 465], ["in", 477], ["response", 480], ["to", 489], ["low", 492], ["dose", 496], ["toxicity", 501], [".", 509], ["This", 511], ["response", 516], ["is", 525], ["conserved", 528], ["between", 538], ["subpopulations", 546], ["of", 561], ["cortical", 564], ["and", 573], ["dopaminergic", 577], ["neurons", 590], [",", 597], ["and", 599], ["confers", 603], ["relative", 611], ["resistance", 620], ["to", 631], ["apoptosis", 634], ["following", 644], ["secondary", 654], ["insult", 664], [".", 670], ["Additional", 672], ["acute", 683], ["oxidative", 689], ["stress", 699], ["leads", 706], ["to", 712], ["intracellular", 715], ["accumulation", 729], ["of", 742], ["\u03b1", 745], ["-", 746], ["synuclein", 747], [".", 756], ["These", 758], ["punctate", 764], ["deposits", 773], ["colocalize", 782], ["with", 793], ["ubiquitin", 798], [",", 807], ["which", 809], ["is", 815], ["central", 818], ["to", 826], ["proteosome", 829], ["-", 839], ["mediated", 840], ["protein", 849], ["degeneration", 857], [",", 869], ["and", 871], ["is", 875], ["the", 878], ["second", 882], ["major", 889], ["component", 895], ["of", 905], ["Lewy", 908], ["bodies", 913], [".", 919], ["The", 921], ["current", 925], ["results", 933], ["imply", 941], ["that", 947], ["differential", 952], ["levels", 965], ["of", 972], ["\u03b1", 975], ["-", 976], ["synuclein", 977], ["expression", 987], ["may", 998], ["influence", 1002], ["neuronal", 1012], ["vulnerability", 1021], ["in", 1035], ["chronic", 1038], ["neurodegenerative", 1046], ["diseases", 1064], [".", 1072], ["They", 1074], ["further", 1079], ["support", 1087], ["a", 1095], ["'", 1097], ["two", 1098], ["hit", 1102], ["'", 1105], ["hypothesis", 1107], ["for", 1118], ["Lewy", 1122], ["body", 1127], ["formation", 1132], [",", 1141], ["whereby", 1143], ["mild", 1151], ["stress", 1156], ["causes", 1163], ["a", 1170], ["protective", 1172], ["upregulation", 1183], ["of", 1196], ["\u03b1", 1199], ["-", 1200], ["synuclein", 1201], [".", 1210], ["However", 1212], [",", 1219], ["such", 1221], ["increased", 1226], ["levels", 1236], ["of", 1243], ["\u03b1", 1246], ["-", 1247], ["synuclein", 1248], ["may", 1258], ["drive", 1262], ["its", 1268], ["accumulation", 1272], [",", 1284], ["following", 1286], ["additional", 1296], ["toxic", 1307], ["insult", 1313], [".", 1319], ["Finally", 1321], [",", 1328], ["these", 1330], ["results", 1336], ["support", 1344], ["a", 1352], ["common", 1354], ["mechanism", 1361], ["for", 1371], ["degeneration", 1375], ["of", 1388], ["dopaminergic", 1391], ["and", 1404], ["cortical", 1408], ["neurons", 1417], [",", 1424], ["affected", 1426], ["in", 1435], ["PD", 1438], [",", 1440], ["and", 1442], ["DLB", 1446], [",", 1449], ["respectively", 1451], [".", 1463]]}
{"context": "Chronic myeloid leukemia (CML) is a pluripotent hematopoietic disorder that is currently considered incurable. The tyrosine kinase product of the Philadelphia chromosome, P210 BCR-ABL, provided a pathogenetic explanation for the initiation of the CML chronic phase and is the molecular therapeutic target for the disease. Imatinib mesylate, an orally available BCR-ABL kinase inhibitor, can induce haematologic and cytogenetic remission of CML. However, imatinib resistance occurs frequently, resulting in relapse. New treatment strategies are focusing on resistant CML stem cells and the bone marrow stroma. The identification of novel pathways and mechanisms in the bone marrow microenvironment could significantly contribute to the development of such strategies. In this work, we used a high-resolution label-free MS(E)  proteomic approach to identify differential protein expression in the CML bone marrow plasma of responsive and resistant patients. Oxidative lipid metabolism and regulation of the switch from canonical to noncanonical WNT signaling may contribute to CML resistance in the bone marrow compartment.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "c3ce02b73a0e40788ece57c69b7aafc1", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[59, 61], [27, 29]], "char_spans": [[361, 367], [176, 182]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["pluripotent", 36], ["hematopoietic", 48], ["disorder", 62], ["that", 71], ["is", 76], ["currently", 79], ["considered", 89], ["incurable", 100], [".", 109], ["The", 111], ["tyrosine", 115], ["kinase", 124], ["product", 131], ["of", 139], ["the", 142], ["Philadelphia", 146], ["chromosome", 159], [",", 169], ["P210", 171], ["BCR", 176], ["-", 179], ["ABL", 180], [",", 183], ["provided", 185], ["a", 194], ["pathogenetic", 196], ["explanation", 209], ["for", 221], ["the", 225], ["initiation", 229], ["of", 240], ["the", 243], ["CML", 247], ["chronic", 251], ["phase", 259], ["and", 265], ["is", 269], ["the", 272], ["molecular", 276], ["therapeutic", 286], ["target", 298], ["for", 305], ["the", 309], ["disease", 313], [".", 320], ["Imatinib", 322], ["mesylate", 331], [",", 339], ["an", 341], ["orally", 344], ["available", 351], ["BCR", 361], ["-", 364], ["ABL", 365], ["kinase", 369], ["inhibitor", 376], [",", 385], ["can", 387], ["induce", 391], ["haematologic", 398], ["and", 411], ["cytogenetic", 415], ["remission", 427], ["of", 437], ["CML", 440], [".", 443], ["However", 445], [",", 452], ["imatinib", 454], ["resistance", 463], ["occurs", 474], ["frequently", 481], [",", 491], ["resulting", 493], ["in", 503], ["relapse", 506], [".", 513], ["New", 515], ["treatment", 519], ["strategies", 529], ["are", 540], ["focusing", 544], ["on", 553], ["resistant", 556], ["CML", 566], ["stem", 570], ["cells", 575], ["and", 581], ["the", 585], ["bone", 589], ["marrow", 594], ["stroma", 601], [".", 607], ["The", 609], ["identification", 613], ["of", 628], ["novel", 631], ["pathways", 637], ["and", 646], ["mechanisms", 650], ["in", 661], ["the", 664], ["bone", 668], ["marrow", 673], ["microenvironment", 680], ["could", 697], ["significantly", 703], ["contribute", 717], ["to", 728], ["the", 731], ["development", 735], ["of", 747], ["such", 750], ["strategies", 755], [".", 765], ["In", 767], ["this", 770], ["work", 775], [",", 779], ["we", 781], ["used", 784], ["a", 789], ["high", 791], ["-", 795], ["resolution", 796], ["label", 807], ["-", 812], ["free", 813], ["MS(E", 818], [")", 822], ["proteomic", 825], ["approach", 835], ["to", 844], ["identify", 847], ["differential", 856], ["protein", 869], ["expression", 877], ["in", 888], ["the", 891], ["CML", 895], ["bone", 899], ["marrow", 904], ["plasma", 911], ["of", 918], ["responsive", 921], ["and", 932], ["resistant", 936], ["patients", 946], [".", 954], ["Oxidative", 956], ["lipid", 966], ["metabolism", 972], ["and", 983], ["regulation", 987], ["of", 998], ["the", 1001], ["switch", 1005], ["from", 1012], ["canonical", 1017], ["to", 1027], ["noncanonical", 1030], ["WNT", 1043], ["signaling", 1047], ["may", 1057], ["contribute", 1061], ["to", 1072], ["CML", 1075], ["resistance", 1079], ["in", 1090], ["the", 1093], ["bone", 1097], ["marrow", 1102], ["compartment", 1109], [".", 1120]]}
{"context": "To determine the change in prevalence of posttraumatic stress disorder (PTSD) symptoms in victims of the March 11 attacks and their relatives, 1 and 6 months after the attacks. Evaluation of PTSD symptoms using the Davidson Trauma Scale (DTS) and General Health Questionnaire (GHQ) in a sample of 56 patients admitted to an emergency room of a general hospital, and assessment of PTSD symptoms in relatives of the patients. At Month 1, 41.1% of patients (31.3% of males and 54.2% of females) presented with PTSD. At Month 6, this figure was 40.9% (30.4% of males and 52.4% of females). There was a significant improvement in perception of health among females between Month 1 and Month 6. Relatives presented similar DTS scores at baseline and at 6 months. We verified that rates of PTSD did not vary substantively between the two evaluations. PTSD symptoms positively correlated with psychological health involvement. This correlation points out that both PTSD symptoms and subjective general health involvement are part of the psychological response to trauma. The prevalence of PTSD symptoms was high and remained stable between Month 1 and Month 6, while subjective perception of health improved significantly.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "c35f27d4167846e1adc3aadd2981e4dc", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[35, 35], [11, 11], [202, 202], [100, 100], [71, 71], [183, 183], [168, 168], [158, 158]], "char_spans": [[191, 194], [72, 75], [1081, 1084], [507, 510], [380, 383], [957, 960], [844, 847], [783, 786]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["change", 17], ["in", 24], ["prevalence", 27], ["of", 38], ["posttraumatic", 41], ["stress", 55], ["disorder", 62], ["(", 71], ["PTSD", 72], [")", 76], ["symptoms", 78], ["in", 87], ["victims", 90], ["of", 98], ["the", 101], ["March", 105], ["11", 111], ["attacks", 114], ["and", 122], ["their", 126], ["relatives", 132], [",", 141], ["1", 143], ["and", 145], ["6", 149], ["months", 151], ["after", 158], ["the", 164], ["attacks", 168], [".", 175], ["Evaluation", 177], ["of", 188], ["PTSD", 191], ["symptoms", 196], ["using", 205], ["the", 211], ["Davidson", 215], ["Trauma", 224], ["Scale", 231], ["(", 237], ["DTS", 238], [")", 241], ["and", 243], ["General", 247], ["Health", 255], ["Questionnaire", 262], ["(", 276], ["GHQ", 277], [")", 280], ["in", 282], ["a", 285], ["sample", 287], ["of", 294], ["56", 297], ["patients", 300], ["admitted", 309], ["to", 318], ["an", 321], ["emergency", 324], ["room", 334], ["of", 339], ["a", 342], ["general", 344], ["hospital", 352], [",", 360], ["and", 362], ["assessment", 366], ["of", 377], ["PTSD", 380], ["symptoms", 385], ["in", 394], ["relatives", 397], ["of", 407], ["the", 410], ["patients", 414], [".", 422], ["At", 424], ["Month", 427], ["1", 433], [",", 434], ["41.1", 436], ["%", 440], ["of", 442], ["patients", 445], ["(", 454], ["31.3", 455], ["%", 459], ["of", 461], ["males", 464], ["and", 470], ["54.2", 474], ["%", 478], ["of", 480], ["females", 483], [")", 490], ["presented", 492], ["with", 502], ["PTSD", 507], [".", 511], ["At", 513], ["Month", 516], ["6", 522], [",", 523], ["this", 525], ["figure", 530], ["was", 537], ["40.9", 541], ["%", 545], ["(", 547], ["30.4", 548], ["%", 552], ["of", 554], ["males", 557], ["and", 563], ["52.4", 567], ["%", 571], ["of", 573], ["females", 576], [")", 583], [".", 584], ["There", 586], ["was", 592], ["a", 596], ["significant", 598], ["improvement", 610], ["in", 622], ["perception", 625], ["of", 636], ["health", 639], ["among", 646], ["females", 652], ["between", 660], ["Month", 668], ["1", 674], ["and", 676], ["Month", 680], ["6", 686], [".", 687], ["Relatives", 689], ["presented", 699], ["similar", 709], ["DTS", 717], ["scores", 721], ["at", 728], ["baseline", 731], ["and", 740], ["at", 744], ["6", 747], ["months", 749], [".", 755], ["We", 757], ["verified", 760], ["that", 769], ["rates", 774], ["of", 780], ["PTSD", 783], ["did", 788], ["not", 792], ["vary", 796], ["substantively", 801], ["between", 815], ["the", 823], ["two", 827], ["evaluations", 831], [".", 842], ["PTSD", 844], ["symptoms", 849], ["positively", 858], ["correlated", 869], ["with", 880], ["psychological", 885], ["health", 899], ["involvement", 906], [".", 917], ["This", 919], ["correlation", 924], ["points", 936], ["out", 943], ["that", 947], ["both", 952], ["PTSD", 957], ["symptoms", 962], ["and", 971], ["subjective", 975], ["general", 986], ["health", 994], ["involvement", 1001], ["are", 1013], ["part", 1017], ["of", 1022], ["the", 1025], ["psychological", 1029], ["response", 1043], ["to", 1052], ["trauma", 1055], [".", 1061], ["The", 1063], ["prevalence", 1067], ["of", 1078], ["PTSD", 1081], ["symptoms", 1086], ["was", 1095], ["high", 1099], ["and", 1104], ["remained", 1108], ["stable", 1117], ["between", 1124], ["Month", 1132], ["1", 1138], ["and", 1140], ["Month", 1144], ["6", 1150], [",", 1151], ["while", 1153], ["subjective", 1159], ["perception", 1170], ["of", 1181], ["health", 1184], ["improved", 1191], ["significantly", 1200], [".", 1213]]}
{"context": "The relevance of the Simpson grading system as a predictor of meningioma progression or recurrence in modern neurosurgical practice has recently been called into question. The aim of our study was to compare the risk of progression/recurrence of tumours that had been treated with different Simpson grade resections in a contemporary population of benign (WHO grade I) meningioma patients. One hundred eighty-three patients with histologically confirmed WHO grade I meningioma were retrospectively analysed. All patients underwent first-time craniotomy as their initial therapy between 2004 and 2012. Univariate analysis was performed using log-rank testing and Kaplan-Meier analysis for progression/recurrence-free survival. Multivariate analysis was performed using Cox proportional hazards regression modelling. The three-year progression/recurrence-free survival rates for patients receiving Simpson grade 1, 2 or 4 resections were 95 %, 87 % and 67 %, respectively. Simpson grade 4 resections progressed/recurred at a significantly greater rate than Simpson grade 1 resections (hazard ratio [HR]\u2009=\u20093.26, P\u2009=\u20090.04), whereas Simpson grade 2 resections did not progress/recur at a significantly greater rate than Simpson grade 1 resections (HR\u2009=\u20091.78, P\u2009=\u20090.29). Subtotal resections progressed/recurred at a significantly greater rate than gross-total resections (HR\u2009=\u20092.47, P\u2009=\u20090.03). Tumours that undergo subtotal resection are at a significantly greater risk of progression/recurrence than tumours that undergo gross-total resection. Gross-total resection should therefore be the aim of surgery. However, given modern access to follow-up imaging and stereotactic radiosurgery, these results should not be used to justify overly 'heroic' tumour resection.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "44e178e35d844cdd95994960d939d4dd", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[11, 11], [77, 77], [62, 62]], "char_spans": [[62, 71], [466, 475], [369, 378]]}]}], "context_tokens": [["The", 0], ["relevance", 4], ["of", 14], ["the", 17], ["Simpson", 21], ["grading", 29], ["system", 37], ["as", 44], ["a", 47], ["predictor", 49], ["of", 59], ["meningioma", 62], ["progression", 73], ["or", 85], ["recurrence", 88], ["in", 99], ["modern", 102], ["neurosurgical", 109], ["practice", 123], ["has", 132], ["recently", 136], ["been", 145], ["called", 150], ["into", 157], ["question", 162], [".", 170], ["The", 172], ["aim", 176], ["of", 180], ["our", 183], ["study", 187], ["was", 193], ["to", 197], ["compare", 200], ["the", 208], ["risk", 212], ["of", 217], ["progression", 220], ["/", 231], ["recurrence", 232], ["of", 243], ["tumours", 246], ["that", 254], ["had", 259], ["been", 263], ["treated", 268], ["with", 276], ["different", 281], ["Simpson", 291], ["grade", 299], ["resections", 305], ["in", 316], ["a", 319], ["contemporary", 321], ["population", 334], ["of", 345], ["benign", 348], ["(", 355], ["WHO", 356], ["grade", 360], ["I", 366], [")", 367], ["meningioma", 369], ["patients", 380], [".", 388], ["One", 390], ["hundred", 394], ["eighty", 402], ["-", 408], ["three", 409], ["patients", 415], ["with", 424], ["histologically", 429], ["confirmed", 444], ["WHO", 454], ["grade", 458], ["I", 464], ["meningioma", 466], ["were", 477], ["retrospectively", 482], ["analysed", 498], [".", 506], ["All", 508], ["patients", 512], ["underwent", 521], ["first", 531], ["-", 536], ["time", 537], ["craniotomy", 542], ["as", 553], ["their", 556], ["initial", 562], ["therapy", 570], ["between", 578], ["2004", 586], ["and", 591], ["2012", 595], [".", 599], ["Univariate", 601], ["analysis", 612], ["was", 621], ["performed", 625], ["using", 635], ["log", 641], ["-", 644], ["rank", 645], ["testing", 650], ["and", 658], ["Kaplan", 662], ["-", 668], ["Meier", 669], ["analysis", 675], ["for", 684], ["progression", 688], ["/", 699], ["recurrence", 700], ["-", 710], ["free", 711], ["survival", 716], [".", 724], ["Multivariate", 726], ["analysis", 739], ["was", 748], ["performed", 752], ["using", 762], ["Cox", 768], ["proportional", 772], ["hazards", 785], ["regression", 793], ["modelling", 804], [".", 813], ["The", 815], ["three", 819], ["-", 824], ["year", 825], ["progression", 830], ["/", 841], ["recurrence", 842], ["-", 852], ["free", 853], ["survival", 858], ["rates", 867], ["for", 873], ["patients", 877], ["receiving", 886], ["Simpson", 896], ["grade", 904], ["1", 910], [",", 911], ["2", 913], ["or", 915], ["4", 918], ["resections", 920], ["were", 931], ["95", 936], ["%", 939], [",", 940], ["87", 942], ["%", 945], ["and", 947], ["67", 951], ["%", 954], [",", 955], ["respectively", 957], [".", 969], ["Simpson", 971], ["grade", 979], ["4", 985], ["resections", 987], ["progressed", 998], ["/", 1008], ["recurred", 1009], ["at", 1018], ["a", 1021], ["significantly", 1023], ["greater", 1037], ["rate", 1045], ["than", 1050], ["Simpson", 1055], ["grade", 1063], ["1", 1069], ["resections", 1071], ["(", 1082], ["hazard", 1083], ["ratio", 1090], ["[", 1096], ["HR", 1097], ["]", 1099], ["=", 1101], ["3.26", 1103], [",", 1107], ["P", 1109], ["=", 1111], ["0.04", 1113], [")", 1117], [",", 1118], ["whereas", 1120], ["Simpson", 1128], ["grade", 1136], ["2", 1142], ["resections", 1144], ["did", 1155], ["not", 1159], ["progress", 1163], ["/", 1171], ["recur", 1172], ["at", 1178], ["a", 1181], ["significantly", 1183], ["greater", 1197], ["rate", 1205], ["than", 1210], ["Simpson", 1215], ["grade", 1223], ["1", 1229], ["resections", 1231], ["(", 1242], ["HR", 1243], ["=", 1246], ["1.78", 1248], [",", 1252], ["P", 1254], ["=", 1256], ["0.29", 1258], [")", 1262], [".", 1263], ["Subtotal", 1265], ["resections", 1274], ["progressed", 1285], ["/", 1295], ["recurred", 1296], ["at", 1305], ["a", 1308], ["significantly", 1310], ["greater", 1324], ["rate", 1332], ["than", 1337], ["gross", 1342], ["-", 1347], ["total", 1348], ["resections", 1354], ["(", 1365], ["HR", 1366], ["=", 1369], ["2.47", 1371], [",", 1375], ["P", 1377], ["=", 1379], ["0.03", 1381], [")", 1385], [".", 1386], ["Tumours", 1388], ["that", 1396], ["undergo", 1401], ["subtotal", 1409], ["resection", 1418], ["are", 1428], ["at", 1432], ["a", 1435], ["significantly", 1437], ["greater", 1451], ["risk", 1459], ["of", 1464], ["progression", 1467], ["/", 1478], ["recurrence", 1479], ["than", 1490], ["tumours", 1495], ["that", 1503], ["undergo", 1508], ["gross", 1516], ["-", 1521], ["total", 1522], ["resection", 1528], [".", 1537], ["Gross", 1539], ["-", 1544], ["total", 1545], ["resection", 1551], ["should", 1561], ["therefore", 1568], ["be", 1578], ["the", 1581], ["aim", 1585], ["of", 1589], ["surgery", 1592], [".", 1599], ["However", 1601], [",", 1608], ["given", 1610], ["modern", 1616], ["access", 1623], ["to", 1630], ["follow", 1633], ["-", 1639], ["up", 1640], ["imaging", 1643], ["and", 1651], ["stereotactic", 1655], ["radiosurgery", 1668], [",", 1680], ["these", 1682], ["results", 1688], ["should", 1696], ["not", 1703], ["be", 1707], ["used", 1710], ["to", 1715], ["justify", 1718], ["overly", 1726], ["'", 1733], ["heroic", 1734], ["'", 1740], ["tumour", 1742], ["resection", 1749], [".", 1758]]}
{"context": "Juvenile neuronal ceroid lipofuscinosis (Batten disease) is a neurodegenerative disorder caused by defective function of the lysosomal membrane glycoprotein CLN3. The activity of the lysosomal acid phosphatase (LAP/ACP2) was found to be significantly increased in the cerebellum and brain stem of Cln3-targeted mice during the early stages of postnatal life. Histochemical localization studies revealed an increased LAP/ACP2 staining intensity in neurons of the cerebral cortex of 48-week-old Cln3-targeted mice as compared with controls. Additionally, the expression of another lysosomal membrane protein LAMP-2 was increased in all brain areas. Knockdown of CLN3 expression in HeLa cells by RNA interference also resulted in increased LAP/ACP2 and LAMP-2 expression. Finally in fibroblasts of two juvenile neuronal ceroid lipofuscinosis patients elevated levels of LAP/ACP2 were found. Both activation of gene transcription and increased protein half-life appear to contribute to increased LAP/ACP2 protein expression in CLN3-deficient cells. The data suggest that lysosomal dysfunction and accumulation of storage material require increased biogenesis of LAP/ACP2 and LAMP-2 positive membranes which makes LAP/ACP2 suitable as biomarker of Batten disease.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "5af94115175949a3aa6007921a11d0a1", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[5, 6], [199, 200]], "char_spans": [[41, 54], [1243, 1256]]}]}], "context_tokens": [["Juvenile", 0], ["neuronal", 9], ["ceroid", 18], ["lipofuscinosis", 25], ["(", 40], ["Batten", 41], ["disease", 48], [")", 55], ["is", 57], ["a", 60], ["neurodegenerative", 62], ["disorder", 80], ["caused", 89], ["by", 96], ["defective", 99], ["function", 109], ["of", 118], ["the", 121], ["lysosomal", 125], ["membrane", 135], ["glycoprotein", 144], ["CLN3", 157], [".", 161], ["The", 163], ["activity", 167], ["of", 176], ["the", 179], ["lysosomal", 183], ["acid", 193], ["phosphatase", 198], ["(", 210], ["LAP", 211], ["/", 214], ["ACP2", 215], [")", 219], ["was", 221], ["found", 225], ["to", 231], ["be", 234], ["significantly", 237], ["increased", 251], ["in", 261], ["the", 264], ["cerebellum", 268], ["and", 279], ["brain", 283], ["stem", 289], ["of", 294], ["Cln3-targeted", 297], ["mice", 311], ["during", 316], ["the", 323], ["early", 327], ["stages", 333], ["of", 340], ["postnatal", 343], ["life", 353], [".", 357], ["Histochemical", 359], ["localization", 373], ["studies", 386], ["revealed", 394], ["an", 403], ["increased", 406], ["LAP", 416], ["/", 419], ["ACP2", 420], ["staining", 425], ["intensity", 434], ["in", 444], ["neurons", 447], ["of", 455], ["the", 458], ["cerebral", 462], ["cortex", 471], ["of", 478], ["48-week", 481], ["-", 488], ["old", 489], ["Cln3-targeted", 493], ["mice", 507], ["as", 512], ["compared", 515], ["with", 524], ["controls", 529], [".", 537], ["Additionally", 539], [",", 551], ["the", 553], ["expression", 557], ["of", 568], ["another", 571], ["lysosomal", 579], ["membrane", 589], ["protein", 598], ["LAMP-2", 606], ["was", 613], ["increased", 617], ["in", 627], ["all", 630], ["brain", 634], ["areas", 640], [".", 645], ["Knockdown", 647], ["of", 657], ["CLN3", 660], ["expression", 665], ["in", 676], ["HeLa", 679], ["cells", 684], ["by", 690], ["RNA", 693], ["interference", 697], ["also", 710], ["resulted", 715], ["in", 724], ["increased", 727], ["LAP", 737], ["/", 740], ["ACP2", 741], ["and", 746], ["LAMP-2", 750], ["expression", 757], [".", 767], ["Finally", 769], ["in", 777], ["fibroblasts", 780], ["of", 792], ["two", 795], ["juvenile", 799], ["neuronal", 808], ["ceroid", 817], ["lipofuscinosis", 824], ["patients", 839], ["elevated", 848], ["levels", 857], ["of", 864], ["LAP", 867], ["/", 870], ["ACP2", 871], ["were", 876], ["found", 881], [".", 886], ["Both", 888], ["activation", 893], ["of", 904], ["gene", 907], ["transcription", 912], ["and", 926], ["increased", 930], ["protein", 940], ["half", 948], ["-", 952], ["life", 953], ["appear", 958], ["to", 965], ["contribute", 968], ["to", 979], ["increased", 982], ["LAP", 992], ["/", 995], ["ACP2", 996], ["protein", 1001], ["expression", 1009], ["in", 1020], ["CLN3-deficient", 1023], ["cells", 1038], [".", 1043], ["The", 1045], ["data", 1049], ["suggest", 1054], ["that", 1062], ["lysosomal", 1067], ["dysfunction", 1077], ["and", 1089], ["accumulation", 1093], ["of", 1106], ["storage", 1109], ["material", 1117], ["require", 1126], ["increased", 1134], ["biogenesis", 1144], ["of", 1155], ["LAP", 1158], ["/", 1161], ["ACP2", 1162], ["and", 1167], ["LAMP-2", 1171], ["positive", 1178], ["membranes", 1187], ["which", 1197], ["makes", 1203], ["LAP", 1209], ["/", 1212], ["ACP2", 1213], ["suitable", 1218], ["as", 1227], ["biomarker", 1230], ["of", 1240], ["Batten", 1243], ["disease", 1250], [".", 1257]]}
{"context": "Tanezumab is a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for chronic pain. This phase IIB study investigated the efficacy and safety of tanezumab for chronic low back pain vs placebo and naproxen. Patients (N=1347) received intravenous tanezumab (5, 10, or 20mg every 8weeks), naproxen (500mg twice daily), or placebo. The primary efficacy end point was mean change in daily average low back pain intensity (LBPI) from baseline to week 16. Secondary end points included mean change from baseline to week 16 in the Roland Morris Disability Questionnaire and Patient's Global Assessment (PGA) of low back pain. Tanezumab 10 and 20mg had similar efficacy profiles and significantly improved LBPI, Roland Morris Disability Questionnaire, and PGA scores vs both placebo and naproxen (P\u2a7d.05). Tanezumab 5mg provided improvement of PGA scores vs placebo (P\u2a7d.05), and naproxen resulted in significant improvement of LBPI vs placebo (P\u2a7d.05). Adverse event incidence was comparable across tanezumab doses but higher than with placebo or naproxen. Arthralgia, pain in extremity, headache, and paresthesia were the most commonly reported adverse events by tanezumab-treated patients. The most frequently reported adverse events resulting in discontinuation of tanezumab treatment were arthralgia and paresthesia; the highest frequency was observed with tanezumab 20mg (both 1.4%). Serious adverse event incidence was similar across treatments. In conclusion, tanezumab provided significantly greater improvement in pain, function, and global scores vs placebo and naproxen in patients with chronic low back pain.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "ccb9b1d3df6f45b2bb19557def943330", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[9, 11]], "char_spans": [[72, 90]]}]}], "context_tokens": [["Tanezumab", 0], ["is", 10], ["a", 13], ["humanized", 15], ["monoclonal", 25], ["antibody", 36], ["that", 45], ["specifically", 50], ["inhibits", 63], ["nerve", 72], ["growth", 78], ["factor", 85], ["as", 92], ["a", 95], ["treatment", 97], ["for", 107], ["chronic", 111], ["pain", 119], [".", 123], ["This", 125], ["phase", 130], ["IIB", 136], ["study", 140], ["investigated", 146], ["the", 159], ["efficacy", 163], ["and", 172], ["safety", 176], ["of", 183], ["tanezumab", 186], ["for", 196], ["chronic", 200], ["low", 208], ["back", 212], ["pain", 217], ["vs", 222], ["placebo", 225], ["and", 233], ["naproxen", 237], [".", 245], ["Patients", 247], ["(", 256], ["N=1347", 257], [")", 263], ["received", 265], ["intravenous", 274], ["tanezumab", 286], ["(", 296], ["5", 297], [",", 298], ["10", 300], [",", 302], ["or", 304], ["20", 307], ["mg", 309], ["every", 312], ["8weeks", 318], [")", 324], [",", 325], ["naproxen", 327], ["(", 336], ["500", 337], ["mg", 340], ["twice", 343], ["daily", 349], [")", 354], [",", 355], ["or", 357], ["placebo", 360], [".", 367], ["The", 369], ["primary", 373], ["efficacy", 381], ["end", 390], ["point", 394], ["was", 400], ["mean", 404], ["change", 409], ["in", 416], ["daily", 419], ["average", 425], ["low", 433], ["back", 437], ["pain", 442], ["intensity", 447], ["(", 457], ["LBPI", 458], [")", 462], ["from", 464], ["baseline", 469], ["to", 478], ["week", 481], ["16", 486], [".", 488], ["Secondary", 490], ["end", 500], ["points", 504], ["included", 511], ["mean", 520], ["change", 525], ["from", 532], ["baseline", 537], ["to", 546], ["week", 549], ["16", 554], ["in", 557], ["the", 560], ["Roland", 564], ["Morris", 571], ["Disability", 578], ["Questionnaire", 589], ["and", 603], ["Patient", 607], ["'s", 614], ["Global", 617], ["Assessment", 624], ["(", 635], ["PGA", 636], [")", 639], ["of", 641], ["low", 644], ["back", 648], ["pain", 653], [".", 657], ["Tanezumab", 659], ["10", 669], ["and", 672], ["20", 676], ["mg", 678], ["had", 681], ["similar", 685], ["efficacy", 693], ["profiles", 702], ["and", 711], ["significantly", 715], ["improved", 729], ["LBPI", 738], [",", 742], ["Roland", 744], ["Morris", 751], ["Disability", 758], ["Questionnaire", 769], [",", 782], ["and", 784], ["PGA", 788], ["scores", 792], ["vs", 799], ["both", 802], ["placebo", 807], ["and", 815], ["naproxen", 819], ["(", 828], ["P\u2a7d.05", 829], [")", 834], [".", 835], ["Tanezumab", 837], ["5", 847], ["mg", 848], ["provided", 851], ["improvement", 860], ["of", 872], ["PGA", 875], ["scores", 879], ["vs", 886], ["placebo", 889], ["(", 897], ["P\u2a7d.05", 898], [")", 903], [",", 904], ["and", 906], ["naproxen", 910], ["resulted", 919], ["in", 928], ["significant", 931], ["improvement", 943], ["of", 955], ["LBPI", 958], ["vs", 963], ["placebo", 966], ["(", 974], ["P\u2a7d.05", 975], [")", 980], [".", 981], ["Adverse", 983], ["event", 991], ["incidence", 997], ["was", 1007], ["comparable", 1011], ["across", 1022], ["tanezumab", 1029], ["doses", 1039], ["but", 1045], ["higher", 1049], ["than", 1056], ["with", 1061], ["placebo", 1066], ["or", 1074], ["naproxen", 1077], [".", 1085], ["Arthralgia", 1087], [",", 1097], ["pain", 1099], ["in", 1104], ["extremity", 1107], [",", 1116], ["headache", 1118], [",", 1126], ["and", 1128], ["paresthesia", 1132], ["were", 1144], ["the", 1149], ["most", 1153], ["commonly", 1158], ["reported", 1167], ["adverse", 1176], ["events", 1184], ["by", 1191], ["tanezumab", 1194], ["-", 1203], ["treated", 1204], ["patients", 1212], [".", 1220], ["The", 1222], ["most", 1226], ["frequently", 1231], ["reported", 1242], ["adverse", 1251], ["events", 1259], ["resulting", 1266], ["in", 1276], ["discontinuation", 1279], ["of", 1295], ["tanezumab", 1298], ["treatment", 1308], ["were", 1318], ["arthralgia", 1323], ["and", 1334], ["paresthesia", 1338], [";", 1349], ["the", 1351], ["highest", 1355], ["frequency", 1363], ["was", 1373], ["observed", 1377], ["with", 1386], ["tanezumab", 1391], ["20", 1401], ["mg", 1403], ["(", 1406], ["both", 1407], ["1.4", 1412], ["%", 1415], [")", 1416], [".", 1417], ["Serious", 1419], ["adverse", 1427], ["event", 1435], ["incidence", 1441], ["was", 1451], ["similar", 1455], ["across", 1463], ["treatments", 1470], [".", 1480], ["In", 1482], ["conclusion", 1485], [",", 1495], ["tanezumab", 1497], ["provided", 1507], ["significantly", 1516], ["greater", 1530], ["improvement", 1538], ["in", 1550], ["pain", 1553], [",", 1557], ["function", 1559], [",", 1567], ["and", 1569], ["global", 1573], ["scores", 1580], ["vs", 1587], ["placebo", 1590], ["and", 1598], ["naproxen", 1602], ["in", 1611], ["patients", 1614], ["with", 1623], ["chronic", 1628], ["low", 1636], ["back", 1640], ["pain", 1645], [".", 1649]]}
{"context": "MicroRNAs (miRNAs) play a major part in the post-transcriptional regulation of gene expression. Mammalian miRNA biogenesis begins with cotranscriptional cleavage of RNA polymerase II (Pol II) transcripts by the Microprocessor complex. Although most miRNAs are located within introns of protein-coding transcripts, a substantial minority of miRNAs originate from long noncoding (lnc) RNAs, for which transcript processing is largely uncharacterized. We show, by detailed characterization of liver-specific lnc-pri-miR-122 and genome-wide analysis in human cell lines, that most lncRNA transcripts containing miRNAs (lnc-pri-miRNAs) do not use the canonical cleavage-and-polyadenylation pathway but instead use Microprocessor cleavage to terminate transcription. Microprocessor inactivation leads to extensive transcriptional readthrough of lnc-pri-miRNA and transcriptional interference with downstream genes. Consequently we define a new RNase III-mediated, polyadenylation-independent mechanism of Pol II transcription termination in mammalian cells.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "cc8c050eacbc476399b7a6d1ccc9c404", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[26, 28]], "char_spans": [[165, 181]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["play", 19], ["a", 24], ["major", 26], ["part", 32], ["in", 37], ["the", 40], ["post", 44], ["-", 48], ["transcriptional", 49], ["regulation", 65], ["of", 76], ["gene", 79], ["expression", 84], [".", 94], ["Mammalian", 96], ["miRNA", 106], ["biogenesis", 112], ["begins", 123], ["with", 130], ["cotranscriptional", 135], ["cleavage", 153], ["of", 162], ["RNA", 165], ["polymerase", 169], ["II", 180], ["(", 183], ["Pol", 184], ["II", 188], [")", 190], ["transcripts", 192], ["by", 204], ["the", 207], ["Microprocessor", 211], ["complex", 226], [".", 233], ["Although", 235], ["most", 244], ["miRNAs", 249], ["are", 256], ["located", 260], ["within", 268], ["introns", 275], ["of", 283], ["protein", 286], ["-", 293], ["coding", 294], ["transcripts", 301], [",", 312], ["a", 314], ["substantial", 316], ["minority", 328], ["of", 337], ["miRNAs", 340], ["originate", 347], ["from", 357], ["long", 362], ["noncoding", 367], ["(", 377], ["lnc", 378], [")", 381], ["RNAs", 383], [",", 387], ["for", 389], ["which", 393], ["transcript", 399], ["processing", 410], ["is", 421], ["largely", 424], ["uncharacterized", 432], [".", 447], ["We", 449], ["show", 452], [",", 456], ["by", 458], ["detailed", 461], ["characterization", 470], ["of", 487], ["liver", 490], ["-", 495], ["specific", 496], ["lnc", 505], ["-", 508], ["pri", 509], ["-", 512], ["miR-122", 513], ["and", 521], ["genome", 525], ["-", 531], ["wide", 532], ["analysis", 537], ["in", 546], ["human", 549], ["cell", 555], ["lines", 560], [",", 565], ["that", 567], ["most", 572], ["lncRNA", 577], ["transcripts", 584], ["containing", 596], ["miRNAs", 607], ["(", 614], ["lnc", 615], ["-", 618], ["pri", 619], ["-", 622], ["miRNAs", 623], [")", 629], ["do", 631], ["not", 634], ["use", 638], ["the", 642], ["canonical", 646], ["cleavage", 656], ["-", 664], ["and", 665], ["-", 668], ["polyadenylation", 669], ["pathway", 685], ["but", 693], ["instead", 697], ["use", 705], ["Microprocessor", 709], ["cleavage", 724], ["to", 733], ["terminate", 736], ["transcription", 746], [".", 759], ["Microprocessor", 761], ["inactivation", 776], ["leads", 789], ["to", 795], ["extensive", 798], ["transcriptional", 808], ["readthrough", 824], ["of", 836], ["lnc", 839], ["-", 842], ["pri", 843], ["-", 846], ["miRNA", 847], ["and", 853], ["transcriptional", 857], ["interference", 873], ["with", 886], ["downstream", 891], ["genes", 902], [".", 907], ["Consequently", 909], ["we", 922], ["define", 925], ["a", 932], ["new", 934], ["RNase", 938], ["III", 944], ["-", 947], ["mediated", 948], [",", 956], ["polyadenylation", 958], ["-", 973], ["independent", 974], ["mechanism", 986], ["of", 996], ["Pol", 999], ["II", 1003], ["transcription", 1006], ["termination", 1020], ["in", 1032], ["mammalian", 1035], ["cells", 1045], [".", 1050]]}
{"context": "Sedation is an important aspect of care for critically ill newborns. Proper sedation reduces stress during procedures such as mechanical ventilation. Midazolam, a short-acting benzodiazepine, is widely administered as a sedative in newborn intensive care units but is not without side effects. Three term newborns developed myoclonic-like abnormal movements after receiving midazolam. In one, flumazenil controlled the abnormal movements. Flumazenil is a potent benzodiazepine antagonist that competitively blocks the central effects of benzodiazepines. It can reverse the sedative effects of benzodiazepines occurring after diagnostic or therapeutic procedures or after benzodiazepine overdose. Flumazenil may be considered in cases of abnormal movements associated with midazolam. However, further studies are needed to provide guidelines for the administration of this drug in newborns.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "53789d187e204d27ba5d871adbcd3fd2", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[105, 105], [65, 65], [71, 71]], "char_spans": [[696, 705], [393, 402], [439, 448]]}]}], "context_tokens": [["Sedation", 0], ["is", 9], ["an", 12], ["important", 15], ["aspect", 25], ["of", 32], ["care", 35], ["for", 40], ["critically", 44], ["ill", 55], ["newborns", 59], [".", 67], ["Proper", 69], ["sedation", 76], ["reduces", 85], ["stress", 93], ["during", 100], ["procedures", 107], ["such", 118], ["as", 123], ["mechanical", 126], ["ventilation", 137], [".", 148], ["Midazolam", 150], [",", 159], ["a", 161], ["short", 163], ["-", 168], ["acting", 169], ["benzodiazepine", 176], [",", 190], ["is", 192], ["widely", 195], ["administered", 202], ["as", 215], ["a", 218], ["sedative", 220], ["in", 229], ["newborn", 232], ["intensive", 240], ["care", 250], ["units", 255], ["but", 261], ["is", 265], ["not", 268], ["without", 272], ["side", 280], ["effects", 285], [".", 292], ["Three", 294], ["term", 300], ["newborns", 305], ["developed", 314], ["myoclonic", 324], ["-", 333], ["like", 334], ["abnormal", 339], ["movements", 348], ["after", 358], ["receiving", 364], ["midazolam", 374], [".", 383], ["In", 385], ["one", 388], [",", 391], ["flumazenil", 393], ["controlled", 404], ["the", 415], ["abnormal", 419], ["movements", 428], [".", 437], ["Flumazenil", 439], ["is", 450], ["a", 453], ["potent", 455], ["benzodiazepine", 462], ["antagonist", 477], ["that", 488], ["competitively", 493], ["blocks", 507], ["the", 514], ["central", 518], ["effects", 526], ["of", 534], ["benzodiazepines", 537], [".", 552], ["It", 554], ["can", 557], ["reverse", 561], ["the", 569], ["sedative", 573], ["effects", 582], ["of", 590], ["benzodiazepines", 593], ["occurring", 609], ["after", 619], ["diagnostic", 625], ["or", 636], ["therapeutic", 639], ["procedures", 651], ["or", 662], ["after", 665], ["benzodiazepine", 671], ["overdose", 686], [".", 694], ["Flumazenil", 696], ["may", 707], ["be", 711], ["considered", 714], ["in", 725], ["cases", 728], ["of", 734], ["abnormal", 737], ["movements", 746], ["associated", 756], ["with", 767], ["midazolam", 772], [".", 781], ["However", 783], [",", 790], ["further", 792], ["studies", 800], ["are", 808], ["needed", 812], ["to", 819], ["provide", 822], ["guidelines", 830], ["for", 841], ["the", 845], ["administration", 849], ["of", 864], ["this", 867], ["drug", 872], ["in", 877], ["newborns", 880], [".", 888]]}
{"context": "Community-acquired pneumonia (CAP) is the leading cause of infectious death in the world. Immune dysregulation during acute lung infection plays a role in lung injury and the systemic inflammatory response. Cytokines seem to be major players in severe lung infection cases. Here, we present a review of published papers in the last 3\u00a0years regarding this topic. The cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as CURB65 or SOFA. Treatment focused in the cytokine environment is an interesting area that could impact the prognosis of CAP. Some of the agents that have been studied as co-adjuvant therapy are corticosteroids, macrolides, and linezolid, but anyone of those have shown a clear or proven efficacy or have been recommended as a part of the standard of care for CAP. More studies designed to define the role of immunomodulatory agents, such as co-adjuvant therapy in pneumonia, are needed.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "77c8c610c2b44cfdadd28ce51c2e8c6b", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[177, 177], [3, 3], [70, 70]], "char_spans": [[984, 992], [19, 27], [391, 399]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["acquired", 10], ["pneumonia", 19], ["(", 29], ["CAP", 30], [")", 33], ["is", 35], ["the", 38], ["leading", 42], ["cause", 50], ["of", 56], ["infectious", 59], ["death", 70], ["in", 76], ["the", 79], ["world", 83], [".", 88], ["Immune", 90], ["dysregulation", 97], ["during", 111], ["acute", 118], ["lung", 124], ["infection", 129], ["plays", 139], ["a", 145], ["role", 147], ["in", 152], ["lung", 155], ["injury", 160], ["and", 167], ["the", 171], ["systemic", 175], ["inflammatory", 184], ["response", 197], [".", 205], ["Cytokines", 207], ["seem", 217], ["to", 222], ["be", 225], ["major", 228], ["players", 234], ["in", 242], ["severe", 245], ["lung", 252], ["infection", 257], ["cases", 267], [".", 272], ["Here", 274], [",", 278], ["we", 280], ["present", 283], ["a", 291], ["review", 293], ["of", 300], ["published", 303], ["papers", 313], ["in", 320], ["the", 323], ["last", 327], ["3", 332], ["years", 334], ["regarding", 340], ["this", 350], ["topic", 355], [".", 360], ["The", 362], ["cytokine", 366], ["response", 375], ["during", 384], ["pneumonia", 391], ["is", 401], ["different", 404], ["in", 414], ["bacterial", 417], ["vs", 427], ["viral", 430], ["infections", 436], [";", 446], ["some", 448], ["of", 453], ["these", 456], ["cytokines", 462], ["correlate", 472], ["with", 482], ["clinical", 487], ["severity", 496], ["scales", 505], ["such", 512], ["as", 517], ["CURB65", 520], ["or", 527], ["SOFA", 530], [".", 534], ["Treatment", 536], ["focused", 546], ["in", 554], ["the", 557], ["cytokine", 561], ["environment", 570], ["is", 582], ["an", 585], ["interesting", 588], ["area", 600], ["that", 605], ["could", 610], ["impact", 616], ["the", 623], ["prognosis", 627], ["of", 637], ["CAP", 640], [".", 643], ["Some", 645], ["of", 650], ["the", 653], ["agents", 657], ["that", 664], ["have", 669], ["been", 674], ["studied", 679], ["as", 687], ["co", 690], ["-", 692], ["adjuvant", 693], ["therapy", 702], ["are", 710], ["corticosteroids", 714], [",", 729], ["macrolides", 731], [",", 741], ["and", 743], ["linezolid", 747], [",", 756], ["but", 758], ["anyone", 762], ["of", 769], ["those", 772], ["have", 778], ["shown", 783], ["a", 789], ["clear", 791], ["or", 797], ["proven", 800], ["efficacy", 807], ["or", 816], ["have", 819], ["been", 824], ["recommended", 829], ["as", 841], ["a", 844], ["part", 846], ["of", 851], ["the", 854], ["standard", 858], ["of", 867], ["care", 870], ["for", 875], ["CAP", 879], [".", 882], ["More", 884], ["studies", 889], ["designed", 897], ["to", 906], ["define", 909], ["the", 916], ["role", 920], ["of", 925], ["immunomodulatory", 928], ["agents", 945], [",", 951], ["such", 953], ["as", 958], ["co", 961], ["-", 963], ["adjuvant", 964], ["therapy", 973], ["in", 981], ["pneumonia", 984], [",", 993], ["are", 995], ["needed", 999], [".", 1005]]}
{"context": "Human selenoprotein P (HSelP) is unique protein that contains 10 selenocysteines encoded by 10 inframe UGA, which typically function as stop codon. The function of HSelP remains unclear, in part due to the inability to express it by gene recombinant technique. This study is to investigate expression and purification of recombinant HSelP in prokaryotic expression system, and its activity to induce apoptosis in vitro. The shorter HSelP isoform was cloned. After the selenocysteine (SeCys) at 40th position from N terminus of the HSelP shorter isoform was mutated into cysteine by PCR, it was expressed in E. coli. The expressed product was purified with DEAE column and identified by Western blot. Subsequently, its function on induction of mitochondrial apoptotic activity was studied. The mutant HSelP shorter isoform expressed in prokaryotic system was purified by DEAE column to 90% homogeneity. The purified product, HSelP280m, induced the opening of mitochondrial permeability transition pore (PTP) and decreased the transmembrane potential in a dose-dependent manner. These events could be abolished by PTP specific inhibitors. HSelP280m can induce the opening of mitochondrial PTP, which provides a basis for investigating the structure and function of recombinant HSelP.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "c67a56187ba94d478fbc8c8608cabb52", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[1, 2]], "char_spans": [[6, 20]]}]}], "context_tokens": [["Human", 0], ["selenoprotein", 6], ["P", 20], ["(", 22], ["HSelP", 23], [")", 28], ["is", 30], ["unique", 33], ["protein", 40], ["that", 48], ["contains", 53], ["10", 62], ["selenocysteines", 65], ["encoded", 81], ["by", 89], ["10", 92], ["inframe", 95], ["UGA", 103], [",", 106], ["which", 108], ["typically", 114], ["function", 124], ["as", 133], ["stop", 136], ["codon", 141], [".", 146], ["The", 148], ["function", 152], ["of", 161], ["HSelP", 164], ["remains", 170], ["unclear", 178], [",", 185], ["in", 187], ["part", 190], ["due", 195], ["to", 199], ["the", 202], ["inability", 206], ["to", 216], ["express", 219], ["it", 227], ["by", 230], ["gene", 233], ["recombinant", 238], ["technique", 250], [".", 259], ["This", 261], ["study", 266], ["is", 272], ["to", 275], ["investigate", 278], ["expression", 290], ["and", 301], ["purification", 305], ["of", 318], ["recombinant", 321], ["HSelP", 333], ["in", 339], ["prokaryotic", 342], ["expression", 354], ["system", 365], [",", 371], ["and", 373], ["its", 377], ["activity", 381], ["to", 390], ["induce", 393], ["apoptosis", 400], ["in", 410], ["vitro", 413], [".", 418], ["The", 420], ["shorter", 424], ["HSelP", 432], ["isoform", 438], ["was", 446], ["cloned", 450], [".", 456], ["After", 458], ["the", 464], ["selenocysteine", 468], ["(", 483], ["SeCys", 484], [")", 489], ["at", 491], ["40th", 494], ["position", 499], ["from", 508], ["N", 513], ["terminus", 515], ["of", 524], ["the", 527], ["HSelP", 531], ["shorter", 537], ["isoform", 545], ["was", 553], ["mutated", 557], ["into", 565], ["cysteine", 570], ["by", 579], ["PCR", 582], [",", 585], ["it", 587], ["was", 590], ["expressed", 594], ["in", 604], ["E.", 607], ["coli", 610], [".", 614], ["The", 616], ["expressed", 620], ["product", 630], ["was", 638], ["purified", 642], ["with", 651], ["DEAE", 656], ["column", 661], ["and", 668], ["identified", 672], ["by", 683], ["Western", 686], ["blot", 694], [".", 698], ["Subsequently", 700], [",", 712], ["its", 714], ["function", 718], ["on", 727], ["induction", 730], ["of", 740], ["mitochondrial", 743], ["apoptotic", 757], ["activity", 767], ["was", 776], ["studied", 780], [".", 787], ["The", 789], ["mutant", 793], ["HSelP", 800], ["shorter", 806], ["isoform", 814], ["expressed", 822], ["in", 832], ["prokaryotic", 835], ["system", 847], ["was", 854], ["purified", 858], ["by", 867], ["DEAE", 870], ["column", 875], ["to", 882], ["90", 885], ["%", 887], ["homogeneity", 889], [".", 900], ["The", 902], ["purified", 906], ["product", 915], [",", 922], ["HSelP280", 924], ["m", 932], [",", 933], ["induced", 935], ["the", 943], ["opening", 947], ["of", 955], ["mitochondrial", 958], ["permeability", 972], ["transition", 985], ["pore", 996], ["(", 1001], ["PTP", 1002], [")", 1005], ["and", 1007], ["decreased", 1011], ["the", 1021], ["transmembrane", 1025], ["potential", 1039], ["in", 1049], ["a", 1052], ["dose", 1054], ["-", 1058], ["dependent", 1059], ["manner", 1069], [".", 1075], ["These", 1077], ["events", 1083], ["could", 1090], ["be", 1096], ["abolished", 1099], ["by", 1109], ["PTP", 1112], ["specific", 1116], ["inhibitors", 1125], [".", 1135], ["HSelP280", 1137], ["m", 1145], ["can", 1147], ["induce", 1151], ["the", 1158], ["opening", 1162], ["of", 1170], ["mitochondrial", 1173], ["PTP", 1187], [",", 1190], ["which", 1192], ["provides", 1198], ["a", 1207], ["basis", 1209], ["for", 1215], ["investigating", 1219], ["the", 1233], ["structure", 1237], ["and", 1247], ["function", 1251], ["of", 1260], ["recombinant", 1263], ["HSelP.", 1275]]}
{"context": "In chronic lymphocytic leukemia (CLL) signals from the B cell receptor (BCR) play a major role in disease development and progression. In this light, new therapies that specifically target signaling molecules downstream of the BCR continue to be developed. While first studies on the selective small molecule inhibitor of Bruton's tyrosine kinase (Btk), Ibrutinib (PCI-32765), demonstrated that Btk inhibition sensitizes CLL cells to apoptosis and alters their migratory behavior, these studies however did not address whether Btk-mediated signaling is involved in the process of CLL leukemogenesis. To investigate the requirement of Btk signaling for CLL development, we modulated Btk expression in the IgH.ET\u03bc CLL mouse model, which is based on sporadic expression of the simian oncovirus SV40 T-antigen in mature B cells. To this end, we crossed IgH.ET\u03bc mice on a Btk-deficient background or introduced a human Btk transgene (CD19-hBtk). Here we show that Btk deficiency fully abrogates CLL formation in IgH.ET\u03bc mice, and that leukemias formed in Btk haplo-insufficient mice selectively expressed the wild-type Btk allele on their active X chromosome. Conversely, Btk overexpression accelerated CLL onset, increased mortality, and was associated with selection of non-stereotypical BCRs into CLL clones. Taken together, these data show that Btk expression represents an absolute prerequisite for CLL development and that Btk mediated signaling enhances leukemogenesis in mice. We therefore conclude that in CLL Btk expression levels set the threshold for malignant transformation.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "f0635aa1d547406894740b04dba27d43", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[64, 64]], "char_spans": [[354, 362]]}]}], "context_tokens": [["In", 0], ["chronic", 3], ["lymphocytic", 11], ["leukemia", 23], ["(", 32], ["CLL", 33], [")", 36], ["signals", 38], ["from", 46], ["the", 51], ["B", 55], ["cell", 57], ["receptor", 62], ["(", 71], ["BCR", 72], [")", 75], ["play", 77], ["a", 82], ["major", 84], ["role", 90], ["in", 95], ["disease", 98], ["development", 106], ["and", 118], ["progression", 122], [".", 133], ["In", 135], ["this", 138], ["light", 143], [",", 148], ["new", 150], ["therapies", 154], ["that", 164], ["specifically", 169], ["target", 182], ["signaling", 189], ["molecules", 199], ["downstream", 209], ["of", 220], ["the", 223], ["BCR", 227], ["continue", 231], ["to", 240], ["be", 243], ["developed", 246], [".", 255], ["While", 257], ["first", 263], ["studies", 269], ["on", 277], ["the", 280], ["selective", 284], ["small", 294], ["molecule", 300], ["inhibitor", 309], ["of", 319], ["Bruton", 322], ["'s", 328], ["tyrosine", 331], ["kinase", 340], ["(", 347], ["Btk", 348], [")", 351], [",", 352], ["Ibrutinib", 354], ["(", 364], ["PCI-32765", 365], [")", 374], [",", 375], ["demonstrated", 377], ["that", 390], ["Btk", 395], ["inhibition", 399], ["sensitizes", 410], ["CLL", 421], ["cells", 425], ["to", 431], ["apoptosis", 434], ["and", 444], ["alters", 448], ["their", 455], ["migratory", 461], ["behavior", 471], [",", 479], ["these", 481], ["studies", 487], ["however", 495], ["did", 503], ["not", 507], ["address", 511], ["whether", 519], ["Btk", 527], ["-", 530], ["mediated", 531], ["signaling", 540], ["is", 550], ["involved", 553], ["in", 562], ["the", 565], ["process", 569], ["of", 577], ["CLL", 580], ["leukemogenesis", 584], [".", 598], ["To", 600], ["investigate", 603], ["the", 615], ["requirement", 619], ["of", 631], ["Btk", 634], ["signaling", 638], ["for", 648], ["CLL", 652], ["development", 656], [",", 667], ["we", 669], ["modulated", 672], ["Btk", 682], ["expression", 686], ["in", 697], ["the", 700], ["IgH.ET\u03bc", 704], ["CLL", 712], ["mouse", 716], ["model", 722], [",", 727], ["which", 729], ["is", 735], ["based", 738], ["on", 744], ["sporadic", 747], ["expression", 756], ["of", 767], ["the", 770], ["simian", 774], ["oncovirus", 781], ["SV40", 791], ["T", 796], ["-", 797], ["antigen", 798], ["in", 806], ["mature", 809], ["B", 816], ["cells", 818], [".", 823], ["To", 825], ["this", 828], ["end", 833], [",", 836], ["we", 838], ["crossed", 841], ["IgH.ET\u03bc", 849], ["mice", 857], ["on", 862], ["a", 865], ["Btk", 867], ["-", 870], ["deficient", 871], ["background", 881], ["or", 892], ["introduced", 895], ["a", 906], ["human", 908], ["Btk", 914], ["transgene", 918], ["(", 928], ["CD19-hBtk", 929], [")", 938], [".", 939], ["Here", 941], ["we", 946], ["show", 949], ["that", 954], ["Btk", 959], ["deficiency", 963], ["fully", 974], ["abrogates", 980], ["CLL", 990], ["formation", 994], ["in", 1004], ["IgH.ET\u03bc", 1007], ["mice", 1015], [",", 1019], ["and", 1021], ["that", 1025], ["leukemias", 1030], ["formed", 1040], ["in", 1047], ["Btk", 1050], ["haplo", 1054], ["-", 1059], ["insufficient", 1060], ["mice", 1073], ["selectively", 1078], ["expressed", 1090], ["the", 1100], ["wild", 1104], ["-", 1108], ["type", 1109], ["Btk", 1114], ["allele", 1118], ["on", 1125], ["their", 1128], ["active", 1134], ["X", 1141], ["chromosome", 1143], [".", 1153], ["Conversely", 1155], [",", 1165], ["Btk", 1167], ["overexpression", 1171], ["accelerated", 1186], ["CLL", 1198], ["onset", 1202], [",", 1207], ["increased", 1209], ["mortality", 1219], [",", 1228], ["and", 1230], ["was", 1234], ["associated", 1238], ["with", 1249], ["selection", 1254], ["of", 1264], ["non", 1267], ["-", 1270], ["stereotypical", 1271], ["BCRs", 1285], ["into", 1290], ["CLL", 1295], ["clones", 1299], [".", 1305], ["Taken", 1307], ["together", 1313], [",", 1321], ["these", 1323], ["data", 1329], ["show", 1334], ["that", 1339], ["Btk", 1344], ["expression", 1348], ["represents", 1359], ["an", 1370], ["absolute", 1373], ["prerequisite", 1382], ["for", 1395], ["CLL", 1399], ["development", 1403], ["and", 1415], ["that", 1419], ["Btk", 1424], ["mediated", 1428], ["signaling", 1437], ["enhances", 1447], ["leukemogenesis", 1456], ["in", 1471], ["mice", 1474], [".", 1478], ["We", 1480], ["therefore", 1483], ["conclude", 1493], ["that", 1502], ["in", 1507], ["CLL", 1510], ["Btk", 1514], ["expression", 1518], ["levels", 1529], ["set", 1536], ["the", 1540], ["threshold", 1544], ["for", 1554], ["malignant", 1558], ["transformation", 1568], [".", 1582]]}
{"context": "Emotion regulation has been associated with perceived health in rheumatoid arthritis, which is diagnosed three times more often in women than men. Our aim was to examine gender differences in styles of emotion regulation (ambiguity, control, orientation, and expression) and gender-specificity of the associations between emotion regulation and perceived health (psychological well-being, social functioning, physical functioning, and disease activity) in 244 female and 91 male patients with rheumatoid arthritis. Women reported more emotional orientation than men, but did not differ from men with regard to ambiguity, control, and expression. Structural equation modelling showed that relationships between emotion regulation and perceived health were more frequent and stronger for women than men. This held especially for the affective dimension of health, while associations were similar for both women and men with regard to social and physical functioning. Only for women, the association between ambiguity and disease activity was significant, which appeared to be mediated by affective functioning. The observations that women are more emotionally oriented than men and that emotion regulation is more interwoven with psychological health in women than men, support the usefulness of a gender-sensitive approach in research and health care of patients with rheumatoid arthritis.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "33ce31f2b31e434a8646df96cc8b9daa", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[128, 128], [203, 203], [86, 86], [148, 148], [20, 20], [185, 185], [161, 161]], "char_spans": [[786, 790], [1252, 1256], [515, 519], [903, 907], [131, 135], [1131, 1135], [974, 978]]}]}], "context_tokens": [["Emotion", 0], ["regulation", 8], ["has", 19], ["been", 23], ["associated", 28], ["with", 39], ["perceived", 44], ["health", 54], ["in", 61], ["rheumatoid", 64], ["arthritis", 75], [",", 84], ["which", 86], ["is", 92], ["diagnosed", 95], ["three", 105], ["times", 111], ["more", 117], ["often", 122], ["in", 128], ["women", 131], ["than", 137], ["men", 142], [".", 145], ["Our", 147], ["aim", 151], ["was", 155], ["to", 159], ["examine", 162], ["gender", 170], ["differences", 177], ["in", 189], ["styles", 192], ["of", 199], ["emotion", 202], ["regulation", 210], ["(", 221], ["ambiguity", 222], [",", 231], ["control", 233], [",", 240], ["orientation", 242], [",", 253], ["and", 255], ["expression", 259], [")", 269], ["and", 271], ["gender", 275], ["-", 281], ["specificity", 282], ["of", 294], ["the", 297], ["associations", 301], ["between", 314], ["emotion", 322], ["regulation", 330], ["and", 341], ["perceived", 345], ["health", 355], ["(", 362], ["psychological", 363], ["well", 377], ["-", 381], ["being", 382], [",", 387], ["social", 389], ["functioning", 396], [",", 407], ["physical", 409], ["functioning", 418], [",", 429], ["and", 431], ["disease", 435], ["activity", 443], [")", 451], ["in", 453], ["244", 456], ["female", 460], ["and", 467], ["91", 471], ["male", 474], ["patients", 479], ["with", 488], ["rheumatoid", 493], ["arthritis", 504], [".", 513], ["Women", 515], ["reported", 521], ["more", 530], ["emotional", 535], ["orientation", 545], ["than", 557], ["men", 562], [",", 565], ["but", 567], ["did", 571], ["not", 575], ["differ", 579], ["from", 586], ["men", 591], ["with", 595], ["regard", 600], ["to", 607], ["ambiguity", 610], [",", 619], ["control", 621], [",", 628], ["and", 630], ["expression", 634], [".", 644], ["Structural", 646], ["equation", 657], ["modelling", 666], ["showed", 676], ["that", 683], ["relationships", 688], ["between", 702], ["emotion", 710], ["regulation", 718], ["and", 729], ["perceived", 733], ["health", 743], ["were", 750], ["more", 755], ["frequent", 760], ["and", 769], ["stronger", 773], ["for", 782], ["women", 786], ["than", 792], ["men", 797], [".", 800], ["This", 802], ["held", 807], ["especially", 812], ["for", 823], ["the", 827], ["affective", 831], ["dimension", 841], ["of", 851], ["health", 854], [",", 860], ["while", 862], ["associations", 868], ["were", 881], ["similar", 886], ["for", 894], ["both", 898], ["women", 903], ["and", 909], ["men", 913], ["with", 917], ["regard", 922], ["to", 929], ["social", 932], ["and", 939], ["physical", 943], ["functioning", 952], [".", 963], ["Only", 965], ["for", 970], ["women", 974], [",", 979], ["the", 981], ["association", 985], ["between", 997], ["ambiguity", 1005], ["and", 1015], ["disease", 1019], ["activity", 1027], ["was", 1036], ["significant", 1040], [",", 1051], ["which", 1053], ["appeared", 1059], ["to", 1068], ["be", 1071], ["mediated", 1074], ["by", 1083], ["affective", 1086], ["functioning", 1096], [".", 1107], ["The", 1109], ["observations", 1113], ["that", 1126], ["women", 1131], ["are", 1137], ["more", 1141], ["emotionally", 1146], ["oriented", 1158], ["than", 1167], ["men", 1172], ["and", 1176], ["that", 1180], ["emotion", 1185], ["regulation", 1193], ["is", 1204], ["more", 1207], ["interwoven", 1212], ["with", 1223], ["psychological", 1228], ["health", 1242], ["in", 1249], ["women", 1252], ["than", 1258], ["men", 1263], [",", 1266], ["support", 1268], ["the", 1276], ["usefulness", 1280], ["of", 1291], ["a", 1294], ["gender", 1296], ["-", 1302], ["sensitive", 1303], ["approach", 1313], ["in", 1322], ["research", 1325], ["and", 1334], ["health", 1338], ["care", 1345], ["of", 1350], ["patients", 1353], ["with", 1362], ["rheumatoid", 1367], ["arthritis", 1378], [".", 1387]]}
{"context": "Mowat-Wilson syndrome (MWS) is a relatively newly described multiple congenital anomaly/mental retardation syndrome. Haploinsufficiency of a gene termed ZFHX1B (also known as SIP1) on chromosome 2 is responsible for this condition, and clinical genetic testing for MWS recently became available. The majority of reports in the literature originate from Northern Europe and Australia. Here we report our clinical experience with 12 patients diagnosed with MWS within a 2-year period of time in the United States, with particular emphasis on clinical characteristics and management strategies. Individuals with this condition have characteristic facial features, including microcephaly, hypertelorism, medially flared and broad eyebrows, prominent columella, pointed chin, and uplifted earlobes, which typically prompt the clinician to consider the diagnosis. Medical issues in our cohort of patients included seizures (75%) with no predeliction for any particular seizure type; agenesis of the corpus callosum (60% of our patients studied); congenital heart defects (75%), particularly involving the pulmonary arteries and/or valves; hypospadias (55% of males); severely impaired or absent speech (100% of individuals over 1 year of age) with relatively spared receptive language; and Hirschsprung disease (50%) or chronic constipation (25%). The incidence of MWS is unknown, but based on the number of patients identified in a short period of time within the US, it is likely greatly under recognized. MWS should be considered in any individual with severely impaired or absent speech, especially in the presence of seizures and anomalies involving the pulmonary arteries (particularly pulmonary artery sling) or pulmonary valves.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "ba508f5b8dfb4fbc83ecf9831706b686", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[25, 25]], "char_spans": [[153, 158]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["relatively", 33], ["newly", 44], ["described", 50], ["multiple", 60], ["congenital", 69], ["anomaly", 80], ["/", 87], ["mental", 88], ["retardation", 95], ["syndrome", 107], [".", 115], ["Haploinsufficiency", 117], ["of", 136], ["a", 139], ["gene", 141], ["termed", 146], ["ZFHX1B", 153], ["(", 160], ["also", 161], ["known", 166], ["as", 172], ["SIP1", 175], [")", 179], ["on", 181], ["chromosome", 184], ["2", 195], ["is", 197], ["responsible", 200], ["for", 212], ["this", 216], ["condition", 221], [",", 230], ["and", 232], ["clinical", 236], ["genetic", 245], ["testing", 253], ["for", 261], ["MWS", 265], ["recently", 269], ["became", 278], ["available", 285], [".", 294], ["The", 296], ["majority", 300], ["of", 309], ["reports", 312], ["in", 320], ["the", 323], ["literature", 327], ["originate", 338], ["from", 348], ["Northern", 353], ["Europe", 362], ["and", 369], ["Australia", 373], [".", 382], ["Here", 384], ["we", 389], ["report", 392], ["our", 399], ["clinical", 403], ["experience", 412], ["with", 423], ["12", 428], ["patients", 431], ["diagnosed", 440], ["with", 450], ["MWS", 455], ["within", 459], ["a", 466], ["2-year", 468], ["period", 475], ["of", 482], ["time", 485], ["in", 490], ["the", 493], ["United", 497], ["States", 504], [",", 510], ["with", 512], ["particular", 517], ["emphasis", 528], ["on", 537], ["clinical", 540], ["characteristics", 549], ["and", 565], ["management", 569], ["strategies", 580], [".", 590], ["Individuals", 592], ["with", 604], ["this", 609], ["condition", 614], ["have", 624], ["characteristic", 629], ["facial", 644], ["features", 651], [",", 659], ["including", 661], ["microcephaly", 671], [",", 683], ["hypertelorism", 685], [",", 698], ["medially", 700], ["flared", 709], ["and", 716], ["broad", 720], ["eyebrows", 726], [",", 734], ["prominent", 736], ["columella", 746], [",", 755], ["pointed", 757], ["chin", 765], [",", 769], ["and", 771], ["uplifted", 775], ["earlobes", 784], [",", 792], ["which", 794], ["typically", 800], ["prompt", 810], ["the", 817], ["clinician", 821], ["to", 831], ["consider", 834], ["the", 843], ["diagnosis", 847], [".", 856], ["Medical", 858], ["issues", 866], ["in", 873], ["our", 876], ["cohort", 880], ["of", 887], ["patients", 890], ["included", 899], ["seizures", 908], ["(", 917], ["75", 918], ["%", 920], [")", 921], ["with", 923], ["no", 928], ["predeliction", 931], ["for", 944], ["any", 948], ["particular", 952], ["seizure", 963], ["type", 971], [";", 975], ["agenesis", 977], ["of", 986], ["the", 989], ["corpus", 993], ["callosum", 1000], ["(", 1009], ["60", 1010], ["%", 1012], ["of", 1014], ["our", 1017], ["patients", 1021], ["studied", 1030], [")", 1037], [";", 1038], ["congenital", 1040], ["heart", 1051], ["defects", 1057], ["(", 1065], ["75", 1066], ["%", 1068], [")", 1069], [",", 1070], ["particularly", 1072], ["involving", 1085], ["the", 1095], ["pulmonary", 1099], ["arteries", 1109], ["and/or", 1118], ["valves", 1125], [";", 1131], ["hypospadias", 1133], ["(", 1145], ["55", 1146], ["%", 1148], ["of", 1150], ["males", 1153], [")", 1158], [";", 1159], ["severely", 1161], ["impaired", 1170], ["or", 1179], ["absent", 1182], ["speech", 1189], ["(", 1196], ["100", 1197], ["%", 1200], ["of", 1202], ["individuals", 1205], ["over", 1217], ["1", 1222], ["year", 1224], ["of", 1229], ["age", 1232], [")", 1235], ["with", 1237], ["relatively", 1242], ["spared", 1253], ["receptive", 1260], ["language", 1270], [";", 1278], ["and", 1280], ["Hirschsprung", 1284], ["disease", 1297], ["(", 1305], ["50", 1306], ["%", 1308], [")", 1309], ["or", 1311], ["chronic", 1314], ["constipation", 1322], ["(", 1335], ["25", 1336], ["%", 1338], [")", 1339], [".", 1340], ["The", 1342], ["incidence", 1346], ["of", 1356], ["MWS", 1359], ["is", 1363], ["unknown", 1366], [",", 1373], ["but", 1375], ["based", 1379], ["on", 1385], ["the", 1388], ["number", 1392], ["of", 1399], ["patients", 1402], ["identified", 1411], ["in", 1422], ["a", 1425], ["short", 1427], ["period", 1433], ["of", 1440], ["time", 1443], ["within", 1448], ["the", 1455], ["US", 1459], [",", 1461], ["it", 1463], ["is", 1466], ["likely", 1469], ["greatly", 1476], ["under", 1484], ["recognized", 1490], [".", 1500], ["MWS", 1502], ["should", 1506], ["be", 1513], ["considered", 1516], ["in", 1527], ["any", 1530], ["individual", 1534], ["with", 1545], ["severely", 1550], ["impaired", 1559], ["or", 1568], ["absent", 1571], ["speech", 1578], [",", 1584], ["especially", 1586], ["in", 1597], ["the", 1600], ["presence", 1604], ["of", 1613], ["seizures", 1616], ["and", 1625], ["anomalies", 1629], ["involving", 1639], ["the", 1649], ["pulmonary", 1653], ["arteries", 1663], ["(", 1672], ["particularly", 1673], ["pulmonary", 1686], ["artery", 1696], ["sling", 1703], [")", 1708], ["or", 1710], ["pulmonary", 1713], ["valves", 1723], [".", 1729]]}
{"context": "We conducted a review of patient medical records to assess treatment response patterns and prognostic indicators of response among chronic myeloid leukemia (CML) patients in the United States, the United Kingdom, Germany, and Japan. All 1,063 patients selected met the following inclusion criteria: aged 18 or older and in chronic phase at the time of diagnosis, Philadelphia chromosome and/or BCR-ABL positive, received first-line treatment with imatinib, and not enrolled in a randomized clinical trial during the period of retrospective review. Multivariable logistic regression models were used to evaluate prognostic indicators of complete hematological response (CHR), complete cytogenetic response (CCyR), and complete or major molecular response (C/MMR). Among patients treated with first-line imatinib, CHR at three months, CCyR at 12 months, and C/MMR at 18 months were observed in 53, 53.1, and 57.8 % of patients, respectively. Among patients treated with second-line dasatinib or nilotinib, CHR was achieved at three months in 49 and 42 %, CCyR at 12 months in 32 and 23 %, and MMR at 18 months in 30.5 and 26.1 % of patients, respectively. Prognostic indicators of first-line response included age, race, and Sokal score. For second-line treatment, duration of first-line hematological response and choice of drug used were also significant.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7f2a7d1273d0421f802f06a3bb2fdbbe", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[67, 69]], "char_spans": [[394, 400]]}]}], "context_tokens": [["We", 0], ["conducted", 3], ["a", 13], ["review", 15], ["of", 22], ["patient", 25], ["medical", 33], ["records", 41], ["to", 49], ["assess", 52], ["treatment", 59], ["response", 69], ["patterns", 78], ["and", 87], ["prognostic", 91], ["indicators", 102], ["of", 113], ["response", 116], ["among", 125], ["chronic", 131], ["myeloid", 139], ["leukemia", 147], ["(", 156], ["CML", 157], [")", 160], ["patients", 162], ["in", 171], ["the", 174], ["United", 178], ["States", 185], [",", 191], ["the", 193], ["United", 197], ["Kingdom", 204], [",", 211], ["Germany", 213], [",", 220], ["and", 222], ["Japan", 226], [".", 231], ["All", 233], ["1,063", 237], ["patients", 243], ["selected", 252], ["met", 261], ["the", 265], ["following", 269], ["inclusion", 279], ["criteria", 289], [":", 297], ["aged", 299], ["18", 304], ["or", 307], ["older", 310], ["and", 316], ["in", 320], ["chronic", 323], ["phase", 331], ["at", 337], ["the", 340], ["time", 344], ["of", 349], ["diagnosis", 352], [",", 361], ["Philadelphia", 363], ["chromosome", 376], ["and/or", 387], ["BCR", 394], ["-", 397], ["ABL", 398], ["positive", 402], [",", 410], ["received", 412], ["first", 421], ["-", 426], ["line", 427], ["treatment", 432], ["with", 442], ["imatinib", 447], [",", 455], ["and", 457], ["not", 461], ["enrolled", 465], ["in", 474], ["a", 477], ["randomized", 479], ["clinical", 490], ["trial", 499], ["during", 505], ["the", 512], ["period", 516], ["of", 523], ["retrospective", 526], ["review", 540], [".", 546], ["Multivariable", 548], ["logistic", 562], ["regression", 571], ["models", 582], ["were", 589], ["used", 594], ["to", 599], ["evaluate", 602], ["prognostic", 611], ["indicators", 622], ["of", 633], ["complete", 636], ["hematological", 645], ["response", 659], ["(", 668], ["CHR", 669], [")", 672], [",", 673], ["complete", 675], ["cytogenetic", 684], ["response", 696], ["(", 705], ["CCyR", 706], [")", 710], [",", 711], ["and", 713], ["complete", 717], ["or", 726], ["major", 729], ["molecular", 735], ["response", 745], ["(", 754], ["C", 755], ["/", 756], ["MMR", 757], [")", 760], [".", 761], ["Among", 763], ["patients", 769], ["treated", 778], ["with", 786], ["first", 791], ["-", 796], ["line", 797], ["imatinib", 802], [",", 810], ["CHR", 812], ["at", 816], ["three", 819], ["months", 825], [",", 831], ["CCyR", 833], ["at", 838], ["12", 841], ["months", 844], [",", 850], ["and", 852], ["C", 856], ["/", 857], ["MMR", 858], ["at", 862], ["18", 865], ["months", 868], ["were", 875], ["observed", 880], ["in", 889], ["53", 892], [",", 894], ["53.1", 896], [",", 900], ["and", 902], ["57.8", 906], ["%", 911], ["of", 913], ["patients", 916], [",", 924], ["respectively", 926], [".", 938], ["Among", 940], ["patients", 946], ["treated", 955], ["with", 963], ["second", 968], ["-", 974], ["line", 975], ["dasatinib", 980], ["or", 990], ["nilotinib", 993], [",", 1002], ["CHR", 1004], ["was", 1008], ["achieved", 1012], ["at", 1021], ["three", 1024], ["months", 1030], ["in", 1037], ["49", 1040], ["and", 1043], ["42", 1047], ["%", 1050], [",", 1051], ["CCyR", 1053], ["at", 1058], ["12", 1061], ["months", 1064], ["in", 1071], ["32", 1074], ["and", 1077], ["23", 1081], ["%", 1084], [",", 1085], ["and", 1087], ["MMR", 1091], ["at", 1095], ["18", 1098], ["months", 1101], ["in", 1108], ["30.5", 1111], ["and", 1116], ["26.1", 1120], ["%", 1125], ["of", 1127], ["patients", 1130], [",", 1138], ["respectively", 1140], [".", 1152], ["Prognostic", 1154], ["indicators", 1165], ["of", 1176], ["first", 1179], ["-", 1184], ["line", 1185], ["response", 1190], ["included", 1199], ["age", 1208], [",", 1211], ["race", 1213], [",", 1217], ["and", 1219], ["Sokal", 1223], ["score", 1229], [".", 1234], ["For", 1236], ["second", 1240], ["-", 1246], ["line", 1247], ["treatment", 1252], [",", 1261], ["duration", 1263], ["of", 1272], ["first", 1275], ["-", 1280], ["line", 1281], ["hematological", 1286], ["response", 1300], ["and", 1309], ["choice", 1313], ["of", 1320], ["drug", 1323], ["used", 1328], ["were", 1333], ["also", 1338], ["significant", 1343], [".", 1354]]}
{"context": "Varespladib methyl is an oral secretory phospholipase A2 inhibitor that is being developed by Anthera Pharmaceuticals Inc for the potential treatment of coronary artery disease, acute coronary syndrome and inflammation. Varespladib methyl is a prodrug that is rapidly metabolized to varespladib, and both compounds are able to potently inhibit the enzymes of the human secretory phospholipase groups IIa, V and X, which play a pivotal role in atherosclerotic disease and inflammation. Phase II clinical trials of varespladib methyl in patients with coronary artery disease, rheumatoid arthritis, asthma and ulcerative colitis revealed that the drug was well tolerated. Varespladib methyl did not demonstrate a good efficacy profile in patients with rheumatoid arthritis, asthma and ulcerative colitis, whereas in patients with coronary artery disease, varespladib methyl consistently reduced LDL-cholesterol levels (elevated LDL-cholesterol levels are a marker of increased cardiovascular risk). At the time of publication, phase II trials were ongoing in patients with acute coronary syndrome and in patients undergoing elective percutaneous coronary intervention, and a phase III trial in patients with acute coronary syndrome was planned. Varespladib methyl could represent a novel therapy for the treatment of cardiovascular disease, although the efficacy, safety profile and advantages of this drug compared with existing therapeutic options would need to be established in upcoming phase III trials.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "206aa6a2af2042ff92e09f48ea2bde5f", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[5, 7]], "char_spans": [[30, 55]]}]}], "context_tokens": [["Varespladib", 0], ["methyl", 12], ["is", 19], ["an", 22], ["oral", 25], ["secretory", 30], ["phospholipase", 40], ["A2", 54], ["inhibitor", 57], ["that", 67], ["is", 72], ["being", 75], ["developed", 81], ["by", 91], ["Anthera", 94], ["Pharmaceuticals", 102], ["Inc", 118], ["for", 122], ["the", 126], ["potential", 130], ["treatment", 140], ["of", 150], ["coronary", 153], ["artery", 162], ["disease", 169], [",", 176], ["acute", 178], ["coronary", 184], ["syndrome", 193], ["and", 202], ["inflammation", 206], [".", 218], ["Varespladib", 220], ["methyl", 232], ["is", 239], ["a", 242], ["prodrug", 244], ["that", 252], ["is", 257], ["rapidly", 260], ["metabolized", 268], ["to", 280], ["varespladib", 283], [",", 294], ["and", 296], ["both", 300], ["compounds", 305], ["are", 315], ["able", 319], ["to", 324], ["potently", 327], ["inhibit", 336], ["the", 344], ["enzymes", 348], ["of", 356], ["the", 359], ["human", 363], ["secretory", 369], ["phospholipase", 379], ["groups", 393], ["IIa", 400], [",", 403], ["V", 405], ["and", 407], ["X", 411], [",", 412], ["which", 414], ["play", 420], ["a", 425], ["pivotal", 427], ["role", 435], ["in", 440], ["atherosclerotic", 443], ["disease", 459], ["and", 467], ["inflammation", 471], [".", 483], ["Phase", 485], ["II", 491], ["clinical", 494], ["trials", 503], ["of", 510], ["varespladib", 513], ["methyl", 525], ["in", 532], ["patients", 535], ["with", 544], ["coronary", 549], ["artery", 558], ["disease", 565], [",", 572], ["rheumatoid", 574], ["arthritis", 585], [",", 594], ["asthma", 596], ["and", 603], ["ulcerative", 607], ["colitis", 618], ["revealed", 626], ["that", 635], ["the", 640], ["drug", 644], ["was", 649], ["well", 653], ["tolerated", 658], [".", 667], ["Varespladib", 669], ["methyl", 681], ["did", 688], ["not", 692], ["demonstrate", 696], ["a", 708], ["good", 710], ["efficacy", 715], ["profile", 724], ["in", 732], ["patients", 735], ["with", 744], ["rheumatoid", 749], ["arthritis", 760], [",", 769], ["asthma", 771], ["and", 778], ["ulcerative", 782], ["colitis", 793], [",", 800], ["whereas", 802], ["in", 810], ["patients", 813], ["with", 822], ["coronary", 827], ["artery", 836], ["disease", 843], [",", 850], ["varespladib", 852], ["methyl", 864], ["consistently", 871], ["reduced", 884], ["LDL", 892], ["-", 895], ["cholesterol", 896], ["levels", 908], ["(", 915], ["elevated", 916], ["LDL", 925], ["-", 928], ["cholesterol", 929], ["levels", 941], ["are", 948], ["a", 952], ["marker", 954], ["of", 961], ["increased", 964], ["cardiovascular", 974], ["risk", 989], [")", 993], [".", 994], ["At", 996], ["the", 999], ["time", 1003], ["of", 1008], ["publication", 1011], [",", 1022], ["phase", 1024], ["II", 1030], ["trials", 1033], ["were", 1040], ["ongoing", 1045], ["in", 1053], ["patients", 1056], ["with", 1065], ["acute", 1070], ["coronary", 1076], ["syndrome", 1085], ["and", 1094], ["in", 1098], ["patients", 1101], ["undergoing", 1110], ["elective", 1121], ["percutaneous", 1130], ["coronary", 1143], ["intervention", 1152], [",", 1164], ["and", 1166], ["a", 1170], ["phase", 1172], ["III", 1178], ["trial", 1182], ["in", 1188], ["patients", 1191], ["with", 1200], ["acute", 1205], ["coronary", 1211], ["syndrome", 1220], ["was", 1229], ["planned", 1233], [".", 1240], ["Varespladib", 1242], ["methyl", 1254], ["could", 1261], ["represent", 1267], ["a", 1277], ["novel", 1279], ["therapy", 1285], ["for", 1293], ["the", 1297], ["treatment", 1301], ["of", 1311], ["cardiovascular", 1314], ["disease", 1329], [",", 1336], ["although", 1338], ["the", 1347], ["efficacy", 1351], [",", 1359], ["safety", 1361], ["profile", 1368], ["and", 1376], ["advantages", 1380], ["of", 1391], ["this", 1394], ["drug", 1399], ["compared", 1404], ["with", 1413], ["existing", 1418], ["therapeutic", 1427], ["options", 1439], ["would", 1447], ["need", 1453], ["to", 1458], ["be", 1461], ["established", 1464], ["in", 1476], ["upcoming", 1479], ["phase", 1488], ["III", 1494], ["trials", 1498], [".", 1504]]}
{"context": "We have investigated the contribution of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) and mitogen-activated protein kinase (MAP kinase) in norepinephrine (NE)-induced arachidonic acid (AA) release in rabbit aortic vascular smooth muscle cells (VSMC). NE enhanced release of AA via activation of cytosolic phospholipase A2 (cPLA2) but not secretory PLA2 in VSMC prelabeled with [3H]AA. NE (10 microM) enhanced CaM kinase II and MAP kinase activity. In cells transiently transfected with antisense oligonucleotides complementary to the translation initiation sites of CaM kinase II and MAP kinase, NE-induced AA release was inhibited by 100 and 35% respectively. Treatment of cells with PD-098059, a MAP kinase kinase inhibitor, or with MAP kinase antisense oligonucleotide reduced NE-induced activation of MAP kinase and cPLA2. NE-induced MAP kinase and cPLA2 activation was also inhibited in cells treated with a CaM kinase II inhibitor, KN-93, or with CaM kinase II antisense oligonucleotide. On the other hand, inhibition of MAP kinase kinase with PD-098059 or of MAP kinase with antisense oligonucleotides did not alter the NE-induced increase in CaM kinase II activity. Phosphorylation of MAP kinase and CaM kinase II by NE, studied by 32P incorporation and immune complex kinase assays, was inhibited by KN-93. Collectively, these data suggest that CaM kinase II can activate MAP kinase, which in turn activates cPLA2 to release AA for prostacyclin synthesis in the rabbit VSMC. This novel pathway for activation of MAP kinase by CaM kinase II appears to be mediated through stimulation of MAP kinase kinase. Activation of adrenergic receptors with NE in VSMC caused translocation of CaM kinase II, MAP kinase, and cPLA2 to the nuclear envelope only in the presence of extracellular Ca2+. Okadaic acid, which increased phosphorylation and activity, did not translocate these enzymes. Therefore, it appears that in rabbit VSMC, NE, by promoting extracellular Ca2+ influx, increases CaM kinase II activity, leading to activation of MAP kinase and cPLA2 and translocation to the nuclear envelope, resulting in release of AA from the nuclear envelope for prostacyclin synthesis.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II", "CAMK2"], "qid": "4c1e2ae7b3044ebdbc54ebb2645c4732", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "CaM kinase II", "token_spans": [[247, 249], [305, 307], [220, 222], [101, 103], [13, 15], [210, 212], [280, 282], [79, 81], [361, 363], [176, 178], [167, 169]], "char_spans": [[1369, 1381], [1704, 1716], [1223, 1235], [581, 593], [86, 98], [1165, 1177], [1550, 1562], [424, 436], [2001, 2013], [968, 980], [928, 940]]}]}], "context_tokens": [["We", 0], ["have", 3], ["investigated", 8], ["the", 21], ["contribution", 25], ["of", 38], ["Ca2+/calmodulin", 41], ["-", 56], ["dependent", 57], ["protein", 67], ["kinase", 75], ["II", 82], ["(", 85], ["CaM", 86], ["kinase", 90], ["II", 97], [")", 99], ["and", 101], ["mitogen", 105], ["-", 112], ["activated", 113], ["protein", 123], ["kinase", 131], ["(", 138], ["MAP", 139], ["kinase", 143], [")", 149], ["in", 151], ["norepinephrine", 154], ["(", 169], ["NE)-induced", 170], ["arachidonic", 182], ["acid", 194], ["(", 199], ["AA", 200], [")", 202], ["release", 204], ["in", 212], ["rabbit", 215], ["aortic", 222], ["vascular", 229], ["smooth", 238], ["muscle", 245], ["cells", 252], ["(", 258], ["VSMC", 259], [")", 263], [".", 264], ["NE", 266], ["enhanced", 269], ["release", 278], ["of", 286], ["AA", 289], ["via", 292], ["activation", 296], ["of", 307], ["cytosolic", 310], ["phospholipase", 320], ["A2", 334], ["(", 337], ["cPLA2", 338], [")", 343], ["but", 345], ["not", 349], ["secretory", 353], ["PLA2", 363], ["in", 368], ["VSMC", 371], ["prelabeled", 376], ["with", 387], ["[", 392], ["3H]AA", 393], [".", 398], ["NE", 400], ["(", 403], ["10", 404], ["microM", 407], [")", 413], ["enhanced", 415], ["CaM", 424], ["kinase", 428], ["II", 435], ["and", 438], ["MAP", 442], ["kinase", 446], ["activity", 453], [".", 461], ["In", 463], ["cells", 466], ["transiently", 472], ["transfected", 484], ["with", 496], ["antisense", 501], ["oligonucleotides", 511], ["complementary", 528], ["to", 542], ["the", 545], ["translation", 549], ["initiation", 561], ["sites", 572], ["of", 578], ["CaM", 581], ["kinase", 585], ["II", 592], ["and", 595], ["MAP", 599], ["kinase", 603], [",", 609], ["NE", 611], ["-", 613], ["induced", 614], ["AA", 622], ["release", 625], ["was", 633], ["inhibited", 637], ["by", 647], ["100", 650], ["and", 654], ["35", 658], ["%", 660], ["respectively", 662], [".", 674], ["Treatment", 676], ["of", 686], ["cells", 689], ["with", 695], ["PD-098059", 700], [",", 709], ["a", 711], ["MAP", 713], ["kinase", 717], ["kinase", 724], ["inhibitor", 731], [",", 740], ["or", 742], ["with", 745], ["MAP", 750], ["kinase", 754], ["antisense", 761], ["oligonucleotide", 771], ["reduced", 787], ["NE", 795], ["-", 797], ["induced", 798], ["activation", 806], ["of", 817], ["MAP", 820], ["kinase", 824], ["and", 831], ["cPLA2", 835], [".", 840], ["NE", 842], ["-", 844], ["induced", 845], ["MAP", 853], ["kinase", 857], ["and", 864], ["cPLA2", 868], ["activation", 874], ["was", 885], ["also", 889], ["inhibited", 894], ["in", 904], ["cells", 907], ["treated", 913], ["with", 921], ["a", 926], ["CaM", 928], ["kinase", 932], ["II", 939], ["inhibitor", 942], [",", 951], ["KN-93", 953], [",", 958], ["or", 960], ["with", 963], ["CaM", 968], ["kinase", 972], ["II", 979], ["antisense", 982], ["oligonucleotide", 992], [".", 1007], ["On", 1009], ["the", 1012], ["other", 1016], ["hand", 1022], [",", 1026], ["inhibition", 1028], ["of", 1039], ["MAP", 1042], ["kinase", 1046], ["kinase", 1053], ["with", 1060], ["PD-098059", 1065], ["or", 1075], ["of", 1078], ["MAP", 1081], ["kinase", 1085], ["with", 1092], ["antisense", 1097], ["oligonucleotides", 1107], ["did", 1124], ["not", 1128], ["alter", 1132], ["the", 1138], ["NE", 1142], ["-", 1144], ["induced", 1145], ["increase", 1153], ["in", 1162], ["CaM", 1165], ["kinase", 1169], ["II", 1176], ["activity", 1179], [".", 1187], ["Phosphorylation", 1189], ["of", 1205], ["MAP", 1208], ["kinase", 1212], ["and", 1219], ["CaM", 1223], ["kinase", 1227], ["II", 1234], ["by", 1237], ["NE", 1240], [",", 1242], ["studied", 1244], ["by", 1252], ["32P", 1255], ["incorporation", 1259], ["and", 1273], ["immune", 1277], ["complex", 1284], ["kinase", 1292], ["assays", 1299], [",", 1305], ["was", 1307], ["inhibited", 1311], ["by", 1321], ["KN-93", 1324], [".", 1329], ["Collectively", 1331], [",", 1343], ["these", 1345], ["data", 1351], ["suggest", 1356], ["that", 1364], ["CaM", 1369], ["kinase", 1373], ["II", 1380], ["can", 1383], ["activate", 1387], ["MAP", 1396], ["kinase", 1400], [",", 1406], ["which", 1408], ["in", 1414], ["turn", 1417], ["activates", 1422], ["cPLA2", 1432], ["to", 1438], ["release", 1441], ["AA", 1449], ["for", 1452], ["prostacyclin", 1456], ["synthesis", 1469], ["in", 1479], ["the", 1482], ["rabbit", 1486], ["VSMC", 1493], [".", 1497], ["This", 1499], ["novel", 1504], ["pathway", 1510], ["for", 1518], ["activation", 1522], ["of", 1533], ["MAP", 1536], ["kinase", 1540], ["by", 1547], ["CaM", 1550], ["kinase", 1554], ["II", 1561], ["appears", 1564], ["to", 1572], ["be", 1575], ["mediated", 1578], ["through", 1587], ["stimulation", 1595], ["of", 1607], ["MAP", 1610], ["kinase", 1614], ["kinase", 1621], [".", 1627], ["Activation", 1629], ["of", 1640], ["adrenergic", 1643], ["receptors", 1654], ["with", 1664], ["NE", 1669], ["in", 1672], ["VSMC", 1675], ["caused", 1680], ["translocation", 1687], ["of", 1701], ["CaM", 1704], ["kinase", 1708], ["II", 1715], [",", 1717], ["MAP", 1719], ["kinase", 1723], [",", 1729], ["and", 1731], ["cPLA2", 1735], ["to", 1741], ["the", 1744], ["nuclear", 1748], ["envelope", 1756], ["only", 1765], ["in", 1770], ["the", 1773], ["presence", 1777], ["of", 1786], ["extracellular", 1789], ["Ca2", 1803], ["+", 1806], [".", 1807], ["Okadaic", 1809], ["acid", 1817], [",", 1821], ["which", 1823], ["increased", 1829], ["phosphorylation", 1839], ["and", 1855], ["activity", 1859], [",", 1867], ["did", 1869], ["not", 1873], ["translocate", 1877], ["these", 1889], ["enzymes", 1895], [".", 1902], ["Therefore", 1904], [",", 1913], ["it", 1915], ["appears", 1918], ["that", 1926], ["in", 1931], ["rabbit", 1934], ["VSMC", 1941], [",", 1945], ["NE", 1947], [",", 1949], ["by", 1951], ["promoting", 1954], ["extracellular", 1964], ["Ca2", 1978], ["+", 1981], ["influx", 1983], [",", 1989], ["increases", 1991], ["CaM", 2001], ["kinase", 2005], ["II", 2012], ["activity", 2015], [",", 2023], ["leading", 2025], ["to", 2033], ["activation", 2036], ["of", 2047], ["MAP", 2050], ["kinase", 2054], ["and", 2061], ["cPLA2", 2065], ["and", 2071], ["translocation", 2075], ["to", 2089], ["the", 2092], ["nuclear", 2096], ["envelope", 2104], [",", 2112], ["resulting", 2114], ["in", 2124], ["release", 2127], ["of", 2135], ["AA", 2138], ["from", 2141], ["the", 2146], ["nuclear", 2150], ["envelope", 2158], ["for", 2167], ["prostacyclin", 2171], ["synthesis", 2184], [".", 2193]]}
{"context": "This case report is about an elderly man who presented with a long-standing history of high-grade fever and weight loss. He initially had only hepatosplenomegaly, but then developed jaundice. He also had pancytopenia and raised liver enzymes. His septic screen was negative, but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus. The liver biopsy showed sinusoidal phagocytosis and the subsequent bone marrow aspiration and biopsy showed significant hemophagocytosis, hence Hemophagocytic syndrome was diagnosed. The fever was refractory to antibiotic and anti-tuberculosis therapy, but it responded only partially to steroids. Full response was only noticed following anti-viral treatment in the form of intravenous Ganciclovir. The patient's general condition, liver enzymes, bilirubin, hematological parameters and even the weight returned back to their normal range 2 weeks after Ganciclovir therapy. Cessation of this drug resulted in relapse of his symptoms and oral antivirals did not help. Splenectomy, steroid pulse therapy and immunosuppressive treatment were only partially helpful. Reintroduction of Ganciclovir did help for a short period. We conclude that our patient had virus-associated hemophagocytic syndrome most likely related to Epstein-Barr virus infection, which was then confirmed by the splenic biopsy, and that Ganciclovir can be of great help in eradicating the virus and treating the disease, provided that it is given for a long enough period.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "27f01386fc37446ab4eaa091c48db4f9", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[62, 65], [212, 215]], "char_spans": [[336, 353], [1276, 1293]]}]}], "context_tokens": [["This", 0], ["case", 5], ["report", 10], ["is", 17], ["about", 20], ["an", 26], ["elderly", 29], ["man", 37], ["who", 41], ["presented", 45], ["with", 55], ["a", 60], ["long", 62], ["-", 66], ["standing", 67], ["history", 76], ["of", 84], ["high", 87], ["-", 91], ["grade", 92], ["fever", 98], ["and", 104], ["weight", 108], ["loss", 115], [".", 119], ["He", 121], ["initially", 124], ["had", 134], ["only", 138], ["hepatosplenomegaly", 143], [",", 161], ["but", 163], ["then", 167], ["developed", 172], ["jaundice", 182], [".", 190], ["He", 192], ["also", 195], ["had", 200], ["pancytopenia", 204], ["and", 217], ["raised", 221], ["liver", 228], ["enzymes", 234], [".", 241], ["His", 243], ["septic", 247], ["screen", 254], ["was", 261], ["negative", 265], [",", 273], ["but", 275], ["he", 279], ["had", 282], ["a", 286], ["positive", 288], ["Monospot", 297], ["test", 306], ["and", 311], ["immunoglobulin", 315], ["G", 330], ["for", 332], ["Epstein", 336], ["-", 343], ["Barr", 344], ["virus", 349], [".", 354], ["The", 356], ["liver", 360], ["biopsy", 366], ["showed", 373], ["sinusoidal", 380], ["phagocytosis", 391], ["and", 404], ["the", 408], ["subsequent", 412], ["bone", 423], ["marrow", 428], ["aspiration", 435], ["and", 446], ["biopsy", 450], ["showed", 457], ["significant", 464], ["hemophagocytosis", 476], [",", 492], ["hence", 494], ["Hemophagocytic", 500], ["syndrome", 515], ["was", 524], ["diagnosed", 528], [".", 537], ["The", 539], ["fever", 543], ["was", 549], ["refractory", 553], ["to", 564], ["antibiotic", 567], ["and", 578], ["anti", 582], ["-", 586], ["tuberculosis", 587], ["therapy", 600], [",", 607], ["but", 609], ["it", 613], ["responded", 616], ["only", 626], ["partially", 631], ["to", 641], ["steroids", 644], [".", 652], ["Full", 654], ["response", 659], ["was", 668], ["only", 672], ["noticed", 677], ["following", 685], ["anti", 695], ["-", 699], ["viral", 700], ["treatment", 706], ["in", 716], ["the", 719], ["form", 723], ["of", 728], ["intravenous", 731], ["Ganciclovir", 743], [".", 754], ["The", 756], ["patient", 760], ["'s", 767], ["general", 770], ["condition", 778], [",", 787], ["liver", 789], ["enzymes", 795], [",", 802], ["bilirubin", 804], [",", 813], ["hematological", 815], ["parameters", 829], ["and", 840], ["even", 844], ["the", 849], ["weight", 853], ["returned", 860], ["back", 869], ["to", 874], ["their", 877], ["normal", 883], ["range", 890], ["2", 896], ["weeks", 898], ["after", 904], ["Ganciclovir", 910], ["therapy", 922], [".", 929], ["Cessation", 931], ["of", 941], ["this", 944], ["drug", 949], ["resulted", 954], ["in", 963], ["relapse", 966], ["of", 974], ["his", 977], ["symptoms", 981], ["and", 990], ["oral", 994], ["antivirals", 999], ["did", 1010], ["not", 1014], ["help", 1018], [".", 1022], ["Splenectomy", 1024], [",", 1035], ["steroid", 1037], ["pulse", 1045], ["therapy", 1051], ["and", 1059], ["immunosuppressive", 1063], ["treatment", 1081], ["were", 1091], ["only", 1096], ["partially", 1101], ["helpful", 1111], [".", 1118], ["Reintroduction", 1120], ["of", 1135], ["Ganciclovir", 1138], ["did", 1150], ["help", 1154], ["for", 1159], ["a", 1163], ["short", 1165], ["period", 1171], [".", 1177], ["We", 1179], ["conclude", 1182], ["that", 1191], ["our", 1196], ["patient", 1200], ["had", 1208], ["virus", 1212], ["-", 1217], ["associated", 1218], ["hemophagocytic", 1229], ["syndrome", 1244], ["most", 1253], ["likely", 1258], ["related", 1265], ["to", 1273], ["Epstein", 1276], ["-", 1283], ["Barr", 1284], ["virus", 1289], ["infection", 1295], [",", 1304], ["which", 1306], ["was", 1312], ["then", 1316], ["confirmed", 1321], ["by", 1331], ["the", 1334], ["splenic", 1338], ["biopsy", 1346], [",", 1352], ["and", 1354], ["that", 1358], ["Ganciclovir", 1363], ["can", 1375], ["be", 1379], ["of", 1382], ["great", 1385], ["help", 1391], ["in", 1396], ["eradicating", 1399], ["the", 1411], ["virus", 1415], ["and", 1421], ["treating", 1425], ["the", 1434], ["disease", 1438], [",", 1445], ["provided", 1447], ["that", 1456], ["it", 1461], ["is", 1464], ["given", 1467], ["for", 1473], ["a", 1477], ["long", 1479], ["enough", 1484], ["period", 1491], [".", 1497]]}
{"context": "Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by extracellular plaques containing amyloid \u03b2 (A\u03b2)-protein and intracellular tangles containing hyperphosphorylated Tau protein. Here, we describe the generation of inducible pluripotent stem cell lines from patients harboring the London familial AD (fAD) amyloid precursor protein (APP) mutation (V717I). We examine AD-relevant phenotypes following directed differentiation to forebrain neuronal fates vulnerable in AD. We observe that over differentiation time to mature neuronal fates, APP expression and levels of A\u03b2 increase dramatically. In both immature and mature neuronal fates, the APPV717I mutation affects both \u03b2- and \u03b3-secretase cleavage of APP. Although the mutation lies near the \u03b3-secretase cleavage site in the transmembrane domain of APP, we find that \u03b2-secretase cleavage of APP is elevated leading to generation of increased levels of both APPs\u03b2 and A\u03b2. Furthermore, we find that this mutation alters the initial cleavage site of \u03b3-secretase, resulting in an increased generation of both A\u03b242 and A\u03b238. In addition to altered APP processing, an increase in levels of total and phosphorylated Tau is observed in neurons with the APPV717I mutation. We show that treatment with A\u03b2-specific antibodies early in culture reverses the phenotype of increased total Tau levels, implicating altered A\u03b2 production in fAD neurons in this phenotype. These studies use human neurons to reveal previously unrecognized effects of the most common fAD APP mutation and provide a model system for testing therapeutic strategies in the cell types most relevant to disease processes.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "cded98aedc6a494e8a1a1d00dd9f85aa", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "AD", "token_spans": [[4, 4], [76, 76], [63, 63], [46, 46]], "char_spans": [[21, 22], [496, 497], [396, 397], [326, 327]]}]}], "context_tokens": [["Alzheimer", 0], ["'s", 9], ["disease", 12], ["(", 20], ["AD", 21], [")", 23], ["is", 25], ["a", 28], ["complex", 30], ["neurodegenerative", 38], ["disorder", 56], ["characterized", 65], ["by", 79], ["extracellular", 82], ["plaques", 96], ["containing", 104], ["amyloid", 115], ["\u03b2", 123], ["(", 125], ["A\u03b2)-protein", 126], ["and", 138], ["intracellular", 142], ["tangles", 156], ["containing", 164], ["hyperphosphorylated", 175], ["Tau", 195], ["protein", 199], [".", 206], ["Here", 208], [",", 212], ["we", 214], ["describe", 217], ["the", 226], ["generation", 230], ["of", 241], ["inducible", 244], ["pluripotent", 254], ["stem", 266], ["cell", 271], ["lines", 276], ["from", 282], ["patients", 287], ["harboring", 296], ["the", 306], ["London", 310], ["familial", 317], ["AD", 326], ["(", 329], ["fAD", 330], [")", 333], ["amyloid", 335], ["precursor", 343], ["protein", 353], ["(", 361], ["APP", 362], [")", 365], ["mutation", 367], ["(", 376], ["V717I", 377], [")", 382], [".", 383], ["We", 385], ["examine", 388], ["AD", 396], ["-", 398], ["relevant", 399], ["phenotypes", 408], ["following", 419], ["directed", 429], ["differentiation", 438], ["to", 454], ["forebrain", 457], ["neuronal", 467], ["fates", 476], ["vulnerable", 482], ["in", 493], ["AD", 496], [".", 498], ["We", 500], ["observe", 503], ["that", 511], ["over", 516], ["differentiation", 521], ["time", 537], ["to", 542], ["mature", 545], ["neuronal", 552], ["fates", 561], [",", 566], ["APP", 568], ["expression", 572], ["and", 583], ["levels", 587], ["of", 594], ["A\u03b2", 597], ["increase", 600], ["dramatically", 609], [".", 621], ["In", 623], ["both", 626], ["immature", 631], ["and", 640], ["mature", 644], ["neuronal", 651], ["fates", 660], [",", 665], ["the", 667], ["APPV717I", 671], ["mutation", 680], ["affects", 689], ["both", 697], ["\u03b2-", 702], ["and", 705], ["\u03b3", 709], ["-", 710], ["secretase", 711], ["cleavage", 721], ["of", 730], ["APP", 733], [".", 736], ["Although", 738], ["the", 747], ["mutation", 751], ["lies", 760], ["near", 765], ["the", 770], ["\u03b3", 774], ["-", 775], ["secretase", 776], ["cleavage", 786], ["site", 795], ["in", 800], ["the", 803], ["transmembrane", 807], ["domain", 821], ["of", 828], ["APP", 831], [",", 834], ["we", 836], ["find", 839], ["that", 844], ["\u03b2", 849], ["-", 850], ["secretase", 851], ["cleavage", 861], ["of", 870], ["APP", 873], ["is", 877], ["elevated", 880], ["leading", 889], ["to", 897], ["generation", 900], ["of", 911], ["increased", 914], ["levels", 924], ["of", 931], ["both", 934], ["APPs\u03b2", 939], ["and", 945], ["A\u03b2", 949], [".", 951], ["Furthermore", 953], [",", 964], ["we", 966], ["find", 969], ["that", 974], ["this", 979], ["mutation", 984], ["alters", 993], ["the", 1000], ["initial", 1004], ["cleavage", 1012], ["site", 1021], ["of", 1026], ["\u03b3", 1029], ["-", 1030], ["secretase", 1031], [",", 1040], ["resulting", 1042], ["in", 1052], ["an", 1055], ["increased", 1058], ["generation", 1068], ["of", 1079], ["both", 1082], ["A\u03b242", 1087], ["and", 1092], ["A\u03b238", 1096], [".", 1100], ["In", 1102], ["addition", 1105], ["to", 1114], ["altered", 1117], ["APP", 1125], ["processing", 1129], [",", 1139], ["an", 1141], ["increase", 1144], ["in", 1153], ["levels", 1156], ["of", 1163], ["total", 1166], ["and", 1172], ["phosphorylated", 1176], ["Tau", 1191], ["is", 1195], ["observed", 1198], ["in", 1207], ["neurons", 1210], ["with", 1218], ["the", 1223], ["APPV717I", 1227], ["mutation", 1236], [".", 1244], ["We", 1246], ["show", 1249], ["that", 1254], ["treatment", 1259], ["with", 1269], ["A\u03b2", 1274], ["-", 1276], ["specific", 1277], ["antibodies", 1286], ["early", 1297], ["in", 1303], ["culture", 1306], ["reverses", 1314], ["the", 1323], ["phenotype", 1327], ["of", 1337], ["increased", 1340], ["total", 1350], ["Tau", 1356], ["levels", 1360], [",", 1366], ["implicating", 1368], ["altered", 1380], ["A\u03b2", 1388], ["production", 1391], ["in", 1402], ["fAD", 1405], ["neurons", 1409], ["in", 1417], ["this", 1420], ["phenotype", 1425], [".", 1434], ["These", 1436], ["studies", 1442], ["use", 1450], ["human", 1454], ["neurons", 1460], ["to", 1468], ["reveal", 1471], ["previously", 1478], ["unrecognized", 1489], ["effects", 1502], ["of", 1510], ["the", 1513], ["most", 1517], ["common", 1522], ["fAD", 1529], ["APP", 1533], ["mutation", 1537], ["and", 1546], ["provide", 1550], ["a", 1558], ["model", 1560], ["system", 1566], ["for", 1573], ["testing", 1577], ["therapeutic", 1585], ["strategies", 1597], ["in", 1608], ["the", 1611], ["cell", 1615], ["types", 1620], ["most", 1626], ["relevant", 1631], ["to", 1640], ["disease", 1643], ["processes", 1651], [".", 1660]]}
{"context": "Spleen tyrosine kinase (Syk) is an important modulator of immune signaling. The objective of this phase 2 study was to evaluate the efficacy and safety of R788, an oral inhibitor of Syk, in patients with active rheumatoid arthritis despite methotrexate therapy. We enrolled 457 patients who had active rheumatoid arthritis despite long-term methotrexate therapy in a 6-month, double-blind, placebo-controlled trial. The primary outcome was the American College of Rheumatology (ACR) 20 response (which indicates at least a 20% reduction in the number of both tender and swollen joints and improvement in at least three of five other criteria) at month 6. R788, at a dose of 100 mg twice daily and at a dose of 150 mg once daily, was significantly superior to placebo at month 6 (ACR 20 response rates of 67% and 57%, respectively, vs. 35%; P<0.001 for the comparison of both doses with placebo). It was also significantly superior with respect to ACR 50, which indicates at least a 50% improvement (43% and 32% vs. 19%; P<0.001 for the comparison of the 100-mg dose with placebo, P=0.007 for the comparison of the 150-mg dose with placebo) and ACR 70 (28% and 14% vs. 10%; P<0.001 for the comparison of the 100-mg dose with placebo, P=0.34 for the comparison of the 150-mg dose with placebo). A clinically significant effect was noted by the end of the first week of treatment. Adverse effects included diarrhea (in 19% of subjects taking the 100-mg dose of R788 vs. 3% of those taking placebo), upper respiratory infections (14% vs. 7%), and neutropenia (6% vs. 1%). R788 was associated with an increase in systolic blood pressure of approximately 3 mm Hg between baseline and month 1, as compared with a decrease of 2 mm Hg with placebo; 23% of the patients taking R788 vs. 7% of the patients receiving placebo required the initiation of or a change in antihypertensive therapy. In this phase 2 study, a Syk inhibitor reduced disease activity in patients with rheumatoid arthritis; adverse events included diarrhea, hypertension, and neutropenia. Additional studies will be needed to further assess the safety and efficacy of Syk-inhibition therapy in patients with rheumatoid arthritis. (Funded by Rigel; ClinicalTrials.gov number, NCT00665925.)", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "f793e627a2a246e4bdb80b8e39f246c4", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["Syk", 24], [")", 27], ["is", 29], ["an", 32], ["important", 35], ["modulator", 45], ["of", 55], ["immune", 58], ["signaling", 65], [".", 74], ["The", 76], ["objective", 80], ["of", 90], ["this", 93], ["phase", 98], ["2", 104], ["study", 106], ["was", 112], ["to", 116], ["evaluate", 119], ["the", 128], ["efficacy", 132], ["and", 141], ["safety", 145], ["of", 152], ["R788", 155], [",", 159], ["an", 161], ["oral", 164], ["inhibitor", 169], ["of", 179], ["Syk", 182], [",", 185], ["in", 187], ["patients", 190], ["with", 199], ["active", 204], ["rheumatoid", 211], ["arthritis", 222], ["despite", 232], ["methotrexate", 240], ["therapy", 253], [".", 260], ["We", 262], ["enrolled", 265], ["457", 274], ["patients", 278], ["who", 287], ["had", 291], ["active", 295], ["rheumatoid", 302], ["arthritis", 313], ["despite", 323], ["long", 331], ["-", 335], ["term", 336], ["methotrexate", 341], ["therapy", 354], ["in", 362], ["a", 365], ["6-month", 367], [",", 374], ["double", 376], ["-", 382], ["blind", 383], [",", 388], ["placebo", 390], ["-", 397], ["controlled", 398], ["trial", 409], [".", 414], ["The", 416], ["primary", 420], ["outcome", 428], ["was", 436], ["the", 440], ["American", 444], ["College", 453], ["of", 461], ["Rheumatology", 464], ["(", 477], ["ACR", 478], [")", 481], ["20", 483], ["response", 486], ["(", 495], ["which", 496], ["indicates", 502], ["at", 512], ["least", 515], ["a", 521], ["20", 523], ["%", 525], ["reduction", 527], ["in", 537], ["the", 540], ["number", 544], ["of", 551], ["both", 554], ["tender", 559], ["and", 566], ["swollen", 570], ["joints", 578], ["and", 585], ["improvement", 589], ["in", 601], ["at", 604], ["least", 607], ["three", 613], ["of", 619], ["five", 622], ["other", 627], ["criteria", 633], [")", 641], ["at", 643], ["month", 646], ["6", 652], [".", 653], ["R788", 655], [",", 659], ["at", 661], ["a", 664], ["dose", 666], ["of", 671], ["100", 674], ["mg", 678], ["twice", 681], ["daily", 687], ["and", 693], ["at", 697], ["a", 700], ["dose", 702], ["of", 707], ["150", 710], ["mg", 714], ["once", 717], ["daily", 722], [",", 727], ["was", 729], ["significantly", 733], ["superior", 747], ["to", 756], ["placebo", 759], ["at", 767], ["month", 770], ["6", 776], ["(", 778], ["ACR", 779], ["20", 783], ["response", 786], ["rates", 795], ["of", 801], ["67", 804], ["%", 806], ["and", 808], ["57", 812], ["%", 814], [",", 815], ["respectively", 817], [",", 829], ["vs.", 831], ["35", 835], ["%", 837], [";", 838], ["P<0.001", 840], ["for", 848], ["the", 852], ["comparison", 856], ["of", 867], ["both", 870], ["doses", 875], ["with", 881], ["placebo", 886], [")", 893], [".", 894], ["It", 896], ["was", 899], ["also", 903], ["significantly", 908], ["superior", 922], ["with", 931], ["respect", 936], ["to", 944], ["ACR", 947], ["50", 951], [",", 953], ["which", 955], ["indicates", 961], ["at", 971], ["least", 974], ["a", 980], ["50", 982], ["%", 984], ["improvement", 986], ["(", 998], ["43", 999], ["%", 1001], ["and", 1003], ["32", 1007], ["%", 1009], ["vs.", 1011], ["19", 1015], ["%", 1017], [";", 1018], ["P<0.001", 1020], ["for", 1028], ["the", 1032], ["comparison", 1036], ["of", 1047], ["the", 1050], ["100-mg", 1054], ["dose", 1061], ["with", 1066], ["placebo", 1071], [",", 1078], ["P=0.007", 1080], ["for", 1088], ["the", 1092], ["comparison", 1096], ["of", 1107], ["the", 1110], ["150-mg", 1114], ["dose", 1121], ["with", 1126], ["placebo", 1131], [")", 1138], ["and", 1140], ["ACR", 1144], ["70", 1148], ["(", 1151], ["28", 1152], ["%", 1154], ["and", 1156], ["14", 1160], ["%", 1162], ["vs.", 1164], ["10", 1168], ["%", 1170], [";", 1171], ["P<0.001", 1173], ["for", 1181], ["the", 1185], ["comparison", 1189], ["of", 1200], ["the", 1203], ["100-mg", 1207], ["dose", 1214], ["with", 1219], ["placebo", 1224], [",", 1231], ["P=0.34", 1233], ["for", 1240], ["the", 1244], ["comparison", 1248], ["of", 1259], ["the", 1262], ["150-mg", 1266], ["dose", 1273], ["with", 1278], ["placebo", 1283], [")", 1290], [".", 1291], ["A", 1293], ["clinically", 1295], ["significant", 1306], ["effect", 1318], ["was", 1325], ["noted", 1329], ["by", 1335], ["the", 1338], ["end", 1342], ["of", 1346], ["the", 1349], ["first", 1353], ["week", 1359], ["of", 1364], ["treatment", 1367], [".", 1376], ["Adverse", 1378], ["effects", 1386], ["included", 1394], ["diarrhea", 1403], ["(", 1412], ["in", 1413], ["19", 1416], ["%", 1418], ["of", 1420], ["subjects", 1423], ["taking", 1432], ["the", 1439], ["100-mg", 1443], ["dose", 1450], ["of", 1455], ["R788", 1458], ["vs.", 1463], ["3", 1467], ["%", 1468], ["of", 1470], ["those", 1473], ["taking", 1479], ["placebo", 1486], [")", 1493], [",", 1494], ["upper", 1496], ["respiratory", 1502], ["infections", 1514], ["(", 1525], ["14", 1526], ["%", 1528], ["vs.", 1530], ["7", 1534], ["%", 1535], [")", 1536], [",", 1537], ["and", 1539], ["neutropenia", 1543], ["(", 1555], ["6", 1556], ["%", 1557], ["vs.", 1559], ["1", 1563], ["%", 1564], [")", 1565], [".", 1566], ["R788", 1568], ["was", 1573], ["associated", 1577], ["with", 1588], ["an", 1593], ["increase", 1596], ["in", 1605], ["systolic", 1608], ["blood", 1617], ["pressure", 1623], ["of", 1632], ["approximately", 1635], ["3", 1649], ["mm", 1651], ["Hg", 1654], ["between", 1657], ["baseline", 1665], ["and", 1674], ["month", 1678], ["1", 1684], [",", 1685], ["as", 1687], ["compared", 1690], ["with", 1699], ["a", 1704], ["decrease", 1706], ["of", 1715], ["2", 1718], ["mm", 1720], ["Hg", 1723], ["with", 1726], ["placebo", 1731], [";", 1738], ["23", 1740], ["%", 1742], ["of", 1744], ["the", 1747], ["patients", 1751], ["taking", 1760], ["R788", 1767], ["vs.", 1772], ["7", 1776], ["%", 1777], ["of", 1779], ["the", 1782], ["patients", 1786], ["receiving", 1795], ["placebo", 1805], ["required", 1813], ["the", 1822], ["initiation", 1826], ["of", 1837], ["or", 1840], ["a", 1843], ["change", 1845], ["in", 1852], ["antihypertensive", 1855], ["therapy", 1872], [".", 1879], ["In", 1881], ["this", 1884], ["phase", 1889], ["2", 1895], ["study", 1897], [",", 1902], ["a", 1904], ["Syk", 1906], ["inhibitor", 1910], ["reduced", 1920], ["disease", 1928], ["activity", 1936], ["in", 1945], ["patients", 1948], ["with", 1957], ["rheumatoid", 1962], ["arthritis", 1973], [";", 1982], ["adverse", 1984], ["events", 1992], ["included", 1999], ["diarrhea", 2008], [",", 2016], ["hypertension", 2018], [",", 2030], ["and", 2032], ["neutropenia", 2036], [".", 2047], ["Additional", 2049], ["studies", 2060], ["will", 2068], ["be", 2073], ["needed", 2076], ["to", 2083], ["further", 2086], ["assess", 2094], ["the", 2101], ["safety", 2105], ["and", 2112], ["efficacy", 2116], ["of", 2125], ["Syk", 2128], ["-", 2131], ["inhibition", 2132], ["therapy", 2143], ["in", 2151], ["patients", 2154], ["with", 2163], ["rheumatoid", 2168], ["arthritis", 2179], [".", 2188], ["(", 2190], ["Funded", 2191], ["by", 2198], ["Rigel", 2201], [";", 2206], ["ClinicalTrials.gov", 2208], ["number", 2227], [",", 2233], ["NCT00665925", 2235], [".", 2246], [")", 2247]]}
{"context": "Mutations in the solute carrier family 9, subfamily A member 6 (SLC9A6) gene, encoding the endosomal Na+/H+ exchanger 6 (NHE6) are associated with Christianson syndrome, a syndromic form of X-linked intellectual disability characterized by microcephaly, severe global developmental delay, autistic behavior, early onset seizures and ataxia. In a 7-year-old boy with characteristic clinical and neuroimaging features of Christianson syndrome and epileptic encephalopathy with continuous spikes and waves during sleep, we identified a novel splice site mutation (IVS10-1G>A) in SLC9A6. These findings expand the clinical spectrum of the syndrome and indicate NHE6 dysfunction as a new cause of electrical status epilepticus during slow-wave sleep (ESES).", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "9051b478ee6f41f98b58e2be06353573", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[100, 100], [13, 13]], "char_spans": [[576, 581], [64, 69]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["solute", 17], ["carrier", 24], ["family", 32], ["9", 39], [",", 40], ["subfamily", 42], ["A", 52], ["member", 54], ["6", 61], ["(", 63], ["SLC9A6", 64], [")", 70], ["gene", 72], [",", 76], ["encoding", 78], ["the", 87], ["endosomal", 91], ["Na+/H+", 101], ["exchanger", 108], ["6", 118], ["(", 120], ["NHE6", 121], [")", 125], ["are", 127], ["associated", 131], ["with", 142], ["Christianson", 147], ["syndrome", 160], [",", 168], ["a", 170], ["syndromic", 172], ["form", 182], ["of", 187], ["X", 190], ["-", 191], ["linked", 192], ["intellectual", 199], ["disability", 212], ["characterized", 223], ["by", 237], ["microcephaly", 240], [",", 252], ["severe", 254], ["global", 261], ["developmental", 268], ["delay", 282], [",", 287], ["autistic", 289], ["behavior", 298], [",", 306], ["early", 308], ["onset", 314], ["seizures", 320], ["and", 329], ["ataxia", 333], [".", 339], ["In", 341], ["a", 344], ["7-year", 346], ["-", 352], ["old", 353], ["boy", 357], ["with", 361], ["characteristic", 366], ["clinical", 381], ["and", 390], ["neuroimaging", 394], ["features", 407], ["of", 416], ["Christianson", 419], ["syndrome", 432], ["and", 441], ["epileptic", 445], ["encephalopathy", 455], ["with", 470], ["continuous", 475], ["spikes", 486], ["and", 493], ["waves", 497], ["during", 503], ["sleep", 510], [",", 515], ["we", 517], ["identified", 520], ["a", 531], ["novel", 533], ["splice", 539], ["site", 546], ["mutation", 551], ["(", 560], ["IVS10", 561], ["-", 566], ["1G", 567], [">", 569], ["A", 570], [")", 571], ["in", 573], ["SLC9A6", 576], [".", 582], ["These", 584], ["findings", 590], ["expand", 599], ["the", 606], ["clinical", 610], ["spectrum", 619], ["of", 628], ["the", 631], ["syndrome", 635], ["and", 644], ["indicate", 648], ["NHE6", 657], ["dysfunction", 662], ["as", 674], ["a", 677], ["new", 679], ["cause", 683], ["of", 689], ["electrical", 692], ["status", 703], ["epilepticus", 710], ["during", 722], ["slow", 729], ["-", 733], ["wave", 734], ["sleep", 739], ["(", 745], ["ESES", 746], [")", 750], [".", 751]]}
{"context": "Transcription coupled repair (TCR) is a nucleotide excision repair (NER) pathway that is dedicated to repair in the transcribed strand of an active gene. The genome overall NER is called global genomic repair (GGR). Elc1, the yeast homolog of the mammalian elongation factor elongin C, has been shown to be a component of a ubiquitin ligase complex that contains Rad7 and Rad16, two factors that are specifically required for GGR. Elc1 has also been suggested to be present in another ubiquitin ligase complex that lacks Rad7 and Rad16 and is involved in UV-induced ubiquitylation and subsequent degradation of RNA polymerase II. Here we show that elc1 deletion increases UV sensitivity of TCR-deficient cells but does not affect the UV sensitivity of otherwise wild type and GGR-deficient cells. Cells deleted for elc1 show normal NER in the transcribed strand of an active gene but have no detectable NER in the non-transcribed strand. Elc1 does not affect UV-induced mutagenesis when TCR is operative, but plays an important role in preventing the mutagenesis if TCR is defective. Furthermore, the levels of Rad7 and Rad16 proteins are not significantly decreased in elc1 cells, and overexpression of Rad7 and Rad16 individually or simultaneously in elc1 cells does not restore repair in the non-transcribed strand of an active gene. Our results suggest that Elc1 has no function in TCR but plays an important role in GGR. Furthermore, the role of Elc1 in GGR may not be subsidiary to that of Rad7 and Rad16.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "e0f30444851747c08e3a6c06ba0be328", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[156, 157], [22, 23], [238, 239], [171, 172]], "char_spans": [[843, 860], [116, 133], [1299, 1316], [918, 935]]}]}], "context_tokens": [["Transcription", 0], ["coupled", 14], ["repair", 22], ["(", 29], ["TCR", 30], [")", 33], ["is", 35], ["a", 38], ["nucleotide", 40], ["excision", 51], ["repair", 60], ["(", 67], ["NER", 68], [")", 71], ["pathway", 73], ["that", 81], ["is", 86], ["dedicated", 89], ["to", 99], ["repair", 102], ["in", 109], ["the", 112], ["transcribed", 116], ["strand", 128], ["of", 135], ["an", 138], ["active", 141], ["gene", 148], [".", 152], ["The", 154], ["genome", 158], ["overall", 165], ["NER", 173], ["is", 177], ["called", 180], ["global", 187], ["genomic", 194], ["repair", 202], ["(", 209], ["GGR", 210], [")", 213], [".", 214], ["Elc1", 216], [",", 220], ["the", 222], ["yeast", 226], ["homolog", 232], ["of", 240], ["the", 243], ["mammalian", 247], ["elongation", 257], ["factor", 268], ["elongin", 275], ["C", 283], [",", 284], ["has", 286], ["been", 290], ["shown", 295], ["to", 301], ["be", 304], ["a", 307], ["component", 309], ["of", 319], ["a", 322], ["ubiquitin", 324], ["ligase", 334], ["complex", 341], ["that", 349], ["contains", 354], ["Rad7", 363], ["and", 368], ["Rad16", 372], [",", 377], ["two", 379], ["factors", 383], ["that", 391], ["are", 396], ["specifically", 400], ["required", 413], ["for", 422], ["GGR", 426], [".", 429], ["Elc1", 431], ["has", 436], ["also", 440], ["been", 445], ["suggested", 450], ["to", 460], ["be", 463], ["present", 466], ["in", 474], ["another", 477], ["ubiquitin", 485], ["ligase", 495], ["complex", 502], ["that", 510], ["lacks", 515], ["Rad7", 521], ["and", 526], ["Rad16", 530], ["and", 536], ["is", 540], ["involved", 543], ["in", 552], ["UV", 555], ["-", 557], ["induced", 558], ["ubiquitylation", 566], ["and", 581], ["subsequent", 585], ["degradation", 596], ["of", 608], ["RNA", 611], ["polymerase", 615], ["II", 626], [".", 628], ["Here", 630], ["we", 635], ["show", 638], ["that", 643], ["elc1", 648], ["deletion", 653], ["increases", 662], ["UV", 672], ["sensitivity", 675], ["of", 687], ["TCR", 690], ["-", 693], ["deficient", 694], ["cells", 704], ["but", 710], ["does", 714], ["not", 719], ["affect", 723], ["the", 730], ["UV", 734], ["sensitivity", 737], ["of", 749], ["otherwise", 752], ["wild", 762], ["type", 767], ["and", 772], ["GGR", 776], ["-", 779], ["deficient", 780], ["cells", 790], [".", 795], ["Cells", 797], ["deleted", 803], ["for", 811], ["elc1", 815], ["show", 820], ["normal", 825], ["NER", 832], ["in", 836], ["the", 839], ["transcribed", 843], ["strand", 855], ["of", 862], ["an", 865], ["active", 868], ["gene", 875], ["but", 880], ["have", 884], ["no", 889], ["detectable", 892], ["NER", 903], ["in", 907], ["the", 910], ["non", 914], ["-", 917], ["transcribed", 918], ["strand", 930], [".", 936], ["Elc1", 938], ["does", 943], ["not", 948], ["affect", 952], ["UV", 959], ["-", 961], ["induced", 962], ["mutagenesis", 970], ["when", 982], ["TCR", 987], ["is", 991], ["operative", 994], [",", 1003], ["but", 1005], ["plays", 1009], ["an", 1015], ["important", 1018], ["role", 1028], ["in", 1033], ["preventing", 1036], ["the", 1047], ["mutagenesis", 1051], ["if", 1063], ["TCR", 1066], ["is", 1070], ["defective", 1073], [".", 1082], ["Furthermore", 1084], [",", 1095], ["the", 1097], ["levels", 1101], ["of", 1108], ["Rad7", 1111], ["and", 1116], ["Rad16", 1120], ["proteins", 1126], ["are", 1135], ["not", 1139], ["significantly", 1143], ["decreased", 1157], ["in", 1167], ["elc1", 1170], ["cells", 1175], [",", 1180], ["and", 1182], ["overexpression", 1186], ["of", 1201], ["Rad7", 1204], ["and", 1209], ["Rad16", 1213], ["individually", 1219], ["or", 1232], ["simultaneously", 1235], ["in", 1250], ["elc1", 1253], ["cells", 1258], ["does", 1264], ["not", 1269], ["restore", 1273], ["repair", 1281], ["in", 1288], ["the", 1291], ["non", 1295], ["-", 1298], ["transcribed", 1299], ["strand", 1311], ["of", 1318], ["an", 1321], ["active", 1324], ["gene", 1331], [".", 1335], ["Our", 1337], ["results", 1341], ["suggest", 1349], ["that", 1357], ["Elc1", 1362], ["has", 1367], ["no", 1371], ["function", 1374], ["in", 1383], ["TCR", 1386], ["but", 1390], ["plays", 1394], ["an", 1400], ["important", 1403], ["role", 1413], ["in", 1418], ["GGR", 1421], [".", 1424], ["Furthermore", 1426], [",", 1437], ["the", 1439], ["role", 1443], ["of", 1448], ["Elc1", 1451], ["in", 1456], ["GGR", 1459], ["may", 1463], ["not", 1467], ["be", 1471], ["subsidiary", 1474], ["to", 1485], ["that", 1488], ["of", 1493], ["Rad7", 1496], ["and", 1501], ["Rad16", 1505], [".", 1510]]}
{"context": "The members of the NOX family of enzymes are expressed in a variety of tissues and serve a number of functions. There is a high level of conservation of primary protein sequence, as well as functional features, although specialized responses are beginning to emerge. In this context, our data demonstrate that the NOX1 cytoplasmic domains interact efficiently with the cytoplasmic subunits of the phagocyte NADPH oxidase and identify the second cytoplasmic loop of NOX electron transporters as a crucial domain for enzyme function. Studies of cytosolic co-factors showed that the C-terminal cytoplasmic domain of NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with NOXA1. Finally, we have provided the first example of how alternative splicing of a NOX co-factor may be involved in the regulation of NADPH oxidase function.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "1d9e22d6ebaa441090217077e2711e57", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[104, 104], [57, 57]], "char_spans": [[613, 616], [314, 317]]}]}], "context_tokens": [["The", 0], ["members", 4], ["of", 12], ["the", 15], ["NOX", 19], ["family", 23], ["of", 30], ["enzymes", 33], ["are", 41], ["expressed", 45], ["in", 55], ["a", 58], ["variety", 60], ["of", 68], ["tissues", 71], ["and", 79], ["serve", 83], ["a", 89], ["number", 91], ["of", 98], ["functions", 101], [".", 110], ["There", 112], ["is", 118], ["a", 121], ["high", 123], ["level", 128], ["of", 134], ["conservation", 137], ["of", 150], ["primary", 153], ["protein", 161], ["sequence", 169], [",", 177], ["as", 179], ["well", 182], ["as", 187], ["functional", 190], ["features", 201], [",", 209], ["although", 211], ["specialized", 220], ["responses", 232], ["are", 242], ["beginning", 246], ["to", 256], ["emerge", 259], [".", 265], ["In", 267], ["this", 270], ["context", 275], [",", 282], ["our", 284], ["data", 288], ["demonstrate", 293], ["that", 305], ["the", 310], ["NOX1", 314], ["cytoplasmic", 319], ["domains", 331], ["interact", 339], ["efficiently", 348], ["with", 360], ["the", 365], ["cytoplasmic", 369], ["subunits", 381], ["of", 390], ["the", 393], ["phagocyte", 397], ["NADPH", 407], ["oxidase", 413], ["and", 421], ["identify", 425], ["the", 434], ["second", 438], ["cytoplasmic", 445], ["loop", 457], ["of", 462], ["NOX", 465], ["electron", 469], ["transporters", 478], ["as", 491], ["a", 494], ["crucial", 496], ["domain", 504], ["for", 511], ["enzyme", 515], ["function", 522], [".", 530], ["Studies", 532], ["of", 540], ["cytosolic", 543], ["co", 553], ["-", 555], ["factors", 556], ["showed", 564], ["that", 571], ["the", 576], ["C", 580], ["-", 581], ["terminal", 582], ["cytoplasmic", 591], ["domain", 603], ["of", 610], ["NOX1", 613], ["was", 618], ["absolutely", 622], ["required", 633], ["for", 642], ["activation", 646], ["with", 657], ["NOXO1", 662], ["and", 668], ["NOXA1", 672], ["and", 678], ["that", 682], ["this", 687], ["activity", 692], ["required", 701], ["interaction", 710], ["of", 722], ["the", 725], ["putative", 729], ["NADPH", 738], ["-", 743], ["binding", 744], ["region", 752], ["of", 759], ["this", 762], ["domain", 767], ["with", 774], ["NOXA1", 779], [".", 784], ["Finally", 786], [",", 793], ["we", 795], ["have", 798], ["provided", 803], ["the", 812], ["first", 816], ["example", 822], ["of", 830], ["how", 833], ["alternative", 837], ["splicing", 849], ["of", 858], ["a", 861], ["NOX", 863], ["co", 867], ["-", 869], ["factor", 870], ["may", 877], ["be", 881], ["involved", 884], ["in", 893], ["the", 896], ["regulation", 900], ["of", 911], ["NADPH", 914], ["oxidase", 920], ["function", 928], [".", 936]]}
{"context": "Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the development and progression of Philadelphia chromosome-positive (Ph(+)) chronic myelogenous leukemia (CML). Imatinib mesylate (STI571), a specific Bcr-Abl tyrosine-kinase signal-transduction inhibitor, has shown encouraging activity in phase I and II studies of CML. Here, we describe the use of imatinib mesylate to treat 75 patients in blast-phase CML (median age, 53 years; 65 with nonlymphoid and 10 with lymphoid blasts), and compare the results with those of a historical control group treated with standard cytarabine-based therapy. Imatinib mesylate was given as oral doses at 300 to 1000 mg per day and was the first salvage therapy for 47 patients. The objective response rate was 52% (39 of 75 patients: 16 had complete and 3 had partial hematologic response; 12 had hematologic improvement; 7 returned to second chronic phase; and 1 had a complete response in extramedullary blastic disease). Response rates were not different between nonlymphoid and lymphoid groups. The cytogenetic response rate was 16% (12 patients: 5 complete, 3 partial [Ph(+) below 35%], and 4 minor [Ph(+), 34% to 90%]). The estimated median overall survival was 6.5 months; the estimated 1-year survival was 22%. Response to therapy (landmark analysis at 8 weeks) was associated with survival prolongation. Compared with standard cytarabine combinations, imatinib mesylate therapy was less toxic and produced a higher response rate (55% versus 29%, P =.001), longer median survival (7 versus 4 months, P =.04), and lower 4-week induction mortality (4% versus 15%, P =.07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "130270c72b1842a69ae47929d7075090", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[42, 44], [6, 8]], "char_spans": [[238, 244], [45, 51]]}]}], "context_tokens": [["Molecular", 0], ["abnormalities", 10], ["caused", 24], ["by", 31], ["the", 34], ["hybrid", 38], ["Bcr", 45], ["-", 48], ["Abl", 49], ["gene", 53], ["are", 58], ["causally", 62], ["associated", 71], ["with", 82], ["the", 87], ["development", 91], ["and", 103], ["progression", 107], ["of", 119], ["Philadelphia", 122], ["chromosome", 135], ["-", 145], ["positive", 146], ["(", 155], ["Ph(+", 156], [")", 160], [")", 161], ["chronic", 163], ["myelogenous", 171], ["leukemia", 183], ["(", 192], ["CML", 193], [")", 196], [".", 197], ["Imatinib", 199], ["mesylate", 208], ["(", 217], ["STI571", 218], [")", 224], [",", 225], ["a", 227], ["specific", 229], ["Bcr", 238], ["-", 241], ["Abl", 242], ["tyrosine", 246], ["-", 254], ["kinase", 255], ["signal", 262], ["-", 268], ["transduction", 269], ["inhibitor", 282], [",", 291], ["has", 293], ["shown", 297], ["encouraging", 303], ["activity", 315], ["in", 324], ["phase", 327], ["I", 333], ["and", 335], ["II", 339], ["studies", 342], ["of", 350], ["CML", 353], [".", 356], ["Here", 358], [",", 362], ["we", 364], ["describe", 367], ["the", 376], ["use", 380], ["of", 384], ["imatinib", 387], ["mesylate", 396], ["to", 405], ["treat", 408], ["75", 414], ["patients", 417], ["in", 426], ["blast", 429], ["-", 434], ["phase", 435], ["CML", 441], ["(", 445], ["median", 446], ["age", 453], [",", 456], ["53", 458], ["years", 461], [";", 466], ["65", 468], ["with", 471], ["nonlymphoid", 476], ["and", 488], ["10", 492], ["with", 495], ["lymphoid", 500], ["blasts", 509], [")", 515], [",", 516], ["and", 518], ["compare", 522], ["the", 530], ["results", 534], ["with", 542], ["those", 547], ["of", 553], ["a", 556], ["historical", 558], ["control", 569], ["group", 577], ["treated", 583], ["with", 591], ["standard", 596], ["cytarabine", 605], ["-", 615], ["based", 616], ["therapy", 622], [".", 629], ["Imatinib", 631], ["mesylate", 640], ["was", 649], ["given", 653], ["as", 659], ["oral", 662], ["doses", 667], ["at", 673], ["300", 676], ["to", 680], ["1000", 683], ["mg", 688], ["per", 691], ["day", 695], ["and", 699], ["was", 703], ["the", 707], ["first", 711], ["salvage", 717], ["therapy", 725], ["for", 733], ["47", 737], ["patients", 740], [".", 748], ["The", 750], ["objective", 754], ["response", 764], ["rate", 773], ["was", 778], ["52", 782], ["%", 784], ["(", 786], ["39", 787], ["of", 790], ["75", 793], ["patients", 796], [":", 804], ["16", 806], ["had", 809], ["complete", 813], ["and", 822], ["3", 826], ["had", 828], ["partial", 832], ["hematologic", 840], ["response", 852], [";", 860], ["12", 862], ["had", 865], ["hematologic", 869], ["improvement", 881], [";", 892], ["7", 894], ["returned", 896], ["to", 905], ["second", 908], ["chronic", 915], ["phase", 923], [";", 928], ["and", 930], ["1", 934], ["had", 936], ["a", 940], ["complete", 942], ["response", 951], ["in", 960], ["extramedullary", 963], ["blastic", 978], ["disease", 986], [")", 993], [".", 994], ["Response", 996], ["rates", 1005], ["were", 1011], ["not", 1016], ["different", 1020], ["between", 1030], ["nonlymphoid", 1038], ["and", 1050], ["lymphoid", 1054], ["groups", 1063], [".", 1069], ["The", 1071], ["cytogenetic", 1075], ["response", 1087], ["rate", 1096], ["was", 1101], ["16", 1105], ["%", 1107], ["(", 1109], ["12", 1110], ["patients", 1113], [":", 1121], ["5", 1123], ["complete", 1125], [",", 1133], ["3", 1135], ["partial", 1137], ["[", 1145], ["Ph(+", 1146], [")", 1150], ["below", 1152], ["35", 1158], ["%", 1160], ["]", 1161], [",", 1162], ["and", 1164], ["4", 1168], ["minor", 1170], ["[", 1176], ["Ph(+", 1177], [")", 1181], [",", 1182], ["34", 1184], ["%", 1186], ["to", 1188], ["90", 1191], ["%", 1193], ["]", 1194], [")", 1195], [".", 1196], ["The", 1198], ["estimated", 1202], ["median", 1212], ["overall", 1219], ["survival", 1227], ["was", 1236], ["6.5", 1240], ["months", 1244], [";", 1250], ["the", 1252], ["estimated", 1256], ["1-year", 1266], ["survival", 1273], ["was", 1282], ["22", 1286], ["%", 1288], [".", 1289], ["Response", 1291], ["to", 1300], ["therapy", 1303], ["(", 1311], ["landmark", 1312], ["analysis", 1321], ["at", 1330], ["8", 1333], ["weeks", 1335], [")", 1340], ["was", 1342], ["associated", 1346], ["with", 1357], ["survival", 1362], ["prolongation", 1371], [".", 1383], ["Compared", 1385], ["with", 1394], ["standard", 1399], ["cytarabine", 1408], ["combinations", 1419], [",", 1431], ["imatinib", 1433], ["mesylate", 1442], ["therapy", 1451], ["was", 1459], ["less", 1463], ["toxic", 1468], ["and", 1474], ["produced", 1478], ["a", 1487], ["higher", 1489], ["response", 1496], ["rate", 1505], ["(", 1510], ["55", 1511], ["%", 1513], ["versus", 1515], ["29", 1522], ["%", 1524], [",", 1525], ["P", 1527], ["=", 1529], [".001", 1530], [")", 1534], [",", 1535], ["longer", 1537], ["median", 1544], ["survival", 1551], ["(", 1560], ["7", 1561], ["versus", 1563], ["4", 1570], ["months", 1572], [",", 1578], ["P", 1580], ["=", 1582], [".04", 1583], [")", 1586], [",", 1587], ["and", 1589], ["lower", 1593], ["4-week", 1599], ["induction", 1606], ["mortality", 1616], ["(", 1626], ["4", 1627], ["%", 1628], ["versus", 1630], ["15", 1637], ["%", 1639], [",", 1640], ["P", 1642], ["=", 1644], [".07", 1645], [")", 1648], [".", 1649], ["Imatinib", 1651], ["mesylate", 1660], ["is", 1669], ["currently", 1672], ["being", 1682], ["tested", 1688], ["in", 1695], ["combination", 1698], ["with", 1710], ["other", 1715], ["drugs", 1721], ["to", 1727], ["improve", 1730], ["the", 1738], ["prognosis", 1742], ["for", 1752], ["blast", 1756], ["-", 1761], ["phase", 1762], ["CML", 1768], [".", 1771]]}
{"context": "To evaluate the results of facial nerve (FN) grafting using great auricular cable graft and fibrin glue without suturing to palliate FN disruption after removal of large cerebellopontine angle (CPA) vestibular schwannoma (VS) or facial nerve schwannoma (FNS). To assess whether tumor size and origin influenced the results. Retrospective review of all patients having undergone removal of FNS/VS and needing intraoperative FN repair between 2001 and 2011. FN was rehabilitated using great auricular nerve cable graft and fibrin glue (Tisseal) without stitching suture. All data recorded were reviewed to access age, sex, tumor type, and tumor size according to the Koos classification and presenting symptoms. FN function was evaluated preoperatively and at 18 months using the House-Brackmann (HB) grading system. Among the 595 patients operated for CPA schwannomas in this period, 15 patients (2.5%) underwent FN repair, including 7 cases of FNS and 8 cases of VS. Tumor removal was total in all cases. FN recovery was HB3 in 13 cases (86.7%) and HB4 in 2. The mean time to the first clinical signs of facial reinnervation was 10 months (6-12 mo). No significant relation was found between postoperative facial function and tumor size or type, even if all cases of preoperative FP were noted in FNS. Immediate FN reconstruction with fibrin glue-aided greater auricular nerve graft can effectively restore FN function with excellent outcomes. The results seem better than those observed by other authors using sutured grafts or delayed hypoglossal-facial nerve anastomosis.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "daa709616eec470dae4a7428b85cf00d", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[34, 35]], "char_spans": [[199, 219]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["results", 16], ["of", 24], ["facial", 27], ["nerve", 34], ["(", 40], ["FN", 41], [")", 43], ["grafting", 45], ["using", 54], ["great", 60], ["auricular", 66], ["cable", 76], ["graft", 82], ["and", 88], ["fibrin", 92], ["glue", 99], ["without", 104], ["suturing", 112], ["to", 121], ["palliate", 124], ["FN", 133], ["disruption", 136], ["after", 147], ["removal", 153], ["of", 161], ["large", 164], ["cerebellopontine", 170], ["angle", 187], ["(", 193], ["CPA", 194], [")", 197], ["vestibular", 199], ["schwannoma", 210], ["(", 221], ["VS", 222], [")", 224], ["or", 226], ["facial", 229], ["nerve", 236], ["schwannoma", 242], ["(", 253], ["FNS", 254], [")", 257], [".", 258], ["To", 260], ["assess", 263], ["whether", 270], ["tumor", 278], ["size", 284], ["and", 289], ["origin", 293], ["influenced", 300], ["the", 311], ["results", 315], [".", 322], ["Retrospective", 324], ["review", 338], ["of", 345], ["all", 348], ["patients", 352], ["having", 361], ["undergone", 368], ["removal", 378], ["of", 386], ["FNS", 389], ["/", 392], ["VS", 393], ["and", 396], ["needing", 400], ["intraoperative", 408], ["FN", 423], ["repair", 426], ["between", 433], ["2001", 441], ["and", 446], ["2011", 450], [".", 454], ["FN", 456], ["was", 459], ["rehabilitated", 463], ["using", 477], ["great", 483], ["auricular", 489], ["nerve", 499], ["cable", 505], ["graft", 511], ["and", 517], ["fibrin", 521], ["glue", 528], ["(", 533], ["Tisseal", 534], [")", 541], ["without", 543], ["stitching", 551], ["suture", 561], [".", 567], ["All", 569], ["data", 573], ["recorded", 578], ["were", 587], ["reviewed", 592], ["to", 601], ["access", 604], ["age", 611], [",", 614], ["sex", 616], [",", 619], ["tumor", 621], ["type", 627], [",", 631], ["and", 633], ["tumor", 637], ["size", 643], ["according", 648], ["to", 658], ["the", 661], ["Koos", 665], ["classification", 670], ["and", 685], ["presenting", 689], ["symptoms", 700], [".", 708], ["FN", 710], ["function", 713], ["was", 722], ["evaluated", 726], ["preoperatively", 736], ["and", 751], ["at", 755], ["18", 758], ["months", 761], ["using", 768], ["the", 774], ["House", 778], ["-", 783], ["Brackmann", 784], ["(", 794], ["HB", 795], [")", 797], ["grading", 799], ["system", 807], [".", 813], ["Among", 815], ["the", 821], ["595", 825], ["patients", 829], ["operated", 838], ["for", 847], ["CPA", 851], ["schwannomas", 855], ["in", 867], ["this", 870], ["period", 875], [",", 881], ["15", 883], ["patients", 886], ["(", 895], ["2.5", 896], ["%", 899], [")", 900], ["underwent", 902], ["FN", 912], ["repair", 915], [",", 921], ["including", 923], ["7", 933], ["cases", 935], ["of", 941], ["FNS", 944], ["and", 948], ["8", 952], ["cases", 954], ["of", 960], ["VS", 963], [".", 965], ["Tumor", 967], ["removal", 973], ["was", 981], ["total", 985], ["in", 991], ["all", 994], ["cases", 998], [".", 1003], ["FN", 1005], ["recovery", 1008], ["was", 1017], ["HB3", 1021], ["in", 1025], ["13", 1028], ["cases", 1031], ["(", 1037], ["86.7", 1038], ["%", 1042], [")", 1043], ["and", 1045], ["HB4", 1049], ["in", 1053], ["2", 1056], [".", 1057], ["The", 1059], ["mean", 1063], ["time", 1068], ["to", 1073], ["the", 1076], ["first", 1080], ["clinical", 1086], ["signs", 1095], ["of", 1101], ["facial", 1104], ["reinnervation", 1111], ["was", 1125], ["10", 1129], ["months", 1132], ["(", 1139], ["6", 1140], ["-", 1141], ["12", 1142], ["mo", 1145], [")", 1147], [".", 1148], ["No", 1150], ["significant", 1153], ["relation", 1165], ["was", 1174], ["found", 1178], ["between", 1184], ["postoperative", 1192], ["facial", 1206], ["function", 1213], ["and", 1222], ["tumor", 1226], ["size", 1232], ["or", 1237], ["type", 1240], [",", 1244], ["even", 1246], ["if", 1251], ["all", 1254], ["cases", 1258], ["of", 1264], ["preoperative", 1267], ["FP", 1280], ["were", 1283], ["noted", 1288], ["in", 1294], ["FNS", 1297], [".", 1300], ["Immediate", 1302], ["FN", 1312], ["reconstruction", 1315], ["with", 1330], ["fibrin", 1335], ["glue", 1342], ["-", 1346], ["aided", 1347], ["greater", 1353], ["auricular", 1361], ["nerve", 1371], ["graft", 1377], ["can", 1383], ["effectively", 1387], ["restore", 1399], ["FN", 1407], ["function", 1410], ["with", 1419], ["excellent", 1424], ["outcomes", 1434], [".", 1442], ["The", 1444], ["results", 1448], ["seem", 1456], ["better", 1461], ["than", 1468], ["those", 1473], ["observed", 1479], ["by", 1488], ["other", 1491], ["authors", 1497], ["using", 1505], ["sutured", 1511], ["grafts", 1519], ["or", 1526], ["delayed", 1529], ["hypoglossal", 1537], ["-", 1548], ["facial", 1549], ["nerve", 1556], ["anastomosis", 1562], [".", 1573]]}
{"context": "Lewy body disease is a heterogeneous group of neurodegenerative disorders characterized by alpha-synuclein accumulation that includes dementia with Lewy bodies (DLB) and Parkinson's Disease (PD). Recent evidence suggests that impairment of lysosomal pathways (i.e. autophagy) involved in alpha-synuclein clearance might play an important role. For this reason, we sought to examine the expression levels of members of the autophagy pathway in brains of patients with DLB and Alzheimer's Disease (AD) and in alpha-synuclein transgenic mice. By immunoblot analysis, compared to controls and AD, in DLB cases levels of mTor were elevated and Atg7 were reduced. Levels of other components of the autophagy pathway such as Atg5, Atg10, Atg12 and Beclin-1 were not different in DLB compared to controls. In DLB brains, mTor was more abundant in neurons displaying alpha-synuclein accumulation. These neurons also showed abnormal expression of lysosomal markers such as LC3, and ultrastructural analysis revealed the presence of abundant and abnormal autophagosomes. Similar alterations were observed in the brains of alpha-synuclein transgenic mice. Intra-cerebral infusion of rapamycin, an inhibitor of mTor, or injection of a lentiviral vector expressing Atg7 resulted in reduced accumulation of alpha-synuclein in transgenic mice and amelioration of associated neurodegenerative alterations. This study supports the notion that defects in the autophagy pathway and more specifically in mTor and Atg7 are associated with neurodegeneration in DLB cases and alpha-synuclein transgenic models and supports the possibility that modulators of the autophagy pathway might have potential therapeutic effects.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "2fa17a29be5d4cdb8b61ce90ede60e4a", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[26, 30]], "char_spans": [[170, 192]]}]}], "context_tokens": [["Lewy", 0], ["body", 5], ["disease", 10], ["is", 18], ["a", 21], ["heterogeneous", 23], ["group", 37], ["of", 43], ["neurodegenerative", 46], ["disorders", 64], ["characterized", 74], ["by", 88], ["alpha", 91], ["-", 96], ["synuclein", 97], ["accumulation", 107], ["that", 120], ["includes", 125], ["dementia", 134], ["with", 143], ["Lewy", 148], ["bodies", 153], ["(", 160], ["DLB", 161], [")", 164], ["and", 166], ["Parkinson", 170], ["'s", 179], ["Disease", 182], ["(", 190], ["PD", 191], [")", 193], [".", 194], ["Recent", 196], ["evidence", 203], ["suggests", 212], ["that", 221], ["impairment", 226], ["of", 237], ["lysosomal", 240], ["pathways", 250], ["(", 259], ["i.e.", 260], ["autophagy", 265], [")", 274], ["involved", 276], ["in", 285], ["alpha", 288], ["-", 293], ["synuclein", 294], ["clearance", 304], ["might", 314], ["play", 320], ["an", 325], ["important", 328], ["role", 338], [".", 342], ["For", 344], ["this", 348], ["reason", 353], [",", 359], ["we", 361], ["sought", 364], ["to", 371], ["examine", 374], ["the", 382], ["expression", 386], ["levels", 397], ["of", 404], ["members", 407], ["of", 415], ["the", 418], ["autophagy", 422], ["pathway", 432], ["in", 440], ["brains", 443], ["of", 450], ["patients", 453], ["with", 462], ["DLB", 467], ["and", 471], ["Alzheimer", 475], ["'s", 484], ["Disease", 487], ["(", 495], ["AD", 496], [")", 498], ["and", 500], ["in", 504], ["alpha", 507], ["-", 512], ["synuclein", 513], ["transgenic", 523], ["mice", 534], [".", 538], ["By", 540], ["immunoblot", 543], ["analysis", 554], [",", 562], ["compared", 564], ["to", 573], ["controls", 576], ["and", 585], ["AD", 589], [",", 591], ["in", 593], ["DLB", 596], ["cases", 600], ["levels", 606], ["of", 613], ["mTor", 616], ["were", 621], ["elevated", 626], ["and", 635], ["Atg7", 639], ["were", 644], ["reduced", 649], [".", 656], ["Levels", 658], ["of", 665], ["other", 668], ["components", 674], ["of", 685], ["the", 688], ["autophagy", 692], ["pathway", 702], ["such", 710], ["as", 715], ["Atg5", 718], [",", 722], ["Atg10", 724], [",", 729], ["Atg12", 731], ["and", 737], ["Beclin-1", 741], ["were", 750], ["not", 755], ["different", 759], ["in", 769], ["DLB", 772], ["compared", 776], ["to", 785], ["controls", 788], [".", 796], ["In", 798], ["DLB", 801], ["brains", 805], [",", 811], ["mTor", 813], ["was", 818], ["more", 822], ["abundant", 827], ["in", 836], ["neurons", 839], ["displaying", 847], ["alpha", 858], ["-", 863], ["synuclein", 864], ["accumulation", 874], [".", 886], ["These", 888], ["neurons", 894], ["also", 902], ["showed", 907], ["abnormal", 914], ["expression", 923], ["of", 934], ["lysosomal", 937], ["markers", 947], ["such", 955], ["as", 960], ["LC3", 963], [",", 966], ["and", 968], ["ultrastructural", 972], ["analysis", 988], ["revealed", 997], ["the", 1006], ["presence", 1010], ["of", 1019], ["abundant", 1022], ["and", 1031], ["abnormal", 1035], ["autophagosomes", 1044], [".", 1058], ["Similar", 1060], ["alterations", 1068], ["were", 1080], ["observed", 1085], ["in", 1094], ["the", 1097], ["brains", 1101], ["of", 1108], ["alpha", 1111], ["-", 1116], ["synuclein", 1117], ["transgenic", 1127], ["mice", 1138], [".", 1142], ["Intra", 1144], ["-", 1149], ["cerebral", 1150], ["infusion", 1159], ["of", 1168], ["rapamycin", 1171], [",", 1180], ["an", 1182], ["inhibitor", 1185], ["of", 1195], ["mTor", 1198], [",", 1202], ["or", 1204], ["injection", 1207], ["of", 1217], ["a", 1220], ["lentiviral", 1222], ["vector", 1233], ["expressing", 1240], ["Atg7", 1251], ["resulted", 1256], ["in", 1265], ["reduced", 1268], ["accumulation", 1276], ["of", 1289], ["alpha", 1292], ["-", 1297], ["synuclein", 1298], ["in", 1308], ["transgenic", 1311], ["mice", 1322], ["and", 1327], ["amelioration", 1331], ["of", 1344], ["associated", 1347], ["neurodegenerative", 1358], ["alterations", 1376], [".", 1387], ["This", 1389], ["study", 1394], ["supports", 1400], ["the", 1409], ["notion", 1413], ["that", 1420], ["defects", 1425], ["in", 1433], ["the", 1436], ["autophagy", 1440], ["pathway", 1450], ["and", 1458], ["more", 1462], ["specifically", 1467], ["in", 1480], ["mTor", 1483], ["and", 1488], ["Atg7", 1492], ["are", 1497], ["associated", 1501], ["with", 1512], ["neurodegeneration", 1517], ["in", 1535], ["DLB", 1538], ["cases", 1542], ["and", 1548], ["alpha", 1552], ["-", 1557], ["synuclein", 1558], ["transgenic", 1568], ["models", 1579], ["and", 1586], ["supports", 1590], ["the", 1599], ["possibility", 1603], ["that", 1615], ["modulators", 1620], ["of", 1631], ["the", 1634], ["autophagy", 1638], ["pathway", 1648], ["might", 1656], ["have", 1662], ["potential", 1667], ["therapeutic", 1677], ["effects", 1689], [".", 1696]]}
{"context": "The management of de Quervain's disease (DD) is nonoperative in the first instance, but surgery should be considered if conservative measures fail. We present the long-term results of operative treatment of DD. From July 1988 to July 1998, 94 consecutive patients with DD were treated operatively by a single surgeon. There were 80 women and 14 men. Average age at the time of operation was 47.4 years (range 22-76). The right wrist was involved in 43 cases, the left in 51 cases. All operations were done under tourniquet control with local infiltration anaesthesia using a longitudinal incision and partial resection of the extensor ligament. There were six perioperative complications, including one superficial wound infection, one delayed wound healing, and four transient lesions of the radial nerve. A successful outcome was achieved in all cases with negative Finkelstein's test. Simple decompression of both tendons and partial resection of the extensor ligament with a maximum of 3 mm can be recommended in operative treatment of DD with excellent long-term results.", "qas": [{"question": "Which disease is diagnosed using the Finkelstein's test?", "answers": ["de Quervain's disease"], "qid": "94956aa6f46c40d6942aab9ac607436f", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["diagnosed", 17], ["using", 27], ["the", 33], ["Finkelstein", 37], ["'s", 48], ["test", 51], ["?", 55]], "detected_answers": [{"text": "de Quervain's disease", "token_spans": [[3, 6]], "char_spans": [[18, 38]]}]}], "context_tokens": [["The", 0], ["management", 4], ["of", 15], ["de", 18], ["Quervain", 21], ["'s", 29], ["disease", 32], ["(", 40], ["DD", 41], [")", 43], ["is", 45], ["nonoperative", 48], ["in", 61], ["the", 64], ["first", 68], ["instance", 74], [",", 82], ["but", 84], ["surgery", 88], ["should", 96], ["be", 103], ["considered", 106], ["if", 117], ["conservative", 120], ["measures", 133], ["fail", 142], [".", 146], ["We", 148], ["present", 151], ["the", 159], ["long", 163], ["-", 167], ["term", 168], ["results", 173], ["of", 181], ["operative", 184], ["treatment", 194], ["of", 204], ["DD", 207], [".", 209], ["From", 211], ["July", 216], ["1988", 221], ["to", 226], ["July", 229], ["1998", 234], [",", 238], ["94", 240], ["consecutive", 243], ["patients", 255], ["with", 264], ["DD", 269], ["were", 272], ["treated", 277], ["operatively", 285], ["by", 297], ["a", 300], ["single", 302], ["surgeon", 309], [".", 316], ["There", 318], ["were", 324], ["80", 329], ["women", 332], ["and", 338], ["14", 342], ["men", 345], [".", 348], ["Average", 350], ["age", 358], ["at", 362], ["the", 365], ["time", 369], ["of", 374], ["operation", 377], ["was", 387], ["47.4", 391], ["years", 396], ["(", 402], ["range", 403], ["22", 409], ["-", 411], ["76", 412], [")", 414], [".", 415], ["The", 417], ["right", 421], ["wrist", 427], ["was", 433], ["involved", 437], ["in", 446], ["43", 449], ["cases", 452], [",", 457], ["the", 459], ["left", 463], ["in", 468], ["51", 471], ["cases", 474], [".", 479], ["All", 481], ["operations", 485], ["were", 496], ["done", 501], ["under", 506], ["tourniquet", 512], ["control", 523], ["with", 531], ["local", 536], ["infiltration", 542], ["anaesthesia", 555], ["using", 567], ["a", 573], ["longitudinal", 575], ["incision", 588], ["and", 597], ["partial", 601], ["resection", 609], ["of", 619], ["the", 622], ["extensor", 626], ["ligament", 635], [".", 643], ["There", 645], ["were", 651], ["six", 656], ["perioperative", 660], ["complications", 674], [",", 687], ["including", 689], ["one", 699], ["superficial", 703], ["wound", 715], ["infection", 721], [",", 730], ["one", 732], ["delayed", 736], ["wound", 744], ["healing", 750], [",", 757], ["and", 759], ["four", 763], ["transient", 768], ["lesions", 778], ["of", 786], ["the", 789], ["radial", 793], ["nerve", 800], [".", 805], ["A", 807], ["successful", 809], ["outcome", 820], ["was", 828], ["achieved", 832], ["in", 841], ["all", 844], ["cases", 848], ["with", 854], ["negative", 859], ["Finkelstein", 868], ["'s", 879], ["test", 882], [".", 886], ["Simple", 888], ["decompression", 895], ["of", 909], ["both", 912], ["tendons", 917], ["and", 925], ["partial", 929], ["resection", 937], ["of", 947], ["the", 950], ["extensor", 954], ["ligament", 963], ["with", 972], ["a", 977], ["maximum", 979], ["of", 987], ["3", 990], ["mm", 992], ["can", 995], ["be", 999], ["recommended", 1002], ["in", 1014], ["operative", 1017], ["treatment", 1027], ["of", 1037], ["DD", 1040], ["with", 1043], ["excellent", 1048], ["long", 1058], ["-", 1062], ["term", 1063], ["results", 1068], [".", 1075]]}
{"context": "The vitamin K antagonists (VKAs) have been the standard (and only) oral anticoagulants used for the long-term treatment or prevention of venous thromboembolism or stroke in patients with atrial fibrillation. The coagulopathy induced by VKAs can be reversed with vitamin K, and in urgent situations, the vitamin K-dependent coagulation factors can be replaced by transfusion. In the last decade, a new class of oral anticoagulants has been developed, direct oral anticoagulants that bind to a specific coagulation factor and neutralize it. These compounds were shown to be effective and safe compared with the VKAs and were licensed for specific indications, but without a specific reversal agent. The absence of a reversal agent is a barrier to more widespread use of these agents. Currently, for the management of major life-threatening bleeding with the direct oral anticoagulants, most authorities recommend the use of four factor prothrombin complex concentrates. There are now three reversal agents in development and poised to enter the market. Idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the USA. Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin. Ciraparantag is an antidote targeted to reverse the direct thrombin and factor Xa inhibitors as well as the indirect inhibitor enoxaparin.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "708d81adb4e44a03ab3e302e8165cec5", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[197, 197]], "char_spans": [[1138, 1147]]}]}], "context_tokens": [["The", 0], ["vitamin", 4], ["K", 12], ["antagonists", 14], ["(", 26], ["VKAs", 27], [")", 31], ["have", 33], ["been", 38], ["the", 43], ["standard", 47], ["(", 56], ["and", 57], ["only", 61], [")", 65], ["oral", 67], ["anticoagulants", 72], ["used", 87], ["for", 92], ["the", 96], ["long", 100], ["-", 104], ["term", 105], ["treatment", 110], ["or", 120], ["prevention", 123], ["of", 134], ["venous", 137], ["thromboembolism", 144], ["or", 160], ["stroke", 163], ["in", 170], ["patients", 173], ["with", 182], ["atrial", 187], ["fibrillation", 194], [".", 206], ["The", 208], ["coagulopathy", 212], ["induced", 225], ["by", 233], ["VKAs", 236], ["can", 241], ["be", 245], ["reversed", 248], ["with", 257], ["vitamin", 262], ["K", 270], [",", 271], ["and", 273], ["in", 277], ["urgent", 280], ["situations", 287], [",", 297], ["the", 299], ["vitamin", 303], ["K", 311], ["-", 312], ["dependent", 313], ["coagulation", 323], ["factors", 335], ["can", 343], ["be", 347], ["replaced", 350], ["by", 359], ["transfusion", 362], [".", 373], ["In", 375], ["the", 378], ["last", 382], ["decade", 387], [",", 393], ["a", 395], ["new", 397], ["class", 401], ["of", 407], ["oral", 410], ["anticoagulants", 415], ["has", 430], ["been", 434], ["developed", 439], [",", 448], ["direct", 450], ["oral", 457], ["anticoagulants", 462], ["that", 477], ["bind", 482], ["to", 487], ["a", 490], ["specific", 492], ["coagulation", 501], ["factor", 513], ["and", 520], ["neutralize", 524], ["it", 535], [".", 537], ["These", 539], ["compounds", 545], ["were", 555], ["shown", 560], ["to", 566], ["be", 569], ["effective", 572], ["and", 582], ["safe", 586], ["compared", 591], ["with", 600], ["the", 605], ["VKAs", 609], ["and", 614], ["were", 618], ["licensed", 623], ["for", 632], ["specific", 636], ["indications", 645], [",", 656], ["but", 658], ["without", 662], ["a", 670], ["specific", 672], ["reversal", 681], ["agent", 690], [".", 695], ["The", 697], ["absence", 701], ["of", 709], ["a", 712], ["reversal", 714], ["agent", 723], ["is", 729], ["a", 732], ["barrier", 734], ["to", 742], ["more", 745], ["widespread", 750], ["use", 761], ["of", 765], ["these", 768], ["agents", 774], [".", 780], ["Currently", 782], [",", 791], ["for", 793], ["the", 797], ["management", 801], ["of", 812], ["major", 815], ["life", 821], ["-", 825], ["threatening", 826], ["bleeding", 838], ["with", 847], ["the", 852], ["direct", 856], ["oral", 863], ["anticoagulants", 868], [",", 882], ["most", 884], ["authorities", 889], ["recommend", 901], ["the", 911], ["use", 915], ["of", 919], ["four", 922], ["factor", 927], ["prothrombin", 934], ["complex", 946], ["concentrates", 954], [".", 966], ["There", 968], ["are", 974], ["now", 978], ["three", 982], ["reversal", 988], ["agents", 997], ["in", 1004], ["development", 1007], ["and", 1019], ["poised", 1023], ["to", 1030], ["enter", 1033], ["the", 1039], ["market", 1043], [".", 1049], ["Idarucizumab", 1051], ["is", 1064], ["a", 1067], ["specific", 1069], ["antidote", 1078], ["targeted", 1087], ["to", 1096], ["reverse", 1099], ["the", 1107], ["direct", 1111], ["thrombin", 1118], ["inhibitor", 1127], [",", 1136], ["dabigatran", 1138], [",", 1148], ["which", 1150], ["was", 1156], ["recently", 1160], ["approved", 1169], ["for", 1178], ["use", 1182], ["in", 1186], ["the", 1189], ["USA", 1193], [".", 1196], ["Andexanet", 1198], ["alfa", 1208], ["is", 1213], ["an", 1216], ["antidote", 1219], ["targeted", 1228], ["to", 1237], ["reverse", 1240], ["the", 1248], ["oral", 1252], ["direct", 1257], ["factor", 1264], ["Xa", 1271], ["inhibitors", 1274], ["as", 1285], ["well", 1288], ["as", 1293], ["the", 1296], ["indirect", 1300], ["inhibitor", 1309], ["enoxaparin", 1319], [".", 1329], ["Ciraparantag", 1331], ["is", 1344], ["an", 1347], ["antidote", 1350], ["targeted", 1359], ["to", 1368], ["reverse", 1371], ["the", 1379], ["direct", 1383], ["thrombin", 1390], ["and", 1399], ["factor", 1403], ["Xa", 1410], ["inhibitors", 1413], ["as", 1424], ["well", 1427], ["as", 1432], ["the", 1435], ["indirect", 1439], ["inhibitor", 1448], ["enoxaparin", 1458], [".", 1468]]}
{"context": "It has been previously shown that disruption of RAD26 in yeast strain W303-1B results in a strain that is deficient in transcription-coupled repair (TCR), the preferential repair of the transcribed strand of an expressed gene over the non-transcribed strand and the rest of the genome. RAD26 encodes a protein that is homologous to Cockayne syndrome group B protein (CSB) and is a member of the SWI2/SNF2 family of DNA-dependent ATPases involved in chromatin remodeling. Like the rad26 mutant, cells from Cockayne syndrome patients are defective in TCR. We examined the role of Rad26 in TCR by disrupting RAD26 in two repair-proficient laboratory strains and, remarkably, observed no effect upon TCR. Our results indicate that disruption of RAD26 alone is insufficient to impair TCR. Thus, W303-1B must already possess a mutation that, together with disruption of RAD26, causes a deficiency in TCR. We suggest that other genes are mutated in Cockayne syndrome cells that contribute to the deficiency in TCR. Surprisingly, deletion of RAD26 results in expression of genes that are repressed by flanking transposon delta elements, an Spt(-) phenotype. The delta elements appear to perturb local chromatin structure. Expression of genes flanked by delta elements in rad26Delta mutants is consistent with a role for Rad26 in chromatin remodeling.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "d013353ea4e742219ed6b636f0489445", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[36, 37], [46, 47]], "char_spans": [[186, 203], [239, 256]]}]}], "context_tokens": [["It", 0], ["has", 3], ["been", 7], ["previously", 12], ["shown", 23], ["that", 29], ["disruption", 34], ["of", 45], ["RAD26", 48], ["in", 54], ["yeast", 57], ["strain", 63], ["W303", 70], ["-", 74], ["1B", 75], ["results", 78], ["in", 86], ["a", 89], ["strain", 91], ["that", 98], ["is", 103], ["deficient", 106], ["in", 116], ["transcription", 119], ["-", 132], ["coupled", 133], ["repair", 141], ["(", 148], ["TCR", 149], [")", 152], [",", 153], ["the", 155], ["preferential", 159], ["repair", 172], ["of", 179], ["the", 182], ["transcribed", 186], ["strand", 198], ["of", 205], ["an", 208], ["expressed", 211], ["gene", 221], ["over", 226], ["the", 231], ["non", 235], ["-", 238], ["transcribed", 239], ["strand", 251], ["and", 258], ["the", 262], ["rest", 266], ["of", 271], ["the", 274], ["genome", 278], [".", 284], ["RAD26", 286], ["encodes", 292], ["a", 300], ["protein", 302], ["that", 310], ["is", 315], ["homologous", 318], ["to", 329], ["Cockayne", 332], ["syndrome", 341], ["group", 350], ["B", 356], ["protein", 358], ["(", 366], ["CSB", 367], [")", 370], ["and", 372], ["is", 376], ["a", 379], ["member", 381], ["of", 388], ["the", 391], ["SWI2/SNF2", 395], ["family", 405], ["of", 412], ["DNA", 415], ["-", 418], ["dependent", 419], ["ATPases", 429], ["involved", 437], ["in", 446], ["chromatin", 449], ["remodeling", 459], [".", 469], ["Like", 471], ["the", 476], ["rad26", 480], ["mutant", 486], [",", 492], ["cells", 494], ["from", 500], ["Cockayne", 505], ["syndrome", 514], ["patients", 523], ["are", 532], ["defective", 536], ["in", 546], ["TCR", 549], [".", 552], ["We", 554], ["examined", 557], ["the", 566], ["role", 570], ["of", 575], ["Rad26", 578], ["in", 584], ["TCR", 587], ["by", 591], ["disrupting", 594], ["RAD26", 605], ["in", 611], ["two", 614], ["repair", 618], ["-", 624], ["proficient", 625], ["laboratory", 636], ["strains", 647], ["and", 655], [",", 658], ["remarkably", 660], [",", 670], ["observed", 672], ["no", 681], ["effect", 684], ["upon", 691], ["TCR", 696], [".", 699], ["Our", 701], ["results", 705], ["indicate", 713], ["that", 722], ["disruption", 727], ["of", 738], ["RAD26", 741], ["alone", 747], ["is", 753], ["insufficient", 756], ["to", 769], ["impair", 772], ["TCR", 779], [".", 782], ["Thus", 784], [",", 788], ["W303", 790], ["-", 794], ["1B", 795], ["must", 798], ["already", 803], ["possess", 811], ["a", 819], ["mutation", 821], ["that", 830], [",", 834], ["together", 836], ["with", 845], ["disruption", 850], ["of", 861], ["RAD26", 864], [",", 869], ["causes", 871], ["a", 878], ["deficiency", 880], ["in", 891], ["TCR", 894], [".", 897], ["We", 899], ["suggest", 902], ["that", 910], ["other", 915], ["genes", 921], ["are", 927], ["mutated", 931], ["in", 939], ["Cockayne", 942], ["syndrome", 951], ["cells", 960], ["that", 966], ["contribute", 971], ["to", 982], ["the", 985], ["deficiency", 989], ["in", 1000], ["TCR", 1003], [".", 1006], ["Surprisingly", 1008], [",", 1020], ["deletion", 1022], ["of", 1031], ["RAD26", 1034], ["results", 1040], ["in", 1048], ["expression", 1051], ["of", 1062], ["genes", 1065], ["that", 1071], ["are", 1076], ["repressed", 1080], ["by", 1090], ["flanking", 1093], ["transposon", 1102], ["delta", 1113], ["elements", 1119], [",", 1127], ["an", 1129], ["Spt(-", 1132], [")", 1137], ["phenotype", 1139], [".", 1148], ["The", 1150], ["delta", 1154], ["elements", 1160], ["appear", 1169], ["to", 1176], ["perturb", 1179], ["local", 1187], ["chromatin", 1193], ["structure", 1203], [".", 1212], ["Expression", 1214], ["of", 1225], ["genes", 1228], ["flanked", 1234], ["by", 1242], ["delta", 1245], ["elements", 1251], ["in", 1260], ["rad26Delta", 1263], ["mutants", 1274], ["is", 1282], ["consistent", 1285], ["with", 1296], ["a", 1301], ["role", 1303], ["for", 1308], ["Rad26", 1312], ["in", 1318], ["chromatin", 1321], ["remodeling", 1331], [".", 1341]]}
{"context": "In eukaryotes, co-translational insertion of selenocysteine into selenoproteins necessitates the participation of the selenocysteine insertion sequence (SECIS), an element lying in the 3'-untranslated region of selenoprotein mRNAs. We report a detailed experimental study of the secondary structures of the SECIS elements of three selenoprotein mRNAs, the rat and human type I iodothyronine deiodinase (5'DI) and rat glutathione peroxidase (GPx). Based on RNase and chemical probing, a new secondary structure model is established. It is characterized by a stem-loop structure, comprising two helices (I and II) separated by an internal loop, with an apical loop surmounting helix II. Sequence comparisons of 20 SECIS elements, arising from 2 5'DI, 13 GPx, 2 selenoprotein P, and 1 selenoprotein W mRNAs, confirm the secondary structure model. The most striking finding of the experimental study concerns a set of conserved sequences in helix II that interact to form a novel RNA structural motif consisting of a quartet composed of non-Watson-Crick base pairs 5'UGAY3': 5'UGAU3'. The potential for forming the quartet is preserved in 15 SECIS elements, but three consecutive non-Watson-Crick base pairs can nevertheless form in the other five SECIS, the central G.A tandem being invariant in all cases. A 3D model, derived by computer modeling with the use of the solution data, suggests that the base pairing interactions in the G.A tandem are of the type found in GNRA loops. The 3D model displays the quartet lying in an accessible position at the foot of helix II, which is bent at the internal loop, suggesting that the non-Watson-Crick base pair arrangement provides an unusual pattern of chemical groups for putative ligand interaction.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "3fe09fafae1c4200bf36faea155c3c62", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[123, 123], [205, 205], [20, 20], [46, 46], [225, 225]], "char_spans": [[712, 716], [1138, 1142], [153, 157], [307, 311], [1244, 1248]]}]}], "context_tokens": [["In", 0], ["eukaryotes", 3], [",", 13], ["co", 15], ["-", 17], ["translational", 18], ["insertion", 32], ["of", 42], ["selenocysteine", 45], ["into", 60], ["selenoproteins", 65], ["necessitates", 80], ["the", 93], ["participation", 97], ["of", 111], ["the", 114], ["selenocysteine", 118], ["insertion", 133], ["sequence", 143], ["(", 152], ["SECIS", 153], [")", 158], [",", 159], ["an", 161], ["element", 164], ["lying", 172], ["in", 178], ["the", 181], ["3'-untranslated", 185], ["region", 201], ["of", 208], ["selenoprotein", 211], ["mRNAs", 225], [".", 230], ["We", 232], ["report", 235], ["a", 242], ["detailed", 244], ["experimental", 253], ["study", 266], ["of", 272], ["the", 275], ["secondary", 279], ["structures", 289], ["of", 300], ["the", 303], ["SECIS", 307], ["elements", 313], ["of", 322], ["three", 325], ["selenoprotein", 331], ["mRNAs", 345], [",", 350], ["the", 352], ["rat", 356], ["and", 360], ["human", 364], ["type", 370], ["I", 375], ["iodothyronine", 377], ["deiodinase", 391], ["(", 402], ["5'DI", 403], [")", 407], ["and", 409], ["rat", 413], ["glutathione", 417], ["peroxidase", 429], ["(", 440], ["GPx", 441], [")", 444], [".", 445], ["Based", 447], ["on", 453], ["RNase", 456], ["and", 462], ["chemical", 466], ["probing", 475], [",", 482], ["a", 484], ["new", 486], ["secondary", 490], ["structure", 500], ["model", 510], ["is", 516], ["established", 519], [".", 530], ["It", 532], ["is", 535], ["characterized", 538], ["by", 552], ["a", 555], ["stem", 557], ["-", 561], ["loop", 562], ["structure", 567], [",", 576], ["comprising", 578], ["two", 589], ["helices", 593], ["(", 601], ["I", 602], ["and", 604], ["II", 608], [")", 610], ["separated", 612], ["by", 622], ["an", 625], ["internal", 628], ["loop", 637], [",", 641], ["with", 643], ["an", 648], ["apical", 651], ["loop", 658], ["surmounting", 663], ["helix", 675], ["II", 681], [".", 683], ["Sequence", 685], ["comparisons", 694], ["of", 706], ["20", 709], ["SECIS", 712], ["elements", 718], [",", 726], ["arising", 728], ["from", 736], ["2", 741], ["5'DI", 743], [",", 747], ["13", 749], ["GPx", 752], [",", 755], ["2", 757], ["selenoprotein", 759], ["P", 773], [",", 774], ["and", 776], ["1", 780], ["selenoprotein", 782], ["W", 796], ["mRNAs", 798], [",", 803], ["confirm", 805], ["the", 813], ["secondary", 817], ["structure", 827], ["model", 837], [".", 842], ["The", 844], ["most", 848], ["striking", 853], ["finding", 862], ["of", 870], ["the", 873], ["experimental", 877], ["study", 890], ["concerns", 896], ["a", 905], ["set", 907], ["of", 911], ["conserved", 914], ["sequences", 924], ["in", 934], ["helix", 937], ["II", 943], ["that", 946], ["interact", 951], ["to", 960], ["form", 963], ["a", 968], ["novel", 970], ["RNA", 976], ["structural", 980], ["motif", 991], ["consisting", 997], ["of", 1008], ["a", 1011], ["quartet", 1013], ["composed", 1021], ["of", 1030], ["non", 1033], ["-", 1036], ["Watson", 1037], ["-", 1043], ["Crick", 1044], ["base", 1050], ["pairs", 1055], ["5'UGAY3", 1061], ["'", 1068], [":", 1069], ["5'UGAU3", 1071], ["'", 1078], [".", 1079], ["The", 1081], ["potential", 1085], ["for", 1095], ["forming", 1099], ["the", 1107], ["quartet", 1111], ["is", 1119], ["preserved", 1122], ["in", 1132], ["15", 1135], ["SECIS", 1138], ["elements", 1144], [",", 1152], ["but", 1154], ["three", 1158], ["consecutive", 1164], ["non", 1176], ["-", 1179], ["Watson", 1180], ["-", 1186], ["Crick", 1187], ["base", 1193], ["pairs", 1198], ["can", 1204], ["nevertheless", 1208], ["form", 1221], ["in", 1226], ["the", 1229], ["other", 1233], ["five", 1239], ["SECIS", 1244], [",", 1249], ["the", 1251], ["central", 1255], ["G.A", 1263], ["tandem", 1267], ["being", 1274], ["invariant", 1280], ["in", 1290], ["all", 1293], ["cases", 1297], [".", 1302], ["A", 1304], ["3D", 1306], ["model", 1309], [",", 1314], ["derived", 1316], ["by", 1324], ["computer", 1327], ["modeling", 1336], ["with", 1345], ["the", 1350], ["use", 1354], ["of", 1358], ["the", 1361], ["solution", 1365], ["data", 1374], [",", 1378], ["suggests", 1380], ["that", 1389], ["the", 1394], ["base", 1398], ["pairing", 1403], ["interactions", 1411], ["in", 1424], ["the", 1427], ["G.A", 1431], ["tandem", 1435], ["are", 1442], ["of", 1446], ["the", 1449], ["type", 1453], ["found", 1458], ["in", 1464], ["GNRA", 1467], ["loops", 1472], [".", 1477], ["The", 1479], ["3D", 1483], ["model", 1486], ["displays", 1492], ["the", 1501], ["quartet", 1505], ["lying", 1513], ["in", 1519], ["an", 1522], ["accessible", 1525], ["position", 1536], ["at", 1545], ["the", 1548], ["foot", 1552], ["of", 1557], ["helix", 1560], ["II", 1566], [",", 1568], ["which", 1570], ["is", 1576], ["bent", 1579], ["at", 1584], ["the", 1587], ["internal", 1591], ["loop", 1600], [",", 1604], ["suggesting", 1606], ["that", 1617], ["the", 1622], ["non", 1626], ["-", 1629], ["Watson", 1630], ["-", 1636], ["Crick", 1637], ["base", 1643], ["pair", 1648], ["arrangement", 1653], ["provides", 1665], ["an", 1674], ["unusual", 1677], ["pattern", 1685], ["of", 1693], ["chemical", 1696], ["groups", 1705], ["for", 1712], ["putative", 1716], ["ligand", 1725], ["interaction", 1732], [".", 1743]]}
{"context": "Pulmonary hypertension (PH) is a progressive disease that is accompanied by a poor prognosis. Pulmonary vasoconstriction is facilitated through multiple pathways and results in increased pulmonary vascular pressure leading to cell proliferation, vascular remodeling, right ventricular hypertrophy/failure, and ultimately death. Until recently, just six medications were approved -all for one subclass of PH. On October 8, 2013, riociguat (Adempas\u00ae) became the first medication approved for multiple etiologies of PH. Preclinical studies have demonstrated safety and efficacy with significant clinical trials supporting its advancement into phase IV trials. Although long-term safety and efficacy and place in therapy remain to be established, riociguat presents as an exciting new option for the treatment of PH and potentially has additional indications in the near future.", "qas": [{"question": "What is generic name of drug Adempas?", "answers": ["riociguat"], "qid": "1a49f6b645ff49e59f4946d1e6242dc5", "question_tokens": [["What", 0], ["is", 5], ["generic", 8], ["name", 16], ["of", 21], ["drug", 24], ["Adempas", 29], ["?", 36]], "detected_answers": [{"text": "riociguat", "token_spans": [[121, 121], [70, 70]], "char_spans": [[743, 751], [428, 436]]}]}], "context_tokens": [["Pulmonary", 0], ["hypertension", 10], ["(", 23], ["PH", 24], [")", 26], ["is", 28], ["a", 31], ["progressive", 33], ["disease", 45], ["that", 53], ["is", 58], ["accompanied", 61], ["by", 73], ["a", 76], ["poor", 78], ["prognosis", 83], [".", 92], ["Pulmonary", 94], ["vasoconstriction", 104], ["is", 121], ["facilitated", 124], ["through", 136], ["multiple", 144], ["pathways", 153], ["and", 162], ["results", 166], ["in", 174], ["increased", 177], ["pulmonary", 187], ["vascular", 197], ["pressure", 206], ["leading", 215], ["to", 223], ["cell", 226], ["proliferation", 231], [",", 244], ["vascular", 246], ["remodeling", 255], [",", 265], ["right", 267], ["ventricular", 273], ["hypertrophy", 285], ["/", 296], ["failure", 297], [",", 304], ["and", 306], ["ultimately", 310], ["death", 321], [".", 326], ["Until", 328], ["recently", 334], [",", 342], ["just", 344], ["six", 349], ["medications", 353], ["were", 365], ["approved", 370], ["-all", 379], ["for", 384], ["one", 388], ["subclass", 392], ["of", 401], ["PH", 404], [".", 406], ["On", 408], ["October", 411], ["8", 419], [",", 420], ["2013", 422], [",", 426], ["riociguat", 428], ["(", 438], ["Adempas", 439], ["\u00ae", 446], [")", 447], ["became", 449], ["the", 456], ["first", 460], ["medication", 466], ["approved", 477], ["for", 486], ["multiple", 490], ["etiologies", 499], ["of", 510], ["PH", 513], [".", 515], ["Preclinical", 517], ["studies", 529], ["have", 537], ["demonstrated", 542], ["safety", 555], ["and", 562], ["efficacy", 566], ["with", 575], ["significant", 580], ["clinical", 592], ["trials", 601], ["supporting", 608], ["its", 619], ["advancement", 623], ["into", 635], ["phase", 640], ["IV", 646], ["trials", 649], [".", 655], ["Although", 657], ["long", 666], ["-", 670], ["term", 671], ["safety", 676], ["and", 683], ["efficacy", 687], ["and", 696], ["place", 700], ["in", 706], ["therapy", 709], ["remain", 717], ["to", 724], ["be", 727], ["established", 730], [",", 741], ["riociguat", 743], ["presents", 753], ["as", 762], ["an", 765], ["exciting", 768], ["new", 777], ["option", 781], ["for", 788], ["the", 792], ["treatment", 796], ["of", 806], ["PH", 809], ["and", 812], ["potentially", 816], ["has", 828], ["additional", 832], ["indications", 843], ["in", 855], ["the", 858], ["near", 862], ["future", 867], [".", 873]]}
{"context": "To define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography. Body indices (height, weight, and body mass index) were analyzed in 60 healthy adults, and electromyography and sonography were also performed. The cross-sectional areas of the proximal and distal median nerve and carpal tunnel were obtained by sonography. The proximal and distal nerve/tunnel indices were obtained by calculating the ratio between the proximal and distal cross-sectional areas of the median nerve to those of the carpal tunnel and multiplying the value by 100. Although the proximal cross-sectional areas of the median nerve and body indices showed statistically significant relationships with weak positive correlations, the proximal and distal areas of the carpal tunnel showed relatively stronger correlations with body indices. Between sexes, there were significant differences in the proximal median nerve cross-sectional area (mean \u00b1 SD: male, 10.48 \u00b1 3.21 mm(2); female, 8.81 \u00b1 3.21 mm(2); P < .05) and proximal carpal tunnel area (male, 182.50 \u00b1 21.15 mm(2); female, 151.23 \u00b1 21.14 mm(2); P < .05). There was no difference in the proximal nerve/tunnel index (male, 5.80% \u00b1 1.72%; female, 5.91% \u00b1 1.63%). There was a statistically significant difference in the distal carpal tunnel cross-sectional area (male, 138.90 \u00b1 20.95 mm(2); female, 121.50 \u00b1 18.99 mm(2); P < .05) between sexes, but the distal median area (male, 9.99 \u00b1 3.42 mm(2); female, 8.46 \u00b1 1.84 mm(2)) and distal nerve/tunnel index (male, 7.15% \u00b1 2.00%; female, 7.01% \u00b1 1.38%) showed no significant differences. The proximal index was significantly higher than the distal index (proximal, 5.85% \u00b1 1.66%; distal, 7.08% \u00b1 1.71%). The nerve/tunnel index is unaffected by body indices or sex and thus may be a useful and objective standard for diagnosing carpal tunnel syndrome.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "75f0878c248e4bbab73420d14772e958", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[181, 181], [310, 310], [116, 116], [140, 140], [20, 20], [81, 81]], "char_spans": [[1072, 1077], [1582, 1587], [658, 663], [786, 791], [117, 122], [453, 458]]}]}], "context_tokens": [["To", 0], ["define", 3], ["the", 10], ["relationship", 14], ["between", 27], ["body", 35], ["indices", 40], ["of", 48], ["healthy", 51], ["adults", 59], ["and", 66], ["cross", 70], ["-", 75], ["sectional", 76], ["areas", 86], ["of", 92], ["the", 95], ["carpal", 99], ["tunnel", 106], ["and", 113], ["median", 117], ["nerve", 124], ["and", 130], ["to", 134], ["obtain", 137], ["the", 144], ["nerve", 148], ["/", 153], ["tunnel", 154], ["index", 161], [",", 166], ["which", 168], ["represents", 174], ["a", 185], ["new", 187], ["standard", 191], ["for", 200], ["diagnosing", 204], ["carpal", 215], ["tunnel", 222], ["syndrome", 229], ["using", 238], ["sonography", 244], [".", 254], ["Body", 256], ["indices", 261], ["(", 269], ["height", 270], [",", 276], ["weight", 278], [",", 284], ["and", 286], ["body", 290], ["mass", 295], ["index", 300], [")", 305], ["were", 307], ["analyzed", 312], ["in", 321], ["60", 324], ["healthy", 327], ["adults", 335], [",", 341], ["and", 343], ["electromyography", 347], ["and", 364], ["sonography", 368], ["were", 379], ["also", 384], ["performed", 389], [".", 398], ["The", 400], ["cross", 404], ["-", 409], ["sectional", 410], ["areas", 420], ["of", 426], ["the", 429], ["proximal", 433], ["and", 442], ["distal", 446], ["median", 453], ["nerve", 460], ["and", 466], ["carpal", 470], ["tunnel", 477], ["were", 484], ["obtained", 489], ["by", 498], ["sonography", 501], [".", 511], ["The", 513], ["proximal", 517], ["and", 526], ["distal", 530], ["nerve", 537], ["/", 542], ["tunnel", 543], ["indices", 550], ["were", 558], ["obtained", 563], ["by", 572], ["calculating", 575], ["the", 587], ["ratio", 591], ["between", 597], ["the", 605], ["proximal", 609], ["and", 618], ["distal", 622], ["cross", 629], ["-", 634], ["sectional", 635], ["areas", 645], ["of", 651], ["the", 654], ["median", 658], ["nerve", 665], ["to", 671], ["those", 674], ["of", 680], ["the", 683], ["carpal", 687], ["tunnel", 694], ["and", 701], ["multiplying", 705], ["the", 717], ["value", 721], ["by", 727], ["100", 730], [".", 733], ["Although", 735], ["the", 744], ["proximal", 748], ["cross", 757], ["-", 762], ["sectional", 763], ["areas", 773], ["of", 779], ["the", 782], ["median", 786], ["nerve", 793], ["and", 799], ["body", 803], ["indices", 808], ["showed", 816], ["statistically", 823], ["significant", 837], ["relationships", 849], ["with", 863], ["weak", 868], ["positive", 873], ["correlations", 882], [",", 894], ["the", 896], ["proximal", 900], ["and", 909], ["distal", 913], ["areas", 920], ["of", 926], ["the", 929], ["carpal", 933], ["tunnel", 940], ["showed", 947], ["relatively", 954], ["stronger", 965], ["correlations", 974], ["with", 987], ["body", 992], ["indices", 997], [".", 1004], ["Between", 1006], ["sexes", 1014], [",", 1019], ["there", 1021], ["were", 1027], ["significant", 1032], ["differences", 1044], ["in", 1056], ["the", 1059], ["proximal", 1063], ["median", 1072], ["nerve", 1079], ["cross", 1085], ["-", 1090], ["sectional", 1091], ["area", 1101], ["(", 1106], ["mean", 1107], ["\u00b1", 1112], ["SD", 1114], [":", 1116], ["male", 1118], [",", 1122], ["10.48", 1124], ["\u00b1", 1130], ["3.21", 1132], ["mm(2", 1137], [")", 1141], [";", 1142], ["female", 1144], [",", 1150], ["8.81", 1152], ["\u00b1", 1157], ["3.21", 1159], ["mm(2", 1164], [")", 1168], [";", 1169], ["P", 1171], ["<", 1173], [".05", 1175], [")", 1178], ["and", 1180], ["proximal", 1184], ["carpal", 1193], ["tunnel", 1200], ["area", 1207], ["(", 1212], ["male", 1213], [",", 1217], ["182.50", 1219], ["\u00b1", 1226], ["21.15", 1228], ["mm(2", 1234], [")", 1238], [";", 1239], ["female", 1241], [",", 1247], ["151.23", 1249], ["\u00b1", 1256], ["21.14", 1258], ["mm(2", 1264], [")", 1268], [";", 1269], ["P", 1271], ["<", 1273], [".05", 1275], [")", 1278], [".", 1279], ["There", 1281], ["was", 1287], ["no", 1291], ["difference", 1294], ["in", 1305], ["the", 1308], ["proximal", 1312], ["nerve", 1321], ["/", 1326], ["tunnel", 1327], ["index", 1334], ["(", 1340], ["male", 1341], [",", 1345], ["5.80", 1347], ["%", 1351], ["\u00b1", 1353], ["1.72", 1355], ["%", 1359], [";", 1360], ["female", 1362], [",", 1368], ["5.91", 1370], ["%", 1374], ["\u00b1", 1376], ["1.63", 1378], ["%", 1382], [")", 1383], [".", 1384], ["There", 1386], ["was", 1392], ["a", 1396], ["statistically", 1398], ["significant", 1412], ["difference", 1424], ["in", 1435], ["the", 1438], ["distal", 1442], ["carpal", 1449], ["tunnel", 1456], ["cross", 1463], ["-", 1468], ["sectional", 1469], ["area", 1479], ["(", 1484], ["male", 1485], [",", 1489], ["138.90", 1491], ["\u00b1", 1498], ["20.95", 1500], ["mm(2", 1506], [")", 1510], [";", 1511], ["female", 1513], [",", 1519], ["121.50", 1521], ["\u00b1", 1528], ["18.99", 1530], ["mm(2", 1536], [")", 1540], [";", 1541], ["P", 1543], ["<", 1545], [".05", 1547], [")", 1550], ["between", 1552], ["sexes", 1560], [",", 1565], ["but", 1567], ["the", 1571], ["distal", 1575], ["median", 1582], ["area", 1589], ["(", 1594], ["male", 1595], [",", 1599], ["9.99", 1601], ["\u00b1", 1606], ["3.42", 1608], ["mm(2", 1613], [")", 1617], [";", 1618], ["female", 1620], [",", 1626], ["8.46", 1628], ["\u00b1", 1633], ["1.84", 1635], ["mm(2", 1640], [")", 1644], [")", 1645], ["and", 1647], ["distal", 1651], ["nerve", 1658], ["/", 1663], ["tunnel", 1664], ["index", 1671], ["(", 1677], ["male", 1678], [",", 1682], ["7.15", 1684], ["%", 1688], ["\u00b1", 1690], ["2.00", 1692], ["%", 1696], [";", 1697], ["female", 1699], [",", 1705], ["7.01", 1707], ["%", 1711], ["\u00b1", 1713], ["1.38", 1715], ["%", 1719], [")", 1720], ["showed", 1722], ["no", 1729], ["significant", 1732], ["differences", 1744], [".", 1755], ["The", 1757], ["proximal", 1761], ["index", 1770], ["was", 1776], ["significantly", 1780], ["higher", 1794], ["than", 1801], ["the", 1806], ["distal", 1810], ["index", 1817], ["(", 1823], ["proximal", 1824], [",", 1832], ["5.85", 1834], ["%", 1838], ["\u00b1", 1840], ["1.66", 1842], ["%", 1846], [";", 1847], ["distal", 1849], [",", 1855], ["7.08", 1857], ["%", 1861], ["\u00b1", 1863], ["1.71", 1865], ["%", 1869], [")", 1870], [".", 1871], ["The", 1873], ["nerve", 1877], ["/", 1882], ["tunnel", 1883], ["index", 1890], ["is", 1896], ["unaffected", 1899], ["by", 1910], ["body", 1913], ["indices", 1918], ["or", 1926], ["sex", 1929], ["and", 1933], ["thus", 1937], ["may", 1942], ["be", 1946], ["a", 1949], ["useful", 1951], ["and", 1958], ["objective", 1962], ["standard", 1972], ["for", 1981], ["diagnosing", 1985], ["carpal", 1996], ["tunnel", 2003], ["syndrome", 2010], [".", 2018]]}
{"context": "Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to compare the levodopa pharmacokinetic profile throughout a day driven by the COMT inhibition either following repeated doses of opicapone or concomitant administration with entacapone. A randomized, double-blind, gender-balanced, parallel-group study was performed in 4 groups of 20 healthy subjects each. Four subjects in each group received placebo during the entire study. Sixteen subjects in one group received placebo once daily for 11 days and on day 12, 200 mg entacapone concomitantly with each levodopa/carbidopa dose (three times separated by a 5-h interval). Sixteen subjects in each of the remaining three groups received respectively 25, 50, and 75 mg opicapone once daily for 11 days and on day 12, placebo concomitantly with each levodopa/carbidopa dose. Levodopa minimum plasma concentration (Cmin) for each levodopa/carbidopa dose and for the mean of all levodopa/carbidopa doses increased substantially with all active treatments (entacapone and opicapone) when compared to the control group (placebo), with values ranging from 1.7-fold (200 mg entacapone) to 3.3-fold (75 mg opicapone). No statistical difference was found for levodopa peak of systemic exposure (as assessed by maximum observed plasma concentration (Cmax)) between all active treatments and placebo. A significant increase in the levodopa extent of systemic exposure (as assessed by concentration-time curve (AUC)) occurred with all opicapone treatments in relation to placebo. No statistical difference was found for levodopa AUC when entacapone was compared to placebo. When compared to entacapone, both 50 and 75 mg opicapone presented a significant increase for the levodopa AUC. All active treatments significantly inhibited both peak (as assessed by Emax) and extent (as assessed by effect-time curve (AUEC)) of the COMT activity in relation to placebo. When compared to entacapone, all opicapone treatments significantly decreased the extent (AUEC) of the COMT activity due to a long-lasting and sustained effect. The tolerability profile was favorable for all active treatments. Opicapone, a novel third generation COMT inhibitor, when compared to entacapone, provides a superior response upon the bioavailability of levodopa associated to more pronounced, long-lasting, and sustained COMT inhibition. The tolerability profile was favorable. On the basis of the results presented in this study and along with the earlier pharmacology studies, it is anticipated that opicapone adjunct therapy at the dosages of 25 and 50 mg will provide an enhancement in levodopa availability that will translate into clinical benefit for Parkinson's disease patients.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "0e5ff4402f1e44c1a1d80868713f9b9f", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[6, 10]], "char_spans": [[38, 65]]}]}], "context_tokens": [["Opicapone", 0], ["is", 10], ["a", 13], ["novel", 15], ["third", 21], ["generation", 27], ["catechol", 38], ["-", 46], ["O", 47], ["-", 48], ["methyltransferase", 49], ["(", 67], ["COMT", 68], [")", 72], ["inhibitor", 74], [".", 83], ["The", 85], ["purpose", 89], ["of", 97], ["this", 100], ["study", 105], ["was", 111], ["to", 115], ["compare", 118], ["the", 126], ["levodopa", 130], ["pharmacokinetic", 139], ["profile", 155], ["throughout", 163], ["a", 174], ["day", 176], ["driven", 180], ["by", 187], ["the", 190], ["COMT", 194], ["inhibition", 199], ["either", 210], ["following", 217], ["repeated", 227], ["doses", 236], ["of", 242], ["opicapone", 245], ["or", 255], ["concomitant", 258], ["administration", 270], ["with", 285], ["entacapone", 290], [".", 300], ["A", 302], ["randomized", 304], [",", 314], ["double", 316], ["-", 322], ["blind", 323], [",", 328], ["gender", 330], ["-", 336], ["balanced", 337], [",", 345], ["parallel", 347], ["-", 355], ["group", 356], ["study", 362], ["was", 368], ["performed", 372], ["in", 382], ["4", 385], ["groups", 387], ["of", 394], ["20", 397], ["healthy", 400], ["subjects", 408], ["each", 417], [".", 421], ["Four", 423], ["subjects", 428], ["in", 437], ["each", 440], ["group", 445], ["received", 451], ["placebo", 460], ["during", 468], ["the", 475], ["entire", 479], ["study", 486], [".", 491], ["Sixteen", 493], ["subjects", 501], ["in", 510], ["one", 513], ["group", 517], ["received", 523], ["placebo", 532], ["once", 540], ["daily", 545], ["for", 551], ["11", 555], ["days", 558], ["and", 563], ["on", 567], ["day", 570], ["12", 574], [",", 576], ["200", 578], ["mg", 582], ["entacapone", 585], ["concomitantly", 596], ["with", 610], ["each", 615], ["levodopa", 620], ["/", 628], ["carbidopa", 629], ["dose", 639], ["(", 644], ["three", 645], ["times", 651], ["separated", 657], ["by", 667], ["a", 670], ["5-h", 672], ["interval", 676], [")", 684], [".", 685], ["Sixteen", 687], ["subjects", 695], ["in", 704], ["each", 707], ["of", 712], ["the", 715], ["remaining", 719], ["three", 729], ["groups", 735], ["received", 742], ["respectively", 751], ["25", 764], [",", 766], ["50", 768], [",", 770], ["and", 772], ["75", 776], ["mg", 779], ["opicapone", 782], ["once", 792], ["daily", 797], ["for", 803], ["11", 807], ["days", 810], ["and", 815], ["on", 819], ["day", 822], ["12", 826], [",", 828], ["placebo", 830], ["concomitantly", 838], ["with", 852], ["each", 857], ["levodopa", 862], ["/", 870], ["carbidopa", 871], ["dose", 881], [".", 885], ["Levodopa", 887], ["minimum", 896], ["plasma", 904], ["concentration", 911], ["(", 925], ["Cmin", 926], [")", 930], ["for", 932], ["each", 936], ["levodopa", 941], ["/", 949], ["carbidopa", 950], ["dose", 960], ["and", 965], ["for", 969], ["the", 973], ["mean", 977], ["of", 982], ["all", 985], ["levodopa", 989], ["/", 997], ["carbidopa", 998], ["doses", 1008], ["increased", 1014], ["substantially", 1024], ["with", 1038], ["all", 1043], ["active", 1047], ["treatments", 1054], ["(", 1065], ["entacapone", 1066], ["and", 1077], ["opicapone", 1081], [")", 1090], ["when", 1092], ["compared", 1097], ["to", 1106], ["the", 1109], ["control", 1113], ["group", 1121], ["(", 1127], ["placebo", 1128], [")", 1135], [",", 1136], ["with", 1138], ["values", 1143], ["ranging", 1150], ["from", 1158], ["1.7-fold", 1163], ["(", 1172], ["200", 1173], ["mg", 1177], ["entacapone", 1180], [")", 1190], ["to", 1192], ["3.3-fold", 1195], ["(", 1204], ["75", 1205], ["mg", 1208], ["opicapone", 1211], [")", 1220], [".", 1221], ["No", 1223], ["statistical", 1226], ["difference", 1238], ["was", 1249], ["found", 1253], ["for", 1259], ["levodopa", 1263], ["peak", 1272], ["of", 1277], ["systemic", 1280], ["exposure", 1289], ["(", 1298], ["as", 1299], ["assessed", 1302], ["by", 1311], ["maximum", 1314], ["observed", 1322], ["plasma", 1331], ["concentration", 1338], ["(", 1352], ["Cmax", 1353], [")", 1357], [")", 1358], ["between", 1360], ["all", 1368], ["active", 1372], ["treatments", 1379], ["and", 1390], ["placebo", 1394], [".", 1401], ["A", 1403], ["significant", 1405], ["increase", 1417], ["in", 1426], ["the", 1429], ["levodopa", 1433], ["extent", 1442], ["of", 1449], ["systemic", 1452], ["exposure", 1461], ["(", 1470], ["as", 1471], ["assessed", 1474], ["by", 1483], ["concentration", 1486], ["-", 1499], ["time", 1500], ["curve", 1505], ["(", 1511], ["AUC", 1512], [")", 1515], [")", 1516], ["occurred", 1518], ["with", 1527], ["all", 1532], ["opicapone", 1536], ["treatments", 1546], ["in", 1557], ["relation", 1560], ["to", 1569], ["placebo", 1572], [".", 1579], ["No", 1581], ["statistical", 1584], ["difference", 1596], ["was", 1607], ["found", 1611], ["for", 1617], ["levodopa", 1621], ["AUC", 1630], ["when", 1634], ["entacapone", 1639], ["was", 1650], ["compared", 1654], ["to", 1663], ["placebo", 1666], [".", 1673], ["When", 1675], ["compared", 1680], ["to", 1689], ["entacapone", 1692], [",", 1702], ["both", 1704], ["50", 1709], ["and", 1712], ["75", 1716], ["mg", 1719], ["opicapone", 1722], ["presented", 1732], ["a", 1742], ["significant", 1744], ["increase", 1756], ["for", 1765], ["the", 1769], ["levodopa", 1773], ["AUC", 1782], [".", 1785], ["All", 1787], ["active", 1791], ["treatments", 1798], ["significantly", 1809], ["inhibited", 1823], ["both", 1833], ["peak", 1838], ["(", 1843], ["as", 1844], ["assessed", 1847], ["by", 1856], ["Emax", 1859], [")", 1863], ["and", 1865], ["extent", 1869], ["(", 1876], ["as", 1877], ["assessed", 1880], ["by", 1889], ["effect", 1892], ["-", 1898], ["time", 1899], ["curve", 1904], ["(", 1910], ["AUEC", 1911], [")", 1915], [")", 1916], ["of", 1918], ["the", 1921], ["COMT", 1925], ["activity", 1930], ["in", 1939], ["relation", 1942], ["to", 1951], ["placebo", 1954], [".", 1961], ["When", 1963], ["compared", 1968], ["to", 1977], ["entacapone", 1980], [",", 1990], ["all", 1992], ["opicapone", 1996], ["treatments", 2006], ["significantly", 2017], ["decreased", 2031], ["the", 2041], ["extent", 2045], ["(", 2052], ["AUEC", 2053], [")", 2057], ["of", 2059], ["the", 2062], ["COMT", 2066], ["activity", 2071], ["due", 2080], ["to", 2084], ["a", 2087], ["long", 2089], ["-", 2093], ["lasting", 2094], ["and", 2102], ["sustained", 2106], ["effect", 2116], [".", 2122], ["The", 2124], ["tolerability", 2128], ["profile", 2141], ["was", 2149], ["favorable", 2153], ["for", 2163], ["all", 2167], ["active", 2171], ["treatments", 2178], [".", 2188], ["Opicapone", 2190], [",", 2199], ["a", 2201], ["novel", 2203], ["third", 2209], ["generation", 2215], ["COMT", 2226], ["inhibitor", 2231], [",", 2240], ["when", 2242], ["compared", 2247], ["to", 2256], ["entacapone", 2259], [",", 2269], ["provides", 2271], ["a", 2280], ["superior", 2282], ["response", 2291], ["upon", 2300], ["the", 2305], ["bioavailability", 2309], ["of", 2325], ["levodopa", 2328], ["associated", 2337], ["to", 2348], ["more", 2351], ["pronounced", 2356], [",", 2366], ["long", 2368], ["-", 2372], ["lasting", 2373], [",", 2380], ["and", 2382], ["sustained", 2386], ["COMT", 2396], ["inhibition", 2401], [".", 2411], ["The", 2413], ["tolerability", 2417], ["profile", 2430], ["was", 2438], ["favorable", 2442], [".", 2451], ["On", 2453], ["the", 2456], ["basis", 2460], ["of", 2466], ["the", 2469], ["results", 2473], ["presented", 2481], ["in", 2491], ["this", 2494], ["study", 2499], ["and", 2505], ["along", 2509], ["with", 2515], ["the", 2520], ["earlier", 2524], ["pharmacology", 2532], ["studies", 2545], [",", 2552], ["it", 2554], ["is", 2557], ["anticipated", 2560], ["that", 2572], ["opicapone", 2577], ["adjunct", 2587], ["therapy", 2595], ["at", 2603], ["the", 2606], ["dosages", 2610], ["of", 2618], ["25", 2621], ["and", 2624], ["50", 2628], ["mg", 2631], ["will", 2634], ["provide", 2639], ["an", 2647], ["enhancement", 2650], ["in", 2662], ["levodopa", 2665], ["availability", 2674], ["that", 2687], ["will", 2692], ["translate", 2697], ["into", 2707], ["clinical", 2712], ["benefit", 2721], ["for", 2729], ["Parkinson", 2733], ["'s", 2742], ["disease", 2745], ["patients", 2753], [".", 2761]]}
{"context": "The efficacy and safety of flumazenil were assessed in comparison to placebo in a double-blind randomised study of 31 adults intoxicated with benzodiazepines. The criteria of efficacy were the degree of sedation, and orientation in time and space. Patients who received flumazenil awoke within minutes but central depression returned partly one hour later, which reflects the short elimination half-life of the drug. Side effects were few and the results indicate that flumazenil is effective in the primary management of benzodiazepine overdose and in states where benzodiazepines have been taken with other drugs.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "6e6cc6752f9047989d4703ae6d6c8051", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[80, 80], [5, 5], [46, 46]], "char_spans": [[469, 478], [27, 36], [270, 279]]}]}], "context_tokens": [["The", 0], ["efficacy", 4], ["and", 13], ["safety", 17], ["of", 24], ["flumazenil", 27], ["were", 38], ["assessed", 43], ["in", 52], ["comparison", 55], ["to", 66], ["placebo", 69], ["in", 77], ["a", 80], ["double", 82], ["-", 88], ["blind", 89], ["randomised", 95], ["study", 106], ["of", 112], ["31", 115], ["adults", 118], ["intoxicated", 125], ["with", 137], ["benzodiazepines", 142], [".", 157], ["The", 159], ["criteria", 163], ["of", 172], ["efficacy", 175], ["were", 184], ["the", 189], ["degree", 193], ["of", 200], ["sedation", 203], [",", 211], ["and", 213], ["orientation", 217], ["in", 229], ["time", 232], ["and", 237], ["space", 241], [".", 246], ["Patients", 248], ["who", 257], ["received", 261], ["flumazenil", 270], ["awoke", 281], ["within", 287], ["minutes", 294], ["but", 302], ["central", 306], ["depression", 314], ["returned", 325], ["partly", 334], ["one", 341], ["hour", 345], ["later", 350], [",", 355], ["which", 357], ["reflects", 363], ["the", 372], ["short", 376], ["elimination", 382], ["half", 394], ["-", 398], ["life", 399], ["of", 404], ["the", 407], ["drug", 411], [".", 415], ["Side", 417], ["effects", 422], ["were", 430], ["few", 435], ["and", 439], ["the", 443], ["results", 447], ["indicate", 455], ["that", 464], ["flumazenil", 469], ["is", 480], ["effective", 483], ["in", 493], ["the", 496], ["primary", 500], ["management", 508], ["of", 519], ["benzodiazepine", 522], ["overdose", 537], ["and", 546], ["in", 550], ["states", 553], ["where", 560], ["benzodiazepines", 566], ["have", 582], ["been", 587], ["taken", 592], ["with", 598], ["other", 603], ["drugs", 609], [".", 614]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a small vessel disease of the brain caused by mutations in the NOTCH3 gene. CADASIL progresses, in some cases, to subcortical dementia with a particular cognitive impairment. Different diseases in the dementia spectrum share a central cholinergic and sensorimotor plasticity alteration. We aimed to study different intracortical circuits and sensorimotor plasticity in CADASIL patients using transcranial magnetic stimulation protocols, and to determine whether these characteristics correlated with the results of clinical neuropsychological evaluation. Ten CADASIL patients and 10 healthy subjects were included in the study. All subjects underwent a transcranial magnetic stimulation study examining different intracortical circuits. Sensorimotor plasticity was also assessed using a paired associative stimulation and extensive neuropsychological tests. CADASIL patients showed a lack of intracortical facilitation, short latency afferent inhibition and sensorimotor plasticity when compared with control subjects. CADASIL patients also showed an altered neuropsychological profile. Correlation between sensorimotor plasticity and neuropsychological alterations was observed in CADASIL patients. These results suggest that acetylcholine and glutamate could be involved in the dementia process in CADASIL and that abnormal sensorimotor plasticity correlates with the neuropsychological profile in CADASIL patients.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "27c99f3d44a94401b785406bd2f20967", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[25, 26]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["a", 104], ["small", 106], ["vessel", 112], ["disease", 119], ["of", 127], ["the", 130], ["brain", 134], ["caused", 140], ["by", 147], ["mutations", 150], ["in", 160], ["the", 163], ["NOTCH3", 167], ["gene", 174], [".", 178], ["CADASIL", 180], ["progresses", 188], [",", 198], ["in", 200], ["some", 203], ["cases", 208], [",", 213], ["to", 215], ["subcortical", 218], ["dementia", 230], ["with", 239], ["a", 244], ["particular", 246], ["cognitive", 257], ["impairment", 267], [".", 277], ["Different", 279], ["diseases", 289], ["in", 298], ["the", 301], ["dementia", 305], ["spectrum", 314], ["share", 323], ["a", 329], ["central", 331], ["cholinergic", 339], ["and", 351], ["sensorimotor", 355], ["plasticity", 368], ["alteration", 379], [".", 389], ["We", 391], ["aimed", 394], ["to", 400], ["study", 403], ["different", 409], ["intracortical", 419], ["circuits", 433], ["and", 442], ["sensorimotor", 446], ["plasticity", 459], ["in", 470], ["CADASIL", 473], ["patients", 481], ["using", 490], ["transcranial", 496], ["magnetic", 509], ["stimulation", 518], ["protocols", 530], [",", 539], ["and", 541], ["to", 545], ["determine", 548], ["whether", 558], ["these", 566], ["characteristics", 572], ["correlated", 588], ["with", 599], ["the", 604], ["results", 608], ["of", 616], ["clinical", 619], ["neuropsychological", 628], ["evaluation", 647], [".", 657], ["Ten", 659], ["CADASIL", 663], ["patients", 671], ["and", 680], ["10", 684], ["healthy", 687], ["subjects", 695], ["were", 704], ["included", 709], ["in", 718], ["the", 721], ["study", 725], [".", 730], ["All", 732], ["subjects", 736], ["underwent", 745], ["a", 755], ["transcranial", 757], ["magnetic", 770], ["stimulation", 779], ["study", 791], ["examining", 797], ["different", 807], ["intracortical", 817], ["circuits", 831], [".", 839], ["Sensorimotor", 841], ["plasticity", 854], ["was", 865], ["also", 869], ["assessed", 874], ["using", 883], ["a", 889], ["paired", 891], ["associative", 898], ["stimulation", 910], ["and", 922], ["extensive", 926], ["neuropsychological", 936], ["tests", 955], [".", 960], ["CADASIL", 962], ["patients", 970], ["showed", 979], ["a", 986], ["lack", 988], ["of", 993], ["intracortical", 996], ["facilitation", 1010], [",", 1022], ["short", 1024], ["latency", 1030], ["afferent", 1038], ["inhibition", 1047], ["and", 1058], ["sensorimotor", 1062], ["plasticity", 1075], ["when", 1086], ["compared", 1091], ["with", 1100], ["control", 1105], ["subjects", 1113], [".", 1121], ["CADASIL", 1123], ["patients", 1131], ["also", 1140], ["showed", 1145], ["an", 1152], ["altered", 1155], ["neuropsychological", 1163], ["profile", 1182], [".", 1189], ["Correlation", 1191], ["between", 1203], ["sensorimotor", 1211], ["plasticity", 1224], ["and", 1235], ["neuropsychological", 1239], ["alterations", 1258], ["was", 1270], ["observed", 1274], ["in", 1283], ["CADASIL", 1286], ["patients", 1294], [".", 1302], ["These", 1304], ["results", 1310], ["suggest", 1318], ["that", 1326], ["acetylcholine", 1331], ["and", 1345], ["glutamate", 1349], ["could", 1359], ["be", 1365], ["involved", 1368], ["in", 1377], ["the", 1380], ["dementia", 1384], ["process", 1393], ["in", 1401], ["CADASIL", 1404], ["and", 1412], ["that", 1416], ["abnormal", 1421], ["sensorimotor", 1430], ["plasticity", 1443], ["correlates", 1454], ["with", 1465], ["the", 1470], ["neuropsychological", 1474], ["profile", 1493], ["in", 1501], ["CADASIL", 1504], ["patients", 1512], [".", 1520]]}
{"context": "SECIS elements are stem-loop structures located in the 3' untranslated regions (UTRs) of eukaryotic selenoprotein mRNAs that are required for directing cotranslational selenocysteine incorporation at UGA codons. In prokaryotes, stem-loops mediating selenocysteine incorporation are located immediately downstream of the UGA selenocysteine codon, in the coding region. Previous characterization studies of the mammalian SECIS elements of type 1 deiodinase, glutathione peroxidase, and selenoprotein P showed that conserved nucleotides in the loops and unpaired bulges, and base pairing in the stems are required for SECIS function. These initial studies utilized approximately 175-230-nt segments of the 3'UTRs of the selenoprotein mRNAs. Here we define the minimal functional rat type 1 deiodinase SECIS element, a 45-nt segment, the 5' boundary of which corresponds precisely to the 5'-most critical conserved nucleotide identified previously. We also define base pairing requirements in the stem of this element. In view of the presence of SECIS elements in the open reading frames (ORFs) of bacterial selenoproteins, we examine the effects in the type 1 deiodinase of extending the ORF into the SECIS element, and find that this dramatically inhibits SECIS function. Finally, we define a minimal spacing requirement of 51-111 nt between a eukaryotic UGA selenocysteine codon and SECIS element.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "5798e357ab44416ea1ecd5323e3e7ae4", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[0, 0], [96, 96], [198, 198], [230, 230], [169, 169], [126, 126], [63, 63], [207, 207]], "char_spans": [[0, 4], [615, 619], [1198, 1202], [1382, 1386], [1042, 1046], [798, 802], [419, 423], [1254, 1258]]}]}], "context_tokens": [["SECIS", 0], ["elements", 6], ["are", 15], ["stem", 19], ["-", 23], ["loop", 24], ["structures", 29], ["located", 40], ["in", 48], ["the", 51], ["3", 55], ["'", 56], ["untranslated", 58], ["regions", 71], ["(", 79], ["UTRs", 80], [")", 84], ["of", 86], ["eukaryotic", 89], ["selenoprotein", 100], ["mRNAs", 114], ["that", 120], ["are", 125], ["required", 129], ["for", 138], ["directing", 142], ["cotranslational", 152], ["selenocysteine", 168], ["incorporation", 183], ["at", 197], ["UGA", 200], ["codons", 204], [".", 210], ["In", 212], ["prokaryotes", 215], [",", 226], ["stem", 228], ["-", 232], ["loops", 233], ["mediating", 239], ["selenocysteine", 249], ["incorporation", 264], ["are", 278], ["located", 282], ["immediately", 290], ["downstream", 302], ["of", 313], ["the", 316], ["UGA", 320], ["selenocysteine", 324], ["codon", 339], [",", 344], ["in", 346], ["the", 349], ["coding", 353], ["region", 360], [".", 366], ["Previous", 368], ["characterization", 377], ["studies", 394], ["of", 402], ["the", 405], ["mammalian", 409], ["SECIS", 419], ["elements", 425], ["of", 434], ["type", 437], ["1", 442], ["deiodinase", 444], [",", 454], ["glutathione", 456], ["peroxidase", 468], [",", 478], ["and", 480], ["selenoprotein", 484], ["P", 498], ["showed", 500], ["that", 507], ["conserved", 512], ["nucleotides", 522], ["in", 534], ["the", 537], ["loops", 541], ["and", 547], ["unpaired", 551], ["bulges", 560], [",", 566], ["and", 568], ["base", 572], ["pairing", 577], ["in", 585], ["the", 588], ["stems", 592], ["are", 598], ["required", 602], ["for", 611], ["SECIS", 615], ["function", 621], [".", 629], ["These", 631], ["initial", 637], ["studies", 645], ["utilized", 653], ["approximately", 662], ["175", 676], ["-", 679], ["230-nt", 680], ["segments", 687], ["of", 696], ["the", 699], ["3'UTRs", 703], ["of", 710], ["the", 713], ["selenoprotein", 717], ["mRNAs", 731], [".", 736], ["Here", 738], ["we", 743], ["define", 746], ["the", 753], ["minimal", 757], ["functional", 765], ["rat", 776], ["type", 780], ["1", 785], ["deiodinase", 787], ["SECIS", 798], ["element", 804], [",", 811], ["a", 813], ["45-nt", 815], ["segment", 821], [",", 828], ["the", 830], ["5", 834], ["'", 835], ["boundary", 837], ["of", 846], ["which", 849], ["corresponds", 855], ["precisely", 867], ["to", 877], ["the", 880], ["5'-most", 884], ["critical", 892], ["conserved", 901], ["nucleotide", 911], ["identified", 922], ["previously", 933], [".", 943], ["We", 945], ["also", 948], ["define", 953], ["base", 960], ["pairing", 965], ["requirements", 973], ["in", 986], ["the", 989], ["stem", 993], ["of", 998], ["this", 1001], ["element", 1006], [".", 1013], ["In", 1015], ["view", 1018], ["of", 1023], ["the", 1026], ["presence", 1030], ["of", 1039], ["SECIS", 1042], ["elements", 1048], ["in", 1057], ["the", 1060], ["open", 1064], ["reading", 1069], ["frames", 1077], ["(", 1084], ["ORFs", 1085], [")", 1089], ["of", 1091], ["bacterial", 1094], ["selenoproteins", 1104], [",", 1118], ["we", 1120], ["examine", 1123], ["the", 1131], ["effects", 1135], ["in", 1143], ["the", 1146], ["type", 1150], ["1", 1155], ["deiodinase", 1157], ["of", 1168], ["extending", 1171], ["the", 1181], ["ORF", 1185], ["into", 1189], ["the", 1194], ["SECIS", 1198], ["element", 1204], [",", 1211], ["and", 1213], ["find", 1217], ["that", 1222], ["this", 1227], ["dramatically", 1232], ["inhibits", 1245], ["SECIS", 1254], ["function", 1260], [".", 1268], ["Finally", 1270], [",", 1277], ["we", 1279], ["define", 1282], ["a", 1289], ["minimal", 1291], ["spacing", 1299], ["requirement", 1307], ["of", 1319], ["51", 1322], ["-", 1324], ["111", 1325], ["nt", 1329], ["between", 1332], ["a", 1340], ["eukaryotic", 1342], ["UGA", 1353], ["selenocysteine", 1357], ["codon", 1372], ["and", 1378], ["SECIS", 1382], ["element", 1388], [".", 1395]]}
{"context": "More than 500 unrelated patients with neurofibromatosis type 1 (NF1) were screened for mutations in the NF1 gene. For each patient, the whole coding sequence and all splice sites were studied for aberrations, either by the protein truncation test (PTT), temperature-gradient gel electrophoresis (TGGE) of genomic PCR products, or, most often, by direct genomic sequencing (DGS) of all individual exons. A total of 301 sequence variants, including 278 bona fide pathogenic mutations, were identified. As many as 216 or 183 of the genuine mutations, comprising 179 or 161 different ones, can be considered novel when compared to the recent findings of Upadhyaya and Cooper, or to the NNFF mutation database. Mutation-detection efficiencies of the various screening methods were similar: 47.1% for PTT, 53.7% for TGGE, and 54.9% for DGS. Some 224 mutations (80.2%) yielded directly or indirectly premature termination codons. These mutations showed even distribution over the whole gene from exon 1 to exon 47. Of all sequence variants determined in our study, <20% represent C-->T or G-->A transitions within a CpG dinucleotide, and only six different mutations also occur in NF1 pseudogenes, with five being typical C-->T transitions in a CpG. Thus, neither frequent deamination of 5-methylcytosines nor interchromosomal gene conversion may account for the high mutation rate of the NF1 gene. As opposed to the truncating mutations, the 28 (10.1%) missense or single-amino-acid-deletion mutations identified clustered in two distinct regions, the GAP-related domain (GRD) and an upstream gene segment comprising exons 11-17. The latter forms a so-called cysteine/serine-rich domain with three cysteine pairs suggestive of ATP binding, as well as three potential cAMP-dependent protein kinase (PKA) recognition sites obviously phosphorylated by PKA. Coincidence of mutated amino acids and those conserved between human and Drosophila strongly suggest significant functional relevance of this region, with major roles played by exons 12a and 15 and part of exon 16.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "beeb58f583fa4c9192e2fdb72f727d1a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[224, 224], [18, 18], [256, 256], [10, 10]], "char_spans": [[1174, 1176], [104, 106], [1382, 1384], [64, 66]]}]}], "context_tokens": [["More", 0], ["than", 5], ["500", 10], ["unrelated", 14], ["patients", 24], ["with", 33], ["neurofibromatosis", 38], ["type", 56], ["1", 61], ["(", 63], ["NF1", 64], [")", 67], ["were", 69], ["screened", 74], ["for", 83], ["mutations", 87], ["in", 97], ["the", 100], ["NF1", 104], ["gene", 108], [".", 112], ["For", 114], ["each", 118], ["patient", 123], [",", 130], ["the", 132], ["whole", 136], ["coding", 142], ["sequence", 149], ["and", 158], ["all", 162], ["splice", 166], ["sites", 173], ["were", 179], ["studied", 184], ["for", 192], ["aberrations", 196], [",", 207], ["either", 209], ["by", 216], ["the", 219], ["protein", 223], ["truncation", 231], ["test", 242], ["(", 247], ["PTT", 248], [")", 251], [",", 252], ["temperature", 254], ["-", 265], ["gradient", 266], ["gel", 275], ["electrophoresis", 279], ["(", 295], ["TGGE", 296], [")", 300], ["of", 302], ["genomic", 305], ["PCR", 313], ["products", 317], [",", 325], ["or", 327], [",", 329], ["most", 331], ["often", 336], [",", 341], ["by", 343], ["direct", 346], ["genomic", 353], ["sequencing", 361], ["(", 372], ["DGS", 373], [")", 376], ["of", 378], ["all", 381], ["individual", 385], ["exons", 396], [".", 401], ["A", 403], ["total", 405], ["of", 411], ["301", 414], ["sequence", 418], ["variants", 427], [",", 435], ["including", 437], ["278", 447], ["bona", 451], ["fide", 456], ["pathogenic", 461], ["mutations", 472], [",", 481], ["were", 483], ["identified", 488], [".", 498], ["As", 500], ["many", 503], ["as", 508], ["216", 511], ["or", 515], ["183", 518], ["of", 522], ["the", 525], ["genuine", 529], ["mutations", 537], [",", 546], ["comprising", 548], ["179", 559], ["or", 563], ["161", 566], ["different", 570], ["ones", 580], [",", 584], ["can", 586], ["be", 590], ["considered", 593], ["novel", 604], ["when", 610], ["compared", 615], ["to", 624], ["the", 627], ["recent", 631], ["findings", 638], ["of", 647], ["Upadhyaya", 650], ["and", 660], ["Cooper", 664], [",", 670], ["or", 672], ["to", 675], ["the", 678], ["NNFF", 682], ["mutation", 687], ["database", 696], [".", 704], ["Mutation", 706], ["-", 714], ["detection", 715], ["efficiencies", 725], ["of", 738], ["the", 741], ["various", 745], ["screening", 753], ["methods", 763], ["were", 771], ["similar", 776], [":", 783], ["47.1", 785], ["%", 789], ["for", 791], ["PTT", 795], [",", 798], ["53.7", 800], ["%", 804], ["for", 806], ["TGGE", 810], [",", 814], ["and", 816], ["54.9", 820], ["%", 824], ["for", 826], ["DGS", 830], [".", 833], ["Some", 835], ["224", 840], ["mutations", 844], ["(", 854], ["80.2", 855], ["%", 859], [")", 860], ["yielded", 862], ["directly", 870], ["or", 879], ["indirectly", 882], ["premature", 893], ["termination", 903], ["codons", 915], [".", 921], ["These", 923], ["mutations", 929], ["showed", 939], ["even", 946], ["distribution", 951], ["over", 964], ["the", 969], ["whole", 973], ["gene", 979], ["from", 984], ["exon", 989], ["1", 994], ["to", 996], ["exon", 999], ["47", 1004], [".", 1006], ["Of", 1008], ["all", 1011], ["sequence", 1015], ["variants", 1024], ["determined", 1033], ["in", 1044], ["our", 1047], ["study", 1051], [",", 1056], ["<", 1058], ["20", 1059], ["%", 1061], ["represent", 1063], ["C-->T", 1073], ["or", 1079], ["G-->A", 1082], ["transitions", 1088], ["within", 1100], ["a", 1107], ["CpG", 1109], ["dinucleotide", 1113], [",", 1125], ["and", 1127], ["only", 1131], ["six", 1136], ["different", 1140], ["mutations", 1150], ["also", 1160], ["occur", 1165], ["in", 1171], ["NF1", 1174], ["pseudogenes", 1178], [",", 1189], ["with", 1191], ["five", 1196], ["being", 1201], ["typical", 1207], ["C-->T", 1215], ["transitions", 1221], ["in", 1233], ["a", 1236], ["CpG.", 1238], ["Thus", 1243], [",", 1247], ["neither", 1249], ["frequent", 1257], ["deamination", 1266], ["of", 1278], ["5-methylcytosines", 1281], ["nor", 1299], ["interchromosomal", 1303], ["gene", 1320], ["conversion", 1325], ["may", 1336], ["account", 1340], ["for", 1348], ["the", 1352], ["high", 1356], ["mutation", 1361], ["rate", 1370], ["of", 1375], ["the", 1378], ["NF1", 1382], ["gene", 1386], [".", 1390], ["As", 1392], ["opposed", 1395], ["to", 1403], ["the", 1406], ["truncating", 1410], ["mutations", 1421], [",", 1430], ["the", 1432], ["28", 1436], ["(", 1439], ["10.1", 1440], ["%", 1444], [")", 1445], ["missense", 1447], ["or", 1456], ["single", 1459], ["-", 1465], ["amino", 1466], ["-", 1471], ["acid", 1472], ["-", 1476], ["deletion", 1477], ["mutations", 1486], ["identified", 1496], ["clustered", 1507], ["in", 1517], ["two", 1520], ["distinct", 1524], ["regions", 1533], [",", 1540], ["the", 1542], ["GAP", 1546], ["-", 1549], ["related", 1550], ["domain", 1558], ["(", 1565], ["GRD", 1566], [")", 1569], ["and", 1571], ["an", 1575], ["upstream", 1578], ["gene", 1587], ["segment", 1592], ["comprising", 1600], ["exons", 1611], ["11", 1617], ["-", 1619], ["17", 1620], [".", 1622], ["The", 1624], ["latter", 1628], ["forms", 1635], ["a", 1641], ["so", 1643], ["-", 1645], ["called", 1646], ["cysteine", 1653], ["/", 1661], ["serine", 1662], ["-", 1668], ["rich", 1669], ["domain", 1674], ["with", 1681], ["three", 1686], ["cysteine", 1692], ["pairs", 1701], ["suggestive", 1707], ["of", 1718], ["ATP", 1721], ["binding", 1725], [",", 1732], ["as", 1734], ["well", 1737], ["as", 1742], ["three", 1745], ["potential", 1751], ["cAMP", 1761], ["-", 1765], ["dependent", 1766], ["protein", 1776], ["kinase", 1784], ["(", 1791], ["PKA", 1792], [")", 1795], ["recognition", 1797], ["sites", 1809], ["obviously", 1815], ["phosphorylated", 1825], ["by", 1840], ["PKA", 1843], [".", 1846], ["Coincidence", 1848], ["of", 1860], ["mutated", 1863], ["amino", 1871], ["acids", 1877], ["and", 1883], ["those", 1887], ["conserved", 1893], ["between", 1903], ["human", 1911], ["and", 1917], ["Drosophila", 1921], ["strongly", 1932], ["suggest", 1941], ["significant", 1949], ["functional", 1961], ["relevance", 1972], ["of", 1982], ["this", 1985], ["region", 1990], [",", 1996], ["with", 1998], ["major", 2003], ["roles", 2009], ["played", 2015], ["by", 2022], ["exons", 2025], ["12a", 2031], ["and", 2035], ["15", 2039], ["and", 2042], ["part", 2046], ["of", 2051], ["exon", 2054], ["16", 2059], [".", 2061]]}
{"context": "Ubiquilin proteins facilitate delivery of ubiquitinated proteins to the proteasome for degradation. Interest in the proteins has been heightened by the discovery that gene mutations in UBQLN2 cause dominant inheritance of amyotrophic lateral sclerosis (ALS). However, the mechanisms by which the mutations cause ALS are not known. Here we report on the underlying defect of ubiquilin-2 proteins containing ALS-linked mutations in affecting proteasome-mediated degradation. We found that overexpression of ubiquilin-2 proteins containing any one of five different ALS mutations slow degradation of Myc, a prototypic proteasome substrate. Examination of coprecipitating proteins indicated that the mutant proteins are generally capable of binding polyubiquitinated proteins, but defective in binding the proteasome. GST-pulldown studies revealed that many of the mutants bind weaker to the S5a subunit of the proteasome, compared with wild type (WT) ubiquilin-2 protein. The results suggest the mutant proteins are unable to deliver their captured cargo to the proteasome for degradation, which presumably leads to toxicity. Quantification of cell death is consistent with this idea. Measurement of protein turnover further indicated the mutant proteins have longer half-lives than WT ubiquilin-2. Our studies provide novel insight into the mechanism by which ALS-linked mutations in UBQLN2 interfere with protein degradation.", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "512ddca4bf4d4b0b858b5f2fc87b8f28", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[48, 48], [64, 64], [36, 36], [217, 217], [88, 88]], "char_spans": [[312, 314], [406, 408], [253, 255], [1358, 1360], [563, 565]]}, {"text": "amyotrophic lateral sclerosis", "token_spans": [[32, 34]], "char_spans": [[222, 250]]}]}], "context_tokens": [["Ubiquilin", 0], ["proteins", 10], ["facilitate", 19], ["delivery", 30], ["of", 39], ["ubiquitinated", 42], ["proteins", 56], ["to", 65], ["the", 68], ["proteasome", 72], ["for", 83], ["degradation", 87], [".", 98], ["Interest", 100], ["in", 109], ["the", 112], ["proteins", 116], ["has", 125], ["been", 129], ["heightened", 134], ["by", 145], ["the", 148], ["discovery", 152], ["that", 162], ["gene", 167], ["mutations", 172], ["in", 182], ["UBQLN2", 185], ["cause", 192], ["dominant", 198], ["inheritance", 207], ["of", 219], ["amyotrophic", 222], ["lateral", 234], ["sclerosis", 242], ["(", 252], ["ALS", 253], [")", 256], [".", 257], ["However", 259], [",", 266], ["the", 268], ["mechanisms", 272], ["by", 283], ["which", 286], ["the", 292], ["mutations", 296], ["cause", 306], ["ALS", 312], ["are", 316], ["not", 320], ["known", 324], [".", 329], ["Here", 331], ["we", 336], ["report", 339], ["on", 346], ["the", 349], ["underlying", 353], ["defect", 364], ["of", 371], ["ubiquilin-2", 374], ["proteins", 386], ["containing", 395], ["ALS", 406], ["-", 409], ["linked", 410], ["mutations", 417], ["in", 427], ["affecting", 430], ["proteasome", 440], ["-", 450], ["mediated", 451], ["degradation", 460], [".", 471], ["We", 473], ["found", 476], ["that", 482], ["overexpression", 487], ["of", 502], ["ubiquilin-2", 505], ["proteins", 517], ["containing", 526], ["any", 537], ["one", 541], ["of", 545], ["five", 548], ["different", 553], ["ALS", 563], ["mutations", 567], ["slow", 577], ["degradation", 582], ["of", 594], ["Myc", 597], [",", 600], ["a", 602], ["prototypic", 604], ["proteasome", 615], ["substrate", 626], [".", 635], ["Examination", 637], ["of", 649], ["coprecipitating", 652], ["proteins", 668], ["indicated", 677], ["that", 687], ["the", 692], ["mutant", 696], ["proteins", 703], ["are", 712], ["generally", 716], ["capable", 726], ["of", 734], ["binding", 737], ["polyubiquitinated", 745], ["proteins", 763], [",", 771], ["but", 773], ["defective", 777], ["in", 787], ["binding", 790], ["the", 798], ["proteasome", 802], [".", 812], ["GST", 814], ["-", 817], ["pulldown", 818], ["studies", 827], ["revealed", 835], ["that", 844], ["many", 849], ["of", 854], ["the", 857], ["mutants", 861], ["bind", 869], ["weaker", 874], ["to", 881], ["the", 884], ["S5a", 888], ["subunit", 892], ["of", 900], ["the", 903], ["proteasome", 907], [",", 917], ["compared", 919], ["with", 928], ["wild", 933], ["type", 938], ["(", 943], ["WT", 944], [")", 946], ["ubiquilin-2", 948], ["protein", 960], [".", 967], ["The", 969], ["results", 973], ["suggest", 981], ["the", 989], ["mutant", 993], ["proteins", 1000], ["are", 1009], ["unable", 1013], ["to", 1020], ["deliver", 1023], ["their", 1031], ["captured", 1037], ["cargo", 1046], ["to", 1052], ["the", 1055], ["proteasome", 1059], ["for", 1070], ["degradation", 1074], [",", 1085], ["which", 1087], ["presumably", 1093], ["leads", 1104], ["to", 1110], ["toxicity", 1113], [".", 1121], ["Quantification", 1123], ["of", 1138], ["cell", 1141], ["death", 1146], ["is", 1152], ["consistent", 1155], ["with", 1166], ["this", 1171], ["idea", 1176], [".", 1180], ["Measurement", 1182], ["of", 1194], ["protein", 1197], ["turnover", 1205], ["further", 1214], ["indicated", 1222], ["the", 1232], ["mutant", 1236], ["proteins", 1243], ["have", 1252], ["longer", 1257], ["half", 1264], ["-", 1268], ["lives", 1269], ["than", 1275], ["WT", 1280], ["ubiquilin-2", 1283], [".", 1294], ["Our", 1296], ["studies", 1300], ["provide", 1308], ["novel", 1316], ["insight", 1322], ["into", 1330], ["the", 1335], ["mechanism", 1339], ["by", 1349], ["which", 1352], ["ALS", 1358], ["-", 1361], ["linked", 1362], ["mutations", 1369], ["in", 1379], ["UBQLN2", 1382], ["interfere", 1389], ["with", 1399], ["protein", 1404], ["degradation", 1412], [".", 1423]]}
{"context": "To develop a clinical prediction rule to identify patients who can be safely discharged one hour after the administration of naloxone for presumed opioid overdose. Patients who received naloxone for known or presumed opioid overdose were formally evaluated one hour later for multiple potential predictor variables. Patients were classified into two groups: those with adverse events within 24 hours and those without. Using classification and regression tree methodology, a decision rule was developed to predict safe discharge. Clinical findings from 573 patients allowed us to develop a clinical prediction rule with a sensitivity of 99% (95% CI = 96% to 100%) and a specificity of 40% (95% CI = 36% to 45%). Patients with presumed opioid overdose can be safely discharged one hour after naloxone administration if they: 1) can mobilize as usual; 2) have oxygen saturation on room air of >92%; 3) have a respiratory rate >10 breaths/min and <20 breaths/min; 4) have a temperature of >35.0 degrees C and <37.5 degrees C; 5) have a heart rate >50 beats/min and <100 beats/min; and 6) have a Glasgow Coma Scale score of 15. This prediction rule for safe early discharge of patients with presumed opioid overdose performs well in this derivation set but requires validation followed by confirmation of safe implementation.", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "70d7878277804532b313a72e5e20e286", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[20, 20], [29, 29], [143, 143]], "char_spans": [[125, 132], [186, 193], [791, 798]]}]}], "context_tokens": [["To", 0], ["develop", 3], ["a", 11], ["clinical", 13], ["prediction", 22], ["rule", 33], ["to", 38], ["identify", 41], ["patients", 50], ["who", 59], ["can", 63], ["be", 67], ["safely", 70], ["discharged", 77], ["one", 88], ["hour", 92], ["after", 97], ["the", 103], ["administration", 107], ["of", 122], ["naloxone", 125], ["for", 134], ["presumed", 138], ["opioid", 147], ["overdose", 154], [".", 162], ["Patients", 164], ["who", 173], ["received", 177], ["naloxone", 186], ["for", 195], ["known", 199], ["or", 205], ["presumed", 208], ["opioid", 217], ["overdose", 224], ["were", 233], ["formally", 238], ["evaluated", 247], ["one", 257], ["hour", 261], ["later", 266], ["for", 272], ["multiple", 276], ["potential", 285], ["predictor", 295], ["variables", 305], [".", 314], ["Patients", 316], ["were", 325], ["classified", 330], ["into", 341], ["two", 346], ["groups", 350], [":", 356], ["those", 358], ["with", 364], ["adverse", 369], ["events", 377], ["within", 384], ["24", 391], ["hours", 394], ["and", 400], ["those", 404], ["without", 410], [".", 417], ["Using", 419], ["classification", 425], ["and", 440], ["regression", 444], ["tree", 455], ["methodology", 460], [",", 471], ["a", 473], ["decision", 475], ["rule", 484], ["was", 489], ["developed", 493], ["to", 503], ["predict", 506], ["safe", 514], ["discharge", 519], [".", 528], ["Clinical", 530], ["findings", 539], ["from", 548], ["573", 553], ["patients", 557], ["allowed", 566], ["us", 574], ["to", 577], ["develop", 580], ["a", 588], ["clinical", 590], ["prediction", 599], ["rule", 610], ["with", 615], ["a", 620], ["sensitivity", 622], ["of", 634], ["99", 637], ["%", 639], ["(", 641], ["95", 642], ["%", 644], ["CI", 646], ["=", 649], ["96", 651], ["%", 653], ["to", 655], ["100", 658], ["%", 661], [")", 662], ["and", 664], ["a", 668], ["specificity", 670], ["of", 682], ["40", 685], ["%", 687], ["(", 689], ["95", 690], ["%", 692], ["CI", 694], ["=", 697], ["36", 699], ["%", 701], ["to", 703], ["45", 706], ["%", 708], [")", 709], [".", 710], ["Patients", 712], ["with", 721], ["presumed", 726], ["opioid", 735], ["overdose", 742], ["can", 751], ["be", 755], ["safely", 758], ["discharged", 765], ["one", 776], ["hour", 780], ["after", 785], ["naloxone", 791], ["administration", 800], ["if", 815], ["they", 818], [":", 822], ["1", 824], [")", 825], ["can", 827], ["mobilize", 831], ["as", 840], ["usual", 843], [";", 848], ["2", 850], [")", 851], ["have", 853], ["oxygen", 858], ["saturation", 865], ["on", 876], ["room", 879], ["air", 884], ["of", 888], [">", 891], ["92", 892], ["%", 894], [";", 895], ["3", 897], [")", 898], ["have", 900], ["a", 905], ["respiratory", 907], ["rate", 919], [">", 924], ["10", 925], ["breaths", 928], ["/", 935], ["min", 936], ["and", 940], ["<", 944], ["20", 945], ["breaths", 948], ["/", 955], ["min", 956], [";", 959], ["4", 961], [")", 962], ["have", 964], ["a", 969], ["temperature", 971], ["of", 983], [">", 986], ["35.0", 987], ["degrees", 992], ["C", 1000], ["and", 1002], ["<", 1006], ["37.5", 1007], ["degrees", 1012], ["C", 1020], [";", 1021], ["5", 1023], [")", 1024], ["have", 1026], ["a", 1031], ["heart", 1033], ["rate", 1039], [">", 1044], ["50", 1045], ["beats", 1048], ["/", 1053], ["min", 1054], ["and", 1058], ["<", 1062], ["100", 1063], ["beats", 1067], ["/", 1072], ["min", 1073], [";", 1076], ["and", 1078], ["6", 1082], [")", 1083], ["have", 1085], ["a", 1090], ["Glasgow", 1092], ["Coma", 1100], ["Scale", 1105], ["score", 1111], ["of", 1117], ["15", 1120], [".", 1122], ["This", 1124], ["prediction", 1129], ["rule", 1140], ["for", 1145], ["safe", 1149], ["early", 1154], ["discharge", 1160], ["of", 1170], ["patients", 1173], ["with", 1182], ["presumed", 1187], ["opioid", 1196], ["overdose", 1203], ["performs", 1212], ["well", 1221], ["in", 1226], ["this", 1229], ["derivation", 1234], ["set", 1245], ["but", 1249], ["requires", 1253], ["validation", 1262], ["followed", 1273], ["by", 1282], ["confirmation", 1285], ["of", 1298], ["safe", 1301], ["implementation", 1306], [".", 1320]]}
{"context": "The purpose of this study was to describe the technique and usefulness of ultrasound-guided intrasheath injection of triamcinolone in the treatment of de Quervain's disease (dQD). Our study was retrospective in design. Seventy-one wrists of 62 patients who were treated with an ultrasound-guided triamcinolone injection for dQD were included. A literature search was performed to compare our results. In the literature we found supportive evidence that accurate injection of triamcinolone in the first dorsal compartment of the wrist is important for a good outcome. In this retrospective study we found that treatment with ultrasound-guided injections of triamcinolone is both safe and effective. After two injections, 91% of the patients had good long-term results, which is a higher cure rate than found in most other studies. Furthermore, we found that Finkelstein's test can give a false positive result. Therefore, ultrasound should not only be considered to improve the treatment outcome, but can also be useful as a diagnostic tool in the management of de Quervain's disease.", "qas": [{"question": "Which disease is diagnosed using the Finkelstein's test?", "answers": ["de Quervain's disease"], "qid": "28c063ee9b8f48c0a4043216a47ce037", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["diagnosed", 17], ["using", 27], ["the", 33], ["Finkelstein", 37], ["'s", 48], ["test", 51], ["?", 55]], "detected_answers": [{"text": "de Quervain's disease", "token_spans": [[190, 193], [24, 27]], "char_spans": [[1061, 1081], [151, 171]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["study", 20], ["was", 26], ["to", 30], ["describe", 33], ["the", 42], ["technique", 46], ["and", 56], ["usefulness", 60], ["of", 71], ["ultrasound", 74], ["-", 84], ["guided", 85], ["intrasheath", 92], ["injection", 104], ["of", 114], ["triamcinolone", 117], ["in", 131], ["the", 134], ["treatment", 138], ["of", 148], ["de", 151], ["Quervain", 154], ["'s", 162], ["disease", 165], ["(", 173], ["dQD", 174], [")", 177], [".", 178], ["Our", 180], ["study", 184], ["was", 190], ["retrospective", 194], ["in", 208], ["design", 211], [".", 217], ["Seventy", 219], ["-", 226], ["one", 227], ["wrists", 231], ["of", 238], ["62", 241], ["patients", 244], ["who", 253], ["were", 257], ["treated", 262], ["with", 270], ["an", 275], ["ultrasound", 278], ["-", 288], ["guided", 289], ["triamcinolone", 296], ["injection", 310], ["for", 320], ["dQD", 324], ["were", 328], ["included", 333], [".", 341], ["A", 343], ["literature", 345], ["search", 356], ["was", 363], ["performed", 367], ["to", 377], ["compare", 380], ["our", 388], ["results", 392], [".", 399], ["In", 401], ["the", 404], ["literature", 408], ["we", 419], ["found", 422], ["supportive", 428], ["evidence", 439], ["that", 448], ["accurate", 453], ["injection", 462], ["of", 472], ["triamcinolone", 475], ["in", 489], ["the", 492], ["first", 496], ["dorsal", 502], ["compartment", 509], ["of", 521], ["the", 524], ["wrist", 528], ["is", 534], ["important", 537], ["for", 547], ["a", 551], ["good", 553], ["outcome", 558], [".", 565], ["In", 567], ["this", 570], ["retrospective", 575], ["study", 589], ["we", 595], ["found", 598], ["that", 604], ["treatment", 609], ["with", 619], ["ultrasound", 624], ["-", 634], ["guided", 635], ["injections", 642], ["of", 653], ["triamcinolone", 656], ["is", 670], ["both", 673], ["safe", 678], ["and", 683], ["effective", 687], [".", 696], ["After", 698], ["two", 704], ["injections", 708], [",", 718], ["91", 720], ["%", 722], ["of", 724], ["the", 727], ["patients", 731], ["had", 740], ["good", 744], ["long", 749], ["-", 753], ["term", 754], ["results", 759], [",", 766], ["which", 768], ["is", 774], ["a", 777], ["higher", 779], ["cure", 786], ["rate", 791], ["than", 796], ["found", 801], ["in", 807], ["most", 810], ["other", 815], ["studies", 821], [".", 828], ["Furthermore", 830], [",", 841], ["we", 843], ["found", 846], ["that", 852], ["Finkelstein", 857], ["'s", 868], ["test", 871], ["can", 876], ["give", 880], ["a", 885], ["false", 887], ["positive", 893], ["result", 902], [".", 908], ["Therefore", 910], [",", 919], ["ultrasound", 921], ["should", 932], ["not", 939], ["only", 943], ["be", 948], ["considered", 951], ["to", 962], ["improve", 965], ["the", 973], ["treatment", 977], ["outcome", 987], [",", 994], ["but", 996], ["can", 1000], ["also", 1004], ["be", 1009], ["useful", 1012], ["as", 1019], ["a", 1022], ["diagnostic", 1024], ["tool", 1035], ["in", 1040], ["the", 1043], ["management", 1047], ["of", 1058], ["de", 1061], ["Quervain", 1064], ["'s", 1072], ["disease", 1075], [".", 1082]]}
{"context": "Women in sub-Saharan Africa are a priority population for evaluation of new biomedical HIV-1 prevention strategies. Antiretroviral pre-exposure prophylaxis is a promising prevention approach; however, clinical trials among young women using daily or coitally-dependent products have found low adherence. Antiretroviral-containing vaginal microbicide rings, which release medication over a month or longer, may reduce these adherence challenges. ASPIRE (A Study to Prevent Infection with a Ring for Extended Use) is a phase III, randomized, double-blind, placebo-controlled trial testing the safety and effectiveness of a vaginal ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine for prevention of HIV-1 infection. We describe the baseline characteristics of African women enrolled in the ASPIRE trial. Between August 2012 and June 2014, 5516 women were screened and 2629 HIV-1 seronegative women between 18-45 years of age were enrolled from 15 research sites in Malawi, South Africa, Uganda, and Zimbabwe. The median age was 26 years (IQR 22-31) and the majority (59%) were unmarried. Nearly 100% of participants reported having a primary sex partner in the prior three months but 43% did not know the HIV-1 status of their primary partner; 17% reported additional concurrent partners. Nearly two-thirds (64%) reported having disclosed to primary partners about planned vaginal ring use in the trial. Sexually transmitted infections were prevalent: 12% had Chlamydia trachomatis, 7% Trichomonas vaginalis, 4% Neisseria gonorrhoeae, and 1% syphilis. African HIV-1 seronegative women at risk of HIV -1 infection were successfully enrolled into a phase III trial of dapivirine vaginal ring for HIV-1 prevention.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "5c077ce1a2b84aa199040b93309cc5b6", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[294, 294]], "char_spans": [[1622, 1624]]}]}], "context_tokens": [["Women", 0], ["in", 6], ["sub", 9], ["-", 12], ["Saharan", 13], ["Africa", 21], ["are", 28], ["a", 32], ["priority", 34], ["population", 43], ["for", 54], ["evaluation", 58], ["of", 69], ["new", 72], ["biomedical", 76], ["HIV-1", 87], ["prevention", 93], ["strategies", 104], [".", 114], ["Antiretroviral", 116], ["pre", 131], ["-", 134], ["exposure", 135], ["prophylaxis", 144], ["is", 156], ["a", 159], ["promising", 161], ["prevention", 171], ["approach", 182], [";", 190], ["however", 192], [",", 199], ["clinical", 201], ["trials", 210], ["among", 217], ["young", 223], ["women", 229], ["using", 235], ["daily", 241], ["or", 247], ["coitally", 250], ["-", 258], ["dependent", 259], ["products", 269], ["have", 278], ["found", 283], ["low", 289], ["adherence", 293], [".", 302], ["Antiretroviral", 304], ["-", 318], ["containing", 319], ["vaginal", 330], ["microbicide", 338], ["rings", 350], [",", 355], ["which", 357], ["release", 363], ["medication", 371], ["over", 382], ["a", 387], ["month", 389], ["or", 395], ["longer", 398], [",", 404], ["may", 406], ["reduce", 410], ["these", 417], ["adherence", 423], ["challenges", 433], [".", 443], ["ASPIRE", 445], ["(", 452], ["A", 453], ["Study", 455], ["to", 461], ["Prevent", 464], ["Infection", 472], ["with", 482], ["a", 487], ["Ring", 489], ["for", 494], ["Extended", 498], ["Use", 507], [")", 510], ["is", 512], ["a", 515], ["phase", 517], ["III", 523], [",", 526], ["randomized", 528], [",", 538], ["double", 540], ["-", 546], ["blind", 547], [",", 552], ["placebo", 554], ["-", 561], ["controlled", 562], ["trial", 573], ["testing", 579], ["the", 587], ["safety", 591], ["and", 598], ["effectiveness", 602], ["of", 616], ["a", 619], ["vaginal", 621], ["ring", 629], ["containing", 634], ["the", 645], ["non", 649], ["-", 652], ["nucleoside", 653], ["reverse", 664], ["transcriptase", 672], ["inhibitor", 686], ["dapivirine", 696], ["for", 707], ["prevention", 711], ["of", 722], ["HIV-1", 725], ["infection", 731], [".", 740], ["We", 742], ["describe", 745], ["the", 754], ["baseline", 758], ["characteristics", 767], ["of", 783], ["African", 786], ["women", 794], ["enrolled", 800], ["in", 809], ["the", 812], ["ASPIRE", 816], ["trial", 823], [".", 828], ["Between", 830], ["August", 838], ["2012", 845], ["and", 850], ["June", 854], ["2014", 859], [",", 863], ["5516", 865], ["women", 870], ["were", 876], ["screened", 881], ["and", 890], ["2629", 894], ["HIV-1", 899], ["seronegative", 905], ["women", 918], ["between", 924], ["18", 932], ["-", 934], ["45", 935], ["years", 938], ["of", 944], ["age", 947], ["were", 951], ["enrolled", 956], ["from", 965], ["15", 970], ["research", 973], ["sites", 982], ["in", 988], ["Malawi", 991], [",", 997], ["South", 999], ["Africa", 1005], [",", 1011], ["Uganda", 1013], [",", 1019], ["and", 1021], ["Zimbabwe", 1025], [".", 1033], ["The", 1035], ["median", 1039], ["age", 1046], ["was", 1050], ["26", 1054], ["years", 1057], ["(", 1063], ["IQR", 1064], ["22", 1068], ["-", 1070], ["31", 1071], [")", 1073], ["and", 1075], ["the", 1079], ["majority", 1083], ["(", 1092], ["59", 1093], ["%", 1095], [")", 1096], ["were", 1098], ["unmarried", 1103], [".", 1112], ["Nearly", 1114], ["100", 1121], ["%", 1124], ["of", 1126], ["participants", 1129], ["reported", 1142], ["having", 1151], ["a", 1158], ["primary", 1160], ["sex", 1168], ["partner", 1172], ["in", 1180], ["the", 1183], ["prior", 1187], ["three", 1193], ["months", 1199], ["but", 1206], ["43", 1210], ["%", 1212], ["did", 1214], ["not", 1218], ["know", 1222], ["the", 1227], ["HIV-1", 1231], ["status", 1237], ["of", 1244], ["their", 1247], ["primary", 1253], ["partner", 1261], [";", 1268], ["17", 1270], ["%", 1272], ["reported", 1274], ["additional", 1283], ["concurrent", 1294], ["partners", 1305], [".", 1313], ["Nearly", 1315], ["two", 1322], ["-", 1325], ["thirds", 1326], ["(", 1333], ["64", 1334], ["%", 1336], [")", 1337], ["reported", 1339], ["having", 1348], ["disclosed", 1355], ["to", 1365], ["primary", 1368], ["partners", 1376], ["about", 1385], ["planned", 1391], ["vaginal", 1399], ["ring", 1407], ["use", 1412], ["in", 1416], ["the", 1419], ["trial", 1423], [".", 1428], ["Sexually", 1430], ["transmitted", 1439], ["infections", 1451], ["were", 1462], ["prevalent", 1467], [":", 1476], ["12", 1478], ["%", 1480], ["had", 1482], ["Chlamydia", 1486], ["trachomatis", 1496], [",", 1507], ["7", 1509], ["%", 1510], ["Trichomonas", 1512], ["vaginalis", 1524], [",", 1533], ["4", 1535], ["%", 1536], ["Neisseria", 1538], ["gonorrhoeae", 1548], [",", 1559], ["and", 1561], ["1", 1565], ["%", 1566], ["syphilis", 1568], [".", 1576], ["African", 1578], ["HIV-1", 1586], ["seronegative", 1592], ["women", 1605], ["at", 1611], ["risk", 1614], ["of", 1619], ["HIV", 1622], ["-1", 1626], ["infection", 1629], ["were", 1639], ["successfully", 1644], ["enrolled", 1657], ["into", 1666], ["a", 1671], ["phase", 1673], ["III", 1679], ["trial", 1683], ["of", 1689], ["dapivirine", 1692], ["vaginal", 1703], ["ring", 1711], ["for", 1716], ["HIV-1", 1720], ["prevention", 1726], [".", 1736]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a common form of muscular dystrophy characterized by an asymmetric progressive weakness and wasting of the facial, shoulder and upper arm muscles, frequently accompanied by hearing loss and retinal vasculopathy. FSHD is an autosomal dominant disease linked to chromosome 4q35, but the causative gene remains controversial. DUX4 is a leading candidate gene as causative of FSHD. However, DUX4 expression is extremely low in FSHD muscle, and there is no DUX4 animal model that mirrors the pathology in human FSHD. Here, we show that the misexpression of very low levels of human DUX4 in zebrafish development recapitulates the phenotypes seen in human FSHD patients. Microinjection of small amounts of human full-length DUX4 (DUX4-fl) mRNA into fertilized zebrafish eggs caused asymmetric abnormalities such as less pigmentation of the eyes, altered morphology of ears, developmental abnormality of fin muscle, disorganization of facial musculature and/or degeneration of trunk muscle later in development. Moreover, DUX4-fl expression caused aberrant localization of myogenic cells marked with \u03b1-actin promoter-driven enhanced green fluorescent protein outside somite boundary, especially in head region. These abnormalities were rescued by coinjection of the short form of DUX4 (DUX4-s). Our results suggest that the misexpression of DUX4-fl, even at extremely low level, can recapitulate the phenotype observed in FSHD patients in a vertebrate model. These results strongly support the current hypothesis for a role of DUX4 in FSHD pathogenesis. We also propose that DUX4 expression during development is important for the pathogenesis of FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "69c2179d41c04582949a39853d960dbb", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[93, 93], [67, 67], [77, 77], [118, 118], [262, 262], [4, 4], [279, 279], [40, 40], [242, 242]], "char_spans": [[555, 558], [421, 424], [472, 475], [699, 702], [1577, 1580], [40, 43], [1689, 1692], [261, 264], [1464, 1467]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["common", 51], ["form", 58], ["of", 63], ["muscular", 66], ["dystrophy", 75], ["characterized", 85], ["by", 99], ["an", 102], ["asymmetric", 105], ["progressive", 116], ["weakness", 128], ["and", 137], ["wasting", 141], ["of", 149], ["the", 152], ["facial", 156], [",", 162], ["shoulder", 164], ["and", 173], ["upper", 177], ["arm", 183], ["muscles", 187], [",", 194], ["frequently", 196], ["accompanied", 207], ["by", 219], ["hearing", 222], ["loss", 230], ["and", 235], ["retinal", 239], ["vasculopathy", 247], [".", 259], ["FSHD", 261], ["is", 266], ["an", 269], ["autosomal", 272], ["dominant", 282], ["disease", 291], ["linked", 299], ["to", 306], ["chromosome", 309], ["4q35", 320], [",", 324], ["but", 326], ["the", 330], ["causative", 334], ["gene", 344], ["remains", 349], ["controversial", 357], [".", 370], ["DUX4", 372], ["is", 377], ["a", 380], ["leading", 382], ["candidate", 390], ["gene", 400], ["as", 405], ["causative", 408], ["of", 418], ["FSHD", 421], [".", 425], ["However", 427], [",", 434], ["DUX4", 436], ["expression", 441], ["is", 452], ["extremely", 455], ["low", 465], ["in", 469], ["FSHD", 472], ["muscle", 477], [",", 483], ["and", 485], ["there", 489], ["is", 495], ["no", 498], ["DUX4", 501], ["animal", 506], ["model", 513], ["that", 519], ["mirrors", 524], ["the", 532], ["pathology", 536], ["in", 546], ["human", 549], ["FSHD", 555], [".", 559], ["Here", 561], [",", 565], ["we", 567], ["show", 570], ["that", 575], ["the", 580], ["misexpression", 584], ["of", 598], ["very", 601], ["low", 606], ["levels", 610], ["of", 617], ["human", 620], ["DUX4", 626], ["in", 631], ["zebrafish", 634], ["development", 644], ["recapitulates", 656], ["the", 670], ["phenotypes", 674], ["seen", 685], ["in", 690], ["human", 693], ["FSHD", 699], ["patients", 704], [".", 712], ["Microinjection", 714], ["of", 729], ["small", 732], ["amounts", 738], ["of", 746], ["human", 749], ["full", 755], ["-", 759], ["length", 760], ["DUX4", 767], ["(", 772], ["DUX4-fl", 773], [")", 780], ["mRNA", 782], ["into", 787], ["fertilized", 792], ["zebrafish", 803], ["eggs", 813], ["caused", 818], ["asymmetric", 825], ["abnormalities", 836], ["such", 850], ["as", 855], ["less", 858], ["pigmentation", 863], ["of", 876], ["the", 879], ["eyes", 883], [",", 887], ["altered", 889], ["morphology", 897], ["of", 908], ["ears", 911], [",", 915], ["developmental", 917], ["abnormality", 931], ["of", 943], ["fin", 946], ["muscle", 950], [",", 956], ["disorganization", 958], ["of", 974], ["facial", 977], ["musculature", 984], ["and/or", 996], ["degeneration", 1003], ["of", 1016], ["trunk", 1019], ["muscle", 1025], ["later", 1032], ["in", 1038], ["development", 1041], [".", 1052], ["Moreover", 1054], [",", 1062], ["DUX4-fl", 1064], ["expression", 1072], ["caused", 1083], ["aberrant", 1090], ["localization", 1099], ["of", 1112], ["myogenic", 1115], ["cells", 1124], ["marked", 1130], ["with", 1137], ["\u03b1", 1142], ["-", 1143], ["actin", 1144], ["promoter", 1150], ["-", 1158], ["driven", 1159], ["enhanced", 1166], ["green", 1175], ["fluorescent", 1181], ["protein", 1193], ["outside", 1201], ["somite", 1209], ["boundary", 1216], [",", 1224], ["especially", 1226], ["in", 1237], ["head", 1240], ["region", 1245], [".", 1251], ["These", 1253], ["abnormalities", 1259], ["were", 1273], ["rescued", 1278], ["by", 1286], ["coinjection", 1289], ["of", 1301], ["the", 1304], ["short", 1308], ["form", 1314], ["of", 1319], ["DUX4", 1322], ["(", 1327], ["DUX4-s", 1328], [")", 1334], [".", 1335], ["Our", 1337], ["results", 1341], ["suggest", 1349], ["that", 1357], ["the", 1362], ["misexpression", 1366], ["of", 1380], ["DUX4-fl", 1383], [",", 1390], ["even", 1392], ["at", 1397], ["extremely", 1400], ["low", 1410], ["level", 1414], [",", 1419], ["can", 1421], ["recapitulate", 1425], ["the", 1438], ["phenotype", 1442], ["observed", 1452], ["in", 1461], ["FSHD", 1464], ["patients", 1469], ["in", 1478], ["a", 1481], ["vertebrate", 1483], ["model", 1494], [".", 1499], ["These", 1501], ["results", 1507], ["strongly", 1515], ["support", 1524], ["the", 1532], ["current", 1536], ["hypothesis", 1544], ["for", 1555], ["a", 1559], ["role", 1561], ["of", 1566], ["DUX4", 1569], ["in", 1574], ["FSHD", 1577], ["pathogenesis", 1582], [".", 1594], ["We", 1596], ["also", 1599], ["propose", 1604], ["that", 1612], ["DUX4", 1617], ["expression", 1622], ["during", 1633], ["development", 1640], ["is", 1652], ["important", 1655], ["for", 1665], ["the", 1669], ["pathogenesis", 1673], ["of", 1686], ["FSHD", 1689], [".", 1693]]}
{"context": "Malaria, which is the result of Plasmodium falciparum infection, is a global health threat that resulted in 655,000 deaths and 216 million clinical cases in 2010 alone. Recent phase 3 trials with malaria vaccine candidate RTS,S/AS01 (RTS,S) in children has demonstrated modest efficacy against clinical and severe malaria. RTS,S targets the pre-erythrocytic phase of the disease and induces high antibody titers against the P. falciparum circumsporozoite protein (CSP) and a moderate CD4(+) T cell response. The individual contribution of these adaptive immune responses to protection from infection remains unknown. Here, we found that prophylactic administration of anti-CSP mAbs derived from an RTS,S-vaccinated recipient fully protected mice with humanized livers from i.v.- and mosquito bite\u2013delivered P. falciparum sporozoite challenge. Titers of anti-CSP that conveyed full protection were within the range observed in human RTS,S vaccine recipients. Increasing anti-CSP titers resulted in a dose-dependent reduction of the liver parasite burden. These data indicate that RTS,S-induced antibodies are protective and provide sterilizing immunity against P. falciparum infection when reaching or exceeding a critical plasma concentration.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "bff1390d69824f58b4c462e5805f90f1", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[0, 0], [35, 35], [58, 58]], "char_spans": [[0, 6], [196, 202], [314, 320]]}]}], "context_tokens": [["Malaria", 0], [",", 7], ["which", 9], ["is", 15], ["the", 18], ["result", 22], ["of", 29], ["Plasmodium", 32], ["falciparum", 43], ["infection", 54], [",", 63], ["is", 65], ["a", 68], ["global", 70], ["health", 77], ["threat", 84], ["that", 91], ["resulted", 96], ["in", 105], ["655,000", 108], ["deaths", 116], ["and", 123], ["216", 127], ["million", 131], ["clinical", 139], ["cases", 148], ["in", 154], ["2010", 157], ["alone", 162], [".", 167], ["Recent", 169], ["phase", 176], ["3", 182], ["trials", 184], ["with", 191], ["malaria", 196], ["vaccine", 204], ["candidate", 212], ["RTS", 222], [",", 225], ["S", 226], ["/", 227], ["AS01", 228], ["(", 233], ["RTS", 234], [",", 237], ["S", 238], [")", 239], ["in", 241], ["children", 244], ["has", 253], ["demonstrated", 257], ["modest", 270], ["efficacy", 277], ["against", 286], ["clinical", 294], ["and", 303], ["severe", 307], ["malaria", 314], [".", 321], ["RTS", 323], [",", 326], ["S", 327], ["targets", 329], ["the", 337], ["pre", 341], ["-", 344], ["erythrocytic", 345], ["phase", 358], ["of", 364], ["the", 367], ["disease", 371], ["and", 379], ["induces", 383], ["high", 391], ["antibody", 396], ["titers", 405], ["against", 412], ["the", 420], ["P.", 424], ["falciparum", 427], ["circumsporozoite", 438], ["protein", 455], ["(", 463], ["CSP", 464], [")", 467], ["and", 469], ["a", 473], ["moderate", 475], ["CD4(+", 484], [")", 489], ["T", 491], ["cell", 493], ["response", 498], [".", 506], ["The", 508], ["individual", 512], ["contribution", 523], ["of", 536], ["these", 539], ["adaptive", 545], ["immune", 554], ["responses", 561], ["to", 571], ["protection", 574], ["from", 585], ["infection", 590], ["remains", 600], ["unknown", 608], [".", 615], ["Here", 617], [",", 621], ["we", 623], ["found", 626], ["that", 632], ["prophylactic", 637], ["administration", 650], ["of", 665], ["anti", 668], ["-", 672], ["CSP", 673], ["mAbs", 677], ["derived", 682], ["from", 690], ["an", 695], ["RTS", 698], [",", 701], ["S", 702], ["-", 703], ["vaccinated", 704], ["recipient", 715], ["fully", 725], ["protected", 731], ["mice", 741], ["with", 746], ["humanized", 751], ["livers", 761], ["from", 768], ["i.v.-", 773], ["and", 779], ["mosquito", 783], ["bite", 792], ["\u2013", 796], ["delivered", 797], ["P.", 807], ["falciparum", 810], ["sporozoite", 821], ["challenge", 832], [".", 841], ["Titers", 843], ["of", 850], ["anti", 853], ["-", 857], ["CSP", 858], ["that", 862], ["conveyed", 867], ["full", 876], ["protection", 881], ["were", 892], ["within", 897], ["the", 904], ["range", 908], ["observed", 914], ["in", 923], ["human", 926], ["RTS", 932], [",", 935], ["S", 936], ["vaccine", 938], ["recipients", 946], [".", 956], ["Increasing", 958], ["anti", 969], ["-", 973], ["CSP", 974], ["titers", 978], ["resulted", 985], ["in", 994], ["a", 997], ["dose", 999], ["-", 1003], ["dependent", 1004], ["reduction", 1014], ["of", 1024], ["the", 1027], ["liver", 1031], ["parasite", 1037], ["burden", 1046], [".", 1052], ["These", 1054], ["data", 1060], ["indicate", 1065], ["that", 1074], ["RTS", 1079], [",", 1082], ["S", 1083], ["-", 1084], ["induced", 1085], ["antibodies", 1093], ["are", 1104], ["protective", 1108], ["and", 1119], ["provide", 1123], ["sterilizing", 1131], ["immunity", 1143], ["against", 1152], ["P.", 1160], ["falciparum", 1163], ["infection", 1174], ["when", 1184], ["reaching", 1189], ["or", 1198], ["exceeding", 1201], ["a", 1211], ["critical", 1213], ["plasma", 1222], ["concentration", 1229], [".", 1242]]}
{"context": "ZFHX1B encodes Smad-interacting protein 1, a transcriptional corepressor involved in the transforming growth factors beta (TGFbeta) signaling pathway. ZFHX1B mutations cause a complex developmental phenotype characterized by severe mental retardation (MR) and multiple congenital defects. We compared the distribution of ZFHX1B transcripts during mouse and human embryogenesis as well as in adult mice and humans. This showed that this gene is strongly transcribed at an early stage in the developing peripheral and central nervous systems of both mice and humans, in all neuronal regions of the brains of 25-week human fetuses and adult mice, and at varying levels in numerous nonneural tissues. Northern blot analysis suggested that ZFHX1B undergoes tissue-specific alternative splicing in both species. These results strongly suggest that ZFHX1B determines the transcriptional levels of target genes in various tissues through the combinatorial interactions of its isoforms with different Smad proteins. Thus, as well as causing neural defects, ZFHX1B mutations may also cause other malformations.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "8870a7ba64174735af9856e72fd82aaa", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[0, 0], [24, 24], [120, 120], [136, 136], [168, 168], [49, 49]], "char_spans": [[0, 5], [151, 156], [735, 740], [842, 847], [1048, 1053], [321, 326]]}]}], "context_tokens": [["ZFHX1B", 0], ["encodes", 7], ["Smad", 15], ["-", 19], ["interacting", 20], ["protein", 32], ["1", 40], [",", 41], ["a", 43], ["transcriptional", 45], ["corepressor", 61], ["involved", 73], ["in", 82], ["the", 85], ["transforming", 89], ["growth", 102], ["factors", 109], ["beta", 117], ["(", 122], ["TGFbeta", 123], [")", 130], ["signaling", 132], ["pathway", 142], [".", 149], ["ZFHX1B", 151], ["mutations", 158], ["cause", 168], ["a", 174], ["complex", 176], ["developmental", 184], ["phenotype", 198], ["characterized", 208], ["by", 222], ["severe", 225], ["mental", 232], ["retardation", 239], ["(", 251], ["MR", 252], [")", 254], ["and", 256], ["multiple", 260], ["congenital", 269], ["defects", 280], [".", 287], ["We", 289], ["compared", 292], ["the", 301], ["distribution", 305], ["of", 318], ["ZFHX1B", 321], ["transcripts", 328], ["during", 340], ["mouse", 347], ["and", 353], ["human", 357], ["embryogenesis", 363], ["as", 377], ["well", 380], ["as", 385], ["in", 388], ["adult", 391], ["mice", 397], ["and", 402], ["humans", 406], [".", 412], ["This", 414], ["showed", 419], ["that", 426], ["this", 431], ["gene", 436], ["is", 441], ["strongly", 444], ["transcribed", 453], ["at", 465], ["an", 468], ["early", 471], ["stage", 477], ["in", 483], ["the", 486], ["developing", 490], ["peripheral", 501], ["and", 512], ["central", 516], ["nervous", 524], ["systems", 532], ["of", 540], ["both", 543], ["mice", 548], ["and", 553], ["humans", 557], [",", 563], ["in", 565], ["all", 568], ["neuronal", 572], ["regions", 581], ["of", 589], ["the", 592], ["brains", 596], ["of", 603], ["25-week", 606], ["human", 614], ["fetuses", 620], ["and", 628], ["adult", 632], ["mice", 638], [",", 642], ["and", 644], ["at", 648], ["varying", 651], ["levels", 659], ["in", 666], ["numerous", 669], ["nonneural", 678], ["tissues", 688], [".", 695], ["Northern", 697], ["blot", 706], ["analysis", 711], ["suggested", 720], ["that", 730], ["ZFHX1B", 735], ["undergoes", 742], ["tissue", 752], ["-", 758], ["specific", 759], ["alternative", 768], ["splicing", 780], ["in", 789], ["both", 792], ["species", 797], [".", 804], ["These", 806], ["results", 812], ["strongly", 820], ["suggest", 829], ["that", 837], ["ZFHX1B", 842], ["determines", 849], ["the", 860], ["transcriptional", 864], ["levels", 880], ["of", 887], ["target", 890], ["genes", 897], ["in", 903], ["various", 906], ["tissues", 914], ["through", 922], ["the", 930], ["combinatorial", 934], ["interactions", 948], ["of", 961], ["its", 964], ["isoforms", 968], ["with", 977], ["different", 982], ["Smad", 992], ["proteins", 997], [".", 1005], ["Thus", 1007], [",", 1011], ["as", 1013], ["well", 1016], ["as", 1021], ["causing", 1024], ["neural", 1032], ["defects", 1039], [",", 1046], ["ZFHX1B", 1048], ["mutations", 1055], ["may", 1065], ["also", 1069], ["cause", 1074], ["other", 1080], ["malformations", 1086], [".", 1099]]}
{"context": "Psychiatric disorders have a great impact on morbidity and mortality. Genotype-phenotype resources for psychiatric diseases are key to enable the translation of research findings to a better care of patients. PsyGeNET is a knowledge resource on psychiatric diseases and their genes, developed by text mining and curated by domain experts. We present psygenet2r, an R package that contains a variety of functions for leveraging PsyGeNET database and facilitating its analysis and interpretation. The package offers different types of queries to the database along with variety of analysis and visualization tools, including the study of the anatomical structures in which the genes are expressed and gaining insight of gene's molecular function. Psygenet2r is especially suited for network medicine analysis of psychiatric disorders. The package is implemented in R and is available under MIT license from Bioconductor (http://bioconductor.org/packages/release/bioc/html/psygenet2r.html). juanr.gonzalez@isglobal.org or laura.furlong@upf.edu. Supplementary data are available at Bioinformatics online.", "qas": [{"question": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?", "answers": ["Psygenet2r"], "qid": "4d4e76e2c6944123bd9d9709e0e9d250", "question_tokens": [["Which", 0], ["R", 6], ["/", 7], ["Bioconductor", 8], ["package", 21], ["has", 29], ["been", 33], ["developed", 38], ["for", 48], ["the", 52], ["analysis", 56], ["of", 65], ["psychiatric", 68], ["disease", 80], ["genes", 88], ["?", 93]], "detected_answers": [{"text": "Psygenet2r", "token_spans": [[121, 121], [58, 58]], "char_spans": [[745, 754], [350, 359]]}]}], "context_tokens": [["Psychiatric", 0], ["disorders", 12], ["have", 22], ["a", 27], ["great", 29], ["impact", 35], ["on", 42], ["morbidity", 45], ["and", 55], ["mortality", 59], [".", 68], ["Genotype", 70], ["-", 78], ["phenotype", 79], ["resources", 89], ["for", 99], ["psychiatric", 103], ["diseases", 115], ["are", 124], ["key", 128], ["to", 132], ["enable", 135], ["the", 142], ["translation", 146], ["of", 158], ["research", 161], ["findings", 170], ["to", 179], ["a", 182], ["better", 184], ["care", 191], ["of", 196], ["patients", 199], [".", 207], ["PsyGeNET", 209], ["is", 218], ["a", 221], ["knowledge", 223], ["resource", 233], ["on", 242], ["psychiatric", 245], ["diseases", 257], ["and", 266], ["their", 270], ["genes", 276], [",", 281], ["developed", 283], ["by", 293], ["text", 296], ["mining", 301], ["and", 308], ["curated", 312], ["by", 320], ["domain", 323], ["experts", 330], [".", 337], ["We", 339], ["present", 342], ["psygenet2r", 350], [",", 360], ["an", 362], ["R", 365], ["package", 367], ["that", 375], ["contains", 380], ["a", 389], ["variety", 391], ["of", 399], ["functions", 402], ["for", 412], ["leveraging", 416], ["PsyGeNET", 427], ["database", 436], ["and", 445], ["facilitating", 449], ["its", 462], ["analysis", 466], ["and", 475], ["interpretation", 479], [".", 493], ["The", 495], ["package", 499], ["offers", 507], ["different", 514], ["types", 524], ["of", 530], ["queries", 533], ["to", 541], ["the", 544], ["database", 548], ["along", 557], ["with", 563], ["variety", 568], ["of", 576], ["analysis", 579], ["and", 588], ["visualization", 592], ["tools", 606], [",", 611], ["including", 613], ["the", 623], ["study", 627], ["of", 633], ["the", 636], ["anatomical", 640], ["structures", 651], ["in", 662], ["which", 665], ["the", 671], ["genes", 675], ["are", 681], ["expressed", 685], ["and", 695], ["gaining", 699], ["insight", 707], ["of", 715], ["gene", 718], ["'s", 722], ["molecular", 725], ["function", 735], [".", 743], ["Psygenet2r", 745], ["is", 756], ["especially", 759], ["suited", 770], ["for", 777], ["network", 781], ["medicine", 789], ["analysis", 798], ["of", 807], ["psychiatric", 810], ["disorders", 822], [".", 831], ["The", 833], ["package", 837], ["is", 845], ["implemented", 848], ["in", 860], ["R", 863], ["and", 865], ["is", 869], ["available", 872], ["under", 882], ["MIT", 888], ["license", 892], ["from", 900], ["Bioconductor", 905], ["(", 918], ["http://bioconductor.org/packages/release/bioc/html/psygenet2r.html", 919], [")", 985], [".", 986], ["juanr.gonzalez@isglobal.org", 988], ["or", 1016], ["laura.furlong@upf.edu", 1019], [".", 1040], ["Supplementary", 1042], ["data", 1056], ["are", 1061], ["available", 1065], ["at", 1075], ["Bioinformatics", 1078], ["online", 1093], [".", 1099]]}
{"context": "Denosumab is a human monoclonal antibody which specifically blocks receptor activator of nuclear factor \u03baB ligand and is a very potent antiresorptive drug. Its efficacy in reducing the risk of vertebral, hip and nonskeletal fracture has been proven in a large prospective, randomized multicenter study of 7808 postmenopausal women with osteoporosis [Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial]. Denosumab causes somewhat greater increases in bone mineral density (BMD) than the class of bisphosphonate antiresorptives. Denosumab also causes an increase in bone mass and bone strength in the spine, ultradistal and diaphysis of the radius, proximal tibia and the hip. Recently long-term treatment with denosumab has been shown to cause a continued almost linear increase in total hip and femoral neck BMD beyond 3 years up to 8 years. In this respect, denosumab seems to differ from the bisphosphonate group in which the rate of improvement of BMD diminishes and for some drugs becomes negative after 3-4 years when the process of secondary mineralization flattens out. This unique property of an antiresorptive drug points towards mechanisms of action which differ from the bisphosphonate group. Both types of antiresorptives decrease cortical porosity but contrary to bisphosphonates the reduction in cortical porosity continues with denosumab which, in addition, also seems to cause a slight continuous modeling-based formation of new bone despite suppression of bone remodeling. The net effect is an increase in cortical thickening and bone mass, and increased strength of cortical bone. This may contribute substantially to the significant further reduction of the nonvertebral fracture risk which was found in the long-term denosumab arm of the FREEDOM extension trial during years 4-7.", "qas": [{"question": "Which is the target of the drug Denosumab?", "answers": ["receptor activator of nuclear factor \u03baB ligand", "RANKL", "receptor activator of nuclear factor-\u03baB ligand"], "qid": "d38d490c5d9f45a0818bec552463879b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["the", 23], ["drug", 27], ["Denosumab", 32], ["?", 41]], "detected_answers": [{"text": "receptor activator of nuclear factor-\u03baB ligand", "token_spans": [[9, 15]], "char_spans": [[67, 112]]}]}], "context_tokens": [["Denosumab", 0], ["is", 10], ["a", 13], ["human", 15], ["monoclonal", 21], ["antibody", 32], ["which", 41], ["specifically", 47], ["blocks", 60], ["receptor", 67], ["activator", 76], ["of", 86], ["nuclear", 89], ["factor", 97], ["\u03baB", 104], ["ligand", 107], ["and", 114], ["is", 118], ["a", 121], ["very", 123], ["potent", 128], ["antiresorptive", 135], ["drug", 150], [".", 154], ["Its", 156], ["efficacy", 160], ["in", 169], ["reducing", 172], ["the", 181], ["risk", 185], ["of", 190], ["vertebral", 193], [",", 202], ["hip", 204], ["and", 208], ["nonskeletal", 212], ["fracture", 224], ["has", 233], ["been", 237], ["proven", 242], ["in", 249], ["a", 252], ["large", 254], ["prospective", 260], [",", 271], ["randomized", 273], ["multicenter", 284], ["study", 296], ["of", 302], ["7808", 305], ["postmenopausal", 310], ["women", 325], ["with", 331], ["osteoporosis", 336], ["[", 349], ["Fracture", 350], ["Reduction", 359], ["Evaluation", 369], ["of", 380], ["Denosumab", 383], ["in", 393], ["Osteoporosis", 396], ["Every", 409], ["6", 415], ["Months", 417], ["(", 424], ["FREEDOM", 425], [")", 432], ["trial].", 434], ["Denosumab", 442], ["causes", 452], ["somewhat", 459], ["greater", 468], ["increases", 476], ["in", 486], ["bone", 489], ["mineral", 494], ["density", 502], ["(", 510], ["BMD", 511], [")", 514], ["than", 516], ["the", 521], ["class", 525], ["of", 531], ["bisphosphonate", 534], ["antiresorptives", 549], [".", 564], ["Denosumab", 566], ["also", 576], ["causes", 581], ["an", 588], ["increase", 591], ["in", 600], ["bone", 603], ["mass", 608], ["and", 613], ["bone", 617], ["strength", 622], ["in", 631], ["the", 634], ["spine", 638], [",", 643], ["ultradistal", 645], ["and", 657], ["diaphysis", 661], ["of", 671], ["the", 674], ["radius", 678], [",", 684], ["proximal", 686], ["tibia", 695], ["and", 701], ["the", 705], ["hip", 709], [".", 712], ["Recently", 714], ["long", 723], ["-", 727], ["term", 728], ["treatment", 733], ["with", 743], ["denosumab", 748], ["has", 758], ["been", 762], ["shown", 767], ["to", 773], ["cause", 776], ["a", 782], ["continued", 784], ["almost", 794], ["linear", 801], ["increase", 808], ["in", 817], ["total", 820], ["hip", 826], ["and", 830], ["femoral", 834], ["neck", 842], ["BMD", 847], ["beyond", 851], ["3", 858], ["years", 860], ["up", 866], ["to", 869], ["8", 872], ["years", 874], [".", 879], ["In", 881], ["this", 884], ["respect", 889], [",", 896], ["denosumab", 898], ["seems", 908], ["to", 914], ["differ", 917], ["from", 924], ["the", 929], ["bisphosphonate", 933], ["group", 948], ["in", 954], ["which", 957], ["the", 963], ["rate", 967], ["of", 972], ["improvement", 975], ["of", 987], ["BMD", 990], ["diminishes", 994], ["and", 1005], ["for", 1009], ["some", 1013], ["drugs", 1018], ["becomes", 1024], ["negative", 1032], ["after", 1041], ["3", 1047], ["-", 1048], ["4", 1049], ["years", 1051], ["when", 1057], ["the", 1062], ["process", 1066], ["of", 1074], ["secondary", 1077], ["mineralization", 1087], ["flattens", 1102], ["out", 1111], [".", 1114], ["This", 1116], ["unique", 1121], ["property", 1128], ["of", 1137], ["an", 1140], ["antiresorptive", 1143], ["drug", 1158], ["points", 1163], ["towards", 1170], ["mechanisms", 1178], ["of", 1189], ["action", 1192], ["which", 1199], ["differ", 1205], ["from", 1212], ["the", 1217], ["bisphosphonate", 1221], ["group", 1236], [".", 1241], ["Both", 1243], ["types", 1248], ["of", 1254], ["antiresorptives", 1257], ["decrease", 1273], ["cortical", 1282], ["porosity", 1291], ["but", 1300], ["contrary", 1304], ["to", 1313], ["bisphosphonates", 1316], ["the", 1332], ["reduction", 1336], ["in", 1346], ["cortical", 1349], ["porosity", 1358], ["continues", 1367], ["with", 1377], ["denosumab", 1382], ["which", 1392], [",", 1397], ["in", 1399], ["addition", 1402], [",", 1410], ["also", 1412], ["seems", 1417], ["to", 1423], ["cause", 1426], ["a", 1432], ["slight", 1434], ["continuous", 1441], ["modeling", 1452], ["-", 1460], ["based", 1461], ["formation", 1467], ["of", 1477], ["new", 1480], ["bone", 1484], ["despite", 1489], ["suppression", 1497], ["of", 1509], ["bone", 1512], ["remodeling", 1517], [".", 1527], ["The", 1529], ["net", 1533], ["effect", 1537], ["is", 1544], ["an", 1547], ["increase", 1550], ["in", 1559], ["cortical", 1562], ["thickening", 1571], ["and", 1582], ["bone", 1586], ["mass", 1591], [",", 1595], ["and", 1597], ["increased", 1601], ["strength", 1611], ["of", 1620], ["cortical", 1623], ["bone", 1632], [".", 1636], ["This", 1638], ["may", 1643], ["contribute", 1647], ["substantially", 1658], ["to", 1672], ["the", 1675], ["significant", 1679], ["further", 1691], ["reduction", 1699], ["of", 1709], ["the", 1712], ["nonvertebral", 1716], ["fracture", 1729], ["risk", 1738], ["which", 1743], ["was", 1749], ["found", 1753], ["in", 1759], ["the", 1762], ["long", 1766], ["-", 1770], ["term", 1771], ["denosumab", 1776], ["arm", 1786], ["of", 1790], ["the", 1793], ["FREEDOM", 1797], ["extension", 1805], ["trial", 1815], ["during", 1821], ["years", 1828], ["4", 1834], ["-", 1835], ["7", 1836], [".", 1837]]}
{"context": "The secreted glycoprotein, sclerostin alters bone formation. To gain insights into the mechanism of action of sclerostin, we examined the interactions of sclerostin with bone proteins using a sclerostin affinity capture technique. Proteins from decalcified rat bone were captured on a sclerostin-maltose binding protein (MBP) amylose column, or on a MBP amylose column. The columns were extensively washed with low ionic strength buffer, and bound proteins were eluted with buffer containing 1M sodium chloride. Eluted proteins were separated by denaturing sodium-dodecyl sulfate gel electrophoresis and were identified by mass spectrometry. Several previously unidentified full-length sclerostin-interacting proteins such as alkaline phosphatase, carbonic anhydrase, gremlin-1, fetuin A, midkine, annexin A1 and A2, and collagen \u03b11, which have established roles in bone formation or resorption processes, were bound to the sclerostin-MBP amylose resin but not to the MBP amylose resin. Other full-length sclerostin-interacting proteins such as casein kinase II and secreted frizzled related protein 4 that modulate Wnt signaling were identified. Several peptides derived from proteins such as Phex, asporin and follistatin that regulate bone metabolism also bound sclerostin. Sclerostin interacts with multiple proteins that alter bone formation and resorption and is likely to function by altering several biologically relevant pathways in bone.", "qas": [{"question": "Sclerostin regulates what process?", "answers": ["bone metabolism"], "qid": "c769d26d6d6e49a8bccbfa8ca3020245", "question_tokens": [["Sclerostin", 0], ["regulates", 11], ["what", 21], ["process", 26], ["?", 33]], "detected_answers": [{"text": "bone metabolism", "token_spans": [[208, 209]], "char_spans": [[1238, 1252]]}]}], "context_tokens": [["The", 0], ["secreted", 4], ["glycoprotein", 13], [",", 25], ["sclerostin", 27], ["alters", 38], ["bone", 45], ["formation", 50], [".", 59], ["To", 61], ["gain", 64], ["insights", 69], ["into", 78], ["the", 83], ["mechanism", 87], ["of", 97], ["action", 100], ["of", 107], ["sclerostin", 110], [",", 120], ["we", 122], ["examined", 125], ["the", 134], ["interactions", 138], ["of", 151], ["sclerostin", 154], ["with", 165], ["bone", 170], ["proteins", 175], ["using", 184], ["a", 190], ["sclerostin", 192], ["affinity", 203], ["capture", 212], ["technique", 220], [".", 229], ["Proteins", 231], ["from", 240], ["decalcified", 245], ["rat", 257], ["bone", 261], ["were", 266], ["captured", 271], ["on", 280], ["a", 283], ["sclerostin", 285], ["-", 295], ["maltose", 296], ["binding", 304], ["protein", 312], ["(", 320], ["MBP", 321], [")", 324], ["amylose", 326], ["column", 334], [",", 340], ["or", 342], ["on", 345], ["a", 348], ["MBP", 350], ["amylose", 354], ["column", 362], [".", 368], ["The", 370], ["columns", 374], ["were", 382], ["extensively", 387], ["washed", 399], ["with", 406], ["low", 411], ["ionic", 415], ["strength", 421], ["buffer", 430], [",", 436], ["and", 438], ["bound", 442], ["proteins", 448], ["were", 457], ["eluted", 462], ["with", 469], ["buffer", 474], ["containing", 481], ["1", 492], ["M", 493], ["sodium", 495], ["chloride", 502], [".", 510], ["Eluted", 512], ["proteins", 519], ["were", 528], ["separated", 533], ["by", 543], ["denaturing", 546], ["sodium", 557], ["-", 563], ["dodecyl", 564], ["sulfate", 572], ["gel", 580], ["electrophoresis", 584], ["and", 600], ["were", 604], ["identified", 609], ["by", 620], ["mass", 623], ["spectrometry", 628], [".", 640], ["Several", 642], ["previously", 650], ["unidentified", 661], ["full", 674], ["-", 678], ["length", 679], ["sclerostin", 686], ["-", 696], ["interacting", 697], ["proteins", 709], ["such", 718], ["as", 723], ["alkaline", 726], ["phosphatase", 735], [",", 746], ["carbonic", 748], ["anhydrase", 757], [",", 766], ["gremlin-1", 768], [",", 777], ["fetuin", 779], ["A", 786], [",", 787], ["midkine", 789], [",", 796], ["annexin", 798], ["A1", 806], ["and", 809], ["A2", 813], [",", 815], ["and", 817], ["collagen", 821], ["\u03b11", 830], [",", 832], ["which", 834], ["have", 840], ["established", 845], ["roles", 857], ["in", 863], ["bone", 866], ["formation", 871], ["or", 881], ["resorption", 884], ["processes", 895], [",", 904], ["were", 906], ["bound", 911], ["to", 917], ["the", 920], ["sclerostin", 924], ["-", 934], ["MBP", 935], ["amylose", 939], ["resin", 947], ["but", 953], ["not", 957], ["to", 961], ["the", 964], ["MBP", 968], ["amylose", 972], ["resin", 980], [".", 985], ["Other", 987], ["full", 993], ["-", 997], ["length", 998], ["sclerostin", 1005], ["-", 1015], ["interacting", 1016], ["proteins", 1028], ["such", 1037], ["as", 1042], ["casein", 1045], ["kinase", 1052], ["II", 1059], ["and", 1062], ["secreted", 1066], ["frizzled", 1075], ["related", 1084], ["protein", 1092], ["4", 1100], ["that", 1102], ["modulate", 1107], ["Wnt", 1116], ["signaling", 1120], ["were", 1130], ["identified", 1135], [".", 1145], ["Several", 1147], ["peptides", 1155], ["derived", 1164], ["from", 1172], ["proteins", 1177], ["such", 1186], ["as", 1191], ["Phex", 1194], [",", 1198], ["asporin", 1200], ["and", 1208], ["follistatin", 1212], ["that", 1224], ["regulate", 1229], ["bone", 1238], ["metabolism", 1243], ["also", 1254], ["bound", 1259], ["sclerostin", 1265], [".", 1275], ["Sclerostin", 1277], ["interacts", 1288], ["with", 1298], ["multiple", 1303], ["proteins", 1312], ["that", 1321], ["alter", 1326], ["bone", 1332], ["formation", 1337], ["and", 1347], ["resorption", 1351], ["and", 1362], ["is", 1366], ["likely", 1369], ["to", 1376], ["function", 1379], ["by", 1388], ["altering", 1391], ["several", 1400], ["biologically", 1408], ["relevant", 1421], ["pathways", 1430], ["in", 1439], ["bone", 1442], [".", 1446]]}
{"context": "Mutations in the SLC9A6 gene cause Christianson syndrome in boys. This X-linked syndrome is characterized by profound mental retardation with autistic behavior, microcephaly, epilepsy, ophthalmoplegia, and ataxia. Progressive cerebellar atrophy with motor regression is a remarkable feature in some patients. We report on a 22year-old male patient with Christianson syndrome carrying the novel p.Gln306X mutation. The infantile phenotype suggested pervasive developmental disorder, then profound mental retardation ensued. In later childhood, progressive cerebellar atrophy was diagnosed on serial brain MRIs and motor regression occurred. Furthermore, ophthalmological evaluations showed a retinitis pigmentosum previously unreported in this condition. We conclude that the natural history of the disease in this patient tends to confirm the degenerative nature of Christianson syndrome, and that retinal degeneration may be part of the condition. Before the onset of degeneration, the syndromic association of severe mental retardation, autistic behavior, external ophthalmoplegia, and facial dysmorphism in male patients is a clue to the diagnosis.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "1c8d376fd6a5424aa7f69d6d2222e256", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[3, 3]], "char_spans": [[17, 22]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["SLC9A6", 17], ["gene", 24], ["cause", 29], ["Christianson", 35], ["syndrome", 48], ["in", 57], ["boys", 60], [".", 64], ["This", 66], ["X", 71], ["-", 72], ["linked", 73], ["syndrome", 80], ["is", 89], ["characterized", 92], ["by", 106], ["profound", 109], ["mental", 118], ["retardation", 125], ["with", 137], ["autistic", 142], ["behavior", 151], [",", 159], ["microcephaly", 161], [",", 173], ["epilepsy", 175], [",", 183], ["ophthalmoplegia", 185], [",", 200], ["and", 202], ["ataxia", 206], [".", 212], ["Progressive", 214], ["cerebellar", 226], ["atrophy", 237], ["with", 245], ["motor", 250], ["regression", 256], ["is", 267], ["a", 270], ["remarkable", 272], ["feature", 283], ["in", 291], ["some", 294], ["patients", 299], [".", 307], ["We", 309], ["report", 312], ["on", 319], ["a", 322], ["22year", 324], ["-", 330], ["old", 331], ["male", 335], ["patient", 340], ["with", 348], ["Christianson", 353], ["syndrome", 366], ["carrying", 375], ["the", 384], ["novel", 388], ["p", 394], [".", 395], ["Gln306X", 396], ["mutation", 404], [".", 412], ["The", 414], ["infantile", 418], ["phenotype", 428], ["suggested", 438], ["pervasive", 448], ["developmental", 458], ["disorder", 472], [",", 480], ["then", 482], ["profound", 487], ["mental", 496], ["retardation", 503], ["ensued", 515], [".", 521], ["In", 523], ["later", 526], ["childhood", 532], [",", 541], ["progressive", 543], ["cerebellar", 555], ["atrophy", 566], ["was", 574], ["diagnosed", 578], ["on", 588], ["serial", 591], ["brain", 598], ["MRIs", 604], ["and", 609], ["motor", 613], ["regression", 619], ["occurred", 630], [".", 638], ["Furthermore", 640], [",", 651], ["ophthalmological", 653], ["evaluations", 670], ["showed", 682], ["a", 689], ["retinitis", 691], ["pigmentosum", 701], ["previously", 713], ["unreported", 724], ["in", 735], ["this", 738], ["condition", 743], [".", 752], ["We", 754], ["conclude", 757], ["that", 766], ["the", 771], ["natural", 775], ["history", 783], ["of", 791], ["the", 794], ["disease", 798], ["in", 806], ["this", 809], ["patient", 814], ["tends", 822], ["to", 828], ["confirm", 831], ["the", 839], ["degenerative", 843], ["nature", 856], ["of", 863], ["Christianson", 866], ["syndrome", 879], [",", 887], ["and", 889], ["that", 893], ["retinal", 898], ["degeneration", 906], ["may", 919], ["be", 923], ["part", 926], ["of", 931], ["the", 934], ["condition", 938], [".", 947], ["Before", 949], ["the", 956], ["onset", 960], ["of", 966], ["degeneration", 969], [",", 981], ["the", 983], ["syndromic", 987], ["association", 997], ["of", 1009], ["severe", 1012], ["mental", 1019], ["retardation", 1026], [",", 1037], ["autistic", 1039], ["behavior", 1048], [",", 1056], ["external", 1058], ["ophthalmoplegia", 1067], [",", 1082], ["and", 1084], ["facial", 1088], ["dysmorphism", 1095], ["in", 1107], ["male", 1110], ["patients", 1115], ["is", 1124], ["a", 1127], ["clue", 1129], ["to", 1134], ["the", 1137], ["diagnosis", 1141], [".", 1150]]}
{"context": "Chronic myelogenous leukemia is characterized by the Philadelphia-chromosome, a shortened chromosome 22 which is the result of a reciprocal translocation between chromosome 9 and 22. The fusion gene is called BCR-ABL. After transcription and translation the constitutively activated p210 BCR-ABL oncoprotein is formed. This leads to uncontrolled activation of the ABL tyrosin kinase. Deregulated cellular proliferation and diminished apoptosis of BCR-ABL transformed cells is the result. Expression of the BCR-ABL oncoprotein is sufficient and necessary for the development of a CML phenotype. Imatinib mesylate (Glivec) is a small molecule that binds to the ATP pocket of ABL and blocks downstream signalling events. Imatinib is very effective in the treatment of CML in all stages of the disease. Patients with newly diagnosed chronic phase CML were randomized to imatinib or to interferon plus cytarabine in the IRIS trial. Imatinib showed significantly superior tolerability, hematologic and cytogenetic resposes and increased time to progression. In patients with advanced phase CML, imatinib is less effective and response duration is short. Median overall survival of blast crisis patients is 6.9 months only. Additional BCR-ABL independent chromosomal abnormalities are common in advanced phase CML and result in resistance to imatinib. BCR-ABL kinase-domaine mutations are frequently found in imatinib resistant patients and confer diminished sensitivity to imatinib. Second generation, more powerful ABL kinase inhibitors, which are effective against most of the known mutations are currently tested in clinical trials.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "d9cb4426446f4f91ae4e64614349182c", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[71, 73], [46, 48], [205, 207], [224, 226], [34, 36], [83, 85]], "char_spans": [[447, 453], [288, 294], [1228, 1234], [1345, 1351], [209, 215], [506, 512]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["is", 29], ["characterized", 32], ["by", 46], ["the", 49], ["Philadelphia", 53], ["-", 65], ["chromosome", 66], [",", 76], ["a", 78], ["shortened", 80], ["chromosome", 90], ["22", 101], ["which", 104], ["is", 110], ["the", 113], ["result", 117], ["of", 124], ["a", 127], ["reciprocal", 129], ["translocation", 140], ["between", 154], ["chromosome", 162], ["9", 173], ["and", 175], ["22", 179], [".", 181], ["The", 183], ["fusion", 187], ["gene", 194], ["is", 199], ["called", 202], ["BCR", 209], ["-", 212], ["ABL", 213], [".", 216], ["After", 218], ["transcription", 224], ["and", 238], ["translation", 242], ["the", 254], ["constitutively", 258], ["activated", 273], ["p210", 283], ["BCR", 288], ["-", 291], ["ABL", 292], ["oncoprotein", 296], ["is", 308], ["formed", 311], [".", 317], ["This", 319], ["leads", 324], ["to", 330], ["uncontrolled", 333], ["activation", 346], ["of", 357], ["the", 360], ["ABL", 364], ["tyrosin", 368], ["kinase", 376], [".", 382], ["Deregulated", 384], ["cellular", 396], ["proliferation", 405], ["and", 419], ["diminished", 423], ["apoptosis", 434], ["of", 444], ["BCR", 447], ["-", 450], ["ABL", 451], ["transformed", 455], ["cells", 467], ["is", 473], ["the", 476], ["result", 480], [".", 486], ["Expression", 488], ["of", 499], ["the", 502], ["BCR", 506], ["-", 509], ["ABL", 510], ["oncoprotein", 514], ["is", 526], ["sufficient", 529], ["and", 540], ["necessary", 544], ["for", 554], ["the", 558], ["development", 562], ["of", 574], ["a", 577], ["CML", 579], ["phenotype", 583], [".", 592], ["Imatinib", 594], ["mesylate", 603], ["(", 612], ["Glivec", 613], [")", 619], ["is", 621], ["a", 624], ["small", 626], ["molecule", 632], ["that", 641], ["binds", 646], ["to", 652], ["the", 655], ["ATP", 659], ["pocket", 663], ["of", 670], ["ABL", 673], ["and", 677], ["blocks", 681], ["downstream", 688], ["signalling", 699], ["events", 710], [".", 716], ["Imatinib", 718], ["is", 727], ["very", 730], ["effective", 735], ["in", 745], ["the", 748], ["treatment", 752], ["of", 762], ["CML", 765], ["in", 769], ["all", 772], ["stages", 776], ["of", 783], ["the", 786], ["disease", 790], [".", 797], ["Patients", 799], ["with", 808], ["newly", 813], ["diagnosed", 819], ["chronic", 829], ["phase", 837], ["CML", 843], ["were", 847], ["randomized", 852], ["to", 863], ["imatinib", 866], ["or", 875], ["to", 878], ["interferon", 881], ["plus", 892], ["cytarabine", 897], ["in", 908], ["the", 911], ["IRIS", 915], ["trial", 920], [".", 925], ["Imatinib", 927], ["showed", 936], ["significantly", 943], ["superior", 957], ["tolerability", 966], [",", 978], ["hematologic", 980], ["and", 992], ["cytogenetic", 996], ["resposes", 1008], ["and", 1017], ["increased", 1021], ["time", 1031], ["to", 1036], ["progression", 1039], [".", 1050], ["In", 1052], ["patients", 1055], ["with", 1064], ["advanced", 1069], ["phase", 1078], ["CML", 1084], [",", 1087], ["imatinib", 1089], ["is", 1098], ["less", 1101], ["effective", 1106], ["and", 1116], ["response", 1120], ["duration", 1129], ["is", 1138], ["short", 1141], [".", 1146], ["Median", 1148], ["overall", 1155], ["survival", 1163], ["of", 1172], ["blast", 1175], ["crisis", 1181], ["patients", 1188], ["is", 1197], ["6.9", 1200], ["months", 1204], ["only", 1211], [".", 1215], ["Additional", 1217], ["BCR", 1228], ["-", 1231], ["ABL", 1232], ["independent", 1236], ["chromosomal", 1248], ["abnormalities", 1260], ["are", 1274], ["common", 1278], ["in", 1285], ["advanced", 1288], ["phase", 1297], ["CML", 1303], ["and", 1307], ["result", 1311], ["in", 1318], ["resistance", 1321], ["to", 1332], ["imatinib", 1335], [".", 1343], ["BCR", 1345], ["-", 1348], ["ABL", 1349], ["kinase", 1353], ["-", 1359], ["domaine", 1360], ["mutations", 1368], ["are", 1378], ["frequently", 1382], ["found", 1393], ["in", 1399], ["imatinib", 1402], ["resistant", 1411], ["patients", 1421], ["and", 1430], ["confer", 1434], ["diminished", 1441], ["sensitivity", 1452], ["to", 1464], ["imatinib", 1467], [".", 1475], ["Second", 1477], ["generation", 1484], [",", 1494], ["more", 1496], ["powerful", 1501], ["ABL", 1510], ["kinase", 1514], ["inhibitors", 1521], [",", 1531], ["which", 1533], ["are", 1539], ["effective", 1543], ["against", 1553], ["most", 1561], ["of", 1566], ["the", 1569], ["known", 1573], ["mutations", 1579], ["are", 1589], ["currently", 1593], ["tested", 1603], ["in", 1610], ["clinical", 1613], ["trials", 1622], [".", 1628]]}
{"context": "To investigate the clinicopathologic features of focal cortical dysplasia (FCD) in patients with refractory epilepsy. The clinical, radiologic and pathologic features of 38 cases of FCD receiving surgical treatment in 2005 were reviewed retrospectively. The mean age of disease onset was 9.2 years. The disease lasted for 11.9 years on average and often presented as complex partial seizure. Radiologic examination revealed hippocampal sclerosis, or abnormal signals in the grey matter in 21 cases. According to Palmini's classification system, the following pathologic subgroups were identified: FCD type IA (3/38), FCD type IB (20/38), FCD type IIA (5/38) and FCD type IIB (5/38). The remaining 5 cases were classified as mild cortical dysplasia. Topographically, FCD type II was often seen in the extratemporal region (8/10), predominantly in the frontal lobe (5/8). Dual pathology was identified only in cases with FCD type IB. Immunohistochemical study showed that the giant neurons, immature neurons and dysmorphic neurons were strongly positive for NeuN. A small number of balloon cells expressed nestin. FCD is a common cause of refractory epilepsy. FCD type IB is the predominant pathologic subtype. Associated hippocampal sclerosis is sometimes seen. Clinicopathologic differences between FCD type I and FCD type II are observed.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "c273e4acf5d244feb5d5fca095c0254f", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[6, 8]], "char_spans": [[49, 72]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["clinicopathologic", 19], ["features", 37], ["of", 46], ["focal", 49], ["cortical", 55], ["dysplasia", 64], ["(", 74], ["FCD", 75], [")", 78], ["in", 80], ["patients", 83], ["with", 92], ["refractory", 97], ["epilepsy", 108], [".", 116], ["The", 118], ["clinical", 122], [",", 130], ["radiologic", 132], ["and", 143], ["pathologic", 147], ["features", 158], ["of", 167], ["38", 170], ["cases", 173], ["of", 179], ["FCD", 182], ["receiving", 186], ["surgical", 196], ["treatment", 205], ["in", 215], ["2005", 218], ["were", 223], ["reviewed", 228], ["retrospectively", 237], [".", 252], ["The", 254], ["mean", 258], ["age", 263], ["of", 267], ["disease", 270], ["onset", 278], ["was", 284], ["9.2", 288], ["years", 292], [".", 297], ["The", 299], ["disease", 303], ["lasted", 311], ["for", 318], ["11.9", 322], ["years", 327], ["on", 333], ["average", 336], ["and", 344], ["often", 348], ["presented", 354], ["as", 364], ["complex", 367], ["partial", 375], ["seizure", 383], [".", 390], ["Radiologic", 392], ["examination", 403], ["revealed", 415], ["hippocampal", 424], ["sclerosis", 436], [",", 445], ["or", 447], ["abnormal", 450], ["signals", 459], ["in", 467], ["the", 470], ["grey", 474], ["matter", 479], ["in", 486], ["21", 489], ["cases", 492], [".", 497], ["According", 499], ["to", 509], ["Palmini", 512], ["'s", 519], ["classification", 522], ["system", 537], [",", 543], ["the", 545], ["following", 549], ["pathologic", 559], ["subgroups", 570], ["were", 580], ["identified", 585], [":", 595], ["FCD", 597], ["type", 601], ["IA", 606], ["(", 609], ["3/38", 610], [")", 614], [",", 615], ["FCD", 617], ["type", 621], ["IB", 626], ["(", 629], ["20/38", 630], [")", 635], [",", 636], ["FCD", 638], ["type", 642], ["IIA", 647], ["(", 651], ["5/38", 652], [")", 656], ["and", 658], ["FCD", 662], ["type", 666], ["IIB", 671], ["(", 675], ["5/38", 676], [")", 680], [".", 681], ["The", 683], ["remaining", 687], ["5", 697], ["cases", 699], ["were", 705], ["classified", 710], ["as", 721], ["mild", 724], ["cortical", 729], ["dysplasia", 738], [".", 747], ["Topographically", 749], [",", 764], ["FCD", 766], ["type", 770], ["II", 775], ["was", 778], ["often", 782], ["seen", 788], ["in", 793], ["the", 796], ["extratemporal", 800], ["region", 814], ["(", 821], ["8/10", 822], [")", 826], [",", 827], ["predominantly", 829], ["in", 843], ["the", 846], ["frontal", 850], ["lobe", 858], ["(", 863], ["5/8", 864], [")", 867], [".", 868], ["Dual", 870], ["pathology", 875], ["was", 885], ["identified", 889], ["only", 900], ["in", 905], ["cases", 908], ["with", 914], ["FCD", 919], ["type", 923], ["IB", 928], [".", 930], ["Immunohistochemical", 932], ["study", 952], ["showed", 958], ["that", 965], ["the", 970], ["giant", 974], ["neurons", 980], [",", 987], ["immature", 989], ["neurons", 998], ["and", 1006], ["dysmorphic", 1010], ["neurons", 1021], ["were", 1029], ["strongly", 1034], ["positive", 1043], ["for", 1052], ["NeuN.", 1056], ["A", 1062], ["small", 1064], ["number", 1070], ["of", 1077], ["balloon", 1080], ["cells", 1088], ["expressed", 1094], ["nestin", 1104], [".", 1110], ["FCD", 1112], ["is", 1116], ["a", 1119], ["common", 1121], ["cause", 1128], ["of", 1134], ["refractory", 1137], ["epilepsy", 1148], [".", 1156], ["FCD", 1158], ["type", 1162], ["IB", 1167], ["is", 1170], ["the", 1173], ["predominant", 1177], ["pathologic", 1189], ["subtype", 1200], [".", 1207], ["Associated", 1209], ["hippocampal", 1220], ["sclerosis", 1232], ["is", 1242], ["sometimes", 1245], ["seen", 1255], [".", 1259], ["Clinicopathologic", 1261], ["differences", 1279], ["between", 1291], ["FCD", 1299], ["type", 1303], ["I", 1308], ["and", 1310], ["FCD", 1314], ["type", 1318], ["II", 1323], ["are", 1326], ["observed", 1330], [".", 1338]]}
{"context": "An outbreak of Clostridium difficile infection (CDI) caused by ribotype 027 (B1/NAP1) began in our hospital in November 2014, and produced 141 episodes in the following months. The aim of this study is to describe this outbreak, assess risk factors for recurrence of CDI-027 and to analyze the implementation of a novel treatment strategy. This is a prospective study of all patients with CDI-027, from November 2014 to November 2015. The epidemiological data were collected daily for each patient. We compared clinical characteristics and treatment between patients with and without recurrence of CDI-027. Interestingly, liver cirrhosis was present in 22% of the patients, and most of them received prophylaxis for hepatic encephalopathy with rifaximin. Patients were also taking antimicrobial drugs (93.6%) and proton pump inhibitors (80.1%). Overall, 27 (23.5%) patients had a first recurrence of CDI-027. Liver cirrhosis increased the risk of recurrence (44.4% vs 14.8%). Patients treated with a prolonged oral vancomycin regimen vs the conventional regimen (oral metronidazole or 10\u00a0days of vancomycin) had fewer recurrences (8.6 versus 44.7% [p\u00a0\u2264\u00a00.01]; OR, 0.91; 95% CI, 0.028-0.294) and less attributable mortality (0% versus 7.1%; p\u00a0=\u00a00.058). We report an outbreak of CDI-027, mainly in patients with liver cirrhosis. Recurrence of CDI-027 was more common in those patients. A novel approach involving high-dose prolonged vancomycin taper as a first-line treatment, together with a bundle of outbreak measures, seemed to reduce the number of cases of CDI-027, recurrences, and attributable mortality. Nevertheless, this approach warrants further investigation.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "38addabed56946b49d470b639537d475", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[11, 12]], "char_spans": [[63, 74]]}]}], "context_tokens": [["An", 0], ["outbreak", 3], ["of", 12], ["Clostridium", 15], ["difficile", 27], ["infection", 37], ["(", 47], ["CDI", 48], [")", 51], ["caused", 53], ["by", 60], ["ribotype", 63], ["027", 72], ["(", 76], ["B1/NAP1", 77], [")", 84], ["began", 86], ["in", 92], ["our", 95], ["hospital", 99], ["in", 108], ["November", 111], ["2014", 120], [",", 124], ["and", 126], ["produced", 130], ["141", 139], ["episodes", 143], ["in", 152], ["the", 155], ["following", 159], ["months", 169], [".", 175], ["The", 177], ["aim", 181], ["of", 185], ["this", 188], ["study", 193], ["is", 199], ["to", 202], ["describe", 205], ["this", 214], ["outbreak", 219], [",", 227], ["assess", 229], ["risk", 236], ["factors", 241], ["for", 249], ["recurrence", 253], ["of", 264], ["CDI-027", 267], ["and", 275], ["to", 279], ["analyze", 282], ["the", 290], ["implementation", 294], ["of", 309], ["a", 312], ["novel", 314], ["treatment", 320], ["strategy", 330], [".", 338], ["This", 340], ["is", 345], ["a", 348], ["prospective", 350], ["study", 362], ["of", 368], ["all", 371], ["patients", 375], ["with", 384], ["CDI-027", 389], [",", 396], ["from", 398], ["November", 403], ["2014", 412], ["to", 417], ["November", 420], ["2015", 429], [".", 433], ["The", 435], ["epidemiological", 439], ["data", 455], ["were", 460], ["collected", 465], ["daily", 475], ["for", 481], ["each", 485], ["patient", 490], [".", 497], ["We", 499], ["compared", 502], ["clinical", 511], ["characteristics", 520], ["and", 536], ["treatment", 540], ["between", 550], ["patients", 558], ["with", 567], ["and", 572], ["without", 576], ["recurrence", 584], ["of", 595], ["CDI-027", 598], [".", 605], ["Interestingly", 607], [",", 620], ["liver", 622], ["cirrhosis", 628], ["was", 638], ["present", 642], ["in", 650], ["22", 653], ["%", 655], ["of", 657], ["the", 660], ["patients", 664], [",", 672], ["and", 674], ["most", 678], ["of", 683], ["them", 686], ["received", 691], ["prophylaxis", 700], ["for", 712], ["hepatic", 716], ["encephalopathy", 724], ["with", 739], ["rifaximin", 744], [".", 753], ["Patients", 755], ["were", 764], ["also", 769], ["taking", 774], ["antimicrobial", 781], ["drugs", 795], ["(", 801], ["93.6", 802], ["%", 806], [")", 807], ["and", 809], ["proton", 813], ["pump", 820], ["inhibitors", 825], ["(", 836], ["80.1", 837], ["%", 841], [")", 842], [".", 843], ["Overall", 845], [",", 852], ["27", 854], ["(", 857], ["23.5", 858], ["%", 862], [")", 863], ["patients", 865], ["had", 874], ["a", 878], ["first", 880], ["recurrence", 886], ["of", 897], ["CDI-027", 900], [".", 907], ["Liver", 909], ["cirrhosis", 915], ["increased", 925], ["the", 935], ["risk", 939], ["of", 944], ["recurrence", 947], ["(", 958], ["44.4", 959], ["%", 963], ["vs", 965], ["14.8", 968], ["%", 972], [")", 973], [".", 974], ["Patients", 976], ["treated", 985], ["with", 993], ["a", 998], ["prolonged", 1000], ["oral", 1010], ["vancomycin", 1015], ["regimen", 1026], ["vs", 1034], ["the", 1037], ["conventional", 1041], ["regimen", 1054], ["(", 1062], ["oral", 1063], ["metronidazole", 1068], ["or", 1082], ["10", 1085], ["days", 1088], ["of", 1093], ["vancomycin", 1096], [")", 1106], ["had", 1108], ["fewer", 1112], ["recurrences", 1118], ["(", 1130], ["8.6", 1131], ["versus", 1135], ["44.7", 1142], ["%", 1146], ["[", 1148], ["p", 1149], ["\u2264", 1151], ["0.01", 1153], ["]", 1157], [";", 1158], ["OR", 1160], [",", 1162], ["0.91", 1164], [";", 1168], ["95", 1170], ["%", 1172], ["CI", 1174], [",", 1176], ["0.028", 1178], ["-", 1183], ["0.294", 1184], [")", 1189], ["and", 1191], ["less", 1195], ["attributable", 1200], ["mortality", 1213], ["(", 1223], ["0", 1224], ["%", 1225], ["versus", 1227], ["7.1", 1234], ["%", 1237], [";", 1238], ["p", 1240], ["=", 1242], ["0.058", 1244], [")", 1249], [".", 1250], ["We", 1252], ["report", 1255], ["an", 1262], ["outbreak", 1265], ["of", 1274], ["CDI-027", 1277], [",", 1284], ["mainly", 1286], ["in", 1293], ["patients", 1296], ["with", 1305], ["liver", 1310], ["cirrhosis", 1316], [".", 1325], ["Recurrence", 1327], ["of", 1338], ["CDI-027", 1341], ["was", 1349], ["more", 1353], ["common", 1358], ["in", 1365], ["those", 1368], ["patients", 1374], [".", 1382], ["A", 1384], ["novel", 1386], ["approach", 1392], ["involving", 1401], ["high", 1411], ["-", 1415], ["dose", 1416], ["prolonged", 1421], ["vancomycin", 1431], ["taper", 1442], ["as", 1448], ["a", 1451], ["first", 1453], ["-", 1458], ["line", 1459], ["treatment", 1464], [",", 1473], ["together", 1475], ["with", 1484], ["a", 1489], ["bundle", 1491], ["of", 1498], ["outbreak", 1501], ["measures", 1510], [",", 1518], ["seemed", 1520], ["to", 1527], ["reduce", 1530], ["the", 1537], ["number", 1541], ["of", 1548], ["cases", 1551], ["of", 1557], ["CDI-027", 1560], [",", 1567], ["recurrences", 1569], [",", 1580], ["and", 1582], ["attributable", 1586], ["mortality", 1599], [".", 1608], ["Nevertheless", 1610], [",", 1622], ["this", 1624], ["approach", 1629], ["warrants", 1638], ["further", 1647], ["investigation", 1655], [".", 1668]]}
{"context": "McLeod syndrome is caused by mutations of XK, an X-chromosomal gene of unknown function. Originally defined as a peculiar Kell blood group variant, the disease affects multiple organs, including the nervous system, but is certainly underdiagnosed. We analyzed the mutations and clinical findings of 22 affected men, aged 27 to 72 years. Fifteen different XK mutations were found, nine of which were novel, including the one of the eponymous case McLeod. Their common result is predicted absence or truncation of the XK protein. All patients showed elevated levels of muscle creatine phosphokinase, but clinical myopathy was less common. A peripheral neuropathy with areflexia was found in all but 2 patients. The central nervous system was affected in 15 patients, as obvious from the occurrence of seizures, cognitive impairment, psychopathology, and choreatic movements. Neuroimaging emphasized the particular involvement of the basal ganglia, which was also detected in 1 asymptomatic young patient. Most features develop with age, mainly after the fourth decade. The resemblance of McLeod syndrome with Huntington's disease and with autosomal recessive chorea-acanthocytosis suggests that the corresponding proteins--XK, huntingtin, and chorein--might belong to a common pathway, the dysfunction of which causes degeneration of the basal ganglia.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "8f600aec47fb4b109b628824fc85d81f", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[64, 64], [208, 208], [7, 7], [94, 94]], "char_spans": [[355, 356], [1221, 1222], [42, 43], [516, 517]]}]}], "context_tokens": [["McLeod", 0], ["syndrome", 7], ["is", 16], ["caused", 19], ["by", 26], ["mutations", 29], ["of", 39], ["XK", 42], [",", 44], ["an", 46], ["X", 49], ["-", 50], ["chromosomal", 51], ["gene", 63], ["of", 68], ["unknown", 71], ["function", 79], [".", 87], ["Originally", 89], ["defined", 100], ["as", 108], ["a", 111], ["peculiar", 113], ["Kell", 122], ["blood", 127], ["group", 133], ["variant", 139], [",", 146], ["the", 148], ["disease", 152], ["affects", 160], ["multiple", 168], ["organs", 177], [",", 183], ["including", 185], ["the", 195], ["nervous", 199], ["system", 207], [",", 213], ["but", 215], ["is", 219], ["certainly", 222], ["underdiagnosed", 232], [".", 246], ["We", 248], ["analyzed", 251], ["the", 260], ["mutations", 264], ["and", 274], ["clinical", 278], ["findings", 287], ["of", 296], ["22", 299], ["affected", 302], ["men", 311], [",", 314], ["aged", 316], ["27", 321], ["to", 324], ["72", 327], ["years", 330], [".", 335], ["Fifteen", 337], ["different", 345], ["XK", 355], ["mutations", 358], ["were", 368], ["found", 373], [",", 378], ["nine", 380], ["of", 385], ["which", 388], ["were", 394], ["novel", 399], [",", 404], ["including", 406], ["the", 416], ["one", 420], ["of", 424], ["the", 427], ["eponymous", 431], ["case", 441], ["McLeod", 446], [".", 452], ["Their", 454], ["common", 460], ["result", 467], ["is", 474], ["predicted", 477], ["absence", 487], ["or", 495], ["truncation", 498], ["of", 509], ["the", 512], ["XK", 516], ["protein", 519], [".", 526], ["All", 528], ["patients", 532], ["showed", 541], ["elevated", 548], ["levels", 557], ["of", 564], ["muscle", 567], ["creatine", 574], ["phosphokinase", 583], [",", 596], ["but", 598], ["clinical", 602], ["myopathy", 611], ["was", 620], ["less", 624], ["common", 629], [".", 635], ["A", 637], ["peripheral", 639], ["neuropathy", 650], ["with", 661], ["areflexia", 666], ["was", 676], ["found", 680], ["in", 686], ["all", 689], ["but", 693], ["2", 697], ["patients", 699], [".", 707], ["The", 709], ["central", 713], ["nervous", 721], ["system", 729], ["was", 736], ["affected", 740], ["in", 749], ["15", 752], ["patients", 755], [",", 763], ["as", 765], ["obvious", 768], ["from", 776], ["the", 781], ["occurrence", 785], ["of", 796], ["seizures", 799], [",", 807], ["cognitive", 809], ["impairment", 819], [",", 829], ["psychopathology", 831], [",", 846], ["and", 848], ["choreatic", 852], ["movements", 862], [".", 871], ["Neuroimaging", 873], ["emphasized", 886], ["the", 897], ["particular", 901], ["involvement", 912], ["of", 924], ["the", 927], ["basal", 931], ["ganglia", 937], [",", 944], ["which", 946], ["was", 952], ["also", 956], ["detected", 961], ["in", 970], ["1", 973], ["asymptomatic", 975], ["young", 988], ["patient", 994], [".", 1001], ["Most", 1003], ["features", 1008], ["develop", 1017], ["with", 1025], ["age", 1030], [",", 1033], ["mainly", 1035], ["after", 1042], ["the", 1048], ["fourth", 1052], ["decade", 1059], [".", 1065], ["The", 1067], ["resemblance", 1071], ["of", 1083], ["McLeod", 1086], ["syndrome", 1093], ["with", 1102], ["Huntington", 1107], ["'s", 1117], ["disease", 1120], ["and", 1128], ["with", 1132], ["autosomal", 1137], ["recessive", 1147], ["chorea", 1157], ["-", 1163], ["acanthocytosis", 1164], ["suggests", 1179], ["that", 1188], ["the", 1193], ["corresponding", 1197], ["proteins", 1211], ["--", 1219], ["XK", 1221], [",", 1223], ["huntingtin", 1225], [",", 1235], ["and", 1237], ["chorein", 1241], ["--", 1248], ["might", 1250], ["belong", 1256], ["to", 1263], ["a", 1266], ["common", 1268], ["pathway", 1275], [",", 1282], ["the", 1284], ["dysfunction", 1288], ["of", 1300], ["which", 1303], ["causes", 1309], ["degeneration", 1316], ["of", 1329], ["the", 1332], ["basal", 1336], ["ganglia", 1342], [".", 1349]]}
{"context": "Previously, autosomal dominant catecholaminergic polymorphic ventricular tachycardia (CPVT [1]) was mapped to chromosome 1q42-43 with identification of pathogenic mutations in RYR2. Autosomal recessive CPVT (2) was mapped to chromosome 1p13-21, leading to the identification of mutations in CASQ2. In this study, we aimed to elucidate clinical phenotypes of a new variant of CPVT (3) in an inbred Arab family and also delineate the chromosomal location of the gene causing CPVT (3). In a highly inbred family, clinical symptoms of CPVT appeared early in childhood (7-12 years) and in three of the four cases, the first appearance of symptoms turned into a fatal outcome. Parents of the affected children were first-degree cousins and without any symptoms. Segregation analysis suggested an autosomal recessive inheritance. A genome-wide search using polymorphic DNA markers mapped the disease locus to a 25-Mb interval on chromosome 7p14-p22. A maximal multipoint LOD score of 3.17 was obtained at marker D7S493. Sequencing of putative candidate genes, SP4, NPY, FKBP9, FKBP14, PDE1C, and TBX20, in and around this locus, did not reveal any mutation. We have identified a novel highly malignant autosomal recessive form of CPVT and mapped this disorder to a 25-Mb interval on chromosome 7p14-p22.", "qas": [{"question": "What is the inheritance pattern of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) caused by RYR2 mutations?", "answers": ["autosomal dominant"], "qid": "67b5647fc6814b5d880a3bc12a5c419c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["inheritance", 12], ["pattern", 24], ["of", 32], ["Catecholaminergic", 35], ["Polymorphic", 53], ["Ventricular", 65], ["Tachycardia", 77], ["(", 89], ["CPVT", 90], [")", 94], ["caused", 96], ["by", 103], ["RYR2", 106], ["mutations", 111], ["?", 120]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[2, 3]], "char_spans": [[12, 29]]}]}], "context_tokens": [["Previously", 0], [",", 10], ["autosomal", 12], ["dominant", 22], ["catecholaminergic", 31], ["polymorphic", 49], ["ventricular", 61], ["tachycardia", 73], ["(", 85], ["CPVT", 86], ["[", 91], ["1", 92], ["]", 93], [")", 94], ["was", 96], ["mapped", 100], ["to", 107], ["chromosome", 110], ["1q42", 121], ["-", 125], ["43", 126], ["with", 129], ["identification", 134], ["of", 149], ["pathogenic", 152], ["mutations", 163], ["in", 173], ["RYR2", 176], [".", 180], ["Autosomal", 182], ["recessive", 192], ["CPVT", 202], ["(", 207], ["2", 208], [")", 209], ["was", 211], ["mapped", 215], ["to", 222], ["chromosome", 225], ["1p13", 236], ["-", 240], ["21", 241], [",", 243], ["leading", 245], ["to", 253], ["the", 256], ["identification", 260], ["of", 275], ["mutations", 278], ["in", 288], ["CASQ2", 291], [".", 296], ["In", 298], ["this", 301], ["study", 306], [",", 311], ["we", 313], ["aimed", 316], ["to", 322], ["elucidate", 325], ["clinical", 335], ["phenotypes", 344], ["of", 355], ["a", 358], ["new", 360], ["variant", 364], ["of", 372], ["CPVT", 375], ["(", 380], ["3", 381], [")", 382], ["in", 384], ["an", 387], ["inbred", 390], ["Arab", 397], ["family", 402], ["and", 409], ["also", 413], ["delineate", 418], ["the", 428], ["chromosomal", 432], ["location", 444], ["of", 453], ["the", 456], ["gene", 460], ["causing", 465], ["CPVT", 473], ["(", 478], ["3", 479], [")", 480], [".", 481], ["In", 483], ["a", 486], ["highly", 488], ["inbred", 495], ["family", 502], [",", 508], ["clinical", 510], ["symptoms", 519], ["of", 528], ["CPVT", 531], ["appeared", 536], ["early", 545], ["in", 551], ["childhood", 554], ["(", 564], ["7", 565], ["-", 566], ["12", 567], ["years", 570], [")", 575], ["and", 577], ["in", 581], ["three", 584], ["of", 590], ["the", 593], ["four", 597], ["cases", 602], [",", 607], ["the", 609], ["first", 613], ["appearance", 619], ["of", 630], ["symptoms", 633], ["turned", 642], ["into", 649], ["a", 654], ["fatal", 656], ["outcome", 662], [".", 669], ["Parents", 671], ["of", 679], ["the", 682], ["affected", 686], ["children", 695], ["were", 704], ["first", 709], ["-", 714], ["degree", 715], ["cousins", 722], ["and", 730], ["without", 734], ["any", 742], ["symptoms", 746], [".", 754], ["Segregation", 756], ["analysis", 768], ["suggested", 777], ["an", 787], ["autosomal", 790], ["recessive", 800], ["inheritance", 810], [".", 821], ["A", 823], ["genome", 825], ["-", 831], ["wide", 832], ["search", 837], ["using", 844], ["polymorphic", 850], ["DNA", 862], ["markers", 866], ["mapped", 874], ["the", 881], ["disease", 885], ["locus", 893], ["to", 899], ["a", 902], ["25-Mb", 904], ["interval", 910], ["on", 919], ["chromosome", 922], ["7p14-p22", 933], [".", 941], ["A", 943], ["maximal", 945], ["multipoint", 953], ["LOD", 964], ["score", 968], ["of", 974], ["3.17", 977], ["was", 982], ["obtained", 986], ["at", 995], ["marker", 998], ["D7S493", 1005], [".", 1011], ["Sequencing", 1013], ["of", 1024], ["putative", 1027], ["candidate", 1036], ["genes", 1046], [",", 1051], ["SP4", 1053], [",", 1056], ["NPY", 1058], [",", 1061], ["FKBP9", 1063], [",", 1068], ["FKBP14", 1070], [",", 1076], ["PDE1C", 1078], [",", 1083], ["and", 1085], ["TBX20", 1089], [",", 1094], ["in", 1096], ["and", 1099], ["around", 1103], ["this", 1110], ["locus", 1115], [",", 1120], ["did", 1122], ["not", 1126], ["reveal", 1130], ["any", 1137], ["mutation", 1141], [".", 1149], ["We", 1151], ["have", 1154], ["identified", 1159], ["a", 1170], ["novel", 1172], ["highly", 1178], ["malignant", 1185], ["autosomal", 1195], ["recessive", 1205], ["form", 1215], ["of", 1220], ["CPVT", 1223], ["and", 1228], ["mapped", 1232], ["this", 1239], ["disorder", 1244], ["to", 1253], ["a", 1256], ["25-Mb", 1258], ["interval", 1264], ["on", 1273], ["chromosome", 1276], ["7p14-p22", 1287], [".", 1295]]}
{"context": "Allele-specific gene silencing by RNA interference (RNAi) is therapeutically useful for specifically suppressing the expression of alleles associated with disease. To realize such allele-specific RNAi (ASPRNAi), the design and assessment of small interfering RNA (siRNA) duplexes conferring ASP-RNAi is vital, but is also difficult. Here, we show ASP-RNAi against the Swedish- and London-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease using two reporter alleles encoding the Photinus and Renilla luciferase genes and carrying mutant and wild-type allelic sequences in their 3'-untranslated regions. We examined the effects of siRNA duplexes against the mutant alleles in allele-specific gene silencing and off-target silencing against the wild-type allele under heterozygous conditions, which were generated by cotransfecting the reporter alleles and siRNA duplexes into cultured human cells. Consistently, the siRNA duplexes determined to confer ASP-RNAi also inhibited the expression of the bona fide mutant APP and the production of either amyloid beta 40- or 42-peptide in Cos-7 cells expressing both the full-length Swedish- and wild-type APP alleles. The present data suggest that the system with reporter alleles may permit the preclinical assessment of siRNA duplexes conferring ASP-RNAi, and thus contribute to the design and selection of the most suitable of such siRNA duplexes.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "32973e8f67554664bd82736f4b992923", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[84, 86]], "char_spans": [[454, 472]]}]}], "context_tokens": [["Allele", 0], ["-", 6], ["specific", 7], ["gene", 16], ["silencing", 21], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["is", 58], ["therapeutically", 61], ["useful", 77], ["for", 84], ["specifically", 88], ["suppressing", 101], ["the", 113], ["expression", 117], ["of", 128], ["alleles", 131], ["associated", 139], ["with", 150], ["disease", 155], [".", 162], ["To", 164], ["realize", 167], ["such", 175], ["allele", 180], ["-", 186], ["specific", 187], ["RNAi", 196], ["(", 201], ["ASPRNAi", 202], [")", 209], [",", 210], ["the", 212], ["design", 216], ["and", 223], ["assessment", 227], ["of", 238], ["small", 241], ["interfering", 247], ["RNA", 259], ["(", 263], ["siRNA", 264], [")", 269], ["duplexes", 271], ["conferring", 280], ["ASP", 291], ["-", 294], ["RNAi", 295], ["is", 300], ["vital", 303], [",", 308], ["but", 310], ["is", 314], ["also", 317], ["difficult", 322], [".", 331], ["Here", 333], [",", 337], ["we", 339], ["show", 342], ["ASP", 347], ["-", 350], ["RNAi", 351], ["against", 356], ["the", 364], ["Swedish-", 368], ["and", 377], ["London", 381], ["-", 387], ["type", 388], ["amyloid", 393], ["precursor", 401], ["protein", 411], ["(", 419], ["APP", 420], [")", 423], ["variants", 425], ["related", 434], ["to", 442], ["familial", 445], ["Alzheimer", 454], ["'s", 463], ["disease", 466], ["using", 474], ["two", 480], ["reporter", 484], ["alleles", 493], ["encoding", 501], ["the", 510], ["Photinus", 514], ["and", 523], ["Renilla", 527], ["luciferase", 535], ["genes", 546], ["and", 552], ["carrying", 556], ["mutant", 565], ["and", 572], ["wild", 576], ["-", 580], ["type", 581], ["allelic", 586], ["sequences", 594], ["in", 604], ["their", 607], ["3'-untranslated", 613], ["regions", 629], [".", 636], ["We", 638], ["examined", 641], ["the", 650], ["effects", 654], ["of", 662], ["siRNA", 665], ["duplexes", 671], ["against", 680], ["the", 688], ["mutant", 692], ["alleles", 699], ["in", 707], ["allele", 710], ["-", 716], ["specific", 717], ["gene", 726], ["silencing", 731], ["and", 741], ["off", 745], ["-", 748], ["target", 749], ["silencing", 756], ["against", 766], ["the", 774], ["wild", 778], ["-", 782], ["type", 783], ["allele", 788], ["under", 795], ["heterozygous", 801], ["conditions", 814], [",", 824], ["which", 826], ["were", 832], ["generated", 837], ["by", 847], ["cotransfecting", 850], ["the", 865], ["reporter", 869], ["alleles", 878], ["and", 886], ["siRNA", 890], ["duplexes", 896], ["into", 905], ["cultured", 910], ["human", 919], ["cells", 925], [".", 930], ["Consistently", 932], [",", 944], ["the", 946], ["siRNA", 950], ["duplexes", 956], ["determined", 965], ["to", 976], ["confer", 979], ["ASP", 986], ["-", 989], ["RNAi", 990], ["also", 995], ["inhibited", 1000], ["the", 1010], ["expression", 1014], ["of", 1025], ["the", 1028], ["bona", 1032], ["fide", 1037], ["mutant", 1042], ["APP", 1049], ["and", 1053], ["the", 1057], ["production", 1061], ["of", 1072], ["either", 1075], ["amyloid", 1082], ["beta", 1090], ["40-", 1095], ["or", 1099], ["42-peptide", 1102], ["in", 1113], ["Cos-7", 1116], ["cells", 1122], ["expressing", 1128], ["both", 1139], ["the", 1144], ["full", 1148], ["-", 1152], ["length", 1153], ["Swedish-", 1160], ["and", 1169], ["wild", 1173], ["-", 1177], ["type", 1178], ["APP", 1183], ["alleles", 1187], [".", 1194], ["The", 1196], ["present", 1200], ["data", 1208], ["suggest", 1213], ["that", 1221], ["the", 1226], ["system", 1230], ["with", 1237], ["reporter", 1242], ["alleles", 1251], ["may", 1259], ["permit", 1263], ["the", 1270], ["preclinical", 1274], ["assessment", 1286], ["of", 1297], ["siRNA", 1300], ["duplexes", 1306], ["conferring", 1315], ["ASP", 1326], ["-", 1329], ["RNAi", 1330], [",", 1334], ["and", 1336], ["thus", 1340], ["contribute", 1345], ["to", 1356], ["the", 1359], ["design", 1363], ["and", 1370], ["selection", 1374], ["of", 1384], ["the", 1387], ["most", 1391], ["suitable", 1396], ["of", 1405], ["such", 1408], ["siRNA", 1413], ["duplexes", 1419], [".", 1427]]}
{"context": "To investigate the clinical feature of Parkinson's disease (PD) with restless leg syndrome (RLS) and the pathogenesis of RLS. We conducted a cross-sectional and control study. The case group concluded 31 PD with RLS patients, meanwhile 39 PD patients were selected as the control group. Clinical history, clinical manifestations, complications and laboratory examinations were compared respectively between the two groups. All the RLS symptoms did not appear in RLS patients until the PD symptoms came out. Significant differences were found in complications such as swallow disturbance, constipation and illusion, when we compared the two PD groups (P < 0.05). Compared with the PD or healthy group, the level of serum ferritin and the H-reflex latency of tibial nerve were significantly decreased in PD with RLS group (P < 0.05). Secondary RLS is a complication of PD. Deficiency of iron and decreased inhibition function of spinal cord may lead to the occurrence of RLS in PD patients. When their motor symptoms are serious and complications are more common, PD patients are more possible to have RLS symptoms.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "174f261677d84e0880d30296aca0dc8a", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[165, 165]], "char_spans": [[885, 888]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["clinical", 19], ["feature", 28], ["of", 36], ["Parkinson", 39], ["'s", 48], ["disease", 51], ["(", 59], ["PD", 60], [")", 62], ["with", 64], ["restless", 69], ["leg", 78], ["syndrome", 82], ["(", 91], ["RLS", 92], [")", 95], ["and", 97], ["the", 101], ["pathogenesis", 105], ["of", 118], ["RLS", 121], [".", 124], ["We", 126], ["conducted", 129], ["a", 139], ["cross", 141], ["-", 146], ["sectional", 147], ["and", 157], ["control", 161], ["study", 169], [".", 174], ["The", 176], ["case", 180], ["group", 185], ["concluded", 191], ["31", 201], ["PD", 204], ["with", 207], ["RLS", 212], ["patients", 216], [",", 224], ["meanwhile", 226], ["39", 236], ["PD", 239], ["patients", 242], ["were", 251], ["selected", 256], ["as", 265], ["the", 268], ["control", 272], ["group", 280], [".", 285], ["Clinical", 287], ["history", 296], [",", 303], ["clinical", 305], ["manifestations", 314], [",", 328], ["complications", 330], ["and", 344], ["laboratory", 348], ["examinations", 359], ["were", 372], ["compared", 377], ["respectively", 386], ["between", 399], ["the", 407], ["two", 411], ["groups", 415], [".", 421], ["All", 423], ["the", 427], ["RLS", 431], ["symptoms", 435], ["did", 444], ["not", 448], ["appear", 452], ["in", 459], ["RLS", 462], ["patients", 466], ["until", 475], ["the", 481], ["PD", 485], ["symptoms", 488], ["came", 497], ["out", 502], [".", 505], ["Significant", 507], ["differences", 519], ["were", 531], ["found", 536], ["in", 542], ["complications", 545], ["such", 559], ["as", 564], ["swallow", 567], ["disturbance", 575], [",", 586], ["constipation", 588], ["and", 601], ["illusion", 605], [",", 613], ["when", 615], ["we", 620], ["compared", 623], ["the", 632], ["two", 636], ["PD", 640], ["groups", 643], ["(", 650], ["P", 651], ["<", 653], ["0.05", 655], [")", 659], [".", 660], ["Compared", 662], ["with", 671], ["the", 676], ["PD", 680], ["or", 683], ["healthy", 686], ["group", 694], [",", 699], ["the", 701], ["level", 705], ["of", 711], ["serum", 714], ["ferritin", 720], ["and", 729], ["the", 733], ["H", 737], ["-", 738], ["reflex", 739], ["latency", 746], ["of", 754], ["tibial", 757], ["nerve", 764], ["were", 770], ["significantly", 775], ["decreased", 789], ["in", 799], ["PD", 802], ["with", 805], ["RLS", 810], ["group", 814], ["(", 820], ["P", 821], ["<", 823], ["0.05", 825], [")", 829], [".", 830], ["Secondary", 832], ["RLS", 842], ["is", 846], ["a", 849], ["complication", 851], ["of", 864], ["PD", 867], [".", 869], ["Deficiency", 871], ["of", 882], ["iron", 885], ["and", 890], ["decreased", 894], ["inhibition", 904], ["function", 915], ["of", 924], ["spinal", 927], ["cord", 934], ["may", 939], ["lead", 943], ["to", 948], ["the", 951], ["occurrence", 955], ["of", 966], ["RLS", 969], ["in", 973], ["PD", 976], ["patients", 979], [".", 987], ["When", 989], ["their", 994], ["motor", 1000], ["symptoms", 1006], ["are", 1015], ["serious", 1019], ["and", 1027], ["complications", 1031], ["are", 1045], ["more", 1049], ["common", 1054], [",", 1060], ["PD", 1062], ["patients", 1065], ["are", 1074], ["more", 1078], ["possible", 1083], ["to", 1092], ["have", 1095], ["RLS", 1100], ["symptoms", 1104], [".", 1112]]}
{"context": "Chronic myeloid leukaemia (CML) is a genetically associated malignancy of haematopoietic stem cells, characterized by a t(9;22) translocation that forms the Philadelphia chromosome and creates a novel fusion gene, BCR-ABL. Treatment with molecular-targeted therapy is usually initiated with imatinib, an inhibitor of BCR-ABL tyrosine kinase. Imatinib resistance is, however, observed in some CML patients, especially in those with advanced disease. Through computerized literature searches, a systematic analysis was conducted to examine the efficacy and benefits of dasatinib therapy for imatinib resistant or intolerant CML patients in the chronic phase (CP), accelerated phase (AP) and fatal blast crisis phase (BC). In terms of major haematological and cytogenetic responses, this meta-analysis showed no significant differences in dasatinib treatment between myeloid BC-CML and lymphoid BC-CML patients with imatinib resistance or intolerance. Dasatinib therapy was, however, significantly more effective in improving major haematological and cytogenetic responses for CP-CML patients than for AP-CML patients with imatinib resistance or intolerance.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "4039d749db1e402c81b273c51d21f59b", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[53, 55], [34, 36]], "char_spans": [[317, 323], [214, 220]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukaemia", 16], ["(", 26], ["CML", 27], [")", 30], ["is", 32], ["a", 35], ["genetically", 37], ["associated", 49], ["malignancy", 60], ["of", 71], ["haematopoietic", 74], ["stem", 89], ["cells", 94], [",", 99], ["characterized", 101], ["by", 115], ["a", 118], ["t(9;22", 120], [")", 126], ["translocation", 128], ["that", 142], ["forms", 147], ["the", 153], ["Philadelphia", 157], ["chromosome", 170], ["and", 181], ["creates", 185], ["a", 193], ["novel", 195], ["fusion", 201], ["gene", 208], [",", 212], ["BCR", 214], ["-", 217], ["ABL", 218], [".", 221], ["Treatment", 223], ["with", 233], ["molecular", 238], ["-", 247], ["targeted", 248], ["therapy", 257], ["is", 265], ["usually", 268], ["initiated", 276], ["with", 286], ["imatinib", 291], [",", 299], ["an", 301], ["inhibitor", 304], ["of", 314], ["BCR", 317], ["-", 320], ["ABL", 321], ["tyrosine", 325], ["kinase", 334], [".", 340], ["Imatinib", 342], ["resistance", 351], ["is", 362], [",", 364], ["however", 366], [",", 373], ["observed", 375], ["in", 384], ["some", 387], ["CML", 392], ["patients", 396], [",", 404], ["especially", 406], ["in", 417], ["those", 420], ["with", 426], ["advanced", 431], ["disease", 440], [".", 447], ["Through", 449], ["computerized", 457], ["literature", 470], ["searches", 481], [",", 489], ["a", 491], ["systematic", 493], ["analysis", 504], ["was", 513], ["conducted", 517], ["to", 527], ["examine", 530], ["the", 538], ["efficacy", 542], ["and", 551], ["benefits", 555], ["of", 564], ["dasatinib", 567], ["therapy", 577], ["for", 585], ["imatinib", 589], ["resistant", 598], ["or", 608], ["intolerant", 611], ["CML", 622], ["patients", 626], ["in", 635], ["the", 638], ["chronic", 642], ["phase", 650], ["(", 656], ["CP", 657], [")", 659], [",", 660], ["accelerated", 662], ["phase", 674], ["(", 680], ["AP", 681], [")", 683], ["and", 685], ["fatal", 689], ["blast", 695], ["crisis", 701], ["phase", 708], ["(", 714], ["BC", 715], [")", 717], [".", 718], ["In", 720], ["terms", 723], ["of", 729], ["major", 732], ["haematological", 738], ["and", 753], ["cytogenetic", 757], ["responses", 769], [",", 778], ["this", 780], ["meta", 785], ["-", 789], ["analysis", 790], ["showed", 799], ["no", 806], ["significant", 809], ["differences", 821], ["in", 833], ["dasatinib", 836], ["treatment", 846], ["between", 856], ["myeloid", 864], ["BC", 872], ["-", 874], ["CML", 875], ["and", 879], ["lymphoid", 883], ["BC", 892], ["-", 894], ["CML", 895], ["patients", 899], ["with", 908], ["imatinib", 913], ["resistance", 922], ["or", 933], ["intolerance", 936], [".", 947], ["Dasatinib", 949], ["therapy", 959], ["was", 967], [",", 970], ["however", 972], [",", 979], ["significantly", 981], ["more", 995], ["effective", 1000], ["in", 1010], ["improving", 1013], ["major", 1023], ["haematological", 1029], ["and", 1044], ["cytogenetic", 1048], ["responses", 1060], ["for", 1070], ["CP", 1074], ["-", 1076], ["CML", 1077], ["patients", 1081], ["than", 1090], ["for", 1095], ["AP", 1099], ["-", 1101], ["CML", 1102], ["patients", 1106], ["with", 1115], ["imatinib", 1120], ["resistance", 1129], ["or", 1140], ["intolerance", 1143], [".", 1154]]}
{"context": "A 50-year-old man presented with worsening, virtually lifelong, chorea and progressive behavioural disturbance, involving disinhibition and hoarding, over 10 years. Clinical assessment revealed chorea, dysarthria, areflexia, an inappropriately jovial, impulsive manner and neuropsychological evidence of frontosubcortical dysfunction. Investigation results included an elevated creatine kinase, caudate atrophy and hypoperfusion, acanthocytes in the peripheral blood and the McLeod phenotype. DNA studies demonstrated a single-base deletion at position 172 in exon 1 of the XK gene, giving rise to a premature stop codon at position 129 in exon 2.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c44de3a52803425c8e515bdb5fb039ac", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[88, 88]], "char_spans": [[574, 575]]}]}], "context_tokens": [["A", 0], ["50-year", 2], ["-", 9], ["old", 10], ["man", 14], ["presented", 18], ["with", 28], ["worsening", 33], [",", 42], ["virtually", 44], ["lifelong", 54], [",", 62], ["chorea", 64], ["and", 71], ["progressive", 75], ["behavioural", 87], ["disturbance", 99], [",", 110], ["involving", 112], ["disinhibition", 122], ["and", 136], ["hoarding", 140], [",", 148], ["over", 150], ["10", 155], ["years", 158], [".", 163], ["Clinical", 165], ["assessment", 174], ["revealed", 185], ["chorea", 194], [",", 200], ["dysarthria", 202], [",", 212], ["areflexia", 214], [",", 223], ["an", 225], ["inappropriately", 228], ["jovial", 244], [",", 250], ["impulsive", 252], ["manner", 262], ["and", 269], ["neuropsychological", 273], ["evidence", 292], ["of", 301], ["frontosubcortical", 304], ["dysfunction", 322], [".", 333], ["Investigation", 335], ["results", 349], ["included", 357], ["an", 366], ["elevated", 369], ["creatine", 378], ["kinase", 387], [",", 393], ["caudate", 395], ["atrophy", 403], ["and", 411], ["hypoperfusion", 415], [",", 428], ["acanthocytes", 430], ["in", 443], ["the", 446], ["peripheral", 450], ["blood", 461], ["and", 467], ["the", 471], ["McLeod", 475], ["phenotype", 482], [".", 491], ["DNA", 493], ["studies", 497], ["demonstrated", 505], ["a", 518], ["single", 520], ["-", 526], ["base", 527], ["deletion", 532], ["at", 541], ["position", 544], ["172", 553], ["in", 557], ["exon", 560], ["1", 565], ["of", 567], ["the", 570], ["XK", 574], ["gene", 577], [",", 581], ["giving", 583], ["rise", 590], ["to", 595], ["a", 598], ["premature", 600], ["stop", 610], ["codon", 615], ["at", 621], ["position", 624], ["129", 633], ["in", 637], ["exon", 640], ["2", 645], [".", 646]]}
{"context": "In order to determine the prevalence of latent infection due to Mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the Monotest and, for reference purposes, to the Mantoux test. The overall prevalence of subjects with a tuberculin skin reaction size > or = 5 mm in the Mantoux test was 25.7%; utilizing a cut-off of > or = 10 mm, the prevalence was 11.4%. Irrespective of cut-off, the Monotest showed a sensitivity of > 90% and a specificity of > 80%. At a prevalence of 25.7%, and with cut-offs of > or = 5 or > or = 10 mm, the positive predictive value was 83% or 62.2%, respectively. Irrespective of cut-off, the negative predictive value was > 97%. In conclusion, the Monotest proved satisfactory as a tool for epidemiological screening in a population with a high prevalence for latent tuberculosis, namely drug users.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "36caa3ccb74340beb0182b812e4fbc13", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[12, 12], [189, 189], [28, 28]], "char_spans": [[78, 89], [902, 913], [169, 180]]}]}], "context_tokens": [["In", 0], ["order", 3], ["to", 9], ["determine", 12], ["the", 22], ["prevalence", 26], ["of", 37], ["latent", 40], ["infection", 47], ["due", 57], ["to", 61], ["Mycobacterium", 64], ["tuberculosis", 78], ["in", 91], ["drug", 94], ["users", 99], ["and", 105], ["to", 109], ["provide", 112], ["centres", 120], ["for", 128], ["drug", 132], ["users", 137], ["with", 143], ["a", 148], ["practical", 150], ["tool", 160], ["for", 165], ["tuberculosis", 169], ["screening", 182], [",", 191], ["237", 193], ["drug", 197], ["users", 202], ["were", 208], ["subjected", 213], ["to", 223], ["the", 226], ["Monotest", 230], ["and", 239], [",", 242], ["for", 244], ["reference", 248], ["purposes", 258], [",", 266], ["to", 268], ["the", 271], ["Mantoux", 275], ["test", 283], [".", 287], ["The", 289], ["overall", 293], ["prevalence", 301], ["of", 312], ["subjects", 315], ["with", 324], ["a", 329], ["tuberculin", 331], ["skin", 342], ["reaction", 347], ["size", 356], [">", 361], ["or", 363], ["=", 366], ["5", 368], ["mm", 370], ["in", 373], ["the", 376], ["Mantoux", 380], ["test", 388], ["was", 393], ["25.7", 397], ["%", 401], [";", 402], ["utilizing", 404], ["a", 414], ["cut", 416], ["-", 419], ["off", 420], ["of", 424], [">", 427], ["or", 429], ["=", 432], ["10", 434], ["mm", 437], [",", 439], ["the", 441], ["prevalence", 445], ["was", 456], ["11.4", 460], ["%", 464], [".", 465], ["Irrespective", 467], ["of", 480], ["cut", 483], ["-", 486], ["off", 487], [",", 490], ["the", 492], ["Monotest", 496], ["showed", 505], ["a", 512], ["sensitivity", 514], ["of", 526], [">", 529], ["90", 531], ["%", 533], ["and", 535], ["a", 539], ["specificity", 541], ["of", 553], [">", 556], ["80", 558], ["%", 560], [".", 561], ["At", 563], ["a", 566], ["prevalence", 568], ["of", 579], ["25.7", 582], ["%", 586], [",", 587], ["and", 589], ["with", 593], ["cut", 598], ["-", 601], ["offs", 602], ["of", 607], [">", 610], ["or", 612], ["=", 615], ["5", 617], ["or", 619], [">", 622], ["or", 624], ["=", 627], ["10", 629], ["mm", 632], [",", 634], ["the", 636], ["positive", 640], ["predictive", 649], ["value", 660], ["was", 666], ["83", 670], ["%", 672], ["or", 674], ["62.2", 677], ["%", 681], [",", 682], ["respectively", 684], [".", 696], ["Irrespective", 698], ["of", 711], ["cut", 714], ["-", 717], ["off", 718], [",", 721], ["the", 723], ["negative", 727], ["predictive", 736], ["value", 747], ["was", 753], [">", 757], ["97", 759], ["%", 761], [".", 762], ["In", 764], ["conclusion", 767], [",", 777], ["the", 779], ["Monotest", 783], ["proved", 792], ["satisfactory", 799], ["as", 812], ["a", 815], ["tool", 817], ["for", 822], ["epidemiological", 826], ["screening", 842], ["in", 852], ["a", 855], ["population", 857], ["with", 868], ["a", 873], ["high", 875], ["prevalence", 880], ["for", 891], ["latent", 895], ["tuberculosis", 902], [",", 914], ["namely", 916], ["drug", 923], ["users", 928], [".", 933]]}
{"context": "We investigated the requirements for selenocysteine insertion at single or multiple UGA codons in eukaryotic selenoproteins. Two functional SECIS elements were identified in the 3' untranslated region of the rat selenoprotein P mRNA, with predicted stem-loops and critical nucleotides similar to those in the SECIS elements in the type I iodothyronine 5' deiodinase (5'DI) and glutathione peroxidase selenoprotein mRNAs. Site-directed mutational analyses of three SECIS elements confirmed that conserved nucleotides in the loop and in unpaired regions of the stem are critical for activity. This indicates that multiple contact sites are required for SECIS function. Stop codon function at any of five out-of-context UGA codons in the 5'DI mRNA was suppressed by SECIS elements from the 5'DI or selenoprotein P genes linked downstream. Thus, the presence of SECIS elements in eukaryotic selenoprotein mRNAs permits complete flexibility in UGA codon position.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "03e383d3bf6142a5983cf58fc309b81d", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[75, 75], [19, 19], [105, 105], [146, 146], [129, 129], [49, 49]], "char_spans": [[464, 468], [140, 144], [651, 655], [858, 862], [763, 767], [309, 313]]}]}], "context_tokens": [["We", 0], ["investigated", 3], ["the", 16], ["requirements", 20], ["for", 33], ["selenocysteine", 37], ["insertion", 52], ["at", 62], ["single", 65], ["or", 72], ["multiple", 75], ["UGA", 84], ["codons", 88], ["in", 95], ["eukaryotic", 98], ["selenoproteins", 109], [".", 123], ["Two", 125], ["functional", 129], ["SECIS", 140], ["elements", 146], ["were", 155], ["identified", 160], ["in", 171], ["the", 174], ["3", 178], ["'", 179], ["untranslated", 181], ["region", 194], ["of", 201], ["the", 204], ["rat", 208], ["selenoprotein", 212], ["P", 226], ["mRNA", 228], [",", 232], ["with", 234], ["predicted", 239], ["stem", 249], ["-", 253], ["loops", 254], ["and", 260], ["critical", 264], ["nucleotides", 273], ["similar", 285], ["to", 293], ["those", 296], ["in", 302], ["the", 305], ["SECIS", 309], ["elements", 315], ["in", 324], ["the", 327], ["type", 331], ["I", 336], ["iodothyronine", 338], ["5", 352], ["'", 353], ["deiodinase", 355], ["(", 366], ["5'DI", 367], [")", 371], ["and", 373], ["glutathione", 377], ["peroxidase", 389], ["selenoprotein", 400], ["mRNAs", 414], [".", 419], ["Site", 421], ["-", 425], ["directed", 426], ["mutational", 435], ["analyses", 446], ["of", 455], ["three", 458], ["SECIS", 464], ["elements", 470], ["confirmed", 479], ["that", 489], ["conserved", 494], ["nucleotides", 504], ["in", 516], ["the", 519], ["loop", 523], ["and", 528], ["in", 532], ["unpaired", 535], ["regions", 544], ["of", 552], ["the", 555], ["stem", 559], ["are", 564], ["critical", 568], ["for", 577], ["activity", 581], [".", 589], ["This", 591], ["indicates", 596], ["that", 606], ["multiple", 611], ["contact", 620], ["sites", 628], ["are", 634], ["required", 638], ["for", 647], ["SECIS", 651], ["function", 657], [".", 665], ["Stop", 667], ["codon", 672], ["function", 678], ["at", 687], ["any", 690], ["of", 694], ["five", 697], ["out", 702], ["-", 705], ["of", 706], ["-", 708], ["context", 709], ["UGA", 717], ["codons", 721], ["in", 728], ["the", 731], ["5'DI", 735], ["mRNA", 740], ["was", 745], ["suppressed", 749], ["by", 760], ["SECIS", 763], ["elements", 769], ["from", 778], ["the", 783], ["5'DI", 787], ["or", 792], ["selenoprotein", 795], ["P", 809], ["genes", 811], ["linked", 817], ["downstream", 824], [".", 834], ["Thus", 836], [",", 840], ["the", 842], ["presence", 846], ["of", 855], ["SECIS", 858], ["elements", 864], ["in", 873], ["eukaryotic", 876], ["selenoprotein", 887], ["mRNAs", 901], ["permits", 907], ["complete", 915], ["flexibility", 924], ["in", 936], ["UGA", 939], ["codon", 943], ["position", 949], [".", 957]]}
{"context": "Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) carrying pvl is an emerging problem worldwide. CA-MRSA tends to harbor staphylococcal cassette chromosome mec type IV (SCCmec IV), to be non-multiantibiotic resistant, and to have different genotypes from the local hospital-acquired MRSA (HA-MRSA). However, in Ireland, 80% of HA-MRSA isolates have the non-multiantibiotic-resistant genotype ST22-MRSA-IV. This study investigated MRSA isolates from Ireland (CA-MRSA, health care-associated MRSA, and HA-MRSA) for the carriage of pvl and determined the genotypic characteristics of all pvl-positive isolates identified. All 1,389 MRSA isolates were investigated by antibiogram-resistogram typing and SmaI DNA macrorestriction analysis. pvl-positive isolates were further characterized by multilocus sequence typing and SCCmec, agr, and toxin gene typing. Twenty-five (1.8%) MRSA isolates belonging to six genotypes (ST30, ST8, ST22, ST80, ST5, and ST154) harbored pvl. Nineteen of these (76%) were CA-MRSA isolates, but a prospective study of MRSA isolates from 401 patients showed that only 6.7% (2/30) of patients with CA-MRSA yielded pvl-positive isolates. Thus, pvl cannot be used as a sole marker for CA-MRSA. Fifty-two percent of pvl-positive MRSA isolates were recovered from patients with skin and soft tissue infections; thirty-six percent were from patients of non-Irish ethnic origin, reflecting the increasing heterogeneity of the Irish population due to immigration. All 25 pvl-positive isolates carried SCCmec IV; 14 (56%) harbored SCCmec IV.1 or IV.3, and the remaining 11 isolates could not be subtyped. This study demonstrates that pvl is not a reliable marker for CA-MRSA in Ireland and reveals the emergence and importation of diverse genotypes of pvl-positive MRSA in Ireland.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "f981f754748548ed8b74416b9b29aedd", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[362, 362], [11, 11], [173, 173], [90, 90], [214, 214], [253, 253], [346, 346], [60, 60], [108, 108], [73, 73], [23, 23], [103, 103], [263, 263], [56, 56], [232, 232], [206, 206], [130, 130], [97, 97]], "char_spans": [[1802, 1805], [67, 70], [896, 899], [453, 456], [1065, 1068], [1231, 1234], [1707, 1710], [315, 318], [526, 529], [353, 356], [123, 126], [513, 516], [1271, 1274], [306, 309], [1146, 1149], [1023, 1026], [652, 655], [484, 487]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["acquired", 10], ["methicillin", 19], ["-", 30], ["resistant", 31], ["Staphylococcus", 41], ["aureus", 56], ["(", 63], ["CA", 64], ["-", 66], ["MRSA", 67], [")", 71], ["carrying", 73], ["pvl", 82], ["is", 86], ["an", 89], ["emerging", 92], ["problem", 101], ["worldwide", 109], [".", 118], ["CA", 120], ["-", 122], ["MRSA", 123], ["tends", 128], ["to", 134], ["harbor", 137], ["staphylococcal", 144], ["cassette", 159], ["chromosome", 168], ["mec", 179], ["type", 183], ["IV", 188], ["(", 191], ["SCCmec", 192], ["IV", 199], [")", 201], [",", 202], ["to", 204], ["be", 207], ["non", 210], ["-", 213], ["multiantibiotic", 214], ["resistant", 230], [",", 239], ["and", 241], ["to", 245], ["have", 248], ["different", 253], ["genotypes", 263], ["from", 273], ["the", 278], ["local", 282], ["hospital", 288], ["-", 296], ["acquired", 297], ["MRSA", 306], ["(", 311], ["HA", 312], ["-", 314], ["MRSA", 315], [")", 319], [".", 320], ["However", 322], [",", 329], ["in", 331], ["Ireland", 334], [",", 341], ["80", 343], ["%", 345], ["of", 347], ["HA", 350], ["-", 352], ["MRSA", 353], ["isolates", 358], ["have", 367], ["the", 372], ["non", 376], ["-", 379], ["multiantibiotic", 380], ["-", 395], ["resistant", 396], ["genotype", 406], ["ST22-MRSA", 415], ["-", 424], ["IV", 425], [".", 427], ["This", 429], ["study", 434], ["investigated", 440], ["MRSA", 453], ["isolates", 458], ["from", 467], ["Ireland", 472], ["(", 480], ["CA", 481], ["-", 483], ["MRSA", 484], [",", 488], ["health", 490], ["care", 497], ["-", 501], ["associated", 502], ["MRSA", 513], [",", 517], ["and", 519], ["HA", 523], ["-", 525], ["MRSA", 526], [")", 530], ["for", 532], ["the", 536], ["carriage", 540], ["of", 549], ["pvl", 552], ["and", 556], ["determined", 560], ["the", 571], ["genotypic", 575], ["characteristics", 585], ["of", 601], ["all", 604], ["pvl", 608], ["-", 611], ["positive", 612], ["isolates", 621], ["identified", 630], [".", 640], ["All", 642], ["1,389", 646], ["MRSA", 652], ["isolates", 657], ["were", 666], ["investigated", 671], ["by", 684], ["antibiogram", 687], ["-", 698], ["resistogram", 699], ["typing", 711], ["and", 718], ["SmaI", 722], ["DNA", 727], ["macrorestriction", 731], ["analysis", 748], [".", 756], ["pvl", 758], ["-", 761], ["positive", 762], ["isolates", 771], ["were", 780], ["further", 785], ["characterized", 793], ["by", 807], ["multilocus", 810], ["sequence", 821], ["typing", 830], ["and", 837], ["SCCmec", 841], [",", 847], ["agr", 849], [",", 852], ["and", 854], ["toxin", 858], ["gene", 864], ["typing", 869], [".", 875], ["Twenty", 877], ["-", 883], ["five", 884], ["(", 889], ["1.8", 890], ["%", 893], [")", 894], ["MRSA", 896], ["isolates", 901], ["belonging", 910], ["to", 920], ["six", 923], ["genotypes", 927], ["(", 937], ["ST30", 938], [",", 942], ["ST8", 944], [",", 947], ["ST22", 949], [",", 953], ["ST80", 955], [",", 959], ["ST5", 961], [",", 964], ["and", 966], ["ST154", 970], [")", 975], ["harbored", 977], ["pvl", 986], [".", 989], ["Nineteen", 991], ["of", 1000], ["these", 1003], ["(", 1009], ["76", 1010], ["%", 1012], [")", 1013], ["were", 1015], ["CA", 1020], ["-", 1022], ["MRSA", 1023], ["isolates", 1028], [",", 1036], ["but", 1038], ["a", 1042], ["prospective", 1044], ["study", 1056], ["of", 1062], ["MRSA", 1065], ["isolates", 1070], ["from", 1079], ["401", 1084], ["patients", 1088], ["showed", 1097], ["that", 1104], ["only", 1109], ["6.7", 1114], ["%", 1117], ["(", 1119], ["2/30", 1120], [")", 1124], ["of", 1126], ["patients", 1129], ["with", 1138], ["CA", 1143], ["-", 1145], ["MRSA", 1146], ["yielded", 1151], ["pvl", 1159], ["-", 1162], ["positive", 1163], ["isolates", 1172], [".", 1180], ["Thus", 1182], [",", 1186], ["pvl", 1188], ["can", 1192], ["not", 1195], ["be", 1199], ["used", 1202], ["as", 1207], ["a", 1210], ["sole", 1212], ["marker", 1217], ["for", 1224], ["CA", 1228], ["-", 1230], ["MRSA", 1231], [".", 1235], ["Fifty", 1237], ["-", 1242], ["two", 1243], ["percent", 1247], ["of", 1255], ["pvl", 1258], ["-", 1261], ["positive", 1262], ["MRSA", 1271], ["isolates", 1276], ["were", 1285], ["recovered", 1290], ["from", 1300], ["patients", 1305], ["with", 1314], ["skin", 1319], ["and", 1324], ["soft", 1328], ["tissue", 1333], ["infections", 1340], [";", 1350], ["thirty", 1352], ["-", 1358], ["six", 1359], ["percent", 1363], ["were", 1371], ["from", 1376], ["patients", 1381], ["of", 1390], ["non", 1393], ["-", 1396], ["Irish", 1397], ["ethnic", 1403], ["origin", 1410], [",", 1416], ["reflecting", 1418], ["the", 1429], ["increasing", 1433], ["heterogeneity", 1444], ["of", 1458], ["the", 1461], ["Irish", 1465], ["population", 1471], ["due", 1482], ["to", 1486], ["immigration", 1489], [".", 1500], ["All", 1502], ["25", 1506], ["pvl", 1509], ["-", 1512], ["positive", 1513], ["isolates", 1522], ["carried", 1531], ["SCCmec", 1539], ["IV", 1546], [";", 1548], ["14", 1550], ["(", 1553], ["56", 1554], ["%", 1556], [")", 1557], ["harbored", 1559], ["SCCmec", 1568], ["IV.1", 1575], ["or", 1580], ["IV.3", 1583], [",", 1587], ["and", 1589], ["the", 1593], ["remaining", 1597], ["11", 1607], ["isolates", 1610], ["could", 1619], ["not", 1625], ["be", 1629], ["subtyped", 1632], [".", 1640], ["This", 1642], ["study", 1647], ["demonstrates", 1653], ["that", 1666], ["pvl", 1671], ["is", 1675], ["not", 1678], ["a", 1682], ["reliable", 1684], ["marker", 1693], ["for", 1700], ["CA", 1704], ["-", 1706], ["MRSA", 1707], ["in", 1712], ["Ireland", 1715], ["and", 1723], ["reveals", 1727], ["the", 1735], ["emergence", 1739], ["and", 1749], ["importation", 1753], ["of", 1765], ["diverse", 1768], ["genotypes", 1776], ["of", 1786], ["pvl", 1789], ["-", 1792], ["positive", 1793], ["MRSA", 1802], ["in", 1807], ["Ireland", 1810], [".", 1817]]}
{"context": "Minors with a stated age <18 years unaccompanied by a responsible adult form an increasing part of refugees to Europe. They are older than other asylum-seeking children and many come from countries with a high tuberculosis (TB) incidence. During the 2015 refugee crisis, 35,369 of 162,877 refugees (22%) seeking asylum in Sweden were unaccompanied minors, which gave us the opportunity to study their burden of TB infection and disease. Of the unaccompanied minors seeking asylum in Sweden during 2015, 2936 (8.3%) were allocated to northern Stockholm. Of these, 2422 were from countries with an incidence of TB exceeding 100/10 Of those screened, 349 had a positive test and were referred to the northern paediatric TB clinic at Astrid Lindgren Children's Hospital. Of these, 16 had TB disease and 278 latent tuberculosis infection (LTBI), while we considered 53 uninfected. In addition, eight sought medical attention with symptomatic TB outside the screening system. Cohort rates were 6.8% of LTBI and 0.5% of TB in minors from Afghanistan and 26-32% of LTBI and 3.4-3.5% of TB among those from Eritrea, Ethiopia or Somalia. We conclude that TB infection and disease is common among asylum-seeking unaccompanied minors, especially among those from the Horn of Africa.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "4b0eb00ff2664722917b55ccb33b9689", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[153, 153], [39, 39]], "char_spans": [[810, 821], [210, 221]]}]}], "context_tokens": [["Minors", 0], ["with", 7], ["a", 12], ["stated", 14], ["age", 21], ["<", 25], ["18", 26], ["years", 29], ["unaccompanied", 35], ["by", 49], ["a", 52], ["responsible", 54], ["adult", 66], ["form", 72], ["an", 77], ["increasing", 80], ["part", 91], ["of", 96], ["refugees", 99], ["to", 108], ["Europe", 111], [".", 117], ["They", 119], ["are", 124], ["older", 128], ["than", 134], ["other", 139], ["asylum", 145], ["-", 151], ["seeking", 152], ["children", 160], ["and", 169], ["many", 173], ["come", 178], ["from", 183], ["countries", 188], ["with", 198], ["a", 203], ["high", 205], ["tuberculosis", 210], ["(", 223], ["TB", 224], [")", 226], ["incidence", 228], [".", 237], ["During", 239], ["the", 246], ["2015", 250], ["refugee", 255], ["crisis", 263], [",", 269], ["35,369", 271], ["of", 278], ["162,877", 281], ["refugees", 289], ["(", 298], ["22", 299], ["%", 301], [")", 302], ["seeking", 304], ["asylum", 312], ["in", 319], ["Sweden", 322], ["were", 329], ["unaccompanied", 334], ["minors", 348], [",", 354], ["which", 356], ["gave", 362], ["us", 367], ["the", 370], ["opportunity", 374], ["to", 386], ["study", 389], ["their", 395], ["burden", 401], ["of", 408], ["TB", 411], ["infection", 414], ["and", 424], ["disease", 428], [".", 435], ["Of", 437], ["the", 440], ["unaccompanied", 444], ["minors", 458], ["seeking", 465], ["asylum", 473], ["in", 480], ["Sweden", 483], ["during", 490], ["2015", 497], [",", 501], ["2936", 503], ["(", 508], ["8.3", 509], ["%", 512], [")", 513], ["were", 515], ["allocated", 520], ["to", 530], ["northern", 533], ["Stockholm", 542], [".", 551], ["Of", 553], ["these", 556], [",", 561], ["2422", 563], ["were", 568], ["from", 573], ["countries", 578], ["with", 588], ["an", 593], ["incidence", 596], ["of", 606], ["TB", 609], ["exceeding", 612], ["100/10", 622], ["Of", 629], ["those", 632], ["screened", 638], [",", 646], ["349", 648], ["had", 652], ["a", 656], ["positive", 658], ["test", 667], ["and", 672], ["were", 676], ["referred", 681], ["to", 690], ["the", 693], ["northern", 697], ["paediatric", 706], ["TB", 717], ["clinic", 720], ["at", 727], ["Astrid", 730], ["Lindgren", 737], ["Children", 746], ["'s", 754], ["Hospital", 757], [".", 765], ["Of", 767], ["these", 770], [",", 775], ["16", 777], ["had", 780], ["TB", 784], ["disease", 787], ["and", 795], ["278", 799], ["latent", 803], ["tuberculosis", 810], ["infection", 823], ["(", 833], ["LTBI", 834], [")", 838], [",", 839], ["while", 841], ["we", 847], ["considered", 850], ["53", 861], ["uninfected", 864], [".", 874], ["In", 876], ["addition", 879], [",", 887], ["eight", 889], ["sought", 895], ["medical", 902], ["attention", 910], ["with", 920], ["symptomatic", 925], ["TB", 937], ["outside", 940], ["the", 948], ["screening", 952], ["system", 962], [".", 968], ["Cohort", 970], ["rates", 977], ["were", 983], ["6.8", 988], ["%", 991], ["of", 993], ["LTBI", 996], ["and", 1001], ["0.5", 1005], ["%", 1008], ["of", 1010], ["TB", 1013], ["in", 1016], ["minors", 1019], ["from", 1026], ["Afghanistan", 1031], ["and", 1043], ["26", 1047], ["-", 1049], ["32", 1050], ["%", 1052], ["of", 1054], ["LTBI", 1057], ["and", 1062], ["3.4", 1066], ["-", 1069], ["3.5", 1070], ["%", 1073], ["of", 1075], ["TB", 1078], ["among", 1081], ["those", 1087], ["from", 1093], ["Eritrea", 1098], [",", 1105], ["Ethiopia", 1107], ["or", 1116], ["Somalia", 1119], [".", 1126], ["We", 1128], ["conclude", 1131], ["that", 1140], ["TB", 1145], ["infection", 1148], ["and", 1158], ["disease", 1162], ["is", 1170], ["common", 1173], ["among", 1180], ["asylum", 1186], ["-", 1192], ["seeking", 1193], ["unaccompanied", 1201], ["minors", 1215], [",", 1221], ["especially", 1223], ["among", 1234], ["those", 1240], ["from", 1246], ["the", 1251], ["Horn", 1255], ["of", 1260], ["Africa", 1263], [".", 1269]]}
{"context": "Previous X-ray crystal structures have shown that linkers of five amino acid residues connecting pairs of chicken brain alpha-spectrin and human erythroid beta-spectrin repeats can undergo bending without losing their alpha-helical structure. To test whether bending at one linker can influence bending at an adjacent linker, the structures of two and three repeat fragments of chicken brain alpha-spectrin have been determined by X-ray crystallography. The structure of the three-repeat fragment clearly shows that bending at one linker can occur independently of bending at an adjacent linker. This observation increases the possible trajectories of modeled chains of spectrin repeats. Furthermore, the three-repeat molecule crystallized as an antiparallel dimer with a significantly smaller buried interfacial area than that of alpha-actinin, a spectrin-related molecule, but large enough and of a type indicating biological specificity. Comparison of the structures of the spectrin and alpha-actinin dimers supports weak association of the former, which could not be detected by analytical ultracentrifugation, versus strong association of the latter, which has been observed by others. To correlate features of the structure with solution properties and to test a previous model of stable spectrin and dystrophin repeats, the number of inter-helical interactions in each repeat of several spectrin structures were counted and compared to their thermal stabilities. Inter-helical interactions, but not all interactions, increased in parallel with measured thermal stabilities of each repeat and in agreement with the thermal stabilities of two and three repeats and also partial repeats of spectrin.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "159e2ef1d3ca4a3b889fd3fd5ef2acb9", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[127, 127]], "char_spans": [[746, 757]]}]}], "context_tokens": [["Previous", 0], ["X", 9], ["-", 10], ["ray", 11], ["crystal", 15], ["structures", 23], ["have", 34], ["shown", 39], ["that", 45], ["linkers", 50], ["of", 58], ["five", 61], ["amino", 66], ["acid", 72], ["residues", 77], ["connecting", 86], ["pairs", 97], ["of", 103], ["chicken", 106], ["brain", 114], ["alpha", 120], ["-", 125], ["spectrin", 126], ["and", 135], ["human", 139], ["erythroid", 145], ["beta", 155], ["-", 159], ["spectrin", 160], ["repeats", 169], ["can", 177], ["undergo", 181], ["bending", 189], ["without", 197], ["losing", 205], ["their", 212], ["alpha", 218], ["-", 223], ["helical", 224], ["structure", 232], [".", 241], ["To", 243], ["test", 246], ["whether", 251], ["bending", 259], ["at", 267], ["one", 270], ["linker", 274], ["can", 281], ["influence", 285], ["bending", 295], ["at", 303], ["an", 306], ["adjacent", 309], ["linker", 318], [",", 324], ["the", 326], ["structures", 330], ["of", 341], ["two", 344], ["and", 348], ["three", 352], ["repeat", 358], ["fragments", 365], ["of", 375], ["chicken", 378], ["brain", 386], ["alpha", 392], ["-", 397], ["spectrin", 398], ["have", 407], ["been", 412], ["determined", 417], ["by", 428], ["X", 431], ["-", 432], ["ray", 433], ["crystallography", 437], [".", 452], ["The", 454], ["structure", 458], ["of", 468], ["the", 471], ["three", 475], ["-", 480], ["repeat", 481], ["fragment", 488], ["clearly", 497], ["shows", 505], ["that", 511], ["bending", 516], ["at", 524], ["one", 527], ["linker", 531], ["can", 538], ["occur", 542], ["independently", 548], ["of", 562], ["bending", 565], ["at", 573], ["an", 576], ["adjacent", 579], ["linker", 588], [".", 594], ["This", 596], ["observation", 601], ["increases", 613], ["the", 623], ["possible", 627], ["trajectories", 636], ["of", 649], ["modeled", 652], ["chains", 660], ["of", 667], ["spectrin", 670], ["repeats", 679], [".", 686], ["Furthermore", 688], [",", 699], ["the", 701], ["three", 705], ["-", 710], ["repeat", 711], ["molecule", 718], ["crystallized", 727], ["as", 740], ["an", 743], ["antiparallel", 746], ["dimer", 759], ["with", 765], ["a", 770], ["significantly", 772], ["smaller", 786], ["buried", 794], ["interfacial", 801], ["area", 813], ["than", 818], ["that", 823], ["of", 828], ["alpha", 831], ["-", 836], ["actinin", 837], [",", 844], ["a", 846], ["spectrin", 848], ["-", 856], ["related", 857], ["molecule", 865], [",", 873], ["but", 875], ["large", 879], ["enough", 885], ["and", 892], ["of", 896], ["a", 899], ["type", 901], ["indicating", 906], ["biological", 917], ["specificity", 928], [".", 939], ["Comparison", 941], ["of", 952], ["the", 955], ["structures", 959], ["of", 970], ["the", 973], ["spectrin", 977], ["and", 986], ["alpha", 990], ["-", 995], ["actinin", 996], ["dimers", 1004], ["supports", 1011], ["weak", 1020], ["association", 1025], ["of", 1037], ["the", 1040], ["former", 1044], [",", 1050], ["which", 1052], ["could", 1058], ["not", 1064], ["be", 1068], ["detected", 1071], ["by", 1080], ["analytical", 1083], ["ultracentrifugation", 1094], [",", 1113], ["versus", 1115], ["strong", 1122], ["association", 1129], ["of", 1141], ["the", 1144], ["latter", 1148], [",", 1154], ["which", 1156], ["has", 1162], ["been", 1166], ["observed", 1171], ["by", 1180], ["others", 1183], [".", 1189], ["To", 1191], ["correlate", 1194], ["features", 1204], ["of", 1213], ["the", 1216], ["structure", 1220], ["with", 1230], ["solution", 1235], ["properties", 1244], ["and", 1255], ["to", 1259], ["test", 1262], ["a", 1267], ["previous", 1269], ["model", 1278], ["of", 1284], ["stable", 1287], ["spectrin", 1294], ["and", 1303], ["dystrophin", 1307], ["repeats", 1318], [",", 1325], ["the", 1327], ["number", 1331], ["of", 1338], ["inter", 1341], ["-", 1346], ["helical", 1347], ["interactions", 1355], ["in", 1368], ["each", 1371], ["repeat", 1376], ["of", 1383], ["several", 1386], ["spectrin", 1394], ["structures", 1403], ["were", 1414], ["counted", 1419], ["and", 1427], ["compared", 1431], ["to", 1440], ["their", 1443], ["thermal", 1449], ["stabilities", 1457], [".", 1468], ["Inter", 1470], ["-", 1475], ["helical", 1476], ["interactions", 1484], [",", 1496], ["but", 1498], ["not", 1502], ["all", 1506], ["interactions", 1510], [",", 1522], ["increased", 1524], ["in", 1534], ["parallel", 1537], ["with", 1546], ["measured", 1551], ["thermal", 1560], ["stabilities", 1568], ["of", 1580], ["each", 1583], ["repeat", 1588], ["and", 1595], ["in", 1599], ["agreement", 1602], ["with", 1612], ["the", 1617], ["thermal", 1621], ["stabilities", 1629], ["of", 1641], ["two", 1644], ["and", 1648], ["three", 1652], ["repeats", 1658], ["and", 1666], ["also", 1670], ["partial", 1675], ["repeats", 1683], ["of", 1691], ["spectrin", 1694], [".", 1702]]}
{"context": "Spleen tyrosine kinase (Syk) is a cytoplasmic tyrosine kinase involved in signalling in many of the cells that drive immune inflammation. The development of small molecules that inhibit Syk kinase may change the way we treat disorders such as rheumatoid arthritis (RA), as well as a range of other inflammatory diseases. Fostamatinib (R-788) is an orally bioavailable small molecule. It is the prodrug of R406, which is a potent Syk inhibitor. Fostamatinib was developed because it has more favourable physiochemical properties. It is rapidly converted to R406 by intestinal enterocytes. It has been evaluated in experimental models of RA, such as collagen-induced arthritis. In these models, fostamatinib suppressed clinical arthritis, bone erosions, pannus formation and synovitis. A phase II programme with fostamatinib has largely been completed. Three key trials have been published, lasting 12-26 weeks and each enrolling 189-457 patients (875 in total). All these trials involved placebo therapy and patients continued to receive methotrexate in addition to active treatment with fostamatinib. The first dose-ranging trial evaluated three treatment doses in RA patients who had not fully responded to methotrexate therapy. The second trial compared two treatment doses in patients who had not responded to methotrexate therapy. The third trial compared a single treatment dose with placebo in patients who had not responded to biological therapy. The primary outcome measure was the number of patients achieving American College of Rheumatology (ACR) 20% (ACR20) responses. Placebo ACR20 response rates in all three trials were similar (35-38%). All three trials involved one treatment arm receiving fostamatinib 100 mg twice daily; ACR20 responses with this active treatment ranged from 38% to 67%. A meta-analysis of ACR responses in these trials, using responses to the highest dose in each trial for comparisons with placebo therapy in a random effects model, showed a borderline benefit with ACR20 responses. There were more significant differences with ACR50 and ACR70 responses. The reason that this meta-analysis was not more strongly positive is that the third trial, which evaluated patients who had failed to respond to biological treatments, gave negative results. Individual ACR response components, such as changes in swollen joint counts, showed significant differences in the first two trials, but there were no definite treatment benefits in the third trial. Overall, the differences were significant in a meta-analysis of all three trials. The most important adverse reactions were diarrhoea, neutropenia and raised ALT levels, which all showed significant excesses with active treatment compared with placebo. Too few patients have been studied for a definitive safety profile to be known. Overall, the results of the phase II trials were sufficiently encouraging for a phase III programme to be initiated. It will be some years before their definitive results are available.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "cdffae7e17c6461b9d318dade835ff28", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["Syk", 24], [")", 27], ["is", 29], ["a", 32], ["cytoplasmic", 34], ["tyrosine", 46], ["kinase", 55], ["involved", 62], ["in", 71], ["signalling", 74], ["in", 85], ["many", 88], ["of", 93], ["the", 96], ["cells", 100], ["that", 106], ["drive", 111], ["immune", 117], ["inflammation", 124], [".", 136], ["The", 138], ["development", 142], ["of", 154], ["small", 157], ["molecules", 163], ["that", 173], ["inhibit", 178], ["Syk", 186], ["kinase", 190], ["may", 197], ["change", 201], ["the", 208], ["way", 212], ["we", 216], ["treat", 219], ["disorders", 225], ["such", 235], ["as", 240], ["rheumatoid", 243], ["arthritis", 254], ["(", 264], ["RA", 265], [")", 267], [",", 268], ["as", 270], ["well", 273], ["as", 278], ["a", 281], ["range", 283], ["of", 289], ["other", 292], ["inflammatory", 298], ["diseases", 311], [".", 319], ["Fostamatinib", 321], ["(", 334], ["R-788", 335], [")", 340], ["is", 342], ["an", 345], ["orally", 348], ["bioavailable", 355], ["small", 368], ["molecule", 374], [".", 382], ["It", 384], ["is", 387], ["the", 390], ["prodrug", 394], ["of", 402], ["R406", 405], [",", 409], ["which", 411], ["is", 417], ["a", 420], ["potent", 422], ["Syk", 429], ["inhibitor", 433], [".", 442], ["Fostamatinib", 444], ["was", 457], ["developed", 461], ["because", 471], ["it", 479], ["has", 482], ["more", 486], ["favourable", 491], ["physiochemical", 502], ["properties", 517], [".", 527], ["It", 529], ["is", 532], ["rapidly", 535], ["converted", 543], ["to", 553], ["R406", 556], ["by", 561], ["intestinal", 564], ["enterocytes", 575], [".", 586], ["It", 588], ["has", 591], ["been", 595], ["evaluated", 600], ["in", 610], ["experimental", 613], ["models", 626], ["of", 633], ["RA", 636], [",", 638], ["such", 640], ["as", 645], ["collagen", 648], ["-", 656], ["induced", 657], ["arthritis", 665], [".", 674], ["In", 676], ["these", 679], ["models", 685], [",", 691], ["fostamatinib", 693], ["suppressed", 706], ["clinical", 717], ["arthritis", 726], [",", 735], ["bone", 737], ["erosions", 742], [",", 750], ["pannus", 752], ["formation", 759], ["and", 769], ["synovitis", 773], [".", 782], ["A", 784], ["phase", 786], ["II", 792], ["programme", 795], ["with", 805], ["fostamatinib", 810], ["has", 823], ["largely", 827], ["been", 835], ["completed", 840], [".", 849], ["Three", 851], ["key", 857], ["trials", 861], ["have", 868], ["been", 873], ["published", 878], [",", 887], ["lasting", 889], ["12", 897], ["-", 899], ["26", 900], ["weeks", 903], ["and", 909], ["each", 913], ["enrolling", 918], ["189", 928], ["-", 931], ["457", 932], ["patients", 936], ["(", 945], ["875", 946], ["in", 950], ["total", 953], [")", 958], [".", 959], ["All", 961], ["these", 965], ["trials", 971], ["involved", 978], ["placebo", 987], ["therapy", 995], ["and", 1003], ["patients", 1007], ["continued", 1016], ["to", 1026], ["receive", 1029], ["methotrexate", 1037], ["in", 1050], ["addition", 1053], ["to", 1062], ["active", 1065], ["treatment", 1072], ["with", 1082], ["fostamatinib", 1087], [".", 1099], ["The", 1101], ["first", 1105], ["dose", 1111], ["-", 1115], ["ranging", 1116], ["trial", 1124], ["evaluated", 1130], ["three", 1140], ["treatment", 1146], ["doses", 1156], ["in", 1162], ["RA", 1165], ["patients", 1168], ["who", 1177], ["had", 1181], ["not", 1185], ["fully", 1189], ["responded", 1195], ["to", 1205], ["methotrexate", 1208], ["therapy", 1221], [".", 1228], ["The", 1230], ["second", 1234], ["trial", 1241], ["compared", 1247], ["two", 1256], ["treatment", 1260], ["doses", 1270], ["in", 1276], ["patients", 1279], ["who", 1288], ["had", 1292], ["not", 1296], ["responded", 1300], ["to", 1310], ["methotrexate", 1313], ["therapy", 1326], [".", 1333], ["The", 1335], ["third", 1339], ["trial", 1345], ["compared", 1351], ["a", 1360], ["single", 1362], ["treatment", 1369], ["dose", 1379], ["with", 1384], ["placebo", 1389], ["in", 1397], ["patients", 1400], ["who", 1409], ["had", 1413], ["not", 1417], ["responded", 1421], ["to", 1431], ["biological", 1434], ["therapy", 1445], [".", 1452], ["The", 1454], ["primary", 1458], ["outcome", 1466], ["measure", 1474], ["was", 1482], ["the", 1486], ["number", 1490], ["of", 1497], ["patients", 1500], ["achieving", 1509], ["American", 1519], ["College", 1528], ["of", 1536], ["Rheumatology", 1539], ["(", 1552], ["ACR", 1553], [")", 1556], ["20", 1558], ["%", 1560], ["(", 1562], ["ACR20", 1563], [")", 1568], ["responses", 1570], [".", 1579], ["Placebo", 1581], ["ACR20", 1589], ["response", 1595], ["rates", 1604], ["in", 1610], ["all", 1613], ["three", 1617], ["trials", 1623], ["were", 1630], ["similar", 1635], ["(", 1643], ["35", 1644], ["-", 1646], ["38", 1647], ["%", 1649], [")", 1650], [".", 1651], ["All", 1653], ["three", 1657], ["trials", 1663], ["involved", 1670], ["one", 1679], ["treatment", 1683], ["arm", 1693], ["receiving", 1697], ["fostamatinib", 1707], ["100", 1720], ["mg", 1724], ["twice", 1727], ["daily", 1733], [";", 1738], ["ACR20", 1740], ["responses", 1746], ["with", 1756], ["this", 1761], ["active", 1766], ["treatment", 1773], ["ranged", 1783], ["from", 1790], ["38", 1795], ["%", 1797], ["to", 1799], ["67", 1802], ["%", 1804], [".", 1805], ["A", 1807], ["meta", 1809], ["-", 1813], ["analysis", 1814], ["of", 1823], ["ACR", 1826], ["responses", 1830], ["in", 1840], ["these", 1843], ["trials", 1849], [",", 1855], ["using", 1857], ["responses", 1863], ["to", 1873], ["the", 1876], ["highest", 1880], ["dose", 1888], ["in", 1893], ["each", 1896], ["trial", 1901], ["for", 1907], ["comparisons", 1911], ["with", 1923], ["placebo", 1928], ["therapy", 1936], ["in", 1944], ["a", 1947], ["random", 1949], ["effects", 1956], ["model", 1964], [",", 1969], ["showed", 1971], ["a", 1978], ["borderline", 1980], ["benefit", 1991], ["with", 1999], ["ACR20", 2004], ["responses", 2010], [".", 2019], ["There", 2021], ["were", 2027], ["more", 2032], ["significant", 2037], ["differences", 2049], ["with", 2061], ["ACR50", 2066], ["and", 2072], ["ACR70", 2076], ["responses", 2082], [".", 2091], ["The", 2093], ["reason", 2097], ["that", 2104], ["this", 2109], ["meta", 2114], ["-", 2118], ["analysis", 2119], ["was", 2128], ["not", 2132], ["more", 2136], ["strongly", 2141], ["positive", 2150], ["is", 2159], ["that", 2162], ["the", 2167], ["third", 2171], ["trial", 2177], [",", 2182], ["which", 2184], ["evaluated", 2190], ["patients", 2200], ["who", 2209], ["had", 2213], ["failed", 2217], ["to", 2224], ["respond", 2227], ["to", 2235], ["biological", 2238], ["treatments", 2249], [",", 2259], ["gave", 2261], ["negative", 2266], ["results", 2275], [".", 2282], ["Individual", 2284], ["ACR", 2295], ["response", 2299], ["components", 2308], [",", 2318], ["such", 2320], ["as", 2325], ["changes", 2328], ["in", 2336], ["swollen", 2339], ["joint", 2347], ["counts", 2353], [",", 2359], ["showed", 2361], ["significant", 2368], ["differences", 2380], ["in", 2392], ["the", 2395], ["first", 2399], ["two", 2405], ["trials", 2409], [",", 2415], ["but", 2417], ["there", 2421], ["were", 2427], ["no", 2432], ["definite", 2435], ["treatment", 2444], ["benefits", 2454], ["in", 2463], ["the", 2466], ["third", 2470], ["trial", 2476], [".", 2481], ["Overall", 2483], [",", 2490], ["the", 2492], ["differences", 2496], ["were", 2508], ["significant", 2513], ["in", 2525], ["a", 2528], ["meta", 2530], ["-", 2534], ["analysis", 2535], ["of", 2544], ["all", 2547], ["three", 2551], ["trials", 2557], [".", 2563], ["The", 2565], ["most", 2569], ["important", 2574], ["adverse", 2584], ["reactions", 2592], ["were", 2602], ["diarrhoea", 2607], [",", 2616], ["neutropenia", 2618], ["and", 2630], ["raised", 2634], ["ALT", 2641], ["levels", 2645], [",", 2651], ["which", 2653], ["all", 2659], ["showed", 2663], ["significant", 2670], ["excesses", 2682], ["with", 2691], ["active", 2696], ["treatment", 2703], ["compared", 2713], ["with", 2722], ["placebo", 2727], [".", 2734], ["Too", 2736], ["few", 2740], ["patients", 2744], ["have", 2753], ["been", 2758], ["studied", 2763], ["for", 2771], ["a", 2775], ["definitive", 2777], ["safety", 2788], ["profile", 2795], ["to", 2803], ["be", 2806], ["known", 2809], [".", 2814], ["Overall", 2816], [",", 2823], ["the", 2825], ["results", 2829], ["of", 2837], ["the", 2840], ["phase", 2844], ["II", 2850], ["trials", 2853], ["were", 2860], ["sufficiently", 2865], ["encouraging", 2878], ["for", 2890], ["a", 2894], ["phase", 2896], ["III", 2902], ["programme", 2906], ["to", 2916], ["be", 2919], ["initiated", 2922], [".", 2931], ["It", 2933], ["will", 2936], ["be", 2941], ["some", 2944], ["years", 2949], ["before", 2955], ["their", 2962], ["definitive", 2968], ["results", 2979], ["are", 2987], ["available", 2991], [".", 3000]]}
{"context": "Fibrillar \u03b1-synuclein (AS) is the major component of Lewy bodies, the pathological hallmark of Parkinson's disease. Mouse AS (mAS) aggregates much faster than human AS (hAS), although mAS differs from hAS at only seven positions in its primary sequence. Currently, little is known about the site-specific structural differences between mAS and hAS fibrils. Here, we applied state-of-the-art solid-state nuclear magnetic resonance (ssNMR) methods to structurally characterize mAS fibrils. The assignment strategy employed a set of high-resolution 2D and 3D ssNMR spectra recorded on uniformly [(13)C, (15)N], [1-(13)C]glucose, and [2-(13)C]glucose labeled mAS fibrils. An almost complete resonance assignment (96% of backbone amide (15)N and 93% of all (13)C nuclei) was obtained for residues from Gly41 to Val95, which form the core of mAS fibrils. Six \u03b2-strands were identified to be within the fibril core of mAS based on a secondary chemical shift and NHHC analysis. Intermolecular (13)C:(15)N labeled restraints obtained from mixed 1:1 (13)C/(15)N-labeled mAS fibrils reveal a parallel, in-register supramolecular \u03b2-sheet arrangement. The results were compared in detail to recent structural studies on hAS fibrils and indicate the presence of a structurally conserved motif comprising residues Glu61-Lys80.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "0a1c02809201488c903f97ee1cd9280f", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[1, 3]], "char_spans": [[10, 20]]}]}], "context_tokens": [["Fibrillar", 0], ["\u03b1", 10], ["-", 11], ["synuclein", 12], ["(", 22], ["AS", 23], [")", 25], ["is", 27], ["the", 30], ["major", 34], ["component", 40], ["of", 50], ["Lewy", 53], ["bodies", 58], [",", 64], ["the", 66], ["pathological", 70], ["hallmark", 83], ["of", 92], ["Parkinson", 95], ["'s", 104], ["disease", 107], [".", 114], ["Mouse", 116], ["AS", 122], ["(", 125], ["mAS", 126], [")", 129], ["aggregates", 131], ["much", 142], ["faster", 147], ["than", 154], ["human", 159], ["AS", 165], ["(", 168], ["hAS", 169], [")", 172], [",", 173], ["although", 175], ["mAS", 184], ["differs", 188], ["from", 196], ["hAS", 201], ["at", 205], ["only", 208], ["seven", 213], ["positions", 219], ["in", 229], ["its", 232], ["primary", 236], ["sequence", 244], [".", 252], ["Currently", 254], [",", 263], ["little", 265], ["is", 272], ["known", 275], ["about", 281], ["the", 287], ["site", 291], ["-", 295], ["specific", 296], ["structural", 305], ["differences", 316], ["between", 328], ["mAS", 336], ["and", 340], ["hAS", 344], ["fibrils", 348], [".", 355], ["Here", 357], [",", 361], ["we", 363], ["applied", 366], ["state", 374], ["-", 379], ["of", 380], ["-", 382], ["the", 383], ["-", 386], ["art", 387], ["solid", 391], ["-", 396], ["state", 397], ["nuclear", 403], ["magnetic", 411], ["resonance", 420], ["(", 430], ["ssNMR", 431], [")", 436], ["methods", 438], ["to", 446], ["structurally", 449], ["characterize", 462], ["mAS", 475], ["fibrils", 479], [".", 486], ["The", 488], ["assignment", 492], ["strategy", 503], ["employed", 512], ["a", 521], ["set", 523], ["of", 527], ["high", 530], ["-", 534], ["resolution", 535], ["2D", 546], ["and", 549], ["3D", 553], ["ssNMR", 556], ["spectra", 562], ["recorded", 570], ["on", 579], ["uniformly", 582], ["[", 592], ["(", 593], ["13)C", 594], [",", 598], ["(", 600], ["15)N", 601], ["]", 605], [",", 606], ["[", 608], ["1-(13)C]glucose", 609], [",", 624], ["and", 626], ["[", 630], ["2-(13)C]glucose", 631], ["labeled", 647], ["mAS", 655], ["fibrils", 659], [".", 666], ["An", 668], ["almost", 671], ["complete", 678], ["resonance", 687], ["assignment", 697], ["(", 708], ["96", 709], ["%", 711], ["of", 713], ["backbone", 716], ["amide", 725], ["(", 731], ["15)N", 732], ["and", 737], ["93", 741], ["%", 743], ["of", 745], ["all", 748], ["(", 752], ["13)C", 753], ["nuclei", 758], [")", 764], ["was", 766], ["obtained", 770], ["for", 779], ["residues", 783], ["from", 792], ["Gly41", 797], ["to", 803], ["Val95", 806], [",", 811], ["which", 813], ["form", 819], ["the", 824], ["core", 828], ["of", 833], ["mAS", 836], ["fibrils", 840], [".", 847], ["Six", 849], ["\u03b2", 853], ["-", 854], ["strands", 855], ["were", 863], ["identified", 868], ["to", 879], ["be", 882], ["within", 885], ["the", 892], ["fibril", 896], ["core", 903], ["of", 908], ["mAS", 911], ["based", 915], ["on", 921], ["a", 924], ["secondary", 926], ["chemical", 936], ["shift", 945], ["and", 951], ["NHHC", 955], ["analysis", 960], [".", 968], ["Intermolecular", 970], ["(", 985], ["13)C:(15)N", 986], ["labeled", 997], ["restraints", 1005], ["obtained", 1016], ["from", 1025], ["mixed", 1030], ["1:1", 1036], ["(", 1040], ["13)C/(15)N", 1041], ["-", 1051], ["labeled", 1052], ["mAS", 1060], ["fibrils", 1064], ["reveal", 1072], ["a", 1079], ["parallel", 1081], [",", 1089], ["in", 1091], ["-", 1093], ["register", 1094], ["supramolecular", 1103], ["\u03b2", 1118], ["-", 1119], ["sheet", 1120], ["arrangement", 1126], [".", 1137], ["The", 1139], ["results", 1143], ["were", 1151], ["compared", 1156], ["in", 1165], ["detail", 1168], ["to", 1175], ["recent", 1178], ["structural", 1185], ["studies", 1196], ["on", 1204], ["hAS", 1207], ["fibrils", 1211], ["and", 1219], ["indicate", 1223], ["the", 1232], ["presence", 1236], ["of", 1245], ["a", 1248], ["structurally", 1250], ["conserved", 1263], ["motif", 1273], ["comprising", 1279], ["residues", 1290], ["Glu61-Lys80", 1299], [".", 1310]]}
{"context": "To assess the pharmacokinetics of dapivirine in plasma and dapivirine concentrations in cervicovaginal fluids (CVF) and cervicovaginal tissues following vaginal administration of dapivirine microbicide gel in healthy, HIV-negative women for 10 days. A randomized, double-blind, phase I study was conducted at a single research center in South Africa. A total of 18 women used dapivirine gel (0.001%, 0.005%, or 0.02%) once daily on Days 1 and 10 and twice daily on Days 2-9. Pharmacokinetics of dapivirine were assessed in plasma on Days 1 and 10. Dapivirine concentrations were measured in CVF on Days 1 and 10 and in cervicovaginal tissues on Day 10. Safety was evaluated through laboratory tests (hematology, clinical chemistry, and urinalysis), physical examinations, and assessment of adverse events. Plasma concentrations of dapivirine increased over time with gel dose and were greater on Day 10 (C(max) 31 to 471\u2009pg/ml) than Day 1 (C(max) 23 to 80\u2009pg/ml). T(max) was 10-12\u2009h on Day 1, and 9\u2009h on Day 10. Concentrations in CVF generally increased with dose but were highly variable among participants. Mean peak values ranged from 4.6-8.3\u2009\u00d7\u200910(6) pg/ml on Day 1 and from 2.3-20.7\u2009\u00d7\u200910(6) pg/ml on Day 10 across dose groups. Dapivirine was detectable in all tissue biopsies on Day 10 at concentrations of 1.0-356\u2009\u00d7\u200910(3) pg/mg. Dapivirine was widely distributed throughout the lower genital tract with low systemic absorption when administered in a vaginal gel formulation for 10 consecutive days. The gel was safe and well tolerated.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "8e635a9039f64438813f3959150c7590", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[30, 30]], "char_spans": [[218, 220]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["pharmacokinetics", 14], ["of", 31], ["dapivirine", 34], ["in", 45], ["plasma", 48], ["and", 55], ["dapivirine", 59], ["concentrations", 70], ["in", 85], ["cervicovaginal", 88], ["fluids", 103], ["(", 110], ["CVF", 111], [")", 114], ["and", 116], ["cervicovaginal", 120], ["tissues", 135], ["following", 143], ["vaginal", 153], ["administration", 161], ["of", 176], ["dapivirine", 179], ["microbicide", 190], ["gel", 202], ["in", 206], ["healthy", 209], [",", 216], ["HIV", 218], ["-", 221], ["negative", 222], ["women", 231], ["for", 237], ["10", 241], ["days", 244], [".", 248], ["A", 250], ["randomized", 252], [",", 262], ["double", 264], ["-", 270], ["blind", 271], [",", 276], ["phase", 278], ["I", 284], ["study", 286], ["was", 292], ["conducted", 296], ["at", 306], ["a", 309], ["single", 311], ["research", 318], ["center", 327], ["in", 334], ["South", 337], ["Africa", 343], [".", 349], ["A", 351], ["total", 353], ["of", 359], ["18", 362], ["women", 365], ["used", 371], ["dapivirine", 376], ["gel", 387], ["(", 391], ["0.001", 392], ["%", 397], [",", 398], ["0.005", 400], ["%", 405], [",", 406], ["or", 408], ["0.02", 411], ["%", 415], [")", 416], ["once", 418], ["daily", 423], ["on", 429], ["Days", 432], ["1", 437], ["and", 439], ["10", 443], ["and", 446], ["twice", 450], ["daily", 456], ["on", 462], ["Days", 465], ["2", 470], ["-", 471], ["9", 472], [".", 473], ["Pharmacokinetics", 475], ["of", 492], ["dapivirine", 495], ["were", 506], ["assessed", 511], ["in", 520], ["plasma", 523], ["on", 530], ["Days", 533], ["1", 538], ["and", 540], ["10", 544], [".", 546], ["Dapivirine", 548], ["concentrations", 559], ["were", 574], ["measured", 579], ["in", 588], ["CVF", 591], ["on", 595], ["Days", 598], ["1", 603], ["and", 605], ["10", 609], ["and", 612], ["in", 616], ["cervicovaginal", 619], ["tissues", 634], ["on", 642], ["Day", 645], ["10", 649], [".", 651], ["Safety", 653], ["was", 660], ["evaluated", 664], ["through", 674], ["laboratory", 682], ["tests", 693], ["(", 699], ["hematology", 700], [",", 710], ["clinical", 712], ["chemistry", 721], [",", 730], ["and", 732], ["urinalysis", 736], [")", 746], [",", 747], ["physical", 749], ["examinations", 758], [",", 770], ["and", 772], ["assessment", 776], ["of", 787], ["adverse", 790], ["events", 798], [".", 804], ["Plasma", 806], ["concentrations", 813], ["of", 828], ["dapivirine", 831], ["increased", 842], ["over", 852], ["time", 857], ["with", 862], ["gel", 867], ["dose", 871], ["and", 876], ["were", 880], ["greater", 885], ["on", 893], ["Day", 896], ["10", 900], ["(", 903], ["C(max", 904], [")", 909], ["31", 911], ["to", 914], ["471", 917], ["pg", 921], ["/", 923], ["ml", 924], [")", 926], ["than", 928], ["Day", 933], ["1", 937], ["(", 939], ["C(max", 940], [")", 945], ["23", 947], ["to", 950], ["80", 953], ["pg", 956], ["/", 958], ["ml", 959], [")", 961], [".", 962], ["T(max", 964], [")", 969], ["was", 971], ["10", 975], ["-", 977], ["12", 978], ["h", 981], ["on", 983], ["Day", 986], ["1", 990], [",", 991], ["and", 993], ["9", 997], ["h", 999], ["on", 1001], ["Day", 1004], ["10", 1008], [".", 1010], ["Concentrations", 1012], ["in", 1027], ["CVF", 1030], ["generally", 1034], ["increased", 1044], ["with", 1054], ["dose", 1059], ["but", 1064], ["were", 1068], ["highly", 1073], ["variable", 1080], ["among", 1089], ["participants", 1095], [".", 1107], ["Mean", 1109], ["peak", 1114], ["values", 1119], ["ranged", 1126], ["from", 1133], ["4.6", 1138], ["-", 1141], ["8.3", 1142], ["\u00d7", 1146], ["10(6", 1148], [")", 1152], ["pg", 1154], ["/", 1156], ["ml", 1157], ["on", 1160], ["Day", 1163], ["1", 1167], ["and", 1169], ["from", 1173], ["2.3", 1178], ["-", 1181], ["20.7", 1182], ["\u00d7", 1187], ["10(6", 1189], [")", 1193], ["pg", 1195], ["/", 1197], ["ml", 1198], ["on", 1201], ["Day", 1204], ["10", 1208], ["across", 1211], ["dose", 1218], ["groups", 1223], [".", 1229], ["Dapivirine", 1231], ["was", 1242], ["detectable", 1246], ["in", 1257], ["all", 1260], ["tissue", 1264], ["biopsies", 1271], ["on", 1280], ["Day", 1283], ["10", 1287], ["at", 1290], ["concentrations", 1293], ["of", 1308], ["1.0", 1311], ["-", 1314], ["356", 1315], ["\u00d7", 1319], ["10(3", 1321], [")", 1325], ["pg", 1327], ["/", 1329], ["mg", 1330], [".", 1332], ["Dapivirine", 1334], ["was", 1345], ["widely", 1349], ["distributed", 1356], ["throughout", 1368], ["the", 1379], ["lower", 1383], ["genital", 1389], ["tract", 1397], ["with", 1403], ["low", 1408], ["systemic", 1412], ["absorption", 1421], ["when", 1432], ["administered", 1437], ["in", 1450], ["a", 1453], ["vaginal", 1455], ["gel", 1463], ["formulation", 1467], ["for", 1479], ["10", 1483], ["consecutive", 1486], ["days", 1498], [".", 1502], ["The", 1504], ["gel", 1508], ["was", 1512], ["safe", 1516], ["and", 1521], ["well", 1525], ["tolerated", 1530], [".", 1539]]}
{"context": "Acrokeratosis paraneoplastica (Bazex' syndrome) is a rare but clinically distinctive dermatosis that has been associated in all reported cases, to our knowledge, with either a primary malignant neoplasm of the upper aerodigestive tract or metastatic cancer to the lymph nodes of the neck. Acrokeratosis paraneoplastica was found in a 53-year-old black man with squamous cell carcinoma of the tonsil. A distinctive series of changes was found on histopathologic examination of biopsy specimens taken from his skin lesions, and direct immunofluorescence microscopy of both lesional and nonlesional skin specimens showed immunoglobulin and complement deposition on the epidermal basement membrane. The skin lesions largely resolved following radiation therapy of the neoplasm and of the presumably involved lymph nodes.", "qas": [{"question": "Name synonym of Acrokeratosis paraneoplastica.", "answers": ["Bazex syndrome"], "qid": "a9d9940bee7341a8a218451d58740c07", "question_tokens": [["Name", 0], ["synonym", 5], ["of", 13], ["Acrokeratosis", 16], ["paraneoplastica", 30], [".", 45]], "detected_answers": [{"text": "Bazex syndrome", "token_spans": [[3, 5]], "char_spans": [[31, 45]]}]}], "context_tokens": [["Acrokeratosis", 0], ["paraneoplastica", 14], ["(", 30], ["Bazex", 31], ["'", 36], ["syndrome", 38], [")", 46], ["is", 48], ["a", 51], ["rare", 53], ["but", 58], ["clinically", 62], ["distinctive", 73], ["dermatosis", 85], ["that", 96], ["has", 101], ["been", 105], ["associated", 110], ["in", 121], ["all", 124], ["reported", 128], ["cases", 137], [",", 142], ["to", 144], ["our", 147], ["knowledge", 151], [",", 160], ["with", 162], ["either", 167], ["a", 174], ["primary", 176], ["malignant", 184], ["neoplasm", 194], ["of", 203], ["the", 206], ["upper", 210], ["aerodigestive", 216], ["tract", 230], ["or", 236], ["metastatic", 239], ["cancer", 250], ["to", 257], ["the", 260], ["lymph", 264], ["nodes", 270], ["of", 276], ["the", 279], ["neck", 283], [".", 287], ["Acrokeratosis", 289], ["paraneoplastica", 303], ["was", 319], ["found", 323], ["in", 329], ["a", 332], ["53-year", 334], ["-", 341], ["old", 342], ["black", 346], ["man", 352], ["with", 356], ["squamous", 361], ["cell", 370], ["carcinoma", 375], ["of", 385], ["the", 388], ["tonsil", 392], [".", 398], ["A", 400], ["distinctive", 402], ["series", 414], ["of", 421], ["changes", 424], ["was", 432], ["found", 436], ["on", 442], ["histopathologic", 445], ["examination", 461], ["of", 473], ["biopsy", 476], ["specimens", 483], ["taken", 493], ["from", 499], ["his", 504], ["skin", 508], ["lesions", 513], [",", 520], ["and", 522], ["direct", 526], ["immunofluorescence", 533], ["microscopy", 552], ["of", 563], ["both", 566], ["lesional", 571], ["and", 580], ["nonlesional", 584], ["skin", 596], ["specimens", 601], ["showed", 611], ["immunoglobulin", 618], ["and", 633], ["complement", 637], ["deposition", 648], ["on", 659], ["the", 662], ["epidermal", 666], ["basement", 676], ["membrane", 685], [".", 693], ["The", 695], ["skin", 699], ["lesions", 704], ["largely", 712], ["resolved", 720], ["following", 729], ["radiation", 739], ["therapy", 749], ["of", 757], ["the", 760], ["neoplasm", 764], ["and", 773], ["of", 777], ["the", 780], ["presumably", 784], ["involved", 795], ["lymph", 804], ["nodes", 810], [".", 815]]}
{"context": "Osteoporosis is characterised by a progressive loss of bone mass and microarchitecture which leads to increased fracture risk. Some of the drugs available to date have shown reductions in vertebral and non-vertebral fracture risk. However, in the ageing population of industrialised countries, still more fractures happen today than are avoided, which highlights the large medical need for new treatment options, models, and strategies. Recent insights into bone biology, have led to a better understanding of bone cell functions and crosstalk between osteoblasts, osteoclasts, and osteocytes at the molecular level. In the future, the armamentarium against osteoporotic fractures will likely be enriched by (1.) new bone anabolic substances such as antibodies directed against the endogenous inhibitors of bone formation sclerostin and dickkopf-1, PTH and PTHrp analogues, and possibly calcilytics; (2.) new inhibitors of bone resorption such as cathepsin K inhibitors which may suppress osteoclast function without impairing osteoclast viability and thus maintain bone formation by preserving the osteoclast-osteoblast crosstalk, and denosumab, an already widely available antibody against RANKL which inhibits osteoclast formation, function, and survival; and (3.) new therapeutic strategies based on an extended understanding of the pathophysiology of osteoporosis which may include sequential therapies with two or more bone active substances aimed at optimising the management of bone capital acquired during adolescence and maintained during adulthood in terms of both quantity and quality. Finally, one of the future challenges will be to identify those patients and patient populations expected to benefit the most from a given drug therapy or regimen. The WHO fracture risk assessment tool FRAX\u00ae and improved access to bone mineral density measurements by DXA will play a key role in this regard.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "66863c5ce37e431c8b6c293c8776da2d", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[194, 194]], "char_spans": [[1192, 1196]]}]}], "context_tokens": [["Osteoporosis", 0], ["is", 13], ["characterised", 16], ["by", 30], ["a", 33], ["progressive", 35], ["loss", 47], ["of", 52], ["bone", 55], ["mass", 60], ["and", 65], ["microarchitecture", 69], ["which", 87], ["leads", 93], ["to", 99], ["increased", 102], ["fracture", 112], ["risk", 121], [".", 125], ["Some", 127], ["of", 132], ["the", 135], ["drugs", 139], ["available", 145], ["to", 155], ["date", 158], ["have", 163], ["shown", 168], ["reductions", 174], ["in", 185], ["vertebral", 188], ["and", 198], ["non", 202], ["-", 205], ["vertebral", 206], ["fracture", 216], ["risk", 225], [".", 229], ["However", 231], [",", 238], ["in", 240], ["the", 243], ["ageing", 247], ["population", 254], ["of", 265], ["industrialised", 268], ["countries", 283], [",", 292], ["still", 294], ["more", 300], ["fractures", 305], ["happen", 315], ["today", 322], ["than", 328], ["are", 333], ["avoided", 337], [",", 344], ["which", 346], ["highlights", 352], ["the", 363], ["large", 367], ["medical", 373], ["need", 381], ["for", 386], ["new", 390], ["treatment", 394], ["options", 404], [",", 411], ["models", 413], [",", 419], ["and", 421], ["strategies", 425], [".", 435], ["Recent", 437], ["insights", 444], ["into", 453], ["bone", 458], ["biology", 463], [",", 470], ["have", 472], ["led", 477], ["to", 481], ["a", 484], ["better", 486], ["understanding", 493], ["of", 507], ["bone", 510], ["cell", 515], ["functions", 520], ["and", 530], ["crosstalk", 534], ["between", 544], ["osteoblasts", 552], [",", 563], ["osteoclasts", 565], [",", 576], ["and", 578], ["osteocytes", 582], ["at", 593], ["the", 596], ["molecular", 600], ["level", 610], [".", 615], ["In", 617], ["the", 620], ["future", 624], [",", 630], ["the", 632], ["armamentarium", 636], ["against", 650], ["osteoporotic", 658], ["fractures", 671], ["will", 681], ["likely", 686], ["be", 693], ["enriched", 696], ["by", 705], ["(", 708], ["1", 709], [".", 710], [")", 711], ["new", 713], ["bone", 717], ["anabolic", 722], ["substances", 731], ["such", 742], ["as", 747], ["antibodies", 750], ["directed", 761], ["against", 770], ["the", 778], ["endogenous", 782], ["inhibitors", 793], ["of", 804], ["bone", 807], ["formation", 812], ["sclerostin", 822], ["and", 833], ["dickkopf-1", 837], [",", 847], ["PTH", 849], ["and", 853], ["PTHrp", 857], ["analogues", 863], [",", 872], ["and", 874], ["possibly", 878], ["calcilytics", 887], [";", 898], ["(", 900], ["2", 901], [".", 902], [")", 903], ["new", 905], ["inhibitors", 909], ["of", 920], ["bone", 923], ["resorption", 928], ["such", 939], ["as", 944], ["cathepsin", 947], ["K", 957], ["inhibitors", 959], ["which", 970], ["may", 976], ["suppress", 980], ["osteoclast", 989], ["function", 1000], ["without", 1009], ["impairing", 1017], ["osteoclast", 1027], ["viability", 1038], ["and", 1048], ["thus", 1052], ["maintain", 1057], ["bone", 1066], ["formation", 1071], ["by", 1081], ["preserving", 1084], ["the", 1095], ["osteoclast", 1099], ["-", 1109], ["osteoblast", 1110], ["crosstalk", 1121], [",", 1130], ["and", 1132], ["denosumab", 1136], [",", 1145], ["an", 1147], ["already", 1150], ["widely", 1158], ["available", 1165], ["antibody", 1175], ["against", 1184], ["RANKL", 1192], ["which", 1198], ["inhibits", 1204], ["osteoclast", 1213], ["formation", 1224], [",", 1233], ["function", 1235], [",", 1243], ["and", 1245], ["survival", 1249], [";", 1257], ["and", 1259], ["(", 1263], ["3", 1264], [".", 1265], [")", 1266], ["new", 1268], ["therapeutic", 1272], ["strategies", 1284], ["based", 1295], ["on", 1301], ["an", 1304], ["extended", 1307], ["understanding", 1316], ["of", 1330], ["the", 1333], ["pathophysiology", 1337], ["of", 1353], ["osteoporosis", 1356], ["which", 1369], ["may", 1375], ["include", 1379], ["sequential", 1387], ["therapies", 1398], ["with", 1408], ["two", 1413], ["or", 1417], ["more", 1420], ["bone", 1425], ["active", 1430], ["substances", 1437], ["aimed", 1448], ["at", 1454], ["optimising", 1457], ["the", 1468], ["management", 1472], ["of", 1483], ["bone", 1486], ["capital", 1491], ["acquired", 1499], ["during", 1508], ["adolescence", 1515], ["and", 1527], ["maintained", 1531], ["during", 1542], ["adulthood", 1549], ["in", 1559], ["terms", 1562], ["of", 1568], ["both", 1571], ["quantity", 1576], ["and", 1585], ["quality", 1589], [".", 1596], ["Finally", 1598], [",", 1605], ["one", 1607], ["of", 1611], ["the", 1614], ["future", 1618], ["challenges", 1625], ["will", 1636], ["be", 1641], ["to", 1644], ["identify", 1647], ["those", 1656], ["patients", 1662], ["and", 1671], ["patient", 1675], ["populations", 1683], ["expected", 1695], ["to", 1704], ["benefit", 1707], ["the", 1715], ["most", 1719], ["from", 1724], ["a", 1729], ["given", 1731], ["drug", 1737], ["therapy", 1742], ["or", 1750], ["regimen", 1753], [".", 1760], ["The", 1762], ["WHO", 1766], ["fracture", 1770], ["risk", 1779], ["assessment", 1784], ["tool", 1795], ["FRAX", 1800], ["\u00ae", 1804], ["and", 1806], ["improved", 1810], ["access", 1819], ["to", 1826], ["bone", 1829], ["mineral", 1834], ["density", 1842], ["measurements", 1850], ["by", 1863], ["DXA", 1866], ["will", 1870], ["play", 1875], ["a", 1880], ["key", 1882], ["role", 1886], ["in", 1891], ["this", 1894], ["regard", 1899], [".", 1905]]}
{"context": "Bone destruction is a prominent feature of multiple myeloma, but conflicting data exist on the expression and pathophysiologic involvement of the bone remodeling ligand RANKL in this disease and the potential therapeutic benefits of its targeted inhibition. Here, we show that RANKL is expressed by primary multiple myeloma and chronic lymphocytic leukemia (CLL) cells, whereas release of soluble RANKL was observed exclusively with multiple myeloma cells and was strongly influenced by posttranscriptional/posttranslational regulation. Signaling via RANKL into multiple myeloma and CLL cells induced release of cytokines involved in disease pathophysiology. Both the effects of RANKL on osteoclastogenesis and cytokine production by malignant cells could be blocked by disruption of RANK-RANKL interaction with denosumab. As we aimed to combine neutralization of RANKL with induction of antibody-dependent cellular cytotoxicity of natural killer (NK) cells against RANKL-expressing malignant cells and as denosumab does not stimulate NK reactivity, we generated RANK-Fc fusion proteins with modified Fc moieties. The latter displayed similar capacity compared with denosumab to neutralize the effects of RANKL on osteoclastogenesis in vitro, but also potently stimulated NK cell reactivity against primary RANKL-expressing malignant B cells, which was dependent on their engineered affinity to CD16. Our findings introduce Fc-optimized RANK-Ig fusion proteins as attractive tools to neutralize the detrimental function of RANKL while at the same time potently stimulating NK cell antitumor immunity.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "513ee6b7112740b7afa36d176c0f833f", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[64, 64], [133, 133], [189, 189], [150, 150], [44, 44], [84, 84], [25, 25], [121, 121], [204, 204], [104, 104], [241, 241]], "char_spans": [[397, 401], [864, 868], [1205, 1209], [966, 970], [277, 281], [551, 555], [169, 173], [789, 793], [1307, 1311], [679, 683], [1523, 1527]]}]}], "context_tokens": [["Bone", 0], ["destruction", 5], ["is", 17], ["a", 20], ["prominent", 22], ["feature", 32], ["of", 40], ["multiple", 43], ["myeloma", 52], [",", 59], ["but", 61], ["conflicting", 65], ["data", 77], ["exist", 82], ["on", 88], ["the", 91], ["expression", 95], ["and", 106], ["pathophysiologic", 110], ["involvement", 127], ["of", 139], ["the", 142], ["bone", 146], ["remodeling", 151], ["ligand", 162], ["RANKL", 169], ["in", 175], ["this", 178], ["disease", 183], ["and", 191], ["the", 195], ["potential", 199], ["therapeutic", 209], ["benefits", 221], ["of", 230], ["its", 233], ["targeted", 237], ["inhibition", 246], [".", 256], ["Here", 258], [",", 262], ["we", 264], ["show", 267], ["that", 272], ["RANKL", 277], ["is", 283], ["expressed", 286], ["by", 296], ["primary", 299], ["multiple", 307], ["myeloma", 316], ["and", 324], ["chronic", 328], ["lymphocytic", 336], ["leukemia", 348], ["(", 357], ["CLL", 358], [")", 361], ["cells", 363], [",", 368], ["whereas", 370], ["release", 378], ["of", 386], ["soluble", 389], ["RANKL", 397], ["was", 403], ["observed", 407], ["exclusively", 416], ["with", 428], ["multiple", 433], ["myeloma", 442], ["cells", 450], ["and", 456], ["was", 460], ["strongly", 464], ["influenced", 473], ["by", 484], ["posttranscriptional", 487], ["/", 506], ["posttranslational", 507], ["regulation", 525], [".", 535], ["Signaling", 537], ["via", 547], ["RANKL", 551], ["into", 557], ["multiple", 562], ["myeloma", 571], ["and", 579], ["CLL", 583], ["cells", 587], ["induced", 593], ["release", 601], ["of", 609], ["cytokines", 612], ["involved", 622], ["in", 631], ["disease", 634], ["pathophysiology", 642], [".", 657], ["Both", 659], ["the", 664], ["effects", 668], ["of", 676], ["RANKL", 679], ["on", 685], ["osteoclastogenesis", 688], ["and", 707], ["cytokine", 711], ["production", 720], ["by", 731], ["malignant", 734], ["cells", 744], ["could", 750], ["be", 756], ["blocked", 759], ["by", 767], ["disruption", 770], ["of", 781], ["RANK", 784], ["-", 788], ["RANKL", 789], ["interaction", 795], ["with", 807], ["denosumab", 812], [".", 821], ["As", 823], ["we", 826], ["aimed", 829], ["to", 835], ["combine", 838], ["neutralization", 846], ["of", 861], ["RANKL", 864], ["with", 870], ["induction", 875], ["of", 885], ["antibody", 888], ["-", 896], ["dependent", 897], ["cellular", 907], ["cytotoxicity", 916], ["of", 929], ["natural", 932], ["killer", 940], ["(", 947], ["NK", 948], [")", 950], ["cells", 952], ["against", 958], ["RANKL", 966], ["-", 971], ["expressing", 972], ["malignant", 983], ["cells", 993], ["and", 999], ["as", 1003], ["denosumab", 1006], ["does", 1016], ["not", 1021], ["stimulate", 1025], ["NK", 1035], ["reactivity", 1038], [",", 1048], ["we", 1050], ["generated", 1053], ["RANK", 1063], ["-", 1067], ["Fc", 1068], ["fusion", 1071], ["proteins", 1078], ["with", 1087], ["modified", 1092], ["Fc", 1101], ["moieties", 1104], [".", 1112], ["The", 1114], ["latter", 1118], ["displayed", 1125], ["similar", 1135], ["capacity", 1143], ["compared", 1152], ["with", 1161], ["denosumab", 1166], ["to", 1176], ["neutralize", 1179], ["the", 1190], ["effects", 1194], ["of", 1202], ["RANKL", 1205], ["on", 1211], ["osteoclastogenesis", 1214], ["in", 1233], ["vitro", 1236], [",", 1241], ["but", 1243], ["also", 1247], ["potently", 1252], ["stimulated", 1261], ["NK", 1272], ["cell", 1275], ["reactivity", 1280], ["against", 1291], ["primary", 1299], ["RANKL", 1307], ["-", 1312], ["expressing", 1313], ["malignant", 1324], ["B", 1334], ["cells", 1336], [",", 1341], ["which", 1343], ["was", 1349], ["dependent", 1353], ["on", 1363], ["their", 1366], ["engineered", 1372], ["affinity", 1383], ["to", 1392], ["CD16", 1395], [".", 1399], ["Our", 1401], ["findings", 1405], ["introduce", 1414], ["Fc", 1424], ["-", 1426], ["optimized", 1427], ["RANK", 1437], ["-", 1441], ["Ig", 1442], ["fusion", 1445], ["proteins", 1452], ["as", 1461], ["attractive", 1464], ["tools", 1475], ["to", 1481], ["neutralize", 1484], ["the", 1495], ["detrimental", 1499], ["function", 1511], ["of", 1520], ["RANKL", 1523], ["while", 1529], ["at", 1535], ["the", 1538], ["same", 1542], ["time", 1547], ["potently", 1552], ["stimulating", 1561], ["NK", 1573], ["cell", 1576], ["antitumor", 1581], ["immunity", 1591], [".", 1599]]}
{"context": "1. In order to investigate the biological function of the human CLN3 gene that is defective in Batten disease, we created a yeast strain by PCR-targeted disruption of the yeast gene (YHC3), which is a homologue of the human CLN3 gene. 2. The phenotypic characterization revealed that the yhc3 delta mutants are more sensitive to combined heat and alkaline stress than the wild-type strains as determined by inhibition of cell proliferation. 3. This suggests that the yhc3 delta mutant is a good model to investigate the biological function of human CLN3 gene in mammalian cells and to understand the pathophysiology of juvenile Batten disease.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "9bb5d9f90f804b34971f0a239f63343b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[18, 19], [115, 116]], "char_spans": [[95, 108], [628, 641]]}]}], "context_tokens": [["1", 0], [".", 1], ["In", 3], ["order", 6], ["to", 12], ["investigate", 15], ["the", 27], ["biological", 31], ["function", 42], ["of", 51], ["the", 54], ["human", 58], ["CLN3", 64], ["gene", 69], ["that", 74], ["is", 79], ["defective", 82], ["in", 92], ["Batten", 95], ["disease", 102], [",", 109], ["we", 111], ["created", 114], ["a", 122], ["yeast", 124], ["strain", 130], ["by", 137], ["PCR", 140], ["-", 143], ["targeted", 144], ["disruption", 153], ["of", 164], ["the", 167], ["yeast", 171], ["gene", 177], ["(", 182], ["YHC3", 183], [")", 187], [",", 188], ["which", 190], ["is", 196], ["a", 199], ["homologue", 201], ["of", 211], ["the", 214], ["human", 218], ["CLN3", 224], ["gene", 229], [".", 233], ["2", 235], [".", 236], ["The", 238], ["phenotypic", 242], ["characterization", 253], ["revealed", 270], ["that", 279], ["the", 284], ["yhc3", 288], ["delta", 293], ["mutants", 299], ["are", 307], ["more", 311], ["sensitive", 316], ["to", 326], ["combined", 329], ["heat", 338], ["and", 343], ["alkaline", 347], ["stress", 356], ["than", 363], ["the", 368], ["wild", 372], ["-", 376], ["type", 377], ["strains", 382], ["as", 390], ["determined", 393], ["by", 404], ["inhibition", 407], ["of", 418], ["cell", 421], ["proliferation", 426], [".", 439], ["3", 441], [".", 442], ["This", 444], ["suggests", 449], ["that", 458], ["the", 463], ["yhc3", 467], ["delta", 472], ["mutant", 478], ["is", 485], ["a", 488], ["good", 490], ["model", 495], ["to", 501], ["investigate", 504], ["the", 516], ["biological", 520], ["function", 531], ["of", 540], ["human", 543], ["CLN3", 549], ["gene", 554], ["in", 559], ["mammalian", 562], ["cells", 572], ["and", 578], ["to", 582], ["understand", 585], ["the", 596], ["pathophysiology", 600], ["of", 616], ["juvenile", 619], ["Batten", 628], ["disease", 635], [".", 642]]}
{"context": "Venous thromboembolism (VTE) is associated with significant morbidity and mortality. Factors such as the presence of transient risk factors for VTE, risk of bleeding, and location of deep vein thrombosis (DVT) determine the duration of anticoagulation. Extended anticoagulation is offered to patients with unprovoked pulmonary embolism (PE) or proximal DVT and a low risk of bleeding. Anticoagulation for 3 months is advised in patients with provoked DVT or PE, high risk of bleeding, and isolated distal or upper extremity DVT. In patients with unprovoked PE or proximal DVT and a low risk of bleeding, who want to stop anticoagulation after 3 months, further risk stratification is necessary. Clinical scoring system, and thrombophilia testing otherwise not routinely performed, may be considered to measure risk of annual recurrence in such cases. Short-term anticoagulation may be considered in subsegmental PE and superficial vein thrombosis, particularly if patients are at low risk of bleeding and have persistent risk factors for recurrent VTE. In cases of catheter-associated thrombosis, the catheter need not be removed routinely, and the patient may be anticoagulated for 3 months or longer if the catheter is maintained in patients with cancer. Extensive screening for occult cancer in cases of unprovoked VTE is not beneficial. New oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "db97a187c75442e883f177344a687937", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[243, 243]], "char_spans": [[1399, 1408]]}]}], "context_tokens": [["Venous", 0], ["thromboembolism", 7], ["(", 23], ["VTE", 24], [")", 27], ["is", 29], ["associated", 32], ["with", 43], ["significant", 48], ["morbidity", 60], ["and", 70], ["mortality", 74], [".", 83], ["Factors", 85], ["such", 93], ["as", 98], ["the", 101], ["presence", 105], ["of", 114], ["transient", 117], ["risk", 127], ["factors", 132], ["for", 140], ["VTE", 144], [",", 147], ["risk", 149], ["of", 154], ["bleeding", 157], [",", 165], ["and", 167], ["location", 171], ["of", 180], ["deep", 183], ["vein", 188], ["thrombosis", 193], ["(", 204], ["DVT", 205], [")", 208], ["determine", 210], ["the", 220], ["duration", 224], ["of", 233], ["anticoagulation", 236], [".", 251], ["Extended", 253], ["anticoagulation", 262], ["is", 278], ["offered", 281], ["to", 289], ["patients", 292], ["with", 301], ["unprovoked", 306], ["pulmonary", 317], ["embolism", 327], ["(", 336], ["PE", 337], [")", 339], ["or", 341], ["proximal", 344], ["DVT", 353], ["and", 357], ["a", 361], ["low", 363], ["risk", 367], ["of", 372], ["bleeding", 375], [".", 383], ["Anticoagulation", 385], ["for", 401], ["3", 405], ["months", 407], ["is", 414], ["advised", 417], ["in", 425], ["patients", 428], ["with", 437], ["provoked", 442], ["DVT", 451], ["or", 455], ["PE", 458], [",", 460], ["high", 462], ["risk", 467], ["of", 472], ["bleeding", 475], [",", 483], ["and", 485], ["isolated", 489], ["distal", 498], ["or", 505], ["upper", 508], ["extremity", 514], ["DVT", 524], [".", 527], ["In", 529], ["patients", 532], ["with", 541], ["unprovoked", 546], ["PE", 557], ["or", 560], ["proximal", 563], ["DVT", 572], ["and", 576], ["a", 580], ["low", 582], ["risk", 586], ["of", 591], ["bleeding", 594], [",", 602], ["who", 604], ["want", 608], ["to", 613], ["stop", 616], ["anticoagulation", 621], ["after", 637], ["3", 643], ["months", 645], [",", 651], ["further", 653], ["risk", 661], ["stratification", 666], ["is", 681], ["necessary", 684], [".", 693], ["Clinical", 695], ["scoring", 704], ["system", 712], [",", 718], ["and", 720], ["thrombophilia", 724], ["testing", 738], ["otherwise", 746], ["not", 756], ["routinely", 760], ["performed", 770], [",", 779], ["may", 781], ["be", 785], ["considered", 788], ["to", 799], ["measure", 802], ["risk", 810], ["of", 815], ["annual", 818], ["recurrence", 825], ["in", 836], ["such", 839], ["cases", 844], [".", 849], ["Short", 851], ["-", 856], ["term", 857], ["anticoagulation", 862], ["may", 878], ["be", 882], ["considered", 885], ["in", 896], ["subsegmental", 899], ["PE", 912], ["and", 915], ["superficial", 919], ["vein", 931], ["thrombosis", 936], [",", 946], ["particularly", 948], ["if", 961], ["patients", 964], ["are", 973], ["at", 977], ["low", 980], ["risk", 984], ["of", 989], ["bleeding", 992], ["and", 1001], ["have", 1005], ["persistent", 1010], ["risk", 1021], ["factors", 1026], ["for", 1034], ["recurrent", 1038], ["VTE", 1048], [".", 1051], ["In", 1053], ["cases", 1056], ["of", 1062], ["catheter", 1065], ["-", 1073], ["associated", 1074], ["thrombosis", 1085], [",", 1095], ["the", 1097], ["catheter", 1101], ["need", 1110], ["not", 1115], ["be", 1119], ["removed", 1122], ["routinely", 1130], [",", 1139], ["and", 1141], ["the", 1145], ["patient", 1149], ["may", 1157], ["be", 1161], ["anticoagulated", 1164], ["for", 1179], ["3", 1183], ["months", 1185], ["or", 1192], ["longer", 1195], ["if", 1202], ["the", 1205], ["catheter", 1209], ["is", 1218], ["maintained", 1221], ["in", 1232], ["patients", 1235], ["with", 1244], ["cancer", 1249], [".", 1255], ["Extensive", 1257], ["screening", 1267], ["for", 1277], ["occult", 1281], ["cancer", 1288], ["in", 1295], ["cases", 1298], ["of", 1304], ["unprovoked", 1307], ["VTE", 1318], ["is", 1322], ["not", 1325], ["beneficial", 1329], [".", 1339], ["New", 1341], ["oral", 1345], ["anticoagulants", 1350], ["such", 1365], ["as", 1370], ["apixaban", 1373], [",", 1381], ["rivaroxaban", 1383], [",", 1394], ["or", 1396], ["dabigatran", 1399], ["may", 1410], ["be", 1414], ["preferred", 1417], ["to", 1427], ["vitamin", 1430], ["K", 1438], ["antagonists", 1440], ["in", 1452], ["patients", 1455], ["without", 1464], ["cancer", 1472], ["or", 1479], ["renal", 1482], ["failure", 1488], [",", 1495], ["more", 1497], ["so", 1502], ["after", 1505], ["the", 1511], ["development", 1515], ["of", 1527], ["reversal", 1530], ["agents", 1539], ["such", 1546], ["as", 1551], ["idarucizumab", 1554], ["and", 1567], ["andexanet", 1571], ["alfa", 1581], [".", 1585]]}
{"context": "With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in oncology, distinct cutaneous and oral adverse events have been identified. In fact, stomatitis and rash are documented as the most frequent and potentially dose-limiting side effects. Clinically, mTOR inhibitor-associated stomatitis (mIAS) more closely resembles aphthous stomatitis than oral mucositis due to conventional anticancer therapies. While most cases of mIAS are mild to moderate and self-limiting, more severe and persistent mIAS can become a dose-limiting toxicity. Small ulcerations may cause significant pain and mucosal sensitivity may occur in the absence of clinical changes. Use of clinical assessment tools that are primarily driven by ulceration size may underestimate mIAS, and assessment should include patient-reported outcomes. This article provides an up-to-date review of the clinical presentation, terminology, pathogenesis, assessment and management of mIAS and other mTOR inhibitor-associated oral adverse events. In addition, areas of future research are considered.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "51c0f6328c564f34adfee63c41eda084", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[7, 10]], "char_spans": [[46, 74]]}]}], "context_tokens": [["With", 0], ["the", 5], ["recent", 9], ["introduction", 16], ["of", 29], ["inhibitors", 32], ["of", 43], ["mammalian", 46], ["target", 56], ["of", 63], ["rapamycin", 66], ["(", 76], ["mTOR", 77], [")", 81], ["in", 83], ["oncology", 86], [",", 94], ["distinct", 96], ["cutaneous", 105], ["and", 115], ["oral", 119], ["adverse", 124], ["events", 132], ["have", 139], ["been", 144], ["identified", 149], [".", 159], ["In", 161], ["fact", 164], [",", 168], ["stomatitis", 170], ["and", 181], ["rash", 185], ["are", 190], ["documented", 194], ["as", 205], ["the", 208], ["most", 212], ["frequent", 217], ["and", 226], ["potentially", 230], ["dose", 242], ["-", 246], ["limiting", 247], ["side", 256], ["effects", 261], [".", 268], ["Clinically", 270], [",", 280], ["mTOR", 282], ["inhibitor", 287], ["-", 296], ["associated", 297], ["stomatitis", 308], ["(", 319], ["mIAS", 320], [")", 324], ["more", 326], ["closely", 331], ["resembles", 339], ["aphthous", 349], ["stomatitis", 358], ["than", 369], ["oral", 374], ["mucositis", 379], ["due", 389], ["to", 393], ["conventional", 396], ["anticancer", 409], ["therapies", 420], [".", 429], ["While", 431], ["most", 437], ["cases", 442], ["of", 448], ["mIAS", 451], ["are", 456], ["mild", 460], ["to", 465], ["moderate", 468], ["and", 477], ["self", 481], ["-", 485], ["limiting", 486], [",", 494], ["more", 496], ["severe", 501], ["and", 508], ["persistent", 512], ["mIAS", 523], ["can", 528], ["become", 532], ["a", 539], ["dose", 541], ["-", 545], ["limiting", 546], ["toxicity", 555], [".", 563], ["Small", 565], ["ulcerations", 571], ["may", 583], ["cause", 587], ["significant", 593], ["pain", 605], ["and", 610], ["mucosal", 614], ["sensitivity", 622], ["may", 634], ["occur", 638], ["in", 644], ["the", 647], ["absence", 651], ["of", 659], ["clinical", 662], ["changes", 671], [".", 678], ["Use", 680], ["of", 684], ["clinical", 687], ["assessment", 696], ["tools", 707], ["that", 713], ["are", 718], ["primarily", 722], ["driven", 732], ["by", 739], ["ulceration", 742], ["size", 753], ["may", 758], ["underestimate", 762], ["mIAS", 776], [",", 780], ["and", 782], ["assessment", 786], ["should", 797], ["include", 804], ["patient", 812], ["-", 819], ["reported", 820], ["outcomes", 829], [".", 837], ["This", 839], ["article", 844], ["provides", 852], ["an", 861], ["up", 864], ["-", 866], ["to", 867], ["-", 869], ["date", 870], ["review", 875], ["of", 882], ["the", 885], ["clinical", 889], ["presentation", 898], [",", 910], ["terminology", 912], [",", 923], ["pathogenesis", 925], [",", 937], ["assessment", 939], ["and", 950], ["management", 954], ["of", 965], ["mIAS", 968], ["and", 973], ["other", 977], ["mTOR", 983], ["inhibitor", 988], ["-", 997], ["associated", 998], ["oral", 1009], ["adverse", 1014], ["events", 1022], [".", 1028], ["In", 1030], ["addition", 1033], [",", 1041], ["areas", 1043], ["of", 1049], ["future", 1052], ["research", 1059], ["are", 1068], ["considered", 1072], [".", 1082]]}
{"context": "The mixed-lineage leukemia protein MLL1 is a transcriptional regulator with an essential role in early development and hematopoiesis. The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain. We have determined the crystal structure of the MLL1 SET domain in complex with cofactor product AdoHcy and a histone H3 peptide. This structure indicates that, in order to form a well-ordered active site, a highly variable but essential component of the SET domain must be repositioned. To test this idea, we compared the effect of the addition of MLL complex members on methyltransferase activity and show that both RbBP5 and Ash2L but not Wdr5 stimulate activity. Additionally, we have determined the effect of posttranslational modifications on histone H3 residues downstream and upstream from the target lysine and provide a structural explanation for why H3T3 phosphorylation and H3K9 acetylation regulate activity.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "76dece4105a44e9e9041be62fc48fbed", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[31, 31]], "char_spans": [[193, 196]]}]}], "context_tokens": [["The", 0], ["mixed", 4], ["-", 9], ["lineage", 10], ["leukemia", 18], ["protein", 27], ["MLL1", 35], ["is", 40], ["a", 43], ["transcriptional", 45], ["regulator", 61], ["with", 71], ["an", 76], ["essential", 79], ["role", 89], ["in", 94], ["early", 97], ["development", 103], ["and", 115], ["hematopoiesis", 119], [".", 132], ["The", 134], ["biological", 138], ["function", 149], ["of", 158], ["MLL1", 161], ["is", 166], ["mediated", 169], ["by", 178], ["the", 181], ["histone", 185], ["H3K4", 193], ["methyltransferase", 198], ["activity", 216], ["of", 225], ["the", 228], ["carboxyl", 232], ["-", 240], ["terminal", 241], ["SET", 250], ["domain", 254], [".", 260], ["We", 262], ["have", 265], ["determined", 270], ["the", 281], ["crystal", 285], ["structure", 293], ["of", 303], ["the", 306], ["MLL1", 310], ["SET", 315], ["domain", 319], ["in", 326], ["complex", 329], ["with", 337], ["cofactor", 342], ["product", 351], ["AdoHcy", 359], ["and", 366], ["a", 370], ["histone", 372], ["H3", 380], ["peptide", 383], [".", 390], ["This", 392], ["structure", 397], ["indicates", 407], ["that", 417], [",", 421], ["in", 423], ["order", 426], ["to", 432], ["form", 435], ["a", 440], ["well", 442], ["-", 446], ["ordered", 447], ["active", 455], ["site", 462], [",", 466], ["a", 468], ["highly", 470], ["variable", 477], ["but", 486], ["essential", 490], ["component", 500], ["of", 510], ["the", 513], ["SET", 517], ["domain", 521], ["must", 528], ["be", 533], ["repositioned", 536], [".", 548], ["To", 550], ["test", 553], ["this", 558], ["idea", 563], [",", 567], ["we", 569], ["compared", 572], ["the", 581], ["effect", 585], ["of", 592], ["the", 595], ["addition", 599], ["of", 608], ["MLL", 611], ["complex", 615], ["members", 623], ["on", 631], ["methyltransferase", 634], ["activity", 652], ["and", 661], ["show", 665], ["that", 670], ["both", 675], ["RbBP5", 680], ["and", 686], ["Ash2L", 690], ["but", 696], ["not", 700], ["Wdr5", 704], ["stimulate", 709], ["activity", 719], [".", 727], ["Additionally", 729], [",", 741], ["we", 743], ["have", 746], ["determined", 751], ["the", 762], ["effect", 766], ["of", 773], ["posttranslational", 776], ["modifications", 794], ["on", 808], ["histone", 811], ["H3", 819], ["residues", 822], ["downstream", 831], ["and", 842], ["upstream", 846], ["from", 855], ["the", 860], ["target", 864], ["lysine", 871], ["and", 878], ["provide", 882], ["a", 890], ["structural", 892], ["explanation", 903], ["for", 915], ["why", 919], ["H3T3", 923], ["phosphorylation", 928], ["and", 944], ["H3K9", 948], ["acetylation", 953], ["regulate", 965], ["activity", 974], [".", 982]]}
{"context": "The Philadelphia chromosome found in leukemia cells of chronic myelogenous leukemia (CML) patients is produced by translocation between chromosomes 9 and 22, resulting in expression of a chimera protein of Bcr and Abl kinase in the cytoplasm. Bcr-Abl kinase attracted oncology researchers as a molecular target for CML therapy, and a variety of small Abl kinase inhibitors were synthesized. STI571 (imatinib mesylate) was produced by modification of 2-phenylaminopyrimidine, a core structure of protein kinase C inhibitor, to improve selectivity, stability, solubility, and bioavailability. STI571 competitively binds to the ATP binding site of Bcr-Abl kinase and inhibits Abl tyrosine kinase activity. STI571 showed significant efficacy in the clinical study with CML patients at all stages: chronic phase, accelerated phase, and blast crisis. More than 90% of the patients showed good hematologic response to STI571. STI571 is also a potent inhibitor of a receptor-type c-Kit tyrosine kinase. Therefore, STI571 was examined for therapeutic efficacy against malignant Gastro-Intestinal Stromal Tumors (GIST), which are mainly caused by aberrant expression of a mutated c-Kit that is constitutively active without binding of a ligand, stem cell factor (SCF). More than a half of the metastatic GIST patients enrolled in the clinical study responded to STI571. Thus, STI571 is now used as a therapeutic drug for both CML and GIST in more than 80 countries worldwide. Certain point mutations in the ATP binding site were found to be a cause of resistance to STI571 in both Bcr-Abl and c-Kit kinases. Therefore, it would be better to make a precise therapeutic strategy with STI571 based on the gene analysis data. It is also expected that it will be possible to design an inhibitor to overcome such resistance by using the structural information on the mutants.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "8061c24a56e44d69a227a7f6c6c90a8f", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[41, 43], [108, 110], [284, 286]], "char_spans": [[243, 249], [645, 651], [1571, 1577]]}]}], "context_tokens": [["The", 0], ["Philadelphia", 4], ["chromosome", 17], ["found", 28], ["in", 34], ["leukemia", 37], ["cells", 46], ["of", 52], ["chronic", 55], ["myelogenous", 63], ["leukemia", 75], ["(", 84], ["CML", 85], [")", 88], ["patients", 90], ["is", 99], ["produced", 102], ["by", 111], ["translocation", 114], ["between", 128], ["chromosomes", 136], ["9", 148], ["and", 150], ["22", 154], [",", 156], ["resulting", 158], ["in", 168], ["expression", 171], ["of", 182], ["a", 185], ["chimera", 187], ["protein", 195], ["of", 203], ["Bcr", 206], ["and", 210], ["Abl", 214], ["kinase", 218], ["in", 225], ["the", 228], ["cytoplasm", 232], [".", 241], ["Bcr", 243], ["-", 246], ["Abl", 247], ["kinase", 251], ["attracted", 258], ["oncology", 268], ["researchers", 277], ["as", 289], ["a", 292], ["molecular", 294], ["target", 304], ["for", 311], ["CML", 315], ["therapy", 319], [",", 326], ["and", 328], ["a", 332], ["variety", 334], ["of", 342], ["small", 345], ["Abl", 351], ["kinase", 355], ["inhibitors", 362], ["were", 373], ["synthesized", 378], [".", 389], ["STI571", 391], ["(", 398], ["imatinib", 399], ["mesylate", 408], [")", 416], ["was", 418], ["produced", 422], ["by", 431], ["modification", 434], ["of", 447], ["2-phenylaminopyrimidine", 450], [",", 473], ["a", 475], ["core", 477], ["structure", 482], ["of", 492], ["protein", 495], ["kinase", 503], ["C", 510], ["inhibitor", 512], [",", 521], ["to", 523], ["improve", 526], ["selectivity", 534], [",", 545], ["stability", 547], [",", 556], ["solubility", 558], [",", 568], ["and", 570], ["bioavailability", 574], [".", 589], ["STI571", 591], ["competitively", 598], ["binds", 612], ["to", 618], ["the", 621], ["ATP", 625], ["binding", 629], ["site", 637], ["of", 642], ["Bcr", 645], ["-", 648], ["Abl", 649], ["kinase", 653], ["and", 660], ["inhibits", 664], ["Abl", 673], ["tyrosine", 677], ["kinase", 686], ["activity", 693], [".", 701], ["STI571", 703], ["showed", 710], ["significant", 717], ["efficacy", 729], ["in", 738], ["the", 741], ["clinical", 745], ["study", 754], ["with", 760], ["CML", 765], ["patients", 769], ["at", 778], ["all", 781], ["stages", 785], [":", 791], ["chronic", 793], ["phase", 801], [",", 806], ["accelerated", 808], ["phase", 820], [",", 825], ["and", 827], ["blast", 831], ["crisis", 837], [".", 843], ["More", 845], ["than", 850], ["90", 855], ["%", 857], ["of", 859], ["the", 862], ["patients", 866], ["showed", 875], ["good", 882], ["hematologic", 887], ["response", 899], ["to", 908], ["STI571", 911], [".", 917], ["STI571", 919], ["is", 926], ["also", 929], ["a", 934], ["potent", 936], ["inhibitor", 943], ["of", 953], ["a", 956], ["receptor", 958], ["-", 966], ["type", 967], ["c", 972], ["-", 973], ["Kit", 974], ["tyrosine", 978], ["kinase", 987], [".", 993], ["Therefore", 995], [",", 1004], ["STI571", 1006], ["was", 1013], ["examined", 1017], ["for", 1026], ["therapeutic", 1030], ["efficacy", 1042], ["against", 1051], ["malignant", 1059], ["Gastro", 1069], ["-", 1075], ["Intestinal", 1076], ["Stromal", 1087], ["Tumors", 1095], ["(", 1102], ["GIST", 1103], [")", 1107], [",", 1108], ["which", 1110], ["are", 1116], ["mainly", 1120], ["caused", 1127], ["by", 1134], ["aberrant", 1137], ["expression", 1146], ["of", 1157], ["a", 1160], ["mutated", 1162], ["c", 1170], ["-", 1171], ["Kit", 1172], ["that", 1176], ["is", 1181], ["constitutively", 1184], ["active", 1199], ["without", 1206], ["binding", 1214], ["of", 1222], ["a", 1225], ["ligand", 1227], [",", 1233], ["stem", 1235], ["cell", 1240], ["factor", 1245], ["(", 1252], ["SCF", 1253], [")", 1256], [".", 1257], ["More", 1259], ["than", 1264], ["a", 1269], ["half", 1271], ["of", 1276], ["the", 1279], ["metastatic", 1283], ["GIST", 1294], ["patients", 1299], ["enrolled", 1308], ["in", 1317], ["the", 1320], ["clinical", 1324], ["study", 1333], ["responded", 1339], ["to", 1349], ["STI571", 1352], [".", 1358], ["Thus", 1360], [",", 1364], ["STI571", 1366], ["is", 1373], ["now", 1376], ["used", 1380], ["as", 1385], ["a", 1388], ["therapeutic", 1390], ["drug", 1402], ["for", 1407], ["both", 1411], ["CML", 1416], ["and", 1420], ["GIST", 1424], ["in", 1429], ["more", 1432], ["than", 1437], ["80", 1442], ["countries", 1445], ["worldwide", 1455], [".", 1464], ["Certain", 1466], ["point", 1474], ["mutations", 1480], ["in", 1490], ["the", 1493], ["ATP", 1497], ["binding", 1501], ["site", 1509], ["were", 1514], ["found", 1519], ["to", 1525], ["be", 1528], ["a", 1531], ["cause", 1533], ["of", 1539], ["resistance", 1542], ["to", 1553], ["STI571", 1556], ["in", 1563], ["both", 1566], ["Bcr", 1571], ["-", 1574], ["Abl", 1575], ["and", 1579], ["c", 1583], ["-", 1584], ["Kit", 1585], ["kinases", 1589], [".", 1596], ["Therefore", 1598], [",", 1607], ["it", 1609], ["would", 1612], ["be", 1618], ["better", 1621], ["to", 1628], ["make", 1631], ["a", 1636], ["precise", 1638], ["therapeutic", 1646], ["strategy", 1658], ["with", 1667], ["STI571", 1672], ["based", 1679], ["on", 1685], ["the", 1688], ["gene", 1692], ["analysis", 1697], ["data", 1706], [".", 1710], ["It", 1712], ["is", 1715], ["also", 1718], ["expected", 1723], ["that", 1732], ["it", 1737], ["will", 1740], ["be", 1745], ["possible", 1748], ["to", 1757], ["design", 1760], ["an", 1767], ["inhibitor", 1770], ["to", 1780], ["overcome", 1783], ["such", 1792], ["resistance", 1797], ["by", 1808], ["using", 1811], ["the", 1817], ["structural", 1821], ["information", 1832], ["on", 1844], ["the", 1847], ["mutants", 1851], [".", 1858]]}
{"context": "Self-report questionnaires are frequently used to identify PTSD among U.S. military personnel and Veterans. Two common scoring methods used to classify PTSD include: (1) a cut score threshold and (2) endorsement of PTSD symptoms meeting DSM-IV-TR symptom cluster criteria (SCM). A third method requiring a cut score in addition to SCM has been proposed, but has received little study. The current study examined the diagnostic accuracy of three scoring methods for the Davidson Trauma Scale (DTS) among 804 Afghanistan and Iraq war-era military Service Members and Veterans. Data were weighted to approximate the prevalence of PTSD and other Axis I disorders in VA primary care. As expected, adding a cut score criterion to SCM improved specificity and positive predictive power. However, a cut score of 68-72 provided optimal diagnostic accuracy. The utility of the DTS, the role of baseline prevalence, and recommendations for future research are discussed.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "30101ccbda904d208ed2525e9f6e992c", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[117, 117], [24, 24], [9, 9], [40, 40]], "char_spans": [[627, 630], [152, 155], [59, 62], [215, 218]]}]}], "context_tokens": [["Self", 0], ["-", 4], ["report", 5], ["questionnaires", 12], ["are", 27], ["frequently", 31], ["used", 42], ["to", 47], ["identify", 50], ["PTSD", 59], ["among", 64], ["U.S.", 70], ["military", 75], ["personnel", 84], ["and", 94], ["Veterans", 98], [".", 106], ["Two", 108], ["common", 112], ["scoring", 119], ["methods", 127], ["used", 135], ["to", 140], ["classify", 143], ["PTSD", 152], ["include", 157], [":", 164], ["(", 166], ["1", 167], [")", 168], ["a", 170], ["cut", 172], ["score", 176], ["threshold", 182], ["and", 192], ["(", 196], ["2", 197], [")", 198], ["endorsement", 200], ["of", 212], ["PTSD", 215], ["symptoms", 220], ["meeting", 229], ["DSM", 237], ["-", 240], ["IV", 241], ["-", 243], ["TR", 244], ["symptom", 247], ["cluster", 255], ["criteria", 263], ["(", 272], ["SCM", 273], [")", 276], [".", 277], ["A", 279], ["third", 281], ["method", 287], ["requiring", 294], ["a", 304], ["cut", 306], ["score", 310], ["in", 316], ["addition", 319], ["to", 328], ["SCM", 331], ["has", 335], ["been", 339], ["proposed", 344], [",", 352], ["but", 354], ["has", 358], ["received", 362], ["little", 371], ["study", 378], [".", 383], ["The", 385], ["current", 389], ["study", 397], ["examined", 403], ["the", 412], ["diagnostic", 416], ["accuracy", 427], ["of", 436], ["three", 439], ["scoring", 445], ["methods", 453], ["for", 461], ["the", 465], ["Davidson", 469], ["Trauma", 478], ["Scale", 485], ["(", 491], ["DTS", 492], [")", 495], ["among", 497], ["804", 503], ["Afghanistan", 507], ["and", 519], ["Iraq", 523], ["war", 528], ["-", 531], ["era", 532], ["military", 536], ["Service", 545], ["Members", 553], ["and", 561], ["Veterans", 565], [".", 573], ["Data", 575], ["were", 580], ["weighted", 585], ["to", 594], ["approximate", 597], ["the", 609], ["prevalence", 613], ["of", 624], ["PTSD", 627], ["and", 632], ["other", 636], ["Axis", 642], ["I", 647], ["disorders", 649], ["in", 659], ["VA", 662], ["primary", 665], ["care", 673], [".", 677], ["As", 679], ["expected", 682], [",", 690], ["adding", 692], ["a", 699], ["cut", 701], ["score", 705], ["criterion", 711], ["to", 721], ["SCM", 724], ["improved", 728], ["specificity", 737], ["and", 749], ["positive", 753], ["predictive", 762], ["power", 773], [".", 778], ["However", 780], [",", 787], ["a", 789], ["cut", 791], ["score", 795], ["of", 801], ["68", 804], ["-", 806], ["72", 807], ["provided", 810], ["optimal", 819], ["diagnostic", 827], ["accuracy", 838], [".", 846], ["The", 848], ["utility", 852], ["of", 860], ["the", 863], ["DTS", 867], [",", 870], ["the", 872], ["role", 876], ["of", 881], ["baseline", 884], ["prevalence", 893], [",", 903], ["and", 905], ["recommendations", 909], ["for", 925], ["future", 929], ["research", 936], ["are", 945], ["discussed", 949], [".", 958]]}
{"context": "Desmosomes are cell-cell adhesion structures that integrate cytoskeletal networks. In addition to binding intermediate filaments, the desmosomal protein desmoplakin (DP) regulates microtubule reorganization in the epidermis. In this paper, we identify a specific subset of centrosomal proteins that are recruited to the cell cortex by DP upon epidermal differentiation. These include Lis1 and Ndel1, which are centrosomal proteins that regulate microtubule organization and anchoring in other cell types. This recruitment was mediated by a region of DP specific to a single isoform, DPI. Furthermore, we demonstrate that the epidermal-specific loss of Lis1 results in dramatic defects in microtubule reorganization. Lis1 ablation also causes desmosomal defects, characterized by decreased levels of desmosomal components, decreased attachment of keratin filaments, and increased turnover of desmosomal proteins at the cell cortex. This contributes to loss of epidermal barrier activity, resulting in completely penetrant perinatal lethality. This work reveals essential desmosome-associated components that control cortical microtubule organization and unexpected roles for centrosomal proteins in epidermal function.", "qas": [{"question": "What are the structures formed when keratin molecules come together?", "answers": ["Intermediate filaments"], "qid": "d4ee2e1fb7364cd6bb5931d72186c5bb", "question_tokens": [["What", 0], ["are", 5], ["the", 9], ["structures", 13], ["formed", 24], ["when", 31], ["keratin", 36], ["molecules", 44], ["come", 54], ["together", 59], ["?", 67]], "detected_answers": [{"text": "Intermediate filaments", "token_spans": [[16, 17]], "char_spans": [[106, 127]]}]}], "context_tokens": [["Desmosomes", 0], ["are", 11], ["cell", 15], ["-", 19], ["cell", 20], ["adhesion", 25], ["structures", 34], ["that", 45], ["integrate", 50], ["cytoskeletal", 60], ["networks", 73], [".", 81], ["In", 83], ["addition", 86], ["to", 95], ["binding", 98], ["intermediate", 106], ["filaments", 119], [",", 128], ["the", 130], ["desmosomal", 134], ["protein", 145], ["desmoplakin", 153], ["(", 165], ["DP", 166], [")", 168], ["regulates", 170], ["microtubule", 180], ["reorganization", 192], ["in", 207], ["the", 210], ["epidermis", 214], [".", 223], ["In", 225], ["this", 228], ["paper", 233], [",", 238], ["we", 240], ["identify", 243], ["a", 252], ["specific", 254], ["subset", 263], ["of", 270], ["centrosomal", 273], ["proteins", 285], ["that", 294], ["are", 299], ["recruited", 303], ["to", 313], ["the", 316], ["cell", 320], ["cortex", 325], ["by", 332], ["DP", 335], ["upon", 338], ["epidermal", 343], ["differentiation", 353], [".", 368], ["These", 370], ["include", 376], ["Lis1", 384], ["and", 389], ["Ndel1", 393], [",", 398], ["which", 400], ["are", 406], ["centrosomal", 410], ["proteins", 422], ["that", 431], ["regulate", 436], ["microtubule", 445], ["organization", 457], ["and", 470], ["anchoring", 474], ["in", 484], ["other", 487], ["cell", 493], ["types", 498], [".", 503], ["This", 505], ["recruitment", 510], ["was", 522], ["mediated", 526], ["by", 535], ["a", 538], ["region", 540], ["of", 547], ["DP", 550], ["specific", 553], ["to", 562], ["a", 565], ["single", 567], ["isoform", 574], [",", 581], ["DPI", 583], [".", 586], ["Furthermore", 588], [",", 599], ["we", 601], ["demonstrate", 604], ["that", 616], ["the", 621], ["epidermal", 625], ["-", 634], ["specific", 635], ["loss", 644], ["of", 649], ["Lis1", 652], ["results", 657], ["in", 665], ["dramatic", 668], ["defects", 677], ["in", 685], ["microtubule", 688], ["reorganization", 700], [".", 714], ["Lis1", 716], ["ablation", 721], ["also", 730], ["causes", 735], ["desmosomal", 742], ["defects", 753], [",", 760], ["characterized", 762], ["by", 776], ["decreased", 779], ["levels", 789], ["of", 796], ["desmosomal", 799], ["components", 810], [",", 820], ["decreased", 822], ["attachment", 832], ["of", 843], ["keratin", 846], ["filaments", 854], [",", 863], ["and", 865], ["increased", 869], ["turnover", 879], ["of", 888], ["desmosomal", 891], ["proteins", 902], ["at", 911], ["the", 914], ["cell", 918], ["cortex", 923], [".", 929], ["This", 931], ["contributes", 936], ["to", 948], ["loss", 951], ["of", 956], ["epidermal", 959], ["barrier", 969], ["activity", 977], [",", 985], ["resulting", 987], ["in", 997], ["completely", 1000], ["penetrant", 1011], ["perinatal", 1021], ["lethality", 1031], [".", 1040], ["This", 1042], ["work", 1047], ["reveals", 1052], ["essential", 1060], ["desmosome", 1070], ["-", 1079], ["associated", 1080], ["components", 1091], ["that", 1102], ["control", 1107], ["cortical", 1115], ["microtubule", 1124], ["organization", 1136], ["and", 1149], ["unexpected", 1153], ["roles", 1164], ["for", 1170], ["centrosomal", 1174], ["proteins", 1186], ["in", 1195], ["epidermal", 1198], ["function", 1208], [".", 1216]]}
{"context": "Henoch-Sch\u00f6nlein purpura (HSP) is the most common form of childhood vasculitis. Various viral and bacterial infections, drugs, vaccines, food allergy and even insect bites have been considered as triggering factors in pathogenesis of HSP. Epstein-Barr virus (EBV) infection, which is associated with HSP, have been rarely reported. Herein we present HSP patient possibly caused by EBV infection. A 8-year old boy was admitted to our department with fever, rashes on legs and arms and intermittent mild abdominal pain. Multiple purpuric rashes were on his extremities, abdomen and buttock. Laboratory investigations revealed that monospot test was positive, EBV serology tests; Anti-EA-D Ig G: 3+, Anti-VCA gp125 Ig G: 3+, Anti-VCA p19 Ig M: 2+, Anti EBNA-1 Ig M: negative, Anti EBNA-1 Ig M: negative, Anti EBNA-1 Ig G: negative. The patient was interpreted as the primary active acute EBV infection. A skin biopsy showed leucocytoclastic vasculitis. The other viral and bacterial investigations were negative. The patient was diagnosed as HSP vasculitis according to EULAR criteria and treated with intravenous hydration and ibuprofen. He was discharged after 15 days with normal laboratory findings and physical examination. We think that EBV infection may be stimulant factor for autoimmune reactions and may cause HSP vasculitis. Hence, it may be useful to investigate the EBV infection in etiology of HSP cases.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "0e6c87f5f0c94291853b04cbabd336bd", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[43, 46]], "char_spans": [[239, 256]]}]}], "context_tokens": [["Henoch", 0], ["-", 6], ["Sch\u00f6nlein", 7], ["purpura", 17], ["(", 25], ["HSP", 26], [")", 29], ["is", 31], ["the", 34], ["most", 38], ["common", 43], ["form", 50], ["of", 55], ["childhood", 58], ["vasculitis", 68], [".", 78], ["Various", 80], ["viral", 88], ["and", 94], ["bacterial", 98], ["infections", 108], [",", 118], ["drugs", 120], [",", 125], ["vaccines", 127], [",", 135], ["food", 137], ["allergy", 142], ["and", 150], ["even", 154], ["insect", 159], ["bites", 166], ["have", 172], ["been", 177], ["considered", 182], ["as", 193], ["triggering", 196], ["factors", 207], ["in", 215], ["pathogenesis", 218], ["of", 231], ["HSP", 234], [".", 237], ["Epstein", 239], ["-", 246], ["Barr", 247], ["virus", 252], ["(", 258], ["EBV", 259], [")", 262], ["infection", 264], [",", 273], ["which", 275], ["is", 281], ["associated", 284], ["with", 295], ["HSP", 300], [",", 303], ["have", 305], ["been", 310], ["rarely", 315], ["reported", 322], [".", 330], ["Herein", 332], ["we", 339], ["present", 342], ["HSP", 350], ["patient", 354], ["possibly", 362], ["caused", 371], ["by", 378], ["EBV", 381], ["infection", 385], [".", 394], ["A", 396], ["8-year", 398], ["old", 405], ["boy", 409], ["was", 413], ["admitted", 417], ["to", 426], ["our", 429], ["department", 433], ["with", 444], ["fever", 449], [",", 454], ["rashes", 456], ["on", 463], ["legs", 466], ["and", 471], ["arms", 475], ["and", 480], ["intermittent", 484], ["mild", 497], ["abdominal", 502], ["pain", 512], [".", 516], ["Multiple", 518], ["purpuric", 527], ["rashes", 536], ["were", 543], ["on", 548], ["his", 551], ["extremities", 555], [",", 566], ["abdomen", 568], ["and", 576], ["buttock", 580], [".", 587], ["Laboratory", 589], ["investigations", 600], ["revealed", 615], ["that", 624], ["monospot", 629], ["test", 638], ["was", 643], ["positive", 647], [",", 655], ["EBV", 657], ["serology", 661], ["tests", 670], [";", 675], ["Anti", 677], ["-", 681], ["EA", 682], ["-", 684], ["D", 685], ["Ig", 687], ["G", 690], [":", 691], ["3", 693], ["+", 694], [",", 695], ["Anti", 697], ["-", 701], ["VCA", 702], ["gp125", 706], ["Ig", 712], ["G", 715], [":", 716], ["3", 718], ["+", 719], [",", 720], ["Anti", 722], ["-", 726], ["VCA", 727], ["p19", 731], ["Ig", 735], ["M", 738], [":", 739], ["2", 741], ["+", 742], [",", 743], ["Anti", 745], ["EBNA-1", 750], ["Ig", 757], ["M", 760], [":", 761], ["negative", 763], [",", 771], ["Anti", 773], ["EBNA-1", 778], ["Ig", 785], ["M", 788], [":", 789], ["negative", 791], [",", 799], ["Anti", 801], ["EBNA-1", 806], ["Ig", 813], ["G", 816], [":", 817], ["negative", 819], [".", 827], ["The", 829], ["patient", 833], ["was", 841], ["interpreted", 845], ["as", 857], ["the", 860], ["primary", 864], ["active", 872], ["acute", 879], ["EBV", 885], ["infection", 889], [".", 898], ["A", 900], ["skin", 902], ["biopsy", 907], ["showed", 914], ["leucocytoclastic", 921], ["vasculitis", 938], [".", 948], ["The", 950], ["other", 954], ["viral", 960], ["and", 966], ["bacterial", 970], ["investigations", 980], ["were", 995], ["negative", 1000], [".", 1008], ["The", 1010], ["patient", 1014], ["was", 1022], ["diagnosed", 1026], ["as", 1036], ["HSP", 1039], ["vasculitis", 1043], ["according", 1054], ["to", 1064], ["EULAR", 1067], ["criteria", 1073], ["and", 1082], ["treated", 1086], ["with", 1094], ["intravenous", 1099], ["hydration", 1111], ["and", 1121], ["ibuprofen", 1125], [".", 1134], ["He", 1136], ["was", 1139], ["discharged", 1143], ["after", 1154], ["15", 1160], ["days", 1163], ["with", 1168], ["normal", 1173], ["laboratory", 1180], ["findings", 1191], ["and", 1200], ["physical", 1204], ["examination", 1213], [".", 1224], ["We", 1226], ["think", 1229], ["that", 1235], ["EBV", 1240], ["infection", 1244], ["may", 1254], ["be", 1258], ["stimulant", 1261], ["factor", 1271], ["for", 1278], ["autoimmune", 1282], ["reactions", 1293], ["and", 1303], ["may", 1307], ["cause", 1311], ["HSP", 1317], ["vasculitis", 1321], [".", 1331], ["Hence", 1333], [",", 1338], ["it", 1340], ["may", 1343], ["be", 1347], ["useful", 1350], ["to", 1357], ["investigate", 1360], ["the", 1372], ["EBV", 1376], ["infection", 1380], ["in", 1390], ["etiology", 1393], ["of", 1402], ["HSP", 1405], ["cases", 1409], [".", 1414]]}
{"context": "Since the early 2000s, the incidence of methicillin-resistant Staphylococcus aureus (MRSA) infections among the community of people lacking known healthcare risk factors has increased. This MRSA infection is referred to as community-associated MRSA (CA-MRSA) infection and is distinct from hospital-associated MRSA (HA-MRSA) infection, which occurs among people with known healthcare risk factors. Understanding the epidemiology of CA-MRSA infections is critical; however, this has not been investigated in detail in Japan. Our objective was to investigate the incidence of CA-MRSA infections in a regional hospital. We investigated CA-MRSA isolates and infections in a rural regional hospital by reviewing medical records of one year. Infections were classified as CA-MRSA if no established risk factors were identified. During 2008, 31 Staphylococcus aureus (S. aureus) isolates were detected in 29 unique patients, with 1 methicillin-sensitive S. aureus (MSSA) isolates obtained from 19 patients (66%) and MRSA obtained from 10 patients (34%). In the 10 patients with MRSA, the number of HA-MRSA and CA-MRSA cases were nine (32% of patients with S. aureus isolates) and one (3%), respectively. The patient with CA-MRSA was diagnosed with cellulitis due to CA-MRSA. All nine patients with HA-MRSA exhibited colonization. We observed a CA-MRSA case in a regional hospital in Japan, suggesting that incidence trends of CA-MRSA should be considered in future research and treatment.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "0d5291094d50485392d99b2aa3d5c380", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[208, 208], [139, 139], [58, 58], [186, 186], [44, 44], [116, 116], [212, 212], [249, 249], [78, 78], [14, 14], [257, 257], [240, 240], [282, 282], [54, 54], [266, 266], [105, 105], [201, 201], [40, 40], [31, 31]], "char_spans": [[1094, 1097], [769, 772], [319, 322], [1009, 1012], [253, 256], [636, 639], [1106, 1109], [1262, 1265], [435, 438], [85, 88], [1294, 1297], [1217, 1220], [1422, 1425], [310, 313], [1340, 1343], [577, 580], [1071, 1074], [244, 247], [190, 193]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["early", 10], ["2000s", 16], [",", 21], ["the", 23], ["incidence", 27], ["of", 37], ["methicillin", 40], ["-", 51], ["resistant", 52], ["Staphylococcus", 62], ["aureus", 77], ["(", 84], ["MRSA", 85], [")", 89], ["infections", 91], ["among", 102], ["the", 108], ["community", 112], ["of", 122], ["people", 125], ["lacking", 132], ["known", 140], ["healthcare", 146], ["risk", 157], ["factors", 162], ["has", 170], ["increased", 174], [".", 183], ["This", 185], ["MRSA", 190], ["infection", 195], ["is", 205], ["referred", 208], ["to", 217], ["as", 220], ["community", 223], ["-", 232], ["associated", 233], ["MRSA", 244], ["(", 249], ["CA", 250], ["-", 252], ["MRSA", 253], [")", 257], ["infection", 259], ["and", 269], ["is", 273], ["distinct", 276], ["from", 285], ["hospital", 290], ["-", 298], ["associated", 299], ["MRSA", 310], ["(", 315], ["HA", 316], ["-", 318], ["MRSA", 319], [")", 323], ["infection", 325], [",", 334], ["which", 336], ["occurs", 342], ["among", 349], ["people", 355], ["with", 362], ["known", 367], ["healthcare", 373], ["risk", 384], ["factors", 389], [".", 396], ["Understanding", 398], ["the", 412], ["epidemiology", 416], ["of", 429], ["CA", 432], ["-", 434], ["MRSA", 435], ["infections", 440], ["is", 451], ["critical", 454], [";", 462], ["however", 464], [",", 471], ["this", 473], ["has", 478], ["not", 482], ["been", 486], ["investigated", 491], ["in", 504], ["detail", 507], ["in", 514], ["Japan", 517], [".", 522], ["Our", 524], ["objective", 528], ["was", 538], ["to", 542], ["investigate", 545], ["the", 557], ["incidence", 561], ["of", 571], ["CA", 574], ["-", 576], ["MRSA", 577], ["infections", 582], ["in", 593], ["a", 596], ["regional", 598], ["hospital", 607], [".", 615], ["We", 617], ["investigated", 620], ["CA", 633], ["-", 635], ["MRSA", 636], ["isolates", 641], ["and", 650], ["infections", 654], ["in", 665], ["a", 668], ["rural", 670], ["regional", 676], ["hospital", 685], ["by", 694], ["reviewing", 697], ["medical", 707], ["records", 715], ["of", 723], ["one", 726], ["year", 730], [".", 734], ["Infections", 736], ["were", 747], ["classified", 752], ["as", 763], ["CA", 766], ["-", 768], ["MRSA", 769], ["if", 774], ["no", 777], ["established", 780], ["risk", 792], ["factors", 797], ["were", 805], ["identified", 810], [".", 820], ["During", 822], ["2008", 829], [",", 833], ["31", 835], ["Staphylococcus", 838], ["aureus", 853], ["(", 860], ["S.", 861], ["aureus", 864], [")", 870], ["isolates", 872], ["were", 881], ["detected", 886], ["in", 895], ["29", 898], ["unique", 901], ["patients", 908], [",", 916], ["with", 918], ["1", 923], ["methicillin", 925], ["-", 936], ["sensitive", 937], ["S.", 947], ["aureus", 950], ["(", 957], ["MSSA", 958], [")", 962], ["isolates", 964], ["obtained", 973], ["from", 982], ["19", 987], ["patients", 990], ["(", 999], ["66", 1000], ["%", 1002], [")", 1003], ["and", 1005], ["MRSA", 1009], ["obtained", 1014], ["from", 1023], ["10", 1028], ["patients", 1031], ["(", 1040], ["34", 1041], ["%", 1043], [")", 1044], [".", 1045], ["In", 1047], ["the", 1050], ["10", 1054], ["patients", 1057], ["with", 1066], ["MRSA", 1071], [",", 1075], ["the", 1077], ["number", 1081], ["of", 1088], ["HA", 1091], ["-", 1093], ["MRSA", 1094], ["and", 1099], ["CA", 1103], ["-", 1105], ["MRSA", 1106], ["cases", 1111], ["were", 1117], ["nine", 1122], ["(", 1127], ["32", 1128], ["%", 1130], ["of", 1132], ["patients", 1135], ["with", 1144], ["S.", 1149], ["aureus", 1152], ["isolates", 1159], [")", 1167], ["and", 1169], ["one", 1173], ["(", 1177], ["3", 1178], ["%", 1179], [")", 1180], [",", 1181], ["respectively", 1183], [".", 1195], ["The", 1197], ["patient", 1201], ["with", 1209], ["CA", 1214], ["-", 1216], ["MRSA", 1217], ["was", 1222], ["diagnosed", 1226], ["with", 1236], ["cellulitis", 1241], ["due", 1252], ["to", 1256], ["CA", 1259], ["-", 1261], ["MRSA", 1262], [".", 1266], ["All", 1268], ["nine", 1272], ["patients", 1277], ["with", 1286], ["HA", 1291], ["-", 1293], ["MRSA", 1294], ["exhibited", 1299], ["colonization", 1309], [".", 1321], ["We", 1323], ["observed", 1326], ["a", 1335], ["CA", 1337], ["-", 1339], ["MRSA", 1340], ["case", 1345], ["in", 1350], ["a", 1353], ["regional", 1355], ["hospital", 1364], ["in", 1373], ["Japan", 1376], [",", 1381], ["suggesting", 1383], ["that", 1394], ["incidence", 1399], ["trends", 1409], ["of", 1416], ["CA", 1419], ["-", 1421], ["MRSA", 1422], ["should", 1427], ["be", 1434], ["considered", 1437], ["in", 1448], ["future", 1451], ["research", 1458], ["and", 1467], ["treatment", 1471], [".", 1480]]}
{"context": "The ubiquitin-proteasome pathway is involved in intracellular protein turnover, and its function is crucial to cellular homeostasis. First synthesized as probes of proteolytic processes, proteasome inhibitors began to be thought of as potential drug candidates when they were found to induce programmed cell death preferentially in transformed cells. They made their first leap into the clinic to be tested as therapeutic agents 10 years ago, and since then, great strides have been made in defining their mechanisms of action, their clinical efficacy and toxicity, and some of their limitations in the form of resistance pathways. Validation of the ubiquitin-proteasome pathway as a target for cancer therapy has come in the form of approvals of the first such inhibitor, bortezomib, for relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this agent has become a standard of care. Lessons learned from this first-in-class agent are now being applied to the development of a new generation of proteasome inhibitors that hold the promise of efficacy in bortezomib-resistant disease and possibly in a broader spectrum of diseases. This saga provides a salient example of the promise of translational medicine and a paradigm by which other agents may be successfully brought from the bench to the bedside.", "qas": [{"question": "Which is the target of bortezomib used in cancer therapy?", "answers": ["The ubiquitin/proteasome pathway"], "qid": "19279b71c3f24df98e4583f3b5b1ad1e", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["bortezomib", 23], ["used", 34], ["in", 39], ["cancer", 42], ["therapy", 49], ["?", 56]], "detected_answers": [{"text": "The ubiquitin/proteasome pathway", "token_spans": [[109, 112], [1, 4]], "char_spans": [[650, 677], [4, 31]]}]}], "context_tokens": [["The", 0], ["ubiquitin", 4], ["-", 13], ["proteasome", 14], ["pathway", 25], ["is", 33], ["involved", 36], ["in", 45], ["intracellular", 48], ["protein", 62], ["turnover", 70], [",", 78], ["and", 80], ["its", 84], ["function", 88], ["is", 97], ["crucial", 100], ["to", 108], ["cellular", 111], ["homeostasis", 120], [".", 131], ["First", 133], ["synthesized", 139], ["as", 151], ["probes", 154], ["of", 161], ["proteolytic", 164], ["processes", 176], [",", 185], ["proteasome", 187], ["inhibitors", 198], ["began", 209], ["to", 215], ["be", 218], ["thought", 221], ["of", 229], ["as", 232], ["potential", 235], ["drug", 245], ["candidates", 250], ["when", 261], ["they", 266], ["were", 271], ["found", 276], ["to", 282], ["induce", 285], ["programmed", 292], ["cell", 303], ["death", 308], ["preferentially", 314], ["in", 329], ["transformed", 332], ["cells", 344], [".", 349], ["They", 351], ["made", 356], ["their", 361], ["first", 367], ["leap", 373], ["into", 378], ["the", 383], ["clinic", 387], ["to", 394], ["be", 397], ["tested", 400], ["as", 407], ["therapeutic", 410], ["agents", 422], ["10", 429], ["years", 432], ["ago", 438], [",", 441], ["and", 443], ["since", 447], ["then", 453], [",", 457], ["great", 459], ["strides", 465], ["have", 473], ["been", 478], ["made", 483], ["in", 488], ["defining", 491], ["their", 500], ["mechanisms", 506], ["of", 517], ["action", 520], [",", 526], ["their", 528], ["clinical", 534], ["efficacy", 543], ["and", 552], ["toxicity", 556], [",", 564], ["and", 566], ["some", 570], ["of", 575], ["their", 578], ["limitations", 584], ["in", 596], ["the", 599], ["form", 603], ["of", 608], ["resistance", 611], ["pathways", 622], [".", 630], ["Validation", 632], ["of", 643], ["the", 646], ["ubiquitin", 650], ["-", 659], ["proteasome", 660], ["pathway", 671], ["as", 679], ["a", 682], ["target", 684], ["for", 691], ["cancer", 695], ["therapy", 702], ["has", 710], ["come", 714], ["in", 719], ["the", 722], ["form", 726], ["of", 731], ["approvals", 734], ["of", 744], ["the", 747], ["first", 751], ["such", 757], ["inhibitor", 762], [",", 771], ["bortezomib", 773], [",", 783], ["for", 785], ["relapsed", 789], ["/", 797], ["refractory", 798], ["multiple", 809], ["myeloma", 818], ["and", 826], ["mantle", 830], ["cell", 837], ["lymphoma", 842], [",", 850], ["for", 852], ["which", 856], ["this", 862], ["agent", 867], ["has", 873], ["become", 877], ["a", 884], ["standard", 886], ["of", 895], ["care", 898], [".", 902], ["Lessons", 904], ["learned", 912], ["from", 920], ["this", 925], ["first", 930], ["-", 935], ["in", 936], ["-", 938], ["class", 939], ["agent", 945], ["are", 951], ["now", 955], ["being", 959], ["applied", 965], ["to", 973], ["the", 976], ["development", 980], ["of", 992], ["a", 995], ["new", 997], ["generation", 1001], ["of", 1012], ["proteasome", 1015], ["inhibitors", 1026], ["that", 1037], ["hold", 1042], ["the", 1047], ["promise", 1051], ["of", 1059], ["efficacy", 1062], ["in", 1071], ["bortezomib", 1074], ["-", 1084], ["resistant", 1085], ["disease", 1095], ["and", 1103], ["possibly", 1107], ["in", 1116], ["a", 1119], ["broader", 1121], ["spectrum", 1129], ["of", 1138], ["diseases", 1141], [".", 1149], ["This", 1151], ["saga", 1156], ["provides", 1161], ["a", 1170], ["salient", 1172], ["example", 1180], ["of", 1188], ["the", 1191], ["promise", 1195], ["of", 1203], ["translational", 1206], ["medicine", 1220], ["and", 1229], ["a", 1233], ["paradigm", 1235], ["by", 1244], ["which", 1247], ["other", 1253], ["agents", 1259], ["may", 1266], ["be", 1270], ["successfully", 1273], ["brought", 1286], ["from", 1294], ["the", 1299], ["bench", 1303], ["to", 1309], ["the", 1312], ["bedside", 1316], [".", 1323]]}
{"context": "Calcineurin, a Ca(2+)/calmodulin-stimulated protein phosphatase, plays a key role in T-cell activation by regulating the activity of NFAT (nuclear factor of activated T cells), a family of transcription factors required for the synthesis of several cytokine genes. Calcineurin is the target of the immunosuppressive drugs cyclosporin A and FK506 complexed with their cytoplasmic receptors cyclophilin and FKBP12, respectively. In this study we report that calcineurin is also the target of a recently identified Ca(2+)-binding protein, CHP (for calcineurin homologous protein), which shares a high degree of homology with the regulatory B subunit of calcineurin and with calmodulin. In Jurkat and HeLa cells, overexpression of CHP specifically impaired the nuclear translocation and transcriptional activity of NFAT but had no effect on AP-1 transcriptional activity and only a small (<25%) inhibitory effect on the transcriptional activity of NFkappaB. Further study indicated that CHP inhibits calcineurin activity. In cells overexpressing CHP, the phosphatase activity of immunoprecipitated calcineurin was inhibited by approximately 50%; and in a reconstituted assay, the activity of purified calcineurin was inhibited up to 97% by the addition of purified recombinant CHP in a dose-dependent manner. Moreover, prolonged activation of Jurkat cells was associated with a decreased abundance of CHP, suggesting a possible regulatory mechanism allowing activation of calcineurin. CHP, therefore, is a previously unrecognized endogenous inhibitor of calcineurin activity.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "e689ed17e25f4a969ae75153c594f23b", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[0, 0], [240, 240], [91, 91], [109, 109], [177, 177], [195, 195], [253, 253], [76, 76], [164, 164], [47, 47]], "char_spans": [[0, 10], [1468, 1478], [545, 555], [650, 660], [1094, 1104], [1197, 1207], [1550, 1560], [456, 466], [996, 1006], [265, 275]]}]}], "context_tokens": [["Calcineurin", 0], [",", 11], ["a", 13], ["Ca(2+)/calmodulin", 15], ["-", 32], ["stimulated", 33], ["protein", 44], ["phosphatase", 52], [",", 63], ["plays", 65], ["a", 71], ["key", 73], ["role", 77], ["in", 82], ["T", 85], ["-", 86], ["cell", 87], ["activation", 92], ["by", 103], ["regulating", 106], ["the", 117], ["activity", 121], ["of", 130], ["NFAT", 133], ["(", 138], ["nuclear", 139], ["factor", 147], ["of", 154], ["activated", 157], ["T", 167], ["cells", 169], [")", 174], [",", 175], ["a", 177], ["family", 179], ["of", 186], ["transcription", 189], ["factors", 203], ["required", 211], ["for", 220], ["the", 224], ["synthesis", 228], ["of", 238], ["several", 241], ["cytokine", 249], ["genes", 258], [".", 263], ["Calcineurin", 265], ["is", 277], ["the", 280], ["target", 284], ["of", 291], ["the", 294], ["immunosuppressive", 298], ["drugs", 316], ["cyclosporin", 322], ["A", 334], ["and", 336], ["FK506", 340], ["complexed", 346], ["with", 356], ["their", 361], ["cytoplasmic", 367], ["receptors", 379], ["cyclophilin", 389], ["and", 401], ["FKBP12", 405], [",", 411], ["respectively", 413], [".", 425], ["In", 427], ["this", 430], ["study", 435], ["we", 441], ["report", 444], ["that", 451], ["calcineurin", 456], ["is", 468], ["also", 471], ["the", 476], ["target", 480], ["of", 487], ["a", 490], ["recently", 492], ["identified", 501], ["Ca(2+)-binding", 512], ["protein", 527], [",", 534], ["CHP", 536], ["(", 540], ["for", 541], ["calcineurin", 545], ["homologous", 557], ["protein", 568], [")", 575], [",", 576], ["which", 578], ["shares", 584], ["a", 591], ["high", 593], ["degree", 598], ["of", 605], ["homology", 608], ["with", 617], ["the", 622], ["regulatory", 626], ["B", 637], ["subunit", 639], ["of", 647], ["calcineurin", 650], ["and", 662], ["with", 666], ["calmodulin", 671], [".", 681], ["In", 683], ["Jurkat", 686], ["and", 693], ["HeLa", 697], ["cells", 702], [",", 707], ["overexpression", 709], ["of", 724], ["CHP", 727], ["specifically", 731], ["impaired", 744], ["the", 753], ["nuclear", 757], ["translocation", 765], ["and", 779], ["transcriptional", 783], ["activity", 799], ["of", 808], ["NFAT", 811], ["but", 816], ["had", 820], ["no", 824], ["effect", 827], ["on", 834], ["AP-1", 837], ["transcriptional", 842], ["activity", 858], ["and", 867], ["only", 871], ["a", 876], ["small", 878], ["(", 884], ["<", 885], ["25", 886], ["%", 888], [")", 889], ["inhibitory", 891], ["effect", 902], ["on", 909], ["the", 912], ["transcriptional", 916], ["activity", 932], ["of", 941], ["NFkappaB.", 944], ["Further", 954], ["study", 962], ["indicated", 968], ["that", 978], ["CHP", 983], ["inhibits", 987], ["calcineurin", 996], ["activity", 1008], [".", 1016], ["In", 1018], ["cells", 1021], ["overexpressing", 1027], ["CHP", 1042], [",", 1045], ["the", 1047], ["phosphatase", 1051], ["activity", 1063], ["of", 1072], ["immunoprecipitated", 1075], ["calcineurin", 1094], ["was", 1106], ["inhibited", 1110], ["by", 1120], ["approximately", 1123], ["50", 1137], ["%", 1139], [";", 1140], ["and", 1142], ["in", 1146], ["a", 1149], ["reconstituted", 1151], ["assay", 1165], [",", 1170], ["the", 1172], ["activity", 1176], ["of", 1185], ["purified", 1188], ["calcineurin", 1197], ["was", 1209], ["inhibited", 1213], ["up", 1223], ["to", 1226], ["97", 1229], ["%", 1231], ["by", 1233], ["the", 1236], ["addition", 1240], ["of", 1249], ["purified", 1252], ["recombinant", 1261], ["CHP", 1273], ["in", 1277], ["a", 1280], ["dose", 1282], ["-", 1286], ["dependent", 1287], ["manner", 1297], [".", 1303], ["Moreover", 1305], [",", 1313], ["prolonged", 1315], ["activation", 1325], ["of", 1336], ["Jurkat", 1339], ["cells", 1346], ["was", 1352], ["associated", 1356], ["with", 1367], ["a", 1372], ["decreased", 1374], ["abundance", 1384], ["of", 1394], ["CHP", 1397], [",", 1400], ["suggesting", 1402], ["a", 1413], ["possible", 1415], ["regulatory", 1424], ["mechanism", 1435], ["allowing", 1445], ["activation", 1454], ["of", 1465], ["calcineurin", 1468], [".", 1479], ["CHP", 1481], [",", 1484], ["therefore", 1486], [",", 1495], ["is", 1497], ["a", 1500], ["previously", 1502], ["unrecognized", 1513], ["endogenous", 1526], ["inhibitor", 1537], ["of", 1547], ["calcineurin", 1550], ["activity", 1562], [".", 1570]]}
{"context": "Erythrasma is a superficial infection caused by Corynebacterium minutissimum and affects the major skin folds and the interdigital regions of the feet. It is characterized by erythematous, brown, scaly patches and maceration, and exhibits coral-red fluorescence under Wood light. The aim of this study was to determine the frequency of erythrasma in patients with interdigital lesions. An open, prospective, longitudinal, observational study was performed in a hospital in Mexico City between March and December, 2006. All patients with interdigital lesions were examined with a Wood lamp and direct examination was performed with 20 % potassium hydroxide. Cultures were done in Sabouraud dextrose agar and brain heart infusion agar, and smears were analyzed. General characteristics and concomitant diseases were recorded. We examined 73 patients, of whom 24 (32.8 %) were diagnosed with erythrasma based on coral-red fluorescence under Wood light and identification of corynebacteria by Gram staining. The disease was more common in women (83.33 %) and the mean age of the patients was 43.5 years. The main clinical findings were scaling and maceration, and the fourth interdigital web was the most commonly affected. Corynebacterium could not be isolated in any of the cases. Mycology was positive in 15 cases (62.5 %) and the following microorganisms were isolated: Candida (16.6 %), dermatophytes (12.5 %), and Trichosporon (4.1 %). Interdigital erythrasma is a common condition and can be easily confused with interdigital tinea. It persists if not treated appropriately. Rapid diagnosis is easily obtained by examination with a Wood lamp, while culture is difficult and unnecessary for diagnosis. The coexistence of erythrasma with dermatophytes and Candida should be considered when the interdigital webs are affected.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "c5a3515ce38440f0bf803e4cbe2c9b10", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[7, 8]], "char_spans": [[48, 75]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["infection", 28], ["caused", 38], ["by", 45], ["Corynebacterium", 48], ["minutissimum", 64], ["and", 77], ["affects", 81], ["the", 89], ["major", 93], ["skin", 99], ["folds", 104], ["and", 110], ["the", 114], ["interdigital", 118], ["regions", 131], ["of", 139], ["the", 142], ["feet", 146], [".", 150], ["It", 152], ["is", 155], ["characterized", 158], ["by", 172], ["erythematous", 175], [",", 187], ["brown", 189], [",", 194], ["scaly", 196], ["patches", 202], ["and", 210], ["maceration", 214], [",", 224], ["and", 226], ["exhibits", 230], ["coral", 239], ["-", 244], ["red", 245], ["fluorescence", 249], ["under", 262], ["Wood", 268], ["light", 273], [".", 278], ["The", 280], ["aim", 284], ["of", 288], ["this", 291], ["study", 296], ["was", 302], ["to", 306], ["determine", 309], ["the", 319], ["frequency", 323], ["of", 333], ["erythrasma", 336], ["in", 347], ["patients", 350], ["with", 359], ["interdigital", 364], ["lesions", 377], [".", 384], ["An", 386], ["open", 389], [",", 393], ["prospective", 395], [",", 406], ["longitudinal", 408], [",", 420], ["observational", 422], ["study", 436], ["was", 442], ["performed", 446], ["in", 456], ["a", 459], ["hospital", 461], ["in", 470], ["Mexico", 473], ["City", 480], ["between", 485], ["March", 493], ["and", 499], ["December", 503], [",", 511], ["2006", 513], [".", 517], ["All", 519], ["patients", 523], ["with", 532], ["interdigital", 537], ["lesions", 550], ["were", 558], ["examined", 563], ["with", 572], ["a", 577], ["Wood", 579], ["lamp", 584], ["and", 589], ["direct", 593], ["examination", 600], ["was", 612], ["performed", 616], ["with", 626], ["20", 631], ["%", 634], ["potassium", 636], ["hydroxide", 646], [".", 655], ["Cultures", 657], ["were", 666], ["done", 671], ["in", 676], ["Sabouraud", 679], ["dextrose", 689], ["agar", 698], ["and", 703], ["brain", 707], ["heart", 713], ["infusion", 719], ["agar", 728], [",", 732], ["and", 734], ["smears", 738], ["were", 745], ["analyzed", 750], [".", 758], ["General", 760], ["characteristics", 768], ["and", 784], ["concomitant", 788], ["diseases", 800], ["were", 809], ["recorded", 814], [".", 822], ["We", 824], ["examined", 827], ["73", 836], ["patients", 839], [",", 847], ["of", 849], ["whom", 852], ["24", 857], ["(", 860], ["32.8", 861], ["%", 866], [")", 867], ["were", 869], ["diagnosed", 874], ["with", 884], ["erythrasma", 889], ["based", 900], ["on", 906], ["coral", 909], ["-", 914], ["red", 915], ["fluorescence", 919], ["under", 932], ["Wood", 938], ["light", 943], ["and", 949], ["identification", 953], ["of", 968], ["corynebacteria", 971], ["by", 986], ["Gram", 989], ["staining", 994], [".", 1002], ["The", 1004], ["disease", 1008], ["was", 1016], ["more", 1020], ["common", 1025], ["in", 1032], ["women", 1035], ["(", 1041], ["83.33", 1042], ["%", 1048], [")", 1049], ["and", 1051], ["the", 1055], ["mean", 1059], ["age", 1064], ["of", 1068], ["the", 1071], ["patients", 1075], ["was", 1084], ["43.5", 1088], ["years", 1093], [".", 1098], ["The", 1100], ["main", 1104], ["clinical", 1109], ["findings", 1118], ["were", 1127], ["scaling", 1132], ["and", 1140], ["maceration", 1144], [",", 1154], ["and", 1156], ["the", 1160], ["fourth", 1164], ["interdigital", 1171], ["web", 1184], ["was", 1188], ["the", 1192], ["most", 1196], ["commonly", 1201], ["affected", 1210], [".", 1218], ["Corynebacterium", 1220], ["could", 1236], ["not", 1242], ["be", 1246], ["isolated", 1249], ["in", 1258], ["any", 1261], ["of", 1265], ["the", 1268], ["cases", 1272], [".", 1277], ["Mycology", 1279], ["was", 1288], ["positive", 1292], ["in", 1301], ["15", 1304], ["cases", 1307], ["(", 1313], ["62.5", 1314], ["%", 1319], [")", 1320], ["and", 1322], ["the", 1326], ["following", 1330], ["microorganisms", 1340], ["were", 1355], ["isolated", 1360], [":", 1368], ["Candida", 1370], ["(", 1378], ["16.6", 1379], ["%", 1384], [")", 1385], [",", 1386], ["dermatophytes", 1388], ["(", 1402], ["12.5", 1403], ["%", 1408], [")", 1409], [",", 1410], ["and", 1412], ["Trichosporon", 1416], ["(", 1429], ["4.1", 1430], ["%", 1434], [")", 1435], [".", 1436], ["Interdigital", 1438], ["erythrasma", 1451], ["is", 1462], ["a", 1465], ["common", 1467], ["condition", 1474], ["and", 1484], ["can", 1488], ["be", 1492], ["easily", 1495], ["confused", 1502], ["with", 1511], ["interdigital", 1516], ["tinea", 1529], [".", 1534], ["It", 1536], ["persists", 1539], ["if", 1548], ["not", 1551], ["treated", 1555], ["appropriately", 1563], [".", 1576], ["Rapid", 1578], ["diagnosis", 1584], ["is", 1594], ["easily", 1597], ["obtained", 1604], ["by", 1613], ["examination", 1616], ["with", 1628], ["a", 1633], ["Wood", 1635], ["lamp", 1640], [",", 1644], ["while", 1646], ["culture", 1652], ["is", 1660], ["difficult", 1663], ["and", 1673], ["unnecessary", 1677], ["for", 1689], ["diagnosis", 1693], [".", 1702], ["The", 1704], ["coexistence", 1708], ["of", 1720], ["erythrasma", 1723], ["with", 1734], ["dermatophytes", 1739], ["and", 1753], ["Candida", 1757], ["should", 1765], ["be", 1772], ["considered", 1775], ["when", 1786], ["the", 1791], ["interdigital", 1795], ["webs", 1808], ["are", 1813], ["affected", 1817], [".", 1825]]}
{"context": "To evaluate the long-term impact of successive interventions on rates of methicillin-resistant Staphylococcus aureus (MRSA) colonization or infection and MRSA bacteremia in an endemic hospital-wide situation. Quasi-experimental, interrupted time-series analysis. The impact of the interventions was analyzed by use of segmented regression. Representative MRSA isolates were typed by use of pulsed-field gel electrophoresis. A 950-bed teaching hospital in Seville, Spain. All patients admitted to the hospital during the period from 1995 through 2008. Three successive interventions were studied: (1) contact precautions, with no active surveillance for MRSA; (2) targeted active surveillance for MRSA in patients and healthcare workers in specific wards, prioritized according to clinical epidemiology data; and (3) targeted active surveillance for MRSA in patients admitted from other medical centers. Neither the preintervention rate of MRSA colonization or infection (0.56 cases per 1,000 patient-days [95% confidence interval {CI}, 0.49-0.62 cases per 1,000 patient-days]) nor the slope for the rate of MRSA colonization or infection changed significantly after the first intervention. The rate decreased significantly to 0.28 cases per 1,000 patient-days (95% CI, 0.17-0.40 cases per 1,000 patient-days) after the second intervention and to 0.07 cases per 1,000 patient-days (95% CI, 0.06-0.08 cases per 1,000 patient-days) after the third intervention, and the rate remained at a similar level for 8 years. The MRSA bacteremia rate decreased by 80%, whereas the rate of bacteremia due to methicillin-susceptible S. aureus did not change. Eighty-three percent of the MRSA isolates identified were clonally related. All MRSA isolates obtained from healthcare workers were clonally related to those recovered from patients who were in their care. Our data indicate that long-term control of endemic MRSA is feasible in tertiary care centers. The use of targeted active surveillance for MRSA in patients and healthcare workers in specific wards (identified by means of analysis of clinical epidemiology data) and the use of decolonization were key to the success of the program.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "195e202a3f16414ebfc5916fde09ab66", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[351, 351], [112, 112], [160, 160], [59, 59], [19, 19], [283, 283], [25, 25], [121, 121], [199, 199], [313, 313], [146, 146], [321, 321], [366, 366]], "char_spans": [[1902, 1905], [653, 656], [939, 942], [355, 358], [118, 121], [1517, 1520], [154, 157], [696, 699], [1107, 1110], [1672, 1675], [849, 852], [1724, 1727], [1989, 1992]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["long", 16], ["-", 20], ["term", 21], ["impact", 26], ["of", 33], ["successive", 36], ["interventions", 47], ["on", 61], ["rates", 64], ["of", 70], ["methicillin", 73], ["-", 84], ["resistant", 85], ["Staphylococcus", 95], ["aureus", 110], ["(", 117], ["MRSA", 118], [")", 122], ["colonization", 124], ["or", 137], ["infection", 140], ["and", 150], ["MRSA", 154], ["bacteremia", 159], ["in", 170], ["an", 173], ["endemic", 176], ["hospital", 184], ["-", 192], ["wide", 193], ["situation", 198], [".", 207], ["Quasi", 209], ["-", 214], ["experimental", 215], [",", 227], ["interrupted", 229], ["time", 241], ["-", 245], ["series", 246], ["analysis", 253], [".", 261], ["The", 263], ["impact", 267], ["of", 274], ["the", 277], ["interventions", 281], ["was", 295], ["analyzed", 299], ["by", 308], ["use", 311], ["of", 315], ["segmented", 318], ["regression", 328], [".", 338], ["Representative", 340], ["MRSA", 355], ["isolates", 360], ["were", 369], ["typed", 374], ["by", 380], ["use", 383], ["of", 387], ["pulsed", 390], ["-", 396], ["field", 397], ["gel", 403], ["electrophoresis", 407], [".", 422], ["A", 424], ["950-bed", 426], ["teaching", 434], ["hospital", 443], ["in", 452], ["Seville", 455], [",", 462], ["Spain", 464], [".", 469], ["All", 471], ["patients", 475], ["admitted", 484], ["to", 493], ["the", 496], ["hospital", 500], ["during", 509], ["the", 516], ["period", 520], ["from", 527], ["1995", 532], ["through", 537], ["2008", 545], [".", 549], ["Three", 551], ["successive", 557], ["interventions", 568], ["were", 582], ["studied", 587], [":", 594], ["(", 596], ["1", 597], [")", 598], ["contact", 600], ["precautions", 608], [",", 619], ["with", 621], ["no", 626], ["active", 629], ["surveillance", 636], ["for", 649], ["MRSA", 653], [";", 657], ["(", 659], ["2", 660], [")", 661], ["targeted", 663], ["active", 672], ["surveillance", 679], ["for", 692], ["MRSA", 696], ["in", 701], ["patients", 704], ["and", 713], ["healthcare", 717], ["workers", 728], ["in", 736], ["specific", 739], ["wards", 748], [",", 753], ["prioritized", 755], ["according", 767], ["to", 777], ["clinical", 780], ["epidemiology", 789], ["data", 802], [";", 806], ["and", 808], ["(", 812], ["3", 813], [")", 814], ["targeted", 816], ["active", 825], ["surveillance", 832], ["for", 845], ["MRSA", 849], ["in", 854], ["patients", 857], ["admitted", 866], ["from", 875], ["other", 880], ["medical", 886], ["centers", 894], [".", 901], ["Neither", 903], ["the", 911], ["preintervention", 915], ["rate", 931], ["of", 936], ["MRSA", 939], ["colonization", 944], ["or", 957], ["infection", 960], ["(", 970], ["0.56", 971], ["cases", 976], ["per", 982], ["1,000", 986], ["patient", 992], ["-", 999], ["days", 1000], ["[", 1005], ["95", 1006], ["%", 1008], ["confidence", 1010], ["interval", 1021], ["{", 1030], ["CI", 1031], ["}", 1033], [",", 1034], ["0.49", 1036], ["-", 1040], ["0.62", 1041], ["cases", 1046], ["per", 1052], ["1,000", 1056], ["patient", 1062], ["-", 1069], ["days", 1070], ["]", 1074], [")", 1075], ["nor", 1077], ["the", 1081], ["slope", 1085], ["for", 1091], ["the", 1095], ["rate", 1099], ["of", 1104], ["MRSA", 1107], ["colonization", 1112], ["or", 1125], ["infection", 1128], ["changed", 1138], ["significantly", 1146], ["after", 1160], ["the", 1166], ["first", 1170], ["intervention", 1176], [".", 1188], ["The", 1190], ["rate", 1194], ["decreased", 1199], ["significantly", 1209], ["to", 1223], ["0.28", 1226], ["cases", 1231], ["per", 1237], ["1,000", 1241], ["patient", 1247], ["-", 1254], ["days", 1255], ["(", 1260], ["95", 1261], ["%", 1263], ["CI", 1265], [",", 1267], ["0.17", 1269], ["-", 1273], ["0.40", 1274], ["cases", 1279], ["per", 1285], ["1,000", 1289], ["patient", 1295], ["-", 1302], ["days", 1303], [")", 1307], ["after", 1309], ["the", 1315], ["second", 1319], ["intervention", 1326], ["and", 1339], ["to", 1343], ["0.07", 1346], ["cases", 1351], ["per", 1357], ["1,000", 1361], ["patient", 1367], ["-", 1374], ["days", 1375], ["(", 1380], ["95", 1381], ["%", 1383], ["CI", 1385], [",", 1387], ["0.06", 1389], ["-", 1393], ["0.08", 1394], ["cases", 1399], ["per", 1405], ["1,000", 1409], ["patient", 1415], ["-", 1422], ["days", 1423], [")", 1427], ["after", 1429], ["the", 1435], ["third", 1439], ["intervention", 1445], [",", 1457], ["and", 1459], ["the", 1463], ["rate", 1467], ["remained", 1472], ["at", 1481], ["a", 1484], ["similar", 1486], ["level", 1494], ["for", 1500], ["8", 1504], ["years", 1506], [".", 1511], ["The", 1513], ["MRSA", 1517], ["bacteremia", 1522], ["rate", 1533], ["decreased", 1538], ["by", 1548], ["80", 1551], ["%", 1553], [",", 1554], ["whereas", 1556], ["the", 1564], ["rate", 1568], ["of", 1573], ["bacteremia", 1576], ["due", 1587], ["to", 1591], ["methicillin", 1594], ["-", 1605], ["susceptible", 1606], ["S.", 1618], ["aureus", 1621], ["did", 1628], ["not", 1632], ["change", 1636], [".", 1642], ["Eighty", 1644], ["-", 1650], ["three", 1651], ["percent", 1657], ["of", 1665], ["the", 1668], ["MRSA", 1672], ["isolates", 1677], ["identified", 1686], ["were", 1697], ["clonally", 1702], ["related", 1711], [".", 1718], ["All", 1720], ["MRSA", 1724], ["isolates", 1729], ["obtained", 1738], ["from", 1747], ["healthcare", 1752], ["workers", 1763], ["were", 1771], ["clonally", 1776], ["related", 1785], ["to", 1793], ["those", 1796], ["recovered", 1802], ["from", 1812], ["patients", 1817], ["who", 1826], ["were", 1830], ["in", 1835], ["their", 1838], ["care", 1844], [".", 1848], ["Our", 1850], ["data", 1854], ["indicate", 1859], ["that", 1868], ["long", 1873], ["-", 1877], ["term", 1878], ["control", 1883], ["of", 1891], ["endemic", 1894], ["MRSA", 1902], ["is", 1907], ["feasible", 1910], ["in", 1919], ["tertiary", 1922], ["care", 1931], ["centers", 1936], [".", 1943], ["The", 1945], ["use", 1949], ["of", 1953], ["targeted", 1956], ["active", 1965], ["surveillance", 1972], ["for", 1985], ["MRSA", 1989], ["in", 1994], ["patients", 1997], ["and", 2006], ["healthcare", 2010], ["workers", 2021], ["in", 2029], ["specific", 2032], ["wards", 2041], ["(", 2047], ["identified", 2048], ["by", 2059], ["means", 2062], ["of", 2068], ["analysis", 2071], ["of", 2080], ["clinical", 2083], ["epidemiology", 2092], ["data", 2105], [")", 2109], ["and", 2111], ["the", 2115], ["use", 2119], ["of", 2123], ["decolonization", 2126], ["were", 2141], ["key", 2146], ["to", 2150], ["the", 2153], ["success", 2157], ["of", 2165], ["the", 2168], ["program", 2172], [".", 2179]]}
{"context": "The histone variant H2AZ is incorporated preferentially at specific locations in chromatin to modulate chromosome functions. In Saccharomyces cerevisiae, deposition of histone H2AZ is mediated by the multiprotein SWR1 complex, which catalyzes ATP-dependent exchange of nucleosomal histone H2A for H2AZ. Here, we define interactions between SWR1 components and H2AZ, revealing a link between the ATPase domain of Swr1 and three subunits required for the binding of H2AZ. We discovered that Swc2 binds directly to and is essential for transfer of H2AZ. Swc6 and Arp6 are necessary for the association of Swc2 and for nucleosome binding, whereas other subunits, Swc5 and Yaf9, are required for H2AZ transfer but neither H2AZ nor nucleosome binding. Finally, the C-terminal alpha-helix of H2AZ is crucial for its recognition by SWR1. These findings provide insight on the initial events of histone exchange.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "62476e02ad284ed2b1d1125d42c416a2", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[143, 143], [52, 52], [65, 65], [30, 30]], "char_spans": [[824, 827], [340, 343], [412, 415], [213, 216]]}]}], "context_tokens": [["The", 0], ["histone", 4], ["variant", 12], ["H2AZ", 20], ["is", 25], ["incorporated", 28], ["preferentially", 41], ["at", 56], ["specific", 59], ["locations", 68], ["in", 78], ["chromatin", 81], ["to", 91], ["modulate", 94], ["chromosome", 103], ["functions", 114], [".", 123], ["In", 125], ["Saccharomyces", 128], ["cerevisiae", 142], [",", 152], ["deposition", 154], ["of", 165], ["histone", 168], ["H2AZ", 176], ["is", 181], ["mediated", 184], ["by", 193], ["the", 196], ["multiprotein", 200], ["SWR1", 213], ["complex", 218], [",", 225], ["which", 227], ["catalyzes", 233], ["ATP", 243], ["-", 246], ["dependent", 247], ["exchange", 257], ["of", 266], ["nucleosomal", 269], ["histone", 281], ["H2A", 289], ["for", 293], ["H2AZ", 297], [".", 301], ["Here", 303], [",", 307], ["we", 309], ["define", 312], ["interactions", 319], ["between", 332], ["SWR1", 340], ["components", 345], ["and", 356], ["H2AZ", 360], [",", 364], ["revealing", 366], ["a", 376], ["link", 378], ["between", 383], ["the", 391], ["ATPase", 395], ["domain", 402], ["of", 409], ["Swr1", 412], ["and", 417], ["three", 421], ["subunits", 427], ["required", 436], ["for", 445], ["the", 449], ["binding", 453], ["of", 461], ["H2AZ", 464], [".", 468], ["We", 470], ["discovered", 473], ["that", 484], ["Swc2", 489], ["binds", 494], ["directly", 500], ["to", 509], ["and", 512], ["is", 516], ["essential", 519], ["for", 529], ["transfer", 533], ["of", 542], ["H2AZ", 545], [".", 549], ["Swc6", 551], ["and", 556], ["Arp6", 560], ["are", 565], ["necessary", 569], ["for", 579], ["the", 583], ["association", 587], ["of", 599], ["Swc2", 602], ["and", 607], ["for", 611], ["nucleosome", 615], ["binding", 626], [",", 633], ["whereas", 635], ["other", 643], ["subunits", 649], [",", 657], ["Swc5", 659], ["and", 664], ["Yaf9", 668], [",", 672], ["are", 674], ["required", 678], ["for", 687], ["H2AZ", 691], ["transfer", 696], ["but", 705], ["neither", 709], ["H2AZ", 717], ["nor", 722], ["nucleosome", 726], ["binding", 737], [".", 744], ["Finally", 746], [",", 753], ["the", 755], ["C", 759], ["-", 760], ["terminal", 761], ["alpha", 770], ["-", 775], ["helix", 776], ["of", 782], ["H2AZ", 785], ["is", 790], ["crucial", 793], ["for", 801], ["its", 805], ["recognition", 809], ["by", 821], ["SWR1", 824], [".", 828], ["These", 830], ["findings", 836], ["provide", 845], ["insight", 853], ["on", 861], ["the", 864], ["initial", 868], ["events", 876], ["of", 883], ["histone", 886], ["exchange", 894], [".", 902]]}
{"context": "Osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL) are dominant regulators of bone resorption. Many hormones, cytokines and growth factors mediate bone resorption by altering the ratio of RANKL to OPG. RANKL and OPG expression is also altered in numerous bone diseases, and these changes can reflect disease etiology or compensatory responses to disease. RANKL stimulates osteoclast formation, function and survival, and each of these effects is inhibited by OPG. OPG suppresses bone resorption and increases the density, area and strength of both cancellous and cortical bone. Denosumab (AMG 162), a fully human monoclonal antibody to RANKL, shares the pharmacologic attributes of OPG but has a significantly longer half-life that allows less frequent administration.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "bd9c8ec49b8446ba9d107c61a8280a06", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[117, 117], [67, 67], [42, 42], [38, 38], [14, 14]], "char_spans": [[670, 674], [389, 393], [236, 240], [222, 226], [78, 82]]}]}], "context_tokens": [["Osteoprotegerin", 0], ["(", 16], ["OPG", 17], [")", 20], ["and", 22], ["receptor", 26], ["activator", 35], ["of", 45], ["nuclear", 48], ["factor", 56], ["-", 62], ["kappaB", 63], ["ligand", 70], ["(", 77], ["RANKL", 78], [")", 83], ["are", 85], ["dominant", 89], ["regulators", 98], ["of", 109], ["bone", 112], ["resorption", 117], [".", 127], ["Many", 129], ["hormones", 134], [",", 142], ["cytokines", 144], ["and", 154], ["growth", 158], ["factors", 165], ["mediate", 173], ["bone", 181], ["resorption", 186], ["by", 197], ["altering", 200], ["the", 209], ["ratio", 213], ["of", 219], ["RANKL", 222], ["to", 228], ["OPG", 231], [".", 234], ["RANKL", 236], ["and", 242], ["OPG", 246], ["expression", 250], ["is", 261], ["also", 264], ["altered", 269], ["in", 277], ["numerous", 280], ["bone", 289], ["diseases", 294], [",", 302], ["and", 304], ["these", 308], ["changes", 314], ["can", 322], ["reflect", 326], ["disease", 334], ["etiology", 342], ["or", 351], ["compensatory", 354], ["responses", 367], ["to", 377], ["disease", 380], [".", 387], ["RANKL", 389], ["stimulates", 395], ["osteoclast", 406], ["formation", 417], [",", 426], ["function", 428], ["and", 437], ["survival", 441], [",", 449], ["and", 451], ["each", 455], ["of", 460], ["these", 463], ["effects", 469], ["is", 477], ["inhibited", 480], ["by", 490], ["OPG", 493], [".", 496], ["OPG", 498], ["suppresses", 502], ["bone", 513], ["resorption", 518], ["and", 529], ["increases", 533], ["the", 543], ["density", 547], [",", 554], ["area", 556], ["and", 561], ["strength", 565], ["of", 574], ["both", 577], ["cancellous", 582], ["and", 593], ["cortical", 597], ["bone", 606], [".", 610], ["Denosumab", 612], ["(", 622], ["AMG", 623], ["162", 627], [")", 630], [",", 631], ["a", 633], ["fully", 635], ["human", 641], ["monoclonal", 647], ["antibody", 658], ["to", 667], ["RANKL", 670], [",", 675], ["shares", 677], ["the", 684], ["pharmacologic", 688], ["attributes", 702], ["of", 713], ["OPG", 716], ["but", 720], ["has", 724], ["a", 728], ["significantly", 730], ["longer", 744], ["half", 751], ["-", 755], ["life", 756], ["that", 761], ["allows", 766], ["less", 773], ["frequent", 778], ["administration", 787], [".", 801]]}
{"context": "The calcium-regulated protein phosphatase calcineurin (PP2B) functions as a regulator of gene expression in diverse tissues through the dephosphorylation and activation of a family of transcription factors known as nuclear factor of activated T cells (NFAT). Here we show that NFATc3, in addition to being calcium responsive, is regulated through an indirect recruitment of class II histone deacetylases (HDACs). Specifically, yeast two-hybrid screening with the rel homology domain of NFATc3 identified the chaperone mammalian relative of DnaJ (Mrj) as a specific interacting factor. Mrj and NFATc3 were shown to directly associate with one another in mammalian cells and in vitro. Mrj served as a potent inhibitor of NFAT transcriptional activity within the nucleus through a mechanism involving histone deacetylase recruitment in conjunction with heat shock stimulation. Indeed, Mrj was determined to interact with class II histone deacetylases, each of which translocated to the nucleus following heat shock stimulation. Mrj also decreased NFATc3 occupancy of the tumor necrosis factor-alpha promoter in cardiomyocytes in an HDAC-dependent manner, and Mrj blocked calcineurin-induced cardiomyocyte hypertrophic growth. Conversely, small-interfering-RNA-mediated reduction of Mrj augmented NFAT transcriptional activity and spontaneously induced cardiac myocyte growth. Collectively, our results define a novel response pathway whereby NFATc3 is negatively regulated by class II histone deacetylases through the DnaJ (heat shock protein-40) superfamily member Mrj.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "ed2c56657551418794065dae4cc3bb3c", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[196, 196], [6, 6]], "char_spans": [[1168, 1178], [42, 52]]}]}], "context_tokens": [["The", 0], ["calcium", 4], ["-", 11], ["regulated", 12], ["protein", 22], ["phosphatase", 30], ["calcineurin", 42], ["(", 54], ["PP2B", 55], [")", 59], ["functions", 61], ["as", 71], ["a", 74], ["regulator", 76], ["of", 86], ["gene", 89], ["expression", 94], ["in", 105], ["diverse", 108], ["tissues", 116], ["through", 124], ["the", 132], ["dephosphorylation", 136], ["and", 154], ["activation", 158], ["of", 169], ["a", 172], ["family", 174], ["of", 181], ["transcription", 184], ["factors", 198], ["known", 206], ["as", 212], ["nuclear", 215], ["factor", 223], ["of", 230], ["activated", 233], ["T", 243], ["cells", 245], ["(", 251], ["NFAT", 252], [")", 256], [".", 257], ["Here", 259], ["we", 264], ["show", 267], ["that", 272], ["NFATc3", 277], [",", 283], ["in", 285], ["addition", 288], ["to", 297], ["being", 300], ["calcium", 306], ["responsive", 314], [",", 324], ["is", 326], ["regulated", 329], ["through", 339], ["an", 347], ["indirect", 350], ["recruitment", 359], ["of", 371], ["class", 374], ["II", 380], ["histone", 383], ["deacetylases", 391], ["(", 404], ["HDACs", 405], [")", 410], [".", 411], ["Specifically", 413], [",", 425], ["yeast", 427], ["two", 433], ["-", 436], ["hybrid", 437], ["screening", 444], ["with", 454], ["the", 459], ["rel", 463], ["homology", 467], ["domain", 476], ["of", 483], ["NFATc3", 486], ["identified", 493], ["the", 504], ["chaperone", 508], ["mammalian", 518], ["relative", 528], ["of", 537], ["DnaJ", 540], ["(", 545], ["Mrj", 546], [")", 549], ["as", 551], ["a", 554], ["specific", 556], ["interacting", 565], ["factor", 577], [".", 583], ["Mrj", 585], ["and", 589], ["NFATc3", 593], ["were", 600], ["shown", 605], ["to", 611], ["directly", 614], ["associate", 623], ["with", 633], ["one", 638], ["another", 642], ["in", 650], ["mammalian", 653], ["cells", 663], ["and", 669], ["in", 673], ["vitro", 676], [".", 681], ["Mrj", 683], ["served", 687], ["as", 694], ["a", 697], ["potent", 699], ["inhibitor", 706], ["of", 716], ["NFAT", 719], ["transcriptional", 724], ["activity", 740], ["within", 749], ["the", 756], ["nucleus", 760], ["through", 768], ["a", 776], ["mechanism", 778], ["involving", 788], ["histone", 798], ["deacetylase", 806], ["recruitment", 818], ["in", 830], ["conjunction", 833], ["with", 845], ["heat", 850], ["shock", 855], ["stimulation", 861], [".", 872], ["Indeed", 874], [",", 880], ["Mrj", 882], ["was", 886], ["determined", 890], ["to", 901], ["interact", 904], ["with", 913], ["class", 918], ["II", 924], ["histone", 927], ["deacetylases", 935], [",", 947], ["each", 949], ["of", 954], ["which", 957], ["translocated", 963], ["to", 976], ["the", 979], ["nucleus", 983], ["following", 991], ["heat", 1001], ["shock", 1006], ["stimulation", 1012], [".", 1023], ["Mrj", 1025], ["also", 1029], ["decreased", 1034], ["NFATc3", 1044], ["occupancy", 1051], ["of", 1061], ["the", 1064], ["tumor", 1068], ["necrosis", 1074], ["factor", 1083], ["-", 1089], ["alpha", 1090], ["promoter", 1096], ["in", 1105], ["cardiomyocytes", 1108], ["in", 1123], ["an", 1126], ["HDAC", 1129], ["-", 1133], ["dependent", 1134], ["manner", 1144], [",", 1150], ["and", 1152], ["Mrj", 1156], ["blocked", 1160], ["calcineurin", 1168], ["-", 1179], ["induced", 1180], ["cardiomyocyte", 1188], ["hypertrophic", 1202], ["growth", 1215], [".", 1221], ["Conversely", 1223], [",", 1233], ["small", 1235], ["-", 1240], ["interfering", 1241], ["-", 1252], ["RNA", 1253], ["-", 1256], ["mediated", 1257], ["reduction", 1266], ["of", 1276], ["Mrj", 1279], ["augmented", 1283], ["NFAT", 1293], ["transcriptional", 1298], ["activity", 1314], ["and", 1323], ["spontaneously", 1327], ["induced", 1341], ["cardiac", 1349], ["myocyte", 1357], ["growth", 1365], [".", 1371], ["Collectively", 1373], [",", 1385], ["our", 1387], ["results", 1391], ["define", 1399], ["a", 1406], ["novel", 1408], ["response", 1414], ["pathway", 1423], ["whereby", 1431], ["NFATc3", 1439], ["is", 1446], ["negatively", 1449], ["regulated", 1460], ["by", 1470], ["class", 1473], ["II", 1479], ["histone", 1482], ["deacetylases", 1490], ["through", 1503], ["the", 1511], ["DnaJ", 1515], ["(", 1520], ["heat", 1521], ["shock", 1526], ["protein-40", 1532], [")", 1542], ["superfamily", 1544], ["member", 1556], ["Mrj", 1563], [".", 1566]]}
{"context": "To investigate whether gender is an independent factor associated with disease expression in early rheumatoid arthritis (RA) patients. 438 patients with early RA (disease duration less than one year) were studied. They all were patients with early RA who presented at the Rheumatology Clinic of the University Hospital of Ioannina during the period 1991-2000. All patients fulfilled the American College of Rheumatology criteria for RA. The demographic, clinical, laboratory, radiological and therapeutic characteristics of the disease at diagnosis, and at the last follow-up were analyzed according to gender. We studied 312 women and 126 men with early RA. The female to male ratio was 2.5:1 and the mean age at diagnosis was 49.4 +/- 14.9 years for women and 55.3 +/-15.6 years for men (P < 0.0003). Women had a longer duration of follow-up (P < 0.0003). There were no differences between genders in the general symptoms or the simmetricity of joint involvement at at disease onset. However at disease onset women had a higher erythrocyte sedimentation rate (ESR) (> 30 mm/1st hour), although there were no significant differences between the two groups concerninig the rest of the clinical, laboratory and radiological findings. At the last follow-up women still had a higher ESR (>30 min/1st hour), but no significant differences were found between the two groups concerning the rest of the parameters investigated independently of the follow-up duration. Finally, women and men showed the same degree of radiological changes and functional ability and were treated similarly except for the more frequent use of hydroxychloroquine in women. It seems that gender does not signficantly influence the expression of RA.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "b3aff0ff72834de8bbd3a3ca13a60532", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[235, 235], [275, 275], [150, 150], [301, 301], [108, 108], [136, 136], [190, 190]], "char_spans": [[1255, 1259], [1470, 1474], [803, 807], [1639, 1643], [626, 630], [752, 756], [1011, 1015]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["gender", 23], ["is", 30], ["an", 33], ["independent", 36], ["factor", 48], ["associated", 55], ["with", 66], ["disease", 71], ["expression", 79], ["in", 90], ["early", 93], ["rheumatoid", 99], ["arthritis", 110], ["(", 120], ["RA", 121], [")", 123], ["patients", 125], [".", 133], ["438", 135], ["patients", 139], ["with", 148], ["early", 153], ["RA", 159], ["(", 162], ["disease", 163], ["duration", 171], ["less", 180], ["than", 185], ["one", 190], ["year", 194], [")", 198], ["were", 200], ["studied", 205], [".", 212], ["They", 214], ["all", 219], ["were", 223], ["patients", 228], ["with", 237], ["early", 242], ["RA", 248], ["who", 251], ["presented", 255], ["at", 265], ["the", 268], ["Rheumatology", 272], ["Clinic", 285], ["of", 292], ["the", 295], ["University", 299], ["Hospital", 310], ["of", 319], ["Ioannina", 322], ["during", 331], ["the", 338], ["period", 342], ["1991", 349], ["-", 353], ["2000", 354], [".", 358], ["All", 360], ["patients", 364], ["fulfilled", 373], ["the", 383], ["American", 387], ["College", 396], ["of", 404], ["Rheumatology", 407], ["criteria", 420], ["for", 429], ["RA", 433], [".", 435], ["The", 437], ["demographic", 441], [",", 452], ["clinical", 454], [",", 462], ["laboratory", 464], [",", 474], ["radiological", 476], ["and", 489], ["therapeutic", 493], ["characteristics", 505], ["of", 521], ["the", 524], ["disease", 528], ["at", 536], ["diagnosis", 539], [",", 548], ["and", 550], ["at", 554], ["the", 557], ["last", 561], ["follow", 566], ["-", 572], ["up", 573], ["were", 576], ["analyzed", 581], ["according", 590], ["to", 600], ["gender", 603], [".", 609], ["We", 611], ["studied", 614], ["312", 622], ["women", 626], ["and", 632], ["126", 636], ["men", 640], ["with", 644], ["early", 649], ["RA", 655], [".", 657], ["The", 659], ["female", 663], ["to", 670], ["male", 673], ["ratio", 678], ["was", 684], ["2.5:1", 688], ["and", 694], ["the", 698], ["mean", 702], ["age", 707], ["at", 711], ["diagnosis", 714], ["was", 724], ["49.4", 728], ["+", 733], ["/-", 734], ["14.9", 737], ["years", 742], ["for", 748], ["women", 752], ["and", 758], ["55.3", 762], ["+", 767], ["/-15.6", 768], ["years", 775], ["for", 781], ["men", 785], ["(", 789], ["P", 790], ["<", 792], ["0.0003", 794], [")", 800], [".", 801], ["Women", 803], ["had", 809], ["a", 813], ["longer", 815], ["duration", 822], ["of", 831], ["follow", 834], ["-", 840], ["up", 841], ["(", 844], ["P", 845], ["<", 847], ["0.0003", 849], [")", 855], [".", 856], ["There", 858], ["were", 864], ["no", 869], ["differences", 872], ["between", 884], ["genders", 892], ["in", 900], ["the", 903], ["general", 907], ["symptoms", 915], ["or", 924], ["the", 927], ["simmetricity", 931], ["of", 944], ["joint", 947], ["involvement", 953], ["at", 965], ["at", 968], ["disease", 971], ["onset", 979], [".", 984], ["However", 986], ["at", 994], ["disease", 997], ["onset", 1005], ["women", 1011], ["had", 1017], ["a", 1021], ["higher", 1023], ["erythrocyte", 1030], ["sedimentation", 1042], ["rate", 1056], ["(", 1061], ["ESR", 1062], [")", 1065], ["(", 1067], [">", 1068], ["30", 1070], ["mm/1st", 1073], ["hour", 1080], [")", 1084], [",", 1085], ["although", 1087], ["there", 1096], ["were", 1102], ["no", 1107], ["significant", 1110], ["differences", 1122], ["between", 1134], ["the", 1142], ["two", 1146], ["groups", 1150], ["concerninig", 1157], ["the", 1169], ["rest", 1173], ["of", 1178], ["the", 1181], ["clinical", 1185], [",", 1193], ["laboratory", 1195], ["and", 1206], ["radiological", 1210], ["findings", 1223], [".", 1231], ["At", 1233], ["the", 1236], ["last", 1240], ["follow", 1245], ["-", 1251], ["up", 1252], ["women", 1255], ["still", 1261], ["had", 1267], ["a", 1271], ["higher", 1273], ["ESR", 1280], ["(", 1284], [">", 1285], ["30", 1286], ["min/1st", 1289], ["hour", 1297], [")", 1301], [",", 1302], ["but", 1304], ["no", 1308], ["significant", 1311], ["differences", 1323], ["were", 1335], ["found", 1340], ["between", 1346], ["the", 1354], ["two", 1358], ["groups", 1362], ["concerning", 1369], ["the", 1380], ["rest", 1384], ["of", 1389], ["the", 1392], ["parameters", 1396], ["investigated", 1407], ["independently", 1420], ["of", 1434], ["the", 1437], ["follow", 1441], ["-", 1447], ["up", 1448], ["duration", 1451], [".", 1459], ["Finally", 1461], [",", 1468], ["women", 1470], ["and", 1476], ["men", 1480], ["showed", 1484], ["the", 1491], ["same", 1495], ["degree", 1500], ["of", 1507], ["radiological", 1510], ["changes", 1523], ["and", 1531], ["functional", 1535], ["ability", 1546], ["and", 1554], ["were", 1558], ["treated", 1563], ["similarly", 1571], ["except", 1581], ["for", 1588], ["the", 1592], ["more", 1596], ["frequent", 1601], ["use", 1610], ["of", 1614], ["hydroxychloroquine", 1617], ["in", 1636], ["women", 1639], [".", 1644], ["It", 1646], ["seems", 1649], ["that", 1655], ["gender", 1660], ["does", 1667], ["not", 1672], ["signficantly", 1676], ["influence", 1689], ["the", 1699], ["expression", 1703], ["of", 1714], ["RA", 1717], [".", 1719]]}
{"context": "Histone variant H2A.Z-containing nucleosomes are incorporated at most eukaryotic promoters. This incorporation is mediated by the conserved SWR1 complex, which replaces histone H2A in canonical nucleosomes with H2A.Z in an ATP-dependent manner. Here, we show that promoter-proximal nucleosomes are highly heterogeneous for H2A.Z in Saccharomyces cerevisiae, with substantial representation of nucleosomes containing one, two, or zero H2A.Z molecules. SWR1-catalyzed H2A.Z replacement in vitro occurs in a stepwise and unidirectional fashion, one H2A.Z-H2B dimer at a time, producing heterotypic nucleosomes as intermediates and homotypic H2A.Z nucleosomes as end products. The ATPase activity of SWR1 is specifically stimulated by H2A-containing nucleosomes without ensuing histone H2A eviction. Remarkably, further addition of free H2A.Z-H2B dimer leads to hyperstimulation of ATPase activity, eviction of nucleosomal H2A-H2B, and deposition of H2A.Z-H2B. These results suggest that the combination of H2A-containing nucleosome and free H2A.Z-H2B dimer acting as both effector and substrate for SWR1 governs the specificity and outcome of the replacement reaction.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "9473f38b4dee41f9afdbbe99bea8b018", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[20, 20], [180, 180], [111, 111]], "char_spans": [[140, 143], [1096, 1099], [696, 699]]}]}], "context_tokens": [["Histone", 0], ["variant", 8], ["H2A.Z", 16], ["-", 21], ["containing", 22], ["nucleosomes", 33], ["are", 45], ["incorporated", 49], ["at", 62], ["most", 65], ["eukaryotic", 70], ["promoters", 81], [".", 90], ["This", 92], ["incorporation", 97], ["is", 111], ["mediated", 114], ["by", 123], ["the", 126], ["conserved", 130], ["SWR1", 140], ["complex", 145], [",", 152], ["which", 154], ["replaces", 160], ["histone", 169], ["H2A", 177], ["in", 181], ["canonical", 184], ["nucleosomes", 194], ["with", 206], ["H2A.Z", 211], ["in", 217], ["an", 220], ["ATP", 223], ["-", 226], ["dependent", 227], ["manner", 237], [".", 243], ["Here", 245], [",", 249], ["we", 251], ["show", 254], ["that", 259], ["promoter", 264], ["-", 272], ["proximal", 273], ["nucleosomes", 282], ["are", 294], ["highly", 298], ["heterogeneous", 305], ["for", 319], ["H2A.Z", 323], ["in", 329], ["Saccharomyces", 332], ["cerevisiae", 346], [",", 356], ["with", 358], ["substantial", 363], ["representation", 375], ["of", 390], ["nucleosomes", 393], ["containing", 405], ["one", 416], [",", 419], ["two", 421], [",", 424], ["or", 426], ["zero", 429], ["H2A.Z", 434], ["molecules", 440], [".", 449], ["SWR1-catalyzed", 451], ["H2A.Z", 466], ["replacement", 472], ["in", 484], ["vitro", 487], ["occurs", 493], ["in", 500], ["a", 503], ["stepwise", 505], ["and", 514], ["unidirectional", 518], ["fashion", 533], [",", 540], ["one", 542], ["H2A.Z", 546], ["-", 551], ["H2B", 552], ["dimer", 556], ["at", 562], ["a", 565], ["time", 567], [",", 571], ["producing", 573], ["heterotypic", 583], ["nucleosomes", 595], ["as", 607], ["intermediates", 610], ["and", 624], ["homotypic", 628], ["H2A.Z", 638], ["nucleosomes", 644], ["as", 656], ["end", 659], ["products", 663], [".", 671], ["The", 673], ["ATPase", 677], ["activity", 684], ["of", 693], ["SWR1", 696], ["is", 701], ["specifically", 704], ["stimulated", 717], ["by", 728], ["H2A", 731], ["-", 734], ["containing", 735], ["nucleosomes", 746], ["without", 758], ["ensuing", 766], ["histone", 774], ["H2A", 782], ["eviction", 786], [".", 794], ["Remarkably", 796], [",", 806], ["further", 808], ["addition", 816], ["of", 825], ["free", 828], ["H2A.Z", 833], ["-", 838], ["H2B", 839], ["dimer", 843], ["leads", 849], ["to", 855], ["hyperstimulation", 858], ["of", 875], ["ATPase", 878], ["activity", 885], [",", 893], ["eviction", 895], ["of", 904], ["nucleosomal", 907], ["H2A", 919], ["-", 922], ["H2B", 923], [",", 926], ["and", 928], ["deposition", 932], ["of", 943], ["H2A.Z", 946], ["-", 951], ["H2B.", 952], ["These", 957], ["results", 963], ["suggest", 971], ["that", 979], ["the", 984], ["combination", 988], ["of", 1000], ["H2A", 1003], ["-", 1006], ["containing", 1007], ["nucleosome", 1018], ["and", 1029], ["free", 1033], ["H2A.Z", 1038], ["-", 1043], ["H2B", 1044], ["dimer", 1048], ["acting", 1054], ["as", 1061], ["both", 1064], ["effector", 1069], ["and", 1078], ["substrate", 1082], ["for", 1092], ["SWR1", 1096], ["governs", 1101], ["the", 1109], ["specificity", 1113], ["and", 1125], ["outcome", 1129], ["of", 1137], ["the", 1140], ["replacement", 1144], ["reaction", 1156], [".", 1164]]}
